Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
stranded O
RNA O
virus O
that O
causes O
neurological O
diseases O
in O
a O
variety O
of O
warm O
- O
blooded O
animal O
species O
. O

Recently O
, O
we O
showed O
that O
the O
nucleoside O
analog O
1 O
- O
beta O
- O
D O
- O
arabinofuranosylcytosine O
( O
Ara O
- O
C O
) O
was O
a O
potent O
inhibitor O
of O
BDV O
. O

Here O
, O
we O
show O
that O
( O
i O
) O
this O
effect O
is O
specific O
for O
an O
arabinoside O
ring O
carrying O
a O
cytosine O
base O
, O
( O
ii O
) O
it O
requires O
phosphorylation O
of O
the O
nucleotide O
, O
and O
( O
iii O
) O
it O
can O
be O
reversed O
by O
an O
excess O
of O
cytidine O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
highly O
neurotropic O
RNA O
virus O
that O
causes O
neurological O
disorders O
in O
many O
vertebrate O
species O
. O

In O
this O
study O
, O
to O
understand O
the O
regulation O
of O
stress O
responses O
in O
BDV O
infection O
, O
we O
investigated O
the O
expression O
of O
heat B
shock I
proteins I
( I
HSPs I
) I
in O
glial O
cells O
persistently O
infected O
with O
BDV O
. O

Finally O
, O
we O
found O
that O
the O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
is O
expressed O
at O
a O
constant O
level O
in O
persistently O
infected O
cells O
with O
or O
without O
heat O
shock O
. O

The O
highly O
attenuated O
Orf O
virus O
strain O
D1701 O
was O
used O
to O
generate O
a O
recombinant O
virus O
( O
D1701 O
- O
VrVp40 O
) O
expressing O
nucleoprotein O
p40 O
of O
Borna O
disease O
virus O
, O
which O
represents O
a O
major O
antigen O
for O
the O
induction O
of O
a O
Borna O
disease O
virus O
- O
specific O
humoral O
and O
cellular O
immune O
response O
. O

Infection O
with O
Borna O
disease O
virus O
leads O
to O
distinct O
neurological O
symptoms O
mediated O
by O
the O
invasion O
of O
activated O
specific O
CD8 O
( O
+ O
) O
T O
cells O
into O
the O
infected O
brain O
. O

Virus O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
often O
results O
in O
chemokine O
upregulation O
. O

In O
vitro O
, O
several O
chemokines O
including O
monocyte B
chemotactic I
protein I
1 I
( I
MCP I
- I
1 I
) I
protect O
neurons O
from O
apoptosis O
. O

Three O
ligands O
for O
CCR2 O
( O
MCP O
- O
1 O
, O
MCP O
- O
3 O
, O
and O
MCP O
- O
5 O
) O
were O
upregulated O
during O
Fr98 O
infection O
of O
the O
brain O
. O

The O
nucleoprotein B
( I
N I
) I
of O
Borna B
disease I
virus I
( I
BDV I
) I
is O
the O
major O
target O
of O
the O
disease O
- O
inducing O
antiviral O
CD8 O
T O
- O
cell O
response O
in O
the O
central O
nervous O
system O
of O
mice O
. O

We O
established O
two O
transgenic O
mouse O
lines O
which O
express O
BDV O
- O
N O
in O
either O
neurons O
( O
Neuro O
- O
N O
) O
or O
astrocytes O
( O
Astro O
- O
N O
) O
. O

Notably O
, O
the O
virus O
failed O
to O
replicate O
in O
the O
transgene O
- O
expressing O
granular O
and O
pyramidal O
neurons O
of O
the O
hippocampus O
( O
which O
are O
usually O
the O
preferred O
host O
cells O
of O
BDV O
) O
. O

Borna B
disease I
virus I
( I
BDV I
) I
induces O
a O
nonpurulent O
CD4 O
- O
and O
CD8 O
- O
T O
- O
cell O
- O
dependent O
meningoencephalitis O
in O
susceptible O
animals O
. O

Upon O
intracerebral O
infection O
, O
BDV O
replicates O
in O
the O
mouse O
central B
nervous I
system I
( I
CNS I
) I
, O
but O
only O
a O
few O
mouse O
strains O
develop O
neurological O
disorder O
. O

Since O
BDV O
does O
not O
replicate O
in O
standard O
mouse O
cell O
cultures O
, O
the O
putative O
role O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
in O
virus O
control O
could O
not O
be O
tested O
experimentally O
. O

Analysis O
of O
the O
composition O
and O
regulation O
of O
the O
Borna B
disease I
virus I
( I
BDV I
) I
polymerase O
complex O
has O
so O
far O
been O
limited O
by O
the O
lack O
of O
a O
functional O
assay O
. O

To O
establish O
such O
an O
assay O
on O
the O
basis O
of O
an O
artificial O
minigenome O
, O
we O
constructed O
expression O
vectors O
encoding O
either O
nucleoprotein B
( I
N I
) I
, O
phosphoprotein B
( I
P I
) I
, O
X O
protein O
, O
or O
polymerase O
( O
L O
) O
of O
BDV O
under O
the O
control O
of O
the O
chicken O
beta O
- O
actin O
promoter O
. O

Vector O
- O
driven O
expression O
of O
L O
, O
N O
, O
and O
P O
in O
BSR O
- O
T7 O
cells O
together O
with O
a O
negative O
- O
sense O
BDV O
minigenome O
carrying O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
resulted O
in O
efficient O
synthesis O
of O
CAT O
protein O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
negative O
- O
strand O
RNA O
virus O
with O
a O
tropism O
for O
neurons O
. O

This O
has O
led O
to O
the O
hypothesis O
that O
BDV O
spreads O
as O
nonenveloped B
ribonucleoproteins I
( I
RNP I
) I
rather O
than O
as O
enveloped O
viral O
particles O
. O

We O
assessed O
whether O
the O
viral O
envelope O
glycoprotein B
( I
GP I
) I
is O
required O
for O
neuronal O
dissemination O
of O
BDV O
by O
using O
primary O
cultures O
of O
rat O
hippocampal O
neurons O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
noncytolytic O
, O
neurotropic O
RNA O
virus O
that O
has O
a O
broad O
host O
range O
in O
warm O
- O
blooded O
animals O
, O
probably O
including O
humans O
. O

Recently O
, O
it O
was O
demonstrated O
that O
a O
24 O
- O
kDa O
phosphoprotein B
( I
P I
) I
of O
BDV O
directly O
binds O
to O
a O
multifunctional O
protein O
, O
amphoterin O
- O
HMGB1 O
, O
and O
. O

Furthermore O
, O
we O
showed O
that O
activation O
of O
p21 O
( O
waf1 O
) O
expression O
was O
repressed O
in O
cyclosporine O
- O
treated O
BDV O
- O
infected O
cells O
, O
as O
well O
as O
p53 O
- O
transduced O
NCI O
- O
H1299 O
cells O
. O

Transition O
from O
G O
( O
2 O
) O
to O
M O
phase O
, O
a O
cell O
cycle O
checkpoint O
, O
is O
regulated O
by O
the O
Cdc2 O
- O
cyclin O
B1 O
complex O
. O

Here O
, O
we O
report O
that O
persistent O
infection O
with O
Borna B
disease I
virus I
( I
BDV I
) I
, O
a O
noncytolytic O
RNA O
virus O
infecting O
the O
central O
nervous O
system O
, O
results O
in O
decelerated O
proliferation O
of O
infected O
host O
cells O
due O
to O
a O
delayed O
G O
( O
2 O
) O
- O
to O
- O
M O
transition O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
strand O
RNA O
virus O
that O
belongs O
to O
the O
Mononegavirales O
order O
. O

In O
this O
study O
, O
to O
understand O
the O
modulation O
of O
subcellular O
localization O
of O
BDV O
proteins O
, O
we O
investigated O
the O
intracellular O
localization O
of O
the O
viral O
phosphoprotein B
( I
P I
) I
. O

Borna B
disease I
virus I
( I
BDV I
) I
infection O
of O
Lewis O
rats O
is O
the O
most O
studied O
animal O
model O
of O
Borna O
disease O
, O
an O
often O
fatal O
encephalomyelitis O
. O

In O
this O
experimental O
model O
, O
BDV O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
play O
a O
prominent O
role O
in O
the O
immunopathogenesis O
of O
infection O
by O
the O
noncytolytic O
, O
persistent O
BDV O
. O

Of O
the O
six O
open O
reading O
frames O
of O
BDV O
, O
CTLs O
to O
BDV O
X O
( O
p10 O
) O
and O
the O
L O
- O
polymerase O
have O
never O
been O
studied O
. O

A O
( O
1 O
) O
major O
histocompatibility O
complex O
class O
I O
molecules O
of O
the O
Lewis O
rats O
, O
were O
identified O
. O

V O
- O
restricted O
A O
( O
230 O
) O
SYAQMTTY O
( O
238 O
) O
peptide O
as O
the O
CTL O
target O
for O
BDV O
N O
. O

We O
present O
evidence O
for O
superinfection O
exclusion O
in O
brains O
of O
Borna B
disease I
virus I
( I
BDV I
) I
- O
infected O
rats O
and O
in O
persistently O
infected O
Vero O
cells O
, O
and O
we O
suggest O
that O
acquired O
resistance O
to O
BDV O
is O
due O
to O
unbalanced O
intracellular O
levels O
of O
viral O
nucleocapsid O
components O
. O

To O
get O
an O
insight O
into O
Borna B
disease I
virus I
( I
BDV I
) I
epidemiology O
, O
an O
isolated O
flock O
of O
approximately O
25 O
sheep O
within O
the O
region O
of O
Southeast O
Germany O
to O
which O
the O
disease O
is O
endemic O
was O
investigated O
over O
a O
3 O
- O
year O
observation O
period O
. O

5 O
( O
year O
1 O
) O
, O
11 O
. O

5 O
( O
year O
2 O
) O
, O
and O
19 O
. O

4 O
% O
( O
year O
3 O
) O
and O
1 O
. O

6 O
( O
year O
1 O
) O
, O
0 O
( O
year O
2 O
) O
, O
and O
14 O
. O

9 O
% O
( O
year O
3 O
) O
of O
the O
animals O
, O
respectively O
. O

Borna B
disease I
virus I
( I
BDV I
) I
infection O
produces O
a O
variety O
of O
clinical O
diseases O
, O
from O
behavioral O
illnesses O
to O
classical O
fatal O
encephalitis O
( O
i O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
negative O
- O
strand O
RNA O
virus O
that O
replicates O
and O
transcribes O
its O
genome O
in O
the O
nucleus O
of O
infected O
cells O
. O

The O
RNA B
- I
dependent I
RNA I
polymerase I
( I
L I
) I
of O
BDV O
is O
postulated O
to O
be O
the O
catalytic O
enzyme O
of O
replication O
and O
transcription O
. O

Nuclear O
localization O
of O
the O
protein O
presupposes O
the O
presence O
of O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
within O
its O
primary O
amino O
acid O
sequence O
or O
cotransport O
to O
the O
nucleus O
with O
another O
karyophilic O
protein O
. O

Although O
the O
majority O
of O
the O
L O
fusion O
proteins O
localized O
to O
the O
cytoplasm O
of O
transfected O
BSR O
- O
T7 O
cells O
, O
a O
strong O
NLS O
( O
844RVVKLRIAP852 O
) O
with O
basic O
and O
proline O
residues O
was O
identified O
. O

Experimental O
Borna B
disease I
virus I
( I
BDV I
) I
infection O
of O
rats O
and O
natural O
infection O
of O
horses O
and O
sheep O
leads O
to O
severe O
central O
nervous O
system O
disease O
based O
on O
immunopathological O
pathways O
. O

CD8 O
( O
+ O
) O
T O
cells O
exert O
effector O
cell O
functions O
, O
and O
their O
activity O
results O
in O
the O
destruction O
of O
virus O
- O
infected O
cells O
. O

High O
- O
dose O
BDV O
( O
10 O
( O
6 O
) O
FFU O
) O
triggers O
an O
early O
virus O
- O
specific O
reaction O
of O
the O
Immune O
system O
, O
as O
demonstrated O
by O
strong O
cellular O
and O
Immoral O
responses O
. O

In O
particular O
, O
the O
early O
presence O
and O
function O
of O
nucleoprotein O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
could O
be O
demonstrated O
in O
the O
brain O
. O

The O
open O
reading O
frame O
III O
of O
Borna B
disease I
virus I
( I
BDV I
) I
codes O
for O
a O
protein O
with O
a O
mass O
of O
16 O
kDa O
, O
named O
p16 O
or O
BDV O
- O
M O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
noncytolytic O
RNA O
virus O
that O
can O
replicate O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
mice O
. O

This O
study O
shows O
that O
BDV O
multiplication O
was O
efficiently O
blocked O
in O
transgenic O
mice O
that O
express O
mouse B
alpha I
- I
1 I
interferon I
( I
IFN I
- I
alpha1 I
) I
in O
astrocytes O
. O

To O
investigate O
whether O
endogenous O
virus O
- O
induced O
IFN O
might O
similarly O
restrict O
BDV O
, O
we O
used O
IFNAR O
( O
0 O
/ O
0 O
) O
mice O
, O
which O
lack O
a O
functional O
alpha B
/ I
beta I
IFN I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptor O
. O

As O
would O
be O
expected O
if O
virus O
- O
induced O
IFN O
were O
important O
to O
control O
BDV O
infection O
, O
we O
found O
that O
cultured O
embryo O
cells O
of O
IFNAR O
( O
0 O
/ O
0 O
) O
mice O
supported O
viral O
multiplication O
, O
whereas O
cells O
from O
wild O
- O
type O
mice O
did O
not O
. O

Unexpectedly O
, O
however O
, O
BDV O
spread O
through O
the O
CNSs O
of O
IFNAR O
( O
0 O
/ O
0 O
) O
and O
wild O
- O
type O
mice O
with O
similar O
kinetics O
, O
suggesting O
that O
activation O
of O
endogenous O
IFN O
- O
alpha O
/ O
beta O
genes O
in O
BDV O
- O
infected O
brains O
was O
too O
weak O
or O
occurred O
too O
late O
to O
be O
effective O
. O

Surprisingly O
, O
Northern O
blot O
analysis O
showed O
that O
the O
levels O
of O
the O
most O
abundant O
viral O
mRNAs O
in O
the O
brains O
of O
persistently O
infected O
IFNAR O
( O
0 O
/ O
0 O
) O
mice O
were O
about O
20 O
- O
fold O
lower O
than O
those O
in O
wild O
- O
type O
mice O
. O

In O
contrast O
, O
genomic O
viral O
RNA O
was O
produced O
in O
about O
a O
10 O
- O
fold O
excess O
in O
the O
brains O
of O
IFNAR O
( O
0 O
/ O
0 O
) O
mice O
. O

The O
Borna B
disease I
virus I
( I
BDV I
) I
p24 O
phosphoprotein O
is O
an O
abundant O
protein O
in O
BDV O
- O
infected O
cultured O
cells O
and O
animal O
brains O
. O

Therefore O
, O
there O
is O
a O
possibility O
that O
binding O
of O
the O
p24 O
protein O
to O
cellular O
factor O
( O
s O
) O
induces O
functional O
alterations O
of O
infected O
neural O
cells O
in O
the O
brain O
. O

To O
identify O
a O
cellular O
protein O
( O
s O
) O
that O
interacts O
with O
BDV O
p24 O
protein O
, O
we O
performed O
far O
- O
Western O
blotting O
with O
extracts O
from O
various O
cell O
lines O
. O

Borna B
disease I
virus I
( I
BDV I
) I
surface B
glycoprotein I
( I
GP I
) I
( O
p56 O
) O
has O
a O
predicted O
molecular O
mass O
of O
56 O
kDa O
. O

Due O
to O
extensive O
posttranslational O
glycosylation O
the O
protein O
migrates O
as O
a O
polypeptide O
of O
84 O
kDa O
( O
gp84 O
) O
, O
The O
processing O
of O
gp84 O
by O
the O
cellular O
protease O
furin O
generates O
gp43 O
, O
which O
corresponds O
to O
the O
C O
- O
terminal O
part O
of O
gp84 O
, O
Both O
gp84 O
and O
gp43 O
have O
been O
implicated O
in O
viral O
entry O
involving O
receptor O
- O
mediated O
endocytosis O
and O
pa O
- O
dependent O
fusion O
, O
We O
have O
investigated O
the O
domains O
of O
BDV O
p56 O
involved O
in O
virus O
entry O
. O

For O
this O
, O
we O
used O
a O
pseudotype O
approach O
based O
on O
a O
recently O
developed O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
in O
which O
the O
gene O
for O
green O
fluorescent O
protein O
was O
substituted O
for O
the O
VSV O
G O
protein O
gene O
( O
VSV O
DeltaG O
* O
) O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
highly O
neurotropic O
virus O
that O
causes O
Borna O
disease O
, O
a O
virus O
- O
induced O
immune O
- O
mediated O
encephalomyelitis O
, O
in O
a O
variety O
of O
warm O
- O
blooded O
animals O
. O

Borna B
disease I
virus I
( I
BDV I
) I
belongs O
to O
the O
order O
Mononegavirales O
and O
replicates O
its O
RNA O
genome O
in O
the O
nucleus O
. O

Previous O
studies O
have O
suggested O
that O
BDV O
nucleoprotein B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
have O
important O
functions O
in O
the O
nuclear O
import O
of O
the O
viral O
ribonucleoprotein B
( I
RNP I
) I
complexes O
via O
their O
nuclear O
targeting O
activity O
. O

Here O
, O
we O
showed O
that O
BDV O
N O
has O
cytoplasmic O
localization O
activity O
, O
which O
is O
mediated O
by O
a O
nuclear B
export I
signal I
( I
NES I
) I
within O
the O
sequence O
. O

The O
RNA O
genome O
of O
Borna B
disease I
virus I
( I
BDV I
) I
shows O
extraordinary O
stability O
in O
persistently O
infected O
fell O
cultures O
, O
We O
performed O
bottleneck O
experiments O
in O
which O
virus O
populations O
from O
single O
infected O
cells O
were O
allowed O
to O
spread O
through O
cultures O
of O
uninfected O
cells O
and O
in O
which O
RNase O
protection O
assays O
were O
used O
to O
identify O
virus O
variants O
with O
mutations O
in O
a O
535 O
- O
nucleotide O
fragment O
of O
the O
M O
- O
G O
open O
reading O
frames O
, O
In O
one O
of O
the O
cell O
cultures O
, O
the O
major O
virus O
species O
( O
designated O
2 O
/ O
1 O
) O
was O
a O
variant O
with O
two O
point O
mutations O
in O
the O
G O
open O
reading O
frame O
. O

Borna B
disease I
virus I
( I
BDV I
) I
, O
the O
causative O
agent O
of O
severe O
meningoencephalitis O
in O
a O
wide O
variety O
of O
animal O
species O
, O
has O
been O
considered O
to O
be O
genetically O
invariable O
and O
to O
form O
a O
single O
type O
within O
the O
genus O
Bornavirus O
of O
the O
family O
Bornaviridae O
, O
BDV O
infections O
are O
of O
particular O
interest O
, O
because O
for O
the O
first O
time O
a O
virus O
infection O
appears O
to O
be O
linked O
to O
human O
psychiatric O
disorders O
. O

The O
nucleotide O
sequence O
of O
this O
new O
strain O
, O
named O
No O
/ O
98 O
, O
differs O
from O
the O
reference O
strains O
by O
more O
than O
15 O
% O
, O
and O
the O
subtype O
is O
difficult O
to O
detect O
by O
standard O
reverse O
transcriptase O
PCR O
protocols O
, O
The O
nucleotide O
exchanges O
of O
the O
novel O
BDV O
isolate O
have O
surprisingly O
little O
effect O
on O
the O
primary O
structures O
of O
most O
viral O
proteins O
, O
with O
the O
notable O
exception O
of O
the O
X O
protein O
( O
p10 O
) O
, O
which O
is O
only O
81 O
% O
identical O
to O
its O
counterpart O
in O
reference O
strains O
. O

The O
products O
of O
five O
open O
reading O
frames O
predicted O
from O
the O
genomic O
sequence O
have O
been O
confirmed O
; O
however O
, O
expression O
of O
the O
sixth O
, O
corresponding O
to O
the O
putative O
viral O
polymerase O
( O
L O
) O
, O
has O
not O
been O
demonstrated O
. O

Serological O
and O
molecular O
epidemiological O
studies O
indicate O
that O
Borna B
disease I
virus I
( I
BDV I
) I
can O
infect O
humans O
and O
is O
possibly O
associated O
with O
certain O
neuropsychiatric O
disorders O
. O

BDV O
RNA O
and O
antigen O
was O
detected O
in O
four O
brain O
regions O
of O
a O
BDV O
- O
seropositive O
schizophrenic O
patient O
( O
P2 O
) O
with O
a O
very O
recent O
( O
2 O
years O
) O
onset O
of O
disease O
. O

Human O
oligodendroglia O
( O
OL O
) O
cells O
inoculated O
with O
brain O
homogenates O
from O
BDV O
- O
positive O
gerbils O
allowed O
propagation O
and O
isolation O
of O
BDVHuP2br O
, O
a O
human O
brain O
- O
derived O
BDV O
Virus O
isolation O
was O
also O
possible O
by O
transfection O
of O
Vero O
cells O
with O
ribonucleoprotein O
complexes O
prepared O
from O
BDV O
- O
positive O
human O
and O
gerbil O
brain O
tissues O
. O

The O
Borna B
disease I
virus I
( I
BDV I
) I
is O
the O
prototype O
member O
of O
the O
Bornaviridae O
, O
and O
it O
replicates O
in O
the O
cell O
nucleus O
. O

The O
BDV O
p24P O
and O
p40N O
proteins O
carry O
nuclear B
localization I
signals I
( I
NLS I
) I
and O
are O
found O
in O
the O
nuclei O
of O
infected O
cells O
. O

Borna B
disease I
virus I
( I
BDV I
) I
infection O
of O
newborn O
rats O
leads O
to O
a O
persistent O
infection O
of O
the O
brain O
, O
which O
is O
associated O
with O
behavioral O
and O
neuroanatonomical O
abnormalities O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
neurotropic O
virus O
with O
a O
broad O
host O
and O
geographic O
range O
. O

Lewis O
rats O
were O
immunized O
against O
BDV O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
the O
BDV O
nucleoprotein O
and O
were O
later O
infected O
with O
BDV O
to O
evaluate O
protection O
against O
Borna B
disease I
( I
BD I
) I
. O

Borna B
disease I
virus I
( I
BDV I
) I
, O
a O
negative O
nonsegmented O
single O
- O
stranded O
RNA O
virus O
, O
has O
not O
been O
fully O
characterized O
morphologically O
. O

Borna B
disease I
virus I
( I
BDV I
) I
uses O
a O
unique O
strategy O
of O
replication O
and O
transcription O
which O
takes O
place O
in O
the O
nucleus O
, O
unlike O
other O
known O
, O
nonsegmented O
, O
negative O
- O
stranded O
RNA O
viruses O
of O
animal O
origin O
. O

This O
transportation O
is O
accomplished O
by O
its O
own O
nuclear B
localization I
signals I
( I
NLSs I
) I
, O
which O
are O
present O
in O
both O
N O
- O
terminal O
( O
29PRPRKIPR36 O
) O
and O
C O
- O
terminal O
( O
( O
181 O
) O
PPRIYPQLPSAPT O
( O
193 O
) O
) O
regions O
of O
the O
protein O
. O

Borna B
disease I
virus I
( I
BDV I
) I
p24 O
RNA O
was O
detected O
in O
the O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
psychiatric O
patients O
and O
blood O
donors O
by O
nested O
reverse B
transcriptase I
PCR I
( I
RT I
- I
PCR I
) I
. O

The O
prevalences O
of O
BDV O
p24 O
RNA O
in O
patients O
with O
mood O
disorders O
( O
4 O
% O
) O
and O
schizophrenia O
( O
4 O
% O
) O
were O
not O
significantly O
different O
from O
that O
in O
blood O
donors O
( O
2 O
% O
) O
. O

Borma O
disease O
virus O
( O
BDV O
) O
is O
a O
negative O
- O
strand O
RNA O
virus O
that O
infects O
the O
central B
nervous I
systems I
( I
CNS I
) I
of O
warm O
- O
blooded O
animals O
and O
causes O
disturbances O
of O
movement O
and O
behavior O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
neurotropic O
nonsegmented O
negative O
- O
strand O
RNA O
virus O
with O
limited O
homology O
to O
rhabdoviruses O
and O
paramyxoviruses O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
neurotropic O
nonsegmented O
negative O
- O
stranded O
RNA O
virus O
that O
persistently O
infects O
warm O
- O
blooded O
animals O
. O

Intracerebral O
infections O
of O
newborn O
beta O
2 O
- O
microglobulin O
- O
deficient O
C57BL O
/ O
6 O
and O
MRL O
mice O
, O
which O
both O
lack O
CD8 O
( O
+ O
) O
T O
cells O
, O
did O
not O
result O
in O
meningoencephalitis O
or O
neurological O
disease O
, O
indicating O
that O
the O
BDV O
- O
induced O
neurological O
disorder O
in O
mice O
is O
a O
cytotoxic O
T O
- O
cell O
- O
mediated O
immunopathological O
process O
. O

Open O
reading O
frame O
IV O
( O
ORF O
- O
IV O
) O
of O
Borna B
disease I
virus I
( I
BDV I
) I
encodes O
a O
protein O
with O
a O
calculated O
molecular O
mass O
of O
ca O
. O

57 O
kDa O
( O
p57 O
) O
, O
which O
increases O
after O
N O
glycosylation O
to O
94 O
kDa O
( O
gp94 O
) O
. O

Borna B
disease I
virus I
( I
BDV I
) I
, O
the O
prototype O
of O
a O
new O
family O
within O
the O
order O
Mononegavirales O
, O
is O
unusual O
in O
its O
nuclear O
localization O
for O
replication O
and O
transcription O
and O
use O
of O
RNA O
splicing O
for O
gene O
expression O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented B
negative I
- I
strand I
( I
NNS I
) I
RNA O
virus O
that O
is O
unusual O
because O
it O
replicates O
in O
the O
nucleus O
, O
The O
most O
abundant O
viral O
protein O
in O
infected O
cells O
is O
a O
38 O
/ O
39 O
- O
kDa O
doublet O
that O
is O
presumed O
to O
represent O
the O
nucleocapsid O
, O
Infectious O
particles O
also O
contain O
high O
levels O
of O
this O
protein O
, O
accounting O
for O
at O
least O
50 O
% O
of O
the O
viral O
proteins O
. O

The O
two O
forms O
of O
the O
protein O
differ O
by O
an O
additional O
13 O
amino O
acids O
that O
are O
present O
at O
the O
amino O
terminus O
of O
the O
39 O
- O
kDa O
form O
and O
missing O
from O
the O
38 O
- O
kDa O
form O
, O
To O
examine O
whether O
this O
difference O
in O
amino O
acid O
content O
affects O
the O
localization O
of O
this O
protein O
in O
cells O
, O
the O
39 O
- O
and O
38 O
- O
kDa O
proteins O
were O
expressed O
in O
transfected O
cells O
, O
The O
39 O
- O
kDa O
form O
was O
concentrated O
in O
the O
nucleus O
, O
whereas O
the O
38 O
- O
kDa O
form O
was O
found O
in O
both O
the O
nucleus O
and O
cytoplasm O
, O
Inspection O
of O
the O
extra O
13 O
amino O
acids O
present O
in O
the O
39 O
- O
kDa O
form O
revealed O
a O
sequence O
( O
Pro O
- O
Lys O
- O
Arg O
- O
Arg O
) O
that O
is O
very O
similar O
to O
the O
nuclear O
localization O
signals O
( O
in O
both O
sequence O
homology O
and O
amino O
- O
terminal O
location O
) O
of O
the O
VP1 O
proteins O
of O
simian O
virus O
40 O
and O
polyomavirus O
. O

The O
Borna O
disease O
virus O
antigenome O
includes O
five O
major O
open B
reading I
frames I
( I
ORFs I
) I
which O
encode O
, O
from O
5 O
' O
to O
3 O
' O
, O
the O
putative O
nucleoprotein B
( I
N I
) I
, O
the O
phosphoprotein B
( I
P I
) I
, O
the O
putative O
matrix B
protein I
( I
M I
) I
, O
the O
major O
glycoprotein B
( I
G I
) I
, O
and O
the O
RNA O
- O
dependent O
RNA O
Polymerase B
( I
Pol I
) I
. O

Expression O
of O
the O
M O
, O
G O
, O
and O
pol O
ORFs O
is O
dependent O
upon O
differential O
splicing O
of O
two O
introns O
( O
intron O
1 O
, O
94 O
nucleotides O
[ O
nt O
] O
; O
intron O
2 O
, O
1 O
, O
294 O
nt O
) O
. O

Cell O
populations O
were O
characterized O
by O
cytofluorometry O
, O
with O
special O
emphasis O
on O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cells O
. O

CD8 O
( O
+ O
) O
T O
cells O
were O
found O
in O
the O
parenchyma O
, O
whereas O
CD4 O
( O
+ O
) O
T O
cells O
were O
found O
predominantly O
in O
perivascular O
locations O
. O

Evidence O
that O
the O
immunopathology O
of O
Borna O
disease O
is O
closely O
related O
to O
the O
presence O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
brain O
parenchyma O
is O
provided O
. O

The O
Borna B
disease I
virus I
( I
BDV I
) I
antigenome O
is O
comprised O
of O
five O
major O
open B
reading I
frames I
( I
ORFs I
) I
. O

Products O
have O
been O
reported O
only O
for O
ORFs O
I O
, O
II O
, O
and O
III O
, O
encoding O
N O
( O
p40 O
) O
, O
P O
( O
p24 O
/ O
p23 O
) O
, O
and O
M O
( O
gp18 O
) O
, O
respectively O
, O
ORF O
IV O
predicts O
a O
57 O
- O
kDa O
protein O
with O
several O
potential O
glycosylation O
sites O
, O
Analysis O
of O
radiolabeled O
extracts O
from O
BDV O
- O
infected O
C6 O
cells O
and O
BHK O
- O
21 O
cells O
transfected O
with O
a O
Semliki O
Forest O
virus O
vector O
that O
contains O
ORF O
IV O
demonstrated O
the O
presence O
of O
a O
94 O
- O
kDa O
protein O
( O
G O
protein O
) O
which O
was O
sensitive O
to O
tunicamycin O
, O
endoglycosidase O
F O
/ O
N O
- O
glycosidase O
, O
and O
endoglycosidase O
H O
but O
not O
to O
O O
- O
glycosidase O
. O

In O
several O
vertebrate O
species O
, O
Borna B
disease I
virus I
( I
BDV I
) I
, O
the O
prototype O
of O
a O
new O
group O
of O
animal O
viruses O
, O
causes O
central O
nervous O
system O
disease O
accompanied O
by O
diverse O
behavioral O
abnormalities O
. O

This O
hypothesis O
is O
further O
supported O
by O
the O
detection O
of O
both O
BDV O
antigens O
and O
BDV O
RNA O
in O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
patients O
with O
psychiatric O
disorders O
and O
the O
isolation O
of O
BDV O
from O
such O
PBMCs O
. O

Using O
a O
novel O
Western O
blot O
( O
immunoblot O
) O
assay O
, O
we O
found O
a O
BDV O
seroprevalence O
of O
9 O
. O

Persistent O
tolerant O
infection O
of O
rats O
with O
Borna B
disease I
virus I
( I
BDV I
) I
results O
in O
a O
central B
nervous I
system I
( I
CNS I
) I
disease O
characterized O
by O
behavioral O
abnormalities O
. O

Previously O
, O
we O
have O
shown O
that O
astrocytes O
in O
the O
CNS O
express O
tissue B
factor I
( I
TF I
) I
. O

A O
cDNA O
fragment O
of O
the O
Borna B
disease I
virus I
( I
BDV I
) I
open I
reading I
frame I
II I
( I
ORF I
- I
II I
) I
, O
which O
encodes O
a O
24 O
- O
kDa O
phosphoprotein O
( O
p24 O
[ O
P O
protein O
] O
) O
, O
was O
amplified O
from O
total O
RNA O
of O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
three O
psychiatric O
inpatients O
. O

Borna O
disease O
is O
an O
immunopathological O
virus O
- O
induced O
encephalopathy O
comprising O
severe O
inflammation O
and O
degenerative O
brain O
cell O
lesions O
which O
results O
in O
organ O
atrophy O
and O
chronic O
debility O
in O
rats O
, O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cells O
have O
been O
reported O
to O
be O
involved O
in O
the O
development O
of O
this O
disease O
of O
the O
central O
nervous O
system O
, O
A O
virus O
- O
specific O
homogeneous O
T O
- O
cell O
line O
, O
established O
in O
vitro O
after O
immunization O
of O
rats O
with O
the O
recombinant O
24 O
- O
kDa O
virus O
- O
specific O
protein O
, O
showed O
antigen O
- O
specific O
proliferation O
in O
the O
presence O
of O
the O
24 O
- O
kDa O
but O
not O
the O
38 O
- O
kDa O
Borna O
disease O
virus O
- O
specific O
protein O
, O
another O
major O
virus O
- O
specific O
antigen O
, O
This O
T O
- O
cell O
line O
, O
P205 O
, O
was O
found O
to O
exhibit O
characteristics O
of O
a O
T O
- O
helper O
cell O
: O
CD4 O
( O
+ O
) O
CD8 O
( O
- O
) O
IL O
- O
2 O
( O
- O
) O
IL O
- O
4 O
( O
- O
) O
IFN O
- O
gamma O
( O
+ O
) O
IL O
- O
6 O
( O
+ O
) O
IL O
- O
10 O
( O
+ O
) O
. O

Furthermore O
, O
this O
T O
- O
cell O
line O
expressed O
the O
alpha O
/ O
beta O
T O
cell O
receptor O
and O
the O
alpha O
4 O
integrin O
( O
VLA O
- O
4 O
) O
, O
Adoptive O
transfer O
of O
this O
helper O
cell O
resulted O
in O
an O
increase O
of O
antibody O
titers O
and O
two O
different O
types O
of O
disease O
in O
virus O
- O
infected O
rats O
after O
cyclophosphamide O
induced O
immunosuppression O
, O
( O
i O
) O
Rats O
receiving O
T O
- O
cells O
between O
10 O
and O
18 O
days O
after O
treatment O
with O
cyclophosphamide O
showed O
an O
acute O
lymphoproliferative O
disease O
in O
the O
gut O
and O
lungs O
within O
9 O
days O
after O
adoptive O
transfer O
and O
died O
, O
( O
ii O
) O
Passive O
transfer O
within O
the O
first O
5 O
days O
after O
immunosuppressive O
treatment O
resulted O
in O
typical O
Borna O
disease O
associated O
with O
neurological O
symptoms O
such O
as O
ataxia O
and O
paresis O
starting O
14 O
to O
16 O
days O
after O
transfer O
, O
Immunohistological O
analysis O
of O
the O
brains O
of O
rats O
with O
Borna O
disease O
uniformly O
revealed O
the O
presence O
of O
CD8 O
( O
+ O
) O
T O
- O
cells O
in O
encephalitic O
lesions O
in O
addition O
to O
CD4 O
( O
+ O
) O
cells O
that O
were O
found O
in O
the O
brains O
of O
recipients O
of O
the O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
line O
, O
irrespective O
of O
whether O
neurological O
symptoms O
developed O
or O
not O
, O
However O
, O
recipient O
rats O
treated O
with O
antibodies O
against O
CD8 O
( O
+ O
) O
T O
- O
cells O
developed O
neither O
encephalitis O
nor O
disease O
, O
Therefore O
, O
CD4 O
( O
+ O
) O
T O
cells O
appear O
to O
accumulate O
in O
the O
brain O
and O
cause O
perivascular O
inflammatory O
lesions O
which O
alone O
obviously O
do O
not O
cause O
disease O
. O

In O
contrast O
, O
the O
presence O
of O
CD8 O
( O
+ O
) O
cells O
apparently O
directly O
correlates O
with O
the O
development O
of O
neurological O
symptoms O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
strand O
RNA O
virus O
that O
causes O
neurologic O
disorders O
in O
a O
wide O
range O
of O
animal O
species O
. O

22 O
g O
/ O
cm O
( O
3 O
) O
) O
in O
CsCl O
contains O
90 O
- O
nm O
particles O
which O
appear O
to O
be O
enveloped O
and O
a O
fraction O
of O
50 O
- O
to O
60 O
- O
nm O
particles O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
strand O
RNA O
virus O
related O
to O
rhabdoviruses O
and O
paramyxoviruses O
. O

Borna B
disease I
virus I
( I
BDV I
) I
causes O
neurological O
disease O
in O
a O
wide O
range O
of O
animal O
species O
, O
providing O
an O
important O
model O
for O
studies O
of O
persistent O
viral O
infection O
of O
the O
central O
nervous O
system O
. O

The O
highest O
variability O
in O
sequence O
( O
10 O
% O
) O
was O
found O
in O
a O
40 O
- O
nucleotide O
stretch O
of O
genomic O
RNA O
between O
coding O
sequences O
for O
the O
40 O
- O
and O
24 O
- O
kDa O
proteins O
. O

We O
report O
the O
sequence O
of O
a O
Borna O
disease O
virus O
clone O
( O
pBDV O
- O
40 O
) O
that O
encodes O
a O
40 O
- O
kDa O
protein O
( O
p40 O
) O
found O
in O
the O
nuclei O
of O
infected O
cells O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
highly O
virulent O
in O
adult O
laboratory O
mice O
, O
while O
Sindbis B
virus I
( I
SINV I
) I
is O
avirulent O
regardless O
of O
dose O
or O
inoculation O
route O
, O
dependent O
upon O
functioning O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
responses O
. O

Postinfection O
IFN O
- O
alpha O
/ O
beta O
treatment O
revealed O
that O
phosphorylation O
of O
STAT1 O
and O
STAT2 O
was O
partially O
blocked O
by O
infection O
with O
either O
virus O
, O
dependent O
upon O
expression O
of O
nonstructural B
proteins I
( I
nsp I
) I
, O
but O
not O
structural B
proteins I
( I
sP I
) I
. O

However O
, O
inhibition O
of O
STAT O
phosphorylation O
by O
VEEV O
replicons O
was O
not O
correlated O
with O
inhibition O
of O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
mRNA O
induction O
, O
yet O
ISG O
induction O
was O
inhibited O
when O
sP O
were O
present O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
an O
enveloped O
, O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
virus O
belonging O
to O
the O
Flaviviridae O
family O
. O

The O
first O
corresponds O
to O
a O
5 O
' O
- O
end O
- O
dependent O
, O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
independent O
mechanism O
, O
while O
the O
second O
relies O
on O
IRES O
- O
dependent O
initiation O
. O

The O
results O
show O
that O
the O
DENV O
IRES O
is O
functional O
in O
the O
rabbit B
reticulocyte I
lysate I
( I
RRL I
) I
. O

In O
accordance O
, O
the O
activity O
of O
the O
DENV O
IRES O
was O
resistant O
to O
the O
cleavage O
of O
eukaryotic B
initiation I
factor I
4G I
( I
eIF4G I
) I
by O
the O
Foot O
- O
and O
- O
mouth O
disease O
virus O
leader O
protease O
in O
RRL O
In O
cells O
, O
the O
DENV O
IRES O
exhibited O
only O
marginal O
activity O
under O
standard O
culture O
conditions O
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
, O
the O
etiological O
agent O
of O
dengue O
, O
a O
febrile O
and O
hemorrhagic O
disease O
, O
infects O
millions O
of O
people O
per O
year O
in O
tropical O
and O
subtropical O
countries O
. O

In O
this O
study O
, O
we O
characterize O
the O
mechanism O
dependent O
on O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

Dengue B
Virus I
( I
DENV I
) I
is O
a O
mosquito O
- O
borne O
virus O
that O
infects O
upward O
of O
300 O
million O
people O
annually O
and O
has O
the O
potential O
to O
cause O
fatal O
hemorrhagic O
fever O
and O
shock O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
the O
accumulation O
of O
reactive B
oxygen I
species I
( I
ROS I
) I
late O
after O
DENV O
infection O
( O
> O
24 O
hpi O
) O
resulted O
from O
a O
disruption O
in O
the O
balance O
between O
oxidative O
stress O
and O
the O
nuclear B
factor I
erythroid I
2 I
- I
related I
factor I
2 I
( I
Nrf2 I
) I
- O
dependent O
antioxidant O
response O
. O

By O
24 O
hpi O
, O
when O
increased O
levels O
of O
ROS O
and O
antiviral O
proteins O
were O
observed O
, O
it O
appeared O
that O
the O
proviral O
effect O
of O
ROS O
overcame O
the O
antiviral O
effects O
of O
the O
interferon B
( I
IFN I
) I
response O
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
is O
a O
mosquito O
- O
borne O
pathogen O
that O
threatens O
2 O
. O

yellow B
fever I
virus I
( I
YFV I
) I
is O
an O
RNA O
virus O
primarily O
targeting O
the O
liver O
. O

pathogen B
recognition I
receptors I
( I
PRRs I
) I
, O
such O
as O
the O
cytoplasmic O
retinoic B
acid I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
like O
receptors O
( O
RLRs O
) O
, O
and O
the O
viral O
RNA O
sensor O
protein B
kinase I
R I
( I
PKR I
) I
, O
are O
known O
to O
initiate O
a O
proinflammatory O
response O
upon O
recognition O
of O
viral O
genomes O
. O

However O
, O
stress O
granule O
disruption O
did O
not O
affect O
the O
cytokine O
response O
to O
YFV O
infection O
, O
as O
assessed O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
knockdown O
- O
mediated O
inhibition O
of O
stress O
granule O
assembly O
. O

IMPORTANCE O
Yellow O
fever O
is O
a O
mosquito O
- O
borne O
acute O
hemorrhagic O
disease O
caused O
by O
yellow B
fever I
virus I
( I
YFV I
) I
. O

Dengue B
Virus I
( I
DENV I
) I
infection O
causes O
serious O
clinical O
symptoms O
, O
including O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
and O
dengue B
shock I
syndrome I
( I
DSS I
) I
. O

Here O
, O
we O
reveal O
a O
distinct O
mechanism O
by O
which O
DENV O
infection O
promotes O
NLRP3 O
inflammasome O
activation O
and O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
release O
to O
induce O
endothelial O
permeability O
and O
vascular O
leakage O
in O
mice O
. O

More O
importantly O
, O
inflammatory O
cell O
infiltration O
and O
tissue O
injuries O
are O
induced O
by O
M O
in O
wild B
- I
type I
( I
WT I
) I
mouse O
tissues O
, O
but O
they O
are O
not O
affected O
by O
M O
in O
NLRP3 O
knockout O
( O
NLRP3 O
( O
- O
/ O
- O
) O
) O
mouse O
tissues O
. O

Evans O
blue O
intensities O
in O
WT O
mouse O
tissues O
are O
significantly O
higher O
than O
in O
NLRP3 O
( O
- O
/ O
- O
) O
mouse O
tissues O
, O
demonstrating O
an O
essential O
role O
of O
NLRP3 O
in O
M O
- O
induced O
vascular O
leakages O
in O
mice O
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
is O
a O
mosquito O
- O
borne O
pathogen O
, O
and O
infections O
by O
this O
virus O
are O
prevalent O
in O
over O
100 O
tropical O
and O
subtropical O
countries O
or O
regions O
, O
with O
approximately O
2 O
. O

DENV O
infection O
induces O
a O
spectrum O
of O
clinical O
symptoms O
, O
ranging O
from O
classical O
dengue B
fever I
( I
DF I
) I
to O
severe O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
and O
dengue B
shock I
syndrome I
( I
DSS I
) I
. O

In O
this O
study O
, O
we O
reveal O
that O
the O
DENV O
membrane B
protein I
( I
M I
) I
interacts O
with O
the O
host O
NLRP3 O
protein O
to O
promote O
NLRP3 O
inflammasome O
activation O
, O
which O
leads O
to O
the O
activation O
and O
release O
of O
a O
proinflammatory O
cytokine O
, O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
. O

In O
this O
study O
, O
we O
focused O
on O
bluetongue B
virus I
( I
BTV I
) I
, O
the O
causative O
agent O
of O
bluetongue O
and O
one O
of O
the O
major O
arboviruses O
of O
ruminants O
. O

Importantly O
, O
testicular O
degeneration O
was O
induced O
in O
rams O
experimentally O
infected O
with O
either O
a O
high O
( O
BTV O
- O
1 O
( O
IT2006 O
) O
) O
- O
or O
a O
low O
( O
BTV O
- O
1 O
( O
IT2013 O
) O
) O
- O
virulence O
strain O
of O
BTV O
. O

Here O
, O
we O
studied O
bluetongue B
virus I
( I
BTV I
) I
, O
an O
arbovirus O
of O
ruminants O
, O
and O
its O
effects O
on O
the O
testes O
of O
rams O
. O

Testicular O
degeneration O
was O
caused O
by O
BTV O
replication O
in O
the O
endothelial O
cells O
of O
the O
peritubular O
area O
surrounding O
the O
seminiferous O
tubules O
( O
the O
functional O
unit O
of O
the O
testes O
) O
and O
was O
associated O
with O
a O
localized O
type O
I O
interferon O
response O
, O
destruction O
of O
the O
cells O
supporting O
the O
developing O
germinal O
cells O
( O
Sertoli O
cells O
) O
, O
and O
reduction O
of O
testosterone O
synthesis O
. O

Here O
we O
describe O
the O
construction O
, O
immunogenicity O
, O
and O
preliminary O
information O
on O
the O
protective O
capacity O
of O
recombinant O
, O
replication B
- I
competent I
rhesus I
monkey I
rhadinovirus I
( I
RRV I
) I
, O
a O
persisting O
herpesvirus O
. O

One O
RRV O
construct O
expressed O
nonstructural B
protein I
5 I
( I
NS5 I
) I
, O
while O
a O
second O
recombinant O
expressed O
a O
soluble O
variant O
of O
the O
E O
protein O
( O
E85 O
) O
of O
dengue B
virus I
2 I
( I
DENV2 I
) I
. O

Four O
rhesus O
macaques O
received O
a O
single O
vaccination O
with O
a O
mixture O
of O
both O
recombinant O
RRVs O
and O
were O
subsequently O
challenged O
19 O
weeks O
later O
with O
1 O
x O
10 O
( O
5 O
) O
PFU O
of O
DENV2 O
. O

Cellular O
immune O
responses O
against O
NS5 O
were O
also O
elicited O
, O
as O
evidenced O
by O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
tetramer O
staining O
in O
the O
one O
vaccinated O
monkey O
that O
was O
Mamu O
- O
A O
* O
01 O
positive O
. O

IMPORTANCE O
Continuing O
studies O
of O
vaccine O
approaches O
against O
Dengue B
Virus I
( I
DENV I
) I
infection O
are O
warranted O
, O
particularly O
ones O
that O
may O
provide O
long O
- O
term O
immunity O
against O
all O
four O
serotypes O
. O

Here O
we O
investigated O
whether O
recombinant O
Rhesus B
monkey I
rhadinovirus I
( I
RRV I
) I
could O
be O
used O
as O
a O
vaccine O
against O
DENV2 O
infection O
in O
rhesus O
monkeys O
. O

Mammarenaviruses O
are O
enveloped O
viruses O
with O
a O
bisegmented O
negativestranded O
RNA O
genome O
that O
encodes O
the O
nucleocapsid B
protein I
( I
NP I
) I
, O
the O
envelope O
glycoprotein B
precursor I
( I
GPC I
) I
, O
the O
RNA O
polymerase O
( O
L O
) O
, O
and O
a O
RING O
matrix O
protein O
( O
Z O
) O
. O

Viral O
proteins O
are O
synthesized O
from O
subgenomic O
mRNAs O
bearing O
a O
capped O
5 B
' I
untranslated I
region I
( I
UTR I
) I
and O
lacking O
3 O
' O
poly O
( O
A O
) O
tail O
. O

We O
analyzed O
the O
translation O
strategy O
of O
Tacaribe B
virus I
( I
TCRV I
) I
, O
a O
prototype O
of O
the O
New O
World O
mammarenaviruses O
. O

Additionally O
, O
translation O
was O
profoundly O
reduced O
in O
eukaryotic B
initiation I
factor I
( I
eIF I
) I
4G O
- O
inactivated O
cells O
, O
whereas O
depletion O
of O
intracellular O
levels O
of O
eIF4E O
had O
less O
impact O
on O
virus O
- O
like O
mRNA O
translation O
than O
on O
a O
cell O
- O
like O
transcript O
. O

stem B
- I
loop I
A I
( I
SLA I
) I
, O
a O
part O
of O
the O
viral O
5 B
' I
untranslated I
region I
( I
UTR I
) I
, O
is O
critical O
for O
the O
initiation O
of O
dengue O
virus O
replication O
, O
but O
quantitative O
analysis O
of O
the O
interactions O
between O
the O
dengue O
virus O
polymerase O
NS5 O
and O
SLA O
in O
solution O
has O
not O
been O
performed O
. O

Additionally O
, O
data O
from O
a O
competition O
assay O
between O
SLA O
and O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
indicate O
that O
SLA O
competes O
with O
ssRNA O
for O
the O
same O
binding O
site O
on O
the O
NS5 O
polymerase O
. O

SLA O
( O
70 O
) O
and O
SLA O
( O
80 O
) O
, O
which O
contain O
the O
first O
70 O
and O
80 O
nucleotides B
( I
nt I
) I
, O
respectively O
, O
bind O
NS5 O
with O
similar O
binding O
affinities O
. O

In O
particular O
, O
stem B
- I
loop I
A I
( I
SLA I
) I
and O
stem B
- I
loop I
B I
( I
SLB I
) I
located O
in O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
are O
critical O
for O
binding O
the O
viral O
polymerase O
NS5 O
to O
initiate O
minus O
- O
strand O
RNA O
synthesis O
. O

The O
four O
Dengue B
Virus I
( I
DENV I
) I
serotypes O
are O
mosquito O
- O
borne O
flaviviruses O
responsible O
for O
dengue O
fever O
and O
dengue O
hemorrhagic O
fever O
. O

People O
exposed O
to O
DENV O
develop O
antibodies B
( I
Abs I
) I
that O
strongly O
neutralize O
the O
serotype O
responsible O
for O
infection O
. O

Historically O
, O
infection O
with O
DENV B
serotype I
4 I
( I
DENV4 I
) I
has O
been O
less O
common O
and O
less O
studied O
than O
infections O
with O
the O
other O
three O
serotypes O
. O

Two O
human B
monoclonal I
antibodies I
( I
MAbs I
) I
that O
neutralized O
DENV4 O
were O
isolated O
, O
and O
their O
epitopes O
were O
finely O
mapped O
using O
recombinant O
viruses O
and O
alanine O
scan O
mutation O
array O
techniques O
. O

Both O
antibodies O
bound O
to O
quaternary O
structure O
epitopes O
near O
the O
hinge O
region O
between O
envelope O
protein O
domain O
I O
( O
EDI O
) O
and O
EDII O
. O

We O
and O
others O
have O
defined O
antigenic O
sites O
on O
the O
envelope B
( I
E I
) I
protein O
of O
viruses O
of O
dengue O
virus O
serotypes O
1 O
, O
2 O
, O
and O
3 O
targeted O
by O
human O
neutralizing O
antibodies O
. O

Here O
, O
we O
provide O
a O
detailed O
analysis O
of O
HLA O
- O
DR O
+ O
CD38 O
( O
+ O
) O
and O
HLA O
- O
DR O
- O
CD38 O
( O
+ O
) O
effector O
CD8 O
T O
cell O
subsets O
in O
dengue O
patients O
from O
India O
and O
Thailand O
. O

Both O
CD8 O
T O
cell O
subsets O
expanded O
and O
expressed O
markers O
indicative O
of O
antigen O
- O
driven O
proliferation O
, O
tissue O
homing O
, O
and O
cytotoxic O
effector O
functions O
, O
with O
the O
HLA O
- O
DR O
+ O
CD38 O
( O
+ O
) O
subset O
being O
the O
most O
striking O
in O
these O
effector O
qualities O
. O

Interestingly O
, O
only O
a O
small O
fraction O
of O
these O
activated O
effector O
CD8 O
T O
cells O
produced O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
when O
stimulated O
with O
dengue O
virus O
peptide O
pools O
. O

Transcriptomics O
revealed O
downregulation O
of O
key O
molecules O
involved O
in O
T B
cell I
receptor I
( I
TCR I
) I
signaling O
. O

Consistent O
with O
this O
, O
the O
majority O
of O
these O
CD8 O
T O
cells O
remained O
IFN O
- O
gamma O
unresponsive O
even O
after O
TCR O
- O
dependent O
polyclonal O
stimulation O
( O
anti O
- O
CD3 O
plus O
anti O
- O
CD28 O
) O
but O
produced O
IFN O
- O
gamma O
by O
TCR O
- O
independent O
polyclonal O
stimulation O
( O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
[ O
PMA O
] O
plus O
ionomycin O
) O
. O

Interestingly O
, O
the O
cells O
were O
fully O
capable O
of O
producing O
the O
cytokine O
when O
stimulated O
in O
a O
T B
cell I
receptor I
( I
TCR I
) I
- O
independent O
manner O
but O
failed O
to O
do O
so O
in O
TCR O
- O
dependent O
stimulation O
. O

To O
gain O
statistical O
power O
, O
we O
used O
innovative O
paired O
multivariate O
analyses O
to O
discriminate O
individuals O
with O
primary O
and O
secondary O
infection O
presenting O
as O
dengue O
fever O
( O
DF O
; O
mild O
) O
and O
dengue O
hemorrhagic O
fever O
( O
DHF O
; O
severe O
) O
and O
subjects O
with O
a O
nonspecific O
nondengue O
( O
ND O
) O
illness O
( O
ND O
subjects O
) O
. O

Our O
results O
showed O
that O
a O
decrease O
in O
plasma O
low B
- I
density I
lipoprotein I
( I
LDL I
) I
and O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
discriminated O
Dengue B
Virus I
( I
DENV I
) I
- O
infected O
subjects O
from O
ND O
subjects O
, O
and O
also O
, O
subjects O
with O
severe O
infection O
even O
presented O
a O
decrease O
in O
lipoprotein O
concentrations O
compared O
to O
the O
concentrations O
in O
subjects O
with O
mild O
infection O
. O

While O
studying O
the O
potential O
role O
of O
the O
actin O
network O
and O
one O
of O
its O
master O
regulators O
, O
the O
small O
GTPase O
Cdc42 O
, O
during O
Junin B
virus I
( I
JUNV I
) I
entry O
, O
we O
serendipitously O
uncovered O
the O
small O
molecule O
ZCL278 O
, O
reported O
to O
inhibit O
Cdc42 O
function O
as O
an O
entry O
inhibitor O
for O
JUNV O
and O
for O
vesicular O
stomatitis O
virus O
, O
lymphocytic O
choriomeningitis O
virus O
, O
and O
dengue O
virus O
but O
not O
for O
the O
nonenveloped O
poliovirus O
. O

We O
also O
identified O
SVG O
- O
A O
astroglial O
cell O
- O
derived O
cells O
to O
be O
highly O
permissive O
for O
JUNV O
infection O
and O
generated O
new O
cell O
lines O
expressing O
fluorescently O
tagged O
Rab5c O
or O
Rab7a O
or O
lacking O
Cdc42 O
using O
clustered B
regularly I
interspaced I
short I
palindromic I
repeat I
( I
CRISPR I
) I
- O
caspase B
9 I
( I
Cas9 I
) I
gene O
- O
editing O
strategies O
. O

The O
four O
serotypes O
of O
Dengue B
Virus I
( I
DENV I
) I
cause O
the O
most O
important O
and O
rapidly O
emerging O
arboviral O
diseases O
in O
humans O
. O

Certain O
type B
- I
specific I
( I
TS I
) I
antibodies O
were O
recently O
discovered O
to O
account O
for O
the O
monotypic O
neutralizing O
activity O
and O
protection O
after O
primaryDENVinfection O
. O

Using O
a O
two O
- O
step O
depletion O
protocol O
to O
remove O
different O
anti O
- O
envelope O
antibodies O
, O
including O
group B
- I
reactive I
( I
GR I
) I
and O
complex B
- I
reactive I
( I
CR I
) I
antibodies O
separately O
, O
we O
foundGRand O
CR O
antibodies O
together O
contributed O
to O
more O
than O
50 O
% O
of O
neutralizing O
activities O
against O
multiple O
serotypes O
after O
secondary O
immunization O
. O

IMPORTANCE O
The O
four O
serotypes O
of O
Dengue B
Virus I
( I
DENV I
) I
are O
the O
leading O
cause O
of O
arboviral O
diseases O
in O
humans O
. O

Wefound O
anti O
- O
envelope O
antibodies O
consist O
of O
group B
- I
reactive I
( I
GR I
) I
, O
complex B
- I
reactive I
( I
CR I
) I
, O
and O
type B
- I
specific I
( I
TS I
) I
antibodies O
, O
and O
that O
bothGRand O
CR O
antibodies O
contribute O
significantly O
to O
multitypic O
neutralizing O
activities O
after O
secondaryDENVimmunization O
. O

Shedding O
of O
microparticles B
( I
MPs I
) I
is O
a O
consequence O
of O
apoptotic O
cell O
death O
and O
cellular O
activation O
. O

Herein O
, O
we O
investigated O
the O
role O
of O
MPs O
in O
Dengue B
Virus I
( I
DENV I
) I
infection O
. O

These O
MPs O
harbored O
a O
viral O
envelope O
protein O
and O
a O
nonstructural B
protein I
1 I
( I
NS1 I
) I
on O
their O
surfaces O
. O

Elevated O
levels O
of O
red B
blood I
cell I
- I
derived I
MPs I
( I
RMPs I
) I
directly O
correlated O
with O
DENV O
disease O
severity O
, O
whereas O
a O
significant O
decrease O
in O
platelet O
- O
derived O
MPs O
was O
associated O
with O
a O
bleeding O
tendency O
. O

Dengue B
Virus I
( I
DENV I
) I
infection O
, O
like O
some O
other O
medical O
conditions O
, O
changes O
the O
level O
and O
composition O
of O
microparticles B
( I
MPs I
) I
, O
tiny O
bag O
- O
like O
structures O
which O
are O
normally O
present O
at O
low O
levels O
in O
the O
blood O
of O
healthy O
individuals O
. O

Decreased O
platelet O
- O
derived O
MPs O
were O
associated O
with O
a O
bleeding O
tendency O
, O
while O
increased O
levels O
of O
red B
blood I
cell I
- I
derived I
MPs I
( I
RMPs I
) I
correlated O
with O
more O
severe O
disease O
. O

The O
mosquito O
- O
borne O
disease O
dengue B
( I
DEN I
) I
is O
caused O
by O
four O
serologically O
and O
genetically O
related O
viruses O
, O
termed O
DENV O
- O
1 O
to O
DENV O
- O
4 O
. O

The O
lack O
of O
a O
small O
- O
animal O
model O
that O
mimics O
systemic O
DEN O
disease O
without O
neurovirulence O
has O
been O
an O
obstacle O
, O
but O
DENV O
- O
2 O
models O
that O
resemble O
human O
disease O
have O
been O
recently O
developed O
in O
AG129 O
mice O
( O
deficient O
in O
interferon O
alpha O
/ O
beta O
and O
interferon O
gamma O
receptor O
signaling O
) O
. O

IMPORTANCE O
dengue B
( I
DEN I
) I
is O
a O
mosquito O
- O
borne O
disease O
caused O
by O
four O
DENV O
serotypes O
( O
DENV O
- O
1 O
, O
- O
2 O
, O
- O
3 O
, O
and O
- O
4 O
) O
that O
have O
no O
treatments O
or O
vaccines O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
causative O
agent O
of O
dengue B
fever I
( I
DF I
) I
. O

This O
disease O
can O
be O
caused O
by O
any O
of O
four O
DENV O
serotypes O
( O
DENV1 O
to O
- O
4 O
) O
which O
share O
67 O
to O
75 O
% O
sequence O
homology O
with O
one O
another O
. O

We O
utilized O
mice O
transgenic O
for O
human B
leukocyte I
antigens I
( I
HLA I
) I
lacking O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptor O
to O
study O
responses O
to O
heterologous O
DENV O
infection O
. O

Disease O
can O
be O
caused O
by O
any O
of O
the O
four O
DENV O
serotypes O
( O
DENV1 O
to O
- O
4 O
) O
, O
which O
share O
a O
high O
degree O
of O
sequence O
homology O
with O
one O
another O
. O

The O
causative O
agent O
of O
dengue O
fever O
, O
Dengue B
Virus I
( I
DENV I
) I
, O
is O
transmitted O
by O
mosquitoes O
, O
and O
as O
distribution O
of O
these O
insects O
has O
expanded O
, O
so O
has O
dengue O
- O
related O
disease O
. O

DENV O
is O
a O
member O
of O
the O
Flaviviridae O
family O
and O
has O
4 O
distinct O
serotypes O
( O
DENV O
- O
1 O
, O
- O
2 O
, O
- O
3 O
, O
and O
- O
4 O
) O
. O

host B
range I
( I
HR I
) I
mutants O
of O
each O
DENV O
serotype O
were O
created O
by O
truncating O
transmembrane O
domain O
1 O
of O
the O
E O
protein O
and O
selecting O
for O
strains O
of O
DENV O
that O
replicated O
well O
in O
insect O
cells O
but O
not O
mammalian O
cells O
. O

These O
vaccine O
strains O
were O
tested O
for O
immunogenicity O
in O
African B
green I
monkeys I
( I
AGMs I
) I
. O

The O
vaccine O
strains O
were O
confirmed O
to O
be O
attenuated O
in O
vivo O
by O
infectious B
center I
assay I
( I
ICA I
) I
. O

Analysis O
by O
50 B
% I
plaque I
reduction I
neutralization I
test I
( I
PRNT50 I
) I
established O
that O
by O
day O
62 O
postvaccination O
, O
100 O
% O
of O
animals O
seroconverted O
to O
DENV O
- O
1 O
, O
- O
2 O
, O
- O
3 O
, O
and O
- O
4 O
. O

Additionally O
, O
the O
DENV O
HR B
tetravalent I
vaccine I
( I
HR I
- I
Tet I
) I
showed O
a O
tetravalent O
anamnestic O
immune O
response O
in O
100 O
% O
( O
16 O
/ O
16 O
) O
of O
AGMs O
after O
challenge O
with O
wild B
- I
type I
( I
WT I
) I
DENV O
strains O
. O

Dengue B
Virus I
( I
DENV I
) I
, O
a O
mosquito O
- O
borne O
virus O
, O
is O
responsible O
for O
millions O
of O
cases O
of O
infections O
worldwide O
. O

There O
are O
four O
DENV O
serotypes O
( O
DENV1 O
to O
- O
4 O
) O
. O

However O
, O
in O
a O
secondary O
infection O
with O
another O
serotype O
, O
the O
preexisting O
antibodies O
may O
cause O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
infection O
of O
macrophage O
cells O
, O
leading O
to O
the O
development O
of O
the O
more O
severe O
form O
of O
disease O
, O
dengue O
hemorrhagic O
fever O
. O

Here O
we O
present O
a O
near O
- O
atomic O
resolution O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structure O
of O
mature O
DENV4 O
. O

Severe B
dengue I
( I
SD I
) I
is O
a O
life O
- O
threatening O
complication O
of O
dengue O
that O
includes O
vascular O
permeability O
syndrome O
( O
VPS O
) O
and O
respiratory O
distress O
. O

Secondary O
infections O
are O
considered O
a O
risk O
factor O
for O
developing O
SD O
, O
presumably O
through O
a O
mechanism O
called O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
. O

This O
work O
compares O
the O
cytokine O
responses O
of O
differentiated O
U937 O
human O
monocytic O
cells O
infected O
directly O
with O
Dengue B
Virus I
( I
DENV I
) I
or O
in O
the O
presence O
of O
enhancing O
concentrations O
of O
a O
humanized O
monoclonal O
antibody O
recognizing O
protein O
E O
( O
ADE O
- O
DENV O
infection O
) O
. O

Using O
a O
cytometric O
bead O
assay O
, O
ADE O
- O
DENV O
- O
infected O
cells O
were O
found O
to O
produce O
significantly O
higher O
levels O
of O
the O
proinflammatory O
cytokines O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
IL O
- O
12p70 O
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
as O
well O
as O
prostaglandin B
E I
- I
2 I
( I
PGE I
( I
2 I
) I
) I
, O
than O
cells O
directly O
infected O
. O

The O
capacity O
of O
conditioned O
supernatants O
( O
conditioned O
medium O
[ O
CM O
] O
) O
to O
disrupt O
tight B
junctions I
( I
TJs I
) I
in O
MDCK O
cell O
cultures O
was O
evaluated O
. O

Exposure O
of O
MDCK O
cell O
monolayers O
to O
CM O
collected O
from O
ADE O
- O
DENV O
- O
infected O
cells O
( O
ADE O
- O
CM O
) O
but O
not O
from O
cells O
infected O
directly O
led O
to O
a O
rapid O
loss O
of O
transepithelial O
electrical O
resistance O
( O
TER O
) O
and O
to O
delocalization O
and O
degradation O
of O
apical O
- O
junction O
complex O
proteins O
. O

In O
this O
study O
, O
we O
demonstrate O
the O
binding O
, O
neutralizing O
activity O
, O
and O
therapeutic O
capacity O
of O
a O
novel O
bispecific O
dual B
- I
affinity I
retargeting I
molecule I
( I
DART I
) I
that O
limits O
infection O
of O
all O
four O
serotypes O
of O
dengue O
virus O
. O

Dengue B
viruses I
( I
DENV I
) I
are O
transmitted O
to O
humans O
by O
the O
bite O
of O
Aedes O
aegypti O
or O
Aedes O
albopictus O
mosquitoes O
, O
with O
millions O
of O
infections O
annually O
in O
over O
100 O
countries O
. O

The O
diseases O
they O
produce O
, O
which O
occur O
exclusively O
in O
humans O
, O
are O
dengue B
fever I
( I
DF I
) I
and O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
. O

aegypti O
to O
transmit O
dengue O
virus O
during O
feeding O
, O
we O
observed O
signs O
of O
more O
severe O
disease O
( O
higher O
and O
more O
sustained O
viremia O
, O
erythema O
, O
and O
thrombocytopenia O
) O
. O

Infected O
mice O
mounted O
innate O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
and O
soluble B
interleukin I
2 I
receptor I
alpha I
( I
sIL I
- I
2R I
alpha I
) I
and O
adaptive O
( O
anti O
- O
DENV O
antibodies O
) O
immune O
responses O
that O
failed O
to O
clear O
viremia O
until O
day O
56 O
, O
while O
a O
mosquito O
bite O
alone O
induced O
strong O
immunomodulators O
( O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
, O
IL O
- O
4 O
, O
and O
IL O
- O
10 O
) O
and O
thrombocytopenia O
. O

Dengue O
viruses O
cause O
two O
severe O
diseases O
that O
alter O
vascular O
fluid O
barrier O
functions O
, O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
and O
dengue B
shock I
syndrome I
( I
DSS I
) I
. O

Preexisting O
antibodies O
to O
dengue O
virus O
disposes O
patients O
to O
immune O
- O
enhanced O
edema O
( O
DSS O
) O
or O
hemorrhagic O
( O
DHF O
) O
disease O
following O
infection O
by O
a O
discrete O
dengue O
virus O
serotype O
. O

Although O
the O
endothelium O
is O
the O
primary O
vascular O
fluid O
barrier O
, O
direct O
effects O
of O
dengue O
virus O
on O
endothelial B
cells I
( I
ECs I
) I
have O
not O
been O
considered O
primary O
factors O
in O
pathogenesis O
. O

Our O
results O
suggest O
that O
rapid O
early O
dengue O
virus O
proliferation O
within O
ECs O
is O
permitted O
by O
dengue O
virus O
regulation O
of O
early O
, O
but O
not O
late O
, O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
responses O
. O

The O
analysis O
of O
EC O
responses O
following O
synchronous O
dengue O
virus O
infection O
revealed O
the O
high O
- O
level O
induction O
and O
secretion O
of O
immune O
cells O
( O
T O
cells O
, O
B O
cells O
, O
and O
mast O
cells O
) O
as O
well O
as O
activating O
and O
recruiting O
cytokines O
BAFF O
( O
119 O
- O
fold O
) O
, O
IL O
- O
6 O
/ O
8 O
( O
4 O
- O
to O
7 O
- O
fold O
) O
, O
CXCL9 O
/ O
10 O
/ O
11 O
( O
45 O
- O
to O
338 O
- O
fold O
) O
, O
RANTES O
( O
724 O
- O
fold O
) O
, O
and O
interleukin O
- O
7 O
( O
IL O
- O
7 O
; O
128 O
- O
fold O
) O
. O

The O
removal O
of O
ubiquitin O
from O
innate O
immunity O
signaling O
factors O
by O
deubiquitinating B
enzymes I
( I
DUBs I
) I
therefore O
provides O
a O
potential O
opportunity O
for O
viruses O
to O
evade O
this O
host O
defense O
system O
. O

It O
was O
previously O
found O
that O
specific O
proteases O
encoded O
by O
the O
unrelated O
arteri O
- O
and O
nairoviruses O
resemble O
the O
ovarian B
tumor I
domain I
- I
containing I
( I
OTU I
) I
family O
of O
DUBs O
. O

In O
arteriviruses O
, O
this O
domain O
has O
been O
characterized O
before O
as O
a O
papain B
- I
like I
protease I
( I
PLP2 I
) I
that O
is O
also O
involved O
in O
replicase O
polyprotein O
processing O
. O

The O
potential O
relevance O
of O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
signaling O
for O
the O
innate O
immune O
response O
against O
arterivirus O
infection O
is O
supported O
by O
our O
finding O
that O
in O
mouse O
embryonic O
fibroblasts O
, O
the O
production O
of O
beta O
interferon O
primarily O
depends O
on O
the O
recognition O
of O
arterivirus O
RNA O
by O
the O
pattern O
- O
recognition O
receptor O
MDA5 O
. O

A O
recent O
( O
2007 O
to O
2009 O
) O
dengue O
outbreak O
caused O
by O
Dengue B
Virus I
( I
DENV I
) I
in O
Paraguay O
presented O
unusual O
severe O
clinical O
outcomes O
associated O
with O
50 O
% O
mortality O
rates O
. O

Using O
human O
dendritic O
cells O
from O
a O
major O
innate O
immune O
cell O
population O
as O
an O
in O
vitro O
model O
, O
we O
have O
investigated O
signature O
cytokine O
responses O
as O
well O
as O
infectivity O
- O
replicative O
profiles O
of O
DENV O
clinical O
isolates O
from O
either O
a O
nonfatal O
case O
of O
classical O
dengue O
fever O
( O
strain O
DENV3 O
/ O
290 O
; O
isolated O
in O
Brazil O
in O
2002 O
) O
or O
a O
fatal O
case O
of O
dengue O
fever O
with O
visceral O
complications O
isolated O
in O
Paraguay O
in O
2007 O
( O
strain O
DENV3 O
/ O
5532 O
) O
. O

Strain O
DENV3 O
/ O
5532 O
was O
found O
to O
display O
significantly O
higher O
replicative O
ability O
than O
DENV3 O
/ O
290 O
in O
monocyte B
- I
derived I
dendritic I
cells I
( I
mdDCs I
) I
. O

The O
observed O
phenotype O
was O
due O
to O
viral O
replication O
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
appears O
to O
exert O
a O
protective O
effect O
on O
virus O
- O
induced O
mdDC O
apoptosis O
. O

antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
is O
implicated O
in O
severe O
, O
usually O
secondary O
, O
dengue B
virus I
( I
DV I
) I
infections O
. O

Preexisting O
heterotypic O
antibodies O
, O
via O
their O
Fc O
- O
gamma O
receptor O
( O
Fc O
gamma O
R O
) O
interactions O
, O
may O
increase O
disease O
severity O
through O
enhanced O
target O
cell O
infection O
. O

Monocytes O
, O
macrophages O
, O
and O
immature O
and O
mature O
dendritic B
cells I
( I
DC I
) I
are O
considered O
major O
cellular O
targets O
of O
DV O
. O

Apheresis O
of O
multiple O
donors O
allowed O
isolation O
of O
autologous O
primary O
myeloid O
target O
cell O
types O
for O
head O
- O
to O
- O
head O
comparison O
of O
infection O
rates O
, O
viral O
output O
, O
and O
cytokine O
production O
under O
direct O
infection O
( O
without O
antibody O
) O
or O
ADE O
conditions O
( O
with O
antibody O
) O
. O

All O
cells O
undergoing O
ADE O
secreted O
proinflammatory O
cytokines O
( O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
] O
and O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
) O
at O
enhancement O
titers O
, O
but O
distinct O
cell O
- O
type O
- O
specific O
patterns O
were O
observed O
for O
other O
relevant O
proteins O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
and O
IL O
- O
10 O
) O
. O

Macrophages O
produced O
type O
I O
interferons O
( O
IFN O
- O
alpha O
/ O
beta O
) O
that O
were O
modulated O
by O
ADE O
. O

While O
ADE O
infection O
rates O
were O
remarkably O
consistent O
in O
monocytes O
( O
10 O
to O
15 O
% O
) O
across O
donors O
, O
IL O
- O
10 O
protein O
levels O
varied O
according O
to O
previously O
described O
regulatory O
single B
nucleotide I
polymorphisms I
( I
SNPs I
) I
in O
the O
IL O
- O
10 O
promoter O
region O
. O

We O
show O
here O
that O
antibody O
- O
enhanced O
dengue O
virus O
infection O
of O
primary O
human O
cord B
blood I
- I
derived I
mast I
cells I
( I
CBMCs I
) I
and O
the O
human O
mast O
cell O
- O
like O
line O
HMC O
- O
1 O
results O
in O
the O
release O
of O
factor O
( O
s O
) O
which O
activate O
human O
endothelial O
cells O
, O
as O
evidenced O
by O
increased O
expression O
of O
the O
adhesion O
molecules O
ICAM O
- O
1 O
and O
VCAM O
- O
1 O
. O

Endothelial O
cell O
activation O
was O
prevented O
by O
pretreatment O
of O
mast O
cell O
- O
derived O
supernatants O
with O
a O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
specific O
blocking O
antibody O
, O
thus O
identifying O
TNF O
as O
the O
endothelial O
cell O
- O
activating O
factor O
. O

Dengue B
Virus I
( I
DENV I
) I
pathogenesis O
is O
related O
to O
the O
host O
responses O
to O
viral O
infection O
within O
target O
cells O
, O
and O
therefore O
, O
this O
study O
assessed O
intracellular O
changes O
in O
host O
proteins O
following O
DENV O
infection O
. O

Two O
- O
dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry O
identified O
upregulation O
of O
the O
host O
endoplasmic B
reticulum I
( I
ER I
) I
chaperone O
GRP78 O
in O
K562 O
cells O
following O
DENV O
infection O
, O
in O
the O
absence O
of O
virus O
- O
induced O
cell O
death O
. O

We O
demonstrate O
the O
presence O
of O
nonstructural B
protein I
1 I
( I
NS1 I
) I
- O
specific O
antibodies O
in O
a O
significant O
proportion O
of O
convalescent O
- O
phase O
human O
serum O
samples O
obtained O
from O
a O
cohort O
in O
an O
area O
where O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
is O
endemic O
. O

The O
antibody O
response O
to O
the O
envelope B
( I
E I
) I
glycoprotein O
of O
Dengue B
Virus I
( I
DENV I
) I
is O
known O
to O
play O
a O
critical O
role O
in O
both O
protection O
from O
and O
enhancement O
of O
disease O
, O
especially O
after O
primary O
infection O
. O

In O
this O
study O
, O
we O
examined O
the O
antibody O
responses O
to O
E O
protein O
as O
well O
as O
to O
precursor B
membrane I
( I
prM I
) I
, O
capsid O
, O
and O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
four O
serotypes O
of O
DENV O
by O
Western O
blot O
analysis O
of O
DENV O
serotype O
2 O
- O
infected O
patients O
with O
different O
disease O
severity O
and O
immune O
status O
during O
an O
outbreak O
in O
southern O
Taiwan O
in O
2002 O
. O

We O
have O
developed O
two O
bivalent O
dengue O
virus O
vaccines O
, O
using O
a O
complex O
adenovirus O
vector O
, O
by O
incorporating O
the O
genes O
expressing O
premembrane B
( I
PrM I
) I
and O
envelope B
( I
E I
) I
proteins O
of O
dengue O
virus O
types O
1 O
and O
2 O
( O
dengue O
- O
1 O
and O
- O
2 O
, O
respectively O
) O
( O
CAdVax O
- O
Den12 O
) O
or O
dengue O
- O
3 O
and O
- O
4 O
( O
CAdVax O
- O
Den34 O
) O
. O

While O
neutralizing O
antibodies O
are O
considered O
to O
play O
a O
major O
role O
in O
protection O
from O
these O
diseases O
, O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
infection O
is O
an O
important O
mechanism O
involved O
in O
disease O
severity O
, O
in O
addition O
to O
the O
involvement O
of O
T O
lymphocytes O
. O

Here O
, O
we O
analyzed O
relationships O
between O
neutralizing O
and O
enhancing O
activities O
at O
a O
clonal O
level O
using O
models O
of O
dengue B
type I
2 I
virus I
( I
DENV2 I
) I
and O
dengue B
type I
4 I
virus I
( I
DENV4 I
) I
. O

Totals O
of O
33 O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
DENV2 O
and O
43 O
against O
DENV4 O
were O
generated O
, O
all O
directed O
to O
the O
envelope O
protein O
. O

These O
results O
indicate O
that O
a O
single O
antibody O
species O
possesses O
two O
distinct O
activities O
( O
neutralizing O
/ O
enhancing O
) O
, O
which O
are O
controlled O
by O
the O
level O
of O
complement O
, O
suggesting O
the O
involvement O
of O
complement O
in O
dengue O
disease O
severity O
. O

Fresh O
human O
sera O
also O
tended O
to O
reduce O
enhancing O
activities O
more O
effectively O
in O
homologous O
than O
heterologous O
combinations O
of O
viruses O
( O
DENV2 O
/ O
DENV4 O
) O
and O
MAbs O
( O
against O
DENV2 O
/ O
DENV4 O
) O
. O

Previous O
studies O
have O
suggested O
that O
Monoclonal B
antibodies I
( I
MAbs I
) I
to O
flavivirus O
nonstructural B
protein I
- I
1 I
( I
NS I
- I
1 I
) I
protect O
against O
infection O
in O
mice O
through O
an O
Fc O
- O
gamma O
receptor O
- O
dependent O
pathway O
. O

Proinflammatory O
cytokines O
secreted O
by O
memory O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
are O
thought O
to O
play O
a O
direct O
role O
in O
the O
pathogenesis O
of O
dengue O
virus O
infection O
by O
increasing O
vascular O
permeability O
and O
thereby O
inducing O
the O
pathophysiologic O
events O
associated O
with O
dengue O
hemorrhagic O
fever O
and O
dengue O
shock O
syndrome O
. O

We O
used O
a O
large O
panel O
of O
well O
- O
characterized O
dengue O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
clones O
isolated O
from O
Pacific O
Islanders O
previously O
infected O
with O
dengue O
virus O
1 O
to O
examine O
effector O
memory O
function O
, O
focusing O
on O
a O
novel O
dominant O
HLA O
- O
B O
* O
5502restricted O
NS5 O
( O
329 O
- O
337 O
) O
epitope O
, O
and O
assessed O
T O
- O
cell O
responses O
to O
stimulation O
with O
variant O
peptides O
representing O
heterologous O
serotypes O
. O

Variant O
peptides O
were O
differentially O
recognized O
by O
dengue O
virus O
1 O
- O
specific O
effector O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
in O
a O
heterogeneous O
and O
clone O
- O
specific O
manner O
, O
in O
which O
cytolytic O
function O
and O
cytokine O
secretion O
could O
be O
enhanced O
, O
diminished O
, O
or O
abrogated O
compared O
with O
cognate O
peptide O
stimulation O
. O

Dengue O
virus O
- O
specific O
CTL O
stimulated O
with O
cognate O
and O
variant O
peptides O
demonstrated O
a O
cytokine O
response O
hierarchy O
of O
gamma O
IFN O
( O
IFN O
- O
gamma O
) O
> O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
> O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
and O
a O
subset O
of O
clones O
also O
produced O
IL O
- O
4 O
and O
IL O
- O
6 O
. O

tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
is O
believed O
to O
play O
a O
significant O
role O
in O
the O
pathogenesis O
of O
dengue B
virus I
( I
DV I
) I
infection O
, O
with O
elevated O
levels O
of O
TNF O
- O
alpha O
in O
the O
sera O
of O
DV O
- O
infected O
patients O
paralleling O
the O
severity O
of O
disease O
and O
TNF O
- O
alpha O
release O
being O
coincident O
with O
the O
peak O
of O
DV O
production O
from O
infected O
monocyte B
- I
derived I
macrophages I
( I
MDM I
) I
in O
vitro O
. O

Fe B
gamma I
receptor I
( I
Fe I
- I
gamma I
R I
) I
- O
mediated O
entry O
of O
infectious O
dengue O
virus O
immune O
complexes O
into O
monocytes O
/ O
macrophages O
is O
hypothesized O
to O
be O
a O
key O
event O
in O
the O
pathogenesis O
of O
complicated O
dengue O
fever O
. O

Fc O
- O
gamma O
RIA O
( O
CD64 O
) O
and O
Fc O
gamma O
RIIA O
( O
CD32 O
) O
, O
which O
predominate O
on O
the O
surface O
of O
such O
dengue O
virus O
- O
permissive O
cells O
, O
were O
compared O
for O
their O
influence O
on O
the O
infectivity O
of O
dengue O
2 O
virus O
immune O
complexes O
formed O
with O
human O
dengue O
virus O
antibodies O
. O

A O
signaling O
immunoreceptor B
tyrosine I
- I
based I
activation I
motif I
( I
ITAM I
) I
incorporated O
into O
the O
accessory O
gamma O
- O
chain O
subunit O
that O
associates O
with O
Fc O
gamma O
RIA O
and O
constitutively O
in O
Fc O
- O
gamma O
RIIA O
is O
required O
for O
phagocytosis O
mediated O
by O
these O
receptors O
. O

The O
increased O
transmission O
and O
geographic O
spread O
of O
dengue B
fever I
( I
DF I
) I
and O
its O
more O
severe O
presentation O
, O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
, O
make O
it O
the O
most O
important O
mosquito O
- O
borne O
viral O
disease O
of O
humans O
( O
50 O
to O
100 O
million O
infections O
/ O
year O
) O
( O
World O
Health O
Organization O
, O
Fact O
sheet O
117 O
, O
2002 O
) O
. O

We O
demonstrate O
that O
nonobese O
diabetic O
/ O
severely O
compromised O
immunodeficient O
( O
NOD O
/ O
SCID O
) O
mice O
xenografted O
with O
human O
CD34 O
( O
+ O
) O
cells O
develop O
clinical O
signs O
of O
DF O
as O
in O
humans O
( O
fever O
, O
rash O
, O
and O
thrombocytopenia O
) O
, O
when O
infected O
in O
a O
manner O
mimicking O
mosquito O
transmission O
( O
dose O
and O
mode O
) O
. O

The O
flavivirus O
nonstructural O
protein O
NS1 O
is O
expressed O
as O
three O
discrete O
species O
in O
infected O
mammalian O
cells O
: O
an O
intracellular O
, O
membrane O
- O
associated O
form O
essential O
for O
viral O
replication O
, O
a O
cell O
surface O
- O
associated O
form O
that O
may O
be O
involved O
in O
signal O
transduction O
, O
and O
a O
secreted O
form O
( O
sNS1 O
) O
, O
the O
biological O
properties O
of O
which O
remain O
elusive O
. O

To O
determine O
the O
distribution O
of O
the O
dengue B
virus I
( I
DEN I
) I
sNS1 O
protein O
in O
vivo O
, O
we O
have O
analyzed O
by O
immunohistological O
means O
the O
tissue O
tropism O
of O
purified O
DEN O
sNS1 O
injected O
intravenously O
into O
adult O
mice O
. O

Three O
tetravalent B
vaccine I
( I
TV I
) I
formulations O
of O
previously O
described O
monovalent O
dengue B
( I
DEN I
) I
virus O
vaccine O
candidates O
were O
compared O
to O
a O
tetravalent O
formulation O
of O
wild O
- O
type O
DEN O
viruses O
( O
T O
- O
wt O
) O
for O
replication O
in O
SCID O
mice O
transplanted O
with O
human O
liver O
cells O
( O
SCID O
- O
HuH O
- O
7 O
) O
or O
for O
replication O
and O
immunogenicity O
in O
rhesus O
monkeys O
. O

TV O
- O
1 O
consists O
of O
recombinant O
DENI O
, O
- O
2 O
, O
- O
3 O
, O
and O
- O
4 O
, O
each O
with O
a O
30 O
- O
nucleotide O
deletion O
in O
the O
3 O
' O
untranslated O
region O
( O
Delta O
30 O
) O
. O

The O
spread O
of O
both O
mosquito O
vectors O
and O
viruses O
has O
led O
to O
the O
resurgence O
of O
epidemic O
dengue O
fever O
( O
a O
self O
- O
limited O
flu O
- O
like O
syndrome O
) O
and O
the O
emergence O
of O
dengue O
hemorrhagic O
fever O
( O
severe O
dengue O
with O
bleeding O
abnormalities O
) O
in O
urban O
centers O
of O
the O
tropics O
. O

We O
developed O
two O
assay O
systems O
( O
using O
human O
dendritic O
cells O
and O
Aedes O
aegypti O
mosquitoes O
) O
for O
measuring O
differences O
in O
virus O
replication O
that O
correlate O
with O
the O
potential O
to O
cause O
hemorrhagic O
dengue O
and O
increased O
virus O
transmission O
. O

Infection O
and O
growth O
experiments O
showed O
that O
dengue O
serotype O
2 O
viruses O
causing O
dengue O
hemorrhagic O
fever O
epidemics O
( O
Southeast O
Asian O
genotype O
) O
can O
outcompete O
viruses O
that O
cause O
dengue O
fever O
only O
( O
American O
genotype O
) O
. O

envelope B
( I
E I
) I
protein O
genes O
sampled O
from O
populations O
of O
dengue B
2 I
( I
DEN I
- I
2 I
) I
virus O
in O
individual O
Aedes O
aegypti O
mosquitoes O
and O
in O
serum O
from O
dengue O
patients O
were O
copied O
to O
cDNA O
, O
cloned O
, O
and O
sequenced O
. O

One O
group O
of O
sequences O
was O
closely O
related O
to O
those O
of O
viruses O
recovered O
from O
dengue O
patients O
in O
the O
same O
locality O
( O
Yangon O
, O
Myanmar O
) O
since O
1995 O
and O
were O
classified O
as O
Asian O
1 O
genotype O
. O

dengue B
virus I
( I
DV I
) I
replication O
, O
antibody O
- O
enhanced O
viral O
infection O
, O
and O
cytokine O
responses O
of O
human O
primary O
B O
lymphocytes O
( O
cells O
) O
were O
characterized O
and O
compared O
with O
those O
of O
monocytes O
. O

The O
presence O
of O
a O
replication O
template O
( O
negative O
- O
strand O
RNA O
intermediate O
) O
, O
viral O
antigens O
including O
core O
and O
nonstructural O
proteins O
, O
and O
increasing O
amounts O
of O
virus O
with O
time O
postinfection O
indicated O
that O
DV O
actively O
replicated O
in O
B O
cells O
. O

dendritic B
cells I
( I
DCs I
) I
play O
a O
pivotal O
role O
as O
antigen O
- O
presenting O
cells O
in O
the O
antiviral O
immune O
response O
. O

Here O
we O
show O
that O
Hantaan B
virus I
( I
HTNV I
) I
, O
which O
belongs O
to O
the O
Bunyaviridae O
family O
( O
genus O
Hantavirus O
) O
and O
causes O
hemorrhagic O
fever O
with O
renal O
syndrome O
, O
productively O
infects O
human O
DCs O
in O
vitro O
. O

, O
human O
cytomegalovirus O
, O
HTNV O
activated O
immature O
DCs O
, O
resulting O
in O
upregulation O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
, O
costimulatory O
, O
and O
adhesion O
molecules O
. O

dengue B
virus I
( I
DV I
) I
primarily O
infects O
blood O
monocytes O
( O
MO O
) O
and O
tissue O
macrophages B
( I
MPhi I
) I
. O

After O
DV O
infection O
, O
the O
in O
vitro O
- O
differentiated O
MO O
/ O
Mphi O
secreted O
multiple O
innate O
cytokines O
and O
chemokines O
, O
including O
tumor O
necrosis O
factor O
alpha O
, O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
interleukin B
- I
1beta I
( I
IL I
- I
1beta I
) I
, O
IL O
- O
8 O
, O
IL O
- O
12 O
, O
MIP O
- O
1alpha O
, O
and O
RANTES O
but O
not O
IL O
- O
6 O
, O
IL O
- O
15 O
, O
or O
nitric O
oxide O
. O

In O
addition O
, O
DV O
replication O
in O
primary O
differentiated O
human O
MO O
/ O
Mphi O
was O
enhanced O
and O
prolonged O
in O
the O
presence O
of O
lipopolysaccharide B
( I
LPS I
) I
, O
and O
LPS O
- O
mediated O
synergistic O
production O
of O
IFN O
- O
alpha O
could O
be O
seen O
in O
DV O
- O
infected O
MO O
/ O
Mphi O
. O

This O
antibody O
- O
enhanced O
dengue O
virus O
infection O
triggered O
a O
four O
- O
to O
fivefold O
increase O
in O
the O
release O
of O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
and O
a O
modest O
increase O
for O
IL O
- O
6 O
but O
not O
for O
an O
alternate O
cytokine O
, O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
. O

ri O
role O
for O
interferon B
( I
IFN I
) I
in O
modulating O
infection O
by O
dengue B
virus I
( I
DV I
) I
has O
been O
suggested O
by O
studies O
in O
DV O
- O
infected O
patients O
and O
IFN O
receptor O
- O
deficient O
mice O
. O

To O
address O
how O
IFN O
modulates O
DV O
type O
2 O
infection O
, O
we O
have O
assayed O
IFN O
- O
alpha O
, O
- O
beta O
, O
and O
- O
gamma O
for O
the O
ability O
to O
enhance O
or O
diminish O
antibody O
- O
independent O
and O
antibody O
- O
dependent O
cell O
infection O
using O
a O
competitive O
, O
asymmetric O
reverse O
transcriptase O
- O
mediated O
PCR O
( O
RT O
- O
PCR O
) O
assay O
that O
quantitates O
positive O
and O
negative O
strands O
of O
viral O
RNA O
, O
a O
flow O
cytometric O
assay O
that O
measures O
viral O
antigen O
, O
and O
a O
plaque O
assay O
that O
analyzes O
virion O
production O
. O

To O
study O
these O
factors O
in O
an O
experimental O
system O
, O
we O
isolated O
dengue O
virus O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
clones O
from O
dengue O
- O
2 O
virus O
- O
immunized O
BALB O
/ O
c O
mice O
, O
The O
T O
- O
cell O
response O
to O
dengue O
vit O
us O
in O
this O
mouse O
strain O
was O
heterogeneous O
; O
we O
identified O
at O
least O
five O
different O
CD4 O
( O
+ O
) O
phenotypes O
and O
six O
different O
CD8 O
( O
+ O
) O
phenotypes O
. O

Individual O
T O
- O
cell O
clones O
recognized O
epitopes O
on O
the O
dengue O
virus O
pre O
- O
M O
, O
E O
, O
NS1 O
/ O
NS2A O
, O
and O
NS3 O
proteins O
and O
were O
restricted O
by O
the O
I O
- O
A O
( O
d O
) O
, O
I O
- O
E O
( O
d O
) O
, O
L O
( O
d O
) O
, O
and O
K O
- O
d O
antigens O
, O
Both O
serotype O
- O
specific O
and O
serotype O
- O
cross O
- O
reactive O
clones O
were O
isolated O
in O
the O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
subsets O
; O
among O
CD8 O
( O
+ O
) O
clones O
, O
those O
that O
recognized O
the O
dengue O
virus O
structural O
proteins O
were O
serotype O
specific O
whereas O
those O
that O
recognized O
the O
nonstructural O
proteins O
were O
serotype O
cross O
- O
reactive O
, O
All O
of O
the O
CD8 O
( O
+ O
) O
and O
one O
of O
five O
CD4 O
( O
+ O
) O
clones O
lysed O
dengue O
virus O
- O
infected O
target O
cells O
, O
Using O
synthetic O
peptides O
, O
we O
identified O
an O
L O
( O
d O
) O
- O
restricted O
epitope O
on O
the O
E O
protein O
( O
residues O
331 O
to O
339 O
, O
SPCKIPFEI O
) O
and O
a O
K O
- O
d O
- O
restricted O
epitope O
on O
the O
NS3 O
protein O
( O
residues O
296 O
to O
310 O
, O
ARGYISTRVEM O
GEAA O
) O
. O

Primary O
infection O
with O
one O
of O
four O
cocirculating O
serotypes O
( O
DENV O
- O
1 O
to O
- O
4 O
) O
causes O
a O
febrile O
illness O
, O
but O
secondary O
infection O
with O
a O
heterologous O
serotype O
can O
result O
in O
severe O
disease O
, O
due O
in O
part O
to O
antibody B
- I
dependent I
enhancement I
of I
infection I
( I
ADE I
) I
. O

Thus O
, O
elicitation O
of O
broadly B
neutralizing I
antibodies I
( I
bNAbs I
) I
, O
but O
not O
nonneutralizing O
antibodies O
, O
is O
desirable O
for O
dengue O
vaccine O
development O
. O

Domain B
III I
of I
the I
envelope I
glycoprotein I
( I
EDIII I
) I
is O
targeted O
by O
bNAbs O
and O
thus O
is O
an O
attractive O
immunogen O
. O

We O
developed O
resurfaced B
EDIII I
immunogens I
( I
rsDIIIs I
) I
in O
which O
the O
A O
/ O
G O
strand O
epitope O
that O
is O
targeted O
by O
bNAb O
4E11 O
is O
maintained O
but O
less O
desirable O
epitopes O
are O
masked O
. O

One O
rsDIII O
and O
, O
unexpectedly O
, O
wild B
- I
type I
( I
WT I
) I
DENV O
- O
2 O
EDIII O
elicited O
cross O
- O
neutralizing O
antibody O
responses O
against O
DENV O
- O
1 O
to O
- O
3 O
in O
mice O
. O

While O
these O
sera O
were O
cross O
- O
neutralizing O
, O
they O
were O
not O
sufficiently O
potent O
to O
protect O
AG129 O
immunocompromised O
mice O
at O
a O
dose O
of O
200 O
mu O
l O
( O
50 O
% O
focus O
reduction O
neutralization O
titer O
[ O
FRNT50 O
] O
, O
similar O
to O
1 O
: O
60 O
to O
1 O
: O
130 O
) O
against O
mouse O
- O
adapted O
DENV O
- O
2 O
. O

Here O
, O
we O
explore O
a O
novel O
strategy O
for O
developing O
immunogens O
based O
on O
domain O
III O
of O
the O
E O
glycoprotein O
, O
where O
undesirable O
epitopes O
( O
nonneutralizing O
or O
nonconserved O
) O
are O
masked O
by O
mutation O
. O

Dengue B
Virus I
( I
DENV I
) I
infection O
results O
in O
the O
production O
of O
both O
type O
- O
specific O
and O
cross O
- O
neutralizing O
antibodies O
. O

To O
understand O
the O
cellular O
and O
functional O
properties O
of O
the O
acute O
dengue O
virus O
B O
cell O
response O
and O
its O
role O
in O
protection O
and O
immunopathology O
, O
we O
characterized O
the O
plasmablast O
response O
in O
four O
secondary O
DENV B
type I
2 I
( I
DENV2 I
) I
patients O
. O

We O
generated O
53 O
Monoclonal B
antibodies I
( I
MAbs I
) I
from O
sorted O
patient O
plasmablasts O
and O
found O
that O
DENV O
- O
reactive O
MAbs O
were O
largely O
envelope O
specific O
and O
cross O
neutralizing O
. O

A O
majority O
of O
DENV O
- O
reactive O
MAbs O
, O
irrespective O
of O
neutralization O
potency O
, O
enhanced O
infection O
by O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
. O

Taken O
together O
, O
these O
findings O
are O
reminiscent O
of O
original B
antigenic I
sin I
( I
OAS I
) I
, O
given O
that O
the O
patients O
had O
prior O
dengue O
virus O
exposures O
. O

Recent O
studies O
characterizing O
memory B
B I
cell I
( I
MBC I
) I
- O
derived O
MAbs O
have O
provided O
valuable O
insight O
into O
the O
targets O
and O
functions O
of O
B O
cell O
responses O
generated O
after O
DENV O
exposure O
. O

The O
four O
Dengue B
Virus I
( I
DENV I
) I
serotypes O
, O
DENV1 O
through O
4 O
, O
are O
endemic O
throughout O
tropical O
and O
subtropical O
regions O
of O
the O
world O
. O

Recent O
studies O
demonstrate O
that O
humans O
exposed O
to O
DENV O
infections O
develop O
neutralizing O
antibodies O
that O
bind O
to O
quaternary O
epitopes O
formed O
by O
the O
viral O
envelope B
( I
E I
) I
protein O
dimers O
or O
higher O
- O
order O
assemblies O
required O
for O
the O
formation O
of O
the O
icosahedral O
viral O
envelope O
. O

Here O
we O
show O
that O
the O
quaternary O
epitope O
target O
of O
the O
human O
DENV3 O
- O
specific O
neutralizing O
monoclonal B
antibody I
( I
Mab I
) I
5J7 O
can O
be O
partially O
transplanted O
into O
a O
DENV1 O
strain O
by O
changing O
the O
core O
residues O
of O
the O
epitope O
contained O
within O
a O
single O
monomeric O
E O
molecule O
. O

However O
, O
the O
5J7 O
epitope O
was O
only O
partially O
recreated O
by O
transplantation O
of O
the O
core O
residues O
because O
MAb O
5J7 O
bound O
and O
neutralized O
wild B
- I
type I
( I
WT I
) I
DENV3 O
better O
than O
the O
DENV1 O
/ O
3 O
recombinant O
. O

Severe O
Dengue B
Virus I
( I
DENV I
) I
- O
associated O
diseases O
can O
occur O
in O
patients O
who O
have O
preexisting O
DENV O
antibodies B
( I
Abs I
) I
through O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
infection O
. O

It O
is O
well O
established O
that O
during O
ADE O
, O
DENV O
- O
antibody O
immune B
complexes I
( I
ICs I
) I
infect O
Fc O
gamma O
receptor O
- O
bearing O
cells O
and O
increase O
the O
systemic O
viral O
burden O
that O
can O
be O
measured O
in O
the O
blood O
. O

We O
further O
demonstrated O
that O
infection O
with O
the O
ICs O
resulted O
in O
increased O
vascular O
permeability O
, O
specifically O
in O
the O
small O
intestine O
, O
accompanied O
with O
increased O
tissue O
viral O
load O
and O
cytokine O
production O
, O
which O
can O
be O
suppressed O
by O
anti O
- O
tumor O
necrosis O
factor O
alpha O
( O
anti O
- O
TNF O
- O
alpha O
) O
Abs O
. O

Flow O
cytometric O
analysis O
identified O
increased O
infection O
in O
CD11b O
( O
int O
) O
CD11c O
( O
int O
/ O
hi O
) O
CD103 O
( O
- O
) O
antigen O
- O
presenting O
cells O
by O
IC O
inoculation O
, O
suggesting O
that O
these O
infected O
cells O
may O
be O
responsible O
for O
the O
increase O
in O
TNF O
- O
alpha O
production O
and O
vascular O
permeability O
in O
the O
small O
intestine O
that O
lead O
to O
mortality O
in O
mice O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
most O
common O
cause O
of O
viral O
hemorrhagic O
fever O
, O
and O
it O
may O
lead O
to O
life O
- O
threating O
dengue O
hemorrhagic O
fever O
and O
shock O
syndrome O
( O
DHF O
/ O
DSS O
) O
. O

Previously O
, O
we O
have O
found O
that O
antithrombin B
antibodies I
( I
ATAs I
) I
with O
both O
antithrombotic O
and O
profibrinolytic O
activities O
are O
present O
in O
the O
sera O
of O
dengue O
patients O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
antibodies O
induced O
by O
DENV O
immunization O
in O
mice O
and O
rabbits O
could O
bind O
to O
DENV O
antigens O
as O
well O
as O
to O
human O
thrombin O
and O
plasminogen B
( I
Plg I
) I
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
infection O
is O
the O
most O
common O
mosquito O
- O
borne O
viral O
disease O
in O
tropical O
and O
subtropical O
areas O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
DENV O
immunization O
could O
induce O
thrombin O
and O
plasminogen B
( I
Plg I
) I
cross O
- O
reactive O
antibodies O
, O
which O
were O
able O
to O
inhibit O
thrombin O
activity O
and O
enhance O
Plg O
activation O
. O

Much O
of O
our O
understanding O
of O
this O
process O
has O
come O
from O
studies O
using O
mouse B
monoclonal I
antibodies I
( I
MAbs I
) I
; O
however O
, O
antibody O
responses O
in O
mice O
typically O
exhibit O
less O
complexity O
than O
those O
in O
humans O
. O

Our O
findings O
indicate O
that O
human O
endothelial O
cells O
are O
highly O
susceptible O
to O
infection O
by O
dengue O
virus O
( O
type O
4 O
) O
. O

We O
found O
that O
dengue O
virus O
productively O
infects O
similar O
to O
80 O
% O
of O
primary O
human O
endothelial O
cells O
, O
resulting O
in O
the O
rapid O
release O
of O
similar O
to O
10 O
( O
5 O
) O
virions O
1 O
day O
postinfection O
. O

In O
children O
, O
dengue B
shock I
syndrome I
( I
DSS I
) I
is O
the O
most O
common O
life O
- O
threatening O
complication O
. O

To O
this O
end O
, O
we O
conducted O
a O
nested O
case O
- O
control O
comparison O
of O
the O
early O
host O
transcriptional O
features O
in O
24 O
DSS O
patients O
and O
56 O
sex O
- O
, O
age O
- O
, O
and O
virus O
serotype O
- O
matched O
uncomplicated B
( I
UC I
) I
dengue O
patients O
. O

The O
transcriptional O
signature O
in O
acute O
rather O
than O
convalescent O
samples O
( O
< O
= O
72 O
h O
post O
- O
illness O
onset O
) O
was O
defined O
by O
an O
overabundance O
of O
interferon O
- O
inducible O
transcripts O
( O
31 O
% O
of O
the O
551 O
overabundant O
transcripts O
) O
and O
canonical O
gene O
ontology O
terms O
that O
included O
the O
following O
: O
response O
to O
virus O
, O
immune O
response O
, O
innate O
immune O
response O
, O
and O
inflammatory O
response O
. O

Strikingly O
, O
the O
only O
difference O
in O
the O
transcriptional O
signatures O
of O
early O
DSS O
and O
UC O
dengue O
cases O
was O
the O
greater O
abundance O
of O
several O
neutrophil O
- O
associated O
transcripts O
in O
patients O
who O
progressed O
to O
DSS O
, O
a O
finding O
supported O
by O
higher O
plasma O
concentrations O
of O
several O
canonical O
proteins O
associated O
with O
neutrophil O
degranulation O
( O
bactericidal O
/ O
permeability O
- O
increasing O
protein O
[ O
BPI O
] O
, O
elastase O
2 O
[ O
ELA2 O
] O
, O
and O
defensin O
1 O
alpha O
[ O
DEF1A O
] O
) O
. O

Elevated O
levels O
of O
neutrophil O
- O
associated O
transcripts O
were O
independent O
of O
the O
neutrophil O
count O
and O
also O
of O
the O
genotype O
of O
the O
infecting O
virus O
, O
as O
genome O
- O
length O
sequences O
of O
dengue B
virus I
serotype I
1 I
( I
DENV I
- I
1 I
) I
( O
n O
= O
15 O
) O
and O
DENV O
- O
2 O
( O
n O
= O
3 O
) O
sampled O
from O
DSS O
patients O
were O
phylogenetically O
indistinguishable O
from O
those O
sampled O
from O
uncomplicated O
dengue O
patients O
( O
32 O
DENV O
- O
1 O
and O
9 O
DENV O
- O
2 O
sequences O
) O
. O

The O
infection O
is O
often O
associated O
with O
serious O
complications O
such O
as O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
or O
dengue B
shock I
syndrome I
( I
DSS I
) I
, O
in O
which O
both O
viral O
and O
host O
factors O
have O
been O
implicated O
. O

RNA B
interference I
( I
RNAi I
) I
is O
a O
potent O
antiviral O
strategy O
and O
a O
potential O
therapeutic O
option O
for O
dengue O
if O
a O
feasible O
strategy O
can O
be O
developed O
for O
delivery O
of O
small B
interfering I
RNA I
( I
siRNA I
) I
to O
dendritic B
cells I
( I
DCs I
) I
and O
macrophages O
, O
the O
major O
in O
vivo O
targets O
of O
the O
virus O
and O
also O
the O
source O
of O
proinflammatory O
cytokines O
. O

Here O
we O
show O
that O
a O
dendritic O
cell O
- O
targeting O
12 O
- O
mer O
peptide O
( O
DC3 O
) O
fused O
to O
nona O
- O
D O
- O
arginine O
( O
9dR O
) O
residues O
( O
DC3 O
- O
9dR O
) O
delivers O
siRNA O
and O
knocks O
down O
endogenous O
gene O
expression O
in O
heterogenous O
DC O
subsets O
, O
( O
monocyte O
- O
derived O
DCs O
[ O
MDDCs O
] O
, O
CD34 O
( O
+ O
) O
hematopoietic O
stem O
cell O
[ O
HSC O
] O
) O
- O
derived O
Langerhans O
DCs O
, O
and O
peripheral O
blood O
DCs O
) O
. O

Moreover O
, O
DC3 O
- O
9dR O
- O
mediated O
delivery O
of O
siRNA O
targeting O
a O
highly O
conserved O
sequence O
in O
the O
dengue O
virus O
envelope O
gene O
( O
siFvE O
( O
D O
) O
) O
effectively O
suppressed O
dengue O
virus O
replication O
in O
MDDCs O
and O
macrophages O
. O

In O
addition O
, O
DC O
- O
specific O
delivery O
of O
siRNA O
targeting O
the O
acute O
- O
phase O
cytokine O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
which O
plays O
a O
major O
role O
in O
dengue O
pathogenesis O
, O
either O
alone O
or O
in O
combination O
with O
an O
antiviral O
siRNA O
, O
significantly O
reduced O
virus O
- O
induced O
production O
of O
the O
cytokine O
in O
MDDCs O
. O

Finally O
to O
validate O
the O
strategy O
in O
vivo O
, O
we O
tested O
the O
ability O
of O
the O
peptide O
to O
target O
human O
DCs O
in O
the O
NOD O
/ O
SCID O
/ O
IL O
- O
2R O
gamma O
( O
- O
/ O
- O
) O
mouse O
model O
engrafted O
with O
human O
CD34 O
( O
+ O
) O
hematopoietic O
stem O
cells O
( O
HuHSC O
mice O
) O
. O

) O
injection O
of O
DC3 O
- O
9dR O
- O
complexed O
siRNA O
targeting O
TNF O
- O
alpha O
effectively O
suppressed O
poly O
( O
I O
: O
C O
) O
- O
induced O
TNF O
- O
alpha O
production O
by O
DCs O
. O

Temporal O
studies O
showed O
that O
beginning O
at O
day O
2 O
, O
there O
was O
macrophage O
infiltration O
into O
the O
vicinity O
of O
the O
endothelium O
, O
increased O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
production O
, O
and O
endothelial O
cell O
apoptosis O
in O
the O
tissues O
. O

In O
the O
meantime O
, O
endothelial O
cells O
in O
the O
hemorrhage O
tissues O
expressed O
inducible B
nitric I
oxide I
synthase I
( I
iNOS I
) I
and O
nitrotyrosine O
. O

Importantly O
, O
hemorrhage O
development O
and O
the O
severity O
of O
hemorrhage O
were O
greatly O
reduced O
in O
mice O
lacking O
iNOS O
or O
p47 O
( O
phox O
) O
or O
treatment O
with O
oxidase O
inhibitor O
, O
pointing O
to O
the O
critical O
roles O
of O
reactive O
nitrogen O
and O
oxygen O
species O
in O
dengue O
hemorrhage O
. O

Understanding O
the O
pathogenesis O
of O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
and O
dengue B
shock I
syndrome I
( I
DSS I
) I
requires O
the O
precise O
identification O
of O
dengue B
virus I
( I
DV I
) I
- O
permissive O
target O
cells O
. O

In O
a O
previous O
study O
using O
unfractionated O
human O
peripheral O
blood O
mononuclear O
cells O
, O
we O
found O
that O
monocytes O
, O
but O
not O
B O
or O
T O
cells O
, O
were O
the O
principal O
DV O
- O
permissive O
cells O
in O
the O
absence O
of O
DV O
- O
immune O
pooled B
human I
sera I
( I
PHS I
) I
and O
the O
major O
mediators O
of O
antibody O
- O
dependent O
enhancement O
in O
the O
presence O
of O
PHS O
. O

To O
further O
identify O
DV O
- O
permissive O
target O
cells O
in O
other O
tissues O
and O
organs O
, O
we O
isolated O
human O
splenic O
mononuclear B
cells I
( I
MNCs I
) I
, O
inoculated O
them O
with O
DV O
type O
2 O
( O
strain O
16681 O
) O
in O
the O
presence O
or O
absence O
of O
PHS O
, O
and O
assessed O
their O
infection O
either O
directly O
using O
flow O
cytometry O
and O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
assays O
or O
indirectly O
by O
plaque O
assay O
. O

Lack O
of O
an O
appropriate O
animal O
model O
for O
dengue B
virus I
( I
DEN I
) I
, O
which O
causes O
dengue O
fever O
and O
dengue B
hemorrhagic I
fever I
/ I
dengue I
shock I
syndrome I
( I
DHF I
/ I
DSS I
) I
, O
has O
impeded O
characterization O
of O
the O
mechanisms O
underlying O
the O
disease O
pathogenesis O
. O

In O
the O
mice O
infected O
with O
D2S10 O
, O
but O
not O
the O
parental O
DEN O
strain O
, O
significant O
levels O
of O
serum O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
were O
produced O
, O
and O
the O
neutralization O
of O
TNF O
- O
alpha O
activity O
prevented O
early O
death O
of O
D2S10 O
- O
infected O
mice O
. O

This O
study O
of O
48 O
Vietnamese O
adults O
with O
secondary O
dengue O
virus O
infections O
defined O
the O
breadth O
and O
magnitude O
of O
peripheral O
T O
- O
cell O
responses O
to O
260 O
overlapping O
peptide O
antigens O
derived O
from O
a O
dengue B
virus I
serotype I
2 I
( I
DV2 I
) I
isolate O
. O

Forty O
- O
seven O
different O
peptides O
evoked O
significant O
gamma O
interferon O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assay O
responses O
in O
39 O
patients O
; O
of O
these O
, O
34 O
peptides O
contained O
potentially O
novel O
T O
- O
cell O
epitopes O
. O

NS3 O
and O
particularly O
NS3 O
( O
200 O
- O
324 O
) O
were O
important O
T O
- O
cell O
targets O
. O

NS3 O
( O
556 O
- O
564 O
) O
and O
Env O
( O
414 O
- O
422 O
) O
were O
identified O
as O
novel O
HIA O
- O
A O
* O
24 O
and O
B O
* O
07 O
- O
restricted O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
, O
respectively O
. O

Acute O
T O
- O
cell O
responses O
to O
natural O
variants O
of O
Env O
( O
114 O
- O
422 O
) O
and O
NS3 O
( O
556 O
- O
564 O
) O
were O
largely O
cross O
- O
reactive O
and O
peaked O
during O
disease O
convalescence O
. O

Dengue O
virus O
, O
the O
causative O
agent O
of O
dengue O
fever O
, O
dengue O
shock O
syndrome O
, O
and O
dengue O
hemorrhagic O
fever O
, O
infects O
susceptible O
cells O
by O
initially O
binding O
to O
a O
receptor O
( O
s O
) O
located O
on O
the O
host O
cell O
surface O
. O

By O
using O
a O
virus B
overlay I
protein I
binding I
assay I
( I
VOPBA I
) I
, O
in O
both O
nondenaturing O
and O
denaturing O
gel O
systems O
, O
a O
putative O
dengue O
virus O
serotype O
1 O
binding O
protein O
of O
approximately O
37 O
kDa O
expressed O
on O
the O
surface O
of O
liver O
( O
HepG2 O
) O
cells O
was O
identified O
. O

dengue B
virus I
( I
DEN I
) I
causes O
dengue O
fever O
and O
dengue O
hemorrhagic O
fever O
/ O
dengue O
shock O
syndrome O
, O
which O
are O
major O
public O
health O
problems O
worldwide O
. O

Our O
results O
demonstrate O
that O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
receptors O
have O
critical O
, O
nonoverlapping O
functions O
in O
resolving O
primary O
DEN O
infection O
. O

Furthermore O
, O
we O
show O
that O
IFN O
- O
alpha O
/ O
beta O
receptor O
- O
mediated O
action O
limits O
initial O
DEN O
replication O
in O
extraneural O
sites O
and O
controls O
subsequent O
viral O
spread O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Mice O
deficient O
in O
B O
, O
CD4 O
( O
+ O
) O
T O
, O
or O
CD8 O
( O
+ O
) O
T O
cells O
had O
no O
increased O
susceptibility O
to O
DEN O
; O
however O
, O
RAG O
mice O
( O
deficient O
in O
both O
B O
and O
T O
cells O
) O
were O
partially O
susceptible O
to O
DEN O
infection O
. O

In O
summary O
, O
( O
i O
) O
IFN O
- O
alpha O
/ O
beta O
is O
critical O
for O
early O
immune O
responses O
to O
DEN O
infection O
, O
( O
ii O
) O
IFN O
- O
gamma O
- O
mediated O
immune O
responses O
are O
crucial O
for O
both O
early O
and O
late O
clearance O
of O
DEN O
infection O
in O
mice O
, O
and O
( O
iii O
) O
the O
IFN O
system O
plays O
a O
more O
important O
role O
than O
T O
- O
and O
B O
- O
cell O
- O
dependent O
immunity O
in O
resistance O
to O
primary O
DEN O
infection O
in O
mice O
. O

The O
dengue O
virus O
type O
2 O
structures O
probably O
involved O
in O
human O
virulence O
were O
previously O
defined O
by O
sequencing O
the O
complete O
genome O
of O
both O
American O
and O
Southeast B
( I
SE I
) I
Asian O
genotype O
templates O
in O
patient O
serum O
( O
K O
. O

We O
have O
now O
evaluated O
the O
effects O
of O
introducing O
a O
mutation O
in O
the O
envelope O
glycoprotein O
( O
E O
) O
gene O
and O
/ O
or O
replacement O
of O
5 O
' O
- O
and O
3 O
' O
- O
nontranslated O
regions O
on O
dengue O
virus O
replication O
in O
human O
primary O
cell O
cultures O
. O

As O
elevated O
interleukin B
- I
8 I
( I
IL I
- I
8 I
) I
levels O
have O
been O
observed O
in O
sera O
from O
patients O
with O
more O
severe O
disease O
manifestations O
, O
a O
study O
was O
initiated O
to O
look O
at O
the O
effect O
of O
dengue O
virus O
infection O
in O
vitro O
on O
proinflammatory O
cytokine O
secretion O
and O
expression O
. O

A O
significant O
increase O
in O
IL O
- O
8 O
levels O
in O
the O
culture O
supernatant O
of O
primary O
human O
monocytes O
infected O
with O
dengue B
2 I
virus I
( I
D2V I
) I
New I
Guinea I
C I
( I
NGC I
) I
was O
found O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
. O

Among O
the O
proinflammatory O
cytokines O
and O
their O
mRNAs O
measured O
( O
IL O
- O
6 O
, O
IL O
- O
1beta O
, O
IL O
- O
8 O
, O
and O
tumor O
necrosis O
factor O
alpha O
) O
, O
IL O
- O
8 O
showed O
the O
greatest O
change O
following O
D2V O
infection O
. O

Similarly O
, O
two O
cell O
lines O
, O
293T O
( O
a O
human O
epithelial O
cell O
line O
) O
and O
ECV304 O
( O
an O
endothelial O
cell O
line O
) O
, O
were O
permissive O
to O
D2V O
NGC O
and O
responded O
to O
the O
infection O
by O
increasing O
the O
synthesis O
of O
IL O
- O
8 O
. O

Nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappaB I
) I
and O
nuclear B
factor I
IL I
- I
6 I
( I
NFIL I
- I
6 I
) I
are O
primary O
mediators O
of O
IL O
- O
8 O
expression O
. O

Although O
prior O
studies O
have O
investigated O
cellular O
infection O
by O
dengue B
virus I
( I
DV I
) I
, O
many O
have O
used O
highly O
passaged O
strains O
. O

We O
have O
reassessed O
cellular O
infection O
by O
DV B
type I
2 I
( I
DV2 I
) I
using O
prototype O
and O
low O
- O
passage O
isolates O
representing O
genotypes O
from O
different O
geographic O
areas O
. O

Although O
endothelial O
cells O
have O
been O
speculated O
to O
be O
a O
target O
in O
the O
pathogenesis O
of O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
, O
there O
has O
been O
little O
evidence O
linking O
dengue O
virus O
infection O
to O
any O
alteration O
in O
endothelial O
cell O
function O
, O
In O
this O
study O
, O
we O
show O
that O
human O
umbilical O
vein O
endothelial O
cells O
become O
activated O
when O
exposed O
to O
culture O
fluids O
from O
dengue O
virus O
- O
infected O
peripheral O
blood O
monocytes O
, O
Maximum O
activation O
was O
achieved O
with O
culture O
fluids O
from O
monocytes O
in O
which O
virus O
infection O
was O
enhanced O
by O
the O
addition O
of O
dengue O
virus O
- O
immune O
serum O
, O
thus O
correlating O
with O
epidemiological O
evidence O
that O
prior O
immunity O
to O
dengue O
virus O
is O
a O
major O
risk O
factor O
for O
DHF O
. O

In O
contrast O
, O
activation O
of O
endothelial O
cell O
E O
- O
selectin O
expression O
appeared O
to O
be O
more O
transient O
, O
as O
indicated O
by O
its O
detection O
at O
3 O
h O
, O
but O
not O
at O
16 O
h O
, O
of O
treatment O
, O
Treatment O
of O
monocyte O
culture O
fluids O
with O
anti B
- I
tumor I
necrosis I
factor I
alpha I
( I
TNF I
- I
a I
) I
antibody O
largely O
abolished O
the O
activation O
effect O
( O
as O
measured O
by O
endothelial O
cell O
expression O
of O
ICAM O
- O
1 O
) O
, O
whereas O
treatment O
with O
IL O
- O
1 O
beta O
receptor O
antagonist O
had O
a O
much O
smaller O
inhibitory O
effect O
on O
activation O
, O
Endothelial O
cells O
inoculated O
directly O
with O
dengue O
virus O
or O
with O
virus O
- O
antibody O
combinations O
were O
poorly O
infectable O
( O
compared O
to O
Vero O
cells O
or O
peripheral O
blood O
monocytes O
) O
, O
and O
virus O
- O
inoculated O
endothelial O
cells O
showed O
no O
increased O
expression O
of O
VCAM O
- O
1 O
, O
ICAM O
- O
1 O
, O
or O
E O
- O
selectin O
, O
Taken O
together O
, O
the O
results O
strongly O
indicate O
that O
dengue O
virus O
can O
modulate O
endothelial O
cell O
function O
by O
an O
indirect O
route O
, O
in O
which O
a O
key O
intermediary O
is O
TNF O
- O
alpha O
released O
from O
virus O
- O
infected O
monocytes O
. O

sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
was O
identified O
as O
a O
functional O
receptor O
for O
hepatitis B
D I
virus I
( I
HDV I
) I
and O
its O
helper O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

This O
study O
shows O
that O
mice O
with O
these O
three O
amino O
acids O
altered O
their O
corresponding O
human O
residues O
( O
H84R O
, O
T86K O
, O
and O
S87N O
) O
in O
endogenous O
mouse O
NTCP O
support O
de O
novo O
HDV O
infection O
in O
vivo O
. O

We O
recently O
showed O
that O
neonatal O
C57BL O
/ O
6 O
transgenic B
( I
Tg I
) I
mice O
exogenously O
expressing O
human B
NTCP I
( I
hNTCP I
- I
Tg I
) I
in O
liver O
support O
transient O
HDV O
infection O
. O

The O
mice O
with O
the O
humanized O
NTCP O
residues O
( O
H84R O
, O
T86K O
, O
and O
S87N O
) O
are O
susceptible O
to O
HDV O
infection O
, O
and O
the O
infection O
can O
be O
established O
in O
both O
neonatal O
and O
adult O
mice O
with O
this O
editing O
. O

Cell O
culture O
( O
cc O
) O
- O
derived O
hepatitis B
B I
virus I
( I
HBV I
) I
can O
infect O
differentiated O
HepaRG O
cells O
, O
but O
efficient O
infection O
requires O
addition O
of O
polyethylene B
glycol I
( I
PEG I
) I
during O
inoculation O
. O

Identification O
of O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
as O
an O
HBV O
receptor O
enabled O
ccHBV O
infection O
of O
NTCP O
reconstituted O
HepG2 O
cells O
, O
although O
very O
little O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
is O
produced O
. O

We O
found O
infection O
by O
patient O
serum O
- O
derived O
HBV O
( O
sHBV O
) O
, O
which O
required O
purification O
of O
viral O
particles O
through O
ultracentrifugation O
or O
PEG O
precipitation O
, O
was O
PEG O
independent O
and O
much O
more O
efficient O
in O
HepaRG O
cells O
than O
in O
HepG2 O
/ O
NTCP O
cells O
. O

In O
contrast O
to O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
, O
HBsAg O
was O
not O
a O
reliable O
marker O
of O
productive O
sHBV O
infection O
at O
early O
time O
points O
. O

A O
low O
HBsAg O
/ O
HBeAg O
ratio O
by O
ccHBV O
- O
infected O
HepG2 O
/ O
NTCP O
cells O
was O
attributable O
to O
dimethyl B
sulfoxide I
( I
DMSO I
) I
in O
culture O
medium O
, O
NTCP O
overexpression O
, O
and O
HBV O
genotype O
D O
. O

IMPORTANCE O
Currently O
in O
vitro O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
depends O
on O
cell O
culture O
- O
derived O
HBV O
inoculated O
in O
the O
presence O
of O
polyethylene O
glycol O
. O

Serum O
- O
derived O
HBV O
has O
poor O
infectivity O
in O
HepG2 O
cells O
reconstituted O
with O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
, O
the O
currently O
accepted O
HBV O
receptor O
. O

Positive O
- O
sense O
RNA O
viruses O
encode O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
essential O
for O
genomic O
replication O
. O

With O
the O
exception O
of O
the O
large O
nidoviruses O
, O
such O
as O
Coronaviruses B
( I
CoVs I
) I
, O
RNA O
viruses O
lack O
proofreading O
and O
thus O
are O
dependent O
on O
RdRps O
to O
control O
nucleotide O
selectivity O
and O
fidelity O
. O

CoVs O
encode O
a O
proofreading O
exonuclease O
in O
nonstructural O
protein O
14 O
( O
nsp14 O
- O
ExoN O
) O
, O
which O
confers O
a O
greater O
- O
than O
- O
10 O
- O
fold O
increase O
in O
fidelity O
compared O
to O
other O
RNA O
viruses O
. O

It O
is O
unknown O
to O
what O
extent O
the O
CoV O
polymerase O
( O
nsp12 O
- O
RdRp O
) O
participates O
in O
replication O
fidelity O
. O

We O
modeled O
the O
CoV O
murine B
hepatitis I
virus I
( I
MHV I
) I
nsp12 O
- O
RdRp O
structure O
and O
superimposed O
it O
on O
solved O
picornaviral O
RdRp O
structures O
. O

Fidelity O
- O
altering O
mutations O
previously O
identified O
in O
Coxsackie B
virus I
B3 I
( I
CVB3 I
) I
were O
mapped O
onto O
the O
nsp12 O
- O
RdRp O
model O
structure O
and O
then O
engineered O
into O
the O
MHV O
genome O
with O
[ O
nsp14 O
- O
ExoN O
( O
+ O
) O
] O
or O
without O
[ O
nsp14 O
- O
ExoN O
( O
- O
) O
] O
ExoN O
activity O
. O

Using O
this O
method O
, O
we O
identified O
two O
mutations O
conferring O
resistance O
to O
the O
mutagen O
5 B
- I
fluorouracil I
( I
5 I
- I
FU I
) I
: O
nsp12 O
- O
M611F O
and O
nsp12 O
- O
V553I O
. O

For O
nsp12 O
- O
V553I O
, O
we O
also O
demonstrate O
resistance O
to O
the O
mutagen O
5 B
- I
azacytidine I
( I
5 I
- I
AZC I
) I
and O
decreased O
accumulation O
of O
mutations O
. O

Coronaviruses B
( I
CoVs I
) I
are O
the O
only O
known O
RNA O
viruses O
to O
encode O
a O
proofreading O
exonuclease O
( O
nsp14 O
- O
ExoN O
) O
, O
as O
well O
as O
other O
replicase O
proteins O
involved O
in O
regulation O
of O
fidelity O
. O

This O
report O
shows O
that O
the O
CoV O
RdRp O
( O
nsp12 O
) O
likely O
functions O
in O
replication O
fidelity O
; O
that O
residue O
determinants O
of O
CoV O
RdRp O
nucleotide O
selectivity O
map O
to O
similar O
structural O
regions O
of O
other O
, O
unrelated O
RNA O
viral O
polymerases O
; O
and O
that O
for O
CoVs O
, O
the O
proofreading O
activity O
of O
the O
nsp14 O
- O
ExoN O
is O
epistatic O
to O
the O
function O
of O
the O
RdRp O
in O
fidelity O
. O

The O
risk O
of O
liver O
cancer O
in O
patients O
infected O
with O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
their O
clinical O
response O
to O
interferon O
alpha O
therapy O
vary O
based O
on O
the O
HBV O
genotype O
. O

2DS O
- O
RNA O
) O
expressed O
by O
wild O
- O
type O
HBV O
genotype O
A O
, O
the O
level O
of O
HBV O
pregenomic B
RNA I
( I
pgRNA I
) I
was O
higher O
than O
that O
in O
cells O
transfected O
with O
an O
HBV O
genotype O
A O
expression O
plasmid O
. O

2DS O
- O
RNA O
interacted O
with O
the O
TATA B
- I
binding I
protein I
( I
TBP I
) I
and O
that O
nucleotides O
432 O
to O
832 O
of O
2 O
. O

2DS O
- O
RNA O
colocalized O
with O
cytoplasmic O
TBP O
and O
the O
stress O
granule O
components O
, O
G3BP O
and O
poly B
( I
A I
) I
- I
binding I
protein I
1 I
( I
PABP1 I
) I
, O
in O
Huh7 O
cells O
. O

Subunit O
vaccines O
based O
on O
the O
herpes B
simplex I
virus I
2 I
( I
HSV I
- I
2 I
) I
glycoprotein I
D I
( I
gD I
- I
2 I
) I
have O
been O
the O
major O
focus O
of O
HSV O
- O
2 O
vaccine O
development O
for O
the O
past O
2 O
decades O
. O

Based O
on O
the O
promising O
data O
generated O
in O
the O
guinea O
pig O
model O
, O
a O
formulation O
containing O
truncated O
gD O
- O
2 O
, O
aluminum O
salt O
, O
and O
MPL O
( O
gD O
/ O
AS04 O
) O
advanced O
to O
clinical O
trials O
. O

To O
address O
this O
discrepancy O
, O
we O
developed O
a O
Depot B
medroxyprogesterone I
acetate I
( I
DMPA I
) I
- O
treated O
cotton O
rat O
Sigmodon O
hispidus O
model O
of O
HSV O
- O
2 O
and O
HSV O
- O
1 O
genital O
infection O
. O

Cotton O
rats O
were O
intramuscularly O
vaccinated O
using O
a O
prime O
boost O
strategy O
with O
gD O
/ O
AS04 O
( O
Simplirix O
vaccine O
) O
or O
control O
vaccine O
formulation O
( O
hepatitis O
B O
vaccine O
FENDrix O
) O
and O
subsequently O
challenged O
intravaginally O
with O
HSV O
- O
2 O
or O
HSV O
- O
1 O
. O

The O
significant O
gap O
in O
knowledge O
on O
genital O
herpes O
pathogenesis O
has O
been O
further O
highlighted O
by O
the O
recent O
failure O
of O
GSK O
HSV O
- O
2 O
vaccine O
Simplirix O
( O
gD O
/ O
AS04 O
) O
to O
protect O
humans O
against O
HSV O
- O
2 O
and O
the O
surprising O
finding O
that O
the O
vaccine O
protected O
against O
HSV O
- O
1 O
genital O
herpes O
instead O
. O

hepatitis B
D I
virus I
( I
HDV I
) I
superinfection O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
carriers O
causes O
severe O
liver O
disease O
and O
a O
high O
rate O
of O
chronicity O
. O

In O
mice O
, O
HDV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
responses O
were O
induced O
by O
a O
DNA O
vaccine O
expressing O
HDV O
p27 O
. O

In O
subsequent O
experiments O
, O
seven O
naive O
woodchucks O
were O
immunized O
with O
a O
DNA O
prime O
and O
adenoviral O
boost O
regimen O
prior O
to O
simultaneous O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
and O
HDV O
infection O
. O

Clearance O
of O
hepatitis B
D I
virus I
( I
HDV I
) I
viremia O
leads O
to O
disease O
remission O
. O

large B
hepatitis I
delta I
antigen I
( I
L I
- I
HDAg I
) I
has O
been O
reported O
to O
activate O
transforming O
growth O
factor O
13 O
, O
which O
may O
induce O
epithelial B
- I
mesenchymal I
transition I
( I
EMT I
) I
and O
fibrogenesis O
. O

This O
study O
analyzed O
serum O
HDV O
RNA O
quasispecies O
in O
HDV O
- O
infected O
patients O
at O
two O
stages O
of O
infection O
: O
before O
and O
after O
alanine B
aminotransferase I
( I
ALT I
) I
elevations O
. O

Using O
an O
in O
vitro O
model O
consisting O
of O
Huh O
- O
7 O
cells O
transfected O
with O
cloned O
HDV O
cDNAs O
, O
the O
pre O
- O
or O
post O
- O
ALT O
elevation O
dominant O
HDV O
RNA O
species O
were O
characterized O
for O
( O
i O
) O
their O
replication O
capacity O
by O
measuring O
HDV O
RNA O
and O
HDAg O
levels O
in O
transfected O
cells O
and O
( O
ii O
) O
their O
capacity O
to O
induce O
EMT O
by O
measuring O
the O
levels O
of O
the O
mesenchymal O
- O
cell O
- O
specific O
protein O
vimentin O
, O
the O
EMT O
regulators O
twist O
and O
snail O
, O
and O
the O
epithelial O
- O
cell O
- O
specific O
protein O
E O
- O
cadherin O
. O

Although O
hepatitis B
B I
virus I
( I
HBV I
) I
classically O
is O
considered O
hepatotropic O
, O
it O
has O
strong O
lymphotropic O
properties O
as O
well O
. O

The O
present O
work O
attempted O
to O
characterize O
HBV O
sequences O
from O
the O
peripheral B
blood I
leukocytes I
( I
PBL I
) I
of O
a O
large O
set O
of O
subjects O
, O
using O
advanced O
molecular O
biology O
and O
computational O
methods O
. O

Interestingly O
, O
entirely O
different O
HBV O
genotypes O
/ O
subgenotypes O
( O
C O
, O
D O
, O
or O
Aa O
/ O
A1 O
) O
were O
found O
to O
predominate O
in O
the O
sera O
of O
the O
same O
study O
populations O
. O

Various O
domains O
of O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
are O
essential O
for O
the O
assembly O
and O
secretion O
of O
hepatitis B
D I
virus I
( I
HDV I
) I
. O

Six O
hepatitis B
B I
virus I
( I
HBV I
) I
producing O
plasmids O
( O
three O
genotype O
B O
and O
three O
genotype O
C O
) O
and O
six O
HBsAg O
expression O
plasmids O
that O
expressed O
various O
HBsAg O
levels O
were O
constructed O
from O
the O
sera O
of O
HDV O
- O
infected O
patients O
. O

Serum O
HBsAg O
and O
HBV O
DNA O
levels O
were O
correlated O
with O
HDV O
RNA O
levels O
and O
outcomes O
of O
chronic B
hepatitis I
D I
( I
CHD I
) I
patients O
. O

, O
based O
upon O
complementation O
studies O
of O
known O
temperature B
- I
sensitive I
( I
ts I
) I
mutants O
of O
murine O
hepatitis O
vir O
- O
us O
( O
MHV O
) O
strain O
A59 O
, O
proposes O
that O
an O
intermediate O
comprised O
of O
nsp4 O
to O
nsp10 O
/ O
11 O
( O
similar O
to O
150 O
kDa O
) O
is O
involved O
in O
negative O
- O
strand O
synthesis O
. O

In O
this O
study O
, O
we O
introduced O
a O
single O
- O
amino O
- O
acid O
change O
( O
nsp10 O
: O
Q65E O
) O
associated O
with O
the O
TS O
- O
LA6 O
phenotype O
into O
nsp10 O
of O
the O
infectious O
clone O
of O
MHV O
. O

In O
BALB O
/ O
c O
( O
H O
- O
2 O
( O
d O
) O
) O
mice O
, O
the O
dominant O
response O
is O
directed O
against O
an O
L O
( O
d O
) O
- O
restricted O
peptide O
in O
the O
nucleocapsid O
protein O
( O
APTAGAFFF O
) O
. O

Virus O
- O
induced O
cytotoxic O
T O
lymphocytes O
to O
other O
L O
( O
d O
) O
motif O
- O
containing O
nucleocapsid O
peptides O
were O
not O
detected O
, O
despite O
the O
identification O
of O
two O
epitopes O
with O
reduced O
L O
( O
d O
) O
affinity O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
is O
the O
most O
pathogenic O
member O
of O
the O
Alphavirus O
genus O
in O
the O
Togaviridae O
family O
. O

Our O
previous O
studies O
demonstrated O
the O
critical O
function O
of O
the O
hypervariable B
domain I
( I
HVD I
) I
in O
EEEV O
nsP3 O
for O
the O
assembly O
of O
viral B
replication I
complexes I
( I
vRCs I
) I
. O

Most O
notably O
, O
despite O
the O
inability O
to O
induce O
detectable O
disease O
, O
the O
designed O
EEEV O
mutants O
remained O
highly O
immunogenic O
and O
, O
after O
a O
single O
dose O
, O
protected O
mice O
against O
subsequent O
infection O
with O
wild B
- I
type I
( I
WT I
) I
EEEV O
. O

IMPORTANCE O
Hypervariable B
domains I
( I
HVDs I
) I
of O
alphavirus O
nsP3 O
proteins O
recruit O
host O
proteins O
into O
viral O
replication O
complexes O
. O

Alphavirus O
infection O
of O
fibroblastic O
cell O
types O
in O
vitro O
inhibits O
host O
cell O
translation O
and O
transcription O
, O
leading O
to O
suppression O
of O
interferon O
alpha O
/ O
beta O
( O
IFN O
alpha O
/ O
beta O
) O
production O
. O

Murine O
infection O
with O
wild O
- O
type O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
a O
highly O
myeloid O
- O
cell O
- O
tropic O
alphavirus O
, O
results O
in O
secretion O
of O
very O
high O
systemic O
levels O
of O
IFN O
- O
alpha O
/ O
beta O
, O
suggesting O
that O
stress O
responses O
in O
responding O
cells O
are O
active O
. O

Furthermore O
, O
the O
interferon B
regulatory I
factor I
7 I
( I
IRF7 I
) I
, O
but O
not O
IRF3 O
, O
transcription O
factor O
was O
critical O
for O
IFN O
- O
alpha O
/ O
beta O
induction O
in O
vitro O
and O
in O
sera O
of O
mice O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
has O
a O
high O
case O
- O
fatality O
rate O
in O
horses O
and O
humans O
, O
and O
Florida O
has O
been O
hypothesized O
to O
be O
the O
source O
of O
EEEV O
epidemics O
for O
the O
northeastern O
United O
States O
. O

IMPORTANCE O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
infections O
are O
severe O
in O
horses O
and O
humans O
on O
the O
east O
coast O
of O
the O
United O
States O
with O
a O
> O
90 O
% O
mortality O
rate O
in O
horses O
, O
an O
similar O
to O
33 O
% O
mortality O
rate O
in O
humans O
, O
and O
significant O
brain O
damage O
in O
most O
human O
survivors O
. O

Recently O
, O
a O
host O
- O
restricted O
, O
mosquito O
- O
borne O
alphavirus O
, O
Eilat B
virus I
( I
EILV I
) I
, O
was O
described O
with O
an O
inability O
to O
infect O
vertebrate O
cells O
based O
on O
defective O
attachment O
and O
/ O
or O
entry O
, O
as O
well O
as O
a O
lack O
of O
genomic O
RNA O
replication O
. O

We O
investigated O
the O
utilization O
of O
EILV O
recombinant O
technology O
as O
a O
vaccine O
platform O
against O
eastern O
( O
EEEV O
) O
and O
Venezuelan B
equine I
encephalitis I
viruses I
( I
VEEV I
) I
, O
two O
important O
pathogens O
of O
humans O
and O
domesticated O
animals O
. O

A O
single O
- O
dose O
immunization O
of O
either O
monovalent O
or O
multivalent O
EILV O
chimera O
( O
s O
) O
generated O
neutralizing O
antibody O
responses O
and O
protected O
animals O
against O
lethal O
challenge O
70 O
days O
later O
. O

We O
explored O
the O
use O
of O
the O
mosquito O
- O
specific O
alphavirus O
EILV O
as O
an O
alphavirus O
vaccine O
platform O
in O
well O
- O
established O
disease O
models O
for O
eastern O
( O
EEE O
) O
and O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
is O
a O
representative O
member O
of O
the O
New O
World O
alphaviruses O
. O

Our O
previously O
published O
data O
and O
those O
of O
other O
teams O
have O
demonstrated O
that O
Hypervariable B
domains I
( I
HVDs I
) I
of O
the O
alphavirus O
nsP3 O
protein O
interact O
with O
virus O
- O
specific O
host O
factors O
and O
play O
critical O
roles O
in O
assembly O
of O
viral B
replication I
complexes I
( I
vRCs I
) I
. O

FXR O
proteins O
drive O
the O
assembly O
of O
vRCs O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
and O
G3BPs O
were O
shown O
to O
function O
in O
vRC O
assembly O
in O
the O
replication O
of O
chikungunya O
and O
Sindbis O
viruses O
. O

IMPORTANCE O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
is O
one O
of O
the O
most O
pathogenic O
New O
World O
alphaviruses O
. O

Alphavirus O
replicons O
were O
evaluated O
as O
potential O
vaccine O
candidates O
for O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
, O
or O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
when O
given O
individually O
or O
in O
combination O
( O
V O
/ O
W O
/ O
E O
) O
to O
mice O
or O
cynomolgus O
macaques O
. O

IMPORTANCE O
Three O
related O
viruses O
belonging O
to O
the O
genus O
Alphavirus O
cause O
severe O
encephalitis O
in O
humans O
: O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
, O
and O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
. O

Recently O
, O
we O
compared O
amino O
acid O
sequences O
of O
the O
E2 O
glycoprotein O
of O
natural O
North B
American I
eastern I
equine I
encephalitis I
virus I
( I
NA I
- I
EEEV I
) I
isolates O
and O
demonstrated O
that O
naturally O
circulating O
viruses O
interact O
with O
heparan B
sulfate I
( I
HS I
) I
and O
that O
this O
interaction O
contributes O
to O
the O
extreme O
neurovirulence O
of O
EEEV O
( O
C O
. O

In O
the O
current O
study O
, O
we O
have O
examined O
the O
contribution O
to O
HS O
binding O
of O
each O
of O
three O
lysine O
residues O
in O
the O
E2 O
71 O
- O
to O
- O
77 O
region O
that O
comprise O
the O
primary O
HS O
binding O
site O
of O
wild B
- I
type I
( I
WT I
) I
NA O
- O
EEEV O
viruses O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
produces O
the O
most O
severe O
human O
arboviral O
disease O
in O
North B
America I
( I
NA I
) I
and O
is O
a O
potential O
biological O
weapon O
. O

However O
, O
genetically O
and O
antigenically O
distinct O
strains O
from O
South B
America I
( I
SA I
) I
have O
seldom O
been O
associated O
with O
human O
disease O
or O
mortality O
despite O
serological O
evidence O
of O
infection O
. O

Because O
mice O
and O
other O
small O
rodents O
do O
not O
respond O
differently O
to O
the O
NA O
versus O
SA O
viruses O
like O
humans O
, O
we O
tested O
common O
marmosets O
( O
Callithrix O
jacchus O
) O
by O
using O
intranasal O
infection O
and O
monitoring O
for O
weight O
loss O
, O
fever O
, O
anorexia O
, O
depression O
, O
and O
neurologic O
signs O
. O

1 O
log O
( O
10 O
) O
PFU O
/ O
ml O
on O
day O
2 O
or O
4 O
after O
infection O
, O
but O
there O
was O
no O
detectable O
viremia O
in O
the O
NA O
EEEV O
- O
infected O
animals O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
is O
a O
human O
and O
veterinary O
pathogen O
that O
causes O
sporadic O
cases O
of O
fatal O
neurological O
disease O
. O

Both O
5 O
- O
and O
20 O
- O
amino O
- O
acid O
deletion O
mutant O
viruses O
exhibited O
increased O
sensitivity O
to O
interferon B
( I
IFN I
) I
in O
cell O
culture O
and O
impaired O
replication O
and O
complete O
attenuation O
in O
mice O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
causes O
human O
encephalitis O
in O
North B
America I
( I
NA I
) I
, O
but O
in O
South B
America I
( I
SA I
) I
it O
has O
rarely O
been O
associated O
with O
human O
disease O
, O
suggesting O
that O
SA O
strains O
are O
less O
virulent O
. O

To O
evaluate O
the O
hypothesis O
that O
this O
virulence O
difference O
is O
due O
to O
a O
greater O
ability O
of O
NA O
strains O
to O
evade O
innate O
immunity O
, O
we O
compared O
replication O
of O
NA O
and O
SA O
strains O
in O
Vero O
cells O
pretreated O
with O
interferon B
( I
IFN I
) I
. O

Mice O
pretreated O
with O
poly O
( O
I O
- O
C O
) O
, O
a O
nonspecific O
IFN O
inducer O
, O
exhibited O
dose O
- O
dependent O
protection O
against O
fatal O
eastern O
equine O
encephalitis O
, O
further O
evidence O
that O
IFN O
is O
important O
in O
controlling O
disease O
. O

The O
alternating O
host O
cycle O
and O
persistent O
vector O
infection O
may O
constrain O
the O
evolution O
of O
arboviruses O
, O
To O
test O
this O
hypothesis O
, O
eastern O
equine O
encephalitis O
virus O
was O
passaged O
in O
BHK O
or O
mosquito O
cells O
, O
as O
well O
as O
in O
alternating O
( O
both O
) O
host O
cell O
passages O
. O

Two O
viral O
nonstructural O
proteins O
, O
p150 O
and O
p90 O
, O
are O
expressed O
in O
Rubella B
virus I
( I
RUBV I
) I
- O
infected O
cells O
and O
mediate O
viral O
genome O
replication O
, O
presumably O
using O
various O
host O
machineries O
. O

Here O
we O
show O
that O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
, O
a O
molecular O
chaperone O
, O
is O
an O
important O
host O
factor O
for O
RUBV O
genome O
replication O
. O

The O
treatment O
of O
RUBV O
- O
infected O
cells O
with O
the O
HSP90 O
inhibitors O
17 O
- O
allylamino O
- O
17 O
- O
desmethoxygeldanamycin O
( O
17 O
- O
AAG O
) O
and O
ganetespib O
suppressed O
RUBV O
genome O
replication O
. O

However O
, O
the O
host O
factors O
involved O
in O
Rubella B
virus I
( I
RUBV I
) I
genome O
replication O
are O
largely O
unknown O
. O

The O
impact O
of O
the O
Zika B
virus I
( I
ZIKV I
) I
epidemic O
highlights O
the O
need O
for O
vaccines O
that O
reduce O
or O
prevent O
infection O
and O
reliably O
prevent O
teratogenic O
complications O
. O

The O
live O
- O
attenuated O
measles B
virus I
( I
MV I
) I
vaccine O
strains O
are O
a O
promising O
vaccine O
platform O
, O
since O
they O
induce O
robust O
humoral O
and O
cellular O
immune O
responses O
against O
additional O
antigens O
and O
have O
an O
excellent O
safety O
record O
. O

To O
explore O
its O
potential O
to O
protect O
against O
ZIKV O
, O
we O
compared O
a O
recombinant O
Schwarz O
strain O
MV O
that O
encodes O
ZIKV O
prM O
and O
soluble O
E O
proteins O
( O
MV O
- O
Zika O
- O
sE O
) O
with O
a O
prototypic O
alum O
- O
adjuvanted O
whole O
inactivated O
ZIKV O
particle O
vaccine O
. O

Immunized O
IFNAR O
( O
- O
/ O
- O
) O
- O
CD46Ge O
mice O
developed O
E O
protein O
- O
specific O
and O
neutralizing O
antibodies O
, O
and O
ZIKV O
E O
- O
specific O
cellular O
immune O
responses O
were O
observed O
by O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
and O
in O
vitro O
T O
cell O
proliferation O
assays O
. O

IMPORTANCE O
Zika B
virus I
( I
ZIKV I
) I
is O
a O
mosquito O
- O
borne O
flavivirus O
that O
causes O
a O
variety O
of O
neurological O
complications O
, O
including O
congenital O
birth O
defects O
. O

Recombinant O
vaccine O
strain O
- O
derived O
measles B
viruses I
( I
MV I
) I
constitute O
a O
promising O
vector O
platform O
to O
induce O
immunity O
against O
foreign O
pathogens O
by O
expressing O
antigens O
from O
additional O
transcription O
units O
while O
at O
the O
same O
time O
possessing O
a O
remarkable O
safety O
profile O
. O

To O
analyze O
such O
an O
impact O
on O
cellular O
metabolism O
, O
rubella B
virus I
( I
RV I
) I
was O
used O
in O
this O
study O
. O

The O
assessment O
of O
the O
mitochondrial O
respiratory O
( O
based O
on O
the O
oxygen O
consumption O
rate O
) O
and O
glycolytic O
( O
based O
on O
the O
extracellular O
acidification O
rate O
) O
rate O
and O
capacity O
by O
respective O
stress O
tests O
through O
Seahorse O
technology O
enabled O
determination O
of O
the O
bioenergetic O
phenotype O
of O
RV O
- O
infected O
cells O
. O

Irrespective O
of O
the O
cellular O
metabolic O
background O
, O
RV O
infection O
induced O
a O
shift O
of O
the O
bioenergetic O
state O
of O
epithelial O
cells O
( O
Vero O
and O
A549 O
) O
and O
human O
umbilical O
vein O
endothelial O
cells O
to O
a O
higher O
oxidative O
and O
glycolytic O
level O
. O

rubella B
virus I
( I
RuV I
) I
causes O
a O
systemic O
infection O
, O
and O
transplacental O
fetal O
infection O
causes O
congenital O
rubella O
syndrome O
. O

Assays O
using O
inhibitors O
of O
serine O
palmitoyl O
transferase O
and O
ceramide O
transport O
protein O
demonstrated O
the O
contribution O
of O
sphingomyelin B
( I
SM I
) I
to O
RuV O
infection O
. O

The O
absence O
of O
either O
SM O
or O
cholesterol O
( O
Chol O
) O
abrogated O
the O
RuV O
- O
liposome O
interaction O
. O

SM B
and I
Chol I
( I
SM I
/ I
Chol I
) I
were O
also O
critical O
for O
RuV O
binding O
to O
erythrocytes O
and O
lymphoid O
cells O
. O

myelin B
oligodendrocyte I
glycoprotein I
( I
MOG I
) I
has O
recently O
been O
identified O
as O
a O
cellular O
receptor O
for O
RuV O
. O

We O
studied O
the O
entry O
mechanism O
of O
rubella B
virus I
( I
RuV I
) I
and O
found O
that O
RuV O
binds O
directly O
to O
the O
host O
plasma O
membrane O
in O
the O
presence O
of O
Ca2 O
+ O
at O
neutral O
pH O
. O

An O
unidentified O
RuV O
receptor O
( O
s O
) O
is O
involved O
in O
this O
Ca2 O
+ O
- O
independent O
binding O
. O

The O
E1 O
membrane O
protein O
of O
rubella B
virus I
( I
RuV I
) I
is O
a O
class O
II O
membrane O
fusion O
protein O
structurally O
related O
to O
the O
fusion O
proteins O
of O
the O
alphaviruses O
, O
flaviviruses O
, O
and O
phleboviruses O
. O

Analyses O
using O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
system O
also O
showed O
that O
the O
self O
- O
interacting O
N O
- O
terminal O
region O
of O
the O
capsid O
protein O
is O
not O
essential O
for O
VLP O
production O
but O
is O
critical O
for O
VLP O
infectivity O
. O

infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
, O
a O
double O
- O
stranded O
RNA O
virus O
belonging O
to O
the O
Birnaviridae O
family O
, O
causes O
immunosuppression O
in O
chickens O
. O

In O
this O
study O
, O
we O
defined O
the O
localization O
of O
IBDV O
replication O
complexes O
based O
on O
colocalization O
analysis O
of O
VP3 O
, O
the O
major O
protein O
component O
of O
IBDV O
ribonucleoproteins B
( I
RNPs I
) I
. O

Triple O
- O
immunostaining O
studies O
between O
VP3 O
, O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
VP1 O
, O
and O
viral O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
showed O
a O
well O
- O
defined O
colocalization O
, O
indicating O
that O
the O
three O
critical O
components O
of O
the O
RNPs O
colocalize O
in O
the O
same O
structure O
, O
likely O
representing O
replication O
complexes O
. O

Similarly O
, O
brefeldin B
A I
( I
BFA I
) I
treatment O
led O
to O
a O
punctate O
distribution O
of O
VP3 O
, O
scattered O
throughout O
the O
cytoplasm O
of O
infected O
cells O
. O

Rubella B
virus I
( I
RUBV I
) I
, O
a O
positive O
- O
strand O
RNA O
virus O
, O
replicates O
its O
RNA O
within O
membrane O
- O
associated O
replication B
complexes I
( I
RCs I
) I
in O
the O
cytoplasm O
of O
infected O
cells O
. O

RNA O
synthesis O
is O
mediated O
by O
the O
nonstructural B
proteins I
( I
nsPs I
) I
P200 O
and O
its O
cleavage O
products O
, O
P150 O
and O
P90 O
( O
N O
and O
C O
terminal O
within O
P200 O
, O
respectively O
) O
, O
which O
are O
processed O
by O
a O
protease O
residing O
at O
the O
C O
terminus O
of O
P150 O
. O

We O
found O
that O
P150 O
- O
P90 O
interactions O
were O
blocked O
by O
mutational O
disruption O
of O
an O
alpha O
helix O
at O
the O
N O
terminus O
( O
amino O
acids O
[ O
aa O
] O
36 O
to O
49 O
) O
of O
P200 O
and O
that O
these O
mutations O
also O
had O
an O
effect O
on O
NSP O
targeting O
, O
processing O
, O
and O
membrane O
association O
. O

While O
the O
P150 O
- O
P90 O
interaction O
also O
required O
residues O
1700 O
to O
1900 O
within O
P90 O
, O
focus O
formation O
required O
the O
entire O
RNA O
- O
dependent O
RNA O
polymerase O
( O
aa O
1700 O
to O
2116 O
) O
. O

Surprisingly O
, O
the O
RUBV O
capsid B
protein I
( I
CP I
) I
rescued O
RNA O
synthesis O
by O
several O
alanine O
- O
scanning O
mutations O
in O
the O
N O
- O
terminal O
alpha O
helix O
, O
and O
packaged O
replicon O
assays O
showed O
that O
rescue O
could O
be O
mediated O
by O
CP O
in O
the O
virus O
particle O
. O

rubella B
virus I
( I
RV I
) I
is O
a O
highly O
transmissible O
pathogenic O
agent O
that O
causes O
the O
disease O
rubella O
. O

In O
this O
study O
, O
we O
found O
that O
the O
myelin B
oligodendrocyte I
glycoprotein I
( I
MOG I
) I
specifically O
bound O
to O
the O
E1 O
envelope O
glycoprotein O
of O
RV O
, O
and O
an O
antibody O
against O
MOG O
could O
block O
RV O
infection O
. O

Recent O
findings O
suggest O
that O
in O
addition O
to O
its O
role O
in O
packaging O
genomic O
RNA O
, O
the O
West B
Nile I
virus I
( I
WNV I
) I
capsid O
protein O
is O
an O
important O
pathogenic O
determinant O
, O
a O
scenario O
that O
requires O
interaction O
of O
this O
viral O
protein O
with O
host O
cell O
proteins O
. O

The O
interaction O
of O
the O
rubella B
virus I
( I
RV I
) I
capsid I
( I
C I
) I
protein O
and O
the O
mitochondrial O
p32 O
protein O
is O
believed O
to O
participate O
in O
virus O
replication O
. O

When O
cell O
lines O
either O
pretreated O
with O
respiratory O
chain O
inhibitors O
or O
cultivated O
under O
( O
mild O
) O
hypoxic O
conditions O
were O
infected O
with O
RV O
, O
viral O
replication O
was O
reduced O
in O
a O
time O
- O
dependent O
fashion O
. O

Conceivably O
, O
this O
contributes O
to O
p32 O
function O
( O
s O
) O
during O
RV O
replication O
. O

These O
virus O
- O
induced O
changes O
result O
in O
the O
induction O
of O
vesicular O
structures O
that O
envelop O
the O
virus O
replication B
complex I
( I
RC I
) I
. O

In O
this O
study O
, O
we O
have O
extended O
our O
previous O
observations O
on O
the O
intracellular O
location O
of O
West B
Nile I
virus I
strain I
Kunjin I
virus I
( I
WNVKUN I
) I
to O
show O
that O
the O
virus O
- O
induced O
recruitment O
of O
host O
proteins O
and O
membrane O
appears O
to O
occur O
at O
a O
pre O
- O
Golgi O
step O
. O

To O
visualize O
the O
WNVKUN O
replication O
complex O
, O
we O
performed O
three B
- I
dimensional I
( I
3D I
) I
modeling O
on O
tomograms O
from O
WNVKUN O
replicon O
- O
transfected O
cells O
. O

In O
addition O
, O
we O
provide O
data O
that O
indicate O
that O
a O
majority O
of O
the O
viral O
RNA O
species O
housed O
within O
the O
RC O
is O
in O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
form O
. O

The O
rubella B
virus I
( I
RV I
) I
capsid O
is O
an O
RNA O
- O
binding O
protein O
that O
functions O
in O
nucleocapsid O
assembly O
at O
the O
Golgi O
complex O
, O
the O
site O
of O
virus O
budding O
. O

The O
Rubella B
virus I
( I
RUBV I
) I
Capsid B
( I
C I
) I
protein O
rescues O
mutants O
with O
a O
lethal O
deletion O
between O
two O
in O
- O
frame O
NotI O
sites O
in O
the O
P150 O
replicase O
gene O
, O
a O
deletion O
encompassing O
nucleotides O
1685 O
to O
2192 O
of O
the O
RUBV O
genome O
and O
amino B
acids I
( I
aa I
) I
548 O
to O
717 O
of O
P150 O
( O
which O
has O
a O
total O
length O
of O
1 O
, O
301 O
aa O
) O
. O

Introduction O
of O
aa O
1 O
to O
277 O
of O
the O
C O
protein O
( O
lacking O
the O
C O
- O
terminal O
E2 O
signal O
sequence O
) O
between O
the O
NotI O
sites O
in O
the O
P150 O
gene O
in O
a O
replicon O
construct O
yielded O
a O
viable O
construct O
that O
synthesized O
viral O
RNA O
with O
wild O
- O
type O
kinetics O
, O
indicating O
that O
C O
and O
this O
region O
of O
P150 O
share O
a O
common O
function O
. O

Here O
we O
report O
that O
the O
rubella B
virus I
( I
RV I
) I
capsid O
protein O
binds O
to O
poly O
( O
A O
) O
- O
binding O
protein O
( O
PABP O
) O
, O
a O
host O
cell O
protein O
that O
enhances O
translational O
efficiency O
by O
circularizing O
mRNAs O
. O

Mapping O
studies O
revealed O
that O
capsid O
binds O
to O
the O
C O
- O
terminal O
half O
of O
PABP O
, O
which O
interestingly O
is O
the O
region O
that O
interacts O
with O
other O
translation O
regulators O
, O
including O
PABP O
- O
interacting O
protein O
1 O
( O
Paip1 O
) O
and O
Paip2 O
. O

Turnip B
yellow I
mosaic I
virus I
( I
TYMV I
) I
, O
a O
positive O
- O
strand O
RNA O
virus O
belonging O
to O
the O
alphavirus O
- O
like O
supergroup O
, O
encodes O
its O
nonstructural O
replication O
proteins O
as O
a O
206K O
precursor O
with O
domains O
indicative O
of O
methyltransferase B
( I
MT I
) I
, O
proteinase B
( I
PRO I
) I
, O
NTPase O
/ O
helicase B
( I
HEL I
) I
, O
and O
Polymerase B
( I
Pol I
) I
activities O
. O

The O
rubella B
virus I
( I
RUB I
) I
nonstructural I
protein I
( I
NS I
) I
open I
reading I
frame I
( I
ORF I
) I
encodes O
a O
polypeptide O
precursor O
that O
is O
proteolytically O
self O
cleaved O
into O
two O
replicase O
components O
involved O
in O
viral O
RNA O
replication O
. O

The O
grafted O
EF O
- O
loop O
bound O
to O
Ca2 O
+ O
and O
its O
trivalent O
analogs O
Tb3 O
+ O
and O
La3 O
+ O
with O
K O
( O
d O
) O
s O
of O
214 O
, O
47 O
, O
and O
14 O
mu O
M O
, O
respectively O
. O

Mutations O
( O
D1210A O
and O
D1217A O
) O
of O
two O
of O
the O
potential O
Ca2 O
+ O
- O
coordinating O
ligands O
in O
the O
EF O
- O
loop O
led O
to O
the O
elimination O
of O
Tb3 O
+ O
binding O
. O

The O
infectivity O
of O
an O
RUB O
infectious O
cDNA O
clone O
containing O
the O
mutations O
D1210A O
/ O
D1217A O
was O
decreased O
by O
similar O
to O
20 O
- O
fold O
in O
comparison O
to O
the O
wild B
- I
type I
( I
WT I
) I
clone O
, O
and O
these O
mutations O
rapidly O
reverted O
to O
the O
wt O
sequence O
. O

The O
rubella O
virus O
Capsid B
protein I
( I
C I
) I
has O
been O
shown O
to O
complement O
a O
lethal O
deletion O
( O
termed O
Delta O
NotI O
) O
in O
P150 O
replicase O
protein O
. O

To O
investigate O
this O
phenomenon O
, O
we O
generated O
two O
lines O
of O
Vero O
cells O
that O
stably O
expressed O
either O
C O
( O
C O
- O
Vero O
cells O
) O
or O
C O
lacking O
the O
eight O
N O
- O
terminal O
residues O
( O
C O
Delta O
8 O
- O
Vero O
cells O
) O
, O
a O
construct O
previously O
shown O
to O
be O
unable O
to O
complement O
Delta O
NotI O
. O

In O
C O
- O
Vero O
cells O
but O
not O
Vero O
or O
C O
Delta O
8 O
- O
Vero O
cells O
, O
replication O
of O
a O
wild B
- I
type I
( I
WT I
) I
replicon O
expressing O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
reporter O
gene O
( O
RUBrep O
/ O
GFP O
) O
was O
enhanced O
, O
and O
replication O
of O
a O
replicon O
with O
Delta O
NotI O
( O
RUBrep O
/ O
GFP O
- O
Delta O
NotI O
) O
was O
rescued O
. O

The O
distribution O
and O
morphology O
of O
mitochondria O
are O
dramatically O
affected O
during O
infection O
with O
rubella B
virus I
( I
RV I
) I
. O

The O
structural B
proteins I
( I
sP I
) I
of O
the O
Togaviridae O
can O
be O
deleted O
in O
defective O
interfering O
RNAs O
. O

Nevertheless O
, O
in O
this O
study O
, O
we O
found O
that O
the O
SP O
of O
rubella B
virus I
( I
RUB I
) I
could O
enhance O
expression O
of O
reporter O
genes O
from O
RUB O
replicons O
in O
trans O
. O

SP O
enhancement O
required O
capsid B
protein I
( I
CP I
) I
expression O
and O
was O
not O
due O
to O
RNA O
- O
RNA O
recombination O
. O

A O
rubella B
virus I
( I
RUB I
) I
replicon O
, O
RUBrep O
/ O
PAC O
, O
was O
constructed O
and O
used O
to O
map O
the O
3 O
' O
cis O
- O
acting O
elements O
( O
3 O
' O
CSE O
) O
of O
the O
RUB O
genome O
required O
for O
RUB O
replication O
. O

The O
RUBrep O
/ O
PAC O
replicon O
had O
the O
structural O
protein O
open O
reading O
frame O
partially O
replaced O
by O
a O
puromycin B
acetyltransferase I
( I
PAC I
) I
gene O
. O

The O
3 O
' O
region O
necessary O
for O
optimal O
relative O
survival O
consisted O
of O
the O
3 O
' O
305 O
nucleotides B
( I
nt I
) I
, O
a O
region O
conserved O
in O
RUB O
defective O
- O
interfering O
RNAs O
, O
and O
thus O
this O
region O
constitutes O
the O
3 O
' O
CSE O
. O

Within O
the O
3 O
' O
CSE O
, O
deletions O
in O
the O
similar O
to245 O
nt O
that O
overlap O
the O
3 O
' O
end O
of O
the O
El O
gene O
resulted O
in O
reduced O
relative O
survivals O
, O
ranging O
from O
20 O
to O
< O
1 O
% O
of O
the O
parental O
replicon O
survival O
level O
while O
most O
mutations O
within O
the O
similar O
to60 O
- O
nt O
3 B
' I
untranslated I
region I
( I
UTR I
) I
were O
lethal O
. O

None O
of O
the O
3 O
' O
CSE O
mutations O
affected O
in O
vitro O
translation O
of O
the O
nonstructural O
protein O
open O
reading O
frame O
( O
which O
is O
5 O
' O
proximal O
in O
the O
genome O
and O
encodes O
the O
enzymes O
involved O
in O
virus O
RNA O
replication O
) O
. O

rubella B
virus I
( I
RUB I
) I
replicons O
with O
an O
in O
- O
frame O
deletion O
of O
507 O
nucleotides O
between O
two O
NotI O
sites O
in O
the O
P150 O
nonstructural O
protein O
( O
DeltaNotI O
) O
do O
not O
replicate O
( O
as O
detected O
by O
expression O
of O
a O
reporter O
gene O
encoded O
by O
the O
replicon O
) O
but O
can O
be O
amplified O
by O
wild O
- O
type O
helper O
virus O
( O
Tzeng O
et O
al O
. O

Introduction O
of O
the O
Capsid B
( I
C I
) I
protein O
gene O
into O
DeltaNotI O
- O
containing O
replicons O
as O
an O
in O
- O
frame O
fusion O
with O
a O
reporter O
gene O
or O
cotransfection O
with O
both O
DeltaNotI O
replicons O
and O
RUB O
replicon O
or O
plasmid O
constructs O
containing O
the O
C O
gene O
resulted O
in O
replication O
of O
the O
DeltaNotI O
replicon O
, O
confirming O
the O
hypothesis O
that O
the O
C O
gene O
was O
the O
structural O
protein O
gene O
responsible O
for O
complementation O
and O
demonstrating O
that O
complementation O
could O
occur O
either O
in O
cis O
or O
in O
trans O
. O

rubella B
virus I
( I
RUB I
) I
, O
the O
sole O
member O
of O
the O
Rubivirus O
genus O
in O
the O
Togaviridae O
family O
of O
positive O
- O
strand O
RNA O
viruses O
, O
synthesizes O
a O
single O
subgenomic B
( I
sg I
) I
RNA O
containing O
sequences O
from O
the O
3 O
' O
end O
of O
the O
genomic O
RNA O
including O
The B
open I
reading I
frame I
( I
ORF I
) I
that O
encodes O
the O
virion O
proteins O
. O

The O
synthesis O
of O
SG O
RNA O
is O
initiated O
internally O
on O
a O
negative O
- O
strand O
, O
genome O
- O
length O
template O
at O
a O
site O
known O
as O
the O
SG B
promoter I
( I
SGP I
) I
. O

In O
dsRobo402 O
/ O
GFP O
, O
the O
5 O
' O
- O
proximal O
nonstructural O
protein O
ORF O
( O
NS O
- O
ORF O
) O
is O
followed O
by O
the O
first O
SGP O
( O
SGP O
- O
1 O
) O
, O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
gene O
, O
the O
second O
SGP O
( O
SGP O
- O
2 O
) O
, O
and O
the O
structural O
protein O
ORF O
. O

The O
duplicated O
SGP O
, O
SGP O
- O
2 O
, O
contained O
nucleotides B
( I
nt I
) I
- O
175 O
to O
+ O
76 O
relative O
to O
the O
SG O
start O
site O
, O
including O
the O
3 O
' O
127 O
nt O
of O
the O
NS O
- O
ORF O
and O
47 O
nt O
between O
the O
NS O
- O
ORF O
and O
the O
SG O
start O
site O
. O

5 O
' O
Deletions O
of O
SGP O
- O
2 O
to O
nt O
- O
40 O
( O
9 O
nt O
beyond O
the O
3 O
' O
end O
of O
the O
NS O
- O
ORF O
) O
resulted O
in O
a O
wild B
- I
type I
( I
WT I
) I
phenotype O
in O
terms O
of O
virus O
replication O
and O
RNA O
synthesis O
. O

The O
rubella B
virus I
( I
RV I
) I
structural O
proteins O
capsid O
, O
E2 O
, O
and O
El O
are O
synthesized O
as O
a O
polyprotein O
precursor O
. O

rubella B
virus I
( I
RV I
) I
virions O
contain O
three O
structural O
proteins O
, O
a O
capsid O
protein O
that O
interacts O
with O
viral O
genomic O
RNA O
to O
form O
a O
nucleocapsid O
and O
two O
membrane O
glycoproteins O
, O
E2 O
and O
E1 O
. O

We O
found O
that O
substitution O
of O
either O
an O
aspartic O
acid O
residue O
at O
Gly93 O
( O
G93D O
) O
or O
a O
glycine O
residue O
at O
Pro104 O
( O
P104G O
) O
in O
the O
internal O
hydrophobic O
domain O
of O
E1 O
affected O
virus O
infectivity O
but O
not O
virus O
assembly O
. O

Mutations O
that O
completely O
abolished O
( O
C1152S O
and O
G1301S O
) O
or O
largely O
abolished O
( O
G1301A O
) O
cleavage O
of O
p200 O
resulted O
in O
noninfectious O
virus O
. O

Mutations O
that O
partially O
impaired O
cleavage O
of O
p200 O
( O
R1299A O
and O
G1300A O
) O
decreased O
virus O
replication O
. O

rubella B
virus I
( I
RV I
) I
genomic O
RNA O
contains O
two O
large O
open B
reading I
frames I
( I
ORFs I
) I
: O
a O
5 O
' O
- O
proximal O
ORF O
encoding O
nonstructural B
proteins I
( I
nsPs I
) I
that O
function O
primarily O
in O
viral O
RNA O
replication O
and O
a O
3 O
' O
- O
proximal O
ORF O
encoding O
the O
viral O
structural O
proteins O
. O

Processing O
of O
p200 O
to O
two O
mature O
products O
( O
p150 O
and O
poll O
) O
in O
the O
order O
NH2 O
- O
p150 O
- O
p90 O
- O
COOH O
is O
carried O
out O
by O
an O
RV O
encoded O
protease O
residing O
in O
the O
C O
- O
terminal O
region O
of O
p150 O
. O

The O
RV O
nonstructural B
protease I
( I
NS I
- I
pro I
) I
belongs O
to O
a O
viral O
papain O
- O
like O
protease O
family O
that O
cleaves O
the O
polyprotein O
both O
in O
trans O
and O
in O
cis O
. O

We O
have O
recently O
demonstrated O
that O
the O
cytoplasmic O
domain O
of O
El O
( O
residues O
469 O
to O
481 O
, O
KCLYYLRGAIAPR O
) O
is O
required O
for O
virus O
release O
. O

Mutants O
with O
substitutions O
at O
the O
amino O
terminal O
region O
( O
leucine O
474 O
, O
arginine O
475 O
, O
and O
glycine O
476 O
) O
in O
the O
El O
cytoplasmic O
domain O
had O
reduced O
virus O
release O
and O
small O
- O
plaque O
phenotype O
, O
while O
mutants O
with O
substitutions O
at O
the O
carboxy O
- O
terminal O
region O
( O
alanine O
477 O
, O
isoleucine O
478 O
, O
alanine O
479 O
, O
proline O
480 O
, O
and O
arginine O
481 O
) O
had O
only O
marginal O
defects O
in O
virus O
release O
. O

rubella B
virus I
( I
RV I
) I
strains O
vary O
in O
their O
abilities O
to O
replicate O
and O
persist O
in O
cell O
cultures O
derived O
from O
human O
joint O
tissue O
( O
synovial O
cells O
[ O
SC O
] O
) O
, O
and O
this O
arthrotropism O
appears O
to O
be O
linked O
to O
their O
association O
with O
joint O
symptoms O
in O
vivo O
. O

In O
order O
to O
map O
the O
genetic O
determinants O
of O
arthrotropism O
, O
an O
infectious O
clone O
of O
the O
Cendehill O
vaccine O
strain O
of O
RV O
was O
constructed O
, O
as O
well O
as O
tw O
chimeric O
clones O
containing O
cDNAs O
from O
both O
Cendehill O
and O
Therien O
( O
wild O
- O
type O
) O
strains O
, O
Replacement O
of O
the O
entire O
structural O
gene O
region O
of O
Therien O
in O
the O
infectious O
clone O
pROBO302 O
with O
the O
corresponding O
region O
of O
Cendehill O
did O
not O
affect O
growth O
in O
SC O
. O

The O
first O
of O
these O
( O
nucleotides O
2803 O
and O
6416 O
) O
resulted O
in O
a O
10 O
- O
fold O
decrease O
in O
yield O
of O
progeny O
virus O
from O
SC O
. O

This O
region O
contained O
five O
mutations O
, O
at O
nucleotides O
2829 O
, O
3060 O
, O
3164 O
, O
and O
3528 O
( O
near O
the O
carboxy O
terminus O
of O
P150 O
where O
the O
protease O
domain O
is O
located O
) O
and O
at O
nucleotide O
4350 O
in O
p90 O
. O

Antiserum O
prepared O
against O
an O
amino O
- O
terminal O
fragment O
of O
rubella B
virus I
( I
RUB I
) I
nonstructural O
polyprotein O
was O
used O
to O
study O
RUB O
- O
infected O
Vero O
cells O
. O

Thermodynamically O
predicted O
secondary O
structure O
analysis O
of O
the O
3 O
' O
- O
terminal O
305 O
nucleotides B
( I
nt I
) I
of O
the O
rubella B
virus I
( I
RUB I
) I
genome O
, O
a O
region O
conserved O
in O
all O
RUB O
defective O
interfering O
RNAs O
, O
revealed O
four O
stem B
- I
loop I
( I
SL I
) I
structures O
; O
SL1 O
and O
SL2 O
are O
both O
located O
in O
the O
E1 O
coding O
region O
, O
while O
SL3 O
and O
SL4 O
are O
within O
the O
59 O
- O
nt O
3 B
' I
untranslated I
region I
( I
UTR I
) I
preceding O
the O
poly O
( O
A O
) O
tract O
. O

SL2 O
is O
a O
structure O
shown O
to O
interact O
with O
human O
calreticulin B
( I
CAL I
) I
, O
an O
autoantigen O
potentially O
involved O
in O
RUB O
RNA O
replication O
and O
pathogenesis O
. O

Site O
- O
directed O
mutagenesis O
of O
the O
3 O
' O
UTR O
with O
a O
RUB O
infectious O
clone O
, O
Robo302 O
, O
revealed O
that O
most O
of O
the O
3 O
' O
UTR O
is O
required O
for O
viral O
viability O
except O
for O
the O
3 O
' O
- O
terminal O
5 O
nt O
and O
the O
poly O
( O
A O
) O
tract O
, O
although O
poly O
( O
A O
) O
was O
rapidly O
regenerated O
during O
subsequent O
replication O
, O
Maintenance O
of O
the O
overall O
SL3 O
structure O
, O
the O
11 O
- O
nt O
single O
- O
stranded O
sequence O
between O
SL3 O
and O
SSL4 O
, O
and O
the O
sequences O
forming O
SL4 O
were O
all O
important O
for O
viral O
viability O
. O

rubella B
virus I
( I
RV I
) I
virions O
contain O
two O
glycosylated O
membrane O
proteins O
, O
E1 O
and O
E2 O
, O
that O
exist O
as O
a O
heterodimer O
and O
form O
the O
viral O
spike O
complexes O
on O
the O
virion O
surface O
. O

To O
investigate O
the O
nature O
of O
the O
E1 O
- O
E2 O
interaction O
, O
we O
have O
introduced O
mutations O
in O
the O
internal O
hydrophobic O
region O
( O
residues O
81 O
to O
109 O
) O
of O
E1 O
. O

Substitution O
of O
serine O
at O
Cys82 O
( O
mutant O
C82S O
) O
or O
deletion O
of O
this O
hydrophobic O
domain O
( O
mutant O
dt O
) O
of O
E1 O
resulted O
in O
a O
disruption O
of O
the O
E1 O
conformation O
that O
ultimately O
affected O
E1 O
- O
E2 O
heterodimer O
formation O
and O
cell O
surface O
expression O
of O
both O
E1 O
and O
E2 O
, O
Substitution O
of O
either O
aspartic O
acid O
at O
Gly93 O
( O
G93D O
) O
or O
glycine O
at O
Pro104 O
( O
P104G O
) O
was O
found O
to O
impair O
neither O
E1 O
- O
E2 O
heterodimer O
formation O
nor O
the O
transport O
of O
E1 O
and O
E2 O
to O
the O
cell O
surface O
. O

The O
rubella B
virus I
( I
RUB I
) I
nonstructural I
( I
NS I
) I
protease O
is O
a O
papain B
- I
like I
cysteine I
protease I
( I
PCP I
) I
located O
in O
the O
NS B
- I
protein I
open I
reading I
frame I
( I
NSP I
- I
ORF I
) I
that O
cleaves O
the O
NSP O
- O
ORF O
translation O
product O
at O
a O
single O
site O
to O
produce O
two O
products O
, O
P150 O
( O
the O
N O
- O
terminal O
product O
) O
and O
P90 O
( O
the O
C O
- O
terminal O
product O
) O
. O

The O
5 O
' O
end O
of O
the O
genomic O
RNA O
of O
rubella B
virus I
( I
RUB I
) I
contains O
a O
14 O
- O
nucleotide B
( I
nt I
) I
single O
- O
stranded O
leader O
( O
ss O
- O
leader O
) O
followed O
by O
a O
stem O
- O
and O
- O
loop O
structure O
[ O
5 O
' O
( O
+ O
) O
SL O
] O
( O
nt O
15 O
to O
65 O
) O
, O
the O
complement O
of O
which O
at O
the O
3 O
' O
end O
of O
the O
minus O
- O
strand O
RNA O
[ O
3 O
' O
( O
- O
) O
SL O
] O
has O
been O
proposed O
to O
function O
as O
a O
promoter O
for O
synthesis O
of O
genomic O
plus O
strands O
. O

A O
second O
intriguing O
feature O
of O
the O
5 O
' O
end O
of O
the O
RUB O
genomic O
RNA O
is O
the O
presence O
of O
a O
short O
( O
17 O
codons O
) O
open B
reading I
frame I
( I
ORF I
) I
located O
between O
nt O
3 O
and O
54 O
; O
the O
ORF O
encoding O
the O
viral O
nonstructural B
proteins I
( I
nsPs I
) I
initiates O
at O
nt O
41 O
in O
an O
alternate O
translational O
frame O
, O
To O
address O
the O
functional O
significance O
of O
these O
features O
, O
we O
compared O
the O
5 O
' O
- O
terminal O
sequences O
of O
six O
different O
strains O
of O
RUB O
, O
with O
the O
result O
that O
the O
short O
ORF O
is O
preserved O
( O
although O
the O
coding O
sequence O
is O
not O
conserved O
) O
as O
is O
the O
stem O
part O
of O
both O
the O
5 O
' O
( O
+ O
) O
SL O
and O
3 O
' O
( O
- O
) O
SL O
, O
while O
the O
upper O
loop O
part O
of O
both O
structures O
varies O
, O
Next O
, O
using O
Robo302 O
, O
an O
infectious O
cDNA O
clone O
of O
RUB O
, O
we O
introduced O
31 O
different O
mutations O
into O
the O
5 O
' O
- O
terminal O
noncoding O
region O
, O
and O
their O
effects O
on O
virus O
replication O
and O
macromolecular O
synthesis O
were O
examined O
, O
This O
mutagenesis O
revealed O
that O
the O
short O
ORF O
is O
not O
essential O
for O
virus O
replication O
. O

None O
of O
the O
other O
mutations O
within O
either O
the O
ss O
- O
leader O
or O
the O
5 O
' O
( O
+ O
) O
SL O
[ O
and O
accordingly O
within O
the O
3 O
' O
( O
- O
) O
SL O
] O
, O
including O
deletions O
of O
up O
to O
15 O
nt O
from O
the O
5 O
' O
( O
+ O
) O
SL O
and O
three O
different O
multiple O
- O
point O
mutations O
that O
lead O
to O
destabilization O
of O
the O
5 O
' O
( O
+ O
) O
SL O
, O
were O
lethal O
, O
Some O
of O
the O
mutations O
within O
both O
ss O
- O
leader O
and O
the O
5 O
' O
( O
+ O
) O
SL O
resulted O
in O
viruses O
that O
grew O
to O
lower O
titers O
than O
the O
wild O
- O
type O
virus O
and O
formed O
opaque O
and O
/ O
or O
small O
plaques O
; O
in O
general O
mutations O
within O
the O
stem O
had O
a O
more O
profound O
effect O
on O
viral O
phenotype O
than O
did O
mutations O
in O
either O
the O
ss O
- O
leader O
or O
upper O
loop O
, O
Mutations O
in O
the O
5 O
' O
( O
+ O
) O
SL O
, O
but O
not O
in O
the O
ss O
- O
leader O
, O
resulted O
in O
a O
significant O
reduction O
in O
NSP O
synthesis O
, O
indicating O
that O
this O
structure O
is O
important O
for O
efficient O
translation O
of O
the O
NSP O
ORF O
, O
In O
contrast O
, O
viral O
plus O
- O
strand O
RNA O
synthesis O
was O
unaffected O
by O
the O
5 O
' O
( O
+ O
) O
SL O
mutations O
as O
well O
as O
the O
ss O
- O
leader O
mutations O
, O
which O
argues O
against O
the O
proposed O
function O
of O
the O
3 O
' O
( O
- O
) O
SL O
as O
a O
promoter O
for O
initiation O
of O
the O
genomic O
plus O
- O
strand O
RNA O
. O

E2 O
and O
E1 O
are O
type O
I O
membrane O
glycoproteins O
that O
form O
a O
heterodimer O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
before O
they O
are O
transported O
to O
and O
retained O
in O
the O
Golgi O
complex O
, O
where O
virus O
assembly O
occurs O
, O
The O
bulk O
of O
unassembled O
E2 O
and O
E1 O
subunits O
are O
not O
transported O
to O
the O
Golgi O
complex O
. O

We O
constructed O
a O
series O
of O
chimeric O
reporter O
proteins O
by O
fusing O
domains O
from O
E1 O
to O
the O
ectodomains O
of O
two O
other O
type O
I O
membrane O
proteins O
which O
are O
normally O
transported O
to O
the O
cell O
surface O
, O
vesicular O
stomatitis O
virus O
G O
protein O
( O
G O
) O
and O
CD8 O
. O

A O
plasmid O
, O
Robo102 O
, O
which O
contains O
a O
cDNA O
copy O
of O
the O
rubella B
virus I
( I
RUB I
) I
genomic O
RNA O
from O
which O
infectious O
transcripts O
can O
be O
synthesized O
in O
vitro O
, O
was O
recently O
developed O
( O
C O
. O

68 O
: O
3550 O
- O
3557 O
, O
1994 O
) O
, O
To O
increase O
the O
specific O
infectivity O
of O
Robo102 O
transcripts O
( O
similar O
to O
5 O
plaques O
/ O
10 O
mu O
g O
of O
transcripts O
) O
, O
a O
modified O
reverse O
transcription O
- O
PCR O
method O
was O
used O
to O
amplify O
nearly O
90 O
% O
of O
the O
RUB O
genome O
in O
three O
fragments O
, O
which O
were O
then O
used O
to O
replace O
the O
corresponding O
fragments O
in O
Robo102 O
. O

Replacement O
of O
a O
fragment O
covering O
nucleotides B
( I
nt I
) I
5352 O
to O
9759 O
of O
the O
RUB O
genome O
yielded O
a O
construct O
, O
Robo202 O
, O
which O
produced O
highly O
infectious O
transcripts O
( O
10 O
( O
4 O
) O
plaques O
/ O
mu O
g O
, O
indicating O
the O
presence O
of O
an O
unrecognized O
deleterious O
mutation O
( O
or O
mutations O
) O
in O
this O
region O
of O
the O
Robo102 O
cDNA O
. O

Although O
Robo202 O
contains O
over O
4 O
, O
000 O
nt O
from O
f O
- O
Therien O
, O
Robo202 O
virus O
produces O
opaque O
plaques O
, O
However O
, O
when O
the O
other O
two O
PCR O
fragments O
amplified O
from O
f O
= O
Therien O
( O
nt O
1 O
to O
1723 O
and O
nt O
2800 O
to O
5352 O
) O
were O
introduced O
into O
Robo202 O
, O
the O
resulting O
construct O
, O
Robo302 O
, O
yielded O
transcripts O
that O
produced O
a O
virus O
that O
formed O
clear O
plaques O
. O

This O
indicates O
that O
the O
determinants O
of O
plaque O
morphology O
map O
to O
the O
regions O
of O
the O
genome O
covered O
by O
these O
two O
fragments O
, O
both O
of O
which O
are O
in O
the O
nonstructural O
open O
reading O
frame O
, O
Generation O
of O
Robo202 O
/ O
302 O
chimeras O
indicated O
that O
the O
most O
5 O
' O
terminal O
fragment O
( O
nt O
1 O
to O
1723 O
) O
had O
the O
greatest O
effect O
on O
plaque O
morphology O
. O

rubella B
virus I
( I
RV I
) I
infections O
in O
adult O
women O
can O
be O
associated O
with O
acute O
and O
chronic O
arthritic O
symptoms O
. O

In O
many O
autoimmune O
individuals O
, O
antibodies O
are O
found O
targeting O
endogenous O
proteins O
, O
called O
autoantigens O
, O
contained O
in O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
. O

Previously O
, O
we O
noted O
that O
cellular O
proteins O
associated O
with O
the O
RV O
5 O
' O
( O
+ O
) O
stem B
- I
loop I
( I
SL I
) I
RNA O
are O
recognized O
by O
serum O
with O
Ro O
reactivity O
. O

A O
subset O
of O
serum O
samples O
recognizing O
autoantigen O
La O
, O
or O
Ro O
and O
La O
, O
immunoprecipitated O
both O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
and O
3 O
' O
( O
+ O
) O
SL O
RNA O
- O
protein O
complexes O
. O

Autoantigens O
binding O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
and O
3 O
' O
( O
+ O
) O
SL O
RNAs O
differed O
in O
molecular O
mass O
, O
specificities O
for O
respective O
RNA O
binding O
substrates O
, O
and O
sensitivity O
to O
alkaline O
phosphatase O
treatment O
. O

The O
La O
autoantigen O
was O
found O
to O
interact O
with O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
RNA O
as O
determined O
by O
immunological O
techniques O
and O
binding O
reactions O
with O
mixtures O
containing O
recombinant O
La O
protein O
. O

in O
contrast O
, O
Gly O
- O
1299 O
and O
Gly O
- O
1301 O
could O
be O
changed O
to O
alanine O
with O
retention O
of O
cleavage O
, O
but O
a O
change O
to O
valine O
abrogated O
cleavage O
, O
Coexpression O
of O
a O
construct O
that O
contains O
a O
cleavage O
site O
mutation O
( O
to O
serve O
as O
a O
protease O
) O
together O
with O
a O
construct O
that O
contains O
a O
protease O
mutation O
( O
to O
serve O
as O
a O
substrate O
) O
failed O
to O
reveal O
trans O
cleavage O
, O
Coexpression O
of O
wild O
- O
type O
constructs O
with O
protease O
- O
mutant O
constructs O
also O
failed O
to O
reveal O
trans O
cleavage O
, O
even O
after O
extended O
in O
vitro O
incubation O
following O
lysis O
. O

As O
a O
first O
step O
toward O
understanding O
the O
assembly O
of O
rubella O
virus O
nucleocapsid O
at O
the O
molecular O
level O
, O
the O
interaction O
between O
capsid O
protein O
and O
genomic O
RNA O
was O
studied O
by O
Northwestern O
( O
RNA O
- O
protein O
) O
blot O
analysis O
. O

We O
have O
identified O
a O
29 O
- O
nucleotide O
RNA O
sequence O
( O
nucleotides O
347 O
to O
375 O
) O
that O
essential O
for O
the O
binding O
. O

By O
using O
overlapping O
synthetic O
peptides O
of O
capsid O
protein O
, O
a O
peptide O
domain O
( O
residues O
28 O
to O
56 O
) O
that O
displays O
specific O
RNA O
- O
binding O
activity O
of O
capsid O
protein O
has O
been O
located O
. O

In O
a O
coimmunoprecipitation O
assay O
, O
vith O
monospecific O
antisera O
, O
the O
two O
major O
envelope O
proteins O
G O
( O
L O
) O
and O
M O
of O
equine O
arteritis O
virus O
were O
found O
to O
occur O
in O
heteromeric O
complexes O
in O
virions O
and O
infected O
cells O
. O

While O
the O
G O
( O
L O
) O
protein O
associated O
with O
M O
rapidly O
and O
efficiently O
, O
newly O
synthesized O
M O
protein O
was O
incorporated O
into O
complexes O
at O
a O
slower O
rate O
, O
which O
implies O
that O
it O
interacts O
with O
G O
( O
L O
) O
molecules O
synthesized O
earlier O
. O

Analysis O
under O
nonreducing O
conditions O
revealed O
that O
the O
G O
( O
L O
) O
/ O
M O
complexes O
consist O
of O
disulfide O
- O
linked O
heterodimeric O
structures O
. O

Pulse O
- O
chase O
experiments O
showed O
that O
virtually O
all O
G O
( O
L O
) O
monomers O
ended O
up O
in O
heterodimers O
, O
whereas O
a O
fraction O
of O
the O
M O
protein O
persisted O
as O
monomers O
. O

Plasmids O
containing O
a O
complete O
cDNA O
copy O
of O
the O
rubella B
virus I
( I
RUB I
) I
genomic O
RNA O
were O
constructed O
. O

rubella B
virus I
( I
RV I
) I
cirions O
contain O
two O
envelope B
glycoproteins I
( I
E1 I
and I
E2 I
) I
and O
a O
Capsid B
protein I
( I
C I
) I
. O

Noninfectious O
RV O
- O
like O
particles O
( O
VLPs O
) O
containing O
three O
structural O
proteins O
were O
expressed O
in O
a O
BHK O
cell O
line O
( O
BHK O
- O
24S O
) O
by O
using O
an O
inducible O
promoter O
. O

Sequences O
at O
the O
5 O
' O
and O
3 O
' O
ends O
of O
the O
rubella B
virus I
( I
RV I
) I
genomic O
RNA O
can O
potentially O
form O
stable O
stem B
- I
loop I
( I
SL I
) I
structures O
that O
are O
postulated O
to O
be O
involved O
in O
virus O
replication O
. O

We O
have O
analyzed O
the O
function O
of O
these O
putative O
SL O
structures O
in O
RNA O
translation O
by O
constructing O
chimeric O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
RNAs O
, O
flanked O
either O
by O
both O
5 O
' O
- O
and O
3 O
' O
- O
terminal O
sequence O
domains O
from O
the O
RV O
genome O
or O
several O
deletion O
derivatives O
of O
the O
same O
sequences O
. O

Both O
in O
vivo O
and O
in O
vitro O
translation O
activities O
of O
the O
chimeric O
RNAs O
revealed O
that O
the O
presence O
of O
5 O
' O
and O
3 O
' O
SL O
sequences O
of O
RV O
RNA O
, O
in O
correct O
( O
+ O
) O
orientation O
and O
context O
[ O
5 O
' O
( O
+ O
) O
SL O
and O
3 O
' O
( O
+ O
) O
SL O
, O
respectively O
] O
was O
necessary O
for O
efficient O
translation O
of O
chimeric O
RV O
/ O
CAT O
RNAs O
. O

The O
presence O
of O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
sequence O
had O
the O
primary O
enhancing O
effect O
on O
translation O
. O

To O
identify O
host O
proteins O
which O
interact O
with O
the O
5 O
' O
( O
+ O
) O
SL O
which O
may O
be O
involved O
in O
RV O
RNA O
translation O
, O
RNA O
gel O
- O
shift O
and O
UV O
cross O
- O
linking O
assays O
were O
employed O
. O

Two O
host O
proteins O
59 O
and O
52 O
kDa O
in O
size O
, O
present O
in O
cytosolic O
extracts O
from O
both O
uninfected O
and O
RV O
- O
infected O
cells O
, O
specifically O
interacted O
with O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
RNA O
. O

Direct O
binding O
comparisons O
between O
wild O
- O
type O
and O
mutant O
5 O
' O
( O
+ O
) O
SL O
RNAs O
demonstrated O
that O
sequences O
in O
and O
around O
the O
bulge O
region O
of O
the O
terminal O
stem O
domain O
of O
this O
structure O
constituted O
a O
protein O
binding O
determinant O
. O

Human O
serum O
, O
qualified O
for O
anti O
- O
Ro O
/ O
SS O
- O
A O
antigen O
specificity O
, O
immunoprecipitated O
59 O
- O
and O
52 O
- O
kDa O
protein O
- O
RNA O
complexes O
containing O
the O
RV O
5 O
' O
( O
+ O
) O
SL O
RNA O
. O

However O
, O
poly O
- O
and O
monoclonal O
antisera O
raised O
against O
the O
recombinant O
60 O
- O
and O
52 O
- O
kDa O
Ro O
proteins O
failed O
to O
precipitate O
complexes O
containing O
the O
5 O
' O
( O
+ O
) O
SL O
RNA O
. O

The O
role O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
- O
restricted O
CD8 O
+ O
cytotoxic O
T O
lymphocytes O
in O
immunity O
to O
rubella B
virus I
( I
RV I
) I
infection O
is O
unknown O
. O

Lymphocytes O
of O
RV O
- O
immune O
individuals O
were O
prestimulated O
on O
an O
RV O
- O
infected O
MHC O
class O
I O
- O
matched O
( O
or O
partially O
matched O
) O
fibroblast O
monolayer O
which O
generated O
CD8 O
+ O
lymphoblasts O
capable O
of O
lysing O
RV O
- O
infected O
fibroblast O
targets O
in O
a O
class O
I O
- O
restricted O
manner O
. O

Using O
an O
infectious O
Sindbis B
virus I
( I
SV I
) I
vector O
which O
expressed O
the O
RV O
capsid O
protein O
( O
SV O
/ O
RubC O
) O
, O
lymphocytes O
from O
17 O
of O
22 O
RV O
- O
immune O
individuals O
prestimulated O
on O
RV O
- O
infected O
fibroblast O
monolayers O
lysed O
SV O
/ O
RubC O
- O
infected O
fibroblast O
targets O
. O

Fibroblast O
targets O
pulsed O
with O
synthetic O
peptides O
representing O
subsequences O
within O
C1 O
to O
C29 O
( O
subscripts O
indicate O
amino O
acid O
positions O
) O
were O
lysed O
effectively O
when O
the O
targets O
and O
effectors O
matched O
at O
multiple O
class O
I O
alleles O
. O

The O
first O
binding O
domain O
was O
found O
in O
the O
first O
60 O
nucleotides O
, O
which O
represents O
the O
complement O
of O
the O
5 O
' O
- O
nontranslated O
region O
, O
the O
second O
in O
the O
next O
60 O
nucleotides O
, O
the O
third O
in O
the O
following O
60 O
nucleotides O
, O
and O
the O
fourth O
between O
nucleotides O
194 O
and O
249 O
( O
all O
numbering O
is O
3 O
' O
to O
5 O
' O
) O
. O

The O
relative O
binding O
constants O
, O
K O
( O
r O
) O
, O
of O
the O
first O
, O
second O
, O
and O
fourth O
sites O
were O
similar O
, O
whereas O
that O
of O
domain O
2 O
was O
fivefold O
less O
. O

The O
K O
( O
r O
) O
value O
for O
the O
Semliki O
Forest O
virus O
probe O
was O
similar O
to O
that O
for O
the O
Sindbis O
virus O
probe O
, O
while O
that O
for O
the O
Ross O
River O
virus O
probe O
was O
four O
times O
greater O
. O

Sets O
of O
overlapping O
synthetic O
peptides O
containing O
predicted O
T O
- O
cell O
epitope O
motifs O
were O
designed O
from O
the O
murine O
monoclonal O
antibody O
- O
defined O
map O
of O
linear O
B O
- O
cell O
epitope O
domains O
within O
each O
of O
the O
structural O
proteins O
of O
rubella B
virus I
( I
RV I
) I
. O

The O
peptides O
represented O
well O
- O
defined O
subsequences O
of O
two O
capsid O
domains O
( O
C1 O
to O
C29 O
and O
C64 O
to O
C97 O
) O
, O
of O
a O
domain O
of O
glycoprotein O
E1 O
containing O
neutralizing O
determinants O
( O
E1 O
( O
202 O
) O
to O
E1 O
( O
283 O
) O
) O
, O
and O
of O
a O
domain O
of O
glycoprotein O
E2 O
( O
E2 O
( O
31 O
) O
to O
E2 O
( O
105 O
) O
) O
. O

With O
the O
exception O
of O
peptides O
representing O
C O
( O
64 O
) O
to O
C O
( O
97 O
) O
, O
each O
set O
of O
peptides O
stimulated O
varied O
but O
individually O
specific O
lymphoproliferative O
responses O
in O
peripheral O
blood O
mononuclear O
cells O
from O
25 O
to O
50 O
% O
of O
a O
representatively O
large O
number O
of O
normal O
, O
RV O
- O
immune O
human O
donors O
with O
diverse O
human B
leukocyte I
antigen I
( I
HLA I
) I
backgrounds O
. O

We O
previously O
described O
a O
monoclonal B
antibody I
( I
Mab I
) I
library O
generated O
by O
infecting O
BALB O
/ O
c O
mice O
with O
rubella B
virus I
( I
RV I
) I
and O
selected O
by O
an O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
using O
purified O
virion O
targets O
. O

Plasmid O
pARV02 O
- O
01 O
, O
which O
expresses O
the O
fusion O
protein O
RecA1 O
- O
35 O
- O
GIGDLGSP O
- O
E1 O
( O
202 O
) O
- O
E1 O
( O
283 O
) O
- O
GDP O
- O
LacZ9 O
- O
1015 O
in O
Escherichia O
coli O
, O
was O
shown O
to O
be O
a O
ligand O
for O
MAbs O
E1 O
- O
18 O
and O
El O
- O
20 O
( O
J O
. O

One O
of O
these O
peptides O
( O
SP15 O
; O
E1 O
( O
208 O
) O
to O
E1 O
( O
239 O
) O
) O
proved O
an O
effective O
ligand O
for O
both O
MAbs O
in O
the O
ELISA O
. O

Stepwise O
synthesis O
of O
SP15 O
defined O
the O
minimal O
amino O
- O
terminal O
requirement O
for O
binding O
MAb O
E1 O
- O
18 O
as O
E1 O
( O
221 O
) O
and O
that O
of O
MAb O
E1 O
- O
20 O
as O
E1 O
( O
223 O
) O
; O
the O
minimal O
carboxyl O
- O
terminal O
requirement O
is O
uncertain O
but O
does O
not O
exceed O
E1 O
( O
239 O
) O
. O

The O
most O
frequently O
recognized O
epitopes O
on O
E2 O
were O
E2 O
- O
4 O
( O
residues O
54 O
to O
74 O
) O
, O
with O
5 O
of O
10 O
tested O
T O
- O
cell O
lines O
responding O
to O
it O
. O

Only O
one O
peptide O
( O
residues O
255 O
to O
280 O
) O
was O
recognized O
by O
all O
four O
T O
- O
cell O
lines O
. O

Seven O
of O
the O
11 O
rabbit O
antipeptide O
antisera O
( O
anti O
- O
1 O
- O
30 O
, O
- O
74 O
- O
100 O
, O
- O
96 O
- O
123 O
, O
- O
119 O
- O
152 O
, O
- O
205 O
- O
233 O
, O
- O
231 O
- O
257 O
, O
and O
- O
255 O
- O
280 O
) O
specifically O
recognized O
the O
capsid O
protein O
on O
immunoblots O
. O

The O
other O
is O
either O
the O
minimal O
Sindbis O
virus O
promoter O
or O
the O
corresponding O
junction O
sequences O
from O
other O
alphaviruses O
, O
which O
are O
placed O
upstream O
of O
the O
bacterial O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
. O

Glycosylated O
, O
membrane O
- O
associated O
E1 O
( O
58 O
- O
kDa O
) O
and O
E2 O
( O
47 O
- O
to O
49 O
- O
kDa O
) O
rubella O
virus O
proteins O
and O
unglycosylated O
nucleoprotein O
C O
( O
33 O
kDa O
) O
, O
from O
separately O
expressed O
vaccinia O
virus O
recombinants O
, O
were O
injected O
into O
golden O
Syrian O
hamsters O
. O

At O
the O
5 O
' O
end O
of O
the O
rubella O
virus O
genomic O
RNA O
, O
there O
are O
sequences O
that O
can O
form O
a O
potentially O
stable O
stem B
- I
loop I
( I
SL I
) I
structure O
. O

The O
complementary O
negative O
- O
strand O
equivalent O
of O
the O
5 O
' O
- O
end O
SL O
structure O
of O
positive O
- O
strand O
rubella O
virus O
RNA O
[ O
5 O
' O
( O
+ O
) O
SL O
structure O
] O
is O
thought O
to O
serve O
as O
a O
promoter O
for O
the O
initiation O
of O
positive O
- O
strand O
synthesis O
. O

We O
screened O
the O
negative O
- O
strand O
equivalent O
of O
the O
5 O
' O
( O
+ O
) O
SL O
structure O
( O
64 O
nucleotides O
) O
and O
the O
adjacent O
region O
of O
the O
negative O
- O
strand O
RNA O
for O
their O
ability O
to O
bind O
to O
host O
cell O
proteins O
. O

An O
expanded O
library O
of O
murine B
monoclonal I
antibodies I
( I
MAbs I
) I
was O
generated O
by O
infecting O
BALB O
/ O
C O
mice O
with O
the O
Therien O
strain O
of O
rubella B
virus I
( I
RV I
) I
and O
selecting O
secreting O
hybrids O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
using O
purified O
virion O
targets O
. O

Hybrid O
RecA O
- O
RV O
- O
beta O
- O
galactosidase O
( O
LacZ O
) O
- O
or O
RecA O
- O
RV O
- O
truncated O
LacZ O
- O
containing O
proteins O
collectively O
representing O
the O
entire O
open O
reading O
frame O
of O
the O
structural O
proteins O
of O
RV O
were O
overexpressed O
in O
Escherichia O
coli O
. O

With O
this O
approach O
, O
MAbs O
that O
appeared O
to O
react O
with O
linear O
determinants O
defined O
epitopes O
localized O
within O
the O
following O
domains O
: O
MAbs O
C O
- O
1 O
, O
C O
- O
2 O
, O
and O
C O
- O
8 O
bind O
epitopes O
within O
the O
predicted O
amino O
- O
terminal O
21 O
amino O
acids O
of O
the O
capsid O
region O
C O
- O
9 O
to O
C29 O
; O
MAb O
C O
- O
9 O
binds O
to O
a O
domain O
bounded O
by O
C64 O
and O
C97 O
; O
MAbs O
E2 O
- O
1 O
through O
E2 O
- O
6 O
bind O
to O
the O
E2 O
glycoprotein O
backbone O
region O
from O
E2 O
( O
1 O
) O
to O
E2 O
( O
115 O
) O
; O
MAbs O
E1 O
- O
18 O
and O
E1 O
- O
20 O
bind O
to O
the O
E1 O
glycoprotein O
region O
from O
E1 O
( O
202 O
) O
to O
E1 O
( O
283 O
) O
. O

In O
an O
effort O
to O
search O
for O
the O
host O
cellular O
protein O
( O
s O
) O
mediating O
the O
differential O
susceptibility O
of O
the O
two O
cell O
lines O
to O
HCoV O
- O
OC43 O
infection O
, O
we O
found O
that O
ArfGAP O
with O
dual O
pleckstrin B
homology I
( I
PH I
) I
domains O
2 O
( O
ADAP2 O
) O
, O
gamma B
- I
interferon I
- I
inducible I
lysosome I
/ I
endosome I
- I
localized I
thiolreductase I
( I
GILT I
) I
, O
and O
lymphocyte B
antigen I
6 I
family I
member I
E I
( I
LY6E I
) I
, O
the O
three O
cellular O
proteins O
identified O
to O
function O
in O
interference O
with O
virus O
entry O
, O
were O
expressed O
at O
significantly O
higher O
levels O
in O
HepG2 O
cells O
. O

Interestingly O
, O
overexpression O
of O
serine O
protease O
TMPRSS2 O
or O
amphotericin O
treatment O
significantly O
neutralized O
the O
IFN B
- I
inducible I
transmembrane I
3 I
( I
IFITM3 I
) I
restriction O
of O
human O
Coronavirus B
( I
CoV I
) I
entry O
, O
but O
did O
not O
compromise O
the O
effect O
of O
LY6E O
on O
the O
entry O
of O
human O
coronaviruses O
. O

The O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
several O
flaviviruses O
, O
including O
West O
Nile O
, O
dengue O
, O
and O
yellow O
fever O
viruses O
, O
is O
capable O
of O
inducing O
variable O
degrees O
of O
protection O
against O
flavivirus O
infection O
in O
animal O
models O
. O

However O
, O
the O
immunogenicity O
of O
NS1 O
protein O
of O
Zika B
virus I
( I
ZIKV I
) I
is O
less O
understood O
. O

Here O
, O
we O
determined O
the O
efficacy O
of O
ZIKV O
NS1 O
- O
based O
vaccine O
candidates O
using O
two O
delivery O
platforms O
, O
methyltransferase B
- I
defective I
recombinant I
vesicular I
stomatitis I
virus I
( I
mtdVSV I
) I
and O
a O
DNA O
vaccine O
. O

In O
Ifnar1 O
( O
- O
/ O
- O
) O
mice O
, O
neither O
NS1 O
- O
based O
vaccine O
provided O
protection O
against O
a O
lethal O
high O
dose O
( O
10 O
( O
5 O
) O
PFU O
) O
ZIKV O
challenge O
, O
but O
mtdVSV O
- O
NS1 O
- O
based O
vaccine O
prevented O
deaths O
from O
a O
low O
dose O
( O
10 O
( O
3 O
) O
PFU O
) O
challenge O
, O
though O
they O
experienced O
viremia O
and O
body O
weight O
loss O
. O

IMPORTANCE O
Most O
Zika B
virus I
( I
ZIKV I
) I
vaccine O
research O
has O
focused O
on O
the O
E O
or O
prM O
- O
E O
proteins O
and O
the O
induction O
of O
high O
levels O
of O
neutralizing O
antibodies O
. O

However O
, O
these O
ZIKV O
neutralizing O
antibodies O
cross O
- O
react O
with O
other O
flaviviruses O
, O
which O
may O
aggravate O
the O
disease O
via O
an O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
mechanism O
. O

West B
Nile I
virus I
( I
WNV I
) I
, O
a O
member O
of O
the O
Flavivirus O
genus O
and O
currently O
one O
of O
the O
most O
common O
arboviruses O
worldwide O
, O
is O
associated O
with O
severe O
neurological O
disease O
in O
humans O
. O

The O
surface O
membrane O
glycoprotein O
( O
M O
) O
has O
been O
associated O
with O
Flavivirus O
- O
induced O
pathogenesis O
. O

IMPORTANCE O
West B
Nile I
virus I
( I
WNV I
) I
is O
a O
worldwide O
( O
re O
) O
emerging O
mosquito O
- O
transmitted O
Flavivirus O
causing O
fatal O
neurological O
diseases O
in O
humans O
. O

In O
this O
study O
, O
we O
tested O
pools O
of O
epitopes O
derived O
from O
dengue O
( O
DENV O
) O
, O
Zika O
( O
ZIKV O
) O
, O
Japanese O
encephalitis O
( O
JEV O
) O
, O
West O
Nile O
( O
WNV O
) O
, O
and O
yellow O
fever O
( O
YFV O
) O
viruses O
by O
intracellular B
cytokine I
staining I
( I
ICS I
) I
using O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
individuals O
naturally O
exposed O
to O
DENV O
or O
immunized O
with O
DENV O
( O
TV005 O
) O
or O
YF17D O
vaccine O
. O

Next O
, O
we O
characterized O
the O
antigen O
sensitivity O
of O
short O
- O
term O
T B
cell I
lines I
( I
TCL I
) I
representing O
29 O
different O
individual O
epitope O
/ O
donor O
combinations O
. O

IMPORTANCE O
The O
envelope B
( I
E I
) I
protein O
is O
the O
dominant O
target O
of O
neutralizing O
antibodies O
for O
Dengue B
Virus I
( I
DENV I
) I
and O
yellow B
fever I
virus I
( I
YFV I
) I
. O

Accordingly O
, O
several O
DENV O
vaccine O
constructs O
use O
the O
E O
protein O
in O
a O
live O
attenuated O
vaccine O
format O
, O
utilizing O
a O
backbone O
derived O
from O
a O
heterologous O
flavivirus O
( O
such O
as O
YF O
) O
as O
a O
delivery O
vector O
. O

This O
backbone O
comprises O
the O
nonstructural B
( I
NS I
) I
and O
Capsid B
( I
C I
) I
antigens O
, O
which O
are O
dominant O
targets O
of O
T O
cell O
responses O
. O

Among O
these O
, O
Oropouche B
orthobunyavirus I
( I
OROV I
) I
is O
a O
relatively O
understudied O
member O
of O
the O
genus O
Orthobunyavirus O
, O
family O
Peribuoyaviridae O
, O
that O
causes O
periodic O
outbreaks O
in O
human O
populations O
in O
Brazil O
and O
other O
South O
American O
countries O
. O

Oropouche B
virus I
( I
OROV I
) I
is O
a O
poorly O
studied O
pathogen O
responsible O
for O
over O
a O
dozen O
outbreaks O
since O
the O
early O
1960s O
and O
represents O
a O
public O
health O
burden O
to O
countries O
such O
as O
Brazil O
, O
Panama O
, O
and O
Peru O
. O

West B
Nile I
virus I
( I
WNV I
) I
and O
Zika B
virus I
( I
ZIKV I
) I
infect O
human B
dendritic I
cells I
( I
DCs I
) I
and O
can O
block O
antiviral O
immune O
responses O
in O
DCs O
. O

Previously O
, O
we O
used O
mRNA O
sequencing O
and O
weighted B
gene I
coexpression I
network I
analysis I
( I
WGCNA I
) I
to O
define O
molecular O
signatures O
of O
antiviral O
DC O
responses O
following O
activation O
of O
innate O
immune O
signaling O
( O
RIG O
- O
I O
, O
MDA5 O
, O
or O
type O
I O
interferon O
[ O
IFN O
) O
signaling O
) O
or O
infection O
with O
WNV O
. O

Mechanistically O
, O
WNV O
and O
ZIKV O
actively O
blocked O
STATS O
phosphorylation O
downstream O
of O
RIG O
- O
I O
, O
IFN O
- O
beta O
, O
and O
interleukin O
- O
4 O
( O
1 O
- O
4 O
) O
, O
but O
not O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
, O
signaling O
. O

Unexpectedly O
, O
dengue O
virus O
serotypes O
1 O
to O
4 O
( O
DENV1 O
to O
DENV4 O
) O
and O
the O
yellow B
fever I
17D I
vaccine I
strain I
( I
YFV I
- I
17D I
) I
did O
not O
antagonize O
STATS O
phosphorylation O
. O

Previously O
, O
we O
used O
a O
computational O
biology O
approach O
to O
define O
molecular O
signatures O
of O
antiviral O
DC O
responses O
following O
activation O
of O
innate O
immune O
signaling O
or O
infection O
with O
West B
Nile I
virus I
( I
WNV I
) I
. O

In O
this O
work O
, O
we O
identify O
STATS O
as O
a O
regulator O
of O
DC O
activation O
and O
antiviral O
immune O
responses O
downstream O
of O
innate O
immune O
signaling O
that O
was O
not O
activated O
during O
either O
WNV O
or O
Zika B
virus I
( I
ZIKV I
) I
infection O
. O

In O
mice O
, O
resistance O
to O
central B
nervous I
system I
( I
CNS I
) I
disease O
induced O
by O
members O
of O
the O
genus O
Flavivirus O
is O
conferred O
by O
an O
allele O
of O
the O
2 O
' O
- O
5 O
' O
oligoadenylate O
synthetase O
1b O
gene O
that O
encodes O
the O
inactive O
full O
- O
length O
protein O
( O
Oas1b O
- O
FL O
) O
. O

The O
susceptibility O
allele O
encodes O
a O
C O
- O
terminally O
truncated O
protein O
( O
Oas1b O
- O
tr O
) O
. O

We O
show O
that O
the O
efficiency O
of O
neuron O
infection O
in O
the O
brains O
of O
resistant O
and O
susceptible O
mice O
is O
similar O
after O
an O
intracranial O
inoculation O
of O
two O
flaviviruses O
, O
but O
amplification O
of O
viral O
proteins O
and O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
is O
inhibited O
in O
infected O
neurons O
in O
resistant O
mouse O
brains O
at O
later O
times O
. O

Active O
OAS O
proteins O
detect O
cytoplasmic O
dsRNA O
and O
synthesize O
short O
2 O
' O
- O
5 O
' O
- O
linked O
oligoadenylates O
( O
2 O
' O
- O
5 O
' O
A O
) O
that O
interact O
with O
the O
latent O
endonuclease O
RNase O
L O
, O
causing O
it O
to O
dimerize O
and O
cleave O
single O
- O
stranded O
RNAs O
. O

To O
evaluate O
the O
contribution O
of O
RNase O
L O
to O
the O
resistance O
phenotype O
in O
vivo O
, O
we O
created O
a O
line O
of O
resistant O
RNase O
L O
( O
- O
/ O
- O
) O
mice O
. O

Activation O
of O
type B
I I
interferon I
( I
IFN I
) I
signaling O
was O
detected O
in O
both O
resistant O
and O
susceptible O
brains O
, O
but O
Oas1a O
and O
Oas1b O
mRNA O
levels O
were O
lower O
in O
RNase O
L O
+ O
/ O
+ O
mice O
of O
both O
types O
, O
suggesting O
that O
activated O
RNase O
L O
also O
has O
a O
proflaviviral O
effect O
. O

To O
determine O
if O
host O
proteins O
are O
specifically O
packaged O
into O
alphavirus O
virions O
, O
Sindbis B
virus I
( I
SINV I
) I
was O
grown O
in O
multiple O
host O
cells O
representing O
vertebrate O
and O
mosquito O
hosts O
, O
and O
total O
protein O
content O
of O
purified O
virions O
was O
determined O
. O

One O
host O
protein O
, O
sorting O
nexin O
5 O
( O
SNX5 O
) O
, O
was O
shown O
to O
be O
critical O
for O
the O
replication O
of O
three O
different O
alphaviruses O
, O
Sindbis O
, O
Mayaro O
, O
and O
Chikungunya O
viruses O
. O

The O
most O
significant O
finding O
was O
that O
in O
addition O
to O
the O
host O
proteins O
, O
SINV O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
was O
detected O
within O
virions O
grown O
in O
all O
host O
cells O
examined O
. O

Alphaviruses O
belong O
to O
a O
group O
of O
viruses O
vectored O
in O
nature O
by O
hematophagous O
( O
blood O
- O
feeding O
) O
insects O
and O
are O
termed O
arboviruses O
( O
arthropod O
- O
borne O
viruses O
) O
. O

Recent O
data O
obtained O
with O
the O
live O
- O
attenuated O
tetravalent O
dengue O
CYD O
- O
TDV O
vaccine O
showed O
higher O
protective O
efficacy O
against O
Dengue B
virus I
type I
4 I
( I
DENV I
- I
4 I
) I
than O
against O
DENV O
- O
2 O
. O

Using O
more O
- O
stringent O
DENV O
infection O
conditions O
consisting O
of O
the O
intravenous O
inoculation O
of O
10 O
( O
7 O
) O
50 O
% O
cell O
culture O
infectious O
doses O
( O
CCID50 O
) O
in O
CYD O
- O
TDV O
- O
vaccinated O
macaques O
, O
complete O
protection O
( O
i O
. O

All O
other O
infected O
macaques O
( O
12 O
/ O
18 O
) O
developed O
sustained O
DENV O
- O
2 O
RNAemia O
( O
defined O
as O
detection O
of O
viral O
RNA O
in O
serum O
samples O
) O
although O
1 O
to O
3 O
log10 O
units O
below O
the O
levels O
achieved O
in O
control O
animals O
. O

Similar O
results O
were O
obtained O
with O
macaques O
immunized O
with O
either O
CYD O
- O
TDV O
or O
monovalent O
( O
MV O
) O
CYD O
- O
2 O
. O

IMPORTANCE O
The O
nonhuman B
primate I
( I
NHP I
) I
model O
is O
the O
most O
widely O
recognized O
tool O
for O
assessing O
the O
protective O
activity O
of O
dengue O
vaccine O
candidates O
, O
based O
on O
the O
prevention O
of O
postinfection O
DENV O
viremia O
. O

Retrovirus O
- O
derived O
virus B
- I
like I
particles I
( I
VLPs I
) I
are O
particularly O
interesting O
vaccine O
platforms O
, O
as O
they O
trigger O
efficient O
humoral O
and O
cellular O
immune O
responses O
and O
can O
be O
used O
to O
display O
heterologous O
antigens O
. O

In O
this O
study O
, O
we O
characterized O
the O
intrinsic O
immunogenicity O
of O
VLPs O
and O
investigated O
their O
possible O
adjuvantization O
by O
incorporation O
of O
Toll B
- I
like I
receptor I
( I
TLR I
) I
ligands O
. O

We O
designed O
a O
noncoding B
singlestranded I
RNA I
( I
ncRNA I
) I
that O
could O
be O
encapsidated O
by O
VLPs O
and O
induce O
TLR7 O
/ O
8 O
signaling O
. O

We O
found O
that O
VLPs O
efficiently O
induce O
in O
vitro O
dendritic O
cell O
activation O
, O
which O
can O
be O
improved O
by O
ncRNA B
encapsidation I
( I
ncRNAVLPs I
) I
. O

In O
vivo O
and O
compared O
with O
standard O
VLPs O
, O
ncRNAVLPs O
promoted O
Th1 O
responses O
and O
improved O
CD8 O
( O
+ O
) O
T O
cell O
proliferation O
in O
a O
MyD88 O
- O
dependent O
manner O
. O

Notably O
, O
this O
immunogenicity O
can O
be O
further O
improved O
and O
/ O
or O
oriented O
by O
the O
incorporation O
into O
VLPs O
of O
ncRNA O
, O
which O
provides O
further O
TLR O
- O
mediated O
activation O
and O
Th1 O
- O
type O
CD4 O
( O
+ O
) O
and O
CD8 O
+ O
T O
cell O
response O
orientation O
. O

A O
detailed O
understanding O
of O
the O
fine O
specificity O
of O
serotype O
- O
specific O
human O
antibodies O
is O
vital O
for O
the O
development O
and O
evaluation O
of O
new O
vaccines O
for O
pathogenic O
flaviviruses O
such O
as O
Dengue B
Virus I
( I
DENV I
) I
and O
Zika O
virus O
. O

In O
this O
study O
, O
we O
thoroughly O
characterize O
the O
structural O
footprint O
of O
an O
anti O
- O
idiotype O
antibody O
( O
E1 O
) O
specific O
for O
a O
potent O
, O
fully O
human O
DENV O
serotype O
1 O
- O
specific O
antibody O
, O
termed O
HM14c10 O
, O
derived O
from O
a O
recovered O
patient O
. O

5 O
angstrom O
of O
a O
complex O
between O
the O
Fab O
fragments O
of O
E1 O
and O
HM14c10 O
provides O
the O
first O
detailed O
molecular O
comparison O
of O
an O
anti O
- O
idiotype O
paratope O
specific O
for O
a O
human O
antibody O
with O
its O
analogous O
epitope O
, O
a O
discontinuous O
quaternary O
structure O
located O
at O
the O
surface O
of O
the O
viral O
particle O
that O
spans O
adjacent O
envelope B
( I
E I
) I
proteins O
. O

Structural O
mimicry O
of O
the O
DENV O
E O
epitope O
by O
the O
E1 O
combining O
site O
is O
achieved O
via O
the O
formation O
of O
numerous O
interactions O
with O
heavy O
chain O
complementarity B
domain I
regions I
( I
CDRs I
) I
of O
HM14c10 O
, O
while O
fewer O
interactions O
are O
observed O
with O
its O
light O
chain O
than O
for O
the O
E O
protein O
. O

We O
show O
that O
E1 O
can O
be O
utilized O
to O
detect O
HM14c10 O
- O
like O
antibodies O
in O
sera O
from O
patients O
who O
recovered O
from O
DENV O
- O
1 O
, O
infection O
suggesting O
that O
this O
is O
a O
public O
( O
common O
) O
idiotype O
. O

Here O
, O
we O
characterize O
how O
an O
anti O
- O
idiotypic O
antibody O
( O
E1 O
) O
binds O
antibody O
HM14c10 O
, O
which O
potently O
neutralizes O
DENV O
serotype O
1 O
. O

Our O
previous O
work O
has O
shown O
that O
antigens O
adjuvanted O
with O
ligands O
specific O
for O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
and O
TLR7 O
/ O
8 O
encapsulated O
in O
poly O
( O
lactic O
- O
co O
- O
glycolic O
) O
acid O
( O
PLGA O
) O
- O
based O
nanoparticles O
( O
NPs O
) O
induce O
robust O
and O
durable O
immune O
responses O
in O
mice O
and O
macaques O
. O

We O
investigated O
the O
efficacy O
of O
these O
NP O
adjuvants O
in O
inducing O
protective O
immunity O
against O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
. O

Rhesus B
macaques I
( I
RMs I
) I
were O
immunized O
with O
NPs O
containing O
TLR4 O
and O
TLR7 O
/ O
8 O
agonists O
mixed O
with O
soluble O
recombinant O
SIVmac239 O
- O
derived O
envelope B
( I
env I
) I
gp140 O
and O
Gag O
p55 O
( O
protein O
) O
or O
with O
virus B
- I
like I
particles I
( I
VLPs I
) I
containing O
SIVmac239 O
Env O
and O
Gag O
. O

NP O
- O
adjuvanted O
vaccines O
induced O
antigen O
- O
specific O
, O
long O
- O
lived O
plasma O
cells O
( O
LLPCs O
) O
, O
which O
persisted O
in O
the O
bone O
marrow O
for O
several O
months O
after O
vaccination O
. O

These O
results O
demonstrate O
the O
adjuvanticity O
of O
the O
NP O
adjuvant O
in O
inducing O
persistent O
and O
protective O
antibody O
responses O
against O
SIV O
in O
RMs O
with O
implications O
for O
the O
design O
of O
vaccines O
against O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
. O

Our O
recent O
work O
in O
mice O
has O
highlighted O
the O
capacity O
of O
nanoparticle O
- O
encapsulated O
TLR O
ligands O
( O
NP O
) O
to O
induce O
potent O
and O
durable O
antibody O
responses O
that O
last O
a O
lifetime O
in O
mice O
. O

Our O
results O
demonstrate O
that O
immunization O
of O
rhesus O
macaques O
with O
NP O
adjuvants O
mixed O
with O
soluble O
SIV O
Env O
or O
a O
virus O
- O
like O
particle O
form O
of O
Env O
( O
VLP O
) O
induces O
potent O
and O
durable O
Env O
- O
specific O
antibody O
responses O
in O
the O
serum O
and O
in O
vaginal O
secretions O
. O

Although O
neutralizing B
antibodies I
( I
NAb I
) I
were O
generated O
, O
they O
were O
against O
sensitive O
viruses O
, O
not O
the O
more O
resistant O
tier O
2 O
isolates O
that O
dominate O
circulating O
strains O
. O

Instead O
, O
risk O
reduction O
correlated O
with O
antibodies O
recognizing O
epitopes O
in O
the O
V1 O
/ O
V2 O
region O
of O
HIV B
- I
1 I
envelope I
glycoprotein I
( I
Env I
) I
. O

We O
studied O
two O
clade O
B O
Envs O
that O
differ O
in O
multiple O
parameters O
, O
including O
tissue O
origin O
, O
neutralization O
sensitivity O
, O
and O
presence O
of O
the O
N197 O
( O
N7 O
) O
glycan O
that O
was O
previously O
shown O
to O
modulate O
the O
exposure O
of O
conserved O
epitopes O
on O
Env O
. O

Some O
of O
these O
activities O
were O
directed O
against O
the O
CD4 B
binding I
site I
( I
CD4bs I
) I
. O

IMPORTANCE O
The O
only O
vaccine O
approach O
shown O
to O
elicit O
any O
protective O
efficacy O
against O
HIV O
- O
1 O
acquisition O
is O
based O
on O
a O
poxvirus O
prime O
- O
protein O
boost O
regimen O
( O
RV144 O
Thai O
trial O
) O
. O

Viral O
nonstructural B
protein I
3 I
( I
NS3 I
) I
is O
a O
key O
component O
of O
the O
viral O
replication O
machinery O
that O
performs O
multiple O
functions O
during O
viral O
replication O
and O
participates O
in O
antiviral O
evasion O
. O

Accumulating O
data O
suggest O
that O
tripartite B
- I
motif I
- I
containing I
( I
TRIM I
) I
proteins O
participate O
in O
host O
responses O
to O
viral O
infections O
, O
either O
by O
acting O
as O
direct O
antiviral O
restriction O
factors O
or O
through O
regulating O
innate O
immune O
signaling O
of O
the O
host O
. O

Of O
> O
70 O
TRIMs O
, O
TRIM56 O
is O
a O
restriction O
factor O
of O
several O
positive O
- O
strand O
RNA O
viruses O
, O
including O
three O
members O
of O
the O
family O
Flaviviridae O
( O
yellow O
fever O
virus O
, O
dengue O
virus O
, O
and O
bovine O
viral O
diarrhea O
virus O
) O
and O
a O
human O
coronavirus O
( O
OC43 O
) O
, O
and O
this O
ability O
invariably O
depends O
upon O
the O
E3 O
ligase O
activity O
of O
TRIM56 O
. O

While O
a O
West B
Nile I
virus I
( I
WNV I
) I
subgenomic O
RNA O
could O
readily O
be O
packaged O
by O
structural O
proteins O
of O
the O
DENV2 O
strain O
16681 O
, O
production O
of O
infectious O
virions O
with O
DENV2 O
strain O
New B
Guinea I
C I
( I
NGC I
) I
structural O
proteins O
was O
not O
possible O
, O
despite O
the O
very O
high O
amino O
acid O
identity O
between O
these O
viruses O
. O

Mutagenesis O
studies O
identified O
a O
single O
residue O
( O
position O
101 O
) O
of O
the O
DENV O
Capsid B
( I
C I
) I
protein O
as O
the O
determinant O
for O
heterologous O
virus O
production O
. O

WNV O
NS2B O
/ O
3 O
cleavage O
of O
the O
DENV O
structural O
polyprotein O
was O
possible O
when O
a O
threonine O
( O
Thr101 O
in O
strain O
16681 O
) O
but O
not O
a O
serine O
( O
Ser101 O
in O
strain O
NGC O
) O
occupied O
the O
P1 O
' O
position O
, O
a O
finding O
not O
predicted O
by O
in O
vitro O
protease O
specificity O
studies O
. O

IMPORTANCE O
West B
Nile I
virus I
( I
WNV I
) I
and O
Dengue B
Virus I
( I
DENV I
) I
are O
mosquito O
- O
borne O
flaviviruses O
that O
cause O
considerable O
morbidity O
and O
mortality O
in O
humans O
. O

We O
report O
the O
first O
in O
- O
depth O
analysis O
of O
the O
dynamics O
of O
the O
CD8 O
( O
+ O
) O
T O
cell O
repertoire O
at O
the O
level O
of O
individual O
T O
cell O
clonal O
lineages O
upon O
vaccination O
of O
human O
volunteers O
with O
a O
single O
dose O
of O
YF O
- O
17D O
. O

We O
identified O
and O
enumerated O
unique O
CD8 O
( O
+ O
) O
T O
cell O
clones O
specifically O
induced O
by O
this O
vaccine O
through O
a O
combined O
experimental O
and O
statistical O
approach O
that O
included O
high O
- O
throughput O
sequencing O
of O
the O
CDR3 O
variable O
region O
of O
the O
T O
cell O
receptor O
beta O
- O
chain O
and O
an O
algorithm O
that O
detected O
significantly O
expanded O
T O
cell O
clones O
. O

This O
allowed O
us O
to O
establish O
that O
( O
i O
) O
on O
average O
, O
similar O
to O
2 O
, O
000 O
CD8 O
( O
+ O
) O
T O
cell O
clones O
were O
induced O
by O
YF O
- O
17D O
, O
( O
ii O
) O
5 O
to O
6 O
% O
of O
the O
responding O
clones O
were O
recruited O
to O
long O
- O
term O
memory O
3 O
months O
postvaccination O
, O
( O
iii O
) O
the O
most O
highly O
expanded O
effector O
clones O
were O
preferentially O
recruited O
to O
the O
memory O
compartment O
, O
and O
( O
iv O
) O
a O
fraction O
of O
the O
YF O
- O
17D O
- O
induced O
clones O
could O
be O
identified O
from O
peripheral O
blood O
lymphocytes O
solely O
by O
measuring O
clonal O
expansion O
. O

The O
yellow O
fever O
vaccine O
( O
YFV O
) O
has O
been O
broadly O
used O
as O
a O
model O
to O
understand O
how O
a O
controlled O
, O
self O
- O
resolving O
acute O
viral O
infection O
induces O
an O
effective O
and O
long O
- O
term O
protective O
immune O
response O
. O

Here O
, O
we O
extend O
this O
previous O
work O
by O
reporting O
the O
identity O
of O
activated O
effector O
T O
cell O
clones O
that O
expand O
in O
response O
to O
the O
YFV O
2 O
weeks O
postvaccination O
( O
as O
defined O
by O
their O
unique O
T O
cell O
receptor O
gene O
sequence O
) O
and O
by O
tracking O
clones O
that O
enter O
the O
memory O
compartment O
3 O
months O
postvaccination O
. O

Since O
the O
1960s O
, O
simian O
hemorrhagic O
fever O
virus O
( O
SHFV O
; O
Nidovirales O
, O
Arteriviridae O
) O
has O
caused O
highly O
fatal O
outbreaks O
of O
viral O
hemorrhagic O
fever O
in O
captive O
Asian O
macaque O
colonies O
. O

However O
, O
the O
source O
( O
s O
) O
of O
these O
outbreaks O
and O
the O
natural O
reservoir O
( O
s O
) O
of O
this O
virus O
remain O
obscure O
. O

Here O
we O
report O
the O
identification O
of O
two O
novel O
, O
highly O
divergent O
simian O
arteriviruses O
related O
to O
SHFV O
, O
Mikumi B
yellow I
baboon I
virus I
1 I
( I
MYBV I
- I
1 I
) I
and O
Southwest B
baboon I
virus I
1 I
( I
SWBV I
- I
1 I
) I
, O
in O
wild O
and O
captive O
baboons O
, O
respectively O
, O
and O
demonstrate O
the O
recent O
transmission O
of O
SWBV O
- O
1 O
among O
captive O
baboons O
. O

Broadly O
targeted O
cellular O
immune O
responses O
are O
thought O
to O
be O
important O
for O
controlling O
replication O
of O
human O
and O
simian O
immunodeficiency O
viruses O
( O
HIV O
and O
SIV O
) O
. O

Wedelivered O
these O
minigenes O
through O
combinations O
of O
recombinant B
Mycobacterium I
bovis I
BCG I
( I
rBCG I
) I
, O
electroporated O
recombinant B
DNA I
( I
rDNA I
) I
along O
with O
an O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
- O
expressing O
plasmid O
( O
EP O
rDNA O
plus O
pIL O
- O
12 O
) O
, O
yellow O
fever O
vaccine O
virus O
17D O
( O
rYF17D O
) O
, O
and O
recombinant B
adenovirus I
serotype I
5 I
( I
rAd5 I
) I
. O

Indeed O
, O
Mamu O
- O
A O
* O
01 O
( O
+ O
) O
vaccinees O
mounted O
CD8 O
( O
+ O
) O
T O
cells O
directed O
against O
only O
one O
subdominant O
epitope O
, O
regardless O
of O
the O
vaccination O
regimen O
. O

Chimeric O
Dengue B
viruses I
( I
DENV I
) I
based O
on O
an O
attenuated O
flavivirus O
have O
been O
well O
developed O
as O
vaccine O
candidates O
by O
using O
reverse O
genetics O
. O

In O
this O
study O
, O
based O
on O
the O
full O
- O
length O
infectious O
cDNA O
clone O
of O
the O
well O
- O
known O
Japanese O
encephalitis O
virus O
live O
vaccine O
strain O
SA14 O
- O
14 O
- O
2 O
as O
a O
backbone O
, O
a O
novel O
chimeric O
dengue O
virus O
( O
named O
ChinDENV O
) O
was O
rationally O
designed O
and O
constructed O
by O
replacement O
with O
the O
premembrane O
and O
envelope O
genes O
of O
dengue O
2 O
virus O
. O

yellow B
fever I
virus I
( I
YFV I
) I
can O
induce O
acute O
, O
life O
- O
threatening O
disease O
that O
is O
a O
significant O
health O
burden O
in O
areas O
where O
yellow O
fever O
is O
endemic O
, O
but O
it O
is O
preventable O
through O
vaccination O
. O

While O
several O
studies O
have O
characterized O
YFV O
- O
specific O
antibody O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
, O
less O
is O
known O
about O
YFV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
. O

Therefore O
, O
CD4 O
( O
+ O
) O
T O
cell O
responses O
could O
be O
effectively O
characterized O
with O
HLA O
- O
DR O
tetramers O
. O

Longitudinal O
analysis O
indicated O
that O
YFV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
reached O
peak O
frequencies O
, O
often O
exceeding O
250 O
cells O
per O
million O
, O
approximately O
2 O
weeks O
after O
vaccination O
. O

Therefore O
, O
YFV O
elicits O
robust O
early O
effector O
CD4 O
( O
+ O
) O
T O
cell O
responses O
that O
contract O
, O
forming O
a O
detectable O
memory O
population O
. O

The O
yellow B
fever I
virus I
( I
YFV I
) I
, O
the O
first O
proven O
human O
- O
pathogenic O
virus O
, O
although O
isolated O
in O
1927 O
, O
is O
still O
a O
major O
public O
health O
problem O
, O
especially O
in O
West O
Africa O
where O
it O
causes O
outbreaks O
every O
year O
. O

Variable O
3 B
' I
noncoding I
region I
( I
3 I
' I
NCR I
) I
patterns O
and O
specific O
mutations O
throughout O
the O
open O
reading O
frame O
altered O
predicted O
secondary O
structures O
. O

The O
mechanism O
by O
which O
DNAJC14 O
stoichiometrically O
participates O
in O
flavivirus O
replication B
complex I
( I
RC I
) I
formation O
is O
unknown O
; O
both O
reduced O
and O
elevated O
levels O
result O
in O
replication O
inhibition O
. O

Using O
yellow B
fever I
virus I
( I
YFV I
) I
, O
we O
demonstrate O
that O
DNAJC14 O
redistributes O
and O
clusters O
with O
YFV O
nonstructural O
proteins O
via O
a O
transmembrane O
domain O
and O
a O
newly O
identified O
membrane B
- I
binding I
domain I
( I
MBD I
) I
, O
which O
both O
mediate O
targeting O
to O
detergent O
- O
resistant O
membranes O
. O

Recombinant B
myxoma I
virus I
( I
MYXV I
) I
can O
be O
produced O
without O
a O
loss O
of O
infectivity O
, O
and O
its O
highly O
specific O
host O
range O
makes O
it O
an O
ideal O
vaccine O
vector O
candidate O
, O
although O
careful O
examination O
of O
its O
interaction O
with O
the O
immune O
system O
is O
necessary O
. O

Similar O
to O
rabbit O
bone O
marrow O
- O
derived O
dendritic O
cells O
( O
BM O
- O
DCs O
) O
, O
ovine O
dendritic O
cells O
can O
be O
infected O
by O
SG33 O
, O
a O
MYXV O
vaccine O
strain O
, O
and O
support O
recombinant O
antigen O
expression O
. O

When O
gene O
expression O
was O
assessed O
in O
infected O
BM O
- O
DC O
cultures O
, O
type B
I I
interferon I
( I
IFN I
) I
- O
related O
and O
inflammatory O
genes O
were O
strongly O
upregulated O
. O

The O
innate O
immune O
pathways O
that O
contribute O
to O
the O
potent O
immunogenicity O
of O
recombinant B
adenovirus I
( I
rAd I
) I
vaccine O
vectors O
remain O
largely O
undefined O
. O

Here O
, O
we O
systematically O
explore O
the O
Toll B
- I
like I
receptor I
( I
TLR I
) I
signaling O
requirements O
for O
the O
generation O
of O
cellular O
immune O
responses O
by O
intramuscular O
immunization O
with O
common O
and O
alternative O
serotype O
rAd O
vectors O
in O
mice O
. O

Antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
lymphocyte O
responses O
elicited O
by O
these O
rAd O
vectors O
were O
significantly O
diminished O
in O
MyD88 O
( O
- O
/ O
- O
) O
mice O
but O
not O
in O
TRIF O
- O
/ O
- O
or O
TLR3 O
( O
- O
/ O
- O
) O
mice O
, O
suggesting O
the O
importance O
of O
MyD88 O
- O
dependent O
TLR O
signaling O
. O

Moreover O
, O
responses O
were O
not O
diminished O
in O
IL O
- O
1R O
( O
- O
/ O
- O
) O
or O
IL O
- O
18R O
( O
- O
/ O
- O
) O
mice O
. O

Samples O
were O
taken O
at O
day O
0 O
( O
prechallenge O
) O
, O
day O
14 O
( O
peak O
viremia O
) O
, O
and O
week O
12 O
( O
set O
point O
) O
from O
animals O
immunized O
with O
replicating O
adenovirus B
type I
5 I
host I
range I
( I
Ad5hr I
) I
recombinant O
viruses O
expressing O
human O
immunodeficiency O
virus O
HIVenv89 O
. O

6P O
challenge O
( O
six O
animals O
per O
group O
plus O
six O
controls O
) O
. O

Divergent O
expression O
profiles O
at O
set O
point O
for O
the O
immunized O
groups O
implied O
distinct O
immunological O
responses O
despite O
phenotypic O
similarities O
in O
viral O
load O
and O
CD4 O
( O
+ O
) O
T O
cell O
levels O
. O

The O
results O
of O
transcomplementation O
of O
a O
series O
of O
C O
- O
terminally O
truncated O
Core O
molecules O
indicate O
the O
importance O
of O
Ala O
( O
255 O
) O
at O
the O
C O
terminus O
. O

The O
plasticity O
of O
Core O
protein O
was O
examined O
by O
the O
construction O
of O
concatemeric O
arrays O
of O
Core O
coding O
regions O
and O
the O
insertion O
of O
up O
to O
three O
yellow B
fluorescent I
protein I
( I
YFP I
) I
genes O
between O
two O
Core O
genes O
. O

Trinidad O
, O
like O
many O
other O
American O
regions O
, O
experiences O
repeated O
epizootics O
of O
yellow B
fever I
virus I
( I
YFV I
) I
. O

However O
, O
it O
is O
unclear O
whether O
these O
result O
from O
in O
situ O
evolution O
( O
enzootic O
maintenance O
) O
or O
regular O
reintroduction O
of O
YFV O
from O
the O
South O
American O
mainland O
. O

The O
results O
suggest O
a O
Brazilian O
origin O
for O
YFV O
in O
the O
Americas O
and O
an O
overall O
dispersal O
rate O
of O
182 O
km O
/ O
year O
( O
95 O
% O
HPD O
, O
52 O
to O
462 O
km O
/ O
year O
) O
, O
with O
Brazil O
as O
the O
major O
source O
population O
for O
surrounding O
countries O
. O

Poxvirus O
- O
based O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
vaccine O
candidates O
are O
currently O
under O
evaluation O
in O
preclinical O
and O
clinical O
trials O
. O

modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
vectors O
have O
excellent O
safety O
and O
immunogenicity O
records O
, O
but O
their O
behavior O
in O
human O
cell O
cultures O
remains O
only O
partly O
characterized O
. O

We O
studied O
here O
various O
virological O
and O
immunological O
aspects O
of O
the O
interactions O
of O
MVA O
- O
HIV O
, O
a O
vaccine O
candidate O
developed O
by O
the O
French O
National O
Agency O
for O
AIDS O
Research O
( O
ANRS O
) O
, O
with O
primary O
human O
cells O
. O

We O
report O
that O
MVA O
- O
HIV O
infects O
and O
drives O
Gag O
expression O
in O
primary O
macrophages O
, O
dendritic B
cells I
( I
DCs I
) I
, O
and O
epithelial O
and O
muscle O
cells O
. O

MVA O
- O
HIV O
- O
infected O
DCs O
matured O
, O
efficiently O
presented O
Gag O
, O
Pol O
, O
and O
Nef O
antigens O
, O
and O
activated O
HIV O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
. O

Coculture O
of O
MVA O
- O
HIV O
- O
infected O
epithelial O
cells O
or O
myotubes O
with O
DCs O
promoted O
efficient O
Gag O
antigen O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
cross O
- O
presentation O
without O
inducing O
direct O
infection O
and O
death O
of O
DCs O
. O

antigen B
- I
presenting I
cells I
( I
APCs I
) I
infected O
with O
MVA O
- O
HIV O
also O
activated O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
. O

Moreover O
, O
exposure O
of O
DCs O
to O
MVA O
- O
HIV O
or O
to O
MVA O
- O
HIV O
- O
infected O
myotubes O
induced O
type B
I I
interferon I
( I
IFN I
) I
production O
and O
inhibited O
subsequent O
HIV O
replication O
and O
transfer O
to O
lymphocytes O
. O

Here O
we O
describe O
a O
novel O
vaccine O
vector O
for O
expressing O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
antigens O
. O

We O
show O
that O
recombinant O
attenuated O
yellow O
fever O
vaccine O
virus O
17D O
expressing O
simian O
immunodeficiency O
virus O
SIVmac239 O
Gag O
sequences O
can O
be O
used O
as O
a O
vector O
to O
generate O
SIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
the O
rhesus O
macaque O
. O

Priming O
with O
recombinant O
BCG O
expressing O
SIV O
antigens O
increased O
the O
frequency O
of O
these O
SIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
after O
recombinant O
YF17D O
boosting O
. O

These O
recombinant O
YF17D O
- O
induced O
SIVspecific O
CD8 O
( O
+ O
) O
T O
cells O
secreted O
several O
cytokines O
, O
were O
largely O
effector O
memory O
T O
cells O
, O
and O
suppressed O
viral O
replication O
in O
CD4 O
( O
+ O
) O
T O
cells O
. O

Similarly O
, O
there O
is O
limited O
information O
on O
the O
molecular O
epidemiology O
of O
yellow B
fever I
virus I
( I
YFV I
) I
in O
Africa O
even O
though O
it O
most O
likely O
first O
emerged O
on O
this O
continent O
. O

Through O
an O
analysis O
of O
complete O
E O
gene O
sequences O
, O
including O
a O
newly O
acquired O
viral O
collection O
from O
Central O
and O
West O
Africa O
( O
Senegal O
, O
Cameroon O
, O
Central O
African O
Republic O
, O
Cote O
d O
' O
Ivoire O
, O
Mali O
, O
and O
Mauritania O
) O
, O
we O
show O
that O
YFV O
exhibits O
markedly O
lower O
rates O
of O
evolutionary O
change O
than O
dengue O
virus O
, O
despite O
numerous O
biological O
similarities O
between O
these O
two O
viruses O
. O

Despite O
a O
reduced O
rate O
of O
nucleotide O
substitution O
, O
phylogenetic O
patterns O
and O
estimates O
of O
times O
to O
common O
ancestry O
in O
YFV O
still O
accord O
well O
with O
the O
dual O
histories O
of O
colonialism O
and O
the O
slave O
trade O
, O
with O
areas O
of O
sylvatic O
transmission O
( O
such O
as O
Kedougou O
, O
Senegal O
) O
acting O
as O
enzootic O
/ O
epidemic O
foci O
. O

To O
examine O
further O
the O
role O
of O
protein O
C O
and O
its O
production O
by O
proteolysis O
, O
we O
replaced O
the O
NS2B O
/ O
3 O
capsid O
cleavage O
site O
in O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
West B
Nile I
virus I
( I
WNV I
) I
by O
the O
2A O
protein O
of O
foot O
- O
and O
- O
mouth O
disease O
virus O
( O
TBEV O
- O
2A O
and O
WNV O
- O
2A O
) O
. O

Serine O
/ O
threonine O
phosphorylation O
of O
the O
nonstructural B
protein I
5 I
( I
NS5 I
) I
is O
a O
conserved O
feature O
of O
flaviviruses O
, O
but O
the O
kinase O
( O
s O
) O
responsible O
and O
function O
( O
s O
) O
remain O
unknown O
. O

Mass O
spectrometry O
was O
used O
to O
compare O
the O
phosphorylation O
sites O
of O
the O
NS5 O
proteins O
of O
yellow B
fever I
virus I
( I
YFV I
) I
and O
Dengue B
Virus I
( I
DENV I
) I
, O
two O
flaviviruses O
transmitted O
by O
mosquitoes O
. O

Seven O
DENV O
phosphopeptides O
were O
identified O
, O
but O
only O
one O
conserved O
phosphoacceptor O
site O
( O
threonine O
449 O
in O
DENV O
) O
was O
identified O
in O
both O
viruses O
. O

This O
site O
is O
predicted O
to O
be O
a O
protein B
kinase I
G I
( I
PKG I
) I
recognition O
site O
and O
is O
a O
strictly O
conserved O
serine O
/ O
threonine O
phosphoacceptor O
site O
in O
mosquito O
- O
borne O
flaviviruses O
. O

The O
isolate O
, O
designated O
Lammi B
virus I
( I
LAMV I
) I
, O
was O
antigenically O
cross O
- O
reactive O
with O
other O
flaviviruses O
and O
exhibited O
typical O
flavivirus O
morphology O
as O
determined O
by O
electron O
microscopy O
. O

#NAME? O
, O
similarly O
to O
the O
newly O
described O
Nounane B
virus I
( I
NOUV I
) I
, O
a O
flavivirus O
from O
Africa O
( O
S O
. O

We O
have O
previously O
described O
a O
novel O
flavivirus O
vaccine O
technology O
based O
on O
a O
single O
- O
cycle O
, O
Capsid B
( I
C I
) I
gene O
- O
deleted O
flavivirus O
called O
RepliVAX O
. O

Here O
we O
report O
that O
we O
have O
adapted O
our O
RepliVAX O
technology O
to O
produce O
a O
dengue O
vaccine O
by O
replacing O
the O
prM O
/ O
E O
genes O
of O
RepliVAX O
WN O
( O
a O
West O
Nile O
virus O
[ O
WNV O
] O
RepliVAX O
) O
with O
the O
same O
genes O
of O
Dengue B
virus I
type I
2 I
( I
DENV2 I
) I
. O

Our O
first O
RepliVAX O
construct O
for O
dengue O
virus O
( O
RepliVAX O
D2 O
) O
replicated O
poorly O
in O
WNV O
C O
- O
expressing O
cells O
. O

2 O
in O
a O
well O
- O
described O
immunodeficient O
mouse O
model O
for O
dengue O
( O
strain O
AG129 O
; O
lacking O
the O
receptors O
for O
both O
type O
I O
and O
type O
II O
interferons O
) O
. O

A O
molecular O
clone O
of O
yellow B
fever I
virus I
( I
YFV I
) I
strain O
17D O
was O
used O
to O
identify O
critical O
determinants O
of O
mouse O
neuroinvasiveness O
previously O
localized O
to O
domain O
III O
of O
the O
neuroadapted O
SPYF O
- O
MN O
virus O
envelope O
protein O
. O

Three O
candidate O
virulence O
substitutions O
( O
305F3V O
, O
326K3E O
, O
and O
380R3T O
) O
were O
individually O
evaluated O
for O
their O
roles O
in O
this O
phenotype O
in O
a O
SCID O
mouse O
model O
. O

The O
virus O
containing O
a O
glutamic O
acid O
residue O
at O
position O
326 O
of O
the O
envelope O
protein O
( O
326E O
) O
caused O
rapidly O
lethal O
encephalitis O
, O
with O
a O
mortality O
rate O
and O
average O
survival O
time O
resembling O
those O
of O
the O
parental O
SPYF O
- O
MN O
virus O
. O

Determinants O
at O
positions O
380 O
( O
380T O
) O
and O
305 O
( O
305V O
) O
did O
not O
independently O
affect O
neuroinvasiveness O
. O

Testing O
a O
panel O
of O
viruses O
with O
various O
amino O
acid O
substitutions O
at O
position O
326 O
revealed O
that O
attenuation O
of O
neuroinvasiveness O
required O
a O
positively O
charged O
residue O
( O
lysine O
or O
arginine O
) O
at O
this O
position O
. O

Using O
cholesterol O
- O
depleted O
insect O
cells O
, O
we O
showed O
that O
fusion O
and O
infection O
by O
the O
alphaviruses O
Semliki B
Forest I
virus I
( I
SFV I
) I
and O
Sindbis O
virus O
were O
strongly O
promoted O
by O
cholesterol O
, O
with O
similar O
sterol O
dependence O
in O
laboratory O
and O
field O
isolates O
and O
in O
viruses O
passaged O
in O
tissue O
culture O
. O

In O
contrast O
, O
fusion O
and O
infection O
by O
numerous O
strains O
of O
the O
flavivirus O
dengue B
virus I
( I
DV I
) I
and O
by O
yellow O
fever O
virus O
17D O
were O
cholesterol O
independent O
, O
and O
the O
DV O
fusion O
protein O
did O
not O
show O
significant O
cholesterol O
binding O
. O

Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
- O
specific O
Fab O
antibodies O
were O
recovered O
by O
repertoire O
cloning O
from O
chimpanzees O
initially O
immunized O
with O
inactivated O
JE O
- O
VAX O
and O
then O
boosted O
with O
attenuated O
JEV O
SA14 O
- O
14 O
- O
2 O
. O

These O
antibodies O
reacted O
with O
epitopes O
in O
different O
domains O
: O
the O
major O
determinant O
for O
Fab O
A3 O
was O
Lys O
( O
179 O
) O
( O
domain O
1 O
) O
, O
that O
for O
Fab O
B2 O
was O
Ile O
( O
132 O
) O
( O
domain O
II O
) O
, O
and O
that O
for O
Fab O
E3 O
was O
Gly O
( O
302 O
) O
( O
domain O
III O
) O
in O
the O
envelope O
protein O
, O
suggesting O
that O
these O
antibodies O
neutralize O
the O
virus O
by O
different O
mechanisms O
. O

These O
three O
Fabs O
and O
derived O
humanized O
Monoclonal B
antibodies I
( I
MAbs I
) I
exhibited O
high O
neutralizing O
activities O
against O
a O
broad O
spectrum O
of O
JEV O
genotype O
strains O
. O

MAb O
B2 O
was O
most O
potent O
, O
with O
a O
50 O
% O
protective O
dose O
( O
ED50 O
) O
of O
0 O
. O

Based O
on O
previous O
preclinical O
evaluation O
in O
mice O
and O
monkeys O
, O
the O
chimeric O
TBEV O
/ O
DEN4 O
Delta O
30 O
virus O
, O
carrying O
the O
prM O
and O
E O
protein O
genes O
from O
a O
highly O
virulent O
Far O
Eastern O
strain O
of O
tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
on O
the O
backbone O
of O
a O
nonneuroinvasive O
dengue B
type I
4 I
virus I
( I
DEN4 I
) I
, O
has O
been O
identified O
as O
a O
promising O
live O
attenuated O
virus O
vaccine O
candidate O
against O
disease O
caused O
by O
TBEV O
. O

In O
the O
present O
study O
, O
we O
compared O
the O
neuropathogeneses O
of O
the O
chimeric O
TBEV O
/ O
DEN4 O
Delta O
30 O
virus O
; O
Langat B
virus I
( I
LGTV I
) I
, O
a O
former O
live O
TBEV O
vaccine O
; O
and O
yellow B
fever I
17D I
virus I
vaccine I
( I
YF I
17D I
) I
in O
rhesus O
monkeys O
inoculated O
intracerebrally O
. O

TBEV O
/ O
DEN4 O
Delta O
30 O
and O
YF O
17D O
demonstrated O
remarkably O
similar O
spatiotemporal O
profiles O
of O
virus O
replication O
and O
virus O
- O
associated O
histopathology O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
that O
were O
high O
in O
cerebral O
hemispheres O
but O
progressively O
decreased O
toward O
the O
spinal O
cord O
. O

It O
was O
previously O
reported O
that O
mutations O
in O
yellow B
fever I
virus I
( I
YFV I
) I
nonstructural O
protein O
NS2A O
blocked O
production O
of O
infectious O
virus O
and O
that O
this O
block O
could O
be O
released O
by O
a O
suppressor O
mutation O
in O
NS3 O
. O

Mutation O
of O
tryptophan O
349 O
to O
alanine O
( O
W349A O
) O
had O
no O
effect O
on O
viral O
replication O
, O
as O
demonstrated O
by O
wild O
- O
type O
levels O
of O
viral O
RNA O
amplification O
and O
protein O
expression O
in O
W349A O
- O
transfected O
cells O
. O

The O
assembly O
defect O
in O
W349A O
could O
be O
trans O
- O
complemented O
inefficiently O
using O
BHK O
- O
REP O
cells O
( O
a O
cell O
line O
containing O
persistently O
replicating O
YFV O
replicon O
RNA O
) O
. O

Wild O
- O
type O
Sindbis B
virus I
( I
SINV I
) I
strain O
MRE16 O
efficiently O
infects O
Aedes O
aegypti O
midgut B
epithelia I
] I
cells I
( I
MEC I
) I
, O
but O
laboratory O
- O
derived O
neurovirulent O
SINV O
strain O
TE O
/ O
5 O
' O
2J O
infects O
MEC O
poorly O
. O

The O
growth O
patterns O
of O
derived O
viruses O
in O
cell O
culture O
were O
determined O
, O
as O
were O
the O
midgut B
infection I
rates I
( I
MIR I
) I
in O
A O
. O

The O
chimpanzee O
monoclonal B
antibody I
( I
Mab I
) I
5H2 O
is O
specific O
for O
Dengue B
virus I
type I
4 I
( I
DENV I
- I
4 I
) I
and O
neutralizes O
the O
virus O
at O
a O
high O
titer O
in O
vitro O
. O

One O
variant O
contained O
a O
Lys O
( O
174 O
) O
- O
Glu O
substitution O
and O
another O
contained O
a O
Pro O
( O
176 O
) O
- O
Leu O
substitution O
in O
domain O
I O
of O
the O
DENV O
- O
4 O
envelope B
protein I
( I
E I
) I
. O

Humanized O
immunoglobulin B
G I
( I
IgG I
) I
5112 O
, O
originally O
produced O
from O
an O
expression O
vector O
, O
has O
been O
shown O
to O
be O
a O
variant O
containing O
a O
nine O
- O
amino O
- O
acid O
deletion O
in O
the O
Fc O
region O
which O
completely O
ablates O
antibody O
- O
dependent O
enhancement O
of O
DENV O
replication O
in O
vitro O
. O

Monkeys O
that O
received O
2 O
mg O
/ O
kg O
of O
body O
weight O
of O
IgG O
5H2 O
AD O
were O
completely O
protected O
against O
100 O
50 O
% O
monkey O
infectious O
doses O
( O
MID O
, O
, O
) O
of O
DENV O
- O
4 O
, O
as O
indicated O
by O
the O
absence O
of O
viremia O
and O
seroconversion O
. O

A O
DENV O
- O
4 O
escape O
mutant O
that O
contained O
a O
Lys O
( O
174 O
) O
- O
Glu O
substitution O
identical O
to O
that O
found O
in O
vitro O
was O
isolated O
from O
monkeys O
challenged O
with O
10 O
( O
6 O
) O
MID50 O
of O
DENV O
- O
4 O
. O

Neutralization O
of O
flaviviruses O
in O
vivo O
correlates O
with O
the O
development O
of O
an O
antibody O
response O
against O
the O
viral O
envelope B
( I
E I
) I
protein O
. O

Previous O
studies O
demonstrated O
that O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
an O
epitope O
on O
the O
lateral O
ridge O
of O
domain B
III I
( I
DIII I
) I
of O
the O
West B
Nile I
virus I
( I
WNV I
) I
E O
protein O
strongly O
protect O
against O
infection O
in O
animals O
. O

Based O
on O
X O
- O
ray O
crystallography O
and O
sequence O
analysis O
, O
an O
analogous O
type O
- O
specific O
neutralizing O
epitope O
for O
individual O
serotypes O
of O
the O
related O
flavivirus O
Dengue B
Virus I
( I
DENV I
) I
was O
hypothesized O
. O

Using O
yeast O
surface O
display O
of O
DIII O
variants O
, O
we O
defined O
contact O
residues O
of O
a O
panel O
of O
type O
- O
specific O
, O
subcomplex O
- O
specific O
, O
and O
cross O
- O
reactive O
Nubs O
that O
recognize O
DIII O
of O
DENV B
type I
2 I
( I
DENV I
- I
2 I
) I
and O
have O
different O
neutralizing O
potentials O
. O

Here O
we O
describe O
a O
two O
- O
component O
genome O
yellow B
fever I
virus I
( I
YFV I
) I
replication O
system O
in O
which O
each O
of O
the O
genomes O
encodes O
complete O
sets O
of O
nonstructural O
proteins O
that O
form O
the O
replication O
complex O
but O
expresses O
either O
only O
capsid O
or O
prM O
/ O
E O
instead O
of O
the O
entire O
structural O
polyprotein O
. O

In O
tissue O
culture O
, O
this O
modified O
YFV O
can O
be O
further O
passaged O
at O
an O
escalating O
scale O
by O
using O
a O
high O
multiplicity B
of I
infection I
( I
MOI I
) I
. O

A O
number O
of O
flaviviruses O
are O
important O
human O
pathogens O
, O
including O
yellow O
fever O
, O
dengue O
, O
West O
Nile O
, O
Japanese O
encephalitis O
, O
and O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
viruses O
. O

Nevertheless O
, O
these O
antibodies O
can O
efficiently O
bind O
to O
the O
major O
envelope B
protein I
( I
E I
) I
, O
which O
is O
the O
main O
target O
of O
neutralizing O
and O
protective O
antibodies O
because O
of O
its O
receptor O
- O
binding O
and O
membrane O
fusion O
functions O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
neutralizing O
West B
Nile I
virus I
( I
WNV I
) I
have O
been O
shown O
to O
protect O
against O
infection O
in O
animal O
models O
and O
have O
been O
identified O
as O
a O
correlate O
of O
protection O
in O
WNV O
vaccine O
studies O
. O

One O
hundred O
twenty O
- O
one O
MAbs O
specifically O
bound O
to O
the O
viral O
envelope B
( I
E I
) I
protein O
and O
four O
MAbs O
to O
the O
premembrane B
( I
PrM I
) I
protein O
. O

Enzyme O
- O
linked O
immunosorbent O
assay O
- O
based O
competitive O
- O
binding O
assays O
with O
representative O
E O
protein O
- O
specific O
MAbs O
demonstrated O
that O
24 O
/ O
51 O
( O
47 O
% O
) O
bound O
to O
domain O
II O
while O
only O
4 O
/ O
51 O
( O
8 O
% O
) O
targeted O
domain O
III O
. O

The O
3 B
' I
noncoding I
region I
( I
3 I
' I
NCR I
) I
of O
flaviviruses O
contains O
secondary O
and O
tertiary O
structures O
essential O
for O
virus O
replication O
. O

Previous O
studies O
of O
yellow B
fever I
virus I
( I
YFV I
) I
and O
dengue O
virus O
have O
found O
that O
modifications O
to O
the O
3 O
' O
NCR O
are O
sometimes O
associated O
with O
attenuation O
in O
vertebrate O
and O
/ O
or O
mosquito O
hosts O
. O

Nineteen O
isolates O
( O
designated O
YF O
- O
XL O
isolates O
) O
from O
Brazil O
, O
Trinidad O
, O
and O
Venezuela O
, O
dating O
from O
1973 O
to O
2001 O
, O
exhibited O
a O
216 O
- O
nucleotide B
( I
nt I
) I
duplication O
, O
yielding O
a O
tandem O
repeat O
of O
conserved O
hairpin O
, O
stem O
- O
loop O
, O
dumbbell O
, O
and O
pseudoknot O
structures O
. O

One O
Brazilian O
isolate O
exhibited O
, O
in O
addition O
to O
the O
216 O
- O
nt O
duplication O
, O
a O
deletion O
of O
a O
40 O
- O
nt O
repeated O
hairpin O
( O
RYF O
) O
motif O
( O
YF O
- O
XL O
- O
DeltaRYF O
) O
. O

Virion O
morphogenesis O
of O
the O
flaviviruses O
occurs O
in O
association O
with O
endoplasmic B
reticulum I
( I
ER I
) I
membranes O
, O
suggesting O
that O
there O
should O
be O
accumulation O
of O
the O
virion O
components O
in O
this O
compartment O
. O

A O
chimeric O
yellow O
fever O
- O
dengue O
1 O
( O
ChimeriVax O
- O
DEN1 O
) O
virus O
was O
produced O
by O
the O
transfection O
of O
Vero O
cells O
with O
chimeric O
in O
vitro O
RNA O
transcripts O
. O

Of O
10 O
plaque O
- O
purified O
clones O
, O
1 O
containing O
no O
mutation O
( O
clone O
J O
) O
was O
selected O
for O
production O
of O
the O
vaccine O
virus O
. O

During O
subsequent O
cell O
culture O
passaging O
of O
this O
clone O
for O
vaccine O
production O
, O
a O
single O
amino O
acid O
substitution O
( O
K O
to O
R O
) O
occurred O
in O
the O
envelope B
( I
E I
) I
protein O
at O
residue O
204 O
( O
E204 O
) O
( O
F O
. O

The O
same O
mutation O
was O
observed O
in O
another O
clone O
( O
clone O
E O
) O
. O

The O
histopathology O
scores O
of O
lesions O
in O
the O
brain O
tissue O
of O
monkeys O
inoculated O
with O
either O
the O
E204K O
or O
E204R O
virus O
were O
reduced O
compared O
to O
those O
for O
monkeys O
inoculated O
with O
the O
reference O
virus O
, O
a O
commercial O
yellow O
fever O
17D O
vaccine O
( O
YF O
- O
VAX O
) O
. O

Fab O
monoclonal O
antibodies O
to O
dengue B
type I
4 I
virus I
( I
DENV I
- I
4 I
) I
were O
recovered O
by O
repertoire O
cloning O
of O
bone O
marrow O
mRNAs O
from O
an O
immune O
chimpanzee O
and O
analyzed O
for O
antigen O
binding O
specificity O
, O
V O
- O
H O
and O
V O
- O
L O
sequences O
, O
and O
neutralizing O
activity O
against O
DENV O
- O
4 O
in O
vitro O
. O

Fab O
5H2 O
recognized O
an O
epitope O
on O
DENV O
- O
4 O
that O
was O
separate O
from O
the O
epitope O
( O
s O
) O
recognized O
by O
other O
Fabs O
. O

58 O
mug O
/ O
ml O
by O
Plaque B
Reduction I
Neutralization I
Test I
( I
PRNT I
) I
, O
whereas O
DENV O
- O
4 O
- O
neutralizing O
activity O
of O
other O
Fabs O
was O
low O
or O
not O
detected O
. O

Fab O
5H2 O
was O
converted O
to O
full O
- O
length O
Immunoglobulin B
G1 I
( I
IgG1 I
) I
by O
combining O
it O
with O
human O
sequences O
. O

The O
humanized O
chimpanzee O
antibody O
IgG1 O
5H2 O
produced O
in O
CHO O
cells O
neutralized O
DENV O
- O
4 O
strains O
from O
different O
geographical O
origins O
at O
a O
similar O
50 B
% I
plaque I
reduction I
( I
PRNT50 I
) I
titer O
of O
0 O
. O

dengue B
virus I
( I
DV I
) I
is O
a O
flavivirus O
and O
infects O
mammalian O
cells O
through O
mosquito O
vectors O
. O

This O
study O
investigates O
the O
roles O
of O
domain O
III O
of O
DV O
type O
2 O
envelope O
protein O
( O
EIII O
) O
in O
DV O
binding O
to O
the O
host O
cell O
. O

Furthermore O
, O
a O
synthetic O
peptide O
that O
includes O
amino B
acids I
( I
aa I
) I
380 O
to O
389 O
of O
EIII O
, O
IGVEPGQLKL O
, O
inhibits O
binding O
of O
EIII O
to O
C6 O
/ O
36 O
but O
not O
BHK21 O
cells O
. O

Three O
consecutive O
plaque O
purifications O
of O
four O
chimeric O
yellow O
fever O
virus O
- O
dengue O
virus O
( O
ChimeriVax O
- O
DEN O
) O
vaccine O
candidates O
against O
dengue O
virus O
types O
1 O
to O
4 O
were O
performed O
. O

34 O
x O
10 O
( O
- O
4 O
) O
per O
copied O
nucleotide O
and O
that O
the O
error O
rate O
of O
the O
yellow O
fever O
virus O
RNA O
polymerase O
employed O
by O
the O
chimeras O
for O
genome O
replication O
in O
infected O
cells O
was O
as O
low O
as O
1 O
. O

9 O
x O
10 O
( O
- O
7 O
) O
to O
2 O
. O

3 O
x O
10 O
( O
- O
7 O
) O
. O

We O
found O
that O
a O
sequence O
of O
18 O
nucleotides O
( O
residues O
146 O
to O
163 O
of O
the O
yellow O
fever O
virus O
genome O
, O
which O
encode O
amino O
acids O
9 O
to O
14 O
of O
the O
capsid O
protein O
) O
is O
essential O
for O
replication O
of O
the O
yellow O
fever O
virus O
replicon O
and O
that O
a O
slightly O
longer O
sequence O
of O
21 O
nucleotides O
( O
residues O
146 O
to O
166 O
, O
encoding O
amino O
acids O
9 O
to O
15 O
) O
is O
required O
for O
full O
replication O
. O

Chimeric O
yellow B
fever I
virus I
( I
YF I
) I
RNAs O
were O
constructed O
in O
which O
the O
YF O
structural O
genes O
were O
replaced O
by O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
structural O
genes O
or O
fusions O
between O
the O
YF O
and O
HCV O
structural O
, O
genes O
. O

The O
( O
chimeric O
- O
) O
HCV O
structural O
proteins O
were O
efficiently O
expressed O
and O
processed O
, O
and O
the O
native O
E1 O
/ O
E2 O
heterodimer O
was O
formed O
. O

double B
- I
stranded I
RNA I
( I
dsRNA I
) I
initiates O
cellular O
posttranscriptional O
responses O
that O
are O
collectively O
called O
RNA O
silencing O
in O
a O
number O
of O
different O
organisms O
, O
including O
plants O
, O
nematodes O
, O
and O
fruit O
flies O
. O

C6 O
/ O
36 O
( O
Aedes O
albopictus O
) O
cells O
were O
stably O
transformed O
with O
a O
plasmid O
designed O
to O
transcribe O
an O
inverted B
- I
repeat I
RNA I
( I
irRNA I
) I
derived O
from O
the O
genome O
of O
Dengue B
virus I
type I
2 I
( I
DEN I
- I
2 I
) I
capable O
of O
forming O
dsRNA O
. O

The O
cell O
lines O
were O
classified O
as O
either O
susceptible O
or O
resistant O
to O
virus O
replication O
, O
based O
on O
the O
percentage O
of O
cells O
expressing O
DEN O
- O
2 O
envelope B
( I
E I
) I
antigen O
7 O
days O
after O
challenge O
. O

Eight O
out O
of O
18 O
( O
44 O
% O
) O
cell O
lines O
designed O
to O
express O
irRNA O
were O
resistant O
to O
DEN O
- O
2 O
challenge O
, O
with O
more O
than O
95 O
% O
of O
the O
cells O
showing O
no O
DEN O
- O
2 O
antigen O
accumulation O
. O

In O
this O
system O
defective O
replicon O
RNAs O
with O
a O
deletion O
( O
s O
) O
in O
the O
nonstructural O
genes O
also O
encoded O
the O
puromycin O
resistance O
gene O
( O
PAC O
gene O
) O
and O
the O
reporter O
gene O
for O
beta O
- O
galactosidase O
( O
beta O
- O
Gal O
) O
. O

Using O
this O
system O
we O
demonstrated O
that O
deletions O
in O
the O
C O
- O
terminal O
434 O
codons O
of O
NS3 O
( O
codons O
178 O
to O
611 O
) O
were O
complemented O
for O
RNA O
replication O
, O
while O
any O
deletions O
in O
the O
first O
178 O
codons O
were O
not O
. O

Expression O
of O
the O
Langat B
( I
LGT I
) I
virus O
NS3 O
protein O
resulted O
in O
a O
cleavage O
of O
cellular O
DNA O
and O
reduced O
the O
viability O
of O
cells O
. O

Coexpression O
of O
NS3 O
with O
apoptotic O
inhibitors O
( O
CrmA O
and O
P35 O
) O
and O
addition O
of O
caspase O
peptide O
substrates O
( O
Z O
- O
VAD O
- O
FMK O
and O
Z O
- O
IETD O
- O
FMK O
) O
to O
NS3 O
- O
transfected O
cells O
blocked O
NS3 O
- O
induced O
apoptosis O
. O

We O
recently O
described O
the O
derivation O
of O
a O
dengue B
serotype I
2 I
virus I
( I
DEN2mutF I
) I
that O
exhibited O
a O
host O
range O
- O
restricted O
phenotype O
; O
it O
was O
severely O
impaired O
for O
replication O
in O
cultured O
mosquito O
cells O
( O
C6 O
/ O
36 O
cells O
) O
. O

DEN2mutF O
virus O
had O
selected O
mutations O
in O
genomic O
, O
sequences O
predicted O
to O
form O
a O
3 O
' O
stem O
- O
loop O
structure O
( O
3 O
' O
- O
SL O
) O
that O
is O
conserved O
among O
all O
flavivirus O
species O
. O

Here O
we O
report O
the O
introduction O
of O
these O
same O
mutational O
changes O
into O
the O
analogous O
region O
of O
an O
infectious O
DNA O
derived O
from O
the O
genome O
of O
a O
human O
- O
virulent O
dengue O
serotype O
1 O
virus O
( O
DEN1 O
) O
, O
strain B
Western I
Pacific I
( I
DEN1WP I
) I
. O

The O
resulting O
DEN1 O
mutant O
( O
DEN1mutF O
) O
exhibited O
a O
host O
range O
- O
restricted O
phenotype O
similar O
to O
that O
of O
DEN2mutF O
virus O
. O

Complete O
nucleotide O
sequence O
analysis O
of O
DEN1mutF O
RNA O
and O
that O
of O
a O
revertant O
virus O
, O
DEN1mutFRev O
, O
revealed O
that O
( O
i O
) O
the O
DEN1mutF O
genome O
contained O
no O
additional O
mutations O
upstream O
from O
the O
3 O
' O
- O
SL O
compared O
to O
the O
DEN1WP O
parent O
genome O
and O
( O
ii O
) O
the O
DEN1mutFRev O
genome O
contained O
de O
novo O
mutations O
, O
consistent O
with O
our O
previous O
hypothesis O
that O
the O
defect O
in O
DEN2mutF O
replication O
in O
C6 O
/ O
36 O
cells O
was O
at O
the O
level O
of O
RNA O
replication O
. O

Isolates O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
the O
prototype O
pestivirus O
, O
are O
divided O
into O
cytopathic B
( I
cp I
) I
and O
noncytopathic B
( I
ncp I
) I
biotypes O
according O
to O
their O
effect O
on O
cultured O
cells O
. O

A O
bicistronic O
BVDV O
( O
cp O
strain O
NADL O
) O
was O
created O
that O
expressed O
puromycin O
acetyltransferase O
as O
a O
dominant O
selectable O
marker O
. O

A O
recombinant O
live O
attenuated O
dengue B
virus I
type I
4 I
( I
DEN4 I
) I
vaccine O
candidate O
, O
2A O
Delta O
30 O
, O
was O
found O
previously O
to O
be O
generally O
well O
tolerated O
in O
humans O
, O
but O
a O
rash O
and O
an O
elevation O
of O
liver O
enzymes O
in O
the O
serum O
occurred O
in O
some O
vaccinees O
. O

2A O
Delta O
30 O
, O
a O
non O
- O
temperature O
- O
sensitive O
( O
non O
- O
ts O
) O
virus O
, O
contains O
a O
30 O
- O
nucleotide O
deletion O
( O
Delta O
30 O
) O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
viral O
genome O
. O

Twenty O
is O
mutant O
viruses O
were O
identified O
that O
were O
is O
in O
both O
simian O
Vero O
and O
human O
liver O
HuH O
- O
7 O
cells O
( O
n O
= O
13 O
) O
or O
only O
in O
HuH O
- O
7 O
cells O
( O
n O
= O
7 O
) O
. O

A O
is O
mutation O
in O
the O
NS3 O
protein O
( O
nucleotide O
position O
4995 O
) O
was O
introduced O
into O
a O
recombinant O
DEN4 O
virus O
possessing O
the O
Delta O
30 O
deletion O
, O
thereby O
creating O
rDEN4 O
Delta O
30 O
- O
4995 O
, O
a O
recombinant O
virus O
which O
is O
is O
and O
more O
attenuated O
than O
rDEN4 O
Delta O
30 O
virus O
in O
the O
brains O
of O
mice O
. O

Previous O
studies O
with O
a O
limited O
number O
of O
strains O
have O
indicated O
that O
there O
are O
two O
genotypes O
of O
yellow B
fever I
( I
YF I
) I
virus O
in O
Africa O
, O
one O
in O
west O
Africa O
and O
the O
other O
in O
east O
and O
central O
Africa O
, O
We O
have O
examined O
the O
prM O
/ O
M O
and O
a O
portion O
of O
the O
E O
protein O
for O
a O
panel O
of O
38 O
wild O
strains O
of O
YF O
virus O
from O
Africa O
representing O
different O
countries O
and O
times O
of O
isolation O
. O

The O
impact O
of O
a O
specific O
region O
of O
the O
envelope O
protein O
E O
of O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
on O
the O
biology O
of O
this O
virus O
was O
investigated O
by O
a O
site O
- O
directed O
mutagenesis O
approach O
. O

The O
four O
amino O
acid O
residues O
that O
were O
analyzed O
in O
detail O
( O
E308 O
to O
E311 O
) O
are O
located O
on O
the O
upper O
- O
lateral O
surface O
of O
domain O
III O
according O
to O
the O
X O
- O
ray O
structure O
of O
the O
TEE O
virus O
protein O
E O
and O
are O
part O
of O
an O
area O
that O
is O
considered O
to O
be O
a O
potential O
receptor O
binding O
determinant O
of O
flaviviruses O
, O
Mutants O
containing O
single O
amino O
acid O
substitutions O
, O
as O
well O
as O
combinations O
of O
mutations O
, O
were O
constructed O
and O
analyzed O
for O
their O
virulence O
in O
mice O
, O
growth O
properties O
in O
cultured O
cells O
, O
and O
genetic O
stability O
. O

Combining O
this O
mutation O
with O
deletion O
mutations O
in O
the O
3 O
' O
- O
noncoding O
region O
yielded O
mutants O
that O
were O
highly O
attenuated O
, O
The O
biological O
effects O
of O
mutation O
Thr O
310 O
to O
Lys O
, O
however O
, O
could O
be O
reversed O
to O
a O
large O
degree O
by O
a O
mutation O
at O
a O
neighboring O
position O
( O
Lys O
311 O
to O
Glu O
) O
that O
arose O
spontaneously O
during O
infection O
of O
a O
mouse O
, O
Mutagenesis O
of O
the O
other O
positions O
provided O
evidence O
for O
the O
functional O
importance O
of O
residue O
308 O
( O
Asp O
) O
and O
its O
charge O
interaction O
with O
residue O
311 O
( O
Lys O
) O
, O
whereas O
residue O
309 O
could O
be O
altered O
or O
even O
deleted O
without O
any O
notable O
consequences O
. O

Deletion O
of O
residue O
309 O
was O
accompanied O
by O
a O
spontaneous O
second O
- O
site O
mutation O
( O
Phe O
to O
Tyr O
) O
at O
position O
332 O
, O
which O
in O
the O
three O
- O
dimensional O
structure O
of O
protein O
E O
is O
spatially O
close O
to O
residue O
309 O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
type B
2 I
dengue I
( I
DEN I
- I
2 I
) I
virus O
infection O
induced O
extensive O
apoptosis O
in O
the O
human O
neuroblastoma O
cell O
line O
SK O
- O
N O
- O
SH O
. O

Phospholipase B
A I
( I
2 I
) I
( I
PLA I
( I
2 I
) I
) I
was O
activated O
by O
DEN O
- O
2 O
infection O
, O
which O
led O
to O
the O
generation O
of O
arachidonic B
acid I
( I
AA I
) I
. O

Inhibition O
of O
PLA O
( O
2 O
) O
activity O
by O
the O
PLA O
( O
2 O
) O
inhibitors O
, O
AACOCF O
( O
3 O
) O
and O
ONO O
- O
RS O
- O
082 O
, O
diminished O
DEN O
- O
2 O
virus O
- O
induced O
apoptosis O
. O

Pretreatment O
with O
superoxide B
dismutase I
( I
SOD I
) I
protected O
cells O
against O
DEN O
- O
2 O
virus O
- O
induced O
apoptosis O
. O

Furthermore O
, O
generation O
of O
superoxide O
anion O
was O
blocked O
by O
AACOCF O
( O
3 O
) O
. O

However O
, O
pretreatment O
of O
cells O
with O
oligodeoxynucleotides O
containing O
NF O
- O
kappa O
B O
, O
but O
not O
c O
- O
Jun O
, O
binding O
sites O
( O
transcription O
factor O
decoy O
) O
strongly O
prevented O
dengue O
virus O
- O
induced O
apoptosis O
. O

The O
finding O
that O
AACOCF O
( O
3 O
) O
and O
SOD O
significantly O
block O
activation O
of O
NF O
- O
kappa O
B O
suggests O
that O
this O
activation O
is O
derived O
from O
the O
AA O
- O
superoxide O
anion O
pathway O
. O

Our O
results O
indicate O
that O
DEN O
- O
2 O
virus O
infection O
of O
human O
neuroblastoma O
cells O
triggers O
an O
apoptotic O
pathway O
through O
PLA O
( O
2 O
) O
activation O
to O
superoxide O
anion O
generation O
and O
subsequently O
to O
NF O
- O
kappa O
B O
activation O
. O

We O
constructed O
chimeric O
dengue O
type O
2 O
/ O
type O
1 O
( O
DEN O
- O
2 O
/ O
DEN O
- O
1 O
) O
viruses O
containing O
the O
nonstructural O
genes O
of O
DEN O
- O
2 O
16681 O
virus O
or O
its O
vaccine O
derivative O
, O
strain O
PDK O
- O
53 O
, O
and O
the O
structural O
genes O
( O
encoding O
capsid O
protein O
, O
premembrane O
protein O
, O
and O
envelope O
glycoprotein O
) O
of O
DEN O
- O
I O
16007 O
virus O
or O
its O
vaccine O
derivative O
, O
strain O
PDK O
- O
13 O
, O
We O
previously O
reported O
that O
attenuation O
markers O
of O
DEN O
- O
2 O
PDK O
- O
53 O
virus O
were O
encoded O
by O
genetic O
loci O
located O
outside O
the O
structural O
gene O
region O
of O
the O
PDK O
- O
53 O
virus O
genome O
. O

Binding O
of O
yellow O
fever O
virus O
wild O
- O
type O
strains O
Asibi O
and O
French O
viscerotropic O
virus O
and O
vaccine O
strains O
17D O
and O
FNV O
to O
monkey O
brain O
and O
monkey O
liver O
cell O
membrane B
receptor I
preparations I
( I
MRPs I
) I
was O
investigated O
. O

Four O
monkey O
brain O
and O
two O
mouse O
brain O
MRP O
escape O
( O
MRPR O
) O
variants O
of O
FNV O
were O
selected O
at O
pH O
7 O
. O

6 O
each O
had O
only O
one O
amino O
acid O
substitution O
in O
the O
envelope B
( I
E I
) I
protein O
in O
domain O
II O
( O
E O
- O
237 O
, O
E O
- O
260 O
, O
or O
E274 O
) O
and O
were O
significantly O
attenuated O
in O
mice O
following O
intracerebral O
inoculation O
, O
Two O
of O
the O
variants O
were O
tested O
in O
monkeys O
and O
retained O
parental O
neurotropism O
following O
intracerebral O
inoculation O
at O
the O
dose O
tested O
. O

6 O
were O
Less O
attenuated O
in O
mice O
, O
and O
each O
had O
an O
amino O
acid O
substitution O
in O
the O
transmembrane O
region O
of O
the O
E O
protein O
( O
E O
- O
457 O
or O
E O
- O
458 O
) O
. O

We O
have O
introduced O
at O
the O
COOH O
terminus O
of O
the O
yellow B
fever I
virus I
( I
YFV I
) I
prM O
signal O
sequence O
amino O
acid O
substitutions O
( O
VPQAQA O
mutation O
) O
which O
uncoupled O
efficient O
signal O
peptidase O
cleavage O
of O
the O
prM O
protein O
from O
its O
dependence O
on O
prior O
cleavage O
in O
the O
cytoplasm O
of O
the O
C O
protein O
mediated O
by O
the O
viral O
NS2B O
- O
3 O
protease O
, O
Infectivity O
assays O
with O
full O
- O
length O
YFV O
RNA O
transcripts O
showed O
that O
the O
VPQAQA O
mutation O
, O
which O
enhanced O
signal O
peptidase O
cleavage O
in O
vitro O
, O
was O
lethal O
for O
infectious O
virus O
production O
, O
Revertants O
or O
second O
- O
site O
mutants O
were O
recovered O
from O
cells O
transfected O
with O
VPQAQA O
RNA O
. O

nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
yellow B
fever I
virus I
( I
YF I
) I
is O
a O
glycoprotein O
localized O
to O
extracytoplasmic O
compartments O
within O
infected O
cells O
. O

Here O
we O
report O
that O
the O
NS1 O
gene O
from O
a O
related O
virus O
, O
dengue B
virus I
( I
DEN I
) I
, O
is O
unable O
to O
function O
in O
the O
process O
of O
YF O
RNA O
replication O
. O

The O
region O
carboxy O
terminal O
to O
the O
protease O
domain O
has O
conserved O
motifs O
present O
in O
several O
viral O
RNA O
- O
stimulated O
nucleoside B
triphosphatase I
( I
NTPase I
) I
/ O
RNA O
helicases O
, O
To O
define O
the O
functional O
domains O
of O
protease O
and O
NTPase O
/ O
RNA O
helicase O
activities O
of O
NS3 O
, O
full O
- O
length O
and O
amino O
- O
terminal O
deletion O
mutants O
of O
NS3 O
were O
expressed O
in O
Escherichia O
coli O
and O
purified O
. O

However O
, O
mutagenesis O
of O
the O
conserved O
P O
- O
loop O
motif O
of O
the O
RNA O
helicase O
domain O
( O
K199E O
) O
resulted O
in O
loss O
of O
ATPase O
activity O
. O

The O
RNA O
- O
stimulated O
NTPase O
activity O
was O
significantly O
affected O
by O
deletion O
of O
20 O
amino O
acid O
residues O
from O
the O
N O
terminus O
or O
by O
substitutions O
of O
the O
cluster O
of O
basic O
residues O
, O
( O
RKRK O
) O
- O
R O
- O
184 O
- O
- O
> O
QNGN O
, O
of O
NS3de1 O
. O

Our O
results O
reveal O
that O
the O
functional O
domains O
required O
for O
serine O
protease O
and O
RNA O
- O
stimulated O
NTPase O
activities O
map O
within O
the O
region O
between O
amino O
acid O
residues O
160 O
and O
180 O
of O
NS3 O
protein O
and O
that O
a O
novel O
motif O
, O
the O
cluster O
of O
basic O
residues O
( O
RKRK O
) O
- O
R O
- O
184 O
, O
plays O
an O
important O
role O
for O
the O
RNA O
- O
stimulated O
NTPase O
activity O
. O

Mutational O
analysis O
of O
the O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
yellow B
fever I
virus I
( I
YF I
) I
has O
implicated O
it O
in O
viral O
RNA O
replication O
. O

The O
severe O
outcome O
of O
the O
dengue B
( I
DEN I
) I
virus O
infection O
known O
as O
DEN O
hemorrhagic O
fever O
- O
DEN O
shock O
syndrome O
( O
DHF O
- O
DSS O
) O
is O
, O
in O
some O
cases O
, O
accompanied O
by O
liver O
injury O
, O
Councilman O
bodies O
observed O
in O
liver O
biopsies O
of O
DHF O
- O
DSS O
cases O
may O
correspond O
to O
hepatocytes O
in O
apoptosis O
, O
We O
show O
, O
here O
that O
infection O
of O
the O
hepatoma O
cell O
line O
HepG2 O
with O
DEN O
type O
1 O
virus O
induced O
cell O
death O
typical O
of O
apoptosis O
late O
in O
the O
virus O
cycle O
. O

The O
evolution O
of O
yellow O
fever O
virus O
over O
67 O
years O
was O
investigated O
by O
comparing O
the O
nucleotide O
sequences O
of O
the O
envelope B
( I
E I
) I
protein O
genes O
of O
20 O
viruses O
isolated O
in O
Africa O
, O
the O
Caribbean O
, O
and O
South O
America O
. O

E O
genotype O
II O
viruses O
were O
divided O
into O
two O
sublineages O
: O
IIA O
viruses O
from O
West O
Africa O
and O
IIB O
viruses O
from O
America O
, O
except O
for O
a O
1979 O
virus O
isolated O
from O
Trinidad O
( O
TRINID79A O
) O
. O

The O
determinants O
of O
cleavage O
site O
specificity O
of O
the O
yellow B
fever I
virus I
( I
YF I
) I
NS3 O
proteinase O
for O
its O
2B O
/ O
3 O
cleavage O
site O
have O
been O
studied O
by O
using O
site O
- O
directed O
mutagenesis O
. O

Mutations O
at O
residues O
within O
the O
GARR O
down O
arrow O
S O
sequence O
were O
tested O
for O
effects O
on O
cia O
cleavage O
of O
an O
NS2B O
- O
3 O
( O
181 O
) O
polyprotein O
during O
cell O
- O
free O
translation O
, O
At O
the O
P1 O
position O
, O
only O
the O
conservative O
substitution O
R O
- O
- O
> O
K O
exhibited O
Significant O
levels O
of O
cleavage O
. O

Processing O
at O
other O
dibasic O
sites O
was O
studied O
by O
using O
transient O
expression O
of O
a O
sig2A O
- O
5 O
( O
356 O
) O
polyprotein O
. O

Most O
proteolytic O
cleavages O
in O
the O
Nonstructural B
protein I
( I
NS I
) I
region O
of O
the O
flavivirus O
polyprotein O
are O
effected O
by O
a O
virus O
- O
encoded O
protease O
composed O
of O
two O
viral O
proteins O
, O
NS2B O
and O
NS3 O
. O

We O
constructed O
a O
series O
of O
deletion O
mutations O
in O
the O
NS2B O
portion O
of O
plasmid O
pTM O
/ O
NS2B O
- O
30 O
% O
NS3 O
, O
which O
expresses O
dengue B
virus I
type I
4 I
( I
DEN4 I
) I
cDNA O
encoding O
NS2B O
and O
the O
N O
- O
terminal O
184 O
residues O
of O
NS3 O
from O
the O
T7 O
RNA O
polymerase O
promoter O
. O

The O
results O
identify O
a O
40 O
- O
amino O
- O
acid O
segment O
of O
NS2B O
( O
DEN4 O
amino O
acids O
1396 O
to O
1435 O
) O
essential O
for O
protease O
activity O
. O

The O
viral O
serine O
proteinase O
, O
which O
consists O
of O
NS2B O
and O
NS3 O
, O
is O
responsible O
for O
cleavage O
of O
at O
least O
four O
dibasic O
sites O
( O
2A O
/ O
2B O
, O
2B O
/ O
3 O
, O
3 O
/ O
4A O
, O
and O
4B O
/ O
5 O
) O
in O
the O
nonstructural O
region O
. O

With O
a O
construct O
which O
contained O
NS4B O
preceded O
by O
17 O
residues O
constituting O
the O
putative O
signal O
peptide O
( O
sig4B O
) O
, O
membrane O
- O
dependent O
cleavage O
at O
the O
4A O
/ O
4B O
site O
was O
demonstrated O
in O
vitro O
. O

From O
these O
results O
, O
we O
propose O
a O
model O
in O
which O
the O
signalase O
cleavage O
generating O
the O
N O
terminus O
of O
NS4B O
requires O
a O
prior O
NS2B O
- O
3 O
proteinase O
- O
mediated O
cleavage O
at O
a O
novel O
site O
( O
called O
the O
4A O
/ O
2K O
site O
) O
which O
is O
conserved O
among O
flaviviruses O
and O
located O
23 O
residues O
upstream O
of O
the O
signalase O
site O
. O

In O
addition O
, O
the O
size O
of O
the O
3 O
( O
502 O
) O
- O
4A O
product O
generated O
by O
trans O
processing O
of O
a O
truncated O
polyprotein O
, O
3 O
( O
502 O
) O
- O
53569 O
was O
consistent O
with O
cleavage O
at O
the O
4A O
/ O
2K O
site O
rather O
than O
at O
the O
downstream O
4A O
/ O
4B O
signalase O
site O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
have O
been O
prepared O
against O
vaccine O
and O
wild O
- O
type O
strains O
of O
yellow B
fever I
( I
YF I
) I
virus O
, O
and O
envelope O
protein O
epitopes O
specific O
for O
vaccine O
( O
MAbs O
H5 O
and O
H6 O
) O
and O
wild O
- O
type O
( O
MAbs O
S17 O
, O
S18 O
, O
S24 O
, O
and O
S56 O
) O
strains O
of O
YF O
virus O
have O
been O
identified O
. O

MAb O
neutralization O
- O
resistant O
( O
MAb O
( O
r O
) O
) O
escape O
variants O
generated O
by O
using O
wild O
- O
type O
- O
specific O
MAbs O
S18 O
and O
S24 O
were O
found O
to O
lose O
the O
epitopes O
recognized O
by O
MAbs O
S18 O
and O
S24 O
and O
to O
acquire O
the O
epitope O
recognized O
by O
vaccine O
- O
specific O
MAb O
H5 O
. O

In O
addition O
, O
the O
MAb O
( O
r O
) O
variants O
became O
attenuated O
for O
mice O
. O

The O
vaccinia O
virus O
- O
T7 O
transient O
expression O
system O
was O
used O
to O
further O
examine O
the O
role O
of O
the O
NS3 O
proteinase O
in O
processing O
of O
the O
yellow B
fever I
( I
YF I
) I
virus O
nonstructural O
polyprotein O
in O
BHK O
cells O
. O

Similar O
results O
were O
obtained O
with O
polyproteins O
whose O
N O
termini O
began O
within O
NS2A O
( O
position O
110 O
) O
or O
with O
NS2B O
. O

A O
poly O
( O
A O
) O
tail O
was O
identified O
on O
the O
3 O
' O
end O
of O
the O
prototype O
tick B
- I
borne I
encephalitis I
( I
TBE I
) I
virus O
strain O
Neudoerfl O
. O

This O
is O
in O
contrast O
to O
the O
general O
lack O
of O
poly O
( O
A O
) O
in O
the O
genomic O
RNAs O
of O
mosquito O
- O
borne O
flaviviruses O
analyzed O
so O
far O
. O

Analysis O
of O
several O
closely O
related O
strains O
of O
TBE O
virus O
, O
however O
, O
revealed O
the O
existence O
of O
two O
different O
types O
of O
3 O
' O
noncoding O
( O
NC O
) O
regions O
. O

One O
type O
( O
represented O
by O
strain O
Neudoerfl O
) O
is O
only O
114 O
nucleotides O
long O
and O
carries O
a O
3 O
' O
- O
terminal O
poly O
( O
A O
) O
structure O
. O

The O
other O
type O
( O
represented O
by O
strain O
Hypr O
) O
is O
461 O
nucleotides O
long O
and O
not O
polyadenylated O
. O

Ross B
River I
virus I
( I
RRV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
that O
causes O
epidemics O
of O
debilitating O
musculoskeletal O
disease O
. O

To O
define O
the O
innate O
immune O
mechanisms O
that O
mediate O
control O
of O
RRV O
infection O
, O
we O
studied O
a O
RRV O
strain O
encoding O
6 O
nonsynonymous O
mutations O
in O
nsP1 O
( O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
) O
that O
is O
attenuated O
in O
wild B
- I
type I
( I
WT I
) I
mice O
and O
Rag1 O
( O
- O
/ O
- O
) O
mice O
, O
which O
are O
unable O
to O
mount O
adaptive O
immune O
responses O
, O
but O
not O
in O
mice O
that O
lack O
the O
capacity O
to O
respond O
to O
type B
I I
interferon I
( I
IFN I
) I
( O
Ifnar1 O
( O
- O
/ O
- O
) O
mice O
) O
. O

Utilizing O
this O
attenuated O
strain O
, O
our O
prior O
studies O
revealed O
that O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
- O
dependent O
production O
of O
type O
I O
IFN O
by O
Ly6C O
( O
hi O
) O
monocytes O
is O
critical O
for O
control O
of O
acute O
RRV O
infection O
. O

Here O
, O
we O
infected O
Mavs O
( O
- O
/ O
- O
) O
mice O
with O
either O
WT O
RRV O
or O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
to O
elucidate O
MAVS O
- O
independent O
protective O
mechanisms O
. O

Mavs O
- O
/ O
mice O
infected O
with O
WT O
RRV O
developed O
severe O
disease O
and O
succumbed O
to O
infection O
, O
whereas O
those O
infected O
with O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
exhibited O
minimal O
disease O
signs O
. O

Mavs O
( O
- O
/ O
- O
) O
mice O
infected O
with O
RRV O
- O
T48 O
- O
nsP1 O
( O
6M O
) O
had O
higher O
levels O
of O
systemic O
type O
I O
IFN O
than O
Mavs O
( O
- O
/ O
- O
) O
mice O
infected O
with O
WT O
virus O
, O
and O
treatment O
of O
Mavs O
- O
/ O
mice O
infected O
with O
the O
attenuated O
nsP1 O
mutant O
virus O
with O
an O
IFNAR1 O
- O
blocking O
antibody O
resulted O
in O
a O
lethal O
infection O
. O

In O
vitro O
, O
type O
I O
IFN O
expression O
was O
induced O
in O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
cocultured O
with O
RRV O
- O
infected O
cells O
in O
a O
MAVS O
- O
independent O
manner O
, O
and O
depletion O
of O
pDCs O
in O
Mavs O
( O
- O
/ O
- O
) O
mice O
resulted O
in O
increased O
viral O
burdens O
in O
joint O
and O
muscle O
tissues O
, O
suggesting O
that O
pDCs O
are O
a O
source O
of O
the O
protective O
IFN O
in O
Mavs O
( O
- O
/ O
- O
) O
mice O
. O

IMPORTANCE O
Arthritogenic O
alphaviruses O
, O
including O
Ross B
River I
virus I
( I
RRV I
) I
, O
are O
human O
pathogens O
that O
cause O
debilitating O
acute O
and O
chronic O
musculoskeletal O
disease O
and O
are O
a O
significant O
public O
health O
burden O
. O

In O
this O
study O
, O
we O
found O
that O
pDCs O
contribute O
to O
the O
protective O
type O
I O
interferon O
response O
during O
RRV O
infection O
through O
a O
mechanism O
that O
is O
independent O
of O
the O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
adaptor O
protein O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
responsible O
for O
chikungunya O
fever O
. O

nonstructural B
protein I
2 I
( I
nsP2 I
) I
, O
a O
multifunctional O
protein O
essential O
for O
viral O
replication O
, O
has O
an O
N O
- O
terminal O
helicase O
region O
( O
nsP2h O
) O
, O
which O
has O
both O
nucleotide O
triphosphatase O
and O
RNA O
triphosphatase O
activities O
, O
as O
well O
as O
a O
C O
- O
terminal O
cysteine O
protease O
region O
( O
nsP2p O
) O
, O
which O
is O
responsible O
for O
nonstructural O
poly O
protein O
processing O
. O

Using O
the O
small B
- I
angle I
X I
- I
ray I
scattering I
( I
SAXS I
) I
method O
, O
we O
demonstrated O
that O
the O
full O
- O
length O
nsP2 O
is O
elongated O
and O
partially O
folded O
in O
solution O
. O

This O
work O
suggests O
that O
increasing O
the O
interdomain O
flexibility O
of O
nsP2 O
could O
facilitate O
the O
assembly O
of O
the O
replication B
complex I
( I
RC I
) I
with O
increased O
efficiency O
and O
promote O
virus O
production O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
and O
rapidly O
spreading O
pathogen O
transmitted O
by O
mosquitoes O
. O

The O
emergence O
of O
new O
epidemic O
variants O
of O
the O
virus O
is O
associated O
with O
genetic O
evolutionary O
traits O
, O
including O
duplication O
of O
repeated O
RNA O
elements O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
that O
seemingly O
favor O
transmission O
by O
mosquitoes O
. O

Compared O
to O
the O
3 O
' O
- O
UTR O
mutant O
, O
we O
observed O
that O
the O
wild O
- O
type O
virus O
had O
a O
short O
extrinsic B
incubation I
period I
( I
EIP I
) I
after O
an O
infectious O
blood O
meal O
and O
was O
expectorated O
into O
mosquito O
saliva O
much O
more O
efficiently O
. O

We O
found O
that O
the O
mutant O
virus O
had O
a O
delayed O
replication O
rate O
in O
mosquitoes O
, O
which O
lengthened O
the O
extrinsic B
incubation I
period I
( I
EIP I
) I
and O
reduced O
fitness O
relative O
to O
the O
wild O
- O
type O
virus O
. O

Phosphatidylserine B
( I
PS I
) I
receptors O
mediate O
clearance O
of O
apoptotic O
cells O
- O
efferocytosis O
- O
by O
recognizing O
the O
PS O
exposed O
on O
those O
cells O
. O

Here O
, O
we O
show O
that O
phosphatidylethanolamine B
( I
PE I
) I
synergizes O
with O
PS O
to O
enhance O
PS O
receptor O
- O
mediated O
efferocytosis O
and O
virus O
entry O
. O

IMPORTANCE O
Phosphatidylserine B
( I
PS I
) I
and O
phosphatidylethanolamine B
( I
PE I
) I
are O
usually O
sequestered O
to O
the O
inner O
leaflet O
of O
the O
plasma O
membrane O
of O
the O
healthy O
eukaryotic O
cells O
. O

Decades O
of O
insufficient O
control O
have O
resulted O
in O
unprecedented O
spread O
of O
chikungunya B
virus I
( I
CHIKV I
) I
around O
the O
globe O
, O
and O
millions O
have O
suffered O
from O
the O
highly O
debilitating O
disease O
. O

Our O
new O
study O
shows O
that O
four O
- O
and O
- O
a O
- O
half O
LIM O
domain O
protein O
( O
FHL1 O
) O
is O
one O
of O
the O
host O
factors O
that O
interact O
with O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
CHIKV O
nsP3 O
. O

However O
, O
its O
expression O
has O
a O
detectable O
stimulatory O
effect O
( O
s O
) O
on O
CHIKV O
replication O
, O
and O
Fhl1 O
knockout B
( I
KO I
) I
cell O
lines O
demonstrate O
slower O
infection O
spread O
. O

Nuclear B
magnetic I
resonance I
( I
NMR I
) I
- O
based O
studies O
revealed O
that O
the O
binding O
site O
of O
FHL1 O
in O
CHIKV O
nsP3 O
HVD O
overlaps O
that O
of O
another O
proviral O
host O
factor O
, O
CD2AP O
. O

IMPORTANCE O
Replication O
of O
chikungunya B
virus I
( I
CHIKV I
) I
is O
determined O
by O
a O
wide O
range O
of O
host O
factors O
. O

Previously O
, O
we O
have O
demonstrated O
that O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
CHIKV O
nsP3 O
contains O
linear O
motifs O
that O
recruit O
defined O
families O
of O
host O
proteins O
into O
formation O
of O
functional O
viral O
replication O
complexes O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
associated O
with O
debilitating O
arthralgia O
in O
humans O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
RNA O
virus O
that O
causes O
febrile O
illness O
and O
debilitating O
arthralgia O
in O
humans O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
arthritogenic O
alphavirus O
that O
causes O
debilitating O
musculoskeletal O
disease O
. O

Cell O
surface O
glycosaminoglycans B
( I
GAGs I
) I
have O
been O
identified O
as O
CHIKV O
attachment O
factors O
. O

While O
all O
strains O
directly O
bound O
to O
heparin O
and O
chondroitin O
sulfate O
in O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISAs I
) I
and O
depended O
on O
heparan O
sulfate O
for O
efficient O
cell O
binding O
and O
infection O
, O
we O
observed O
some O
variation O
by O
strain O
. O

chikungunya B
virus I
( I
CHIKV I
) I
, O
a O
mosquito O
- O
transmitted O
alphavirus O
, O
enters O
a O
cell O
through O
endocytosis O
, O
followed O
by O
viral O
and O
cell O
membrane O
fusion O
. O

molecular B
dynamics I
( I
MD I
) I
simulation O
of O
the O
CHIKV O
E1 O
or O
E2 O
- O
E1 O
structure O
predicted O
that O
the O
spring O
- O
twisted O
region O
untwists O
at O
pH O
5 O
. O

In O
the O
first O
, O
a O
spring O
- O
twisted O
region O
in O
a O
loop O
connecting O
two O
domains O
( O
I O
and O
III O
) O
untwists O
, O
bringing O
a O
swiveling O
motion O
of O
domains O
on O
each O
other O
. O

Chikungunya O
fever O
, O
a O
mosquito O
- O
borne O
disease O
manifested O
by O
fever O
, O
rash O
, O
myalgia O
, O
and O
arthralgia O
, O
is O
caused O
by O
chikungunya B
virus I
( I
CHIKV I
) I
, O
which O
belongs O
to O
the O
genus O
Alphavirus O
of O
the O
family O
Togaviridae O
. O

Here O
, O
we O
show O
a O
detailed O
model O
of O
the O
docking O
between O
the O
envelope O
glycoprotein O
of O
CHIKV O
and O
our O
unique O
anti O
- O
CHIKV O
- O
neutralizing O
monoclonal O
antibody O
( O
CHE19 O
) O
, O
which O
inhibits O
CHIKV O
membrane O
fusion O
and O
virion O
release O
from O
CHIKV O
- O
infected O
cells O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
important O
reemerging O
human O
pathogen O
transmitted O
by O
mosquitoes O
. O

The O
virus O
causes O
an O
acute O
febrile O
illness O
, O
chikungunya O
fever O
, O
which O
is O
characterized O
by O
headache O
, O
rash O
, O
and O
debilitating O
( O
poly O
) O
arthralgia O
that O
can O
reside O
for O
months O
to O
years O
after O
infection O
. O

The O
serotonergic O
drug O
5 B
- I
nonyloxytryptamine I
( I
5 I
- I
NT I
) I
was O
previously O
identified O
as O
a O
potential O
host O
- O
directed O
inhibitor O
for O
CHIKV O
infection O
. O

Intriguingly O
, O
however O
, O
no O
effect O
was O
seen O
during O
virus O
- O
cell O
binding O
, O
internalization O
, O
membrane O
fusion O
and O
genomic B
RNA I
( I
gRNA I
) I
release O
into O
the O
cell O
cytosol O
. O

In O
addition O
, O
we O
show O
that O
the O
serotonin O
receptor O
antagonist O
methiothepin B
mesylate I
( I
MM I
) I
also O
has O
antiviral O
properties O
toward O
CHIKV O
and O
specifically O
interferes O
with O
the O
cell O
entry O
process O
and O
/ O
or O
membrane O
fusion O
. O

For O
many O
of O
these O
infections O
, O
including O
those O
caused O
by O
chikungunya B
virus I
( I
CHIKV I
) I
, O
there O
are O
no O
specific O
treatment O
possibilities O
to O
alleviate O
disease O
symptoms O
. O

This O
interaction O
with O
lipid O
bilayers O
is O
mediated O
through O
the O
viral O
methyl O
/ O
guanylyltransferase O
nsP1 O
and O
reinforced O
by O
palmitoylation O
of O
cysteine O
residue O
( O
s O
) O
in O
the O
C O
- O
terminal O
region O
of O
this O
protein O
. O

Using O
the O
medically O
important O
chikungunya B
virus I
( I
CHIKV I
) I
as O
a O
model O
, O
we O
report O
that O
nsP1 O
cosegregates O
with O
cholesterol O
- O
rich O
detergent B
- I
resistant I
membrane I
microdomains I
( I
DRMs I
) I
, O
also O
called O
lipid O
rafts O
. O

A O
parallel O
study O
of O
Sindbis B
virus I
( I
SINV I
) I
revealed O
that O
nsP1 O
from O
this O
divergent O
alphavirus O
displays O
a O
low O
affinity O
for O
cholesterol O
and O
only O
moderately O
segregates O
with O
DRMs O
. O

We O
show O
that O
nsP1 O
has O
affinity O
for O
cholesterol O
- O
rich O
membrane O
microdomains O
formed O
at O
the O
plasma O
membrane O
and O
identify O
conserved O
palmitoylated O
cysteine O
( O
s O
) O
in O
nsP1 O
as O
the O
key O
determinant O
for O
cholesterol O
affinity O
. O

We O
observed O
that O
all O
sensitive O
viruses O
have O
an O
Arg O
residue O
at O
the O
P4 O
position O
of O
the O
cleavage O
site O
between O
the O
nonstructural B
protein I
P1 I
( I
nsP1 I
) I
and O
nsP2 O
regions O
of O
the O
replicase O
precursor O
polyprotein O
( O
1 O
/ O
2 O
site O
) O
, O
while O
a O
different O
residue O
is O
found O
at O
this O
site O
in O
viruses O
resistant O
to O
G3BP O
deletion O
. O

In O
the O
absence O
of O
G3BP O
, O
chikungunya B
virus I
( I
CHIKV I
) I
replication O
is O
at O
the O
limit O
of O
detection O
. O

type B
I I
interferons I
( I
IFNs I
) I
are O
key O
mediators O
of O
the O
innate O
immune O
response O
. O

While O
previous O
work O
has O
demonstrated O
that O
type O
I O
IFNs O
are O
essential O
to O
control O
infection O
by O
chikungunya B
virus I
( I
CHIKV I
) I
, O
a O
globally O
emerging O
alphavirus O
, O
the O
contributions O
of O
individual O
IFN O
subtypes O
remain O
undefined O
. O

To O
address O
this O
question O
, O
we O
evaluated O
CHIKV O
pathogenesis O
in O
mice O
lacking O
IFN O
- O
beta O
( O
IFN O
- O
beta O
knockout O
[ O
IFN O
- O
beta O
- O
KO O
] O
mice O
or O
mice O
treated O
with O
an O
IFN O
- O
beta O
- O
blocking O
antibody O
) O
or O
IFN O
- O
alpha O
( O
IFN O
regulatory O
factor O
7 O
knockout O
[ O
IRF7 O
- O
KO O
] O
mice O
or O
mice O
treated O
with O
a O
pan O
- O
IFN O
- O
alpha O
- O
blocking O
antibody O
) O
. O

IMPORTANCE O
type B
I I
interferons I
( I
IFNs I
) I
possess O
a O
range O
of O
biological O
activity O
and O
protect O
against O
a O
number O
of O
viruses O
, O
including O
alphaviruses O
. O

The O
significance O
of O
our O
research O
is O
in O
demonstrating O
that O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
both O
have O
protective O
roles O
during O
acute O
chikungunya B
virus I
( I
CHIKV I
) I
infection O
but O
do O
so O
by O
distinct O
mechanisms O
. O

Agonistic O
anti O
- O
CD137 O
monoclonal B
antibody I
( I
Mab I
) I
therapy O
has O
been O
combined O
with O
other O
chemotherapeutic O
agents O
in O
human O
cancer O
trials O
. O

We O
evaluated O
anti O
- O
CD137 O
MAb O
therapy O
in O
a O
mouse O
infection O
model O
of O
chikungunya B
virus I
( I
CHIKV I
) I
, O
an O
alphavirus O
that O
causes O
chronic O
polyarthritis O
in O
humans O
and O
is O
associated O
with O
reservoirs O
of O
CHIKV O
RNA O
that O
are O
not O
cleared O
efficiently O
by O
adaptive O
immune O
responses O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerged O
arbovirus O
, O
a O
member O
of O
the O
Togaviridae O
family O
. O

In O
doing O
so O
, O
the O
virus O
mutational O
robustness O
( O
capacity O
to O
maintain O
phenotype O
despite O
introduction O
of O
mutations O
to O
genotype O
) O
is O
decreased O
, O
driving O
the O
viral O
population O
toward O
deleterious O
evolutionary O
trajectories O
. O

Using O
deep O
- O
sequencing O
technology O
, O
we O
observed O
an O
increase O
in O
detrimental O
( O
stop O
) O
codons O
, O
which O
confirmed O
the O
effectiveness O
of O
this O
genomic O
design O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
. O

It O
has O
a O
positive O
- O
sense O
RNA O
genome O
that O
also O
serves O
as O
the O
mRNA O
for O
four O
nonstructural B
proteins I
( I
nsPs I
) I
representing O
subunits O
of O
the O
viral O
replicase O
. O

In O
both O
mammalian O
and O
mosquito O
cells O
, O
novel O
trans O
- O
replicase O
assays O
had O
exceptional O
sensitivity O
, O
with O
up O
to O
10 O
( O
5 O
) O
- O
fold O
higher O
reporter O
expression O
in O
the O
presence O
of O
replicase O
relative O
to O
background O
. O

Using O
this O
highly O
sensitive O
assay O
to O
analyze O
CHIKV O
nsP1 O
functionality O
, O
several O
mutations O
that O
severely O
reduced O
, O
but O
did O
not O
completely O
block O
, O
CHIKV O
replicase O
activity O
were O
identified O
: O
( O
i O
) O
nsP1 O
tagged O
at O
its O
N O
terminus O
with O
enhanced O
green O
fluorescent O
protein O
; O
( O
ii O
) O
mutations O
D63A O
and O
Y248A O
, O
blocking O
the O
RNA O
capping O
; O
and O
( O
iii O
) O
mutation O
R252E O
, O
affecting O
nsP1 O
membrane O
anchoring O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
medically O
important O
pathogen O
responsible O
for O
recent O
large O
- O
scale O
epidemics O
. O

The O
development O
of O
efficient O
therapies O
against O
CHIKV O
has O
been O
hampered O
by O
gaps O
in O
our O
understanding O
of O
how O
nonstructural B
proteins I
( I
nsPs I
) I
function O
to O
form O
the O
viral O
replicase O
and O
replicate O
virus O
RNA O
. O

Here O
we O
describe O
an O
extremely O
sensitive O
assay O
to O
analyze O
the O
effects O
of O
mutations O
on O
the O
virus O
RNA O
synthesis O
machinery O
in O
cells O
of O
both O
mammalian O
( O
host O
) O
and O
mosquito O
( O
vector O
) O
origin O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
that O
causes O
epidemics O
of O
debilitating O
disease O
worldwide O
. O

In O
this O
study O
, O
we O
generated O
a O
novel O
live B
attenuated I
vaccine I
( I
LAV I
) I
candidate O
for O
CHIKV O
with O
a O
complete O
deficiency O
of O
capsid O
( O
Delta O
C O
- O
CHIKV O
) O
. O

Vaccination O
of O
either O
immunocompromised O
IFNAR O
( O
- O
/ O
- O
) O
mice O
or O
immunocompetent O
C57BL O
/ O
6 O
mice O
with O
a O
single O
dose O
of O
Delta O
C O
- O
CHIKV O
conferred O
complete O
protection O
upon O
challenge O
with O
wild B
- I
type I
( I
WT I
) I
CHIKV O
. O

Chandipura B
virus I
( I
CHPV I
) I
, O
a O
cytoplasmic O
RNA O
virus O
, O
has O
been O
implicated O
in O
several O
outbreaks O
of O
acute O
encephalitis O
in O
India O
. O

In O
response O
to O
viral O
infections O
, O
mammalian O
cells O
activate O
RelA O
/ O
NF O
- O
kappa O
B O
heterodimers O
, O
which O
induce O
genes O
encoding O
interferon B
beta I
( I
IFN I
- I
beta I
) I
and O
other O
immune O
mediators O
. O

Unexpectedly O
, O
infection O
of O
Rela O
( O
- O
/ O
- O
) O
fibroblasts O
led O
to O
a O
decreased O
CHPV O
yield O
. O

In O
particular O
, O
the O
development O
of O
novel O
antivirals O
for O
high O
- O
risk O
populations O
such O
as O
pregnant O
women O
is O
essential O
to O
prevent O
devastating O
disease O
such O
as O
that O
which O
was O
experienced O
with O
the O
recent O
outbreak O
of O
Zika B
virus I
( I
ZIKV I
) I
in O
the O
Americas O
. O

Here O
, O
we O
identify O
the O
DExH B
- I
box I
RNA I
helicase I
9 I
( I
DHX9 I
) I
as O
a O
binding O
partner O
of O
chikungunya B
virus I
( I
CHIKV I
) I
nsP3 O
mainly O
interacting O
with O
the O
C O
- O
terminal O
hypervariable O
domain O
. O

IMPORTANCE O
The O
reemergence O
of O
chikungunya B
virus I
( I
CHIKV I
) I
, O
an O
alphavirus O
that O
is O
transmitted O
to O
humans O
by O
Aedes O
mosquitoes O
, O
is O
a O
serious O
global O
health O
threat O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
global O
health O
threat O
that O
produces O
debilitating O
arthritis O
in O
people O
. O

Both O
high O
- O
and O
low O
- O
fidelity O
mutations O
were O
hypothesized O
to O
attenuate O
CHIKV O
arthritic O
disease O
, O
replication O
, O
and O
neutralizing O
antibody O
levels O
compared O
to O
wild B
- I
type I
( I
WT I
) I
CHIKV O
. O

Using O
next B
- I
generation I
sequencing I
( I
NGS I
) I
, O
the O
high O
- O
fidelity O
mutations O
were O
demonstrated O
to O
be O
genetically O
stable O
but O
produced O
more O
genetically O
diverse O
populations O
than O
WT O
CHIKV O
in O
mice O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
transmitted O
to O
people O
by O
mosquitoes O
, O
and O
CHIKV O
infection O
causes O
fever O
and O
joint O
pain O
. O

fatty B
acid I
synthase I
( I
FASN I
) I
has O
been O
identified O
as O
a O
proviral O
factor O
for O
CHIKV O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
palmitic O
acid O
( O
PA O
) O
can O
restore O
the O
suppression O
of O
CHIKV O
replication O
by O
FASN O
inhibitors O
. O

Furthermore O
, O
two O
zinc O
finger O
DHHC O
domain O
- O
containing O
palmitoyltransferases O
( O
ZDHHCs O
) O
, O
ZDHHC2 O
and O
ZDHHC19 O
, O
promoted O
nsP1 O
palmitoylation O
and O
CHIKV O
replication O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
that O
has O
evolved O
effective O
mechanisms O
to O
counteract O
the O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

Upon O
recognition O
of O
the O
virus O
, O
cells O
secrete O
IFNs O
, O
which O
signal O
through O
transmembrane O
receptors O
( O
IFNAR O
) O
to O
phosphorylate B
STAT I
proteins I
( I
pSTAT I
) I
. O

pSTAT O
dimers O
are O
transported O
into O
the O
nucleus O
by O
importin O
- O
alpha O
5 O
and O
activate O
the O
transcription O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
increasing O
cellular O
resistance O
to O
infection O
. O

CHIKV O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
reduces O
ISG O
expression O
by O
inhibiting O
general O
host O
cell O
transcription O
and O
by O
specifically O
reducing O
the O
levels O
of O
nuclear O
pSTAT1 O
via O
an O
unknown O
mechanism O
. O

In O
most O
patients O
, O
infection O
results O
in O
high O
fever O
, O
rash O
, O
and O
incapacitating O
( O
chronic O
) O
arthralgia O
. O

As O
a O
result O
, O
stimulation O
of O
the O
innate O
immune O
response O
with O
Interferons B
( I
IFNs I
) I
is O
ineffective O
as O
a O
treatment O
for O
CHIKV O
disease O
. O

The O
IFN O
response O
requires O
an O
intact O
downstream O
signaling O
cascade O
called O
the O
JAK O
/ O
STAT O
signaling O
pathway O
, O
which O
is O
effectively O
inhibited O
by O
CHIKV O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
via O
an O
unknown O
mechanism O
. O

chikungunya B
virus I
( I
CHIKV I
) I
, O
a O
mosquito O
- O
borne O
human O
pathogen O
, O
causes O
a O
disabling O
disease O
characterized O
by O
severe O
joint O
pain O
that O
can O
persist O
for O
weeks O
, O
months O
, O
or O
even O
years O
in O
patients O
. O

The O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
plays O
essential O
roles O
during O
acute O
infection O
, O
but O
little O
is O
known O
about O
the O
function O
of O
nsP3 O
during O
chronic O
disease O
. O

Round O
cytoplasmic O
granules O
of O
various O
sizes O
( O
i O
) O
contained O
nsP3 O
and O
stress O
granule O
assembly O
factors O
1 O
and O
2 O
( O
G3BP1 O
/ O
2 O
) O
, O
( O
ii O
) O
were O
next O
to O
double O
- O
stranded O
RNA O
foci O
and O
nsP1 O
- O
positive O
structures O
, O
and O
( O
iii O
) O
were O
close O
to O
the O
nuclear O
membrane O
and O
the O
nuclear O
pore O
complex O
protein O
Nup98 O
. O

This O
continued O
presence O
of O
viral O
and O
cellular O
protein O
complexes O
has O
implications O
for O
the O
study O
of O
the O
pathogenic O
consequences O
of O
lingering O
CHIKV O
infection O
and O
the O
development O
of O
strategies O
to O
mitigate O
the O
burden O
of O
chronic O
musculoskeletal O
disease O
brought O
about O
by O
a O
medically O
important O
arthropod O
- O
borne O
virus O
( O
arbovirus O
) O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
alphavirus O
transmitted O
by O
mosquitos O
and O
causes O
transient O
sickness O
but O
also O
chronic O
disease O
affecting O
muscles O
and O
joints O
. O

Here O
we O
established O
human O
cells O
that O
stably O
replicate O
replicon O
RNA O
and O
express O
tagged O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
medically O
important O
alphavirus O
that O
is O
transmitted O
by O
Aedes O
aegypti O
and O
Aedes O
albopictus O
mosquitoes O
. O

The O
viral O
replicase O
complex O
consists O
of O
four O
nonstructural B
proteins I
( I
nsPs I
) I
expressed O
as O
a O
polyprotein O
precursor O
and O
encompasses O
all O
enzymatic O
activities O
required O
for O
viral O
RNA O
replication O
. O

A O
CHIKV O
trans O
- O
replicase O
system O
that O
allows O
the O
uncoupling O
of O
RNA O
replication O
and O
nsP O
expression O
was O
adapted O
to O
mosquito O
cells O
and O
subsequently O
used O
for O
analysis O
of O
universal O
and O
host O
- O
specific O
effects O
of O
17 O
different O
nonstructural O
polyprotein O
( O
ns O
- O
polyprotein O
) O
mutations O
. O

It O
was O
found O
that O
mutations O
blocking O
nsP O
enzymatic O
activities O
as O
well O
as O
insertions O
of O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
into O
different O
nsPs O
had O
similar O
effects O
on O
trans O
- O
replicase O
activity O
regardless O
of O
the O
host O
( O
i O
. O

Increased O
RNA O
replication O
in O
mosquito O
cells O
was O
counteracted O
by O
an O
antiviral O
RNA B
interference I
( I
RNAi I
) I
response O
. O

This O
is O
partly O
due O
to O
the O
lack O
of O
reliable O
systems O
for O
functional O
analysis O
of O
viral O
nonstructural O
polyproteins O
( O
ns O
- O
polyproteins O
) O
and O
nonstructural B
proteins I
( I
nsPs I
) I
in O
mosquito O
cells O
. O

The O
data O
presented O
here O
introduce O
a O
robust O
viral O
RNA O
- O
protein O
discovery O
method O
to O
elucidate O
the O
Sindbis B
virus I
( I
SINV I
) I
RNA O
- O
protein O
host O
interface O
. O

Cross B
- I
link I
- I
assisted I
mRNP I
purification I
( I
CLAMP I
) I
assessment O
revealed O
an O
extensive O
array O
of O
host O
- O
pathogen O
interactions O
centered O
on O
the O
viral B
RNAs I
( I
vRNAs I
) I
. O

After O
prioritization O
of O
the O
host O
proteins O
associated O
with O
the O
vRNAs O
, O
we O
identified O
the O
site O
of O
protein O
- O
vRNA O
interaction O
by O
a O
UV O
cross B
- I
linking I
and I
immunoprecipitation I
sequencing I
( I
CLIP I
- I
seq I
) I
approach O
and O
assessed O
the O
consequences O
of O
the O
RNA O
- O
protein O
binding O
event O
of O
hnRNP O
K O
, O
hnRNP O
I O
, O
and O
hnRNP O
M O
in O
regard O
to O
viral O
infection O
. O

Here O
, O
we O
established O
a O
protocol O
to O
purify O
these O
membranous O
replication B
complexes I
( I
RCs I
) I
from O
cells O
infected O
with O
Semliki B
Forest I
virus I
( I
SFV I
) I
. O

We O
removed O
soluble O
proteins O
, O
the O
Golgi O
membranes O
, O
and O
most O
of O
the O
mitochondria O
, O
but O
plasma O
membrane O
, O
endoplasmic B
reticulum I
( I
ER I
) I
, O
and O
late O
endosome O
markers O
were O
retained O
in O
the O
membrane O
fraction O
that O
contained O
viral O
RNA O
synthesizing O
activity O
, O
replicase O
proteins O
, O
and O
minus O
- O
and O
plus O
- O
strand O
RNA O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
transmitted O
alphavirus O
that O
causes O
debilitating O
musculoskeletal O
pain O
and O
inflammation O
and O
can O
persist O
for O
months O
to O
years O
after O
acute O
infection O
. O

To O
evaluate O
this O
further O
, O
we O
isolated O
CHIKV O
from O
the O
serum O
of O
persistently O
infected O
Rag1 O
( O
- O
/ O
- O
) O
mice O
at O
day O
28 O
. O

When O
inoculated O
into O
naive O
wild B
- I
type I
( I
WT I
) I
mice O
, O
this O
persistently O
circulating O
CHIKV O
strain O
displayed O
a O
capacity O
for O
earlier O
dissemination O
and O
greater O
pathogenicity O
than O
the O
parental O
virus O
. O

Sequence O
analysis O
revealed O
a O
nonsynonymous O
mutation O
in O
the O
E2 O
glycoprotein O
( O
E2 O
K200R O
) O
and O
a O
deletion O
within O
the O
3 B
' I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
. O

Finally O
, O
studies O
with O
Irf3 O
/ O
Irf7 O
( O
- O
/ O
- O
) O
and O
Ifnar1 O
( O
- O
/ O
- O
) O
mice O
suggest O
that O
the O
E2 O
K200R O
mutation O
enhances O
viral O
dissemination O
from O
the O
site O
of O
inoculation O
independently O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
- O
, O
IRF7 O
- O
, O
and O
IFNAR1 O
- O
mediated O
responses O
. O

chikungunya B
virus I
( I
CHIKV I
) I
relies O
on O
polyamines O
for O
translation O
of O
the O
viral O
genome O
upon O
viral O
entry O
, O
and O
pharmacological O
depletion O
of O
polyamines O
limits O
viral O
replication O
. O

We O
have O
isolated O
CHIKV O
that O
is O
resistant O
to O
polyamine O
depletion O
and O
contains O
two O
mutations O
in O
the O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
- O
coding O
region O
in O
combination O
with O
a O
mutation O
to O
the O
opal O
stop O
codon O
preceding O
nsP4 O
. O

Here O
, O
we O
investigated O
the O
repertoire O
of O
endogenous B
flaviviral I
elements I
( I
EFVEs I
) I
in O
Aedes O
mosquitoes O
, O
the O
vectors O
of O
arboviruses O
such O
as O
dengue O
and O
chikungunya O
viruses O
. O

IMPORTANCE O
endogenous B
viral I
elements I
( I
EVEs I
) I
are O
whole O
or O
partial O
viral O
sequences O
integrated O
in O
host O
genomes O
. O

All O
Zika B
virus I
( I
ZIKV I
) I
suppression O
studies O
are O
limited O
to O
the O
wMel O
Wolbachia O
strain O
. O

Here O
we O
show O
ZIKV O
inhibition O
by O
two O
different O
Wolbachia O
strains O
: O
wAlbB O
( O
isolated O
from O
Aedes O
albopictus O
mosquitoes O
) O
and O
wStri O
( O
isolated O
from O
the O
planthopper O
Laodelphax O
striatellus O
) O
in O
mosquito O
cells O
. O

IMPORTANCE O
Zika B
virus I
( I
ZIKV I
) I
has O
swiftly O
spread O
throughout O
most O
of O
the O
Western O
Hemisphere O
. O

The O
molecular O
mechanisms O
underlying O
chikungunya B
virus I
( I
CHIKV I
) I
infection O
are O
poorly O
characterized O
. O

Analysis O
of O
genes O
enriched O
in O
the O
cells O
resistant O
to O
the O
pseudotyped O
virus O
infection O
unveiled O
a O
critical O
role O
of O
N O
- O
sulfation O
of O
heparan B
sulfate I
( I
HS I
) I
for O
the O
infectivity O
of O
the O
clinically O
isolated O
CHIKV O
Thai#16856 O
strain O
to O
HAP1 O
cells O
. O

Knockout O
of O
NDST1 O
that O
catalyzes O
N O
- O
sulfation O
of O
HS O
greatly O
decreased O
the O
binding O
and O
infectivity O
of O
CHIKV O
Thai#16856 O
strain O
but O
not O
infectivity O
of O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
and O
yellow B
fever I
virus I
( I
YFV I
) I
. O

Expression O
of O
chondroitin B
sulfate I
( I
CS I
) I
in O
NOSTI O
- O
knockout O
HAP1 O
cells O
did O
not O
restore O
the O
binding O
of O
CHIKV O
Thai#16856 O
strain O
and O
the O
infectivity O
of O
its O
pseudotype O
but O
restored O
the O
infectivity O
of O
authentic O
CHIKV O
Thai#16856 O
, O
suggesting O
that O
CS O
functions O
at O
later O
steps O
after O
CHIKV O
binding O
. O

chikungunya B
virus I
( I
CHIKV I
) I
utilizes O
host O
glycosaminoglycans O
to O
bind O
efficiently O
to O
its O
target O
cells O
. O

Favipiravir O
( O
T O
- O
705 O
) O
is O
a O
broad O
- O
spectrum O
antiviral O
agent O
that O
has O
been O
approved O
in O
Japan O
for O
the O
treatment O
of O
influenza O
virus O
infections O
. O

T O
- O
705 O
also O
inhibits O
the O
replication O
of O
various O
RNA O
viruses O
, O
including O
chikungunya B
virus I
( I
CHIKV I
) I
. O

We O
demonstrated O
earlier O
that O
the O
K291R O
mutation O
in O
the O
F1 O
motif O
of O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
of O
CHIKV O
is O
responsible O
for O
low O
- O
level O
resistance O
to O
T O
- O
705 O
. O

Interestingly O
, O
this O
lysine O
is O
highly O
conserved O
in O
the O
RdRp O
of O
positive O
- O
sense O
singlestranded O
RNA O
( O
+ O
ssRNA O
) O
viruses O
. O

To O
obtain O
insights O
into O
the O
unique O
broad O
- O
spectrum O
antiviral O
activity O
of O
T O
- O
705 O
, O
we O
explored O
the O
role O
of O
this O
lysine O
using O
another O
+ O
ssRNA O
virus O
, O
namely O
, O
coxsackievirus B
B3 I
( I
CVB3 I
) I
. O

Introduction O
of O
the O
corresponding O
K O
- O
to O
- O
R O
substitution O
in O
the O
CVB3 O
RdRp O
( O
K159R O
) O
resulted O
in O
a O
nonviable O
virus O
. O

IMPORTANCE O
In O
this O
study O
, O
we O
report O
the O
key O
role O
of O
a O
highly O
conserved O
lysine O
residue O
of O
the O
viral O
polymerase O
in O
the O
broad O
- O
spectrum O
antiviral O
activity O
of O
favipiravir O
( O
T705 O
) O
against O
positive O
- O
sense O
single O
- O
stranded O
RNA O
viruses O
. O

Recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
based O
chimeric O
viruses O
that O
include O
genes O
from O
other O
viruses O
show O
promise O
as O
vaccines O
and O
oncolytic O
viruses O
. O

VSVs O
that O
include O
the O
VSV O
glycoprotein B
( I
G I
) I
gene O
, O
even O
in O
most O
recombinant O
attenuated O
strains O
, O
can O
still O
show O
substantial O
adverse O
or O
lethal O
actions O
in O
the O
brain O
. O

Here O
, O
we O
test O
4 O
chimeric O
viruses O
in O
the O
brain O
, O
including O
those O
in O
which O
glycoprotein O
genes O
from O
Nipah O
, O
chikungunya O
( O
CHIKV O
) O
, O
and O
influenza O
H5N1 O
viruses O
were O
substituted O
for O
the O
VSV O
glycoprotein O
gene O
. O

We O
also O
test O
a O
virus B
- I
like I
vesicle I
( I
VLV I
) I
in O
which O
the O
VSV O
glycoprotein O
gene O
is O
expressed O
from O
a O
replicon O
encoding O
the O
nonstructural O
proteins O
of O
Semliki O
Forest O
virus O
. O

IMPORTANCE O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
shows O
considerable O
promise O
both O
as O
a O
vaccine O
vector O
and O
as O
an O
oncolytic O
virus O
. O

Since O
the O
India O
and O
Indian O
Ocean O
outbreaks O
of O
2005 O
and O
2006 O
, O
the O
global O
distribution O
of O
chikungunya B
virus I
( I
CHIKV I
) I
and O
the O
locations O
of O
epidemics O
have O
dramatically O
shifted O
. O

First O
, O
the O
Indian O
Ocean O
lineage O
( O
IOL O
) O
caused O
sustained O
epidemics O
in O
India O
and O
has O
radiated O
to O
many O
other O
countries O
. O

To O
do O
so O
, O
we O
conducted O
the O
most O
comprehensive O
phylogenetic O
analysis O
to O
date O
, O
examined O
CHIKV O
evolution O
and O
transmission O
, O
and O
explored O
distinct O
genetic O
factors O
associated O
with O
the O
emergence O
of O
the O
East B
/ I
Central I
/ I
South I
African I
( I
ECSA I
) I
lineage O
, O
the O
IOL O
, O
and O
the O
Asian O
lineage O
. O

Here O
, O
we O
describe O
the O
antiviral O
effects O
of O
two O
molecules O
that O
alter O
polyamine O
levels O
: O
difluoromethylornithine O
( O
DFMO O
; O
also O
called O
eflornithine O
) O
, O
which O
is O
a O
suicide O
inhibitor O
of O
ornithine B
decarboxylase I
1 I
( I
ODC1 I
) I
, O
and O
diethylnorspermine B
( I
DENSpm I
) I
, O
an O
activator O
of O
spermidine B
/ I
spermine I
N I
- I
1 I
- I
acetyltransferase I
( I
SAT1 I
) I
. O

chikungunya B
virus I
( I
CHIKV I
) I
has O
infected O
millions O
of O
people O
in O
the O
tropical O
and O
subtropical O
regions O
since O
its O
reemergence O
in O
the O
last O
decade O
. O

A O
human O
phosphokinase O
array O
revealed O
that O
CHIKV O
infection O
specifically O
activated O
the O
major O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
signaling O
pathways O
extracellular B
signal I
- I
related I
kinase I
( I
ERK I
) I
, O
p38 O
and O
c B
- I
Jun I
NH2 I
- I
terminal I
kinase I
( I
JNK I
) I
. O

Host O
cells O
respond O
to O
viral O
infections O
by O
producing O
type B
I I
interferon I
( I
IFN I
) I
, O
which O
induces O
the O
expression O
of O
hundreds O
of O
interfernon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

Here O
, O
we O
show O
that O
alphavirus O
infection O
is O
increased O
in O
Ifitm3 O
( O
- O
/ O
- O
) O
and O
Ifitm O
locus O
deletion O
( O
Ifitm O
- O
del O
) O
fibroblasts O
and O
, O
reciprocally O
, O
reduced O
in O
fibroblasts O
transcomplemented O
with O
Ifitm3 O
. O

In O
a O
murine O
model O
of O
chikungunya O
virus O
arthritis O
, O
Ifitm3 O
( O
- O
/ O
- O
) O
mice O
sustained O
greater O
joint O
swelling O
in O
the O
ipsilateral O
ankle O
at O
days O
3 O
and O
7 O
postinfection O
, O
and O
this O
correlated O
with O
higher O
levels O
of O
proinflammatory O
cytokines O
and O
viral O
burden O
. O

Flow O
cytometric O
analysis O
suggested O
that O
Ifitm3 O
( O
- O
/ O
- O
) O
macrophages O
from O
the O
spleen O
were O
infected O
at O
greater O
levels O
than O
observed O
in O
wild B
- I
type I
( I
WT I
) I
mice O
, O
results O
that O
were O
supported O
by O
experiments O
with O
Ifitm3 O
( O
- O
/ O
- O
) O
bone O
marrow O
- O
derived O
macrophages O
. O

Ifitm3 O
( O
- O
/ O
- O
) O
mice O
also O
were O
more O
susceptible O
than O
WT O
mice O
to O
lethal O
alphavirus O
infection O
with O
Venezuelan O
equine O
encephalitis O
virus O
, O
and O
this O
was O
associated O
with O
greater O
viral O
burden O
in O
multiple O
organs O
. O

IMPORTANCE O
The O
interferon B
- I
induced I
transmembrane I
protein I
3 I
( I
IFITM3 I
) I
inhibits O
infection O
of O
multiple O
families O
of O
viruses O
in O
cell O
culture O
. O

Using O
a O
small B
interfering I
RNA I
( I
siRNA I
) I
screen O
in O
human O
cells O
, O
we O
previously O
identified O
TSPAN9 O
as O
a O
host O
factor O
that O
promotes O
infection O
by O
the O
alphaviruses O
Sindbis B
virus I
( I
SINV I
) I
, O
Semliki B
Forest I
virus I
( I
SFV I
) I
, O
and O
chikungunya B
virus I
( I
CHIKV I
) I
. O

Comparative O
studies O
showed O
that O
TSPAN9 O
depletion O
strongly O
inhibited O
infection O
by O
several O
viruses O
that O
fuse O
in O
early O
endosomes O
( O
SFV O
, O
SINV O
, O
CHIKV O
, O
and O
vesicular O
stomatitis O
virus O
[ O
VSV O
] O
) O
, O
while O
viruses O
that O
fuse O
in O
the O
late O
endosome O
( O
recombinant O
VSV O
- O
Lassa O
and O
VSV O
- O
Junin O
) O
, O
including O
an O
SFV O
point O
mutant O
with O
a O
lower O
pH O
threshold O
for O
fusion O
( O
SFV O
E2 O
T12I O
) O
, O
were O
relatively O
resistant O
. O

The O
alphaviral O
6k O
gene O
region O
encodes O
the O
two O
structural O
proteins O
6K O
protein O
and O
, O
due O
to O
a O
ribosomal O
frameshift O
event O
, O
the O
transframe B
protein I
( I
TF I
) I
. O

Here O
, O
we O
characterized O
the O
role O
of O
the O
6k O
proteins O
in O
the O
arthritogenic O
alphavirus O
Ross B
River I
virus I
( I
RRV I
) I
in O
infected O
cells O
and O
in O
mice O
, O
using O
a O
novel O
6k O
in O
- O
frame O
deletion O
mutant O
. O

RRV O
virions O
that O
lack O
the O
6k O
proteins O
6K O
and O
TF O
[ O
RRV O
- O
( O
Delta O
6K O
) O
] O
were O
more O
vulnerable O
to O
changes O
in O
pH O
, O
and O
the O
corresponding O
virus O
had O
increased O
sensitivity O
to O
a O
higher O
temperature O
. O

Subsequent O
in O
vivo O
studies O
demonstrated O
that O
RRV O
- O
( O
Delta O
6K O
) O
caused O
a O
milder O
disease O
than O
wild O
- O
type O
virus O
, O
with O
viral O
titers O
being O
reduced O
in O
infected O
mice O
. O

Immunization O
of O
mice O
with O
RRV O
- O
( O
Delta O
6K O
) O
resulted O
in O
a O
reduced O
viral O
load O
and O
accelerated O
viral O
elimination O
upon O
secondary O
infection O
with O
wild O
- O
type O
RRV O
or O
another O
alphavirus O
, O
chikungunya B
virus I
( I
CHIKV I
) I
. O

IMPORTANCE O
Arthritogenic O
alphaviruses O
, O
such O
as O
chikungunya B
virus I
( I
CHIKV I
) I
and O
Ross B
River I
virus I
( I
RRV I
) I
, O
cause O
epidemics O
of O
debilitating O
rheumatic O
disease O
in O
areas O
where O
they O
are O
endemic O
and O
can O
emerge O
in O
new O
regions O
worldwide O
. O

Structures O
of O
chikungunya O
virus O
- O
like O
particles O
in O
complex O
with O
strongly O
neutralizing O
antibody O
Fab O
fragments O
( O
8B10 O
and O
5F10 O
) O
were O
determined O
using O
cryo O
- O
electron O
microscopy O
and O
X O
- O
ray O
crystallography O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
alphavirus O
responsible O
for O
causing O
epidemic O
outbreaks O
of O
polyarthralgia O
in O
humans O
. O

gamma O
delta O
T O
cell O
/ O
mice O
demonstrated O
exacerbated O
CHIKV O
disease O
characterized O
by O
less O
weight O
gain O
and O
greater O
foot O
swelling O
than O
occurred O
in O
wild O
- O
type O
( O
- O
/ O
- O
) O
mice O
, O
as O
well O
as O
a O
transient O
increase O
in O
monocytes O
and O
altered O
cytokine O
/ O
chemokine O
expression O
in O
the O
foot O
. O

Histologically O
, O
gamma O
delta O
T O
cell O
( O
- O
/ O
- O
) O
mice O
had O
increased O
inflammation O
- O
mediated O
oxidative O
damage O
in O
the O
ipsilateral O
foot O
and O
ankle O
joint O
compared O
to O
wild O
- O
type O
mice O
which O
was O
independent O
of O
differences O
in O
CHIKV O
replication O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
etiological O
agent O
of O
the O
major O
human O
arboviral O
disease O
. O

We O
previously O
demonstrated O
that O
the O
TIM O
and O
TAM O
families O
of O
phosphatidylserine B
( I
PtdSer I
) I
receptors O
involved O
in O
the O
phagocytosis O
of O
apoptotic O
cells O
mediate O
DENV O
entry O
into O
target O
cells O
. O

CD300a O
recognizes O
predominantly O
phosphatidylethanolamine B
( I
PtdEth I
) I
and O
to O
a O
lesser O
extent O
PtdSer O
associated O
with O
viral O
particles O
. O

We O
identified O
a O
novel O
variant O
in O
the O
alphavirus O
viral O
helicase O
/ O
protease O
, O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
that O
operates O
in O
concert O
with O
the O
viral O
polymerase O
nsP4 O
to O
further O
alter O
replication O
complex O
fidelity O
, O
a O
functional O
linkage O
that O
was O
conserved O
among O
the O
alphavirus O
genus O
. O

Many O
viruses O
affect O
or O
exploit O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( I
PI3K I
) I
- O
Akt O
- O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
pathway O
, O
a O
crucial O
prosurvival O
signaling O
cascade O
. O

We O
report O
that O
this O
pathway O
was O
strongly O
activated O
in O
cells O
upon O
infection O
with O
the O
Old O
World O
alphavirus O
Semliki B
Forest I
virus I
( I
SFV I
) I
, O
even O
under O
conditions O
of O
complete O
nutrient O
starvation O
. O

Viruses O
with O
a O
deletion O
of O
this O
domain O
( O
SFV O
- O
Delta O
50 O
) O
but O
not O
of O
other O
regions O
in O
nsP3 O
displayed O
a O
clearly O
delayed O
and O
reduced O
capacity O
of O
Akt O
stimulation O
. O

Ectopic O
expression O
of O
the O
nsP3 B
of I
SFV I
wild I
type I
( I
nsP3 I
- I
wt I
) I
, O
but O
not O
nsP3 O
- O
Delta O
50 O
, O
equipped O
with O
a O
membrane O
anchor O
was O
sufficient O
to O
activate O
Akt O
. O

In O
cells O
infected O
with O
the O
closely O
related O
chikungunya B
virus I
( I
CHIKV I
) I
, O
the O
PI3K O
- O
Akt O
- O
mTOR O
pathway O
was O
only O
moderately O
activated O
. O

We O
mapped O
this O
activation O
capacity O
to O
a O
region O
in O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
of O
SFV O
and O
could O
functionally O
transfer O
this O
region O
to O
CHIKV O
. O

chikungunya B
virus I
( I
CHIKV I
) I
infection O
is O
a O
reemerging O
pandemic O
human O
arboviral O
disease O
. O

CD4 O
( O
+ O
) O
T O
cells O
were O
previously O
shown O
to O
contribute O
to O
joint O
inflammation O
in O
the O
course O
of O
CHIKV O
infection O
in O
mice O
. O

The O
JES6 O
- O
1 O
anti O
- O
IL O
- O
2 O
antibody O
selectively O
expands O
mouse O
regulatory O
T O
cells O
( O
Tregs O
) O
by O
forming O
a O
complex O
with O
IL O
- O
2 O
. O

It O
does O
so O
by O
inhibiting O
the O
infiltration O
of O
CD4 O
( O
+ O
) O
T O
cells O
due O
to O
the O
induction O
of O
anergy O
in O
CHIKV O
- O
specific O
CD4 O
( O
+ O
) O
effector O
T O
cells O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
has O
reemerged O
as O
a O
pathogen O
of O
global O
significance O
. O

While O
T O
cell O
- O
mediated O
immunopathology O
in O
CHIKV O
infections O
has O
been O
reported O
, O
the O
role O
of O
regulatory O
T O
cells O
( O
Tregs O
) O
has O
not O
been O
explored O
. O

The O
JES6 O
- O
1 O
anti O
- O
interleukin B
2 I
( I
IL I
- I
2 I
) I
antibody O
has O
been O
demonstrated O
to O
selectively O
expand O
mouse O
Tregs O
by O
forming O
a O
complex O
with O
IL O
- O
2 O
. O

We O
reveal O
here O
that O
IL O
- O
2 O
JES6 O
- O
1 O
- O
mediated O
expansion O
of O
Tregs O
ameliorates O
CHIKV O
- O
induced O
joint O
pathology O
in O
mice O
by O
neutralizing O
virus O
- O
specific O
CD4 O
( O
+ O
) O
effector O
T O
( O
Teff O
) O
cells O
. O

We O
show O
that O
this O
treatment O
abrogates O
the O
infiltration O
of O
pathogenic O
CD4 O
( O
+ O
) O
T O
cells O
through O
induction O
of O
anergy O
in O
CHIKV O
- O
specific O
CD4 O
( O
+ O
) O
Teff O
cells O
. O

Arthritogenic O
alphaviruses O
such O
as O
Ross B
River I
virus I
( I
RRV I
) I
and O
chikungunya B
virus I
( I
CHIKV I
) I
cause O
large O
- O
scale O
epidemics O
of O
severe O
musculoskeletal O
disease O
and O
have O
been O
progressively O
expanding O
their O
global O
distribution O
. O

Here O
, O
we O
describe O
the O
promising O
therapeutic O
potential O
of O
the O
glycosaminoglycan B
( I
GAG I
) I
- O
like O
molecule O
pentosan B
polysulfate I
( I
PPS I
) I
to O
alleviate O
virus O
- O
induced O
arthritis O
. O

This O
was O
assessed O
using O
histological O
analysis O
, O
real O
- O
time O
PCR O
, O
and O
fluorescence B
- I
activated I
cell I
sorting I
( I
FACS I
) I
. O

pentosan B
polysulfate I
( I
PPS I
) I
is O
a O
glycan O
derivative O
that O
is O
orally O
bioavailable O
, O
has O
few O
toxic O
side O
effects O
, O
and O
is O
currently O
licensed O
under O
the O
name O
Elmiron O
for O
the O
treatment O
of O
cystitis O
in O
the O
United O
States O
. O

Semliki B
Forest I
virus I
( I
SFV I
) I
provides O
a O
well O
- O
characterized O
model O
system O
to O
study O
the O
pathogenesis O
of O
virus O
encephalitis O
. O

The O
phenotypic O
difference O
mapped O
to O
a O
single O
amino O
acid O
residue O
at O
position O
162 O
in O
the O
E2 O
envelope O
glycoprotein O
( O
lysine O
in O
SFV4 O
, O
glutamic O
acid O
in O
SFV6 O
) O
. O

Viruses O
with O
a O
positively O
charged O
lysine O
at O
E2 O
162 O
or O
247 O
were O
more O
reliant O
on O
glycosaminoglycans B
( I
GAGs I
) I
to O
enter O
cells O
and O
were O
selected O
for O
by O
passage O
in O
BHK O
- O
21 O
cells O
. O

Interestingly O
, O
viruses O
with O
the O
greatest O
reliance O
on O
binding O
to O
GAGs O
replicated O
to O
higher O
titers O
in O
the O
brain O
and O
more O
efficiently O
crossed O
an O
in O
vitro O
blood B
- I
brain I
barrier I
( I
BBB I
) I
. O

IMPORTANCE O
Virus O
encephalitis O
is O
a O
major O
disease O
, O
and O
alphaviruses O
, O
as O
highlighted O
by O
the O
recent O
epidemic O
of O
chikungunya B
virus I
( I
CHIKV I
) I
, O
are O
medically O
important O
pathogens O
. O

Together O
with O
studies O
on O
Sindbis B
virus I
( I
SINV I
) I
, O
this O
study O
provides O
an O
important O
advance O
in O
understanding O
alphavirus O
, O
and O
probably O
other O
virus O
, O
encephalitis O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
arthralgic O
alphavirus O
that O
has O
garnered O
international O
attention O
as O
an O
important O
emerging O
pathogen O
since O
2005 O
. O

Based O
on O
systemic O
cytokine O
analysis O
, O
localized O
immunophenotyping O
, O
and O
gene O
expression O
profiles O
in O
the O
popliteal O
lymph O
node O
and O
inflamed O
joints O
, O
two O
pathogenic O
phases O
were O
defined O
for O
CHIKV O
infection O
: O
early O
acute O
( O
2 O
to O
3 O
days O
postinfection O
[ O
dpi O
] O
) O
and O
late O
acute O
( O
6 O
to O
8 O
dpi O
) O
. O

Reduced O
joint O
pathology O
during O
early O
acute O
phase O
of O
CNR20235 O
infection O
was O
associated O
with O
a O
weaker O
proinflammatory O
Th1 O
response O
and O
natural B
killer I
( I
NK I
) I
cell O
activity O
. O

Stress B
granules I
( I
SGs I
) I
are O
protein O
- O
mRNA O
aggregates O
that O
are O
formed O
in O
response O
to O
environmental O
stresses O
, O
resulting O
in O
translational O
inhibition O
. O

GTPase O
- O
activating O
protein O
( O
SH3 O
domain O
) O
- O
binding O
protein O
1 O
( O
G3BP1 O
) O
is O
a O
key O
component O
and O
commonly O
used O
marker O
of O
SGs O
. O

Here O
, O
we O
demonstrate O
that O
chikungunya B
virus I
( I
CHIKV I
) I
infection O
induces O
cytoplasmic O
G3BP1 O
- O
and O
G3BP2 O
- O
containing O
granules O
that O
differ O
from O
bona O
fide O
SGs O
in O
terms O
of O
morphology O
, O
composition O
, O
and O
behavior O
. O

For O
several O
Old O
World O
alphaviruses O
it O
has O
been O
shown O
that O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
interacts O
with O
G3BPs O
, O
presumably O
to O
inhibit O
SG O
formation O
, O
and O
we O
have O
confirmed O
this O
interaction O
in O
CHIKV O
- O
infected O
cells O
. O

Depletion O
of O
G3BPs O
did O
not O
affect O
viral O
entry O
, O
translation O
of O
incoming O
genomes O
, O
or O
nonstructural O
polyprotein O
processing O
but O
resulted O
in O
severely O
reduced O
levels O
of O
negative O
- O
stranded O
( O
and O
consequently O
also O
positive O
- O
stranded O
) O
RNA O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
causes O
a O
severe O
polyarthritis O
that O
has O
affected O
millions O
of O
people O
since O
its O
reemergence O
in O
2004 O
. O

Stress B
granules I
( I
SGs I
) I
are O
cytoplasmic O
protein O
- O
mRNA O
aggregates O
formed O
in O
response O
to O
various O
stresses O
, O
including O
viral O
infection O
. O

chikungunya B
virus I
( I
CHIKV I
) I
( O
genus O
Alphavirus O
) O
has O
a O
positive O
- O
sense O
RNA O
genome O
. O

CHIKV O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
proteolytically O
processes O
the O
viral O
nonstructural O
polyprotein O
, O
possesses O
nucleoside B
triphosphatase I
( I
NTPase I
) I
, O
RNA O
triphosphatase O
, O
and O
RNA O
helicase O
activities O
, O
and O
induces O
cytopathic O
effects O
in O
vertebrate O
cells O
. O

In O
this O
study O
, O
we O
introduced O
a O
P718G O
( O
PG O
) O
mutation O
and O
selected O
for O
additional O
mutations O
in O
CHIKV O
nsP2 O
that O
resulted O
in O
a O
CHIKV O
replicon O
with O
a O
noncytotoxic O
phenotype O
in O
BHK O
- O
21 O
cells O
. O

Combinations O
of O
PG O
and O
either O
an O
E116K O
( O
EK O
) O
substitution O
or O
a O
GEEGS O
sequence O
insertion O
after O
residue O
T648 O
( O
5A O
) O
markedly O
reduced O
RNA O
synthesis O
; O
however O
, O
neither O
PG O
nor O
5A O
prevented O
nsP2 O
nuclear O
translocation O
. O

ISG15 O
( O
- O
/ O
- O
) O
mice O
exhibit O
increased O
susceptibility O
to O
viral O
infection O
, O
and O
in O
the O
case O
of O
influenza O
B O
virus O
and O
vaccinia O
virus O
, O
ISG15 O
conjugation O
has O
been O
shown O
to O
restrict O
virus O
replication O
in O
vivo O
. O

In O
order O
to O
better O
understand O
the O
function O
of O
ISG15 O
in O
vivo O
, O
we O
characterized O
the O
pathogenesis O
of O
influenza O
A O
virus O
and O
Sendai O
virus O
in O
ISG15 O
( O
- O
/ O
- O
) O
mice O
. O

IMPORTANCE O
It O
has O
previously O
been O
demonstrated O
that O
ISG15 O
( O
- O
/ O
- O
) O
mice O
are O
more O
susceptible O
to O
a O
number O
of O
viral O
infections O
. O

In O
these O
studies O
we O
have O
found O
that O
while O
ISG15 O
( O
- O
/ O
- O
) O
mice O
are O
more O
susceptible O
to O
influenza O
A O
virus O
and O
Sendai O
virus O
infections O
, O
ISGylation O
does O
not O
appear O
to O
mediate O
this O
protection O
through O
the O
direct O
inhibition O
of O
virus O
replication O
or O
the O
modulation O
of O
the O
acute O
immune O
response O
. O

The O
recent O
global O
resurgence O
of O
arthritogenic O
alphaviruses O
, O
in O
particular O
chikungunya B
virus I
( I
CHIKV I
) I
, O
highlights O
an O
urgent O
need O
for O
the O
development O
of O
therapeutic O
intervention O
strategies O
. O

Here O
, O
we O
used O
microcomputed O
tomographic O
( O
mu O
CT O
) O
and O
histomorphometric O
analyses O
to O
provide O
previously O
undescribed O
evidence O
of O
reduced O
bone O
volume O
in O
the O
proximal O
tibial O
epiphysis O
of O
CHIKV O
- O
infected O
mice O
compared O
to O
the O
results O
for O
mock O
controls O
. O

This O
was O
associated O
with O
a O
significant O
increase O
in O
the O
receptor O
activator O
of O
nuclear O
factor O
- O
kappa O
B O
ligand O
/ O
osteoprotegerin O
( O
RANKL O
/ O
OPG O
) O
ratio O
in O
infected O
murine O
joints O
and O
in O
the O
serum O
of O
CHIKV O
patients O
. O

The O
expression O
levels O
of O
the O
monocyte B
chemoattractant I
proteins I
( I
MCPs I
) I
, O
including O
MCP O
- O
1 O
/ O
CCL2 O
, O
MCP O
- O
2 O
/ O
CCL8 O
, O
and O
MCP O
- O
3 O
/ O
CCL7 O
, O
were O
also O
highly O
elevated O
in O
joints O
of O
CHIKV O
- O
infected O
mice O
, O
accompanied O
by O
increased O
cellularity O
within O
the O
bone O
marrow O
in O
tibial O
epiphysis O
and O
ankle O
joints O
. O

IMPORTANCE O
Arthritogenic O
alphaviruses O
, O
including O
chikungunya B
virus I
( I
CHIKV I
) I
and O
Ross B
River I
virus I
( I
RRV I
) I
, O
cause O
worldwide O
outbreaks O
of O
polyarthritis O
, O
which O
can O
persist O
in O
patients O
for O
months O
following O
infection O
. O

Furthermore O
, O
it O
is O
established O
that O
chemokine O
( O
C O
- O
C O
motif O
) O
ligand O
2 O
( O
CCL2 O
/ O
MCP O
- O
1 O
) O
is O
important O
in O
cellular O
recruitment O
and O
inducing O
bone O
- O
resorbing O
osteoclast O
( O
OC O
) O
formation O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
alphavirus O
that O
causes O
a O
debilitating O
arthritic O
disease O
and O
infects O
millions O
of O
people O
and O
for O
which O
no O
specific O
treatment O
is O
available O
. O

Here O
we O
used O
phage O
display O
against O
virus B
- I
like I
particles I
( I
VLPs I
) I
to O
isolate O
seven O
human B
monoclonal I
antibodies I
( I
MAbs I
) I
against O
the O
CHIKV O
envelope O
glycoproteins O
E2 O
and O
E1 O
. O

4 O
ng O
/ O
ml O
) O
, O
demonstrated O
high O
- O
affinity O
binding O
( O
320 O
pM O
) O
, O
and O
was O
capable O
of O
therapeutic O
and O
prophylactic O
protection O
in O
multiple O
animal O
models O
up O
to O
24 O
h O
postexposure O
. O

Epitope O
mapping O
of O
these O
MAbs O
demonstrates O
how O
some O
E2 O
/ O
E1 O
epitopes O
are O
exposed O
or O
hidden O
from O
the O
human O
immune O
system O
and O
suggests O
a O
structural O
mechanism O
by O
which O
these O
MAbs O
protect O
( O
or O
fail O
to O
protect O
) O
against O
CHIKV O
infection O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
that O
has O
reemerged O
to O
cause O
profound O
epidemics O
of O
fever O
, O
rash O
, O
and O
arthralgia O
throughout O
sub O
- O
Saharan O
Africa O
, O
Southeast O
Asia O
, O
and O
the O
Caribbean O
. O

Using O
wild O
- O
type O
and O
glycosaminoglycan B
( I
GAG I
) I
- O
deficient O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cell O
lines O
and O
soluble O
GAGs O
, O
we O
found O
that O
an O
arginine O
at O
residue O
82 O
conferred O
greater O
dependence O
on O
GAGs O
for O
infection O
of O
mammalian O
cells O
. O

Alphavirus O
replicons O
are O
potent O
inducers O
of O
CD8 O
( O
+ O
) O
T O
cell O
responses O
and O
thus O
constitute O
an O
attractive O
vaccine O
vector O
platform O
for O
developing O
novel O
vaccines O
. O

However O
, O
the O
kinetics O
and O
memory O
phenotype O
of O
CD8 O
( O
+ O
) O
T O
cell O
responses O
induced O
by O
alphavirus O
replicons O
are O
not O
well O
characterized O
. O

We O
demonstrate O
here O
that O
a O
single O
immunization O
with O
an O
alphavirus O
replicon O
, O
administered O
as O
viral O
particles O
or O
naked O
DNA O
, O
induced O
an O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
response O
that O
had O
a O
sharp O
peak O
, O
followed O
by O
a O
rapid O
contraction O
. O

In O
contrast O
, O
boosting O
after O
contraction O
when O
CD8 O
( O
+ O
) O
T O
cells O
had O
obtained O
a O
memory O
phenotype O
( O
based O
on O
CD127 O
/ O
CD62L O
expression O
) O
, O
resulted O
in O
maintenance O
of O
CD8 O
( O
+ O
) O
T O
cells O
with O
a O
high O
recall O
capacity O
( O
based O
on O
CD27 O
/ O
CD43 O
expression O
) O
. O

Increasing O
the O
dose O
of O
replicon O
particles O
promoted O
T B
effector I
memory I
( I
TEM I
) I
and O
inhibited O
T O
central O
memory O
development O
. O

Moreover O
, O
infection O
with O
a O
replicating O
alphavirus O
induced O
a O
similar O
distribution O
of O
CD8 O
( O
+ O
) O
T O
cells O
as O
the O
replicon O
vector O
. O

For O
instance O
, O
boosting O
with O
a O
poxvirus O
vector O
( O
MVA O
) O
favored O
expansion O
of O
the O
Tem O
compartment O
. O

In O
summary O
, O
we O
have O
characterized O
the O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
response O
induced O
by O
alphavirus O
replicon O
vectors O
and O
demonstrated O
how O
it O
can O
be O
altered O
by O
homologous O
and O
heterologous O
boost O
immunizations O
. O

In O
order O
to O
rationally O
design O
prime O
- O
boost O
immunization O
schedules O
with O
these O
vectors O
, O
characterization O
of O
the O
magnitude O
and O
phenotype O
of O
CD8 O
( O
+ O
) O
T O
cell O
responses O
induced O
by O
alphavirus O
replicons O
is O
needed O
. O

These O
findings O
are O
important O
for O
designing O
future O
clinical O
trials O
with O
alphaviruses O
, O
since O
they O
can O
be O
used O
to O
tailor O
vaccination O
regimens O
in O
order O
to O
induce O
a O
CD8 O
( O
+ O
) O
T O
cell O
response O
that O
is O
optimal O
for O
control O
and O
/ O
or O
clearance O
of O
a O
specific O
pathogen O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
mosquito O
- O
borne O
alphavirus O
that O
causes O
debilitating O
arthralgia O
in O
humans O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
transmitted O
alphavirus O
that O
causes O
acute O
fever O
and O
acute O
and O
chronic O
musculoskeletal O
pain O
in O
humans O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
mosquito O
- O
transmitted O
alphavirus O
that O
causes O
epidemics O
of O
debilitating O
polyarthritis O
in O
humans O
. O

A O
prior O
study O
identified O
two O
anti O
- O
CHIKV O
monoclonal O
antibodies O
( O
[ O
MAbs O
] O
CHK O
- O
152 O
and O
CHK O
- O
166 O
) O
against O
the O
E2 O
and O
E1 O
structural O
proteins O
, O
which O
had O
therapeutic O
efficacy O
in O
immunocompetent O
and O
immunocompromised O
mice O
. O

To O
evaluate O
the O
possible O
significance O
of O
MAb O
resistance O
, O
we O
engineered O
neutralization O
escape O
variant O
viruses O
( O
E1 O
- O
K61T O
, O
E2 O
- O
D59N O
, O
and O
the O
double O
mutant O
E1 O
- O
K61T O
E2 O
- O
D59N O
) O
that O
conferred O
resistance O
to O
CHK O
- O
152 O
and O
CHK O
- O
166 O
and O
tested O
them O
for O
fitness O
in O
mosquito O
cells O
, O
mammalian O
cells O
, O
mice O
, O
and O
Aedes O
albopictus O
mosquitoes O
. O

In O
both O
cell O
culture O
and O
mosquitoes O
, O
the O
mutant O
viruses O
grew O
equivalently O
and O
did O
not O
revert O
to O
wild B
- I
type I
( I
WT I
) I
sequence O
. O

All O
escape O
variants O
showed O
evidence O
of O
mild O
clinical O
attenuation O
, O
with O
decreased O
musculoskeletal O
disease O
at O
early O
times O
after O
infection O
in O
WT O
mice O
and O
a O
prolonged O
survival O
time O
in O
immunocompromised O
Ifnar1 O
( O
- O
/ O
- O
) O
mice O
. O

Competition O
studies O
with O
CHIKV O
WT O
also O
revealed O
no O
fitness O
compromise O
of O
the O
double O
mutant O
( O
E1 O
- O
K61T O
E2 O
- O
D59N O
) O
neutralization O
escape O
variant O
in O
WT O
mice O
. O

IMPORTANCE O
chikungunya B
virus I
( I
CHIKV I
) I
causes O
explosive O
epidemics O
of O
acute O
and O
chronic O
arthritis O
in O
humans O
in O
Africa O
, O
the O
Indian O
subcontinent O
, O
and O
Southeast O
Asia O
and O
recently O
has O
spread O
to O
the O
New O
World O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
member O
of O
a O
globally O
distributed O
group O
of O
arthritogenic O
alphaviruses O
that O
cause O
weeks O
to O
months O
of O
debilitating O
polyarthritis O
/ O
arthralgia O
, O
which O
is O
often O
poorly O
managed O
with O
current O
treatments O
. O

Here O
we O
used O
CCR2 O
( O
- O
/ O
- O
) O
mice O
to O
determine O
the O
effect O
of O
CCR2 O
deficiency O
on O
CHIKV O
infection O
and O
arthritis O
. O

Although O
there O
were O
no O
significant O
changes O
in O
viral O
load O
or O
RNA O
persistence O
and O
only O
marginal O
changes O
in O
antiviral O
immunity O
, O
arthritic O
disease O
was O
substantially O
increased O
and O
prolonged O
in O
CCR2 O
( O
- O
/ O
- O
) O
mice O
compared O
to O
wild O
- O
type O
mice O
. O

The O
monocyte O
/ O
macrophage O
infiltrate O
was O
replaced O
in O
CCR2 O
( O
- O
/ O
- O
) O
mice O
by O
a O
severe O
neutrophil O
( O
followed O
by O
an O
eosinophil O
) O
infiltrate O
and O
was O
associated O
with O
changes O
in O
the O
expression O
levels O
of O
multiple O
inflammatory O
mediators O
( O
including O
CXCL1 O
, O
CXCL2 O
, O
granulocyte O
colony O
- O
stimulating O
factor O
[ O
G O
- O
CSF O
] O
, O
interleukin O
- O
1 O
beta O
[ O
IL O
- O
1 O
beta O
] O
, O
and O
IL O
- O
10 O
) O
. O

Clear O
evidence O
of O
cartilage O
damage O
was O
also O
seen O
in O
CHIKV O
- O
infected O
CCR2 O
( O
- O
/ O
- O
) O
mice O
, O
a O
feature O
not O
normally O
associated O
with O
alphaviral O
arthritides O
. O

Although O
recruitment O
of O
CCR2 O
( O
+ O
) O
monocytes O
/ O
macrophages O
can O
contribute O
to O
inflammation O
, O
it O
also O
appears O
to O
be O
critical O
for O
preventing O
excessive O
pathology O
and O
resolving O
inflammation O
following O
alphavirus O
infection O
. O

chikungunya B
virus I
( I
CHIKV I
) I
causes O
a O
major O
public O
health O
problem O
. O

Intriguingly O
, O
no O
local O
transmission O
of O
chikungunya B
virus I
( I
CHIKV I
) I
had O
been O
reported O
in O
the O
Americas O
until O
recently O
, O
despite O
the O
presence O
of O
vectors O
and O
annually O
reported O
imported O
cases O
. O

In O
contrast O
, O
differences O
in O
transmission B
efficiency I
( I
TE I
) I
were O
underlined O
in O
populations O
of O
both O
species O
through O
the O
Americas O
, O
suggesting O
the O
role O
of O
salivary O
glands O
in O
selecting O
CHIKV O
for O
highly O
efficient O
transmission O
. O

albopictus O
better O
transmitted O
the O
epidemic O
mutant O
strain O
CHIKV_0621 O
of O
the O
East B
- I
Central I
- I
South I
African I
( I
ECSA I
) I
genotype O
than O
did O
A O
. O

T B
- I
cell I
immunoglobulin I
and I
mucin I
domain I
1 I
( I
TIM I
- I
1 I
) I
and O
other O
TIM O
family O
members O
were O
recently O
identified O
as O
phosphatidylserine B
( I
PtdSer I
) I
- O
mediated O
virus O
entry O
- O
enhancing O
receptors O
( O
PVEERs O
) O
. O

These O
proteins O
enhance O
entry O
of O
Ebola B
virus I
( I
EBOV I
) I
and O
other O
viruses O
by O
binding O
PtdSer O
on O
the O
viral O
envelope O
, O
concentrating O
virus O
on O
the O
cell O
surface O
, O
and O
promoting O
subsequent O
internalization O
. O

The O
PtdSer O
- O
binding O
activity O
of O
the O
immunoglobulin B
- I
like I
variable I
( I
IgV I
) I
domain O
is O
essential O
for O
both O
virus O
binding O
and O
internalization O
by O
TIM O
- O
1 O
. O

The O
Old O
World O
alphaviruses O
block O
stress O
granule O
assembly O
by O
sequestration O
of O
RasGAP O
SH3 O
- O
domain O
binding O
protein O
( O
G3BP O
) O
. O

Here O
, O
we O
show O
that O
the O
proline O
- O
rich O
sequences O
in O
the O
hypervariable O
domain O
of O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
of O
both O
Semliki O
Forest O
virus O
and O
Chikungunya O
virus O
were O
dispensable O
for O
binding O
to O
G3BP O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
inhibitory O
effect O
of O
a O
RIG O
- O
I O
agonist O
on O
the O
replication O
of O
two O
emerging O
arthropod O
- O
borne O
viral O
pathogens O
, O
Dengue B
Virus I
( I
DENV I
) I
and O
chikungunya B
virus I
( I
CHIKV I
) I
, O
for O
which O
no O
therapeutic O
options O
currently O
exist O
. O

We O
demonstrate O
that O
when O
a O
low O
, O
noncytotoxic O
dose O
of O
an O
optimized O
5 O
' O
triphosphorylated O
RNA O
( O
5 O
' O
pppRNA O
) O
molecule O
was O
administered O
, O
RIG O
- O
I O
stimulation O
generated O
a O
robust O
antiviral O
response O
against O
these O
two O
viruses O
. O

There O
is O
a O
need O
to O
develop O
a O
single O
and O
highly O
effective O
vaccine O
against O
the O
emerging O
chikungunya B
virus I
( I
CHIKV I
) I
, O
which O
causes O
a O
severe O
disease O
in O
humans O
. O

Here O
, O
we O
have O
generated O
and O
characterized O
the O
immunogenicity O
profile O
and O
the O
efficacy O
of O
a O
novel O
CHIKV O
vaccine O
candidate O
based O
on O
the O
highly O
attenuated O
poxvirus O
vector O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
expressing O
the O
CHIKV O
C O
, O
E3 O
, O
E2 O
, O
6K O
, O
and O
E1 O
structural O
genes O
( O
termed O
MVA O
- O
CHIKV O
) O
. O

Furthermore O
, O
MVA O
- O
CHIKV O
elicited O
robust O
innate O
immune O
responses O
in O
human O
macrophages O
and O
monocy O
- O
te O
- O
derived O
dendritic O
cells O
, O
with O
production O
of O
beta O
interferon O
( O
IFN O
- O
( O
1 O
) O
, O
proinflammatory O
cytokines O
, O
and O
chemokines O
. O

After O
immunization O
of O
C57BL O
/ O
6 O
mice O
with O
a O
homologous O
protocol O
( O
MVA O
- O
CHIKV O
/ O
MVA O
- O
CHIKV O
) O
, O
strong O
, O
broad O
, O
polyfunctional O
, O
and O
durable O
CHIKVspecific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
were O
elicited O
. O

The O
CHIKV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
preferentially O
directed O
against O
El O
and O
E2 O
proteins O
and O
, O
to O
a O
lesser O
extent O
, O
against O
C O
protein O
. O

CHIKV O
- O
specific O
CD8 O
( O
+ O
) O
memory O
T O
cells O
of O
a O
mainly O
effector O
memory O
phenotype O
were O
also O
induced O
. O

In O
summary O
, O
MVA O
- O
CHIKV O
is O
an O
effective O
vaccine O
against O
chikungunya O
virus O
infection O
that O
induced O
strong O
, O
broad O
, O
highly O
polyfunctional O
, O
and O
long O
- O
lasting O
CHIKV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
, O
together O
with O
neutralizing O
antibodies O
against O
CHIKV O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
alphavirus O
transmitted O
by O
mosquitoes O
that O
is O
known O
to O
cause O
severe O
arthritis O
and O
myositis O
in O
affected O
patients O
. O

To O
test O
this O
hypothesis O
, O
we O
used O
a O
murine O
model O
of O
CHIKV O
to O
compare O
the O
disease O
pathogeneses O
of O
two O
recombinant O
strains O
of O
CHIKV O
, O
the O
first O
derived O
from O
the O
La O
Reunion O
outbreak O
in O
2006 O
( O
LR2006 O
OPY1 O
) O
and O
the O
second O
isolated O
from O
Senegal O
in O
1983 O
( O
37997 O
) O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
mosquito O
- O
borne O
alphavirus O
that O
has O
caused O
severe O
epidemics O
in O
Africa O
and O
Asia O
and O
occasionally O
in O
Europe O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
reemerging O
mosquito O
- O
borne O
pathogen O
that O
causes O
incapacitating O
disease O
in O
humans O
characterized O
by O
intense O
joint O
pain O
that O
can O
persist O
for O
weeks O
, O
months O
, O
or O
even O
years O
. O

Inoculation O
of O
Rag1 O
( O
- O
/ O
- O
) O
mice O
, O
which O
lack O
T O
and O
B O
cells O
, O
resulted O
in O
higher O
viral O
levels O
in O
a O
variety O
of O
tissues O
, O
suggesting O
that O
adaptive O
immunity O
controls O
the O
tissue O
specificity O
and O
persistence O
of O
CHIKV O
infection O
. O

The O
presence O
of O
CHIKV O
RNA O
in O
tissues O
of O
wild O
- O
type O
and O
Rag1 O
( O
- O
/ O
- O
) O
mice O
was O
associated O
with O
histopathological O
evidence O
of O
synovitis O
, O
arthritis O
, O
and O
tendonitis O
; O
thus O
, O
CHIKV O
- O
induced O
persistent O
arthritis O
is O
not O
mediated O
primarily O
by O
adaptive O
immune O
responses O
. O

Many O
viruses O
induce O
type O
I O
interferon O
responses O
by O
activating O
cytoplasmic O
RNA O
sensors O
, O
including O
the O
RIG B
- I
I I
- I
like I
receptors I
( I
RLRs I
) I
. O

Recent O
studies O
have O
demonstrated O
that O
MAVS O
, O
the O
adaptor O
central O
to O
RLR O
signaling O
, O
is O
required O
to O
trigger O
innate O
immune O
defenses O
and O
program O
adaptive O
immune O
responses O
, O
which O
together O
restrict O
West B
Nile I
virus I
( I
WNV I
) I
infection O
in O
vivo O
. O

MDA5 O
( O
- O
/ O
- O
) O
mice O
exhibited O
enhanced O
susceptibility O
, O
as O
characterized O
by O
reduced O
survival O
and O
elevated O
viral O
burden O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
at O
late O
times O
after O
infection O
, O
even O
though O
small O
effects O
on O
systemic O
type O
I O
interferon O
response O
or O
viral O
replication O
were O
observed O
in O
peripheral O
tissues O
. O

Rather O
, O
subtle O
defects O
were O
observed O
in O
CNS O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
MDA5 O
( O
- O
/ O
- O
) O
mice O
. O

Adoptive O
transfer O
into O
recipient O
MDA5 O
( O
- O
/ O
- O
) O
mice O
established O
that O
a O
non O
- O
cell O
- O
autonomous O
deficiency O
of O
MDA5 O
was O
associated O
with O
functional O
defects O
in O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
resulted O
in O
a O
failure O
to O
clear O
WNV O
efficiently O
from O
CNS O
tissues O
. O

Our O
studies O
suggest O
that O
MDA5 O
in O
the O
immune O
priming O
environment O
shapes O
optimal O
CD8 O
( O
+ O
) O
T O
cell O
activation O
and O
subsequent O
clearance O
of O
WNV O
from O
the O
CNS O
. O

In O
this O
study O
, O
a O
fraction O
of O
modified O
lysosomes O
carrying O
functionally O
intact O
replicase O
complexes O
was O
obtained O
by O
feeding O
Semliki B
Forest I
virus I
( I
SFV I
) I
- O
infected O
HeLa O
cells O
with O
dextran O
- O
covered O
magnetic O
nanoparticles O
and O
later O
magnetically O
isolating O
the O
nanoparticle O
- O
containing O
lysosomes O
. O

Silencing O
of O
hnRNPM O
and O
hnRNP O
C O
expression O
enhanced O
the O
replication O
of O
SFV O
, O
chikungunya B
virus I
( I
CHIKV I
) I
, O
and O
Sindbis B
virus I
( I
SINV I
) I
. O

Alphavirus O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
has O
pivotal O
roles O
in O
viral O
RNA O
replication O
, O
host O
cell O
shutoff O
, O
and O
inhibition O
of O
antiviral O
responses O
. O

Results O
show O
that O
( O
i O
) O
nsP2 O
mutation O
P718S O
only O
in O
combination O
with O
KR649AA O
or O
adaptive O
mutation O
D711G O
allowed O
noncytopathic O
replicon O
RNA O
replication O
, O
( O
ii O
) O
prohibiting O
nsP2 O
nuclear O
localization O
abrogates O
inhibition O
of O
antiviral O
interferon O
- O
induced O
JAK O
- O
STAT O
signaling O
, O
and O
( O
iii O
) O
nsP2 O
independently O
affects O
RNA O
replication O
, O
cytopathicity O
, O
and O
JAK O
- O
STAT O
signaling O
. O

Specifically O
, O
a O
frameshift O
event O
is O
suggested O
to O
occur O
during O
translation O
of O
the O
6K O
gene O
, O
yielding O
production O
of O
a O
novel O
protein O
, O
termed B
transframe I
( I
TF I
) I
, O
comprised O
of O
a O
C O
- O
terminal O
extension O
of O
the O
6K O
protein O
in O
the O
- O
1 O
open B
reading I
frame I
( I
ORF I
) I
. O

Alphaviruses O
are O
small O
enveloped O
RNA O
viruses O
that O
include O
important O
emerging O
human O
pathogens O
, O
such O
as O
chikungunya B
virus I
( I
CHIKV I
) I
. O

The O
E1 O
fusion O
protein O
inserts O
into O
the O
target O
membrane O
, O
trimerizes O
, O
and O
refolds O
to O
a O
hairpin O
- O
like O
conformation O
in O
which O
the O
combination O
of O
E1 O
domain B
III I
( I
DIII I
) I
and O
the O
stem O
region O
( O
DIII O
- O
stem O
) O
pack O
against O
a O
core O
trimer O
composed O
of O
E1 O
domains O
I O
and O
II O
( O
DI O
/ O
II O
) O
. O

Addition O
of O
exogenous O
DIII O
proteins O
from O
Semliki B
Forest I
virus I
( I
SFV I
) I
has O
been O
shown O
to O
inhibit O
E1 O
hairpin O
formation O
and O
SFV O
fusion O
and O
infection O
. O

We O
developed O
a O
fluorescence O
anisotropy O
- O
based O
assay O
for O
the O
binding O
of O
SFV O
DIII O
- O
stem O
to O
the O
core O
trimer O
and O
used O
it O
to O
demonstrate O
the O
relatively O
high O
affinity O
of O
this O
interaction O
( O
K O
- O
d O
[ O
dissociation O
constant O
] O
, O
similar O
to O
85 O
nM O
) O
and O
the O
importance O
of O
the O
stem O
region O
. O

A O
vaccine O
against O
chikungunya B
virus I
( I
CHIKV I
) I
, O
a O
reemerging O
pathogenic O
arbovirus O
, O
has O
been O
made O
by O
attenuating O
wild B
- I
type I
( I
WT I
) I
virus O
via O
truncation O
of O
the O
transmembrane B
domain I
( I
TMD I
) I
of O
E2 O
and O
selecting O
for O
host B
range I
( I
HR I
) I
mutants O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
borne O
alphavirus O
responsible O
for O
recent O
epidemic O
outbreaks O
of O
debilitating O
disease O
in O
humans O
. O

Alphaviruses O
are O
known O
to O
interact O
with O
members O
of O
the O
C O
- O
type O
lectin O
receptor O
family O
of O
pattern O
recognition O
proteins O
, O
and O
given O
that O
the O
dendritic B
cell I
immunoreceptor I
( I
DCIR I
) I
is O
known O
to O
act O
as O
a O
negative O
regulator O
of O
the O
host O
inflammatory O
response O
and O
has O
previously O
been O
associated O
with O
rheumatoid O
arthritis O
, O
we O
evaluated O
DCIR O
' O
s O
role O
in O
response O
to O
CHIKV O
infection O
. O

In O
vitro O
, O
bone O
marrow O
- O
derived O
dendritic O
cells O
from O
DCIR O
- O
deficient O
( O
DCIR O
- O
/ O
- O
) O
mice O
exhibited O
altered O
cytokine O
expression O
following O
exposure O
to O
CHIKV O
. O

The O
alphavirus O
chikungunya B
virus I
( I
CHIKV I
) I
has O
caused O
multiple O
recent O
outbreaks O
of O
chikungunya O
fever O
. O

We O
report O
here O
on O
the O
development O
of O
a O
potent O
experimental O
vaccine O
for O
CHIKV O
based O
on O
a O
chimeric O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
expressing O
the O
entire O
CHIKV O
envelope O
polyprotein O
( O
E3 O
- O
E2 O
- O
6K O
- O
E1 O
) O
in O
place O
of O
the O
VSV O
glycoprotein B
( I
G I
) I
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
alphavirus O
which O
causes O
chronic O
and O
incapacitating O
arthralgia O
in O
humans O
. O

Data O
also O
illustrated O
the O
effect O
of O
a O
single O
K O
( O
252 O
) O
Q O
amino O
acid O
change O
at O
the O
E2 O
glycoprotein O
that O
was O
able O
to O
influence O
antibody O
binding O
and O
interaction O
between O
the O
antibodies O
and O
epitope O
because O
of O
the O
changes O
of O
epitope O
- O
antibody O
binding O
capacity O
. O

Arthralgia O
- O
associated O
alphaviruses O
, O
including O
chikungunya B
virus I
( I
CHIKV I
) I
and O
Ross B
River I
virus I
( I
RRV I
) I
, O
pose O
significant O
public O
health O
threats O
because O
of O
their O
ability O
to O
cause O
explosive O
outbreaks O
of O
debilitating O
arthralgia O
and O
myalgia O
in O
human O
populations O
. O

Although O
the O
host O
inflammatory O
response O
is O
known O
to O
contribute O
to O
the O
pathogenesis O
of O
alphavirus O
- O
induced O
arthritis O
and O
myositis O
, O
the O
role O
that O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
, O
which O
are O
major O
regulators O
of O
host O
antiviral O
and O
inflammatory O
responses O
, O
play O
in O
the O
pathogenesis O
of O
alphavirus O
- O
induced O
arthritis O
and O
myositis O
has O
not O
been O
extensively O
studied O
. O

Using O
a O
mouse O
model O
of O
RRV O
- O
induced O
myositis O
/ O
arthritis O
, O
we O
found O
that O
myeloid B
differentiation I
primary I
response I
gene I
88 I
( I
Myd88 I
) I
- O
dependent O
TLR7 O
signaling O
is O
involved O
in O
protection O
from O
severe O
RRV O
- O
associated O
disease O
. O

Infections O
of O
Myd88 O
- O
and O
TLR7 O
- O
deficient O
mouse O
strains O
with O
RRV O
revealed O
that O
both O
Myd88 O
and O
TLR7 O
significantly O
contributed O
to O
protection O
from O
RRV O
- O
induced O
mortality O
, O
and O
both O
mouse O
strains O
exhibited O
more O
severe O
tissue O
damage O
than O
wild B
- I
type I
( I
WT I
) I
mice O
following O
RRV O
infection O
. O

Chikungunya O
virus O
nonstructural O
protein O
nsP3 O
has O
an O
essential O
but O
unknown O
role O
in O
alphavirus O
replication O
and O
interacts O
with O
Ras O
- O
GAP O
SH3 O
domain O
- O
binding O
protein O
( O
G3BP O
) O
. O

chikungunya B
virus I
( I
CHIKV I
) I
infections O
can O
produce O
severe O
disease O
and O
mortality O
. O

Here O
we O
show O
that O
CHIKV O
infection O
of O
adult O
mice O
deficient O
in O
interferon O
response O
factors O
3 O
and O
7 O
( O
IRF3 O
/ O
7 O
( O
- O
/ O
- O
) O
) O
is O
lethal O
. O

Mortality O
was O
associated O
with O
undetectable O
levels O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
serum O
, O
similar O
to O
50 O
- O
and O
similar O
to O
10 O
- O
fold O
increases O
in O
levels O
of O
IFN O
- O
gamma O
and O
Tumor B
necrosis I
factor I
( I
TNF I
) I
, O
respectively O
, O
increased O
virus O
replication O
, O
edema O
, O
vasculitis O
, O
hemorrhage O
, O
fever O
followed O
by O
hypothermia O
, O
oliguria O
, O
thrombocytopenia O
, O
and O
raised O
hematocrits O
. O

In O
situ O
hybridization O
suggested O
CHIKV O
infection O
of O
endothelium O
, O
fibroblasts O
, O
skeletal O
muscle O
, O
mononuclear O
cells O
, O
chondrocytes O
, O
and O
keratinocytes O
in O
IRF3 O
/ O
7 O
( O
- O
/ O
- O
) O
mice O
; O
all O
but O
the O
latter O
two O
stained O
positive O
in O
wild O
- O
type O
mice O
. O

Vaccination O
protected O
IRF3 O
/ O
7 O
( O
- O
/ O
- O
) O
mice O
, O
suggesting O
that O
defective O
antibody O
responses O
were O
not O
responsible O
for O
mortality O
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
can O
be O
generated O
from O
chikungunya B
virus I
( I
CHIKV I
) I
, O
but O
different O
strains O
yield O
variable O
quantities O
of O
particles O
. O

This O
site O
is O
located O
within O
the O
acid B
- I
sensitive I
region I
( I
ASR I
) I
known O
to O
initiate O
a O
major O
conformational O
change O
in O
E1 O
/ O
E2 O
. O

This O
function O
of O
nsP2 O
depends O
on O
the O
integrity O
of O
the O
helicase O
and O
S B
- I
adenosylmethionine I
( I
SAM I
) I
- O
dependent O
methyltransferase O
- O
like O
domains O
, O
and O
point O
mutations O
in O
either O
of O
these O
domains O
abolish O
Rpb1 O
degradation O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
the O
mosquito O
- O
borne O
alphavirus O
that O
is O
the O
etiologic O
agent O
of O
massive O
outbreaks O
of O
arthralgic O
febrile O
illness O
that O
recently O
affected O
millions O
of O
people O
in O
Africa O
and O
Asia O
. O

To O
identify O
the O
determinants O
of O
attenuation O
, O
we O
therefore O
tested O
the O
five O
nonsynonymous O
mutations O
by O
cloning O
them O
individually O
or O
in O
different O
combinations O
into O
infectious O
clones O
derived O
from O
two O
wild B
- I
type I
( I
WT I
) I
CHIICV O
strains O
, O
La O
Reunion O
and O
AF15561 O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
transmitted O
alphavirus O
that O
has O
been O
responsible O
for O
an O
epidemic O
outbreak O
of O
unprecedented O
magnitude O
in O
recent O
years O
. O

Here O
we O
describe O
the O
extensive O
use O
of O
high B
- I
throughput I
yeast I
two I
- I
hybrid I
( I
HT I
- I
Y2H I
) I
assays O
to O
characterize O
interactions O
between O
CHIKV O
and O
human O
proteins O
. O

A O
total O
of O
22 O
high O
- O
confidence O
interactions O
, O
which O
essentially O
involved O
the O
viral O
nonstructural O
protein O
nsP2 O
, O
were O
identified O
and O
further O
validated O
in O
protein O
complementation O
assay O
( O
PCA O
) O
. O

Collected O
data O
showed O
that O
heterogeneous O
nuclear O
ribonucleoprotein O
K O
( O
hnRNP O
- O
K O
) O
and O
ubiquilin O
4 O
( O
UBQLN4 O
) O
participate O
in O
CHIKV O
replication O
in O
vitro O
. O

In O
addition O
, O
we O
showed O
that O
CHIKV O
nsP2 O
induces O
a O
cellular O
shutoff O
, O
as O
previously O
reported O
for O
other O
Old O
World O
alphaviruses O
, O
and O
determined O
that O
among O
binding O
partners O
identified O
by O
yeast O
two O
- O
hybrid O
methods O
, O
the O
tetratricopeptide O
repeat O
protein O
7B O
( O
TTC7B O
) O
plays O
a O
significant O
role O
in O
this O
activity O
. O

Alphaviruses O
such O
as O
Semliki B
Forest I
virus I
( I
SFV I
) I
are O
enveloped O
viruses O
that O
infect O
cells O
through O
a O
low O
- O
pH O
- O
triggered O
membrane O
fusion O
reaction O
mediated O
by O
the O
transmembrane O
fusion O
protein O
E1 O
. O

In O
this O
postfusion O
conformation O
, O
the O
immunoglobulin O
- O
like O
domain B
III I
( I
DIII I
) I
and O
the O
stem O
region O
pack O
against O
the O
central O
core O
of O
the O
trimer O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
important O
pathogen O
causing O
outbreaks O
of O
highly O
debilitating O
and O
often O
chronic O
, O
arthralgic O
human O
disease O
. O

These O
chimeras O
demonstrate O
a O
highly O
attenuated O
phenotype O
in O
both O
immunocompetent O
and O
immunocompromised O
( O
A129 O
) O
mice O
. O

The O
alphavirus O
Semliki B
Forest I
virus I
( I
SFV I
) I
infects O
cells O
through O
a O
low O
- O
pH O
- O
dependent O
membrane O
fusion O
reaction O
mediated O
by O
the O
virus O
fusion O
protein O
E1 O
. O

A O
highly O
conserved O
histidine O
( O
H3 O
) O
on O
the O
E1 O
protein O
was O
previously O
shown O
to O
promote O
low O
- O
pH O
- O
dependent O
E1 O
refolding O
. O

An O
SFV O
mutant O
with O
an O
alanine O
substitution O
at O
this O
position O
( O
H3A O
) O
has O
a O
lower O
pH O
threshold O
and O
reduced O
efficiency O
of O
virus O
fusion O
and O
E1 O
trimer O
formation O
than O
wild O
- O
type O
SFV O
. O

These O
revertants O
implicated O
a O
network O
of O
interactions O
that O
connect O
the O
domain O
I O
- O
domain O
III O
( O
DI O
- O
DIII O
) O
linker O
region O
with O
the O
E1 O
core O
trimer O
, O
including O
H3 O
. O

Rheumatic O
disease O
was O
associated O
with O
a O
prolific O
infiltrate O
of O
monocytes O
, O
macrophages O
, O
and O
NK O
cells O
and O
the O
production O
of O
monocyte B
chemoattractant I
protein I
1 I
( I
MCP I
- I
1 I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

chikungunya B
virus I
( I
CHIKV I
) I
, O
a O
mosquito O
- O
borne O
alphavirus O
, O
has O
traditionally O
circulated O
in O
Africa O
and O
Asia O
, O
causing O
human O
febrile O
illness O
accompanied O
by O
severe O
, O
chronic O
joint O
pain O
. O

Macro O
domains O
( O
also O
called O
X O
domains O
) O
constitute O
a O
protein O
module O
family O
present O
in O
all O
kingdoms O
of O
life O
, O
including O
viruses O
of O
the O
Coronaviridae O
and O
Togaviridae O
families O
. O

Crystal O
structures O
of O
the O
macro O
domain O
from O
the O
Chikungunya O
virus O
( O
an O
Old O
World O
alphavirus O
) O
and O
the O
Venezuelan O
equine O
encephalitis O
virus O
( O
a O
New O
World O
alphavirus O
) O
were O
determined O
at O
resolutions O
of O
1 O
. O

Sequence O
- O
unspecific O
binding O
to O
long O
, O
negatively O
charged O
polymers O
such O
as O
poly O
( O
ADP O
- O
ribose O
) O
, O
DNA O
, O
and O
RNA O
is O
observed O
and O
attributed O
to O
positively O
charged O
patches O
outside O
of O
the O
active O
site O
pocket O
, O
as O
judged O
by O
mutagenesis O
and O
binding O
studies O
. O

Alphaviruses O
such O
as O
Ross B
River I
virus I
( I
RRV I
) I
and O
chikungunya O
virus O
are O
mosquito O
- O
transmitted O
viruses O
that O
cause O
explosive O
epidemics O
of O
debilitating O
arthritis O
and O
myositis O
affecting O
millions O
of O
humans O
worldwide O
. O

Previous O
studies O
using O
a O
mouse O
model O
of O
RRV O
- O
induced O
disease O
demonstrated O
that O
viral O
infection O
results O
in O
a O
severe O
inflammatory O
arthritis O
and O
myositis O
and O
that O
complement O
component O
3 O
( O
C3 O
) O
contributes O
to O
the O
destructive O
phase O
of O
the O
inflammatory O
disease O
but O
not O
the O
recruitment O
of O
cellular O
infiltrates O
to O
the O
sites O
of O
RRV O
- O
induced O
inflammation O
. O

Here O
, O
we O
demonstrate O
that O
mice O
deficient O
in O
complement B
receptor I
3 I
( I
CR3 I
) I
( O
CD11b O
( O
- O
/ O
- O
) O
) O
, O
a O
signaling O
receptor O
activated O
by O
multiple O
ligands O
including O
the O
C3 O
cleavage O
fragment O
iC3b O
, O
develop O
less O
- O
severe O
disease O
signs O
and O
decreased O
tissue O
destruction O
compared O
to O
RRV O
- O
infected O
wild O
- O
type O
mice O
. O

Arthritogenic O
alphaviruses O
, O
including O
Ross B
River I
virus I
( I
RRV I
) I
and O
chikungunya O
virus O
, O
are O
mosquito O
- O
borne O
viruses O
that O
cause O
significant O
human O
disease O
worldwide O
, O
including O
; O
explosive O
epidemics O
that O
can O
result O
in O
thousands O
to O
millions O
of O
infected O
individuals O
. O

Furthermore O
, O
mice O
deficient O
in O
C3 O
( O
C3 O
( O
- O
/ O
- O
) O
) O
, O
the O
central O
component O
of O
the O
complement O
system O
, O
developed O
much O
less O
severe O
disease O
signs O
than O
did O
wild O
- O
type O
mice O
. O

Complement O
- O
mediated O
chemotaxis O
is O
essential O
for O
many O
inflammatory O
arthritides O
; O
however O
, O
RRV O
- O
infected O
wild O
- O
type O
and O
C3 O
( O
- O
/ O
- O
) O
mice O
had O
similar O
numbers O
and O
composition O
of O
inflammatory O
infiltrates O
within O
hind O
limb O
skeletal O
muscle O
tissue O
. O

Despite O
similar O
inflammatory O
infiltrates O
, O
RRV O
- O
infected O
C3 O
( O
- O
/ O
- O
) O
mice O
exhibited O
far O
less O
severe O
destruction O
of O
skeletal O
muscle O
tissue O
. O

influenza B
A I
virus I
( I
IAV I
) I
nonstructural I
protein I
1 I
( I
NS1 I
) I
is O
a O
protein O
with O
multiple O
functions O
that O
are O
regulated O
by O
phosphorylation O
. O

Interestingly O
, O
S205 O
is O
one O
of O
six O
amino O
acid O
changes O
in O
NS1 O
of O
post O
- O
pandemic O
H1N1 O
viruses O
currently O
circulating O
in O
humans O
compared O
to O
the O
original O
swine O
- O
origin O
2009 O
pandemic O
( O
H1N1pdm09 O
) O
virus O
, O
suggesting O
a O
role O
in O
host O
adaptation O
. O

To O
identify O
NS1 O
functions O
regulated O
by O
S205 O
phosphorylation O
, O
we O
generated O
recombinant O
PR8 O
H1N1 O
NS1 O
mutants O
with O
S205G O
( O
nonphosphorylatable O
) O
or O
S205N O
( O
H1N1pdm09 O
signature O
) O
, O
as O
well O
as O
H1N1pdm09 O
viruses O
harboring O
the O
reverse O
mutation O
NS1 O
N205S O
or O
N205D O
( O
phosphomimetic O
) O
. O

Replication O
of O
PR8 O
NS1 O
mutants O
was O
attenuated O
relative O
to O
wild B
- I
type I
( I
WT I
) I
virus O
replication O
in O
a O
porcine O
cell O
line O
. O

Analysis O
of O
the O
respective O
kinase O
mediating O
S205 O
phosphorylation O
indicated O
an O
involvement O
of O
casein B
kinase I
2 I
( I
CK2 I
) I
. O

IMPORTANCE O
influenza B
A I
viruses I
( I
IAVs I
) I
still O
pose O
a O
major O
threat O
to O
human O
health O
worldwide O
. O

The O
extracellular O
domain O
of O
the O
M2 B
- I
ion I
channel I
( I
M2e I
) I
is O
an O
ideal O
antigenic O
target O
for O
a O
universal O
therapeutic O
agent O
, O
as O
it O
is O
highly O
conserved O
across O
influenza O
A O
serotypes O
, O
has O
a O
low O
mutation O
rate O
, O
and O
is O
essential O
for O
viral O
entry O
and O
replication O
. O

Previous O
M2e B
- I
specific I
monoclonal I
antibodies I
( I
M2e I
- I
MAbs I
) I
show O
protective O
potential O
against O
influenza O
A O
; O
however O
, O
they O
are O
either O
strain O
specific O
or O
have O
limited O
efficacy O
. O

The O
extracellular O
domain O
of O
the O
M2 B
- I
ion I
channel I
( I
M2e I
) I
has O
huge O
potential O
as O
a O
target O
for O
a O
vaccine O
or O
treatment O
against O
influenza O
A O
. O

Swine B
influenza I
A I
virus I
( I
swIAV I
) I
infection O
causes O
substantial O
economic O
loss O
and O
disease O
burden O
in O
humans O
and O
animals O
. O

The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
influenza O
A O
virus O
is O
now O
endemic O
in O
both O
populations O
. O

Pigs O
were O
immunized O
with O
either O
adjuvanted O
, O
whole B
inactivated I
virus I
( I
WIV I
) I
vaccines O
or O
virus O
- O
vectored O
( O
ChAdOx1 O
and O
MVA O
) O
vaccines O
expressing O
either O
the O
homologous O
or O
heterologous O
influenza O
A O
virus O
Hemagglutinin B
( I
HA I
) I
glycoprotein O
, O
as O
well O
as O
an O
influenza O
virus O
pseudotype O
( O
S O
- O
FLU O
) O
vaccine O
expressing O
heterologous O
HA O
. O

This O
is O
the O
case O
for O
human O
- O
origin O
influenza O
A O
( O
H1N1 O
) O
pandemic O
2009 O
( O
pdm09 O
) O
viruses O
detected O
in O
pigs O
following O
numerous O
reverse O
zoonosis O
events O
since O
the O
2009 O
pandemic O
. O

We O
report O
the O
identification O
of O
two O
human O
infections O
with O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
originating O
from O
swine O
hosts O
and O
classify O
them O
as O
swine O
- O
origin O
variant O
influenza O
viruses O
based O
on O
phylogenetic O
analysis O
and O
sequence O
comparison O
methods O
. O

Phylogenetic O
analyses O
of O
viral O
genomes O
from O
two O
cases O
revealed O
these O
viruses O
were O
reassortants O
containing O
A O
( O
H1N1 O
) O
pdm09 O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
with O
genetic O
combinations O
derived O
from O
the O
triple O
reassortant O
internal O
gene O
cassette O
. O

The O
swine O
- O
origin O
A O
( O
H1N1 O
) O
variant O
cases O
were O
resolved O
by O
full O
genome O
sequence O
comparison O
of O
the O
variant O
viruses O
to O
swine O
influenza O
genomes O
. O

We O
have O
developed O
a O
pipeline O
that O
performs O
maximum O
likelihood O
analyses O
, O
a O
k O
- O
mer O
- O
based O
set O
difference O
algorithm O
, O
and O
random O
forest O
algorithms O
to O
identify O
swine O
- O
associated O
sequences O
in O
the O
hemagglutinin O
gene O
to O
differentiate O
between O
human O
- O
origin O
and O
swine O
- O
origin O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
. O

In O
this O
work O
, O
we O
have O
identified O
the O
first O
case O
of O
a O
swine O
- O
origin O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
virus O
resulting O
in O
a O
human O
infection O
. O

We O
show O
that O
unique O
genetic O
signatures O
can O
differentiate O
circulating O
swine O
- O
associated O
strains O
from O
circulating O
human O
- O
associated O
strains O
of O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
, O
and O
these O
signatures O
can O
be O
used O
to O
enhance O
surveillance O
of O
swine O
- O
origin O
influenza O
. O

In O
these O
studies O
, O
we O
isolated O
primary O
swine O
nasal O
and O
tracheal O
respiratory O
epithelial O
cells O
and O
immortalized O
swine B
nasal I
epithelial I
cells I
( I
siNEC I
) I
and O
tracheal O
epithelial O
cells O
( O
siTEC O
) O
that O
retained O
the O
abilities O
to O
form O
tight O
junctions O
and O
cilia O
and O
to O
differentiate O
at O
the O
air O
- O
liquid O
interface O
like O
primary O
cells O
. O

Critically O
, O
both O
human O
and O
swine O
influenza O
viruses O
replicated O
in O
the O
immortalized O
cells O
, O
which O
generally O
yielded O
higher O
- O
titer O
viral O
isolates O
from O
human O
and O
swine O
nasal O
swabs O
, O
supported O
the O
replication O
of O
isolates O
that O
failed O
to O
grow O
in O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
, O
and O
resulted O
in O
fewer O
dominating O
mutations O
during O
viral O
passaging O
than O
MDCK O
cells O
. O

Every O
summer O
in O
the O
United O
States O
, O
youths O
attending O
agricultural O
fairs O
are O
exposed O
to O
genetically O
diverse O
influenza B
A I
viruses I
( I
IAVs I
) I
circulating O
in O
exhibition O
swine O
, O
resulting O
in O
over O
450 O
lab O
- O
confirmed O
zoonotic O
infections O
since O
2010 O
. O

states O
in O
2018 O
( O
n O
= O
212 O
) O
, O
we O
characterized O
how O
a O
heterogeneous O
circuit O
of O
swine O
shows O
, O
comprising O
fairs O
with O
different O
sizes O
and O
geographic O
coverage O
, O
facilitates O
IAV O
transmission O
among O
exhibition O
swine O
and O
into O
humans O
. O

Specifically O
, O
we O
identified O
the O
role O
of O
an O
early O
season O
national O
show O
in O
the O
propagation O
and O
spatial O
dissemination O
of O
a O
specific O
virus O
( O
H18 O
- O
2 O
) O
that O
becomes O
dominant O
among O
exhibition O
swine O
and O
is O
associated O
with O
the O
majority O
of O
zoonotic O
infections O
in O
2018 O
. O

IMPORTANCE O
The O
varying O
influenza B
A I
virus I
( I
IAV I
) I
exposure O
and O
infection O
status O
of O
individual O
swine O
facilitates O
introduction O
, O
transmission O
, O
and O
dissemination O
of O
diverse O
IAVs O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
infection O
eliminates O
production O
of O
type B
I I
interferons I
( I
IFNs I
) I
in O
host O
cells O
, O
which O
triggers O
an O
antiviral O
immune O
response O
through O
the O
induction O
of O
downstream O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
thus O
escaping O
the O
fate O
of O
host O
- O
mediated O
clearance O
. O

The O
IFN O
- O
induced O
trans O
membrane O
3 O
( O
IFITM3 O
) O
has O
recently O
been O
identified O
as O
an O
ISG O
and O
plays O
a O
pivotal O
role O
against O
enveloped O
RNA O
viruses O
by O
restricting O
cell O
entry O
. O

IMPORTANCE O
Porcine B
reproductive I
and I
respiratory I
syndrome I
( I
PRRS I
) I
, O
which O
is O
caused O
by O
PRRS B
virus I
( I
PRRSV I
) I
, O
is O
of O
great O
economic O
significance O
to O
the O
swine O
industry O
. O

As O
an O
interferon B
( I
IFN I
) I
- O
stimulated O
gene O
, O
the O
role O
of O
IFN B
- I
induced I
transmembrane I
3 I
( I
IFITM3 I
) I
in O
PRRSV O
infection O
has O
not O
been O
reported O
as O
of O
yet O
. O

For O
enveloped O
viruses O
, O
such O
as O
the O
influenza B
A I
virus I
( I
IAV I
) I
, O
large O
N O
- O
linked O
glycans O
can O
also O
be O
added O
to O
prevent O
access O
to O
epitopes O
on O
the O
surface O
antigens O
hemagglutinin O
( O
HA O
or O
H O
) O
and O
neuraminidase O
( O
NA O
or O
N O
) O
. O

Sequence O
analyses O
of O
the O
influenza B
A I
virus I
( I
IAV I
) I
surface O
antigen O
neuraminidase O
( O
NA O
or O
N O
) O
showed O
that O
the O
conservation O
of O
N O
- O
linked O
glycosylation O
sites O
on O
the O
NA O
enzymatic O
head O
domain O
differs O
by O
IAV O
subtype O
( O
H1N1 O
versus O
H3N2 O
) O
and O
species O
of O
origin O
, O
with O
human O
- O
derived O
IAVs O
possessing O
the O
most O
variability O
. O

Since O
its O
detection O
in O
swine O
, O
influenza B
D I
virus I
( I
IDV I
) I
has O
been O
shown O
to O
be O
present O
in O
multiple O
animal O
hosts O
, O
and O
bovines O
have O
been O
identified O
as O
its O
natural O
reservoir O
. O

IMPORTANCE O
Influenza B
D I
viruses I
( I
IDVs I
) I
are O
panzootic O
in O
multiple O
animal O
hosts O
, O
but O
the O
underlying O
mechanism O
is O
unclear O
. O

influenza B
A I
viruses I
( I
IAV I
) I
sporadically O
transmit O
from O
swine O
to O
humans O
, O
typically O
associated O
with O
agricultural O
fairs O
in O
the O
United O
States O
. O

commercial O
swine O
population O
, O
subsequently O
spilling O
over O
into O
exhibition O
swine O
, O
and O
caused O
a O
majority O
of O
H3N2 B
variant I
( I
H3N2v I
) I
cases O
in O
humans O
in O
2016 O
and O
2017 O
. O

1 O
H3N2 O
IAV O
( O
A O
/ O
swine O
/ O
Ohio O
/ O
A01354299 O
/ O
2017 O
[ O
sw O
/ O
OH O
/ O
2017 O
] O
) O
isolated O
from O
a O
pig O
in O
the O
agricultural O
fair O
outbreak O
to O
replicate O
in O
ferrets O
and O
transmit O
from O
swine O
to O
ferret O
. O

1 O
) O
influenza B
A I
virus I
( I
IAV I
) I
from O
swine O
has O
been O
frequently O
detected O
in O
commercial O
and O
exhibition O
swine O
in O
recent O
years O
and O
has O
been O
associated O
with O
H3N2 O
variant O
cases O
in O
humans O
from O
2016 O
and O
2017 O
. O

To O
assess O
the O
current O
status O
of O
influenza B
A I
viruses I
of I
swine I
( I
IAVs I
- I
S I
) I
throughout O
Japan O
and O
to O
investigate O
how O
these O
viruses O
persisted O
and O
evolve O
on O
pig O
farms O
, O
we O
genetically O
characterized O
IAVs O
- O
S O
isolated O
during O
2015 O
to O
2019 O
. O

During O
2015 O
to O
2019 O
, O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
repeatedly O
became O
introduced O
into O
farms O
and O
reassorted O
with O
endemic O
H1N2 O
and O
H3N2 O
IAVs O
- O
S O
. O

At O
farms O
where O
IAVs O
- O
S O
were O
frequently O
isolated O
for O
at O
least O
3 O
years O
, O
multiple O
introductions O
of O
IAVs O
- O
S O
with O
phylogenetically O
distinct O
Hemagglutinin B
( I
HA I
) I
genes O
occurred O
. O

In O
addition O
, O
at O
one O
farm O
, O
IAVs O
- O
S O
derived O
from O
a O
single O
introduction O
persisted O
for O
at O
least O
3 O
years O
and O
carried O
no O
mutations O
at O
the O
deduced O
antigenic O
sites O
of O
the O
hemagglutinin O
protein O
, O
except O
for O
one O
at O
the O
antigenic O
site O
( O
Sa O
) O
. O

IMPORTANCE O
Understanding O
the O
current O
status O
of O
influenza B
A I
viruses I
of I
swine I
( I
IAVs I
- I
S I
) I
and O
their O
evolution O
at O
the O
farm O
level O
is O
important O
for O
controlling O
these O
pathogens O
. O

A O
( O
H1N1 O
) O
pdm09 O
- O
derived O
H1 O
genes O
became O
introduced O
repeatedly O
and O
reassorted O
with O
endemic O
IAVs O
- O
S O
, O
resulting O
in O
various O
combinations O
of O
surface O
and O
internal O
genes O
among O
pig O
populations O
in O
Japan O
. O

Porcine B
reproductive I
and I
respiratory I
syndrome I
( I
PRRS I
) I
is O
a O
serious O
viral O
disease O
affecting O
the O
global O
swine O
industry O
. O

Its O
causative O
agent O
, O
PRRS B
virus I
( I
PRRSV I
) I
, O
is O
an O
enveloped O
virus O
, O
and O
therefore O
membrane O
fusion O
between O
its O
envelope O
and O
host O
cell O
target O
membrane O
is O
critical O
for O
viral O
infection O
. O

In O
the O
present O
study O
, O
we O
performed O
confocal O
microscopy O
in O
combination O
with O
a O
constitutively B
active I
( I
CA I
) I
or O
dominant B
negative I
( I
DN I
) I
mutant O
, O
specific O
inhibitors O
, O
and O
small B
interfering I
RNAs I
( I
siRNAs I
) I
, O
as O
well O
as O
multiple O
other O
approaches O
, O
to O
explore O
PRRSV O
membrane O
fusion O
. O

Moreover O
, O
PRRSV O
glycoprotein B
5 I
( I
GP5 I
) I
is O
identified O
as O
being O
cleaved O
by O
cathepsin O
E O
during O
this O
process O
. O

influenza B
D I
virus I
( I
IDV I
) I
was O
initially O
isolated O
in O
the O
United O
States O
in O
2011 O
. O

IDV O
is O
distributed O
worldwide O
and O
is O
one O
of O
the O
causative O
agents O
of O
the O
bovine B
respiratory I
disease I
complex I
( I
BRDC I
) I
, O
which O
causes O
high O
morbidity O
and O
mortality O
in O
feedlot O
cattle O
. O

We O
first O
verified O
that O
the O
3 O
' O
- O
terminal O
nucleotide O
of O
each O
7 O
- O
segmented O
genomic O
RNA O
contained O
uracil O
( O
U O
) O
, O
contrary O
to O
previous O
reports O
, O
and O
we O
were O
then O
able O
to O
successfully O
generate O
recombinant O
IDV O
by O
cotransfecting O
7 O
plasmids O
containing O
these O
genomic O
RNAs O
along O
with O
4 O
plasmids O
expressing O
polymerase O
proteins O
and O
nucleoprotein O
into O
human B
rectal I
tumor I
18G I
( I
HRT I
- I
18G I
) I
cells O
. O

IMPORTANCE O
The O
bovine B
respiratory I
disease I
complex I
( I
BRDC I
) I
causes O
high O
mortality O
and O
morbidity O
in O
cattle O
, O
causing O
economic O
losses O
worldwide O
. O

influenza B
D I
virus I
( I
IDV I
) I
is O
considered O
to O
be O
a O
causative O
agent O
of O
the O
BRDC O
. O

A O
novel O
genus O
within O
the O
Orthomyxoviridae O
family O
was O
identified O
in O
the O
United O
States O
and O
named O
influenza B
D I
virus I
( I
IDV I
) I
. O

Bovines O
have O
been O
proposed O
to O
be O
the O
primary O
host O
, O
and O
three O
main O
viral O
lineages O
( O
D O
/ O
OK O
- O
like O
, O
D O
/ O
660 O
- O
like O
, O
and O
D O
/ O
Japanlike O
) O
have O
been O
described O
. O

DBA O
/ O
2 O
mice O
were O
inoculated O
with O
10 O
( O
5 O
) O
50 B
% I
tissue I
culture I
infective I
dose I
( I
TCID50 I
) I
of O
D O
/ O
bovine O
/ O
France O
/ O
5920 O
/ O
2014 O
( O
D O
/ O
OK O
- O
like O
) O
. O

Viral O
replication O
was O
observed O
mainly O
in O
the O
upper O
respiratory O
tract O
( O
nasal O
turbinates O
) O
but O
also O
in O
the O
lower O
respiratory O
tract O
of O
infected O
mice O
, O
with O
a O
peak O
at O
4 O
days O
postinfection O
. O

Transcriptomic O
analyses O
demonstrated O
that O
IDV O
induced O
the O
activation O
of O
proinflammatory O
genes O
, O
such O
as O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
CCL2 O
. O

Inoculation O
of O
NF O
- O
kappa O
B O
- O
luciferase O
and O
Ifnar1 O
( O
- O
/ O
- O
) O
mice O
demonstrated O
that O
IDV O
induced O
mild O
inflammation O
and O
that O
a O
type O
I O
interferon O
response O
was O
not O
necessary O
in O
IDV O
clearance O
. O

Taken O
together O
, O
present O
data O
and O
comparisons O
with O
the O
calf O
model O
show O
that O
our O
mouse O
model O
allows O
for O
the O
study O
of O
IDV O
replication O
and O
fitness O
( O
before O
selected O
viruses O
may O
be O
inoculated O
on O
calves O
) O
and O
also O
of O
the O
immune O
response O
. O

IMPORTANCE O
influenza B
D I
virus I
( I
IDV I
) I
, O
a O
new O
genus O
of O
Orthomyxoviridae O
family O
, O
presents O
a O
large O
host O
range O
and O
a O
worldwide O
circulation O
. O

Hemagglutinin B
( I
HA I
) I
stability O
, O
or O
the O
pH O
at O
which O
HA O
is O
activated O
to O
cause O
membrane O
fusion O
, O
has O
been O
associated O
with O
the O
replication O
, O
pathogenicity O
, O
transmissibility O
, O
and O
interspecies O
adaptation O
of O
influenza O
A O
viruses O
. O

0 O
) O
, O
attenuates O
virus O
replication O
and O
pathogenicity O
in O
DBA O
/ O
2 O
mice O
compared O
to O
wildtype B
( I
WT I
) I
virus O
( O
activation O
pH O
, O
5 O
. O

7 O
cells O
when O
inoculated O
at O
a O
multiplicity B
of I
infection I
( I
MOI I
) I
of O
3 O
PFU O
/ O
cell O
. O

The O
destabilizing O
mutation O
also O
increased O
early O
infectivity O
and O
type B
I I
interferon I
( I
IFN I
) I
responses O
in O
mouse O
bone O
marrow O
- O
derived O
dendritic B
cells I
( I
DCs I
) I
. O

influenza B
D I
virus I
( I
IDV I
) I
of O
the O
Orthomyxoviridae O
family O
has O
a O
wide O
host O
range O
and O
a O
broad O
geographical O
distribution O
. O

To O
better O
study O
IDV O
at O
the O
molecular O
level O
, O
a O
reverse B
- I
genetics I
system I
( I
RGS I
) I
is O
urgently O
needed O
, O
but O
to O
date O
, O
no O
RGS O
had O
been O
described O
for O
IDV O
. O

In O
this O
study O
, O
we O
rescued O
the O
recombinant O
influenza O
D O
/ O
swine O
/ O
Oklahoma O
/ O
1314 O
/ O
2011 O
( O
D O
/ O
OK O
) O
virus O
by O
using O
a O
bidirectional O
seven O
- O
plasmidbased O
system O
and O
further O
characterized O
rescued O
viruses O
in O
terms O
of O
growth O
kinetics O
, O
replication O
stability O
, O
and O
receptor O
- O
binding O
capacity O
. O

In O
addition O
, O
we O
developed O
an O
IDV O
minigenome O
replication O
assay O
and O
identified O
the O
E697K O
mutation O
in O
PB1 O
and O
the O
L462F O
mutation O
in O
PB2 O
that O
directly O
affected O
the O
activity O
of O
the O
IDV O
ribonucleoprotein B
( I
RNP I
) I
complex O
, O
resulting O
in O
either O
attenuated O
or O
replication O
- O
incompetent O
viruses O
. O

Finally O
, O
by O
using O
the O
minigenome O
replication O
assay O
, O
we O
demonstrated O
that O
a O
single O
nucleotide O
polymorphism O
at O
position O
5 O
of O
the O
3 O
' O
conserved O
noncoding O
region O
in O
IDV O
and O
influenza B
C I
virus I
( I
ICV I
) I
resulted O
in O
the O
inefficient O
cross O
- O
recognition O
of O
the O
heterotypic O
promoter O
by O
the O
viral O
RNP O
complex O
. O

IMPORTANCE O
influenza B
D I
virus I
( I
IDV I
) I
is O
a O
new O
type O
of O
influenza O
virus O
that O
uses O
cattle O
as O
the O
primary O
reservoir O
and O
infects O
multiple O
agricultural O
animals O
. O

pandemic B
H1N1 I
( I
pH1N1 I
) I
influenza O
virus O
emerged O
from O
swine O
in O
2009 O
with O
an O
adequate O
capability O
to O
infect O
and O
transmit O
between O
people O
. O

Mutations O
in O
the O
Hemagglutinin B
( I
HA I
) I
stalk O
that O
increase O
pH O
stability O
have O
been O
associated O
with O
human O
adaptation O
and O
airborne O
transmission O
of O
pH1N1 O
virus O
. O

The O
recently O
discovered O
influenza B
D I
virus I
( I
IDV I
) I
of O
the O
Orthomyxoviridae O
family O
has O
been O
detected O
in O
swine O
and O
ruminants O
with O
a O
worldwide O
distribution O
. O

Results O
show O
that O
IDV O
replicates O
not O
only O
in O
the O
upper O
respiratory O
tract O
but O
also O
in O
the O
lower O
respiratory O
tract O
( O
LRT O
) O
, O
inducing O
moderate O
bronchopneumonia O
with O
restricted O
lesions O
of O
interstitial O
pneumonia O
. O

Finally O
, O
virological O
examination O
of O
three O
aerosol O
- O
sentinel O
animals O
, O
housed O
3 O
m O
apart O
from O
inoculated O
calves O
( O
and O
thus O
subject O
to O
infection O
by O
aerosol O
transmission O
) O
, O
and O
IDV O
detection O
in O
air O
samples O
collected O
in O
different O
areas O
showed O
that O
IDV O
can O
be O
airborne O
transmitted O
and O
infect O
naive O
contact O
calves O
on O
short O
distances O
. O

IMPORTANCE O
influenza B
D I
virus I
( I
IDV I
) I
, O
a O
new O
genus O
of O
the O
Orthomyxoviridae O
family O
, O
has O
a O
broad O
geographical O
distribution O
and O
can O
infect O
several O
animal O
species O
. O

We O
demonstrated O
that O
under O
experimental O
conditions O
( O
in O
a O
controlled O
environment O
and O
in O
the O
absence O
of O
coinfecting O
pathogens O
) O
, O
IDV O
is O
able O
to O
cause O
mild O
to O
moderate O
disease O
and O
targets O
both O
the O
upper O
and O
lower O
respiratory O
tracts O
. O

The O
Hemagglutinin B
( I
HA I
) I
, O
a O
glycoprotein O
on O
the O
surface O
of O
influenza B
A I
virus I
( I
IAV I
) I
, O
initiates O
the O
virus O
life O
cycle O
by O
binding O
to O
terminal O
sialic B
acid I
( I
SA I
) I
residues O
on O
host O
cells O
. O

All O
identified O
residues O
are O
located O
adjacent O
to O
the O
HA O
Receptor B
binding I
site I
( I
RBS I
) I
, O
suggesting O
that O
substitutions O
associated O
with O
antigenic O
drift O
may O
also O
influence O
receptor O
binding O
. O

On O
the O
Hemagglutinin B
( I
HA I
) I
of O
the O
H3N2 O
IAVs O
, O
the O
amino O
acid O
substitution O
N O
145 O
K O
causes O
significant O
antigenic O
changes O
. O

Pseudorabies B
virus I
( I
PRV I
) I
is O
an O
alphaherpesvirus O
that O
infects O
the O
peripheral B
nervous I
system I
( I
PNS I
) I
. O

Using O
a O
footpad O
inoculation O
model O
, O
we O
established O
that O
mice O
inoculated O
with O
PRV O
- O
Becker O
( O
virulent O
strain O
) O
develop O
a O
severe O
pruritus O
in O
the O
foot O
and O
become O
moribund O
at O
82 O
h B
postinoculation I
( I
hpi I
) I
. O

We O
found O
necrosis O
and O
inflammation O
with O
a O
massive O
neutrophil O
infiltration O
only O
in O
the O
footpad O
and O
dorsal B
root I
ganglia I
( I
DRGs I
) I
by O
hematoxylin O
and O
eosin O
staining O
. O

Infected O
mice O
had O
elevated O
plasma O
levels O
of O
proinflammatory O
cytokines O
( O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
] O
and O
granulocyte O
colony O
- O
stimulating O
factor O
[ O
G O
- O
CSF O
] O
) O
and O
chemokines O
( O
Gro O
- O
1 O
and O
monocyte O
chemoattractant O
protein O
1 O
) O
. O

Moreover O
, O
mice O
inoculated O
with O
PRV O
- O
Bartha O
( O
attenuated O
, O
live O
vaccine O
strain O
) O
did O
not O
develop O
pruritus O
at O
82 O
hpi O
. O

IMPORTANCE O
Pseudorabies B
virus I
( I
PRV I
) I
is O
an O
alphaherpesvirus O
related O
to O
human O
pathogens O
such O
as O
herpes O
simplex O
virus O
1 O
and O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
. O

Influenza O
A O
viruses O
in O
swine O
( O
IAV O
- O
S O
) O
circulating O
in O
the O
United O
States O
of O
America O
are O
phylogenetically O
and O
antigenically O
distinct O
. O

A O
human O
H3 O
Hemagglutinin B
( I
HA I
) I
was O
introduced O
into O
the O
IAV O
- O
S O
gene O
pool O
in O
the O
late O
1990s O
, O
sustained O
continued O
circulation O
, O
and O
evolved O
into O
five O
monophyletic O
genetic O
clades O
, O
H3 O
clades O
IV O
- O
A O
to O
- O
E O
, O
after O
2009 O
. O

Across O
these O
phylogenetic O
clades O
, O
distinct O
antigenic O
clusters O
were O
identified O
, O
with O
three O
clusters O
( O
cyan O
, O
red O
, O
and O
green O
antigenic O
cluster O
) O
among O
the O
most O
frequently O
detected O
antigenic O
phenotypes O
( O
Abente O
EJ O
, O
Santos O
J O
, O
Lewis O
NS O
, O
Gauger O
PC O
, O
Stratton O
J O
, O
et O
al O
. O

Using O
antigenically O
representative O
H3N2 O
viruses O
, O
we O
compared O
whole B
inactivated I
virus I
( I
WIV I
) I
and O
live B
- I
attenuated I
influenza I
virus I
( I
LAIV I
) I
vaccines O
for O
protection O
against O
challenge O
with O
antigenically O
distinct O
H3N2 O
viruses O
in O
pigs O
. O

Recently O
isolated O
from O
humans O
( O
termed O
variants O
) O
, O
swine O
viruses O
were O
shown O
to O
display O
great O
genetic O
and O
antigenic O
diversity O
, O
hence O
posing O
considerable O
public O
health O
risk O
. O

However O
, O
with O
respect O
to O
Hemagglutinin B
( I
HA I
) I
activation O
pH O
, O
the O
variant O
viruses O
had O
fusion O
pH O
thresholds O
closer O
to O
that O
of O
most O
classical O
swine O
and O
triple O
- O
reassortant O
H1 O
isolates O
rather O
than O
viruses O
that O
had O
adapted O
to O
humans O
. O

In O
2009 O
, O
a O
pandemic O
H1N1 O
influenza B
A I
virus I
( I
IAV I
) I
( O
pH1N1 O
) O
emerged O
in O
the O
human O
population O
from O
swine O
causing O
a O
pandemic O
. O

To O
analyze O
the O
evolution O
of O
pH1N1 O
in O
humans O
, O
we O
sequenced O
viral O
genes O
encoding O
proteins O
inhibiting O
general O
gene O
expression O
( O
nonstructural O
protein O
1 O
[ O
NS1 O
] O
and O
PA O
- O
X O
) O
from O
circulating O
seasonal O
viruses O
and O
compared O
them O
to O
the O
viruses O
isolated O
at O
the O
origin O
of O
the O
pandemic O
. O

Recent O
pH1N1 O
viruses O
contain O
amino O
acid O
changes O
in O
the O
NS1 O
protein O
( O
E55K O
, O
L90I O
, O
I123V O
, O
E125D O
, O
K131E O
, O
and O
N205S O
) O
, O
as O
previously O
described O
( O
A O
. O

00721 O
- O
17 O
) O
, O
and O
amino O
acid O
changes O
in O
the O
PA O
- O
X O
protein O
( O
V100I O
, O
N204S O
, O
R221Q O
, O
and O
L229S O
) O
. O

In O
addition O
, O
currently O
circulating O
pH1N1 O
viruses O
have O
acquired O
amino O
acid O
changes O
in O
the O
PA O
protein O
( O
V100I O
, O
P224S O
, O
N321K O
, O
I330V O
, O
and O
R362K O
) O
. O

Currently O
circulating O
viruses O
have O
incorporated O
amino O
acid O
changes O
in O
two O
viral O
proteins O
( O
NS1 O
and O
PA O
- O
X O
) O
, O
affecting O
innate O
immune O
responses O
, O
and O
in O
the O
PA O
gene O
. O

While O
several O
swine O
- O
origin O
influenza O
A O
H3N2 B
variant I
( I
H3N2v I
) I
viruses O
isolated O
from O
humans O
prior O
to O
2011 O
have O
been O
previously O
characterized O
for O
their O
virulence O
and O
transmissibility O
in O
ferrets O
, O
the O
recent O
genetic O
and O
antigenic O
divergence O
of O
H3N2v O
viruses O
warrants O
an O
updated O
assessment O
of O
their O
pandemic O
potential O
. O

We O
found O
that O
all O
four O
H3N2v O
viruses O
possessed O
similar O
or O
enhanced O
replication O
capacities O
in O
a O
human O
bronchial O
epithelium O
cell O
line O
( O
Calu O
- O
3 O
) O
compared O
to O
a O
human O
seasonal O
influenza O
virus O
, O
suggestive O
of O
strong O
fitness O
in O
human O
respiratory O
tract O
cells O
. O

IMPORTANCE O
Swine O
- O
origin O
influenza O
viruses O
of O
the O
H3N2 O
subtype O
, O
with O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
derived O
from O
historic O
human O
seasonal O
influenza O
viruses O
, O
continue O
to O
cross O
species O
barriers O
and O
cause O
human O
infections O
, O
posing O
an O
indelible O
threat O
to O
public O
health O
. O

Wild O
ducks O
and O
gulls O
are O
the O
major O
reservoirs O
for O
avian B
influenza I
A I
viruses I
( I
AIVs I
) I
. O

For O
six O
complete O
study O
years O
( O
2010 O
to O
2016 O
) O
, O
we O
collected O
AIV O
samples O
from O
various O
duck O
and O
gull O
species O
that O
breed O
, O
migrate O
, O
and O
overwinter O
in O
Georgia O
. O

Low B
- I
pathogenic I
AIV I
( I
LPAIV I
) I
subtypes O
included O
H1N1 O
, O
H2N3 O
, O
H2N5 O
, O
H2N7 O
, O
H3N8 O
, O
H4N2 O
, O
H6N2 O
, O
H7N3 O
, O
H7N7 O
, O
H9N1 O
, O
H9N3 O
, O
H10N4 O
, O
H10N7 O
, O
H11N1 O
, O
H13N2 O
, O
H13N6 O
, O
H13N8 O
, O
and O
H16N3 O
, O
and O
two O
highly B
pathogenic I
AIVs I
( I
HPAIVs I
) I
belonging O
to O
clade O
23 O
. O

, O
gulls O
and O
ducks O
) O
are O
natural O
reservoirs O
of O
avian B
influenza I
viruses I
( I
AIVs I
) I
and O
have O
been O
shown O
to O
mediate O
the O
dispersal O
of O
AIVs O
at O
inter O
- O
continental O
scales O
during O
seasonal O
migration O
. O

Phylogenetic O
analysis O
with O
an O
expansive O
human O
and O
swine O
influenza O
virus O
data O
set O
comprising O
> O
40 O
, O
000 O
sequences O
sampled O
globally O
revealed O
evidence O
of O
the O
pervasive O
introduction O
and O
long O
- O
term O
establishment O
of O
gene O
segments O
derived O
from O
several O
human O
influenza O
viruses O
of O
past O
seasons O
, O
including O
the O
H1N1 O
/ O
1977 O
, O
H1N1 O
/ O
1995 O
, O
H3N2 O
/ O
1968 O
, O
and O
H3N2 O
/ O
2003 O
, O
and O
the O
H1N1 O
2009 O
pandemic O
( O
H1N1pdm09 O
) O
influenza O
A O
viruses O
, O
and O
a O
genotype O
that O
contained O
gene O
segments O
derived O
from O
the O
past O
three O
pandemics O
( O
1968 O
, O
reemerged O
1977 O
, O
and O
2009 O
) O
. O

Influenza O
A O
( O
H1 O
) O
viruses O
circulating O
in O
swine O
represent O
an O
emerging O
virus O
threat O
, O
as O
zoonotic O
infections O
occur O
sporadically O
following O
exposure O
to O
swine O
. O

A O
fatal O
infection O
caused O
by O
an O
H1N1 B
variant I
( I
H1N1v I
) I
virus O
was O
detected O
in O
a O
patient O
with O
reported O
exposure O
to O
swine O
and O
who O
presented O
with O
pneumonia O
, O
respiratory O
failure O
, O
and O
cardiac O
arrest O
. O

A O
substitution O
in O
the O
H1 O
hemagglutinin O
( O
G155E O
) O
was O
identified O
that O
likely O
impacted O
antigenicity O
, O
and O
reverse O
genetics O
was O
employed O
to O
understand O
the O
molecular O
mechanism O
of O
antibody O
escape O
. O

Reversion O
of O
the O
substitution O
to O
155G O
, O
in O
a O
reverse O
genetics O
A O
/ O
Ohio O
/ O
09 O
/ O
2015 O
virus O
, O
showed O
that O
this O
residue O
was O
central O
to O
the O
loss O
of O
hemagglutination O
inhibition O
by O
ferret O
antisera O
raised O
against O
a O
prototypical O
H1N1 O
pandemic O
2009 O
virus O
( O
A O
/ O
California O
/ O
07 O
/ O
2009 O
) O
, O
as O
well O
as O
gamma O
lineage O
classical O
swine O
H1N1 O
viruses O
, O
demonstrating O
the O
importance O
of O
this O
residue O
for O
antibody O
recognition O
of O
this O
H1 O
lineage O
. O

IMPORTANCE O
Human O
infections O
with O
classical O
swine O
influenza O
A O
( O
H1N1 O
) O
viruses O
that O
circulate O
in O
pigs O
continue O
to O
occur O
in O
the O
United O
States O
following O
exposure O
to O
swine O
. O

To O
understand O
the O
genetic O
and O
virologic O
characteristics O
of O
a O
virus O
( O
A O
/ O
Ohio O
/ O
09 O
/ O
2015 O
) O
associated O
with O
a O
fatal O
infection O
and O
a O
virus O
associated O
with O
a O
nonfatal O
infection O
( O
A O
/ O
Iowa O
/ O
39 O
/ O
2015 O
) O
, O
we O
performed O
genome O
sequence O
analysis O
, O
antigenic O
testing O
, O
and O
pathogenicity O
and O
transmission O
studies O
in O
a O
ferret O
model O
. O

Reverse O
genetics O
was O
employed O
to O
identify O
a O
single O
antigenic O
site O
substitution O
( O
HA O
G155E O
) O
responsible O
for O
antigenic O
variation O
of O
A O
/ O
Ohio O
/ O
09 O
/ O
2015 O
compared O
to O
related O
classical O
swine O
influenza O
A O
( O
H1N1 O
) O
viruses O
. O

Ferrets O
with O
preexisting O
immunity O
to O
the O
pandemic O
A O
( O
H1N1 O
) O
virus O
were O
challenged O
with O
A O
/ O
Ohio O
/ O
09 O
/ O
2015 O
, O
demonstrating O
decreased O
protection O
. O

nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
influenza O
A O
virus O
regulates O
innate O
immune O
responses O
via O
various O
mechanisms O
. O

We O
previously O
showed O
that O
a O
naturally O
occurring O
deletion O
( O
the O
EALQR O
motif O
) O
in O
the O
NS1 O
effector O
domain O
of O
an O
H5N1 O
swine O
- O
origin O
avian O
influenza O
virus O
impairs O
the O
inhibition O
of O
type B
I I
interferon I
( I
IFN I
) I
in O
chicken O
fibroblasts O
and O
attenuates O
virulence O
in O
chickens O
. O

We O
further O
showed O
that O
deletion O
of O
the O
EALQR O
motif O
disrupted O
NS1 O
dimerization O
, O
impairing O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
sequestration O
and O
competitive O
binding O
with O
RIG O
- O
I O
. O

Among O
viral O
proteins O
, O
nonstructural B
protein I
1 I
( I
NS1 I
) I
of O
influenza O
virus O
is O
considered O
a O
key O
determinant O
for O
type B
I I
interferon I
( I
IFN I
) I
antagonism O
, O
pathogenicity O
, O
and O
host O
range O
. O

Here O
we O
report O
that O
a O
naturally O
occurring O
deletion O
( O
of O
the O
EALQR O
motif O
) O
in O
the O
NS1 O
effector O
domain O
of O
an O
H5N1 O
swine O
- O
origin O
avian O
influenza O
virus O
disrupted O
NS1 O
dimerization O
, O
which O
diminished O
the O
blockade O
of O
IFN O
induction O
via O
the O
RIG O
- O
I O
signaling O
pathway O
, O
thereby O
impairing O
virus O
replication O
and O
virulence O
in O
the O
host O
. O

When O
the O
NLRP3 O
inflammasome O
is O
activated O
, O
it O
causes O
ASC O
speck O
formation O
and O
caspase O
- O
1 O
activation O
, O
resulting O
in O
the O
maturation O
of O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
. O

influenza B
A I
virus I
( I
IAV I
) I
infection O
induces O
NLRP3 O
inflammasome O
- O
dependent O
IL O
- O
1 O
beta O
secretion O
, O
which O
contributes O
to O
the O
host O
antiviral O
defense O
. O

In O
this O
study O
, O
we O
compared O
IL O
- O
1 O
beta O
production O
in O
porcine O
alveolar O
macrophages O
in O
response O
to O
IAV O
infection O
and O
found O
that O
the O
2009 O
pandemic O
H1N1 O
induced O
less O
IL O
- O
1 O
beta O
than O
swine B
influenza I
viruses I
( I
SIVs I
) I
. O

IMPORTANCE O
influenza B
A I
virus I
( I
IAV I
) I
infection O
activates O
the O
NLRP3 O
inflammasome O
, O
resulting O
in O
the O
production O
of O
IL O
- O
1 O
beta O
, O
which O
contributes O
to O
the O
host O
innate O
immune O
response O
. O

Each O
genomic O
RNA O
segment O
exists O
in O
the O
form O
of O
a O
ribonucleoprotein B
complex I
( I
RNP I
) I
in O
association O
with O
nucleoproteins O
and O
an O
RNA O
- O
dependent O
RNA O
polymerase O
in O
virions O
. O

Here O
, O
we O
examined O
the O
morphological O
characteristics O
of O
D O
/ O
bovine O
/ O
Yamagata O
/ O
10710 O
/ O
2016 O
( O
D O
/ O
Yamagata O
) O
and O
C O
/ O
Ann O
Arbor O
/ O
50 O
( O
C O
/ O
AA O
) O
, O
focusing O
on O
RNPs O
packaged O
within O
the O
virions O
. O

In O
this O
study O
, O
we O
explored O
the O
molecular O
basis O
for O
transmission O
of O
Eurasian B
avian I
- I
like I
H1N1 I
( I
EAH1N1 I
) I
swine O
influenza O
viruses O
by O
comparing O
two O
viruses O
that O
are O
genetically O
similar O
but O
differ O
in O
their O
transmissibility O
in O
guinea O
pigs O
: O
the O
A O
/ O
swine O
/ O
Guangxi O
/ O
18 O
/ O
2011 O
virus O
( O
GX O
/ O
18 O
) O
is O
highly O
transmissible O
by O
respiratory O
droplet O
in O
guinea O
pigs O
, O
whereas O
the O
A O
/ O
swine O
/ O
Heilongjiang O
/ O
27 O
/ O
2012 O
virus O
( O
HLJ O
/ O
27 O
) O
does O
not O
transmit O
in O
this O
animal O
model O
. O

We O
found O
that O
a O
single O
- O
amino O
- O
acid O
substitution O
of O
Glycine B
( I
G I
) I
for O
Glutamic B
acid I
( I
E I
) I
at O
position O
225 O
( O
E225G O
) O
in O
the O
HA1 O
protein O
completely O
abolished O
the O
respiratory O
droplet O
transmission O
of O
GX O
/ O
18 O
, O
whereas O
the O
substitution O
of O
E O
for O
G O
at O
the O
same O
position O
( O
G225E O
) O
in O
HA1 O
enabled O
HLJ O
/ O
27 O
to O
transmit O
in O
guinea O
pigs O
. O

Several O
amino O
acids O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
of O
influenza O
viruses O
have O
been O
shown O
to O
be O
important O
for O
transmissibility O
, O
usually O
by O
increasing O
virus O
affinity O
for O
human O
- O
type O
receptors O
. O

In O
this O
study O
, O
we O
explored O
the O
genetic O
basis O
of O
the O
transmissibility O
difference O
between O
two O
Eurasian B
avian I
- I
like I
H1N1 I
( I
EAH1N1 I
) I
swine O
influenza O
viruses O
in O
guinea O
pigs O
and O
found O
that O
the O
amino O
acid O
glutamic O
acid O
at O
position O
225 O
in O
the O
HA1 O
protein O
plays O
a O
critical O
role O
in O
the O
transmission O
of O
EAH1N1 O
virus O
by O
increasing O
the O
efficiency O
of O
viral O
assembly O
and O
budding O
. O

It O
was O
previously O
shown O
that O
the O
NS1 O
protein O
from O
this O
human O
2009 B
pandemic I
H1N1 I
( I
pH1N1 I
) I
virus O
was O
an O
effective O
interferon B
( I
IFN I
) I
antagonist O
but O
could O
not O
inhibit O
general O
host O
gene O
expression O
, O
unlike O
other O
NS1 O
proteins O
from O
seasonal O
human O
H1N1 O
and O
H3N2 O
viruses O
. O

Here O
we O
show O
that O
the O
NS1 O
protein O
from O
currently O
circulating O
pH1N1 O
viruses O
has O
evolved O
to O
encode O
6 O
amino O
acid O
changes O
( O
E55K O
, O
L90I O
, O
I123V O
, O
E125D O
, O
K131E O
, O
and O
N205S O
) O
with O
respect O
to O
the O
original O
protein O
. O

Importantly O
, O
a O
recombinant O
pH1N1 O
virus O
containing O
these O
6 O
amino O
acid O
changes O
in O
the O
NS1 O
protein O
( O
pH1N1 O
/ O
NSs O
- O
6mut O
) O
inhibited O
host O
IFN O
and O
proinflammatory O
responses O
to O
a O
greater O
extent O
than O
that O
with O
the O
parental O
virus O
( O
pH1N1 O
/ O
NS1 O
- O
wt O
) O
, O
yet O
virus O
titers O
were O
not O
significantly O
increased O
in O
cell O
cultures O
or O
in O
mouse O
lungs O
, O
and O
the O
disease O
was O
partially O
attenuated O
. O

IMPORTANCE O
Seasonal O
influenza B
A I
viruses I
( I
IAVs I
) I
are O
among O
the O
most O
common O
causes O
of O
respiratory O
infections O
in O
humans O
. O

In O
2009 O
, O
a O
swine O
- O
origin O
H1N1 O
IAV O
( O
pH1N1 O
) O
was O
transmitted O
to O
humans O
, O
infecting O
people O
then O
and O
up O
to O
the O
present O
. O

It O
was O
previously O
shown O
that O
the O
NS1 O
protein O
from O
The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
virus O
is O
not O
able O
to O
inhibit O
general O
gene O
expression O
. O

However O
, O
currently O
circulating O
pH1N1 O
viruses O
have O
evolved O
to O
encode O
6 O
amino O
acid O
changes O
( O
E55K O
, O
L90I O
, O
I123V O
, O
E125D O
, O
K131E O
, O
and O
N205S O
) O
that O
allow O
the O
NS1 O
protein O
of O
contemporary O
pH1N1 O
strains O
to O
inhibit O
host O
gene O
expression O
, O
which O
correlates O
with O
its O
ability O
to O
interact O
with O
CPSF30 O
. O

Infection O
with O
a O
recombinant O
pH1N1 O
virus O
encoding O
these O
6 O
amino O
acid O
changes O
( O
pH1N1 O
/ O
NSs O
- O
6mut O
) O
induced O
lower O
levels O
of O
proinflammatory O
cytokines O
, O
resulting O
in O
viral O
attenuation O
in O
vivo O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
are O
endemic O
in O
swine O
and O
represent O
a O
public O
health O
risk O
. O

Based O
on O
the O
IAV O
hemagglutinin O
, O
seven O
different O
influenza O
A O
viral B
groups I
( I
VGs I
) I
were O
identified O
. O

Most O
of O
the O
remaining O
IAV O
gene O
segments O
allowed O
us O
to O
differentiate O
the O
same O
VGs O
, O
although O
an O
additional O
viral O
group O
was O
identified O
for O
gene O
segment O
3 O
( O
PA O
) O
. O

Moreover O
, O
the O
codetection O
of O
more O
than O
one O
IAV O
VG O
was O
documented O
at O
different O
levels O
( O
farm O
, O
subpopulation O
, O
and O
individual O
pigs O
) O
, O
highlighting O
the O
environment O
for O
potential O
IAV O
reassortment O
. O

Additionally O
, O
3 O
out O
of O
5 O
farms O
contained O
IAV O
isolates O
( O
n O
= O
5 O
) O
with O
gene O
segments O
from O
more O
than O
one O
VG O
, O
and O
79 O
% O
of O
all O
the O
IAVs O
sequenced O
contained O
a O
signature O
mutation O
( O
S31N O
) O
in O
the O
matrix O
gene O
that O
has O
been O
associated O
with O
resistance O
to O
the O
antiviral O
amantadine O
. O

IMPORTANCE O
On O
a O
global O
scale O
, O
swine O
are O
one O
of O
the O
main O
reservoir O
species O
for O
influenza B
A I
viruses I
( I
IAVs I
) I
and O
play O
a O
key O
role O
in O
the O
transmission O
of O
IAVs O
between O
species O
. O

Reassortment O
of O
gene O
segments O
between O
coinfecting O
influenza B
A I
viruses I
( I
IAVs I
) I
facilitates O
viral O
diversification O
and O
has O
a O
significant O
epidemiological O
impact O
on O
seasonal O
and O
pandemic O
influenza O
. O

We O
evaluated O
the O
potential O
for O
viruses O
of O
The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
and O
seasonal O
H3N2 O
lineages O
to O
reassort O
under O
experimental O
conditions O
. O

Microtubules B
( I
MTs I
) I
form O
a O
rapidly O
adaptable O
network O
of O
filaments O
that O
radiate O
throughout O
the O
cell O
. O

The O
dynamic O
behavior O
and O
organization O
of O
the O
MT O
array O
is O
regulated O
by O
MT B
- I
associated I
proteins I
( I
MAPs I
) I
, O
which O
include O
a O
subset O
of O
highly O
specialized O
plus O
- O
end O
- O
tracking O
proteins O
( O
+ O
TIPs O
) O
that O
respond O
to O
signaling O
cues O
to O
alter O
MT O
behavior O
. O

influenza B
A I
virus I
( I
IAV I
) I
RNA O
packaging O
signals O
serve O
to O
direct O
the O
incorporation O
of O
IAV O
gene O
segments O
into O
virus O
particles O
, O
and O
this O
process O
is O
thought O
to O
be O
mediated O
by O
segment O
- O
segment O
interactions O
. O

Our O
study O
aimed O
to O
quantify O
the O
impact O
of O
packaging O
signal O
mismatch O
on O
IAV O
reassortment O
using O
the O
human O
seasonal O
influenza O
A O
/ O
Panama O
/ O
2007 O
/ O
99 O
( O
H3N2 O
) O
and O
pandemic O
influenza O
A O
/ O
Netherlands O
/ O
602 O
/ O
2009 O
( O
H1N1 O
) O
viruses O
. O

We O
found O
that O
, O
when O
segment O
4 O
( O
HA O
) O
of O
coinfecting O
parental O
viruses O
was O
modified O
, O
there O
was O
a O
significant O
preference O
for O
the O
segment O
containing O
matched O
packaging O
signals O
relative O
to O
the O
background O
of O
the O
virus O
. O

Conversely O
, O
when O
segment O
6 O
( O
NA O
) O
or O
segment O
8 O
( O
NS O
) O
carried O
modified O
packaging O
signals O
, O
there O
was O
no O
significant O
preference O
for O
homologous O
packaging O
signals O
. O

IMPORTANCE O
influenza B
A I
viruses I
( I
IAVs I
) I
can O
exchange O
genes O
through O
reassortment O
. O

Repeated O
spillovers O
of O
the O
H1N1 O
pandemic O
virus O
( O
H1N1pdm09 O
) O
from O
humans O
to O
pigs O
resulted O
in O
substantial O
evolution O
of O
influenza O
A O
viruses O
infecting O
swine O
, O
contributing O
to O
the O
genetic O
and O
antigenic O
diversity O
of O
influenza B
A I
viruses I
( I
IAV I
) I
currently O
circulating O
in O
swine O
. O

33 O
% O
) O
containing O
a O
clade O
IV O
- O
A O
HA O
gene O
, O
a O
2002 O
- O
lineage O
NA O
gene O
, O
an O
M O
- O
pdm09 O
gene O
, O
and O
remaining O
gene O
segments O
of O
triple B
reassortant I
internal I
gene I
( I
TRIG I
) I
origin O
. O

IMPORTANCE O
People O
continue O
to O
spread O
the O
2009 O
H1N1 O
pandemic O
( O
H1N1pdm09 O
) O
IAV O
to O
pigs O
, O
allowing O
H1N1pdm09 O
to O
reassort O
with O
endemic O
swine O
IAV O
. O

Active O
surveillance O
of O
influenza B
A I
viruses I
of I
swine I
( I
IAV I
- I
S I
) I
involving O
262 O
farms O
and O
10 O
slaughterhouses O
in O
seven O
provinces O
in O
northern O
and O
southern O
Vietnam O
from O
2010 O
to O
2015 O
yielded O
388 O
isolates O
from O
32 O
farms O
; O
these O
viruses O
were O
classified O
into O
H1N1 O
, O
H1N2 O
, O
and O
H3N2 O
subtypes O
. O

All O
of O
the O
H1N1 O
viruses O
were O
entirely O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
, O
whereas O
all O
of O
the O
H1N2 O
and O
H3N2 O
viruses O
were O
reassortants O
among O
5 O
distinct O
ancestral O
viruses O
: O
H1 O
and O
H3 O
triple B
- I
reassortant I
( I
TR I
) I
IAV O
- O
S O
that O
originated O
from O
North O
American O
pre O
- O
2009 O
human O
seasonal O
H1 O
, O
human O
seasonal O
H3N2 O
, O
and O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
. O

Notably O
, O
93 O
% O
of O
the O
reassortant O
IAV O
- O
S O
retained O
M O
genes O
that O
were O
derived O
from O
A O
( O
H1N1 O
) O
pdm09 O
, O
suggesting O
some O
advantage O
in O
terms O
of O
their O
host O
adaptation O
. O

Bayesian O
Markov O
chain O
Monte O
Carlo O
analysis O
revealed O
that O
multiple O
introductions O
of O
A O
( O
H1N1 O
) O
pdm09 O
and O
TR O
IAV O
- O
S O
into O
the O
Vietnamese O
pig O
population O
have O
driven O
the O
genetic O
diversity O
of O
currently O
circulating O
Vietnamese O
IAV O
- O
S O
. O

In O
addition O
, O
our O
results O
indicate O
that O
a O
reassortant O
IAV O
- O
S O
with O
human O
- O
like O
H3 O
and O
N2 O
genes O
and O
an O
A O
( O
H1N1 O
) O
pdm09 O
origin O
M O
gene O
likely O
caused O
a O
human O
case O
in O
Ho O
Chi O
Minh O
City O
in O
2010 O
. O

IMPORTANCE O
This O
comprehensive O
genetic O
characterization O
of O
388 O
influenza B
A I
viruses I
of I
swine I
( I
IAV I
- I
S I
) I
isolated O
through O
active O
surveillance O
of O
Vietnamese O
pig O
farms O
from O
2010 O
through O
2015 O
provides O
molecular O
epidemiological O
insight O
into O
the O
genetic O
diversification O
of O
IAV O
- O
S O
in O
Vietnam O
after O
the O
emergence O
of O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
. O

Multiple O
reassortments O
among O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
and O
enzootic O
IAV O
- O
S O
yielded O
14 O
genotypes O
, O
9 O
of O
which O
carried O
novel O
gene O
combinations O
. O

The O
reassortants O
that O
carried O
M O
genes O
derived O
from O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
became O
predominant O
, O
replacing O
those O
of O
the O
IAV O
- O
S O
that O
had O
been O
endemic O
in O
Vietnam O
since O
2011 O
. O

Influenza O
A O
H3N2 O
variant O
[ O
A O
( O
H3N2 O
) O
v O
] O
viruses O
, O
which O
have O
caused O
human O
infections O
in O
the O
United O
States O
in O
recent O
years O
, O
originated O
from O
human O
seasonal O
H3N2 O
viruses O
that O
were O
introduced O
into O
North O
American O
swine O
in O
the O
mid O
- O
1990s O
, O
but O
they O
are O
antigenically O
distinct O
from O
both O
the O
ancestral O
and O
current O
circulating O
H3N2 O
strains O
. O

A O
reference O
A O
( O
H3N2 O
) O
v O
virus O
, O
A O
/ O
Minnesota O
/ O
11 O
/ O
2010 O
( O
MN O
/ O
10 O
) O
, O
and O
a O
seasonal O
H3N2 O
strain O
, O
A O
/ O
Beijing O
/ O
32 O
/ O
1992 O
( O
BJ O
/ O
92 O
) O
, O
were O
chosen O
to O
determine O
the O
molecular O
basis O
for O
the O
antigenic O
difference O
between O
A O
( O
H3N2 O
) O
v O
and O
the O
ancestral O
viruses O
. O

Viruses O
containing O
wild O
- O
type O
and O
mutant O
MN O
/ O
10 O
or O
BJ O
/ O
92 O
hemagglutinins B
( I
HAs I
) I
were O
constructed O
and O
probed O
for O
reactivity O
with O
ferret O
antisera O
against O
MN O
/ O
10 O
and O
BJ O
/ O
92 O
in O
hemagglutination O
inhibition O
assays O
. O

Our O
study O
demonstrates O
that O
antigenic O
site O
B O
residues O
play O
a O
critical O
role O
in O
determining O
both O
the O
unique O
antigenic O
phenotype O
and O
receptor O
specificity O
of O
A O
( O
H3N2 O
) O
v O
viruses O
, O
a O
finding O
that O
may O
facilitate O
future O
surveillance O
and O
risk O
assessment O
of O
novel O
influenza O
viruses O
. O

IMPORTANCE O
Influenza O
A O
H3N2 O
variant O
[ O
A O
( O
H3N2 O
) O
v O
] O
viruses O
have O
caused O
hundreds O
of O
human O
infections O
in O
multiple O
states O
in O
the O
United O
States O
since O
2009 O
. O

swine O
population O
in O
the O
mid O
- O
1990s O
, O
but O
they O
are O
different O
from O
both O
these O
ancestral O
viruses O
and O
current O
circulating O
human O
seasonal O
H3N2 O
strains O
in O
terms O
of O
their O
antigenic O
characteristics O
as O
measured O
by O
hemagglutination B
inhibition I
( I
HI I
) I
assay O
. O

In O
this O
study O
, O
we O
identified O
amino O
acids O
in O
antigenic O
site O
B O
of O
the O
surface O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
that O
explain O
the O
antigenic O
difference O
between O
A O
( O
H3N2 O
) O
v O
and O
the O
ancestral O
H3N2 O
strains O
. O

neuraminidase B
( I
NA I
) I
is O
a O
sialidase O
expressed O
on O
the O
surface O
of O
influenza O
A O
viruses O
that O
releases O
progeny O
viruses O
from O
the O
surface O
of O
infected O
cells O
and O
prevents O
viruses O
becoming O
trapped O
in O
mucus O
. O

We O
recently O
characterized O
two O
swine O
viruses O
of O
the O
pandemic O
H1N1 O
lineage O
, O
A O
/ O
swine O
/ O
Virginia O
/ O
1814 O
- O
1 O
/ O
2012 O
( O
pH1N1 O
( O
low O
) O
- O
1 O
) O
and O
A O
/ O
swine O
/ O
Virginia O
/ O
1814 O
- O
2 O
/ O
2012 O
( O
pH1N1 O
( O
low O
) O
- O
2 O
) O
, O
with O
almost O
undetectable O
NA O
enzymatic O
activity O
compared O
to O
that O
of O
the O
highly O
homologous O
A O
/ O
swine O
/ O
Pennsylvania O
/ O
2436 O
/ O
2012 O
( O
pH1N1 O
- O
1 O
) O
and O
A O
/ O
swine O
/ O
Minnesota O
/ O
2499 O
/ O
2012 O
( O
pH1N1 O
- O
2 O
) O
viruses O
. O

pH1N1 O
- O
1 O
transmitted O
to O
aerosol O
contact O
ferrets O
, O
but O
pH1N1 O
( O
low O
) O
- O
1 O
did O
not O
. O

We O
identified O
the O
shared O
unique O
substitutions O
M19V O
, O
A232V O
, O
D248N O
, O
and O
I436V O
( O
N1 O
numbering O
) O
in O
pH1N1 O
( O
low O
) O
- O
1 O
and O
pH1N1 O
( O
low O
) O
- O
2 O
. O

Restoration O
of O
66Y O
was O
critical O
for O
the O
NA O
activity O
of O
pH1N1 O
( O
low O
) O
- O
1 O
NA O
, O
although O
19M O
or O
248D O
in O
conjunction O
with O
66Y O
was O
required O
to O
recover O
the O
level O
of O
activity O
to O
that O
of O
pH1N1 O
viruses O
. O

IMPORTANCE O
neuraminidase B
( I
NA I
) I
is O
a O
sialidase O
that O
is O
one O
of O
the O
major O
surface O
glycoproteins O
of O
influenza O
A O
viruses O
and O
the O
target O
for O
the O
influenza O
drugs O
oseltamivir O
and O
zanamivir O
. O

We O
identified O
66Y O
( O
N1 O
numbering O
) O
, O
a O
highly O
conserved O
amino O
acid O
that O
was O
critical O
for O
the O
stability O
of O
the O
NA O
tetramer O
and O
, O
subsequently O
, O
for O
NA O
enzymatic O
activity O
. O

Nucleotide O
sequences O
of O
influenza O
A O
virus O
isolates O
collected O
from O
exhibition O
swine O
in O
Ohio O
( O
n O
= O
262 O
) O
and O
Indiana O
( O
n O
= O
103 O
) O
during O
2009 O
to O
2013 O
were O
used O
to O
investigate O
viral O
evolution O
and O
movement O
within O
this O
niche O
sector O
of O
the O
swine O
industry O
. O

Importantly O
, O
we O
detected O
an O
association O
between O
the O
high O
number O
of O
human B
variant I
H3N2 I
( I
H3N2v I
) I
virus O
infections O
in O
2012 O
and O
the O
widespread O
circulation O
of O
influenza O
A O
viruses O
of O
the O
same O
genotype O
in O
exhibition O
swine O
in O
Ohio O
fairs O
sampled O
that O
year O
. O

Influenza O
A O
( O
H1N1 O
) O
viruses O
entered O
the O
U O
. O

In O
1998 O
, O
there O
was O
an O
outbreak O
of O
influenza O
- O
like O
illness O
among O
swine O
that O
was O
caused O
by O
A O
( O
H3N2 O
) O
viruses O
containing O
the O
triple B
reassortant I
internal I
gene I
( I
TRIG I
) I
cassette O
. O

Reverse O
genetic O
viruses O
were O
generated O
from O
the O
classical O
H1N1 O
virus O
A O
/ O
swine O
/ O
MN O
/ O
37866 O
/ O
1999 O
( O
MN O
/ O
99 O
) O
, O
the O
TRIG O
virus O
A O
/ O
swine O
/ O
NC O
/ O
18161 O
/ O
2002 O
( O
NC O
/ O
02 O
) O
, O
and O
a O
seasonal O
human O
H3N2 O
virus O
, O
A O
/ O
TX O
/ O
6 O
/ O
1996 O
( O
TX O
/ O
96 O
) O
, O
to O
measure O
in O
vitro O
reassortment O
and O
growth O
potentials O
. O

During O
the O
first O
wave O
of O
the O
2009 O
pandemic O
, O
caused O
by O
a O
H1N1 O
influenza O
virus O
( O
pH1N1 O
) O
of O
swine O
origin O
, O
antivirals O
were O
the O
only O
form O
of O
therapeutic O
available O
to O
control O
the O
proliferation O
of O
disease O
until O
the O
conventional O
strain O
- O
matched O
vaccine O
was O
produced O
. O

Oseltamivir O
is O
an O
antiviral O
that O
inhibits O
the O
sialidase O
activity O
of O
the O
viral O
neuraminidase B
( I
NA I
) I
protein O
and O
was O
shown O
to O
be O
effective O
against O
pH1N1 O
viruses O
in O
ferrets O
. O

In O
contrast O
, O
an O
identical O
treatment O
regime O
alleviated O
all O
signs O
of O
illness O
in O
mice O
infected O
with O
the O
pathogenic O
mouse O
- O
adapted O
virus O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
. O

We O
performed O
a O
thorough O
analysis O
of O
both O
the O
local O
and O
systemic O
T O
- O
cell O
response O
in O
influenza O
virus O
- O
infected O
pigs O
, O
addressing O
kinetics O
and O
phenotype O
as O
well O
as O
multifunctionality O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
, O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
, O
and O
interleukin O
- O
2 O
[ O
IL O
- O
2 O
] O
) O
and O
cross O
- O
reactivity O
. O

A O
total O
of O
31 O
pigs O
were O
intratracheally O
infected O
with O
an O
H1N2 O
swine O
influenza O
A O
virus O
( O
FLUAVsw O
) O
and O
consecutively O
euthanized O
. O

Ex O
vivo O
flow O
cytometry O
of O
lung O
lymphocytes O
revealed O
an O
increase O
in O
proliferating O
( O
Ki O
- O
67 O
( O
+ O
) O
) O
CD8 O
( O
+ O
) O
T O
cells O
with O
an O
early O
effector O
phenotype O
( O
perforin O
( O
+ O
) O
CD27 O
( O
+ O
) O
) O
at O
day O
6 O
p O
. O

Low O
frequencies O
of O
influenza O
virus O
- O
specific O
IFN O
- O
gamma O
- O
producing O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
could O
be O
detected O
in O
the O
lung O
as O
early O
as O
4 O
days O
p O
. O

On O
consecutive O
days O
, O
influenza O
virus O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
produced O
mainly O
IFN O
- O
gamma O
and O
/ O
or O
TNF O
- O
alpha O
, O
reaching O
peak O
frequencies O
around O
day O
9 O
p O
. O

, O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
memory O
T O
cells O
had O
accumulated O
in O
lung O
tissue O
. O

We O
have O
previously O
shown O
that O
11 O
patients O
became O
naturally O
coinfected O
with O
seasonal O
H1N1 O
( O
A O
/ O
H1N1 O
) O
and O
pandemic O
H1N1 O
( O
pdm O
/ O
H1N1 O
) O
during O
the O
Southern O
hemisphere O
winter O
of O
2009 O
in O
New O
Zealand O
. O

We O
show O
here O
that O
multiple O
reassortant O
viruses O
were O
generated O
during O
natural O
coinfection O
of O
a O
patient O
with O
pandemic O
H1N1 O
( O
2009 O
) O
and O
seasonal O
H1N1 O
influenza O
A O
viruses O
. O

influenza B
A I
virus I
( I
IAV I
) I
of O
the O
H3 O
subtype O
is O
an O
important O
respiratory O
pathogen O
that O
affects O
both O
humans O
and O
swine O
. O

Vaccination O
to O
induce O
neutralizing O
antibodies O
against O
the O
surface O
glycoprotein O
Hemagglutinin B
( I
HA I
) I
is O
the O
primary O
method O
used O
to O
control O
disease O
. O

Six O
of O
the O
7 O
positions O
previously O
identified O
in O
human O
seasonal O
H3 O
( O
positions O
145 O
, O
155 O
, O
156 O
, O
158 O
, O
159 O
, O
189 O
, O
and O
193 O
) O
were O
also O
indicated O
in O
swine O
H3 O
antigenic O
evolution O
. O

We O
tested O
the O
antigenic O
effect O
of O
these O
introduced O
substitutions O
by O
using O
hemagglutination B
inhibition I
( I
HI I
) I
data O
with O
monovalent O
swine O
antisera O
and O
antigenic O
cartography O
to O
evaluate O
the O
antigenic O
phenotype O
of O
the O
mutant O
viruses O
. O

IMPORTANCE O
A O
key O
component O
of O
influenza O
virus O
evolution O
is O
antigenic O
drift O
mediated O
by O
the O
accumulation O
of O
amino O
acid O
substitutions O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
, O
resulting O
in O
escape O
from O
prior O
immunity O
generated O
by O
natural O
infection O
or O
vaccination O
. O

The O
lack O
of O
a O
peptide B
- I
swine I
leukocyte I
antigen I
class I
I I
( I
pSLA I
I I
) I
complex O
structure O
presents O
difficulties O
for O
the O
study O
of O
swine O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
immunity O
and O
molecule O
vaccine O
development O
to O
eliminate O
important O
swine O
viral O
diseases O
, O
such O
as O
influenza B
A I
virus I
( I
IAV I
) I
. O

SLA O
- O
3 O
* O
hs0202 O
binding O
with O
s O
beta O
2m O
and O
a O
KMNTQFTAV O
( O
hemagglutinin O
[ O
HA O
] O
- O
KMN9 O
) O
peptide O
from O
the O
2009 O
pandemic O
swine O
H1N1 O
strain O
clearly O
displayed O
two O
distinct O
conformations O
with O
HA O
- O
KMN9 O
peptides O
in O
the O
structures O
, O
which O
are O
believed O
to O
be O
beneficial O
to O
stimulate O
a O
broad O
spectrum O
of O
CTL O
immune O
responses O
. O

Notably O
, O
we O
found O
that O
different O
HA O
- O
KMN9 O
conformations O
are O
caused O
, O
not O
only O
by O
the O
flexibility O
of O
the O
side O
chains O
of O
residues O
in O
the O
peptide O
- O
binding O
groove O
( O
PBG O
) O
, O
but O
also O
by O
the O
skewing O
of O
alpha O
1 O
and O
alpha O
2 O
helixes O
forming O
the O
PBG O
. O

In O
addition O
, O
alanine O
scanning O
and O
circular B
- I
dichroism I
( I
CD I
) I
spectra O
confirmed O
that O
the O
B O
, O
D O
, O
and O
F O
pockets O
play O
critical O
biochemical O
roles O
in O
determining O
the O
peptide O
- O
binding O
motif O
of O
SLA O
- O
3 O
* O
hs0202 O
. O

Based O
on O
biochemical O
parameters O
and O
comparisons O
to O
similar O
pockets O
in O
other O
known O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
structures O
, O
the O
fundamental O
motif O
for O
SLA O
- O
3 O
* O
hs0202 O
was O
determined O
to O
be O
X O
- O
( O
M O
/ O
A O
/ O
R O
) O
- O
( O
N O
/ O
Q O
/ O
R O
/ O
F O
) O
- O
X O
- O
XX O
- O
X O
- O
X O
- O
( O
V O
/ O
I O
) O
by O
refolding O
in O
vitro O
and O
multiple O
mutant O
peptides O
. O

We O
also O
determined O
the O
fundamental O
motif O
for O
SLA O
- O
3 O
* O
hs0202 O
to O
be O
X O
- O
( O
M O
/ O
A O
/ O
R O
) O
- O
( O
N O
/ O
Q O
/ O
R O
/ O
F O
) O
- O
X O
- O
X O
- O
X O
- O
X O
- O
X O
- O
( O
V O
/ O
I O
) O
based O
on O
a O
series O
of O
structural O
and O
biochemical O
analyses O
, O
and O
28 O
SLA O
- O
3 O
* O
hs0202 O
- O
restricted O
epitope O
candidates O
were O
identified O
from O
important O
IAV O
strains O
. O

Cattle O
have O
been O
proposed O
as O
the O
natural O
reservoir O
of O
a O
novel O
member O
of O
the O
virus O
family O
Orthomyxoviridae O
, O
which O
has O
been O
tentatively O
classified O
as O
influenza B
D I
virus I
( I
IDV I
) I
. O

To O
address O
this O
aspect O
of O
Koch O
' O
s O
postulates O
, O
three O
dairy O
calves O
( O
treatment O
animals O
) O
held O
in O
individual O
pens O
were O
inoculated O
intranasally O
with O
IDV O
strain O
D O
/ O
bovine O
/ O
Mississippi O
/ O
C00046N O
/ O
2014 O
. O

At O
1 O
day O
postinoculation O
, O
a O
seronegative O
calf O
( O
contact O
animal O
) O
was O
added O
to O
each O
of O
the O
treatment O
animal O
pens O
. O

IMPORTANCE O
A O
novel O
influenza O
virus O
, O
tentatively O
classified O
as O
influenza B
D I
virus I
( I
IDV I
) I
, O
was O
identified O
in O
swine O
, O
cattle O
, O
sheep O
, O
and O
goats O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
nonstructural B
protein I
1 I
beta I
( I
nsp1 I
beta I
) I
is O
a O
multifunctional O
viral O
protein O
, O
which O
is O
involved O
in O
suppressing O
the O
host O
innate O
immune O
response O
and O
activating O
a O
unique O
- O
2 O
/ O
- O
1 O
programmed B
ribosomal I
frameshifting I
( I
PRF I
) I
signal O
for O
the O
expression O
of O
frameshifting O
products O
. O

In O
this O
study O
, O
site O
- O
directed O
mutagenesis O
analysis O
showed O
that O
the O
R128A O
or O
R129A O
mutation O
introduced O
into O
a O
highly O
conserved O
motif O
( O
( O
123 O
) O
GKYLQRRLQ O
( O
131 O
) O
) O
reduced O
the O
ability O
of O
nsp1 O
beta O
to O
suppress O
interferon B
beta I
( I
IFN I
- I
beta I
) I
activation O
and O
also O
impaired O
nsp1 O
beta O
' O
s O
function O
as O
a O
PRF O
transactivator O
. O

In O
comparison O
to O
the O
wild B
- I
type I
( I
WT I
) I
virus O
, O
vR128A O
and O
vR129A O
showed O
slightly O
reduced O
growth O
abilities O
, O
while O
the O
vRR129AA O
mutant O
had O
a O
significantly O
reduced O
growth O
ability O
in O
infected O
cells O
. O

Compared O
to O
the O
WT O
virus O
in O
infected O
cells O
, O
all O
three O
mutated O
viruses O
stimulated O
high O
levels O
of O
IFN O
- O
alpha O
expression O
and O
exhibited O
a O
reduced O
ability O
to O
suppress O
the O
mRNA O
expression O
of O
selected O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

We O
have O
applied O
a O
similar O
technology O
to O
deoptimize O
the O
capsid O
- O
coding O
region O
( O
P1 O
) O
of O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
. O

Despite O
the O
introduction O
of O
489 O
nucleotide O
changes O
( O
19 O
% O
) O
, O
synonymous O
deoptimization O
of O
the O
P1 O
region O
rendered O
a O
viable O
FMDV O
progeny O
. O

The O
resulting O
strain O
was O
stable O
and O
reached O
cell O
culture O
titers O
similar O
to O
those O
obtained O
for O
wild B
- I
type I
( I
WT I
) I
virus O
, O
but O
at O
reduced O
specific O
infectivity O
. O

Studies O
in O
mice O
showed O
that O
100 O
% O
of O
animals O
inoculated O
with O
the O
FMDV O
A12 O
P1 O
deoptimized O
mutant O
( O
A12 O
- O
P1 O
deopt O
) O
survived O
, O
even O
when O
the O
animals O
were O
infected O
at O
doses O
100 O
times O
higher O
than O
the O
dose O
required O
to O
cause O
death O
by O
WT O
virus O
. O

Influenza O
D O
virus O
( O
FLUDV O
) O
is O
a O
novel O
influenza O
virus O
that O
infects O
cattle O
and O
swine O
. O

IMPORTANCE O
Influenza O
D O
virus O
( O
FLUDV O
) O
is O
a O
novel O
emerging O
pathogen O
with O
bovine O
as O
its O
primary O
host O
. O

Numerous O
experimental O
studies O
have O
demonstrated O
that O
CD8 O
( O
+ O
) O
T O
cells O
contribute O
to O
immunity O
against O
influenza O
by O
limiting O
viral O
replication O
. O

It O
is O
therefore O
surprising O
that O
rigorous O
statistical O
tests O
have O
failed O
to O
find O
evidence O
of O
positive O
selection O
in O
the O
epitopes O
targeted O
by O
CD8 O
( O
+ O
) O
T O
cells O
. O

Here O
we O
use O
a O
novel O
computational O
approach O
to O
test O
for O
selection O
in O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
. O

We O
define O
all O
epitopes O
in O
the O
nucleoprotein B
( I
NP I
) I
and O
Matrix B
protein I
( I
M1 I
) I
with O
experimentally O
identified O
human O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
and O
then O
compare O
the O
evolution O
of O
these O
epitopes O
in O
parallel O
lineages O
of O
human O
and O
swine O
influenza O
viruses O
that O
have O
been O
diverging O
since O
roughly O
1918 O
. O

We O
find O
a O
significant O
enrichment O
of O
substitutions O
that O
alter O
human O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
in O
NP O
of O
human O
versus O
swine O
influenza O
virus O
, O
consistent O
with O
the O
idea O
that O
these O
epitopes O
are O
under O
positive O
selection O
. O

Overall O
, O
our O
work O
demonstrates O
that O
there O
is O
clear O
selection O
from O
CD8 O
( O
+ O
) O
T O
cells O
in O
human O
influenza O
virus O
NP O
and O
illustrates O
how O
comparative O
analyses O
of O
viral O
lineages O
from O
different O
hosts O
can O
identify O
positive O
selection O
that O
is O
otherwise O
obscured O
by O
strong O
functional O
constraint O
. O

CD8 O
( O
+ O
) O
T O
cells O
provide O
such O
broad O
immunity O
, O
since O
they O
target O
conserved O
viral O
proteins O
. O

Overall O
, O
our O
results O
show O
that O
CD8 O
( O
+ O
) O
T O
cells O
targeting O
nucleoprotein O
play O
an O
important O
role O
in O
shaping O
influenza O
virus O
evolution O
. O

Human O
- O
like O
swine O
H3 O
influenza B
A I
viruses I
( I
IAV I
) I
were O
detected O
by O
the O
USDA O
surveillance O
system O
. O

We O
characterized O
two O
novel O
swine O
human O
- O
like O
H3N2 O
and O
H3N1 O
viruses O
with O
Hemagglutinin B
( I
HA I
) I
genes O
similar O
to O
those O
in O
human O
seasonal O
H3 O
strains O
and O
internal O
genes O
closely O
related O
to O
those O
of O
2009 O
H1N1 O
pandemic O
viruses O
. O

The O
H3N2 O
neuraminidase B
( I
NA I
) I
was O
of O
the O
contemporary O
human O
N2 O
lineage O
, O
while O
the O
H3N1 O
NA O
was O
of O
the O
classical O
swine O
N1 O
lineage O
. O

IMPORTANCE O
Pigs O
are O
important O
hosts O
in O
the O
evolution O
of O
influenza B
A I
viruses I
( I
IAV I
) I
. O

Two O
scenarios O
were O
tested O
in O
a O
guinea O
pig O
model O
, O
using O
influenza O
A O
/ O
Panama O
/ O
2007 O
/ O
99 O
( O
H3N2 O
) O
virus O
( O
wt O
) O
and O
a O
silently O
mutated O
variant O
( O
var O
) O
thereof O
as O
parental O
virus O
strains O
. O

The O
first O
is O
the O
introduction O
of O
random O
errors O
into O
the O
genome O
by O
the O
viral O
polymerase O
, O
which O
occurs O
with O
a O
frequency O
of O
approximately O
10 O
( O
- O
5 O
) O
errors O
/ O
nucleotide O
replicated O
. O

The O
A O
/ O
H3N8 O
canine B
influenza I
virus I
( I
CIV I
) I
emerged O
from O
A O
/ O
H3N8 O
equine B
influenza I
virus I
( I
EIV I
) I
around O
the O
year O
2000 O
through O
the O
transfer O
of O
a O
single O
virus O
from O
horses O
to O
dogs O
. O

We O
defined O
and O
compared O
the O
biological O
properties O
of O
EIV O
and O
CIV O
by O
examining O
their O
genetic O
variation O
, O
infection O
, O
and O
growth O
in O
different O
cell O
cultures O
, O
receptor O
specificity O
, O
Hemagglutinin B
( I
HA I
) I
cleavage O
, O
and O
infection O
and O
growth O
in O
horse O
and O
dog O
tracheal O
explant O
cultures O
. O

The O
rescued O
viruses O
, O
including O
HA O
and O
neuraminidase B
( I
NA I
) I
double O
reassortants O
, O
exhibited O
similar O
degrees O
of O
long O
- O
term O
growth O
in O
MDCK O
cells O
. O

The O
diversity O
of O
influenza B
A I
viruses I
in I
swine I
( I
swIAVs I
) I
presents O
an O
important O
pandemic O
threat O
. O

Through O
phylogenetic O
analysis O
of O
contemporary O
swIAVs O
in O
the O
United O
States O
, O
we O
demonstrate O
that O
human O
- O
to O
- O
swine O
transmission O
of O
pandemic B
H1N1 I
( I
pH1N1 I
) I
viruses O
has O
occurred O
continuously O
in O
the O
years O
following O
the O
2009 O
H1N1 O
pandemic O
and O
has O
been O
an O
important O
contributor O
to O
the O
genetic O
diversity O
of O
U O
. O

swine O
population O
, O
with O
periodic O
reemergence O
of O
pandemic O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
segments O
in O
association O
with O
seasonal O
pH1N1 O
epidemics O
in O
humans O
. O

Department O
of O
Agriculture O
' O
s O
national O
surveillance O
system O
to O
identify O
the O
central O
role O
of O
humans O
in O
the O
reemergence O
of O
pandemic B
H1N1 I
( I
pH1N1 I
) I
influenza O
viruses O
in O
U O
. O

A O
balance O
between O
the O
functions O
of O
the O
influenza O
virus O
surface O
proteins O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
is O
thought O
to O
be O
important O
for O
the O
transmission O
of O
viruses O
between O
humans O
. O

Here O
we O
describe O
two O
pandemic O
H1N1 O
viruses O
, O
A O
/ O
swine O
/ O
Virginia O
/ O
1814 O
- O
1 O
/ O
2012 O
and O
A O
/ O
swine O
/ O
Virginia O
/ O
1814 O
- O
2 O
/ O
2012 O
( O
pH1N1 O
( O
low O
) O
- O
1 O
and O
- O
2 O
, O
respectively O
) O
, O
that O
were O
isolated O
from O
swine O
symptomatic O
for O
influenza O
. O

The O
enzymatic O
activity O
of O
the O
NA O
of O
these O
viruses O
was O
almost O
undetectable O
, O
while O
the O
HA O
binding O
affinity O
for O
alpha O
2 O
, O
6 O
sialic O
acids O
was O
greater O
than O
that O
of O
the O
highly O
homologous O
pH1N1 O
viruses O
A O
/ O
swine O
/ O
Pennsylvania O
/ O
2436 O
/ O
2012 O
and O
A O
/ O
swine O
/ O
Minnesota O
/ O
2499 O
/ O
2012 O
( O
pH1N1 O
- O
1 O
and O
- O
2 O
) O
, O
which O
exhibited O
better O
- O
balanced O
HA O
and O
NA O
activities O
. O

The O
in O
vitro O
growth O
kinetics O
of O
pH1N1 O
( O
low O
) O
and O
pH1N1 O
viruses O
were O
similar O
, O
but O
aerosol O
transmission O
of O
pH1N1 O
( O
low O
) O
- O
1 O
was O
abrogated O
and O
transmission O
via O
direct O
contact O
in O
ferrets O
was O
significantly O
impaired O
compared O
to O
pH1N1 O
- O
1 O
, O
which O
transmitted O
by O
direct O
and O
aerosol O
contact O
. O

In O
normal O
human O
bronchial O
epithelial O
cells O
, O
pH1N1 O
( O
low O
) O
- O
1 O
was O
significantly O
inhibited O
by O
mucus O
but O
pH1N1 O
- O
1 O
was O
not O
. O

In O
Madin O
- O
Darby O
canine O
kidney O
cell O
cultures O
overlaid O
with O
human O
or O
swine O
mucus O
, O
human O
mucus O
inhibited O
pH1N1 O
( O
low O
) O
- O
1 O
but O
swine O
mucus O
did O
not O
. O

IMPORTANCE O
A O
balance O
between O
the O
functions O
of O
the O
influenza O
virus O
surface O
proteins O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
is O
thought O
to O
be O
important O
for O
transmission O
of O
viruses O
from O
swine O
to O
humans O
. O

Here O
we O
show O
that O
a O
swine O
virus O
with O
extremely O
functionally O
mismatched O
HA O
and O
NAs O
( O
pH1N1 O
( O
low O
) O
- O
1 O
) O
cannot O
transmit O
via O
aerosol O
in O
ferrets O
, O
while O
another O
highly O
homologous O
virus O
with O
HA O
and O
NAs O
that O
are O
better O
matched O
functionally O
( O
pH1N1 O
- O
1 O
) O
can O
transmit O
via O
aerosol O
. O

These O
viruses O
show O
similar O
growth O
kinetics O
in O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
, O
but O
pH1N1 O
( O
low O
) O
- O
1 O
is O
significantly O
inhibited O
by O
mucus O
in O
normal O
human O
bronchial O
epithelial O
cells O
whereas O
pH1N1 O
- O
1 O
is O
not O
. O

Coinfection O
of O
swine O
cells O
with O
2009 O
pandemic O
H1N1 O
virus O
( O
huH1N1 O
) O
and O
an O
endemic O
swine O
H1N2 O
( O
A O
/ O
swine O
/ O
Illinois O
/ O
02860 O
/ O
09 O
) O
virus O
( O
swH1N2 O
) O
resulted O
in O
a O
23 O
% O
reassortment O
rate O
that O
was O
independent O
of O
alpha O
2 O
, O
3 O
- O
or O
alpha O
2 O
, O
6 O
- O
sialic O
acid O
distribution O
on O
the O
cells O
. O

The O
reassortants O
had O
altered O
pathogenic O
phenotypes O
linked O
to O
introduction O
of O
the O
swine O
virus O
PA O
and O
neuraminidase B
( I
NA I
) I
into O
huH1N1 O
. O

Reassortments O
among O
subtypes O
from O
avian O
and O
human O
viruses O
led O
to O
the O
1957 O
( O
H2N2 O
subtype O
) O
and O
1968 O
( O
H3N2 O
subtype O
) O
human O
influenza O
pandemics O
. O

The O
findings O
also O
establish O
that O
circulating O
neuraminidase B
( I
NA I
) I
and O
PA O
genes O
could O
alter O
the O
pathogenic O
phenotype O
of O
the O
pandemic O
H1N1 O
virus O
, O
resulting O
in O
enhanced O
disease O
. O

influenza B
B I
virus I
( I
IBV I
) I
causes O
seasonal O
epidemics O
in O
humans O
. O

5 O
% O
( O
20 O
/ O
52 O
) O
of O
sampled O
farms O
, O
and O
7 O
. O

3 O
% O
( O
41 O
/ O
560 O
) O
of O
tested O
swine O
serum O
samples O
were O
positive O
for O
IBV O
antibodies O
. O

Furthermore O
, O
swine O
herds O
infected O
with O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
showed O
a O
higher O
prevalence O
of O
IBV O
antibodies O
in O
our O
2014 O
survey O
. O

Finally O
, O
an O
experimental O
infection O
in O
pigs O
, O
via O
intranasal O
and O
intratracheal O
routes O
, O
was O
performed O
using O
one O
representative O
virus O
from O
each O
of O
the O
two O
genetically O
and O
antigenically O
distinct O
lineages O
of O
IBVs O
: O
B O
/ O
Brisbane O
/ O
60 O
/ O
2008 O
( O
Victoria O
lineage O
) O
and O
B O
/ O
Yamagata O
/ O
16 O
/ O
1988 O
( O
Yamagata O
lineage O
) O
. O

Human B
interferon I
- I
inducible I
transmembrane I
proteins I
( I
IFITMs I
) I
were O
identified O
as O
restriction O
factors O
of O
influenza B
A I
virus I
( I
IAV I
) I
. O

Given O
the O
important O
role O
of O
pigs O
in O
the O
zoonotic O
cycle O
of O
IAV O
, O
we O
cloned O
swine O
IFITMs O
( O
swIFITMs O
) O
and O
found O
two O
IFITM1 O
- O
like O
proteins O
, O
one O
homologue O
of O
IFITM2 O
, O
and O
a O
homologue O
of O
IFITM3 O
. O

Viruses O
with O
approximately O
50 O
% O
homology O
to O
human O
influenza O
C O
virus O
( O
ICY O
) O
have O
recently O
been O
isolated O
from O
swine O
and O
cattle O
. O

The O
overall O
low O
homology O
to O
ICY O
, O
lack O
of O
antibody O
cross O
- O
reactivity O
to O
ICY O
in O
hemagglutination B
inhibition I
( I
HI I
) I
and O
agar O
gel O
immunodiffusion O
assays O
, O
and O
inability O
to O
productively O
reassort O
with O
ICY O
led O
to O
the O
proposal O
that O
these O
viruses O
represented O
a O
new O
genus O
of O
influenza O
virus O
, O
influenzavirus O
D O
( O
IDV O
) O
. O

Phylogenetic O
analysis O
of O
full O
- O
genome O
sequences O
of O
these O
six O
new O
viruses O
and O
four O
previously O
reported O
viruses O
revealed O
two O
distinct O
cocirculating O
lineages O
represented O
by O
D O
/ O
swine O
/ O
Oklahoma O
/ O
1334 O
/ O
2011 O
( O
D O
/ O
OK O
) O
and O
D O
/ O
bovine O
/ O
Oklahoma O
/ O
660 O
/ O
2013 O
( O
D O
/ O
660 O
) O
, O
which O
frequently O
reassorted O
with O
one O
another O
. O

One O
isolate O
, O
D O
/ O
bovine O
/ O
Texas O
/ O
3 O
- O
13 O
/ O
2011 O
( O
D O
/ O
3 O
- O
13 O
) O
, O
clustered O
with O
the O
D O
/ O
660 O
lineage O
, O
but O
also O
had O
high O
HI O
titers O
to O
heterologous O
( O
D O
/ O
OK O
) O
clade O
antiserum O
. O

Detailed O
genetic O
and O
antigenic O
studies O
led O
to O
the O
proposal O
that O
this O
virus O
represents O
a O
new O
genus O
of O
influenza O
, O
influenzavirus O
D O
( O
IDV O
) O
. O

Here O
, O
we O
show O
that O
IDV O
is O
common O
in O
clinical O
samples O
of O
bovine B
respiratory I
disease I
complex I
( I
BRDC I
) I
, O
with O
a O
prevalence O
similar O
to O
that O
of O
other O
established O
BRDC O
etiological O
agents O
. O

We O
determined O
the O
antigenic O
structure O
of O
pandemic O
influenza O
A O
( O
H1N1 O
) O
pdm09 O
virus O
Hemagglutinin B
( I
HA I
) I
using O
599 O
escape O
mutants O
that O
were O
selected O
using O
16 O
anti O
- O
HA O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
A O
/ O
Narita O
/ O
1 O
/ O
2009 O
. O

The O
sequencing O
of O
mutant O
HA O
genes O
revealed O
43 O
amino O
acid O
substitutions O
at O
24 O
positions O
in O
three O
antigenic O
sites O
, O
Sa O
, O
Sb O
, O
and O
Ca2 O
, O
which O
were O
previously O
mapped O
onto O
A O
/ O
PuertoRico O
/ O
8 O
/ O
34 O
( O
A O
/ O
PR O
/ O
8 O
/ O
34 O
) O
HA O
( O
A O
. O

, O
amino O
acid O
residues O
141 O
, O
142 O
, O
143 O
, O
171 O
, O
172 O
, O
174 O
, O
177 O
, O
and O
180 O
in O
the O
Sa O
site O
, O
residues O
170 O
, O
173 O
, O
202 O
, O
206 O
, O
210 O
, O
211 O
, O
and O
212 O
in O
the O
Sb O
site O
, O
residues O
151 O
, O
154 O
, O
156 O
, O
157 O
, O
158 O
, O
159 O
, O
200 O
, O
and O
238 O
in O
the O
Ca2 O
site O
, O
and O
residue O
147 O
in O
the O
undesignated O
site O
( O
numbering O
begins O
at O
the O
first O
methionine O
) O
. O

MAb O
n2 O
lost O
reactivity O
when O
mutations O
were O
introduced O
at O
positions O
147 O
, O
159 O
( O
site O
Ca2 O
) O
, O
170 O
( O
site O
Sb O
) O
, O
and O
172 O
( O
site O
Sa O
) O
. O

From O
2009 O
to O
2013 O
, O
no O
antigenic O
drift O
was O
detected O
for O
the O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
. O

IMPORTANCE O
The O
first O
influenza O
pandemic O
of O
the O
21st O
century O
occurred O
in O
2009 O
with O
the O
emergence O
of O
a O
novel O
virus O
originating O
with O
swine O
influenza O
, O
A O
( O
H1N1 O
) O
pdm09 O
. O

Although O
HA O
of O
A O
( O
H1N1 O
) O
pdm09 O
has O
a O
common O
origin O
( O
1918 O
H1N1 O
) O
with O
seasonal O
H1N1 O
, O
the O
antigenic O
divergence O
of O
HA O
between O
the O
seasonal O
H1N1 O
and O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
gave O
rise O
to O
the O
influenza O
pandemic O
in O
2009 O
. O

To O
take O
precautions O
against O
the O
antigenic O
drift O
of O
the O
A O
( O
H1N1 O
) O
pdm09 O
virus O
in O
the O
near O
future O
, O
it O
is O
important O
to O
identify O
its O
precise O
antigenic O
structure O
. O

We O
characterized O
599 O
escape O
mutants O
that O
were O
obtained O
by O
neutralizing O
four O
parent O
viruses O
of O
A O
( O
H1N1 O
) O
pdm09 O
in O
the O
presence O
of O
16 O
MAbs O
. O

Second O
- O
and O
third O
- O
wave O
viruses O
replicated O
more O
rapidly O
in O
human B
airway I
epithelial I
( I
HAE I
) I
cells O
than O
did O
the O
first O
- O
wave O
virus O
. O

A O
mutation O
in O
PA O
( O
N321K O
) O
enhanced O
polymerase O
activity O
of O
third O
- O
wave O
viruses O
and O
also O
provided O
a O
replicative O
advantage O
in O
HAE O
cells O
. O

Therefore O
, O
multiple O
mutations O
allowed O
incremental O
changes O
in O
viral O
fitness O
, O
which O
together O
may O
have O
contributed O
to O
the O
apparent O
increase O
in O
severity O
of O
A O
( O
H1N1 O
) O
pdm09 O
influenza O
virus O
during O
successive O
waves O
. O

These O
adaptations O
may O
explain O
the O
remarkable O
ability O
of O
A O
( O
H1N1 O
) O
pdm09 O
virus O
to O
continue O
to O
circulate O
despite O
widespread O
immunity O
and O
the O
apparent O
increase O
in O
severity O
of O
influenza O
over O
successive O
waves O
of O
infection O
. O

Here O
, O
we O
subjected O
a O
recombinant O
virus O
( O
rH1N1 O
) O
with O
the O
same O
constellation O
makeup O
as O
the O
pandemic O
H1N1 O
/ O
2009 O
virus O
to O
nine O
serial O
passages O
in O
pigs O
. O

Mutations O
in O
the O
Hemagglutinin B
( I
HA I
) I
protein O
, O
however O
, O
differed O
greatly O
between O
the O
upper O
and O
lower O
respiratory O
tracts O
. O

Specifically O
, O
two O
mutants O
of O
rH1N1 O
( O
PB1 O
A469T O
and O
a O
combination O
of O
NS1 O
N205K O
and O
NEP O
T48N O
) O
were O
identified O
as O
determinants O
of O
transmissibility O
in O
guinea O
pigs O
. O

Compared O
to O
the O
classical O
reverse O
genetics O
system O
, O
the O
eight O
- O
in O
- O
one O
bacmids O
( O
bcmd O
- O
RGFlu O
) O
showed O
higher O
efficiency O
of O
virus O
rescue O
in O
various O
cell O
types O
. O

Using O
a O
transfection B
- I
based I
inoculation I
( I
TBI I
) I
system O
, O
intranasal O
delivery O
to O
DBA O
/ O
2J O
and O
BALB O
/ O
c O
mice O
of O
bcmd O
- O
RGFlu O
plus O
293T O
cells O
led O
to O
the O
generation O
of O
lethal O
PR8 O
virus O
in O
vivo O
. O

We O
propose O
a O
radical O
change O
in O
the O
way O
influenza O
vaccination O
is O
approached O
, O
in O
which O
a O
recombinant O
bacmid O
, O
a O
shuttle O
vector O
that O
can O
be O
propagated O
in O
both O
Escherichia O
coli O
and O
insect O
cells O
, O
carries O
an O
influenza O
virus O
infectious O
clone O
( O
bcmd O
- O
RGFlu O
) O
. O

A O
molecular O
clock O
analysis O
indicates O
that O
this O
virus O
- O
A O
/ O
sw O
/ O
Saskatchewan O
/ O
02903 O
/ O
2009 O
( O
H3N2 O
) O
- O
has O
likely O
circulated O
undetected O
in O
swine O
for O
at O
least O
7 O
years O
. O

Notably O
, O
human O
- O
origin O
hemagglutinin O
( O
H1 O
and O
H3 O
) O
and O
neuraminidase O
( O
particularly O
N2 O
) O
segments O
were O
detected O
in O
swine O
at O
a O
much O
higher O
rate O
than O
the O
six O
internal O
gene O
segments O
, O
suggesting O
an O
association O
between O
the O
acquisition O
of O
swine O
- O
origin O
internal O
genes O
via O
reassortment O
and O
the O
adaptation O
of O
human O
influenza O
viruses O
to O
new O
swine O
hosts O
. O

The O
influenza O
A O
virus O
genome O
possesses O
eight O
negative O
- O
strand O
RNA O
segments O
in O
the O
form O
of O
viral B
ribonucleoprotein I
particles I
( I
vRNPs I
) I
in O
association O
with O
the O
three O
viral O
RNA O
polymerase O
subunits O
( O
PB2 O
, O
PB1 O
, O
and O
PA O
) O
and O
the O
nucleoprotein B
( I
NP I
) I
. O

In O
order O
to O
gain O
insight O
into O
the O
potential O
roles O
of O
RNP O
subunits O
in O
the O
modulation O
of O
the O
host O
' O
s O
innate O
immune O
response O
, O
the O
interactions O
of O
each O
RNP O
subunit O
with O
retinoic O
acid O
- O
inducible O
gene O
I O
protein O
( O
RIG O
- O
I O
) O
from O
mammalian O
and O
avian O
species O
were O
investigated O
. O

Studies O
using O
coimmunoprecipitation B
( I
co I
- I
IP I
) I
, O
bimolecular B
fluorescence I
complementation I
( I
BiFC I
) I
, O
and O
colocalization O
using O
confocal O
microscopy O
provided O
direct O
evidence O
for O
the O
RNA O
- O
independent O
binding O
of O
PB2 O
, O
PB1 O
, O
and O
PA O
with O
RIG O
- O
I O
from O
various O
hosts O
( O
human O
, O
swine O
, O
mouse O
, O
and O
duck O
) O
. O

The O
association O
of O
each O
individual O
virus O
polymerase O
component O
with O
RIG O
- O
I O
failed O
to O
significantly O
affect O
the O
interferon B
( I
IFN I
) I
induction O
elicited O
by O
RIG O
- O
I O
and O
5 B
' I
triphosphate I
( I
5 I
' I
ppp I
) I
RNA O
in O
reporter O
assays O
, O
quantitative O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
, O
and O
IRF3 O
phosphorylation O
tests O
. O

IMPORTANCE O
RIG O
- O
I O
is O
an O
important O
RNA O
sensor O
to O
elicit O
the O
innate O
immune O
response O
in O
mammals O
and O
some O
bird O
species O
( O
such O
as O
duck O
) O
upon O
influenza O
A O
virus O
infection O
. O

Although O
the O
5 O
' O
- O
triphosphate O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
panhandle O
structure O
at O
the O
end O
of O
viral O
genome O
RNA O
is O
responsible O
for O
the O
binding O
and O
subsequent O
activation O
of O
RIG O
- O
I O
, O
this O
structure O
is O
supposedly O
wrapped O
by O
RNA O
polymerase O
complex O
( O
PB2 O
, O
PB1 O
, O
and O
PA O
) O
, O
which O
may O
interfere O
with O
the O
induction O
of O
RIG O
- O
I O
signaling O
pathway O
. O

influenza B
A I
viruses I
( I
IAVs I
) I
can O
jump O
species O
barriers O
and O
occasionally O
cause O
epidemics O
, O
epizootics O
, O
pandemics O
, O
and O
panzootics O
. O

Canine O
influenza O
virus O
( O
CIV O
; O
H3N8 O
) O
originated O
after O
the O
transfer O
of O
an O
equine B
influenza I
virus I
( I
EIV I
) I
into O
dogs O
. O

Inoculating O
dog O
tracheas O
with O
various O
human B
IAVs I
( I
hIAVs I
) I
showed O
that O
they O
infected O
the O
tracheal O
epithelium O
with O
various O
efficiencies O
depending O
on O
the O
virus O
tested O
. O

Finally O
, O
we O
show O
that O
reassortant O
viruses O
carrying O
gene O
segments O
of O
CIV O
and O
hIAV O
are O
viable O
and O
that O
addition O
of O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
of O
CIV O
to O
the O
2009 O
human O
pandemic O
virus O
results O
in O
a O
virus O
that O
replicates O
at O
high O
levels O
and O
causes O
significant O
lesions O
. O

The O
influenza O
A O
virus O
nuclear B
export I
protein I
( I
NEP I
) I
plays O
crucial O
roles O
in O
the O
nuclear O
export O
of O
the O
viral O
ribonucleoprotein O
complex O
through O
the O
Chromosome B
region I
maintenance I
1 I
( I
CRM1 I
) I
- O
mediated O
cellular O
protein O
transport O
system O
. O

Here O
, O
we O
investigated O
the O
subcellular O
localization O
of O
NEP O
from O
two O
strains O
of O
H1N1 O
influenza O
A O
virus O
and O
found O
that O
2009 O
swine O
- O
origin O
H1N1 O
influenza O
A O
virus O
A O
/ O
California O
/ O
04 O
/ O
2009 O
( O
CA04 O
) O
NEP O
displayed O
a O
distinct O
cellular O
distribution O
pattern O
, O
forming O
unique O
nuclear O
aggregates O
, O
compared O
to O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
( O
WSN O
) O
NEP O
. O

The O
two O
identified O
nuclear B
export I
signals I
( I
NESs I
) I
on O
the O
two O
NEPs O
functioned O
similarly O
despite O
differences O
in O
their O
amino O
acid O
sequences O
. O

The O
present O
study O
revealed O
the O
dissimilarity O
in O
subcellular O
NEP O
transport O
processes O
between O
the O
2009 O
pandemic O
( O
H1N1 O
) O
influenza O
A O
virus O
CA04 O
and O
the O
laboratory O
- O
adapted O
H1N1 O
virus O
WSN O
and O
uncovered O
the O
mechanism O
responsible O
for O
this O
difference O
. O

To O
address O
this O
we O
analyzed O
the O
biological O
characteristics O
, O
pathogenicity O
, O
and O
transmissibility O
of O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
virus O
and O
variants O
in O
vitro O
and O
in O
vivo O
using O
a O
synthetically O
created O
wild O
- O
type O
virus O
( O
rAnhui O
- O
WT O
) O
and O
two O
mutants O
( O
rAnhui O
- O
HA O
- O
226Q O
and O
rAnhui O
- O
PB2 O
- O
627E O
) O
. O

IMPORTANCE O
The O
genomes O
of O
the O
zoonotic O
avian O
H7N9 O
viruses O
emerging O
in O
China O
have O
mutations O
in O
critical O
genes O
( O
PB2 O
- O
E627K O
and O
HA O
- O
Q226L O
) O
that O
may O
be O
important O
in O
their O
pandemic O
potential O
. O

This O
study O
shows O
that O
( O
i O
) O
HA O
- O
226L O
of O
zoonotic O
H7N9 O
strains O
is O
critical O
for O
binding O
the O
alpha O
- O
2 O
, O
6 O
- O
linked O
receptor O
and O
enables O
transmission O
in O
pigs O
; O
( O
ii O
) O
wild O
- O
type O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
( O
H7N9 O
) O
shows O
modest O
replication O
, O
virulence O
, O
and O
transmissibility O
in O
pigs O
, O
suggesting O
that O
it O
is O
not O
well O
adapted O
to O
the O
mammalian O
host O
; O
and O
( O
iii O
) O
both O
wild O
- O
type O
and O
variant O
H7N9 O
viruses O
rapidly O
develop O
additional O
mammalian O
- O
signature O
mutations O
in O
pigs O
, O
indicating O
that O
they O
represent O
an O
important O
potential O
intermediate O
host O
. O

The O
Hemagglutinin B
( I
HA I
) I
protein O
is O
the O
primary O
target O
of O
protective O
immune O
responses O
and O
the O
major O
component O
in O
swine O
influenza O
A O
vaccines O
. O

hemagglutination B
inhibition I
( I
HI I
) I
assay O
data O
for O
swine O
and O
human O
H3N2 O
viruses O
were O
used O
with O
antigenic O
cartography O
to O
quantify O
the O
antigenic O
differences O
among O
H3N2 O
viruses O
isolated O
from O
pigs O
in O
the O
United O
States O
from O
1998 O
to O
2013 O
and O
the O
relative O
cross O
- O
reactivity O
between O
these O
viruses O
and O
current O
human O
seasonal O
influenza O
A O
virus O
strains O
. O

We O
examined O
the O
molecular O
basis O
of O
virulence O
of O
pandemic O
H1N1 O
/ O
09 O
influenza O
viruses O
by O
reverse O
genetics O
based O
on O
two O
H1N1 O
/ O
09 O
virus O
isolates O
( O
A O
/ O
California O
/ O
04 O
/ O
2009 O
[ O
CA04 O
] O
and O
A O
/ O
swine O
/ O
Shandong O
/ O
731 O
/ O
2009 O
[ O
SD731 O
] O
) O
with O
contrasting O
pathogenicities O
in O
mice O
. O

We O
found O
that O
four O
amino O
acid O
mutations O
( O
P224S O
in O
the O
PA O
protein O
[ O
PA O
- O
P224S O
] O
, O
PB2 O
- O
T588I O
, O
NA O
- O
V106I O
, O
and O
NS1 O
- O
I123V O
) O
contributed O
to O
the O
lethal O
phenotype O
of O
SD731 O
. O

In O
particular O
, O
the O
PA O
- O
P224S O
mutation O
when O
combined O
with O
PA O
- O
A70V O
in O
CA04 O
drastically O
reduced O
the O
virus O
' O
s O
50 O
% O
mouse O
lethal B
dose I
( I
LD50 I
) I
, O
by O
almost O
1 O
, O
000 O
- O
fold O
. O

Three O
reassortant O
cold B
- I
adapted I
( I
ca I
) I
H2 O
pandemic O
influenza O
vaccine O
candidates O
with O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
genes O
derived O
from O
the O
wildtype O
A O
/ O
Japan O
/ O
305 O
/ O
1957 O
( O
H2N2 O
) O
( O
Jap O
/ O
57 O
) O
, O
A O
/ O
mallard O
/ O
6750 O
/ O
1978 O
( O
H2N2 O
) O
( O
mal O
/ O
78 O
) O
, O
or O
A O
/ O
swine O
/ O
MO O
/ O
4296424 O
/ O
2006 O
( O
H2N3 O
) O
( O
sw O
/ O
06 O
) O
viruses O
and O
the O
internal O
protein O
gene O
segments O
from O
the O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
ca O
virus O
were O
generated O
by O
plasmid O
- O
based O
reverse O
genetics O
( O
Jap O
/ O
57 O
ca O
, O
mal O
/ O
78 O
ca O
, O
and O
sw O
/ O
06 O
ca O
, O
respectively O
) O
. O

Since O
neutralizing O
antibodies O
to O
the O
Hemagglutinin B
( I
HA I
) I
globular O
head O
domain O
of O
the O
virus O
are O
virtually O
absent O
in O
the O
human O
population O
, O
there O
is O
interest O
in O
identifying O
other O
correlates O
of O
protection O
, O
such O
as O
cross O
- O
reactive O
CD8 O
( O
+ O
) O
T O
cells O
( O
cytotoxic O
T O
lymphocytes O
[ O
CTLs O
] O
) O
elicited O
during O
seasonal O
influenza O
A O
virus O
infections O
. O

These O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
known O
to O
recognize O
conserved O
internal O
proteins O
of O
influenza O
A O
viruses O
predominantly O
, O
but O
it O
is O
unknown O
to O
what O
extent O
they O
cross O
- O
react O
with O
the O
newly O
emerging O
H7N9 O
virus O
. O

Here O
, O
we O
assessed O
the O
cross O
- O
reactivity O
of O
seasonal O
H3N2 O
and O
H1N1 O
and O
pandemic O
H1N1 O
influenza O
A O
virus O
- O
specific O
polyclonal O
CD8 O
( O
+ O
) O
T O
cells O
, O
obtained O
from O
HLA O
- O
typed O
study O
subjects O
, O
with O
the O
novel O
H7N9 O
virus O
. O

The O
cross O
- O
reactivity O
of O
CD8 O
( O
+ O
) O
T O
cells O
to O
H7N9 O
variants O
of O
known O
influenza O
A O
virus O
epitopes O
and O
H7N9 O
virus O
- O
infected O
cells O
was O
determined O
by O
their O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
response O
and O
lytic O
activity O
. O

It O
was O
concluded O
that O
, O
apart O
from O
recognition O
of O
individual O
H7N9 O
variant O
epitopes O
, O
CD8 O
( O
+ O
) O
T O
cells O
to O
seasonal O
influenza O
viruses O
display O
considerable O
cross O
- O
reactivity O
with O
the O
novel O
H7N9 O
virus O
. O

The O
presence O
of O
these O
cross O
- O
reactive O
CD8 O
( O
+ O
) O
T O
cells O
may O
afford O
some O
protection O
against O
infection O
with O
the O
new O
virus O
. O

The O
2009 O
pandemic O
H1N1 O
influenza O
virus O
( O
pdm O
/ O
09 O
) O
is O
typically O
mildly O
virulent O
in O
mice O
. O

To O
investigate O
whether O
the O
PB2 O
with O
the O
T5581 O
mutation O
( O
PB2 O
- O
T558I O
) O
has O
an O
effect O
on O
the O
increased O
pathogenicity O
, O
we O
rescued O
a O
variant O
containing O
PB2 O
- O
588I O
( O
Mex_PB2 O
- O
588I O
) O
in O
the O
pdm O
/ O
09 O
virus O
, O
A O
/ O
Mexico O
/ O
4486 O
/ O
2009 O
( O
H1N1 O
) O
, O
referred O
to O
as O
Mex_WT O
( O
where O
WT O
is O
wild O
type O
) O
, O
and O
characterized O
the O
variant O
in O
vitro O
and O
in O
vivo O
. O

We O
determined O
that O
the O
mutation O
exacerbated O
PB2 O
inhibition O
of O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
- O
mediated O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
, O
and O
PB2 O
- O
588I O
was O
observed O
to O
bind O
to O
MAVS O
more O
efficiently O
than O
PB2 O
- O
588T O
. O

Influenza O
H3N2 O
A O
viruses O
continue O
to O
circulate O
in O
swine O
and O
occasionally O
infect O
humans O
, O
resulting O
in O
outbreaks O
of O
variant O
influenza O
H3N2 O
[ O
A O
( O
H3N2 O
) O
v O
] O
virus O
. O

It O
has O
been O
previously O
demonstrated O
in O
ferrets O
that O
A O
( O
H3N2 O
) O
v O
viruses O
transmit O
as O
efficiently O
as O
seasonal O
influenza O
viruses O
, O
raising O
concern O
over O
the O
pandemic O
potential O
of O
these O
viruses O
. O

However O
, O
A O
( O
H3N2 O
) O
v O
viruses O
have O
not O
acquired O
the O
ability O
to O
transmit O
efficiently O
among O
humans O
, O
which O
may O
be O
due O
in O
part O
to O
existing O
cross O
- O
reactive O
immunity O
to O
A O
( O
H3N2 O
) O
v O
viruses O
. O

Although O
current O
seasonal O
H3N2 O
and O
A O
( O
H3N2 O
) O
v O
viruses O
are O
antigenically O
distinct O
from O
one O
another O
, O
historical O
H3N2 O
viruses O
have O
some O
antigenic O
similarity O
to O
A O
( O
H3N2 O
) O
v O
viruses O
and O
previous O
exposure O
to O
these O
viruses O
may O
provide O
a O
measure O
of O
immune O
protection O
sufficient O
to O
dampen O
A O
( O
H3N2 O
) O
v O
virus O
transmission O
. O

Here O
, O
we O
evaluated O
whether O
prior O
seasonal O
H3N2 O
influenza O
virus O
vaccination O
or O
infection O
affects O
virus O
replication O
and O
transmission O
of O
A O
( O
H3N2 O
) O
v O
virus O
in O
the O
ferret O
animal O
model O
. O

We O
found O
that O
the O
seasonal O
trivalent O
inactivated O
influenza O
virus O
vaccine O
( O
TIV O
) O
or O
a O
monovalent O
vaccine O
prepared O
from O
an O
antigenically O
related O
1992 O
seasonal O
influenza O
H3N2 O
( O
A O
/ O
Beijing O
/ O
32 O
/ O
1992 O
) O
virus O
failed O
to O
substantially O
reduce O
A O
( O
H3N2 O
) O
v O
( O
A O
/ O
Indiana O
/ O
08 O
/ O
2011 O
) O
virus O
shedding O
and O
subsequent O
transmission O
to O
naive O
hosts O
. O

Conversely O
, O
ferrets O
primed O
by O
seasonal O
H3N2 O
virus O
infection O
displayed O
reduced O
A O
( O
H3N2 O
) O
v O
virus O
shedding O
following O
challenge O
, O
which O
blunted O
transmission O
to O
naive O
ferrets O
. O

The O
data O
demonstrate O
in O
ferrets O
that O
the O
efficiency O
of O
A O
( O
H3N2 O
) O
v O
transmission O
is O
disrupted O
by O
preexisting O
immunity O
induced O
by O
seasonal O
H3N2 O
virus O
infection O
. O

Pigs O
are O
an O
important O
intermediate O
host O
for O
influenza O
; O
thus O
, O
we O
assessed O
the O
replication O
ability O
of O
three O
human O
H7N9 O
viruses O
( O
A O
/ O
Anhui O
/ O
1 O
/ O
2013 O
, O
A O
/ O
Shanghai O
/ O
1 O
/ O
2013 O
, O
A O
/ O
Shanghai O
/ O
2 O
/ O
2013 O
) O
in O
swine O
tissue O
explants O
. O

We O
previously O
reported O
that O
influenza O
A O
/ O
swine O
/ O
Korea O
/ O
1204 O
/ O
2009 O
( O
H1N2 O
) O
virus O
was O
virulent O
and O
transmissible O
in O
ferrets O
in O
which O
the O
respiratory O
- O
droplet O
- O
transmissible O
virus O
( O
CT O
- O
Sw O
/ O
1204 O
) O
had O
acquired O
simultaneous O
hemagglutinin O
( O
HA O
( O
D225G O
) O
) O
and O
neuraminidase O
( O
NA O
( O
S315N O
) O
) O
mutations O
. O

Incorporating O
these O
mutations O
into O
the O
nonpathogenic O
A O
/ O
swine O
/ O
Korea O
/ O
1130 O
/ O
2009 O
( O
H1N2 O
, O
Sw O
/ O
1130 O
) O
virus O
consequently O
altered O
pathogenicity O
and O
growth O
in O
animal O
models O
but O
could O
not O
establish O
efficient O
transmission O
or O
noticeable O
disease O
. O

In O
ferrets O
, O
homologous O
expression O
of O
viral O
RNA O
polymerase O
complex O
genes O
in O
the O
context O
of O
the O
mutant O
Sw O
/ O
1130 O
carrying O
the O
HA O
( O
225G O
) O
and O
NA O
( O
315N O
) O
modifications O
induced O
optimal O
replication O
in O
the O
upper O
nasal O
and O
lower O
respiratory O
tracts O
and O
also O
promoted O
efficient O
aerosol O
transmission O
to O
respiratory O
droplet O
contact O
ferrets O
. O

Our O
findings O
may O
help O
elucidate O
previously O
undefined O
viral O
factors O
that O
could O
expand O
the O
host O
range O
and O
disease O
severity O
induced O
by O
triple O
- O
reassortant O
swine O
viruses O
, O
including O
the O
A O
( O
H1N1 O
) O
pdm09 O
virus O
, O
and O
therefore O
further O
justify O
the O
ongoing O
development O
of O
novel O
antiviral O
drugs O
targeting O
the O
viral O
polymerase O
complex O
subunits O
. O

Previous O
structural O
studies O
suggest O
that O
the O
group O
specific O
252 O
residue O
( O
Y252 O
in O
group O
1 O
and O
T252 O
in O
group O
2 O
) O
might O
be O
a O
key O
factor O
underlying O
H274Y O
resistance O
. O

Comparative O
structural O
analysis O
of O
N3 O
, O
N1 O
, O
and O
their O
274Y O
variants O
indicates O
that O
the O
interaction O
of O
residue O
296 O
( O
H O
in O
N1 O
and O
nonaromatic O
for O
other O
serotypes O
) O
with O
conserved O
W295 O
is O
another O
important O
determinant O
of O
oseltamivir O
resistance O
. O

swine B
influenza I
virus I
( I
SIV I
) I
infections O
continue O
to O
cause O
production O
losses O
in O
the O
agricultural O
industry O
in O
addition O
to O
being O
a O
human O
public O
health O
concern O
. O

Live B
attenuated I
influenza I
vaccines I
( I
LAIV I
) I
provide O
strong O
, O
long O
- O
lived O
cell O
- O
mediated O
and O
humoral O
immunity O
against O
different O
influenza O
virus O
subtypes O
with O
no O
need O
for O
antigen O
matching O
. O

Here O
we O
report O
the O
generation O
of O
a O
new O
potential O
LAIV O
, O
an O
eight O
- O
segment O
SIV O
harboring O
two O
different O
SIV O
hemagglutinins B
( I
HAs I
) I
, O
H1 O
and O
H3 O
, O
in O
the O
genetic O
background O
of O
H1N1 O
SIV O
. O

This O
mutant O
SIV O
was O
generated O
by O
fusing O
the O
H3 O
HA O
ectodomain O
from O
A O
/ O
Swine O
/ O
Texas O
/ O
4199 O
- O
2 O
/ O
98 O
( O
H3N2 O
) O
to O
the O
cytoplasmic O
tail O
, O
transmembrane O
domain O
, O
and O
stalk O
region O
of O
neuraminidase B
( I
NA I
) I
from O
A O
/ O
Swine O
/ O
Saskatchewan O
/ O
18789 O
/ O
02 O
( O
H1N1 O
) O
SIV O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
commercial O
inactivated O
swine O
influenza B
A I
virus I
( I
IAV I
) I
vaccines O
and O
experimental O
live B
attenuated I
influenza I
virus I
( I
LAIV I
) I
vaccines O
against O
infection O
with O
H3N2 O
virus O
and O
subsequent O
indirect O
transmission O
to O
naive O
pigs O
. O

Interspecies O
transmission O
( O
host O
switching O
/ O
jumping O
) O
of O
influenza O
viruses O
is O
a O
key O
scientific O
question O
that O
must O
be O
addressed O
. O

In O
addition O
to O
the O
vigorous O
research O
on O
highly B
pathogenic I
avian I
influenza I
viruses I
( I
HPAIVs I
) I
, O
studies O
of O
the O
mechanism O
of O
interspecies O
transmission O
of O
low B
- I
pathogenic I
avian I
influenza I
viruses I
( I
LPAIVs I
) I
could O
also O
provide O
insights O
into O
host O
tropism O
and O
virulence O
evolution O
. O

Influenza O
A O
viruses O
harboring O
Hemagglutinin B
( I
HA I
) I
H13 O
( O
e O
. O

Since O
the O
1918 O
influenza O
A O
pandemic O
, O
human O
H1N1 O
viruses O
had O
acquired O
additional O
N B
- I
linked I
glycosylation I
( I
NLG I
) I
sites O
within O
the O
globular O
head O
region O
of O
Hemagglutinin B
( I
HA I
) I
until O
the O
NLG O
- O
free O
HA O
head O
pattern O
of O
the O
1918 O
H1N1 O
virus O
was O
renewed O
with O
the O
swine O
- O
derived O
2009 O
pandemic O
H1N1 O
virus O
. O

The O
demonstrated O
link O
between O
the O
emergence O
of O
H3N2 B
variant I
( I
H3N2v I
) I
influenza I
A I
viruses I
( I
IAVs I
) I
and O
swine O
exposure O
at O
agricultural O
fairs O
has O
raised O
concerns O
about O
the O
human O
health O
risk O
posed O
by O
IAV O
- O
infected O
swine O
. O

Here O
, O
68 O
H3N2 O
IAV O
isolates O
recovered O
from O
pigs O
at O
Ohio O
fairs O
( O
2009 O
to O
2011 O
) O
were O
antigenically O
characterized O
. O

Antigenic O
cartography O
demonstrated O
that O
H3N2 O
IAV O
isolates O
from O
Ohio O
fairs O
could O
be O
divided O
into O
two O
antigenic O
groups O
: O
( O
i O
) O
the O
2009 O
fair O
isolates O
and O
( O
ii O
) O
the O
2010 O
and O
2011 O
fair O
isolates O
. O

We O
report O
that O
swine O
influenza O
virus O
- O
like O
substitutions O
T200A O
and O
E227A O
in O
the O
Hemagglutinin B
( I
HA I
) I
of O
the O
2009 O
pandemic O
influenza O
virus O
alter O
its O
pathogenesis O
and O
transmission O
. O

Influenza O
A O
virus O
uses O
sialic O
acids O
as O
cell O
entry O
receptors O
, O
and O
there O
are O
two O
main O
receptor O
forms O
, O
alpha O
2 O
, O
6 O
linkage O
or O
alpha O
2 O
, O
3 O
linkage O
to O
galactose O
, O
that O
determine O
virus O
host O
ranges O
( O
mammalian O
or O
avian O
) O
. O

The O
receptor O
binding O
hemagglutinins B
( I
HAs I
) I
of O
both O
1918 O
and O
2009 O
pandemic O
H1N1 O
( O
18H1 O
and O
09H1 O
, O
respectively O
) O
influenza O
A O
viruses O
preferentially O
bind O
to O
the O
human O
alpha O
2 O
, O
6 O
linkage O
receptor O
. O

A O
novel O
swine O
- O
origin O
H1N1 O
influenza O
virus O
[ O
A O
( O
H1N1 O
) O
pdm09 O
virus O
] O
caused O
the O
2009 O
influenza O
pandemic O
. O

To O
better O
understand O
the O
mechanism O
of O
pathogenicity O
of O
the O
A O
( O
H1N1 O
) O
pdm09 O
virus O
, O
here O
, O
we O
compared O
five O
viruses O
that O
are O
genetically O
similar O
but O
were O
isolated O
from O
patients O
with O
either O
severe O
or O
mild O
symptoms O
. O

In O
a O
mouse O
model O
, O
A O
/ O
Norway O
/ O
3487 O
/ O
2009 O
( O
Norway3487 O
) O
virus O
exhibited O
greater O
pathogenicity O
than O
did O
A O
/ O
Osaka O
/ O
164 O
/ O
2009 O
( O
Osaka164 O
) O
virus O
. O

By O
exploiting O
reassortant O
viruses O
between O
these O
two O
viruses O
, O
we O
found O
that O
viruses O
possessing O
the O
Hemagglutinin B
( I
HA I
) I
gene O
of O
Norway3487 O
in O
the O
genetic O
background O
of O
Osaka164 O
were O
more O
pathogenic O
in O
mice O
than O
other O
reassortant O
viruses O
, O
indicating O
a O
role O
for O
HA O
in O
the O
high O
virulence O
of O
Norway3487 O
virus O
. O

These O
findings O
demonstrate O
that O
reassortment O
between O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
can O
lead O
to O
increased O
pathogenicity O
and O
highlight O
the O
need O
for O
continued O
surveillance O
of O
A O
( O
H1N1 O
) O
pdm09 O
viruses O
. O

The O
recent O
increase O
in O
human O
cases O
of O
influenza O
A O
H3N2 O
variant O
virus O
[ O
A O
( O
H3N2 O
) O
v O
] O
highlights O
the O
need O
to O
assess O
whether O
seasonal O
influenza O
vaccination O
provides O
cross O
- O
protection O
against O
A O
( O
H3N2 O
) O
v O
virus O
. O

Our O
data O
demonstrate O
that O
the O
2011 O
- O
2012 O
trivalent B
inactivated I
influenza I
vaccine I
( I
TIV I
) I
protected O
ferrets O
against O
homologous O
H3N2 O
virus O
challenge O
but O
provided O
minimal O
to O
no O
protection O
against O
A O
( O
H3N2 O
) O
v O
virus O
. O

The O
complete O
absence O
of O
specific O
hemagglutination O
inhibition O
antibody O
response O
to O
A O
( O
H3N2 O
) O
v O
is O
consistent O
with O
the O
poor O
cross O
- O
protection O
observed O
among O
TIV O
- O
immune O
animals O
. O

Compensatory O
mutations O
contribute O
to O
the O
appearance O
of O
the O
oseltamivir O
resistance O
substitution O
H274Y O
in O
the O
neuraminidase B
( I
NA I
) I
gene O
of O
H1N1 O
influenza O
viruses O
. O

We O
found O
four O
mutations O
that O
can O
either O
fully O
( O
R194G O
, O
E214D O
) O
or O
partially O
( O
L250P O
, O
F239Y O
) O
compensate O
for O
the O
fitness O
deficiency O
of O
the O
H274Y O
mutant O
. O

polymerase B
basic I
protein I
2 I
( I
PB2 I
) I
and O
nucleoprotein B
( I
NP I
) I
were O
suggested O
to O
be O
the O
possible O
target O
of O
Mx1 O
, O
but O
a O
direct O
interaction O
between O
Mx1 O
and O
any O
of O
the O
viral O
proteins O
has O
not O
been O
reported O
. O

With O
a O
new O
serotype O
( O
H17 O
) O
of O
Hemagglutinin B
( I
HA I
) I
recently O
being O
discovered O
, O
there O
are O
now O
17 O
serotypes O
( O
H1 O
to O
H17 O
) O
of O
influenza O
A O
viruses O
in O
total O
. O

Here O
, O
the O
crystal O
structures O
of O
H16 O
( O
a O
low O
- O
pathogenicity O
avian O
influenza O
virus O
) O
in O
their O
HA0 O
form O
( O
H16HA0 O
) O
have O
been O
solved O
at O
1 O
. O

Lack O
of O
a O
universal O
vaccine O
against O
all O
serotypes O
of O
influenza O
A O
viruses O
and O
recent O
progress O
on O
T O
cell O
- O
related O
vaccines O
against O
influenza O
A O
virus O
illuminate O
the O
important O
role O
of O
human B
leukocyte I
antigen I
( I
HLA I
) I
- O
restricted O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
in O
anti O
- O
influenza O
virus O
immunity O
. O

Here O
, O
we O
evaluated O
the O
2009 O
pandemic O
influenza O
A O
( O
H1N1 O
) O
virus O
- O
specific O
T O
cell O
responses O
among O
the O
HLA O
- O
A24 O
( O
+ O
) O
population O
using O
a O
rationally O
designed O
peptide O
pool O
during O
the O
2009 O
pandemic O
. O

Unexpectedly O
, O
cross O
- O
HLA O
allele O
T O
cell O
responses O
against O
the O
influenza O
A O
virus O
peptides O
were O
detected O
among O
both O
HLA O
- O
A11 O
( O
+ O
) O
and O
HLA O
- O
A24 O
( O
+ O
) O
donors O
. O

Furthermore O
, O
we O
found O
cross O
- O
responses O
in O
the O
entire O
HLA O
- O
A3 O
supertype O
population O
( O
including O
HLA O
- O
A11 O
, O
- O
A31 O
, O
- O
A33 O
, O
and O
- O
A30 O
) O
. O

The O
cross O
- O
allele O
antigenic O
peptides O
within O
the O
peptide O
pool O
were O
identified O
and O
characterized O
, O
and O
the O
crystal O
structures O
of O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
- O
peptide O
complexes O
were O
determined O
. O

The O
subsequent O
HLA O
- O
A24 O
- O
defined O
cross O
- O
allele O
peptides O
recognized O
by O
the O
HLA O
- O
A11 O
( O
+ O
) O
population O
were O
shown O
to O
mildly O
bind O
to O
the O
HLA O
- O
A O
* O
1101 O
molecule O
. O

PA O
- O
X O
is O
a O
fusion O
protein O
of O
influenza O
A O
virus O
encoded O
in O
part O
from O
a O
+ O
1 O
frameshifted O
X B
open I
reading I
frame I
( I
X I
- I
ORF I
) I
in O
segment O
3 O
. O

The O
H275Y O
neuraminidase B
( I
NA I
) I
mutation O
, O
which O
confers O
resistance O
to O
oseltamivir O
carboxylate O
, O
has O
been O
identified O
among O
the O
seasonal O
H1N1 O
and O
2009 O
pandemic O
influenza O
viruses O
; O
however O
, O
those O
H275Y O
resistant O
variants O
demonstrated O
distinct O
epidemiological O
outcomes O
in O
humans O
. O

Here O
, O
we O
systematically O
analyze O
the O
effect O
of O
the O
H275Y O
NA O
mutation O
on O
viral O
fitness O
and O
transmissibility O
of O
A O
( O
H1N1 O
) O
pdm09 O
and O
seasonal O
H1N1 O
influenza O
viruses O
. O

The O
NA O
genes O
from O
A O
( O
H1N1 O
) O
pdm09 O
A O
/ O
California O
/ O
04 O
/ O
09 O
( O
CA04 O
) O
, O
seasonal O
H1N1 O
A O
/ O
New O
Caledonia O
/ O
20 O
/ O
1999 O
( O
NewCal O
) O
, O
and O
A O
/ O
Brisbane O
/ O
59 O
/ O
2007 O
( O
Brisbane O
) O
were O
individually O
introduced O
into O
the O
genetic O
background O
of O
CA04 O
. O

Attenuated O
pathogenicity O
in O
both O
RG O
- O
CA04 O
( O
NA O
- O
H275Y O
) O
and O
RG O
- O
CA04 O
x O
Brisbane O
( O
NA O
- O
H275Y O
) O
viruses O
was O
observed O
in O
ferrets O
compared O
to O
RG O
- O
CA04 O
virus O
, O
although O
the O
transmissibility O
was O
minimally O
affected O
. O

In O
parallel O
experiments O
using O
recombinant O
Brisbane O
viruses O
differing O
by O
hemagglutinin O
and O
NA O
, O
comparable O
direct O
contact O
and O
respiratory O
droplet O
transmissibilities O
were O
observed O
among O
RG O
- O
NewCal O
( O
HA O
, O
NA O
) O
, O
RG O
- O
NewCal O
( O
HA O
, O
NA O
- O
H275Y O
) O
, O
RG O
- O
Brisbane O
( O
HA O
, O
NA O
- O
H275Y O
) O
, O
and O
RG O
- O
NewCal O
( O
HA O
) O
x O
Brisbane O
( O
NA O
- O
H275Y O
) O
viruses O
. O

Control O
of O
swine O
influenza B
A I
virus I
( I
IAV I
) I
in O
the O
United O
States O
is O
hindered O
because O
inactivated O
vaccines O
do O
not O
provide O
robust O
cross O
- O
protection O
against O
the O
multiple O
antigenic O
variants O
cocirculating O
in O
the O
field O
. O

We O
previously O
demonstrated O
that O
a O
recombinant O
A O
/ O
sw O
/ O
Texas O
/ O
4199 O
- O
2 O
/ O
1998 O
( O
TX98 O
) O
( O
H3N2 O
) O
virus O
expressing O
a O
truncated O
NS1 O
protein O
is O
attenuated O
in O
swine O
and O
has O
potential O
for O
use O
as O
an O
intranasal O
live B
attenuated I
influenza I
virus I
( I
LAIV I
) I
vaccine O
. O

In O
the O
present O
study O
, O
we O
compared O
1 O
dose O
of O
intranasal O
LAIV O
with O
2 O
intramuscular O
doses O
of O
TX98 O
whole B
inactivated I
virus I
( I
WIV I
) I
with O
adjuvant O
in O
weanling O
pigs O
with O
and O
without O
TX98 O
- O
specific O
maternally B
derived I
antibodies I
( I
MDA I
) I
. O

Pigs O
were O
subsequently O
challenged O
with O
wild O
- O
type O
homologous O
TX98 O
H3N2 O
virus O
or O
with O
an O
antigenic O
variant O
, O
A O
/ O
sw O
/ O
Colorado O
/ O
23619 O
/ O
1999 O
( O
CO99 O
) O
( O
H3N2 O
) O
. O

In O
the O
absence O
of O
MDA O
, O
both O
vaccines O
protected O
against O
homologous O
TX98 O
and O
heterologous O
CO99 O
shedding O
, O
although O
the O
LAIV O
elicited O
lower O
hemagglutination B
inhibition I
( I
HI I
) I
antibody O
titers O
in O
serum O
. O

The O
efficacy O
of O
both O
vaccines O
was O
reduced O
by O
the O
presence O
of O
MDA O
; O
however O
, O
WIV O
vaccination O
of O
MDA O
- O
positive O
pigs O
led O
to O
dramatically O
enhanced O
pneumonia O
following O
heterologous O
challenge O
, O
a O
phenomenon O
known O
as O
vaccine B
- I
associated I
enhanced I
respiratory I
disease I
( I
VAERD I
) I
. O

Here O
, O
we O
show O
that O
an O
amino O
acid O
in O
Hemagglutinin B
( I
HA I
) I
is O
important O
for O
the O
2009 O
H1N1 O
influenza O
pandemic O
virus O
( O
2009 O
/ O
H1N1 O
) O
to O
bind O
to O
human O
virus O
receptors O
and O
confer O
respiratory O
droplet O
transmissibility O
in O
mammals O
. O

We O
found O
that O
the O
change O
from O
Glutamine B
( I
Q I
) I
to O
Arginine B
( I
R I
) I
at O
position O
226 O
of O
HA O
, O
which O
causes O
a O
switch O
in O
receptor O
- O
binding O
preference O
from O
human O
alpha O
- O
2 O
, O
6 O
to O
avian O
alpha O
- O
2 O
, O
3 O
sialic O
acid O
, O
resulted O
in O
a O
virus O
incapable O
of O
respiratory O
droplet O
transmission O
in O
guinea O
pigs O
and O
reduced O
the O
virus O
' O
s O
ability O
to O
replicate O
in O
the O
lungs O
of O
ferrets O
. O

The O
change O
from O
Alanine B
( I
A I
) I
to O
threonine B
( I
T I
) I
at O
position O
271 O
of O
PB2 O
also O
abolished O
the O
virus O
' O
s O
respiratory O
droplet O
transmission O
in O
guinea O
pigs O
, O
and O
this O
mutation O
, O
together O
with O
the O
HA O
Q226R O
mutation O
, O
abolished O
the O
virus O
' O
s O
respiratory O
droplet O
transmission O
in O
ferrets O
. O

Specifically O
, O
these O
studies O
have O
incorporated O
isogenic O
viruses O
that O
differ O
in O
the O
PB1 O
- O
F2 O
expressed O
, O
but O
there O
is O
still O
knowledge O
to O
be O
gained O
from O
evaluation O
of O
natural O
variants O
derived O
from O
a O
nonhuman O
host O
species O
( O
swine O
) O
. O

We O
surveyed O
swine O
progenitors O
and O
human O
viruses O
from O
the O
2009 O
pandemic O
and O
measured O
the O
activities O
of O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
, O
which O
are O
the O
two O
viral O
surface O
proteins O
that O
interact O
with O
host O
glycan O
receptors O
. O

A O
functional O
balance O
of O
these O
two O
activities O
( O
HA O
binding O
and O
NA O
cleavage O
) O
is O
found O
in O
human O
viruses O
but O
not O
in O
the O
swine O
progenitors O
. O

Compared O
to O
seasonal O
influenza O
viruses O
, O
The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
virus O
caused O
greater O
morbidity O
and O
mortality O
in O
children O
and O
young O
adults O
. O

To O
define O
the O
basis O
for O
this O
cross O
- O
reactivity O
, O
ferrets O
were O
infected O
with O
H1N1 O
viruses O
of O
variable O
antigenic O
distance O
that O
circulated O
during O
different O
decades O
from O
the O
1930s O
( O
Alaska O
/ O
35 O
) O
, O
1940s O
( O
Fort O
Monmouth O
/ O
47 O
) O
, O
1950s O
( O
Fort O
Warren O
/ O
50 O
) O
, O
and O
1990s O
( O
New O
Caledonia O
/ O
99 O
) O
and O
challenged O
with O
2009 O
pH1N1 O
virus O
6 O
weeks O
later O
. O

Ferrets O
primed O
with O
the O
homologous O
CA O
/ O
09 O
or O
New O
Jersey O
/ O
76 O
( O
NJ O
/ O
76 O
) O
virus O
served O
as O
a O
positive O
control O
, O
while O
the O
negative O
control O
was O
an O
influenza O
B O
virus O
that O
should O
not O
cross O
- O
protect O
against O
influenza O
A O
virus O
infection O
. O

The O
hemagglutinins B
( I
HAs I
) I
of O
AK O
/ O
35 O
, O
FM O
/ O
47 O
, O
and O
FW O
/ O
50 O
differ O
in O
the O
presence O
of O
glycosylation O
sites O
. O

Novel O
H3N2 O
influenza O
viruses O
( O
H3N2v O
) O
containing O
seven O
genome O
segments O
from O
swine O
lineage O
triple O
- O
reassortant O
H3N2 O
viruses O
and O
a O
2009 O
pandemic O
H1N1 O
( O
H1N1 O
pdm09 O
) O
matrix O
protein O
segment O
( O
pM O
) O
were O
isolated O
from O
12 O
humans O
in O
the O
United O
States O
between O
August O
and O
December O
2011 O
. O

We O
identified O
34 O
swine O
influenza O
viruses O
( O
termed O
rH3N2p O
) O
with O
the O
same O
combination O
of O
H3 O
, O
N2 O
, O
and O
pM O
segments O
as O
the O
H3N2v O
viruses O
isolated O
from O
humans O
. O

Recent O
studies O
have O
demonstrated O
that O
the O
Hemagglutinin B
( I
HA I
) I
protein O
of O
the O
1918 O
virus O
and O
2009 O
H1N1 O
pandemic O
virus O
[ O
A O
( O
H1N1 O
) O
pdm09 O
] O
, O
the O
latter O
now O
a O
component O
of O
the O
seasonal O
trivalent B
inactivated I
influenza I
vaccine I
( I
TIV I
) I
, O
share O
cross O
- O
reactive O
antigenic O
determinants O
. O

These O
findings O
suggest O
that O
exposure O
to O
A O
( O
H1N1 O
) O
pdm09 O
through O
immunization O
may O
provide O
protection O
against O
the O
reconstructed O
1918 O
virus O
which O
, O
as O
a O
select O
agent O
, O
is O
considered O
to O
pose O
both O
biosafety O
and O
biosecurity O
threats O
. O

The O
progenitor O
epithelial O
colony O
cells O
expressed O
stem O
cell O
markers O
such O
as O
octamer O
binding O
transcription O
factor O
4 O
( O
Oct4 O
) O
and O
stage O
- O
specific O
embryonic O
antigen O
1 O
( O
SSEA O
- O
1 O
) O
, O
as O
well O
as O
the O
epithelial O
markers O
pancytokeratin O
, O
cytokeratin O
- O
18 O
, O
and O
occludin O
, O
but O
not O
mesenchymal O
( O
CD44 O
, O
CD29 O
, O
and O
CD90 O
) O
and O
hematopoietic O
( O
CD45 O
) O
markers O
. O

swine B
influenza I
virus I
( I
SIV I
) I
H3N2 O
with O
triple B
reassorted I
internal I
genes I
( I
TRIG I
) I
has O
been O
enzootic O
in O
Unites O
States O
since O
1998 O
. O

Transmission O
of O
The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
virus O
to O
pigs O
in O
the O
United O
States O
was O
followed O
by O
reassortment O
with O
endemic O
Sly O
, O
resulting O
in O
reassorted O
viruses O
that O
include O
novel O
H3N2 O
genotypes O
( O
rH3N2p O
) O
. O

Between O
July O
and O
December O
2011 O
, O
12 O
cases O
of O
human O
infections O
with O
swine O
- O
lineage O
H3N2 O
viruses O
containing O
the O
pandemic B
matrix I
( I
pM I
) I
gene O
[ O
A O
( O
H3N2 O
) O
v O
] O
were O
detected O
. O

We O
compared O
the O
pathogenic O
, O
transmission O
, O
genetic O
, O
and O
antigenic O
properties O
of O
a O
human O
A O
( O
H3N2 O
) O
v O
isolate O
and O
two O
swine O
H3N2 O
isolates O
, O
H3N2 O
- O
TRIG O
and O
rH3N2p O
. O

Our O
in O
vivo O
study O
detected O
no O
increased O
virulence O
in O
A O
( O
H3N2 O
) O
v O
or O
rH3N2p O
viruses O
compared O
to O
endemic O
H3N2 O
- O
TRIG O
virus O
. O

Antibodies O
to O
cluster O
IV O
H3N2 O
- O
TRIG O
and O
rH3N2p O
viruses O
had O
reduced O
cross O
- O
reactivity O
to O
A O
( O
H3N2 O
) O
v O
compared O
to O
other O
cluster O
IV O
H3N2 O
- O
TRIG O
and O
rH3N2p O
viruses O
. O

Genetic O
analysis O
of O
the O
hemagglutinin O
gene O
indicated O
that O
although O
rH3N2p O
and O
A O
( O
H3N2 O
) O
v O
are O
related O
to O
cluster O
IV O
of O
H3N2 O
- O
TRIG O
, O
some O
recent O
rH3N2p O
isolates O
appeared O
to O
be O
forming O
a O
separate O
cluster O
along O
with O
the O
human O
isolates O
of O
A O
( O
H3N2 O
) O
v O
. O

We O
generated O
five O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
- O
reactive O
human B
monoclonal I
antibodies I
( I
MAbs I
) I
by O
hybridoma O
technology O
from O
the O
peripheral O
blood O
of O
healthy O
donors O
who O
were O
born O
between O
1950 O
and O
1968 O
. O

MAbs O
8M2 O
and O
2G1 O
shared O
the O
V O
( O
H O
) O
1 O
- O
69 O
germ O
line O
gene O
, O
but O
these O
antibodies O
were O
otherwise O
not O
genetically O
related O
. O

Outbreaks O
of O
domestic O
pigs O
infected O
with O
the O
2009 O
pandemic O
H1N1 O
influenza O
virus O
( O
pH1N1 O
) O
have O
been O
detected O
worldwide O
. O

In O
this O
study O
, O
we O
assessed O
whether O
restoring O
the O
full O
- O
length O
PB1 O
- O
F2 O
open B
reading I
frame I
( I
ORF I
) I
in O
the O
pH1N1 O
background O
would O
have O
an O
effect O
on O
virus O
replication O
and O
virulence O
in O
pigs O
. O

There O
was O
an O
increase O
in O
the O
severity O
of O
pneumonia O
in O
pigs O
infected O
with O
isogenic O
virus O
expressing O
PB1 O
- O
F2 O
compared O
to O
the O
wild B
- I
type I
( I
WT I
) I
pH1N1 O
. O

During O
the O
2009 O
HIN1 O
influenza O
virus O
pandemic O
( O
pdmH1N1 O
) O
outbreak O
, O
it O
was O
found O
that O
most O
individuals O
lacked O
antibodies O
against O
the O
new O
pdmH1N1 O
virus O
, O
and O
only O
the O
elderly O
showed O
anti O
- O
hemagglutinin O
( O
anti O
- O
HA O
) O
antibodies O
that O
were O
cross O
- O
reactive O
with O
the O
new O
strains O
. O

In O
this O
study O
, O
we O
have O
found O
that O
a O
first O
infection O
with O
the O
A O
/ O
Brisbane O
/ O
59 O
/ O
2007 O
virus O
strain O
confers O
heterologous O
protection O
in O
ferrets O
and O
mice O
against O
a O
subsequent O
pdmH1N1 O
( O
A O
/ O
Mexico O
/ O
4108 O
/ O
2009 O
) O
virus O
infection O
through O
a O
cross O
- O
reactive O
but O
non O
- O
neutralizing O
antibody O
mechanism O
. O

Heterologous O
immunity O
is O
abrogated O
in O
B O
cell O
- O
deficient O
mice O
but O
maintained O
in O
CD8 O
( O
- O
/ O
- O
) O
and O
perforin O
- O
1 O
( O
- O
/ O
- O
) O
mice O
. O

In O
this O
study O
, O
influenza O
virus B
- I
like I
particles I
( I
VLPs I
) I
were O
engineered O
to O
express O
the O
Hemagglutinin B
( I
HA I
) I
and O
genes O
from O
the O
1918 O
influenza O
virus O
to O
evaluate O
the O
duration O
of O
cross O
- O
protection O
to O
the O
H1N1 O
pandemic O
strain O
by O
vaccinating O
young O
mice O
( O
8 O
to O
12 O
weeks O
) O
and O
then O
allowing O
the O
animals O
to O
age O
to O
20 O
months O
. O

The O
2009 O
pandemic O
influenza O
virus O
( O
pdm O
/ O
09 O
) O
has O
been O
frequently O
introduced O
to O
pigs O
and O
has O
reassorted O
with O
other O
swine O
viruses O
. O

First O
, O
using O
overlapping O
peptide O
libraries O
encompassing O
the O
entire O
translated O
sequences O
of O
5 O
major O
influenza O
virus O
proteins O
, O
we O
assessed O
the O
specificity O
of O
CD4 O
T O
cell O
reactivity O
toward O
epitopes O
conserved O
among O
H1N1 O
viruses O
or O
unique O
to O
the O
seasonal O
or O
pandemic O
strain O
by O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assays O
. O

2 O
and O
C57BL O
/ O
6 O
mice O
generate O
comparable O
humoral O
responses O
upon O
equivalent O
50 B
% I
mouse I
lethal I
dose I
( I
MLD50 I
) I
challenges O
with O
influenza O
virus O
. O

The O
presentation O
of O
viral O
epitopes O
to O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
by O
swine B
leukocyte I
antigen I
class I
I I
( I
SLA I
I I
) I
is O
crucial O
for O
swine O
immunity O
. O

To O
illustrate O
the O
structural O
basis O
of O
swine O
CTL O
epitope O
presentation O
, O
the O
first O
SLA O
crystal O
structures O
, O
SLA O
- O
1 O
* O
0401 O
, O
complexed O
with O
peptides O
derived O
from O
either O
2009 B
pandemic I
H1N1 I
( I
pH1N1 I
) I
swine O
- O
origin O
influenza O
A O
virus O
( O
S O
- O
OIVNW9 O
; O
NSDTVGWSW O
) O
or O
Ebola O
virus O
( O
Ebola O
( O
AY9 O
) O
; O
ATAAATEAY O
) O
were O
determined O
in O
this O
study O
. O

The O
overall O
peptide O
- O
SLA O
- O
1 O
* O
0401 O
structures O
resemble O
, O
as O
expected O
, O
the O
general O
conformations O
of O
other O
structure O
- O
solved O
peptide B
major I
histocompatibility I
complexes I
( I
pMHC I
) I
. O

The O
major O
distinction O
of O
SLA O
- O
1 O
* O
0401 O
is O
that O
Arg O
( O
156 O
) O
has O
a O
one O
- O
ballot O
veto O
function O
in O
peptide O
binding O
, O
due O
to O
its O
flexible O
side O
chain O
. O

Further O
analyses O
showed O
that O
SLA O
- O
1 O
* O
0401 O
and O
human B
leukocyte I
antigen I
( I
HLA I
) I
class O
I O
HLA O
- O
A O
* O
0101 O
can O
present O
the O
same O
peptides O
, O
but O
in O
different O
conformations O
, O
demonstrating O
cross O
- O
species O
epitope O
presentation O
. O

Three O
peptides O
were O
identified O
as O
potential O
cross O
- O
species O
influenza B
virus I
( I
IV I
) I
CTL O
epitopes O
. O

Single O
or O
multiple O
segment O
reassortments O
were O
made O
between O
the O
pandemic O
A O
/ O
California O
/ O
04 O
/ O
09 O
( O
H1N1 O
) O
( O
Cal O
/ O
09 O
) O
virus O
and O
another O
H1N1 O
strain O
, O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
( O
PR8 O
) O
. O

We O
confirmed O
our O
findings O
by O
generating O
recombinant O
A O
/ O
swine O
/ O
Texas O
/ O
1998 O
( O
H3N2 O
) O
( O
sw O
/ O
Tx O
/ O
98 O
) O
virus O
, O
a O
representative O
triple O
- O
reassortant O
swine O
virus O
, O
containing O
segments O
of O
the O
Cal O
/ O
09 O
virus O
. O

The B
2009 I
pandemic I
H1N1 I
( I
pH1N1 I
) I
, O
of O
apparent O
swine O
origin O
, O
may O
have O
evolved O
in O
pigs O
unnoticed O
because O
of O
insufficient O
surveillance O
. O

Isolates O
from O
May O
2009 O
were O
comprised O
of O
hemagglutinin O
and O
neuraminidase B
( I
NA I
) I
genes O
of O
classical O
SIV O
origin O
in O
combination O
with O
the O
North O
American O
triple B
- I
reassortant I
internal I
gene I
( I
TRIG I
) I
cassette O
, O
here O
termed O
contemporary B
SIV I
( I
conSIV I
) I
H1N1 O
. O

The O
NS O
gene O
of O
one O
of O
these O
seasonal B
human I
- I
like I
SIV I
( I
shSIV I
) I
H1N1 O
isolates O
was O
homologous O
to O
pH1N1 O
NS O
, O
implicating O
reassortment O
between O
the O
two O
strains O
. O

Here O
, O
using O
reverse O
genetics O
and O
a O
replicon O
assay O
, O
we O
demonstrated O
that O
a O
mixed O
polymerase O
complex O
containing O
a O
pandemic O
( O
H1N1 O
) O
2009 O
influenza O
virus O
PB2 O
on O
a O
seasonal O
H1N1 O
virus O
background O
has O
reduced O
polymerase O
activity O
, O
leading O
to O
impaired O
virus O
viability O
. O

Virus O
replication O
and O
pulmonary O
disease O
pathogenesis O
in O
ferrets O
following O
intranasal O
infection O
with O
a O
pandemic O
influenza O
virus O
strain O
( O
A O
/ O
California O
/ O
4 O
/ O
09 O
[ O
CA09 O
] O
) O
, O
a O
human O
seasonal O
influenza O
H1N1 O
virus O
isolate O
( O
A O
/ O
New O
Caledonia O
/ O
20 O
/ O
99 O
[ O
Ncal99 O
] O
) O
, O
a O
classical O
swine O
influenza O
H1N1 O
virus O
isolate O
( O
A O
/ O
Swine O
/ O
Iowa O
/ O
15 O
/ O
30 O
[ O
Sw30 O
] O
) O
, O
or O
an O
avian O
H1N1 O
virus O
isolate O
( O
A O
/ O
Mallard O
/ O
MN O
/ O
A108 O
- O
2355 O
/ O
08 O
[ O
Mal08 O
] O
) O
were O
compared O
. O

1 O
) O
50 B
% I
tissue I
culture I
infectious I
doses I
( I
TCID50 I
) I
/ O
ml O
and O
10 O
( O
5 O
. O

but O
was O
higher O
( O
10 O
( O
7 O
) O
TCID50 O
/ O
ml O
) O
. O

Serum O
antibodies O
induced O
by O
seasonal O
influenza O
or O
seasonal O
influenza O
vaccination O
exhibit O
limited O
or O
no O
cross O
- O
reactivity O
against O
the O
2009 O
pandemic O
swine O
- O
origin O
influenza O
virus O
of O
the O
H1N1 O
subtype O
( O
pH1N1 O
) O
. O

The O
first O
influenza O
pandemic O
of O
the O
new O
millennium O
was O
caused O
by O
a O
newly O
emerged O
swine B
- I
origin I
influenza I
virus I
( I
SOIV I
) I
( O
H1N1 O
) O
. O

We O
here O
show O
that O
infection O
of O
macaques O
with O
two O
genetically O
similar O
but O
clinically O
distinct O
SOIV O
isolates O
from O
the O
early O
stage O
of O
the O
pandemic O
( O
A O
/ O
Mexico O
/ O
4108 O
/ O
2009 O
and O
A O
/ O
Mexico O
/ O
InDRE4487 O
/ O
2009 O
) O
resulted O
in O
upper O
and O
lower O
respiratory O
tract O
infections O
and O
clinical O
disease O
ranging O
from O
mild O
to O
severe O
pneumonia O
that O
was O
clearly O
advanced O
over O
the O
mild O
infection O
caused O
by O
A O
/ O
Kawasaki O
/ O
UTK O
- O
4 O
/ O
2009 O
, O
a O
current O
seasonal O
strain O
. O

Moreover O
, O
triple O
- O
reassortant O
swine O
( O
TRS O
) O
H1N1 O
viruses O
, O
which O
share O
similar O
host O
and O
lineage O
origins O
with O
2009 O
H1N1 O
viruses O
, O
have O
been O
responsible O
for O
sporadic O
human O
cases O
since O
2005 O
. O

Genetic O
mutation O
and O
reassortment O
of O
influenza O
virus O
gene O
segments O
, O
in O
particular O
those O
of O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
, O
that O
lead O
to O
antigenic O
drift O
and O
shift O
are O
the O
major O
strategies O
for O
influenza O
virus O
to O
escape O
preexisting O
immunity O
. O

On O
11 O
June O
2009 O
, O
the O
World B
Health I
Organization I
( I
WHO I
) I
declared O
that O
the O
outbreaks O
caused O
by O
novel O
swine O
- O
origin O
influenza O
A O
( O
H1N1 O
) O
virus O
had O
reached O
pandemic O
proportions O
. O

The O
pandemic O
H1N1 O
( O
H1N1pdm O
) O
virus O
is O
the O
predominant O
influenza O
virus O
strain O
in O
the O
human O
population O
. O

We O
have O
previously O
demonstrated O
that O
the O
introduction O
of O
temperature O
- O
sensitive O
mutations O
into O
the O
PB2 O
and O
PB1 O
genes O
of O
an O
avian O
H9N2 O
virus O
, O
combined O
with O
the O
insertion O
of O
a O
Hemagglutinin B
( I
HA I
) I
tag O
in O
PB1 O
, O
resulted O
in O
an O
attenuated B
( I
att I
) I
vaccine O
backbone O
for O
both O
chickens O
and O
mice O
. O

Because O
the O
new O
pandemic O
strain O
is O
a O
triple B
- I
reassortant I
( I
TR I
) I
virus O
, O
we O
chose O
to O
introduce O
the O
double O
attenuating O
modifications O
into O
a O
swine O
- O
like O
TR O
virus O
isolate O
, O
A O
/ O
turkey O
/ O
OH O
/ O
313053 O
/ O
04 O
( O
H3N2 O
) O
( O
ty O
/ O
04 O
) O
, O
with O
the O
goal O
of O
producing O
Live B
attenuated I
influenza I
vaccines I
( I
LAIV I
) I
. O

The O
pandemic O
H1N1 O
virus O
of O
2009 O
( O
2009 O
H1N1 O
) O
produced O
a O
spectrum O
of O
disease O
ranging O
from O
mild O
illness O
to O
severe O
illness O
and O
death O
. O

Additionally O
, O
the O
H1N1 O
viruses O
of O
swine O
origin O
replicated O
less O
efficiently O
at O
the O
temperature O
of O
the O
human O
proximal O
airways O
( O
33 O
degrees O
C O
) O
. O

An O
influenza O
pandemic O
caused O
by O
swine O
- O
origin O
influenza O
virus O
A O
/ O
H1N1 O
( O
H1N1pdm O
) O
spread O
worldwide O
in O
2009 O
, O
with O
12 O
, O
080 O
confirmed O
cases O
and O
626 O
deaths O
occurring O
in O
Argentina O
. O

In O
addition O
, O
the O
analysis O
of O
another O
16 O
Hemagglutinin B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
and O
matrix B
( I
M I
) I
gene O
sequences O
of O
Argentinean O
isolates O
was O
performed O
. O

nonstructural B
protein I
1 I
( I
NS1 I
) I
is O
one O
of O
the O
major O
factors O
resulting O
in O
the O
efficient O
infection O
rate O
and O
high O
level O
of O
virulence O
of O
influenza O
A O
virus O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
NS1 O
of O
the O
highly O
pathogenic O
avian O
influenza O
A O
/ O
Duck O
/ O
Hubei O
/ O
L O
- O
1 O
/ O
2004 O
( O
H5N1 O
) O
virus O
interacts O
with O
human O
Ubc9 O
, O
which O
is O
the O
E2 O
conjugating O
enzyme O
for O
sumoylation O
, O
and O
we O
show O
that O
SUMO1 O
is O
conjugated O
to O
H5N1 O
NS1 O
in O
both O
transfected O
and O
infected O
cells O
. O

Studies O
of O
different O
influenza O
A O
virus O
strains O
of O
human O
and O
avian O
origin O
showed O
that O
the O
majority O
of O
viruses O
possess O
an O
NS1 O
protein O
that O
is O
modified O
by O
SUMO1 O
, O
except O
for O
the O
recently O
emerged O
swine B
- I
origin I
influenza I
A I
virus I
( I
S I
- I
OIV I
) I
( O
H1N1 O
) O
. O

Our O
results O
show O
that O
influenza O
A O
virus O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
replication O
results O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
phase O
accumulation O
of O
infected O
cells O
and O
that O
this O
accumulation O
is O
caused O
by O
the O
prevention O
of O
cell O
cycle O
entry O
from O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
into O
S O
phase O
. O

Consistent O
with O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
phase O
accumulation O
, O
the O
amount O
of O
hyperphosphorylated O
retinoblastoma O
protein O
, O
a O
necessary O
active O
form O
for O
cell O
cycle O
progression O
through O
late O
G O
( O
1 O
) O
into O
S O
phase O
, O
decreased O
after O
infection O
with O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
virus O
. O

In O
addition O
, O
other O
key O
molecules O
in O
the O
regulation O
of O
the O
cell O
cycle O
, O
such O
as O
p21 O
, O
cyclin O
E O
, O
and O
cyclin O
D1 O
, O
were O
also O
changed O
and O
showed O
a O
pattern O
of O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
phase O
cell O
cycle O
arrest O
. O

It O
is O
interesting O
that O
increased O
viral O
protein O
expression O
and O
progeny O
virus O
production O
in O
cells O
synchronized O
in O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
were O
observed O
compared O
to O
those O
in O
either O
unsynchronized O
cells O
or O
cells O
synchronized O
in O
the O
G O
( O
2 O
) O
/ O
M O
phase O
. O

G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
phase O
cell O
cycle O
arrest O
is O
likely O
a O
common O
strategy O
, O
since O
the O
effect O
was O
also O
observed O
in O
other O
strains O
, O
such O
as O
H3N2 O
, O
H9N2 O
, O
PR8 O
H1N1 O
, O
and O
pandemic O
swine O
H1N1 O
viruses O
. O

These O
findings O
, O
in O
all O
, O
suggest O
that O
influenza O
A O
virus O
may O
provide O
favorable O
conditions O
for O
viral O
protein O
accumulation O
and O
virus O
production O
by O
inducing O
a O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
phase O
cell O
cycle O
arrest O
in O
infected O
cells O
. O

Therefore O
, O
we O
chose O
a O
H1N1 O
swine O
influenza O
virus O
, O
Sw O
/ O
OH O
/ O
24366 O
/ O
07 O
( O
SwIV O
) O
, O
which O
has O
a O
history O
of O
transmission O
to O
humans O
. O

Higher O
frequencies O
of O
cytotoxic O
T O
lymphocytes O
, O
gamma O
delta O
T O
cells O
, O
dendritic O
cells O
, O
activated O
T O
cells O
, O
and O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
detected O
in O
SwIV O
- O
infected O
pig O
lungs O
. O

Since O
dendritic O
cells O
may O
play O
a O
key O
role O
in O
defense O
against O
influenza O
virus O
infection O
, O
we O
examined O
the O
effects O
of O
recombinant O
Hemagglutinin B
( I
HA I
) I
proteins O
derived O
from O
mouse O
- O
adapted O
H1N1 O
( O
A O
/ O
WSN O
/ O
1933 O
) O
, O
swine O
- O
origin O
2009 O
pandemic O
H1N1 O
( O
A O
/ O
Texas O
/ O
05 O
/ O
2009 O
) O
, O
and O
highly O
pathogenic O
avian O
influenza O
H5N1 O
( O
A O
/ O
Thailand O
/ O
KAN O
- O
1 O
/ O
2004 O
) O
viruses O
on O
mouse O
myeloid B
dendritic I
cells I
( I
mDCs I
) I
. O

The O
results O
reveal O
that O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
p70 O
, O
and O
major B
histocompatibility I
complex I
class I
II I
( I
MHC I
- I
II I
) I
expression O
was O
increased O
in O
mDCs O
after O
treatment O
with O
recombinant O
HA O
proteins O
of O
H1N1 O
and O
H5N1 O
. O

Influenza O
viruses O
of O
the O
N1 O
neuraminidase B
( I
NA I
) I
subtype O
affecting O
both O
animals O
and O
humans O
caused O
the O
2009 O
pandemic O
. O

7 O
% O
) O
had O
reduced O
susceptibility O
( O
IC50 O
, O
> O
50 O
nM O
) O
but O
were O
sensitive O
to O
the O
NA O
inhibitors O
zanamivir O
and O
peramivir O
. O

Introducing O
Leu O
into O
positions O
69 O
( O
Q69L O
) O
and O
75 O
( O
H75L O
) O
in O
the O
C O
terminus O
of O
H5N1 O
PB1 O
- O
F2 O
drove O
40 O
. O

Lastly O
, O
although O
the O
swine B
- I
origin I
influenza I
virus I
( I
S I
- I
OIV I
) I
contained O
a O
truncated O
form O
of O
PB1 O
- O
F2 O
( O
12 O
amino O
acids O
[ O
aa O
] O
) O
, O
potential O
mutation O
in O
the O
future O
may O
enable O
it O
to O
contain O
a O
full O
- O
length O
product O
. O

Therefore O
, O
the O
functions O
of O
this O
putative O
S O
- O
OIV O
PB1 O
- O
F2 O
( O
87 O
aa O
) O
were O
also O
investigated O
. O

The O
emergence O
and O
subsequent O
swift O
and O
global O
spread O
of O
the O
swine O
- O
origin O
influenza O
virus O
A O
( O
H1N1 O
) O
in O
2009 O
once O
again O
emphasizes O
the O
strong O
need O
for O
effective O
vaccines O
that O
can O
be O
developed O
rapidly O
and O
applied O
safely O
. O

With O
this O
aim O
, O
we O
produced O
soluble O
, O
multimeric O
forms O
of O
the O
2009 O
A O
( O
H1N1 O
) O
HA O
( O
sHA O
( O
3 O
) O
) O
and O
NA O
( O
sNA O
( O
4 O
) O
) O
surface O
glycoproteins O
using O
a O
virus O
- O
free O
mammalian O
expression O
system O
and O
evaluated O
their O
efficacy O
as O
vaccines O
in O
ferrets O
. O

Whereas O
vaccination O
with O
sHA O
( O
3 O
) O
dramatically O
reduced O
virus O
replication O
( O
e O
. O

, O
by O
lowering O
pulmonary O
titers O
by O
about O
5 O
log O
( O
10 O
) O
units O
) O
, O
immunization O
with O
sNA O
( O
4 O
) O
markedly O
decreased O
the O
clinical O
effects O
of O
infection O
, O
such O
as O
body O
weight O
loss O
and O
lung O
pathology O
. O

Here O
, O
we O
coinfected O
cultured O
cells O
with O
the O
pandemic O
swine B
- I
origin I
influenza I
virus I
( I
S I
- I
OIV I
) I
and O
a O
contemporary O
H5N1 O
virus O
and O
found O
that O
these O
two O
viruses O
have O
high O
genetic O
compatibility O
. O

In O
both O
mice O
and O
ferrets O
, O
A O
/ O
Japan O
/ O
305 O
/ O
1957 O
( O
H2N2 O
) O
, O
A O
/ O
mallard O
/ O
NY O
/ O
1978 O
( O
H2N2 O
) O
, O
and O
A O
/ O
swine O
/ O
MO O
/ O
2006 O
( O
H2N3 O
) O
elicited O
the O
broadest O
cross O
- O
reactive O
antibody O
responses O
against O
heterologous O
H2 O
influenza O
viruses O
as O
measured O
by O
hemagglutination O
inhibition O
and O
microneutralization O
assays O
. O

While O
few O
children O
and O
young O
adults O
have O
cross O
- O
protective O
antibodies O
to O
the O
pandemic O
H1N1 O
2009 O
( O
pdmH1N1 O
) O
virus O
, O
the O
illness O
remains O
mild O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
bulk O
memory O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
established O
by O
seasonal O
influenza O
viruses O
from O
healthy O
individuals O
who O
have O
not O
been O
exposed O
to O
pdmH1N1 O
can O
directly O
lyse O
pdmH1N1 O
- O
infected O
target O
cells O
and O
produce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

Using O
influenza O
A O
virus O
matrix O
protein O
1 O
( O
M1 O
( O
58 O
- O
66 O
) O
) O
epitope O
- O
specific O
CTLs O
isolated O
from O
healthy O
HLA O
- O
A2 O
( O
+ O
) O
individuals O
, O
we O
further O
found O
that O
M1 O
( O
58 O
- O
66 O
) O
epitope O
- O
specific O
CTLs O
efficiently O
killed O
both O
M1 O
( O
58 O
- O
66 O
) O
peptide O
- O
pulsed O
and O
pdmH1N1 O
- O
infected O
target O
cells O
ex O
vivo O
. O

These O
M1 O
( O
58 O
- O
66 O
) O
- O
specific O
CTLs O
showed O
an O
effector O
memory O
phenotype O
and O
expressed O
CXCR3 O
and O
CCR5 O
chemokine O
receptors O
. O

Of O
94 O
influenza O
A O
virus O
CD8 O
T O
- O
cell O
epitopes O
obtained O
from O
the O
Immune B
Epitope I
Database I
( I
IEDB I
) I
, O
17 O
epitopes O
are O
conserved O
in O
pdmH1N1 O
, O
and O
more O
than O
half O
of O
these O
conserved O
epitopes O
are O
derived O
from O
M1 O
protein O
. O

In O
addition O
, O
65 O
% O
( O
11 O
/ O
17 O
) O
of O
these O
epitopes O
were O
100 O
% O
conserved O
in O
seasonal O
influenza O
vaccine O
H1N1 O
strains O
during O
the O
last O
20 O
years O
. O

Importantly O
, O
seasonal O
influenza O
vaccination O
could O
expand O
the O
functional O
M1 O
( O
58 O
- O
66 O
) O
epitope O
- O
specific O
CTLs O
in O
20 O
% O
( O
4 O
/ O
20 O
) O
of O
HLA O
- O
A2 O
( O
+ O
) O
individuals O
. O

Although O
the O
2009 O
H1N1 O
virus O
NS1 O
protein O
( O
2009 O
/ O
NS1 O
) O
is O
an O
effective O
interferon O
antagonist O
, O
we O
found O
that O
this O
NS1 O
( O
unlike O
those O
of O
previous O
human O
- O
adapted O
influenza O
A O
viruses O
) O
is O
unable O
to O
block O
general O
host O
gene O
expression O
in O
human O
or O
swine O
cells O
. O

A O
recombinant O
2009 O
H1N1 O
influenza O
A O
virus O
( O
A O
/ O
California O
/ O
04 O
/ O
09 O
) O
expressing O
NS1 O
with O
these O
gain O
- O
of O
- O
function O
substitutions O
was O
more O
efficient O
than O
the O
wild O
type O
at O
antagonizing O
host O
innate O
immune O
responses O
in O
primary O
human O
epithelial O
cells O
. O

The O
initial O
wave O
of O
swine O
- O
origin O
influenza O
A O
virus O
( O
pandemic O
H1N1 O
/ O
09 O
) O
in O
the O
United O
States O
during O
the O
spring O
and O
summer O
of O
2009 O
also O
resulted O
in O
an O
increased O
vigilance O
and O
sampling O
of O
seasonal O
influenza O
viruses O
( O
H1N1 O
and O
H3N2 O
) O
, O
even O
though O
they O
are O
normally O
characterized O
by O
very O
low O
incidence O
outside O
of O
the O
winter O
months O
. O

The O
pandemic O
H1N1 O
virus O
of O
2009 O
( O
2009 O
H1N1 O
) O
continues O
to O
cause O
illness O
worldwide O
, O
primarily O
in O
younger O
age O
groups O
. O

We O
have O
previously O
shown O
that O
mutations O
in O
the O
PB1 O
and O
PB2 O
genes O
of O
the O
live B
- I
attenuated I
influenza I
vaccine I
( I
LAIV I
) I
from O
the O
cold B
- I
adapted I
( I
c I
alpha I
) I
influenza O
virus O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
( O
H2N2 O
) O
could O
be O
transferred O
to O
avian O
influenza O
viruses O
and O
produce O
partially O
attenuated O
viruses O
. O

We O
also O
demonstrated O
that O
avian O
influenza O
viruses O
carrying O
the O
PB1 O
and O
PB2 O
mutations O
could O
be O
further O
attenuated O
by O
stably O
introducing O
a O
Hemagglutinin B
( I
HA I
) I
epitope O
tag O
in O
the O
PB1 O
gene O
. O

In O
this O
work O
, O
we O
wanted O
to O
determine O
whether O
these O
modifications O
would O
also O
result O
in O
attenuation O
of O
a O
so O
- O
called O
triple B
reassortant I
( I
TR I
) I
swine I
influenza I
virus I
( I
SIV I
) I
. O

Thus O
, O
the O
TR O
influenza O
A O
/ O
swine O
/ O
Wisconsin O
/ O
14094 O
/ O
99 O
( O
H3N2 O
) O
virus O
was O
generated O
by O
reverse O
genetics O
and O
subsequently O
mutated O
in O
the O
PB1 O
and O
PB2 O
genes O
. O

Furthermore O
, O
we O
show O
the O
potential O
of O
our O
TR O
backbone O
as O
a O
vaccine O
that O
provides O
protection O
against O
the O
2009 O
swine O
- O
origin O
pandemic O
influenza O
H1N1 O
virus O
( O
S O
- O
OIV O
) O
when O
carrying O
the O
surface O
of O
a O
classical O
swine O
strain O
. O

In O
addition O
, O
our O
data O
provide O
evidence O
that O
the O
use O
of O
these O
alternative O
backbones O
could O
potentially O
circumvent O
the O
effects O
of O
original B
antigenic I
sin I
( I
OAS I
) I
in O
certain O
circumstances O
. O

Very O
limited O
evidence O
has O
been O
reported O
to O
show O
human O
adaptive O
immune O
responses O
to O
the O
2009 O
pandemic O
H1N1 O
swine B
- I
origin I
influenza I
A I
virus I
( I
S I
- I
OIV I
) I
. O

We O
studied O
17 O
S O
- O
OIV O
peptides O
homologous O
to O
immunodominant O
CD4 O
T O
epitopes O
from O
Hemagglutinin B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
nuclear B
protein I
( I
NP I
) I
, O
M1 O
matrix O
protein O
( O
MP O
) O
, O
and O
PB1 O
of O
a O
seasonal O
H1N1 O
strain O
. O

With O
the O
ongoing O
pandemic O
of O
influenza O
A O
( O
H1N1 O
) O
virus O
infection O
and O
the O
threat O
of O
high O
fatality O
rates O
for O
recent O
human O
cases O
of O
infection O
with O
highly O
pathogenic O
H5N1 O
strains O
, O
there O
has O
been O
considerable O
interest O
in O
developing O
pandemic O
vaccines O
. O

The O
subjects O
developed O
antibody O
responses O
against O
the O
influenza O
A O
( O
H5N1 O
) O
virus O
. O

A O
vaccine O
using O
the O
same O
methods O
as O
those O
described O
in O
this O
report O
, O
but O
based O
on O
a O
wild O
- O
type O
swine O
- O
origin O
2009 O
( O
H1N1 O
) O
influenza O
A O
virus O
isolate O
from O
the O
United O
States O
( O
supplied O
by O
the O
CDC O
) O
, O
has O
been O
developed O
and O
is O
currently O
being O
tested O
by O
our O
group O
. O

In O
less O
than O
3 O
months O
after O
the O
first O
cases O
of O
swine O
origin O
2009 O
influenza O
A O
( O
H1N1 O
) O
virus O
infections O
were O
reported O
from O
Mexico O
, O
WHO O
declared O
a O
pandemic O
. O

We O
have O
studied O
the O
activation O
of O
innate O
immune O
responses O
in O
pandemic O
virus O
- O
infected O
human O
monocyte O
- O
derived O
dendritic B
cells I
( I
DC I
) I
and O
macrophages O
. O

The O
pandemic O
virus O
, O
as O
well O
as O
the O
seasonal O
A O
/ O
Brisbane O
/ O
59 O
/ O
07 O
( O
H1N1 O
) O
and O
A O
/ O
New O
Caledonia O
/ O
20 O
/ O
99 O
( O
H1N1 O
) O
viruses O
, O
induced O
type O
I O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
and O
type O
III O
( O
IFN O
- O
lambda O
1 O
to O
- O
lambda O
3 O
) O
IFN O
, O
CXCL10 O
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
gene O
expression O
weakly O
in O
DCs O
. O

Mouse O
- O
adapted O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
and O
human O
A O
/ O
Udorn O
/ O
72 O
( O
H3N2 O
) O
viruses O
, O
instead O
, O
induced O
efficiently O
the O
expression O
of O
antiviral O
and O
proinflammatory O
genes O
. O

Both O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
inhibited O
the O
replication O
of O
the O
pandemic O
( O
H1N1 O
) O
virus O
. O

However O
, O
the O
pandemic O
virus O
was O
more O
sensitive O
to O
the O
antiviral O
IFN O
- O
lambda O
3 O
than O
the O
seasonal O
A O
/ O
Brisbane O
/ O
59 O
/ O
07 O
( O
H1N1 O
) O
virus O
. O

The O
present O
study O
demonstrates O
that O
the O
novel O
pandemic O
( O
H1N1 O
) O
influenza O
A O
virus O
can O
readily O
replicate O
in O
human O
primary O
DCs O
and O
macrophages O
and O
efficiently O
avoid O
the O
activation O
of O
innate O
antiviral O
responses O
. O

Two O
novel O
paramyxoviruses O
, O
81 O
- O
19252 O
( O
Texas81 O
) O
and O
92 O
- O
7783 O
( O
ISU92 O
) O
, O
isolated O
from O
the O
brains O
of O
pigs O
in O
the O
United O
States O
in O
the O
1980s O
and O
1990s O
, O
were O
characterized O
. O

The O
complete O
genome O
of O
Texas81 O
virus O
was O
15 O
, O
456 O
nucleotides B
( I
nt I
) I
in O
length O
, O
that O
of O
ISU92 O
was O
15 O
, O
480 O
nt O
, O
and O
both O
genomes O
consisted O
of O
six O
nonoverlapping O
genes O
, O
predicted O
to O
encode O
nine O
proteins O
, O
with O
conserved O
and O
complementary O
3 O
' O
leader O
and O
5 O
' O
trailer O
regions O
and O
conserved O
gene O
starts O
, O
gene O
stops O
, O
and O
trinucleotide O
intergenic O
sequences O
similar O
to O
those O
in O
paramyxoviruses O
. O

The O
P O
genes O
of O
swine O
viruses O
were O
predicted O
to O
produce O
V O
and O
D O
mRNAs O
by O
RNA O
editing O
( O
one O
to O
four O
G O
insertions O
in O
Texas81 O
and O
one O
to O
nine O
G O
insertions O
in O
ISU92 O
) O
or O
C O
mRNA O
by O
alternative O
translation O
initiation O
. O

Sequence O
- O
specific O
features O
related O
to O
virus O
replication O
and O
host O
- O
specific O
amino O
acid O
signatures O
indicated O
that O
these O
viruses O
originated O
from O
bovine B
parainfluenzavirus I
3 I
( I
bPIV3 I
) I
. O

Several O
live O
attenuated O
influenza O
virus O
A O
/ O
California O
/ O
7 O
/ O
09 O
( O
H1N1 O
) O
( O
CA09 O
) O
candidate O
vaccine O
variants O
that O
possess O
the O
Hemagglutinin B
( I
HA I
) I
and O
neuraminidase B
( I
NA I
) I
gene O
segments O
from O
the O
CA09 O
virus O
and O
six O
internal O
protein O
gene O
segments O
from O
the O
cold O
- O
adapted O
influenza O
virus O
A O
/ O
Ann O
Arbor O
/ O
6 O
/ O
60 O
( O
H2N2 O
) O
virus O
were O
generated O
by O
reverse O
genetics O
. O

swine B
influenza I
virus I
( I
SIV I
) I
infection O
also O
poses O
important O
human O
public O
health O
concerns O
. O

Previously O
, O
we O
generated O
two O
elastase O
- O
dependent O
mutant O
SIVs O
derived O
from O
A O
/ O
Sw O
/ O
Saskatchewan O
/ O
18789 O
/ O
02 O
( O
H1N1 O
) O
: O
A O
/ O
Sw O
/ O
Sk O
- O
R345V O
( O
R345V O
) O
and O
A O
/ O
Sw O
/ O
Sk O
- O
R345A O
( O
R345A O
) O
. O

We O
report O
that O
intratracheally O
administrated O
R345V O
and O
R345A O
induced O
antigen O
- O
specific O
humoral O
and O
cell O
- O
mediated O
immunity O
characterized O
by O
increased O
production O
of O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgA O
antibodies O
in O
the O
serum O
and O
in O
bronchoalveolar O
lavage O
fluid O
, O
high O
hemagglutination O
inhibition O
titers O
in O
serum O
, O
an O
enhanced O
level O
of O
lymphocyte O
proliferation O
, O
and O
higher O
numbers O
of O
gamma O
interferon O
- O
secreting O
cells O
at O
the O
site O
of O
infection O
. O

We O
developed O
a O
multisegment B
reverse I
transcription I
- I
PCR I
( I
M I
- I
RTPCR I
) I
approach O
that O
simultaneously O
amplifies O
eight O
genomic O
RNA O
segments O
, O
irrespective O
of O
virus O
subtype O
. O

Together O
, O
M O
- O
RTPCR O
and O
the O
modified O
reverse O
- O
genetics O
plasmids O
that O
we O
designed O
streamline O
the O
creation O
of O
vaccine O
seed O
stocks O
( O
9 O
to O
12 O
days O
) O
. O

The O
aim O
of O
this O
work O
was O
to O
determine O
the O
virulence O
of O
a O
plasmid O
- O
derived O
human O
1918 O
pandemic O
H1N1 O
influenza O
virus O
( O
reconstructed O
1918 O
, O
or O
1918 O
/ O
rec O
, O
virus O
) O
in O
swine O
using O
a O
plasmid O
- O
derived O
A O
/ O
swine O
/ O
Iowa O
/ O
15 O
/ O
1930 O
H1N1 O
virus O
( O
1930 O
/ O
rec O
virus O
) O
, O
representing O
the O
first O
isolated O
influenza O
virus O
, O
as O
a O
reference O
. O

In O
contrast O
to O
other O
mammalian O
hosts O
( O
mice O
, O
ferrets O
, O
and O
macaques O
) O
where O
infection O
with O
the O
1918 O
/ O
rec O
virus O
was O
lethal O
, O
the O
pigs O
did O
not O
develop O
severe O
respiratory O
distress O
or O
become O
moribund O
. O

Virus O
titers O
in O
the O
lower O
respiratory O
tract O
as O
well O
as O
macro O
- O
and O
microscopic O
lesions O
at O
3 O
and O
5 O
days O
postinfection O
( O
dpi O
) O
were O
comparable O
between O
the O
1930 O
/ O
rec O
and O
1918 O
/ O
rec O
virus O
- O
inoculated O
animals O
. O

Using O
a O
parental O
H4N6 O
swine O
isolate O
and O
hemagglutinin O
mutant O
viruses O
( O
at O
residues O
226 O
and O
/ O
or O
228 O
) O
, O
we O
determined O
that O
viruses O
which O
contain O
L226 O
had O
a O
higher O
affinity O
for O
sialic O
acid O
alpha O
2 O
, O
6 O
galactose O
( O
SA O
alpha O
2 O
, O
6Gal O
) O
and O
a O
higher O
infectivity O
level O
for O
primary O
swine O
and O
human O
respiratory O
epithelial O
cells O
, O
whereas O
viruses O
which O
contain O
Q226 O
had O
lower O
SA O
alpha O
2 O
, O
6Gal O
affinity O
and O
lower O
infectivity O
levels O
for O
both O
types O
of O
cells O
. O

The O
effectiveness O
and O
potential O
immunosuppressive O
effects O
of O
anti O
- O
inflammatory O
glucocorticoids O
in O
the O
lungs O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
patients O
are O
undefined O
. O

We O
treated O
porcine B
respiratory I
coronavirus I
( I
PRCV I
) I
- O
infected O
conventional O
pigs O
with O
the O
corticosteroid O
dexamethasone B
( I
DEX I
) I
as O
a O
model O
for O
SARS O
. O

Innate O
and O
Th1 O
cytokines O
in O
Bronchoalveolar B
lavage I
( I
BAL I
) I
and O
serum O
were O
elevated O
in O
PRCV O
- O
infected O
pigs O
compared O
to O
controls O
, O
but O
were O
decreased O
after O
DEX O
treatment O
in O
the O
PRCV O
- O
infected O
, O
DEX O
- O
treated O
( O
PRCV O
/ O
DEX O
) O
pigs O
. O

PRCV O
infection O
increased O
T O
- O
cell O
frequencies O
in O
BAL O
, O
but O
DEX O
treatment O
of O
PRCV O
- O
infected O
pigs O
reduced O
frequencies O
of O
T O
cells O
; O
interestingly O
B O
and O
SWC3a O
( O
+ O
) O
( O
monocytes O
/ O
macrophages O
/ O
granulocytes O
) O
cell O
frequencies O
were O
increased O
. O

In O
2001 O
and O
2003 O
, O
we O
isolated O
two O
H5N1 O
viruses O
, O
A O
/ O
swine O
/ O
Fujian O
/ O
1 O
/ O
01 O
( O
SW O
/ O
FJ O
/ O
01 O
) O
and O
A O
/ O
swine O
/ O
Fujian O
/ O
1 O
/ O
03 O
( O
SW O
/ O
FJ O
/ O
03 O
) O
, O
from O
pigs O
in O
Fujian O
Province O
, O
southern O
China O
. O

We O
also O
found O
that O
viruses O
expressing O
the O
mutant O
NS1 O
protein O
of O
SW O
/ O
FJ O
/ O
03 O
did O
not O
antagonize O
the O
induction O
of O
interferon B
( I
IFN I
) I
protein O
. O

In O
the O
early O
1970s O
, O
a O
human O
influenza O
A O
/ O
Port O
Chalmers O
/ O
1 O
/ O
73 O
( O
H3N2 O
) O
- O
like O
virus O
colonized O
the O
European O
swine O
population O
. O

Analyses O
of O
swine O
influenza O
A O
( O
H3N2 O
) O
viruses O
isolated O
in O
The O
Netherlands O
and O
Belgium O
revealed O
that O
in O
the O
early O
1990s O
, O
antigenic O
drift O
had O
occurred O
, O
away O
from O
A O
/ O
Port O
Chalmers O
/ O
1 O
/ O
73 O
, O
the O
strain O
commonly O
used O
in O
influenza O
vaccines O
for O
pigs O
. O

Here O
we O
show O
that O
Italian O
swine O
influenza O
A O
( O
H3N2 O
) O
viruses O
displayed O
antigenic O
and O
genetic O
changes O
similar O
to O
those O
observed O
in O
Northern O
European O
viruses O
in O
the O
same O
period O
. O

Although O
the O
antigenic O
drift O
of O
swine O
and O
human O
H3N2 O
viruses O
has O
followed O
distinct O
evolutionary O
paths O
, O
potential O
cluster O
- O
differentiating O
amino O
acid O
substitutions O
in O
the O
influenza O
virus O
surface O
protein O
Hemagglutinin B
( I
HA I
) I
were O
in O
part O
the O
same O
. O

It O
has O
been O
shown O
previously O
that O
the O
nonstructural O
protein O
NS1 O
of O
influenza O
virus O
is O
an O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
antagonist O
, O
both O
in O
vitro O
and O
in O
experimental O
animal O
model O
systems O
. O

The O
virulent O
wild O
- O
type O
A O
/ O
Swine O
/ O
Texas O
/ O
4199 O
- O
2 O
/ O
98 O
( O
TX O
/ O
98 O
) O
virus O
and O
various O
mutants O
encoding O
carboxy O
- O
truncated O
NS1 O
proteins O
were O
rescued O
. O

We O
previously O
generated O
recombinant O
vesicular B
stomatitis I
viruses I
( I
VSV I
) I
based O
on O
the O
Indiana O
serotype O
genome O
which O
contained O
either O
the O
homologous O
glycoprotein O
gene O
from O
the O
Indiana O
serotype O
( O
VSIV O
- O
G O
( O
I O
) O
) O
or O
the O
heterologous O
glycoprotein O
gene O
from O
the O
New O
Jersey O
serotype O
( O
VSIV O
- O
G O
( O
NJ O
) O
) O
. O

The O
virus O
expressing O
the O
G O
( O
NJ O
) O
gene O
was O
more O
pathogenic O
than O
the O
parental O
VSIV O
- O
G O
( O
I O
) O
virus O
in O
swine O
, O
a O
natural O
host O
( O
26 O
) O
. O

For O
the O
present O
study O
, O
we O
investigated O
the O
biological O
differences O
between O
the O
G O
( O
I O
) O
and O
G O
( O
NJ O
) O
proteins O
that O
may O
be O
related O
to O
the O
differences O
in O
pathogenesis O
between O
VSIV O
- O
G O
( O
I O
) O
and O
VSIV O
- O
G O
( O
NJ O
) O
. O

We O
show O
that O
the O
capacities O
of O
viruses O
with O
either O
the O
G O
( O
NJ O
) O
or O
G O
( O
I O
) O
glycoprotein O
to O
infect O
cultured O
cells O
differ O
depending O
on O
the O
pH O
. O

VSIV O
- O
G O
( O
NJ O
) O
could O
infect O
cells O
at O
acidic O
pHs O
, O
while O
the O
infectivity O
of O
VSIV O
- O
G O
( O
I O
) O
was O
severely O
reduced O
. O

VSIV O
- O
G O
( O
NJ O
) O
infection O
was O
also O
more O
sensitive O
to O
inhibition O
by O
ammonium O
chloride O
, O
indicating O
that O
the O
G O
( O
NJ O
) O
protein O
had O
a O
lower O
pH O
threshold O
for O
membrane O
fusion O
. O

We O
applied O
selective O
pressure O
to O
VSIV O
- O
G O
( O
I O
) O
by O
growing O
it O
at O
successively O
lower O
pH O
values O
and O
isolated O
variant O
viruses O
in O
which O
we O
identified O
amino O
acid O
changes O
that O
conferred O
low O
- O
pH O
- O
resistant O
infectivity O
. O

8 O
resulted O
in O
the O
selection O
of O
a O
VSIV O
- O
G O
( O
I O
) O
variant O
( O
VSIV O
- O
6 O
. O

8 O
) O
that O
was O
similar O
to O
VSIV O
- O
G O
( O
NJ O
) O
regarding O
its O
pH O
- O
and O
ammonium O
chloride O
- O
dependent O
infectivity O
. O

8 O
revealed O
that O
it O
had O
a O
single O
amino O
acid O
substitution O
in O
the O
amino O
- O
terminal O
region O
of O
the O
glycoprotein O
( O
F18L O
) O
. O

This O
alteration O
was O
shown O
to O
be O
responsible O
for O
the O
observed O
phenotype O
by O
site O
- O
directed O
mutagenesis O
of O
a O
VSIV O
- O
G O
( O
I O
) O
full O
- O
length O
cDNA O
and O
analysis O
of O
the O
recovered O
engineered O
virus O
. O

We O
used O
a O
panel O
of O
monoclonal O
antibodies O
to O
H9 O
hemagglutinin O
to O
select O
18 O
escape O
mutants O
of O
mouse O
- O
adapted O
influenza O
A O
/ O
Swine O
/ O
Hong O
Kong O
/ O
9 O
/ O
98 O
( O
H9N2 O
) O
virus O
. O

Positions O
145 O
and O
193 O
( O
H3 O
numbering O
) O
, O
which O
in O
H3 O
hemagglutinin O
belong O
to O
sites O
A O
and O
B O
, O
respectively O
, O
are O
within O
one O
site O
in O
H9 O
hemagglutinin O
. O

The O
distribution O
of O
sialic B
acid I
( I
SA I
) I
species O
varies O
among O
animal O
species O
, O
but O
the O
biological O
role O
of O
this O
variation O
is O
largely O
unknown O
. O

Influenza O
viruses O
differ O
in O
their O
ability O
to O
recognize O
SA O
- O
galactose O
( O
Gal O
) O
linkages O
, O
depending O
on O
the O
animal O
hosts O
from O
which O
they O
are O
isolated O
. O

For O
example O
, O
human O
viruses O
preferentially O
recognize O
SA O
linked O
to O
Gal O
by O
the O
alpha2 O
, O
6 O
( O
SA O
alpha2 O
, O
6Gal O
) O
linkage O
, O
while O
equine O
viruses O
favor O
SA O
alpha2 O
, O
3Gal O
. O

However O
, O
whether O
a O
difference O
in O
relative O
abundance O
of O
specific O
SA O
species O
( O
N O
- O
acetylneuraminic O
acid O
[ O
NeuAc O
] O
and O
N O
- O
glycolylneuraminic O
acid O
[ O
NeuGc O
] O
) O
among O
different O
animals O
affects O
the O
replicative O
potential O
of O
influenza O
viruses O
is O
uncertain O
. O

We O
therefore O
examined O
the O
requirement O
for O
the O
Hemagglutinin B
( I
HA I
) I
for O
support O
of O
viral O
replication O
in O
horses O
, O
using O
viruses O
whose O
HAs O
differ O
in O
receptor O
specificity O
. O

Particle O
- O
mediated O
delivery O
of O
a O
DNA O
expression O
vector O
encoding O
the O
Hemagglutinin B
( I
HA I
) I
of O
an O
H1N1 O
influenza O
virus O
( O
A O
/ O
Swine O
/ O
Indiana O
/ O
l726 O
/ O
88 O
) O
to O
porcine O
epidermis O
elicits O
a O
humoral O
immune O
response O
and O
accelerates O
the O
clearance O
of O
virus O
in O
pigs O
following O
a O
homotypic O
challenge O
. O

In O
contrast O
, O
delivery O
of O
a O
plasmid O
encoding O
an O
influenza O
virus O
nucleoprotein O
from O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
to O
the O
epidermis O
elicits O
a O
strong O
humoral O
response O
but O
no O
detectable O
protection O
in O
terms O
of O
nasal O
virus O
shed O
. O

We O
determined O
the O
deduced O
amino O
acid O
sequences O
of O
two O
H1 O
duck O
influenza O
A O
virus O
hemagglutinins B
( I
HAs I
) I
and O
found O
that O
the O
consensus O
sequence O
of O
the O
HA O
, O
determined O
directly O
from O
virus O
recovered O
from O
the O
intestinal O
tract O
, O
remains O
unchanged O
through O
many O
generations O
of O
growth O
in O
MDCK O
cells O
and O
chicken O
embryos O
. O

The O
Hemagglutinin B
( I
HA I
) I
of O
a O
recent O
swine O
influenza O
virus O
, O
A O
/ O
Sw O
/ O
IN O
/ O
1726 O
/ O
88 O
( O
H1N1 O
) O
, O
was O
shown O
previously O
to O
have O
four O
antigenic O
sites O
, O
as O
determined O
from O
analysis O
of O
monoclonal B
antibody I
( I
Mab I
) I
- O
selected O
escape O
mutants O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
causes O
liver O
pathologies O
, O
including O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Homeobox B
( I
HOX I
) I
gene O
products O
regulate O
embryonic O
development O
and O
are O
associated O
with O
tumorigenesis O
, O
although O
the O
regulation O
of O
HOX O
genes O
by O
HCV O
infection O
has O
not O
been O
clarified O
in O
detail O
. O

In O
this O
study O
, O
HCV O
infection O
induced O
more O
than O
half O
of O
the O
HOX O
genes O
and O
reduced O
the O
level O
of O
histone O
H2A O
monoubiquitination O
on O
lysine O
119 O
( O
K119 O
) O
( O
H2Aub O
) O
, O
which O
represses O
HOX O
gene O
promoter O
activity O
. O

Treatment O
with O
LY O
- O
411575 O
, O
which O
can O
reduce O
HCV O
core O
protein O
expression O
via O
signal B
peptide I
peptidase I
( I
SPP I
) I
inhibition O
without O
affecting O
other O
viral O
proteins O
, O
dose O
- O
dependently O
restored O
the O
amounts O
of O
RNF2 O
and O
H2Aub O
in O
HCV O
- O
infected O
cells O
and O
impaired O
the O
induction O
of O
HOX O
genes O
and O
production O
of O
viral O
particles O
but O
not O
viral O
replication O
. O

IMPORTANCE O
Recently O
sustained O
virologic O
response O
can O
be O
achieved O
by O
direct B
- I
acting I
antiviral I
( I
DAA I
) I
therapy O
in O
most O
hepatitis O
C O
patients O
. O

Unfortunately O
, O
DAA O
therapy O
does O
not O
completely O
eliminate O
a O
risk O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Several O
epigenetic O
factors O
, O
including O
histone O
modifications O
, O
are O
well O
known O
to O
contribute O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
associated O
HCC O
. O

In O
this O
study O
, O
our O
data O
suggest O
that O
HCV O
infection O
or O
HCV O
core O
protein O
expression O
impairs O
monoubiquitination O
of O
histone O
H2A O
K119 O
in O
the O
Homeobox B
( I
HOX I
) I
gene O
promoter O
via O
destabilization O
of O
RNF2 O
and O
then O
induces O
HOX O
genes O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
public O
health O
problem O
. O

Although O
several O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
recognize O
the O
receptor O
binding O
domain O
in O
preS1 O
and O
neutralize O
HBV O
infection O
have O
been O
isolated O
, O
details O
of O
neutralizing O
epitopes O
are O
not O
understood O
. O

IMPORTANCE O
The O
HBV O
preS1 B
amino I
acid I
2 I
to I
47 I
region I
( I
preS1 I
/ I
2 I
- I
47 I
) I
is O
essential O
for O
virus O
binding O
to O
sodium O
taurocholate O
cotransporting O
polypeptide O
. O

Several O
MAbs O
targeting O
preS1 O
/ O
2 O
- O
47 O
have O
been O
reported O
to O
neutralize O
HBV O
infection O
; O
however O
, O
which O
region O
in O
preS1 O
/ O
2 O
- O
47 O
contains O
the O
critical O
neutralizing O
epitope O
( O
s O
) O
for O
HBV O
infection O
is O
unclear O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
triggers O
Golgi O
fragmentation O
through O
the O
Golgi O
- O
resident O
protein O
immunity B
- I
related I
GTPase I
M I
( I
IRGM I
) I
. O

Here O
, O
we O
report O
the O
roles O
of O
NLRP3 O
( O
NOD O
- O
, O
LRR O
- O
and O
pyrin O
domain O
- O
containing O
protein O
3 O
) O
and O
ASC O
( O
apoptosis O
- O
associated O
speck O
- O
like O
protein O
containing O
a O
caspase B
activation I
and I
recruitment I
domain I
( I
CARD I
) I
) O
, O
two O
inflammasome O
components O
, O
in O
the O
initial O
events O
leading O
to O
this O
fragmentation O
. O

A O
similar O
mechanism O
occurs O
in O
response O
to O
nigericin O
treatment O
, O
but O
not O
in O
cells O
infected O
with O
another O
member O
of O
the O
Flavividdae O
family O
, O
Zika B
virus I
( I
ZIKV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
triggers O
Golgi O
fragmentation O
through O
the O
immunity B
- I
related I
GTPase I
M I
( I
IRGM I
) I
, O
a O
resident O
Golgi O
protein O
, O
to O
enhance O
its O
lipid O
supply O
for O
replication O
. O

The O
biosynthesis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
covalently I
closed I
circular I
DNA I
( I
cccDNA I
) I
requires O
the O
removal O
of O
the O
covalently O
linked O
viral O
polymerase O
from O
the O
5 O
' O
end O
of O
the O
minus O
strand O
[ O
( O
- O
) O
strand O
] O
of O
viral O
relaxed B
circular I
DNA I
( I
rcDNA I
) I
, O
which O
generates O
a O
deproteinated B
rcDNA I
( I
DP I
- I
rcDNA I
) I
intermediate O
. O

In O
the O
present O
study O
, O
we O
systematically O
characterized O
the O
four O
termini O
of O
cytoplasmic O
HBV O
DP O
- O
rcDNA O
by O
5 O
' O
/ O
3 O
' O
rapid B
amplification I
of I
cDNA I
ends I
( I
RACE I
) I
, O
5 O
' O
radiolabeling O
, O
and O
exonuclease O
digestion O
, O
which O
revealed O
the O
following O
observations O
: O
( O
i O
) O
DP O
- O
rcDNA O
and O
rcDNA O
possess O
an O
identical O
3 O
' O
end O
of O
( O
- O
) O
strand O
DNA O
; O
( O
ii O
) O
compared O
to O
rcDNA O
, O
DP O
- O
rcDNA O
has O
an O
extended O
but O
variable O
3 O
' O
end O
of O
plus O
strand O
[ O
( O
+ O
) O
strand O
] O
DNA O
, O
most O
of O
which O
is O
in O
close O
proximity O
to O
direct B
repeat I
2 I
( I
DR2 I
) I
; O
( O
iii O
) O
DP O
- O
rcDNA O
exhibits O
an O
RNA O
primer O
- O
free O
5 O
' O
terminus O
of O
( O
+ O
) O
strand O
DNA O
with O
either O
a O
phosphate O
or O
hydroxyl O
group O
; O
and O
( O
iv O
) O
the O
5 O
' O
end O
of O
the O
DP O
- O
rcDNA O
( O
- O
) O
strand O
is O
unblocked O
at O
nucleotide O
G1828 O
, O
bearing O
a O
phosphate O
moiety O
, O
indicating O
the O
complete O
removal O
of O
polymerase O
from O
rcDNA O
via O
unlinking O
the O
tyrosyl O
- O
DNA O
phosphodiester O
bond O
during O
rcDNA O
deproteination O
. O

However O
, O
knockout O
of O
cellular O
5 O
' O
tyrosyl O
- O
DNA O
phosphodiesterase O
2 O
( O
TDP2 O
) O
did O
not O
markedly O
affect O
rcDNA O
deproteination O
or O
cccDNA O
formation O
. O

IMPORTANCE O
The O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
is O
the O
persistent O
form O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
in O
viral O
infection O
and O
an O
undisputed O
antiviral O
target O
for O
an O
HBV O
cure O
. O

HBV O
cccDNA O
is O
converted O
from O
viral O
genomic O
relaxed B
circular I
DNA I
( I
rcDNA I
) I
through O
a O
complex O
process O
that O
involves O
removing O
the O
covalently O
bound O
viral O
polymerase O
from O
rcDNA O
, O
which O
produces O
a O
deproteinated B
- I
rcDNA I
( I
DP I
- I
rcDNA I
) I
intermediate O
for O
cccDNA O
formation O
. O

While O
rcDNA O
and O
DP O
- O
rcDNA O
have O
an O
identical O
3 O
' O
terminus O
of O
( O
- O
) O
strand O
DNA O
, O
the O
3 O
' O
terminus O
of O
( O
+ O
) O
strand O
DNA O
on O
DP O
- O
rcDNA O
is O
further O
elongated O
. O

Furthermore O
, O
the O
peculiarities O
on O
rcDNA O
5 O
' O
termini O
, O
specifically O
the O
RNA O
primer O
on O
the O
( O
+ O
) O
strand O
and O
the O
polymerase O
on O
the O
( O
- O
) O
strand O
, O
are O
absent O
from O
DPrcDNA O
. O

Some O
plus O
- O
stranded O
RNA O
viruses O
generate O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
, O
one O
type O
of O
the O
membrane O
replication O
factories O
, O
as O
replication O
sites O
. O

sphingomyelin B
( I
SM I
) I
is O
required O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
, O
but O
the O
mechanism O
of O
SM O
involvement O
remains O
poorly O
understood O
. O

SM O
biosynthesis O
starts O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
gives O
rise O
to O
ceramide O
, O
which O
is O
transported O
from O
the O
ER O
to O
the O
Golgi O
by O
the O
action O
of O
ceramide B
transfer I
protein I
( I
CERT I
) I
, O
where O
it O
can O
be O
converted O
to O
SM O
. O

In O
this O
study O
, O
inhibition O
of O
SM O
biosynthesis O
, O
either O
by O
using O
small O
- O
molecule O
inhibitors O
or O
by O
knockout B
( I
KO I
) I
of O
CERT O
, O
suppressed O
HCV O
replication O
in O
a O
genotype O
- O
independent O
manner O
. O

IMPORTANCE O
Previous O
reports O
assumed O
that O
sphingomyelin B
( I
SM I
) I
is O
essential O
for O
HCV O
replication O
, O
but O
the O
mechanism O
was O
unclear O
. O

In O
this O
study O
, O
we O
showed O
for O
the O
first O
time O
that O
SM O
and O
ceramide B
transfer I
protein I
( I
CERT I
) I
, O
which O
is O
in O
the O
SM O
biosynthesis O
pathway O
, O
are O
essential O
for O
the O
biosynthesis O
of O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
, O
the O
sites O
of O
viral O
replication O
. O

HCV O
replication O
was O
rescued O
by O
ectopic O
expression O
of O
the O
CERT O
protein O
, O
but O
not O
by O
CERT O
mutants O
, O
that O
abolishes O
the O
binding O
of O
CERT O
to O
vesicle B
- I
associated I
membrane I
protein I
- I
associated I
protein I
( I
VAP I
) I
or O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
, O
indicating O
new O
roles O
for O
VAP O
and O
PI4P O
in O
HCV O
replication O
. O

Zika B
virus I
( I
ZIKV I
) I
is O
an O
emerging O
mosquito O
- O
borne O
flavivirus O
which O
has O
become O
a O
global O
epidemic O
threat O
due O
to O
its O
rapid O
spread O
and O
association O
with O
serious O
consequences O
of O
infection O
, O
including O
neonatal O
microcephaly O
. O

Inositol B
- I
requiring I
enzyme I
1 I
alpha I
( I
IRE1 I
alpha I
) I
is O
an O
endoplasmic B
reticulum I
( I
ER I
) I
- O
related O
transmembrane O
protein O
that O
mediates O
unfolded B
protein I
response I
( I
UPR I
) I
pathway O
and O
has O
been O
indicated O
to O
play O
an O
important O
role O
in O
flavivirus O
replication O
. O

Importantly O
, O
we O
found O
that O
IRE1 O
alpha O
promoted O
the O
replication O
of O
ZIKV O
through O
upregulating O
the O
accumulation O
of O
monounsaturated B
fatty I
acid I
( I
MUFA I
) I
rate O
limiting O
enzyme O
stearoyl B
coenzyme I
A I
( I
stearoyl I
- I
CoA I
) I
desaturase O
1 O
( O
SCD1 O
) O
, O
which O
further O
affected O
the O
production O
of O
oleic B
acid I
( I
OA I
) I
and O
lipid O
droplet O
. O

IMPORTANCE O
Zika B
virus I
( I
ZIKV I
) I
has O
been O
linked O
to O
serious O
neurologic O
disorders O
and O
causes O
widespread O
concern O
in O
the O
field O
of O
global O
public O
health O
. O

Inositol O
requiring O
enzyme O
1 O
alpha O
( O
IRE1 O
alpha O
) O
is O
an O
ER O
- O
related O
transmembrane O
protein O
that O
mediates O
unfolded B
protein I
response I
( I
UPR I
) I
pathway O
. O

Importantly O
, O
we O
further O
provided O
evidence O
that O
upon O
ZIKV O
infection O
, O
IRE1 O
alpha O
is O
activated O
and O
splices O
XBP1 O
mRNA O
which O
enhances O
the O
expression O
of O
monounsaturated O
fatty O
acids O
rate O
- O
limiting O
enzyme O
stearoyl B
coenzyme I
A I
( I
stearoyl I
- I
CoA I
) I
desaturase O
1 O
( O
SCD1 O
) O
and O
subsequent O
lipid O
droplet O
production O
. O

interferon B
- I
stimulated I
gene I
15 I
( I
ISG15 I
) I
is O
a O
ubiquitin O
- O
like O
protein O
that O
is O
covalently O
conjugated O
to O
many O
substrate O
proteins O
in O
order O
to O
modulate O
their O
functions O
; O
this O
conjugation O
is O
called O
ISGylation O
. O

Several O
groups O
reported O
that O
the O
ISGylation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
NS5A O
protein O
affects O
HCV O
replication O
. O

Here O
, O
we O
investigated O
the O
role O
of O
NS5A O
ISGylation O
in O
HCV O
replication O
by O
using O
HCV O
RNA O
replicons O
that O
encode O
a O
mutation O
at O
each O
lysine B
( I
Lys I
) I
residue O
of O
the O
NS5A O
protein O
. O

Immunoblot O
analyses O
revealed O
that O
5 O
Lys O
residues O
( O
K44 O
, O
K68 O
, O
K166 O
, O
K215 O
, O
and O
K308 O
) O
of O
the O
14 O
Lys O
residues O
within O
NS5A O
( O
genotype O
1b O
, O
Con1 O
) O
have O
the O
potential O
to O
accept O
ISGylation O
. O

Using O
an O
HCV O
luciferase O
reporter O
replicon O
assay O
revealed O
that O
residue O
K308 O
of O
NS5A O
is O
important O
for O
HCV O
( O
1b O
, O
Con1 O
) O
RNA O
replication O
. O

We O
observed O
that O
K308 O
, O
one O
of O
the O
Lys O
residues O
for O
NS5A O
ISGylation O
, O
is O
located O
within O
the O
binding O
region O
of O
cyclophilin B
A I
( I
CypA I
) I
, O
which O
is O
the O
critical O
host O
factor O
for O
HCV O
replication O
. O

IMPORTANCE O
Host O
cells O
have O
evolved O
host O
defense O
machinery O
( O
such O
as O
innate O
immunity O
) O
to O
eliminate O
viral O
infections O
. O

Viruses O
have O
evolved O
several O
counteracting O
strategies O
for O
achieving O
an O
immune O
escape O
from O
host O
defense O
machinery O
, O
including O
type B
I I
interferons I
( I
IFNs I
) I
and O
inflammatory O
cytokines O
. O

alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
signaling O
through O
the O
IFN B
- I
alpha I
/ I
beta I
receptor I
( I
IFNAR I
) I
is O
essential O
to O
limit O
virus O
dissemination O
throughout O
the O
central B
nervous I
system I
( I
CNS I
) I
following O
many O
neurotropic O
virus O
infections O
. O

Here O
we O
show O
that O
mice O
devoid O
of O
IFNAR1 O
signaling O
in O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
II I
alpha I
( I
CaMKII I
alpha I
) I
expressing O
neurons O
( O
CaMKIIcre O
: O
IFNAR O
( O
fl O
/ O
fl O
) O
mice O
) O
infected O
with O
a O
mildly O
pathogenic O
neurotropic O
coronavirus O
( O
mouse O
hepatitis O
virus O
A59 O
strain O
[ O
MHV O
- O
A59 O
] O
) O
developed O
severe O
encephalomyelitis O
with O
hind O
- O
limb O
paralysis O
and O
succumbed O
within O
7 O
days O
. O

Increased O
virus O
spread O
in O
CaMKIIcre O
: O
IFNAR O
( O
fl O
/ O
fl O
) O
mice O
compared O
to O
IFNAR O
( O
fl O
/ O
fl O
) O
mice O
affected O
neurons O
not O
only O
in O
the O
forebrain O
but O
also O
in O
the O
mid O
- O
hind O
brain O
and O
spinal O
cords O
but O
excluded O
the O
cerebellum O
. O

The O
lack O
of O
viral O
control O
in O
CaMKIIcre O
: O
IFNAR O
( O
fl O
/ O
fl O
) O
relative O
to O
control O
mice O
coincided O
with O
sustained O
Cxcl1 O
and O
Ccl2 O
mRNAs O
but O
a O
decrease O
in O
mRNA O
levels O
of O
IFN O
alpha O
/ O
beta O
pathway O
genes O
as O
well O
as O
Il6 O
, O
Tnf O
, O
and O
Il1 O
beta O
between O
days O
4 O
and O
6 O
postinfection O
( O
p O
. O

Using O
a O
neurotropic O
mouse O
hepatitis O
virus O
encephalomyelitis O
model O
, O
this O
study O
demonstrated O
an O
essential O
role O
of O
IFN B
- I
alpha I
/ I
beta I
receptor I
1 I
( I
IFNAR1 I
) I
specifically O
in O
neurons O
to O
control O
virus O
spread O
, O
regulate O
IFN O
- O
gamma O
signaling O
, O
and O
prevent O
acute O
mortality O
. O

Replication O
of O
the O
genotype O
2 O
hepatitis B
C I
virus I
( I
HCV I
) I
requires O
hyperphosphorylation O
of O
the O
nonstructural O
protein O
NS5A O
. O

It O
has O
been O
known O
that O
NS5A O
hyperphosphorylation O
results O
from O
the O
phosphorylation O
of O
a O
cluster O
of O
highly O
conserved O
serine O
residues O
( O
S2201 O
, O
S2208 O
, O
S2211 O
, O
and O
S2214 O
) O
in O
a O
sequential O
manner O
. O

Mutations O
( O
T1661R O
, O
T1661Y O
, O
or O
T1661D O
) O
that O
prohibited O
proper O
cleavage O
at O
the O
NS3 O
- O
4A O
junction O
also O
abolished O
NS5A O
hyperphosphorylation O
and O
phosphorylation O
at O
all O
serine O
residues O
, O
whereas O
mutations O
at O
the O
other O
cleavage O
sites O
, O
NS4A O
- O
4B O
( O
C1715S O
) O
or O
NS4B O
- O
5A O
( O
C1976F O
) O
, O
did O
not O
. O

In O
fact O
, O
any O
combinatory O
mutations O
that O
prohibited O
NS3 O
- O
4A O
cleavage O
( O
T1661Y O
/ O
C1715S O
or O
T1661Y O
/ O
C1976F O
) O
abrogated O
NS5A O
hyperphosphorylation O
and O
phosphorylation O
at O
all O
serine O
residues O
. O

covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
of O
hepadnaviruses O
exists O
as O
an O
episomal O
minichromosome O
in O
the O
nucleus O
of O
an O
infected O
hepatocyte O
and O
serves O
as O
the O
template O
for O
the O
transcription O
of O
viral O
mRNAs O
. O

It O
had O
been O
demonstrated O
by O
others O
and O
us O
that O
interferon B
alpha I
( I
IFN I
- I
alpha I
) I
treatment O
of O
hepatocytes O
induced O
a O
prolonged O
suppression O
of O
human O
and O
duck O
hepatitis O
B O
virus O
cccDNA O
transcription O
, O
which O
is O
associated O
with O
the O
reduction O
of O
cccDNA O
- O
associated O
histone O
modifications O
specifying O
active O
transcription O
( O
H3K9 O
( O
ac O
) O
or O
H3K27 O
( O
ac O
) O
) O
, O
but O
not O
the O
histone O
modifications O
marking O
constitutive O
( O
H3K9 O
( O
me3 O
) O
) O
or O
facultative O
( O
H3K27 O
( O
me3 O
) O
) O
heterochromatin O
formation O
. O

In O
our O
efforts O
to O
identify O
IFN O
- O
induced O
cellular O
proteins O
that O
mediate O
the O
suppression O
of O
cccDNA O
transcription O
by O
the O
cytokine O
, O
we O
found O
that O
downregulating O
the O
expression O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
, O
structural B
maintenance I
of I
chromosomes I
flexible I
hinge I
domain I
containing I
1 I
( I
SMCHD1 I
) I
, O
or O
promyelocytic B
leukemia I
( I
PML I
) I
protein O
increased O
basal O
level O
of O
cccDNA O
transcription O
activity O
and O
partially O
attenuated O
IFN O
- O
alpha O
suppression O
of O
cccDNA O
transcription O
. O

PML O
is O
a O
component O
of O
nuclear B
domain I
10 I
( I
ND10 I
) I
and O
is O
involved O
in O
suppressing O
the O
replication O
of O
many O
DNA O
viruses O
. O

By O
a O
loss O
- O
of O
- O
function O
genetic O
screening O
of O
individual O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
on O
hepadnaviral O
mRNAs O
transcribed O
from O
cccDNA O
, O
we O
found O
that O
downregulating O
the O
expression O
of O
STAT1 O
, O
SMCHD1 O
, O
or O
PML O
significantly O
increased O
the O
level O
of O
viral O
RNAs O
without O
altering O
the O
level O
of O
cccDNA O
. O

A O
large O
number O
of O
rabbits O
have O
been O
infected O
by O
rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
in O
natural O
and O
artificial O
pandemics O
in O
the O
past O
. O

Differences O
in O
presentation O
of O
antigenic O
peptides O
by O
polymorphic O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecules O
to O
T B
- I
cell I
receptors I
( I
TCR I
) I
on O
T O
lymphocytes O
are O
associated O
with O
viral O
clearance O
in O
mammals O
. O

Moreover O
, O
the O
rabbit O
molecule O
is O
characterized O
by O
an O
uncommon O
residue O
combination O
of O
Gly53 O
, O
Val55 O
, O
and O
Glu56 O
, O
making O
the O
3 O
( O
10 O
) O
helix O
and O
the O
loop O
between O
the O
3 O
( O
10 O
) O
and O
alpha O
1 O
helices O
closer O
to O
the O
alpha O
2 O
helix O
. O

IMPORTANCE O
We O
screened O
rabbit O
MHC O
class O
I O
RLA O
- O
A1 O
- O
restricted O
peptides O
from O
the O
capsid O
protein O
VP60 O
of O
rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
and O
determined O
the O
structures O
of O
RLA O
- O
A1 O
complexed O
with O
three O
peptides O
, O
VP60 O
- O
1 O
, O
VP60 O
- O
2 O
, O
and O
VP60 O
- O
10 O
. O

In O
addition O
, O
uncommon O
residues O
Gly53 O
, O
Va155 O
, O
and O
Glu56 O
of O
RLA O
- O
A1 O
are O
located O
between O
the O
3 O
( O
10 O
) O
, O
helix O
and O
alpha O
1 O
helix O
, O
which O
makes O
the O
steric O
position O
of O
the O
3 O
( O
10 O
) O
helix O
in O
RLA O
- O
A1 O
much O
closer O
to O
the O
alpha O
2 O
helix O
than O
that O
found O
in O
other O
mammalian O
MHC O
class O
I O
molecules O
. O

This O
special O
conformation O
between O
the O
3 O
( O
10 O
) O
helix O
and O
alpha O
1 O
helix O
plays O
a O
pivotal O
role O
in O
rabbit O
MHC O
class O
I O
assembly O
. O

Sirtuin B
2 I
( I
Sirt2 I
) I
, O
an O
NAD O
+ O
- O
dependent O
protein O
deacetylase O
, O
deacetylates O
tubulin O
, O
AKT O
, O
and O
other O
proteins O
. O

1 O
) O
increased O
replication O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

5 O
) O
is O
a O
catalytically O
inactive O
nuclear O
protein O
with O
a O
spliced O
- O
out O
nuclear B
export I
signal I
( I
NES I
) I
, O
we O
speculated O
that O
its O
different O
localization O
affects O
its O
activity O
. O

5 O
reduced O
expression O
of O
HBV O
mRNAs O
, O
replicative O
intermediate O
DNAs O
, O
and O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
an O
activity O
opposite O
that O
of O
Sirt2 O
. O

The O
recruitment O
of O
histone B
lysine I
methyltransferases I
( I
HKMTs I
) I
, O
such O
as O
SETDB1 O
, O
SUV39H1 O
, O
EZH2 O
, O
and O
PR O
- O
Set7 O
, O
and O
their O
respective O
transcriptional O
repressive O
markers O
, O
H3K9me3 O
, O
H3K27me3 O
, O
and O
H4K2Ome1 O
, O
to O
cccDNA O
also O
increased O
in O
Sirt2 O
. O

The O
rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
, O
which O
belongs O
to O
the O
family O
Caliciviridae O
and O
the O
genus O
Lagovirus O
, O
causes O
lethal O
fulminant O
hepatitis O
in O
rabbits O
. O

However O
, O
the O
mechanism O
underlying O
the O
regulation O
of O
the O
Nrf2 B
- I
antioxidant I
response I
element I
( I
ARE I
) I
signaling O
pathway O
by O
RHDV O
remains O
unclear O
. O

Using O
isobaric B
tags I
for I
relative I
and I
absolute I
quantification I
( I
iTRAQ I
) I
technology O
, O
the O
current O
study O
demonstrated O
that O
RHDV O
inhibits O
the O
induction O
of O
ARE O
- O
regulated O
genes O
and O
increases O
the O
expression O
of O
the O
p50 O
subunit O
of O
the O
NF O
- O
kappa O
B O
transcription O
factor O
. O

We O
showed O
that O
RHDV O
replication O
causes O
a O
remarkable O
increase O
in O
reactive B
oxygen I
species I
( I
ROS I
) I
, O
which O
is O
simultaneously O
accompanied O
by O
a O
significant O
decrease O
in O
Nrf2 O
. O

Moreover O
, O
upregulation O
of O
Nrf2 O
protein O
levels O
in O
liver O
cell O
nuclei O
by O
tert B
- I
butylhydroquinone I
( I
tBHQ I
) I
delayed O
rabbit O
deaths O
due O
to O
RHDV O
infection O
. O

IMPORTANCE O
Recent O
studies O
have O
reported O
that O
rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
infection O
reduced O
Nrf2 O
- O
related O
antioxidant O
function O
. O

Previous O
studies O
documented O
that O
long O
- O
term O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
in O
human O
hepatoma O
Huh O
- O
7 O
. O

In O
the O
present O
work O
, O
we O
show O
that O
mutational O
waves O
( O
changes O
in O
frequency O
of O
individual O
mutations O
) O
occurred O
continuously O
and O
became O
more O
prominent O
as O
the O
virus O
gained O
fitness O
. O

Thus O
, O
HCV O
adaptation O
to O
a O
specific O
constant O
environment O
( O
cell O
culture O
without O
external O
influences O
) O
broadens O
the O
mutant O
repertoire O
and O
does O
not O
focus O
the O
population O
toward O
a O
limited O
number O
of O
dominant O
genomes O
. O

The O
aryl B
hydrocarbon I
receptor I
( I
AhR I
) I
is O
a O
cytoplasmic O
receptor O
/ O
transcription O
factor O
that O
modulates O
several O
cellular O
and O
immunological O
processes O
following O
activation O
by O
pathogen O
- O
associated O
stimuli O
, O
though O
its O
role O
during O
virus O
infection O
is O
largely O
unknown O
. O

Here O
, O
we O
show O
that O
AhR O
is O
activated O
in O
cells O
infected O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
Coronavirus B
( I
CoV I
) I
, O
and O
contributes O
to O
the O
upregulation O
of O
downstream O
effector O
TCDD O
- O
inducible O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
( O
TiPARP O
) O
during O
infection O
. O

Further O
, O
we O
found O
that O
chemically O
inhibiting O
or O
activating O
AhR O
reciprocally O
modulated O
the O
expression O
levels O
of O
cytokines O
induced O
by O
infection O
, O
specifically O
, O
interleukin B
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
, O
IL O
- O
10 O
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
consistent O
with O
a O
role O
for O
AhR O
activation O
in O
the O
host O
response O
to O
MHV O
infection O
. O

Furthermore O
, O
while O
indoleamine O
2 O
, O
3 O
- O
dioxygenase O
( O
IDO1 O
) O
drives O
AhR O
activation O
in O
other O
settings O
, O
MHV O
infection O
induced O
equal O
expression O
of O
downstream O
genes O
in O
wild B
- I
type I
( I
WT I
) I
and O
IDO1 O
( O
- O
/ O
- O
) O
macrophages O
, O
suggesting O
an O
alternative O
pathway O
of O
AhR O
activation O
. O

Here O
, O
we O
show O
that O
the O
aryl B
hydrocarbon I
receptor I
( I
AhR I
) I
is O
activated O
in O
cells O
infected O
with O
a O
prototypic O
coronavirus O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
resulting O
in O
the O
expression O
of O
several O
effector O
genes O
. O

A O
number O
of O
positive O
- O
strand O
RNA O
viruses O
, O
such O
as O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
poliovirus O
, O
use O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
as O
replication O
sites O
. O

Our O
previous O
screen O
of O
NS4B O
- O
associated O
host O
membrane O
proteins O
by O
dual O
- O
affinity O
purification O
, O
liquid O
chromatography O
coupled O
to O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
, O
and O
small B
interfering I
RNA I
( I
siRNA I
) I
methods O
revealed O
that O
the O
Surfeit O
4 O
( O
Surf4 O
) O
gene O
, O
which O
encodes O
an O
integral O
membrane O
protein O
, O
is O
involved O
in O
the O
replication O
of O
the O
JFH1 O
subgenomic O
replicon O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
NS4B O
protein O
induces O
the O
formation O
of O
a O
membranous B
web I
( I
MW I
) I
structure O
that O
provides O
a O
platform O
for O
the O
assembly O
of O
viral O
replication O
complexes O
. O

The O
main O
constituents O
of O
the O
MW O
are O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
. O

Here O
, O
we O
found O
that O
the O
cellular O
protein O
Surf4 O
, O
which O
maintains O
endoplasmic B
reticulum I
( I
ER I
) I
- O
Golgi O
intermediate O
compartments O
and O
the O
Golgi O
compartment O
, O
is O
recruited O
into O
HCV O
RNA O
replication O
complexes O
by O
NS4B O
and O
is O
involved O
in O
the O
formation O
of O
DMVs O
. O

To O
counteract O
the O
serious O
health O
threat O
posed O
by O
known O
and O
novel O
viral O
pathogens O
, O
drugs O
that O
target O
a O
variety O
of O
viruses O
through O
a O
common O
mechanism O
have O
attracted O
recent O
attention O
due O
to O
their O
potential O
in O
treating O
( O
re O
) O
emerging O
infections O
, O
for O
which O
direct O
- O
acting O
antivirals O
are O
not O
available O
. O

Mechanistic O
studies O
on O
viral O
particles O
revealed O
that O
labyrinthopeptins O
induce O
a O
virolytic O
effect O
through O
binding O
to O
the O
viral O
membrane O
lipid O
phosphatidylethanolamine B
( I
PE I
) I
. O

Time O
- O
resolved O
experiments O
with O
large B
unilamellar I
vesicles I
( I
LUVs I
) I
reveal O
that O
membrane O
lipid O
raft O
compositions O
( O
phosphatidylcholine O
[ O
PC O
] O
/ O
PE O
/ O
cholesterol O
/ O
sphingomyelin O
at O
17 O
: O
10 O
: O
33 O
: O
40 O
) O
are O
particularly O
sensitive O
to O
labyrinthopeptins O
in O
comparison O
to O
PC O
/ O
PE O
( O
90 O
: O
10 O
) O
LUVs O
, O
even O
though O
the O
overall O
PE O
amount O
remains O
constant O
. O

Labyrinthopeptins O
exhibited O
low O
cytotoxicity O
and O
had O
favorable O
pharmacokinetic O
properties O
in O
mice O
( O
half O
- O
life O
[ O
t O
( O
1 O
/ O
2 O
) O
] O
= O
10 O
. O

Because O
the O
development O
of O
each O
antiviral O
drug O
is O
time O
- O
consuming O
and O
expensive O
, O
the O
prospect O
of O
finding O
broad O
- O
spectrum O
antivirals O
that O
can O
fight O
multiple O
, O
diverse O
viruses O
- O
well O
- O
known O
viruses O
as O
well O
as O
( O
re O
) O
emerging O
species O
- O
has O
gained O
attention O
, O
especially O
for O
the O
treatment O
of O
viral O
coinfections O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
- O
NS4A O
protease O
complex O
is O
required O
for O
viral O
replication O
and O
is O
the O
major O
viral O
innate O
immune O
evasion O
factor O
. O

Here O
, O
we O
identified O
a O
Tyr B
- I
16 I
- I
Phe I
( I
Y16F I
) I
change O
in O
the O
NS4A O
transmembrane O
domain O
that O
prevents O
NS3 O
- O
NS4A O
targeting O
of O
Riplet O
but O
not O
MAVS O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
protein O
possesses O
protease O
and O
helicase O
activities O
and O
is O
considered O
an O
oncoprotein O
in O
virus O
- O
derived O
hepatocellular O
carcinoma O
. O

In O
this O
study O
, O
we O
have O
identified O
novel O
interactions O
of O
the O
NS3 O
protein O
with O
DNA O
repair O
factors O
, O
Werner B
syndrome I
protein I
( I
WRN I
) I
and O
Ku70 O
, O
in O
both O
an O
HCV O
subgenomic O
replicon O
system O
and O
Huh7 O
cells O
expressing O
NS3 O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
( O
HBc O
) O
accumulates O
frequent O
mutations O
in O
natural O
infection O
. O

Mutant O
I97L O
in O
mice O
exhibited O
pleiotropic O
phenotypes O
: O
( O
i O
) O
excessive O
numbers O
of O
serum O
HBV O
virions O
containing O
immature O
genomes O
, O
( O
ii O
) O
significantly O
reduced O
numbers O
of O
intracellular O
relaxed O
- O
circle O
and O
single O
- O
stranded O
DNAs O
, O
and O
( O
iii O
) O
less O
persistent O
intrahepatic O
and O
secreted O
HBV O
DNAs O
than O
wild O
- O
type O
HBV O
. O

IMPORTANCE O
Chronic O
infection O
with O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
could O
lead O
to O
cirrhosis O
and O
hepatoma O
. O

The O
most O
frequent O
naturally O
occurring O
mutation O
in O
HBV O
core O
protein O
occurs O
at O
amino O
acid O
97 O
, O
changing O
an O
isoleucine O
to O
leucine O
( O
I97L O
) O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
one O
of O
the O
most O
common O
causes O
of O
acute O
hepatitis O
and O
jaundice O
in O
the O
world O
. O

Viable O
insertions O
in O
the O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
protein O
were O
selected O
in O
a O
hepatoblastoma O
cell O
line O
. O

Functional O
insertion O
sites O
were O
identified O
downstream O
of O
the O
methyltransferase O
domain O
, O
in O
the O
hypervariable B
region I
( I
HVR I
) I
, O
and O
between O
the O
helicase O
and O
RNA O
- O
dependent O
RNA O
polymerase O
domains O
. O

HEV O
genomes O
harboring O
a O
Hemagglutinin B
( I
HA I
) I
epitope O
tag O
or O
a O
small O
luciferase O
( O
NanoLuc O
) O
in O
the O
HVR O
were O
found O
to O
be O
fully O
functional O
and O
to O
allow O
the O
production O
of O
infectious O
virus O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
infection O
is O
an O
important O
cause O
of O
acute O
hepatitis O
and O
may O
lead O
to O
chronic O
infection O
in O
immunocompromised O
patients O
. O

Previously O
, O
the O
cyclophilin O
inhibitors O
Cyclosporine B
( I
CsA I
) I
and O
alisporivir B
( I
ALV I
) I
were O
shown O
to O
inhibit O
the O
replication O
of O
diverse O
RNA O
viruses O
, O
including O
arteriviruses O
and O
coronaviruses O
, O
which O
both O
belong O
to O
the O
order O
Nidovirales O
. O

Repeated O
passaging O
of O
the O
arterivirus O
prototype O
equine B
arteritis I
virus I
( I
EAV I
) I
in O
the O
presence O
of O
CsA O
revealed O
that O
reduced O
drug O
sensitivity O
is O
associated O
with O
the O
emergence O
of O
adaptive O
mutations O
in O
nonstructural B
protein I
5 I
( I
NSP5 I
) I
, O
one O
of O
the O
transmembrane O
subunits O
of O
the O
arterivirus O
replicase O
polyprotein O
. O

Introduction O
of O
singular O
nsp5 O
mutations O
( O
nsp5 O
Q21R O
, O
Y113H O
, O
or O
A134V O
) O
led O
to O
an O
similar O
to O
2 O
- O
fold O
decrease O
in O
sensitivity O
to O
CsA O
treatment O
, O
whereas O
combinations O
of O
mutations O
further O
increased O
EAV O
' O
s O
CsA O
resistance O
. O

Interestingly O
, O
for O
increased O
sensitivity O
to O
the O
closely O
related O
drug O
ALV O
, O
CsA O
- O
resistant O
nsp5 O
mutants O
required O
the O
incorporation O
of O
an O
additional O
adaptive O
mutation O
, O
which O
resided O
in O
nsp2 O
( O
H114R O
) O
, O
another O
transmembrane O
subunit O
of O
the O
arterivirus O
replicase O
. O

Previously O
, O
the O
cyclophilin O
inhibitors O
Cyclosporine B
( I
CsA I
) I
and O
alisporivir B
( I
ALV I
) I
were O
shown O
to O
inhibit O
the O
replication O
of O
diverse O
nidoviruses O
( O
both O
arteriviruses O
and O
coronaviruses O
) O
, O
and O
they O
may O
thus O
represent O
a O
class O
of O
pannidovirus O
inhibitors O
. O

Using O
an O
inducible O
proteolipid B
protein I
( I
Plp I
) I
promoter O
- O
driven O
Cre O
- O
loxP O
recombination O
system O
, O
we O
were O
able O
to O
assess O
how O
timed O
ablation O
of O
Cxcr2 O
in O
oligodendroglia O
affected O
disease O
following O
intracranial O
infection O
with O
the O
neurotropic O
JHM B
strain I
of I
mouse I
hepatitis I
virus I
( I
JHMV I
) I
. O

Generation O
of O
Plp O
- O
Cre O
- O
ER O
( O
T O
) O
: O
: O
Cxcr2 O
( O
flox O
/ O
flox O
) O
transgenic O
mice O
( O
termed O
Cxcr2 O
- O
CKO O
mice O
) O
allows O
for O
Cxcr2 O
to O
be O
silenced O
in O
oligo O
- O
dendrocytes O
in O
adult O
mice O
following O
treatment O
with O
tamoxifen O
. O

Infiltration O
of O
activated O
T O
cells O
or O
myeloid O
cells O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
was O
not O
affected O
, O
nor O
was O
the O
ability O
to O
control O
viral O
infection O
. O

Notably O
, O
deletion O
of O
Cxcr2 O
resulted O
in O
increased O
remyelination O
, O
as O
assessed O
by O
g O
- O
ratio O
( O
the O
ratio O
of O
the O
inner O
axonal O
diameter O
to O
the O
total O
outer O
fiber O
diameter O
) O
calculation O
, O
compared O
to O
that O
in O
vehicle O
- O
treated O
control O
mice O
. O

Collectively O
, O
our O
findings O
argue O
that O
CXCR2 O
signaling O
in O
oligodendroglia O
is O
dispensable O
with O
regard O
to O
contributing O
to O
neuroinflammation O
, O
but O
its O
deletion O
enhances O
remyelination O
in O
a O
preclinical O
model O
of O
the O
human O
demyelinating O
disease O
multiple B
sclerosis I
( I
MS I
) I
. O

IMPORTANCE O
Signaling O
through O
the O
chemokine O
receptor O
CXCR2 O
in O
oligodendroglia O
is O
important O
for O
developmental O
myelination O
in O
rodents O
, O
while O
chemical O
inhibition O
or O
nonspecific O
genetic O
deletion O
of O
CXCR2 O
appears O
to O
augment O
myelin O
repair O
in O
animal O
models O
of O
the O
human O
demyelinating O
disease O
multiple B
sclerosis I
( I
MS I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
promotes O
metabolic O
disorders O
, O
and O
the O
severity O
of O
lipogenic O
disease O
depends O
upon O
the O
infecting O
virus O
genotype O
. O

Here O
, O
we O
have O
examined O
HCV O
genotype O
1 O
- O
, O
2 O
- O
, O
or O
3 O
- O
specific O
regulation O
of O
lipid O
metabolism O
, O
involving O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
- O
regulated O
phospho B
- I
Akt I
( I
p I
- I
Akt I
) I
and O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
axes O
. O

The O
expression O
of O
regulatory O
molecules O
, O
TGF O
- O
beta O
1 O
/ O
2 O
, O
phospho O
- O
Akt O
( O
Ser473 O
) O
, O
PPAR O
alpha O
, O
sterol B
regulatory I
element I
- I
binding I
protein I
1 I
( I
SREBP I
- I
1 I
) I
, O
fatty B
acid I
synthase I
( I
FASN I
) I
, O
hormone B
- I
sensitive I
lipase I
( I
HSL I
) I
, O
and O
acyl O
dehydrogenases O
was O
analyzed O
in O
virus O
- O
infected O
hepatocytes O
. O

The O
key O
role O
of O
TGF O
- O
beta O
was O
further O
verified O
using O
specific O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

IMPORTANCE O
Hepatic O
steatosis O
is O
a O
frequent O
complication O
associated O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
and O
is O
a O
key O
prognostic O
indicator O
for O
progression O
to O
fibrosis O
and O
cirrhosis O
. O

Our O
observations O
suggest O
that O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
and O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
- O
associated O
mechanistic O
pathways O
in O
hepatocytes O
infected O
with O
HCV O
genotype O
2a O
and O
3a O
differ O
from O
those O
in O
cells O
infected O
with O
genotype O
1a O
. O

However O
, O
the O
role O
of O
autophagy O
in O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
infection O
is O
unclear O
. O

Here O
, O
we O
show O
that O
N B
- I
Myc I
downstream I
- I
regulated I
gene I
1 I
( I
NDRG1 I
) I
deficiency O
induced O
autophagy O
, O
which O
facilitated O
PRRSV O
replication O
by O
regulating O
lipid O
metabolism O
. O

NDRG1 O
deficiency O
reduced O
the O
number O
of O
intracellular O
lipid B
droplets I
( I
LDs I
) I
, O
but O
the O
expression O
levels O
of O
key O
genes O
in O
lipogenesis O
and O
lipolysis O
were O
not O
altered O
. O

Our O
results O
also O
show O
that O
NDRG1 O
deficiency O
promoted O
autophagy O
and O
increased O
the O
subsequent O
yields O
of O
hydrolyzed O
free B
fatty I
acids I
( I
FFAs I
) I
. O

IMPORTANCE O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
, O
an O
enveloped O
single O
- O
positive O
- O
stranded O
RNA O
virus O
, O
causes O
acute O
respiratory O
distress O
in O
piglets O
and O
reproductive O
failure O
in O
sows O
. O

The O
structural B
maintenance I
of I
chromosomes I
5 I
/ I
6 I
complex I
( I
Smc5 I
/ I
6 I
) I
is O
a O
host O
restriction O
factor O
that O
suppresses O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
. O

HBV O
counters O
this O
restriction O
by O
expressing O
the O
X O
protein O
( O
HBx O
) O
, O
which O
redirects O
the O
host B
DNA I
damage I
- I
binding I
protein I
1 I
( I
DDB1 I
) I
E3 O
ubiquitin O
ligase O
to O
target O
Smc5 O
/ O
6 O
for O
degradation O
. O

HBx O
is O
an O
attractive O
therapeutic O
target O
for O
the O
treatment O
of O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
but O
it O
is O
challenging O
to O
study O
this O
important O
viral O
protein O
in O
the O
context O
of O
natural O
infection O
due O
to O
the O
lack O
of O
a O
highly O
specific O
and O
sensitive O
HBx O
antibody O
. O

In O
this O
study O
, O
we O
developed O
a O
novel O
monoclonal O
antibody O
that O
enables O
detection O
of O
HBx O
protein O
in O
HBV O
- O
infected O
primary B
human I
hepatocytes I
( I
PHH I
) I
by O
Western O
blotting O
and O
immunofluorescence O
. O

Our O
study O
also O
revealed O
that O
HBx O
is O
expressed O
early O
after O
infection O
and O
has O
a O
short O
half O
- O
life O
( O
similar O
to O
3 O
h O
) O
in O
HBV O
- O
infected O
PHH O
. O

In O
addition O
, O
we O
found O
that O
treatment O
with O
small B
interfering I
RNAs I
( I
siRNAs I
) I
that O
target O
DDB1 O
or O
HBx O
mRNA O
decreased O
HBx O
protein O
levels O
and O
led O
to O
the O
reappearance O
of O
Smc6 O
in O
the O
nuclei O
of O
HBV O
- O
infected O
PHH O
. O

IMPORTANCE O
Hepatitis B
B I
virus I
X I
protein I
( I
HBx I
) I
is O
a O
promising O
drug O
target O
since O
it O
promotes O
the O
degradation O
of O
the O
host B
structural I
maintenance I
of I
chromosomes I
5 I
/ I
6 I
complex I
( I
Smc5 I
/ I
6 I
) I
that O
inhibits O
HBV O
transcription O
. O

The O
host B
structural I
maintenance I
of I
chromosomes I
5 I
/ I
6 I
complex I
( I
Smc5 I
/ I
6 I
) I
suppresses O
hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
. O

HBV O
counters O
this O
restriction O
by O
expressing O
the O
X O
protein O
( O
HBx O
) O
, O
which O
redirects O
the O
cellular O
DNA B
damage I
- I
binding I
protein I
1 I
( I
DDB1 I
) I
- O
containing O
E3 O
ubiquitin O
ligase O
to O
target O
Smc5 O
/ O
6 O
for O
degradation O
. O

In O
this O
study O
, O
we O
performed O
biophysical O
analyses O
of O
recombinant O
HBx O
and O
functional O
analysis O
of O
HBx O
mutants O
in O
HBV O
- O
infected O
primary B
human I
hepatocytes I
( I
PHH I
) I
to O
identify O
key O
regions O
and O
residues O
that O
are O
required O
for O
HBx O
function O
. O

Mass O
spectrometry O
- O
based O
hydrogen O
- O
deuterium O
exchange O
and O
cysteine O
- O
specific O
chemical O
footprinting O
of O
the O
HBx O
: O
DDB1 O
complex O
identified O
several O
HBx O
cysteine O
residues O
( O
located O
between O
amino O
acids O
61 O
and O
137 O
) O
that O
are O
likely O
involved O
in O
zinc O
binding O
. O

IMPORTANCE O
The O
structural B
maintenance I
of I
chromosomes I
5 I
/ I
6 I
complex I
( I
Smc5 I
/ I
6 I
) I
is O
a O
host O
restriction O
factor O
that O
suppresses O
HBV O
transcription O
. O

HBV O
counters O
this O
restriction O
by O
expressing O
HBV B
X I
protein I
( I
HBx I
) I
, O
which O
redirects O
a O
host O
ubiquitin O
ligase O
to O
target O
Smc5 O
/ O
6 O
for O
degradation O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
causes O
chronic O
infection O
in O
an O
estimated O
240 O
million O
people O
; O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
an O
HBV O
homologue O
, O
has O
been O
an O
important O
model O
system O
for O
drug O
development O
. O

The O
dimeric B
capsid I
protein I
( I
Cp I
) I
has O
multiple O
functions O
during O
the O
viral O
life O
cycle O
and O
thus O
has O
become O
an O
important O
target O
for O
a O
new O
generation O
of O
antivirals O
. O

5 O
- O
A O
resolution O
by O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
and O
of O
the O
WHV O
Cp O
dimer O
to O
2 O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
7 O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
emerging O
virus O
found O
predominately O
in O
developing O
countries O
; O
it O
causes O
an O
estimated O
20 O
million O
infections O
, O
which O
result O
in O
approximately O
57 O
, O
000 O
deaths O
a O
year O
. O

Analysis O
of O
temperature B
- I
sensitive I
( I
ts I
) I
mutant O
viruses O
is O
a O
classic O
method O
allowing O
researchers O
to O
identify O
genetic O
loci O
involved O
in O
viral O
replication O
and O
patho O
- O
genesis O
. O

Here O
, O
we O
report O
genetic O
analysis O
of O
a O
ts O
strain O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
tsNC11 O
, O
focusing O
on O
the O
role O
of O
mutations O
in O
the O
macrodomain B
( I
MAC I
) I
and O
the O
papain B
- I
like I
protease I
2 I
( I
PLP2 I
) I
domain O
of O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
, O
a O
component O
of O
the O
viral O
replication O
complex O
. O

IMPORTANCE O
Coronaviruses B
( I
CoVs I
) I
are O
emerging O
human O
and O
veterinary O
pathogens O
with O
pandemic O
potential O
. O

Recent O
emergence O
of O
direct B
- I
acting I
antivirals I
( I
DAAs I
) I
targeting O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
has O
considerably O
enhanced O
the O
success O
of O
antiviral O
therapy O
. O

Interestingly O
, O
dehydrojuncusol O
was O
able O
to O
inhibit O
RNA O
replication O
of O
two O
frequent O
daclatasvir O
- O
resistant O
mutants O
( O
L31M O
or O
Y93H O
in O
NS5A O
) O
. O

IMPORTANCE O
Tens O
of O
millions O
of O
people O
are O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
worldwide O
. O

Recently O
marketed O
direct B
- I
acting I
antivirals I
( I
DAAs I
) I
targeting O
HCV O
proteins O
have O
enhanced O
the O
efficacy O
of O
treatment O
. O

enterovirus B
D68 I
( I
EV I
- I
D68 I
) I
is O
a O
viral O
pathogen O
that O
leads O
to O
severe O
respiratory O
illness O
and O
has O
been O
linked O
with O
the O
development O
of O
acute B
flaccid I
myelitis I
( I
AFM I
) I
in O
children O
. O

Here O
, O
we O
report O
the O
expression O
of O
the O
EV O
- O
D68 O
2A O
protease O
( O
2A B
( I
pro I
) I
) O
and O
characterization O
of O
its O
enzymatic O
activity O
. O

Furthermore O
, O
we O
discovered O
that O
telaprevir O
, O
an O
FDA O
- O
approved O
drug O
used O
for O
the O
treatment O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
, O
is O
a O
potent O
antiviral O
against O
EV O
- O
D68 O
by O
targeting O
the O
2A B
( I
pro I
) I
enzyme O
. O

Using O
a O
fluorescence O
resonance O
energy O
transfer O
- O
based O
substrate O
cleavage O
assay O
, O
we O
showed O
that O
the O
purified O
EV O
- O
D68 O
2A B
( I
pro I
) I
has O
proteolytic O
activity O
selective O
against O
a O
peptide O
sequence O
corresponding O
to O
the O
viral O
VP1 O
- O
2A O
polyprotein O
junction O
. O

Telaprevir O
inhibits O
EV O
- O
D68 O
2A B
( I
pro I
) I
through O
a O
nearly O
irreversible O
, O
biphasic O
binding O
mechanism O
. O

An O
N84T O
mutation O
near O
the O
active O
site O
of O
2A B
( I
pro I
) I
was O
identified O
in O
resistant O
viruses O
, O
and O
this O
mutation O
reduced O
the O
potency O
of O
telaprevir O
in O
both O
the O
enzymatic O
and O
cellular O
antiviral O
assays O
. O

Collectively O
, O
we O
report O
for O
the O
first O
time O
the O
in O
vitro O
enzymatic O
activity O
of O
EV O
- O
D68 O
2A B
( I
pro I
) I
and O
the O
identification O
of O
telaprevir O
as O
a O
potent O
EV O
- O
D68 O
2A B
( I
pro I
) I
inhibitor O
. O

These O
findings O
implicate O
EV O
- O
D68 O
2A B
( I
pro I
) I
as O
an O
antiviral O
drug O
target O
and O
highlight O
the O
repurposing O
potential O
of O
telaprevir O
to O
treat O
EV O
- O
D68 O
infection O
. O

Here O
, O
we O
characterize O
and O
validate O
a O
new O
EV O
- O
D68 O
drug O
target O
, O
the O
2A B
( I
pro I
) I
, O
and O
identify O
telaprevir O
- O
an O
FDA O
- O
approved O
drug O
used O
to O
treat O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
- O
as O
a O
potent O
antiviral O
with O
a O
novel O
mechanism O
of O
action O
toward O
2A B
( I
pro I
) I
. O

2A B
( I
pro I
) I
functions O
as O
a O
viral O
protease O
that O
cleaves O
a O
peptide O
sequence O
corresponding O
to O
the O
VP1 O
- O
2A O
polyprotein O
junction O
. O

The O
binding O
of O
telaprevir O
potently O
inhibits O
its O
enzymatic O
activity O
, O
and O
using O
drug O
resistance O
selection O
, O
we O
show O
that O
the O
potent O
antiviral O
activity O
of O
telaprevir O
was O
due O
to O
2A B
( I
pro I
) I
inhibition O
. O

This O
is O
the O
first O
inhibitor O
to O
selectively O
target O
the O
2A B
( I
pro I
) I
from O
EV O
- O
D68 O
and O
can O
be O
used O
as O
a O
starting O
point O
for O
the O
development O
of O
therapeutics O
with O
selective O
activity O
against O
EV O
- O
D68 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
utilizes O
cellular O
factors O
for O
efficient O
propagation O
. O

We O
found O
that O
inhibition O
of O
deubiquitinating B
enzymes I
( I
DUBs I
) I
or O
overexpression O
of O
nonspecific O
DUBs O
impaired O
HCV O
replication O
, O
suggesting O
that O
ubiquitination O
regulates O
HCV O
replication O
. O

To O
identify O
specific O
DUBs O
involved O
in O
HCV O
propagation O
, O
we O
set O
up O
RNA B
interference I
( I
RNAi I
) I
screening O
against O
DUBs O
and O
successfully O
identified O
ubiquitin B
- I
specific I
protease I
15 I
( I
USP15 I
) I
as O
a O
novel O
host O
factor O
for O
HCV O
propagation O
. O

In O
addition O
, O
deficiency O
of O
USP15 O
in O
human O
hepatic O
cell O
lines O
( O
Huh7 O
and O
Hep3B O
/ O
miR O
- O
122 O
cells O
) O
but O
not O
in O
a O
nonhepatic O
cell O
line O
( O
293T O
cells O
) O
impaired O
HCV O
propagation O
, O
suggesting O
that O
USP15 O
participates O
in O
HCV O
propagation O
through O
the O
regulation O
of O
hepatocyte O
- O
specific O
functions O
. O

We O
also O
found O
that O
USP15 O
- O
deficient O
Huh7 O
cells O
showed O
reductions O
in O
the O
amounts O
of O
lipid B
droplets I
( I
LDs I
) I
, O
and O
the O
addition O
of O
palmitic O
acids O
restored O
the O
production O
of O
infectious O
HCV O
particles O
. O

IMPORTANCE O
Although O
ubiquitination O
has O
been O
shown O
to O
play O
important O
roles O
in O
the O
HCV O
life O
cycle O
, O
the O
roles O
of O
deubiquitinating B
enzymes I
( I
DUBs I
) I
, O
which O
cleave O
ubiquitin O
chains O
from O
their O
substrates O
, O
in O
HCV O
propagation O
have O
not O
been O
investigated O
. O

Therapeutic O
vaccines O
may O
be O
an O
important O
component O
of O
a O
treatment O
regimen O
for O
curing O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
. O

We O
previously O
demonstrated O
that O
recombinant O
wild O
- O
type O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
expressing O
the O
HBV O
middle O
surface O
glycoprotein O
( O
MHBs O
) O
elicits O
functional O
immune O
responses O
in O
mouse O
models O
of O
HBV O
replication O
. O

Compared O
to O
wild O
- O
type O
VSV O
, O
the O
highly O
attenuated O
virus O
displayed O
markedly O
reduced O
pathogenesis O
but O
induced O
similar O
MHBsspecific O
CD8 O
( O
+ O
) O
T O
cell O
and O
antibody O
responses O
. O

The O
CD8 O
( O
+ O
) O
T O
cell O
responses O
elicited O
by O
this O
vector O
in O
naive O
mice O
prevented O
HBV O
replication O
in O
animals O
that O
were O
later O
challenged O
by O
hydrodynamic O
injection O
or O
transduction O
with O
adeno O
- O
associated O
virus O
encoding O
the O
HBV O
genome O
( O
AAV O
- O
HBV O
) O
. O

In O
mice O
in O
which O
persistent O
HBV O
replication O
was O
first O
established O
by O
AAV O
- O
HBV O
transduction O
, O
subsequent O
immunization O
with O
the O
attenuated O
VSV O
induced O
MHBs O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
that O
corresponded O
with O
reductions O
in O
serum O
and O
liver O
HBV O
antigens O
and O
nucleic O
acids O
. O

HBV O
control O
was O
associated O
with O
an O
increase O
in O
the O
frequency O
of O
intrahepatic O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
and O
a O
transient O
elevation O
in O
serum O
alanine O
aminotransferase O
activity O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
and O
its O
hepadnavirus O
relatives O
infect O
a O
wide O
range O
of O
vertebrates O
, O
from O
fish O
to O
human O
. O

Here O
, O
we O
present O
evidence O
suggesting O
that O
the O
adaptive O
evolution O
of O
the O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
, O
an O
HBV O
receptor O
, O
has O
been O
influenced O
by O
virus O
infection O
. O

Evolutionary O
analysis O
of O
the O
NTCPencoding O
genes O
from O
20 O
mammals O
showed O
that O
most O
NTCP O
residues O
are O
highly O
conserved O
among O
species O
, O
exhibiting O
evolution O
under O
negative O
selection O
( O
dN O
/ O
dS O
ratio O
[ O
ratio O
of O
nonsynonymous O
to O
synonymous O
evolutionary O
changes O
] O
of O
< O
1 O
) O
; O
this O
observation O
implies O
that O
the O
evolution O
of O
NTCP O
is O
restricted O
by O
maintaining O
its O
original O
protein O
function O
. O

7 O
% O
of O
NTCP O
amino O
acid O
residues O
exhibit O
rapid O
evolution O
under O
positive O
selection O
( O
dN O
/ O
dS O
ratio O
of O
> O
1 O
) O
. O

Notably O
, O
a O
substitution O
at O
amino B
acid I
( I
aa I
) I
158 O
, O
a O
positively O
selected O
residue O
, O
converting O
the O
human O
NTCP O
to O
a O
monkeytype O
sequence O
abrogated O
the O
capacity O
to O
support O
HBV O
infection O
; O
conversely O
, O
a O
substitution O
at O
this O
residue O
converting O
the O
monkey O
Ntcp O
to O
the O
human O
sequence O
was O
sufficient O
to O
confer O
HBV O
susceptibility O
. O

IMPORTANCE O
HBV O
and O
its O
hepadnavirus O
relatives O
infect O
a O
wide O
range O
of O
vertebrates O
, O
with O
a O
long O
infectious O
history O
( O
hundreds O
of O
millions O
of O
years O
) O
. O

In O
the O
present O
study O
, O
we O
performed O
coevolutionary O
phylogenetic O
analysis O
between O
hepadnaviruses O
and O
the O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
, O
an O
HBV O
receptor O
, O
combined O
with O
virological O
experimental O
assays O
for O
investigating O
the O
biological O
significance O
of O
NTCP O
sequence O
variation O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
common O
cause O
of O
acute O
viral O
hepatitis O
worldwide O
. O

Most O
HEV O
infections O
are O
asymptomatic O
, O
but O
immunocompromised O
patients O
infected O
with O
HEV O
genotype O
3 O
( O
HEV3 O
) O
, O
HEV4 O
, O
or O
HEV7 O
may O
develop O
chronic O
infections O
. O

The O
HEV O
particles O
in O
stools O
are O
naked O
( O
nHEV O
) O
, O
while O
those O
in O
the O
serum O
and O
culture O
supernatants O
( O
eHEV O
) O
are O
associated O
with O
lipids O
. O

Hepatocytes O
are O
polarized O
epithelial O
cells O
that O
have O
basolateral O
( O
oriented O
toward O
the O
blood O
) O
and O
apical O
( O
oriented O
toward O
the O
bile O
) O
exosomal O
pathways O
. O

Confocal O
microscopy O
indicated O
that O
the O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
capsid O
protein O
colocalized O
apically O
with O
ORF3 O
virus O
protein O
, O
the O
apical O
marker O
DPP4 O
, O
and O
the O
recycling O
endosome O
GTPase O
Rab27a O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
in O
stools O
is O
naked O
, O
while O
that O
in O
culture O
supernatants O
and O
patients O
' O
blood O
is O
lipid O
associated O
. O

Similar O
amounts O
of O
the O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
soluble O
capsid O
protein O
were O
secreted O
from O
both O
sides O
of O
the O
hepatocytes O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
may O
cause O
chronic O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

We O
demonstrate O
here O
that O
ubiquitin B
- I
conjugating I
enzyme I
E2S I
( I
UBE2S I
) I
, O
a O
member O
of O
the O
ubiquitin O
- O
conjugating O
enzyme O
family O
( O
E2s O
) O
, O
was O
downregulated O
by O
endoplasmic O
reticulum O
stress O
caused O
by O
HCV O
in O
Huh7 O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
virus O
that O
is O
prevalent O
worldwide O
, O
manipulates O
the O
host O
' O
s O
innate O
immune O
system O
to O
evade O
scavenging O
. O

It O
is O
reported O
that O
the O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
can O
interfere O
with O
NF O
- O
kappa O
B O
activity O
, O
which O
then O
leads O
to O
high O
viral O
loads O
, O
while O
HBV O
with O
the O
G1896A O
mutation O
remains O
infectious O
without O
the O
production O
of O
HBeAg O
but O
can O
induce O
more O
severe O
proinfiammatory O
response O
and O
liver O
damage O
. O

The O
aim O
of O
current O
work O
was O
to O
study O
the O
molecular O
mechanism O
by O
which O
HBeAg O
suppresses O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
- O
stimulated O
NF O
- O
kappa O
B O
activity O
, O
which O
leads O
to O
the O
suppression O
of O
the O
innate O
immune O
responses O
to O
HBV O
infection O
. O

HBeAg O
suppressed O
the O
IL O
- O
1 O
beta O
- O
induced O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
associated O
factor O
6 O
( O
TRAF6 O
) O
- O
dependent O
K63 O
- O
linked O
ubiquitination O
of O
NEMO O
, O
thereby O
downregulating O
NF O
- O
kappa O
B O
activity O
and O
promoting O
virus O
replication O
. O

IMPORTANCE O
The O
role O
of O
HBeAg O
in O
inflammatory O
responses O
during O
the O
infection O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
not O
fully O
understood O
, O
and O
several O
previous O
reports O
with O
regard O
to O
the O
NF O
- O
kappa O
B O
pathway O
are O
controversial O
. O

In O
this O
study O
, O
we O
showed O
that O
HBeAg O
could O
suppress O
both O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
- O
and O
IL O
- O
1 O
beta O
- O
induced O
activation O
of O
NF O
- O
kappa O
B O
in O
cells O
and O
clinical O
samples O
, O
and O
we O
further O
revealed O
novel O
molecular O
mechanisms O
. O

We O
found O
that O
HBeAg O
can O
associate O
with O
NEMO O
, O
the O
regulatory O
subunit O
for O
I B
kappa I
B I
kinase I
( I
IKK I
) I
that O
controls O
the O
NF O
- O
kappa O
B O
signaling O
pathway O
, O
and O
thereby O
inhibits O
TRAF6 O
- O
mediated O
K63 O
- O
linked O
ubiquitination O
of O
NEMO O
, O
resulting O
in O
downregulation O
of O
NF O
- O
kappa O
B O
activity O
and O
promotion O
of O
virus O
replication O
. O

plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
are O
innate O
immune O
cells O
with O
high O
antiviral O
activity O
triggered O
by O
Toll B
- I
like I
receptor I
7 I
( I
TLR I
- I
7 I
) I
and O
TLR O
- O
9 O
stimulation O
. O

Although O
nowadays O
there O
is O
available O
an O
effective O
therapeutic O
arsenal O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
protective O
vaccine O
is O
not O
available O
. O

We O
have O
analyzed O
the O
pDCs O
' O
response O
to O
HCV O
infection O
in O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
Huh7 O
. O

pDCs O
were O
cocultured O
following O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
aldrithiol O
- O
2 O
( O
AT O
- O
2 O
[ O
TLR O
- O
7 O
agonist O
] O
) O
inactivation O
and O
CpG O
( O
TLR O
- O
9 O
agonist O
) O
stimulation O
. O

We O
employed O
three O
virus O
derivatives O
- O
wild O
- O
type O
Jc1 O
, O
interferon B
( I
IFN I
) I
- O
resistant O
virus O
IR O
, O
and O
high O
- O
replicative O
- O
fitness O
virus O
P100 O
- O
in O
order O
to O
explore O
additional O
IFN O
- O
alpha O
- O
related O
virus O
inhibition O
mechanisms O
. O

TLR O
- O
7 O
stimulation O
drove O
higher O
TNF B
- I
related I
apoptosis I
- I
inducing I
ligand I
( I
TRAIL I
) I
expression O
in O
pDCs O
. O

The O
quasi O
- O
envelopment O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
capsids O
in O
exosome O
- O
like O
virions O
( O
eHAV O
) O
is O
an O
important O
but O
incompletely O
understood O
aspect O
of O
the O
hepatovirus O
life O
cycle O
. O

The O
endosomal B
sorting I
complexes I
required I
for I
transport I
( I
ESCRT I
) I
are O
key O
to O
this O
process O
, O
as O
is O
the O
ESCRT O
- O
III O
- O
associated O
protein O
, O
ALIX O
, O
which O
also O
contributes O
to O
membrane O
budding O
of O
conventional O
enveloped O
viruses O
. O

Mutational O
studies O
of O
these O
domains O
are O
confounded O
by O
the O
fact O
that O
the O
Tyr O
residues O
( O
important O
for O
interactions O
of O
YPX1or3L O
peptides O
with O
ALIX O
) O
are O
required O
for O
efficient O
capsid O
assembly O
. O

However O
, O
single O
Leu O
- O
to O
- O
Ala O
substitutions O
within O
either O
VP2 O
YPX3L O
motif O
( O
L1 O
- O
A O
and O
L2 O
- O
A O
mutants O
) O
were O
well O
tolerated O
, O
albeit O
associated O
with O
significantly O
reduced O
eHAV O
release O
. O

In O
contrast O
, O
simultaneous O
substitutions O
in O
both O
motifs O
( O
L1 O
, O
2 O
- O
A O
) O
eliminated O
virus O
release O
but O
did O
not O
inhibit O
assembly O
of O
infectious O
intracellular O
particles O
. O

IMPORTANCE O
Nonlytic O
release O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
as O
exosome O
like O
quasi O
- O
enveloped O
virions O
is O
a O
unique O
but O
incompletely O
understood O
aspect O
of O
the O
hepatovirus O
life O
cycle O
. O

Chronic O
infection O
with O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
is O
a O
major O
health O
problem O
. O

Virus O
persistence O
requires O
the O
establishment O
and O
maintenance O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
the O
episomal O
virus O
template O
in O
the O
nucleus O
of O
infected O
hepatocytes O
. O

Compared O
to O
replicative O
DNA O
intermediates O
( O
relaxed O
circular O
DNA O
[ O
rcDNA O
) O
) O
, O
copy O
numbers O
of O
cccDNA O
in O
infected O
hepatocytes O
are O
low O
. O

Accordingly O
, O
accurate O
analyses O
of O
cccDNA O
require O
enrichment O
of O
nuclear O
fractions O
and O
Southern O
blotting O
or O
selective O
quantitative B
PCR I
( I
qPCR I
) I
methods O
allowing O
discrimination O
of O
cccDNA O
and O
rcDNA O
. O

We O
further O
analyzed O
the O
kinetics O
of O
cccDNA O
formation O
and O
the O
effect O
of O
drugs O
( O
interferon O
, O
entry O
inhibitors O
, O
and O
capsid O
inhibitors O
) O
on O
cccDNA O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
roles O
of O
interactions O
among O
the O
poly O
( O
A O
) O
tail O
, O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
, O
and O
poly O
( O
A O
) O
- O
binding O
protein O
( O
PABP O
) O
in O
the O
regulation O
of O
coronavirus O
gene O
expression O
. O

Through O
dissociation O
constant O
( O
k O
( O
d O
) O
) O
comparison O
, O
we O
found O
that O
the O
coronavirus O
N O
protein O
can O
bind O
to O
the O
poly O
( O
A O
) O
tail O
with O
high O
affinity O
, O
establishing O
N O
protein O
as O
a O
PABP O
. O

A O
subsequent O
analysis O
with O
UV O
cross O
- O
linking O
and O
immunoprecipitation O
revealed O
that O
the O
N O
protein O
is O
able O
to O
bind O
to O
the O
poly O
( O
A O
) O
tail O
in O
infected O
cells O
. O

Further O
examination O
demonstrated O
that O
poly O
( O
A O
) O
tail O
binding O
by O
the O
N O
protein O
negatively O
regulates O
translation O
of O
coronaviral O
RNA O
and O
host O
mRNA O
both O
in O
vitro O
and O
in O
cells O
. O

Although O
the O
N O
protein O
can O
interact O
with O
PABP O
and O
eukaryotic B
initiation I
factor I
4G I
( I
eIF4G I
) I
, O
the O
poor O
interaction O
efficiency O
between O
the O
poly O
( O
A O
) O
- O
bound O
N O
protein O
and O
elF4E O
may O
explain O
the O
observed O
decreased O
translation O
efficiency O
. O

In O
addition O
to O
interaction O
with O
translation O
factor O
elF4G O
, O
the O
N O
protein O
is O
able O
to O
interact O
with O
coronavirus O
nonstructural B
protein I
9 I
( I
nsp9 I
) I
, O
a O
replicase O
protein O
required O
for O
replication O
. O

The O
study O
demonstrates O
interactions O
among O
the O
poly O
( O
A O
) O
tail O
, O
N O
protein O
, O
and O
PABP O
both O
in O
vitro O
and O
in O
infected O
cells O
. O

Of O
the O
interactions O
, O
binding O
of O
the O
poly O
( O
A O
) O
tail O
to O
N O
protein O
decreases O
the O
interaction O
efficiency O
between O
the O
poly O
( O
A O
) O
tail O
and O
elF4E O
, O
leading O
to O
translation O
inhibition O
. O

The O
poly O
( O
A O
) O
- O
dependent O
translation O
inhibition O
by O
N O
protein O
has O
not O
been O
previously O
demonstrated O
and O
thus O
extends O
our O
understanding O
of O
coronavirus O
gene O
expression O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
coronavirus O
N O
protein O
is O
able O
to O
bind O
to O
the O
poly O
( O
A O
) O
tail O
with O
high O
affinity O
, O
establishing O
N O
protein O
as O
a O
PABP O
. O

We O
also O
show O
how O
the O
interplay O
between O
coronavirus O
3 O
' O
poly O
( O
A O
) O
tail O
, O
PABP O
, O
and O
N O
protein O
regulates O
gene O
expression O
of O
the O
coronavirus O
and O
host O
cell O
. O

Of O
the O
interactions O
, O
poly O
( O
A O
) O
tail O
binding O
by O
the O
N O
protein O
negatively O
regulates O
translation O
, O
and O
to O
our O
knowledge O
, O
this O
inhibition O
of O
translation O
by O
binding O
of O
the O
N O
protein O
to O
poly O
( O
A O
) O
tail O
has O
not O
been O
previously O
studied O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
an O
arbovirus O
that O
causes O
disease O
in O
livestock O
and O
humans O
in O
Africa O
and O
the O
Middle O
East O
. O

To O
test O
this O
hypothesis O
in O
vivo O
, O
we O
used O
an O
attenuated O
virus O
( O
DelNSsRVFV O
) O
that O
does O
not O
typically O
cause O
disease O
in O
mice O
. O

To O
determine O
how O
coinfection O
by O
these O
two O
unrelated O
respiratory O
viruses O
affects O
pathogenesis O
, O
we O
established O
a O
mouse O
model O
using O
a O
minor O
serogroup O
rhinovirus O
( O
rhinovirus O
strain O
1B O
[ O
RV1B O
] O
) O
and O
mouse O
- O
adapted O
influenza O
A O
virus O
( O
A O
/ O
Puerto O
Rico O
/ O
8 O
/ O
1934 O
[ O
PR8 O
] O
) O
. O

Finally O
, O
disease O
attenuation O
was O
not O
unique O
to O
RV1B O
: O
dose O
- O
dependent O
coinfection O
by O
a O
murine O
coronavirus O
( O
mouse O
hepatitis O
virus O
strain O
1 O
[ O
MHV O
- O
1 O
] O
) O
also O
reduced O
the O
severity O
of O
PR8 O
infection O
. O

Unlike O
RV1B O
, O
coinfection O
with O
MHV O
- O
1 O
reduced O
early O
PR8 O
replication O
, O
which O
was O
associated O
with O
upregulation O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
. O

To O
understand O
how O
viral O
coinfection O
affects O
disease O
severity O
, O
we O
inoculated O
mice O
with O
a O
mild O
viral O
pathogen O
( O
rhinovirus O
or O
murine O
coronavirus O
) O
, O
followed O
2 O
days O
later O
by O
a O
virulent O
viral O
pathogen O
( O
influenza O
A O
virus O
) O
. O

Hepatitis B
B I
spliced I
protein I
( I
HBSP I
) I
is O
known O
to O
associate O
with O
viral O
persistence O
and O
pathogenesis O
, O
however O
, O
its O
biological O
and O
clinical O
significance O
remains O
poorly O
defined O
. O

Acquired O
resistance O
to O
Fas O
- O
mediated O
apoptosis O
is O
thought O
as O
one O
of O
the O
major O
promotors O
for O
hepatitis B
B I
virus I
( I
HBV I
) I
chronicity O
and O
malignancy O
. O

We O
showed O
here O
that O
HBSP O
mediated O
resistance O
of O
hepatoma O
cells O
or O
primary B
human I
hepatocytes I
( I
PHH I
) I
to O
agonistic O
anti O
- O
Fas O
antibody O
( O
CH11 O
) O
- O
or O
FasL O
- O
induced O
apoptosis O
. O

Under O
Fas O
signaling O
stimulation O
, O
expression O
of O
HBSP O
inhibited O
Fas O
aggregation O
and O
prevented O
recruitment O
of O
the O
adaptor O
molecule O
Fas B
- I
associated I
death I
domain I
( I
FADD I
) I
and O
procaspase O
- O
8 O
( O
or O
FADD O
like O
interleukin O
1 O
beta O
- O
converting O
enzyme O
, O
FLICE O
) O
into O
the O
death B
- I
inducing I
signaling I
complex I
( I
DISC I
) I
, O
while O
increasing O
recruitment O
of O
cellular O
FLICE B
- I
inhibitory I
protein I
L I
( I
FLIPL I
) I
into O
the O
DISC O
. O

Middle B
East I
respiratory I
syndrome I
coronavirus I
( I
MERS I
- I
CoV I
) I
nspl O
suppresses O
host O
gene O
expression O
in O
expressed O
cells O
by O
inhibiting O
translation O
and O
inducing O
endonucleolytic O
cleavage O
of O
host O
mRNAs O
, O
the O
latter O
of O
which O
leads O
to O
mRNA O
decay O
. O

Sirtuin B
2 I
( I
Sirt2 I
) I
, O
a O
NAD O
- O
dependent O
protein O
deacetylase O
, O
is O
overexpressed O
in O
many O
hepatocellular B
carcinomas I
( I
HCCs I
) I
and O
can O
deacetylate O
many O
proteins O
, O
including O
tubulins O
and O
AKT O
, O
prior O
to O
AKT O
activation O
. O

Here O
, O
we O
found O
that O
endogenous O
Sirt2 O
was O
upregulated O
in O
wild B
- I
type I
hepatitis I
B I
virus I
( I
HBV I
WT I
) I
- O
replicating O
cells O
, O
leading O
to O
tubulin O
deacetylation O
; O
however O
, O
this O
was O
not O
the O
case O
in O
HBV O
replicationdeficient O
- O
mutant O
- O
transfected O
cells O
and O
1 O
. O

3 O
- O
mer O
HBV O
WT O
- O
transfected O
and O
reverse O
transcriptase O
inhibitor O
( O
entecavir O
or O
lamivudine O
) O
- O
treated O
cells O
, O
but O
all O
HBV O
proteins O
were O
expressed O
. O

In O
HBV O
WT O
- O
replicating O
cells O
, O
upregulation O
of O
Sirt2 O
induced O
AKT O
activation O
, O
which O
consequently O
downregulated O
glycogen B
synthase I
kinase I
3 I
beta I
( I
GSK I
- I
3 I
beta I
) I
and O
increased O
beta O
- O
catenin O
levels O
; O
however O
, O
downregulation O
of O
Sirt2 O
in O
HBV O
- O
nonreplicating O
cells O
impaired O
AKT O
/ O
GSK O
- O
3 O
beta O
/ O
beta O
- O
catenin O
signaling O
. O

Knockdown O
of O
Sirt2 O
by O
short B
hairpin I
RNAs I
( I
shRNAs I
) I
, O
inhibition O
by O
2 O
- O
cyano O
- O
3 O
[ O
5 O
- O
( O
2 O
, O
5 O
- O
dichlorophenyl O
) O
- O
2 O
- O
furanyl O
] O
- O
N O
- O
5 O
- O
quinolinyl O
- O
2 O
- O
propenamide O
( O
AGK2 O
) O
, O
or O
dominant O
negative O
mutant O
expression O
inhibited O
HBV O
replication O
, O
reduced O
AKT O
activation O
, O
and O
decreased O
beta O
- O
catenin O
levels O
. O

IMPORTANCE O
Even O
though O
Sirt2 O
, O
a O
NAD O
( O
+ O
) O
- O
dependent O
protein O
deacetylase O
, O
is O
overexpressed O
in O
many O
HCCs O
, O
and O
overexpressed O
Sirt2 O
promotes O
hepatic O
fibrosis O
and O
associates O
positively O
with O
vascular O
invasion O
by O
primary O
HCCs O
through O
AKT O
/ O
GSK O
- O
3 O
beta O
/ O
beta O
- O
catenin O
signaling O
, O
the O
relationship O
between O
Sirt2 O
, O
HBV O
, O
HBx O
, O
and O
/ O
or O
HBV O
- O
associated O
hepatocarcinogenesis O
is O
unclear O
. O

The O
spike B
( I
S I
) I
glycoprotein O
of O
the O
avian O
gammacoronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
is O
comprised O
of O
two O
subunits O
( O
S1 O
and O
S2 O
) O
, O
has O
a O
role O
in O
virulence O
in O
vivo O
, O
and O
is O
responsible O
for O
cellular O
tropism O
in O
vitro O
. O

We O
have O
previously O
demonstrated O
that O
replacement O
of O
the O
S O
glycoprotein O
ectodomain O
from O
the O
avirulent O
Beaudette O
strain O
of O
IBV O
with O
the O
corresponding O
region O
from O
the O
virulent O
M41 O
- O
CK O
strain O
resulted O
in O
a O
recombinant O
virus O
, O
BeauR O
- O
M41 O
( O
S O
) O
, O
with O
the O
in O
vitro O
cell O
tropism O
of O
M41 O
- O
CK O
. O

A O
third O
of O
humans O
carry O
genetic O
variants O
of O
the O
ITP B
pyrophosphatase I
( I
ITPase I
) I
gene O
( O
ITPA O
) O
that O
lead O
to O
reduced O
enzyme O
activity O
. O

Reduced O
ITPase O
activity O
was O
earlier O
reported O
to O
protect O
against O
ribavirin O
- O
induced O
hemolytic O
anemia O
and O
to O
diminish O
relapse O
following O
ribavirin O
and O
interferon O
therapy O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
2 O
or O
3 O
infections O
. O

5 O
cells O
) O
with O
a O
small B
interfering I
RNA I
( I
siRNA I
) I
directed O
against O
ITPA O
or O
a O
negative O
- O
control O
siRNA O
in O
the O
presence O
or O
absence O
of O
ribavirin O
in O
an O
HCV O
culture O
system O
. O

Ribavirin B
triphosphate I
( I
RTP I
) I
was O
dephosphorylated O
in O
vitro O
by O
recombinant O
ITPase O
to O
a O
similar O
extent O
as O
ITP O
, O
a O
naturally O
occurring O
substrate O
of O
ITPase O
, O
and O
reducing O
ITPA O
expression O
in O
Huh O
7 O
. O

In O
cell O
culture O
, O
reduced O
ITP B
pyrophosphatase I
( I
ITPase I
) I
enzyme O
activity O
affected O
the O
intracellular O
concentrations O
of O
Ribavirin B
triphosphate I
( I
RTP I
) I
and O
augmented O
the O
impact O
of O
ribavirin O
on O
the O
mutation O
rate O
and O
virus O
production O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
or O
core B
protein I
( I
Cp I
) I
can O
self O
- O
assemble O
to O
form O
an O
icosahedral O
capsid O
. O

These O
small O
molecules O
are O
thus O
called O
core B
protein I
allosteric I
modulators I
( I
CpAMs I
) I
. O

We O
examined O
the O
effects O
of O
two O
closely O
related O
CpAMs O
, O
HAP12 O
and O
HAP13 O
, O
which O
differ O
by O
a O
single O
atom O
but O
have O
drastically O
different O
antiviral O
activities O
, O
on O
the O
assembly O
of O
wild O
- O
type O
Cp O
and O
three O
T109 O
mutants O
( O
T109M O
, O
T109I O
, O
and O
T109S O
) O
that O
display O
a O
range O
of O
resistances O
. O

In O
crystal O
and O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structures O
of O
T O
= O
4 O
capsids O
with O
bound O
CpAMs O
, O
the O
CpAMs O
preferentially O
fit O
into O
two O
of O
four O
quasiequivalent O
sites O
. O

IMPORTANCE O
The O
HBV O
core O
protein O
and O
its O
assembly O
into O
capsids O
have O
become O
important O
targets O
for O
development O
of O
core B
protein I
allosteric I
modulators I
( I
CpAMs I
) I
as O
antivirals O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
protein O
NS5A O
is O
a O
phosphorylated O
protein O
with O
crucial O
roles O
in O
viral O
replication O
and O
assembly O
. O

1 O
cells O
, O
suggestive O
of O
intramolecular O
sequential O
NS5A O
phosphorylation O
from O
S232 O
through O
S235 O
to O
S238 O
by O
casein O
kinase O
I O
alpha O
( O
CKI O
alpha O
) O
. O

IMPORTANCE O
The O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
of O
the O
hepatitis O
C O
virus O
was O
thought O
to O
undergo O
sequential O
intramolecular O
phosphorylation O
on O
a O
series O
of O
serine O
residues O
; O
however O
, O
direct O
evidence O
was O
missing O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
- O
infected O
cells O
release O
extracellular B
vesicles I
( I
EVs I
) I
that O
deliver O
to O
uninfected O
cells O
viral O
factors O
and O
host O
components O
, O
such O
as O
the O
stimulator B
of I
interferon I
genes I
( I
STING I
) I
, O
which O
activates O
type O
I O
interferon O
upon O
foreign O
DNA O
sensing O
. O

Perturbations O
in O
the O
biogenesis O
of O
EVs O
by O
silencing O
CD63 O
or O
blocking O
the O
activity O
of O
the O
neutral B
spingomyelinase I
- I
2 I
( I
nSMase I
- I
2 I
) I
increased O
the O
HSV O
- O
1 O
yields O
. O

IMPORTANCE O
extracellular B
vesicles I
( I
EVs I
) I
are O
released O
by O
all O
types O
of O
cells O
as O
they O
constitute O
major O
mechanism O
of O
intercellular O
communication O
and O
have O
the O
capacity O
to O
alter O
the O
functions O
of O
recipient O
cells O
despite O
their O
limited O
capacity O
for O
cargo O
. O

nonstructural B
protein I
9 I
( I
nsp9 I
) I
is O
an O
essential O
RNA O
binding O
protein O
for O
coronavirus O
replication O
. O

Here O
, O
we O
report O
four O
crystal O
structures O
, O
including O
wild O
- O
type O
porcine B
delta I
coronavirus I
( I
PDCoV I
) I
nsp9 O
, O
PDCoV O
nsp9 O
- O
Delta O
N7 O
( O
N O
- O
terminal O
7 O
amino O
acids O
deleted O
) O
, O
wild O
- O
type O
porcine B
epidemic I
diarrhea I
virus I
( I
PEDV I
) I
nsp9 O
, O
and O
PEDV O
nsp9 O
- O
C59A O
mutant O
. O

Porcine B
deltacoronavirus I
( I
PDCoV I
) I
has O
recently O
emerged O
as O
an O
enteric O
pathogen O
that O
can O
cause O
serious O
vomiting O
and O
diarrhea O
in O
suckling O
piglets O
. O

Here O
, O
we O
found O
that O
ectopic O
expression O
of O
accessory O
protein O
NS6 O
significantly O
inhibits O
Sendai O
virus O
- O
induced O
interferon B
beta I
( I
IFN I
- I
beta I
) I
production O
as O
well O
as O
the O
activation O
of O
transcription O
factors O
IRF3 O
and O
NF O
- O
kB O
. O

Interestingly O
, O
NS6 O
does O
not O
impede O
the O
IFN O
- O
beta O
promoter O
activation O
mediated O
via O
key O
molecules O
in O
the O
RIG B
- I
l I
- I
like I
receptor I
( I
RLR I
) I
signaling O
pathway O
, O
specifically O
RIG O
- O
I O
, O
MDA5 O
, O
and O
their O
downstream O
molecules O
MAVS O
, O
TBK1 O
, O
IKK O
epsilon O
, O
and O
IRF3 O
. O

This O
is O
an O
efficient O
strategy O
of O
antagonizing O
type O
I O
IFN O
production O
by O
disrupting O
the O
binding O
of O
host O
pattern B
recognition I
receptors I
( I
PRRs I
) I
and O
pathogen B
- I
associated I
molecular I
patterns I
( I
PAMPs I
) I
. O

The O
accumulating O
data O
suggest O
that O
this O
adaptation O
is O
determined O
not O
only O
by O
changes O
in O
their O
glycoproteins O
but O
also O
by O
the O
amino O
acid O
sequence O
of O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
the O
alphavirus O
nsP3 O
protein O
. O

We O
performed O
a O
detailed O
investigation O
of O
chikungunya B
virus I
( I
CHIKV I
) I
nsP3 O
HVD O
interactions O
with O
host O
factors O
and O
their O
roles O
in O
viral O
replication O
in O
vertebrate O
and O
mosquito O
cells O
. O

IMPORTANCE O
Alphaviruses O
utilize O
a O
broad O
spectrum O
of O
cellular O
factors O
for O
efficient O
formation O
and O
function O
of O
replication B
complexes I
( I
RCs I
) I
. O

Our O
data O
demonstrate O
for O
the O
first O
time O
that O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
chikungunya O
virus O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
is O
intrinsically O
disordered O
. O

Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
cause O
of O
liver O
disease O
and O
cancer O
in O
humans O
. O

HBVs O
( O
family O
Hepadnaviridae O
) O
have O
been O
associated O
with O
mammals O
for O
millions O
of O
years O
. O

IMPORTANCE O
Infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
led O
to O
887 O
, O
000 O
human O
deaths O
in O
2015 O
. O

Long O
noncoding O
RNAs O
( O
lncRNAs O
) O
are O
involved O
in O
many O
aspects O
of O
cellular O
processes O
, O
including O
the O
antiviral O
immune O
response O
. O

To O
identify O
influenza B
A I
virus I
( I
IAV I
) I
- O
related O
lncRNAs O
, O
we O
performed O
RNA O
deep O
sequencing O
to O
compare O
the O
profiles O
of O
lncRNAs O
in O
A549 O
and O
HEK293T O
cells O
with O
or O
without O
IAV O
infection O
. O

Indeed O
, O
we O
identified O
that O
microRNA O
326 O
( O
miR O
- O
326 O
) O
is O
a O
mutual O
microRNA O
for O
both O
ISG20 O
and O
lnc O
- O
ISG20 O
that O
targets O
the O
3 O
' O
untranslated O
region O
of O
ISG20 O
mRNA O
to O
inhibit O
its O
translation O
. O

In O
recent O
years O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
related O
viruses O
were O
identified O
in O
several O
species O
, O
including O
dogs O
, O
horses O
, O
bats O
, O
and O
rodents O
. O

In O
addition O
, O
a O
novel O
virus O
of O
the O
genus O
Hepacivirus O
has O
been O
discovered O
in O
bovine O
samples O
and O
was O
termed O
bovine B
hepacivirus I
( I
BovHepV I
) I
. O

Prediction O
of O
the O
BovHepV O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
structure O
revealed O
strong O
similarities O
to O
the O
HCV O
IRES O
structure O
comprising O
domains O
II O
, O
IIIabcde O
, O
pseudoknot O
IIIf O
, O
and O
IV O
with O
the O
initiation O
codon O
AUG O
. O

Unlike O
HCV O
, O
only O
one O
microRNA B
- I
122 I
( I
miR I
- I
122 I
) I
binding O
site O
could O
be O
identified O
in O
the O
BovHepV O
5 O
' O
nontranslated O
region O
. O

IMPORTANCE O
Several O
members O
of O
the O
family O
Flaviviridae O
, O
including O
HCV O
, O
have O
adapted O
cap O
- O
independent O
translation O
strategies O
to O
overcome O
canonical O
eukaryotic O
translation O
pathways O
and O
use O
cis O
- O
acting O
RNA O
- O
elements O
, O
designated O
viral O
internal B
ribosome I
entry I
sites I
( I
IRES I
) I
, O
to O
initiate O
translation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
closely O
associated O
with O
type O
2 O
diabetes O
. O

We O
reported O
that O
HCV O
infection O
induces O
the O
lysosomal O
degradation O
of O
hepatocyte B
nuclear I
factor I
1 I
alpha I
( I
HNF I
- I
1 I
alpha I
) I
via O
interaction O
with O
HCV B
nonstructural I
protein I
5A I
( I
NS5A I
) I
protein O
, O
thereby O
suppressing O
GLUT2 O
gene O
expression O
. O

Chaperone B
- I
mediated I
autophagy I
( I
CMA I
) I
is O
a O
selective O
lysosomal O
degradation O
pathway O
. O

Here O
, O
we O
investigated O
whether O
CMA O
is O
involved O
in O
the O
selective O
degradation O
of O
HNF O
- O
1 O
alpha O
in O
HCV O
- O
infected O
cells O
and O
observed O
that O
the O
pentapeptide O
spanning O
from O
amino B
acid I
( I
aa I
) I
130 O
to O
aa O
134 O
of O
HNF O
- O
1 O
alpha O
matches O
the O
rule O
for O
the O
CMA O
- O
targeting O
motif O
, O
also O
known O
as O
KFERQ O
motif O
. O

A O
cytosolic O
chaperone O
protein O
, O
heat O
shock O
cognate O
protein O
of O
70 O
kDa O
( O
HSC70 O
) O
, O
and O
a O
lysosomal O
membrane O
protein O
, O
lysosome O
- O
associated O
membrane O
protein O
type O
2A O
( O
LAMP O
- O
2A O
) O
, O
are O
key O
components O
of O
CMA O
. O

Immunoprecipitation O
analysis O
revealed O
that O
HNF O
- O
1 O
alpha O
was O
coimmunoprecipitated O
with O
HSC70 O
, O
whereas O
the O
Q130A O
mutation O
( O
mutation O
of O
Q O
to O
A O
at O
position O
130 O
) O
of O
HNF O
- O
1 O
alpha O
disrupted O
the O
interaction O
with O
HSC70 O
, O
indicating O
that O
the O
CMA O
- O
targeting O
motif O
of O
HNF O
- O
1 O
alpha O
is O
important O
for O
the O
association O
with O
HSC70 O
. O

To O
determine O
whether O
LAMP O
- O
2A O
plays O
a O
role O
in O
the O
degradation O
of O
HNF O
- O
1 O
alpha O
protein O
, O
we O
knocked O
down O
LAMP O
- O
2A O
mRNA O
by O
RNA O
interference O
; O
this O
knockdown O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
recovered O
the O
level O
of O
HNF O
- O
1 O
alpha O
protein O
in O
HCV O
J6 O
/ O
JFH1 O
- O
infected O
cells O
. O

We O
investigated O
the O
mechanistic O
details O
of O
the O
selective O
lysosomal O
degradation O
of O
hepatocyte B
nuclear I
factor I
1 I
alpha I
( I
HNF I
- I
1 I
alpha I
) I
induced O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
NS5A O
protein O
. O

Using O
site O
- O
directed O
mutagenesis O
, O
we O
demonstrated O
that O
HNF O
- O
1 O
alpha O
contains O
a O
pentapeptide O
Chaperone B
- I
mediated I
autophagy I
( I
CMA I
) I
- O
targeting O
motif O
within O
the O
POU O
- O
specific O
domain O
of O
HNF O
- O
1 O
alpha O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
global O
health O
problem O
, O
with O
nearly O
2 O
million O
new O
infections O
occurring O
every O
year O
and O
up O
to O
85 O
% O
of O
these O
infections O
becoming O
chronic O
infections O
that O
pose O
serious O
long O
- O
term O
health O
risks O
. O

The O
contribution O
of O
distinct O
central B
nervous I
system I
( I
CNS I
) I
resident O
cells O
to O
protective O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
function O
following O
viral O
infections O
is O
poorly O
understood O
. O

Based O
on O
numerous O
immune O
regulatory O
functions O
of O
astrocytes O
, O
we O
evaluated O
the O
contribution O
of O
astrocyte O
IFN O
- O
alpha O
/ O
beta O
signaling O
toward O
protection O
against O
the O
nonlethal O
glia O
- O
and O
neuronotropic O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
A59 O
. O

, O
pattern B
recognition I
receptors I
( I
PRRs I
) I
and O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
revealed O
lower O
basal O
mRNA O
levels O
in O
brain O
- O
derived O
astrocytes O
than O
in O
microglia O
. O

Ablation O
of O
the O
IFN B
- I
alpha I
/ I
beta I
receptor I
( I
IFNAR I
) I
in O
astrocytes O
using O
mGFAPcre O
IFNAR O
( O
fl O
/ O
fl O
) O
mice O
resulted O
in O
severe O
encephalomyelitis O
and O
mortality O
, O
coincident O
with O
uncontrolled O
virus O
replication O
. O

Unexpectedly O
however O
, O
poor O
induction O
of O
IFN O
- O
gamma O
- O
dependent O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
expression O
on O
microglia O
supported O
that O
defective O
IFN O
- O
gamma O
signaling O
contributes O
to O
uncontrolled O
virus O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
causes O
500 O
, O
000 O
deaths O
annually O
, O
in O
association O
with O
end O
- O
stage O
liver O
diseases O
. O

Through O
a O
high O
- O
content O
virus O
infection O
screening O
analysis O
with O
a O
library O
of O
1 O
, O
120 O
biologically O
active O
chemical O
compounds O
, O
we O
identified O
SB258585 O
, O
an O
antagonist O
of O
serotonin O
receptor O
6 O
( O
5 O
- O
HT6 O
) O
, O
as O
a O
new O
inhibitor O
of O
HCV O
entry O
in O
liver O
- O
derived O
cell O
lines O
as O
well O
as O
primary O
hepatocytes O
. O

A O
functional O
characterization O
suggested O
a O
role O
for O
this O
compound O
and O
the O
compound O
SB399885 O
, O
which O
share O
similar O
structures O
, O
as O
inhibitors O
of O
a O
late O
HCV O
entry O
step O
, O
modulating O
the O
localization O
of O
the O
coreceptor O
tight O
junction O
protein O
Claudin B
- I
1 I
( I
CLDN1 I
) I
in O
a O
5 O
- O
HT6 O
- O
independent O
manner O
. O

This O
regulation O
correlated O
with O
the O
modulation O
of O
protein B
kinase I
A I
( I
PKA I
) I
activity O
. O

We O
thus O
highlighted O
the O
involvement O
of O
the O
PKA O
pathway O
in O
modulating O
HCV O
entry O
at O
a O
postbinding O
step O
and O
in O
the O
recycling O
of O
the O
tight O
junction O
protein O
Claudin B
- I
1 I
( I
CLDN1 I
) I
toward O
the O
cell O
surface O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
glycoprotein O
is O
a O
major O
target O
of O
the O
Neutralizing B
antibody I
( I
NAb I
) I
response O
, O
with O
multiple O
type O
- O
specific O
and O
broadly B
neutralizing I
antibody I
( I
bnAb I
) I
epitopes O
identified O
. O

In O
this O
study O
, O
we O
reveal O
the O
structure O
of O
rodent O
monoclonal B
antibody I
24 I
( I
MAb24 I
) I
with O
an O
extensive O
contact O
area O
toward O
a O
peptide O
spanning O
the O
412 O
- O
to O
- O
423 O
region O
. O

IMPORTANCE O
Understanding O
how O
antibodies O
neutralize O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
essential O
for O
vaccine O
development O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
such O
an O
unconventional O
open B
reading I
frame I
( I
ORF I
) I
within O
the O
core O
- O
coding O
region O
, O
encoding O
an O
additional O
protein O
, O
initially O
designated O
ARFP O
, O
F O
, O
or O
core O
+ O
1 O
. O

This O
pathological O
mechanism O
( O
s O
) O
may O
complement O
the O
action O
of O
other O
viral O
proteins O
with O
oncogenic O
properties O
, O
leading O
to O
the O
development O
of O
hepatocellular O
carcinoma O
. O

Defective O
viral O
genomes O
( O
DVGs O
) O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
exist O
, O
but O
their O
biological O
significances O
have O
not O
been O
thoroughly O
investigated O
. O

No O
correlation O
between O
DVGs O
, O
viremia O
, O
and O
alanine B
aminotransferase I
( I
ALT I
) I
levels O
was O
found O
. O

Mechanistic O
studies O
showed O
that O
transmembrane B
segment I
3 I
( I
TMS3 I
) I
of O
NS2 O
, O
located O
immediately O
upstream O
of O
its O
protease O
domain O
, O
was O
required O
for O
the O
cleavage O
of O
NS2 O
- O
NS3 O
and O
the O
replication O
of O
DVGs O
. O

Moreover O
, O
we O
identified O
a O
highly O
conserved O
secondary O
structure O
( O
SL750 O
) O
within O
the O
core O
domain O
2 O
- O
coding O
region O
that O
is O
critical O
for O
HCV O
genome O
packaging O
. O

We O
identified O
a O
highly O
conserved O
secondary O
structure O
( O
SL750 O
) O
within O
the O
core O
- O
coding O
region O
that O
is O
critical O
for O
HCV O
genome O
packaging O
. O

The O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
which O
is O
composed O
of O
four O
domains O
( O
I O
, O
II O
, O
III O
, O
and O
IV O
) O
and O
a O
pseudoknot O
, O
is O
essential O
for O
translation O
and O
viral O
replication O
. O

Equine B
nonprimate I
hepacivirus I
( I
EHcV I
) I
harbors O
a O
5 O
' O
UTR O
consisting O
of O
a O
large O
5 O
' O
- O
terminal O
domain O
( O
I O
) O
; O
three O
additional O
domains O
( O
I O
' O
, O
II O
, O
and O
III O
) O
, O
which O
are O
homologous O
to O
domains O
I O
, O
II O
, O
and O
III O
, O
respectively O
, O
of O
HCV O
; O
and O
a O
pseudoknot O
, O
in O
the O
order O
listed O
. O

The O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
activity O
of O
the O
EHcV O
5 O
' O
UTR O
was O
lower O
than O
that O
of O
the O
HCV O
5 O
' O
UTR O
in O
several O
cell O
lines O
due O
to O
structural O
differences O
in O
domain O
III O
. O

Domains O
I O
and O
III O
of O
EHcV O
were O
functional O
in O
the O
HCV O
5 O
' O
UTR O
in O
terms O
of O
IRES O
activity O
and O
the O
replication O
of O
the O
subgenomic B
replicon I
( I
SGR I
) I
, O
although O
domain O
II O
was O
not O
exchangeable O
between O
EHcV O
and O
HCV O
for O
SGR O
replication O
. O

Furthermore O
, O
the O
region O
spanning O
domains O
I O
and O
I O
' O
of O
EHcV O
( O
the O
5 O
' O
- O
proximal O
EHcV O
- O
specific O
region O
) O
improved O
RNA O
stability O
and O
provided O
the O
HCV O
SGR O
with O
microRNA B
122 I
( I
miR I
- I
122 I
) I
- O
independent O
replication O
capability O
, O
while O
EHcV O
domain O
I O
alone O
improved O
SGR O
replication O
and O
RNA O
stability O
irrespective O
of O
miR O
- O
122 O
. O

In O
this O
study O
, O
our O
data O
suggest O
that O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
EHcV O
is O
composed O
of O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
element O
that O
is O
functionally O
exchangeable O
with O
HCV O
IRES O
elements O
. O

The O
tetraspanin O
protein O
CD63 O
has O
been O
recently O
described O
as O
a O
key O
factor O
in O
extracellular B
vesicle I
( I
EV I
) I
production O
and O
endosomal O
cargo O
sorting O
. O

In O
the O
context O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
infection O
, O
CD63 O
is O
required O
for O
the O
efficient O
packaging O
of O
the O
major O
viral O
oncoprotein O
latent B
membrane I
protein I
1 I
( I
LMP1 I
) I
into O
exosomes O
and O
other O
EV O
populations O
and O
acts O
as O
a O
negative O
regulator O
of O
LMP1 O
intracellular O
signaling O
. O

Indeed O
, O
LMP1 O
can O
activate O
the O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
pathway O
to O
suppress O
host O
cell O
autophagy O
and O
facilitate O
cell O
growth O
and O
proliferation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
leading O
cause O
of O
chronic O
hepatitis O
in O
humans O
. O

human B
hepatitis I
A I
virus I
( I
HAV I
) I
cellular O
receptor O
1 O
( O
HAVCR1 O
) O
, O
CD365 O
, O
also O
known O
as O
TIM O
- O
1 O
, O
functions O
as O
a O
phospholipid O
receptor O
involved O
in O
cell O
entry O
of O
several O
enveloped O
viruses O
. O

HAVCR1 O
soluble O
constructs O
neutralized O
HCV O
, O
which O
did O
not O
require O
the O
HAVCR1 O
mucinlike O
region O
and O
was O
abrogated O
by O
a O
mutation O
of O
N B
to I
A I
at I
position I
94 I
( I
N94A I
) I
in O
the O
Ig B
variable I
( I
IgV I
) I
domain O
phospholipid O
- O
binding O
pocket O
, O
indicating O
a O
direct O
interaction O
of O
the O
HAVCR1 O
IgV O
domain O
with O
HCV O
virions O
. O

Our O
data O
show O
that O
the O
phospholipidbinding O
function O
and O
other O
determinant O
( O
s O
) O
in O
the O
IgV O
domain O
of O
human O
HAVCR1 O
enhance O
HCV O
infection O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
enters O
cells O
through O
a O
multifaceted O
process O
. O

We O
identified O
the O
human B
hepatitis I
A I
virus I
cellular I
receptor I
1 I
( I
HAVCR1 I
) I
, O
CD365 O
, O
also O
known O
as O
TIM O
- O
1 O
, O
as O
a O
facilitator O
of O
HCV O
entry O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
global O
major O
health O
problem O
, O
with O
over O
one O
million O
deaths O
annually O
caused O
by O
chronic O
liver O
damage O
. O

These O
results O
contribute O
to O
our O
enhanced O
understanding O
of O
the O
molecular O
mechanism O
of O
HBV O
transcription O
associated O
with O
the O
chromatin O
structure O
of O
HBV O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
an O
Arterivirus O
that O
has O
been O
devastating O
the O
global O
swine O
industry O
since O
the O
late O
1980s O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
occurs O
in O
tight O
association O
with O
remodeled O
host O
cell O
membranes O
, O
presenting O
as O
cytoplasmic O
accumulations O
of O
single O
- O
, O
double O
- O
, O
and O
multimembrane O
vesicles O
in O
infected O
cells O
. O

Of O
these O
, O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
, O
an O
integral O
transmembrane O
protein O
, O
appears O
to O
play O
a O
key O
role O
, O
but O
little O
is O
known O
about O
the O
molecular O
mechanisms O
of O
how O
this O
protein O
contributes O
to O
organelle O
biogenesis O
. O

Here O
we O
show O
that O
N B
- I
Myc I
downstream I
- I
regulated I
gene I
1 I
( I
NDRG1 I
) I
limits O
productive O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
by O
inhibiting O
viral O
assembly O
. O

The O
upregulation O
of O
MYC O
also O
leads O
to O
the O
reduced O
expression O
of O
the O
NDRG1 O
- O
specific O
kinase O
serum B
/ I
glucocorticoid I
- I
regulated I
kinase I
1 I
( I
SGK1 I
) I
, O
resulting O
in O
a O
markedly O
diminished O
phosphorylation O
of O
NDRG1 O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
enveloped O
single O
- O
stranded O
RNA O
virus O
that O
targets O
hepatocytes O
in O
the O
liver O
. O

Coronaviruses B
( I
CoVs I
) I
are O
positive O
- O
sense O
RNA O
viruses O
that O
infect O
numerous O
mammalian O
and O
avian O
species O
and O
are O
capable O
of O
causing O
severe O
and O
lethal O
disease O
in O
humans O
. O

CoV O
nonstructural B
protein I
14 I
( I
nsp14 I
) I
encodes O
3 O
' O
- O
to O
- O
5 O
' O
exoribonuclease O
activity O
( O
ExoN O
) O
, O
which O
performs O
a O
proofreading O
function O
and O
is O
required O
for O
high O
- O
fidelity O
replication O
. O

Outside O
of O
the O
order O
Nidovirales O
, O
arenaviruses O
are O
the O
only O
RNA O
viruses O
that O
encode O
an O
ExoN O
, O
which O
functions O
to O
degrade O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
replication O
intermediates O
. O

We O
demonstrate O
that O
viruses O
lacking O
ExoN O
activity O
[ O
ExoN O
( O
- O
) O
] O
are O
sensitive O
to O
cellular O
pretreatment O
with O
interferon B
beta I
( I
IFN I
- I
beta I
) I
in O
a O
dose O
- O
dependent O
manner O
. O

In O
addition O
, O
ExoN O
( O
- O
) O
virus O
replication O
was O
attenuated O
in O
wild O
- O
type O
bone B
marrow I
- I
derived I
macrophages I
( I
BMMs I
) I
and O
partially O
restored O
in O
interferon O
alpha O
/ O
beta O
receptor O
- O
deficient O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
BMMs O
. O

ExoN O
( O
- O
) O
virus O
replication O
did O
not O
result O
in O
IFN O
- O
beta O
gene O
expression O
, O
and O
in O
the O
presence O
of O
an O
IFN O
- O
beta O
- O
mediated O
antiviral O
state O
, O
ExoN O
( O
- O
) O
viral O
RNA O
levels O
were O
not O
substantially O
reduced O
relative O
to O
those O
of O
untreated O
samples O
. O

However O
, O
ExoN O
( O
- O
) O
virus O
generated O
from O
IFN O
- O
beta O
- O
pretreated O
cells O
had O
reduced O
specific O
infectivity O
and O
decreased O
relative O
fitness O
, O
suggesting O
that O
ExoN O
( O
- O
) O
virus O
generated O
during O
an O
antiviral O
state O
is O
less O
viable O
to O
establish O
a O
subsequent O
infection O
. O

Overall O
, O
our O
data O
suggest O
murine B
hepatitis I
virus I
( I
MHV I
) I
ExoN O
activity O
is O
required O
for O
resistance O
to O
the O
innate O
immune O
response O
, O
and O
antiviral O
mechanisms O
affecting O
the O
viral O
RNA O
sequence O
and O
/ O
or O
an O
RNA O
modification O
act O
on O
viruses O
lacking O
ExoN O
activity O
. O

The O
basis O
for O
the O
persistence O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
hepatocytes O
, O
even O
in O
the O
presence O
of O
available O
antiviral O
therapies O
, O
lies O
in O
the O
accumulation O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
in O
nuclei O
of O
infected O
cells O
. O

To O
fill O
the O
gaps O
in O
knowledge O
concerning O
cccDNA O
biology O
, O
we O
have O
developed O
a O
fluorescence B
imaging I
in I
situ I
hybridization I
( I
FISH I
) I
- O
based O
assay O
for O
the O
detection O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
cccDNA O
and O
HBV O
nuclear O
DNA O
in O
established O
cell O
lines O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
can O
be O
transmitted O
from O
mother O
to O
child O
during O
pregnancy O
and O
childbirth O
. O

Here O
we O
report O
results O
of O
a O
longitudinal O
assessment O
of O
HCV O
quasispecies O
diversity O
and O
composition O
in O
5 O
cases O
of O
vertical O
HCV O
transmission O
, O
including O
3 O
women O
coinfected O
with O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

The O
population O
structure O
of O
HCV O
variant O
spectra O
based O
on O
E2 O
envelope O
gene O
sequences O
( O
nucleotide O
positions O
1491 O
to O
1787 O
) O
, O
including O
hypervariable O
regions O
1 O
and O
2 O
, O
was O
characterized O
using O
next O
- O
generation O
sequencing O
and O
median O
- O
joining O
network O
analysis O
. O

IMPORTANCE O
Although O
it O
is O
well O
established O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
be O
transmitted O
from O
mother O
to O
child O
, O
the O
manner O
and O
the O
moment O
at O
which O
transmission O
operates O
have O
been O
the O
subject O
of O
conjecture O
. O

In O
addition O
, O
we O
showed O
that O
when O
the O
mother O
also O
carried O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
many O
more O
HCV O
variants O
were O
shared O
between O
her O
and O
her O
child O
, O
suggesting O
that O
the O
mechanism O
and O
/ O
or O
the O
route O
of O
transmission O
of O
HCV O
differed O
in O
the O
presence O
of O
coinfection O
with O
HIV O
- O
1 O
. O

Porcine B
hemagglutinating I
encephalomyelitis I
virus I
( I
PHEV I
) I
is O
a O
highly O
neurovirulent O
coronavirus O
that O
invades O
the O
central B
nervous I
system I
( I
CNS I
) I
in O
piglets O
. O

Here O
we O
dissected O
the O
molecular O
mechanism O
underlying O
cellular O
entry O
and O
intracellular O
trafficking O
of O
PHEV O
in O
mouse O
neuroblastoma O
( O
Neuro O
- O
2a O
) O
cells O
. O

We O
first O
performed O
a O
thin O
- O
section O
Transmission B
electron I
microscopy I
( I
TEM I
) I
assay O
to O
characterize O
the O
kinetics O
of O
PHEV O
, O
and O
we O
found O
that O
viral O
entry O
and O
transfer O
occur O
via O
membranous O
coating O
- O
mediated O
endo O
- O
and O
exocytosis O
. O

To O
verify O
the O
roles O
of O
distinct O
endocytic O
pathways O
, O
systematic O
approaches O
were O
used O
, O
including O
pharmacological O
inhibition O
, O
RNA O
interference O
, O
confocal O
microscopy O
analysis O
, O
use O
of O
fluorescently O
labeled O
virus O
particles O
, O
and O
overexpression O
of O
a O
dominant B
negative I
( I
DN I
) I
mutant O
. O

Quantification O
of O
infected O
cells O
showed O
that O
PHEV O
enters O
cells O
by O
clathrin B
- I
mediated I
endocytosis I
( I
CME I
) I
and O
that O
low O
pH O
, O
dynamin O
, O
cholesterol O
, O
and O
Eps15 O
are O
indispensably O
involved O
in O
this O
process O
. O

IMPORTANCE O
Porcine B
hemagglutinating I
encephalomyelitis I
virus I
( I
PHEV I
) I
, O
a O
nonsegmented O
, O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
coronavirus O
, O
invades O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
causes O
neurological O
dysfunction O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
an O
acute O
, O
self O
- O
limiting O
hepatitis O
in O
healthy O
individuals O
and O
leads O
to O
chronic O
disease O
in O
immunocompromised O
individuals O
. O

In O
a O
human O
hepatoma O
cell O
( O
Huh7 O
) O
culture O
model O
, O
zinc O
salts O
inhibited O
the O
replication O
of O
genotype O
1 O
( O
g O
- O
1 O
) O
and O
g O
- O
3 O
HEV O
replicons O
and O
g O
- O
1 O
HEV O
infectious O
genomic O
RNA O
in O
a O
dose O
- O
dependent O
manner O
. O

Furthermore O
, O
our O
data O
reveal O
that O
zinc O
salts O
directly O
inhibit O
the O
activity O
of O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
leading O
to O
inhibition O
of O
viral O
replication O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
public O
health O
concern O
in O
resource O
- O
starved O
countries O
due O
to O
frequent O
outbreaks O
. O

Here O
we O
report O
a O
full O
- O
length O
crystal O
structure O
of O
the O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
NS3 O
in O
complex O
with O
its O
NS4A O
protease B
cofactor I
segment I
( I
PCS I
) I
at O
a O
2 O
. O

The O
structure O
reveals O
a O
previously O
unidentified O
similar O
to O
2 O
, O
200 O
- O
angstrom O
( O
2 O
) O
intramolecular O
protease O
- O
helicase O
interface O
comprising O
three O
clusters O
of O
interactions O
, O
representing O
a O
closed O
global O
conformation O
related O
to O
the O
NS3 O
- O
NS4A O
cis O
- O
cleavage O
event O
. O

Here O
we O
report O
a O
previously O
unidentified O
conformation O
of O
pestivirus O
NS3 O
in O
complex O
with O
its O
NS4A O
protease B
cofactor I
segment I
( I
PCS I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
to O
induce O
autophagy O
to O
enhance O
its O
own O
replication O
. O

In O
the O
human O
hepatoma O
cell O
line O
Huh7 O
, O
the O
coexpression O
of O
the O
coactivators B
peroxisome I
proliferator I
- I
activated I
receptor I
gamma I
coactivator I
1 I
alpha I
( I
PGC1 I
alpha I
) I
, O
cyclic B
AMP I
- I
responsive I
element I
binding I
protein I
binding I
protein I
( I
CBP I
) I
, O
steroid B
receptor I
coactivator I
1 I
( I
SRC1 I
) I
, O
and O
protein B
arginine I
methyltransferase I
1 I
( I
PRMT1 I
) I
only O
modestly O
increase O
hepatitis B
B I
virus I
( I
HBV I
) I
biosynthesis O
. O

Although O
this O
change O
in O
transcription O
is O
associated O
with O
a O
similar O
modest O
change O
in O
hepatitis B
B I
virus I
core I
antigen I
polypeptide I
( I
HBcAg I
/ I
p21 I
) I
synthesis O
, O
it O
mediates O
a O
dramatic O
increase O
in O
viral O
capsid O
production O
and O
robust O
viral O
replication O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
human O
pathogen O
, O
and O
novel O
targets O
for O
the O
development O
of O
additional O
therapeutic O
agents O
are O
urgently O
needed O
. O

Here O
we O
demonstrate O
that O
the O
coactivator B
peroxisome I
proliferator I
- I
activated I
receptor I
gamma I
coactivator I
1 I
alpha I
( I
PGC1 I
alpha I
) I
serves O
as O
a O
unique O
adaptor O
molecule O
for O
the O
recruitment O
of O
additional O
coactivator O
proteins O
, O
which O
can O
finely O
regulate O
HBV O
transcription O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
primarily O
infects O
hepatocytes O
, O
which O
are O
highly O
polarized O
cells O
. O

To O
obtain O
similar O
clones O
, O
HepG2 B
cells I
expressing I
CD81 I
( I
HepG2 I
- I
CD81 I
) I
were O
used O
, O
and O
clones O
were O
isolated O
by O
limiting O
dilutions O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
primarily O
infects O
hepatocytes O
, O
which O
are O
highly O
polarized O
cells O
with O
a O
complex O
organization O
. O

Claudin O
- O
1 O
is O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
coreceptor O
required O
for O
viral O
entry O
. O

Here O
, O
we O
identified O
an O
interaction O
between O
claudin O
- O
1 O
and O
Sec24C O
, O
a O
cargo O
- O
sorting O
component O
of O
the O
coat B
protein I
complex I
II I
( I
COPII I
) I
vesicular O
transport O
system O
. O

By O
interacting O
with O
Sec24C O
through O
its O
C O
- O
terminal O
YV O
, O
claudin O
- O
1 O
is O
transported O
from O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
is O
eventually O
targeted O
to O
the O
cell O
surface O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
covalently I
closed I
circular I
( I
CCC I
) I
DNA O
functions O
as O
the O
only O
viral O
template O
capable O
of O
coding O
for O
all O
the O
viral O
RNA O
species O
and O
is O
thus O
essential O
to O
initiate O
and O
sustain O
viral O
replication O
. O

CCC O
DNA O
is O
converted O
, O
in O
a O
multistep O
and O
ill O
- O
understood O
process O
, O
from O
a O
relaxed B
circular I
( I
RC I
) I
DNA O
, O
in O
which O
neither O
of O
the O
two O
DNA O
strands O
is O
covalently O
closed O
. O

To O
detect O
putative O
intermediates O
during O
RC O
DNA O
to O
CCC O
DNA O
conversion O
, O
two O
3 O
' O
exonucleases O
, O
exonuclease B
I I
( I
Exo I
I I
) I
and O
Exo O
III O
, O
were O
used O
in O
combination O
to O
degrade O
all O
DNA O
strands O
with O
a O
free O
3 O
' O
end O
, O
which O
would O
nevertheless O
preserve O
closed O
circular O
DNA O
in O
either O
single B
- I
stranded I
( I
ss I
) I
or O
double B
- I
stranded I
( I
ds I
) I
form O
. O

Indeed O
, O
an O
RC O
DNA O
species O
with O
a O
covalently O
closed O
minus O
strand O
but O
an O
open O
plus O
strand O
( O
closed O
minus O
- O
strand O
RC O
DNA O
[ O
cM O
- O
RC O
DNA O
] O
) O
was O
detected O
by O
this O
approach O
. O

IMPORTANCE O
The O
hepatitis B
B I
virus I
( I
HBV I
) I
covalently I
closed I
circular I
( I
CCC I
) I
DNA O
, O
by O
serving O
as O
the O
viral O
transcriptional O
template O
, O
is O
the O
molecular O
basis O
of O
viral O
persistence O
. O

CCC O
DNA O
is O
converted O
, O
in O
a O
multistep O
and O
ill O
- O
understood O
process O
, O
from O
relaxed B
circular I
( I
RC I
) I
DNA O
. O

In O
this O
study O
, O
we O
elucidated O
the O
mechanism O
by O
which O
human B
choline I
kinase I
- I
alpha I
( I
hCK I
alpha I
) I
interacts O
with O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
and O
Phosphatidylinositol B
- I
4 I
- I
kinase I
III I
alpha I
( I
PI4KIII I
alpha I
) I
, O
the O
lipid O
kinase O
crucial O
for O
maintaining O
the O
integrity O
of O
virus O
- O
induced O
membranous O
webs O
, O
and O
modulates O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

hCK O
alpha O
activity O
positively O
modulated O
phosphatidylinositol B
- I
4 I
- I
phosphate I
( I
PI4P I
) I
levels O
in O
HCV O
- O
expressing O
cells O
, O
and O
hCK O
alpha O
- O
mediated O
PI4P O
accumulation O
was O
abolished O
by O
AL O
- O
9 O
, O
a O
PI4KIII O
alpha O
specific O
inhibitor O
. O

PI4KIII O
alpha O
inactivation O
by O
AL O
- O
9 O
or O
hCK O
alpha O
inactivation O
by O
CK37 O
, O
a O
specific O
hCK O
alpha O
inhibitor O
, O
impaired O
the O
endoplasmic B
reticulum I
( I
ER I
) I
localization O
and O
colocalization O
of O
these O
three O
molecules O
. O

Concurring O
with O
the O
upregulation O
of O
PI4P O
production O
and O
viral O
replication O
, O
overexpression O
of O
active O
hCK O
alpha O
- O
R O
( O
but O
not O
the O
D288A O
mutant O
) O
restored O
PI4KIII O
alpha O
and O
NS5A O
translocation O
to O
the O
ER O
in O
hCK O
alpha O
stable O
knockdown O
cells O
. O

In O
the O
present O
study O
, O
we O
investigated O
how O
hCK O
alpha O
interacts O
with O
PI4KIII O
alpha O
( O
a O
key O
element O
that O
maintains O
the O
integrity O
of O
the O
membranous O
web O
structure O
) O
and O
NS5A O
to O
regulate O
viral O
replication O
. O

The O
antiviral O
effects O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
CD8 O
T O
cells O
have O
been O
shown O
in O
an O
HCV O
replicon O
system O
but O
not O
in O
an O
authentic O
infectious O
HCV B
cell I
culture I
( I
HCVcc I
) I
system O
. O

Infectious O
HCV O
epitope O
mutants O
encoding O
the O
well O
- O
defined O
genotype O
1a O
- O
derived O
HLA O
- O
A2 O
- O
restricted O
HCV O
NS3 O
- O
1073 O
or O
NS5 O
- O
2594 O
epitope O
were O
generated O
from O
a O
genotype O
2a O
- O
derived O
HCV O
clone O
( O
Jc1Gluc2A O
) O
by O
site O
- O
directed O
mutagenesis O
. O

HCV O
- O
specific O
CD8 O
T O
- O
cell O
activation O
( O
CD107a O
, O
gamma O
interferon O
, O
macrophage O
inflammatory O
protein O
1 O
beta O
, O
tumor O
necrosis O
factor O
alpha O
) O
was O
dependent O
on O
the O
peptide O
concentrations O
and O
the O
relative O
percentages O
of O
HCV O
- O
infected O
Huh7 O
. O

Here O
, O
we O
evaluate O
the O
adaptation O
, O
mutant O
spectrum O
dynamics O
, O
and O
phenotypic O
diversification O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
the O
course O
of O
200 O
passages O
in O
human O
hepatoma O
cells O
in O
an O
experimental O
design O
that O
precluded O
coevolution O
of O
the O
cells O
with O
the O
virus O
. O

In O
the O
present O
study O
, O
we O
investigate O
genetic O
and O
phenotypic O
changes O
that O
occur O
upon O
prolonged O
passage O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
human O
hepatoma O
cells O
in O
an O
experimental O
design O
in O
which O
host O
cell O
evolutionary O
change O
is O
prevented O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
enveloped O
RNA O
virus O
belonging O
to O
the O
Flaviviridae O
family O
. O

E1 O
system O
, O
we O
explored O
the O
role O
of O
a O
putative O
fusion B
peptide I
( I
FP I
) I
of O
E1 O
in O
HCV O
infection O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
an O
enveloped O
RNA O
virus O
, O
encodes O
two O
envelope O
proteins O
, O
E1 O
and O
E2 O
, O
that O
form O
a O
heterodimeric O
complex O
to O
mediate O
virus O
entry O
. O

The O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
complicated O
process O
in O
which O
many O
viral O
and O
cellular O
factors O
are O
involved O
, O
has O
not O
been O
thoroughly O
deciphered O
. O

NS3 O
is O
a O
multifunctional O
protein O
that O
contains O
an O
N O
- O
terminal O
amphipathic O
alpha O
helix O
( O
designated O
helix O
alpha O
( O
0 O
) O
) O
, O
which O
is O
crucial O
for O
the O
membrane O
association O
and O
stability O
of O
NS3 O
protein O
, O
followed O
by O
a O
serine O
protease O
domain O
and O
a O
C O
- O
terminal O
helicase O
/ O
NTPase O
domain O
. O

In O
this O
study O
, O
we O
determined O
that O
the O
N O
- O
terminal O
helix O
alpha O
( O
0 O
) O
of O
NS3 O
may O
contribute O
to O
HCV O
assembly O
. O

We O
identified O
a O
single O
mutation O
from O
methionine O
to O
threonine O
at O
amino O
acid O
position O
21 O
( O
M21T O
) O
in O
helix O
alpha O
( O
0 O
) O
, O
which O
significantly O
promoted O
viral O
production O
while O
having O
no O
apparent O
effect O
on O
the O
membrane O
association O
and O
protease O
activity O
of O
NS3 O
. O

Further O
study O
revealed O
a O
shift O
in O
the O
subcellular O
localization O
of O
core O
protein O
from O
lipid B
droplets I
( I
LD I
) I
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

Collectively O
, O
the O
results O
of O
our O
study O
revealed O
a O
new O
function O
of O
NS3 O
helix O
alpha O
( O
0 O
) O
and O
aid O
understanding O
of O
the O
role O
of O
NS3 O
in O
HCV O
virion O
morphogenesis O
. O

Our O
study O
identified O
, O
for O
the O
first O
time O
to O
our O
knowledge O
, O
an O
adaptive O
mutation O
within O
the O
N O
- O
terminal O
helix O
alpha O
( O
0 O
) O
domain O
of O
NS3 O
that O
significantly O
enhanced O
virus O
assembly O
while O
having O
no O
effect O
on O
viral O
genome O
replication O
. O

Our O
results O
revealed O
a O
possible O
new O
function O
of O
helix O
alpha O
( O
0 O
) O
in O
the O
HCV O
life O
cycle O
and O
provided O
new O
clues O
to O
understanding O
the O
molecular O
mechanisms O
for O
the O
action O
of O
NS3 O
in O
HCV O
assembly O
. O

Fibrogenic O
pathways O
in O
the O
liver O
are O
principally O
regulated O
by O
activation O
of O
hepatic B
stellate I
cells I
( I
HSC I
) I
. O

Fibrosis O
is O
associated O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
although O
the O
mechanism O
is O
poorly O
understood O
. O

Primary O
or O
immortalized O
human O
hepatic O
stellate O
( O
LX2 O
) O
cells O
were O
exposed O
to O
exosomes O
derived O
from O
HCV O
- O
infected O
hepatocytes O
( O
HCV O
- O
exo O
) O
, O
and O
the O
expression O
of O
fibrosis O
- O
related O
genes O
was O
examined O
. O

Further O
analysis O
suggested O
that O
HCV O
- O
exo O
carry O
miR O
- O
19a O
and O
target O
SOCS3 O
in O
HSC O
, O
which O
in O
turn O
activates O
the O
STAT3 O
- O
mediated O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
signaling O
pathway O
and O
enhances O
fibrosis O
marker O
genes O
. O

In O
contrast O
to O
other O
available O
next O
- O
generation O
sequencing O
platforms O
, O
PacBio O
single B
- I
molecule I
, I
real I
- I
time I
( I
SMRT I
) I
sequencing O
has O
the O
advantage O
of O
generating O
long O
reads O
albeit O
with O
a O
relatively O
higher O
error O
rate O
in O
unprocessed O
data O
. O

Using O
this O
platform O
, O
we O
longitudinally O
sampled O
and O
sequenced O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
genome O
region O
( O
1 O
, O
680 O
nucleotides O
[ O
nt O
] O
) O
from O
individuals O
belonging O
to O
a O
cluster O
of O
sexually O
transmitted O
cases O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
causes O
chronic O
infections O
in O
at O
least O
150 O
million O
individuals O
worldwide O
. O

At O
the O
level O
of O
entry O
, O
differences O
in O
the O
amino O
acid O
sequences O
between O
the O
human O
and O
mouse O
orthologues O
of O
two O
essential O
host O
factors O
, O
the O
tetraspanin O
CD81 O
and O
the O
tight O
junction O
protein O
occludin B
( I
OCLN I
) I
, O
explain O
, O
at O
least O
in O
part O
, O
HCV O
' O
s O
limited O
ability O
to O
enter O
mouse O
hepatocytes O
. O

IMPORTANCE O
At O
least O
150 O
million O
individuals O
are O
chronically O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Here O
, O
we O
describe O
the O
characterization O
of O
a O
new O
mouse O
model O
in O
which O
the O
parts O
of O
two O
host O
factors O
that O
are O
essential O
for O
HCV O
uptake O
, O
CD81 O
and O
occludin B
( I
OCLN I
) I
, O
which O
differ O
between O
mice O
and O
humans O
, O
were O
humanized O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
strain O
JFH O
- O
1 O
, O
which O
belongs O
to O
genotype O
2a O
, O
replicates O
autonomously O
in O
cultured O
cells O
, O
whereas O
another O
genotype O
2a O
strain O
, O
J6CF O
, O
does O
not O
. O

microRNAs B
( I
miRNAs I
) I
play O
an O
important O
role O
in O
the O
regulation O
of O
immune O
responses O
. O

Previous O
studies O
have O
indicated O
that O
dysregulating O
the O
miRNAs O
leads O
to O
the O
immunosuppression O
of O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
. O

The O
present O
work O
suggests O
that O
PRRSV O
upregulated O
the O
expression O
of O
miR O
- O
373 O
through O
elevating O
the O
expression O
of O
specificity B
protein I
1 I
( I
Sp1 I
) I
in O
MARC O
- O
145 O
cells O
. O

Furthermore O
, O
this O
work O
demonstrated O
that O
miR O
- O
373 O
promoted O
the O
replication O
of O
PRRSV O
, O
since O
miR O
- O
373 O
was O
a O
novel O
negative O
miRNA O
for O
the O
production O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
by O
targeting O
nuclear B
factor I
IA I
( I
NFIA I
) I
, O
NFIB O
, O
interleukin B
- I
1 I
receptor I
- I
associated I
kinase I
1 I
( I
IRAK1 I
) I
, O
IRAK4 O
, O
and O
interferon B
regulatory I
factor I
1 I
( I
IRF1 I
) I
. O

Here O
, O
we O
report O
on O
the O
evolutionary O
, O
biological O
, O
and O
structural O
characterization O
of O
a O
novel O
bat B
adenovirus I
( I
BtAdV I
) I
recovered O
from O
a O
Rafinesque O
' O
s O
big O
- O
eared O
bat O
( O
Corynorhinus O
rafinesquii O
) O
in O
Kentucky O
, O
USA O
, O
which O
is O
the O
first O
adenovirus O
isolated O
from O
North O
American O
bats O
. O

This O
virus O
( O
BtAdV O
250 O
- O
A O
) O
exhibits O
a O
close O
phylogenetic O
relationship O
with O
Canine B
mastadenovirus I
A I
( I
CAdV I
A I
) I
, O
as O
previously O
observed O
with O
other O
BtAdVs O
. O

The O
wide O
geographic O
distribution O
and O
genetic O
diversity O
of O
adenoviruses O
in O
bats O
and O
their O
close O
phylogenetic O
relationship O
to O
Canine B
mastadenovirus I
A I
( I
CAdV I
A I
) I
has O
raised O
important O
questions O
about O
how O
CAdV O
A O
, O
and O
possibly O
other O
mammalian O
adenoviruses O
, O
may O
have O
emerged O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
causes O
severe O
liver O
disease O
and O
affects O
ca O
. O

The O
retinoic B
acid I
- I
inducible I
gene I
1 I
( I
RIG I
- I
I I
) I
signaling O
pathway O
is O
essential O
for O
the O
recognition O
of O
viruses O
and O
the O
initiation O
of O
host O
interferon B
( I
IFN I
) I
- O
mediated O
antiviral O
responses O
. O

Once O
activated O
, O
RIG O
- O
I O
interacts O
with O
polyubiquitin O
chains O
generated O
by O
TRIM25 O
and O
binds O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
, O
leading O
to O
the O
production O
of O
type O
I O
IFN O
. O

We O
now O
show O
specific O
interactions O
among O
these O
key O
partners O
in O
the O
RLR O
pathway O
through O
the O
use O
of O
bimolecular B
fluorescence I
complementation I
( I
BiFC I
) I
and O
super O
- O
resolution O
microscopy O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
human O
pathogen O
. O

The O
closest O
relative O
of O
HCV O
is O
found O
in O
horses O
( O
termed O
equine O
hepacivirus O
[ O
EqHV O
] O
) O
. O

IMPORTANCE O
The O
evolutionary O
origins O
of O
the O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
unclear O
. O

The O
closest O
animal O
- O
associated O
relative O
of O
HCV O
occurs O
in O
horses O
( O
equine O
hepacivirus O
[ O
EqHV O
] O
) O
. O

We O
analyzed O
hepatitis B
C I
virus I
( I
HCV I
) I
morphogenesis O
using O
viral O
genomes O
encoding O
a O
mCherry O
- O
tagged O
E1 O
glycoprotein O
. O

IMPORTANCE O
The O
goal O
of O
this O
study O
was O
to O
shed O
light O
on O
the O
poorly O
understood O
trafficking O
and O
release O
routes O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

The O
NS3 O
/ O
4A O
serine O
protease O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
critical O
for O
cleavage O
of O
the O
viral O
polyprotein O
. O

It O
also O
cleaves O
the O
cellular O
innate O
immune O
adaptor O
MAVS O
, O
thus O
decreasing O
interferon B
( I
IFN I
) I
production O
and O
contributing O
to O
HCV O
persistence O
in O
the O
human O
host O
. O

The O
interferon B
( I
IFN I
) I
response O
to O
viral O
pathogens O
is O
critical O
for O
host O
survival O
. O

In O
humans O
and O
mouse O
models O
, O
defects O
in O
IFN O
responses O
can O
result O
in O
lethal O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
infections O
, O
usually O
from O
encephalitis O
. O

In O
this O
study O
, O
we O
used O
bone O
marrow O
chimeras O
of O
IFN O
- O
alpha O
beta O
gamma O
R O
- O
/ O
- O
( O
AG129 O
) O
and O
wild O
- O
type O
( O
WT O
; O
129SvEv O
) O
mice O
to O
probe O
the O
underlying O
IFN O
- O
dependent O
mechanisms O
that O
control O
HSV O
- O
1 O
pathogenesis O
. O

Consistent O
with O
this O
, O
the O
inability O
of O
IFN O
- O
alpha O
beta O
gamma O
R O
- O
/ O
- O
immune O
cells O
to O
control O
liver O
infection O
in O
IFN O
- O
alpha O
beta O
gamma O
R O
- O
/ O
- O
mice O
manifested O
as O
profoundly O
elevated O
aspartate B
transaminase I
( I
AST I
) I
and O
alanine B
transaminase I
( I
ALT I
) I
levels O
, O
indicative O
of O
severe O
liver O
damage O
. O

IMPORTANCE O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
infection O
is O
an O
incurable O
viral O
infection O
with O
the O
most O
significant O
morbidity O
and O
mortality O
occurring O
in O
neonates O
and O
patients O
with O
compromised O
immune O
systems O
. O

The O
NS2 O
( O
H126R O
) O
mutant O
is O
attenuated O
in O
liver O
replication O
due O
to O
loss O
of O
phosphodiesterase O
activity O
, O
which O
the O
wild B
- I
type I
( I
WT I
) I
virus O
uses O
to O
block O
the O
2 O
' O
, O
5 B
' I
- I
oligoadenylate I
synthetase I
( I
OAS I
) I
- O
RNase O
L O
( O
RNase O
L O
) O
antiviral O
pathway O
. O

The O
activation O
of O
RNase O
L O
by O
NS2 O
( O
H126R O
) O
is O
cell O
type O
dependent O
and O
correlates O
with O
high O
basal O
expression O
levels O
of O
OAS O
, O
as O
found O
in O
myeloid O
cells O
. O

We O
tested O
the O
hypothesis O
that O
the O
resident O
liver O
macrophages O
, O
Kupffer O
cells O
( O
KC O
) O
, O
represent O
the O
cell O
type O
most O
likely O
to O
restrict O
NS2 O
( O
H126R O
) O
and O
prevent O
hepatitis O
. O

As O
found O
previously O
, O
A59 O
and O
NS2 O
( O
H126R O
) O
replicate O
similarly O
in O
hepatocytes O
and O
neither O
activates O
RNase O
L O
, O
as O
assessed O
by O
an O
rRNA O
degradation O
assay O
. O

In O
contrast O
, O
in O
KC O
, O
A59 O
exhibited O
a O
100 O
- O
fold O
- O
higher O
titer O
than O
NS2 O
( O
H126R O
) O
and O
NS2 O
( O
H126R O
) O
induced O
rRNA O
degradation O
. O

Interestingly O
, O
in O
liver B
sinusoidal I
endothelial I
cells I
( I
LSEC I
) I
, O
the O
cells O
that O
form O
a O
barrier O
between O
blood O
and O
liver O
parenchymal O
cells O
, O
NS2 O
( O
H126R O
) O
activates O
RNase O
L O
, O
which O
limits O
viral O
replication O
. O

Similar O
growth O
kinetics O
were O
observed O
for O
the O
two O
viruses O
in O
KC O
and O
LSEC O
from O
RNase O
L O
- O
/ O
- O
mice O
, O
demonstrating O
that O
both O
use O
RNase O
L O
to O
limit O
NS2 O
( O
H126R O
) O
replication O
. O

Depletion O
of O
KC O
by O
gadolinium O
( O
III O
) O
chloride O
or O
of O
LSEC O
by O
cyclophosphamide O
partially O
restores O
liver O
replication O
of O
NS2 O
( O
H126R O
) O
, O
leading O
to O
hepatitis O
. O

Thus O
, O
during O
mouse B
hepatitis I
virus I
( I
MHV I
) I
infection O
, O
hepatitis O
, O
which O
damages O
the O
parenchyma O
, O
is O
prevented O
by O
RNase O
L O
activity O
in O
both O
KC O
and O
LSEC O
but O
not O
in O
hepatocytes O
. O

Like O
almost O
all O
of O
the O
positive O
- O
strand O
RNA O
viruses O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
induces O
host O
intracellular O
membrane O
modification O
to O
form O
the O
membrane O
- O
bound O
viral O
replication B
complex I
( I
RC I
) I
, O
within O
which O
viral O
replicases O
amplify O
the O
viral O
RNA O
genome O
. O

We O
identified O
valosin B
- I
containing I
protein I
( I
VCP I
) I
, O
a O
member O
of O
the O
ATPases O
associated O
with O
diverse O
cellular O
activities O
( O
AAA O
+ O
ATPase O
) O
family O
, O
as O
an O
active O
viral O
replication O
modulator O
whose O
ATPase O
activity O
is O
required O
for O
viral O
replication O
. O

The O
mitogen O
- O
activated O
protein O
kinase O
kinase O
/ O
extracellular O
regulated O
kinase O
( O
MEK1 O
/ O
2 O
/ O
ERK1 O
/ O
2 O
) O
cascade O
is O
involved O
in O
the O
replication O
of O
several O
members O
of O
the O
Flaviviridae O
family O
, O
including O
hepatitis O
C O
virus O
and O
dengue O
virus O
. O

The O
effects O
of O
the O
cascade O
on O
the O
replication O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
a O
fatal O
pestivirus O
of O
pigs O
, O
remain O
unknown O
. O

The O
C O
termini O
of O
E2 O
( O
amino O
acids O
[ O
aa O
] O
890 O
to O
1053 O
) O
and O
MEK2 O
( O
aa O
266 O
to O
400 O
) O
were O
mapped O
to O
be O
crucial O
for O
the O
interaction O
. O

Furthermore O
, O
the O
replication O
of O
CSFV O
was O
markedly O
inhibited O
in O
PK O
- O
15 O
cells O
treated O
with O
U0126 O
, O
a O
specific O
inhibitor O
for O
MEK1 O
/ O
2 O
/ O
ERK1 O
/ O
2 O
, O
whereas O
MEK2 O
did O
not O
affect O
CSFV O
replication O
after O
blocking O
the O
interferon O
- O
induced O
Janus O
kinasesignal O
transducer O
and O
activator O
of O
transcription O
( O
JAK O
- O
STAT O
) O
signaling O
pathway O
by O
ruxolitinib O
, O
a O
JAK O
- O
STAT O
- O
specific O
inhibitor O
. O

IMPORTANCE O
Mitogen O
- O
activated O
protein O
kinase O
kinase O
2 O
( O
MEK2 O
) O
is O
a O
kinase O
that O
operates O
immediately O
upstream O
of O
extracellular O
regulated O
kinase O
1 O
/ O
2 O
( O
ERK1 O
/ O
2 O
) O
and O
links O
to O
Raf O
and O
ERK O
via O
phosphorylation O
. O

Currently O
, O
little O
is O
known O
about O
the O
role O
of O
MEK2 O
in O
the O
replication O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
a O
devastating O
porcine O
pestivirus O
. O

Despite O
its O
importance O
in O
shaping O
adaptive O
immune O
responses O
, O
viral O
clearance O
, O
and O
immune O
- O
based O
inflammation O
, O
tissue O
- O
specific O
innate O
immunity O
remains O
poorly O
characterized O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
due O
to O
the O
lack O
of O
access O
to O
acutely O
infected O
tissues O
. O

In O
this O
study O
, O
we O
evaluated O
the O
impact O
of O
natural B
killer I
( I
NK I
) I
cells O
and O
myeloid O
( O
mDCs O
) O
and O
plasmacytoid O
( O
pDCs O
) O
dendritic O
cells O
on O
control O
of O
virus O
replication O
and O
virus O
- O
induced O
pathology O
caused O
by O
another O
, O
more O
rapidly O
resolving O
hepacivirus O
, O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
in O
infections O
of O
common O
marmosets O
. O

Finally O
, O
soluble O
factors O
associated O
with O
NK O
cells O
and O
DCs O
, O
including O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
RANTES O
, O
were O
increased O
in O
acute O
infection O
and O
also O
were O
associated O
with O
viral O
loads O
and O
hepatitis O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
created O
a O
global O
health O
crisis O
, O
and O
despite O
new O
effective O
antivirals O
, O
it O
is O
still O
a O
leading O
cause O
of O
liver O
disease O
and O
death O
worldwide O
. O

Here O
we O
tested O
several O
derivatives O
of O
4 O
- O
aminoquinolines O
and O
piperazines O
for O
their O
activity O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Of O
these O
, O
we O
selected O
a O
compound O
( O
B5 O
) O
that O
is O
currently O
ending O
clinical O
phase O
I O
evaluation O
for O
neurodegenerative O
diseases O
. O

Virus O
with O
resistance O
to O
B5 O
was O
selected O
by O
sequential O
passage O
in O
the O
presence O
of O
the O
drug O
, O
and O
reverse O
genetics O
experiments O
indicated O
that O
resistance O
was O
conferred O
mainly O
by O
a O
single O
mutation O
in O
the O
putative O
fusion O
peptide O
of O
E1 O
envelope O
glycoprotein O
( O
F291I O
) O
. O

The O
present O
study O
reports O
the O
identification O
and O
characterization O
of O
a O
compound O
( O
B5 O
) O
that O
inhibits O
HCV O
propagation O
in O
cell O
culture O
and O
is O
currently O
ending O
clinical O
phase O
I O
evaluation O
for O
neurodegenerative O
diseases O
. O

To O
understand O
subcellular O
sites O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
, O
we O
visualized O
core O
( O
Cp O
) O
, O
Polymerase B
( I
Pol I
) I
, O
and O
pregenomic B
RNA I
( I
pgRNA I
) I
in O
infected O
cells O
. O

The O
mitochondrial O
localization O
of O
Pol O
was O
independent O
of O
both O
the O
cell O
type O
and O
other O
viral O
components O
, O
indicating O
that O
Pol O
contains O
an O
intrinsic O
mitochondrial B
targeting I
signal I
( I
MTS I
) I
. O

The O
Pol O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
also O
localized O
to O
the O
mitochondria O
. O

To O
map O
the O
MTS O
within O
HBV O
Pol O
, O
we O
generated O
a O
series O
of O
Pol B
- I
green I
fluorescent I
protein I
( I
Pol I
- I
GFP I
) I
fusions O
and O
found O
that O
a O
stretch O
spanning O
amino B
acids I
( I
aa I
) I
141 O
to O
160 O
of O
Pol O
was O
sufficient O
to O
target O
GFP O
to O
the O
mitochondria O
. O

Human B
noroviruses I
( I
HuNoVs I
) I
, O
named O
after O
the O
prototype O
strain O
Norwalk B
virus I
( I
NV I
) I
, O
are O
a O
leading O
cause O
of O
acute O
gastroenteritis O
outbreaks O
worldwide O
. O

Studies O
on O
the O
related O
murine B
norovirus I
( I
MNV I
) I
have O
demonstrated O
the O
importance O
of O
an O
interferon B
( I
IFN I
) I
response O
in O
host O
control O
of O
virus O
replication O
, O
but O
this O
remains O
unclear O
for O
HuNoVs O
. O

Using O
this O
system O
, O
we O
show O
here O
that O
NV O
RNA O
replication O
is O
sensitive O
to O
type O
I O
( O
alpha O
/ O
beta O
) O
and O
III O
( O
interleukin O
- O
29 O
[ O
IL O
- O
29 O
] O
) O
IFN O
treatment O
. O

However O
, O
in O
cells O
capable O
of O
a O
strong O
IFN O
response O
to O
Sendai B
virus I
( I
SeV I
) I
and O
poly O
( O
I O
. O

Consistent O
with O
a O
lack O
of O
IFN O
induction O
, O
NV O
RNA O
replication O
is O
enhanced O
neither O
by O
neutralization O
of O
type O
I O
/ O
III O
IFNs O
through O
neutralizing O
antibodies O
or O
the O
soluble O
IFN O
decoy O
receptor O
B18R O
nor O
by O
short B
hairpin I
RNA I
( I
shRNA I
) I
knockdown O
of O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
or O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
in O
the O
IFN O
induction O
pathways O
. O

IMPORTANCE O
Human B
noroviruses I
( I
HuNoVs I
) I
are O
a O
leading O
cause O
of O
epidemic O
gastroenteritis O
worldwide O
. O

Studies O
on O
murine B
norovirus I
( I
MNV I
) I
have O
shown O
the O
importance O
of O
an O
interferon B
( I
IFN I
) I
response O
in O
host O
control O
of O
MNV O
replication O
, O
but O
this O
remains O
unclear O
for O
HuNoVs O
. O

chronic B
hepatitis I
B I
( I
CHB I
) I
is O
prevalent O
worldwide O
. O

The O
infectious O
agent O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
replicates O
via O
an O
RNA O
intermediate O
and O
is O
error O
prone O
, O
leading O
to O
the O
rapid O
generation O
of O
closely O
related O
but O
not O
identical O
viral O
variants O
, O
including O
those O
that O
can O
escape O
host O
immune O
responses O
and O
antiviral O
treatments O
. O

The O
complexity O
of O
CHB O
can O
be O
further O
enhanced O
by O
the O
presence O
of O
HBV O
variants O
with O
large O
deletions O
in O
the O
genome O
generated O
via O
splicing O
( O
spHBV O
variants O
) O
. O

Syntaxin O
17 O
is O
an O
autophagosomal O
SNARE O
( O
soluble O
N O
- O
ethylmaleimide O
- O
sensitive O
factor O
attachment O
protein O
receptor O
) O
protein O
required O
for O
the O
fusion O
of O
autophagosomes O
with O
lysosomes O
to O
form O
autolysosomes O
and O
thereby O
to O
deliver O
the O
enclosed O
contents O
for O
degradation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
induces O
autophagy O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
induces O
autophagy O
. O

Although O
all O
12 O
subtypes O
of O
human O
interferon B
alpha I
( I
IFN I
- I
alpha I
) I
bind O
the O
same O
receptor O
, O
recent O
results O
have O
demonstrated O
that O
they O
elicit O
unique O
host O
responses O
and O
display O
distinct O
efficacies O
in O
the O
control O
of O
different O
viral O
infections O
. O

Whereas O
ineffective O
IFN O
- O
alpha O
2 O
therapy O
was O
associated O
with O
CD8 O
( O
+ O
) O
T O
cell O
activation O
, O
successful O
IFN O
- O
alpha O
14 O
therapy O
was O
associated O
with O
increased O
intrinsic O
and O
innate O
immunity O
, O
including O
significantly O
higher O
induction O
of O
tetherin O
and O
MX2 O
, O
increased O
APOBEC3G O
signature O
mutations O
in O
HIV O
- O
1 O
proviral O
DNA O
, O
and O
higher O
frequencies O
of O
TRAIL O
( O
+ O
) O
NK O
cells O
. O

IMPORTANCE O
The O
naturally O
occurring O
antiviral O
protein O
IFN O
- O
alpha O
2 O
is O
used O
to O
treat O
hepatitis O
viruses O
but O
has O
proven O
rather O
ineffective O
against O
HIV O
in O
comparison O
to O
triple O
therapy O
with O
the O
antiretroviral B
( I
ARV I
) I
drugs O
. O

coronavirus B
( I
CoV I
) I
nonstructural I
protein I
14 I
( I
nsp14 I
) I
is O
a O
60 O
- O
kDa O
protein O
encoded O
by O
the O
replicase O
gene O
that O
is O
part O
of O
the O
replication O
- O
transcription O
complex O
. O

It O
is O
a O
bifunctional O
enzyme O
bearing O
3 O
' O
- O
to O
- O
5 O
' O
exoribonuclease B
( I
ExoN I
) I
and O
guanine B
- I
N7 I
- I
methyltransferase I
( I
N7 I
- I
MTase I
) I
activities O
. O

ExoN O
hydrolyzes O
single O
- O
stranded O
RNAs O
and O
double B
- I
stranded I
RNAs I
( I
dsRNAs I
) I
and O
is O
part O
of O
a O
proofreading O
system O
responsible O
for O
the O
high O
fidelity O
of O
CoV O
replication O
. O

A O
specific O
mutation O
within O
zinc B
finger I
1 I
( I
ZF I
- I
C I
) I
led O
to O
production O
of O
a O
viable O
virus O
with O
growth O
and O
viral O
RNA O
synthesis O
kinetics O
similar O
to O
that O
of O
the O
parental O
virus O
. O

Mutant O
recombinant O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
ZF O
- O
C O
( O
rTGEV O
- O
ZF O
- O
C O
) O
caused O
decreased O
cytopathic O
effect O
and O
apoptosis O
compared O
with O
the O
wild O
- O
type O
virus O
and O
reduced O
levels O
of O
dsRNA O
accumulation O
at O
late O
times O
postinfection O
. O

The O
expression O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
, O
Tumor B
necrosis I
factor I
( I
TNF I
) I
, O
and O
interferon O
- O
stimulated O
genes O
in O
cells O
infected O
with O
mutant O
rTGEV O
- O
ZF O
- O
C O
was O
reduced O
compared O
to O
the O
levels O
seen O
with O
the O
parental O
virus O
. O

Work O
investigating O
gammaherpesviruses O
and O
bacterial O
pathogens O
indicates O
that O
microbial O
pathogens O
deploy O
deamidases O
or O
enzyme O
- O
deficient O
homologues O
( O
pseudoenzymes O
) O
to O
induce O
deamidation O
of O
key O
signaling O
components O
and O
evade O
host O
immune O
responses O
. O

Many O
viruses O
trigger O
the O
type B
I I
interferon I
( I
IFN I
) I
pathway O
upon O
infection O
, O
resulting O
in O
the O
transcription O
of O
hundreds O
of O
interfer B
- I
on I
- I
stimulated I
genes I
( I
ISGs I
) I
, O
which O
define O
the O
antiviral O
state O
of O
the O
host O
. O

classical B
swine I
fever I
virus I
( I
CSFV I
) I
is O
the O
causative O
agent O
of O
classical B
swine I
fever I
( I
CSF I
) I
, O
a O
highly O
contagious O
viral O
disease O
endangering O
the O
pig O
industry O
in O
many O
countries O
. O

Here O
we O
screened O
20 O
ISGs O
that O
are O
commonly O
induced O
by O
type O
I O
IFNs O
against O
CSFV O
in O
lentivirus O
- O
delivered O
cell O
lines O
, O
resulting O
in O
the O
identification O
of O
guanylate B
- I
binding I
protein I
1 I
( I
GBP1 I
) I
as O
a O
potent O
anti O
- O
CSFV O
ISG O
. O

Coimmunoprecipitation O
and O
glutathione B
S I
- I
transferase I
( I
GST I
) I
pulldown O
assays O
revealed O
that O
GBP1 O
interacted O
with O
the O
NS5A O
protein O
of O
CSFV O
, O
and O
this O
interaction O
was O
mapped O
in O
the O
N O
- O
terminal O
globular O
GTPase O
domain O
of O
GBP1 O
. O

In O
a O
previous O
study O
, O
ribavirin O
- O
resistant O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
mutants O
( O
RVRp13 O
and O
RVRp22 O
) O
were O
selected O
, O
and O
their O
resistance O
against O
random O
mutation O
was O
shown O
in O
cultured O
cells O
. O

In O
the O
present O
study O
, O
these O
ribavirin O
- O
resistant O
mutants O
were O
evaluated O
in O
terms O
of O
their O
genetic O
and O
phenotypic O
stability O
during O
three O
pig O
- O
to O
- O
pig O
passages O
in O
comparison O
with O
modified B
live I
virus I
( I
MLV I
) I
( O
Ingelvac O
PRRS O
MLV O
) O
. O

Nine O
unique O
mutations O
were O
found O
in O
open B
reading I
frames I
( I
ORFs I
) I
1a O
, O
2 O
, O
and O
6 O
in O
the O
RVRp22 O
genome O
based O
on O
full O
- O
length O
sequence O
comparisons O
with O
RVRp13 O
, O
VR2332 O
( O
the O
parental O
virus O
of O
RVRp13 O
and O
RVRp22 O
) O
, O
and O
MLV O
. O

During O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
broadly B
neutralizing I
antibody I
( I
bnAb I
) I
responses O
targeting O
E1E2 O
envelope O
glycoproteins O
are O
generated O
in O
many O
individuals O
. O

The O
breadth O
of O
intergenotype O
neutralization O
did O
not O
correlate O
with O
any O
clinical O
parameters O
; O
however O
, O
analysis O
of O
individuals O
with O
genotype O
1 O
( O
gt1 O
) O
HCV O
infection O
( O
n O
= O
20 O
) O
, O
using O
an O
intragenotype O
pseudoparticle O
panel O
, O
found O
a O
strong O
association O
between O
neutralization O
breadth O
and O
reduced O
liver O
fibrosis O
( O
P O
= O
0 O
. O

A O
broad O
bNAb O
response O
in O
our O
cohort O
with O
chronic O
infection O
was O
associated O
with O
a O
single B
nucleotide I
polymorphism I
( I
SNP I
) I
in O
the O
HLA O
- O
DQB1 O
gene O
( O
P O
= O
0 O
. O

Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
, O
for O
which O
neither O
a O
vaccine O
nor O
an O
effective O
therapeutic O
treatment O
is O
currently O
available O
, O
is O
the O
leading O
cause O
of O
severe O
lower O
respiratory O
tract O
infections O
in O
children O
. O

interferon B
- I
stimulated I
gene I
15 I
( I
ISG15 I
) I
is O
a O
ubiquitin O
- O
like O
protein O
that O
is O
highly O
increased O
during O
viral O
infections O
and O
has O
been O
reported O
to O
have O
an O
antiviral O
or O
a O
proviral O
activity O
, O
depending O
on O
the O
virus O
. O

ISG15 O
overexpression O
and O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
silencing O
experiments O
, O
along O
with O
ISG15 O
knockout O
( O
ISG15 O
( O
- O
/ O
- O
) O
) O
cells O
, O
revealed O
an O
anti O
- O
RSV O
effect O
of O
the O
molecule O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
comprises O
the O
first O
27 O
N O
- O
terminal O
amino O
acid O
residues O
of O
E2 O
. O

HVR1 O
phenotypes O
were O
observed O
to O
be O
under O
strong O
purifying O
( O
stationary O
) O
and O
strong O
positive O
( O
antigenic O
drift O
) O
selection O
pressures O
, O
which O
were O
coincident O
with O
advancing O
patient O
age O
and O
cirrhosis O
of O
the O
liver O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
envelope O
glycoprotein O
is O
crucial O
for O
virus O
entry O
into O
hepatocytes O
. O

A O
conserved O
region O
of O
E2 O
encompassing O
amino O
acids O
412 O
to O
423 O
( O
epitope O
I O
) O
and O
containing O
Trp420 O
, O
a O
residue O
critical O
for O
virus O
entry O
, O
is O
recognized O
by O
several O
broadly O
neutralizing O
antibodies O
. O

Peptides O
embodying O
this O
epitope O
I O
sequence O
adopt O
a O
beta O
- O
hairpin O
conformation O
when O
bound O
to O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
AP33 O
and O
HCV1 O
. O

We O
therefore O
generated O
new O
mouse O
MAbs O
that O
were O
able O
to O
bind O
to O
a O
cyclic O
peptide O
containing O
E2 O
residues O
412 O
to O
422 O
( O
C O
- O
epitope O
I O
) O
but O
not O
to O
the O
linear O
counterpart O
. O

Structural O
analysis O
of O
the O
complex O
between O
C O
- O
epitope O
I O
and O
one O
of O
our O
MAbs O
( O
C2 O
) O
showed O
that O
the O
Trp420 O
side O
chain O
is O
largely O
buried O
in O
the O
combining O
site O
and O
that O
the O
Asn417 O
side O
chain O
, O
which O
is O
glycosylated O
in O
E2 O
and O
solvent O
exposed O
in O
other O
complexes O
, O
is O
slightly O
buried O
upon O
C2 O
binding O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
global O
health O
problem O
, O
with O
millions O
of O
chronically O
infected O
individuals O
at O
risk O
for O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

HCV O
vaccine O
development O
is O
vital O
in O
the O
effort O
toward O
disease O
control O
and O
eradication O
, O
an O
undertaking O
aided O
by O
an O
increased O
understanding O
of O
the O
mechanisms O
of O
resistance O
to O
broadly B
neutralizing I
antibodies I
( I
bNAbs I
) I
. O

IMPORTANCE O
Worldwide O
, O
more O
than O
170 O
million O
people O
are O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
the O
leading O
cause O
of O
hepatocellular O
carcinoma O
and O
liver O
transplantation O
in O
the O
United O
States O
. O

Control O
of O
the O
HCV O
pandemic O
with O
drug O
treatment O
alone O
is O
likely O
to O
fail O
due O
to O
limited O
access O
to O
treatment O
, O
reinfections O
in O
high O
- O
risk O
individuals O
, O
and O
the O
potential O
for O
resistance O
to O
direct B
- I
acting I
antivirals I
( I
DAAs I
) I
. O

broadly B
neutralizing I
antibodies I
( I
bNAbs I
) I
block O
infection O
by O
diverse O
HCV O
variants O
and O
therefore O
serve O
as O
a O
useful O
guide O
for O
vaccine O
development O
, O
but O
our O
understanding O
of O
resistance O
to O
bNAbs O
is O
incomplete O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
disease O
and O
is O
highly O
dependent O
on O
cellular O
proteins O
for O
virus O
propagation O
. O

To O
identify O
the O
cellular O
factors O
involved O
in O
HCV O
propagation O
, O
we O
recently O
performed O
protein O
microarray O
assays O
using O
the O
HCV B
nonstructural I
5A I
( I
NS5A I
) I
protein O
as O
a O
probe O
. O

Of O
90 O
cellular O
protein O
candidates O
, O
we O
selected O
the O
soluble O
resistance O
- O
related O
calcium O
- O
binding O
protein O
( O
sorcin O
) O
for O
further O
characterization O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
sorcin O
impaired O
HCV O
propagation O
. O

We O
further O
demonstrated O
that O
polo B
- I
like I
kinase I
1 I
( I
PLK1 I
) I
- O
mediated O
phosphorylation O
of O
sorcin O
was O
increased O
by O
NS5A O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
requires O
proteins O
from O
the O
NS3 O
- O
NS5B O
polyprotein O
to O
create O
a O
replicase O
unit O
for O
replication O
of O
its O
genome O
. O

We O
recently O
reported O
on O
intragenomic O
replicons O
, O
bicistronic O
viral O
transcripts O
expressing O
an O
authentic O
replicase O
from O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
and O
a O
second O
duplicate O
nonstructural B
( I
NS I
) I
polyprotein O
from O
ORF1 O
. O

Three O
mutations O
were O
identified O
as O
more O
refractile O
to O
rescue O
: O
one O
that O
blocked O
cleavage O
of O
the O
NS4B5A O
boundary O
( O
S1977P O
) O
, O
another O
in O
the O
NS3 O
helicase O
( O
K1240N O
) O
, O
and O
a O
third O
in O
NS4A O
( O
V1665G O
) O
. O

It O
has O
been O
proposed O
that O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
NS4B O
protein O
triggers O
the O
membranous O
HCV O
replication O
compartment O
, O
but O
the O
underlying O
molecular O
mechanism O
is O
not O
fully O
understood O
. O

Subsequent O
screening O
of O
replicon O
cells O
with O
small O
interfering O
RNA O
identified O
prolactin B
regulatory I
element I
binding I
( I
PREB I
) I
to O
be O
a O
novel O
HCV O
host O
cofactor O
. O

Furthermore O
, O
PREB O
shifted O
to O
detergent B
- I
resistant I
membranes I
( I
DRMs I
) I
, O
where O
HCV O
replication O
complexes O
reside O
, O
in O
the O
presence O
of O
NS4B O
expression O
in O
Huh7 O
cells O
. O

However O
, O
a O
PREB O
mutant O
lacking O
the O
NS4B O
- O
binding O
region O
( O
PREBd3 O
) O
could O
not O
colocalize O
with O
double O
- O
stranded O
RNA O
and O
did O
not O
shift O
to O
the O
DRM O
in O
the O
presence O
of O
NS4B O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
( O
amino O
acids O
[ O
aa O
] O
384 O
to O
410 O
) O
on O
the O
E2 O
glycoprotein O
of O
hepatitis O
C O
virus O
contributes O
to O
persistent O
infection O
by O
evolving O
escape O
mutations O
that O
attenuate O
binding O
of O
inhibitory O
antibodies O
and O
by O
blocking O
access O
of O
broadly O
neutralizing O
antibodies O
to O
their O
epitopes O
. O

Epitope O
mapping O
of O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
that O
bind O
to O
an O
adjacent O
, O
conserved O
domain O
on O
E2 O
encompassing O
aa O
412 O
to O
423 O
revealed O
two O
subsets O
, O
designated O
HC33 O
HMAbs O
. O

The O
oligoadenylate B
synthetase I
( I
OAS I
) I
- O
RNase O
L O
pathway O
is O
a O
potent O
interferon B
( I
IFN I
) I
- O
induced O
antiviral O
activity O
. O

Upon O
sensing O
double O
- O
stranded O
RNA O
, O
OAS O
produces O
2 O
' O
, O
5 O
' O
- O
oligoadenylates O
( O
2 O
- O
5A O
) O
, O
which O
activate O
RNase O
L O
. O

Murine O
coronavirus O
( O
mouse O
hepatitis O
virus O
[ O
MHV O
] O
) O
nonstructural B
protein I
2 I
( I
NS2 I
) I
is O
a O
2 O
' O
, O
5 O
' O
- O
phosphodiesterase B
( I
PDE I
) I
that O
cleaves O
2 O
- O
5A O
, O
thereby O
antagonizing O
RNase O
L O
activation O
. O

PDE O
activity O
is O
required O
for O
robust O
replication O
in O
myeloid O
cells O
, O
as O
a O
mutant O
of O
MHV O
( O
ns O
( O
2H126R O
) O
) O
encoding O
an O
inactive O
PDE O
fails O
to O
antagonize O
RNase O
L O
activation O
and O
replicates O
poorly O
in O
bone B
marrow I
- I
derived I
macrophages I
( I
BMM I
) I
, O
while O
ns O
( O
2H126R O
) O
replicates O
to O
high O
titer O
in O
several O
types O
of O
nonmyeloid O
cells O
, O
as O
well O
as O
in O
IFN O
receptor O
- O
deficient O
( O
Ifnar1 O
( O
- O
/ O
- O
) O
) O
BMM O
. O

Infection O
with O
ns O
( O
2H126R O
) O
activated O
RNase O
L O
in O
Ifih1 O
( O
- O
/ O
- O
) O
BMM O
to O
a O
similar O
extent O
as O
in O
wild B
- I
type I
( I
WT I
) I
BMM O
, O
despite O
the O
lack O
of O
IFN O
induction O
in O
the O
absence O
of O
MDA5 O
expression O
. O

However O
, O
ns O
( O
2H126R O
) O
failed O
to O
induce O
RNase O
L O
activation O
in O
BMM O
treated O
with O
IFNAR1 O
- O
blocking O
antibody O
, O
as O
well O
as O
in O
Ifnar1 O
( O
- O
/ O
- O
) O
BMM O
, O
both O
expressing O
low O
basal O
levels O
of O
Oas O
genes O
. O

Human B
astroviruses I
( I
HAstVs I
) I
are O
nonenveloped O
, O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
viruses O
that O
are O
a O
leading O
cause O
of O
viral O
gastroenteritis O
. O

HAstV O
particles O
display O
T O
= O
3 O
icosahedral O
symmetry O
formed O
by O
180 O
copies O
of O
the O
capsid B
protein I
( I
CP I
) I
, O
which O
undergoes O
proteolytic O
maturation O
to O
generate O
infectious O
HAstV O
particles O
. O

Ebola B
virus I
( I
EBOV I
) I
is O
an O
RNA O
virus O
that O
can O
cause O
hemorrhagic O
fever O
with O
high O
fatality O
rates O
, O
and O
there O
are O
no O
approved O
vaccines O
or O
therapies O
. O

In O
vitro O
, O
the O
presence O
of O
ribavirin O
increased O
the O
error O
rate O
, O
and O
the O
50 B
% I
inhibitory I
concentration I
( I
IC50 I
) I
was O
27 O
mu O
M O
. O

IMPORTANCE O
Ebola B
virus I
( I
EBOV I
) I
causes O
a O
severe O
hemorrhagic O
disease O
with O
high O
case O
fatality O
rates O
; O
there O
are O
no O
approved O
vaccines O
or O
therapies O
. O

The O
cellular O
response O
to O
virus O
infection O
is O
initiated O
when O
pathogen B
recognition I
receptors I
( I
PRR I
) I
engage O
viral O
pathogen B
- I
associated I
molecular I
patterns I
( I
PAMPs I
) I
. O

This O
process O
results O
in O
induction O
of O
downstream O
signaling O
pathways O
that O
activate O
the O
transcription O
factor O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
. O

Compound O
administration O
significantly O
decreased O
the O
viral O
RNA O
load O
in O
cultured O
cells O
that O
were O
infected O
with O
viruses O
of O
the O
family O
Flaviviridae O
, O
including O
West O
Nile O
virus O
, O
dengue O
virus O
, O
and O
hepatitis O
C O
virus O
, O
as O
well O
as O
viruses O
of O
the O
families O
Filoviridae O
( O
Ebola O
virus O
) O
, O
Orthomyxoviridae O
( O
influenza O
A O
virus O
) O
, O
Arenaviridae O
( O
Lassa O
virus O
) O
, O
and O
Paramyxoviridae O
( O
respiratory O
syncytial O
virus O
, O
Nipah O
virus O
) O
to O
suppress O
infectious O
virus O
production O
. O

Gap B
junctions I
( I
GJs I
) I
form O
intercellular O
channels O
which O
directly O
connect O
the O
cytoplasm O
between O
neighboring O
cells O
to O
facilitate O
the O
transfer O
of O
ions O
and O
small O
molecules O
. O

Mutations O
of O
gap O
junction O
proteins O
, O
connexins B
( I
Cxs I
) I
, O
cause O
dysmyelination O
and O
leukoencephalopathy O
. O

In O
multiple B
sclerosis I
( I
MS I
) I
patients O
and O
its O
animal O
model O
experimental B
autoimmune I
encephalitis I
( I
EAE I
) I
, O
Cx43 O
was O
shown O
to O
be O
modulated O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
infection O
- O
induced O
demyelination O
is O
one O
of O
the O
best O
- O
studied O
experimental O
animal O
models O
for O
MS O
. O

After O
infection O
, O
a O
significant O
amount O
of O
Cx43 O
was O
retained O
in O
endoplasmic B
reticulum I
/ I
endoplasmic I
reticulum I
Golgi I
intermediate I
complex I
( I
ER I
/ I
ERGIC I
) I
and O
GJ O
plaque O
formation O
was O
impaired O
at O
the O
cell O
surface O
, O
as O
evidenced O
by O
a O
reduction O
of O
the O
Triton O
X O
- O
100 O
insoluble O
fraction O
of O
Cx43 O
. O

This O
study O
demonstrates O
that O
astrocytic O
Cx43 O
expression O
and O
function O
can O
be O
modulated O
due O
to O
virus O
stress O
and O
can O
be O
an O
appropriate O
model O
to O
understand O
the O
basis O
of O
cellular O
mechanisms O
involved O
in O
the O
alteration O
of O
gap B
junction I
intercellular I
communication I
( I
GJIC I
) I
in O
CNS O
neuroinflammation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
in O
humans O
. O

To O
understand O
the O
mechanism O
for O
reduced O
extracellular O
infectious O
HCV O
in O
the O
exosome O
, O
we O
observed O
that O
an O
interferon B
( I
IFN I
) I
- O
stimulated O
BST O
- O
2 O
gene O
is O
upregulated O
in O
autophagy O
knockdown O
cells O
and O
associated O
with O
the O
exosome O
marker O
CD63 O
, O
which O
may O
inhibit O
HCV O
assembly O
or O
release O
. O

To O
better O
understand O
their O
diversity O
, O
evolutionary O
history O
, O
and O
genomic O
flexibility O
, O
we O
used O
transcriptome O
sequencing O
( O
RNA O
- O
seq O
) O
to O
search O
for O
the O
viruses O
related O
to O
the O
Flaviviridae O
in O
a O
range O
of O
potential O
invertebrate O
and O
vertebrate O
hosts O
. O

Accordingly O
, O
we O
recovered O
the O
full O
genomes O
of O
five O
segmented O
jingmenviruses O
and O
12 O
distant O
relatives O
of O
the O
known O
Flaviviridae B
( I
flavilike I
viruses I
) I
from O
a O
range O
of O
arthropod O
species O
. O

For O
the O
vertebrate O
viruses O
, O
we O
expanded O
the O
previously O
mammal O
- O
only O
pegivirus O
- O
hepacivirus O
group O
to O
include O
a O
virus O
from O
the O
graceful O
catshark O
( O
Proscyllium O
habereri O
) O
, O
which O
in O
turn O
implies O
that O
these O
viruses O
possess O
a O
larger O
host O
range O
than O
is O
currently O
known O
. O

Despite O
the O
recent O
development O
of O
highly O
effective O
anti O
- O
hepatitis B
C I
virus I
( I
HCV I
) I
drugs O
, O
the O
global O
burden O
of O
this O
pathogen O
remains O
immense O
. O

A O
precise O
molecular O
identification O
of O
transmitted B
/ I
founder I
( I
T I
/ I
F I
) I
HCV O
genomes O
that O
lead O
to O
productive O
clinical O
infection O
could O
play O
a O
critical O
role O
in O
vaccine O
research O
, O
as O
it O
has O
for O
HIV O
- O
1 O
. O

Using O
single B
- I
genome I
sequencing I
( I
SGS I
) I
of O
plasma O
vRNA O
, O
we O
found O
that O
inferred O
T O
/ O
F O
sequences O
in O
recipients O
were O
identical O
to O
viral O
sequences O
in O
their O
respective O
donors O
. O

The O
cyclic O
dinucleotide O
2 O
' O
, O
3 O
' O
- O
cGAMP O
can O
bind O
the O
adaptor O
protein O
STING O
( O
stimulator O
of O
interferon O
[ O
IFN O
] O
genes O
) O
to O
activate O
the O
production O
of O
type O
I O
IFNs O
and O
proinflammatory O
cytokines O
. O

We O
found O
that O
cGAMP O
added O
to O
the O
culture O
medium O
could O
suppress O
the O
replication O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
1b O
strain O
Con1 O
subgenomic O
replicon O
in O
human O
hepatoma O
cells O
. O

Transient O
expression O
of O
2a O
NS4B O
resulted O
in O
a O
pronounced O
inhibitory O
effect O
on O
STING O
- O
mediated O
beta O
IFN O
( O
IFN O
- O
beta O
) O
reporter O
activation O
compared O
to O
that O
of O
1b O
NS4B O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoproteins O
E1 O
and O
E2 O
form O
a O
heterodimer O
and O
mediate O
receptor O
interactions O
and O
viral O
fusion O
. O

Both O
E1 O
and O
E2 O
are O
targets O
of O
the O
Neutralizing B
antibody I
( I
NAb I
) I
response O
and O
are O
candidates O
for O
the O
production O
of O
vaccines O
that O
generate O
humoral O
immunity O
. O

Previous O
studies O
demonstrated O
that O
N O
- O
terminal O
hypervariable B
region I
1 I
( I
HVR1 I
) I
can O
modulate O
the O
neutralization O
potential O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
but O
no O
information O
is O
available O
on O
the O
influence O
of O
HVR2 O
or O
the O
intergenotypic B
variable I
region I
( I
IgVR I
) I
on O
antigenicity O
. O

In O
this O
study O
, O
we O
examined O
how O
the O
variable O
regions O
influence O
the O
antigenicity O
of O
the O
receptor O
binding O
domain O
of O
E2 O
spanning O
HCV O
polyprotein O
residues O
384 O
to O
661 O
( O
E2 O
( O
661 O
) O
) O
using O
a O
panel O
of O
MAbs O
raised O
against O
E2 O
( O
661 O
) O
and O
E2 O
( O
661 O
) O
lacking O
HVR1 O
, O
HVR2 O
, O
and O
the O
igVR O
( O
Delta O
123 O
) O
and O
well O
- O
characterized O
MAbs O
isolated O
from O
infected O
humans O
. O

We O
show O
for O
a O
subset O
of O
both O
neutralizing O
and O
nonneutralizing O
MAbs O
that O
all O
three O
variable O
regions O
decrease O
the O
ability O
of O
MAbs O
to O
bind O
E2 O
( O
661 O
) O
and O
reduce O
the O
ability O
of O
MAbs O
to O
inhibit O
E2 O
- O
CD81 O
interactions O
. O

In O
addition O
, O
we O
describe O
a O
new O
MAb O
directed O
toward O
the O
region O
spanning O
residues O
411 O
to O
428 O
of O
E2 O
( O
MAb24 O
) O
that O
demonstrates O
broad O
neutralization O
against O
all O
7 O
genotypes O
of O
HCV O
. O

IMPORTANCE O
This O
study O
reveals O
conformational O
and O
antigenic O
differences O
between O
the O
Delta O
123 O
and O
intact O
E2 O
( O
661 O
) O
glycoproteins O
and O
provides O
new O
structural O
and O
functional O
data O
about O
the O
three O
variable O
regions O
and O
their O
role O
in O
occluding O
neutralizing O
and O
nonneutralizing O
epitopes O
on O
the O
E2 O
core O
domain O
. O

Dideoxy O
sequencing O
confirmed O
that O
the O
white B
sucker I
hepatitis I
B I
virus I
( I
WSHBV I
) I
has O
a O
circular O
genome O
( O
3 O
, O
542 O
bp O
) O
with O
the O
prototypical O
codon O
organization O
of O
hepadnaviruses O
. O

5 O
% O
( O
16 O
of O
169 O
) O
of O
white O
suckers O
evaluated O
. O

The O
innate O
immune O
response O
is O
the O
first O
line O
of O
defense O
against O
viruses O
, O
and O
type B
I I
interferon I
( I
IFN I
) I
is O
a O
critical O
component O
of O
this O
response O
. O

Similar O
to O
other O
viruses O
, O
the O
gammacoronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
has O
evolved O
under O
evolutionary O
pressure O
to O
evade O
and O
counteract O
the O
IFN O
response O
to O
enable O
its O
survival O
. O

IMPORTANCE O
In O
the O
present O
study O
, O
we O
show O
that O
infectious B
bronchitis I
virus I
( I
IBV I
) I
is O
resistant O
to O
IFN O
treatment O
and O
identify O
a O
role O
for O
accessory O
protein O
3a O
in O
the O
resistance O
against O
the O
type O
I O
IFN O
response O
. O

One O
of O
these O
pathways O
is O
the O
2 O
' O
- O
5 B
' I
- I
oligoadenylate I
synthetase I
( I
OAS I
) I
/ O
RNase O
L O
pathway O
. O

OAS O
is O
activated O
by O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
to O
produce O
2 O
' O
- O
5 O
' O
oligoadenylates O
, O
which O
are O
the O
activators O
of O
RNase O
L O
; O
this O
enzyme O
degrades O
viral O
and O
cellular O
RNAs O
, O
restricting O
viral O
infection O
. O

It O
has O
been O
recently O
found O
that O
the O
carboxy B
- I
terminal I
domain I
( I
CTD I
) I
of O
rotavirus O
VP3 O
has O
a O
2 O
' O
- O
5 O
' O
- O
phosphodiesterase B
( I
PDE I
) I
activity O
that O
is O
able O
to O
functionally O
substitute O
for O
the O
PDE O
activity O
of O
the O
mouse O
hepatitis O
virus O
ns2 O
protein O
. O

Infection O
with O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
activates O
the O
pattern O
recognition O
receptors O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
and O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
to O
induce O
transcription O
of O
type O
I O
interferon O
. O

Mice O
deficient O
in O
MDA5 O
expression O
( O
MDA5 O
( O
- O
/ O
- O
) O
mice O
) O
experienced O
more O
severe O
disease O
following O
MHV O
infection O
, O
with O
reduced O
survival O
, O
increased O
spread O
of O
virus O
to O
additional O
sites O
of O
infection O
, O
and O
more O
extensive O
liver O
damage O
than O
did O
wild O
- O
type O
mice O
. O

Although O
type O
I O
interferon O
transcription O
decreased O
in O
MDA5 O
( O
- O
/ O
- O
) O
mice O
, O
the O
interferon O
- O
stimulated O
gene O
response O
remained O
intact O
. O

Cytokine O
production O
by O
innate O
and O
adaptive O
immune O
cells O
was O
largely O
intact O
in O
MDA5 O
( O
- O
/ O
- O
) O
mice O
, O
but O
perforin O
induction O
by O
natural O
killer O
cells O
and O
levels O
of O
interferon O
gamma O
, O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
in O
serum O
were O
elevated O
. O

Viral O
replication O
in O
the O
liver O
was O
similar O
in O
mice O
with O
and O
without O
MDA5 O
, O
but O
liver O
damage O
was O
increased O
in O
MDA5 O
( O
- O
/ O
- O
) O
mice O
, O
suggesting O
that O
the O
immune O
response O
is O
causing O
the O
damage O
. O

Production O
of O
several O
proinflammatory O
cytokines O
was O
elevated O
in O
MDA5 O
( O
- O
/ O
- O
) O
mice O
, O
suggesting O
that O
MDA5 O
may O
be O
responsible O
for O
keeping O
pathological O
inflammatory O
responses O
in O
check O
. O

Despite O
the O
introduction O
of O
direct B
- I
acting I
antiviral I
( I
DAA I
) I
drugs O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
infection O
remains O
a O
major O
public O
health O
concern O
because O
DAA O
therapeutics O
do O
not O
prevent O
reinfection O
and O
patients O
can O
still O
progress O
to O
chronic O
liver O
disease O
. O

Transmission O
of O
HCV O
involves O
one O
or O
a O
few O
transmitted B
/ I
founder I
( I
T I
/ I
F I
) I
variants O
. O

In O
infected O
hepatocytes O
, O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
protein O
recognizes O
5 B
' I
triphosphate I
( I
5 I
' I
ppp I
) I
of O
the O
HCV O
RNA O
and O
a O
pathogen B
- I
associated I
molecular I
pattern I
( I
PAMP I
) I
motif O
located O
within O
the O
3 O
' O
untranslated O
region O
consisting O
of O
poly O
- O
U O
/ O
UC O
. O

Here O
, O
we O
report O
a O
novel O
role O
for O
HuR O
, O
as O
a O
regulator O
of O
proteins O
assembling O
at O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
viral O
RNA O
in O
the O
context O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

HuR O
relocalizes O
from O
the O
nucleus O
to O
the O
cytoplasm O
upon O
HCV O
infection O
, O
interacts O
with O
the O
viral O
polymerase O
( O
NS5B O
) O
, O
and O
gets O
redistributed O
into O
compartments O
of O
viral O
RNA O
synthesis O
. O

We O
further O
demonstrate O
that O
the O
interaction O
of O
HuR O
with O
the O
3 O
' O
UTR O
of O
the O
viral O
RNA O
affects O
the O
interaction O
of O
two O
host O
proteins O
, O
La O
and O
polypyrimidine B
tract I
binding I
protein I
( I
PTB I
) I
, O
at O
this O
site O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
dependent O
on O
various O
host O
factors O
for O
efficient O
replication O
of O
the O
viral O
RNA O
. O

Here O
, O
we O
have O
shown O
how O
a O
host O
factor O
( O
HuR O
) O
migrates O
from O
the O
nucleus O
to O
the O
cytoplasm O
and O
gets O
recruited O
in O
the O
protein O
complex O
assembling O
at O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
HCV O
RNA O
. O

The O
molecular O
mechanisms O
that O
govern O
hepatitis B
C I
virus I
( I
HCV I
) I
assembly O
, O
release O
, O
and O
infectivity O
are O
still O
not O
yet O
fully O
understood O
. O

In O
the O
present O
study O
, O
we O
sequenced O
a O
genotype O
2A O
strain O
of O
HCV O
( O
JFH O
- O
1 O
) O
that O
had O
been O
cell O
culture O
adapted O
in O
Huh O
- O
7 O
. O

Turnip B
crinkle I
virus I
( I
TCV I
) I
contains O
a O
structured O
3 O
' O
region O
with O
hairpins O
and O
pseudoknots O
that O
form O
a O
complex O
network O
of O
non O
- O
canonical O
RNA O
: O
RNA O
interactions O
supporting O
higher O
- O
order O
structure O
critical O
for O
translation O
and O
replication O
. O

We O
investigated O
several O
second O
- O
site O
mutations O
in O
the O
p38 O
coat O
protein O
open B
reading I
frame I
( I
ORF I
) I
that O
arose O
in O
response O
to O
a O
mutation O
in O
the O
asymmetric O
loop O
of O
a O
critical O
3 B
' I
untranslated I
region I
( I
UTR I
) I
hairpin O
that O
disrupts O
local O
higher O
- O
order O
structure O
. O

All O
tested O
second O
- O
site O
mutations O
improved O
accumulation O
of O
TCV O
in O
conjunction O
with O
a O
partial O
reversion O
of O
the O
primary O
mutation O
( O
TCV O
- O
rev1 O
) O
but O
had O
neutral O
or O
a O
negative O
effect O
on O
wild B
- I
type I
( I
WT I
) I
TCV O
or O
TCV O
with O
the O
primary O
mutation O
. O

SHAPE O
( O
selective O
2 O
' O
- O
hydroxyl O
acylation O
analyzed O
by O
primer O
extension O
) O
structure O
probing O
indicated O
that O
these O
second O
- O
site O
mutations O
reside O
in O
an O
RNA O
domain O
that O
includes O
most O
of O
p38 O
( O
domain O
2 O
) O
, O
and O
evidence O
for O
RNA O
: O
RNA O
interactions O
between O
domain O
2 O
and O
3 O
' O
UTR O
- O
containing O
domain O
1 O
was O
found O
. O

One O
second O
- O
site O
mutation O
reduced O
silencing O
suppressor O
activity O
of O
p38 O
by O
altering O
one O
of O
two O
GW O
motifs O
that O
are O
required O
for O
p38 O
binding O
to O
double B
- I
stranded I
RNAs I
( I
dsRNAs I
) I
and O
interaction O
with O
RNA B
- I
induced I
silencing I
complex I
( I
RISC I
) I
- O
associated O
AGO1 O
/ O
AGO2 O
. O

A O
more O
comprehensive O
understanding O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
transmission O
dynamics O
could O
facilitate O
public O
health O
initiatives O
to O
reduce O
the O
prevalence O
of O
HCV O
in O
people O
who O
inject O
drugs O
. O

A O
Scottish O
data O
set O
with O
embedded O
demographic O
data O
was O
created O
by O
sequencing O
the O
NS5B O
of O
125 O
genotype B
1a I
( I
Gt1a I
) I
samples O
and O
166 O
Gt3a O
samples O
and O
analyzed O
alongside O
sequences O
from O
public O
databases O
. O

Scottish O
sequences O
mainly O
formed O
discrete O
clusters O
interspersed O
between O
sequences O
from O
the O
rest O
of O
the O
world O
; O
the O
most O
recent O
common O
ancestors O
of O
these O
clusters O
dated O
to O
1942 O
to O
1952 O
( O
Gt1a O
) O
and O
1926 O
to O
1942 O
( O
Gt3a O
) O
, O
coincident O
with O
global O
diversification O
and O
distribution O
. O

Extant O
Scottish O
sequences O
originated O
in O
Edinburgh O
( O
Gt1a O
) O
and O
Glasgow O
( O
Gt3a O
) O
in O
the O
1970s O
, O
but O
both O
genotypes O
spread O
from O
Glasgow O
to O
other O
regions O
. O

The O
dominant O
Gt1a O
strain O
differed O
between O
Edinburgh O
( O
cluster O
2 O
[ O
C2 O
] O
) O
, O
Glasgow O
( O
C3 O
) O
, O
and O
Aberdeen O
( O
C4 O
) O
, O
whereas O
significant O
Gt3a O
strain O
specificity O
occurred O
only O
in O
Aberdeen O
. O

Public O
health O
needle O
exchange O
and O
treatment O
as O
prevention O
strategies O
targeting O
HCV O
are O
designed O
to O
reduce O
prevalence O
of O
the O
virus O
in O
people B
who I
inject I
drugs I
( I
PWID I
) I
, O
potentially O
mitigating O
the O
future O
burden O
of O
HCV O
- O
associated O
liver O
disease O
. O

In O
hepatitisCvirus O
( O
HCV O
) O
- O
infected O
cells O
, O
the O
envelope O
glycoproteins O
E1 O
and O
E2 O
assemble O
as O
a O
heterodimer O
. O

This O
revealed O
the O
presence O
of O
SDS O
- O
resistant O
trimers O
of O
E1 O
in O
the O
context O
of O
cell B
- I
cultured I
HCV I
( I
HCVcc I
) I
as O
well O
as O
in O
the O
context O
of O
HCV B
pseudo I
particles I
( I
HCVpp I
) I
. O

To O
further O
understand O
the O
origin O
of O
E1 O
trimer O
formation O
, O
we O
coexpressed O
in O
bacteria O
the O
transmembrane B
( I
TM I
) I
domains O
of O
E1 O
( O
TME1 O
) O
and O
E2 O
( O
TME2 O
) O
fused O
to O
reporter O
proteins O
and O
analyzed O
the O
fusion O
proteins O
by O
SDS O
- O
PAGE O
and O
Western O
blotting O
. O

Single O
or O
double O
mutations O
of O
the O
glycine O
residues O
( O
Gly354 O
and O
Gly358 O
) O
in O
this O
motif O
markedly O
decreased O
or O
abrogated O
the O
formation O
of O
TME1 O
homotrimers O
in O
bacteria O
, O
as O
well O
as O
homotrimers O
of O
E1 O
in O
both O
HCVpp O
and O
HCVcc O
systems O
. O

Since O
positive O
- O
sense O
RNA O
viruses O
have O
frequently O
been O
found O
to O
replicate O
in O
association O
with O
membranous O
structures O
, O
in O
this O
work O
we O
characterized O
the O
replication O
of O
the O
human O
astrovirus O
serotype O
8 O
strain O
Yuc8 O
in O
Caco O
- O
2 O
cells O
, O
using O
density O
gradient O
centrifugation O
and O
free B
- I
flow I
zonal I
electrophoresis I
( I
FFZE I
) I
to O
fractionate O
cellular O
membranes O
. O

Silencing O
of O
the O
expression O
of O
genes O
involved O
in O
cholesterol O
( O
DHCR7 O
, O
CYP51A1 O
) O
and O
fatty B
acid I
( I
FASN I
) I
synthesis O
, O
phosphatidylinositol O
( O
PI4KIII O
beta O
) O
and O
inositol B
phosphate I
( I
ITPR3 I
) I
metabolism O
, O
and O
RNA O
helicase O
activity O
( O
DDX23 O
) O
significantly O
decreased O
the O
amounts O
of O
Yuc8 O
genomic O
and O
antigenomic O
RNA O
, O
synthesis O
of O
the O
structural O
protein O
VP90 O
, O
and O
virus O
yield O
. O

The O
life O
cycle O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
dependent O
on O
host O
cellular O
proteins O
for O
virus O
propagation O
. O

In O
order O
to O
identify O
the O
cellular O
factors O
involved O
in O
HCV O
propagation O
, O
we O
performed O
protein O
microarray O
assay O
using O
the O
HCV B
nonstructural I
5A I
( I
NS5A I
) I
protein O
as O
a O
probe O
. O

Of O
these O
candidates O
, O
Pim1 O
, O
a O
member O
of O
serine O
/ O
threonine O
kinase O
family O
composed O
of O
three O
different O
isoforms O
( O
Pim1 O
, O
Pim2 O
, O
and O
Pim3 O
) O
, O
was O
selected O
for O
further O
study O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
or O
pharmacological O
inhibition O
of O
Pim O
kinase O
abrogated O
HCV O
propagation O
. O

All O
major O
types O
of O
interferon B
( I
IFN I
) I
efficiently O
inhibit O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
in O
vitro O
and O
in O
vivo O
. O

We O
performed O
transcriptome O
analyses O
between O
Huh6 O
and O
Huh O
- O
7 O
cells O
to O
identify O
effector O
genes O
of O
the O
IFN O
- O
gamma O
response O
and O
thereby O
identified O
the O
DExD O
/ O
H O
box O
helicase O
DEAD O
box O
polypeptide O
60 O
- O
like O
( O
DDX60L O
) O
as O
a O
restriction O
factor O
of O
HCV O
replication O
. O

DDX60L O
and O
its O
homolog O
DEAD O
box O
polypeptide O
60 O
( O
DDX60 O
) O
were O
both O
induced O
upon O
viral O
infection O
and O
IFN O
treatment O
in O
primary O
human O
hepatocytes O
. O

DDX60L O
knockdown O
did O
not O
alter O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
induction O
after O
IFN O
treatment O
but O
inhibited O
HCV O
replication O
upon O
ectopic O
expression O
, O
suggesting O
that O
it O
is O
a O
direct O
effector O
of O
the O
innate O
immune O
response O
. O

IMPORTANCE O
Interferons O
induce O
a O
plethora O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
which O
are O
our O
first O
line O
of O
defense O
against O
viral O
infections O
. O

In O
addition O
, O
IFNs O
have O
been O
used O
in O
antiviral O
therapy O
, O
in O
particular O
against O
the O
human O
pathogen O
hepatitis B
C I
virus I
( I
HCV I
) I
; O
still O
, O
their O
mechanism O
of O
action O
is O
not O
well O
understood O
, O
since O
diverse O
, O
overlapping O
sets O
of O
antagonistic O
effector O
ISGs O
target O
viruses O
with O
different O
biologies O
. O

Assembly O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
begins O
with O
packaging O
of O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
into O
immature O
nucleocapsids B
( I
NC I
) I
, O
which O
are O
converted O
to O
mature O
NCs O
containing O
the O
genomic O
relaxed B
circular I
( I
RC I
) I
DNA O
as O
a O
result O
of O
reverse O
transcription O
. O

Mature O
NCs O
have O
two O
alternative O
fates O
: O
( O
i O
) O
envelopment O
by O
viral O
envelope O
proteins O
, O
leading O
to O
secretion O
extracellularly O
as O
virions O
, O
or O
( O
ii O
) O
disassembly O
( O
uncoating O
) O
to O
deliver O
their O
RC O
DNA O
content O
into O
the O
host O
cell O
nucleus O
for O
conversion O
to O
the O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
the O
template O
for O
viral O
transcription O
. O

The O
NC O
shell O
is O
composed O
of O
multiple O
copies O
of O
a O
single O
viral O
protein O
, O
the O
HBV B
core I
( I
HBc I
) I
protein O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
health O
issue O
worldwide O
. O

HBV O
assembly O
begins O
with O
the O
packaging O
into O
immature O
nucleocapsids B
( I
NCs I
) I
of O
a O
viral O
RNA O
pregenome O
, O
which O
is O
converted O
to O
the O
DNA O
genome O
in O
mature O
NCs O
. O

Myd88 O
signaling O
is O
critical O
to O
the O
control O
of O
numerous O
central B
nervous I
system I
( I
CNS I
) I
infections O
by O
promoting O
both O
innate O
and O
adaptive O
immune O
responses O
. O

Nevertheless O
, O
the O
extent O
to O
which O
Myd88 O
regulates O
type B
I I
interferon I
( I
IFN I
) I
versus O
proinflammatory O
factors O
and O
T O
cell O
function O
, O
as O
well O
as O
the O
anatomical O
site O
of O
action O
, O
varies O
extensively O
with O
the O
pathogen O
. O

CNS O
infection O
by O
neurotropic O
coronavirus O
with O
replication O
confined O
to O
the O
brain O
and O
spinal O
cord O
induces O
protective O
IFN O
- O
alpha O
/ O
beta O
via O
Myd88 O
- O
independent O
activation O
of O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
. O

Infected O
Myd88 O
( O
- O
/ O
- O
) O
mice O
failed O
to O
control O
virus O
, O
exhibited O
enhanced O
clinical O
disease O
coincident O
with O
increased O
demyelination O
, O
and O
succumbed O
to O
infection O
within O
3 O
weeks O
. O

Ineffective O
virus O
control O
indeed O
correlated O
most O
prominently O
with O
reduced O
antiviral O
IFN O
- O
gamma O
in O
the O
CNS O
of O
Myd88 O
( O
- O
/ O
- O
) O
mice O
. O

IMPORTANCE O
During O
central B
nervous I
system I
( I
CNS I
) I
infections O
, O
signaling O
through O
the O
adaptor O
protein O
Myd88 O
promotes O
both O
innate O
and O
adaptive O
immune O
responses O
. O

Mammalian O
orthoreoviruses O
( O
reoviruses O
) O
are O
nonenveloped O
double O
- O
stranded O
RNA O
viruses O
that O
infect O
most O
mammalian O
species O
, O
including O
humans O
. O

Reovirus O
binds O
to O
cell O
surface O
glycans O
, O
junctional B
adhesion I
molecule I
A I
( I
JAM I
- I
A I
) I
, O
and O
the O
Nogo O
- O
1 O
receptor O
( O
depending O
on O
the O
cell O
type O
) O
and O
enters O
cells O
by O
receptor O
- O
mediated O
endocytosis O
. O

In O
a O
small O
- O
molecule O
screen O
to O
identify O
host O
mediators O
of O
reovirus O
infection O
, O
we O
found O
that O
treatment O
of O
cells O
with O
5 B
- I
nonyloxytryptamine I
( I
5 I
- I
NT I
) I
, O
a O
prototype O
serotonin O
receptor O
agonist O
, O
diminished O
reovirus O
cytotoxicity O
. O

We O
found O
that O
5 B
- I
nonyloxytryptamine I
( I
5 I
- I
NT I
) I
impairs O
reovirus O
infection O
by O
altering O
viral O
transport O
during O
cell O
entry O
. O

RNA B
interference I
( I
RNAi I
) I
is O
a O
process O
of O
eukaryotic O
posttranscriptional O
gene O
silencing O
that O
functions O
in O
antiviral O
immunity O
in O
plants O
, O
nematodes O
, O
and O
insects O
. O

To O
combat O
RNAi O
- O
mediated O
antiviral O
responses O
, O
many O
viruses O
encode O
viral B
suppressors I
of I
RNA I
silencing I
( I
VSR I
) I
to O
facilitate O
their O
replication O
. O

We O
identified O
a O
novel O
VSR O
from O
coronaviruses O
, O
a O
group O
of O
medically O
important O
mammalian O
viruses O
including O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
and O
showed O
that O
the O
nucleocapsid B
protein I
( I
N I
protein I
) I
of O
coronaviruses O
suppresses O
RNAi O
triggered O
by O
either O
short O
hairpin O
RNAs O
or O
small O
interfering O
RNAs O
in O
mammalian O
cells O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
closely O
related O
to O
SARS O
- O
CoV O
in O
the O
family O
Coronaviridae O
and O
was O
used O
as O
a O
coronavirus O
replication O
model O
. O

The O
importance O
of O
neutralizing B
antibodies I
( I
NAbs I
) I
in O
protection O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
remains O
controversial O
. O

There O
are O
3 O
to O
4 O
million O
new O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
annually O
around O
the O
world O
, O
but O
no O
vaccine O
is O
available O
. O

Adjuvants O
are O
often O
required O
for O
effective O
vaccination O
, O
but O
during O
natural O
lytic O
viral O
infections O
damage B
- I
associated I
molecular I
patterns I
( I
DAMPs I
) I
are O
released O
, O
which O
act O
as O
natural O
adjuvants O
. O

Hence O
, O
a O
vaccine O
that O
induces O
cell O
necrosis O
and O
releases O
DAMPs O
will O
result O
in O
cell B
- I
mediated I
immunity I
( I
CMI I
) I
, O
similar O
to O
that O
resulting O
from O
natural O
lytic O
viral O
infection O
. O

We O
have O
generated O
a O
DNA O
vaccine O
with O
the O
ability O
to O
elicit O
strong O
CMI O
against O
the O
HCV O
nonstructural B
( I
NS I
) I
proteins O
( O
3 O
, O
4A O
, O
4B O
, O
and O
5B O
) O
by O
encoding O
a O
cytolytic O
protein O
, O
perforin B
( I
PRF I
) I
, O
and O
the O
antigens O
on O
a O
single O
plasmid O
. O

A O
small O
number O
of O
African B
green I
monkeys I
( I
AGMs I
) I
were O
introduced O
into O
the O
Caribbean O
from O
West O
Africa O
in O
the O
1600s O
. O

To O
determine O
the O
impact O
of O
this O
population O
bottleneck O
on O
the O
AGM O
virome O
, O
we O
used O
metagenomics O
to O
compare O
the O
viral O
nucleic O
acids O
in O
the O
plasma O
of O
43 O
wild O
AGMs O
from O
West O
Africa O
( O
Gambia O
) O
to O
those O
in O
44 O
AGMs O
from O
the O
Caribbean O
( O
St O
. O

Three O
viruses O
were O
detected O
in O
the O
blood O
of O
Gambian O
primates O
: O
simian O
immunodeficiency O
virus O
( O
SIVagm O
; O
in O
42 O
% O
of O
animals O
) O
, O
a O
novel O
simian O
pegivirus O
( O
SPgVagm O
; O
in O
7 O
% O
of O
animals O
) O
, O
and O
numerous O
novel O
simian O
anelloviruses O
( O
in O
100 O
% O
of O
animals O
) O
. O

We O
performed O
a O
detailed O
characterization O
of O
CD8 O
( O
+ O
) O
T O
cells O
specific O
to O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
epitope O
( O
NS3 O
- O
1073 O
) O
in O
121 O
HCV O
- O
seronegative O
individuals O
. O

We O
show O
that O
in O
vitro O
HCV O
NS3 O
- O
1073 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
were O
rather O
abundantly O
detectable O
in O
one O
- O
third O
of O
HCV O
- O
seronegative O
individuals O
irrespective O
of O
risk O
factors O
for O
HCV O
exposure O
. O

Ex O
vivo O
, O
these O
NS3 O
- O
1073 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
found O
to O
be O
both O
naive O
and O
memory O
cells O
. O

Importantly O
, O
recognition O
of O
various O
peptides O
derived O
from O
unrelated O
viruses O
by O
NS3 O
- O
1073 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
showed O
a O
considerable O
degree O
of O
T O
cell O
cross O
- O
reactivity O
, O
suggesting O
that O
they O
might O
in O
part O
originate O
from O
previous O
heterologous O
infections O
. O

Finally O
, O
we O
further O
provide O
evidence O
that O
preexisting O
NS3 O
- O
1073 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
can O
impact O
the O
T O
cell O
response O
toward O
peptide O
vaccination O
. O

Based O
on O
our O
findings O
, O
we O
suggest O
that O
HCV O
CD8 O
( O
+ O
) O
T O
cells O
are O
abundant O
in O
HCV O
- O
seronegative O
individuals O
but O
that O
their O
repertoire O
is O
highly O
diverse O
due O
to O
the O
involvement O
of O
both O
naive O
precursors O
and O
cross O
- O
reactive O
memory O
cells O
of O
different O
specificities O
, O
which O
can O
influence O
the O
response O
to O
vaccines O
. O

Dengue B
Virus I
( I
DENV I
) I
infection O
causes O
the O
most O
prevalent O
arthropod O
- O
borne O
viral O
disease O
worldwide O
. O

One O
possible O
drug O
target O
is O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
, O
because O
it O
is O
absolutely O
required O
for O
virus O
replication O
; O
however O
, O
its O
exact O
role O
in O
the O
DENV O
replication O
cycle O
is O
largely O
unknown O
. O

IMPORTANCE O
With O
no O
approved O
therapy O
or O
vaccine O
against O
dengue O
virus O
infection O
, O
the O
viral O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
represents O
a O
possible O
drug O
target O
, O
because O
it O
is O
indispensable O
for O
virus O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5A I
( I
NS5A I
) I
is O
essential O
for O
HCV O
genome O
replication O
and O
virion O
production O
and O
is O
involved O
in O
the O
regulation O
of O
multiple O
host O
signaling O
pathways O
. O

As O
a O
proline O
- O
rich O
protein O
, O
NS5A O
is O
capable O
of O
interacting O
with O
various O
host O
proteins O
containing O
Src B
homology I
3 I
( I
SH3 I
) I
domains O
. O

Previous O
studies O
have O
suggested O
that O
vinexin O
, O
a O
member O
of O
the O
Sorbin B
Homology I
( I
SoHo I
) I
adaptor O
family O
, O
might O
be O
a O
potential O
binding O
partner O
of O
NS5A O
by O
yeast O
two O
- O
hybrid O
screening O
. O

Two O
residues O
, O
tryptophan O
( O
W307 O
) O
and O
tyrosine O
( O
Y325 O
) O
, O
in O
the O
third O
SH3 O
domain O
of O
vinexin O
beta O
and O
conserved O
Pro O
- O
X O
- O
X O
- O
Pro O
- O
X O
- O
Arg O
motifs O
at O
the O
C O
terminus O
of O
NS5A O
were O
indispensable O
for O
the O
vinexin O
- O
NS5A O
interaction O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural O
protein O
NS5A O
is O
a O
phosphoprotein O
, O
and O
its O
phosphorylation O
states O
are O
usually O
modulated O
by O
host O
kinases O
and O
other O
viral O
nonstructural O
elements O
. O

Additionally O
, O
cellular O
factors O
containing O
Src B
homology I
3 I
( I
SH3 I
) I
domains O
have O
been O
reported O
to O
interact O
with O
proline O
- O
rich O
regions O
of O
NS5A O
. O

Overall O
, O
our O
findings O
not O
only O
elucidate O
the O
relationships O
between O
NS5A O
phosphorylation O
and O
the O
NS5A O
- O
SH3 O
interaction O
but O
also O
shed O
new O
mechanistic O
insight O
on O
Flaviviridae O
NS5A O
( O
NS5 O
) O
phosphorylation O
. O

CD8 O
( O
+ O
) O
T O
cells O
are O
the O
main O
effector O
lymphocytes O
in O
the O
control O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
. O

However O
, O
limitations O
of O
model O
systems O
, O
such O
as O
low O
infection O
rates O
, O
restrict O
mechanistic O
studies O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Here O
, O
we O
established O
a O
novel O
immunological O
cell O
culture O
model O
based O
on O
HBV O
- O
infected O
HepG2 O
( O
hNTCP O
) O
cells O
that O
endogenously O
processed O
viral O
antigens O
and O
presented O
them O
to O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

This O
induced O
cytolytic O
and O
noncytolytic O
CD8 O
( O
+ O
) O
T O
- O
cell O
effector O
functions O
and O
reduction O
of O
viral O
loads O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
continues O
to O
represent O
one O
of O
the O
most O
significant O
threats O
to O
human O
health O
. O

6 O
% O
( O
n O
= O
5 O
) O
of O
320 O
individual O
animals O
and O
3 O
. O

2 O
% O
( O
n O
= O
5 O
) O
of O
158 O
investigated O
cattle O
herds O
in O
Germany O
were O
positive O
for O
bovine O
hepacivirus O
. O

Repeated B
reverse I
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
analyses O
of O
animals O
from O
one O
dairy O
herd O
proved O
that O
a O
substantial O
percentage O
of O
cows O
were O
infected O
, O
with O
some O
of O
them O
being O
viremic O
for O
over O
6 O
months O
. O

Coronaviruses B
( I
CoVs I
) I
are O
unique O
in O
encoding O
a O
3 O
' O
- O
> O
5 O
' O
exoribonuclease O
within O
nonstructural O
protein O
14 O
( O
nsp14 O
- O
ExoN O
) O
that O
is O
required O
for O
high O
- O
fidelity O
replication O
, O
likely O
via O
proofreading O
. O

nsp14 O
associates O
with O
the O
CoV O
RNA O
- O
dependent O
RNA O
polymerase O
( O
nsp12 O
- O
RdRp O
) O
, O
and O
nsp14 O
- O
ExoN O
activity O
is O
enhanced O
by O
binding O
nsp10 O
, O
a O
small O
nonenzymatic O
protein O
. O

To O
test O
this O
, O
we O
engineered O
single O
and O
double O
alanine O
substitution O
mutations O
into O
the O
genome O
of O
murine O
hepatitis O
virus O
( O
MHV O
- O
A59 O
) O
containing O
ExoN O
activity O
[ O
ExoN O
( O
+ O
) O
] O
at O
positions O
within O
nsp10 O
known O
to O
disrupt O
the O
nsp10 O
- O
nsp14 O
interaction O
in O
vitro O
. O

We O
show O
that O
an O
nsp10 O
mutant O
, O
R80A O
/ O
E82A O
- O
ExoN O
( O
+ O
) O
, O
was O
five O
to O
ten O
times O
more O
sensitive O
to O
treatment O
with O
the O
RNA O
mutagen O
5 B
- I
fluorouracil I
( I
5 I
- I
FU I
) I
than O
wild B
- I
type I
( I
WT I
) I
- O
ExoN O
( O
+ O
) O
, O
suggestive O
of O
decreased O
replication O
fidelity O
. O

R80A O
/ O
E82A O
- O
ExoN O
( O
+ O
) O
reached O
a O
peak O
titer O
similar O
to O
and O
demonstrated O
RNA O
synthesis O
kinetics O
comparable O
to O
those O
seen O
with O
WT O
- O
ExoN O
( O
+ O
) O
. O

No O
change O
in O
5 O
- O
FU O
sensitivity O
was O
observed O
for O
R80A O
/ O
E82A O
- O
ExoN O
( O
- O
) O
relative O
to O
MHV O
- O
ExoN O
( O
- O
) O
, O
indicating O
that O
the O
decreased O
- O
fidelity O
phenotype O
of O
R80A O
/ O
E82A O
- O
ExoN O
( O
- O
) O
is O
linked O
to O
the O
presence O
of O
ExoN O
activity O
. O

The O
hepatitis O
C O
virus O
( O
HCV O
; O
genus O
Hepacivirus O
) O
is O
a O
highly O
relevant O
human O
pathogen O
. O

Unique O
hepaciviruses B
( I
HV I
) I
were O
discovered O
recently O
in O
animal O
hosts O
. O

To O
investigate O
whether O
other O
peridomestic O
animals O
also O
carry O
HVs O
, O
we O
analyzed O
sera O
from O
Ghanaian O
cattle O
for O
HVs O
by O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
. O

6 O
x O
10 O
( O
5 O
) O
copies O
/ O
ml O
. O

IMPORTANCE O
HCV O
( O
genus O
Hepacivirus O
) O
is O
a O
major O
human O
pathogen O
, O
causing O
liver O
failure O
and O
cancer O
. O

Unique B
hepaciviruses I
( I
HVs I
) I
were O
discovered O
over O
the O
last O
few O
years O
in O
animals O
, O
but O
the O
direct O
ancestor O
of O
HCV O
has O
not O
been O
found O
. O

miR O
- O
122 O
is O
a O
liver O
- O
specific O
microRNA B
( I
miRNA I
) I
that O
binds O
to O
two O
sites O
( O
S1 O
and O
S2 O
) O
on O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
and O
promotes O
the O
viral O
life O
cycle O
. O

To O
unravel O
the O
roles O
of O
miR O
- O
122 O
binding O
at O
each O
site O
alone O
or O
in O
combination O
, O
we O
employed O
miR O
- O
122 O
binding O
site O
mutant O
viral O
RNAs O
, O
Hep3B O
cells O
( O
which O
lack O
detectable O
miR O
- O
122 O
) O
, O
and O
complementation O
with O
wild O
- O
type O
miR O
- O
122 O
, O
an O
miR O
- O
122 O
with O
the O
matching O
mutation O
, O
or O
both O
. O

RNA O
synthesis O
by O
the O
prototype O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
carried O
out O
by O
a O
replicase O
- O
transcriptase O
composed O
of O
16 O
nonstructural B
protein I
( I
nsp I
) I
subunits O
. O

nsp3 O
comprises O
multiple O
structural O
domains O
, O
including O
two O
papain B
- I
like I
proteases I
( I
PLPs I
) I
and O
a O
highly O
conserved O
ADP B
- I
ribose I
- I
1 I
- I
phosphatase I
( I
ADRP I
) I
macrodomain O
. O

Because O
of O
recent O
advances O
in O
deep O
sequencing O
technology O
, O
detailed O
analysis O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
quasispecies O
and O
their O
dynamic O
changes O
in O
response O
to O
direct B
antiviral I
agents I
( I
DAAs I
) I
became O
possible O
, O
although O
the O
role O
of O
quasispecies O
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
to O
clarify O
the O
evolution O
of O
viral O
quasispecies O
and O
the O
origin O
of O
drug O
- O
resistant O
mutations O
induced O
by O
interferon B
( I
IFN I
) I
- O
based O
protease O
inhibitor O
therapy O
, O
the O
nonstructural B
- I
3 I
( I
NS3 I
) I
region O
of O
genotype O
1b O
HCV O
in O
34 O
chronic O
hepatitis O
patients O
treated O
with O
telaprevir B
( I
TVR I
) I
/ O
Pegylated B
interferon I
( I
PEG I
- I
IFN I
) I
/ O
ribavirin B
( I
RBV I
) I
was O
subjected O
to O
a O
deep O
sequencing O
study O
coupled O
with O
phylogenetic O
analysis O
. O

5 O
% O
) O
achieved O
a O
sustained B
viral I
response I
( I
SVR I
) I
, O
while O
8 O
patients O
did O
not O
( O
non O
- O
SVR O
; O
23 O
. O

When O
the O
complexity O
of O
the O
quasispecies O
was O
expressed O
as O
the O
mutation O
frequency O
or O
Shannon O
entropy O
value O
, O
a O
significant O
decrease O
in O
the O
IFNL3 O
( O
rs8099917 O
) O
TT O
group O
and O
a O
marginal O
decrease O
in O
the O
SVR O
group O
were O
found O
soon O
( O
12 O
h O
) O
after O
the O
introduction O
of O
treatment O
, O
whereas O
there O
was O
no O
decrease O
in O
the O
non O
- O
SVR O
group O
and O
no O
significant O
decrease O
in O
mutation O
frequency O
in O
the O
IFNL3 O
TG O
/ O
GG O
group O
. O

IMPORTANCE O
In O
the O
host O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
consists O
of O
a O
variety O
of O
populations O
( O
quasispecies O
) O
, O
and O
it O
is O
supposed O
that O
dynamic O
changes O
in O
quasispecies O
are O
closely O
related O
to O
pathogenesis O
, O
although O
this O
is O
poorly O
understood O
. O

In O
this O
study O
, O
recently O
developed O
deep O
sequencing O
technology O
was O
introduced O
, O
and O
changes O
in O
quasispecies O
associated O
with O
telaprevir B
( I
TVR I
) I
/ O
Pegylated B
interferon I
( I
PEG I
- I
IFN I
) I
/ O
ribavirin B
( I
RBV I
) I
triple O
therapy O
and O
their O
clinical O
significance O
were O
investigated O
extensively O
by O
phylogenetic O
tree O
analysis O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
is O
a O
multifunctional O
protein O
composed O
of O
a O
protease O
domain O
and O
a O
helicase O
domain O
linked O
by O
a O
flexible O
linker O
. O

Protease O
activity O
is O
required O
to O
generate O
viral O
nonstructural B
( I
NS I
) I
proteins O
involved O
in O
RNA O
replication O
. O

Binding O
of O
Protease B
inhibitors I
( I
PIs I
) I
to O
the O
protease O
active O
site O
blocks O
NS3 O
- O
dependent O
polyprotein O
processing O
but O
might O
impact O
other O
steps O
of O
the O
virus O
life O
cycle O
. O

In O
addition O
to O
the O
active O
- O
site O
PI O
telaprevir O
, O
we O
examined O
an O
allosteric B
protease I
- I
helicase I
inhibitor I
( I
APHI I
) I
that O
binds O
a O
site O
in O
the O
interdomain O
interface O
. O

The O
APHI O
and O
active O
- O
site O
PI O
were O
both O
able O
to O
block O
virus O
assembly O
soon O
( O
< O
12 O
h O
) O
after O
drug O
treatment O
, O
suggesting O
that O
they O
rapidly O
engage O
with O
and O
block O
a O
pool O
of O
NS3 O
involved O
in O
assembly O
. O

IMPORTANCE O
The O
NS3 O
/ O
4A O
protease O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
important O
antiviral O
target O
. O

Feline O
infectious O
peritonitis O
and O
virulent O
, O
systemic O
calicivirus O
infection O
are O
caused O
by O
certain O
types O
of O
feline B
coronaviruses I
( I
FCoVs I
) I
and O
feline B
caliciviruses I
( I
FCVs I
) I
, O
respectively O
, O
and O
are O
important O
infectious O
diseases O
with O
high O
fatality O
rates O
in O
members O
of O
the O
Felidae O
family O
. O

While O
FCoV O
and O
FCV O
belong O
to O
two O
distinct O
virus O
families O
, O
the O
Coronaviridae O
and O
the O
Caliciviridae O
, O
respectively O
, O
they O
share O
a O
dependence O
on O
viral O
3C B
- I
like I
protease I
( I
3CLpro I
) I
for O
their O
replication O
. O

IMPORTANCE O
feline B
infectious I
peritonitis I
virus I
( I
FIPV I
) I
is O
the O
leading O
cause O
of O
death O
in O
young O
cats O
, O
and O
virulent O
, O
systemic O
feline O
calicivirus O
( O
vs O
- O
FCV O
) O
causes O
a O
highly O
fatal O
disease O
in O
cats O
for O
which O
no O
preventive O
or O
therapeutic O
measure O
is O
available O
. O

The O
genomes O
of O
these O
distinct O
viruses O
, O
which O
belong O
to O
different O
virus O
families O
, O
encode O
a O
structurally O
and O
functionally O
conserved O
3C B
- I
like I
protease I
( I
3CLpro I
) I
which O
is O
a O
potential O
target O
for O
broad O
- O
spectrum O
antiviral O
drug O
development O
. O

The O
ubiquitous O
ATP O
- O
dependent O
RNA O
helicase O
DDX3X O
is O
involved O
in O
many O
cellular O
functions O
, O
including O
innate O
immunity O
, O
and O
is O
a O
pivotal O
host O
factor O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Recently O
, O
we O
showed O
that O
DDX3X O
specifically O
recognizes O
the O
HCV O
3 B
' I
untranslated I
region I
( I
UTR I
) I
, O
leading O
to O
the O
activation O
of O
IKK O
- O
alpha O
and O
a O
cascade O
of O
lipogenic O
signaling O
to O
facilitate O
lipid O
droplet O
biogenesis O
and O
viral O
assembly O
( O
Q O
. O

Upon O
HCV O
infection O
, O
the O
HCV O
3 O
' O
UTR O
interacts O
with O
DDX3X O
and O
IKK O
- O
alpha O
, O
which O
redistribute O
to O
speckle O
- O
like O
cytoplasmic O
structures O
shown O
to O
be O
Stress B
granules I
( I
SGs I
) I
. O

As O
viral O
proteins O
accumulate O
in O
infected O
cells O
, O
DDX3X O
granules O
together O
with O
SG O
- O
associated O
proteins O
redistribute O
and O
colocalize O
with O
HCV O
core O
protein O
around O
lipid B
droplets I
( I
LDs I
) I
. O

Short B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
silencing O
of O
DDX3X O
and O
multiple O
SG O
components O
markedly O
inhibits O
HCV O
infection O
. O

The O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
uniquely O
dependent O
on O
a O
host O
microRNA O
, O
miR O
- O
122 O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
depletion O
experiments O
indicated O
that O
Xrn1 O
restricts O
replication O
of O
all O
HCV O
strains O
tested O
: O
JFH1 O
, O
H77S O
. O

3 O
, O
H77D O
( O
a O
robustly O
replicating O
genotype O
1a O
variant O
) O
, O
and O
HJ3 O
- O
5 O
( O
a O
genotype O
1a O
/ O
2a O
chimeric O
virus O
) O
. O

Here O
we O
demonstrate O
for O
the O
first O
time O
expression O
of O
core O
+ O
1 O
/ O
ARF O
protein O
in O
the O
context O
of O
a O
bicistronic O
JFH1 O
- O
based O
replicon O
and O
report O
the O
production O
of O
two O
isoforms O
, O
core O
+ O
1 O
/ O
L B
( I
long I
) I
and O
core O
+ O
1 O
/ O
S B
( I
short I
) I
, O
with O
different O
kinetics O
. O

Here O
we O
report O
the O
crystal O
structure O
of O
the O
soluble O
region O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
protein O
2B O
, O
consisting O
of O
two O
domains O
: O
a O
C O
- O
terminal O
helical O
bundle O
preceded O
by O
an O
N O
- O
terminally O
curved O
five O
- O
stranded O
antiparallel O
beta O
- O
sheet O
that O
displays O
striking O
structural O
similarity O
to O
the O
beta O
- O
barrel O
domain O
of O
enteroviral O
2A O
proteins O
. O

The O
course O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
and O
disease O
progression O
involves O
alterations O
in O
lipid O
metabolism O
, O
leading O
to O
symptoms O
such O
as O
hypocholesterolemia O
and O
steatosis O
. O

A O
previous O
proteomics O
study O
revealed O
that O
HCV O
interacted O
with O
both O
the O
alpha O
- O
and O
beta O
- O
subunits O
of O
the O
mitochondrial B
trifunctional I
protein I
( I
MTP I
) I
, O
an O
enzyme O
complex O
which O
catalyzes O
the O
last O
3 O
steps O
of O
mitochondrial O
lipid O
beta O
- O
oxidation O
for O
cellular O
energy O
production O
. O

A O
loss O
- O
of O
- O
function O
study O
showed O
that O
MTP O
depletion O
rendered O
cells O
less O
responsive O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
treatment O
by O
impairing O
IFN O
- O
stimulated O
gene O
expression O
. O

IMPORTANCE O
HCV O
infection O
triggers O
metabolic O
alterations O
, O
which O
lead O
to O
significant O
disease O
outcomes O
, O
such O
as O
fatty O
liver O
( O
steatosis O
) O
. O

Viral O
replication O
in O
this O
family O
requires O
the O
activity O
of O
a O
superfamily O
2 O
RNA O
helicase O
contained O
in O
the O
C O
- O
terminal O
domain O
of O
nonstructural B
protein I
3 I
( I
NS3 I
) I
. O

NS3 O
features O
two O
conserved O
RecA O
- O
like O
domains O
( O
D1 O
and O
D2 O
) O
with O
ATPase O
activity O
, O
plus O
a O
third O
domain O
( O
D3 O
) O
that O
is O
important O
for O
unwinding O
nucleic O
acid O
duplexes O
. O

We O
report O
here O
the O
X O
- O
ray O
structure O
of O
the O
pestivirus B
NS3 I
helicase I
domain I
( I
pNS3h I
) I
at O
a O
2 O
. O

We O
reported O
that O
artificially O
engineered O
5 B
' I
untranslated I
region I
( I
UTR I
) I
interspecies O
rhinovirus O
/ O
rhinovirus O
or O
rhinovirus O
/ O
non O
- O
rhinovirus O
enterovirus O
recombinants O
are O
fully O
viable O
. O

Chronic O
HIV O
infection O
results O
in O
a O
loss O
of O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
effector O
function O
, O
termed O
exhaustion O
, O
which O
is O
mediated O
, O
in O
part O
, O
by O
the O
membrane O
coinhibitory O
receptor O
T O
cell O
immunoglobulin O
mucin O
domain O
- O
3 O
( O
Tim O
- O
3 O
) O
. O

However O
, O
soluble O
Tim O
- O
3 O
( O
sTim O
- O
3 O
) O
is O
poorly O
characterized O
, O
and O
its O
role O
in O
HIV O
disease O
is O
unknown O
. O

Here O
, O
we O
show O
that O
Tim O
- O
3 O
is O
shed O
from O
the O
surface O
of O
responding O
CD8 O
( O
+ O
) O
T O
cells O
by O
the O
matrix O
metalloproteinase O
ADAM10 O
, O
producing O
a O
soluble O
form O
of O
the O
coinhibitory O
receptor O
. O

Shed O
sTim O
- O
3 O
was O
found O
in O
human O
plasma O
and O
was O
significantly O
elevated O
during O
early O
and O
chronic O
untreated O
HIV O
infection O
, O
but O
it O
was O
not O
found O
differentially O
modulated O
in O
highly B
active I
antiretroviral I
therapy I
( I
HAART I
) I
- O
treated O
HIV O
- O
infected O
subjects O
or O
in O
elite O
controllers O
compared O
to O
HIV O
- O
uninfected O
subjects O
. O

Despite O
these O
correlations O
, O
we O
found O
that O
shedding O
Tim O
- O
3 O
did O
not O
improve O
the O
function O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
terms O
of O
gamma O
interferon O
production O
or O
prevent O
their O
apoptosis O
through O
galectin O
- O
9 O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
one O
of O
the O
most O
economically O
important O
viruses O
affecting O
the O
swine O
industry O
worldwide O
. O

Our O
previous O
research O
showed O
that O
PRRSV O
downregulates O
the O
expression O
of O
heme B
oxygenase I
- I
1 I
( I
HO I
- I
1 I
) I
, O
a O
pivotal O
cytoprotective O
enzyme O
, O
postinfection O
and O
that O
overexpression O
of O
HO O
- O
1 O
inhibits O
PRRSV O
replication O
. O

The O
suppressive O
effect O
of O
HO O
- O
1 O
induction O
by O
protoporphyrin O
IX O
cobalt O
chloride O
( O
CoPP O
; O
a O
classical O
inducer O
of O
HO O
- O
1 O
expression O
) O
on O
PRRSV O
replication O
in O
MARC O
- O
145 O
cells O
and O
primary O
porcine O
alveolar O
macrophages O
could O
also O
be O
reversed O
by O
overexpression O
of O
miR O
- O
24 O
- O
3p O
. O

IMPORTANCE O
microRNAs B
( I
miRNAs I
) I
play O
vital O
roles O
in O
viral O
infections O
by O
regulating O
the O
expression O
of O
viral O
or O
host O
genes O
at O
the O
posttranscriptional O
level O
. O

heme B
oxygenase I
- I
1 I
( I
HO I
- I
1 I
) I
, O
a O
pivotal O
cytoprotective O
enzyme O
, O
has O
antiviral O
activity O
for O
a O
number O
of O
viruses O
, O
such O
as O
Ebola O
virus O
, O
hepatitis O
C O
virus O
, O
human O
immunodeficiency O
virus O
, O
and O
our O
focus O
, O
PRRSV O
, O
which O
causes O
great O
economic O
losses O
each O
year O
in O
the O
swine O
industry O
worldwide O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
5A I
( I
NS5A I
) I
protein O
is O
highly O
phosphorylated O
and O
involved O
in O
both O
virus O
genome O
replication O
and O
virion O
assembly O
. O

Here O
we O
describe O
the O
phenotype O
of O
mutants O
with O
mutations O
at O
serine O
225 O
; O
this O
residue O
was O
mutated O
to O
either O
alanine O
( O
S225A O
; O
phosphoablatant O
) O
or O
aspartic O
acid O
( O
S225D O
; O
phosphomimetic O
) O
in O
the O
context O
of O
both O
the O
JFH O
- O
1 O
cell O
culture O
infectious O
virus O
and O
a O
corresponding O
subgenomic O
replicon O
. O

This O
phenotype O
was O
shared O
by O
viruses O
with O
other O
mutations O
in O
the O
low B
- I
complexity I
sequence I
I I
( I
LCS I
I I
) I
, O
namely O
, O
S229D O
, O
S232A O
, O
and O
S235D O
, O
but O
not O
by O
viruses O
with O
mutations O
that O
caused O
a O
comparable O
replication O
defect O
that O
mapped O
to O
domain O
II O
of O
NS5A O
( O
P315A O
, O
L321A O
) O
. O

Together O
with O
other O
components O
of O
the O
genome O
replication O
complex O
( O
NS3 O
, O
double O
- O
stranded O
RNA O
, O
and O
cellular O
lipids O
, O
including O
phosphatidylinositol O
4 O
- O
phosphate O
) O
, O
the O
mutation O
in O
NS5A O
was O
restricted O
to O
a O
perinuclear O
region O
. O

Worldwide O
, O
approximately O
160 O
million O
people O
are O
chronically O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
seven O
distinct O
genotypes O
of O
which O
are O
discriminated O
. O

To O
this O
end O
, O
we O
stimulated O
human O
primary O
plasmacytoid B
dendritic I
cells I
( I
pDC I
) I
with O
crude O
preparations O
of O
different O
cell O
culture O
- O
derived O
genotype O
2a O
HCV O
variants O
. O

Parental O
Japanese B
fulminant I
hepatitis I
C I
virus I
( I
JFH1 I
) I
did O
not O
induce O
interferon B
alpha I
( I
IFN I
- I
alpha I
) I
, O
whereas O
the O
intragenotypic O
chimera O
Jc1 O
triggered O
massive O
IFN O
- O
alpha O
responses O
. O

Surprisingly O
, O
a O
chimeric O
genotype O
2a O
virus O
carrying O
the O
nonstructural O
genes O
of O
Japanese B
fulminant I
hepatitis I
C I
virus I
( I
JFH1 I
) I
induced O
massive O
type O
I O
interferon O
responses O
, O
whereas O
the O
original O
genotype O
2a O
JFH1 O
strain O
did O
not O
. O

A O
major O
component O
of O
the O
protective O
antiviral O
host O
defense O
is O
contributed O
by O
the O
intracellular O
actions O
of O
the O
proteins O
encoded O
by O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
; O
among O
these O
are O
the O
interferon B
- I
induced I
proteins I
with I
tetratricopeptide I
repeats I
( I
IFITs I
) I
, O
consisting O
of O
four O
members O
in O
human O
and O
three O
in O
mouse O
. O

In O
this O
study O
, O
we O
show O
that O
replication O
- O
competent O
subgenomic O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
can O
be O
transferred O
to O
permissive O
Huh7 O
cells O
, O
leading O
to O
the O
establishment O
of O
viral O
RNA O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
serious O
global O
health O
problem O
and O
establishes O
chronic O
infection O
in O
a O
significant O
number O
of O
infected O
humans O
worldwide O
. O

interferon B
( I
IFN I
) I
and O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
are O
amplified O
during O
HCV O
infection O
but O
fail O
to O
eliminate O
virus O
from O
the O
liver O
in O
a O
large O
number O
of O
infected O
patients O
, O
and O
the O
mechanism O
is O
not O
fully O
understood O
. O

microRNAs B
( I
miRNAs I
) I
have O
been O
implicated O
in O
the O
control O
of O
many O
biological O
processes O
, O
including O
IFN O
signaling O
. O

Furthermore O
, O
we O
discovered O
that O
miR O
- O
373 O
directly O
targets O
Janus B
kinase I
1 I
( I
JAK1 I
) I
and O
IFN B
- I
regulating I
factor I
9 I
( I
IRF9 I
) I
, O
important O
factors O
in O
the O
IFN O
signaling O
pathway O
. O

The O
upregulation O
of O
miR O
- O
373 O
by O
HCV O
also O
inhibited O
STAT1 O
phosphorylation O
, O
which O
is O
involved O
in O
ISG B
factor I
3 I
( I
ISGF3 I
) I
complex O
formation O
and O
ISG O
expression O
. O

Although O
the O
recent O
introduction O
of O
direct B
- I
acting I
antiviral I
( I
DAA I
) I
therapy O
is O
extremely O
encouraging O
, O
some O
infected O
individuals O
do O
not O
respond O
to O
this O
therapy O
. O

The O
receptor O
- O
binding O
S1 O
subunit O
of O
coronavirus O
spike O
proteins O
contains O
two O
distinctive O
domains O
, O
the O
N B
- I
terminal I
domain I
( I
S1 I
- I
NTD I
) I
and O
the O
C B
- I
terminal I
domain I
( I
S1 I
- I
CTD I
) I
, O
both O
of O
which O
can O
function O
as O
receptor B
- I
binding I
domains I
( I
RBDs I
) I
. O

Coronaviruses O
induce O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
, O
but O
the O
role O
of O
DMVs O
in O
replication O
and O
virus O
fitness O
remains O
unclear O
. O

Coronaviruses O
encode O
16 O
nonstructural B
proteins I
( I
nsPs I
) I
, O
three O
of O
which O
, O
nsp3 O
, O
nsp4 O
, O
and O
nsp6 O
, O
are O
necessary O
and O
sufficient O
for O
DMV O
formation O
. O

It O
has O
been O
shown O
previously O
that O
mutations O
in O
murine B
hepatitis I
virus I
( I
MHV I
) I
nsp4 O
loop O
1 O
that O
alter O
nsp4 O
glycosylation O
are O
associated O
with O
disrupted O
DMV O
formation O
and O
result O
in O
changes O
in O
virus O
replication O
and O
RNA O
synthesis O
. O

Residues O
in O
nsp4 O
distinct O
from O
glycosylation O
sites O
, O
particularly O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
luminal O
loop O
1 O
, O
independently O
disrupted O
both O
the O
number O
and O
morphology O
of O
DMVs O
and O
exacerbated O
DMV O
changes O
associated O
with O
loss O
of O
glycosylation O
. O

Coronavirus O
- O
induced O
membrane O
changes O
include O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
and O
convoluted O
membranes O
. O

Three O
viral O
nonstructural B
proteins I
( I
nsPs I
) I
, O
nsp3 O
, O
nsp4 O
, O
and O
nsp6 O
, O
are O
known O
to O
be O
required O
for O
DMV O
formation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
exploits O
host O
membrane O
cholesterol O
and O
its O
metabolism O
for O
progeny O
virus O
production O
. O

Here O
, O
we O
examined O
the O
impact O
of O
targeting O
cellular O
squalene B
synthase I
( I
SQS I
) I
, O
the O
first O
committed O
enzyme O
for O
cholesterol O
biosynthesis O
, O
on O
HCV O
production O
. O

Similarly O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
SQS O
led O
to O
significantly O
reduced O
HCV O
production O
, O
confirming O
the O
enzyme O
as O
an O
antiviral O
target O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
known O
to O
be O
closely O
associated O
with O
host O
cholesterol O
and O
its O
metabolism O
throughout O
the O
viral O
life O
cycle O
. O

neutralizing B
antibodies I
( I
NAbs I
) I
targeting O
glycoprotein O
E2 O
are O
important O
for O
the O
control O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

One O
conserved O
antigenic O
site O
( O
amino O
acids O
412 O
to O
423 O
) O
is O
disordered O
in O
the O
reported O
E2 O
structure O
, O
but O
a O
synthetic O
peptide O
mimicking O
this O
site O
forms O
a O
beta O
- O
hairpin O
in O
complex O
with O
three O
independent O
NAbs O
. O

NAbs O
3 O
/ O
11 O
and O
AP33 O
( O
recognizing O
the O
extended O
and O
beta O
- O
hairpin O
conformations O
, O
respectively O
) O
display O
similar O
neutralizing O
activities O
despite O
converse O
binding O
kinetics O
. O

IMPORTANCE O
Approximately O
180 O
million O
people O
worldwide O
are O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
and O
neutralizing O
antibodies O
play O
an O
important O
role O
in O
controlling O
the O
replication O
of O
this O
major O
human O
pathogen O
. O

We O
show O
here O
that O
one O
of O
the O
most O
conserved O
antigenic O
sites O
within O
the O
major O
glycoprotein O
E2 O
( O
amino O
acids O
412 O
to O
423 O
) O
, O
which O
is O
disordered O
in O
the O
recently O
reported O
crystal O
structure O
of O
an O
E2 O
core O
fragment O
, O
can O
adopt O
different O
conformations O
in O
the O
context O
of O
the O
infectious O
virus O
particle O
. O

Several O
members O
of O
the O
phospholipase O
family O
have O
been O
reported O
to O
be O
involved O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

Here O
, O
we O
identified O
another O
phospholipase O
, O
phosphatidylserine O
- O
specific O
phospholipase B
A1 I
( I
PLA1A I
) I
, O
as O
a O
host O
factor O
involved O
in O
HCV O
assembly O
. O

PLA1A O
was O
upregulated O
by O
HCV O
infection O
, O
and O
PLA1A O
knockdown O
significantly O
reduced O
J399EM O
( O
genotype O
2a O
) O
HCV O
propagation O
at O
the O
assembly O
step O
but O
not O
the O
entry O
, O
RNA O
replication O
, O
and O
protein O
translation O
steps O
of O
the O
life O
cycle O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
genomic O
replication O
is O
driven O
by O
the O
replication O
complex O
and O
occurs O
at O
the O
membranous O
web O
, O
while O
the O
lipid O
droplet O
is O
the O
organelle O
in O
which O
virion O
assembly O
is O
initiated O
. O

In O
this O
study O
, O
we O
identified O
phosphatidylserine O
- O
specific O
phospholipase B
A1 I
( I
PLA1A I
) I
, O
a O
member O
of O
phospholipase O
A O
1 O
family O
, O
as O
a O
novel O
host O
factor O
involved O
in O
the O
assembly O
process O
of O
HCV O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
rarely O
detectable O
ex O
vivo O
by O
conventional O
methods O
during O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

In O
this O
study O
, O
however O
, O
we O
were O
able O
to O
detect O
and O
characterize O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
all O
chronically O
HCV O
genotype O
1a O
- O
infected O
, O
HLA O
- O
A O
* O
02 O
: O
01 O
- O
positive O
patients O
analyzed O
by O
performing O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
tetramer O
enrichment O
. O

Two O
- O
thirds O
of O
these O
enriched O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
displayed O
an O
effector O
memory O
phenotype O
, O
whereas O
, O
surprisingly O
, O
one O
- O
third O
displayed O
a O
naive O
- O
like O
phenotype O
despite O
ongoing O
viral O
replication O
. O

CD8 O
( O
+ O
) O
T O
cells O
with O
an O
effector O
memory O
phenotype O
could O
not O
expand O
in O
vitro O
, O
suggesting O
exhaustion O
of O
these O
cells O
. O

Interestingly O
, O
some O
of O
the O
naive O
- O
like O
CD8 O
( O
+ O
) O
T O
cells O
proliferated O
vigorously O
upon O
in O
vitro O
priming O
, O
whereas O
others O
did O
not O
. O

Indeed O
, O
naive O
- O
like O
CD8 O
( O
+ O
) O
T O
cells O
from O
patients O
with O
the O
consensus O
sequence O
in O
the O
corresponding O
T O
- O
cell O
epitope O
did O
not O
expand O
in O
vitro O
. O

In O
contrast O
, O
in O
patients O
displaying O
sequence O
variations O
, O
we O
were O
able O
to O
induce O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
proliferation O
, O
which O
may O
indicate O
infection O
with O
a O
variant O
virus O
. O

Collectively O
, O
these O
data O
reveal O
the O
presence O
of O
phenotypically O
and O
functionally O
diverse O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
at O
very O
low O
frequencies O
that O
are O
detectable O
in O
all O
chronically O
infected O
patients O
despite O
viral O
persistence O
. O

IMPORTANCE O
In O
this O
study O
, O
we O
analyzed O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
specific O
for O
HLA O
- O
A O
* O
02 O
: O
01 O
- O
restricted O
epitopes O
in O
chronically O
HCV O
- O
infected O
patients O
, O
using O
MHC O
class O
I O
tetramer O
enrichment O
. O

Importantly O
, O
we O
could O
detect O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
in O
all O
patients O
. O

To O
further O
characterize O
these O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
that O
are O
not O
detectable O
using O
conventional O
techniques O
, O
we O
performed O
phenotypic O
, O
functional O
, O
and O
viral O
sequence O
analyses O
. O

These O
data O
revealed O
different O
mechanisms O
for O
CD8 O
( O
+ O
) O
T O
- O
cell O
failure O
in O
HCV O
infection O
, O
including O
T O
- O
cell O
exhaustion O
, O
viral O
escape O
, O
and O
functional O
impairment O
of O
naive O
- O
like O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

The O
precise O
role O
( O
s O
) O
and O
topological O
organization O
of O
different O
factors O
in O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
complex O
are O
not O
well O
understood O
. O

Human B
replication I
protein I
A I
( I
RPA I
) I
and O
HCV O
NS5A O
recruit O
NS5B O
Delta O
21 O
to O
the O
template O
. O

Both O
RPA O
and O
NS5A O
( O
( O
S25 O
- O
C447 O
) O
) O
, O
but O
not O
NS5A O
( O
( O
S25 O
- O
K215 O
) O
) O
, O
enabled O
the O
NS5B O
Delta O
21 O
- O
NS3 O
helicase O
complex O
to O
be O
stably O
associated O
with O
the O
template O
and O
synthesize O
RNA O
product O
in O
a O
highly O
processive O
manner O
in O
vitro O
. O

IMPORTANCE O
The O
molecular O
mechanism O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
is O
not O
fully O
understood O
, O
but O
viral O
and O
host O
proteins O
collaborate O
in O
this O
process O
. O

We O
showed O
that O
HCV O
NS5A O
( O
S25 O
- O
C447 O
) O
and O
cellular O
replication B
protein I
A I
( I
RPA I
) I
functionally O
cooperate O
as O
a O
processivity O
factor O
to O
stimulate O
HCV O
replication O
by O
HCV O
NS5B O
Delta O
21 O
polymerase O
and O
NS3 O
helicase O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
glycoprotein O
E2 O
is O
considered O
a O
major O
target O
for O
generating O
neutralizing O
antibodies O
against O
HCV O
, O
primarily O
due O
to O
its O
role O
of O
engaging O
host O
entry O
factors O
, O
such O
as O
CD81 O
, O
a O
key O
cell O
surface O
protein O
associated O
with O
HCV O
entry O
. O

The O
virus O
side O
of O
this O
interface O
includes O
a O
hydrophobic O
helix O
motif O
comprised O
of O
residues O
W O
( O
437 O
) O
LAGLF O
( O
442 O
) O
, O
which O
encompasses O
the O
binding O
site O
of O
a O
neutralizing O
monoclonal O
antibody O
, O
mAb41 O
. O

Our O
illustration O
of O
this O
virus O
- O
host O
interface O
suggests O
an O
important O
role O
played O
by O
the O
W O
( O
437 O
) O
LAGLF O
( O
442 O
) O
helix O
of O
the O
E2 O
protein O
in O
the O
hydrophobic O
interaction O
with O
the O
D O
- O
helix O
of O
CD81 O
, O
thereby O
facilitating O
our O
understanding O
of O
the O
mechanism O
for O
antibody O
- O
mediated O
neutralization O
of O
HCV O
. O

The O
interface O
that O
enables O
hepatitis B
C I
virus I
( I
HCV I
) I
to O
infect O
human O
liver O
cells O
has O
not O
been O
well O
understood O
because O
of O
the O
number O
of O
cell O
surface O
proteins O
, O
factors O
, O
and O
conditions O
found O
to O
be O
associated O
with O
the O
infection O
process O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
respiratory O
paramyxovirus O
that O
is O
distributed O
worldwide O
and O
induces O
significant O
airway O
morbidity O
. O

Using O
in O
vitro O
and O
in O
vivo O
systems O
, O
we O
show O
that O
hMPV O
is O
able O
to O
induce O
expression O
of O
lambda O
interferon O
1 O
( O
IFN O
- O
lambda O
1 O
) O
, O
IFN O
- O
lambda O
2 O
, O
IFN O
- O
lambda O
3 O
, O
and O
IFN O
- O
lambda O
4 O
. O

The O
induction O
of O
IFN O
- O
lambda O
expression O
by O
hMPV O
was O
dependent O
on O
interferon B
regulatory I
factor I
7 I
( I
IRF I
- I
7 I
) I
expression O
but O
not O
on O
IRF O
- O
3 O
expression O
. O

These O
results O
show O
that O
type O
III O
interferons O
( O
IFN O
- O
lambda O
s O
) O
play O
a O
critical O
protective O
role O
in O
hMPV O
infection O
. O

IMPORTANCE O
human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
pathogen O
of O
worldwide O
importance O
. O

Interferons B
( I
IFNs I
) I
, O
including O
IFN O
- O
lambda O
, O
the O
newest O
addition O
to O
the O
interferon O
family O
, O
constitute O
an O
indispensable O
part O
of O
the O
innate O
immune O
response O
. O

ribavirin B
( I
RBV I
) I
continues O
to O
be O
an O
important O
component O
of O
interferon O
- O
free O
hepatitis O
C O
treatment O
regimens O
, O
as O
RBV O
alone O
does O
not O
inhibit O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
effectively O
; O
the O
reason O
for O
this O
ineffectiveness O
has O
not O
been O
established O
. O

The O
antiviral O
activity O
of O
RBV O
against O
HCV O
was O
progressively O
impaired O
in O
the O
persistently O
infected O
culture O
, O
whereas O
interferon O
lambda O
1 O
( O
IFN O
- O
lambda O
1 O
) O
, O
a O
type O
III O
IFN O
, O
showed O
a O
strong O
antiviral O
response O
and O
induced O
viral O
clearance O
. O

We O
found O
that O
HCV O
replication O
in O
persistently O
infected O
cultures O
induces O
an O
autophagy O
response O
that O
impairs O
RBV O
uptake O
by O
preventing O
the O
expression O
of O
equilibrative B
nucleoside I
transporter I
1 I
( I
ENT1 I
) I
. O

In O
contrast O
, O
the O
autophagy O
inhibitors O
hydroxychloroquine B
( I
HCQ I
) I
, O
3 B
- I
methyladenine I
( I
3 I
- I
MA I
) I
, O
and O
bafilomycin B
A1 I
( I
BafA1 I
) I
prevented O
ENT1 O
degradation O
and O
enhanced O
RBV O
antiviral O
activity O
. O

ribavirin B
( I
RBV I
) I
remains O
an O
important O
component O
of O
interferon O
- O
free O
hepatitis O
C O
treatment O
regimens O
. O

The O
first O
discovered O
and O
sequenced O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
and O
the O
first O
in O
vivo O
infectious O
HCV O
clones O
originated O
from O
the O
HCV O
prototype O
strains O
HCV O
- O
1 O
and O
H77 O
, O
respectively O
, O
both O
widely O
used O
in O
research O
of O
this O
important O
human O
pathogen O
. O

We O
initially O
adapted O
a O
genome O
with O
the O
HCV O
- O
1 O
5 O
' O
UTR O
- O
NS5A O
( O
where O
UTR O
stands O
for O
untranslated O
region O
) O
and O
the O
JFH1 O
NS5B O
- O
3 O
' O
UTR O
( O
5 O
- O
5A O
recombinant O
) O
, O
including O
the O
genotype O
2a O
- O
derived O
mutations O
F1464L O
/ O
A1672S O
/ O
D2979G O
( O
LSG O
) O
, O
to O
grow O
efficiently O
in O
Huh7 O
. O

The O
combination O
of O
LSG O
/ O
S399F O
and O
reported O
TNcc O
( O
1a O
) O
- O
adaptive O
mutations O
A1226G O
/ O
Q1773H O
/ O
N1927T O
/ O
Y2981F O
/ O
F2994S O
promoted O
adaptation O
of O
the O
full O
- O
length O
HCV O
- O
1 O
clone O
. O

An O
HCV O
- O
1 O
recombinant O
with O
17 O
mutations O
( O
HCV1cc O
) O
replicated O
efficiently O
in O
Huh7 O
. O

0 O
) O
focus B
- I
forming I
units I
( I
FFU I
) I
/ O
ml O
. O

Using O
a O
similar O
approach O
, O
we O
found O
that O
NS5B O
mutation O
F2994R O
, O
identified O
here O
from O
culture O
- O
adapted O
full O
- O
length O
TN O
viruses O
and O
a O
common O
NS3 O
helicase O
mutation O
( O
S1368P O
) O
derived O
from O
viable O
H77C O
and O
HCV O
- O
1 O
5 O
- O
5A O
recombinants O
, O
initiated O
replication O
and O
culture O
adaptation O
of O
H77C O
containing O
LSG O
and O
TNcc O
( O
1a O
) O
- O
adaptive O
mutations O
. O

An O
H77C O
recombinant O
harboring O
19 O
mutations O
( O
H77Ccc O
) O
replicated O
and O
spread O
efficiently O
after O
transfection O
and O
subsequent O
infection O
of O
naive O
Huh7 O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
was O
discovered O
in O
1989 O
with O
the O
cloning O
of O
the O
prototype O
strain O
HCV O
- O
1 O
genome O
. O

HCV O
research O
was O
hampered O
by O
a O
lack O
of O
infectious O
cell O
culture O
systems O
, O
which O
became O
available O
only O
in O
2005 O
with O
the O
discovery O
of O
JFH1 O
( O
genotype O
2a O
) O
, O
a O
genome O
that O
could O
establish O
infection O
in O
Huh7 O
. O

Recently O
, O
we O
developed O
in O
vitro O
infectious O
clones O
for O
genotype O
1a O
( O
TN O
) O
, O
2a O
( O
J6 O
) O
, O
and O
2b O
( O
J8 O
, O
DH8 O
, O
and O
DH10 O
) O
strains O
by O
identifying O
key O
adaptive O
mutations O
. O

Coronaviruses O
from O
both O
the O
Alphacorona O
virus O
and O
Betacoronavirus O
genera O
interfere O
with O
the O
type O
1 O
interferon O
( O
LEN O
) O
response O
in O
various O
ways O
, O
ensuring O
the O
limited O
activation O
of O
the O
LEN O
response O
in O
most O
cell O
types O
. O

We O
show O
that O
the O
prototypical O
Gammacoronavirus O
, O
infectious B
bronchitis I
virus I
( I
IBV I
) I
, O
induces O
a O
delayed O
activation O
of O
the O
LEN O
response O
in O
primary O
renal O
cells O
, O
tracheal O
epithelial O
cells O
, O
and O
a O
chicken O
cell O
line O
. O

In O
fact O
, O
Ifn O
beta O
expression O
is O
delayed O
with O
respect O
to O
the O
peak O
of O
viral O
replication O
and O
the O
accompanying O
accumulation O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
causes O
chronic O
infection O
in O
up O
to O
50 O
% O
to O
80 O
% O
of O
infected O
individuals O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
variability O
is O
frequently O
studied O
to O
gain O
an O
insight O
into O
the O
mechanisms O
of O
HCV O
adaptation O
during O
chronic O
infection O
, O
but O
the O
changes O
to O
and O
persistence O
of O
HCV O
subpopulations O
during O
intrahost O
evolution O
are O
poorly O
understood O
. O

In O
this O
study O
, O
we O
used O
ultradeep B
pyrosequencing I
( I
UDPS I
) I
to O
map O
the O
viral O
heterogeneity O
of O
a O
single O
patient O
over O
9 O
. O

Using O
this O
methodology O
, O
we O
were O
able O
to O
( O
i O
) O
detect O
multiple O
instances O
of O
hepatitis O
C O
virus O
intrasubtype O
recombination O
at O
the O
E1 O
/ O
E2 O
junction O
( O
a O
phenomenon O
rarely O
reported O
in O
the O
literature O
) O
and O
( O
ii O
) O
interrogate O
the O
longitudinal O
quasispecies O
complexity O
of O
the O
virome O
. O

The O
tripartite B
motif I
- I
containing I
( I
TRIM I
) I
proteins O
have O
emerged O
as O
a O
new O
class O
of O
host O
antiviral O
restriction O
factors O
, O
with O
several O
demonstrating O
roles O
in O
regulating O
innate O
antiviral O
responses O
. O

Of O
> O
70 O
known O
TRIMs O
, O
TRIM56 O
inhibits O
replication O
of O
bovine O
viral O
diarrhea O
virus O
, O
a O
ruminant O
pestivirus O
of O
the O
family O
Flaviviridae O
, O
but O
has O
no O
appreciable O
effect O
on O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
a O
rhabdovirus O
. O

Herein O
, O
we O
show O
that O
TRIM56 O
poses O
a O
barrier O
to O
infections O
by O
yellow B
fever I
virus I
( I
YFV I
) I
, O
dengue B
virus I
serotype I
2 I
( I
DENV2 I
) I
, O
and O
human B
coronavirus I
virus I
( I
HCoV I
) I
OC43 O
but O
not O
encephalomyocarditis B
virus I
( I
EMCV I
) I
. O

IMPORTANCE O
We O
previously O
reported O
tripartite B
motif I
protein I
56 I
( I
TRIM56 I
) I
as O
a O
host O
restriction O
factor O
of O
bovine O
viral O
diarrhea O
virus O
, O
a O
ruminant O
pathogen O
. O

Herein O
, O
we O
demonstrate O
that O
TRIM56 O
restricts O
two O
medically O
important O
flaviviruses O
, O
yellow B
fever I
virus I
( I
YFV I
) I
and O
dengue B
virus I
serotype I
2 I
( I
DENV2 I
) I
, O
and O
a O
human O
coronavirus O
, O
HCoV O
- O
OC43 O
, O
but O
not O
encephalomyocarditis O
virus O
, O
a O
picornavirus O
. O

The O
recent O
epidemic O
history O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infections O
in O
the O
United O
States O
is O
complex O
, O
as O
indicated O
by O
current O
disparity O
in O
HBV O
genotype O
distribution O
between O
acute O
and O
chronic O
hepatitis O
B O
cases O
and O
the O
rapid O
decline O
in O
hepatitis O
B O
incidence O
since O
the O
1990s O
. O

We O
report O
temporal O
changes O
in O
the O
genetic O
composition O
of O
the O
HBV O
population O
using O
whole O
- O
genome O
sequences O
( O
n O
= O
179 O
) O
from O
acute O
hepatitis O
B O
cases O
( O
n O
= O
1 O
, O
206 O
) O
identified O
through O
the O
Sentinel O
County O
Surveillance O
for O
Acute O
Hepatitis O
( O
1998 O
to O
2006 O
) O
. O

HBV O
belonged O
mainly O
to O
subtypes O
A2 O
( O
75 O
% O
) O
and O
D3 O
( O
18 O
% O
) O
, O
with O
times O
of O
their O
most O
recent O
common O
ancestors O
being O
1979 O
and O
1987 O
, O
respectively O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
remains O
an O
important O
cause O
of O
acute O
and O
chronic O
liver O
disease O
globally O
and O
in O
the O
United O
States O
. O

Genetic O
analysis O
of O
HBV O
whole O
genomes O
from O
cases O
of O
acute O
hepatitis O
B O
identified O
from O
1998 O
to O
2006 O
in O
the O
United O
States O
showed O
dominance O
of O
genotype O
A2 O
( O
75 O
% O
) O
, O
followed O
by O
D3 O
( O
18 O
% O
) O
. O

Equine B
hepacivirus I
( I
EHcV I
) I
has O
been O
identified O
as O
a O
closely O
related O
homologue O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
the O
United O
States O
, O
the O
United O
Kingdom O
, O
and O
Germany O
, O
but O
not O
in O
Asian O
countries O
. O

We O
determined O
the O
full O
sequence O
of O
the O
EHcV O
genome O
, O
including O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
, O
which O
had O
previously O
not O
been O
completely O
revealed O
. O

A O
comparison O
of O
the O
EHcV O
and O
HCV O
core O
proteins O
revealed O
that O
Ile O
( O
190 O
) O
and O
Phe O
( O
191 O
) O
of O
the O
EHcV O
core O
protein O
could O
be O
important O
for O
cleavage O
of O
the O
core O
protein O
by O
signal B
peptide I
peptidase I
( I
SPP I
) I
and O
were O
replaced O
with O
Ala O
and O
Leu O
, O
respectively O
, O
which O
inhibited O
intramembrane O
cleavage O
of O
the O
EHcV O
core O
protein O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
assembles O
its O
replication O
complex O
on O
cytosolic O
membrane O
vesicles O
often O
clustered O
in O
a O
membranous B
web I
( I
MW I
) I
. O

During O
infection O
, O
HCV O
NS5A O
protein O
activates O
PI4KIII O
alpha O
enzyme O
, O
causing O
massive O
production O
and O
redistribution O
of O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
lipid O
to O
the O
replication O
complex O
. O

To O
test O
this O
hypothesis O
, O
we O
generated O
cell O
lines O
for O
doxycycline O
- O
inducible O
expression O
of O
short B
hairpin I
RNAs I
( I
shRNAs I
) I
targeting O
the O
PI4P O
effector O
, O
four B
- I
phosphate I
adaptor I
protein I
2 I
( I
FAPP2 I
) I
. O

Interestingly O
, O
FAPP2 O
is O
redistributed O
to O
the O
replication B
complex I
( I
RC I
) I
characterized O
by O
HCV O
NS5A O
, O
NS4B O
, O
or O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
foci O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
is O
tightly O
regulated O
by O
lipid O
metabolism O
of O
host O
cells O
. O

In O
order O
to O
identify O
host O
factors O
involved O
in O
HCV O
propagation O
, O
we O
have O
recently O
screened O
a O
small B
interfering I
RNA I
( I
siRNA I
) I
library O
targeting O
host O
genes O
that O
control O
lipid O
metabolism O
and O
lipid O
droplet O
formation O
using O
cell B
culture I
- I
grown I
HCV I
( I
HCVcc I
) I
- O
infected O
cells O
. O

We O
selected O
and O
characterized O
the O
gene O
encoding O
stearoyl O
coenzyme B
A I
( I
CoA I
) I
desaturase O
1 O
( O
SCD1 O
) O
. O

SCD1 O
was O
coimmunoprecipitated O
with O
HCV O
nonstructural O
proteins O
and O
colocalized O
with O
both O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
and O
HCV O
nonstructural O
proteins O
, O
indicating O
that O
SCD1 O
is O
associated O
with O
HCV O
replication O
complex O
. O

IMPORTANCE O
Stearoyl O
coenzyme B
A I
( I
CoA I
) I
desaturase O
1 O
( O
SCD1 O
) O
, O
a O
liver O
- O
specific O
enzyme O
, O
regulates O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
through O
its O
enzyme O
activity O
. O

However O
, O
there O
is O
not O
much O
information O
on O
the O
membrane O
- O
penetrating O
capsid O
components O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
, O
an O
unusual O
member O
of O
this O
family O
. O

The O
positive O
- O
stranded O
RNA O
genome O
of O
the O
prototypic O
virulence O
- O
attenuating O
hypovirus O
CHV O
- O
1 O
/ O
EP713 O
contains O
two O
open B
reading I
frames I
( I
ORF I
) I
, O
each O
encoding O
an O
autocatalytic O
papain O
- O
like O
leader O
protease O
. O

This O
study O
shows O
that O
lytic O
induction O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
increases O
the O
membrane O
- O
bound O
form O
of O
LC3 O
( O
LC3 O
- O
II O
) O
and O
LC3 O
- O
containing O
punctate O
structures O
in O
EBV O
- O
positive O
cells O
. O

Additionally O
, O
treatment O
with O
U0126 O
inhibits O
the O
Rta O
- O
induced O
autophagy O
and O
the O
expression O
of O
autophagy O
genes O
, O
indicating O
that O
the O
autophagic O
activation O
is O
caused O
by O
the O
activation O
of O
extracellular B
signal I
- I
regulated I
kinase I
( I
ERK I
) I
signaling O
by O
Rta O
. O

This O
study O
finds O
that O
a O
transcription O
factor O
that O
is O
encoded O
by O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
, O
Rta O
, O
activates O
autophagy O
, O
and O
the O
inhibition O
of O
autophagy O
reduces O
the O
ability O
of O
the O
virus O
to O
express O
viral O
lytic O
proteins O
and O
to O
generate O
progeny O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
widespread O
human O
pathogen O
causing O
liver O
cirrhosis O
and O
cancer O
. O

Initial O
experiments O
with O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
suggesting O
a O
role O
in O
HCV O
replication O
led O
us O
to O
examine O
the O
interaction O
using O
biochemical O
and O
structural O
approaches O
. O

Biosensor O
binding O
assays O
identified O
a O
highly O
conserved O
, O
18 O
- O
amino O
- O
acid O
binding O
site O
in O
domain O
II O
of O
NS5A O
, O
which O
encompasses O
residues O
implicated O
in O
cyclophilin B
A I
( I
CypA I
) I
dependent O
HCV O
RNA O
replication O
. O

We O
initially O
identified O
a O
cellular O
protein O
, O
MOBKL1B O
, O
as O
a O
binding O
partner O
with O
the O
NS5A O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Collectively O
, O
our O
results O
suggest O
that O
stricter O
controls O
must O
be O
utilized O
in O
all O
RNA B
interference I
( I
RNAi I
) I
- O
mediated O
gene O
knockdown O
experiments O
to O
ensure O
sound O
conclusions O
and O
a O
reliable O
scientific O
knowledge O
database O
. O

A4 O
( O
1 O
) O
inhibited O
both O
the O
formation O
and O
functioning O
of O
the O
replication O
complexes O
, O
while O
E5 O
( O
1 O
) O
and O
E7 O
( O
2 O
) O
were O
most O
effective O
during O
the O
formation O
but O
not O
the O
functioning O
step O
. O

Poliovirus O
resistant O
to O
E7 O
( O
2 O
) O
had O
a O
G5318A O
mutation O
in O
the O
3A O
protein O
. O

This O
mutation O
was O
previously O
found O
to O
confer O
resistance O
to O
enviroxime O
- O
like O
compounds O
, O
which O
target O
a O
phosphatidylinositol O
4 O
- O
kinase O
III O
beta O
( O
PI4KIII O
beta O
) O
- O
dependent O
step O
in O
viral O
replication O
. O

Analysis O
of O
host O
protein O
recruitment O
showed O
that O
E7 O
( O
2 O
) O
reduced O
the O
amount O
of O
GBF1 O
on O
the O
replication O
complexes O
; O
however O
, O
the O
level O
of O
PI4KIII O
beta O
remained O
intact O
. O

E7 O
( O
2 O
) O
as O
well O
as O
another O
enviroxime O
- O
like O
compound O
, O
GW5074 O
, O
interfered O
with O
viral O
polyprotein O
processing O
affecting O
both O
3C O
- O
and O
2A O
- O
dependent O
cleavages O
, O
and O
the O
resistant O
G5318A O
mutation O
partially O
rescued O
this O
defect O
. O

Moreover O
, O
E7 O
( O
2 O
) O
induced O
abnormal O
recruitment O
to O
membranes O
of O
the O
viral O
proteins O
; O
thus O
, O
enviroxime O
- O
like O
compounds O
likely O
severely O
compromise O
the O
interaction O
of O
the O
viral O
polyprotein O
with O
membranes O
. O

A4 O
( O
1 O
) O
demonstrated O
partial O
protection O
from O
paralysis O
in O
a O
murine O
model O
of O
poliomyelitis O
. O

Multiple O
attempts O
to O
isolate O
resistant O
mutants O
in O
the O
presence O
of O
A4 O
( O
1 O
) O
or O
E5 O
( O
1 O
) O
were O
unsuccessful O
, O
showing O
that O
effective O
broad O
- O
spectrum O
antivirals O
could O
be O
developed O
on O
the O
basis O
of O
these O
compounds O
. O

Superinfection B
exclusion I
( I
SIE I
) I
, O
the O
ability O
of O
an O
established O
virus O
infection O
to O
interfere O
with O
a O
secondary O
infection O
by O
the O
same O
or O
a O
closely O
related O
virus O
, O
has O
been O
described O
for O
different O
viruses O
, O
including O
important O
pathogens O
of O
humans O
, O
animals O
, O
and O
plants O
. O

Citrus B
tristeza I
virus I
( I
CTV I
) I
, O
a O
positive O
- O
sense O
RNA O
virus O
, O
represents O
a O
valuable O
model O
system O
for O
studying O
SIE O
due O
to O
the O
existence O
of O
several O
phylogenetically O
distinct O
strains O
. O

The O
obtained O
observations O
, O
along O
with O
estimates O
of O
the O
cellular O
multiplicity B
of I
infection I
( I
MOI I
) I
and O
MOI O
model O
selection O
, O
suggested O
that O
low O
levels O
of O
cellular O
coinfection O
appear O
to O
be O
best O
explained O
by O
exclusion O
at O
the O
cellular O
level O
. O

IMPORTANCE O
Many O
viruses O
exhibit O
Superinfection B
exclusion I
( I
SIE I
) I
, O
the O
ability O
of O
an O
established O
virus O
infection O
to O
interfere O
with O
a O
secondary O
infection O
by O
related O
viruses O
. O

The O
p33 O
protein O
of O
Citrus B
tristeza I
virus I
( I
CTV I
) I
, O
an O
RNA O
virus O
, O
was O
shown O
to O
mediate O
SIE O
at O
the O
whole O
- O
organism O
level O
, O
while O
it O
appeared O
not O
to O
be O
required O
for O
exclusion O
at O
the O
cellular O
level O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
, O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
is O
the O
key O
enzyme O
for O
HCV O
RNA O
replication O
. O

We O
previously O
showed O
that O
HCV O
RdRp O
is O
phosphorylated O
by O
protein B
kinase I
C I
- I
related I
kinase I
2 I
( I
PRK2 I
) I
. O

IMPORTANCE O
While O
the O
role O
of O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
in O
viral O
RNA O
replication O
is O
clear O
, O
little O
is O
known O
about O
their O
functional O
regulation O
by O
phosphorylation O
. O

In O
this O
study O
, O
we O
addressed O
several O
important O
questions O
about O
the O
function O
and O
structure O
of O
phosphorylated O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
. O

Little O
is O
known O
about O
virus O
adaptation O
in O
immunocompromised O
patients O
with O
chronic O
genotype O
3 O
hepatitis O
E O
virus O
( O
HEV3 O
) O
infections O
. O

The O
nature O
and O
incidence O
of O
such O
recombinant O
events O
occurring O
during O
infections O
of O
solid B
- I
organ I
transplant I
( I
SOT I
) I
recipients O
are O
essentially O
unknown O
. O

The O
polyproline B
region I
( I
PPR I
) I
of O
strains O
isolated O
from O
SOT O
patients O
was O
sequenced O
during O
the O
acute O
- O
infection O
phase O
( O
n O
= O
59 O
) O
and O
during O
follow O
- O
up O
of O
patients O
whose O
infections O
became O
chronic O
( O
n O
= O
27 O
) O
. O

These O
27 O
HEV O
strains O
included O
3 O
( O
11 O
% O
) O
that O
showed O
recombinant O
events O
12 O
, O
34 O
, O
48 O
, O
or O
88 O
months O
after O
infection O
. O

In O
the O
second O
, O
a O
fragment O
of O
a O
human B
tyrosine I
aminotransferase I
( I
TAT I
) I
gene O
was O
inserted O
first O
, O
followed O
by O
a O
fragment O
of O
PPR O
. O

A O
fragment O
of O
the O
human O
inter B
- I
alpha I
- I
trypsin I
inhibitor I
( I
ITI I
) I
gene O
was O
inserted O
in O
the O
third O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
can O
cause O
chronic O
infections O
in O
immunocompromised O
patients O
, O
including O
solid B
- I
organ I
transplant I
( I
SOT I
) I
recipients O
. O

The O
4 O
inserted O
sequences O
were O
of O
different O
origins O
( O
human O
gene O
or O
HEV O
genome O
) O
, O
but O
all O
were O
enriched O
in O
aliphatic O
and O
basic O
amino O
acids O
and O
provided O
potential O
regulation O
sites O
. O

Passage O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
human O
hepatoma O
cells O
resulted O
in O
populations O
that O
displayed O
partial O
resistance O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
telaprevir O
, O
daclatasvir O
, O
cyclosporine O
, O
and O
ribavirin O
, O
despite O
no O
prior O
exposure O
to O
these O
drugs O
. O

The O
lipid O
kinase O
phosphatidylinositol B
4 I
- I
kinase I
III I
alpha I
( I
PI4KIII I
alpha I
) I
is O
an O
endoplasmic B
reticulum I
( I
ER I
) I
- O
resident O
enzyme O
that O
synthesizes O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
. O

PI4KIII O
alpha O
is O
an O
essential O
host O
factor O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

Interaction O
with O
HCV B
nonstructural I
protein I
5A I
( I
NS5A I
) I
leads O
to O
kinase O
activation O
and O
accumulation O
of O
PI4P O
at O
intracellular O
membranes O
. O

In O
spite O
of O
the O
high O
variability O
of O
its O
sequence O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E2 O
contains O
several O
conserved O
regions O
. O

In O
this O
study O
, O
we O
explored O
the O
structural O
and O
functional O
features O
of O
the O
highly O
conserved O
E2 O
segment O
from O
amino B
acid I
( I
aa I
) I
502 O
to O
520 O
, O
which O
had O
been O
proposed O
as O
a O
fusion O
peptide O
and O
shown O
to O
strongly O
overlap O
a O
potential O
conserved O
neutralizing O
epitope O
. O

Of O
particular O
interest O
, O
we O
identified O
three O
specific O
mutations O
( O
Y507L O
, O
V514A O
, O
and O
V515A O
) O
located O
within O
this O
neutralizing O
epitope O
which O
only O
mildly O
reduced O
infectivity O
and O
showed O
no O
assembly O
defect O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
proteins O
E1 O
and O
E2 O
exhibit O
sequence O
variability O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
- O
4A O
is O
required O
for O
viral O
replication O
and O
assembly O
. O

NEMO O
( O
NF O
- O
kappa O
B O
essential O
modulator O
) O
is O
a O
bridging O
adaptor O
indispensable O
for O
viral O
activation O
of O
interferon B
( I
IFN I
) I
antiviral O
response O
. O

Herein O
, O
we O
show O
that O
hepatitis B
A I
virus I
( I
HAV I
) I
3C O
protease O
( O
3C B
( I
pro I
) I
) O
cleaves O
NEMO O
at O
the O
Q304 O
residue O
, O
negating O
its O
signaling O
adaptor O
function O
and O
abrogating O
viral O
induction O
of O
IFN O
- O
beta O
synthesis O
via O
the O
retinoic O
acid O
- O
inducible O
gene O
I O
/ O
melanoma O
differentiation O
- O
associated O
protein O
5 O
( O
RIG O
- O
I O
/ O
MDA5 O
) O
and O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
pathways O
. O

NEMO O
cleavage O
and O
IFN O
antagonism O
, O
however O
, O
were O
lost O
upon O
ablation O
of O
the O
catalytic O
activity O
of O
3C B
( I
pro I
) I
. O

The O
mechanisms O
by O
which O
hepatitis B
B I
virus I
( I
HBV I
) I
establishes O
and O
maintains O
chronic B
hepatitis I
B I
infection I
( I
CHB I
) I
are O
poorly O
defined O
. O

HBV O
has O
developed O
numerous O
mechanisms O
to O
escape O
these O
responses O
, O
including O
the O
production O
of O
the O
secreted O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
, O
which O
has O
been O
shown O
to O
regulate O
antiviral O
Toll B
- I
like I
receptor I
( I
TLR I
) I
and O
interleukin B
- I
1 I
( I
IL I
- I
1 I
) I
signaling O
. O

IL O
- O
18 O
is O
a O
related O
cytokine O
that O
inhibits O
HBV O
replication O
in O
hepatoma O
cell O
lines O
and O
in O
the O
liver O
through O
the O
induction O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
by O
NK O
cells O
and O
T O
cells O
. O

Genomes O
of O
positive O
( O
+ O
) O
- O
strand O
RNA O
viruses O
use O
cis O
- O
acting O
signals O
to O
direct O
both O
translation O
and O
replication O
. O

Here O
we O
examine O
two O
5 O
' O
- O
proximal O
cis O
- O
replication O
signals O
of O
different O
character O
in O
a O
Defective B
interfering I
( I
DI I
) I
RNA O
of O
the O
bovine B
coronavirus I
( I
BCoV I
) I
that O
map O
within O
a O
322 O
- O
nucleotide B
( I
nt I
) I
sequence O
( O
136 O
nt O
from O
the O
genomic O
5 O
' O
untranslated O
region O
and O
186 O
nt O
from O
the O
nonstructural O
protein O
1 O
[ O
nsp1 O
] O
- O
coding O
region O
) O
not O
found O
in O
the O
otherwise O
- O
identical O
nonreplicating O
subgenomic B
mRNA7 I
( I
sgmRNA7 I
) I
. O

( O
i O
) O
In O
the O
first O
examination O
, O
mutation O
analyses O
of O
a O
recently O
discovered O
long O
- O
range O
RNA O
- O
RNA O
base O
- O
paired O
structure O
between O
the O
5 O
' O
untranslated O
region O
and O
the O
partial O
nsp1 O
- O
coding O
region O
showed O
that O
it O
, O
possibly O
in O
concert O
with O
adjacent O
stem O
- O
loops O
, O
is O
a O
cis O
- O
acting O
replication O
signal O
in O
the O
( O
+ O
) O
strand O
. O

We O
postulate O
that O
the O
higher O
- O
order O
structure O
promotes O
( O
+ O
) O
- O
strand O
synthesis O
. O

( O
ii O
) O
In O
the O
second O
examination O
, O
analyses O
of O
multiple O
frame O
shifts O
, O
truncations O
, O
and O
point O
mutations O
within O
the O
partial O
nsp1 O
- O
coding O
region O
showed O
that O
synthesis O
of O
a O
PEFP O
core O
amino O
acid O
sequence O
within O
a O
group O
A O
lineage O
betacoronavirus O
- O
conserved O
NH2 O
- O
proximal O
WAPEFPWM O
domain O
is O
required O
in O
cis O
for O
DI O
RNA O
replication O
. O

The O
envelope O
proteins O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
bear O
an O
N O
- O
linked O
glycosylation O
site O
at O
N146 O
within O
the O
immunodominant O
a O
- O
determinant O
in O
the O
antigenic B
loop I
( I
AGL I
) I
region O
. O

We O
observed O
that O
the O
removal O
of O
the O
N146 O
glycosylation O
site O
by O
mutagenesis O
was O
permissive O
to O
envelope O
protein O
synthesis O
and O
stability O
and O
to O
secretion O
of O
subviral B
particles I
( I
SVPs I
) I
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
virions O
, O
but O
it O
was O
detrimental O
to O
HBV O
virion O
production O
. O

Infectivity O
- O
compatible O
N O
- O
glycosylation O
sites O
could O
be O
inserted O
at O
3 O
positions O
( O
positions O
115 O
, O
129 O
, O
and O
136 O
) O
, O
but O
when O
all O
three O
positions O
were O
glycosylated O
, O
the O
hyperglycosylated O
mutant O
was O
substantially O
attenuated O
at O
viral O
entry O
, O
while O
it O
acquired O
resistance O
to O
neutralizing O
antibodies O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
quasispecies O
contain O
a O
large O
number O
of O
variants O
that O
serve O
as O
a O
reservoir O
for O
viral O
selection O
under O
antiviral O
treatment O
and O
the O
immune O
response O
, O
leading O
to O
the O
acute O
exacerbation O
and O
subsequent O
development O
of O
liver O
failure O
. O

Western O
blotting O
, O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
, O
and O
immunofluorescence O
staining O
were O
performed O
to O
analyze O
the O
expression O
, O
secretion O
, O
and O
subcellular O
localization O
of O
viral O
proteins O
in O
vitro O
. O

HBV O
gene O
expression O
and O
replication O
and O
the O
induction O
of O
specific O
immune O
responses O
in O
an O
HBV O
hydrodynamic B
injection I
( I
HI I
) I
mouse O
model O
were O
investigated O
. O

The O
variant O
SH O
- O
DPS O
expressed O
only O
a O
nonexportable O
hepatitis B
B I
virus I
surface I
antigen I
( I
HBsAg I
) I
with O
abnormal O
intracellular O
accumulation O
. O

The O
coexistence O
of O
the O
HBV O
variants O
at O
a O
ratio O
of O
1 O
to O
4 O
( O
SH O
to O
SH O
- O
DPS O
) O
increased O
HBV O
replication O
. O

Significantly O
stronger O
intrahepatic O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
responses O
and O
antibody O
responses O
specific O
to O
HBsAg O
were O
induced O
in O
mice O
by O
the O
HBV O
variants O
when O
coapplied O
by O
HI O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
an O
important O
human O
pathogen O
. O

We O
report O
here O
that O
the O
coexistence O
of O
two O
naturally O
occurring O
HBV O
variants O
at O
a O
ratio O
of O
1 O
to O
4 O
increased O
HBV O
replication O
and O
induced O
significantly O
stronger O
intrahepatic O
cytotoxic O
T O
lymphocyte O
responses O
and O
antibody O
responses O
specific O
to O
HBV B
surface I
antigen I
( I
HBsAg I
) I
in O
mice O
. O

porcine B
epidemic I
diarrhea I
virus I
( I
PEDV I
) I
, O
a O
porcine O
enteropathogenic O
coronavirus O
, O
causes O
lethal O
watery O
diarrhea O
in O
piglets O
and O
results O
in O
large O
economic O
losses O
in O
many O
Asian O
and O
European O
countries O
. O

Previous O
studies O
have O
shown O
that O
PEDV O
infection O
inhibits O
the O
synthesis O
of O
type B
I I
interferon I
( I
IFN I
) I
, O
and O
viral O
papain O
- O
like O
protease O
2 O
has O
been O
identified O
as O
an O
IFN O
antagonist O
. O

In O
this O
study O
, O
we O
found O
that O
the O
PEDV O
- O
encoded O
nucleocapsid B
( I
N I
) I
protein O
also O
inhibits O
Sendai O
virus O
- O
induced O
IFN O
- O
beta O
production O
, O
IFN O
- O
stimulated O
gene O
expression O
, O
and O
activation O
of O
the O
transcription O
factors O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
NF O
- O
kappa O
B O
. O

We O
also O
found O
that O
N O
protein O
significantly O
impedes O
the O
activation O
of O
the O
IFN O
- O
beta O
promoter O
stimulated O
by O
TBK1 O
or O
its O
upstream O
molecules O
( O
RIG O
- O
I O
, O
MDA5 O
, O
IPS O
- O
1 O
, O
and O
TRAF3 O
) O
but O
does O
not O
counteract O
its O
activation O
by O
IRF3 O
. O

Diacylglycerol B
acyltransferase I
- I
1 I
( I
DGAT1 I
) I
is O
involved O
in O
the O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
by O
facilitating O
the O
trafficking O
of O
the O
HCV O
core O
protein O
to O
the O
lipid O
droplet O
. O

5 O
cells O
by O
using O
either O
the O
transcription B
activator I
- I
like I
effector I
nuclease I
( I
TALEN I
) I
or O
lentivirus O
vector O
short B
hairpin I
RNA I
( I
shRNA I
) I
and O
achieved O
complete O
long O
- O
term O
silencing O
of O
DGAT1 O
. O

5 O
cell O
lines O
, O
which O
showed O
markedly O
diminished O
Claudin B
- I
1 I
( I
CLDN1 I
) I
expression O
. O

The O
expression O
of O
the O
gene O
coding O
for O
hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
and O
other O
hepatocyte O
- O
specific O
genes O
was O
also O
reduced O
in O
DGAT1 O
- O
silenced O
cell O
lines O
. O

Some O
viruses O
, O
such O
as O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
bind O
to O
heparan O
sulfate O
, O
whereas O
others O
, O
such O
as O
influenza B
A I
virus I
( I
IAV I
) I
, O
bind O
to O
sialic O
acid O
. O

Epigallocatechin B
gallate I
( I
EGCG I
) I
, O
a O
green O
tea O
catechin O
, O
is O
active O
against O
many O
unrelated O
viruses O
, O
including O
several O
that O
bind O
to O
heparan O
sulfate O
or O
to O
sialic O
acid O
. O

Instead O
, O
EGCG O
interacts O
with O
virion O
surface O
proteins O
to O
inhibit O
the O
attachment O
of O
HSV O
- O
1 O
, O
HCV O
, O
IAV O
, O
vaccinia O
virus O
, O
adenovirus O
, O
reovirus O
, O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
virions O
. O

The O
virion O
of O
Dengue B
Virus I
( I
DENV I
) I
is O
composed O
of O
a O
viral O
envelope O
covering O
a O
nucleocapsid O
formed O
by O
a O
complex O
of O
viral O
genomic O
RNA O
and O
core B
protein I
( I
Cp I
) I
. O

Loss O
of O
association O
between O
CP O
and O
lipid B
droplets I
( I
LDs I
) I
due O
to O
mutation O
suggests O
that O
the O
CP O
hydrophobic O
surface O
was O
not O
exposed O
, O
offering O
a O
possible O
explanation O
for O
the O
absence O
of O
dimers O
. O

IMPORTANCE O
Structure O
- O
based O
mutagenesis O
study O
of O
the O
dengue O
virus O
core B
protein I
( I
Cp I
) I
reveals O
that O
the O
alpha O
4 O
- O
alpha O
4 O
' O
= O
helix O
pair O
is O
the O
key O
to O
maintaining O
its O
dimer O
conformation O
, O
which O
is O
the O
basis O
of O
CP O
function O
in O
nucleocapsid O
formation O
and O
virus O
production O
. O

In O
vitro O
inefficiency O
and O
size O
of O
nucleocapsid B
- I
like I
particle I
( I
NLP I
) I
formation O
offer O
a O
possible O
explanation O
for O
in O
vivo O
virus O
production O
inefficiency O
upon O
CP O
mutation O
. O

Further O
, O
the O
transition O
of O
NLP O
morphology O
from O
an O
incomplete O
state O
to O
an O
intact O
particle O
shown O
by O
alpha O
4 O
- O
alpha O
4 O
' O
= O
helix O
pair O
mutants O
in O
the O
presence O
of O
a O
nonionic O
detergent O
suggests O
the O
regulatory O
role O
of O
the O
intracellular O
lipid B
droplet I
( I
LD I
) I
in O
CP O
- O
LD O
interaction O
and O
in O
promoting O
nucleocapsid O
formation O
. O

Despite O
its O
strong O
host O
tropism O
for O
erythroid O
progenitor O
cells O
, O
human B
parvovirus I
B19 I
( I
B19V I
) I
can O
also O
infect O
a O
variety O
of O
additional O
cell O
types O
. O

To O
elucidate O
the O
mechanisms O
of O
B19V O
uptake O
into O
endothelium O
, O
we O
first O
analyzed O
the O
surface O
expression O
of O
the O
well O
- O
characterized O
primary O
B19V O
receptor O
P O
antigen O
and O
the O
putative O
coreceptors O
alpha O
( O
5 O
) O
beta O
( O
1 O
) O
integrins O
and O
Ku80 O
antigen O
on O
primary O
and O
permanent O
endothelial O
cells O
. O

As O
an O
alternative O
B19V O
uptake O
mechanism O
in O
endothelial O
cells O
, O
we O
demonstrated O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
, O
with O
up O
to O
a O
4 O
, O
000 O
- O
fold O
increase O
in O
B19V O
uptake O
in O
the O
presence O
of O
B19V O
- O
specific O
human O
antibodies O
. O

In O
contrast O
to O
monocytes O
, O
where O
ADE O
of O
B19V O
has O
been O
described O
previously O
, O
enhancement O
does O
not O
rely O
on O
interaction O
of O
the O
virus O
- O
antibody O
complexes O
with O
Fc B
receptors I
( I
FcRs I
) I
, O
but O
rather O
, O
involves O
an O
alternative O
mechanism O
mediated O
by O
the O
heat O
- O
sensitive O
complement O
factor O
C1q O
and O
its O
receptor O
, O
CD93 O
. O

IMPORTANCE O
Both O
efficient O
entry O
and O
productive O
infection O
of O
human B
parvovirus I
B19 I
( I
B19V I
) I
seem O
to O
be O
limited O
to O
erythroid O
progenitor O
cells O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
uptake O
of O
B19V O
into O
endothelial O
cells O
most O
probably O
does O
not O
rely O
on O
the O
classical O
receptor O
- O
mediated O
route O
via O
the O
primary O
B19V O
receptor O
P O
antigen O
and O
coreceptors O
, O
such O
as O
alpha O
( O
5 O
) O
beta O
( O
1 O
) O
integrins O
, O
but O
rather O
on O
antibody O
- O
dependent O
mechanisms O
. O

Since O
the O
strong O
antibody B
- I
dependent I
enhancement I
( I
ADE I
) I
of O
B19V O
entry O
requires O
the O
CD93 O
surface O
protein O
, O
it O
very O
likely O
involves O
bridging O
of O
the O
B19V O
- O
antibody O
complexes O
to O
this O
receptor O
by O
the O
complement O
factor O
C1q O
, O
leading O
to O
enhanced O
endocytosis O
of O
the O
virus O
. O

The O
circular O
genome O
and O
antigenome O
RNAs O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
form O
characteristic O
unbranched O
, O
quasi O
- O
doublestranded O
RNA O
secondary O
structures O
in O
which O
short O
double O
- O
stranded O
helical O
segments O
are O
interspersed O
with O
internal O
loops O
and O
bulges O
. O

The O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
formed O
by O
these O
RNAs O
with O
the O
virus O
- O
encoded O
protein O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
perform O
essential O
roles O
in O
the O
viral O
life O
cycle O
, O
including O
viral O
replication O
and O
virion O
formation O
. O

Selective B
2 I
' I
OH I
acylation I
analyzed I
by I
primer I
extension I
( I
SHAPE I
) I
applied O
to O
free O
and O
HDAg O
- O
bound O
HDV O
RNAs O
indicated O
that O
the O
characteristic O
secondary O
structure O
of O
the O
RNA O
is O
preserved O
when O
bound O
to O
HDAg O
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
multiple O
functions O
in O
the O
viral O
life O
cycle O
. O

Casein B
kinase I
I I
- I
alpha I
( I
CKI I
- I
alpha I
) I
was O
identified O
as O
an O
NS5A O
- O
associated O
kinase O
involved O
in O
NS5A O
hyperphosphorylation O
and O
infectious O
virus O
production O
. O

Subcellular O
fractionation O
and O
immunofluorescence O
confocal O
microscopy O
analyses O
showed O
that O
CKI O
- O
alpha O
- O
mediated O
hyperphosphorylation O
of O
NS5A O
contributes O
to O
the O
recruitment O
of O
NS5A O
to O
low O
- O
density O
membrane O
structures O
around O
lipid B
droplets I
( I
LDs I
) I
and O
facilitates O
its O
interaction O
with O
core O
protein O
and O
the O
viral O
assembly O
. O

This O
region O
contains O
eight O
serine O
residues O
that O
are O
highly O
conserved O
among O
HCV O
isolates O
, O
and O
subsequent O
mutagenesis O
analysis O
demonstrated O
that O
serine O
residues O
at O
amino O
acids O
225 O
and O
232 O
in O
NS5A O
( O
genotype O
2a O
) O
may O
be O
involved O
in O
NS5A O
hyperphosphorylation O
and O
hyperphosphorylation O
- O
dependent O
regulation O
of O
virion O
production O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
one O
of O
the O
leading O
causes O
of O
liver O
failure O
and O
liver O
cancer O
, O
affecting O
around O
3 O
% O
of O
the O
world O
' O
s O
population O
. O

It O
is O
known O
that O
vigorous O
and O
multispecific O
cellular O
immune O
responses O
, O
involving O
both O
helper O
CD4 O
( O
+ O
) O
and O
cytotoxic O
CD8 O
( O
+ O
) O
T O
cells O
, O
are O
associated O
with O
the O
spontaneous O
clearance O
of O
acute O
HCV O
infection O
. O

In O
this O
paper O
, O
we O
identify O
groups O
of O
coevolving O
residues O
within O
HCV B
nonstructural I
protein I
3 I
( I
NS3 I
) I
by O
analyzing O
diverse O
sequences O
of O
this O
protein O
using O
ideas O
from O
random O
matrix O
theory O
and O
associated O
methods O
. O

It O
remains O
crucial O
to O
develop O
a O
laboratory O
model O
for O
studying O
hepatitis B
B I
virus I
( I
HBV I
) I
chronic O
infection O
. O

We O
hereby O
produced O
a O
recombinant O
covalently O
closed O
circular O
DNA O
( O
rcccDNA O
) O
in O
view O
of O
the O
key O
role O
of O
cccDNA O
in O
HBV O
persistence O
. O

A O
loxP O
- O
chimeric O
intron O
was O
engineered O
into O
a O
monomeric O
HBV O
genome O
in O
a O
precursor O
plasmid O
( O
prcccDNA O
) O
, O
which O
was O
excised O
using O
Cre O
/ O
loxP O
- O
mediated O
DNA O
recombination O
into O
a O
3 O
. O

In O
cultured O
hepatoma O
cells O
, O
cotransfection O
of O
prcccDNA O
and O
pCMV O
- O
Cre O
( O
encoding O
Cre O
recombinase O
) O
resulted O
in O
accumulation O
of O
nuclear O
rcccDNA O
that O
was O
heat O
stable O
and O
epigenetically O
organized O
as O
a O
minichromosome O
. O

IMPORTANCE O
( O
i O
) O
Unlike O
plasmids O
that O
contain O
a O
linear O
HBV O
replicon O
, O
rcccDNA O
established O
HBV O
persistence O
with O
sustained O
liver O
injury O
in O
immunocompetent O
mice O
. O

( O
ii O
) O
An O
exogenous O
intron O
was O
engineered O
into O
the O
HBV O
genome O
for O
functionally O
seamless O
DNA O
recombination O
. O

( O
iii O
) O
rcccDNA O
was O
substantially O
induced O
in O
the O
nuclei O
of O
hepatocytes O
and O
could O
be O
easily O
distinguished O
by O
its O
exogenous O
intron O
using O
PCR O
. O

phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
is O
well O
known O
to O
be O
upregulated O
during O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

The O
elevation O
of O
PI4P O
induced O
by O
HCV O
NS5A O
is O
abrogated O
when O
the O
coatomer B
protein I
I I
( I
COPI I
) I
pathway O
is O
inhibited O
. O

Coronaviruses O
express O
a O
deubiquitinating O
protein O
, O
the O
papain B
- I
like I
protease I
- I
2 I
( I
PLP2 I
) I
, O
that O
removes O
both O
ubiquitin O
and O
the O
ubiquitin O
- O
like O
interferon B
( I
IFN I
) I
- O
stimulated O
gene O
15 O
( O
ISG15 O
) O
protein O
from O
target O
proteins O
. O

ISG15 O
has O
antiviral O
activity O
against O
a O
number O
of O
viruses O
; O
therefore O
, O
we O
examined O
the O
effect O
of O
ISG15 O
conjugation O
( O
ISGylation O
) O
in O
a O
model O
of O
acute O
viral O
hepatitis O
induced O
by O
the O
murine B
hepatitis I
virus I
strain I
3 I
( I
MHV I
- I
3 I
) I
coronavirus O
. O

Mice O
deficient O
in O
the O
ISG15 O
deconjugating O
enzyme O
, O
ubiquitin B
- I
specific I
peptidase I
- I
18 I
( I
USP18 I
) I
, O
accumulate O
high O
levels O
of O
ISG15 O
- O
conjugated O
proteins O
and O
are O
hypersensitive O
to O
type O
I O
IFN O
. O

Infecting O
USP18 O
( O
- O
/ O
- O
) O
mice O
with O
MHV O
- O
3 O
resulted O
in O
extended O
survival O
( O
8 O
+ O
/ O
- O
1 O
. O

2 O
versus O
4 O
days O
) O
and O
in O
improved O
liver O
histology O
, O
a O
decreased O
inflammatory O
response O
, O
and O
viral O
titers O
1 O
to O
2 O
logs O
lower O
than O
in O
USP18 O
( O
+ O
/ O
+ O
) O
mice O
. O

The O
suppression O
of O
viral O
replication O
was O
not O
due O
to O
increased O
IFN O
since O
infected O
USP18 O
( O
- O
/ O
- O
) O
mice O
had O
neither O
increased O
hepatic O
IFN O
- O
alpha O
, O
- O
beta O
, O
or O
- O
gamma O
mRNA O
nor O
circulating O
protein O
. O

Decreasing O
ISGylation O
by O
knockdown O
of O
the O
ISG15 O
E1 O
enzyme O
, O
Ube1L O
, O
in O
primary O
USP18 O
( O
+ O
/ O
+ O
) O
and O
USP18 O
( O
- O
/ O
- O
) O
hepatocytes O
led O
to O
increased O
MHV O
- O
3 O
replication O
. O

Proteolytic O
processing O
of O
coronavirus O
spike B
( I
S I
) I
fusion O
proteins O
during O
virus O
entry O
has O
been O
suggested O
but O
not O
yet O
formally O
demonstrated O
, O
while O
the O
nature O
and O
functionality O
of O
the O
resulting O
subunit O
is O
still O
unclear O
. O

We O
used O
a O
prototype O
coronavirus O
- O
mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
to O
develop O
a O
conditional O
biotinylation O
assay O
that O
enables O
the O
specific O
identification O
and O
biochemical O
characterization O
of O
viral O
S O
proteins O
on O
virions O
that O
mediated O
membrane O
fusion O
with O
the O
target O
cell O
. O

We O
have O
recently O
shown O
that O
a O
cocktail O
of O
two O
short B
synthetic I
hairpin I
RNAs I
( I
sshRNAs I
) I
, O
targeting O
the O
internal O
ribosome O
entry O
site O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
formulated O
with O
lipid O
nanoparticles O
, O
was O
able O
to O
suppress O
viral O
replication O
in O
chimeric O
mice O
infected O
with O
HCV O
GT1a O
by O
up O
to O
2 O
. O

5 O
log O
( O
10 O
) O
( O
H O
. O

These O
results O
demonstrate O
a O
direct O
antiviral O
activity O
with O
effective O
HCV O
suppression O
, O
demonstrate O
the O
added O
selective O
pressure O
of O
combination O
therapy O
, O
and O
confirm O
an O
RNA B
interference I
( I
RNAi I
) I
mechanism O
of O
action O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
a O
highly O
biased O
and O
deoptimized O
codon O
usage O
compared O
to O
the O
host O
cell O
and O
fails O
to O
inhibit O
host O
protein O
synthesis O
. O

Despite O
the O
recent O
progress O
in O
the O
development O
of O
new O
antiviral O
agents O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
remains O
a O
major O
global O
health O
problem O
, O
and O
there O
is O
a O
need O
for O
a O
preventive O
vaccine O
. O

Heterologous O
prime O
- O
boost O
immunization O
regimens O
with O
adenovirus O
and O
recombinant O
E1E2 O
glycoprotein O
( O
genotype O
1a O
) O
plus O
MF59 O
were O
evaluated O
in O
mice O
and O
guinea O
pigs O
. O

Adenovirus O
prime O
and O
protein O
boost O
induced O
broad O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
responses O
and O
functional O
Th1 O
- O
type O
IgG O
responses O
. O

Immune O
sera O
neutralized O
luciferase O
reporter O
pseudoparticles O
expressing O
HCV B
envelope I
glycoproteins I
( I
HCVpp I
) I
and O
a O
diverse O
panel O
of O
recombinant O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
strains O
and O
limited O
cell O
- O
to O
- O
cell O
HCV O
transmission O
. O

We O
have O
previously O
shown O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
modulates O
the O
expression O
of O
forkhead O
box O
transcription O
factors O
, O
including O
FoxO1 O
and O
FoxA2 O
, O
which O
play O
key O
roles O
in O
gluconeogenesis O
and O
beta O
- O
oxidation O
of O
fatty O
acid O
, O
respectively O
. O

5 O
cells O
increased O
expression O
of O
sterol B
regulatory I
element I
binding I
protein I
1c I
( I
SREBP I
- I
1c I
) I
and O
its O
downstream O
target O
, O
fatty B
acid I
synthase I
( I
FASN I
) I
, O
which O
are O
key O
proteins O
involved O
in O
lipid O
synthesis O
. O

5 O
cells O
significantly O
decreased O
the O
expression O
of O
medium B
- I
chain I
acyl I
coenzyme I
A I
dehydrogenase I
( I
MCAD I
) I
and O
short B
- I
chain I
acyl I
coenzyme I
A I
dehydrogenase I
( I
SCAD I
) I
, O
involved O
in O
the O
regulation O
of O
beta O
- O
oxidation O
of O
fatty O
acids O
. O

This O
was O
further O
verified O
by O
the O
increased O
expression O
of O
perilipin O
- O
2 O
and O
decreased O
activity O
of O
hormone B
- I
sensitive I
lipase I
( I
HSL I
) I
in O
HCV O
- O
infected O
hepatocytes O
, O
implying O
increased O
accumulation O
of O
neutral O
lipids O
. O

Thus O
, O
knockdown O
of O
FoxO1 O
( O
decreased O
lipogenesis O
) O
and O
overexpression O
of O
FoxA2 O
( O
increased O
beta O
- O
oxidation O
) O
resulted O
in O
a O
significant O
disruption O
of O
the O
platform O
and O
, O
hence O
, O
a O
decrease O
in O
HCV O
genome O
replication O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
forms O
a O
helical O
ribonucleoprotein O
with O
the O
viral O
positive O
- O
strand O
RNA O
genome O
and O
binds O
to O
the O
principal O
constituent O
of O
the O
virion O
envelope O
, O
the O
membrane B
( I
M I
) I
protein O
, O
to O
facilitate O
assembly O
and O
budding O
. O

To O
probe O
the O
functions O
of O
these O
domains O
in O
the O
N O
protein O
of O
the O
model O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
we O
constructed O
mutants O
in O
which O
each O
RNA O
- O
binding O
domain O
was O
replaced O
by O
its O
counterpart O
from O
the O
N O
protein O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS5A O
is O
essential O
for O
viral O
genome O
replication O
within O
cytoplasmic O
replication O
complexes O
and O
virus O
assembly O
at O
the O
lipid B
droplet I
( I
LD I
) I
surface O
, O
although O
its O
definitive O
functions O
are O
poorly O
understood O
. O

Persistent O
infection O
is O
a O
key O
feature O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

However O
, O
chimpanzee O
infections O
with O
cell O
culture O
- O
derived O
viruses O
( O
JFH1 O
or O
related O
chimeric O
viruses O
that O
replicate O
efficiently O
in O
cell O
culture O
) O
have O
been O
limited O
to O
acute O
- O
transient O
infections O
with O
no O
pathogenicity O
. O

Following O
acute O
- O
transient O
infection O
with O
a O
chimeric O
H77 O
/ O
JFH1 O
virus O
( O
HJ3 O
- O
5 O
) O
, O
intravenous O
( O
i O
. O

) O
challenge O
with O
10 O
( O
6 O
) O
FFU O
H77S O
. O

2 O
virus O
resulted O
in O
immediate O
seroconversion O
and O
, O
following O
an O
unusual O
4 O
- O
to O
6 O
- O
week O
delay O
, O
persistent O
viremia O
accompanied O
by O
alanine B
aminotransferase I
( I
ALT I
) I
elevation O
, O
intrahepatic O
innate O
immune O
responses O
, O
and O
diffuse O
hepatopathy O
. O

2 O
, O
Q1067R O
( O
NS3 O
) O
had O
reverted O
to O
Q1067 O
and O
S2204I O
( O
NS5A O
) O
was O
replaced O
by O
T2204 O
within O
8 O
weeks O
of O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
- O
mediated O
liver O
diseases O
are O
one O
of O
the O
major O
health O
issues O
in O
the O
United O
States O
and O
worldwide O
. O

HCV O
infection O
has O
been O
reported O
to O
modulate O
microRNAs B
( I
miRNAs I
) I
that O
control O
various O
cell O
surface O
receptors O
and O
gene O
- O
regulatory O
complexes O
involved O
in O
hepatic O
inflammation O
and O
liver O
diseases O
. O

We O
report O
here O
that O
specific O
downregulation O
of O
miRNA O
- O
107 O
and O
miRNA O
- O
449a O
following O
HCV O
infection O
in O
patients O
with O
HCV O
- O
mediated O
liver O
diseases O
modulates O
expression O
of O
CCL2 O
, O
an O
inflammatory O
chemokine O
upregulated O
in O
patients O
with O
chronic O
liver O
diseases O
, O
by O
targeting O
components O
of O
the O
interleukin B
- I
6 I
receptor I
( I
IL I
- I
6R I
) I
complex O
. O

Taken O
together O
, O
our O
results O
demonstrate O
a O
novel O
gene O
- O
regulatory O
mechanism O
in O
which O
HCV O
- O
induced O
changes O
in O
miRNAs O
( O
miRNA449a O
and O
miRNA O
- O
107 O
) O
regulate O
CCL2 O
expression O
by O
activation O
of O
the O
IL O
- O
6 O
- O
mediated O
signaling O
cascade O
, O
which O
we O
propose O
will O
result O
in O
HCV O
- O
mediated O
induction O
of O
inflammatory O
responses O
and O
fibrosis O
. O

Lipids O
play O
a O
crucial O
role O
in O
multiple O
aspects O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
. O

low B
- I
density I
lipoprotein I
receptor I
( I
LDLr I
) I
is O
involved O
in O
uptake O
of O
cholesterol O
rich O
low B
- I
density I
lipoprotein I
( I
LDL I
) I
particles O
from O
the O
bloodstream O
. O

Here O
, O
we O
investigate O
the O
effect O
of O
HCV O
infection O
on O
LDLR O
expression O
and O
the O
underlying O
mechanism O
( O
s O
) O
involved O
. O

Analysis O
of O
LDLR O
gene O
promoter O
identified O
a O
pivotal O
role O
of O
sterol B
- I
regulatory I
element I
binding I
proteins I
( I
SREBPs I
) I
, O
in O
the O
HCV O
- O
mediated O
stimulation O
of O
LDLR O
transcription O
. O

In O
addition O
, O
HCV O
negatively O
modulated O
the O
expression O
of O
proprotein B
convertase I
subtilisin I
/ I
kexin I
type I
9 I
( I
PCSK9 I
) I
, O
a O
protein O
that O
facilitates O
LDLR O
degradation O
. O

Within O
the O
polyprotein O
encoded O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
the O
minimum O
components O
required O
for O
viral O
RNA O
replication O
lie O
in O
the O
NS3 O
- O
5B O
region O
, O
while O
virion O
assembly O
requires O
expression O
of O
all O
virus O
components O
. O

Combined O
with O
the O
findings O
of O
confocal O
microscope O
analysis O
examining O
the O
extent O
to O
which O
the O
two O
copies O
of O
NS5A O
from O
the O
various O
expression O
systems O
colocalize O
, O
the O
results O
point O
to O
NS3 O
- O
5A O
playing O
a O
role O
in O
facilitating O
the O
integration O
of O
nonstructural B
( I
NS I
) I
proteins O
into O
viral O
membrane O
- O
associated O
foci O
, O
with O
this O
representing O
an O
early O
stage O
in O
the O
steps O
leading O
to O
replication O
complex O
formation O
. O

The O
isogenic O
host O
attachment O
spike O
protein O
recombinant O
demyelinating O
strain O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
( O
RSA59 O
) O
and O
the O
nondemyelinating O
strain O
( O
RSMHV2 O
) O
differ O
in O
their O
abilities O
to O
infect O
distinct O
types O
of O
neural O
cells O
, O
spread O
from O
cell O
to O
cell O
, O
and O
induce O
subsequent O
demyelination O
and O
axonal O
loss O
. O

human B
cytomegalovirus I
( I
HCMV I
) I
, O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
, O
Kaposi B
' I
s I
sarcoma I
- I
associated I
herpesvirus I
( I
KSHV I
) I
, O
and O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
been O
shown O
recently O
to O
reprogram O
cell O
metabolism O
to O
support O
their O
replication O
. O

Using O
protein O
complementation O
assays O
and O
coimmunoprecipitation O
, O
we O
identified O
a O
direct O
interaction O
between O
the O
HCV O
NS5A O
protein O
and O
cellular O
hexokinase B
2 I
( I
HK2 I
) I
, O
the O
first O
rate O
- O
limiting O
enzyme O
of O
glycolysis O
. O

Finally O
, O
determination O
of O
recombinant O
HK2 O
catalytic O
parameters O
( O
V O
- O
max O
, O
and O
K O
- O
m O
) O
in O
the O
presence O
of O
NS5A O
identified O
this O
viral O
protein O
as O
an O
activator O
of O
the O
enzyme O
. O

This O
effect O
was O
studied O
in O
vitro O
during O
lepidopteran O
- O
specific O
nucleopolyhedrovirus O
( O
genus O
Alpha O
baculovirus O
, O
family O
Baculoviridae O
) O
infection O
. O

Homologous O
interference O
was O
detected O
in O
Sf9 O
cells O
sequentially O
infected O
with O
two O
genotypes O
of O
Autographa B
californica I
multiple I
nucleopolyhedrovirus I
( I
AcMNPV I
) I
, O
each O
one O
expressing O
a O
different O
fluorescent O
protein O
. O

Superinfection O
exclusion O
was O
concurrent O
with O
reorganization O
of O
cytoplasmic O
actin O
to O
F O
- O
actin O
in O
the O
nucleus O
, O
followed O
by O
budded O
virus O
production O
( O
16 O
to O
20 O
h O
postinfection O
) O
. O

Protection O
against O
heterologous O
nucleopolyhedrovirus O
infection O
was O
also O
demonstrated O
, O
as O
productive O
infection O
of O
Sf9 O
cells O
by O
Spodoptera B
frugiperda I
nudeopolyhedrovirus I
( I
SfMNPV I
) I
was O
inhibited O
by O
prior O
infection O
with O
AcMNPV O
, O
and O
vice O
versa O
. O

The O
baculovirus O
Autographa B
californica I
nucleopolyhedrovirus I
( I
AcNPV I
) I
has O
been O
widely O
used O
to O
achieve O
a O
high O
level O
of O
foreign O
gene O
expression O
in O
insect O
cells O
, O
as O
well O
as O
for O
efficient O
gene O
transduction O
into O
mammalian O
cells O
without O
any O
replication O
. O

The O
reporter O
gene O
expression O
in O
IRF3 O
- O
deficient O
mouse B
embryonic I
fibroblasts I
( I
MEFs I
) I
infected O
with O
the O
recombinant O
baculovirus O
was O
shown O
to O
be O
enhanced O
in O
accordance O
with O
the O
suppression O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
. O

Furthermore O
, O
efficient O
gene O
transduction O
by O
the O
recombinant O
baculovirus O
was O
achieved O
in O
MEFs O
deficient O
for O
stimulator B
of I
interferon I
genes I
( I
STING I
) I
, O
TANK B
binding I
kinase I
1 I
( I
TBK1 I
) I
, O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
, O
or O
IFN B
- I
beta I
promoter I
stimulator I
1 I
( I
IPS I
- I
1 I
) I
, O
but O
not O
in O
those O
deficient O
for O
IRF7 O
, O
MyD88 O
, O
or O
Z B
- I
DNA I
binding I
protein I
1 I
( I
ZBP1 I
) I
/ O
DAI O
. O

Enhancement O
of O
gene O
expression O
by O
the O
recombinant O
baculovirus O
was O
also O
observed O
in O
human O
hepatoma O
cell O
lines O
replicating O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
in O
which O
innate O
immunity O
was O
impaired O
by O
the O
cleavage O
of O
IPS O
- O
1 O
by O
the O
viral O
protease O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
leading O
cause O
of O
chronic O
liver O
diseases O
. O

We O
developed O
a O
novel O
strategy O
to O
construct O
infectious O
HCV O
cDNA O
clone O
by O
combining O
functional O
screening O
of O
sequences O
directly O
from O
a O
genotype O
2a O
clinical O
isolate O
( O
PR63 O
) O
and O
cell O
culture O
adaptation O
. O

6 O
+ O
/ O
- O
10 O
( O
5 O
) O
focus O
- O
forming O
units O
/ O
ml O
. O

In O
a O
recent O
clinical O
trial O
, O
balapiravir O
, O
a O
prodrug O
of O
a O
cytidine O
analog O
( O
R1479 O
) O
, O
failed O
to O
achieve O
efficacy O
( O
reducing O
viremia O
after O
treatment O
) O
in O
dengue O
patients O
, O
although O
the O
plasma O
trough O
concentration O
of O
R1479 O
remained O
above O
the O
50 B
% I
effective I
concentration I
( I
EC50 I
) I
. O

R1479 O
lost O
its O
potency O
by O
125 O
- O
fold O
when O
balapiravir O
was O
used O
to O
treat O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
; O
one O
of O
the O
major O
cells O
targeted O
for O
viral O
replication O
) O
that O
were O
preinfected O
with O
dengue O
virus O
. O

Mechanistically O
, O
dengue O
virus O
infection O
triggered O
PBMCs O
to O
generate O
cytokines O
, O
which O
decreased O
their O
efficiency O
of O
conversion O
of O
R1479 O
to O
its O
triphosphate O
form O
( O
the O
active O
antiviral O
ingredient O
) O
, O
resulting O
in O
decreased O
antiviral O
potency O
. O

In O
contrast O
to O
the O
cytidine O
- O
based O
compound O
R1479 O
, O
the O
potency O
of O
an O
adenosine O
- O
based O
inhibitor O
of O
dengue O
virus O
( O
NITD008 O
) O
was O
much O
less O
affected O
. O

Rigid B
amphipathic I
fusion I
inhibitors I
( I
RAFIs I
) I
are O
lipophilic O
inverted O
- O
cone O
- O
shaped O
molecules O
thought O
to O
antagonize O
the O
membrane O
curvature O
transitions O
that O
occur O
during O
virus O
- O
cell O
fusion O
and O
are O
broad B
- I
spectrum I
antivirals I
against I
enveloped I
viruses I
( I
Broad I
- I
SAVE I
) I
. O

Here O
, O
we O
show O
that O
RAFIs O
act O
like O
membrane O
- O
binding O
photosensitizers O
: O
their O
antiviral O
effect O
is O
dependent O
on O
light O
and O
the O
generation O
of O
singlet O
oxygen O
( O
O O
- O
1 O
( O
2 O
) O
) O
, O
similar O
to O
the O
mechanistic O
paradigm O
established O
for O
LJ001 O
, O
a O
chemically O
unrelated O
class O
of O
Broad O
- O
SAVE O
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
is O
a O
hydrophilic O
phosphoprotein O
with O
RNA O
binding O
activity O
and O
a O
critical O
component O
of O
the O
viral O
replicase O
. O

In O
silico O
analysis O
suggests O
that O
NS5A O
encompasses O
three O
domains O
interconnected O
by O
two O
low B
- I
complexity I
sequences I
( I
LCSs I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS4A O
is O
a O
single O
- O
pass O
transmembrane B
( I
TM I
) I
protein O
essential O
for O
viral O
replication O
and O
particle O
assembly O
. O

Switching O
between O
codon O
types O
therefore O
occurs O
via O
intermediates O
( O
threonine O
or O
cysteine O
) O
or O
via O
simultaneous O
tandem O
substitutions O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
chronically O
infects O
2 O
to O
3 O
% O
of O
the O
global O
population O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
suppresses O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
replication O
in O
vitro O
by O
inducing O
cell O
- O
intrinsic O
retroviral O
restriction O
mechanisms O
. O

We O
investigated O
the O
effects O
of O
IFN O
- O
alpha O
/ O
ribavirin O
( O
IFN O
- O
alpha O
/ O
riba O
) O
treatment O
on O
34 O
anti O
- O
HIV O
- O
1 O
restriction O
factors O
in O
vivo O
. O

Expression O
of O
several O
anti O
- O
HIV O
- O
1 O
restriction O
factors O
was O
significantly O
induced O
by O
IFN O
- O
alpha O
/ O
riba O
in O
HIV O
/ O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
coinfected O
individuals O
. O

Fold O
induction O
of O
cumulative O
restriction O
factor O
expression O
in O
CD4 O
+ O
T O
cells O
was O
significantly O
correlated O
with O
viral O
load O
reduction O
during O
IFN O
- O
alpha O
/ O
riba O
treatment O
( O
r O
( O
2 O
) O
= O
0 O
. O

An O
AUG O
- O
initiated O
upstream B
open I
reading I
frame I
( I
uORF I
) I
encoding O
a O
potential O
polypeptide O
of O
3 O
to O
13 O
amino B
acids I
( I
aa I
) I
is O
found O
within O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
> O
75 O
% O
of O
coronavirus O
genomes O
based O
on O
38 O
reference O
strains O
. O

( O
i O
) O
When O
the O
uORF O
AUG O
- O
initiating O
codon O
was O
replaced O
with O
a O
UAG O
stop O
codon O
along O
with O
a O
U112A O
mutation O
to O
maintain O
a O
uORF O
- O
harboring O
stem O
- O
loop O
4 O
structure O
, O
an O
unimpaired O
virus O
with O
wild B
- I
type I
( I
WT I
) I
growth O
kinetics O
was O
recovered O
. O

( O
ii O
) O
When O
the O
uORF O
was O
fused O
with O
genomic O
( O
main O
) O
ORF1 O
by O
converting O
three O
in O
- O
frame O
stop O
codons O
to O
nonstop O
codons O
, O
a O
uORF O
- O
ORF1 O
fusion O
protein O
was O
made O
, O
and O
virus O
replicated O
at O
WT O
levels O
. O

( O
iii O
) O
When O
uAUG O
- O
eliminating O
deletions O
of O
20 O
, O
30 O
, O
or O
51 O
nucleotides B
( I
nt I
) I
were O
made O
within O
stem O
- O
loop O
4 O
, O
viable O
but O
debilitated O
virus O
was O
recovered O
. O

Variation O
of O
core O
amino B
acid I
( I
aa I
) I
70 O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
recently O
to O
be O
closely O
correlated O
with O
liver O
disease O
progression O
, O
suggesting O
that O
the O
core O
region O
might O
be O
present O
as O
a O
quasispecies O
during O
persistent O
infection O
and O
that O
this O
quasispecies O
nature O
might O
have O
an O
influence O
on O
the O
progression O
of O
disease O
. O

In O
our O
investigation O
, O
the O
subjects O
were O
79 O
patients O
infected O
with O
HCV O
genotype O
1b O
( O
25 O
with O
chronic O
hepatitis O
[ O
CH O
] O
, O
29 O
with O
liver O
cirrhosis O
[ O
LC O
] O
, O
and O
25 O
with O
hepatocellular O
carcinoma O
[ O
HCC O
] O
) O
. O

Based O
on O
a O
plasmid O
containing O
a O
cloned O
HCV O
sequence O
( O
pCV O
- O
J4L6S O
) O
, O
the O
background O
error O
rate O
associated O
with O
pyrosequencing O
, O
including O
the O
PCR O
procedure O
, O
was O
calculated O
as O
0 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
variable O
and O
associated O
with O
chronic O
liver O
disease O
. O

Viral O
isolates O
are O
grouped O
into O
seven O
genotypes B
( I
GTs I
) I
. O

On O
the O
one O
hand O
, O
insertion O
of O
GT1a O
- O
derived O
( O
H77 O
) O
E1 O
- O
E2 O
sequences O
into O
a O
chimeric O
GT2a O
virus O
( O
Jc1 O
) O
strongly O
suppressed O
virus O
production O
. O

On O
the O
other O
hand O
, O
replacement O
of O
H77 O
glycoproteins O
within O
the O
GT1a O
- O
GT2a O
chimeric O
genome O
H77 O
/ O
C3 O
by O
GT2a O
- O
derived O
( O
Jc1 O
) O
E1 O
- O
E2 O
increased O
infectious O
particle O
production O
. O

Cells O
that O
are O
productively O
infected O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
refractory O
to O
a O
second O
infection O
by O
HCV O
via O
a O
block O
in O
viral O
replication O
known O
as O
superinfection O
exclusion O
. O

We O
produced O
a O
high O
- O
titer O
HC O
- O
J6 O
/ O
JFH1 O
( O
Jc1 O
) O
viral O
genome O
with O
a O
fluorescent O
reporter O
inserted O
between O
NS5A O
and O
NS5B O
and O
used O
it O
to O
infect O
Huh7 O
. O

Viral O
competition O
experiments O
, O
using O
a O
novel O
strategy O
of O
sequence O
- O
barcoding O
viral O
strains O
, O
as O
well O
as O
superinfection O
of O
replicon O
cells O
demonstrated O
that O
mutations O
in O
E1 O
, O
p7 O
, O
NS5A O
, O
and O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
of O
the O
3 O
' O
untranslated O
region O
were O
important O
for O
superinfection O
. O

Interestingly O
, O
viruses O
with O
a O
shorter O
poly O
( O
U O
/ O
UC O
) O
and O
an O
NS5A O
domain O
II O
mutation O
were O
most O
effective O
in O
overcoming O
the O
postentry O
block O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
is O
an O
essential O
component O
of O
innate O
antiviral O
immunity O
and O
of O
treatment O
regimens O
for O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Using O
genotype O
( O
strain O
) O
1a O
( O
H77 O
) O
and O
3a O
( O
S52 O
) O
Core O
- O
NS2 O
JFH1 O
- O
based O
recombinants O
, O
we O
aimed O
at O
identifying O
viral O
correlates O
of O
IFN O
- O
alpha O
resistance O
in O
vitro O
. O

Reverse O
genetic O
studies O
showed O
that O
primarily O
amino O
acid O
changes O
I348T O
in O
1a O
( O
H77 O
) O
E1 O
and O
F345V O
/ O
V414A O
in O
3a O
( O
S52 O
) O
E1 O
/ O
E2 O
increased O
viral O
fitness O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
orchestrates O
the O
different O
stages O
of O
its O
life O
cycle O
in O
time O
and O
space O
through O
the O
sequential O
participation O
of O
HCV O
proteins O
and O
cellular O
machineries O
; O
hence O
, O
these O
represent O
tractable O
molecular O
host O
targets O
for O
HCV O
elimination O
by O
combination O
therapies O
. O

We O
recently O
identified O
multifunctional O
Y O
- O
box O
- O
binding O
protein O
1 O
( O
YB O
- O
1 O
or O
YBX1 O
) O
as O
an O
interacting O
partner O
of O
NS3 O
/ O
4A O
protein O
and O
HCV O
genomic O
RNA O
that O
negatively O
regulates O
the O
equilibrium O
between O
viral O
translation O
/ O
replication O
and O
particle O
production O
. O

Human O
noroviruses O
are O
a O
major O
cause O
of O
food O
- O
borne O
illness O
, O
accountable O
for O
50 O
% O
of O
all O
- O
etiologies O
outbreaks O
of O
acute O
gastroenteritis O
( O
in O
both O
developing O
and O
developed O
countries O
) O
. O

We O
recently O
reported O
the O
inhibitory O
effect O
of O
2 B
' I
- I
C I
- I
methylcytidine I
( I
2CMC I
) I
, O
a O
hepatitis O
C O
virus O
polymerase O
inhibitor O
, O
on O
the O
in O
vitro O
replication O
of O
murine B
norovirus I
( I
MNV I
) I
. O

Treatment O
of O
MNV O
- O
infected O
AG129 O
mice O
with O
2CMC O
( O
i O
) O
prevented O
norovirusinduced O
diarrhea O
; O
( O
ii O
) O
markedly O
delayed O
the O
appearance O
of O
viral O
RNA O
and O
reduced O
viral O
RNA O
titers O
in O
the O
intestine O
, O
mesenteric O
lymph O
nodes O
, O
spleen O
, O
lungs O
, O
and O
stool O
; O
( O
iii O
) O
completely O
prevented O
virus O
- O
induced O
mortality O
; O
and O
( O
iv O
) O
resulted O
in O
protective O
immunity O
against O
a O
rechallenge O
. O

In O
this O
study O
, O
we O
investigated O
hepatitis B
C I
virus I
( I
HCV I
) I
molecular O
epidemiology O
and O
evolutionary O
dynamics O
. O

Five O
Bayesian B
skyline I
plots I
( I
BSPs I
) I
were O
estimated O
for O
the O
five O
subtypes O
. O

Because O
these O
rates O
differed O
significantly O
( O
P O
< O
1e O
- O
9 O
) O
from O
each O
other O
, O
they O
may O
help O
explain O
why O
6a O
is O
increasingly O
prevalent O
in O
southern O
China O
and O
1b O
is O
predominant O
nationwide O
. O

Previous O
studies O
indicate O
that O
the O
processing O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
- O
p7 O
- O
NS2 O
precursor O
mediated O
by O
host O
signal O
peptidase O
is O
relatively O
inefficient O
, O
resulting O
in O
the O
accumulation O
of O
E2 O
- O
p7 O
- O
NS2 O
and O
E2 O
- O
p7 O
precursors O
in O
addition O
to O
E2 O
in O
mammalian O
cells O
. O

However O
, O
complete O
separation O
of O
E2 O
and O
p7 O
by O
inserting O
an O
encephalomyocarditis B
virus I
( I
EMCV I
) I
internal I
ribosome I
entry I
site I
( I
IRES I
) I
between O
these O
two O
proteins O
also O
moderately O
inhibited O
virus O
production O
. O

We O
further O
demonstrated O
that O
disrupting O
E2 O
- O
p7 O
processing O
inhibits O
both O
NS2 O
localization O
to O
the O
putative O
virus O
assembly O
sites O
near O
lipid B
droplets I
( I
LD I
) I
and O
NS2 O
interaction O
with O
NS3 O
and O
E2 O
. O

Previous O
studies O
have O
shown O
that O
the O
abundant O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
tegument O
protein O
VP11 O
/ O
12 O
, O
encoded O
by O
gene O
UL46 O
, O
stimulates O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3 I
- I
kinase I
) I
/ O
Akt O
signaling O
: O
it O
binds O
the O
Src B
family I
kinase I
( I
SFK I
) I
Lck O
, O
is O
tyrosine O
phosphorylated O
, O
recruits O
the O
p85 O
subunit O
of O
PI3 O
- O
kinase O
, O
and O
is O
essential O
for O
the O
activation O
of O
Akt O
during O
HSV O
- O
1 O
infection O
. O

The O
C O
- O
terminal O
region O
of O
VP11 O
/ O
12 O
contains O
tyrosine O
- O
based O
motifs O
predicted O
to O
bind O
the O
SH2 O
domains O
of O
SFKs O
( O
YETV O
and O
YEEI O
) O
, O
p85 O
( O
YTHM O
) O
, O
and O
Grb2 O
( O
YENV O
) O
and O
the O
phosphotyrosine B
- I
binding I
( I
PTB I
) I
domain O
of O
Shc O
( O
NPLY O
) O
. O

Inactivating O
the O
p85 O
, O
Grb2 O
, O
or O
Shc O
motif O
reduced O
( O
p85 O
) O
or O
eliminated O
( O
Grb2 O
and O
Shc O
) O
the O
interaction O
with O
the O
cognate O
signaling O
molecule O
without O
greatly O
affecting O
the O
other O
interactions O
or O
activation O
of O
Lck O
. O

In O
contrast O
, O
inactivation O
of O
both O
SFK O
motifs O
severely O
reduced O
Lck O
binding O
and O
activation O
and O
tyrosine O
phosphorylation O
of O
VP11 O
/ O
12 O
and O
reduced O
( O
p85 O
) O
or O
eliminated O
( O
Grb2 O
and O
Shc O
) O
binding O
of O
other O
signaling O
proteins O
. O

Overall O
, O
these O
data O
demonstrate O
the O
key O
redundant O
roles O
of O
the O
VP11 O
/ O
12 O
SFK O
- O
binding O
motifs O
in O
the O
recruitment O
and O
activation O
of O
SFKs O
and O
indicate O
that O
activated O
SFKs O
then O
lead O
( O
directly O
or O
indirectly O
) O
to O
phosphorylation O
of O
the O
additional O
motifs O
involved O
in O
recruiting O
p85 O
, O
Grb2 O
, O
and O
Shc O
. O

A O
novel O
picornavirus O
was O
isolated O
from O
specimens O
of O
a O
diseased O
European O
eel O
( O
Anguilla O
anguilla O
) O
. O

Passive O
immunoprophylaxis O
or O
immunotherapy O
with O
norovirus O
- O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
could O
be O
a O
useful O
treatment O
for O
high O
- O
risk O
populations O
, O
including O
infants O
and O
young O
children O
, O
the O
elderly O
, O
and O
certain O
patients O
who O
are O
debilitated O
or O
immunocompromised O
. O

In O
order O
to O
obtain O
antinorovirus O
MAbs O
with O
therapeutic O
potential O
, O
we O
stimulated O
a O
strong O
adaptive O
immune O
response O
in O
chimpanzees O
to O
the O
prototype O
norovirus O
strain O
Norwalk B
virus I
( I
NV I
) I
( O
genogroup O
I O
. O

A O
combinatorial O
phage O
Fab O
display O
library O
derived O
from O
mRNA O
of O
the O
chimpanzees O
' O
bone O
marrow O
was O
prepared O
, O
and O
four O
distinct O
Fabs O
reactive O
with O
Norwalk O
recombinant B
virus I
- I
like I
particles I
( I
rVLPs I
) I
were O
recovered O
, O
with O
estimated O
binding O
affinities O
in O
the O
subnanomolar O
range O
. O

Mapping O
studies O
showed O
that O
the O
four O
Fabs O
recognized O
three O
different O
conformational O
epitopes O
in O
the O
protruding O
( O
P O
) O
domain O
of O
NV O
VP1 O
, O
the O
major O
capsid O
protein O
. O

One O
additional O
specific O
Fab O
( O
F11 O
) O
was O
recovered O
months O
later O
from O
immortalized O
memory O
B O
cells O
and O
partially O
characterized O
. O

The O
anti O
- O
NV O
Fabs O
were O
converted O
into O
full O
- O
length O
IgG O
( O
MAbs O
) O
with O
human O
gamma O
1 O
heavy O
chain O
constant O
regions O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
plays O
a O
multifunctional O
role O
in O
the O
virus O
life O
cycle O
, O
from O
regulation O
of O
replication O
and O
transcription O
and O
genome O
packaging O
to O
modulation O
of O
host O
cell O
processes O
. O

The O
potential O
interactome O
of O
the O
infectious B
bronchitis I
virus I
( I
IBV I
) I
N O
protein O
was O
mapped O
using O
stable B
isotope I
labeling I
with I
amino I
acids I
in I
cell I
culture I
( I
SILAC I
) I
coupled O
to O
a O
green O
fluorescent O
protein O
- O
nanotrap O
pulldown O
methodology O
and O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
. O

In O
the O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
as O
a O
model O
, O
we O
previously O
reported O
that O
accessory O
gene O
7 O
counteracts O
the O
host O
antiviral O
response O
by O
associating O
with O
the O
catalytic O
subunit O
of O
protein B
phosphatase I
1 I
( I
PP1c I
) I
. O

The O
pattern O
of O
gene O
expression O
of O
cells O
infected O
with O
a O
recombinant O
mutant O
TGEV O
, O
lacking O
gene O
7 O
expression O
( O
rTGEV O
- O
Delta O
7 O
) O
, O
was O
compared O
to O
that O
of O
cells O
infected O
with O
the O
parental O
virus O
( O
rTGEV O
- O
wt O
) O
. O

Previous O
studies O
have O
demonstrated O
that O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
nonstructural B
protein I
2 I
( I
NS2 I
) I
is O
a O
2 O
' O
, O
5 O
' O
- O
phosphodiesterase O
that O
inhibits O
activation O
of O
the O
interferon O
- O
induced O
oligoadenylate B
synthetase I
( I
OAS I
) I
- O
RNase O
L O
pathway O
. O

The O
replication O
of O
wild O
- O
type O
MHV O
strain O
A59 O
( O
A59 O
) O
and O
a O
mutant O
with O
an O
inactive O
phosphodiesterase O
( O
ns2 O
- O
H126R O
) O
was O
assessed O
in O
primary O
hepatocytes O
and O
primary O
central B
nervous I
system I
( I
CNS I
) I
cell O
types O
- O
neurons O
, O
astrocytes O
, O
and O
oligodendrocytes O
. O

However O
, O
rRNA O
degradation O
was O
induced O
by O
treatment O
of O
astrocytes O
or O
oligodendrocytes O
with O
poly O
( O
I O
center O
dot O
C O
) O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
and O
packaging O
require O
interactions O
between O
the O
unbranched O
rodlike O
structure O
of O
HDV O
RNA O
and O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
a O
basic O
, O
disordered O
, O
oligomeric O
protein O
. O

The O
most O
widely O
cited O
model O
suggests O
that O
RNA O
binding O
involves O
two O
proposed O
arginine O
- O
rich O
motifs O
( O
ARMs O
I O
and O
II O
) O
in O
the O
middle O
of O
HDAg O
. O

The O
coronavirus O
Nucleocapsid B
protein I
( I
N I
) I
plays O
an O
essential O
structural O
role O
in O
virions O
through O
a O
network O
of O
interactions O
with O
positive O
- O
strand O
viral O
genomic O
RNA O
, O
the O
envelope O
membrane B
protein I
( I
M I
) I
, O
and O
other O
N O
molecules O
. O

We O
previously O
uncovered O
an O
unanticipated O
interaction O
between O
N O
and O
the O
largest O
subunit O
of O
the O
viral O
replicase O
- O
transcriptase O
complex O
, O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

This O
was O
found O
through O
analysis O
of O
revertants O
of O
a O
severely O
defective O
mutant O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
in O
which O
the O
N O
gene O
was O
replaced O
with O
that O
of O
its O
close O
relative O
, O
bovine B
coronavirus I
( I
BCoV I
) I
. O

The O
cell O
surface O
receptor O
T B
cell I
immunoglobulin I
mucin I
domain I
1 I
( I
TIM I
- I
1 I
) I
dramatically O
enhances O
filovirus O
infection O
of O
epithelial O
cells O
. O

Here O
, O
we O
showed O
that O
key O
phosphatidylserine B
( I
PtdSer I
) I
binding O
residues O
of O
the O
TIM O
- O
1 O
IgV O
domain O
are O
critical O
for O
Ebola B
virus I
( I
EBOV I
) I
entry O
through O
direct O
interaction O
with O
PtdSer O
on O
the O
viral O
envelope O
. O

Further O
, O
annexin B
V I
( I
AnxV I
) I
substituted O
for O
the O
TIM O
- O
1 O
IgV O
domain O
, O
supporting O
a O
PtdSer O
- O
dependent O
mechanism O
. O

As O
further O
evidence O
of O
the O
critical O
role O
of O
enveloped O
- O
virion O
- O
associated O
PtdSer O
in O
TIM O
- O
1 O
- O
mediated O
uptake O
, O
TIM O
- O
1 O
enhanced O
internalization O
of O
pseudovirions O
and O
virus B
- I
like I
proteins I
( I
VLPs I
) I
lacking O
a O
glycoprotein O
, O
providing O
evidence O
that O
TIM O
- O
1 O
and O
PtdSer O
- O
binding O
receptors O
can O
mediate O
virus O
uptake O
independent O
of O
a O
glycoprotein O
. O

Here O
we O
report O
the O
crystal O
structure O
of O
the O
turkey B
astrovirus I
2 I
( I
TAstV I
- I
2 I
) I
capsid O
surface O
spike O
domain O
, O
determined O
to O
1 O
. O

However O
, O
there O
is O
evidence O
for O
carbohydrate O
- O
binding O
sites O
in O
both O
human O
and O
avian O
spikes O
, O
and O
studies O
with O
human B
astrovirus I
1 I
( I
HAstV I
- I
1 I
) I
suggest O
a O
minor O
role O
in O
infection O
for O
chondroitin O
sulfate O
but O
not O
heparin O
. O

Mutations O
in O
the O
core O
protein O
( O
HBc O
) O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
associated O
with O
aggressive O
hepatitis O
and O
advanced O
liver O
diseases O
in O
chronic B
hepatitis I
B I
( I
CHB I
) I
. O

In O
this O
study O
, O
we O
identified O
the O
L60V O
variation O
in O
HBc O
that O
generates O
a O
new O
HLA O
- O
A2 O
- O
restricted O
CD8 O
( O
+ O
) O
T O
cell O
epitope O
by O
screening O
an O
overlapping O
9 O
- O
mer O
peptide O
pool O
covering O
HBc O
and O
its O
variants O
. O

Immunization O
with O
the O
defined O
HBV O
epitope O
V60 O
peptide O
elicited O
specific O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
- O
induced O
liver O
injury O
in O
HLA O
- O
A2 O
( O
+ O
) O
HBV O
transgenic O
mice O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
hepatotropic O
RNA O
virus O
that O
is O
closely O
associated O
with O
chronic O
liver O
inflammation O
, O
fibrosis O
, O
and O
hepatocellular O
carcinoma O
. O

During O
the O
progression O
of O
HCV O
- O
related O
diseases O
, O
hepatic B
stellate I
cells I
( I
HSCs I
) I
contribute O
to O
the O
inflammatory O
response O
triggered O
by O
HCV O
infection O
. O

By O
coculturing O
HSCs O
with O
HCV O
- O
infected O
hepatocytes O
in O
vitro O
, O
we O
found O
that O
HSCs O
stimulated O
HCV O
- O
infected O
hepatocytes O
, O
leading O
to O
the O
expression O
of O
proinflammatory O
cytokines O
and O
chemokines O
such O
as O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
IL O
- O
8 O
, O
macrophage B
inflammatory I
protein I
1 I
alpha I
( I
MIP I
- I
1 I
alpha I
) I
, O
and O
MIP O
- O
1 O
beta O
. O

HCV O
infection O
enhanced O
production O
of O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
beta O
mRNA O
, O
and O
HSC O
- O
dependent O
IL O
- O
1 O
alpha O
production O
contributed O
to O
the O
stimulation O
of O
C O
/ O
EBP O
beta O
target O
cytokines O
and O
chemokines O
in O
HCV O
- O
infected O
hepatocytes O
. O

Cell O
culture O
- O
produced O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
subjected O
to O
up O
to O
100 O
serial O
passages O
in O
human O
hepatoma O
cells O
in O
the O
absence O
or O
presence O
of O
different O
doses O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
. O

While O
high O
initial O
IFN O
- O
alpha O
doses O
( O
increasing O
from O
1 O
to O
4 O
IU O
/ O
ml O
) O
did O
not O
allow O
HCV O
survival O
beyond O
passage O
40 O
, O
a O
gradual O
exposure O
( O
from O
0 O
. O

The O
trait O
was O
associated O
with O
enhanced O
phosphorylation O
of O
protein B
kinase I
R I
( I
PKR I
) I
and O
IFN O
alpha O
, O
although O
other O
contributing O
factors O
are O
likely O
. O

Red O
foxes O
( O
Vulpes O
vulpes O
) O
are O
the O
most O
widespread O
members O
of O
the O
order O
of O
Carnivora O
. O

Since O
they O
often O
live O
in O
( O
peri O
) O
urban O
areas O
, O
they O
are O
a O
potential O
reservoir O
of O
viruses O
that O
transmit O
from O
wildlife O
to O
humans O
or O
domestic O
animals O
. O

Induction O
of O
the O
unfolded B
protein I
response I
( I
UPR I
) I
is O
an O
adaptive O
cellular O
response O
to O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
that O
allows O
a O
cell O
to O
reestablish O
ER O
homeostasis O
. O

In O
this O
study O
, O
we O
investigated O
the O
activation O
of O
the O
protein B
kinase I
R I
- I
like I
ER I
kinase I
( I
PERK I
) I
pathway O
of O
UPR O
in O
cells O
infected O
with O
the O
coronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
and O
its O
relationship O
with O
IBV O
- O
induced O
apoptosis O
. O

Meanwhile O
, O
activating B
transcription I
factor I
4 I
( I
ATF4 I
) I
was O
upregulated O
at O
the O
protein O
level O
in O
the O
infected O
cells O
, O
resulting O
in O
the O
induction O
in O
trans O
of O
the O
transcription O
factor O
ATF3 O
and O
the O
proapoptotic O
growth O
arrest O
and O
DNA O
damage O
- O
inducible O
protein O
GADD153 O
. O

Knockdown O
of O
PERK O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
suppressed O
the O
activation O
of O
GADD153 O
and O
the O
IBV O
- O
induced O
apoptosis O
. O

Interestingly O
, O
knockdown O
of O
protein B
kinase I
R I
( I
PKR I
) I
by O
siRNA O
and O
inhibition O
of O
the O
PKR O
kinase O
activity O
by O
2 B
- I
aminopurine I
( I
2 I
- I
AP I
) I
also O
reduced O
the O
IBV O
- O
induced O
upregulation O
of O
GADD153 O
and O
apoptosis O
induction O
. O

Analysis O
of O
the O
pathways O
downstream O
of O
GADD153 O
revealed O
much O
more O
activation O
of O
the O
extracellular B
signal I
- I
related I
kinase I
( I
ERK I
) I
pathway O
in O
GADD153 O
- O
knockdown O
cells O
during O
IBV O
infection O
, O
indicating O
that O
GADD153 O
may O
modulate O
apoptosis O
through O
suppression O
of O
the O
pathway O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
contains O
numerous O
RNA O
elements O
that O
are O
required O
for O
its O
replication O
. O

Most O
of O
the O
identified O
RNA O
structures O
are O
located O
within O
the O
5 O
' O
and O
3 O
' O
untranslated B
regions I
( I
UTRs I
) I
. O

One O
prominent O
RNA O
structure O
, O
termed O
the O
cis B
- I
acting I
replication I
element I
( I
CRE I
) I
, O
is O
located O
within O
the O
NS5B O
coding O
region O
. O

Particularly O
under O
contest O
are O
possible O
mutagenic O
effects O
of O
ribavirin O
that O
may O
lead O
to O
viral O
extinction O
by O
lethal O
mutagenesis O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
. O

We O
applied O
ultradeep O
sequencing O
to O
determine O
ribavirin O
- O
induced O
sequence O
changes O
in O
the O
HCV O
coding O
region O
( O
nucleotides O
[ O
nt O
] O
330 O
to O
9351 O
) O
of O
patients O
treated O
with O
6 O
- O
week O
ribavirin O
monotherapy O
( O
n O
= O
6 O
) O
in O
comparison O
to O
placebo O
( O
n O
= O
6 O
) O
. O

1 O
log O
( O
10 O
) O
IU O
/ O
ml O
in O
ribavirin O
- O
versus O
placebo O
- O
treated O
patients O
. O

The O
rotavirus B
( I
RV I
) I
genome O
consists O
of O
11 O
segments O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
. O

Typically O
, O
each O
segment O
contains O
5 O
' O
and O
3 O
' O
untranslated B
regions I
( I
UTRs I
) I
that O
flank O
an O
open B
reading I
frame I
( I
ORF I
) I
encoding O
a O
single O
protein O
. O

To O
probe O
the O
limits O
of O
the O
RV O
genome O
to O
accommodate O
additional O
genetic O
sequence O
, O
we O
used O
reverse O
genetics O
to O
insert O
duplications O
( O
analogous O
to O
synthetic O
rearrangements O
) O
and O
heterologous O
sequences O
into O
the O
3 O
' O
UTR O
of O
the O
segment O
encoding O
NSP2 O
( O
gene O
8 O
) O
. O

The O
approach O
allowed O
the O
recovery O
of O
recombinant O
RVs O
that O
contained O
sequence O
duplications O
( O
up O
to O
200 O
bp O
) O
and O
heterologous O
sequences O
, O
including O
those O
for O
FLAG O
, O
the O
hepatitis O
C O
virus O
E2 O
epitope O
, O
and O
the O
internal O
ribosome O
entry O
site O
of O
cricket O
paralysis O
virus O
. O

The O
recombinant O
RVs O
grew O
to O
high O
titer O
( O
> O
10 O
( O
7 O
) O
PFU O
/ O
ml O
) O
and O
remained O
genetically O
stable O
during O
serial O
passage O
. O

Coronaviruses O
possess O
a O
cap O
structure O
at O
the O
5 O
' O
ends O
of O
viral O
genomic O
RNA O
and O
subgenomic O
RNAs O
, O
which O
is O
generated O
through O
consecutive O
methylations O
by O
virally O
encoded O
guanine B
- I
N7 I
- I
methyltransferase I
( I
N7 I
- I
MTase I
) I
and O
2 B
' I
- I
O I
- I
methyltransferase I
( I
2 I
' I
- I
O I
- I
MTase I
) I
. O

The O
coronaviral O
N7 O
- O
MTase O
is O
unique O
for O
its O
physical O
linkage O
with O
an O
exoribonuclease B
( I
ExoN I
) I
harbored O
in O
nonstructural B
protein I
14 I
( I
nsp14 I
) I
of O
coronaviruses O
. O

In O
this O
study O
, O
the O
structure O
- O
function O
relationships O
of O
the O
N7 O
- O
MTase O
were O
analyzed O
by O
deletion O
and O
site O
- O
directed O
mutagenesis O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
nsp14 O
. O

The O
other O
10 O
critical O
residues O
were O
distributed O
throughout O
the O
N7 O
- O
MTase O
domain O
but O
localized O
mainly O
in O
the O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( I
SAM I
) I
- O
binding O
pocket O
and O
key O
structural O
elements O
of O
the O
MTase O
fold O
of O
nsp14 O
. O

The O
sequence O
motif O
DxGxPxA O
( O
amino O
acids O
[ O
aa O
] O
331 O
to O
338 O
) O
was O
identified O
as O
the O
key O
part O
of O
the O
SAM O
- O
binding O
site O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
genome O
replication O
is O
thought O
to O
occur O
in O
a O
membranous O
cellular O
compartment O
derived O
from O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

In O
this O
study O
, O
we O
describe O
the O
discovery O
of O
nonopioid O
sigma B
- I
1 I
receptor I
( I
S1R I
) I
as O
a O
cellular O
factor O
that O
mediates O
the O
early O
steps O
of O
viral O
RNA O
replication O
. O

S1R O
is O
a O
cholesterol O
- O
binding O
protein O
that O
resides O
in O
lipid O
- O
rich O
areas O
of O
the O
ER O
and O
in O
mitochondrion B
- I
associated I
ER I
membranes I
( I
MAMs I
) I
. O

Downregulation O
of O
S1R O
expression O
by O
RNA B
interference I
( I
RNAi I
) I
in O
Huh O
- O
7 O
cells O
leads O
to O
a O
proportional O
decrease O
in O
susceptibility O
to O
HCV O
infection O
, O
as O
shown O
by O
reduced O
HCV O
RNA O
accumulation O
and O
intra O
- O
and O
extracellular O
infectivity O
in O
single O
- O
cycle O
infection O
experiments O
. O

By O
using O
a O
system O
that O
allows O
the O
replication O
of O
the O
insect O
flock B
house I
virus I
( I
FHV I
) I
in O
yeast O
, O
here O
we O
show O
that O
LSm1 O
- O
7 O
, O
Pat1 O
, O
and O
Dhh1 O
control O
the O
ratio O
of O
subgenomic O
RNA3 O
to O
genomic O
RNA1 O
production O
, O
a O
key O
feature O
in O
the O
FHV O
life O
cycle O
mediated O
by O
a O
long O
- O
distance O
base O
pairing O
within O
RNA1 O
. O

Despite O
important O
progress O
toward O
deciphering O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
entry O
into O
host O
cells O
, O
many O
aspects O
of O
the O
early O
steps O
of O
the O
life O
cycle O
remained O
completely O
obscure O
. O

Expression O
of O
key O
Rab O
proteins O
, O
involved O
in O
specific O
pathways O
leading O
to O
different O
intracellular O
locations O
, O
was O
modulated O
in O
HepaRG O
cells O
, O
using O
a O
stable O
and O
inducible O
short B
hairpin I
RNA I
( I
shRNA I
) I
expression O
system O
. O

Some O
studies O
have O
reported O
that O
dendritic B
cells I
( I
DCs I
) I
may O
be O
dysfunctional O
in O
a O
subset O
of O
patients O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Here O
, O
we O
examined O
the O
phenotype O
and O
function O
of O
myeloid B
DCs I
( I
mDCs I
) I
and O
plasmacytoid B
DCs I
( I
pDCs I
) I
during O
acute O
HCV O
infection O
. O

Three O
groups O
of O
injection O
drug O
users O
( O
IDUs O
) O
at O
high O
risk O
of O
HCV O
infection O
were O
studied O
: O
an O
uninfected O
group O
, O
a O
group O
with O
acute O
HCV O
infection O
with O
spontaneous O
resolution O
, O
and O
a O
group O
with O
acute O
infection O
with O
chronic O
evolution O
. O

We O
examined O
the O
frequency O
, O
maturation O
status O
, O
and O
cytokine O
production O
capacity O
of O
DCs O
in O
response O
to O
the O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
and O
TLR7 O
/ O
8 O
ligands O
lipopolysaccharide B
( I
LPS I
) I
and O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
, O
respectively O
. O

First O
, O
we O
observed O
a O
decrease O
in O
the O
frequency O
of O
mature O
CD86 O
( O
+ O
) O
, O
programmed O
death O
- O
1 O
receptor O
ligand O
- O
positive O
( O
PDL1 O
( O
+ O
) O
) O
, O
and O
PDL2 O
( O
+ O
) O
pDCs O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
, O
a O
serious O
public O
health O
problem O
leading O
to O
cirrhosis O
and O
hepatocellular O
carcinoma O
, O
is O
currently O
treated O
with O
either O
pegylated B
alpha I
interferon I
( I
pegIFN I
- I
alpha I
) I
or O
one O
of O
the O
five O
nucleos O
( O
t O
) O
ide O
analogue O
viral O
DNA O
polymerase O
inhibitors O
. O

However O
, O
neither O
pegIFN O
- O
alpha O
nor O
nucleos O
( O
t O
) O
ide O
analogues O
are O
capable O
of O
reliably O
curing O
the O
viral O
infection O
. O

Screening O
of O
a O
library O
consisting O
of O
26 O
, O
900 O
small O
molecules O
led O
to O
the O
discovery O
of O
a O
series O
of O
sulfamoylbenzamide B
( I
SBA I
) I
derivatives O
that O
significantly O
reduced O
the O
amount O
of O
cytoplasmic O
HBV O
DNA O
. O

Mechanistic O
analyses O
reveal O
that O
the O
compounds O
dose O
dependently O
inhibit O
the O
formation O
of O
pregenomic B
RNA I
( I
pgRNA I
) I
- O
containing O
nucleocapsids O
of O
HBV O
but O
not O
other O
animal O
hepadnaviruses O
, O
such O
as O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
and O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
. O

The O
novel O
human B
coronavirus I
EMC I
( I
hCoV I
- I
EMC I
) I
, O
which O
recently O
emerged O
in O
Saudi O
Arabia O
, O
is O
highly O
pathogenic O
and O
could O
pose O
a O
significant O
threat O
to O
public O
health O
. O

We O
found O
that O
the O
spike B
protein I
of I
hCoV I
- I
EMC I
( I
EMC I
- I
S I
) I
is O
incorporated O
into O
lentiviral O
particles O
and O
mediates O
transduction O
of O
human O
cell O
lines O
derived O
from O
different O
organs O
, O
including O
the O
lungs O
, O
kidneys O
, O
and O
colon O
, O
as O
well O
as O
primary O
human O
macrophages O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5A I
( I
NS5A I
) I
is O
involved O
in O
regulating O
viral O
replication O
through O
its O
direct O
interaction O
with O
the O
HCV O
RNA O
- O
dependent O
RNA O
polymerase O
. O

To O
study O
this O
, O
HCV O
NS5A O
variants O
were O
amplified O
from O
hepatic O
tissue O
from O
an O
HCV O
- O
infected O
patient O
, O
and O
their O
abilities O
to O
activate O
gene O
transcription O
were O
analyzed O
in O
a O
single O
- O
hybrid O
yeast O
( O
Saccharomyces O
cerevisiae O
) O
model O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
dependent O
on O
cellular O
proteins O
for O
its O
own O
propagation O
. O

Of O
these O
candidates O
, O
mitogen B
- I
activated I
protein I
kinase I
- I
activated I
protein I
kinase I
3 I
( I
MAPKAPK3 I
) I
was O
selected O
for O
further O
characterization O
. O

In O
addition O
, O
both O
RNA O
and O
protein O
levels O
of O
MAPKAPK3 O
were O
elevated O
in O
both O
HCV O
subgenomic O
replicon O
cells O
and O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
- O
infected O
cells O
. O

Patients O
with O
chronic O
infection O
with O
either O
hepatitis B
C I
virus I
( I
HCV I
) I
or O
HIV O
have O
elevated O
circulating O
levels O
. O

Limited O
data O
exist O
on O
the O
regulation O
of O
natural B
killer I
( I
NK I
) I
cell O
function O
through O
interaction O
with O
galectin O
- O
9 O
. O

We O
found O
that O
galectin O
- O
9 O
ligation O
downregulates O
multiple O
immune O
- O
activating O
genes O
, O
including O
eight O
involved O
in O
the O
NK O
cell O
- O
mediated O
cytotoxicity O
pathway O
, O
impairs O
lymphokine O
- O
activated O
killing O
, O
and O
decreases O
the O
proportion O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
NK O
cells O
that O
had O
been O
stimulated O
with O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
/ O
IL O
- O
15 O
. O

We O
also O
show O
that O
in O
the O
setting O
of O
a O
short O
- O
term O
( O
4 O
- O
day O
) O
murine O
cytomegalovirus O
infection O
, O
terminally O
differentiated O
NKs O
accumulate O
in O
the O
livers O
of O
galectin O
- O
9 O
knockout O
mice O
, O
and O
that O
hepatic O
NKs O
spontaneously O
produce O
significantly O
more O
IFN O
- O
gamma O
in O
this O
setting O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
is O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
that O
acts O
as O
a O
key O
player O
in O
the O
HCV O
replication O
complex O
. O

Understanding O
the O
interplay O
between O
the O
viral O
and O
cellular O
components O
of O
the O
HCV O
replication O
complex O
could O
provide O
new O
insight O
for O
prevention O
of O
the O
progression O
of O
HCV O
- O
associated O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

After O
mass O
spectrophotometric O
analysis O
, O
fatty B
acid I
synthase I
( I
FASN I
) I
was O
found O
to O
interact O
with O
NS5B O
. O

In O
addition O
, O
overexpression O
of O
FASN O
enhanced O
HCV O
expression O
in O
Huh7 O
/ O
Rep O
- O
Feo O
cells O
, O
while O
transfection O
of O
FASN O
small B
interfering I
RNA I
( I
siRNA I
) I
or O
treatment O
with O
FASN O
- O
specific O
inhibitors O
decreased O
HCV O
replication O
and O
viral O
production O
. O

HIV O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
are O
preferentially O
primed O
for O
apoptosis O
, O
and O
this O
may O
represent O
a O
viral O
escape O
mechanism O
. O

We O
hypothesized O
that O
HIV O
- O
infected O
individuals O
that O
control O
virus O
to O
undetectable O
levels O
without O
antiretroviral B
therapy I
( I
ART I
) I
( O
elite O
controllers O
[ O
EC O
] O
) O
have O
the O
capacity O
to O
upregulate O
survival O
factors O
that O
allow O
them O
to O
resist O
apoptosis O
. O

To O
address O
this O
, O
we O
performed O
cross O
- O
sectional O
and O
longitudinal O
analysis O
of O
proapoptotic O
( O
cleaved O
caspase O
- O
3 O
) O
and O
antiapoptotic O
( O
Bcl O
- O
2 O
) O
markers O
of O
cytomegalovirus B
( I
CMV I
) I
and O
HIV O
- O
specific O
CD8 O
T O
cells O
in O
a O
cohort O
of O
HIV O
- O
infected O
subjects O
with O
various O
degrees O
of O
viral O
control O
on O
and O
off O
ART O
. O

We O
demonstrated O
that O
HIV O
- O
specific O
CTL O
from O
EC O
are O
more O
resistant O
to O
apoptosis O
than O
those O
with O
pharmacologic O
control O
( O
successfully O
treated O
patients O
[ O
ST O
] O
) O
, O
despite O
similar O
in O
vivo O
conditions O
. O

The O
genomic O
packaging B
signal I
( I
PS I
) I
for O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
was O
originally O
identified O
as O
an O
element O
that O
conferred O
packaging O
capability O
to O
defective O
interfering O
RNAs O
. O

The O
Capsid B
( I
C I
) I
protein O
of O
the O
Flaviviridae O
family O
members O
is O
involved O
in O
nucleocapsid O
formation O
and O
virion O
assembly O
. O

In O
this O
study O
, O
hemoglobin B
subunit I
beta I
( I
HB I
) I
was O
identified O
as O
a O
C O
protein O
- O
binding O
protein O
by O
glutathione O
S O
- O
transferase O
pulldown O
and O
subsequent O
mass O
spectrometry O
analysis O
of O
PK O
- O
15 O
cells O
, O
which O
are O
permissive O
cells O
for O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
. O

Interestingly O
, O
HB O
was O
found O
to O
interact O
with O
retinoic O
acid O
- O
inducible O
gene O
I O
and O
increase O
its O
expression O
, O
resulting O
in O
increased O
production O
of O
type B
I I
interferon I
( I
IFN I
) I
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS2 O
protein O
has O
dual O
roles O
within O
the O
HCV O
life O
cycle O
. O

In O
order O
to O
map O
the O
determinants O
necessary O
for O
infectious O
virus O
production O
and O
gain O
further O
insight O
into O
the O
multiple O
points O
at O
which O
NS2 O
may O
impact O
this O
process O
, O
a O
detailed O
mutational O
analysis O
of O
residues O
spanning O
amino B
acids I
( I
aa I
) I
1 O
to O
92 O
was O
performed O
. O

Initial O
block O
mutagenesis O
( O
5 O
or O
7 O
amino O
acid O
residues O
) O
in O
both O
bicistronic O
and O
monocistronic O
HCV B
cell I
culture I
- I
based I
( I
HCVcc I
) I
genomes O
revealed O
that O
all O
but O
two O
blocks O
had O
various O
levels O
of O
impaired O
infectious O
virus O
production O
. O

In O
this O
report O
, O
we O
studied O
T B
cell I
immunoglobulin I
mucin I
domain I
protein I
3 I
( I
Tim I
- I
3 I
) I
expression O
on O
monocytes O
and O
its O
regulatory O
effect O
on O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
/ O
IL O
- O
23 O
production O
by O
CD14 O
( O
+ O
) O
monocytes O
, O
as O
well O
as O
IL O
- O
17 O
production O
by O
CD4 O
( O
+ O
) O
T O
cells O
in O
individuals O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

We O
found O
that O
Tim O
- O
3 O
and O
IL O
- O
23p19 O
are O
highly O
expressed O
and O
that O
IL O
- O
12p35 O
is O
inhibited O
in O
human O
CD14 O
( O
+ O
) O
monocytes O
, O
while O
IL O
- O
17 O
expression O
is O
upregulated O
in O
CD4 O
( O
+ O
) O
T O
cells O
, O
in O
chronically O
HCV O
- O
infected O
individuals O
compared O
to O
healthy O
subjects O
. O

Interestingly O
, O
Tim O
- O
3 O
expression O
is O
closely O
associated O
with O
the O
differential O
regulation O
of O
IL O
- O
12 O
/ O
IL O
- O
23 O
expression O
in O
CD14 O
( O
+ O
) O
monocytes O
and O
correlated O
to O
IL O
- O
17 O
production O
by O
CD4 O
( O
+ O
) O
T O
cells O
. O

Our O
findings O
suggest O
that O
Tim O
- O
3 O
- O
mediated O
differential O
regulation O
of O
IL O
- O
12 O
/ O
IL O
- O
23 O
drives O
T O
( O
H O
) O
17 O
cell O
development O
, O
a O
milieu O
favoring O
viral O
persistence O
and O
autoimmune O
phenomenon O
during O
HCV O
infection O
. O

We O
previously O
identified O
a O
compound O
, O
5 O
- O
( O
perylen O
- O
3 O
- O
yl O
) O
ethynyl O
- O
2 O
' O
- O
deoxy O
- O
uridine O
( O
dUY11 O
) O
, O
with O
overall O
shape O
and O
amphipathicity O
similar O
to O
those O
of O
these O
phospholipids O
. O

dUY11 O
inhibited O
the O
formation O
of O
the O
negative O
curvature O
necessary O
for O
stalk O
formation O
and O
the O
fusion O
of O
a O
model O
enveloped O
virus O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

To O
test O
this O
model O
, O
we O
have O
now O
characterized O
the O
mechanisms O
against O
influenza O
virus O
and O
HCV O
of O
5 O
- O
( O
perylen O
- O
3 O
- O
yl O
) O
ethynyl O
- O
arabino O
- O
uridine O
( O
aUY11 O
) O
, O
which O
has O
shape O
and O
amphipathicity O
similar O
to O
those O
of O
dUY11 O
but O
contains O
an O
arabino O
- O
nucleoside O
. O

aUY11 O
interacted O
with O
envelope O
lipids O
to O
inhibit O
the O
infectivity O
of O
influenza O
virus O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
herpes B
simplex I
virus I
1 I
and I
2 I
( I
HSV I
- I
1 I
/ I
2 I
) I
, O
and O
other O
enveloped O
viruses O
. O

Enviroxime O
is O
an O
antipicornavirus O
compound O
that O
targets O
host O
phosphatidylinositol B
4 I
- I
kinase I
III I
beta I
( I
PI4KB I
) I
activity O
for O
its O
antipicornavirus O
activity O
. O

To O
date O
, O
several O
antipoliovirus O
( O
PV O
) O
compounds O
similar O
to O
enviroxime O
that O
are O
associated O
with O
a O
common O
resistance O
mutation O
in O
viral O
protein O
3A O
( O
a O
G5318A O
[ O
3A O
- O
Ala70Thr O
] O
mutation O
in O
PV O
) O
have O
been O
identified O
. O

Most O
of O
these O
compounds O
have O
a O
direct O
inhibitory O
effect O
on O
PI4KB O
activity O
, O
as O
well O
as O
enviroxime O
( O
designated O
major O
enviroxime O
- O
like O
compounds O
) O
. O

However O
, O
one O
of O
the O
compounds O
, O
AN O
- O
12 O
- O
H5 O
, O
showed O
no O
inhibitory O
effect O
on O
PI4KB O
and O
was O
considered O
to O
belong O
to O
another O
group O
of O
enviroxime O
- O
like O
compounds O
( O
designated O
minor O
enviroxime O
- O
like O
compounds O
) O
. O

In O
the O
present O
study O
, O
we O
performed O
a O
small B
interfering I
RNA I
( I
siRNA I
) I
sensitization O
assay O
targeting O
PI4KB O
- O
related O
genes O
and O
identified O
oxysterol B
- I
binding I
protein I
( I
OSBP I
) I
as O
a O
target O
of O
minor O
enviroxime O
- O
like O
compounds O
. O

A O
ligand O
of O
OSBP O
, O
25 O
- O
hydroxycholesterol O
( O
25 O
- O
HC O
) O
, O
acted O
as O
a O
minor O
enviroxime O
- O
like O
compound O
. O

Treatment O
of O
the O
cells O
with O
major O
or O
minor O
enviroxime O
- O
like O
compounds O
suppressed O
the O
expression O
of O
genes O
( O
HMGCS1 O
and O
SQLE O
) O
in O
the O
SREBP O
/ O
SCAP O
regulatory O
pathway O
and O
diminished O
endogenous O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
at O
the O
Golgi O
apparatus O
. O

We O
have O
determined O
the O
cleavage O
specificity O
and O
the O
crystal O
structure O
of O
the O
3C B
protease I
of I
enterovirus I
68 I
( I
EV68 I
3C I
( I
pro I
) I
) I
. O

Glu O
catalytic O
triad O
; O
its O
three O
- O
dimensional O
structure O
is O
closely O
related O
to O
that O
of O
the O
3C B
( I
pro I
) I
of O
rhinovirus O
2 O
, O
as O
well O
as O
to O
that O
of O
poliovirus O
. O

The O
phylogenetic O
position O
of O
the O
EV68 O
3C B
( I
pro I
) I
between O
the O
corresponding O
enzymes O
of O
rhinoviruses O
on O
the O
one O
hand O
and O
classical O
enteroviruses O
on O
the O
other O
prompted O
us O
to O
use O
the O
crystal O
structure O
for O
the O
design O
of O
irreversible O
inhibitors O
, O
with O
the O
goal O
of O
discovering O
broad O
- O
spectrum O
antiviral O
compounds O
. O

We O
synthesized O
a O
series O
of O
peptidic O
alpha O
, O
beta O
- O
unsaturated O
ethyl O
esters O
of O
increasing O
length O
and O
for O
each O
inhibitor O
candidate O
, O
we O
determined O
a O
crystal O
structure O
of O
its O
complex O
with O
the O
EV68 O
3C B
( I
pro I
) I
, O
which O
served O
as O
the O
basis O
for O
the O
next O
design O
round O
. O

The O
most O
potent O
inhibitor O
, O
SG85 O
, O
exhibited O
activity O
with O
EC O
( O
50 O
) O
s O
of O
approximate O
to O
180 O
nM O
against O
EV71 O
and O
approximate O
to O
60 O
nM O
against O
human O
rhinovirus O
14 O
in O
a O
live O
virus O
- O
cell O
- O
based O
assay O
. O

Even O
the O
shorter O
SG75 O
, O
spanning O
only O
P3 O
to O
P1 O
' O
, O
displayed O
significant O
activity O
( O
EC50 O
= O
2 O
to O
5 O
mu O
M O
) O
against O
various O
rhinoviruses O
. O

JC B
polyomavirus I
( I
JCV I
) I
infection O
is O
highly O
prevalent O
and O
usually O
kept O
in O
a O
persistent O
state O
without O
clinical O
signs O
and O
symptoms O
. O

It O
is O
only O
during O
immunocompromise O
and O
especially O
impaired O
CD4 O
( O
+ O
) O
T O
cell O
function O
in O
the O
brain O
, O
as O
seen O
in O
AIDS O
patients O
or O
natalizumab O
- O
treated O
multiple O
sclerosis O
patients O
, O
that O
JCV O
may O
cause O
progressive B
multifocal I
leukoencephalopathy I
( I
PML I
) I
, O
an O
often O
life O
- O
threatening O
brain O
disease O
. O

Since O
CD4 O
( O
+ O
) O
T O
cells O
likely O
play O
an O
important O
role O
in O
controlling O
JCV O
infection O
, O
we O
here O
describe O
the O
T O
cell O
response O
to O
JCV O
in O
a O
group O
of O
predominantly O
HLA O
- O
DR O
- O
heterozygotic O
healthy B
donors I
( I
HD I
) I
by O
using O
a O
series O
of O
overlapping O
15 O
- O
mer O
peptides O
spanning O
all O
JCV O
- O
encoded O
open O
reading O
frames O
. O

Four O
immunodominant O
peptides O
were O
mapped O
, O
and O
at O
least O
one O
immunogenic O
peptide O
per O
HLA O
- O
DRB1 O
allele O
was O
detected O
in O
DRB1 O
* O
01 O
( O
+ O
) O
, O
DRB1 O
* O
07 O
( O
+ O
) O
, O
DRB1 O
* O
11 O
( O
+ O
) O
, O
DRB1 O
* O
13 O
( O
+ O
) O
, O
DRB1 O
* O
15 O
( O
+ O
) O
, O
and O
DRB1 O
* O
03 O
( O
+ O
) O
individuals O
. O

Heterozygotic O
DRB1 O
* O
04 O
: O
01 O
( O
+ O
) O
individuals O
showed O
very O
low O
T O
cell O
responses O
to O
JCV O
together O
with O
normal O
anti O
- O
VP1 O
antibody O
levels O
and O
no O
urinary O
viral O
shedding O
, O
indicating O
a O
dominant O
- O
negative O
effect O
of O
this O
allele O
on O
global O
JCV O
- O
directed O
T O
cell O
responses O
. O

Coronaviruses B
( I
CoVs I
) I
are O
positive O
- O
sense O
, O
single O
- O
stranded O
, O
enveloped O
RNA O
viruses O
that O
infect O
a O
variety O
of O
vertebrate O
hosts O
. O

The O
CoV O
nucleocapsid B
( I
N I
) I
protein O
contains O
two O
structurally O
independent O
RNA O
binding O
domains O
, O
designated O
the O
N B
- I
terminal I
domain I
( I
NTD I
) I
and O
the O
dimeric O
C B
- I
terminal I
domain I
( I
CTD I
) I
, O
joined O
by O
a O
charged O
linker O
region O
rich O
in O
serine O
and O
arginine O
residues O
( O
SR O
- O
rich O
linker O
) O
. O

Here O
we O
present O
the O
solution O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
structure O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
nsp3a O
and O
show O
, O
using O
isothermal O
titration O
calorimetry O
, O
that O
MHV O
N219 O
, O
an O
N O
construct O
that O
extends O
into O
the O
SR O
- O
rich O
linker O
( O
residues O
60 O
to O
219 O
) O
, O
binds O
cognate O
nsp3a O
with O
high O
affinity O
( O
equilibrium O
association O
constant O
[ O
K O
- O
a O
] O
, O
[ O
1 O
. O

3 O
] O
x O
10 O
( O
6 O
) O
M O
- O
1 O
) O
. O

In O
contrast O
, O
neither O
N197 O
, O
an O
N O
construct O
containing O
only O
the O
folded O
NTD O
( O
residues O
60 O
to O
197 O
) O
, O
nor O
the O
CTD O
dimer O
( O
residues O
260 O
to O
380 O
) O
binds O
nsp3a O
with O
detectable O
affinity O
. O

NMR O
chemical O
shift O
perturbation O
analysis O
reveals O
that O
the O
N O
- O
terminal O
region O
of O
an O
MHV O
N O
SR O
- O
rich O
linker O
peptide O
( O
residues O
198 O
to O
230 O
) O
binds O
to O
the O
acidic O
face O
of O
MHV O
nsp3a O
containing O
the O
acidic O
alpha O
2 O
helix O
with O
an O
affinity O
( O
expressed O
as O
K O
- O
a O
) O
of O
8 O
. O

1 O
x O
10 O
( O
3 O
) O
M O
- O
1 O
. O

Chemokine O
( O
C O
- O
C O
motif O
) O
ligand O
2 O
( O
CCL2 O
) O
, O
a O
chemoattractant O
for O
macrophages O
, O
T O
cells O
, O
and O
cells O
expressing O
CCR2 O
, O
is O
upregulated O
during O
acute O
and O
chronic O
inflammation O
. O

To O
examine O
the O
role O
of O
CCL2 O
during O
virus O
infection O
, O
we O
infected O
mice O
transgenically O
expressing O
CCL2 O
in O
the O
central O
nervous O
system O
( O
CCL2 O
Tg O
) O
with O
an O
attenuated O
neurotropic O
coronavirus O
( O
rJ2 O
. O

CCL2 O
Tg O
mice O
mounted O
a O
dysregulated O
immune O
response O
, O
characterized O
by O
augmented O
accumulation O
of O
regulatory O
Foxp3 O
( O
+ O
) O
CD4 O
( O
+ O
) O
T O
cells O
and O
of O
nitric O
- O
oxide O
- O
and O
YM O
- O
1 O
- O
expressing O
macrophages O
and O
microglia O
, O
suggestive O
of O
mixed O
M1 O
/ O
M2 O
macrophage O
activation O
. O

Further O
, O
macrophages O
from O
infected O
CCL2 O
Tg O
brains O
relative O
to O
non O
- O
Tg O
controls O
were O
less O
activated O
/ O
mature O
, O
expressing O
lower O
levels O
of O
major B
histocompatibility I
complex I
class I
II I
( I
MHC I
- I
II I
) I
, O
CD86 O
, O
and O
CD40 O
. O

PARV4 O
is O
a O
small O
DNA O
human O
virus O
that O
is O
strongly O
associated O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
HIV O
infections O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
inhibiting O
autophagy O
on O
the O
growth O
of O
dengue O
virus O
was O
tested O
using O
a O
novel O
inhibitor O
, O
spautin O
- O
1 O
( O
specific O
and O
potent O
autophagy O
inhibitor O
1 O
) O
. O

Chronic O
infection O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
cause O
of O
the O
global O
burden O
of O
liver O
diseases O
. O

The O
recently O
reported O
amphipathic O
alpha O
- O
helical O
virucidal O
peptide O
( O
C5A O
) O
from O
the O
HCV O
NS5A O
protein O
suggests O
a O
new O
category O
of O
antiviral O
drug O
candidates O
. O

A O
peptide O
from O
GB B
virus I
A I
( I
GBV I
- I
A I
) I
, O
but O
not O
other O
flaviviruses O
, O
demonstrated O
an O
inhibitory O
effect O
on O
HCV O
infection O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
viroporin O
p7 O
is O
crucial O
for O
production O
of O
infectious O
viral O
progeny O
. O

To O
circumvent O
this O
obstacle O
, O
we O
inserted O
two O
consecutive O
Hemagglutinin B
( I
HA I
) I
epitope O
tags O
at O
its O
N O
terminus O
. O

In O
HCV O
- O
producing O
cells O
, O
p7 O
displayed O
a O
reticular O
staining O
pattern O
which O
colocalized O
with O
the O
HCV O
envelope B
glycoprotein I
2 I
( I
E2 I
) I
but O
also O
partially O
with O
viral O
nonstructural O
proteins O
2 O
, O
3 O
, O
and O
5A O
. O

Here O
we O
report O
that O
the O
replication O
of O
the O
arteriviruses O
equine B
arteritis I
virus I
( I
EAV I
) I
and O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
strongly O
affected O
by O
low O
- O
micromolar O
concentrations O
of O
cyclosporine B
A I
( I
CsA I
) I
, O
an O
inhibitor O
of O
members O
of O
the O
cyclophilin B
( I
Cyp I
) I
family O
. O

In O
infected O
cells O
, O
the O
expression O
of O
a O
green B
fluorescent I
protein I
( I
GFP I
) I
reporter O
gene O
inserted O
into O
the O
PRRSV O
genome O
was O
inhibited O
with O
a O
half B
- I
maximal I
inhibitory I
concentration I
( I
IC50 I
) I
of O
5 O
. O

The O
prevalence O
of O
naturally O
occurring O
hepatitis B
C I
virus I
( I
HCV I
) I
variants O
that O
are O
less O
sensitive O
to O
direct B
- I
acting I
antiviral I
( I
DAA I
) I
inhibitors O
has O
not O
been O
fully O
characterized O
. O

In O
general O
, O
HCV O
variants O
with O
lower O
- O
level O
resistance O
( O
3 O
- O
to O
25 O
- O
fold O
increased O
50 O
% O
inhibitor O
concentration O
[ O
IC50 O
] O
) O
to O
telaprevir O
were O
observed O
as O
the O
dominant O
species O
in O
0 O
to O
3 O
% O
of O
patients O
, O
depending O
on O
the O
specific O
variant O
, O
whereas O
higher O
- O
level O
resistant O
variants O
( O
> O
25 O
- O
fold O
- O
increased O
IC50 O
) O
were O
not O
observed O
. O

Most O
variants O
resistant O
to O
nucleo O
( O
s O
/ O
t O
) O
ide O
active O
- O
site O
NS5B O
polymerase O
inhibitors O
were O
not O
observed O
, O
whereas O
variants O
resistant O
to O
non O
- O
nucleoside O
allosteric O
inhibitors O
were O
observed O
in O
up O
to O
18 O
% O
of O
patients O
. O

The O
presence O
of O
DAA O
- O
resistant O
variants O
in O
NS5A O
, O
NS5B O
, O
or O
NS3 O
( O
including O
telaprevir O
- O
resistant O
variants O
) O
, O
in O
baseline O
samples O
of O
treatment O
- O
naive O
patients O
receiving O
a O
telaprevir O
- O
based O
regimen O
in O
phase O
3 O
studies O
did O
not O
affect O
the O
sustained B
viral I
response I
( I
SVR I
) I
. O

Although O
the O
second O
protein O
, O
which O
carries O
the O
membrane O
fusion O
function O
, O
is O
in O
general O
well O
characterized O
, O
the O
companion O
protein O
, O
which O
is O
a O
protein O
chaperone O
for O
the O
folding O
of O
the O
fusion O
protein O
, O
is O
less O
well O
characterized O
for O
some O
viruses O
, O
like O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
does O
not O
replicate O
efficiently O
in O
wild O
- O
type O
human O
hepatoma O
Huh O
- O
7 O
cells O
, O
but O
it O
replicates O
robustly O
in O
certain O
subclones O
of O
Huh O
- O
7 O
cells O
. O

Previously O
, O
we O
demonstrated O
that O
silencing O
of O
cyclic B
AMP I
( I
cAMP I
) I
response O
element O
binding O
protein O
3 O
- O
like O
1 O
( O
CREB3L1 O
) O
, O
a O
cellular O
transcription O
factor O
that O
inhibits O
HCV O
replication O
, O
allows O
HCV O
to O
replicate O
in O
HRP1 O
cells O
, O
a O
subclone O
of O
Huh O
- O
7 O
cells O
permissive O
for O
HCV O
replication O
. O

Here O
we O
show O
that O
silencing O
of O
myxovirus B
resistant I
1 I
( I
MX1 I
) I
, O
a O
known O
interferon O
- O
induced O
antiviral O
gene O
, O
is O
responsible O
for O
HRP4 O
cells O
, O
another O
subclone O
of O
Huh O
- O
7 O
cells O
, O
being O
permissive O
for O
HCV O
replication O
. O

In O
the O
human O
hepatoma O
cell O
line O
HepG2 O
, O
retinoic O
acid O
, O
clofibric O
acid O
, O
and O
bile O
acid O
treatment O
can O
only O
modestly O
increase O
hepatitis B
B I
virus I
( I
HBV I
) I
biosynthesis O
. O

Utilizing O
the O
human O
embryonic O
kidney O
cell O
line O
293T O
, O
it O
was O
possible O
to O
demonstrate O
that O
the O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
plus O
its O
ligand O
can O
support O
viral O
biosynthesis O
independently O
of O
additional O
nuclear O
receptors O
. O

In O
addition O
, O
RXR O
alpha O
/ O
peroxisome B
proliferator I
- I
activated I
receptor I
alpha I
( I
PPAR I
alpha I
) I
and O
RXR O
alpha O
/ O
farnesoid B
X I
receptor I
alpha I
( I
FXR I
alpha I
) I
heterodimeric O
nuclear O
receptors O
can O
also O
mediate O
ligand O
- O
dependent O
HBV O
transcription O
and O
replication O
when O
activated O
by O
clofibric O
acid O
and O
bile O
acid O
, O
respectively O
, O
independently O
of O
a O
requirement O
for O
the O
ligand O
- O
dependent O
activation O
of O
RXR O
alpha O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
binds O
to O
the O
40S O
ribosomal O
subunit O
and O
inhibits O
translation O
, O
and O
it O
also O
induces O
a O
template O
- O
dependent O
endonucleolytic O
cleavage O
of O
host O
mRNAs O
. O

nsp1 O
inhibits O
the O
translation O
of O
cap O
- O
dependent O
and O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
driven O
mRNAs O
, O
including O
SARS O
coronavirus O
mRNAs O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
and O
cricket B
paralysis I
virus I
( I
CrPV I
) I
IRES O
- O
driven O
mRNAs O
that O
are O
resistant O
to O
nsp1 O
- O
induced O
RNA O
cleavage O
. O

We O
used O
an O
nsp1 O
mutant O
, O
nsp1 O
- O
CD O
, O
lacking O
the O
RNA O
cleavage O
function O
, O
to O
delineate O
the O
mechanism O
of O
nsp1 O
- O
mediated O
translation O
inhibition O
and O
identify O
the O
translation O
step O
( O
s O
) O
targeted O
by O
nsp1 O
. O

We O
report O
here O
the O
complete O
genome O
sequence O
of O
a O
novel O
duck B
hepatitis I
A I
virus I
type I
3 I
( I
DHAV I
- I
3 I
) I
isolated O
from O
a O
dead O
Cherry O
Valley O
duckling O
in O
eastern O
China O
. O

Extraordinary O
viral O
sequence O
diversity O
and O
rapid O
viral O
genetic O
evolution O
are O
hallmarks O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Viral O
sequence O
evolution O
has O
previously O
been O
shown O
to O
mediate O
escape O
from O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
and O
neutralizing O
antibody O
responses O
in O
acute O
HCV O
infection O
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
indispensable O
component O
of O
the O
HCV O
replication O
and O
assembly O
machineries O
. O

Although O
its O
precise O
mechanism O
of O
action O
is O
not O
yet O
clear O
, O
current O
evidence O
indicates O
that O
its O
structure O
and O
function O
are O
regulated O
by O
the O
cellular B
peptidylprolyl I
isomerase I
cyclophilin I
A I
( I
CyPA I
) I
. O

Cyclophilin B
inhibitors I
( I
CPIs I
) I
, O
including O
Cyclosporine B
( I
CsA I
) I
and O
its O
nonimmunosuppressive O
derivatives O
, O
inhibit O
HCV O
infection O
of O
diverse O
genotypes O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

Although O
the O
interaction O
between O
NS5A O
and O
other O
viral O
proteins O
is O
not O
affected O
by O
CPIs O
, O
RNA O
binding O
by O
NS5A O
in O
cell B
culture I
- I
based I
HCV I
( I
HCVcc I
) I
- O
infected O
cells O
is O
significantly O
inhibited O
by O
CPI O
treatment O
, O
and O
sensitivity O
of O
RNA O
binding O
is O
correlated O
with O
previously O
characterized O
CyPA O
dependence O
or O
CsA O
sensitivity O
of O
HCV O
mutants O
. O

The O
E2 O
envelope O
glycoprotein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
binds O
to O
the O
host O
entry O
factor O
CD81 O
and O
is O
the O
principal O
target O
for O
neutralizing B
antibodies I
( I
NAbs I
) I
. O

We O
have O
determined O
the O
crystal O
structure O
of O
the O
broadly B
neutralizing I
antibody I
( I
bnAb I
) I
AP33 O
, O
bound O
to O
a O
peptide O
corresponding O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
envelope O
glycoprotein O
antigenic O
site O
412 O
to O
423 O
. O

We O
report O
here O
the O
complete O
genome O
sequence O
of O
a O
duck O
astrovirus O
( O
DAstV O
) O
isolated O
from O
a O
dead O
duckling O
in O
eastern O
China O
. O

Previously O
we O
demonstrated O
that O
antibody O
- O
mediated O
thrombocytopenia O
is O
strongly O
enhanced O
by O
lactate B
dehydrogenase I
- I
elevating I
virus I
( I
LDV I
) I
infection O
. O

Phosphatidylinositol B
- I
4 I
- I
kinase I
III I
alpha I
( I
PI4KIII I
alpha I
) I
is O
an O
essential O
host O
cell O
factor O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

This O
genetic O
bottlenecking O
is O
observed O
during O
hepatitis B
C I
virus I
( I
HCV I
) I
transmission O
and O
can O
arise O
via O
a O
selective O
sweep O
or O
through O
the O
founder O
effect O
. O

E1E2 O
glycoprotein O
gene O
sequences O
in O
the O
donor O
inoculum O
and O
recipient O
mice O
were O
determined O
following O
single B
- I
genome I
amplification I
( I
SGA I
) I
. O

Notably O
, O
all O
posttransmission O
E1E2s O
had O
lost O
a O
Potential B
N I
- I
linked I
glycosylation I
site I
( I
PNGS I
) I
in O
E2 O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
( O
SCoV O
) O
is O
an O
enveloped O
virus O
containing O
a O
single O
- O
stranded O
, O
positive O
- O
sense O
RNA O
genome O
. O

Nine O
mRNAs O
carrying O
a O
set O
of O
common O
5 O
' O
and O
3 O
' O
untranslated B
regions I
( I
UTR I
) I
are O
synthesized O
from O
the O
incoming O
viral O
genomic O
RNA O
in O
cells O
infected O
with O
SCoV O
. O

An O
RNA O
- O
protein O
binding O
assay O
and O
RNA O
decay O
assay O
revealed O
that O
nsp1 O
bound O
to O
stem B
- I
loop I
1 I
( I
SL1 I
) I
in O
the O
5 O
' O
UTR O
of O
SCoV O
RNA O
and O
that O
the O
specific O
interaction O
with O
nsp1 O
stabilized O
the O
mRNA O
carrying O
SL1 O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
highly O
pathogenic O
Phlebovirus O
that O
infects O
humans O
and O
ruminants O
. O

To O
identify O
parameters O
of O
the O
CD4 O
response O
that O
may O
contribute O
to O
viral O
control O
rather O
than O
merely O
reflect O
a O
persistently O
low O
viremia O
, O
we O
compared O
the O
T O
helper O
profiles O
in O
two O
groups O
of O
patients O
with O
more O
than O
10 O
years O
of O
viral O
suppression O
: O
HIV O
controllers O
from O
the O
Agence O
Nationale O
de O
Recherche O
sur O
le O
SIDA O
et O
les O
Hepatites O
Virales O
( O
ANRS O
) O
CO18 O
cohort O
( O
n O
= O
26 O
) O
and O
efficiently O
treated O
patients O
( O
n O
= O
16 O
) O
. O

Cells O
specific O
for O
immunodominant O
Gag O
and O
cytomegalovirus B
( I
CMV I
) I
peptides O
were O
evaluated O
for O
the O
production O
of O
10 O
cytokines O
and O
cytotoxicity O
markers O
and O
were O
also O
directly O
quantified O
ex O
vivo O
by O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
tetramer O
staining O
. O

HIV O
controller O
CD4 O
( O
+ O
) O
T O
cells O
were O
characterized O
by O
a O
higher O
frequency O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
, O
perforin O
( O
+ O
) O
/ O
CD107a O
( O
+ O
) O
expression O
, O
and O
polyfunctionality O
in O
response O
to O
Gag O
peptides O
. O

While O
interleukin B
4 I
( I
IL I
- I
4 I
) I
, O
IL O
- O
17 O
, O
and O
IL O
- O
21 O
production O
did O
not O
differ O
between O
groups O
, O
the O
cells O
of O
treated O
patients O
produced O
more O
IL O
- O
10 O
in O
response O
to O
Gag O
and O
CMV O
peptides O
, O
pointing O
to O
persistent O
negative O
immunoregulation O
after O
long O
- O
term O
antiretroviral O
therapy O
. O

12 O
% O
) O
and O
correlated O
positively O
with O
IFN O
- O
gamma O
- O
producing O
CD4 O
( O
+ O
) O
T O
cells O
in O
the O
controller O
group O
( O
R O
= O
0 O
. O

Tetramer O
- O
positive O
cells O
were O
fewer O
in O
the O
highly B
active I
antiretroviral I
therapy I
( I
HAART I
) I
group O
( O
0 O
. O

04 O
% O
) O
and O
did O
not O
correlate O
with O
IFN O
- O
gamma O
production O
, O
supporting O
the O
notion O
of O
a O
persistent O
immune O
dysfunction O
in O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
of O
treated O
patients O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
hepatotropic O
virus O
that O
can O
cause O
severe O
liver O
diseases O
. O

By O
conducting O
studies O
using O
four O
different O
transgenic O
mouse O
lines O
that O
carry O
either O
the O
wild O
- O
type O
HBV O
genome O
or O
the O
HBV O
genome O
incapable O
of O
expressing O
the O
X O
gene O
, O
we O
found O
that O
liver O
injury O
and O
regeneration O
induced O
by O
a O
partial B
hepatectomy I
( I
PHx I
) I
could O
have O
different O
effects O
on O
HBV O
replication O
depending O
on O
the O
mouse O
lines O
. O

These O
effects O
of O
liver O
injury O
and O
regeneration O
on O
HBV O
were O
independent O
of O
the O
HBV O
X O
protein O
and O
apparently O
due O
to O
alpha O
and O
beta O
interferons O
( O
IFN O
- O
alpha O
/ O
beta O
) O
, O
as O
the O
effects O
could O
be O
abolished O
by O
the O
injection O
of O
anti O
- O
IFN O
- O
alpha O
/ O
beta O
antibodies O
. O

Further O
analysis O
indicated O
that O
PHx O
could O
induce O
the O
expression O
of O
hepatocyte B
nuclear I
factor I
3 I
gamma I
( I
HNF3 I
gamma I
) I
when O
viral O
load O
was O
low O
and O
activate O
the O
signal B
transducer I
and I
activator I
of I
transcription I
3 I
( I
STAT3 I
) I
and O
suppress O
the O
expression O
of O
the O
suppressor B
of I
cytokine I
signaling I
3 I
( I
SOCS3 I
) I
irrespective O
of O
viral O
load O
. O

Hepadnaviral O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
exists O
as O
an O
episomal O
minichromosome O
in O
the O
nucleus O
of O
virus O
- O
infected O
hepatocytes O
, O
and O
serves O
as O
the O
transcriptional O
template O
for O
the O
synthesis O
of O
viral O
mRNAs O
. O

To O
obtain O
insight O
on O
the O
structure O
of O
hepadnaviral O
cccDNA O
minichromosomes O
, O
we O
utilized O
ducks O
infected O
with O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
as O
a O
model O
and O
determined O
the O
in O
vivo O
nucleosome O
distribution O
pattern O
on O
viral O
cccDNA O
by O
the O
micrococcal B
nuclease I
( I
MNase I
) I
mapping O
and O
genome O
- O
wide O
PCR O
amplification O
of O
isolated O
mononucleosomal O
DHBV O
DNA O
. O

Several O
nucleosome O
- O
protected O
sites O
in O
a O
region O
of O
the O
DHBV O
genome O
[ O
nucleotides B
( I
nt I
) I
2000 O
to O
27001 O
, O
known O
to O
harbor O
various O
cis O
transcription O
regulatory O
elements O
, O
were O
consistently O
identified O
in O
all O
DHBV O
- O
positive O
liver O
samples O
. O

The O
hepatitis B
E I
virus I
( I
HEV I
) I
polyproline I
region I
( I
PPR I
) I
is O
an O
intrinsically B
unstructured I
region I
( I
IDR I
) I
. O

We O
report O
here O
the O
complete O
genomic O
sequence O
of O
a O
novel O
duck B
hepatitis I
A I
virus I
( I
DHAV I
) I
isolated O
from O
mixed O
infections O
with O
DHAV B
type I
1 I
( I
DHAV I
- I
1 I
) I
and O
DHAV O
- O
3 O
in O
ducklings O
in O
Southern O
China O
. O

The O
whole O
nucleotide O
sequence O
had O
the O
highest O
homology O
with O
the O
sequence O
of O
DHAV O
- O
3 O
( O
GenBank O
accession O
number O
DQ812093 O
) O
( O
96 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
causes O
chronic O
liver O
disease O
, O
cirrhosis O
, O
and O
primary O
liver O
cancer O
. O

The O
HCV O
E2 O
glycoprotein O
recognizes O
CD81 O
through O
a O
dynamic O
loop O
on O
the O
helical O
bundle O
, O
which O
was O
shown O
by O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
spectroscopy O
to O
adopt O
a O
conformation O
distinct O
from O
that O
seen O
in O
crystals O
. O

Innate O
defenses O
are O
triggered O
when O
pattern B
recognition I
receptor I
( I
PRR I
) I
proteins O
of O
the O
host O
cell O
engage O
pathogen B
- I
associated I
molecule I
patterns I
( I
PAMPs I
) I
present O
in O
viral O
products O
. O

interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
plays O
a O
central O
role O
in O
PRR O
signaling O
of O
innate O
immunity O
to O
drive O
the O
expression O
of O
type B
I I
interferon I
( I
IFN I
) I
and O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
including O
a O
variety O
of O
HIV O
restriction O
factors O
, O
that O
serve O
to O
limit O
viral O
replication O
directly O
and O
/ O
or O
program O
adaptive O
immunity O
. O

Modulation O
of O
translation O
initiation O
efficiency O
on O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
RNA O
can O
be O
achieved O
by O
targeted O
mutations O
within O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

In O
this O
study O
, O
cDNAs O
corresponding O
to O
the O
wild B
- I
type I
( I
WT I
) I
or O
mutant O
forms O
of O
the O
IRES O
of O
CSFV O
strain O
Paderborn O
were O
amplified O
and O
inserted O
into O
dicistronic O
reporter O
plasmids O
encoding O
Fluc O
and O
Rluc O
under O
the O
control O
of O
a O
T7 O
promoter O
. O

The O
mutations O
were O
within O
domains O
II O
, O
IIId O
( O
1 O
) O
, O
and O
IIIf O
of O
the O
IRES O
. O

The O
plasmids O
were O
transfected O
into O
baby B
hamster I
kidney I
( I
BHK I
) I
cells O
infected O
with O
recombinant O
vaccinia O
virus O
vTF7 O
- O
3 O
, O
which O
expresses O
the O
T7 O
RNA O
polymerase O
. O

IRES O
mutants O
with O
different O
levels O
of O
IRES O
activity O
were O
identified O
and O
then O
introduced O
by O
homologous O
recombination O
into O
bacterial B
artificial I
chromosomes I
( I
BACs I
) I
containing O
CSFV O
Paderborn O
cDNA O
downstream O
of O
a O
T7 O
promoter O
. O

Processing B
bodies I
( I
P I
- I
bodies I
) I
are O
highly O
dynamic O
cytoplasmic O
granules O
conserved O
among O
eukaryotes O
. O

They O
are O
present O
under O
normal O
growth O
conditions O
and O
contain O
translationally O
repressed O
mRNAs O
together O
with O
proteins O
from O
the O
mRNA O
decay O
and O
microRNA B
( I
miRNA I
) I
machineries O
. O

We O
have O
previously O
shown O
that O
the O
core O
P O
- O
body O
components O
PatL1 O
, O
LSm1 O
, O
and O
DDX6 O
( O
Rck O
/ O
p54 O
) O
are B
required I
for I
hepatitis I
C I
virus I
( I
HCV I
) I
RNA O
replication O
; O
however O
, O
how O
HCV O
infection O
affects O
P O
- O
body O
granules O
and O
whether O
P O
- O
body O
granules O
per O
se O
influence O
the O
HCV O
life O
cycle O
remain O
unresolved O
issues O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
previously O
been O
reported O
to O
bind O
to O
human O
red O
blood O
cells O
through O
interaction O
with O
glycophorin O
A O
. O

We O
also O
tested O
whether O
memory O
and O
exhausted O
CD8 O
T O
cells O
arose O
from O
different O
subpopulations O
of O
effector O
CD8 O
T O
cells O
and O
found O
that O
only O
the O
KLRG1 O
( O
lo O
) O
memory O
precursor O
subset O
gave O
rise O
to O
exhausted O
CD8 O
T O
cells O
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
is O
essential O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
and O
assembly O
and O
is O
a O
critical O
drug O
target O
. O

We O
used O
fluorescence B
resonance I
energy I
transfer I
( I
FRET I
) I
to O
probe O
whether O
or O
not O
different O
regions O
of O
NS5A O
are O
in O
close O
proximity O
within O
the O
cell O
. O

Overall O
, O
this O
assay O
provides O
a O
new O
window O
on O
the O
intracellular O
conformation O
( O
s O
) O
of O
NS5A O
and O
how O
the O
conformation O
changes O
in O
response O
to O
cellular O
and O
viral O
components O
of O
the O
replication O
and O
assembly O
complex O
as O
well O
as O
antiviral O
drugs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
induces O
autophagosome O
formation O
in O
infected O
human O
hepatocytes O
. O

mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
is O
a O
positive O
regulator O
of O
cell O
growth O
and O
is O
recognized O
as O
an O
inhibitor O
of O
autophagy O
induction O
. O

Endogenous O
hepadnaviruses O
( O
hepatitis O
B O
viruses O
[ O
HBVs O
] O
) O
were O
recently O
discovered O
in O
the O
genomes O
of O
passerine O
birds O
. O

We O
mined O
six O
additional O
avian O
genomes O
and O
discovered O
multiple O
copies O
of O
endogenous O
HBVs O
in O
the O
budgerigar O
( O
order O
Psittaciformes O
) O
, O
designated O
eBHBV O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS5B O
protein O
is O
an O
RNA O
- O
dependent O
RNA O
polymerase O
essential O
for O
replication O
of O
the O
viral O
RNA O
genome O
. O

We O
also O
recently O
published O
a O
combined O
structural O
and O
functional O
analysis O
of O
genotype O
2 O
HCV O
- O
NS5B O
proteins O
( O
of O
strains O
JFH1 O
and O
J6 O
) O
that O
established O
residue O
405 O
as O
a O
key O
element O
in O
de O
novo O
RNA O
synthesis O
( O
P O
. O

Using O
high O
- O
throughput O
screening O
methods O
, O
including O
computational O
docking O
studies O
and O
an O
interferon O
- O
stimulated O
gene O
54 O
( O
ISG54 O
) O
- O
luciferase O
reporter O
assay O
, O
we O
identified O
a O
class O
of O
isoflavone O
compounds O
that O
act O
as O
specific O
agonists O
of O
innate O
immune O
signaling O
pathways O
and O
cause O
activation O
of O
the O
interferon B
regulatory I
factor I
( I
IRF I
- I
3 I
) I
transcription O
factor O
. O

The O
isoflavone O
compounds O
activated O
the O
ISG54 O
promoter O
, O
mediated O
nuclear O
translocation O
of O
IRF O
- O
3 O
, O
and O
displayed O
highly O
potent O
activity O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
influenza O
virus O
. O

Replication O
and O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
depend O
on O
the O
host O
' O
s O
secretory O
and O
lipid O
- O
biosynthetic O
machinery O
. O

Viral O
replication O
occurs O
on O
endoplasmic B
reticulum I
( I
ER I
) I
- O
derived O
modified O
membranes O
, O
while O
viral O
assembly O
is O
thought O
to O
occur O
on O
lipid B
droplets I
( I
LDs I
) I
. O

Nonstructural B
protein I
5A I
( I
NS5A I
) I
, O
which O
localizes O
both O
to O
the O
ER O
and O
LDs O
, O
is O
an O
ideal O
candidate O
for O
this O
function O
. O

In O
cells O
, O
expression O
of O
the O
Rab1 B
dominant I
negative I
( I
Rab1DN I
) I
GTPase O
mutant O
abolished O
steady O
- O
state O
LDs O
. O

The O
replication O
of O
the O
hepatitis O
C O
viral O
( O
HCV O
) O
genome O
is O
accomplished O
by O
the O
NS5B O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
for O
which O
mechanistic O
understanding O
and O
structure O
- O
guided O
drug O
design O
efforts O
have O
been O
hampered O
by O
its O
propensity O
to O
crystallize O
in O
a O
closed O
, O
polymerization O
- O
incompetent O
state O
. O

The O
hepadnavirus O
reverse B
transcriptase I
( I
RT I
) I
has O
the O
unique O
ability O
to O
initiate O
viral O
DNA O
synthesis O
using O
RT O
itself O
as O
a O
protein O
primer O
. O

Protein O
priming O
requires O
complex O
interactions O
between O
the O
N O
- O
terminal O
TP B
( I
terminal I
protein I
) I
domain O
, O
where O
the O
primer O
( O
a O
specific O
Y O
residue O
) O
resides O
, O
and O
the O
central O
RT O
domain O
, O
which O
harbors O
the O
polymerase O
active O
site O
. O

While O
it O
normally O
utilizes O
the O
cis O
- O
linked O
TP O
to O
prime O
DNA O
synthesis O
( O
cis O
- O
priming O
) O
, O
we O
found O
that O
the O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
RT O
domain O
, O
in O
the O
context O
of O
the O
full O
- O
length O
RT O
protein O
or O
a O
mini O
- O
RT O
construct O
containing O
only O
truncated O
TP O
and O
RT O
domains O
, O
could O
additionally O
use O
a O
separate O
TP O
or O
RT O
domain O
in O
trans O
as O
a O
primer O
( O
trans O
- O
priming O
) O
. O

trans O
interaction O
could O
also O
be O
demonstrated O
by O
the O
inhibitory O
effect O
( O
trans O
- O
inhibition O
) O
on O
cis O
- O
priming O
by O
TP O
and O
RT O
domain O
sequences O
provided O
in O
trans O
. O

The O
nonstructural O
protein O
p7 O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
is O
a O
small O
hydrophobic O
polypeptide O
with O
an O
apparent O
molecular O
mass O
of O
6 O
to O
7 O
kDa O
. O

Mutations O
in O
the O
genes O
that O
encode O
Fas O
or O
Fas B
ligand I
( I
FasL I
) I
can O
result O
in O
poor O
restraints O
on O
lymphocyte O
activation O
and O
in O
increased O
susceptibility O
to O
autoimmune O
disorders O
. O

To O
examine O
this O
possibility O
, O
the O
immune O
response O
to O
, O
morbidity O
caused O
by O
, O
and O
clearance O
of O
vaccinia B
virus I
( I
VACV I
) I
Western O
Reserve O
was O
examined O
in O
5 O
- O
to O
7 O
- O
week O
- O
old O
Fas O
mutant O
( O
lpr O
) O
mice O
, O
before O
an O
overt O
lymphoproliferative O
disorder O
was O
observable O
. O

On O
day O
6 O
after O
VACV O
infection O
, O
C57BL O
/ O
6 O
- O
lpr O
( O
B6 O
- O
lpr O
) O
mice O
had O
decreased O
morbidity O
, O
decreased O
viral O
titers O
, O
and O
an O
increased O
percentage O
and O
number O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

As O
early O
as O
day O
2 O
after O
infection O
, O
B6 O
- O
lpr O
mice O
had O
decreased O
liver O
and O
spleen O
viral O
titers O
and O
increased O
numbers O
of O
and O
increased O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
by O
several O
different O
effector O
cell O
populations O
. O

Uninfected O
B6 O
- O
lpr O
mice O
also O
had O
increased O
numbers O
of O
NK O
cells O
, O
gamma O
delta O
( O
+ O
) O
T O
cells O
, O
and O
CD44 O
( O
+ O
) O
CD4 O
( O
+ O
) O
and O
CD44 O
( O
+ O
) O
CDS O
+ O
T O
cells O
compared O
to O
uninfected O
B6 O
mice O
. O

The O
mechanisms O
of O
induction O
of O
liver O
injury O
during O
chronic O
infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
not O
well O
understood O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
inducible B
protein I
10 I
( I
IP I
- I
10 I
) I
, O
a O
member O
of O
the O
CXC O
chemokine O
family O
, O
is O
expressed O
in O
the O
liver O
of O
chronic B
hepatitis I
C I
( I
CHC I
) I
patients O
and O
selectively O
recruits O
activated O
T O
cells O
to O
the O
sites O
of O
inflammation O
. O

In O
this O
study O
, O
we O
examined O
the O
role O
of O
the O
Toll B
- I
like I
receptor I
( I
TLR I
) I
pathway O
on O
IP O
- O
10 O
production O
in O
cells O
replicating O
HCV O
. O

CD44 O
is O
a O
broadly O
distributed O
type O
I O
transmembrane O
glycoprotein O
and O
a O
receptor O
for O
the O
glycosaminoglycan O
hyaluronan B
( I
HA I
) I
. O

Here O
, O
we O
show O
that O
autophagosomes O
accumulate O
in O
Semliki B
Forest I
virus I
( I
SFV I
) I
- O
infected O
cells O
. O

Coronaviruses O
induce O
in O
infected O
cells O
the O
formation O
of O
replicative O
structures O
, O
consisting O
of O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
and O
convoluted O
membranes O
, O
where O
viral O
RNA O
synthesis O
supposedly O
takes O
place O
and O
to O
which O
the O
nonstructural B
proteins I
( I
nsp I
' I
s I
) I
localize O
. O

double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
the O
presumed O
intermediate O
in O
RNA O
synthesis O
, O
is O
localized O
to O
the O
DMV O
interior O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
research O
is O
hampered O
by O
the O
use O
of O
arbitrary O
representative O
isolates O
in O
cell O
culture O
and O
immunology O
. O

The O
most O
replicative O
isolate O
in O
vitro O
is O
a O
subtype O
2a O
virus O
( O
JFH O
- O
1 O
) O
; O
however O
, O
genotype O
1 O
is O
more O
prevalent O
worldwide O
and O
represents O
about O
70 O
% O
of O
infections O
in O
the O
United O
States O
, O
and O
genotypes O
differ O
from O
one O
another O
by O
31 O
% O
to O
33 O
% O
at O
the O
nucleotide O
level O
. O

For O
phylogenetic O
and O
immunologic O
analyses O
, O
viruses O
H77 O
and O
HCV O
- O
1 O
( O
both O
subtype O
la O
) O
are O
commonly O
used O
based O
on O
their O
historic O
importance O
. O

In O
an O
effort O
to O
rationally O
design O
a O
representative O
subtype O
la O
virus O
( O
Bole1a O
) O
, O
we O
used O
Bayesian O
phylogenetics O
, O
ancestral O
sequence O
reconstruction O
, O
and O
covariance O
analysis O
on O
a O
curated O
set O
of O
390 O
full O
- O
length O
human O
HCV O
la O
sequences O
from O
GenBank O
. O

In O
a O
proof O
of O
concept O
for O
infectivity O
, O
the O
envelope O
genes O
( O
E1 O
and O
E2 O
) O
of O
Bole1a O
were O
expressed O
in O
an O
HIV O
pseudoparticle O
system O
containing O
HCV O
envelope O
genes O
and O
HIV O
nonenvelope O
genes O
with O
luciferase O
expression O
. O

Coronaviruses B
( I
CoVs I
) I
carry O
genes O
that O
encode O
an O
nsp5 O
protease O
( O
also O
known O
as O
3CLpro O
or O
Mpro O
) O
responsible O
for O
11 O
maturation O
cleavages O
. O

The O
nsp5 O
structure O
contains O
two O
chymotrypsin O
- O
like O
domains O
( O
D1 O
and O
D2 O
) O
and O
a O
unique O
domain O
( O
D3 O
) O
, O
and O
forms O
functional O
dimers O
. O

Using O
reverse O
genetic O
mutagenesis O
of O
the O
CoV O
murine B
hepatitis I
virus I
( I
MHV I
) I
nsp5 O
, O
we O
identified O
a O
new O
temperature B
- I
sensitive I
( I
ts I
) I
mutation O
in O
D2 O
of O
nsp5 O
( O
Ser133Ala O
) O
and O
confirmed O
a O
ts O
residue O
in O
D3 O
( O
Phe219Leu O
) O
. O

Analysis O
of O
multiple O
CoV O
nsp5 O
structures O
, O
and O
alignment O
of O
nonredundant O
nsp5 O
primary O
sequences O
, O
demonstrated O
that O
ts O
and O
suppressor O
residues O
are O
not O
conserved O
across O
CoVs O
and O
are O
physically O
distant O
( O
> O
10 O
angstrom O
) O
from O
each O
other O
, O
from O
catalytic O
and O
substrate O
- O
binding O
residues O
, O
and O
from O
the O
nsp5 O
dimer O
interface O
. O

cyclophilin B
A I
( I
CypA I
) I
and O
its O
peptidyl B
- I
prolyl I
isomerase I
( I
PPIase I
) I
activity O
play O
an O
essential O
role O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
, O
and O
mounting O
evidence O
indicates O
that O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
is O
the O
major O
target O
of O
CyPA O
. O

However O
, O
neither O
a O
consensus O
CyPA O
- O
binding O
motif O
nor O
specific O
proline O
substrates O
that O
regulate O
CyPA O
dependence O
and O
sensitivity O
to O
Cyclophilin B
inhibitors I
( I
CPIs I
) I
have O
been O
defined O
to O
date O
. O

We O
systematically O
characterized O
all O
proline O
residues O
in O
NS5A O
domain O
II O
, O
low B
- I
complexity I
sequence I
II I
( I
LCS I
- I
II I
) I
, O
and O
domain O
III O
with O
both O
biochemical O
binding O
and O
functional O
replication O
assays O
. O

The O
first O
site O
contains O
a O
consensus O
sequence O
motif O
of O
AOPXW O
( O
where O
O O
is O
a O
hydrophobic O
residue O
) O
that O
is O
highly O
conserved O
in O
the O
majority O
of O
the O
genotypes O
of O
HCV O
( O
six O
of O
seven O
; O
the O
remaining O
genotype O
has O
VOPXW O
) O
. O

The O
two O
prolines O
( O
P310 O
and O
P341 O
of O
Japanese O
fulminant O
hepatitis O
1 O
[ O
JFH O
- O
1 O
] O
) O
contained O
in O
these O
motifs O
, O
as O
well O
as O
a O
conserved O
tryptophan O
in O
the O
spacer O
region O
, O
were O
required O
for O
CyPA O
binding O
, O
HCV O
replication O
, O
and O
CPI O
resistance O
. O

The O
p7 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
viroporin O
that O
is O
dispensable O
for O
viral O
genome O
replication O
but O
plays O
a O
critical O
role O
in O
virus O
morphogenesis O
. O

In O
this O
study O
, O
we O
generated O
a O
JFH1 O
- O
based O
intergenotypic O
chimeric O
genome O
that O
encoded O
a O
heterologous O
genotype B
1b I
( I
GT1b I
) I
p7 O
. O

Sequence O
analysis O
of O
the O
entire O
polyprotein O
- O
coding O
region O
of O
the O
recovered O
chimeric O
virus O
revealed O
one O
predominant O
amino O
acid O
substitution O
in O
nonstructural B
protein I
2 I
( I
NS2 I
) I
, O
T23N O
, O
and O
one O
in O
NS5B O
, O
K151R O
. O

High O
- O
risk O
human B
papillomavirus I
type I
16 I
( I
HPV16 I
) I
is O
the O
primary O
causative O
agent O
of O
cervical O
cancer O
and O
therefore O
is O
responsible O
for O
significant O
morbidity O
and O
mortality O
worldwide O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replicates O
in O
hepatic O
cells O
by O
forming O
a O
replication O
complex O
on O
the O
lipid O
raft O
( O
detergent O
- O
resistant O
membrane O
[ O
DRM O
] O
) O
. O

Replication O
complex O
formation O
requires O
various O
viral O
nonstructural B
( I
NS I
) I
proteins O
as O
well O
as O
host O
cellular O
proteins O
. O

82 O
: O
8838 O
- O
8848 O
, O
2008 O
) O
, O
we O
found O
that O
a O
cellular O
protein O
, O
annexin B
A2 I
( I
ANXA2 I
) I
, O
interacts O
with O
NS3 O
/ O
NS4A O
. O

Subcellular O
fractionation O
and O
bimolecular O
fluorescence O
complementation O
analysis O
revealed O
that O
Anxa2 O
was O
partially O
associated O
with O
HCV O
at O
the O
lipid O
raft O
enriched O
with O
phosphatidylinositol B
- I
4 I
- I
phosphate I
( I
PI4P I
) I
and O
caveolin O
- O
2 O
. O

Sequence O
analysis O
revealed O
a O
retinoblastoma O
protein O
- O
binding O
motif O
( O
LXCXE O
/ O
D O
) O
in O
the O
majority O
of O
the O
Nsp15 O
of O
the O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
and O
its O
orthologs O
in O
the O
alpha O
and O
beta O
coronaviruses O
. O

The O
endoribonuclease O
activity O
of O
the O
SARS B
- I
CoV I
Nsp15 I
( I
sNsp15 I
) I
was O
stimulated O
by O
retinoblastoma B
protein I
( I
pRB I
) I
in O
vitro O
, O
and O
the O
two O
proteins O
can O
be O
coimmunoprecipitated O
from O
cellular O
extracts O
. O

The O
endoribonuclease O
activity O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
A59 O
Nsp15 O
was O
also O
increased O
by O
pRb O
in O
vitro O
, O
and O
an O
MHV O
with O
mutations O
in O
the O
LXCXE O
/ O
D O
- O
motif O
, O
named O
vLC O
, O
exhibited O
a O
smaller O
plaque O
diameter O
and O
reduced O
the O
virus O
titer O
by O
similar O
to O
1 O
log O
. O

Nonstructural O
proteins O
7 O
and O
8 O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
have O
previously O
been O
shown O
by O
X O
- O
ray O
crystallography O
to O
form O
an O
8 O
: O
8 O
hexadecamer O
. O

In O
addition O
, O
it O
has O
been O
demonstrated O
that O
N O
- O
terminally O
His O
( O
6 O
) O
- O
tagged O
SARS O
- O
CoV O
Nsp8 O
is O
a O
primase O
able O
to O
synthesize O
RNA O
oligonucleotides O
with O
a O
length O
of O
up O
to O
6 O
nucleotides O
. O

6 O
- O
angstrom O
crystal O
structure O
of O
the O
feline B
coronavirus I
( I
FCoV I
) I
Nsp7 O
: O
Nsp8 O
complex O
, O
which O
is O
a O
2 O
: O
1 O
heterotrimer O
containing O
two O
copies O
of O
the O
alpha O
- O
helical O
Nsp7 O
with O
conformational O
differences O
between O
them O
, O
and O
one O
copy O
of O
Nsp8 O
that O
consists O
of O
an O
alpha O
/ O
beta O
domain O
and O
a O
long O
- O
alpha O
- O
helix O
domain O
. O

Furthermore O
, O
we O
show O
that O
FCoV O
Nsp8 O
, O
like O
its O
SARS O
- O
CoV O
counterpart O
, O
is O
able O
to O
synthesize O
short O
oligoribonucleotides O
of O
up O
to O
6 O
nucleotides O
in O
length O
when O
carrying O
an O
N O
- O
terminal O
His O
( O
6 O
) O
tag O
. O

Remarkably O
, O
the O
same O
protein O
harboring O
the O
sequence O
GPLG O
instead O
of O
the O
His O
( O
6 O
) O
tag O
at O
its O
N O
terminus O
exhibits O
a O
substantially O
increased O
, O
primer O
- O
independent O
RNA O
polymerase O
activity O
. O

Upon O
addition O
of O
Nsp7 O
, O
the O
RNA O
polymerase O
activity O
is O
further O
enhanced O
so O
that O
RNA O
up O
to O
template O
length O
( O
67 O
nucleotides O
) O
can O
be O
synthesized O
. O

Further O
, O
we O
show O
that O
the O
unprocessed O
intermediate O
polyprotein O
Nsp7 O
- O
10 O
of O
human B
coronavirus I
( I
HCoV I
) I
229E O
is O
also O
capable O
of O
synthesizing O
oligoribonucleotides O
up O
to O
a O
chain O
length O
of O
six O
. O

Higher O
- O
order O
RNA O
structures O
in O
the O
5 B
' I
untranslated I
regions I
( I
UTRs I
) I
of O
the O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
and O
bovine B
coronavirus I
( I
BCoV I
) I
, O
separate O
species O
in O
the O
betacoronavirus O
genus O
, O
appear O
to O
be O
largely O
conserved O
despite O
an O
similar O
to O
36 O
% O
nucleotide O
sequence O
divergence O
. O

In O
a O
previous O
study O
, O
each O
of O
three O
5 O
' O
- O
end O
- O
proximal O
cis O
- O
acting O
stem O
- O
loop O
domains O
in O
the O
BCoV O
genome O
, O
I O
/ O
II O
, O
III O
, O
and O
IV O
, O
yielded O
near O
- O
wild B
- I
type I
( I
WT I
) I
MHV O
phenotypes O
when O
used O
by O
reverse O
genetics O
to O
replace O
its O
counterpart O
in O
the O
MHV O
genome O
. O

Replacement O
with O
the O
BCoV O
32 O
- O
nucleotide B
( I
nt I
) I
inter O
- O
stem O
- O
loop O
fourth O
domain O
between O
stem O
- O
loops O
III O
and O
IV O
, O
however O
, O
required O
blind O
cell O
passaging O
for O
virus O
recovery O
. O

Here O
, O
we O
describe O
suppressor O
mutations O
within O
the O
transplanted O
BCoV O
32 O
- O
nt O
domain O
that O
along O
with O
appearance O
of O
potential O
base O
pairings O
identify O
an O
RNA O
- O
RNA O
interaction O
between O
this O
domain O
and O
a O
32 O
- O
nt O
region O
similar O
to O
200 O
nt O
downstream O
within O
the O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
- O
coding O
region O
. O

In O
this O
study O
, O
a O
comprehensive O
cysteine O
- O
alanine O
mutagenesis O
scan O
of O
all O
18 O
cysteine O
residues O
was O
performed O
in O
E1E2 O
- O
pseudotyped O
retroviruses O
( O
HCVpp O
) O
and O
recombinant O
E2 O
receptor O
- O
binding O
domain O
( O
E2 O
residues O
384 O
to O
661 O
[ O
E2 O
( O
661 O
) O
] O
) O
. O

The O
phenotypes O
of O
individual O
cysteines O
and O
pairwise O
mutation O
of O
disulfides O
were O
largely O
the O
same O
for O
retrovirion O
- O
incorporated O
E2 O
and O
E2 O
( O
661 O
) O
, O
suggesting O
their O
disulfide O
arrangements O
are O
similar O
. O

Individual O
Cys O
- O
to O
- O
Ala O
mutations O
revealed O
discordant O
effects O
, O
where O
removal O
of O
one O
Cys O
within O
a O
pair O
had O
minimal O
effect O
on O
H53 O
recognition O
and O
CD81 O
binding O
( O
C486 O
and O
C569 O
) O
while O
mutation O
of O
its O
partner O
abolished O
these O
functions O
( O
C494 O
and O
C564 O
) O
. O

Remarkably O
, O
E2 O
( O
661 O
) O
tolerates O
the O
presence O
of O
four O
free O
cysteines O
, O
as O
simultaneous O
mutation O
of O
C452A O
, O
C486A O
, O
C569A O
, O
C581A O
, O
C585A O
, O
C597A O
, O
and O
C652A O
( O
M O
+ O
C597A O
) O
retained O
wild O
- O
type O
CD81 O
binding O
. O

Thus O
, O
only O
one O
disulfide O
from O
each O
of O
the O
three O
predicted O
domains O
, O
C429 O
- O
C552 O
( O
DI O
) O
, O
C503 O
- O
C508 O
( O
DII O
) O
, O
and O
C607 O
- O
C644 O
( O
DIII O
) O
, O
is O
essential O
for O
the O
assembly O
of O
the O
E2 O
( O
661 O
) O
CD81 O
- O
binding O
site O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
sensed O
in O
the O
host O
cell O
by O
the O
cytosolic O
pathogen O
recognition O
receptor O
RIG O
- O
I O
. O

However O
, O
HCV O
blocks O
RIG O
- O
I O
signaling O
through O
viral O
NS3 O
/ O
4A O
protease O
cleavage O
of O
MAVS O
on O
the O
mitochondrion O
- O
associated O
endoplasmic B
reticulum I
( I
ER I
) I
membrane O
( O
MAM O
) O
. O

The O
multifunctional O
HCV O
NS3 O
/ O
4A O
serine O
protease O
is O
associated O
with O
intracellular O
membranes O
, O
including O
the O
MAM O
, O
through O
membrane O
- O
targeting O
domains O
within O
NS4A O
and O
also O
at O
the O
amphipathic O
helix O
alpha O
( O
0 O
) O
of O
NS3 O
. O

Here O
, O
we O
show O
that O
hydrophobic O
amino O
acids O
in O
the O
NS3 O
helix O
alpha O
( O
0 O
) O
are O
required O
for O
selective O
cleavage O
of O
membrane O
- O
anchored O
portions O
of O
the O
HCV O
polyprotein O
and O
for O
cleavage O
of O
MAVS O
for O
control O
of O
RIG O
- O
I O
pathway O
signaling O
of O
innate O
immunity O
. O

Further O
, O
we O
found O
that O
the O
hydrophobic O
composition O
of O
NS3 O
helix O
alpha O
( O
0 O
) O
is O
essential O
to O
establish O
HCV O
replication O
and O
infection O
. O

Alanine O
substitution O
of O
individual O
hydrophobic O
amino O
acids O
in O
the O
NS3 O
helix O
alpha O
( O
0 O
) O
impaired O
HCV O
RNA O
replication O
in O
cells O
with O
a O
functional O
RIG O
- O
I O
pathway O
, O
but O
viral O
RNA O
replication O
was O
rescued O
in O
cells O
lacking O
RIG O
- O
I O
signaling O
. O

Therefore O
, O
the O
hydrophobic O
amphipathic O
helix O
alpha O
( O
0 O
) O
of O
NS3 O
is O
required O
for O
NS3 O
/ O
4A O
control O
of O
RIG O
- O
I O
signaling O
and O
HCV O
replication O
by O
directing O
the O
membrane O
targeting O
of O
both O
viral O
and O
cellular O
substrates O
. O

The O
replicase O
proteins O
of O
arteriviruses O
are O
associated O
with O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
, O
which O
were O
previously O
proposed O
to O
derive O
from O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

Using O
electron O
tomography O
, O
we O
performed O
an O
in O
- O
depth O
ultrastructural O
analysis O
of O
cells O
infected O
with O
the O
prototypic O
arterivirus O
equine B
arteritis I
virus I
( I
EAV I
) I
. O

We O
established O
that O
the O
outer O
membranes O
of O
EAV O
- O
induced O
DMVs O
are O
interconnected O
with O
each O
other O
and O
with O
the O
ER O
, O
thus O
forming O
a O
reticulovesicular B
network I
( I
RVN I
) I
resembling O
that O
previously O
described O
for O
the O
distantly O
related O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
can O
persist O
even O
in O
the O
presence O
of O
a O
broadly O
neutralizing O
antibody O
response O
. O

To O
investigate O
this O
phenomenon O
, O
we O
characterized O
the O
neutralizing O
and O
inhibitory O
effects O
of O
human O
- O
derived O
affinity O
- O
purified O
immunoglobulin O
fractions O
and O
murine O
monoclonal O
antibodies O
and O
show O
that O
antibodies O
to O
both O
regions O
neutralize O
HCV B
pseudoparticle I
( I
HCVpp I
) I
and O
cell O
culture O
- O
infectious O
virus O
( O
HCVcc O
) O
infection O
albeit O
with O
different O
breadths O
and O
potencies O
. O

To O
establish O
a O
cell O
culture O
system O
for O
chimeric O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
2b O
, O
we O
prepared O
a O
chimeric O
construct O
harboring O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
to O
the O
E2 O
region O
of O
the O
MA O
strain O
( O
genotype O
2b O
) O
and O
the O
region O
of O
p7 O
to O
the O
3 O
' O
UTR O
of O
the O
JFH O
- O
1 O
strain O
( O
genotype O
2a O
) O
. O

In O
a O
long O
- O
term O
follow O
- O
up O
study O
, O
we O
identified O
a O
cell O
culture O
- O
adaptive O
mutation O
in O
the O
core O
region O
( O
R167G O
) O
and O
found O
that O
it O
enhanced O
virus O
assembly O
. O

We O
previously O
reported O
that O
the O
NS3 B
helicase I
( I
N3H I
) I
and O
the O
region O
of O
NS5B O
to O
3 O
' O
X O
( O
N5BX O
) O
of O
JFH O
- O
1 O
enabled O
replication O
of O
the O
J6CF O
strain O
( O
genotype O
2a O
) O
, O
which O
could O
not O
replicate O
in O
cells O
. O

2 O
, O
we O
produced O
a O
chimeric O
viral O
genome O
for O
MA O
harboring O
the O
N3H O
and O
N5BX O
regions O
of O
JFH O
- O
1 O
, O
combined O
with O
a O
JFH O
- O
1 O
5 O
' O
UTR O
replacement O
and O
the O
R167G O
mutation O
( O
MA O
/ O
N3H O
+ O
N5BX O
- O
JFH1 O
/ O
R167G O
) O
. O

The O
third O
component O
of O
human O
complement O
( O
C3 O
) O
plays O
a O
central O
role O
in O
innate O
immune O
function O
as O
its O
activation O
is O
required O
to O
trigger O
classical O
as O
well O
as O
alternative O
complement O
pathways O
. O

In O
this O
study O
, O
we O
have O
observed O
that O
sera O
from O
patients O
chronically O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
displayed O
significantly O
lower O
C3 O
levels O
than O
sera O
from O
healthy O
individuals O
. O

Further O
analysis O
suggested O
that O
HCV O
core O
protein O
displayed O
a O
weak O
repression O
of O
C3 O
promoter O
activity O
by O
downregulating O
the O
transcription O
factor O
farnesoid B
X I
receptor I
( I
FXR I
) I
. O

On O
the O
other O
hand O
, O
HCV O
NS5A O
protein O
strongly O
downregulated O
C3 O
promoter O
activity O
at O
the O
basal O
level O
or O
in O
the O
presence O
of O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
as O
an O
inducer O
. O

In O
addition O
, O
the O
expression O
of O
the O
transcription O
factor O
CAAT B
/ I
enhancer I
binding I
protein I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
, O
which O
binds O
to O
the O
IL O
- O
1 O
/ O
IL O
- O
6 O
response O
element O
in O
the O
C3 O
promoter O
, O
was O
inhibited O
in O
liver O
biopsy O
specimens O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
interaction O
with O
epithelial O
and O
dendritic B
cells I
( I
DCs I
) I
is O
known O
to O
require O
divalent O
cations O
, O
suggesting O
involvement O
of O
C O
- O
type O
lectins O
. O

Therefore O
, O
we O
asked O
whether O
RSV O
infection O
involves O
DC O
- O
SIGN O
( O
CD209 O
) O
or O
its O
isoform O
L O
- O
SIGN O
( O
CD299 O
) O
( O
DC O
- O
SIGN O
/ O
R O
) O
. O

However O
, O
inhibition O
of O
these O
interactions O
increased O
DC O
activation O
, O
as O
evidenced O
by O
significantly O
higher O
levels O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
MIP O
- O
1 O
alpha O
, O
and O
MIP O
- O
1 O
beta O
in O
plasmacytoid B
DCs I
( I
pDCs I
) I
exposed O
to O
RSV O
after O
neutralization O
of O
DC O
- O
and O
L O
- O
SIGN O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
diseases O
worldwide O
, O
often O
leading O
to O
the O
development O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

We O
further O
demonstrated O
that O
this O
effect O
is O
regulated O
through O
attenuation O
of O
the O
interferon B
( I
IFN I
) I
- O
JAK O
- O
STAT O
pathway O
. O

Activation O
of O
the O
Ras O
/ O
Raf O
/ O
MEK O
pathway O
downregulates O
the O
expression O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
attenuates O
the O
phosphorylation O
of O
STAT1 O
/ O
2 O
, O
and O
inhibits O
the O
expression O
of O
interferon O
( O
alpha O
, O
beta O
, O
and O
omega O
) O
receptors O
1 O
and O
2 O
( O
IFNAR1 O
/ O
2 O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
reorganizes O
intracellular O
membranes O
to O
establish O
sites O
of O
replication O
. O

We O
used O
a O
lentivirus O
- O
based O
RNA B
interference I
( I
RNAi I
) I
screening O
approach O
to O
identify O
the O
potential O
cellular O
factors O
that O
are O
involved O
in O
HCV O
replication O
. O

A O
protein O
with O
membrane O
- O
deforming O
activity O
, O
proline B
- I
serine I
- I
threonine I
phosphatase I
- I
interacting I
protein I
2 I
( I
PSTPIP2 I
) I
, O
was O
identified O
as O
a O
potential O
factor O
. O

PSTPIP2 O
was O
localized O
predominantly O
in O
detergent B
- I
resistant I
membranes I
( I
DRMs I
) I
, O
which O
contain O
the O
RNA O
replication O
complex O
. O

The O
5 B
' I
- I
untranslated I
regions I
( I
5 I
' I
UTRs I
) I
of O
picornavirus O
genomes O
contain O
an O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
that O
promotes O
the O
end O
- O
independent O
initiation O
of O
translation O
. O

Here O
, O
we O
identify O
a O
fifth O
IRES O
class O
in O
members O
of O
Kobuvirus O
, O
Salivirus O
, O
and O
Paraturdivirus O
genera O
of O
Picornaviridae O
: O
Aichi B
virus I
( I
AV I
) I
, O
bovine B
kobuvirus I
( I
BKV I
) I
, O
canine B
kobuvirus I
( I
CKoV I
) I
, O
mouse B
kobuvirus I
( I
MKoV I
) I
, O
sheep B
kobuvirus I
( I
SKV I
) I
, O
salivirus B
A I
( I
SV I
- I
A I
) I
, O
turdivirus B
2 I
( I
TV2 I
) I
, O
and O
TV3 O
. O

The O
410 O
- O
nucleotide B
( I
nt I
) I
- O
long O
AV O
IRES O
comprises O
four O
domains O
( O
I O
to O
L O
) O
, O
including O
a O
hairpin O
( O
L O
) O
that O
overlaps O
a O
Yn O
- O
Xm O
- O
AUG O
( O
pyrimidine O
tract O
/ O
spacer O
/ O
initiation O
codon O
) O
motif O
. O

Petersburg O
, O
Russia O
, O
the O
recombinant O
hepatitis B
C I
virus I
( I
HCV I
) I
2k O
/ O
1b O
has O
been O
isolated O
from O
several O
countries O
throughout O
Eurasia O
. O

microRNA B
- I
122 I
( I
miR I
- I
122 I
) I
enhances O
hepatitis B
C I
virus I
( I
HCV I
) I
fitness O
via O
targeting O
two O
sites O
in O
the O
5 O
' O
- O
untranslated B
region I
( I
UTR I
) I
of O
HCV O
. O

Coronavirus O
replication O
and O
transcription O
are O
processes O
mediated O
by O
a O
protein O
complex O
, O
with O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
as O
a O
main O
component O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
highly O
conserved O
residue O
G33 O
, O
located O
within O
domain O
1 O
of O
the O
core O
protein O
, O
is O
important O
for O
the O
production O
of O
cell O
culture O
- O
infectious O
virus O
( O
HCVcc O
) O
. O

The O
examination O
of O
the O
helix O
- O
loop O
- O
helix O
motif O
observed O
in O
the O
core O
protein O
structure O
( O
residues O
15 O
to O
41 O
; O
Protein O
Data O
Bank O
entry O
1CWX O
) O
indicated O
that O
the O
residues O
G33 O
and O
F24 O
are O
in O
close O
contact O
with O
each O
other O
, O
and O
that O
the O
G33A O
mutation O
induces O
a O
steric O
clash O
with O
F24 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
often O
leads O
to O
persistent O
infection O
. O

interferon B
( I
IFN I
) I
and O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
are O
amplified O
during O
HCV O
infection O
but O
fail O
to O
eliminate O
virus O
from O
the O
liver O
in O
a O
large O
number O
of O
infected O
patients O
. O

We O
have O
observed O
previously O
that O
HCV O
infection O
induces O
IFN O
- O
beta O
production O
in O
immortalized B
human I
hepatocytes I
( I
IHH I
) I
as O
early O
as O
24 O
h O
after O
infection O
, O
although O
virus O
replication O
is O
not O
inhibited O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
diseases O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
prominent O
risk O
factor O
for O
the O
development O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Similar O
to O
most O
solid O
tumors O
, O
HCCs O
are O
believed O
to O
contain O
poorly O
differentiated O
cancer B
stem I
cell I
- I
like I
cells I
( I
CSCs I
) I
that O
initiate O
tumorigenesis O
and O
confer O
resistance O
to O
chemotherapy O
. O

These O
traits O
include O
enhanced O
expression O
of O
doublecortin B
and I
CaM I
kinase I
- I
like I
- I
1 I
( I
DCAMKL I
- I
1 I
) I
, O
Lgr5 O
, O
CD133 O
, O
alpha O
- O
fetoprotein O
, O
cytokeratin B
- I
19 I
( I
CK19 I
) I
, O
Lin28 O
, O
and O
c O
- O
Myc O
. O

The O
DCAMKL O
- O
1 O
- O
positive O
cells O
isolated O
from O
hepatoma O
cell O
lines O
by O
fluorescence B
- I
activated I
cell I
sorting I
( I
FACS I
) I
form O
spheroids O
in O
Matrigel O
. O

The O
HCV O
RNA O
abundance O
and O
NS5B O
levels O
are O
significantly O
reduced O
by O
the O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
led O
depletion O
of O
DCAMKL O
- O
1 O
. O

By O
analogy O
to O
other O
members O
of O
the O
Flaviviridae O
family O
, O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
presumed O
to O
oligomerize O
to O
form O
the O
viral O
nucleocapsid O
, O
which O
encloses O
the O
single O
- O
stranded O
RNA O
genome O
. O

Core O
protein O
is O
directed O
to O
lipid B
droplets I
( I
LDs I
) I
by O
domain B
2 I
( I
D2 I
) I
of O
the O
protein O
, O
and O
this O
process O
is O
critical O
for O
virus O
production O
. O

Domain B
1 I
( I
D1 I
) I
of O
core O
is O
also O
important O
for O
infectious O
particle O
morphogenesis O
, O
although O
its O
precise O
contribution O
to O
this O
process O
is O
poorly O
understood O
. O

Further O
investigation O
of O
the O
defective O
64 O
to O
66 O
mutant O
( O
termed O
JFH1T O
- O
64 O
- O
66 O
) O
revealed O
it O
to O
be O
incapable O
of O
producing O
infectious O
intracellular O
virions O
, O
suggesting O
a O
fault O
during O
HCV O
assembly O
. O

Passaging O
of O
JFH1T O
- O
64 O
- O
66 O
led O
to O
the O
emergence O
of O
a O
single O
compensatory O
mutation O
( O
K1302R O
) O
within O
the O
helicase O
domain O
of O
NS3 O
that O
completely O
rescued O
its O
ability O
to O
produce O
infectious O
virus O
. O

Rotaviruses O
( O
group O
A O
rotaviruses O
) O
are O
the O
most O
important O
cause O
of O
severe O
gastroenteritis O
in O
infants O
and O
children O
worldwide O
. O

Since O
farnesoid B
X I
receptor I
( I
FXR I
) I
and O
its O
natural O
ligands O
bile O
acids O
( O
such O
as O
chenodeoxycholic O
acid O
[ O
CDCA O
] O
) O
play O
major O
roles O
in O
cholesterol O
and O
lipid O
homeostasis O
, O
we O
examined O
the O
effects O
of O
bile O
acids O
and O
synthetic O
FXR O
agonists O
on O
rotavirus O
replication O
in O
association O
with O
cellular O
lipid O
levels O
. O

Second O
, O
CDCA O
, O
deoxycholic B
acid I
( I
DCA I
) I
, O
and O
other O
synthetic O
FXR O
agonists O
, O
such O
as O
GW4064 O
, O
significantly O
reduced O
rotavirus O
replication O
in O
cell O
culture O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
reduction O
of O
virus O
replication O
correlated O
positively O
with O
activation O
of O
the O
FXR O
pathway O
and O
reduction O
of O
cellular O
triglyceride O
contents O
( O
r O
( O
2 O
) O
= O
0 O
. O

The O
unfolded B
protein I
response I
( I
UPR I
) I
is O
a O
cellular O
mechanism O
that O
is O
triggered O
in O
order O
to O
cope O
with O
the O
stress O
caused O
by O
the O
accumulation O
of O
misfolded O
proteins O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

This O
response O
is O
initiated O
by O
the O
endoribonuclease O
inositol B
- I
requiring I
enzyme I
1 I
( I
IRE1 I
) I
, O
activating B
transcription I
factor I
6 I
( I
ATF6 I
) I
, O
and O
PKR O
- O
like O
ER O
kinase O
, O
which O
increase O
the O
expression O
of O
the O
genes O
involved O
in O
the O
folding O
and O
degradation O
processes O
and O
decrease O
the O
protein O
input O
into O
the O
ER O
by O
inhibiting O
translation O
. O

Our O
findings O
indicated O
that O
during O
rotavirus O
infection O
two O
of O
the O
three O
arms O
of O
the O
UPR O
( O
IRE1 O
and O
ATF6 O
) O
become O
activated O
; O
however O
, O
these O
pathways O
are O
interrupted O
at O
the O
translational O
level O
by O
the O
general O
inhibition O
of O
protein O
synthesis O
caused O
by O
NSP3 O
. O

This O
response O
seems O
to O
be O
triggered O
by O
more O
than O
one O
viral O
protein O
synthesized O
during O
the O
replication O
of O
the O
virus O
, O
but O
not O
by O
the O
viral O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
since O
cells O
transfected O
with O
psoralen O
- O
inactivated O
virions O
, O
or O
with O
naked O
viral O
dsRNA O
, O
did O
not O
induce O
UPR O
. O

The O
RNA O
genome O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
diversifies O
rapidly O
during O
the O
acute O
phase O
of O
infection O
, O
but O
the O
selective O
forces O
that O
drive O
this O
process O
remain O
poorly O
defined O
. O

Here O
we O
examined O
whether O
Darwinian O
selection O
pressure O
imposed O
by O
CD8 O
( O
+ O
) O
T O
cells O
is O
a O
dominant O
force O
driving O
early O
amino O
acid O
replacement O
in O
HCV O
viral O
populations O
. O

This O
question O
was O
addressed O
in O
two O
chimpanzees O
followed O
for O
8 O
to O
10 O
years O
after O
infection O
with O
a O
well O
- O
defined O
inoculum O
composed O
of O
a O
clonal O
genotype O
1a O
( O
isolate O
H77C O
) O
HCV O
genome O
. O

Detailed O
characterization O
of O
CD8 O
( O
+ O
) O
T O
cell O
responses O
combined O
with O
sequencing O
of O
recovered O
virus O
at O
frequent O
intervals O
revealed O
that O
most O
acute O
- O
phase O
nonsynonymous O
mutations O
were O
clustered O
in O
class O
I O
epitopes O
and O
appeared O
much O
earlier O
than O
those O
in O
the O
remainder O
of O
the O
HCV O
genome O
. O

Together O
these O
observations O
indicate O
that O
during O
acute O
hepatitis O
C O
, O
virus O
evolution O
was O
driven O
primarily O
by O
positive O
selection O
pressure O
exerted O
by O
CD8 O
( O
+ O
) O
T O
cells O
. O

While O
human B
leukocyte I
antigen I
B57 I
( I
HLA I
- I
B57 I
) I
is O
associated O
with O
the O
spontaneous O
clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
the O
mechanisms O
behind O
this O
control O
remain O
unclear O
. O

Immunodominant O
CD8 O
( O
+ O
) O
T O
cell O
responses O
against O
the O
B57 O
- O
restricted O
epitopes O
comprised O
of O
residues O
2629 O
to O
2637 O
of O
nonstructural O
protein O
5B O
( O
NS5B O
( O
2629 O
- O
2637 O
) O
) O
( O
KSKKTPMGF O
) O
and O
E2 O
( O
541 O
- O
549 O
) O
( O
NTRPPLGNW O
) O
were O
recently O
shown O
to O
be O
crucial O
in O
the O
control O
of O
HCV O
infection O
. O

Here O
, O
we O
investigated O
whether O
the O
selection O
of O
deleterious O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
escape O
mutations O
in O
the O
NS5B O
KSKKTPMGF O
epitope O
might O
impair O
viral O
replication O
and O
contribute O
to O
the O
B57 O
- O
mediated O
control O
of O
HCV O
. O

We O
demonstrate O
that O
while O
escape O
mutations O
at O
residue O
2633 O
( O
position O
5 O
) O
of O
the O
epitope O
had O
little O
or O
no O
impact O
on O
HCV O
replication O
in O
vitro O
, O
mutations O
at O
residue O
2629 O
( O
position O
1 O
) O
substantially O
impaired O
replication O
. O

The O
liver O
- O
specific O
microRNA O
miR O
- O
122 O
is O
required O
for O
efficient O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
both O
in O
cell O
culture O
and O
in O
vivo O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
/ O
4A O
protein O
has O
several O
essential O
roles O
in O
the O
virus O
life O
cycle O
, O
most O
probably O
through O
dynamic O
interactions O
with O
host O
factors O
. O

To O
discover O
cellular O
cofactors O
that O
are O
co O
- O
opted O
by O
HCV O
for O
its O
replication O
, O
we O
elucidated O
the O
NS3 O
/ O
4A O
interactome O
using O
mass O
spectrometry O
and O
identified O
Y B
- I
box I
- I
binding I
protein I
1 I
( I
YB I
- I
1 I
) I
as O
an O
interacting O
partner O
of O
NS3 O
/ O
4A O
protein O
and O
HCV O
genomic O
RNA O
. O

Cellular B
inhibitor I
of I
apoptosis I
protein I
2 I
( I
cIAP2 I
) I
is O
a O
potent O
suppressor O
of O
apoptotic O
cell O
death O
. O

We O
have O
shown O
previously O
that O
cIAP2 O
is O
involved O
in O
the O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
induced O
anti O
- O
hepatitis B
B I
virus I
( I
HBV I
) I
response O
; O
however O
, O
the O
mechanism O
for O
this O
antiviral O
effect O
remains O
unclear O
. O

Domain O
- O
mapping O
analysis O
revealed O
that O
the O
carboxy O
- O
terminal O
domains O
of O
cIAP2 O
were O
indispensable O
for O
this O
anti O
- O
HBV O
ability O
and O
that O
an O
E3 O
ligase O
- O
deficient O
mutant O
of O
cIAP2 O
( O
termed O
cIAP2 O
* O
) O
completely O
lost O
its O
antiviral O
activity O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
are O
essentially O
restricted O
to O
hepatocytes O
because O
liver O
- O
enriched O
transcription O
factors O
govern O
viral O
RNA O
synthesis O
. O

Peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
coactivator I
1 I
alpha I
( I
PGC1 I
alpha I
) I
enhances O
the O
activity O
of O
nuclear O
receptors O
and O
, O
consequently O
, O
HBV O
biosynthesis O
. O

Consistent O
with O
this O
suggestion O
, O
v B
- I
akt I
murine I
thymoma I
viral I
oncogene I
homolog I
/ I
protein I
kinase I
B I
( I
AKT I
/ I
PKB I
) I
is O
shown O
to O
modulate O
PGC1 O
alpha O
activity O
and O
, O
hence O
, O
HBV O
transcription O
and O
replication O
in O
a O
cell O
line O
- O
specific O
manner O
. O

Previous O
studies O
have O
demonstrated O
that O
mouse B
hepatitis I
virus I
( I
MHV I
) I
hepatotropism O
is O
determined O
largely O
by O
postentry O
events O
rather O
than O
by O
availability O
of O
the O
viral O
receptor O
. O

In O
addition O
, O
mutation O
of O
MHV O
nonstructural B
protein I
2 I
( I
NS2 I
) I
abrogates O
the O
ability O
of O
the O
virus O
to O
replicate O
in O
the O
liver O
and O
induce O
hepatitis O
but O
does O
not O
affect O
replication O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Here O
we O
show O
that O
replication O
of O
ns2 O
mutant O
viruses O
is O
attenuated O
in O
bone B
marrow I
- I
derived I
macrophages I
( I
BMM I
) I
generated O
from O
wild B
- I
type I
( I
WT I
) I
mice O
but O
not O
in O
L2 O
fibroblasts O
, O
primary O
astrocytes O
, O
or O
BMM O
generated O
from O
type O
I O
interferon O
receptor O
- O
deficient O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
mice O
. O

In O
addition O
, O
ns2 O
mutants O
are O
more O
sensitive O
than O
wt O
virus O
to O
pretreatment O
of O
BMM O
, O
but O
not O
L2 O
fibroblasts O
or O
primary O
astrocytes O
, O
with O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
. O

The O
ns2 O
mutants O
induced O
similar O
levels O
of O
IFN O
- O
alpha O
/ O
beta O
in O
wt O
and O
IFNAR O
( O
- O
/ O
- O
) O
BMM O
, O
indicating O
that O
ns2 O
expression O
has O
no O
effect O
on O
the O
induction O
of O
IFN O
but O
rather O
that O
it O
antagonizes O
a O
later O
step O
in O
IFN O
signaling O
. O

Understanding O
the O
interaction O
between O
broadly O
neutralizing O
antibodies O
and O
their O
epitopes O
provides O
a O
basis O
for O
the O
rational O
design O
of O
a O
preventive O
hepatitis B
C I
virus I
( I
HCV I
) I
vaccine O
. O

An O
HCV B
pseudoparticle I
( I
HCVpp I
) I
containing O
the O
L438F O
mutation O
bound O
to O
CD81 O
half O
as O
efficiently O
as O
did O
wild B
- I
type I
( I
WT I
) I
HCVpp O
. O

Epitope O
mapping O
revealed O
contact O
residues O
for O
CBH O
- O
2 O
and O
HC O
- O
11 O
in O
two O
regions O
of O
the O
E2 O
glycoprotein O
, O
amino B
acids I
( I
aa I
) I
425 O
to O
443 O
and O
aa O
529 O
to O
535 O
. O

enterovirus B
71 I
( I
EV71 I
) I
infections O
continue O
to O
remain O
an O
important O
public O
health O
problem O
around O
the O
world O
, O
especially O
in O
the O
Asia O
- O
Pacific O
region O
. O

Three O
of O
these O
proteins O
, O
heterogeneous B
nuclear I
ribonucleoprotein I
A1 I
( I
hnRNP I
A1 I
) I
, O
far B
- I
upstream I
element I
- I
binding I
protein I
2 I
( I
FBP2 I
) I
, O
and O
FBP1 O
are O
nuclear O
proteins O
which O
in O
EV71 O
- O
infected O
cells O
are O
relocalized O
to O
the O
cytoplasm O
, O
and O
they O
influence O
EV71 O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
activity O
. O

The O
cleavage B
stimulation I
factor I
64K I
subunit I
( I
CstF I
- I
64 I
) I
is O
a O
host O
protein O
that O
is O
involved O
in O
the O
3 O
' O
polyadenylation O
of O
cellular O
pre O
- O
mRNAs O
, O
and O
recent O
work O
suggests O
that O
in O
EV71 O
- O
infected O
cells O
, O
it O
may O
be O
cleaved O
by O
the O
EV71 O
3C O
protease O
. O

Phosphatidylinositol B
4 I
- I
kinase I
III I
alpha I
( I
PI4KA I
) I
is O
an O
essential O
cofactor O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

Moreover O
, O
HCV O
infection O
or O
subgenomic O
HCV O
replicons O
produced O
a O
dramatic O
increase O
in O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
accumulation O
throughout O
the O
cytoplasm O
, O
which O
partially O
colocalized O
with O
the O
endoplasmic O
reticulum O
. O

Glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase I
( I
GAPDH I
) I
is O
an O
abundant O
metabolic O
enzyme O
that O
is O
recruited O
to O
the O
replicase O
complex O
of O
Tomato B
bushy I
stunt I
virus I
( I
TBSV I
) I
and O
affects O
asymmetric O
viral O
RNA O
synthesis O
. O

To O
further O
our O
understanding O
on O
the O
role O
of O
GAPDH O
in O
TBSV O
replication O
, O
we O
used O
an O
in O
vitro O
TBSV O
replication O
assay O
based O
on O
recombinant O
p33 O
and O
p92 O
( O
pol O
) O
viral O
replication O
proteins O
and O
cell O
- O
free O
yeast O
extract O
. O

Our O
data O
also O
demonstrate O
that O
GAPDH O
interacts O
with O
p92 O
( O
pol O
) O
viral O
replication O
protein O
, O
which O
may O
facilitate O
the O
recruitment O
of O
GAPDH O
into O
the O
viral O
replicase O
complex O
in O
the O
yeast O
model O
host O
. O

High B
- I
mobility I
group I
box I
1 I
( I
HMGB1 I
) I
, O
an O
abundant O
nuclear O
protein O
that O
triggers O
host O
immune O
responses O
, O
is O
an O
endogenous O
danger O
signal O
involved O
in O
the O
pathogenesis O
of O
various O
infectious O
agents O
. O

However O
, O
its O
role O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
not O
known O
. O

The O
life O
cycle O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
dependent O
on O
cellular O
factors O
. O

Using O
small B
interfering I
RNA I
( I
siRNA I
) I
library O
screening O
, O
we O
identified O
peptidyl O
- O
prolyl O
cis O
- O
trans O
isomerase O
NIMA O
- O
interacting O
1 O
( O
Pin1 O
) O
as O
a O
host O
factor O
involved O
in O
HCV O
propagation O
. O

Here O
we O
demonstrated O
that O
silencing O
of O
Pin1 O
expression O
resulted O
in O
decreases O
in O
HCV O
replication O
in O
both O
HCV O
replicon O
cells O
and O
cell B
culture I
- I
grown I
HCV I
( I
HCVcc I
) I
- O
infected O
cells O
, O
whereas O
overexpression O
of O
Pin1 O
increased O
HCV O
replication O
. O

The O
5 O
' O
140 O
nucleotides O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
5 I
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
are O
predicted O
to O
contain O
three O
secondary O
structures O
, O
stem B
- I
loop I
1 I
( I
SL1 I
) I
, O
SL2 O
, O
and O
SL4 O
. O

Neither O
the O
structure O
, O
the O
sequence O
, O
nor O
the O
putative O
8 O
- O
amino O
- O
acid O
open B
reading I
frame I
( I
ORF I
) I
in O
SL4b O
is O
required O
for O
viral O
replication O
. O

Deletion O
of O
( O
131 O
) O
ACA O
( O
133 O
) O
just O
3 O
' O
to O
SL4 O
has O
a O
profound O
impact O
on O
viral O
replication O
. O

Viruses O
carrying O
the O
( O
131 O
) O
ACA O
( O
133 O
) O
deletion O
were O
heterogeneous O
in O
plaque O
size O
. O

We O
isolated O
three O
viruses O
with O
second O
- O
site O
mutations O
in O
the O
5 O
' O
UTR O
which O
compensated O
for O
decreased O
plaque O
sizes O
, O
delayed O
growth O
kinetics O
, O
and O
lower O
titers O
associated O
with O
the O
( O
131 O
) O
ACA O
( O
133 O
) O
deletion O
. O

These O
results O
suggest O
that O
the O
proposed O
SL4 O
in O
the O
MHV O
5 O
' O
UTR O
functions O
in O
part O
as O
a O
spacer O
element O
that O
orients O
SL1 O
, O
SL2 O
, O
and O
the O
transcriptional B
regulatory I
sequence I
( I
TRS I
) I
, O
and O
this O
spacer O
function O
may O
play O
an O
important O
role O
in O
directing O
subgenomic O
RNA O
synthesis O
. O

The O
anti O
- O
glycoprotein B
H I
( I
gH I
) I
monoclonal O
antibody O
( O
anti O
- O
gH O
- O
MAb O
) O
that O
neutralizes O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
inhibited O
cell O
- O
to O
- O
cell O
infection O
, O
resulting O
in O
a O
single O
infected O
cell O
without O
apoptosis O
or O
necrosis O
, O
and O
the O
number O
of O
infectious O
cells O
in O
cultures O
treated O
with O
anti O
- O
gH O
- O
MAb O
declined O
to O
undetectable O
levels O
in O
7 O
to O
10 O
days O
. O

Anti O
- O
gH O
- O
MAb O
modulated O
the O
wide O
cytoplasmic O
distribution O
of O
gH O
colocalized O
with O
glycoprotein B
E I
( I
gE I
) I
to O
the O
cytoplasmic O
compartment O
with O
endoplasmic B
reticulum I
( I
ER I
) I
and O
Golgi O
markers O
near O
the O
nucleus O
, O
while O
gE O
retained O
its O
cytoplasmic O
distribution O
. O

Cells O
were O
infected O
with O
Oka O
varicella O
vaccine O
expressing O
hepatitis O
B O
surface O
antigen O
( O
ROka O
) O
and O
treated O
with O
anti O
- O
gH O
- O
MAb O
for O
4 O
weeks O
, O
and O
ROka O
was O
recovered O
from O
the O
quiescently O
infected O
cells O
by O
superinfection O
with O
the O
parent O
Oka O
vaccine O
. O

Adenosine B
deaminases I
acting I
on I
RNA I
( I
ADARs I
) I
catalyze O
the O
C O
- O
6 O
deamination O
of O
adenosine O
( O
A O
) O
to O
produce O
inosine O
( O
I O
) O
, O
which O
behaves O
as O
Guanine B
( I
G I
) I
, O
thereby O
altering O
base O
pairing O
in O
RNAs O
with O
double O
- O
stranded O
character O
. O

Furthermore O
, O
two O
size O
forms O
of O
ADAR1 O
are O
expressed O
by O
alternative O
promoter O
usage O
, O
a O
short O
( O
p110 O
) O
nuclear O
form O
that O
is O
constitutively O
made O
and O
a O
long O
( O
p150 O
) O
form O
that O
is O
interferon O
inducible O
and O
present O
in O
both O
the O
cytoplasm O
and O
nucleus O
. O

Extensive O
A O
- O
to O
- O
G O
substitution O
has O
been O
described O
in O
mouse O
polyomavirus B
( I
PyV I
) I
RNA O
isolated O
late O
times O
after O
infection O
, O
suggesting O
modification O
by O
ADAR O
. O

The O
single O
- O
cycle O
yields O
and O
growth O
kinetics O
of O
PyV O
were O
comparable O
between O
adar1 O
( O
- O
/ O
- O
) O
and O
adar2 O
( O
- O
/ O
- O
) O
genetic O
null O
fibroblast O
cells O
. O

While O
large O
T O
antigen O
was O
expressed O
to O
higher O
levels O
in O
adar1 O
( O
- O
/ O
- O
) O
cells O
than O
adar2 O
( O
- O
/ O
- O
) O
cells O
, O
less O
difference O
was O
seen O
in O
VP1 O
protein O
expression O
levels O
between O
the O
two O
knockout O
MEFs O
. O

However O
, O
virus O
- O
induced O
cell O
killing O
was O
greatly O
enhanced O
in O
PyV O
- O
infected O
adar1 O
( O
- O
/ O
- O
) O
cells O
compared O
to O
that O
of O
adar2 O
( O
- O
/ O
- O
) O
cells O
. O

UV O
- O
irradiated O
PyV O
did O
not O
display O
any O
enhanced O
cytopathic O
effect O
in O
adar1 O
( O
- O
/ O
- O
) O
cells O
. O

Reovirus O
and O
vesicular O
stomatitis O
virus O
single O
- O
cycle O
yields O
were O
comparable O
between O
adar1 O
( O
- O
/ O
- O
) O
and O
adar2 O
( O
- O
/ O
- O
) O
cells O
, O
and O
neither O
reovirus O
nor O
VSV O
showed O
enhanced O
cytotoxicity O
in O
adar1 O
( O
- O
/ O
- O
) O
- O
infected O
cells O
. O

Retrovirus O
genomes O
, O
such O
as O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
genomes O
deficient O
in O
the O
vif O
gene O
and O
the O
hepatitis O
B O
virus O
genome O
, O
are O
particularly O
vulnerable O
. O

This O
is O
indeed O
the O
case O
for O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
in O
tissue O
culture O
, O
where O
APOBEC3C B
( I
A3C I
) I
overexpression O
can O
reduce O
virus O
titers O
and O
the O
particle O
/ O
PFU O
ratio O
similar O
to O
10 O
- O
fold O
. O

The O
phenomenon O
is O
not O
restricted O
to O
HSV O
, O
since O
hyperedited O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genomes O
were O
readily O
recovered O
from O
4 O
/ O
5 O
established O
cell O
lines O
, O
indicating O
that O
episomes O
are O
vulnerable O
to O
editing O
. O

Sequences O
in O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
is O
important O
for O
modulating O
both O
translation O
and O
RNA O
replication O
. O

The O
translation O
of O
the O
HCV O
genome O
depends O
on O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
located O
within O
the O
341 O
- O
nucleotide O
5 O
' O
UTR O
, O
while O
RNA O
replication O
requires O
a O
smaller O
region O
. O

We O
also O
found O
that O
poly O
( O
C O
) O
- O
binding O
protein O
2 O
( O
PCBP2 O
) O
bound O
to O
the O
replication O
region O
of O
the O
5 O
' O
UTR O
and O
associated O
with O
detergent O
- O
resistant O
membrane O
fractions O
, O
which O
are O
the O
sites O
of O
the O
HCV O
replication O
complex O
. O

The O
intrahost O
evolution O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
holds O
keys O
to O
understanding O
mechanisms O
responsible O
for O
the O
establishment O
of O
chronic O
infections O
and O
to O
development O
of O
a O
vaccine O
and O
therapeutics O
. O

The O
microRNA O
miR O
- O
122 O
and O
DDX6 O
/ O
Rck O
/ O
p54 O
, O
a O
microRNA O
effector O
, O
have O
been O
implicated O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

In O
this O
study O
, O
we O
demonstrated O
for O
the O
first O
time O
that O
HCV O
- O
JFH1 O
infection O
disrupted O
processing O
( O
P O
) O
- O
body O
formation O
of O
the O
microRNA O
effectors O
DDX6 O
, O
Lsm1 O
, O
Xrn1 O
, O
PATL1 O
, O
and O
Ago2 O
, O
but O
not O
the O
decapping O
enzyme O
DCP2 O
, O
and O
dynamically O
redistributed O
these O
microRNA O
effectors O
to O
the O
HCV O
production O
factory O
around O
lipid O
droplets O
in O
HuH O
- O
7 O
- O
derived O
RSc O
cells O
. O

Notably O
, O
HCV O
- O
JFH1 O
infection O
also O
redistributed O
the O
stress O
granule O
components O
GTPase O
- O
activating O
protein O
( O
SH3 O
domain O
) O
- O
binding O
protein O
1 O
( O
G3BP1 O
) O
, O
ataxin O
- O
2 O
( O
ATX2 O
) O
, O
and O
poly B
( I
A I
) I
- I
binding I
protein I
1 I
( I
PABP1 I
) I
to O
the O
HCV O
production O
factory O
. O

The O
nonpathogenic O
human B
GB I
virus I
C I
( I
GBV I
- I
C I
) I
, O
a O
member O
of O
the O
Flaviviridae O
, O
is O
highly O
prevalent O
in O
individuals O
with O
HIV O
- O
1 O
infections O
or O
with O
parenteral O
and O
sexual O
risk O
factors O
. O

We O
demonstrate O
here O
that O
peptides O
representing O
the O
N O
- O
terminal O
part O
of O
the O
E2 O
protein O
from O
amino B
acids I
( I
aa I
) I
29 O
to O
72 O
are O
able O
to O
inhibit O
efficiently O
HIV O
- O
1 O
replication O
in O
vitro O
. O

In O
particular O
, O
the O
peptides O
P6 O
- O
2 O
( O
representing O
the O
E2 O
- O
region O
from O
aa O
45 O
to O
64 O
) O
and O
P4762 O
( O
aa O
37 O
to O
64 O
) O
showed O
the O
highest O
potency O
in O
HIV O
replication O
assays O
performed O
on O
TZM O
- O
bl O
cells O
with O
50 O
% O
inhibitory O
concentrations O
between O
0 O
. O

progressive B
multifocal I
leukoencephalopathy I
( I
PML I
) I
is O
a O
severe O
demyelinating O
disease O
of O
the O
brain O
caused O
by O
JC B
virus I
( I
JCV I
) I
. O

To O
assess O
the O
role O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cells O
against O
JCV O
in O
the O
clinical O
outcome O
of O
PML O
and O
PML O
in O
the O
setting O
of O
immune B
reconstitution I
inflammatory I
syndrome I
( I
IRIS I
) I
, O
we O
tested O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
response O
by O
enzyme B
- I
linked I
immunosorbent I
spot I
( I
ELISpot I
) I
and O
intracellular B
cytokine I
staining I
( I
ICS I
) I
in O
117 O
subjects O
, O
including O
66 O
PML O
patients O
with O
different O
clinical O
outcomes O
. O

PML O
survivors O
had O
an O
early O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
more O
frequently O
than O
PML O
progressors O
( O
100 O
% O
versus O
27 O
. O

001 O
) O
, O
while O
only O
a O
trend O
was O
observed O
for O
the O
early O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
between O
these O
two O
groups O
( O
80 O
% O
versus O
45 O
. O

Although O
IRIS O
itself O
was O
more O
frequent O
in O
the O
PML O
survivor O
group O
, O
there O
was O
no O
difference O
in O
IFN O
- O
gamma O
- O
producing O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cells O
between O
IRIS O
and O
non O
- O
IRIS O
PML O
patients O
, O
suggesting O
that O
T O
- O
cells O
expressing O
other O
cytokines O
likely O
have O
a O
role O
in O
the O
immunopathogenesis O
of O
IRIS O
. O

BMS O
- O
790052 O
, O
targeting O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
, O
is O
the O
most O
potent O
hepatitis B
C I
virus I
( I
HCV I
) I
inhibitor O
described O
to O
date O
. O

BMS O
- O
790052 O
inhibits O
genotype O
2a O
JFH1 O
replicon O
cells O
and O
cell O
culture O
infectious O
virus O
with O
50 B
% I
effective I
concentrations I
( I
EC I
( I
50 I
) I
s I
) I
of O
46 O
. O

Second O
- O
site O
replacements O
at O
NS5A O
residue O
30 O
( O
K30E O
/ O
Q O
) O
restored O
efficient O
replication O
of O
the O
C92R O
viral O
variant O
, O
thus O
demonstrating O
a O
genetic O
interaction O
between O
NS5A O
residues O
30 O
and O
92 O
. O

The O
protein O
consists O
of O
three O
domains O
, O
each O
of O
which O
is O
able O
to O
bind O
independently O
to O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
viral O
positive O
strand O
genomic O
RNA O
. O

The O
peptidyl O
- O
prolyl O
isomerase O
cyclophilin B
A I
( I
CypA I
) I
binds O
to O
domain O
II O
, O
catalyzing O
cis O
- O
trans O
isomerization O
. O

CypA O
inhibitors O
such O
as O
Cyclosporine B
( I
CsA I
) I
have O
been O
shown O
to O
inhibit O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

An O
isomerase O
mutant O
of O
CypA O
( O
H126Q O
) O
failed O
to O
bind O
to O
domain O
II O
and O
did O
not O
stimulate O
RNA O
binding O
. O

The O
findings O
reported O
here O
demonstrate O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
can O
enhance O
the O
autophagic O
process O
in O
hepatoma O
cells O
without O
promoting O
protein O
degradation O
by O
the O
lysosome O
. O

Mutation O
analysis O
showed O
that O
HBV B
small I
surface I
protein I
( I
SHBs I
) I
was O
required O
for O
HBV O
to O
induce O
autophagy O
. O

Furthermore O
, O
SHBs O
could O
trigger O
unfolded B
protein I
responses I
( I
UPR I
) I
, O
and O
the O
blockage O
of O
UPR O
signaling O
pathways O
abrogated O
the O
SHB O
- O
induced O
lipidation O
of O
LC3 O
- O
I O
. O

The O
inhibition O
of O
autophagosome O
formation O
by O
the O
autophagy O
inhibitor O
3 B
- I
methyladenine I
( I
3 I
- I
MA I
) I
or O
small O
interfering O
RNA O
duplexes O
targeting O
the O
genes O
critical O
for O
autophagosome O
formation O
( O
Beclin1 O
and O
ATG5 O
genes O
) O
markedly O
inhibited O
HBV O
production O
, O
and O
the O
induction O
of O
autophagy O
by O
rapamycin O
or O
starvation O
greatly O
contributed O
to O
HBV O
production O
. O

major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
- O
presented O
peptides O
can O
be O
derived O
from O
both O
exogenous O
( O
extracellular O
) O
and O
endogenous O
( O
biosynthesized O
) O
sources O
of O
antigen O
. O

Although O
several O
endogenous O
antigen O
- O
processing O
pathways O
have O
been O
reported O
, O
little O
is O
known O
about O
their O
relative O
contributions O
to O
global O
CD4 O
( O
+ O
) O
T O
cell O
responses O
against O
complex O
antigens O
. O

However O
, O
validated O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assays O
of O
influenza O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
from O
infected O
mice O
using O
a O
variety O
of O
antigen O
- O
presenting O
cells O
, O
including O
primary O
dendritic O
cells O
, O
revealed O
no O
detectable O
macroautophagy O
- O
dependent O
component O
. O

In O
contrast O
, O
the O
contribution O
of O
proteasome O
- O
dependent O
endogenous O
antigen O
processing O
to O
the O
global O
influenza O
CD4 O
( O
+ O
) O
response O
was O
readily O
appreciated O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
Nonstructural B
protein I
4B I
( I
NS4B I
) I
is O
an O
integral O
membrane O
protein O
, O
which O
plays O
an O
important O
role O
in O
the O
organization O
and O
function O
of O
the O
HCV O
replication B
complex I
( I
RC I
) I
. O

Although O
much O
is O
understood O
about O
its O
amphipathic O
N O
- O
terminal O
and O
C O
- O
terminal O
domains O
, O
we O
know O
very O
little O
about O
the O
role O
of O
the O
transmembrane B
domains I
( I
TMDs I
) I
in O
NS4B O
function O
. O

We O
have O
mapped O
this O
incompatibility O
to O
NS4B O
TMD1 O
and O
TMD2 O
sequences O
, O
and O
we O
have O
defined O
putative O
TMD O
dimerization O
motifs O
( O
GXXXG O
in O
TMD2 O
and O
TMD3 O
; O
the O
S O
/ O
T O
cluster O
in O
TMD1 O
) O
as O
key O
structural O
/ O
functional O
determinants O
. O

Although O
hepatitis B
C I
virus I
( I
HCV I
) I
assembly O
remains O
incompletely O
understood O
, O
recent O
studies O
with O
the O
genotype O
2a O
JFH O
- O
1 O
strain O
suggest O
that O
it O
is O
dependent O
upon O
the O
phosphorylation O
of O
Ser O
residues O
near O
the O
C O
terminus O
of O
NS5A O
, O
a O
multifunctional O
nonstructural O
protein O
. O

The O
exchange O
of O
complete O
NS5A O
sequences O
between O
these O
viruses O
was O
highly O
detrimental O
to O
replication O
, O
while O
exchanges O
of O
the O
C O
- O
terminal O
domain O
III O
sequence O
( O
46 O
% O
amino O
acid O
sequence O
identity O
) O
were O
well O
tolerated O
, O
with O
little O
effect O
on O
RNA O
synthesis O
. O

The O
mechanism O
by O
which O
viral O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRp I
) I
specifically O
amplify O
viral O
genomes O
is O
still O
unclear O
. O

In O
the O
case O
of O
flaviviruses O
, O
a O
model O
has O
been O
proposed O
that O
involves O
the O
recognition O
of O
an O
RNA O
element O
present O
at O
the O
viral O
5 O
' O
untranslated O
region O
, O
stem B
- I
loop I
A I
( I
SLA I
) I
, O
that O
serves O
as O
a O
promoter O
for O
NS5 O
polymerase O
binding O
and O
activity O
. O

By O
measuring O
polymerase O
activity O
using O
nonspecific O
poly O
( O
rC O
) O
templates O
or O
specific O
viral O
RNA O
molecules O
, O
we O
identified O
four O
mutants O
with O
impaired O
polymerase O
activity O
. O

Interestingly O
, O
one O
recombinant O
NS5 O
protein O
carrying O
the O
mutations O
K456A O
and O
K457A O
located O
in O
the O
F1 O
motif O
lacked O
RNA O
synthesis O
dependent O
on O
the O
SLA O
promoter O
but O
displayed O
high O
activity O
using O
a O
poly O
( O
rC O
) O
template O
. O

Substitution O
of O
amino O
acids O
70 O
and O
91 O
in O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
region O
is O
a O
significant O
predictor O
of O
poor O
responses O
to O
peginterferon O
- O
plus O
- O
ribavirin O
therapy O
, O
while O
their O
molecular O
mechanisms O
remain O
unclear O
. O

Here O
we O
investigated O
these O
differences O
in O
the O
response O
to O
alpha O
interferon B
( I
IFN I
) I
by O
using O
HCV O
cell O
culture O
with O
R70Q O
, O
R70H O
, O
and O
L91M O
substitutions O
. O

interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
which O
upregulates O
SOCS3 O
, O
was O
significantly O
higher O
for O
the O
R70Q O
, O
R70H O
, O
and O
L91M O
mutants O
than O
for O
the O
wild O
type O
, O
suggesting O
interferon O
resistance O
, O
possibly O
through O
IL O
- O
6 O
- O
induced O
, O
SOCS3 O
- O
mediated O
suppression O
of O
interferon O
signaling O
. O

Expression O
levels O
of O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
proteins O
were O
significantly O
higher O
in O
cells O
transfected O
with O
a O
core O
mutant O
than O
in O
those O
transfected O
with O
the O
wild O
type O
. O

The O
RNA O
replication O
and O
transcription O
complex O
of O
coronaviruses O
is O
associated O
with O
an O
elaborate O
reticulo B
- I
vesicular I
network I
( I
RVN I
) I
of O
modified O
endoplasmic O
reticulum O
. O

Following O
infection O
with O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
in O
most O
cases O
immunity O
fails O
to O
eradicate O
the O
virus O
, O
resulting O
in O
slowly O
progressing O
immunopathology O
in O
the O
HCV O
- O
infected O
liver O
. O

We O
are O
the O
first O
to O
examine O
intrahepatic O
T O
cells O
and O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
FoxP3 O
( O
+ O
) O
regulatory B
T I
cells I
( I
Treg I
) I
in O
patients O
chronically O
infected O
with O
HCV O
( O
chronic O
HCV O
patients O
) O
during O
and O
after O
antiviral O
therapy O
by O
collecting O
multiple O
aspiration O
biopsy O
samples O
from O
the O
liver O
at O
different O
time O
points O
. O

Ebola B
virus I
( I
EBOV I
) I
, O
an O
enveloped O
, O
single O
- O
stranded O
, O
negative O
- O
sense O
RNA O
virus O
, O
causes O
severe O
hemorrhagic O
fever O
in O
humans O
and O
nonhuman O
primates O
. O

The O
EBOV O
glycoprotein B
( I
GP I
) I
gene O
encodes O
the O
nonstructural O
soluble B
glycoprotein I
( I
sGP I
) I
but O
also O
produces O
the O
transmembrane O
glycoprotein O
( O
GP O
( O
1 O
, O
2 O
) O
) O
through O
transcriptional O
editing O
. O

A O
third O
GP O
gene O
product O
, O
a O
small B
soluble I
glycoprotein I
( I
ssGP I
) I
, O
has O
long O
been O
postulated O
to O
be O
produced O
also O
as O
a O
result O
of O
transcriptional O
editing O
. O

To O
identify O
and O
characterize O
the O
expression O
of O
this O
new O
EBOV O
protein O
, O
we O
first O
analyzed O
the O
relative O
ratio O
of O
GP O
gene O
- O
derived O
transcripts O
produced O
during O
infection O
in O
vitro O
( O
in O
Vero O
E6 O
cells O
or O
Huh7 O
cells O
) O
and O
in O
vivo O
( O
in O
mice O
) O
. O

The O
average O
percentages O
of O
transcripts O
encoding O
sGP O
, O
GP O
( O
1 O
, O
2 O
) O
, O
and O
ssGP O
were O
approximately O
70 O
, O
25 O
, O
and O
5 O
% O
, O
respectively O
, O
indicating O
that O
ssGP O
transcripts O
are O
indeed O
produced O
via O
transcriptional O
editing O
. O

Optimized O
2 O
- O
dimensional O
( O
2D O
) O
gel O
electrophoresis O
analyses O
finally O
verified O
the O
expression O
and O
secretion O
of O
ssGP O
in O
tissue O
culture O
during O
EBOV O
infection O
. O

The O
recent O
development O
of O
a O
cell O
culture O
model O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
based O
on O
the O
JFH O
- O
1 O
molecular O
clone O
has O
enabled O
discovery O
of O
new O
antiviral O
agents O
. O

The O
288 O
- O
nucleotide B
( I
nt I
) I
3 I
' I
untranslated I
region I
( I
UTR I
) I
in O
the O
genome O
of O
the O
bovine B
coronavirus I
( I
BCoV I
) I
and O
339 O
- O
nt O
3 O
' O
UTR O
in O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
( O
SCoV O
) O
can O
each O
replace O
the O
301 O
- O
nt O
3 O
' O
UTR O
in O
the O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
for O
virus O
replication O
, O
thus O
demonstrating O
common O
3 O
' O
cis O
- O
replication O
signals O
. O

To O
identify O
potential O
smaller O
, O
5 O
' O
- O
common O
signals O
, O
each O
of O
three O
stem B
- I
loop I
( I
SL I
) I
signaling O
domains O
and O
one O
inter O
- O
stem O
- O
loop O
domain O
from O
the O
BCoV O
5 O
' O
UTR O
was O
tested O
by O
replacing O
its O
counterpart O
in O
the O
MHV O
genome O
. O

The O
SLI O
/ O
II O
domain O
( O
nucleotides O
1 O
to O
84 O
) O
and O
SLIII O
domain O
( O
nucleotides O
85 O
to O
141 O
) O
each O
immediately O
enabled O
near O
- O
wild B
- I
type I
( I
WT I
) I
MHV O
- O
like O
progeny O
, O
thus O
behaving O
similarly O
to O
comparable O
5 O
' O
- O
proximal O
regions O
of O
the O
SCoV O
5 O
' O
UTR O
as O
shown O
by O
others O
. O

The O
inter O
- O
stem O
- O
loop O
domain O
( O
nt O
142 O
to O
173 O
between O
SLs O
III O
and O
IV O
) O
enabled O
small O
plaques O
only O
after O
genetic O
adaptation O
. O

The O
SLIV O
domain O
( O
nt O
174 O
to O
210 O
) O
required O
a O
16 O
- O
nt O
extension O
into O
BCoV O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
for O
apparent O
stabilization O
of O
a O
longer O
BCoV O
SLIV O
( O
nt O
174 O
to O
226 O
) O
and O
optimal O
virus O
replication O
. O

The O
infection O
of O
human B
fetal I
foreskin I
fibroblasts I
( I
HFFF2 I
) I
with O
human B
cytomegalovirus I
( I
HCMV I
) I
resulted O
in O
the O
induction O
of O
autophagy O
. O

This O
was O
demonstrated O
by O
the O
increased O
lipidation O
of O
microtubule O
- O
associated O
protein O
1 O
light B
chain I
3 I
( I
LC3 I
) I
, O
a O
hallmark O
of O
autophagy O
, O
and O
by O
the O
visualization O
of O
characteristic O
vesicles O
within O
infected O
cells O
. O

Infection O
with O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
under O
conditions O
that O
inhibited O
viral O
gene O
expression O
provoked O
autophagy O
, O
whereas O
UV O
- O
irradiated O
respiratory O
syncytial O
virus O
did O
not O
. O

The O
fourth O
component O
of O
human O
complement O
( O
C4 O
) O
plays O
an O
important O
role O
in O
innate O
immune O
function O
. O

C4 O
activity O
has O
been O
observed O
to O
be O
significantly O
lower O
in O
patients O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
, O
although O
the O
mechanism O
remains O
unknown O
. O

Further O
, O
C4 O
mRNA O
levels O
of O
the O
two O
isoforms O
( O
C4A O
and O
C4B O
) O
were O
significantly O
reduced O
in O
hepatocytes O
transfected O
with O
RNA O
from O
HCV O
genotype O
1a O
or O
2a O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
induced O
C4 O
promoter O
activation O
was O
also O
impaired O
in O
the O
presence O
of O
HCV O
proteins O
. O

We O
further O
demonstrated O
that O
HCV O
core O
reduced O
the O
expression O
of O
upstream O
stimulating O
factor O
1 O
( O
USF O
- O
1 O
) O
, O
a O
transcription O
factor O
important O
for O
basal O
C4 O
expression O
. O

On O
the O
other O
hand O
, O
the O
expression O
of O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
, O
which O
is O
important O
for O
IFN O
- O
gamma O
- O
induced O
C4 O
expression O
, O
was O
inhibited O
by O
hepatocytes O
expressing O
HCV O
NS5A O
. O

The O
nonstructural B
protein I
3 I
( I
NS3 I
) I
helicase O
/ O
protease O
is O
an O
important O
component O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
. O

To O
test O
this O
hypothesis O
, O
we O
removed O
the O
beta O
- O
strand O
and O
explored O
the O
structural O
and O
functional O
attributes O
of O
the O
truncated O
NS3 O
protein O
( O
NS3 O
Delta O
C7 O
) O
. O

Limited O
proteolysis O
, O
hydrodynamic O
, O
and O
kinetic O
measurements O
indicate O
that O
NS3 O
Delta O
C7 O
adopts O
an O
extended O
conformation O
that O
contrasts O
with O
the O
compact O
form O
of O
the O
wild B
- I
type I
( I
WT I
) I
protein O
. O

The O
RNA O
genome O
of O
Seneca B
Valley I
virus I
( I
SVV I
) I
, O
a O
recently O
identified O
picornavirus O
, O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
element O
which O
has O
structural O
and O
functional O
similarity O
to O
that O
from O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
and O
hepatitis O
C O
virus O
, O
members O
of O
the O
Flaviviridae O
. O

Mutagenesis O
of O
the O
SVV O
IRES O
, O
coupled O
to O
functional O
assays O
, O
support O
the O
core O
elements O
of O
the O
IRES O
structure O
model O
, O
but O
surprisingly O
, O
deletion O
of O
the O
conserved O
IIId O
( O
2 O
) O
domain O
had O
no O
effect O
on O
IRES O
activity O
, O
including O
40S O
and O
eIF3 O
binding O
. O

Genotype O
- O
specific O
sensitivity O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
to O
interferon B
- I
ribavirin I
( I
IFN I
- I
RBV I
) I
combination O
therapy O
and O
reduced O
HCV O
response O
to O
IFN O
- O
RBV O
as O
infection O
progresses O
from O
acute O
to O
chronic O
infection O
suggest O
that O
HCV O
genetic O
factors O
and O
intrahost O
HCV O
evolution O
play O
important O
roles O
in O
therapy O
outcomes O
. O

HCV O
polyprotein O
sequences O
( O
n O
= O
40 O
) O
from O
10 O
patients O
with O
unsustainable B
response I
( I
UR I
) I
( O
breakthrough O
and O
relapse O
) O
and O
10 O
patients O
with O
no O
response O
( O
NR O
) O
following O
therapy O
were O
identified O
through O
the O
Virahep O
- O
C O
study O
. O

Bayesian B
networks I
( I
BNs I
) I
were O
constructed O
to O
relate O
interrelationships O
among O
HCV O
polymorphic O
sites O
to O
UR O
/ O
NR O
outcomes O
. O

Genetic O
studies O
with O
immunocompetent O
mice O
show O
the O
importance O
of O
both O
T O
cells O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
for O
survival O
of O
a O
measles B
virus I
( I
MV I
) I
challenge O
; O
however O
, O
the O
direct O
role O
of O
T O
cells O
and O
IFN O
- O
gamma O
within O
the O
MV O
- O
infected O
brain O
has O
not O
been O
addressed O
. O

Organotypic O
brain O
explants O
represent O
a O
successful O
ex O
vivo O
system O
to O
define O
central B
nervous I
system I
( I
CNS I
) I
- O
specific O
mechanisms O
of O
leukocyte O
migration O
, O
activation O
, O
and O
MV O
clearance O
. O

Secretion O
of O
IFN O
- O
gamma O
is O
stimulated O
by O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
in O
the O
brain O
, O
as O
neutralization O
of O
IL O
- O
12 O
results O
in O
loss O
of O
antiviral O
activity O
and O
stimulation O
of O
leukocytes O
with O
IL O
- O
12 O
/ O
IL O
- O
18 O
enhances O
their O
immune O
effector O
function O
of O
viral O
clearance O
. O

The O
tripartite B
motif I
( I
TRIM I
) I
protein O
family O
comprises O
more O
than O
60 O
members O
that O
have O
diverse O
functions O
in O
various O
biological O
processes O
. O

Here O
we O
identify O
TRIM56 O
as O
a O
cellular O
protein O
associated O
with O
the O
N B
- I
terminal I
protease I
( I
N I
- I
pro I
) I
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
pestiviral O
interferon O
antagonist O
which O
degrades O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
through O
the O
proteasome O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
establishes O
persistent O
infections O
and O
leads O
to O
chronic O
liver O
disease O
. O

It O
only O
recently O
became O
possible O
to O
study O
the O
entire O
HCV O
life O
cycle O
due O
to O
the O
ability O
of O
a O
unique O
cloned O
patient O
isolate O
( O
JFH O
- O
1 O
) O
to O
produce O
infectious O
particles O
in O
tissue O
culture O
. O

These O
three O
mutations O
conferred O
a O
100 O
- O
fold O
increase O
in O
specific O
infectivity O
compared O
to O
the O
parental O
J6 O
/ O
JFH O
- O
1 O
virus O
, O
and O
media O
collected O
from O
cells O
infected O
with O
the O
adapted O
virus O
yielded O
infectious O
titers O
as O
high O
as O
1 O
x O
10 O
( O
8 O
) O
50 B
% I
tissue I
culture I
infective I
doses I
( I
TCID50 I
) I
/ O
ml O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
2a O
isolate O
JFH1 O
represents O
the O
only O
cloned O
HCV O
wild O
- O
type O
sequence O
capable O
of O
efficient O
replication O
in O
cell O
culture O
as O
well O
as O
in O
vivo O
. O

Previous O
reports O
have O
pointed O
to O
NS5B O
, O
the O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
as O
a O
major O
determinant O
for O
efficient O
replication O
of O
this O
isolate O
. O

It O
is O
widely O
recognized O
that O
sialic B
acid I
( I
SA I
) I
can O
mediate O
attachment O
of O
influenza O
virus O
to O
the O
cell O
surface O
, O
and O
yet O
the O
specific O
receptors O
that O
mediate O
virus O
entry O
are O
not O
known O
. O

We O
examined O
influenza O
virus O
infection O
of O
Lec2 O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cells O
, O
a O
mutant O
cell O
line O
deficient O
in O
SA O
. O

Virus O
strain O
BJx109 O
( O
H3N2 O
) O
bound O
to O
Lec2 O
CHO O
cells O
expressing O
DC O
- O
SIGN O
or O
L O
- O
SIGN O
in O
a O
Ca2 O
+ O
- O
dependent O
manner O
, O
and O
transfected O
cells O
were O
susceptible O
to O
virus O
infection O
. O

Moreover O
, O
virus O
strain O
PR8 O
( O
H1N1 O
) O
bears O
low O
levels O
of O
mannose O
- O
rich O
glycans O
and O
was O
inefficient O
at O
infecting O
Lec2 O
CHO O
cells O
expressing O
either O
DC O
- O
SIGN O
or O
L O
- O
SIGN O
, O
whereas O
other O
glycosylated O
H1N1 O
subtype O
viruses O
could O
infect O
cells O
efficiently O
. O

Together O
, O
these O
data O
indicate O
that O
human O
C O
- O
type O
lectins O
( O
DC O
- O
SIGN O
and O
L O
- O
SIGN O
) O
can O
mediate O
attachment O
and O
entry O
of O
influenza O
viruses O
independently O
of O
cell O
surface O
SA O
. O

Over O
the O
past O
decade O
, O
a O
family O
of O
host O
proteins O
known O
as O
suppressors B
of I
cytokine I
signaling I
( I
SOCS I
) I
have O
emerged O
as O
frequent O
targets O
of O
viral O
exploitation O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
envelope O
glycoprotein O
has O
been O
implicated O
in O
virus O
neutralization O
and O
persistence O
. O

The O
2a O
( O
Delta O
HVR1 O
) O
, O
5a O
( O
Delta O
HVR1 O
) O
, O
and O
6a O
( O
Delta O
HVR1 O
) O
Core O
- O
NS2 O
recombinants O
retained O
viability O
in O
Huh7 O
. O

5 O
cells O
, O
whereas O
1a O
( O
Delta O
HVR1 O
) O
, O
1b O
( O
Delta O
HVR1 O
) O
, O
2b O
( O
Delta O
HVR1 O
) O
, O
3a O
( O
Delta O
HVR1 O
) O
, O
and O
4a O
( O
Delta O
HVR1 O
) O
recombinants O
were O
severely O
attenuated O
. O

However O
, O
except O
for O
recombinant O
4a O
( O
Delta O
HVR1 O
) O
, O
viruses O
eventually O
spread O
, O
and O
reverse O
genetics O
studies O
revealed O
adaptive O
envelope O
mutations O
that O
rescued O
the O
infectivity O
of O
1a O
( O
Delta O
HVR1 O
) O
, O
1b O
( O
Delta O
HVR1 O
) O
, O
2b O
( O
Delta O
HVR1 O
) O
, O
and O
3a O
( O
Delta O
HVR1 O
) O
recombinants O
. O

In O
vivo O
relevance O
for O
the O
role O
of O
HVR1 O
in O
protecting O
HCV O
from O
neutralization O
was O
demonstrated O
by O
ex O
vivo O
neutralization O
of O
2a O
and O
2a O
( O
Delta O
HVR1 O
) O
produced O
in O
human O
liver O
chimeric O
mice O
. O

microRNA B
122 I
( I
miR I
- I
122 I
) I
increases O
the O
accumulation O
and O
translation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
in O
infected O
cells O
through O
direct O
interactions O
with O
homologous O
sequences O
in O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
HCV O
genome O
. O

Argonaute B
2 I
( I
Ago2 I
) I
is O
a O
component O
of O
the O
RNA B
- I
induced I
silencing I
complex I
( I
RISC I
) I
and O
mediates O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
directed O
mRNA O
cleavage O
and O
microRNA O
translational O
suppression O
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
longitudinally O
hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
T O
- O
cell O
reactivity O
and O
viral O
behavior O
versus O
treatment O
response O
in O
tolerant O
children O
during O
combined O
antiviral O
therapy O
. O

Twenty O
- O
three O
children O
with O
infancy O
- O
acquired O
hepatitis O
B O
( O
HBeAg O
+ O
) O
belonging O
to O
a O
published O
pilot O
study O
of O
1 O
- O
year O
treatment O
with O
lamivudine O
/ O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
were O
investigated O
. O

Five O
seroconverted O
to O
anti O
- O
HBs O
( O
responders O
) O
. O

Nine O
were O
HLA O
- O
A2 O
( O
+ O
) O
( O
4 O
responders O
and O
5 O
nonresponders O
) O
. O

Mutations O
within O
the O
HBV O
core O
gene O
were O
determined O
at O
baseline O
in O
liver O
and O
in O
serial O
serum O
samples O
by O
direct O
sequencing O
at O
baseline O
; O
during O
treatment B
week I
2 I
( I
TW2 I
) I
, O
TW9 O
, O
TW28 O
, O
and O
TW52 O
; O
and O
after O
follow B
- I
up I
week I
24 I
( I
FUW24 I
) I
and O
FUW52 O
. O

HBV O
- O
specific O
reactivity O
was O
evaluated O
by O
T O
- O
cell O
proliferation O
with O
16 O
HBV O
core O
20 O
- O
mer O
overlapping O
peptides O
and O
by O
HLA O
- O
A2 O
- O
restricted O
core O
( O
18 O
- O
27 O
) O
pentamer O
staining O
and O
CD8 O
( O
+ O
) O
IFN O
- O
gamma O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assay O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS2 O
protein O
is O
essential O
for O
particle O
assembly O
, O
but O
its O
function O
in O
this O
process O
is O
unknown O
. O

The O
carboxy B
- I
terminal I
domain I
( I
CTD I
) I
of O
the O
core O
protein O
of O
hepatitis O
B O
virus O
is O
not O
necessary O
for O
capsid O
assembly O
. O

However O
, O
the O
CTD O
does O
contribute O
to O
encapsidation O
of O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

The O
rapid O
induction O
of O
type B
I I
interferon I
( I
IFN I
) I
is O
essential O
for O
establishing O
innate O
antiviral O
responses O
. O

We O
demonstrate O
the O
existence O
of O
an O
evasion O
mechanism O
based O
on O
the O
inhibition O
of O
the O
RIG O
- O
I O
sensor O
through O
the O
action O
of O
the O
HIV O
- O
1 O
Protease B
( I
Pr I
) I
. O

Indeed O
, O
the O
ectopic O
expression O
of O
PR O
resulted O
in O
the O
inhibition O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
phosphorylation O
and O
decreased O
expression O
of O
IFN O
and O
interferon O
- O
stimulated O
genes O
. O

Little O
is O
known O
about O
the O
structure O
of O
the O
envelope O
glycoproteins O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

To O
identify O
new O
regions O
essential O
for O
the O
function O
of O
these O
glycoproteins O
, O
we O
generated O
HCV B
pseudoparticles I
( I
HCVpp I
) I
containing O
HCV O
envelope O
glycoproteins O
, O
E1 O
and O
E2 O
, O
from O
different O
genotypes O
in O
order O
to O
detect O
intergenotypic O
incompatibilities O
between O
these O
two O
proteins O
. O

The O
functionality O
of O
these O
chimeric O
envelope O
proteins O
in O
the O
HCVpp O
system O
and O
/ O
or O
the O
cell O
- O
cultured O
infectious O
virus O
( O
HCVcc O
) O
was O
analyzed O
. O

We O
showed O
that O
the O
intergenotypic B
variable I
region I
( I
IgVR I
) I
, O
hypervariable B
region I
2 I
( I
HVR2 I
) I
, O
and O
another O
segment O
in O
domain O
II O
play O
a O
role O
in O
E1E2 O
assembly O
. O

Importantly O
, O
we O
also O
identified O
a O
segment O
( O
amino O
acids O
[ O
aa O
] O
705 O
to O
715 O
[ O
segment O
705 O
- O
715 O
] O
) O
in O
the O
stem O
region O
of O
E2 O
, O
which O
is O
essential O
for O
HCVcc O
entry O
. O

Many O
aspects O
of O
the O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
remain O
incompletely O
understood O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
interplay O
was O
investigated O
by O
examining O
liver O
and O
serum O
samples O
from O
21 O
coinfected O
and O
22 O
HBV O
- O
monoinfected O
patients O
with O
chronic O
liver O
disease O
. O

Different O
real O
- O
time O
PCR O
assays O
were O
applied O
to O
evaluate O
intrahepatic O
amounts O
of O
HBV O
DNA O
, O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
pre O
- O
S O
/ O
S O
RNAs O
, O
and O
HDV O
RNA O
. O

HDV O
- O
coinfected O
cases O
showed O
significantly O
lower O
median O
levels O
of O
serum O
HBV O
DNA O
( O
- O
5 O
log O
) O
, O
intrahepatic O
relaxed O
- O
circular O
DNA O
( O
- O
2 O
log O
) O
, O
and O
cccDNA O
( O
- O
2 O
log O
) O
than O
those O
of O
HBV O
- O
monoinfected O
cases O
. O

Interestingly O
, O
pgRNA O
and O
pre O
- O
S O
/ O
S O
RNA O
amounts O
were O
significantly O
lower O
( O
both O
- O
1 O
log O
) O
in O
HDV O
- O
positive O
patients O
, O
whereas O
serum O
HBsAg O
concentrations O
were O
comparable O
between O
the O
two O
patient O
groups O
. O

Pre O
- O
S O
/ O
S O
RNA O
and O
HBsAg O
amounts O
per O
cccDNA O
molecule O
were O
higher O
in O
HDV O
- O
positive O
patients O
( O
3 O
- O
fold O
and O
1 O
log O
, O
respectively O
) O
, O
showing O
that O
HBV O
replication O
was O
reduced O
, O
whereas O
synthesis O
of O
envelope O
proteins O
was O
not O
specifically O
decreased O
. O

We O
hypothesized O
that O
ADP B
- I
ribosylation I
factor I
1 I
( I
Arf1 I
) I
plays O
an O
important O
role O
in O
the O
biogenesis O
and O
maintenance O
of O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Fluorescence O
analyses O
showed O
that O
the O
viral O
nonstructural B
( I
NS I
) I
proteins O
NS5A O
and O
NS3 O
, O
but O
not O
the O
viral O
structural O
protein O
core O
, O
shifted O
their O
localization O
from O
speckle O
- O
like O
structures O
in O
untreated O
cells O
to O
the O
rims O
of O
lipid B
droplets I
( I
LDs I
) I
in O
treated O
cells O
. O

Downregulation O
of O
Arf1 O
expression O
by O
small B
interfering I
RNA I
( I
siRNA I
) I
decreased O
both O
the O
levels O
of O
HCV O
RNA O
and O
the O
production O
of O
infectious O
viral O
particles O
and O
altered O
the O
localization O
of O
NS5A O
to O
the O
peripheries O
of O
LDs O
. O

RIG O
- O
I O
is O
an O
intracellular O
RNA O
virus O
sensor O
that O
mediates O
a O
signaling O
pathway O
that O
triggers O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
immune O
defenses O
. O

Here O
we O
show O
that O
RIG O
- O
I O
activity O
is O
regulated O
by O
phosphorylation O
and O
dephosphorylation O
in O
its O
repressor B
domain I
( I
RD I
) I
. O

Threonine O
at O
amino B
acid I
( I
aa I
) I
770 O
and O
serine O
at O
aa O
854 O
to O
855 O
of O
RIG O
- O
I O
are O
phosphorylated O
by O
casein B
kinase I
II I
( I
CK2 I
) I
in O
the O
resting O
state O
of O
the O
cell O
and O
dephosphorylated O
when O
cells O
are O
infected O
by O
RNA O
virus O
. O

Parvovirus B
B19 I
( I
B19V I
) I
infection O
is O
highly O
restricted O
to O
human O
erythroid O
progenitor O
cells O
. O

In O
the O
study O
reported O
here O
, O
we O
have O
investigated O
the O
basis O
of O
this O
tropism O
, O
and O
a O
potential O
role O
of O
erythropoietin B
( I
Epo I
) I
signaling O
, O
in O
erythroid B
progenitor I
cells I
( I
EPCs I
) I
expanded O
ex O
vivo O
from O
CD34 O
( O
+ O
) O
hematopoietic O
cells O
in O
the O
absence O
of O
Epo O
( O
CD36 O
( O
+ O
) O
/ O
Epo O
( O
- O
) O
EPCs O
) O
. O

We O
show O
, O
first O
, O
that O
CD36 O
( O
+ O
) O
/ O
Epo O
( O
- O
) O
EPCs O
do O
not O
support O
B19V O
replication O
, O
in O
spite O
of O
B19V O
entry O
, O
but O
Epo O
exposure O
either O
prior O
to O
infection O
or O
after O
virus O
entry O
enabled O
active O
B19V O
replication O
. O

Second O
, O
when O
Janus B
kinase I
2 I
( I
JAK2 I
) I
phosphorylation O
was O
inhibited O
using O
the O
inhibitor O
AG490 O
, O
phosphorylation O
of O
the O
Epo B
receptor I
( I
EpoR I
) I
was O
also O
inhibited O
, O
and O
B19V O
replication O
in O
ex O
vivo O
- O
expanded O
erythroid O
progenitor O
cells O
exposed O
to O
Epo O
( O
CD36 O
( O
+ O
) O
/ O
Epo O
( O
+ O
) O
EPCs O
) O
was O
abolished O
. O

Third O
, O
expression O
of O
constitutively O
active O
EpoR O
in O
CD36 O
( O
+ O
) O
/ O
Epo O
( O
- O
) O
EPCs O
led O
to O
efficient O
B19V O
replication O
. O

Finally O
, O
B19V O
replication O
in O
CD36 O
( O
+ O
) O
/ O
Epo O
( O
+ O
) O
EPCs O
required O
Epo O
, O
and O
the O
replication O
response O
was O
dose O
dependent O
. O

A O
major O
function O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
the O
interaction O
with O
genomic O
RNA O
to O
form O
the O
nucleocapsid O
, O
an O
essential O
component O
of O
the O
virus O
particle O
. O

The O
development O
of O
a O
cell O
culture O
system O
for O
HCV O
( O
HCVcc O
) O
allows O
a O
more O
precise O
analysis O
of O
these O
core O
protein O
amino O
acids O
during O
the O
HCV O
life O
cycle O
. O

We O
focused O
our O
analysis O
on O
basic O
residues O
located O
in O
two O
clusters O
( O
cluster O
1 O
, O
amino O
acids O
[ O
aa O
] O
6 O
to O
23 O
; O
cluster O
2 O
, O
aa O
39 O
to O
62 O
) O
within O
the O
N O
- O
terminal O
62 O
amino O
acids O
of O
the O
HCV O
core O
protein O
. O

Furthermore O
, O
only O
four O
basic O
amino O
acids O
residues O
of O
the O
second O
cluster O
( O
R50 O
, O
K51 O
, O
R59 O
, O
and O
R62 O
) O
were O
essential O
for O
the O
production O
of O
infectious O
viral O
particles O
. O

Nonstructural B
protein I
4B I
( I
NS4B I
) I
is O
a O
key O
organizer O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
formation O
. O

Based O
on O
fluorescence B
resonance I
energy I
transfer I
( I
FRET I
) I
and O
confirmatory O
coimmunoprecipitation O
analyses O
, O
we O
provide O
evidence O
for O
an O
oligomerization O
of O
NS4B O
in O
the O
membrane O
environment O
of O
intact O
cells O
. O

Resistance O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
inhibitors O
targeting O
viral O
enzymes O
has O
been O
observed O
in O
in O
vitro O
replicon O
studies O
and O
during O
clinical O
trials O
. O

To O
assess O
the O
dynamics O
of O
variants O
emerging O
in O
vitro O
under O
various O
selective O
pressures O
with O
TMC380765 O
, O
a O
potent O
macrocyclic O
HCV O
NS3 O
/ O
4A O
protease O
inhibitor O
, O
HCV O
genotype O
1b O
replicon O
- O
containing O
cells O
were O
cultured O
in O
the O
presence O
of O
a O
low O
, O
high O
, O
or O
stepwise O
- O
increasing O
TMC380765 O
concentration O
( O
s O
) O
. O

HCV O
replicon O
RNA O
from O
representative O
samples O
thus O
obtained O
was O
analyzed O
using O
( O
i O
) O
population O
, O
( O
ii O
) O
clonal O
, O
and O
( O
iii O
) O
454 O
deep O
sequencing O
technologies O
. O

In O
particular O
, O
culturing O
with O
low O
concentrations O
resulted O
in O
the O
selection O
of O
low O
- O
level O
resistance O
mutations O
( O
F43S O
and O
A156G O
) O
, O
whereas O
high O
concentrations O
resulted O
in O
the O
selection O
of O
high O
- O
level O
resistance O
mutations O
( O
A156V O
, O
D168V O
, O
and O
D168A O
) O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
is O
a O
virion O
structural O
protein O
. O

It O
also O
functions O
, O
however O
, O
in O
an O
unknown O
way O
in O
viral O
replication O
and O
localizes O
to O
the O
viral O
replication B
- I
transcription I
complexes I
( I
RTCs I
) I
. O

Here O
we O
investigated O
, O
using O
recombinant O
murine O
coronaviruses O
expressing O
green B
fluorescent I
protein I
( I
GFP I
) I
- O
tagged O
versions O
of O
the O
N O
protein O
, O
the O
dynamics O
of O
its O
interactions O
with O
the O
RTCs O
and O
the O
domain O
( O
s O
) O
involved O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoproteins O
are O
highly O
glycosylated O
, O
with O
generally O
4 O
and O
11 O
N O
- O
linked O
glycans O
on O
E1 O
and O
E2 O
, O
respectively O
. O

Studies O
using O
mutated O
recombinant O
HCV O
envelope O
glycoproteins O
incorporated O
into O
retroviral O
pseudoparticles O
( O
HCVpp O
) O
suggest O
that O
some O
glycans O
play O
a O
role O
in O
protein O
folding O
, O
virus O
entry O
, O
and O
protection O
against O
neutralization O
. O

The O
development O
of O
a O
cell O
culture O
system O
producing O
infectious O
particles O
( O
HCVcc O
) O
in O
hepatoma O
cells O
provides O
an O
opportunity O
to O
characterize O
the O
role O
of O
these O
glycans O
in O
the O
context O
of O
authentic O
infectious O
virions O
. O

Furthermore O
, O
our O
data O
demonstrate O
that O
at O
least O
five O
glycans O
on O
E2 O
( O
denoted O
E2N1 O
, O
E2N2 O
, O
E2N4 O
, O
E2N6 O
, O
and O
E2N11 O
) O
strongly O
reduce O
the O
sensitivity O
of O
HCVcc O
to O
antibody O
neutralization O
, O
with O
four O
of O
them O
surrounding O
the O
CD81 O
binding O
site O
. O

Although O
the O
elimination O
of O
infected O
hepatocytes O
is O
required O
to O
combat O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
it O
is O
still O
unknown O
which O
consequences O
hepatocyte O
apoptosis O
has O
for O
the O
virus O
and O
whether O
or O
not O
it O
is O
advantageous O
to O
the O
virus O
. O

Mutations O
in O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
have O
been O
associated O
with O
enhanced O
in O
vitro O
replication O
and O
viral O
attenuation O
in O
animal O
models O
. O

To O
address O
the O
possible O
role O
of O
IRES O
variability O
in O
clinical O
presentation O
, O
IRES O
sequences O
were O
obtained O
from O
HAV O
isolates O
associated O
with O
benign O
( O
n O
= O
8 O
) O
or O
severe O
( O
n O
= O
4 O
) O
hepatitis O
. O

IRES O
activity O
was O
assessed O
using O
a O
bicistronic O
dual O
- O
luciferase O
expression O
system O
in O
adenocarcinoma O
( O
HeLa O
) O
and O
hepatoma O
( O
HuH7 O
) O
cell O
lines O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
plays O
an O
essential O
role O
in O
virion O
assembly O
via O
interactions O
with O
the O
large O
, O
positive O
- O
strand O
RNA O
viral O
genome O
and O
the O
carboxy O
- O
terminal O
endodomain O
of O
the O
membrane B
protein I
( I
M I
) I
. O

To O
learn O
about O
the O
functions O
of O
N O
protein O
domains O
in O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
we O
replaced O
the O
MHV O
N O
gene O
with O
its O
counterpart O
from O
the O
closely O
related O
bovine B
coronavirus I
( I
BCoV I
) I
. O

The O
lesion O
in O
the O
BCoV O
N O
substitution O
mutant O
could O
be O
compensated O
for O
by O
reverting O
mutations O
in O
the O
central O
, O
serine B
- I
and I
arginine I
- I
rich I
( I
SR I
) I
domain O
of O
the O
N O
protein O
. O

Surprisingly O
, O
a O
second O
class O
of O
reverting O
mutations O
were O
mapped O
to O
the O
amino O
terminus O
of O
a O
replicase O
subunit O
, O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
. O

Moreover O
, O
we O
found O
a O
direct O
correlation O
between O
the O
N O
- O
nsp3 O
interaction O
and O
the O
ability O
of O
N O
protein O
to O
stimulate O
the O
infectivity O
of O
transfected O
MHV O
genomic B
RNA I
( I
gRNA I
) I
. O

The O
eukaryotic B
initiation I
translation I
factor I
2 I
( I
eIF2 I
) I
represents O
a O
key O
point O
in O
the O
regulation O
of O
protein O
synthesis O
. O

leniusculus O
C1qR O
( O
PlgC1qR O
) O
in O
various O
tissues O
. O

The O
gC1qR O
/ O
p32 O
transcript O
was O
significantly O
enhanced O
by O
white B
spot I
syndrome I
virus I
( I
WSSV I
) I
infection O
6 O
h O
after O
viral O
infection O
both O
in O
vitro O
in O
a O
hematopoietic O
tissue O
cell O
culture O
( O
Hpt O
) O
and O
in O
vivo O
compared O
to O
appropriate O
controls O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
forms O
the O
nucleocapsid O
of O
the O
HCV O
particle O
. O

Here O
we O
show O
that O
the O
nucleocapsid O
- O
like O
particle O
of O
HCV O
is O
composed O
of O
a O
disulfide O
- O
bonded O
core O
protein O
complex O
( O
dbc O
- O
complex O
) O
. O

We O
also O
found O
that O
the O
disulfide O
- O
bonded O
dimer O
of O
the O
core O
protein O
( O
dbd O
- O
core O
) O
is O
formed O
at O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
where O
the O
core O
protein O
is O
initially O
produced O
and O
processed O
. O

Mutational O
analysis O
revealed O
that O
the O
cysteine B
residue I
at I
amino I
acid I
position I
128 I
( I
Cys128 I
) I
of O
the O
core O
protein O
, O
a O
highly O
conserved O
residue O
among O
almost O
all O
reported O
isolates O
, O
is O
responsible O
for O
dbd O
- O
core O
formation O
and O
virus O
- O
like O
particle O
production O
but O
has O
no O
effect O
on O
the O
replication O
of O
the O
HCV O
RNA O
genome O
or O
the O
several O
known O
functions O
of O
the O
core O
protein O
, O
including O
RNA O
binding O
ability O
and O
localization O
to O
the O
lipid O
droplet O
. O

We O
also O
obtained O
the O
results O
that O
the O
dbc O
- O
complex O
in O
the O
nucleocapsid O
- O
like O
structure O
was O
sensitive O
to O
proteinase O
K O
but O
not O
trypsin O
digestion O
, O
suggesting O
that O
the O
capsid O
is O
built O
up O
of O
a O
tightly O
packed O
structure O
of O
the O
core O
protein O
, O
with O
its O
amino O
( O
N O
) O
- O
terminal O
arginine O
- O
rich O
region O
being O
concealed O
inside O
. O

Type O
III O
interferons O
( O
[ O
IFNs O
] O
IFN O
- O
lambda O
and O
interleukin O
- O
28 O
and O
- O
29 O
[ O
IL O
- O
28 O
/ O
29 O
] O
) O
are O
recently O
recognized O
cytokines O
with O
innate O
antiviral O
effects O
similar O
to O
those O
of O
type O
I O
IFNs O
( O
IFN O
- O
alpha O
/ O
beta O
) O
. O

Hantaviruses O
are O
weak O
IFN O
- O
alpha O
/ O
beta O
inducers O
and O
have O
surprisingly O
been O
shown O
to O
activate O
IFN O
- O
alpha O
/ O
beta O
- O
independent O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
expression O
. O

Here O
, O
we O
show O
that O
in O
Hantaan B
virus I
( I
HTNV I
) I
- O
infected O
human O
epithelial O
A549 O
cells O
, O
induction O
of O
IFN O
- O
lambda O
1 O
preceded O
induction O
of O
MxA O
and O
IFN O
- O
beta O
by O
12 O
and O
24 O
h O
, O
respectively O
, O
and O
IFN O
- O
alpha O
was O
not O
induced O
at O
all O
. O

Induction O
of O
both O
IFN O
- O
beta O
and O
IFN O
- O
lambda O
1 O
in O
A549 O
cells O
after O
poly O
( O
I O
: O
C O
) O
- O
stimulation O
was O
strongly O
inhibited O
in O
HTNV O
- O
infected O
cells O
, O
suggesting O
that O
HTNV O
can O
inhibit O
signaling O
pathways O
used O
to O
simultaneously O
activate O
types O
I O
and O
III O
IFNs O
. O

We O
report O
here O
investigation O
into O
the O
genetic O
basis O
of O
mouse B
hepatitis I
virus I
strain I
1 I
( I
MHV I
- I
1 I
) I
pneumovirulence O
. O

The O
hemagglutinin B
esterase I
( I
HE I
) I
protein O
was O
truncated O
, O
and O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
studies O
confirmed O
previous O
work O
that O
suggested O
that O
the O
MHV O
- O
1 O
HE O
is O
a O
pseudogene O
. O

Challenge O
studies O
in O
mice O
demonstrated O
that O
expression O
of O
the O
MHV O
- O
1 O
S O
gene O
within O
the O
MHV O
- O
A59 O
background O
( O
rA59 O
/ O
SMHV O
- O
1 O
) O
increased O
the O
pneumovirulence O
of O
MHV O
- O
A59 O
, O
and O
mice O
infected O
with O
this O
recombinant O
virus O
developed O
pulmonary O
lesions O
that O
were O
similar O
to O
those O
observed O
with O
MHV O
- O
1 O
, O
although O
rA59 O
/ O
SMHV O
- O
1 O
was O
significantly O
less O
virulent O
. O

Chimeras O
containing O
all O
of O
the O
MHV O
- O
1 O
structural O
genes O
on O
an O
MHV O
- O
A59 O
background O
were O
able O
to O
reproduce O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
like O
pathology O
observed O
with O
MHV O
- O
1 O
and O
reproducibly O
increased O
pneumovirulence O
relative O
to O
rA59 O
/ O
SMHV O
- O
1 O
, O
but O
were O
still O
much O
less O
virulent O
than O
MHV O
- O
1 O
. O

The O
X O
protein O
( O
HBX O
) O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
essential O
for O
HBV O
productive O
infection O
in O
vivo O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
has O
a O
positive O
- O
sense O
RNA O
genome O
with O
a O
5 O
' O
- O
m7G O
cap O
. O

HEV O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
encodes O
a O
polyprotein O
with O
multiple O
enzyme O
domains O
required O
for O
replication O
. O

HEV O
helicase O
is O
a O
nucleoside B
triphosphatase I
( I
NTPase I
) I
with O
the O
ability O
to O
unwind O
RNA O
duplexes O
in O
the O
5 O
' O
- O
to O
- O
3 O
' O
direction O
. O

Removal O
of O
gamma O
- O
phosphate O
from O
the O
5 O
' O
end O
of O
the O
primary O
transcripts O
( O
pppRNA O
to O
ppRNA O
) O
by O
RNA O
triphosphatase O
is O
an O
essential O
step O
during O
cap O
formation O
. O

The O
members O
of O
Betacoronavirus O
phylocluster O
A O
possess O
two O
types O
of O
surface O
projections O
, O
one O
comprised O
of O
the O
spike B
protein I
( I
S I
) I
and O
the O
other O
of O
hemagglutinin B
- I
esterase I
( I
HE I
) I
. O

Purportedly O
, O
these O
viruses O
bind O
to O
O B
- I
acetylated I
sialic I
acids I
( I
O I
- I
Ac I
- I
Sias I
) I
primarily O
through O
S O
, O
with O
HE O
serving O
merely O
as O
receptor O
- O
destroying O
enzyme O
. O

The O
type B
I I
interferon I
( I
IFN I
) I
response O
plays O
an O
essential O
role O
in O
the O
control O
of O
in O
vivo O
infection O
by O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infections O
are O
associated O
with O
persistent O
immune O
killing O
of O
infected O
hepatocytes O
. O

The O
present O
study O
was O
carried O
out O
to O
determine O
( O
i O
) O
if O
extensive O
clonal O
expansion O
of O
hepatocytes O
also O
occurred O
in O
human O
HBV O
carriers O
, O
particularly O
in O
the O
noncirrhotic O
liver O
, O
and O
( O
ii O
) O
if O
clonal O
expansion O
included O
normal O
- O
appearing O
hepatocytes O
, O
not O
just O
hepatocytes O
that O
appear O
premalignant O
. O

Host O
DNA O
extracted O
from O
fragments O
of O
noncancerous O
liver O
, O
collected O
during O
surgical O
resection O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
, O
was O
analyzed O
by O
inverse O
PCR O
for O
randomly O
integrated O
HBV O
DNA O
as O
a O
marker O
of O
expanding O
hepatocyte O
lineages O
. O

Tissue O
sections O
were O
stained O
with O
hematoxylin B
and I
eosin I
( I
H&E I
) I
, O
and O
DNA O
was O
extracted O
from O
the O
adjacent O
section O
for O
inverse O
PCR O
to O
detect O
integrated O
HBV O
DNA O
. O

Interferons B
( I
IFNs I
) I
are O
key O
mediators O
of O
the O
host O
innate O
antiviral O
immune O
response O
. O

To O
identify O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
that O
instigate O
an O
antiviral O
state O
against O
two O
medically O
important O
flaviviruses O
, O
West B
Nile I
virus I
( I
WNV I
) I
and O
Dengue B
Virus I
( I
DENV I
) I
, O
we O
tested O
36 O
ISGs O
that O
are O
commonly O
induced O
by O
IFN O
- O
alpha O
for O
antiviral O
activity O
against O
the O
two O
viruses O
. O

Mechanistic O
analyses O
revealed O
that O
two O
structurally O
related O
cell O
plasma O
membrane O
proteins O
, O
IFITM2 O
and O
IFITM3 O
, O
disrupted O
early O
steps O
( O
entry O
and O
/ O
or O
uncoating O
) O
of O
the O
viral O
infection O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
, O
an O
atypical O
member O
of O
the O
Picornaviridae O
, O
grows O
poorly O
in O
cell O
culture O
. O

To O
define O
determinants O
of O
HAV O
growth O
, O
we O
introduced O
a O
blasticidin O
( O
Bsd O
) O
resistance O
gene O
into O
the O
virus O
genome O
and O
selected O
variants O
that O
grew O
at O
high O
concentrations O
of O
Bsd O
. O

Nucleotide O
sequence O
analysis O
and O
reverse O
genetic O
studies O
revealed O
that O
a O
T6069G O
change O
resulting O
in O
a O
F42L O
amino O
acid O
substitution O
in O
the O
viral O
polymerase O
( O
3D O
( O
pol O
) O
) O
was O
required O
for O
growth O
at O
high O
Bsd O
concentrations O
whereas O
a O
silent O
C7027T O
mutation O
enhanced O
the O
growth O
rate O
. O

Here O
, O
we O
identified O
a O
novel O
determinant O
( O
s O
) O
in O
3D O
( O
pol O
) O
that O
controls O
the O
kinetics O
of O
HAV O
growth O
. O

As O
one O
of O
the O
world O
' O
s O
most O
common O
infectious O
diseases O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
serious O
worldwide O
public O
health O
problem O
, O
with O
HBV O
- O
associated O
liver O
disease O
accounting O
for O
more O
than O
half O
a O
million O
deaths O
each O
year O
. O

We O
produced O
a O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
based O
vaccine O
vector O
expressing O
the O
HBV O
middle O
envelope O
surface O
protein O
( O
MS O
) O
and O
found O
that O
this O
vector O
was O
able O
to O
efficiently O
generate O
a O
strong O
HBs O
- O
specific O
antibody O
response O
following O
a O
single O
immunization O
in O
mice O
. O

Many O
viruses O
, O
including O
Coronaviruses B
( I
CoVs I
) I
, O
depend O
on O
a O
functional O
cellular O
proteasome O
for O
efficient O
infection O
in O
vitro O
. O

Hence O
, O
the O
proteasome O
inhibitor O
Velcade O
( O
bortezomib O
) O
, O
a O
clinically O
approved O
anticancer O
drug O
, O
shown O
in O
an O
accompanying O
study O
( O
M O
. O

84 O
: O
7869 O
- O
7879 O
, O
2010 O
) O
to O
strongly O
inhibit O
mouse B
hepatitis I
CoV I
( I
MHV I
) I
infection O
in O
cultured O
cells O
, O
seemed O
an O
attractive O
candidate O
for O
testing O
its O
antiviral O
properties O
in O
vivo O
. O

The O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
induced O
the O
expression O
of O
type O
I O
interferon O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
in O
mouse O
oligodendrocytic O
N20 O
. O

We O
show O
that O
MHV O
infection O
activated O
both O
transcription O
factors O
, O
the O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
and O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
, O
as O
evidenced O
by O
phosphorylation O
and O
nuclear O
translocation O
of O
IRF O
- O
3 O
and O
an O
increased O
promoter O
binding O
activity O
for O
IRF O
- O
3 O
and O
NF O
- O
kappa O
B O
. O

Furthermore O
, O
the O
cytoplasmic O
pattern O
recognition O
receptor O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
was O
induced O
by O
MHV O
infection O
. O

Knockdown O
of O
another O
cytoplasmic O
receptor O
, O
the O
melanoma B
- I
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
, O
by O
small O
interfering O
RNAs O
also O
blocked O
IFN O
- O
beta O
induction O
. O

miR O
- O
122 O
is O
a O
liver O
- O
specific O
microRNA O
that O
positively O
regulates O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
abundance O
and O
is O
essential O
for O
production O
of O
infectious O
HCV O
. O

We O
conclude O
that O
miR O
- O
122 O
promotes O
replication O
by O
binding O
directly O
to O
both O
sites O
in O
the O
genomic O
RNA O
and O
, O
at O
least O
in O
part O
, O
by O
stimulating O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
mediated O
translation O
. O

Although O
most O
inbred O
mouse O
strains O
are O
highly O
susceptible O
to O
mouse B
hepatitis I
virus I
( I
MHV I
) I
infection O
, O
the O
inbred O
SJL O
line O
of O
mice O
is O
highly O
resistant O
to O
its O
infection O
. O

The O
principal O
receptor O
for O
MHV O
is O
murine O
CEACAM1 O
( O
mCEACAM1 O
) O
. O

mCEACAM1a O
( O
1a O
) O
has O
a O
10 O
- O
to O
100 O
- O
fold O
- O
higher O
receptor O
activity O
than O
does O
mCEACAM1b O
( O
1b O
) O
. O

To O
explore O
the O
hypothesis O
that O
MHV O
susceptibility O
is O
due O
to O
the O
different O
MHV O
receptor O
activities O
of O
1a O
and O
1b O
, O
we O
established O
a O
chimeric O
C57BL O
/ O
6 O
mouse O
( O
cB61ba O
) O
in O
which O
a O
part O
of O
the O
N O
- O
terminal O
immunoglobulin B
( I
Ig I
) I
- O
like O
domain O
of O
the O
mCeacam1a O
( O
1a O
) O
gene O
, O
which O
is O
responsible O
for O
MHV O
receptor O
function O
, O
is O
replaced O
by O
the O
corresponding O
region O
of O
mCeacam1b O
( O
1b O
) O
. O

B6 O
mice O
that O
are O
homozygous O
for O
1a O
are O
highly O
susceptible O
to O
MHV O
- O
A59 O
infection O
, O
with O
a O
50 B
% I
lethal I
dose I
( I
LD I
( I
50 I
) I
) I
of O
10 O
( O
2 O
. O

5 O
) O
PFU O
, O
while O
chimeric O
cB61ba O
mice O
and O
SJL O
mice O
homozygous O
for O
1ba O
and O
1b O
, O
respectively O
, O
survived O
following O
inoculation O
with O
10 O
( O
5 O
) O
PFU O
. O

Furthermore O
, O
SJL O
mice O
produced O
antiviral O
antibodies O
after O
MHV O
- O
A59 O
inoculation O
with O
10 O
( O
5 O
) O
PFU O
, O
but O
cB61ba O
mice O
did O
not O
. O

Confocal O
microscopy O
demonstrated O
that O
viroplasms O
associate O
with O
lipids O
and O
proteins O
( O
perilipin O
A O
, O
ADRP O
) O
characteristic O
of O
lipid B
droplets I
( I
LDs I
) I
. O

LD O
- O
associated O
proteins O
were O
also O
found O
to O
colocalize O
with O
viroplasms O
containing O
a O
rotaviral O
NSP5 B
- I
enhanced I
green I
fluorescent I
protein I
( I
EGFP I
) I
fusion O
protein O
and O
with O
viroplasm O
- O
like O
structures O
in O
uninfected O
cells O
coexpressing O
viral O
NSP2 O
and O
NSP5 O
. O

Viral O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
NSP5 O
, O
and O
perilipin O
A O
cosedimented O
in O
low O
- O
density O
gradient O
fractions O
of O
rotavirus O
- O
infected O
cell O
extracts O
. O

Chemical O
compounds O
interfering O
with O
LD O
formation O
( O
isoproterenol O
plus O
isobutylmethylxanthine O
; O
triacsin O
C O
) O
decreased O
the O
number O
of O
viroplasms O
and O
inhibited O
dsRNA O
replication O
and O
the O
production O
of O
infectious O
progeny O
virus O
; O
this O
effect O
correlated O
with O
significant O
protection O
of O
cells O
from O
virus O
- O
associated O
cyto O
- O
pathicity O
. O

DDX6 O
( O
Rck O
/ O
p54 O
) O
is O
an O
evolutionarily O
conserved O
member O
of O
the O
SF2 O
DEAD O
- O
box O
RNA O
helicase O
family O
that O
contributes O
to O
the O
regulation O
of O
translation O
and O
storage O
and O
the O
degradation O
of O
cellular O
mRNAs O
. O

It O
interacts O
with O
multiple O
proteins O
and O
is O
a O
component O
of O
the O
micro O
- O
RNA O
( O
miRNA O
) O
- O
induced O
silencing O
complex O
( O
miRISC O
) O
. O

Since O
miRNA O
- O
122 O
( O
miR O
- O
122 O
) O
is O
essential O
for O
efficient O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
, O
we O
investigated O
the O
requirement O
for O
DDX6 O
in O
HCV O
replication O
in O
cultured O
hepatoma O
cells O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
DDX6 O
and O
rescue O
with O
an O
siRNA O
- O
resistant O
mutant O
demonstrated O
that O
DDX6 O
expression O
is O
indeed O
required O
for O
optimal O
HCV O
replication O
. O

Overexpression O
of O
DDX6 O
fused O
to O
EYFP O
( O
EYFP O
- O
DDX6 O
) O
enhanced O
replication O
, O
whereas O
a O
helicase O
- O
deficient O
mutant O
with O
a O
substitution O
in O
the O
conserved O
DEAD O
- O
box O
motif O
II O
( O
DQAD O
) O
had O
a O
dominant O
- O
negative O
effect O
, O
reducing O
HCV O
yields O
. O

Importantly O
, O
DDX6 O
knockdown O
caused O
minimal O
reductions O
in O
cellular O
proliferation O
, O
generally O
stimulated O
cellular O
translation O
( O
[ O
S O
- O
35 O
] O
Met O
incorporation O
) O
, O
and O
did O
not O
impair O
translation O
directed O
by O
the O
HCV O
internal O
ribosome O
entry O
site O
. O

Coronavirus O
nonstructural O
proteins O
1 O
to O
3 O
are O
processed O
by O
one O
or O
two O
papain O
- O
like O
proteases O
( O
PLP1 O
and O
PLP2 O
) O
at O
specific O
cleavage O
sites O
( O
CS1 O
to O
- O
3 O
) O
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
PLP2 O
and O
orthologs O
recognize O
and O
cleave O
at O
a O
position O
following O
a O
p4 O
- O
Leu O
- O
X O
- O
Gly O
- O
Gly O
- O
p1 O
tetrapeptide O
, O
but O
it O
is O
unknown O
whether O
these O
residues O
are O
sufficient O
to O
result O
in O
processing O
by O
PLP2 O
at O
sites O
normally O
cleaved O
by O
PLP1 O
. O

In O
vivo O
, O
phosphorylated O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
specifically O
encapsidates O
a O
complex O
of O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
viral O
polymerase O
; O
it O
has O
been O
suggested O
that O
packaging O
is O
specific O
for O
the O
complex O
. O

The O
importance O
of O
the O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
system O
in O
limiting O
coronavirus O
replication O
and O
dissemination O
has O
been O
unequivocally O
demonstrated O
by O
rapid O
lethality O
following O
infection O
of O
mice O
lacking O
the O
alpha B
/ I
beta I
IFN I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptor O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
murine O
coronavirus O
. O

In O
primary O
bone O
- O
marrow O
- O
derived O
macrophages O
and O
mouse O
embryonic O
fibroblasts O
, O
MHV O
replication O
was O
significantly O
reduced O
by O
the O
IFN O
- O
alpha O
/ O
beta O
- O
induced O
antiviral O
state O
, O
whereas O
IFN O
treatment O
of O
cell O
lines O
( O
L2 O
and O
293T O
) O
has O
only O
minor O
effects O
on O
replication O
( O
K O
. O

Replication O
of O
other O
RNA O
viruses O
, O
including O
Theiler B
' I
s I
murine I
encephalitis I
virus I
( I
TMEV I
) I
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
Sindbis O
virus O
, O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
and O
Sendai B
virus I
( I
SeV I
) I
, O
was O
significantly O
inhibited O
in O
L2 O
cells O
treated O
with O
IFN O
- O
alpha O
/ O
beta O
, O
and O
MHV O
had O
the O
ability O
to O
rescue O
only O
SeV O
replication O
. O

We O
present O
evidence O
that O
MHV O
infection O
can O
delay O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
induction O
mediated O
by O
both O
SeV O
and O
IFN O
- O
beta O
but O
only O
when O
MHV O
infection O
precedes O
SeV O
or O
IFN O
- O
beta O
exposure O
. O

The O
ability O
of O
MHV O
to O
delay O
SeV O
- O
mediated O
ISG O
production O
may O
partially O
involve O
limiting O
the O
ability O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
to O
function O
as O
a O
transcription O
factor O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
most O
prevalent O
mosquito O
- O
borne O
viral O
pathogen O
in O
humans O
. O

We O
report O
here O
that O
N O
- O
sulfonylanthranilic O
acid O
derivatives O
are O
allosteric O
inhibitors O
of O
DENV O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

The O
inhibitor O
was O
identified O
through O
high O
- O
throughput O
screening O
of O
one O
million O
compounds O
using O
a O
primer O
extension O
- O
based O
RdRp O
assay O
[ O
substrate O
poly O
( O
C O
) O
/ O
oligo O
( O
G O
) O
20 O
] O
. O

Chemical O
modification O
of O
the O
initial O
hit O
improved O
the O
compound O
potency O
to O
an O
IC50 O
( O
that O
is O
, O
a O
concentration O
that O
inhibits O
50 O
% O
RdRp O
activity O
) O
of O
0 O
. O

In O
addition O
to O
suppressing O
the O
primer O
extension O
- O
based O
RNA O
elongation O
, O
the O
compound O
also O
inhibited O
de O
novo O
RNA O
synthesis O
using O
a O
DENV O
subgenomic O
RNA O
, O
but O
at O
a O
lower O
potency O
( O
IC50 O
of O
5 O
mu O
M O
) O
. O

Remarkably O
, O
the O
observed O
anti O
- O
polymerase O
activity O
is O
specific O
to O
DENV O
RdRp O
; O
the O
compound O
did O
not O
inhibit O
WNV O
RdRp O
and O
exhibited O
IC O
( O
50 O
) O
s O
of O
> O
100 O
mu O
M O
against O
hepatitis O
C O
virus O
RdRp O
and O
human O
DNA O
polymerase O
alpha O
and O
beta O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
important O
human O
pathogen O
affecting O
170 O
million O
chronically O
infected O
individuals O
. O

In O
search O
for O
cellular O
proteins O
involved O
in O
HCV O
replication O
, O
we O
have O
developed O
a O
purification O
strategy O
for O
viral O
replication O
complexes O
and O
identified O
annexin B
A2 I
( I
ANXA2 I
) I
as O
an O
associated O
host O
factor O
. O

By O
the O
deletion O
of O
individual O
NS5A O
subdomains O
, O
we O
identified O
domain B
III I
( I
DIII I
) I
as O
being O
responsible O
for O
ANXA2 O
recruitment O
. O

In O
this O
study O
, O
we O
used O
an O
RNA B
polymerase I
I I
( I
Pol I
I I
) I
transcription O
system O
for O
development O
of O
a O
reverse O
genetics O
protocol O
to O
produce O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
which O
is O
an O
uncapped O
positive O
- O
strand O
RNA O
virus O
. O

The O
effects O
of O
inhibitors O
of O
N O
- O
linked O
glycosylation O
on O
HCV O
production O
were O
evaluated O
using O
this O
cell O
line O
, O
and O
the O
results O
suggest O
that O
certain O
step O
( O
s O
) O
, O
such O
as O
virion O
assembly O
, O
intracellular O
trafficking O
, O
and O
secretion O
, O
are O
potentially O
up O
- O
and O
downregulated O
according O
to O
modifications O
of O
HCV O
envelope O
protein O
glycans O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA I
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
has O
been O
proposed O
to O
change O
conformations O
in O
association O
with O
RNA O
synthesis O
and O
to O
interact O
with O
cellular O
proteins O
. O

Initiation O
- O
defective O
mutants O
of O
the O
HCV O
polymerase O
can O
increase O
de O
novo O
initiation O
by O
the O
wild B
- I
type I
( I
WT I
) I
polymerase O
. O

We O
and O
others O
have O
observed O
that O
hepatic O
levels O
of O
suppressor B
of I
cytokine I
signaling I
3 I
( I
SOCS3 I
) I
are O
significantly O
higher O
in O
persons O
with O
chronic O
hepatitis O
C O
, O
particularly O
those O
who O
are O
nonresponders O
to O
interferon B
( I
IFN I
) I
treatment O
, O
than O
in O
healthy O
individuals O
. O

However O
, O
the O
relationship O
between O
SOCS3 O
and O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
remains O
unclear O
. O

We O
therefore O
used O
the O
OR6 O
cell O
line O
, O
which O
harbors O
a O
genotype O
1b O
full O
- O
length O
HCV O
replicon O
, O
and O
the O
genotype O
2a O
full O
- O
length O
HCV O
strain O
JFH1 O
infection O
system O
to O
analyze O
the O
effects O
of O
SOCS3 O
overexpression O
and O
short B
hairpin I
RNA I
( I
shRNA I
) I
- O
mediated O
knockdown O
on O
HCV O
replication O
. O

Passage O
of O
poliovirus B
( I
PV I
) I
or O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
in O
the O
presence O
of O
ribavirin O
( O
R O
) O
selected O
for O
viruses O
with O
decreased O
sensitivity O
to O
R O
, O
which O
included O
different O
mutations O
in O
their O
polymerase O
( O
3D O
) O
: O
G64S O
located O
in O
the O
finger O
subdomain O
in O
the O
case O
of O
PV O
and O
M296I O
located O
within O
loop O
beta O
9 O
- O
alpha O
11 O
at O
the O
active O
site O
in O
the O
case O
of O
FMDV O
. O

To O
investigate O
why O
disparate O
substitutions O
were O
selected O
in O
two O
closely O
related O
3Ds O
, O
we O
constructed O
FMDVs O
with O
a O
3D O
that O
included O
either O
G62S O
( O
the O
equivalent O
replacement O
in O
FMDV O
of O
PV O
G64S O
) O
, O
M296I O
, O
or O
both O
substitutions O
. O

The O
corresponding O
mutant O
polymerases O
, O
3D O
( O
G62S O
) O
, O
3D O
( O
M296I O
) O
, O
and O
3D O
( O
G62S O
- O
M296I O
) O
, O
were O
analyzed O
functionally O
and O
structurally O
. O

The O
X O
- O
ray O
structures O
of O
the O
3D O
( O
G62S O
) O
- O
RNA O
, O
3D O
( O
M296I O
) O
- O
RNA O
, O
and O
3D O
( O
G62S O
- O
M296I O
) O
- O
RNA O
complexes O
show O
that O
although O
the O
two O
positions O
are O
separated O
by O
13 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replication O
in O
infected O
patients O
produces O
large O
and O
diverse O
viral O
populations O
, O
which O
give O
rise O
to O
drug O
- O
resistant O
and O
immune O
escape O
variants O
. O

To O
sample O
diversity O
, O
four O
locations O
in O
the O
HCV O
genome O
were O
analyzed O
, O
ranging O
from O
high O
diversity O
( O
the O
envelope O
hypervariable O
region O
1 O
[ O
HVR1 O
] O
) O
to O
almost O
no O
diversity O
( O
the O
5 O
' O
untranslated O
region O
[ O
UTR O
] O
) O
. O

Specifically O
, O
infectious O
clones O
of O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
associated O
coronavirus O
harboring O
mutations O
that O
lower O
frameshift O
efficiency O
decreased O
infectivity O
by O
> O
4 O
orders O
of O
magnitude O
. O

Protease B
inhibitors I
( I
PIs I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
provide O
an O
additional O
or O
alternative O
therapy O
for O
chronic O
infection O
. O

To O
address O
this O
problem O
, O
we O
constructed O
a O
panel O
of O
replication O
- O
competent O
chimeric O
Jc1 O
( O
pFK O
JFH1 O
/ O
J6 O
/ O
C O
- O
846 O
) O
clones O
containing O
protease O
and O
NS4A O
coding O
sequences O
from O
all O
six O
major O
genotypes O
, O
enabling O
the O
determination O
of O
replication O
and O
the O
susceptibility O
to O
PIs O
. O

Through O
calculation O
of O
50 B
% I
inhibitory I
concentrations I
( I
IC I
( I
50 I
) I
s I
) I
of O
BILN O
2061 O
, O
measuring O
reduction O
in O
the O
number O
of O
focus O
- O
forming O
units O
/ O
ml O
( O
FFU O
/ O
ml O
) O
and O
replication O
inhibition O
, O
consistent O
genotype O
- O
associated O
differences O
in O
antiviral O
susceptibilities O
were O
observed O
. O

IC50s O
for O
genotype O
1b O
, O
4a O
, O
and O
6a O
- O
derived O
chimeras O
( O
1 O
to O
3 O
nM O
) O
were O
approximately O
100 O
- O
fold O
lower O
than O
those O
for O
genotypes O
2a O
, O
3a O
, O
and O
5a O
( O
range O
, O
80 O
to O
720 O
nM O
) O
, O
implying O
major O
differences O
in O
response O
to O
therapy O
. O

During O
the O
transition O
from O
acute O
to O
chronic O
infection O
in O
individuals O
persistently O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
cellular O
responses O
initiate O
within O
the O
first O
6 O
months O
of O
primary O
infection O
and O
collapse O
thereafter O
, O
whereas O
humoral O
responses O
activate O
later O
during O
the O
chronic O
phase O
. O

Significantly O
different O
evolutionary O
rates O
were O
observed O
in O
envelope O
versus O
nonenvelope O
genes O
, O
with O
an O
increasing O
rate O
of O
nonsynonymous O
change O
( O
dN O
) O
in O
envelope O
genes O
and O
a O
stable O
dN O
in O
nonenvelope O
genes O
( O
P O
= O
0 O
. O

Centripetal O
changes O
( O
reversions O
toward O
matching O
of O
the O
worldwide O
subtype O
1a O
consensus O
sequence O
) O
were O
frequently O
observed O
during O
the O
3 O
- O
year O
transition O
from O
acute O
infection O
to O
chronicity O
, O
even O
in O
the O
presence O
of O
Neutralizing B
antibody I
( I
NAb I
) I
pressure O
. O

Remarkably O
, O
sequences O
of O
hypervariable B
region I
1 I
( I
HVR1 I
) I
remained O
stable O
for O
up O
to O
21 O
months O
in O
the O
absence O
of O
NAb O
pressure O
in O
one O
subject O
, O
followed O
by O
rapid O
changes O
that O
were O
temporally O
associated O
with O
the O
detection O
of O
NAb O
responses O
, O
which O
strongly O
suggests O
that O
HVR1 O
evolution O
is O
shaped O
by O
NAb O
pressure O
. O

Previously O
, O
RNA O
transcripts O
of O
cDNA O
clones O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
genotypes O
1a O
( O
strains O
H77 O
, O
HCV O
- O
1 O
, O
and O
HC O
- O
TN O
) O
, O
1b O
( O
HC O
- O
J4 O
, O
Con1 O
, O
and O
HCV O
- O
N O
) O
, O
and O
2a O
( O
HC O
- O
J6 O
and O
JFH1 O
) O
were O
found O
to O
be O
infectious O
in O
chimpanzees O
. O

We O
performed O
genetic O
analysis O
of O
HCV O
genotype O
3a O
( O
strain O
S52 O
) O
and O
4a O
( O
strain O
ED43 O
) O
prototype O
strains O
and O
generated O
full O
- O
length O
consensus O
cDNA O
clones O
( O
pS52 O
and O
pED43 O
) O
. O

5 O
log O
( O
10 O
) O
international B
units I
( I
IU I
) I
/ O
ml O
. O

However O
, O
the O
onset O
and O
broadness O
of O
intrahepatic O
T O
- O
cell O
responses O
varied O
greatly O
in O
the O
two O
animals O
, O
with O
an O
early O
( O
week O
4 O
) O
multispecific O
response O
in O
the O
ED43 O
- O
infected O
animal O
( O
3 O
weeks O
before O
the O
first O
evidence O
of O
viral O
control O
) O
and O
a O
late O
( O
week O
11 O
) O
response O
with O
limited O
breadth O
in O
the O
S52 O
- O
infected O
animal O
( O
without O
evidence O
of O
viral O
control O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
chronic O
liver O
disease O
. O

The O
expression O
of O
host O
genes O
involved O
in O
cellular O
defense O
mechanisms O
( O
apoptosis O
, O
proliferation O
, O
and O
antioxidant O
responses O
) O
, O
cellular O
metabolism O
( O
lipid O
and O
protein O
metabolism O
) O
, O
and O
intracellular O
transport O
( O
vesicle O
trafficking O
and O
cytoskeleton O
regulation O
) O
was O
significantly O
altered O
by O
HCV O
infection O
. O

To O
investigate O
whether O
any O
of O
the O
host O
genes O
regulated O
by O
infection O
were O
required O
by O
HCV O
during O
replication O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
silencing O
of O
host O
gene O
expression O
in O
HCV O
- O
infected O
cells O
was O
performed O
. O

Decreasing O
the O
expression O
of O
host O
genes O
involved O
in O
lipid O
metabolism O
( O
TXNIP O
and O
CYP1A1 O
genes O
) O
and O
intracellular O
transport O
( O
RAB33b O
and O
ABLIM3 O
genes O
) O
reduced O
the O
replication O
and O
secretion O
of O
HCV O
, O
indicating O
that O
they O
may O
be O
important O
factors O
for O
the O
virus O
replication O
cycle O
. O

The O
mechanisms O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
remain O
poorly O
understood O
, O
and O
the O
cellular O
factors O
required O
for O
HCV O
replication O
are O
yet O
to O
be O
completely O
defined O
. O

The O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
accessory I
protein I
6 I
( I
p6 I
) I
is O
a O
63 O
- O
amino O
- O
acid O
multifunctional O
Golgi B
- I
endoplasmic I
reticulum I
( I
ER I
) I
membrane O
- O
associated O
protein O
, O
with O
roles O
in O
enhancing O
virus O
replication O
and O
in O
evading O
the O
innate O
immune O
response O
to O
infection O
by O
inhibiting O
STAT1 B
( I
signal I
transducer I
and I
activator I
of I
transcription I
factor I
1 I
) I
translocation O
to O
the O
nucleus O
. O

Consistent O
with O
a O
role O
in O
virus O
replication O
, O
p6 O
partially O
colocalized O
with O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
, O
a O
marker O
for O
virus O
replication O
complexes O
. O

We O
have O
now O
undertaken O
a O
more O
detailed O
analysis O
of O
RNA O
structures O
present O
at O
the O
3 O
' O
extremity O
of O
the O
murine B
norovirus I
( I
MNV I
) I
genome O
. O

Biochemical O
data O
indicate O
the O
presence O
of O
three O
stable O
stem O
- O
loops O
, O
including O
two O
in O
the O
untranslated O
region O
, O
and O
a O
single O
- O
stranded O
polypyrimidine O
tract O
[ O
p O
( O
Y O
) O
] O
of O
variable O
length O
between O
MNV O
isolates O
, O
within O
the O
terminal O
stem O
- O
loop O
structure O
. O

Viruses O
lacking O
the O
p O
( O
Y O
) O
tract O
were O
viable O
both O
in O
cell O
culture O
and O
upon O
mouse O
infection O
, O
demonstrating O
that O
this O
interaction O
was O
not O
essential O
for O
virus O
replication O
. O

However O
, O
competition O
analysis O
with O
wild O
- O
type O
MNV O
in O
cell O
culture O
indicated O
that O
the O
loss O
of O
the O
p O
( O
Y O
) O
tract O
was O
associated O
with O
a O
fitness O
cost O
. O

Furthermore O
, O
a O
p O
( O
Y O
) O
- O
deleted O
mutant O
showed O
a O
reduction O
in O
virulence O
in O
the O
STAT1 O
( O
- O
/ O
- O
) O
mouse O
model O
, O
highlighting O
the O
role O
of O
RNA O
structures O
in O
norovirus O
pathogenesis O
. O

The O
RNA O
- O
dependent O
RNA O
polymerase O
( O
NS5B O
) O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
unusually O
attractive O
target O
for O
drug O
discovery O
since O
it O
contains O
five O
distinct O
drugable O
sites O
. O

Infection O
of O
BALB O
/ O
c O
( O
H O
- O
2 O
( O
d O
) O
) O
mice O
expressing O
a O
dominant O
negative O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
receptor O
specifically O
in O
oligodendrocytes O
was O
examined O
to O
determine O
the O
influence O
of O
IFN O
- O
gamma O
signaling O
on O
pathogenesis O
. O

IFN O
- O
gamma O
levels O
and O
the O
inflammatory O
response O
were O
not O
altered O
, O
although O
the O
level O
of O
Tumor B
necrosis I
factor I
( I
TNF I
) I
mRNA O
was O
increased O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
liver O
- O
tropic O
pathogen O
with O
severe O
health O
consequences O
for O
infected O
individuals O
. O

Previous O
studies O
showed O
that O
the O
N O
- O
terminal O
75 O
amino O
acids O
of O
the O
pre O
- O
S1 O
domain O
of O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
L O
protein O
are O
essential O
for O
HBV O
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
infectivity O
. O

Using O
the O
HepaRG O
cell O
line O
and O
a O
genotype O
D O
- O
derived O
virus O
, O
we O
determined O
the O
specific O
inhibitory O
activities O
of O
the O
peptides O
and O
found O
that O
( O
i O
) O
lipopeptides O
with O
an O
artificial O
consensus O
sequence O
inhibit O
HBV O
genotype O
D O
infection O
more O
potently O
than O
the O
corresponding O
genotype O
D O
peptides O
; O
( O
ii O
) O
point O
mutations O
, O
D O
- O
amino O
acid O
exchanges O
, O
or O
deletions O
introduced O
into O
the O
highly O
conserved O
part O
of O
the O
pre O
- O
S1 O
domain O
result O
in O
an O
almost O
complete O
loss O
of O
activity O
; O
and O
( O
iii O
) O
the O
flanking O
sequences O
comprising O
amino O
acids O
2 O
to O
8 O
, O
16 O
to O
20 O
, O
and O
, O
to O
a O
less O
pronounced O
extent O
, O
34 O
to O
48 O
gradually O
increase O
the O
inhibitory O
activity O
, O
while O
amino O
acids O
21 O
to O
33 O
behave O
indifferently O
. O

Coronaviruses O
induce O
in O
infected O
cells O
the O
formation O
of O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
in O
which O
the O
replication B
- I
transcription I
complexes I
( I
RTCs I
) I
are O
anchored O
. O

Yet O
, O
no O
recovery O
of O
fluorescence O
was O
observed O
when O
( O
part O
of O
) O
the O
nsp2 O
- O
positive O
foci O
were O
bleached O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
forms O
an O
unbranched O
rod O
structure O
that O
is O
associated O
with O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
in O
cells O
replicating O
HDV O
. O

Previous O
in O
vitro O
binding O
experiments O
using O
bacterially O
expressed O
HDAg O
showed O
that O
the O
formation O
of O
a O
minimal O
ribonucleoprotein O
complex O
requires O
an O
HDV O
unbranched O
rod O
RNA O
of O
at O
least O
about O
300 O
nucleotides B
( I
nt I
) I
and O
suggested O
that O
HDAg O
binds O
the O
RNA O
as O
a O
multimer O
of O
fixed O
size O
. O

The O
present O
study O
specifically O
examines O
the O
role O
of O
HDAg O
multimerization O
in O
the O
formation O
of O
the O
HDV O
ribonucleoprotein B
complex I
( I
RNP I
) I
. O

NS4B O
is O
one O
of O
the O
nonstructural O
proteins O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
the O
etiological O
agent O
of O
a O
severe O
, O
highly O
lethal O
disease O
of O
swine O
. O

Protein O
domain O
analysis O
of O
the O
predicted O
amino O
acid O
sequence O
of O
the O
NS4B O
protein O
of O
highly O
pathogenic O
CSFV O
strain O
Brescia O
( O
BICv O
) O
identified O
a O
putative O
Toll B
/ I
interleukin I
- I
1 I
receptor I
( I
TIR I
) I
- O
like O
domain O
. O

This O
TIR O
- O
like O
motif O
harbors O
two O
conserved O
domains O
, O
box O
1 O
and O
box O
2 O
, O
also O
observed O
in O
other O
members O
of O
the O
TIR O
superfamily O
, O
including O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
. O

Mutations O
within O
the O
BICv O
NS4B O
box O
2 O
domain O
( O
V2566A O
, O
G2567A O
, O
I2568A O
) O
produced O
recombinant O
virus O
NS4B O
. O

VGIv O
, O
with O
an O
altered O
phenotype O
displaying O
enhanced O
transcriptional O
activation O
of O
TLR O
- O
7 O
- O
induced O
genes O
in O
swine O
macrophages O
, O
including O
a O
significant O
sustained O
accumulation O
of O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
mRNA O
. O

Transfection O
of O
swine O
macrophages O
with O
the O
wild O
- O
type O
NS4B O
gene O
partially O
blocked O
the O
TLR O
- O
7 O
- O
activating O
effect O
of O
imiquimod O
( O
R837 O
) O
, O
while O
transfection O
with O
the O
NS4B O
gene O
harboring O
mutations O
in O
either O
of O
the O
putative O
boxes O
displayed O
decreased O
blocking O
activity O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
is O
a O
nuclear O
protein O
that O
is O
intimately O
involved O
in O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
replication O
. O

HDAg O
consists O
of O
two O
protein O
species O
, O
the O
small O
form O
( O
S O
- O
HDAg O
) O
and O
the O
large O
form O
( O
L O
- O
HDAg O
) O
. O

In O
this O
study O
, O
we O
show O
that O
S O
- O
HDAg O
is O
a O
small B
ubiquitin I
- I
like I
modifier I
1 I
( I
SUMO1 I
) I
target O
protein O
. O

The O
dicistrovirus O
is O
a O
positive O
- O
strand O
single O
- O
stranded O
RNA O
virus O
that O
possesses O
two O
internal B
ribosome I
entry I
sites I
( I
IRES I
) I
that O
direct O
translation O
of O
distinct O
open O
reading O
frames O
encoding O
the O
viral O
structural O
and O
nonstructural O
proteins O
. O

Through O
an O
unusual O
mechanism O
, O
the O
intergenic B
region I
( I
IGR I
) I
IRES O
responsible O
for O
viral O
structural O
protein O
expression O
mimics O
a O
tRNA O
to O
directly O
recruit O
the O
ribosome O
and O
set O
the O
ribosome O
into O
translational O
elongation O
. O

In O
this O
study O
, O
we O
explored O
the O
mechanism O
of O
host O
translational O
shutoff O
in O
Drosophila O
S2 O
cells O
infected O
by O
the O
dicistrovirus O
, O
cricket B
paralysis I
virus I
( I
CrPV I
) I
. O

CrPV O
infection O
resulted O
in O
the O
dissociation O
of O
eukaryotic B
translation I
initiation I
factor I
4G I
( I
eIF4G I
) I
and O
eIF4E O
early O
in O
infection O
and O
the O
induction O
of O
deIF2 O
alpha O
phosphorylation O
at O
3 O
h O
postinfection O
, O
which O
lags O
after O
the O
initial O
inhibition O
of O
host O
translation O
. O

Finally O
, O
translation O
mediated O
by O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
and O
the O
IGR O
IRES O
were O
resistant O
to O
impairment O
of O
eIF4F O
or O
eIF2 O
in O
translation O
extracts O
. O

The O
DNA O
genome O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
replicates O
via O
reverse O
transcription O
within O
capsids O
following O
the O
encapsidation O
of O
an O
RNA O
template O
, O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

We O
previously O
demonstrated O
that O
the O
5 O
' O
cap O
proximity O
of O
the O
stem O
- O
loop O
structure O
( O
epsilon O
or O
epsilon O
) O
, O
an O
encapsidation O
signal O
, O
is O
critically O
important O
for O
the O
encapsidation O
of O
the O
pgRNA O
( O
J O
. O

Therefore O
, O
we O
speculated O
that O
the O
viral O
Polymerase B
( I
Pol I
) I
, O
while O
bound O
to O
the O
5 O
' O
epsilon O
stem O
- O
loop O
structure O
, O
could O
recognize O
the O
cap O
via O
its O
interaction O
with O
eIF4E O
, O
a O
eukaryotic O
translation O
initiation O
factor O
. O

Further O
, O
we O
demonstrated O
that O
eIF4E O
interacts O
with O
the O
Pol O
- O
epsilon O
ribonucleoprotein B
complex I
( I
RNP I
) I
rather O
than O
Pol O
alone O
, O
resulting O
in O
eIF4E O
- O
Pol O
- O
epsilon O
RNP O
complex O
formation O
. O

For O
coronaviruses O
, O
replicase O
nonstructural B
protein I
4 I
( I
nsp4 I
) I
has O
been O
proposed O
to O
function O
in O
the O
formation O
and O
organization O
of O
replication O
complexes O
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
nsp4 O
is O
glycosylated O
at O
residues O
Asn176 O
( O
N176 O
) O
and O
N237 O
during O
plasmid O
expression O
of O
nsp4 O
in O
cells O
. O

The O
N176A O
, O
N237A O
, O
and O
N176A O
/ O
N237A O
mutant O
viruses O
were O
viable O
, O
and O
N176 O
and O
N237 O
were O
glycosylated O
during O
infection O
of O
wild B
- I
type I
( I
WT I
) I
and O
mutant O
viruses O
. O

Electron O
microscopic O
analysis O
of O
ultrastructure O
from O
infected O
cells O
demonstrated O
that O
the O
nsp4 O
mutants O
had O
aberrant O
morphology O
of O
virus O
- O
induced O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
compared O
to O
those O
infected O
with O
wt O
virus O
. O

Using O
a O
cell O
- O
based O
replicon O
screen O
, O
we O
identified O
a O
class O
of O
compounds O
with O
a O
thiazolidinone O
core O
structure O
as O
inhibitors O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

A O
combination O
of O
amino O
acid O
substitutions O
of O
leucine O
to O
valine O
at O
residue O
31 O
( O
L31V O
) O
and O
glutamine O
to O
leucine O
at O
residue O
54 O
( O
Q54L O
) O
in O
NS5A O
conferred O
resistance O
to O
this O
chemotype O
, O
as O
did O
a O
single O
substitution O
of O
tyrosine O
to O
histidine O
at O
amino O
acid O
93 O
( O
Y93H O
) O
in O
NS5A O
. O

To O
further O
explore O
the O
region O
( O
s O
) O
of O
NS5A O
involved O
in O
inhibitor O
sensitivity O
, O
genotype O
- O
specific O
NS5A O
inhibitors O
were O
used O
to O
evaluate O
a O
series O
of O
genotype O
1a O
/ O
1b O
hybrid O
replicons O
. O

The O
full O
repertoire O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
peptides O
that O
bind O
to O
the O
common O
HLA O
class O
I O
molecules O
found O
in O
areas O
with O
a O
high O
prevalence O
of O
chronic O
HBV O
infection O
has O
not O
been O
determined O
. O

The O
repertoires O
of O
positively O
selected O
sites O
in O
groups O
of O
subjects O
who O
were O
homozygous O
for O
either O
HLA O
- O
B O
* O
4001 O
( O
n O
= O
10 O
) O
or O
HLA O
- O
B O
* O
5602 O
( O
n O
= O
7 O
) O
were O
compared O
. O

This O
is O
consistent O
with O
published O
evidence O
that O
CD8 O
( O
+ O
) O
T O
cells O
have O
a O
role O
in O
suppressing O
viral O
replication O
in O
inactive O
, O
HBeAg O
- O
negative O
chronic O
HBV O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
induces O
a O
state O
of O
oxidative O
stress O
by O
affecting O
mitochondrial O
- O
respiratorychain O
activity O
. O

Here O
, O
we O
show O
that O
HCV O
protein O
expression O
activates O
hypoxia B
- I
inducible I
factor I
1 I
( I
HIF I
- I
1 I
) I
by O
normoxic O
stabilization O
of O
its O
alpha O
subunit O
. O

The O
hepatitis B
E I
virus I
( I
HEV I
) I
, O
a O
nonenveloped O
RNA O
virus O
, O
is O
the O
causative O
agent O
of O
hepatitis O
E O
. O

Open B
reading I
frame I
2 I
( I
ORF2 I
) I
of O
HEV O
encodes O
its O
major O
capsid O
protein O
, O
pORF2 O
, O
which O
is O
likely O
to O
have O
the O
determinants O
for O
virus O
attachment O
and O
entry O
. O

Using O
an O
similar O
to O
56 O
- O
kDa O
recombinant O
pORF2 O
that O
can O
self O
- O
assemble O
as O
virus O
- O
like O
particles O
, O
we O
demonstrated O
that O
cell O
surface O
heparan B
sulfate I
proteoglycans I
( I
HSPGs I
) I
, O
specifically O
syndecans O
, O
play O
a O
crucial O
role O
in O
the O
binding O
of O
pORF2 O
to O
Huh O
- O
7 O
liver O
cells O
. O

Removal O
of O
cell O
surface O
heparan O
sulfate O
by O
enzymatic O
( O
heparinase O
) O
or O
chemical O
( O
sodium O
chlorate O
) O
treatment O
of O
cells O
or O
competition O
with O
heparin O
, O
heparan O
sulfate O
, O
and O
their O
oversulfated O
derivatives O
caused O
a O
marked O
reduction O
in O
pORF2 O
binding O
to O
the O
cells O
. O

The O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
structure O
of O
a O
globular O
domain O
of O
residues O
1071 O
to O
1178 O
within O
the O
previously O
annotated O
nucleic B
acid I
- I
binding I
region I
( I
NAB I
) I
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
nonstructural B
protein I
3 I
( I
nsP3 I
) I
has O
been O
determined O
, O
and O
N O
- O
and O
C O
- O
terminally O
adjoining O
polypeptide O
segments O
of O
37 O
and O
25 O
residues O
, O
respectively O
, O
have O
been O
shown O
to O
form O
flexibly O
extended O
linkers O
to O
the O
preceding O
globular O
domain O
and O
to O
the O
following O
, O
as O
yet O
uncharacterized O
domain O
. O

This O
extension O
of O
the O
structural O
coverage O
of O
nsp3 O
was O
obtained O
from O
NMR O
studies O
with O
an O
nsp3 O
construct O
comprising O
residues O
1066 O
to O
1181 O
[ O
nsp3 O
( O
1066 O
- O
1181 O
) O
] O
and O
the O
constructs O
nsp3 O
( O
1066 O
- O
1203 O
) O
and O
nsp3 O
( O
1035 O
- O
1181 O
) O
. O

Two O
antiparallel O
two O
- O
strand O
beta O
- O
sheets O
and O
two O
3 O
( O
10 O
) O
- O
helices O
are O
anchored O
against O
the O
surface O
of O
this O
barrel O
- O
like O
molecular O
core O
. O

Chemical O
shift O
changes O
upon O
the O
addition O
of O
single B
- I
stranded I
RNAs I
( I
ssRNAs I
) I
identified O
a O
group O
of O
residues O
that O
form O
a O
positively O
charged O
patch O
on O
the O
protein O
surface O
as O
the O
binding O
site O
responsible O
for O
the O
previously O
reported O
affinity O
for O
nucleic O
acids O
. O

Stem O
- O
loop O
2 O
( O
SL2 O
) O
of O
the O
5 O
' O
- O
untranslated O
region O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
contains O
a O
highly O
conserved O
pentaloop O
( O
C47 O
- O
U48 O
- O
U49 O
- O
G50 O
- O
U51 O
) O
stacked O
on O
a O
5 O
- O
bp O
stem O
. O

Solution O
nuclear O
magnetic O
resonance O
experiments O
are O
consistent O
with O
a O
5 O
' O
- O
uYNMG O
( O
U O
) O
a O
or O
uCUYG O
( O
U O
) O
a O
tetraloop O
conformation O
characterized O
by O
an O
anti O
- O
C47 O
- O
syn O
- O
G50 O
base O
- O
pairing O
interaction O
, O
with O
U51 O
flipped O
out O
into O
solution O
and O
G50 O
stacked O
on O
A52 O
. O

These O
functional O
data O
suggest O
that O
the O
Watson O
- O
Crick O
edges O
of O
C47 O
and O
G50 O
( O
or O
A47 O
and O
U50 O
in O
the O
G50U O
/ O
C47A O
mutant O
) O
are O
in O
close O
enough O
proximity O
to O
a O
hydrogen O
bond O
with O
U51 O
flipped O
out O
of O
the O
hairpin O
. O

Previous O
studies O
have O
shown O
that O
proinflammatory O
cytokines O
, O
such O
as O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
are O
differentially O
induced O
in O
primary O
mouse O
astrocytes O
by O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
and O
MHV O
- O
2 O
. O

Interestingly O
, O
while O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
, O
a O
key O
transcription O
factor O
required O
for O
the O
expression O
of O
proinflammatory O
cytokines O
in O
most O
cell O
types O
, O
was O
activated O
in O
astrocytes O
during O
MHV O
- O
A59 O
infection O
, O
disruption O
of O
the O
NF O
- O
kappa O
B O
pathway O
by O
peptide O
inhibitors O
did O
not O
significantly O
inhibit O
TNF O
- O
alpha O
and O
IL O
- O
6 O
expression O
. O

A O
vector O
based O
on O
Semliki B
Forest I
virus I
( I
SFV I
) I
expressing O
high O
levels O
of O
interleukin O
- O
12 O
( O
SFV O
- O
enhIL O
- O
12 O
) O
has O
previously O
demonstrated O
potent O
antitumoral O
efficacy O
in O
small O
rodents O
with O
hepatocellular B
carcinoma I
( I
HCC I
) I
induced O
by O
transplantation O
of O
tumor O
cells O
. O

In O
the O
present O
study O
, O
the O
infectivity O
and O
antitumoral O
/ O
antiviral O
effects O
of O
SFV O
vectors O
were O
evaluated O
in O
the O
clinically O
more O
relevant O
woodchuck O
model O
, O
in O
which O
primary O
HCC O
is O
induced O
by O
chronic O
infection O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

In O
five O
( O
83 O
% O
) O
of O
six O
woodchucks O
, O
a O
dose O
- O
dependent O
, O
partial O
tumor O
remission O
was O
observed O
, O
with O
reductions O
in O
tumor O
volume O
of O
up O
to O
80 O
% O
, O
but O
tumor O
growth O
was O
restored O
thereafter O
. O

5 O
- O
log O
( O
10 O
) O
reductions O
in O
serum O
WHV O
DNA O
in O
half O
of O
the O
woodchucks O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
envelope O
proteins O
bear O
two O
determinants O
of O
viral O
entry O
: O
a O
receptor B
- I
binding I
site I
( I
RBS I
) I
in O
the O
pre O
- O
S1 O
domain O
of O
the O
large O
envelope O
protein O
and O
a O
conformation O
- O
dependent O
determinant O
, O
of O
unknown O
function O
, O
in O
the O
antigenic B
loop I
( I
AGL I
) I
of O
the O
small O
, O
middle O
, O
and O
large O
envelope O
proteins O
. O

Using O
an O
in O
vitro O
infection O
assay O
consisting O
of O
susceptible O
HepaRG O
cells O
and O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
as O
a O
surrogate O
of O
HBV O
, O
we O
first O
investigated O
whether O
subelements O
of O
the O
pre O
- O
S1 O
determinant O
( O
amino O
acids O
2 O
to O
75 O
) O
, O
i O
. O

, O
the O
N O
- O
terminal O
myristoyl O
anchor O
, O
subdomain O
2 O
- O
48 O
( O
RBS O
) O
, O
and O
subdomain O
49 O
- O
75 O
, O
were O
functionally O
separable O
. O

We O
next O
investigated O
the O
AGL O
activity O
in O
the O
small O
or O
large O
envelope O
protein O
background O
( O
S O
- O
and O
L O
- O
AGL O
, O
respectively O
) O
and O
found O
that O
lesions O
in O
S O
- O
AGL O
were O
more O
deleterious O
to O
infectivity O
than O
in O
L O
- O
AGL O
, O
a O
difference O
that O
reflects O
the O
relative O
stoichiometry O
of O
the O
small O
and O
large O
envelope O
proteins O
in O
the O
viral O
envelope O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
core I
protein I
( I
CP I
) I
forms O
the O
shell O
of O
an O
icosahedral O
nucleocapsid O
. O

We O
now O
introduced O
several O
other O
amino O
acids O
at O
six O
of O
these O
positions O
and O
found O
that O
almost O
all O
27 O
tested O
point O
mutations O
at O
S17 O
, O
K96 O
, O
and O
I126 O
reproduced O
the O
phenotype O
of O
the O
alanine O
mutation O
( O
with O
only O
two O
exceptions O
) O
: O
the O
formation O
of O
nucleocapsids O
and O
of O
the O
viral O
DNA O
genome O
was O
wild O
type O
, O
but O
capsid O
envelopment O
and O
virion O
release O
were O
strongly O
inhibited O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
p7 O
is O
an O
integral O
membrane O
protein O
that O
forms O
ion O
channels O
in O
vitro O
and O
that O
is O
crucial O
for O
the O
efficient O
assembly O
and O
release O
of O
infectious O
virions O
. O

Due O
to O
these O
properties O
, O
p7 O
was O
included O
in O
the O
family O
of O
viroporins O
that O
comprises O
proteins O
like O
influenza O
A O
virus O
M2 O
and O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
vpu O
, O
which O
alter O
membrane O
permeability O
and O
facilitate O
the O
release O
of O
infectious O
viruses O
. O

Chronic O
immune O
activation O
is O
a O
driver O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
disease O
progression O
. O

Here O
, O
we O
describe O
that O
subjects O
with O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
/ O
HIV O
- O
1 O
coinfection O
display O
sharply O
elevated O
immune O
activation O
as O
determined O
by O
CD38 O
expression O
in O
T O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5A I
( I
NS5A I
) I
is O
a O
component O
of O
the O
replication O
complex O
consisting O
of O
several O
host O
and O
viral O
proteins O
. O

We O
have O
previously O
reported O
that O
human B
butyrate I
- I
induced I
transcript I
1 I
( I
hB I
- I
ind1 I
) I
recruits O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
and O
FK506 B
- I
binding I
protein I
8 I
( I
FKBP8 I
) I
to O
the O
replication O
complex O
through O
interaction O
with O
NS5A O
. O

HCV O
replicon O
cells O
exhibited O
a O
more O
potent O
unfolded B
- I
protein I
response I
( I
UPR I
) I
than O
the O
parental O
and O
the O
cured O
cells O
upon O
treatment O
with O
an O
inhibitor O
for O
Hsp90 O
. O

We O
observed O
that O
the O
nonfusogenic O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
MHV O
- O
2 O
reached O
a O
titer O
of O
similar O
to O
2 O
log O
( O
10 O
) O
higher O
than O
that O
of O
the O
fusogenic O
strain O
A59 O
in O
astrocytoma O
DBT O
cells O
. O

Furthermore O
, O
cell O
fractionation O
experiments O
revealed O
that O
significantly O
more O
genomic O
RNAs O
for O
the O
nonfusogenic O
MHVs O
were O
detected O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
within O
the O
first O
2 O
h O
after O
infection O
than O
for O
the O
fusogenic O
MHVs O
. O

2 O
) O
is O
conserved O
throughout O
all O
hepatitis B
C I
virus I
( I
HCV I
) I
isolates O
, O
although O
this O
motif O
was O
shown O
to O
be O
dispensable O
for O
replication O
of O
the O
genotype O
1b O
subgenomic O
replicon O
. O

However O
, O
the O
P342A O
mutation O
resulted O
in O
both O
a O
delay O
to O
virus O
release O
and O
a O
modest O
( O
up O
to O
10 O
- O
fold O
) O
reduction O
in O
virus O
production O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
often O
causes O
chronic O
infection O
and O
may O
lead O
to O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

In O
this O
study O
, O
a O
mammalian O
two O
- O
hybrid O
screen O
identified O
a O
novel O
binding O
partner O
, O
HS1 B
- I
associated I
protein I
X I
- I
1 I
( I
HAX I
- I
1 I
) I
, O
for O
HCV O
core O
protein O
from O
a O
human O
liver O
cDNA O
library O
. O

An O
association O
between O
HAX O
- O
1 O
and O
HCV O
core O
protein O
was O
further O
verified O
by O
confocal O
microscopy O
and O
coimmunoprecipitation O
in O
HepG2 O
cells O
expressing O
HCV O
core O
or O
full B
- I
length I
( I
FL I
) I
gene O
. O

Both O
HCV O
core O
protein O
and O
a O
chemotherapeutic O
agent O
for O
HCC O
, O
5 O
- O
flouorouracil O
( O
5 O
- O
FU O
) O
, O
are O
known O
to O
modulate O
p53 O
. O

The O
molecular O
basis O
underlying O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
maturation O
and O
morphogenesis O
remains O
elusive O
. O

Analyses O
of O
core O
proteins O
expressed O
from O
a O
subgenomic O
system O
showed O
that O
the O
signal O
sequence O
located O
between O
the O
core O
and O
envelope O
glycoprotein O
E1 O
is O
critical O
for O
core O
association O
with O
endoplasmic B
reticula I
( I
ER I
) I
/ O
late O
endosomes O
and O
the O
core O
' O
s O
envelopment O
by O
membranes O
, O
which O
was O
judged O
by O
the O
core O
' O
s O
acquisition O
of O
resistance O
to O
proteinase O
K O
digestion O
. O

Despite O
exerting O
an O
inhibitory O
effect O
on O
the O
core O
' O
s O
association O
with O
membranes O
, O
( O
Z O
- O
LL O
) O
( O
2 O
) O
- O
ketone O
, O
a O
specific O
inhibitor O
of O
signal B
peptide I
peptidase I
( I
SPP I
) I
, O
did O
not O
affect O
core O
multimeric O
complex O
formation O
, O
suggesting O
that O
oligomeric O
core O
complex O
formation O
proceeds O
prior O
to O
or O
upon O
core O
attachment O
to O
membranes O
. O

Protease O
- O
resistant O
core O
complexes O
that O
contained O
both O
innate O
and O
processed O
proteins O
were O
detected O
in O
the O
presence O
of O
( O
Z O
- O
LL O
) O
( O
2 O
) O
- O
ketone O
, O
implying O
that O
core O
envelopment O
occurs O
after O
intramembrane O
cleavage O
. O

Treatment O
with O
( O
Z O
- O
LL O
) O
( O
2 O
) O
- O
ketone O
or O
coexpression O
with O
D219A O
mutant O
SPP O
interfered O
with O
both O
core O
envelopment O
and O
infectious O
HCV O
production O
, O
indicating O
a O
critical O
role O
of O
core O
envelopment O
in O
HCV O
morphogenesis O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
known O
to O
modulate O
apoptosis O
and O
contribute O
to O
viral O
replication O
and O
pathogenesis O
. O

In O
this O
study O
, O
we O
have O
identified O
a O
Bcl B
- I
2 I
homology I
3 I
( I
BH3 I
) I
domain O
in O
the O
core O
protein O
that O
is O
essential O
for O
its O
proapoptotic O
property O
. O

Coimmunoprecipitation O
experiments O
showed O
that O
the O
core O
protein O
interacts O
specifically O
with O
the O
human B
myeloid I
cell I
factor I
1 I
( I
Mcl I
- I
1 I
) I
, O
a O
prosurvival O
member O
of O
the O
Bcl O
- O
2 O
family O
, O
but O
not O
with O
other O
prosurvival O
members O
( O
Bcl O
- O
X O
- O
L O
and O
Bcl O
- O
w O
) O
. O

Furthermore O
, O
the O
genotype O
1b O
core O
protein O
is O
more O
effective O
than O
the O
genotype O
2a O
core O
protein O
in O
inducing O
apoptosis O
due O
to O
a O
single O
- O
amino O
- O
acid O
difference O
at O
one O
of O
these O
hydrophobic O
residues O
( O
residue O
119 O
) O
. O

Replacing O
this O
residue O
in O
the O
J6 O
/ O
JFH O
- O
1 O
infectious O
clone O
( O
genotype O
2a O
) O
with O
the O
corresponding O
amino O
acid O
in O
the O
genotype O
1b O
core O
protein O
produced O
a O
mutant O
virus O
, O
J6 O
/ O
JFH O
- O
1 O
( O
V119L O
) O
, O
which O
induced O
significantly O
higher O
levels O
of O
apoptosis O
in O
the O
infected O
cells O
than O
the O
parental O
J6 O
/ O
JFH O
- O
1 O
virus O
. O

Furthermore O
, O
the O
core O
protein O
of O
J6 O
/ O
JFH O
- O
1 O
( O
V119L O
) O
, O
but O
not O
that O
of O
J6 O
/ O
JFH O
- O
1 O
, O
interacted O
with O
Mcl O
- O
1 O
in O
virus O
- O
infected O
cells O
. O

Host O
factor O
pathways O
are O
known O
to O
be O
essential O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
and O
replication O
in O
human O
liver O
cells O
. O

To O
search O
for O
novel O
host O
factor O
proteins O
required O
for O
HCV O
replication O
, O
we O
screened O
a O
subgenomic O
genotype O
1b O
replicon O
cell O
line O
( O
Luc O
- O
1b O
) O
with O
a O
kinome O
and O
druggable O
collection O
of O
20 O
, O
779 O
siRNAs O
. O

We O
identified O
and O
validated O
several O
enzymes O
required O
for O
HCV O
replication O
, O
including O
class O
III O
phosphatidylinositol B
4 I
- I
kinases I
( I
PI4KA I
and I
PI4KB I
) I
, O
carbamoyl O
- O
phosphate O
synthetase O
2 O
, O
aspartate O
transcarbamylase O
, O
and O
dihydroorotase O
( O
CAD O
) O
, O
and O
mevalonate O
( O
diphospho O
) O
decarboxylase O
. O

Knockdown O
of O
PI4KA O
could O
inhibit O
the O
replication O
and O
/ O
or O
HCV O
RNA O
levels O
of O
the O
two O
subgenomic O
genotype O
1b O
clones O
( O
SG O
- O
1b O
and O
Luc O
- O
1b O
) O
, O
two O
subgenomic O
genotype O
1a O
clones O
( O
SG O
- O
1a O
and O
Luc O
- O
1a O
) O
, O
JFH O
- O
1 O
genotype O
2a O
infectious O
virus O
( O
JFH1 O
- O
2a O
) O
, O
and O
the O
genomic O
genotype O
1a O
( O
FL O
- O
1a O
) O
replicon O
. O

The O
small O
molecule O
inhibitor O
, O
PIK93 O
, O
was O
found O
to O
block O
subgenomic O
genotype O
1b O
( O
Luc O
- O
1b O
) O
, O
subgenomic O
genotype O
1a O
( O
Luc O
- O
1a O
) O
, O
and O
genomic O
genotype O
2a O
( O
JFH1 O
- O
2a O
) O
infectious O
virus O
replication O
in O
the O
nanomolar O
range O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
utilizes O
strategies O
to O
suppress O
or O
evade O
the O
host O
immune O
response O
for O
establishment O
of O
persistent O
infection O
. O

We O
have O
shown O
previously O
that O
HCV B
nonstructural I
protein I
5A I
( I
NS5A I
) I
impairs O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
apoptosis O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
immunomodulatory O
role O
of O
HCV O
NS5A O
protein O
in O
transgenic O
mouse O
( O
NS5A O
- O
Tg O
) O
liver O
when O
mice O
were O
challenged O
with O
an O
unrelated O
hepatotropic O
adenovirus O
as O
a O
nonspecific O
stimulus O
. O

Subsequent O
study O
revealed O
that O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
expression O
is O
inhibited O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
NS5A O
- O
Tg O
mice O
, O
and O
an O
inverse O
expression O
of O
transcription O
factors O
Gata O
- O
3 O
and O
Tbx21 O
is O
observed O
. O

The O
widely O
used O
hepatitis B
B I
virus I
( I
HBV I
) I
vaccine O
is O
based O
on O
three O
doses O
of O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
protein O
. O

We O
previously O
showed O
that O
vectored O
measles B
viruses I
( I
MV I
) I
expressing O
HBsAg O
retain O
measles O
vaccine O
function O
in O
monkeys O
but O
do O
not O
induce O
a O
protective O
anti O
- O
HBs O
response O
in O
all O
animals O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
chronically O
infects O
170 O
million O
individuals O
, O
causing O
severe O
liver O
disease O
. O

To O
investigate O
this O
potential O
, O
we O
redirected O
the O
coronavirus O
murine B
hepatitis I
virus I
( I
MHV I
) I
, O
which O
is O
normally O
unable O
to O
infect O
human O
cells O
, O
to O
human O
tumor O
cells O
by O
using O
a O
soluble B
receptor I
( I
soR I
) I
- O
based O
expression O
construct O
fused O
to O
an O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor O
targeting O
moiety O
. O

Addition O
of O
this O
adapter O
protein O
to O
MHV O
allowed O
infection O
of O
otherwise O
nonsusceptible O
, O
EGF B
receptor I
( I
EGFR I
) I
- O
expressing O
cell O
cultures O
. O

Hepatits O
B O
virus O
( O
HBV O
) O
- O
specific O
T O
cells O
play O
a O
key O
role O
both O
in O
the O
control O
of O
HBV O
replication O
and O
in O
the O
pathogenesis O
of O
liver O
disease O
. O

human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
coinfection O
and O
the O
presence O
or O
absence O
of O
HBV O
e O
( O
precore O
) O
antigen O
( O
HBeAg O
) O
significantly O
alter O
the O
natural O
history O
of O
chronic O
HBV O
infection O
. O

We O
examined O
the O
HBV O
- O
specific O
T O
- O
cell O
responses O
in O
treatment O
- O
naive O
HBeAg O
- O
positive O
and O
HBeAg O
- O
negative O
HIV O
- O
1 O
- O
HBV O
- O
coinfected O
( O
n O
= O
24 O
) O
and O
HBV O
- O
monoinfected O
( O
n O
= O
39 O
) O
Asian O
patients O
. O

Peripheral O
blood O
was O
stimulated O
with O
an O
overlapping O
peptide O
library O
for O
the O
whole O
HBV O
genome O
, O
and O
tumor O
necrosis O
factor O
alpha O
and O
gamma O
interferon O
cytokine O
expression O
in O
CD8 O
( O
+ O
) O
T O
cells O
was O
measured O
by O
intracellular O
cytokine O
staining O
and O
flow O
cytometry O
. O

Overall O
, O
the O
frequency O
and O
quality O
of O
the O
HBV O
- O
specific O
T O
- O
cell O
responses O
increased O
with O
a O
higher O
CD4 O
( O
+ O
) O
T O
- O
cell O
count O
( O
P O
= O
0 O
. O

The O
quality O
of O
the O
HBV O
- O
specific O
T O
- O
cell O
response O
is O
impaired O
in O
the O
setting O
of O
HIV O
- O
1 O
- O
HBV O
coinfection O
and O
is O
related O
to O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
count O
. O

While O
characterizing O
modified O
vaccinia O
virus O
recombinants O
( O
rMVAs O
) O
containing O
human O
immunodeficiency O
virus O
env O
and O
gag O
- O
pol O
genes O
, O
we O
detected O
nonexpressing O
mutants O
by O
immunostaining O
individual O
plaques O
. O

Although O
replicons O
have O
been O
used O
to O
demonstrate O
hepatitis B
C I
virus I
( I
HCV I
) I
inhibition O
by O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
the O
detailed O
inhibition O
kinetics O
required O
to O
mathematically O
model O
HCV O
RNA O
decline O
have O
been O
lacking O
. O

Therefore O
, O
we O
measured O
genotype O
1b O
subgenomic O
replicon O
( O
sg1b O
) O
RNA O
levels O
under O
various O
IFN O
- O
alpha O
concentrations O
to O
assess O
the O
inhibition O
kinetics O
of O
intracellular O
HCV O
RNA O
. O

Based O
on O
these O
data O
, O
we O
developed O
a O
mathematical O
model O
of O
IFN O
- O
alpha O
- O
induced O
intracellular O
sg1b O
RNA O
decline O
, O
and O
we O
show O
that O
the O
mechanism O
( O
s O
) O
mediating O
IFN O
- O
alpha O
inhibition O
of O
HCV O
acts O
primarily O
by O
reducing O
sg1b O
RNA O
amplification O
, O
with O
an O
additional O
effect O
on O
HCV O
RNA O
stability O
/ O
degradation O
detectable O
at O
a O
dose O
of O
250 O
U O
/ O
ml O
IFN O
- O
alpha O
. O

As O
such O
, O
dissection O
of O
HCV O
IFN O
- O
alpha O
inhibition O
kinetics O
in O
vitro O
has O
brought O
us O
closer O
to O
understanding O
the O
mechanism O
( O
s O
) O
by O
which O
IFN O
- O
alpha O
may O
be O
inhibiting O
HCV O
in O
vivo O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
encodes O
one O
protein O
, O
hepatitis O
delta B
antigen I
( I
delta I
Ag I
) I
, O
a O
195 O
- O
amino O
- O
acid O
RNA O
binding O
protein O
essential O
for O
the O
accumulation O
of O
HDV O
RNA O
- O
directed O
RNA O
transcripts O
. O

It O
has O
been O
accepted O
that O
delta O
Ag O
localizes O
predominantly O
to O
the O
nucleolus O
in O
the O
absence O
of O
HDV O
genome O
replication O
while O
in O
the O
presence O
of O
replication O
, O
delta O
Ag O
facilitates O
HDV O
RNA O
transport O
to O
the O
nucleoplasm O
and O
helps O
redirect O
host O
RNA B
polymerase I
II I
( I
Pol I
II I
) I
to O
achieve O
transcription O
and O
accumulation O
of O
processed O
HDV O
RNA O
species O
. O

Replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
occurs O
on O
intracellular O
membranes O
, O
and O
the O
replication B
complex I
( I
RC I
) I
contains O
viral O
RNA O
, O
nonstructural O
proteins O
, O
and O
cellular O
cofactors O
. O

We O
previously O
demonstrated O
that O
cyclophilin B
A I
( I
CypA I
) I
is O
an O
essential O
cofactor O
for O
HCV O
infection O
and O
the O
intracellular O
target O
of O
cyclosporine O
' O
s O
anti O
- O
HCV O
effect O
. O

Finally O
, O
we O
introduced O
point O
mutations O
in O
the O
prolyl O
- O
peptidyl O
isomerase O
( O
PPIase O
) O
motif O
of O
CyPA O
and O
demonstrated O
a O
critical O
role O
of O
this O
motif O
in O
HCV O
replication O
in O
cDNA O
rescue O
experiments O
. O

Replication O
and O
infectivity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
with O
a O
defective O
genome O
is O
ambiguous O
. O

nonstructural B
protein I
1 I
( I
nsp1 I
) I
, O
a O
28 O
- O
kDa O
protein O
in O
the O
bovine B
coronavirus I
( I
BCoV I
) I
and O
closely O
related O
mouse O
hepatitis O
coronavirus O
, O
is O
the O
first O
protein O
cleaved O
from O
the O
open B
reading I
frame I
1 I
( I
ORF I
1 I
) I
polyprotein O
product O
of O
genome O
translation O
. O

Recently O
, O
a O
30 O
- O
nucleotide B
( I
nt I
) I
cis O
- O
replication O
stem B
- I
loop I
VI I
( I
SLVI I
) I
has O
been O
mapped O
at O
nt O
101 O
to O
130 O
within O
a O
288 O
- O
nt O
5 O
' O
- O
terminal O
segment O
of O
the O
738 O
- O
nt O
nsp1 O
cistron O
in O
a O
BCoV O
Defective B
interfering I
( I
DI I
) I
RNA O
. O

Here O
, O
we O
( O
i O
) O
establish O
by O
mutation O
analysis O
that O
the O
72 O
- O
nt O
intracistronic O
SLV O
immediately O
upstream O
of O
SLVI O
is O
also O
a O
DI O
RNA O
cis O
- O
replication O
signal O
, O
( O
ii O
) O
show O
by O
gel O
shift O
and O
UV O
- O
cross O
- O
linking O
analyses O
that O
cellular O
proteins O
of O
similar O
to O
60 O
and O
100 O
kDa O
, O
but O
not O
viral O
proteins O
, O
bind O
SLV O
and O
SLVI O
, O
( O
SLV O
- O
VI O
) O
and O
( O
iii O
) O
demonstrate O
by O
gel O
shift O
analysis O
that O
nsp1 O
purified O
from O
Escherichia O
coli O
does O
not O
bind O
SLV O
- O
VI O
but O
does O
bind O
three O
5 B
' I
untranslated I
region I
( I
UTR I
) I
- O
and O
one O
3 O
' O
UTR O
- O
located O
cis O
- O
replication O
SLs O
. O

During O
acute O
infection O
, O
West B
Nile I
virus I
( I
WNV I
) I
has O
been O
reported O
to O
infect O
a O
variety O
of O
cell O
types O
in O
various O
tissues O
of O
both O
experimentally O
and O
naturally O
infected O
hosts O
. O

Nonstructural B
protein I
4B I
( I
NS4B I
) I
plays O
an O
essential O
role O
in O
the O
formation O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
. O

Here O
, O
we O
describe O
a O
novel O
determinant O
for O
membrane O
association O
represented O
by O
amino B
acids I
( I
aa I
) I
40 O
to O
69 O
in O
the O
N O
- O
terminal O
portion O
of O
NS4B O
. O

Claudin O
- O
1 O
, O
a O
component O
of O
tight O
junctions O
between O
liver O
hepatocytes O
, O
is O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
late O
- O
stage O
entry O
cofactor O
. O

Most O
of O
the O
critical O
residues O
belong O
to O
the O
highly O
conserved O
claudin O
motif O
W O
- O
30 O
- O
GLW O
( O
51 O
) O
- O
C O
- O
54 O
- O
C O
- O
64 O
. O

High O
- O
resolution O
diffracting O
crystals O
of O
NS5A O
domain O
I O
( O
amino O
acids O
33 O
to O
202 O
) O
[ O
NS5A O
( O
33 O
- O
202 O
) O
] O
were O
obtained O
by O
using O
detergent O
additive O
crystallization O
screens O
, O
leading O
to O
the O
structure O
of O
a O
homodimer O
which O
is O
organized O
differently O
from O
that O
published O
previously O
( O
T O
. O

The O
monomer O
- O
monomer O
interface O
of O
NS5A O
( O
33 O
- O
202 O
) O
features O
an O
extensive O
buried O
surface O
area O
involving O
the O
most O
- O
highly O
conserved O
face O
of O
each O
monomer O
. O

Treatment O
for O
hepatitis O
C O
virus O
infection O
currently O
consists O
of O
pegylated O
interferon O
and O
ribavirin B
( I
RBV I
) I
, O
a O
nucleoside O
analog O
. O

Overexpression O
of O
equilibrative B
nucleoside I
transporter I
1 I
( I
ENT1 I
) I
or O
concentrative B
nucleoside I
transporter I
3 I
( I
CNT3 I
) I
increased O
RBV O
uptake O
in O
RBV O
- O
sensitive O
cell O
lines O
and O
restored O
the O
uptake O
defect O
in O
most O
RBV O
- O
resistant O
cell O
lines O
. O

The O
murine B
hepatitis I
virus I
( I
MHV I
) I
strain O
A59 O
ns2 O
protein O
is O
a O
30 O
- O
kDa O
nonstructural O
protein O
that O
is O
expressed O
from O
a O
subgenomic O
mRNA O
in O
the O
cytoplasm O
of O
virus O
- O
infected O
cells O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
gene O
is O
more O
conserved O
at O
the O
nucleic O
acid O
level O
than O
is O
necessary O
to O
preserve O
the O
sequence O
of O
the O
core O
protein O
, O
suggesting O
that O
it O
contains O
information O
for O
additional O
functions O
. O

Three O
infectious O
viruses O
, O
JFH O
- O
1 O
( O
2a O
core O
) O
, O
J6 O
/ O
JFH O
( O
2a O
core O
) O
, O
and O
H77 O
/ O
JFH O
( O
1a O
core O
) O
, O
and O
a O
bicistronic O
construct O
, O
Bi O
- O
H77 O
/ O
JFH O
, O
all O
expressed O
both O
p8 O
and O
larger O
isoforms O
. O

nonstructural B
protein I
3 I
( I
NS3 I
) I
is O
an O
essential O
replicative O
component O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
a O
member O
of O
the O
DExH O
/ O
D O
- O
box O
family O
of O
proteins O
. O

The O
C O
- O
terminal O
region O
of O
NS3 O
( O
NS3hel O
) O
exhibits O
RNA O
- O
stimulated O
NTPase O
and O
helicase O
activity O
, O
while O
the O
N O
- O
terminal O
serine O
protease O
domain O
of O
NS3 O
enhances O
RNA O
binding O
and O
unwinding O
by O
NS3hel O
. O

The O
nonstructural B
protein I
4A I
( I
NS4A I
) I
binds O
to O
the O
NS3 O
protease O
domain O
and O
serves O
as O
an O
obligate O
cofactor O
for O
NS3 O
serine O
protease O
activity O
. O

Oncostatin B
M I
( I
OSM I
) I
is O
released O
together O
with O
type B
I I
interferon I
( I
IFN I
) I
by O
activated O
dendritic O
cells O
, O
suggesting O
a O
concerted O
action O
of O
these O
cytokines O
in O
the O
biological O
response O
against O
infection O
. O

Moreover O
, O
OSM O
, O
alone O
or O
in O
combination O
with O
IFN O
- O
alpha O
, O
upregulated O
relevant O
innate O
immunity O
molecules O
and O
increased O
the O
expression O
of O
intracellular O
adhesion O
molecule O
1 O
and O
interleukin B
- I
15 I
receptor I
alpha I
( I
IL I
- I
15R I
alpha I
) I
in O
liver O
cells O
. O

To O
better O
understand O
the O
components O
of O
an O
effective O
immune O
response O
to O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
, O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
HIV O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
and O
cytomegalovirus B
( I
CMV I
) I
were O
compared O
with O
regard O
to O
frequency O
, O
immunodominance O
, O
phenotype O
, O
and O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
responsiveness O
. O

Responses O
were O
examined O
in O
rare O
patients O
exhibiting O
durable O
immune O
- O
mediated O
control O
over O
HIV O
, O
termed O
long B
- I
term I
nonprogressors I
( I
LTNP I
) I
or O
elite O
controllers O
, O
and O
patients O
with O
progressive O
HIV O
infection O
( O
progressors O
) O
. O

The O
magnitude O
of O
the O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
targeting O
HIV O
, O
CMV O
, O
and O
HCV O
was O
not O
significantly O
different O
between O
LTNP O
and O
progressors O
, O
even O
though O
their O
capacity O
to O
proliferate O
to O
HIV O
antigens O
was O
preserved O
only O
in O
LTNP O
. O

In O
contrast O
to O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
of O
LTNP O
, O
HLA O
B5701 O
- O
restricted O
responses O
within O
CMV O
pp65 O
were O
rare O
and O
did O
not O
dominate O
the O
total O
CMV O
- O
specific O
response O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
predominantly O
CD27 O
( O
+ O
) O
45RO O
( O
+ O
) O
for O
HIV O
and O
CD27 O
( O
- O
) O
45RA O
( O
+ O
) O
for O
CMV O
; O
however O
, O
these O
phenotypes O
were O
highly O
variable O
and O
heavily O
influenced O
by O
the O
degree O
of O
viremia O
. O

Although O
IL O
- O
2 O
induced O
significant O
expansions O
of O
CMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
LTNP O
and O
progressors O
by O
increasing O
both O
the O
numbers O
of O
cells O
entering O
the O
proliferating O
pool O
and O
the O
number O
of O
divisions O
, O
the O
proliferative O
capacity O
of O
a O
significant O
proportion O
of O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
was O
not O
restored O
with O
exogenous O
IL O
- O
2 O
. O

They O
also O
suggest O
that O
poor O
responsiveness O
to O
IL O
- O
2 O
is O
a O
property O
of O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
of O
progressors O
that O
is O
not O
shared O
with O
responses O
to O
other O
viruses O
over O
which O
immunologic O
control O
is O
maintained O
. O

Studies O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
have O
been O
aided O
by O
development O
of O
in O
vitro O
systems O
that O
enable O
replication O
of O
viral O
RNA O
and O
production O
of O
infectious O
virus O
. O

It O
is O
considered O
that O
NS4B O
, O
one O
of O
the O
replicase O
components O
, O
creates O
sites O
for O
genome O
synthesis O
, O
which O
appear O
as O
punctate O
foci O
at O
the O
endoplasmic B
reticulum I
( I
ER I
) I
membrane O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
encodes O
several O
accessory O
proteins O
of O
unknown O
function O
. O

One O
of O
these O
proteins O
, O
protein O
6 O
( O
p6 O
) O
, O
which O
is O
encoded O
by O
ORF6 O
, O
enhances O
virus O
replication O
when O
introduced O
into O
a O
heterologous O
murine O
coronavirus O
( O
mouse O
hepatitis O
virus O
[ O
MHV O
] O
) O
but O
is O
not O
essential O
for O
optimal O
SARS O
- O
CoV O
replication O
after O
infection O
at O
a O
relatively O
high O
multiplicity B
of I
infection I
( I
MOI I
) I
. O

Previously O
, O
we O
reported O
that O
three O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
segments O
, O
designated O
L O
- O
, O
M O
- O
, O
and O
S O
- O
dsRNAs O
, O
were O
detected O
in O
Sclerotinia O
sclerotiorum O
strain O
Ep O
- O
1PN O
. O

Here O
, O
we O
present O
the O
complete O
nucleotide O
sequence O
of O
the O
L O
- O
dsRNA O
, O
which O
is O
6 O
, O
043 O
nucleotides O
in O
length O
, O
excluding O
the O
poly O
( O
A O
) O
tail O
. O

Sequence O
analysis O
revealed O
the O
presence O
of O
a O
single O
open O
reading O
frame O
( O
nucleotide O
positions O
42 O
to O
5936 O
) O
that O
encodes O
a O
protein O
with O
significant O
similarity O
to O
the O
replicases O
of O
the O
alphavirus O
- O
like O
supergroup O
of O
positive O
- O
strand O
RNA O
viruses O
. O

Our O
results O
suggest O
that O
the O
L O
- O
dsRNA O
from O
strain O
Ep O
- O
1PN O
is O
derived O
from O
the O
genomic O
RNA O
of O
a O
positive O
- O
strand O
RNA O
virus O
, O
which O
we O
named O
Sclerotinia B
sclerotiorum I
RNA I
virus I
L I
( I
SsRV I
- I
L I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
F O
protein O
is O
encoded O
by O
the O
+ O
1 O
reading O
frame O
of O
the O
viral O
genome O
. O

Human O
coronavirus O
229E O
, O
classified O
as O
a O
group O
I O
coronavirus O
, O
utilizes O
human O
aminopeptidase B
N I
( I
APN I
) I
as O
a O
receptor O
; O
however O
, O
its O
entry O
mechanism O
has O
not O
yet O
been O
fully O
elucidated O
. O

We O
found O
that O
HeLa O
cells O
infected O
with O
229E O
via O
APN O
formed O
syncytia O
when O
treated O
with O
trypsin O
or O
other O
proteases O
but O
not O
in O
a O
low O
- O
pH O
environment O
, O
a O
finding O
consistent O
with O
syncytium O
formation O
by O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
. O

We O
found O
that O
cathepsin B
L I
( I
CPL I
) I
inhibitors O
blocked O
229E O
infection O
the O
most O
remarkably O
among O
a O
variety O
of O
protease O
inhibitors O
tested O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
which O
currently O
infects O
an O
estimated O
3 O
% O
of O
people O
worldwide O
, O
has O
been O
present O
in O
some O
human O
populations O
for O
several O
centuries O
, O
notably O
HCV O
genotypes O
1 O
and O
2 O
in O
West O
Africa O
and O
genotype O
6 O
in O
Southeast O
Asia O
. O

Our O
analysis O
includes O
new O
HCV O
core O
( O
n O
= O
16 O
) O
and O
NS5B O
( O
n O
= O
14 O
) O
gene O
sequences O
, O
obtained O
from O
serum O
samples O
of O
jaundiced O
patients O
from O
Laos O
. O

We O
have O
recently O
shown O
that O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Pr55 O
( O
gag O
) O
virus B
- I
like I
particles I
( I
HIV I
- I
VLPs I
) I
, O
produced O
in O
a O
baculovirus O
expression O
system O
and O
presenting O
a O
gp120 O
molecule O
from O
a O
Ugandan O
HIV O
- O
1 O
isolate O
of O
clade O
A O
, O
induce O
maturation O
and O
activation O
of O
monocyte B
- I
derived I
dendritic I
cells I
( I
mdDCs I
) I
with O
a O
production O
of O
Th1 O
- O
and O
Th2 O
- O
specific O
cytokines O
. O

Furthermore O
, O
HIV O
- O
VLP O
- O
loaded O
MDDCs O
are O
able O
to O
induce O
a O
primary O
and O
secondary O
response O
in O
autologous O
human O
CD4 O
( O
+ O
) O
T O
cells O
in O
an O
ex O
vivo O
immunization O
assay O
. O

In O
the O
present O
study O
, O
we O
show O
that O
similar O
data O
can O
be O
obtained O
directly O
with O
fresh O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
, O
and O
the O
HIV O
- O
1 O
seropositivity O
status O
, O
with O
either O
low O
or O
high O
viremia O
, O
does O
not O
significantly O
impair O
the O
immune O
activation O
status O
and O
the O
responsiveness O
of O
circulating O
monocyte O
CD14 O
( O
+ O
) O
cell O
populations O
to O
an O
immunogenic O
stimulus O
. O

Some O
HIV O
- O
1 O
- O
seropositive O
subjects O
, O
however O
, O
show O
a O
complete O
lack O
of O
maturation O
induced O
by O
HIV O
- O
VLPs O
in O
CD14 O
( O
+ O
) O
circulating O
cells O
, O
which O
does O
not O
consistently O
correlate O
with O
an O
advanced O
status O
of O
HIV O
- O
1 O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
dependent O
on O
at O
least O
three O
coreceptors O
: O
CD81 O
, O
scavenger B
receptor I
BI I
( I
SR I
- I
BI I
) I
, O
and O
claudin O
- O
1 O
. O

In O
this O
study O
we O
demonstrate O
that O
a O
cell O
culture O
- O
adapted O
JFH O
- O
1 O
mutant O
, O
with O
an O
amino O
acid O
change O
in O
E2 O
at O
position O
451 O
( O
G451R O
) O
, O
has O
a O
reduced O
dependency O
on O
SR O
- O
BI O
. O

Finally O
, O
an O
association O
was O
observed O
between O
JFH O
- O
1 O
particle O
density O
and O
sensitivity O
to O
neutralizing B
antibodies I
( I
NAbs I
) I
, O
suggesting O
that O
lipoprotein O
association O
reduces O
the O
sensitivity O
of O
particles O
to O
NAbs O
. O

How O
these O
structures O
are O
assembled O
is O
still O
largely O
unknown O
, O
but O
it O
is O
likely O
that O
the O
membrane O
- O
spanning O
members O
of O
these O
nonstructural B
proteins I
( I
nsPs I
) I
are O
responsible O
for O
the O
induction O
of O
the O
double O
- O
membrane O
vesicles O
and O
for O
anchoring O
the O
replication O
complexes O
to O
these O
membranes O
. O

The O
antiviral O
role O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
virus O
- O
induced O
pathologies O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
has O
not O
been O
explored O
extensively O
. O

Control O
of O
neurotropic O
mouse O
hepatitis O
virus O
( O
JIIMV O
) O
requires O
the O
collaboration O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
, O
with O
CD8 O
( O
+ O
) O
T O
cells O
providing O
direct O
perforin O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
mediated O
antiviral O
activity O
. O

To O
distinguish O
bystander O
from O
direct O
antiviral O
contributions O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
virus O
clearance O
and O
pathology O
, O
memory O
CD4 O
( O
+ O
) O
T O
cells O
purified O
from O
wild B
type I
( I
Wt I
) I
, O
perforin B
- I
deficient I
( I
PKO I
) I
, O
and O
IFN O
- O
gamma O
- O
deficient O
( O
GKO O
) O
immune O
donors O
were O
transferred O
to O
immunodeficient O
SCID O
mice O
prior O
to O
CNS O
challenge O
. O

All O
three O
donor O
CD4 O
( O
+ O
) O
T O
- O
cell O
populations O
controlled O
CNS O
virus O
replication O
at O
8 O
days O
postinfection O
, O
indicating O
IFN O
- O
gamma O
- O
and O
perforin O
- O
independent O
antiviral O
function O
. O

Recipients O
of O
GKO O
CD4 O
( O
+ O
) O
T O
cells O
succumbed O
more O
rapidly O
to O
fatal O
disease O
than O
untreated O
control O
infected O
mice O
. O

In O
contrast O
, O
wt O
and O
PKO O
donor O
CD4 O
( O
+ O
) O
T O
cells O
cleared O
infectious O
virus O
to O
undetectable O
levels O
and O
protected O
from O
fatal O
disease O
. O

Recipients O
of O
all O
CD4 O
( O
+ O
) O
T O
- O
cell O
populations O
exhibited O
demyelination O
. O

However O
, O
it O
was O
more O
severe O
in O
wt O
CD4 O
( O
+ O
) O
T O
- O
cell O
recipients O
. O

These O
data O
support O
a O
role O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
virus O
clearance O
and O
demyelination O
. O

Four O
conserved O
RNA O
stem O
- O
loop O
structures O
designated O
SL47 O
, O
SL87 O
, O
SL248 O
, O
and O
SL443 O
have O
been O
predicted O
in O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
encoding O
region O
. O

Moreover O
, O
alternative O
translation O
products O
have O
been O
detected O
from O
a O
reading O
frame O
overlapping O
the O
core O
gene O
( O
core O
+ O
1 O
/ O
ARFP O
/ O
F O
) O
. O

The O
activation O
state O
, O
differentiation O
state O
, O
and O
functions O
of O
liver O
lymphocytes O
and O
perihepatic O
lymph O
nodes O
during O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
are O
not O
well O
understood O
. O

We O
measured O
lymphocyte O
subset O
frequency O
and O
memory O
T O
- O
cell O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
proliferative O
responses O
to O
HCV O
peptide O
and O
control O
viral O
antigens O
in O
direct O
ex O
vivo O
assays O
. O

Genome B
- I
scale I
ordered I
RNA I
structure I
( I
GORS I
) I
was O
widely O
distributed O
in O
many O
animal O
and O
plant O
viruses O
, O
much O
greater O
in O
extent O
than O
RNA O
structures O
required O
for O
viral O
translation O
or O
replication O
, O
but O
in O
mammalian O
viruses O
was O
associated O
with O
host O
persistence O
. O

To O
substantiate O
the O
existence O
of O
large O
- O
scale O
RNA O
structure O
differences O
between O
viruses O
, O
a O
large O
set O
of O
alignments O
of O
mammalian O
RNA O
viruses O
and O
rRNA O
sequences O
as O
controls O
were O
examined O
by O
thermodynamic O
methods O
( O
to O
calculate O
minimum O
free O
energy O
differences O
) O
and O
by O
algorithmically O
independent O
RNAz O
and O
Pfold O
methods O
. O

Transcripts O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
hepatitis B
G I
virus I
/ I
GB I
virus I
- I
C I
( I
HGV I
/ I
GBV I
- I
C I
) I
, O
and O
murine O
norovirus O
, O
which O
are O
predicted O
to O
be O
structured O
, O
were O
largely O
inaccessible O
to O
hybridization O
in O
solution O
, O
in O
contrast O
to O
the O
almost O
universal O
binding O
of O
probes O
to O
a O
range O
of O
unstructured O
virus O
transcripts O
irrespective O
of O
G O
+ O
C O
content O
. O

We O
previously O
reported O
that O
cells O
harboring O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replicon O
as O
well O
as O
those O
expressing O
HCV O
NS3 O
/ O
4A O
exhibited O
increased O
sensitivity O
to O
suboptimal O
doses O
of O
apoptotic O
stimuli O
to O
undergo O
mitochondrion O
- O
mediated O
apoptosis O
( O
Y O
. O

The O
cell O
death O
was O
associated O
with O
activation O
of O
caspase O
3 O
, O
nuclear O
translocation O
of O
activated O
caspase O
3 O
, O
and O
cleavage O
of O
DNA O
repair O
enzyme O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
, O
which O
is O
known O
to O
be O
an O
important O
substrate O
for O
activated O
caspase O
3 O
. O

On O
the O
other O
hand O
, O
HCV O
infection O
did O
not O
mediate O
increased O
expression O
of O
glucose B
- I
regulated I
protein I
78 I
( I
GRP78 I
) I
or O
GRP94 O
, O
which O
are O
known O
as O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
- O
induced O
proteins O
; O
this O
result O
suggests O
that O
ER O
stress O
is O
not O
primarily O
involved O
in O
HCV O
- O
induced O
apoptosis O
in O
our O
experimental O
system O
. O

Taken O
together O
, O
our O
present O
results O
suggest O
that O
HCV O
infection O
induces O
apoptosis O
of O
the O
host O
cell O
through O
a O
Bax O
- O
triggered O
, O
mitochondrion O
- O
mediated O
, O
caspase O
3 O
- O
dependent O
pathway O
( O
s O
) O
. O

Intrahepatic O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
thought O
to O
be O
important O
for O
the O
control O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
yet O
the O
precise O
kinetics O
for O
the O
expansion O
of O
epitope O
- O
specific O
T O
cells O
over O
the O
course O
of O
infection O
are O
difficult O
to O
determine O
with O
currently O
available O
methods O
. O

We O
used O
a O
real O
- O
time O
PCR O
assay O
to O
measure O
the O
frequency O
of O
clonotypic O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
peripheral O
blood O
and O
snap O
- O
frozen O
liver O
biopsy O
specimens O
of O
two O
chimpanzees O
( O
Pan O
troglodytes O
) O
with O
previously O
resolved O
HCV O
infection O
who O
were O
rechallenged O
with O
HCV O
. O

After O
antibody O
- O
mediated O
CD8 O
( O
+ O
) O
T O
- O
cell O
depletion O
and O
another O
viral O
challenge O
, O
the O
rebound O
of O
these O
clonotypes O
was O
seen O
prior O
to O
an O
appreciable O
reconstitution O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
values O
and O
, O
again O
, O
at O
higher O
frequencies O
in O
the O
liver O
than O
in O
peripheral O
blood O
. O

These O
data O
demonstrate O
the O
importance O
of O
intrahepatic O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
for O
the O
clearance O
of O
infection O
and O
the O
rapid O
kinetics O
of O
expansion O
after O
virus O
challenge O
. O

ADARs O
( O
adenosine O
deaminases O
that O
act O
on O
double O
- O
stranded O
RNA O
) O
are O
RNA O
editing O
enzymes O
that O
catalyze O
a O
change O
from O
adenosine O
to O
inosine O
, O
which O
is O
then O
recognized O
as O
guanosine O
by O
translational O
machinery O
. O

We O
demonstrate O
here O
that O
overexpression O
of O
ADARs O
but O
not O
of O
an O
ADAR O
mutant O
lacking O
editing O
activity O
could O
upregulate O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
structural O
protein O
expression O
and O
viral O
production O
. O

Given O
the O
failures O
of O
nonreplicating O
vaccines O
against O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
we O
hypothesized O
that O
a O
replicating O
viral O
vector O
may O
provide O
protective O
immunity O
. O

Four O
chimpanzees O
were O
immunized O
transdermally O
twice O
with O
recombinant B
vaccinia I
viruses I
( I
rVV I
) I
expressing O
HCV O
genes O
. O

During O
the O
acute O
phase O
after O
the O
multigenotype O
challenge O
, O
all O
animals O
had O
high O
- O
titer O
viremia O
in O
which O
genotype O
4 O
dominated O
( O
87 O
% O
) O
, O
followed O
by O
genotype O
5 O
( O
13 O
% O
) O
. O

The O
small O
hepatitis B
delta I
virus I
( I
HDV I
) I
antigen O
( O
SHDAg O
) O
plays O
an O
essential O
role O
in O
HDV O
RNA O
double O
- O
rolling O
- O
circle O
replication O
. O

Several O
posttranslational B
modifications I
( I
PTMs I
) I
of O
HDAgs O
, O
including O
phosphorylation O
, O
acetylation O
, O
and O
methylation O
, O
have O
been O
characterized O
. O

Using O
coimmunoprecipitation O
analysis O
, O
the O
cellular O
kinases O
extracellular B
signal I
- I
related I
kinases I
1 I
and I
2 I
( I
ERK1 I
/ I
2 I
) I
are O
found O
to O
be O
associated O
with O
the O
Flag O
- O
tagged O
SHDAg O
mutant O
( O
Ser O
- O
177 O
replaced O
with O
Cys O
- O
177 O
) O
. O

Activation O
of O
endogenous O
ERK1 O
/ O
2 O
by O
a O
constitutively O
active O
MEK1 O
( O
hemagglutinin O
- O
AcMEK1 O
) O
increased O
phosphorylation O
of O
SHDAg O
at O
Ser O
- O
177 O
; O
this O
phosphorylation O
was O
confirmed O
by O
immunoblotting O
using O
an O
antibody O
against O
phosphorylated O
S177 O
and O
mass O
spectrometric O
analysis O
. O

The O
Ser O
- O
177 O
residue O
was O
critical O
for O
SHDAg O
interaction O
with O
RNA B
polymerase I
II I
( I
RNAPII I
) I
, O
the O
enzyme O
proposed O
to O
regulate O
antigenomic O
RNA O
replication O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
a O
viroid O
- O
like O
, O
1 O
. O

In O
this O
study O
, O
we O
developed O
a O
unique O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
procedure O
for O
detection O
of O
various O
HDV O
RNA O
species O
from O
an O
RNA O
transfection O
system O
. O

Using O
this O
qRT O
- O
PCR O
procedure O
and O
a O
series O
of O
HDV O
mutants O
, O
we O
demonstrated O
that O
Arg O
- O
13 O
methylation O
, O
Lys O
- O
72 O
acetylation O
, O
and O
Ser O
- O
177 O
phosphorylation O
of O
small B
hepatitis I
delta I
antigen I
( I
S I
- I
HDAg I
) I
are O
important O
for O
HDV O
mRNA O
transcription O
. O

Neonatal O
injection O
of O
recombinant B
adeno I
- I
associated I
virus I
serotype I
8 I
( I
rAAV8 I
) I
vectors O
results O
in O
widespread O
transduction O
in O
multiple O
organs O
and O
therefore O
holds O
promise O
in O
neonatal O
gene O
therapy O
. O

0 O
x O
10 O
( O
11 O
) O
vector O
genomes O
at O
birth O
. O

Twenty O
- O
three O
of O
34 O
integrations O
( O
68 O
% O
) O
occurred O
in O
genes O
, O
but O
none O
of O
them O
were O
near O
the O
mir O
- O
341 O
locus O
, O
the O
common O
rAAV O
integration O
site O
found O
in O
mouse O
hepatocellular O
carcinoma O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
and O
the O
expression O
of O
the O
HCV O
nonstructural O
protein O
NS3 O
and O
core O
protein O
have O
been O
proposed O
as O
factors O
involved O
in O
the O
induction O
of O
double O
- O
stranded O
DNA O
breaks O
and O
enhancement O
of O
the O
mutation O
frequency O
of O
cellular O
genes O
. O

Since O
DNA O
damage O
sensors O
, O
such O
as O
the O
ataxia B
- I
telangiectasia I
mutated I
kinase I
( I
ATM I
) I
, O
ATM B
- I
and I
Rad3 I
- I
related I
kinase I
( I
ATR I
) I
, O
poly O
( O
ADP O
- O
ribose O
) O
polymerase B
1 I
( I
PARP I
- I
1 I
) I
, O
and O
checkpoint B
kinase I
2 I
( I
Chk2 I
) I
, O
play O
central O
roles O
in O
the O
response O
to O
genotoxic O
stress O
, O
we O
hypothesized O
that O
these O
sensors O
might O
affect O
HCV O
replication O
. O

Consequently O
, O
we O
found O
that O
replication O
of O
both O
genome O
- O
length O
HCV O
RNA O
( O
HCV O
- O
O O
, O
genotype O
1b O
) O
and O
the O
subgenomic O
replicon O
RNA O
were O
notably O
suppressed O
in O
ATM O
- O
or O
Chk2 O
- O
knockdown O
cells O
. O

In O
addition O
, O
the O
RNA O
replication O
of O
HCV O
- O
JFH1 O
( O
genotype O
2a O
) O
and O
the O
release O
of O
core O
protein O
into O
the O
culture O
supernatants O
were O
suppressed O
in O
these O
knockdown O
cells O
after O
inoculation O
of O
the O
cell O
culture O
- O
generated O
HCV O
. O

Peripheral O
blood O
T O
- O
cell O
responses O
are O
used O
as O
biomarkers O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
vaccine O
trials O
. O

Such O
structures O
are O
often O
called O
subviral B
particles I
( I
SVP I
) I
. O

Foamy B
viruses I
( I
FVs I
) I
, O
a O
special O
type O
of O
retroviruses O
with O
a O
replication O
strategy O
combining O
features O
of O
both O
orthoretroviruses O
and O
hepadnaviruses O
, O
express O
a O
glycoprotein O
( O
Env O
) O
which O
has O
the O
ability O
to O
induce O
SVP O
release O
. O

However O
, O
unlike O
human O
hepatitis O
B O
virus O
, O
prototype B
FV I
( I
PFV I
) I
naturally O
secretes O
only O
small O
amounts O
of O
SVPs O
, O
because O
ubiquitination O
of O
the O
Env O
protein O
seems O
to O
suppress O
the O
intrinsic O
capacity O
for O
induction O
of O
SVP O
release O
. O

In O
this O
study O
, O
we O
characterized O
the O
structural O
determinants O
influencing O
PFV O
SVP O
release O
, O
examined O
the O
role O
of O
specific O
Env O
ubiquitination O
sites O
in O
the O
regulation O
of O
this O
process O
, O
and O
analyzed O
the O
requirement O
of O
the O
cellular B
vacuolar I
protein I
sorting I
( I
VPS I
) I
machinery O
for O
SVP O
egress O
. O

We O
observed O
that O
the O
cytoplasmic O
and O
membrane O
- O
spanning O
domains O
of O
both O
the O
leader B
peptide I
( I
LP I
) I
and O
the O
transmembrane B
( I
TM I
) I
subunit O
harbor O
essential O
as O
well O
as O
inhibitory O
domains O
. O

Furthermore O
, O
only O
ubiquitination O
at O
the O
most O
N O
- O
terminal O
lysine O
residues O
( O
K O
- O
14 O
and O
K O
- O
15 O
) O
in O
LP O
reduced O
cell O
surface O
expression O
and O
suppressed O
SVP O
release O
to O
wild O
- O
type O
levels O
. O

The O
majority O
of O
acute O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
progress O
to O
chronicity O
and O
progressive O
liver O
damage O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
antiviral O
therapy O
achieves O
the O
highest O
rate O
of O
success O
when O
IFN O
- O
alpha O
is O
administered O
early O
during O
the O
acute O
phase O
, O
but O
the O
underlying O
mechanisms O
are O
unknown O
. O

We O
demonstrate O
that O
spontaneous O
resolution O
correlates O
with O
the O
early O
development O
of O
polyfunctional O
( O
IFN O
- O
gamma O
- O
and O
IL O
- O
2 O
- O
producing O
and O
CD107a O
( O
+ O
) O
) O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
contrast O
, O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
acute O
infections O
evolving O
to O
chronicity O
expressed O
low O
levels O
of O
CD127 O
and O
Bcl O
- O
2 O
, O
exhibited O
diminished O
proliferation O
and O
cytokine O
production O
, O
and O
eventually O
disappeared O
from O
the O
periphery O
. O

Here O
we O
take O
advantage O
of O
heteroaryldihydropyrimidines B
( I
HAPs I
) I
, O
which O
affect O
hepatitis B
B I
virus I
( I
HBV I
) I
assembly O
, O
to O
gain O
insight O
and O
correlate O
in O
vitro O
assembly O
with O
HBV O
replication O
in O
culture O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
has O
shown O
to O
be O
localized O
in O
the O
detergent B
- I
resistant I
membrane I
( I
DRM I
) I
, O
which O
is O
distinct O
from O
the O
classical O
raft O
fraction O
including O
caveolin O
, O
although O
the O
biological O
significance O
of O
the O
DRM O
localization O
of O
the O
core O
protein O
has O
not O
been O
determined O
. O

The O
HCV O
core O
protein O
is O
cleaved O
off O
from O
a O
precursor O
polyprotein O
at O
the O
lumen O
side O
of O
Ala O
( O
191 O
) O
by O
signal O
peptidase O
and O
is O
then O
further O
processed O
by O
signal B
peptide I
peptidase I
( I
SPP I
) I
within O
the O
transmembrane O
region O
. O

The O
C O
terminus O
of O
the O
HCV O
core O
protein O
cleaved O
by O
SPP O
in O
293T O
cells O
was O
identified O
as O
Phe O
( O
177 O
) O
by O
mass O
spectrometry O
. O

Mutations O
introduced O
into O
two O
residues O
( O
Ile O
( O
176 O
) O
and O
Phe O
( O
177 O
) O
) O
upstream O
of O
the O
cleavage O
site O
of O
the O
core O
protein O
abrogated O
processing O
by O
SPP O
and O
localization O
in O
the O
DRM O
fraction O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
is O
an O
enterically O
transmitted O
virus O
that O
replicates O
predominantly O
in O
hepatocytes O
within O
the O
liver O
before O
excretion O
via O
bile O
through O
feces O
. O

We O
have O
developed O
a O
subclone O
of O
hepatocyte O
- O
derived O
HepG2 O
cells O
( O
clone O
N6 O
) O
that O
maintains O
functional O
characteristics O
of O
polarized O
hepatocytes O
but O
displays O
morphology O
typical O
of O
columnar O
epithelial O
cells O
, O
rather O
than O
the O
complex O
morphology O
that O
is O
typical O
of O
hepatocytes O
. O

When O
N6 O
microcolonies O
were O
exposed O
to O
HAV O
, O
infection O
was O
restricted O
to O
peripheral O
cells O
of O
polarized O
colonies O
, O
whereas O
all O
cells O
could O
be O
infected O
in O
colonies O
of O
nonpolarized O
HepG2 O
cells O
( O
clone O
C11 O
) O
or O
following O
disruption O
of O
tight O
junctions O
in O
N6 O
colonies O
with O
EGTA O
. O

Optic B
neuritis I
( I
ON I
) I
, O
an O
inflammatory O
demyelinating O
optic O
nerve O
disease O
, O
occurs O
in O
multiple B
sclerosis I
( I
MS I
) I
. O

We O
demonstrate O
that O
MHV O
- O
A59 O
, O
a O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
that O
causes O
brain O
and O
spinal O
cord O
inflammation O
and O
demyelination O
, O
induces O
ON O
by O
promoting O
mixed O
inflammatory O
cell O
infiltration O
. O

The O
genome O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
cis B
- I
acting I
replication I
elements I
( I
CREs I
) I
comprised O
of O
RNA O
stem O
- O
loop O
structures O
located O
in O
both O
the O
5 O
' O
and O
3 O
' O
noncoding O
regions O
( O
5 O
' O
and O
3 O
' O
NCRs O
) O
and O
in O
the O
NS5B O
coding O
sequence O
. O

The O
replication O
and O
transcription O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
viruses O
occur O
within O
a O
polymerase O
complex O
particle O
in O
which O
the O
viral O
genome O
is O
enclosed O
throughout O
the O
entire O
life O
cycle O
of O
the O
virus O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
and O
hepatitis B
delta I
virus I
( I
HDV I
) I
share O
the O
HBV O
envelope O
proteins O
. O

When O
woodchucks O
chronically O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
are O
superinfected O
with O
HDV O
, O
they O
produce O
HDV O
with O
a O
WHV O
envelope O
, O
wHDV O
. O

Several O
lines O
of O
evidence O
are O
provided O
that O
wHDV O
infects O
not O
only O
cultured O
primary B
woodchuck I
hepatocytes I
( I
PWH I
) I
but O
also O
primary B
human I
hepatocytes I
( I
PHH I
) I
. O

Surprisingly O
, O
HBV B
- I
enveloped I
HDV I
( I
hHDV I
) I
and O
wHDV O
infected O
PHH O
with O
comparable O
efficiencies O
; O
however O
, O
hHDV O
did O
not O
infect O
PWH O
. O

The O
basis O
for O
these O
host O
range O
specificities O
was O
investigated O
using O
as O
inhibitors O
peptides O
bearing O
species O
- O
specific O
pre O
- O
S O
( O
where O
S O
is O
the O
small O
envelope O
protein O
) O
sequences O
. O

The O
frequency O
that O
multiple O
different O
subtypes O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
simultaneously O
infect O
a O
given O
individual O
is O
controversial O
. O

To O
address O
this O
question O
, O
heteroduplex B
mobility I
analysis I
( I
HMA I
) I
of O
portions O
of O
the O
HCV O
core O
and O
envelope O
1 O
region O
was O
optimized O
for O
sensitive O
and O
specific O
detection O
of O
mixtures O
of O
HCV O
genomes O
of O
different O
genotype O
or O
subtype O
. O

Using O
the O
standard O
HCV O
genotyping O
approach O
of O
5 B
' I
- I
untransiated I
region I
( I
UTR I
) I
analysis O
, O
28 O
of O
374 O
( O
7 O
. O

5 O
% O
) O
chronic O
hepatitis O
C O
research O
subjects O
were O
classified O
as O
having O
either O
multiple O
- O
subtype O
HCV O
infections O
( O
n O
= O
21 O
) O
or O
switching O
HCV O
subtypes O
over O
time O
( O
n O
= O
7 O
) O
, O
the O
latter O
pattern O
implying O
viral O
superinfection O
. O

To O
address O
the O
hypothesis O
of O
tissue O
sequestration O
of O
multiple O
- O
subtype O
HCV O
infections O
, O
liver O
( O
n O
= O
22 O
) O
, O
peripheral O
blood O
mononuclear O
cell O
( O
n O
= O
13 O
) O
, O
perihepatic O
lymph O
node O
( O
n O
= O
16 O
) O
, O
and O
serum O
( O
n O
= O
19 O
) O
specimens O
from O
23 O
subjects O
with O
end O
- O
stage O
hepatitis O
C O
were O
collected O
and O
analyzed O
by O
the O
HMA O
technique O
. O

Whereas O
5 O
' O
- O
UTR O
results O
implicated O
mixed O
- O
subtype O
HCV O
infections O
in O
2 O
subjects O
, O
HMA O
testing O
revealed O
no O
evidence O
of O
a O
second O
HCV O
subtype O
in O
any O
tissue O
compartment O
( O
0 O
of O
70 O
compartments O
[ O
0 O
% O
] O
) O
or O
within O
any O
given O
subject O
( O
0 O
of O
23 O
subjects O
[ O
0 O
% O
] O
) O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
which O
is O
closely O
related O
to O
human O
hepatitis O
B O
virus O
, O
infects O
the O
liver O
but O
also O
invariably O
establishes O
persistent O
infection O
in O
the O
lymphatic O
system O
. O

To O
address O
these O
issues O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
CD8 O
T O
- O
cell O
responses O
were O
monitored O
, O
at O
the O
single O
- O
cell O
level O
, O
using O
HLA O
class O
I O
pentamers O
specific O
for O
HCV O
core O
and O
HCV O
NS3 O
epitopes O
, O
in O
23 O
chronically O
infected O
patients O
during O
treatment O
with O
pegylated O
alpha O
interferon O
and O
ribavirin O
. O

Intraperitoneal O
infection O
of O
newborn O
mice O
with O
, O
rhesus B
rotavirus I
( I
RRV I
) I
results O
in O
biliary B
atresia I
( I
BA I
) I
, O
and O
this O
condition O
is O
influenced O
by O
the O
host O
interferon O
response O
. O

We O
studied O
orally O
inoculated O
5 O
- O
day O
- O
old O
suckling O
mice O
that O
were O
deficient O
in O
interferon B
( I
IFN I
) I
signaling O
to O
evaluate O
the O
role O
of O
interferon O
on O
the O
outcome O
of O
local O
and O
systemic O
infection O
after O
enteric O
inoculation O
. O

We O
found O
that O
systemic O
replication O
of O
RRV O
, O
but O
not O
murine O
rotavirus O
strain O
EC O
, O
was O
greatly O
enhanced O
in O
IFN O
- O
alpha O
/ O
beta O
and O
IFN O
- O
gamma O
receptor O
double O
- O
knockout B
( I
KO I
) I
or O
STAT1 O
KO O
mice O
but O
not O
in O
mice O
deficient O
in O
B O
- O
or O
T O
- O
cell O
immunity O
. O

A O
mutation O
within O
subdomain O
1 O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
helicase O
( O
NS3 O
- O
Q221L O
) O
( O
M O
. O

81 O
: O
629 O
- O
638 O
, O
2007 O
) O
rescues O
a O
defect O
in O
production O
of O
infectious O
virus O
by O
an O
intergenotypic O
chimeric O
RNA O
( O
HJ3 O
) O
. O

However O
, O
while O
transfection O
of O
unmodified O
HJ3 O
RNA O
failed O
to O
produce O
either O
extracellular O
or O
intracellular O
infectious O
virus O
, O
transfection O
of O
HJ3 O
RNA O
containing O
the O
Q221L O
substitution O
( O
HJ3 O
/ O
QL O
) O
resulted O
in O
rapid O
accumulation O
of O
intracellular O
infectious O
particles O
with O
release O
into O
extracellular O
fluids O
. O

It O
has O
recently O
been O
shown O
that O
cell O
entry O
of O
mouse B
hepatitis I
virus I
type I
2 I
( I
MHV I
- I
2 I
) I
is O
mediated O
through O
endocytosis O
( O
Z O
. O

Interestingly O
, O
when O
the O
cells O
transiently O
overexpressed O
a O
dominant O
- O
negative O
form O
( O
DIII O
) O
of O
Eps15 O
, O
which O
is O
thought O
to O
be O
an O
essential O
component O
of O
the O
clathrin O
pathway O
, O
viral O
gene O
expression O
and O
infectivity O
were O
unaffected O
, O
although O
DIII O
expression O
blocked O
transferrin O
uptake O
and O
vesicular O
stomatitis O
virus O
infection O
, O
which O
are O
dependent O
on O
clathrin O
- O
mediated O
endocytosis O
. O

Protective O
immunity O
after O
resolved O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
been O
reported O
. O

In O
the O
present O
study O
, O
two O
chimpanzees O
( O
CH96A008 O
and O
CH1494 O
) O
with O
resolved O
monoclonal O
H77C O
( O
genotype O
1a O
) O
infection O
were O
rechallenged O
with O
low O
- O
dose O
homologous O
H77C O
virus O
about O
12 O
months O
after O
viral O
clearance O
; O
CH96A008 O
became O
persistently O
infected O
, O
and O
CH1494 O
had O
transient O
viremia O
lasting O
2 O
weeks O
. O

CH1494 O
was O
subsequently O
either O
partially O
or O
completely O
protected O
following O
five O
homologous O
rechallenges O
with O
monoclonal O
H77C O
or O
polyclonal O
H77 O
and O
after O
six O
heterologous O
rechallenges O
with O
HC O
- O
J4 O
( O
genotype O
1b O
) O
or O
HC O
- O
J6 O
( O
genotype O
2a O
) O
viruses O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
protection O
against O
neurotropic O
coronaviruses O
; O
however O
, O
central B
nervous I
system I
( I
CNS I
) I
infection O
with O
the O
recombinant B
JHM I
( I
RJHM I
) I
strain O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
elicits O
a O
weak O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
in O
the O
brain O
and O
causes O
lethal O
encephalomyelitis O
. O

An O
adoptive O
transfer O
model O
was O
used O
to O
elucidate O
the O
kinetics O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
priming O
during O
CNS O
infection O
with O
RJHM O
as O
well O
as O
with O
two O
MRV O
strains O
that O
induce O
a O
robust O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
( O
RA59 O
and O
SJHM O
/ O
RA59 O
, O
a O
recombinant O
A59 O
virus O
expressing O
the O
JHM O
spike O
) O
. O

While O
RA59 O
and O
SJHM O
/ O
RA59 O
infections O
resulted O
in O
CD8 O
( O
+ O
) O
T O
- O
cell O
priming O
within O
the O
first O
2 O
days O
postinfection O
, O
RJHM O
infection O
did O
not O
lead O
to O
proliferation O
of O
naive O
CD8 O
( O
+ O
) O
T O
cells O
. O

While O
all O
three O
viruses O
replicated O
efficiently O
in O
the O
brain O
, O
only O
RA59 O
and O
SJHM O
/ O
RA59 O
replicated O
to O
appreciable O
levels O
in O
the O
cervical B
lymph I
nodes I
( I
CLN I
) I
, O
the O
site O
of O
T O
- O
cell O
priming O
during O
acute O
CNS O
infection O
. O

RJHM O
was O
unable O
to O
suppress O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
elicited O
by O
RA59 O
in O
mice O
simultaneously O
infected O
with O
both O
strains O
, O
suggesting O
that O
RJHM O
does O
not O
cause O
generalized O
immunosuppression O
. O

RJHM O
was O
also O
unable O
to O
elicit O
a O
secondary O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
in O
the O
brain O
following O
peripheral O
immunization O
against O
a O
viral O
epitope O
. O

Notably O
, O
the O
weak O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
elicited O
by O
RJHM O
was O
unique O
to O
CNS O
infection O
, O
since O
peripheral O
inoculation O
induced O
a O
robust O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
in O
the O
spleen O
. O

These O
findings O
suggest O
that O
the O
failure O
of O
RJHM O
to O
prime O
a O
robust O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
during O
CNS O
infection O
is O
likely O
due O
to O
its O
failure O
to O
replicate O
in O
the O
CLN O
. O

Mutations O
in O
several O
subgenomic O
regions O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
been O
implicated O
in O
influencing O
the O
response O
to O
interferon B
( I
IFN I
) I
therapy O
. O

Sequences O
within O
HCV O
NS5A O
( O
PKR O
binding O
domain O
[ O
PKRBD O
] O
, O
IFN O
sensitivity O
- O
determining O
region O
[ O
ISDR O
] O
, O
and O
variable O
region O
3 O
[ O
V3 O
] O
) O
were O
analyzed O
for O
the O
pretreatment O
serum O
samples O
of O
60 O
HCV O
genotype O
1 O
- O
infected O
patients O
treated O
with O
pegylated O
IFN O
plus O
ribavirin O
( O
1b O
, O
n O
= O
47 O
; O
1a O
, O
n O
= O
13 O
) O
but O
with O
different O
treatment O
outcomes O
, O
those O
with O
sustained O
virologic O
responses O
( O
SVR O
; O
n O
= O
36 O
) O
or O
non O
- O
responders O
( O
NR O
; O
n O
= O
24 O
) O
. O

Additionally O
, O
the O
sequence O
of O
the O
PKR O
/ O
eIF O
- O
2 O
alpha O
phosphorylation O
homology O
domain O
( O
E2 O
- O
PePHD O
) O
region O
was O
determined O
for O
23 O
patients O
( O
11 O
SVR O
and O
12 O
NR O
) O
. O

001 O
) O
and O
early O
virologic O
responses O
( O
EVR O
; O
12 O
weeks O
) O
( O
P O
= O
0 O
. O

037 O
) O
but O
not O
rapid O
virologic O
responses O
( O
4 O
weeks O
) O
. O

Finally O
, O
the O
E2 O
- O
PePHD O
( O
n O
= O
23 O
) O
region O
was O
well O
conserved O
. O

The O
genetic O
variability O
in O
the O
PKRBD O
( O
> O
4 O
mutations O
) O
is O
a O
predictive O
factor O
of O
SVR O
and O
EVR O
in O
HCV O
genotype O
1 O
patients O
treated O
with O
pegylated O
IFN O
and O
ribavirin O
. O

APOBEC3G B
( I
A3G I
) I
is O
a O
cytidine O
deaminase O
that O
can O
inhibit O
a O
wide O
range O
of O
retroviruses O
, O
including O
the O
para O
- O
retrovirus O
hepatitis B
B I
virus I
( I
HBV I
) I
. O

By O
adopting O
a O
native O
agarose O
gel O
electrophoresis O
assay O
that O
can O
specifically O
measure O
the O
levels O
of O
A3G O
incorporation O
into O
HBV O
nucleocapsids O
, O
we O
found O
that O
A3G O
is O
specifically O
packaged O
into O
replication O
- O
competent O
HBV O
nucleocapsids O
in O
a O
fashion O
that O
is O
dependent O
on O
both O
the O
viral O
reverse B
transcriptase I
( I
RT I
) I
and O
viral O
RNA O
packaging O
signal O
, O
epsilon O
. O

To O
investigate O
these O
issues O
, O
healthy O
woodchucks O
( O
Marmota O
monax O
) O
were O
infected O
with O
liver O
- O
pathogenic O
doses O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
and O
investigated O
unchallenged O
or O
after O
challenge O
with O
the O
same O
virus O
. O

Interestingly O
, O
almost O
immediately O
after O
infection O
, O
lymphocytes O
acquired O
a O
heightened O
capacity O
to O
proliferate O
in O
response O
to O
mitogenic O
( O
nonspecific O
) O
stimuli O
. O

The O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
encodes O
numerous O
accessory O
proteins O
whose O
importance O
in O
the O
natural O
infection O
process O
is O
currently O
unclear O
. O

One O
of O
these O
accessory O
proteins O
is O
set O
apart O
by O
its O
function O
in O
the O
context O
of O
a O
related O
murine B
hepatitis I
virus I
( I
MHV I
) I
infection O
. O

To O
determine O
whether O
this O
augmentation O
provided O
by O
the O
C O
terminus O
was O
derived O
from O
interference O
with O
nuclear O
import O
, O
we O
evaluated O
the O
virus O
- O
modulating O
effects O
of O
small B
interfering I
RNAs I
( I
siRNAs I
) I
directed O
against O
importin O
- O
beta O
mRNAs O
, O
which O
down O
- O
regulated O
classical O
nuclear O
import O
pathways O
. O

Cyclosporine B
( I
CsA I
) I
and O
its O
derivatives O
potently O
suppress O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

A O
strong O
correlation O
between O
CsA O
resistance O
and O
reduced O
dependency O
on O
cyclophillin B
A I
( I
CyPA I
) I
for O
replication O
was O
identified O
. O

Silencing O
of O
CyPB O
or O
CyPC O
expression O
had O
no O
significant O
effect O
on O
replication O
, O
whereas O
various O
forms O
of O
small B
interfering I
RNA I
( I
siRNA I
) I
directed O
at O
CyPA O
inhibited O
HCV O
replication O
of O
wild O
- O
type O
but O
not O
CsA O
- O
resistant O
replicons O
. O

The O
dependency O
on O
CyPA O
for O
replication O
was O
observed O
for O
both O
genotype B
( I
gt I
) I
1a O
and O
1b O
replicons O
as O
well O
as O
a O
GT O
2a O
infectious O
virus O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
infection O
and O
growth O
are O
dependent O
on O
initiating O
signaling O
and O
enzyme O
actions O
upon O
viral O
entry O
into O
the O
host O
cell O
. O

Surprisingly O
, O
the O
hub O
with O
the O
most O
potential O
connections O
was O
not O
the O
viral O
M O
protein O
but O
the O
nonstructurall B
protein I
3 I
( I
nsp3 I
) I
, O
which O
is O
one O
of O
the O
novel O
virion O
components O
identified O
by O
mass O
spectrometry O
. O

Some O
strains O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
can O
induce O
chronic O
inflammatory O
demyelination O
in O
mice O
that O
mimics O
certain O
pathological O
features O
of O
multiple O
sclerosis O
. O

We O
have O
examined O
neural O
cell O
tropism O
of O
demyelinating O
and O
nondemyelinating O
strains O
of O
MHV O
in O
order O
to O
determine O
whether O
central B
nervous I
system I
( I
CNS I
) I
cell O
tropism O
plays O
a O
role O
in O
demyelination O
. O

Here O
we O
demonstrate O
that O
these O
strains O
also O
differ O
in O
their O
abilities O
to O
infect O
a O
particular O
cell O
type O
( O
s O
) O
in O
the O
brain O
. O

In O
this O
study O
, O
we O
establish O
that O
cholesterol O
and O
sphingolipid O
associated O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
are O
important O
for O
virion O
maturation O
and O
infectivity O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
the O
leading O
cause O
of O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
and O
one O
of O
the O
primary O
indications O
for O
liver O
transplantation O
. O

FUSE O
( O
far O
upstream O
element O
of O
the O
c O
- O
myc O
protooncogene O
) O
binding O
protein O
( O
FBP O
) O
is O
a O
cellular O
factor O
that O
we O
have O
identified O
as O
a O
binder O
of O
HCV O
3 O
' O
nontranslated O
region O
( O
3 O
' O
NTR O
) O
. O

Mapping O
of O
the O
binding O
site O
showed O
that O
FBP O
specifically O
interacts O
with O
the O
poly O
( O
U O
) O
tract O
within O
the O
poly O
( O
U O
/ O
UC O
) O
region O
of O
the O
3 O
' O
NTR O
. O

FBP O
immunoprecipitation O
coprecipitated O
HCV B
nonstructural I
protein I
5A I
( I
NS5A I
) I
, O
indicating O
that O
FBP O
interacts O
with O
HCV O
NS5A O
, O
which O
is O
known O
to O
function O
as O
a O
link O
between O
HCV O
translation O
and O
replication O
. O

Sequencing O
and O
reversion O
analysis O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
temperature I
- I
sensitive I
( I
ts I
) I
viruses O
has O
identified O
putative O
ts O
mutations O
in O
the O
replicase O
nonstructural B
proteins I
( I
nsp I
' I
s I
) I
of O
these O
coronaviruses O
. O

In O
this O
study O
, O
reverse O
transcriptase O
PCR O
sequencing O
of O
the O
RNA O
genome O
of O
an O
isolate O
of O
the O
MRV O
ts O
virus O
Alb O
ts6 O
, O
referred O
to O
as O
Alb O
/ O
ts O
/ O
nsp5 O
/ O
V148A O
, O
identified O
a O
putative O
ts O
mutation O
in O
nsp5 O
( O
T10651C O
, O
Val148Ala O
) O
, O
the O
viral O
3C B
- I
like I
proteinase I
( I
3CLpro I
) I
. O

The O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
nsp1 O
protein O
has O
unique O
biological O
functions O
that O
have O
not O
been O
described O
in O
the O
viral O
proteins O
of O
any O
RNA O
viruses O
; O
expressed O
SARS O
- O
CoV O
nsp1 O
protein O
has O
been O
found O
to O
suppress O
host O
gene O
expression O
by O
promoting O
host O
mRNA O
degradation O
and O
inhibiting O
translation O
. O

We O
generated O
an O
nsp1 B
mutant I
( I
nsp1 I
- I
mt I
) I
that O
neither O
promoted O
host O
mRNA O
degradation O
nor O
suppressed O
host O
protein O
synthesis O
in O
expressing O
cells O
. O

Both O
a O
SARS O
- O
CoV O
mutant O
virus O
, O
encoding O
the O
nsp1 O
- O
mt O
protein O
( O
SARS O
- O
CoV O
- O
mt O
) O
, O
and O
a O
wild O
- O
type O
virus O
( O
SARS O
- O
CoV O
- O
WT O
) O
replicated O
efficiently O
and O
exhibited O
similar O
one O
- O
step O
growth O
kinetics O
in O
susceptible O
cells O
. O

Notably O
, O
SARS O
- O
CoV O
- O
mt O
infection O
, O
but O
not O
SARS O
- O
CoV O
- O
WT O
infection O
, O
induced O
high O
levels O
of O
beta O
interferon B
( I
IFN I
) I
mRNA O
accumulation O
and O
high O
titers O
of O
type O
I O
IFN O
production O
. O

The O
replication O
/ O
transcription O
complex O
of O
the O
arterivirus O
equine B
arteritis I
virus I
( I
EAV I
) I
is O
associated O
with O
paired O
membranes O
and O
/ O
or O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
that O
are O
thought O
to O
originate O
from O
the O
endoplasmic O
reticulum O
. O

Previously O
, O
coexpression O
of O
two O
putative O
transmembrane O
nonstructural O
proteins O
( O
usp2 O
and O
nsp3 O
) O
was O
found O
to O
suffice O
to O
induce O
these O
remarkable O
membrane O
structures O
, O
which O
are O
typical O
of O
arterivirus O
infection O
. O

Failure O
of O
the O
adaptive O
immune O
response O
to O
control O
infection O
with O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
result O
from O
mutational O
escape O
in O
targeted O
T O
- O
cell O
epitopes O
. O

In O
our O
cohort O
of O
subjects O
with O
chronic O
HCV O
infection O
( O
genotype O
1b O
or O
3a O
) O
, O
it O
is O
a O
frequently O
recognized O
CD8 O
epitope O
in O
HLA O
- O
A O
* O
01 O
- O
positive O
subjects O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5A I
( I
NS5A I
) I
regulates O
viral O
replication O
through O
its O
interaction O
with O
host O
and O
other O
viral O
proteins O
. O

We O
have O
previously O
shown O
that O
FK506 B
- I
binding I
protein I
8 I
( I
FKBP8 I
) I
binds O
to O
NS5A O
and O
recruits O
Hsp90 O
to O
form O
a O
complex O
that O
participates O
in O
the O
replication O
of O
HCV O
. O

Substitution O
of O
the O
Val O
( O
121 O
) O
to O
Ala O
drastically O
impaired O
the O
replication O
of O
HCV O
replicon O
cells O
, O
and O
the O
drug O
- O
resistant O
replicon O
cells O
emerging O
after O
drug O
selection O
were O
shown O
to O
have O
reverted O
to O
the O
original O
arrangement O
by O
replacing O
Ala O
( O
121 O
) O
with O
Val O
. O

Examination O
of O
individual O
fields O
of O
the O
replicon O
cells O
by O
both O
fluorescence O
microscopy O
and O
electron O
microscopy O
( O
the O
correlative O
fluorescence O
microscopy O
- O
electron O
microscopy O
technique O
) O
revealed O
that O
FKBP8 O
is O
partially O
colocalized O
with O
NS5A O
in O
the O
cytoplasmic O
structure O
known O
as O
the O
membranous O
web O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
liver O
disease O
in O
humans O
. O

In O
addition O
, O
we O
show O
that O
claudin O
- O
6 O
and O
claudin O
- O
9 O
expressed O
in O
CD81 O
( O
+ O
) O
cells O
also O
enable O
the O
entry O
of O
HCV O
pseudoparticles O
derived O
from O
six O
of O
the O
major O
genotypes O
. O

The O
enterovirus O
2B O
protein O
is O
a O
small O
hydrophobic O
protein O
that O
, O
upon O
individual O
expression O
, O
is O
localized O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
the O
Golgi O
complex O
, O
reduces O
ER O
and O
Golgi O
complex O
Ca2 O
+ O
levels O
, O
most O
likely O
by O
forming O
transmembrane O
pores O
, O
and O
inhibits O
protein O
trafficking O
through O
the O
Golgi O
complex O
. O

Replication O
of O
the O
neurotropic O
mouse B
hepatitis I
virus I
strain I
JHM I
( I
JHMV I
) I
is O
controlled O
primarily O
by O
CD8 O
( O
+ O
) O
T O
- O
cell O
effectors O
utilizing O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
perforin O
- O
mediated O
cytotoxicity O
. O

CD4 O
( O
+ O
) O
T O
cells O
provide O
an O
auxiliary O
function O
( O
s O
) O
for O
CD8 O
( O
+ O
) O
T O
- O
cell O
survival O
; O
however O
, O
their O
direct O
contribution O
to O
control O
of O
virus O
replication O
and O
pathology O
is O
unclear O
. O

To O
examine O
a O
direct O
role O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
viral O
clearance O
and O
pathology O
, O
pathogenesis O
was O
compared O
in O
mice O
deficient O
in O
both O
perforin O
and O
IFN O
- O
gamma O
that O
were O
selectively O
reconstituted O
for O
these O
functions O
via O
transfer O
of O
virus O
- O
specific O
memory O
CD4 O
( O
+ O
) O
T O
cells O
. O

CD4 O
( O
+ O
) O
T O
cells O
from O
immunized O
wild O
- O
type O
, O
perforin O
- O
deficient O
, O
and O
IFN O
- O
gamma O
- O
deficient O
donors O
all O
initially O
reduced O
virus O
replication O
. O

Local O
release O
of O
IFN O
- O
gamma O
was O
evident O
by O
up O
- O
regulation O
of O
class O
II O
molecules O
on O
microglia O
in O
recipients O
of O
IFN O
- O
gamma O
producing O
CD4 O
( O
+ O
) O
T O
cells O
. O

CD4 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
antiviral O
activity O
correlated O
with O
diminished O
clinical O
symptoms O
, O
pathology O
, O
and O
demyelination O
. O

2 O
CD4 O
( O
+ O
) O
T O
cells O
tracked O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
parenchyma O
and O
localized O
to O
infected O
white O
matter O
, O
correlating O
with O
decreased O
numbers O
of O
virus O
- O
infected O
oligodendrocytes O
in O
the O
CNS O
. O

These O
data O
support O
a O
direct O
, O
if O
limited O
, O
antiviral O
role O
for O
CD4 O
( O
+ O
) O
T O
cells O
early O
during O
acute O
JHMV O
encephalomyelitis O
. O

Although O
the O
antiviral O
effector O
mechanism O
is O
initially O
independent O
of O
IFN O
- O
gamma O
secretion O
, O
sustained O
control O
of O
CNS O
virus O
replication O
by O
CD4 O
( O
+ O
) O
T O
cells O
requires O
IFN O
- O
gamma O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
often O
causes O
a O
persistent O
infection O
associated O
with O
hypergammaglobulinemia O
, O
high O
levels O
of O
antiviral O
antibody O
and O
circulating O
immune O
complexes O
, O
and O
immune O
complex O
disease O
. O

Treatment O
of O
cells O
with O
antibody O
to O
Fc B
receptor I
I I
( I
FcRI I
) I
or O
FCRII O
, O
but O
not O
FcRIII O
, O
also O
led O
to O
an O
inhibition O
of O
pseudotype O
titer O
enhancement O
in O
an O
additive O
manner O
. O

Human O
lymphoblastoid O
cell O
line O
( O
Raji O
) O
, O
a O
poor O
host O
for O
HCV O
pseudotype O
infection O
, O
exhibited O
a O
four O
- O
to O
sixfold O
enhancement O
of O
pseudotype O
- O
mediated O
cell O
death O
upon O
incubation O
with O
antibody O
at O
nonneutralizing O
concentrations O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
is O
a O
positive O
- O
strand O
RNA O
virus O
and O
a O
member O
of O
the O
genus O
Pestivirus O
in O
the O
family O
Flaviviridae O
. O

2 O
- O
kb O
insertion O
spanning O
the O
carboxy O
terminus O
of O
the O
envelope O
glycoprotein O
1 O
( O
El O
) O
, O
the O
envelope O
glycoprotein O
E2 O
, O
and O
the O
amino O
terminus O
of O
p7 O
. O

Peptides O
based O
on O
heptad B
repeat I
( I
HR I
) I
domains O
of O
class O
I O
viral O
fusion O
proteins O
are O
considered O
promising O
antiviral O
drugs O
targeting O
virus O
cell O
entry O
. O

The O
essential O
role O
of O
multispecific O
immune O
responses O
for O
the O
control O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
implies O
the O
need O
of O
multimodal O
therapeutic O
strategies O
for O
chronic O
HBV O
infection O
, O
including O
antiviral O
chemotherapy O
and O
immunomodulation O
. O

The O
immunizations O
were O
performed O
with O
DNA O
vaccines O
or O
antigen O
- O
antibody O
immune B
complexes I
( I
IC I
) I
/ O
DNA O
vaccines O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5A I
( I
NS5A I
) I
is O
required O
for O
the O
replication O
of O
the O
viral O
genome O
and O
is O
involved O
in O
several O
host O
signaling O
pathways O
. O

To O
gain O
further O
insight O
into O
the O
functional O
role O
of O
NS5A O
in O
HCV O
replication O
, O
we O
screened O
human O
cDNA O
libraries O
by O
a O
yeast O
two O
- O
hybrid O
system O
using O
NS5A O
as O
the O
bait O
and O
identified O
human B
butyrate I
- I
induced I
transcript I
1 I
( I
hB I
- I
ind1 I
) I
as O
a O
novel O
NS5A O
- O
binding O
protein O
. O

The O
small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
knockdown O
of O
hB O
- O
ind1 O
in O
human O
hepatoma O
cell O
lines O
suppressed O
the O
replication O
of O
HCV O
RNA O
replicons O
and O
the O
production O
of O
infectious O
particles O
of O
HCV O
genotype O
2a O
strain O
JFH1 O
. O

Infection O
of O
SCID O
mice O
with O
a O
recombinant O
murine O
coronavirus O
( O
mouse O
hepatitis O
virus O
[ O
MHV O
] O
) O
expressing O
the O
T O
- O
cell O
chemoattractant O
CXC B
chemokine I
ligand I
10 I
( I
CXCL10 I
) I
resulted O
in O
increased O
survival O
and O
reduced O
viral O
burden O
within O
the O
brain O
and O
liver O
compared O
to O
those O
of O
mice O
infected O
with O
an O
isogenic O
control O
virus O
( O
MHV O
) O
, O
supporting O
an O
important O
role O
for O
CXCL10 O
in O
innate O
immune O
responses O
following O
viral O
infection O
. O

Enhanced O
protection O
in O
MHV O
- O
CXCL10 O
- O
infected O
mice O
correlated O
with O
increased O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
by O
infiltrating O
natural B
killer I
( I
NK I
) I
cells O
within O
the O
brain O
and O
reduced O
liver O
pathology O
. O

These O
data O
indicate O
that O
( O
i O
) O
CXCL10 O
enhances O
innate O
immune O
responses O
, O
resulting O
in O
protection O
from O
MHV O
- O
induced O
neurological O
and O
liver O
disease O
; O
( O
ii O
) O
elevated O
NK O
cell O
IFN O
- O
gamma O
expression O
in O
the O
brain O
of O
MIIV O
- O
CXCL10 O
- O
infected O
mice O
occurs O
independently O
of O
NKG2D O
; O
and O
( O
iii O
) O
NKG2D O
signaling O
promotes O
antiviral O
activity O
within O
the O
livers O
of O
MRV O
- O
infected O
mice O
that O
is O
not O
dependent O
on O
IFN O
- O
gamma O
and O
tumor O
necrosis O
factor O
alpha O
secretion O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
clearance O
has O
been O
associated O
with O
reduced O
viral O
evolution O
in O
targeted O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitopes O
, O
suggesting O
that O
HCV O
clearers O
may O
mount O
CTL O
responses O
with O
a O
superior O
ability O
to O
recognize O
epitope O
variants O
and O
prevent O
viral O
immune O
escape O
. O

We O
monitored O
expression O
of O
PD O
- O
1 O
( O
a O
mediator O
of O
T O
- O
cell O
exhaustion O
and O
viral O
persistence O
) O
on O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
from O
blood O
and O
liver O
during O
acute O
and O
chronic O
infections O
and O
after O
the O
resolved O
infection O
stage O
. O

The O
NS5A O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
plays O
an O
important O
but O
undefined O
role O
in O
viral O
RNA O
replication O
. O

The O
majority O
of O
the O
mutants O
containing O
15 O
small O
( O
8 O
- O
to O
15 O
- O
amino O
- O
acid O
) O
deletions O
analyzed O
were O
capable O
of O
efficient O
RNA O
replication O
. O

Previous O
studies O
have O
indicated O
that O
the O
replication O
of O
the O
RNA O
genome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
involves O
redirection O
of O
RNA B
polymerase I
II I
( I
Pol I
II I
) I
, O
a O
host O
enzyme O
that O
normally O
uses O
DNA O
as O
a O
template O
. O

The O
present O
study O
applied O
a O
recently O
described O
cell O
system O
( O
293 O
- O
HDV O
) O
of O
tetracycline O
- O
inducible O
HDV O
RNA O
replication O
to O
provide O
new O
data O
regarding O
the O
involvement O
of O
host O
polymerases O
in O
HDV O
transcription O
. O

The O
upstream O
end O
of O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
mouse O
hepatitis O
virus O
genome O
contains O
two O
essential O
and O
overlapping O
RNA O
secondary O
structures O
, O
a O
bulged O
stem O
- O
loop O
and O
a O
pseudoknot O
, O
which O
have O
been O
proposed O
to O
be O
elements O
of O
a O
molecular O
switch O
that O
is O
critical O
for O
viral O
RNA O
synthesis O
. O

The O
structural O
context O
of O
a O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitope O
is O
known O
to O
influence O
immunodominance O
at O
the O
level O
of O
antigen O
processing O
, O
but O
general O
rules O
have O
not O
emerged O
. O

This O
mechanism O
probably O
arose O
in O
order O
to O
direct O
CD4 O
( O
+ O
) O
responses O
onto O
sequences O
that O
are O
conserved O
for O
structure O
and O
function O
. O

Neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
are O
increasingly O
being O
considered O
for O
blunting O
human O
viral O
infections O
. O

We O
have O
recently O
shown O
that O
a O
short O
( O
several O
- O
day O
) O
period O
of O
immunotherapy O
with O
the O
neutralizing O
667 O
MAb O
of O
mouse O
neonates O
shortly O
after O
infection O
with O
the O
lethal O
FrCaSE O
retrovirus O
not O
only O
has O
an O
immediate O
effect O
on O
the O
viral O
load O
but O
also O
permits O
an O
endogenous O
antiviral O
immunity O
to O
emerge O
. O

Even O
though O
passive O
immunotherapy O
was O
administered O
during O
the O
particular O
period O
of O
immunocompetence O
acquisition O
, O
the O
endogenous O
response O
eventually O
arising O
was O
protective O
and O
persisted O
long O
( O
> O
1 O
year O
) O
after O
the O
MAb O
has O
disappeared O
. O

As O
very O
high O
levels O
of O
anti O
- O
FrCaSE O
antibodies O
, O
predominantly O
of O
the O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
isotype O
and O
showing O
strong O
neutralization O
activity O
, O
were O
found O
in O
the O
sera O
of O
MAb O
- O
treated O
mice O
, O
it O
was O
necessary O
to O
address O
whether O
this O
Immoral O
immunity O
was O
sufficient O
on O
its O
own O
to O
confer O
full O
protection O
against O
FrCaSE O
or O
whether O
a O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
was O
also O
necessary O
. O

This O
cytotoxic O
activity O
is O
indispensable O
for O
long O
- O
term O
antiviral O
protective O
immunity O
, O
as O
high O
neutralizing O
antibody O
titers O
, O
even O
enhanced O
in O
in O
vivo O
CD8 O
( O
+ O
) O
cell O
depletion O
experiments O
, O
cannot O
prevent O
the O
FrCaSE O
- O
induced O
death O
of O
infected O
/ O
treated O
mice O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
common O
cause O
of O
chronic O
hepatitis O
and O
is O
currently O
treated O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
- O
based O
therapies O
. O

To O
identify O
the O
cellular O
proteins O
that O
mediate O
the O
antiviral O
effects O
of O
IFN O
- O
alpha O
, O
we O
created O
a O
HEK293 O
- O
based O
cell O
culture O
system O
to O
inducibly O
express O
individual O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
and O
determined O
their O
antiviral O
effects O
against O
HCV O
. O

By O
screening O
29 O
ISGs O
that O
are O
induced O
in O
Huh7 O
cells O
by O
IFN O
- O
alpha O
and O
/ O
or O
up O
- O
regulated O
in O
HCV O
- O
infected O
livers O
, O
we O
discovered O
that O
viperin O
, O
ISG20 O
, O
and O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
noncytolytically O
inhibited O
the O
replication O
of O
HCV O
replicons O
. O

Moreover O
, O
our O
work O
, O
for O
the O
first O
time O
, O
provides O
strong O
evidence O
suggesting O
that O
viperin O
is O
a O
putative O
radical O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( I
SAM I
) I
enzyme O
. O

Severe O
structural O
constraints O
in O
the O
hepatitis B
A I
virus I
( I
HAV I
) I
capsid O
have O
been O
suggested O
as O
the O
reason O
for O
the O
lack O
of O
emergence O
of O
new O
serotypes O
in O
spite O
of O
the O
occurrence O
of O
complex O
distributions O
of O
mutants O
or O
quasi O
- O
species O
. O

Analysis O
of O
the O
HAV O
mutant O
spectra O
under O
immune O
pressure O
by O
the O
Monoclonal B
antibodies I
( I
MAbs I
) I
K34C8 O
( O
immunodominant O
site O
) O
and O
H7C27 O
( O
glycophorin O
binding O
site O
) O
has O
revealed O
different O
evolutionary O
dynamics O
. O

The O
mechanisms O
mediating O
protective O
immunity O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
are O
incompletely O
understood O
because O
early O
infection O
in O
humans O
is O
rarely O
identified O
, O
particularly O
in O
those O
individuals O
who O
subsequently O
demonstrate O
spontaneous O
virus O
eradication O
. O

Here O
, O
we O
comprehensively O
examined O
total O
HCV O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
and O
identified O
functional O
T O
- O
cell O
thresholds O
that O
predict O
recovery O
. O

Interestingly O
, O
we O
found O
that O
the O
presence O
of O
HCV O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
that O
can O
proliferate O
, O
exhibit O
cytotoxicity O
, O
and O
produce O
gamma O
interferon O
does O
not O
ensure O
recovery O
, O
but O
whether O
these O
CTLs O
were O
primed O
in O
the O
presence O
or O
absence O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
help O
( O
HCV O
- O
specific O
interleukin O
- O
2 O
production O
) O
is O
a O
critical O
determinant O
. O

In O
this O
study O
we O
report O
the O
complete O
sequence O
and O
genome O
organization O
of O
the O
serotype O
I O
feline B
coronavirus I
( I
FCoV I
) I
strain O
Black O
. O

This O
clone O
served O
as O
basis O
for O
the O
generation O
of O
recombinant B
FCoV I
( I
recFCoV I
) I
that O
was O
shown O
to O
bear O
the O
same O
features O
in O
vitro O
as O
the O
parental O
FCoV O
. O

Using O
this O
system O
, O
accessory O
3abc O
genes O
in O
the O
FCoV O
genome O
were O
replaced O
by O
green O
fluorescent O
protein O
( O
recFCoV O
- O
GFP O
) O
and O
Renilla B
luciferase I
genes I
( I
recFCoV I
- I
RL I
) I
. O

In O
addition O
, O
we O
showed O
that O
feline O
CD14 O
( O
+ O
) O
blood O
monocytes O
and O
dendritic O
cells O
can O
be O
easily O
detected O
after O
infection O
with O
recFCoV O
- O
GFP O
. O

Avian B
encephalomyelitis I
virus I
( I
AEV I
) I
is O
a O
picornavirus O
that O
causes O
disease O
in O
poultry O
worldwide O
, O
and O
flocks O
must O
be O
vaccinated O
for O
protection O
. O

AEV O
is O
currently O
classified O
within O
the O
hepatovirus O
genus O
, O
since O
its O
proteins O
are O
most O
closely O
related O
to O
those O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
. O

We O
now O
provide O
evidence O
that O
the O
494 O
- O
nucleotide O
- O
long O
5 O
' O
untranslated O
region O
of O
the O
AEV O
genome O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
element O
that O
functions O
efficiently O
in O
vitro O
and O
in O
mammalian O
cells O
. O

These O
properties O
are O
reminiscent O
of O
the O
recently O
discovered O
class O
of O
IRES O
elements O
within O
certain O
other O
picornaviruses O
, O
such O
as O
porcine B
teschovirus I
1 I
( I
PTV I
- I
1 I
) I
. O

Like O
the O
PTV O
- O
1 O
IRES O
, O
the O
AEV O
IRES O
shows O
significant O
similarity O
to O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
IRES O
in O
sequence O
, O
function O
, O
and O
predicted O
secondary O
structure O
. O

During O
herpes O
simplex O
virus O
1 O
infection O
, O
translation O
of O
the O
DNA O
Polymerase B
( I
Pol I
) I
catalytic O
subunit O
is O
inefficient O
relative O
to O
other O
proteins O
of O
the O
same O
temporal O
class O
( O
D O
. O

We O
found O
that O
a O
short O
sequence O
( O
similar O
to O
55 O
bases O
) O
in O
the O
5 O
' O
leader O
of O
the O
transcript O
is O
both O
necessary O
and O
sufficient O
to O
inhibit O
translation O
in O
rabbit O
reticulocyte O
lysates O
and O
sufficient O
to O
inhibit O
reporter O
gene O
translation O
in O
transfected O
cells O
. O

nonstructural B
protein I
3 I
( I
NS3 I
) I
carries O
out O
enzymatic O
reactions O
essential O
for O
viral O
replication O
, O
including O
proteolysis O
of O
the O
polyprotein O
through O
its O
serine O
protease O
N O
- O
terminal O
domain O
, O
with O
a O
segment O
of O
40 O
residues O
from O
the O
NS2B O
protein O
acting O
as O
a O
cofactor O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genomic O
RNA O
possesses O
conserved O
structural O
elements O
that O
are O
essential O
for O
its O
replication O
. O

The O
3 B
' I
nontranslated I
region I
( I
NTR I
) I
contains O
several O
of O
these O
elements O
: O
a O
variable O
region O
, O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
, O
and O
a O
highly O
conserved O
3 O
' O
X O
tail O
, O
consisting O
of O
stem B
- I
loop I
1 I
( I
SL1 I
) I
, O
SL2 O
, O
and O
SL3 O
. O

Recent O
advances O
now O
allow O
the O
efficient O
propagation O
of O
unadapted O
HCV O
genomes O
in O
the O
context O
of O
a O
complete O
infectious O
life O
cycle O
( O
HCV O
cell O
culture O
[ O
HCVcc O
] O
) O
. O

Remarkably O
, O
the O
overall O
integrity O
of O
the O
5BSL3 O
cruciform O
is O
not O
an O
absolute O
requirement O
for O
the O
kissing O
- O
loop O
interaction O
, O
suggesting O
a O
model O
in O
which O
trans O
- O
acting O
factor O
( O
s O
) O
that O
stabilize O
this O
interaction O
may O
interact O
initially O
with O
the O
3 O
' O
X O
tail O
rather O
than O
5BSL3 O
. O

The O
length O
and O
composition O
of O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
were O
also O
critical O
determinants O
of O
HCVcc O
replication O
, O
with O
a O
length O
of O
33 O
consecutive O
U O
residues O
required O
for O
maximal O
RNA O
amplification O
. O

Finally O
, O
we O
show O
that O
both O
the O
poly O
( O
U O
) O
and O
kissing O
- O
loop O
RNA O
elements O
can O
function O
outside O
of O
their O
normal O
genome O
contexts O
. O

This O
suggests O
that O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
does O
not O
function O
simply O
as O
an O
unstructured O
spacer O
to O
position O
the O
kissing O
- O
loop O
elements O
. O

Nucleic O
acids O
from O
an O
unidentified O
virus O
from O
ringed O
seals O
( O
Phoca O
hispida O
) O
were O
amplified O
using O
sequence O
- O
independent O
PCR O
, O
subcloned O
, O
and O
then O
sequenced O
. O

The O
phylogenetic O
position O
of O
the O
tentatively O
named O
seal B
picornavirus I
I I
( I
SePV I
- I
1 I
) I
as O
an O
outlier O
to O
the O
grouping O
of O
parechoviruses O
was O
found O
consistently O
in O
alignable O
regions O
of O
the O
genome O
. O

Virus O
infection O
in O
vitro O
can O
either O
result O
in O
a O
cytopathic B
effect I
( I
CPE I
) I
or O
proceed O
without O
visible O
changes O
in O
infected O
cells O
( O
noncytopathic O
infection O
) O
. O

To O
this O
end O
, O
we O
compared O
a O
productive O
, O
noncytopathic O
infection O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
strain O
A59 O
in O
the O
fibroblastlike O
cell O
line O
NIH O
3T3 O
with O
cytopathic O
MHV O
infections O
. O

Infected O
NIH O
3T3 O
cells O
could O
be O
cultured O
for O
up O
to O
4 O
weeks O
without O
apparent O
CPE O
and O
yet O
produce O
virus O
at O
10 O
( O
7 O
) O
to O
10 O
( O
8 O
) O
PFU O
/ O
ml O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
small O
RNA O
virus O
that O
contains O
one O
1 O
. O

The O
HDV O
particle O
also O
contains O
two O
isoforms O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
small O
( O
SHDAg O
) O
and O
large O
HDAg O
. O

In O
this O
study O
, O
using O
recombinant O
SHDAg O
fused O
with O
a O
heterologous O
nucleolar B
localization I
sequence I
( I
NoLS I
) I
to O
confine O
its O
subcellular O
localization O
in O
nucleoli O
, O
we O
aimed O
to O
study O
the O
effect O
of O
SHDAg O
subcellular O
localization O
on O
HDV O
RNA O
replication O
. O

These O
data O
strongly O
suggest O
that O
nuclear O
polymerase O
( O
RNA O
polymerase O
II O
) O
is O
involved O
in O
the O
synthesis O
of O
genomic O
RNA O
and O
that O
the O
synthesis O
of O
antigenomic O
RNA O
can O
occur O
in O
nucleoli O
. O

Identification O
of O
anti O
- O
hepatitis O
C O
virus O
( O
anti O
- O
HCV O
) O
human O
antibody O
clones O
with O
broad O
neutralizing O
activity O
is O
important O
for O
a O
better O
understanding O
of O
the O
interplay O
between O
the O
virus O
and O
host O
and O
for O
the O
design O
of O
an O
effective O
passive O
immunotherapy O
and O
an O
effective O
vaccine O
. O

We O
report O
the O
identification O
of O
a O
human O
monoclonal O
Fab O
( O
e137 O
) O
able O
to O
bind O
the O
HCV O
E2 O
glycoprotein O
of O
all O
HCV O
genotypes O
but O
genotype O
5 O
. O

The O
results O
of O
antibody O
competition O
assays O
and O
testing O
the O
reactivity O
to O
alanine O
mutant O
E2 O
proteins O
confirmed O
that O
the O
e137 O
epitope O
includes O
residues O
( O
T416 O
, O
W420 O
, O
W529 O
, O
G530 O
, O
and O
D535 O
) O
highly O
conserved O
across O
all O
HCV O
genotypes O
. O

Fab O
e137 O
was O
also O
able O
to O
inhibit O
cell O
culture O
- O
grown O
HCV O
( O
genotype O
2a O
) O
. O

The O
icosahedral O
capsid O
of O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
is O
formed O
by O
a O
single O
core O
protein O
species O
( O
DHBc O
) O
. O

Mutation O
within O
virus O
- O
derived O
CD8 O
T O
- O
cell O
epitopes O
can O
effectively O
abrogate O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
recognition O
and O
impede O
virus O
clearance O
in O
infected O
hosts O
. O

DDX3 O
, O
a O
DEAD O
- O
box O
RNA O
helicase O
, O
binds O
to O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
. O

However O
, O
the O
role O
( O
s O
) O
of O
DDX3 O
in O
HCV O
replication O
is O
still O
not O
understood O
. O

Here O
we O
demonstrate O
that O
the O
accumulation O
of O
both O
genome O
- O
length O
HCV O
RNA O
( O
HCV O
- O
O O
, O
genotype O
1b O
) O
and O
its O
replicon O
RNA O
were O
significantly O
suppressed O
in O
HuH O
- O
7 O
- O
derived O
cells O
expressing O
short O
hairpin O
RNA O
targeted O
to O
DDX3 O
by O
lentivirus O
vector O
transduction O
. O

As O
well O
, O
RNA O
replication O
of O
JFH1 O
( O
genotype O
2a O
) O
and O
release O
of O
the O
core O
into O
the O
culture O
supernatants O
were O
suppressed O
in O
DDX3 O
knockdown O
cells O
after O
inoculation O
of O
the O
cell O
culture O
- O
generated O
HCVcc O
. O

Previous O
analysis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
indicated O
base O
pairing O
between O
two O
cis O
- O
acting O
sequences O
, O
the O
5 O
' O
half O
of O
the O
upper O
stem O
of O
e O
and O
( O
, O
contributes O
to O
the O
synthesis O
of O
minus O
- O
strand O
DNA O
. O

Our O
goal O
was O
to O
identify O
other O
cis O
- O
acting O
sequences O
on O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
involved O
in O
the O
synthesis O
of O
minus O
- O
strand O
DNA O
. O

In O
addition O
, O
we O
found O
that O
the O
first O
- O
strand O
template O
switch O
could O
be O
directed O
to O
a O
new O
location O
when O
a O
72 O
- O
nucleotide B
( I
nt I
) I
fragment O
, O
which O
contained O
the O
cis O
- O
acting O
sequences O
present O
near O
the O
3 O
' O
end O
of O
the O
pgRNA O
, O
was O
introduced O
at O
that O
location O
. O

Thus O
, O
base O
pairing O
between O
three O
cis O
- O
acting O
elements O
( O
5 O
' O
half O
of O
the O
upper O
stem O
of O
epsilon O
, O
phi O
, O
and O
omega O
) O
are O
necessary O
for O
the O
synthesis O
of O
HBV O
minus O
- O
strand O
DNA O
. O

CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
play O
an O
important O
role O
in O
the O
containment O
and O
clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
and O
an O
association O
between O
viral O
persistence O
and O
development O
of O
viral O
escape O
mutations O
has O
been O
postulated O
. O

While O
escape O
from O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
has O
been O
identified O
as O
a O
major O
driving O
force O
for O
the O
evolution O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
and O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
, O
a O
broader O
characterization O
of O
this O
relationship O
is O
needed O
in O
HCV O
infection O
. O

In O
contrast O
to O
studies O
in O
HIV O
and O
SIV O
, O
however O
, O
only O
11 O
% O
of O
these O
were O
associated O
with O
detectable O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

Finally O
, O
the O
rate O
of O
sequence O
evolution O
was O
observed O
to O
decline O
over O
the O
course O
of O
infection O
, O
possibly O
reflective O
of O
diminishing O
selection O
pressure O
by O
dysfunctional O
CD8 O
( O
+ O
) O
T O
cells O
. O

Taken O
together O
, O
these O
data O
provide O
insight O
into O
the O
extent O
to O
which O
HCV O
is O
capable O
of O
evading O
early O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
and O
support O
the O
hypothesis O
that O
dysfunction O
of O
CD8 O
( O
+ O
) O
T O
cells O
may O
be O
associated O
with O
failure O
to O
resolve O
HCV O
infections O
. O

West B
Nile I
virus I
( I
WNV I
) I
is O
a O
neurotropic O
flavivirus O
that O
causes O
encephalitis O
, O
most O
frequently O
in O
elderly O
and O
immunocompromised O
humans O
. O

Previous O
studies O
demonstrated O
that O
CD8 O
( O
+ O
) O
T O
cells O
utilize O
perforin O
- O
dependent O
cytolytic O
mechanisms O
to O
limit O
VNW O
infection O
. O

Nonetheless O
, O
the O
phenotype O
of O
perforin O
- O
deficient O
CD8 O
( O
+ O
) O
T O
cells O
was O
not O
as O
severe O
as O
that O
of O
an O
absence O
of O
CD8 O
( O
+ O
) O
T O
cells O
, O
suggesting O
additional O
effector O
control O
mechanisms O
. O

In O
this O
study O
, O
we O
evaluated O
the O
contribution O
of O
Fas B
- I
Fas I
ligand I
( I
FasL I
) I
interactions O
to O
CD8 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
control O
of O
WNV O
infection O
. O

Although O
antigen O
- O
specific O
priming O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
peripheral O
lymphoid O
tissues O
was O
normal O
in O
gld O
mice O
, O
increased O
central B
nervous I
system I
( I
CNS I
) I
viral O
burdens O
and O
delayed O
clearance O
were O
observed O
. O

Moreover O
, O
the O
adoptive O
transfer O
of O
WNV O
- O
primed O
wild O
- O
type O
but O
not O
gld O
CD8 O
+ O
T O
cells O
to O
recipient O
CD8 O
( O
- O
/ O
- O
) O
or O
gld O
mice O
efficiently O
limited O
infection O
in O
the O
CNS O
and O
enhanced O
survival O
rates O
. O

Overall O
, O
our O
data O
suggest O
that O
CD8 O
( O
+ O
) O
T O
cells O
also O
utilize O
FasL O
effector O
mechanisms O
to O
contain O
WNV O
infection O
in O
Fas O
- O
expressing O
neurons O
in O
the O
CNS O
. O

A O
Coronavirus B
( I
CoV I
) I
nonstructural O
protein O
, O
nsp14 O
, O
contains O
conserved O
active O
- O
site O
motifs O
of O
cellular O
exonucleases O
, O
including O
DNA O
proofreading O
enzymes O
, O
and O
the O
severe B
acute I
respiratory I
syndrome I
CoV I
( I
SARS I
- I
CoV I
) I
nsp14 O
has O
3 O
' O
- O
to O
- O
5 O
' O
exoribonuclease B
( I
ExoN I
) I
activity O
in O
vitro O
. O

Here O
, O
we O
show O
that O
nsp14 O
ExoN O
remarkably O
increases O
replication O
fidelity O
of O
the O
CoV O
murine B
hepatitis I
virus I
( I
MHV I
) I
. O

Human O
histo O
- O
blood O
group O
antigens O
have O
been O
regarded O
as O
receptors O
for O
norovirus O
infection O
, O
and O
expression O
of O
the O
alpha O
( O
1 O
, O
2 O
) O
fucosyltransferase B
gene I
( I
FUT2 I
) I
responsible O
for O
the O
secretor O
phenotype O
is O
required O
for O
susceptibility O
to O
Norwalk B
virus I
( I
NV I
) I
infection O
. O

1 O
cells O
, O
which O
contain O
an O
inactivating O
mutation O
in O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
, O
suggesting O
that O
the O
RIG O
- O
I O
pathway O
does O
not O
play O
a O
role O
in O
limiting O
NV O
replication O
. O

Our O
results O
strongly O
suggest O
that O
the O
block O
( O
s O
) O
to O
NV O
replication O
in O
vitro O
is O
at O
the O
stage O
of O
receptor O
and O
/ O
or O
coreceptor O
binding O
and O
/ O
or O
uncoating O
, O
either O
because O
cells O
lack O
some O
specific O
factor O
or O
activation O
of O
cellular O
antiviral O
responses O
independent O
of O
RIG O
- O
I O
inhibits O
virus O
replication O
. O

Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
is O
triggered O
by O
double O
- O
stranded O
RNA O
, O
a O
common O
intermediate O
in O
the O
replication O
of O
many O
viruses O
including O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

In O
this O
study O
, O
we O
have O
examined O
the O
IFN O
- O
beta O
signaling O
pathway O
following O
infection O
of O
immortalized B
human I
hepatocytes I
( I
IHH I
) I
with O
HCV O
genotype O
la O
( O
clone O
1177 O
) O
or O
2a O
( O
clone O
JFH1 O
) O
. O

HCV O
infection O
in O
IHH O
enhanced O
IFN O
- O
beta O
and O
IFN B
- I
stimulated I
gene I
56 I
( I
ISG56 I
) I
promoter O
activities O
; O
however O
, O
poly O
( O
I O
- O
C O
) O
- O
induced O
IFN O
- O
beta O
and O
ISG56 O
expression O
levels O
were O
modestly O
inhibited O
upon O
HCV O
infection O
. O

IHH O
infected O
with O
HCV O
( O
genotype O
la O
or O
2a O
) O
exhibited O
various O
levels O
of O
translocation O
of O
IRF O
- O
3 O
into O
the O
nucleus O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
has O
a O
linear O
positive O
- O
stranded O
RNA O
genome O
of O
similar O
to O
9 O
, O
600 O
nucleotides O
in O
length O
and O
displays O
a O
high O
level O
of O
sequence O
diversity O
caused O
by O
high O
mutation O
rates O
and O
recombination O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
important O
human O
pathogen O
affecting O
an O
estimated O
3 O
% O
of O
the O
world O
' O
s O
population O
. O

Coronaviruses O
express O
open B
reading I
frame I
la I
( I
ORF1a I
) I
and O
ORF1b O
polyproteins O
from O
which O
16 O
nonstructural B
proteins I
( I
nsp I
) I
are O
derived O
. O

The O
highly O
conserved O
region O
at O
the O
carboxy O
terminus O
of O
ORF1a O
is O
processed O
by O
the O
nsp5 O
proteinase O
( O
M O
- O
pro O
) O
into O
mature O
products O
, O
including O
nsp7 O
, O
nsp8 O
, O
nsp9 O
, O
and O
nsp10 O
, O
proteins O
with O
predicted O
or O
identified O
activities O
involved O
in O
RNA O
synthesis O
. O

We O
determined O
the O
requirement O
for O
the O
nsp7 O
to O
nsp10 O
proteins O
and O
their O
processing O
during O
murine B
hepatitis I
virus I
( I
MHV I
) I
replication O
. O

Arteriviruses O
and O
coronaviruses O
( O
order O
Nidovirales O
) O
are O
unique O
among O
plus O
- O
stranded O
RNA O
viruses O
for O
using O
a O
mechanism O
of O
discontinuous O
RNA O
synthesis O
to O
produce O
a O
nested O
set O
of O
5 O
' O
- O
and O
3 O
' O
- O
coterminal O
subgenomic O
mRNAs O
, O
which O
serve O
to O
express O
the O
viral O
structural O
protein O
genes O
. O

Nidovirus O
genome O
amplification O
( O
replication O
) O
and O
subgenomic O
mRNA O
synthesis O
( O
transcription O
) O
are O
driven O
by O
13 O
to O
16 O
nonstructural B
proteins I
( I
nsp I
' I
s I
) I
, O
generated O
by O
autocatalytic O
processing O
of O
two O
large O
replicase O
polyproteins O
. O

Previously O
, O
using O
a O
replicon O
system O
, O
the O
N O
- O
terminal O
nsp1 O
replicase O
subunit O
of O
the O
arterivirus O
equine B
arteritis I
virus I
( I
EAV I
) I
was O
found O
to O
be O
dispensable O
for O
replication O
but O
crucial O
for O
transcription O
. O

Infection O
by O
the O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
requires O
the O
release O
of O
the O
viral O
genome O
by O
fusion O
with O
the O
respective O
target O
membrane O
of O
the O
host O
cell O
. O

Ethyl O
2 O
- O
methylimidazo O
[ O
1 O
, O
2 O
- O
a O
] O
pyrrolo O
[ O
2 O
, O
3 O
- O
c O
] O
pyridin O
- O
8 O
- O
carboxylate O
( O
AG110 O
) O
was O
identified O
as O
a O
potent O
inhibitor O
of O
pestivirus O
replication O
. O

The O
50 O
% O
effective O
concentration O
values O
for O
inhibition O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
- O
induced O
cytopathic O
effect O
, O
viral O
RNA O
synthesis O
, O
and O
production O
of O
infectious O
virus O
were O
1 O
. O

Drug O
- O
resistant O
mutants O
carry O
the O
E291G O
mutation O
in O
the O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

Moreover O
, O
BVDV O
that O
carries O
the O
F224S O
mutation O
( O
because O
of O
resistance O
to O
the O
imidazopyridine O
5 O
- O
[ O
( O
4 O
- O
bromophenyl O
) O
methyl O
] O
- O
2 O
- O
phenyl O
- O
5H O
- O
imidazo O
[ O
4 O
, O
5 O
- O
c O
] O
pyridine O
[ O
BPIP O
] O
and O
VP32947 O
) O
is O
also O
resistant O
to O
AG110 O
. O

AG110 O
did O
not O
inhibit O
the O
in O
vitro O
activity O
of O
recombinant O
BVDV O
RdRp O
but O
inhibited O
the O
activity O
of O
BVDV O
replication B
complexes I
( I
RCs I
) I
. O

Numerous O
studies O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
assembly O
and O
budding O
mechanisms O
have O
been O
reported O
, O
but O
relatively O
little O
is O
known O
about O
these O
fundamental O
pathways O
among O
animal O
lentiviruses O
. O

While O
there O
may O
be O
a O
general O
assumption O
that O
lentiviruses O
share O
common O
assembly O
mechanisms O
, O
studies O
of O
equine B
infectious I
anemia I
virus I
( I
EIAV I
) I
have O
indicated O
alternative O
cellular O
pathways O
and O
cofactors O
employed O
among O
lentiviruses O
for O
assembly O
and O
budding O
. O

The O
results O
of O
these O
studies O
demonstrated O
that O
replacing O
the O
natural O
RNA O
nuclear O
export O
element O
( O
Rev O
- O
response O
element O
[ O
RRE O
] O
) O
used O
by O
HIV O
- O
1 O
and O
EIAV O
with O
the O
hepatitis O
B O
virus O
posttranscriptional B
regulatory I
element I
( I
PRE I
) I
altered O
HIV O
- O
1 O
, O
but O
not O
EIAV O
, O
Gag O
assembly O
sites O
and O
budding O
efficiency O
in O
human O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural B
protein I
4A I
( I
NS4A I
) I
is O
only O
54 O
amino B
acids I
( I
aa I
) I
in O
length O
, O
yet O
it O
is O
a O
key O
regulator O
of O
the O
essential O
serine O
protease O
and O
RNA O
helicase O
activities O
of O
the O
NS3 O
- O
4A O
complex O
, O
as O
well O
as O
a O
determinant O
of O
NS5A O
phosphorylation O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
an O
enveloped O
DNA O
virus O
that O
presumably O
buds O
at O
intracellular O
membranes O
of O
infected O
cells O
. O

Here O
, O
we O
demonstrate O
that O
HBV O
release O
also O
requires O
the O
cellular O
machinery O
that O
generates O
internal O
vesicles O
of O
multivesicular B
bodies I
( I
MVBs I
) I
. O

Infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
associated O
with O
persistence O
in O
the O
majority O
of O
individuals O
. O

We O
demonstrate O
here O
that O
the O
inhibitory O
molecule O
programmed B
death I
- I
1 I
( I
PD I
- I
1 I
) I
is O
significantly O
upregulated O
on O
total O
and O
HCV O
- O
specific O
CD8 O
+ O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
in O
the O
peripheral O
blood O
and O
livers O
of O
patients O
with O
chronic O
infection O
compared O
to O
subjects O
with O
spontaneous O
HCV O
resolution O
, O
patients O
with O
nonviral O
liver O
disease O
, O
and O
normal O
controls O
. O

HCV O
- O
specific O
CTLs O
that O
are O
PD O
- O
1 O
( O
high O
) O
express O
higher O
levels O
of O
the O
senescence O
marker O
CD57 O
than O
PD O
- O
1 O
( O
low O
) O
CTLs O
, O
and O
CD57 O
expression O
is O
greater O
in O
chronic O
than O
in O
resolved O
infection O
. O

In O
vitro O
blockade O
of O
PD O
- O
1 O
by O
monoclonal O
antibodies O
specific O
to O
its O
ligands O
( O
PD O
- O
L1 O
and O
PD O
- O
L2 O
) O
results O
in O
restoration O
of O
functional O
competence O
( O
proliferation O
and O
gamma O
interferon O
and O
interleukin O
- O
2 O
secretion O
) O
of O
HCV O
- O
specific O
CTLs O
, O
including O
those O
residing O
in O
the O
liver O
. O

In O
this O
study O
, O
we O
have O
analyzed O
the O
signals O
for O
minus O
- O
strand O
RNA O
synthesis O
in O
the O
prototype O
of O
the O
arterivirus O
family O
, O
equine B
arteritis I
virus I
( I
EAV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
cause O
of O
chronic O
liver O
disease O
, O
with O
more O
than O
170 O
million O
persistently O
infected O
individuals O
worldwide O
. O

Although O
the O
combination O
therapy O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
ribavirin O
is O
effective O
for O
chronic O
HCV O
infection O
, O
around O
half O
of O
all O
patients O
infected O
with O
HCV O
genotype O
I O
fail O
to O
show O
sustained O
virologic O
responses O
and O
remain O
chronically O
infected O
. O

We O
incubated O
HCV O
replicon O
- O
harboring O
cells O
( O
genotype O
1b O
, O
Conl O
) O
in O
the O
presence O
of O
various O
bile O
acids O
and O
monitored O
the O
expression O
of O
HCV O
RNA O
and O
protein O
( O
NS5B O
) O
. O

The O
addition O
of O
an O
individual O
bile O
acid O
( O
deoxycholic O
acid O
, O
chenodeoxycholic O
acid O
, O
ursodeoxycholic O
acid O
, O
or O
glyco O
- O
chenodeoxycholic O
acid O
) O
in O
the O
medium O
increased O
the O
levels O
of O
HCV O
RNA O
and O
proteins O
up O
to O
fivefold O
at O
48 O
h O
of O
incubation O
. O

An O
antagonist O
of O
bile O
acid O
receptor O
farnesoid B
X I
receptor I
( I
FXR I
) I
, O
Z O
- O
guggulsterone O
, O
reduced O
the O
bile O
acid O
- O
mediated O
increase O
of O
HCV O
RNA O
. O

When O
IFN O
( O
alpha O
or O
gamma O
) O
and O
each O
bile O
acid O
were O
incubated O
together O
, O
we O
observed O
that O
bile O
acid O
significantly O
reduced O
the O
anti O
- O
HCV O
effect O
of O
IFN O
. O

The O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
of O
porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
is O
a O
multidomain O
protein O
and O
has O
been O
shown O
to O
undergo O
remarkable O
genetic O
variation O
, O
primarily O
in O
its O
middle O
region O
, O
while O
exhibiting O
high O
conservation O
in O
the O
N O
- O
terminal O
putative O
protease O
domain O
and O
the O
C O
- O
terminal O
predicted O
transmembrane O
region O
. O

The O
results O
demonstrated O
that O
the O
cysteine O
protease O
domain O
( O
PL2 O
) O
, O
the O
PL2 O
downstream O
flanking O
sequence O
( O
amino O
acids O
[ O
aal O
181 O
to O
323 O
) O
, O
and O
the O
putative O
transmembrane O
domain O
were O
critical O
for O
replication O
. O

In O
contrast O
, O
the O
segment O
of O
nsp2 O
preceding O
the O
PL2 O
domain O
( O
aa O
13 O
to O
35 O
) O
was O
dispensable O
for O
viral O
replication O
, O
and O
the O
nsp2 O
middle O
hypervariable O
region O
( O
aa O
324 O
to O
813 O
) O
tolerated O
100 O
- O
aa O
or O
200 O
- O
aa O
deletions O
but O
could O
not O
be O
removed O
as O
a O
whole O
; O
the O
largest O
deletion O
was O
about O
400 O
aa O
( O
nsp2 O
Delta O
324 O
- O
726 O
) O
. O

Finally O
, O
the O
utilization O
of O
the O
genetic O
flexibility O
of O
nsp2 O
to O
express O
foreign O
genes O
was O
examined O
by O
inserting O
the O
gene O
encoding O
green B
fluorescent I
protein I
( I
GFP I
) I
in O
frame O
into O
one O
nsp2 O
deletion O
mutant O
construct O
. O

The O
NS3 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
protease O
activity O
responsible O
for O
the O
proteolytic O
cleavage O
of O
the O
viral O
polyprotein O
at O
the O
junctions O
of O
nonstructural O
proteins O
downstream O
of O
NS3 O
. O

Three O
potential O
cleavage O
sites O
were O
detected O
in O
the O
NS3 O
protein O
( O
genotype O
1b O
) O
, O
with O
IPT402 O
vertical O
bar O
S O
being O
the O
major O
one O
. O

The O
JFH O
- O
I O
strain O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
genotype O
2a O
strain O
that O
can O
replicate O
autonomously O
in O
Huh7 O
cells O
. O

Via O
subgenomic O
- O
RNA O
- O
replication O
assays O
, O
we O
found O
that O
both O
the O
JFH O
- O
1 O
NS5B O
- O
to O
- O
3 O
' O
X O
( O
N5BX O
) O
and O
the O
NS3 B
helicase I
( I
N3H I
) I
regions O
are O
important O
for O
the O
replication O
of O
the O
WIT O
replicon O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoproteins O
are O
highly O
glycosylated O
, O
with O
up O
to O
5 O
and O
11 O
N O
- O
linked O
glycans O
on O
E1 O
and O
E2 O
, O
respectively O
. O

HCV B
pseudoparticles I
( I
HCVpp I
) I
bearing O
wild O
- O
type O
glycoproteins O
or O
mutants O
at O
individual O
glycosylation O
sites O
were O
evaluated O
for O
their O
sensitivity O
to O
neutralization O
by O
antibodies O
from O
the O
sera O
of O
infected O
patients O
and O
anti O
- O
E2 O
monoclonal O
antibodies O
. O

While O
we O
did O
not O
find O
any O
evidence O
that O
N O
- O
linked O
glycans O
of O
El O
contribute O
to O
the O
masking O
of O
neutralizing O
epitopes O
, O
our O
data O
demonstrate O
that O
at O
least O
three O
glycans O
on O
E2 O
( O
denoted O
E2N1 O
, O
E2N6 O
, O
and O
E2N11 O
) O
reduce O
the O
sensitivity O
of O
HCVpp O
to O
antibody O
neutralization O
. O

Although O
in O
vitro O
replication O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
JFH1 O
clone O
of O
genotype O
2a O
( O
HCVcc O
) O
has O
been O
developed O
, O
a O
robust O
cell O
culture O
system O
for O
the O
la O
and O
1b O
genotypes O
, O
which O
are O
the O
most O
prevalent O
viruses O
in O
the O
world O
and O
resistant O
to O
interferon O
therapy O
, O
has O
not O
yet O
been O
established O
. O

As O
a O
surrogate O
virus O
system O
, O
pseudotype O
viruses O
transiently O
bearing O
HCV O
envelope O
proteins O
based O
on O
the O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
retrovirus O
have O
been O
developed O
. O

Here O
, O
we O
have O
developed O
a O
replication O
- O
competent O
recombinant O
VSV O
with O
a O
genome O
encoding O
unmodified O
HCV O
El O
and O
E2 O
proteins O
in O
place O
of O
the O
VSV O
envelope O
protein O
( O
HCVrv O
) O
in O
human O
cell O
lines O
. O

HCVrv O
and O
a O
pseudotype O
VSV O
bearing O
the O
unmodified O
HCV B
envelope I
proteins I
( I
HCVpv I
) I
generated O
in O
293T O
or O
Huh7 O
cells O
exhibited O
high O
infectivity O
in O
Huh7 O
cells O
. O

The O
infectivity O
of O
HCVrv O
was O
inhibited O
by O
an O
endoplasmic O
reticulum O
alpha O
- O
glucosidase O
inhibitor O
, O
N O
- O
( O
n O
- O
nonyl O
) O
deoxynojirimycin O
( O
Nn O
- O
DNJ O
) O
, O
but O
not O
by O
a O
Golgi O
mannosidase O
inhibitor O
, O
deoxymannojirimycin O
. O

An O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
cDNA O
clone O
( O
JFH1 O
) O
was O
generated O
recently O
. O

We O
generated O
infectious O
HCV O
clones O
containing O
the O
convenient O
reporters O
green B
fluorescent I
protein I
( I
GFP I
) I
and O
Renilla O
luciferase O
in O
the O
NS5a O
- O
coding O
sequence O
. O

Responses O
of O
individual O
cells O
containing O
HCV O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
were O
monitored O
using O
GFP O
- O
tagged O
HCV O
and O
time O
- O
lapse O
confocal O
microscopy O
. O

Woodchucks O
infected O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
are O
an O
excellent O
model O
for O
studying O
acute O
, O
self O
- O
limited O
and O
chronic O
hepadnaviral O
infections O
. O

Specific O
T O
- O
helper O
cell O
responses O
to O
WHV O
core O
and O
surface O
antigens O
( O
WHcAg O
and O
WHsAg O
, O
respectively O
) O
are O
associated O
with O
acute O
resolving O
infection O
; O
however O
, O
they O
are O
undetectable O
in O
chronic O
infection O
. O

Up O
to O
now O
, O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
could O
not O
be O
determined O
in O
the O
woodchuck O
. O

The O
splenocytes O
of O
woodchucks O
in O
the O
postacute O
phase O
of O
WHV O
infection O
( O
18 O
months O
postinfection O
) O
were O
isolated O
and O
stimulated O
with O
overlapping O
peptides O
covering O
the O
whole O
WHcAg O
. O

One O
peptide O
( O
c96 O
- O
110 O
) O
turned O
out O
to O
be O
accountable O
for O
T O
- O
cell O
expansion O
and O
CD107a O
staining O
. O

We O
found O
a O
vigorous O
T O
- O
cell O
response O
against O
peptide O
c96 O
- O
110 O
with O
peripheral O
blood O
cells O
beginning O
at O
the O
peak O
of O
viral O
load O
( O
week O
5 O
) O
and O
lasting O
up O
to O
15 O
weeks O
postinfection O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
was O
used O
as O
a O
model O
to O
study O
the O
interaction O
of O
coronaviruses O
with O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
response O
. O

While O
MHV O
strain O
A59 O
appeared O
to O
induce O
IFN O
- O
beta O
gene O
transcription O
and O
low O
levels O
of O
nuclear O
translocation O
of O
the O
IFN O
- O
beta O
transcription O
factor O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
MHV O
did O
not O
induce O
IFN O
- O
beta O
protein O
production O
during O
the O
course O
of O
infection O
in O
L2 O
mouse O
fibroblast O
cells O
. O

In O
addition O
, O
MHV O
was O
able O
to O
significantly O
decrease O
the O
level O
of O
IFN O
- O
beta O
protein O
induced O
by O
both O
Newcastle B
disease I
virus I
( I
NDV I
) I
and O
Sendai O
virus O
infections O
, O
without O
targeting O
it O
for O
proteasomal O
degradation O
and O
without O
altering O
the O
nuclear O
translocation O
of O
IRF O
- O
3 O
or O
IFN O
- O
beta O
mRNA O
production O
or O
stability O
. O

Tumor O
necrosis O
factor O
TNF O
) O
is O
critical O
for O
the O
control O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
the O
clinical O
setting O
and O
in O
model O
systems O
. O

TNF O
destabilized O
human O
HBV O
nucleocapsids O
in O
a O
variety O
of O
human O
hepatocytic O
cell O
lines O
and O
in O
primary O
rat O
hepatocytes O
and O
also O
destabilized O
duck B
HBV I
( I
DHBV I
) I
nucleocapsids O
in O
chicken O
hepatocytic O
cells O
. O

Occult O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
of O
patients O
with O
abnormal O
liver O
function O
tests O
of O
unknown O
origin O
who O
are O
anti O
- O
HCV O
and O
serum O
HCV O
RNA O
negative O
but O
who O
have O
HCV O
RNA O
in O
the O
liver O
has O
been O
described O
. O

Two O
milliliters O
of O
serum O
was O
ultracentrifuged O
over O
a O
10 O
% O
sucrose O
cushion O
for O
17 O
h O
at O
100 O
, O
000 O
x O
g O
( O
av O
) O
, O
where O
av O
means O
average O
, O
and O
HCV O
RNA O
detection O
was O
performed O
by O
strand O
- O
specific O
real O
- O
time O
PCR O
. O

5 O
copies O
/ O
ml O
( O
range O
, O
18 O
to O
192 O
) O
. O

5 O
x O
10 O
( O
4 O
) O
[ O
range O
, O
7 O
. O

0 O
x O
10 O
( O
6 O
) O
] O
versus O
2 O
. O

3 O
x O
10 O
( O
4 O
) O
[ O
range O
, O
4 O
. O

0 O
x O
10 O
( O
2 O
) O
to O
2 O
. O

2 O
x O
10 O
( O
5 O
) O
] O
) O
were O
found O
. O

Higher O
- O
order O
cis O
- O
acting O
RNA O
replication O
structures O
have O
been O
identified O
in O
the O
3 O
' O
- O
and O
5 O
' O
- O
terminal O
untranslated B
regions I
( I
UTRs I
) I
of O
a O
bovine B
coronavirus I
( I
BCoV I
) I
defective I
interfering I
( I
DI I
) I
RNA O
. O

2 O
- O
kb O
DI O
RNA O
is O
composed O
of O
only O
the O
two O
ends O
of O
the O
genome O
fused O
between O
an O
internal O
site O
within O
the O
738 O
- O
nucleotide B
( I
nt I
) I
5 O
' O
- O
most O
coding O
region O
( O
the O
nsp1 O
, O
or O
p28 O
, O
coding O
region O
) O
and O
a O
site O
just O
4 O
nt O
upstream O
of O
the O
3 O
' O
- O
most O
open B
reading I
frame I
( I
ORF I
) I
( O
the O
N O
gene O
) O
. O

We O
observed O
that O
( O
i O
) O
the O
5 O
' O
- O
terminal O
186 O
nt O
of O
the O
nspl O
coding O
region O
are O
necessary O
and O
sufficient O
for O
DI O
RNA O
replication O
, O
( O
ii O
) O
two O
Mfold O
- O
predicted O
stem O
- O
loops O
within O
the O
186 O
- O
nt O
sequence O
, O
named O
SLV O
( O
nt O
239 O
to O
310 O
) O
and O
SLVI O
( O
nt O
311 O
to O
340 O
) O
, O
are O
supported O
by O
RNase O
structure O
probing O
and O
by O
nucleotide O
covariation O
among O
closely O
related O
group O
2 O
coronaviruses O
, O
and O
( O
iii O
) O
SLVI O
is O
a O
required O
higher O
- O
order O
structure O
for O
DI O
RNA O
replication O
based O
on O
mutation O
analyses O
. O

The O
early O
events O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
remain O
unclear O
. O

proposed O
a O
new O
entry O
mechanism O
involving O
a O
translocation B
motif I
( I
TLM I
) I
present O
in O
the O
pre O
- O
S2 O
domain O
of O
envelope O
proteins O
( O
L O
. O

The O
role O
of O
peripheral O
dendritic B
cells I
( I
DCs I
) I
in O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
unclear O
. O

Independently O
of O
the O
serum O
viral O
load O
, O
fluorescence O
- O
activated O
cell O
sorter O
- O
purified O
total O
DCs O
had O
a O
wide O
range O
of O
cell O
- O
associated O
HCV O
genomic O
RNA O
copy O
numbers O
( O
mean O
log O
( O
10 O
) O
, O
5 O
. O

0 O
per O
10 O
( O
6 O
) O
cells O
; O
range O
, O
4 O
. O

Here O
we O
report O
that O
for O
viremic O
patients O
with O
high O
viral O
loads O
in O
their O
total O
DCs O
, O
the O
myeloid O
DC O
( O
MDC O
) O
subset O
displayed O
impaired O
expression O
of O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
but O
normal O
IL O
- O
6 O
or O
chemokine O
CCL3 O
expression O
in O
response O
to O
poly O
( O
I O
: O
C O
) O
and O
lipopolysaccharide B
( I
LPS I
) I
. O

IL O
- O
6 O
- O
expressing O
cells O
from O
this O
subgroup O
of O
viremic O
patients O
demonstrated O
a O
significant O
increase O
( O
sixfold O
more O
) O
in O
TNF O
- O
alpha O
( O
- O
) O
IL O
- O
12 O
( O
- O
) O
cell O
frequency O
compared O
to O
healthy O
donors O
( O
mean O
, O
38 O
. O

0001 O
) O
, O
indicating O
a O
functional O
defect O
in O
a O
subpopulation O
of O
cytokine O
- O
producing O
MDCs O
( O
similar O
to O
6 O
% O
of O
MDCs O
) O
. O

Attenuation O
of O
poly O
( O
I O
: O
C O
) O
and O
LPS O
innate O
sensing O
was O
HCV O
RNA O
density O
dependent O
and O
did O
not O
correlate O
with O
viremia O
or O
deficits O
in O
circulating O
MDC O
frequencies O
in O
HCV O
- O
infected O
patients O
. O

We O
have O
used O
several O
strains O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
in O
cell O
culture O
and O
in O
vivo O
in O
mouse O
models O
to O
investigate O
the O
antiviral O
characteristics O
of O
peptide B
- I
conjugated I
antisense I
phosphorodiamidate I
morpholino I
oligomers I
( I
P I
- I
PMOs I
) I
. O

Ten O
P O
- O
PMOs O
directed O
against O
various O
target O
sites O
in O
the O
viral O
genome O
were O
tested O
in O
cell O
culture O
, O
and O
one O
of O
these O
( O
5TERM O
) O
, O
which O
was O
complementary O
to O
the O
5 O
' O
terminus O
of O
the O
genomic O
RNA O
, O
was O
effective O
against O
six O
strains O
of O
MHV O
. O

5 O
hepatoma O
cell O
line O
, O
replication O
of O
the O
genotype O
1a O
H77 O
strain O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
attenuated O
compared O
to O
that O
of O
the O
genotype O
1b O
Con1 O
strain O
. O

Human B
coronavirus I
NL63 I
( I
HCoV I
- I
NL63 I
) I
, O
a O
common O
human O
respiratory O
pathogen O
, O
is O
associated O
with O
both O
upper O
and O
lower O
respiratory O
tract O
disease O
in O
children O
and O
adults O
. O

Here O
, O
we O
identify O
HCoV O
- O
NL63 O
replicase O
gene O
products O
and O
characterize O
two O
viral O
papain B
- I
like I
proteases I
( I
PLPs I
) I
, O
PLP1 O
and O
PLP2 O
, O
which O
process O
the O
viral O
replicase O
polyprotein O
. O

We O
generated O
polyclonal O
antisera O
directed O
against O
two O
of O
the O
predicted O
replicase O
nonstructural O
proteins O
( O
nsp3 O
and O
nsp4 O
) O
and O
detected O
replicase O
proteins O
from O
HCoV O
- O
NL63 O
- O
infected O
LLC O
- O
MK2 O
cells O
by O
immunofluorescence O
, O
immunoprecipitation O
, O
and O
Western O
blot O
assays O
. O

Furthermore O
, O
by O
using O
K48 O
- O
linked O
hexa O
- O
ubiquitin O
substrate O
and O
ubiquitin O
- O
vinylsulfone O
inhibitor O
specific O
for O
deubiquitinating B
enzymes I
( I
DUBs I
) I
, O
we O
confirmed O
that O
, O
like O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
CoV O
PLpro O
, O
HCoV O
- O
NL63 O
PLP2 O
has O
DUB O
activity O
. O

To O
investigate O
the O
role O
of O
nsp10 O
in O
coronavirus O
transcription O
/ O
replication O
, O
alanine O
replacements O
were O
engineered O
into O
a O
murine B
hepatitis I
virus I
( I
MHV I
) I
infectious O
clone O
in O
place O
of O
conserved O
residues O
in O
predicted O
functional O
domains O
or O
charged O
amino O
acid O
pairs O
/ O
triplets O
, O
and O
rescued O
viruses O
were O
analyzed O
for O
mutant O
phenotypes O
. O

This O
association O
is O
dependent O
on O
an O
N O
- O
terminal O
amphipathic B
helix I
( I
AH I
) I
within O
NS5A O
and O
is O
restricted O
to O
a O
subset O
of O
host O
cell O
intracellular O
membranes O
. O

Here O
we O
have O
probed O
the O
mechanistic O
details O
of O
NS5A O
AH O
- O
mediated O
binding O
to O
both O
cell O
- O
derived O
and O
model O
membranes O
by O
use O
of O
biochemical O
membrane O
flotation O
and O
quartz B
crystal I
microbalance I
( I
QCM I
) I
with O
dissipation O
. O

Mature O
nonstructural B
protein I
- I
15 I
( I
nsp15 I
) I
from O
the O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
contains O
a O
novel O
uridylate O
- O
specific O
Mn2 O
+ O
- O
dependent O
Endoribonuclease B
( I
NendoU I
) I
. O

Here O
, O
we O
report O
the O
structure O
of O
a O
trimmed O
, O
monomeric O
form O
of O
SARS O
- O
CoV O
nsp15 O
( O
residues O
28 O
to O
335 O
) O
determined O
to O
a O
resolution O
of O
2 O
. O

The O
catalytic O
loop O
( O
residues O
234 O
to O
249 O
) O
with O
its O
two O
reactive O
histidines O
( O
His O
234 O
and O
His O
249 O
) O
is O
dramatically O
Hipped O
by O
similar O
to O
120 O
degrees O
into O
the O
active O
site O
cleft O
. O

Furthermore O
, O
the O
catalytic O
nucleophile O
Lys O
289 O
points O
in O
a O
diametrically O
opposite O
direction O
, O
a O
consequence O
of O
an O
outward O
displacement O
of O
the O
supporting O
loop O
( O
residues O
276 O
to O
295 O
) O
. O

A O
190 O
- O
nucleotide B
( I
nt I
) I
packaging I
signal I
( I
PS I
) I
located O
in O
the O
3 O
' O
end O
of O
open O
reading O
frame O
1b O
in O
the O
mouse O
hepatitis O
virus O
, O
a O
group O
IIa O
coronavirus O
, O
was O
previously O
postulated O
to O
direct O
genome O
RNA O
packaging O
. O

Based O
on O
phylogenetic O
data O
and O
structure O
probing O
, O
we O
have O
identified O
a O
95 O
- O
nt O
hairpin O
within O
the O
190 O
- O
nt O
PS O
domain O
which O
is O
conserved O
in O
all O
group O
IIa O
coronaviruses O
but O
not O
in O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
group O
IIb O
) O
, O
group O
I O
coronaviruses O
, O
or O
group O
III O
coronaviruses O
. O

A O
unique O
hepatitis B
C I
virus I
( I
HCV I
) I
strain O
JFH O
- O
1 O
has O
been O
shown O
to O
replicate O
efficiently O
in O
cell O
culture O
with O
production O
of O
infectious O
HCV O
. O

In O
this O
study O
, O
we O
produced O
HCV O
particles O
of O
various O
genotypes O
, O
including O
la O
( O
1177 O
) O
, O
1b O
( O
CG1b O
) O
, O
and O
2a O
( O
J6 O
and O
JFH O
- O
1 O
) O
, O
in O
the O
HCV O
- O
ribozyme O
system O
. O

Studies O
of O
the O
complete O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
have O
become O
possible O
with O
the O
development O
of O
an O
infectious O
cell O
culture O
system O
using O
the O
genotype O
2a O
isolate O
JFH O
- O
1 O
. O

The O
nonstructural B
protein I
1 I
( I
nsp1 I
) I
of O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
has O
179 O
residues O
and O
is O
the O
N O
- O
terminal O
cleavage O
product O
of O
the O
viral O
replicase O
polyprotein O
that O
mediates O
RNA O
replication O
and O
processing O
. O

Here O
we O
report O
the O
nuclear O
magnetic O
resonance O
structure O
of O
the O
nsp1 O
segment O
from O
residue O
13 O
to O
128 O
, O
which O
represents O
a O
novel O
alpha O
/ O
beta O
- O
fold O
formed O
by O
a O
mixed O
parallel O
/ O
antiparallel O
six O
- O
stranded O
beta O
- O
barrel O
, O
an O
alpha O
- O
helix O
covering O
one O
opening O
of O
the O
barrel O
, O
and O
a O
3 O
( O
10 O
) O
- O
helix O
alongside O
the O
barrel O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
enters O
cells O
via O
a O
pH O
- O
and O
clathrin O
- O
dependent O
endocytic O
pathway O
. O

scavenger B
receptor I
BI I
( I
SR I
- I
BI I
) I
and O
CD81 O
are O
important O
entry O
factors O
for O
HCV O
internalization O
into O
target O
cells O
. O

Coronaviruses O
have O
a O
positive O
- O
strand O
RNA O
genome O
and O
replicate O
through O
the O
use O
of O
a O
3 O
' O
nested O
set O
of O
subgenomic O
mRNAs O
each O
possessing O
a O
leader O
( O
65 O
to O
90 O
nucleotides O
[ O
nt O
] O
in O
length O
, O
depending O
on O
the O
viral O
species O
) O
identical O
to O
and O
derived O
from O
the O
genomic O
leader O
. O

With O
experimentally O
placed O
22 O
- O
nt O
- O
long O
donor O
sequences O
within O
a O
bovine O
coronavirus O
Defective B
interfering I
( I
DI I
) I
RNA O
we O
have O
shown O
that O
matching O
sites O
occurring O
anywhere O
within O
a O
65 O
- O
nt O
- O
wide O
5 O
' O
- O
proximal O
genomic O
acceptor O
hot O
spot O
( O
nt O
33 O
through O
97 O
) O
can O
be O
used O
for O
production O
of O
templates O
for O
subgenomic O
mRNA O
synthesis O
from O
the O
DI O
RNA O
. O

For O
these O
, O
a O
3 O
' O
- O
proximal O
89 O
- O
nt O
acceptor O
hot O
spot O
on O
the O
viral O
antigenome O
( O
nt O
35 O
through O
123 O
) O
, O
largely O
complementary O
to O
that O
described O
above O
, O
was O
found O
. O

Treating O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
using O
pegylated O
alpha O
interferon O
and O
ribavirin O
leads O
to O
sustained O
clearance O
of O
virus O
and O
clinical O
improvement O
in O
approximately O
50 O
% O
of O
patients O
. O

Response O
rates O
are O
lower O
among O
patients O
with O
genotype O
1 O
than O
with O
genotypes O
2 O
and O
3 O
and O
among O
African B
- I
American I
( I
AA I
) I
patients O
compared O
to O
Caucasian O
( O
CA O
) O
patients O
. O

5 O
log O
( O
10 O
) O
- O
IU O
/ O
ml O
decrease O
at O
28 O
days O
) O
compared O
to O
those O
in O
patients O
with O
a O
marked O
( O
> O
3 O
. O

5 O
log O
( O
10 O
) O
- O
IU O
/ O
ml O
decrease O
) O
or O
intermediate O
( O
1 O
. O

5 O
log O
( O
10 O
) O
- O
IU O
/ O
ml O
decrease O
) O
response O
. O

The O
hepatitis B
A I
virus I
cellular I
receptor I
1 I
( I
HAVCR1 I
/ I
TIM1 I
) I
, O
a O
member O
of O
the O
T B
- I
cell I
immunoglobulin I
mucin I
( I
TIM I
) I
family O
, O
is O
an O
important O
atopy O
susceptibility O
gene O
in O
humans O
. O

The O
transfected O
cells O
that O
bound O
to O
the O
human O
HAVCR1 O
/ O
TIM1 O
Fc O
contained O
cDNA O
of O
human B
immunoglobulin I
alpha I
1 I
heavy I
( I
Ig I
alpha I
1 I
) I
and O
lambda B
light I
( I
Ig I
lambda I
) I
chain O
and O
secreted O
human O
IgA1 O
lambda O
antibody O
that O
bound O
to O
the O
cell O
surface O
. O

The O
interaction O
of O
HAVCR1 O
/ O
TIM1 O
with O
IgA O
was O
inhibited O
by O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
Ig O
alpha O
1 O
and O
Ig O
lambda O
, O
excess O
IgA1 O
lambda O
, O
or O
anti O
- O
HAVCR1 O
/ O
TIM1 O
MAN O
IgA O
did O
not O
inhibit O
HAV O
infection O
of O
African O
green O
monkey O
cells O
, O
suggesting O
that O
the O
IgA O
and O
the O
virus O
binding O
sites O
are O
in O
different O
epitopes O
on O
HAVCR1 O
/ O
TIM1 O
. O

Poliovirus O
3CD O
is O
a O
multifunctional O
protein O
that O
serves O
as O
a O
precursor O
to O
the O
protease O
3C B
( I
pro I
) I
and O
the O
viral O
polymerase O
3D O
( O
pol O
) O
and O
also O
plays O
a O
role O
in O
the O
control O
of O
viral O
replication O
. O

4 O
- O
angstrom O
resolution O
and O
the O
G64S O
fidelity O
mutant O
of O
3D O
( O
pol O
) O
at O
a O
3 O
. O

The O
polymerase O
active O
site O
is O
intact O
in O
both O
the O
3CD O
and O
the O
3D O
( O
pol O
) O
G64S O
structures O
, O
despite O
the O
disruption O
of O
a O
network O
proposed O
to O
position O
key O
residues O
in O
the O
active O
site O
. O

Extensive O
packing O
contacts O
between O
symmetry O
- O
related O
3CD O
molecules O
and O
the O
approach O
of O
the O
3C O
domain O
' O
s O
N O
terminus O
to O
the O
VPg O
binding O
site O
suggest O
how O
3D O
( O
pol O
) O
makes O
biologically O
relevant O
interactions O
with O
the O
3C O
, O
3CD O
, O
and O
3BCD O
proteins O
that O
control O
the O
uridylylation O
of O
VPg O
during O
the O
initiation O
of O
viral O
replication O
. O

Coronavirus O
envelope B
( I
E I
) I
proteins O
are O
small O
( O
similar O
to O
75 O
- O
to O
110 O
- O
amino O
- O
acid O
) O
membrane O
proteins O
that O
have O
a O
short O
hydrophilic O
amino O
terminus O
, O
a O
relatively O
long O
hydrophobic O
membrane O
domain O
, O
and O
a O
long O
hydrophilic O
carboxyterminal O
domain O
. O

We O
investigated O
the O
importance O
of O
the O
hydrophobic O
domain O
of O
the O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
A59 O
E O
protein O
. O

indoleamine B
2 I
, I
3 I
- I
dioxygenase I
( I
IDO I
) I
is O
induced O
by O
proinflammatory O
cytokines O
and O
by O
CTLA O
- O
4 O
- O
expressing O
T O
cells O
and O
constitutes O
an O
important O
mediator O
of O
peripheral O
immune O
tolerance O
. O

In O
chronic O
hepatitis O
C O
, O
we O
found O
upregulation O
of O
IDO O
expression O
in O
the O
liver O
and O
an O
increased O
serum O
kynurenine O
/ O
tryptophan O
ratio O
( O
a O
reflection O
of O
IDO O
activity O
) O
. O

Huh7 O
cells O
supporting O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
expressed O
higher O
levels O
of O
IDO O
mRNA O
than O
noninfected O
cells O
when O
stimulated O
with O
gamma O
interferon O
or O
when O
cocultured O
with O
activated O
T O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
positive O
- O
sense O
single O
- O
stranded O
RNA O
virus O
. O

Moreover O
, O
hnRNP O
A1 O
interacts O
with O
the O
5 O
' O
- O
nontranslated O
region O
( O
5 O
' O
NTR O
) O
and O
the O
3 O
' O
NTR O
of O
HCV O
RNA O
containing O
the O
cis O
- O
acting O
elements O
required O
for O
replication O
. O

Expression O
of O
the O
exceptionally O
large O
RNA O
genomes O
of O
CoVs O
involves O
multiple O
regulatory O
mechanisms O
, O
including O
extensive O
proteolytic O
processing O
of O
the O
large O
replicase O
polyproteins O
, O
pp1a O
and O
pp1ab O
, O
by O
two O
types O
of O
cysteine O
proteases O
: O
the O
chymotrypsin O
- O
like O
main O
protease O
and O
papain O
- O
like O
accessory O
proteases O
( O
PL O
( O
pro O
) O
s O
) O
. O

Here O
, O
we O
characterized O
the O
proteolytic O
processing O
of O
the O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
amino O
- O
proximal O
pp1a O
/ O
pp1ab O
region O
by O
two O
paralogous O
PLpro O
activities O
. O

Reverse O
- O
genetics O
data O
revealed O
that O
replacement O
of O
the O
PL2 O
( O
pro O
) O
active O
- O
site O
cysteine O
was O
lethal O
. O

By O
contrast O
, O
the O
PL1 O
( O
pro O
) O
activity O
proved O
to O
be O
dispensable O
for O
HCoV O
- O
229E O
virus O
replication O
, O
although O
reversion O
of O
the O
PL1 O
( O
pro O
) O
active O
- O
site O
substitution O
to O
the O
wild O
- O
type O
sequence O
after O
several O
passages O
in O
cell O
culture O
indicated O
that O
there O
was O
selection O
pressure O
to O
restore O
the O
PL1 O
( O
pro O
) O
activity O
. O

Further O
experiments O
showed O
that O
both O
PL1 O
( O
pro O
) O
and O
PL2 O
( O
pro O
) O
were O
able O
to O
cleave O
the O
nsp1 O
- O
nsp2 O
cleavage O
site O
, O
with O
PL2 O
( O
pro O
) O
cleaving O
the O
site O
less O
efficiently O
. O

The O
PL1 O
( O
pro O
) O
- O
negative O
mutant O
genotype O
could O
be O
stably O
maintained O
in O
cell O
culture O
when O
the O
nsp1 O
- O
nsp2 O
site O
was O
replaced O
by O
a O
short O
autoproteolytic O
sequence O
, O
suggesting O
that O
the O
major O
driving O
force O
for O
the O
observed O
reversion O
of O
the O
PL1 O
( O
pro O
) O
mutation O
was O
the O
requirement O
for O
efficient O
nsp1 O
- O
nsp2 O
cleavage O
. O

Within O
the O
tightly O
controlled O
interplay O
of O
the O
two O
protease O
activities O
, O
PL2 O
( O
pro O
) O
plays O
a O
universal O
and O
essential O
proteolytic O
role O
that O
appears O
to O
be O
assisted O
by O
the O
PL1 O
( O
pro O
) O
paralog O
at O
specific O
sites O
. O

The O
mechanism O
of O
entry O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
through O
interactions O
between O
the O
envelope O
glycoproteins O
and O
specific O
cell O
surface O
receptors O
remains O
unclear O
at O
this O
time O
. O

We O
have O
previously O
shown O
with O
the O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
/ O
HCV O
pseudotype O
model O
that O
the O
hypervariable O
region O
I O
of O
the O
HCV O
E2 O
envelope O
glycoprotein O
helps O
in O
binding O
with O
glycosaminoglycans O
present O
on O
the O
cell O
surface O
. O

Furthermore O
, O
we O
have O
determined O
the O
functional O
relevance O
of O
the O
interaction O
of O
heparin O
derivatives O
with O
HCV O
envelope O
glycoproteins O
for O
infectivity O
by O
using O
a O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
/ O
HCV O
pseudotype O
, O
a O
VSV O
/ O
HCV O
pseudotype O
, O
and O
cell O
culture O
- O
grown O
HCV O
genotype O
1a O
. O

2 O
- O
kb O
sequence O
from O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
strain O
found O
in O
southwest O
France O
was O
compared O
to O
sequences O
from O
reference O
strains O
in O
HCV O
sequence O
databases O
. O

We O
previously O
hypothesized O
that O
efficient O
translation O
of O
influenza O
virus O
mRNA O
requires O
the O
recruitment O
of O
P58 O
( O
IPK O
) O
, O
the O
cellular O
inhibitor O
of O
PKR O
, O
an O
interferon O
- O
induced O
kinase O
that O
targets O
the O
eukaryotic O
translation O
initiation O
factor O
eIF2 O
alpha O
. O

P58 O
( O
IPK O
) O
also O
inhibits O
PERK O
, O
an O
eIF2 O
alpha O
kinase O
that O
is O
localized O
in O
the O
encloplasmic O
reticulum O
( O
ER O
) O
and O
induced O
during O
ER O
stress O
. O

The O
ability O
of O
P58 O
( O
IPK O
) O
to O
interact O
with O
and O
inhibit O
multiple O
eIF2 O
alpha O
kinases O
suggests O
it O
is O
a O
critical O
regulator O
of O
both O
cellular O
and O
viral O
mRNA O
translation O
. O

In O
this O
study O
, O
we O
sought O
to O
definitively O
define O
the O
role O
of O
P58 O
( O
IPK O
) O
during O
viral O
infection O
of O
mammalian O
cells O
. O

Using O
mouse O
embryo O
fibroblasts O
from O
P58 O
( O
IPK O
- O
/ O
- O
) O
mice O
, O
we O
demonstrated O
that O
the O
absence O
of O
P58 O
( O
IPK O
) O
led O
to O
an O
increase O
in O
eIF2 O
alpha O
phosphorylation O
and O
decreased O
influenza O
virus O
mRNA O
translation O
. O

The O
absence O
of O
P58 O
( O
IPK O
) O
also O
resulted O
in O
decreased O
vesicular O
stomatitis O
virus O
replication O
but O
enhanced O
reovirus O
yields O
. O

In O
cells O
lacking O
the O
P58 O
( O
IPK O
) O
target O
, O
PKR O
, O
the O
trends O
were O
reversed O
- O
eIF2 O
alpha O
phosphorylation O
was O
decreased O
, O
and O
influenza O
virus O
mRNA O
translation O
was O
increased O
. O

Although O
P58 O
( O
IPK O
) O
also O
inhibits O
PERK O
, O
the O
presence O
or O
absence O
of O
this O
kinase O
had O
little O
effect O
on O
influenza O
virus O
mRNA O
translation O
, O
despite O
reduced O
levels O
of O
eIF2 O
alpha O
phosphorylation O
in O
cells O
lacking O
PERK O
. O

Taken O
together O
, O
our O
results O
support O
a O
model O
in O
which O
P58 O
( O
IPK O
) O
regulates O
influenza O
virus O
mRNA O
translation O
and O
infection O
through O
a O
PKR O
- O
mediated O
mechanism O
which O
is O
independent O
of O
PERK O
. O

The O
small B
envelope I
protein I
( I
E I
) I
plays O
a O
role O
of O
central O
importance O
in O
the O
assembly O
of O
coronaviruses O
. O

This O
was O
initially O
established O
by O
studies O
demonstrating O
that O
cellular O
expression O
of O
only O
E O
protein O
and O
the O
membrane B
protein I
( I
M I
) I
was O
necessary O
and O
sufficient O
for O
the O
generation O
and O
release O
of O
virus O
- O
like O
particles O
. O

To O
investigate O
the O
role O
of O
E O
protein O
in O
the O
whole O
virus O
, O
we O
previously O
generated O
E O
gene O
mutants O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
that O
were O
defective O
in O
viral O
growth O
and O
produced O
aberrantly O
assembled O
virions O
. O

Surprisingly O
, O
however O
, O
we O
were O
also O
able O
to O
isolate O
a O
viable O
MHV O
mutant O
( O
Delta O
E O
) O
in O
which O
the O
entire O
E O
gene O
, O
as O
well O
as O
the O
nonessential O
upstream O
genes O
4 O
and O
5a O
, O
were O
deleted O
. O

The O
transmembrane B
( I
TM I
) I
domains O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoproteins O
El O
and O
E2 O
have O
been O
shown O
to O
play O
multiple O
roles O
during O
the O
biogenesis O
of O
the O
E1E2 O
heterodimer O
. O

Our O
tryptophan O
mutants O
were O
also O
used O
to O
generate O
retrovirus O
- O
based O
, O
HCV B
- I
pseudotyped I
particles I
( I
HCVpp I
) I
in O
order O
to O
analyze O
the O
effects O
of O
these O
mutations O
on O
virus O
entry O
. O

The O
majority O
of O
people O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
fail O
to O
generate O
or O
maintain O
a O
T O
- O
cell O
response O
effective O
for O
viral O
clearance O
. O

Evidence O
from O
murine O
chronic O
viral O
infections O
shows O
that O
expression O
of O
the O
coinhibitory O
molecule O
PD O
- O
1 O
predicts O
CD8 O
( O
+ O
) O
antiviral O
T O
- O
cell O
exhaustion O
and O
may O
contribute O
to O
inadequate O
pathogen O
control O
. O

To O
investigate O
whether O
human O
CD8 O
+ O
T O
cells O
express O
PD O
- O
1 O
and O
demonstrate O
a O
dysfunctional O
phenotype O
during O
chronic O
HCV O
infection O
, O
peripheral O
and O
intrahepatic O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
examined O
. O

Importantly O
, O
intrahepatic O
HCV O
- O
specific O
T O
cells O
, O
in O
contrast O
to O
those O
in O
the O
periphery O
, O
express O
not O
only O
high O
levels O
of O
PD O
- O
1 O
but O
also O
decreased O
interleukin O
- O
7 O
receptor O
alpha O
( O
CD127 O
) O
, O
an O
exhausted O
phenotype O
that O
was O
HCV O
antigen O
specific O
and O
compartmentalized O
to O
the O
liver O
, O
the O
site O
of O
viral O
replication O
. O

We O
used O
mouse B
hepatitis I
virus I
( I
MHV I
) I
A59 O
as O
a O
model O
to O
gain O
insight O
into O
how O
coronaviruses O
affect O
the O
type O
I O
alpha O
/ O
beta O
interferon B
( I
IFN I
) I
system O
. O

protein B
kinase I
R I
( I
PKR I
) I
and O
the O
alpha O
subunit O
of O
eukaryotic O
translation O
initiation O
factor O
are O
not O
phosphorylated O
in O
infected O
cells O
. O

We O
used O
a O
well O
- O
established O
recombinant O
vaccinia B
virus I
( I
VV I
) I
- O
based O
expression O
system O
that O
lacks O
the O
viral O
IFN O
antagonist O
E3L O
to O
screen O
viral O
genes O
for O
their O
ability O
to O
rescue O
the O
IFN O
sensitivity O
of O
the O
mutant O
. O

The O
nucleocapsid B
( I
N I
) I
gene O
rescued O
VV O
Delta O
E3L O
from O
IFN O
sensitivity O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
significant O
worldwide O
health O
problem O
with O
limited O
therapeutic O
options O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
a O
major O
component O
of O
viral O
nucleocapsid O
and O
a O
multifunctional O
Protein O
involved O
in O
viral O
pathogenesis O
and O
hepatocarcinogenesis O
. O

One O
or O
more O
of O
the O
unique O
3 O
' O
- O
proximal O
open B
reading I
frames I
( I
ORFs I
) I
of O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
may O
encode O
determinants O
of O
virus O
virulence O
. O

feline B
coronavirus I
( I
FCoV I
) I
, O
porcine O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
, O
canine B
coronavirus I
( I
CCoV I
) I
, O
and O
human O
coronavirus O
HCoV O
- O
229E O
, O
which O
belong O
to O
the O
group O
1 O
coronavirus O
, O
use O
aminopeptidase B
N I
( I
APN I
) I
of O
their O
natural O
host O
and O
feline B
APN I
( I
fAPN I
) I
as O
receptors O
. O

Using O
mouse O
- O
feline O
APN O
chimeras O
, O
we O
identified O
three O
small O
, O
discontinuous O
regions O
, O
amino B
acids I
( I
aa I
) I
288 O
to O
290 O
, O
aa O
732 O
to O
746 O
( O
called O
R1 O
) O
, O
and O
aa O
764 O
to O
788 O
( O
called O
R2 O
) O
in O
fAPN O
that O
determined O
the O
host O
ranges O
of O
these O
coronaviruses O
. O

N740 O
and O
T742 O
in O
fAPN O
and O
the O
homologous O
R741 O
in O
human B
APN I
( I
hAPN I
) I
were O
key O
determinants O
of O
host O
range O
for O
FCoV O
, O
TGEV O
, O
and O
CCoV O
. O

The O
3 O
' O
cis O
- O
acting O
element O
for O
mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
synthesis O
resides O
entirely O
within O
the O
301 O
- O
nucleotide O
3 B
' I
untranslated I
region I
( I
3 I
' I
UTR I
) I
of O
the O
viral O
genome O
and O
consists O
of O
three O
regions O
. O

Between O
these O
two O
ends O
is O
a O
hypervariable B
region I
( I
HVR I
) I
that O
is O
only O
poorly O
conserved O
between O
MHV O
and O
other O
group O
2 O
coronaviruses O
. O

Paradoxically O
, O
buried O
within O
the O
HVR O
is O
an O
octanucleotide O
motif O
( O
oct O
) O
, O
5 O
' O
- O
GGAAGAGC O
- O
3 O
' O
, O
which O
is O
almost O
universally O
conserved O
in O
coronaviruses O
and O
is O
therefore O
assumed O
to O
have O
a O
critical O
biological O
function O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
a O
component O
of O
nucleocapsids O
and O
a O
pathogenic O
factor O
for O
hepatitis O
C O
. O

We O
have O
previously O
reported O
that O
HCV O
core O
gene O
- O
transgenic O
( O
PA28 O
gamma O
( O
+ O
/ O
+ O
) O
CoreTg O
) O
mice O
develop O
marked O
insulin O
resistance O
and O
that O
the O
HCV O
core O
protein O
is O
degraded O
in O
the O
nucleus O
through O
a O
PA28 O
gamma O
- O
dependent O
pathway O
. O

HCV O
core O
gene O
- O
transgenic O
mice O
lacking O
the O
PA28 O
gamma O
gene O
( O
PA28 O
gamma O
( O
- O
/ O
- O
) O
CoreTg O
) O
were O
prepared O
by O
mating O
of O
PA28 O
gamma O
( O
+ O
/ O
+ O
) O
CoreTg O
with O
PA28 O
gamma O
- O
knockout O
mice O
. O

Although O
there O
was O
no O
significant O
difference O
in O
the O
glucose O
tolerance O
test O
results O
among O
the O
mice O
, O
the O
insulin O
sensitivity O
in O
PA28 O
gamma O
( O
- O
/ O
- O
) O
CoreTg O
mice O
was O
recovered O
to O
a O
normal O
level O
in O
the O
insulin O
tolerance O
test O
. O

Tyrosine O
phosphorylation O
of O
insulin B
receptor I
substrate I
1 I
( I
IRS1 I
) I
, O
production O
of O
IRS2 O
, O
and O
phosphorylation O
of O
Akt O
were O
suppressed O
in O
the O
livers O
of O
PA28 O
gamma O
( O
+ O
/ O
+ O
) O
CoreTg O
mice O
in O
response O
to O
insulin O
stimulation O
, O
whereas O
they O
were O
restored O
in O
the O
livers O
of O
PA28 O
gamma O
( O
+ O
/ O
+ O
) O
CoreTg O
mice O
. O

They O
form O
a O
tight O
genetic O
cluster O
( O
genus O
) O
in O
the O
Caliciviridae O
family O
that O
regroups O
both O
animal O
and O
human O
pathogenic O
strains O
. O

We O
report O
here O
on O
the O
first O
extensive O
characterization O
of O
the O
key O
enzyme O
of O
replication O
, O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
associated O
with O
the O
3D O
( O
pol O
) O
- O
like O
protein O
. O

Enzymatically O
active O
sapovirus O
3D O
( O
pol O
) O
and O
its O
defective O
mutant O
were O
expressed O
in O
Escherichia O
coli O
and O
purified O
. O

The O
overall O
structure O
of O
the O
sapovirus O
3D O
( O
pol O
) O
was O
determined O
by O
X O
- O
ray O
crystallography O
to O
2 O
. O

The O
carboxyl O
terminus O
is O
located O
within O
the O
active O
site O
cleft O
, O
as O
observed O
in O
the O
RdRp O
of O
some O
( O
norovirus O
) O
but O
not O
other O
( O
lagovirus O
) O
caliciviruses O
. O

Sapovirus O
3D O
( O
pol O
) O
prefers O
Mn2 O
+ O
over O
Mg2 O
+ O
but O
may O
utilize O
either O
as O
a O
cofactor O
in O
vitro O
. O

In O
a O
synthetic O
RNA O
template O
- O
dependent O
reaction O
, O
sapovirus O
3D O
( O
pol O
) O
synthesizes O
a O
double O
- O
stranded O
RNA O
or O
labels O
the O
template O
3 O
' O
terminus O
by O
terminal O
transferase O
activity O
. O

This O
first O
experimental O
evidence O
makes O
sapovirus O
3D O
( O
pol O
) O
an O
attractive O
target O
for O
developing O
drugs O
to O
control O
calicivirus O
infection O
in O
humans O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
pegylated O
IFN O
- O
alpha O
( O
pegIFN O
- O
alpha O
) O
are O
used O
for O
the O
treatment O
of O
chronic B
hepatitis I
B I
( I
CHB I
) I
. O

The O
mechanisms O
responsible O
for O
hepatitis B
B I
virus I
( I
HBV I
) I
resistance O
to O
pegIFN O
- O
a O
treatment O
are O
not O
known O
. O

pegIFN O
- O
alpha O
is O
also O
used O
to O
treat O
patients O
with O
chronic B
hepatitis I
C I
( I
CHC I
) I
. O

In O
CHC O
, O
IFN O
- O
a O
signaling O
has O
been O
found O
to O
be O
inhibited O
by O
an O
upregulation O
of O
protein B
phosphatase I
2A I
( I
PP2A I
) I
. O

PP2A O
inhibits O
protein B
arginine I
methyltransferase I
1 I
( I
PRMT1 I
) I
, O
the O
enzyme O
that O
catalyzes O
the O
methylation O
of O
the O
important O
IFN O
- O
alpha O
signal O
transducer O
STAT1 O
. O

We O
analyzed O
the O
expression O
of O
PP2A O
, O
the O
enzymatic O
activity O
of O
PRMT1 O
( O
methylation O
assays O
) O
, O
the O
phosphorylation O
and O
methylation O
of O
STATI O
, O
the O
association O
of O
STATI O
with O
PIAS1 O
( O
via O
coimmunoprecipitation O
assays O
) O
, O
the O
binding O
of O
activated O
STATI O
to O
interferon O
- O
stimulated O
response O
elements O
( O
via O
electrophoretic O
mobility O
shift O
assays O
) O
, O
and O
the O
induction O
of O
interferon O
target O
genes O
( O
via O
real O
- O
time O
RT O
- O
PCR O
) O
in O
human O
hepatoma O
cells O
expressing O
HBV O
proteins O
as O
well O
as O
in O
liver O
biopsies O
from O
patients O
with O
chronic O
hepatitis O
B O
and O
from O
controls O
. O

We O
previously O
demonstrated O
that O
infection O
of O
cultured O
cells O
with O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
resulted O
in O
activation O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
( O
Raf O
/ O
MEK O
/ O
ERK O
) O
signal O
transduction O
pathway O
( O
Y O
. O

Here O
we O
show O
that O
inhibition O
of O
the O
Raf O
/ O
MEK O
/ O
ERK O
signaling O
pathway O
by O
the O
MEK O
inhibitor O
UO126 O
significantly O
impaired O
MHV O
progeny O
production O
( O
a O
reduction O
of O
95 O
to O
99 O
% O
in O
virus O
titer O
) O
, O
which O
correlated O
with O
the O
phosphorylation O
status O
of O
ERK1 O
/ O
2 O
. O

However O
, O
synthesis O
of O
viral O
genomic O
and O
subgenomic O
RNAs O
was O
severely O
suppressed O
by O
UO126 O
treatment O
, O
as O
demonstrated O
by O
a O
reduced O
incorporation O
of O
[ O
H O
- O
3 O
] O
uridine O
and O
a O
decrease O
in O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
activity O
in O
a O
defective O
- O
interfering O
RNA O
- O
CAT O
reporter O
assay O
. O

There O
is O
little O
understanding O
of O
mechanisms O
underlying O
the O
assembly O
and O
release O
of O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
from O
cultured O
cells O
. O

Cells O
transfected O
with O
synthetic O
genomic O
RNA O
from O
a O
unique O
genotype O
2a O
virus O
( O
JFH1 O
) O
produce O
high O
titers O
of O
virus O
, O
while O
virus O
yields O
are O
much O
lower O
with O
a O
prototype O
genotype O
1a O
RNA O
containing O
multiple O
cell O
culture O
- O
adaptive O
mutations O
( O
H77S O
) O
. O

RNAs O
encoding O
polyproteins O
fused O
at O
the O
NS2 O
/ O
NS3 O
junction O
( O
H O
- O
NS2 O
/ O
NS3 O
- O
J O
) O
and O
at O
a O
site O
of O
natural O
, O
intergenotypic O
recombination O
within O
NS2 O
[ O
H O
- O
( O
NS2 O
) O
- O
J O
] O
produced O
infectious O
virus O
. O

Chimera O
H O
- O
NS2 O
/ O
NS3 O
- O
J O
virus O
( O
vH O
- O
NS2 O
/ O
NS3 O
- O
J O
) O
recovered O
from O
transfected O
cultures O
contained O
compensatory O
mutations O
in O
E1 O
and O
NS3 O
that O
were O
essential O
for O
the O
production O
of O
infectious O
virus O
, O
while O
yields O
of O
infectious O
vH O
- O
( O
NS2 O
) O
- O
J O
were O
enhanced O
by O
mutations O
within O
p7 O
and O
NS2 O
. O

Mutations O
in O
p7 O
and O
NS2 O
acted O
additively O
and O
increased O
the O
specific O
infectivity O
of O
vH O
- O
( O
NS2 O
) O
- O
J O
particles O
, O
while O
having O
less O
impact O
on O
the O
numbers O
of O
particles O
released O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

In O
the O
present O
study O
, O
we O
have O
examined O
vectors O
carrying O
short B
hairpin I
RNA I
( I
shRNA I
) I
targeting O
the O
5 O
' O
nontranslated O
conserved O
region O
of O
the O
HCV O
genome O
for O
inhibition O
of O
virus O
replication O
. O

Initially O
, O
three O
sequences O
were O
selected O
, O
and O
all O
three O
shRNAs O
( O
psh O
- O
53 O
, O
psh O
- O
274 O
, O
and O
psh O
- O
375 O
) O
suppressed O
HCV O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
mediated O
translation O
to O
different O
degrees O
in O
Huh O
- O
7 O
cells O
. O

5 O
cells O
persistently O
infected O
with O
HCV O
genotype O
2a O
( O
JFH1 O
) O
. O

The O
effect O
of O
psh O
- O
274 O
on O
cell O
- O
culture O
- O
grown O
HCV O
genotype O
1a O
( O
H77 O
) O
was O
also O
evaluated O
, O
and O
inhibition O
of O
virus O
replication O
and O
infectivity O
titers O
was O
observed O
. O

Cell O
- O
based O
hepatitis B
C I
virus I
( I
HCV I
) I
replicon O
systems O
have O
provided O
a O
means O
for O
understanding O
HCV O
replication O
mechanisms O
and O
for O
testing O
new O
antiviral O
agents O
. O

We O
predict O
the O
following O
: O
( O
i O
) O
about O
6 O
x O
103 O
ribosomes O
are O
involved O
in O
generating O
millions O
of O
HCV O
NS5B O
- O
polymerase O
molecules O
in O
a O
Huh O
- O
7 O
cell O
, O
( O
ii O
) O
the O
observed O
10 O
: O
1 O
asymmetry O
of O
plus O
- O
to O
minus O
- O
strand O
RNA O
levels O
can O
be O
explained O
by O
a O
higher O
- O
affinity O
( O
200 O
- O
fold O
) O
interaction O
of O
HCV O
NS5B O
polymerase O
- O
containing O
replication O
complexes O
with O
HCV O
minus O
- O
strand O
RNA O
over O
HCV O
plus O
- O
strand O
RNA O
in O
order O
to O
initiate O
synthesis O
, O
( O
iii O
) O
the O
latter O
higher O
affinity O
can O
also O
account O
for O
the O
observed O
similar O
to O
6 O
: O
1 O
plus O
- O
strand O
/ O
minus O
- O
strand O
ratio O
in O
vesicular O
- O
membrane O
structures O
, O
and O
( O
iv O
) O
the O
introduction O
of O
higher O
numbers O
of O
HCV O
plus O
- O
strand O
RNA O
by O
transfection O
leads O
to O
faster O
attainment O
of O
steady O
- O
state O
but O
does O
not O
change O
the O
steady O
- O
state O
HCV O
RNA O
level O
. O

The O
immunity O
elicited O
against O
nucleocapsid O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
closely O
related O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
has O
been O
shown O
to O
be O
important O
in O
resolution O
of O
hepatitis O
and O
protection O
from O
infection O
. O

Further O
, O
activity O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
which O
may O
directly O
inhibit O
hepadnavirus O
replication O
, O
promotes O
antiviral O
defense O
and O
favors O
T B
helper I
cell I
type I
1 I
( I
Th1 I
) I
response O
, O
which O
is O
seemingly O
a O
prerequisite O
of O
HBV O
clearance O
. O

In O
this O
study O
, O
to O
enhance O
induction O
of O
protective O
immunity O
against O
hepadnavirus O
, O
healthy O
woodchucks O
were O
immunized O
with O
a O
bicistronic O
DNA O
vaccine O
carrying O
WHV B
core I
( I
WHc I
) I
and O
woodchuck B
IFN I
- I
gamma I
( I
wIFN I
- I
gamma I
) I
gene O
sequences O
. O

The O
RNA O
- O
editing O
enzyme O
ADAR1 O
is O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
binding O
protein O
that O
modifies O
cellular O
and O
viral O
RNA O
sequences O
by O
adenosine O
deamination O
. O

Here O
, O
we O
report O
a O
proviral O
effect O
of O
ADAR1 O
that O
enhances O
replication O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
through O
a O
mechanism O
independent O
of O
dsRNA O
editing O
. O

We O
demonstrate O
that O
ADAR1 O
interacts O
with O
dsRNA O
- O
activated O
protein O
kinase O
PKR O
, O
inhibits O
its O
kinase O
activity O
, O
and O
suppresses O
the O
a O
subunit O
of O
eukaryotic B
initiation I
factor I
2 I
( I
eIF I
- I
2 I
alpha I
) I
phosphorylation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
human O
pathogen O
associated O
with O
life O
- O
threatening O
liver O
disease O
. O

In O
this O
study O
, O
we O
elucidated O
the O
postreceptor O
attachment O
stages O
of O
HCV O
entry O
using O
HCV B
pseudoparticles I
( I
HCVpp I
) I
as O
a O
model O
system O
. O

The O
positive O
- O
strand O
RNA O
genome O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
flanked O
by O
5 O
' O
- O
and O
3 B
' I
- I
untranslated I
regions I
( I
UTRs I
) I
. O

Translation O
of O
the O
viral O
RNA O
is O
directed O
by O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
in O
the O
5 O
' O
- O
UTR O
, O
and O
subsequent O
viral O
RNA O
replication O
requires O
sequences O
in O
the O
3 O
' O
- O
UTR O
and O
in O
the O
5 O
' O
- O
UTR O
. O

The O
variable O
region O
, O
the O
poly O
( O
U O
center O
dot O
C O
) O
tract O
, O
and O
the O
most O
3 O
' O
terminal O
stem O
- O
loop O
I O
of O
the O
highly O
conserved O
3 O
' O
X O
region O
contribute O
significantly O
to O
translation O
enhancement O
, O
whereas O
stem O
- O
loops O
2 O
and O
3 O
of O
the O
3 O
' O
X O
region O
are O
involved O
only O
to O
a O
minor O
extent O
. O

Coronaviruses O
are O
positive O
- O
strand O
RNA O
viruses O
that O
translate O
their O
genome O
RNA O
into O
polyproteins O
that O
are O
co O
- O
and O
posttranslationally O
processed O
into O
intermediate O
and O
mature O
replicase O
nonstructural B
proteins I
( I
nsPs I
) I
. O

In O
murine B
hepatitis I
virus I
( I
MHV I
) I
, O
nsps O
1 O
, O
2 O
, O
and O
3 O
are O
processed O
by O
two O
papain O
- O
like O
proteinase O
activities O
within O
nsp3 O
( O
PLP1 O
and O
PLP2 O
) O
to O
yield O
nspl O
, O
an O
nsp2 O
- O
3 O
intermediate O
, O
and O
mature O
nsp2 O
and O
nsp3 O
. O

To O
determine O
the O
role O
in O
replication O
of O
processing O
between O
nsp2 O
and O
nsp3 O
at O
cleavage B
site I
2 I
( I
CS2 I
) I
and O
PLP1 O
proteinase O
activity O
, O
mutations O
were O
engineered O
into O
the O
MHV O
genome O
at O
CS2 O
, O
at O
CS1 O
and O
CS2 O
, O
and O
at O
the O
PLP1 O
catalytic O
site O
, O
alone O
and O
in O
combination O
. O

Mutant O
viruses O
with O
abolished O
cleavage O
at O
CS2 O
were O
delayed O
in O
growth O
and O
RNA O
synthesis O
but O
grew O
to O
wild O
- O
type O
titers O
of O
> O
10 O
( O
7 O
) O
PFU O
/ O
ml O
. O

Mutant O
viruses O
with O
deletion O
of O
both O
CS1 O
and O
CS2 O
exhibited O
both O
a O
delay O
in O
growth O
and O
a O
decrease O
in O
peak O
viral O
titer O
to O
similar O
to O
10 O
( O
4 O
) O
PFU O
/ O
ml O
. O

Inactivation O
of O
PLP1 O
catalytic O
residues O
resulted O
in O
a O
mutant O
virus O
that O
did O
not O
process O
at O
either O
CS1 O
or O
CS2 O
and O
was O
severely O
debilitated O
in O
growth O
, O
achieving O
only O
10 O
( O
2 O
) O
PFU O
/ O
ml O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
is O
a O
life O
- O
threatening O
infectious O
disease O
which O
has O
been O
difficult O
to O
study O
and O
treat O
because O
of O
the O
lack O
of O
a O
readily O
available O
animal O
model O
. O

Intranasal O
infection O
of O
A O
/ O
J O
mice O
with O
the O
coronavirus O
murine B
hepatitis I
virus I
strain I
1 I
( I
MHV I
- I
1 I
) I
produced O
pulmonary O
pathological O
features O
of O
SARS O
. O

Infected O
A O
/ O
J O
mice O
had O
significantly O
higher O
cytokine O
levels O
, O
particularly O
macrophage B
chemoattractant I
protein I
1 I
( I
MCP I
- I
1 I
/ I
CCL I
- I
2 I
) I
, O
gamma O
interferon O
, O
and O
tumor O
necrosis O
factor O
alpha O
. O

The O
virological O
and O
cellular O
consequences O
of O
persistent O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
have O
been O
elusive O
due O
to O
the O
absence O
of O
the O
requisite O
experimental O
systems O
. O

Cellular O
immune O
responses O
are O
an O
important O
correlate O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
outcome O
. O

These O
responses O
are O
governed O
by O
the O
host O
' O
s O
human B
leukocyte I
antigen I
( I
HLA I
) I
type O
, O
and O
HLA O
- O
restricted O
viral O
escape O
mutants O
are O
a O
critical O
aspect O
of O
this O
host O
- O
virus O
interaction O
. O

We O
examined O
the O
driving O
forces O
of O
HCV O
evolution O
by O
characterizing O
the O
in O
vivo O
selective O
pressure O
( O
s O
) O
exerted O
on O
single O
amino O
acid O
residues O
within O
nonstructural B
protein I
3 I
( I
NS3 I
) I
by O
the O
HLA O
types O
present O
in O
two O
host O
populations O
. O

Associations O
between O
polymorphisms O
within O
NS3 O
and O
HILA O
class O
I O
alleles O
were O
assessed O
in O
118 O
individuals O
from O
Western O
Australia O
and O
Switzerland O
with O
chronic O
hepatitis O
C O
infection O
, O
of O
whom O
82 O
( O
69 O
% O
) O
were O
coinfected O
with O
human O
immunodeficiency O
virus O
. O

To O
investigate O
the O
nature O
of O
recombination O
and O
selection O
processes O
underlying O
the O
evolution O
of O
serotypes O
within O
different O
picornavirus O
genera O
, O
large O
- O
scale O
analysis O
of O
recombination O
frequencies O
and O
sites O
, O
segregation O
by O
serotype O
within O
each O
genus O
, O
and O
sequence O
selection O
and O
composition O
was O
performed O
, O
and O
results O
were O
compared O
with O
those O
for O
other O
nonenveloped O
positive O
- O
stranded O
viruses O
( O
astroviruses O
and O
human O
noroviruses O
) O
and O
with O
flavivirus O
and O
alphavirus O
control O
groups O
. O

The O
evolution O
of O
peptide O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
acute O
viral O
infections O
of O
humans O
is O
poorly O
understood O
. O

We O
analyzed O
the O
response O
to O
parvovirus O
B19 O
( O
B19 O
) O
, O
a O
ubiquitous O
and O
clinically O
significant O
pathogen O
with O
a O
compact O
and O
conserved O
genome O
. O

The O
magnitude O
and O
breadth O
of O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
to O
the O
two O
B19 O
capsid O
proteins O
were O
investigated O
using O
a O
set O
of O
overlapping O
peptides O
and O
gamma O
interferon O
- O
specific O
enzyme O
- O
linked O
immunospot O
assays O
of O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
from O
a O
cohort O
of O
acutely O
infected O
individuals O
who O
presented O
with O
acute O
arthropathy O
. O

These O
were O
compared O
to O
those O
for O
a O
cohort O
of O
B19 O
- O
specific O
immunoglobulin O
M O
- O
negative O
( O
IgM O
( O
- O
) O
) O
, O
IgG O
( O
+ O
) O
remotely O
infected O
individuals O
. O

Both O
cohorts O
of O
individuals O
were O
found O
to O
make O
broad O
CD4 O
( O
+ O
) O
responses O
. O

One O
epitope O
( O
LASEESAFYVLEHSSFQLLG O
) O
was O
consistently O
targeted O
by O
both O
acutely O
( O
10 O
/ O
12 O
) O
and O
remotely O
( O
6 O
/ O
7 O
) O
infected O
individuals O
. O

042 O
% O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

Tetramer O
- O
positive O
populations O
were O
initially O
CD62L O
( O
lo O
) O
; O
unlike O
the O
case O
for O
B19 O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
, O
however O
, O
CD62L O
was O
reexpressed O
at O
later O
times O
, O
as O
responses O
remained O
stable O
or O
declined O
slowly O
. O

This O
first O
identification O
of O
B19 O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitopes O
, O
including O
a O
key O
immunodominant O
peptide O
, O
provides O
the O
tools O
to O
investigate O
the O
breadth O
, O
frequency O
, O
and O
functions O
of O
cellular O
responses O
to O
this O
virus O
in O
a O
range O
of O
specific O
clinical O
settings O
and O
gives O
an O
important O
reference O
point O
for O
analysis O
of O
peptide O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
during O
acute O
and O
persistent O
virus O
infections O
of O
humans O
. O

Replication O
of O
the O
plus O
- O
stranded O
RNA O
genome O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
occurs O
in O
a O
membrane O
- O
bound O
replication O
complex O
consisting O
of O
viral O
and O
cellular O
proteins O
and O
viral O
RNA O
. O

Mutations O
of O
two O
other O
highly O
conserved O
amino O
acids O
( O
L588A O
and O
P589A O
) O
reduced O
but O
did O
not O
eliminate O
colony O
formation O
. O

Recent O
reports O
demonstrated O
an O
association O
of O
human O
parvovirus O
B19 O
with O
inflammatory B
cardiomyopathy I
( I
iCMP I
) I
, O
which O
is O
accompanied O
by O
endothelial O
dysfunction O
. O

A O
secreted O
phospholipase B
A2 I
( I
PLA2 I
) I
- O
like O
activity O
has O
been O
located O
in O
the O
VP1 O
unique O
region O
of O
the O
B19 O
minor O
capsid O
protein O
. O

After O
the O
transfection O
of O
human B
endothelial I
cells I
( I
HMEC I
- I
1 I
) I
, O
cytosolic O
Ca2 O
+ O
activity O
was O
determined O
by O
utilizing O
Fura O
- O
2 O
fluorescence O
. O

Recovery O
from O
Lassa B
virus I
( I
LASV I
) I
infection O
usually O
precedes O
the O
appearance O
of O
neutralizing O
antibodies O
, O
indicating O
that O
cellular O
immunity O
plays O
a O
primary O
role O
in O
viral O
clearance O
. O

To O
date O
, O
the O
role O
of O
LASV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
has O
not O
been O
evaluated O
in O
humans O
. O

To O
facilitate O
such O
studies O
, O
we O
utilized O
a O
predictive O
algorithm O
to O
identify O
candidate O
HLA O
- O
A2 O
supertype O
epitopes O
from O
the O
LASV O
nucleoprotein O
and O
glycoprotein B
precursor I
( I
GPC I
) I
genes O
. O

We O
identified O
three O
peptides O
( O
GPC O
( O
42 O
- O
50 O
) O
, O
GLVGLVTFL O
; O
GPC O
( O
60 O
- O
68 O
) O
, O
SLYKGVYEL O
; O
and O
GPC O
( O
441 O
- O
449 O
) O
, O
YLISIFLHL O
) O
that O
displayed O
high O
- O
affinity O
binding O
( O
< O
= O
98 O
nM O
) O
to O
HLA O
- O
A O
* O
0201 O
, O
induced O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
of O
high O
functional O
avidity O
in O
HLA O
- O
A O
* O
0201 O
transgenic O
mice O
, O
and O
were O
naturally O
processed O
from O
native O
LASV O
GPC O
in O
human O
HLA O
- O
A O
* O
0201 O
- O
positive O
target O
cells O
. O

HLA O
- O
A O
* O
0201 O
mice O
immunized O
with O
either O
GPC O
( O
42 O
- O
50 O
) O
or O
GPC O
( O
60 O
- O
68 O
) O
were O
protected O
against O
challenge O
with O
a O
recombinant O
vaccinia O
virus O
that O
expressed O
LASV O
GPC O
. O

Presentation O
of O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
is O
severely O
down O
- O
regulated O
on O
hepatocytes O
in O
chronic O
hepatitis O
caused O
by O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

In O
contrast O
, O
hepatocytes O
transfected O
with O
WHV O
X O
gene O
alone O
demonstrated O
a O
profound O
enhancement O
in O
the O
class O
I O
antigen O
display O
, O
whereas O
those O
expressing O
virus O
major O
S O
protein O
or O
nucleocapsid O
( O
core O
) O
protein O
were O
not O
different O
from O
control O
hepatocytes O
. O

Interestingly O
, O
treatment O
with O
recombinant O
woodchuck O
gamma O
interferon O
( O
rwIFN O
- O
gamma O
) O
restored O
the O
inhibited O
presentation O
of O
the O
class O
I O
antigen O
. O

Moreover O
, O
the O
class O
I O
antigen O
suppression O
was O
not O
associated O
with O
down O
- O
regulation O
of O
hepatocyte O
genes O
for O
class O
I O
MHC O
heavy O
chain O
, O
beta O
( O
2 O
) O
- O
microglobulin O
, O
transporters O
associated O
with O
antigen O
processing O
, O
and O
proteasome O
subunits O
. O

Platelets O
can O
engulf O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
and O
a O
significant O
amount O
of O
HIV O
- O
1 O
in O
the O
blood O
of O
infected O
individuals O
is O
associated O
with O
these O
cells O
. O

DC O
- O
SIGN O
and O
other O
lectins O
contribute O
to O
capture O
of O
HIV O
- O
1 O
by O
dendritic B
cells I
( I
DCs I
) I
and O
facilitate O
HIV O
- O
1 O
spread O
in O
DC O
/ O
T O
- O
cell O
cocultures O
. O

Here O
, O
we O
show O
that O
platelets O
express O
both O
the O
C B
- I
type I
lectin I
- I
like I
receptor I
2 I
( I
CLEC I
- I
2 I
) I
and O
low O
levels O
of O
DC O
- O
SIGN O
. O

Emerging O
data O
have O
indicated O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
subverts O
the O
host O
antiviral O
response O
to O
ensure O
its O
persistence O
. O

We O
previously O
demonstrated O
that O
HCV O
protein O
expression O
suppresses O
type B
I I
interferon I
( I
IFN I
) I
signaling O
by O
leading O
to O
the O
reduction O
of O
phosphorylated B
STAT1 I
( I
P I
- I
STAT1 I
) I
. O

In O
this O
report O
, O
we O
show O
that O
the O
STAT1 O
interaction O
domain O
resides O
in O
the O
N O
- O
terminal O
portion O
of O
HCV O
core O
( O
amino O
acids O
[ O
aa O
] O
1 O
to O
23 O
) O
. O

Conversely O
, O
the O
C O
- O
terminal O
region O
of O
STAT1 O
, O
specifically O
the O
SH2 O
domain O
( O
aa O
577 O
to O
684 O
) O
, O
is O
required O
for O
the O
interaction O
of O
HCV O
core O
with O
STAT1 O
. O

The O
recent O
demonstration O
that O
the O
NS5A O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
an O
unconventional O
zinc O
- O
binding O
site O
with O
the O
format O
Cx O
( O
17 O
) O
CxCx O
( O
20 O
) O
C O
and O
the O
presence O
of O
a O
similar O
sequence O
element O
in O
the O
NS5A O
proteins O
of O
members O
of O
the O
Pestivirus O
genus O
has O
led O
to O
the O
hypothesis O
that O
the O
NS5A O
protein O
of O
the O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
is O
a O
zinc O
- O
binding O
protein O
. O

The O
recently O
determined O
crystal O
structure O
of O
the O
N O
- O
terminal O
zinc O
- O
binding O
domain O
of O
the O
HCV O
NS5A O
protein O
, O
combined O
with O
secondary O
structure O
predictions O
of O
the O
region O
surrounding O
the O
mapped O
BVDV O
zinc O
- O
binding O
region O
, O
indicates O
that O
the O
BVDV O
zinc O
- O
binding O
motif O
fits O
the O
general O
template O
Cx O
( O
22 O
) O
CxCx O
( O
24 O
) O
C O
and O
likely O
comprises O
a O
three O
- O
stranded O
antiparallel O
beta O
- O
sheet O
fold O
. O

We O
have O
examined O
the O
entry O
process O
of O
feline B
calicivirus I
( I
FCV I
) I
. O

The O
interferon B
( I
IFN I
) I
system O
, O
including O
various O
IFNs O
and O
IFN O
- O
inducible O
gene O
products O
, O
is O
well O
known O
for O
its O
potent O
innate O
immunity O
against O
wide O
- O
range O
viruses O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
through O
a O
regular O
IFN O
- O
alpha O
/ O
beta O
signal O
transduction O
pathway O
, O
IFN O
- O
alpha O
can O
significantly O
enhance O
the O
expression O
of O
apolipoprotein O
B O
mRNA O
- O
editing O
enzyme O
- O
catalytic O
polypeptide O
- O
like O
3G O
( O
APOBEC3G O
) O
in O
human O
primary O
resting O
but O
not O
activated O
CD4 O
T O
cells O
and O
the O
amounts O
of O
APOBEC3G O
associated O
with O
a O
low O
molecular O
mass O
. O

Interestingly O
, O
short O
- O
time O
treatments O
of O
newly O
infected O
resting O
CD4 O
T O
cells O
with O
IFN O
- O
alpha O
will O
significantly O
inactivate O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
at O
its O
early O
stage O
. O

We O
have O
generated O
replication O
- O
competent O
( O
VSV O
- O
C O
/ O
E1 O
/ O
E2 O
) O
and O
nonpropagating O
( O
VSV O
Delta O
G O
- O
C O
/ O
E1 O
/ O
E2 O
) O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
contiguously O
expressing O
the O
structural O
proteins O
of O
hepatitis O
C O
virus O
( O
HCV O
; O
core O
[ O
C O
] O
and O
glycoproteins O
E1 O
and O
E2 O
) O
and O
report O
on O
their O
immunogenicity O
in O
murine O
models O
. O

Both O
VSV O
- O
expressed O
HCV O
E1 O
- O
E2 O
glycoproteins O
were O
found O
to O
form O
noncovalently O
linked O
heterodimers O
and O
appeared O
to O
be O
correctly O
folded O
, O
as O
confirmed O
by O
coimmunoprecipitation O
analysis O
using O
conformationally O
sensitive O
anti O
- O
HCV O
- O
E2 O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

In O
addition O
, O
both O
virus O
types O
generated O
HCV O
C O
- O
, O
E1 O
- O
, O
or O
E2 O
- O
specific O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
CD8 O
( O
+ O
) O
T O
cells O
, O
as O
determined O
by O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
analysis O
. O

Mice O
immunized O
with O
VSVOG O
- O
C O
/ O
E1 O
/ O
E2 O
were O
also O
protected O
against O
the O
formation O
of O
tumors O
expressing O
HCV O
E2 O
( O
CT26 O
- O
hghE2t O
) O
and O
exhibited O
CT26 O
- O
hghE2t O
- O
specific O
IFN O
- O
gamma O
- O
producing O
and O
E2 O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
activity O
. O

Replication O
- O
competent O
retrovirus O
vectors O
based O
on O
murine B
leukemia I
virus I
( I
MLV I
) I
have O
been O
shown O
to O
effectively O
transfer O
therapeutic O
genes O
over O
multiple O
serial O
infections O
in O
cell O
culture O
and O
through O
solid O
tumors O
in O
vivo O
with O
a O
high O
degree O
of O
genomic O
stability O
. O

In O
this O
study O
, O
we O
used O
the O
promiscuous O
murine O
cytomegalovirus O
promoter O
, O
a O
chimeric O
regulatory O
sequence O
consisting O
of O
the O
hepatitis O
B O
virus O
enhancer B
II I
and I
the I
human I
alpha I
1 I
- I
antitrypsin I
( I
EII I
- I
Pa1AT I
) I
promoter O
, O
and O
a O
synthetic O
regulatory O
sequence O
consisting O
of O
a O
series O
of O
T O
- O
cell O
factor O
binding O
sites O
named O
the O
CTP4 O
promoter O
to O
generate O
replicating O
MLV O
vectors O
, O
whereby O
the O
last O
two O
are O
transcriptionally O
restricted O
to O
liver O
- O
and O
beta O
- O
catenin O
/ O
T O
- O
cell O
factor O
- O
deregulated O
cells O
, O
respectively O
. O

The O
lack O
of O
an O
efficient O
system O
to O
produce O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
has O
impeded O
the O
analysis O
of O
the O
HCV O
life O
cycle O
. O

Recently O
, O
we O
along O
with O
others O
demonstrated O
that O
transfection O
of O
Huh7 O
hepatoma O
cells O
with O
a O
novel O
HCV O
isolate O
( O
JFH1 O
) O
yields O
infectious O
viruses O
. O

To O
expand O
the O
scope O
of O
the O
system O
, O
we O
created O
two O
chimeric O
JFH1 O
luciferase O
reporter O
viruses O
with O
structural O
proteins O
from O
the O
Con1 O
( O
genotype O
1b O
) O
and O
J6CF O
( O
genotype O
2a O
) O
strains O
. O

Infection O
by O
hepatitis B
A I
virus I
( I
HAV I
) I
can O
cause O
acute O
hepatitis O
and O
, O
rarely O
, O
fulminant O
liver O
failure O
, O
in O
particular O
in O
patients O
chronically O
infected O
with O
hepatitis O
C O
virus O
. O

Based O
on O
our O
previous O
observation O
that O
small B
interfering I
RNAs I
( I
siRNAs I
) I
can O
silence O
translation O
and O
replication O
of O
the O
firefly O
luciferase O
- O
encoding O
HAV O
replicon O
, O
we O
now O
exploited O
this O
technology O
to O
demonstrate O
the O
effect O
of O
siRNAs O
on O
viral O
infection O
in O
Huh O
- O
7 O
cells O
. O

In O
most O
instances O
, O
multiple O
applications O
of O
a O
single O
siRNA O
led O
to O
the O
emergence O
of O
viral O
escape O
mutants O
with O
mutated O
target O
sites O
that O
rendered O
these O
genomes O
resistant O
to O
RNA B
interference I
( I
RNAi I
) I
. O

Hepatitis O
E O
virus O
replicons O
containing O
the O
neomycin O
resistance O
gene O
expressed O
from O
open B
reading I
frames I
( I
ORFs I
) I
2 O
and O
3 O
were O
transfected O
into O
Huh O
- O
7 O
cells O
, O
and O
stable O
cell O
lines O
containing O
functional O
replicons O
were O
selected O
by O
constant O
exposure O
to O
G418 O
sulfate O
. O

The O
RNA O
replication O
complexes O
of O
mammalian O
positive O
- O
stranded O
RNA O
viruses O
are O
generally O
associated O
with O
( O
modified O
) O
intracellular O
membranes O
, O
a O
feature O
thought O
to O
be O
important O
for O
creating O
an O
environment O
suitable O
for O
viral O
RNA O
synthesis O
, O
recruitment O
of O
host O
components O
, O
and O
possibly O
evasion O
of O
host O
defense O
mechanisms O
. O

Here O
, O
using O
a O
panel O
of O
replicase O
- O
specific O
antisera O
, O
we O
have O
analyzed O
the O
earlier O
stages O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
infection O
in O
Vero O
E6 O
cells O
, O
in O
particular O
focusing O
on O
the O
subcellular O
localization O
of O
the O
replicase O
and O
the O
ultrastructure O
of O
the O
associated O
membranes O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS4B O
protein O
induces O
a O
specialized O
membrane O
structure O
which O
may O
serve O
as O
the O
replication O
platform O
for O
HCV O
RNA O
replication O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
NS4B O
has O
lipid O
modifications O
( O
palmitoylation O
) O
on O
two O
cysteine O
residues O
( O
cysteines O
257 O
and O
261 O
) O
at O
the O
C O
- O
terminal O
end O
. O

Multiple O
normucleoside O
inhibitor O
binding O
sites O
have O
been O
identified O
within O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
polymerase O
, O
including O
in O
the O
palm O
and O
thumb O
domains O
. O

After O
a O
single O
treatment O
with O
a O
thumb O
site O
inhibitor O
( O
thiophene O
- O
2 O
- O
carboxylic O
acid O
NNI O
- O
1 O
) O
, O
resistant O
HCV O
replicon O
variants O
emerged O
that O
contained O
mutations O
at O
residues O
Leu419 O
, O
Met423 O
, O
and O
Ile482 O
in O
the O
polymerase O
thumb O
domain O
. O

Binding O
studies O
using O
wild B
- I
type I
( I
WT I
) I
and O
mutant O
enzymes O
and O
structure O
- O
based O
modeling O
showed O
that O
the O
mechanism O
of O
resistance O
is O
through O
the O
reduced O
binding O
of O
the O
inhibitor O
to O
the O
mutant O
enzymes O
. O

Epidemiological O
and O
phylogenetic O
studies O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
identified O
six O
major O
HCV O
genotypes O
and O
have O
attempted O
to O
characterize O
their O
origin O
and O
spread O
worldwide O
. O

The O
3 B
' I
nontranslated I
region I
( I
NTR I
) I
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
is O
highly O
conserved O
and O
contains O
specific O
cis O
- O
acting O
RNA O
motifs O
that O
are O
essential O
in O
directing O
the O
viral O
replication O
machinery O
to O
initiate O
at O
the O
correct O
3 O
' O
end O
of O
the O
viral O
genome O
. O

Furthermore O
, O
we O
found O
several O
genomes O
in O
these O
replicon O
colonies O
that O
contained O
a O
poly O
( O
A O
) O
tail O
and O
a O
short O
linker O
sequence O
preceding O
the O
poly O
( O
A O
) O
tail O
. O

After O
recloning O
and O
subsequent O
passage O
in O
Huh O
- O
7 O
cells O
, O
these O
poly O
( O
A O
) O
tails O
persisted O
and O
varied O
in O
length O
. O

The O
possible O
terminal O
repair O
mechanisms O
, O
including O
roles O
for O
the O
poly O
( O
A O
) O
tail O
addition O
, O
are O
discussed O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
is O
a O
multifunctional O
viral O
gene O
product O
that O
encapsidates O
the O
RNA O
genome O
and O
also O
plays O
some O
as O
yet O
not O
fully O
defined O
role O
in O
viral O
RNA O
replication O
and O
/ O
or O
transcription O
. O

Previous O
studies O
suggested O
that O
the O
negatively O
charged O
residues O
are O
involved O
in O
virus O
assembly O
by O
mediating O
interaction O
between O
the O
membrane B
( I
M I
) I
protein O
carboxy O
tail O
and O
nucleocapsids O
. O

We O
have O
previously O
shown O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
modulates O
multiple O
cellular O
processes O
, O
including O
those O
that O
inhibit O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
apoptosis O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
signaling O
mechanism O
for O
inhibition O
of O
TNF O
- O
alpha O
- O
mediated O
apoptosis O
in O
human O
hepatoma O
( O
HepG2 O
) O
cells O
expressing O
core O
protein O
alone O
or O
in O
context O
with O
other O
HCV O
proteins O
. O

Activation O
of O
caspase O
- O
3 O
and O
the O
cleavage O
of O
DNA O
repair O
enzyme O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
were O
inhibited O
upon O
TNF O
- O
alpha O
exposure O
in O
HCV O
core O
protein O
- O
expressing O
HepG2 O
cells O
. O

In O
vivo O
protein O
- O
protein O
interaction O
studies O
displayed O
an O
association O
between O
TNF B
receptor I
1 I
( I
TNFR1 I
) I
and O
TNFR1 B
- I
associated I
death I
domain I
protein I
( I
TRADD I
) I
, O
suggesting O
that O
the O
core O
protein O
does O
not O
perturb O
this O
interaction O
. O

A O
coimmunoprecipitation O
assay O
also O
suggested O
that O
HCV O
core O
protein O
does O
not O
interfere O
with O
the O
TRADD B
- I
Fas I
- I
associated I
death I
domain I
protein I
( I
FADD I
) I
- O
procaspase O
- O
8 O
interaction O
. O

Further O
studies O
indicated O
that O
HCV O
core O
protein O
expression O
inhibits O
caspase O
- O
8 O
activation O
by O
sustaining O
the O
expression O
of O
cellular O
FLICE O
( O
FADD O
- O
like O
interleukin O
- O
1 O
beta O
- O
converting O
enzyme O
) O
- O
like O
inhibitory O
protein O
( O
c O
- O
FLIP O
) O
. O

Recently O
, O
a O
production O
system O
for O
infectious O
particles O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
utilizing O
the O
genotype O
2a O
JFH1 O
strain O
has O
been O
developed O
. O

Cyclosporine B
( I
CsA I
) I
has O
a O
suppressive O
effect O
on O
HCV O
replication O
. O

Replication O
of O
JFH1 O
did O
not O
require O
the O
cellular O
replication O
cofactor O
, O
cyclophilin B
B I
( I
CyPB I
) I
. O

A O
highly O
neurovirulent O
murine O
coronavirus O
JHMV O
( O
wild O
- O
type O
[ O
wt O
] O
JHMV O
) O
is O
known O
to O
spread O
from O
cells O
infected O
via O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
receptor I
( I
MHVR I
) I
to O
cells O
without O
MHVR O
( O
MHVR O
- O
independent O
infection O
) O
, O
whereas O
it O
mutant O
virus O
isolated O
front O
wt O
JHMV O
, O
srr7 O
, O
spread O
only O
in O
in O
MVHR O
- O
dependent O
fashion O
. O

The O
CD81 O
tetraspanin O
was O
first O
identified O
as O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
receptor O
by O
its O
ability O
to O
bind O
the O
soluble B
ectodomain I
of I
envelope I
glycoprotein I
E2 I
( I
sE2 I
) I
. O

Here O
we O
present O
further O
evidence O
that O
putative O
human O
hepatocyte O
- O
specific O
factors O
act O
in O
concert O
with O
CD81 O
to O
mediate O
sE2 O
binding O
and O
HCV B
pseudoparticle I
( I
HCVpp I
) I
entry O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
involves O
processing O
and O
accumulation O
of O
three O
RNA O
species O
: O
the O
genome O
, O
its O
exact O
complement O
( O
the O
antigenome O
) O
, O
and O
a O
polyadenylated O
mRNA O
that O
acts O
as O
a O
template O
for O
the O
small O
delta B
antigen I
( I
delta I
Ag I
) I
, O
the O
only O
protein O
of O
HDV O
and O
essential O
for O
genome O
replication O
. O

In O
contrast O
, O
no O
inhibition O
was O
observed O
with O
L O
- O
FMAU O
( O
2 O
' O
- O
fluoro O
- O
5 O
- O
methyl O
- O
beta O
- O
L O
- O
arabinofuranosyl O
- O
uridine O
) O
, O
alpha O
interferon O
, O
or O
pegylated O
alpha O
interferon O
. O

After O
modifications O
to O
the O
experimental O
system O
, O
it O
was O
also O
possible O
to O
examine O
the O
effects O
of O
three O
known O
host O
RNA O
polymerase O
inhibitors O
on O
HDV O
genome O
replication O
: O
amanitin O
, O
5 O
, O
6 O
- O
dichloro O
- O
1 O
- O
beta O
- O
D O
) O
- O
ribofuranosylbenzimidazole O
( O
DRB O
) O
, O
and O
actinomycin O
. O

Enteroviruses B
( I
EVs I
) I
overcome O
their O
host O
cells O
by O
usurping O
the O
translation O
machinery O
to O
benefit O
viral O
gene O
expression O
. O

This O
is O
accomplished O
through O
alternative O
translation O
initiation O
in O
a O
cap O
- O
independent O
manner O
at O
the O
viral O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
. O

We O
previously O
reported O
that O
nucleolin O
, O
a O
representative O
nucleolar O
marker O
, O
interacts O
with O
nonstructural B
protein I
5B I
( I
NS5B I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
through O
two O
independent O
regions O
of O
NS5B O
, O
amino O
acids O
208 O
to O
214 O
and O
500 O
to O
506 O
. O

We O
constructed O
one O
alanine O
- O
substituted O
clustered B
mutant I
( I
CM I
) I
replicon O
, O
in O
which O
all O
the O
amino O
acids O
in O
this O
region O
were O
changed O
to O
alanine O
, O
as O
well O
as O
seven O
different O
point B
mutant I
( I
PM I
) I
replicons O
, O
each O
of O
which O
harbored O
an O
alanine O
substitution O
at O
one O
of O
the O
amino O
acids O
in O
the O
region O
. O

To O
gain O
further O
insight O
into O
the O
role O
of O
nucleolin O
in O
HCV O
replication O
, O
we O
utilized O
the O
small B
interfering I
RNA I
( I
siRNA I
) I
technique O
to O
investigate O
the O
knockdown O
effect O
of O
nucleolin O
on O
HCV O
replication O
. O

These O
are O
processed O
primarily O
by O
the O
chymotrypsin O
- O
like O
main O
proteinases O
( O
M O
( O
pro O
) O
s O
) O
. O

So O
far O
, O
M O
( O
pro O
) O
s O
have O
been O
studied O
only O
for O
corona O
- O
, O
arteri O
- O
, O
and O
roniviruses O
. O

Comparative O
sequence O
analysis O
of O
polyprotein O
la O
of O
equine B
torovirus I
( I
EToV I
) I
strain O
Berne O
, O
identified O
a O
serine O
proteinase O
domain O
, O
flanked O
by O
hydrophobic O
regions O
. O

N O
- O
terminal O
sequence O
analysis O
of O
cleavage O
products O
tentatively O
identified O
FxxQ O
down O
arrow O
( O
S O
, O
A O
) O
as O
the O
substrate O
consensus O
sequence O
. O

With O
respect O
to O
substrate O
specificity O
, O
the O
EToV O
M O
- O
pro O
resembles O
its O
coronavirus O
homologue O
in O
its O
preference O
for O
P1 O
- O
Gln O
, O
but O
its O
substrate O
- O
binding O
subsite O
, O
SI O
, O
more O
closely O
resembles O
that O
of O
arteri O
- O
and O
ronivirus O
M O
( O
pro O
) O
s O
, O
which O
prefer O
P1 O
- O
Glu O
. O

Surprisingly O
, O
in O
contrast O
to O
the O
M O
( O
pro O
) O
s O
of O
corona O
- O
and O
roniviruses O
, O
but O
like O
that O
of O
arterivirus O
, O
the O
torovirus O
M O
- O
pro O
uses O
serine O
instead O
of O
cysteine O
as O
its O
principal O
nucleophile O
. O

Under O
the O
premise O
that O
the O
M O
( O
pro O
) O
s O
of O
corona O
- O
and O
toroviruses O
are O
more O
closely O
related O
to O
each O
other O
than O
to O
those O
of O
arteri O
- O
and O
roniviruses O
, O
the O
transition O
from O
serine O
- O
to O
cysteine O
- O
based O
proteolytic O
catalysis O
( O
or O
vice O
versa O
) O
must O
have O
happened O
more O
than O
once O
in O
the O
course O
of O
nidovirus O
evolution O
. O

Coronaviruses O
are O
positive O
- O
strand O
, O
RNA O
- O
dependent O
RNA O
polymerase O
- O
utilizing O
viruses O
that O
require O
a O
polymerase O
template O
switch O
, O
characterized O
as O
discontinuous O
transcription O
, O
to O
place O
a O
5 O
' O
- O
terminal O
genomic O
leader O
onto O
subgenomic B
mRNAs I
( I
sgmRNAs I
) I
. O

The O
usually O
precise O
switch O
is O
thought O
to O
occur O
during O
the O
synthesis O
of O
negative O
- O
strand O
templates O
for O
sgmRNA O
production O
and O
to O
be O
directed O
by O
heptameric O
core O
donor O
sequences O
within O
the O
genome O
that O
match O
an O
acceptor O
core O
( O
UCUAAAC O
in O
the O
case O
of O
bovine O
coronavirus O
) O
near O
the O
3 O
' O
end O
of O
the O
5 O
' O
- O
terminal O
genomic O
leader O
. O

Here O
it O
is O
shown O
that O
a O
22 O
- O
nucleotide B
( I
nt I
) I
donor O
sequence O
engineered O
into O
a O
packageable O
bovine O
coronavirus O
Defective B
interfering I
( I
DI I
) I
RNA O
and O
made O
to O
match O
a O
sequence O
within O
the O
65 O
- O
nt O
virus O
genomic O
leader O
caused O
a O
template O
switch O
yielding O
an O
sgmRNA O
with O
only O
a O
33 O
- O
nt O
minileader O
. O

By O
changing O
the O
donor O
sequence O
, O
acceptor O
sites O
between O
genomic O
nt O
33 O
and O
97 O
( O
identical O
between O
the O
DI O
RNA O
and O
the O
viral O
genome O
) O
could O
be O
used O
to O
generate O
sgmRNAs O
detectable O
by O
Northern O
analysis O
( O
- O
2 O
to O
32 O
molecules O
per O
cell O
) O
by O
24 O
h O
postinfection O
. O

These O
results O
show O
that O
crossover O
acceptor O
sites O
for O
discontinuous O
transcription O
( O
i O
) O
need O
not O
include O
the O
UCUAAAC O
core O
and O
( O
ii O
) O
rest O
within O
a O
surprisingly O
wide O
5 O
' O
- O
proximal O
hotspot O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
characterize O
markers O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
and O
replication O
in O
liver O
biopsy O
specimens O
obtained O
from O
65 O
genotype O
1 O
- O
infected O
subjects O
, O
including O
31 O
who O
were O
coinfected O
with O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
, O
and O
to O
analyze O
associations O
between O
intrahepatic O
viral O
markers O
and O
hepatitis O
C O
disease O
severity O
. O

The O
percentages O
of O
liver O
cells O
harboring O
HCV O
genomes O
( O
% O
G O
) O
and O
replicative O
- O
intermediate O
RNAs O
( O
% O
RI O
) O
were O
evaluated O
using O
strand O
- O
specific O
in O
situ O
hybridization O
, O
while O
HCV O
core O
and O
NS3 O
antigens O
were O
assessed O
by O
immunocytochemistry O
. O

NS3 O
antigen O
( O
but O
not O
core O
) O
was O
more O
frequently O
detected O
in O
HCV O
RI O
- O
positive O
versus O
RI O
- O
negative O
specimens O
( O
P O
= O
0 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
circulates O
in O
the O
blood O
of O
persistently O
infected O
patients O
in O
lipoviroparticles B
( I
LVPs I
) I
, O
which O
are O
heterogeneous O
in O
density O
and O
associated O
with O
host O
lipoproteins O
and O
antibodies O
. O

Passive O
immunotherapy O
is O
potentially O
effective O
in O
preventing O
reinfection O
of O
liver O
grafts O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
associated O
liver O
transplant O
patients O
. O

Two O
human B
monoclonal I
antibodies I
( I
HumAbs I
) I
against O
the O
E2 O
envelope O
protein O
of O
HCV O
were O
developed O
and O
tested O
for O
the O
ability O
to O
neutralize O
the O
virus O
and O
prevent O
human O
liver O
infection O
. O

Both O
HumAbs O
are O
immunoglobulin O
G1 O
and O
have O
affinity O
constants O
to O
recombinant O
E2 O
constructs O
in O
the O
range O
of O
10 O
( O
- O
10 O
) O
M O
. O

Due O
to O
the O
recent O
development O
of O
a O
cell O
culture O
model O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
be O
efficiently O
propagated O
in O
cell O
culture O
. O

We O
have O
previously O
shown O
that O
West B
Nile I
virus I
NY I
( I
WNV I
- I
NY I
) I
delays O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
a O
transcription O
factor O
critical O
to O
the O
initiation O
of O
the O
antiviral O
response O
. O

To O
better O
understand O
this O
process O
, O
we O
assessed O
the O
role O
of O
the O
pathogen B
recognition I
receptor I
( I
PRR I
) I
retinoic I
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
in O
sensing O
WNV O
- O
NY O
infection O
. O

RIG O
- O
I O
null O
mouse B
embryo I
fibroblasts I
( I
MEFs I
) I
retained O
the O
ability O
to O
respond O
to O
WNV O
- O
NY O
infection O
; O
however O
, O
the O
onset O
of O
the O
host O
response O
was O
delayed O
compared O
to O
wild B
- I
type I
( I
WT I
) I
MEFs O
. O

An O
intimate O
relationship O
between O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
and O
the O
physiological O
state O
of O
the O
host O
liver O
cells O
has O
been O
reported O
. O

Murine O
hepatitis O
coronavirus O
( O
MHV O
) O
- O
A59 O
infection O
depends O
on O
the O
interaction O
of O
its O
spike B
( I
S I
) I
protein O
with O
the O
cellular O
receptor O
mCEACAM1a O
present O
on O
murine O
cells O
. O

The O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
porcine B
teschovirus I
I I
( I
PTV I
- I
1 I
) I
, O
a O
member O
of O
the O
Picornaviridae O
family O
, O
is O
quite O
distinct O
from O
other O
well O
- O
characterized O
picornavirus O
IRES O
elements O
, O
but O
it O
displays O
functional O
similarities O
to O
the O
IRES O
from O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
member O
of O
the O
Flaviviridae O
family O
. O

Coronavirus O
spike B
( I
S I
) I
proteins O
are O
pallmitoyllated O
at O
several O
cysteine O
residues O
clustered O
near O
their O
transmembrane O
- O
spanning O
domains O
. O

This O
is O
achieved O
by O
cellular O
palmitoyl B
acyltransferases I
( I
PATs I
) I
, O
which O
can O
modify O
newly O
synthesized O
S O
proteins O
before O
they O
are O
assembled O
into O
virion O
envelopes O
at O
the O
intermediate O
compartment O
of O
the O
exocytic O
pathway O
. O

To O
address O
the O
importance O
of O
these O
fatty O
acylations O
to O
coronavirus O
infection O
, O
we O
exposed O
infected O
cells O
to O
2 B
- I
bromopalmitate I
( I
2 I
- I
BP I
) I
, O
a O
specific O
PAT O
inhibitor O
. O

2 O
- O
BP O
effected O
only O
two O
- O
to O
fivefold O
reductions O
in O
S O
palmitoylation O
, O
yet O
this O
correlated O
with O
reduced O
S O
complexing O
with O
virion O
membrane B
( I
M I
) I
proteins O
and O
consequent O
exclusion O
of O
S O
from O
virions O
. O

Notably O
, O
some O
mutations O
( O
C1347F O
and O
C1348S O
) O
did O
not O
interfere O
with O
S O
incorporation O
into O
virions O
, O
indicating O
that O
only O
a O
subset O
of O
the O
cysteine O
- O
rich O
region O
provides O
the O
essential O
S O
- O
assembly O
functions O
. O

The O
spike B
protein I
( I
S I
) I
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
is O
responsible O
for O
receptor O
binding O
and O
membrane O
fusion O
. O

SARS B
- I
CoV I
S I
- I
pseudotyped I
retrovirus I
( I
SARSpp I
) I
was O
used O
to O
measure O
S O
- O
mediated O
infectivity O
. O

S O
- O
VSV O
- O
( O
Cyt O
) O
, O
an O
S O
chimera O
with O
a O
cytoplasmic O
tail O
derived O
from O
vesicular B
stomatitis I
virus I
G I
protein I
( I
VSV I
- I
G I
) I
, O
and O
SMHV O
- O
TMDcyt O
, O
an O
S O
chimera O
with O
the O
cytoplasmic O
and O
transmembrane O
domains O
of O
mouse O
hepatitis O
virus O
, O
displayed O
wild O
- O
type O
- O
like O
activity O
in O
both O
assays O
. O

Human O
wild B
- I
type I
( I
wt I
) I
hepatitis I
A I
virus I
( I
HAV I
) I
, O
the O
causative O
agent O
of O
acute O
hepatitis O
, O
barely O
grows O
in O
cell O
culture O
and O
in O
the O
process O
accumulates O
attenuating O
and O
cell O
culture O
- O
adapting O
mutations O
. O

Success O
in O
resolving O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
been O
correlated O
to O
vigorous O
, O
multispecific O
, O
and O
sustained O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
in O
humans O
and O
chimpanzees O
. O

To O
evaluate O
the O
less O
prevalent O
adenovirus O
serotype O
6 O
( O
Ad6 O
) O
as O
an O
alternative O
vector O
for O
and O
HCV O
vaccine O
development O
, O
we O
have O
generated O
serotype O
5 O
and O
6 O
adenoviral O
vectors O
directing O
expression O
of O
the O
nonstructural O
region O
of O
HCV O
( O
MRKAd5 O
- O
NSmut O
and O
MRKAd6 O
- O
NSmut O
) O
. O

C O
- O
terminal O
processing O
of O
the O
core O
protein O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
was O
blocked O
by O
the O
inhibitor O
( O
Z O
- O
LL O
) O
( O
2 O
) O
- O
ketone O
, O
which O
is O
specific O
for O
signal B
peptide I
peptidase I
( I
SPP I
) I
. O

The O
same O
effect O
was O
obtained O
by O
overexpression O
of O
the O
dominant O
- O
negative O
SPP O
D O
( O
265 O
) O
A O
mutant O
. O

The O
presence O
of O
( O
Z O
- O
LL O
) O
( O
2 O
) O
- O
ketone O
reduced O
the O
viability O
of O
CSFV O
almost O
100 O
- O
fold O
in O
a O
concentration O
- O
dependent O
manner O
. O

Reduction O
of O
virus O
viability O
was O
also O
observed O
in O
infection O
experiments O
using O
a O
cell O
line O
that O
inducibly O
expressed O
SPP O
D O
( O
265 O
) O
A O
. O

The O
C O
terminus O
of O
CSFV O
core O
protein O
is O
alanine O
( O
255 O
) O
, O
and O
is O
located O
in O
the O
hydrophobic O
center O
of O
the O
signal O
peptide O
. O

A O
previous O
study O
demonstrated O
that O
infection O
of O
rat O
oligodendrocytes O
by O
mouse B
hepatitis I
virus I
( I
MHV I
) I
resulted O
in O
apoptosis O
, O
which O
is O
caspase O
dependent O
( O
Y O
. O

Mutations O
were O
introduced O
into O
the O
NS3 O
helicase O
region O
of O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
Con1 O
subgenomic O
replicon O
to O
ascertain O
the O
role O
of O
the O
helicase O
in O
viral O
replication O
. O

One O
new O
replicon O
lacked O
two O
- O
thirds O
of O
the O
NS3 O
helicase O
( O
Delta O
hel O
) O
, O
and O
six O
others O
contained O
one O
of O
the O
following O
six O
amino O
acid O
substitutions O
in O
NS3 O
: O
R393A O
, O
F438A O
, O
T4501 O
, O
E493K O
, O
W501A O
, O
and O
W501F O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genome O
' O
s O
3 O
' O
untranslated O
region O
contains O
cis O
- O
acting O
sequences O
necessary O
for O
replication O
. O

Previous O
work O
in O
our O
laboratory O
has O
identified O
four O
proteins O
which O
form O
ribonucleoprotein O
complexes O
with O
the O
3 O
' O
- O
terminal O
42 O
nucleotides O
[ O
3 O
' O
( O
+ O
) O
42 O
] O
of O
the O
MHV O
genome O
. O

Defective B
interfering I
( I
DI I
) I
RNA O
replication O
assays O
have O
demonstrated O
a O
role O
for O
the O
3 O
' O
( O
+ O
) O
42 O
host O
protein O
binding O
element O
in O
the O
MHV O
life O
cycle O
. O

DI O
RNA O
replication O
assays O
demonstrated O
that O
mutations O
in O
the O
3 O
' O
( O
+ O
) O
42 O
host O
protein O
binding O
element O
had O
a O
deleterious O
effect O
on O
the O
accumulation O
of O
DI O
RNA O
. O

Dengue B
virus I
type I
4 I
( I
DENV I
- I
4 I
) I
was O
first O
reported O
in O
the O
Americas O
in O
1981 O
, O
where O
it O
caused O
epidemics O
of O
dengue O
fever O
throughout O
the O
region O
. O

In O
the O
same O
year O
, O
the O
region O
' O
s O
first O
epidemic O
of O
dengue O
hemorrhagic O
fever O
was O
reported O
, O
caused O
by O
an O
Asian O
strain O
of O
dengue B
virus I
type I
2 I
( I
DENV I
- I
2 I
) I
that O
was O
distinct O
from O
the O
American O
subtype O
circulating O
previously O
. O

During O
the O
construction O
of O
the O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
full O
- O
length O
cDNA O
clone O
, O
a O
point O
mutation O
at O
position O
637 O
that O
was O
present O
in O
the O
defective O
minigenome O
DI O
- O
C O
was O
maintained O
as O
a O
genetic O
marker O
. O

This O
position O
is O
predicted O
to O
map O
in O
the O
N O
- O
terminal O
polyprotein O
papain B
- I
like I
proteinase I
( I
PLP I
- I
1 I
) I
cleavage O
site O
at O
the O
p9 O
/ O
p87 O
junction O
. O

Replacement O
of O
G O
- O
637 O
by O
A O
, O
which O
causes O
a O
drastic O
amino O
acid O
change O
( O
Gly O
to O
Asp O
) O
at O
position O
108 O
, O
affected O
PLP O
- O
1 O
- O
mediated O
cleavage O
in O
vitro O
. O

Group O
2 O
coronaviruses O
encode O
an O
accessory O
envelope O
glycoprotein O
species O
, O
the O
hemagglutinin B
esterase I
( I
HE I
) I
, O
which O
possesses O
sialate O
- O
O O
- O
acetylesterase O
activity O
and O
which O
, O
presumably O
, O
promotes O
virus O
spread O
and O
entry O
in O
vivo O
by O
facilitating O
reversible O
virion O
attachment O
to O
O O
- O
acetyllated O
siallic O
acids O
. O

While O
HE O
may O
provide O
a O
strong O
selective O
advantage O
during O
natural O
infection O
, O
many O
laboratory O
strains O
of O
mouse B
hepatitis I
virus I
( I
MRV I
) I
fail O
to O
produce O
the O
protein O
. O

By O
using O
targeted O
RNA O
recombination O
, O
we O
generated O
isogenic O
recombinant O
MHVs O
which O
differ O
exclusively O
in O
their O
expression O
of O
HE O
and O
produce O
either O
the O
wild O
- O
type O
protein O
( O
HE O
+ O
) O
, O
an O
enzymatically O
inactive O
HE B
protein I
( I
HE0 I
) I
, O
or O
no O
HE O
at O
all O
. O

Sexual O
partners O
of O
patients O
infected O
with O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
often O
have O
detectable O
HCV O
- O
specific O
T O
- O
cell O
responses O
in O
the O
absence O
of O
seroconversion O
, O
suggesting O
unapparent O
, O
spontaneously O
resolving O
infection O
. O

To O
determine O
whether O
differences O
in O
the O
evolutionary O
potential O
of O
bottlenecked O
inoculum O
may O
explain O
the O
low O
rate O
of O
HCV O
persistence O
after O
sexual O
exposure O
, O
we O
have O
investigated O
changes O
in O
the O
entire O
HCV O
nonstructural B
3 I
( I
NS3 I
) I
gene O
over O
time O
in O
a O
chronic O
carrier O
and O
compared O
his O
viral O
quasispecies O
with O
that O
of O
the O
acute O
- O
phase O
isolate O
of O
his O
sexual O
partner O
, O
who O
developed O
acute O
resolving O
hepatitis O
C O
. O

5 O
x O
10 O
( O
- O
3 O
) O
mutations O
per O
site O
per O
year O
, O
with O
small O
intersample O
fluctuations O
related O
to O
changes O
in O
environmental O
conditions O
. O

Replication O
of O
the O
genomic O
RNA O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
is O
mediated O
by O
replicase O
polyproteins O
that O
are O
processed O
by O
two O
viral O
proteases O
, O
papain B
- I
like I
protease I
( I
PLpro I
) I
and O
3C B
- I
like I
protease I
( I
3CLpro I
) I
. O

We O
performed O
bioinformatics O
analysis O
on O
16 O
papain O
- O
like O
protease O
domains O
from O
nine O
different O
coronaviruses O
and O
identified O
a O
putative O
catalytic O
triad O
( O
Cys1651 O
- O
His1812 O
- O
Asp1826 O
) O
and O
zinc O
- O
binding O
site O
. O

SARS O
CoV O
- O
PLpro O
hydrolyzed O
both O
diubiquitin O
and O
ubiquitin O
- O
7 O
- O
amino O
- O
4 O
- O
methylcoumarin O
( O
AMC O
) O
substrates O
, O
and O
hydrolysis O
of O
ubiquitin O
- O
AMC O
is O
approximately O
180 O
- O
fold O
more O
efficient O
than O
hydrolysis O
of O
a O
peptide O
substrate O
that O
mimics O
the O
PLpro O
replicase O
recognition O
sequence O
. O

The O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
infects O
murine O
cells O
by O
binding O
of O
its O
spike B
( I
S I
) I
protein O
to O
murine O
CEACAM1a O
. O

The O
N O
- O
terminal O
part O
of O
this O
cellular O
receptor O
( O
soR O
) O
is O
sufficient O
for O
S O
binding O
and O
for O
subsequent O
induction O
of O
the O
conformational O
changes O
required O
for O
virus O
- O
cell O
membrane O
fusion O
. O

To O
this O
end O
, O
the O
soR O
domain O
was O
coupled O
to O
single O
- O
chain O
monoclonal O
antibody O
425 O
, O
which O
is O
directed O
against O
the O
human B
epidermal I
growth I
factor I
receptor I
( I
EGFR I
) I
, O
resulting O
in O
a O
bispecific O
adapter O
protein O
( O
soR O
- O
425 O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
disease O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
worldwide O
. O

One O
of O
these O
proteins O
, O
nonstructural B
protein I
3 I
( I
NS3 I
) I
, O
has O
serine O
protease O
and O
NTPase O
/ O
RNA O
helicase O
activity O
. O

Arginine O
467 O
in O
the O
helicase O
domain O
of O
NS3 O
( O
arginine O
1493 O
in O
the O
polyprotein O
) O
can O
be O
methylated O
by O
protein B
arginine I
methyltransferase I
1 I
( I
PRMT1 I
) I
. O

Furthermore O
, O
we O
found O
that O
PRMT1 O
activity O
itself O
is O
regulated O
by O
protein B
phosphatase I
2A I
( I
PP2A I
) I
. O

Interestingly O
, O
up O
- O
regulation O
of O
PP2A O
not O
only O
modulates O
the O
enzymatic O
activity O
of O
an O
important O
viral O
protein O
, O
NS3 O
helicase O
, O
but O
also O
interferes O
with O
the O
cellular O
defense O
against O
viruses O
by O
inhibiting O
interferon O
- O
induced O
signaling O
through O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
. O

T O
cells O
play O
an O
important O
role O
in O
the O
control O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Specifically O
, O
chronic O
core O
isolates O
bind O
to O
gC1qR O
more O
efficiently O
and O
inhibit O
T O
- O
cell O
proliferation O
as O
well O
as O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
more O
profoundly O
than O
resolved O
core O
isolates O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
emerged O
in O
2002 O
as O
an O
important O
cause O
of O
severe O
lower O
respiratory O
tract O
infection O
in O
humans O
, O
and O
in O
vitro O
models O
of O
the O
lung O
are O
needed O
to O
elucidate O
cellular O
targets O
and O
the O
consequences O
of O
viral O
infection O
. O

The O
SARS O
- O
CoV O
receptor O
, O
human B
angiotensin I
I I
- I
converting I
enzyme I
2 I
( I
hACE2 I
) I
, O
was O
detected O
in O
ciliated O
airway O
epithelial O
cells O
of O
human O
airway O
tissues O
derived O
from O
nasal O
or O
trachcobronchial O
regions O
, O
suggesting O
that O
SARS O
- O
CoV O
may O
infect O
the O
proximal O
airways O
. O

To O
assess O
infectivity O
in O
an O
in O
vitro O
model O
of O
human B
ciliated I
airway I
epithelia I
( I
HAE I
) I
derived O
from O
nasal O
and O
tracheobronchial O
airway O
regions O
, O
we O
generated O
recombinant O
SARS O
- O
CoV O
by O
deletion O
of O
open B
reading I
frame I
7a I
/ I
7b I
( I
ORF7a I
/ I
7b I
) I
and O
insertion O
of O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
, O
resulting O
in O
SARS O
- O
CoV O
GFP O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
p7 O
protein O
forms O
an O
amantadine O
- O
sensitive O
ion O
channel O
required O
for O
viral O
replication O
in O
chimpanzees O
, O
though O
its O
precise O
role O
in O
the O
life O
cycle O
of O
HCV O
is O
unknown O
. O

Immunolluorescence O
labeling O
of O
p7 O
at O
its O
C O
terminus O
revealed O
an O
endoplasmic B
reticulum I
( I
ER I
) I
localization O
independent O
of O
the O
presence O
of O
its O
signal O
peptide O
, O
whereas O
labeling O
the O
N O
terminus O
gave O
a O
mitochondrial O
- O
type O
distribution O
in O
brightly O
labeled O
cells O
. O

dengue B
virus I
( I
DEN I
) I
is O
the O
most O
prevalent O
cause O
of O
arthropod O
- O
borne O
viral O
illness O
in O
humans O
. O

We O
determined O
the O
influence O
of O
cellular O
growth O
state O
on O
DEN B
type I
2 I
( I
DEN2 I
) I
replication O
in O
mosquito O
and O
human O
cells O
, O
based O
on O
the O
hypothesis O
that O
manipulation O
of O
cellular O
growth O
state O
will O
facilitate O
identification O
of O
viral O
and O
cellular O
determinants O
of O
productive O
infection O
. O

When O
C6 O
/ O
36 O
cells O
were O
stalled O
in O
S O
- O
phase O
via O
a O
thymidine B
( I
THY I
) I
block O
, O
titers O
of O
low O
- O
passage O
DEN2 O
isolates O
and O
a O
high O
- O
passage O
strain O
, O
16681 O
, O
were O
increased O
approximately O
30 O
- O
fold O
and O
10 O
- O
fold O
, O
respectively O
. O

Previous O
studies O
have O
defined O
a O
novel O
cell O
culture O
system O
in O
which O
a O
modified O
RNA O
genome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
able O
to O
maintain O
a O
low O
level O
of O
continuous O
replication O
for O
at O
least O
I O
year O
, O
using O
a O
separate O
and O
limited O
DNA O
- O
directed O
source O
of O
mRNA O
for O
the O
essential O
small O
delta O
protein O
. O

The O
positive O
- O
stranded O
RNA O
genome O
of O
the O
coronaviruses O
is O
translated O
from O
ORF1 O
to O
yield O
polyproteins O
that O
are O
proteolytically O
processed O
into O
intermediate O
and O
mature O
nonstructural B
proteins I
( I
nsPs I
) I
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
and O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
polyproteins O
incorporate O
16 O
protein O
domains O
( O
nsps O
) O
, O
with O
nsp1 O
and O
nsp2 O
being O
the O
most O
variable O
among O
the O
coronaviruses O
and O
having O
no O
experimentally O
confirmed O
or O
predicted O
functions O
in O
replication O
. O

To O
determine O
if O
nsp2 O
is O
essential O
for O
viral O
replication O
, O
MHV O
and O
SARS O
- O
CoV O
genome O
RNA O
was O
generated O
with O
deletions O
of O
the O
nsp2 O
coding O
sequence O
( O
MHV O
Delta O
nsp2 O
and O
SARS O
Delta O
nsp2 O
, O
respectively O
) O
. O

5 O
to O
I O
log O
( O
10 O
) O
reductions O
in O
peak O
titers O
in O
single O
- O
cycle O
growth O
assays O
, O
as O
well O
as O
a O
reduction O
in O
viral O
RNA O
synthesis O
that O
was O
not O
specific O
for O
any O
positive O
- O
stranded O
RNA O
species O
. O

Borna B
disease I
virus I
( I
BDV I
) I
frequently O
causes O
meningoencephalitis O
and O
fatal O
neurological O
disease O
in O
young O
but O
not O
old O
mice O
of O
strain O
MRL O
. O

Rather O
, O
it O
is O
mediated O
by O
H O
- O
2 O
( O
k O
) O
- O
restricted O
antiviral O
CD8 O
T O
cells O
that O
recognize O
a O
peptide O
derived O
from O
the O
BDV O
nucleoprotein O
N O
. O

We O
report O
here O
that O
N O
- O
specific O
vaccination O
can O
protect O
wild O
- O
type O
MRL O
mice O
but O
not O
mutant O
MRL O
mice O
lacking O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
from O
persistent O
infection O
with O
BDV O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
encodes O
a O
large O
polyprotein O
; O
therefore O
, O
all O
viral O
proteins O
are O
produced O
in O
equimolar O
amounts O
regardless O
of O
their O
function O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
negative O
- O
strand O
RNA O
virus O
with O
intrinsic O
oncolytic O
specificity O
due O
to O
substantially O
attenuated O
antiviral O
responses O
in O
many O
tumors O
. O

We O
have O
recently O
reported O
that O
recombinant O
VSV O
vector O
can O
be O
used O
as O
an O
effective O
oncolytic O
agent O
to O
safely O
treat O
multifocal O
hepatocellular B
carcinoma I
( I
HCC I
) I
in O
the O
livers O
of O
immune O
- O
competent O
rats O
via O
hepatic O
artery O
infusion O
. O

When O
administered O
at O
doses O
above O
the O
maximum B
tolerated I
dose I
( I
MTD I
) I
, O
however O
, O
the O
animals O
suffered O
from O
neurotoxicity O
and O
/ O
or O
acute O
lethal O
hepatotoxicity O
. O

Since O
VSV O
is O
extremely O
sensitive O
to O
the O
antiviral O
actions O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
normal O
cells O
, O
we O
tested O
if O
prophylactic O
treatment O
with O
rat O
IFN O
- O
alpha O
would O
enhance O
VSV O
safety O
without O
compromising O
treatment O
efficacy O
in O
tumor O
- O
bearing O
rats O
. O

We O
found O
that O
VSV O
retained O
its O
replication O
potential O
in O
human O
and O
rat O
HCC O
cells O
after O
preincubation O
with O
relatively O
high O
doses O
of O
rat O
and O
human O
IFN O
- O
alpha O
in O
vitro O
, O
and O
its O
MTD O
in O
tumor O
- O
bearing O
rats O
treated O
systemically O
with O
rat O
IFN O
- O
alpha O
at O
66 O
IU O
/ O
g O
body B
weight I
( I
BW I
) I
, O
equivalent O
to O
a O
human O
IFN O
- O
alpha O
dose O
that O
is O
currently O
prescribed O
for O
patients O
with O
viral O
hepatitis O
, O
was O
elevated O
by O
more O
than O
1 O
/ O
2 O
log O
unit O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
member O
of O
the O
family O
Flaviviridae O
, O
is O
a O
major O
cause O
of O
chronic O
- O
liver O
disease O
. O

Patients O
are O
currently O
treated O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
that O
is O
given O
alone O
or O
in O
combination O
with O
ribavirin O
. O

However O
, O
three O
major O
differences O
exist O
: O
in O
HuH6 O
cells O
, O
viral O
replication O
is O
( O
i O
) O
independent O
from O
ongoing O
cell O
proliferation O
, O
( O
ii O
) O
less O
sensitive O
to O
certain O
antiviral O
compounds O
, O
and O
( O
iii O
) O
highly O
resistant O
to O
IFN O
- O
gamma O
. O

The O
latter O
is O
not O
due O
to O
a O
general O
defect O
in O
IFN O
signaling O
, O
as O
IFN O
- O
gamma O
induces O
the O
nuclear O
translocation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
, O
the O
enhanced O
transcription O
of O
several O
IFN O
- O
regulated O
genes O
, O
and O
the O
inhibition O
of O
unrelated O
viruses O
such O
as O
influenza O
A O
virus O
and O
Semliki O
Forest O
virus O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
chronically O
infects O
approximately O
170 O
million O
people O
worldwide O
, O
with O
an O
increased O
risk O
of O
developing O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

Stable O
cell O
lines O
robustly O
produce O
HCV O
virions O
with O
up O
to O
108 O
Copies O
of O
HCV O
viral O
RNA O
per O
milliliter B
( I
ml I
) I
of O
the O
culture O
medium O
. O

Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
cause O
clinically O
important O
persistent O
infections O
. O

We O
examined O
the O
frequency O
, O
phenotype O
, O
and O
function O
of O
peripheral O
blood O
CD3 O
( O
- O
) O
CD56 O
( O
+ O
) O
NK O
subsets O
in O
HIV O
( O
+ O
) O
and O
HCV O
( O
+ O
) O
patients O
and O
identified O
significantly O
reduced O
numbers O
of O
total O
NK O
cells O
and O
a O
striking O
shift O
in O
NK O
subsets O
, O
with O
a O
marked O
decrease O
in O
the O
CD56 O
( O
dim O
) O
cell O
fraction O
compared O
to O
CD56 O
( O
bright O
) O
cells O
, O
in O
both O
infections O
. O

This O
shift O
influenced O
the O
phenotype O
and O
functional O
capacity O
( O
gamma O
interferon O
production O
, O
killing O
) O
of O
the O
total O
NK O
pool O
. O

In O
addition O
, O
abnormalities O
in O
the O
functional O
capacity O
of O
the O
CD56 O
( O
dim O
) O
NK O
subset O
were O
observed O
in O
HIV O
( O
+ O
) O
patients O
. O

The O
shared O
NK O
alterations O
were O
found O
to O
be O
associated O
with O
a O
significant O
reduction O
in O
serum O
levels O
of O
the O
innate O
cytokine O
interleukin O
15 O
( O
IL O
- O
15 O
) O
. O

In O
vitro O
stimulation O
with O
IL O
- O
15 O
rescued O
NK O
cells O
of O
HIV O
( O
+ O
) O
and O
HCV O
( O
+ O
) O
patients O
from O
apoptosis O
and O
enhanced O
proliferation O
and O
functional O
activity O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
against O
nonstructural O
proteins O
is O
strongly O
associated O
with O
successful O
viral O
clearance O
during O
acute O
hepatitis O
C O
. O

To O
further O
develop O
these O
observations O
into O
peptide O
- O
based O
vaccines O
and O
clinical O
immunomonitoring O
tools O
like O
HLA O
class O
II O
tetramers O
, O
a O
detailed O
characterization O
of O
immunodominant O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitopes O
is O
required O
. O

Eight O
peptides O
were O
recognized O
by O
> O
= O
40 O
% O
of O
patients O
, O
and O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
were O
obtained O
for O
seven O
of O
these O
and O
three O
additional O
, O
subdominant O
epitopes O
. O

In O
conclusion O
, O
using O
two O
different O
approaches O
we O
identified O
and O
characterized O
a O
set O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
epitopes O
in O
the O
HCV O
NS3 O
- O
NS4 O
region O
which O
are O
immunodominant O
in O
patients O
achieving O
transient O
or O
persistent O
viral O
control O
. O

This O
information O
allows O
the O
construction O
of O
a O
valuable O
panel O
of O
HCV O
- O
specific O
HLA O
class O
II O
tetramers O
for O
further O
study O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
chronic O
hepatitis O
C O
. O

The O
210 O
- O
nucleotide B
( I
nt I
) I
5 I
' I
untranslated I
region I
( I
UTR I
) I
in O
the O
positive O
- O
strand O
bovine B
coronavirus I
( I
BCoV I
) I
genome O
is O
predicted O
to O
contain O
four O
higher O
- O
order O
structures O
identified O
as O
stem O
- O
loops O
I O
to O
IV O
, O
which O
may O
function O
as O
cis O
- O
acting O
elements O
in O
genomic O
RNA O
replication O
. O

Here O
, O
we O
describe O
evidence O
that O
stem O
- O
loop O
IV O
, O
a O
bulged O
stem O
- O
loop O
mapping O
at O
nt O
186 O
through O
215 O
, O
( O
i O
) O
is O
phylogenetically O
conserved O
among O
group O
2 O
coronaviruses O
and O
may O
have O
a O
homolog O
in O
groups O
1 O
and O
3 O
, O
( O
ii O
) O
exists O
as O
a O
higher O
- O
order O
structure O
on O
the O
basis O
of O
enzyme O
probing O
, O
( O
iii O
) O
is O
required O
as O
a O
higher O
- O
order O
element O
for O
replication O
of O
a O
BCoV O
Defective B
interfering I
( I
DI I
) I
RNA O
in O
the O
positive O
but O
not O
the O
negative O
strand O
, O
and O
( O
iv O
) O
as O
a O
higher O
- O
order O
structure O
in O
wild B
- I
type I
( I
WT I
) I
and O
mutant O
molecules O
that O
replicate O
, O
specifically O
binds O
six O
cellular O
proteins O
in O
the O
molecular O
mass O
range O
of O
25 O
to O
58 O
kDa O
as O
determined O
by O
electrophoretic O
mobility O
shift O
and O
UV O
cross O
- O
linking O
assays O
; O
binding O
to O
viral O
proteins O
was O
not O
detected O
. O

Interestingly O
, O
the O
predicted O
stem O
- O
loop O
IV O
homolog O
in O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
appears O
to O
be O
group O
1 O
- O
like O
in O
that O
it O
is O
in O
part O
duplicated O
with O
a O
group O
1 O
- O
like O
conserved O
loop O
sequence O
and O
is O
not O
group O
2 O
- O
like O
, O
as O
would O
be O
expected O
by O
the O
SARS O
coronavirus O
group O
2 O
- O
like O
3 O
' O
UTR O
structure O
. O

Replication O
of O
the O
similar O
to O
30 O
- O
kb O
plus O
- O
strand O
RNA O
genome O
of O
coronaviruses O
and O
synthesis O
of O
an O
extensive O
set O
of O
subgenome O
- O
length O
RNAs O
are O
mediated O
by O
the O
replicase O
- O
transcriptase O
, O
a O
membrane O
- O
bound O
protein O
complex O
containing O
several O
cellular O
proteins O
and O
up O
to O
16 O
viral O
nonstructural B
proteins I
( I
nsPs I
) I
with O
multiple O
enzymatic O
activities O
, O
including O
protease O
, O
polymerase O
, O
helicase O
, O
methyltransferase O
, O
and O
RNase O
activities O
. O

To O
get O
further O
insight O
into O
the O
replicase O
gene O
- O
encoded O
functions O
, O
we O
characterized O
the O
coronavirus O
X O
domain O
, O
which O
is O
part O
of O
nsp3 O
and O
has O
been O
predicted O
to O
be O
an O
ADP B
- I
ribose I
- I
1l I
- I
monophosphate I
( I
Appr I
- I
1 I
- I
p I
) I
processing O
enzyme O
. O

Bacterially O
expressed O
forms O
of O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
and O
severe O
acute O
respiratory O
syndromecoronavirus O
X O
domains O
were O
shown O
to O
dephosphorylate O
Appr O
- O
1 O
- O
p O
, O
a O
side O
product O
of O
cellular O
tRNA O
splicing O
, O
to O
ADP O
- O
ribose O
in O
a O
highly O
specific O
manner O
. O

Here O
, O
we O
report O
the O
three O
- O
dimensional O
structure O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARSCoV I
) I
nsP7 O
, O
a O
component O
of O
the O
SARS O
- O
CoV O
replicase O
polyprotein O
. O

Three O
helices O
( O
alpha O
2 O
to O
alpha O
4 O
) O
form O
a O
flat O
up O
- O
down O
- O
up O
antiparallel O
alpha O
- O
helix O
sheet O
. O

The O
N O
- O
terminal O
segment O
of O
residues O
1 O
to O
22 O
, O
containing O
two O
turns O
of O
alpha O
- O
helix O
and O
one O
turn O
of O
3 O
( O
10 O
) O
- O
helix O
, O
is O
packed O
across O
the O
surface O
of O
alpha O
2 O
and O
alpha O
3 O
in O
the O
helix O
sheet O
, O
with O
the O
alpha O
- O
helical O
region O
oriented O
at O
a O
60 O
degrees O
angle O
relative O
to O
alpha O
2 O
and O
alpha O
3 O
. O

Multispecific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
are O
thought O
to O
be O
important O
for O
the O
control O
of O
acute O
hepatitis O
C O
virus O
( O
KCV O
) O
infection O
, O
but O
to O
date O
little O
information O
is O
actually O
available O
on O
the O
breadth O
of O
responses O
at O
early O
time O
points O
. O

To O
investigate O
this O
issue O
, O
we O
performed O
comprehensive O
analysis O
of O
the O
breadth O
and O
frequencies O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
on O
the O
single O
epitope O
level O
in O
eight O
acutely O
infected O
individuals O
who O
were O
all O
started O
on O
early O
therapy O
. O

During O
therapy O
, O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
decreased O
rather O
than O
increased O
as O
virus O
was O
controlled O
, O
and O
no O
new O
specificities O
emerged O
. O

A O
sustained O
virological O
response O
following O
completion O
of O
treatment O
was O
independent O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
, O
as O
well O
as O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

Rapid O
recrudescence O
also O
occurred O
despite O
broad O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

Importantly O
, O
in O
vivo O
suppression O
of O
CD3 O
( O
+ O
) O
T O
cells O
using O
OKT3 O
in O
one O
subject O
did O
not O
result O
in O
recurrence O
of O
viremia O
. O

These O
data O
suggest O
that O
broad O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
alone O
may O
be O
insufficient O
to O
contain O
HCV O
replication O
, O
and O
also O
that O
early O
therapy O
is O
effective O
independent O
of O
such O
responses O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
remains O
a O
significant O
threat O
to O
the O
general O
health O
of O
the O
world O
' O
s O
population O
, O
and O
there O
is O
a O
pressing O
need O
for O
the O
development O
of O
new O
treatments O
and O
preventative O
vaccines O
. O

Here O
, O
we O
describe O
the O
generation O
of O
retrovirus O
- O
based O
pseudoparticles O
( O
HCVpp O
) O
incorporating O
a O
panel O
of O
full O
- O
length O
E1E2 O
clones O
representative O
of O
the O
major O
genotypes O
1 O
through O
6 O
, O
and O
their O
application O
to O
assess O
the O
reactivity O
and O
neutralizing O
capability O
of O
antisera O
and O
monoclonal O
antibodies O
raised O
against O
portions O
of O
the O
HCV O
E2 O
envelope O
protein O
. O

By O
contrast O
, O
the O
monoclonal B
antibody I
( I
Mab I
) I
AP33 O
demonstrated O
potent O
neutralization O
of O
infectivity O
against O
HCVpp O
carrying O
E1E2 O
representative O
of O
all O
genotypes O
tested O
. O

RNA O
editing O
of O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
antigenome O
at O
the O
amber O
/ O
NV O
site O
by O
the O
host O
RNA O
adenosine O
deaminase O
ADAR1 O
is O
a O
critical O
step O
in O
the O
HDV O
replication O
cycle O
. O

Editing O
is O
required O
for O
production O
of O
the O
viral O
protein O
hepatitis B
delta I
antigen I
long I
form I
( I
HDAg I
- I
L I
) I
, O
which O
is O
necessary O
for O
viral O
particle O
production O
but O
can O
inhibit O
HDV O
RNA O
replication O
. O

The O
RNA O
secondary O
structural O
features O
in O
ADAR1 O
substrates O
are O
not O
completely O
defined O
, O
but O
base O
pairing O
in O
the O
20 O
- O
nucleotide B
( I
nt I
) I
region O
3 O
' O
of O
editing O
sites O
is O
thought O
to O
be O
important O
. O

Viruses O
can O
exploit O
a O
variety O
of O
strategies O
to O
evade O
immune O
surveillance O
by O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
including O
the O
acquisition O
of O
mutations O
in O
CTL O
epitopes O
. O

Also O
for O
influenza O
A O
viruses O
a O
number O
of O
amino O
acid O
substitutions O
in O
the O
nucleoprotein B
( I
NP I
) I
have O
been O
associated O
with O
escape O
from O
CTL O
. O

However O
, O
other O
previously O
identified O
influenza O
A O
virus O
CTL O
epitopes O
are O
highly O
conserved O
, O
including O
the O
immunodominant O
HLA O
- O
A O
* O
0201 O
- O
restricted O
epitope O
from O
the O
matrix O
protein O
, O
M1 O
( O
58 O
- O
66 O
) O
. O

Alanine O
replacements O
for O
each O
of O
the O
nine O
amino O
acids O
of O
the O
M1 O
( O
58 O
- O
66 O
) O
epitope O
were O
tolerated O
to O
various O
extents O
, O
except O
for O
the O
anchor O
residue O
at O
the O
second O
position O
. O

The O
building O
block O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
nucleocapsid O
, O
the O
core O
protein O
, O
together O
with O
viral O
RNA O
, O
is O
composed O
of O
different O
domains O
involved O
in O
RNA O
binding O
and O
homo O
- O
oligomerization O
. O

The O
HCV O
core O
protein O
1 O
- O
169 O
( O
C O
( O
HCV O
) O
169 O
) O
and O
its O
N O
- O
terminal O
region O
from O
positions O
1 O
to O
117 O
( O
C O
( O
HCV O
) O
117 O
) O
were O
expressed O
in O
Escherichia O
coli O
and O
purified O
to O
homogeneity O
suitable O
for O
biochemical O
and O
biophysical O
characterizations O
. O

The O
overall O
conformation O
and O
the O
oligomeric O
properties O
of O
the O
resulting O
proteins O
C O
( O
HCV O
) O
169 O
and O
C O
( O
HCV O
) O
17 O
were O
investigated O
by O
using O
analytical O
centrifugation O
, O
circular O
dichroism O
, O
intrinsic O
fluorescence O
measurements O
, O
and O
limited O
proteolysis O
. O

Altogether O
, O
our O
results O
show O
that O
core O
protein O
( O
C O
( O
HCV O
) O
169 O
) O
behaves O
as O
a O
membranous O
protein O
and O
forms O
heterogeneous O
soluble O
micelle O
- O
like O
aggregates O
of O
high O
molecular O
weight O
in O
the O
absence O
of O
detergent O
. O

Similar O
to O
findings O
observed O
for O
core O
proteins O
of O
HCV O
- O
related O
flaviviruses O
, O
the O
HCV O
core O
protein O
is O
essentially O
composed O
of O
a O
- O
helices O
( O
50 O
% O
) O
. O

In O
contrast O
; O
C O
( O
HCV O
) O
117 O
is O
soluble O
and O
monodispersed O
in O
the O
absence O
of O
detergent O
but O
is O
unfolded O
. O

It O
appears O
that O
the O
folding O
of O
the O
highly O
basic O
domain O
from O
positions O
2 O
to O
117 O
( O
2 O
- O
117 O
domain O
) O
depends O
on O
the O
presence O
of O
the O
117 O
- O
169 O
hydrophobic O
domain O
, O
which O
contains O
the O
structural O
determinants O
ensuring O
the O
binding O
of O
core O
with O
cellular O
membranes O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
is O
the O
virus O
- O
encoded O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
essential O
for O
HCV O
RNA O
replication O
. O

Murine O
models O
have O
suggested O
that O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
peak O
early O
in O
acute O
viral O
infections O
and O
are O
not O
sustained O
, O
but O
no O
evidence O
for O
humans O
has O
been O
available O
. O

To O
address O
this O
, O
we O
longitudinally O
analyzed O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
to O
human O
parvovirus O
B19 O
in O
acutely O
infected O
individuals O
. O

We O
observed O
striking O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
, O
which O
were O
sustained O
or O
even O
increased O
over O
many O
months O
after O
the O
resolution O
of O
acute O
disease O
, O
indicating O
that O
CD8 O
( O
+ O
) O
T O
cells O
may O
play O
a O
prominent O
role O
in O
the O
control O
of O
parvovirus O
B19 O
and O
other O
acute O
viral O
infections O
of O
humans O
, O
including O
potentially O
those O
generated O
by O
live O
vaccines O
. O

gamma O
delta O
T O
cells O
mediate O
demyelination O
in O
athymic O
( O
nude O
) O
mice O
infected O
with O
the O
neurotropic O
coronavirus O
mouse O
hepatitis O
virus O
strain O
JHM O
. O

Now O
, O
we O
show O
that O
these O
cells O
also O
mediate O
the O
same O
process O
in O
mice O
lacking O
up O
T O
cells O
( O
T O
- O
cell O
receptor O
beta O
- O
deficient O
[ O
TCR O
beta O
( O
- O
/ O
- O
) O
] O
mice O
) O
and O
demyelination O
is O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
dependent O
. O

We O
show O
that O
NKG2D O
( O
+ O
) O
gamma O
delta O
T O
cells O
in O
the O
JHM O
- O
infected O
central O
nervous O
system O
express O
the O
adaptor O
molecule O
DAP12 O
and O
an O
NKG2D O
isoform O
, O
( O
NKG2D O
short O
) O
, O
both O
required O
for O
NKG2D O
to O
serve O
as O
a O
primary O
receptor O
. O

Human O
La O
protein O
is O
known O
to O
interact O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
internal I
ribosome I
entry I
site I
( I
IRES I
) I
and O
stimulate O
translation O
. O

Previously O
, O
we O
demonstrated O
that O
mutations O
within O
HCV O
SL O
IV O
lead O
to O
reduced O
binding O
to O
La B
- I
RNA I
recognition I
motif I
2 I
( I
RRM2 I
) I
and O
drastically O
affect O
HCV O
IRES O
- O
mediated O
translation O
. O

Translation O
initiation O
of O
some O
viral O
and O
cellular O
mRNAs O
occurs O
by O
ribosome O
binding O
to O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

Internal O
initiation O
mediated O
by O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
IRES O
in O
Saccharomyces O
cerevisiae O
was O
shown O
by O
translation O
of O
the O
second O
open O
reading O
frame O
in O
a O
bicistronic O
mRNA O
. O

polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
and O
poly B
- I
( I
rC I
) I
- I
binding I
protein I
2 I
( I
Pcbp2 I
) I
, O
which O
may O
be O
required O
for O
HCV O
IRES O
- O
dependent O
initiation O
in O
mammalian O
cells O
, O
are O
not O
encoded O
within O
the O
S O
. O

yellow B
fever I
virus I
( I
YFV I
) I
, O
a O
member O
of O
the O
Flavivirus O
genus O
, O
has O
a O
plus O
- O
sense O
RNA O
genome O
encoding O
a O
single O
polyprotein O
. O

We O
have O
previously O
identified O
a O
chromosome O
region O
maintenance O
1 O
- O
independent O
nuclear B
export I
signal I
( I
NES I
) I
at O
the O
C O
terminus O
of O
the O
large O
form O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
designated O
NES O
( O
HDAg O
- O
L O
) O
that O
is O
required O
for O
the O
assembly O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
( O
C O
. O

To O
look O
for O
interacting O
proteins O
of O
the O
NES O
( O
HDAg O
- O
L O
) O
, O
yeast O
two O
- O
hybrid O
screening O
was O
applied O
using O
the O
GAL4 O
- O
binding O
domain O
fused O
to O
the O
NES O
( O
HDAg O
- O
L O
) O
as O
bait O
. O

Among O
the O
positive O
clones O
, O
one O
encodes O
a O
protein O
, O
designated O
NESI O
[ O
NES O
( O
HDAg O
- O
L O
) O
interacting O
protein O
] O
that O
specifically O
interacted O
with O
the O
wild O
- O
type O
NES O
( O
HDAg O
- O
L O
) O
but O
not O
with O
the O
export O
/ O
package O
- O
defective O
HDAg O
- O
L O
mutant O
, O
NES O
* O
( O
HDAg O
- O
L O
) O
, O
in O
which O
Pro O
- O
205 O
has O
been O
replaced O
by O
Ala O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
genome O
replication O
requires O
the O
virus O
- O
encoded O
small O
delta O
protein O
( O
delta O
Ag O
) O
. O

A O
line O
of O
human O
embryonic O
kidney O
cells O
was O
stably O
transfected O
with O
a O
single O
copy O
of O
cDNA O
encoding O
small O
delta O
Ag O
, O
with O
expression O
under O
tetracycline B
( I
TET I
) I
control O
. O

Within O
2 O
days O
, O
there O
was O
a O
fivefold O
enhancement O
of O
G O
( O
1 O
) O
/ O
G O
( O
0 O
) O
cells O
relative O
to O
both O
S O
and O
G O
( O
2 O
) O
/ O
M O
cells O
, O
and O
by O
6 O
days O
, O
there O
was O
extensive O
cell O
detachment O
and O
death O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
circulates O
in O
the O
bloodstream O
in O
different O
forms O
, O
including O
complexes O
with O
immunoglobulins O
and O
/ O
or O
lipoproteins O
. O

To O
address O
the O
significance O
of O
such O
associations O
, O
we O
produced O
or O
treated O
HCV B
pseudoparticles I
( I
HCVpp I
) I
, O
a O
valid O
model O
of O
HCV O
cell O
entry O
and O
its O
inhibition O
, O
with O
naive O
or O
patient O
- O
derived O
sera O
. O

We O
demonstrate O
that O
infection O
of O
hepatocarcinoma O
cells O
by O
HCVpp O
is O
increased O
more O
than O
10 O
- O
fold O
by O
human O
serum O
factors O
, O
of O
which O
high B
- I
density I
lipoprotein I
( I
HDL I
) I
is O
a O
major O
component O
. O

Infection O
enhancement O
requires O
scavenger O
receptor O
BI O
, O
a O
molecule O
known O
to O
mediate O
HDL O
uptake O
into O
cells O
as O
well O
as O
HCVpp O
entry O
, O
and O
involves O
conserved O
amino O
acid O
positions O
in O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
E2 O
glycoprotein O
. O

Toroviruses O
( O
order O
Nidovirales O
) O
are O
enveloped O
positive O
- O
strand O
RNA O
viruses O
of O
mammals O
. O

The O
prototype O
torovirus O
, O
equine O
torovirus O
strain O
Berne O
( O
Berne O
virus O
[ O
BEV O
] O
) O
, O
uses O
two O
different O
transcription O
strategies O
to O
produce O
a O
3 O
' O
- O
coterminal O
nested O
set O
of O
subgenomic B
( I
sg I
) I
mRNAs O
. O

Their O
synthesis O
is O
supposedly O
regulated O
by O
short O
conserved O
sequence O
motifs O
, O
5 O
' O
- O
ACN O
( O
3 O
- O
4 O
) O
CUUUAGA O
- O
3 O
' O
, O
within O
the O
noncoding O
intergenic O
regions O
that O
precede O
the O
M O
, O
HE O
, O
and O
N O
genes O
( O
A O
. O

We O
have O
now O
studied O
the O
- O
for O
nidoviruses O
unusual O
- O
non O
- O
discontinuous O
transcription O
mechanism O
in O
further O
detail O
by O
probing O
the O
role O
of O
the O
postulated O
transcription B
- I
regulating I
sequences I
( I
TRSs I
) I
. O

To O
this O
end O
, O
we O
constructed O
a O
synthetic O
Defective B
interfering I
( I
DI I
) I
RNA O
, O
carrying O
a O
24 O
- O
nucleotide O
segment O
of O
the O
intergenic O
region O
between O
the O
HE O
and O
N O
genes O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
encodes O
two O
viral O
envelope O
glycoproteins O
. O

The O
mutants O
were O
named O
with O
an O
N O
followed O
by O
a O
number O
related O
to O
the O
relative O
position O
of O
the O
potential O
glycosylation O
site O
in O
each O
glycoprotein O
( O
E1N1 O
to O
E1N4 O
for O
E1 O
mutants O
and O
E2N1 O
to O
E2N11 O
for O
E2 O
mutants O
) O
. O

For O
the O
first O
group O
( O
E1N3 O
, O
E2N3 O
, O
E2N5 O
, O
E2N6 O
, O
E2N7 O
, O
and O
E2N9 O
) O
, O
the O
infectivities O
of O
the O
mutants O
were O
close O
to O
that O
of O
the O
wild O
type O
. O

The O
second O
group O
( O
E1N1 O
, O
E1N2 O
, O
E1N4 O
, O
E2N1 O
, O
and O
E2N11 O
) O
contained O
mutants O
that O
were O
still O
infectious O
but O
whose O
infectivities O
were O
reduced O
to O
< O
50 O
% O
that O
of O
the O
wild O
type O
. O

The O
third O
group O
( O
E2N2 O
, O
E2N4 O
, O
E2N8 O
, O
and O
E2N10 O
) O
contained O
mutants O
that O
had O
almost O
totally O
lost O
infectivity O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
3 I
( I
NS3 I
) I
possesses O
multiple O
enzyme O
activities O
. O

We O
performed O
biochemical O
studies O
to O
examine O
the O
functional O
interdependence O
of O
the O
NS3 O
protease O
and O
helicase O
domains O
and O
the O
modulation O
of O
NS3 O
helicase O
by O
NS5B O
, O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

We O
found O
that O
the O
NS3 O
protease O
domain O
of O
the O
full O
- O
length O
NS3 O
( O
NS3FL O
) O
enhances O
the O
NS3 O
helicase O
activity O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
is O
localized O
within O
detergent O
- O
resistant O
membranes O
or O
lipid O
rafts O
. O

N O
- O
Ras O
is O
an O
activator O
of O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( I
PI3K I
) I
- O
Akt O
pathway O
. O

Reduction O
of O
N O
- O
Ras O
expression O
by O
transfection O
of O
N O
- O
Ras O
small B
interfering I
RNA I
( I
siRNA I
) I
resulted O
in O
increased O
replication O
of O
HCV O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
quasispecies O
heterogeneity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
the O
plasma O
, O
cryoprecipitate O
, O
and O
peripheral O
lymphocytes O
of O
chronically O
infected O
HCV O
patients O
with O
mixed B
cryoglobulinemia I
( I
MC I
) I
. O

A O
partial O
nucleotide O
sequence O
encompassing O
the O
E1 O
/ O
E2 O
region O
, O
including O
hypervariable B
region I
1 I
( I
HVR1 I
) I
, O
was O
amplified O
and O
cloned O
from O
plasma O
, O
cryoprecipitates O
, O
and O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
and O
the O
genetic O
diversity O
and O
complexity O
and O
synonymous O
and O
nonsynonymous O
substitution O
rates O
were O
determined O
. O

Compartmentalization O
was O
estimated O
by O
phylogenetic O
and O
phenetic O
( O
Mantel O
' O
s O
test O
) O
approaches O
. O

Significant O
compartmentalization O
of O
HCV O
quasispecies O
was O
observed O
in O
the O
PBMC O
of O
four O
of O
nine O
subjects O
( O
three O
with O
MC O
) O
and O
seven O
of O
nine O
cryoprecipitates O
. O

The O
coronavirus O
nucleocapsid B
( I
N I
) I
protein O
is O
a O
structural O
protein O
that O
forms O
a O
ribonucleoprotein O
complex O
with O
genomic O
RNA O
. O

We O
found O
that O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
vector O
RNAs O
that O
lack O
the O
N O
gene O
were O
greatly O
impaired O
in O
their O
ability O
to O
replicate O
, O
whereas O
the O
transcription O
of O
subgenomic O
mRNA O
from O
these O
vectors O
was O
easily O
detectable O
. O

Significant O
advances O
have O
been O
made O
in O
understanding O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
through O
development O
of O
replicon O
systems O
. O

We O
developed O
an O
in O
vitro O
translation O
extract O
from O
Krebs O
- O
2 O
cells O
that O
translates O
the O
entire O
open O
reading O
frame O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
strain O
H77 O
and O
properly O
processes O
the O
viral O
protein O
precursors O
when O
supplemented O
with O
canine B
microsomal I
membranes I
( I
CMMs I
) I
. O

Evidence O
for O
posttranslational O
modification O
of O
the O
viral O
proteins O
, O
the O
N O
- O
terminal O
glycosylation O
of O
El O
and O
the O
E2 O
precursor O
( O
E2 O
- O
p7 O
) O
, O
and O
phosphorylation O
of O
NS5A O
is O
presented O
. O

Finally O
, O
the O
formyl O
- O
[ O
S O
- O
35 O
] O
methionyl O
moiety O
of O
the O
initiator O
tRNA O
( O
Met O
) O
was O
incorporated O
exclusively O
into O
the O
core O
protein O
portion O
of O
the O
polyprotein O
, O
demonstrating O
that O
translation O
initiation O
in O
this O
system O
occurs O
with O
high O
fidelity O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
frequently O
persists O
with O
an O
apparently O
ineffective O
antiviral O
T O
- O
cell O
response O
. O

To O
test O
this O
hypothesis O
, O
CD4 O
T O
- O
cell O
responses O
to O
three O
genotype O
la O
- O
derived O
HCV O
antigens O
and O
HCV O
antibody O
serotype O
were O
examined O
in O
chronically O
HCV O
infected O
( O
genotypes O
1a O
, O
1b O
, O
2 O
, O
3 O
, O
and O
4 O
) O
and O
spontaneously O
HCV O
recovered O
subjects O
. O

Consistent O
with O
multiple O
HCV O
exposure O
, O
63 O
% O
of O
patients O
infected O
with O
genotypes O
2 O
to O
4 O
( O
genotypes O
2 O
- O
4 O
) O
and O
36 O
% O
of O
those O
infected O
with O
genotype O
1b O
displayed O
CD4 O
T O
- O
cell O
responses O
to O
la O
- O
derived O
HCV O
antigens O
, O
while O
29 O
% O
of O
genotype O
2 O
- O
4 O
- O
infected O
patients O
showed O
serotype O
responses O
to O
genotype O
1 O
. O

Remarkably O
, O
CD4 O
T O
- O
cell O
responses O
to O
1a O
- O
derived O
HCV O
antigens O
were O
weakest O
in O
patients O
with O
homologous O
1a O
infection O
and O
greater O
in O
non O
- O
1a O
- O
infected O
patients O
: O
proportions O
of O
patients O
responding O
were O
19 O
% O
( O
1a O
) O
, O
36 O
% O
( O
1b O
) O
, O
and O
63 O
% O
( O
2 O
- O
4 O
) O
( O
P O
= O
0 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
disease O
and O
affects O
over O
270 O
million O
individuals O
worldwide O
. O

The O
HCV O
genome O
is O
a O
single O
- O
stranded O
RNA O
that O
functions O
as O
both O
an O
mRNA O
and O
a O
replication O
template O
, O
making O
it O
an O
attractive O
target O
for O
therapeutic O
approaches O
using O
Short B
interfering I
RNA I
( I
siRNA I
) I
. O

Demyelination O
does O
not O
develop O
in O
infected O
RAG1 O
( O
- O
/ O
- O
) O
( O
recombination O
activation O
gene O
- O
deficient O
) O
mice O
but O
can O
be O
induced O
by O
several O
experimental O
interventions O
, O
including O
adoptive O
transfer O
of O
virus O
- O
specific O
T O
cells O
or O
antibodies O
. O

Extensive O
macrophage O
/ O
microglia O
infiltration O
and O
demyelination O
has O
developed O
in O
RAG1 O
( O
- O
/ O
- O
) O
mice O
infected O
with O
this O
recombinant O
virus O
. O

The O
development O
of O
a O
reproducible O
model O
system O
for O
the O
study O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
the O
potential O
to O
significantly O
enhance O
the O
study O
of O
virus O
- O
host O
interactions O
and O
provide O
future O
direction O
for O
modeling O
the O
pathogenesis O
of O
HCV O
. O

We O
detected O
> O
41 O
, O
200 O
proteins O
in O
this O
cell O
line O
, O
including O
HCV O
replicon O
proteins O
, O
using O
multidimensional O
liquid B
chromatographic I
( I
LC I
) I
separations O
coupled O
to O
mass O
spectrometry O
. O

These O
in O
vitro O
isolated O
mutants O
encoded O
two O
amino O
acids O
substitutions O
in O
the O
spike B
( I
S I
) I
gene O
: O
Q159L O
lies O
in O
the O
putative O
receptor O
binding O
domain O
of O
S O
, O
and O
H716D O
, O
within O
the O
cleavage O
signal O
of O
S O
. O

Here O
, O
we O
show O
that O
hepatotropic O
revertant O
variants O
may O
be O
selected O
from O
these O
in O
vitro O
isolated O
mutants O
( O
Q159L O
- O
H716D O
) O
by O
multiple O
passages O
in O
the O
mouse O
liver O
. O

The O
S O
gene O
of O
hr2 O
( O
Q159L O
- O
( O
R654H O
) O
under O
bar O
- O
H716D O
- O
( O
E1035D O
) O
under O
bar O
) O
differed O
from O
the O
in O
vitro O
isolates O
( O
Q159L O
- O
H716D O
) O
in O
only O
2 O
amino O
acids O
( O
R654H O
and O
E1035D O
) O
. O

Using O
targeted O
RNA O
recombination O
, O
we O
have O
constructed O
isogenic O
recombinant O
MHV O
- O
A59 O
viruses O
differing O
only O
in O
these O
specific O
amino O
acids O
in O
S O
( O
Q159L O
- O
R654H O
- O
H716D O
- O
E1035D O
) O
. O

The O
pathogenesis O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
remains O
unclear O
. O

Macrophages O
are O
key O
sentinel O
cells O
in O
the O
respiratory O
system O
, O
and O
it O
is O
therefore O
relevant O
to O
compare O
the O
responses O
of O
human O
macrophages O
to O
infections O
with O
the O
SARS B
coronavirus I
( I
SARS I
- I
CoV I
) I
and O
other O
respiratory O
viruses O
. O

The O
gene O
expression O
profiles O
of O
macrophages O
infected O
with O
SARS O
- O
CoV O
, O
human O
coronavirus O
229E O
, O
and O
influenza O
A O
( O
H1N1 O
) O
virus O
were O
compared O
by O
using O
microarrays O
and O
real O
- O
time O
quantitative O
reverse O
transcriptase O
PCR O
. O

In O
contrast O
to O
the O
case O
with O
human O
coronavirus O
229E O
and O
influenza O
A O
virus O
, O
there O
was O
little O
or O
no O
induction O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
in O
SARS O
- O
CoV O
- O
infected O
macrophages O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
associated O
with O
impaired O
proliferative O
, O
cytokine O
, O
and O
cytotoxic O
effector O
functions O
of O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
that O
probably O
contribute O
significantly O
to O
viral O
persistence O
. O

Here O
, O
we O
investigated O
the O
potential O
role O
of O
T O
cells O
with O
a O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
regulatory O
phenotype O
in O
suppressing O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
proliferation O
during O
chronic O
HCV O
infection O
. O

In O
vitro O
depletion O
studies O
and O
coculture O
experiments O
revealed O
that O
peptide O
specific O
proliferation O
as O
well O
as O
gamma O
interferon O
production O
of O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
inhibited O
by O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
. O

Interestingly O
, O
the O
T O
- O
cell O
- O
mediated O
suppression O
in O
chronically O
HCV O
- O
infected O
patients O
was O
not O
restricted O
to O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
but O
also O
to O
influenza O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Importantly O
, O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
from O
persons O
recovered O
from O
HCV O
infection O
and O
from O
healthy O
blood O
donors O
exhibited O
significantly O
less O
suppressor O
activity O
. O

Thus O
, O
the O
inhibition O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
proliferation O
was O
enhanced O
in O
chronically O
HCV O
- O
infected O
patients O
. O

This O
was O
associated O
with O
a O
higher O
frequency O
of O
circulating O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
cells O
observed O
in O
this O
patient O
group O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
chronic O
HCV O
infection O
leads O
to O
the O
expansion O
of O
CD4 O
( O
+ O
) O
D25 O
( O
+ O
) O
T O
cells O
that O
are O
able O
to O
suppress O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
different O
viral O
antigens O
. O

Our O
results O
further O
suggest O
that O
CD4 O
( O
+ O
) O
CD25 O
( O
+ O
) O
T O
cells O
may O
contribute O
to O
viral O
persistence O
in O
chronically O
HCV O
- O
infected O
patients O
and O
may O
be O
a O
target O
for O
immunotherapy O
of O
chronic O
hepatitis O
C O
. O

Protein O
- O
protein O
interactions O
involved O
in O
formation O
of O
the O
membrane O
- O
associated O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
complex O
are O
poorly O
understood O
. O

The O
expression O
of O
the O
genomic O
information O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
CoV I
) I
involves O
synthesis O
of O
a O
nested O
set O
of O
subgenomic B
RNAs I
( I
sgRNAs I
) I
by O
discontinuous O
transcription O
. O

Sequence O
analysis O
of O
the O
leader O
- O
body O
fusion O
sites O
of O
each O
sgRNA O
showed O
that O
the O
junction O
sequences O
and O
the O
corresponding O
transcription B
- I
regulatory I
sequence I
( I
TRS I
) I
are O
unique O
for O
each O
species O
of O
sgRNA O
and O
are O
consistent O
after O
virus O
passages O
. O

For O
the O
two O
novel O
sgRNAs O
, O
each O
used O
a O
variant O
of O
the O
TRS O
that O
has O
one O
nucleotide O
mismatch O
in O
the O
conserved O
hexanucleotide O
core O
( O
ACGAAC O
) O
in O
the O
TRS O
. O

alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
is O
a O
key O
mediator O
of O
innate O
antiviral O
responses O
but O
has O
little O
effect O
on O
the O
established O
replication O
of O
dengue O
viruses O
, O
which O
are O
mosquito O
- O
borne O
flaviviruses O
of O
immense O
global O
health O
importance O
. O

In O
a O
recent O
study O
analyzing O
the O
ability O
of O
individual O
dengue O
virus O
- O
encoded O
proteins O
to O
antagonize O
the O
IFN O
response O
, O
nonstructural B
( I
NS I
) I
protein O
4B O
and O
possibly O
NS2A O
and O
NS4A O
were O
identified O
as O
candidate O
IFN O
antagonists O
. O

For O
this O
study O
, O
we O
examined O
the O
effects O
of O
dengue O
virus O
on O
the O
human O
IFN O
system O
, O
using O
cell O
lines O
that O
were O
stably O
transfected O
with O
self O
- O
replicating O
subgenomic O
dengue O
virus O
RNA O
( O
replicons O
) O
and O
that O
expressed O
all O
of O
the O
dengue O
virus O
nonstructural O
proteins O
together O
. O

In O
cells O
containing O
replicons O
or O
infected O
with O
dengue O
virus O
, O
we O
found O
reduced O
levels O
of O
signal B
transducer I
and I
activator I
of I
transcription I
2 I
( I
STAT2 I
) I
, O
which O
is O
a O
key O
component O
of O
IFN O
- O
alpha O
but O
not O
IFN O
- O
gamma O
signaling O
. O

We O
describe O
here O
a O
novel O
targeting O
gene O
therapy O
strategy O
to O
direct O
gene O
expression O
responsive O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

The O
factors O
leading O
to O
spontaneous O
clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
or O
to O
viral O
persistence O
are O
elusive O
. O

Here O
, O
using O
a O
sensitive O
neutralization O
assay O
based O
on O
infectious O
HCV B
pseudoparticles I
( I
HCVpp I
) I
, O
we O
have O
studied O
the O
kinetics O
of O
humorall O
responses O
in O
a O
cohort O
of O
acute O
- O
phase O
patients O
infected O
during O
a O
single O
nosocomial O
outbreak O
in O
a O
hemodialysis O
center O
. O

Blood O
samples O
were O
taken O
frequently O
( O
15 O
+ O
/ O
- O
4 O
per O
patient O
) O
. O

Phylogenetic O
analysis O
of O
the O
predominant O
virus O
( O
es O
) O
revealed O
infection O
by O
only O
one O
of O
two O
genotype O
1b O
strains O
. O

Although O
neurovirulent O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
JHMV O
multiplies O
in O
a O
variety O
of O
brain O
cells O
, O
expression O
of O
its O
receptor O
carcinoembryonic B
antigen I
cell I
adhesion I
molecule I
1 I
( I
CEACAM I
1 I
) I
( O
MHVR O
) O
is O
restricted O
only O
in O
microglia O
. O

In O
contrast O
to O
wild B
- I
type I
( I
WT I
) I
JHMV O
, O
a O
soluble B
- I
receptor I
- I
resistant I
mutant I
( I
srr7 I
) I
infects O
and O
spreads O
solely O
in O
an O
MHVR O
- O
dependent O
fashion O
( O
F O
. O

Fluorescence O
- O
activated O
cell O
sorter O
analysis O
showed O
that O
about O
80 O
% O
of O
the O
brain O
cells O
stained O
with O
anti O
- O
MHVR O
antibody O
( O
CC1 O
) O
were O
also O
positive O
for O
GS O
- O
lectin O
. O

The O
pathogenesis O
of O
severe B
acute I
respiratory I
syndrome I
- I
associated I
coronavirus I
( I
SARS I
- I
CoV I
) I
at O
the O
cellular O
level O
is O
unclear O
. O

Huh7 O
cells O
were O
found O
to O
be O
susceptible O
to O
both O
SARS O
- O
CoV O
, O
associated O
with O
SARS O
, O
and O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
, O
usually O
associated O
with O
the O
common O
cold O
. O

The O
early O
transcriptional O
profiles O
of O
host O
cell O
response O
to O
both O
types O
of O
infection O
at O
2 O
and O
4 O
h O
postinoculation O
were O
determined O
by O
using O
the O
Affymetrix O
HG O
- O
U133A O
microarray O
( O
about O
22 O
, O
000 O
genes O
) O
. O

While O
many O
clinical O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
are O
resistant O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
therapy O
, O
subgenomic O
in O
vitro O
self O
- O
replicating O
HCV O
RNAs O
( O
HCV O
replicons O
) O
are O
characterized O
by O
marked O
IFN O
- O
alpha O
sensitivity O
. O

IFN O
- O
alpha O
treatment O
of O
replicon O
- O
containing O
cells O
results O
in O
a O
rapid O
loss O
of O
viral O
RNA O
via O
translation O
inhibition O
through O
double B
- I
stranded I
RNA I
- I
activated I
protein I
kinase I
( I
PKR I
) I
and O
also O
through O
a O
new O
pathway O
involving O
RNA O
editing O
by O
an O
adenosine O
deaminase O
that O
acts O
on O
double O
- O
stranded O
RNA O
( O
ADAR1 O
) O
. O

Differences O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
variants O
of O
the O
highly O
conserved O
5 B
' I
untranslated I
region I
( I
UTR I
) I
have O
been O
observed O
between O
plasma O
and O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
. O

Plasma O
and O
PBMC O
HCV O
variants O
were O
compared O
by O
single B
- I
strand I
conformation I
polymorphism I
( I
SSCP I
) I
and O
by O
cloning O
or O
by O
genotyping O
with O
a O
line B
probe I
assay I
( I
LiPA I
) I
in O
116 O
chronically O
infected O
patients O
, O
including O
44 O
liver O
transplant O
recipients O
. O

SSCP O
patterns O
differed O
between O
compartments O
in O
43 O
/ O
109 O
analyzable O
patients O
( O
39 O
% O
) O
. O

01 O
) O
and O
in O
those O
who O
acquired O
HCV O
through O
multiple O
transfusions O
before O
1991 O
( O
15 O
/ O
20 O
; O
75 O
% O
) O
or O
through O
drug O
injection O
( O
16 O
/ O
31 O
; O
52 O
% O
) O
than O
in O
those O
infected O
through O
an O
unknown O
route O
( O
7 O
/ O
29 O
; O
24 O
% O
) O
or O
through O
a O
single O
transfusion O
( O
5 O
/ O
29 O
; O
17 O
% O
; O
P O
< O
0 O
. O

Cloning O
of O
the O
5 O
' O
UTR O
, O
LiPA O
analysis O
, O
and O
nonstructural O
region O
5B O
sequencing O
revealed O
different O
genotypes O
in O
the O
two O
compartments O
from O
10 O
patients O
( O
9 O
% O
) O
. O

Production O
of O
multiply O
deleted O
adenoviral O
( O
Ad O
) O
vectors O
with O
increased O
cloning O
capacity O
and O
reduced O
immunogenicity O
to O
adenovirus O
gene O
products O
requires O
the O
concomitant O
generation O
of O
efficient O
packaging O
cell O
lines O
. O

To O
this O
end O
, O
we O
developed O
a O
novel O
adenovirus O
- O
based O
amplicon O
with O
an O
Epstein O
- O
Barr O
virus O
origin O
of O
replication O
, O
Ad O
type O
5 O
( O
Ad5 O
) O
inverted O
terminal O
repeats O
, O
all O
Ad5 O
early O
region O
2 O
( O
E2 O
) O
genes O
, O
and O
the O
early O
region O
4 O
( O
E4 O
) O
open B
reading I
frame I
6 I
( I
ORF6 I
) I
under O
the O
control O
of O
a O
tetracycline O
- O
dependent O
promoter O
. O

The O
amplicon O
( O
pE2 O
) O
was O
stably O
maintained O
in O
multiple O
copies O
in O
the O
nuclei O
of O
293 O
cells O
stably O
expressing O
the O
Epstein B
- I
Barr I
virus I
nuclear I
antigen I
1 I
( I
EBNA1 I
) I
and O
allowed O
replication O
as O
a O
linear O
DNA O
upon O
induction O
of O
E2 O
and O
ORF6 O
gene O
expression O
. O

A O
stable O
cell O
line O
( O
M O
) O
was O
generated O
by O
introducing O
pE2 O
into O
293EBNATet O
cells O
expressing O
the O
tetracycline O
- O
dependent O
transcriptional O
silencer O
and O
the O
reverse B
Tet I
transactivator I
( I
rtTA2 I
) I
. O

Upon O
induction O
with O
doxicycline O
, O
2E2 O
cells O
produced O
higher O
levels O
of O
polymerase O
, O
precursor B
terminal I
protein I
( I
pTP I
) I
, O
and O
DNA O
binding O
protein O
than O
noninduced O
2E2 O
cells O
infected O
with O
first O
- O
generation O
Ad5 O
vector O
and O
supported O
efficient O
amplification O
of O
a O
multiply O
deleted O
Ad5 O
vector O
lacking O
E1 O
, O
E2 O
, O
E3 O
, O
and O
E4 O
genes O
( O
Ad5 O
Delta O
E1 O
- O
4 O
) O
. O

6 O
kb O
) O
was O
exploited O
to O
construct O
a O
vector O
encoding O
the O
entire O
hepatitis B
C I
virus I
( I
HCV I
) I
polyprotein O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infections O
may O
be O
initiated O
by O
multiple O
infectious O
particles O
, O
resulting O
in O
a O
genetically O
heterogeneous O
viral O
population O
, O
or O
by O
a O
single O
particle O
, O
leading O
to O
a O
clonal O
population O
in O
the O
initial O
stage O
of O
infection O
. O

RNA O
isolated O
from O
plasma O
and O
a O
region O
of O
the O
HCV O
envelope O
gene O
including O
the O
first B
hypervariable I
region I
( I
HVR I
- I
1 I
) I
was O
reverse O
transcription O
- O
PCR O
amplified O
and O
subcloned O
, O
and O
multiple O
plasmid O
clones O
were O
sequenced O
. O

3 O
kb O
in O
length O
with O
a O
19 O
- O
nucleotide O
conserved B
sequence I
element I
( I
3 I
' I
CSE I
) I
immediately O
preceding O
the O
3 O
' O
- O
poly O
( O
A O
) O
tail O
. O

The O
3 O
' O
CSE O
and O
poly O
( O
A O
) O
tail O
have O
been O
assumed O
to O
constitute O
the O
core O
promoter O
for O
minus O
- O
strand O
RNA O
synthesis O
during O
genome O
replication O
; O
however O
, O
their O
involvement O
in O
this O
process O
has O
not O
been O
formally O
demonstrated O
. O

The O
major O
findings O
of O
this O
study O
with O
regard O
to O
efficient O
minus O
- O
strand O
RNA O
synthesis O
are O
the O
following O
: O
( O
i O
) O
the O
wild O
- O
type O
3 O
' O
CSE O
and O
the O
poly O
( O
A O
) O
tail O
are O
required O
, O
( O
ii O
) O
the O
poly O
( O
A O
) O
tail O
must O
be O
a O
minimum O
of O
11 O
to O
12 O
residues O
in O
length O
and O
immediately O
follow O
the O
3 O
' O
CSE O
, O
( O
iii O
) O
deletion O
or O
substitution O
of O
the O
3 O
' O
13 O
nucleotides O
of O
the O
3 O
' O
CSE O
severely O
inhibits O
minus O
- O
strand O
RNA O
synthesis O
, O
( O
iv O
) O
templates O
possessing O
non O
- O
wild O
- O
type O
3 O
' O
sequences O
previously O
demonstrated O
to O
support O
virus O
replication O
do O
not O
program O
efficient O
RNA O
synthesis O
, O
and O
( O
v O
) O
insertion O
of O
uridylate O
residues O
between O
the O
poly O
( O
A O
) O
tail O
and O
a O
non O
- O
wild O
- O
type O
3 O
' O
sequence O
can O
restore O
promoter O
function O
to O
a O
limited O
extent O
. O

This O
study O
shows O
that O
the O
optimal O
structure O
of O
the O
3 O
' O
component O
of O
the O
minus O
- O
strand O
promoter O
is O
the O
wild O
- O
type O
3 O
' O
CSE O
followed O
a O
poly O
( O
A O
) O
tail O
of O
at O
least O
11 O
residues O
. O

Using O
the O
prototypical O
tombusvirus O
, O
Tomato B
bushy I
stunt I
virus I
( I
TBSV I
) I
, O
we O
show O
that O
recombinant O
p33 O
replicase O
protein O
binds O
specifically O
to O
an O
internal B
replication I
element I
( I
IRE I
) I
located O
within O
the O
p92 O
RNA O
- O
dependent O
RNA O
polymerase O
coding O
region O
of O
the O
viral O
genome O
. O

We O
show O
that O
structured O
hepatitis B
C I
virus I
( I
HCV I
) I
genomic O
RNA O
activates O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
, O
thereby O
inducing O
interferon O
in O
cultured O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural B
2 I
( I
NS2 I
) I
protein O
is O
a O
hydrophobic O
transmembrane O
protein O
, O
described O
to O
be O
involved O
in O
different O
functions O
, O
such O
as O
apoptosis O
inhibition O
and O
gene O
transcription O
modulation O
. O

In O
the O
quest O
of O
a O
protein O
kinase O
for O
NS2 O
, O
we O
identified O
by O
sequence O
analysis O
that O
the O
serine O
residue O
168 O
was O
part O
of O
a O
consensus O
casein B
kinase I
2 I
( I
CK2 I
) I
recognition O
site O
( O
S O
/ O
TXXE O
) O
. O

We O
describe O
the O
development O
of O
a O
selectable O
, O
bi O
- O
cistronic O
subgenomic O
replicon O
for O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
in O
Huh O
- O
7 O
cells O
, O
similar O
to O
that O
established O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

The O
selection O
marker O
and O
reporter O
( O
Luc O
- O
Ubi O
- O
Neo O
) O
in O
the O
BVDV O
replicon O
was O
fused O
with O
the O
amino O
- O
terminal O
protease O
N O
- O
pro O
, O
and O
expression O
of O
the O
nonstructural O
proteins O
( O
NS3 O
to O
NS5B O
) O
was O
driven O
by O
an O
encephalomyocarditis O
virus O
internal O
ribosome O
entry O
site O
. O

The O
BVDV O
replicon O
showed O
similar O
sensitivity O
as O
the O
HCV O
replicon O
to O
interferons O
( O
alpha O
, O
beta O
, O
and O
gamma O
) O
and O
2 O
' O
- O
beta O
- O
C O
- O
methyl O
ribonucleoside O
inhibitors O
. O

The O
HCV O
replicon O
has O
been O
shown O
to O
block O
, O
via O
the O
NS3 O
/ O
4A O
serine O
protease O
, O
Sendai O
virus O
- O
induced O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
a O
key O
antiviral O
signaling O
molecule O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
been O
adapted O
to O
grow O
efficiently O
in O
primate O
and O
some O
nonprimate O
cell O
lines O
but O
not O
in O
cells O
of O
murine O
origin O
. O

A O
series O
of O
29 O
patients O
undergoing O
treatment O
for O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
1 O
infection O
with O
pegylated O
alpha O
- O
2a O
interferon O
plus O
ribavirin O
were O
studied O
for O
patterns O
of O
response O
to O
antiviral O
therapy O
and O
viral O
quasispecies O
evolution O
. O

As O
part O
of O
an O
analysis O
of O
pretreatment O
variables O
that O
might O
affect O
the O
outcome O
of O
treatment O
, O
genetic O
heterogeneity O
within O
the O
viral O
E1 O
- O
E2 O
glycoprotein O
region O
( O
nucleotides O
851 O
to O
2280 O
) O
was O
assessed O
by O
sequencing O
10 O
to O
15 O
quasispecies O
clones O
per O
patient O
from O
serum O
- O
derived O
PCR O
products O
. O

Genetic O
parameters O
were O
examined O
with O
respect O
to O
response O
to O
therapy O
based O
on O
serum O
viral O
RNA O
loads O
at O
12 O
weeks O
( O
early O
viral O
response O
) O
and O
at O
24 O
weeks O
posttreatment O
( O
sustained O
viral O
response O
) O
. O

Nucleotide O
and O
amino O
acid O
quasispecies O
complexities O
of O
the O
hypervariable B
region I
1 I
( I
HVR I
- I
1 I
) I
were O
less O
in O
the O
responder O
group O
in O
comparison O
to O
the O
nonresponder O
group O
at O
12 O
weeks O
, O
and O
genetic O
diversity O
was O
also O
less O
both O
within O
and O
outside O
of O
the O
HVR O
- O
1 O
, O
with O
the O
difference O
being O
most O
pronounced O
for O
the O
non O
- O
HVR O
- O
1 O
region O
of O
E2 O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
the O
prototype O
of O
group O
I O
coronaviruses O
and O
one O
of O
the O
most O
extensively O
studied O
coronaviruses O
. O

Here O
, O
we O
describe O
a O
reverse O
genetic O
system O
for O
MHV O
( O
strain O
A59 O
) O
based O
upon O
the O
cloning O
of O
a O
full O
- O
length O
genomic O
cDNA O
in O
vaccinia O
virus O
. O

We O
show O
that O
the O
recombinant O
virus O
generated O
from O
cloned O
cDNA O
replicates O
to O
the O
same O
titers O
as O
the O
parental O
virus O
in O
cell O
culture O
( O
similar O
to10 O
( O
9 O
) O
PFU O
/ O
ml O
) O
, O
has O
the O
same O
plaque O
morphology O
, O
and O
produces O
the O
same O
amounts O
and O
proportions O
of O
genomic O
and O
subgenomic O
mRNAs O
in O
virus O
- O
infected O
cells O
. O

These O
modifications O
facilitate O
( O
i O
) O
the O
mutagenesis O
of O
cloned O
cDNA O
by O
using O
vaccinia O
virus O
- O
mediated O
homologous O
recombination O
and O
( O
ii O
) O
the O
rescue O
of O
recombinant O
coronaviruses O
by O
using O
a O
stable O
nucleocapsid O
protein O
- O
expressing O
cell O
line O
for O
the O
electroporation O
of O
infectious O
full O
- O
length O
genomes O
. O

The O
present O
study O
showed O
the O
association O
of O
a O
Severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SCoV I
) I
accessory O
protein O
, O
3a O
, O
with O
plasma O
membrane O
and O
intracellular O
SCoV O
particles O
in O
infected O
cells O
. O

Nonstructural O
protein O
5A O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
highly O
phosphorylated O
molecule O
implicated O
in O
multiple O
interactions O
with O
the O
host O
cell O
and O
most O
likely O
involved O
in O
RNA O
replication O
. O

Two O
phosphorylated O
variants O
of O
NS5A O
have O
been O
described O
, O
designated O
according O
to O
their O
apparent O
molecular O
masses O
( O
in O
kilodaltons O
) O
as O
p56 O
and O
p58 O
, O
which O
correspond O
to O
the O
basal O
and O
hyperphosphorylated O
forms O
, O
respectively O
. O

A O
reverse O
genetic O
system O
was O
recently O
established O
for O
the O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
in O
which O
cDNA O
fragments O
of O
the O
RNA O
genome O
are O
assembled O
in O
vitro O
into O
a O
full O
- O
length O
genome O
cDNA O
, O
followed O
by O
electroporation O
of O
in O
vitro O
- O
transcribed O
genome O
RNA O
into O
cells O
with O
recovery O
of O
viable O
virus O
. O

The O
in O
vitro O
- O
assembled O
wild O
- O
type O
MHV O
- O
A59 O
virus O
( O
icMHV O
- O
A59 O
) O
demonstrated O
replication O
identical O
to O
laboratory O
strains O
of O
MHV O
- O
A59 O
in O
tissue O
culture O
; O
however O
, O
icMHV O
- O
A59 O
was O
avirulent O
following O
intracranial O
inoculation O
of O
C57BL O
/ O
6 O
mice O
. O

Sequencing O
of O
the O
cloned O
genome O
cDNA O
fragments O
identified O
two O
single O
- O
nucleotide O
mutations O
in O
cloned O
genome O
fragment O
F O
, O
encoding O
a O
Tyr6398His O
substitution O
in O
open B
reading I
frame I
( I
ORF I
) I
1b O
p59 O
- O
nsp14 O
and O
a O
Leu94Pro O
substitution O
in O
the O
ORF O
2a O
30 O
- O
kDa O
protein O
. O

Following O
intracranial O
inoculation O
of O
mice O
, O
the O
viruses O
encoding O
Tyr6398His O
/ O
Leu94Pro O
substitutions O
and O
the O
Tyr6398His O
substitution O
alone O
demonstrated O
log O
( O
10 O
) O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
values O
too O
great O
to O
be O
measured O
. O

The O
Leu94Pro O
mutant O
virus O
had O
reduced O
but O
measurable O
log O
( O
10 O
) O
LD50 O
and O
the O
corrected O
Tyr6398 O
/ O
Leu94 O
virus O
had O
a O
log O
( O
10 O
) O
LD50 O
identical O
to O
wild O
- O
type O
MHV O
- O
A59 O
. O

Advances O
in O
treating O
and O
preventing O
AIDS O
depend O
on O
understanding O
how O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
is O
eliminated O
in O
vivo O
and O
on O
the O
manipulation O
of O
effective O
immune O
responses O
to O
HIV O
. O

During O
the O
development O
of O
assays O
quantifying O
the O
elimination O
of O
fluorescent O
autologous O
cells O
coated O
with O
overlapping O
15 O
- O
mer O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
or O
HIV O
- O
1 O
peptides O
, O
we O
made O
a O
remarkable O
observation O
: O
the O
reinfusion O
of O
macaque O
peripheral O
blood O
mononuclear O
cells O
, O
or O
even O
whole O
blood O
, O
pulsed O
with O
SIV O
and O
/ O
or O
HIV O
peptides O
generated O
sharply O
enhanced O
SIV O
- O
and O
HIV O
- O
1 O
- O
specific O
T O
- O
cell O
immunity O
. O

Strong O
, O
broad O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
could O
be O
enhanced O
simultaneously O
against O
peptide O
pools O
spanning O
87 O
% O
of O
all O
SIV O
- O
and O
HIV O
- O
1 O
- O
expressed O
proteins O
- O
highly O
desirable O
characteristics O
of O
HIV O
- O
specific O
immunity O
. O

De O
novo O
hepatitis O
C O
virus O
- O
specific O
CD4 O
( O
+ O
) O
- O
and O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
were O
generated O
in O
macaques O
by O
the O
same O
method O
. O

Therefore O
, O
the O
antiviral O
activities O
of O
( O
i O
) O
ribavirin O
, O
( O
ii O
) O
its O
5 O
- O
ethynyl O
analogue O
, O
5 O
- O
ethynyl O
- O
1 O
- O
beta O
- O
D O
- O
ribofuranosylimidazole O
- O
4 O
- O
carboxamide O
( O
EICAR O
) O
, O
and O
( O
iii O
) O
mycophenolic B
acid I
( I
MPA I
) I
( O
a O
compound O
that O
. O

When O
the O
50 B
% I
effective I
concentrations I
( I
EC I
( I
50 I
) I
s I
) I
for O
the O
antiviral O
activities O
of O
ribavirin O
, O
EICAR O
, O
and O
MPA O
were O
plotted O
against O
the O
respective O
EC50 O
values O
for O
GTP O
pool O
depletion O
, O
a O
linear O
correlation O
was O
calculated O
. O

Here O
, O
we O
provide O
the O
first O
report O
of O
intergenotypic O
recombination O
in O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
the O
only O
animal O
RNA O
virus O
that O
requires O
host O
RNA O
polymerase O
( O
s O
) O
for O
viral O
replication O
. O

In O
vivo O
, O
we O
analyzed O
RNA O
species O
derived O
from O
the O
serum O
of O
a O
patient O
with O
mixed O
genotype O
I O
and O
genotype O
IIb O
HDV O
infection O
by O
using O
multiple O
restriction B
fragment I
length I
polymorphism I
( I
RFLP I
) I
assays O
and O
sequence O
analysis O
of O
cloned O
reverse B
transcription I
( I
RT I
) I
- O
PCR O
products O
. O

Alterations O
of O
cytokine O
responses O
are O
thought O
to O
favor O
the O
establishment O
of O
persistent O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
, O
enhancing O
the O
risk O
of O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

Here O
we O
demonstrate O
that O
the O
expression O
of O
the O
HCV O
core B
( I
C I
) I
protein O
in O
stably O
transfected O
T O
cells O
correlates O
with O
a O
selective O
reduction O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter O
activity O
and O
IL O
- O
2 O
production O
in O
response O
to O
T O
- O
cell O
receptor O
triggering O
, O
whereas O
the O
activation O
of O
IL O
- O
4 O
, O
IL O
- O
10 O
, O
gamma O
interferon O
, O
and O
tumor O
necrosis O
factor O
alpha O
was O
moderately O
increased O
. O

This O
altered O
cytokine O
expression O
profile O
was O
associated O
with O
a O
perturbation O
of O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinase O
responses O
. O

Extracellular O
regulated O
kinase O
and O
p38 O
were O
constitutively O
phosphorylated O
in O
C O
- O
expressing O
cells O
, O
while O
triggering O
of O
the O
costimulatory O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
signaling O
cascade O
and O
activation O
of O
the O
CD28 O
response O
element O
within O
the O
IL O
- O
2 O
promoter O
appeared O
to O
be O
impaired O
. O

ribavirin B
( I
RBV I
) I
, O
used O
in O
combination O
with O
alpha O
interferon O
to O
treat O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
, O
is O
a O
guanosine O
nucleotide O
analog O
that O
can O
increase O
the O
error O
rate O
of O
viral O
RNA O
- O
dependent O
RNA O
polymerases O
, O
imbalance O
intracellular O
nucleotide O
pools O
, O
and O
cause O
toxicity O
in O
many O
cell O
types O
. O

Murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
causes O
persistent O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
in O
rodents O
, O
which O
has O
been O
associated O
with O
demyelination O
. O

Here O
we O
show O
that O
the O
progenitor O
oligodendrocytes O
( O
central O
glial O
4 O
[ O
CG O
- O
4 O
] O
cells O
) O
derived O
from O
newborn O
rat O
brain O
were O
permissive O
to O
MHV O
infection O
, O
which O
resulted O
in O
cell O
death O
, O
although O
viral O
replication O
was O
restricted O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
positive O
- O
strand O
RNA O
virus O
belonging O
to O
the O
Flaviviridae O
. O

Its O
genome O
carries O
at O
either O
end O
highly O
conserved O
nontranslated B
regions I
( I
NTRs I
) I
containing O
cis O
- O
acting O
RNA O
elements O
that O
are O
crucial O
for O
replication O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
2a O
subgenomic O
replicon O
can O
replicate O
in O
two O
human O
non O
- O
hepatocytederived O
cell O
lines O
, O
HeLa O
and O
293 O
, O
with O
in O
vitro O
- O
transcribed O
replicon O
RNA O
. O

The O
Taura B
syndrome I
virus I
( I
TSV I
) I
, O
a O
member O
of O
the O
Dicistroviridae O
family O
of O
viruses O
, O
is O
a O
single O
- O
stranded O
positive O
- O
sense O
RNA O
virus O
which O
contains O
two O
nonoverlapping O
reading O
frames O
separated O
by O
a O
230 O
- O
nucleotide O
intergenic O
region O
. O

This O
intergenic O
region O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
which O
directs O
the O
synthesis O
of O
the O
TSV O
capsid O
proteins O
. O

Unlike O
other O
dicistroviruses O
, O
the O
TSV O
IRES O
contains O
an O
AUG O
codon O
that O
is O
in O
frame O
with O
the O
capsid O
region O
, O
suggesting O
that O
the O
IRES O
initiates O
translation O
at O
this O
AUG O
codon O
by O
using O
initiator O
tRNA O
( O
met O
) O
. O

Like O
the O
IRES O
in O
cricket B
paralysis I
virus I
( I
CrPV I
) I
, O
the O
TSV O
IRES O
can O
assemble O
80S O
ribosomes O
in O
the O
absence O
of O
initiation O
factors O
and O
can O
direct O
protein O
synthesis O
in O
a O
reconstituted O
system O
that O
contains O
only O
purified O
ribosomal O
subunits O
, O
eukaryotic O
elongation O
factors O
1A O
and O
2 O
, O
and O
aminoacylated O
tRNAs O
. O

Phosphorylation O
of O
the O
coronavirus O
nucleoprotein O
( O
N O
protein O
) O
has O
been O
predicted O
to O
play O
a O
role O
in O
RNA O
binding O
. O

To O
investigate O
this O
hypothesis O
, O
we O
examined O
the O
kinetics O
of O
RNA O
binding O
between O
nonphosphorylated O
and O
phosphorylated O
infectious O
bronchitis O
virus O
N O
protein O
with O
nonviral O
and O
viral O
RNA O
by O
surface O
plasmon O
resonance O
( O
Biacore O
) O
. O

The O
data O
also O
indicated O
that O
a O
known O
N O
protein O
binding O
site O
( O
involved O
in O
transcriptional O
regulation O
) O
consisting O
of O
a O
conserved O
core O
sequence O
present O
near O
the O
5 O
' O
end O
of O
the O
genome O
( O
in O
the O
leader O
sequence O
) O
functioned O
by O
promoting O
high O
association O
rates O
of O
N O
protein O
binding O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
a O
putative O
nucleocapsid O
protein O
with O
a O
number O
of O
regulatory O
functions O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
has O
evolved O
complex O
strategies O
to O
evade O
host O
immune O
responses O
and O
establish O
chronic O
infection O
. O

The O
only O
treatment O
available O
for O
HCV O
infections O
, O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
is O
effective O
in O
a O
limited O
percentage O
of O
patients O
. O

We O
reported O
that O
conventional B
protein I
kinase I
C I
( I
cPKC I
) I
activity O
is O
important O
for O
the O
effectiveness O
of O
IFN O
- O
alpha O
treatment O
. O

We O
have O
previously O
reported O
that O
a O
pseudotype O
virus O
generated O
by O
reconstitution O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
chimeric O
envelope O
glycoprotein O
E1 O
- O
G O
or O
E2 O
- O
G O
on O
the O
surface O
of O
a O
temperature O
- O
sensitive O
mutant O
of O
vesicular O
stomatitis O
virus O
( O
VSVts045 O
) O
interacts O
independently O
with O
mammalian O
cells O
to O
initiate O
infection O
. O

Stable O
transfectants O
of O
baby B
hamster I
kidney I
( I
BHK I
) I
epithelial O
cells O
expressing O
either O
one O
or O
both O
of O
the O
chimeric O
envelope O
glycoproteins O
of O
HCV O
on O
the O
cell O
surface O
were O
generated O
. O

Treatment O
of O
the O
E1 O
- O
G O
/ O
E2 O
- O
G O
pseudotype O
with O
a O
negatively O
charged O
sulfated O
sialyl O
lipid O
( O
NMS03 O
) O
displayed O
a O
similar O
to4 O
- O
fold O
- O
higher O
sensitivity O
to O
neutralization O
than O
pseudotypes O
with O
either O
of O
the O
two O
individual O
glycoproteins O
. O

Several O
cellular O
proteins O
, O
including O
several O
heterogeneous B
nuclear I
ribonucleoproteins I
( I
hnRNPs I
) I
, O
have O
been O
shown O
to O
function O
as O
regulatory O
factors O
for O
mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
synthesis O
as O
a O
result O
of O
their O
binding O
to O
the O
5 O
' O
and O
3 O
' O
untranslated B
regions I
( I
UTRs I
) I
of O
the O
viral O
RNA O
. O

Matrix B
- I
assisted I
laser I
desorption I
ionization I
( I
MALDI I
) I
- O
mass O
spectrometry O
identified O
it O
as O
synaptotagmin B
- I
binding I
cytoplasmic I
RNA I
- I
interacting I
protein I
( I
SYNCRIP I
) I
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA I
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
represented O
by O
nonstructural B
protein I
5B I
( I
NS5B I
) I
, O
belongs O
to O
a O
class O
of O
integral O
membrane O
proteins O
termed O
tail O
- O
anchored O
proteins O
. O

Efficient O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
subgenomic O
RNA O
in O
cell O
culture O
requires O
the O
introduction O
of O
adaptive O
mutations O
. O

The O
starting O
hypothesis O
was O
that O
high O
amounts O
of O
the O
NS5A O
hyperphosphorylated O
form O
, O
p58 O
, O
inhibit O
replication O
and O
that O
reduction O
of O
p58 O
by O
inhibition O
of O
specific O
kinase O
( O
s O
) O
below O
a O
certain O
threshold O
enables O
HCV O
replication O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
a O
circular O
RNA O
which O
encodes O
a O
single O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
. O

HDAg O
exists O
in O
two O
forms O
, O
a O
small O
form O
( O
S O
- O
HDAg O
) O
and O
a O
large O
form O
( O
L O
- O
HDAg O
) O
. O

Here O
we O
show O
that O
S O
- O
HDAg O
can O
be O
methylated O
by O
protein B
arginine I
methyltransferase I
( I
PRMT1 I
) I
in O
vitro O
and O
in O
vivo O
. O

The O
major O
methylation O
site O
is O
at O
arginine O
- O
13 O
( O
1113 O
) O
, O
which O
is O
in O
the O
RGGR O
motif O
of O
an O
RNA O
- O
binding O
domain O
. O

Gene O
1 O
of O
the O
coronavirus O
associated O
with O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
encodes O
replicase O
polyproteins O
that O
are O
predicted O
to O
be O
processed O
into O
16 O
nonstructural O
proteins O
( O
nsps O
1 O
to O
16 O
) O
by O
two O
viral O
proteases O
, O
a O
papain B
- I
like I
protease I
( I
PLpro I
) I
and O
a O
3C B
- I
like I
protease I
( I
3CLpro I
) I
. O

We O
found O
that O
nsp1 O
( O
p20 O
) O
is O
rapidly O
processed O
from O
the O
replicase O
polyprotein O
. O

In O
contrast O
, O
processing O
at O
the O
nsp2 O
/ O
3 O
site O
is O
less O
efficient O
, O
since O
a O
approximate O
to300 O
- O
kDa O
intermediate O
( O
NSP2 O
- O
3 O
) O
is O
detected O
, O
but O
ultimately O
nsp2 O
( O
p71 O
) O
and O
nsp3 O
( O
p213 O
) O
are O
generated O
. O

RNA O
interference O
, O
a O
natural O
biological O
phenomenon O
mediated O
by O
small B
interfering I
RNAs I
( I
siRNAs I
) I
, O
has O
been O
demonstrated O
in O
recent O
studies O
to O
be O
an O
effective O
strategy O
against O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

These O
sequences O
are O
conserved O
in O
select O
neurotropic O
strains O
of O
HIV O
- O
1 O
( O
JR O
- O
FL O
, O
JR O
- O
CSF O
, O
and O
YU O
- O
2 O
) O
. O

To O
test O
a O
possible O
functional O
role O
of O
the O
recently O
proposed O
Phix O
( O
3 O
) O
Phi O
motif O
in O
NS3 O
protease O
activation O
, O
we O
targeted O
six O
residues O
within O
the O
NS2B O
cofactor O
by O
site O
- O
specific O
mutagenesis O
. O

The O
effects O
of O
these O
mutations O
on O
the O
activity O
of O
the O
NS2B O
( O
H O
) O
- O
NS3pro O
protease O
were O
analyzed O
in O
vitro O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
analysis O
of O
autoproteolytic O
cleavage O
at O
the O
NS2B O
/ O
NS3 O
site O
and O
by O
assay O
of O
the O
enzyme O
with O
the O
fluorogenic O
peptide O
substrate O
GRR O
- O
AMC O
. O

With O
exception O
of O
the O
S71A O
mutant O
, O
which O
had O
a O
k O
( O
cat O
) O
/ O
K O
- O
m O
value O
for O
the O
GRR O
- O
AMC O
peptide O
similar O
to O
that O
of O
the O
wild O
type O
, O
all O
other O
mutants O
exhibited O
drastically O
reduced O
k O
( O
cat O
) O
values O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infections O
represent O
a O
global O
health O
problem O
and O
are O
a O
major O
contributor O
to O
end O
- O
stage O
liver O
disease O
including O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

As O
with O
acute O
- O
resolving O
HCV O
infections O
, O
many O
interferon B
( I
IFN I
) I
stimulated O
genes O
( O
ISGs O
) O
were O
transcriptionally O
elevated O
, O
suggesting O
an O
ongoing O
response O
to O
IFN O
and O
/ O
or O
double O
- O
stranded O
RNA O
which O
is O
amplified O
in O
downstream O
ISG O
expression O
. O

For O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
the O
first O
proteolytic O
processing O
event O
of O
the O
replicase O
polyprotein O
liberates O
an O
amino O
- O
terminal O
28 O
- O
kDa O
product O
( O
p28 O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replicates O
through O
an O
error O
- O
prone O
process O
that O
may O
support O
the O
evolution O
of O
genetic O
variants O
resistant O
to O
the O
host O
cell O
antiviral O
response O
and O
interferon B
( I
IFN I
) I
- O
based O
therapy O
. O

In O
contrast O
, O
a O
replicon O
with O
an O
L2198S O
point O
mutation O
replicated O
poorly O
and O
triggered O
a O
cellular O
response O
characterized O
by O
IFN O
- O
beta O
production O
and O
low O
- O
level O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
expression O
. O

When O
maintained O
in O
long O
term O
- O
culture O
, O
the O
L2198S O
RNA O
evolved O
into O
a O
stable O
high B
- I
passage I
( I
HP I
) I
variant O
with O
six O
additional O
point O
mutations O
throughout O
the O
HCV O
protein O
- O
encoding O
region O
that O
enhanced O
viral O
replication O
. O

The O
immature O
core O
protein O
( O
p23 O
, O
residues O
1 O
to O
191 O
) O
of O
hepatitis O
C O
virus O
undergoes O
posttranslational O
modifications O
including O
intramembranous O
proteolysis O
within O
its O
C O
- O
terminal O
signal O
sequence O
by O
signal O
peptide O
peptidase O
to O
generate O
the O
mature O
form O
( O
p21 O
) O
. O

Matrix B
- I
assisted I
laser I
desorption I
ionization I
- I
time I
of I
flight I
mass I
spectrometry I
( I
MALDI I
- I
TOF I
MS I
) I
analysis O
of O
purified O
p21 O
showed O
that O
the O
average O
molecular O
mass O
( O
m O
/ O
z O
19 O
, O
307 O
) O
of O
its O
single O
- O
charged O
ion O
differs O
by O
m O
/ O
z O
1 O
, O
457 O
from O
that O
calculated O
for O
p23 O
. O

Analysis O
of O
these O
peptides O
by O
MALDI O
- O
TOF O
tandem O
MS O
revealed O
that O
they O
correspond O
to O
N O
- O
terminal O
peptides O
( O
residues O
2 O
to O
9 O
and O
2 O
to O
10 O
) O
starting O
with O
alpha O
- O
N O
- O
acetylserine O
and O
C O
- O
terminal O
peptide O
( O
residues O
150 O
to O
177 O
) O
ending O
with O
phenylalanine O
. O

These O
results O
suggest O
that O
the O
mature O
core O
protein O
( O
molecular O
mass O
of O
19 O
, O
306 O
Da O
) O
includes O
residues O
2 O
to O
177 O
and O
that O
its O
N O
terminus O
is O
blocked O
with O
an O
acetyl O
group O
. O

To O
investigate O
interactions O
between O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
complexes O
, O
a O
system O
was O
developed O
to O
simultaneously O
select O
different O
HCV O
subgenomic O
replicons O
within O
the O
same O
cell O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA I
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
has O
several O
distinct O
biochemical O
activities O
, O
including O
initiation O
of O
RNA O
synthesis O
by O
a O
de O
novo O
mechanism O
, O
extension O
from O
a O
primed O
template O
, O
nontemplated O
nucleotide O
addition O
, O
and O
synthesis O
of O
a O
recombinant O
RNA O
product O
from O
two O
or O
more O
noncovalently O
linked O
templates O
( O
template O
switch O
) O
. O

All O
of O
these O
activities O
require O
specific O
interaction O
with O
nucleoside B
triphosphates I
( I
NTPs I
) I
. O

5 O
muM O
, O
all O
of O
the O
mutations O
except O
one O
had O
K O
( O
m O
) O
s O
that O
were O
three O
- O
to O
sevenfold O
higher O
. O

Unexpectedly O
, O
many O
of O
the O
mutations O
also O
affected O
the O
addition O
of O
nontemplated O
nucleotide O
, O
indicating O
that O
residues O
in O
the O
initiating B
NTP I
( I
NTPi I
) I
- O
binding O
pocket O
are O
required O
for O
nontemplated O
nucleotide O
additions O
. O

Nonstructural B
protein I
15 I
( I
Nsp15 I
) I
of O
the O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
produced O
in O
Escherichia O
coli O
has O
endoribonuclease O
activity O
that O
preferentially O
cleaved O
5 O
' O
of O
uridylates O
of O
RNAs O
. O

Concentrations O
of O
Mn2 O
+ O
needed O
for O
endoribonuclease O
activity O
induced O
significant O
conformation O
change O
( O
s O
) O
in O
the O
protein O
, O
as O
measured O
by O
changes O
in O
tryptophan O
fluorescence O
. O

The O
recently O
emerged O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
contains O
four O
structural O
genes O
, O
two O
replicase O
- O
transcriptase O
open O
reading O
frames O
, O
and O
more O
than O
five O
potential O
genes O
of O
unknown O
function O
. O

Here O
, O
we O
report O
that O
two O
viral O
genes O
, O
encoding O
the O
SARS B
- I
CoV I
membrane I
( I
M I
) I
and O
nucleocapsid B
( I
N I
) I
proteins O
, O
are O
necessary O
and O
sufficient O
for O
formation O
of O
virus O
- O
like O
particles O
. O

The O
addition O
of O
a O
third O
gene O
, O
encoding O
the O
spike B
( I
S I
) I
glycoprotein O
, O
facilitated O
budding O
of O
particles O
that O
contained O
a O
corona O
- O
like O
halo O
resembling O
SARS O
- O
CoV O
when O
examined O
by O
transmission O
electron O
microscopy O
, O
with O
a O
buoyant O
density O
characteristic O
of O
coronaviruses O
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
caused O
by O
a O
newly O
identified O
coronavirus O
( O
SARS O
- O
CoV O
) O
is O
a O
serious O
emerging O
human O
infectious O
disease O
. O

In O
this O
report O
, O
we O
immunized O
ferrets O
( O
Mustela O
putorius O
furo O
) O
with O
recombinant B
modified I
vaccinia I
virus I
Ankara I
( I
rMVA I
) I
expressing O
the O
SARS O
- O
CoV O
spike B
( I
S I
) I
protein O
. O

noncytopathogenic B
( I
noncp I
) I
strains O
of O
the O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
can O
establish O
persistent O
infection O
. O

In O
persistently O
infected O
animals O
, O
noncp O
BVDVs O
occasionally O
acquire O
mutations O
in O
viral O
nonstructural B
protein I
2 I
( I
NS2 I
) I
that O
give O
rise O
to O
cytopathogenic B
( I
cp I
) I
BVDV O
variants O
, O
and O
, O
eventually O
, O
lead O
to O
the O
onset O
of O
lethal O
disease O
. O

The O
regulation O
of O
TT B
virus I
( I
TTV I
) I
gene O
expression O
was O
characterized O
. O

Transient O
- O
transfection O
assays O
using O
reporter O
constructs O
revealed O
that O
a O
113 O
- O
nucleotide B
( I
nt I
) I
sequence O
within O
the O
untranslated O
region O
, O
proximal O
to O
the O
transcription O
initiation O
site O
and O
containing O
a O
TATA O
box O
motif O
, O
has O
a O
basal O
promoter O
activity O
. O

The O
cis O
- O
replicating O
RNA O
elements O
in O
the O
5 O
' O
and O
3 O
' O
nontranslated B
regions I
( I
NTRs I
) I
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
have O
been O
thoroughly O
studied O
before O
. O

We O
have O
selected O
for O
our O
studies O
a O
249 O
- O
nt O
- O
long O
RNA O
segment O
in O
the O
C O
- O
terminal O
NS5B B
coding I
region I
( I
NS5BCR I
) I
, O
which O
is O
predicted O
to O
form O
four O
stable O
stem O
- O
loop O
structures O
( O
SL O
- O
IV O
to O
SL O
- O
VII O
) O
. O

By O
deletion O
and O
mutational O
analyses O
of O
the O
RNA O
structures O
, O
we O
have O
determined O
that O
two O
of O
the O
stem O
- O
loops O
( O
SL O
- O
V O
and O
SL O
- O
VI O
) O
are O
essential O
for O
replication O
of O
the O
HCV O
sub O
- O
genomic O
replicon O
in O
Huh O
- O
7 O
cells O
. O

The O
other O
two O
stem O
- O
loops O
( O
SL O
- O
IV O
and O
SL O
- O
VII O
) O
of O
the O
NS5BCR O
domain O
were O
found O
to O
be O
important O
but O
not O
essential O
for O
colony O
formation O
by O
the O
subgenomic O
replicon O
. O

The O
precise O
function O
( O
s O
) O
of O
these O
cis O
- O
acting O
RNA O
elements O
is O
not O
known O
. O

Mutations O
critical O
for O
the O
central B
nervous I
system I
( I
CNS I
) I
attenuation O
of O
the O
Sabin O
vaccine O
strains O
of O
poliovirus B
( I
PV I
) I
are O
located O
within O
the O
viral O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

We O
examined O
the O
interaction O
of O
the O
IRESs O
of O
PV B
type I
3 I
( I
PV3 I
) I
and O
Sabin B
type I
3 I
( I
Sabin3 I
) I
with O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
and O
a O
neural O
cell O
- O
specific O
homologue O
, O
nPTB O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
viral O
hepatitis O
. O

We O
have O
identified O
a O
nucleotide B
binding I
motif I
( I
NBM I
) I
in O
one O
of O
the O
virus O
' O
s O
nonstructural O
proteins O
, O
NS4B O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
is O
the O
pathogen O
of O
SARS O
, O
which O
caused O
a O
global O
panic O
in O
2003 O
. O

We O
achieved O
this O
by O
using O
a O
two O
- O
step O
screening O
method O
consisting O
of O
frontal O
affinity O
chromatography O
- O
mass O
spectrometry O
coupled O
with O
a O
viral O
infection O
assay O
based O
on O
a O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
- O
luc O
/ O
SARS O
pseudotyped O
virus O
. O

Two O
small O
molecules O
, O
tetra O
- O
O O
- O
galloyl O
- O
beta O
- O
D O
- O
glucose O
( O
TGG O
) O
and O
luteolin O
, O
were O
identified O
, O
whose O
anti O
- O
SARS O
- O
CoV O
activities O
were O
confirmed O
by O
using O
a O
wild O
- O
type O
SARS O
- O
CoV O
infection O
system O
. O

Like O
other O
positive O
- O
strand O
RNA O
viruses O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
believed O
to O
replicate O
its O
RNA O
in O
association O
with O
host O
cell O
cytoplasmic O
membranes O
. O

We O
identified O
a O
putative O
N O
- O
terminal O
amphipathic B
helix I
( I
AH I
) I
in O
NS4B O
that O
mediates O
membrane O
association O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
chronic O
viral O
hepatitis O
worldwide O
. O

The O
HCV O
structural O
proteins O
have O
been O
shown O
to O
assemble O
into O
noninfectious O
HCV B
- I
like I
particles I
( I
HCV I
- I
LPs I
) I
. O

Using O
a O
library O
of O
homologous O
overlapping O
envelope O
peptides O
covering O
the O
entire O
HCV O
envelope O
, O
we O
identified O
an O
epitope O
in O
the O
N O
- O
terminal O
E2 O
region O
( O
SQKIQLVN O
TNGSWHI O
; O
amino O
acid O
positions O
408 O
to O
422 O
) O
as O
one O
target O
of O
human O
antiviral O
antibodies O
inhibiting O
cellular O
particle O
binding O
. O

Searching O
the O
sequence O
databases O
has O
revealed O
two O
novel O
cytokines O
: O
Interleukin B
- I
23 I
( I
IL I
- I
23 I
) I
and O
IL O
- O
27 O
. O

Previously O
, O
we O
evaluated O
the O
prime O
- O
boost O
immunization O
consisting O
of O
priming O
and O
the O
first O
boosting O
with O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
core O
expression O
plasmid O
, O
followed O
by O
a O
second O
boosting O
with O
recombinant O
adenovirus O
expressing O
HCV O
core O
for O
induction O
of O
HCV O
core O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
in O
BALB O
/ O
c O
mice O
. O

Coadministration O
of O
either O
an O
IL O
- O
23 O
or O
an O
IL O
- O
27 O
expression O
plasmid O
, O
as O
well O
as O
an O
IL O
- O
12 O
expression O
plasmid O
, O
in O
a O
prime O
- O
boost O
immunization O
enhanced O
induction O
of O
HCV O
- O
specific O
CTLs O
and O
led O
to O
dramatic O
increases O
in O
the O
numbers O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
, O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
cells O
. O

Further O
, O
preinjections O
of O
IL O
- O
12 O
, O
IL O
- O
23 O
, O
or O
IL O
- O
27 O
expression O
plasmids O
before O
immunization O
resulted O
in O
great O
increases O
in O
the O
number O
of O
IFN O
- O
gamma O
- O
producing O
, O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
cells O
in O
response O
to O
immunization O
with O
recombinant O
adenovirus O
. O

The O
assembly O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
poorly O
understood O
, O
largely O
due O
to O
the O
lack O
of O
mammalian O
cell O
culture O
systems O
that O
are O
easily O
manipulated O
and O
produce O
high O
titers O
of O
virus O
. O

A O
novel O
mutant O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
was O
found O
with O
a O
virion O
assembly O
phenotype O
attributable O
to O
an O
insertion O
into O
the O
NS5B O
polymerase O
locus O
. O

Pseudorevertants O
of O
mutant O
5B O
- O
741 O
that O
released O
infectious O
virions O
and O
formed O
plaques O
revealed O
a O
single O
nucleotide O
change O
( O
T12369C O
) O
. O

This O
change O
resulted O
in O
a O
leucine O
- O
to O
- O
proline O
substitution O
within O
the O
NS5B O
tag O
( O
L726P O
) O
. O

A O
subgenomic O
BVDV O
reporter O
replicon O
( O
rNS3 O
- O
5B O
) O
was O
used O
to O
analyze O
the O
consequences O
of O
alterations O
of O
the O
genomic O
region O
encoding O
the O
NS5B O
C O
terminus O
on O
replication O
and O
assembly O
. O

Interestingly O
, O
rNS3 O
- O
5B O
- O
L726P O
( O
revertant O
) O
replicated O
with O
the O
same O
efficiency O
as O
the O
rNS3 O
- O
5B O
- O
741 O
mutant O
but O
produced O
10 O
times O
more O
virions O
in O
a O
trans O
- O
packaging O
assay O
. O

Persistent O
replication O
of O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
replicon O
suggests O
that O
the O
replicon O
does O
not O
elicit O
cellular O
innate O
antiviral O
responses O
. O

Luciferase O
reporter O
assays O
revealed O
that O
the O
baseline O
activity O
of O
the O
interferon B
- I
stimulated I
response I
element I
( I
ISRE I
) I
was O
significantly O
lower O
in O
cells O
harboring O
the O
replicon O
than O
in O
naive O
cells O
. O

Among O
the O
proteins O
involved O
in O
the O
IFN O
/ O
jak O
/ O
STAT O
pathway O
and O
in O
ISRE O
activity O
, O
the O
expression O
level O
of O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
was O
found O
to O
be O
significantly O
lower O
in O
cells O
harboring O
the O
replicon O
. O

Two O
chimpanzees O
, O
1535 O
and O
1536 O
, O
became O
persistently O
infected O
following O
inoculation O
with O
RNA O
transcripts O
from O
cDNA O
clones O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

However O
, O
extensive O
mutations O
were O
not O
incorporated O
into O
hypervariable B
region I
1 I
( I
HVR1 I
) I
. O

3 O
X O
10 O
( O
- O
3 O
) O
( O
chimpanzee O
1535 O
) O
and O
3 O
. O

2 O
X O
10 O
( O
- O
3 O
) O
( O
chimpanzee O
1536 O
) O
substitutions O
/ O
site O
/ O
year O
at O
week O
26 O
to O
1 O
. O

4 O
X O
10 O
( O
- O
3 O
) O
( O
chimpanzee O
1535 O
) O
and O
1 O
. O

7 O
X O
10 O
( O
- O
3 O
) O
( O
chimpanzee O
1536 O
) O
at O
week O
216 O
, O
while O
the O
synonymous O
substitution O
rate O
remained O
steady O
at O
similar O
to1 O
X O
10 O
( O
- O
3 O
) O
substitutions O
/ O
site O
/ O
year O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
previously O
been O
reported O
to O
agglutinate O
human O
red O
blood O
cells O
at O
acidic O
pHs O
. O

At O
the O
same O
time O
, O
HAV O
- O
induced O
hemagglutination O
could O
also O
be O
blocked O
by O
either O
monoclonal O
antibody O
H7C27 O
or O
an O
anti O
- O
VP3 O
( O
102 O
- O
121 O
) O
ascitic O
fluid O
, O
indicating O
that O
lysine O
221 O
of O
VP1 O
and O
the O
surrounding O
VP3 O
residues O
lining O
the O
capsid O
pit O
are O
involved O
in O
HAV O
binding O
to O
erythrocytes O
. O

The O
coronavirus O
spike B
protein I
( I
S I
) I
forms O
the O
distinctive O
virion O
surface O
structures O
that O
are O
characteristic O
of O
this O
viral O
family O
, O
appearing O
in O
negatively O
stained O
electron O
microscopy O
as O
stems O
capped O
with O
spherical O
bulbs O
. O

For O
the O
prototype O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
it O
has O
previously O
been O
established O
that O
S O
protein O
assembly O
into O
virions O
is O
specified O
by O
the O
carboxy O
- O
terminal O
segment O
, O
which O
comprises O
the O
transmembrane O
domain O
and O
the O
endodomain O
. O

The O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
encodes O
proteins O
required O
for O
RNA O
transcription O
and O
genome O
replication O
as O
large O
polyproteins O
that O
are O
proteolytically O
processed O
by O
virus O
- O
encoded O
proteinases O
to O
produce O
mature O
replicase O
proteins O
. O

In O
this O
report O
, O
we O
generated O
antibodies O
against O
SARS O
- O
CoV O
predicted O
replicase O
protein O
and O
used O
the O
antibodies O
to O
identify O
and O
characterize O
12 O
of O
the O
16 O
predicted O
mature O
replicase O
proteins O
( O
nsp1 O
, O
nsp2 O
, O
nsp3 O
, O
nsp4 O
, O
nsp5 O
, O
nsp8 O
, O
nsp9 O
, O
nsp12 O
, O
nsp13 O
, O
nsp14 O
, O
nsp15 O
, O
and O
nsp16 O
) O
in O
SARS O
- O
CoV O
- O
infected O
Vero O
cells O
. O

Antibodies O
directed O
against O
mouse B
hepatitis I
virus I
( I
MHV I
) I
virions O
and O
against O
the O
putative O
RNA O
- O
dependent O
RNA O
Polymerase B
( I
Pol I
) I
detected O
SARS O
- O
CoV O
nucleocapsid O
and O
nsp12 O
( O
Pol O
) O
, O
respectively O
, O
in O
SARS O
- O
CoV O
- O
infected O
Vero O
cells O
. O

CEACAM1a O
glycoproteins O
are O
members O
of O
the O
immunoglobulin B
( I
Ig I
) I
superfamily O
and O
the O
carcinoembryonic O
antigen O
family O
. O

Moreover O
, O
the O
mouse O
and O
human O
CEACAM1a O
proteins O
are O
targets O
of O
viral O
or O
bacterial O
pathogens O
, O
respectively O
, O
including O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
Haemophilus O
influenzae O
, O
Neisseria O
gonorrhoeae O
, O
and O
Neisseria O
meningitidis O
, O
as O
well O
as O
Moraxella O
catarrhalis O
in O
humans O
. O

We O
have O
shown O
that O
targeted O
disruption O
of O
the O
Ceacam1a O
( O
MHVR O
) O
gene O
resulting O
in O
a O
partial O
ablation O
of O
the O
protein O
in O
mice O
( O
p O
/ O
p O
mice O
) O
led O
to O
reduced O
susceptibility O
to O
MHV O
- O
A59 O
infection O
of O
the O
modified O
mice O
in O
the O
BALB O
/ O
c O
background O
. O

We O
have O
now O
engineered O
and O
produced O
a O
Ceacam1a O
( O
- O
/ O
- O
) O
mouse O
that O
exhibits O
complete O
ablation O
of O
the O
CEACAM1a O
protein O
in O
every O
tissue O
where O
it O
is O
normally O
expressed O
. O

We O
report O
that O
3 O
- O
week O
- O
old O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
in O
the O
C57BL O
/ O
6 O
genetic O
background O
are O
fully O
resistant O
to O
MHV O
- O
A59 O
infection O
by O
both O
intranasal O
and O
intracerebral O
routes O
. O

Whereas O
virus O
- O
inoculated O
wildtype O
+ O
/ O
+ O
C57BL O
/ O
6 O
mice O
showed O
profound O
liver O
damage O
and O
spinal O
cord O
demyelination O
under O
these O
conditions O
, O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
displayed O
normal O
livers O
and O
spinal O
cords O
. O

Biochemical O
characterization O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
using O
purified O
, O
membrane O
- O
associated O
replication O
complexes O
is O
hampered O
by O
the O
presence O
of O
endogenous O
nuclease O
activity O
that O
copurifies O
with O
the O
replication O
complex O
. O

In O
this O
study O
, O
pulse O
- O
chase O
analyses O
were O
used O
to O
demonstrate O
that O
newly O
synthesized O
replicon O
RNA O
was O
protected O
from O
nuclease O
activity O
by O
a O
factor O
( O
s O
) O
that O
was O
sensitive O
to O
0 O
. O

These O
results O
suggest O
that O
a O
protease O
- O
sensitive O
factor O
( O
s O
) O
protects O
newly O
synthesized O
RNA O
from O
nuclease O
degradation O
. O

Despite O
recent O
successes O
in O
generating O
subgenomic O
RNA O
replicons O
derived O
from O
genotype O
1b O
strains O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
that O
replicate O
efficiently O
in O
cultured O
cells O
, O
it O
has O
proven O
difficult O
to O
generate O
efficiently O
replicating O
RNAs O
from O
any O
other O
genotype O
of O
HCV O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
represents O
the O
first O
191 O
amino O
acids O
of O
the O
viral O
precursor O
polyprotein O
and O
is O
cotranslationally O
inserted O
into O
the O
membrane O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

The O
subgenomic B
( I
sg I
) I
mRNAs O
of O
arteriviruses O
( O
order O
Nidovirales O
) O
form O
a O
5 O
' O
- O
and O
3 O
' O
- O
coterminal O
nested O
set O
with O
the O
viral O
genome O
. O

Presumably O
during O
minus O
- O
strand O
synthesis O
, O
the O
nascent O
RNA O
strand O
is O
transferred O
from O
one O
site O
in O
the O
genomic O
template O
to O
another O
, O
a O
process O
guided O
by O
conserved O
transcription B
- I
regulating I
sequences I
( I
TRSs I
) I
at O
these O
template O
sites O
. O

Factors O
thought O
to O
influence O
sg O
RNA O
synthesis O
are O
size O
differences O
between O
sg O
RNA O
species O
, O
differences O
in O
sequence O
context O
between O
body O
TRSs O
, O
and O
the O
mutual O
influence O
( O
or O
competition O
) O
between O
strand O
transfer O
reactions O
occurring O
at O
different O
body O
TRSs O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
expresses O
two O
essential O
proteins O
with O
distinct O
functions O
. O

The O
small B
hepatitis I
delta I
antigen I
( I
HDAg I
- I
S I
) I
is O
expressed O
throughout O
replication O
and O
is O
needed O
to O
promote O
that O
process O
. O

The O
large O
form O
( O
HDAg O
- O
L O
) O
is O
farnesylated O
, O
is O
expressed O
only O
at O
later O
times O
via O
RNA O
editing O
of O
the O
amber O
/ O
W O
site O
, O
and O
is O
required O
for O
virion O
assembly O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
health O
problem O
. O

We O
demonstrate O
that O
the O
dendritic B
cell I
( I
DC I
) I
- O
specific O
C O
- O
type O
lectin O
DC O
- O
SIGN O
and O
its O
liver O
- O
expressed O
homologue O
L O
- O
SIGN O
/ O
DC O
- O
SIGNR O
are O
important O
receptors O
for O
HCV O
envelope O
glycoproteins O
E1 O
and O
E2 O
. O

Mutagenesis O
analyses O
demonstrated O
that O
both O
HCV O
E1 O
and O
E2 O
bind O
the O
same O
binding O
site O
on O
DC O
- O
SIGN O
as O
the O
pathogens O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
and O
mycobacteria O
, O
which O
is O
distinct O
from O
the O
cellular O
ligand O
ICAM O
- O
3 O
. O

We O
recently O
reported O
that O
retroviral O
pseudotypes O
bearing O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
strain O
H O
and O
Con1 O
glycoproteins O
, O
genotype O
1a O
and O
1b O
, O
respectively O
, O
require O
CD81 O
as O
a O
coreceptor O
for O
virus O
- O
cell O
entry O
and O
infection O
. O

Our O
current O
model O
of O
HCV O
infection O
suggests O
that O
CD81 O
, O
together O
with O
additional O
unknown O
liver O
specific O
receptor O
( O
s O
) O
, O
mediate O
the O
virus O
- O
cell O
entry O
process O
. O

To O
characterize O
the O
induction O
of O
antigen O
- O
specific O
immune O
response O
mediated O
by O
baculovirus O
, O
vectors O
expressing O
the O
E2 O
glycoprotein O
of O
hepatitis O
C O
virus O
or O
the O
carcinoembryonic B
antigen I
( I
CEA I
) I
under O
the O
control O
of O
the O
cytomegalovirus O
immediate O
- O
early O
promoter O
- O
enhancer O
were O
constructed O
. O

Additionally O
, O
a O
baculovirus O
vector O
encoding O
the O
E2 O
glycoprotein O
( O
Bac O
- O
G O
- O
E2 O
) O
and O
expressing O
vesicular B
stomatitis I
virus I
glycoprotein I
( I
VSV I
- I
G I
) I
in O
the O
viral O
envelope O
was O
generated O
by O
inserting O
the O
VSV O
- O
G O
coding O
sequence O
downstream O
of O
the O
polyhedrin O
promoter O
. O

Induction O
of O
a O
measurable O
anti O
- O
E2 O
T O
- O
cell O
response O
was O
observed O
only O
after O
intramuscular O
injection O
and O
was O
predominantly O
CD8 O
( O
+ O
) O
specific O
. O

The O
immunogenic O
properties O
of O
baculovirus O
as O
vaccine O
vector O
were O
not O
restricted O
to O
E2 O
because O
a O
CEA O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
was O
observed O
upon O
intramuscular O
injection O
of O
Bac O
- O
CEA O
. O

Most O
importantly O
, O
both O
vectors O
elicited O
CD8 O
( O
+ O
) O
T O
cells O
with O
effector O
function O
capable O
of O
lysing O
target O
cells O
loaded O
with O
a O
hepatitis O
C O
virus O
- O
specific O
epitope O
. O

The O
complete O
genome O
sequences O
of O
the O
human B
coronavirus I
OC43 I
( I
HCoV I
- I
OC43 I
) I
laboratory O
strain O
from O
the O
American B
Type I
Culture I
Collection I
( I
ATCC I
) I
, O
and O
a O
HCoV O
- O
OC43 O
clinical O
isolate O
, O
designated O
Paris O
, O
were O
obtained O
. O

Both O
genomes O
are O
30 O
, O
713 O
nucleotides O
long O
, O
excluding O
the O
poly O
( O
A O
) O
tail O
, O
and O
only O
differ O
by O
6 O
nucleotides O
. O

These O
six O
mutations O
are O
scattered O
throughout O
the O
genome O
and O
give O
rise O
to O
only O
two O
amino O
acid O
substitutions O
: O
one O
in O
the O
spike O
protein O
gene O
( O
1958F O
) O
and O
the O
other O
in O
the O
nucleocapsid O
protein O
gene O
( O
V81A O
) O
. O

Furthermore O
, O
the O
two O
variants O
were O
shown O
to O
reach O
the O
central B
nervous I
system I
( I
CNS I
) I
after O
intranasal O
inoculation O
in O
BALB O
/ O
c O
mice O
, O
demonstrating O
neuroinvasive O
properties O
. O

2 O
% O
identity O
with O
those O
of O
mouse O
hepatitis O
virus O
A59 O
, O
severe B
acute I
respiratory I
syndrome I
human I
coronavirus I
Tor2 I
strain I
( I
SARS I
- I
HCoV I
Tor2 I
) I
, O
and O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
, O
respectively O
. O

The O
recent O
development O
of O
infectious O
retroviral O
pseudotypes O
bearing O
hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
represents O
an O
opportunity O
to O
study O
the O
functionally O
active O
form O
of O
the O
HCV O
El O
and O
E2 O
glycoproteins O
. O

Endoglycosidase B
H I
( I
endo I
- I
H I
) I
treatment O
of O
particles O
demonstrated O
that O
the O
incorporated O
El O
was O
partially O
or O
completely O
sensitive O
to O
digestion O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
displays O
a O
high O
degree O
of O
genetic O
variability O
. O

In O
vitro O
sensitivity O
studies O
with O
BILN O
2061 O
showed O
a O
decrease O
in O
affinity O
for O
proteases O
of O
genotypes O
2 O
and O
3 O
( O
K O
- O
i O
, O
80 O
to O
90 O
nM O
) O
compared O
to O
genotype O
1 O
enzymes O
( O
K O
- O
i O
, O
1 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replicates O
its O
genome O
in O
a O
membrane O
- O
associated O
replication O
complex O
, O
composed O
of O
viral O
proteins O
, O
replicating O
RNA O
and O
altered O
cellular O
membranes O
. O

Viable O
replicons O
selected O
from O
a O
library O
of O
Tn7 O
- O
mediated O
random O
insertions O
in O
the O
coding O
sequence O
of O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
allowed O
the O
identification O
of O
two O
sites O
near O
the O
NS5A O
C O
terminus O
that O
tolerated O
insertion O
of O
heterologous O
sequences O
. O

Replicons O
encoding O
green B
fluorescent I
protein I
( I
GFP I
) I
at O
these O
locations O
were O
only O
moderately O
impaired O
for O
HCV O
RNA O
replication O
. O

Nucleotide O
sequence O
analyses O
revealed O
five O
distinct O
genotypes O
( O
tth3 O
, O
tth4 O
, O
tth5 O
, O
tth6 O
, O
and O
tth7 O
) O
. O

A O
group O
of O
6 O
isolates O
( O
the O
tth7 O
group O
) O
revealed O
a O
reorganization O
of O
open B
reading I
frame I
1 I
( I
ORFI I
) I
leading O
to O
one O
larger O
and O
a O
varying O
number O
of O
smaller O
ORFs O
. O

A O
variation O
of O
69 O
to O
97 O
% O
in O
amino O
acids O
of O
a O
second O
group O
of O
8 O
isolates O
( O
the O
tth3 O
group O
) O
was O
restricted O
to O
the O
hypervariable O
region O
of O
ORF1 O
, O
indicating O
the O
existence O
of O
a O
quasi O
- O
species O
. O

An O
alignment O
of O
these O
isolates O
with O
79 O
previously O
reported O
TT O
virus O
genotypes O
permits O
the O
proposal O
of O
TT O
virus O
genera O
and O
species O
within O
the O
family O
Anelloviridae O
in O
analogy O
to O
a O
previous O
proposal O
for O
the O
papillomaviruses O
( O
family O
Papillomaviridae O
) O
. O

Recent O
outbreaks O
of O
West B
Nile I
virus I
( I
WNV I
) I
have O
been O
associated O
with O
an O
increase O
in O
morbidity O
and O
mortality O
in O
humans O
, O
birds O
, O
and O
many O
other O
species O
. O

Biochemical O
and O
microarray O
analyses O
demonstrated O
that O
WNV O
induced O
the O
expression O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
several O
IFN O
- O
stimulated O
genes O
late O
in O
infection O
of O
cultured O
human O
cells O
. O

The O
late O
expression O
of O
these O
antiviral O
genes O
was O
due O
to O
the O
delayed O
activation O
of O
the O
transcription O
factor O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
. O

The O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
replicase O
gene O
- O
encoded O
nonstructural B
protein I
13 I
( I
nsp13 I
) I
contains O
an O
N O
- O
terminal O
zinc O
- O
binding O
domain O
and O
a O
C O
- O
terminal O
superfamily O
1 O
helicase O
domain O
. O

Characterization O
of O
the O
nsp13 O
- O
associated O
nucleoside B
triphosphatase I
( I
NTPase I
) I
activities O
revealed O
that O
all O
natural O
ribonucleotides O
and O
nucleotides O
are O
substrates O
of O
nsp13 O
, O
with O
ATP O
, O
dATP O
, O
and O
GTP O
being O
hydrolyzed O
most O
efficiently O
. O

In O
models O
of O
the O
replication O
of O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
, O
it O
is O
generally O
assumed O
that O
circular O
RNAs O
are O
the O
only O
templates O
. O

It O
is O
presumed O
that O
resolution O
of O
hepatitis O
C O
, O
as O
evidenced O
by O
normalization O
of O
liver O
function O
tests O
and O
disappearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
from O
serum O
, O
as O
determined O
by O
conventional O
laboratory O
assays O
, O
reflects O
virus O
eradication O
. O

In O
this O
study O
, O
we O
examined O
the O
expression O
of O
the O
HCV O
genome O
in O
the O
sera O
, O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
and O
, O
on O
some O
occasions O
, O
monocyte O
- O
derived O
dendritic B
cells I
( I
DC I
) I
long O
after O
resolution O
of O
hepatitis O
C O
by O
using O
a O
highly O
sensitive O
reverse B
transcription I
( I
RT I
) I
- O
PCR O
- O
nucleic O
acid O
hybridization O
( O
RT O
- O
PCR O
- O
NAH O
) O
assay O
. O

The O
samples O
obtained O
from O
16 O
randomly O
selected O
patients O
( O
5 O
with O
spontaneous O
and O
11 O
with O
treatment O
- O
induced O
resolution O
) O
, O
monitored O
for O
up O
to O
5 O
years O
, O
were O
studied O
by O
qualitative O
and O
semiquantitative O
RT O
- O
PCR O
- O
NAH O
and O
by O
real O
- O
time O
RT O
- O
PCR O
to O
detect O
the O
HCV O
RNA O
positive O
strand O
. O

The O
p28 O
and O
p65 O
proteins O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
are O
the O
most O
amino O
- O
terminal O
protein O
domains O
of O
the O
replicase O
polyprotein O
. O

Cleavage O
between O
p28 O
and O
p65 O
has O
been O
shown O
to O
occur O
in O
vitro O
at O
cleavage B
site I
1 I
( I
CS1 I
) I
, O
( O
247 O
) O
Glydown O
arrowVal O
( O
248 O
) O
, O
in O
the O
polyprotein O
. O

Coronavirus O
discontinuous O
transcription O
uses O
a O
highly O
conserved B
sequence I
( I
CS I
) I
in O
the O
joining O
of O
leader O
and O
body O
RNAs O
. O

dendritic B
cells I
( I
DCs I
) I
, O
which O
are O
potent O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
, O
are O
used O
as O
adjuvants O
for O
the O
treatment O
of O
cancer O
and O
infectious O
diseases O
in O
human O
and O
nonhuman O
primates O
, O
with O
documented O
clinical O
efficacy O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
chimpanzee O
model O
is O
the O
best O
available O
model O
for O
testing O
the O
immunotherapeutic O
effects O
of O
DCs O
in O
the O
setting O
of O
a O
chronic O
infection O
, O
as O
chimpanzees O
develop O
a O
persistent O
infection O
resembling O
that O
seen O
in O
humans O
. O

As O
a O
prelude O
to O
clinical O
studies O
, O
we O
evaluated O
whether O
functionally O
mature O
DCs O
could O
be O
generated O
in O
chimpanzee O
plasma O
by O
good O
manufacturing O
practice O
using O
CD14 O
( O
+ O
) O
mononuclear O
precursors O
from O
chronically O
infected O
chimpanzees O
. O

Mature O
DCs O
were O
capable O
of O
stimulating O
allogeneic O
T O
cells O
, O
antigen O
- O
specific O
memory O
CD4 O
( O
+ O
) O
T O
cells O
, O
and O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
clones O
. O

Here O
, O
we O
demonstrate O
that O
direct O
binding O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
to O
gC1qR O
on O
T O
cells O
leads O
to O
impaired O
Lck O
/ O
Akt O
activation O
and O
T O
- O
cell O
function O
. O

8 O
x O
10 O
( O
- O
7 O
) O
M O
. O

Interestingly O
, O
gC1qR O
is O
expressed O
at O
higher O
levels O
on O
CD8 O
( O
+ O
) O
than O
on O
CD4 O
( O
+ O
) O
T O
cells O
, O
resulting O
in O
more O
severe O
core O
- O
induced O
suppression O
of O
the O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
population O
. O

The O
insect O
- O
borne O
bluetongue B
virus I
( I
BTV I
) I
is O
considered O
the O
prototypic O
Orbivirus O
, O
a O
member O
of O
the O
Reovirus O
family O
. O

In O
the O
present O
study O
we O
generated O
a O
mammalian O
cell O
line O
that O
expresses O
a O
recombinant O
single B
- I
chain I
antibody I
fragment I
( I
scFv I
) I
derived O
from O
an O
NS1 O
- O
specific O
monoclonal O
antibody O
( O
10B1 O
) O
and O
analyzed O
the O
effect O
that O
this O
intracellular O
antibody O
has O
on O
BTV O
replication O
. O

the B
hypervariable I
region I
1 I
( I
HVR1 I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
E2 O
envelope O
glycoprotein O
is O
a O
27 O
- O
amino O
- O
acid O
sequence O
located O
at O
its O
N O
terminus O
. O

The O
C O
- O
terminal O
truncated O
E2 O
glycoprotein O
was O
appended O
to O
a O
transmembrane O
domain O
and O
cytoplasmic O
tail O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
G O
protein O
for O
generation O
of O
the O
chimeric O
E2 O
- O
G O
gene O
construct O
. O

Pseudotype O
virus O
, O
generated O
separately O
by O
infection O
of O
a O
stable O
cell O
line O
expressing O
E2 O
- O
G O
or O
E2DeltaHVR1 O
- O
G O
with O
a O
temperature O
- O
sensitive O
mutant O
of O
VSV O
( O
VSVts045 O
) O
, O
displayed O
unique O
functional O
properties O
compared O
to O
VSVts045 O
as O
a O
negative O
control O
. O

Virus O
generated O
from O
E2DeltaHVR1 O
- O
G O
had O
a O
reduced O
plaquing O
efficiency O
( O
similar O
to50 O
% O
) O
in O
HepG2 O
cells O
compared O
to O
that O
for O
the O
E2 O
- O
G O
virus O
. O

5 O
U O
/ O
ml O
) O
displayed O
a O
complete O
inhibition O
of O
infectivity O
of O
the O
E2DeltaHVR1 O
- O
G O
or O
E2 O
- O
G O
pseudotypes O
, O
whereas O
heparinase O
I O
treatment O
( O
8 O
U O
/ O
ml O
) O
of O
cells O
reduced O
40 O
% O
E2 O
- O
G O
pseudotype O
virus O
titer O
only O
. O

E2DeltaHVR1 O
- O
G O
pseudotypes O
were O
not O
sensitive O
to O
heparin O
( O
6 O
to O
50 O
mug O
/ O
ml O
) O
as O
an O
inhibitor O
of O
plaque O
formation O
compared O
to O
the O
E2 O
- O
G O
pseudotype O
virus O
. O

This O
binding O
was O
competitively O
inhibited O
by O
a O
peptide O
from O
the O
V3 O
loop O
of O
a O
human O
immunodeficiency O
virus O
glycoprotein O
subunit O
( O
gp120 O
) O
known O
to O
bind O
with O
cell O
surface O
heparin O
. O

Initiation O
of O
protein O
synthesis O
on O
picornavirus O
RNA O
requires O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

Typically O
, O
picornavirus O
IRES O
elements O
contain O
about O
450 O
nucleotides B
( I
nt I
) I
and O
use O
most O
of O
the O
cellular O
translation O
initiation O
factors O
. O

However O
, O
it O
is O
now O
shown O
that O
just O
280 O
nt O
of O
the O
porcine O
teschovirus O
type O
1 O
Talfan O
( O
PTV O
- O
1 O
) O
5 O
' O
untranslated O
region O
direct O
the O
efficient O
internal O
initiation O
of O
translation O
in O
vitro O
and O
within O
cells O
. O

In O
toeprinting O
assays O
, O
assembly O
of O
48S O
preinitiation O
complexes O
from O
purified O
components O
on O
the O
PTV O
- O
1 O
IRES O
was O
achieved O
with O
just O
40S O
ribosomal O
subunits O
plus O
eIF2 O
and O
Met O
- O
tRNA O
( O
1 O
) O
( O
MET O
) O
. O

Thus O
, O
the O
PTV O
- O
1 O
IRES O
has O
properties O
that O
are O
entirely O
different O
from O
other O
picornavirus O
IRES O
elements O
but O
highly O
reminiscent O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
IRES O
. O

Intrinsic O
to O
the O
life O
cycle O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
the O
fact O
that O
its O
RNAs O
undergo O
different O
forms O
of O
posttranscriptional O
RNA O
processing O
. O

The O
first O
represented O
an O
examination O
under O
more O
controlled O
conditions O
of O
mutations O
in O
the O
poly O
( O
A O
) O
signal O
, O
AAUAAA O
, O
which O
is O
essential O
for O
this O
processing O
. O

A O
novel O
coronavirus O
, O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
has O
recently O
been O
identified O
as O
the O
causative O
agent O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
. O

It O
is O
known O
for O
other O
coronaviruses O
that O
the O
spike B
( I
S I
) I
glycoprotein O
is O
required O
for O
both O
viral O
attachment O
to O
permissive O
cells O
and O
for O
fusion O
of O
the O
viral O
envelope O
with O
the O
host O
cell O
membrane O
. O

Here O
we O
describe O
the O
construction O
and O
expression O
of O
a O
soluble O
codon O
- O
optimized O
SARS O
- O
CoV O
S O
glycoprotein O
comprising O
the O
first O
1 O
, O
190 O
amino O
acids O
of O
the O
native O
S O
glycoprotein O
( O
S O
- O
1190 O
) O
. O

We O
speculate O
that O
amino O
acids O
1 O
to O
510 O
of O
the O
SARS O
- O
CoV O
S O
glycoprotein O
represent O
a O
unique O
domain O
containing O
the O
receptor O
- O
binding O
site O
( O
amino O
acids O
270 O
to O
510 O
) O
, O
analogous O
to O
the O
S1 O
subunit O
of O
other O
coronavirus O
S O
glycoproteins O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
behaves O
in O
infected O
patients O
as O
a O
complex O
mixture O
of O
genetically O
distinct O
but O
closely O
related O
variants O
referred O
to O
as O
a O
quasispecies O
. O

By O
using O
quasispecies O
analysis O
strategies O
, O
we O
showed O
that O
HCV B
nonstructural I
protein I
5A I
( I
NS5A I
) I
has O
a O
quasispecies O
distribution O
in O
infected O
humans O
and O
that O
NS5A O
quasispecies O
undergo O
significant O
genetic O
evolution O
over O
time O
, O
as O
a O
result O
of O
random O
accumulation O
of O
nucleotide O
mutations O
during O
replication O
. O

By O
using O
the O
functional O
in O
vitro O
model O
of O
HCV O
NS5A O
transcriptional O
activation O
in O
Saccharomyces O
cerevisiae O
, O
we O
showed O
that O
natural O
NS5A O
quasispecies O
variants O
induce O
different O
levels O
of O
transcriptional O
activation O
, O
according O
to O
the O
charge O
of O
the O
residues O
( O
and O
possibly O
minor O
conformationall O
changes O
) O
in O
the O
quasispecies O
variant O
sequence O
. O

The O
fact O
that O
each O
new O
variant O
protein O
is O
initially O
produced O
in O
a O
single O
infected O
hepatocyte O
and O
may O
or O
may O
not O
subsequently O
spread O
throughout O
the O
liver O
( O
depending O
on O
the O
replication O
capacities O
of O
the O
variant O
virus O
) O
points O
to O
cellular O
compartmentalization O
of O
virus O
- O
host O
interactions O
during O
chronic O
infection O
. O

In O
their O
natural O
replication O
cycle O
, O
certain O
viruses O
employ O
a O
rolling O
- O
circle O
mechanism O
to O
propagate O
their O
circular O
genomes O
, O
and O
multiply O
primed O
rolling B
- I
circle I
amplification I
( I
RCA I
) I
with O
phi29 O
DNA O
polymerase O
has O
recently O
been O
applied O
in O
the O
amplification O
of O
circular O
plasmid O
vectors O
used O
in O
cloning O
. O

We O
optimized O
this O
RCA O
technique O
with O
extracted O
human B
papillomavirus I
type I
16 I
( I
HPV I
- I
16 I
) I
DNA O
from O
W12 O
cells O
, O
using O
a O
real O
- O
time O
quantitative O
PCR O
assay O
to O
determine O
amplification O
efficiency O
, O
and O
obtained O
a O
2 O
. O

4 O
x O
10 O
( O
4 O
) O
- O
fold O
increase O
in O
HPV O
- O
16 O
DNA O
concentration O
. O

Reports O
of O
cerebral O
dysfunction O
in O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
have O
led O
to O
the O
suggestion O
that O
HCV O
may O
infect O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

We O
used O
reverse O
transcription O
- O
PCR O
, O
cloning O
, O
and O
sequencing O
to O
define O
quasispecies O
for O
the O
HCV O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
and O
hypervariable B
region I
1 I
( I
HVR1 I
) I
in O
autopsy O
- O
derived O
brain O
, O
liver O
, O
lymph O
node O
, O
and O
serum O
samples O
. O

Two O
unique O
brain O
- O
derived O
IRES O
mutations O
( O
C O
- O
204 O
- O
- O
> O
A O
and O
G O
( O
243 O
) O
- O
- O
> O
A O
) O
, O
which O
have O
previously O
been O
associated O
with O
lymphoid O
replication O
and O
altered O
translational O
efficiency O
in O
cell O
culture O
, O
were O
found O
in O
one O
patient O
. O

The O
translational O
efficiencies O
of O
the O
brain O
- O
derived O
IRES O
sequences O
were O
generally O
reduced O
compared O
to O
those O
of O
the O
master O
serum O
and O
liver O
sequences O
in O
rabbit O
reticulocyte O
cell O
lysates O
and O
two O
human O
cell O
lines O
, O
HuH7 O
( O
liver O
) O
and O
CHME3 O
( O
microglial O
) O
. O

The O
C O
- O
204 O
- O
- O
> O
A O
and O
G O
( O
243 O
) O
- O
- O
> O
A O
mutations O
showed O
preserved O
translational O
efficiency O
in O
HuH7 O
cells O
but O
reduced O
efficiency O
in O
CHME3 O
cells O
. O

Chronic O
infection O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
can O
lead O
to O
severe O
hepatitis O
and O
cirrhosis O
and O
is O
closely O
associated O
with O
hepatocellular O
carcinoma O
. O

In O
this O
report O
, O
we O
show O
that O
NS5B O
, O
the O
HCV O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
interacts O
with O
a O
human O
RNA O
helicase O
, O
p68 O
. O

Deletion O
of O
the O
C O
- O
terminal O
two O
- O
thirds O
of O
NS5B O
( O
NS5BDeltaC O
) O
dramatically O
reduces O
its O
coimmunoprecipitation B
( I
co I
- I
IP I
) I
with O
endogenous O
p68 O
, O
while O
the O
deletion O
of O
the O
N O
- O
terminal O
region O
( O
NS5BDeltaN1 O
and O
NS5BDeltaN2 O
) O
does O
not O
affect O
its O
interaction O
with O
p68 O
. O

With O
a O
replicon O
cell O
line O
, O
we O
were O
not O
able O
to O
detect O
a O
change O
in O
positive O
- O
and O
negative O
- O
strand O
synthesis O
when O
p68 O
levels O
were O
reduced O
using O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

In O
cells O
transiently O
transfected O
with O
a O
full O
- O
length O
HCV O
construct O
, O
however O
, O
the O
depletion O
( O
using O
specific O
p68 O
siRNA O
) O
of O
endogenous O
p68 O
correlated O
with O
a O
reduction O
in O
the O
transcription O
of O
negative O
- O
strand O
from O
positive O
- O
strand O
HCV O
RNA O
. O

Overexpression O
of O
NS5B O
and O
NS5BDeltaN1 O
, O
but O
not O
that O
of O
NS5BDeltaC O
, O
causes O
a O
reduction O
in O
the O
negative O
- O
strand O
synthesis O
, O
indicating O
that O
overexpressed O
NS5B O
and O
NS5BDeltaN1 O
sequesters O
p68 O
from O
the O
replication O
complexes O
( O
thus O
reducing O
their O
replication O
activity O
levels O
) O
. O

We O
show O
a O
potential O
role O
of O
dendritic B
cells I
( I
DC I
) I
in O
murine O
coronavirus O
- O
induced O
immune O
modulation O
and O
pathogenesis O
by O
demonstrating O
that O
the O
JAW O
SII O
DC O
line O
and O
primary O
DC O
from O
BALB O
/ O
c O
mice O
and O
p O
/ O
p O
mice O
with O
reduced O
expression O
of O
the O
murine O
coronavirus O
receptor O
, O
murine O
CEACAM1a O
, O
are O
susceptible O
to O
murine O
coronavirus O
infection O
by O
a O
receptor O
- O
dependent O
pathway O
. O

Since O
neurovirulence O
may O
be O
determined O
at O
the O
early O
stages O
of O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
we O
hypothesize O
that O
it O
may O
depend O
on O
the O
ability O
of O
the O
virus O
to O
induce O
proinflammatory O
signals O
from O
brain O
cells O
for O
the O
recruitment O
of O
blood O
- O
derived O
inflammatory O
cells O
. O

To O
test O
this O
hypothesis O
, O
we O
studied O
the O
interaction O
between O
coronaviruses O
( O
mouse O
hepatitis O
virus O
) O
of O
different O
neurovirulences O
with O
primary O
cell O
cultures O
of O
brain O
immune O
cells O
( O
astrocytes O
and O
microglia O
) O
and O
mouse O
tissues O
. O

We O
found O
that O
the O
level O
of O
neurovirulence O
of O
the O
virus O
correlates O
with O
its O
differential O
ability O
to O
induce O
proinflammatory O
cytokines O
( O
interleukin O
12 O
[ O
IL O
- O
12 O
] O
p40 O
, O
tumor O
necrosis O
factor O
alpha O
, O
IL O
- O
6 O
, O
IL O
- O
15 O
, O
and O
IL O
- O
1beta O
) O
in O
astrocytes O
and O
microglia O
and O
in O
mouse O
brains O
and O
spinal O
cords O
. O

Persistent O
infection O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
chronic O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

It O
has O
recently O
been O
shown O
that O
HCV O
RNA O
replication O
is O
susceptible O
to O
small B
interfering I
RNAs I
( I
siRNAs I
) I
, O
but O
the O
antiviral O
activity O
of O
siRNAs O
depends O
very O
much O
on O
their O
complementarity O
to O
the O
target O
sequence O
. O

In O
one O
approach O
, O
we O
used O
endoribonuclease B
- I
prepared I
siRNAs I
( I
esiRNAs I
) I
to O
simultaneously O
target O
multiple O
sites O
of O
the O
viral O
genome O
. O

We O
show O
that O
esiRNAs O
directed O
against O
various O
regions O
of O
the O
HCV O
coding O
sequence O
as O
well O
as O
the O
5 B
' I
nontranslated I
region I
( I
5 I
' I
NTR I
) I
efficiently O
block O
the O
replication O
of O
subgenomic O
and O
genomic O
HCV O
replicons O
. O

In O
an O
alternative O
approach O
, O
we O
generated O
pseudotyped O
retroviruses O
encoding O
short B
hairpin I
RNAs I
( I
shRNAs I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
persists O
in O
the O
majority O
of O
those O
infected O
despite O
host O
immune O
responses O
. O

Evidence O
has O
accrued O
that O
selectively O
fixed O
mutations O
in O
the O
envelope O
genes O
( O
E1 O
and O
E2 O
) O
are O
associated O
with O
viral O
persistence O
, O
particularly O
those O
that O
occur O
within O
the O
first O
hypervariable B
region I
of I
E2 I
( I
HVR1 I
) I
. O

The O
lipid O
raft O
membrane O
has O
been O
shown O
to O
be O
the O
site O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
. O

We O
show O
here O
that O
the O
formation O
of O
the O
HCV O
RNA O
replication O
complex O
on O
lipid O
raft O
( O
detergent O
- O
resistant O
membranes O
) O
requires O
interactions O
among O
the O
HCV O
nonstructural B
( I
NS I
) I
proteins O
and O
may O
be O
initiated O
by O
the O
precursor O
of O
NS4B O
, O
which O
has O
the O
intrinsic O
property O
of O
anchoring O
to O
lipid O
raft O
membrane O
. O

Furthermore O
, O
we O
show O
that O
a O
cellular O
vesicle O
membrane O
transport O
protein O
named O
hVAP O
- O
33 O
( O
the O
human O
homologue O
of O
the O
33 O
- O
kDa O
vesicle O
- O
associated O
membrane O
protein O
- O
associated O
protein O
) O
, O
which O
binds O
to O
both O
NS5A O
and O
NS5B O
, O
plays O
a O
critical O
role O
in O
the O
formation O
of O
HCV O
replication O
complex O
. O

Replication O
of O
nearly O
all O
RNA O
viruses O
depends O
on O
a O
virus O
- O
encoded O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

Our O
earlier O
work O
found O
that O
purified O
recombinant O
hepatitis B
C I
virus I
( I
HCV I
) I
RdRp O
( O
NS5B O
) O
was O
able O
to O
initiate O
RNA O
synthesis O
de O
novo O
by O
using O
purine O
( O
A O
and O
G O
) O
but O
not O
pyrimidine O
( O
C O
and O
U O
) O
nucleotides O
( O
G O
. O

For O
most O
human O
RNA O
viruses O
, O
the O
initiation O
nucleotides O
of O
both O
positive O
- O
and O
negative O
- O
strand O
RNAs O
were O
found O
to O
be O
either O
an O
adenylate O
( O
A O
) O
or O
guanylate O
( O
G O
) O
. O

Collectively O
, O
these O
findings O
demonstrate O
that O
replication O
of O
positive O
- O
strand O
HCV O
RNA O
was O
preferentially O
initiated O
with O
purine O
nucleotides O
( O
ATP O
and O
GTP O
) O
, O
whereas O
the O
negative O
- O
strand O
HCV O
RNA O
replication O
is O
invariably O
initiated O
with O
an O
ATP O
. O

La O
, O
a O
52 O
- O
kDa O
autoantigen O
in O
patients O
with O
systemic O
lupus O
erythematosus O
, O
was O
one O
of O
the O
first O
cellular O
proteins O
identified O
to O
interact O
with O
viral O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
elements O
and O
stimulate O
poliovirus B
( I
PV I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
IRES O
- O
mediated O
translation O
. O

Previous O
results O
from O
our O
laboratory O
have O
shown O
that O
a O
small O
, O
yeast O
RNA O
( O
IRNA O
) O
could O
selectively O
inhibit O
PV O
and O
HCV O
IRES O
- O
mediated O
translation O
by O
sequestering O
the O
La O
protein O
. O

Here O
we O
have O
identified O
an O
18 O
- O
amino O
- O
acid O
- O
long O
sequence O
from O
the O
N O
- O
terminal O
La O
motif O
' O
which O
is O
required O
for O
efficient O
interaction O
of O
La O
with O
IRNA O
and O
viral O
5 B
' I
Untranslated I
Region I
( I
5 I
' I
- I
UTR I
) I
elements O
. O

A O
synthetic O
peptide O
( O
called O
LAP O
, O
for O
La O
peptide O
) O
corresponding O
to O
this O
sequence O
( O
amino O
acids O
11 O
to O
28 O
) O
of O
La O
was O
found O
to O
efficiently O
inhibit O
viral O
IRES O
- O
mediated O
translation O
in O
vitro O
. O

when O
one O
of O
these O
mutations O
( O
Y23Q O
) O
is O
introduced O
into O
full O
- O
length O
La O
, O
the O
mutant O
protein O
is O
severely O
defective O
in O
interacting O
with O
the O
PV O
IRES O
element O
and O
consequently O
unable O
to O
stimulate O
IRES O
- O
mediated O
translation O
. O

However O
, O
the O
La O
protein O
with O
a O
mutation O
of O
the O
next O
tyrosine O
moiety O
( O
Y24Q O
) O
could O
still O
interact O
with O
PV O
5 O
' O
- O
UTR O
and O
stimulate O
viral O
IRES O
- O
mediated O
translation O
significantly O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
is O
dependent O
on O
the O
enzymatic O
activities O
of O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
NS5B O
, O
which O
is O
a O
membrane O
- O
anchored O
protein O
. O

Recombinant O
NS5B O
lacking O
the O
C O
- O
terminal O
transmembrane O
domain O
( O
21 O
amino O
acids O
) O
is O
enzymatically O
active O
. O

Replication O
of O
Positive O
- O
strand O
caliciviruses O
is O
mediated O
by O
a O
virus O
- O
encoded O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

To O
study O
the O
replication O
of O
Norovirus B
( I
NV I
) I
, O
a O
member O
of O
the O
family O
Caliciviridae O
, O
we O
used O
a O
recombinant O
baculovirus O
system O
to O
express O
an O
enzymatically O
active O
RdRp O
protein O
from O
the O
3D O
region O
of O
the O
W O
genome O
and O
defined O
conditions O
for O
optimum O
enzymatic O
activity O
. O

Using O
an O
RNA O
template O
from O
the O
W O
3 O
' O
genomic O
region O
, O
we O
observed O
similar O
levels O
of O
enzymatic O
activity O
in O
assays O
with O
and O
without O
a O
poly O
( O
A O
) O
tail O
. O

Thus O
, O
the O
W O
RdRp O
exhibited O
primer O
- O
and O
poly O
( O
A O
) O
- O
independent O
RNA O
polymerase O
activity O
. O

Despite O
increasing O
characterization O
of O
pestivirus O
- O
encoded O
proteins O
, O
functions O
for O
nonstructural B
( I
NS I
) I
proteins O
NS2 O
, O
NS2 O
- O
3 O
, O
NS4B O
, O
and O
NS5A O
have O
not O
yet O
been O
reported O
. O

Here O
we O
investigated O
the O
function O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
uncleaved O
NS2 O
- O
3 O
. O

To O
test O
whether O
NS2 O
- O
3 O
has O
a O
discrete O
function O
, O
the O
uncleaved O
protein O
was O
specifically O
abolished O
in O
two O
ways O
: O
first O
by O
inserting O
a O
ubiquitin O
monomer O
between O
NS2 O
and O
NS3 O
, O
and O
second O
by O
placing O
an O
internal O
ribosome O
entry O
site O
between O
the O
two O
proteins O
( O
a O
bicistronic O
genome O
) O
. O

Previous O
reports O
have O
documented O
that O
cholesterol O
supplementations O
increase O
cytopathic O
effects O
in O
tissue O
culture O
and O
also O
intensify O
in O
vivo O
pathogenicities O
during O
infection O
by O
the O
enveloped O
coronavirus O
murine B
hepatitis I
virus I
( I
MHV I
) I
. O

These O
various O
cholesterol O
levels O
had O
no O
effect O
on O
the O
binding O
of O
viral O
spike B
( I
S I
) I
proteins O
to O
cellular B
carcinoembryonic I
antigen I
- I
related I
cell I
adhesion I
molecule I
( I
CEACAM I
) I
receptors O
, O
rather O
they O
correlated O
directly O
with O
S O
- O
protein O
- O
mediated O
membrane O
fusion O
activities O
. O

However O
, O
the O
vast O
majority O
of O
CEACAMs O
were O
solubilized O
by O
cold O
Triton B
X I
- I
100 I
( I
TX I
- I
100 I
) I
, O
indicating O
their O
absence O
from O
lipid O
rafts O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS5A O
has O
been O
reported O
to O
be O
important O
for O
the O
establishment O
of O
replication O
by O
adaptive O
mutations O
or O
localization O
, O
although O
its O
role O
in O
viral O
replication O
remains O
unclear O
. O

Infectious B
salmon I
anemia I
virus I
( I
ISAV I
) I
is O
the O
causative O
agent O
of O
infections O
in O
farmed O
Atlantic O
salmon O
. O

The O
poliovirus O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
in O
the O
5 B
' I
nontranslated I
region I
( I
NTR I
) I
has O
been O
implicated O
as O
a O
cis O
- O
active O
RNA O
required O
for O
both O
viral O
mRNA O
translation O
and O
viral O
RNA O
replication O
. O

CD81 O
has O
been O
described O
as O
a O
putative O
receptor O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
; O
however O
, O
its O
role O
in O
HCV O
cell O
entry O
has O
not O
been O
characterized O
due O
to O
the O
lack O
of O
an O
efficient O
cell O
culture O
system O
. O

Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
pseudotypes O
bearing O
HCV O
E1E2 O
glycoproteins O
show O
a O
restricted O
tropism O
for O
human O
liver O
cell O
lines O
. O

CD81 O
is O
required O
for O
HIV O
- O
HCV O
pseudotype O
infection O
since O
( O
i O
) O
a O
monoclonal O
antibody O
specific O
for O
CD81 O
inhibited O
infection O
of O
susceptible O
target O
cells O
and O
( O
ii O
) O
silencing O
of O
CD81 O
expression O
in O
Huh O
- O
7 O
. O

Considerable O
controversy O
surrounds O
the O
impact O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
protein O
expression O
on O
viability O
of O
host O
cells O
and O
regulation O
of O
the O
cell O
cycle O
. O

Recent O
studies O
in O
humans O
and O
chimpanzees O
suggest O
that O
immunity O
can O
be O
induced O
to O
diminish O
the O
incidence O
of O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
with O
the O
neurotropic O
JHM O
strain O
of O
mouse O
hepatitis O
virus O
produces O
acute O
and O
chronic O
demyelination O
. O

The O
contributions O
of O
perforin O
- O
mediated O
cytolysis O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
secretion O
by O
CD8 O
( O
+ O
) O
T O
cells O
to O
the O
control O
of O
infection O
and O
the O
induction O
of O
demyelination O
were O
examined O
by O
adoptive O
transfer O
into O
infected O
SCID O
recipients O
. O

Memory O
CD8 O
( O
+ O
) O
T O
cells O
from O
syngeneic O
wild B
- I
type I
( I
WT I
) I
, O
perforin O
- O
deficient O
, O
or O
IFN O
- O
gamma O
- O
deficient O
( O
GKO O
) O
donors O
all O
trafficked O
into O
the O
infected O
CNS O
in O
the O
absence O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
localized O
to O
similar O
areas O
. O

Although O
CD8 O
( O
+ O
) O
T O
cells O
from O
all O
three O
donors O
suppressed O
virus O
replication O
in O
the O
CNS O
, O
GKO O
CD8 O
( O
+ O
) O
T O
cells O
expressed O
the O
least O
antiviral O
activity O
. O

While O
wt O
CD8 O
( O
+ O
) O
T O
cells O
inhibited O
virus O
replication O
in O
all O
CNS O
cell O
types O
, O
cytolytic O
activity O
in O
the O
absence O
of O
IFN O
- O
gamma O
suppressed O
the O
infection O
of O
astrocytes O
, O
but O
not O
oligodendroglia O
. O

Demyelination O
was O
most O
severe O
following O
viral O
control O
by O
wt O
CD8 O
( O
+ O
) O
T O
cells O
but O
was O
independent O
of O
macrophage O
infiltration O
. O

These O
data O
demonstrate O
the O
effective O
control O
of O
virus O
replication O
by O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
absence O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
support O
the O
necessity O
for O
the O
expression O
of O
distinct O
effector O
mechanisms O
in O
the O
control O
of O
viral O
replication O
in O
distinct O
CNS O
glial O
cell O
types O
. O

The O
role O
of O
Fas O
- O
mediated O
lysis O
of O
hepatocytes O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
induced O
injury O
is O
frequently O
discussed O
. O

Prophylactic O
hepatitis B
C I
virus I
( I
HCV I
) I
vaccine O
trials O
with O
human O
volunteers O
are O
pending O
. O

By O
using O
a O
multicomponent O
DNA O
priming O
- O
protein O
boosting O
vaccine O
strategy O
, O
naive O
chimpanzees O
were O
immunized O
against O
HCV O
structural O
proteins O
( O
core O
, O
E1 O
, O
and O
E2 O
) O
as O
well O
as O
a O
nonstructural O
( O
NS3 O
) O
protein O
. O

Compared O
to O
the O
naive O
infection O
control O
and O
nine O
additional O
historical O
controls O
which O
became O
chronic O
, O
vaccinee B
2 I
( I
Vac2 I
) I
rapidly O
resolved O
the O
infection O
, O
while O
the O
other O
( O
Vac1 O
) O
clearly O
controlled O
HCV O
infection O
. O

Immunization O
induced O
antibodies O
, O
peptide O
- O
specific O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
protein O
- O
specific O
lymphoproliferative O
responses O
, O
IFN O
- O
gamma O
, O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
and O
IL O
- O
4 O
T O
- O
helper O
responses O
in O
both O
vaccinees O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
receptor O
( O
MHVR O
) O
, O
CEACAM1 O
, O
has O
two O
different O
functions O
for O
MHV O
entry O
into O
cells O
: O
binding O
to O
MHV O
spike O
protein O
( O
S O
protein O
) O
and O
activation O
of O
the O
S O
protein O
to O
execute O
virus O
- O
cell O
membrane O
fusion O
, O
the O
latter O
of O
which O
is O
accompanied O
by O
conformational O
changes O
of O
the O
S O
protein O
. O

The O
MHVR O
comprising O
the O
N O
- O
terminal O
and O
fourth O
domains O
[ O
R1 O
( O
1 O
, O
4 O
) O
] O
displays O
these O
two O
activities O
, O
and O
the O
N O
domain O
is O
thought O
to O
be O
critical O
for O
binding O
to O
MHV O
. O

We O
examined O
three O
types O
of O
soluble O
form O
MHVR O
( O
soMHVR O
) O
, O
one O
consisting O
of O
the O
N O
domain O
alone O
[ O
soR1 O
( O
1 O
) O
] O
, O
one O
with O
the O
N O
and O
second O
domains O
[ O
soR1 O
( O
1 O
, O
2 O
) O
] O
, O
and O
one O
[ O
soR1 O
( O
1 O
, O
4 O
) O
] O
expressed O
by O
recombinant O
baculoviruses O
. O

However O
, O
R1 O
( O
1 O
) O
expressed O
on O
the O
BHK O
cell O
surface O
failed O
to O
serve O
as O
a O
receptor O
in O
spite O
of O
a O
sufficient O
level O
of O
expression O
. O

The O
inability O
of O
expressed O
R1 O
( O
1 O
) O
to O
work O
as O
a O
receptor O
was O
due O
to O
the O
inaccessibility O
of O
virions O
to O
R1 O
( O
1 O
) O
; O
however O
, O
these O
were O
accessible O
using O
the O
MHVR O
- O
specific O
monoclonal O
antibody O
CC1 O
. O

A O
fraction O
of O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
- O
infected O
macaques O
develop O
rapidly O
progressive O
disease O
in O
the O
apparent O
absence O
of O
detectable O
SIV O
- O
specific O
antibody O
responses O
. O

To O
characterize O
the O
immunopathogenesis O
of O
this O
syndrome O
, O
we O
studied O
viral O
load O
, O
CD4 O
( O
+ O
) O
T O
- O
lymphocyte O
numbers O
as O
well O
as O
cellular O
and O
humoral O
immune O
responses O
to O
SIV O
and O
other O
exogenous O
antigens O
in O
four O
SIVsm O
- O
infected O
rhesus O
macaques O
that O
progressed O
to O
AIDS O
9 O
to O
16 O
weeks O
postinoculation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infects O
liver O
cells O
and O
its O
replication O
in O
other O
cells O
is O
incompletely O
defined O
. O

Relative O
to O
Huh O
- O
7 O
replicons O
, O
the O
293 O
cell O
replicons O
were O
less O
sensitive O
to O
inhibition O
by O
alpha O
interferon O
and O
substantially O
more O
sensitive O
to O
inhibition O
by O
poly O
( O
I O
) O
- O
poly O
( O
C O
) O
double O
- O
stranded O
RNA O
. O

How O
chemokines O
shape O
the O
immune O
response O
to O
viral O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
has O
largely O
been O
considered O
within O
the O
context O
of O
recruitment O
and O
activation O
of O
antigen O
- O
specific O
lymphocytes O
. O

Herein O
, O
we O
evaluated O
the O
contributions O
of O
CXC B
chemokine I
ligand I
10 I
( I
CXCL10 I
) I
in O
promoting O
innate O
defense O
mechanisms O
following O
coronavirus O
infection O
of O
the O
CNS O
. O

Intracerebral O
infection O
of O
RAG1 O
( O
- O
/ O
- O
) O
mice O
with O
a O
recombinant O
CXCL10 O
- O
expressing O
murine O
coronavirus O
( O
mouse O
hepatitis O
virus O
) O
resulted O
in O
protection O
from O
disease O
and O
increased O
survival O
that O
correlated O
with O
a O
significant O
increase O
in O
recruitment O
and O
activation O
of O
natural B
killer I
( I
NK I
) I
cells O
within O
the O
CNS O
. O

We O
previously O
identified O
a O
bulged O
stem O
- O
loop O
secondary O
structure O
at O
the O
upstream O
end O
of O
the O
3 B
' I
untranslated I
region I
( I
3 I
' I
UTR I
) I
of O
the O
genome O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

Other O
investigators O
discovered O
an O
adjacent O
downstream O
pseudoknot O
in O
the O
3 O
' O
UTR O
of O
the O
closely O
related O
bovine B
coronavirus I
( I
BCoV I
) I
. O

Inspection O
of O
over O
250 O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
sequences O
shows O
that O
a O
threonine O
is O
strictly O
conserved O
at O
the O
P1 O
position O
in O
the O
NS3 O
- O
NS4A O
( O
NS3 O
- O
4A O
) O
autoproteolysis O
junction O
, O
while O
a O
cysteine O
is O
maintained O
as O
the O
P1 O
residue O
in O
all O
of O
the O
putative O
trans O
cleavage O
sites O
( O
NS4A O
- O
4B O
, O
NS4B O
- O
5A O
, O
and O
NS5A O
- O
5B O
) O
. O

To O
understand O
why O
T631 O
is O
conserved O
at O
the O
NS3 O
- O
4A O
junction O
of O
HCV O
, O
a O
series O
of O
in O
vitro O
transcription O
- O
translation O
studies O
were O
carried O
out O
using O
wild O
- O
type O
and O
mutant O
( O
T631C O
) O
NS3 O
- O
4A O
constructs O
bearing O
native O
, O
truncated O
, O
and O
mutant O
NS4A O
segments O
. O

The O
autocleavage O
of O
the O
wild O
- O
type O
junction O
was O
found O
to O
be O
dependent O
on O
the O
presence O
of O
the O
central O
cofactor O
domain O
of O
NS4A O
( O
residues O
21 O
to O
34 O
) O
. O

These O
data O
suggest O
that O
the O
threonine O
is O
conserved O
at O
position O
631 O
because O
it O
serves O
two O
functions O
: O
( O
i O
) O
to O
slow O
processing O
at O
the O
NS3 O
- O
4A O
cleavage O
site O
, O
ensuring O
proper O
intercalation O
of O
the O
NS4A O
cofactor O
with O
NS3 O
prior O
to O
polyprotein O
scission O
, O
and O
( O
ii O
) O
to O
prevent O
subsequent O
product O
inhibition O
by O
the O
NS3 O
C O
terminus O
. O

The O
RNA O
- O
dependent O
RNA O
polymerase O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
necessary O
for O
the O
replication O
of O
viral O
RNA O
and O
thus O
represents O
an O
attractive O
target O
for O
drug O
development O
. O

Several O
structural O
classes O
of O
nonnucleoside B
inhibitors I
( I
NNIs I
) I
of O
HCV O
RNA O
polymerase O
have O
been O
described O
, O
including O
a O
promising O
series O
of O
benzothiadiazine O
compounds O
that O
efficiently O
block O
replication O
of O
HCV O
subgenomic O
replicons O
in O
tissue O
culture O
. O

The O
mutations O
( O
M414T O
, O
C451R O
, O
G558R O
, O
and O
H95R O
) O
render O
the O
HCV O
replicons O
resistant O
to O
inhibition O
by O
benzothiadiazines O
, O
though O
the O
mutant O
replicons O
remain O
sensitive O
to O
inhibition O
by O
other O
nucleoside O
and O
NNIs O
of O
the O
HCV O
RNA O
polymerase O
. O

The O
origin O
( O
ori O
) O
- O
binding O
protein O
of O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
, O
encoded O
by O
the O
UL9 O
open O
reading O
frame O
, O
has O
been O
shown O
to O
physically O
interact O
with O
a O
number O
of O
cellular O
and O
viral O
proteins O
, O
including O
three O
HSV O
- O
1 O
proteins O
( O
ICP8 O
, O
UL42 O
, O
and O
UL8 O
) O
essential O
for O
ori O
- O
dependent O
DNA O
replication O
. O

The O
RNA O
- O
dependent O
RNA O
polymerase O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
catalytic O
subunit O
of O
the O
viral O
RNA O
amplification O
machinery O
and O
is O
an O
appealing O
target O
for O
the O
development O
of O
new O
therapeutic O
agents O
against O
HCV O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
Positive O
- O
strand O
RNA O
virus O
that O
replicates O
exclusively O
in O
the O
cytoplasm O
of O
infected O
cells O
. O

Several O
features O
make O
these O
viruses O
attractive O
as O
vaccine O
and O
therapeutic O
vectors O
: O
( O
i O
) O
deletion O
of O
their O
nonessential O
genes O
is O
strongly O
attenuating O
; O
( O
ii O
) O
the O
genetic O
space O
thus O
created O
allows O
insertion O
of O
foreign O
information O
; O
and O
( O
iii O
) O
their O
tropism O
can O
be O
modified O
by O
manipulation O
of O
the O
viral O
spike O
. O

Renilla O
and O
firefly O
luciferase O
expression O
cassettes O
, O
each O
provided O
with O
viral O
transcription B
regulatory I
sequences I
( I
TRSs I
) I
, O
were O
inserted O
at O
several O
genomic O
positions O
, O
both O
independently O
in O
different O
viruses O
and O
combined O
within O
one O
viral O
genome O
. O

Altogether O
, O
our O
observations O
clearly O
demonstrate O
the O
potential O
of O
coronaviruses O
as O
( O
multivalent O
) O
expression O
vectors O
. O

Here O
, O
we O
investigated O
the O
effect O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
antigen O
modifications O
on O
the O
induction O
of O
T O
- O
cell O
responses O
in O
DNA O
immunization O
. O

The O
endonuclease O
dicer O
cleaves O
RNAs O
that O
are O
100 O
% O
double O
stranded O
and O
certain O
RNAs O
with O
extensive O
but O
< O
100 O
% O
pairing O
to O
release O
similar O
to21 O
- O
nucleotide B
( I
nt I
) I
fragments O
. O

Circular O
1 O
, O
679 O
- O
nt O
genomic O
and O
antigenomic O
RNAs O
of O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
can O
fold O
into O
a O
rod O
- O
like O
structure O
with O
74 O
% O
pairing O
. O

Similarly O
, O
rod O
- O
like O
RNAs O
of O
potato B
spindle I
tuber I
viroid I
( I
PSTVd I
) I
and O
avocado B
sunblotch I
viroid I
( I
ASBVd I
) I
were O
only O
0 O
. O

Murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
causes O
demyelination O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
in O
rats O
and O
mice O
. O

The O
positive O
- O
stranded O
RNA O
genome O
of O
Plautia B
stali I
intestine I
virus I
( I
PSIV I
) I
has O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
in O
an O
intergenic B
region I
( I
IGR I
) I
. O

73 O
: O
1219 O
- O
1226 O
, O
1999 O
) O
that O
IGR O
- O
IRES O
extended O
by O
several O
nucleotides O
into O
the O
capsid O
open B
reading I
frame I
( I
ORF I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
two O
RNA O
species O
( O
HDV O
- O
S O
and O
HDV O
- O
L O
) O
, O
which O
encode O
the O
small O
and O
large O
forms O
of O
hepatitis O
delta O
antigens O
( O
S O
- O
and O
L O
- O
HDAg O
) O
, O
respectively O
. O

Unexpectedly O
, O
when O
the O
kinetics O
of O
RNA O
replication O
was O
examined O
daily O
, O
HDV O
- O
L O
was O
found O
to O
replicate O
at O
a O
low O
level O
at O
the O
early O
time O
points O
( O
1 O
to O
2 O
days O
posttransfection O
) O
but O
then O
lose O
this O
capability O
at O
later O
time O
points O
. O

We O
investigated O
whether O
unique O
intracellular O
membranes O
are O
required O
for O
viral O
RNA O
replication O
complex O
formation O
and O
function O
in O
yeast O
by O
retargeting O
protein O
A O
, O
the O
flock B
house I
virus I
( I
FHV I
) I
RNA O
- O
dependent O
RNA O
polymerase O
. O

We O
replaced O
the O
FHV O
protein O
A O
mitochondrial O
outer O
membrane O
- O
targeting O
sequence O
with O
the O
N O
- O
terminal O
endoplasmic B
reticulum I
( I
ER I
) I
- O
targeting O
sequence O
from O
the O
yeast O
NADP O
cytochrome O
P450 O
oxidoreductase O
or O
inverted O
C O
- O
terminal O
ER O
- O
targeting O
sequences O
from O
the O
hepatitis O
C O
virus O
NS5B O
polymerase O
or O
the O
yeast O
t O
- O
SNARE O
Ufe1p O
. O

nucleotides B
( I
nt I
) I
108 O
to O
742 O
of O
an O
infectious O
cDNA O
clone O
of O
poliovirus B
( I
PV I
) I
Mahoney O
strain O
, O
including O
the O
corresponding O
region O
of O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
, O
was O
replaced O
by O
nt O
28 O
to O
710 O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
cDNA O
corresponding O
to O
the O
whole O
HCV O
IRES O
. O

A O
chimeric O
PV O
( O
2A O
- O
369 O
) O
was O
generated O
by O
transfecting O
mammalian O
cells O
with O
an O
RNA O
transcribed O
in O
vitro O
from O
the O
cDNA O
. O

To O
examine O
replicating O
capacity O
of O
virus O
2A O
- O
369 O
in O
the O
brain O
and O
liver O
of O
a O
mouse O
model O
for O
poliomyelitis O
, O
a O
new O
mouse O
model O
( O
MPVRTg25 O
- O
61 O
) O
that O
is O
transgenic O
for O
human O
PV O
receptor O
( O
hPVR O
; O
CD155 O
) O
was O
generated O
in O
order O
to O
obtain O
a O
higher O
expression O
level O
of O
hPVR O
in O
the O
liver O
than O
those O
of O
hPVRTg O
mouse O
lines O
generated O
by O
us O
so O
far O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
synthesis O
is O
mediated O
by O
a O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
on O
membrane O
- O
bound O
replication O
complexes O
in O
the O
host O
cell O
cytoplasm O
. O

However O
, O
it O
is O
not O
known O
how O
the O
putative O
MHV O
RdRp O
( O
Poll O
) O
is O
targeted O
to O
and O
retained O
on O
cellular O
membranes O
. O

The O
same O
preference O
for O
cytidine O
in O
the O
3 O
' O
- O
terminal O
dinucleotide O
was O
noted O
in O
reports O
of O
the O
in O
vitro O
activity O
of O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
for O
the O
other O
genera O
of O
Flaviviridae O
that O
also O
employ O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
template O
to O
initiate O
asymmetric O
semiconservative O
RNA O
positive O
- O
strand O
synthesis O
. O

Transient O
expression O
of O
wild B
- I
type I
( I
WT I
) I
and O
mutant O
viral O
RNAs O
and O
proteins O
by O
agroinfiltration O
of O
plant O
leaves O
was O
used O
to O
study O
cis O
- O
and O
trans O
- O
acting O
functions O
of O
the O
helicase O
- O
like O
domain O
in O
P1 O
and O
the O
polymerase O
- O
like O
domain O
in O
P2 O
. O

Virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
function O
is O
thought O
to O
play O
a O
central O
role O
in O
induction O
and O
maintenance O
of O
effective O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
experimental O
animals O
or O
humans O
. O

However O
, O
the O
reasons O
that O
diminished O
proliferation O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
is O
observed O
in O
the O
majority O
of O
infected O
patients O
and O
the O
role O
of O
these O
diminished O
responses O
in O
the O
loss O
of O
control O
of O
replication O
during O
the O
chronic O
phase O
of O
HIV O
infection O
remain O
incompletely O
understood O
. O

In O
a O
cohort O
of O
15 O
patients O
that O
were O
selected O
for O
particularly O
strong O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
, O
the O
effects O
of O
viremia O
on O
these O
responses O
were O
explored O
. O

Restriction O
of O
HIV O
replication O
was O
not O
observed O
during O
one O
to O
eight O
interruptions O
of O
antiretroviral O
therapy O
in O
the O
majority O
of O
patients O
( O
12 O
of O
15 O
) O
. O

In O
a O
subset O
of O
patients O
with O
elevated O
frequencies O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
- O
producing O
cells O
, O
IL O
- O
2 O
production O
in O
response O
to O
HIV O
antigens O
was O
diminished O
during O
viremia O
. O

Addition O
of O
exogenous O
IL O
- O
2 O
was O
sufficient O
to O
rescue O
in O
vitro O
proliferation O
of O
DR0101 O
class O
II O
Gag O
or O
Pol O
tetramer O
( O
+ O
) O
or O
total O
- O
Gag O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
. O

These O
observations O
suggest O
that O
, O
during O
viremia O
, O
diminished O
in O
vitro O
proliferation O
of O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
is O
likely O
related O
to O
diminished O
IL O
- O
2 O
production O
. O

These O
results O
also O
suggest O
that O
relatively O
high O
frequencies O
of O
HIV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
persist O
in O
the O
peripheral O
blood O
during O
viremia O
, O
are O
not O
replicatively O
senescent O
, O
and O
proliferate O
when O
IL O
- O
2 O
is O
provided O
exogenously O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
pandemic O
affects O
the O
health O
of O
more O
than O
170 O
million O
people O
and O
is O
the O
major O
indication O
for O
orthotopic O
liver O
transplantations O
. O

Tomato B
bushy I
stunt I
virus I
( I
TBSV I
) I
, O
a O
tombusvirus O
with O
a O
nonsegmented O
, O
plus O
- O
stranded O
RNA O
genome O
, O
codes O
for O
two O
essential O
replicase O
proteins O
. O

The O
sequence O
of O
one O
of O
the O
replicase O
proteins O
, O
namely O
p33 O
, O
overlaps O
with O
the O
N O
- O
terminal O
domain O
of O
p92 O
, O
which O
contains O
the O
signature O
motifs O
of O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRps I
) I
in O
its O
nonoverlapping O
C O
- O
terminal O
portion O
. O

We O
also O
show O
evidence O
that O
the O
binding O
of O
p33 O
to O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
is O
stronger O
than O
binding O
to O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
ssDNA O
, O
or O
dsDNA O
in O
vitro O
. O

Using O
deletion O
derivatives O
of O
the O
Escherichia O
coli O
- O
expressed O
recombinant O
proteins O
in O
gel O
mobility O
shift O
and O
Northwestern O
assays O
, O
we O
demonstrate O
that O
p33 O
and O
the O
overlapping O
domain O
of O
p92 O
, O
based O
on O
its O
sequence O
identity O
with O
p33 O
, O
contain O
an O
arginine O
- O
and O
proline O
- O
rich O
RNA O
- O
binding O
motif O
( O
termed O
RPR O
, O
which O
has O
the O
sequence O
RPRRRP O
) O
. O

Limitin O
has O
sequence O
homology O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
beta O
and O
utilizes O
the O
IFN O
- O
alpha O
/ O
beta O
receptor O
. O

Limitin O
inhibited O
not O
only O
cytopathic O
effects O
in O
encephalomyocarditis O
virus O
- O
or O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
type O
1 O
- O
infected O
L929 O
cells O
, O
but O
also O
plaque O
formation O
in O
mouse B
hepatitis I
virus I
( I
MHV I
) I
type O
2 O
- O
infected O
DBT O
cells O
. O

While O
limitin O
has O
antiviral O
activity O
as O
strong O
as O
that O
of O
IFN O
- O
et O
in O
vitro O
( O
the O
concentration O
that O
provided O
50 O
% O
inhibition O
of O
cytopathic O
effect O
is O
similar O
to30 O
pg O
/ O
ml O
) O
, O
IFN B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
dependencies O
for O
induction O
of O
an O
antiviral O
state O
were O
different O
for O
limitin O
and O
IFN O
- O
alpha O
. O

In O
the O
absence O
of O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
culture O
system O
, O
the O
use O
of O
a O
Semliki O
Forest O
virus O
replicon O
expressing O
genes O
encoding O
HCV O
structural O
proteins O
that O
assemble O
into O
HCV O
- O
like O
particles O
provides O
an O
opportunity O
to O
study O
HCV O
morphogenesis O
. O

he O
mechanisms O
of O
immune O
evasion O
and O
the O
role O
of O
the O
early O
immune O
response O
in O
chronic O
infection O
caused O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
still O
unclear O
. O

The O
HCV O
core O
protein O
induced O
p53 O
- O
dependent O
gene O
expression O
of O
TAP1 B
( I
Transporter I
associated I
with I
antigen I
processing I
1 I
) I
and O
consecutive O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
upregulation O
. O

As O
a O
consequence O
of O
increased O
MHC O
class O
I O
expression O
, O
a O
significantly O
downregulated O
cytotoxic O
activity O
of O
natural B
killer I
( I
NK I
) I
cells O
against O
HCV O
core O
- O
transfected O
liver O
cells O
was O
observed O
, O
whereas O
lysis O
by O
HCV O
- O
specific O
cytotoxic O
T O
cells O
was O
not O
affected O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
infects O
African O
green O
monkey O
kidney O
cells O
via O
HAV B
cellular I
receptor I
I I
( I
haver I
- I
1 I
) I
. O

The O
ectodomain O
of O
havcr O
- O
1 O
contains O
an O
N O
- O
terminal O
cysteine O
- O
rich O
immunoglobulin O
- O
like O
region O
( O
D1 O
) O
, O
followed O
by O
a O
mucin O
- O
like O
region O
that O
extends O
D1 O
well O
above O
the O
cell O
surface O
. O

D1 O
is O
required O
for O
binding O
of O
HAV O
, O
and O
a O
soluble O
construct O
containing O
D1 O
fused O
to O
the O
hinge O
and O
Fc O
portions O
of O
human B
immunoglobulin I
G1 I
( I
IgG1 I
) I
, O
D1 O
- O
Fc O
, O
bound O
and O
neutralized O
HAV O
inefficiently O
. O

Recently O
, O
the O
possibility O
of O
using O
virus O
vectors O
to O
immunize O
cattle O
against O
selected O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
genes O
has O
gained O
widespread O
interest O
. O

However O
, O
when O
we O
attempted O
to O
express O
the O
E2 O
protein O
from O
type O
2 O
( O
890 O
strain O
) O
BVDV O
in O
a O
bovine O
herpesvirus O
1 O
( O
BHV1 O
. O

In O
Mason O
- O
Pfizer O
monkey O
virus O
, O
the O
required O
RNA O
sequence O
element O
is O
known O
as O
a O
constitutive B
transport I
element I
( I
CTE I
) I
. O

A O
related O
element O
from O
woodchuck O
hepatitis O
virus O
is O
known O
as O
the O
woodchuck B
posttranscriptional I
regulatory I
element I
( I
WPRE I
) I
. O

Coronavirus O
entry O
is O
mediated O
by O
the O
viral O
spike B
( I
S I
) I
glycoprotein O
. O

The O
latter O
is O
thought O
to O
contain O
an O
internal O
fusion O
peptide O
and O
has O
two O
4 O
, O
3 O
hydrophobic O
( O
heptad O
) O
repeat O
regions O
designated O
HR1 O
and O
HR2 O
. O

HR2 O
is O
located O
close O
to O
the O
membrane O
anchor O
, O
and O
HR1 O
is O
some O
170 O
amino B
acids I
( I
aa I
) I
upstream O
of O
it O
. O

heptad B
repeat I
( I
HR I
) I
regions O
are O
found O
in O
fusion O
proteins O
of O
many O
different O
viruses O
and O
form O
an O
important O
characteristic O
of O
class O
I O
viral O
fusion O
proteins O
. O

Peptides O
HR1 O
( O
96 O
aa O
) O
and O
HR2 O
( O
39 O
aa O
) O
, O
corresponding O
to O
the O
HR1 O
and O
HR2 O
regions O
, O
were O
produced O
in O
Escherichia O
coli O
. O

By O
using O
a O
purified O
dengue O
virus O
RNA O
- O
dependent O
RNA O
polymerase O
and O
a O
subgenomic O
770 O
- O
nucleotide O
RNA O
template O
, O
it O
was O
shown O
previously O
that O
the O
ratio O
of O
the O
de O
novo O
synthesis O
product O
to O
hairpin O
product O
formed O
was O
inversely O
proportional O
to O
increments O
of O
assay O
temperatures O
( O
20 O
to O
40degreesC O
) O
. O

In O
this O
study O
, O
the O
components O
of O
the O
de O
novo O
preinitiation O
complex O
are O
defined O
as O
ATP O
, O
a O
high O
concentration O
of O
GTP O
( O
500 O
muM O
) O
, O
the O
polymerase O
, O
and O
the O
template O
RNA O
. O

The O
NS5B O
RNA O
- O
dependent O
RNA O
polymerase O
encoded O
by O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
key O
component O
of O
the O
viral O
replicase O
. O

The O
replicase O
polyprotein O
of O
murine O
coronavirus O
is O
extensively O
processed O
by O
three O
proteinases O
, O
two O
papain B
- I
like I
proteinases I
( I
PLPs I
) I
, O
termed O
PLP1 O
and O
PLP2 O
, O
and O
a O
picornavirus O
X O
- O
like O
proteinase O
( O
3CLpro O
) O
. O

Previously O
, O
we O
established O
a O
trans O
- O
cleavage O
assay O
and O
showed O
that O
PLP2 O
cleaves O
the O
replicase O
polyprotein O
between O
p210 O
and O
membrane B
protein I
1 I
( I
MP1 I
) I
( O
A O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
levels O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
, O
interleukin B
4 I
( I
IL I
- I
4 I
) I
- O
, O
and O
IL O
- O
8 O
- O
producing O
cells O
in O
peripheral O
blood O
mononuclear O
cells O
from O
mink O
infected O
with O
the O
Aleutian B
mink I
disease I
parvovirus I
( I
ADV I
) I
. O

As O
expected O
, O
ADV O
- O
infected O
mink O
developed O
high O
plasma O
gamma O
globulin O
values O
( O
hypergammaglobulinemia O
) O
and O
enhanced O
quantities O
of O
CD8 O
- O
positive O
( O
CD8 O
( O
+ O
) O
) O
cells O
in O
the O
blood O
during O
the O
infection O
. O

In O
order O
to O
characterize O
the O
phenotype O
of O
the O
cytokine O
- O
producing O
cells O
, O
we O
performed O
double O
- O
labeling O
fluorescence B
- I
activated I
cell I
sorter I
( I
FACS I
) I
experiments O
with O
CD8 O
surface O
labeling O
in O
one O
channel O
and O
cytokine O
intracellular O
staining O
in O
the O
other O
. O

We O
found O
that O
most O
IFN O
- O
gamma O
and O
IL O
- O
4 O
in O
ADV O
- O
infected O
mink O
was O
produced O
by O
CD8 O
( O
+ O
) O
cells O
, O
while O
in O
the O
uninfected O
mink O
, O
these O
cytokines O
were O
primarily O
produced O
by O
a O
cell O
type O
that O
was O
not O
CD8 O
( O
possibly O
CD4 O
- O
positive O
cells O
) O
. O

The O
virus O
- O
encoded O
nonstructural B
protein I
5B I
( I
NS5B I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
RNA O
- O
dependent O
RNA O
polymerase O
and O
is O
absolutely O
required O
for O
replication O
of O
the O
virus O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
produces O
two O
essential O
forms O
of O
the O
sole O
viral O
protein O
from O
the O
same O
open O
reading O
frame O
by O
using O
host O
RNA O
editing O
activity O
at O
the O
amber O
/ O
W O
site O
in O
the O
antigenomic O
RNA O
. O

To O
locate O
the O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
packaging O
signal O
, O
the O
incorporation O
of O
TGEV O
subgenomic B
mRNAs I
( I
sgmRNAs I
) I
into O
virions O
was O
first O
addressed O
. O

Detection O
of O
sgmRNAs O
in O
virions O
by O
specific O
reverse B
transcription I
- I
PCRs I
( I
RT I
- I
PCRs I
) I
was O
related O
to O
the O
purity O
of O
virus O
preparations O
. O

Lack O
of O
sgmRNA O
encapsidation O
was O
probably O
due O
to O
the O
absence O
of O
a O
packaging B
signal I
( I
psi I
) I
within O
these O
mRNAs O
. O

To O
confirm O
that O
this O
was O
the O
case O
, O
a O
set O
of O
minigenomes O
was O
expressed O
that O
included O
an O
expression O
cassette O
for O
an O
mRNA O
including O
the O
beta B
- I
glucuronidase I
gene I
( I
GUS I
) I
plus O
variable O
sequence O
fragments O
from O
the O
5 O
' O
end O
of O
the O
virus O
genome O
potentially O
including O
psi O
. O

Insertion O
of O
the O
first O
649 O
nucleotides B
( I
nt I
) I
of O
the O
TGEV O
genome O
led O
to O
the O
specific O
encapsidation O
of O
the O
mRNA O
, O
indicating O
that O
a O
psi O
was O
located O
within O
this O
region O
which O
was O
absent O
from O
all O
of O
the O
other O
virus O
mRNAs O
. O

In O
contrast O
, O
viral O
mRNAs O
presented O
significantly O
lower O
encapsidation O
efficiencies O
( O
about O
100 O
- O
fold O
) O
than O
those O
of O
the O
virus O
genome O
, O
strongly O
suggesting O
that O
TGEV O
mRNAs O
in O
fact O
lacked O
an O
alternative O
TGEV O
psi O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
thought O
to O
mostly O
become O
chronic O
and O
rarely O
resolves O
. O

5 O
x O
10 O
( O
5 O
) O
versus O
2 O
. O

9 O
x O
10 O
( O
6 O
) O
IU O
/ O
ml O
; O
P O
= O
0 O
. O

HCV O
genotype O
2 O
was O
largely O
predominant O
( O
87 O
% O
) O
. O

Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
induce O
potent O
antiviral O
and O
antiproliferative O
responses O
and O
are O
used O
to O
treat O
a O
wide O
range O
of O
human O
diseases O
, O
including O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

A O
search O
for O
IFN B
- I
stimulated I
response I
elements I
( I
ISREs I
) I
in O
genomic O
DNA O
located O
upstream O
of O
IFN O
- O
stimulated O
genes O
revealed O
both O
previously O
identified O
and O
novel O
putative O
ISREs O
. O

To O
determine O
whether O
HCV O
can O
alter O
IFN O
- O
regulated O
gene O
expression O
, O
we O
performed O
microarray O
analyses O
on O
IFN O
- O
treated O
HeLa O
cells O
expressing O
the O
HCV B
nonstructural I
5A I
( I
NS5A I
) I
protein O
and O
on O
IFN O
- O
treated O
Huh7 O
cells O
containing O
an O
HCV O
subgenomic O
replicon O
. O

Higher O
- O
order O
structures O
in O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
plus O
- O
strand O
RNA O
viruses O
are O
known O
in O
many O
cases O
to O
function O
as O
cis O
- O
acting O
elements O
in O
RNA O
translation O
, O
replication O
, O
or O
transcription O
. O

Here O
we O
describe O
evidence O
supporting O
the O
structure O
and O
a O
cis O
- O
acting O
function O
in O
Defective B
interfering I
( I
DI I
) I
RNA O
replication O
of O
stem O
- O
loop O
III O
, O
the O
third O
of O
four O
predicted O
higher O
- O
order O
structures O
mapping O
within O
the O
210 O
- O
nucleotide B
( I
nt I
) I
5 O
' O
UTR O
of O
the O
32 O
- O
kb O
bovine B
coronavirus I
( I
BCoV I
) I
genome O
. O

0 O
kcal O
/ O
mol O
in O
the O
negative O
strand O
, O
and O
has O
associated O
with O
it O
beginning O
at O
nt O
100 O
an O
open B
reading I
frame I
( I
ORF I
) I
potentially O
encoding O
an O
8 O
- O
amino O
- O
acid O
peptide O
. O

Stem O
- O
loop O
III O
( O
i O
) O
shows O
phylogenetic O
conservation O
among O
group O
2 O
coronaviruses O
and O
appears O
to O
have O
a O
homolog O
in O
coronavirus O
groups O
1 O
and O
3 O
, O
( O
ii O
) O
has O
in O
all O
coronaviruses O
for O
which O
sequence O
is O
known O
a O
closely O
associated O
short O
, O
AUG O
- O
initiated O
intra O
- O
5 O
' O
UTR O
ORF O
, O
( O
iii O
) O
is O
supported O
by O
enzyme O
structure O
- O
probing O
evidence O
in O
BCoV O
RNA O
, O
( O
iv O
) O
must O
maintain O
stem O
integrity O
for O
DI O
RNA O
replication O
in O
BCoV O
DI O
RNA O
, O
and O
( O
v O
) O
shows O
a O
positive O
correlation O
between O
maintenance O
of O
the O
short O
ORF O
and O
maximal O
DI O
RNA O
accumulation O
in O
BCoV O
DI O
RNA O
. O

Recently O
, O
cell O
- O
based O
replicon O
systems O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
in O
which O
the O
nonstructural O
proteins O
stably O
replicate O
subgenomic O
viral O
RNA O
in O
Huh7 O
cells O
, O
were O
developed O
. O

To O
date O
, O
one O
limitation O
of O
using O
these O
replicon O
systems O
to O
advance O
drug O
discovery O
is O
the O
inability O
of O
other O
genotypic O
derivatives O
, O
beyond O
those O
of O
two O
distinct O
strains O
of O
genotype O
1b O
( O
HCV O
- O
N O
and O
Con1 O
) O
, O
to O
stably O
replicate O
in O
Huh7 O
cells O
. O

Furthermore O
, O
addition O
of O
an O
NS5A O
adaptive O
mutation O
( O
S22041 O
) O
which O
enhances O
type O
1b O
replicon O
efficiency O
was O
insufficient O
to O
confer O
replication O
to O
the O
wild O
- O
type O
la O
replicon O
. O

Therefore O
, O
to O
ensure O
efficient O
translation O
and O
thereby O
support O
replication O
of O
the O
la O
genome O
, O
the O
coding O
sequence O
for O
first O
75 O
residues O
from O
type O
la O
were O
replaced O
with O
the O
type O
1b O
( O
strain O
Con O
1 O
) O
NS3 O
coding O
sequence O
. O

Although O
nonstructural O
proteins O
were O
expressed O
at O
lower O
levels O
with O
this O
replicon O
than O
with O
type O
1b O
and O
although O
the O
amount O
of O
viral O
RNA O
was O
also O
severalfold O
lower O
( O
150 O
copies O
of O
positive O
- O
strand O
RNA O
per O
cell O
) O
, O
the O
replicon O
stably O
replicated O
in O
Huh7 O
cells O
. O

These O
la O
hybrid O
replicons O
maintained O
sensitivity O
to O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
albeit O
with O
an O
eightfold O
- O
higher O
50 O
% O
inhibitory O
concentration O
than O
type O
1b O
replicons O
. O

Replication O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
has O
been O
proposed O
to O
take O
place O
close O
to O
the O
membrane O
of O
the O
endoplasmic O
reticulum O
in O
membrane O
- O
associated O
replicase O
complexes O
, O
as O
is O
the O
case O
with O
several O
other O
plus O
- O
strand O
RNA O
viruses O
, O
such O
as O
poliovirus O
and O
flaviviruses O
. O

Indeed O
, O
HCV O
nonstructural B
( I
NS I
) I
proteins O
were O
clearly O
colocalized O
in O
association O
with O
membranes O
derived O
from O
the O
endoplasmic O
reticulum O
. O

This O
observation O
, O
together O
with O
the O
demonstration O
of O
the O
existence O
of O
several O
physical O
interactions O
between O
HCV O
NS O
proteins O
, O
supports O
the O
idea O
of O
assembly O
of O
a O
highly O
ordered O
multisubunit O
protein O
complex O
( O
es O
) O
probably O
involved O
in O
the O
replication O
of O
the O
viral O
genome O
. O

The O
objective O
of O
this O
study O
, O
therefore O
, O
was O
to O
examine O
all O
potential O
interactions O
between O
HCV O
NS O
proteins O
which O
could O
result O
in O
the O
formation O
of O
a O
replication O
complex O
( O
es O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
belongs O
to O
the O
Hepacivirus O
genus O
in O
the O
Flaviviridae O
family O
. O

The O
protein O
localized O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
but O
also O
induced O
a O
pattern O
of O
cytoplasmic O
foci O
positive O
for O
markers O
of O
the O
ER O
. O

Here O
, O
we O
demonstrate O
the O
presence O
of O
a O
specific O
membrane O
alteration O
, O
designated O
the O
membranous O
web O
, O
that O
contains O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural O
proteins O
, O
as O
well O
as O
viral O
plus O
- O
strand O
RNA O
, O
in O
Huh O
- O
7 O
cells O
harboring O
autonomously O
replicating O
subgenomic O
HCV O
RNAs O
. O

interleukin B
- I
1 I
( I
IL I
- I
1 I
) I
plays O
an O
important O
role O
in O
the O
inflammatory O
process O
. O

Some O
studies O
have O
demonstrated O
that O
IL O
- O
1 O
production O
was O
impaired O
in O
patients O
with O
chronic O
infections O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
implying O
that O
IL O
- O
1 O
may O
play O
a O
role O
in O
viral O
clearance O
. O

The O
inhibitory O
effect O
is O
associated O
with O
the O
extracellular B
regulatory I
kinase I
( I
ERK I
) I
activation O
. O

In O
addition O
, O
we O
also O
show O
that O
IL O
- O
1 O
can O
induce O
one O
of O
the O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
1 O
- O
8U O
, O
which O
exhibits O
antiviral O
activity O
. O

We O
identified O
an O
N O
- O
terminal O
amphipathic B
helix I
( I
AH I
) I
in O
one O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
' O
s O
nonstructural O
proteins O
, O
NS5A O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
treated O
with O
interferon B
( I
IFN I
) I
- O
based O
therapy O
. O

In O
the O
present O
study O
we O
characterized O
the O
effects O
of O
IFN O
action O
upon O
the O
replication O
of O
two O
distinct O
quasispecies O
of O
an O
HCV O
replicon O
whose O
encoded O
NS5A O
protein O
exhibited O
differential O
abilities O
to O
bind O
and O
inhibit O
protein B
kinase I
R I
( I
PKR I
) I
. O

However O
, O
within O
cells O
expressing O
an O
NS5A O
variant O
that O
inhibited O
PW O
we O
observed O
a O
reduced O
level O
of O
eukaryotic B
initiation I
factor I
2 I
alpha I
subunit I
( I
eIF2alpha I
) I
phosphorylation O
and O
a O
concomitant O
increase O
in O
HCV O
protein O
synthetic O
rates O
, O
enhancement O
of O
viral O
RNA O
replication O
, O
and O
a O
partial O
rescue O
of O
viral O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
function O
from O
IFN O
suppression O
. O

The O
NS3 O
ATPase O
/ O
helicase O
was O
isolated O
and O
characterized O
from O
three O
different O
infectious O
clones O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

One O
helicase O
was O
from O
a O
genotype O
that O
normally O
responds O
to O
therapy O
( O
Hel O
- O
2a O
) O
, O
and O
the O
other O
two O
were O
from O
more O
resistant O
genotypes O
, O
la O
( O
Hel O
- O
1a O
) O
and O
1b O
( O
Hel O
- O
1b O
) O
. O

In O
the O
present O
study O
, O
the O
contributions O
of O
the O
CC O
chemokine B
ligand I
3 I
( I
Ccl3 I
) I
to O
the O
differentiation O
and O
migration O
of O
effector O
T O
cells O
in O
response O
to O
viral O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
were O
analyzed O
. O

CCL3 O
( O
- O
/ O
- O
) O
mice O
infected O
with O
mouse O
hepatitis O
virus O
exhibited O
a O
significant O
reduction O
of O
virus O
- O
specific O
CD8 O
+ O
T O
cells O
within O
the O
CNS O
, O
correlating O
with O
delayed O
viral O
clearance O
. O

Decreased O
infiltration O
of O
CD8 O
+ O
T O
cells O
into O
infected O
CCL3 O
( O
- O
/ O
- O
) O
mice O
was O
associated O
with O
enhanced O
accumulation O
of O
primed O
CD8 O
+ O
T O
cells O
in O
cervical O
lymph O
nodes O
. O

Although O
virus O
- O
specific O
CD8 O
+ O
T O
cells O
from O
CCL3 O
( O
- O
/ O
- O
) O
mice O
were O
CD44 O
( O
high O
) O
, O
they O
remained O
CD62L O
( O
high O
) O
and O
CD25 O
( O
low O
) O
, O
retained O
CCR7 O
expression O
, O
and O
contained O
limited O
transcripts O
of O
the O
proinflammatory O
chemokine O
receptors O
CCR5 O
and O
CXCR3 O
compared O
with O
virus O
- O
specific O
CD8 O
+ O
T O
cells O
from O
CCL3 O
( O
+ O
/ O
+ O
) O
mice O
. O

In O
addition O
, O
macrophage O
accumulation O
within O
the O
CNS O
was O
significantly O
decreased O
in O
infected O
CCL3 O
( O
- O
/ O
- O
) O
mice O
, O
correlating O
with O
reduced O
demyelination O
. O

The O
mechanism O
and O
machinery O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
are O
still O
poorly O
understood O
. O

In O
this O
study O
, O
we O
labeled O
de O
novo O
- O
synthesized O
viral O
RNA O
in O
situ O
with O
bromouridine B
triphosphate I
( I
BrUTP I
) I
in O
Huh7 O
cells O
expressing O
an O
HCV O
subgenomic O
replicon O
. O

By O
immunofluorescence O
staining O
using O
an O
anti O
- O
BrUTP O
antibody O
and O
confocal O
microscopy O
, O
we O
showed O
that O
the O
newly O
synthesized O
HCV O
RNA O
was O
localized O
to O
distinct O
speckle O
- O
like O
structures O
, O
which O
also O
contain O
all O
of O
the O
HCV O
nonstructural B
( I
NS I
) I
proteins O
. O

These O
speckles O
are O
distinct O
from O
lipid O
droplets O
and O
are O
separated O
from O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
where O
some O
HCV O
NS O
proteins O
also O
reside O
. O

The O
genome O
of O
the O
coronavirus O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
has O
been O
engineered O
as O
an O
expression O
vector O
with O
an O
infectious O
cDNA O
. O

The O
vector O
led O
to O
the O
efficient O
( O
> O
40 O
mug O
/ O
10 O
( O
6 O
) O
cells O
) O
and O
stable O
( O
> O
20 O
passages O
) O
expression O
of O
a O
heterologous O
gene O
( O
green O
fluorescent O
protein O
[ O
GFP O
] O
) O
, O
driven O
by O
the O
transcription B
- I
regulating I
sequences I
( I
TRS I
) I
of O
open B
reading I
frame I
( I
ORF I
) I
3a O
inserted O
in O
the O
site O
previously O
occupied O
by O
the O
nonessential O
ORFs O
3a O
and O
3b O
. O

The O
recombinant O
TGEV O
including O
the O
GFP O
gene O
was O
still O
enteropathogenic O
, O
albeit O
with O
a O
10 O
- O
to O
10 O
( O
2 O
) O
- O
fold O
reduction O
in O
enteric O
tissue O
growth O
. O

feline B
infectious I
peritonitis I
virus I
( I
FIPV I
) I
, O
a O
coronavirus O
, O
is O
the O
causative O
agent O
of O
an O
invariably O
lethal O
infection O
in O
cats O
. O

We O
describe O
here O
the O
development O
and O
use O
of O
a O
reverse O
genetics O
strategy O
for O
FIPV O
based O
on O
targeted O
RNA O
recombination O
that O
is O
analogous O
to O
what O
has O
been O
described O
for O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
( O
L O
. O

In O
this O
fashion O
, O
we O
reconstructed B
a I
wild I
- I
type I
recombinant I
virus I
( I
r I
- I
wtFIPV I
) I
and O
generated O
a O
directed O
mutant O
FIPV O
in O
which O
the O
initiation O
codon O
of O
the O
nonstructural O
gene O
7b O
had O
been O
disrupted O
( O
FIPVDelta7b O
) O
. O

Recombinant O
murine O
coronaviruses O
, O
differing O
only O
in O
the O
spike O
gene O
and O
containing O
the O
strain O
A59 O
( O
moderately O
hepatotropic O
) O
and O
JHM O
( O
neurotropic O
) O
spike O
genes O
in O
the O
background O
of O
the O
JHM O
genome O
, O
were O
compared O
for O
the O
ability O
to O
replicate O
in O
the O
liver O
and O
induce O
hepatitis O
in O
weanling O
C57BL O
/ O
6 O
mice O
. O

For O
any O
of O
the O
enveloped O
RNA O
viruses O
studied O
to O
date O
, O
recognition O
of O
a O
specific O
RNA O
packaging O
signal O
by O
the O
virus O
' O
s O
nucleocapsid B
( I
N I
) I
protein O
is O
the O
first O
step O
described O
in O
the O
process O
of O
viral O
RNA O
packaging O
. O

Progress O
toward O
development O
of O
better O
therapies O
for O
the O
treatment O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
been O
hampered O
by O
poor O
understanding O
of O
HCV O
biology O
and O
the O
lack O
of O
biological O
assays O
suitable O
for O
drug O
screening O
. O

Here O
we O
describe O
a O
powerful O
HCV O
replication O
system O
that O
employs O
HCV O
replicons O
expressing O
the O
beta O
- O
lactamase O
reporter O
( O
bla O
replicons O
) O
and O
subpopulations O
of O
Huh7 O
cells O
that O
are O
more O
permissive O
( O
or O
enhanced O
) O
to O
HCV O
replication O
than O
naive O
Huh7 O
cells O
. O

Enhanced O
cells O
represent O
a O
small O
fraction O
of O
permissive O
cells O
present O
among O
naive O
Huh7 O
cells O
that O
is O
enriched O
during O
selection O
with O
replicons O
expressing O
the O
neomycin O
phosphotransferase O
gene O
( O
neo O
replicons O
) O
. O

Studies O
on O
the O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
been O
facilitated O
by O
the O
development O
of O
selectable O
subgenomic O
replicons O
replicating O
in O
the O
human O
hepatoma O
cell O
line O
Huh O
- O
7 O
at O
a O
surprisingly O
high O
level O
. O

Mutations O
enhancing O
replication O
were O
found O
in O
nearly O
every O
nonstructural B
( I
NS I
) I
protein O
, O
and O
they O
could O
be O
subdivided O
into O
at O
least O
two O
groups O
by O
their O
effect O
on O
replication O
efficiency O
and O
cooperativity O
: O
( O
i O
) O
mutations O
in O
NS3 O
with O
a O
low O
impact O
on O
replication O
but O
that O
enhanced O
replication O
cooperatively O
when O
combined O
with O
highly O
adaptive O
mutations O
and O
( O
ii O
) O
mutations O
in O
NS4B O
, O
- O
5A O
, O
and O
- O
5B O
, O
causing O
a O
strong O
increase O
in O
replication O
but O
being O
incompatible O
with O
each O
other O
. O

In O
a O
search O
for O
cellular O
factor O
( O
s O
) O
that O
might O
be O
responsible O
for O
the O
different O
levels O
of O
permissiveness O
of O
Huh O
- O
7 O
cells O
, O
we O
found O
that O
replication O
efficiency O
decreased O
with O
increasing O
amounts O
of O
transfected O
replicon O
RNA O
, O
indicating O
that O
viral O
RNA O
or O
proteins O
are O
cytopathic O
or O
that O
host O
cell O
factors O
in O
Huh O
- O
7 O
cells O
limit O
RNA O
amplification O
. O

Sequences O
of O
the O
untranslated O
regions O
at O
the O
5 O
' O
and O
3 O
' O
ends O
( O
5 O
' O
UTR O
and O
3 O
' O
UTR O
) O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
genome O
are O
highly O
conserved O
and O
contain O
cis O
- O
acting O
RNA O
elements O
for O
HCV O
RNA O
replication O
. O

The O
HCV O
5 O
' O
UTR O
consists O
of O
two O
distinct O
RNA O
elements O
, O
a O
short O
5 O
' O
- O
proximal O
stem O
- O
loop O
RNA O
element O
( O
nucleotides O
1 O
to O
43 O
) O
and O
a O
longer O
element O
of O
internal O
ribosome O
entry O
site O
. O

A O
protein O
- O
protein O
interaction O
within O
the O
helicase O
domain O
of O
the O
Tobacco B
mosaic I
virus I
( I
TMV I
) I
126 O
- O
and O
183 O
- O
kDa O
replicase O
proteins O
was O
previously O
implicated O
in O
virus O
replication O
( O
S O
. O

We O
describe O
a O
mutational O
analysis O
of O
the O
3 B
' I
nontranslated I
RNA I
( I
3 I
' I
NTR I
) I
signals O
required O
for O
replication O
of O
subgenomic O
hepatitis B
C I
virus I
( I
HCV I
) I
RNAs O
. O

A O
series O
of O
deletion O
mutants O
was O
constructed O
within O
the O
background O
of O
an O
HCV O
- O
N O
replicon O
that O
induces O
the O
expression O
of O
secreted O
alkaline O
phosphatase O
in O
order O
to O
examine O
the O
requirements O
for O
each O
of O
the O
three O
domains O
comprising O
the O
3 O
' O
NTR O
, O
namely O
, O
the O
highly O
conserved O
3 O
' O
terminal O
98 O
- O
nucleotide B
( I
nt I
) I
segment O
( O
3 O
' O
X O
) O
, O
an O
upstream O
poly O
( O
U O
) O
- O
poly O
( O
UC O
) O
[ O
poly O
( O
U O
/ O
UC O
) O
] O
tract O
, O
and O
the O
variable B
region I
( I
VR I
) I
located O
at O
the O
5 O
' O
end O
of O
the O
3 O
' O
NTR O
. O

Similarly O
, O
complete O
deletion O
of O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
abolished O
replication O
. O

Replacement O
of O
a O
minimum O
of O
50 O
to O
62 O
nt O
of O
poly O
( O
U O
/ O
UC O
) O
sequence O
was O
required O
for O
detectable O
RNA O
replication O
when O
the O
native O
sequence O
was O
restored O
in O
a O
stepwise O
fashion O
from O
its O
3 O
' O
end O
. O

Lengthier O
poly O
( O
U O
/ O
UC O
) O
sequences O
, O
and O
possibly O
pure O
homopolymeric O
poly O
( O
U O
) O
tracts O
, O
were O
associated O
with O
more O
efficient O
RNA O
amplification O
. O

The O
results O
indicate O
that O
the O
3 O
' O
- O
most O
150 O
nt O
of O
the O
HCV O
- O
N O
genome O
[ O
the O
3 O
' O
X O
region O
and O
the O
3 O
' O
52 O
nt O
of O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
] O
contain O
RNA O
signals O
that O
are O
essential O
for O
replication O
, O
while O
the O
remainder O
of O
the O
3 O
' O
NTR O
plays O
a O
facilitating O
role O
in O
replication O
but O
is O
not O
absolutely O
required O
. O

The O
hepatitis O
C O
virus O
envelope O
protein O
, O
E2 O
, O
is O
an O
endoplasmic B
reticulum I
( I
ER I
) I
- O
bound O
protein O
that O
contains O
a O
region O
of O
sequence O
homology O
with O
the O
double O
- O
stranded O
RNA O
- O
activated O
protein O
kinase O
PKR O
and O
its O
substrate O
, O
the O
eukaryotic B
translation I
initiation I
factor I
2 I
( I
eIF2 I
) I
. O

We O
previously O
reported O
that O
E2 O
modulates O
global O
translation O
through O
inhibition O
of O
the O
interferon O
- O
induced O
antiviral O
protein O
PKR O
through O
its O
PKR B
- I
eIF2alpha I
phosphorylation I
site I
homology I
domain I
( I
PePHD I
) I
. O

Here O
we O
show O
that O
the O
PKR B
- I
like I
ER I
- I
resident I
kinase I
( I
PERK I
) I
binds O
to O
and O
is O
also O
inhibited O
by O
E2 O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
serine O
protease O
is O
necessary O
for O
viral O
replication O
and O
represents O
a O
valid O
target O
for O
developing O
new O
therapies O
for O
HCV O
infection O
. O

The O
envelope O
glycoprotein O
E2 O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
target O
of O
neutralizing O
antibodies O
and O
is O
presently O
being O
evaluated O
as O
an O
HCV O
vaccine O
candidate O
. O

A O
first O
segment O
centered O
around O
amino O
acid O
residues O
613 O
to O
618 O
is O
essential O
for O
recognition O
, O
while O
a O
second O
element O
including O
the O
two O
hypervariable B
regions I
( I
HVRs I
) I
modulates O
E2 O
receptor O
binding O
. O

A O
number O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
, O
including O
NS5B O
, O
the O
RNA O
- O
dependent O
RNA O
polymerase O
, O
were O
detected O
in O
membrane O
fractions O
from O
Huh7 O
cells O
containing O
autonomously O
replicating O
HCV O
RNA O
replicons O
. O

Replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
in O
virus O
- O
infected O
cells O
is O
believed O
to O
be O
catalyzed O
by O
viral O
replicase B
complexes I
( I
RCs I
) I
, O
which O
may O
consist O
of O
various O
virally O
encoded O
nonstructural O
proteins O
and O
host O
factors O
. O

The O
RC O
preparation O
was O
able O
to O
use O
endogenous O
replicon O
RNA O
as O
a O
template O
to O
synthesize O
both O
single B
- I
stranded I
( I
ss I
) I
and O
double B
- I
stranded I
( I
ds I
) I
RNA O
products O
. O

Divalent O
cations O
( O
Mg2 O
+ O
and O
Mn2 O
+ O
) O
showed O
different O
effects O
on O
RNA O
synthesis O
. O

The O
natural O
history O
and O
pathogenic O
potential O
of O
the O
recently O
identified O
TT B
virus I
( I
TTV I
) I
are O
currently O
a O
matter O
of O
intensive O
investigation O
. O

In O
an O
attempt O
to O
shed O
some O
light O
on O
these O
issues O
, O
nasal O
and O
blood O
specimens O
of O
1 O
- O
to O
24 O
- O
month O
- O
old O
children O
hospitalized O
with O
a O
clinical O
diagnosis O
of O
acute B
respiratory I
disease I
( I
ARD I
) I
were O
examined O
for O
the O
presence O
, O
load O
, O
and O
genetic O
characteristics O
of O
TTV O
. O

Although O
we O
found O
no O
compelling O
evidence O
that O
TTV O
was O
the O
direct O
cause O
of O
ARD O
in O
some O
of O
the O
children O
studied O
, O
the O
average O
loads O
of O
TTV O
were O
considerably O
higher O
in O
patients O
with O
bronchopneumonia B
( I
BP I
) I
than O
in O
those O
with O
milder O
ARD O
, O
raising O
interesting O
questions O
about O
the O
pathophysiological O
significance O
of O
TTV O
at O
this O
site O
. O

In O
infected O
cells O
, O
translation O
of O
the O
plus O
- O
strand O
poliovirus O
RNA O
genome O
is O
directed O
by O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
, O
a O
cis O
- O
acting O
RNA O
element O
that O
facilitates O
the O
cap O
- O
independent O
binding O
of O
ribosomes O
to O
an O
internal O
site O
of O
the O
viral O
RNA O
. O

Intracranial O
infection O
of O
C57BL O
/ O
6 O
mice O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
results O
in O
an O
acute O
encephalomyelitis O
followed O
by O
a O
demyelinating O
disease O
similar O
in O
pathology O
to O
the O
human O
disease O
multiple B
sclerosis I
( I
MS I
) I
. O

CD4 O
( O
+ O
) O
T O
cells O
are O
important O
in O
amplifying O
demyelination O
by O
attracting O
macrophages O
into O
the O
central B
nervous I
system I
( I
CNS I
) I
following O
viral O
infection O
; O
however O
, O
the O
mechanisms O
governing O
the O
entry O
of O
these O
cells O
into O
the O
CNS O
are O
poorly O
understood O
. O

The O
role O
of O
chemokine O
receptor O
CCR5 O
in O
trafficking O
of O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
into O
the O
CNS O
of O
MHV O
- O
infected O
mice O
was O
investigated O
. O

CD4 O
( O
+ O
) O
T O
cells O
from O
immunized O
CCR5 O
( O
+ O
/ O
+ O
) O
and O
CCR5 O
( O
- O
/ O
- O
) O
mice O
were O
expanded O
in O
the O
presence O
of O
the O
immunodominant O
epitope O
present O
in O
the O
MHV O
transmembrane O
( O
M O
) O
protein O
encompassing O
amino O
acids O
133 O
to O
147 O
( O
M133 O
- O
147 O
) O
. O

Adoptive O
transfer O
of O
CCR5 O
( O
+ O
/ O
+ O
) O
- O
derived O
CD4 O
( O
+ O
) O
T O
cells O
to O
MHV O
- O
infected O
RAG1 O
( O
- O
/ O
- O
) O
mice O
resulted O
in O
CD4 O
( O
+ O
) O
- O
T O
- O
cell O
entry O
into O
the O
CNS O
and O
clearance O
of O
virus O
from O
the O
brain O
. O

Conversely O
, O
CD4 O
( O
+ O
) O
T O
cells O
from O
CCR5 O
( O
- O
/ O
- O
) O
mice O
displayed O
an O
impaired O
ability O
to O
traffic O
into O
the O
CNS O
of O
MHV O
- O
infected O
RAG1 O
( O
- O
/ O
- O
) O
recipients O
, O
which O
correlated O
with O
increased O
viral O
titers O
, O
diminished O
macrophage O
accumulation O
, O
and O
limited O
demyelination O
. O

Analysis O
of O
chemokine O
receptor O
mRNA O
expression O
by O
M133 O
- O
147 O
- O
expanded O
CCR5 O
( O
- O
/ O
- O
) O
- O
derived O
CD4 O
( O
+ O
) O
T O
cells O
revealed O
reduced O
expression O
of O
CCR1 O
, O
CCR2 O
, O
and O
CXCR3 O
, O
indicating O
that O
CCR5 O
signaling O
is O
important O
in O
increased O
expression O
of O
these O
receptors O
, O
which O
aid O
in O
trafficking O
of O
CD4 O
( O
+ O
) O
T O
cells O
into O
the O
CNS O
. O

Collectively O
these O
results O
demonstrate O
that O
CCR5 O
signaling O
is O
important O
to O
migration O
of O
CD4 O
( O
+ O
) O
T O
cells O
to O
the O
CNS O
following O
MHV O
infection O
. O

The O
number O
of O
synonymous O
mutations O
per O
synonymous O
site O
( O
K O
- O
s O
) O
, O
the O
number O
of O
nonsynonymous O
mutations O
per O
nonsynonymous O
site O
( O
K O
- O
a O
) O
, O
and O
the O
codon O
usage O
statistic O
( O
N O
- O
c O
) O
were O
calculated O
for O
several O
hepatitis B
A I
virus I
( I
HAV I
) I
isolates O
. O

While O
K O
- O
s O
was O
similar O
to O
those O
of O
poliovirus B
( I
PV I
) I
and O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
, O
K O
- O
a O
was O
1 O
order O
of O
magnitude O
lower O
. O

We O
used O
a O
baculovirus O
- O
based O
system O
to O
prepare O
structural O
proteins O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
la O
. O

This O
binding O
was O
decreased O
by O
calcium O
depletion O
and O
was O
partially O
prevented O
by O
ligands O
of O
the O
asialoglycoprotein B
receptor I
( I
ASGP I
- I
R I
) I
, O
thyroglobulin O
, O
asialothyroglobulin O
, O
and O
antibody O
against O
a O
peptide O
in O
the O
carbohydrate O
recognition O
domain O
of O
ASGP O
- O
R O
but O
not O
preimmune O
antibody O
. O

The O
two O
preparations O
bound O
to O
transfected O
3T3 O
- O
L1 O
cells O
expressing O
either O
both O
( O
hH1 O
and O
hH2 O
) O
subunits O
of O
the O
ASGP O
- O
R O
( O
3T3 O
- O
22Z O
cells O
) O
or O
both O
hH1 O
and O
a O
functionally O
defective O
variant O
of O
hH2 O
( O
3T3 O
- O
24X O
cells O
) O
but O
not O
to O
parental O
cells O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
positive O
- O
strand O
RNA O
virus O
that O
encodes O
a O
helicase O
required O
for O
viral O
replication O
. O

An O
X O
- O
ray O
crystal O
structure O
of O
the O
HCV O
helicase O
complexed O
with O
( O
dU O
) O
( O
8 O
) O
has O
been O
solved O
, O
and O
the O
substrate O
- O
amino O
acids O
interactions O
within O
the O
catalytic O
pocket O
were O
shown O
. O

Clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
in O
humans O
and O
chimpanzees O
is O
thought O
to O
be O
associated O
with O
the O
induction O
of O
strong O
T O
- O
cell O
responses O
. O

A O
comparison O
of O
the O
frequency O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
peripheral O
blood O
by O
ELISpot O
assay O
did O
not O
reveal O
any O
correlation O
between O
viral O
clearance O
and O
T O
- O
cell O
responses O
. O

The O
recently O
developed O
hepatitis B
C I
virus I
( I
HCV I
) I
subgenomic O
replicon O
system O
was O
utilized O
to O
evaluate O
the O
efficacy O
of O
several O
known O
antiviral O
agents O
. O

A O
replicon O
constructed O
from O
the O
infectious O
clone O
of O
the O
HCV O
- O
1 O
strain O
( O
genotype O
1a O
) O
was O
not O
capable O
of O
inducing O
colony O
formation O
even O
after O
the O
introduction O
of O
adaptive O
mutations O
identified O
in O
the O
genotype O
1b O
replicon O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
IFN O
- O
gamma O
, O
and O
ribavirin O
exhibited O
antiviral O
activity O
, O
while O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
and O
tumor O
necrosis O
factor O
alpha O
did O
not O
. O

Analysis O
of O
transcript O
levels O
for O
a O
series O
of O
genes O
stimulated O
by O
IFN O
( O
ISGs O
) O
or O
dsRNA O
following O
treatment O
with O
IFN O
- O
alpha O
, O
IFN O
- O
gamma O
, O
and O
dsRNA O
revealed O
that O
both O
IFNs O
increased O
ISG O
transcript O
levels O
, O
but O
that O
some O
aspect O
of O
the O
dsRNA O
response O
pathway O
was O
defective O
in O
Huh7 O
cells O
and O
replicon O
cell O
lines O
in O
comparison O
to O
primary O
chimpanzee O
and O
tamarin O
hepatocytes O
. O

Subgenomic O
mRNAs O
of O
nidoviruses O
( O
arteriviruses O
and O
coronaviruses O
) O
are O
composed O
of O
a O
common O
leader O
sequence O
and O
a O
body O
part O
of O
variable O
size O
, O
which O
are O
derived O
from O
the O
5 O
' O
- O
and O
3 O
' O
- O
proximal O
part O
of O
the O
genome O
, O
respectively O
. O

This O
discontinuous O
step O
in O
subgenomic O
RNA O
synthesis O
is O
guided O
by O
short O
transcription B
- I
regulating I
sequences I
( I
TRSs I
) I
that O
are O
present O
at O
both O
these O
template O
sites O
( O
leader O
TRS O
and O
body O
TRS O
) O
. O

Here O
we O
show O
that O
extending O
the O
leader O
TRS O
- O
body O
TRS O
duplex O
beyond O
its O
wild O
- O
type O
length O
dramatically O
enhanced O
the O
subgenomic O
mRNA O
synthesis O
of O
the O
arterivirus O
equine B
arteritis I
virus I
( I
EAV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
F O
protein O
is O
a O
newly O
discovered O
HCV O
gene O
product O
that O
is O
expressed O
by O
translational O
ribosomal O
frameshift O
. O

The O
majority O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
infected O
individuals O
progress O
from O
acute O
to O
chronic O
disease O
, O
despite O
the O
presence O
of O
a O
strong O
humoral O
immune O
response O
I O
to O
the O
envelope O
glycoproteins O
E1 O
and O
E2 O
. O

Previously O
, O
we O
identified O
10 O
human B
monoclonal I
antibodies I
( I
HMAbs I
) I
that O
bind O
E2 O
glycoproteins O
from O
different O
genotypes O
. O

Although O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
enters O
cells O
by O
virus O
- O
cell O
membrane O
fusion O
triggered O
by O
its O
spike B
( I
S I
) I
protein O
, O
it O
is O
not O
well O
known O
how O
the O
S O
protein O
participates O
in O
fusion O
events O
. O

We O
reported O
that O
the O
soluble O
form O
of O
MHV O
receptor O
( O
soMHVR O
) O
transformed O
a O
nonfusogenic O
S O
protein O
into O
a O
fusogenic O
one O
( O
F O
. O

A O
cl O
- O
2 O
mutant O
, O
srr7 O
, O
of O
the O
MHV O
JHM B
virus I
( I
JHMV I
) I
was O
digested O
with O
proteinase O
K O
after O
treatment O
with O
soMHVR O
, O
and O
the O
resultant O
S O
protein O
was O
analyzed O
by O
Western O
blotting O
using O
monoclonal B
antibody I
( I
Mab I
) I
10G O
, O
specific O
for O
the O
membrane O
- O
anchored O
S2 O
subunit O
. O

soMHVR O
induced O
conformational O
changes O
of O
the O
S O
proteins O
of O
wild B
- I
type I
( I
WT I
) I
JHMV O
cl O
- O
2 O
, O
as O
well O
as O
revertants O
from O
srr7 O
, O
srr7A O
and O
srr7B O
; O
however O
, O
a O
major O
proportion O
of O
these O
S O
proteins O
were O
resistant O
to O
proteinase O
K O
even O
without O
soMHVR O
treatment O
. O

The O
consequences O
of O
a O
hepatitis B
A I
virus I
( I
HAV I
) I
infection O
on O
cell O
- O
based O
antiviral O
responses O
and O
the O
interactions O
between O
virus O
and O
host O
cells O
resulting O
in O
persistent O
infections O
are O
poorly O
understood O
. O

In O
this O
report O
, O
we O
show O
that O
HAV O
does O
inhibit O
double O
- O
stranded O
( O
dsRNA O
) O
- O
induced O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
expression O
by O
influencing O
the O
IFN O
- O
beta O
enhanceosome O
, O
as O
well O
as O
dsRNA O
- O
induced O
apoptosis O
, O
which O
suggests O
that O
both O
effects O
may O
be O
connected O
by O
shared O
viral O
and O
/ O
or O
cellular O
factors O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
plus O
- O
strand O
RNA O
genome O
. O

The O
5 B
' I
noncoding I
region I
( I
NCR I
) I
of O
the O
viral O
genome O
functions O
as O
an O
internal O
ribosome O
entry O
site O
, O
and O
its O
unique O
3 O
' O
NCR O
is O
required O
for O
the O
assembly O
of O
the O
replication O
complex O
during O
initiation O
of O
HCV O
RNA O
replication O
. O

These O
lysates O
, O
which O
contain O
ribonucleoprotein O
complexes O
associated O
with O
cellular O
membranes O
, O
were O
capable O
of O
incorporating O
[ O
alpha O
( O
32 O
) O
P O
] O
CTP O
into O
newly O
synthesized O
RNA O
from O
subgenomic O
replicons O
in O
vitro O
. O

Replicative O
forms O
( O
RFs O
) O
and O
replicative O
intermediates O
( O
RIs O
) O
were O
synthesized O
from O
the O
endogenous O
HCV O
RNA O
templates O
. O

The O
availability O
of O
a O
cell O
- O
free O
replication O
system O
offers O
opportunities O
to O
probe O
the O
mechanism O
( O
s O
) O
of O
HCV O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
major O
etiologic O
agent O
of O
hepatocellular O
carcinoma O
, O
presently O
infects O
approximately O
400 O
million O
people O
worldwide O
, O
making O
the O
development O
of O
protective O
measures O
against O
HCV O
infection O
a O
key O
objective O
. O

Here O
we O
have O
generated O
a O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
which O
expresses O
the O
HCV O
structural O
proteins O
, O
by O
inserting O
the O
contiguous O
Core O
, O
E1 O
, O
and O
E2 O
coding O
region O
of O
HCV O
into O
the O
VSV O
genome O
. O

Recombinant O
VSV O
expressing O
HCV O
Core O
, O
E1 O
, O
and O
E2 O
( O
VSV O
- O
HCV O
- O
C O
/ O
E1 O
/ O
E2 O
) O
grew O
to O
high O
titers O
in O
vitro O
and O
efficiently O
expressed O
the O
incorporated O
HCV O
gene O
product O
, O
which O
became O
fully O
processed O
into O
the O
individual O
HCV O
structural O
proteins O
. O

Biochemical O
and O
biophysical O
analysis O
indicated O
that O
the O
HCV O
Core O
, O
E1 O
, O
and O
E2 O
proteins O
assembled O
to O
form O
HCV B
- I
like I
particles I
( I
HCV I
- I
LPs I
) I
possessing O
properties O
similar O
to O
the O
ultrastructural O
properties O
of O
HCV O
virions O
. O

A O
few O
cellular O
and O
viral O
mRNAs O
, O
such O
as O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
mRNA O
genome O
, O
lack O
3 O
' O
- O
terminal O
polyadenosine O
sequences O
. O

A O
polyepitopic O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
is O
thought O
to O
be O
critical O
for O
control O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replication O
appears O
to O
be O
restricted O
to O
the O
human O
hepatoma O
cell O
line O
Huh O
- O
7 O
, O
indicating O
that O
a O
favorable O
cellular O
environment O
exists O
within O
these O
cells O
. O

Here O
we O
show O
that O
self O
- O
replicating O
subgenomic O
RNA O
could O
be O
eliminated O
from O
Huh O
- O
7 O
clones O
by O
prolonged O
treatment O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
that O
a O
higher O
frequency O
of O
cured O
cells O
could O
support O
both O
subgenomic O
and O
full O
- O
length O
HCV O
replication O
. O

Studies O
on O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
have O
been O
greatly O
advanced O
by O
the O
development O
of O
cell O
culture O
models O
for O
HCV O
known O
as O
replicon O
systems O
. O

The O
prototype O
replicon O
consists O
of O
a O
subgenomic O
HCV O
RNA O
in O
which O
the O
HCV O
structural O
region O
is O
replaced O
by O
the O
neomycin B
phosphotransferase I
II I
( I
NPTII I
) I
gene O
, O
and O
translation O
of O
the O
HCV O
proteins O
NS3 O
to O
NS5 O
is O
directed O
by O
the O
encephalomyocarditis B
virus I
( I
EMCV I
) I
internal O
ribosome O
entry O
site O
( O
TRES O
) O
. O

The O
interferon B
( I
IFN I
) I
- O
inducible O
protein O
kinase O
PKR O
plays O
an O
important O
role O
in O
cell O
defense O
against O
virus O
infection O
by O
impairing O
protein O
synthesis O
as O
a O
result O
of O
eIF O
- O
2alpha O
phosphorylation O
. O

Here O
, O
we O
show O
that O
expression O
of O
the O
viral O
nonstructural B
( I
NS I
) I
and O
PKR O
proteins O
and O
eIF O
- O
2alpha O
phosphorylation O
are O
all O
variably O
regulated O
in O
proliferating O
replicon O
Huh7 O
cells O
. O

A O
novel O
method O
was O
developed O
to O
assemble O
a O
full O
- O
length O
infectious O
cDNA O
of O
the O
group O
II O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
. O

Molecularly O
cloned O
viruses O
recognized O
the O
MHV B
receptor I
( I
MHVR I
) I
for O
docking O
and O
entry O
, O
and O
pretreatment O
of O
cells O
with O
monoclonal O
antibodies O
against O
MHVR O
blocked O
virus O
entry O
and O
replication O
. O

Cells O
infected O
with O
molecularly O
cloned O
MHV O
- O
A59 O
virus O
expressed O
replicase O
( O
gene O
1 O
) O
proteins O
identical O
to O
those O
of O
laboratory O
MHV O
- O
A59 O
. O

The O
binding O
of O
hepatitis O
C O
virus O
glycoprotein O
E2 O
to O
the O
large B
extracellular I
loop I
( I
LEL I
) I
of O
CD81 O
has O
been O
shown O
to O
modulate O
human O
T O
- O
cell O
and O
NK O
cell O
activity O
in O
vitro O
. O

Using O
random O
mutagenesis O
of O
a O
chimera O
of O
maltose O
- O
binding O
protein O
and O
LEL O
residues O
113 O
to O
201 O
, O
we O
have O
determined O
that O
the O
E2 O
- O
binding O
site O
on O
CD81 O
comprises O
residues O
Ile O
( O
182 O
, O
) O
Phe O
( O
186 O
) O
, O
Asn O
( O
184 O
) O
, O
and O
Len O
( O
162 O
) O
. O

These O
findings O
reveal O
an O
E2 O
- O
binding O
surface O
of O
approximately O
806 O
Angstrom O
( O
2 O
) O
and O
potential O
target O
sites O
for O
the O
development O
of O
small O
- O
molecule O
inhibitors O
of O
E2 O
binding O
. O

A O
direct O
comparison O
of O
the O
inhibitory O
effects O
of O
alpha O
, O
beta O
, O
and O
gamma O
Interferons B
( I
IFNs I
) I
on O
replication O
of O
a O
hepatitis O
C O
virus O
subgenomic O
replicon O
in O
a O
hepatoma O
cell O
line O
revealed O
similarities O
in O
antiviral O
potency O
. O

Most O
of O
the O
genome O
sequence O
of O
the O
porcine B
teschovirus I
- I
1 I
( I
PTV I
) I
Talfan O
and O
several O
other O
strains O
is O
known O
. O

We O
now O
demonstrate O
that O
initiation O
of O
protein O
synthesis O
occurs O
at O
nucleotide B
( I
nt I
) I
412 O
on O
the O
PTV O
Talfan O
RNA O
and O
that O
nt O
I O
to O
405 O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
that O
functions O
efficiently O
in O
vitro O
and O
within O
mammalian O
cells O
. O

The O
3 O
' O
- O
terminal O
sequences O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
positive O
- O
and O
negative O
- O
strand O
RNAs O
contribute O
cis O
- O
acting O
functions O
essential O
for O
viral O
replication O
. O

We O
therefore O
used O
a O
novel O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
system O
to O
determine O
relative O
mutation O
frequencies O
in O
variable O
and O
conserved O
regions O
of O
the O
HCV O
genome O
, O
and O
we O
further O
evaluated O
these O
frequencies O
in O
response O
to O
ribavirin O
. O

We O
sequenced O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
and O
the O
core O
, O
E2 O
HVR O
- O
1 O
, O
NS5A O
, O
and O
NS5B O
regions O
of O
replicating O
HCV O
RNA O
isolated O
from O
cells O
transfected O
with O
a O
T7 O
polymerase O
- O
driven O
full O
- O
length O
HCV O
cDNA O
plasmid O
containing O
a O
cis O
- O
acting O
hepatitis O
delta O
virus O
ribozyme O
to O
control O
3 O
' O
cleavage O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
sets O
up O
a O
persistent O
infection O
in O
patients O
that O
likely O
involves O
a O
complex O
virus O
- O
host O
interaction O
. O

We O
previously O
found O
that O
the O
HCV B
nonstructural I
5A I
( I
NS5A I
) I
protein O
interacts O
with O
growth O
factor O
receptor O
- O
binding O
protein O
2 O
( O
Grb2 O
) O
adaptor O
protein O
and O
inhibits O
the O
activation O
of O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
( I
ERK1 I
/ I
2 I
) I
by O
epidermal B
growth I
factor I
( I
EGF I
) I
. O

Interestingly O
, O
NS5A O
could O
also O
form O
a O
complex O
with O
the O
Grb2 O
- O
associated O
binder O
I O
( O
Gab1 O
) O
protein O
in O
an O
EGF O
treatment O
- O
dependent O
manner O
. O

However O
, O
the O
NS5A O
- O
Gab1 O
association O
, O
which O
appeared O
indirect O
, O
was O
not O
mediated O
by O
direct O
NS5A O
- O
Grb2 O
interaction O
but O
was O
likely O
dependent O
on O
direct O
NS5A O
interaction O
with O
the O
p85 O
subunit O
of O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
. O

Hepatitis B
C I
virus I
- I
like I
particles I
( I
HCV I
- I
LPs I
) I
containing O
the O
structural O
proteins O
of O
HCV O
H77 O
strain O
( O
1a O
genotype O
) O
was O
used O
as O
a O
model O
for O
HCV O
virion O
to O
study O
virus O
- O
cell O
interaction O
. O

22 O
g O
/ O
cm O
( O
3 O
) O
in O
a O
sucrose O
gradient O
and O
formed O
double O
- O
shelled O
particles O
35 O
to O
49 O
nm O
in O
diameter O
. O

Flow O
cytometry O
analysis O
by O
an O
indirect O
method O
( O
detection O
with O
anti O
- O
E2 O
antibody O
) O
and O
a O
direct O
method O
( O
use O
of O
dye O
- O
labeled O
HCV O
- O
LPs O
) O
showed O
that O
HCV O
- O
LPs O
binds O
to O
several O
human O
hepatic O
( O
primary O
hepatocytes O
, O
HepG2 O
, O
HuH7 O
, O
and O
NKNT O
- O
3 O
) O
and O
T O
- O
cell O
( O
Molt O
- O
4 O
) O
lines O
. O

Scatchard O
plot O
analysis O
suggests O
the O
presence O
of O
two O
binding O
sites O
for O
HCV O
- O
LPs O
with O
high O
( O
K O
- O
d O
similar O
to1 O
mug O
/ O
ml O
) O
and O
low O
( O
K O
- O
d O
similar O
to50 O
to O
60 O
mug O
/ O
ml O
) O
affinities O
of O
binding O
. O

While O
preincubation O
of O
HCV O
- O
LPs O
with O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
, O
low B
- I
density I
lipoprotein I
( I
LDL I
) I
, O
or O
high B
- I
density I
lipoprotein I
( I
HDL I
) I
blocked O
its O
binding O
to O
cells O
, O
preincubation O
of O
cells O
with O
VLDL O
, O
LDL O
, O
HDL O
, O
or O
anti O
- O
LDL O
- O
R O
antibody O
did O
not O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
is O
a O
positive O
- O
stranded O
RNA O
virus O
in O
the O
genus O
Hepatovirus O
in O
the O
family O
Picornaviridae O
. O

RNA O
editing O
at O
the O
amber O
/ O
W O
site O
plays O
a O
central O
role O
in O
the O
replication O
scheme O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
allowing O
the O
virus O
to O
produce O
two O
functionally O
distinct O
forms O
of O
the O
sole O
viral O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
from O
the O
same O
open O
, O
reading O
frame O
. O

Editing O
is O
carried O
out O
by O
a O
cellular O
activity O
known O
as O
ADAR O
( O
adenosine O
deaminase O
) O
, O
which O
acts O
on O
RNA O
substrates O
that O
are O
at O
least O
partially O
double O
stranded O
. O

Unlike O
all O
other O
picornaviruses O
, O
the O
primary O
cleavage O
of O
the O
hepatitis B
A I
virus I
( I
HAV I
) I
polyprotein O
occurs O
at O
the O
2A O
/ O
2B O
junction O
and O
is O
carried O
out O
by O
the O
only O
proteinase O
encoded O
by O
the O
virus O
, O
3C B
( I
pro I
) I
. O

The O
resulting O
P1 O
- O
2A O
capsid O
protein O
precursor O
is O
subsequently O
cleaved O
by O
3C B
( I
pro I
) I
to O
generate O
VP0 O
, O
VP3 O
, O
and O
VP1 O
- O
2A O
, O
which O
associate O
as O
pentamers O
. O

C O
- O
terminal O
deletions O
in O
2A O
had O
no O
effect O
on O
RNA O
replication O
kinetics O
under O
one O
- O
step O
growth O
conditions O
, O
nor O
did O
they O
have O
an O
effect O
on O
capsid O
protein O
synthesis O
and O
3C B
( I
pro I
) I
- O
mediated O
processing O
. O

When O
the O
capsid O
proteins O
were O
expressed O
from O
recombinant O
vaccinia O
viruses O
, O
the O
N O
- O
terminal O
part O
of O
2A O
was O
required O
for O
efficient O
cleavage O
of O
the O
P1 O
- O
2A O
precursor O
by O
3C B
( I
pro I
) I
and O
assembly O
of O
structural O
precursors O
into O
pentamers O
. O

These O
data O
indicate O
that O
the O
N O
- O
terminal O
domain O
of O
2A O
must O
be O
present O
as O
a O
C O
- O
terminal O
extension O
of O
P1 O
for O
folding O
of O
the O
capsid O
protein O
precursor O
to O
allow O
efficient O
3C B
( I
pro I
) I
- O
mediated O
cleavages O
and O
to O
promote O
pentamer O
assembly O
, O
after O
which O
cleavage O
at O
the O
VP1 O
/ O
2A O
junction O
releases O
the O
mature O
VP1 O
protein O
, O
a O
process O
that O
appears O
to O
be O
necessary O
to O
produce O
highly O
infectious O
particles O
. O

The O
3 O
' O
- O
terminal O
ends O
of O
both O
the O
positive O
and O
negative O
strands O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
, O
the O
latter O
being O
the O
replicative O
intermediate O
, O
are O
most O
likely O
the O
initiation O
sites O
for O
replication O
by O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
, O
NS5B O
. O

The O
structural O
features O
of O
the O
very O
conserved O
3 O
' O
plus O
[ O
( O
+ O
) O
] O
strand O
untranslated O
region O
[ O
3 O
' O
( O
+ O
) O
UTR O
] O
are O
well O
established O
( O
K O
. O

However O
, O
little O
information O
is O
available O
concerning O
the O
3 O
' O
end O
of O
the O
minus O
[ O
( O
- O
) O
] O
strand O
RNA O
. O

In O
the O
present O
work O
, O
we O
used O
chemical O
and O
enzymatic O
probing O
to O
investigate O
the O
conformation O
of O
that O
region O
, O
which O
is O
complementary O
to O
the O
5 O
' O
( O
+ O
) O
UTR O
and O
the O
first O
74 O
nucleotides O
of O
the O
HCV O
polyprotein O
coding O
sequence O
. O

In O
our O
model O
, O
the O
last O
220 O
nucleotides O
, O
where O
initiation O
of O
the O
( O
+ O
) O
strand O
RNA O
synthesis O
presumably O
takes O
place O
, O
fold O
into O
five O
stable O
stem O
- O
loops O
, O
forming O
domain O
I O
. O

Domain O
I O
is O
linked O
to O
an O
overall O
less O
stable O
structure O
, O
named O
domain O
11 O
, O
containing O
the O
sequences O
complementary O
to O
the O
pseudoknot O
of O
the O
internal O
ribosomal O
entry O
site O
in O
the O
5 O
' O
( O
+ O
) O
UTR O
. O

Our O
results O
show O
that O
, O
even O
though O
the O
( O
- O
) O
strand O
3 O
' O
- O
terminal O
region O
has O
the O
antisense O
sequence O
of O
the O
5 O
' O
( O
+ O
) O
UTR O
, O
it O
does O
not O
fold O
into O
its O
mirror O
image O
. O

Treatment O
of O
chronic O
hepatitis O
C O
is O
based O
on O
the O
use O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
. O

Recently O
, O
indirect O
evidence O
based O
on O
mathematical O
modeling O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
dynamics O
during O
human O
IFN O
- O
alpha O
therapy O
suggested O
that O
the O
major O
initial O
effect O
of O
IFN O
- O
alpha O
is O
to O
block O
HCV O
virion O
production O
or O
release O
. O

Here O
, O
we O
used O
primary O
cultures O
of O
healthy O
, O
uninfected O
human O
hepatocytes O
to O
show O
that O
: O
( O
i O
) O
healthy O
human O
hepatocytes O
can O
be O
infected O
in O
vitro O
and O
support O
HCV O
genome O
replication O
, O
( O
ii O
) O
hepatocyte O
treatment O
with O
IFN O
- O
alpha O
results O
in O
expression O
of O
IFN O
- O
alpha O
- O
induced O
genes O
, O
and O
( O
iii O
) O
IFN O
- O
alpha O
inhibits O
HCV O
replication O
in O
infected O
human O
hepatocytes O
. O

To O
define O
the O
role O
of O
Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
infection O
, O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
mRNA O
levels O
and O
mRNA O
levels O
of O
Mx O
, O
an O
antiviral O
effector O
molecule O
, O
were O
determined O
in O
lymphoid O
tissues O
of O
rhesus O
macaques O
infected O
with O
pathogenic O
SIV O
. O

Responses O
in O
three O
chimpanzees O
were O
compared O
following O
challenge O
with O
a O
clonal O
hepatitis B
C I
virus I
( I
HCV I
) I
contained O
in O
plasma O
from O
an O
animal O
that O
had O
received O
infectious O
RNA O
transcripts O
. O

Two O
of O
the O
chimpanzees O
( O
Ch1552 O
and O
ChX0186 O
) O
had O
recovered O
from O
a O
previous O
infection O
with O
HCV O
, O
while O
the O
third O
( O
Ch1605 O
) O
was O
a O
naive O
animal O
. O

) O
, O
reaching O
a O
peak O
of O
10 O
( O
6 O
) O
copies O
/ O
ml O
at O
week O
9 O
p O
. O

, O
and O
alanine B
aminotransferase I
( I
ALT I
) I
elevations O
and O
seroconversion O
to O
HCV O
antibodies O
at O
week O
10 O
p O
. O

In O
contrast O
, O
both O
ChI552 O
and O
ChX0186 O
exhibited O
much O
shorter O
periods O
of O
viremia O
( O
4 O
weeks O
) O
, O
low O
serum O
RNA O
levels O
( O
peak O
, O
10 O
( O
3 O
) O
copies O
/ O
ml O
) O
, O
and O
minimal O
ALT O
elevations O
. O

A O
comparison O
of O
intrahepatic O
cytokine O
levels O
in O
ChI552 O
and O
Ch1605 O
showed O
greater O
and O
earlier O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor O
necrosis O
factor O
alpha O
responses O
in O
the O
previously O
infected O
animal O
, O
responses O
that O
were O
30 O
- O
fold O
greater O
than O
baseline O
responses O
at O
week O
4 O
p O
. O

These O
data O
indicate O
( O
i O
) O
that O
clonal O
HCV O
generated O
from O
an O
infectious O
RNA O
transcript O
will O
lead O
to O
a O
typical O
HCV O
infection O
in O
naive O
chimpanzees O
, O
( O
ii O
) O
that O
there O
are O
memory O
immune O
responses O
in O
recovered O
chimpanzees O
that O
control O
HCV O
infection O
upon O
rechallenge O
, O
and O
( O
iii O
) O
that O
these O
responses O
seem O
to O
be O
T O
- O
cell O
mediated O
, O
as O
none O
of O
the O
animals O
had O
detectable O
antibody O
against O
the O
HCV O
envelope O
glycoproteins O
. O

We O
generated O
recombinant O
vesicular B
stomatitis I
viruses I
( I
VSV I
) I
expressing O
genes O
encoding O
hybrid O
proteins O
consisting O
of O
the O
extracellular O
domains O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
fused O
at O
different O
positions O
to O
the O
transmembrane O
and O
cytoplasmic O
domains O
of O
the O
VSV O
G O
glycoprotein O
( O
E1G O
and O
E2G O
) O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
encoded O
NS5B O
protein O
is O
an O
RNA O
- O
dependent O
RNA O
polymerase O
which O
plays O
a O
substantial O
role O
in O
viral O
replication O
. O

Also O
, O
we O
attempted O
to O
determine O
the O
initiation O
site O
( O
s O
) O
of O
de O
novo O
synthesis O
by O
NS5B O
on O
X O
RNA O
, O
which O
contains O
the O
last O
98 O
nucleotides O
of O
HCV O
positive O
- O
strand O
RNA O
. O

The O
initiation O
site O
( O
s O
) O
on O
X O
RNA O
was O
localized O
in O
the O
pyrimidine O
- O
rich O
region O
of O
stem O
I O
. O

De O
novo O
RNA O
synthesis O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
5B I
( I
NS5B I
) I
RNA O
- O
dependent O
RNA O
polymerase O
has O
been O
investigated O
using O
short O
RNA O
templates O
. O

The O
genome O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
plus O
- O
strand O
RNA O
molecule O
that O
carries O
a O
single O
long O
open O
reading O
frame O
. O

It O
is O
flanked O
at O
either O
end O
by O
highly O
conserved O
nontranslated B
regions I
( I
NTRs I
) I
that O
mediate O
crucial O
steps O
in O
the O
viral O
life O
cycle O
. O

The O
3 O
' O
NTR O
of O
HCV O
has O
a O
tripartite O
structure O
composed O
of O
an O
about O
40 O
- O
nucleotide O
variable O
region O
, O
a O
poly O
( O
U O
/ O
UC O
) O
tract O
that O
has O
a O
heterogeneous O
length O
, O
and O
a O
highly O
conserved O
98 O
- O
nucleotide O
3 O
' O
- O
terminal O
sequence O
designated O
the O
X O
tail O
or O
3 O
' O
X O
. O

Only O
replicons O
in O
which O
the O
poly O
( O
U O
/ O
UC O
) O
tract O
was O
replaced O
by O
a O
homouridine O
stretch O
of O
at O
least O
26 O
nucleotides O
were O
able O
to O
replicate O
, O
whereas O
RNAs O
with O
homopolymeric O
guanine O
, O
adenine O
, O
or O
cytosine O
sequences O
were O
inactive O
. O

Analyses O
of O
mitogen B
- I
activated I
protein I
kinases I
( I
MAPKs I
) I
in O
a O
mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
infected O
macrophage O
- O
derived O
J774 O
. O

1 O
cell O
line O
showed O
activation O
of O
two O
MAPKs O
, O
p38 O
MAPK O
and O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
, O
but O
not O
of O
extracellular B
signal I
- I
regulated I
kinase I
( I
ERK I
) I
. O

Experiments O
with O
a O
specific O
inhibitor O
of O
p38 O
MAPK O
, O
SB O
203580 O
, O
demonstrated O
that O
MHV O
- O
induced O
p38 O
MAPK O
activation O
resulted O
in O
the O
accumulation O
of O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
mRNAs O
and O
an O
increase O
in O
the O
production O
of O
IL O
- O
6 O
, O
regardless O
of O
MHV O
- O
induced O
general O
host O
protein O
synthesis O
inhibition O
. O

Interestingly O
, O
there O
was O
a O
transient O
increase O
in O
the O
amount O
of O
phosphorylation O
of O
the O
translation B
initiation I
factor I
4E I
( I
eIF4E I
) I
in O
infected O
cells O
, O
and O
this O
eIF4E O
phosphorylation O
was O
p38 O
MAPK O
dependent O
; O
it O
is O
known O
that O
phosphorylated O
eIF4E O
enhances O
translation O
rates O
of O
cap O
- O
containing O
mRNAs O
. O

To O
identify O
active O
- O
site O
amino O
acid O
residues O
in O
this O
protease O
, O
37 O
charged O
amino O
acid O
residues O
and O
a O
putative O
nucleophile O
, O
Cys139 O
, O
within O
the O
GDCG O
sequence O
were O
individually O
replaced O
with O
Ala O
in O
the O
3BC O
precursor O
, O
followed O
by O
expression O
in O
Escherichia O
coli O
, O
where O
the O
active O
3C O
- O
like O
protease O
would O
cleave O
3BC O
into O
3B O
( O
VPg O
) O
and O
3C O
( O
protease O
) O
. O

Among O
38 O
Ala O
mutants O
, O
7 O
mutants O
( O
R8A O
, O
H30A O
, O
K88A O
, O
R89A O
, O
D138A O
, O
C139A O
, O
and O
H157A O
) O
completely O
or O
nearly O
completely O
lost O
the O
proteolytic O
activity O
. O

Although O
Arg8 O
was O
also O
not O
replaceable O
for O
the O
3B O
/ O
3C O
cleavage O
and O
the O
3C O
/ O
3D O
cleavage O
, O
the O
N O
- O
terminal O
truncated O
mutant O
devoid O
of O
Arg8 O
significantly O
cleaved O
3CD O
into O
3C O
and O
3D O
( O
polymerase O
) O
, O
indicating O
that O
Arg8 O
itself O
was O
not O
directly O
involved O
in O
the O
proteolytic O
cleavage O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
is O
thought O
to O
play O
a O
critical O
role O
in O
HCV O
infection O
. O

In O
order O
to O
determine O
the O
actual O
breadth O
and O
magnitude O
of O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
in O
the O
context O
of O
diverse O
HLA O
class O
I O
alleles O
, O
we O
performed O
a O
comprehensive O
analysis O
of O
responses O
to O
all O
expressed O
HCV O
proteins O
. O

By O
using O
a O
panel O
of O
301 O
overlapping O
peptides O
, O
we O
analyzed O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
a O
cohort O
of O
14 O
anti O
- O
HCV O
- O
positive O
, O
HLA O
A2 O
- O
positive O
individuals O
in O
an O
enzyme O
- O
linked O
immunospot O
assay O
. O

These O
results O
indicate O
that O
circulating O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
can O
be O
detected O
in O
PBMC O
in O
the O
majority O
of O
infected O
persons O
and O
that O
these O
responses O
are O
heterogeneous O
with O
no O
immunodominant O
epitopes O
consistently O
recognized O
. O

Since O
responses O
to O
epitopes O
restricted O
by O
single O
HLA O
alleles O
such O
as O
HLA O
A2 O
do O
not O
predict O
the O
overall O
response O
in O
an O
individual O
, O
more O
comprehensive O
approaches O
, O
as O
shown O
here O
, O
should O
facilitate O
definition O
of O
the O
role O
of O
the O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
in O
HCV O
infection O
. O

To O
analyze O
the O
pathogenetic O
mechanism O
of O
hematopoietic O
dysregulation O
associated O
with O
hepatitis B
A I
virus I
( I
HAV I
) I
infections O
, O
we O
studied O
the O
influence O
of O
HAV O
on O
monocyte O
( O
MO O
) O
- O
to O
- O
macrophage O
( O
MAC O
) O
maturation O
in O
vitro O
. O

Exposure O
of O
peripheral O
blood O
- O
derived O
mononuclear O
cells O
( O
MNC O
) O
to O
HAV O
led O
to O
diminished O
adherence O
of O
MO O
to O
plastic O
. O

We O
also O
determined O
the O
influence O
of O
HAV O
on O
the O
MO O
/ O
MAC O
population O
in O
human B
long I
- I
term I
bone I
marrow I
cultures I
( I
LTBMCs I
) I
. O

The O
coronavirus O
membrane B
( I
M I
) I
protein O
is O
the O
most O
abundant O
virion O
protein O
and O
the O
key O
component O
in O
viral O
assembly O
and O
morphogenesis O
. O

The O
M O
protein O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
an O
integral O
membrane O
protein O
with O
a O
short O
ectodomain O
, O
three O
transmembrane O
segments O
, O
and O
a O
large O
carboxy O
- O
terminal O
endodomain O
facing O
the O
interior O
of O
the O
viral O
envelope O
. O

This O
mutant O
was O
isolated O
by O
means O
of O
targeted O
RNA O
recombination O
with O
a O
powerful O
host O
range O
- O
based O
selection O
allowed O
by O
the O
interspecies O
chimeric O
virus O
fMHV O
( O
MHV O
containing O
the O
ectodomain O
of O
the O
feline O
infectious O
peritonitis O
virus O
S O
protein O
) O
. O

Analysis O
of O
multiple O
second O
- O
site O
revertants O
of O
the O
MDelta2 O
mutant O
has O
revealed O
changes O
in O
regions O
of O
both O
the O
M O
protein O
and O
the O
nucleocapsid B
( I
N I
) I
protein O
that O
can O
compensate O
for O
the O
loss O
of O
the O
last O
two O
residues O
of O
the O
M O
protein O
. O

The O
importance O
of O
certain O
structural O
features O
of O
the O
5 O
' O
untranslated O
region O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
RNA O
for O
the O
function O
of O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
was O
investigated O
by O
mutagenesis O
followed O
by O
in O
vitro O
transcription O
and O
translation O
. O

Patients O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
have O
an O
impaired O
response O
against O
HCV O
antigens O
while O
keeping O
immune O
competence O
for O
other O
antigens O
. O

We O
hypothesized O
that O
expression O
of O
HCV O
proteins O
in O
infected O
dendritic B
cells I
( I
DC I
) I
might O
impair O
their O
antigen O
- O
presenting O
function O
, O
leading O
to O
a O
defective O
anti O
- O
HCV O
T O
- O
cell O
immunity O
. O

To O
test O
this O
hypothesis O
, O
DC O
from O
normal O
donors O
were O
transduced O
with O
an O
adenovirus O
coding O
for O
HCV O
core O
and O
El O
proteins O
and O
these O
cells O
( O
DC O
- O
CE1 O
) O
were O
used O
to O
stimulate O
T O
lymphocytes O
. O

The O
same O
pattern O
of O
incomplete O
lymphocyte O
activation O
was O
observed O
in O
CD4 O
( O
+ O
) O
T O
cells O
responding O
to O
HCV O
core O
in O
patients O
with O
chronic O
HCV O
infection O
. O

However O
, O
CD4 O
( O
+ O
) O
response O
to O
HCV O
core O
was O
normal O
in O
patients O
who O
cleared O
HCV O
after O
alpha O
interferon O
therapy O
. O

Moreover O
, O
a O
normal O
CD4 O
( O
+ O
) O
response O
to O
tetanus O
toxoid O
was O
found O
in O
both O
chronic O
HCV O
carriers O
and O
patients O
who O
had O
eliminated O
the O
infection O
. O

Coronavirus O
nucleoproteins B
( I
N I
proteins I
) I
localize O
to O
the O
cytoplasm O
and O
the O
nucleolus O
, O
a O
subnuclear O
structure O
, O
in O
both O
virus O
- O
infected O
primary O
cells O
and O
in O
cells O
transfected O
with O
plasmids O
that O
express O
N O
protein O
. O

We O
have O
found O
that O
fibrillarin O
is O
reorganized O
in O
primary O
cells O
infected O
with O
the O
avian O
coronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
and O
in O
continuous O
cell O
lines O
that O
express O
either O
IBV O
or O
mouse O
hepatitis O
virus O
N O
protein O
. O

The O
nucleocapsid B
( I
N I
) I
protein O
of O
hantaviruses O
encapsidates O
both O
viral O
genomic O
and O
antigenomic O
RNAs O
, O
although O
only O
the O
genomic O
viral B
RNA I
( I
vRNA I
) I
is O
packaged O
into O
virions O
. O

To O
define O
the O
domain O
within O
the O
Hantaan B
virus I
( I
HTNV I
) I
N O
protein O
that O
mediates O
these O
interactions O
, O
14 O
N O
- O
and O
C O
- O
terminal O
deletion O
constructs O
were O
cloned O
into O
a O
bacterial O
expression O
vector O
, O
expressed O
, O
and O
purified O
to O
homogeneity O
. O

These O
studies O
mapped O
a O
minimal O
region O
within O
the O
HTNV O
N O
protein O
( O
amino O
acids O
175 O
to O
217 O
) O
that O
bound O
vRNA O
. O

Two O
peptides O
corresponding O
to O
amino O
acids O
175 O
to O
196 O
( O
N1 O
) O
and O
197 O
to O
218 O
( O
N2 O
) O
were O
synthesized O
. O

We O
report O
here O
the O
results O
of O
a O
systematic O
high O
- O
resolution O
X O
- O
ray O
crystallographic O
analysis O
of O
complexes O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
polymerase O
with O
ribonucleoside B
triphosphates I
( I
rNTPs I
) I
and O
divalent O
metal O
ions O
. O

Replication O
of O
cytomegalovirus B
( I
CMV I
) I
is O
largely O
controlled O
by O
the O
cellular O
arm O
of O
the O
immune O
response O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
human O
pathogen O
that O
uses O
specific O
RNA O
editing O
activity O
of O
the O
host O
to O
produce O
two O
essential O
forms O
of O
the O
sole O
viral O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
. O

Editing O
at O
the O
amber O
/ O
W O
site O
of O
HDV O
antigenomic O
RNA O
leads O
to O
the O
production O
of O
the O
longer O
form O
( O
HDAg O
- O
L O
) O
, O
which O
is O
required O
for O
RNA O
packaging O
but O
which O
is O
a O
potent O
trans O
- O
dominant O
inhibitor O
of O
HDV O
RNA O
replication O
. O

Editing O
in O
infected O
cells O
is O
thought O
to O
be O
catalyzed O
by O
one O
or O
more O
of O
the O
cellular O
enzymes O
known O
as O
adenosine O
deaminases O
that O
act O
on O
RNA O
( O
ADARs O
) O
. O

The O
NS5B O
RNA O
- O
dependent O
RNA O
polymerase O
encoded O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
plays O
a O
key O
role O
in O
viral O
replication O
. O

The O
recently O
developed O
subgenomic O
hepatitis B
C I
virus I
( I
HCV I
) I
replicons O
were O
limited O
by O
the O
fact O
that O
the O
sequence O
encoding O
the O
structural O
proteins O
was O
missing O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
evolution O
is O
thought O
to O
proceed O
by O
mutations O
within O
the O
six O
genotypes O
. O

Two O
phylogenetically O
related O
HCV O
strains O
were O
found O
to O
belong O
to O
different O
subtypes O
, O
2k O
and O
1b O
, O
according O
to O
sequence O
analysis O
of O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
- O
core O
and O
the O
NS5B O
regions O
, O
respectively O
. O

By O
sequencing O
of O
the O
E2 O
- O
p7 O
- O
NS2 O
region O
, O
the O
crossover O
point O
was O
mapped O
within O
the O
NS2 O
region O
, O
probably O
between O
positions O
3175 O
and O
3176 O
( O
according O
to O
the O
numbering O
system O
for O
strain O
pj6CF O
) O
. O

Sequencing O
of O
the O
5 O
' O
UTR O
- O
core O
regions O
of O
four O
other O
HCV O
strains O
, O
phylogenetically O
related O
to O
the O
above O
- O
mentioned O
two O
strains O
( O
based O
on O
analysis O
within O
the O
NS5B O
region O
) O
, O
revealed O
that O
these O
four O
strains O
were O
also O
recombinants O
. O

Poliovirus O
translation O
is O
initiated O
at O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

Both O
human B
immunodeficiency I
virus I
type I
I I
( I
HIV I
- I
1 I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
lead O
to O
chronic O
infection O
in O
a O
high O
percentage O
of O
persons O
, O
and O
an O
expanding O
epidemic O
of O
HIV O
- O
1 O
- O
HCV O
coinfection O
has O
recently O
been O
identified O
. O

In O
this O
study O
we O
analyzed O
the O
breadth O
and O
magnitude O
of O
the O
CD8 O
( O
+ O
) O
- O
and O
CD4 O
( O
+ O
) O
- O
T O
- O
lymphocyte O
responses O
in O
22 O
individuals O
infected O
with O
both O
HIV O
- O
1 O
and O
HCV O
. O

A O
CD8 O
( O
+ O
) O
- O
T O
- O
lymphocyte O
response O
against O
HIV O
- O
1 O
was O
readily O
detected O
in O
all O
subjects O
over O
a O
broad O
range O
of O
viral O
loads O
. O

In O
marked O
contrast O
, O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
lymphocyte O
responses O
were O
rarely O
detected O
, O
despite O
viral O
loads O
in O
plasma O
that O
were O
on O
average O
1 O
, O
000 O
- O
fold O
higher O
. O

Dicistronic O
, O
selectable O
subgenomic O
replicons O
derived O
from O
the O
Con1 O
strain O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
capable O
of O
autonomous O
replication O
in O
cultured O
Huh7 O
Cells O
( O
Lohmann O
et O
aL O
, O
Science O
285 O
: O
110 O
- O
113 O
, O
1999 O
) O
. O

Here O
, O
we O
demonstrate O
that O
a O
subgenomic O
replicon O
( O
NNeo O
/ O
3 O
- O
5B O
) O
derived O
from O
an O
infectious O
molecular O
clone O
of O
a O
second O
genotype O
1b O
virus O
, O
HCV O
- O
N O
( O
Beard O
et O
aL O
, O
Hepatology O
30 O
: O
316 O
- O
324 O
, O
1999 O
) O
is O
also O
capable O
of O
efficient O
replication O
in O
Huh7 O
cells O
. O

However O
, O
the O
deletion O
of O
a O
unique O
4 O
- O
amino O
- O
acid O
insertion O
that O
is O
present O
within O
the O
interferon B
sensitivity I
- I
determining I
region I
( I
ISDR I
) I
of O
the O
NS5A O
protein O
in O
wild O
- O
type O
HCV O
- O
N O
drastically O
decreased O
the O
number O
of O
G418 O
- O
resistant O
colonies O
obtained O
following O
transfection O
of O
Huh7 O
cells O
. O

This O
effect O
could O
be O
reversed O
by O
inclusion O
of O
a O
previously O
described O
Con1 O
cell O
culture O
- O
adaptive O
mutation O
( O
S2005 O
- O
- O
> O
I O
) O
, O
confirming O
that O
this O
natural O
insertion O
has O
a O
controlling O
role O
in O
determining O
the O
replication O
capacity O
of O
wild O
- O
type O
HCV O
- O
N O
RNA O
in O
Huh7 O
cells O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
infection O
spreads O
from O
MHV O
- O
infected O
DBT O
cells O
, O
which O
express O
the O
MHV B
receptor I
CEACAM1 I
( I
MHVR I
) I
, O
to O
BHK O
cells O
, O
which O
are O
devoid O
of O
the O
receptor O
, O
by O
intercellular O
membrane O
fusion O
( O
MHVR O
- O
independent O
fusion O
) O
. O

This O
mode O
of O
infection O
is O
a O
property O
of O
wild B
- I
type I
( I
WT I
) I
JHMV O
cl O
- O
2 O
virus O
but O
is O
not O
seen O
in O
cultures O
infected O
with O
the O
mutant O
virus O
JHMV O
srr7 O
. O

In O
this O
study O
, O
we O
show O
that O
soluble O
MHVR O
( O
soMHVR O
) O
potentiates O
MHVR O
- O
independent O
fusion O
in O
JHMV O
srr7 O
- O
infected O
cultures O
. O

These O
effects O
were O
dependent O
on O
the O
concentration O
of O
soMHVR O
in O
the O
culture O
and O
were O
specifically O
blocked O
by O
the O
anti O
- O
MHVR O
monoclonal O
antibody O
CC1 O
Together O
with O
these O
observations O
, O
direct O
binding O
of O
soMHVR O
to O
the O
virus O
spike B
( I
S I
) I
glycoprotein O
as O
revealed O
by O
coimmunoprecipitation O
demonstrated O
that O
the O
effect O
is O
mediated O
by O
the O
binding O
of O
soMHVR O
to O
the O
S O
protein O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
is O
among O
the O
most O
conserved O
proteins O
in O
HCV O
and O
is O
known O
to O
induce O
sensitization O
of O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

Replication O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
in O
cultured O
cells O
is O
inefficient O
and O
difficult O
to O
study O
due O
to O
its O
protracted O
and O
generally O
noncytopathic O
cycle O
. O

Replication O
of O
this O
RNA O
in O
transfected O
Huh O
- O
7 O
cells O
( O
derived O
from O
a O
human O
hepatocellular O
carcinoma O
) O
led O
to O
increased O
expression O
of O
luciferase O
relative O
to O
that O
in O
cells O
transfected O
with O
similar O
RNA O
transcripts O
containing O
a O
lethal O
premature O
termination O
mutation O
in O
3D O
( O
pol O
) O
( O
RNA O
polymerase O
) O
. O

Amplification O
of O
the O
replicon O
RNA O
was O
profoundly O
enhanced O
by O
the O
inclusion O
of O
P2 O
( O
but O
not O
5 O
' O
noncoding O
sequence O
or O
P3 O
) O
segment O
mutations O
associated O
with O
adaptation O
of O
wild O
- O
type O
virus O
to O
growth O
in O
cell O
culture O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
chronic O
hepatitis O
in O
the O
world O
. O

Recent O
studies O
have O
shown O
that O
in O
insect O
cells O
, O
the O
HCV O
structural O
proteins O
assemble O
into O
HCV B
- I
like I
particles I
( I
HCV I
- I
LPs I
) I
with O
morphological O
, O
biophysical O
, O
and O
antigenic O
properties O
similar O
to O
those O
of O
putative O
virions O
isolated O
from O
HCV O
- O
infected O
humans O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
protein O
E2 O
has O
been O
shown O
to O
accumulate O
in O
the O
lumen O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
as O
a O
properly O
folded O
glycoprotein O
as O
well O
as O
large O
aggregates O
of O
misfolded O
proteins O
. O

In O
the O
present O
study O
, O
we O
have O
identified O
an O
additional O
unglycosylated O
species O
, O
with O
an O
apparent O
molecular O
mass O
of O
38 O
kDa O
( O
E2 O
- O
p38 O
) O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
treatment O
or O
overexpression O
of O
the O
double B
- I
stranded I
RNA I
- I
activated I
protein I
kinase I
( I
PKR I
) I
significantly O
increased O
the O
stability O
of O
E2 O
- O
p38 O
, O
consistent O
with O
a O
previous O
report O
( O
D O
. O

A O
genetically O
determined O
resistance O
or O
susceptibility O
to O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
may O
make O
an O
important O
contribution O
to O
the O
course O
of O
liver O
disease O
and O
may O
be O
linked O
to O
the O
human B
major I
histocompatibility I
complex I
( I
MHC I
) I
. O

The O
HLA O
class O
II O
allele O
, O
DRB1 O
* O
11 O
, O
was O
found O
at O
reduced O
frequency O
in O
49 O
patients O
with O
chronic O
hepatitis O
C O
( O
anti O
- O
HCV O
and O
HCV O
RNA O
positive O
) O
compared O
to O
that O
for O
controls O
( O
22 O
. O

DRB1 O
* O
11 O
was O
also O
found O
at O
reduced O
frequency O
in O
all O
HCV O
antibody O
- O
positive O
patients O
compared O
to O
controls O
( O
corrected O
P O
= O
not O
significant O
) O
. O

Type B
2 I
porcine I
circovirus I
( I
PCV2 I
) I
bas O
been O
incriminated O
as O
the O
cause O
of O
Postweaning B
multisystemic I
wasting I
syndrome I
( I
PMWS I
) I
, O
an O
emerging O
disease O
in O
pigs O
. O

The O
PCV2 O
molecular O
clone O
was O
generated O
by O
ligating O
two O
copies O
of O
the O
complete O
PCV2 O
genome O
in O
tandem O
into O
the O
pBluescript B
SK I
( I
pSK I
) I
vector O
and O
was O
shown O
to O
be O
infectious O
, O
in O
vitro O
when O
transfected O
into O
PK O
- O
15 O
cells O
. O

9 O
x O
10 O
( O
5 O
) O
50 O
% O
tissue O
culture O
infective O
doses O
of O
a O
homogeneous O
PCV2 O
live O
virus O
Stock O
derived O
from O
the O
molecular O
clone O
. O

Seroconversion O
to O
PCV2 O
- O
specific O
antibody O
was O
detected O
in O
the O
majority O
of O
pigs O
from O
the O
three O
inoculated O
groups O
at O
35 O
days B
postinoculation I
( I
dpi I
) I
. O

Patients O
with O
chronic O
hepatitis O
C O
are O
more O
likely O
to O
have O
significant O
changes O
in O
their O
physical O
and O
mental O
well O
- O
being O
than O
patients O
with O
liver O
disease O
of O
other O
etiology O
, O
and O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
occasionally O
implicated O
in O
diseases O
of O
the O
central O
nervous O
system O
. O

The O
influence O
of O
viral O
factors O
on O
the O
severity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
related O
liver O
disease O
Is O
controversial O
. O

In O
the O
particular O
setting O
of O
liver O
transplantation O
, O
and O
among O
strains O
with O
closely O
related O
phylogenetic O
backgrounds O
( O
genotype O
1 O
) O
, O
this O
study O
points O
to O
a O
correlation O
between O
the O
HCV O
genetic O
sequence O
and O
the O
variability O
of O
disease O
expression O
. O

The O
cellular O
immune O
response O
contributes O
to O
viral O
clearance O
as O
well O
as O
to O
liver O
injury O
in O
acute O
and O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

An O
immunodominant O
determinant O
frequently O
recognized O
by O
liver O
- O
infiltrating O
and O
circulating O
CD8 O
( O
+ O
) O
T O
cells O
of O
HCV O
- O
infected O
patients O
is O
the O
HCVNS3 O
- O
1073 O
peptide O
CVNGVCWTV O
. O

Using O
a O
sensitive O
in O
vitro O
technique O
with O
HCV O
peptides O
and O
multiple O
cytokines O
, O
we O
were O
able O
to O
expand O
cytotoxic O
T O
cells O
specific O
for O
this O
determinant O
not O
only O
from O
the O
blood O
of O
11 O
of O
20 O
HCV O
- O
infected O
patients O
( O
55 O
% O
) O
but O
also O
from O
the O
blood O
of O
9 O
of O
15 O
HCV O
- O
negative O
blood O
donors O
( O
60 O
% O
) O
, O
while O
a O
second O
HCV O
NS3 O
determinant O
was O
recognized O
only O
by O
HCV O
- O
infected O
patients O
and O
not O
by O
seronegative O
controls O
. O

The O
T O
- O
cell O
response O
of O
these O
healthy O
blood O
donors O
was O
mediated O
by O
memory O
T O
cells O
, O
which O
cross O
- O
reacted O
with O
a O
novel O
T O
- O
cell O
determinant O
of O
the O
A O
/ O
PR O
/ O
8 O
/ O
34 O
influenza O
A O
virus O
( O
IV O
) O
that O
is O
endogenously O
processed O
from O
the O
neuraminidase B
( I
NA I
) I
protein O
. O

Both O
the O
HCV O
NS3 O
and O
the O
IV O
NA O
peptide O
displayed O
a O
high O
degree O
of O
sequence O
homology O
, O
bound O
to O
the O
HLA O
- O
A2 O
molecule O
with O
high O
affinity O
, O
and O
were O
recognized O
by O
cytotoxic O
T O
lymphocytes O
with O
similar O
affinity O
( O
10 O
( O
- O
8 O
) O
M O
) O
. O

Splenocytes O
harvested O
from O
IV O
- O
infected O
mice O
at O
the O
peak O
of O
the O
primary O
response O
( O
day O
7 O
effector O
cells O
) O
or O
following O
complete O
recovery O
( O
day O
21 O
memory O
cells O
) O
recognized O
the O
HCV O
NS3 O
peptide O
, O
lysed O
peptide O
- O
pulsed O
target O
cells O
, O
and O
produced O
gamma O
interferon O
. O

Several O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
have O
been O
shown O
in O
vitro O
to O
interact O
with O
host O
cellular O
components O
that O
are O
involved O
in O
immune O
regulation O
. O

Both O
groups O
of O
mice O
mounted O
similar O
immunoglobulin B
G I
( I
IgG I
) I
, O
IgG2a O
, O
interleukin O
- O
2 O
, O
and O
tumor O
necrosis O
factor O
alpha O
responses O
against O
the O
virus O
. O

TT B
virus I
( I
TTV I
) I
is O
a O
recently O
identified O
widespread O
DNA O
virus O
of O
humans O
that O
produces O
persistent O
viremia O
in O
the O
absence O
of O
overt O
clinical O
manifestations O
. O

In O
an O
attempt O
to O
shed O
light O
on O
the O
dynamics O
of O
chronic O
infection O
, O
we O
measured O
the O
levels O
of O
TTV O
in O
the O
plasma O
of O
25 O
persistently O
infected O
patients O
during O
the O
first O
3 O
months O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
treatment O
for O
concomitant O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

8 O
X O
10 O
( O
10 O
) O
virions O
generated O
per O
day O
. O

In O
previous O
cross O
- O
sectional O
studies O
, O
we O
demonstrated O
that O
, O
in O
most O
patients O
with O
chronic O
hepatitis O
C O
, O
the O
composition O
and O
complexity O
of O
the O
circulating O
hepatitis B
C I
virus I
( I
HCV I
) I
population O
do O
not O
coincide O
with O
those O
of O
the O
virus O
replicating O
in O
the O
liver O
. O

In O
the O
subgroup O
of O
patients O
with O
similar O
complexities O
in O
both O
compartments O
, O
the O
ratio O
of O
quasispecies O
complexity O
in O
the O
liver O
to O
that O
in O
serum O
( O
liver O
/ O
serum O
complexity O
ratio O
) O
of O
paired O
samples O
correlated O
with O
disease O
stage O
. O

We O
sequenced O
359 O
clones O
of O
a O
genomic O
fragment O
encompassing O
the O
E2 O
( O
p7 O
) O
- O
NS2 O
junction O
, O
in O
two O
consecutive O
liver O
- O
serum O
sample O
pairs O
from O
the O
four O
patients O
and O
in O
four O
intermediate O
serum O
samples O
from O
one O
of O
the O
patients O
. O

mouse B
adenovirus I
type I
1 I
( I
MAV I
- I
1 I
) I
targets O
endothelial O
and O
monocyte O
/ O
macrophage O
cells O
throughout O
the O
mouse O
. O

We O
surveyed O
inbred O
mouse O
strains O
and O
found O
that O
for O
the O
majority O
tested O
the O
50 B
% I
lethal I
doses I
( I
LD I
( I
50 I
) I
s I
) I
were O
> O
10 O
( O
4 O
. O

Infected O
C3H O
/ O
HeJ O
( O
resistant O
) O
and O
SJL O
/ O
J O
( O
susceptible O
) O
mice O
showed O
only O
modest O
differences O
in O
histopathology O
. O

Antiviral O
immunoglobulin B
G I
( I
IgG I
) I
levels O
were O
measured O
in O
susceptible O
and O
resistant O
mice O
infected O
by O
an O
early O
region O
IA O
null O
mutant O
virus O
that O
is O
less O
virulent O
that O
wild O
- O
type O
virus O
. O

In O
case O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
plus O
- O
strand O
RNA O
virus O
of O
the O
family O
Flaviviridae O
, O
a O
341 O
- O
nucleotide O
- O
long O
nontranslated B
region I
( I
NTR I
) I
is O
located O
at O
the O
5 O
' O
end O
of O
the O
genome O
. O

This O
sequence O
contains O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
that O
is O
located O
downstream O
of O
an O
about O
40 O
- O
nucleotide O
- O
long O
sequence O
of O
unknown O
function O
. O

By O
generating O
a O
series O
of O
replicons O
with O
HCV O
- O
poliovirus B
( I
PV I
) I
chimeric O
5 O
' O
NTRs O
, O
we O
could O
show O
that O
the O
first O
125 O
nucleotides O
of O
the O
HCV O
genome O
are O
essential O
and O
sufficient O
for O
RNA O
replication O
. O

These O
data O
show O
that O
( O
i O
) O
sequences O
upstream O
of O
the O
HCV O
IRES O
are O
essential O
for O
RNA O
replication O
, O
( O
ii O
) O
the O
first O
125 O
nucleotides O
of O
the O
HCV O
5 O
' O
NTR O
are O
sufficient O
for O
RNA O
replication O
, O
but O
such O
replicon O
molecules O
are O
severely O
impaired O
for O
multiplication O
, O
and O
( O
iii O
) O
high O
- O
level O
HCV O
replication O
requires O
sequences O
located O
within O
the O
IRES O
. O

We O
investigated O
the O
role O
played O
by O
N O
- O
glycans O
in O
the O
immunogenicity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
E1 O
envelope O
glycoprotein O
, O
a O
naturally O
poor O
immunogen O
. O

Whereas O
some O
mutations O
had O
no O
or O
only O
minor O
effects O
on O
the O
antibody O
titers O
induced O
, O
mutation O
of O
the O
fourth O
glycosylation O
site O
( O
N4 O
) O
significantly O
enhanced O
the O
anti O
- O
E1 O
humoral O
response O
in O
terms O
of O
both O
seroconversion O
rates O
and O
antibody O
titers O
. O

Epitope O
mapping O
indicated O
that O
the O
E1 O
mutant O
antigens O
induced O
antibody O
directed O
at O
two O
major O
domains O
: O
one O
, O
located O
at O
amino B
acids I
( I
aa I
) I
313 O
to O
332 O
, O
which O
is O
known O
to O
be O
reactive O
with O
sera O
from O
HCV O
patients O
, O
and O
a O
second O
one O
, O
located O
in O
the O
N O
- O
terminal O
domain O
of O
E1 O
( O
aa O
192 O
to O
226 O
) O
. O

Previously O
, O
we O
characterized O
two O
host O
protein O
binding O
elements O
located O
within O
the O
3 O
' O
- O
terminal O
166 O
nucleotides O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genome O
and O
assessed O
their O
functions O
in O
defective B
- I
interfering I
( I
DI I
) I
RNA O
replication O
. O

The O
upstream O
side O
of O
this O
conserved O
stem O
- O
loop O
is O
contained O
within O
a O
host O
protein O
binding O
element O
( O
nucleotides O
166 O
to O
129 O
) O
. O

To O
study O
the O
effect O
of O
genetic O
immunization O
on O
transgenic O
expression O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
, O
we O
evaluated O
the O
immunological O
response O
of O
HCV O
transgenic O
mice O
to O
HCV O
expression O
plasmids O
. O

FVB O
/ O
n O
transgenic O
mice O
expressing O
HCV O
structural O
proteins O
( O
core O
, O
E1 O
, O
and O
E2 O
) O
and O
wild B
- I
type I
( I
WT I
) I
FVB O
/ O
n O
mice O
were O
immunized O
intramuscularly O
with O
plasmids O
expressing O
core O
( O
pHCVcore O
) O
or O
core O
/ O
E1 O
/ O
E2 O
( O
pHCVSt O
) O
. O

In O
WT O
mice O
immunized O
with O
pHCVSt O
, O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
activities O
were O
detected O
against O
E2 O
but O
not O
against O
core O
or O
E1 O
, O
whereas O
strong O
CTL O
activities O
against O
core O
could O
be O
detected O
in O
WT O
mice O
immunized O
with O
pHCVcore O
. O

1 O
molecules O
( O
AAD O
mice O
) O
. O

Our O
study O
suggests O
a O
hierarchy O
of O
CTL O
response O
against O
the O
HCV O
structural O
proteins O
( O
E2 O
> O
core O
> O
E1 O
) O
in O
vivo O
when O
the O
proteins O
are O
expressed O
as O
a O
polyprotein O
. O

In O
this O
report O
, O
we O
describe O
the O
assembly O
of O
a O
full O
- O
length O
cDNA O
from O
the O
positive O
- O
sense O
genomic O
RNA O
of O
the O
avian O
coronavirus O
, O
infectious B
bronchitis I
virus I
( I
IBV I
) I
, O
an O
important O
poultry O
pathogen O
. O

Frequent O
mutations O
in O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
main O
envelope O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
mechanism O
of O
persistence O
by O
escaping O
the O
host O
immune O
recognition O
. O

This O
study O
was O
aimed O
to O
prepare O
broadly O
cross O
- O
reacting O
, O
high O
- O
affinity O
, O
monoclonal B
antibodies I
( I
MAb I
) I
to O
the O
HVR1 O
C O
terminus O
of O
HCV O
with O
potential O
therapeutic O
neutralizing O
capacity O
. O

A O
conserved O
amino O
residue O
group O
of O
Glycine B
( I
G I
) I
at O
position O
23 O
and O
glutamic O
acid O
( O
Q O
) O
at O
position O
26 O
in O
HVR1 O
was O
confirmed O
as O
a O
key O
epitope O
against O
which O
two O
MAbs O
were O
selected O
and O
characterized O
. O

MAbs O
2P24 O
and O
15H4 O
were O
immunoglobulin O
G1 O
kappa O
chain O
[ O
IgG1 O
( O
kappa O
) O
] O
, O
cross O
- O
reacted O
with O
32 O
and O
30 O
of O
39 O
random O
C O
- O
terminal O
HVR1 O
peptides O
, O
respectively O
, O
and O
did O
not O
react O
with O
other O
HCV O
peptides O
. O

The O
affinity O
( O
K O
- O
d O
) O
of O
2P24 O
and O
15H4 O
( O
10 O
( O
- O
9 O
) O
or O
10 O
( O
- O
8 O
) O
M O
with O
two O
immunizing O
peptides O
and O
10 O
( O
- O
8 O
) O
M O
with O
two O
nonimmunizing O
HVR1 O
peptides O
) O
paralleled O
the O
reactivity O
obtained O
with O
peptide O
enzyme O
immunoassay O
. O

MAbs O
2P24 O
and O
15H4 O
captured O
25 O
of O
31 O
( O
81 O
% O
) O
HCV O
in O
unselected O
patients O
' O
plasmas O
. O

Replication O
of O
the O
genome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
requires O
RNA O
- O
directed O
RNA O
synthesis O
using O
a O
host O
polymerase O
( O
s O
) O
. O

Overall O
, O
the O
data O
support O
the O
interpretation O
that O
HDV O
transcription O
does O
not O
require O
host O
polymerase O
I O
or O
III O
( O
pol O
I O
or O
Ell O
) O
but O
at O
least O
primarily O
involves O
an O
enzyme O
resembling O
pol O
II O
. O

Perforin O
- O
mediated O
lysis O
of O
target O
cells O
is O
the O
major O
antiviral O
effector O
mechanism O
of O
CD8 O
( O
+ O
) O
T O
lymphocytes O
. O

We O
have O
analyzed O
the O
role O
of O
perforin O
in O
a O
mouse O
model O
for O
CD8 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
central B
nervous I
system I
( I
CNS I
) I
immunopathology O
induced O
by O
Borna O
disease O
virus O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
CD8 O
( O
+ O
) O
T O
cells O
mediate O
Borna O
disease O
independent O
of O
perforin O
. O

They O
further O
suggest O
that O
the O
pathogenic O
potential O
of O
CNS O
- O
infiltrating O
CD8 O
( O
+ O
) O
T O
cells O
does O
not O
primarily O
reside O
in O
their O
lytic O
activity O
but O
rather O
in O
other O
functions O
. O

HFE O
is O
a O
nonclassical O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecule O
that O
is O
mutated O
in O
the O
autosomal O
recessive O
iron O
overload O
disease O
hereditary O
hemochromatosis O
. O

There O
is O
evidence O
linking O
HFE O
with O
reduced O
iron O
uptake O
by O
the O
transferrin B
receptor I
( I
TfR I
) I
. O

Using O
a O
panel O
of O
HFE O
and O
TfR O
monoclonal O
antibodies O
to O
examine O
human B
HFE I
( I
hHFE I
) I
- O
expressing O
cell O
lines O
, O
we O
demonstrate O
the O
expression O
of O
stable O
and O
fully O
glycosylated O
TfR O
- O
free O
and O
TfR O
- O
associated O
hHFE O
/ O
beta O
2m O
complexes O
. O

We O
show O
that O
both O
the O
stability O
and O
assembly O
of O
hHFE O
complexes O
can O
be O
modified O
by O
the O
human B
cytomegalovirus I
( I
HCMV I
) I
viral O
protein O
US2 O
, O
known O
to O
interfere O
with O
the O
expression O
of O
classical O
class O
I O
MHC O
molecules O
. O

Chimeric O
poliovirus O
RNAs O
, O
possessing O
the O
5 B
' I
nontranslated I
region I
( I
NTR I
) I
of O
hepatitis O
C O
virus O
in O
place O
of O
the O
5 O
' O
NTR O
of O
poliovirus O
, O
were O
used O
to O
examine O
the O
role O
of O
the O
poliovirus O
5 O
' O
NTR O
in O
viral O
replication O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
proteins O
, O
E1 O
and O
E2 O
, O
form O
noncovalent O
heterodimers O
and O
are O
leading O
candidate O
antigens O
for O
a O
vaccine O
against O
HCV O
. O

Unfolded O
or O
partially O
folded O
E1 O
bound O
to O
the O
endoplasmic O
reticulum O
chaperones O
calnexin O
and O
( O
with O
lower O
efficiency O
) O
calreticulin O
, O
whereas O
no O
binding O
to O
BiP O
/ O
GRP78 O
or O
GRP94 O
could O
be O
detected O
. O

Murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
produces O
a O
genome O
- O
length O
mRNA O
, O
mRNA O
1 O
, O
and O
six O
or O
seven O
species O
of O
subgenomic O
mRNAs O
in O
infected O
cells O
. O

The O
subcellular O
localization O
of O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
and O
mouse B
hepatitis I
virus I
( I
MHV I
) I
( O
group O
I O
and O
group O
II O
coronaviruses O
, O
respectively O
) O
nucleoproteins B
( I
N I
proteins I
) I
were O
examined O
by O
confocal O
microscopy O
. O

These O
findings O
are O
consistent O
with O
our O
previous O
report O
for O
infectious O
bronchitis O
virus O
( O
group O
III O
coronavirus O
) O
( O
J O
. O

The O
most O
likely O
explanation O
for O
this O
is O
that O
the O
N O
protein O
induced O
a O
cell O
cycle O
delay O
or O
arrest O
, O
most O
likely O
in O
the O
G O
( O
2 O
) O
/ O
M O
phase O
. O

In O
a O
fraction O
of O
transfected O
cells O
expressing O
coronavirus O
N O
proteins O
, O
we O
observed O
multinucleate O
cells O
and O
dividing O
cells O
with O
nucleoli O
( O
which O
are O
only O
present O
during O
interphase O
) O
. O

Mounting O
evidence O
suggests O
that O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
- O
specific O
T O
helper O
cells O
contribute O
to O
effective O
antiviral O
control O
, O
but O
their O
functional O
characteristics O
and O
the O
precise O
epitopes O
targeted O
by O
this O
response O
remain O
to O
be O
defined O
. O

In O
this O
study O
, O
we O
generated O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
specific O
for O
Gag O
from O
HIV O
- O
1 O
- O
infected O
persons O
with O
vigorous O
Gag O
- O
specific O
responses O
detectable O
in O
peripheral O
blood O
mononuclear O
cells O
. O

Multiple O
peptides O
containing O
T O
helper O
epitopes O
were O
identified O
, O
including O
a O
minimal O
peptide O
, O
VHAGPIAG O
( O
amino O
acids O
218 O
to O
226 O
) O
, O
in O
the O
cyclophilin O
binding O
domain O
of O
Gag O
. O

Peptide O
recognition O
by O
all O
clones O
examined O
induced O
cell O
proliferation O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
secretion O
, O
and O
cytolytic O
activity O
. O

The O
question O
of O
whether O
translation O
initiation O
factor O
eIF4E O
and O
the O
complete O
eIF4G O
polypeptide O
are O
required O
for O
initiation O
dependent O
on O
the O
IRES B
( I
internal I
ribosome I
entry I
site I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
has O
been O
examined O
using O
in O
vitro O
translation O
in O
standard O
and O
eIF4G O
- O
depleted O
rabbit O
reticulocyte O
lysates O
. O

The O
HAV O
IRES O
was O
also O
inhibited O
by O
addition O
of O
m O
( O
7 O
) O
GpppG O
cap O
analogue O
, O
irrespective O
of O
whether O
the O
RNA O
tested O
was O
capped O
or O
not O
. O

This O
suggests O
two O
alternative O
models O
: O
( O
i O
) O
initiation O
requires O
a O
direct O
interaction O
between O
an O
internal O
site O
in O
the O
IRES O
and O
eIF4E O
/ O
4G O
, O
an O
interaction O
which O
involves O
the O
cap O
- O
binding O
pocket O
of O
eIF4E O
in O
addition O
to O
any O
direct O
eIF4G O
- O
RNA O
interactions O
; O
or O
( O
ii O
) O
it O
requires O
eIF4G O
in O
a O
particular O
conformation O
which O
can O
be O
attained O
only O
if O
eIF4E O
is O
bound O
to O
it O
, O
with O
the O
cap O
- O
binding O
pocket O
of O
the O
eIF4E O
unoccupied O
. O

The O
hepatitis B
A I
virus I
( I
HAV I
) I
internal I
ribosome I
entry I
segment I
( I
IRES I
) I
is O
unique O
among O
the O
picornavirus O
IRESs O
in O
that O
it O
is O
inactive O
in O
the O
presence O
of O
either O
the O
entero O
- O
and O
rhinovirus O
2A O
or O
aphthovirus O
Lb O
proteinases O
. O

Since O
these O
proteinases O
both O
cleave O
eukaryotic B
initiation I
factor I
4G I
( I
eIF4G I
) I
and O
HAV O
IRES O
activity O
could O
be O
rescued O
in O
vitro O
by O
addition O
of O
eIF4F O
to O
proteinase O
- O
treated O
extracts O
, O
it O
was O
concluded O
that O
the O
HAV O
IRES O
requires O
eIF4F O
containing O
intact O
eIF4G O
. O

Effectively O
, O
HAV O
IRES O
activity O
, O
but O
not O
that O
of O
the O
human O
rhinovirus O
IRES O
, O
was O
sensitive O
to O
the O
rotavirus O
nonstructural O
protein O
NSP3 O
[ O
which O
displaces O
poly O
( O
A O
) O
- O
binding O
protein O
from O
the O
eIF4F O
complex O
] O
, O
to O
recombinant O
eIF4E O
- O
binding O
protein O
( O
which O
prevents O
the O
association O
of O
the O
cap O
binding O
protein O
eIF4E O
with O
eIF4G O
) O
, O
and O
to O
cap O
analogue O
. O

The O
NS3 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
protease O
and O
RNA O
helicase O
activities O
, O
both O
of O
which O
are O
likely O
to O
be O
essential O
for O
HCV O
propagation O
. O

An O
arginine O
residue O
present O
in O
the O
arginine B
- I
glycine I
( I
RG I
) I
- O
rich O
region O
of O
many O
RNA O
- O
binding O
proteins O
is O
posttranslationally O
methylated O
by O
protein B
arginine I
methyltransferases I
( I
PRMTs I
) I
. O

Mutational O
analyses O
indicate O
that O
the O
Arg O
( O
1493 O
) O
in O
the O
QRR O
( O
1488 O
) O
GRTGR O
( O
1493 O
) O
G O
region O
of O
the O
NS3 O
RNA O
helicase O
is O
essential O
for O
NS3 O
protein O
methylation O
and O
that O
Arg O
( O
1488 O
) O
is O
likely O
methylated O
. O

The O
results O
suggest O
that O
an O
arginine O
residue O
( O
s O
) O
in O
QRXGRXGR O
motif O
IV O
conserved O
in O
the O
virus O
- O
encoded O
RNA O
helicases O
can O
be O
posttranslationally O
methylated O
by O
the O
PRMT1 O
. O

The O
CEACAM1 O
glycoproteins O
( O
formerly O
called O
biliary O
glycoproteins O
; O
BGP O
, O
C O
- O
CAM O
, O
CD66a O
, O
or O
MHVR O
) O
are O
members O
of O
the O
carcinoembryonic O
antigen O
family O
of O
cell O
adhesion O
molecules O
. O

In O
the O
mouse O
, O
splice O
variants O
of O
CEACAM1 O
have O
either O
two O
or O
four O
immunoglobulin B
( I
Ig I
) I
domains O
linked O
through O
a O
transmembrane O
domain O
to O
either O
a O
short O
or O
a O
long O
cytoplasmic O
tail O
. O

CEACAM1 O
isoforms O
serve O
as O
receptors O
for O
several O
viral O
and O
bacterial O
pathogens O
, O
including O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
and O
Haemophilus O
influenzae O
, O
Neisseria O
gonorrhoeae O
, O
and O
Neisseria O
meningitidis O
in O
humans O
. O

This O
resulted O
in O
the O
markedly O
reduced O
expression O
of O
the O
two O
CEACAM1a O
isoforms O
with O
four O
Ig O
domains O
, O
whereas O
the O
expression O
of O
the O
two O
isoforms O
with O
two O
Ig O
domains O
was O
doubled O
relative O
to O
that O
in O
wild O
- O
type O
BALB O
/ O
c O
( O
+ O
/ O
+ O
) O
mice O
. O

Homozygous O
( O
p O
/ O
p O
) O
Ceacam1a O
- O
targeted O
mice O
( O
Ceacam1a O
Delta O
4D O
) O
had O
no O
gross O
tissue O
abnormalities O
and O
were O
viable O
and O
fertile O
; O
however O
, O
they O
were O
more O
resistant O
to O
MHV O
A59 O
infection O
and O
death O
than O
normal O
( O
+ O
/ O
+ O
) O
mice O
. O

Following O
intranasal O
inoculation O
with O
MHV O
A59 O
, O
p O
/ O
p O
mice O
developed O
markedly O
fewer O
and O
smaller O
lesions O
in O
the O
liver O
than O
+ O
/ O
+ O
or O
heterozygous O
( O
+ O
/ O
p O
) O
mice O
. O

One O
of O
the O
characteristics O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
high O
incidence O
of O
persistent O
infection O
. O

34 O
g O
/ O
ml O
in O
CsCl O
, O
are O
heterogeneous O
in O
size O
( O
with O
predominance O
of O
particles O
38 O
to O
43 O
or O
54 O
to O
62 O
nm O
in O
diameter O
on O
electron O
microscopy O
) O
, O
and O
express O
on O
their O
surface O
epitopes O
located O
in O
amino O
acids O
24 O
to O
68 O
of O
the O
core O
protein O
. O

HCV O
core O
particles O
isolated O
from O
plasma O
were O
used O
to O
generate O
anti O
- O
core O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
can O
be O
cured O
only O
in O
a O
fraction O
of O
patients O
treated O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
ribavirin O
combination O
therapy O
. O

The O
mechanism O
of O
the O
IFN O
- O
alpha O
response O
against O
HCV O
is O
not O
understood O
, O
but O
evidence O
for O
a O
role O
for O
viral O
Nonstructural B
protein I
5A I
( I
NS5A I
) I
in O
IFN O
resistance O
has O
been O
provided O
. O

A O
host O
- O
mediated O
RNA O
- O
editing O
event O
allows O
hepatitis B
delta I
virus I
( I
HDV I
) I
to O
express O
two O
essential O
proteins O
, O
the O
small O
delta O
antigen O
( O
HDAg O
- O
S O
) O
and O
the O
large O
delta O
antigen O
( O
HDAg O
- O
L O
) O
, O
from O
a O
single O
open O
reading O
frame O
. O

One O
or O
several O
members O
of O
the O
ADAR O
( O
adenosine O
deaminases O
that O
act O
on O
RNA O
) O
family O
are O
thought O
to O
convert O
the O
adenosine O
to O
an O
inosine O
( O
I O
) O
within O
the O
HDAg O
- O
S O
amber O
codon O
in O
antigenomic O
RNA O
. O

As O
a O
consequence O
of O
replication O
, O
the O
UIG O
codon O
is O
converted O
to O
a O
UGG O
( O
tryptophan O
[ O
W O
] O
) O
codon O
in O
the O
resulting O
HDAg O
- O
L O
message O
. O

In O
cultured O
cells O
, O
we O
observed O
that O
both O
human O
ADAR1 O
( O
hADAR1 O
) O
and O
hADAR2 O
were O
capable O
of O
editing O
the O
amber O
/ O
W O
site O
with O
comparable O
efficiencies O
. O

Recombinant O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA I
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
was O
reported O
to O
possess O
terminal O
transferase O
( O
TNTase O
) O
activity O
, O
the O
ability O
to O
add O
nontemplated O
nucleotides O
to O
the O
3 O
' O
end O
of O
viral O
RNAs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
poses O
a O
worldwide O
health O
problem O
in O
that O
the O
majority O
of O
individuals O
exposed O
to O
HCV O
become O
chronically O
infected O
and O
are O
predisposed O
for O
developing O
significant O
liver O
disease O
, O
DNA O
microarray O
technology O
provides O
an O
opportunity O
to O
survey O
transcription O
modulation O
in O
the O
context O
of O
an O
infectious O
disease O
and O
is O
a O
particularly O
attractive O
approach O
in O
characterizing O
HCV O
- O
host O
interactions O
, O
since O
the O
mechanisms O
underlying O
viral O
persistence O
and O
disease O
progression O
are O
not O
understood O
and O
are O
difficult O
to O
study O
. O

Clearance O
of O
viremia O
in O
this O
animal O
occurred O
between O
weeks O
6 O
and O
8 O
, O
while O
clearance O
of O
residual O
infected O
hepatocytes O
did O
not O
occur O
until O
14 O
weeks O
postinfection O
, O
The O
most O
notable O
changes O
in O
gene O
expression O
occurred O
in O
numerous O
interferon O
response O
genes O
( O
including O
all O
three O
classical O
interferon O
antiviral O
pathways O
) O
that O
increased O
dramatically O
, O
some O
as O
early O
as O
day O
2 O
postinfection O
, O
The O
data O
suggest O
a O
biphasic O
mechanism O
of O
viral O
clearance O
dependent O
on O
both O
the O
innate O
and O
adaptive O
immune O
responses O
and O
provide O
insight O
into O
the O
response O
of O
the O
liver O
to O
a O
hepatotropic O
viral O
infection O
. O

Mechanisms O
leading O
to O
subgenomic B
mRNA I
( I
sgmRNA I
) I
synthesis O
in O
coronaviruses O
are O
poorly O
understood O
but O
are O
known O
to O
involve O
a O
heptameric O
signaling O
motif O
, O
originally O
called O
the O
intergenic O
sequence O
. O

The O
intergenic O
sequence O
is O
the O
presumed O
crossover O
region O
( O
fusion O
site O
) O
for O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
during O
discontinuous O
transcription O
, O
a O
process O
leading O
to O
sgmRNAs O
that O
are O
both O
5 O
' O
and O
3 O
' O
coterminal O
. O

In O
the O
bovine O
coronavirus O
, O
the O
major O
fusion O
site O
for O
synthesis O
of O
mRNA O
5 O
( O
GGUAGAC O
) O
does O
not O
conform O
to O
the O
canonical O
motif O
( O
UC O
[ O
U O
, O
C O
] O
AAAC O
) O
at O
three O
positions O
( O
underlined O
) O
, O
yet O
it O
lies O
just O
14 O
nucleotides O
downstream O
from O
such O
a O
sequence O
( O
UCCAAAC O
) O
. O

We O
learned O
that O
( O
i O
) O
mutations O
that O
were O
predicted O
to O
unfold O
the O
stem O
- O
loop O
in O
various O
ways O
did O
not O
switch O
RdRp O
crossover O
to O
the O
upstream O
canonical O
site O
, O
( O
ii O
) O
a O
totally O
nonconforming O
downstream O
motif O
resulted O
in O
no O
measurable O
transcription O
from O
either O
site O
, O
( O
iii O
) O
the O
canonical O
upstream O
site O
does O
not O
function O
ectopically O
to O
lend O
competence O
to O
the O
downstream O
noncanonical O
site O
, O
and O
( O
iv O
) O
altering O
flanking O
sequences O
downstream O
of O
the O
downstream O
noncanonical O
motif O
in O
ways O
that O
diminish O
sequence O
similarity O
with O
the O
virus O
genome O
5 O
' O
end O
caused O
a O
dramatic O
switch O
to O
the O
upstream O
canonical O
site O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infects O
an O
estimated O
170 O
million O
people O
worldwide O
, O
the O
majority O
of O
whom O
develop O
a O
chronic O
infection O
which O
can O
lead O
to O
severe O
liver O
disease O
, O
and O
for O
which O
no O
generally O
effective O
treatment O
yet O
exists O
. O

A O
promising O
target O
for O
treatment O
is O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
HCV O
, O
a O
highly O
conserved O
domain O
within O
a O
highly O
variable O
RNA O
. O

Mice O
infected O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
JHM O
develop O
primary O
demyelination O
. O

Immunodeficient O
MHV O
- O
infected O
RAG1 O
- O
/ O
- O
mice O
( O
mice O
defective O
in O
recombinase O
activating O
gene O
1 O
expression O
) O
do O
not O
develop O
demyelination O
unless O
they O
receive O
splenocytes O
from O
a O
mouse O
previously O
immunized O
against O
MHV O
( O
G O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
major O
cause O
of O
liver O
disease O
worldwide O
, O
is O
frequently O
resistant O
to O
the O
antiviral O
alpha O
interferon B
( I
IFN I
) I
. O

Alfalfa B
mosaic I
virus I
( I
AMV I
) I
RNAs O
1 O
and O
2 O
encode O
the O
replicase O
proteins O
P1 O
and O
P2 O
, O
respectively O
, O
whereas O
RNA O
3 O
encodes O
the O
movement O
protein O
and O
the O
coat B
protein I
( I
CP I
) I
. O

When O
RNAs O
1 O
and O
2 O
were O
transiently O
expressed O
from O
a O
T O
- O
DNA O
vector O
( O
R12 O
construct O
) O
by O
agroinfiltration O
of O
Nicotinana O
benthamiana O
, O
the O
infiltrated O
leaves O
accumulated O
minus O
- O
strand O
RNAs O
1 O
and O
2 O
and O
relatively O
small O
amounts O
of O
plus O
strand O
RNAs O
. O

In O
addition O
, O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
could O
be O
detected O
in O
extracts O
of O
the O
infiltrated O
leaves O
. O

After O
transient O
expression O
of O
RNAs O
1 O
and O
2 O
with O
the O
3 B
' I
- I
untranslated I
regions I
( I
UTRs I
) I
of O
both O
RNAs O
deleted O
( O
R1 O
Delta O
/ O
2 O
Delta O
construct O
) O
, O
no O
replication O
of O
RNAs O
1 O
and O
2 O
was O
observed O
, O
while O
the O
infiltrated O
leaves O
supported O
replication O
of O
RNA O
3 O
after O
inoculation O
of O
the O
leaves O
with O
RNA O
3 O
or O
expression O
of O
RNA O
3 O
from O
a O
T O
- O
DNA O
vector O
( O
R3 O
construct O
) O
. O

RdRp O
activity O
could O
be O
isolated O
from O
leaves O
infiltrated O
with O
constructs O
R1 O
Delta O
/ O
2 O
( O
3 O
' O
- O
UTR O
of O
RNA O
1 O
deleted O
) O
, O
R1 O
/ O
2 O
Delta O
( O
3 O
' O
- O
UTR O
of O
RNA O
2 O
deleted O
) O
, O
or O
R1 O
Delta O
/ O
2 O
Delta O
plus O
R3 O
. O

5 O
- O
kbp O
cDNA O
that O
represents O
the O
5 O
' O
and O
3 O
' O
ends O
of O
the O
human B
coronavirus I
229E I
( I
HCoV I
229E I
) I
genome O
, O
the O
HCoV O
229E O
replicase O
gene O
, O
and O
a O
single O
reporter O
gene O
( O
coding O
for O
green O
fluorescent O
protein O
[ O
GFP O
] O
) O
located O
downstream O
of O
a O
regulatory O
element O
for O
coronavirus O
mRNA O
transcription O
. O

The O
3 B
' I
- I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
regulates O
the O
replication O
of O
and O
transcription O
from O
the O
viral O
RNA O
. O

By O
immunoprecipitation O
of O
UV O
- O
cross O
- O
linked O
cellular O
proteins O
and O
in O
vitro O
binding O
of O
the O
recombinant O
protein O
, O
we O
have O
identified O
the O
major O
RNA O
- O
binding O
protein O
species O
as O
heterogeneous B
nuclear I
ribonucleoprotein I
A1 I
( I
hnRNP I
A1 I
) I
. O

These O
binding O
sites O
are O
complementary O
to O
the O
sites O
on O
the O
negative O
- O
strand O
RNA O
that O
bind O
another O
cellular O
protein O
, O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
. O

The O
NS5A O
nonstructural O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
to O
inhibit O
the O
cellular O
interferon B
( I
IFN I
) I
- O
induced O
protein B
kinase I
R I
( I
PKR I
) I
, O
PKR O
mediates O
the O
host O
IFN O
- O
induced O
antiviral O
response O
at O
least O
in O
part O
by O
inhibiting O
mRNA O
translation O
initiation O
through O
phosphorylation O
of O
the O
or O
subunit O
of O
eukaryotic B
initiation I
factor I
2 I
( I
eIF2 I
alpha I
) I
. O

We O
thus O
examined O
the O
effect O
of O
NS5A O
inhibition O
of O
PKR O
on O
mRNA O
translation O
within O
the O
context O
of O
virus O
infection O
by O
using O
a O
recombinant O
vaccinia B
virus I
( I
VV I
) I
- O
based O
assay O
. O

The O
VV O
E3L O
protein O
is O
a O
potent O
inhibitor O
of O
PKR O
, O
Accordingly O
, O
infection O
of O
IFN O
- O
pretreated O
HeLa O
S3 O
cells O
with O
an O
E3L O
- O
deficient O
VV O
( O
VV O
Delta O
E3L O
) O
resulted O
in O
increased O
phosphorylation O
levels O
of O
both O
PKR O
and O
eIF2 O
alpha O
, O
IFN O
- O
pretreated O
cells O
infected O
with O
VV O
in O
which O
the O
E3L O
locus O
was O
replaced O
with O
the O
NS5A O
gene O
( O
VVNS5A O
) O
displayed O
diminished O
phosphorylation O
of O
PKR O
and O
eIF2 O
alpha O
in O
a O
transient O
manner O
. O

Furthermore O
, O
these O
cells O
exhibited B
increased I
phosphorylation I
of I
the I
cap I
- I
binding I
initiation I
factor I
4E I
( I
eIF4E I
) I
, O
which O
is O
downstream O
of O
the O
p38 O
pathway O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
sets O
up O
persistent O
infection O
in O
the O
majority O
of O
those O
exposed O
. O

We O
investigated O
this O
by O
using O
major O
histocompatibility O
complex O
class O
I O
- O
peptide O
tetrameric O
complexes O
( O
tetramers O
) O
, O
which O
allow O
direct O
detection O
of O
specific O
CD8 O
( O
+ O
) O
T O
lymphocytes O
ex O
vivo O
, O
independently O
of O
function O
. O

Here O
we O
show O
that O
, O
early O
after O
infection O
, O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
lymphocytes O
detected O
with O
a O
panel O
of O
four O
such O
tetramers O
are O
abnormal O
in O
terms O
of O
their O
synthesis O
of O
antiviral O
cytokines O
and O
lytic O
activity O
. O

Overall O
, O
HCV O
- O
specific O
CD8 O
( O
+ O
) O
T O
lymphocytes O
show O
reduced O
synthesis O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
after O
stimulation O
with O
either O
mitogens O
or O
peptides O
, O
compared O
to O
responses O
to O
Epstein O
- O
Barr O
virus O
and O
/ O
or O
cytomegalovirus O
. O

This O
behavior O
of O
antiviral O
CD8 O
( O
+ O
) O
T O
lymphocytes O
induced O
after O
HCV O
infection O
may O
contribute O
to O
viral O
persistence O
through O
failure O
to O
effectively O
suppress O
viral O
replication O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
major O
cause O
of O
liver O
disease O
. O

The O
HCV O
polyprotein O
contains O
a O
hypervariable B
region I
( I
HVR1 I
) I
located O
at O
the O
N O
terminus O
of O
the O
second O
envelope O
glycoprotein O
E2 O
. O

We O
sequenced O
460 O
HVR1 O
clones O
isolated O
at O
various O
times O
from O
six O
HCV O
- O
infected O
patients O
receiving O
alpha O
interferon O
therapy O
( O
which O
exerts O
strong O
pressure O
towards O
quasispecies O
genetic O
evolution O
) O
and O
analyzed O
their O
amino O
acid O
sequences O
together O
with O
those O
of O
1 O
, O
382 O
nonredundant O
HVR1 O
sequences O
collected O
from O
the O
EMBL O
database O
. O

We O
found O
that O
( O
i O
) O
despite O
strong O
amino O
acid O
sequence O
variability O
related O
to O
strong O
pressures O
towards O
change O
, O
the O
chemicophysical O
properties O
and O
conformation O
of O
HVR1 O
were O
highly O
conserved O
, O
and O
( O
ii O
) O
HVR1 O
is O
a O
globally O
basic O
stretch O
, O
with O
the O
basic O
residues O
located O
at O
specific O
sequence O
positions O
. O

This O
conservation O
of O
positively O
charged O
residues O
indicates O
that O
HVR1 O
is O
involved O
in O
interactions O
with O
negatively O
charged O
molecules O
such O
as O
lipids O
, O
proteins O
, O
or O
glycosaminoglycans B
( I
GAGs I
) I
. O

An O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
mediates O
translation O
initiation O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
RNA O
, O
Studies O
have O
suggested O
that O
a O
portion O
of O
the O
N O
- O
pro O
open O
. O

reading O
frame O
( O
ORF O
) O
is O
required O
, O
although O
its O
ex O
- O
act O
function O
has O
not O
been O
defined O
. O

Here O
ne O
show O
that O
a O
subgenomic B
( I
sg I
) I
BVDV O
RNA O
in O
which O
the O
NS3 O
ORF O
is O
preceded O
only O
bu O
the O
5 O
' O
nontranslated O
region O
did O
not O
replicate O
to O
detectable O
levels O
following O
transfection O
. O

Five O
sg O
clones O
derived O
from O
the O
passaged O
virus O
contained O
an O
identical O
, O
silent O
substitution O
near O
the O
beginning O
of O
the O
NS3 O
coding O
sequence O
( O
G400U O
) O
, O
as O
well O
as O
additional O
mutations O
. O

Four O
of O
the O
reconstructed O
mutant O
RNAs O
replicated O
in O
transfected O
cells O
, O
and O
in O
vitro O
translation O
shelved O
increased O
levels O
of O
NS3 O
for O
the O
mutant O
RNAs O
compared O
to O
that O
of O
wild B
- I
type I
( I
WT I
) I
MetNS3 O
. O

7 O
and O
ad3 O
, O
10 O
, O
but O
not O
fft O
MetNS3 O
, O
formed O
toeprints O
downstream O
of O
the O
initiator O
AUG O
codon O
in O
an O
assay O
for O
detecting O
the O
binding O
of O
40S O
ribosomal O
subunits O
and O
43S O
ribosomal O
complexes O
to O
the O
IRES O
, O
These O
results O
suggest O
that O
a O
lack O
of O
stable O
RNA O
secondary O
structure O
( O
s O
) O
, O
rather O
than O
a O
specific O
RNA O
sequence O
, O
immediately O
downstream O
of O
the O
initiator O
AUG O
is O
important O
for O
optimal O
translation O
initiation O
of O
pestivirus O
RNAs O
. O

Studies O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
cycle O
have O
been O
made O
possible O
with O
the O
development O
of O
subgenomic O
selectable O
RNAs O
that O
replicate O
autonomously O
in O
cultured O
cells O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
pestivirus O
of O
the O
Flaviviridae O
family O
, O
is O
an O
economically O
important O
cattle O
pathogen O
with O
a O
worldwide O
distribution O
. O

Both O
noncytopathic B
( I
ncp I
) I
and O
cytopathic B
( I
cp I
) I
biotypes O
of O
BVDV O
can O
be O
isolated O
from O
persistently O
infected O
cattle O
suffering O
from O
the O
lethal O
mucosal O
disease O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
ncp O
BVDV O
inhibits O
the O
induction O
of O
apoptosis O
and O
the O
expression O
of O
interferon O
alpha O
/ O
beta O
by O
poly O
( O
IC O
) O
, O
a O
synthetic O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
. O

Inhibition O
was O
observed O
only O
in O
cells O
which O
had O
been O
infected O
with O
ncp O
BVDV O
at O
least O
12 O
h O
prior O
to O
the O
addition O
of O
dsRNA O
, O
which O
indicates O
that O
expression O
of O
viral O
proteins O
is O
necessary O
for O
the O
ncp O
virus O
to O
inhibit O
the O
effects O
of O
poly O
( O
IC O
) O
, O
Additional O
experiments O
using O
transfected O
poly O
( O
IC O
) O
showed O
that O
ncp O
BVDV O
interfered O
with O
the O
intracellular O
action O
of O
dsRNA O
rather O
than O
with O
its O
uptake O
into O
the O
cells O
. O

When O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infections O
are O
complicated O
by O
acquisition O
of O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
, O
liver O
disease O
appears O
to O
accelerate O
and O
serum O
levels O
of O
HCV O
RNA O
may O
rise O
. O

We O
hypothesized O
that O
HIV O
might O
affect O
the O
HCV O
quasispecies O
by O
decreasing O
both O
complexity O
( O
if O
HIV O
- O
induced O
immunosuppression O
lessens O
pressure O
for O
selecting O
HCV O
substitutions O
) O
and O
the O
ratio O
of O
nonsynonymous O
( O
d O
( O
N O
) O
) O
to O
synonymous O
( O
d O
( O
S O
) O
) O
substitutions O
, O
because O
d O
( O
N O
) O
may O
be O
lower O
( O
if O
there O
is O
less O
selective O
pressure O
) O
. O

From O
each O
subject O
, O
four O
serum O
specimens O
were O
selected O
with O
reference O
to O
HIV O
seroconversion O
: O
( O
i O
) O
more O
than O
2 O
years O
prior O
, O
( O
ii O
) O
less O
than O
2 O
years O
prior O
, O
( O
iii O
) O
less O
than O
2 O
years O
after O
, O
and O
( O
iv O
) O
more O
than O
2 O
years O
after O
. O

The O
HCV O
quasispecies O
in O
these O
specimens O
was O
characterized O
by O
generating O
clones O
containing O
I O
kb O
of O
cDNA O
that O
spanned O
the O
E1 O
gene O
and O
the O
E2 O
hypervariable B
region I
1 I
( I
HVR1 I
) I
, O
followed O
by O
analysis O
of O
clonal O
frequencies O
( O
via O
electrophoretic O
migration O
) O
and O
nucleotide O
sequences O
. O

We O
examined O
1 O
, O
320 O
cDNA O
clones O
( O
33 O
per O
time O
point O
) O
and O
287 O
sequences O
( O
median O
of O
7 O
per O
time O
point O
) O
. O

We O
observed O
a O
trend O
toward O
lower O
d O
( O
N O
) O
/ O
d O
( O
S O
) O
after O
HIV O
seroconversion O
in O
7 O
of O
10 O
subjects O
and O
lower O
d O
( O
N O
) O
/ O
d O
( O
S O
) O
in O
those O
with O
rapid O
HIV O
disease O
progression O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
member O
of O
the O
Coronaviridae O
, O
contains O
a O
polyadenylated O
positive O
- O
sense O
single O
- O
stranded O
genomic O
RNA O
which O
is O
31 O
kb O
long O
. O

Internal B
ribosomal I
entry I
sites I
( I
IRESs I
) I
of O
certain O
plus O
- O
strand O
RNA O
viruses O
direct O
cap O
- O
independent O
initiation O
of O
protein O
synthesis O
both O
in O
vitro O
and O
in O
vivo O
, O
as O
can O
be O
shown O
with O
artificial O
dicistronic O
mRNAs O
or O
with O
chimeric O
viral O
genomes O
in O
which O
IRES O
elements O
were O
exchanged O
from O
one O
virus O
to O
another O
. O

Whereas O
IRESs O
of O
picornaviruses O
can O
be O
readily O
analyzed O
in O
the O
context O
of O
their O
cognate O
genome O
by O
genetics O
, O
the O
IRES O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
Hepacivirus O
belonging O
to O
Flaviviridae O
, O
cannot O
as O
yet O
be O
subjected O
to O
such O
analyses O
because O
of O
difficulties O
in O
propagating O
HCV O
in O
tissue O
culture O
or O
in O
experimental O
animals O
. O

This O
enigma O
has O
been O
overcome O
by O
constructing O
a O
poliovirus B
( I
PV I
) I
whose O
translation O
is O
controled O
by O
the O
HCV O
IRES O
. O

Within O
the O
PV O
/ O
HCV O
chimera O
, O
the O
HCV O
IRES O
has O
been O
subjected O
to O
systematic O
5 O
' O
deletion O
analyses O
to O
yield O
a O
virus O
( O
P O
/ O
H710 O
- O
d40 O
) O
whose O
replication O
kinetics O
match O
that O
of O
the O
parental O
poliovirus O
type O
1 O
( O
Mahoney O
) O
. O

We O
have O
analyzed O
three O
cases O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
infected O
recipients O
who O
received O
blood O
from O
HCV O
- O
infected O
donors O
. O

Little O
is O
known O
about O
the O
assembly O
pathway O
and O
structure O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
since O
insufficient O
quantities O
of O
purified O
virus O
are O
available O
for O
detailed O
biophysical O
and O
structural O
studies O
. O

Recombinant O
mouse O
hepatitis O
viruses O
( O
MHV O
) O
differing O
only O
in O
the O
spike O
gene O
, O
containing O
A59 O
, O
MHV O
- O
4 O
, O
and O
MHV O
- O
2 O
spike O
genes O
in O
the O
background O
of O
the O
A59 O
genome O
, O
were O
compared O
for O
their O
ability O
to O
replicate O
in O
the O
liver O
and O
induce O
hepatitis O
in O
weanling O
C57BL O
/ O
6 O
mice O
infected O
with O
500 O
PFU O
of O
each O
virus O
by O
intrahepatic O
injection O
. O

S O
( O
A59 O
) O
R13 O
, O
expressing O
the O
A59 O
spike O
gene O
, O
replicated O
to O
a O
somewhat O
lower O
titer O
and O
induced O
moderate O
to O
severe O
hepatitis O
with O
zonal O
necrosis O
, O
similar O
to O
MW O
- O
A59 O
. O

S O
( O
4 O
) O
R21 O
, O
expressing O
the O
MHV O
- O
4 O
spike O
gene O
, O
replicated O
to O
a O
minimal O
extent O
and O
induced O
few O
if O
any O
pathological O
changes O
, O
similar O
to O
MHV O
- O
4 O
. O

The O
prototype O
JHM O
strain O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
is O
an O
enveloped O
, O
RNA O
- O
containing O
, O
a O
coronavirus O
that O
has O
been O
selected O
in O
vivo O
for O
extreme O
neurovirulence O
, O
This O
virus O
encodes O
spike B
( I
S I
) I
glycoproteins O
that O
are O
extraordinarily O
effective O
mediators O
of O
intercellular O
membrane O
fusion O
, O
unique O
in O
their O
ability O
to O
initiate O
fusion O
even O
without O
prior O
interaction O
with O
the O
primary O
MHV O
receptor O
, O
a O
murine O
carcinoembryonic O
antigen O
- O
related O
cell O
adhesion O
molecule O
( O
CEACAM O
) O
. O

Among O
the O
collection O
of O
variants O
, O
mutations O
were O
identified O
in O
regions O
encoding O
both O
the O
receptor O
- O
binding O
( O
S1 O
) O
and O
fusion O
- O
inducing O
( O
S2 O
) O
subunits O
of O
the O
spike O
protein O
, O
Each O
mutation O
was O
separately O
introduced O
into O
cDNA O
encoding O
the O
prototype O
JHM O
spike O
, O
and O
the O
set O
of O
cDNAs O
was O
expressed O
using O
vaccinia O
virus O
vectors O
. O

To O
study O
the O
function O
of O
this O
binding O
activity O
, O
a O
series O
of O
single O
- O
point O
substitutions O
were O
introduced O
in O
this O
domain O
, O
and O
the O
mutants O
were O
tested O
for O
their O
ability O
to O
support O
simian B
virus I
40 I
( I
SV40 I
) I
replication O
and O
to O
bind O
to O
single O
- O
stranded O
DNA O
. O

Two O
replication O
- O
defective O
mutants O
( O
429DA O
and O
460EA O
) O
were O
grossly O
impaired O
in O
single O
- O
stranded O
DNA O
binding O
. O

To O
identify O
proteins O
that O
can O
bind O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
we O
screened O
human O
cDNA O
libraries O
using O
the O
Saccharomyces O
cerevisiae O
three O
- O
hybrid O
system O
, O
Screening O
with O
an O
RNA O
sequence O
derived O
from O
the O
3 O
' O
- O
terminal O
98 O
nucleotides O
( O
3 O
' O
X O
region O
) O
of O
an O
infectious O
clone O
of O
HCV O
( O
H77c O
) O
yielded O
clones O
of O
human O
ribosomal O
proteins O
L22 O
, O
L3 O
, O
S3 O
, O
and O
mL3 O
, O
a O
mitochondrial O
homologue O
of O
L3 O
. O

We O
have O
further O
characterized O
the O
interaction O
between O
3 O
' O
X O
and O
L22 O
, O
Since O
this O
protein O
is O
known O
to O
be O
associated O
with O
two O
small O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- O
encoded O
RNA O
species O
( O
EBERs O
) O
which O
are O
abundantly O
produced O
in O
cells O
latently O
infected O
with O
EBV O
. O

To O
confirm O
that O
L22 O
binds O
HCV O
3 O
' O
X O
we O
performed O
in O
vitro O
binding O
assays O
using O
recombinant O
L22 O
( O
expressed O
as O
a O
glutathione O
S O
- O
transferase O
[ O
GST O
] O
fusion O
protein O
) O
together O
with O
a O
3 O
' O
X O
riboprobe O
, O
The O
3 O
' O
X O
region O
binds O
to O
the O
GST O
- O
L22 O
fusion O
protein O
( O
but O
not O
to O
GST O
alone O
) O
, O
and O
this O
interaction O
is O
subject O
to O
competition O
with O
unlabeled O
3 O
' O
X O
RNA O
. O

To O
establish O
the O
functional O
role O
played O
by O
L22 O
in O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
mediated O
translation O
of O
HCV O
sequences O
we O
performed O
translational O
analysis O
in O
HuH O
- O
7 O
cells O
using O
monecistronic O
and O
bicistronic O
reporter O
constructs O
. O

We O
have O
previously O
demonstrated O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
NS5A O
protein O
promotes O
cell O
growth O
and O
transcriptionally O
regulates O
the O
p21 O
/ O
waf1 O
promoter O
, O
a O
downstream O
effector O
gene O
of O
p53 O
. O

We O
observed O
that O
transcriptional O
repression O
of O
the O
p21 O
/ O
waf1 O
gene O
by O
NS5A O
is O
p53 O
dependent O
by O
using O
p53 O
wild O
- O
type O
( O
+ O
/ O
+ O
) O
and O
null O
( O
- O
/ O
- O
) O
cells O
. O

Interestingly O
, O
p53 O
- O
mediated O
transcriptional O
activation O
from O
a O
synthetic O
promoter O
containing O
multiple O
p53 O
binding O
sites O
( O
PG13 O
- O
LUC O
) O
was O
abrogated O
following O
expression O
of O
HCV O
NS5A O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
differs O
from O
other O
members O
of O
the O
family O
Picornaviridae O
in O
that O
the O
cleavage O
of O
the O
polyprotein O
at O
the O
2A O
/ O
2B O
junction O
, O
commonly O
considered O
to O
be O
the O
primary O
polyprotein O
cleavage O
by O
analogy O
with O
other O
picornaviruses O
, O
is O
mediated O
by O
3C B
( I
pro I
) I
, O
the O
only O
proteinase O
encoded O
by O
the O
virus O
. O

However O
, O
infectious O
virus O
was O
recovered O
from O
recombinant O
HAV O
genomes O
containing O
exogenous O
protein O
- O
coding O
sequences O
inserted O
in O
- O
frame O
at O
the O
2A O
/ O
2B O
junction O
and O
flanked O
by O
consensus O
3C B
( I
pro I
) I
cleavage O
sites O
. O

Inserted O
sequences O
were O
deleted O
from O
replicating O
viruses O
, O
but O
this O
did O
not O
result O
from O
homologous O
recombination O
at O
the O
flanking O
3C B
( I
pro I
) I
cleavage O
sites O
, O
since O
the O
5 O
' O
and O
3 O
' O
segments O
of O
the O
inserted O
sequence O
were O
retained O
in O
the O
deletion O
mutants O
. O

As O
an O
initial O
approach O
to O
studying O
the O
molecular O
replication O
mechanisms O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
major O
causative O
agent O
of O
acute O
and O
chronic O
liver O
disease O
, O
we O
have O
recently O
developed O
selectable O
self O
- O
replicating O
RNAs O
. O

Here O
we O
show O
that O
this O
deletion O
is O
present O
in O
the O
earliest O
type O
O O
virus O
examined O
from O
the O
region O
( O
from O
1970 O
) O
, O
whereas O
substitutions O
surrounding O
the O
deletion O
accumulated O
over O
the O
last O
29 O
years O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
encoded O
protease O
/ O
helicase O
NS3 O
is O
likely O
to O
be O
involved O
in O
viral O
RNA O
replication O
. O

We O
have O
expressed O
and O
purified O
recombinant O
NS3 O
( O
protease O
and O
helicase O
domains O
) O
and O
Delta O
pNS3 O
( O
helicase O
domain O
only O
) O
and O
examined O
their O
abilities O
to O
interact O
with O
the O
3 O
' O
- O
terminal O
sequence O
of O
both O
positive O
and O
negative O
strands O
of O
HCV O
RNA O
. O

These O
regions O
of O
RNA O
were O
chosen O
because O
initiation O
of O
RNA O
synthesis O
is O
likely O
to O
occur O
at O
or O
near O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
. O

The O
results O
presented O
here O
demonstrate O
that O
NS3 O
( O
and O
Delta O
pNS3 O
) O
interacts O
efficiently O
and O
specifically O
with O
the O
3 O
' O
terminal O
sequences O
of O
both O
positive O
- O
and O
negative O
strand O
RNA O
but O
not O
with O
the O
corresponding O
complementary O
5 O
' O
- O
terminal O
RNA O
sequences O
. O

The O
interaction O
of O
NS3 O
with O
the O
S O
' O
- O
terminal O
negative O
strand O
[ O
called O
3 O
' O
( O
- O
) O
UTR127 O
] O
was O
specific O
in O
that O
only O
homologous O
land O
not O
heterologous O
) O
RNA O
competed O
efficiently O
in O
the O
binding O
reaction O
. O

A O
predicted O
stem O
- O
loop O
structure O
present O
at O
the O
3 O
' O
terminus O
( O
nucleotides O
5 O
to O
20 O
from O
the O
3 O
' O
end O
) O
of O
the O
negative O
- O
strand O
RNA O
appears O
to O
be O
important O
for O
NS3 O
binding O
to O
the O
negative O
- O
strand O
UTR O
. O

Deletion O
of O
the O
stem O
- O
loop O
structure O
almost O
totally O
impaired O
NS3 O
( O
and O
Delta O
pNS3 O
) O
binding O
. O

In O
contrast O
to O
the O
relatively O
stringent O
requirement O
for O
3 O
' O
( O
- O
) O
UTR O
binding O
, O
specific O
interaction O
of O
NS3 O
( O
or O
Delta O
pNS3 O
) O
with O
the O
3 O
' O
- O
terminal O
sequences O
of O
the O
positive O
- O
strand O
RNA O
[ O
3 O
' O
( O
+ O
) O
UTR O
] O
appears O
to O
require O
the O
entire O
3 O
' O
( O
+ O
) O
UTR O
of O
HCV O
. O

Deletion O
of O
either O
the O
98 O
- O
nucleotide O
3 O
' O
- O
terminal O
conserved O
region O
or O
the O
5 O
' O
half O
sequence O
containing O
the O
variable O
region O
and O
the O
poly O
( O
U O
) O
and O
/ O
or O
poly O
( O
UC O
) O
stretch O
significantly O
impaired O
RNA O
- O
protein O
interaction O
. O

The O
parts O
of O
the O
RNA O
genome O
of O
infectious B
bronchitis I
virus I
( I
IBV I
) I
required O
for O
replication O
and O
packaging O
of O
the O
RNA O
were O
investigated O
using O
deletion O
mutagenesis O
of O
a O
defective B
RNA I
( I
D I
- I
RNA I
) I
CD O
- O
61 O
( O
6 O
. O

A O
D O
- O
RNA O
, O
vith O
the O
first O
544 O
, O
but O
not O
as O
few O
as O
338 O
, O
nucleotides B
( I
nt I
) I
of O
the O
5 O
' O
terminus O
was O
replicated O
; O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
comprises O
528 O
nt O
. O

Mixing O
a O
mutant O
helicase O
( O
Y267S O
) O
with O
wild O
- O
type O
helicase O
did O
not O
dramatically O
affect O
helicase O
activity O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
infects O
African B
green I
monkey I
kidney I
( I
AGR I
IK I
) I
cells O
via O
the O
HAV O
cellular O
receptor O
- O
1 O
( O
havcr O
- O
1 O
) O
, O
a O
mucin O
- O
like O
type O
1 O
integral O
- O
membrane O
glycoprotein O
of O
unknown O
natural O
function O
. O

The O
ectodomain O
of O
havcr O
- O
1 O
contains O
an O
N O
- O
terminal O
immunoglobulin O
- O
like O
cysteine O
- O
rich O
region O
( O
D1 O
) O
, O
which O
binds O
protective O
monoclonal B
antibody I
( I
Mab I
) I
190 O
/ O
4 O
, O
followed O
by O
an O
O O
- O
glycosylated O
mucin O
- O
like O
threonine O
- O
serine O
- O
proline O
- O
rich O
region O
that O
extends O
D1 O
well O
above O
the O
cell O
surface O
. O

To O
study O
the O
interaction O
of O
HAV O
with O
havcr O
- O
1 O
, O
we O
constructed O
immunoadhesins O
fusing O
the O
hinge O
and O
Fc B
portion I
of I
human I
IgG1 I
to I
D1 I
( I
D1 I
- I
Fc I
) I
or O
the O
ectodomain O
of O
the O
poliovirus B
receptor I
( I
PVR I
- I
Fc I
) I
and O
expressed O
them O
in O
CHO O
cells O
. O

The O
mechanisms O
underlying O
the O
hepatotropism O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
and O
the O
relapsing O
courses O
of O
HAV O
infections O
are O
unknown O
. O

In O
this O
report O
, O
we O
show O
for O
a O
mouse O
hepatocyte O
model O
that O
HAV O
- O
specific O
immunoglobulin B
A I
( I
IgA I
) I
mediates O
infection O
of O
hepatocytes O
with O
HAV O
via O
the O
asialoglycoprotein O
receptor O
, O
which O
binds O
and O
internalizes O
IgA O
molecules O
. O

The O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
from O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
nonstructural B
protein I
5B I
( I
NS5B I
) I
, O
has O
recently O
been O
shown O
to O
direct O
de O
novo O
initiation O
using O
a O
number O
of O
complex O
RNA O
templates O
. O

NS5B O
was O
found O
to O
protect O
RNA O
fragments O
of O
8 O
to O
10 O
nucleotides B
( I
nt I
) I
from O
RNase O
digestion O
. O

Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
is O
a O
Novirhabdovirus O
and O
is O
the O
causative O
agent O
of O
a O
devastating O
acute O
, O
lethal O
disease O
in O
wild O
and O
farmed O
rainbow O
trout O
. O

A O
full O
- O
length O
cDNA O
of O
the O
IHNV O
antigenome O
( O
pIHNV O
- O
Pst O
) O
was O
assembled O
from O
subgenomic O
overlapping O
cDNA O
fragments O
and O
cloned O
in O
a O
transcription O
plasmid O
between O
the O
T7 O
RNA O
polymerase O
promoter O
and O
the O
autocatalytic O
hepatitis O
delta O
virus O
ribozyme O
. O

Recombinant B
IHNV I
( I
rIHNV I
) I
was O
recovered O
from O
fish O
cells O
at O
14 O
degreesC O
, O
following O
infection O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
the O
T7 O
RNA O
polymerase O
( O
vTF7 O
- O
3 O
) O
and O
cotransfection O
of O
pIHNV O
- O
Pst O
together O
with O
plasmids O
encoding O
the O
nucleoprotein O
N O
( O
pT7 O
- O
N O
) O
, O
the O
phosphoprotein O
P O
( O
pT7 O
- O
P O
) O
, O
the O
RNA O
polymerase O
L O
( O
pT7 O
- O
L O
) O
, O
and O
the O
nonvirion O
protein O
NV O
( O
pT7 O
- O
NV O
) O
. O

To O
express O
its O
structural O
proteins O
, O
the O
arterivirus O
equine B
arteritis I
virus I
( I
EAV I
) I
produces O
a O
nested O
set O
of O
six O
subgenomic B
( I
sg I
) I
RNA O
species O
. O

The O
connection O
between O
the O
leader O
and O
body O
parts O
of O
an O
mRNA O
is O
formed O
by O
a O
short O
, O
conserved O
sequence O
element O
termed O
the O
transcription B
- I
regulating I
sequence I
( I
TRS I
) I
, O
which O
is O
present O
at O
the O
3 O
' O
end O
of O
the O
leader O
as O
well O
as O
upstream O
of O
each O
of O
the O
structural O
protein O
genes O
. O

Examination O
of O
the O
1 O
, O
679 O
- O
nucleotide B
( I
nt I
) I
unit O
- O
length O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNAs O
in O
the O
livers O
of O
two O
HDV O
- O
infected O
woodchucks O
showed O
that O
96 O
% O
of O
the O
antigenomic O
RNA O
but O
only O
50 O
% O
of O
the O
genomic O
RNA O
was O
circular O
. O

A O
permuted O
whole O
- O
genome O
construct O
of O
a O
TT B
virus I
( I
TTV I
) I
, O
named O
VT416 O
, O
had O
3 O
, O
852 O
nucleotides B
( I
nt I
) I
98 O
. O

The O
poly O
( O
A O
) O
( O
+ O
) O
RNAs O
expressed O
in O
COS1 O
cells O
48 O
h O
posttransfection O
contained O
three O
TTV O
mRNA O
species O
3 O
. O

These O
mRNAs O
in O
the O
antigenomic O
orientation O
possessed O
in O
common O
the O
3 O
' O
terminus O
downstream O
of O
a O
poly O
( O
A O
) O
signal O
( O
A O
( O
3073 O
) O
ATAAA O
) O
and O
the O
5 O
' O
terminus O
downstream O
of O
a O
cap O
site O
( O
C O
( O
98 O
) O
ACTTC O
) O
. O

A O
common O
splicing O
to O
join O
nt O
185 O
with O
nt O
277 O
was O
detected O
in O
all O
mRNAs O
, O
The O
coding O
region O
of O
the O
largest O
open B
reading I
frame I
( I
ORF I
) I
was O
maintained O
in O
3 O
. O

0 O
- O
kb O
mRNA O
, O
because O
this O
splicing O
was O
located O
upstream O
of O
its O
initiation O
codon O
( O
A O
( O
589 O
) O
TG O
) O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
or O
HCV O
- O
low B
- I
density I
lipoprotein I
( I
LDL I
) I
complexes O
interact O
with O
the O
LDL B
receptor I
( I
LDLr I
) I
and O
the O
HCV O
envelope O
glycoprotein O
E2 O
interacts O
with O
CD81 O
in O
vitro O
. O

07 O
g O
/ O
cm O
( O
3 O
) O
) O
, O
intermediate O
- O
density O
particles O
( O
1 O
. O

18 O
g O
/ O
cm O
( O
3 O
) O
) O
, O
recombinant O
E2 O
protein O
, O
or O
control O
proteins O
, O
we O
assessed O
binding O
to O
MOLT O
- O
4 O
cells O
, O
foreskin O
fibroblasts O
, O
or O
LDLr O
- O
deficient O
foreskin O
fibroblasts O
at O
4 O
degrees O
C O
by O
flow O
cytometry O
and O
confocal O
microscopy O
, O
Viral O
entry O
was O
determined O
by O
measuring O
the O
coentry O
of O
alpha O
- O
sarcin O
, O
a O
protein O
synthesis O
inhibitor O
. O

peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
harbored O
TT B
virus I
( I
TTV I
) I
of O
genotypes O
( O
3 O
and O
4 O
) O
different O
from O
those O
( O
1 O
and O
2 O
) O
of O
free O
virions O
in O
plasma O
of O
the O
same O
individuals O
, O
PBMC O
may O
act O
as O
a O
reservoir O
, O
and O
TTV O
of O
particular O
genotypes O
might O
have O
tropism O
for O
hematopoietic O
cells O
. O

As O
a O
model O
we O
used O
the O
serine O
protease O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

While O
the O
5 O
' O
cis O
- O
acting O
sequence O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
for O
genomic O
RNA O
replication O
has O
been O
determined O
in O
several O
Defective B
interfering I
( I
DI I
) I
RNA O
systems O
, O
it O
remains O
elusive O
for O
subgenomic O
RNA O
transcription O
. O

This O
deletion O
effectively O
eliminated O
the O
replication O
of O
the O
DI O
- O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
, O
as O
demonstrated O
by O
the O
sensitive O
reverse B
transcription I
( I
RT I
) I
- O
PCR O
. O

Results O
from O
both O
CAT O
activity O
and O
mRNA O
transcripts O
detected O
by O
RT O
- O
PCR O
showed O
that O
a O
5 O
' O
- O
proximal O
sequence O
of O
35 O
nucleotides B
( I
nt I
) I
at O
nt O
25 O
to O
59 O
is O
a O
cis O
- O
acting O
sequence O
required O
for O
subgenomic O
RNA O
transcription O
, O
while O
the O
consensus O
repeat O
sequence O
of O
the O
leader O
RNA O
does O
not O
have O
such O
effect O
. O

We O
have O
assembled O
a O
full O
- O
length O
infectious O
construct O
of O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
, O
an O
important O
pathogen O
in O
swine O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
translation O
initiation O
is O
dependent O
on O
the O
presence O
of O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
that O
is O
found O
mostly O
in O
its O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
. O

We O
characterized O
a O
novel O
28S O
rRNA O
cleavage O
in O
cells O
infected O
with O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

Human B
coronaviruses I
( I
hCoV I
) I
cause O
common O
colds O
but O
can O
also O
infect O
neural O
cell O
cultures O
. O

To O
provide O
definitive O
experimental O
evidence O
for O
the O
neurotropism O
and O
neuroinvasion O
of O
HCoV O
and O
its O
possible O
association O
with O
multiple B
sclerosis I
( I
MS I
) I
, O
we O
have O
performed O
an O
extensive O
search O
and O
characterization O
of O
HCoV O
RNA O
in O
a O
large O
panel O
of O
human O
brain O
autopsy O
samples O
. O

Very O
stringent O
reverse O
transcription O
- O
PCR O
, O
vith O
two O
primer O
pairs O
for O
both O
viral O
strains O
( O
229E O
and O
OC43 O
) O
, O
combined O
with O
Southern O
hybridization O
, O
was O
performed O
on O
samples O
from O
90 O
coded O
donors O
with O
various O
neurological O
diseases O
( O
39 O
with O
MS O
and O
26 O
with O
other O
neurological O
diseases O
) O
or O
normal O
controls O
( O
25 O
patients O
) O
. O

We O
report O
that O
34 O
% O
( O
40 O
of O
90 O
) O
of O
donors O
mere O
positive O
for O
229E O
and O
that O
23 O
% O
( O
21 O
of O
90 O
) O
were O
positive O
for O
OC43 O
. O

Sequencing O
of O
Nucleocapsid B
protein I
( I
N I
) I
gene O
amplicons O
revealed O
point O
mutations O
in O
OC43 O
, O
some O
consistently O
found O
in O
three O
MS O
patient O
brains O
and O
one O
normal O
control O
but O
never O
observed O
in O
laboratory O
viruses O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
5A I
( I
NS5A I
) I
protein O
has O
been O
controversially O
implicated O
in O
the O
inherent O
resistance O
of O
HCV O
to O
interferon B
( I
IFN I
) I
antiviral O
therapy O
in O
clinical O
studies O
, O
In O
this O
study O
, O
the O
relationship O
between O
NS5A O
mutations O
and O
selection O
pressures O
before O
and O
during O
antiviral O
therapy O
and O
virologic O
response O
to O
therapy O
were O
investigated O
. O

Full O
- O
length O
NS5A O
clones O
were O
sequenced O
from O
20 O
HCV O
genotype O
1 O
- O
infected O
patients O
in O
a O
prospective O
, O
randomized O
clinical O
trial O
of O
IFN O
induction O
( O
daily O
) O
therapy O
and O
IFN O
plus O
ribavirin O
combination O
therapy O
. O

A O
consensus O
IFN O
sensitivity O
- O
determining O
region O
( O
ISDR237 O
- O
276 O
) O
sequence O
associated O
with O
IFN O
resistance O
was O
not O
found O
, O
although O
the O
presence O
of O
Ala O
( O
245 O
) O
within O
the O
ISDR O
was O
associated O
with O
nonresponse O
to O
treatment O
in O
genotype O
1a O
- O
infected O
patients O
( O
P O
< O
0 O
. O

nonstructural B
protein I
5B I
( I
NS5B I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
possesses O
an O
RNA O
- O
dependent O
RNA O
polymerase O
activity O
responsible O
for O
viral O
genome O
RNA O
replication O
. O

Several O
experimental O
animal O
models O
have O
been O
developed O
to O
study O
the O
mechanism O
of O
virus O
- O
induced O
demyelination O
, O
including O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
infection O
in O
mice O
. O

The O
envelope O
spike B
( I
S I
) I
glycoprotein O
of O
MHV O
contains O
determinants O
of O
properties O
essential O
for O
virus O
- O
host O
interactions O
. O

Using O
targeted O
RNA O
recombination O
, O
we O
replaced O
the O
S O
gene O
of O
a O
demyelinating O
virus O
( O
MHV O
- O
A59 O
) O
with O
the O
S O
gene O
of O
a O
closely O
related O
, O
nondemyelinating O
virus O
( O
MHV O
- O
2 O
) O
. O

Recombinant O
viruses O
containing O
an O
S O
gene O
derived O
from O
MHV O
- O
2 O
in O
an O
MHV O
- O
A59 O
background O
( O
Penn98 O
- O
1 O
and O
Penn98 O
- O
2 O
) O
exhibited O
a O
persistence O
- O
positive O
, O
demyelination O
- O
negative O
phenotype O
. O

The O
genes O
encoding O
pestivirus O
E2 O
and O
NS2 O
- O
3 O
are O
separated O
by O
a O
sequence O
that O
encodes O
a O
small O
hydrophobic O
polypeptide O
with O
an O
apparent O
molecular O
mass O
of O
6 O
to O
7 O
kDa O
( O
p7 O
) O
, O
It O
has O
been O
shown O
that O
cleavage O
between O
E2 O
and O
p7 O
is O
incomplete O
, O
resulting O
in O
proteins O
E2 O
- O
p7 O
, O
E2 O
, O
and O
p7 O
, O
We O
found O
no O
precursor O
- O
product O
relationship O
between O
E2 O
- O
p7 O
and O
E2 O
, O
which O
indicates O
a O
stable O
nature O
of O
E2 O
- O
p7 O
, O
To O
study O
the O
function O
of O
the O
E2 O
- O
p7 O
region O
of O
the O
polyprotein O
, O
mutations O
were O
introduced O
into O
an O
infectious O
cDNA O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
. O

In O
the O
case O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
decreases O
in O
fitness O
after O
a O
limited O
number O
of O
plaque O
- O
to O
- O
plaque O
transfers O
in O
MT O
- O
4 O
cells O
were O
very O
drastic O
. O

Clones O
accumulated O
4 O
to O
28 O
mutations O
per O
genome O
, O
with O
dominance O
of O
A O
- O
- O
> O
G O
and O
G O
- O
- O
> O
A O
transitions O
( O
57 O
% O
of O
all O
mutations O
) O
and O
49 O
% O
nonsynonymous O
replacements O
. O

The O
5 B
' I
nontranslated I
region I
( I
NTR I
) I
of O
pestiviruses O
functions O
as O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
that O
mediates O
cap O
- O
independent O
translation O
of O
the O
viral O
polyprotein O
and O
probably O
contains O
additional O
cis O
- O
acting O
RNA O
signals O
involved O
in O
crucial O
processes O
of O
the O
viral O
life O
cycle O
. O

The O
analyses O
show O
that O
( O
i O
) O
deletion O
of O
the O
entire O
Ib O
loop O
region O
resulted O
in O
almost O
complete O
loss O
of O
infectivity O
that O
mas O
rapidly O
restored O
during O
passages O
in O
cell O
culture O
by O
insertions O
of O
variable O
numbers O
of O
A O
residues O
; O
( O
ii O
) O
mutations O
within O
the O
5 O
' O
- O
terminal O
4 O
nucleotides O
of O
the O
genomic O
RNA O
severely O
impaired O
virus O
replication O
; O
passaging O
of O
the O
supernatants O
obtained O
after O
transfection O
resulted O
in O
the O
emergence O
of O
efficiently O
replicating O
mutants O
that O
had O
regained O
the O
conserved O
5 O
' O
- O
terminal O
sequence O
; O
( O
iii O
) O
provided O
the O
conserved O
sequence O
motif O
5 O
' O
- O
GUAU O
was O
retained O
at O
the O
5 O
' O
end O
of O
the O
genomic O
RNA O
, O
substitutions O
and O
deletions O
of O
various O
parts O
of O
hairpin O
Ia O
or O
deletion O
of O
all O
of O
Is O
and O
part O
of O
Ib O
were O
found O
to O
support O
replication O
, O
but O
to O
a O
lower O
degree O
than O
the O
parent O
virus O
. O

The O
continued O
presence O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
within O
the O
central B
nervous I
system I
( I
CNS I
) I
following O
resolution O
of O
acute O
viral O
encephalomyelitis O
implicates O
organ O
- O
specific O
retention O
. O

The O
role O
of O
viral O
persistence O
in O
locally O
maintaining O
T O
cells O
was O
investigated O
by O
infecting O
mice O
with O
either O
a O
demyelinating O
, O
paralytic O
( O
V O
- O
1 O
) O
or O
nonpathogenic O
( O
V O
- O
2 O
) O
variant O
of O
a O
neurotropic O
mouse O
hepatitis O
virus O
, O
which O
differ O
in O
the O
ability O
to O
persist O
within O
the O
CNS O
. O

Class O
I O
tetramer O
technology O
revealed O
more O
infiltrating O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
during O
acute O
V O
- O
1 O
compared O
to O
V O
- O
2 O
infection O
. O

However O
, O
both O
total O
and O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
accumulated O
at O
similar O
peak O
levels O
in O
spinal O
cords O
by O
day O
10 O
postinfection O
( O
p O
. O

Decreasing O
viral O
RNA O
levels O
in O
both O
brains O
and O
spinal O
cords O
following O
initial O
virus O
clearance O
coincided O
with O
an O
overall O
progressive O
loss O
of O
both O
total O
and O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

By O
contrast O
, O
a O
significant O
number O
of O
CD8 O
( O
+ O
) O
T O
cells O
which O
contained O
detectable O
viral O
RNA O
were O
recovered O
from O
spinal O
cords O
of O
V O
- O
1 O
- O
infected O
mice O
. O

The O
data O
indicate O
that O
residual O
virus O
from O
a O
primary O
CNS O
infection O
is O
a O
vital O
component O
in O
mediating O
local O
retention O
of O
both O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
and O
that O
once O
minimal O
thresholds O
of O
stimuli O
are O
lost O
, O
T O
cells O
within O
the O
CNS O
cannot O
survive O
in O
an O
autonomous O
fashion O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
a O
31 O
- O
kb O
positive O
- O
strand O
RNA O
virus O
that O
is O
replicated O
in O
the O
cytoplasm O
of O
infected O
cells O
by O
a O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
, O
termed O
the O
replicase O
, O
The O
replicase O
is O
encoded O
in O
the O
5 O
' O
- O
most O
22 O
kb O
of O
the O
genomic O
RNA O
, O
which O
is O
translated O
to O
produce O
a O
polyprotein O
of O
> O
800 O
kDa O
, O
The O
replicase O
polyprotein O
is O
extensively O
processed O
by O
viral O
and O
perhaps O
cellular O
proteinases O
to O
give O
rise O
to O
a O
functional O
replicase O
complex O
. O

To O
date O
, O
two O
of O
the O
MHV O
replicase O
- O
encoded O
proteinases O
, O
papain B
- I
like I
proteinase I
1 I
( I
PLP1 I
) I
and O
the O
poliovirus O
3C B
- I
like I
proteinase I
( I
3CLpro I
) I
, O
have O
been O
shown O
to O
process O
the O
replicase O
polyprotein O
. O

In O
this O
report O
, O
we O
describe O
the O
cloning O
, O
expression O
, O
and O
activity O
of O
the O
third O
MHV O
proteinase O
domain O
, O
PLP2 O
, O
We O
show O
that O
PLP2 O
cleaves O
a O
substrate O
encoding O
the O
first O
predicted O
membrane O
- O
spanning O
domain O
( O
MP1 O
) O
of O
the O
replicase O
polyprotein O
. O

Using O
an O
antiserum O
( O
anti O
- O
D11 O
) O
directed O
against O
the O
C O
terminus O
of O
the O
MP1 O
domain O
, O
we O
verified O
that O
p150 O
encompasses O
the O
MP1 O
domain O
and O
identified O
a O
44 B
- I
kDa I
protein I
( I
p44 I
) I
as O
a O
processed O
product O
of O
p150 O
. O

human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
- O
specific O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
play O
a O
major O
role O
in O
the O
antiviral O
immune O
response O
, O
but O
the O
relative O
contribution O
of O
CTL O
responses O
restricted O
by O
different O
HLA O
class O
I O
molecules O
is O
less O
well O
defined O
. O

Here O
we O
report O
the O
definition O
of O
five O
novel O
HLA O
- O
B60 O
- O
restricted O
HIV O
- O
1 O
- O
specific O
CTL O
epitopes O
, O
using O
peripheral O
blood O
mononuclear O
cells O
in O
enzyme B
- I
linked I
immunospot I
( I
ELISPOT I
) I
assays O
and O
using O
CTL O
clones O
and O
lines O
in O
cytolytic O
assays O
. O

The O
lack O
of O
a O
susceptible O
cell O
line O
and O
an O
animal O
model O
for O
Norwalk B
virus I
( I
NV I
) I
infection O
has O
prompted O
the O
development O
of O
alternative O
strategies O
to O
generate O
in O
vitro O
RNAs O
that O
approximate O
the O
authentic O
viral O
genome O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
the O
leading O
causative O
agent O
of O
blood O
- O
borne O
chronic O
hepatitis O
and O
is O
the O
target O
of O
intensive O
vaccine O
research O
. O

The O
quality O
of O
recombinant O
E2 O
protein O
was O
evaluated O
by O
both O
the O
capacity O
to O
bind O
its O
putative O
receptor O
CD81 O
on O
human O
cells O
and O
the O
ability O
to O
elicit O
antibodies O
that O
inhibited O
this O
binding O
( O
NOB O
antibodies O
) O
. O

Low O
- O
level O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
cultured O
lymphoblastoid O
cells O
inoculated O
with O
H77 O
serum O
inoculum O
led O
to O
the O
appearance O
of O
new O
virus O
variants O
containing O
identical O
substitutions O
at O
three O
sites O
within O
the O
viral O
5 B
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
: O
G O
( O
107 O
) O
- O
- O
> O
A O
, O
C O
- O
204 O
- O
- O
> O
A O
, O
and O
G O
( O
243 O
) O
- O
- O
> O
A O
( O
N O
, O
Nakajima O
, O
hi O
. O

Hijikata O
, O
II O
, O
Yoshikura O
, O
and O
Y O
, O
K O
, O
Shimizu O
, O
J O
, O
Virol O
, O
70 O
: O
3325 O
- O
3329 O
, O
1996 O
) O
, O
These O
results O
suggest O
that O
virus O
with O
this O
5 O
' O
NTR O
sequence O
may O
have O
a O
greater O
capacity O
for O
replication O
in O
such O
cells O
, O
possibly O
due O
to O
more O
efficient O
capindependent O
translation O
, O
since O
these O
nucleotide O
substitutions O
reside O
within O
the O
viral O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
, O
To O
test O
this O
hypothesis O
, O
we O
examined O
the O
translation O
of O
dicistronic O
RNAs O
containing O
upstream O
and O
downstream O
reporter O
sequences O
( O
Renilla O
and O
firefly O
luciferases O
, O
respectively O
) O
separated O
by O
IRES O
sequences O
containing O
different O
combinations O
of O
these O
substitutions O
, O
The O
activity O
of O
the O
IRES O
was O
assessed O
by O
determining O
the O
relative O
firefly O
and O
Renilla O
luciferase O
activities O
expressed O
in O
transfected O
cells O
. O

Compared O
with O
the O
IRES O
present O
in O
the O
dominant O
H77 O
quasispecies O
, O
an O
IRES O
containing O
all O
three O
nucleotide O
substitutions O
had O
significantly O
greater O
translational O
activity O
in O
three O
of O
five O
human O
lymphoblastoid O
cell O
lines O
( O
Raji O
, O
Bjab O
, O
and O
Molt4 O
but O
not O
Jurkat O
or O
HPBMa10 O
- O
2 O
cells O
) O
. O

In O
contrast O
, O
these O
substitutions O
did O
not O
enhance O
IRES O
activity O
in O
cell O
lines O
derived O
from O
monocytes O
or O
granulocytes O
( O
HL O
- O
60 O
, O
KG O
- O
1 O
, O
or O
THP O
- O
1 O
) O
or O
hepatocytes O
( O
Huh O
- O
7 O
) O
or O
in O
cell O
- O
free O
translation O
assays O
carried O
out O
with O
rabbit O
reticulocyte O
lysates O
, O
Each O
of O
the O
three O
substitutions O
was O
required O
for O
maximally O
increased O
translational O
activity O
in O
the O
lymphoblastoid O
cells O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
unique O
relative O
to O
all O
known O
animal O
viruses O
, O
especially O
in O
terms O
of O
its O
ability O
to O
redirect O
host O
RNA O
polymerase O
( O
s O
) O
to O
transcribe O
its O
1 O
, O
679 O
- O
nucleotide B
( I
nt I
) I
circular O
RNA O
genome O
. O

Previously O
, O
we O
showed O
that O
the O
5 O
' O
end O
of O
this O
RNA O
was O
located O
in O
the O
majority O
of O
species O
, O
at O
nt O
1630 O
, O
The O
present O
studies O
show O
that O
( O
1 O
) O
at O
least O
some O
of O
this O
RNA O
, O
as O
extracted O
from O
the O
liver O
of O
an O
HDV O
- O
infected O
woodchuck O
, O
behaved O
as O
if O
it O
contained O
a O
5 O
' O
- O
cap O
structure O
; O
( O
ii O
) O
in O
the O
infected O
liver O
there O
were O
additional O
polyadenylated O
antigenomic O
HDV O
RNA O
species O
with O
5 O
' O
ends O
located O
at O
least O
202 O
nt O
and O
even O
335 O
nt O
beyond O
the O
nt O
1630 O
site O
, O
( O
iii O
) O
the O
5 O
' O
end O
at O
nt O
1630 O
was O
not O
detected O
in O
transfected O
cells O
, O
following O
DNA O
- O
directed O
HDV O
RNA O
transcription O
, O
in O
the O
absence O
of O
genome O
replication O
, O
and O
( O
iv O
) O
nevertheless O
, O
using O
in O
vitro O
transcription O
with O
purified O
human O
RNA O
polymerase O
II O
holoenzyme O
and O
genomic O
RNA O
template O
, O
we O
did O
not O
detect O
initiation O
of O
template O
- O
dependent O
RNA O
synthesis O
; O
we O
observed O
only O
low O
levels O
of O
3 O
' O
- O
end O
addition O
to O
the O
template O
, O
These O
new O
findings O
support O
the O
interpretation O
that O
the O
5 O
' O
end O
detected O
at O
nt O
1630 O
during O
HDV O
replication O
represents O
a O
specific O
site O
for O
the O
initiation O
of O
an O
RNA O
- O
directed O
RNA O
synthesis O
, O
which O
is O
then O
modified O
by O
capping O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
two O
types O
of O
hepatitis B
delta I
antigens I
( I
HDAg I
) I
in O
the O
virion O
, O
The O
small O
form O
( O
S O
- O
HDAg O
) O
is O
required O
for O
HDV O
RNA O
replication O
, O
whereas O
the O
large O
form O
( O
L O
- O
HDAg O
) O
potently O
inhibits O
it O
by O
a O
dominant O
- O
negative O
inhibitory O
mechanism O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
Pestivirus O
member O
of O
the O
Flaviviridae O
family O
, O
has O
a O
positive O
- O
stranded O
RNA O
genome O
which O
consists O
of O
a O
single O
open B
reading I
frame I
( I
ORF I
) I
and O
untranslated B
regions I
( I
UTRs I
) I
at O
the O
5 O
' O
and O
3 O
' O
ends O
. O

The O
5 O
' O
UTR O
harbors O
extensive O
RNA O
structure O
motifs O
; O
most O
of O
them O
were O
shown O
to O
contribute O
to O
an O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
, O
which O
mediates O
cap O
- O
independent O
translation O
of O
the O
ORF O
. O

The O
extreme O
5 O
' O
- O
terminal O
region O
of O
the O
BVDV O
genome O
had O
so O
far O
been O
believed O
not O
to O
be O
required O
for O
IRES O
function O
, O
By O
structure O
probing O
techniques O
, O
we O
initially O
verified O
the O
existence O
of O
a O
computer O
- O
predicted O
stem O
- O
loop O
motif O
at O
the O
5 O
' O
end O
of O
the O
viral O
genome O
( O
hairpin O
Ia O
) O
as O
well O
as O
at O
the O
3 O
' O
end O
of O
the O
complementary O
negative O
- O
strand O
replication O
intermediate O
[ O
termed O
hairpin O
Ia O
( O
- O
) O
] O
. O

Taking O
a O
reverse O
genetics O
approach O
to O
a O
subgenomic O
BVDV O
replicon O
RNA O
( O
DI9c O
) O
which O
could O
be O
equally O
employed O
in O
a O
translation O
as O
well O
as O
replication O
assay O
system O
based O
on O
BHK O
- O
21 O
cells O
, O
we O
obtained O
the O
following O
results O
. O

( O
i O
) O
Proper O
folding O
of O
the O
Ia O
stem O
was O
found O
to O
be O
crucial O
for O
efficient O
translation O
. O

( O
ii O
) O
An O
intact O
loop O
structure O
and O
a O
stretch O
of O
nucleotide O
residues O
that O
constitute O
a O
portion O
of O
the O
stem O
of O
the O
Ia O
or O
the O
Ia O
( O
- O
) O
motif O
, O
respectively O
, O
were O
defined O
to O
represent O
important O
determinants O
of O
the O
RNA O
replication O
pathway O
, O
( O
iii O
) O
Formation O
of O
the O
stem O
structure O
of O
the O
Ia O
( O
- O
) O
motif O
was O
determined O
to O
be O
not O
critical O
for O
RNA O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
glycoprotein O
E2 O
binds O
to O
human O
cells O
by O
interacting O
with O
the O
CD81 O
molecule O
, O
which O
has O
been O
proposed O
to O
be O
the O
viral O
receptor O
. O

Tamarin O
CD81 O
( O
t O
- O
CD81 O
) O
differs O
from O
the O
human O
molecule O
at O
5 O
amino O
acid O
positions O
( O
155 O
, O
163 O
, O
169 O
, O
180 O
, O
and O
196 O
) O
within O
the O
large B
extracellular I
loop I
( I
LEL I
) I
, O
where O
the O
binding O
site O
for O
E2 O
has O
been O
located O
, O
Soluble O
recombinant O
forms O
of O
human B
CD81 I
( I
h I
- I
CD81 I
) I
, O
t O
- O
CD81 O
, O
and O
African B
green I
monkey I
CD81 I
( I
agm I
- I
CD81 I
) I
LEL O
molecules O
were O
analyzed O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
for O
binding O
to O
E2 O
glycoprotein O
, O
Both O
h O
- O
CD81 O
and O
t O
- O
CD81 O
molecules O
were O
able O
to O
bind O
E2 O
. O

Mutation O
of O
residue O
186 O
( O
F186L O
) O
dramatically O
reduced O
the O
binding O
capability O
of O
t O
- O
CD81 O
, O
a O
result O
that O
has O
already O
been O
demonstrated O
for O
the O
human O
receptor O
, O
whereas O
the O
opposite O
mutation O
( O
L186F O
) O
in O
agm O
- O
CD81 O
resulted O
in O
a O
neat O
gain O
of O
binding O
activity O
. O

Finally O
, O
the O
in O
vitro O
data O
were O
confirmed O
by O
detection O
of O
E2 O
binding O
to O
cotton O
- O
top O
tamarin O
( O
Saguinus O
oedipus O
) O
cell O
line O
B95 O
- O
8 O
expressing O
endogenous O
CD81 O
, O
These O
results O
indicate O
that O
the O
binding O
of O
E2 O
to O
CD81 O
is O
not O
predictive O
of O
an O
infection O
- O
producing O
interaction O
between O
HCV O
and O
host O
cells O
. O

The O
rubella B
virus I
( I
RUB I
) I
nonstructural I
( I
NS I
) I
protein O
( O
NSP O
) O
ORF O
encodes O
a O
protease O
that O
cleaves O
the O
NSP O
precursor O
( O
240 O
kDa O
) O
at O
a O
single O
site O
to O
produce O
two O
products O
, O
A O
cleavage O
site O
mutation O
was O
introduced O
into O
a O
RUB O
infectious O
cDNA O
clone O
and O
found O
to O
be O
lethal O
, O
demonstrating O
that O
cleavage O
of O
the O
NSP O
precursor O
is O
necessary O
for O
RUB O
replication O
. O

Based O
on O
computer O
alignments O
, O
the O
RUB O
NS O
protease O
was O
predicted O
to O
be O
a O
papain B
- I
like I
cysteine I
protease I
( I
PCP I
) I
with O
the O
residues O
Cys1152 O
and O
His1273 O
as O
the O
catalytic O
dyad O
; O
however O
, O
the O
RUB O
NS O
protease O
was O
recently O
found O
to O
require O
divalent O
cations O
such O
as O
Zn O
, O
Co O
, O
and O
Cd O
for O
activity O
( O
X O
, O
Liu O
, O
S O
. O

L O
, O
Ropp O
, O
R O
, O
J O
, O
Jackson O
, O
and O
T O
, O
K O
, O
Frey O
, O
J O
, O
Virol O
, O
72 O
: O
4463 O
- O
1466 O
, O
1998 O
) O
, O
To O
analyze O
the O
function O
of O
metal O
cation O
binding O
in O
protease O
activity O
, O
Zn O
binding O
studies O
were O
performed O
using O
the O
minimal O
NS O
protease O
domain O
within O
the O
NSP O
ORF O
, O
When O
expressed O
as O
a O
Maltose B
binding I
protein I
( I
MBP I
) I
fusion O
protein O
by O
bacteria O
, O
the O
NS O
protease O
exhibited O
activity O
both O
in O
the O
bacteria O
and O
in O
vitro O
following O
purification O
when O
denatured O
and O
refolded O
in O
the O
presence O
of O
Zn O
, O
Atomic O
absorption O
analysis O
detected O
1 O
. O

Far O
- O
UV O
circular B
dichroism I
( I
CD I
) I
analysis O
of O
the O
MBP O
- O
NS O
protease O
fusion O
protein O
showed O
that O
the O
protease O
domain O
contained O
a O
large O
amount O
of O
alpha O
- O
helical O
structure O
, O
which O
is O
consistent O
with O
the O
results O
of O
secondary O
- O
structural O
prediction O
. O

Internal B
ribosomal I
entry I
sites I
( I
IRESs I
) I
can O
function O
in O
foreign O
viral O
genomes O
or O
in O
artificial O
dicistronic O
mRNAs O
. O

We O
describe O
an O
interaction O
between O
the O
wild O
- O
type O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
specific O
sequence O
and O
the O
poliovirus B
( I
PV I
) I
5 O
' O
- O
terminal O
cloverleaf O
in O
a O
PV O
/ O
HCV O
chimeric O
virus O
( O
containing O
the O
HCV O
IRES O
) O
, O
resulting O
in O
a O
replication O
phenotype O
. O

Either O
a O
point O
mutation O
at O
nucleotide B
( I
nt I
) I
29 O
or O
a O
deletion O
up O
to O
nt O
40 O
in O
the O
HCV O
5 O
' O
nontranslated O
region O
relieved O
the O
replication O
block O
, O
yielding O
PV O
/ O
HCV O
variants O
replicating O
to O
high O
titers O
. O

Hepatitis O
C O
virus O
translation O
is O
initiated O
on O
a O
similar O
to O
330 O
- O
nucleotide B
( I
nt I
) I
- O
long O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
at O
the O
5 O
' O
end O
of O
the O
genome O
. O

In O
this O
process O
, O
a O
43S O
preinitiation O
complex O
( O
comprising O
a O
40S O
ribosomal O
subunit O
, O
Eukaryotic B
initiation I
factor I
3 I
( I
eIF3 I
) I
, O
and O
a O
ternary O
[ O
eIF2 O
- O
GTP O
- O
initiator O
tRNA O
] O
complex O
) O
binds O
the O
IRES O
in O
a O
precise O
manner O
so O
that O
the O
initiation O
codon O
is O
placed O
at O
the O
ribosomal O
P O
site O
. O

Interaction O
sites O
were O
identified O
in O
locations O
that O
have O
been O
found O
to O
be O
essential O
for O
IRES O
function O
, O
including O
( O
i O
) O
the O
epical O
loop O
residues O
GGG O
( O
266 O
- O
268 O
) O
in O
subdomain O
IIId O
and O
( O
ii O
) O
the O
pseudoknot O
. O

A O
series O
of O
mouse B
monoclonal I
antibodies I
( I
MAbs I
) I
to O
the O
nonstructural B
protein I
3 I
( I
NS3 I
) I
of O
hepatitis O
C O
virus O
was O
prepared O
. O

This O
inhibition O
was O
competitive O
with O
respect O
to O
the O
substrate O
peptide O
( O
K O
- O
i O
= O
39 O
nM O
) O
but O
was O
significantly O
decreased O
by O
the O
addition O
of O
the O
NS4A O
peptide O
, O
a O
coactivator O
of O
the O
NS3 O
protease O
. O

Epitope O
mapping O
of O
8D4 O
with O
a O
random O
peptide O
library O
revealed O
a O
consensus O
sequence O
, O
DxDLV O
, O
that O
matched O
residues O
79 O
to O
83 O
( O
DQDLV O
) O
of O
NS3 O
, O
a O
region O
containing O
the O
catalytic O
residue O
Asp O
- O
81 O
. O

Although O
hepatitis B
A I
virus I
( I
HAV I
) I
is O
typically O
transmitted O
by O
the O
fecal O
- O
oral O
route O
, O
little O
is O
known O
of O
its O
interactions O
with O
cells O
of O
the O
gastrointestinal O
tract O
. O

RNA O
viruses O
have O
5 O
' O
and O
3 O
/ O
untranslated B
regions I
( I
UTRs I
) I
that O
contain O
specific O
signals O
for O
RNA O
synthesis O
. O

The O
coronavirus O
genome O
is O
capped O
at O
the O
5 O
' O
end O
and O
has O
a O
3 O
' O
UTR O
that O
consists O
of O
300 O
to O
500 O
nucleotides B
( I
nt I
) I
plus O
a O
poly O
( O
A O
) O
tail O
. O

To O
further O
our O
understanding O
of O
coronavirus O
replication O
, O
we O
have O
begun O
to O
examine O
the O
involvement O
of O
host O
factors O
in O
this O
process O
for O
two O
group O
II O
viruses O
, O
bovine B
coronavirus I
( I
BCV I
) I
and O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
. O

Specific O
host O
protein O
interactions O
with O
the O
BCV O
3 O
' O
UTR O
[ O
287 O
nt O
plus O
poly O
( O
A O
) O
tail O
] O
were O
identified O
using O
gel O
mobility O
shift O
assays O
, O
Competition O
with O
the O
MHV O
3 O
/ O
UTR O
[ O
301 O
nt O
plus O
poly O
( O
A O
) O
tail O
] O
suggests O
that O
the O
interactions O
are O
conserved O
for O
the O
two O
viruses O
. O

Less O
heavily O
labeled O
proteins O
were O
also O
detected O
in O
the O
ranges O
of O
40 O
to O
50 O
and O
30 O
kDa O
, O
The O
poly O
( O
A O
) O
tail O
was O
required O
for O
binding O
of O
the O
73 O
- O
kDa O
protein O
. O

Immunoprecipitation O
of O
UV O
- O
cross O
- O
linked O
proteins O
identified O
the O
73 O
kDa O
protein O
as O
the O
cytoplasmic O
poly O
( O
A O
) O
- O
binding O
protein O
( O
PABP O
) O
. O

Replication O
of O
the O
defective O
genomes O
BCV O
Drep O
and O
MHV O
MIDI O
- O
C O
, O
along O
with O
several O
mutants O
, O
was O
used O
to O
determine O
the O
importance O
of O
the O
poly O
( O
A O
) O
tail O
. O

Defective O
genomes O
with O
shortened O
poly O
( O
A O
) O
tails O
consisting O
of O
5 O
or O
10 O
A O
residues O
were O
replicated O
after O
transfection O
into O
helper O
virus O
- O
infected O
cells O
. O

BCV O
Drep O
RNA O
that O
lacked O
a O
poly O
( O
A O
) O
tail O
did O
not O
replicate O
, O
whereas O
replication O
of O
MHV O
MADI O
- O
C O
RNA O
with O
a O
deleted O
tail O
was O
detected O
after O
several O
virus O
passages O
. O

Detectable O
extension O
or O
addition O
of O
the O
poly O
( O
A O
) O
tail O
to O
the O
mutants O
correlated O
with O
the O
appearance O
of O
these O
RNAs O
in O
the O
replication O
assay O
. O

RNAs O
with O
shortened O
poly O
( O
A O
) O
tails O
exhibited O
less O
in O
vitro O
PABP O
binding O
, O
suggesting O
that O
decreased O
interactions O
with O
the O
protein O
may O
affect O
RNA O
replication O
. O

The O
data O
strongly O
indicate O
that O
the O
poly O
( O
A O
) O
tail O
is O
an O
important O
cis O
- O
acting O
signal O
for O
coronavirus O
replication O
. O

TT B
virus I
( I
TTV I
) I
is O
an O
unenveloped O
, O
circular O
, O
and O
single O
- O
stranded O
DNA O
virus O
commonly O
infecting O
human O
beings O
worldwide O
, O
TTV O
DNAs O
in O
paired O
serum O
and O
liver O
tissues O
from O
three O
viremic O
individuals O
were O
separated O
by O
gel O
electrophoresis O
and O
characterized O
biophysically O
, O
ITV O
DNAs O
in O
sera O
migrated O
in O
sizes O
ranging O
from O
2 O
. O

equine B
arteritis I
virus I
( I
EAV I
) I
, O
the O
prototype O
Arterivirus O
, O
is O
a O
positive O
- O
stranded O
RNA O
virus O
that O
expresses O
its O
replicase O
in O
the O
form O
of O
two O
large O
polyproteins O
of O
1 O
, O
727 O
and O
3 O
, O
175 O
amino O
acids O
. O

The O
functional O
replicase O
subunits O
( O
nonstructural O
proteins O
) O
, O
which O
drive O
EAV O
genome O
replication O
and O
subgenomic O
mRNA O
transcription O
, O
are O
generated O
by O
extensive O
proteolytic O
processing O
. O

Subgenomic O
mRNA O
transcription O
involves O
an O
unusual O
discontinuous O
step O
and O
generates O
the O
mRNAs O
for O
structural O
protein O
expression O
, O
Previously O
, O
the O
phenotype O
of O
mutant O
EAV030F O
, O
which O
carries O
a O
single O
replicase O
point O
mutation O
( O
Ser O
- O
2429 O
- O
- O
> O
Pro O
) O
, O
had O
implicated O
the O
nsp10 O
replicase O
subunit O
( O
51 O
kDa O
) O
in O
viral O
RNA O
synthesis O
, O
and O
in O
particular O
in O
subgenomic O
mRNA O
transcription O
. O

nsp10 O
contains O
an O
N O
- O
terminal O
( O
putative O
) O
metal B
- I
binding I
domain I
( I
MBD I
) I
, O
located O
just O
upstream O
of O
the O
Ser O
- O
2429 O
- O
- O
> O
Pro O
mutation O
, O
and O
a O
helicase O
activity O
in O
its O
C O
- O
terminal O
part O
. O

The O
195 O
- O
and O
214 O
- O
amino O
- O
acid O
( O
aa O
) O
forms O
of O
the O
delta O
protein O
( O
delta O
Ag O
- O
S O
and O
delta O
Ag O
- O
L O
, O
respectively O
) O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
differ O
only O
in O
the O
19 O
- O
aa O
C O
- O
terminal O
extension O
unique O
to O
delta O
Ag O
- O
L O
. O

Zuccola O
et O
al O
, O
( O
Structure O
6 O
: O
821 O
- O
830 O
, O
1998 O
) O
reported O
a O
crystal O
structure O
for O
a O
peptide O
spanning O
this O
region O
which O
demonstrates O
an O
antiparallel O
coiled O
- O
coil O
dimer O
interaction O
with O
the O
potential O
to O
form O
tetramers O
of O
dimers O
. O

We O
found O
that O
the O
predicted O
hierarchy O
of O
importance O
of O
these O
nine O
mutations O
correlated O
to O
a O
significant O
extent O
with O
the O
observed O
in O
vivo O
effects O
on O
the O
ability O
of O
these O
proteins O
to O
( O
i O
) O
support O
in O
trans O
the O
replication O
of O
the O
HDV O
genome O
when O
expressed O
on O
delta O
AgS O
and O
( O
ii O
) O
act O
as O
dominant O
- O
negative O
inhibitors O
of O
replication O
when O
expressed O
on O
delta O
Ag O
- O
L O
. O

The O
coronavirus O
replicase O
gene O
( O
gene O
1 O
) O
is O
translated O
into O
two O
co O
- O
amino O
- O
terminal O
polyproteins O
that O
are O
proteolytically O
processed O
to O
yield O
more O
than O
15 O
mature O
proteins O
. O

However O
, O
both O
immunofluorescence O
and O
electron O
microscopic O
studies O
have O
also O
detected O
gene O
1 O
proteins O
at O
sites O
distinct O
from O
the O
putative O
sites O
of O
viral O
RNA O
synthesis O
or O
virus O
assembly O
, O
In O
this O
study O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
infected O
cells O
were O
fractionated O
and O
analyzed O
to O
determine O
if O
gene O
1 O
proteins O
segregated O
to O
more O
than O
one O
membrane O
population O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
infected O
cells O
contain O
full O
- O
length O
and O
subgenomic O
- O
length O
positive O
- O
and O
negative O
- O
strand O
RNAs O
. O

The O
dynamics O
of O
the O
genetic O
diversification O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
populations O
was O
addressed O
in O
perinatal O
infection O
. O

Clonal O
sequences O
of O
hypervariable O
region O
1 O
of O
the O
putative O
E2 O
envelope O
protein O
of O
HCV O
were O
obtained O
from O
four O
HCV O
- O
infected O
newborns O
( O
sequential O
samples O
spanning O
a O
period O
of O
6 O
to O
13 O
months O
after O
birth O
) O
and O
from O
their O
mothers O
( O
all O
samples O
collected O
at O
delivery O
) O
. O

In O
the O
newborns O
, O
a O
unique O
viral O
variant O
( O
or O
a O
small O
group O
of O
closely O
related O
variants O
) O
remained O
stable O
for O
weeks O
despite O
active O
viral O
replication O
. O

Diversification O
of O
the O
intrahost O
HCV O
population O
was O
observed O
6 O
to O
13 O
months O
after O
birth O
and O
was O
substantially O
higher O
in O
two O
of O
the O
four O
subjects O
, O
as O
documented O
by O
the O
intersample O
genetic B
distance I
( I
GD I
) I
( O
P O
= O
0 O
. O

Importantly O
, O
a O
significant O
correlation O
between O
increasing O
GD O
and O
high O
values O
for O
the O
intersample O
K O
- O
a O
/ O
K O
- O
s O
ratio O
( O
the O
ratio O
between O
antonymous O
and O
synonymous O
substitutions O
; O
an O
index O
of O
the O
action O
of O
selective O
forces O
) O
was O
observed O
, O
as O
documented O
by O
the O
increase O
of O
both O
parameters O
over O
time O
( O
P O
= O
0 O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
human O
pathogen O
causing O
chronic O
liver O
disease O
. O

We O
have O
recently O
found O
that O
the O
large B
extracellular I
loop I
( I
LEL I
) I
of O
human O
CD81 O
binds O
HCV O
. O

Altogether O
our O
data O
suggest O
that O
neutralizing O
antibodies O
aimed O
at O
interfering O
with O
HCV O
binding O
to O
human O
cells O
should O
have O
an O
affinity O
higher O
than O
10 O
( O
- O
9 O
) O
M O
, O
that O
HCV O
binding O
to O
hepatcytes O
may O
not O
entirely O
depend O
on O
CD81 O
, O
that O
CD81 O
is O
an O
attachment O
receptor O
with O
poor O
capacity O
to O
mediate O
virus O
entry O
, O
and O
that O
reducing O
environments O
do O
not O
favor O
CD81 O
- O
HCV O
interaction O
. O

equine B
arteritis I
virus I
( I
EAV I
) I
, O
the O
type O
member O
of O
the O
family O
Arteriviridae O
, O
is O
a O
single O
- O
stranded O
RNA O
virus O
with O
a O
positive O
- O
stranded O
genome O
of O
approximately O
13 O
kb O
. O

We O
have O
generated O
the O
first O
documented O
arterivirus O
Defective B
interfering I
( I
DI I
) I
RNAs O
by O
serial O
undiluted O
passaging O
of O
a O
wild O
- O
type O
EAV O
stock O
in O
BHK O
- O
21 O
cells O
. O

Upon O
transfection O
into O
EAV O
- O
infected O
BHK O
- O
21 O
cells O
, O
transcripts O
derived O
from O
this O
clone O
( O
pEDI O
) O
were O
replicated O
and O
packaged O
. O

Sequencing O
of O
pEDI O
revealed O
that O
the O
DI O
RNA O
was O
composed O
of O
three O
segments O
of O
the O
EAV O
genome O
( O
nucleotides O
1 O
to O
1057 O
, O
1388 O
to O
1684 O
, O
and O
8530 O
to O
12704 O
) O
which O
were O
fused O
in O
frame O
with O
respect O
to O
the O
replicase O
reading O
frame O
. O

The O
replicase O
gene O
( O
gene O
1 O
) O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
encodes O
two O
co O
- O
amino O
- O
terminal O
polyproteins O
presumed O
to O
incorporate O
all O
the O
virus O
- O
encoded O
proteins O
necessary O
for O
viral O
RNA O
synthesis O
. O

Monospecific O
antibodies O
directed O
against O
the O
four O
distinct O
domains O
detected O
proteins O
of O
10 O
, O
12 O
, O
and O
15 O
kDa O
( O
p1a O
- O
10 O
, O
p1a O
- O
12 O
, O
and O
p1a O
- O
15 O
) O
in O
MHV O
- O
A59 O
- O
infected O
DBT O
cells O
, O
in O
addition O
to O
a O
previously O
identified O
22 O
- O
kDa O
protein O
( O
p1a O
- O
22 O
) O
. O

It O
is O
proposed O
that O
the O
heterogenous O
mixture O
of O
infectious O
hepatitis O
A O
virus O
particles O
( O
virions O
and O
provirions O
) O
typically O
present O
in O
inocula O
is O
responsible O
for O
the O
normally O
asynchronous O
nature O
of O
hepatitis O
A O
virus O
uncoating O
kinetics O
. O

To O
test O
whether O
both O
aspartic O
acid O
residues O
are O
in O
fact O
involved O
in O
the O
catalytic O
activity O
and O
metal O
ion O
coordination O
of O
the O
enzyme O
, O
several O
defined O
mutations O
have O
been O
made O
in O
order O
to O
replace O
them O
by O
glutamate O
, O
asparagine O
, O
or O
glycine O
, O
All O
six O
mutant O
enzymes O
were O
produced O
in O
Escherichia O
coli O
, O
and O
their O
in O
vitro O
poly O
( O
U O
) O
polymerase O
activity O
was O
characterized O
. O

A O
tetracycline O
- O
regulated O
gene O
expression O
system O
and O
a O
panel O
of O
novel O
monoclonal O
antibodies O
were O
used O
to O
examine O
the O
subcellular O
localization O
, O
stability O
, O
and O
trans O
- O
cleavage O
competence O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
- O
NS4A O
complex O
in O
inducible O
cell O
lines O
. O

Coexpression O
of O
NS4A O
, O
however O
, O
directed O
NS3 O
to O
the O
endoplasmic B
: I
reticulum I
( I
ER I
) I
or O
an O
ER O
- O
like O
modified O
compartment O
, O
as O
demonstrated O
by O
colocalization O
with O
3 O
, O
3 O
' O
- O
dihexyloxacarbocyanine O
iodide O
, O
protein O
disulfide O
isomerase O
, O
and O
calnexin O
, O
as O
well O
as O
subcellular O
fractionation O
analyses O
. O

In O
addition O
, O
coexpression O
with O
NS4A O
dramatically O
increased O
the O
intracellular O
stability O
of O
NS3 O
( O
mean O
protein O
half O
- O
life O
of O
26 O
versus O
3 O
h O
) O
and O
allowed O
for O
NS4A O
- O
dependent O
trans O
- O
cleavage O
at O
the O
NS4B O
- O
NS5A O
junction O
. O

Six O
donor O
- O
recipient O
clusters O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
infected O
individuals O
were O
studied O
. O

Reactivity O
of O
antibody O
against O
the O
first B
hypervariable I
region I
( I
HVR1 I
) I
of O
HCV O
in O
donor O
and O
recipient O
sera O
was O
evaluated O
and O
correlated O
to O
the O
calculated O
evolutionary O
rate O
. O

The O
induction O
of O
strong O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
and O
humoral O
responses O
appear O
to O
be O
essential O
for O
the O
elimination O
of O
persistently O
infecting O
viruses O
, O
such O
as O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

This O
combined O
vaccine O
regimen O
augments O
E2 O
- O
specific O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
and O
CD8 O
( O
+ O
) O
CTL O
responses O
to O
a O
greater O
extent O
than O
immunizations O
with O
recombinant O
E2 O
protein O
and O
E2 O
DNA O
alone O
, O
respectively O
. O

Furthermore O
, O
the O
enhanced O
CD8 O
( O
+ O
) O
CTL O
and O
IgG2a O
responses O
induced O
by O
our O
combined O
vaccine O
regimens O
are O
closely O
associated O
with O
the O
protection O
of O
BALB O
/ O
c O
mice O
from O
challenge O
with O
modified O
CT26 O
tumor O
cells O
expressing O
HCV O
E2 O
protein O
. O

Using O
targeted O
RNA O
recombination O
, O
we O
constructed O
a O
mutant O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
in O
which O
the O
ectodomain O
of O
the O
Spike B
glycoprotein I
( I
S I
) I
was O
replaced O
with O
the O
highly O
divergent O
ectodomain O
of O
the O
S O
protein O
of O
feline O
infectious O
peritonitis O
virus O
. O

Infection O
of O
C57BL O
/ O
6 O
mice O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
results O
in O
a O
demyelinating O
encephalomyelitis O
characterized O
by O
mononuclear O
cell O
infiltration O
and O
white O
matter O
destruction O
similar O
to O
the O
pathology O
of O
the O
human O
demyelinating O
disease O
multiple O
sclerosis O
, O
The O
contributions O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
pathogenesis O
of O
the O
disease O
were O
investigated O
. O

Significantly O
less O
severe O
inflammation O
and O
demyelination O
were O
observed O
in O
CD4 O
( O
- O
/ O
- O
) O
mice O
than O
in O
CD8 O
( O
- O
/ O
- O
) O
and O
C57BL O
/ O
6 O
mice O
( O
P O
less O
than O
or O
equal O
to O
0 O
. O

Immunophenotyping O
of O
central B
nervous I
system I
( I
CNS I
) I
infiltrates O
revealed O
that O
CD4 O
( O
- O
/ O
- O
) O
mice O
had O
a O
significant O
reduction O
in O
numbers O
of O
activated O
macrophages O
/ O
microglial O
cells O
in O
the O
brain O
compared O
to O
the O
numbers O
in O
CD8 O
( O
- O
/ O
- O
) O
and O
C57BL O
/ O
6 O
mice O
, O
indicating O
a O
role O
for O
these O
cells O
in O
myelin O
destruction O
. O

Furthermore O
, O
CD4 O
( O
- O
/ O
- O
) O
mice O
displayed O
lower O
levels O
of O
RANTES O
( O
a O
C O
- O
C O
chemokine O
) O
mRNA O
transcripts O
and O
protein O
, O
suggesting O
a O
role O
for O
this O
molecule O
in O
the O
pathogenesis O
of O
MEN O
- O
induced O
neurologic O
disease O
. O

These O
data O
indicate O
that O
CD4 O
( O
+ O
) O
T O
cells O
have O
a O
pivotal O
role O
in O
accelerating O
CNS O
inflammation O
and O
demyelination O
within O
infected O
mice O
, O
possibly O
by O
regulating O
RANTES O
expression O
, O
which O
in O
turn O
coordinates O
the O
trafficking O
of O
macrophages O
into O
the O
CNS O
, O
leading O
to O
myelin O
destruction O
. O

Newly O
discovered O
TT B
virus I
( I
TTV I
) I
is O
widely O
distributed O
in O
human O
populations O
. O

TTV O
DNA O
was O
detected O
in O
87 O
of O
98 O
( O
89 O
% O
) O
chimpanzees O
and O
3 O
of O
21 O
( O
14 O
% O
) O
crab O
- O
eating O
macaques O
. O

From O
these O
results O
, O
we O
tentatively O
named O
this O
TTV O
simian B
TTV I
( I
s I
- I
TTV I
) I
. O

To O
this O
aim O
, O
He O
used O
the O
virus B
- I
like I
particle I
( I
VLP I
) I
system O
that O
, O
ve O
developed O
earlier O
for O
the O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
and O
, O
which O
we O
describe O
now O
also O
for O
the O
unrelated O
coronavirus O
feline O
infectious O
peritonitis O
virus O
( O
FIPV O
; O
strain O
79 O
- O
1146 O
) O
. O

Thus O
, O
the O
64 O
- O
terminal O
- O
residue O
sequence O
suffices O
to O
draw O
the O
1308 O
( O
MHV O
) O
- O
or O
1433 O
( O
FIPV O
) O
- O
amino O
- O
acid O
- O
long O
mature O
S O
protein O
into O
VLPs O
. O

Persistent O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
major O
cause O
of O
chronic O
liver O
dysfunction O
in O
humans O
and O
is O
epidemiologically O
protein O
has O
been O
reported O
to O
be O
implicated O
in O
cell O
growth O
regulation O
both O
in O
vitro O
and O
in O
vivo O
, O
although O
mechanisms O
explaining O
those O
effects O
are O
still O
unclear O
. O

Helicase B
/ I
nucleoside I
triphosphatase I
( I
NTPase I
) I
motifs O
have O
been O
identified O
in O
many O
RNA O
virus O
genomes O
. O

To O
determine O
the O
role O
of O
the O
NS3 O
helicase O
/ O
NTPase O
in O
the O
viral O
life O
cycle O
, O
deletion O
and O
point O
mutations O
in O
the O
helicase O
/ O
NTPase O
motifs O
of O
the O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
( O
NADL O
strain O
) O
NS3 O
protein O
designed O
to O
abolish O
either O
helicase O
activity O
alone O
( O
motif O
II O
, O
DBY O
( O
H O
) O
under O
bar O
to O
DEY O
( O
A O
) O
under O
bar O
) O
or O
both O
NTPase O
and O
helicase O
activity O
( O
motif O
I O
, O
G O
( O
K O
) O
under O
bar O
T O
to O
G O
( O
A O
) O
under O
bar O
T O
and O
deletion O
of O
motif O
VI O
) O
were O
generated O
. O

The O
C O
- O
terminal O
domain O
of O
NS3 O
( O
BVDV O
amino O
acids O
1854 O
to O
2362 O
) O
of O
these O
mutants O
and O
wild O
type O
was O
expressed O
in O
bacteria O
, O
purified O
, O
and O
assayed O
for O
RNA O
helicase O
and O
ATPase O
activity O
. O

When O
engineered O
back O
into O
an O
infectious O
cDNA O
for O
BVDV O
( O
NADL O
strain O
) O
, O
point O
mutations O
in O
either O
the O
GKT O
or O
DEYH O
motif O
or O
deletion O
of O
motif O
VI O
yielded O
RNA O
transcripts O
that O
no O
longer O
produced O
infectious O
virus O
upon O
transfection O
of O
EBTr O
cells O
. O

RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
encoded O
by O
positive O
- O
strand O
RNA O
viruses O
is O
critical O
to O
the O
replication O
of O
viral O
RNA O
genome O
. O

Like O
other O
positive O
- O
strand O
RNA O
viruses O
, O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
is O
mediated O
through O
a O
negative O
- O
strand O
intermediate O
, O
which O
is O
generated O
through O
copying O
the O
positive O
- O
strand O
genomic O
RNA O
. O

The O
NS5B O
used O
HCV O
3 O
' O
X O
- O
tail O
RNA O
( O
98 O
nucleotides O
) O
as O
the O
template O
to O
synthesize O
an O
RNA O
product O
of O
monomer O
size O
, O
which O
can O
be O
labeled O
by O
[ O
gamma O
- O
P O
- O
32 O
] O
nucleoside O
triphosphate O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
widespread O
major O
human O
health O
concern O
, O
Significant O
obstacles O
in O
the O
study O
of O
this O
virus O
include O
the O
absence O
of O
a O
reliable O
tissue O
culture O
system O
and O
a O
small O
- O
animal O
model O
. O

A O
region O
of O
the O
bovine B
coronavirus I
( I
BCV I
) I
genome O
that O
functions O
as O
a O
packaging O
signal O
has O
been O
cloned O
, O
The O
291 O
- O
nucleotide O
clone O
shares O
72 O
% O
homology O
with O
the O
region O
of O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
gene O
Ib O
that O
contains O
the O
packaging O
signal O
. O

The O
E2 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
believed O
to O
be O
a O
virion O
surface O
glycoprotein O
that O
is O
a O
candidate O
for O
inclusion O
in O
an O
antiviral O
vaccine O
. O

To O
analyze O
the O
specificity O
of O
interaction O
between O
E2 O
and O
CD81 O
, O
the O
aggregated O
and O
monomeric O
forms O
of O
a O
truncated O
E2 O
glycoprotein O
( O
E2 O
( O
661 O
) O
) O
were O
separated O
by O
high O
- O
pressure O
liquid O
chromatography O
and O
analyzed O
for O
CD81 O
binding O
. O

Nonaggregated O
forms O
of O
E2 O
preferentially O
bound O
CD81 O
and O
a O
number O
of O
conformation O
- O
dependent O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

Furthermore O
, O
intracellular O
forms O
of O
E2 O
( O
661 O
) O
were O
found O
to O
bind O
CD81 O
with O
greater O
affinity O
than O
the O
extracellular O
forms O
. O

Intracellular O
and O
secreted O
forms O
of O
E2 O
( O
661 O
) O
were O
also O
found O
to O
differ O
in O
reactivity O
with O
MAbs O
and O
human O
sera O
, O
consistent O
with O
differences O
in O
antigenicity O
. O

The O
quasispecies O
nature O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
thought O
to O
play O
a O
central O
role O
in O
maintaining O
and O
modulating O
viral O
replication O
. O

Patients O
with O
HCV O
quasispecies O
in O
serum O
more O
complex O
( O
26 O
% O
) O
than O
, O
less O
complex O
( O
28 O
% O
) O
than O
, O
or O
similarly O
complex O
( O
41 O
% O
) O
to O
those O
in O
liver O
were O
found O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS5B O
protein O
possesses O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
, O
a O
major O
function O
responsible O
for O
replication O
of O
the O
viral O
RNA O
genome O
. O

As O
a O
result O
, O
a O
highly O
active O
NS5B O
RdRp O
( O
lb O
- O
42 O
) O
, O
which O
contains O
an O
18 O
- O
amino O
acid O
C O
- O
terminal O
truncation O
resulting O
from O
a O
newly O
created O
stop O
codon O
, O
was O
identified O
among O
a O
number O
of O
independent O
isolates O
. O

One O
is O
a O
complementary O
RNA O
identical O
in O
size O
to O
the O
input O
RNA O
template O
( O
monomer O
) O
, O
while O
the O
other O
is O
a O
hairpin O
dimer O
RNA O
synthesized O
by O
a O
copy O
- O
back O
mechanism O
. O

Moreover O
, O
synthesis O
of O
RNA O
on O
poly O
( O
C O
) O
and O
poly O
( O
U O
) O
homopolymer O
templates O
by O
lb O
- O
42 O
NS5B O
did O
not O
require O
the O
oligonucleotide O
primer O
at O
high O
concentrations O
( O
greater O
than O
or O
equal O
to O
50 O
mu O
M O
) O
of O
GTP O
and O
ATP O
, O
further O
supporting O
a O
de O
novo O
initiation O
mechanism O
. O

However O
, O
the O
pathogenesis O
of O
liver O
injury O
resulting O
from O
chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
not O
well O
understood O
. O

For O
the O
current O
study O
, O
both O
genomic O
( O
sense O
) O
and O
replicative O
- O
intermediate O
( O
antisense O
) O
HCV O
RNAs O
were O
detected O
and O
quantified O
in O
8 O
of O
8 O
liver O
tissue O
specimens O
from O
infected O
patients O
versus O
0 O
of O
11 O
liver O
tissue O
specimens O
from O
noninfected O
controls O
. O

In O
1997 O
, O
a O
devastating O
outbreak O
of O
foot B
- I
and I
- I
mouth I
disease I
( I
FMD I
) I
in O
Taiwan O
was O
caused O
by O
a O
serotype O
O O
virus O
( O
referred O
to O
here O
as O
OTai O
) O
with O
atypical O
virulence O
. O

lThe O
orchestrated O
liberation O
of O
viral O
proteins O
by O
3C B
( I
pro I
) I
- O
mediated O
proteolysis O
is O
pivotal O
for O
gene O
expression O
by O
picornaviruses O
. O

To O
determine O
the O
role O
of O
the O
amino O
acid O
sequence O
at O
cleavage O
sites O
3A O
/ O
3B O
and O
3B O
/ O
3C O
that O
are O
essential O
for O
the O
liberation O
of O
3C B
( I
pro I
) I
from O
its O
precursors O
and O
to O
assess O
the O
function O
of O
the O
stable O
processing O
intermediates O
3AB O
and O
3ABC O
, O
we O
studied O
the O
effect O
of O
cleavage O
site O
mutations O
on O
hepatitis B
A I
virus I
( I
HAV I
) I
polyprotein O
processing O
, O
particle O
formation O
, O
and O
replication O
. O

The O
nonstructural O
protein O
NS5A O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
demonstrated O
to O
be O
a O
phosphoprotein O
with O
an O
apparent O
molecular O
mass O
of O
56 O
kDa O
. O

In O
the O
presence O
of O
other O
viral O
proteins O
, O
p56 O
is O
converted O
into O
a O
slower O
- O
migrating O
form O
of O
NSSA O
( O
p58 O
) O
by O
additional O
phosphorylation O
events O
. O

In O
this O
report O
, O
we O
show O
that O
the O
presence O
of O
NS3 O
, O
NS4A O
, O
and O
NS4B O
together O
with O
NSSA O
is O
necessary O
and O
sufficient O
for O
the O
generation O
of O
the O
hyperphosphorylated O
form O
of O
NSSA O
( O
p58 O
) O
and O
that O
all O
proteins O
must O
be O
encoded O
on O
the O
same O
polyprotein O
( O
in O
cis O
) O
. O

Two O
pairs O
of O
Sindbis B
virus I
( I
SV I
) I
variants O
that O
differ O
in O
their O
neuroinvasive O
and O
neurovirulent O
traits O
in O
mice O
have O
been O
isolated O
. O

The O
genetic O
determinants O
responsible O
for O
the O
pathogenic O
properties O
of O
SVNI O
were O
mapped O
to O
the O
E2 O
glycoprotein O
and O
the O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
. O

Substitution O
of O
two O
amino O
acids O
in O
SVN O
E2 O
with O
the O
corresponding O
residues O
of O
SVNI O
( O
Met O
- O
190 O
and O
Lys O
- O
260 O
) O
led O
to O
paralysis O
in O
3 O
- O
and O
5 O
- O
week O
- O
old O
rats O
. O

More O
dramatically O
, O
a O
single O
substitution O
in O
the O
5 O
' O
NCR O
of O
SVN O
( O
G O
at O
position O
8 O
) O
transformed O
the O
virus O
into O
a O
lethal O
pathogen O
for O
3 O
- O
week O
- O
old O
rats O
like O
SVNI O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
requires O
both O
the O
cellular O
RNA O
polymerase O
and O
one O
virus O
- O
encoded O
protein O
, O
small O
delta O
antigen O
( O
S O
- O
HDAg O
) O
, O
S O
- O
HDAg O
has O
been O
shown O
to O
be O
a O
phosphoprotein O
, O
but O
its O
phosphorylation O
status O
is O
not O
yet O
clear O
. O

By O
carefully O
adjusting O
the O
pH O
of O
solubilization O
solution O
, O
the O
ampholyte O
composition O
, O
and O
the O
appropriate O
electrophoresis O
time O
periods O
, O
we O
were O
able O
to O
clearly O
resolve O
S O
- O
HDAg O
into O
two O
phosphorylated O
isoforms O
and O
one O
unphosphorylated O
form O
, O
In O
contrast O
, O
the O
viral O
large O
delta O
antigen O
( O
L O
- O
HDAg O
) O
can O
only O
be O
separated O
into O
one O
phosphorylated O
and O
one O
unphosphorylated O
form O
, O
By O
metabolic O
P O
- O
32 O
labeling O
, O
both O
immunoprecipitated O
S O
- O
HDAg O
and O
L O
- O
HD O
, O
Sg O
were O
found O
to O
incorporate O
radioactive O
phosphate O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
RNA O
transcription O
is O
regulated O
mainly O
by O
the O
leader O
and O
intergenic O
( O
IG O
) O
sequences O
. O

However O
, O
a O
previous O
study O
has O
shown O
that O
the O
3 B
' I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
of O
the O
viral O
genome O
is O
also O
required O
for O
subgenomic O
mRNA O
transcription O
; O
deletion O
of O
nucleotides B
( I
nt I
) I
270 O
to O
305 O
from O
the O
3 O
' O
- O
UTR O
completely O
abolished O
subgenomic O
mRNA O
transcription O
without O
affecting O
minus O
- O
strand O
RNA O
synthesis O
( O
Y O
. O

The O
major O
protein O
species O
, O
p55 O
, O
was O
identified O
as O
the O
polypyrimidine O
tract O
- O
binding O
protein O
( O
PTB O
, O
also O
known O
as O
heterogeneous O
nuclear O
RNP O
I O
) O
by O
immunoprecipitation O
of O
the O
W O
- O
cross O
- O
linked O
protein O
and O
binding O
of O
the O
recombinant O
PTB O
. O

A O
strong O
PTB O
- O
binding O
site O
was O
mapped O
to O
nt O
53 O
to O
149 O
, O
and O
another O
weak O
binding O
site O
was O
mapped O
to O
nt O
270 O
to O
307 O
on O
the O
complementary O
strand O
of O
the O
3 O
' O
- O
UTR O
( O
c3 O
' O
- O
UTR O
) O
, O
Partial O
substitutions O
of O
the O
PTB O
- O
binding O
nucleotides O
reduced O
PTB O
binding O
in O
vitro O
. O

Furthermore O
, O
Defective B
interfering I
( I
DI I
) I
RNAs O
harboring O
these O
mutations O
showed O
a O
substantially O
reduced O
ability O
to O
synthesize O
subgenomic O
mRNA O
. O

The O
existence O
of O
an O
extrahepatic O
reservoir O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
suggested O
by O
differences O
in O
quasispecies O
composition O
between O
the O
liver O
, O
peripheral O
blood O
mononuclear O
cells O
, O
and O
serum O
. O

We O
studied O
HCV O
RNA O
compartmentalization O
in O
the O
plasma O
of O
nine O
patients O
, O
in O
CD19 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
and O
CD4 O
( O
+ O
) O
positively O
selected O
cells O
, O
and O
also O
in O
the O
negatively O
selected O
cell O
fraction O
( O
NF O
) O
. O

HCV O
RNA O
was O
detected O
in O
all O
plasma O
samples O
, O
in O
seven O
of O
nine O
CD19 O
( O
+ O
) O
, O
three O
of O
eight O
CD8 O
+ O
, O
and O
one O
of O
nine O
CD4 O
( O
+ O
) O
cell O
samples O
, O
and O
in O
seven O
of O
eight O
NF O
cells O
. O

Cloning O
and O
sequencing O
of O
HVR1 O
in O
two O
patients O
showed O
a O
sequence O
grouping O
: O
quasispecies O
from O
a O
given O
compartment O
( O
all O
studied O
compartments O
for O
one O
patient O
and O
CD8 O
( O
+ O
) O
and O
NF O
for O
the O
other O
) O
were O
statistically O
more O
genetically O
like O
each O
other O
than O
like O
quasispecies O
from O
any O
other O
compartment O
. O

During O
the O
life O
cycle O
of O
the O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
, O
two O
types O
of O
virus O
- O
related O
particles O
are O
detected O
in O
infected O
swine O
testis O
cells O
: O
large O
annular O
viruses O
and O
small O
dense O
viruses O
. O

Secondary O
and O
tertiary O
structures O
in O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
plus O
- O
strand O
RNA O
viruses O
have O
been O
postulated O
to O
function O
as O
control O
elements O
in O
RNA O
replication O
, O
transcription O
, O
and O
translation O
. O

Here O
we O
describe O
a O
M O
- O
nucleotide B
( I
nt I
) I
hairpin O
- O
type O
pseudoknot O
within O
the O
288 O
- O
nt O
3 O
' O
UTR O
of O
the O
bovine O
coronavirus O
genome O
and O
show O
by O
mutational O
analysis O
of O
both O
stems O
that O
the O
pseudoknotted O
structure O
is O
required O
for O
the O
replication O
of O
a O
defective O
interfering O
RNA O
genome O
. O

We O
previously O
reported O
that O
Daudi O
cells O
, O
a O
Burkitt O
' O
s O
lymphoma O
cell O
line O
, O
were O
capable O
of O
supporting O
productive O
infection O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
During O
continual O
cultivation O
after O
HCV O
infection O
, O
the O
culture O
became O
resistant O
to O
Interferons B
( I
IFNs I
) I
, O
This O
resistant O
cell O
line O
, O
coded O
as O
H O
- O
903 O
, O
was O
used O
as O
host O
cells O
for O
replication O
of O
GB B
virus I
C I
( I
GBV I
- I
C I
) I
, O
also O
known O
as O
hepatitis O
G O
virus O
. O

The O
NS3 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
bifunctional O
protein O
containing O
a O
serine O
protease O
in O
the O
N O
- O
terminal O
one O
- O
third O
, O
which O
is O
stimulated O
upon O
binding O
of O
the O
NS4A O
cofactor O
, O
and O
an O
RNA O
helicase O
in O
the O
C O
- O
terminal O
two O
- O
thirds O
. O

Recently O
, O
we O
published O
an O
X O
- O
ray O
crystallographic O
structure O
of O
a O
binary O
complex O
of O
the O
HCV O
helicase O
with O
a O
( O
dU O
) O
( O
8 O
) O
oligonucleotide O
, O
in O
which O
several O
conserved O
residues O
of O
the O
HCV O
helicase O
were O
shown O
to O
be O
involved O
in O
interactions O
between O
the O
HCV O
helicase O
and O
oligonucleotide O
, O
Here O
, O
site O
- O
directed O
mutagenesis O
was O
used O
to O
elucidate O
the O
roles O
of O
these O
residues O
in O
helicase O
function O
. O

Four O
individual O
mutations O
, O
Thr O
to O
Ala O
at O
position O
269 O
, O
Thr O
to O
Ala O
at O
position O
411 O
, O
Trp O
to O
Leu O
at O
: O
position O
501 O
, O
and O
Trp O
to O
Ala O
at O
position O
501 O
, O
produced O
a O
severe O
reduction O
of O
RNA O
binding O
and O
completely O
abolished O
unwinding O
activity O
and O
stimulation O
of O
ATPase O
activity O
by O
poly O
( O
U O
) O
, O
although O
the O
basal O
ATPase O
activity O
( O
activity O
in O
the O
absence O
of O
polynucleotide O
) O
of O
these O
mutants O
remained O
intact O
. O

Interestingly O
, O
ATPase O
activity O
of O
this O
mutant O
became O
less O
responsive O
to O
stimulation O
by O
poly O
( O
U O
) O
But O
not O
to O
stimulation O
by O
other O
polynucleotides O
, O
such O
as O
poly O
( O
C O
) O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
treatment O
is O
effective O
on O
a O
long O
- O
term O
basis O
in O
only O
15 O
to O
25 O
% O
of O
patients O
with O
chronic O
hepatitis O
C O
, O
The O
results O
of O
recent O
trials O
indicate O
that O
response O
rates O
can O
be O
significantly O
increased O
when O
IFN O
- O
alpha O
is O
given O
in O
combination O
with O
ribavirin O
, O
However O
, O
a O
large O
number O
of O
patients O
do O
not O
respond O
even O
to O
combination O
therapy O
. O

Nonresponsiveness O
to O
IFN O
is O
characterized O
by O
evolution O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
quasispecies O
. O

In O
the O
present O
study O
we O
have O
examined O
the O
genetic O
divergence O
of O
HCV O
quasispecies O
during O
unsuccessful O
retreatment O
with O
IFN O
or O
IFN O
plus O
ribavirin O
, O
Fifteen O
nonresponder O
patients O
with O
HCV O
- O
1 O
( O
4 O
patients O
with O
HCV O
- O
1a O
and O
11 O
patients O
with O
HCV O
- O
lb O
) O
infection O
were O
studied O
while O
being O
retreated O
for O
2 O
months O
( O
phase O
1 O
) O
with O
IFN O
- O
alpha O
( O
6 O
MU O
given O
three O
times O
a O
week O
) O
, O
followed O
by O
IFN O
plus O
ribavirin O
or O
IFN O
alone O
for O
an O
additional O
6 O
months O
( O
phase O
2 O
) O
. O

HCV O
quasispecies O
diversification O
in O
the O
E2 O
hypervariable B
region I
- I
1 I
( I
HVR1 I
) I
and O
in O
the O
putative O
NS5A O
IFN B
sensitivity I
determining I
region I
( I
ISDR I
) I
were O
analyzed O
for O
phase O
1 O
and O
phase O
2 O
by O
using O
the O
heteroduplex O
tracking O
assay O
and O
clonal O
frequency O
analysis O
techniques O
. O

The O
ability O
of O
DNA O
vaccination O
to O
induce O
antibodies O
directed O
at O
such O
structures O
was O
investigated O
by O
using O
eight O
different O
expression O
plasmids O
engineered O
either O
to O
favor O
or O
to O
prevent O
interaction O
between O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoproteins O
E1 O
and O
E2 O
. O

Independently O
of O
the O
injection O
route O
( O
intramuscular O
or O
intraepidermal O
) O
, O
plasmids O
expressing O
antigens O
capable O
of O
forming O
heterodimers O
presumed O
to O
be O
the O
prebudding O
form O
of O
the O
HCV O
envelope O
protein O
complex O
: O
failed O
to O
induce O
any O
significant O
, O
stable O
antibodies O
following O
injection O
in O
mice O
. O

In O
addition O
, O
only O
a O
truncated O
form O
of O
E2 O
induced O
antibodies O
reacting O
against O
the O
hypervariable O
region O
1 O
of O
E2 O
( O
specifically O
with O
the O
C O
- O
terminal O
part O
of O
it O
) O
known O
to O
contain O
a O
neutralization O
site O
. O

Most O
eukaryotic B
initiation I
factors I
( I
eIFs I
) I
are O
required O
for O
internal O
translation O
initiation O
at O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
picornaviruses O
. O

eIF4B O
is O
incorporated O
into O
ribosomal O
48S O
initiation O
complexes O
with O
the O
IRES O
RNA O
of O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
. O

The O
aim O
of O
the O
present O
study O
was O
to O
define O
the O
site O
of O
replication O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

Antibodies O
directed O
against O
several O
proteins O
derived O
from O
the O
gene O
1 O
polyprotein O
, O
including O
the O
3C B
- I
like I
protease I
( I
3CLpro I
) I
, O
the O
putative B
polymerase I
( I
POL I
) I
, O
helicase O
, O
and O
a O
recently O
described O
protein O
( O
p22 O
) O
derived O
from O
the O
C O
terminus O
of O
the O
open O
reading O
frame O
la O
protein O
( O
CT1a O
) O
, O
were O
used O
to O
probe O
MHV O
- O
infected O
cells O
by O
indirect O
immunofluorescence B
( I
IF I
) I
and O
electron B
microscopy I
( I
EM I
) I
. O

When O
infected O
cells O
were O
metabolically O
labeled O
with O
5 O
- O
bromouridine O
5 O
' O
- O
triphosphate O
( O
BrUTP O
) O
, O
the O
site O
of O
viral O
RNA O
synthesis O
was O
shown O
by O
IF O
to O
colocalize O
with O
CT1a O
and O
the O
3CLpro O
. O

All O
of O
the O
previously O
reported O
recombinant O
RNA B
- I
dependent I
RNA I
polymerases I
( I
RdRp I
) I
, O
the O
NS5B O
enzymes O
, O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
could O
function O
only O
in O
a O
primer O
- O
dependent O
and O
template O
- O
nonspecific O
manner O
, O
which O
is O
different O
from O
the O
expected O
properties O
of O
the O
functional O
viral O
enzymes O
in O
the O
cells O
. O

This O
RdRp O
was O
also O
able O
to O
accept O
heterologous O
viral O
RNA O
templates O
, O
including O
poly O
( O
A O
) O
- O
and O
non O
- O
poly O
( O
A O
) O
- O
tailed O
RNA O
, O
in O
a O
primer O
- O
independent O
manner O
, O
but O
the O
products O
in O
these O
cases O
were O
heterogeneous O
. O

By O
using O
the O
3 O
' O
- O
end O
98 O
nucleotides B
( I
nt I
) I
of O
HCV O
RNA O
, O
which O
is O
conserved O
in O
all O
genotypes O
of O
HCV O
, O
as O
a O
template O
, O
a O
distinct O
RNA O
product O
was O
generated O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
spike O
glycoprotein O
, O
S O
, O
has O
been O
implicated O
as O
a O
major O
determinant O
of O
viral O
pathogenesis O
. O

Relative O
to O
wild O
- O
type O
control O
recombinant O
viruses O
( O
wtR13 O
and O
wtR9 O
) O
, O
containing O
the O
MHV O
- O
A59 O
S O
gene O
, O
the O
MHV4 O
S O
gene O
recombinants O
exhibited O
a O
dramatic O
increase O
in O
virulence O
and O
an O
increase O
in O
both O
viral O
antigen O
staining O
and O
inflammation O
in O
the O
central O
nervous O
system O
, O
There O
was O
not O
, O
however O
, O
an O
increase O
in O
the O
level O
of O
viral O
replication O
in O
the O
brain O
. O

Tomato B
bushy I
stunt I
virus I
( I
TBSV I
) I
cDNA O
, O
positioned O
between O
a O
modified O
cauliflower O
mosaic O
virus O
35S O
promoter O
and O
the O
hepatitis O
delta O
virus O
antigenomic O
ribozyme O
with O
a O
downstream O
nopaline O
synthase O
gene O
polyadenylation O
signal O
, O
established O
infections O
upon O
rub O
- O
inoculation O
of O
plants O
with O
intact O
plasmids O
. O

The O
guanosine O
analogue O
ribavirin O
was O
tested O
for O
antiviral O
activity O
in O
two O
neural O
cell O
lines O
, O
human O
oligodendrocytes O
and O
rat O
glia O
, O
against O
Borna B
disease I
virus I
( I
BDV I
) I
strains O
V O
and O
He O
/ O
80 O
. O

Most O
details O
of O
the O
processing O
of O
the O
hepatitis B
A I
virus I
( I
HAV I
) I
polyprotein O
are O
known O
. O

Unique O
among O
members O
of O
the O
family O
Picornaviridae O
, O
the O
primary O
cleavage O
of O
the O
HAV O
polyprotein O
is O
mediated O
by O
3C B
( I
pro I
) I
, O
the O
only O
proteinase O
known O
to O
be O
encoded O
by O
the O
virus O
, O
at O
the O
2A O
/ O
2B O
junction O
, O
All O
other O
cleavages O
of O
the O
polyprotein O
have O
been O
considered O
to O
be O
due O
to O
3C B
( I
pro I
) I
, O
although O
the O
precise O
location O
and O
mechanism O
responsible O
for O
the O
VP1 O
/ O
2A O
cleavage O
have O
been O
controversial O
. O

Here O
we O
present O
data O
that O
argue O
strongly O
against O
the O
involvement O
of O
the O
HAV O
3C B
( I
pro I
) I
proteinase O
in O
the O
maturation O
of O
VP1 O
from O
its O
VP1 O
- O
2A O
precursor O
. O

Using O
a O
heterologous O
expression O
system O
based O
on O
recombinant O
vaccinia O
viruses O
directing O
the O
expression O
of O
full O
- O
length O
or O
truncated O
capsid O
protein O
precursors O
, O
we O
show O
that O
the O
C O
terminus O
of O
the O
mature O
VP1 O
capsid O
protein O
is O
located O
near O
residue O
764 O
of O
the O
polyprotein O
, O
However O
, O
a O
proteolytically O
active O
HAV O
3C B
( I
pro I
) I
that O
was O
capable O
of O
directing O
both O
VP0 O
/ O
VP3 O
and O
VP3 O
/ O
VP1 O
cleavages O
in O
vaccinia O
virus O
- O
infected O
cells O
failed O
to O
process O
the O
VP1 O
- O
2A O
precursor O
. O

Using O
site O
- O
directed O
mutagenesis O
of O
an O
infectious O
molecular O
clone O
of O
HAV O
, O
me O
modified O
potential O
VP1 O
/ O
2A O
cleavage O
sites O
that O
fit O
known O
3C B
( I
pro I
) I
recognition O
criteria O
and O
found O
that O
a O
substitution O
that O
ablates O
the O
presumed O
3C B
( I
pro I
) I
dipeptide O
recognition O
sequence O
at O
Glu O
( O
764 O
) O
- O
Ser O
( O
765 O
) O
abolished O
neither O
infectivity O
nor O
normal O
VP1 O
maturation O
, O
Altered O
electrophoretic O
mobility O
of O
VP1 O
from O
a O
viable O
mutant O
virus O
with O
an O
Arg O
( O
764 O
) O
substitution O
indicated O
that O
this O
residue O
is O
present O
in O
VP1 O
and O
that O
the O
VP1 O
/ O
2A O
cleavage O
occurs O
downstream O
of O
this O
residue O
. O

These O
data O
indicate O
that O
maturation O
of O
the O
HAV O
VP1 O
capsid O
protein O
is O
not O
dependent O
on O
3C B
( I
pro I
) I
processing O
and O
may O
thus O
be O
uniquely O
dependent O
on O
a O
cellular O
proteinase O
. O

Mice O
infected O
with O
the O
neurotropic O
coronavirus O
Mouse B
hepatitis I
virus I
strain I
JHM I
( I
MHV I
- I
JHM I
) I
develop O
a O
chronic O
demyelinating O
disease O
with O
symptoms O
of O
hindlimb O
paralysis O
. O

Sustained O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
clearance O
is O
achieved O
in O
8 O
to O
12 O
% O
of O
patients O
with O
chronic O
HCV O
infection O
treated O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
at O
the O
approved O
dose O
of O
3 O
MU O
three O
times O
a O
week O
for O
6 O
months O
and O
in O
about O
25 O
% O
of O
those O
receiving O
this O
treatment O
for O
12 O
months O
. O

We O
used O
single O
- O
strand O
conformation O
polymorphism O
analysis O
combined O
with O
cloning O
and O
sequencing O
strategies O
to O
characterize O
the O
genetic O
evolution O
of O
HCV O
second O
envelope O
gene O
hypervariable B
region I
1 I
( I
HVR1 I
) I
quasispecies O
during O
and O
after O
IFN O
therapy O
in O
patients O
who O
failed O
to O
clear O
HCV O
RNA O
. O

The O
genome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
1 O
, O
679 O
- O
nucleotide B
( I
nt I
) I
single O
- O
stranded O
circular O
RNA O
that O
is O
predicted O
to O
fold O
into O
an O
unbranched O
rodlike O
structure O
. O

The O
analyzed O
RNAs O
were O
from O
the O
liver O
of O
an O
infected O
woodchuck O
and O
from O
a O
liver O
cell O
line O
at O
6 O
days O
after O
transfection O
with O
either O
an O
HDV O
cDNA O
or O
ribonucleoprotein B
( I
RNP I
) I
complexes O
assembled O
in O
vitro O
with O
HDV O
genomic O
RNA O
and O
purified O
recombinant O
small O
delta O
protein O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
El O
and O
E2 O
, O
when O
expressed O
in O
eukaryotic O
cells O
, O
are O
retained O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

C O
- O
terminal O
truncation O
of O
E2 O
at O
residue O
661 O
or O
715 O
( O
position O
on O
the O
polyprotein O
) O
leads O
to O
secretion O
, O
consistent O
with O
deletion O
of O
a O
proposed O
hydrophobic O
transmembrane O
anchor O
sequence O
. O

We O
demonstrate O
cell O
surface O
expression O
of O
a O
chimeric O
glycoprotein O
consisting O
of O
E2 O
residues O
384 O
to O
661 O
fused O
to O
the O
transmembrane O
and O
cytoplasmic O
domains O
of O
influenza O
A O
virus O
Hemagglutinin B
( I
HA I
) I
, O
termed O
E2 O
( O
661 O
) O
- O
HA O
( O
TMCT O
) O
. O

The O
E2 O
( O
661 O
) O
- O
HA O
( O
TMCT O
) O
chimeric O
glycoprotein O
was O
able O
to O
bind O
a O
number O
of O
conformation O
- O
dependent O
monoclonal O
antibodies O
and O
a O
recombinant O
soluble O
form O
of O
CD81 O
, O
suggesting O
that O
: O
it O
was O
folded O
in O
a O
manner O
comparable O
to O
native O
E2 O
. O

Furthermore O
, O
cell O
surface O
- O
expressed O
E2 O
( O
661 O
) O
- O
HA O
( O
TMCT O
) O
demonstrated O
pH O
- O
dependent O
changes O
in O
antigen O
conformation O
, O
consistent O
with O
an O
acid O
- O
mediated O
fusion O
mechanism O
, O
However O
, O
E2 O
( O
661 O
) O
- O
HA O
( O
TMCT O
) O
was O
unable O
to O
induce O
cell O
fusion O
of O
CD81 O
- O
positive O
HEK O
cells O
after O
neutral O
- O
or O
low O
- O
pH O
treatment O
. O

We O
demonstrate O
that O
influenza O
virus O
can O
incorporate O
E2 O
( O
661 O
) O
- O
HA O
( O
TMCT O
) O
into O
particles O
and O
discuss O
experiments O
to O
address O
the O
relevance O
of O
the O
E2 O
- O
CD81 O
interaction O
for O
HCV O
attachment O
and O
entry O
. O

The O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
translates O
its O
replicase O
gene O
( O
gene O
1 O
) O
into O
two O
co O
- O
aminoterminal O
polyproteins O
, O
polyprotein O
la O
and O
polyprotein O
lab O
. O

Antibodies O
directed O
against O
polypeptides O
encoded O
by O
open O
reading O
frame O
Ib O
were O
used O
to O
characterize O
the O
expression O
and O
processing O
of O
the O
MHV O
helicase O
and O
to O
define O
the O
relationship O
of O
helicase O
to O
the O
viral O
Nucleocapsid B
protein I
( I
N I
) I
and O
to O
sites O
of O
viral O
RNA O
synthesis O
in O
MHV O
- O
infected O
cells O
, O
The O
antihelicase O
antibodies O
detected O
a O
67 O
- O
kDa O
protein O
in O
MHV O
- O
infected O
cells O
that O
was O
translated O
and O
processed O
throughout O
the O
virus O
life O
cycle O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
NS5B O
protein O
is O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
capable O
of O
directing O
RNA O
synthesis O
. O

Furthermore O
, O
two O
independent O
RNA B
- I
binding I
domains I
( I
RBDs I
) I
of O
NS5B O
were O
identified O
, O
RBD1 O
, O
from O
amino O
acid O
residues O
83 O
to O
194 O
, O
and O
RBD2 O
, O
from O
residues O
196 O
to O
298 O
, O
Interestingly O
, O
the O
conserved O
motifs O
of O
RNA O
- O
dependent O
RNA O
polymerase O
for O
putative O
RNA O
binding O
( O
220 O
- O
DxxxxD O
- O
225 O
) O
and O
template O
/ O
primer O
position O
( O
282 O
- O
S O
/ O
TGxxxTxxxNS O
/ O
T O
- O
292 O
) O
are O
present O
in O
the O
RBD2 O
. O

The O
recently O
discovered O
hepatitis B
G I
virus I
( I
HGV I
) I
or O
GB B
virus I
C I
( I
GBV I
- I
C I
) I
is O
widely O
distributed O
in O
human O
populations O
, O
and O
homologues O
such O
as O
HGV O
/ O
GBV O
- O
C O
- O
CPZ O
and O
GBV O
- O
A O
are O
found O
in O
a O
variety O
of O
different O
primate O
species O
. O

Comparison O
of O
complete O
coding O
sequences O
( O
8 O
, O
500 O
bases O
) O
of O
different O
genotypes O
of O
HGV O
/ O
GBV O
- O
C O
showed O
an O
excess O
of O
invariant O
synonymous O
sites O
( O
at O
23 O
% O
of O
all O
codons O
) O
compared O
with O
the O
frequency O
expected O
by O
chance O
( O
10 O
% O
) O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
encodes O
a O
single O
polyprotein O
which O
is O
posttranslationally O
processed O
into O
the O
functional O
structural O
and O
nonstructural O
proteins O
. O

Processing O
of O
the O
capsid O
protein O
precursor O
region O
generates O
a O
unique O
intermediate O
, O
PX O
( O
VP1 O
- O
2A O
) O
, O
which O
accumulates O
in O
infected O
cells O
and O
is O
assumed O
to O
serve O
as O
precursor O
to O
VP1 O
found O
in O
virions O
, O
although O
the O
details O
of O
this O
reaction O
have O
not O
been O
determined O
. O

We O
propose O
the O
involvement O
of O
host O
cell O
protease O
( O
s O
) O
in O
the O
production O
of O
HAV O
VP1 O
. O

The O
subgenomic O
mRNAs O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
are O
composed O
of O
a O
leader O
sequence O
, O
identical O
to O
the O
5 O
' O
70 O
nucleotides O
of O
the O
genome O
, O
joined O
at O
distant O
downstream O
sites O
to O
a O
stretch O
of O
sequence O
that O
is O
identical O
to O
the O
3 O
' O
end O
of O
the O
genome O
. O

The O
points O
of O
fusion O
occur O
at O
intergenic B
sequences I
( I
IGSs I
) I
, O
loci O
on O
the O
genome O
that O
contain O
a O
tract O
of O
sequence O
homologous O
to O
the O
3 O
' O
end O
of O
the O
leader O
RNA O
. O

We O
have O
constructed O
a O
mutant O
of O
MHV O
- O
A59 O
containing O
an O
extra O
IGS O
inserted O
into O
the O
genome O
immediately O
downstream O
of O
the O
3 O
' O
- O
most O
gene O
, O
that O
encoding O
the O
nucleocapsid B
( I
N I
) I
protein O
. O

Our O
study O
demonstrates O
that O
( O
i O
) O
an O
IGS O
can O
be O
a O
sufficient O
cis O
- O
acting O
element O
to O
dictate O
MHV O
transcription O
, O
( O
ii O
) O
the O
relative O
efficiency O
of O
an O
IGS O
must O
be O
influenced O
by O
factors O
other O
than O
the O
nucleotides O
immediately O
adjacent O
to O
the O
5 O
' O
AAUCUA O
AAC3 O
' O
core O
consensus O
sequence O
or O
its O
position O
relative O
to O
the O
3 O
' O
end O
of O
the O
genome O
, O
( O
iii O
) O
a O
downstream O
IGS O
can O
exert O
a O
polar O
attenuating O
effect O
on O
upstream O
IGSs O
, O
and O
( O
iv O
) O
unknown O
factors O
prevent O
the O
insertion O
of O
large O
exogenous O
elements O
between O
the O
N O
gene O
and O
the O
3 O
' O
untranslated O
region O
of O
MHV O
. O

By O
comparative O
analysis O
of O
the O
hemagglutinin B
- I
esterase I
( I
HE I
) I
protein O
of O
mouse B
hepatitis I
virus I
strain I
S I
( I
MHV I
- I
S I
) I
and O
the O
HE O
protein O
of O
influenza O
C O
virus O
, O
we O
found O
major O
differences O
in O
substrate O
specificities O
. O

Analysis O
with O
free O
sialic O
acid O
derivatives O
revealed O
that O
the O
MHV O
- O
S O
HE O
protein O
specifically O
de O
- O
O O
- O
acetylates O
5 O
- O
N O
- O
acetyl O
- O
4 O
- O
O O
- O
acetyl O
sialic O
acid O
( O
Neu4 O
, O
5Ac O
( O
2 O
) O
) O
but O
not O
5 O
- O
N O
- O
acetyl O
- O
9 O
- O
O O
- O
acetyl O
sialic O
acid O
( O
Neu5 O
, O
9Ac O
( O
2 O
) O
) O
, O
which O
is O
the O
major O
substrate O
for O
esterases O
of O
influenza O
C O
virus O
and O
bovine O
coronaviruses O
. O

In O
addition O
, O
the O
MHV O
- O
S O
esterase O
converted O
glycosidically O
bound O
Neu4 O
, O
5Ac O
( O
2 O
) O
of O
guinea O
pig O
serum O
glycoproteins O
to O
Neu5Ac O
. O

The O
5 B
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
of O
a O
genotype O
1b O
hepatitis O
C O
virus O
( O
HCV O
- O
N O
) O
directs O
cap O
- O
independent O
translation O
of O
the O
HCV O
- O
N O
polyprotein O
with O
about O
twofold O
less O
efficiency O
than O
the O
5 O
' O
NTR O
of O
a O
genotype O
la O
virus O
under O
physiologic O
conditions O
( O
Hutchinson O
strain O
, O
or O
HCV O
- O
H O
) O
( O
M O
. O

Here O
, O
we O
show O
by O
mutational O
analysis O
that O
substitution O
of O
the O
AG O
dinucleotide O
sequence O
at O
nucleotides B
( I
nt I
) I
34 O
and O
35 O
of O
HCV O
- O
N O
with O
GA O
( O
present O
in O
HCV O
- O
H O
) O
restores O
the O
translational O
activity O
to O
that O
of O
the O
HCV O
- O
H O
5 O
' O
NTR O
both O
in O
vitro O
and O
in O
vivo O
. O

These O
nucleotides O
are O
located O
upstream O
of O
the O
minimal O
essential O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
, O
as O
a O
6 O
- O
nt O
deletion O
spanning O
nt O
32 O
to O
37 O
also O
increased O
the O
translational O
activity O
of O
the O
HCV O
- O
N O
5 O
' O
NTR O
to O
that O
of O
HCV O
- O
H O
. O

Surprisingly O
, O
however O
, O
this O
inhibitory O
effect O
was O
observed O
only O
when O
the O
translated O
, O
downstream O
RNA O
sequence O
contained O
nt O
408 O
to O
929 O
of O
HCV O
( O
capsid O
- O
coding O
RNA O
) O
. O

Okamoto O
et O
al O
, O
, O
Hepatol O
, O
Res O
, O
10 O
: O
1 O
- O
16 O
, O
1998 O
) O
of O
a O
neu O
ly O
discovered O
single O
- O
stranded O
DNA O
virus O
, O
TT O
virus O
( O
( O
TTV O
) O
, O
showed O
that O
it O
did O
not O
have O
the O
terminal O
structure O
typical O
of O
a O
parvovirus O
. O

0 O
- O
kb O
amplified O
product O
from O
serum O
samples O
of O
four O
TTV O
carriers O
by O
an O
inverted O
, O
nested O
long O
PCR O
targeted O
for O
nucleotides B
( I
nt I
) I
3025 O
to O
3739 O
and O
1 O
to O
216 O
of O
TTV O
. O

The O
complete O
circular O
TTV O
genome O
contained O
a O
novel O
sequence O
of O
113 O
nt O
( O
nt O
3740 O
to O
3852 O
[ O
= O
0 O
] O
) O
in O
between O
the O
known O
3 O
' O
- O
and O
5 O
' O
- O
end O
arms O
, O
forming O
a O
117 O
- O
nt O
GC O
- O
rich O
stretch O
( O
GC O
content O
, O
90 O
. O

6 O
% O
at O
nt O
3736 O
to O
3852 O
) O
, O
We O
found O
a O
36 O
- O
nt O
stretch O
( O
nt O
3816 O
to O
3851 O
) O
with O
an O
80 O
. O

6 O
% O
similarity O
to O
chicken B
anemia I
virus I
( I
CAV I
) I
( O
nt O
2237 O
to O
2272 O
of O
M55918 O
) O
, O
a O
vertebrate O
circovirus O
. O

A O
putative O
SP O
- O
I O
site O
was O
located O
at O
nt O
3834 O
to O
3839 O
, O
followed O
by O
a O
TATA O
bos O
at O
nt O
85 O
to O
90 O
, O
the O
first O
initiation O
codon O
of O
a O
putative O
VP2 O
at O
nt O
107 O
to O
109 O
, O
the O
termination O
codon O
of O
a O
putative O
VP1 O
at O
nt O
2899 O
to O
2901 O
, O
and O
a O
poly O
( O
A O
) O
signal O
at O
nt O
3073 O
to O
3078 O
. O

Dengue O
virus O
capsid O
protein O
- O
specific O
CD4 O
( O
+ O
) O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
clones O
were O
shown O
to O
be O
capable O
of O
mediating O
bystander O
lysis O
of O
non O
- O
antigen O
- O
presenting O
target O
cells O
. O

After O
activation O
by O
anti O
- O
CD3 O
or O
in O
the O
presence O
of O
unlabeled O
antigen O
- O
presenting O
target O
cells O
, O
these O
clones O
could O
lyse O
both O
Jurkat O
tells O
and O
HepG2 O
cells O
as O
bystander O
targets O
, O
Lysis O
of O
HepG2 O
cells O
suggests O
a O
potential O
role O
for O
CD4 O
( O
+ O
) O
CTL O
in O
the O
liver O
involvement O
observed O
during O
dengue O
virus O
infection O
. O

Three O
CD4 O
( O
+ O
) O
CTL O
clones O
were O
demonstrated O
to O
lyse O
cognate O
, O
antigen O
- O
presenting O
target O
cells O
by O
a O
mechanism O
that O
primarily O
involves O
perforin O
, O
while O
bystander O
lysis O
occurred O
through O
Fas O
/ O
Fas O
ligand O
interactions O
. O

In O
response O
to O
stimulation O
with O
D2 O
antigen O
, O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
produced O
gamma O
interferon O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
TNF O
- O
beta O
, O
The O
data O
suggest O
that O
CD4 O
( O
+ O
) O
CTL O
clones O
may O
contribute O
to O
the O
immunopathology O
observed O
upon O
secondary O
dengue O
virus O
infections O
through O
direct O
cytolysis O
and O
/ O
or O
cytokine O
production O
. O

Since O
secretory O
proteins O
which O
are O
retained O
in O
the O
endoplasmic O
reticulum O
frequently O
can O
activate O
the O
transcription O
of O
intraluminal O
chaperone O
proteins O
, O
we O
measured O
the O
effect O
of O
the O
E1 O
and O
E2 O
proteins O
on O
the O
promoters O
of O
two O
such O
chaperones O
, O
GRP78 O
( O
BiP O
) O
and O
GRP94 O
. O

We O
have O
characterized O
the O
hemagglutinin B
- I
esterase I
( I
HE I
) I
of O
puffinosis B
virus I
( I
PV I
) I
, O
a O
coronavirus O
closely O
related O
to O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

Solid O
- O
phase O
binding O
assays O
revealed O
that O
purified O
PV O
was O
unable O
to O
bind O
to O
sialic O
acid O
- O
containing O
glycoconjugates O
like O
bovine O
submaxillary O
mucin O
, O
mouse O
alpha O
( O
1 O
) O
macroglobulin O
or O
bovine O
brain O
extract O
. O

GB B
virus I
C I
( I
GBV I
- I
C I
) I
, O
also O
known O
as O
hepatitis O
G O
Virus O
, O
is O
a O
recently O
discovered O
flavivirus O
- O
like O
RNA O
agent O
with O
unclear O
pathogenic O
implications O
. O

To O
investigate O
whether O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMC I
) I
are O
susceptible O
to O
in O
vitro O
GBV O
- O
C O
infection O
, O
we O
have O
incubated O
PBMC O
from O
four O
healthy O
blood O
donors O
with O
a O
human O
GBV O
- O
C O
RNA O
- O
positive O
serum O
. O

By O
means O
of O
( O
i O
) O
strand O
- O
specific O
reverse O
transcription O
- O
PCR O
, O
cloning O
, O
and O
sequencing O
; O
( O
ii O
) O
sucrose O
ultracentrifugation O
and O
RNase O
sensitivity O
assays O
; O
( O
iii O
) O
fluorescent O
in O
situ O
hybridization O
; O
and O
( O
iv O
) O
Western O
blot O
analysis O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
E1 O
and O
E2 O
assemble O
to O
form O
a O
noncovalent O
heterodimer O
which O
, O
in O
the O
cell O
, O
accumulates O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
Contrary O
to O
what O
is O
observed O
for O
proteins O
with O
a O
KDEL O
or O
a O
KKXX O
ER O
- O
targeting O
signal O
, O
the O
ER O
localization O
of O
the O
HCV O
glycoprotein O
complex O
is O
due O
to O
a O
static O
retention O
in O
this O
compartment O
rather O
than O
to O
its O
retrieval O
from O
the O
cis O
- O
Golgi O
region O
. O

A O
static O
retention O
in O
the O
ER O
is O
also O
observed O
when O
E2 O
is O
expressed O
in O
the O
absence O
of O
E1 O
or O
for O
a O
chimeric O
protein O
containing O
the O
ectodomain O
of O
CD4 O
in O
fusion O
with O
the O
transmembrane B
domain I
( I
TMD I
) I
of O
E2 O
. O

Together O
, O
these O
data O
suggest O
that O
at O
least O
two O
signals O
( O
TMDs O
of O
E1 O
and O
E2 O
) O
are O
involved O
in O
ER O
retention O
of O
the O
HCV O
glycoprotein O
complex O
. O

Proteolytic O
processing O
of O
the O
replicase O
gene O
product O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
essential O
for O
viral O
replication O
, O
In O
MHV B
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
the O
replicase O
gene O
encodes O
two O
predicted O
papain B
- I
like I
proteinase I
( I
PLP I
) I
domains O
, O
PLP O
- O
1 O
and O
PLP O
- O
2 O
. O

Previous O
work O
using O
viral O
polypeptide O
substrates O
synthesized O
by O
in O
vitro O
transcription O
and O
translation O
from O
the O
replicase O
gene O
demonstrated O
both O
cis O
and O
trans O
cleavage O
activities O
for O
PLP O
- O
1 O
, O
We O
have O
cloned O
and O
overexpressed O
the O
PLP O
- O
1 O
domain O
in O
Escherichia O
coli O
by O
using O
a O
T7 O
RNA O
polymerase O
promoter O
system O
or O
as O
a O
maltose B
- I
binding I
protein I
( I
MBP I
) I
fusion O
protein O
. O

Here O
, O
we O
explored O
the O
possibility O
that O
the O
posttranscriptional O
regulatory O
element O
of O
woodchuck O
hepatitis O
virus O
( O
WPRE O
) O
might O
help O
resolve O
this O
problem O
. O

hepatitis B
G I
virus I
( I
HGV I
) I
nonstructural B
protein I
3 I
( I
NS3 I
) I
contains O
amino O
acid O
sequence O
motifs O
typical O
of O
ATPase O
and O
RNA O
helicase O
proteins O
. O

In O
order O
to O
examine O
the O
RNA O
helicase O
activity O
of O
the O
HGV O
NS3 O
protein O
, O
the O
NS3 O
region O
( O
amino O
acids O
904 O
to O
1580 O
) O
was O
fused O
with O
maltose B
- I
binding I
protein I
( I
MBP I
) I
, O
and O
the O
fusion O
protein O
was O
expressed O
in O
Escherichia O
coli O
and O
purified O
with O
amylose O
resin O
and O
anion O
- O
exchange O
chromatography O
. O

A O
satellite O
RNA O
of O
836 O
nucleotides O
[ O
excluding O
the O
poly O
( O
A O
) O
tail O
] O
depends O
on O
the O
bamboo B
mosaic I
potexvirus I
( I
BaMV I
) I
for O
its O
replication O
and O
encapsidation O
. O

The O
BaMV B
satellite I
RNA I
( I
satBaMV I
) I
contains O
a O
single O
open O
reading O
frame O
encoding O
a O
20 O
- O
kDa O
nonstructural O
protein O
( O
P20 O
) O
. O

P20 O
preferred O
binding O
to O
satBaMV O
- O
or O
BaMV O
- O
related O
sequences O
rather O
than O
to O
nonrelated O
sequences O
, O
By O
deletion O
analysis O
, O
the O
P20 O
binding O
sites O
were O
mainly O
located O
at O
the O
5 O
' O
and O
3 O
' O
untranslated O
regions O
of O
satBaMV O
RNA O
, O
and O
the O
RNA O
- O
protein O
interactions O
could O
compete O
with O
the O
poly O
( O
G O
) O
and O
, O
less O
efficiently O
, O
with O
the O
poly O
( O
U O
) O
homopolymers O
, O
The O
N O
- O
terminal O
arginine O
- O
rich O
motif O
of O
P20 O
was O
the O
RNA O
binding O
domain O
, O
as O
shown O
by O
in O
- O
frame O
deletion O
analysis O
. O

Human B
coronaviruses I
( I
HuCV I
) I
cause O
common O
colds O
. O

Human B
coronaviruses I
( I
HuCV I
) I
are O
recognized O
respiratory O
pathogens O
. O

Viral O
antigen O
and O
RNA O
and O
release O
of O
infectious O
virions O
were O
observed O
during O
persistent O
HuCV O
- O
OC43 O
infections O
( O
similar O
to O
130 O
days O
of O
culture O
) O
of O
U O
- O
87 O
MG O
, O
U O
- O
373 O
MG O
, O
MO3 O
. O

Cap O
- O
independent O
translation O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genomic O
RNA O
is O
mediated O
by O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
within O
the O
5 B
' I
untranslated I
region I
( I
5 I
' I
UTR I
) I
of O
the O
virus O
RNA O
. O

To O
investigate O
the O
effects O
of O
alterations O
to O
the O
primary O
sequence O
of O
the O
5 O
' O
UTR O
on O
IRES O
activity O
, O
a O
series O
of O
HCV B
genotype I
Ib I
( I
HCV I
- I
lb I
) I
variant O
IRES O
elements O
was O
generated O
and O
cloned O
into O
a O
bicistronic O
reporter O
construct O
. O

In O
the O
human O
central O
nervous O
system O
, O
susceptibility O
to O
poliovirus B
( I
PV I
) I
infection O
is O
largely O
confined O
to O
a O
specific O
subpopulation O
of O
neuronal O
cells O
. O

We O
reported O
previously O
that O
the O
exchange O
of O
the O
cognate B
internal I
ribosomal I
entry I
site I
( I
IRES I
) I
within O
the O
5 O
' O
nontranslated O
region O
of O
PV O
with O
its O
counterpart O
from O
human B
rhinovirus I
type I
2 I
( I
HRV2 I
) I
can O
eliminate O
the O
neuropathogenic O
phenotype O
in O
a O
transgenic O
mouse O
model O
for O
poliomyelitis O
without O
diminishing O
the O
growth O
properties O
in O
HeLa O
cells O
. O

We O
have O
dissected O
the O
PV O
and O
HRV2 O
IRES O
elements O
to O
determine O
those O
structures O
responsible O
for O
neurovirulence O
( O
or O
attenuation O
) O
of O
these O
chimeric O
viruses O
. O

The O
relationship O
of O
viral O
persistence O
, O
the O
immune O
response O
to O
hepatitis B
C I
virus I
( I
BCV I
) I
envelope O
proteins O
, O
and O
envelope O
sequence O
variability O
was O
examined O
in O
chimpanzees O
. O

Antibody O
reactivity O
to O
the O
HCV O
envelope O
proteins O
E1 O
or O
E2 O
was O
detected O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
in O
more O
than O
90 O
% O
of O
a O
human O
serum O
panel O
. O

Although O
the O
ELISAs O
appeared O
to O
be O
sensitive O
indicators O
of O
WCV O
infection O
in O
human O
serum O
panels O
, O
the O
results O
of O
a O
cross O
- O
sectional O
study O
revealed O
that O
a O
low O
percentage O
of O
HCV O
- O
inoculated O
chimpanzees O
had O
detectable O
antibody O
to O
E1 O
( O
22 O
% O
) O
and O
E2 O
( O
15 O
% O
) O
, O
Viral O
clearance O
, O
which O
was O
recognized O
in O
28 O
( O
61 O
% O
) O
of O
the O
chimpanzees O
, O
was O
not O
associated O
with O
an O
antibody O
response O
to O
E1 O
or O
E2 O
. O

In O
10 O
chronically O
infected O
animals O
, O
the O
sequence O
variation O
in O
the O
E2 O
hypervariable O
region O
( O
HVR O
- O
1 O
) O
was O
minimal O
and O
did O
not O
coincide O
with O
antibody O
to O
E2 O
or O
to O
the O
HVR O
- O
1 O
. O

The O
sequences O
involved O
in O
the O
replication O
and O
packaging O
of O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
RNA O
have O
been O
studied O
. O

7 O
kb O
( O
DI O
- O
C O
) O
was O
described O
previously O
( O
A O
. O

A O
collection O
of O
14 O
DI O
- O
C O
RNA O
deletion O
mutants O
( O
TGEV O
minigenomes O
) O
was O
synthetically O
generated O
and O
tested O
for O
their O
ability O
to O
be O
replicated O
and O
packaged O
. O

The O
smallest O
minigenome O
( O
M33 O
) O
that O
was O
replicated O
by O
the O
helper O
virus O
and O
efficiently O
packaged O
was O
3 O
. O

1 O
kb O
( O
M21 O
) O
was O
also O
replicated O
, O
but O
it O
was O
packaged O
with O
much O
lower O
efficiency O
than O
the O
M33 O
minigenome O
, O
suggesting O
that O
it O
had O
lost O
either O
the O
sequences O
containing O
the O
main O
packaging O
signal O
or O
the O
required O
secondary O
structure O
in O
the O
packaging O
signal O
due O
to O
alteration O
of O
the O
flanking O
sequences O
. O

This O
system O
and O
the O
use O
of O
the O
reporter O
gene O
P O
- O
glucuronidase O
( O
GUS O
) O
allowed O
minigenome O
detection O
at O
passage O
zero O
, O
making O
it O
possible O
to O
distinguish O
replication O
efficiency O
from O
packaging O
capability O
. O

0 O
mu O
g O
/ O
10 O
( O
6 O
) O
cells O
of O
GUS O
. O

Production O
of O
soluble O
full O
- O
length O
nonstructural B
protein I
5B I
( I
NS5B I
) I
of O
hepatitis B
C I
virus I
( I
HCV I
) I
has O
been O
shown O
to O
be O
problematic O
and O
requires O
the O
addition O
of O
salts O
, O
glycerol O
, O
and O
detergents O
. O

In O
an O
effort O
to O
improve O
the O
solubility O
of O
NS5B O
, O
the O
hydrophobic O
C O
terminus O
containing O
21 O
amino O
acids O
was O
removed O
, O
yielding O
a O
truncated O
NS5B O
( O
NS5B O
Delta O
CT O
) O
which O
is O
highly O
soluble O
and O
monodispersed O
in O
the O
absence O
of O
detergents O
. O

Fine O
deletional O
analysis O
of O
this O
region O
revealed O
that O
a O
four O
- O
leucine O
motif O
( O
LLLL O
) O
in O
the O
hydrophobic O
domain O
is O
responsible O
for O
the O
solubility O
profile O
of O
the O
full O
- O
length O
NS5B O
. O

Enzymatic O
characterization O
revealed O
that O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
of O
this O
truncated O
NS5B O
was O
comparable O
to O
those O
reported O
previously O
by O
others O
. O

For O
optimal O
enzyme O
activity O
, O
divalent O
manganese O
ions O
( O
Mn2 O
+ O
) O
are O
preferred O
rather O
than O
magnesium O
ions O
( O
Mg2 O
+ O
) O
, O
whereas O
zinc O
ions O
( O
Zn2 O
+ O
) O
inhibit O
the O
RdRp O
activity O
. O

Antibodies O
against O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
are O
able O
to O
suppress O
most O
of O
the O
inhibitory O
activity O
, O
suggesting O
that O
IFN O
- O
gamma O
is O
the O
dominant O
component O
. O

The O
NS3 O
- O
NS4A O
serine O
protease O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
mediates O
four O
specific O
cleavages O
of O
the O
viral O
polyprotein O
and O
its O
activity O
is O
considered O
essential O
for O
the O
biogenesis O
of O
the O
HCV O
replication O
machinery O
. O

Our O
original O
chimeric O
viruses O
displayed O
a O
temperature O
- O
sensitive O
phenotype O
and O
formed O
lysis O
plaques O
much O
smaller O
than O
those O
formed O
by O
wild B
- I
type I
( I
WT I
) I
Sindbis O
virus O
. O

Persistent O
infection O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strain O
A59 O
in O
murine O
DBT O
( O
delayed O
brain O
tumor O
) O
cells O
resulted O
in O
the O
emergence O
of O
host O
range O
variants O
, O
designated O
V51A O
and O
V51B O
, O
at O
210 O
days O
postinfection O
, O
These O
host O
range O
mutants O
replicated O
efficiently O
in O
normally O
nonpermissive O
Chinese B
hamster I
ovary I
( I
CHO I
) I
, O
in O
human O
hepatocarcinoma O
( O
HepG2 O
) O
, O
and O
to O
a O
lesser O
extent O
in O
human O
breast O
carcinoma O
( O
MCF7 O
) O
cell O
lines O
. O

Little O
if O
any O
replication O
was O
noted O
in O
baby B
hamster I
kidney I
( I
BHK I
) I
, O
green O
African O
monkey O
kidney O
( O
COS O
- O
7 O
) O
, O
feline O
kidney O
( O
CRFK O
) O
, O
and O
swine B
testicular I
( I
ST I
) I
cell O
lines O
. O

By O
fluorescent B
antibody I
( I
FA I
) I
staining O
, O
persistent O
viruses O
V10B O
and O
V30B O
, O
isolated O
at O
days O
38 O
and O
119 O
days O
postinfection O
, O
also O
demonstrated O
very O
low O
levels O
of O
replication O
in O
human O
HepG2 O
cells O
. O

Pretreatment O
of O
HepG2 O
cells O
with O
a O
polyclonal O
antibody O
directed O
against O
human O
carcinoembryonic B
antigens I
( I
CEA I
) I
or O
with O
some O
monoclonal O
antibodies O
( O
Col O
- O
1 O
, O
Col O
- O
4 O
, O
Col O
- O
12 O
, O
and O
Col O
- O
14 O
) O
that O
bind O
human O
CEA O
significantly O
inhibited O
V51B O
infection O
, O
Under O
identical O
conditions O
, O
little O
or O
no O
blockade O
was O
evident O
with O
other O
monoclonal O
antibodies O
( O
kat4c O
or O
Col O
- O
6 O
) O
which O
also O
bind O
the O
human O
CEA O
glycoproteins O
, O
In O
addition O
, O
an O
antibody O
( O
EDDA O
) O
directed O
against O
irrelevant O
antigens O
did O
not O
block O
V51B O
replication O
. O

To O
test O
this O
hypothesis O
, O
the O
human B
biliary I
glycoprotein I
( I
Bgp I
) I
and O
CEA O
genes O
were O
cloned O
and O
expressed O
in O
normally O
nonpermissive O
BHK O
cell O
lines O
by O
using O
noncytopathic O
Sindbis O
virus O
replicons O
( O
pSinRep19 O
) O
, O
By O
growth O
curves O
and O
FA O
staining O
, O
human O
CEA O
and O
to O
a O
much O
lesser O
extent O
human O
Bgp O
functioned O
as O
receptors O
for O
V51B O
entry O
. O

A O
cellular O
protein O
, O
previously O
described O
as O
p55 O
, O
binds O
specifically O
to O
the O
plus O
strand O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
leader O
RNA O
, O
We O
have O
purified O
this O
protein O
and O
determined O
by O
partial O
peptide O
sequencing O
that O
it O
is O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
( O
also O
known O
as O
heterogeneous O
nuclear O
ribonucleoprotein O
[ O
hnRNP O
] O
I O
) O
, O
a O
nuclear O
protein O
which O
shuttles O
between O
the O
nucleus O
and O
cytoplasm O
, O
PTB O
plays O
a O
role O
in O
the O
regulation O
of O
alternative O
splicing O
of O
pre O
- O
mRNAs O
in O
normal O
cells O
and O
translation O
of O
several O
viruses O
. O

Previous O
studies O
of O
a O
group O
of O
mutants O
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
A59 O
, O
isolated O
from O
persistently O
infected O
glial O
cells O
, O
have O
shown O
a O
strong O
correlation O
between O
a O
Q159L O
amino O
acid O
substitution O
in O
the O
S1 O
subunit O
of O
the O
spike O
gene O
and O
a O
loss O
in O
the O
ability O
to O
induce O
hepatitis O
and O
demyelination O
. O

Recombination O
was O
carried O
out O
between O
the O
genome O
of O
a O
temperature O
- O
sensitive O
mutant O
of O
MHV O
- O
A59 O
( O
Alb4 O
) O
and O
RNA O
transcribed O
from O
a O
plasmid O
( O
pFV1 O
) O
containing O
the O
spike O
gene O
as O
well O
as O
downstream O
regions O
, O
through O
the O
3 O
' O
end O
, O
of O
the O
MHV O
- O
A59 O
genome O
. O

These O
recombinant O
viruses O
( O
159R36 O
and O
159R40 O
) O
replicate O
in O
the O
brains O
of O
C57BL O
/ O
6 O
mice O
and O
induce O
encephalitis O
to O
a O
similar O
extent O
as O
wild O
- O
type O
MHV O
- O
A59 O
. O

Utilization O
of O
internal B
ribosome I
entry I
segment I
( I
IRES I
) I
structures O
in O
the O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
of O
piconavirus O
RNAs O
for O
initiation O
of O
translation O
requires O
a O
number O
of O
host O
cell O
factors O
whose O
distribution O
may O
vary O
in O
different O
cells O
and O
whose O
requirement O
may O
vary O
for O
different O
picornaviruses O
. O

We O
have O
examined O
the O
requirement O
of O
the O
cellular O
protein O
poly B
( I
rC I
) I
binding I
protein I
2 I
( I
PCBP2 I
) I
for O
hepatitis B
A I
virus I
( I
HAV I
) I
RNA O
translation O
. O

PCBP2 O
has O
recently O
been O
identified O
as O
a O
factor O
required O
for O
translation O
and O
replication O
of O
poliovirus B
( I
PV I
) I
RNA O
. O

To O
investigate O
the O
role O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
quasispecies O
mutation O
in O
the O
pathogenesis O
of O
HCV O
infection O
, O
we O
analyzed O
changes O
in O
the O
genetic O
diversity O
of O
HCV O
genomes O
in O
22 O
patients O
before O
and O
after O
liver O
transplantation O
by O
using O
heteroduplex B
mobility I
assay I
( I
HMA I
) I
technology O
. O

Bamboo B
mosaic I
virus I
( I
BaMV I
) I
, O
a O
member O
of O
the O
potexvirus O
group O
, O
infects O
primarily O
members O
of O
the O
Bambusoideae O
. O

The O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
of O
BaMV O
encodes O
a O
155 O
- O
kDa O
polypeptide O
that O
was O
postulated O
to O
be O
involved O
in O
the O
replication O
and O
the O
formation O
of O
cap O
structure O
at O
the O
5 O
' O
end O
of O
the O
viral O
genome O
. O

To O
characterize O
the O
activities O
associated O
with O
the O
155 O
- O
kDa O
viral O
protein O
, O
it O
was O
expressed O
in O
Escherichia O
coli O
BL21 O
( O
DE3 O
) O
cells O
with O
thioredoxin O
, O
hexahistidine O
, O
and O
S O
Tag O
fused O
consecutively O
at O
its O
amino O
terminus O
, O
and O
the O
fusion O
protein O
was O
purified O
by O
metal O
affinity O
chromatography O
. O

Several O
RNA O
fragments O
, O
prepared O
by O
in O
vitro O
transcription O
, O
were O
tested O
as O
substrates O
for O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
. O

We O
studied O
the O
accumulation O
kinetics O
of O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
RNAs O
early O
in O
infection O
by O
using O
cloned O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
that O
contained O
an O
intergenic O
sequence O
from O
which O
subgenomic O
DI O
RNA O
is O
synthesized O
in O
MHV O
- O
infected O
cells O
. O

Translation O
initiation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
occurs O
by O
internal O
entry O
of O
a O
ribosome O
into O
the O
5 O
' O
nontranslated O
region O
in O
a O
cap O
- O
independent O
manner O
. O

The O
HCV O
RNA O
sequence O
from O
about O
nucleotide O
40 O
pip O
to O
the O
N O
terminus O
of O
the O
coding O
sequence O
of O
the O
coke O
protein O
is O
required O
for O
efficient O
internal O
initiation O
of O
translation O
, O
though O
the O
precise O
border O
of O
the O
HCV O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
has O
yet O
to O
he O
determined O
. O

This O
protein O
with O
an O
apparent O
molecular O
mass O
of O
68 O
kDa O
turned O
out O
to O
be O
heterogeneous B
nuclear I
ribonucleoprotein I
L I
( I
hnRNP I
L I
) I
. O

Translation O
of O
most O
eukaryotic O
mRNAs O
and O
many O
viral O
RNAs O
is O
enhanced O
by O
their O
poly O
( O
A O
) O
tails O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
positive O
- O
stranded O
RNA O
genome O
which O
does O
not O
have O
a O
poly O
( O
A O
) O
tail O
but O
has O
a O
stretch O
of O
98 O
nucleotides O
( O
X O
region O
) O
at O
the O
3 B
' I
- I
untranslated I
region I
( I
UTR I
) I
, O
which O
assumes O
a O
highly O
conserved O
stem O
- O
loop O
structure O
. O

This O
X O
region O
binds O
a O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
, O
which O
also O
binds O
to O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
in O
HCV O
5 O
' O
- O
UTR O
. O

The O
X O
region O
also O
enhanced O
translation O
from O
another O
unrelated O
IRES O
( O
from O
encephalomyocarditis O
virus O
RNA O
) O
, O
but O
did O
not O
affect O
the O
5 O
' O
- O
end O
- O
dependent O
translation O
of O
globin O
mRNA O
in O
either O
monocistronic O
or O
bicistronic O
RNAs O
, O
It O
did O
not O
appear O
to O
affect O
RNA O
stability O
. O

When O
the O
swine O
alphaherpesvirus O
Pseudorabies B
virus I
( I
PRV I
) I
infects O
the O
rat O
retina O
, O
it O
replicates O
in O
retinal O
ganglion O
cells O
and O
invades O
the O
central B
nervous I
system I
( I
CNS I
) I
via O
anterograde O
transynaptic O
spread O
through O
axons O
in O
the O
optic O
nerve O
, O
Virus O
can O
also O
spread O
to O
the O
CNS O
via O
retrograde O
transport O
through O
the O
oculomotor O
nucleus O
that O
innervates O
extraocular O
muscles O
of O
the O
eye O
, O
Since O
retrograde O
infection O
of O
the O
CNS O
precedes O
anterograde O
transynaptic O
infection O
, O
the O
temporal O
sequence O
of O
infection O
of O
the O
CNS O
depends O
on O
the O
route O
of O
invasion O
. O

Thus O
, O
motor O
neurons O
are O
infected O
first O
( O
retrograde O
infection O
) O
, O
followed O
by O
CNS O
neurons O
innervated O
by O
the O
optic O
nerve O
( O
anterograde O
transynaptic O
infection O
) O
. O

The O
data O
revealed O
focal O
trafficking O
of O
peripheral O
immune O
cells O
into O
areas O
of O
the O
CNS O
infected O
by O
retrograde O
or O
anterograde O
transport O
after O
PRV O
Becker O
was O
injected O
into O
the O
vitreous O
body O
of O
the O
eye O
, O
Cells O
expressing O
the O
leukocyte O
common O
antigen O
, O
CD45 O
( O
+ O
) O
, O
entered O
the O
area O
of O
infection O
from O
local O
capillaries O
prior O
to O
any O
overt O
expression O
of O
neuropathology O
, O
and O
quantitative O
analysis O
demonstrated O
that O
the O
number O
of O
cells O
increased O
in O
proportion O
to O
the O
number O
of O
infected O
neurons O
within O
a O
given O
region O
, O
Recruitment O
of O
cells O
of O
monocyte O
/ O
macrophage O
lineage O
began O
prior O
to O
the O
appearance O
of O
CD8 O
( O
+ O
) O
cytotoxic O
lymphocytes O
, O
which O
were O
, O
in O
turn O
, O
followed O
by O
CD4 O
( O
+ O
) O
lymphocytes O
. O

These O
data O
demonstrate O
that O
PRV O
replication O
in O
CNS O
neurons O
stimulates O
the O
focal O
infiltration O
of O
specific O
classes O
of O
CD45 O
( O
+ O
) O
cells O
in O
a O
time O
- O
dependent O
, O
temporally O
organized O
fashion O
that O
is O
correlated O
directly O
with O
the O
number O
of O
infected O
neurons O
and O
the O
time O
that O
a O
given O
region O
has O
been O
infected O
. O

A O
detailed O
map O
of O
the O
transcriptional O
organization O
of O
the O
CELO O
virus O
genome O
mas O
produced O
, O
Recent O
computer O
analysis O
of O
CELO O
virus O
has O
indicated O
the O
presence O
of O
38 O
putative O
open B
reading I
frames I
( I
ORFs I
) I
, O
This O
study O
, O
based O
on O
analysis O
of O
the O
transcriptional O
products O
of O
CELO O
in O
vitro O
, O
confirmed O
the O
presence O
of O
RNAs O
for O
26 O
of O
these O
38 O
ORFs O
, O
hll O
of O
the O
results O
were O
obtained O
by O
cDNA O
isolation O
or O
specific O
reverse O
transcriptase O
PCR O
, O
Observation O
of O
ORF O
transcription O
kinetics O
postinfection O
revealed O
the O
existence O
of O
early O
and O
late O
expression O
, O
with O
the O
earliest O
starting O
at O
2 O
h O
postinfection O
. O

Gamma O
interferon O
- O
deficient O
( O
IFN O
- O
gamma O
- O
/ O
- O
) O
mice O
with O
a O
C57BL O
/ O
6 O
background O
were O
infected O
intraperitoneally O
with O
moose B
hepatitis I
virus I
strain I
JHM I
( I
JHMV I
) I
. O

nonstructural B
protein I
5B I
( I
NS5B I
) I
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
contains O
sequence O
motifs O
that O
are O
predictive O
of O
an O
RNA O
- O
dependent O
RNA O
polymerase O
activity O
. O

We O
describe O
the O
expression O
and O
purification O
of O
the O
BVDV O
NSSB O
protein O
derived O
from O
an O
infectious O
cDNA O
clone O
of O
BVDV O
( O
NADL O
strain O
) O
. O

The O
RNA O
elements O
that O
are O
required O
for O
replication O
of O
Defective B
interfering I
( I
DI I
) I
RNA O
of O
the O
JHM O
strain O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
consist O
of O
three O
discontinuous O
genomic O
regions O
: O
about O
0 O
. O

47 O
kb O
from O
both O
terminal O
sequences O
and O
an O
internal O
58 O
- O
nucleotide B
( I
nt I
) I
- O
long O
sequence O
( O
58 O
- O
nt O
region O
) O
present O
at O
about O
0 O
. O

( O
i O
) O
The O
positive O
- O
strand O
RNA O
structure O
in O
solution O
was O
comparable O
with O
that O
predicted O
by O
computer O
modeling O
. O

( O
ii O
) O
Positive O
- O
strand O
RNA O
secondary O
structure O
, O
but O
not O
negative O
- O
strand O
RNA O
structure O
, O
was O
important O
for O
the O
biological O
function O
of O
the O
region O
. O

( O
iii O
) O
The O
biological O
function O
had O
a O
sequence O
- O
specific O
requirement O
. O

When O
poliovirus O
capsid O
proteins O
were O
supplied O
in O
trans O
, O
> O
2 O
x O
10 O
( O
6 O
) O
infectious O
particles O
/ O
ml O
were O
produced O
. O

When O
coxsackievirus O
B3 O
, O
human O
rhinovirus O
14 O
, O
mengovirus O
, O
or O
hepatitis B
A I
virus I
( I
HAV I
) I
capsid O
proteins O
were O
supplied O
in O
trans O
, O
all O
but O
HAV O
showed O
some O
encapsidation O
of O
the O
replicon O
. O

Proteolytic O
processing O
of O
the O
picornaviral O
polyprotein O
mediated O
by O
the O
differential O
action O
of O
virus O
- O
encoded O
proteinase O
( O
s O
) O
is O
pivotal O
to O
both O
RNA O
genome O
replication O
and O
capsid O
formation O
, O
Possibly O
to O
enlarge O
the O
array O
of O
viral O
proteins O
, O
picornaviral O
polyprotein O
processing O
results O
in O
intermediate O
and O
mature O
products O
which O
apparently O
have O
distinct O
functions O
within O
the O
viral O
life O
cycle O
. O

For O
hepatitis B
A I
virus I
( I
HAV I
) I
, O
we O
report O
here O
on O
the O
autoproteolysis O
of O
precursor O
polypeptides O
comprising O
the O
only O
viral O
proteinase O
, O
3C B
( I
pro I
) I
, O
and O
on O
their O
role O
in O
viral O
particle O
formation O
. O

Following O
transient O
expression O
of O
a O
nested O
set O
of O
3C B
( I
pro I
) I
- O
containing O
proteins O
( O
P3 O
, O
3ABC O
, O
3BCD O
, O
3CD O
, O
3BC O
, O
and O
3C O
) O
in O
eukaryotic O
cells O
, O
the O
extent O
of O
processing O
was O
determined O
by O
analyzing O
the O
cleavage O
products O
. O

These O
data O
support O
the O
notion O
that O
efficient O
liberation O
of O
structural O
proteins O
from O
P1 O
- O
2A O
is O
necessary O
but O
not O
sufficient O
for O
productive O
HAV O
capsid O
formation O
and O
suggest O
that O
the O
polypeptides O
flanking O
3C B
( I
pro I
) I
promote O
the O
assembly O
of O
viral O
particles O
. O

The O
strain O
- O
specific O
spectrum O
of O
liver O
disease O
following O
murine B
hepatitis I
virus I
type I
3 I
( I
MHV I
- I
3 I
) I
infection O
is O
dependent O
on O
inflammatory O
mediators O
released O
by O
macrophages O
. O

Production O
of O
nitric B
oxide I
( I
NO I
) I
by O
macrophages O
has O
been O
implicated O
in O
resistance O
to O
a O
number O
of O
viruses O
, O
including O
ectromelia O
virus O
, O
vaccinia O
virus O
, O
and O
herpes O
simplex O
virus O
type O
1 O
. O

Viral O
inhibitory O
activity O
was O
reproduced O
by O
the O
NO O
donor O
S B
- I
nitroso I
- I
N I
- I
acetyl I
- I
DL I
- I
penicillamine I
( I
SNAP I
) I
, O
whereas O
N B
- I
acetyl I
- I
DL I
- I
pencillamine I
( I
NAP I
) I
, O
an O
inactive O
analog O
of O
SNAP O
, O
had O
no O
effect O
. O

The O
Human B
papillomavirus I
( I
HPV I
) I
El O
and O
E2 O
proteins O
bind O
cooperatively O
to O
the O
viral O
Origin B
of I
Replication I
( I
Ori I
) I
, O
forming O
an O
E1 O
- O
E2 O
- O
ori O
complex O
that O
is O
essential O
for O
initiation O
of O
DNA O
replication O
, O
All O
other O
replication O
proteins O
, O
including O
DNA O
polymerase O
alpha O
- O
primase O
( O
pol O
alpha O
- O
primase O
) O
, O
are O
derived O
from O
the O
host O
cell O
. O

We O
have O
carried O
out O
a O
detailed O
analysis O
of O
the O
interactions O
of O
HPV B
type I
16 I
( I
HPV I
- I
16 I
) I
El O
with O
E2 O
, O
ori O
, O
and O
the O
four O
pol O
alpha O
- O
primase O
subunits O
, O
Deletion O
analysis O
showed O
that O
a O
C O
- O
terminal O
region O
of O
El O
( O
amino O
acids O
[ O
aa O
] O
432 O
to O
583 O
or O
617 O
) O
is O
required O
for O
E2 O
binding O
, O
HPV O
16 O
El O
was O
unable O
to O
bind O
the O
ori O
in O
the O
absence O
of O
E2 O
, O
but O
the O
same O
C O
- O
terminal O
domain O
of O
El O
was O
sufficient O
to O
tether O
El O
to O
the O
ori O
via O
E2 O
, O
Of O
the O
pol O
alpha O
- O
primase O
subunits O
, O
only O
p68 O
bound O
El O
, O
and O
binding O
was O
competitive O
with O
E2 O
, O
The O
El O
region O
required O
( O
aa O
397 O
to O
583 O
) O
was O
the O
same O
as O
that O
required O
for O
E2 O
binding O
but O
additionally O
contained O
34 O
N O
- O
terminal O
residues O
. O

In O
confirmation O
of O
these O
differences O
, O
we O
found O
that O
a O
monoclonal O
antibody O
, O
mapping O
adjacent O
to O
the O
N O
- O
terminal O
junction O
of O
the O
p68 O
binding O
region O
, O
blocked O
E1 O
- O
p68 O
but O
not O
E1 O
- O
E2 O
binding O
, O
Sequence O
alignments O
and O
secondary O
- O
structure O
prediction O
for O
HPV O
- O
16 O
El O
and O
other O
superfamily B
3 I
( I
SF3 I
) I
viral O
helicases O
closely O
parallel O
the O
mapping O
data O
in O
suggesting O
that O
aa O
439 O
to O
623 O
constitute O
a O
discrete O
helicase O
domain O
. O

Assuming O
a O
common O
nucleoside O
triphosphate O
- O
binding O
fold O
, O
we O
have O
generated O
a O
structural O
model O
of O
this O
domain O
based O
on O
the O
X O
- O
ray O
structures O
of O
the O
hepatitis O
C O
virus O
and O
Bacillus O
stearothermophilus O
( O
SF2 O
) O
helicases O
, O
The O
modelling O
closely O
matches O
the O
deletion O
analysis O
in O
suggesting O
that O
this O
region O
of O
El O
is O
indeed O
a O
structural O
domain O
, O
and O
our O
results O
suggest O
that O
it O
is O
multifunctional O
and O
critical O
to O
several O
stages O
of O
HPV O
DNA O
replication O
. O

Chimeras O
between O
human O
( O
HM O
- O
175 O
) O
and O
simian O
( O
AGM O
- O
27 O
) O
strains O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
were O
constructed O
to O
evaluate O
the O
effect O
of O
the O
2C O
gene O
of O
AGM O
- O
27 O
on O
HAV O
replication O
in O
cell O
culture O
and O
virulence O
in O
tamarins O
( O
Saguinus O
mystax O
) O
and O
chimpanzees O
( O
Pan O
troglodytes O
) O
. O

Previous O
studies O
have O
shown O
that O
human O
respiratory O
coronavirus O
HCV O
- O
229E O
uses O
human O
aminopeptidase O
N O
( O
hAPN O
[ O
CD13 O
] O
) O
as O
its O
cellular O
receptor O
for O
infection O
of O
lung O
fibroblasts O
. O

An O
hAPN O
- O
specific O
monoclonal O
antibody O
( O
WM15 O
) O
, O
but O
not O
control O
antibody O
, O
inhibited O
the O
attachment O
of O
radiolabeled O
HCV O
- O
229E O
to O
astrocytic O
, O
neuronal O
, O
and O
oligodendrocytic O
cell O
lines O
. O

These O
results O
indicate O
that O
hAPN O
( O
CD13 O
) O
is O
expressed O
on O
neuronal O
and O
glial O
cell O
lines O
in O
vitro O
and O
serves O
as O
the O
receptor O
for O
infection O
by O
HCV O
- O
229E O
. O

The O
hepatitis B
A I
virus I
cellular I
receptor I
1 I
( I
HAVcr I
- I
1 I
) I
cDNA O
was O
isolated O
from O
a O
cDNA O
expression O
library O
of O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
cells O
by O
using O
protective O
monoclonal B
antibody I
( I
Mab I
) I
190 O
/ O
4 O
, O
which O
blocks O
the O
binding O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
to O
AGMK O
cells O
. O

To O
determine O
the O
existence O
of O
a O
human O
homolog O
( O
s O
) O
of O
HAVcr O
- O
1 O
( O
huHAVcr O
- O
1 O
) O
, O
we O
used O
HAVcr O
- O
1 O
- O
specific O
primers O
to O
amplify O
cDNAs O
from O
human O
liver O
and O
kidney O
mRNA O
by O
reverse O
transcription O
- O
PCR O
Nucleotide O
sequence O
analysis O
revealed O
that O
the O
amplified O
liver O
and O
kidney O
huHAVcr O
- O
1 O
cDNAs O
were O
identical O
and O
that O
they O
coded O
for O
a O
359 O
- O
amino O
- O
acid O
glycoprotein O
, O
termed O
huhavcr O
- O
1 O
, O
which O
was O
approximately O
79 O
% O
identical O
to O
havcr O
- O
1 O
. O

Northern O
blot O
analysis O
of O
poIy O
( O
A O
) O
RNA O
showed O
that O
huhavcr O
- O
1 O
is O
expressed O
in O
every O
organ O
analyzed O
, O
including O
the O
liver O
, O
small O
intestine O
, O
colon O
, O
and O
spleen O
, O
and O
that O
it O
is O
expressed O
at O
higher O
levels O
in O
the O
kidney O
and O
testis O
. O

Although O
dog O
cells O
transfected O
with O
the O
huHAVcr O
- O
1 O
cDNA O
did O
not O
express O
the O
protective O
190 O
/ O
4 O
epitope O
, O
they O
bound O
hepatitis B
A I
virus I
( I
HAV I
) I
and O
gained O
limited O
susceptibility O
to O
HAV O
infection O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
replicates O
by O
RNA O
- O
dependent O
RNA O
synthesis O
according O
to O
a O
double O
rolling O
circle O
model O
. O

8 O
- O
kb O
, O
polyadenylated O
mRNA O
encoding O
the O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
It O
has O
been O
proposed O
that O
this O
mRNA O
species O
represents O
the O
initial O
product O
of O
HDV O
RNA O
replication O
; O
subsequent O
production O
of O
genomic O
- O
length O
HDV O
RNA O
relies O
on O
suppression O
of O
the O
HDV O
RNA O
polyadenylation O
signal O
by O
HDAg O
. O

C57BL O
/ O
6 O
mice O
infected O
with O
Mouse B
hepatitis I
virus I
strain I
JHM I
( I
MHV I
- I
JHM I
) I
develop O
a O
chronic O
demyelinating O
encephalomyelitis O
several O
weeks O
after O
inoculation O
. O

Previously O
, O
we O
showed O
that O
mutations O
in O
the O
immunodominant O
CD8 O
T O
- O
cell O
epitope O
( O
S O
- O
510 O
- O
518 O
) O
could O
be O
detected O
in O
nearly O
all O
samples O
of O
RNA O
and O
virus O
isolated O
from O
these O
mice O
. O

These O
results O
suggested O
that O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
escape O
mutants O
contributed O
to O
virus O
amplification O
and O
the O
development O
of O
clinical O
disease O
in O
mice O
infected O
with O
wild O
- O
type O
virus O
. O

The O
infection O
of O
woodchucks O
with O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
provides O
an O
experimental O
model O
to O
study O
early O
immune O
responses O
during O
hepadnavirus O
infection O
that O
cannot O
be O
tested O
in O
patients O
. O

The O
first O
T O
- O
cell O
responses O
were O
directed O
against O
WHsAg O
3 O
weeks O
after O
infection O
; O
these O
were O
followed O
by O
responses O
to O
rWHcAg O
including O
the O
immunodominant O
T O
- O
cell O
epitope O
of O
WHcAg O
( O
amino O
acids O
97 O
to O
110 O
) O
, O
Maximal O
proliferative O
responses O
were O
detected O
when O
the O
animals O
seroconvered O
to O
anti O
- O
WHs O
and O
anti O
- O
WHc O
( O
week O
6 O
) O
, O
A O
decrease O
in O
the O
T O
- O
cell O
response O
to O
viral O
antigens O
coincided O
with O
clearance O
of O
viral O
DNA O
, O
Polyclonal O
rWHcAg O
- O
specific O
T O
- O
cell O
lines O
were O
established O
6 O
, O
12 O
, O
18 O
, O
and O
24 O
weeks O
postinfection O
, O
and O
their O
responses O
to O
WHcAg O
peptides O
were O
assessed O
. O

Five O
to O
seven O
peptides O
including O
the O
immunodominant O
epitope O
were O
recognized O
throughout O
the O
observation O
period O
( O
6 O
months O
) O
. O

Phosphorylation O
of O
the O
expressed O
NS5A O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
member O
of O
the O
Hepacivirus O
genus O
of O
the O
family O
Flaviviridae O
, O
has O
been O
demonstrated O
in O
mammalian O
cells O
and O
in O
a O
cell O
- O
free O
assay O
by O
an O
associated O
kinase O
activity O
. O

In O
this O
report O
, O
phosphorylation O
is O
also O
shown O
for O
the O
NS5A O
and O
NS5 O
proteins O
, O
respectively O
, O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
and O
yellow B
fever I
virus I
( I
YF I
) I
, O
members O
of O
the O
other O
two O
established O
genera O
in O
this O
family O
. O

monoclonal B
antibody I
( I
Mab I
) I
190 O
/ O
4 O
blocks O
binding O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
to O
the O
HAV B
cellular I
receptor I
1 I
( I
havcr I
- I
1 I
) I
and O
protects O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
clone O
GL37 B
cells I
( I
GL37 I
cells I
) I
against O
HAV O
infection O
. O

The O
hypervariable B
region I
1 I
( I
HVR I
- I
1 I
) I
of O
the O
putative O
envelope O
encoding O
E2 O
region O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
was O
analyzed O
in O
sequential O
samples O
from O
three O
patients O
with O
acute O
type O
C O
hepatitis O
infected O
from O
different O
sources O
to O
address O
( O
i O
) O
the O
dynamics O
of O
intrahost O
HCV O
variability O
during O
the O
primary O
infection O
and O
( O
ii O
) O
the O
role O
of O
host O
selective O
pressure O
in O
driving O
viral O
genetic O
evolution O
. O

The O
intrasample O
evolutionary O
analysis O
( O
nonsynonymous O
mutations O
per O
nonsynonymous O
site O
[ O
K O
- O
a O
] O
, O
synonymous O
mutations O
per O
synonymous O
site O
[ O
K O
- O
s O
] O
, O
K O
- O
a O
/ O
K O
- O
s O
ratio O
, O
and O
genetic O
distances O
[ O
gd O
] O
) O
documented O
low O
gd O
in O
early O
samples O
( O
ranging O
from O
2 O
. O

The O
intersample O
analysis O
( O
pairwise O
comparisons O
of O
intrapatient O
sequences O
; O
rK O
( O
a O
) O
, O
rK O
( O
s O
) O
, O
rK O
( O
a O
) O
/ O
rK O
( O
s O
) O
ratio O
, O
and O
gd O
) O
confirmed O
the O
individual O
features O
of O
HCV O
genetic O
evolution O
in O
the O
three O
subjects O
and O
pointed O
to O
the O
relative O
contribution O
of O
either O
neutral O
evolution O
or O
selective O
forces O
in O
driving O
viral O
variability O
, O
documenting O
that O
adaptation O
of O
HCV O
for O
persistence O
in O
vivo O
follows O
different O
routes O
, O
probably O
representing O
the O
molecular O
counterpart O
of O
the O
viral O
fitness O
for O
individual O
environments O
. O

Translation O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
RNAs O
is O
initiated O
by O
cap O
independent O
attachment O
( O
internal O
entry O
) O
of O
ribosomes O
to O
the O
similar O
to O
350 O
- O
nucleotide O
internal O
ribosomal O
entry O
segment O
( O
IRES O
) O
at O
the O
5 O
' O
end O
of O
both O
RNAs O
, O
Eukaryotic B
initiation I
factor I
3 I
( I
eIF3 I
) I
binds O
specifically O
to O
HCV O
and O
CSFV O
IRESs O
and O
plays O
an O
essential O
role O
in O
the O
initiation O
process O
on O
them O
. O

UV O
cross O
- O
linking O
of O
eIF3 O
to O
[ O
P O
- O
32 O
] O
UTP O
- O
labelled O
HCV O
and O
CSFV O
IRES O
elements O
resulted O
in O
strong O
labelling O
of O
4 O
( O
p170 O
, O
p116 O
, O
p66 O
, O
and O
p47 O
) O
of O
the O
10 O
subunits O
of O
eIF3 O
, O
1 O
or O
more O
of O
which O
are O
likely O
to O
be O
determinants O
of O
these O
interactions O
. O

The O
long O
- O
term O
evolution O
of O
the O
hepatitis O
C O
virus O
hypervariable B
region I
( I
HVR I
) I
and O
flanking O
regions O
of O
the O
El O
and O
E2 O
envelope O
proteins O
have O
been O
studied O
in O
a O
cohort O
of O
women O
infected O
from O
a O
common O
source O
of O
anti O
- O
D O
immunoglobulin O
. O

The O
putative O
envelope O
glycoproteins O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
likely O
play O
an O
important O
role O
in O
the O
initiation O
of O
viral O
infection O
. O

In O
this O
study O
, O
genomic O
regions O
which O
include O
the O
putative O
ectodomain O
of O
the O
E1 O
( O
amino O
acids O
174 O
to O
359 O
) O
and O
E2 O
( O
amino O
acids O
371 O
to O
742 O
) O
glycoproteins O
were O
appended O
to O
the O
transmembrane O
domain O
and O
cytoplasmic O
tail O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
G O
protein O
. O

When O
infected O
with O
a O
temperature O
- O
sensitive O
VSV O
mutant O
( O
ts045 O
) O
and O
grown O
at O
the O
nonpermissive O
temperature O
( O
40 O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
, O
unlike O
other O
picornaviruses O
, O
has O
a O
stow O
- O
growth O
phenotype O
in O
permissive O
cell O
lines O
and O
in O
general O
does O
not O
induce O
host O
cell O
cytopathology O
. O

The O
5 O
' O
noncoding O
region O
of O
HAV O
was O
fused O
to O
poliovirus B
( I
PV I
) I
coding O
sequences O
to O
determine O
the O
effect O
on O
translation O
efficiency O
in O
HeLa O
cell O
extracts O
in O
vitro O
, O
Conditions O
were O
optimized O
for O
utilization O
of O
the O
HAV O
internal B
ribosome I
entry I
segment I
( I
IRES I
) I
, O
Transcripts O
from O
chimeric O
constructs O
fused O
precisely O
at O
the O
initiation O
codon O
were O
translated O
very O
poorly O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
replicates O
in O
the O
nuclei O
of O
virus O
- O
infected O
cells O
. O

Using O
a O
fluorescein O
- O
labeled O
HDV O
RNA O
introduced O
into O
partially O
permeabilized O
HeLa O
cells O
, O
we O
found O
that O
HDV O
RNA O
accumulated O
only O
in O
the O
cytoplasm O
, O
However O
, O
in O
the O
presence O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
which O
is O
the O
only O
protein O
encoded O
by O
HDV O
RNA O
, O
the O
HDV O
RNA O
was O
translocated O
into O
the O
nucleus O
, O
suggesting O
that O
nuclear O
import O
of O
HDV O
RNA O
is O
mediated O
by O
HDAg O
. O

Deletion O
of O
the O
nuclear B
localization I
signal I
( I
NLS I
) I
or O
RNA O
- O
binding O
motifs O
of O
HDAg O
resulted O
in O
the O
failure O
of O
nuclear O
import O
of O
HDV O
RNA O
, O
indicating O
that O
both O
the O
NLS O
and O
an O
RNA O
- O
binding O
motif O
of O
HDAg O
are O
required O
for O
the O
RNA O
- O
transporting O
activity O
of O
HDAg O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
encodes O
two O
envelope O
glycoproteins O
( O
El O
and O
E2 O
) O
which O
interact O
noncovalently O
to O
form O
a O
heterodimer O
( O
E1 O
- O
E2 O
) O
. O

The O
intracellular O
assembly O
of O
the O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
was O
studied O
in O
infected O
swine B
testis I
( I
ST I
) I
cells O
at O
different O
postinfection O
times O
by O
using O
ultrathin O
sections O
of O
conventionally O
embedded O
infected O
cells O
, O
freeze O
substitution O
, O
and O
methods O
for O
detecting O
viral O
proteins O
and O
RNA O
at O
the O
electron O
microscopy O
level O
. O

While O
large O
virions O
with O
an O
electron O
- O
dense O
internal O
periphery O
and O
a O
clear O
central O
area O
are O
abundant O
at O
perinuclear O
regions O
, O
smaller O
viral O
particles O
, O
with O
the O
characteristic O
morphology O
of O
extracellular O
virions O
( O
exhibiting O
compact O
internal O
cores O
with O
polygonal O
contours O
) O
accumulate O
inside O
secretory O
vesicles O
that O
reach O
the O
plasma O
membrane O
. O

To O
study O
hepatitis B
C I
virus I
( I
HCV I
) I
genetic O
mutation O
during O
interferon B
( I
IFN I
) I
therapy O
, O
the O
temporal O
changes O
in O
HCV O
quasispecies O
heterogeneity O
were O
compared O
before O
and O
after O
treatment O
for O
nine O
patients O
infected O
with O
HCV O
genotype O
1 O
, O
including O
four O
nonresponders O
, O
four O
responders O
who O
relapsed O
after O
therapy O
, O
and O
one O
responder O
who O
experienced O
a O
breakthrough O
of O
viremia O
during O
therapy O
. O

Sequences O
from O
the O
second O
envelope O
glycoprotein O
gene O
hypervariable B
region I
1 I
( I
HVR1 I
) I
and O
the O
putative O
IFN B
sensitivity I
determining I
region I
( I
ISDR I
) I
of O
the O
nonstructural O
NS5A O
gene O
were O
analyzed O
by O
heteroduplex O
mobility O
assays O
and O
nucleotide O
sequencing O
. O

A O
strong O
positive O
correlation O
was O
found O
between O
the O
percent O
change O
in O
a O
heteroduplex B
mobility I
ratio I
( I
HMR I
) I
and O
percent O
change O
in O
nucleotide O
sequence O
( O
r O
= O
0 O
. O

12 O
) O
, O
On O
an O
individual O
patient O
basis O
, O
IFN O
therapy O
was O
associated O
with O
measurable O
HVR1 O
and O
ISDR O
mutation O
in O
nine O
of O
nine O
( O
100 O
% O
) O
and O
two O
of O
nine O
( O
22 O
. O

The O
3 O
' O
noncoding B
region I
( I
NCR I
) I
of O
the O
negative O
- O
strand O
RNA O
[ O
3 O
' O
( O
- O
) O
NCR O
RNA O
] O
of O
the O
arterivirus O
simian B
hemorrhagic I
fever I
virus I
( I
SHFV I
) I
is O
209 O
nucleotides B
( I
nt I
) I
in O
length O
. O

Since O
this O
3 O
' O
region O
, O
designated O
3 O
' O
( O
- O
) O
209 O
, O
is O
the O
site O
of O
initiation O
of O
full O
- O
length O
positive O
- O
strand O
RNA O
and O
is O
the O
template O
for O
the O
synthesis O
of O
the O
5 O
' O
leader O
sequence O
, O
which O
is O
found O
on O
both O
full O
- O
length O
and O
subgenomic O
mRNAs O
, O
it O
is O
likely O
to O
contain O
cis O
- O
acting O
signals O
for O
RNA O
synthesis O
and O
to O
interact O
with O
cellular O
and O
viral O
proteins O
to O
form O
replication O
complexes O
. O

Gel O
mobility O
shift O
assays O
showed O
that O
cellular O
proteins O
in O
MA104 O
S100 O
cytoplasmic O
extracts O
formed O
two O
complexes O
with O
the O
SHFV O
3 O
' O
( O
- O
) O
209 O
RNA O
, O
and O
results O
from O
competition O
gel O
mobility O
shift O
assays O
demonstrated O
that O
these O
interactions O
were O
specific O
. O

Four O
proteins O
with O
molecular O
masses O
of O
103 O
, O
86 O
, O
55 O
, O
and O
36 O
kDa O
were O
detected O
in O
UV O
- O
induced O
cross O
- O
linking O
assays O
, O
and O
three O
of O
these O
proteins O
( O
103 O
, O
55 O
, O
and O
36 O
kDa O
) O
were O
also O
detected O
by O
Northwestern O
blotting O
assays O
. O

Identical O
gel O
mobility O
shift O
and O
UV O
- O
induced O
cross O
- O
linking O
patterns O
were O
obtained O
with O
uninfected O
and O
SHFV O
- O
infected O
extracts O
, O
indicating O
that O
the O
four O
proteins O
detected O
are O
cellular O
, O
not O
viral O
, O
proteins O
, O
The O
binding O
sites O
for O
the O
four O
cellular O
proteins O
were O
mapped O
to O
the O
region O
between O
nt O
117 O
and O
184 O
( O
68 O
- O
nt O
sequence O
) O
from O
the O
3 O
' O
end O
of O
the O
SHFV O
negative O
- O
strand O
RNA O
. O

The O
3 O
' O
( O
- O
) O
NCR O
RNA O
of O
another O
arterivirus O
, O
lactate B
dehydrogenase I
- I
elevating I
virus I
C I
( I
LDV I
- I
C I
) I
, O
competed O
with O
the O
SHFV O
3 O
' O
( O
- O
) O
209 O
RNA O
in O
competition O
gel O
mobility O
shift O
assays O
. O

W O
- O
induced O
cross O
- O
linking O
assays O
showed O
that O
four O
MA104 O
cellular O
proteins O
with O
the O
same O
molecular O
masses O
as O
those O
that O
bind O
to O
the O
SHFV O
3 O
' O
( O
- O
) O
209 O
RNA O
also O
bind O
to O
the O
LDV O
- O
C O
3 O
' O
( O
- O
) O
NCR O
RNA O
and O
equine O
arteritis O
virus O
3 O
' O
( O
- O
) O
NCR O
RNA O
. O

The O
binding O
sites O
for O
the O
MA104 O
cellular O
proteins O
were O
shown O
to O
be O
located O
in O
similar O
positions O
in O
the O
LDV O
- O
C O
3 O
' O
( O
- O
) O
NCR O
and O
SHFV O
3 O
' O
( O
- O
) O
209 O
RNAs O
. O

In O
order O
to O
elucidate O
the O
structure O
and O
morphology O
of O
hepatitis B
G I
virus I
( I
HGV I
) I
, O
a O
recently O
isolated O
flavivirus O
, O
we O
generated O
a O
panel O
of O
eight O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
the O
putative O
second O
envelope O
protein O
( O
E2 O
) O
following O
DNA O
immunization O
. O

Hepatitis O
G O
virus O
( O
HGV O
or O
GB O
- O
C O
virus O
) O
is O
a O
newly O
described O
virus O
that O
is O
closely O
related O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

The O
replication O
sites O
of O
the O
recently O
discovered O
hepatitis B
G I
virus I
( I
HGV I
) I
remain O
unknown O
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
infections O
exhibit O
remarkable O
variability O
in O
cytopathology O
ranging O
from O
acutely O
cytolytic O
to O
essentially O
asymptomatic O
levels O
, O
In O
this O
report O
, O
we O
assess O
the O
role O
of O
the O
MHV B
receptor I
( I
MHVR I
) I
in O
controlling O
this O
variable O
virus O
- O
induced O
cytopathology O
, O
We O
developed O
human O
( O
HeLa O
) O
cell O
lines O
in O
which O
the O
MHVR O
was O
produced O
in O
a O
regulated O
fashion O
by O
placing O
MHVR O
cDNA O
under O
the O
control O
of O
an O
inducible O
promoter O
, O
Depending O
on O
the O
extent O
of O
induction O
, O
MHVR O
levels O
ranged O
from O
less O
than O
similar O
to O
1 O
, O
500 O
molecules O
per O
cell O
( O
designated O
R O
- O
lo O
) O
to O
similar O
to O
300 O
, O
000 O
molecules O
per O
cell O
( O
designated O
R O
- O
hi O
) O
. O

When O
the O
HeLa O
- O
MHVR O
cells O
were O
infected O
with O
vaccinia O
virus O
recombinants O
encoding O
MHV O
spike B
( I
S I
) I
proteins O
, O
the O
R O
- O
hi O
cells O
succumbed O
within O
12 O
h O
postinfection O
; O
R O
- O
lo O
cells O
infected O
in O
parallel O
were O
intact O
, O
as O
judged O
by O
trypan O
blue O
exclusion O
. O

We O
have O
previously O
reported O
that O
chimpanzees O
chronically O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
could O
be O
reinfected O
, O
even O
with O
the O
original O
infecting O
strain O
. O

The O
inoculum O
used O
in O
these O
studies O
( O
HCV O
- O
II O
, O
genotype O
la O
) O
revealed O
17 O
separate O
variants O
among O
46 O
clones O
sequenced O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
encodes O
two O
envelope O
glycoproteins O
( O
El O
and O
E2 O
) O
. O

These O
glycoproteins O
interact O
to O
form O
a O
noncovalent O
heterodimeric O
complex O
which O
is O
retained O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
To O
identify O
whether O
El O
and O
/ O
or O
E2 O
contains O
an O
ER O
- O
targeting O
signal O
potentially O
involved O
in O
ER O
retention O
of O
the O
E1 O
- O
E2 O
complex O
, O
these O
proteins O
were O
expressed O
alone O
and O
their O
intracellular O
localization O
was O
studied O
. O

Chimeric O
proteins O
in O
which O
E2 O
domains O
were O
exchanged O
with O
corresponding O
domains O
of O
a O
protein O
normally O
transported O
to O
the O
plasma O
membrane O
( O
CD4 O
) O
were O
constructed O
to O
identify O
the O
sequence O
responsible O
for O
its O
ER O
retention O
, O
The O
transmembrane B
domain I
( I
TMD I
) I
of O
E2 O
( O
C O
- O
terminal O
29 O
amino O
acids O
) O
was O
shown O
to O
be O
sufficient O
for O
retention O
of O
the O
ectodomain O
of O
CD4 O
in O
the O
ER O
compartment O
, O
Replacement O
of O
the O
E2 O
TMD O
by O
the O
anchor O
signal O
of O
CD4 O
or O
a O
glycosyl B
phosphatidylinositol I
( I
GPI I
) I
moiety O
led O
to O
its O
expression O
on O
the O
cell O
surface O
, O
In O
addition O
, O
replacement O
of O
the O
E2 O
TMD O
by O
the O
anchor O
signal O
of O
CD4 O
or O
a O
GPI O
moiety O
abolished O
the O
formation O
of O
E1 O
- O
E2 O
complexes O
. O

WH44KA O
cells O
contain O
a O
single O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
DNA O
integration O
in O
the O
3 O
' O
untranslated O
region O
of O
exon O
3 O
of O
the O
woodchuck O
N O
- O
myc1 O
gene O
, O
The O
highly O
rearranged O
WHV O
DNA O
contains O
WHV O
enhancers O
which O
activate O
the O
N O
- O
myc O
promoter O
, O
and O
a O
hybrid O
N O
- O
myc1 O
- O
WHV O
mRNA O
is O
produced O
, O
which O
leads O
to O
a O
high O
steady O
- O
state O
level O
of O
N O
- O
myc1 O
protein O
, O
To O
investigate O
whether O
continuous O
N O
- O
myc1 O
expression O
is O
required O
to O
maintain O
the O
tumor O
phenotype O
, O
we O
knocked O
out O
N O
- O
myc O
expression O
using O
a O
WHV O
- O
N O
- O
myc1 O
antisense O
vector O
. O

We O
identified O
two O
WH44KA O
antisense O
cell O
lines O
, O
designated O
4 O
- O
5 O
and O
4 O
- O
11 O
, O
in O
which O
steady O
- O
state O
N O
- O
myc1 O
protein O
levels O
were O
reduced O
by O
95 O
and O
80 O
% O
, O
respectively O
, O
The O
growth O
rates O
of O
both O
antisense O
cell O
lines O
were O
reduced O
in O
comparison O
to O
those O
of O
wild O
- O
type O
and O
vector O
controls O
, O
The O
phenotype O
of O
4 O
- O
5 O
and O
4 O
- O
11 O
cells O
changed O
to O
a O
flattened O
appearance O
, O
and O
the O
cells O
exhibited O
contact O
inhibition O
, O
Colony O
- O
forming O
ability O
in O
soft O
agar O
was O
reduced O
by O
92 O
% O
for O
4 O
- O
5 O
tells O
and O
by O
88 O
% O
for O
4 O
- O
11 O
cells O
, O
Cell O
line O
4 O
- O
11 O
formed O
only O
small O
, O
slow O
- O
growing O
tumors O
in O
nude O
mice O
, O
consistent O
with O
a O
low O
level O
of O
N O
- O
myc1 O
remaining O
in O
the O
cells O
, O
In O
contrast O
, O
4 O
- O
5 O
cells O
, O
in O
which O
N O
- O
myc O
protein O
was O
reduced O
by O
greater O
than O
95 O
% O
, O
foiled O
to O
form O
tumors O
in O
nude O
mice O
, O
The O
integrated O
WHV O
DNA O
contained O
the O
complete O
WHV B
X I
gene I
( I
WHx I
) I
and O
its O
promoter O
; O
however O
, O
we O
did O
not O
detect O
any O
WHx O
protein O
in O
the O
cells O
by O
using O
a O
sensitive O
assay O
, O
These O
data O
demonstrate O
that O
N O
- O
myc O
overexpression O
is O
required O
to O
maintain O
the O
malignant O
phenotype O
of O
WH44KA O
woodchuck O
hepatoma O
cells O
and O
provide O
a O
direct O
function O
for O
integrated O
WHV O
DNA O
in O
hepatocarcinogenesis O
. O

The O
3C B
- I
like I
proteinase I
( I
3CLpro I
) I
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
predicted O
to O
cleave O
at O
least O
11 O
sites O
in O
the O
803 O
- O
kDa O
gene O
I O
polyprotein O
, O
resulting O
in O
maturation O
of O
proteinase O
, O
polymerase O
, O
and O
helicase O
proteins O
, O
However O
, O
most O
of O
these O
cleavage O
sites O
have O
not O
been O
experimentally O
confirmed O
and O
the O
proteins O
have O
not O
been O
identified O
in O
vitro O
or O
in O
virus O
- O
infected O
cells O
, O
We O
used O
specific O
antibodies O
to O
identify O
and O
characterize O
a O
22 O
- O
kDa O
protein O
( O
p1a O
- O
22 O
) O
expressed O
from O
gene O
1 O
in O
MHV O
A59 O
- O
infected O
DBT O
cells O
, O
Processing O
of O
p1a O
- O
22 O
from O
the O
polyprotein O
began O
immediately O
after O
translation O
, O
but O
some O
processing O
continued O
for O
several O
hours O
, O
Amino O
- O
terminal O
sequencing O
of O
p1a O
- O
22 O
purified O
from O
MIN O
- O
infected O
cells O
showed O
that O
it O
was O
cleaved O
at O
a O
putative O
3CLpro O
cleavage O
site O
, O
Gln_Ser O
( O
4014 O
) O
( O
where O
the O
underscore O
indicates O
the O
site O
of O
cleavage O
) O
, O
that O
is O
located O
between O
the O
3CLpro O
domain O
and O
the O
end O
of O
open B
reading I
frame I
( I
ORF I
) I
la O
, O
Subclones O
of O
this O
region O
of O
gene O
1 O
were O
used O
to O
express O
polypeptides O
in O
vitro O
that O
contained O
one O
or O
more O
3CLpro O
cleavage O
sites O
, O
and O
cleavage O
of O
these O
substrates O
by O
recombinant O
3CLpro O
in O
vitro O
confirmed O
that O
amino O
- O
terminal O
cleavage O
of O
p1a O
- O
22 O
occurred O
at O
Gln_Ser O
( O
4014 O
) O
. O

We O
demonstrated O
that O
the O
carboxy O
- O
terminal O
cleavage O
of O
the O
p1a O
- O
22 O
protein O
occurred O
at O
Gln_Asn O
( O
4208 O
) O
, O
a O
sequence O
that O
had O
not O
been O
predicted O
as O
a O
site O
for O
cleavage O
by O
MHV O
3CLpro O
, O
Our O
results O
demonstrate O
the O
usefulness O
of O
recombinant O
MW O
3CLpro O
in O
identifying O
and O
confirming O
cleavage O
sites O
within O
the O
gene O
1 O
polyprotein O
. O

As O
an O
initial O
approach O
to O
define O
the O
requirements O
for O
the O
replication O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
member O
of O
the O
Flaviviridae O
family O
with O
a O
positive O
- O
strand O
RNA O
genome O
, O
full O
- O
length O
genomic O
and O
subgenomic O
RNAs O
were O
originated O
by O
in O
vitro O
transcription O
of O
diverse O
BVDV O
cDNA O
constructs O
and O
transfected O
into O
eucaryotic O
host O
cells O
, O
RNA O
replication O
was O
measured O
either O
directly O
by O
an O
RNase O
protection O
method O
or O
by O
monitoring O
the O
synthesis O
of O
viral O
protein O
, O
When O
full O
- O
length O
BVDV O
cRNA O
was O
initially O
applied O
, O
the O
synthesis O
of O
negative O
- O
strand O
RNA O
intermediates O
as O
well O
as O
progeny O
positive O
- O
strand O
RNA O
was O
detected O
posttransfection O
in O
the O
cytoplasm O
of O
the O
host O
cells O
, O
Compared O
to O
the O
negative O
- O
strand O
RNA O
, O
intermediate O
, O
an O
excess O
of O
positive O
- O
strand O
RNA O
was O
synthesized O
, O
Surprisingly O
, O
a O
subgenomic O
RNA O
molecule O
, O
DI9c O
, O
corresponding O
to O
a O
previously O
characterized O
defective O
interfering O
particle O
, O
was O
found O
to O
support O
both O
steps O
of O
RNA O
replication O
in O
the O
absence O
of O
a O
helper O
virus O
as O
, O
yell O
, O
thus O
functioning O
as O
an O
autonomous O
replicon O
, O
DI9c O
comprises O
the O
5 O
' O
and O
3 O
' O
untranslated O
regions O
of O
the O
BVDV O
genome O
and O
the O
coding O
regions O
of O
the O
autoprotease O
N O
- O
pro O
and O
the O
nonstructural O
proteins O
NS3 O
, O
NS4A O
NS4B O
, O
NS5A O
, O
and O
NS5B O
, O
Most O
interestingly O
, O
the O
NS2 O
polypeptide O
was O
thus O
determined O
to O
be O
nonessential O
for O
RNA O
replication O
, O
As O
expected O
, O
deletion O
of O
the O
genomic O
3 O
' O
end O
as O
well O
as O
abolition O
of O
the O
catalytic O
function O
of O
the O
virus O
- O
encoded O
serine O
protease O
resulted O
in O
DI9c O
molecules O
that O
were O
unable O
to O
replicate O
, O
Deletion O
of O
the O
entire O
N O
- O
pro O
gene O
also O
destroyed O
the O
ability O
of O
DI9c O
molecules O
to O
replicate O
, O
On O
the O
ether O
hand O
, O
DI9c O
derivatives O
in O
which O
the O
5 O
' O
third O
of O
the O
N O
- O
pro O
gene O
was O
fused O
to O
a O
ubiquitin O
gene O
, O
allowing O
the O
proteolytic O
release O
of O
NS3 O
in O
trans O
, O
turned O
out O
to O
be O
replication O
competent O
, O
These O
results O
suggest O
that O
the O
RNA O
sequence O
located O
at O
the O
5 O
' O
end O
of O
the O
open O
reading O
frame O
exerts O
an O
essential O
role O
during O
BVDV O
replication O
. O

mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
produces O
meningoencephalitis O
and O
severe O
hepatitis O
during O
acute O
infection O
. O

Infection O
of O
primary O
cells O
derived O
from O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
liver O
was O
examined O
to O
analyze O
the O
interaction O
of O
virus O
with O
individual O
cell O
types O
derived O
from O
the O
two O
principal O
sites O
of O
viral O
replication O
in O
vivo O
. O

For O
MHV O
- O
A59 O
, O
lack O
of O
syncytium O
formation O
correlates O
with O
lack O
of O
cleavage O
of O
the O
fusion O
glycoprotein O
, O
or O
spike B
( I
S I
) I
protein O
. O

To O
determine O
whether O
hepatitis B
A I
virus I
( I
HAV I
) I
could O
tolerate O
the O
insertion O
of O
exogenous O
sequences O
, O
we O
constructed O
full O
- O
length O
HAV O
cDNAs O
containing O
in O
- O
frame O
insertions O
at O
the O
N O
terminus O
of O
the O
polyprotein O
and O
transfected O
the O
derived O
T7 O
RNA O
polymerase O
in O
vitro O
transcripts O
into O
FRhK O
- O
4 O
cells O
. O

Replication O
of O
HAVvec1 O
, O
a O
construct O
containing O
an O
insertion O
of O
60 O
nucleotides O
coding O
for O
a O
polylinker O
, O
a O
2B O
/ O
2C O
cleavage O
site O
for O
HAV O
protease O
3C B
( I
pro I
) I
, O
and O
two O
initiation O
codons O
that O
restored O
the O
sequence O
of O
the O
N O
terminus O
of O
the O
polyprotein O
, O
was O
detected O
2 O
weeks O
after O
transfection O
by O
indirect O
immunofluorescence O
analysis O
using O
anti O
- O
HAV O
monoclonal O
antibodies O
. O

Replacement O
of O
the O
FLAG O
epitope O
with O
an O
epitope O
of O
the O
circumsporozoite B
protein I
( I
CSP I
) I
of O
Plasmodium O
falciparum O
resulted O
in O
its O
stable O
HAV O
- O
mediated O
expression O
for O
at O
least O
six O
serial O
passages O
in O
FRhK O
- O
4 O
cells O
. O

The O
genome O
of O
a O
recently O
identified O
virus O
, O
hepatitis B
G I
virus I
( I
HGV I
) I
, O
shows O
considerable O
homology O
to O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

NS4A O
of O
HGV O
was O
demonstrated O
to O
be O
a O
cofactor O
for O
NS3 O
- O
mediated O
proteolysis O
, O
with O
a O
region O
critical O
for O
activity O
residing O
between O
Leu O
( O
1561 O
) O
and O
Ala O
( O
1598 O
) O
. O

We O
previously O
demonstrated O
by O
site O
- O
directed O
mutagenesis O
analysis O
that O
the O
amino O
acid O
residues O
at O
positions O
62 O
and O
214 O
to O
216 O
in O
the O
N O
- O
terminal O
region O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
spike I
( I
S I
) I
protein O
are O
important O
for O
receptor O
- O
binding O
activity O
( O
H O
. O

To O
further O
identify O
the O
residues O
responsible O
for O
the O
activity O
, O
we O
isolated O
the O
mutant O
viruses O
that O
were O
not O
neutralized O
with O
the O
soluble O
form O
of O
MHV O
receptor O
proteins O
, O
since O
such O
mutants O
were O
expected O
to O
have O
mutations O
in O
amino O
acids O
responsible O
for O
receptor O
- O
binding O
activity O
, O
Five O
soluble B
- I
receptor I
- I
resistant I
( I
srr I
) I
mutants O
isolated O
had O
mutations O
in O
a O
single O
amino O
acid O
at O
three O
different O
positions O
: O
one O
was O
at O
position O
65 O
( O
Leu O
to O
His O
) O
( O
srr11 O
) O
in O
the O
S1 O
subunit O
and O
three O
were O
at O
position O
1114 O
( O
Leu O
to O
Phe O
) O
( O
srr3 O
, O
srr4 O
, O
and O
srr7 O
) O
and O
one O
was O
at O
position O
1163 O
( O
Cys O
to O
Phe O
) O
( O
srr18 O
) O
in O
the O
S2 O
subunit O
. O

Activation O
of O
the O
immune O
coagulation O
system O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
fulminant O
liver O
failure O
caused O
by O
murine B
hepatitis I
virus I
strain I
3 I
( I
MHV I
- I
3 I
) I
. O

The O
recent O
discovery O
of O
the O
fgl2 O
gene O
, O
which O
encodes O
for O
MHV O
- O
3 O
- O
induced O
prothrombinase O
( O
fgl2 O
prothrombinase O
) O
, O
allows O
for O
fundamental O
studies O
to O
determine O
the O
molecular O
basis O
for O
fulminant O
liver O
failure O
. O

We O
have O
used O
the O
bovine B
coronavirus I
( I
BCV I
) I
as O
a O
model O
to O
study O
interactions O
between O
the O
viral O
proteins O
in O
virus O
- O
infected O
cells O
that O
are O
important O
for O
coronavirus O
assembly O
. O

BCV O
is O
a O
prototype O
for O
the O
coronaviruses O
that O
express O
an O
additional O
major O
structural O
protein O
, O
the O
hemagglutinin B
esterase I
( I
HE I
) I
, O
in O
addition O
to O
the O
spike B
( I
S I
) I
glycoprotein O
, O
membrane B
( I
M I
) I
glycoprotein O
, O
and O
nucleocapsid B
( I
N I
) I
protein O
. O

The O
carboxyl O
- O
terminal O
three O
- O
fourths O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
protein O
has O
been O
shown O
to O
possess O
an O
RNA O
helicase O
activity O
, O
typical O
of O
members O
of O
the O
DEAD O
box O
family O
of O
RNA O
helicases O
. O

In O
order O
to O
inspect O
the O
roles O
of O
individual O
amino O
acid O
residues O
in O
the O
four O
conserved O
motifs O
( O
AXXXXGKS O
, O
DECH O
, O
TAT O
, O
and O
QRRGRTGR O
) O
of O
the O
NS3 O
protein O
, O
mutational O
analysis O
was O
used O
in O
this O
study O
. O

Lys1235 O
in O
the O
AXXXXGKS O
motif O
was O
important O
for O
basal O
nucleoside B
triphosphatase I
( I
NTPase I
) I
activity O
in O
the O
absence O
of O
polynucleotide O
cofactor O
. O

The O
synthesis O
of O
picornavirus O
polyproteins O
is O
initiated O
cap O
independently O
far O
downstream O
from O
the O
5 O
' O
end O
of O
the O
viral O
RNA O
at O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

The O
cellular O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
binds O
to O
the O
IRES O
of O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
positive O
- O
stranded O
RNA O
genome O
of O
approximately O
9 O
. O

5 O
kb O
, O
Despite O
the O
overall O
sequence O
diversity O
among O
individual O
HCV O
isolates O
, O
the O
3 O
' O
- O
end O
98 O
nucleotides B
( I
nt I
) I
of O
the O
HCV O
RNA O
, O
which O
constitute O
part O
of O
the O
3 B
' I
- I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
, O
are O
highly O
conserved O
. O

This O
conserved O
region O
may O
contain O
the O
cis O
- O
acting O
signals O
for O
RNA O
replication O
involving O
possibly O
both O
viral O
and O
cellular O
proteins O
, O
We O
carried O
out O
RNase O
digestion O
studies O
, O
which O
revealed O
that O
this O
98 O
- O
nt O
region O
contains O
three O
stem O
- O
loops O
but O
may O
also O
assume O
alternative O
structures O
, O
We O
further O
performed O
UV O
cross O
- O
linking O
experiments O
to O
detect O
cellular O
proteins O
that O
bound O
to O
this O
region O
, O
A O
58 O
- O
kDa O
cellular O
protein O
( O
p58 O
) O
was O
detected O
, O
Its O
binding O
site O
was O
mapped O
to O
the O
stem O
- O
loops O
2 O
and O
3 O
, O
which O
are O
the O
most O
conserved O
region O
of O
the O
3 O
' O
- O
UTR O
. O

Site O
- O
directed O
mutagenesis O
studies O
revealed O
that O
both O
stem O
structures O
and O
specific O
nucleotide O
sequence O
within O
the O
two O
loops O
are O
important O
for O
p58 O
binding O
, O
Mutations O
that O
disrupted O
stem O
structures O
abolished O
protein O
binding O
, O
while O
the O
compensatory O
mutations O
restored O
its O
binding O
, O
This O
region O
also O
contains O
partial O
sequence O
similarity O
to O
the O
reported O
consensus O
binding O
sequence O
for O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
( O
a O
57 O
- O
kDa O
protein O
) O
, O
The O
UV O
- O
cross O
- O
linked O
protein O
could O
be O
immunoprecipitated O
with O
the O
anti O
- O
PTB O
antibody O
, O
and O
the O
recombinant O
PTB O
bound O
to O
the O
HCV O
3 O
' O
- O
UTR O
with O
the O
same O
binding O
specificity O
as O
p58 O
, O
establishing O
that O
this O
protein O
is O
PTB O
, O
However O
, O
the O
reported O
PTB O
- O
binding O
sequence O
was O
not O
sufficient O
, O
but O
rather O
the O
entire O
stem O
- O
loops O
2 O
and O
3 O
were O
required O
, O
for O
PTB O
binding O
; O
thus O
, O
its O
binding O
specificity O
is O
significantly O
different O
from O
the O
reported O
PTB O
- O
binding O
sequence O
requirement O
, O
This O
protein O
was O
detected O
in O
both O
the O
nuclei O
and O
cytoplasm O
of O
most O
mammalian O
cell O
lines O
tested O
and O
human O
primary O
hepatocytes O
, O
PTB O
may O
participate O
in O
the O
regulation O
of O
HCV O
RNA O
synthesis O
or O
translation O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
region I
5A I
( I
NS5A I
) I
protein O
, O
without O
its O
146 O
amino O
- O
terminal O
amino O
acids O
and O
fused O
to O
the O
DNA O
- O
binding O
domain O
of O
GAL4 O
, O
strongly O
activates O
transcription O
in O
yeast O
and O
human O
hepatoma O
cells O
. O

NS5A O
derived O
from O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
Ib O
isolate O
has O
previously O
been O
shown O
to O
undergo O
phosphorylation O
on O
serine O
residues O
( O
T O
, O
Kaneko O
, O
Y O
, O
Tanji O
, O
S O
. O

Phosphoamino O
acid O
analysis O
of O
NS5A O
from O
the O
la O
isolate O
indicated O
that O
phosphorylation O
occurs O
predominantly O
on O
serine O
, O
with O
a O
minor O
fraction O
of O
threonine O
residues O
also O
being O
phosphorylated O
, O
NS5A O
phosphorylation O
was O
observed O
in O
diverse O
cell O
types O
, O
including O
COS O
- O
1 O
, O
BHK O
- O
21 O
, O
HeLa O
, O
and O
the O
hepatoma O
cell O
line O
HuH O
- O
7 O
, O
Phosphorylation O
of O
a O
glutathione B
S I
- I
transferase I
( I
GST I
) I
/ O
HCV O
- O
H O
NS5A O
fusion O
protein O
was O
also O
demonstrated O
in O
an O
in O
vitro O
kinase O
assay O
, O
This O
activity O
seemed O
to O
be O
highest O
when O
the O
pH O
of O
the O
reaction O
was O
neutral O
or O
slightly O
alkaline O
and O
displayed O
a O
preference O
for O
Mn2 O
+ O
over O
Mg2 O
+ O
, O
with O
an O
optimum O
concentration O
of O
approximately O
10 O
mM O
Mn2 O
+ O
, O
Somewhat O
surprisingly O
, O
in O
vitro O
phosphorylation O
of O
NS5A O
was O
inhibited O
by O
the O
addition O
of O
greater O
than O
or O
equal O
to O
0 O
. O

25 O
mM O
Ca2 O
+ O
to O
reaction O
buffer O
containing O
Mn2 O
+ O
and O
/ O
or O
Mg2 O
+ O
, O
Comparison O
of O
phosphopeptide O
maps O
of O
NS5A O
phosphorylated O
in O
vitro O
and O
in O
cultured O
cells O
showed O
that O
most O
of O
the O
phosphopeptides O
comigrated O
, O
suggesting O
that O
one O
or O
more O
kinases O
involved O
in O
NS5A O
phosphorylation O
in O
vivo O
and O
in O
vitro O
are O
the O
same O
, O
The O
effects O
of O
various O
kinase O
inhibitors O
on O
NS5A O
phosphorylation O
were O
consistent O
with O
a O
kinase O
activity O
belonging O
to O
the O
CMGC O
group O
of O
serine O
- O
threonine O
kinases O
, O
The O
development O
of O
an O
in O
vitro O
kinase O
assay O
for O
NS5A O
phosphorylation O
should O
facilitate O
identification O
of O
kinase O
( O
s O
) O
responsible O
for O
its O
phosphorylation O
and O
of O
phosphorylation O
sites O
which O
may O
influence O
the O
function O
of O
NS5A O
in O
HCV O
propagation O
. O

The O
RNA O
genome O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
terminates O
with O
a O
highly O
conserved O
98 O
- O
base O
sequence O
. O

DNA O
vaccine O
candidates O
for O
foot B
and I
- I
mouth I
disease I
( I
FMD I
) I
were O
engineered O
to O
produce O
FMD O
virus O
( O
FMDV O
particles O
that O
were O
noninfectious O
in O
cell O
culture O
or O
animals O
, O
The O
prototype O
plasmid O
, O
pWRM O
, O
contains O
a O
cytomegalovirus O
immediate O
- O
early O
promoter O
- O
driven O
genome O
- O
length O
type O
All O
cDNA O
followed O
by O
the O
bovine O
growth O
hormone O
polyadenylation O
site O
, O
BHK O
cells O
transfected O
with O
this O
plasmid O
produced O
virus O
, O
but O
the O
specific O
infectivity O
of O
pWRM O
was O
much O
lon O
- O
er O
than O
that O
achieved O
with O
in O
vitro O
- O
generated O
RNA O
genomes O
, O
To O
improve O
the O
infectivity O
of O
the O
plasmid O
, O
a O
cDNA O
encoding O
the O
hepatitis O
delta O
virus O
ribozyme O
was O
added O
to O
the O
3 O
' O
end O
of O
the O
FMDV O
cDNA O
. O

A O
derivative O
of O
pWRMHX O
, O
pWRMHX O
- O
pol O
( O
- O
) O
, O
harboring O
a O
mutation O
designed O
to O
inactivate O
the O
viral O
polymerase O
was O
much O
less O
immunogenic O
, O
indicating O
that O
immunogenicity O
of O
pWRMHX O
resulted O
, O
in O
part O
, O
from O
amplification O
of O
the O
viral O
genome O
in O
the O
animal O
. O

The O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
positive O
- O
sense O
RNA O
genome O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
contains O
sequences O
that O
are O
necessary O
for O
the O
synthesis O
of O
negative O
- O
strand O
viral O
RNA O
as O
well O
as O
sequences O
that O
may O
be O
crucial O
for O
both O
genomic O
and O
subgenomic O
positive O
- O
strand O
RNA O
synthesis O
. O

We O
have O
found O
that O
the O
entire O
3 O
' O
UTR O
of O
MHV O
could O
be O
replaced O
by O
the O
3 O
' O
UTR O
of O
bovine B
coronavirus I
( I
BCV I
) I
, O
which O
diverges O
overall O
by O
31 O
% O
in O
nucleotide O
sequence O
. O

Under O
certain O
conditions O
, O
C57BL O
/ O
6 O
mice O
persistently O
infected O
with O
Mouse B
hepatitis I
virus I
strain I
JHM I
( I
MHV I
- I
JHM I
) I
develop O
clinical O
disease O
and O
histological O
evidence O
of O
demyelination O
several O
weeks O
after O
inocula O
tion O
with O
virus O
. O

In O
a O
previous O
report O
, O
we O
showed O
that O
mutations O
in O
the O
RNA O
encoding O
an O
immunodominant O
CD8 O
T O
- O
cell O
epitope O
within O
the O
surface O
glycoprotein O
( O
epitope O
S O
- O
510 O
- O
518 O
) O
were O
present O
in O
all O
persistently O
infected O
animals O
and O
that O
these O
mutations O
abrogated O
recognition O
by O
virus O
- O
specific O
cytotoxic B
T I
cells I
( I
CTLs I
) I
in O
direct O
es O
vivo O
cytotoxicity O
assays O
, O
To O
obtain O
further O
evidence O
that O
these O
mutations O
were O
necessary O
for O
the O
development O
of O
clinical O
disease O
, O
the O
temporal O
course O
of O
their O
appearance O
was O
determined O
, O
Mutations O
in O
the O
epitope O
were O
identified O
by O
10 O
to O
12 O
days O
after O
inoculation O
, O
and O
in O
some O
mice O
, O
virus O
containing O
mutated O
epitope O
was O
the O
dominant O
species O
detected O
by O
15 O
days O
, O
In O
addition O
, O
most O
mice O
that O
remain O
asymptomatic O
at O
80 O
days O
after O
inoculation O
, O
a O
time O
after O
which O
clinical O
disease O
almost O
never O
develops O
, O
were O
infected O
with O
only O
wild O
- O
type O
virus O
, O
Finally O
, O
analysis O
of O
virus O
isolated O
from O
mice O
with O
severe B
combined I
immunodeficiency I
( I
SCID I
) I
revealed O
the O
presence O
only O
of O
wild O
- O
type O
epitope O
S O
- O
510 O
- O
518 O
, O
These O
results O
, O
by O
showing O
that O
mutations O
are O
not O
selected O
in O
SCID O
mice O
and O
occur O
at O
earl O
; O
. O

Processing O
at O
the O
C O
terminus O
of O
the O
NS2 O
protein O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
mediated O
by O
a O
virus O
- O
encoded O
protease O
which O
spans O
most O
of O
the O
NS2 O
protein O
and O
part O
of O
the O
NS3 O
polypeptide O
. O

A O
serine O
proteinase O
encoded O
in O
the O
N O
- O
terminal O
181 O
residues O
of O
the O
NS3 O
nonstructural O
protein O
is O
responsible O
for O
cleavage O
at O
four O
sites O
( O
3 O
/ O
4A O
, O
4A O
/ O
4B O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
) O
in O
the O
nonstructural O
region O
. O

In O
addition O
, O
two O
more O
hydrophobic O
residues O
in O
the O
NS4A O
central O
region O
( O
valine O
- O
23 O
and O
isoleucine O
- O
25 O
) O
were O
also O
shown O
to O
be O
essential O
for O
the O
cofactor O
activity O
and O
for O
the O
interaction O
with O
either O
the O
NS3 O
proteinase O
or O
the O
NS4B5A O
polyprotein O
substrate O
. O

Phylogenetic O
analysis O
of O
44 O
GB B
virus I
C I
( I
GBV I
- I
C I
) I
5 I
' I
- I
untranslated I
region I
( I
5 I
' I
- I
UTR I
) I
sequences O
from O
37 O
individuals O
suggested O
the O
presence O
of O
GBV O
- O
C O
genotypes O
( O
A O
. O

We O
have O
extended O
our O
analysis O
to O
include O
5 O
' O
- O
UTR O
sequences O
from O
129 O
globally O
distributed O
GBV O
- O
C O
isolates O
and O
sequences O
from O
the O
second O
envelope O
protein O
( O
E2 O
) O
gene O
and O
nonstructural B
( I
NS I
) I
regions O
3 O
and O
5b O
from O
a O
subset O
of O
these O
isolates O
. O

We O
previously O
identified O
a O
highly O
conserved O
98 O
- O
nucleotide B
( I
nt I
) I
sequence O
, O
the O
3 O
' O
X O
, O
as O
the O
extreme O
3 O
' O
- O
terminal O
structure O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
( O
T O
. O

In O
this O
study O
, O
we O
found O
that O
both O
38 O
- O
and O
57 O
- O
kDa O
proteins O
in O
the O
human O
hepatocyte O
line O
PH5CH O
bound O
specifically O
to O
the O
3 O
' O
- O
end O
structure O
of O
HCV O
positive O
- O
strand O
RNA O
by O
a O
UV O
- O
induced O
cross O
- O
linking O
assay O
, O
The O
57 B
- I
kDa I
protein I
( I
p57 I
) I
, O
which O
had O
higher O
affinities O
to O
RNA O
probes O
, O
recognized O
a O
26 O
- O
nt O
sequence O
including O
the O
5 O
' O
- O
terminal O
19 O
nt O
of O
the O
3 O
' O
X O
and O
7 O
flanking O
nt O
, O
designated O
the O
transitional O
region O
. O

This O
sequence O
contains O
pyrimidine O
- O
rich O
motifs O
and O
show O
' O
s O
similarity O
to O
the O
consensus O
binding O
sequence O
of O
the O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
, O
which O
has O
been O
implicated O
in O
alternative O
pre O
- O
mRNA O
splicing O
and O
cap O
- O
independent O
translation O
. O

Of O
13 O
different O
strains O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
the O
inoculum O
used O
, O
only O
1 O
persisted O
in O
human O
lymphocyte O
cell O
lines O
infected O
in O
vitro O
( O
N O
. O

To O
determine O
whether O
that O
particular O
strain O
( O
designated O
H1 O
- O
2 O
) O
has O
a O
tropism O
for O
lymphocytes O
in O
vivo O
, O
we O
sequenced O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
genome O
of O
HCV O
recovered O
from O
the O
sera O
, O
livers O
, O
and O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
of O
chimpanzees O
infected O
with O
plasma O
H77 O
, O
the O
same O
inoculum O
used O
for O
the O
in O
vitro O
studies O
, O
In O
the O
PBMC O
collected O
from O
two O
chimpanzees O
during O
the O
early O
phase O
of O
infection O
, O
H1 O
- O
2 O
was O
detected O
as O
the O
only O
or O
predominant O
HVR1 O
sequence O
, O
H1 O
- O
2 O
was O
also O
detected O
in O
PBMC O
obtained O
during O
persistent O
infection O
from O
a O
chimpanzee O
that O
had O
been O
treated O
with O
immunosuppressants O
, O
From O
the O
livers O
of O
these O
chimpanzees O
, O
two O
to O
six O
different O
strains O
were O
recovered O
but O
H1 O
- O
2 O
was O
not O
detected O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
has O
two O
envelope O
proteins O
, O
E1 O
and O
E2 O
, O
which O
form O
a O
heterooligomer O
, O
During O
dissection O
of O
interacting O
regions O
of O
HCV O
E1 O
and O
E2 O
, O
we O
found O
the O
presence O
of O
an O
interfering O
compound O
or O
compounds O
in O
skim O
milk O
, O
Here O
we O
report O
that O
human O
as O
well O
as O
bovine O
lactoferrin O
, O
a O
multifunctional O
immunomodulator O
, O
binds O
two O
HCV O
envelope O
proteins O
. O

As O
determined O
by O
far O
- O
Western O
blotting O
, O
the O
bacterially O
expressed O
E1 O
and O
E2 O
could O
bind O
lactoferrin O
in O
human O
milk O
directly O
separated O
or O
immunopurified O
and O
separated O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
, O
The O
bindings O
of O
lactoferrin O
and O
HCV O
envelope O
proteins O
in O
vitro O
were O
confirmed O
by O
another O
method O
, O
the O
pull O
- O
down O
assay O
, O
with O
immunoprecipitated O
lactoferrin O
- O
bound O
protein O
A O
resin O
, O
By O
the O
same O
assay O
, O
mammal O
- O
expressed O
recombinant O
E1 O
and O
E2 O
were O
also O
demonstrated O
to O
bind O
human O
lactoferrin O
efficiently O
in O
vitro O
, O
Direct O
interaction O
between O
E2 O
and O
lactoferrin O
was O
proved O
in O
vivo O
, O
since O
anti O
- O
human O
lactoferrin O
antibody O
efficiently O
coimmunoprecipitated O
with O
secreted O
and O
intracellular O
forms O
of O
the O
E2 O
protein O
, O
but O
not O
glutathione B
S I
- I
transferase I
( I
GST I
) I
, O
from O
lysates O
of O
HepG2 O
cells O
transiently O
cotransfected O
with O
the O
expression O
plasmids O
of O
human O
lactoferrin O
and O
gE2t O
- O
GST O
( O
the O
N O
- O
terminal O
two O
- O
thirds O
of O
E2 O
fused O
to O
GST O
) O
or O
GST O
, O
The O
N O
- O
terminal O
loop O
of O
lactoferrin O
, O
the O
region O
important O
for O
the O
antibacterial O
activity O
, O
has O
only O
a O
little O
role O
in O
the O
binding O
ability O
to O
HCV O
E2 O
but O
affected O
the O
secretion O
or O
stability O
of O
lactoferrin O
, O
Taken O
together O
, O
these O
results O
indicate O
the O
specific O
interaction O
between O
lactoferrin O
and O
HCV O
envelope O
proteins O
in O
vivo O
and O
in O
vitro O
. O

We O
previously O
reported O
the O
association O
between O
a O
strong O
and O
sustained O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
to O
nonstructural B
protein I
3 I
( I
NS3 I
) I
of O
the O
hepatitis O
C O
virus O
and O
a O
self O
- O
limited O
course O
of O
acute O
hepatitis O
C O
infection O
. O

In O
this O
study O
, O
, O
ve O
identify O
an O
immunodominant O
CD4 O
( O
+ O
) O
T O
cell O
epitope O
( O
amino O
acids O
1248 O
to O
1261 O
) O
that O
was O
recognized O
by O
the O
majority O
( O
14 O
of O
23 O
) O
of O
NS3 O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
clones O
from O
four O
of O
five O
patients O
with O
acute O
hepatitis O
C O
infection O
. O

This O
epitope O
can O
be O
presented O
to O
CD4 O
( O
+ O
) O
T O
cells O
by O
HLA O
- O
DR4 O
, O
- O
DR11 O
, O
- O
DR12 O
, O
- O
DR13 O
, O
and O
- O
DR16 O
. O

HLA O
- O
binding O
studies O
revealed O
a O
high O
binding O
affinity O
for O
10 O
of O
13 O
common O
HLA O
- O
DR O
alleles O
, O
Two O
additional O
CD4 O
( O
+ O
) O
T O
cell O
epitopes O
, O
amino O
acids O
1388 O
to O
1407 O
and O
amino O
acids O
1450 O
to O
1469 O
, O
showed O
a O
very O
narrow O
pattern O
of O
binding O
to O
individual O
HLA O
- O
DR O
alleles O
. O

Our O
data O
suggest O
that O
the O
NS3 O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
in O
acute O
hepatitis O
C O
infection O
is O
dominated O
by O
a O
single O
, O
promiscuous O
peptide O
epitope O
which O
could O
become O
a O
promising O
candidate O
for O
the O
development O
of O
a O
CD4 O
( O
+ O
) O
T O
- O
cell O
vaccine O
. O

Coronavirus O
RNA O
evolves O
in O
the O
central B
nervous I
systems I
( I
CNS I
) I
of O
mice O
during O
persistent O
infection O
. O

This O
evolution O
can O
be O
monitored O
by O
detection O
of O
a O
viral O
quasispecies O
of O
spike B
deletion I
variants I
( I
SDVs I
) I
( O
C O
. O

We O
probed O
the O
substrate O
specificity O
of O
a O
recombinant O
noncovalent O
complex O
of O
the O
full O
- O
length O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
serine O
protease O
and O
NS4A O
cofactor O
, O
using O
a O
series O
of O
small O
synthetic O
peptides O
derived O
from O
the O
three O
trans O
- O
cleavage O
sites O
of O
the O
HCV O
nonstructural O
protein O
sequence O
. O

The O
values O
of O
the O
turnover O
number O
( O
k O
( O
cat O
) O
) O
for O
the O
most O
efficient O
NS4A O
/ O
4B O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
peptide O
substrates O
were O
1 O
. O

6 O
, O
11 O
, O
and O
8 O
min O
( O
- O
1 O
) O
, O
respectively O
, O
and O
the O
values O
for O
the O
corresponding O
Michaelis O
- O
Menten O
constants O
( O
K O
- O
m O
) O
were O
280 O
, O
160 O
, O
and O
16 O
mu O
M O
, O
providing O
catalytic O
efficiency O
values O
( O
k O
( O
cat O
) O
/ O
K O
- O
m O
) O
of O
92 O
, O
1 O
, O
130 O
, O
and O
8 O
, O
300 O
M O
- O
1 O
s O
( O
- O
1 O
) O
. O

An O
alanine O
- O
scanning O
study O
for O
an O
NS5A O
/ O
5B O
substrate O
( O
P6P4 O
' O
) O
revealed O
that O
P1 O
Cys O
and O
P3 O
Val O
were O
critical O
. O

Finally O
, O
substitutions O
at O
the O
scissile O
P1 O
Cys O
residue O
by O
homocysteine B
( I
Hcy I
) I
, O
S B
- I
methylcysteine I
( I
Mcy I
) I
, O
Ala O
, O
S B
- I
ethylcysteine I
( I
Ecy I
) I
, O
Thr O
, O
Met O
, O
D O
- O
Cys O
, O
Ser O
, O
and O
penicillamine B
( I
Pen I
) I
produced O
progressively O
less O
efficient O
substrates O
, O
revealing O
a O
stringent O
stereochemical O
requirement O
for O
a O
Cys O
residue O
at O
this O
position O
. O

Subcellular O
localization O
of O
the O
NS2 O
and O
NS3 O
proteins O
of O
hepatitis O
C O
virus O
was O
analysed O
, O
In O
stable O
Ltk O
transfectants O
inducibly O
expressing O
an O
NS2 O
- O
NS3 O
polyprotein O
( O
amino O
acids O
[ O
aa O
] O
810 O
to O
1463 O
) O
, O
processed O
full O
- O
size O
NS2 O
( O
aa O
810 O
to O
1026 O
) O
was O
detected O
exclusively O
in O
a O
cytoplasmic O
membrane O
fraction O
, O
On O
the O
other O
hand O
, O
the O
other O
processed O
product O
, O
carboxy O
- O
truncated O
NS3 O
( O
NS3 O
Delta O
C1463 O
; O
aa O
1027 O
to O
1463 O
) O
, O
was O
present O
in O
both O
cytoplasmic O
and O
nuclear O
fractions O
, O
To O
further O
analyze O
subcellular O
localization O
of O
NS3 O
, O
NS3 O
Delta O
C1459 O
( O
aa O
1027 O
to O
1459 O
) O
, O
full O
- O
size O
NS3 O
( O
NS3F O
; O
aa O
1027 O
to O
1657 O
) O
and O
both O
amino O
- O
and O
carboxy O
- O
truncated O
NS3 O
( O
NS3 O
Delta O
N O
Delta O
C O
; O
aa O
1201 O
to O
1459 O
) O
were O
expressed O
in O
HeLa O
cells O
by O
using O
a O
vaccinia O
virus O
- O
T7 O
hybrid O
expression O
system O
. O

NS3 O
Delta O
C1459 O
and O
NS3F O
accumulated O
in O
the O
nucleus O
as O
well O
as O
in O
the O
cytoplasm O
, O
exhibiting O
a O
dot O
- O
like O
staining O
pattern O
, O
On O
the O
other O
hand O
; O
NS3 O
Delta O
N O
Delta O
C O
was O
localized O
predominantly O
in O
the O
cytoplasm O
, O
suggesting O
the O
presence O
of O
a O
nuclear O
localization O
signal O
( O
s O
) O
in O
the O
amino O
- O
terminal O
sequence O
of O
NS3 O
. O

Previous O
studies O
of O
attenuated O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
vaccines O
in O
rhesus O
macaques O
have O
demonstrated O
the O
development O
of O
broad O
protection O
against O
experimental O
challenge O
, O
indicating O
the O
potential O
for O
the O
production O
of O
highly O
effective O
immune O
responses O
to O
SIV O
antigens O
. O

However O
, O
the O
development O
of O
this O
protective O
immune O
status O
was O
found O
to O
be O
critically O
dependent O
on O
the O
length O
of O
time O
postvaccination O
with O
the O
attenuated O
virus O
strain O
, O
suggesting O
a O
necessary O
maturation O
of O
immune O
responses O
, O
In O
this O
study O
, O
the O
evolution O
of O
SIV O
envelope O
- O
specific O
antibodies O
in O
monkeys O
experimentally O
infected O
with O
various O
attenuated O
strains O
of O
SIV O
was O
characterized O
by O
using O
a O
comprehensive O
panel O
of O
serological O
assays O
to O
assess O
the O
progression O
of O
antibodies O
in O
longitudinal O
serum O
samples O
that O
indicate O
the O
development O
of O
protective O
immunity O
, O
In O
parallel O
studies O
, O
we O
also O
used O
the O
same O
panel O
of O
antibody O
assays O
to O
characterize O
the O
properties O
of O
SN O
envelope O
- O
specific O
antibodies O
elicited O
by O
inactivated O
whole O
- O
virus O
and O
envelope O
subunit O
vaccines O
previously O
reported O
to O
be O
ineffective O
in O
producing O
protective O
immunity O
, O
The O
results O
of O
these O
studies O
demonstrate O
that O
the O
evolution O
of O
protective O
immunity O
in O
monkeys O
inoculated O
with O
attenuated O
strains O
of O
SIV O
is O
associated O
with O
a O
complex O
and O
lengthy O
maturation O
of O
antibody O
responses O
over O
the O
first O
6 O
to O
8 O
months O
postinoculation O
, O
as O
reflected O
in O
progressive O
changes O
in O
antibody O
conformational O
dependence O
and O
avidity O
properties O
, O
The O
establishment O
of O
long O
- O
term O
protective O
immunity O
at O
this O
time O
in O
general O
parallels O
the O
absence O
of O
further O
detectable O
changes O
in O
antibody O
responses O
and O
a O
maintenance O
of O
relatively O
constant O
antibody O
titer O
, O
avidity O
, O
conformational O
dependence O
, O
and O
the O
presence O
of O
neutralizing O
antibody O
for O
at O
least O
2 O
years O
postinoculation O
, O
In O
contrast O
to O
the O
mature O
antibody O
responses O
elicited O
by O
the O
attenuated O
SN O
vaccines O
, O
the O
whole O
- O
virus O
and O
envelope O
subunit O
vaccines O
in O
general O
elicited O
only O
immature O
antibody O
responses O
characterized O
by O
poor O
reactivity O
with O
native O
envelope O
proteins O
, O
low O
avidity O
, O
low O
conformational O
dependence O
, O
and O
the O
absence O
of O
neutralization O
activity O
against O
the O
challenge O
strain O
, O
Thus O
, O
these O
studies O
establish O
for O
the O
first O
time O
an O
association O
between O
the O
effectiveness O
of O
experimental O
vaccines O
and O
the O
capacity O
of O
the O
vaccine O
to O
produce O
a O
mature O
antibody O
response O
to O
SIV O
envelope O
proteins O
and O
further O
indicate O
that O
a O
combination O
of O
several O
antibody O
parameters O
( O
including O
titer O
, O
avidity O
, O
conformational O
dependence O
, O
and O
virus O
neutralization O
) O
are O
superior O
to O
any O
single O
antibody O
parameter O
as O
prognostic O
indicators O
to O
evaluate O
candidate O
AIDS O
vaccines O
. O

We O
have O
inserted O
heterologous O
genetic O
material O
into O
the O
nonessential O
gene O
4 O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
in O
order O
to O
test O
the O
applicability O
of O
targeted O
RNA O
recombination O
for O
site O
- O
directed O
mutagenesis O
of O
the O
MHV O
genome O
upstream O
of O
the O
nucleocapsid O
( O
N O
gene O
and O
to O
develop O
further O
genetic O
tools O
for O
site O
- O
directed O
mutagenesis O
of O
structural O
genes O
other O
than O
N O
, O
Initially O
, O
a O
19 O
- O
nucleotide O
tag O
was O
inserted O
into O
the O
start O
of O
gene O
4a O
of O
MHV O
strain O
A59 O
with O
the O
N O
gene O
deletion O
mutant O
AIb O
- O
4 O
as O
the O
recipient O
virus O
. O

In O
further O
work O
, O
the O
entire O
gene O
for O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
was O
inserted O
in O
place O
of O
gene O
4 O
, O
creating O
the O
currently O
largest O
known O
RNA O
virus O
. O

Members O
of O
the O
Flaviviridae O
encode O
a O
serine O
proteinase O
termed O
NS3 O
that O
is O
responsible O
for O
processing O
at O
several O
sites O
in O
the O
viral O
polyproteins O
, O
In O
this O
report O
, O
we O
show O
that O
the O
NS3 O
proteinase O
of O
the O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
( O
NADL O
strain O
) O
is O
required O
for O
processing O
at O
nonstructural B
( I
NS I
) I
protein O
sites O
3 O
/ O
4A O
, O
4A O
/ O
4B O
, O
4E O
/ O
5A O
, O
and O
5A O
/ O
5B O
but O
not O
for O
cleavage O
at O
the O
junction O
between O
NS2 O
and O
NS3 O
, O
Cleavage O
sites O
of O
the O
proteinase O
were O
determined O
by O
amino O
- O
terminal O
sequence O
analysis O
of O
the O
NS4A O
, O
NS4B O
, O
NS5A O
, O
and O
NS5B O
proteins O
. O

A O
conserved O
leucine O
residue O
is O
found O
at O
the O
P1 O
position O
of O
all O
four O
cleavage O
sites O
, O
followed O
by O
either O
serine O
( O
3 O
/ O
4A O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
sites O
) O
or O
alanine O
( O
4A O
/ O
4B O
site O
) O
at O
the O
P1 O
' O
position O
. O

The O
circular O
RNA O
genome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
can O
fold O
into O
an O
unbranched O
rodlike O
structure O
, O
We O
mutagenized O
the O
two O
ends O
of O
this O
structure O
and O
assayed O
the O
effects O
on O
the O
ability O
of O
the O
genomes O
to O
replicate O
and O
accumulate O
processed O
RNA O
transcripts O
in O
transfected O
cells O
, O
The O
top O
end O
, O
defined O
as O
that O
nearest O
to O
the O
5 O
' O
end O
of O
the O
putative O
mRNA O
for O
delta O
antigen O
, O
was O
much O
more O
sensitive O
than O
the O
other O
end O
, O
defined O
as O
the O
bottom O
, O
Most O
of O
the O
22 O
mutants O
made O
at O
the O
bottom O
were O
able O
to O
accumulate O
RNA O
as O
well O
as O
the O
wild O
type O
, O
For O
deletions O
extending O
as O
close O
as O
2 O
nucleotides B
( I
nt I
) I
from O
the O
predicted O
domains O
needed O
for O
the O
two O
ribozymes O
, O
the O
accumulation O
levels O
dropped O
to O
< O
0 O
. O

The O
single O
- O
stranded O
genomic O
RNA O
of O
pestiviruses O
is O
of O
positive O
polarity O
and O
encompasses O
one O
large O
open O
reading O
frame O
of O
about O
4 O
, O
000 O
codons O
, O
The O
resulting O
polyprotein O
is O
processed O
co O
- O
and O
posttranslationally O
by O
virus O
- O
encoded O
and O
host O
cell O
proteases O
to O
give O
rise O
to O
the O
mature O
viral O
proteins O
, O
A O
serine O
protease O
residing O
in O
the O
nonstructural B
( I
NS I
) I
protein O
NS3 O
( O
p80 O
) O
has O
been O
shown O
to O
be O
essential O
for O
the O
release O
of O
the O
NS O
proteins O
located O
downstream O
of O
NS3 O
, O
In O
this O
report O
the O
NS3 O
serine O
protease O
- O
dependent O
cleavage O
sites O
for O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
strain O
CP7 O
are O
described O
, O
Proteins O
used O
for O
analysis O
were O
generated O
in O
Escherichia O
coli O
or O
in O
eukaryotic O
cells O
by O
the O
use O
of O
the O
T7 O
vaccinia O
virus O
system O
, O
The O
N O
termini O
of O
NS4A O
, O
NS4B O
, O
NS5A O
, O
and O
NS5B O
were O
determined O
by O
protein O
sequencing O
, O
Analysis O
of O
the O
data O
obtained O
showed O
that O
leucine O
at O
P1 O
is O
the O
only O
position O
conserved O
for O
all O
cleavage O
sites O
, O
At O
P1 O
' O
alanine O
is O
found O
at O
the O
NS4A O
- O
NS4B O
site O
, O
whereas O
serine O
resides O
at O
this O
position O
at O
the O
NS3 O
- O
NS4A O
, O
NS4B O
- O
NS5A O
, O
and O
NS5A O
- O
NS5B O
cleavage O
sites O
, O
For O
all O
cleavage O
sites O
the O
amino O
acids O
found O
at O
P1 O
and O
P1 O
' O
are O
conserved O
for O
different O
genotypes O
of O
pestiviruses O
, O
despite O
the O
high O
degree O
of O
sequence O
variation O
found O
between O
these O
viruses O
, O
It O
is O
therefore O
assumed O
that O
the O
cleavage O
sites O
determined O
for O
BVDV O
CP7 O
are O
representative O
of O
those O
for O
all O
pestiviruses O
. O

In O
infected O
cells O
, O
only O
the O
genomic O
RNA O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
is O
packaged O
into O
the O
virions O
, O
In O
this O
study O
, O
we O
show O
that O
a O
subgenomic B
( I
sg I
) I
defective I
interfering I
( I
DI I
) I
RNA O
can O
be O
packaged O
into O
virions O
when O
it O
contains O
the O
DI B
RNA I
packaging I
signal I
( I
DI I
RNA I
- I
Ps I
) I
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
3 I
protein I
( I
NS3 I
) I
is O
a O
70 O
- O
kDa O
multifunctional O
enzyme O
with O
three O
known O
catalytic O
activities O
segregated O
in O
two O
somewhat O
independent O
domains O
. O

The O
essential O
machinery O
of O
a O
serine O
protease O
is O
localized O
in O
the O
N O
- O
terminal O
one O
- O
third O
of O
the O
protein O
, O
and O
nucleoside B
triphosphatase I
( I
NTPase I
) I
and O
helicase O
activities O
reside O
in O
the O
remaining O
C O
- O
terminal O
region O
. O

All O
three O
NS3 O
- O
NS4A O
activities O
were O
modulated O
by O
polynucleotides O
, O
with O
poly O
( O
U O
) O
having O
the O
most O
remarkable O
effect O
. O

In O
the O
presence O
of O
an O
RNA O
( O
- O
) O
temperature B
- I
sensitive I
( I
ts I
) I
mutant O
helper O
virus O
, O
two O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
defective I
interfering I
( I
DI I
) I
RNAs O
complemented O
each O
other O
, O
resulting O
in O
the O
assembly O
of O
MHV O
particles O
; O
we O
used O
this O
ability O
to O
complement O
as O
a O
means O
to O
study O
coronavirus O
assembly O
. O

Epitopes O
of O
hypervariable B
region I
1 I
( I
HVR1 I
) I
were O
mapped O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
using O
follow O
- O
up O
sera O
of O
patients O
, O
all O
of O
whom O
were O
infected O
with O
the O
same O
isolate O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Our O
results O
suggest O
that O
( O
i O
) O
an O
early O
appearance O
( O
up O
to O
month O
13 O
postinfection O
) O
of O
antibodies O
directed O
to O
the O
N O
terminus O
of O
HVR1 O
is O
associated O
with O
acute O
self O
- O
limiting O
infections O
of O
HCV O
and O
( O
ii O
) O
isolate O
- O
independent O
antibodies O
which O
are O
mainly O
directed O
to O
the O
C O
terminus O
of O
HVR1 O
seem O
to O
persist O
in O
chronically O
infected O
patients O
. O

Chronic O
hepatitis O
resulting O
from O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
develops O
into O
cirrhosis O
in O
at O
least O
half O
of O
infected O
patients O
and O
increases O
the O
risk O
of O
hepatocellular O
carcinoma O
. O

we O
investigated O
the O
interaction O
of O
nonstructural B
protein I
3 I
( I
NS3 I
) I
of O
HCV O
with O
the O
cyclic O
AMP O
- O
dependent O
signal O
pathway O
. O

We O
found O
a O
similarity O
between O
the O
HCV O
sequence O
Arg O
- O
Arg O
- O
Gly O
- O
Agr O
- O
Thr O
- O
Gly O
- O
Arg O
- O
Glu O
- O
Arg O
- O
Agr O
- O
Gly O
- O
Ile O
- O
Tyr O
- O
Arg O
localized O
in O
NS3 O
and O
the O
general O
consensus O
sequence O
of O
protein B
kinase I
A I
( I
PKA I
) I
. O

Consequently O
, O
the O
catalytic B
( I
C I
) I
subunit O
of O
PKA O
bound O
to O
a O
bacterially O
expressed O
fragment O
of O
HCV O
polyprotein O
containing O
amino O
acid O
residues O
1189 O
to O
1525 O
. O

NS3 O
proteinase O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
contained O
within O
the O
N O
- O
terminal O
domain O
of O
the O
NS3 O
protein O
, O
is O
a O
chymotrypsin O
- O
like O
serine O
proteinase O
responsible O
for O
processing O
of O
the O
nonstructural O
region O
of O
the O
HCV O
polyprotein O
. O

By O
using O
a O
cell O
- O
free O
coupled O
transcription O
- O
translation O
system O
, O
we O
found O
that O
HCV O
polyprotein O
processing O
can O
be O
activated O
by O
Zn2 O
+ O
( O
and O
, O
to O
a O
lesser O
degree O
, O
by O
Cd2 O
+ O
, O
Pb2 O
+ O
, O
and O
Co2 O
+ O
) O
and O
inhibited O
by O
Cu2 O
+ O
and O
Hg2 O
+ O
ions O
. O

We O
found O
that O
11 O
of O
20 O
persistently O
infected O
mice O
harbored O
spike B
deletion I
variants I
( I
SDVs I
) I
, O
indicating O
that O
deletions O
are O
common O
but O
not O
required O
for O
persistent O
infection O
. O

Furthermore O
, O
we O
found O
that O
each O
mouse O
harbored O
distinct O
variants O
in O
its O
central B
nervous I
system I
( I
CNS I
) I
, O
suggesting O
that O
SDVs O
are O
generated O
during O
viral O
replication O
in O
the O
CNS O
. O

Picornavirus O
3C O
proteases O
( O
3C B
( I
pro I
) I
) O
are O
cysteine O
proteases O
related O
by O
amino O
acid O
sequence O
to O
trypsin O
- O
like O
serine O
proteases O
. O

Comparisons O
of O
3C B
( I
pro I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
to O
those O
of O
other O
picornaviruses O
have O
resulted O
in O
prediction O
of O
active O
- O
site O
residues O
: O
histidine O
at O
position O
44 O
( O
H44 O
) O
, O
aspartic O
acid O
( O
D98 O
) O
, O
and O
cysteine O
( O
C172 O
) O
. O

To O
test O
whether O
these O
residues O
are O
key O
members O
of O
a O
putative O
catalytic O
triad O
, O
oligonucleotide O
- O
directed O
mutagenesis O
was O
targeted O
to O
3C B
( I
pro I
) I
in O
the O
contest O
of O
natural O
poly O
peptide O
precursor O
P3 O
. O

Autocatalytic O
processing O
of O
the O
poly O
- O
protein O
containing O
wild O
- O
type O
or O
variant O
3C B
( I
pro I
) I
was O
tested O
by O
in O
vivo O
expression O
of O
vaccinia O
virus O
- O
HAV O
chimeras O
in O
an O
animal O
cell O
- O
T7 O
hybrid O
system O
and O
by O
in O
vitro O
translation O
of O
corresponding O
RNAs O
. O

In O
contrast O
, O
a O
P3 O
polyprotein O
in O
which O
D98 O
was O
substituted O
by O
asparagine O
underwent O
only O
slightly O
delayed O
processing O
, O
while O
an O
additional O
substitution O
of O
valine O
( O
V47 O
) O
by O
glycine O
within O
putative O
protein O
3A O
caused O
a O
more O
pronounced O
loss O
of O
processing O
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
coronavirus O
, O
initiates O
infection O
by O
binding O
to O
its O
cellular O
receptor O
( O
MHVR O
) O
via O
spike B
( I
S I
) I
proteins O
projecting O
from O
the O
virion O
membrane O
, O
The O
structures O
of O
these O
S O
proteins O
vary O
considerably O
among O
MHV O
strains O
, O
and O
this O
variation O
is O
generally O
considered O
to O
be O
important O
in O
determining O
the O
strain O
- O
specific O
pathologies O
of O
MHV O
infection O
, O
perhaps O
by O
affecting O
the O
interaction O
between O
MHV O
and O
the O
MHVR O
. O

sMHVR O
- O
Ig O
was O
stably O
expressed O
as O
a O
disulfide O
- O
linked O
dimer O
in O
human O
293 O
EBNA O
cells O
and O
was O
immobilized O
to O
Sepharose O
- O
protein O
G O
via O
the O
Fc O
domain O
, O
The O
resulting O
Sepharose O
beads O
were O
used O
to O
adsorb O
radiolabelled O
MHV O
particles O
, O
At O
4 O
degrees O
C O
, O
the O
beads O
specifically O
adsorbed O
two O
prototype O
MHV O
strains O
, O
MHV O
JHM O
( O
strain O
4 O
) O
and O
a O
tissue O
culture O
- O
adapted O
mutant O
of O
MHV O
JHM O
, O
the O
JHMX O
strain O
, O
A O
shift O
to O
37 O
degrees O
C O
resulted O
in O
elution O
of O
JHM O
but O
not O
JHMX O
. O

This O
in O
vitro O
observation O
of O
JHM O
( O
but O
not O
JHMX O
) O
elution O
from O
its O
receptor O
at O
37 O
degrees O
C O
was O
paralleled O
by O
a O
corresponding O
37 O
degrees O
C O
elution O
of O
receptor O
- O
associated O
JHM O
( O
but O
not O
JHMX O
) O
from O
tissue O
culture O
cells O
, O
The O
basis O
for O
this O
difference O
in O
maintenance O
of O
receptor O
association O
was O
correlated O
with O
a O
large O
deletion O
mutation O
present O
within O
the O
JHMX O
S O
protein O
, O
as O
sMHVR O
- O
Ig O
exhibited O
relatively O
thermostable O
binding O
to O
vaccinia O
virus O
- O
expressed O
S O
proteins O
containing O
the O
deletion O
, O
These O
results O
indicate O
that O
naturally O
occurring O
mutations O
in O
the O
coronavirus O
S O
protein O
affect O
the O
stability O
of O
the O
initial O
interaction O
with O
the O
host O
cell O
and O
thus O
contribute O
to O
the O
likelihood O
of O
successful O
infection O
by O
incoming O
virions O
. O

To O
develop O
vector O
systems O
that O
combine O
high O
transcription O
activity O
with O
biologically O
safe O
delivery O
vehicles O
, O
we O
have O
explored O
the O
use O
of O
RNA O
replication O
to O
amplify O
mRNAs O
, O
by O
using O
flock B
house I
virus I
( I
FHV I
) I
as O
a O
model O
system O
. O

Molecular O
mechanisms O
permitting O
the O
establishment O
and O
dissemination O
of O
a O
virus O
within O
a O
newly O
adopted O
host O
species O
are O
poorly O
understood O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
strains O
( O
MHV O
- O
A59 O
, O
MHV O
- O
JHM O
, O
and O
MHV O
- O
A59 O
/ O
MHV O
- O
JHM O
) O
were O
passaged O
in O
mixed O
cultures O
containing O
progressively O
increasing O
concentrations O
of O
nonpermissive O
Syrian O
baby B
hamster I
kidney I
( I
BHK I
) I
cells O
and O
decreasing O
concentrations O
of O
permissive O
murine O
DBT O
cells O
. O

From O
MHV O
- O
A59 O
/ O
MHW O
- O
JHM O
mixed O
infection O
, O
variant O
viruses O
( O
MHV O
- O
H1 O
and O
MHV O
- O
H2 O
) O
which O
replicated O
efficiently O
in O
BHK O
cells O
were O
isolated O
, O
Under O
identical O
treatment O
conditions O
, O
the O
parental O
MHV O
- O
A59 O
or O
MHV O
- O
JHM O
strains O
failed O
to O
produce O
infectious O
virus O
or O
transcribe O
detectable O
levels O
of O
viral O
RNA O
or O
protein O
, O
The O
MHV O
- O
H O
isolates O
were O
polytrophic O
, O
replicating O
efficiently O
in O
normally O
nonpermissive O
Syrian O
hamster O
smooth O
muscle O
( O
DDT O
- O
1 O
) O
, O
Chinese B
hamster I
ovary I
( I
CHO I
) I
, O
human B
adenocarcinoma I
( I
HRT I
) I
, O
primate O
kidney O
( O
Vero O
) O
, O
and O
murine O
17Cl O
- O
1 O
cell O
lines O
. O

Little O
if O
any O
virus O
replication O
was O
detected O
in O
feline O
kidney O
( O
CRFK O
) O
and O
porcine B
testicular I
( I
ST I
) I
cell O
lines O
. O

7 O
- O
kb O
replicase O
locus O
of O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
encodes O
several O
putative O
functional O
domains O
, O
including O
three O
proteinase O
domains O
. O

Encoded O
closest O
to O
the O
5 O
' O
terminus O
of O
this O
locus O
is O
the O
first O
papain B
- I
like I
proteinase I
( I
PLP I
- I
1 I
) I
( O
S O
. O

Mutants O
in O
which O
the O
p28 O
cleavage O
site O
( O
Gly247 O
down O
arrow O
Val248 O
) O
was O
replaced O
by O
the O
Ala832 O
down O
arrow O
Gly833 O
cleavage O
site O
and O
vice O
versa O
were O
found O
to O
retain O
processing O
activity O
. O

The O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
contains O
a O
large O
open O
reading O
frame O
embedded O
entirely O
within O
the O
5 O
' O
half O
of O
its O
nucleocapsid B
( I
N I
) I
gene O
. O

This O
internal O
gene O
( O
designated O
I O
) O
is O
in O
the O
+ O
1 O
reading O
frame O
with O
respect O
to O
the O
N O
gene O
, O
and O
it O
encodes O
a O
mostly O
hydrophobic O
23 O
- O
kDa O
polypeptide O
. O

Receptors O
for O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
are O
members O
of O
the O
murine B
carcinoembryonic I
antigen I
( I
CEA I
) I
gene O
family O
. O

, O
Virology O
188 O
: O
274 O
- O
284 O
, O
1992 O
) O
, O
we O
examined O
whether O
human O
CEA O
- O
related O
molecules O
can O
be O
used O
by O
MHV O
as O
potential O
receptors O
, O
Transfection O
of O
plasmids O
expressing O
human B
carcinoembryonic I
antigen I
( I
hCEA I
) I
and O
human O
biliary O
glycoprotein O
into O
COS O
- O
7 O
cells O
, O
which O
lack O
a O
functional O
MHV O
receptor O
, O
conferred O
susceptibility O
to O
two O
MHV O
strains O
, O
A59 O
and O
MHV O
- O
2 O
. O

We O
have O
analyzed O
the O
population O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
sequences O
in O
paired O
liver O
and O
serum O
samples O
from O
four O
patients O
with O
chronic O
hepatitis O
C O
, O
Sequences O
from O
three O
different O
biopsy O
specimens O
from O
a O
liver O
explant O
from O
one O
patient O
were O
compared O
with O
each O
other O
and O
with O
the O
circulating O
sequences O
. O

Bicistronic O
RNAs O
containing O
the O
373 O
- O
nucleotide O
- O
long O
5 B
' I
nontranslated I
region I
( I
NTR I
) I
of O
the O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
genome O
as O
intercistronic O
spacer O
were O
used O
to O
show O
the O
presence O
of O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
in O
the O
5 O
' O
end O
of O
the O
CSFV O
genome O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
( O
E1 O
and O
E2 O
) O
interact O
to O
form O
a O
heterodimeric O
complex O
, O
which O
has O
been O
proposed O
as O
a O
functional O
subunit O
of O
the O
HCV O
virion O
envelope O
. O

Here O
we O
report O
the O
isolation O
and O
characterization O
of O
a O
conformation O
- O
sensitive O
E2 O
- O
reactive O
monoclonal O
antibody O
( O
H2 O
) O
. O

We O
previously O
showed O
that O
two O
proteins O
, O
a O
56 B
- I
kDa I
protein I
( I
p56 I
) I
and O
a O
58 B
- I
kDa I
protein I
( I
p58 I
) I
, O
are O
produced O
from O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
5A I
region I
( I
NS5A I
) I
and O
that O
the O
production O
of O
p58 O
is O
enhanced O
by O
the O
presence O
of O
NS4A O
( O
T O
. O

Studies O
of O
Defective B
interfering I
( I
DI I
) I
RNAs O
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
suggest O
that O
a O
69 O
- O
nucleotide O
- O
long O
packaging O
signal O
is O
necessary O
for O
MHV O
genomic O
RNA O
packaging O
into O
MHV O
particles O
. O

To O
assess O
the O
RNA O
helicase O
activity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
protein I
3 I
( I
NS3 I
) I
, O
a O
polypeptide O
encompassing O
amino O
acids O
1175 O
to O
1657 O
, O
which O
cover O
only O
the O
putative O
helicase O
domain O
, O
was O
expressed O
in O
Escherichia O
coli O
by O
a O
pET O
expression O
vector O
, O
The O
protein O
was O
purified O
to O
near O
homogeneity O
and O
assayed O
for O
RNA O
helicase O
activity O
in O
vitro O
with O
double O
- O
stranded O
RNA O
substrates O
prepared O
from O
a O
multiple O
cloning O
sequence O
and O
an O
HCV O
5 O
' O
nontranslated O
region O
( O
5 O
' O
- O
NTR O
) O
or O
3 O
' O
- O
NTR O
, O
The O
enzyme O
acted O
successfully O
on O
substrates O
containing O
both O
5 O
' O
and O
3 O
' O
single O
- O
stranded O
regions O
( O
standard O
) O
or O
on O
substrates O
containing O
only O
the O
3 O
' O
single O
- O
stranded O
regions O
( O
3 O
' O
/ O
3 O
' O
) O
but O
failed O
to O
act O
on O
substrates O
containing O
only O
the O
5 O
' O
single O
- O
stranded O
regions O
( O
5 O
' O
/ O
5 O
' O
) O
or O
on O
substrates O
lacking O
the O
single O
- O
stranded O
regions O
( O
blunt O
) O
, O
These O
results O
thus O
suggest O
3 O
' O
to O
5 O
' O
directionality O
for O
HCV O
RNA O
helicase O
activity O
. O

Two O
members O
of O
coronavirus O
serogroup O
I O
, O
human O
respiratory O
coronavirus O
HCV O
- O
229E O
and O
porcine B
transmissible I
gastroenteritis I
virus I
( I
TGEV I
) I
, O
use O
aminopeptidase B
N I
( I
APN I
) I
as O
their O
cellular O
receptors O
. O

To O
determine O
whether O
feline O
APN O
could O
serve O
as O
a O
receptor O
for O
two O
feline O
coronaviruses O
in O
serogroup O
I O
, O
feline B
infectious I
peritonitis I
virus I
( I
FIPV I
) I
and O
feline B
enteric I
coronavirus I
( I
FeCV I
) I
, O
we O
cloned O
the O
cDNA O
encoding O
feline B
APN I
( I
fAPN I
) I
by O
PCR O
from O
cDNA O
isolated O
from O
a O
feline O
cell O
line O
and O
stably O
expressed O
it O
in O
FIPV O
- O
and O
FeCV O
- O
resistant O
mouse O
and O
hamster O
cells O
. O

In O
addition O
to O
serving O
as O
a O
receptor O
for O
the O
feline O
coronaviruses O
, O
fAPN O
also O
served O
as O
a O
functional O
receptor O
for O
each O
of O
these O
serogroup O
I O
coronaviruses O
as O
shown O
by O
development O
of O
viral O
antigens O
in O
the O
cytoplasm O
of O
infected O
mouse O
or O
hamster O
cells O
stably O
transfected O
with O
fAPN O
, O
In O
contrast O
, O
fAPN O
did O
not O
serve O
as O
a O
functional O
receptor O
for O
mouse B
hepatitis I
virus I
( I
MHV I
- I
A59 I
) I
, O
which O
is O
in O
serogroup O
II O
and O
utilizes O
mouse O
biliary O
glycoprotein O
receptors O
unrelated O
to O
APN O
, O
Thus O
, O
fAPN O
serves O
as O
a O
receptor O
for O
a O
much O
broader O
range O
of O
group O
I O
coronaviruses O
than O
human O
and O
porcine O
APNs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
positive O
- O
strand O
RNA O
virus O
, O
is O
the O
major O
infectious O
agent O
responsible O
for O
causing O
chronic O
hepatitis O
. O

Sequences O
from O
the O
putative O
5 O
' O
nontranslated O
region O
of O
GB O
virus O
A O
were O
isolated O
from O
mystax O
, O
owl O
monkeys O
, O
and O
tamarins O
, O
Though O
sequences O
of O
isolates O
from O
each O
animal O
species O
are O
virtually O
identical O
at O
the O
nucleotide O
level O
( O
95 O
% O
) O
, O
isolates O
from O
different O
species O
are O
dramatically O
different O
( O
52 O
to O
79 O
% O
identical O
) O
and O
genetically O
cluster O
on O
this O
basis O
. O

a O
role O
in O
the O
pathogenesis O
of O
progressive O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
we O
performed O
a O
detailed O
evaluation O
of O
HCV O
quasispecies O
before O
and O
after O
liver O
transplantation O
in O
five O
patients O
infected O
with O
HCV O
genotype O
1 O
, O
three O
of O
whom O
developed O
severe O
recurrent O
hepatitis O
C O
and O
two O
of O
whom O
developed O
asymptomatic O
posttransplant O
infections O
with O
high O
- O
titered O
viremia O
, O
HCT O
I O
quasispecies O
were O
characterized O
by O
using O
a O
combination O
of O
nucleotide O
sequencing O
plus O
heteroduplex O
tracking O
assay O
of O
the O
second O
envelope O
gene O
hypervariable B
region I
( I
HVR I
) I
. O

Genetic O
analysis O
suggested O
that O
in O
these O
cases O
, O
the O
new O
quasispecies O
variants O
were O
derived O
from O
minor O
variants O
present O
at O
relatively O
low O
clonal O
frequency O
( O
less O
than O
5 O
% O
of O
HVR O
clones O
) O
within O
the O
pretransplant O
quasispecies O
populations O
. O

cytopathogenic B
( I
cp I
) I
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
strains O
are O
generated O
in O
cattle O
persistently O
infected O
with O
noncytopathogenic B
( I
noncp I
) I
BVDV O
. O

Comparative O
analysis O
of O
cp O
and O
noncp O
BVDV O
strains O
isolated O
from O
one O
animal O
suffering O
from O
mucosal O
disease O
revealed O
that O
the O
genomes O
of O
the O
cp O
BVDV O
strain O
( O
CP7 O
) O
and O
the O
corresponding O
noncp B
BVDV I
strain I
( I
NCP7 I
) I
are O
highly O
homologous O
. O

Chimeric O
viral O
genomes O
of O
the O
HM O
- O
175 O
strain O
were O
constructed O
from O
cDNA O
clones O
derived O
from O
a O
virulent O
virus O
and O
from O
two O
attenuated O
viruses O
adapted O
to O
growth O
in O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
and O
MRC O
- O
5 O
cells O
, O
respectively O
. O

Viruses O
encoded O
by O
these O
chimeric O
genomes O
were O
recovered O
by O
in O
vitro O
or O
in O
vivo O
transfection O
and O
assessed O
for O
their O
ability O
to O
grow O
in O
cultured O
MRC O
- O
5 O
cells O
or O
to O
cause O
hepatitis O
in O
primates O
( O
tamarins O
) O
. O

When O
the O
small O
form O
of O
the O
delta O
antigen O
( O
delta O
Ag O
- O
S O
) O
was O
expressed O
from O
a O
cDNA O
expression O
plasmid O
and O
subsequently O
detected O
by O
immunofluorescence O
, O
it O
was O
found O
localized O
to O
the O
nucleoli O
. O

However O
, O
if O
the O
cDNA O
was O
cotransfected O
with O
a O
cDNA O
expressing O
a O
mutated O
hepatitis B
delta I
virus I
( I
HDV I
) I
genome O
that O
could O
only O
replicate O
by O
using O
the O
delta O
Ag O
- O
S O
provided O
by O
the O
first O
plasmid O
, O
then O
most O
of O
the O
delta O
Ag O
- O
S O
was O
redistributed O
to O
the O
nucleoplasm O
, O
largely O
to O
specific O
discrete O
nucleoplasmic O
sites O
or O
speckles O
; O
this O
pattern O
was O
stable O
for O
at O
least O
50 O
days O
after O
transfection O
. O

The O
SC35 O
- O
like O
speckle O
pattern O
of O
accumulation O
of O
delta B
antigen I
( I
delta I
Ag I
) I
was O
maintained O
for O
only O
6 O
days O
, O
after O
which O
the O
pattern O
began O
to O
change O
. O

This O
pattern O
of O
change O
occurs O
at O
a O
time O
when O
the O
large O
form O
of O
the O
delta B
antigen I
( I
delta I
Ag I
- I
L I
) I
appears O
and O
HDV O
RNA O
synthesis O
begins O
to O
shut O
down O
. O

Molecular O
characterization O
of O
bovine O
viral O
diarrhea O
virus O
pair O
13 O
revealed O
that O
isolate O
CP13 O
is O
composed O
of O
a O
cytopathogenic B
( I
cp I
) I
defective I
interfering I
particle I
( I
DI13 I
) I
and O
a O
noncytopathogenic B
( I
noncp I
) I
helper O
virus O
. O

These O
pseudoknots O
lie O
adjacent O
to O
a O
pyrimidine O
- O
rich O
sequence O
, O
which O
in O
cardio O
- O
and O
apthoviruses O
takes O
the O
form O
of O
a O
homopolymeric O
poly O
( O
C O
) O
tract O
. O

Larger O
plaque O
revertants O
were O
isolated O
and O
partially O
characterized O
, O
and O
each O
proved O
to O
be O
a O
second O
site O
pseudorevertant O
with O
( O
unmapped O
) O
changes O
elsewhere O
in O
the O
genome O
. O

The O
infectious O
PKC O
mutant O
viruses O
were O
highly O
lethal O
to O
mice O
, O
and O
deletions O
in O
this O
motif O
did O
not O
affect O
mengovirus O
virulence O
in O
the O
same O
manner O
as O
deletions O
in O
the O
adjacent O
poly O
( O
C O
) O
tract O
. O

Polymerase B
basic I
protein I
1 I
( I
PBL I
) I
can O
interact O
with O
PB2 O
in O
the O
presence O
or O
absence O
of O
polymerase O
acidic O
protein O
. O

Both O
of O
these O
regions O
are O
located O
at O
the O
NH2 O
, O
terminus O
of O
PBI O
; O
the O
COOH O
- O
terminal O
half O
of O
PB1 O
is O
not O
involved O
in O
interacting O
with O
PB2 O
, O
Deletion O
analysis O
further O
demonstrated O
that O
the O
interacting O
regions O
of O
PB1 O
encompass O
amino B
acids I
( I
aa I
) I
48 O
to O
145 O
and O
aa O
251 O
to O
321 O
, O
Linker O
insertions O
throughout O
the O
PB1 O
sequences O
did O
not O
affect O
complex O
formation O
with O
PB2 O
. O

For O
this O
analysis O
, O
we O
developed O
a O
simplified O
assay O
for O
viral O
polymerase O
activity O
that O
uses O
a O
reporter O
chloramphenicol O
acetyltransferase O
gene O
containing O
the O
5 O
' O
and O
3 O
' O
ends O
of O
influenza O
viral O
promoter O
and O
nontranslating O
regions O
( O
minus O
sense O
) O
of O
the O
NS O
gene O
joined O
to O
a O
hepatitis O
delta O
virus O
ribozyme O
at O
its O
3 O
' O
end O
. O

This O
assay O
demonstrated O
that O
all O
deletion O
mutants O
of O
PBL O
exhibited O
either O
background O
or O
greatly O
reduced O
polymerase O
activity O
irrespective O
of O
the O
ability O
to O
interact O
with O
PB2 O
and O
that O
all O
linker O
- O
insertion O
mutants O
except O
one O
al O
the O
extreme O
COOH O
end O
( O
L O
- O
746 O
) O
of O
PBL O
were O
also O
negative O
for O
viral O
polymerase O
activity O
. O

The O
3 O
' O
- O
end O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genomic O
RNA O
contains O
a O
recognition O
sequence O
( O
55 O
nucleotides O
[ O
nt O
] O
) O
required O
for O
minus O
- O
strand O
RNA O
synthesis O
. O

To O
determine O
whether O
the O
3 O
' O
- O
end O
sequence O
is O
also O
involved O
in O
subgenomic O
mRNA O
transcription O
, O
we O
have O
constructed O
MHV O
Defective B
interfering I
( I
DI I
) I
RNAs O
which O
contain O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
placed O
behind O
an O
intergenic O
sequence O
and O
a O
3 O
' O
- O
end O
sequence O
with O
various O
degrees O
of O
internal O
deletions O
. O

The O
DI O
RNAs O
were O
transfected O
into O
MHV O
- O
infected O
cells O
, O
and O
CAT O
activities O
, O
which O
represent O
subgenomic O
mRNA O
transcription O
from O
the O
intergenic O
site O
, O
were O
determined O
, O
The O
results O
demonstrated O
that O
the O
deletions O
of O
sequence O
upstream O
of O
the O
350 O
nt O
at O
the O
3 O
' O
- O
end O
, O
which O
include O
the O
3 B
' I
- I
untranslated I
region I
( I
3 I
' I
- I
UTR I
) I
, O
of O
MHV O
genomic O
RNA O
did O
not O
affect O
subgenomic O
mRNA O
transcription O
, O
Non O
ever O
, O
deletions O
that O
reduced O
the O
3 O
' O
- O
end O
sequences O
to O
270 O
nt O
or O
less O
completely O
abolished O
the O
mRNA O
transcription O
despite O
the O
fact O
that O
all O
of O
these O
clones O
synthesized O
minus O
- O
strand O
RNAs O
, O
These O
results O
indicated O
that O
mRNA O
transcription O
from O
an O
intergenic O
site O
in O
the O
MHV O
Df O
RNA O
requires O
most O
of O
the O
3 O
' O
- O
UTR O
as O
a O
cis O
- O
acting O
signal O
, O
which O
likely O
exerts O
its O
effects O
during O
plus O
- O
strand O
RNA O
synthesis O
, O
A O
substitution O
of O
the O
corresponding O
bovine O
coronavirus O
sequence O
for O
the O
MHV O
sequence O
within O
nt O
270 O
to O
305 O
from O
the O
3 O
' O
- O
end O
abrogated O
the O
CAT O
gene O
expression O
, O
suggesting O
a O
very O
rigid O
sequence O
requirement O
in O
this O
region O
, O
The O
deletion O
of O
a O
putative O
pseudoknot O
structure O
within O
the O
3 O
' O
- O
UTR O
also O
abolished O
the O
CAT O
gene O
expression O
, O
These O
findings O
suggest O
that O
the O
3 O
' O
- O
UTR O
may O
interact O
with O
the O
other O
RNA O
regulatory O
elements O
to O
regulate O
mRNA O
transcription O
. O

The O
positive O
- O
strand O
Defective B
interfering I
( I
DI I
) I
RNA O
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
when O
introduced O
into O
MHV O
- O
infected O
cells O
, O
results O
in O
DI O
RNA O
replication O
and O
accumulation O
. O

The O
latency B
- I
associated I
transcripts I
( I
LATs I
) I
of O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
are O
the O
only O
viral O
gene O
products O
that O
accumulate O
to O
abundant O
levels O
in O
latently O
infected O
cells O
, O
Others O
have O
reported O
species O
of O
2 O
. O

0 O
- O
kb O
species O
is O
seen O
in O
productively O
infected O
cells O
, O
and O
there O
is O
evidence O
that O
it O
behaves O
as O
an O
intron O
, O
We O
examined O
the O
LATs O
both O
in O
trigeminal O
ganglia O
of O
latently O
infected O
mice O
and O
in O
productively O
infected O
cultures O
of O
monkey O
CV O
- O
I O
cells O
, O
After O
glyoxalation O
, O
RNA O
was O
subjected O
to O
high O
- O
resolution O
agarose O
gel O
electrophoresis O
and O
Northern O
( O
RNA O
) O
analysis O
, O
a O
procedure O
capable O
of O
resolving O
linear O
and O
nonlinear O
RNA O
species O
, O
Under O
these O
conditions O
, O
we O
resolved O
the O
2 O
. O

GB O
viruses O
A O
and O
C O
( O
GBV O
- O
A O
and O
GBV O
- O
C O
) O
are O
two O
recently O
described O
RNA O
viruses O
which O
appear O
to O
be O
members O
of O
the O
Flaviviridae O
. O

Although O
both O
viruses O
appear O
to O
contain O
long O
5 O
' O
nontranslated O
regions O
, O
the O
sites O
of O
polyprotein O
initiation O
and O
the O
presence O
of O
core O
- O
like O
proteins O
remain O
to O
be O
determined O
, O
Translation O
studies O
were O
undertaken O
to O
determine O
the O
mechanism O
and O
sites O
of O
polyprotein O
initiation O
in O
GBV O
- O
A O
and O
GBV O
- O
C O
, O
Rabbit O
reticulocyte O
lysates O
programmed O
, O
vith O
monocistronic O
RNAs O
containing O
5 O
' O
ends O
of O
GBV O
- O
A O
or O
GBV O
- O
C O
fused O
in O
- O
frame O
with O
the O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
open O
reading O
frame O
generated O
GBV O
- O
CAT O
fusion O
proteins O
in O
vitro O
. O

N O
- O
myc2 O
and O
insulin B
- I
like I
growth I
factor I
II I
( I
IGF I
- I
II I
) I
are O
coordinately O
overexpressed O
in O
the O
great O
majority O
of O
altered O
hepatic O
foci O
, O
which O
are O
the O
earliest O
precancerous O
lesions O
observed O
in O
the O
liver O
of O
woodchuck O
hepatitis O
virus O
carrier O
woodchucks O
, O
and O
these O
genes O
continue O
to O
be O
overexpressed O
in O
hepatocellular B
carcinomas I
( I
HCCs I
) I
. O

We O
have O
investigated O
the O
function O
of O
these O
genes O
in O
woodchuck O
hepatocarcinogenesis O
by O
using O
a O
woodchuck O
liver O
epithelial O
cell O
line O
( O
WC O
- O
3 O
) O
, O
WC O
- O
3 O
cells O
react O
positively O
with O
a O
monoclonal O
antibody O
( O
12 O
. O

The O
death O
of O
N O
- O
myc2 O
- O
expressing O
WC O
- O
3 O
cells O
was O
accompanied O
by O
nucleosomal O
fragmentation O
of O
cellular O
DNA O
, O
and O
DAPI B
( I
4 I
' I
, I
6 I
- I
diamidino I
- I
2 I
- I
phenylindole I
) I
staining O
revealed O
condensation O
and O
fragmentation O
of O
the O
nuclei O
, O
suggesting O
that O
N O
- O
myc2 O
- O
expressing O
WC O
- O
3 O
cells O
undergo O
apoptosis O
in O
the O
absence O
of O
serum O
. O

The O
C O
gene O
encodes O
the O
core O
( O
capsid O
) O
protein O
and O
the O
E1 O
and O
E2 O
genes O
encode O
the O
envelope O
proteins O
. O

We O
have O
tested O
the O
ability O
of O
delta O
agent O
RNA O
to O
participate O
in O
reactions O
with O
a O
protein O
containing O
a O
motif O
which O
confers O
the O
ability O
to O
bind O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
. O

Surprisingly O
, O
highly O
purified O
delta O
agent O
RNA O
preparations O
from O
which O
all O
traces O
of O
contaminating O
dsRNA O
have O
been O
removed O
activate O
PKR O
, O
the O
dsRNA O
- O
dependent O
protein O
kinase O
activity O
of O
mammalian O
cells O
( O
also O
known O
as O
DAI O
, O
P1 O
- O
eIF O
- O
2 O
, O
and O
p68 O
kinase O
) O
. O

The O
mechanism O
of O
regulation O
for O
the O
ribozyme O
activity O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
in O
infected O
cells O
is O
unknown O
. O

In O
this O
study O
, O
we O
used O
this O
method O
to O
examine O
the O
effects O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
on O
the O
ribozyme O
activities O
of O
HDV O
RNA O
in O
vivo O
. O

The O
HDV O
multimer O
cDNAs O
were O
cotransfected O
with O
plasmids O
encoding O
either O
HDV O
small B
delta I
antigen I
( I
SHDAg I
) I
or O
large B
delta I
antigen I
( I
LHDAg I
) I
, O
and O
the O
self O
- O
cleavage O
of O
the O
primary O
transcripts O
from O
the O
HDV O
cDNA O
was O
analyzed O
at O
day O
2 O
posttransfection O
. O

( O
i O
) O
Both O
HDAgs O
, O
particularly O
LHDAg O
, O
enhanced O
the O
self O
- O
cleavage O
activity O
of O
HDV O
RNA O
; O
however O
, O
HDAgs O
are O
not O
required O
for O
HDV O
RNA O
cleavage O
, O
( O
ii O
) O
HDAg O
could O
not O
restore O
the O
ribozyme O
activity O
of O
mutant O
HDV O
RNAs O
which O
have O
lost O
the O
ribozyme O
function O
, O
( O
iii O
) O
The O
enhancement O
of O
ribozyme O
activity O
by O
HDAg O
does O
not O
require O
HDV O
RNA O
replication O
. O

( O
iv O
) O
RNA O
- O
binding O
activity O
of O
HDAg O
is O
required O
for O
the O
enhancement O
of O
RNA O
cleavage O
. O

( O
v O
) O
The O
self O
- O
ligation O
activities O
of O
HDV O
ribozyme O
also O
were O
enhanced O
by O
HDAg O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
NS3 O
protein O
possesses O
three O
enzymatic O
activities O
: O
an O
N O
- O
terminal O
serine O
protease O
activity O
, O
a O
C O
- O
terminal O
RNA O
- O
stimulated O
NTPase O
activity O
, O
and O
an O
RNA O
helicase O
activity O
. O

To O
characterize O
them O
, O
the O
full O
- O
length O
NS3 O
( O
631 O
) O
/ O
4A O
and O
three O
C O
- O
terminal O
truncated O
proteases O
( O
NS3 O
( O
201 O
) O
/ O
4A O
, O
NS3 O
( O
181 O
) O
/ O
4A O
, O
and O
NS3 O
( O
155 O
) O
/ O
4A O
) O
were O
expressed O
in O
mammalian O
cells O
with O
HSV O
amplicon O
- O
defective O
viruses O
, O
Our O
results O
revealed O
that O
all O
of O
the O
NS3 O
/ O
4A O
proteins O
produced O
in O
mammalian O
cells O
( O
except O
NS3 O
( O
155 O
) O
/ O
4A O
) O
are O
active O
in O
processing O
both O
cis O
and O
trans O
cleavage O
sites O
. O

The O
RNA O
- O
stimulated O
ATPase O
activity O
was O
characterized O
with O
a O
partially O
purified O
NS3 O
( O
631 O
) O
/ O
4A O
fraction O
and O
has O
a O
higher O
optimal O
temperature O
at O
37 O
to O
42 O
degrees O
C O
. O

Zwitterionic O
detergent O
such O
as O
3 O
- O
[ O
( O
3 O
- O
cholamidopropyl O
) O
- O
dimethyl O
- O
ammonio O
] O
- O
1 O
- O
propanesulfonate O
( O
CHAPS O
) O
inhibited O
protease O
activity O
at O
a O
concentration O
of O
0 O
. O

5 O
% O
( O
8 O
mM O
) O
, O
which O
had O
no O
effect O
on O
ATPase O
activity O
, O
Finally O
, O
RNA O
- O
unwinding O
activity O
was O
demonstrated O
in O
the O
NS3 O
( O
631 O
) O
/ O
4A O
fraction O
but O
not O
in O
the O
similarly O
purified O
NS3 O
( O
181 O
) O
/ O
4A O
and O
NS3 O
( O
201 O
) O
/ O
4A O
fractions O
. O

NS3 O
( O
631 O
) O
/ O
4A O
unwinds O
RNA O
duplexes O
with O
3 O
' O
but O
not O
5 O
' O
single O
- O
stranded O
overhangs O
, O
suggesting O
that O
the O
NS3 O
RNA O
helicase O
functions O
in O
a O
3 O
' O
- O
to O
- O
5 O
' O
direction O
. O

Activation O
of O
the O
immune O
coagulation O
system O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
liver O
injury O
following O
infection O
of O
inbred O
mice O
with O
murine B
hepatitis I
virus I
strain I
3 I
( I
MHV I
- I
3 I
) I
. O

Following O
MHV O
- O
3 O
infection O
, O
macrophages O
isolated O
from O
MHV O
- O
3 O
- O
susceptible O
acid O
- O
semisusceptible O
inbred O
strains O
of O
mice O
express O
increased O
procoagulant O
activity O
( O
PCA O
) O
, O
whereas O
macrophages O
from O
resistant O
strains O
express O
no O
increase O
in O
PCA O
over O
basal O
levels O
, O
The O
PCA O
induced O
by O
MHV O
- O
3 O
is O
a O
prothrombinase O
, O
encoded O
by O
the O
gene O
Fgl O
- O
2 O
, O
which O
encodes O
a O
fibrinogen O
- O
like O
protein O
( O
musfiblp O
) O
. O

We O
have O
previously O
demonstrated O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
regulates O
cellular O
proto O
- O
oncogenes O
at O
the O
transcriptional O
level O
; O
this O
observation O
implicates O
core O
protein O
in O
the O
alteration O
of O
normal O
hepatocyte O
growth O
. O

In O
the O
present O
study O
, O
the O
transforming O
potential O
of O
the O
HCV O
core O
gene O
was O
investigated O
by O
using O
primary O
rat B
embryo I
fibroblast I
( I
REF I
) I
cells O
which O
were O
transfected O
with O
or O
without O
cooperative O
oncogenes O
, O
Integration O
of O
the O
HCV O
core O
gene O
resulted O
in O
expression O
of O
the O
viral O
protein O
in O
REF O
stable O
transformants O
. O

The O
envelopes O
of O
murine B
hepatitis I
virus I
( I
MHV I
) I
particles O
are O
studded O
with O
glycoprotein O
spikes O
that O
function O
both O
to O
promote O
virion O
binding O
to O
its O
cellular O
receptor O
and O
to O
mediate O
virion O
- O
cell O
membrane O
fusion O
. O

Relative O
to O
untreated O
virus O
, O
1 O
mM O
Ellman O
reagent O
reduced O
infectivity O
by O
2 O
log O
( O
10 O
) O
after O
1 O
h O
. O

The O
results O
revealed O
a O
correlation O
between O
the O
severity O
of O
inhibition O
mediated O
by O
Ellman O
reagent O
and O
the O
presence O
of O
a O
JHM O
- O
specific O
cysteine O
( O
Cys O
- O
1163 O
) O
. O

Previous O
reports O
suggest O
that O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
RNA O
terminates O
with O
homopolymer O
tracts O
of O
either O
poly O
( O
U O
) O
or O
poly O
( O
A O
) O
, O
By O
ligation O
of O
synthetic O
oligonucleotides O
followed O
by O
reverse O
transcription O
- O
PCR O
, O
cDNA O
cloning O
, O
and O
sequence O
analysis O
, O
we O
determined O
the O
3 O
' O
- O
terminal O
sequence O
of O
HCV O
genome O
RNA O
, O
Our O
results O
show O
that O
the O
HCV O
3 O
' O
nontranslated O
region O
consists O
of O
four O
elements O
( O
positive O
sense O
, O
5 O
' O
to O
3 O
' O
) O
: O
( O
i O
) O
a O
short O
sequence O
with O
significant O
variability O
among O
genotypes O
, O
( O
ii O
) O
a O
homopolymeric O
poly O
( O
U O
) O
tract O
, O
( O
iii O
) O
a O
polypyrimidine O
stretch O
consisting O
of O
mainly O
U O
with O
interspersed O
C O
residues O
, O
( O
iv O
) O
a O
novel O
sequence O
of O
98 O
bases O
, O
This O
latter O
nucleotide O
sequence O
is O
not O
present O
in O
human O
genomic O
DNA O
and O
is O
highly O
conserved O
among O
HCV O
genotypes O
, O
The O
3 O
' O
- O
terminal O
46 O
bases O
are O
predicted O
to O
form O
a O
stable O
stem O
- O
loop O
structure O
, O
Using O
a O
quantitative O
competitive O
reverse O
transcription O
- O
PCR O
assay O
, O
we O
show O
that O
a O
substantial O
fraction O
of O
HCV O
genome O
RNAs O
from O
a O
high O
- O
specific O
- O
infectivity O
inoculum O
contain O
this O
3 O
' O
- O
terminal O
sequence O
element O
, O
These O
results O
indicate O
that O
the O
HCV O
genome O
RNA O
terminates O
with O
a O
highly O
conserved O
RNA O
element O
which O
is O
likely O
to O
be O
required O
for O
authentic O
HCV O
replication O
and O
recovery O
of O
infectious O
RNA O
from O
cDNA O
. O

Persistent O
infection O
of O
murine O
astrocytoma O
( O
DBT O
) O
cells O
with O
mouse B
hepatitis I
virus I
( I
MHV I
) I
has O
been O
established O
. O

From O
this O
in O
vitro O
virus O
- O
host O
system O
, O
persistence O
is O
mediated O
at O
the O
level O
of O
cellular O
MHV B
receptor I
( I
MHVR I
) I
expression O
and O
increased O
virus O
virulence O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
receptor O
, O
the O
receptor O
for O
the O
murine O
coronavirus O
MHV O
, O
was O
expressed O
in O
MHV O
- O
resistant O
hamster O
and O
human O
cells O
as O
a O
series O
of O
mutant O
, O
recombinant O
glycoproteins O
with O
carboxyterminal O
deletions O
lacking O
the O
cytoplasmic O
tail O
, O
transmembrane O
domain O
, O
and O
various O
amounts O
of O
the O
immunoglobulin O
constant O
- O
region O
- O
like O
domains O
. O

A O
persistently O
coronavirus O
- O
infected O
embryonic B
stem I
( I
ES I
) I
cell O
line O
A3 O
/ O
MHV O
was O
established O
by O
infecting O
an O
ES O
cell O
line O
, O
A3 O
- O
1 O
, O
with O
mouse O
hepatitis O
virus O
type O
- O
2 O
. O

The O
65 O
- O
nucleotide O
leader O
on O
the O
cloned O
bovine O
coronavirus O
Defective B
interfering I
( I
DI I
) I
RNA O
, O
when O
marked O
by O
mutations O
, O
has O
been O
shown O
to O
rapidly O
convert O
to O
the O
wild O
- O
type O
leader O
of O
the O
helper O
virus O
following O
DI O
RNA O
transfection O
into O
helper O
virus O
- O
infected O
cells O
. O

The O
role O
of O
the O
5 O
' O
nontranslated O
region O
in O
the O
replication O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
was O
studied O
by O
analyzing O
the O
translation O
and O
replication O
of O
chimeric O
RNAs O
containing O
the O
encephalomyocarditis B
virus I
( I
EMCV I
) I
internal I
ribosome I
entry I
segment I
( I
IRES I
) I
and O
various O
lengths O
( O
237 O
, O
151 O
, O
or O
98 O
nucleotides O
[ O
nt O
] O
) O
of O
the O
5 O
' O
- O
terminal O
HAV O
sequence O
. O

As O
a O
first O
step O
towards O
using O
ribozymes O
fog O
the O
treatment O
of O
liver O
disorders O
such O
as O
viral O
hepatitis O
, O
adenovirus O
vectors O
that O
contain O
a O
ribozyme O
expression O
cassette O
under O
the O
control O
of O
different O
promoters O
directed O
against O
human B
growth I
hormone I
( I
hGH I
) I
were O
constructed O
and O
infused O
into O
transgenic O
mice O
that O
produce O
hGH O
from O
the O
gastrointestinal O
tract O
and O
liver O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
known O
to O
express O
a O
protein O
termed O
the O
small O
delta O
antigen O
, O
a O
structural O
protein O
which O
is O
also O
essential O
for O
genome O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
, O
a O
positive O
- O
strand O
RNA O
virus O
, O
has O
been O
considered O
to O
have O
a O
poly O
( O
U O
) O
stretch O
at O
the O
3 O
' O
terminus O
of O
the O
genome O
. O

We O
previously O
found O
a O
novel O
98 O
- O
nucleotide O
sequence O
downstream O
from O
the O
poly O
( O
U O
) O
stretch O
on O
the O
HCV O
genome O
by O
primer O
extension O
analysis O
of O
the O
5 O
' O
end O
of O
the O
antigenomic O
- O
strand O
RNA O
in O
infected O
liver O
( O
T O
. O

The O
ribozymes O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
have O
so O
far O
been O
studied O
primarily O
in O
vitro O
. O

It O
has O
been O
found O
that O
a O
domain O
composed O
of O
330 O
amino O
acids O
of O
the O
N O
terminus O
of O
murine O
corona O
, O
virus O
spike O
protein O
[ O
S1N O
( O
330 O
) O
] O
is O
involved O
in O
receptor O
- O
binding O
activity O
( O
H O
. O

To O
delineate O
the O
amino O
acid O
sequences O
involved O
in O
receptor O
- O
binding O
activity O
, O
we O
have O
compared O
the O
S1N O
( O
330 O
) O
proteins O
of O
seven O
different O
mouse O
hepatitis O
virus O
MHV O
strains O
that O
are O
able O
to O
utilize O
the O
MHV O
receptor O
protein O
. O

Three O
conserved O
regions O
( O
sites O
I O
, O
II O
, O
and O
III O
) O
were O
found O
to O
consist O
of O
more O
than O
10 O
identical O
amino O
acids O
, O
and O
they O
were O
analyzed O
for O
receptor O
- O
binding O
activity O
by O
site O
- O
directed O
mutagenesis O
. O

S1N O
( O
330 O
) O
with O
a O
substitution O
at O
position O
62 O
from O
the O
N O
terminus O
of O
S1 O
in O
region O
I O
and O
that O
with O
substitutions O
at O
positions O
212 O
, O
214 O
, O
and O
216 O
in O
region O
II O
showed O
no O
receptor O
- O
binding O
activity O
. O

The O
S1N O
( O
330 O
) O
mutants O
without O
receptor O
- O
binding O
activity O
were O
not O
able O
to O
prevent O
virus O
binding O
to O
the O
receptor O
. O

These O
results O
suggest O
that O
the O
receptor O
- O
binding O
site O
on O
S1N O
( O
330 O
) O
is O
composed O
of O
regions O
located O
apart O
from O
each O
other O
in O
the O
protein O
' O
s O
primary O
structure O
, O
in O
which O
Thr O
at O
position O
62 O
as O
well O
as O
amino O
acids O
located O
at O
positions O
212 O
, O
214 O
, O
and O
216 O
are O
particularly O
important O
. O

The O
adenovirus O
major B
late I
transcription I
unit I
( I
MLTU I
) I
encodes O
five O
families O
of O
mRNAs O
, O
L1 O
to O
L5 O
, O
each O
distinguished O
by O
a O
unique O
poly O
( O
A O
) O
site O
. O

Use O
of O
the O
promoter O
- O
proximal O
L1 O
poly O
( O
A O
) O
site O
predominates O
during O
early O
infection O
, O
whereas O
poly O
( O
A O
) O
site O
choice O
shifts O
to O
the O
promoter O
- O
distal O
sites O
during O
late O
infection O
. O

A O
mini O
- O
MLTU O
containing O
only O
the O
L1 O
and O
L3 O
poly O
( O
A O
) O
sites O
has O
been O
shown O
to O
reproduce O
this O
processing O
switch O
. O

In O
vivo O
analysis O
has O
revealed O
that O
sequences O
extending O
5 O
' O
and O
3 O
' O
of O
the O
L1 O
core O
poly O
( O
A O
) O
site O
are O
required O
for O
efficient O
processing O
as O
well O
as O
for O
regulated O
expression O
. O

By O
replacement O
of O
the O
L1 O
core O
poly O
( O
A O
) O
site O
with O
that O
of O
the O
ground O
squirrel O
hepatitis O
virus O
poly O
( O
A O
) O
site O
, O
we O
now O
demonstrate O
that O
the O
L1 O
flanking O
sequences O
can O
enhance O
the O
processing O
of O
a O
heterologous O
poly O
( O
A O
) O
site O
. O

Upon O
recombination O
of O
the O
chimeric O
L1 O
- O
ground O
squirrel O
hepatitis O
virus O
poly O
( O
A O
) O
site O
onto O
the O
viral O
chromosome O
, O
the O
L1 O
flanking O
sequences O
were O
also O
found O
to O
be O
sufficient O
to O
reproduce O
the O
processing O
switch O
during O
the O
course O
of O
viral O
infection O
. O

Subsequent O
in O
vitro O
analysis O
has O
shown O
that O
the O
L1 O
flanking O
sequences O
function O
to O
enhance O
the O
stability O
of O
binding O
of O
cleavage O
and O
polyadenylation O
specificity O
factor O
to O
the O
core O
poly O
( O
A O
) O
site O
. O

The O
impact O
of O
L1 O
flanking O
sequences O
on O
the O
binding O
of O
cleavage O
and O
polyadenylation O
specificity O
factor O
suggests O
that O
the O
regulation O
of O
the O
MLTU O
poly O
( O
A O
) O
site O
selection O
is O
mediated O
by O
the O
interaction O
of O
constitutive O
processing O
factors O
. O

The O
regulative O
cis O
- O
acting O
terminal O
RNA O
structures O
and O
the O
proteins O
involved O
in O
the O
amplification O
of O
the O
hepatitis B
A I
virus I
( I
HAV I
) I
genome O
are O
unknown O
. O

By O
UV O
cross O
- O
linking O
/ O
label O
transfer O
experiments O
, O
we O
have O
analyzed O
sequences O
of O
the O
3 B
' I
- I
nontranslated I
region I
( I
3 I
' I
- I
NTR I
) I
and O
preceding O
domains O
of O
the O
viral O
genome O
for O
their O
ability O
to O
interact O
with O
host O
proteins O
, O
A O
series O
of O
cDNA O
constructs O
were O
used O
to O
create O
genomic O
- O
and O
antigenomic O
- O
sense O
transcripts O
. O

The O
results O
show O
that O
the O
3 O
' O
- O
NTR O
- O
poly O
( O
A O
) O
interacted O
with O
host O
cell O
proteins O
with O
molecular O
masses O
of O
38 O
, O
45 O
, O
57 O
, O
84 O
, O
and O
110 O
kDa O
only O
weakly O
, O
compared O
with O
RNA O
structures O
also O
consisting O
of O
3D O
- O
coding O
regions O
, O
Protein O
p38 O
was O
most O
efficiently O
labeled O
after O
interaction O
with O
secondary O
- O
structure O
elements O
located O
at O
the O
3 O
' O
end O
of O
the O
HAV O
RNA O
, O
p38 O
also O
interacted O
with O
a O
5 O
' O
- O
terminal O
RNA O
probe O
, O
Optimal O
RNA O
binding O
was O
found O
to O
be O
dependent O
on O
the O
salt O
concentration O
. O

The O
specificity O
of O
the O
RNA O
- O
protein O
interaction O
was O
proven O
by O
competition O
assays O
, O
These O
data O
might O
indicate O
that O
a O
higher O
- O
order O
structure O
formed O
at O
the O
junction O
of O
the O
3D O
( O
pol O
) O
- O
coding O
sequence O
and O
the O
3 O
' O
- O
NTR O
of O
the O
HAV O
genome O
( O
putative O
RNA O
pseudoknot O
) O
significantly O
improves O
binding O
of O
host O
proteins O
and O
thus O
suggests O
that O
this O
structure O
might O
he O
essential O
for O
the O
formation O
of O
the O
replication O
complex O
initiating O
minus O
- O
strand O
RNA O
synthesis O
. O

Coronavirus O
transcription O
is O
a O
discontinuous O
process O
, O
involving O
interactions O
between O
a O
trans O
- O
acting O
leader O
and O
the O
intergenic O
transcription O
initiation O
sequences O
, O
A O
9 O
- O
nucleotide B
( I
nt I
) I
sequence O
( O
UUUAUAAAC O
) O
, O
which O
is O
located O
immediately O
downstream O
of O
the O
leader O
at O
the O
5 O
' O
terminus O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genomic O
RNA O
, O
contains O
a O
sequence O
resembling O
the O
consensus O
intergenic O
sequence O
( O
UCUAAAC O
) O
, O
It O
has O
been O
shown O
previously O
that O
the O
presence O
of O
the O
9 O
- O
nt O
sequence O
facilitates O
leader O
RNA O
switching O
and O
may O
enhance O
subgenomic O
mRNA O
transcription O
, O
It O
is O
unclear O
how O
the O
9 O
- O
nt O
sequence O
exerts O
these O
functions O
, O
In O
this O
study O
, O
we O
inserted O
the O
9 O
- O
nt O
sequence O
into O
a O
Defective B
interfering I
( I
DI I
) I
RNA O
reporter O
system O
and O
demonstrated O
that O
mRNA O
transcription O
could O
be O
initiated O
from O
the O
9 O
- O
nt O
sequence O
almost O
as O
efficiently O
as O
from O
the O
intergenic O
sequence O
between O
genes O
6 O
and O
7 O
. O

These O
results O
thus O
suggest O
that O
the O
heterogeneity O
of O
the O
copy O
number O
of O
UCUAA O
sequences O
at O
the O
5 O
' O
end O
, O
the O
deletion O
of O
the O
9 O
- O
nt O
sequence O
in O
viral O
and O
DI O
RNAs O
, O
and O
the O
leader O
RNA O
switching O
are O
the O
results O
of O
transcriptional O
initiation O
from O
the O
9 O
- O
nt O
site O
, O
They O
also O
show O
that O
an O
mRNA O
species O
( O
mRNA O
1 O
) O
that O
lacks O
the O
9 O
- O
nt O
sequence O
can O
be O
synthesized O
during O
MHV O
infection O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
glycoproteins O
( O
E1 O
and O
E2 O
) O
are O
released O
from O
the O
polyprotein O
by O
signal O
peptidase O
- O
mediated O
cleavage O
and O
interact O
to O
form O
a O
heterodimer O
. O

In O
contrast O
, O
folding O
of O
E1 O
is O
slow O
( O
> O
1 O
h O
) O
, O
suggesting O
that O
this O
step O
may O
be O
rate O
limiting O
for O
E1E2 O
oligomerization O
. O

To O
investigate O
the O
function O
and O
the O
sequence O
of O
NS4A O
required O
for O
the O
enhancement O
of O
NS3 O
protease O
activity O
, O
we O
developed O
an O
in O
vitro O
NS3 O
protease O
assay O
system O
consisting O
of O
three O
purified O
viral O
elements O
: O
( O
i O
) O
a O
recombinant O
NS3 O
protease O
which O
was O
expressed O
in O
Escherichia O
coli O
as O
a O
maltose B
binding I
protein I
- I
NS3 I
fusion I
protein I
( I
MBP I
- I
NS3 I
) I
, O
( O
ii O
) O
synthetic O
NSJA O
fragments O
, O
and O
( O
iii O
) O
a O
synthetic O
peptide O
substrate O
which O
mimics O
the O
NS5A O
/ O
5B O
junction O
. O

The O
coefficient O
for O
proteolytic O
efficiency O
, O
k O
( O
cat O
) O
/ O
K O
- O
m O
of O
NS3 O
protease O
was O
increased O
by O
about O
40 O
times O
by O
the O
addition O
of O
a O
10 O
- O
fold O
molar O
excess O
of O
4A18 O
- O
40 O
. O

Using O
a O
series O
of O
truncations O
of O
4A18 O
- O
30 O
, O
we O
estimated O
that O
amino O
acid O
residues O
22 O
to O
31 O
in O
NS4A O
( O
SVVIVGRIIL O
) O
constituted O
the O
core O
sequence O
for O
the O
effector O
activity O
. O

Single O
- O
substitution O
experiments O
with O
4A21 O
- O
34 O
, O
a O
peptide O
composed O
of O
amino O
acid O
residues O
21 O
to O
34 O
of O
NS4A O
, O
suggested O
the O
importance O
of O
several O
residues O
( O
Val O
- O
23 O
, O
Ile O
- O
25 O
, O
Gly O
- O
27 O
, O
Arg O
- O
28 O
, O
Ile O
- O
29 O
, O
and O
Leu O
- O
31 O
) O
for O
its O
activity O
. O

Genetically O
engineered O
RNA O
transcripts O
coding O
for O
various O
Sindbis B
virus I
( I
SIN I
) I
genes O
were O
used O
to O
study O
structure O
and O
sequence O
requirements O
of O
RNA O
recombination O
in O
BHK O
cells O
. O

Three O
different O
groups O
of O
RNA O
transcripts O
were O
made O
: O
( O
i O
) O
RNAs O
which O
retain O
the O
ability O
to O
replicate O
and O
which O
carry O
sequences O
coding O
for O
either O
viral O
polymerase O
or O
viral O
structural O
proteins O
; O
( O
ii O
) O
RNAs O
which O
lack O
the O
complete O
3 O
' O
end O
of O
the O
SIN O
genome O
and O
thus O
are O
incapable O
of O
replicating O
; O
and O
( O
iii O
) O
RNAs O
which O
lack O
the O
complete O
5 O
' O
end O
of O
the O
SIN O
genome O
and O
also O
are O
incapable O
of O
replicating O
. O

We O
demonstrate O
in O
vivo O
generation O
of O
infectious O
SIN O
by O
fusion O
of O
( O
i O
) O
replicative O
RNAs O
to O
nonreplicative O
RNAs O
and O
( O
ii O
) O
two O
nonreplicative O
RNA O
precursors O
. O

The O
role O
of O
the O
3 B
' I
untranslated I
region I
( I
3 I
' I
UTR I
) I
in O
the O
replication O
of O
enteroviruses O
has O
been O
studied O
with O
a O
series O
of O
mutants O
derived O
from O
either O
poliovirus B
type I
3 I
( I
PV3 I
) I
or O
a O
PV3 O
replicon O
containing O
the O
reporter O
gene O
chloramphenicol O
acetyltransferase O
, O
Replication O
was O
observed O
when O
the O
PV3 O
3 O
' O
UTR O
was O
replaced O
, O
vith O
that O
of O
either O
coxsackie O
B4 O
virus O
, O
human B
rhinovirus I
14 I
( I
HRV14 I
) I
, O
bovine O
enterovirus O
, O
or O
hepatitis O
A O
virus O
, O
despite O
the O
lack O
of O
sequence O
and O
secondary O
structure O
homology O
of O
the O
3 O
' O
UTRs O
of O
these O
viruses O
, O
The O
levels O
of O
replication O
observed O
for O
recombinants O
containing O
the O
3 O
' O
UTRs O
of O
hepatitis O
A O
virus O
and O
bovine O
enterovirus O
were O
lower O
than O
those O
for O
PV3 O
and O
the O
other O
recombinants O
, O
Extensive O
site O
- O
directed O
mutagenesis O
of O
the O
single O
stem O
- O
loop O
structure O
formed O
by O
the O
HRV14 O
3 O
' O
UTR O
indicated O
the O
importance O
of O
( O
i O
) O
the O
loop O
sequence O
, O
( O
ii O
) O
the O
stability O
of O
the O
stem O
, O
and O
( O
iii O
) O
the O
location O
of O
the O
stem O
immediately O
upstream O
of O
the O
poly O
( O
A O
) O
tail O
, O
The O
role O
of O
a O
4 O
- O
bp O
motif O
at O
the O
base O
of O
the O
HRV14 O
stem O
, O
highly O
conserved O
among O
rhinoviruses O
, O
was O
examined O
by O
site O
- O
directed O
mutagenesis O
of O
individual O
base O
pairs O
, O
This O
analysis O
did O
not O
pinpoint O
a O
particular O
base O
pair O
as O
crucial O
for O
function O
. O

Coronaviruses O
synthesize O
a O
nested O
set O
of O
six O
to O
eight O
subgenomic B
( I
sg I
) I
mRNAs O
in O
infected O
cells O
. O

To O
determine O
whether O
the O
intergenic B
sequence I
( I
IS I
) I
involved O
in O
sg O
mRNA O
synthesis O
could O
affect O
the O
transcription O
efficiencies O
of O
other O
ISs O
and O
in O
this O
way O
regulate O
transcription O
levels O
, O
we O
inserted O
multiple O
ISs O
at O
different O
positions O
into O
a O
mouse O
hepatitis O
virus O
defective O
interfering O
RNA O
. O

Quantitation O
of O
the O
sg O
RNAs O
produced O
by O
identical O
ISs O
in O
different O
sequence O
contexts O
led O
to O
the O
following O
conclusions O
: O
( O
i O
) O
transcription O
efficiency O
depends O
on O
the O
location O
of O
the O
IS O
in O
the O
defective O
interfering O
virus O
genome O
, O
( O
ii O
) O
downstream O
ISs O
have O
a O
negative O
effect O
on O
transcription O
levels O
from O
upstream O
ISs O
, O
and O
( O
iii O
) O
upstream O
ISs O
have O
little O
or O
no O
effect O
on O
downstream O
ISs O
. O

During O
the O
replication O
cycle O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
RNA O
editing O
occurs O
at O
position O
1012 O
on O
the O
1679 O
- O
nucleotide O
RNA O
genome O
. O

This O
changes O
an O
A O
to O
G O
in O
the O
amber O
termination O
codon O
, O
UAG O
, O
of O
the O
small O
form O
of O
the O
delta B
antigen I
( I
delta I
Ag I
) I
. O

The O
resultant O
UGG O
codon O
, O
tryptophan O
, O
allows O
the O
translation O
of O
a O
larger O
form O
of O
the O
6Ag O
with O
a O
19 O
- O
amino O
- O
acid O
C O
- O
terminal O
extension O
, O
Using O
HDV O
cDNA O
- O
transfected O
cells O
, O
we O
examined O
the O
editing O
potential O
of O
HDV O
RNA O
mutated O
from O
G O
to O
A O
at O
1011 O
on O
the O
antigenome O
, O
adjacent O
to O
normal O
editing O
site O
at O
1012 O
, O
Four O
procedures O
were O
used O
to O
study O
not O
only O
the O
editing O
of O
the O
A O
at O
1012 O
, O
but O
also O
that O
of O
the O
new O
A O
at O
1011 O
: O
( O
i O
) O
nucleotide O
sequencing O
, O
( O
ii O
) O
a O
PCR O
- O
based O
RNA O
- O
editing O
assay O
, O
( O
iii O
) O
immunoblot O
assays O
, O
and O
( O
iv O
) O
immunofluorescence O
, O
Five O
findings O
are O
reported O
, O
( O
i O
) O
Even O
after O
the O
mutation O
at O
1011 O
, O
editing O
still O
occurred O
at O
1012 O
, O
( O
ii O
) O
Site O
1011 O
itself O
now O
acted O
as O
a O
novel O
RNA O
- O
editing O
site O
, O
( O
iii O
) O
Sites O
1011 O
and O
1012 O
were O
edited O
independently O
. O

( O
iv O
) O
At O
later O
times O
, O
both O
sites O
became O
edited O
, O
thereby O
allowing O
the O
synthesis O
of O
the O
large O
form O
of O
the O
delta B
Ag I
( I
delta I
Ag I
- I
L I
) I
. O

( O
v O
) O
Via O
immunofluorescence O
, O
such O
double O
editing O
became O
apparent O
as O
a O
stochastic O
event O
, O
in O
that O
groups O
of O
cells O
arose O
in O
which O
the O
changes O
had O
taken O
place O
, O
Evaluation O
of O
these O
findings O
and O
of O
those O
from O
previous O
studies O
of O
the O
stability O
of O
the O
HDV O
genomic O
sequence O
( O
H O
. O

Virol O
, O
69 O
: O
1687 O
- O
1692 O
, O
1995 O
) O
supports O
both O
the O
recent O
reevaluation O
of O
HDV O
RNA O
editing O
as O
occurring O
on O
antigenomic O
RNA O
( O
Casey O
and O
Gerin O
, O
personal O
communication O
) O
and O
the O
interpretation O
that O
editing O
occurs O
via O
the O
RNA O
- O
modifying O
enzyme O
known O
as O
DRADA O
. O

The O
subgenomic O
mRNAs O
of O
the O
coronavirus O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
are O
not O
produced O
in O
equimolar O
amounts O
. O

A O
series O
of O
gene O
cassettes O
was O
produced O
; O
these O
cassettes O
comprised O
the O
reporter O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
downstream O
of O
transcription B
- I
associated I
sequences I
( I
TASs I
) I
( O
also O
referred O
to O
as O
intergenic O
sequences O
and O
promoters O
) O
believed O
to O
be O
involved O
in O
the O
synthesis O
of O
TGEV O
subgenomic O
mRNAs O
6 O
and O
7 O
. O

Our O
results O
indicated O
that O
the O
CAT O
mRNAs O
were O
transcribed O
from O
the O
in O
situ O
- O
synthesized O
negative O
- O
sense O
RNA O
templates O
without O
the O
requirement O
of O
TGEV O
genomic O
5 O
' O
or O
3 O
' O
sequences O
on O
the O
T7 O
- O
generated O
negative O
- O
sense O
transcripts O
( O
3 O
' O
- O
TAS O
- O
CAT O
- O
5 O
' O
) O
. O

Modification O
of O
the O
TGEV O
TASs O
indicated O
( O
i O
) O
that O
the O
degree O
of O
potential O
base O
pairing O
between O
the O
3 O
' O
end O
of O
the O
leader O
RNA O
and O
the O
TGEV O
negative O
- O
sense O
TAS O
was O
not O
the O
sole O
determinant O
of O
the O
amount O
of O
subgenomic O
mRNA O
transcribed O
and O
( O
ii O
) O
that O
other O
factors O
, O
including O
nucleotides O
flanking O
the O
TAS O
, O
are O
involved O
in O
the O
regulation O
of O
transcription O
of O
TGEV O
subgenomic O
mRNAs O
. O

Initiation O
of O
translation O
of O
the O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
genome O
occurs O
by O
internal O
ribosome O
entry O
into O
the O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
in O
a O
cap O
- O
independent O
manner O
. O

Here O
we O
report O
the O
interaction O
of O
polypyrimidine B
tract I
- I
binding I
protein I
( I
PTB I
) I
at O
three O
distinct O
regions O
within O
the O
5 O
' O
NCR O
by O
UV O
cross O
- O
linking O
assays O
. O

Mouse B
hepatitis I
virus I
A59 I
( I
MHV I
- I
A59 I
) I
infection O
of O
adult O
BALB O
/ O
c O
mice O
induced O
a O
severe O
, O
transient O
atrophy O
of O
the O
thymus O
. O

In O
infected O
thymus O
, O
immature O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
lymphocytes O
were O
selectively O
depleted O
, O
and O
apoptosis O
of O
lymphocytes O
was O
increased O
. O

The O
binding O
domains O
of O
four O
Monoclonal B
antibodies I
( I
MAbs I
) I
specific O
for O
the O
M O
protein O
of O
the O
PUR46 O
- O
MAD O
strain O
of O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
have O
been O
located O
in O
the O
46 O
carboxy O
- O
terminal O
amino O
acids O
of O
the O
protein O
by O
studying O
the O
binding O
of O
MAbs O
to O
recombinant O
M O
protein O
fragments O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
is O
a O
positive O
- O
strand O
RNA O
virus O
with O
a O
genome O
length O
of O
approximately O
7 O
, O
480 O
nucleotides O
. O

Targeted O
RNA O
recombination O
was O
used O
to O
construct O
mouse B
hepatitis I
virus I
( I
MHV I
) I
mutants O
containing O
chimeric O
nucleocapsid B
( I
N I
) I
protein O
genes O
in O
which O
segments O
of O
the O
bovine O
coronavirus O
N O
gene O
were O
substituted O
in O
place O
of O
their O
corresponding O
MHV O
sequences O
. O

By O
contrast O
, O
the O
amino O
terminus O
of O
N O
, O
the O
acidic O
carboxy O
- O
terminal O
domain O
, O
and O
a O
serine O
- O
and O
arginine O
- O
rich O
segment O
of O
the O
central O
domain O
could O
not O
be O
transferred O
from O
bovine O
coronavirus O
to O
MHV O
, O
presumably O
because O
these O
parts O
of O
the O
molecule O
participate O
in O
protein O
- O
protein O
interactions O
that O
are O
specific O
for O
each O
virus O
( O
or O
, O
possibly O
, O
each O
host O
) O
. O

The O
A59 O
strain O
of O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
can O
cause O
persistent O
infection O
of O
17C1 O
- O
1 O
cells O
and O
other O
murine O
cell O
lines O
, O
Persistently O
infected O
cultures O
released O
large O
amounts O
of O
virus O
( O
10 O
( O
7 O
) O
to O
10 O
( O
8 O
) O
PFU O
/ O
ml O
) O
and O
were O
resistant O
to O
superinfection O
with O
MHV O
but O
not O
to O
infection O
with O
unrelated O
Semliki O
Forest O
and O
vesicular O
stomatitis O
viruses O
, O
The O
culture O
medium O
from O
persistently O
infected O
cultures O
did O
not O
contain O
a O
soluble O
inhibitor O
such O
as O
interferon O
that O
protected O
uninfected O
cells O
from O
infection O
by O
MHV O
or O
vesicular O
stomatitis O
virus O
, O
The O
persistent O
infection O
was O
cured O
if O
fewer O
than O
100 O
cells O
were O
transferred O
during O
subculturing O
, O
and O
such O
cured O
cultures O
were O
susceptible O
to O
reinfection O
and O
the O
reestablishment O
of O
persistent O
infection O
, O
Cultures O
of O
17C1 O
- O
1 O
cells O
that O
had O
been O
newly O
cloned O
from O
single O
cells O
consisted O
of O
a O
mixture O
of O
MHV O
- O
resistant O
and O
- O
susceptible O
cells O
, O
17C1 O
- O
1 O
/ O
#97 O
cells O
, O
which O
were O
cured O
by O
subcloning O
after O
97 O
passages O
of O
a O
persistently O
infected O
culture O
over O
a O
1 O
- O
year O
period O
, O
contained O
5 O
to O
10 O
% O
of O
their O
population O
as O
susceptible O
cells O
, O
while O
17C1 O
- O
1 O
/ O
#402 O
cells O
, O
which O
were O
cured O
by O
subcloning O
after O
402 O
passages O
over O
a O
3 O
- O
year O
period O
, O
had O
less O
than O
1 O
% O
susceptible O
cells O
. O

Susceptibility O
to O
infection O
correlated O
, O
vith O
the O
expression O
of O
MHV O
receptor O
glycoprotein O
( O
MHVR O
[ O
Bgp1 O
( O
a O
) O
] O
) O
. O

The O
2A O
gene O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
bears O
no O
obvious O
similarity O
to O
the O
corresponding O
genes O
of O
other O
picornaviruses O
and O
has O
no O
known O
function O
. O

Tyrosine O
kinase O
inhibition O
precluded O
this O
increase O
and O
abrogated O
expression O
of O
the O
virus O
- O
induced O
procoagulant O
mouse O
fibrinogen O
- O
like O
protein O
( O
musfiblp O
) O
gene O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
sequences O
required O
for O
replication O
of O
the O
JHM O
strain O
of O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
consist O
of O
three O
discontinuous O
genomic O
regions O
: O
about O
0 O
. O

Previously O
, O
we O
demonstrated O
induction O
of O
a O
unique O
macrophage O
prothrombinase O
during O
infection O
of O
BALB O
/ O
cJ O
mice O
by O
mouse B
hepatitis I
virus I
strain I
3 I
( I
MHV I
- I
3 I
) I
, O
By O
immunologic O
screening O
, O
a O
clone O
representing O
this O
prothrombinase O
was O
isolated O
from O
a O
cDNA O
library O
and O
sequenced O
. O

Two O
proteins O
, O
a O
56 B
- I
kDa I
protein I
( I
p56 I
) I
and O
a O
58 B
- I
kDa I
protein I
( I
p58 I
) I
, O
are O
produced O
from O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
region I
5A I
( I
NS5A I
) I
. O

Cleavage O
at O
the O
2 O
/ O
3 O
site O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
thought O
to O
be O
mediated O
by O
a O
virus O
- O
encoded O
protease O
composed O
of O
the O
region O
of O
the O
polyprotein O
encoding O
NS2 O
and O
the O
N O
- O
terminal O
one O
- O
third O
of O
NS3 O
. O

Site O
directed O
mutagenesis O
of O
residues O
surrounding O
the O
2 O
/ O
3 O
cleavage O
site O
showed O
that O
cleavage O
is O
remarkably O
resistant O
to O
single O
- O
amino O
- O
acid O
substitutions O
from O
P5 O
to O
P3 O
' O
( O
GWRLL O
down O
arrow O
API O
) O
. O

Infection O
of O
cultures O
of O
peritoneal O
macrophages O
with O
both O
lactate B
dehydrogenase I
- I
elevating I
virus I
( I
LDV I
) I
and O
mouse B
hepatitis I
virus I
( I
MHV I
) I
resulted O
in O
the O
formation O
of O
pseudotype O
virions O
containing O
LDV O
RNA O
which O
productively O
infected O
cells O
that O
are O
resistant O
to O
infection O
by O
intact O
LDV O
virions O
but O
not O
to O
infection O
by O
MHV O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
frequent O
cause O
of O
chronic O
liver O
disease O
. O

We O
have O
sequenced O
the B
hypervariable I
region I
1 I
( I
HVR1 I
) I
of O
the O
virus O
isolated O
from O
three O
serum O
samples O
, O
collected O
during O
18 O
months O
of O
follow O
- O
up O
, O
from O
an O
asymptomatic O
HCV O
- O
infected O
patient O
. O

A O
synthetic O
peptide O
of O
27 O
amino O
acids O
, O
corresponding O
to O
the O
HVR1 O
sequence O
found O
to O
be O
predominant O
in O
both O
the O
second O
and O
third O
samples O
, O
was O
used O
as O
the O
antigen O
for O
detection O
of O
antibodies O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

The O
Alb4 O
mutant O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
both O
temperature O
sensitive O
and O
thermolabile O
owing O
to O
a O
deletion O
in O
the O
gene O
encoding O
its O
nucleocapsid B
( I
N I
) I
protein O
, O
The O
deletion O
removes O
29 O
amino O
acids O
that O
constitute O
a O
putative O
spacer O
region O
preceding O
the O
carboxyl O
- O
terminal O
domain O
of O
the O
protein O
. O

As O
a O
step O
toward O
understanding O
the O
structure O
and O
function O
of O
the O
MHV O
N O
protein O
, O
we O
isolated O
multiple O
independent O
revertants O
of O
Alb4 O
that O
totally O
or O
partially O
regained O
the O
ability O
to O
form O
large O
( O
wild O
- O
type O
- O
sized O
) O
plaques O
at O
the O
nonpermissive O
temperature O
. O

The O
Defective B
interfering I
( I
DI I
) I
RNA O
MIDI O
of O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
contains O
a O
large O
open B
reading I
frame I
( I
ORF I
) I
spanning O
almost O
its O
entire O
genome O
, O
This O
ORF O
consists O
of O
sequences O
derived O
from O
ORF1a O
, O
ORF1b O
and O
the O
nucleocapsid O
gene O
. O

Four O
new O
porcine B
respiratory I
coronavirus I
( I
PRCV I
) I
isolates O
were O
genetically O
characterized O
. O

Subgenomic O
mRNA O
patterns O
and O
the O
nucleotide O
sequences O
of O
the O
5 O
' O
ends O
of O
the O
S O
genes O
, O
The B
open I
reading I
frame I
( I
ORF I
) I
3 O
/ O
3a O
genes O
, O
and O
the O
ORF O
3 O
- O
1 O
/ O
3b O
genes O
of O
these O
PRCV O
isolates O
were O
determined O
and O
compared O
with O
those O
of O
other O
PRCV O
and O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
isolates O
. O

The O
S O
, O
ORF O
3 O
/ O
3a O
, O
and O
ORF O
3 O
- O
1 O
/ O
3b O
genes O
are O
under O
intense O
study O
because O
of O
their O
possible O
roles O
in O
determining O
tissue O
tropism O
and O
virulence O
, O
Northern O
( O
RNA O
) O
blot O
analysis O
of O
subgenomic O
mRNAs O
revealed O
that O
mRNA O
2 O
, O
which O
encodes O
for O
the O
S O
gene O
, O
of O
the O
PRCV O
isolates O
migrated O
faster O
than O
the O
mRNA O
2 O
of O
TGEV O
. O

The O
initial O
step O
in O
mouse B
hepatitis I
virus I
( I
MIN I
) I
RNA O
replication O
is O
the O
synthesis O
of O
negative O
- O
strand O
RNA O
from O
a O
positive O
- O
strand O
genomic O
RNA O
template O
. O

The O
first O
protein O
- O
binding O
element O
was O
mapped O
in O
the O
3 O
' O
- O
most O
42 O
nucleotides O
of O
the O
genomic O
RNA O
[ O
3 O
' O
( O
+ O
42 O
) O
RNA O
] O
, O
and O
the O
second O
element O
was O
mapped O
within O
an O
86 O
- O
nucleotide O
sequence O
encompassing O
nucleotides O
171 O
to O
85 O
from O
the O
3 O
' O
end O
of O
the O
genome O
( O
171 O
- O
85 O
RNA O
) O
. O

A O
single O
potential O
stem O
- O
loop O
structure O
is O
predicted O
for O
the O
3 O
' O
( O
+ O
) O
42 O
RNA O
, O
and O
two O
stem O
loop O
structures O
are O
predicted O
for O
the O
171 O
- O
85 O
RNA O
. O

We O
identified O
two O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genes O
that O
suffice O
for O
MHV O
RNA O
synthesis O
by O
using O
an O
MW O
- O
JHM O
- O
derived O
Defective B
interfering I
( I
DI I
) I
RNA O
, O
DIssA O
. O

Coinfection O
of O
MHV O
- O
JHM O
containing O
DIssA O
DI O
particles O
and O
an O
MHV O
- O
A59 O
RNA O
( O
- O
) O
temperature O
- O
sensitive O
mutant O
followed O
by O
subsequent O
passage O
of O
virus O
at O
the O
permissive O
temperature O
resulted O
in O
elimination O
of O
most O
of O
the O
MHV O
- O
JHM O
helper O
virus O
. O

Northern O
( O
RNA O
) O
blot O
analysis O
of O
intracellular O
RNA O
species O
and O
virus O
- O
specific O
protein O
analysis O
confirmed O
the O
sequence O
data O
. O

Antiviral O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
may O
play O
a O
role O
in O
clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
infected O
cells O
and O
thereby O
cause O
hepatocellular O
injury O
during O
acute O
and O
chronic O
HCV O
infection O
. O

HLA O
- O
A2 O
- O
negative O
patients O
, O
vith O
chronic O
hepatitis O
C O
as O
well O
as O
healthy O
HLA O
- O
A2 O
- O
positive O
( O
anti O
- O
HCV O
- O
negative O
) O
donors O
served O
as O
controls O
. O

Peripheral O
blood O
mononuclear O
cells O
stimulated O
repeatedly O
with O
several O
HCV O
- O
encoded O
peptides O
( O
three O
in O
core O
, O
one O
in O
NS4B O
, O
and O
one O
in O
NS5B O
) O
yielded O
cytolytic O
responses O
. O

A O
transient O
protein O
expression O
system O
in O
COS O
- O
1 O
cells O
was O
used O
to O
study O
the O
role O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
encoded O
NS4A O
protein O
on O
HCV O
nonstructural O
polyprotein O
processing O
. O

By O
analyzing O
the O
protein O
expression O
and O
processing O
of O
a O
deletion O
mutant O
polypeptide O
, O
NS O
Delta O
4A O
, O
which O
encodes O
the O
entire O
putative O
HCV O
nonstructural O
polyprotein O
except O
the O
region O
encoding O
NS4A O
, O
the O
versatile O
functions O
of O
NS4A O
were O
revealed O
, O
Most O
of O
the O
NS3 O
processed O
from O
NS O
Delta O
4A O
was O
localized O
in O
the O
cytosol O
fraction O
and O
was O
degraded O
promptly O
, O
Coproduction O
of O
NS4A O
stabilizes O
NS3 O
and O
assists O
in O
its O
localization O
in O
the O
membrane O
, O
NS4A O
was O
found O
to O
be O
indispensable O
for O
cleavage O
at O
the O
4B O
/ O
5A O
site O
but O
not O
essential O
for O
cleavage O
at O
the O
5A O
/ O
5B O
site O
in O
NS O
Delta O
4A O
The O
functioning O
of O
NS4A O
as O
a O
cofactor O
for O
cleavage O
at O
the O
4B O
/ O
5A O
site O
was O
also O
observed O
when O
30 O
amino O
acids O
around O
this O
site O
was O
used O
as O
a O
substrate O
and O
a O
serine O
proteinase O
domain O
of O
167 O
amino O
acids O
, O
from O
Gly O
- O
1049 O
to O
Ser O
- O
1215 O
, O
was O
used O
as O
an O
enzyme O
protein O
, O
suggesting O
that O
possible O
domains O
for O
the O
interaction O
of O
NS4A O
were O
in O
those O
regions O
of O
the O
enzyme O
protein O
( O
NS3 O
) O
and O
/ O
or O
the O
substrate O
protein O
, O
Two O
proteins O
, O
p58 O
and O
p56 O
, O
were O
produced O
from O
NS5A O
. O

Cultured O
cells O
were O
cotransfected O
with O
a O
fully O
sequenced O
1 O
, O
679 O
- O
base O
cDNA O
clone O
of O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
genome O
and O
a O
cDNA O
for O
the O
genome O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

From O
the O
sequences O
of O
31 O
clones O
, O
we O
found O
32 O
% O
( O
10 O
of O
31 O
) O
to O
be O
identical O
to O
the O
original O
single O
nucleotide O
sequence O
. O

Of O
the O
40 O
changes O
detected O
on O
HDV O
, O
35 O
% O
( O
14 O
of O
40 O
) O
occurred O
within O
an O
eight O
- O
nucleotide O
region O
that O
included O
position O
1012 O
, O
previously O
shown O
to O
be O
a O
site O
of O
RNA O
editing O
. O

The O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
p80 O
protein O
( O
referred O
to O
here O
as O
the O
NS3 O
protein O
) O
contains O
amino O
acid O
sequence O
motifs O
predictive O
of O
three O
enzymatic O
activities O
: O
serine O
proteinase O
, O
nucleoside O
triphosphatase O
, O
and O
RNA O
helicase O
. O

However O
, O
the O
enzyme O
did O
not O
act O
on O
substrates O
having O
a O
single O
- O
stranded O
region O
only O
to O
the O
5 O
' O
end O
of O
the O
duplex O
or O
on O
substrates O
lacking O
single O
- O
stranded O
regions O
altogether O
( O
blunt O
- O
ended O
duplex O
substrates O
) O
, O
suggesting O
that O
the O
directionality O
of O
the O
BVDV O
RNA O
helicase O
was O
3 O
' O
to O
5 O
' O
with O
respect O
to O
the O
template O
strand O
. O

Hepatitis O
A O
virus O
( O
HSV O
) O
3C O
proteinase O
expressed O
in O
Escherichia O
call O
was O
purified O
to O
homogeneity O
, O
and O
its O
cleavage O
specificity O
towards O
various O
parts O
of O
the O
viral O
polyprotein O
was O
analyzed O
, O
Intermolecular O
cleavage O
of O
the O
P2 O
P3 O
domain O
of O
the O
HAV O
polyprotein O
gave O
rise O
to O
proteins O
2A O
, O
2B O
, O
2C O
, O
3ABC O
, O
and O
3D O
, O
suggesting O
that O
in O
addition O
to O
the O
primary O
cleavage O
site O
, O
all O
secondary O
sites O
within O
P2 O
as O
well O
as O
the O
3C O
/ O
3D O
junction O
are O
cleaved O
by O
3C O
, O
3C O
- O
mediated O
processing O
of O
the O
P1 O
- O
P2 O
precursor O
liberated O
2A O
and O
2BC O
, O
in O
addition O
to O
the O
structural O
proteins O
VP0 O
, O
VP3 O
, O
and O
VP1 O
- O
2A O
and O
the O
respective O
intermediate O
products O
. O

The O
electrophoretic O
mobility O
of O
processing O
product O
2B O
, O
as O
well O
as O
cleavage O
of O
the O
synthetic O
peptide O
KGLFSQ O
( O
double O
dagger O
) O
AKISLFYT O
, O
suggests O
that O
the O
2A O
/ O
2B O
junction O
is O
located O
at O
amino O
acid O
position O
836 O
/ O
837 O
of O
the O
HAV O
polyprotein O
, O
Furthermore O
, O
using O
suitable O
substrates O
we O
obtained O
evidence O
that O
sites O
VP3 O
/ O
VP1 O
and O
VP1 O
/ O
2A O
are O
alternatively O
processed O
by O
3C O
, O
leading O
to O
either O
VP1 O
- O
2A O
or O
to O
P1 O
and O
2k O
The O
results O
with O
regard O
to O
intermolecular O
cleavage O
by O
purified O
3C O
were O
confirmed O
by O
the O
product O
pattern O
derived O
from O
cell O
- O
free O
expression O
and O
intramolecular O
processing O
of O
the O
entire O
polyprotein O
, O
We O
therefore O
propose O
that O
polyprotein O
processing O
of O
HAV O
relies O
on O
3C O
as O
the O
single O
proteinase O
, O
possibly O
assisted O
by O
as O
- O
yet O
- O
undetermined O
viral O
or O
host O
cell O
factors O
and O
presumably O
controlled O
in O
a O
concentration O
- O
dependent O
fashion O
. O

Mouse B
hepatitis I
virus I
strain I
JHM I
( I
MHV I
- I
JHM I
) I
causes O
a O
chronic O
encephalomyelitis O
in O
susceptible O
mice O
, O
with O
histological O
evidence O
of O
demyelination O
in O
the O
spinal O
cord O
. O

Under O
these O
conditions O
, O
virus O
was O
observed O
to O
enter O
specific O
layers O
( O
primarily O
laminae O
V O
to O
VII O
) O
in O
the O
gray O
matter O
of O
the O
upper O
spinal O
cord O
, O
consistent O
with O
transneuronal O
spread O
, O
While O
the O
brain O
structures O
which O
are O
the O
sources O
for O
virus O
spread O
to O
the O
spinal O
cord O
cannot O
be O
determined O
with O
certainty O
, O
the O
ventral O
reticular O
nucleus O
is O
likely O
to O
be O
important O
since O
it O
is O
consistently O
and O
extensively O
labeled O
in O
all O
mice O
and O
receives O
projections O
from O
subsequently O
infected O
areas O
of O
the O
spinal O
cord O
. O

Acute O
infection O
of O
the O
central O
nervous O
system O
by O
the O
neurotropic O
JHM B
strain I
of I
mouse I
hepatitis I
virus I
( I
JHMV I
) I
induces O
nucleocapsid O
protein O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
not O
found O
in O
the O
periphery O
( O
S O
. O

Sequence O
evolution O
of O
the B
hypervariable I
region I
1 I
( I
HVR1 I
) I
in O
the O
N O
terminus O
of O
E2 O
/ O
NS1 O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
was O
studied O
retrospectively O
in O
six O
chimpanzees O
inoculated O
with O
the O
same O
genotype O
1b O
strain O
, O
containing O
a O
unique O
predominant O
HVR1 O
sequence O
. O

Anti O
- O
HVR1 O
immunoglobulin B
G I
( I
IgG I
) I
was O
produced O
40 O
to O
60 O
days O
after O
inoculation O
and O
rapidly O
disappeared O
after O
normalization O
of O
transaminases O
. O

Mouse O
hepatitis O
virus O
strain O
A59 O
encodes O
a O
papain B
- I
like I
cysteine I
proteinase I
( I
PLP I
- I
1 I
) I
that O
, O
during O
translation O
of O
ORF1a O
, O
cleaves O
p28 O
from O
the O
amino O
terminus O
of O
the O
growing O
polypeptide O
chain O
. O

Site O
- O
directed O
mutagenesis O
of O
amino O
acids O
surrounding O
the O
p28 O
cleavage O
site O
revealed O
that O
substitutions O
of O
Arg O
- O
246 O
( O
P2 O
) O
and O
Gly O
- O
247 O
( O
P1 O
) O
nearly O
eliminated O
cleavage O
of O
p28 O
. O

In O
addition O
to O
the O
spike B
( I
S I
) I
glycoprotein O
that O
binds O
to O
carcinoembryonic O
antigen O
- O
related O
receptors O
on O
the O
host O
cell O
membrane O
, O
some O
strains O
of O
mouse O
coronavirus O
( O
mouse O
hepatitis O
virus O
[ O
MHV O
] O
) O
express O
a O
hemagglutinin B
esterase I
( I
HE I
) I
glycoprotein O
with O
hemagglutinating O
and O
acetylesterase O
activity O
. O

Insertion O
of O
an O
intergenic O
region O
from O
the O
murine O
coronavirus O
mouse O
hepatitis O
virus O
into O
a O
mouse O
hepatitis O
virus O
Defective B
interfering I
( I
DI I
) I
RNA O
led O
to O
transcription O
of O
subgenomic O
DI O
RNA O
in O
helper O
virus O
- O
infected O
cells O
. O

When O
two O
intergenic O
regions O
were O
separated O
by O
more O
than O
100 O
nucleotides O
, O
slightly O
less O
of O
the O
larger O
subgenomic O
DI O
RNA O
( O
synthesized O
from O
the O
upstream O
intergenic O
region O
) O
was O
made O
; O
this O
difference O
was O
significant O
when O
the O
intergenic O
region O
separation O
was O
less O
than O
about O
35 O
nucleotides O
. O

We O
used O
reovirus O
reassortant O
genetics O
and O
severe B
combined I
immunodeficient I
( I
SCID I
) I
mice O
to O
define O
viral O
genes O
important O
for O
organ O
tropism O
and O
virulence O
in O
the O
absence O
of O
antigen O
- O
specific O
immunity O
. O

Adult O
SCID O
mice O
infected O
with O
reovirus B
serotype I
1 I
strain I
Lang I
( I
T1L I
) I
died O
after O
20 O
+ O
/ O
- O
6 O
days O
, O
while O
infection O
with O
serotype B
3 I
strain I
Dearing I
( I
T3D I
) I
was O
lethal O
after O
77 O
+ O
/ O
- O
22 O
days O
. O

Gene O
segments O
L1 O
( O
encoding O
a O
core O
protein O
) O
and O
L2 O
( O
encoding O
the O
core O
spike O
of O
the O
virion O
) O
were O
important O
in O
all O
of O
the O
organs O
analyzed O
. O

The O
M1 O
gene O
segment O
( O
encoding O
a O
core O
protein O
) O
, O
but O
not O
the O
S1 O
gene O
segment O
, O
was O
a O
critical O
determinant O
of O
reovirus O
titer O
in O
the O
liver O
and O
severity O
of O
hepatitis O
. O

The O
S1 O
gene O
segment O
( O
encoding O
the O
viral O
cell O
attachment O
protein O
and O
a O
nonstructural O
protein O
) O
, O
but O
not O
the O
M1 O
gene O
segment O
, O
was O
a O
critical O
determinant O
of O
titers O
in O
intestines O
and O
brains O
. O

The O
virion O
- O
associated O
protein O
products O
of O
the O
four O
gene O
segments O
( O
L1 O
, O
L2 O
, O
M1 O
, O
and O
S1 O
) O
important O
for O
virulence O
and O
organ O
tropism O
in O
SCID O
mice O
likely O
form O
a O
structural O
unit O
, O
the O
reovirus O
vertex O
. O

Organs O
( O
the O
brain O
and O
intestines O
versus O
the O
liver O
) O
differ O
in O
properties O
that O
determine O
which O
virulence O
genes O
, O
and O
thus O
which O
parts O
of O
this O
structural O
unit O
, O
are O
important O
. O

Minus O
- O
strand O
RNA O
is O
the O
first O
RNA O
species O
made O
by O
plus O
- O
strand O
RNA O
viruses O
, O
such O
as O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
and O
serves O
as O
a O
template O
for O
subsequent O
RNA O
replication O
and O
transcription O
. O

We O
have O
optimized O
a O
ribonuclease B
( I
RNase I
) I
protection O
assay O
which O
enabled O
the O
detection O
of O
minus O
- O
strand O
RNA O
synthesis O
from O
nonreplicating O
RNAs O
, O
thus O
clearly O
separating O
minus O
- O
strand O
from O
plus O
strand O
RNA O
synthesis O
. O

Ve O
used O
an O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
containing O
a O
chloramphenicol O
acetyltransferase O
gene O
as O
a O
reporter O
to O
determine O
the O
cis O
- O
acting O
signal O
for O
MHV O
minus O
- O
strand O
RNA O
synthesis O
. O

By O
using O
various O
deletion O
clones O
, O
we O
demonstrated O
that O
the O
cis O
- O
acting O
signal O
for O
minus O
- O
strand O
RNA O
synthesis O
resides O
in O
the O
55 O
nucleotides O
From O
the O
3 O
' O
end O
plus O
poly O
( O
A O
) O
tail O
of O
the O
MHV O
genome O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
A59 O
temperature O
- O
sensitive O
( O
fs O
) O
mutants O
belonging O
to O
complementation O
group O
C O
were O
characterized O
and O
mapped O
by O
standard O
genetic O
recombination O
techniques O
. O

Since O
previous O
data O
indicated O
that O
the O
group O
C1 O
mutants O
probably O
contained O
an O
early O
defect O
which O
affects O
negative O
- O
strand O
synthesis O
, O
RNA O
synthesis O
was O
further O
examined O
by O
analyzing O
replicative O
- O
form O
( O
RF O
) O
RNA O
. O

To O
test O
the O
hypothesis O
that O
the O
65 O
- O
nucleotide B
( I
nt I
) I
leader O
on O
subgenomic O
mRNAs O
suffices O
as O
a O
5 O
' O
- O
terminal O
cis O
- O
acting O
signal O
for O
RNA O
replication O
, O
a O
corollary O
to O
the O
notion O
that O
coronavirus O
mRNAs O
behave O
as O
replicons O
, O
synthetic O
RNA O
transcripts O
of O
a O
cloned O
, O
reporter O
- O
containing O
N O
mRNA O
( O
mRNA O
7 O
) O
of O
the O
bovine O
coronavirus O
with O
a O
precise O
5 O
' O
terminus O
and O
a O
3 O
' O
poly O
( O
li O
) O
of O
68 O
nt O
were O
tested O
for O
replication O
after O
being O
transfected O
into O
helper O
virus O
- O
infected O
cells O
. O

No O
replication O
was O
observed O
, O
but O
synthetic O
transcripts O
of O
a O
cloned O
reporter O
- O
containing O
Defective B
interfering I
( I
DI I
) I
RNA O
differing O
from O
the O
N O
mRNA O
construct O
by O
433 O
nt O
of O
continuous O
5 O
' O
- O
proximal O
genomic O
sequence O
between O
the O
leader O
and O
the O
N O
open O
reading O
frame O
did O
replicate O
and O
become O
packaged O
, O
indicating O
the O
insufficiency O
of O
the O
leader O
atone O
as O
a O
5 O
' O
signal O
for O
replication O
of O
transfected O
RNA O
molecules O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
serine O
proteinase O
( O
Cpro O
- O
2 O
) O
is O
responsible O
for O
the O
processing O
of O
HCV O
nonstructural B
( I
NS I
) I
protein O
processing O
. O

Production O
of O
p70 O
( O
NS3 O
) O
and O
p66 O
( O
NS5B O
) O
were O
rapid O
. O

An O
89 O
- O
kDa O
processing O
intermediate O
protein O
( O
p89 O
) O
was O
observed O
during O
the O
early O
part O
of O
the O
chase O
. O

p89 O
seemed O
to O
be O
cleaved O
first O
into O
a O
31 O
- O
kDa O
protein O
( O
p31 O
) O
and O
a O
p58 O
/ O
56 O
( O
NS5A O
) O
. O

p31 O
was O
further O
processed O
into O
p4 O
( O
NS4A O
) O
and O
p27 O
( O
NS4B O
) O
. O

Cleavage O
at O
four O
sites O
( O
3 O
/ O
4A O
, O
4A O
/ O
4B O
, O
4B O
/ O
5A O
, O
and O
5A O
/ O
5B O
) O
in O
the O
hepatitis O
C O
virus O
polyprotein O
requires O
a O
viral O
serine O
protease O
activity O
residing O
in O
the O
N O
- O
terminal O
one O
- O
third O
of O
the O
NS3 O
protein O
. O

Sequence O
comparison O
of O
the O
residues O
Banking O
these O
cleavage O
sites O
reveals O
conserved O
features O
including O
an O
acidic O
residue O
( O
Asp O
or O
Glu O
) O
at O
the O
P6 O
position O
, O
a O
Cys O
or O
Thr O
residue O
at O
the O
P1 O
position O
, O
and O
a O
Ser O
or O
Ala O
residue O
at O
the O
P1 O
' O
position O
. O

1 O
cells O
cocultured O
, O
vith O
cloned O
mouse O
hepatitis O
virus O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic O
T O
lymphocytes O
were O
examined O
by O
electron O
microscopy O
. O

The O
prevailing O
hypothesis O
is O
that O
the O
intracellular O
site O
of O
budding O
of O
coronaviruses O
is O
determined O
by O
the O
localization O
of O
its O
membrane O
protein O
M O
( O
previously O
called O
E1 O
) O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
and O
infectious B
bronchitis I
virus I
( I
IBV I
) I
grown O
in O
Sac O
( O
- O
) O
cells O
, O
and O
feline O
infectious O
peritonitis O
virus O
( O
Fl O
[ O
PV O
) O
and O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
grown O
in O
CrFK O
cells O
, O
all O
budded O
exclusively O
into O
smooth O
- O
walled O
, O
tubulovesicular O
membranes O
located O
intermediately O
between O
the O
rough O
endoplasmic O
reticulum O
and O
Golgi O
complex O
, O
identical O
to O
the O
so O
- O
called O
budding O
compartment O
previously O
identified O
for O
MHV O
. O

Coronavirus O
mRNA O
transcription O
was O
thought O
to O
be O
regulated O
by O
the O
interaction O
between O
the O
leader O
RNA O
and O
the O
intergenic B
sequence I
( I
IS I
) I
, O
probably O
involving O
direct O
RNA O
- O
RNA O
interactions O
between O
complementary O
sequences O
. O

In O
this O
study O
, O
we O
found O
that O
a O
particular O
strain O
of O
mouse O
hepatitis O
virus O
, O
JHM2c O
, O
which O
has O
a O
deletion O
of O
a O
9 O
- O
nucleotide B
( I
nt I
) I
sequence O
( O
UUUAUAAAC O
) O
immediately O
downstream O
of O
the O
leader O
RNA O
, O
transcribed O
subgenomic O
mRNA O
species O
containing O
a O
whole O
array O
of O
heterogeneous O
leader O
fusion O
sites O
. O

Using O
a O
transfected O
defective O
interfering O
RNA O
which O
contains O
an O
IS O
and O
a O
reporter O
( O
chloramphenicol O
acetyltransferase O
) O
gene O
and O
JHM2c O
as O
a O
helper O
virus O
, O
we O
demonstrated O
that O
subgenomic O
mRNAs O
transcribed O
from O
the O
defective O
interfering O
RNAs O
were O
extremely O
heterogeneous O
. O

To O
investigate O
the O
mechanism O
by O
which O
viruses O
are O
cleared O
from O
neurons O
in O
the O
central O
nervous O
system O
, O
we O
have O
utilized O
a O
mouse O
model O
involving O
infection O
with O
a O
neurotropic O
variant O
of O
mouse O
hepatitis O
virus O
( O
OBLV60 O
) O
. O

Both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
subsets O
were O
important O
, O
as O
depletion O
of O
either O
of O
these O
subsets O
delayed O
viral O
clearance O
. O

Gliosis O
and O
infiltrates O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cells O
were O
detected O
by O
immunohistochemical O
analysis O
at O
6 O
days O
. O

( O
IL O
- O
1 O
alpha O
) O
, O
IL O
- O
1 O
beta O
, O
IL O
- O
2 O
, O
IL O
- O
3 O
, O
IL O
- O
4 O
, O
IL O
- O
5 O
, O
IL O
- O
6 O
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
TNF O
- O
beta O
, O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

Induction O
of O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
molecules O
on O
cells O
in O
infected O
brains O
was O
demonstrated O
by O
immunohistochemical O
analyses O
in O
normal O
and O
nude O
mice O
, O
suggesting O
that O
IFN O
- O
gamma O
may O
not O
be O
necessary O
for O
induction O
of O
MHC O
- O
I O
on O
neural O
cells O
in O
vivo O
. O

The O
5 B
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
of O
the O
HM175 O
strain O
of O
human O
hepatitis O
A O
virus O
contains O
several O
pyrimidine O
- O
rich O
regions O
, O
the O
largest O
and O
most O
5 O
' O
of O
which O
( O
pY1 O
) O
is O
an O
almost O
pure O
polypyrimidine O
tract O
located O
between O
nucleotides B
( I
nt I
) I
99 O
and O
138 O
, O
which O
includes O
five O
tandem O
repents O
of O
tile O
sequence O
motif O
( O
U O
) O
UUCC O
( O
C O
) O
. O

Previous O
modeling O
of O
the O
RNA O
secondary O
structure O
suggested O
that O
this O
region O
was O
likely O
to O
be O
single O
- O
stranded O
, O
but O
repetitive O
RNase O
V1 O
cleavage O
sites O
within O
these O
( O
U O
) O
UUCC O
( O
C O
) O
motifs O
indicated O
that O
pY1 O
possesses O
an O
ordered O
structure O
, O
To O
assess O
the O
role O
of O
this O
domain O
in O
replication O
of O
the O
virus O
, O
a O
series O
of O
large O
deletion O
mutations O
were O
created O
which O
involved O
the O
pY1 O
domain O
of O
an O
infectious O
cDNA O
clone O
. O

In O
contrast O
, O
viable O
virus O
could O
not O
be O
recovered O
from O
transfected O
RNAs O
in O
which O
the O
deletion O
was O
extended O
in O
a O
5 O
' O
direction O
by O
an O
additional O
3 O
nt O
( O
Delta O
93 O
- O
134 O
) O
, O
most O
likely O
because O
of O
the O
destabilization O
of O
a O
predicted O
stem O
- O
loop O
structure O
upstream O
of O
pY1 O
. O

Deletion O
mutations O
extending O
in O
a O
3 O
' O
fashion O
to O
nt O
140 O
, O
141 O
, O
or O
144 O
resulted O
in O
moderately O
( O
Delta O
96 O
- O
140 O
and O
Delta O
96 O
- O
141 O
) O
or O
strongly O
( O
Delta O
99 O
- O
144 O
, O
Delta O
116 O
- O
144 O
, O
and O
Delta O
131 O
- O
144 O
) O
temperature O
- O
sensitive O
replication O
phenotypes O
. O

Although O
deletion O
of O
the O
pY1 O
domain O
did O
not O
by O
itself O
affect O
the O
replication O
phenotype O
of O
virus O
, O
the O
additional O
deletion O
of O
sequence O
elements O
within O
the O
pY1 O
domain O
( O
nt O
99 O
to O
130 O
) O
substantially O
enhanced O
the O
temperature O
- O
sensitive O
phenotype O
of O
Delta O
131 O
- O
144 O
virus O
. O

These O
data O
suggest O
that O
the O
CU O
) O
UUCC O
( O
C O
) O
motifs O
within O
the O
pY1 O
domain O
are O
conserved O
among O
wild O
- O
type O
viruses O
in O
order O
to O
serve O
a O
function O
required O
during O
infection O
in O
vivo O
but O
not O
in O
cell O
culture O
. O

In O
contrast O
, O
the O
single O
- O
stranded O
region O
located O
immediately O
downstream O
of O
pY1 O
( O
nt O
140 O
to O
144 O
) O
is O
essential O
for O
efficient O
replication O
in O
cultured O
cells O
at O
physiological O
temperature O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
been O
adapted O
to O
grow O
in O
primate O
cell O
cultures O
. O

Therefore O
, O
the O
cell O
surface O
receptor O
( O
s O
) O
and O
other O
host O
factor O
( O
s O
) O
required O
for O
HAV O
replication O
are O
present O
in O
nonprimate O
as O
well O
as O
primate O
cells O
. O

We O
have O
developed O
a O
Defective B
interfering I
( I
DI I
) I
RNA O
containing O
a O
chloramphenicol O
acetyltransferase O
reporter O
gene O
, O
placed O
behind O
an O
intergenic O
sequence O
, O
for O
studying O
subgenomic O
mRNA O
transcription O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
prototype O
coronavirus O
. O

In O
addition O
to O
the O
previously O
identified O
requirement O
for O
an O
intergenic O
( O
promoter O
) O
sequence O
, O
additional O
sequences O
from O
the O
5 O
' O
end O
of O
genomic O
RNA O
are O
required O
for O
subgenomic O
mRNA O
transcription O
. O

These O
results O
strongly O
suggest O
that O
the O
wild O
- O
type O
viral O
subgenomic O
mRNAs O
( O
mRNA2 O
to O
mRNA7 O
) O
and O
probably O
their O
counterpart O
subgenomic O
negative O
- O
sense O
RNAs O
cannot O
be O
utilized O
for O
mRNA O
amplification O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
coronavirus O
, O
utilizes O
a O
discontinuous O
transcription O
mechanism O
for O
subgenomic O
mRNA O
synthesis O
. O

In O
this O
study O
, O
we O
constructed O
a O
series O
of O
Defective B
interfering I
( I
DI I
) I
RNAs O
containing O
the O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
gene O
behind O
a O
differentially O
expressed O
transcription O
initiation O
( O
intergenic O
) O
sequence O
( O
for O
mRNA2 O
- O
1 O
) O
. O

Furthermore O
, O
insertion O
of O
a O
UA O
- O
rich O
sequence O
( O
UUUAUAAAC O
) O
immediately O
downstream O
of O
the O
leader O
in O
DI O
RNA O
, O
to O
match O
the O
sequence O
of O
helper O
viral O
RNA O
, O
enhanced O
the O
CAT O
activity O
by O
threefold O
, O
suggesting O
that O
this O
nine O
- O
nucleotide O
sequence O
is O
a O
cis O
- O
acting O
element O
. O

However O
, O
when O
a O
constitutively O
expressed O
intergenic O
sequence O
( O
for O
mRNA7 O
) O
was O
used O
, O
no O
difference O
in O
transcription O
efficiency O
was O
noted O
, O
regardless O
of O
the O
copy O
number O
of O
UCUAA O
in O
the O
DI O
RNA O
and O
helper O
virus O
. O

This O
study O
thus O
indicates O
that O
MHV O
subgenomic O
RNA O
transcription O
requires O
the O
interaction O
among O
the O
intergenic O
( O
promoter O
) O
sequence O
, O
a O
trans O
- O
acting O
leader O
, O
and O
a O
cis O
- O
acting O
leader O
sequence O
. O

To O
characterize O
in O
vivo O
the O
translational O
control O
elements O
present O
in O
the O
5 B
' I
nontranslated I
region I
( I
5 I
' I
NTR I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
RNA O
, O
we O
created O
an O
HAV O
- O
permissive O
monkey O
kidney O
cell O
line O
( O
BT7 O
- O
H O
) O
that O
stably O
expresses O
T7 O
RNA O
polymerase O
and O
carries O
out O
cytoplasmic O
transcription O
of O
uncapped O
RNA O
from O
transfected O
DNA O
containing O
the O
T7 O
promoter O
. O

The O
presence O
of O
an O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
within O
the O
5 O
' O
NTR O
of O
HAV O
was O
confirmed O
by O
using O
BT7 O
- O
H O
cells O
transcribing O
bicistronic O
RNAs O
in O
which O
the O
5 O
' O
NTR O
was O
placed O
within O
the O
intercistronic O
space O
, O
controlling O
translation O
of O
a O
downstream O
reporter O
protein O
( O
bacterial O
chloramphenicol O
acetyltransferase O
) O
. O

However O
, O
translation O
directed O
by O
the O
5 O
' O
NTR O
in O
these O
bicistronic O
transcripts O
and O
in O
monocistronic O
T7 O
transcripts O
in O
which O
the O
HAV O
5 O
' O
NTR O
was O
placed O
upstream O
of O
the O
chloramphenicol O
acetyltransferase O
coding O
sequence O
was O
very O
inefficient O
compared O
with O
the O
translation O
of O
monocistronic O
transcripts O
containing O
either O
the O
IRES O
of O
encephalomyocarditis B
( I
EMC I
) I
virus O
or O
a O
short O
nonpicornavirus O
5 O
' O
nontranslated O
leader O
sequence O
. O

A O
large O
deletion O
within O
the O
HAV O
IRES O
( O
Delta O
355 O
- O
532 O
) O
eliminated O
IRES O
activity O
in O
bicistronic O
transcripts O
. O

In O
contrast O
, O
larger O
deletions O
within O
the O
IRES O
in O
monocistronic O
transcripts O
( O
Delta O
1 O
- O
354 O
, O
Delta O
1 O
- O
532 O
, O
Delta O
1 O
- O
633 O
, O
and O
Delta O
158 O
- O
633 O
) O
resulted O
in O
4 O
- O
to O
14 O
- O
fold O
increases O
in O
translation O
. O

Translation O
of O
RNAs O
containing O
either O
the O
EMC O
virus O
IRES O
or O
the O
nonpicornavirus O
leader O
was O
significantly O
enhanced O
by O
cotransfection O
of O
the O
reporter O
constructs O
with O
pEP2A O
, O
which O
directs O
transcription O
of O
RNA O
containing O
the O
EMC O
virus O
IRES O
fused O
to O
the O
poliovirus O
2A B
( I
pro I
) I
coding O
region O
. O

This O
2A B
( I
pro I
) I
enhancement O
of O
cap O
- O
independent O
translation O
suggests O
a O
greater O
availability O
of O
limiting O
cellular O
translation O
factors O
following O
2A B
( I
pro I
) I
- O
mediated O
cleavage O
of O
the O
p220 O
subunit O
of O
the O
eukaryotic O
initiation O
factor O
eIF O
- O
4F O
and O
subsequent O
shutdown O
of O
5 O
' O
cap O
- O
dependent O
translation O
. O

This O
inhibition O
was O
due O
to O
competition O
from O
the O
EMC O
virus O
IRES O
present O
in O
pEP O
- O
2A O
transcripts O
, O
as O
well O
as O
the O
expression O
of O
proteolytically O
active O
2A B
( I
pro I
) I
. O

2A B
( I
pro I
) I
- O
mediated O
suppression O
of O
HAV O
translation O
was O
not O
seen O
with O
transcripts O
containing O
large O
deletions O
in O
the O
HAV O
IRES O
( O
Delta O
158 O
- O
633 O
, O
Delta O
1 O
- O
532 O
, O
or O
Delta O
1 O
- O
633 O
) O
. O

Chimeric O
peptides O
in O
which O
the O
optimal O
H O
- O
2 O
( O
d O
) O
mouse B
hepatitis I
virus I
nucleocapsid I
( I
pN I
) I
and O
human O
immunodeficiency O
virus O
type O
1 O
( O
p18 O
) O
epitopes O
, O
separated O
by O
38 O
, O
7 O
, O
or O
2 O
amino O
acids O
, O
were O
expressed O
from O
a O
single O
open O
reading O
frame O
by O
using O
recombinant O
vaccinia O
viruses O
to O
analyze O
antigen O
processing O
of O
proximal O
class O
I O
- O
restricted O
epitopes O
. O

By O
contrast O
, O
proximity O
of O
the O
carboxy O
- O
terminal O
epitope O
decreased O
recognition O
of O
the O
amino O
- O
terminal O
L O
( O
d O
) O
- O
restricted O
pN O
epitope O
. O

We O
hale O
used O
a O
full O
- O
length O
cDNA O
clone O
of O
a O
mouse O
hepatitis O
virus O
strain O
A59 O
Defective B
interfering I
( I
DI I
) I
RNA O
pMIDI O
- O
C O
, O
and O
cassette O
mutagenesis O
to O
study O
the O
mechanism O
of O
coronavirus O
subgenomic O
mRNA O
synthesis O
. O

From O
a O
mutagenic O
analysis O
of O
the O
promoters O
we O
concluded O
the O
following O
, O
( O
i O
) O
The O
extent O
of O
base O
pairing O
between O
the O
leader O
RNA O
and O
the O
intergenic O
promoter O
sequence O
does O
not O
control O
subgenomic O
RNA O
abundance O
. O

( O
ii O
) O
Promoter O
recognition O
does O
not O
rely O
on O
base O
pairing O
only O
. O

( O
iii O
) O
Fusion O
of O
leader O
and O
body O
sequences O
takes O
place O
at O
multiple O
- O
possibly O
random O
- O
sites O
within O
the O
intergenic O
promoter O
sequence O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
consists O
of O
two O
species O
, O
large O
( O
SHDAg O
) O
and O
small O
( O
SHDAg O
) O
, O
which O
are O
identical O
in O
sequence O
except O
that O
the O
large O
form O
contains O
19 O
extra O
amino O
acids O
at O
the O
C O
terminus O
. O

We O
have O
studied O
the O
distribution O
of O
viral O
sequences O
from O
the O
5 O
' O
noncoding O
region O
and O
from O
a O
fragment O
of O
the O
E2 O
/ O
NS2 O
region O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
genome O
in O
samples O
obtained O
before O
and O
after O
liver O
transplantation O
in O
two O
patients O
with O
HCV O
cirrhosis O
. O

This O
study O
examined O
whether O
coronavirus O
transcription O
involves O
a O
discontinuous O
transcription O
step O
; O
the O
possibility O
that O
a O
leader O
sequence O
from O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genomic O
RNA O
could O
be O
used O
for O
MHV O
subgenomic O
Defective B
interfering I
( I
DI I
) I
RNA O
transcription O
was O
examined O
. O

MHV O
JHM O
variant O
JHM O
( O
2 O
) O
, O
which O
synthesizes O
a O
subgenomic O
mRNA O
encoding O
the O
HE O
gene O
, O
and O
variant O
JHM O
( O
3 O
- O
9 O
) O
, O
which O
does O
not O
synthesize O
this O
mRNA O
, O
were O
used O
. O

An O
MHV O
DI O
RNA O
, O
DI O
( O
J3 O
- O
9 O
) O
, O
was O
constructed O
to O
contain O
a O
JHM O
( O
3 O
- O
9 O
) O
- O
derived O
leader O
sequence O
and O
an O
inserted O
intergenic O
region O
derived O
from O
the O
region O
preceding O
the O
MHV O
JHM O
HE O
gene O
. O

DI O
( O
J3 O
- O
9 O
) O
replicated O
efficiently O
in O
JHM O
( O
2 O
) O
- O
or O
JHM O
( O
3 O
- O
9 O
) O
- O
infected O
cells O
, O
whereas O
synthesis O
of O
subgenomic O
DI O
RNAs O
was O
observed O
only O
in O
JHM O
( O
2 O
) O
- O
infected O
cells O
. O

Sequence O
analyses O
demonstrated O
that O
the O
5 O
' O
regions O
of O
both O
helper O
virus O
genomic O
RNAs O
and O
genomic O
DI O
RNAs O
maintained O
their O
original O
sequences O
in O
DI O
RNA O
- O
replicating O
cells O
, O
indicating O
that O
the O
genomic O
leader O
sequences O
derived O
from O
JHM O
( O
2 O
) O
functioned O
for O
subgenomic O
DI O
RNA O
transcription O
. O

Replication O
and O
transcription O
of O
DI O
( O
J3 O
- O
9 O
) O
were O
observed O
in O
cells O
infected O
with O
an O
MHV O
A59 O
strain O
whose O
leader O
sequence O
was O
similar O
to O
that O
of O
JHM O
( O
2 O
) O
, O
except O
for O
one O
nucleotide O
substitution O
within O
the O
leader O
sequence O
. O

The O
5 O
' O
region O
of O
the O
helper O
virus O
genomic O
RNA O
and O
that O
of O
the O
DI O
RNA O
mere O
the O
same O
as O
their O
original O
structures O
in O
virus O
- O
infected O
cells O
, O
and O
the O
leader O
sequence O
of O
DI O
( O
J3 O
- O
9 O
) O
subgenomic O
DI O
RNA O
contained O
the O
MHV O
A59 O
- O
derived O
leader O
sequence O
. O

We O
determined O
the O
partial O
amino O
( O
N O
) O
- O
terminal O
amino O
acid O
sequence O
of O
hepatitis O
C O
virus O
p21 O
( O
nonstructural O
protein O
2 O
[ O
NS2 O
] O
) O
. O

Cleavage O
at O
the O
p21 O
( O
NS2 O
) O
N O
terminus O
depended O
on O
the O
presence O
of O
microsomal O
membranes O
. O

The O
amino O
- O
terminal O
position O
of O
p21 O
( O
NS2 O
) O
was O
assigned O
to O
amino O
acid O
810 O
of O
the O
hepatitis O
C O
virus O
strain O
IIj O
precursor O
polyprotein O
. O

This O
alteration O
in O
processing O
together O
with O
the O
fact O
that O
hydrophobic O
amino O
acid O
residues O
are O
clustered O
upstream O
of O
the O
putative O
cleavage O
site O
suggested O
the O
involvement O
of O
a O
signal O
peptidase O
( O
s O
) O
in O
the O
cleavage O
. O

Furthermore O
, O
mutation O
analysis O
of O
this O
possible O
cleavage O
site O
revealed O
the O
presence O
of O
another O
microsome O
membrane O
- O
dependent O
cleavage O
site O
upstream O
of O
the O
N O
terminus O
of O
p21 O
( O
NS2 O
) O
. O

The O
lengthy O
5 B
' I
nontranslated I
region I
( I
5 I
' I
NTR I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
forms O
a O
highly O
ordered O
secondary O
structure O
, O
which O
has O
been O
suggested O
to O
play O
an O
important O
role O
in O
controlling O
viral O
translation O
by O
allowing O
for O
translation O
initiation O
by O
internal O
ribosome O
entry O
. O

In O
the O
presence O
of O
an O
upstream O
cistron O
designed O
to O
block O
ribosomal O
scanning O
, O
the O
HAV O
5 O
' O
NTR O
was O
capable O
of O
directing O
the O
internal O
initiation O
of O
translation O
, O
confirming O
the O
presence O
of O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

The O
addition O
of O
a O
5 O
' O
cap O
structure O
( O
m O
( O
7 O
) O
GpppN O
) O
to O
monocistronic O
or O
bicistronic O
transcripts O
decreased O
the O
translation O
of O
a O
reporter O
gene O
downstream O
of O
the O
HAV O
5 O
' O
NTR O
but O
enhanced O
translation O
of O
the O
upstream O
cistron O
in O
bicistronic O
transcripts O
. O

The O
efficiency O
with O
which O
monocistronic O
constructs O
containing O
the O
HAV O
5 O
' O
NTR O
directed O
translation O
in O
reticulocyte O
lysates O
was O
compared O
with O
results O
for O
monocistronic O
constructs O
containing O
the O
IRES O
of O
the O
more O
rapidly O
growing O
encephalomyocarditis B
virus I
( I
EMCV I
) I
. O

A O
live O
candidate O
hepatitis O
A O
virus O
vaccine O
, O
developed O
from O
the O
HM O
- O
175 O
strain O
and O
adapted O
to O
growth O
in O
primary O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
cells O
, O
was O
adapted O
to O
growth O
in O
MRC O
- O
5 O
cells O
. O

Four O
of O
the O
unique O
mutations O
were O
located O
in O
a O
cluster O
in O
the O
5 O
' O
noncoding O
region O
( O
NC O
) O
, O
and O
three O
of O
the O
remaining O
nine O
mutations O
encoded O
amino O
acid O
changes O
. O

The O
viruses O
encoded O
by O
these O
plasmids O
were O
recovered O
after O
transfection O
of O
cultured O
cells O
with O
in O
vitro O
transcripts O
, O
and O
their O
growth O
phenotypes O
in O
fetal B
rhesus I
kidney I
4 I
( I
FRhK I
- I
4 I
) I
and O
MRC O
- O
5 O
cells O
were O
determined O
. O

Thougout O
subsequent O
purification O
of O
this O
fraction O
by O
Sephadex O
partition O
, O
ion O
- O
exchange O
, O
silicic O
acid O
, O
and O
thin O
- O
layer O
chromatography O
, O
blocking O
activity O
behaved O
as O
a O
monosialoganglioside O
( O
GMX O
) O
that O
displayed O
a O
thin O
- O
layer O
chromatographic O
mobility O
between O
those O
of O
GM2 O
and O
GM3 O
. O

The O
blocking O
activity O
of O
GMX O
was O
inhibited O
by O
treatment O
with O
neuraminidase O
and O
ceramide O
glycanase O
but O
not O
by O
treatment O
with O
protease O
or O
heat O
( O
100 O
degrees O
C O
) O
. O

We O
have O
recently O
described O
a O
method O
of O
introducing O
site O
- O
specific O
mutations O
into O
the O
genome O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
by O
RNA O
recombination O
between O
cotransfected O
genomic O
RNA O
and O
a O
J O
. O

By O
using O
a O
thermolabile O
N O
protein O
mutant O
of O
MHV O
( O
Alb4 O
) O
as O
the O
recipient O
virus O
and O
synthetic O
RNA7 O
( O
the O
mRNA O
for O
the O
nucleocapsid O
protein O
N O
) O
as O
the O
donor O
, O
we O
selected O
engineered O
recombinant O
viruses O
as O
heat O
- O
stable O
progeny O
resulting O
from O
cotransfection O
. O

We O
have O
now O
been O
able O
to O
greatly O
increase O
the O
efficiency O
of O
targeted O
recombination O
in O
this O
process O
by O
using O
a O
synthetic O
Defective B
interfering I
( I
DI I
) I
RNA O
in O
place O
of O
RNA7 O
. O

The O
virus O
encodes O
only O
a O
single O
protein O
, O
the O
delta O
antigen O
, O
which O
both O
is O
small O
( O
22 O
kDa O
) O
and O
lacks O
sequence O
homology O
to O
known O
RNA O
polymerases O
, O
suggesting O
that O
the O
virus O
employs O
a O
cellular O
polymerase O
for O
replication O
. O

The O
mouse B
hepatitis I
virus I
( I
MHV I
) I
JHM O
strain O
( O
JHMV O
) O
produces O
primary O
demyelination O
in O
the O
central O
nervous O
system O
associated O
with O
acute O
encephalomyelitis O
. O

A O
subset O
of O
the O
CD8 O
+ O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
induced O
by O
immunization O
of O
BALB O
/ O
c O
( O
H O
- O
2d O
) O
mice O
with O
JHMV O
is O
specific O
for O
the O
viral O
nucleocapsid O
protein O
. O

This O
CTL O
population O
recognizes O
an O
epitope O
located O
within O
the O
carboxy O
- O
terminal O
149 O
amino O
acids O
in O
association O
with O
the O
L O
( O
d O
) O
class O
I O
molecule O
( O
S O
. O

This O
sequence O
, O
encompassing O
the O
MHV O
epitope O
, O
contains O
the O
L O
( O
d O
) O
- O
specific O
binding O
motif O
. O

The O
predicted O
9 O
- O
mer O
peptide O
( O
residues O
318 O
to O
326 O
: O
APTAGAFFF O
) O
was O
sufficient O
and O
highly O
active O
in O
sensitizing O
target O
cells O
for O
CTL O
recognition O
when O
either O
added O
exogenously O
or O
synthesized O
intracellularly O
. O

These O
data O
define O
a O
novel O
9 O
- O
mer O
L O
( O
d O
) O
- O
restricted O
CTL O
epitope O
which O
represents O
the O
first O
MHV O
CTL O
epitope O
. O

The O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
activity O
of O
spleen O
cells O
from O
BALB O
/ O
c O
( O
H O
- O
2d O
) O
mice O
immunized O
with O
the O
neurotropic O
JHM B
strain I
of I
mouse I
hepatitis I
virus I
( I
JHMV I
) I
was O
stimulated O
in O
vitro O
for O
7 O
days O
. O

Three O
of O
the O
JHMV O
- O
specific O
T O
- O
cell O
lines O
were O
unable O
to O
recognize O
target O
cells O
expressing O
any O
of O
the O
JHMV O
structural O
proteins O
, O
indicating O
that O
they O
are O
specific O
for O
an O
epitope O
of O
a O
nonstructural O
protein O
( O
s O
) O
of O
JHMV O
. O

We O
have O
analyzed O
the O
effects O
of O
reducing O
conditions O
on O
the O
folding O
of O
the O
spike B
( I
S I
) I
protein O
and O
on O
the O
intracellular O
transport O
of O
the O
membrane B
( I
M I
) I
protein O
of O
the O
mouse O
hepatitis O
coronavirus O
. O

These O
proteins O
differ O
in O
their O
potential O
to O
form O
disulfide O
bonds O
in O
the O
lumen O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

To O
reduce O
disulfide O
bonds O
in O
vivo O
, O
we O
added O
Dithiothreitol B
( I
DTT I
) I
to O
the O
culture O
medium O
of O
mouse O
hepatitis O
coronavirus O
- O
infected O
cells O
following O
a O
procedure O
recently O
described O
by O
Braakman O
et O
al O
. O

The O
5 B
' I
nontranslated I
region I
( I
5 I
' I
NTR I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
RNA O
contains O
structural O
elements O
which O
facilitate O
5 O
' O
cap O
- O
independent O
initiation O
of O
virus O
translation O
and O
are O
likely O
to O
interact O
with O
cellular O
proteins O
functioning O
as O
translation O
initiation O
factors O
. O

Four O
major O
proteins O
( O
p30 O
, O
p39 O
, O
p57 O
, O
and O
p110 O
) O
were O
identified O
. O

Efficient O
transfer O
of O
label O
to O
p30 O
occurred O
with O
minimal O
RNA O
probes O
representing O
nucleotides B
( I
nt I
) I
96 O
to O
155 O
, O
151 O
to O
354 O
, O
and O
, O
to O
a O
much O
lesser O
extent O
, O
634 O
to O
744 O
, O
while O
label O
transfer O
to O
p39 O
occurred O
with O
probes O
representing O
nt O
96 O
to O
155 O
and O
634 O
to O
744 O
. O

Competitive O
inhibition O
studies O
indicated O
that O
both O
p30 O
and O
p39 O
bound O
with O
greater O
affinity O
to O
sites O
in O
the O
5 O
' O
half O
of O
the O
NTR O
( O
a O
probe O
representing O
nt O
1 O
to O
354 O
) O
than O
to O
the O
more O
3 O
' O
site O
( O
nt O
634 O
to O
744 O
) O
. O

7 O
- O
kb O
region O
between O
the O
substrate O
( O
p28 O
) O
and O
proteinase O
domain O
could O
be O
deleted O
without O
affecting O
the O
proteolytic O
cleavage O
. O

All O
of O
the O
Defective B
interfering I
( I
DI I
) I
RNAs O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
contain O
both O
the O
5 O
' O
and O
3 O
' O
ends O
of O
the O
viral O
genomic O
RNA O
, O
which O
presumably O
include O
the O
cis O
sequences O
required O
for O
RNA O
replication O
. O

Following O
infection O
of O
susceptible O
cells O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
T7 O
RNA O
polymerase O
, O
various O
cDNA O
clones O
derived O
from O
a O
DI O
RNA O
( O
DIssF O
) O
of O
the O
JHM O
strain O
of O
MHV O
, O
which O
is O
a O
3 O
. O

Sequence O
motifs O
within O
the O
nonstructural O
protein O
NS3 O
of O
members O
of O
the O
Flaviviridae O
family O
suggest O
that O
this O
protein O
possesses O
nucleoside B
triphosphatase I
( I
NTPase I
) I
and O
RNA O
helicase O
activity O
. O

Here O
, O
we O
experimentally O
demonstrate O
that O
the O
NS3 O
protein O
from O
a O
member O
of O
the O
third O
genus O
of O
Flaviviridae O
, O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
also O
possesses O
a O
polynucleotide O
- O
stimulated O
NTPase O
activity O
. O

Addition O
of O
trypsin O
to O
mutant O
- O
infected O
fibroblast O
cultures O
enhanced O
cell O
fusion O
a O
small O
( O
two O
- O
to O
fivefold O
) O
but O
significant O
degree O
, O
indicating O
that O
the O
defect O
could O
be O
due O
to O
a O
lack O
of O
cleavage O
of O
the O
viral O
spike O
( O
fusion O
) O
protein O
. O

These O
data O
confirm O
and O
extend O
previous O
reports O
concluding O
cleavage O
of O
S O
is O
required O
for O
efficient O
cell O
- O
cell O
fusion O
by O
mouse O
hepatitis O
vims O
but O
not O
for O
virus O
- O
cell O
fusion O
( O
infectivity O
) O
. O

The O
addition O
of O
the O
hepatitis O
delta O
virus O
genomic O
ribozyme O
to O
the O
3 O
' O
end O
sequence O
of O
a O
Sendai O
virus O
defective O
interfering O
RNA O
( O
DI O
- O
H4 O
) O
allowed O
the O
reproducible O
and O
efficient O
replication O
of O
this O
RNA O
by O
the O
viral O
functions O
expressed O
from O
cloned O
genes O
when O
the O
DI O
RNA O
was O
synthesized O
from O
plasmid O
. O

Limited O
nucleotide O
additions O
or O
deletions O
( O
+ O
7 O
to O
- O
7 O
nucleotides O
) O
in O
the O
DI O
RNA O
sequence O
were O
then O
made O
at O
five O
different O
sites O
, O
and O
the O
different O
RNA O
derivatives O
were O
tested O
for O
their O
abilities O
to O
replicate O
. O

We O
have O
studied O
processing O
of O
the O
nonstructural B
( I
NS I
) I
polyprotein O
of O
the O
hepatitis O
C O
virus O
. O

Substitution O
of O
the O
serine O
residue O
of O
the O
putative O
catalytic O
triad O
( O
H O
, O
D O
, O
and O
S O
) O
by O
alanine O
blocked O
cleavage O
at O
the O
NS3 O
/ O
4 O
junction O
, O
while O
processing O
between O
NS2 O
and O
NS3 O
was O
not O
affected O
. O

To O
demonstrate O
vertical O
transmission O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
from O
an O
HCV O
- O
infected O
, O
non O
- O
human O
immunodeficiency O
virus O
type O
1 O
- O
infected O
mother O
to O
her O
infant O
and O
to O
assess O
the O
distribution O
of O
viral O
species O
in O
the O
mother O
and O
infant O
, O
the O
hypervariable O
region O
of O
the O
gene O
encoding O
the O
putative O
envelope O
glycoprotein O
E2 O
( O
E2HV O
) O
was O
sequenced O
in O
three O
mothers O
and O
one O
mother O
- O
infant O
pair O
. O

The O
data O
indicate O
that O
( O
i O
) O
quasispecies O
distributions O
of O
HCV O
E2HV O
variants O
were O
found O
in O
all O
four O
mothers O
, O
( O
ii O
) O
a O
single O
predominant O
HCV O
E2HV O
variant O
was O
found O
in O
the O
infant O
of O
a O
mother O
shown O
to O
have O
nine O
predominant O
E2HV O
variants O
, O
and O
( O
iii O
) O
the O
infant O
' O
s O
E2HV O
variant O
was O
highly O
related O
to O
, O
but O
not O
identical O
with O
, O
the O
nine O
variants O
identified O
in O
the O
mother O
at O
the O
time O
of O
birth O
. O

We O
report O
the O
identification O
of O
a O
region O
of O
the O
genome O
of O
a O
persistent O
virus O
( O
S11 O
) O
that O
was O
sufficient O
to O
confer O
to O
a O
recombinant O
virus O
the O
phenotype O
that O
causes O
persistent O
infection O
in O
HEp O
- O
2 O
cells O
. O

Insertion O
of O
a O
region O
, O
including O
the O
18 O
- O
nucleotide O
- O
long O
intergenic O
sequence O
between O
genes O
6 O
and O
7 O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genomic O
RNA O
, O
into O
an O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
leads O
to O
transcription O
of O
subgenomic O
DI O
RNA O
in O
helper O
virus O
- O
infected O
cells O
( O
S O
. O

hepatitis B
delta I
antigen I
( I
HDAg I
) I
is O
an O
RNA O
- O
binding O
protein O
with O
binding O
specificity O
for O
hepatitis B
delta I
virus I
( I
HDV I
) I
RNA O
( O
J O
. O

By O
amino O
acid O
sequence O
homology O
search O
, O
we O
have O
identified O
within O
its O
RNA O
- O
binding O
domain O
two O
stretches O
of O
an O
arginine B
- I
rich I
motif I
( I
ARM I
) I
, O
which O
is O
present O
in O
many O
prokaryotic O
and O
eukaryotic O
RNA O
- O
binding O
proteins O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
a O
circular O
RNA O
genome O
of O
1 O
. O

In O
constructs O
which O
synthesize O
primary O
transcripts O
of O
genomic O
sense O
, O
all O
of O
the O
antigenomic O
self O
- O
cleavage O
mutants O
produced O
as O
much O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
as O
did O
the O
wild O
- O
type O
construct O
, O
even O
in O
the O
absence O
of O
detectable O
HDV O
RNA O
replication O
, O
whereas O
the O
genomic O
self O
- O
cleavage O
mutants O
produced O
very O
little O
HDAg O
. O

These O
and O
other O
data O
suggest O
that O
( O
i O
) O
the O
primary O
HDV O
RNA O
transcripts O
of O
both O
genomic O
and O
antigenomic O
polarities O
must O
first O
be O
processed O
to O
serve O
as O
a O
template O
for O
HDV O
RNA O
transcription O
, O
( O
ii O
) O
efficient O
cleavage O
at O
the O
antigenomic O
self O
- O
cleavage O
site O
is O
not O
required O
for O
HDAg O
expression O
, O
and O
( O
iii O
) O
HDV O
RNA O
replication O
most O
likely O
occurs O
by O
a O
double O
- O
rolling O
- O
circle O
mechanism O
. O

The O
fusogenic O
properties O
of O
the O
uncleaved O
spike B
( I
S I
) I
protein O
of O
murine O
coronavirus O
JHMV O
variant O
cl O
- O
2 O
were O
studied O
by O
expressing O
the O
S O
protein O
with O
a O
deleted O
putative O
cleavage O
site O
. O

Recombinant O
vaccinia O
viruses O
containing O
the O
cl O
- O
2 O
S O
cDNA O
[ O
RW O
t O
( O
+ O
) O
] O
or O
the O
mutated O
cDNA O
[ O
RW O
t O
( O
- O
) O
] O
were O
constructed O
and O
monitored O
for O
fusion O
formation O
and O
cleavage O
of O
the O
expressed O
S O
proteins O
. O

When O
cultured O
DBT O
cells O
were O
infected O
with O
RW O
t O
( O
+ O
) O
at O
a O
multiplicity O
of O
infection O
of O
0 O
. O

In O
cells O
infected O
with O
RW O
t O
( O
- O
) O
under O
the O
same O
conditions O
, O
fusion O
formation O
appeared O
by O
12 O
to O
14 O
h O
. O

By O
25 O
to O
30 O
h O
, O
most O
of O
the O
cells O
infected O
by O
RW O
t O
( O
- O
) O
had O
fused O
. O

By O
immunoprecipitation O
and O
Western O
blotting O
( O
immunoblotting O
) O
, O
the O
170 O
- O
kDa O
S O
protein O
was O
detected O
in O
DBT O
cells O
expressing O
the O
wild O
- O
type O
S O
protein O
and O
the O
mutated O
S O
protein O
. O

However O
, O
interestingly O
, O
the O
cleavage O
products O
of O
the O
S O
protein O
, O
S1 O
and O
S2 O
, O
were O
not O
detected O
in O
RW O
t O
( O
- O
) O
- O
infected O
cells O
, O
producing O
the O
mutated O
S O
protein O
, O
even O
though O
fusion O
was O
clearly O
visible O
. O

Both O
products O
were O
, O
of O
course O
, O
detected O
in O
RW O
t O
( O
+ O
) O
- O
infected O
DBT O
cells O
, O
producing O
the O
wild O
- O
type O
S O
protein O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
has O
an O
immunodominant O
neutralization O
antigenic O
site O
. O

By O
using O
a O
panel O
of O
monoclonal O
antibodies O
targeted O
against O
the O
HAV O
neutralization O
antigenic O
site O
, O
it O
was O
shown O
that O
three O
epitopes O
within O
this O
site O
are O
present O
on O
14S O
subunits O
( O
pentamers O
of O
the O
structural O
unit O
) O
. O

This O
open O
reading O
frame O
encodes O
two O
distinct O
molecular O
species O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
p24delta O
and O
p27delta O
, O
depending O
on O
the O
location O
of O
the O
stop O
codon O
which O
terminates O
translation O
. O

The O
SJL O
mouse O
strain O
is O
resistant O
to O
infection O
by O
some O
strains O
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
such O
as O
JHM O
and O
A59 O
. O

Cloning O
and O
sequencing O
of O
the O
cDNAs O
of O
both O
mmCGMs O
RNAs O
from O
SJL O
mice O
revealed O
that O
they O
were O
identical O
in O
size O
to O
those O
of O
the O
susceptible O
C57BL O
/ O
6 O
( O
B6 O
) O
mouse O
. O

We O
concluded O
that O
the O
MHV O
receptor O
molecules O
in O
the O
SJL O
mouse O
are O
functional O
and O
that O
the O
resistance O
of O
SJL O
mice O
to O
infection O
by O
some O
MHV O
strains O
most O
likely O
results O
from O
some O
other O
factor O
( O
s O
) O
required O
for O
virus O
entry O
or O
some O
other O
step O
( O
s O
) O
in O
virus O
replication O
. O

This O
signal O
functions O
inefficiently O
and O
must O
be O
augmented O
by O
multiple O
activator O
elements O
located O
in O
the O
upstream O
400 O
nucleotides B
( I
nt I
) I
to O
promote O
efficient O
processing O
. O

During O
genomic O
RNA O
synthesis O
, O
the O
poly O
( O
A O
) O
signals O
in O
the O
5 O
' O
repeat O
are O
bypassed O
, O
while O
those O
in O
the O
3 O
' O
copy O
are O
used O
. O

The O
ability O
of O
PS2 O
to O
function O
independently O
of O
the O
other O
, O
more O
upstream O
activators O
suggests O
that O
the O
absence O
of O
the O
latter O
elements O
from O
the O
5 O
' O
redundancy O
is O
insufficient O
to O
account O
for O
bypass O
of O
the O
5 O
' O
poly O
( O
A O
) O
site O
, O
as O
we O
had O
earlier O
proposed O
. O

Previously O
, O
a O
system O
in O
which O
an O
intergenic O
region O
from O
mouse B
hepatitis I
virus I
( I
MHV I
) I
inserted O
into O
an O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
led O
to O
transcription O
of O
a O
subgenomic O
DI O
RNA O
in O
helper O
virus O
- O
infected O
cells O
was O
established O
. O

Passage O
of O
human B
hepatitis I
A I
virus I
( I
HAV I
) I
in O
cell O
culture O
results O
in O
attenuation O
of O
the O
virus O
as O
well O
as O
Progressive O
increases O
in O
the O
efficiency O
of O
virus O
replication O
in O
cell O
culture O
. O

Because O
the O
presence O
of O
identical O
mutations O
within O
the O
5 B
' I
nontranslated I
regions I
( I
5 I
' I
NTRs I
) I
of O
several O
independently O
isolated O
cell O
culture O
- O
adapted O
HAV O
variants O
suggests O
that O
the O
5 O
' O
NTR O
may O
play O
a O
role O
in O
determining O
this O
change O
in O
virus O
host O
range O
, O
we O
constructed O
chimeric O
infectious O
cDNA O
clones O
in O
which O
portions O
of O
the O
5 O
' O
NTR O
of O
cell O
culture O
- O
adapted O
HM175 O
/ O
p35 O
virus O
were O
replaced O
with O
cDNA O
from O
either O
wild O
- O
type O
virus O
( O
HM175 O
/ O
wt O
) O
or O
a O
second O
independently O
isolated O
, O
but O
closely O
related O
cell O
culture O
- O
adapted O
virus O
( O
HM175 O
/ O
p16 O
) O
. O

Substitution O
of O
the O
complete O
5 O
' O
NTR O
of O
HM175 O
/ O
p35 O
with O
the O
5 O
' O
NTR O
of O
HM175 O
/ O
wt O
resulted O
in O
virus O
with O
very O
small O
replication O
foci O
in O
continuous O
African O
green O
monkey O
kidney O
( O
BS O
- O
C O
- O
1 O
) O
cells O
, O
indicating O
that O
5 O
' O
NTR O
mutations O
in O
HM175 O
/ O
p35 O
virus O
are O
required O
for O
optimal O
growth O
in O
these O
cells O
. O

In O
contrast O
to O
their O
effect O
in O
BS O
- O
C O
- O
1 O
cells O
, O
these O
5 O
' O
NTR O
mutations O
did O
not O
enhance O
replication O
in O
continuous O
fetal B
rhesus I
monkey I
kidney I
( I
FRhK I
- I
4 I
) I
cells O
. O

Two O
forms O
of O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
have O
different O
roles O
in O
the O
replication O
cycle O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
; O
the O
small O
form O
trans O
activates O
HDV O
RNA O
replication O
, O
whereas O
the O
large O
form O
suppresses O
it O
but O
is O
needed O
for O
virion O
assembly O
. O

The O
in O
vivo O
biological O
activities O
of O
both O
forms O
of O
HDAg O
( O
trans O
activation O
and O
trans O
- O
dominant O
inhibition O
of O
HDV O
RNA O
replication O
, O
respectively O
) O
correlated O
with O
the O
extent O
of O
HDAg O
oligomerization O
in O
vitro O
. O

Active O
proteinase O
3C O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
was O
expressed O
in O
bacteria O
either O
as O
a O
mature O
enzyme O
or O
as O
a O
protein O
fused O
to O
the O
entire O
polymerase O
3D O
or O
to O
a O
part O
of O
it O
, O
and O
their O
identities O
were O
shown O
by O
immunoblot O
analysis O
. O

The O
genome O
of O
the O
Defective B
interfering I
( I
DI I
) I
mouse O
hepatitis O
virus O
DI O
- O
a O
carries O
a O
large O
open B
reading I
frame I
( I
ORF I
) I
consisting O
of O
ORF1a O
, O
ORF1b O
, O
and O
nucleocapsid O
sequences O
. O

( O
i O
) O
Truncation O
of O
the O
fusion O
ORF O
was O
not O
lethal O
but O
led O
to O
reduced O
accumulation O
of O
DI O
RNA O
. O

( O
ii O
) O
When O
pairs O
of O
nearly O
identical O
in O
- O
frame O
and O
out O
- O
of O
- O
frame O
DI O
RNAs O
were O
directly O
compared O
by O
cotransfection O
, O
DI O
viruses O
containing O
in O
- O
frame O
genomic O
RNAs O
prevailed O
within O
three O
successive O
passages O
even O
when O
the O
out O
- O
of O
- O
frame O
RNAs O
were O
transfected O
in O
10 O
- O
fold O
molar O
excess O
. O

( O
iii O
) O
When O
DI O
viruses O
containing O
out O
- O
of O
- O
frame O
genomic O
RNAs O
were O
passaged O
, O
mutants O
emerged O
and O
were O
selected O
for O
that O
had O
restored O
the O
reading O
frame O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
coronavirus O
, O
has O
been O
shown O
to O
undergo O
a O
high O
frequency O
of O
RNA O
recombination O
both O
in O
tissue O
culture O
and O
in O
animal O
infection O
. O

However O
, O
when O
an O
RNA O
fragment O
with O
a O
nine O
- O
nucleotide O
( O
CUUUAUAAA O
) O
deletion O
immediately O
downstream O
of O
a O
pentanucleotide O
( O
UCUAA O
) O
repeat O
sequence O
in O
the O
leader O
RNA O
was O
transfected O
into O
MHV O
- O
infected O
cells O
, O
most O
of O
the O
recombinants O
between O
this O
RNA O
and O
the O
MHV O
genome O
contained O
crossover O
sites O
near O
this O
pentanucleotide O
repeat O
sequence O
. O

The O
cellular O
receptor O
for O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
has O
been O
identified O
as O
a O
member O
of O
the O
murine B
carcinoembryonic I
antigen I
( I
CEA I
) I
family O
( O
R O
. O

By O
polymerase O
chain O
reaction O
with O
the O
conserved O
sequences O
of O
murine O
CEA O
gene O
family O
members O
( O
mmCGM O
) O
as O
primers O
, O
we O
detected O
two O
CEA O
- O
encoding O
RNAs O
in O
the O
mouse O
liver O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
synthesizes O
seven O
to O
eight O
mRNAs O
, O
each O
of O
which O
contains O
a O
leader O
RNA O
derived O
from O
the O
5 O
' O
end O
of O
the O
genome O
. O

When O
MHV O
- O
infected O
cells O
were O
UV O
irradiated O
at O
a O
late O
time O
in O
infection O
( O
5 O
h O
postinfection O
) O
, O
the O
syntheses O
of O
the O
various O
mRNAs O
were O
inhibited O
to O
different O
extents O
in O
proportion O
to O
the O
sizes O
of O
the O
mRNAs O
. O

The O
possibility O
that O
the O
genomic O
- O
length O
RNA O
required O
early O
in O
the O
infection O
was O
used O
only O
for O
the O
synthesis O
of O
a O
polymerase O
rather O
than O
as O
a O
template O
for O
mRNA O
synthesis O
was O
ruled O
out O
by O
examining O
the O
UV O
sensitivity O
of O
a O
Defective B
interfering I
( I
DI I
) I
RNA O
. O

This O
result O
indicates O
that O
even O
though O
DI O
RNA O
and O
viral O
mRNAs O
are O
synthesized O
by O
the O
same O
polymerase O
, O
mRNAs O
are O
synthesized O
from O
a O
larger O
( O
genomic O
- O
length O
) O
template O
. O

It O
has O
been O
shown O
previously O
that O
during O
replication O
of O
the O
genome O
of O
human O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
a O
specific O
nucleotide O
change O
occurs O
to O
eliminate O
the O
termination O
codon O
for O
the O
small O
delta O
antigen O
( O
G O
. O

Previously O
, O
we O
established O
a O
system O
whereby O
an O
intergenic O
region O
from O
mouse B
hepatitis I
virus I
( I
MHV I
) I
inserted O
into O
an O
MHV O
Defective B
interfering I
( I
DI I
) I
RNA O
led O
to O
transcription O
of O
a O
subgenomic O
DI O
RNA O
in O
helper O
virus O
- O
infected O
cells O
. O

Previously O
, O
a O
mouse B
hepatitis I
virus I
( I
MHV I
) I
genomic O
sequence O
necessary O
for O
Defective B
interfering I
( I
DI I
) I
RNA O
packaging O
into O
MHV O
particles O
( O
packaging O
signal O
) O
was O
mapped O
to O
within O
a O
region O
of O
1 O
, O
480 O
nucleotides O
in O
the O
MHV O
polymerase O
gene O
by O
comparison O
of O
two O
DI O
RNAs O
. O

Some O
of O
mouse O
hepatitis O
virus O
strains O
contain O
an O
optional O
envelope O
glycoprotein O
, O
hemagglutinin B
- I
esterase I
( I
HE I
) I
protein O
. O

To O
understand O
the O
functional O
significance O
of O
this O
protein O
, O
Monoclonal B
antibodies I
( I
MAbs I
) I
specific O
for O
this O
protein O
were O
generated O
and O
used O
for O
passive O
immunization O
of O
mice O
. O

The O
same O
protective O
effects O
were O
observed O
for O
both O
JHM O
( O
2 O
) O
and O
JHM O
( O
3 O
) O
viruses O
, O
which O
expressed O
different O
amounts O
of O
the O
HE O
protein O
. O

The O
genetic O
characterization O
of O
a O
nucleocapsid B
( I
N I
) I
protein O
mutant O
of O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
is O
described O
. O

The O
mutant O
, O
Albany B
4 I
( I
Alb4 I
) I
, O
is O
both O
temperature O
sensitive O
and O
thermolabile O
. O

We O
examined O
the O
antigenic O
structure O
of O
human B
hepatitis I
A I
virus I
( I
HAV I
) I
by O
characterizing O
a O
series O
of O
21 O
murine O
monoclonal O
- O
antibody O
- O
resistant O
neutralization O
escape O
mutants O
derived O
from O
the O
HM175 O
virus O
strain O
. O

The O
mechanism O
of O
initiation O
of O
translation O
on O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
was O
investigated O
in O
vitro O
. O

The O
results O
strongly O
suggest O
that O
HCV O
RNA O
carries O
an O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
subviral O
agent O
with O
a O
small O
RNA O
genome O
that O
is O
replicated O
in O
the O
nucleus O
of O
an O
infected O
cell O
. O

( O
i O
) O
The O
polyadenylation O
process O
occurs O
independent O
of O
the O
functionality O
of O
a O
unique O
self O
- O
cleavage O
domain O
located O
just O
3 O
' O
of O
the O
polyadenylation O
site O
. O

( O
ii O
) O
RNA O
transcripts O
that O
proceed O
beyond O
the O
polyadenylation O
site O
can O
be O
stabilized O
by O
the O
self O
- O
cleavage O
reaction O
. O

( O
iii O
) O
If O
the O
nascent O
RNA O
species O
can O
fold O
on O
itself O
, O
into O
the O
so O
- O
called O
rodlike O
structure O
, O
then O
the O
presence O
of O
the O
delta O
antigen O
leads O
to O
a O
major O
suppression O
of O
polyadenylation O
. O

The O
cellular O
receptor O
for O
murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
- O
A59 O
is O
a O
member O
of O
the O
carcinoembryonic B
antigen I
( I
CEA I
) I
family O
of O
glycoproteins O
in O
the O
immunoglobulin O
superfamily O
. O

We O
isolated O
a O
cDNA O
clone O
( O
MHVR1 O
) O
encoding O
the O
MHV O
receptor O
. O

MHVR1 O
is O
closely O
related O
to O
the O
murine O
CEA O
- O
related O
clone O
mmCGM1 O
( O
Mus O
musculus O
carcinoembryonic O
antigen O
gene O
family O
member O
) O
. O

Western O
blot O
( O
immunoblot O
) O
analysis O
performed O
with O
antireceptor O
antibodies O
detected O
a O
glycoprotein O
of O
120 O
kDa O
in O
BHK O
cells O
stably O
transfected O
with O
MHVR1 O
. O

Although O
the O
lengthy O
5 B
' I
nontranslated I
regions I
( I
5 I
' I
NTRs I
) I
of O
other O
picornaviral O
RNAs O
form O
highly O
ordered O
structures O
with O
important O
functions O
in O
viral O
translation O
, O
little O
is O
known O
about O
the O
5 O
' O
NTR O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
. O

We O
determined O
the O
nearly O
complete O
5 O
' O
NTR O
nucleotide O
sequences O
of O
two O
genetically O
divergent O
HAV O
strains O
( O
PA21 O
and O
CF53 O
) O
and O
included O
these O
data O
in O
a O
comparative O
phylogenetic O
analysis O
of O
the O
HAV O
5 O
' O
NTR O
. O

Domains O
I O
and O
II O
( O
bases O
1 O
to O
95 O
) O
contain O
a O
5 O
' O
- O
terminal O
hairpin O
and O
two O
stem O
- O
loops O
followed O
by O
a O
single O
- O
stranded O
and O
highly O
variable O
pyrimidine O
- O
rich O
tract O
( O
bases O
96 O
to O
154 O
) O
. O

The O
remainder O
of O
the O
5 O
' O
NTR O
( O
domains O
III O
to O
VI O
, O
bases O
155 O
to O
734 O
) O
contains O
several O
complex O
stem O
- O
loops O
, O
one O
of O
which O
may O
form O
a O
pseudoknot O
, O
and O
terminates O
in O
a O
highly O
conserved O
region O
containing O
an O
oligopyrimidine O
tract O
preceding O
the O
putative O
start O
codon O
by O
13 O
bases O
. O

A O
system O
that O
exploits O
Defective B
interfering I
( I
DI I
) I
RNAs O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
for O
deciphering O
the O
mechanisms O
of O
coronavirus O
mRNA O
transcription O
was O
developed O
. O

S1 O
nuclease O
protection O
experiments O
, O
sequence O
analysis O
, O
and O
Northern O
( O
RNA O
) O
blotting O
analysis O
revealed O
that O
the O
subgenomic O
DI O
RNA O
contained O
the O
leader O
sequence O
at O
its O
5 O
' O
end O
and O
that O
the O
body O
of O
the O
subgenomic O
DI O
RNA O
started O
from O
the O
inserted O
intergenic O
sequence O
. O

Genes O
4 O
and O
5 O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
are O
known O
to O
encode O
nonstructural O
proteins O
ns4 O
, O
ns5a O
, O
and O
ns5b O
, O
whose O
function O
is O
unknown O
. O

These O
results O
suggest O
that O
ns4 O
and O
ns5a O
are O
not O
essential O
for O
viral O
replication O
in O
tissue O
culture O
cells O
, O
and O
thus O
join O
gene O
2 O
and O
the O
hemagglutinin B
- I
esterase I
( I
HE I
) I
gene O
as O
nonessential O
viral O
genes O
in O
MHV O
. O

The O
two O
glial O
lineages O
present O
in O
mixed O
telencephalic O
cultures O
were O
separated O
into O
type O
- O
1 O
astrocytes O
and O
oligodendrocyte O
- O
type O
- O
2 O
astrocyte O
( O
O O
- O
2A O
) O
lineage O
cells O
and O
individually O
assessed O
for O
their O
ability O
to O
support O
virus O
growth O
. O

Virus O
multiplication O
was O
however O
significantly O
reduced O
by O
preconditioning O
the O
medium O
with O
mixed O
telencephalic O
or O
enriched O
type O
- O
1 O
astrocyte O
cultures O
, O
suggesting O
that O
intercellular O
interactions O
mediated O
by O
soluble O
factor O
( O
s O
) O
can O
influence O
the O
infectious O
process O
in O
O O
- O
2A O
lineage O
cells O
. O

The O
presence O
of O
these O
cytokines O
, O
which O
synergistically O
block O
O O
- O
2A O
cells O
from O
differentiating O
into O
oligodendrocytes O
was O
correlated O
with O
specific O
and O
reversible O
resistance O
to O
JHM B
virus I
( I
JHMV I
) I
infection O
. O

These O
data O
, O
combined O
with O
our O
finding O
that O
accelerated O
terminal O
differentiation O
of O
the O
oligodendrocyte O
phenotype O
confers O
resistance O
to O
JHMV O
( O
Beushausen O
and O
Dales O
, O
Virology O
, O
1985 O
) O
, O
suggest O
that O
the O
permissiveness O
of O
O O
- O
2A O
cells O
for O
JHMV O
is O
restricted O
to O
a O
discrete O
developmental O
stage O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
contains O
a O
single O
- O
stranded O
, O
plus O
- O
sense O
RNA O
genome O
with O
a O
single O
long O
open O
reading O
frame O
encoding O
a O
polyprotein O
of O
approximately O
250 O
kDa O
. O

We O
constructed O
recombinant O
vaccinia O
viruses O
which O
expressed O
the O
HAV O
polyprotein O
( O
rV O
- O
ORF O
) O
and O
the O
P1 O
structural O
region O
( O
rV O
- O
P1 O
) O
. O

The O
only O
known O
protein O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
the O
delta O
antigen O
, O
is O
found O
both O
within O
virus O
particles O
and O
within O
the O
nucleus O
of O
the O
infected O
cell O
, O
where O
it O
has O
one O
or O
more O
roles O
essential O
for O
RNA O
genome O
replication O
. O

From O
Northwestern O
( O
RNA O
- O
immunoblot O
) O
analyses O
with O
both O
complete O
and O
various O
subdomains O
of O
HDV O
genomic O
and O
antigenomic O
RNAs O
, O
we O
found O
that O
a O
necessary O
feature O
for O
specific O
binding O
was O
that O
the O
RNA O
be O
able O
to O
fold O
to O
some O
extent O
into O
the O
so O
- O
called O
rodlike O
structure O
; O
this O
structure O
is O
a O
predicted O
intramolecular O
partial O
base O
- O
pairing O
of O
the O
circular O
RNA O
, O
with O
about O
70 O
% O
of O
all O
bases O
involved O
, O
so O
as O
to O
produce O
an O
unbranched O
rodlike O
structure O
. O

Quantitative O
fitness O
vector O
plots O
demonstrate O
graphically O
that O
even O
clones O
of O
an O
RNA O
virus O
are O
composed O
of O
complex O
variant O
populations O
( O
quasispecies O
) O
. O

Variants O
of O
greater O
fitness O
( O
competitive O
replication O
ability O
) O
were O
selected O
within O
very O
few O
passages O
of O
virus O
clones O
in O
new O
host O
cells O
or O
animals O
. O

The O
polypeptides O
encoded O
in O
open B
reading I
frame I
( I
ORF I
) I
1b O
of O
the O
mouse O
hepatitis O
virus O
A59 O
putative O
polymerase O
gene O
of O
RNA O
1 O
were O
identified O
in O
the O
products O
of O
in O
vitro O
translation O
of O
genome O
RNA O
. O

Two O
murine O
hepatitis O
virus O
strain O
A59 O
Defective B
interfering I
( I
DI I
) I
RNAs O
were O
generated O
by O
undiluted O
virus O
passages O
. O

Infection O
with O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
an O
important O
cause O
of O
acute O
and O
chronic O
liver O
disease O
and O
can O
be O
rapidly O
fatal O
. O

One O
genome O
type O
( O
termed O
the O
S O
genome O
) O
synthesizes O
a O
24 O
- O
kDa O
protein O
thought O
to O
be O
required O
for O
genome O
replication O
. O

Another O
genome O
type O
( O
termed O
the O
L O
genome O
) O
extends O
the O
reading O
frame O
by O
19 O
amino O
acids O
as O
a O
result O
of O
a O
single O
base O
change O
. O

Hepatitis O
A O
virus O
capsid O
proteins O
( O
VP0 O
, O
VP3 O
, O
and O
VP1 O
) O
have O
been O
synthesized O
in O
Escherichia O
coli O
for O
use O
in O
antigenic O
and O
immunogenic O
analyses O
. O

A O
series O
of O
plasmids O
containing O
hepatitis B
A I
virus I
( I
HAV I
) I
cDNA O
was O
constructed O
such O
that O
positive O
- O
strand O
HAV O
RNA O
could O
be O
transcribed O
with O
T7 O
RNA O
polymerase O
. O

Removal O
of O
either O
CD4 O
+ O
T O
cells O
or O
Ia O
+ O
antigen B
- I
presenting I
cells I
( I
APC I
) I
from O
the O
spleen O
cells O
abrogated O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
production O
. O

Addition O
of O
anti O
- O
CD4 O
or O
anti O
- O
Ia O
( O
d O
) O
monoclonal O
antibodies O
to O
the O
culture O
suppressed O
IL O
- O
2 O
production O
. O

Infection O
of O
susceptible O
murine O
cells O
with O
the O
coronavirus O
mouse B
hepatitis I
virus I
type I
4 I
( I
MHV4 I
) I
results O
in O
extensive O
cell O
- O
cell O
fusion O
at O
pHs O
from O
5 O
. O

Wild O
- O
type O
and O
variant O
viruses O
were O
compared O
at O
the O
level O
of O
the O
fusion O
- O
active O
Surface B
( I
S I
) I
glycoprotein O
gene O
. O

Expression O
of O
hybrid O
S O
genes O
prepared O
by O
exchange O
of O
restriction O
fragments O
between O
wild O
- O
type O
and O
variant O
cDNAs O
revealed O
that O
elimination O
of O
neutral O
pH O
fusion O
was O
solely O
dependent O
on O
amino O
acid O
alterations O
at O
positions O
1067 O
( O
Q O
to O
H O
) O
, O
1094 O
( O
Q O
to O
H O
) O
, O
and O
1114 O
( O
L O
to O
R O
) O
. O

These O
changes O
lie O
within O
a O
predicted O
heptad O
region O
of O
the O
transmembrane O
cleavage O
fragment O
of O
S O
( O
S2 O
) O
. O

Variants O
of O
hepatitis O
A O
virus O
( O
pHM175 O
virus O
) O
recovered O
from O
persistently O
infected O
green O
monkey O
kidney O
( O
BS O
- O
C O
- O
1 O
) O
cells O
induced O
a O
cytopathic O
effect O
during O
serial O
passage O
in O
BS O
- O
C O
- O
1 O
or O
fetal O
rhesus O
kidney O
( O
FRhK O
- O
4 O
) O
cells O
. O

Viruses O
of O
each O
type O
were O
clonally O
isolated O
; O
both O
wer O
cytopathic O
in O
cell O
cultures O
and O
displayed O
a O
rapid O
replication O
phenotype O
when O
compared O
with O
the O
noncytopathic O
passage O
16 O
( O
p16 O
) O
HM175 O
virus O
which O
was O
used O
to O
establish O
the O
original O
persistent O
infection O
. O

Both O
shared O
a O
common O
5 O
' O
sequence O
( O
bases O
30 O
to O
1677 O
) O
, O
as O
well O
as O
sequence O
identity O
in O
the O
P2 O
- O
P3 O
region O
( O
bases O
3249 O
to O
5303 O
and O
6462 O
to O
6781 O
) O
and O
3 O
' O
terminus O
( O
bases O
7272 O
to O
7478 O
) O
. O

VP3 O
, O
VP1 O
, O
and O
3C B
( I
pro I
) I
contained O
different O
mutations O
in O
the O
two O
virus O
clones O
, O
with O
amino O
acid O
substitutions O
at O
residues O
70 O
of O
VP3 O
and O
197 O
and O
276 O
of O
VP1 O
of O
the O
antigenic O
variant O
. O

A O
comparison O
of O
the O
nearly O
complete O
genomic O
sequences O
of O
three O
clonally O
isolated O
cytopathic O
variants O
was O
suggestive O
of O
genetic O
recombination O
between O
these O
viruses O
during O
persistent O
infection O
and O
indicated O
that O
mutations O
in O
both O
5 O
' O
and O
3 O
' O
nontranslated O
regions O
and O
in O
the O
nonstructural O
proteins O
2A O
, O
2B O
, O
2C O
, O
3A O
, O
and O
3D O
( O
pol O
) O
may O
be O
related O
to O
the O
cytopathic O
phenotype O
. O

In O
2011 O
, O
ticks O
were O
collected O
from O
livestock O
following O
an O
outbreak O
of O
Crimean B
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
in O
Gujarat O
state O
, O
India O
. O

CCHF O
- O
negative O
Hyalomma O
anatolicurn O
tick O
pools O
were O
passaged O
for O
virus O
isolation O
, O
and O
two O
virus O
isolates O
were O
obtained O
, O
designated O
Karyana B
virus I
( I
KARYV I
) I
and O
Kundal B
virus I
( I
KUNDV I
) I
, O
respectively O
. O

Traditional O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
identification O
of O
known O
viruses O
was O
unsuccessful O
, O
but O
a O
next B
- I
generation I
sequencing I
( I
NGS I
) I
approach O
identified O
KARYV O
and O
KUNDV O
as O
viruses O
in O
the O
Reoviridoe O
family O
, O
Orbivirus O
and O
Coltivirus O
genera O
, O
respectively O
. O

The O
VP1 O
gene O
of O
KARYV O
shared O
a O
most O
recent O
common O
ancestor O
with O
Wad B
Medani I
virus I
( I
WMV I
) I
, O
strain O
Ar495 O
, O
and O
based O
on O
nucleotide O
identity O
we O
demonstrate O
that O
it O
is O
a O
novel O
WMV O
strain O
. O

With O
the O
help O
of O
next B
- I
generation I
sequencing I
( I
NGS I
) I
, O
previously O
unreported O
reoviruses O
such O
as O
equine O
encephalosis O
virus O
, O
Wad B
Medani I
virus I
( I
WMV I
) I
, O
Kammavanpettai B
virus I
( I
KVPTV I
) I
, O
and O
, O
with O
this O
report O
, O
KARYV O
and O
KUNDV O
have O
been O
discovered O
and O
characterized O
in O
India O
. O

However O
, O
two O
novel O
viruses O
discovered O
in O
ticks O
feeding O
on O
bandicoot O
marsupials O
clustered O
closely O
within O
the O
mammal O
- O
associated O
hepacivirus O
and O
pestivirus O
groups O
( O
family O
Flaviviridae O
) O
. O

Another O
bandicoot O
tick O
yielded O
a O
novel O
coltivirus O
( O
family O
Reoviridae O
) O
, O
a O
group O
of O
largely O
tick O
- O
associated O
viruses O
containing O
the O
known O
human O
pathogen O
Colorado O
tick O
fever O
virus O
and O
its O
relative O
, O
Eyach O
virus O
. O

RNA O
viruses O
of O
filamentous O
fungi O
fall O
into O
two O
broad O
categories O
, O
those O
that O
contain O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
genomes O
in O
rigid O
particles O
and O
those O
that O
are O
more O
closely O
related O
to O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
viruses O
with O
dsRNA O
replicative O
intermediates O
found O
within O
lipid O
vesicles O
. O

The O
World O
Health O
Organization O
estimates O
that O
there O
may O
be O
three O
billion O
people O
at O
risk O
of O
infection O
by O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
a O
highly O
lethal O
emerging O
Orthonairovirus O
carried O
by O
ticks O
. O

On O
the O
other O
hand O
, O
the O
closely O
related O
Hazara B
virus I
( I
HAZV I
) I
, O
a O
member O
of O
the O
same O
serogroup O
, O
has O
not O
been O
reported O
as O
a O
pathogen O
for O
humans O
. O

Given O
the O
structural O
and O
phylogenetic O
similarities O
between O
these O
two O
viruses O
, O
we O
evaluated O
the O
immunological O
similarities O
of O
the O
nucleocapsid B
protein I
( I
NP I
) I
of O
these O
two O
viruses O
in O
multiple O
species O
. O

IMPORTANCE O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
and O
Hazara B
virus I
( I
HAZV I
) I
, O
members O
of O
the O
Nairoviridae O
family O
, O
are O
transmitted O
to O
mammals O
by O
tick O
bites O
. O

HAZV O
, O
on O
the O
other O
hand O
, O
is O
not O
a O
pathogen O
to O
humans O
and O
can O
be O
studied O
under O
biosafety B
level I
2 I
( I
BSL2 I
) I
conditions O
. O

Here O
, O
we O
demonstrate O
cross O
- O
reactivity O
in O
anti O
- O
nucleocapsid B
protein I
( I
NP I
) I
humoral O
immune O
response O
between O
NPs O
of O
HAZV O
and O
CCHFV O
in O
multiple O
species O
. O

Hazara B
nairovirus I
( I
HAZY I
) I
is O
a O
member O
of O
the O
family O
Nairoviridae O
in O
the O
order O
Bunyavirales O
and O
closely O
related O
to O
Crimean O
- O
Congo O
hemorrhagic O
fever O
virus O
, O
which O
is O
responsible O
for O
severe O
and O
fatal O
human O
disease O
. O

The O
HAZV O
genome O
comprises O
three O
segments O
of O
negative O
- O
sense O
RNA O
, O
named O
S O
, O
M O
, O
and O
L O
, O
with O
nontranslated B
regions I
( I
NTRs I
) I
flanking O
a O
single O
open O
reading O
frame O
. O

The O
terminal O
- O
proximal O
nucleotides O
of O
3 O
' O
and O
5 O
' O
NTRs O
exhibit O
extensive O
terminal O
complementarity O
; O
the O
first O
11 O
nucleotides O
are O
strictly O
conserved O
and O
form O
promoter B
element I
1 I
( I
PE1 I
) I
, O
with O
adjacent O
segment O
- O
specific O
nucleotides O
forming O
PE2 O
. O

The O
ability O
of O
nairoviruses O
to O
multiply O
and O
cause O
disease O
is O
controlled O
in O
major O
part O
by O
nucleotides O
that O
flank O
the O
3 O
' O
and O
5 O
' O
ends O
of O
nairoviral O
genes O
, O
called O
nontranslated B
regions I
( I
NTRs I
) I
. O

Hazara B
nairovirus I
( I
HAZV I
) I
is O
an O
enveloped O
trisegmented O
negative O
- O
strand O
RNA O
virus O
classified O
within O
the O
Nairoviridae O
family O
of O
the O
Bunyavirales O
order O
and O
a O
member O
of O
the O
same O
subtype O
as O
Crimean O
- O
Congo O
hemorrhagic O
fever O
virus O
, O
responsible O
for O
fatal O
human O
disease O
. O

The O
screen O
revealed O
prominent O
roles O
for O
subunits O
of O
the O
coat B
protein I
1 I
( I
COPI I
) I
- O
vesicle O
coatomer O
, O
which O
regulates O
retrograde O
trafficking O
of O
cargo O
between O
the O
Golgi O
apparatus O
and O
the O
endoplasmic O
reticulum O
, O
as O
well O
as O
intra O
- O
Golgi O
transport O
. O

Treatment O
of O
HAZV O
- O
infected O
cells O
with O
brefeldin B
A I
( I
BFA I
) I
, O
an O
inhibitor O
of O
Arf1 O
activation O
required O
for O
COPI O
coatomer O
formation O
, O
revealed O
that O
this O
late O
COPI O
- O
dependent O
stage O
was O
Arf1 O
dependent O
, O
consistent O
with O
the O
established O
role O
of O
Arf1 O
in O
COPI O
vesicle O
formation O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
the O
causative O
agent O
of O
the O
most O
widespread O
tick O
- O
borne O
viral O
infection O
in O
humans O
. O

CCHFV O
encodes O
a O
secreted O
glycoprotein O
( O
GP38 O
) O
of O
unknown O
function O
that O
is O
the O
target O
of O
a O
protective O
antibody O
. O

Sequence O
alignment O
and O
homology O
modeling O
showed O
distant O
homology O
between O
GP38 O
and O
the O
ectodomain O
of O
Gn O
( O
a O
structural O
glycoprotein O
in O
CCHFV O
) O
, O
suggestive O
of O
a O
gene O
duplication O
event O
. O

IMPORTANCE O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
a O
priority O
pathogen O
that O
poses O
a O
high O
risk O
to O
public O
health O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
a O
cause O
of O
severe O
hemorrhagic O
fever O
. O

A O
notable O
member O
is O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
which O
is O
the O
most O
widely O
distributed O
tick O
- O
borne O
pathogen O
and O
is O
associated O
with O
devastating O
human O
disease O
, O
with O
case O
fatality O
rates O
averaging O
30 O
% O
. O

Hazara B
virus I
( I
HAZV I
) I
is O
closely O
related O
to O
CCHFV O
, O
sharing O
the O
same O
serogroup O
and O
many O
structural O
, O
biochemical O
, O
and O
cellular O
properties O
. O

IMPORTANCE O
HAZV O
is O
classified O
within O
the O
Nairoviridae O
family O
with O
CCHFV O
, O
which O
is O
one O
of O
the O
most O
lethal O
human O
pathogens O
in O
existence O
, O
requiring O
the O
highest O
biosafety B
level I
( I
BSL I
) I
containment O
( O
BSL4 O
) O
. O

Hazara B
nairovirus I
( I
HAZV I
) I
is O
a O
trisegmented O
RNA O
virus O
most O
closely O
related O
to O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
in O
the O
order O
Bunyavirales O
. O

The O
terminal O
roughly O
20 O
nucleotides B
( I
nt I
) I
of O
its O
genome O
ends O
are O
highly O
complementary O
, O
similar O
to O
those O
of O
other O
segmented B
negative I
- I
strand I
RNA I
viruses I
( I
sNSV I
) I
, O
and O
act O
as O
promoters O
for O
RNA O
synthesis O
. O

These O
promoters O
contain O
two O
elements O
: O
the O
extreme O
termini O
of O
both O
strands O
( O
promoter O
element O
1 O
[ O
PE1 O
] O
) O
are O
conserved O
and O
virus O
specific O
and O
are O
found O
bound O
to O
separate O
sites O
on O
the O
polymerase O
surface O
in O
crystal O
structures O
of O
promoter O
- O
polymerase O
complexes O
. O

The O
following O
sequences O
( O
PE2 O
) O
are O
segment O
specific O
, O
with O
the O
potential O
to O
form O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
and O
the O
latter O
aspect O
is O
also O
important O
for O
promoter O
activity O
. O

Nairovirus O
promoters O
differ O
from O
the O
other O
sNSV O
cited O
in O
that O
they O
contain O
a O
short O
single B
stranded I
RNA I
( I
ssRNA I
) I
region O
between O
the O
two O
elements O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
can O
cause O
severe O
hepatic O
injury O
in O
humans O
. O

However O
, O
the O
mechanism O
( O
s O
) O
causing O
this O
damage O
is O
poorly O
characterized O
. O

CCHFV O
produces O
an O
acute O
disease O
, O
including O
liver O
damage O
, O
in O
mice O
lacking O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
signaling O
due O
to O
either O
STAT O
- O
1 O
gene O
deletion O
or O
disruption O
of O
the O
IFN O
- O
I O
receptor O
1 O
gene O
. O

Similar O
experiments O
in O
CCHFV O
- O
exposed O
NOD B
- I
SCID I
- I
gamma I
( I
NSG I
) I
, O
Rag2 O
- O
deficient O
, O
and O
perforin O
- O
deficient O
mice O
also O
demonstrated O
liver O
injury O
, O
suggesting O
that O
cytotoxic O
immune O
cells O
are O
dispensable O
for O
hepatic O
damage O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
a O
tick O
- O
borne O
Nairovirus O
of O
the O
Bunyaviridae O
family O
, O
causing O
severe O
illness O
with O
high O
mortality O
rates O
in O
humans O
. O

Here O
, O
we O
demonstrate O
that O
CCHFV B
nucleocapsid I
protein I
( I
CCHFV I
- I
NP I
) I
augments O
mRNA O
translation O
. O

CCHFV O
- O
NP O
binds O
to O
the O
viral O
mRNA O
5 B
' I
untranslated I
region I
( I
UTR I
) I
with O
high O
affinity O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
a O
bunyavirus O
causing O
severe O
hemorrhagic O
fever O
disease O
in O
humans O
, O
with O
high O
mortality O
rates O
. O

Using O
the O
recently O
developed O
interferon O
alpha O
receptor O
knockout O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
mouse O
model O
, O
which O
replicates O
human O
disease O
, O
we O
investigated O
the O
immunogenicity O
and O
protection O
of O
two O
novel O
CCHFV O
vaccine O
candidates O
: O
a O
DNA O
vaccine O
encoding O
a O
ubiquitin O
- O
linked O
version O
of O
CCHFV O
Gc O
, O
Gn O
, O
and O
N O
and O
one O
using O
transcriptionally B
competent I
virus I
- I
like I
particles I
( I
tc I
- I
VLPs I
) I
. O

Moreover O
, O
we O
found O
that O
in O
challenged O
mice O
with O
a O
Th1 O
response O
( O
immunized O
by O
DNA O
/ O
DNA O
and O
boosted O
by O
tc O
- O
VLPs O
) O
, O
the O
immune O
response O
changed O
to O
Th2 O
at O
day O
9 O
postchallenge O
. O

IMPORTANCE O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
responsible O
for O
hemorrhagic O
diseases O
in O
humans O
, O
with O
a O
high O
mortality O
rate O
. O

Of O
these O
serogroups O
, O
the O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
serogroup O
comprises O
sole O
members O
CCHFV O
and O
Hazara B
virus I
( I
HAZV I
) I
. O

The O
three O
RNA O
segments O
that O
form O
the O
nairovirus O
genome O
are O
encapsidated O
by O
the O
viral O
Nucleocapsid B
protein I
( I
N I
) I
to O
form O
ribonucleoprotein B
( I
RNP I
) I
complexes O
that O
are O
substrates O
for O
RNA O
synthesis O
and O
packaging O
into O
virus O
particles O
. O

One O
member O
is O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
which O
is O
responsible O
for O
fatal O
human O
disease O
and O
is O
recognized O
as O
an O
emerging O
threat O
within O
Europe O
in O
response O
to O
climate O
change O
. O

The O
regulation O
of O
the O
interferon B
type I
I I
( I
IFN I
- I
I I
) I
response O
has O
been O
shown O
to O
rely O
on O
posttranslational O
modification O
by O
ubiquitin B
( I
Ub I
) I
and O
Ub O
- O
like O
interferon B
- I
stimulated I
gene I
product I
15 I
( I
ISG15 I
) I
to O
stabilize O
, O
or O
activate O
, O
a O
variety O
of O
IFN O
- O
I O
signaling O
and O
downstream O
effector O
proteins O
. O

Since O
zoonotic O
viruses O
rely O
on O
viral O
proteins O
to O
recognize O
, O
or O
cleave O
, O
ISG15 O
conjugates O
in O
order O
to O
evade O
, O
or O
suppress O
, O
innate O
immunity O
, O
the O
impact O
of O
ISG15 O
biodiversity O
on O
deISGylating O
proteases O
of O
the O
ovarian B
tumor I
family I
( I
vOTU I
) I
from O
nairoviruses O
was O
evaluated O
. O

IMPORTANCE O
Viral B
ovarian I
tumor I
domain I
proteases I
( I
vOTUs I
) I
are O
one O
of O
the O
two O
principal O
classes O
of O
viral O
proteases O
observed O
to O
reverse O
posttranslational O
modification O
of O
host O
proteins O
by O
ubiquitin O
and O
interferon B
- I
stimulated I
gene I
product I
15 I
( I
ISG15 I
) I
, O
subsequently O
facilitating O
downregulation O
of O
IFN O
- O
I O
signaling O
pathways O
. O

As O
negative O
- O
sense O
single O
- O
stranded O
RNA O
( O
- O
ssRNA O
) O
viruses O
, O
nairoviruses O
encode O
nucleoprotein B
( I
NP I
) I
that O
encapsidates O
the O
genomic O
RNA O
and O
further O
forms O
ribonucleoprotein B
( I
RNP I
) I
complex O
with O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

We O
previously O
revealed O
that O
the O
monomeric O
NP O
encoded O
by O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
presents O
a O
racket O
- O
shaped O
structure O
and O
shows O
unusual O
DNA O
- O
specific O
endonuclease O
activity O
. O

To O
examine O
the O
structural O
and O
biological O
variation O
of O
nairovirus O
- O
encoded O
NPs O
, O
here O
, O
we O
systematically O
solved O
the O
crystal O
structures O
of O
NPs O
encoded O
by O
various O
nairoviruses O
, O
including O
Hazara B
virus I
( I
HAZV I
) I
, O
Kupe B
virus I
( I
KUPV I
) I
, O
and O
Erve B
virus I
( I
ERVEV I
) I
. O

In O
the O
cytoplasm O
, O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
senses O
the O
RNA O
genomes O
of O
several O
RNA O
viruses O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
a O
negative O
- O
sense O
RNA O
virus O
with O
a O
5 O
' O
- O
monophosphorylated O
genome O
, O
is O
a O
highly O
pathogenic O
zoonotic O
agent O
with O
significant O
public O
health O
implications O
. O

We O
found O
that O
, O
during O
CCHFV O
infection O
, O
RIG O
- O
I O
mediated O
a O
type B
I I
interferon I
( I
IFN I
) I
response O
via O
MAVS O
. O

Crimean O
- O
Congo O
hemorrhagic O
fever O
virus O
( O
CCHFV O
; O
genus O
Nairovirus O
) O
is O
an O
extremely O
pathogenic O
member O
of O
the O
Bunyaviridae O
family O
. O

Since O
handling O
of O
the O
virus O
requires O
a O
biosafety B
level I
4 I
( I
BSL I
- I
4 I
) I
facility O
, O
little O
is O
known O
about O
pathomechanisms O
and O
host O
interactions O
. O

Here O
, O
we O
describe O
the O
establishment O
of O
a O
transcriptionally B
competent I
virus I
- I
like I
particle I
( I
tc I
- I
VLP I
) I
system O
for O
CCHFV O
. O

Recombinant O
polymerase O
( O
L O
) O
, O
Nucleocapsid B
protein I
( I
N I
) I
and O
a O
reporter O
minigenome O
expressed O
in O
human O
HuH O
- O
7 O
cells O
resulted O
in O
formation O
of O
transcriptionally O
active O
nucleocapsids O
that O
could O
be O
packaged O
by O
coexpressed O
CCHFV O
glycoproteins O
into O
tc O
- O
VLPs O
. O

IMPORTANCE O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
an O
extremely O
virulent O
pathogen O
of O
humans O
. O

Recent O
work O
has O
implicated O
the O
viral B
ovarian I
tumor I
domain I
( I
vOTU I
) I
as O
a O
possible O
nairovirus O
virulence O
factor O
due O
to O
its O
ability O
to O
edit O
ubiquitin B
( I
Ub I
) I
bound O
to O
cellular O
proteins O
and O
, O
at O
least O
in O
the O
case O
of O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
to O
cleave O
the O
Ub O
- O
like O
protein O
interferon B
- I
stimulated I
gene I
15 I
( I
ISG15 I
) I
, O
a O
protein O
involved O
in O
the O
regulation O
of O
host O
immunity O
. O

Crimean O
- O
Congo O
hemorrhagic O
fever O
, O
a O
severe O
hemorrhagic O
disease O
found O
throughout O
Africa O
, O
Europe O
, O
and O
Asia O
, O
is O
caused O
by O
the O
tick O
- O
borne O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
. O

CCHFV O
is O
a O
negative O
- O
sense O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
virus O
belonging O
to O
the O
Nairovirus O
genus O
of O
the O
Bunyaviridae O
family O
. O

Its O
genome O
of O
three O
single O
- O
stranded O
RNA O
segments O
is O
encapsidated O
by O
the O
nucleocapsid O
protein O
( O
CCHFV O
N O
) O
to O
form O
the O
ribonucleoprotein O
complex O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
causes O
viral O
hemorrhagic O
fever O
with O
high O
case O
- O
fatality O
rates O
and O
is O
geographically O
widely O
distributed O
. O

Due O
to O
the O
requirement O
for O
a O
biosafety B
level I
4 I
( I
BSL I
- I
4 I
) I
laboratory O
and O
the O
lack O
of O
an O
animal O
model O
, O
knowledge O
of O
the O
viral O
pathogenesis O
is O
limited O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
is O
characterized O
by O
hemorrhage O
and O
vascular O
permeability O
, O
indicating O
the O
involvement O
of O
endothelial B
cells I
( I
ECs I
) I
. O

In O
a O
previous O
study O
, O
we O
found O
that O
CCHFV O
- O
infected O
monocyte B
- I
derived I
dendritic I
cells I
( I
moDCs I
) I
activated O
ECs O
; O
however O
, O
the O
direct O
effect O
of O
CCHFV O
on O
ECs O
was O
not O
investigated O
. O

Here O
, O
we O
report O
that O
ECs O
are O
activated O
upon O
infection O
, O
as O
demonstrated O
by O
upregulation O
of O
mRNA O
levels O
for O
E O
- O
selectin O
, O
vascular B
cell I
adhesion I
molecule I
1 I
( I
VCAM1 I
) I
, O
and O
intercellular B
adhesion I
molecule I
1 I
( I
ICAM1 I
) I
. O

Furthermore O
, O
we O
examined O
vascular B
endothelial I
( I
VE I
) I
cadherin O
in O
CCHFV O
- O
infected O
ECs O
by O
different O
approaches O
. O

Infected O
ECs O
released O
higher O
levels O
of O
interleukin B
6 I
( I
IL I
- I
6 I
) I
and O
IL O
- O
8 O
; O
however O
, O
stimulation O
of O
resting O
ECs O
with O
supernatants O
derived O
from O
infected O
ECs O
did O
not O
result O
in O
increased O
ICAM1 O
expression O
. O

Interestingly O
, O
the O
moDC O
- O
mediated O
activation O
of O
ECs O
was O
abrogated O
by O
addition O
of O
neutralizing O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
antibody O
to O
moDC O
supernatants O
, O
thereby O
identifying O
this O
soluble O
mediator O
as O
the O
key O
cytokine O
causing O
EC O
activation O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
virus O
is O
a O
tick O
- O
borne O
, O
negative O
- O
sense O
, O
single O
- O
stranded O
RNA O
[ O
ssRNA O
( O
- O
) O
] O
nairovirus O
that O
produces O
fever O
, O
prostration O
, O
and O
severe O
hemorrhages O
in O
humans O
. O

Recent O
reports O
have O
identified O
a O
viral B
homologue I
of I
the I
ovarian I
tumor I
protease I
superfamily I
( I
vOTU I
) I
within O
its O
L O
protein O
. O

This O
protease O
has O
subsequently O
been O
implicated O
in O
downregulation O
of O
the O
type O
I O
interferon O
immune O
response O
through O
cleavage O
of O
posttranslational O
modifying O
proteins O
ubiquitin B
( I
Ub I
) I
and O
the O
Ub O
- O
like O
interferon B
- I
simulated I
gene I
15 I
( I
ISG15 I
) I
. O

Additionally O
, O
homologues O
of O
vOTU O
have O
been O
suggested O
to O
perform O
similar O
roles O
in O
the O
positive O
- O
sense O
, O
single O
- O
stranded O
RNA O
[ O
ssRNA O
( O
+ O
) O
] O
arteriviruses O
. O

In O
addition O
, O
kinetic O
studies O
were O
carried O
out O
with O
aminomethylcoumarin B
( I
AMC I
) I
conjugates O
of O
monomeric O
Ub O
, O
ISG15 O
, O
and O
NEDD8 O
( O
neural O
precursor O
cell O
expressed O
, O
developmentally O
downregulated O
8 O
) O
substrates O
in O
order O
to O
provide O
quantitative O
insights O
into O
vOTU O
' O
s O
preference O
for O
Ub O
and O
Ub O
- O
like O
substrates O
. O

Tick O
- O
borne O
Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
causes O
a O
severe O
hemorrhagic O
syndrome O
in O
humans O
but O
not O
in O
its O
vertebrate O
animal O
hosts O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
a O
tick O
- O
borne O
virus O
( O
genus O
Nairovirus O
, O
family O
Bunyaviridae O
) O
associated O
with O
high O
case O
fatality O
disease O
outbreaks O
in O
regions O
of O
Africa O
, O
Europe O
, O
and O
Asia O
. O

The O
unusually O
large O
virus O
L O
polymerase O
protein O
and O
the O
need O
for O
biosafety B
level I
4 I
( I
BSL I
- I
4 I
) I
containment O
conditions O
for O
work O
with O
infectious O
virus O
have O
hampered O
the O
study O
of O
CCHFV O
replication O
. O

The O
L O
protein O
has O
an O
ovarian B
tumor I
( I
OTU I
) I
protease O
domain O
located O
in O
the O
N O
terminus O
, O
which O
has O
led O
to O
speculation O
that O
the O
protein O
may O
be O
autoproteolytically O
cleaved O
to O
generate O
the O
active O
virus O
L O
polymerase O
and O
additional O
functions O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
causes O
severe O
human O
disease O
. O

Subtilisin B
kexin I
isozyme I
- I
1 I
/ I
site I
- I
1 I
protease I
( I
SKI I
- I
1 I
/ I
SIP I
) I
plays O
a O
central O
role O
in O
Gn O
processing O
. O

Only O
nucleoprotein O
- O
containing O
particles O
which O
lacked O
virus O
glycoproteins O
( O
Gn O
/ O
Ge O
or O
PreGn O
/ O
PreGc O
) O
were O
secreted O
. O

Complementation O
of O
SKI O
- O
1 O
/ O
SlP O
- O
deficient O
cells O
with O
a O
SKI O
- O
1 O
/ O
SIP O
expression O
vector O
restored O
release O
of O
infectious O
virus O
( O
> O
10 O
( O
6 O
) O
PFU O
/ O
ml O
) O
, O
confirming O
that O
SKI O
- O
1 O
/ O
SIP O
processing O
is O
required O
for O
incorporation O
of O
viral O
glycoproteins O
. O

The O
structural O
glycoproteins O
of O
Crimean O
- O
Congo O
hemorrhagic O
fever O
virus O
( O
CCHFV O
; O
genus O
Nairovirus O
, O
family O
Bunyaviridae O
) O
are O
derived O
through O
endoproteolytic O
cleavage O
of O
a O
1 O
, O
684 O
- O
amino O
- O
acid O
M O
RNA O
segment O
- O
encoded O
polyprotein O
. O

This O
polyprotein O
is O
cotranslationally O
cleaved O
into O
the O
PreG O
( O
N O
) O
and O
PreG O
( O
C O
) O
precursors O
, O
which O
are O
then O
cleaved O
by O
SKI O
- O
1 O
and O
a O
SKI O
- O
1 O
- O
like O
protease O
to O
generate O
the O
N O
termini O
of O
G O
( O
N O
) O
and O
G O
( O
C O
) O
, O
respectively O
. O

However O
, O
the O
resulting O
polypeptide O
defined O
by O
the O
N O
termini O
of O
G O
( O
N O
) O
and O
G O
( O
C O
) O
is O
predicted O
to O
be O
larger O
( O
58 O
kDa O
) O
than O
mature O
GN O
( O
37 O
kDa O
) O
. O

By O
analogy O
to O
the O
topologically O
similar O
M O
segment O
- O
encoded O
polyproteins O
of O
viruses O
in O
the O
Orthobunyavirus O
genus O
, O
the O
C O
- O
terminal O
region O
of O
PreG O
( O
N O
) O
that O
contains O
four O
predicted O
transmembrane O
domains O
may O
also O
contain O
a O
nonstructural O
protein O
, O
NSM O
. O

To O
characterize O
potential O
PreG O
( O
N O
) O
C O
- O
terminal O
cleavage O
events O
, O
a O
panel O
of O
epitope O
- O
tagged O
PreG O
( O
N O
) O
truncation O
and O
internal O
deletion O
mutants O
was O
developed O
. O

These O
constructs O
allowed O
for O
the O
identification O
of O
a O
C O
- O
terminal O
endoproteolytic O
cleavage O
within O
, O
or O
very O
proximal O
to O
, O
the O
second O
predicted O
transmembrane O
domain O
following O
the O
G O
( O
N O
) O
ectodomain O
and O
the O
subsequent O
generation O
of O
a O
C O
- O
terminal O
fragment O
. O

Pulse O
- O
chase O
experiments O
showed O
that O
PreG O
( O
N O
) O
C O
- O
terminal O
cleavage O
occurred O
shortly O
after O
synthesis O
of O
the O
precursor O
and O
prior O
to O
generation O
of O
the O
G O
( O
N O
) O
glycoprotein O
. O

Development O
of O
an O
antiserum O
specific O
to O
the O
second O
cytoplasmic O
loop O
of O
PreG O
( O
N O
) O
allowed O
detection O
of O
cell O
- O
associated O
NSM O
proteins O
derived O
from O
transient O
expression O
of O
the O
complete O
CCHFV O
M O
segment O
and O
also O
in O
the O
context O
of O
virus O
infection O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
an O
etiological O
agent O
of O
a O
disease O
with O
mortality O
rates O
in O
patients O
averaging O
30 O
% O
. O

Possibly O
, O
a O
direct O
or O
indirect O
viral O
effect O
on O
tight B
junctions I
( I
TJ I
) I
could O
cause O
the O
hemorrhage O
observed O
in O
patients O
, O
as O
TJ O
play O
a O
crucial O
role O
in O
vascular O
homeostasis O
and O
can O
cause O
leakage O
upon O
deregulation O
. O

For O
the O
first O
time O
, O
we O
have O
shown O
preferential O
basolateral O
entry O
of O
CCHFV O
in O
Madin B
- I
Darby I
canine I
kidney I
1 I
( I
MDCK I
- I
1 I
) I
epithelial O
cells O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
is O
a O
severe O
illness O
with O
high O
case O
fatality O
that O
occurs O
in O
Africa O
, O
Europe O
, O
the O
Middle O
East O
, O
and O
Asia O
. O

The O
complete O
genomes O
of O
13 O
geographically O
and O
temporally O
diverse O
virus O
strains O
were O
determined O
, O
and O
CCHF O
viruses O
were O
found O
to O
be O
highly O
variable O
with O
20 O
and O
8 O
% O
, O
31 O
and O
27 O
% O
, O
and O
22 O
and O
10 O
% O
nucleotide O
and O
deduced O
amino O
acid O
differences O
detected O
among O
virus O
S O
( O
nucleocapsid O
) O
, O
M O
( O
glycoprotein O
) O
, O
and O
L O
( O
polymerase O
) O
genome O
segments O
, O
respectively O
. O

Crimean O
- O
Congo O
hemorrhagic O
fever O
virus O
( O
genus O
Nairovirus O
, O
family O
Bunyaviridae O
) O
genome O
M O
segment O
encodes O
an O
unusually O
large O
( O
in O
comparison O
to O
members O
of O
other O
genera O
) O
polyprotein O
( O
1 O
, O
684 O
amino O
acids O
in O
length O
) O
containing O
the O
two O
major O
structural O
glycoproteins O
, O
Gn O
and O
Gc O
, O
that O
are O
posttranslationally O
processed O
from O
precursors O
PreGn O
and O
PreGc O
by O
SKI O
- O
1 O
and O
SKI O
- O
1 O
- O
like O
proteases O
, O
respectively O
. O

A O
highly O
conserved O
furin O
/ O
proprotein B
convertase I
( I
PC I
) I
cleavage O
site O
motif O
( O
RSKR247 O
) O
is O
located O
between O
the O
variable O
N O
- O
terminal O
region O
that O
is O
predicted O
to O
have O
mucin O
- O
like O
properties O
and O
the O
rest O
of O
PreGn O
. O

We O
report O
the O
successful O
infection O
of O
the O
cell O
line O
ISE6 O
derived O
from O
Ixodes O
scapularis O
tick O
embryos O
by O
the O
tick O
- O
borne O
Hazara B
virus I
( I
HAZV I
) I
, O
a O
nairovirus O
in O
the O
family O
Bunyaviridae O
. O

The O
widespread O
geographical O
distribution O
of O
Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
virus O
( O
more O
than O
30 O
countries O
) O
and O
its O
ability O
to O
produce O
severe O
human O
disease O
with O
high O
mortality O
rates O
( O
up O
to O
60 O
% O
) O
make O
CCHF O
a O
major O
public O
health O
concern O
worldwide O
. O

The O
RNA O
polymerase O
I O
( O
pol O
1 O
) O
system O
was O
used O
to O
generate O
artificial O
viral O
RNA O
genome O
segments O
( O
minigenomes O
) O
, O
which O
contained O
different O
reporter O
genes O
in O
antisense O
( O
virus O
RNA O
) O
or O
sense O
( O
virus O
- O
complementary O
RNA O
) O
orientation O
flanked O
by O
the O
noncoding O
regions O
of O
the O
CCHF O
virus O
S O
segment O
. O

Mononegavirales O
, O
known O
as O
nonsegmented B
negative I
- I
sense I
( I
NNS I
) I
RNA O
viruses O
, O
are O
a O
class O
of O
pathogenic O
and O
sometimes O
deadly O
viruses O
that O
include O
rabies B
virus I
( I
RABV I
) I
, O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
, O
and O
Ebola B
virus I
( I
EBOV I
) I
. O

Mononegavirales O
mimic O
RNA O
synthesis O
of O
their O
eukaryotic O
counterparts O
by O
utilizing O
multifunctional O
RNA O
polymerases O
to O
replicate O
entire O
viral O
genomes O
and O
transcribe O
viral O
mRNAs O
from O
individual O
viral O
genes O
as O
well O
as O
synthesize O
5 O
' O
methylated O
cap O
and O
3 O
' O
poly O
( O
A O
) O
tail O
of O
the O
transcribed O
viral O
mRNAs O
. O

The O
catalytic O
subunit O
large B
protein I
( I
L I
) I
and O
cofactor O
phosphoprotein B
( I
P I
) I
constitute O
the O
Mononegavirales O
polymerases O
. O

We O
outline O
the O
structural O
analyses O
of O
the O
Mononegavirales O
polymerases O
since O
the O
first O
structure O
of O
the O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
L O
protein O
determined O
in O
2015 O
and O
highlight O
multiple O
high O
- O
resolution O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structures O
of O
the O
polymerases O
of O
Mononegavirales O
, O
namely O
, O
VSV O
, O
RABV O
, O
HRSV O
, O
human B
metapneumovirus I
( I
HMPV I
) I
, O
and O
human B
parainfluenza I
virus I
( I
hPIV I
) I
, O
that O
have O
been O
reported O
in O
recent O
months O
( O
2019 O
to O
2020 O
) O
. O

Rabies O
, O
caused O
by O
rabies B
virus I
( I
RABV I
) I
, O
is O
an O
ancient O
zoonosis O
and O
still O
a O
major O
public O
health O
problem O
for O
humans O
, O
especially O
in O
developing O
countries O
. O

RABV O
can O
be O
recognized O
by O
specific O
innate O
recognition O
receptors O
, O
resulting O
in O
the O
production O
of O
hundreds O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
which O
can O
inhibit O
viral O
replication O
at O
different O
stages O
. O

Interferon O
- O
inducible O
GTPase O
1 O
( O
IIGP1 O
) O
is O
a O
mouse O
- O
specific O
ISG O
and O
belongs O
to O
the O
immunity O
- O
related O
GTPases O
( O
IRGs O
) O
family O
. O

Furthermore O
, O
we O
found O
that O
IIGP1 O
could O
interact O
with O
RABV O
phosphoprotein B
( I
P I
protein I
) I
. O

In O
this O
study O
, O
we O
show O
that O
infection O
with O
a O
typical O
neurotropic O
virus O
, O
RABV O
, O
can O
induce O
upregulation O
of O
IIGP1 O
, O
which O
, O
in O
turn O
, O
suppresses O
RABV O
by O
interacting O
with O
its O
phosphoprotein B
( I
P I
protein I
) I
and O
thus O
blocking O
the O
dimerization O
of O
P O
protein O
. O

nonsegmented B
negative I
- I
strand I
( I
NNS I
) I
RNA O
viruses O
possess O
a O
ribonucleoprotein O
template O
in O
which O
the O
genomic O
RNA O
is O
sequestered O
within O
a O
homopolymer O
of O
Nucleocapsid B
protein I
( I
N I
) I
. O

The O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
resides O
within O
an O
approximately O
250 O
- O
kDa O
large B
protein I
( I
L I
) I
, O
along O
with O
unconventional O
mRNA O
capping O
enzymes O
: O
a O
GDP O
: O
polyribonucleotidyltransferase O
( O
PRNT O
) O
and O
a O
dual O
- O
specificity O
mRNA O
cap O
methylase O
( O
MT O
) O
. O

To O
gain O
access O
to O
the O
N O
- O
RNA O
template O
and O
orchestrate O
the O
L O
- O
RdRP O
, O
L O
- O
PRNT O
, O
and O
L O
- O
MT O
, O
an O
oligomeric O
phosphoprotein B
( I
P I
) I
is O
required O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
P O
is O
dimeric O
with O
an O
oligomerization B
domain I
( I
OD I
) I
separating O
two O
largely O
disordered O
regions O
followed O
by O
a O
globular O
C O
- O
terminal O
domain O
that O
binds O
the O
template O
. O

We O
show O
VSV O
P O
lacking O
the O
OD O
( O
P O
- O
Delta O
OD O
) O
is O
monomeric O
but O
is O
indistinguishable O
from O
wild O
- O
type O
P O
in O
supporting O
mRNA O
transcription O
in O
vitro O
. O

A O
well O
- O
characterized O
defective O
interfering O
particle O
of O
VSV O
( O
DI O
- O
T O
) O
that O
is O
only O
competent O
for O
RNA O
replication O
requires O
significantly O
higher O
levels O
of O
N O
to O
drive O
RNA O
replication O
in O
the O
presence O
of O
P O
- O
Delta O
OD O
. O

Using O
a O
prototype O
of O
NNS O
RNA O
virus O
gene O
expression O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
we O
determined O
the O
importance O
of O
P O
oligomerization O
. O

rabies B
virus I
( I
RABV I
) I
causes O
a O
severe O
and O
fatal O
neurological O
disease O
, O
but O
morbidity O
is O
vaccine O
preventable O
and O
treatable O
prior O
to O
the O
onset O
of O
clinical O
symptoms O
. O

However O
, O
immunoglobulin O
( O
IgG O
) O
- O
based O
rabies O
postexposure B
prophylaxis I
( I
PEP I
) I
is O
expensive O
, O
restricting O
access O
to O
life O
- O
saving O
treatment O
, O
especially O
for O
patients O
in O
low O
- O
income O
countries O
where O
the O
clinical O
need O
is O
greatest O
, O
and O
does O
not O
confer O
cross O
- O
protection O
against O
newly O
emerging O
phylogroup O
II O
lyssaviruses O
. O

A O
large O
- O
scale O
screen O
and O
subsequent O
direct O
and O
orthogonal O
counter O
- O
screens O
identified O
a O
first O
- O
in O
- O
class O
direct O
- O
acting O
RABV O
inhibitor O
, O
GRP O
- O
60367 O
, O
with O
a O
specificity B
index I
( I
SI I
) I
of O
> O
100 O
, O
0 O
. O

Mechanistic O
characterization O
through O
time O
- O
of O
- O
addition O
studies O
, O
transient O
cell O
- O
to O
- O
cell O
fusion O
assays O
, O
and O
chimeric O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
recombinants O
expressing O
the O
RABV O
glycoprotein B
( I
G I
) I
demonstrated O
that O
GRP O
- O
60367 O
inhibits O
entry O
of O
a O
subset O
of O
RABV O
strains O
. O

Recently O
, O
divergent O
filoviruses O
( O
FiVs O
) O
have O
been O
identified O
in O
bats O
within O
this O
region O
, O
which O
pose O
a O
potential O
risk O
to O
public O
health O
, O
but O
the O
true O
infection O
situation O
in O
bats O
remains O
largely O
unclear O
. O

Here O
, O
689 O
archived O
bat O
serum O
samples O
were O
analyzed O
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
, O
Western O
blotting O
, O
and O
neutralization O
assay O
to O
investigate O
the O
seroprevalence O
and O
cross O
- O
reactivity O
of O
four O
divergent O
FiVs O
and O
two O
other O
viruses O
( O
rabies O
virus O
and O
Tuhoko O
pararubulavirus O
1 O
) O
of O
different O
families O
within O
the O
order O
Morionegavirales O
. O

3 O
% O
( O
250 O
/ O
689 O
) O
, O
with O
infection O
by O
the O
indigenous O
Chinese O
FiV O
DH04 O
or O
an O
antigenically O
related O
one O
being O
the O
most O
widely O
and O
the O
most O
highly O
prevalent O
. O

rabies B
virus I
( I
RABV I
) I
is O
a O
widespread O
pathogen O
that O
causes O
fatal O
disease O
in O
humans O
and O
animals O
. O

Here O
, O
we O
showed O
that O
RABV O
uses O
integrin B
beta I
1 I
( I
ITGB1 I
) I
for O
cellular O
entry O
. O

We O
found O
that O
Arg B
- I
Gly I
- I
Asp I
( I
RGD I
) I
peptide O
and O
antibody O
to O
ITGB1 O
significantly O
blocked O
RABV O
infection O
in O
cells O
in O
vitro O
and O
street O
RABV O
infection O
in O
mice O
via O
intramuscular O
inoculation O
but O
not O
the O
intracerebral O
route O
. O

IMPORTANCE O
Rabies O
is O
a O
severe O
zoonotic O
disease O
caused O
by O
rabies B
virus I
( I
RABV I
) I
. O

Here O
, O
we O
showed O
that O
integrin B
beta I
1 I
( I
ITGB1 I
) I
directly O
interacts O
with O
RABV O
glycoprotein O
, O
and O
both O
proteins O
are O
internalized O
together O
into O
host O
cells O
. O

Differential O
expression O
of O
ITGB1 O
in O
mature O
muscle O
and O
cerebral O
cortex O
of O
mice O
led O
to O
A O
- O
4 O
( O
ITGB1 O
- O
specific O
antibody O
) O
, O
and O
RGD O
peptide O
( O
competitive O
inhibitor O
for O
interaction O
between O
ITGB1 O
and O
fibronectin O
) O
blocked O
street O
RABV O
infection O
via O
intramuscular O
but O
not O
intracerebral O
inoculation O
in O
mice O
, O
suggesting O
that O
ITGB1 O
plays O
a O
role O
in O
RABV O
peripheral O
entry O
. O

Superinfection B
exclusion I
( I
SIE I
) I
or O
cross O
- O
protection O
phenomena O
have O
been O
documented O
for O
plant O
viruses O
for O
nearly O
a O
century O
and O
are O
widespread O
among O
taxonomically O
diverse O
viruses O
, O
but O
little O
information O
is O
available O
about O
SIE O
of O
plant O
negative O
- O
strand O
RNA O
viruses O
. O

Here O
, O
we O
demonstrate O
that O
SIE O
by O
sonchus B
yellow I
net I
nucleorhabdovirus I
virus I
( I
SYNV I
) I
is O
mediated O
by O
the O
viral O
matrix B
( I
M I
) I
protein O
, O
a O
multifunctional O
protein O
involved O
in O
transcription O
regulation O
, O
virion O
assembly O
, O
and O
virus O
budding O
. O

However O
, O
M O
protein O
mutants O
with O
weakened O
nuclear B
localization I
signals I
( I
NLS I
) I
and O
deficient O
nuclear O
interactions O
with O
the O
SYNV O
nucleocapsid O
protein O
were O
unable O
to O
suppress O
transcription O
. O

IMPORTANCE O
Superinfection B
exclusion I
( I
SIE I
) I
is O
a O
widespread O
phenomenon O
in O
which O
an O
established O
virus O
infection O
prevents O
reinfection O
by O
closely O
related O
viruses O
. O

In O
this O
study O
, O
we O
show O
that O
sonchus B
yellow I
net I
virus I
( I
SYNV I
) I
SIE O
is O
mediated O
by O
the O
viral O
matrix B
( I
M I
) I
protein O
. O

Our O
previous O
study O
showed O
that O
pentagalloylglucose B
( I
PGG I
) I
, O
a O
naturally O
occurring O
hydrolyzable O
phenolic O
tannin O
, O
possesses O
significant O
anti O
- O
rabies B
virus I
( I
RABV I
) I
activity O
. O

In O
BHK O
- O
21 O
cells O
, O
RABV O
induced O
the O
overactivation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
3 I
( I
STAT3 I
) I
by O
suppressing O
the O
expression O
of O
suppressor B
of I
cytokine I
signaling I
3 I
( I
SOCS3 I
) I
. O

Additionally O
, O
RABV O
- O
induced O
upregulation O
of O
microRNA O
455 O
- O
5p O
( O
miR O
- O
455 O
- O
5p O
) O
downregulated O
SOCS3 O
by O
directly O
binding O
to O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
of O
SOCS3 O
. O

Finally O
, O
activated O
STAT3 O
elicited O
the O
expression O
of O
interleukin O
- O
6 O
( O
1 O
- O
6 O
) O
, O
thereby O
contributing O
to O
RABV O
- O
associated O
encephalomyelitis O
; O
however O
, O
PGG O
restored O
the O
level O
of O
IL O
- O
6 O
in O
vitro O
and O
in O
vivo O
in O
a O
SOCS3 O
/ O
STAT3 O
- O
dependent O
manner O
. O

Positive O
- O
stranded O
RNA O
virus O
movement B
proteins I
( I
MPs I
) I
generally O
lack O
sequence O
- O
specific O
nucleic O
acid O
- O
binding O
activities O
and O
display O
cross O
- O
family O
movement O
complementarity O
with O
related O
and O
unrelated O
viruses O
. O

In O
contrast O
, O
movement O
of O
recombinant O
MP O
deletion O
mutants O
of O
sonchus B
yellow I
net I
nucleorhabdovirus I
( I
SYNV I
) I
and O
tomato B
yellow I
mottle I
- I
associated I
cytorhabdovirus I
( I
TYMaV I
) I
was O
rescued O
only O
by O
their O
corresponding O
MPs O
, O
i O
. O

A O
split O
- O
ubiquitin O
membrane O
yeast O
two O
- O
hybrid O
assay O
demonstrated O
specific O
interactions O
of O
the O
membrane O
- O
associated O
rhabdovirus O
MPs O
only O
with O
their O
cognate O
nucleoproteins O
( O
N O
) O
and O
phosphoproteins O
( O
P O
) O
. O

viral B
hemorrhagic I
septicemia I
virus I
( I
VHSV I
) I
, O
a O
rhabdovirus O
infecting O
teleost O
fish O
, O
has O
repeatedly O
crossed O
the O
boundary O
from O
marine O
fish O
species O
to O
freshwater O
cultured O
rainbow O
trout O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
was O
selected O
as O
a O
prototype O
virus O
to O
test O
this O
possibility O
since O
its O
genomic O
RNA O
encapsidated O
in O
the O
nucleocapsid O
forms O
a O
structure O
resembling O
one O
strand O
of O
an O
A O
- O
form O
RNA O
duplex O
. O

To O
confirm O
that O
the O
polyamide O
targeted O
the O
nucleocapsid O
, O
a O
nucleocapsid B
- I
like I
particle I
( I
NLP I
) I
was O
incubated O
with O
UMSL1011 O
. O

IMPORTANCE O
Negative B
- I
strand I
RNA I
viruses I
( I
NSVs I
) I
include O
several O
life O
- O
threatening O
pathogens O
, O
such O
as O
rabies O
virus O
, O
respiratory O
syncytial O
virus O
, O
and O
Ebola O
virus O
. O

Here O
, O
we O
studied O
infection O
with O
an O
attenuated O
rabies O
virus O
, O
Evelyn B
- I
Rotnycki I
- I
Abelseth I
( I
ERA I
) I
virus O
, O
and O
observed O
increased O
susceptibility O
with O
ERA O
virus O
in O
MALT1 O
( O
- O
/ O
- O
) O
mice O
. O

Indeed O
, O
after O
intranasal O
infection O
with O
ERA O
virus O
, O
wild O
- O
type O
mice O
developed O
mild O
transient O
clinical O
signs O
with O
recovery O
at O
35 O
days B
postinoculation I
( I
dpi I
) I
. O

Interestingly O
, O
MALT1 O
( O
- O
/ O
- O
) O
mice O
developed O
severe O
disease O
requiring O
euthanasia O
at O
around O
17 O
dpi O
. O

A O
decreased O
induction O
of O
inflammatory O
gene O
expression O
and O
cell O
infiltration O
and O
activation O
was O
observed O
in O
MALT1 O
( O
- O
/ O
- O
) O
mice O
at O
10 O
dpi O
compared O
to O
MALT1 O
( O
- O
/ O
- O
) O
infected O
mice O
. O

At O
17 O
dpi O
, O
however O
, O
the O
level O
of O
inflammatory O
cell O
activation O
was O
comparable O
to O
that O
observed O
in O
MALT1 O
( O
- O
/ O
- O
) O
mice O
. O

Moreover O
, O
MALT1 O
( O
- O
/ O
- O
) O
mice O
failed O
to O
produce O
virus O
- O
neutralizing O
antibodies O
. O

Elephant B
endotheliotropic I
herpesvirus I
( I
EEHV I
) I
can O
cause O
lethal O
hemorrhagic O
disease O
in O
juvenile O
Asian O
elephants O
, O
an O
endangered O
species O
. O

To O
address O
this O
deficiency O
, O
we O
validated O
the O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
enzyme O
- O
linked O
immunospot O
assay O
for O
tracking O
antigen O
- O
directed O
T O
cell O
activity O
by O
monitoring O
rabies O
- O
specific O
responses O
in O
vaccinated O
elephants O
. O

We O
identified O
glycoprotein B
B I
( I
gB I
) I
and O
the O
putative O
regulatory O
protein O
E40 O
as O
the O
most O
immunogenic O
T O
cell O
targets O
( O
IFN O
- O
gamma O
responses O
in O
five O
of O
seven O
elephants O
) O
, O
followed O
by O
the O
major O
capsid O
protein O
( O
IFN O
- O
gamma O
responses O
in O
three O
of O
seven O
elephants O
) O
. O

We O
also O
observed O
that O
IFN O
- O
gamma O
responses O
were O
largely O
from O
CD4 O
( O
+ O
) O
T O
cells O
. O

We O
detected O
no O
activity O
against O
the O
predicted O
major O
immediate O
early O
( O
E44 O
) O
and O
large O
tegument O
( O
E34 O
) O
proteins O
, O
both O
immunodominant O
T O
cell O
targets O
in O
humans O
latently O
infected O
with O
cytomegalovirus O
. O

IMPORTANCE O
Endangered O
Asian O
elephants O
are O
facing O
many O
threats O
, O
including O
lethal O
hemorrhagic O
disease O
from O
Elephant B
endotheliotropic I
herpesvirus I
( I
EEHV I
) I
. O

human B
metapneumovirus I
( I
HMPV I
) I
causes O
significant O
upper O
and O
lower O
respiratory O
disease O
in O
all O
age O
groups O
worldwide O
. O

3 O
kb O
encapsidated O
by O
multiple O
copies O
of O
the O
nucleoprotein B
( I
N I
) I
, O
giving O
rise O
to O
helical O
nucleocapsids O
. O

In O
addition O
, O
copies O
of O
the O
phosphoprotein B
( I
P I
) I
and O
the O
large O
RNA O
polymerase O
( O
L O
) O
decorate O
the O
viral O
nucleocapsids O
. O

To O
visualize O
the O
subsequent O
steps O
of O
genome O
transcription O
and O
replication O
, O
a O
fluorescence B
in I
situ I
hybridization I
( I
FISH I
) I
protocol O
was O
established O
to O
detect O
different O
viral O
RNA O
subpopulations O
in O
infected O
cells O
. O

The O
FISH O
probes O
were O
specific O
for O
detection O
of O
HMPV O
positive O
- O
sense O
RNA O
( O
+ O
RNA O
) O
and O
viral O
genomic O
RNA O
( O
vRNA O
) O
. O

Time O
course O
analysis O
of O
human O
bronchial O
epithelial O
BEAS O
- O
2B O
cells O
infected O
with O
HMPV O
revealed O
the O
formation O
of O
inclusion B
bodies I
( I
IBs I
) I
from O
early O
times O
postinfection O
. O

IMPORTANCE O
human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
recently O
discovered O
pathogen O
that O
affects O
human O
populations O
of O
all O
ages O
worldwide O
. O

While O
the O
RNA O
- O
dependent O
RNA O
polymerase O
L O
protein O
of O
rabies B
virus I
( I
RABV I
) I
, O
a O
member O
of O
the O
genus O
Lyssavirus O
of O
the O
family O
Rhabdoviridae O
, O
has O
potential O
to O
be O
a O
therapeutic O
target O
for O
rabies O
, O
the O
molecular O
functions O
of O
this O
protein O
have O
remained O
largely O
unknown O
. O

In O
this O
study O
, O
to O
obtain O
a O
novel O
experimental O
tool O
for O
molecular O
function O
analysis O
of O
the O
RABV O
L O
protein O
, O
we O
established O
by O
using O
a O
reverse O
genetics O
approach O
an O
L O
gene O
- O
deficient O
RABV O
( O
Nishi O
- O
Delta O
L O
/ O
Nluc O
) O
, O
which O
infects O
, O
propagates O
, O
and O
correspondingly O
produces O
NanoLuc O
luciferase O
in O
cultured O
neuroblastoma O
cells O
transfected O
to O
express O
the O
L O
protein O
. O

The O
results O
revealed O
that O
the O
amino O
acid O
sequence O
at O
positions O
1929 O
to O
1933 O
( O
NPYNE O
) O
is O
functionally O
important O
, O
and O
this O
was O
supported O
by O
other O
findings O
that O
this O
sequence O
is O
critical O
for O
binding O
of O
the O
L O
protein O
with O
its O
essential O
cofactor O
, O
P O
protein O
, O
and O
thus O
also O
for O
L O
protein O
' O
s O
RNA O
polymerase O
activity O
. O

Understanding O
the O
interactions O
between O
rabies B
virus I
( I
RABV I
) I
and O
individual O
host O
cell O
proteins O
is O
critical O
for O
the O
development O
of O
targeted O
therapies O
. O

Here O
we O
report O
that O
interferon O
- O
induced O
protein O
with O
tetratricopeptide O
repeats O
2 O
( O
Ifit2 O
) O
, O
an O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
with O
possible O
RNA O
- O
binding O
capacity O
, O
is O
an O
important O
restriction O
factor O
for O
rabies O
virus O
. O

Transcriptomic O
studies O
revealed O
the O
presence O
of O
the O
interferon O
- O
induced O
antiviral O
myxovirus O
resistance O
( O
Mx O
) O
proteins O
in O
bats O
, O
but O
detailed O
functional O
aspects O
have O
not O
been O
assessed O
. O

The O
follicular O
pathway O
gives O
rise O
to O
germinal B
centers I
( I
GCs I
) I
that O
can O
take O
weeks O
to O
fully O
develop O
. O

The O
extrafollicular O
pathway O
gives O
rise O
to O
short O
- O
lived O
plasma B
cells I
( I
PCs I
) I
that O
can O
rapidly O
secrete O
protective O
antibodies O
within O
days O
of O
vaccination O
. O

rabies B
virus I
( I
RABV I
) I
postexposure B
prophylaxis I
( I
PEP I
) I
requires O
rapid O
vaccine O
- O
induced O
humoral O
immunity O
for O
protection O
. O

To O
test O
this O
hypothesis O
, O
we O
constructed O
, O
recovered O
, O
and O
characterized O
a O
recombinant O
RABV O
- O
based O
vaccine O
expressing O
murine O
B B
cell I
activating I
factor I
( I
BAFF I
) I
( O
rRABV O
- O
mBAFF O
) O
. O

To O
confirm O
that O
rRABV O
- O
mBAFF O
modulated O
the O
extrafollicular O
pathway O
, O
we O
used O
a O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
- O
associated O
protein O
( O
SAP O
) O
- O
deficient O
mouse O
model O
. O

In O
order O
to O
diminish O
the O
requirements O
for O
rabies B
immunoglobulin I
( I
RIG I
) I
and O
multiple O
vaccinations O
for O
effective O
prevention O
of O
clinical O
rabies O
, O
a O
more O
rapidly O
protective O
vaccine O
is O
needed O
. O

In O
this O
study O
, O
a O
recombinant O
rabies B
virus I
( I
RABV I
) I
that O
expressed O
murine O
interleukin B
- I
7 I
( I
IL I
- I
7 I
) I
, O
referred O
to O
here O
as O
rLBNSE O
- O
IL O
- O
7 O
, O
was O
constructed O
, O
and O
its O
effectiveness O
was O
evaluated O
in O
a O
mouse O
model O
. O

rLBNSE O
- O
IL O
- O
7 O
induced O
higher O
rates O
of O
T B
follicular I
helper I
( I
Tfh I
) I
cells O
and O
germinal B
center I
( I
GC I
) I
B O
cells O
from O
draining O
lymph B
nodes I
( I
LNs I
) I
than O
the O
parent O
virus O
rLBNSE O
. O

Interestingly O
, O
rLBNSE O
- O
IL O
- O
7 O
improved O
the O
percentages O
of O
long O
- O
lived O
memory O
B O
cells O
( O
Bmem O
) O
in O
the O
draining O
LNs O
and O
plasma B
cells I
( I
PCs I
) I
in O
the O
bone B
marrow I
( I
BM I
) I
for O
up O
to O
360 O
days O
postimmunization O
( O
dpi O
) O
. O

As O
a O
result O
of O
the O
presence O
of O
the O
long O
- O
lived O
PCs O
, O
it O
also O
generated O
prolonged O
virus B
- I
neutralizing I
antibodies I
( I
VNAs I
) I
, O
resulting O
in O
better O
protection O
against O
a O
lethal O
challenge O
than O
that O
seen O
with O
rLBNSE O
. O

Moreover O
, O
we O
found O
that O
the O
long O
- O
lived O
PCs O
that O
were O
elicited O
by O
the O
IL O
- O
7 O
- O
expressing O
recombinant O
virus O
( O
rLBNSE O
- O
IL O
- O
7 O
) O
were O
able O
to O
sustain O
VNA O
levels O
much O
longer O
than O
those O
elicited O
by O
the O
parent O
rLBNSE O
virus O
. O

The O
GDP O
polyribonucleotidyltransferase B
( I
PRNTase I
) I
domain O
of O
the O
multifunctional O
L O
protein O
of O
rhabdoviruses O
, O
such O
as O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
rabies O
virus O
, O
catalyzes O
the O
transfer O
of O
5 O
' O
- O
phospho O
- O
RNA O
( O
pRNA O
) O
from O
5 O
' O
- O
triphospho O
- O
RNA O
( O
pppRNA O
) O
to O
GDP O
via O
a O
covalent O
enzyme O
- O
pRNA O
intermediate O
to O
generate O
a O
5 O
' O
- O
cap O
structure O
( O
GpppA O
) O
. O

Here O
, O
using O
an O
improved O
oligo O
- O
RNA O
capping O
assay O
with O
the O
VSV O
L O
protein O
, O
we O
showed O
that O
the O
Michaelis O
constants O
for O
GDP O
and O
pppAACAG O
( O
VSV O
mRNA O
- O
start O
sequence O
) O
are O
0 O
. O

2 O
, O
6 O
- O
Diaminopurine O
- O
riboside O
( O
DAP O
) O
, O
7 O
- O
deazaguanosine O
( O
7 O
- O
deaza O
- O
G O
) O
, O
and O
7 O
- O
methylguanosine O
( O
m O
( O
7 O
) O
G O
) O
diphosphates O
efficiently O
accepted O
pRNA O
, O
resulting O
in O
the O
formation O
of O
DAPpppA O
, O
7 O
- O
deaza O
- O
GpppA O
, O
and O
m O
( O
7 O
) O
GpppA O
( O
cap O
0 O
) O
, O
respectively O
. O

IMPORTANCE O
mRNAs O
of O
nonsegmented B
negative I
- I
strand I
( I
NNS I
) I
RNA O
viruses O
, O
such O
as O
VSV O
, O
possess O
a O
fully O
methylated O
cap O
structure O
, O
which O
is O
required O
for O
mRNA O
stability O
, O
efficient O
translation O
, O
and O
evasion O
of O
antiviral O
innate O
immunity O
in O
host O
cells O
. O

GDP O
polyribonucleotidyltransferase B
( I
PRNTase I
) I
is O
an O
unconventional O
mRNA O
capping O
enzyme O
of O
NNS O
RNA O
viruses O
that O
is O
distinct O
from O
the O
eukaryotic O
mRNA O
capping O
enzyme O
, O
guanylyltransferase O
. O

Our O
previous O
studies O
demonstrate O
that O
overexpression O
of O
chemokines O
/ O
cytokines O
such O
as O
CCL O
- O
3 O
( O
MIP O
- O
1 O
alpha O
) O
and O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
can O
enhance O
the O
immunogenicity O
of O
rabies O
vaccines O
. O

In O
the O
present O
study O
, O
the O
chemokine O
CXCL13 O
was O
inserted O
into O
the O
genome O
of O
the O
recombinant O
rabies O
virus O
( O
rRABV O
) O
strain O
LBNSE O
, O
and O
the O
effect O
of O
the O
chemokine O
CXCL13 O
on O
the O
immunogenicity O
of O
RABV O
was O
investigated O
. O

It O
was O
found O
that O
LBNSE O
- O
CXCL13 O
recruited O
follicular O
helper O
T O
( O
Tfh O
) O
and O
germinal B
center I
( I
GC I
) I
B O
cells O
, O
promoted O
the O
formation O
of O
GCs O
, O
and O
increased O
the O
population O
of O
plasma O
cells O
in O
immunized O
mice O
. O

Further O
studies O
showed O
that O
mice O
immunized O
with O
LBNSE O
- O
CXCL13 O
produced O
more O
rabies O
virus B
- I
neutralizing I
antibodies I
( I
VNAs I
) I
and O
developed O
better O
protection O
than O
those O
immunized O
with O
the O
parent O
virus O
LBNSE O
or O
the O
GM O
- O
CSF O
- O
expressing O
RABV O
( O
LBNSE O
- O
GM O
- O
CSF O
) O
. O

As O
expected O
, O
the O
overexpression O
of O
CXCL13 O
resulted O
in O
enhanced O
virus B
- I
neutralizing I
antibody I
( I
VNA I
) I
production O
and O
protection O
against O
a O
virulent O
RABV O
challenge O
. O

We O
report O
an O
in O
vitro O
RNA O
synthesis O
assay O
for O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
of O
rabies B
virus I
( I
RABV I
) I
. O

We O
expressed O
RABV O
large O
polymerase O
protein O
( O
L O
) O
in O
insect O
cells O
from O
a O
recombinant O
baculovirus O
vector O
and O
the O
phosphoprotein O
cofactor O
( O
P O
) O
in O
Escherichia O
coli O
and O
purified O
the O
resulting O
proteins O
by O
affinity O
and O
size O
exclusion O
chromatography O
. O

Using O
chemically O
synthesized O
short O
RNA O
corresponding O
to O
the O
first O
19 O
nucleotides B
( I
nt I
) I
of O
the O
rabies O
virus O
genome O
, O
we O
demonstrate O
that O
L O
alone O
initiates O
synthesis O
on O
naked O
RNA O
and O
that O
P O
serves O
to O
enhance O
the O
initiation O
and O
processivity O
of O
the O
RdRP O
. O

The O
L O
- O
P O
complex O
lacks O
full O
processivity O
, O
which O
we O
interpret O
to O
reflect O
the O
lack O
of O
the O
viral O
Nucleocapsid B
protein I
( I
N I
) I
on O
the O
template O
. O

Using O
this O
assay O
, O
we O
define O
the O
requirements O
in O
P O
for O
stimulation O
of O
RdRP O
activity O
as O
residues O
11 O
to O
50 O
of O
P O
and O
formally O
demonstrate O
that O
Ribavirin B
triphosphate I
( I
RTP I
) I
inhibits O
the O
RdRP O
. O

By O
comparing O
the O
properties O
of O
RABV O
RdRP O
with O
those O
of O
the O
related O
rhabdovirus O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
we O
demonstrate O
that O
both O
polymerases O
can O
copy O
the O
heterologous O
promoter O
sequence O
. O

The O
requirements O
for O
engagement O
of O
the O
N O
- O
RNA O
template O
of O
VSV O
by O
its O
polymerase O
are O
provided O
by O
the O
C B
- I
terminal I
domain I
( I
CTD I
) I
of O
P O
. O

A O
chimeric O
RABV O
P O
protein O
in O
which O
the O
oligomerization B
domain I
( I
OD I
) I
and O
the O
CTD O
were O
replaced O
by O
those O
of O
VSV O
P O
stimulated O
RABV O
RdRP O
activity O
on O
naked O
RNA O
but O
was O
insufficient O
to O
permit O
initiation O
on O
the O
VSV O
N O
- O
RNA O
template O
. O

rabies B
virus I
( I
RABV I
) I
P O
gene O
mRNA O
encodes O
five O
in O
- O
frame O
start O
codons O
, O
resulting O
in O
expression O
of O
full O
- O
length O
P O
protein O
( O
P1 O
) O
and O
N O
- O
terminally O
truncated O
P O
proteins O
( O
tPs O
) O
, O
designated O
P2 O
, O
P3 O
, O
P4 O
, O
and O
P5 O
. O

Despite O
the O
fact O
that O
some O
tPs O
are O
known O
as O
interferon B
( I
IFN I
) I
antagonists O
, O
the O
importance O
of O
tPs O
in O
the O
pathogenesis O
of O
RABV O
is O
still O
unclear O
. O

In O
this O
study O
, O
to O
examine O
whether O
tPs O
contribute O
to O
pathogenesis O
, O
we O
exploited O
a O
reverse O
genetics O
approach O
to O
generate O
CE O
( O
NiP O
) O
Delta O
P2 O
- O
5 O
, O
a O
mutant O
of O
pathogenic O
CE O
( O
NiP O
) O
in O
which O
the O
P O
gene O
was O
mutated O
by O
replacing O
all O
of O
the O
start O
codons O
( O
AUG O
) O
for O
tPs O
with O
AUA O
. O

We O
confirmed O
that O
while O
CE O
( O
NiP O
) O
expresses O
detectable O
levels O
of O
P2 O
and O
P3 O
, O
CE O
( O
NiP O
) O
Delta O
P2 O
- O
5 O
has O
an O
impaired O
ability O
to O
express O
these O
tPs O
. O

After O
intramuscular O
inoculation O
, O
CE O
( O
NiP O
) O
Delta O
P2 O
- O
5 O
caused O
significantly O
lower O
morbidity O
and O
mortality O
rates O
in O
mice O
than O
did O
CE O
( O
NiP O
) O
, O
indicating O
that O
tPs O
play O
a O
critical O
role O
in O
RABV O
neuroinvasiveness O
. O

Further O
examinations O
revealed O
that O
this O
less O
neuroinvasive O
phenotype O
of O
CE O
( O
NiP O
) O
Delta O
P2 O
- O
5 O
correlates O
with O
its O
impaired O
ability O
to O
replicate O
in O
muscle O
cells O
, O
indicative O
of O
the O
importance O
of O
tPs O
in O
viral O
replication O
in O
muscle O
cells O
. O

We O
also O
demonstrated O
that O
CE O
( O
NiP O
) O
Delta O
P2 O
- O
5 O
infection O
induced O
a O
higher O
level O
of O
Ifn O
- O
beta O
gene O
expression O
in O
muscle O
cells O
than O
did O
CE O
( O
NiP O
) O
infection O
, O
consistent O
with O
the O
results O
of O
an O
IFN O
- O
beta O
promoter O
reporter O
assay O
suggesting O
that O
all O
tPs O
function O
to O
antagonize O
IFN O
induction O
in O
muscle O
cells O
. O

Multiple O
cellular O
pathways O
are O
regulated O
by O
small B
ubiquitin I
- I
like I
modifier I
( I
SUMO I
) I
modification O
, O
including O
ubiquitin O
- O
mediated O
proteolysis O
, O
signal O
transduction O
, O
innate O
immunity O
, O
and O
antiviral O
defense O
. O

In O
the O
study O
described O
in O
this O
report O
, O
we O
investigated O
the O
effects O
of O
SUMO O
on O
the O
replication O
of O
two O
members O
of O
the O
Rhabdoviridae O
family O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
rabies B
virus I
( I
RABV I
) I
. O

Furthermore O
, O
SUMO O
expression O
resulted O
in O
interferon B
- I
regulatory I
factor I
3 I
( I
IRF3 I
) I
SUMOylation O
, O
subsequently O
decreasing O
RABV O
- O
induced O
IRF3 O
phosphorylation O
and O
interferon O
synthesis O
. O

Imported O
measles B
virus I
( I
MV I
) I
outbreaks O
are O
maintained O
by O
poor O
vaccine O
responders O
and O
unvaccinated O
people O
. O

interferon B
beta I
( I
IFN I
- I
beta I
) I
is O
a O
key O
component O
of O
cellular O
innate O
immunity O
in O
mammals O
, O
and O
it O
constitutes O
the O
first O
line O
of O
defense O
during O
viral O
infection O
. O

Its O
pathogen O
, O
rabies B
virus I
( I
RABV I
) I
, O
can O
utilize O
its O
viral O
proteins O
, O
such O
as O
the O
nucleoprotein O
and O
phosphorylation O
protein O
, O
to O
subvert O
the O
host O
innate O
immune O
system O
. O

For O
a O
long O
time O
, O
the O
large B
( I
L I
) I
protein O
was O
believed O
to O
be O
essential O
for O
RABV O
transcription O
and O
replication O
, O
but O
its O
role O
in O
viral O
pathogenicity O
and O
immune O
evasion O
was O
not O
known O
. O

Recent O
studies O
have O
found O
that O
the O
conserved O
K O
- O
D O
- O
K O
- O
E O
tetrad O
motif O
in O
the O
L O
protein O
is O
related O
to O
the O
methyltransferase B
( I
MTase I
) I
activity O
in O
the O
viral O
mRNA O
process O
. O

In O
the O
present O
study O
, O
a O
series O
of O
RABV O
mutations O
in O
this O
motif O
was O
constructed O
with O
the O
recombinant O
CVS O
- O
B2c O
( O
rB2c O
) O
virus O
. O

rabies B
virus I
( I
RABV I
) I
polymerase O
L O
together O
with O
phosphoprotein O
P O
forms O
the O
PL O
polymerase O
complex O
that O
is O
essential O
for O
replication O
and O
transcription O
. O

Here O
by O
imaging O
a O
fluorescently O
tagged O
polymerase O
( O
mCherry O
- O
RABV O
- O
L O
) O
, O
we O
show O
that O
L O
accumulates O
at O
acetylated O
and O
reorganized O
microtubules O
( O
MT O
) O
. O

In O
silico O
analysis O
revealed O
a O
dynein B
light I
chain I
1 I
( I
DLC1 I
) I
binding O
motif O
in O
L O
that O
could O
mediate O
MT O
binding O
through O
dynein O
motors O
. O

Although O
cellular O
dynein B
light I
chain I
1 I
( I
DLC1 I
) I
has O
been O
reported O
to O
increase O
primary O
transcription O
by O
binding O
to O
polymerase O
cofactor O
phosphoprotein O
P O
, O
the O
detailed O
mechanism O
is O
unknown O
, O
and O
it O
is O
also O
not O
known O
whether O
the O
large O
enzymatic O
polymerase O
subunit O
L O
is O
involved O
. O

Here O
, O
we O
took O
a O
promising O
oncolytic O
virus O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
and O
tested O
the O
hypothesis O
that O
the O
neurotoxicity O
associated O
with O
the O
virus O
could O
be O
eliminated O
without O
blocking O
its O
oncolytic O
potential O
in O
the O
brain O
by O
replacing O
the O
neurotropic O
VSV O
glycoprotein O
with O
the O
glycoprotein O
from O
one O
of O
five O
different O
viruses O
, O
including O
Ebola O
virus O
, O
Marburg O
virus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
rabies O
virus O
, O
and O
Lassa O
virus O
. O

In O
contrast O
, O
a O
novel O
chimeric O
virus O
( O
VSV O
- O
LASV O
- O
GPC O
) O
containing O
genes O
from O
both O
the O
Lassa O
virus O
glycoprotein B
precursor I
( I
GPC I
) I
and O
VSV O
showed O
no O
adverse O
actions O
within O
or O
outside O
the O
brain O
and O
targeted O
and O
completely O
destroyed O
brain O
cancer O
, O
including O
high O
- O
grade O
glioblastoma O
and O
melanoma O
, O
even O
in O
metastatic O
cancer O
models O
. O

When O
mice O
had O
two O
brain O
tumors O
, O
intratumoral O
VSV O
- O
LASV O
- O
GPC O
injection O
in O
one O
tumor O
( O
glioma O
or O
melanoma O
) O
led O
to O
complete O
tumor O
destruction O
; O
importantly O
, O
the O
virus O
moved O
contralaterally O
within O
the O
brain O
to O
selectively O
infect O
the O
second O
noninjected O
tumor O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
has O
shown O
substantial O
promise O
, O
but O
a O
key O
problem O
is O
that O
if O
it O
enters O
the O
brain O
, O
it O
can O
generate O
adverse O
neurologic O
consequences O
, O
including O
death O
. O

Replication B
- I
deficient I
rabies I
virus I
( I
RABV I
) I
- O
based O
vaccines O
induce O
rapid O
and O
potent O
antibody O
responses O
via O
T O
cell O
- O
independent O
and O
T O
cell O
- O
dependent O
mechanisms O
. O

In O
this O
report O
, O
we O
show O
that O
a O
recombinant O
matrix O
gene O
- O
deleted O
RABV O
- O
based O
vaccine O
( O
rRABV O
- O
Delta O
M O
) O
infects O
and O
activates O
primary O
murine O
macrophages O
in O
vitro O
. O

In O
this O
work O
, O
we O
tested O
a O
recombinant O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
strain O
expressing O
the O
glycoprotein B
( I
G I
) I
of O
rabies O
( O
PIV5 O
- O
G O
) O
as O
a O
therapy O
for O
rabies O
virus O
infection O
: O
we O
have O
found O
that O
PIV5 O
- O
G O
protected O
mice O
as O
late O
as O
6 O
days O
after O
rabies O
virus O
infection O
. O

The O
rabies B
virus I
( I
RABV I
) I
phosphoprotein O
P O
is O
a O
multifunctional O
protein O
: O
it O
plays O
an O
essential O
role O
in O
viral O
transcription O
and O
replication O
, O
and O
in O
addition O
, O
RABV O
P O
has O
been O
identified O
as O
an O
interferon O
antagonist O
. O

Here O
, O
a O
yeast O
two O
- O
hybrid O
screen O
revealed O
that O
RABV O
P O
interacts O
with O
the O
focal B
adhesion I
kinase I
( I
FAK I
) I
. O

Here O
, O
we O
identified O
another O
cellular O
partner O
of O
P O
, O
the O
focal B
adhesion I
kinase I
( I
FAK I
) I
. O

Rabies O
virus O
replicates O
in O
the O
cytoplasm O
of O
host O
cells O
, O
but O
rabies O
virus O
phosphoprotein O
( O
P O
- O
protein O
) O
undergoes O
active O
nucleocytoplasmic O
trafficking O
. O

The O
emerging O
zoonotic O
pathogens O
Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
are O
in O
the O
genus O
Henipavirus O
in O
the O
family O
Paramyxoviridae O
. O

The O
goal O
of O
this O
study O
was O
to O
develop O
candidate O
vaccines O
against O
henipaviruses O
utilizing O
two O
well O
- O
established O
rhabdoviral O
vaccine O
vector O
platforms O
, O
recombinant O
rabies B
virus I
( I
RABV I
) I
and O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
expressing O
either O
the O
codon O
- O
optimized O
or O
the O
wild B
- I
type I
( I
WT I
) I
HeV O
glycoprotein B
( I
G I
) I
gene O
. O

IMPORTANCE O
Scientists O
have O
been O
tracking O
two O
new O
viruses O
carried O
by O
the O
Pteropid O
fruit O
bats O
: O
Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
. O

In O
this O
study O
, O
we O
performed O
an O
extensive O
comparison O
of O
live O
and O
killed O
particles O
of O
two O
recombinant O
rhabdoviral O
vectors O
, O
rabies O
virus O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
expressing O
wild O
- O
type O
or O
codon O
- O
optimized O
HeV O
glycoprotein O
, O
with O
the O
goal O
of O
developing O
a O
candidate O
vaccine O
against O
HeV O
. O

Previous O
animal O
model O
experiments O
have O
shown O
a O
correlation O
between O
interferon O
gamma O
( O
IFN O
- O
gamma O
) O
expression O
and O
both O
survival O
from O
infection O
with O
attenuated O
rabies B
virus I
( I
RABV I
) I
and O
reduction O
of O
neurological O
sequelae O
. O

Morbidity O
and O
mortality O
were O
monitored O
in O
mice O
infected O
intranasally O
with O
SPBN O
gamma O
or O
SPBN O
( O
- O
) O
control O
virus O
to O
determine O
the O
degree O
of O
attenuation O
caused O
by O
the O
expression O
of O
IFN O
- O
gamma O
. O

SPBN O
has O
a O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
more O
than O
100 O
- O
fold O
greater O
than O
SPBN O
( O
- O
) O
. O

Furthermore O
, O
knockout O
mice O
lacking O
the O
ability O
to O
signal O
through O
the O
type O
I O
interferon O
receptor O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
cannot O
control O
the O
SPBN O
gamma O
infection O
and O
rapidly O
die O
. O

Once O
the O
virus O
reaches O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
this O
becomes O
highly O
problematic O
. O

It O
has O
been O
shown O
that O
enhancement O
of O
blood B
- I
brain I
barrier I
( I
BBB I
) I
permeability O
is O
modulated O
by O
the O
expression O
of O
chemokines O
/ O
cytokines O
and O
reduction O
of O
tight B
junction I
( I
TJ I
) I
proteins O
in O
the O
brains O
of O
mice O
infected O
with O
rabies B
virus I
( I
RABV I
) I
. O

Neutralization O
of O
CXCL10 O
by O
treatment O
with O
anti O
- O
CXCL10 O
antibodies O
reduced O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
and O
Th17 O
cell O
infiltration O
, O
as O
well O
as O
restoring O
TJ O
protein O
expression O
and O
BBB O
integrity O
. O

The O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
core O
viral O
RNA O
polymerase O
comprises O
the O
large O
polymerase O
protein O
( O
L O
) O
and O
its O
cofactor O
, O
the O
phosphoprotein B
( I
P I
) I
, O
which O
associate O
with O
the O
viral O
ribonucleoprotein O
complex O
to O
replicate O
the O
genome O
and O
, O
together O
with O
the O
M2 O
- O
1 O
protein O
, O
transcribe O
viral O
mRNAs O
. O

In O
this O
study O
, O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
- O
tagged O
L O
- O
and O
P O
- O
protein O
expression O
was O
coupled O
with O
high O
- O
affinity O
anti O
- O
GFP O
antibody O
- O
based O
immunoprecipitation O
and O
quantitative O
proteomics O
to O
identify O
cellular O
proteins O
that O
interacted O
with O
either O
the O
L O
- O
or O
the O
P O
- O
proteins O
when O
expressed O
as O
part O
of O
a O
biologically O
active O
viral O
RNP O
. O

IMPORTANCE O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
represents O
a O
major O
health O
care O
and O
economic O
burden O
, O
being O
the O
main O
cause O
of O
severe O
respiratory O
infections O
in O
infants O
worldwide O
. O

In O
particular O
, O
protein O
chaperones O
( O
heat O
shock O
proteins O
70 O
and O
90 O
) O
, O
which O
aid O
protein O
folding O
and O
function O
, O
were O
identified O
. O

Budding O
of O
filoviruses O
, O
arenaviruses O
, O
and O
rhabdoviruses O
is O
facilitated O
by O
subversion O
of O
host O
proteins O
, O
such O
as O
Nedd4 O
E3 O
ubiquitin O
ligase O
, O
by O
viral O
PPxY O
late B
( I
L I
) I
budding O
domains O
expressed O
within O
the O
matrix O
proteins O
of O
these O
RNA O
viruses O
. O

Using O
PPxY O
- O
dependent O
budding O
of O
Marburg B
( I
MARV I
) I
VP40 O
virus B
- I
like I
particles I
( I
VLPs I
) I
as O
our O
model O
system O
, O
we O
identified O
small O
- O
molecule O
hit O
1 O
that O
inhibited O
Nedd4 O
- O
PPxY O
interaction O
and O
PPxY O
- O
dependent O
budding O
. O

This O
lead O
candidate O
was O
subsequently O
improved O
with O
additional O
structure B
- I
activity I
relationship I
( I
SAR I
) I
analog O
testing O
which O
enhanced O
antibudding O
activity O
into O
the O
nanomolar O
range O
. O

In O
addition O
, O
lead O
compounds O
4 O
and O
5 O
exhibited O
antibudding O
activity O
against O
Ebola O
and O
Lassa O
fever O
VLPs O
, O
as O
well O
as O
vesicular O
stomatitis O
and O
rabies O
viruses O
( O
VSV O
and O
RABV O
, O
respectively O
) O
. O

Infection O
with O
laboratory O
- O
attenuated O
rabies B
virus I
( I
RABV I
) I
enhances O
blood B
- I
brain I
barrier I
( I
BBB I
) I
permeability O
, O
which O
has O
been O
demonstrated O
to O
be O
an O
important O
factor O
for O
host O
survival O
, O
since O
it O
allows O
immune O
effectors O
to O
enter O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
clear O
RABV O
. O

To O
probe O
the O
mechanism O
by O
which O
RABV O
infection O
enhances O
BBB O
permeability O
, O
the O
expression O
of O
tight B
junction I
( I
TJ I
) I
proteins O
in O
the O
CNS O
was O
investigated O
following O
intracranial O
inoculation O
with O
laboratory O
- O
attenuated O
or O
wild B
- I
type I
( I
WT I
) I
RABV O
. O

The O
expression O
levels O
of O
TJ O
proteins O
( O
claudin O
- O
5 O
, O
occludin O
, O
and O
zonula O
occludens O
- O
1 O
) O
were O
decreased O
in O
mice O
infected O
with O
laboratory O
- O
attenuated O
, O
but O
not O
wt O
, O
RABV O
, O
suggesting O
that O
enhancement O
of O
BBB O
permeability O
is O
associated O
with O
the O
reduction O
of O
TJ O
protein O
expression O
in O
RABV O
infection O
. O

RABV O
neither O
infects O
the O
brain B
microvascular I
endothelial I
cells I
( I
BMECs I
) I
nor O
modulates O
the O
expression O
of O
TJ O
proteins O
in O
BMECs O
. O

Pathway O
analysis O
indicates O
that O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
located O
in O
the O
center O
of O
the O
cytokine O
network O
in O
the O
RABV O
- O
infected O
mouse O
brain O
, O
and O
neutralization O
of O
IFN O
- O
gamma O
reduced O
both O
the O
disruption O
of O
BBB O
permeability O
in O
vivo O
and O
the O
downregulation O
of O
TJ O
protein O
expression O
in O
vitro O
. O

Interferons B
( I
IFNs I
) I
are O
cytokines O
produced O
by O
host O
cells O
in O
response O
to O
the O
infection O
with O
pathogens O
. O

However O
, O
studies O
of O
type O
I O
IFNs O
have O
mainly O
focused O
on O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
IFN O
- O
beta O
subtypes O
. O

To O
investigate O
the O
potential O
benefits O
which O
may O
arise O
from O
pseudotyping O
the O
HIV O
- O
1 O
lentiviral O
vector O
with O
its O
homologous O
gp41 O
envelope O
glycoprotein B
( I
GP I
) I
cytoplasmic I
tail I
( I
CT I
) I
, O
we O
created O
chimeric O
RVG O
/ O
HIV O
- O
1gp41 O
GPs O
composed O
of O
the O
extracellular O
and O
transmembrane O
sequences O
of O
RVG O
and O
either O
the O
full O
- O
length O
gp41 O
CT O
or O
C O
terminus O
gp41 O
truncations O
sequentially O
removing O
existing O
conserved O
motifs O
. O

Lentiviruses B
( I
LVs I
) I
pseudotyped O
with O
the O
chimeric O
GPs O
were O
evaluated O
in O
terms O
of O
particle O
release O
( O
physical O
titer O
) O
, O
biological O
titers O
, O
infectivity O
, O
and O
in O
vivo O
central B
nervous I
system I
( I
CNS I
) I
transduction O
. O

Removal O
of O
all O
C O
- O
terminal O
gp41 O
CT O
conserved O
motifs O
, O
leaving O
just O
17 O
amino B
acids I
( I
aa I
) I
, O
appeared O
to O
preserve O
infectivity O
and O
resulted O
in O
a O
significantly O
increased O
physical O
titer O
. O

A O
particular O
observation O
was O
the O
improved O
retrograde O
transduction O
of O
neurons O
in O
connected O
distal O
sites O
that O
resulted O
from O
the O
chimeric O
envelope O
R5 O
which O
included O
the O
Kennedy B
sequence I
( I
Ken I
) I
and O
lentivirus B
lytic I
peptide I
2 I
( I
LLP2 I
) I
conserved O
motifs O
in O
the O
CT O
, O
and O
although O
it O
did O
not O
exhibit O
a O
comparable O
high O
titer O
upon O
pseudotyping O
, O
it O
led O
to O
a O
significant O
increase O
in O
distal O
retrograde O
transduction O
of O
neurons O
. O

IMPORTANCE O
In O
this O
study O
, O
we O
have O
produced O
novel O
chimeric O
envelopes O
bearing O
the O
extracellular O
domain O
of O
rabies O
fused O
to O
the O
cytoplasmic B
tail I
( I
CT I
) I
of O
gp41 O
and O
pseudotyped O
lentiviral O
vectors O
with O
them O
. O

rabies B
virus I
( I
RABV I
) I
, O
which O
is O
transmitted O
via O
a O
bite O
wound O
caused O
by O
a O
rabid O
animal O
, O
infects O
peripheral O
nerves O
and O
then O
spreads O
to O
the O
central B
nervous I
system I
( I
CNS I
) I
before O
causing O
severe O
neurological O
symptoms O
and O
death O
in O
the O
infected O
individual O
. O

Despite O
the O
importance O
of O
this O
ability O
of O
the O
virus O
to O
spread O
from O
a O
peripheral O
site O
to O
the O
CNS O
( O
neuroinvasiveness O
) O
in O
the O
pathogenesis O
of O
rabies O
, O
little O
is O
known O
about O
the O
mechanism O
underlying O
the O
neuroinvasiveness O
of O
RABV O
. O

Examination O
of O
a O
series O
of O
chimeric O
viruses O
harboring O
the O
respective O
genes O
from O
Nishigahara O
in O
the O
genetic O
background O
of O
Ni O
- O
CE O
revealed O
that O
the O
Nishigahara O
phosphoprotein B
( I
P I
) I
gene O
plays O
a O
major O
role O
in O
the O
neuroinvasiveness O
by O
mediating O
infection O
of O
peripheral O
nerves O
. O

Further O
investigation O
based O
on O
the O
previous O
finding O
that O
RABV O
phosphoprotein O
counteracts O
the O
host O
interferon B
( I
IFN I
) I
system O
demonstrated O
that O
the O
Nishigahara O
P O
gene O
, O
but O
not O
the O
Ni O
- O
CE O
P O
gene O
, O
functions O
to O
suppress O
expression O
of O
the O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
gene O
( O
Ifn O
- O
beta O
) O
and O
IFN O
- O
stimulated O
genes O
in O
muscle O
cells O
. O

Lettuce B
necrotic I
yellows I
virus I
( I
LNYV I
) I
is O
a O
prototype O
of O
the O
plant O
- O
adapted O
cytorhabdoviruses O
. O

rabies B
virus I
( I
RABV I
) I
maintenance O
in O
bats O
is O
not O
well O
understood O
. O

Big O
brown O
bats O
( O
Eptesicus O
fuscus O
) O
, O
little O
brown O
bats O
( O
Myotis O
lucifugus O
) O
, O
and O
Mexican O
free O
- O
tailed O
bats O
( O
Tadarida O
brasiliensis O
) O
are O
the O
most O
common O
bats O
species O
in O
the O
United O
States O
. O

However O
, O
the O
silver O
- O
haired O
bat O
( O
Lasionycteris O
noctivagans O
) O
RABV O
is O
associated O
with O
the O
majority O
of O
human O
rabies O
virus O
infections O
in O
the O
United O
States O
and O
Canada O
. O

Replication B
- I
deficient I
rabies I
viruses I
( I
RABV I
) I
are O
promising O
rabies O
postexposure O
vaccines O
due O
to O
their O
prompt O
and O
potent O
stimulation O
of O
protective O
virus O
neutralizing O
antibody O
titers O
, O
which O
are O
produced O
in O
mice O
by O
both O
T O
- O
dependent O
and O
T O
- O
independent O
mechanisms O
. O

To O
promote O
such O
early O
and O
robust O
B O
cell O
stimulation O
, O
we O
hypothesized O
that O
live O
RABV O
- O
based O
vaccines O
directly O
infect O
B O
cells O
, O
thereby O
activating O
a O
large O
pool O
of O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
capable O
of O
providing O
early O
priming O
and O
costimulation O
to O
CD4 O
( O
+ O
) O
T O
cells O
. O

Infection O
of O
B O
cells O
resulted O
in O
the O
significant O
upregulation O
of O
early O
markers O
of O
B O
cell O
activation O
and O
antigen O
presentation O
, O
including O
CD69 O
, O
major B
histocompatibility I
complex I
class I
II I
( I
MHC I
- I
II I
) I
, O
and O
CD40 O
in O
murine O
B O
cells O
or O
HLA O
- O
DR O
and O
CD40 O
in O
human O
B O
cells O
compared O
to O
mock O
- O
infected O
cells O
or O
cells O
treated O
with O
an O
inactivated O
RABV O
- O
based O
vaccine O
. O

Furthermore O
, O
primary O
B O
cells O
infected O
with O
a O
live O
RABV O
expressing O
ovalbumin O
were O
able O
to O
prime O
and O
stimulate O
naive O
CD4 O
( O
+ O
) O
OT O
- O
II O
T O
cells O
to O
proliferate O
and O
to O
secrete O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
demonstrating O
a O
functional O
consequence O
of O
B O
cell O
infection O
and O
activation O
by O
live O
RABV O
- O
based O
vaccine O
vectors O
. O

B O
cells O
secreting O
IgG O
antibodies O
, O
but O
not O
IgM O
, O
are O
thought O
to O
be O
solely O
responsible O
for O
vaccine O
- O
induced O
protection O
against O
rabies B
virus I
( I
RABV I
) I
infections O
in O
postexposure O
settings O
. O

Immunocompetent O
mice O
immunized O
with O
an O
experimental O
live O
replication O
- O
deficient O
RABV O
- O
based O
vaccine O
produced O
virus O
neutralizing O
antibodies O
( O
VNAs O
) O
within O
3 O
days O
of O
vaccination O
. O

However O
, O
mice O
unable O
to O
produce O
soluble O
IgM O
( O
sIgM O
( O
- O
/ O
- O
) O
) O
did O
not O
produce O
VNAs O
until O
7 O
days O
postimmunization O
. O

Furthermore O
, O
sIgM O
( O
- O
/ O
- O
) O
mice O
were O
not O
protected O
against O
RABV O
infection O
when O
challenged O
3 O
days O
postimmunization O
, O
while O
all O
wild O
- O
type O
mice O
survived O
challenge O
. O

Consistent O
with O
the O
lack O
of O
protection O
against O
pathogenic O
RABV O
challenge O
, O
approximately O
50 O
- O
to O
100 O
- O
fold O
higher O
viral O
loads O
of O
challenge O
virus O
were O
detected O
in O
the O
muscle O
, O
spinal O
cord O
, O
and O
brain O
of O
immunized O
sIgM O
( O
- O
/ O
- O
) O
mice O
compared O
to O
control O
mice O
. O

In O
addition O
, O
IgG O
antibody O
titers O
in O
vaccinated O
wild O
- O
type O
and O
sIgM O
( O
- O
/ O
- O
) O
mice O
were O
similar O
at O
all O
time O
points O
postimmunization O
, O
suggesting O
that O
protection O
against O
RABV O
challenge O
is O
due O
to O
the O
direct O
effects O
of O
IgM O
and O
not O
the O
influence O
of O
IgM O
on O
the O
development O
of O
effective O
IgG O
antibody O
titers O
. O

Immune O
evasion O
by O
rabies O
virus O
depends O
on O
targeting O
of O
the O
signal B
transducers I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
and O
STAT2 O
proteins O
by O
the O
viral O
interferon O
antagonist O
P O
protein O
, O
but O
targeting O
of O
other O
STAT O
proteins O
has O
not O
been O
investigated O
. O

Here O
, O
we O
investigated O
the O
expression O
, O
cellular O
localization O
, O
and O
function O
of O
neuronal O
CCT O
gamma O
during O
neurotropic O
rabies B
virus I
( I
RABV I
) I
infection O
using O
mouse O
N2a O
cells O
as O
a O
model O
. O

In O
mouse O
N2a O
cells O
infected O
with O
RABV O
or O
cotransfected O
with O
RABV O
genes O
encoding O
nucleoprotein B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
, O
confocal O
microscopy O
demonstrated O
that O
upregulated O
cellular O
CCT O
gamma O
was O
colocalized O
with O
viral O
proteins O
N O
and O
P O
, O
which O
formed O
a O
hollow O
cricoid O
inclusion O
within O
the O
region O
around O
the O
nucleus O
. O

These O
inclusions O
, O
which O
correspond O
to O
Negri B
bodies I
( I
NBs I
) I
, O
did O
not O
form O
in O
mouse O
N2a O
cells O
only O
expressing O
the O
viral O
protein O
N O
or O
P O
. O

However O
, O
the O
mechanism O
by O
which O
the O
inflammasome O
recognizes O
RNA O
viruses O
and O
its O
role O
in O
rabies B
virus I
( I
RABV I
) I
pathogenicity O
and O
immunogenicity O
remain O
poorly O
defined O
. O

To O
determine O
the O
function O
of O
the O
inflammasome O
in O
response O
to O
RABV O
infection O
, O
we O
infected O
murine O
bone B
marrow I
- I
derived I
dendritic I
cells I
( I
BMDCs I
) I
with O
RABV O
. O

Our O
results O
indicate O
that O
the O
infection O
of O
BMDCs O
with O
RABV O
induces O
both O
the O
production O
of O
pro O
- O
interleukin O
- O
1 O
beta O
( O
pro O
- O
IL O
- O
1 O
beta O
) O
and O
its O
processing O
, O
resulting O
in O
the O
secretion O
of O
active O
IL O
- O
1 O
beta O
through O
activation O
of O
the O
NLRP3 O
- O
, O
ASC O
- O
, O
and O
caspase O
- O
1 O
- O
dependent O
inflammasome O
. O

Untreated O
rabies B
virus I
( I
RABV I
) I
infection O
leads O
to O
death O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
is O
thought O
to O
contribute O
to O
kennel O
cough O
, O
and O
kennel O
cough O
vaccines O
containing O
live O
PIV5 O
have O
been O
used O
in O
dogs O
for O
many O
years O
. O

A O
recombinant O
PIV5 O
encoding O
RABV O
glycoprotein B
( I
G I
) I
( O
rPIV5 O
- O
RV O
- O
G O
) O
was O
administered O
to O
mice O
via O
intranasal O
( O
i O
. O

The O
vaccinated O
mice O
were O
challenged O
with O
a O
50 O
% O
lethal O
challenge O
dose O
( O
LD50 O
) O
of O
RABV O
challenge O
virus O
standard O
24 O
( O
CVS O
- O
24 O
) O
intracerebrally O
. O

A O
single O
dose O
of O
10 O
( O
6 O
) O
PFU O
of O
rPIV5 O
- O
RV O
- O
G O
was O
sufficient O
for O
100 O
% O
protection O
when O
administered O
via O
the O
i O
. O

The O
mice O
vaccinated O
with O
a O
single O
dose O
of O
10 O
( O
8 O
) O
PFU O
of O
rPIV5 O
- O
RV O
- O
G O
via O
the O
i O
. O

route O
showed O
very O
robust O
protection O
( O
90 O
% O
to O
100 O
% O
) O
. O

Intriguingly O
, O
the O
mice O
vaccinated O
orally O
with O
a O
single O
dose O
of O
10 O
( O
8 O
) O
PFU O
of O
rPIV5 O
- O
RV O
- O
G O
showed O
a O
50 O
% O
survival O
rate O
, O
which O
is O
comparable O
to O
the O
60 O
% O
survival O
rate O
among O
mice O
inoculated O
with O
an O
attenuated O
rabies O
vaccine O
strain O
, O
recombinant O
LBNSE O
. O

The O
present O
study O
describes O
the O
generation O
of O
a O
new O
Orf B
virus I
( I
ORFV I
) I
recombinant O
, O
D1701 O
- O
V O
- O
RabG O
, O
expressing O
the O
rabies B
virus I
( I
RABV I
) I
glycoprotein O
that O
is O
correctly O
presented O
on O
the O
surface O
of O
infected O
cells O
without O
the O
need O
of O
replication O
or O
production O
of O
infectious O
recombinant O
virus O
. O

One O
single O
immunization O
with O
recombinant O
ORFV O
can O
stimulate O
high O
RABV O
- O
specific O
virus B
- I
neutralizing I
antibody I
( I
VNA I
) I
titers O
in O
mice O
, O
cats O
, O
and O
dogs O
, O
representing O
all O
nonpermissive O
hosts O
for O
the O
ORFV O
vector O
. O

Single O
applications O
of O
higher O
doses O
( O
10 O
( O
7 O
) O
PFU O
) O
can O
be O
sufficient O
to O
confer O
complete O
protection O
against O
intracranial O
( O
i O
. O

A O
single O
intramuscular O
application O
of O
the O
live O
but O
not O
UV O
- O
inactivated O
recombinant O
rabies B
virus I
( I
RABV I
) I
variant O
TriGAS O
in O
mice O
induces O
the O
robust O
and O
sustained O
production O
of O
RABV O
- O
neutralizing O
antibodies O
that O
correlate O
with O
long O
- O
term O
protection O
against O
challenge O
with O
an O
otherwise O
lethal O
dose O
of O
the O
wild O
- O
type O
RABV O
. O

To O
obtain O
insight O
into O
the O
mechanism O
by O
which O
live O
TriGAS O
induces O
long O
- O
lasting O
protective O
immunity O
, O
quantitative B
PCR I
( I
qPCR I
) I
analysis O
of O
muscle O
tissue O
, O
draining O
lymph O
nodes O
, O
spleen O
, O
spinal O
cord O
, O
and O
brain O
at O
different O
times O
after O
TriGAS O
inoculation O
revealed O
the O
presence O
of O
significant O
copy O
numbers O
of O
RABV O
- O
specific O
RNA O
in O
muscle O
, O
lymph O
node O
, O
and O
to O
a O
lesser O
extent O
, O
spleen O
for O
several O
days O
postinfection O
. O

Comparison O
of O
genomic O
RNA O
and O
mRNA O
obtained O
from O
isolated O
lymph O
node O
cells O
showed O
the O
highest O
mRNA O
- O
to O
- O
genomic O
- O
RNA O
ratios O
in O
B O
cells O
and O
dendritic B
cells I
( I
DCs I
) I
, O
suggesting O
that O
these O
cells O
represent O
the O
major O
cell O
population O
that O
is O
infected O
in O
the O
lymph O
node O
. O

The O
relationship O
between O
bats O
and O
Coronaviruses B
( I
CoVs I
) I
has O
received O
considerable O
attention O
since O
the O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
like O
CoV O
was O
identified O
in O
the O
Chinese O
horseshoe O
bat O
( O
Rhinolophidae O
) O
in O
2005 O
. O

Here O
, O
we O
show O
by O
molecular O
clock O
analysis O
that O
alphacoronavirus B
( I
alpha I
- I
CoV I
) I
sequences O
derived O
from O
the O
North O
American O
tricolored O
bat O
( O
Perimyotis O
subflavus O
) O
are O
predicted O
to O
share O
common O
ancestry O
with O
human O
CoV O
( O
HCoV O
) O
- O
NL63 O
, O
with O
the O
most O
recent O
common O
ancestor O
between O
these O
viruses O
occurring O
approximately O
563 O
to O
822 O
years O
ago O
. O

While O
SARS O
- O
CoV O
, O
mouse B
- I
adapted I
SARS I
- I
CoV I
( I
MA15 I
) I
, O
and O
chimeric O
SARS O
- O
CoVs O
bearing O
the O
spike O
genes O
of O
early O
human O
strains O
replicated O
inefficiently O
, O
HCoV O
- O
NL63 O
replicated O
for O
multiple O
passages O
in O
the O
immortalized O
lung O
cells O
from O
this O
bat O
species O
. O

Given O
the O
parasitic O
nature O
of O
viruses O
, O
it O
is O
sometimes O
assumed O
that O
rates O
of O
viral O
replication O
and O
dissemination O
within O
hosts O
( O
within O
- O
host O
fitness O
) O
correlate O
with O
virulence O
. O

To O
test O
this O
, O
we O
quantified O
the O
fitness O
and O
virulence O
of O
21 O
single O
- O
or O
double O
- O
nucleotide O
mutants O
of O
the O
vesicular O
stomatitis O
virus O
in O
Baby B
Hamster I
Kidney I
cells I
( I
BHK I
- I
21 I
) I
. O

Particularly O
, O
a O
single O
mutation O
in O
the O
conserved O
C O
terminus O
of O
the O
N O
nucleocapsid O
( O
U1323A O
) O
had O
a O
strongly O
deleterious O
fitness O
effect O
but O
did O
not O
alter O
or O
even O
slightly O
increased O
virulence O
. O

We O
also O
found O
a O
double O
mutant O
of O
the O
M O
matrix O
protein O
and O
G O
glycoprotein O
( O
U2617G O
/ O
A3802G O
mutant O
) O
with O
high O
fitness O
yet O
low O
virulence O
. O

A O
major O
goal O
in O
rabies B
virus I
( I
RV I
) I
research O
is O
to O
develop O
a O
single O
- O
dose O
postexposure B
prophylaxis I
( I
PEP I
) I
that O
would O
simplify O
vaccination O
protocols O
, O
reduce O
costs O
associated O
with O
rabies O
prevention O
in O
humans O
, O
and O
save O
lives O
. O

Typically O
, O
vaccines O
induce O
B O
cells O
secreting O
high O
- O
affinity O
, O
class O
- O
switched O
antibodies O
during O
germinal B
center I
( I
GC I
) I
reactions O
; O
however O
, O
there O
is O
a O
lag O
time O
between O
vaccination O
and O
the O
generation O
of O
GC O
B O
cells O
. O

In O
this O
report O
, O
we O
show O
that O
RV O
- O
specific O
antibodies O
are O
detected O
in O
mice O
immunized O
with O
live O
but O
not O
inactivated O
RV O
- O
based O
vaccines O
before O
B O
cells O
displaying O
a O
GC O
B O
cell O
phenotype O
( O
B220 O
( O
+ O
) O
GL7 O
( O
hi O
) O
CD95 O
( O
hi O
) O
) O
are O
formed O
, O
indicating O
a O
potential O
role O
for O
T O
cell O
- O
independent O
and O
early O
extrafollicular O
T O
cell O
- O
dependent O
antibody O
responses O
in O
the O
protection O
against O
RV O
infection O
. O

Using O
two O
mouse O
models O
of O
CD4 O
( O
+ O
) O
T O
cell O
deficiency O
, O
we O
show O
that O
B O
cells O
secreting O
virus B
- I
neutralizing I
antibodies I
( I
VNAs I
) I
are O
induced O
via O
T O
cell O
- O
independent O
mechanisms O
within O
4 O
days O
postimmunization O
with O
a O
replication O
- O
deficient O
RV O
- O
based O
vaccine O
. O

129P2 O
- O
Tcr O
beta O
( O
tm1Mom O
) O
Tcr O
delta O
( O
tm1Mom O
) O
/ O
J O
) O
show O
protection O
against O
pathogenic O
challenge O
shortly O
after O
immunization O
with O
a O
live O
replication O
- O
deficient O
RV O
- O
based O
vaccine O
. O

A O
virulent O
rabies B
virus I
( I
RABV I
) I
strain O
, O
GD O
- O
SH O
- O
01 O
, O
was O
isolated O
from O
brain O
tissue O
of O
a O
rabid O
pig O
in O
China O
. O

A O
rabies B
virus I
( I
RABV I
) I
was O
isolated O
from O
a O
dog O
in O
Anhui O
Province O
, O
China O
, O
in O
2008 O
. O

Its O
entire O
genome O
was O
sequenced O
and O
found O
to O
be O
closely O
related O
to O
RABV O
recently O
isolated O
in O
China O
and O
other O
Asian O
countries O
( O
homology O
of O
87 O
to O
98 O
% O
) O
but O
distantly O
related O
to O
RABV O
in O
the O
cosmopolitan O
group O
( O
homology O
of O
84 O
to O
85 O
% O
) O
in O
the O
clade O
I O
of O
RABV O
. O

A O
canine O
rabies B
virus I
( I
RABV I
) I
has O
been O
used O
as O
a O
street O
rabies O
virus O
in O
laboratory O
investigations O
. O

Sequence O
comparison O
indicates O
that O
the O
virus O
is O
closely O
related O
to O
those O
in O
the O
cosmopolitan O
group O
, O
with O
high O
homology O
( O
89 O
to O
93 O
% O
) O
to O
clade O
I O
of O
rabies O
viruses O
. O

The O
virus O
is O
now O
termed O
dog O
rabies O
virus O
- O
Mexico O
( O
DRV O
- O
Mexico O
) O
. O

The O
evasion O
of O
host O
innate O
immunity O
by O
Rabies O
virus O
, O
the O
prototype O
of O
the O
genus O
Lyssavirus O
, O
depends O
on O
a O
unique O
mechanism O
of O
selective O
targeting O
of O
interferon O
- O
activated O
STAT O
proteins O
by O
the O
viral O
phosphoprotein O
( O
P O
- O
protein O
) O
. O

Lyssaviruses O
( O
family O
Rhabdoviridae O
) O
constitute O
one O
of O
the O
most O
important O
groups O
of O
viral O
zoonoses O
globally O
. O

Using O
next O
- O
generation O
sequencing O
technologies O
, O
we O
have O
obtained O
the O
whole O
- O
genome O
sequence O
for O
a O
novel O
lyssavirus O
, O
Ikoma B
lyssavirus I
( I
IKOV I
) I
, O
isolated O
from O
an O
African O
civet O
in O
Tanzania O
displaying O
clinical O
signs O
of O
rabies O
. O

Cultured O
adult O
rat O
dorsal B
root I
ganglion I
( I
DRG I
) I
neurons O
infected O
with O
the O
challenge O
virus O
standard O
- O
11 O
strain O
of O
rabies O
virus O
( O
CVS O
) O
showed O
axonal O
swellings O
and O
immunostaining O
for O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( I
4 I
- I
HNE I
) I
, O
indicating O
evidence O
of O
lipid O
peroxidation O
associated O
with O
oxidative O
stress O
and O
reduced O
axonal O
growth O
compared O
to O
that O
of O
mock O
- O
infected O
DRG O
neurons O
. O

We O
have O
evaluated O
whether O
nuclear B
factor I
( I
NF I
) I
- O
kappa O
B O
might O
act O
as O
a O
critical O
bridge O
linking O
CVS O
infection O
and O
oxidative O
stress O
. O

Tacaribe B
virus I
( I
TCRV I
) I
was O
first O
isolated O
from O
11 O
Artibeus O
species O
bats O
captured O
in O
Trinidad O
in O
the O
1950s O
during O
a O
rabies O
virus O
surveillance O
program O
. O

To O
examine O
this O
hypothesis O
, O
we O
conducted O
experimental O
infections O
of O
Jamaican O
fruit O
bats O
( O
Artibeus O
jamaicensis O
) O
to O
determine O
whether O
they O
could O
be O
persistently O
infected O
without O
substantial O
pathology O
. O

We O
subcutaneously O
or O
intranasally O
infected O
bats O
with O
TCRV O
strain O
TRVL O
- O
11573 O
, O
the O
only O
remaining O
strain O
of O
TCRV O
, O
and O
found O
that O
low O
- O
dose O
( O
10 O
( O
4 O
) O
50 O
% O
tissue O
culture O
infective O
dose O
[ O
TCID50 O
] O
) O
inoculations O
resulted O
in O
asymptomatic O
and O
apathogenic O
infection O
and O
virus O
clearance O
, O
while O
high O
- O
dose O
( O
10 O
( O
6 O
) O
TCID50 O
) O
inoculations O
caused O
substantial O
morbidity O
and O
mortality O
as O
early O
as O
10 O
days O
postinfection O
. O

These O
results O
indicate O
that O
Hsp70 O
has O
a O
proviral O
function O
during O
rabies O
virus O
infection O
and O
suggest O
that O
Hsp70 O
is O
involved O
in O
at O
least O
one O
stage O
( O
s O
) O
of O
the O
viral O
life O
cycle O
, O
such O
as O
viral O
transcription O
, O
translation O
, O
and O
/ O
or O
production O
. O

Surveys O
were O
carried O
out O
to O
better O
understand O
the O
tick O
vector O
ecology O
and O
genetic O
diversity O
of O
Huaiyangshan B
virus I
( I
HYSV I
) I
in O
both O
regions O
of O
endemicity O
and O
regions O
of O
nonendemicity O
. O

Postexposure B
treatment I
( I
PET I
) I
of O
wild O
- O
type O
rabies B
virus I
( I
RV I
) I
- O
infected O
mice O
with O
a O
live O
- O
attenuated O
triple B
- I
glycoprotein I
RV I
variant I
( I
TriGAS I
) I
promotes O
survival O
but O
does O
not O
prevent O
the O
pathogenic O
RV O
from O
invading O
and O
replicating O
in O
the O
brain O
. O

Comparison O
of O
the O
transcriptomes O
of O
normal O
mouse O
brain O
with O
those O
of O
wild O
- O
type O
- O
RV O
- O
infected O
mice O
that O
had O
received O
either O
mock O
or O
TriGAS O
PET O
treatment O
revealed O
that O
many O
of O
the O
host O
genes O
activated O
in O
the O
mock O
- O
treated O
mice O
represent O
type B
I I
interferon I
( I
IFN I
) I
response O
genes O
. O

These O
findings O
were O
confirmed O
by O
quantitative B
PCR I
( I
qPCR I
) I
array O
studies O
, O
which O
showed O
that O
3 O
genes O
in O
particular O
, O
encoding O
chemokine B
ligand I
3 I
( I
Ccl3 I
) I
, O
natural O
killer O
cell O
activator O
2 O
( O
interleukin O
12B O
[ O
IL O
- O
12B O
] O
) O
, O
and O
granzyme B
A I
( I
gzmA I
) I
, O
were O
activated O
earlier O
and O
to O
a O
greater O
extent O
in O
the O
brains O
of O
RV O
- O
infected O
mice O
treated O
with O
TriGAS O
than O
in O
the O
brains O
of O
mock O
- O
treated O
mice O
. O

We O
have O
developed O
( O
i O
) O
replication O
- O
competent O
, O
( O
ii O
) O
replication O
- O
deficient O
, O
and O
( O
iii O
) O
chemically O
inactivated O
rabies B
virus I
( I
RABV I
) I
vaccines O
expressing O
Zaire B
Ebola I
virus I
( I
ZEBOV I
) I
glycoprotein I
( I
GP I
) I
by O
a O
reverse O
genetics O
system O
based O
on O
the O
SAD O
B19 O
RABV O
wildlife O
vaccine O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
has O
shown O
promise O
as O
a O
vaccine O
vector O
for O
mammals O
. O

Here O
, O
we O
generated O
a O
recombinant O
avirulent O
NDV O
La O
Sota O
strain O
expressing O
the O
Rabies B
virus I
glycoprotein I
( I
RVG I
) I
and O
evaluated O
its O
potential O
to O
serve O
as O
a O
vaccine O
against O
rabies O
. O

8 O
) O
50 B
% I
egg I
infective I
doses I
( I
EID50 I
) I
/ O
ml O
of O
allantoic O
fluid O
. O

Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
is O
an O
important O
fish O
pathogen O
that O
infects O
both O
wild O
and O
cultured O
salmonids O
. O

In O
this O
study O
, O
quantum B
dots I
( I
QDs I
) I
were O
used O
as O
fluorescent O
labels O
for O
sensitive O
, O
long O
- O
term O
tracking O
of O
IHNV O
entry O
. O

Pretreatment O
of O
host O
cells O
with O
chlorpromazine O
, O
a O
drug O
that O
blocks O
clathrin O
- O
mediated O
endocytosis O
, O
and O
clathrin O
light B
chain I
( I
LCa I
) I
depletion O
using O
RNA O
interference O
both O
resulted O
in O
a O
marked O
reduction O
in O
viral O
entry O
. O

The O
NS1 O
protein O
of O
human O
influenza O
A O
viruses O
binds O
the O
30 O
- O
kDa O
subunit O
of O
the O
cleavage B
and I
polyadenylation I
specificity I
factor I
( I
CPSF30 I
) I
, O
a O
protein O
required O
for O
3 O
' O
end O
processing O
of O
cellular O
pre O
- O
mRNAs O
, O
thereby O
inhibiting O
production O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
mRNA O
. O

The O
neurotropic O
rabies B
virus I
( I
RABV I
) I
has O
developed O
several O
evasive O
strategies O
, O
including O
immunoevasion O
, O
to O
successfully O
infect O
the O
nervous B
system I
( I
NS I
) I
and O
trigger O
a O
fatal O
encephalomyelitis O
. O

We O
used O
a O
new O
transgenic O
mouse O
model O
( O
LGP2 O
TG O
) O
overexpressing O
LGP2 O
to O
impair O
the O
innate O
immune O
response O
to O
RABV O
and O
thus O
revealed O
the O
role O
of O
the O
RIG O
- O
I O
- O
mediated O
innate O
immune O
response O
in O
RABV O
pathogenesis O
. O

After O
infection O
, O
LGP2 O
TG O
mice O
exhibited O
reduced O
expression O
of O
inflammatory O
/ O
chemoattractive O
molecules O
, O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
, O
and O
IFN O
- O
stimulated O
genes O
in O
their O
NS O
compared O
to O
wild B
- I
type I
( I
WT I
) I
mice O
, O
demonstrating O
the O
inhibitory O
function O
of O
LGP2 O
in O
the O
innate O
immune O
response O
to O
RABV O
. O

LGP2 O
TG O
mice O
exhibited O
similar O
neutralizing O
antibodies O
and O
microglia O
activation O
to O
those O
of O
WT O
mice O
but O
showed O
a O
reduction O
of O
infiltrating O
CD4 O
( O
+ O
) O
T O
cells O
and O
less O
disappearance O
of O
infiltrating O
CD8 O
( O
+ O
) O
T O
cells O
. O

This O
occurred O
concomitantly O
with O
reduced O
neural O
expression O
of O
the O
IFN O
- O
inducible O
protein O
B7 O
- O
H1 O
, O
an O
immunoevasive O
protein O
involved O
in O
the O
elimination O
of O
infiltrated O
CD8 O
( O
+ O
) O
T O
cells O
. O

Our O
study O
shows O
that O
the O
host O
innate O
immune O
response O
favors O
the O
infiltration O
of O
T O
cells O
and O
, O
at O
the O
same O
time O
, O
promotes O
CD8 O
( O
+ O
) O
T O
cell O
elimination O
. O

Our O
previous O
studies O
indicated O
that O
recruitment O
and O
/ O
or O
activation O
of O
dendritic B
cells I
( I
DCs I
) I
is O
important O
in O
enhancing O
the O
protective O
immune O
responses O
against O
rabies B
virus I
( I
RABV I
) I
( O
L O
. O

, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
GM I
- I
CSF I
) I
, O
macrophage B
- I
derived I
chemokine I
( I
MDC I
) I
, O
and O
macrophage B
inflammatory I
protein I
1 I
alpha I
( I
MIP I
- I
1 I
alpha I
) I
, O
were O
individually O
cloned O
into O
RABV O
. O

Infection O
of O
mouse O
bone O
marrow O
- O
derived O
DCs O
with O
each O
of O
the O
recombinant O
viruses O
resulted O
in O
DC O
activation O
, O
as O
shown O
by O
increased O
surface O
expression O
of O
CD11c O
and O
CD86 O
as O
well O
as O
an O
increased O
level O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
production O
compared O
to O
levels O
observed O
after O
infection O
with O
the O
parent O
virus O
. O

Yet O
, O
these O
viruses O
did O
not O
show O
more O
virulence O
than O
the O
parent O
virus O
, O
since O
direct O
intracerebral O
inoculation O
with O
each O
virus O
at O
up O
to O
1 O
x O
10 O
( O
7 O
) O
fluorescent O
focus O
units O
each O
did O
not O
induce O
any O
overt O
clinic O
symptom O
, O
such O
as O
abnormal O
behavior O
, O
or O
any O
neurological O
signs O
. O

Previous O
comparisons O
of O
different O
rabies B
virus I
( I
RV I
) I
strains O
suggested O
an O
inverse O
relationship O
between O
pathogenicity O
and O
the O
amount O
of O
glycoprotein O
produced O
in O
infected O
cells O
. O

The O
rabies B
virus I
( I
RV I
) I
phosphoprotein I
( I
P I
) I
is O
a O
type B
I I
interferon I
( I
IFN I
) I
antagonist O
preventing O
both O
transcriptional O
induction O
of O
IFN O
and O
IFN O
- O
mediated O
JAK O
/ O
STAT O
signaling O
. O

Phosphoproteins O
lacking O
amino B
acids I
( I
aa I
) I
176 O
to O
181 O
, O
182 O
to O
186 O
, O
or O
176 O
to O
186 O
were O
severely O
compromised O
in O
counteracting O
phosphorylation O
of O
IRF3 O
and O
IRF7 O
by O
TBK1 O
or O
IKKi O
while O
retaining O
the O
full O
capacity O
of O
preventing O
nuclear O
import O
of O
activated O
STATs O
and O
of O
supporting O
virus O
transcription O
and O
replication O
. O

Recombinant O
RV O
carrying O
the O
mutated O
phosphoproteins O
( O
the O
SAD O
Delta O
Ind1 O
, O
SAD O
Delta O
Ind2 O
, O
and O
SAD O
Delta O
Ind1 O
/ O
2 O
viruses O
) O
activated O
IRF3 O
and O
beta O
IFN O
( O
IFN O
- O
beta O
) O
transcription O
in O
infected O
cells O
but O
still O
blocked O
STAT O
- O
mediated O
expression O
of O
IFN O
- O
stimulated O
genes O
. O

After O
intracerebral O
injection O
into O
mouse O
brains O
at O
high O
doses O
, O
the O
SAD O
Delta O
Ind1 O
virus O
was O
completely O
apathogenic O
for O
wild B
- I
type I
( I
WT I
) I
mice O
, O
while O
the O
SAD O
Delta O
Ind2 O
virus O
was O
partially O
attenuated O
and O
caused O
a O
slower O
progression O
of O
lethal O
rabies O
than O
wt O
RV O
. O

Matrix O
proteins O
( O
M O
) O
direct O
the O
process O
of O
assembly O
and O
budding O
of O
viruses O
belonging O
to O
the O
Mononegavirales O
order O
. O

Using O
the O
two O
- O
hybrid O
system O
, O
the O
amino O
- O
terminal O
part O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
M O
was O
shown O
to O
interact O
with O
dynamin O
pleckstrin O
homology O
domain O
. O

A O
role O
for O
dynamin O
in O
the O
viral O
cycle O
( O
in O
addition O
to O
its O
role O
in O
virion O
endocytosis O
) O
was O
suggested O
by O
the O
fact O
that O
a O
late O
stage O
of O
the O
viral O
cycle O
was O
sensitive O
to O
dynasore O
. O

The O
lyssavirus O
matrix B
( I
M I
) I
protein O
induces O
apoptosis O
. O

We O
therefore O
compared O
the O
M O
proteins O
from O
two O
viruses O
that O
have O
contrasting O
characteristics O
in O
terms O
of O
cellular O
apoptosis O
: O
a O
genotype O
3 O
lyssavirus O
, O
Mokola B
virus I
( I
MOK I
) I
, O
and O
a O
genotype O
1 O
rabies O
virus O
isolated O
from O
a O
dog O
from O
Thailand B
( I
THA I
) I
. O

We O
identified O
a O
20 O
- O
amino O
- O
acid O
fragment O
( O
corresponding O
to O
positions O
67 O
to O
86 O
) O
that O
retained O
the O
cell O
death O
activities O
of O
the O
full O
- O
length O
M O
protein O
from O
MOK O
via O
both O
the O
tumor B
necrosis I
factor I
- I
related I
apoptosis I
- I
inducing I
ligand I
( I
TRAIL I
) I
and O
inhibition O
of O
cytochrome B
c I
oxidase I
( I
CcO I
) I
activity O
. O

Various O
reports O
implicate O
PML O
and O
PML O
nuclear B
bodies I
( I
NBs I
) I
in O
an O
intrinsic O
antiviral O
response O
targeting O
diverse O
cytoplasmic O
replicating O
RNA O
viruses O
. O

PML O
conjugation O
to O
the O
small B
ubiquitin I
- I
like I
modifier I
( I
SUMO I
) I
is O
required O
for O
its O
localization O
within O
NBs O
. O

PML O
displays O
antiviral O
effects O
in O
vivo O
, O
as O
PML O
deficiency O
renders O
mice O
more O
susceptible O
to O
infection O
with O
the O
rhabdovirus O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

However O
, O
the O
expression O
of O
other O
nuclear O
isoforms O
( O
PMLI O
to O
- O
VI O
) O
and O
cytoplasmic O
PMLVIIb O
failed O
to O
impair O
viral O
production O
. O

Previously O
, O
we O
showed O
that O
overexpression O
of O
MIP O
- O
1 O
alpha O
in O
mouse O
brain O
further O
decreased O
rabies B
virus I
( I
RABV I
) I
pathogenicity O
( O
L O
. O

In O
the O
present O
study O
, O
the O
immunogenicity O
of O
recombinant O
RABV O
expressing O
MIP O
- O
1 O
alpha O
( O
rHEP O
- O
MIP1 O
alpha O
) O
was O
determined O
. O

It O
was O
found O
that O
intramuscular O
immunization O
of O
BALB O
/ O
c O
mice O
with O
rHEP O
- O
MIP1 O
alpha O
resulted O
in O
a O
higher O
level O
of O
expression O
of O
MIP O
- O
1 O
alpha O
at O
the O
site O
of O
inoculation O
, O
increased O
recruitment O
of O
dendritic B
cells I
( I
DCs I
) I
and O
mature O
B O
cells O
into O
the O
draining O
lymph O
nodes O
and O
the O
peripheral O
blood O
, O
and O
higher O
virus O
- O
neutralizing O
antibody O
titers O
than O
immunization O
with O
the O
parent O
rHEP O
and O
recombinant O
RABVs O
expressing O
RANTES O
( O
CCL5 O
) O
or O
IP O
- O
10 O
( O
CXCL10 O
) O
. O

The O
molecular O
mechanisms O
associated O
with O
rabies B
virus I
( I
RV I
) I
virulence O
are O
not O
fully O
understood O
. O

In O
this O
study O
, O
the O
RV O
Flury O
low B
- I
egg I
- I
passage I
( I
LEP I
) I
and O
high B
- I
egg I
- I
passage I
( I
HEP I
) I
strains O
were O
used O
as O
models O
to O
explore O
the O
attenuation O
mechanism O
of O
RV O
. O

The O
results O
of O
our O
studies O
confirmed O
that O
the O
R333Q O
mutation O
in O
the O
glycoprotein O
( O
G O
( O
R333Q O
) O
) O
is O
crucial O
for O
the O
attenuation O
of O
Flury O
RV O
in O
mice O
. O

Further O
investigation O
using O
chimeric O
viruses O
revealed O
that O
the O
polymerase O
L O
gene O
determines O
the O
genetic O
stability O
of O
the O
G O
( O
R333Q O
) O
mutation O
during O
replication O
. O

Viral O
vectors O
based O
on O
influenza O
virus O
, O
rabies B
virus I
( I
RV I
) I
, O
and O
vaccinia B
virus I
( I
VV I
) I
were O
used O
to O
express O
large O
polypeptide O
segments O
derived O
from O
the O
Bacillus O
anthracis O
protective B
antigen I
( I
PA I
) I
. O

For O
the O
infectious O
influenza O
virus O
vector O
and O
recombinant O
VV O
constructs O
, O
the O
receptor O
binding O
domain O
( O
RBD O
or O
domain O
4 O
) O
or O
the O
lethal O
and O
edema O
factor O
binding O
domain O
( O
LEF O
or O
domain O
1 O
' O
) O
were O
engineered O
into O
functional O
chimeric O
Hemagglutinin B
( I
HA I
) I
glycoproteins O
. O

In O
the O
case O
of O
the O
RV O
vector O
, O
the O
viral O
glycoprotein B
( I
G I
) I
was O
used O
as O
a O
carrier O
for O
RBD O
in O
an O
inactivated O
form O
of O
the O
vector O
. O

The O
fixed O
rabies B
virus I
( I
RV I
) I
strain O
Nishigahara O
kills O
adult O
mice O
after O
intracerebral O
inoculation O
, O
whereas O
the O
chicken O
embryo O
fibroblast O
cell O
- O
adapted O
strain O
Ni O
- O
CE O
causes O
nonlethal O
infection O
in O
adult O
mice O
. O

We O
previously O
reported O
that O
the O
chimeric O
CE O
( O
NiP O
) O
strain O
, O
which O
has O
the O
phosphoprotein B
( I
P I
protein I
) I
gene O
from O
the O
Nishigahara O
strain O
in O
the O
genetic O
background O
of O
the O
Ni O
- O
CE O
strain O
, O
causes O
lethal O
infection O
in O
adult O
mice O
, O
indicating O
that O
the O
P O
gene O
is O
responsible O
for O
the O
different O
pathogenicities O
of O
the O
Nishigahara O
and O
Ni O
- O
CE O
strains O
. O

Previous O
studies O
demonstrated O
that O
RV O
P O
protein O
binds O
to O
the O
interferon B
( I
IFN I
) I
- O
activated O
transcription O
factor O
STAT1 O
and O
blocks O
IFN O
signaling O
by O
preventing O
its O
translocation O
to O
the O
nucleus O
. O

Rabies O
virus O
infection O
of O
dorsal B
root I
ganglia I
( I
DRG I
) I
was O
studied O
in O
vitro O
with O
cultured O
adult O
mouse O
DRG O
neurons O
. O

Recent O
in O
vivo O
studies O
of O
transgenic O
mice O
that O
express O
the O
yellow O
fluorescent O
protein O
indicate O
that O
neuronal O
process O
degeneration O
, O
involving O
both O
dendrites O
and O
axons O
, O
occurs O
in O
mice O
infected O
with O
the O
challenge B
virus I
standard I
( I
CVS I
) I
strain O
of O
rabies O
virus O
by O
footpad O
inoculation O
. O

Immunostaining O
was O
evaluated O
with O
CVS O
- O
and O
mock O
- O
infected O
cultures O
for O
neuron O
specific O
beta O
- O
tubulin O
, O
rabies O
virus O
antigen O
, O
and O
amino O
acid O
adducts O
of O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( I
4 I
- I
HNE I
) I
( O
marker O
of O
lipid O
peroxidation O
and O
hence O
oxidative O
stress O
) O
. O

Neuronal O
viability O
( O
by O
trypan O
blue O
exclusion O
) O
, O
terminal O
deoxynucleotidyl O
transferase B
- I
mediated I
dUTP I
nick I
end I
- I
labeling I
( I
TUNEL I
) I
staining O
, O
and O
axonal O
growth O
were O
also O
assessed O
with O
the O
cultures O
. O

The O
rabies O
virus O
Ni O
- O
CE O
strain O
causes O
nonlethal O
infection O
in O
adult O
mice O
after O
intracerebral O
inoculation O
, O
whereas O
the O
parental O
Nishigahara B
( I
Ni I
) I
strain O
kills O
mice O
. O

We O
previously O
reported O
that O
the O
chimeric O
CE O
( O
NiN O
) O
strain O
with O
the O
N O
gene O
from O
the O
Ni O
strain O
in O
the O
genetic O
background O
of O
the O
Ni O
- O
CE O
strain O
kills O
adult O
mice O
, O
indicating O
that O
the O
N O
gene O
is O
related O
to O
the O
different O
pathogenicities O
of O
Ni O
and O
Ni O
- O
CE O
strains O
. O

In O
the O
present O
study O
, O
to O
obtain O
an O
insight O
into O
the O
mechanism O
by O
which O
the O
N O
gene O
determines O
viral O
pathogenicity O
, O
we O
compared O
the O
effects O
of O
Ni O
, O
Ni O
- O
CE O
, O
and O
CE O
( O
NiN O
) O
infections O
on O
host O
gene O
expressions O
using O
a O
human O
neuroblastoma O
cell O
line O
. O

Microarray O
analysis O
of O
these O
infected O
cells O
revealed O
that O
the O
expression O
levels O
of O
particular O
genes O
in O
Ni O
- O
and O
CE O
( O
NiN O
) O
- O
infected O
cells O
, O
including O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
chemokine O
genes O
( O
i O
. O

We O
also O
demonstrated O
that O
Ni O
- O
CE O
infection O
activated O
the O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
- O
dependent O
IFN O
- O
beta O
promoter O
and O
induced O
IRF O
- O
3 O
nuclear O
translocation O
more O
efficiently O
than O
did O
Ni O
or O
CE O
( O
NiN O
) O
infection O
. O

Furthermore O
, O
we O
showed O
that O
Ni O
- O
CE O
infection O
, O
but O
not O
Ni O
or O
CE O
( O
NiN O
) O
infection O
, O
strongly O
activates O
the O
IRF O
- O
3 O
pathway O
through O
activation O
of O
RIG O
- O
I O
, O
which O
is O
known O
as O
a O
cellular O
sensor O
of O
virus O
infection O
. O

These O
findings O
indicate O
that O
the O
N O
protein O
of O
rabies O
virus O
( O
Ni O
strain O
) O
has O
a O
function O
to O
evade O
the O
activation O
of O
RIG O
- O
I O
. O

Recombinant B
rabies I
virus I
( I
RV I
) I
- O
based O
vectors O
have O
demonstrated O
their O
efficacy O
in O
generating O
long O
- O
term O
, O
antigen O
- O
specific O
immune O
responses O
in O
murine O
and O
monkey O
models O
. O

RV O
pathogenicity O
is O
largely O
attributed O
to O
its O
glycoprotein O
( O
RV O
- O
G O
) O
, O
which O
facilitates O
the O
attachment O
and O
entry O
of O
RV O
into O
host O
cells O
. O

We O
have O
developed O
a O
live O
, O
single O
- O
cycle O
RV O
by O
deletion O
of O
the O
G O
gene O
from O
an O
RV O
vaccine O
vector O
expressing O
HIV O
- O
1 O
Gag O
( O
SPBN O
- O
Delta O
G O
- O
Gag O
) O
. O

The O
in O
vivo O
immunogenicity O
data O
comparing O
single O
- O
cycle O
RV O
to O
a O
replication O
- O
competent O
control O
( O
BNSP O
- O
Gag O
) O
showed O
lower O
RV O
- O
specific O
antibodies O
; O
however O
, O
the O
overall O
isotype O
profiles O
( O
IgG2a O
/ O
IgG1 O
) O
were O
similar O
for O
the O
two O
vaccine O
vectors O
. O

Despite O
this O
difference O
, O
mice O
immunized O
with O
SPBN O
- O
Delta O
G O
- O
Gag O
and O
BNSP O
- O
Gag O
mounted O
similar O
levels O
of O
Gag O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
as O
measured O
by O
major O
histocompatibility O
complex O
class O
I O
Gag O
- O
tetramer O
staining O
, O
gamma O
interferon O
- O
enzyme O
- O
linked O
immunospot O
assay O
, O
and O
cytotoxic O
T O
- O
cell O
assay O
. O

CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
were O
significantly O
enhanced O
by O
a O
boost O
with O
a O
single O
- O
cycle O
RV O
complemented O
with O
a O
heterologous O
vesicular O
stomatitis O
virus O
glycoprotein O
. O

Lyssavirus O
assembly O
depends O
on O
the O
matrix B
protein I
( I
M I
) I
. O

We O
compared O
lyssavirus O
M O
proteins O
from O
different O
genotypes O
for O
their O
ability O
to O
support O
assembly O
and O
egress O
of O
genotype O
1 O
rabies B
virus I
( I
RABV I
) I
. O

Transcomplementation O
of O
M O
- O
deficient O
RABV O
with O
M O
from O
European B
bat I
lyssavirus I
( I
EBLV I
) I
types O
1 O
and O
2 O
reduced O
the O
release O
of O
infectious O
virus O
. O

Mokola B
virus I
( I
MOKV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
sense O
RNA O
virus O
that O
belongs O
to O
the O
Lyssavirus O
genus O
and O
Rhabdoviridae O
family O
. O

P O
recruits O
the O
viral O
polymerase O
to O
the O
nucleoprotein O
- O
bound O
viral O
RNA O
( O
N O
- O
RNA O
) O
via O
an O
interaction O
between O
its O
C O
- O
terminal O
domain O
and O
the O
N O
- O
RNA O
complex O
. O

The O
structure O
has O
a O
high O
degree O
of O
homology O
with O
P O
of O
rabies O
virus O
, O
another O
member O
of O
Lyssavirus O
genus O
, O
and O
to O
a O
lesser O
degree O
with O
P O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
a O
member O
of O
the O
related O
Vesiculovirus O
genus O
. O

It O
was O
found O
previously O
that O
induction O
of O
innate O
immunity O
, O
particularly O
chemokines O
, O
is O
an O
important O
mechanism O
of O
rabies B
virus I
( I
RABV I
) I
attenuation O
. O

To O
evaluate O
the O
effect O
of O
overexpression O
of O
chemokines O
on O
RABV O
infection O
, O
chemokines O
macrophage B
inflammatory I
protein I
1 I
alpha I
( I
MIP I
- I
1 I
alpha I
) I
, O
RANTES O
, O
and O
IP O
- O
10 O
were O
individually O
cloned O
into O
the O
genome O
of O
attenuated O
RABV O
strain O
HEP O
- O
Flury O
. O

Because O
this O
complex O
( O
nucleoprotein O
N O
- O
RNA O
template O
processed O
by O
the O
L O
polymerase O
and O
its O
cofactor O
, O
the O
phosphoprotein O
P O
) O
is O
similar O
to O
that O
of O
other O
negative O
- O
strand O
RNA O
viruses O
, O
we O
aimed O
to O
design O
broad O
- O
spectrum O
antiviral O
drugs O
that O
could O
be O
used O
as O
a O
complement O
to O
postexposure O
vaccination O
and O
immunotherapy O
. O

Recent O
progress O
in O
understanding O
the O
structure O
/ O
function O
of O
the O
rabies O
virus O
P O
, O
N O
, O
and O
L O
proteins O
predicts O
that O
the O
amino O
- O
terminal O
end O
of O
P O
is O
an O
excellent O
target O
for O
destabilizing O
the O
replication O
complex O
because O
it O
interacts O
with O
both O
L O
( O
for O
positioning O
onto O
the O
N O
- O
RNA O
template O
) O
and O
N O
( O
for O
keeping O
N O
soluble O
, O
as O
needed O
for O
viral O
RNA O
encapsidation O
) O
. O

Thus O
, O
peptides O
mimicking O
various O
lengths O
of O
the O
amino O
- O
terminal O
end O
of O
P O
have O
been O
evaluated O
, O
as O
follows O
: O
( O
i O
) O
for O
binding O
properties O
to O
the O
N O
- O
P O
- O
L O
partners O
by O
the O
two O
- O
hybrid O
method O
; O
( O
ii O
) O
for O
their O
capacity O
to O
inhibit O
the O
transcription O
/ O
replication O
of O
a O
rabies O
virus O
minigenome O
encoding O
luciferase O
in O
BHK O
- O
21 O
- O
T7 O
cells O
; O
and O
( O
iii O
) O
for O
their O
capacity O
to O
inhibit O
rabies O
virus O
infection O
of O
BHK O
- O
21 O
- O
T7 O
cells O
and O
of O
two O
derivatives O
of O
the O
neuronal O
SK O
- O
N O
- O
SH O
cell O
line O
. O

Peptides O
P60 O
and O
P57 O
( O
the O
first O
60 O
and O
first O
57 O
NH2 O
residues O
of O
P O
, O
respectively O
) O
exhibited O
a O
rapid O
, O
strong O
, O
and O
long O
- O
lasting O
inhibitory O
potential O
on O
luciferase O
expression O
( O
> O
95 O
% O
from O
24 O
h O
to O
55 O
h O
) O
. O

P42 O
was O
less O
efficient O
in O
its O
inhibition O
level O
( O
75 O
% O
for O
18 O
to O
30 O
h O
) O
and O
duration O
( O
40 O
% O
after O
48 O
h O
) O
. O

We O
have O
studied O
the O
morphogenesis O
and O
the O
role O
of O
these O
Negri O
body O
- O
like O
structures O
( O
NBLs O
) O
during O
viral O
infection O
. O

The O
results O
indicate O
that O
these O
spherical O
structures O
( O
one O
or O
two O
per O
cell O
in O
the O
initial O
stage O
of O
infection O
) O
, O
composed O
of O
the O
viral O
N O
and O
P O
proteins O
, O
grow O
during O
the O
virus O
cycle O
before O
appearing O
as O
smaller O
structures O
at O
late O
stages O
of O
infection O
. O

Specifically O
, O
using O
in O
situ O
fluorescent O
hybridization O
techniques O
, O
we O
show O
that O
all O
viral O
RNAs O
( O
genome O
, O
antigenome O
, O
and O
every O
mRNA O
) O
are O
located O
inside O
the O
inclusion O
bodies O
. O

The O
viral O
protein O
VP35 O
of O
ebolavirus B
( I
EBOV I
) I
is O
implicated O
to O
have O
diverse O
roles O
in O
the O
viral O
life O
cycle O
. O

We O
employed O
a O
yeast O
two O
- O
hybrid O
screen O
to O
search O
for O
VP35 O
binding O
partners O
and O
identified O
the O
cytoplasmic O
dynein O
light O
chain O
( O
DLC8 O
) O
as O
a O
protein O
that O
interacts O
with O
VP35 O
. O

A O
recombinant O
vesicular O
stomatitis O
virus O
( O
VSV O
- O
PeGFP O
- O
M O
- O
MmRFP O
) O
encoding O
enhanced O
green O
fluorescent O
protein O
fused O
in O
frame O
with O
P O
( O
PeGFP O
) O
in O
place O
of O
P O
and O
a O
fusion O
matrix O
protein O
( O
monomeric O
red O
fluorescent O
protein O
fused O
in O
frame O
at O
the O
carboxy O
terminus O
of O
M O
[ O
MmRFP O
] O
) O
at O
the O
G O
- O
L O
gene O
junction O
, O
in O
addition O
to O
wild B
- I
type I
( I
WT I
) I
M O
protein O
in O
its O
normal O
location O
, O
was O
recovered O
, O
but O
the O
MmRFP O
was O
not O
incorporated O
into O
the O
virions O
. O

Subsequently O
, O
we O
generated O
recombinant O
viruses O
( O
VSV O
- O
PeGFP O
- O
Delta O
M O
- O
Mtc O
and O
VSV O
- O
Delta O
M O
- O
Mtc O
) O
encoding O
M O
protein O
with O
a O
carboxy O
- O
terminal O
tetracysteine O
tag O
( O
Mtc O
) O
in O
place O
of O
the O
M O
protein O
. O

Virions O
released O
from O
cells O
infected O
with O
VSV O
- O
PeGFP O
- O
Delta O
M O
- O
Mtc O
and O
labeled O
with O
the O
biarsenical O
red O
dye O
( O
ReAsH O
) O
were O
dually O
fluorescent O
, O
fluorescing O
green O
due O
to O
incorporation O
of O
PeGFP O
in O
the O
nucleocapsids O
and O
red O
due O
to O
incorporation O
of O
ReAsH O
- O
labeled O
Mtc O
in O
the O
viral O
envelope O
. O

Sequential O
labeling O
of O
VSV O
- O
Delta O
M O
- O
Mtc O
- O
infected O
cells O
with O
the O
biarsenical O
dyes O
ReAsH O
and O
FlAsH O
( O
green O
) O
revealed O
that O
newly O
synthesized O
M O
protein O
reaches O
the O
plasma O
membrane O
in O
less O
than O
30 O
min O
and O
continues O
to O
accumulate O
there O
for O
up O
to O
2 O
1 O
/ O
2 O
hours O
. O

Here O
, O
we O
have O
used O
internal B
ribosome I
entry I
sites I
( I
IRES I
) I
from O
picornaviruses O
to O
control O
the O
expression O
level O
of O
the O
phosphoprotein O
P O
of O
the O
neurotropic O
rabies O
virus O
( O
RV O
; O
Rhabdoviridae O
) O
, O
which O
is O
critically O
required O
for O
both O
viral O
replication O
and O
escape O
from O
the O
host O
interferon O
response O
. O

In O
a O
dual O
luciferase O
reporter O
RV O
, O
the O
IRES O
elements O
of O
poliovirus B
( I
PV I
) I
and O
human B
rhinovirus I
type I
2 I
( I
HRV2 I
) I
were O
active O
in O
a O
variety O
of O
cell O
lines O
from O
different O
host O
species O
. O

Recombinant O
RVs O
expressing O
P O
exclusively O
from O
a O
bicistronic O
nucleoprotein B
( I
N I
) I
- O
IRES O
- O
P O
mRNA O
showed O
IRES O
- O
specific O
reduction O
of O
replication O
in O
cell O
culture O
and O
in O
neurons O
of O
organotypic O
brain O
slice O
cultures O
, O
an O
increased O
activation O
of O
the O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
promoter O
, O
and O
increased O
sensitivity O
to O
IFN O
. O

Intracerebral O
infection O
revealed O
a O
complete O
loss O
of O
virulence O
of O
both O
PV O
- O
and O
HRV2 O
IRES O
- O
controlled O
RV O
for O
wild O
- O
type O
mice O
and O
for O
transgenic O
mice O
lacking O
a O
functional O
IFN O
- O
alpha O
receptor O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
. O

The O
virulence O
of O
HRV2 O
IRES O
- O
controlled O
RV O
was O
most O
severely O
attenuated O
and O
could O
be O
demonstrated O
only O
in O
newborn O
IFNAR O
( O
- O
/ O
) O
- O
mice O
. O

late B
( I
L I
) I
domains O
containing O
the O
highly O
conserved O
sequence O
PPXY O
were O
first O
described O
for O
retroviruses O
, O
and O
later O
research O
confirmed O
their O
conservation O
and O
importance O
for O
efficient O
budding O
of O
several O
negative O
- O
stranded O
RNA O
viruses O
. O

rabies B
virus I
( I
RV I
) I
, O
a O
member O
of O
the O
Rhabdoviridae O
family O
, O
contains O
the O
sequence O
PPEY O
( O
amino O
acids O
35 O
to O
38 O
) O
within O
the O
N O
terminus O
of O
the O
matrix B
( I
M I
) I
protein O
, O
but O
the O
functions O
of O
this O
potential O
L O
- O
domain O
in O
the O
viral O
life O
cycle O
, O
viral O
pathogenicity O
, O
and O
immunogenicity O
have O
not O
been O
established O
. O

In O
addition O
, O
results O
from O
electron O
microscopy O
demonstrated O
that O
the O
M4A O
mutant O
virus O
( O
PPEY O
- O
- O
> O
SAEA O
) O
displayed O
a O
more O
cell O
- O
associated O
phenotype O
than O
that O
of O
wild O
- O
type O
RV O
. O

Previous O
observations O
have O
indicated O
that O
the O
matrix O
proteins O
( O
M O
) O
of O
some O
lyssaviruses O
induce O
strong O
neuronal O
apoptosis O
. O

However O
, O
the O
molecular O
mechanism O
( O
s O
) O
involved O
in O
this O
phenomenon O
is O
still O
unknown O
. O

We O
show O
that O
for O
Mokola B
virus I
( I
MOK I
) I
, O
a O
lyssavirus O
of O
low O
pathogenicity O
, O
the O
M O
( O
M O
- O
MOK O
) O
targets O
mitochondria O
, O
disrupts O
the O
mitochondrial O
morphology O
, O
and O
induces O
apoptosis O
. O

Our O
analysis O
of O
truncated O
M O
- O
MOK O
mutants O
suggests O
that O
the O
information O
required O
for O
efficient O
mitochondrial O
targeting O
and O
dysfunction O
, O
as O
well O
as O
caspase O
- O
9 O
activation O
and O
apoptosis O
, O
is O
held O
between O
residues O
46 O
and O
110 O
of O
M O
- O
MOK O
We O
used O
a O
yeast O
two O
- O
hybrid O
approach O
, O
a O
coimmunoprecipitation O
assay O
, O
and O
confocal O
microscopy O
to O
demonstrate O
that O
M O
- O
MOK O
physically O
associates O
with O
the O
subunit O
I O
of O
the O
cytochrome O
c O
( O
cyt O
- O
c O
) O
oxidase O
( O
CcO O
) O
of O
the O
mitochondrial O
respiratory O
chain O
; O
this O
is O
in O
contrast O
to O
the O
M O
of O
the O
highly O
pathogenic O
Thailand O
lyssavirus O
( O
M O
- O
THA O
) O
. O

M O
- O
MOK O
mutations O
( O
K77R O
and O
N81E O
) O
resulting O
in O
a O
similar O
sequence O
to O
M O
- O
THA O
at O
positions O
77 O
and O
81 O
annul O
cyt O
- O
c O
release O
and O
apoptosis O
and O
restore O
CcO O
activity O
. O

While O
the O
glycoprotein B
( I
G I
) I
of O
rabies B
virus I
( I
RV I
) I
is O
known O
to O
play O
a O
predominant O
role O
in O
the O
pathogenesis O
of O
rabies O
, O
the O
function O
of O
the O
RV O
matrix B
protein I
( I
M I
) I
in O
RV O
pathogenicity O
is O
not O
completely O
clear O
. O

Here O
we O
describe O
a O
strategy O
to O
fluorescently O
label O
the O
envelope O
of O
rabies B
virus I
( I
RV I
) I
, O
of O
the O
Rhabdoviridae O
family O
, O
in O
order O
to O
track O
the O
transport O
of O
single O
enveloped O
viruses O
in O
living O
cells O
. O

Red O
fluorescent O
proteins O
( O
tm O
- O
REP O
) O
were O
engineered O
to O
comprise O
the O
N O
- O
terminal O
signal O
sequence O
and O
C O
- O
terminal O
transmembrane O
spanning O
and O
cytoplasmic O
domain O
sequences O
of O
the O
RV O
glycoprotein B
( I
G I
) I
. O

In O
this O
study O
, O
the O
effects O
of O
rabies O
virus O
infection O
on O
the O
structure O
of O
neurons O
were O
investigated O
with O
experimentally O
infected O
transgenic O
mice O
expressing O
yellow B
fluorescent I
protein I
( I
YFP I
) I
in O
neuronal O
subpopulations O
. O

Six O
- O
week O
- O
old O
mice O
were O
inoculated O
in O
the O
hind O
- O
limb O
footpad O
with O
the O
CVS O
strain O
of O
fixed O
virus O
or O
were O
mock O
infected O
with O
vehicle O
( O
phosphate O
- O
buffered O
saline O
) O
. O

Rabies B
virus I
glycoprotein I
( I
RVG I
) I
is O
known O
to O
be O
the O
only O
factor O
that O
mediates O
rabies O
infection O
. O

The O
neurotrophin O
receptor O
( O
p75 O
( O
NTR O
) O
) O
, O
through O
its O
cysteine O
- O
rich O
domain O
1 O
, O
is O
a O
specific O
receptor O
for O
RVG O
and O
neutralizes O
virus O
infectivity O
, O
but O
its O
role O
in O
virus O
infection O
has O
remained O
obscure O
. O

We O
used O
adult O
mouse O
dorsal B
root I
ganglion I
( I
DRG I
) I
neurons O
as O
a O
model O
to O
study O
the O
role O
of O
p75NTR O
in O
RV O
infection O
of O
primary O
neurons O
. O

Surprisingly O
, O
RV O
binding O
and O
infection O
are O
absent O
in O
about O
half O
of O
the O
p75 O
( O
NTR O
) O
- O
expressing O
DRG O
neurons O
which O
have O
small O
diameters O
and O
are O
often O
capsaicin O
sensitive O
. O

This O
indicates O
that O
p75 O
( O
NTR O
) O
is O
not O
sufficient O
to O
mediate O
RV O
interaction O
in O
sensory O
neurons O
. O

The O
rate O
and O
specificity O
of O
neural O
infection O
are O
unchanged O
in O
RV O
- O
infected O
p75 O
( O
NTRExon O
- O
/ O
- O
) O
mice O
that O
lack O
all O
extracellular O
receptor O
domains O
and O
in O
wild O
- O
type O
mice O
infected O
with O
two O
independent O
RV O
mutants O
that O
lack O
p75NTR O
binding O
. O

Accordingly O
, O
the O
mortality O
rate O
is O
unchanged O
in O
the O
absence O
of O
RV O
- O
p75 O
( O
NTR O
) O
interaction O
. O

We O
conclude O
that O
although O
p75NTR O
is O
a O
receptor O
for O
soluble O
RVG O
in O
transfected O
cells O
of O
heterologous O
expression O
systems O
, O
an O
RVG O
- O
p75 O
( O
NTR O
) O
interaction O
is O
not O
necessary O
for O
RV O
infection O
of O
primary O
neurons O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
a O
nonsegmented O
, O
negative O
- O
sense O
RNA O
- O
containing O
virus O
, O
is O
a O
common O
cause O
of O
lower O
respiratory O
tract O
disease O
. O

Expression O
of O
RSV O
Nucleocapsid B
protein I
( I
N I
) I
in O
insect O
cells O
using O
the O
baculovirus O
expression O
system O
leads O
to O
the O
formation O
of O
N O
- O
RNA O
complexes O
that O
are O
morphologically O
indistinguishable O
from O
viral O
nucleocapsids O
. O

Silver B
- I
haired I
bat I
rabies I
virus I
( I
SHBRV I
) I
infection O
induces O
a O
strong O
virus O
- O
specific O
immune O
response O
in O
the O
periphery O
of O
the O
host O
, O
but O
death O
is O
common O
due O
to O
the O
failure O
to O
open O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
and O
deliver O
immune O
effectors O
to O
central B
nervous I
system I
( I
CNS I
) I
tissues O
. O

In O
addition O
, O
these O
animals O
are O
known O
to O
have O
reduced O
hypothalamus O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
activity O
and O
an O
elevated O
capacity O
to O
mediate O
CNS O
inflammatory O
responses O
. O

The O
nonpathogenic O
phenotype O
of O
the O
live O
rabies B
virus I
( I
RV I
) I
vaccine O
SPBNGAN O
is O
determined O
by O
an O
Arg O
- O
> O
Glu O
exchange O
at O
position O
333 O
in O
the O
glycoprotein O
, O
designated O
GAN O
. O

Because O
an O
RV O
vaccine O
candidate O
containing O
two O
GAN O
genes O
( O
SPBNGAN O
- O
GAN O
) O
exhibits O
increased O
immunogenicity O
in O
vivo O
compared O
to O
the O
single O
- O
GAN O
construct O
, O
we O
tested O
whether O
the O
presence O
of O
two O
GAN O
genes O
might O
also O
enhance O
the O
probability O
of O
reversion O
to O
pathogenicity O
. O

Comparison O
of O
SPBNGAN O
- O
GAN O
with O
RVs O
constructed O
to O
contain O
either O
both O
GAN O
and O
GAK O
genes O
( O
SPBNGAN O
- O
GAK O
and O
SPBNGAK O
- O
GAN O
) O
or O
two O
GAK O
genes O
( O
SPBNGAK O
- O
GAK O
) O
showed O
that O
while O
SPBNGAK O
- O
GAK O
was O
pathogenic O
, O
SPBNGAN O
- O
GAN O
and O
SPBNGAN O
- O
GAK O
were O
completely O
nonpathogenic O
and O
SPBNGAK O
- O
GAN O
showed O
strongly O
reduced O
pathogenicity O
. O

Rabies O
virus O
P O
protein O
inhibits O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
- O
and O
IFN O
- O
gamma O
- O
stimulated O
Jak O
- O
STAT O
signaling O
by O
retaining O
phosphorylated O
STAT1 O
in O
the O
cytoplasm O
. O

We O
show O
that O
the O
localization O
of O
STAT1 O
is O
correlated O
with O
the O
localization O
of O
P O
: O
in O
cells O
expressing O
a O
nuclear O
form O
of O
P O
( O
the O
short O
P3 O
isoform O
or O
the O
complete O
P O
in O
the O
presence O
of O
the O
export O
inhibitor O
leptomycin O
B O
) O
, O
STAT1 O
is O
nuclear O
, O
whereas O
in O
cells O
expressing O
a O
cytoplasmic O
form O
of O
P O
, O
STAT1 O
is O
cytoplasmic O
. O

Over O
the O
last O
decade O
, O
rabies O
viruses O
associated O
with O
the O
silver B
- I
haired I
bat I
( I
SHBRV I
) I
have O
emerged O
as O
the O
leading O
cause O
of O
human O
deaths O
from O
rabies O
in O
the O
United O
States O
and O
Canada O
as O
a O
consequence O
of O
the O
fact O
that O
exposure O
to O
these O
viruses O
is O
often O
unnoticed O
. O

While O
a O
fully O
functional O
immune O
response O
to O
SHBRV O
develops O
in O
the O
periphery O
of O
infected O
animals O
, O
the O
invasion O
of O
central B
nervous I
system I
( I
CNS I
) I
tissues O
by O
immune O
cells O
is O
reduced O
and O
, O
consequently O
, O
the O
virus O
is O
not O
cleared O
. O

The O
objective O
of O
this O
study O
was O
to O
quantify O
the O
extent O
to O
which O
the O
genetic O
diversity O
of O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
arising O
over O
the O
course O
of O
infection O
of O
an O
individual O
animal O
becomes O
fixed O
, O
is O
transmitted O
to O
other O
animals O
, O
and O
thereby O
accumulates O
over O
the O
course O
of O
an O
outbreak O
. O

Complete O
consensus O
sequences O
of O
23 O
genomes O
( O
each O
of O
8 O
, O
200 O
nucleotides O
) O
of O
FMDV O
were O
recovered O
directly O
from O
epithelium O
tissue O
acquired O
from O
21 O
farms O
infected O
over O
a O
nearly O
7 O
- O
month O
period O
during O
the O
2001 O
FMDV O
outbreak O
in O
the O
United O
Kingdom O
. O

75 O
X O
10 O
( O
- O
5 O
) O
to O
2 O
. O

80 O
X O
10 O
( O
- O
5 O
) O
) O
and O
nucleotide O
substitutions O
to O
accrue O
in O
the O
consensus O
sequence O
at O
an O
average O
rate O
of O
1 O
. O

Coalescent O
methods O
indicated O
that O
the O
date O
at O
which O
FMDV O
first O
infected O
livestock O
in O
the O
United O
Kingdom O
was O
7 O
February O
2001 O
( O
95 O
% O
CI O
, O
20 O
January O
to O
19 O
February O
2001 O
) O
, O
which O
was O
identical O
to O
estimates O
obtained O
on O
the O
basis O
of O
purely O
clinical O
evidence O
. O

The O
NMDA O
( O
N O
- O
methyl O
- O
D O
- O
aspartate O
acid O
) O
antagonists O
ketamine O
( O
125 O
mu O
M O
) O
and O
MK O
- O
801 O
( O
60 O
mu O
M O
) O
were O
found O
to O
have O
no O
significant O
neuroprotective O
effect O
on O
CVS O
- O
infected O
neurons O
, O
while O
the O
caspase O
inhibitor O
Ac O
- O
Asp O
- O
Glu O
- O
Val O
aspartic O
acid O
aldehyde O
( O
25 O
mu O
M O
) O
exerted O
a O
marked O
neuroprotective O
effect O
. O

Ketamine O
( O
120 O
mg O
/ O
kg O
of O
body O
weight O
/ O
day O
intraperitoneally O
) O
given O
to O
CVS O
- O
infected O
adult O
mice O
produced O
no O
beneficial O
effects O
. O

Greater O
cytopathic O
capacity O
translated O
into O
a O
greater O
degree O
of O
cross O
- O
priming O
to O
CD8 O
( O
+ O
) O
T O
cells O
( O
TCD8 O
+ O
) O
and O
more O
- O
robust O
short O
- O
term O
Immoral O
and O
cellular O
responses O
. O

The O
phosphoprotein B
( I
P I
) I
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
subunit O
of O
the O
viral O
RNA O
polymerase O
. O

In O
the O
present O
study O
, O
we O
inserted O
full O
- O
length O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
in O
frame O
into O
the O
hinge O
region O
of O
P O
and O
show O
that O
the O
fusion O
protein O
( O
PeGFP O
) O
is O
functional O
in O
viral O
genome O
transcription O
and O
replication O
, O
albeit O
with O
reduced O
activity O
. O

A O
recombinant O
vesicular O
stomatitis O
virus O
encoding O
PeGFP O
in O
place O
of O
the O
P O
protein O
( O
VSV O
- O
PeGFP O
) O
, O
which O
possessed O
reduced O
growth O
kinetics O
compared O
to O
the O
wild O
- O
type O
VSV O
, O
was O
recovered O
. O

Real O
- O
time O
imaging O
of O
the O
cells O
infected O
with O
the O
eGFP O
- O
tagged O
virus O
revealed O
that O
, O
following O
synthesis O
, O
the O
nucleocapsids O
are O
transported O
toward O
the O
cell O
periphery O
via O
a O
microtubule B
( I
MT I
) I
- O
mediated O
process O
, O
and O
the O
nucleocapsids O
were O
seen O
to O
be O
closely O
associated O
with O
mitochondria O
. O

In O
the O
replication O
cycle O
of O
nonsegmented O
negative O
- O
strand O
RNA O
viruses O
, O
the O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
L I
) I
recognizes O
a O
nucleoprotein B
( I
N I
) I
- O
enwrapped O
RNA O
template O
during O
the O
RNA O
polymerase O
reaction O
. O

The O
viral O
phosphoprotein B
( I
P I
) I
is O
a O
polymerase O
cofactor O
essential O
for O
this O
recognition O
. O

3 O
- O
angstrom O
- O
resolution O
crystal O
structure O
of O
the O
central O
domain O
( O
residues O
107 O
to O
177 O
) O
of O
P O
from O
vesicular O
stomatitis O
virus O
. O

We O
show O
here O
that O
two O
viruses O
- O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
, O
a O
neuronotropic O
virus O
inducing O
acute O
infection O
and O
neuron O
latency O
; O
and O
rabies B
virus I
( I
RABV I
) I
, O
a O
neuronotropic O
virus O
triggering O
acute O
neuron O
infection O
- O
upregulate O
the O
neuronal O
expression O
of O
several O
HIA O
- O
G O
isoforms O
, O
including O
HLA O
- O
G1 O
and O
HLA O
- O
G5 O
, O
the O
two O
main O
biologically O
active O
isoforms O
. O

Soluble O
mediators O
, O
such O
as O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
IFN O
- O
gamma O
, O
upregulate O
HLA O
- O
G O
expression O
in O
uninfected O
cells O
. O

Thus O
, O
neuronotropic O
viruses O
that O
escape O
the O
host O
immune O
response O
totally O
( O
RABV O
) O
or O
partially O
( O
HSV O
- O
1 O
) O
regulate O
HLA O
- O
G O
expression O
on O
human O
neuronal O
cells O
differentially O
. O

Several O
rabies B
virus I
( I
RV I
) I
vaccine O
strains O
containing O
an O
aspartic B
acid I
( I
Asp I
) I
or O
glutamic O
acid O
( O
Glu O
) O
instead O
of O
an O
arginine B
( I
Arg I
) I
at O
position O
333 O
of O
the O
RV O
glycoprotein B
( I
G I
) I
are O
apathogenic O
for O
immunocompetent O
mice O
even O
after O
intracranial O
inoculation O
. O

While O
the O
Glu O
( O
333 O
) O
remained O
unchanged O
after O
five O
mouse O
passages O
, O
an O
Asn O
( O
194 O
) O
- O
> O
Lys O
( O
194 O
) O
mutation O
occurred O
in O
RV O
G O
. O

Using O
site O
- O
directed O
mutagenesis O
to O
exchange O
Asn O
( O
194 O
) O
with O
Lys O
( O
194 O
) O
in O
the O
G O
protein O
of O
SPBNGA O
, O
resulting O
in O
SPBNGA O
- O
K O
, O
we O
show O
here O
that O
this O
mutation O
is O
solely O
responsible O
for O
the O
increase O
in O
pathogenicity O
and O
that O
the O
Asn O
( O
194 O
) O
- O
> O
Lys O
( O
194 O
) O
mutation O
does O
not O
arise O
when O
Asn O
( O
194 O
) O
is O
exchanged O
with O
Ser O
( O
194 O
) O
( O
SPBNGA O
- O
S O
) O
. O

We O
investigated O
other O
potential O
roles O
of O
P O
( O
CVS O
strain O
) O
by O
searching O
for O
cellular O
partners O
using O
two O
- O
hybrid O
screening O
. O

We O
isolated O
a O
cDNA O
encoding O
the O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
that O
is O
a O
critical O
component O
of O
interferon O
type O
I O
( O
IFN O
- O
alpha O
/ O
beta O
) O
and O
type O
II O
( O
IFN O
- O
gamma O
) O
signaling O
. O

rabies B
virus I
( I
RV I
) I
induces O
encephalomyelitis O
in O
humans O
and O
animals O
. O

To O
investigate O
the O
host O
responses O
to O
RV O
infection O
, O
we O
examined O
and O
compared O
the O
pathology O
, O
particularly O
the O
inflammatory O
responses O
, O
and O
the O
gene O
expression O
profiles O
in O
the O
brains O
of O
mice O
infected O
with O
wild B
- I
type I
( I
WT I
) I
virus O
silver O
- O
haired O
bat O
RV O
( O
SHBRV O
) O
or O
laboratory O
- O
adapted O
virus O
B2C O
, O
using O
a O
mouse O
genomic O
array O
( O
Affymetrix O
) O
. O

Furthermore O
, O
attenuated O
RV O
induced O
the O
expression O
of O
the O
genes O
involved O
in O
the O
innate O
immune O
and O
antiviral O
responses O
, O
especially O
those O
related O
to O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
signaling O
pathways O
and O
inflammatory O
chemokines O
. O

To O
study O
the O
capacity O
of O
human O
neurons O
to O
mount O
innate O
immunity O
responses O
to O
viral O
infections O
, O
we O
infected O
cells O
of O
a O
human O
postmitotic O
neuron O
- O
derivative O
cell O
line O
, O
NT2 O
- O
N O
, O
with O
rabies B
virus I
( I
RABV I
) I
and O
herpes B
simplex I
type I
1 I
( I
HSV I
- I
1 I
) I
. O

Following O
RABV O
infection O
, O
the O
most O
upregulated O
genes O
belong O
to O
the O
immunity O
cluster O
and O
included O
almost O
exclusively O
genes O
for O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
primary O
and O
secondary O
responses O
as O
well O
as O
genes O
for O
chemokines O
( O
CCL O
- O
5 O
, O
CXCL O
- O
10 O
) O
and O
inflammatory O
cytokines O
( O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
I O
alpha O
) O
. O

They O
produced O
IFN O
- O
beta O
after O
treatment O
with O
poly O
( O
I O
: O
C O
) O
but O
not O
with O
lipopolysaccharide O
. O

In O
the O
present O
study O
, O
we O
have O
systemically O
examined O
the O
growth O
characteristics O
of O
rabies B
virus I
( I
RV I
) I
in O
microglia O
and O
the O
activation O
of O
cellular O
signaling O
pathways O
leading O
to O
chemokine O
expression O
upon O
RV O
infection O
. O

Transcriptional O
analyses O
of O
the O
expression O
profiles O
of O
chemokine O
genes O
revealed O
that O
RV O
infection O
, O
but O
not O
exposure O
to O
inactivated O
virions O
, O
strongly O
induces O
the O
expression O
of O
CXC B
chemokine I
ligand I
10 I
( I
CXCL10 I
) I
and O
CC B
chemokine I
ligand I
5 I
( I
CCL5 I
) I
in O
microglia O
. O

RV O
infection O
triggered O
the O
activation O
of O
signaling O
pathways O
mediated O
by O
mitogen O
- O
activated O
protein O
kinases O
, O
including O
p38 O
, O
extracellular B
signal I
- I
regulated I
kinases I
1 I
and I
2 I
( I
ERK1 I
/ I
2 I
) I
, O
and O
c O
- O
Jun O
N O
- O
terminal O
kinase O
, O
and O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
. O

The O
structural O
alterations O
of O
neuronal O
processes O
in O
mice O
were O
investigated O
after O
the O
mice O
were O
infected O
with O
rabies B
virus I
( I
RV I
) I
. O

European B
bat I
lyssaviruses I
types I
I I
and I
2 I
( I
EBLV I
- I
1 I
and I
EBLV I
- I
2 I
) I
are O
widespread O
in O
Europe O
, O
although O
little O
is O
known O
of O
their O
evolutionary O
history O
. O

Our O
study O
encompassed O
data O
from O
12 O
countries O
collected O
over O
a O
time O
span O
of O
35 O
years O
and O
focused O
on O
the O
glycoprotein B
( I
G I
) I
and O
nucleoprotein B
( I
N I
) I
genes O
. O

Our O
inferred O
rate O
of O
nucleotide O
substitution O
in O
EBLV O
- O
1 O
, O
approximately O
5 O
X O
10 O
( O
- O
5 O
) O
substitutions O
per O
site O
per O
year O
, O
was O
also O
one O
of O
the O
lowest O
recorded O
for O
RNA O
viruses O
and O
implied O
that O
the O
current O
genetic O
diversity O
in O
the O
virus O
arose O
500 O
to O
750 O
years O
ago O
. O

The O
need O
to O
replace O
rabies B
immune I
globulin I
( I
RIG I
) I
as O
an O
essential O
component O
of O
rabies O
postexposure O
prophylaxis O
is O
widely O
acknowledged O
. O

We O
set O
out O
to O
discover O
a O
unique O
combination O
of O
human B
monoclonal I
antibodies I
( I
MAbs I
) I
able O
to O
replace O
RIG O
. O

Stringent O
criteria O
concerning O
neutralizing O
potency O
, O
affinity O
, O
breadth O
of O
neutralization O
, O
and O
coverage O
of O
natural O
rabies B
virus I
( I
RV I
) I
isolates O
and O
in O
vitro O
escape O
mutants O
were O
set O
for O
each O
individual O
antibody O
, O
and O
the O
complementarities O
of O
the O
two O
MAbs O
were O
defined O
at O
the O
onset O
. O

First O
, O
we O
identified O
and O
characterized O
one O
human O
MAb O
( O
CR57 O
) O
with O
high O
in O
vitro O
and O
in O
vivo O
neutralizing O
potency O
and O
a O
broad O
neutralization O
spectrum O
. O

Secondly O
, O
we O
selected O
using O
phage O
display O
a O
complementing O
antibody O
( O
CR4098 O
) O
that O
recognized O
a O
distinct O
, O
nonoverlapping O
epitope O
( O
antigenic O
site O
III O
) O
, O
showed O
similar O
neutralizing O
potency O
and O
breadth O
as O
CR57 O
, O
and O
neutralized O
CR57 O
escape O
mutants O
. O

rabies B
virus I
( I
RV I
) I
of O
the O
Rhabdoviridae O
family O
grows O
in O
alpha O
/ O
beta O
interferon B
( I
IFN I
) I
- O
competent O
cells O
, O
suggesting O
the O
existence O
of O
viral O
mechanisms O
preventing O
IFN O
gene O
expression O
. O

The O
critical O
involvement O
of O
P O
was O
first O
suggested O
by O
the O
observation O
that O
an O
RV O
expressing O
an O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
- O
P O
fusion O
protein O
( O
SAD O
eGFP O
- O
P O
) O
( O
S O
. O

78 O
: O
12333 O
- O
12343 O
, O
2004 O
) O
was O
eliminated O
in O
IFN O
- O
competent O
HEp O
- O
2 O
cell O
cultures O
, O
in O
contrast O
to O
wild B
- I
type I
( I
WT I
) I
RV O
or O
an O
RV O
replicon O
lacking O
the O
genes O
for O
matrix O
protein O
and O
glycoprotein O
. O

Similarly O
, O
an O
RV O
expressing O
low O
levels O
of O
P O
, O
which O
was O
generated O
by O
moving O
the O
P O
gene O
to O
a O
promoter O
- O
distal O
gene O
position O
( O
SAD O
APLP O
) O
, O
lost O
the O
ability O
to O
prevent O
IFN O
induction O
. O

In O
contrast O
to O
wt O
RV O
, O
the O
IFN O
- O
inducing O
SAD O
APLP O
caused O
S386 O
phosphorylation O
, O
dimerization O
, O
and O
transcriptional O
activity O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
. O

For O
cost O
and O
safety O
reasons O
, O
replacement O
of O
the O
human O
or O
equine O
polyclonal O
immunoglobulin O
is O
advocated O
, O
and O
the O
use O
of O
rabies O
virus O
- O
specific O
Monoclonal B
antibodies I
( I
MAbs I
) I
is O
recommended O
. O

Using O
CR57 O
and O
a O
set O
of O
15 O
- O
mer O
overlapping O
peptides O
covering O
the O
glycoprotein O
ectodomain O
, O
a O
neutralization O
domain O
was O
identified O
between O
amino B
acids I
( I
aa I
) I
218 O
and O
240 O
. O

The O
minimal O
binding O
region O
was O
identified O
as O
KLCGVL O
( O
aa O
226 O
to O
231 O
) O
, O
with O
key O
residues O
K O
- O
CGV O
- O
identified O
by O
alanine O
replacement O
scanning O
. O

Without O
exception O
, O
the O
CR57 O
- O
resistant O
variants O
showed O
a O
mutation O
at O
key O
residues O
within O
the O
defined O
minimal O
binding O
region O
, O
while O
the O
CRJB O
escape O
viruses O
showed O
a O
single O
mutation O
distant O
from O
the O
CR57 O
epitope O
( O
N182D O
) O
combined O
with O
mutations O
in O
the O
CR57 O
epitope O
. O

rabies B
virus I
( I
RV I
) I
has O
recently O
been O
developed O
as O
a O
novel O
vaccine O
candidate O
for O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

The O
RV O
glycoprotein B
( I
G I
) I
can O
be O
functionally O
replaced O
by O
HIV B
- I
1 I
envelope I
glycoprotein I
( I
Env I
) I
if O
the O
gp160 O
cytoplasmic B
domain I
( I
CD I
) I
of O
HIV O
- O
1 O
Env O
is O
replaced O
by O
that O
of O
RV O
G O
. O

Here O
, O
we O
describe O
a O
pilot O
study O
of O
the O
in O
vivo O
replication O
and O
immunogenicity O
of O
an O
RV O
with O
a O
deletion O
of O
G O
( O
DeltaG O
) O
expressing O
a O
simian O
/ O
human O
immunodeficiency O
virus O
SHIV89 O
. O

There O
was O
no O
evidence O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
loss O
, O
and O
plasma O
viremia O
was O
controlled O
to O
undetectable O
levels O
by O
6 O
weeks O
postchallenge O
and O
has O
remained O
suppressed O
out O
to O
22 O
weeks O
postchallenge O
. O

Rhabdoviruses O
such O
as O
rabies B
virus I
( I
RV I
) I
encode O
only O
five O
multifunctional O
proteins O
accomplishing O
viral O
gene O
expression O
and O
virus O
formation O
. O

The O
viral O
phosphoprotein O
, O
P O
, O
is O
a O
structural O
component O
of O
the O
viral O
ribonucleoprotein B
( I
RNP I
) I
complex O
and O
an O
essential O
cofactor O
for O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
. O

We O
show O
here O
that O
RV O
P O
fused O
to O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
can O
substitute O
for O
P O
throughout O
the O
viral O
life O
cycle O
, O
allowing O
fluorescence O
labeling O
and O
tracking O
of O
RV O
RNPs O
under O
live O
cell O
conditions O
. O

Recombinant O
RVs O
expressing O
eGFP O
- O
P O
or O
an O
eGFP O
- O
P O
mutant O
lacking O
the O
binding O
site O
for O
dynein B
light I
chain I
1 I
( I
DLC1 I
) I
instead O
of O
P O
were O
used O
to O
track O
interaction O
with O
cellular O
proteins O
. O

Macrophages O
represent O
an O
essential O
part O
of O
innate O
immunity O
, O
and O
the O
viral O
infection O
of O
macrophages O
results O
in O
the O
release O
of O
multiple O
proinflammatory O
mediators O
, O
such O
as O
nitric B
oxide I
( I
NO I
) I
, O
cytokines O
, O
and O
chemokines O
. O

This O
study O
was O
undertaken O
to O
define O
the O
molecular O
mechanism O
of O
macrophage O
activation O
in O
response O
to O
rabies B
virus I
( I
RV I
) I
infection O
. O

Transcriptional O
analyses O
for O
the O
expression O
of O
inducible O
forms O
of O
NO O
synthase O
( O
iNOS O
) O
, O
cytokines O
, O
and O
chemokines O
revealed O
that O
RV O
virions O
potentiate O
the O
gene O
expression O
of O
iNOS O
and O
CXC B
chemokine I
ligand I
10 I
( I
CXCL10 I
) I
, O
a O
major O
chemoattractant O
of O
T O
helper O
cell O
type O
1 O
. O

In O
macrophages O
stimulated O
with O
UV O
- O
inactivated O
RV O
virions O
, O
as O
well O
as O
infectious O
viruses O
, O
the O
phosphorylation O
of O
extracellular B
signal I
- I
regulated I
kinase I
( I
ERK I
) I
1 O
and O
2 O
, O
members O
of O
the O
mitogen O
- O
activated O
protein O
kinase O
family O
, O
was O
significantly O
induced O
. O

Fusion O
of O
rabies O
virus O
with O
membranes O
is O
triggered O
at O
a O
low O
pH O
and O
is O
mediated O
by O
a O
viral O
glycoprotein B
( I
G I
) I
. O

We O
have O
developed O
a O
new O
strategy O
for O
antiviral O
peptide O
discovery O
by O
using O
lyssaviruses O
( O
rabies O
virus O
and O
rabies O
- O
related O
viruses O
) O
as O
models O
. O

Based O
on O
the O
mimicry O
of O
natural O
bioactive O
peptides O
, O
two O
genetically O
encoded O
combinatorial O
peptide O
libraries O
composed O
of O
intrinsically O
constrained O
peptides O
( O
coactamers O
) O
were O
designed O
. O

Proteomic O
knowledge O
concerning O
the O
functional O
network O
of O
interactions O
in O
the O
lyssavirus O
transcription O
- O
replication O
complex O
highlights O
the O
phosphoprotein B
( I
P I
) I
as O
a O
prime O
target O
for O
inhibitors O
of O
viral O
replication O
. O

Our O
approach O
combines O
( O
i O
) O
an O
exhaustive O
two O
- O
hybrid O
selection O
of O
peptides O
binding O
two O
phylogenetically O
divergent O
lyssavirus O
P O
' O
s O
, O
( O
ii O
) O
a O
functional O
analysis O
of O
protein O
interaction O
inhibition O
in O
a O
viral O
reverse O
genetic O
assay O
, O
coupled O
with O
a O
physical O
analysis O
of O
viral O
nucleoprotein O
- O
P O
complex O
by O
protein O
chip O
mass O
spectrometry O
, O
and O
( O
iii O
) O
an O
assay O
for O
inhibition O
of O
lyssavirus O
infection O
in O
mammalian O
cells O
. O

In O
our O
model O
, O
Fas O
ligand O
( O
CD95L O
) O
appears O
to O
play O
a O
limited O
role O
in O
lyssavirus O
- O
mediated O
neuroblastoma O
cell O
death O
. O

VP40 O
, O
the O
matrix O
protein O
of O
Marburg O
virus O
, O
is O
a O
peripheral O
membrane O
protein O
that O
has O
been O
shown O
to O
associate O
with O
membranes O
of O
multivesicular B
bodies I
( I
MVBs I
) I
( O
L O
. O

First O
, O
VP40 O
was O
homogenously O
distributed O
throughout O
the O
cytoplasm O
, O
although O
the O
majority O
of O
protein O
( O
70 O
% O
) O
was O
already O
membrane O
associated O
. O

Viral O
matrix O
proteins O
of O
several O
enveloped O
RNA O
viruses O
play O
important O
roles O
in O
virus O
assembly O
and O
budding O
and O
are O
by O
themselves O
able O
to O
bud O
from O
the O
cell O
surface O
in O
the O
form O
of O
lipid O
- O
enveloped O
, O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Three O
motifs O
( O
PT O
/ O
SAP O
, O
PPxY O
, O
and O
YxxL O
) O
have O
been O
identified O
as O
late O
budding O
domains O
( O
L O
- O
domains O
) O
responsible O
for O
efficient O
budding O
. O

L O
- O
domains O
can O
functionally O
interact O
with O
cellular O
proteins O
involved O
in O
vacuolar O
sorting O
( O
VPS4A O
and O
TSG101 O
) O
and O
endocytic O
pathways O
( O
Nedd4 O
) O
, O
suggesting O
involvement O
of O
these O
pathways O
in O
virus O
budding O
. O

As O
for O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
a O
PPPY O
motif O
within O
M O
protein O
can O
interact O
with O
Nedd4 O
. O

In O
this O
study O
, O
we O
compared O
L O
- O
domain O
functions O
between O
Ebola O
virus O
and O
VSV O
by O
constructing O
a O
chimeric O
M O
protein O
( O
M40 O
) O
, O
in O
which O
the O
PPPY O
motif O
of O
VSV O
M O
is O
replaced O
by O
the O
L O
domains O
of O
VP40 O
. O

The O
budding O
efficiency O
of O
M40 O
was O
10 O
- O
fold O
higher O
than O
that O
of O
wild B
- I
type I
( I
WT I
) I
M O
protein O
. O

These O
findings O
suggest O
that O
the O
PSAP O
motif O
of O
M O
protein O
is O
not O
critical O
for O
budding O
and O
that O
there O
are O
fundamental O
differences O
between O
PTAP O
- O
containing O
viruses O
( O
Ebola O
virus O
and O
human O
immunodeficiency O
virus O
type O
1 O
) O
and O
PPPY O
- O
containing O
viruses O
( O
VSV O
and O
rabies O
virus O
) O
regarding O
their O
dependence O
on O
specific O
host O
factors O
for O
efficient O
budding O
. O

The O
inhibition O
of O
viral B
hemorrhagic I
septicemia I
rhabdovirus I
( I
VHSV I
) I
in O
vitro O
infection O
by O
pHs O
of O
< O
7 O
( O
low O
pH O
) O
has O
been O
previously O
reported O
. O

Thus O
, O
while O
VHSV O
bound O
, O
replicated O
within O
single O
cells O
, O
and O
presented O
its O
G O
protein O
on O
the O
membranes O
of O
infected O
cells O
at O
both O
low O
and O
physiological O
pHs O
, O
both O
cell O
- O
to O
- O
cell O
spreading O
of O
infection O
( O
as O
estimated O
by O
the O
appearance O
of O
foci O
of O
infected O
cells O
) O
and O
fusion O
( O
as O
estimated O
by O
a O
syncytium O
assay O
) O
were O
inhibited O
by O
this O
low O
pH O
. O

Here O
we O
present O
the O
genomic O
sequence O
, O
with O
analysis O
, O
of O
a O
canarypox B
virus I
( I
CNPV I
) I
. O

Comparison O
with O
the O
previously O
characterized O
fowlpox B
virus I
( I
FWPV I
) I
genome O
revealed O
avipoxvirus O
- O
specific O
genomic O
features O
, O
including O
large O
genomic O
rearrangements O
relative O
to O
other O
chordopoxviruses O
and O
novel O
cellular O
homologues O
and O
gene O
families O
. O

rabies B
virus I
( I
RV I
) I
vaccine O
strain O
- O
based O
vectors O
show O
significant O
promise O
as O
potential O
live O
- O
attenuated O
vaccines O
against O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

This O
covallently O
linked O
gp140 O
( O
gp140 O
SOS O
) O
is O
fused O
in O
frame O
to O
the O
cytoplasmic O
domain O
of O
RV O
G O
glycoprotein O
and O
is O
efficiently O
incorporated O
into O
the O
RV O
virion O
. O

Recently O
, O
we O
have O
shown O
that O
the O
rabies B
virus I
( I
RV I
) I
matrix I
( I
M I
) I
protein O
regulates O
the O
balance O
of O
virus O
RNA O
synthesis O
by O
shifting O
synthesis O
activity O
from O
transcription O
to O
replication O
( O
S O
. O

A O
recombinant O
virus O
having O
this O
amino O
acid O
exchanged O
with O
a O
glycine O
, O
SAD O
M O
( O
R58G O
) O
, O
has O
lost O
the O
abilities O
to O
downregulate O
RV O
transcription O
and O
to O
stimulate O
replication O
. O

Most O
importantly O
, O
the O
efficiencies O
of O
virus O
assembly O
and O
budding O
were O
equal O
for O
wild O
- O
type O
M O
and O
M O
( O
R58G O
) O
, O
as O
determined O
in O
assays O
studying O
the O
transient O
complementation O
of O
an O
M O
- O
and O
G O
- O
deficient O
RV O
construct O
, O
NPgrL O
. O

In O
addition O
, O
virus O
particle O
density O
, O
protein O
composition O
, O
and O
specific O
infectivity O
of O
SAD O
L16 O
and O
SAD O
M O
( O
R58G O
) O
viruses O
were O
identical O
. O

We O
showed O
that O
, O
unlike O
pathogenic O
rabies B
virus I
( I
RV I
) I
strain O
CVS O
, O
attenuated O
RV O
strain O
ERA O
triggers O
the O
caspase O
- O
dependent O
apoptosis O
of O
human O
cells O
. O

To O
determine O
whether O
one O
of O
these O
two O
major O
RV O
proteins O
( O
G O
and O
N O
proteins O
) O
triggers O
apoptosis O
, O
we O
constructed O
transgenic O
Jurkat O
T O
- O
cell O
lines O
that O
drive O
tetracycline O
- O
inducible O
gene O
expression O
to O
produce O
the O
G O
and O
N O
proteins O
of O
ERA O
and O
CVS O
individually O
. O

The O
induction O
of O
ERA O
G O
protein O
( O
G O
- O
ERA O
) O
expression O
but O
not O
of O
ERA O
N O
protein O
expression O
resulted O
in O
apoptosis O
, O
and O
G O
- O
ERA O
was O
more O
efficient O
at O
triggering O
apoptosis O
than O
was O
CVS O
G O
protein O
. O

To O
test O
whether O
other O
viral O
proteins O
participated O
in O
the O
induction O
of O
apoptosis O
, O
human O
cells O
were O
infected O
with O
recombinant O
RV O
in O
which O
the O
G O
protein O
gene O
from O
the O
attenuated O
strain O
had O
been O
replaced O
by O
its O
virulent O
strain O
counterpart O
( O
CVS O
) O
. O

E1 O
deletion O
adenoviral O
vectors O
of O
the O
human O
serotype O
5 O
( O
AdHu5 O
) O
and O
the O
chimpanzee O
serotype O
68 O
( O
AdC68 O
) O
expressing O
the O
rabies O
virus O
glycoprotein O
( O
rab O
. O

Recombinant B
rabies I
virus I
( I
RV I
) I
vaccine O
strain O
- O
based O
vectors O
have O
been O
successfully O
developed O
as O
vaccines O
against O
other O
viral O
diseases O
( O
J O
. O

4 O
kb O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
- O
Pol O
precursor O
Pr160 O
. O

Electron O
microscopy O
studies O
showed O
both O
immature O
and O
mature O
HIV O
- O
1 O
virus B
- I
like I
particles I
( I
VLPs I
) I
, O
indicating O
that O
the O
expressed O
HIV O
- O
1 O
Gag O
Pr55 O
precursor O
was O
processed O
properly O
by O
the O
HIV O
- O
1 O
protease O
. O

A O
functional O
assay O
also O
confirmed O
the O
cleavage O
and O
functional O
expression O
of O
the O
HIV O
- O
1 O
reverse B
transcriptase I
( I
RT I
) I
from O
the O
modified O
RV O
genome O
. O

6P O
) O
RV O
envelope O
protein O
from O
an O
additional O
RV O
transcription O
unit O
located O
between O
the O
RV O
nucleoprotein B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
in O
addition O
to O
HIV O
- O
1 O
Pr160 O
. O

2 O
- O
kb O
chimeric O
HIV O
- O
1 O
/ O
RV O
envelope O
protein O
is O
composed O
of O
the O
HIV O
- O
1 O
Env O
ectodomain O
( O
ED O
) O
and O
transmembrane B
domain I
( I
TD I
) I
fused O
to O
RV O
glycoprotein B
( I
G I
) I
cytoplasmic I
domain I
( I
CD I
) I
, O
which O
is O
required O
for O
efficient O
incorporation O
of O
HIV O
- O
1 O
Env O
into O
RV O
particles O
. O

In O
this O
study O
, O
we O
examined O
the O
efficiency O
of O
gene O
transfer O
both O
in O
vitro O
and O
in O
vivo O
by O
recombinant O
baculoviruses O
possessing O
envelope O
proteins O
derived O
from O
either O
vesicular B
stomatitis I
virus I
( I
VSVG I
) I
or O
rabies O
virus O
. O

We O
have O
previously O
shown O
that O
the O
nonstructural B
( I
NS I
) I
proteins O
NS1 O
and O
NS2 O
of O
bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
mediate O
resistance O
to O
the O
alpha O
/ O
beta O
interferon B
( I
IFN I
) I
- O
mediated O
antiviral O
response O
. O

Here O
, O
we O
show O
that O
they O
, O
in O
addition O
, O
are O
able O
to O
prevent O
the O
induction O
of O
beta O
IFN O
( O
IFN O
- O
beta O
) O
after O
virus O
infection O
or O
double O
- O
stranded O
RNA O
stimulation O
. O

In O
BRSV O
- O
infected O
MDBK O
cells O
upregulation O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
such O
as O
MxA O
did O
not O
occur O
, O
although O
IFN O
signaling O
via O
JAK O
/ O
STAT O
was O
found O
intact O
. O

Biological O
IFN O
activity O
and O
IFN O
- O
beta O
were O
detected O
only O
in O
supernatants O
of O
cells O
infected O
with O
the O
NS O
deletion O
mutants O
but O
not O
with O
wild B
- I
type I
( I
WT I
) I
BRSV O
. O

Induction O
of O
the O
IFN O
- O
beta O
promoter O
depends O
on O
the O
activation O
of O
three O
distinct O
transcription O
factors O
, O
NF O
- O
kappaB O
, O
ATF O
- O
2 O
/ O
c O
- O
Jun O
, O
and O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
. O

There O
are O
two O
major O
serotypes O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
Indiana O
( O
VSIV O
) O
and O
New O
Jersey O
( O
VSNJV O
) O
. O

We O
recovered O
recombinant O
VSIVs O
from O
engineered O
cDNAs O
that O
contained O
either O
( O
i O
) O
one O
copy O
of O
the O
VSIV O
G O
gene O
( O
VSIV O
- O
G O
( O
I O
) O
) O
; O
( O
ii O
) O
two O
copies O
of O
the O
G O
gene O
, O
one O
from O
each O
serotype O
( O
VSIV O
- O
G O
( O
NJ O
) O
G O
( O
I O
) O
) O
; O
or O
( O
iii O
) O
a O
single O
copy O
of O
the O
G O
( O
NJ O
) O
gene O
instead O
of O
the O
GI O
gene O
( O
VSIV O
- O
G O
( O
NJ O
) O
) O
. O

The O
recombinant O
viruses O
expressed O
the O
appropriate O
glycoproteins O
, O
incorporated O
them O
into O
virions O
, O
and O
were O
neutralized O
by O
antibodies O
specific O
for O
VSIV O
( O
VSIV O
- O
G O
( O
I O
) O
) O
, O
VSNJV O
( O
VSIV O
- O
G O
( O
NJ O
) O
) O
, O
or O
both O
( O
VSIV O
- O
G O
( O
NJ O
) O
G O
( O
I O
) O
) O
, O
according O
to O
the O
glycoprotein O
( O
s O
) O
they O
expressed O
. O

In O
mice O
, O
VSIV O
- O
G O
( O
NJ O
) O
and O
VSIV O
- O
G O
( O
NJ O
) O
G O
( O
I O
) O
were O
attenuated O
. O

However O
, O
in O
swine O
, O
a O
natural O
host O
for O
VSV O
, O
the O
G O
( O
NJ O
) O
glycoprotein O
- O
containing O
viruses O
caused O
more O
severe O
lesions O
and O
replicated O
to O
higher O
titers O
than O
the O
parental O
virus O
, O
VSIV O
- O
G O
( O
I O
) O
. O

To O
examine O
the O
requirements O
of O
the O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
SH I
( I
small I
hydrophobic I
) I
, O
G O
( O
attachment O
) O
, O
and O
F O
( O
fusion O
) O
proteins O
for O
virus O
infectivity O
and O
morphology O
, O
we O
used O
the O
prototype O
A2 O
strain O
of O
HRSV O
to O
generate O
a O
series O
of O
cDNAs O
from O
which O
( O
i O
) O
the O
SH O
open B
reading I
frame I
( I
ORF I
) I
, O
( O
ii O
) O
the O
SH O
and O
G O
ORFs O
, O
or O
( O
iii O
) O
the O
SH O
, O
G O
, O
and O
F O
ORFs O
were O
deleted O
. O

Each O
deleted O
ORF O
was O
replaced O
as O
follows O
: O
the O
SH O
ORF O
was O
replaced O
with O
that O
of O
green O
fluorescent O
protein O
; O
the O
G O
ORF O
was O
replaced O
with O
that O
of O
G O
( O
vsv O
) O
, O
a O
chimeric O
glycoprotein O
consisting O
of O
the O
Vesicular B
stomatitis I
Indiana I
virus I
( I
VSIV I
) I
G O
protein O
ecto O
- O
and O
transmembrane O
domains O
coupled O
to O
the O
HRSV O
F O
cytoplasmic O
tail O
; O
and O
the O
F O
ORF O
was O
replaced O
with O
that O
of O
marker O
protein O
beta O
- O
glucuronidase O
. O

Infectious O
viruses O
were O
recovered O
from O
all O
three O
engineered O
cDNAs O
and O
designated O
RSDeltaSH O
, O
RSDeltaSH O
, O
G O
/ O
G O
( O
vsv O
) O
, O
and O
RSDeltaSH O
, O
G O
, O
F O
/ O
G O
( O
vsv O
) O
, O
respectively O
. O

Low O
- O
pH O
- O
induced O
syncytium O
formation O
was O
observed O
in O
cells O
infected O
with O
viruses O
RSDeltaSH O
, O
G O
/ O
G O
( O
vsv O
) O
and O
RSDeltaSH O
, O
G O
, O
F O
/ O
G O
( O
vsv O
) O
indicating O
that O
G O
( O
vsv O
) O
was O
expressed O
and O
functional O
. O

Neutralization O
of O
infectivity O
by O
anti O
- O
VSIV O
G O
antibodies O
and O
inhibition O
of O
entry O
by O
ammonium O
chloride O
showed O
that O
RSDeltaSH O
, O
G O
, O
F O
/ O
G O
( O
vsv O
) O
infectivity O
was O
mediated O
by O
G O
( O
vsv O
) O
and O
that O
an O
acidification O
step O
was O
required O
for O
entry O
into O
the O
host O
cell O
, O
similar O
to O
VSIV O
virions O
. O

rabies B
virus I
( I
RV I
) I
vaccine O
strain O
- O
based O
vectors O
show O
great O
promise O
as O
vaccines O
against O
other O
viral O
diseases O
such O
as O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
and O
hepatitis O
C O
, O
but O
a O
low O
residual O
pathogenicity O
remains O
a O
concern O
for O
their O
use O
. O

For O
this O
approach O
, O
we O
modified O
the O
previously O
described O
RV O
vaccine O
vector O
SPBN O
by O
replacing O
the O
arginine O
at O
position O
333 O
( O
R333 O
) O
within O
the O
RV O
glycoprotein B
( I
G I
) I
with O
glutamic O
acid O
( O
E333 O
) O
, O
deleting O
43 O
amino O
acids O
of O
the O
RV O
G O
cytoplasmic B
domain I
( I
CD I
) I
, O
or O
combining O
the O
R333 O
exchange O
and O
the O
CD O
deletion O
. O

In O
addition O
, O
we O
constructed O
a O
new O
RV O
vector O
that O
expresses O
HIV O
- O
1 O
Gag O
from O
an O
RV O
transcription O
unit O
upstream O
of O
the O
RV O
phosphoprotein O
gene O
( O
BNSP O
- O
Gag O
) O
instead O
of O
upstream O
of O
the O
G O
gene O
. O

However O
, O
the O
new O
, O
second O
- O
generation O
vaccine O
vectors O
containing O
modifications O
in O
the O
RV O
G O
were O
also O
apathogenic O
after O
intracranial O
infection O
with O
10 O
( O
5 O
) O
infectious O
particles O
, O
and O
BNSP O
- O
Gag O
produced O
a O
50 O
% O
- O
reduced O
mortality O
in O
mice O
. O

The O
neurotrophin O
receptor O
( O
p75NTR O
) O
serves O
as O
a O
receptor O
for O
rabies B
virus I
( I
RV I
) I
. O

We O
expressed O
and O
purified O
a O
soluble O
chimera O
consisting O
of O
the O
p75NTR O
ectodomain O
fused O
to O
the O
human B
immunoglobulin I
G1 I
( I
IgG1 I
) I
Fc O
fragment O
( O
p75 O
- O
Fc O
) O
. O

However O
, O
when O
it O
was O
subsequently O
incubated O
with O
an O
antihuman O
IgG O
directed O
against O
the O
Fc O
fragment O
of O
p75 O
- O
Fc O
, O
the O
infectivity O
of O
RV O
was O
significantly O
lowered O
( O
> O
90 O
% O
) O
, O
whereas O
incubation O
with O
antihuman O
IgG O
alone O
had O
no O
effect O
. O

We O
then O
selected O
eight O
independent O
RV O
mutants O
that O
were O
not O
neutralized O
by O
p75 O
- O
Fc O
and O
antihuman O
IgG O
( O
srr O
[ O
soluble O
receptor O
resistant O
] O
mutants O
) O
. O

Two O
of O
the O
mutations O
were O
located O
at O
position O
318 O
( O
phenylalanine O
replaced O
by O
a O
serine O
or O
a O
valine O
residue O
) O
, O
and O
two O
were O
located O
at O
position O
352 O
( O
histidine O
replaced O
by O
a O
tyrosine O
or O
an O
arginine O
residue O
) O
. O

Two O
mutants O
( O
F318S O
) O
and O
( O
H352R O
) O
resulted O
in O
the O
formation O
of O
small O
plaques O
on O
BSR O
cells O
, O
probably O
due O
to O
the O
slower O
maturation O
of O
the O
glycoprotein O
. O

Immunoprecipitation O
, O
immunofluorescence O
, O
and O
neutralization O
assays O
showed O
that O
the O
four O
mutated O
glycoproteins O
still O
interacted O
with O
representative O
anti O
- O
RV O
glycoprotein O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
indicating O
that O
p75NTR O
binds O
outside O
of O
the O
known O
RV O
glycoprotein O
antigenic O
sites O
. O

Rabies O
virus O
nucleoprotein B
( I
N I
) I
plays O
vital O
roles O
in O
regulation O
of O
viral O
RNA O
transcription O
and O
replication O
by O
encapsidation O
of O
the O
nascent O
genomic O
RNA O
. O

In O
the O
present O
study O
, O
we O
mutated O
the O
serine B
( I
S I
) I
at O
position O
389 O
to O
Alanine B
( I
A I
) I
, O
Glycine B
( I
G I
) I
, O
Aspartic B
acid I
( I
D I
) I
, O
Asparagine B
( I
N I
) I
, O
Glutamic B
acid I
( I
E I
) I
, O
and O
Glutamine B
( I
Q I
) I
and O
examined O
the O
effects O
of O
these O
mutations O
on O
rabies O
virus O
transcription O
and O
replication O
in O
the O
minigenome O
. O

Growth O
curve O
studies O
indicated O
that O
production O
of O
the O
mutant O
virus O
with O
the O
S O
- O
to O
- O
A O
mutation O
( O
L16A O
) O
was O
as O
much O
as O
10 O
, O
000 O
- O
fold O
less O
than O
that O
of O
the O
wild O
- O
type O
virus O
( O
L16 O
) O
. O

bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
escapes O
from O
cellular O
responses O
to O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
by O
a O
concerted O
action O
of O
the O
two O
viral O
nonstructural O
proteins O
, O
NS1 O
and O
NS2 O
. O

Here O
we O
show O
that O
the O
NS O
proteins O
of O
human B
RSV I
( I
hRSV I
) I
are O
also O
able O
to O
counteract O
IFN O
responses O
and O
that O
they O
have O
the O
capacity O
to O
protect O
replication O
of O
an O
unrelated O
rhabdovirus O
. O

A O
chimeric O
BRSV O
with O
HRSV O
NS O
genes O
( O
BRSV O
h1 O
/ O
2 O
) O
was O
severely O
attenuated O
in O
bovine O
IFN O
competent O
MDBK O
and O
Klu O
cells O
, O
whereas O
it O
replicated O
like O
BRSV O
in O
IFN O
- O
incompetent O
Vero O
cells O
or O
in O
IFN O
- O
competent O
human O
HEp O
- O
2 O
cells O
. O

When O
the O
Ebola O
virus O
glycoprotein B
( I
GP I
) I
responsible O
for O
receptor O
binding O
and O
membrane O
fusion O
was O
expressed O
in O
cells O
, O
we O
found O
pleomorphic O
particles O
budding O
from O
the O
plasma O
membrane O
. O

A O
Recombinant B
rabies I
virus I
( I
RV I
) I
carrying O
two O
identical O
glycoprotein B
( I
G I
) I
genes O
( O
SPBNGA O
- O
GA O
) O
was O
constructed O
and O
used O
to O
determine O
the O
effect O
of O
RV O
G O
overexpression O
on O
cell O
viability O
and O
immunity O
. O

Immunoprecipitation O
analysis O
and O
flow O
cytometry O
showed O
that O
tissue O
culture O
cells O
infected O
with O
SPBNGA O
- O
GA O
, O
produced O
, O
on O
average O
, O
twice O
as O
much O
RV O
G O
as O
cells O
infected O
with O
RV O
carrying O
only O
a O
single O
RV O
G O
gene O
( O
SPBNGA O
) O
. O

An O
E1 O
- O
deletion O
- O
containing O
adenoviral O
recombinant O
based O
on O
the O
chimpanzee O
serotype O
68 O
( O
AdC68 O
) O
was O
developed O
to O
express O
the O
rabies O
virus O
glycoprotein O
. O

gp O
were O
comparable O
with O
regard O
to O
both O
titers O
and O
isotype O
profiles O
to O
those O
induced O
by O
an O
adenoviral O
recombinant O
based O
on O
human O
serotype O
5 O
( O
Adhu5 O
) O
expressing O
the O
same O
transgene O
product O
. O

Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
and O
viral B
hemorrhagic I
septicemia I
virus I
( I
VHSV I
) I
are O
two O
salmonid O
rhabdoviruses O
replicating O
at O
low O
temperatures O
( O
14 O
to O
20degreesC O
) O
. O

This O
study O
was O
extended O
by O
exchanging O
IHNV O
G O
with O
that O
of O
a O
fish O
vesiculovirus O
able O
to O
replicate O
at O
high O
temperatures O
( O
up O
to O
28degreesC O
) O
, O
the O
spring B
viremia I
of I
carp I
virus I
( I
SVCV I
) I
. O

To O
determine O
to O
what O
extent O
the O
matrix B
( I
M I
) I
protein O
interacts O
with O
G O
, O
a O
series O
of O
chimeric O
pIHNV O
constructs O
in O
which O
all O
or O
part O
of O
the O
M O
gene O
was O
replaced O
with O
the O
VHSV O
counterpart O
was O
engineered O
and O
used O
to O
recover O
the O
respective O
recombinant O
viruses O
. O

Despite O
the O
very O
low O
percentage O
( O
38 O
% O
) O
of O
amino O
acid O
identity O
between O
the O
IHNV O
and O
VHSV O
matrix O
proteins O
, O
viable O
chimeric O
IHNVs O
, O
harboring O
either O
the O
matrix O
protein O
or O
both O
the O
glycoprotein O
and O
the O
matrix O
protein O
from O
VHSV O
, O
were O
recovered O
and O
propagated O
. O

By O
comparing O
three O
expression O
vectors O
for O
the O
rabies B
virus I
( I
RV I
) I
minigenome O
, O
we O
show O
that O
the O
characteristic O
of O
the O
Rv O
RNA O
is O
important O
for O
efficient O
rescue O
despite O
its O
not O
being O
crucial O
for O
replication O
. O

We O
describe O
replication O
- O
competent O
, O
vaccine O
strain O
- O
based O
rabies B
viruses I
( I
RVs I
) I
that O
lack O
their O
own O
single O
glycoprotein O
and O
express O
, O
instead O
, O
a O
chimeric O
RV O
- O
human B
immunodeficiency I
virus I
type I
I I
( I
HIV I
- I
1 I
) I
envelope O
protein O
composed O
of O
the O
ectodomain O
and O
transmembrane O
domains O
of O
HIV O
- O
1 O
gp160 O
and O
the O
cytoplasmic O
domain O
of O
RV O
G O
. O

The O
envelope O
proteins O
from O
both O
X4 O
( O
NL4 O
- O
3 O
) O
- O
and O
R5X4 O
( O
89 O
. O

As O
observed O
for O
HIV O
- O
1 O
, O
the O
surrogate O
viruses O
were O
able O
to O
target O
human O
peripheral O
blood O
mononuclear O
cells O
, O
macrophages O
, O
and O
immature O
and O
mature O
human B
dendritic I
cells I
( I
DC I
) I
. O

The O
presence O
of O
a O
novel O
form O
of O
zebrafish O
fibronectin O
( O
FN2 O
) O
on O
the O
cell O
surface O
increased O
the O
cell O
' O
s O
susceptibility O
to O
infection O
by O
Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
. O

Fish O
embryo O
cells O
expressing O
recombinant O
FN2 O
were O
more O
susceptible O
to O
IHNV O
infection O
, O
with O
a O
greater O
percentage O
of O
cells O
exhibiting O
cytopathic B
effect I
( I
CPE I
) I
compared O
to O
nontransfected O
control O
cells O
. O

rabies B
virus I
( I
RV I
) I
is O
a O
highly O
neurotropic O
virus O
that O
migrates O
from O
the O
portal O
of O
entry O
to O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

The O
cytoplasmic O
dynein O
light B
chain I
( I
LC8 I
) I
, O
which O
is O
involved O
in O
a O
variety O
of O
intracellular O
motile O
events O
, O
was O
shown O
to O
interact O
with O
RV O
phosphoprotein B
( I
P I
) I
. O

In O
order O
to O
determine O
the O
functional O
significance O
of O
this O
interaction O
, O
P O
residues O
143 O
to O
149 O
or O
139 O
to O
149 O
encompassing O
a O
conserved O
LC8 O
- O
interacting O
motif O
( O
K O
/ O
RXTQT O
) O
were O
deleted O
from O
recombinant O
viruses O
SAD O
- O
L16 O
and O
SAD O
- O
D29 O
. O

These O
viruses O
are O
identical O
except O
for O
a O
replacement O
of O
the O
arginine O
at O
position O
333 O
( O
R333 O
) O
of O
the O
RV O
glycoprotein O
ky O
an O
aspartic O
acid O
in O
SAD O
- O
D29 O
. O

The O
matrix B
( I
M I
) I
proteins O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
rabies B
virus I
( I
RV I
) I
play O
a O
key O
role O
in O
both O
assembly O
and O
budding O
of O
progeny O
virions O
. O

A O
PPPY O
motif O
( O
PY O
motif O
or O
late O
- O
budding O
domain O
) O
is O
conserved O
in O
the O
M O
proteins O
of O
VSV O
and O
RV O
. O

The O
extent O
of O
apoptosis O
was O
strongly O
increased O
in O
primary O
neuron O
cultures O
infected O
with O
the O
recombinant O
virus O
carrying O
the O
active O
cytochrome O
c O
gene O
[ O
SPBN O
- O
Cyto O
c O
( O
+ O
) O
] O
, O
compared O
with O
cells O
infected O
with O
the O
recombinant O
virus O
containing O
the O
inactive O
cytochrome O
c O
gene O
[ O
SPBN O
- O
Cyto O
c O
( O
- O
) O
] O
. O

Mortality O
in O
mice O
infected O
intranasally O
with O
SPBN O
- O
Cyto O
c O
( O
+ O
) O
was O
substantially O
lower O
than O
in O
SPBN O
- O
Cyto O
c O
( O
- O
) O
- O
infected O
mice O
. O

Furthermore O
, O
virus B
- I
neutralizing I
antibody I
( I
VNA I
) I
titers O
were O
significantly O
higher O
in O
mice O
immunized O
with O
SPBN O
- O
Cyto O
c O
( O
+ O
) O
at O
the O
same O
dose O
. O

The O
VNA O
titers O
induced O
by O
these O
recombinant O
viruses O
paralleled O
their O
protective O
activities O
against O
a O
lethal O
rabies O
virus O
challenge O
infection O
, O
with O
SPBN O
- O
Cyto O
c O
( O
+ O
) O
revealing O
an O
effective O
dose O
20 O
times O
lower O
than O
that O
of O
SPBN O
- O
Cyto O
c O
( O
- O
) O
. O

The O
strong O
increase O
in O
immunogenicity O
, O
coupled O
with O
the O
marked O
reduction O
in O
pathogenicity O
, O
identifies O
the O
SPBN O
- O
Cyto O
c O
( O
+ O
) O
construct O
as O
a O
candidate O
for O
a O
live O
rabies O
virus O
vaccine O
. O

Tests O
of O
neutrality O
indicated O
a O
neutral O
model O
of O
evolution O
, O
also O
supported O
by O
globally O
high O
ratios O
of O
synonymous O
substitutions O
( O
d O
( O
S O
) O
) O
to O
nonsynonymous O
substitutions O
( O
d O
( O
N O
) O
) O
( O
> O
7 O
) O
. O

3 O
X O
10 O
( O
- O
4 O
) O
d O
( O
S O
) O
/ O
site O
/ O
year O
. O

Glycoprotein O
segments O
accumulating O
more O
d O
( O
N O
) O
than O
d O
( O
S O
) O
were O
distinctly O
detected O
in O
carnivoran O
and O
chiropteran O
lyssaviruses O
. O

A O
replication O
- O
competent O
rhabdovirus O
- O
based O
vector O
expressing O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
protein O
was O
characterized O
on O
human O
cell O
lines O
and O
analyzed O
for O
the O
induction O
of O
a O
cellular O
immune O
response O
in O
mice O
. O

We O
previously O
described O
a O
rabies B
virus I
( I
RV I
) I
vaccine O
strain O
- O
based O
vector O
expressing O
HIV O
- O
1 O
gp160 O
. O

8 O
% O
of O
CD8 O
( O
+ O
) O
T O
cells O
from O
mice O
immunized O
with O
RV O
expressing O
HIV O
- O
1 O
Gag O
produced O
gamma O
interferon O
after O
challenge O
with O
a O
recombinant O
vaccinia O
virus O
expressing O
HIV O
- O
1 O
Gag O
. O

Novel O
viral O
vectors O
that O
are O
able O
to O
induce O
both O
strong O
and O
long O
- O
lasting O
immune O
responses O
may O
be O
required O
as O
effective O
vaccines O
for O
human B
immunodeficiency I
virus I
type I
I I
( I
HIV I
- I
1 I
) I
infection O
. O

Our O
previous O
experiments O
with O
a O
replication O
- O
competent O
vaccine O
strain O
- O
based O
rabies B
virus I
( I
RV I
) I
expressing O
HIV O
- O
1 O
envelope O
protein O
from O
a O
laboratory O
- O
adapted O
HIV O
- O
1 O
strain O
( O
NL4 O
- O
3 O
) O
and O
a O
primary O
HIV O
- O
1 O
isolate O
( O
89 O
. O

Here O
we O
report O
that O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
against O
HIV O
- O
I O
gp160 O
are O
induced O
by O
recombinant O
RVs O
. O

The O
genetic O
diversity O
of O
representative O
members O
of O
the O
Lyssavirus O
genus O
( O
rabies O
and O
rabies O
- O
related O
viruses O
) O
was O
evaluated O
using O
the O
gene O
encoding O
the O
transmembrane O
glycoprotein O
involved O
in O
the O
virus O
- O
host O
interaction O
, O
immunogenicity O
, O
and O
pathogenicity O
. O

Phylogroup O
I O
comprises O
the O
worldwide O
genotype O
1 O
( O
classic O
Rabies O
virus O
) O
, O
the O
European B
bat I
lyssavirus I
( I
EBL I
) I
genotypes O
5 O
( O
EBL1 O
) O
and O
6 O
( O
EBL2 O
) O
, O
the O
African O
genotype O
4 O
( O
Duvenhage O
virus O
) O
, O
and O
the O
Australian O
bat O
lyssavirus O
genotype O
7 O
, O
Phylogroup O
II O
comprises O
the O
divergent O
African O
genotypes O
2 O
( O
Lagos O
bat O
virus O
) O
and O
3 O
( O
Mokola O
virus O
) O
, O
We O
studied O
immunogenic O
and O
pathogenic O
properties O
to O
investigate O
the O
biological O
significance O
of O
this O
phylogenetic O
grouping O
. O

Viruses O
from O
phylogroup O
I O
( O
Rabies O
virus O
and O
EBL1 O
) O
were O
found O
to O
be O
pathogenic O
for O
mice O
when O
injected O
by O
the O
intracerebral O
or O
the O
intramuscular O
route O
, O
whereas O
viruses O
from O
phylogroup O
II O
( O
Mokola O
and O
Lagos O
bat O
viruses O
) O
were O
only O
pathogenic O
by O
the O
intracerebral O
route O
. O

5 O
% O
and O
the O
cross O
- O
neutralization O
was O
absent O
, O
explaining O
why O
the O
classical O
rabies O
vaccines O
( O
phylogroup O
I O
) O
cannot O
protect O
against O
lyssaviruses O
from O
phylogroup O
II O
. O

The O
role O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
lymphotoxin O
signaling O
in O
the O
control O
of O
rabies O
virus O
ocular O
infection O
and O
inflammatory O
cell O
infiltration O
was O
assessed O
using O
mire O
lacking O
the O
p55 O
TNF O
- O
alpha O
receptor O
( O
p55TNFR O
( O
- O
/ O
- O
) O
mice O
) O
. O

The O
incidence O
of O
ocular O
disease O
and O
the O
intensity O
of O
retinal O
infection O
were O
greater O
in O
p55TNFR O
( O
- O
/ O
- O
) O
mice O
than O
in O
C57BL O
/ O
6 O
mice O
: O
the O
aggravation O
correlated O
with O
less O
neutrophil O
and O
T O
- O
cell O
infiltration O
. O

Rabies O
virus O
nucleoprotein B
( I
N I
) I
was O
produced O
in O
insect O
cells O
, O
in O
which O
it O
forms O
nucleoprotein O
- O
RNA O
( O
N O
- O
RNA O
) O
complexes O
that O
are O
biochemically O
and O
biophysically O
indistinguishable O
from O
rabies O
virus O
N O
- O
RNA O
. O

Trypsin O
- O
treated O
N O
- O
RNA O
no O
longer O
bound O
to O
recombinant O
rabies O
virus O
phosphoprotein O
( O
the O
viral O
polymerase O
cofactor O
) O
, O
so O
the O
presence O
of O
the O
C O
- O
terminal O
part O
of O
N O
is O
needed O
for O
binding O
of O
the O
phosphoprotein O
. O

To O
get O
insights O
into O
the O
role O
played O
by O
each O
of O
the O
influenza O
A O
virus O
polypeptides O
in O
morphogenesis O
and O
virus O
particle O
assembly O
, O
the O
generation O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
has O
been O
examined O
in O
COS O
- O
1 O
cell O
cultures O
expressing O
, O
from O
recombinant O
plasmids O
, O
different O
combinations O
of O
the O
viral O
structural O
proteins O
. O

It O
is O
demonstrated O
that O
the O
matrix B
( I
Ml I
) I
protein O
is O
the O
only O
viral O
component O
which O
is O
essential O
for O
VLP O
formation O
and O
that O
the O
viral O
ribonucleoproteins O
are O
not O
required O
for O
virus O
particle O
formation O
. O

We O
investigated O
the O
role O
of O
P O
( O
CVS O
strain O
) O
by O
searching O
for O
cellular O
partners O
by O
using O
a O
two O
- O
hybrid O
screening O
of O
a O
PC12 O
cDNA O
library O
. O

We O
isolated O
a O
cDNA O
encoding O
a O
10 O
- O
kDa O
dynein O
light B
chain I
( I
LC8 I
) I
. O

Series O
of O
deletions O
from O
the O
N O
- O
and O
C O
- O
terminal O
ends O
of O
P O
protein O
were O
used O
to O
map O
the O
LC8 O
- O
binding O
domain O
to O
the O
central O
part O
of O
P O
( O
residues O
138 O
to O
172 O
) O
. O

Using O
a O
yeast O
two O
- O
hybrid O
human O
brain O
cDNA O
library O
screen O
, O
the O
cytoplasmic O
dynein O
light B
chain I
( I
LC8 I
) I
, O
a O
10 O
- O
kDa O
protein O
, O
was O
found O
to O
interact O
strongly O
with O
the O
phosphoprotein B
( I
P I
) I
of O
two O
lyssaviruses O
: O
rabies O
virus O
( O
genotype O
1 O
) O
and O
Mokola O
virus O
( O
genotype O
3 O
) O
. O

The O
high O
degree O
of O
sequence O
divergence O
between O
these O
P O
proteins O
( O
only O
46 O
% O
amino O
acid O
identity O
) O
favors O
the O
hypothesis O
that O
this O
interaction O
is O
a O
common O
property O
shared O
by O
all O
lyssaviruses O
. O

The O
functions O
of O
bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
nonstructural O
proteins O
NS1 O
and O
NS2 O
were O
studied O
by O
generation O
and O
analysis O
of O
recombinant O
BRSV O
carrying O
single O
and O
double O
gene O
deletions O
. O

Whereas O
in O
MDBK O
cells O
the O
lack O
of O
either O
or O
both O
NS O
genes O
resulted O
in O
a O
5 O
, O
000 O
- O
to O
10 O
, O
000 O
- O
fold O
reduction O
of O
virus O
titers O
, O
in O
Vero O
cells O
a O
moderate O
( O
IO O
- O
fold O
) O
reduction O
was O
observed O
. O

Interestingly O
, O
cell O
culture O
supernatants O
from O
infected O
MDBK O
cells O
were O
able O
to O
restrain O
the O
growth O
of O
NS O
deletion O
mutants O
in O
Vero O
cells O
, O
suggesting O
the O
involvement O
of O
NS O
proteins O
in O
escape O
from O
cytokine O
- O
mediated O
host O
cell O
responses O
, O
The O
responsible O
factors O
in O
MDBK O
supernatants O
were O
identified O
as O
type O
I O
interferons O
by O
neutralization O
of O
the O
inhibitory O
effect O
with O
antibodies O
blocking O
the O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
receptor O
. O

To O
verify O
this O
finding O
, O
we O
generated O
recombinant B
rabies I
virus I
( I
rRV I
) I
expressing O
either O
NS1 O
or O
NS2 O
and O
determined O
their O
IFN O
sensitivity O
. O

To O
address O
the O
role O
of O
the O
heterogeneous O
rabies B
virus I
( I
RV I
) I
intergenic I
regions I
( I
IGRs I
) I
in O
transcription O
attenuation O
, O
we O
constructed O
bicistronic O
model O
RNAs O
in O
which O
two O
reporter O
genes O
are O
separated O
by O
the O
RV O
NIP O
gene O
border O
, O
Replacement O
of O
the O
2 O
- O
nucleotide B
( I
nt I
) I
NIP O
IGR O
with O
the O
5 O
- O
nt O
IGRs O
from O
the O
P O
/ O
M O
or O
MIG O
border O
resulted O
in O
attenuation O
of O
downstream O
gene O
transcription O
to O
78 O
or O
81 O
% O
, O
respectively O
. O

This O
indicated O
that O
attenuation O
in O
RV O
is O
correlated O
with O
the O
length O
of O
the O
IGR O
, O
and O
, O
in O
particular O
, O
severe O
downregulation O
of O
the O
L O
( O
polymerase O
) O
gene O
by O
the O
24 O
nt O
IGR O
, O
By O
reverse O
genetics O
, O
we O
recovered O
viable O
RVs O
in O
which O
the O
strongly O
attenuating O
G O
/ O
L O
gene O
border O
of O
wild B
- I
type I
( I
WT I
) I
RV O
( O
SAD O
L16 O
) O
was O
replaced O
with O
N O
/ O
P O
- O
derived O
gene O
borders O
( O
SAD O
T O
and O
SAD O
T2 O
) O
, O
In O
these O
viruses O
, O
transcription O
of O
L O
mRNA O
was O
enhanced O
by O
factors O
of O
1 O
. O

The O
promoters O
involved O
in O
transcription O
and O
RNA O
replication O
by O
respiratory B
syncytial I
virus I
( I
RSV I
) I
were O
examined O
by O
using O
a O
plasmid O
- O
based O
minireplicon O
system O
. O

The O
3 O
' O
ends O
of O
the O
genome O
and O
antigenome O
, O
which O
, O
respectively O
, O
contain O
the O
44 O
- O
nucleotide B
( I
nt I
) I
leader O
( O
Le O
) O
and O
155 O
- O
nt O
trailer B
- I
complement I
( I
TrC I
) I
regions O
, O
should O
each O
contain O
a O
promoter O
for O
RNA O
replication O
. O

Substitution O
for O
the O
Le O
with O
various O
lengths O
of O
TrC O
demonstrated O
that O
the O
3 O
' O
- O
terminal O
36 O
nt O
of O
TrC O
are O
sufficient O
for O
extensive O
( O
but O
not O
maximal O
) O
replication O
and O
that O
when O
juxtaposed O
with O
a O
transcription O
gene B
- I
start I
( I
GS I
) I
signal O
, O
this O
sequence O
was O
also O
able O
to O
direct O
transcription O
. O

The O
phosphoprotein B
( I
P I
) I
gene O
of O
rabies O
virus O
( O
CVS O
strain O
) O
was O
cloned O
and O
expressed O
in O
bacteria O
. O

The O
purified O
protein O
was O
used O
as O
the O
substrate O
for O
phosphorylation O
by O
the O
protein O
kinase O
( O
s O
) O
present O
in O
cell O
extract O
prepared O
from O
rat O
brain O
. O

Further O
purification O
of O
the O
cell O
fractions O
revealed O
that O
the O
protein B
kinase I
C I
( I
PKC I
) I
isomers O
constitute O
the O
staurosporin O
- O
sensitive O
kinases O
alpha O
, O
beta O
, O
gamma O
, O
and O
zeta O
, O
with O
the O
PKC O
gamma O
isomer O
being O
the O
most O
elective O
in O
phosphorylating O
the O
P O
protein O
. O

A O
unique O
heparin O
- O
sensitive O
kinase O
was O
characterized O
as O
a O
71 O
- O
kDa O
protein O
with O
biochemical O
properties O
not O
demonstrated O
by O
any O
known O
protein O
kinases O
stored O
in O
the O
protein O
data O
bank O
This O
protein O
kinase O
, O
designated O
RVPK O
( O
rabies O
virus O
protein O
kinase O
) O
, O
phosphorylates O
P O
protein O
( O
36 O
kDa O
) O
and O
alters O
its O
mobility O
in O
gel O
to O
migrate O
at O
40 O
kDa O
. O

Entry O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
the O
prototype O
member O
of O
the O
rhabdovirus O
family O
, O
occurs O
by O
receptor O
- O
mediated O
endocytosis O
. O

Three O
Monoclonal B
antibodies I
( I
MAbs I
) I
generated O
against O
rainbow B
trout I
gonad I
cells I
( I
RTG I
- I
2 I
) I
have O
been O
selected O
for O
their O
ability O
to O
protect O
cells O
from O
the O
viral B
hemorrhagic I
septicemia I
virus I
( I
VHSV I
) I
infection O
, O
a O
salmonid O
rhabdovirus O
. O

( O
i O
) O
An O
antiserum O
generated O
against O
the O
200 O
- O
kDa O
protein O
reacted O
against O
the O
recombinant O
rainbow O
trout O
fibronectin O
expressed O
in O
Escherichia O
coli O
. O

( O
ii O
) O
The O
purified O
rainbow O
trout O
fibronectin O
was O
able O
to O
bind O
specificality O
to O
VHSV O
. O

Typical O
Defective B
interfering I
( I
DI I
) I
RNAs O
are O
more O
successful O
in O
the O
competition O
for O
viral O
polymerase O
than O
the O
parental O
( O
helper O
) O
virus O
, O
which O
is O
mostly O
due O
to O
an O
altered O
DI O
promoter O
composition O
. O

rabies B
virus I
( I
RV I
) I
internal O
deletion O
RNAs O
which O
possess O
the O
authentic O
RV O
terminal O
promoters O
, O
and O
which O
therefore O
are O
transcriptionally O
active O
and O
can O
be O
used O
as O
vectors O
for O
foreign O
gene O
expression O
, O
are O
poorly O
propagated O
in O
RV O
- O
infected O
cells O
and O
do O
not O
interfere O
with O
RV O
replication O
. O

To O
allow O
DI O
- O
like O
amplification O
and O
high O
- O
level O
gene O
expression O
from O
such O
mini O
- O
RNA O
vectors O
, O
we O
have O
used O
an O
engineered O
3 O
' O
copy O
- O
back O
( O
ambisense O
) O
helper O
RV O
in O
which O
the O
strong O
replication O
promoter O
of O
the O
antigenome O
was O
replaced O
with O
the O
50 O
- O
fold O
- O
weaker O
genome O
promoter O
. O

In O
cells O
coinfected O
with O
ambisense O
helper O
virus O
and O
mini O
- O
RNAs O
encoding O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
and O
luciferase O
, O
mini O
- O
RNAs O
were O
amplified O
to O
high O
levels O
. O

The O
matrix B
( I
M I
) I
protein O
of O
rhabdoviruses O
has O
been O
shown O
to O
play O
a O
key O
role O
in O
virus O
assembly O
and O
budding O
; O
however O
, O
the O
precise O
mechanism O
by O
which O
M O
mediates O
these O
processes O
remains O
unclear O
. O

We O
have O
associated O
a O
highly O
conserved O
, O
proline O
- O
rich O
motif O
( O
PPxY O
or O
PY O
motif O
, O
where O
P O
denotes O
proline O
, O
Y O
represents O
tyrosine O
, O
and O
x O
denotes O
any O
amino O
acid O
) O
of O
rhabdoviral O
M O
proteins O
with O
a O
possible O
role O
in O
budding O
mediated O
by O
the O
M O
protein O
. O

Point O
mutations O
that O
disrupt O
the O
PY O
motif O
of O
the O
M O
protein O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
have O
no O
obvious O
effect O
on O
membrane O
localization O
of O
M O
but O
instead O
lead O
to O
a O
decrease O
in O
the O
amount O
of O
M O
protein O
released O
from O
cells O
in O
a O
functional O
budding O
assay O
. O

These O
properties O
of O
the O
PY O
motif O
of O
rhabdovirus O
M O
proteins O
are O
strikingly O
analogous O
tea O
those O
of O
the O
late B
( I
L I
) I
budding O
domain O
identified O
in O
the O
gag O
- O
specific O
protein O
p2b O
of O
Rous O
sarcoma O
virus O
. O

One O
of O
the O
major O
structural O
differences O
between O
rabies O
virus O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
that O
the O
nucleoprotein B
( I
N I
) I
is O
the O
major O
phosphoprotein O
and O
the O
nominal O
phosphoprotein B
( I
P I
) I
is O
less O
phosphorylated O
in O
rabies O
virus O
, O
whereas O
P O
is O
the O
major O
phosphoprotein O
and O
N O
is O
not O
phosphorylated O
in O
VSV O
. O

The O
rabies O
virus O
glycoprotein O
molecule O
( O
G O
) O
can O
be O
divided O
into O
two O
parts O
separated O
by O
a O
flexible O
hinge O
: O
the O
NH O
, O
half O
( O
site O
II O
part O
) O
containing O
antigenic O
site O
II O
up O
to O
the O
linear O
region O
( O
amino O
acids O
[ O
aa O
] O
253 O
to O
275 O
encompassing O
epitope O
VI O
[ O
aa O
264 O
] O
) O
and O
the O
COOH O
half O
( O
site O
III O
part O
) O
containing O
antigenic O
site O
III O
and O
the O
transmembrane O
and O
cytoplasmic O
domains O
. O

The O
structural O
and O
immunological O
roles O
of O
each O
part O
were O
investigated O
by O
cell O
transfection O
and O
mouse O
DNA O
- O
based O
immunization O
with O
homogeneous O
and O
chimeric O
G O
genes O
formed O
by O
fusion O
of O
the O
site O
II O
part O
of O
one O
genotype B
( I
gt I
) I
with O
the O
site O
III O
part O
of O
the O
same O
or O
another O
CT O
. O

Various O
site O
II O
- O
site O
III O
combinations O
between O
G O
genes O
of O
PV O
( O
Pasteur O
virus O
strain O
) O
rabies O
( O
CTI O
) O
, O
Mokola O
( O
GT3 O
) O
, O
and O
EBL1 O
( O
European O
bat O
lyssavirus O
1 O
[ O
GT5 O
] O
) O
viruses O
were O
tested O
. O

Plasmids O
pGPV O
- O
PV O
, O
pGMok O
- O
Mok O
, O
pGMok O
- O
PV O
, O
and O
pGEBL1 O
- O
PV O
induced O
transient O
expression O
of O
correctly O
transported O
and O
folded O
antigens O
in O
neuroblastoma O
cells O
and O
virus O
- O
neutralizing O
antibodies O
against O
parental O
viruses O
in O
mice O
, O
whereas O
, O
pG O
- O
PVIII O
( O
site O
III O
part O
only O
) O
and O
pGPV O
- O
Mok O
did O
not O
. O

The O
site O
III O
part O
of O
PV O
( O
GT1 O
) O
was O
a O
strong O
inducer O
of O
T O
helper O
cells O
and O
was O
very O
effective O
at O
presenting O
the O
site O
II O
part O
of O
various O
GTs O
. O

Chimeric O
plasmid O
pGEBL1 O
- O
PV O
broadens O
the O
spectrum O
of O
protection O
against O
European O
lyssavirus O
genotypes O
( O
GT1 O
, O
GT5 O
, O
and O
GT6 O
) O
. O

To O
elucidate O
the O
functions O
of O
rhabdovirus O
matrix B
( I
M I
) I
protein O
, O
we O
determined O
the O
localization O
of O
M O
in O
rabies B
virus I
( I
RV I
) I
and O
analyzed O
the O
properties O
of O
an O
M O
- O
deficient O
RV O
mutant O
. O

We O
provide O
evidence O
that O
M O
completely O
covers O
the O
ribonucleoprotein B
( I
RNP I
) I
coil O
and O
keeps O
it O
in O
a O
condensed O
form O
. O

The O
cis O
- O
acting O
genomic O
RNA O
requirements O
for O
the O
assembly O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
ribonucleocapsids O
into O
infectious O
particles O
were O
investigated O
. O

Using O
a O
biological O
assay O
based O
on O
particle O
infectivity O
, O
we O
demonstrated O
that O
subgenomic O
replicons O
that O
contained O
all O
four O
possible O
combinations O
of O
the O
natural O
genomic O
termini O
, O
the O
3 O
' O
leader O
( O
Le O
) O
and O
5 O
' O
trailer O
( O
Tr O
) O
regions O
, O
were O
replication O
competent O
; O
however O
, O
a O
3 O
' O
copyback O
replicon O
( O
3 O
' O
CB O
) O
, O
containing O
the O
natural O
3 O
' O
terminus O
but O
having O
the O
5 O
' O
Tr O
replaced O
by O
a O
sequence O
complementary O
to O
the O
3 O
' O
Le O
for O
46 O
nucleotides O
, O
was O
unable O
to O
assemble O
infectious O
particles O
, O
despite O
efficient O
replication O
. O

The O
glycoprotein O
( O
G O
protein O
) O
, O
which O
has O
previously O
been O
implicated O
in O
rabies O
virus O
pathogenicity O
, O
shows O
substantial O
structural O
differences O
between O
these O
variants O
. O

While O
nucleoprotein O
( O
N O
protein O
) O
expression O
levels O
were O
similar O
in O
neurons O
infected O
with O
either O
variant O
, O
the O
transport O
of O
N O
protein O
into O
neuronal O
processes O
was O
strongly O
inhibited O
in O
CVS O
- O
B2c O
- O
infected O
cells O
, O
Thus O
, O
downregulation O
of O
G O
protein O
expression O
in O
neuronal O
cells O
evidently O
contributes O
to O
rabies O
virus O
pathogenesis O
by O
preventing O
apoptosis O
and O
the O
apparently O
associated O
failure O
of O
the O
axonal O
transport O
of O
N O
protein O
. O

Previously O
we O
designed O
novel O
pseudotyped O
high O
- O
titer O
replication O
defective O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
vectors O
to O
deliver O
genes O
into O
nondividing O
cells O
( O
J O
. O

A O
three O
- O
plasmid O
expression O
system O
is O
used O
to O
generate O
pseudotyped O
HIV O
- O
1 O
particles O
by O
transient O
transfection O
of O
human O
embryonic O
kidney O
293T O
cells O
with O
a O
defective O
packaging O
construct O
, O
a O
plasmid O
coding O
for O
a O
heterologous O
envelope B
( I
env I
) I
protein O
, O
and O
a O
vector O
construct O
harboring O
a O
reporter O
gene O
such O
as O
neo O
, O
ShlacZ O
( O
encoding O
a O
phleomycin O
resistance O
/ O
beta O
- O
galactosidase O
fusion O
protein O
) O
, O
HSA O
( O
encoding O
mouse O
heat O
- O
stable O
antigen O
) O
, O
or O
EGFP O
( O
encoding O
enhanced O
green O
fluorescent O
protein O
) O
. O

Using O
G418 O
selection O
, O
we O
routinely O
obtained O
vector O
particles O
pseudotyped O
with O
the O
vesicular B
stomatitis I
virus I
G I
glycoprotein I
( I
VSV I
- I
G I
) I
with O
titers O
of O
up O
to O
8 O
x O
10 O
( O
7 O
) O
CFU O
/ O
mu O
g O
of O
p24 O
, O
provided O
that O
a O
functional O
Tat O
coding O
region O
was O
present O
in O
the O
vector O
. O

Vector O
constructs O
lacking O
a O
functional O
Tat O
protein O
yielded O
titers O
of O
around O
4 O
x O
10 O
( O
6 O
) O
to O
8 O
x O
10 O
( O
6 O
) O
CFU O
/ O
mu O
g O
of O
p24 O
. O

Packaging O
constructs O
with O
a O
mutation O
within O
the O
integrase B
( I
IN I
) I
core O
domain O
profoundly O
affected O
colony O
formation O
and O
expression O
of O
the O
reporter O
genes O
, O
indicating O
that O
a O
functional O
IN O
protein O
is O
required O
for O
efficient O
transduction O
. O

Previous O
reports O
strongly O
suggest O
that O
, O
in O
addition O
to O
the O
nicotinic O
acetylcholine O
receptor O
, O
rabies O
virus O
can O
use O
other O
, O
as O
- O
yet O
- O
unidentified O
receptors O
, O
We O
found O
that O
laboratory O
cell O
lines O
susceptible O
to O
rabies O
virus O
infection O
express O
the O
neural B
cell I
adhesion I
molecule I
( I
NCAM I
) I
( O
CD56 O
) O
on O
their O
surface O
, O
whereas O
resistant O
cells O
do O
not O
, O
supporting O
the O
idea O
that O
NCAM O
could O
be O
a O
rabies O
virus O
receptor O
. O

We O
observed O
that O
( O
i O
) O
incubation O
with O
rabies O
virus O
decreases O
the O
surface O
expression O
of O
NCAM O
; O
( O
ii O
) O
treatment O
of O
susceptible O
cells O
with O
heparan O
sulfate O
, O
a O
ligand O
for O
NCAM O
, O
or O
with O
NCAM O
antibodies O
significantly O
reduces O
the O
rabies O
virus O
infection O
; O
and O
( O
iii O
) O
preincubation O
of O
rabies O
virus O
inoculum O
with O
soluble O
NCAM O
protein O
as O
a O
receptor O
decoy O
drastically O
neutralizes O
the O
capacity O
of O
rabies O
virus O
to O
infect O
susceptible O
cells O
. O

In O
this O
study O
, O
we O
used O
a O
dicistronic O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
minigenome O
to O
investigate O
the O
effects O
of O
either O
single O
or O
multiple O
nucleotide O
insertions O
placed O
immediately O
after O
the O
nontranscribed O
intergenic O
dinucleotide O
of O
the O
M O
gene O
on O
VSV O
transcription O
. O

We O
also O
examined O
the O
transcriptional O
events O
that O
occurred O
when O
a O
natural O
, O
tl O
- O
nucleotide O
intergenic O
region O
located O
between O
the O
G O
and O
L O
genes O
from O
the O
New B
Jersey I
( I
NJ I
) I
serotype O
of O
VSV O
was O
inserted O
into O
the O
minigenome O
gene O
junction O
, O
In O
contrast O
to O
the O
normal O
25 O
to O
30 O
% O
attenuation O
observed O
for O
downstream O
transcription O
at O
gene O
junctions O
containing O
the O
typical O
dinucleotide O
( O
3 O
' O
- O
GA O
- O
5 O
' O
) O
intergenic O
region O
, O
the O
NJ O
variant O
showed O
greater O
than O
75 O
% O
attenuation O
at O
the O
gene O
junction O
, O
In O
addition O
, O
the O
polymerase O
initiated O
transcription O
at O
two O
major O
start O
sites O
, O
one O
of O
which O
was O
located O
within O
the O
intergenic O
sequence O
. O

We O
developed O
a O
system O
to O
identify O
the O
viral O
proteins O
required O
for O
the O
packaging O
acid O
passage O
of O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
by O
reconstructing O
these O
events O
with O
cDNA O
- O
encoded O
components O
. O

To O
investigate O
the O
involvement O
of O
various O
cellular O
and O
humoral O
aspects O
of O
immunity O
in O
the O
clearance O
of O
rabies O
virus O
from O
the O
central O
nervous O
system O
, O
( O
CNS O
) O
, O
we O
studied O
the O
development O
of O
clinical O
signs O
and O
virus O
clearance O
from O
the O
CNS O
in O
knockout O
mice O
lacking O
either O
B O
and O
T O
cells O
, O
CD8 O
( O
+ O
) O
cytotoxic O
T O
cells O
, O
B O
cells O
, O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptors O
, O
IFN O
- O
gamma O
receptors O
, O
or O
complement O
components O
C3 O
and O
C4 O
. O

Mice O
lacking O
either O
CD8 O
( O
+ O
) O
T O
cells O
, O
IFN O
receptors O
, O
or O
complement O
components O
C3 O
and O
C4 O
showed O
no O
, O
significant O
differences O
in O
the O
development O
of O
clinical O
signs O
by O
comparison O
with O
intact O
counterparts O
having O
the O
same O
genetic O
background O
. O

) O
production O
of O
significant O
levels O
of O
virus B
- I
neutralizing I
antibody I
( I
VNA I
) I
, O
These O
studies O
confirm O
that O
rabies O
VNA O
is O
an O
absolute O
requirement O
for O
clearance O
of O
an O
established O
rabies O
virus O
infection O
. O

The O
RNA O
polymerase O
of O
rabies O
virus O
consists O
of O
two O
subunits O
, O
the O
large B
( I
L I
) I
protein O
and O
the O
phosphoprotein B
( I
P I
) I
, O
with O
2 O
, O
127 O
and O
297 O
amino O
acids O
, O
respectively O
, O
When O
these O
proteins O
were O
coexpressed O
via O
the O
vaccinia O
virus O
- O
T7 O
RNA O
polymerase O
recombinant O
in O
mammalian O
cells O
, O
they O
formed O
a O
complex O
as O
detected O
by O
coimmunoprecipitation O
, O
Analysis O
of O
P O
and O
L O
deletion O
mutants O
was O
performed O
to O
identify O
the O
regions O
of O
both O
proteins O
involved O
in O
complex O
formation O
, O
The O
interaction O
of O
P O
with O
L O
was O
not O
disrupted O
by O
large O
deletions O
removing O
the O
carboxy O
- O
terminal O
half O
of O
the O
P O
protein O
. O

Moreover O
, O
fusion O
proteins O
containing O
the O
19 O
or O
the O
52 O
first O
residues O
of O
P O
in O
frame O
with O
green B
fluorescent I
protein I
( I
GFP I
) I
still O
bound O
to O
L O
, O
These O
results O
indicate O
that O
the O
major O
L O
binding O
site O
resides O
within O
the O
19 O
first O
residues O
of O
the O
P O
protein O
. O

An O
antigenic O
double O
mutant O
of O
rabies O
virus O
( O
challenge O
virus O
standard O
[ O
CVS O
] O
strain O
) O
was O
selected O
by O
successive O
use O
of O
two O
neutralizing O
antiglycoprotein O
monoclonal O
antibodies O
, O
both O
specific O
for O
antigenic O
site O
III O
. O

We O
have O
recovered O
from O
cDNA O
a O
rabies B
virus I
( I
RV I
) I
containing O
identical O
, O
transcriptionally O
active O
promoters O
at O
its O
genome O
( O
negative O
- O
strand O
) O
and O
antigenome O
RNA O
and O
directing O
efficient O
expression O
of O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
from O
the O
antigenome O
. O

While O
in O
standard O
RV O
- O
infected O
cells O
genome O
and O
antigenome O
RNAs O
mere O
present O
in O
a O
49 O
: O
1 O
ratio O
, O
the O
ambisense O
virus O
directed O
synthesis O
of O
equal O
amounts O
of O
genome O
and O
antigenome O
RNA O
( O
1 O
: O
1 O
) O
. O

Successful O
packaging O
of O
ambisense O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
into O
virions O
demonstrated O
that O
the O
parental O
5 O
' O
end O
of O
the O
RV O
genome O
RNA O
does O
not O
contain O
putative O
signals O
required O
for O
incorporation O
into O
virions O
. O

As O
determined O
both O
for O
standard O
RV O
and O
ambisense O
RV O
, O
virus O
particles O
contained O
genome O
and O
antigenome O
RNPs O
in O
the O
same O
ratios O
as O
those O
present O
in O
infected O
cells O
( O
49 O
: O
1 O
and O
1 O
: O
1 O
, O
respectively O
) O
, O
indicating O
indiscriminate O
incorporation O
of O
RNPs O
independent O
of O
signals O
in O
the O
RNA O
. O

Attenuated O
and O
highly O
neurovirulent O
rabies O
virus O
strains O
have O
distinct O
cellular O
tropisms O
, O
Highly O
neuroviru O
lent O
strains O
such O
as O
the O
challenge B
virus I
standard I
( I
CVS I
) I
are O
highly O
neurotropic O
, O
whereas O
the O
attenuated O
strain O
ERA O
also O
infects O
nonneuronal O
cells O
, O
We O
report O
that O
both O
rabies O
virus O
strains O
infect O
activated O
murine O
lymphocytes O
and O
the O
human O
lymphoblastoid O
Jurkat O
T O
- O
cell O
Line O
in O
vitro O
, O
The O
lymphocytes O
are O
more O
permissive O
to O
the O
attenuated O
ERA O
. O

rabies O
virus O
strain O
than O
to O
the O
CVS O
strain O
in O
both O
cases O
, O
We O
also O
report O
that O
in O
contrast O
to O
that O
of O
the O
CVS O
strain O
, O
ERA O
viral O
replication O
induces O
apoptosis O
of O
infected O
Jurkat O
T O
cells O
, O
and O
cell O
death O
is O
con O
- O
comitant O
with O
viral O
glycoprotein O
expression O
, O
suggesting O
that O
this O
protein O
has O
a O
role O
in O
the O
induction O
of O
apoptosis O
, O
Our O
data O
indicate O
that O
( O
i O
) O
rabies O
virus O
infects O
lymphocytes O
, O
iii O
) O
lymphocyte O
infection O
with O
the O
attenuated O
rabies O
virus O
strain O
causes O
apoptosis O
, O
and O
( O
iii O
) O
apoptosis O
does O
not O
hinder O
rabies O
virus O
production O
, O
In O
contrast O
to O
CVS O
, O
ERA O
rabies O
virus O
and O
other O
attenuated O
rabies O
virus O
vaccines O
stimulate O
a O
strong O
immune O
response O
and O
are O
efficient O
live O
vaccines O
, O
The O
paradoxical O
finding O
that O
a O
rabies O
virus O
triggers O
a O
strong O
immune O
response O
despite O
the O
fact O
that O
it O
infects O
lymphocytes O
and O
induces O
apoptosis O
is O
discussed O
in O
terms O
of O
the O
function O
of O
apoptosis O
in O
the O
immune O
response O
. O

BHK O
( O
TK O
- O
) O
cells O
selected O
for O
resistance O
to O
polyethylene O
glycol O
- O
mediated O
fusion O
give O
rise O
to O
clones O
that O
are O
resistant O
to O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
infection O
. O

We O
have O
characterized O
one O
such O
clone O
, O
designated O
95 O
- O
19 O
, O
and O
Pound O
that O
it O
is O
resistant O
to O
entry O
of O
HSV B
type I
1 I
( I
HSV I
- I
1 I
) I
, O
HSV O
- O
2 O
, O
and O
the O
related O
alphaherpesvirus O
pseudo O
- O
rabies O
virus O
( O
PRV O
) O
. O

( O
i O
) O
Measurements O
of O
binding O
of O
radiolabeled O
virus O
show O
that O
heparin O
- O
sensitive O
binding O
of O
HSV O
- O
1 O
and O
HSV O
- O
2 O
to O
95 O
- O
19 O
cells O
is O
identical O
to O
binding O
to O
BHK O
( O
TK O
- O
) O
cells O
, O
suggesting O
that O
the O
block O
to O
replication O
occurs O
after O
attachment O
to O
heparan O
sulfate O
proteoglycan O
. O

( O
ii O
) O
95 O
- O
19 O
cells O
exposed O
to O
HSV O
- O
1 O
or O
HSV O
- O
2 O
, O
at O
high O
multiplicity O
show O
no O
detectable O
immediate B
- I
early I
( I
IE I
) I
mRNA O
expression O
. O

( O
iii O
) O
Exposure O
of O
attached O
virus O
and O
cells O
to O
polyethylene O
glycol O
results O
in O
partial O
recovery O
of O
both O
IE O
gene O
expression O
and O
virus O
yield O
in O
single O
- O
step O
growth O
. O

Cultured O
rat O
prostatic O
adenocarcinoma O
( O
AT3 O
) O
cells O
infected O
with O
the O
challenge B
virus I
standard I
( I
CVS I
) I
strain O
of O
fixed O
rabies O
virus O
showed O
characteristic O
morphologic O
features O
of O
apoptosis O
, O
evidence O
of O
oligonucleosomal O
DNA O
fragmentation O
, O
and O
expression O
of O
the O
Bax O
protein O
. O

Four O
well O
- O
characterized O
Monoclonal B
antibodies I
( I
MAbs I
) I
directed O
against O
rabies O
virus O
glycoprotein B
( I
G I
) I
were O
used O
to O
study O
G O
folding O
in O
vivo O
. O

To O
investigate O
the O
role O
played O
by O
the O
intergenic O
dinucleotide O
sequence O
of O
the O
conserved O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
gene O
junction O
in O
modulation O
of O
polymerase O
activity O
, O
we O
analyzed O
the O
RNA O
synthesis O
activities O
of O
bicistrionic O
genomic O
analogs O
that O
contained O
either O
the O
authentic O
N O
/ O
P O
gene O
junction O
or O
gene O
junctions O
that O
had O
been O
altered O
to O
contain O
either O
the O
16 O
possible O
dinucleotide O
combinations O
, O
single O
nucleotide O
intergenic O
sequences O
, O
or O
no O
intergenic O
sequence O
at O
all O
. O

Alteration O
or O
removal O
of O
the O
intergenic O
sequence O
such O
that O
the O
U O
tract O
responsible O
for O
synthesis O
of O
the O
upstream O
mRNA O
poly O
( O
A O
) O
tail O
was O
effectively O
positioned O
adjacent O
to O
the O
consensus O
downstream O
gene O
start O
signal O
resulted O
in O
almost O
complete O
abrogation O
of O
downstream O
mRNA O
synthesis O
, O
thus O
defining O
the O
intergenic O
sequence O
as O
an O
essential O
sequence O
element O
of O
the O
gene O
junction O
. O

We O
have O
used O
dicistronic O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
minigenomes O
to O
dissect O
the O
functional O
importance O
of O
the O
nontranscribed O
intergenic O
dinucleotide O
and O
the O
conserved O
transcription O
start O
sequence O
found O
at O
the O
beginning O
of O
all O
VSV O
genes O
. O

Therefore O
, O
this O
conserved O
sequence O
appears O
to O
be O
required O
for O
efficient O
transcript O
initiation O
following O
polyadenylation O
of O
the O
upstream O
mRNA O
While O
the O
minimum O
sequence O
for O
efficient O
transcription O
( O
3 O
' O
- O
UYGnn O
- O
5 O
' O
) O
is O
similar O
to O
that O
of O
other O
rhabdoviruses O
, O
it O
is O
not O
homologous O
to O
the O
start O
sites O
for O
viruses O
from O
the O
Paramyxoviridae O
or O
Filoviridae O
families O
. O

sonchus B
yellow I
net I
virus I
( I
SYNV I
) I
is O
the O
best O
- O
characterized O
member O
of O
a O
group O
of O
plant O
rhabdoviruses O
that O
replicate O
in O
the O
host O
cell O
nucleus O
. O

70 O
: O
468 O
- O
477 O
, O
1996 O
) O
, O
we O
have O
identified O
the O
nucleocapsid B
( I
N I
) I
, O
M2 O
, O
and O
L O
proteins O
as O
polymerase O
complex O
components O
( O
based O
on O
copurification O
with O
the O
polymerase O
activity O
and O
by O
coimmunoprecipitation O
assays O
) O
. O

The O
glycoprotein B
( I
G I
) I
of O
rabies O
virus O
assumes O
at O
least O
three O
different O
conformations O
: O
the O
native O
state O
detected O
at O
the O
viral O
surface O
above O
pH O
7 O
, O
the O
activated O
state O
involved O
in O
the O
first O
step O
of O
the O
fusion O
process O
, O
and O
the O
fusion O
- O
inactive O
conformation O
( O
I O
) O
. O

A O
new O
category O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
which O
recognized O
specifically O
the O
I O
conformation O
at O
the O
viral O
surface O
has O
recently O
been O
described O
. O

These O
MAbs O
( O
17A4 O
and O
29EC2 O
) O
became O
neutralizing O
when O
the O
virus O
was O
preincubated O
at O
acidic O
pH O
to O
induce O
the O
conformational O
change O
toward O
the O
I O
state O
of O
G O
. O

All O
of O
these O
mutants O
have O
fusion O
properties O
similar O
to O
those O
of O
the O
CVS O
parental O
strain O
, O
but O
five O
mutants O
( O
E282K O
, O
M44I O
, O
M44V O
, O
V392G O
, O
and O
M396T O
) O
were O
considerably O
slowed O
in O
their O
conformational O
change O
leading O
to O
the O
I O
state O
. O

Mice O
immunized O
with O
two O
intragastrically O
administered O
doses O
of O
a O
replication O
deficient O
recombinant O
vaccinia O
virus O
containing O
the O
hemagglutinin O
and O
nucleoprotein O
genes O
from O
H1N1 O
influenza O
virus O
developed O
serum O
anti O
- O
H1 O
immunoglobulin B
G I
( I
IgG I
) I
antibody O
that O
completely O
protected O
the O
lungs O
from O
challenge O
with O
H1N1 O
. O

We O
also O
found O
that O
the O
vaccine O
enhanced O
recovery O
from O
infection O
caused O
by O
a O
shifted O
( O
H3N2 O
) O
influenza O
virus O
, O
probably O
through O
the O
induction O
of O
nucleoprotein O
- O
specific O
cytotoxic O
T O
- O
lymphocyte O
activity O
. O

Two O
myxoma O
virus O
- O
rabbit B
hemorrhagic I
disease I
virus I
( I
RHDV I
) I
recombinant O
viruses O
were O
constructed O
with O
the O
SG33 O
strain O
of O
myxoma O
virus O
to O
protect O
rabbits O
against O
myxomatosis O
and O
rabbit O
viral O
hemorrhagic O
disease O
. O

These O
recombinant O
viruses O
expressed O
the O
RHDV O
capsid O
proteid O
( O
VP60 O
) O
. O

Previously O
we O
identified O
the O
locations O
of O
three O
neutralization O
epitopes O
( O
a O
, O
b1 O
, O
and O
b2 O
) O
of O
Ross B
River I
virus I
( I
RRV I
) I
by O
sequencing O
a O
number O
of O
variants O
resistant O
to O
monoclonal O
antibody O
neutralization O
which O
were O
found O
to O
have O
single O
amino O
acid O
substitutions O
in O
the O
E2 O
protein O
( O
S O
. O

They O
had O
a O
four O
- O
to O
fivefold O
- O
higher O
50 B
% I
lethal I
dose I
( I
LD I
( I
50 I
) I
) I
, O
although O
no O
change O
in O
the O
average O
survival O
time O
of O
infected O
mice O
was O
observed O
. O

The O
LD O
( O
50 O
) O
of O
the O
triple O
variant O
was O
unchanged O
, O
but O
infected O
mice O
had O
an O
increased O
average O
survival O
time O
. O

The O
glycoprotein B
( I
G I
) I
of O
rabies O
virus O
can O
assume O
at O
least O
three O
different O
conformations O
: O
the O
native O
( O
N O
) O
state O
detected O
at O
the O
viral O
surface O
above O
pH O
7 O
; O
the O
activated O
( O
A O
) O
hydrophobic O
state O
, O
which O
is O
probably O
involved O
in O
the O
first O
steps O
of O
the O
fusion O
process O
; O
and O
the O
fusion O
- O
inactive O
( O
I O
) O
conformation O
. O

To O
determine O
the O
feasibility O
of O
developing O
a O
vaccine O
with O
worldwide O
applicability O
, O
we O
investigated O
whether O
recombinant O
vaccinia O
viruses O
expressing O
either O
the O
glycoprotein B
( I
G I
) I
, O
the O
nucleoprotein B
( I
N I
) I
, O
or O
both O
the O
G O
and O
N O
( O
GN O
) O
of O
the O
challenge B
virus I
strain I
( I
CVS I
) I
of O
rabies O
virus O
would O
cross O
protect O
mice O
against O
17 O
rabies O
virus O
isolates O
representing O
the O
spectrum O
of O
rabies O
virus O
variants O
found O
worldwide O
. O

The O
results O
were O
compared O
with O
the O
commercially O
available O
human B
diploid I
cell I
vaccine I
( I
HDVC I
) I
. O

The O
role O
of O
innate O
, O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
- O
dependent O
protection O
versus O
specific O
antibody O
- O
mediated O
protection O
against O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
was O
evaluated O
in O
IFN O
- O
alpha O
/ O
beta O
receptor O
- O
deficient O
mice O
( O
IFN O
- O
alpha O
/ O
beta O
R O
( O
0 O
/ O
0 O
) O
mice O
) O
. O

In O
contrast O
to O
normal O
mice O
, O
IFN O
- O
alpha O
/ O
beta O
R O
( O
0 O
/ O
0 O
) O
mice O
were O
highly O
susceptible O
to O
infection O
with O
VSV O
because O
of O
ubiquitous O
high O
viral O
replication O
. O

Adoptive O
transfer O
experiments O
showed O
that O
neutralizing O
antibodies O
against O
the O
glycoprotein O
of O
VSV O
( O
VSV O
- O
G O
) O
protected O
these O
mice O
efficiently O
against O
systemic O
infection O
and O
against O
peripheral O
subcutaneous O
infection O
but O
protected O
only O
to O
a O
limited O
degree O
against O
intranasal O
infection O
with O
VSV O
. O

In O
contrast O
, O
VSV O
- O
specific O
T O
cells O
or O
antibodies O
specific O
for O
the O
nucleoprotein B
of I
VSV I
( I
VSV I
- I
N I
) I
were O
unable O
to O
protect O
IFN O
- O
alpha O
/ O
beta O
R O
( O
0 O
/ O
0 O
) O
mice O
against O
VSV O
. O

A O
reverse O
genetics O
approach O
which O
allows O
the O
generation O
of O
infectious O
defective O
rabies B
virus I
( I
RV I
) I
particles O
entirely O
from O
plasmid O
- O
encoded O
genomes O
and O
proteins O
( O
K O
. O

68 O
: O
713 O
- O
719 O
, O
1994 O
) O
was O
used O
to O
investigate O
the O
ability O
of O
a O
heterologous O
lyssavirus O
glycoprotein B
( I
G I
) I
and O
chimeric O
G O
constructs O
to O
function O
in O
the O
formation O
of O
infectious O
RV O
- O
like O
particles O
. O

Virions O
containing O
a O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
( O
SDI O
- O
CAT O
) O
were O
generated O
in O
cells O
simultaneously O
expressing O
the O
genomic O
RNA O
analog O
, O
the O
RV O
N O
, O
P O
, O
M O
, O
and O
L O
proteins O
, O
and O
engineered O
G O
constructs O
from O
transfected O
plasmids O
. O

The O
heterologous O
G O
protein O
from O
Eth O
- O
16 O
virus O
( O
Mokola O
virus O
, O
lyssavirus O
serotype O
3 O
) O
as O
well O
as O
a O
construct O
in O
which O
the O
ectodomain O
of O
RV O
G O
was O
fused O
to O
the O
cytoplasmic O
and O
transmembrane O
domains O
of O
the O
Eth O
- O
16 O
virus O
G O
rescued O
infectious O
SDI O
- O
CAT O
particles O
. O

Immunoprecipitation O
experiments O
using O
a O
monoclonal O
antiserum O
directed O
against O
the O
P O
protein O
detected O
the O
P O
protein O
and O
at O
least O
four O
additional O
shorter O
products O
in O
infected O
cells O
, O
cells O
transfected O
with O
a O
plasmid O
encoding O
the O
wild O
- O
type O
P O
protein O
, O
and O
purified O
virus O
( O
CVS O
strain O
) O
. O

Changes O
in O
the O
5 O
' O
- O
terminal O
region O
of O
the O
P O
mRNA O
( O
including O
site O
- O
specific O
mutations O
, O
deletions O
, O
and O
insertions O
) O
demonstrated O
that O
a O
leaky O
scanning O
mechanism O
is O
responsible O
for O
translation O
initiation O
of O
the O
P O
gene O
at O
several O
sites O
. O

To O
determine O
whether O
rabies O
viruses O
replicate O
in O
macrophage O
or O
macrophage O
- O
like O
cells O
, O
several O
human O
and O
murine O
macrophage O
- O
like O
cell O
lines O
, O
as O
well O
as O
primary O
cultures O
of O
murine O
bone O
marrow O
macrophages O
, O
were O
incubated O
with O
the O
Evelyn B
- I
Rokitnicki I
- I
Abelseth I
( I
ERA I
) I
virus O
and O
several O
different O
street B
rabies I
viruses I
( I
SRV I
) I
. O

Minimal O
replication O
was O
detected O
in O
murine O
monocytic O
WEHI O
- O
3BD O
( O
- O
) O
and O
PU5 O
- O
1R O
cells O
, O
and O
ERA O
virus O
did O
not O
replicate O
in O
murine O
monocytic O
P388D1 O
or O
J774A O
. O

To O
determine O
whether O
rabies O
virus O
replication O
is O
dependent O
upon O
the O
state O
of O
differentiation O
of O
the O
macrophage O
- O
like O
cell O
, O
human O
promyelocytic O
HL O
- O
60 O
cells O
were O
differentiated O
with O
12 B
- I
O I
- I
tetradecanoylphorbol I
- I
13 I
- I
acetate I
( I
TPA I
) I
. O

Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
is O
a O
rhabdovirus O
that O
causes O
an O
acute O
disease O
in O
salmon O
and O
trout O
. O

In O
this O
study O
, O
a O
correlation O
between O
changes O
in O
tissue O
tropism O
and O
specific O
changes O
in O
the O
virus O
genome O
appeared O
to O
be O
made O
by O
examining O
four O
IHNV O
neutralization O
- O
resistant O
variants O
( O
RB O
- O
1 O
, O
RB O
- O
2 O
, O
RB O
- O
3 O
, O
and O
RB O
- O
4 O
) O
that O
had O
been O
selected O
with O
the O
glycoprotein B
( I
G I
) I
- O
specific O
monoclonal O
antibody O
RB O
/ O
B5 O
. O

These O
variants O
were O
compared O
with O
the O
parental O
strain O
( O
RB O
- O
76 O
) O
for O
their O
virulence O
and O
pathogenicity O
in O
rainbow O
trout O
after O
waterborne O
challenge O
. O

JHM B
virus I
( I
JHMV I
) I
replication O
and O
trafficking O
of O
viral O
proteins O
and O
virions O
in O
cultured O
rat O
hippocampal O
neurons O
and O
a O
neuronal O
cell O
line O
, O
OBL O
- O
21 O
, O
were O
examined O
, O
with O
an O
emphasis O
placed O
on O
the O
role O
of O
the O
microtubular O
network O
. O

A O
specific O
interaction O
between O
antibodies O
derived O
against O
the O
microtubule O
- O
associated O
protein O
tau O
and O
JHMV O
Nucleocapsid B
protein I
( I
N I
) I
was O
observed O
, O
which O
can O
presumably O
be O
explained O
by O
an O
overall O
amino O
acid O
similarity O
of O
44 O
% O
and O
an O
identity O
of O
20 O
% O
between O
proteins O
N O
and O
tau O
, O
with O
optimal O
alignment O
at O
the O
microtubule O
binding O
domain O
of O
tau O
. O

Proteins O
entirely O
expressed O
from O
cDNA O
were O
used O
to O
rescue O
synthetic O
RNA O
genome O
analogs O
into O
infectious O
defective O
particles O
of O
rabies B
virus I
( I
RV I
) I
. O

Insertion O
of O
the O
bacterial O
chloramphenicol O
acetyltransferase O
gene O
or O
beta O
- O
galactosidase O
( O
lacZ O
) O
gene O
between O
the O
3 O
' O
and O
5 O
' O
termini O
containing O
transcriptional O
signal O
sequences O
resulted O
in O
transcription O
of O
mRNAs O
and O
expression O
of O
chloramphenicol O
acetyltransferase O
and O
beta O
- O
galactosidase O
, O
respectively O
. O

To O
determine O
whether O
central O
neuropathogenesis O
associated O
with O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
infection O
is O
regulated O
by O
T O
cells O
, O
we O
have O
examined O
the O
effects O
of O
intranasal O
infection O
of O
mice O
lacking O
T O
cells O
. O

The O
mice O
examined O
were O
of O
two O
kinds O
: O
( O
i O
) O
thymus O
- O
deficient O
BALB O
/ O
c O
nu O
/ O
nu O
nice O
and O
( O
ii O
) O
BALB O
/ O
c O
mice O
experimentally O
depleted O
of O
T O
cells O
by O
systemic O
infusions O
of O
a O
monoclonal O
antibody O
to O
the O
CD4 O
or O
CD8 O
cell O
surface O
molecules O
. O

In O
histological O
sections O
of O
brain O
, O
the O
distribution O
of O
viral O
antigens B
( I
Ags I
) I
was O
examined O
by O
immunocytochemistry O
. O

In O
experiments O
with O
BALB O
/ O
c O
mice O
depleted O
of O
either O
CD4 O
+ O
or O
CD8 O
+ O
T O
cells O
by O
in O
vivo O
antibody O
treatment O
, O
histological O
analysis O
revealed O
an O
increase O
in O
viral O
Ag O
distribution O
in O
comparison O
with O
control O
( O
medium O
- O
infused O
) O
infected O
mice O
. O

We O
previously O
reported O
that O
A O
/ O
WySnJ O
mice O
vaccinated O
via O
a O
tail O
scratch O
with O
a O
recombinant O
raccoon B
poxvirus I
( I
RCN I
) I
expressing O
the O
rabies O
virus O
internal O
structural O
nucleoprotein B
( I
N I
) I
( O
RCN O
- O
N O
) O
were O
protected O
against O
a O
street O
rabies O
virus O
( O
D O
. O

To O
improve O
our O
understanding O
of O
the O
mechanism O
( O
s O
) O
of O
this O
protection O
, O
we O
investigated O
whether O
sera O
of O
A O
/ O
WySnj O
mice O
that O
had O
been O
vaccinated O
with O
RCN O
- O
N O
but O
not O
challenged O
with O
street O
rabies O
virus O
had O
anti O
- O
rabies O
virus O
activity O
. O

Fusion O
of O
rabies O
virus O
with O
membranes O
occurs O
at O
acidic O
pH O
and O
is O
mediated O
by O
the O
viral O
spike O
glycoprotein B
( I
G I
) I
. O

Third O
, O
besides O
these O
two O
conformations O
, O
we O
, O
using O
the O
fluorescent O
probe O
ANS O
( O
8 O
- O
anilino O
- O
1 O
- O
naphthalenesulfonic O
acid O
) O
, O
provide O
evidence O
for O
the O
existence O
of O
a O
transient O
third O
state O
which O
appears O
to O
be O
more O
hydrophobic O
than O
the O
native O
state O
. O

To O
understand O
the O
assembly O
process O
of O
bluetongue B
virus I
( I
BTV I
) I
, O
we O
have O
established O
a O
functional O
assay O
which O
allows O
us O
to O
produce O
and O
manipulate O
BTV O
core B
- I
like I
particles I
( I
CLPs I
) I
composed O
of O
the O
viral O
VP7 O
and O
VP3 O
proteins O
. O

Substitution O
of O
either O
of O
two O
cysteine O
residues O
of O
VP7 O
( O
Cys O
- O
15 O
or O
Cys O
- O
65 O
) O
by O
serine O
also O
did O
not O
prevent O
CLP O
formation O
; O
however O
, O
substitution O
of O
the O
single O
lysine O
residue O
of O
VP7 O
( O
Lys O
- O
255 O
) O
by O
leucine O
abrogated O
CLP O
formation O
, O
indicating O
a O
critical O
role O
for O
this O
lysine O
. O

We O
have O
developed O
idiotype O
- O
anti O
- O
idiotype O
monoclonal O
antibodies O
that O
provide O
evidence O
for O
rabies O
virus O
binding O
to O
the O
acetylcholine B
receptor I
( I
AChR I
) I
. O

It O
also O
neutralized O
infectivity O
in O
vitro O
when O
PC12 O
cells O
, O
which O
express O
neuronal O
AChR O
, O
but O
not O
CER O
cells O
or O
neuroblastoma O
cells O
( O
clone O
N18 O
) O
, O
which O
have O
no O
AChR O
, O
were O
used O
. O

A O
recombinant O
human O
anti O
- O
rabies O
monoclonal O
antibody O
( O
MAb O
- O
57 O
) O
Fab O
was O
prepared O
by O
cloning O
the O
heavy O
( O
Fd O
) O
- O
and O
light O
- O
chain O
domains O
into O
the O
same O
bacterial O
expression O
vector O
. O

To O
construct O
the O
recombinant O
Fab O
, O
mRNA O
was O
extracted O
from O
MAb O
- O
57 O
- O
producing O
hybridoma O
cells O
, O
reverse O
transcribed O
, O
and O
then O
amplified O
by O
polymerase B
chain I
reaction I
( I
PCR I
) I
by O
using O
oligonucleotides O
specific O
for O
immunoglobulin O
heavy O
- O
and O
light O
- O
chain O
DNA O
sequences O
. O

PCR O
- O
amplified O
Fd O
- O
chain O
cDNA O
was O
fused O
, O
in O
frame O
, O
between O
a O
bacterial O
leader O
peptide O
( O
PelB O
) O
at O
the O
amino O
terminus O
and O
a O
10 O
- O
amino O
- O
acid O
peptide O
tag O
at O
the O
carboxy O
terminus O
. O

The O
immunoglobulin O
Fab O
was O
then O
expressed O
as O
a O
dicistronic O
message O
in O
bacteria O
by O
using O
the O
isopropyl O
- O
beta O
- O
D O
- O
thiogalactopyranoside O
- O
inducible O
lactose O
promotor O
( O
lacZ O
) O
. O

DNA O
sequencing O
was O
used O
to O
define O
the O
gamma O
- O
chain O
isotype O
( O
immunoglobulin O
G1 O
) O
and O
V O
( O
H O
) O
( O
V O
( O
H O
) O
I O
) O
chain O
and O
V O
( O
L O
) O
( O
VlambdaII O
) O
chain O
gene O
usage O
. O

The O
recombinant O
Fab O
( O
rFab57 O
) O
specifically O
bound O
the O
rabies O
virus O
cost O
glycoprotein O
, O
while O
the O
Fd O
and O
lambda O
chains O
, O
when O
expressed O
individually O
, O
did O
not O
. O

Two O
pathogenetically O
distinct O
disease O
manifestations O
are O
distinguished O
in O
a O
murine O
model O
of O
primary O
rabies O
virus O
infection O
with O
the O
Evelyn O
- O
Rokitnicky O
- O
Abelseth O
strain O
, O
rabies B
virus I
neuritic I
paralysis I
( I
RVNP I
) I
and O
fatal O
encephalopathogenic O
rabies O
. O

The O
anti O
- O
idiotypic O
antibody O
( O
anti O
- O
Id O
209 O
) O
bound O
to O
N18 O
mouse O
neuroblastoma O
cells O
and O
inhibited O
adsorption O
of O
S O
- O
35 O
- O
labeled O
virus O
by O
50 O
% O
. O

The O
antigenic O
determinant O
responsible O
for O
stimulating O
this O
class O
I O
- O
restricted O
cytolytic O
response O
was O
mapped O
to O
50 O
amino O
acids O
( O
residues O
180 O
to O
229 O
) O
of O
the O
phosphoprotein O
by O
using O
vaccinia O
virus O
recombinants O
expressing O
either O
the O
full O
- O
length O
phosphoprotein O
or O
C O
- O
terminal O
truncations O
of O
the O
phosphoprotein O
. O

In O
an O
attempt O
to O
understand O
the O
implication O
of O
the O
rabies O
virus O
glycoprotein B
( I
G I
) I
in O
the O
first O
steps O
of O
the O
viral O
cycle O
, O
we O
studied O
the O
pH O
dependence O
of O
virus O
- O
induced O
fusion O
and O
hemagglutination O
, O
as O
well O
as O
modifications O
of O
the O
structure O
and O
properties O
of O
the O
viral O
glycoprotein O
following O
pH O
acidification O
. O

Here O
we O
provide O
a O
more O
precise O
description O
of O
the O
antigenicity O
of O
the O
protein O
in O
mice O
of O
the O
H O
- O
2d O
haplotype O
; O
we O
developed O
this O
description O
by O
using O
264 O
newly O
isolated O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
a O
collection O
of O
neutralization O
- O
resistant O
( O
MAR O
) O
mutants O
. O

Most O
of O
the O
MAbs O
( O
97 O
% O
) O
recognized O
antigenic O
sites O
previously O
described O
as O
II O
and O
III O
. O

One O
minor O
antigenic O
site O
separated O
from O
site O
III O
by O
three O
amino O
acids O
, O
including O
a O
proline O
, O
was O
identified O
( O
minor O
site O
a O
) O
. O

One O
of O
our O
MAbs O
, O
1D1 O
, O
reacted O
with O
sodium O
dodecyl O
sulfate O
- O
treated O
glycoprotein O
in O
Western O
blots O
( O
immunoblots O
) O
under O
reducing O
conditions O
and O
was O
therefore O
probably O
directed O
against O
a O
linear O
epitope O
. O

This O
linear O
epitope O
was O
called O
G1 O
( O
G O
, O
Gif O
) O
. O

As O
a O
general O
rule O
, O
we O
propose O
to O
reserve O
the O
term O
antigenic O
site O
( O
either O
major O
or O
minor O
) O
for O
regions O
of O
the O
protein O
which O
are O
defined O
by O
several O
MAbs O
originating O
from O
different O
fusions O
and O
to O
describe O
regions O
of O
the O
protein O
which O
are O
defined O
by O
a O
single O
MAb O
as O
epitopes O
. O

The O
ribonucleoprotein O
gene O
of O
Infectious B
hematopoietic I
necrosis I
virus I
( I
IHNV I
) I
has O
been O
expressed O
in O
Escherichia O
coli O
as O
a O
trpE O
fusion O
protein O
. O

Mice O
of O
the O
SJL O
/ O
J O
and O
BALB O
/ O
cByJ O
inbred O
strains O
are O
naturally O
resistant O
to O
Street B
rabies I
virus I
( I
SRV I
) I
injected O
via O
the O
intraperitoneal O
route O
. O

Elimination O
of O
CD4 O
+ O
T O
- O
helper O
cells O
abrogated O
the O
production O
of O
immunoglobulin B
G I
( I
IgG I
) I
neutralizing O
antibodies O
in O
response O
to O
rabies O
virus O
infection O
and O
reversed O
the O
resistant O
status O
of O
SJL O
/ O
J O
and O
BALB O
/ O
cByJ O
mice O
. O

H O
- O
3 O
- O
labeled O
single O
- O
stranded O
RNA O
probes O
were O
prepared O
which O
were O
specific O
for O
genomic O
RNA O
and O
mRNAs O
coding O
for O
the O
five O
rabies O
virus O
proteins O
( O
N O
, O
NS O
, O
M O
, O
G O
, O
and O
L O
) O
. O

Paraffin O
- O
embedded O
brain O
tissues O
from O
human O
cases O
of O
rabies O
and O
mice O
experimentally O
infected O
with O
the O
challenge B
virus I
standard I
( I
CVS I
) I
- O
11 O
strain O
of O
rabies O
virus O
and O
street O
rabies O
virus O
were O
examined O
. O

raccoon B
poxvirus I
( I
RCN I
) I
recombinants O
expressing O
the O
rabies O
virus O
internal O
structural O
nucleoprotein O
( O
RCN O
- O
N O
) O
protected O
A O
/ O
WySnJ O
mice O
against O
a O
lethal O
challenge O
with O
Street B
rabies I
virus I
( I
SRV I
) I
. O

Maximum O
survival O
was O
achieved O
following O
vaccination O
by O
tail O
scratch O
and O
footpad O
( O
FP O
) O
SRV O
challenge O
. O

Protection O
was O
also O
elicited O
by O
RCN O
recombinants O
expressing O
the O
rabies O
virus O
glycoprotein O
( O
RCN O
- O
G O
) O
. O

The O
mechanism O
( O
s O
) O
of O
N O
- O
induced O
resistance O
appears O
to O
correlate O
with O
the O
failure O
of O
peripherally O
inoculated O
SRV O
to O
enter O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

A O
characterization O
of O
the O
antigenic O
determinants O
( O
epitopes O
) O
of O
the O
glycoprotein B
( I
G I
) I
of O
infectious O
hematopoietic O
necrosis O
virus O
was O
made O
by O
expressing O
different O
regions O
of O
the O
G O
gene O
in O
Escherichia O
coli O
. O

A O
comparison O
of O
reactivities O
of O
the O
fusion O
proteins O
encoded O
by O
these O
plasmids O
was O
made O
by O
Western O
immunoblot O
and O
radioimmunoassay O
with O
a O
number O
of O
anti O
- O
G O
specific O
Monoclonal B
antibodies I
( I
MAbs I
) I
. O

Lassa B
fever I
( I
LF I
) I
is O
a O
zoonotic O
viral O
hemorrhagic O
fever O
caused O
by O
Lassa B
virus I
( I
LASV I
) I
, O
which O
is O
endemic O
to O
West O
African O
countries O
. O

The O
arenaviruses O
Lassa B
virus I
( I
LASV I
) I
, O
Junin B
virus I
( I
JUNV I
) I
, O
and O
Machupo B
virus I
( I
MACV I
) I
can O
cause O
severe O
and O
fatal O
diseases O
in O
humans O
. O

In O
contrast O
, O
JUNV O
and O
MACV O
infections O
stimulate O
a O
robust O
interferon B
( I
IFN I
) I
response O
in O
a O
retinoic B
acidinducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
dependent O
manner O
and O
readily O
activate O
protein B
kinase I
R I
( I
PKR I
) I
, O
a O
known O
host O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
sensor O
. O

Arenavirus O
nucleoproteins B
( I
NPs I
) I
contain O
a O
highly O
conserved O
exoribonuclease B
( I
ExoN I
) I
motif O
, O
through O
which O
LASV O
NP O
has O
been O
shown O
to O
degrade O
virus O
- O
derived O
immunostimulatory O
dsRNA O
in O
biochemical O
assays O
. O

We O
are O
interested O
in O
identifying O
drugs O
that O
block O
both O
Ebola B
virus I
( I
EBOV I
) I
and O
Lassa B
virus I
( I
LASV I
) I
, O
two O
unrelated O
but O
highly O
pathogenic O
hemorrhagic O
fever O
viruses O
that O
have O
caused O
outbreaks O
in O
similar O
regions O
in O
Africa O
and O
share O
features O
of O
virus O
entry O
: O
use O
of O
cell O
surface O
attachment O
factors O
, O
macropinocytosis O
, O
endosomal O
receptors O
, O
and O
low O
pH O
to O
trigger O
fusion O
in O
late O
endosomes O
. O

Five O
drugs O
( O
amodiaquine O
, O
apilimod O
, O
arbidol O
, O
niclosamide O
, O
and O
zoniporide O
) O
showed O
roughly O
equivalent O
degrees O
of O
inhibition O
of O
LASV O
and O
EBOV O
glycoprotein B
( I
GP I
) I
- O
bearing O
pseudoviruses O
; O
three O
( O
clomiphene O
, O
sertraline O
, O
and O
toremifene O
) O
were O
more O
potent O
against O
EBOV O
. O

The O
GP1 O
subunit O
of O
the O
envelope O
- O
displayed O
arenaviral O
glycoprotein B
spike I
complex I
( I
GPC I
) I
mediates O
host O
cell O
recognition O
and O
is O
an O
important O
determinant O
of O
cross O
- O
species O
transmission O
. O

RIG O
- O
I O
is O
a O
major O
cytoplasmic O
sensor O
of O
viral O
pathogen B
- I
associated I
molecular I
pattern I
( I
PAMP I
) I
RNA O
and O
induces O
type B
I I
interferon I
( I
IFN I
) I
production O
upon O
viral O
infection O
. O

A O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
binding O
protein O
, O
PACT O
, O
plays O
an O
important O
role O
in O
potentiating O
RIG O
- O
I O
function O
. O

We O
have O
shown O
previously O
that O
arenaviral O
nucleoproteins B
( I
NPs I
) I
suppress O
type O
I O
IFN O
production O
via O
their O
RNase O
activity O
to O
degrade O
PAMP O
RNA O
. O

To O
understand O
the O
biological O
roles O
of O
PACT O
and O
RIG O
- O
I O
in O
authentic O
arenavirus O
infection O
, O
we O
analyze O
growth O
kinetics O
of O
recombinant O
Pichinde B
virus I
( I
PICV I
) I
, O
a O
prototypical O
arenavirus O
, O
in O
RIG O
- O
I O
knockout B
( I
KO I
) I
and O
PACT O
KO O
mouse B
embryonic I
fibroblast I
( I
MEF I
) I
cells O
. O

wild B
- I
type I
( I
WT I
) I
PICV O
grew O
at O
higher O
titers O
in O
both O
KO O
MEF O
lines O
than O
in O
normal O
MEFs O
, O
suggesting O
the O
important O
roles O
of O
these O
cellular O
proteins O
in O
restricting O
virus O
replication O
. O

IMPORTANCE O
We O
report O
here O
a O
new O
role O
of O
the O
nucleoproteins O
of O
arenaviruses O
that O
can O
block O
type O
I O
IFN O
production O
via O
their O
specific O
inhibition O
of O
the O
cellular O
protein O
sensors O
of O
virus O
infection O
( O
RIG O
- O
I O
and O
PACT O
) O
. O

The O
arenavirus O
family O
consists O
of O
several O
highly O
pathogenic O
viruses O
, O
including O
the O
Old B
World I
( I
OW I
) I
arenavirus O
Lassa B
fever I
virus I
( I
LASV I
) I
and O
the O
New B
World I
( I
NW I
) I
Junin I
virus I
( I
JUNV I
) I
and O
Machupo B
virus I
( I
MACV I
) I
. O

JUNV O
and O
MACV O
infections O
readily O
induce O
an O
interferon B
( I
IFN I
) I
response O
in O
human O
cells O
, O
while O
LASV O
infection O
usually O
triggers O
an O
undetectable O
or O
weak O
IFN O
response O
. O

JUNV O
induces O
an O
IFN O
response O
through O
RIG O
- O
I O
, O
suggesting O
that O
the O
host O
non O
- O
self O
RNA O
sensor O
readily O
detects O
JUNV O
viral B
RNAs I
( I
vRNAs I
) I
during O
infection O
and O
activates O
IFN O
response O
. O

Double O
- O
stranded O
- O
RNA O
( O
dsRNA O
) O
- O
activated O
protein B
kinase I
R I
( I
PKR I
) I
is O
another O
host O
non O
- O
self O
RNA O
sensor O
classically O
known O
for O
its O
vRNA O
recognition O
activity O
. O

Here O
we O
report O
that O
infection O
with O
NW O
arenaviruses O
JUNV O
and O
MACV O
, O
but O
not O
OW O
LASV O
, O
activated O
PKR O
, O
concomitant O
with O
elevated O
phosphorylation O
of O
the O
translation O
initiation O
factor O
alpha O
subunit O
of O
eukaryotic B
initiation I
factor I
2 I
( I
eIF2 I
alpha I
) I
. O

Despite O
the O
antiviral O
activity O
known O
for O
PKR O
against O
many O
other O
viruses O
, O
the O
replication O
of O
JUNV O
and O
MACV O
was O
not O
impaired O
but O
was O
slightly O
augmented O
in O
wild B
- I
type I
( I
WT I
) I
cells O
compared O
to O
that O
in O
PKR O
- O
deficient O
cells O
, O
suggesting O
that O
PKR O
or O
PKR O
activation O
did O
not O
negatively O
affect O
JUNV O
and O
MACV O
infection O
. O

Lassa B
virus I
( I
LASV I
) I
is O
an O
enveloped O
RNA O
virus O
endemic O
to O
West O
Africa O
and O
responsible O
for O
severe O
cases O
of O
hemorrhagic O
fever O
. O

Several O
cellular O
receptors O
can O
interact O
with O
the O
GP1 O
subunit O
and O
mediate O
viral O
entry O
, O
including O
alpha B
- I
dystroglycan I
( I
alpha I
DG I
) I
and O
lysosome B
- I
associated I
membrane I
protein I
1 I
( I
LAMP1 I
) I
. O

To O
examine O
virus O
- O
to O
- O
cell O
entry O
, O
49 O
constructs O
were O
incorporated O
onto O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
pseudoparticles O
and O
transduction O
efficiencies O
were O
monitored O
in O
HAP1 O
and O
HAP1 O
- O
triangle O
DAG1 O
cells O
that O
differentially O
produce O
the O
alpha O
DG O
cell O
surface O
receptor O
. O

Several O
arenaviruses O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
, O
cause O
hemorrhagic O
fever O
disease O
in O
humans O
and O
pose O
serious O
public O
health O
concerns O
in O
their O
regions O
of O
endemicity O
. O

Moreover O
, O
mounting O
evidence O
indicates O
that O
the O
worldwide O
- O
distributed O
prototypic O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
is O
a O
neglected O
human O
pathogen O
of O
clinical O
significance O
. O

We O
have O
documented O
that O
a O
recombinant O
LCMV O
containing O
the O
glycoprotein B
( I
GPC I
) I
gene O
of O
LASV O
within O
the O
backbone O
of O
the O
immunosuppressive B
clone I
13 I
( I
Cl I
- I
13 I
) I
variant O
of O
the O
Armstrong O
strain O
of O
LCMV O
( O
rCl O
- O
13 O
/ O
LASV O
- O
GPC O
) O
exhibited O
Cl O
- O
13 O
- O
like O
growth O
properties O
in O
cultured O
cells O
, O
but O
in O
contrast O
to O
Cl O
- O
13 O
, O
rCl O
- O
13 O
/ O
LASV O
- O
GPC O
was O
unable O
to O
establish O
persistence O
in O
immunocompetent O
adult O
mice O
, O
which O
prevented O
its O
use O
for O
some O
in O
vivo O
experiments O
. O

Recently O
, O
V459K O
and O
K461G O
mutations O
within O
the O
GP2 O
cytoplasmic B
domain I
( I
CD I
) I
of O
rCl O
- O
13 O
/ O
LASV O
- O
GPC O
were O
shown O
to O
increase O
rCl O
- O
13 O
/ O
LASV O
- O
GPC O
infectivity O
in O
mice O
. O

Here O
, O
we O
generated O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
by O
introducing O
the O
corresponding O
revertant O
mutations O
K465V O
and O
G467K O
within O
GP2 O
of O
rCl O
- O
13 O
and O
we O
show O
that O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
was O
unable O
to O
persist O
in O
mice O
. O

In O
addition O
, O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
grew O
to O
high O
titers O
in O
cultured O
cell O
lines O
and O
in O
immunodeficient O
mice O
. O

Further O
analysis O
revealed O
that O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
infected O
fewer O
splenic O
plasmacytoid O
dendritic O
cells O
than O
rCl O
- O
13 O
, O
yet O
the O
two O
viruses O
induced O
similar O
type O
I O
interferon O
responses O
in O
mice O
. O

IMPORTANCE O
The O
prototypic O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
provides O
investigators O
with O
a O
superb O
experimental O
model O
system O
to O
investigate O
virus O
- O
host O
interactions O
. O

The O
Armstrong B
strain I
( I
ARM I
) I
of O
LCMV O
causes O
an O
acute O
infection O
, O
whereas O
its O
derivative O
, O
clone B
13 I
( I
Cl I
- I
13 I
) I
, O
causes O
a O
persistent O
infection O
. O

Here O
, O
we O
report O
that O
mutations O
K465V O
and O
G467K O
within O
the O
cytoplasmic O
domain O
of O
Cl O
- O
13 O
GP2 O
resulted O
in O
a O
virus O
, O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
, O
that O
failed O
to O
persist O
in O
mice O
despite O
exhibiting O
Cl O
- O
13 O
wild O
- O
type O
- O
like O
fitness O
in O
cultured O
cells O
and O
immunocompromised O
mice O
. O

This O
finding O
has O
uncovered O
novel O
viral O
determinants O
of O
viral O
persistence O
, O
and O
a O
detailed O
characterization O
of O
rCl O
- O
13 O
( O
GPC O
/ O
VGKS O
) O
can O
provide O
novel O
insights O
into O
the O
mechanisms O
underlying O
persistent O
viral O
infection O
. O

It O
has O
been O
reported O
that O
arenavirus O
infection O
can O
suppress O
the O
innate O
immune O
response O
, O
and O
NP O
and O
Z O
proteins O
of O
pathogenic O
arenaviruses O
can O
disrupt O
RLR O
/ O
MAVS O
signaling O
, O
thus O
inhibiting O
production O
of O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
. O

In O
this O
study O
, O
we O
determined O
that O
the O
L O
polymerase O
( O
Lp O
) O
of O
Mopeia B
virus I
( I
MOPV I
) I
, O
an O
Old B
World I
( I
OW I
) I
arenavirus O
, O
can O
activate O
the O
RLR O
/ O
MAVS O
pathway O
and O
thus O
induce O
the O
production O
of O
IFN O
- O
I O
. O

The O
arenaviral O
glycoprotein O
stable B
signal I
peptide I
( I
SSP I
) I
is O
unique O
among O
signal O
peptides O
in O
that O
it O
is O
an O
integral O
component O
of O
the O
mature O
glycoprotein B
complex I
( I
GPC I
) I
and O
plays O
important O
roles O
not O
only O
in O
GPC O
expression O
and O
processing O
but O
also O
in O
the O
membrane O
fusion O
process O
during O
viral O
entry O
. O

Using O
the O
Pichinde B
virus I
( I
PICV I
) I
reverse O
genetics O
system O
, O
we O
analyzed O
the O
effects O
of O
alanine O
substitutions O
at O
many O
conserved O
residues O
within O
the O
SSP O
on O
viral O
replication O
in O
cell O
culture O
and O
in O
a O
guinea O
pig O
infection O
model O
. O

Two O
other O
mutations O
( O
N37A O
and O
R55A O
) O
did O
not O
affect O
membrane O
fusion O
or O
viral O
growth O
in O
vitro O
but O
significantly O
reduced O
viral O
virulence O
in O
vivo O
. O

Using O
a O
reverse O
genetics O
system O
of O
a O
prototypic O
arenavirus O
, O
Pichinde B
virus I
( I
PICV I
) I
, O
we O
have O
shown O
for O
the O
first O
time O
in O
the O
context O
of O
virus O
infections O
of O
cell O
culture O
and O
of O
guinea O
pigs O
that O
the O
SSP O
plays O
an O
essential O
role O
in O
mediating O
the O
membrane O
fusion O
step O
as O
well O
as O
in O
other O
yet O
- O
to O
- O
be O
- O
determined O
processes O
during O
viral O
infection O
. O

Chemically O
distinct O
small O
- O
molecule O
inhibitors O
of O
arenavirus O
entry O
have O
recently O
been O
identified O
and O
shown O
to O
act O
on O
the O
arenavirus O
envelope O
glycoprotein B
( I
GPC I
) I
to O
prevent O
membrane O
fusion O
. O

In O
the O
tripartite O
GPC O
complex O
, O
pH O
- O
dependent O
membrane O
fusion O
is O
triggered O
through O
a O
poorly O
understood O
interaction O
between O
the O
stable B
signal I
peptide I
( I
SSP I
) I
and O
the O
transmembrane O
fusion O
subunit O
GP2 O
, O
and O
our O
genetic O
studies O
have O
suggested O
that O
these O
small O
- O
molecule O
inhibitors O
act O
at O
this O
interface O
to O
antagonize O
fusion O
activation O
. O

Here O
, O
we O
have O
designed O
and O
synthesized O
photoaffinity O
derivatives O
of O
the O
4 O
- O
acyl O
- O
1 O
, O
6 O
- O
dialkylpiperazin O
- O
2 O
- O
one O
class O
of O
fusion O
inhibitors O
and O
demonstrate O
specific O
labeling O
of O
both O
the O
SSP O
and O
GP2 O
subunits O
in O
a O
native O
- O
like O
Lassa B
virus I
( I
LASV I
) I
GPC O
trimer O
expressed O
in O
insect O
cells O
. O

Lead O
small O
- O
molecule O
inhibitors O
that O
target O
the O
arenavirus O
envelope O
glycoprotein B
( I
GPC I
) I
have O
recently O
been O
identified O
and O
shown O
to O
block O
GPC O
- O
mediated O
fusion O
of O
the O
viral O
and O
cellular O
endosomal O
membranes O
, O
thereby O
preventing O
virus O
entry O
into O
the O
host O
cell O
. O

Here O
we O
used O
X O
- O
ray O
protein O
crystallography O
to O
decipher O
the O
crystal O
structure O
of O
the O
receptor O
- O
binding O
domain O
( O
GP1 O
) O
from O
Lassa O
virus O
. O

The O
highly O
pathogenic O
Old B
World I
( I
OW I
) I
arenavirus O
Lassa B
fever I
virus I
( I
LASV I
) I
is O
the O
causative O
agent O
of O
Lassa B
fever I
( I
LF I
) I
disease O
in O
humans O
. O

LASV O
infections O
in O
severe O
cases O
are O
generally O
immunosuppressive O
without O
stimulating O
interferon B
( I
IFN I
) I
induction O
, O
a O
proinflammatory O
response O
, O
or O
T O
cell O
activation O
. O

However O
, O
the O
host O
innate O
immune O
responses O
to O
highly O
pathogenic O
New B
World I
( I
NW I
) I
arenaviruses O
are O
not O
well O
understood O
. O

We O
have O
previously O
shown O
that O
the O
highly O
pathogenic O
NW O
arenavirus O
, O
Junin B
virus I
( I
JUNV I
) I
, O
induced O
an O
IFN O
response O
in O
human O
A549 O
cells O
. O

Here O
, O
we O
report O
that O
Machupo B
virus I
( I
MACV I
) I
, O
another O
highly O
pathogenic O
NW O
arenavirus O
, O
also O
induces O
an O
IFN O
response O
. O

Previous O
structural O
and O
functional O
analyses O
of O
arenavirus O
nucleoproteins B
( I
NPs I
) I
revealed O
a O
conserved O
DEDDH O
exoribonuclease O
( O
RNase O
) O
domain O
that O
is O
important O
for O
type B
I I
interferon I
( I
IFN I
) I
suppression O
, O
but O
the O
biological O
roles O
of O
the O
NP O
RNase O
in O
viral O
replication O
and O
host O
immune O
suppression O
have O
not O
been O
well O
characterized O
. O

Infection O
of O
guinea O
pigs O
with O
Pichinde B
virus I
( I
PICV I
) I
, O
a O
prototype O
arenavirus O
, O
can O
serve O
as O
a O
surrogate O
small O
animal O
model O
for O
arenavirus O
hemorrhagic O
fevers O
. O

Recombinant O
PICVs O
with O
RNase O
catalytic O
mutations O
can O
induce O
high O
levels O
of O
IFNs O
and O
barely O
grow O
in O
IFN O
- O
competent O
A549 O
cells O
, O
in O
sharp O
contrast O
to O
the O
wild B
- I
type I
( I
WT I
) I
virus O
, O
while O
in O
IFN O
- O
deficient O
Vero O
cells O
, O
both O
WT O
and O
mutant O
viruses O
can O
replicate O
at O
relatively O
high O
levels O
. O

The O
nucleoprotein B
( I
NPs I
) I
of O
all O
arenaviruses O
carry O
a O
unique O
exoribonuclease O
( O
RNase O
) O
domain O
that O
has O
been O
shown O
to O
be O
critical O
for O
the O
suppression O
of O
type O
I O
interferons O
. O

Using O
a O
prototype O
arenavirus O
, O
Pichinde B
virus I
( I
PICV I
) I
, O
we O
characterized O
the O
viral O
growth O
and O
innate O
immune O
suppression O
of O
recombinant O
RNase O
- O
defective O
mutants O
in O
both O
cell O
culture O
and O
guinea O
pig O
models O
. O

simian B
hemorrhagic I
fever I
virus I
( I
SHFV I
) I
causes O
a O
severe O
and O
almost O
uniformly O
fatal O
viral O
hemorrhagic O
fever O
in O
Asian O
macaques O
but O
is O
thought O
to O
be O
nonpathogenic O
for O
humans O
. O

Treatment O
of O
target O
cells O
with O
proteases O
( O
proteinase O
K O
, O
papain O
, O
alpha O
- O
chymotrypsin O
, O
and O
trypsin O
) O
abrogated O
entry O
, O
indicating O
that O
the O
SHFV O
cell O
surface O
receptor O
is O
a O
protein O
. O

IMPORTANCE O
simian B
hemorrhagic I
fever I
virus I
( I
SHFV I
) I
causes O
highly O
lethal O
disease O
in O
Asian O
macaques O
resembling O
human O
illness O
caused O
by O
Ebola O
or O
Lassa O
virus O
. O

The O
infection O
causes O
immunosuppression O
, O
probably O
due O
to O
the O
absence O
of O
activation O
of O
antigen O
- O
presenting O
cells O
( O
dendritic O
cells O
and O
macrophages O
) O
, O
low O
type B
I I
interferon I
( I
IFN I
) I
production O
, O
and O
deficient O
NK O
cell O
function O
. O

We O
report O
that O
infected O
dendritic O
cells O
and O
macrophages O
express O
the O
NKG2D O
ligands O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
- O
related O
chains O
A O
and O
B O
and O
that O
they O
may O
produce O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
, O
IL O
- O
15 O
, O
and O
IL O
- O
18 O
, O
all O
involved O
in O
NK O
cell O
functions O
. O

Lassa B
virus I
( I
LASV I
) I
, O
which O
causes O
a O
viral O
hemorrhagic O
fever O
, O
inhibits O
the O
innate O
immune O
response O
. O

The O
exonuclease O
( O
ExoN O
) O
domain O
of O
its O
nucleoprotein B
( I
NP I
) I
is O
implicated O
in O
the O
suppression O
of O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
signaling O
. O

Machupo B
virus I
( I
MACV I
) I
is O
the O
etiologic O
agent O
of O
Bolivian B
hemorrhagic I
fever I
( I
BHF I
) I
. O

Here O
, O
we O
describe O
gain O
- O
of O
- O
function O
mutations O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
expressing O
Lassa B
virus I
( I
LASV I
) I
GP O
, O
which O
can O
prolong O
viremia O
in O
mice O
depending O
on O
the O
sequences O
in O
the O
GP O
- O
2 O
cytoplasmic O
tail O
. O

The O
initial O
mutant O
variant O
( O
rLCMV O
/ O
LASV O
mut O
GP O
) O
carried O
a O
point O
mutation O
in O
the O
cytosolic O
tail O
of O
the O
LASV O
glycoprotein O
GP O
corresponding O
to O
a O
K461G O
substitution O
. O

Unlike O
what O
occurred O
with O
the O
original O
rLCMV O
/ O
LASV O
wild B
- I
type I
( I
WT I
) I
GP O
, O
infection O
of O
C57BL O
/ O
6 O
mice O
with O
the O
mutated O
recombinant O
virus O
led O
to O
a O
detectable O
viremia O
of O
2 O
weeks O
' O
duration O
. O

The O
50 B
% I
inhibitory I
dose I
( I
IC50 I
) I
for O
the O
peptide O
is O
7 O
mu O
M O
, O
with O
complete O
inhibition O
of O
viral O
plaque O
formation O
at O
approximately O
20 O
mu O
M O
, O
and O
its O
antiviral O
activity O
is O
largely O
sequence O
dependent O
. O

Machupo B
virus I
( I
MACV I
) I
is O
the O
etiological O
agent O
of O
Bolivian B
hemorrhagic I
fever I
( I
BHF I
) I
, O
a O
reemerging O
and O
neglected O
tropical O
disease O
associated O
with O
high O
mortality O
. O

The O
recombinant B
MACV I
( I
rMACV I
) I
had O
in O
vitro O
growth O
properties O
similar O
to O
those O
of O
the O
parental O
MACV O
. O

Lassa B
fever I
( I
LF I
) I
is O
a O
potentially O
lethal O
human O
disease O
that O
is O
caused O
by O
the O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
. O

A O
crucial O
step O
of O
the O
arenavirus O
life O
cycle O
is O
maturation O
of O
the O
envelope O
glycoprotein B
precursor I
( I
GPC I
) I
by O
the O
cellular O
subtilisin B
kexin I
isozyme I
1 I
( I
SKI I
- I
1 I
) I
/ O
site B
1 I
protease I
( I
S1P I
) I
. O

Identification O
of O
host O
factors O
that O
are O
needed O
for O
Zaire O
ebolavirus B
( I
EBOV I
) I
entry O
provides O
insights O
into O
the O
mechanism O
( O
s O
) O
of O
filovirus O
uptake O
, O
and O
these O
factors O
may O
serve O
as O
potential O
antiviral O
targets O
. O

In O
order O
to O
identify O
novel O
host O
genes O
and O
pathways O
involved O
in O
EBOV O
entry O
, O
gene O
array O
findings O
in O
the O
National O
Cancer O
Institute O
' O
s O
NCI O
- O
60 O
panel O
of O
human O
tumor O
cell O
lines O
were O
correlated O
with O
permissivity O
for O
EBOV O
glycoprotein B
( I
GP I
) I
- O
mediated O
entry O
. O

We O
found O
that O
the O
gene O
encoding O
the O
gamma O
2 O
subunit O
of O
AMP B
- I
activated I
protein I
kinase I
( I
AMPK I
) I
strongly O
correlated O
with O
EBOV O
transduction O
in O
the O
tumor O
panel O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
is O
an O
emerging O
tick O
- O
borne O
virus O
of O
the O
Bunyaviridae O
family O
that O
is O
responsible O
for O
a O
fatal O
human O
disease O
for O
which O
preventative O
or O
therapeutic O
measures O
do O
not O
exist O
. O

We O
solved O
the O
crystal O
structure O
of O
the O
CCHFV O
strain O
Baghdad O
- O
12 O
Nucleocapsid B
protein I
( I
N I
) I
, O
a O
potential O
therapeutic O
target O
, O
at O
a O
resolution O
of O
2 O
. O

By O
taking O
advantage O
of O
the O
available O
reverse O
genetics O
system O
for O
a O
model O
arenavirus O
, O
Pichinde B
virus I
( I
PICV I
) I
, O
we O
provide O
the O
direct O
evidence O
for O
the O
essential O
biological O
roles O
of O
the O
Z O
protein O
' O
s O
conserved O
residues O
, O
including O
the O
G2 O
myristylation O
site O
, O
the O
conserved O
C O
and O
H O
residues O
of O
RING O
domain O
, O
and O
the O
poorly O
characterized O
C O
- O
terminal O
L79 O
and O
P80 O
residues O
. O

Dicodon O
substitutions O
within O
the O
late B
( I
L I
) I
domain O
( O
( O
PS O
) O
under O
barA O
( O
PP O
) O
under O
barY O
( O
EP O
) O
under O
bar O
) O
of O
the O
PICV O
Z O
protein O
, O
although O
producing O
viable O
mutant O
viruses O
, O
have O
significantly O
reduced O
virus O
growth O
, O
a O
finding O
suggestive O
of O
an O
important O
role O
for O
the O
intact O
L O
domain O
in O
viral O
replication O
. O

A O
crucial O
step O
in O
the O
life O
cycle O
of O
arenaviruses O
is O
the O
biosynthesis O
of O
the O
mature O
fusion O
- O
active O
viral O
envelope O
glycoprotein B
( I
GP I
) I
that O
is O
essential O
for O
virus O
- O
host O
cell O
attachment O
and O
entry O
. O

The O
maturation O
of O
the O
arenavirus O
GP B
precursor I
( I
GPC I
) I
critically O
depends O
on O
proteolytic O
processing O
by O
the O
cellular O
proprotein B
convertase I
( I
PC I
) I
subtilisin I
kexin I
isozyme I
- I
1 I
( I
SKI I
- I
1 I
) I
/ O
site B
- I
1 I
protease I
( I
S1P I
) I
. O

Here O
we O
undertook O
a O
molecular O
characterization O
of O
the O
SKI O
- O
1 O
/ O
S1P O
processing O
of O
the O
GPCs O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
the O
pathogenic O
Lassa B
virus I
( I
LASV I
) I
. O

Previous O
studies O
showed O
that O
the O
GPC O
of O
LASV O
undergoes O
processing O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
/ O
cis O
- O
Golgi O
compartment O
, O
whereas O
the O
LCMV O
GPC O
is O
cleaved O
in O
a O
late O
Golgi O
compartment O
. O

Lassa B
virus I
( I
LASV I
) I
is O
the O
causative O
agent O
of O
Lassa O
hemorrhagic O
fever O
( O
LF O
) O
in O
humans O
, O
a O
deadly O
disease O
endemic O
to O
West O
Africa O
that O
results O
in O
5 O
, O
000 O
to O
10 O
, O
000 O
deaths O
annually O
. O

Here O
we O
present O
results O
demonstrating O
that O
functional O
type O
I O
and O
type O
II O
interferon B
( I
IFN I
) I
signaling O
is O
required O
for O
efficient O
control O
of O
LASV O
dissemination O
and O
clearance O
. O

Lassa O
virus O
( O
LASV O
; O
Arenaviridae O
) O
is O
responsible O
for O
severe O
hemorrhagic O
fevers O
in O
Africa O
. O

LASV O
nucleoprotein B
( I
NP I
) I
plays O
important O
roles O
in O
regulating O
viral O
transcription O
and O
replication O
and O
in O
inhibiting O
type B
I I
interferon I
( I
IFN I
) I
production O
. O

We O
have O
established O
a O
murine O
Polymerase B
( I
Pol I
) I
I O
reverse O
genetics O
system O
for O
LASV O
, O
showing O
that O
residues O
D389 O
and O
G392 O
of O
NP O
were O
critical O
for O
LASV O
viability O
, O
while O
the O
D389A O
/ O
G392A O
and O
D389T O
/ O
392A O
double O
mutants O
were O
severely O
altered O
in O
the O
ability O
to O
suppress O
IFN O
in O
macrophages O
and O
dendritic O
cells O
. O

The O
events O
leading O
to O
death O
in O
severe O
cases O
of O
Lassa B
fever I
( I
LF I
) I
are O
unknown O
. O

We O
previously O
compared O
Lassa B
virus I
( I
LV I
) I
with O
its O
genetically O
close O
but O
nonpathogenic O
homolog O
Mopeia B
virus I
( I
MV I
) I
, O
which O
was O
used O
to O
model O
nonfatal O
LF O
. O

We O
showed O
that O
strong O
and O
early O
activation O
of O
antigen B
- I
presenting I
cells I
( I
APC I
) I
may O
play O
a O
crucial O
role O
in O
controlling O
infection O
. O

Here O
we O
developed O
an O
in O
vitro O
model O
of O
dendritic O
- O
cell O
( O
DC O
) O
- O
T O
- O
cell O
coculture O
in O
order O
to O
characterize O
human O
T O
- O
cell O
responses O
induced O
by O
MV O
- O
or O
LV O
- O
infected O
DCs O
. O

MV O
strongly O
and O
durably O
stimulated O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
, O
showing O
early O
and O
high O
activation O
, O
a O
strong O
proliferative O
response O
, O
and O
acquisition O
of O
effector O
and O
memory O
phenotypes O
. O

Furthermore O
, O
robust O
and O
functional O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
were O
generated O
. O

Lassa B
virus I
( I
LASV I
) I
, O
is O
a O
significant O
cause O
of O
severe O
, O
often O
fatal O
, O
hemorrhagic O
fever O
in O
humans O
throughout O
western O
Africa O
, O
with O
an O
estimated O
100 O
, O
000 O
infections O
each O
year O
. O

We O
report O
the O
development O
of O
an O
efficient O
reverse O
genetics O
system O
to O
rescue O
recombinant O
LASV O
and O
to O
investigate O
the O
contributions O
of O
the O
long O
5 O
' O
and O
3 O
' O
noncoding B
regions I
( I
NCRs I
) I
of O
the O
S O
genomic O
segment O
to O
in O
vitro O
growth O
and O
in O
vivo O
virulence O
. O

Arenaviruses O
cause O
severe O
human O
disease O
ranging O
from O
aseptic O
meningitis O
following O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
to O
hemorrhagic O
fever O
syndromes O
following O
infection O
with O
Guanarito B
virus I
( I
GTOV I
) I
, O
Junin B
virus I
( I
JUNV I
) I
, O
Lassa B
virus I
( I
LASV I
) I
, O
Machupo B
virus I
( I
MACV I
) I
, O
Sabia B
virus I
( I
SABV I
) I
, O
or O
White B
- I
water I
Arroyo I
virus I
( I
WWAV I
) I
. O

Cellular O
immunity O
, O
chiefly O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
, O
plays O
a O
critical O
role O
in O
providing O
protective O
immunity O
following O
infection O
with O
the O
Old O
World O
arenaviruses O
LASV O
and O
LCMV O
. O

We O
were O
able O
to O
identify O
a O
panel O
of O
HLA O
- O
A O
* O
0201 O
- O
restricted O
peptides O
derived O
from O
the O
same O
region O
of O
the O
glycoprotein B
precursor I
( I
GPC I
) I
of O
LASV O
( O
GPC O
spanning O
residues O
441 O
to O
449 O
[ O
GPC O
( O
441 O
- O
449 O
) O
] O
) O
, O
LCMV O
( O
GPC O
( O
447 O
- O
455 O
) O
) O
, O
JUNV O
( O
GPC O
( O
429 O
- O
437 O
) O
) O
, O
MACV O
( O
GPC O
( O
444 O
- O
452 O
) O
) O
, O
GTOV O
( O
GPC O
( O
427 O
- O
435 O
) O
) O
, O
and O
WWAV O
( O
GPC O
( O
428 O
- O
436 O
) O
) O
that O
displayed O
high O
- O
affinity O
binding O
to O
HLA O
- O
A O
* O
0201 O
and O
were O
recognized O
by O
CD8 O
( O
+ O
) O
T O
cells O
in O
a O
cross O
- O
reactive O
manner O
following O
LCMV O
infection O
or O
peptide O
immunization O
of O
HLA O
- O
A O
* O
0201 O
transgenic O
mice O
. O

Immunization O
of O
HLA O
- O
A O
* O
0201 O
mice O
with O
the O
Old O
World O
peptide O
LASV O
GPC O
( O
441 O
- O
449 O
) O
or O
LCMV O
GPC O
( O
447 O
- O
455 O
) O
induced O
high O
- O
avidity O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
that O
were O
able O
to O
kill O
syngeneic O
target O
cells O
pulsed O
with O
either O
LASV O
GPC O
( O
441 O
- O
449 O
) O
or O
LCMV O
GPC O
( O
447 O
- O
455 O
) O
in O
vivo O
and O
provided O
significant O
protection O
against O
viral O
challenge O
with O
LCMV O
. O

Bone O
marrow O
stromal O
antigen O
2 O
( O
BST O
- O
2 O
/ O
tetherin O
) O
is O
a O
cellular O
membrane O
protein O
that O
inhibits O
the O
release O
of O
HIV O
- O
1 O
. O

Specifically O
, O
infectious O
Lassa B
virus I
( I
LASV I
) I
release O
significantly O
decreased O
or O
increased O
in O
human O
cells O
in O
which O
BST O
- O
2 O
was O
either O
stably O
expressed O
or O
knocked O
down O
, O
respectively O
. O

In O
contrast O
, O
replication O
and O
spread O
of O
infectious O
Zaire B
Ebolavirus I
( I
ZEBOV I
) I
and O
Lake O
Victoria O
Marburgvirus B
( I
MARV I
) I
were O
not O
affected O
by O
these O
conditions O
. O

Replication O
of O
infectious O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
and O
cowpox B
virus I
( I
CPXV I
) I
was O
also O
not O
affected O
by O
BST O
- O
2 O
expression O
. O

Elevated O
cellular O
levels O
of O
human O
or O
murine O
BST O
- O
2 O
inhibited O
the O
release O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
consisting O
of O
the O
matrix O
proteins O
of O
multiple O
highly O
virulent O
NIAID O
Priority O
Pathogens O
, O
including O
arenaviruses O
( O
LASV O
and O
Machupo O
virus O
[ O
MACV O
] O
) O
, O
filoviruses O
( O
ZEBOV O
and O
MARV O
) O
, O
and O
paramyxoviruses O
( O
Nipah O
virus O
) O
. O

Although O
the O
glycoproteins O
of O
filoviruses O
counteracted O
the O
antiviral O
activity O
of O
BST O
- O
2 O
in O
the O
context O
of O
VLPs O
, O
they O
could O
not O
rescue O
arenaviral O
( O
LASV O
and O
MACV O
) O
VLP O
release O
upon O
BST O
- O
2 O
overexpression O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
( O
genus O
Phlebovirus O
, O
family O
Bunyaviridae O
) O
causes O
mosquito O
- O
borne O
epidemic O
diseases O
in O
humans O
and O
livestock O
. O

Coexpression O
of O
N O
, O
Hemagglutinin B
( I
HA I
) I
- O
tagged O
L O
, O
and O
viral O
minigenome O
resulted O
in O
minigenome O
replication O
and O
transcription O
, O
a O
finding O
that O
demonstrated O
HA O
- O
tagged O
L O
was O
biologically O
active O
. O

Likewise O
L O
tagged O
with O
green B
fluorescent I
protein I
( I
GFP I
) I
was O
biologically O
competent O
. O

Several O
arenaviruses O
can O
cause O
hemorrhagic O
fever O
diseases O
( O
VHFs O
) O
in O
humans O
, O
the O
pathogenic O
mechanism O
of O
which O
is O
poorly O
understood O
due O
to O
their O
virulent O
nature O
and O
the O
lack O
of O
molecular O
clones O
. O

A O
safe O
, O
convenient O
, O
and O
economical O
small O
animal O
model O
of O
arenavirus O
hemorrhagic O
fever O
is O
based O
on O
guinea O
pigs O
infected O
by O
the O
arenavirus O
Pichinde B
( I
PICV I
) I
. O

PICV O
does O
not O
cause O
disease O
in O
humans O
, O
but O
an O
adapted O
strain O
of O
PICV O
( O
P18 O
) O
causes O
a O
disease O
in O
guinea O
pigs O
that O
mimics O
arenavirus O
hemorrhagic O
fever O
in O
humans O
in O
many O
aspects O
, O
while O
a O
low O
- O
passaged O
strain O
( O
P2 O
) O
remains O
avirulent O
in O
infected O
animals O
. O

The O
utility O
of O
the O
system O
is O
demonstrated O
by O
generating O
Junin O
viruses O
which O
encode O
a O
glycoprotein B
precursor I
( I
GPC I
) I
containing O
the O
following O
: O
( O
i O
) O
the O
wild O
- O
type O
( O
SKI O
- O
1 O
/ O
S1P O
peptidase O
) O
cleavage O
site O
, O
( O
ii O
) O
no O
cleavage O
site O
, O
or O
( O
iii O
) O
a O
cleavage O
site O
where O
the O
SKI O
- O
1 O
/ O
S1P O
motif O
( O
RSLK O
) O
is O
replaced O
by O
a O
furin O
cleavage O
site O
( O
RRKR O
) O
. O

Although O
all O
animals O
developed O
strong O
humoral O
responses O
, O
antibodies O
appeared O
more O
rapidly O
in O
survivors O
and O
were O
directed O
against O
GP O
( O
1 O
) O
, O
GP O
( O
2 O
) O
, O
and O
NP O
. O

The O
mRNAs O
for O
CXCL10 O
( O
IP O
- O
10 O
) O
and O
CXCL11 O
( O
I O
- O
TAC O
) O
were O
abundant O
in O
peripheral O
blood O
mononuclear O
cells O
and O
lymph O
nodes O
from O
infected O
animals O
, O
but O
plasma O
interleukin O
- O
6 O
was O
detected O
only O
in O
fatalities O
. O

The O
Old O
World O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
is O
the O
causative O
agent O
of O
severe O
viral B
hemorrhagic I
fever I
( I
VHF I
) I
in O
humans O
and O
is O
the O
most O
prevalent O
human O
pathogen O
among O
arenaviruses O
. O

The O
present O
study O
investigated O
the O
largely O
unknown O
mechanisms O
of O
cell O
entry O
of O
LASV O
, O
a O
process O
know O
to O
be O
mediated O
solely O
by O
the O
virus O
envelope O
glycoprotein B
( I
GP I
) I
. O

To O
circumvent O
biosafety O
restrictions O
associated O
with O
the O
use O
of O
live O
LASV O
, O
we O
used O
reverse O
genetics O
to O
generate O
a O
recombinant O
variant O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
expressing O
the O
LASV O
GP O
( O
rLCMV O
- O
LASVGP O
) O
. O

The O
kinetics O
of O
pH O
- O
dependent O
membrane O
fusion O
of O
rLCMV O
- O
LASVGP O
resembled O
those O
of O
the O
human O
- O
pathogenic O
New O
World O
arenavirus O
Junin B
virus I
( I
JUNV I
) I
and O
other O
enveloped O
viruses O
that O
use O
clathrin O
- O
mediated O
endocytosis O
for O
entry O
. O

The O
human B
immunodeficiency I
virus I
( I
HIV I
) I
envelope I
( I
Env I
) I
protein O
is O
incorporated O
into O
HIV O
virions O
or O
virus B
- I
like I
particles I
( I
VLPs I
) I
at O
very O
low O
levels O
compared O
to O
the O
glycoproteins O
of O
most O
other O
enveloped O
viruses O
. O

To O
test O
factors O
that O
influence O
HIV O
Env O
particle O
incorporation O
, O
we O
generated O
a O
series O
of O
chimeric O
gene O
constructs O
in O
which O
the O
coding O
sequences O
for O
the O
signal B
peptide I
( I
SP I
) I
, O
transmembrane B
( I
TM I
) I
, O
and O
cytoplasmic B
tail I
( I
CT I
) I
domains O
of O
HIV O
- O
1 O
Env O
were O
replaced O
with O
those O
of O
other O
viral O
or O
cellular O
proteins O
individually O
or O
in O
combination O
. O

All O
constructs O
tested O
were O
derived O
from O
HIV B
type I
1 I
( I
HIV I
- I
1 I
) I
Con O
- O
S O
Delta O
CFI O
gp145 O
, O
which O
itself O
was O
found O
to O
be O
incorporated O
into O
VLPs O
much O
more O
efficiently O
than O
full O
- O
length O
Con O
- O
S O
Env O
. O

Substitution O
of O
the O
HIV O
TM O
- O
CT O
with O
sequences O
derived O
from O
the O
mouse B
mammary I
tumor I
virus I
( I
MMTV I
) I
envelope O
glycoprotein O
, O
influenza O
virus O
hemagglutinin O
, O
or O
baculovirus B
( I
BV I
) I
gp64 O
, O
but O
not O
from O
Lassa O
fever O
virus O
glycoprotein O
, O
was O
found O
to O
enhance O
Env O
incorporation O
into O
VLPs O
. O

Generation O
of O
infectious O
arenavirus O
- O
like O
particles O
requires O
the O
virus O
RING O
finger O
Z O
protein O
and O
surface O
glycoprotein B
precursor I
( I
GPC I
) I
and O
the O
correct O
processing O
of O
GPC O
into O
GP1 O
, O
GP2 O
, O
and O
a O
stable B
signal I
peptide I
( I
SSP I
) I
. O

Z O
is O
the O
driving O
force O
of O
arenavirus O
budding O
, O
whereas O
the O
GP B
complex I
( I
GPc I
) I
, O
consisting O
of O
hetero O
- O
oligomers O
of O
SSP O
, O
GP1 O
, O
and O
GP2 O
, O
forms O
the O
viral O
envelope O
spikes O
that O
mediate O
receptor O
recognition O
and O
cell O
entry O
. O

Our O
results O
from O
mutation O
- O
function O
analysis O
reveal O
that O
Z O
myristoylation O
, O
but O
not O
the O
Z O
late B
( I
L I
) I
or O
RING O
domain O
, O
is O
required O
for O
Z O
- O
GPc O
interaction O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
virus O
is O
a O
tick O
- O
borne O
member O
of O
the O
genus O
Nairovirus O
, O
family O
Bunyaviridae O
. O

The O
mature O
virus O
glycoproteins O
, O
Gn O
and O
Gc O
( O
previously O
referred O
to O
as O
G2 O
and O
G1 O
) O
, O
are O
generated O
by O
proteolytic O
cleavage O
from O
precursor O
proteins O
. O

The O
efficient O
cleavage O
of O
RRLL O
peptide O
is O
consistent O
with O
the O
known O
recognition O
sequences O
of O
SKI O
- O
1 O
, O
including O
the O
sequence O
determinants O
involved O
in O
the O
cleavage O
of O
the O
Lassa O
virus O
( O
family O
Arenaviridae O
) O
glycoprotein O
precursor O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
( I
CCHF I
) I
virus O
is O
the O
cause O
of O
an O
important O
tick O
- O
borne O
disease O
of O
humans O
throughout O
regions O
of O
Africa O
, O
Europe O
, O
and O
Asia O
. O

Sequence O
analysis O
of O
the O
CCHF O
virus O
( O
Matin O
strain O
) O
M O
RNA O
segment O
revealed O
one O
major O
open O
reading O
frame O
that O
potentially O
encodes O
a O
precursor O
polyprotein O
1 O
, O
689 O
amino B
acids I
( I
aa I
) I
in O
length O
. O

Analysis O
of O
released O
virus O
revealed O
two O
major O
structural O
glycoproteins O
, O
G2 O
( O
37 O
kDa O
) O
and O
G1 O
( O
75 O
kDa O
) O
. O

Virus O
protein O
analysis O
by O
various O
techniques O
, O
including O
pulse O
- O
chase O
analysis O
and O
/ O
or O
reactivity O
with O
CCHF O
virus O
- O
specific O
polyclonal O
and O
antipeptide O
antibodies O
, O
demonstrated O
that O
the O
140 O
- O
kDa O
( O
which O
contains O
the O
mucin O
- O
like O
region O
) O
and O
85 O
- O
kDa O
nonstructural O
proteins O
are O
the O
precursors O
of O
the O
mature O
G2 O
and O
G1 O
proteins O
, O
respectively O
. O

The O
amino O
termini O
of O
the O
CCHF O
virus O
( O
Matin O
strain O
) O
G2 O
and O
G1 O
proteins O
were O
established O
by O
microsequencing O
to O
be O
equivalent O
to O
aa O
525 O
and O
1046 O
, O
respectively O
, O
of O
the O
encoded O
polyprotein O
precursor O
. O

These O
are O
completely O
conserved O
among O
the O
predicted O
polyprotein O
sequences O
of O
all O
the O
CCHF O
virus O
strains O
and O
closely O
resemble O
the O
tetrapeptides O
that O
represent O
the O
major O
cleavage O
recognition O
sites O
present O
in O
the O
glycoprotein O
precursors O
of O
arenaviruses O
, O
such O
as O
Lassa O
fever O
virus O
( O
RRLL O
) O
and O
Pichinde O
virus O
( O
RKLL O
) O
. O

These O
results O
strongly O
suggest O
that O
CCHF O
viruses O
( O
and O
other O
members O
of O
the O
genus O
Nairovirus O
) O
likely O
utilize O
the O
subtilase O
SKI O
- O
1 O
/ O
S1P O
- O
like O
cellular O
proteases O
for O
the O
major O
glycoprotein O
precursor O
cleavage O
events O
, O
as O
has O
recently O
been O
demonstrated O
for O
the O
arenaviruses O
. O

An O
attenuated O
Pichinde O
virus O
variant O
( O
P2 O
) O
and O
a O
virulent O
variant O
( O
P18 O
) O
are O
being O
used O
to O
delineate O
pathogenic O
mechanisms O
that O
culminate O
in O
shock O
. O

In O
order O
to O
study O
human O
T O
- O
cell O
reactivity O
to O
single O
Lassa O
virus O
proteins O
, O
the O
nucleoprotein B
( I
NP I
) I
of O
Lassa O
virus O
, O
strain O
Josiah O
, O
was O
cloned O
, O
expressed O
in O
Escherichia O
coli O
, O
and O
affinity O
purified O
, O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
obtained O
from O
8 O
of O
13 O
healthy O
, O
Lassa O
virus O
antibody O
- O
positive O
individuals O
living O
in O
the O
Republic O
of O
Guinea O
, O
western O
Africa O
, O
were O
found O
to O
proliferate O
in O
response O
to O
the O
recombinant O
protein O
( O
proliferation O
index O
greater O
than O
or O
equal O
to O
10 O
) O
. O

PBMC O
obtained O
from O
one O
individual O
with O
a O
particularly O
high O
proliferative O
response O
were O
used O
to O
generate O
50 O
NP O
- O
specific O
T B
- I
cell I
clones I
( I
TCC I
) I
, O
For O
six O
of O
these O
the O
epitopes O
were O
mapped O
with O
overlapping O
synthetic O
peptides O
derived O
from O
the O
sequence O
of O
the O
NP O
. O

These O
CD4 O
( O
+ O
) O
TCC O
displayed O
high O
specific O
proliferation O
and O
produced O
mainly O
gamma O
interferon O
upon O
stimulation O
with O
NP O
, O
Because O
variation O
of O
up O
to O
15 O
% O
in O
the O
amino O
acid O
sequences O
of O
the O
structural O
proteins O
of O
naturally O
occurring O
Lassa O
virus O
variants O
has O
been O
observed O
, O
the O
reactivity O
of O
the O
TCC O
with O
peptides O
derived O
from O
the O
homologous O
epitopes O
of O
the O
Nigeria O
strain O
of O
Lassa O
virus O
and O
of O
the O
eastern O
Africa O
arenavirus O
Mopeia O
was O
tested O
. O

This O
report O
shows O
for O
the O
first O
time O
that O
seropositive O
individuals O
from O
areas O
of O
endemicity O
have O
very O
strong O
memory O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
against O
the O
NP O
of O
Lassa O
virus O
, O
which O
are O
partly O
strain O
specific O
and O
partly O
cross O
- O
reactive O
with O
other O
Lassa O
virus O
strains O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
, O
which O
has O
been O
designated O
a O
priority O
disease O
by O
the O
World B
Health I
Organization I
( I
WHO I
) I
, O
is O
one O
of O
the O
most O
pathogenic O
zoonotic O
diseases O
endemic O
to O
Africa O
and O
the O
Arabian O
Peninsula O
. O

This O
study O
demonstrates O
the O
rescue O
of O
RVF B
virus I
( I
RVFV I
) I
MP O
- O
12 O
infectious O
clones O
in O
Vero O
cells O
using O
plasmids O
encoding O
the O
Macaca O
mulatta O
RNA O
polymerase O
I O
promoter O
. O

The O
reamplification O
of O
rescued O
recombinant B
MP I
- I
12 I
( I
rMP I
- I
12 I
) I
in O
Vero O
cells O
led O
to O
an O
increase O
in O
the O
genetic O
subpopulations O
, O
affecting O
the O
viral O
phenotype O
via O
amino O
acid O
substitutions O
in O
the O
NSs O
gene O
, O
whereas O
rMP O
- O
12 O
reamplified O
in O
human O
diploid O
MRC O
- O
5 O
cells O
did O
not O
increase O
viral O
subpopulations O
with O
NSs O
gene O
mutations O
. O

This O
study O
demonstrated O
the O
generation O
of O
infectious O
Rift B
Valley I
fever I
( I
RVF I
) I
virus O
from O
cloned O
cDNA O
using O
Vero O
cells O
, O
which O
are O
one O
of O
a O
few O
mammalian O
cell O
lines O
used O
for O
vaccine O
manufacturing O
. O

Schmallenberg B
virus I
( I
SBV I
) I
is O
an O
insect O
- O
transmitted O
orthobunyavirus O
that O
can O
cause O
abortions O
and O
congenital O
malformations O
in O
the O
offspring O
of O
ruminants O
. O

Using O
genome O
- O
wide O
CRISPR O
- O
Cas9 O
forward O
screening O
, O
we O
identified O
3 O
' O
- O
phosphoadenosine O
5 O
' O
phosphosulfate O
( O
PAPS O
) O
transporter O
1 O
( O
PAPST1 O
) O
as O
an O
essential O
factor O
for O
SBV O
infection O
. O

PAPST1 O
is O
a O
sulfotransferase O
involved O
in O
heparan O
sulfate O
proteoglycan O
synthesis O
encoded O
by O
the O
solute O
carrier O
family O
35 O
member O
B2 O
gene O
( O
SLC3582 O
) O
. O

IMPORTANCE O
SBV O
is O
a O
newly O
emerging O
orthobunyavirus O
( O
family O
Peribunyaviridae O
) O
that O
has O
spread O
rapidly O
across O
Europe O
since O
2011 O
, O
resulting O
in O
substantial O
economic O
losses O
in O
livestock O
farming O
. O

The O
small B
messenger I
RNA I
( I
SmRNA I
) I
of O
the O
Andes B
orthohantavirus I
( I
ANDV I
) I
, O
a O
rodent O
- O
borne O
member O
of O
the O
Hantaviridae O
family O
of O
viruses O
of O
the O
Bunyavirales O
order O
, O
encodes O
a O
multifunctional O
nucleocapsid B
( I
N I
) I
protein O
and O
for O
a O
nonstructural O
( O
NSs O
) O
protein O
of O
unknown O
function O
. O

Next O
, O
we O
show O
, O
using O
a O
virus O
- O
free O
system O
, O
that O
the O
ANDV O
- O
NSs O
protein O
antagonizes O
the O
type B
I I
interferon I
( I
IFN I
) I
induction O
pathway O
by O
suppressing O
signals O
downstream O
of O
the O
Melanoma B
Differentiation I
- I
Associated I
protein I
5 I
( I
MDA5 I
) I
and O
the O
retinoic B
acid I
- I
inducible I
gene I
1 I
( I
RIG I
- I
I I
) I
and O
upstream O
of O
TBK1 O
. O

Consistent O
with O
this O
observation O
, O
the O
ANDV O
- O
NSs O
protein O
antagonized O
mitochondrial B
antiviral I
- I
signaling I
protein I
( I
MAVS I
) I
- O
induced O
IFN O
- O
beta O
, O
NF O
- O
kappa O
B O
, O
IFN B
- I
regulatory I
factor I
3 I
( I
IRF3 I
) I
, O
and O
IFN B
- I
sensitive I
response I
element I
( I
ISRE I
) I
promoter O
activity O
. O

IMPORTANCE O
Andes B
orthohantavirus I
( I
ANDV I
) I
is O
endemic O
in O
Argentina O
and O
Chile O
and O
is O
the O
primary O
etiological O
agent O
of O
hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
in O
South O
America O
. O

Mosquito O
- O
borne O
La O
Crosse O
virus O
( O
LACV O
; O
genus O
Orthobunyavirus O
, O
family O
Peribunyaviridae O
, O
order O
Bunyavirales O
) O
causes O
up O
to O
100 O
annual O
cases O
of O
severe O
meningoencephalitis O
in O
children O
and O
young O
adults O
in O
the O
United O
States O
. O

A O
major O
virulence O
factor O
of O
LACV O
is O
the O
nonstructural O
protein O
NSs O
, O
which O
inhibits O
host O
cell O
mRNA O
synthesis O
to O
prevent O
the O
induction O
of O
antiviral O
type O
I O
interferons O
( O
IFN O
- O
alpha O
/ O
beta O
) O
. O

IMPORTANCE O
The O
mosquito O
- O
borne O
La O
Crosse O
virus O
( O
LACV O
; O
genus O
Orthobunyavirus O
, O
family O
Peribunyaviridae O
, O
order O
Bunyavirales O
) O
is O
prevalent O
in O
the O
United O
States O
and O
can O
cause O
severe O
childhood O
meningoencephalitis O
. O

Its O
main O
virulence O
factor O
, O
the O
nonstructural O
protein O
NSs O
, O
is O
a O
strong O
inhibitor O
of O
the O
antiviral O
type B
I I
interferon I
( I
IFN I
) I
system O
. O

Here O
, O
we O
show O
that O
RPB1 O
degradation O
commences O
as O
early O
as O
1 O
h O
postinfection O
, O
and O
identify O
the O
E3 O
ubiquitin O
ligase O
subunit O
Elongin O
C O
( O
and O
its O
binding O
partners O
Elongins O
A O
and O
B O
) O
as O
an O
NSs O
cofactor O
involved O
in O
RPB1 O
degradation O
and O
in O
suppression O
of O
global O
as O
well O
as O
IFN O
- O
related O
mRNA O
synthesis O
. O

Vesicular B
stomatitis I
Indiana I
virus I
( I
VSIV I
) I
, O
formerly O
known O
as O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
Indiana O
( O
VSVIND O
) O
, O
is O
a O
model O
virus O
that O
is O
exceptionally O
sensitive O
to O
the O
inhibitory O
action O
of O
Interferons B
( I
IFNs I
) I
. O

Interferons O
induce O
an O
antiviral O
state O
by O
stimulating O
the O
expression O
of O
hundreds O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

IMPORTANCE O
Vesicular B
stomatitis I
Indiana I
virus I
( I
VSIV I
) I
is O
a O
veterinary O
pathogen O
that O
is O
also O
used O
as O
a O
backbone O
for O
many O
oncolytic O
and O
vaccine O
strategies O
. O

Schlafen B
11 I
( I
Slfn11 I
) I
is O
an O
interferon O
- O
stimulated O
gene O
that O
controls O
the O
synthesis O
of O
proteins O
by O
regulating O
tRNA O
abundance O
. O

Likely O
through O
this O
mechanism O
, O
Slfn11 O
has O
previously O
been O
shown O
to O
impair O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
and O
the O
expression O
of O
codon O
- O
biased O
open O
reading O
frames O
. O

Because O
replication O
of O
positive O
- O
sense O
single O
- O
stranded O
RNA O
[ O
( O
+ O
) O
ssRNA O
] O
viruses O
requires O
the O
immediate O
translation O
of O
the O
incoming O
viral O
genome O
, O
whereas O
negative O
- O
sense O
single O
- O
stranded O
RNA O
[ O
( O
- O
) O
ssRNA O
] O
viruses O
carry O
at O
infection O
an O
RNA O
replicase O
that O
makes O
multiple O
translation O
- O
competent O
copies O
of O
the O
incoming O
viral O
genome O
, O
we O
reasoned O
that O
( O
- O
) O
ssRNA O
viruses O
will O
be O
more O
sensitive O
to O
the O
effect O
of O
Slfn11 O
on O
protein O
synthesis O
than O
( O
- O
) O
ssRNA O
viruses O
. O

Depletion O
of O
Slfn11 O
significantly O
increased O
the O
replication O
of O
( O
- O
) O
ssRNA O
viruses O
from O
the O
Flavivirus O
genus O
, O
including O
West B
Nile I
virus I
( I
WNV I
) I
, O
Dengue B
Virus I
( I
DENV I
) I
, O
and O
Zika B
virus I
( I
ZIKV I
) I
, O
but O
had O
no O
significant O
effect O
on O
the O
replication O
of O
the O
( O
- O
) O
ssRNA O
viruses O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
( O
Rhabdoviridae O
family O
) O
and O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
( O
Phenuiviridae O
family O
) O
. O

IMPORTANCE O
We O
provide O
evidence O
that O
the O
cellular O
protein O
Schlafen B
11 I
( I
Slfn11 I
) I
impairs O
replication O
of O
flaviviruses O
, O
including O
West B
Nile I
virus I
( I
WNV I
) I
, O
Dengue B
Virus I
( I
DENV I
) I
, O
and O
Zika B
virus I
( I
ZIKV I
) I
. O

In O
response O
to O
viral O
infections O
, O
Interferons B
( I
IFNs I
) I
upregulate O
the O
expression O
of O
hundreds O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
whose O
cumulative O
action O
can O
potently O
inhibit O
the O
replication O
of O
bunyaviruses O
. O

We O
used O
a O
flow O
cytometry O
- O
based O
method O
to O
screen O
the O
ability O
of O
similar O
to O
500 O
unique O
ISGs O
from O
humans O
and O
rhesus O
macaques O
to O
inhibit O
the O
replication O
of O
Bunyamwera B
orthobunyavirus I
( I
BUNV I
) I
, O
the O
prototype O
of O
both O
the O
Peribunyaviridae O
family O
and O
the O
Bunyavirales O
order O
. O

Interestingly O
, O
one O
candidate O
, O
ISG20 O
, O
exhibited O
potent O
antibunyaviral O
activity O
against O
most O
viruses O
examined O
from O
the O
Peribunyaviridae O
, O
Hantaviridae O
, O
and O
Nairoviridae O
families O
, O
whereas O
phleboviruses O
( O
Phenuiviridae O
) O
largely O
escaped O
inhibition O
. O

Through O
use O
of O
an O
infectious O
virus B
- I
like I
particle I
( I
VLP I
) I
assay O
( O
based O
on O
the O
BUNV O
minigenome O
system O
) O
, O
we O
confirmed O
that O
gene O
expression O
from O
all O
3 O
viral O
segments O
is O
strongly O
inhibited O
by O
ISG20 O
. O

The O
interferon B
( I
IFN I
) I
system O
is O
a O
key O
component O
of O
innate O
immunity O
, O
and O
type O
I O
IFNs O
limit O
bunyaviral O
propagation O
both O
in O
vitro O
and O
in O
vivo O
. O

Type O
I O
IFN O
signaling O
results O
in O
the O
upregulation O
of O
hundreds O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
whose O
concerted O
action O
generates O
an O
antiviral O
state O
. O

Using O
ISG O
- O
expression O
screening O
, O
we O
examined O
the O
ability O
of O
similar O
to O
500 O
unique O
ISGs O
to O
inhibit O
Bunyamwera B
orthobunyavirus I
( I
BUNV I
) I
, O
the O
prototypical O
bunyavirus O
. O

There O
is O
an O
urgent O
need O
for O
therapeutic O
development O
to O
combat O
infections O
caused O
by O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
which O
causes O
devastating O
disease O
in O
both O
humans O
and O
animals O
. O

In O
addition O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
studies O
suggested O
that O
nonclassical O
targets O
of O
sorafenib O
are O
important O
for O
the O
propagation O
of O
RVFV O
. O

Confocal O
microscopy O
imaging O
revealed O
that O
glycoprotein O
Gn O
colocalizes O
and O
accumulates O
within O
the O
endoplasmic B
reticulum I
( I
ER I
) I
and O
the O
transport O
of O
Gn O
from O
the O
Golgi O
complex O
to O
the O
host O
cell O
membrane O
is O
reduced O
. O

p97 O
/ O
valosin B
- I
containing I
protein I
( I
VCP I
) I
, O
which O
is O
involved O
in O
membrane O
remodeling O
in O
the O
secretory O
pathway O
and O
a O
known O
target O
of O
sorafenib O
, O
was O
found O
to O
be O
important O
for O
RVFV O
egress O
. O

SFTS O
phlebovirus O
( O
SFTSV O
) O
is O
an O
emerging O
tick O
- O
borne O
bunyavirus O
that O
was O
first O
reported O
in O
China O
in O
2009 O
. O

Here O
we O
report O
the O
generation O
of O
a O
recombinant O
SFTSV O
( O
rHB29NSsKO O
) O
that O
cannot O
express O
the O
viral O
nonstructural O
protein O
( O
NSs O
) O
upon O
infection O
of O
cells O
in O
culture O
. O

We O
show O
that O
rHB29NSsKO O
replication O
kinetics O
are O
greater O
in O
interferon B
( I
IFN I
) I
- O
incompetent O
cells O
and O
that O
the O
virus O
is O
unable O
to O
suppress O
IFN O
induced O
in O
response O
to O
viral O
replication O
. O

Using O
3 O
' O
rapid B
amplification I
of I
cDNA I
ends I
( I
RACE I
) I
, O
we O
mapped O
the O
3 O
' O
end O
of O
the O
N O
and O
NSs O
mRNAs O
, O
showing O
that O
the O
mRNAs O
terminate O
within O
the O
coding O
region O
of O
the O
opposite O
open O
reading O
frame O
. O

With O
this O
knowledge O
, O
and O
using O
virus O
- O
like O
particles O
, O
we O
could O
demonstrate O
that O
the O
last O
36 O
nucleotides O
of O
the O
NSs O
open B
reading I
frame I
( I
ORF I
) I
were O
needed O
to O
ensure O
the O
efficient O
termination O
of O
the O
N O
mRNA O
and O
were O
required O
for O
recombinant O
virus O
rescue O
. O

We O
demonstrate O
that O
it O
is O
possible O
to O
recover O
viruses O
lacking O
NSs O
( O
expressing O
just O
a O
12 O
- O
amino O
- O
acid O
NSs O
peptide O
or O
encoding O
enhanced O
green O
fluorescent O
protein O
[ O
eGFP O
] O
) O
or O
an O
NSs O
- O
eGFP O
fusion O
protein O
in O
the O
NSs O
locus O
. O

Rift O
Valley O
fever O
virus O
( O
RVFV O
, O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
is O
a O
relevant O
pathogen O
of O
both O
humans O
and O
livestock O
in O
Africa O
. O

The O
nonstructural O
protein O
NSs O
is O
a O
major O
virulence O
factor O
known O
to O
suppress O
the O
type B
I I
interferon I
( I
IFN I
) I
response O
by O
inhibiting O
host O
cell O
transcription O
and O
by O
proteasomal O
degradation O
of O
a O
major O
antiviral O
IFN O
effector O
, O
the O
translation O
- O
inhibiting O
protein O
kinase O
PKR O
. O

Here O
, O
we O
identified O
components O
of O
the O
modular O
SCF O
( O
Skp1 O
, O
Cul1 O
, O
F O
- O
box O
protein O
) O
- O
type O
E3 O
ubiquitin O
ligases O
as O
mediators O
of O
PKR O
destruction O
by O
NSs O
. O

small B
interfering I
RNAs I
( I
siRNAs I
) I
against O
the O
conserved O
SCF O
subunit O
Skp1 O
protected O
PKR O
from O
NSs O
- O
mediated O
degradation O
. O

We O
performed O
an O
siRNA O
screen O
for O
all O
( O
about O
70 O
) O
human O
F O
- O
box O
proteins O
and O
found O
FBXW11 O
to O
be O
involved O
in O
PKR O
degradation O
. O

To O
maximally O
protect O
PKR O
from O
the O
action O
of O
NSs O
, O
knockdown O
of O
structurally O
and O
functionally O
related O
FBXW1 O
( O
also O
known O
as O
beta O
- O
TRCP1 O
) O
, O
in O
addition O
to O
FBXW11 O
deletion O
, O
was O
necessary O
. O

Severe B
fever I
with I
thrombocytopenia I
syndrome I
( I
SFTS I
) I
is O
an O
emerging O
hemorrhagic O
fever O
with O
a O
high O
case O
fatality O
rate O
caused O
by O
SFTS O
virus O
( O
SFTSV O
) O
. O

In O
this O
study O
, O
we O
have O
developed O
a O
pseudotype O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
bearing O
the O
unmodified O
Gn O
/ O
Gc O
glycoproteins B
( I
GPs I
) I
of O
SFTSV O
( O
SFTSVpv O
) O
. O

Entry O
of O
SFTSVpv O
and O
growth O
of O
SFTSV O
were O
increased O
in O
Raji O
cells O
expressing O
not O
only O
the O
C O
- O
type O
lectin O
dendritic O
cell O
- O
specific O
intercellular O
adhesion O
molecule O
3 O
- O
grabbing O
nonintegrin O
( O
DC O
- O
SIGN O
) O
but O
also O
DC O
- O
SIGN O
- O
related O
( O
DC O
- O
SIGNR O
) O
and O
liver O
and O
lymph O
node O
sinusoidal O
endothelial O
cell O
C O
- O
type O
lectin O
( O
LSECtin O
) O
. O

25 B
- I
Hydroxycholesterol I
( I
25HC I
) I
, O
a O
soluble O
oxysterol O
metabolite O
, O
inhibited O
the O
cell O
entry O
of O
SFTSVpv O
and O
the O
membrane O
fusion O
of O
SFTSV O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
causes O
recurrent O
insect O
- O
borne O
epizootics O
throughout O
the O
African O
continent O
, O
and O
infection O
of O
humans O
can O
lead O
to O
a O
lethal O
hemorrhagic O
fever O
syndrome O
. O

This O
screen O
identified O
a O
suite O
of O
enzymes O
involved O
in O
glycosaminoglycan B
( I
GAG I
) I
biogenesis O
and O
transport O
, O
including O
several O
components O
of O
the O
cis B
- I
oligomeric I
Golgi I
( I
COG I
) I
complex O
, O
one O
of O
the O
central O
components O
of O
Golgi O
complex O
trafficking O
. O

We O
generated O
a O
recombinant O
Akabane B
virus I
( I
AKAV I
) I
expressing O
enhanced B
green I
fluorescence I
protein I
( I
eGFP I
- I
AKAV I
) I
by O
using O
reverse O
genetics O
. O

We O
artificially O
constructed O
an O
ambisense O
AKAV O
S O
genome O
encoding O
N O
/ O
NSs O
on O
the O
negative O
- O
sense O
strand O
, O
and O
eGFP O
on O
the O
positive O
- O
sense O
strand O
with O
an O
intergenic B
region I
( I
IGR I
) I
derived O
from O
the O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
S O
genome O
. O

Replicon O
particles O
of O
Rift O
Valley O
fever O
virus O
, O
referred O
to O
as O
nonspreading O
Rift O
Valley O
fever O
virus O
( O
NSR O
) O
, O
are O
intrinsically O
safe O
and O
highly O
immunogenic O
. O

Here O
, O
we O
demonstrate O
that O
NSR O
- O
infected O
human O
dendritic O
cells O
can O
activate O
CD8 O
( O
+ O
) O
T O
cells O
in O
vitro O
and O
that O
prophylactic O
and O
therapeutic O
vaccinations O
of O
mice O
with O
NSR O
encoding O
a O
tumor O
- O
associated O
CD8 O
peptide O
can O
control O
the O
outgrowth O
of O
lymphoma O
cells O
in O
vivo O
. O

Severe B
fever I
with I
thrombocytopenia I
syndrome I
virus I
( I
SFTSV I
) I
is O
an O
emerging O
tick O
- O
borne O
pathogen O
that O
was O
first O
reported O
in O
China O
in O
2009 O
. O

We O
then O
generated O
recombinant O
viruses O
from O
cloned O
cDNAs O
prepared O
to O
the O
antigenomic O
RNAs O
both O
of O
the O
minimally O
passaged O
virus O
( O
HB29 O
) O
and O
of O
a O
cell O
culture O
- O
adapted O
strain O
designated O
HB29pp O
. O

The O
growth O
properties O
, O
pattern O
of O
viral O
protein O
synthesis O
, O
and O
subcellular O
localization O
of O
viral O
N O
and O
NSs O
proteins O
of O
wild B
- I
type I
HB29pp I
( I
wtHB29pp I
) I
and O
recombinant O
HB29pp O
viruses O
were O
indistinguishable O
. O

Bunyavirus O
genomes O
comprise O
a O
small B
( I
S I
) I
, O
a O
medium B
( I
M I
) I
, O
and O
a O
large B
( I
L I
) I
RNA O
segment O
of O
negative O
polarity O
. O

One O
of O
the O
most O
important O
members O
of O
the O
Bunyaviridae O
family O
that O
causes O
devastating O
disease O
in O
ruminants O
and O
occasionally O
humans O
is O
the O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
. O

We O
studied O
the O
flexibility O
of O
RVFV O
genome O
packaging O
by O
splitting O
the O
glycoprotein O
precursor O
gene O
, O
encoding O
the O
( O
NSm O
) O
GnGc O
polyprotein O
, O
into O
two O
individual O
genes O
encoding O
either O
( O
NSm O
) O
Gn O
or O
Gc O
. O

Using O
reverse O
genetics O
, O
six O
viruses O
with O
a O
segmented O
glycoprotein O
precursor O
gene O
were O
rescued O
, O
varying O
from O
a O
virus O
comprising O
two O
S O
- O
type O
segments O
in O
the O
absence O
of O
an O
M O
- O
type O
segment O
to O
a O
virus O
consisting O
of O
four O
segments O
( O
RVFV O
- O
4s O
) O
, O
of O
which O
three O
are O
M O
- O
type O
. O

IMPORTANCE O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
causes O
devastating O
disease O
in O
ruminants O
and O
occasionally O
humans O
. O

Virions O
capable O
of O
productive O
infection O
comprise O
at O
least O
one O
copy O
of O
the O
small B
( I
S I
) I
, O
medium B
( I
M I
) I
, O
and O
large B
( I
L I
) I
RNA O
genome O
segments O
. O

The O
M O
segment O
encodes O
a O
glycoprotein B
precursor I
( I
GPC I
) I
protein O
that O
is O
cotranslationally O
cleaved O
into O
Gn O
and O
Gc O
, O
which O
are O
required O
for O
virus O
entry O
and O
fusion O
. O

Several O
RVFV O
variants O
, O
varying O
from O
viruses O
comprising O
two O
S O
- O
type O
segments O
to O
viruses O
consisting O
of O
four O
segments O
( O
RVFV O
- O
4s O
) O
, O
of O
which O
three O
are O
M O
- O
type O
, O
could O
be O
rescued O
and O
were O
shown O
to O
induce O
a O
rapid O
protective O
immune O
response O
. O

Uukuniemi B
virus I
( I
UUKV I
) I
is O
a O
model O
system O
for O
investigating O
the O
genus O
Phlebovirus O
of O
the O
Bunyaviridae O
. O

The O
nonstructural O
protein O
NSs O
is O
the O
main O
virulence O
factor O
of O
Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
, O
a O
serious O
pathogen O
of O
livestock O
and O
humans O
in O
Africa O
. O

RVFV O
NSs O
blocks O
transcriptional O
upregulation O
of O
antiviral O
type O
I O
interferons B
( I
IFN I
) I
and O
destroys O
the O
general O
transcription O
factor O
TFIII1 O
subunit O
p62 O
via O
the O
ubiquitin O
/ O
proteasome O
pathway O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
depletion O
of O
FBXO3 O
rescued O
p62 O
protein O
levels O
in O
RVFV O
- O
infected O
cells O
and O
elevated O
IFN O
transcription O
by O
1 O
order O
of O
magnitude O
. O

NSs O
interacts O
with O
the O
full O
- O
length O
FBXO3 O
protein O
as O
well O
as O
with O
a O
truncated O
isoform O
that O
lacks O
the O
C O
- O
terminal O
acidic O
and O
poly O
( O
R O
) O
- O
rich O
domains O
. O

F O
- O
box O
proteins O
form O
the O
variable O
substrate O
recognition O
subunit O
of O
the O
so O
- O
called O
SCF O
ubiquitin O
ligases O
, O
which O
also O
contain O
the O
constant O
components O
Skpl O
, O
cullin O
1 O
( O
or O
cullin O
7 O
) O
, O
and O
Rbxl O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
an O
ambisense O
member O
of O
the O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
, O
is O
the O
causative O
agent O
of O
Rift O
Valley O
fever O
, O
an O
important O
zoonotic O
infection O
in O
Africa O
and O
the O
Middle O
East O
. O

PABP1 O
relocalization O
was O
sharply O
decreased O
in O
cells O
infected O
with O
a O
strain O
of O
RVFV O
lacking O
the O
gene O
encoding O
the O
RVFV O
nonstructural B
protein I
S I
( I
NSs I
) I
. O

To O
determine O
whether O
PABP1 O
was O
required O
for O
RVFV O
infection O
, O
we O
measured O
the O
production O
of O
Nucleocapsid B
protein I
( I
N I
) I
in O
cells O
transfected O
with O
small B
interfering I
RNAs I
( I
siRNAs I
) I
targeting O
PABP1 O
. O

For O
La O
Crosse O
virus O
( O
LACV O
; O
genus O
Orthobunyavirus O
) O
, O
the O
nuclease O
responsible O
for O
host O
cell O
mRNA O
cleavage O
is O
located O
at O
the O
N O
terminus O
of O
the O
L O
protein O
, O
with O
an O
active O
site O
of O
five O
conserved O
amino O
acids O
( O
H34 O
, O
D52 O
, O
D79 O
, O
D92 O
, O
and O
K94 O
) O
surrounding O
two O
Mn2 O
+ O
ions O
( O
J O
. O

Transcription O
was O
evaluated O
with O
an O
enhanced O
minigenome O
system O
consisting O
of O
the O
viral O
polymerase O
L O
, O
nucleocapsid O
protein O
N O
, O
a O
negative O
- O
sense O
minigenome O
, O
and O
- O
to O
alleviate O
antiviral O
host O
responses O
- O
a O
dominant O
- O
negative O
mutant O
( O
PKR O
Delta O
E7 O
) O
of O
the O
antiviral O
kinase O
protein B
kinase I
R I
( I
PKR I
) I
. O

The O
replication O
activity O
of O
the O
L O
mutants O
was O
measured O
by O
packaging O
of O
progeny O
minigenomes O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

To O
test O
the O
broader O
applicability O
of O
our O
results O
, O
we O
introduced O
the O
homolog O
of O
mutation O
D79A O
( O
D111A O
) O
into O
the O
L O
sequence O
of O
Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
genus O
Phlebovirus O
) O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
causes O
outbreaks O
of O
severe O
disease O
in O
people O
and O
livestock O
throughout O
Africa O
and O
the O
Arabian O
Peninsula O
. O

Experiments O
utilizing O
B O
- O
cell O
- O
deficient O
mice O
or O
targeted O
T O
cell O
depletions O
of O
wild O
- O
type O
mice O
demonstrated O
that O
B O
cells O
and O
CD4 O
( O
+ O
) O
T O
cells O
, O
but O
not O
CD8 O
( O
+ O
) O
T O
cells O
, O
were O
critical O
for O
mediating O
viral O
clearance O
, O
even O
in O
the O
presence O
of O
a O
functional O
innate O
response O
. O

CD4 O
( O
+ O
) O
T O
cells O
were O
required O
for O
robust O
IgG O
and O
neutralizing O
antibody O
responses O
that O
correlated O
with O
RVFV O
clearance O
from O
peripheral O
tissues O
. O

Furthermore O
, O
CD4 O
- O
depleted O
mice O
demonstrated O
significantly O
stronger O
proinflammatory O
responses O
relative O
to O
controls O
, O
suggesting O
CD4 O
( O
+ O
) O
T O
cells O
regulate O
immune O
responses O
to O
RVFV O
infection O
. O

Together O
, O
these O
results O
indicate O
CD4 O
( O
+ O
) O
T O
cells O
are O
critical O
determinants O
of O
RVFV O
pathogenesis O
and O
play O
an O
important O
role O
in O
preventing O
onset O
of O
neurologic O
disease O
. O

Severe B
fever I
with I
thrombocytopenia I
syndrome I
virus I
( I
SFTSV I
) I
is O
a O
novel O
bunyavirus O
that O
recently O
emerged O
in O
China O
. O

Employing O
lentiviral O
and O
rhabdoviral O
vectors O
, O
we O
found O
that O
the O
Gn O
/ O
Gc O
glycoproteins O
( O
Gn O
/ O
Gc O
) O
of O
SFTSV O
mediate O
entry O
into O
a O
broad O
range O
of O
human O
and O
animal O
cell O
lines O
, O
as O
well O
as O
human O
macrophages O
and O
dendritic O
cells O
. O

The O
Gn O
/ O
Gc O
proteins O
of O
La B
Crosse I
virus I
( I
LACV I
) I
and O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
other O
members O
of O
the O
bunyavirus O
family O
, O
facilitated O
entry O
into O
an O
overlapping O
but O
not O
identical O
range O
of O
cell O
lines O
, O
suggesting O
that O
SFTSV O
, O
LACV O
, O
and O
RVFV O
might O
differ O
in O
their O
receptor O
requirements O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
Phlebovirus O
( O
Bunyaviridae O
family O
) O
transmitted O
by O
mosquitoes O
. O

Analysis O
of O
virus O
- O
derived O
small O
interfering O
RNAs O
( O
viRNAs O
) O
by O
deep O
sequencing O
indicated O
that O
production O
of O
viRNAs O
was O
very O
low O
in O
C6 O
/ O
36 O
cells O
, O
which O
are O
known O
to O
be O
Dicer O
- O
2 O
deficient O
but O
expressed O
some O
viRNAs O
presenting O
a O
Piwi O
signature O
. O

Whereas O
21 O
- O
nucleotide B
( I
nt I
) I
Dicer O
- O
2 O
viRNAs O
were O
prominent O
during O
early O
infection O
, O
the O
population O
of O
24 O
- O
to O
27 O
- O
nt O
Piwi B
RNAs I
( I
piRNAs I
) I
increased O
progressively O
and O
became O
predominant O
later O
during O
the O
acute O
infection O
and O
during O
persistence O
. O

In O
C6 O
/ O
36 O
cells O
, O
Piwi O
- O
mediated O
RNA B
interference I
( I
RNAi I
) I
appeared O
to O
be O
sufficient O
to O
mount O
an O
antiviral O
response O
against O
a O
secondary O
infection O
with O
a O
superinfecting O
virus O
. O

The O
NSm O
nonstructural O
protein O
of O
Rift O
Valley O
fever O
virus O
( O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
has O
an O
antiapoptotic O
function O
and O
affects O
viral O
pathogenesis O
. O

We O
performed O
high O
- O
throughput O
sequencing O
of O
MP O
- O
12 O
vaccine O
, O
ZH548 O
, O
and O
recombinant B
MP I
- I
12 I
( I
rMP I
- I
12 I
) I
viruses O
. O

The O
entry O
of O
the O
enveloped O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
into O
its O
host O
cell O
is O
mediated O
by O
the O
viral O
glycoproteins O
Gn O
and O
Gc O
. O

Exposure O
of O
plasma O
membrane O
- O
bound O
virions O
to O
an O
acidic O
pH O
( O
< O
pH O
6 O
) O
equivalent O
to O
the O
pH O
of O
late O
endolysosomal O
compartments O
allowed O
the O
virus O
to O
bypass O
the O
endosomal O
route O
of O
infection O
. O

By O
targeted O
mutagenesis O
of O
conserved O
histidines O
in O
Gn O
and O
Gc O
, O
we O
demonstrated O
that O
mutation O
of O
a O
single O
histidine O
( O
H857 O
) O
in O
Gc O
completely O
abrogated O
virus O
entry O
, O
as O
well O
as O
acid O
- O
induced O
Gc O
oligomerization O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
zoonotic O
pathogen O
capable O
of O
causing O
serious O
morbidity O
and O
mortality O
in O
both O
humans O
and O
livestock O
. O

Caveolae O
are O
lipid O
raft O
domains O
composed O
of O
caveolin O
( O
the O
main O
structural O
component O
) O
, O
cholesterol O
, O
and O
sphingolipids O
. O

To O
determine O
the O
cellular O
entry O
mechanism O
of O
RVFV O
, O
we O
used O
small O
- O
molecule O
inhibitors O
, O
RNA B
interference I
( I
RNAi I
) I
, O
and O
dominant B
negative I
( I
DN I
) I
protein O
expression O
to O
inhibit O
the O
major O
mammalian O
cell O
endocytic O
pathways O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
an O
emerging O
arthropod O
- O
borne O
pathogen O
, O
has O
a O
broad O
host O
and O
cell O
tropism O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
belonging O
to O
the O
genus O
Phlebovirus O
, O
family O
Bunyaviridae O
, O
is O
endemic O
to O
sub O
- O
Saharan O
Africa O
and O
causes O
a O
high O
rate O
of O
abortion O
in O
ruminants O
and O
hemorrhagic O
fever O
, O
encephalitis O
, O
or O
blindness O
in O
humans O
. O

MP O
- O
12 O
is O
the O
only O
RVFV O
strain O
excluded O
from O
the O
select O
- O
agent O
rule O
and O
handled O
at O
a O
biosafety B
level I
2 I
( I
BSL2 I
) I
laboratory O
. O

We O
found O
that O
100 O
% O
of O
mice O
subcutaneously O
vaccinated O
with O
recombinant B
MP I
- I
12 I
( I
rMP12 I
) I
- O
murine O
PKRN167 O
( O
mPKRN167 O
) O
, O
which O
encodes O
a O
dominant O
- O
negative O
form O
of O
mouse O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
dependent O
protein B
kinase I
( I
PKR I
) I
in O
place O
of O
NSs O
, O
were O
protected O
from O
wild B
- I
type I
( I
WT I
) I
RVFV O
challenge O
, O
while O
72 O
% O
of O
mice O
vaccinated O
with O
MP O
- O
12 O
were O
protected O
after O
challenge O
. O

rMP12 O
- O
mPKRN167 O
induced O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
in O
sera O
, O
accumulated O
RVFV O
antigens O
in O
dendritic O
cells O
at O
the O
local O
draining O
lymph O
nodes O
, O
and O
developed O
high O
levels O
of O
neutralizing O
antibodies O
, O
while O
parental O
MP O
- O
12 O
induced O
neither O
IFN O
- O
alpha O
nor O
viral O
- O
antigen O
accumulation O
at O
the O
draining O
lymph O
node O
yet O
induced O
a O
high O
level O
of O
neutralizing O
antibodies O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
causes O
outbreaks O
of O
severe O
disease O
in O
people O
and O
livestock O
throughout O
Africa O
and O
the O
Arabian O
Peninsula O
. O

Here O
, O
we O
demonstrate O
a O
robust O
system O
for O
the O
reverse O
genetics O
generation O
of O
a O
RVF B
virus I
replicon I
particle I
( I
VRPRVF I
) I
vaccine O
candidate O
. O

Single O
- O
dose O
subcutaneous O
immunization O
with O
VRPRVF O
, O
although O
it O
is O
highly O
attenuated O
, O
completely O
protected O
mice O
against O
a O
virulent O
RVFV O
challenge O
dose O
which O
was O
100 O
, O
000 O
- O
fold O
greater O
than O
the O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
. O

Rift B
Valley I
fever I
( I
RVF I
) I
virus O
( O
RVFV O
) O
can O
cause O
severe O
human O
disease O
characterized O
by O
either O
acute O
- O
onset O
hepatitis O
, O
delayed O
- O
onset O
encephalitis O
, O
retinitis O
and O
blindness O
, O
or O
a O
hemorrhagic O
syndrome O
. O

The O
existing O
nonhuman B
primate I
( I
NHP I
) I
model O
for O
RVF O
utilizes O
an O
intravenous O
( O
i O
. O

) O
exposure O
route O
in O
rhesus O
macaques O
( O
Macaca O
mulatta O
) O
. O

To O
overcome O
these O
drawbacks O
, O
we O
evaluated O
the O
infectivity O
and O
pathogenicity O
of O
RVFV O
in O
the O
common O
marmoset O
( O
Callithrix O
jacchus O
) O
by O
i O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
mosquito O
- O
borne O
human O
and O
veterinary O
pathogen O
causing O
large O
outbreaks O
of O
severe O
disease O
throughout O
Africa O
and O
the O
Arabian O
Peninsula O
. O

We O
report O
here O
on O
the O
safety O
, O
immunogenicity O
, O
and O
efficacy O
of O
the O
Delta O
NSs O
- O
Delta O
NSm O
recombinant B
RVFV I
( I
rRVFV I
) I
vaccine O
( O
which O
lacks O
the O
NSs O
and O
NSm O
virulence O
factors O
) O
in O
a O
total O
of O
41 O
sheep O
, O
including O
29 O
timed O
- O
pregnant O
ewes O
. O

0 O
x O
10 O
( O
3 O
) O
to O
1 O
. O

0 O
x O
10 O
( O
5 O
) O
PFU O
administered O
subcutaneously O
( O
s O
. O

0 O
x O
10 O
( O
4 O
) O
PFU O
s O
. O

Vaccination O
resulted O
in O
a O
rapid O
increase O
in O
anti O
- O
RVFV O
IgM O
( O
day O
4 O
) O
and O
IgG O
( O
day O
7 O
) O
titers O
. O

0 O
x O
10 O
( O
6 O
) O
PFU O
intravenously O
) O
. O

Following O
challenge O
, O
100 O
% O
( O
9 O
/ O
9 O
) O
of O
the O
animals O
were O
protected O
, O
progressed O
to O
full O
term O
, O
and O
delivered O
healthy O
lambs O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
is O
a O
mosquito O
- O
borne O
zoonotic O
disease O
caused O
by O
a O
phlebovirus O
of O
the O
family O
Bunyaviridae O
, O
which O
affects O
humans O
and O
ruminants O
in O
Africa O
and O
the O
Middle O
East O
. O

RFV B
virus I
( I
RVFV I
) I
possesses O
a O
single O
- O
stranded O
tripartite O
RNA O
genome O
of O
negative O
/ O
ambisense O
polarity O
. O

The O
two O
open B
reading I
frames I
( I
ORFs I
) I
are O
separated O
by O
an O
intergenic B
region I
( I
IGR I
) I
highly O
conserved O
among O
strains O
and O
containing O
a O
motif O
, O
5 O
' O
- O
GCUGC O
- O
3 O
' O
, O
present O
on O
the O
genome O
and O
antigenome O
, O
which O
was O
shown O
previously O
to O
play O
a O
role O
in O
transcription O
termination O
( O
C O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
mosquito O
- O
borne O
zoonotic O
bunyavirus O
of O
the O
genus O
Phlebovirus O
and O
a O
serious O
human O
and O
veterinary O
pathogen O
. O

RVFV O
contains O
a O
three O
- O
segmented O
RNA O
genome O
, O
which O
is O
comprised O
of O
the O
large B
( I
L I
) I
, O
medium B
( I
M I
) I
, O
and O
small B
( I
S I
) I
segments O
. O

We O
have O
produced O
BHK B
replicon I
cell I
lines I
( I
BHK I
- I
Rep I
) I
that O
maintain O
replicating O
L O
and O
S O
genome O
segments O
. O

Transfection O
of O
BHK O
- O
Rep O
cells O
with O
a O
plasmid O
encoding O
the O
structural O
glycoproteins O
results O
in O
the O
efficient O
production O
of O
RVFV B
replicon I
particles I
( I
RRPs I
) I
. O

Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
family O
Bunyaviridae O
) O
is O
a O
clinically O
important O
, O
mosquito O
- O
borne O
pathogen O
of O
both O
livestock O
and O
humans O
, O
which O
is O
found O
mainly O
in O
sub O
- O
Saharan O
Africa O
and O
the O
Arabian O
Peninsula O
. O

RVFV O
has O
a O
trisegmented O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
genome O
. O

The O
L O
and O
M O
segments O
are O
negative O
sense O
and O
encode O
the O
L O
protein O
( O
viral O
polymerase O
) O
on O
the O
L O
segment O
and O
the O
virion O
glycoproteins O
Gn O
and O
Gc O
as O
well O
as O
two O
other O
proteins O
, O
NSm O
and O
78K O
, O
on O
the O
M O
segment O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
zoonotic O
pathogen O
that O
primarily O
affects O
ruminants O
but O
can O
also O
be O
lethal O
in O
humans O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
a O
mosquito O
- O
borne O
phlebovirus O
, O
has O
been O
detected O
in O
Madagascar O
since O
1979 O
, O
with O
occasional O
outbreaks O
. O

Rift O
Valley O
fever O
virus O
( O
RVFV O
; O
family O
Bunyaviridae O
, O
genus O
Phlebovirus O
) O
is O
an O
important O
emerging O
pathogen O
of O
humans O
and O
ruminants O
. O

Its O
NSs O
protein O
has O
previously O
been O
identified O
as O
a O
major O
virulence O
factor O
that O
suppresses O
host O
defense O
through O
three O
distinct O
mechanisms O
: O
it O
directly O
inhibits O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
promoter O
activity O
, O
it O
promotes O
the O
degradation O
of O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
, O
and O
it O
suppresses O
host O
transcription O
by O
disrupting O
the O
assembly O
of O
the O
basal O
transcription O
factor O
TFIIH O
through O
sequestration O
of O
its O
p44 O
subunit O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
an O
emerging O
, O
highly O
pathogenic O
virus O
; O
RVFV O
infection O
can O
lead O
to O
encephalitis O
, O
retinitis O
, O
or O
fatal O
hepatitis O
associated O
with O
hemorrhagic O
fever O
in O
humans O
, O
as O
well O
as O
death O
, O
abortions O
, O
and O
fetal O
deformities O
in O
animals O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
continues O
to O
cause O
large O
outbreaks O
of O
acute O
febrile O
and O
often O
fatal O
illness O
among O
humans O
and O
domesticated O
animals O
in O
Africa O
, O
Saudi O
Arabia O
, O
and O
Yemen O
. O

The O
high O
pathogenicity O
of O
this O
bunyavirus O
is O
mainly O
due O
to O
the O
viral O
protein O
NSs O
, O
which O
was O
shown O
to O
prevent O
transcriptional O
induction O
of O
the O
antivirally O
active O
type O
I O
interferons O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
. O

We O
demonstrate O
here O
in O
vitro O
and O
in O
vivo O
that O
a O
substantial O
part O
of O
the O
antiviral O
activity O
of O
IFN O
against O
RVFV O
is O
due O
to O
a O
double O
- O
stranded O
RNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
. O

In O
vivo O
, O
Clone O
13 O
was O
nonpathogenic O
for O
wild B
- I
type I
( I
WT I
) I
mice O
but O
could O
regain O
pathogenicity O
if O
mice O
lacked O
the O
PKR O
gene O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
member O
of O
the O
genus O
Phlebovirus O
within O
the O
family O
Bunyaviridae O
. O

The O
enveloped O
RVFV O
virions O
are O
known O
to O
be O
covered O
by O
capsomers O
of O
the O
glycoproteins O
G O
( O
N O
) O
and O
GC O
, O
organized O
on O
a O
T O
= O
12 O
icosahedral O
lattice O
. O

Conflicting O
biochemical O
results O
for O
another O
phlebovirus O
( O
Uukuniemi O
virus O
) O
have O
indicated O
the O
existence O
of O
either O
GN O
and O
GC O
homodimers O
or O
G O
( O
N O
) O
- O
G O
( O
C O
) O
heterodimers O
in O
virions O
. O

2 O
- O
nm O
resolution O
revealed O
the O
organization O
of O
the O
glycoprotein O
shell O
, O
the O
lipid O
bilayer O
, O
and O
a O
layer O
of O
ribonucleoprotein B
( I
RNP I
) I
. O

Molecular O
- O
mass O
measurements O
suggest O
a O
G O
( O
N O
) O
- O
G O
( O
C O
) O
heterodimer O
as O
the O
most O
likely O
candidate O
for O
this O
structural O
unit O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
virus O
historically O
has O
caused O
widespread O
and O
extensive O
outbreaks O
of O
severe O
human O
and O
livestock O
disease O
throughout O
Africa O
, O
Madagascar O
, O
and O
the O
Arabian O
Peninsula O
. O

A O
total O
of O
3 O
, O
250 O
specimens O
from O
a O
variety O
of O
animal O
species O
, O
including O
domesticated O
livestock O
( O
cattle O
, O
sheep O
, O
goats O
, O
and O
camels O
) O
and O
wildlife O
collected O
from O
a O
total O
of O
55 O
of O
71 O
Kenyan O
administrative O
districts O
, O
were O
tested O
by O
molecular O
and O
serologic O
assays O
. O

The O
complete O
S O
, O
M O
, O
and O
/ O
or O
L O
genome O
segment O
sequence O
was O
obtained O
from O
a O
total O
of O
31 O
RVF O
virus O
specimens O
spanning O
the O
entire O
known O
outbreak O
period O
( O
December O
- O
May O
) O
and O
geographic O
areas O
affected O
by O
RVF O
virus O
activity O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
member O
of O
the O
Bunyaviridae O
virus O
family O
( O
genus O
Phlebovirus O
) O
and O
is O
considered O
to O
be O
one O
of O
the O
most O
important O
pathogens O
in O
Africa O
, O
causing O
viral O
zoonoses O
in O
livestock O
and O
humans O
. O

Rift B
Valley I
fever I
( I
RVF I
) I
virus O
is O
a O
mosquito O
- O
borne O
human O
and O
veterinary O
pathogen O
associated O
with O
large O
outbreaks O
of O
severe O
disease O
throughout O
Africa O
and O
more O
recently O
the O
Arabian O
peninsula O
. O

0 O
X O
10 O
( O
4 O
) O
PFU O
) O
in O
the O
rat O
lethal O
disease O
model O
. O

A O
single O
- O
dose O
immunization O
regimen O
induced O
robust O
anti O
- O
RVF O
virus O
immunoglobulin O
G O
antibodies O
( O
titer O
, O
similar O
to O
1 O
: O
6 O
, O
400 O
) O
by O
day O
26 O
postvaccination O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
member O
of O
the O
genus O
Phlebovirus O
within O
the O
family O
Bunyaviridae O
. O

arMP O
- O
12 O
- O
del21 O
/ O
384 O
replication O
triggered O
apoptosis O
, O
including O
the O
cleavage O
of O
caspase O
- O
3 O
, O
the O
cleavage O
of O
its O
downstream O
substrate O
, O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
, O
and O
activation O
of O
the O
initiator O
caspases O
, O
caspase O
- O
8 O
and O
- O
9 O
, O
earlier O
in O
infection O
than O
arMP O
- O
12 O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
( O
genus O
Phlebovirus O
, O
family O
Bunyaviridae O
) O
has O
a O
tripartite O
negative O
- O
strand O
genome O
and O
causes O
a O
mosquito O
- O
borne O
disease O
among O
humans O
and O
livestock O
in O
sub O
- O
Saharan O
African O
and O
Arabian O
Peninsula O
countries O
. O

The O
L B
- I
segment I
5 I
' I
- I
untranslated I
region I
( I
L I
- I
5 I
' I
UTR I
) I
had O
neither O
the O
pentanucleotide O
sequence O
nor O
homopolymeric O
sequences O
, O
yet O
replacement O
of O
the O
S O
- O
segment O
intergenic O
region O
with O
the O
L O
- O
5 O
' O
UTR O
exerted O
N O
mRNA O
termination O
in O
an O
infectious O
virus O
. O

The O
Phlebovirus O
genus O
( O
family O
Bunyaviridae O
) O
is O
composed O
of O
a O
diverse O
group O
of O
arboviruses O
that O
cause O
disease O
syndromes O
ranging O
from O
mild O
febrile O
illness O
to O
hemorrhagic O
fever O
with O
high O
fatality O
. O

Surprisingly O
, O
analysis O
of O
the O
termini O
of O
mRNAs O
from O
both O
S O
and O
M O
segments O
of O
these O
three O
viruses O
revealed O
that O
transcription O
termination O
occurred O
immediately O
upstream O
of O
a O
conserved O
sequence O
motif O
with O
the O
general O
features O
3 O
' O
- O
C O
( O
1 O
- O
3 O
) O
GUCG O
/ O
A O
- O
5 O
' O
. O

Two O
strains O
of O
Punta B
Toro I
virus I
( I
PTV I
) I
, O
isolated O
from O
febrile O
humans O
in O
Panama O
, O
cause O
a O
differential O
pathogenesis O
in O
Syrian O
hamsters O
, O
which O
could O
be O
a O
useful O
model O
for O
understanding O
the O
virulence O
characteristics O
and O
differential O
outcomes O
in O
other O
phleboviral O
infections O
such O
as O
Rift O
Valley O
fever O
virus O
. O

Genetic O
reassortants O
produced O
between O
the O
lethal O
Adames O
( O
A O
/ O
A O
/ O
A O
) O
and O
nonlethal O
Balliet O
( O
B O
/ O
B O
/ O
B O
) O
strains O
were O
used O
in O
this O
study O
to O
investigate O
viral O
genetic O
determinants O
for O
pathogenesis O
and O
lethality O
in O
the O
hamster O
model O
. O

The O
S O
segment O
was O
revealed O
to O
be O
a O
critical O
genome O
segment O
, O
determining O
lethality O
with O
log O
, O
, O
50 O
% O
lethal O
doses O
for O
each O
PTV O
genotype O
as O
follows O
( O
L O
/ O
M O
/ O
S O
convention O
) O
: O
A O
/ O
A O
/ O
A O
, O
< O
0 O
. O

In O
addition O
, O
the O
Adames O
strain O
inhibits O
the O
induction O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
vivo O
and O
in O
vitro O
and O
inhibits O
the O
activation O
of O
the O
IFN O
- O
beta O
promoter O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
( O
genus O
Phlebovirus O
, O
family O
Bunytiviridae O
) O
has O
a O
tripartite O
negative O
- O
strand O
genome O
, O
causes O
a O
mosquito O
- O
borne O
disease O
that O
is O
endemic O
in O
sub O
- O
Saharan O
African O
countries O
and O
that O
also O
causes O
large O
epidemics O
among O
humans O
and O
livestock O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
a O
Phlebovirus O
in O
the O
Bunyaviridae O
family O
. O

The O
nucleoprotein O
N O
is O
the O
most O
abundant O
component O
of O
the O
virion O
; O
numerous O
copies O
of O
N O
associate O
with O
the O
viral O
RNA O
genome O
and O
form O
pseudohelicoidal O
ribonucleoproteins B
( I
RNPs I
) I
circularized O
by O
a O
panhandle O
structure O
formed O
by O
the O
base O
- O
paired O
RNA O
sequences O
at O
the O
3 O
' O
and O
5 O
' O
termini O
. O

Analysis O
of O
purified O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
particles O
demonstrated O
the O
presence O
of O
three O
negativesense O
RNA O
genomes O
, O
plus O
three O
anti O
- O
viral O
- O
sense O
RNA O
segments O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
which O
belongs O
to O
the O
genus O
Phlebovirus O
, O
family O
Bunyaviridae O
, O
has O
a O
tripartite O
negative O
- O
strand O
genome O
( O
S O
, O
M O
, O
and O
L O
segments O
) O
and O
is O
an O
important O
mosquito O
- O
borne O
pathogen O
for O
domestic O
animals O
and O
humans O
. O

Enhancement O
of O
minigenome O
RNA O
synthesis O
by O
NSs O
protein O
occurred O
in O
cells O
lacking O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
genes O
, O
indicating O
that O
the O
effect O
of O
NSs O
protein O
on O
minigenome O
RNA O
replication O
was O
unrelated O
to O
a O
putative O
NSs O
protein O
- O
induced O
inhibition O
of O
IFN O
- O
alpha O
/ O
beta O
production O
. O

Our O
finding O
that O
RVFV O
NSs O
protein O
augmented O
minigenome O
RNA O
synthesis O
was O
in O
sharp O
contrast O
to O
reports O
that O
Bunyamwera O
virus O
( O
genus O
Bunyavirus O
) O
NSs O
protein O
inhibits O
viral O
minigenome O
RNA O
synthesis O
, O
suggesting O
that O
RVFV O
NSs O
protein O
and O
Bunyamwera O
virus O
NSs O
protein O
have O
distinctly O
different O
biological O
roles O
in O
viral O
RNA O
synthesis O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
, O
a O
member O
of O
the O
genus O
Nairovirus O
of O
the O
family O
Bunyaviridae O
, O
causes O
severe O
disease O
with O
high O
rates O
of O
mortality O
in O
humans O
. O

The O
CCHFV O
M O
RNA O
segment O
encodes O
the O
virus O
glycoproteins O
G O
( O
N O
) O
and O
G O
( O
C O
) O
. O

To O
understand O
the O
processing O
and O
intracellular O
localization O
of O
the O
CCHFV O
glycoproteins O
as O
well O
as O
their O
neutralization O
and O
protection O
determinants O
, O
we O
produced O
and O
characterized O
Monoclonal B
antibodies I
( I
MAbs I
) I
specific O
for O
both O
G O
( O
N O
) O
and O
G O
( O
C O
) O
. O

Using O
these O
MAbs O
, O
we O
found O
that O
G O
( O
N O
) O
predominantly O
colocalized O
with O
a O
Golgi O
marker O
when O
expressed O
alone O
or O
with O
G O
( O
C O
) O
, O
while O
G O
( O
C O
) O
was O
transported O
to O
the O
Golgi O
apparatus O
only O
in O
the O
presence O
of O
G O
( O
N O
) O
. O

Golgi O
targeting O
information O
partly O
resides O
within O
the O
G O
( O
N O
) O
ectodomain O
, O
because O
a O
soluble O
version O
of O
G O
( O
N O
) O
lacking O
its O
transmembrane O
and O
cytoplasmic O
domains O
also O
localized O
to O
the O
Golgi O
apparatus O
. O

Coexpression O
of O
soluble O
versions O
of O
G O
( O
N O
) O
and O
G O
( O
C O
) O
also O
resulted O
in O
localization O
of O
soluble O
G O
( O
C O
) O
to O
the O
Golgi O
apparatus O
, O
indicating O
that O
the O
ectodomains O
of O
these O
proteins O
are O
sufficient O
for O
the O
interactions O
needed O
for O
Golgi O
targeting O
. O

Finally O
, O
the O
mucin O
- O
like O
and O
P35 O
domains O
, O
located O
at O
the O
N O
terminus O
of O
the O
G O
( O
N O
) O
precursor O
protein O
and O
removed O
posttranslationally O
by O
endoproteolysis O
, O
were O
required O
for O
Golgi O
targeting O
of O
G O
( O
N O
) O
when O
it O
was O
expressed O
alone O
but O
were O
dispensable O
when O
G O
( O
C O
) O
was O
coexpressed O
. O

In O
neutralization O
assays O
on O
SW O
- O
13 O
cells O
, O
MAbs O
to O
G O
( O
C O
) O
, O
but O
not O
to O
G O
( O
N O
) O
prevented O
CCHFV O
infection O
. O

However O
, O
only O
a O
subset O
of O
G O
( O
C O
) O
MAbs O
protected O
mice O
in O
passive O
- O
immunization O
experiments O
, O
while O
some O
nonneutralizing O
G O
( O
N O
) O
MAbs O
efficiently O
protected O
animals O
from O
a O
lethal O
CCHFV O
challenge O
. O

In O
addition O
, O
nonneutralizing O
antibody O
- O
dependent O
mechanisms O
, O
such O
as O
antibody O
- O
dependent O
cell O
- O
mediated O
cytotoxicity O
, O
may O
be O
involved O
in O
the O
in O
vivo O
protection O
seen O
with O
the O
MAbs O
to O
G O
( O
C O
) O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
an O
important O
cause O
of O
epizootics O
and O
epidemics O
in O
Africa O
and O
a O
potential O
agent O
of O
bioterrorism O
. O

We O
have O
previously O
shown O
that O
RVFV O
strains O
with O
mutations O
in O
the O
NSs O
gene O
are O
excellent O
inducers O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
are O
highly O
attenuated O
in O
mice O
. O

In O
cells O
transiently O
expressing O
NSs O
, O
IFN O
- O
beta O
transcripts O
were O
not O
inducible O
by O
viral O
infection O
or O
by O
transfection O
of O
poly O
( O
I O
: O
C O
) O
. O

IFN O
synthesis O
is O
regulated O
by O
specific O
transcription O
factors O
, O
including O
interferon B
regulatory I
factor I
( I
IRF I
- I
3 I
) I
, O
NF O
- O
kappaB O
, O
and O
AP O
- O
1 O
. O

Two O
isolates O
of O
a O
virus O
of O
the O
genus O
Orthobunyavirus O
( O
family O
Bunyaviridae O
) O
were O
obtained O
from O
hemorrhagic O
fever O
cases O
during O
a O
large O
disease O
outbreak O
in O
East O
Africa O
in O
1997 O
and O
1998 O
. O

Sequence O
analysis O
of O
regions O
of O
the O
three O
genomic O
RNA O
segments O
of O
the O
virus O
( O
provisionally O
referred O
to O
as O
Garissa O
virus O
) O
suggested O
that O
it O
was O
a O
genetic O
reassortant O
virus O
with O
S O
and O
L O
segments O
derived O
from O
Bunyamwera O
virus O
but O
an O
M O
segment O
from O
an O
unidentified O
virus O
of O
the O
genus O
Orthobunyavirus O
. O

While O
high O
genetic O
diversity O
( O
52 O
% O
) O
was O
revealed O
by O
analysis O
of O
virus O
M O
segment O
nucleotide O
sequences O
obtained O
from O
21 O
members O
of O
the O
genus O
Orthobunyavirus O
, O
the O
Garissa O
and O
Ngari O
virus O
M O
segments O
were O
almost O
identical O
. O

Crimean B
- I
Congo I
hemorrhagic I
fever I
virus I
( I
CCHFV I
) I
belongs O
to O
the O
genus O
Nairovirus O
within O
the O
family O
Bunyaviridae O
and O
is O
the O
causative O
agent O
of O
severe O
hemorrhagic O
fever O
. O

Confocal O
microscopy O
revealed O
that O
MxA O
colocalizes O
with O
the O
nucleocapsid B
protein I
( I
NP I
) I
of O
CCHFV O
in O
the O
perinuclear O
regions O
of O
infected O
cells O
. O

We O
also O
found O
that O
an O
amino O
acid O
substitution O
( O
E645R O
) O
within O
the O
C O
- O
terminal O
domain O
of O
MxA O
resulted O
in O
a O
loss O
of O
MxA O
antiviral O
activity O
and O
, O
concomitantly O
, O
in O
the O
capacity O
to O
interact O
with O
CCHFV O
NP O
. O

As O
Rift B
Valley I
fever I
( I
RVF I
) I
virus O
, O
and O
probably O
all O
members O
of O
the O
family O
Bunyaviridae O
, O
matures O
in O
the O
Golgi O
apparatus O
, O
the O
targeting O
of O
the O
virus O
glycoproteins O
to O
the O
Golgi O
apparatus O
plays O
a O
pivotal O
role O
in O
the O
virus O
replication O
cycle O
. O

The O
viruses O
of O
the O
family O
Bunyaviridae O
synthesize O
their O
glycoproteins O
, O
G O
( O
N O
) O
and O
G O
( O
C O
) O
, O
as O
a O
polyprotein O
. O

The O
Golgi O
localization O
signal O
of O
RVF O
virus O
has O
been O
shown O
to O
reside O
within O
the O
G O
( O
N O
) O
protein O
by O
use O
of O
a O
plasmid O
- O
based O
transient O
expression O
system O
to O
synthesize O
individual O
G O
( O
N O
) O
and O
G O
( O
C O
) O
proteins O
. O

While O
the O
distribution O
of O
individually O
expressed O
G O
( O
N O
) O
significantly O
overlaps O
with O
cellular O
Golgi O
proteins O
such O
as O
beta O
- O
COP O
and O
GS O
- O
28 O
, O
G O
( O
C O
) O
expressed O
in O
the O
absence O
of O
G O
( O
N O
) O
localizes O
to O
the O
endoplasmic O
reticulum O
. O

Further O
analysis O
of O
expressed O
G O
( O
N O
) O
truncated O
proteins O
and O
green O
fluorescent O
protein O
/ O
G O
( O
N O
) O
chimeric O
proteins O
demonstrated O
that O
the O
RVF O
virus O
Golgi O
localization O
signal O
mapped O
to O
a O
48 O
- O
amino O
- O
acid O
region O
of O
G O
( O
N O
) O
encompassing O
the O
20 O
- O
amino O
- O
acid O
transmembrane O
domain O
and O
the O
adjacent O
28 O
amino O
acids O
of O
the O
cytosolic O
tail O
. O

Production O
of O
Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
in O
response O
to O
viral O
infection O
is O
one O
of O
the O
main O
defense O
mechanisms O
of O
the O
innate O
immune O
system O
. O

Bunyamwera O
virus O
( O
BUN O
) O
is O
the O
prototype O
of O
the O
Bunyaviridae O
family O
. O

By O
using O
reverse O
genetics O
, O
we O
previously O
produced O
a O
recombinant O
virus O
lacking O
the O
nonstructural O
protein O
NSs O
( O
BUNdelNSs O
) O
and O
showed O
that O
NSs O
is O
a O
nonessential O
gene O
product O
that O
contributes O
to O
viral O
pathogenesis O
. O

Here O
we O
demonstrate O
that O
BUNdelNSs O
is O
a O
strong O
inducer O
of O
IFN O
- O
alpha O
/ O
beta O
, O
whereas O
in O
cells O
infected O
with O
the O
wild O
- O
type O
counterpart O
expressing O
NSs O
( O
wild O
- O
type O
BUN O
) O
, O
neither O
IFN O
nor O
IFN O
mRNA O
could O
be O
detected O
. O

Rift O
Valley O
fever O
vints O
( O
RVFV O
) O
, O
a O
phlebovirus O
of O
the O
family O
Bunyaviridae O
, O
is O
a O
major O
public O
health O
threat O
in O
Egypt O
and O
sub O
- O
Saharan O
Africa O
. O

All O
pathogenic O
RVFV O
strains O
direct O
the O
synthesis O
of O
a O
nonstructural B
phosphoprotein I
( I
NSs I
) I
that O
is O
encoded O
by O
the O
smallest O
( O
S O
) O
segment O
of O
the O
tripartite O
genome O
and O
has O
an O
undefined O
accessory O
function O
. O

In O
this O
report O
, O
we O
show O
that O
MP12 O
and O
clone O
13 O
, O
two O
attenuated O
RVFV O
strains O
with O
mutations O
in O
the O
NSs O
gene O
, O
were O
highly O
virulent O
in O
IFNAR O
( O
- O
/ O
- O
) O
mice O
lacking O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptor O
but O
remained O
attenuated O
in O
IFN O
- O
gamma O
receptor O
- O
deficient O
mice O
. O

To O
investigate O
whether O
the O
presence O
of O
the O
wild O
- O
type O
NSs O
gene O
correlated O
with O
inhibition O
of O
IFN O
- O
alpha O
/ O
beta O
production O
, O
we O
infected O
susceptible O
IFNAR O
( O
- O
/ O
- O
) O
mice O
with O
S O
gene O
reassortant O
viruses O
. O

Unlike O
all O
the O
other O
Rift O
Valley O
fever O
virus O
strains O
( O
Bunyaviridae O
, O
Phlebovirus O
) O
studied O
so O
far O
, O
clone O
13 O
, O
a O
naturally O
attenuated O
virus O
, O
does O
not O
form O
the O
filaments O
composed O
of O
the O
NSs O
nonstructural O
protein O
in O
the O
nuclei O
of O
infected O
cells O
( O
R O
. O

Here O
, O
we O
show O
that O
the O
truncated O
NSs O
protein O
of O
clone O
13 O
is O
expressed O
and O
remains O
in O
the O
cytoplasm O
, O
where O
it O
is O
degraded O
rapidly O
by O
the O
proteasome O
, O
Through O
the O
analysis O
of O
reassortants O
between O
clone O
13 O
and O
a O
virulent O
strain O
, O
we O
localized O
the O
marker O
( O
s O
) O
of O
attenuation O
in O
the O
S O
segment O
of O
this O
attenuated O
virus O
. O

The O
ambisense O
S O
segment O
of O
Rift B
Valley I
fever I
( I
RVF I
) I
virus O
( O
a O
phlebovirus O
in O
the O
Bunyaviridae O
family O
) O
codes O
for O
two O
proteins O
: O
the O
viral O
complementary O
- O
sense O
RNA O
for O
the O
N O
nucleoprotein O
and O
the O
genomic O
- O
sense O
RNA O
for O
the O
nonstructural O
protein O
NSs O
. O

The O
transcriptase O
activity O
of O
the O
L O
protein O
was O
assayed O
with O
two O
types O
of O
templates O
: O
natural O
ribonucleoproteins B
( I
RNPs I
) I
and O
artificial O
genome O
- O
like O
RNAs O
. O

Recent O
studies O
on O
chronic O
viral O
infections O
have O
defined O
a O
novel O
programmed O
cell O
death O
1 O
- O
positive O
( O
PD O
- O
1 O
( O
+ O
) O
) O
T O
cell O
factor O
1 O
- O
positive O
( O
TCF1 O
( O
+ O
) O
) O
stem O
- O
like O
CD8 O
T O
cell O
subset O
that O
gives O
rise O
to O
the O
terminally O
differentiated O
exhausted O
CD8 O
T O
cells O
. O

In O
this O
study O
, O
we O
performed O
T B
cell I
receptor I
beta I
( I
TCR I
beta I
) I
sequencing O
of O
virus O
- O
specific O
CD8 O
T O
cells O
during O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
to O
examine O
the O
TCR O
diversity O
and O
lineage O
relationship O
of O
these O
two O
functionally O
distinct O
subsets O
. O

The O
TCR O
repertoires O
of O
both O
CD8 O
T O
cell O
subsets O
were O
composed O
mostly O
of O
a O
few O
dominant O
clonotypes O
, O
but O
there O
was O
slightly O
more O
breadth O
and O
diversity O
in O
the O
stemlike O
CD8 O
T O
cells O
than O
their O
exhausted O
counterpart O
( O
similar O
to O
40 O
versus O
similar O
to O
15 O
GP33 O
( O
+ O
) O
clonotypes O
; O
similar O
to O
20 O
versus O
similar O
to O
7 O
GP276 O
( O
+ O
) O
clonotypes O
) O
. O

Interestingly O
, O
the O
breadth O
of O
the O
TCR O
repertoire O
was O
broader O
during O
the O
early O
stages O
( O
day O
8 O
) O
of O
the O
chronic O
infection O
than O
the O
later O
stages O
( O
days O
45 O
to O
60 O
) O
, O
showing O
that O
there O
was O
a O
narrowing O
of O
the O
TCR O
repertoire O
during O
chronic O
infection O
( O
similar O
to O
2 O
- O
fold O
GP33 O
( O
+ O
) O
and O
GP276 O
( O
+ O
) O
stem O
- O
like O
subset O
; O
similar O
to O
10 O
- O
fold O
GP33 O
( O
+ O
) O
and O
similar O
to O
5 O
- O
fold O
GP276 O
( O
+ O
) O
exhausted O
subset O
) O
. O

In O
contrast O
, O
during O
acute O
LCMV O
infection O
, O
the O
TCR O
repertoire O
was O
much O
broader O
in O
both O
GP33 O
- O
specific O
effector O
( O
similar O
to O
160 O
clonotypes O
) O
and O
memory O
CD8 O
T O
cells O
( O
similar O
to O
160 O
clonotypes O
) O
. O

IMPORTANCE O
CD8 O
TCR O
repertoires O
responding O
to O
chronic O
viral O
infections O
( O
HIV O
, O
hepatitis O
C O
virus O
[ O
HCV O
] O
, O
Epstein O
- O
Barr O
virus O
[ O
EBV O
] O
, O
and O
cytomegalovirus O
[ O
CMV O
] O
) O
have O
limited O
breadth O
and O
diversity O
. O

Checkpoint O
inhibitors O
are O
effective O
in O
restoring O
exhausted O
CD8 O
( O
+ O
) O
T O
cell O
responses O
in O
persistent O
viral O
infections O
or O
tumors O
. O

In O
a O
mouse O
model O
of O
persistent O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
, O
it O
was O
shown O
that O
checkpoint O
inhibitor O
treatment O
increased O
T O
cell O
proliferation O
and O
functionality O
, O
but O
its O
influence O
on O
the O
antigen O
- O
specific O
T B
cell I
receptor I
( I
TCR I
) I
repertoire O
is O
unknown O
. O

NP396 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
dominate O
during O
acute O
LCMV O
infection O
and O
are O
predominantly O
exhausted O
during O
chronic O
infection O
. O

In O
conclusion O
, O
although O
targeting O
the O
PD O
- O
1 O
/ O
PD O
- O
L1 O
pathway O
reinvigorates O
exhausted O
CD8 O
( O
+ O
) O
T O
cells O
, O
it O
fails O
to O
restore O
T O
cell O
repertoire O
diversity O
. O

IMPORTANCE O
Checkpoint O
inhibitors O
are O
effective O
immunotherapeutics O
to O
restore O
cancerand O
virus O
- O
induced O
exhausted O
CD8 O
( O
+ O
) O
T O
cells O
, O
by O
enhancing O
the O
quality O
and O
survival O
of O
immune O
responses O
. O

Although O
checkpoint O
inhibitors O
are O
already O
used O
as O
therapy O
against O
various O
cancers O
, O
not O
much O
is O
known O
about O
their O
multifaceted O
impact O
on O
the O
exhausted O
CD8 O
( O
+ O
) O
T B
cell I
receptor I
( I
TCR I
) I
repertoire O
. O

This O
report O
describes O
for O
the O
first O
time O
the O
evolvement O
of O
an O
exhausted O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
TCR O
repertoire O
under O
checkpoint O
inhibitor O
treatment O
. O

By O
using O
a O
well O
- O
established O
virus O
model O
, O
we O
were O
able O
to O
show O
major O
shifts O
toward O
oligoclonality O
of O
the O
CD8 O
( O
+ O
) O
TCR O
repertoire O
response O
against O
a O
massively O
exhausted O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
epitope O
. O

Early O
and O
robust O
T O
cell O
responses O
have O
been O
associated O
with O
survival O
from O
Lassa B
fever I
( I
LF I
) I
, O
but O
the O
Lassa O
virus O
- O
specific O
memory O
responses O
have O
not O
been O
well O
characterized O
. O

Regions O
within O
the O
virus O
surface O
glycoprotein B
( I
GPC I
) I
and O
nucleoprotein B
( I
NP I
) I
are O
the O
main O
targets O
of O
the O
Lassa O
virus O
- O
specific O
T O
cell O
responses O
, O
but O
, O
to O
date O
, O
only O
a O
few O
T O
cell O
epitopes O
within O
these O
proteins O
have O
been O
identified O
. O

We O
identified O
12 O
CD8 O
- O
positive O
( O
CD8 O
( O
+ O
) O
) O
T O
cell O
epitopes O
, O
including O
epitopes O
common O
to O
both O
Nigerian O
and O
Sierra O
Leonean O
survivors O
. O

IMPORTANCE O
The O
high O
morbidity O
and O
mortality O
associated O
with O
clinical O
cases O
of O
Lassa O
fever O
, O
together O
with O
the O
lack O
of O
licensed O
vaccines O
and O
limited O
and O
partially O
effective O
interventions O
, O
make O
Lassa B
virus I
( I
LASV I
) I
an O
important O
health O
concern O
in O
its O
regions O
of O
endemicity O
in O
West O
Africa O
. O

human B
papillomavirus I
16 I
( I
HPV16 I
) I
, O
the O
leading O
cause O
of O
cervical O
cancer O
, O
exploits O
a O
novel O
endocytic O
pathway O
during O
host O
cell O
entry O
. O

Previous O
work O
indicated O
a O
role O
of O
the O
epidermal B
growth I
factor I
receptor I
( I
EGFR I
) I
in O
HPV16 O
endocytosis O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
mosquito O
- O
transmitted O
alphavirus O
that O
causes O
explosive O
epidemics O
of O
a O
febrile O
illness O
characterized O
by O
debilitating O
arthralgia O
and O
arthritis O
that O
can O
endure O
for O
months O
to O
years O
following O
infection O
. O

Using O
a O
recombinant O
CHIKV O
strain O
encoding O
a O
CD8 O
( O
+ O
) O
T O
cell O
receptor O
epitope O
from O
ovalbumin O
, O
as O
well O
as O
a O
viral O
peptide O
- O
specific O
major O
histocompatibility O
complex O
class O
I O
tetramer O
, O
we O
interrogated O
CD8 O
( O
+ O
) O
T O
cell O
responses O
during O
CHIKV O
infection O
. O

Epitope O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
were O
reduced O
in O
Batf3 O
( O
- O
/ O
- O
) O
and O
Wdfy4 O
( O
- O
/ O
- O
) O
mice O
with O
known O
defects O
in O
antigen O
cross O
- O
presentation O
, O
accumulated O
in O
joint O
tissue O
and O
the O
spleen O
. O

Antigen O
- O
specific O
ex O
vivo O
restimulation O
assays O
and O
in O
vivo O
killing O
assays O
demonstrated O
that O
CD8 O
( O
+ O
) O
T O
cells O
produce O
cytokine O
and O
have O
cytolytic O
activity O
. O

Despite O
the O
induction O
of O
a O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
response O
, O
the O
CHIKV O
burden O
in O
joint O
- O
associated O
tissues O
and O
the O
spleen O
were O
equivalent O
in O
wild B
- I
type I
( I
WT I
) I
and O
CD8 O
alpha O
( O
- O
/ O
- O
) O
mice O
during O
both O
the O
acute O
and O
the O
chronic O
phases O
of O
infection O
. O

In O
comparison O
, O
CD8 O
( O
+ O
) O
T O
cells O
were O
essential O
for O
the O
control O
of O
acute O
and O
chronic O
lymphocytic O
choriomeningitis O
virus O
infection O
in O
the O
joint O
and O
spleen O
. O

Moreover O
, O
adoptive O
transfer O
of O
virus O
- O
specific O
effector O
CD8 O
( O
+ O
) O
T O
cells O
or O
immunization O
with O
a O
vaccine O
that O
induces O
virus O
- O
specific O
effector O
CD8 O
( O
+ O
) O
T O
cells O
prior O
to O
infection O
enhanced O
the O
clearance O
of O
CHIKV O
infection O
in O
the O
spleen O
but O
had O
a O
minimal O
impact O
on O
CHIKV O
infection O
in O
the O
joint O
. O

Collectively O
, O
these O
data O
suggest O
that O
CHIKV O
establishes O
and O
maintains O
a O
persistent O
infection O
in O
joint O
- O
associated O
tissue O
in O
part O
by O
evading O
CD8 O
( O
+ O
) O
T O
cell O
immunity O
. O

In O
this O
study O
, O
we O
found O
that O
CHIKV O
establishes O
and O
maintains O
a O
persistent O
infection O
in O
joint O
- O
associated O
tissue O
in O
part O
by O
evading O
antiviral O
CD8 O
( O
+ O
) O
T O
cell O
immunity O
. O

Thus O
, O
immunomodulatory O
therapies O
that O
improve O
CD8 O
( O
+ O
) O
T O
cell O
immune O
surveillance O
and O
clearance O
of O
CHIKV O
infection O
could O
be O
a O
strategy O
for O
mitigating O
chronic O
CHIKV O
disease O
. O

We O
have O
recently O
shown O
that O
C57BL O
/ O
6 O
( O
B6 O
) O
mice O
lose O
their O
natural O
resistance O
to O
wild B
- I
type I
( I
WT I
) I
ectromelia I
virus I
( I
ECTV I
) I
when O
chronically O
infected O
with O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone I
13 I
( I
CL13 I
) I
. O

Here O
we O
compared O
the O
T O
- O
cell O
response O
to O
ECTV O
in O
previously O
immunologically O
naive O
mice O
that O
were O
chronically O
infected O
with O
CL13 O
or O
that O
were O
convalescent O
from O
acute O
infection O
with O
the O
Armstrong B
( I
Arm I
) I
strain O
of O
LCMV O
. O

Our O
results O
show O
that O
mice O
that O
were O
chronically O
infected O
with O
CL13 O
but O
not O
those O
that O
had O
recovered O
from O
Arm O
infection O
have O
highly O
defective O
ECTV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
WT O
ECTV O
. O

For O
example O
, O
we O
have O
recently O
shown O
that O
mice O
chronically O
infected O
with O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone I
13 I
( I
CL13 I
) I
are O
highly O
susceptible O
to O
mousepox O
, O
a O
disease O
that O
is O
caused O
by O
ectromelia O
virus O
and O
that O
is O
the O
mouse O
homolog O
of O
human O
smallpox O
. O

like O
those O
of O
humans O
with O
cytomegalovirus O
, O
human O
immunodeficiency O
virus O
( O
even O
when O
under O
antiretroviral O
therapy O
) O
, O
and O
hepatitis O
C O
virus O
or O
those O
of O
mice O
with O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone I
13 I
( I
CL13 I
) I
, O
result O
in O
immune O
dysfunction O
that O
predisposes O
the O
host O
to O
severe O
infections O
with O
unrelated O
pathogens O
. O

It O
is O
known O
that O
C57BU6 O
( O
B6 O
) O
mice O
are O
resistant O
to O
mousepox O
, O
a O
lethal O
disease O
caused O
by O
the O
orthopoxvirus O
ectromelia B
virus I
( I
ECTV I
) I
, O
and O
that O
this O
resistance O
requires O
natural B
killer I
( I
NK I
) I
cells O
and O
other O
immune O
cells O
. O

We O
show O
that O
most O
B6 O
mice O
chronically O
infected O
with O
CL13 O
succumb O
to O
mousepox O
but O
that O
most O
of O
those O
that O
recovered O
from O
acute O
infection O
with O
the O
LCMV O
Armstrong B
( I
Arm I
) I
strain O
survive O
. O

IMPORTANCE O
Infection O
of O
adult O
mice O
with O
the O
clone B
13 I
( I
CL13 I
) I
strain O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
extensively O
used O
as O
a O
model O
of O
chronic O
infection O
. O

In O
this O
paper O
, O
we O
show O
that O
mice O
chronically O
infected O
with O
CL13 O
succumb O
to O
challenge O
with O
ectromelia O
virus O
( O
ECTV O
; O
the O
agent O
of O
mousepox O
) O
and O
that O
natural B
killer I
( I
NK I
) I
cells O
in O
CL13 O
- O
infected O
mice O
are O
reduced O
in O
numbers O
and O
have O
an O
immature O
and O
partially O
activated O
phenotype O
but O
do O
respond O
to O
ECTV O
. O

Lassa B
virus I
( I
LASV I
) I
is O
the O
causative O
agent O
of O
a O
fatal O
hemorrhagic O
fever O
in O
humans O
. O

The O
glycoprotein B
( I
GP I
) I
of O
LASV O
mediates O
viral O
entry O
into O
host O
cells O
, O
and O
correct O
processing O
and O
modification O
of O
GP O
by O
host O
factors O
is O
a O
prerequisite O
for O
virus O
replication O
. O

Here O
, O
using O
an O
affinity B
purification I
- I
coupled I
mass I
spectrometry I
( I
AP I
- I
MS I
) I
strategy O
, O
591 O
host O
proteins O
were O
identified O
as O
interactors O
of O
LASV O
GP O
. O

Gene O
ontology O
analysis O
was O
performed O
to O
functionally O
annotate O
these O
proteins O
, O
and O
the O
oligosacch B
- I
aryltransferase I
( I
OST I
) I
complex O
was O
highly O
enriched O
. O

Furthermore O
, O
double O
knockout O
of O
magnesium B
transporter I
1 I
( I
MAGT1 I
) I
and O
tumor B
suppressor I
candidate I
3 I
( I
TUSC3 I
) I
, O
two O
specific O
subunits O
of O
STT3B O
- O
OST O
, O
also O
caused O
hypoglycosylation O
of O
LASV O
GP O
and O
affected O
virus O
propagation O
. O

Arenavirus O
cell O
entry O
is O
mediated O
by O
the O
viral O
glycoprotein B
( I
GP I
) I
complex O
, O
which O
consists O
of O
the O
stable B
signal I
peptide I
( I
SSP I
) I
, O
the O
receptor O
- O
binding O
subunit O
GP1 O
, O
and O
the O
transmembrane O
subunit O
GP2 O
. O

The O
GP2 O
cytoplasmic B
tail I
( I
CT I
) I
is O
relatively O
conserved O
among O
arenaviruses O
and O
is O
known O
to O
interact O
with O
the O
SSP O
to O
regulate O
GP O
processing O
and O
membrane O
fusion O
, O
but O
its O
biological O
role O
in O
the O
context O
of O
an O
infectious O
virus O
has O
not O
been O
fully O
characterized O
. O

Using O
a O
Pichinde B
virus I
( I
PICV I
) I
GP O
expression O
vector O
and O
a O
PICV O
reverse O
genetics O
system O
, O
we O
systematically O
characterized O
the O
functional O
roles O
of O
12 O
conserved O
residues O
within O
the O
GP2 O
CT O
in O
GP O
processing O
, O
trafficking O
, O
assembly O
, O
and O
fusion O
, O
as O
well O
as O
in O
viral O
replication O
. O

Both O
P480A O
and O
R482A O
mutant O
viruses O
were O
rescued O
, O
grew O
similarly O
to O
wild B
- I
type I
( I
WT I
) I
virus O
, O
and O
produced O
evidently O
processed O
GP1 O
and O
GP2 O
subunits O
in O
virus O
- O
infected O
cells O
, O
despite O
the O
fact O
that O
the O
same O
mutations O
abolished O
GP O
processing O
and O
membrane O
fusion O
in O
a O
plasmid O
- O
based O
protein O
expression O
system O
, O
illustrating O
the O
importance O
of O
using O
an O
infectious O
- O
virus O
system O
for O
analyzing O
viral O
glycoprotein O
function O
. O

IMPORTANCE O
Several O
arenaviruses O
, O
such O
as O
Lassa B
virus I
( I
LASV I
) I
, O
can O
cause O
severe O
and O
lethal O
hemorrhagic O
fever O
diseases O
with O
high O
mortality O
and O
morbidity O
, O
for O
which O
no O
FDA O
- O
approved O
vaccines O
or O
therapeutics O
are O
available O
. O

Viral O
entry O
is O
mediated O
by O
the O
arenavirus O
GP O
complex O
, O
which O
consists O
of O
the O
stable B
signal I
peptide I
( I
SSP I
) I
, O
the O
receptor O
- O
binding O
subunit O
GP1 O
, O
and O
the O
transmembrane O
subunit O
GP2 O
. O

The O
cytoplasmic B
tail I
( I
CT I
) I
of O
GP2 O
is O
highly O
conserved O
among O
arenaviruses O
, O
but O
its O
functional O
role O
in O
viral O
replication O
is O
not O
completely O
understood O
. O

Using O
a O
reverse O
genetics O
system O
of O
a O
prototypic O
arenavirus O
, O
Pichinde B
virus I
( I
PICV I
) I
, O
we O
show O
that O
the O
GP2 O
CT O
contains O
certain O
conserved O
residues O
that O
are O
essential O
for O
virus O
replication O
, O
implicating O
it O
as O
a O
potentially O
good O
target O
for O
developing O
antivirals O
and O
live O
- O
attenuated O
viral O
vaccines O
against O
deadly O
arenavirus O
pathogens O
. O

We O
describe O
a O
novel O
function O
for O
the O
interferon B
( I
IFN I
) I
- O
induced O
protein O
44 O
- O
like O
( O
IFI44L O
) O
gene O
in O
negatively O
modulating O
innate O
immune O
responses O
induced O
after O
virus O
infections O
. O

Furthermore O
, O
we O
show O
that O
decreasing O
IFI44L O
expression O
impairs O
virus O
production O
and O
that O
IFI44L O
expression O
negatively O
modulates O
the O
antiviral O
state O
induced O
by O
an O
analog O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
or O
by O
IFN O
treatment O
. O

The O
mechanism O
likely O
involves O
the O
interaction O
of O
IFI44L O
with O
cellular O
FK506 O
- O
binding O
protein O
5 O
( O
FKBP5 O
) O
, O
which O
in O
turn O
interacts O
with O
kinases O
essential O
for O
type O
I O
and O
III O
IFN O
responses O
, O
such O
as O
inhibitor O
of O
nuclear O
factor O
kappa O
B O
( O
I O
kappa O
B O
) O
kinase O
alpha O
( O
IKK O
alpha O
) O
, O
IKK O
beta O
, O
and O
IKK O
epsilon O
. O

Consequently O
, O
binding O
of O
IFI44L O
to O
FKBP5 O
decreased O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
- O
mediated O
and O
nuclear O
factor O
kappa O
- O
B O
( O
NF O
- O
kappa O
B O
) O
inhibitor O
( O
I O
kappa O
B O
alpha O
) O
- O
mediated O
phosphorylation O
by O
IKK O
epsilon O
and O
IKK O
beta O
respectively O
. O

The O
New B
World I
( I
NW I
) I
arenaviruses O
are O
a O
diverse O
group O
of O
zoonotic O
viruses O
, O
including O
several O
causative O
agents O
of O
severe O
hemorrhagic O
fevers O
in O
humans O
. O

, O
the O
highly O
pathogenic O
Junin O
( O
JUNV O
) O
and O
Machupo O
viruses O
with O
the O
nonpathogenic O
Tacaribe B
virus I
( I
TCRV I
) I
. O

Despite O
similar O
levels O
of O
viral O
replication O
, O
infection O
with O
TCRV O
consistently O
induced O
a O
stronger O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
response O
than O
JUNV O
infection O
did O
. O

However O
, O
in O
comparison O
to O
JUNV O
, O
TCRV O
induced O
stronger O
activation O
of O
the O
innate O
sensor O
double O
- O
strand O
RNA O
- O
dependent O
protein B
kinase I
R I
( I
PKR I
) I
, O
resulting O
in O
phosphorylation O
of O
eukaryotic O
translation O
initiation O
factor O
eIF2 O
alpha O
. O

IMPORTANCE O
New B
World I
( I
NW I
) I
arenaviruses O
are O
a O
diverse O
family O
of O
emerging O
zoonotic O
viruses O
that O
merit O
significant O
attention O
as O
important O
public O
health O
problems O
. O

Here O
we O
undertook O
a O
side O
- O
by O
- O
side O
comparison O
of O
the O
innate O
immune O
responses O
against O
the O
highly O
pathogenic O
Junin B
virus I
( I
JUNV I
) I
and O
the O
related O
nonpathogenic O
Tacaribe B
virus I
( I
TCRV I
) I
in O
human O
cells O
. O

We O
consistently O
found O
that O
TCRV O
induces O
a O
stronger O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
response O
than O
JUNV O
. O

However O
, O
the O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
dependent O
protein B
kinase I
R I
( I
PKR I
) I
contributed O
to O
the O
control O
of O
TCRV O
, O
but O
not O
JUNV O
, O
providing O
the O
first O
evidence O
for O
differential O
innate O
recognition O
and O
control O
of O
JUNV O
and O
TCRV O
. O

We O
and O
others O
previously O
showed O
that O
pseudotyping O
of O
oncolytic O
rhabdoviruses O
such O
as O
maraba O
virus O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
with O
the O
lymphocytic B
choriomeningitis I
virus I
glycoprotein I
( I
LCMV I
- I
GP I
) I
results O
in O
only O
a O
weak O
induction O
of O
neutralizing O
antibodies O
. O

Moreover O
, O
LCMV O
- O
GP O
- O
pseudotyped O
VSV O
( O
VSV O
- O
GP O
) O
was O
significantly O
more O
stable O
in O
normal B
human I
serum I
( I
NHS I
) I
than O
VSV O
. O

The O
NHS O
- O
mediated O
titer O
reduction O
of O
VSV O
- O
GP O
was O
dependent O
on O
activation O
of O
the O
classical O
complement O
pathway O
, O
mainly O
by O
natural O
IgM O
antibodies O
against O
xenoantigens O
such O
as O
galactose O
- O
alpha O
- O
( O
1 O
, O
3 O
) O
- O
galactose O
( O
alpha O
- O
Gal O
) O
or O
N O
- O
glycolylneuraminic O
acid O
( O
Neu5Gc O
) O
expressed O
on O
nonhuman O
production O
cell O
lines O
. O

lymphocytic B
choriomeningitis I
mammarenavirus I
( I
LCMV I
) I
is O
an O
enveloped O
, O
negative O
- O
strand O
RNA O
virus O
that O
causes O
serious O
disease O
in O
humans O
but O
establishes O
an O
asymptomatic O
, O
lifelong O
infection O
in O
reservoir O
rodents O
. O

To O
better O
understand O
LCMV O
replication O
and O
transcription O
at O
the O
single O
- O
cell O
level O
, O
we O
established O
a O
high O
- O
throughput O
, O
single O
- O
molecule O
fluorescence O
in O
situ O
hybridization O
( O
smFISH O
) O
image O
acquisition O
and O
analysis O
pipeline O
and O
examined O
viral O
RNA O
species O
at O
discrete O
time O
points O
from O
virus O
entry O
through O
the O
late O
stages O
of O
persistent O
infection O
in O
vitro O
. O

We O
developed O
a O
high O
- O
throughput O
, O
smFISH O
assay O
and O
used O
it O
to O
quantitate O
lymphocytic B
choriomeningitis I
mammarenavirus I
( I
LCMV I
) I
replicative O
and O
transcriptional O
RNA O
species O
in O
individual O
cells O
at O
distinct O
time O
points O
following O
infection O
. O

natural B
killer I
( I
NK I
) I
cells O
respond O
rapidly O
as O
a O
first O
line O
of O
defense O
against O
infectious O
pathogens O
. O

We O
used O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone O
13 O
infection O
model O
to O
address O
whether O
NK O
cells O
regulate O
T O
cell O
responses O
in O
adenovirus O
vector O
- O
vaccinated O
mice O
following O
challenge O
. O

As O
expected O
, O
NK O
cell O
depletion O
in O
unvaccinated O
mice O
resulted O
in O
increased O
virus O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
and O
immunopathology O
following O
LCMV O
challenge O
. O

In O
contrast O
, O
NK O
cell O
depletion O
had O
minimal O
to O
no O
impact O
on O
antigen O
- O
specific O
T O
cell O
responses O
in O
mice O
that O
were O
vaccinated O
with O
an O
adenovirus B
serotype I
5 I
( I
Ad5 I
) I
- O
GP O
vector O
prior O
to O
LCMV O
challenge O
. O

To O
gain O
a O
better O
understanding O
of O
how O
the O
Z O
protein O
exerts O
its O
several O
different O
functions O
, O
we O
investigated O
the O
interaction O
between O
Z O
and O
viral O
polymerase O
L O
protein O
using O
the O
prototypic O
mammarenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

We O
found O
that O
in O
the O
presence O
of O
an O
active O
viral B
ribonucleoprotein I
( I
vRNP I
) I
, O
the O
Z O
protein O
translocated O
from O
nonionic O
detergent O
- O
resistant O
, O
membrane O
- O
rich O
structures O
to O
a O
subcellular O
compartment O
with O
a O
different O
membrane O
composition O
susceptible O
to O
disruption O
by O
nonionic O
detergents O
. O

Alanine B
( I
A I
) I
substitution O
of O
a O
highly O
conserved O
leucine B
( I
L I
) I
at O
position O
72 O
in O
LCMV O
Z O
protein O
abrogated O
Z O
- O
L O
interaction O
. O

IMPORTANCE O
Several O
mammarenaviruses O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
, O
cause O
hemorrhagic O
fever O
disease O
in O
humans O
and O
pose O
important O
public O
health O
concerns O
in O
their O
regions O
of O
endemicity O
. O

Moreover O
, O
mounting O
evidence O
indicates O
that O
the O
worldwide O
- O
distributed O
, O
prototypic O
mammarenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
is O
a O
neglected O
human O
pathogen O
of O
clinical O
significance O
. O

The O
L72A O
mutation O
did O
not O
affect O
Z O
budding O
activity O
but O
promoted O
its O
rapid O
degradation O
in O
the O
presence O
of O
an O
active O
viral B
ribonucleoprotein I
( I
vRNP I
) I
. O

Fatal O
infection O
with O
the O
highly O
pathogenic O
Lassa B
virus I
( I
LASV I
) I
is O
characterized O
by O
extensive O
viral O
dissemination O
, O
indicating O
broad O
tissue O
tropism O
. O

The O
major O
cellular O
receptor O
for O
LASV O
is O
the O
highly O
conserved O
extracellular O
matrix O
receptor O
dystroglycan B
( I
DG I
) I
. O

The O
broadly O
expressed O
Phosphatidylserine B
( I
PS I
) I
receptors O
Axl O
and O
Tyro3 O
were O
recently O
identified O
as O
alternative O
LASV O
receptor O
candidates O
. O

To O
study O
LASV O
receptor O
use O
in O
the O
context O
of O
productive O
arenavirus O
infection O
, O
we O
employed O
recombinant O
lymphocytic O
choriomeningitis O
virus O
expressing O
LASV O
glycoprotein O
( O
rLCMV O
- O
LASV O
GP O
) O
as O
a O
validated O
biosafety B
level I
2 I
( I
BSL2 I
) I
model O
. O

IMPORTANCE O
The O
highly O
pathogenic O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
represents O
a O
serious O
public O
health O
problem O
in O
Africa O
. O

Although O
the O
principal O
LASV O
receptor O
, O
dystroglycan B
( I
DG I
) I
, O
is O
ubiquitously O
expressed O
, O
virus O
binding O
critically O
depends O
on O
DG O
' O
s O
posttranslational O
modification O
, O
which O
does O
not O
always O
correlate O
with O
tissue O
tropism O
. O

Effective O
CD8 O
( O
+ O
) O
T O
cell O
responses O
play O
an O
important O
role O
in O
determining O
the O
course O
of O
a O
viral O
infection O
. O

Overwhelming O
antigen O
exposure O
can O
result O
in O
suboptimal O
CD8 O
( O
+ O
) O
T O
cell O
responses O
, O
leading O
to O
chronic O
infection O
. O

This O
altered O
CD8 O
( O
+ O
) O
T O
cell O
differentiation O
state O
, O
termed O
exhaustion O
, O
is O
characterized O
by O
reduced O
effector O
function O
, O
upregulation O
of O
inhibitory O
receptors O
, O
and O
altered O
expression O
of O
transcription O
factors O
. O

Prevention O
of O
overwhelming O
antigen O
exposure O
to O
limit O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
is O
of O
significant O
interest O
for O
the O
control O
of O
chronic O
infection O
. O

The O
transcription O
factor O
interferon B
regulatory I
factor I
9 I
( I
IRF9 I
) I
is O
a O
component O
of O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
signaling O
downstream O
of O
the O
IFN O
- O
I O
receptor O
( O
IFNAR O
) O
. O

Using O
acute O
infection O
of O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strain O
Armstrong O
, O
we O
show O
here O
that O
IRF9 O
limited O
early O
LCMV O
replication O
by O
regulating O
expression O
of O
interferon O
- O
stimulated O
genes O
and O
IFN O
- O
I O
and O
by O
controlling O
levels O
of O
IRF7 O
, O
a O
transcription O
factor O
essential O
for O
IFN O
- O
I O
production O
. O

Infection O
of O
IRF9 O
- O
or O
IFNAR O
- O
deficient O
mice O
led O
to O
a O
loss O
of O
early O
restriction O
of O
viral O
replication O
and O
impaired O
antiviral O
responses O
in O
dendritic O
cells O
, O
resulting O
in O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
and O
chronic O
infection O
. O

Thus O
, O
our O
findings O
illustrate O
a O
CD8 O
( O
+ O
) O
T O
cell O
extrinsic O
function O
for O
IRF9 O
, O
as O
a O
signaling O
factor O
downstream O
of O
IFNAR O
, O
in O
preventing O
overwhelming O
antigen O
exposure O
resulting O
in O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
and O
, O
ultimately O
, O
chronic O
infection O
. O

IMPORTANCE O
During O
early O
viral O
infection O
, O
overwhelming O
antigen O
exposure O
can O
cause O
functional O
exhaustion O
of O
CD8 O
( O
+ O
) O
T O
cells O
and O
lead O
to O
chronic O
infection O
. O

Here O
we O
show O
that O
the O
transcription O
factor O
interferon B
regulatory I
factor I
9 I
( I
IRF9 I
) I
plays O
a O
decisive O
role O
in O
preventing O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
. O

Using O
acute O
infection O
of O
mice O
with O
LCMV O
strain O
Armstrong O
, O
we O
found O
that O
IRF9 O
limited O
early O
LCMV O
replication O
by O
regulating O
expression O
of O
interferon O
- O
stimulated O
genes O
and O
Irf7 O
, O
encoding O
a O
transcription O
factor O
crucial O
for O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
production O
, O
as O
well O
as O
by O
controlling O
the O
levels O
of O
IFN O
- O
I O
. O

Infection O
of O
IRF9 O
- O
deficient O
mice O
led O
to O
a O
chronic O
infection O
that O
was O
accompanied O
by O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
due O
to O
defects O
extrinsic O
to O
T O
cells O
. O

Our O
findings O
illustrate O
an O
essential O
role O
for O
IRF9 O
, O
as O
a O
mediator O
downstream O
of O
IFNAR O
, O
in O
preventing O
overwhelming O
antigen O
exposure O
causing O
CD8 O
( O
+ O
) O
T O
cell O
exhaustion O
and O
leading O
to O
chronic O
viral O
infection O
. O

Here O
we O
used O
immunoprecipitation O
and O
mass O
spectrometry O
to O
identify O
human O
proteins O
that O
interact O
with O
the O
nucleoproteins B
( I
NPs I
) I
of O
the O
Old O
World O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
the O
New O
World O
arenavirus O
Junin B
virus I
( I
JUNV I
) I
strain O
Candid O
#1 O
. O

In O
particular O
, O
NP O
associates O
with O
the O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
activated O
protein B
kinase I
( I
PKR I
) I
, O
a O
well O
- O
characterized O
antiviral O
protein O
that O
inhibits O
cap O
- O
dependent O
protein O
translation O
initiation O
via O
phosphorylation O
of O
eIF2 O
alpha O
. O

The O
glycoprotein B
complex I
( I
GPC I
) I
of O
arenaviruses O
, O
composed O
of O
stable O
signal O
peptide O
, O
GP1 O
, O
and O
GP2 O
, O
is O
the O
only O
antigen O
correlated O
with O
antibody O
- O
mediated O
neutralization O
. O

Two O
closely O
related O
clade O
B O
viruses O
, O
Machupo B
virus I
( I
MACV I
) I
and O
Junin B
virus I
( I
JUNV I
) I
, O
have O
nearly O
identical O
overall O
GPC O
architecture O
and O
share O
a O
host O
receptor O
, O
transferrin B
receptor I
1 I
( I
TfR1 I
) I
. O

Given O
structural O
and O
functional O
similarities O
of O
the O
GP1 O
Receptor B
binding I
site I
( I
RBS I
) I
of O
these O
viruses O
and O
the O
recent O
demonstration O
that O
the O
RBS O
is O
an O
important O
target O
for O
neutralizing O
antibodies O
, O
it O
is O
not O
clear O
how O
these O
viruses O
avoid O
cross O
- O
neutralization O
. O

To O
address O
this O
, O
MACV O
/ O
JUNV O
chimeric O
GPCs O
were O
assessed O
for O
interaction O
with O
a O
group O
of O
alpha O
- O
JUNV O
GPC O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
mouse O
antisera O
against O
JUNV O
or O
MACV O
GPC O
. O

However O
, O
these O
MAbs O
were O
unable O
to O
bind O
to O
a O
chimeric O
GPC O
composed O
of O
JUNV O
GP1 O
containing O
a O
small O
disulfide O
bonded O
loop O
( O
loop O
10 O
) O
unique O
to O
MACV O
GPC O
, O
suggesting O
that O
this O
loop O
may O
block O
MAbs O
interaction O
with O
the O
GP1 O
RBS O
. O

In O
our O
studies O
, O
we O
found O
that O
neutralizing O
antibodies O
against O
two O
New O
World O
arenaviruses O
, O
Machupo B
virus I
( I
MACV I
) I
and O
Junin B
virus I
( I
JUNV I
) I
, O
bound O
to O
the O
envelope O
glycoprotein B
1 I
( I
GP1 I
) I
with O
JUNV O
monoclonal O
antibodies O
targeting O
the O
Receptor B
binding I
site I
( I
RBS I
) I
. O

adenovirus B
serotype I
5 I
( I
Ad5 I
) I
is O
one O
of O
the O
most O
widely O
used O
viral O
vectors O
and O
is O
known O
to O
generate O
potent O
T O
cell O
responses O
. O

Here O
, O
we O
immunized O
mice O
with O
Ad5 O
vectors O
encoding O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
glycoprotein I
( I
GP I
) I
and O
examined O
GP O
- O
specific O
CD4 O
T O
cell O
responses O
elicited O
by O
Ad5 O
vectors O
and O
compared O
them O
to O
those O
induced O
by O
an O
acute O
LCMV O
infection O
. O

In O
contrast O
to O
LCMV O
infection O
, O
where O
balanced O
CD4 O
T B
helper I
1 I
( I
Th1 I
) I
and O
T B
follicular I
helper I
( I
Tfh I
) I
responses O
were O
induced O
, O
Ad5 O
immunization O
resulted O
in O
a O
significantly O
reduced O
frequency O
of O
Th1 O
cells O
. O

Analysis O
at O
early O
time O
points O
( O
day O
3 O
or O
4 O
) O
after O
immunization O
with O
Ad5 O
vectors O
revealed O
a O
defect O
in O
the O
expression O
of O
CD25 O
( O
interleukin O
- O
2 O
[ O
IL O
- O
2 O
] O
receptor O
alpha O
chain O
) O
on O
Ad5 O
- O
elicited O
CD4 O
T O
cells O
, O
and O
administration O
of O
exogenous O
IL O
- O
2 O
following O
Ad5 O
immunization O
partially O
restored O
CD4 O
Th1 O
responses O
. O

Rapamycin O
treatment O
resulted O
in O
suppression O
of O
virus O
- O
specific O
B O
cell O
responses O
by O
inhibiting O
proliferation O
of O
germinal B
center I
( I
GC I
) I
B O
cells O
. O

However O
, O
the O
drug O
treatment O
caused O
a O
striking O
bias O
of O
CD4 O
T O
cell O
differentiation O
into O
Th1 O
cells O
and O
substantially O
impaired O
formation O
of O
follicular O
helper O
T O
( O
Tfh O
) O
cells O
, O
which O
are O
essential O
for O
humoral O
immunity O
. O

Further O
experiments O
in O
which O
mTOR O
signaling O
was O
modulated O
by O
RNA B
interference I
( I
RNAi I
) I
revealed O
that O
B O
cells O
were O
the O
primary O
target O
cells O
of O
rapamycin O
for O
the O
impaired O
humoral O
immunity O
and O
that O
reduced O
Tfh O
formation O
in O
rapamycin O
- O
treated O
mice O
was O
due O
to O
lower O
GC O
B O
cell O
responses O
that O
are O
essential O
for O
Tfh O
generation O
. O

Additionally O
, O
we O
found O
that O
rapamycin O
had O
minimal O
effects O
on O
B O
cell O
responses O
activated O
by O
lipopolysaccharide B
( I
LPS I
) I
, O
which O
stimulates O
B O
cells O
in O
an O
antigen O
- O
independent O
manner O
, O
suggesting O
that O
rapamycin O
specifically O
inhibits O
B O
cell O
responses O
induced O
by O
B O
cell O
receptor O
stimulation O
with O
antigen O
. O

This O
can O
occur O
after O
acute O
viral O
infections O
, O
such O
as O
infections O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
vaccinia O
virus O
, O
where O
the O
pathogens O
are O
cleared O
, O
but O
it O
becomes O
a O
more O
complex O
issue O
in O
the O
context O
of O
persistent O
infections O
. O

In O
this O
study O
, O
murine B
cytomegalovirus I
( I
MCMV I
) I
was O
used O
as O
a O
persistent O
infection O
model O
to O
study O
heterologous O
immunity O
with O
LCMV O
. O

If O
mice O
were O
previously O
immune O
to O
LCMV O
and O
then O
infected O
with O
MCMV O
( O
LCMV O
+ O
MCMV O
) O
, O
they O
had O
more O
severe O
immunopathology O
, O
enhanced O
viral O
burden O
in O
multiple O
organs O
, O
and O
suppression O
of O
MCMV O
- O
specific O
T O
cell O
memory O
inflation O
. O

When O
MCMV O
infection O
was O
given O
first O
( O
MCMV O
+ O
LCMV O
) O
, O
the O
magnitude O
of O
the O
acute O
T O
cell O
response O
to O
LCMV O
declined O
with O
age O
though O
this O
age O
- O
dependent O
decline O
was O
not O
dependent O
on O
MCMV O
. O

However O
, O
some O
of O
these O
MCMV O
persistently O
infected O
mice O
with O
acute O
LCMV O
infection O
( O
7 O
of O
36 O
) O
developed O
a O
robust O
immunodominant O
CD8 O
T O
cell O
response O
apparently O
cross O
- O
reactive O
between O
a O
newly O
defined O
putative O
MCMV O
epitope O
sequence O
, O
M57727 O
- O
734 O
, O
and O
the O
normally O
subdominant O
LCMV O
epitope O
L2062 O
- O
2069 O
, O
indicating O
a O
profound O
private O
specificity O
effect O
in O
heterologous O
immunity O
between O
these O
two O
viruses O
. O

To O
assess O
if O
PD O
- O
1 O
promoter O
DNA O
demethylation O
is O
impacted O
by O
prolonged O
stimulation O
during O
effector O
phase O
of O
chronic O
infection O
, O
we O
adoptively O
transferred O
virus O
- O
specific O
day O
8 O
effector O
CD8 O
T O
cells O
from O
mice O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone O
13 O
into O
recipient O
mice O
that O
had O
cleared O
an O
acute O
infection O
. O

The O
observed O
maintenance O
of O
PD O
- O
1 O
surface O
expression O
and O
the O
demethylated O
PD O
- O
1 O
promoter O
were O
not O
a O
result O
of O
residual O
antigen O
in O
the O
recipient O
mice O
, O
because O
similar O
results O
were O
seen O
when O
chronic O
infection O
- O
induced O
effector O
cells O
were O
transferred O
into O
mice O
infected O
with O
a O
variant O
strain O
of O
LCMV O
( O
LCMV O
V35A O
) O
bearing O
a O
mutation O
in O
the O
cognate O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
epitope O
that O
is O
recognized O
by O
the O
donor O
CD8 O
T O
cells O
. O

The O
pathogenic O
Old O
World O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
causes O
a O
severe O
hemorrhagic O
fever O
with O
a O
high O
rate O
of O
mortality O
in O
humans O
. O

Several O
LASV O
receptors O
, O
including O
dystroglycan B
( I
DG I
) I
, O
TAM O
receptor O
tyrosine O
kinases O
, O
and O
C O
- O
type O
lectins O
, O
have O
been O
identified O
, O
suggesting O
complex O
receptor O
use O
. O

Here O
we O
investigated O
the O
mechanisms O
underlying O
LASV O
endocytosis O
in O
human O
cells O
in O
the O
context O
of O
productive O
arenavirus O
infection O
, O
using O
recombinant B
lymphocytic I
choriomeningitis I
virus I
( I
rLCMV I
) I
expressing O
the O
LASV O
glycoprotein O
( O
rLCMV O
- O
LASVGP O
) O
. O

Dystroglycan O
- O
mediated O
entry O
of O
rLCMV O
- O
LASVGP O
required O
sodium O
hydrogen O
exchangers O
, O
actin O
, O
and O
the O
GTPase O
Cdc42 O
and O
its O
downstream O
targets O
, O
p21 B
- I
activating I
kinase I
- I
1 I
( I
PAK1 I
) I
and O
Wiskott O
- O
Aldrich O
syndrome O
protein O
( O
N O
- O
Wasp O
) O
. O

Screening O
of O
kinase O
inhibitors O
identified O
protein O
kinase O
C O
, O
phosphoinositide O
3 O
- O
kinase O
, O
and O
the O
receptor O
tyrosine O
kinase O
human B
hepatocyte I
growth I
factor I
receptor I
( I
HGFR I
) I
to O
be O
regulators O
of O
rLCMV O
- O
LASVGP O
entry O
. O

Approximately O
one O
- O
third O
of O
Lassa B
virus I
( I
LASV I
) I
- O
infected O
patients O
develop O
sensorineural B
hearing I
loss I
( I
SNHL I
) I
in O
the O
late O
stages O
of O
acute O
disease O
or O
in O
early O
convalescence O
. O

With O
500 O
, O
000 O
annual O
cases O
of O
Lassa B
fever I
( I
LF I
) I
, O
LASV O
is O
a O
major O
cause O
of O
hearing O
loss O
in O
regions O
of O
West O
Africa O
where O
LF O
is O
endemic O
. O

Hemorrhagic B
fever I
arenaviruses I
( I
HFAs I
) I
pose O
important O
public O
health O
problems O
in O
regions O
where O
they O
are O
endemic O
. O

We O
have O
recently O
shown O
that O
the O
noncoding O
intergenic B
region I
( I
IGR I
) I
present O
in O
each O
arenavirus O
genome O
segment O
, O
the O
S O
and O
L O
segments O
( O
S O
- O
IGR O
and O
L O
- O
IGR O
, O
respectively O
) O
, O
plays O
important O
roles O
in O
the O
control O
of O
virus O
protein O
expression O
and O
that O
this O
knowledge O
could O
be O
harnessed O
for O
the O
development O
of O
live O
- O
attenuated O
vaccine O
strains O
to O
combat O
HFAs O
. O

We O
demonstrate O
that O
recombinants B
of I
the I
prototypic I
arenavirus I
lymphocytic I
choriomeningitis I
virus I
( I
rLCMVs I
) I
, O
whose O
S O
- O
IGRs O
were O
replaced O
by O
the O
S O
- O
IGR O
of O
Lassa B
virus I
( I
LASV I
) I
or O
an O
entirely O
nonviral O
S O
- O
IGR O
- O
like O
sequence O
( O
Ssyn O
) O
, O
are O
viable O
, O
indicating O
that O
the O
function O
of O
S O
- O
IGR O
tolerates O
a O
high O
degree O
of O
sequence O
plasticity O
. O

In O
addition O
, O
rLCMVs O
whose O
L O
- O
IGRs O
were O
replaced O
by O
Ssyn O
or O
S O
- O
IGRs O
of O
the O
very O
distantly O
related O
reptarenavirus O
Golden B
Gate I
virus I
( I
GGV I
) I
were O
viable O
and O
severely O
attenuated O
in O
vivo O
but O
able O
to O
elicit O
protective O
immunity O
against O
a O
lethal O
challenge O
with O
wild O
- O
type O
LCMV O
. O

Pichinde B
virus I
( I
PICV I
) I
is O
a O
bisegmented O
enveloped O
RNA O
virus O
that O
targets O
macrophages O
and O
dendritic B
cells I
( I
DCs I
) I
early O
in O
infection O
and O
induces O
strong O
innate O
and O
adaptive O
immunity O
in O
mice O
. O

We O
have O
developed O
a O
reverse O
genetics O
system O
to O
produce O
live O
recombinant O
PICV O
( O
strain O
P18 O
) O
with O
a O
trisegmented O
RNA O
genome O
( O
rP18tri O
) O
, O
which O
encodes O
all O
four O
PICV O
gene O
products O
and O
as O
many O
as O
two O
foreign O
genes O
. O

We O
have O
engineered O
the O
vector O
to O
express O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
reporter O
gene O
( O
abbreviated O
as O
G O
in O
virus O
designations O
) O
and O
either O
the O
hemagglutination O
( O
HA O
[ O
H O
] O
) O
or O
the O
nucleoprotein O
( O
NP O
[ O
P O
] O
) O
gene O
of O
the O
influenza O
A O
/ O
PR8 O
virus O
. O

IMPORTANCE O
We O
have O
developed O
a O
novel O
Pichinde B
virus I
( I
PICV I
) I
- O
based O
live O
viral O
vector O
, O
rP18tri O
, O
that O
packages O
three O
RNA O
segments O
and O
encodes O
as O
many O
as O
two O
foreign O
genes O
. O

Hemorrhagic B
fever I
arenaviruses I
( I
HFA I
) I
pose O
important O
public O
health O
problems O
in O
regions O
where O
they O
are O
endemic O
. O

Thus O
, O
Lassa B
virus I
( I
LASV I
) I
infects O
several O
hundred O
thousand O
individuals O
yearly O
in O
West O
Africa O
, O
causing O
a O
large O
number O
of O
Lassa O
fever O
cases O
associated O
with O
high O
morbidity O
and O
mortality O
. O

The O
Mopeia B
virus I
( I
MOPV I
) I
/ O
LASV O
reassortant O
( O
ML29 O
) O
is O
a O
LASV O
candidate O
live B
- I
attenuated I
vaccine I
( I
LAV I
) I
that O
has O
shown O
promising O
results O
in O
animal O
models O
. O

We O
used O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
to O
develop O
a O
general O
molecular O
strategy O
for O
arenavirus O
attenuation O
. O

Our O
approach O
involved O
replacement O
of O
the O
noncoding O
intergenic B
region I
( I
IGR I
) I
of O
the O
L O
genome O
segment O
with O
the O
IGR O
of O
the O
S O
genome O
segment O
to O
generate O
a O
recombinant O
LCMV O
, O
rLCMV O
( O
IGR O
/ O
S O
- O
S O
) O
, O
that O
was O
highly O
attenuated O
in O
vivo O
but O
induced O
protection O
against O
a O
lethal O
challenge O
with O
wild O
- O
type O
LCMV O
. O

Attenuation O
of O
rLCMV O
( O
IGR O
/ O
S O
- O
S O
) O
was O
associated O
with O
a O
stable O
reorganization O
of O
the O
control O
of O
viral O
gene O
expression O
. O

IMPORTANCE O
Hemorrhagic B
fever I
arenaviruses I
( I
HFA I
) I
cause O
high O
morbidity O
and O
mortality O
, O
and O
pose O
important O
public O
health O
problems O
in O
the O
regions O
where O
they O
are O
endemic O
. O

Implementation O
of O
live B
- I
attenuated I
vaccines I
( I
LAV I
) I
will O
represent O
a O
major O
step O
in O
combatting O
HFA O
. O

We O
show O
that O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
also O
inhibit O
macrophage O
activation O
, O
in O
contrast O
to O
Pichinde O
and O
Tacaribe O
viruses O
, O
which O
are O
not O
known O
to O
naturally O
cause O
human O
diseases O
. O

Using O
a O
recombinant O
Pichinde O
virus O
system O
, O
we O
show O
that O
the O
LCMV O
Z O
N B
- I
terminal I
domain I
( I
NTD I
) I
mediates O
the O
inhibition O
of O
macrophage O
activation O
and O
immune O
functions O
. O

Using O
two O
different O
models O
of O
coinfection O
, O
including O
the O
well O
- O
studied O
lymphocytic B
choriomeningitis I
( I
LCMV I
) I
and O
Pichinde B
( I
PICV I
) I
viruses O
, O
several O
differences O
were O
observed O
within O
the O
CD8 O
T O
cell O
responses O
to O
either O
virus O
. O

Some O
mice O
had O
an O
overall O
reduced O
number O
of O
virus O
- O
specific O
cells O
to O
either O
one O
of O
the O
viruses O
, O
and O
other O
mice O
developed O
an O
immunodominant O
response O
to O
a O
normally O
subdominant O
, O
cross O
- O
reactive O
epitope O
( O
nucleoprotein O
residues O
205 O
to O
212 O
, O
or O
NP205 O
) O
. O

In O
addition O
, O
evidence O
indicates O
that O
the O
worldwide O
- O
distributed O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
an O
important O
neglected O
human O
pathogen O
. O

We O
used O
this O
novel O
assay O
to O
screen O
a O
library O
of O
30 O
, O
400 O
small O
molecules O
and O
identified O
compound O
F3406 O
( O
chemical O
name O
: O
N O
- O
[ O
3 O
, O
5 O
- O
bis O
( O
fluoranyl O
) O
phenyl O
] O
- O
2 O
- O
[ O
5 O
, O
7 O
- O
bis O
( O
oxidanylidene O
) O
- O
6 O
- O
propyl O
- O
2 O
- O
pyrrolidin O
- O
1 O
- O
yl O
- O
[ O
1 O
, O
3 O
] O
thiazolo O
[ O
4 O
, O
5 O
- O
d O
] O
pyrimidin O
- O
4 O
- O
yl O
] O
ethanamide O
) O
, O
which O
exhibited O
strong O
anti O
- O
LCMV O
activity O
in O
the O
absence O
of O
cell O
toxicity O
. O

IMPORTANCE O
Hemorrhagic B
fever I
arenaviruses I
( I
HFA I
) I
are O
important O
human O
pathogens O
that O
cause O
high O
morbidity O
and O
mortality O
in O
areas O
where O
these O
viruses O
are O
endemic O
. O

In O
addition O
, O
evidence O
indicates O
that O
the O
worldwide O
- O
distributed O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
neglected O
human O
pathogen O
of O
clinical O
significance O
. O

Recombinant O
glycoprotein O
- O
deficient O
lymphocytic O
choriomeningitis O
virus O
- O
based O
vaccine O
vectors O
( O
rLCMV O
/ O
Delta O
GP O
) O
are O
potent O
CD8 O
( O
+ O
) O
T O
cell O
inducers O
. O

To O
investigate O
the O
underlying O
molecular O
requirements O
, O
we O
generated O
a O
nucleoprotein O
- O
deficient O
vector O
counterpart O
( O
rLCMV O
/ O
Delta O
NP O
) O
. O

We O
found O
that O
, O
unlike O
rLCMV O
/ O
Delta O
GP O
, O
rLCMV O
/ O
Delta O
NP O
failed O
to O
elicit O
detectable O
CD8 O
( O
+ O
) O
T O
cell O
responses O
unless O
NP O
was O
trans O
complemented O
in O
a O
transgenic O
host O
. O

natural B
killer I
( I
NK I
) I
cells O
provide O
a O
first O
line O
of O
defense O
against O
infection O
via O
the O
production O
of O
antiviral O
cytokines O
and O
direct O
lysis O
of O
target O
cells O
. O

Cytokines O
such O
as O
interleukin B
12 I
( I
IL I
- I
12 I
) I
and O
IL O
- O
18 O
are O
critical O
regulators O
of O
NK O
cell O
activation O
, O
but O
much O
remains O
to O
be O
learned O
about O
how O
cytokines O
interact O
to O
regulate O
NK O
cell O
function O
. O

Here O
, O
we O
have O
examined O
cytokine O
- O
mediated O
activation O
of O
NK O
cells O
during O
infection O
with O
two O
natural O
mouse O
pathogens O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
murine B
cytomegalovirus I
( I
MCMV I
) I
. O

Using O
a O
systematic O
screen O
of O
1 O
, O
849 O
cytokine O
pairs O
, O
we O
identified O
the O
most O
potent O
combinations O
capable O
of O
eliciting O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
in O
NK O
cells O
. O

Ly49H O
- O
positive O
( O
Ly49H O
( O
+ O
) O
) O
NK O
cells O
recognizing O
viral O
ligand O
m157 O
showed O
preferential O
proliferation O
during O
early O
MCMV O
infection O
. O

Instead O
, O
the O
maturation O
state O
of O
the O
NK O
cells O
( O
as O
determined O
by O
CD11b O
or O
CD27 O
surface O
phenotype O
) O
was O
predictive O
of O
responsiveness O
to O
cytokines O
, O
regardless O
of O
Ly49H O
expression O
. O

Ly49H O
( O
+ O
) O
NK O
cells O
, O
which O
can O
be O
directly O
activated O
by O
MCMV O
protein O
m157 O
, O
preferentially O
proliferated O
during O
MCMV O
infection O
but O
did O
not O
show O
enhanced O
IFN O
- O
gamma O
production O
following O
direct O
ex O
vivo O
cytokine O
stimulation O
. O

Instead O
, O
mature O
CD11b O
( O
+ O
) O
and O
/ O
or O
CD27 O
( O
+ O
) O
NK O
cells O
responded O
similarly O
to O
innate O
cytokine O
stimulation O
regardless O
of O
Ly49H O
expression O
. O

We O
therefore O
adapted O
a O
reverse O
- O
genetics O
minigenome B
( I
MG I
) I
rescue O
system O
based O
on O
Junin O
virus O
, O
the O
causative O
agent O
of O
Argentine O
hemorrhagic O
fever O
, O
for O
high B
- I
throughput I
screening I
( I
HTS I
) I
. O

The O
MG O
rescue O
system O
recapitulates O
all O
stages O
of O
the O
virus O
life O
cycle O
and O
enables O
screening O
of O
small O
- O
molecule O
libraries O
under O
biosafety B
containment I
level I
2 I
( I
BSL2 I
) I
conditions O
. O

Here O
we O
have O
used O
minigenome O
- O
based O
approaches O
to O
evaluate O
expression O
levels O
of O
reporter O
genes O
from O
the O
nucleoprotein B
( I
NP I
) I
and O
glycoprotein B
precursor I
( I
GPC I
) I
loci O
within O
the O
S O
segment O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

We O
then O
used O
reverse O
genetics O
to O
rescue O
a O
recombinant B
LCMV I
( I
rLCMV I
) I
containing O
a O
translocated O
viral O
S O
segment O
( O
rLCMV O
/ O
TransS O
) O
, O
where O
the O
viral O
NP O
and O
GPC O
open O
reading O
frames O
replaced O
one O
another O
. O

Here O
we O
describe O
, O
for O
the O
first O
time O
, O
the O
generation O
of O
a O
recombinant O
LCMV O
where O
the O
viral O
protein O
products O
encoded O
by O
the O
S O
RNA O
segment O
( O
NP O
and O
GPC O
) O
were O
swapped O
to O
generate O
rLCMV O
/ O
TransS O
. O

Despite O
high O
levels O
of O
viral O
replication O
, O
persistently O
infected O
carrier O
hosts O
show O
only O
mildly O
elevated O
levels O
of O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
. O

Accordingly O
, O
the O
arenavirus O
nucleoprotein B
( I
NP I
) I
has O
been O
identified O
as O
a O
potent O
IFN O
- O
I O
antagonist O
capable O
of O
blocking O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
via O
the O
retinoic O
acid O
inducible O
gene O
( O
RIG O
) O
- O
I O
/ O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
pathway O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
ability O
of O
the O
prototypic O
Old O
World O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
to O
interfere O
with O
RIG O
- O
I O
/ O
MAVS O
- O
dependent O
apoptosis O
. O

Here O
, O
we O
investigated O
the O
ability O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
to O
interfere O
with O
the O
induction O
of O
programmed O
cell O
death O
, O
or O
apoptosis O
, O
in O
response O
to O
superinfection O
with O
cytopathic O
RNA O
viruses O
. O

The O
New O
World O
arenavirus O
Junin B
virus I
( I
JUNV I
) I
is O
the O
causative O
agent O
of O
Argentine B
hemorrhagic I
fever I
( I
AHF I
) I
, O
a O
potentially O
deadly O
disease O
endemic O
to O
central O
regions O
of O
Argentina O
. O

The O
live O
- O
attenuated O
Candid B
#1 I
( I
Can I
) I
strain O
of O
JUNV O
is O
currently O
used O
to O
vaccinate O
the O
human O
population O
at O
risk O
. O

Here O
, O
we O
utilized O
a O
reverse O
genetics O
approach O
to O
generate O
recombinant B
JUNV I
( I
rJUNV I
) I
strains O
encoding O
different O
gene O
combinations O
of O
the O
pathogenic O
Romero B
( I
Rom I
) I
and O
attenuated O
Can O
strains O
of O
JUNV O
. O

Analysis O
of O
virulence O
of O
the O
rJUNV O
in O
a O
guinea O
pig O
model O
of O
lethal O
infection O
that O
closely O
reproduces O
the O
features O
of O
AHF O
identified O
the O
envelope O
glycoproteins B
( I
GPs I
) I
as O
the O
major O
determinants O
of O
pathogenesis O
and O
attenuation O
of O
JUNV O
. O

We O
document O
that O
in O
the O
guinea O
pig O
model O
of O
AHF O
, O
mutation O
F427I O
in O
GP2 O
is O
also O
highly O
attenuating O
but O
insufficient O
to O
prevent O
virus O
dissemination O
and O
development O
of O
mild O
clinical O
and O
pathological O
symptoms O
, O
indicating O
that O
complete O
attenuation O
of O
JUNV O
requires O
additional O
mutations O
present O
in O
Can O
glycoprotein B
precursor I
( I
GPC I
) I
. O

In O
this O
study O
, O
we O
document O
that O
efficient O
interaction O
between O
arenavirus O
nucleoprotein B
( I
NP I
) I
and O
RNA O
- O
dependent O
RNA O
polymerase O
( O
L O
protein O
) O
, O
the O
two O
trans O
- O
acting O
viral O
factors O
required O
for O
both O
virus O
RNA O
replication O
and O
gene O
transcription O
, O
requires O
the O
presence O
of O
virus O
- O
specific O
RNA O
sequences O
located O
within O
the O
untranslated O
5 O
' O
and O
3 O
' O
termini O
of O
the O
viral O
genome O
. O

The O
B B
cell I
- I
activating I
factor I
( I
BAFF I
) I
is O
critical O
for O
B O
cell O
development O
and O
humoral O
immunity O
in O
mice O
and O
humans O
. O

Using O
BAFF B
receptor I
( I
BAFFR I
) I
- O
deficient O
mice O
, O
we O
characterized O
BAFFR O
- O
related O
innate O
and O
adaptive O
immune O
functions O
following O
infection O
with O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

We O
identified O
a O
critical O
role O
for O
BAFFR O
signaling O
in O
the O
generation O
and O
maintenance O
of O
the O
CD169 O
( O
+ O
) O
macrophage O
compartment O
. O

Consequently O
, O
Baffr O
( O
- O
/ O
- O
) O
mice O
exhibited O
limited O
induction O
of O
innate O
type O
I O
interferon O
production O
after O
viral O
infection O
. O

Mechanistically O
, O
transient O
lack O
of O
B O
cells O
in O
Baffr O
( O
- O
/ O
- O
) O
animals O
resulted O
in O
limited O
lymphotoxin O
expression O
, O
which O
is O
critical O
for O
maintenance O
of O
CD169 O
( O
+ O
) O
cells O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
hemorrhagic O
fevers O
with O
high O
mortality O
rates O
. O

We O
found O
that O
while O
macropinocytotic O
uptake O
of O
filamentous O
EBOV O
viruslike O
particles O
( O
VLPs O
) O
expressing O
the O
EBOV O
glycoprotein B
( I
GP I
) I
occurs O
relatively O
quickly O
, O
VLPs O
only O
begin O
to O
enter O
the O
cytoplasm O
after O
a O
30 O
- O
min O
lag O
, O
considerably O
later O
than O
particles O
bearing O
the O
influenza O
hemagglutinin O
or O
GP O
from O
lymphocytic O
choriomeningitis O
virus O
, O
which O
enter O
through O
late B
endosomes I
( I
LE I
) I
. O

In O
contrast O
, O
since O
we O
observed O
that O
EBOV O
entry O
occurs O
upon O
arrival O
in O
Niemann B
- I
Pick I
C1 I
( I
NPC1 I
) I
- O
positive O
endolysosomes O
( O
LE O
/ O
Lys O
) O
, O
we O
propose O
that O
trafficking O
to O
LE O
/ O
Lys O
is O
a O
key O
rate O
- O
defining O
step O
. O

Additional O
experiments O
revealed O
, O
unexpectedly O
, O
that O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
S O
- O
mediated O
entry O
also O
begins O
only O
after O
a O
30 O
- O
min O
lag O
. O

Since O
the O
only O
endosomal O
requirement O
for O
SARS O
entry O
is O
cathepsin O
L O
activity O
, O
we O
tested O
and O
provide O
evidence O
that O
NPC1 O
( O
+ O
) O
LE O
/ O
Lys O
have O
higher O
cathepsin O
L O
activity O
than O
LE O
, O
with O
no O
detectable O
activity O
in O
earlier O
endosomes O
. O

Infection O
by O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
causes O
severe O
respiratory O
distress O
in O
infected O
patients O
. O

We O
present O
evidence O
that O
both O
viruses O
traffic O
late O
into O
the O
endocytic O
pathway O
, O
to O
NPC1 O
( O
+ O
) O
LE O
/ O
Lys O
, O
in O
order O
to O
enter O
host O
cells O
, O
and O
that O
they O
do O
so O
to O
access O
high O
levels O
of O
cathepsin O
activity O
, O
which O
both O
viruses O
use O
in O
their O
fusion O
- O
triggering O
mechanisms O
. O

This O
unexpected O
similarity O
suggests O
an O
unexplored O
vulnerability O
, O
trafficking O
to O
NPC1 O
( O
+ O
) O
LE O
/ O
Lys O
, O
as O
a O
therapeutic O
target O
for O
SARS O
and O
EBOV O
. O

transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
is O
a O
potent O
immune O
suppressor O
that O
is O
upregulated O
early O
upon O
viral O
infection O
and O
maintained O
during O
chronic O
infections O
in O
both O
mice O
and O
humans O
. O

Using O
infections O
with O
two O
different O
persistent O
viruses O
, O
murine B
cytomegalovirus I
( I
MCMV I
) I
and O
lymphocytic O
choriomeningitis O
virus O
( O
LCMV O
; O
Cl13 O
) O
, O
in O
their O
natural O
rodent O
host O
, O
we O
observed O
that O
TGF O
- O
beta O
signaling O
on O
dendritic B
cells I
( I
DCs I
) I
did O
not O
dampen O
DC O
maturation O
or O
cytokine O
production O
in O
the O
early O
stages O
of O
chronic O
infection O
with O
either O
virus O
in O
vivo O
. O

In O
contrast O
, O
TGF O
- O
beta O
signaling O
prior O
to O
( O
but O
not O
during O
) O
chronic O
viral O
infection O
directly O
restricted O
the O
natural B
killer I
( I
NK I
) I
cell O
number O
and O
effector O
function O
. O

regulatory B
T I
( I
Treg I
) I
cells O
are O
important O
in O
the O
maintenance O
of O
self O
- O
tolerance O
, O
and O
the O
depletion O
of O
Treg O
cells O
correlates O
with O
autoimmune O
development O
. O

It O
has O
been O
shown O
that O
type B
I I
interferon I
( I
IFN I
) I
responses O
induced O
early O
in O
the O
infection O
of O
mice O
can O
drive O
memory O
( O
CD44hi O
) O
CD8 O
and O
CD4 O
T O
cells O
into O
apoptosis O
, O
and O
we O
questioned O
here O
whether O
the O
apoptosis O
of O
CD44 O
- O
expressing O
Treg O
cells O
might O
be O
involved O
in O
the O
infection O
- O
associated O
autoimmune O
development O
. O

The O
infection O
caused O
a O
downregulation O
of O
the O
interleukin B
- I
7 I
( I
IL I
- I
7 I
) I
receptor O
, O
needed O
for O
survival O
of O
conventional O
T O
cells O
, O
while O
increasing O
on O
Treg O
cells O
the O
expression O
of O
the O
high O
- O
affinity O
IL O
- O
2 O
receptor O
, O
needed O
for O
STAT5 O
- O
dependent O
survival O
of O
Treg O
cells O
. O

IMPORTANCE O
Autoimmune O
diseases O
are O
controlled O
in O
part O
by O
regulatory B
T I
cells I
( I
Treg I
) I
and O
are O
thought O
to O
sometimes O
be O
initiated O
by O
viral O
infections O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
cause O
acute O
fatal O
disease O
on O
all O
continents O
but O
was O
never O
detected O
in O
Africa O
. O

We O
report O
the O
first O
detection O
of O
LCMV O
RNA O
in O
a O
common O
European O
house O
mouse O
( O
Mus O
musculus O
domesticus O
) O
in O
Africa O
. O

Mice O
were O
first O
infected O
with O
murine O
gammaherpesvirus O
68 O
( O
MHV68 O
) O
, O
a O
model O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
infection O
, O
and O
then O
after O
latency O
was O
established O
, O
they O
were O
challenged O
with O
the O
Armstrong O
strain O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Although O
the O
number O
of O
LCMV O
- O
specific O
effector O
CD8 O
( O
+ O
) O
T O
cells O
was O
not O
altered O
, O
they O
were O
skewed O
to O
a O
memory O
phenotype O
. O

In O
contrast O
, O
LCMV O
- O
specific O
effector O
CD4 O
( O
+ O
) O
T O
cells O
were O
increased O
in O
latently O
infected O
mice O
compared O
to O
those O
in O
mice O
infected O
solely O
with O
LCMV O
. O

Importantly O
, O
LCMV O
- O
specific O
memory O
CD8 O
( O
+ O
) O
T O
cells O
had O
decreased O
CD27 O
and O
increased O
killer B
cell I
lectin I
- I
like I
receptor I
G1 I
( I
KLRG1 I
) I
expression O
. O

Upon O
secondary O
challenge O
, O
LCMV O
- O
specific O
secondary O
effector O
CD8 O
( O
+ O
) O
T O
cells O
expanded O
and O
cleared O
the O
infection O
. O

However O
, O
the O
LCMV O
- O
specific O
secondary O
memory O
CD8 O
( O
+ O
) O
T O
cell O
pool O
was O
decreased O
in O
latently O
infected O
animals O
, O
abrogating O
the O
boosting O
effect O
normally O
observed O
following O
rechallenge O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
ongoing O
gammaherpesvirus O
latency O
affects O
the O
number O
and O
phenotype O
of O
primary O
versus O
secondary O
memory O
CD8 O
( O
+ O
) O
T O
cells O
during O
acute O
infection O
. O

IMPORTANCE O
CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
the O
clearance O
of O
intracellular O
pathogens O
, O
including O
viruses O
, O
certain O
bacteria O
, O
and O
tumors O
. O

However O
, O
current O
models O
for O
memory O
CD8 O
( O
+ O
) O
T O
cell O
differentiation O
are O
derived O
from O
pathogen O
- O
free O
laboratory O
mice O
challenged O
with O
a O
single O
pathogen O
or O
vaccine O
vector O
. O

Unlike O
laboratory O
animals O
, O
all O
humans O
are O
infected O
with O
multiple O
acute O
and O
chronic O
pathogens O
, O
including O
the O
highly O
prevalent O
herpesviruses O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
, O
cytomegalovirus B
( I
CMV I
) I
, O
herpes B
simplex I
viruses I
( I
HSV I
) I
, O
and O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
. O

We O
observed O
that O
ongoing O
gammaherpesvirus O
latency O
affects O
the O
number O
and O
phenotype O
of O
primary O
versus O
secondary O
memory O
CD8 O
( O
+ O
) O
T O
cells O
during O
acute O
infection O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
lymphoid O
organs O
contract O
at O
the O
resolution O
of O
virus O
infections O
by O
apoptosis O
or O
by O
dissemination O
into O
peripheral O
tissues O
, O
and O
those O
residing O
in O
nonlymphoid O
organs O
, O
including O
the O
peritoneal O
cavity O
and O
fat O
pads O
, O
are O
more O
resistant O
to O
apoptosis O
than O
those O
in O
the O
spleen O
and O
lymph O
nodes O
. O

Here O
, O
we O
show O
that O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
nonlymphoid O
tissues O
were O
enriched O
for O
memory O
precursors O
( O
expressing O
high O
levels O
of O
interleukin O
- O
7 O
receptor O
and O
low O
levels O
of O
killer O
cell O
lectin O
- O
like O
receptor O
G1 O
[ O
IL O
- O
7R O
( O
hi O
) O
KLRG1 O
( O
lo O
) O
] O
) O
and O
had O
higher O
expression O
of O
CD27 O
, O
CXCR3 O
, O
and O
T B
cell I
factor I
- I
1 I
( I
TCF I
- I
1 I
) I
, O
each O
a O
marker O
that O
is O
individually O
correlated O
with O
decreased O
apoptosis O
. O

CD8 O
( O
+ O
) O
T O
cells O
in O
the O
peritoneal O
cavity O
of O
TCF O
- O
1 O
- O
deficient O
mice O
had O
decreased O
survival O
, O
suggesting O
a O
role O
for O
TCF O
- O
1 O
in O
promoting O
survival O
in O
the O
nonlymphoid O
tissues O
. O

CXCR3 O
( O
+ O
) O
CD8 O
( O
+ O
) O
T O
cells O
resisted O
apoptosis O
and O
accumulated O
in O
the O
lymph O
nodes O
of O
mice O
treated O
with O
FTY720 O
, O
which O
blocks O
the O
export O
of O
lymph O
node O
cells O
into O
peripheral O
tissue O
. O

The O
peritoneal B
exudate I
cells I
( I
PEC I
) I
expressed O
increased O
amounts O
of O
CXCR3 O
ligands O
, O
CXCL9 O
and O
CXCL10 O
, O
which O
may O
normally O
recruit O
these O
nonapoptotic O
cells O
from O
the O
lymph O
nodes O
. O

In O
addition O
, O
adoptive O
transfer O
of O
splenic O
CD8 O
( O
+ O
) O
T O
cells O
into O
PEC O
or O
spleen O
environments O
showed O
that O
the O
peritoneal O
environment O
promoted O
survival O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

Thus O
, O
intrinsic O
stability O
of O
T O
cells O
which O
are O
present O
in O
the O
nonlymphoid O
tissues O
along O
with O
preferential O
migration O
of O
apoptosis O
- O
resistant O
CD8 O
( O
+ O
) O
T O
cells O
into O
peripheral O
sites O
and O
the O
availability O
of O
tissue O
- O
specific O
factors O
that O
enhance O
memory O
cell O
survival O
may O
collectively O
account O
for O
the O
tissue O
- O
dependent O
apoptotic O
differences O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
nonlymphoid O
tissues O
are O
more O
resistant O
to O
apoptosis O
than O
those O
in O
lymphoid O
organs O
during O
the O
resolution O
and O
memory O
phase O
of O
the O
immune O
response O
to O
acute O
LCMV O
infection O
. O

This O
increased O
resistance O
to O
apoptosis O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
nonlymphoid O
tissues O
was O
due O
to O
several O
factors O
. O

Nonlymphoid O
tissues O
were O
enriched O
in O
memory O
phenotype O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
were O
intrinsically O
resistant O
to O
apoptosis O
irrespective O
of O
the O
tissue O
environment O
. O

Furthermore O
, O
apoptosis O
- O
resistant O
CD8 O
( O
+ O
) O
T O
cells O
preferentially O
migrated O
into O
the O
nonlymphoid O
tissues O
, O
where O
the O
availability O
of O
tissue O
- O
specific O
factors O
may O
enhance O
memory O
cell O
survival O
. O

During O
the O
chronic O
phase O
of O
HIV O
- O
1 O
infection O
, O
polyfunctional O
CD8 O
( O
+ O
) O
T O
cell O
responses O
, O
which O
are O
characterized O
by O
a O
high O
frequency O
of O
cells O
able O
to O
secrete O
multiple O
cytokines O
simultaneously O
, O
are O
associated O
with O
lower O
virus O
loads O
and O
slower O
disease O
progression O
. O

Lastly O
, O
polyfunctional O
responses O
could O
contain O
more O
CD8 O
( O
+ O
) O
T O
cells O
that O
mediate O
a O
specific O
key O
function O
that O
is O
primarily O
responsible O
for O
viral O
control O
. O

We O
developed O
a O
mathematical O
model O
to O
study O
how O
polyfunctional O
CD8 O
( O
+ O
) O
T O
cell O
responses O
mediating O
lytic O
and O
nonlytic O
effector O
functions O
affect O
the O
CD4 O
( O
+ O
) O
T O
cell O
count O
and O
plasma O
viral O
load O
. O

We O
based O
our O
model O
on O
in O
vitro O
data O
on O
the O
efficacy O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
macrophage O
inflammatory O
protein O
1 O
beta O
( O
MIP O
- O
1 O
beta O
) O
/ O
RANTES O
against O
HIV O
. O

IMPORTANCE O
It O
is O
an O
open O
question O
in O
HIV O
research O
why O
polyfunctional O
CD8 O
( O
+ O
) O
T O
cell O
responses O
are O
associated O
with O
better O
viral O
control O
, O
while O
individual O
functional O
correlates O
of O
protection O
have O
not O
been O
identified O
so O
far O
. O

Identifying O
the O
role O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
HIV O
- O
1 O
infection O
has O
important O
implications O
for O
the O
potential O
development O
of O
effective O
T O
cell O
- O
based O
vaccines O
. O

Our O
analysis O
provides O
new O
ways O
to O
think O
about O
a O
causative O
role O
of O
CD8 O
( O
+ O
) O
T O
cells O
by O
studying O
different O
hypotheses O
regarding O
why O
polyfunctional O
CD8 O
( O
+ O
) O
T O
cells O
might O
be O
more O
advantageous O
. O

We O
identify O
measurements O
that O
have O
to O
be O
obtained O
in O
order O
to O
evaluate O
the O
role O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
HIV O
- O
1 O
infection O
. O

Here O
, O
we O
investigated O
how O
two O
independent O
mutants O
of O
the O
bacteriophage O
Q O
beta O
replicase O
( O
Thr210Ala O
and O
Tyr410His O
) O
reduce O
sensitivity O
to O
the O
nucleoside O
analogue O
5 O
- O
azacytidine O
( O
AZC O
) O
. O

Also O
, O
both O
substitutions O
were O
costly O
in O
the O
absence O
of O
AZC O
or O
when O
the O
action O
of O
the O
drug O
was O
suppressed O
by O
adding O
an O
excess O
of O
natural O
pyrimidines O
( O
uridine O
or O
cytosine O
) O
. O

We O
confirm O
that O
most O
effector O
and O
memory O
CD8 O
T O
cells O
are O
found O
in O
the O
vasculature O
after O
an O
intranasal O
infection O
with O
the O
systemic O
pathogens O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
or O
vaccinia B
virus I
( I
VACV I
) I
. O

In O
contrast O
, O
following O
pulmonary O
viral O
infections O
with O
either O
respiratory B
syncytial I
virus I
( I
RSV I
) I
or O
influenza B
A I
virus I
( I
IAV I
) I
, O
80 O
to O
90 O
% O
of O
the O
antigen O
- O
specific O
effector O
CD8 O
T O
cells O
were O
located O
within O
lung O
tissue O
. O

Furthermore O
, O
a O
greater O
proportion O
of O
gamma O
interferon O
- O
positive O
( O
IFN O
- O
gamma O
( O
+ O
) O
) O
effector O
CD8 O
and O
CD4 O
T O
cells O
were O
located O
within O
lung O
tissue O
following O
a O
localized O
respiratory O
viral O
infection O
. O

Virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
provide O
classical O
adaptive O
immunity O
by O
responding O
to O
cognate O
peptide O
antigen O
, O
but O
they O
may O
also O
act O
in O
an O
innate O
capacity O
by O
responding O
directly O
to O
cytokine O
stimulation O
. O

Here O
, O
we O
examined O
regulation O
of O
these O
distinct O
T O
cell O
functions O
by O
anti O
- O
inflammatory O
cytokines O
( O
interleukin O
- O
4 O
[ O
IL O
- O
4 O
] O
, O
IL O
- O
10 O
, O
and O
transforming O
growth O
factor O
beta O
[ O
TGF O
- O
beta O
] O
) O
. O

Innate O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
by O
CD8 O
( O
+ O
) O
T O
cells O
following O
exposure O
to O
IL O
- O
12 O
plus O
IL O
- O
18 O
, O
IL O
- O
12 O
plus O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
gamma O
) O
, O
or O
IL O
- O
12 O
plus O
IL O
- O
15 O
was O
inhibited O
by O
exposure O
to O
anti O
- O
inflammatory O
cytokines O
either O
before O
or O
shortly O
after O
stimulation O
. O

Following O
systemic O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
STAT1 O
knockout B
( I
KO I
) I
mice O
but O
not O
wild O
- O
type O
, O
STAT2 O
KO O
, O
IRF9 O
KO O
, O
or O
IFNAR O
KO O
mice O
develop O
lethal O
disease O
perpetrated O
by O
CD4 O
( O
+ O
) O
T O
cells O
. O

IRF7 O
is O
a O
key O
transcriptional O
activator O
of O
type O
I O
IFN O
( O
IFN O
- O
I O
) O
during O
LCMV O
infection O
. O

In O
contrast O
to O
STAT1 O
KO O
mice O
, O
STAT1 O
/ O
IRF7 O
double B
KO I
( I
DKO I
) I
mice O
survived O
LCMV O
infection O
with O
a O
reduced O
immune O
pathology O
in O
key O
organs O
, O
such O
as O
the O
liver O
and O
spleen O
. O

We O
conclude O
that O
the O
lethal O
immune O
- O
mediated O
disease O
resulting O
from O
LCMV O
infection O
in O
STAT1 O
KO O
mice O
is O
( O
i O
) O
dependent O
on O
IRF7 O
- O
induced O
IFN O
- O
I O
production O
and O
( O
ii O
) O
driven O
by O
noncanonical O
IFN O
- O
I O
signaling O
via O
STAT2 O
and O
IRF9 O
. O

To O
evaluate O
this O
, O
we O
primed O
mice O
with O
replication O
- O
defective O
adenovirus O
vectors O
expressing O
the O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
glycoprotein I
( I
GP I
) I
, O
followed O
by O
boosting O
with O
either O
LCMV O
Armstrong O
, O
which O
is O
rapidly O
controlled O
, O
or O
LCMV O
CL O
- O
13 O
, O
which O
leads O
to O
a O
more O
prolonged O
exposure O
to O
the O
boosting O
antigen O
. O

Here O
, O
we O
describe O
a O
new O
, O
potent O
vaccine O
vector O
based O
on O
replication O
- O
competent O
vesicular B
stomatitis I
virus I
pseudotyped I
with I
the I
glycoprotein I
of I
the I
lymphocytic I
choriomeningitis I
virus I
( I
VSV I
- I
GP I
) I
, O
which O
we O
previously O
showed O
to O
be O
safe O
in O
mice O
. O

In O
mice O
, O
VSV O
and O
VSV O
- O
GP O
encoding O
ovalbumin B
( I
OVA I
) I
as O
a O
model O
antigen O
( O
VSV O
- O
OVA O
and O
VSV O
- O
GP O
- O
OVA O
) O
induced O
equal O
levels O
of O
OVA O
- O
specific O
humoral O
and O
cellular O
immune O
responses O
upon O
a O
single O
immunization O
. O

OVA O
- O
specific O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
induced O
by O
VSV O
- O
GP O
- O
OVA O
were O
at O
least O
as O
potent O
as O
those O
induced O
by O
an O
adenoviral O
state O
- O
of O
- O
the O
- O
art O
vaccine O
vector O
and O
completely O
protected O
mice O
in O
a O
Listeria O
monocytogenes O
challenge O
model O
. O

Mutagenic O
nucleoside O
analogues O
can O
be O
used O
to O
isolate O
RNA O
virus O
high O
- O
fidelity O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
variants O
, O
the O
majority O
of O
which O
are O
attenuated O
in O
vivo O
. O

However O
, O
attenuated O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
high O
- O
fidelity O
RdRp O
variants O
have O
not O
been O
isolated O
, O
and O
the O
correlations O
between O
RdRp O
fidelity O
and O
virulence O
remain O
unclear O
. O

Here O
, O
the O
mutagen O
ribavirin O
was O
used O
to O
select O
a O
ribavirin O
- O
resistant O
population O
of O
FMDV O
, O
and O
4 O
amino O
acid O
substitutions O
( O
D5N O
, O
A38V O
, O
M194I O
, O
and O
M296V O
) O
were O
identified O
in O
the O
RdRp O
- O
coding O
region O
of O
the O
population O
. O

IMPORTANCE O
The O
ribavirin O
- O
isolated O
poliovirus B
( I
PV I
) I
RdRp O
G64S O
variant O
, O
the O
polymerases O
of O
which O
were O
of O
high O
replication O
fidelity O
, O
was O
attenuated O
in O
vivo O
. O

In O
our O
previous O
studies O
, O
ML29 O
elicited O
sterilizing O
immunity O
against O
Lassa O
virus O
challenge O
in O
guinea O
pigs O
and O
marmosets O
and O
virus O
- O
specific O
cell O
- O
mediated O
immunity O
in O
both O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
- O
infected O
and O
uninfected O
rhesus O
macaques O
. O

Twenty O
- O
seven O
isolates O
bore O
approximately O
77 O
mutations O
that O
exceeded O
20 O
% O
of O
the O
single B
- I
nucleotide I
polymorphism I
( I
SNP I
) I
changes O
at O
any O
single O
locus O
. O

natural B
killer I
( I
NK I
) I
cells O
contribute O
to O
establishment O
of O
persistent O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
in O
mice O
through O
suppression O
of O
virus O
- O
specific O
T O
cell O
responses O
during O
the O
first O
few O
days O
of O
infection O
, O
but O
NK O
cell O
depletion O
during O
those O
early O
time O
points O
can O
enable O
severe O
T O
cell O
- O
mediated O
immune O
pathology O
and O
death O
of O
the O
host O
. O

Targeting O
of O
NK O
cells O
could O
thus O
be O
considered O
in O
combination O
with O
blockade O
of O
other O
immunosuppressive O
pathways O
, O
such O
as O
the O
interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
and O
programmed B
death I
1 I
( I
PD I
- I
1 I
) I
pathways O
, O
as O
a O
therapy O
to O
cure O
chronic O
human O
infections O
, O
including O
those O
with O
HIV O
or O
hepatitis O
C O
virus O
. O

Here O
we O
establish O
that O
natural B
killer I
( I
NK I
) I
cells O
actively O
contribute O
to O
immune O
dysfunction O
and O
viral O
persistence O
at O
later O
stages O
of O
infection O
. O

Several O
arenaviruses O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
, O
cause O
hemorrhagic B
fever I
( I
HF I
) I
disease O
in O
humans O
and O
pose O
a O
great O
public O
health O
concern O
in O
the O
regions O
in O
which O
they O
are O
endemic O
. O

Moreover O
, O
evidence O
indicates O
that O
the O
worldwide O
- O
distributed O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
neglected O
human O
pathogen O
of O
clinical O
significance O
. O

A O
genome O
- O
wide O
small B
interfering I
RNA I
( I
siRNA I
) I
screen O
identified O
sodium O
hydrogen O
exchanger O
3 O
( O
NHE3 O
) O
as O
required O
for O
efficient O
multiplication O
of O
LCMV O
in O
HeLa O
cells O
, O
but O
the O
mechanisms O
by O
which O
NHE O
activity O
contributed O
to O
the O
life O
cycle O
of O
LCMV O
remain O
unknown O
. O

Here O
we O
show O
that O
treatment O
with O
the O
NHE O
inhibitor O
5 O
- O
( O
N O
- O
ethyl O
- O
N O
- O
isopropyl O
) O
amiloride O
( O
EIPA O
) O
resulted O
in O
a O
robust O
inhibition O
of O
LCMV O
multiplication O
in O
both O
rodent O
( O
BHK O
- O
21 O
) O
and O
human O
( O
A549 O
) O
cells O
. O

EIPA O
also O
inhibited O
cell O
entry O
mediated O
by O
the O
glycoproteins O
of O
the O
HF O
arenaviruses O
LASV O
and O
Junin B
virus I
( I
JUNV I
) I
. O

In O
this O
study O
, O
we O
evaluated O
the O
antiviral O
activity O
of O
A3 O
against O
representative O
Old O
World O
( O
lymphocytic O
choriomeningitis O
virus O
) O
and O
New O
World O
( O
Junin O
virus O
) O
arenaviruses O
in O
rodent O
, O
monkey O
, O
and O
human O
cell O
lines O
. O

Ocozocoautla B
de I
Espinosa I
virus I
( I
OCEV I
) I
is O
a O
novel O
, O
uncultured O
arenavirus O
. O

We O
found O
that O
the O
OCEV O
glycoprotein O
mediates O
entry O
into O
grivet O
and O
bat O
cells O
through O
transferrin B
receptor I
1 I
( I
TfR1 I
) I
binding O
but O
that O
OCEV O
glycoprotein B
precursor I
( I
GPC I
) I
- O
pseudotyped O
retroviruses O
poorly O
entered O
53 O
human O
cancer O
cell O
lines O
. O

Guanarito B
virus I
( I
GTOV I
) I
is O
an O
emergent O
and O
deadly O
pathogen O
. O

The O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
causes O
a O
severe O
hemorrhagic O
fever O
with O
high O
mortality O
in O
humans O
. O

Antigen O
- O
presenting O
cells O
, O
in O
particular O
dendritic B
cells I
( I
DCs I
) I
, O
are O
early O
and O
preferred O
targets O
of O
LASV O
, O
and O
their O
productive O
infection O
contributes O
to O
the O
virus O
- O
induced O
immunosuppression O
observed O
in O
fatal O
disease O
. O

Here O
, O
we O
characterized O
the O
role O
of O
the O
C O
- O
type O
lectin O
DC B
- I
specific I
ICAM I
- I
3 I
- I
grabbing I
nonintegrin I
( I
DC I
- I
SIGN I
) I
in O
LASV O
entry O
into O
primary O
human O
DCs O
using O
a O
chimera O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
expressing O
the O
LASV O
glycoprotein O
( O
rLCMV O
- O
LASVGP O
) O
. O

We O
provide O
evidence O
that O
DC O
- O
SIGN O
serves O
as O
an O
attachment O
factor O
for O
rLCMV O
- O
LASVGP O
in O
monocyte B
- I
derived I
immature I
dendritic I
cells I
( I
MDDC I
) I
and O
can O
accelerate O
the O
capture O
of O
free O
virus O
. O

However O
, O
in O
contrast O
to O
the O
phlebovirus O
Uukuniemi B
virus I
( I
UUKV I
) I
, O
which O
uses O
DC O
- O
SIGN O
as O
an O
authentic O
entry O
receptor O
, O
productive O
infection O
with O
rLCMV O
- O
LASVGP O
was O
less O
dependent O
on O
DC O
- O
SIGN O
. O

The O
generation O
of O
these O
long O
- O
lived O
plasma O
cells O
depends O
upon O
a O
series O
of O
highly O
orchestrated O
interactions O
between O
antigen O
- O
specific O
CD4 O
T O
cells O
and O
B O
cells O
and O
the O
formation O
of O
germinal B
centers I
( I
GCs I
) I
. O

In O
this O
study O
, O
we O
have O
examined O
the O
role O
of O
the O
cytokine O
interleukin B
- I
21 I
( I
IL I
- I
21 I
) I
in O
regulating O
humoral O
immunity O
during O
acute O
viral O
infections O
. O

Using O
IL O
- O
21 O
receptor O
- O
deficient O
( O
IL O
- O
21R O
( O
- O
/ O
- O
) O
) O
mice O
, O
we O
found O
that O
virus O
- O
specific O
CD4 O
T O
cells O
were O
generated O
after O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
that O
these O
CD4 O
T O
cells O
differentiated O
into O
T B
follicular I
helper I
( I
T I
- I
FH I
) I
- O
like O
cells O
in O
the O
absence O
of O
IL O
- O
21 O
signaling O
. O

There O
was O
also O
no O
defect O
in O
the O
formation O
of O
GCs O
, O
although O
after O
day O
15 O
these O
GCs O
disappeared O
faster O
in O
IL O
- O
21R O
( O
- O
/ O
- O
) O
mice O
than O
in O
wild O
- O
type O
mice O
. O

Isotype O
switching O
and O
the O
initial O
LCMV O
- O
specific O
IgG O
response O
were O
normal O
in O
IL O
- O
21R O
( O
- O
/ O
- O
) O
mice O
. O

Similar O
results O
were O
seen O
after O
infection O
of O
IL O
- O
21R O
( O
- O
/ O
- O
) O
mice O
with O
vesicular O
stomatitis O
virus O
and O
influenza O
virus O
. O

Using O
chimeric O
mice O
containing O
wild O
- O
type O
or O
IL O
- O
21R O
( O
- O
/ O
- O
) O
CD4 O
T O
cells O
and O
B O
cells O
, O
we O
showed O
that O
both O
B O
and O
CD4 O
T O
cells O
need O
IL O
- O
21 O
signaling O
for O
generating O
long O
- O
term O
humoral O
immunity O
. O

Several O
arenaviruses O
are O
responsible O
for O
causing O
viral B
hemorrhagic I
fevers I
( I
VHF I
) I
in O
humans O
. O

Lassa B
virus I
( I
LASV I
) I
, O
the O
causative O
agent O
of O
Lassa O
fever O
, O
is O
a O
biosafety B
level I
4 I
( I
BSL4 I
) I
pathogen O
that O
requires O
handling O
in O
BSL4 O
facilities O
. O

In O
contrast O
, O
the O
Pichinde B
arenavirus I
( I
PICV I
) I
is O
a O
BSL2 O
pathogen O
that O
can O
cause O
hemorrhagic O
fever O
- O
like O
symptoms O
in O
guinea O
pigs O
that O
resemble O
those O
observed O
in O
human O
Lassa O
fever O
. O

Using O
reverse O
genetics O
systems O
that O
we O
have O
recently O
developed O
, O
we O
have O
mapped O
the O
sequence O
changes O
in O
the O
large B
( I
L I
) I
segment O
of O
the O
PICV O
genome O
that O
are O
responsible O
for O
the O
heightened O
virulence O
phenotype O
of O
the O
P18 O
strain O
. O

Through O
quantitative O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
analysis O
, O
we O
have O
confirmed O
that O
the O
same O
set O
of O
residues O
is O
responsible O
for O
the O
increased O
viral O
replicative O
potential O
of O
the O
P18 O
strain O
and O
its O
heightened O
disease O
severity O
in O
vivo O
. O

Cytomegaloviruses B
( I
CMVs I
) I
establish O
lifelong O
infections O
that O
are O
controlled O
in O
part O
by O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
. O

During O
the O
acute O
phase O
of O
infection O
, O
the O
magnitudes O
of O
CMV O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
were O
decreased O
in O
mice O
with O
abrogated O
CD27 O
- O
CD70 O
costimulation O
. O

It O
has O
been O
reported O
that O
adenovirus B
( I
Ad I
) I
- O
primed O
CD8 O
T O
cells O
may O
display O
a O
distinct O
and O
partially O
exhausted O
phenotype O
. O

Given O
the O
practical O
implications O
of O
this O
claim O
, O
we O
decided O
to O
analyze O
in O
detail O
the O
quality O
of O
Ad O
- O
primed O
CD8 O
T O
cells O
by O
directly O
comparing O
these O
cells O
to O
CD8 O
T O
cells O
induced O
through O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

In O
this O
case O
, O
the O
vaccination O
led O
to O
the O
generation O
of O
a O
population O
of O
memory O
cells O
characterized O
by O
relatively O
low O
CD27 O
expression O
and O
high O
CD127 O
and O
killer B
cell I
lectin I
- I
like I
receptor I
subfamily I
G I
member I
1 I
( I
KLRG1 I
) I
expression O
. O

Based O
on O
these O
findings O
, O
we O
suggest O
that O
adenovirus O
- O
based O
prime O
- O
boost O
regimens O
( O
including O
Ad O
serotype O
5 O
[ O
Ad5 O
] O
and O
Ad5 O
- O
like O
vectors O
) O
represent O
an O
effective O
means O
to O
induce O
a O
substantially O
expanded O
, O
long O
- O
lived O
population O
of O
high O
- O
quality O
transgene O
- O
specific O
memory O
CD8 O
T O
cells O
. O

One O
of O
these O
, O
T O
- O
705 O
( O
favipiravir O
) O
, O
has O
a O
mechanism O
of O
action O
that O
is O
not O
fully O
understood O
but O
is O
suggested O
to O
target O
influenza O
virus O
RNA O
- O
dependent O
RNA O
polymerase O
. O

We O
investigated O
the O
mechanism O
of O
T O
- O
705 O
activity O
against O
influenza O
A O
( O
H1N1 O
) O
viruses O
by O
applying O
selective O
drug O
pressure O
over O
multiple O
sequential O
passages O
in O
MDCK O
cells O
. O

0001 O
) O
during O
serial O
passage O
in O
MDCK O
cells O
inoculated O
with O
seasonal O
influenza O
A O
( O
H1N1 O
) O
viruses O
at O
a O
low O
multiplicity O
of O
infection O
( O
MOI O
; O
0 O
. O

0001 O
PFU O
/ O
cell O
) O
or O
with O
2009 O
pandemic O
H1N1 O
viruses O
at O
a O
high O
MOI O
( O
10 O
PFU O
/ O
cell O
) O
. O

There O
was O
no O
corresponding O
decrease O
in O
the O
number O
of O
viral O
RNA O
copies O
; O
therefore O
, O
specific O
virus O
infectivity O
( O
the O
ratio O
of O
infectious O
virus O
yield O
to O
viral O
RNA O
copy O
number O
) O
was O
reduced O
. O

A O
recent O
publication O
indicated O
that O
overexpression O
of O
Axl O
, O
a O
cellular O
receptor O
that O
negatively O
regulates O
Toll O
- O
like O
receptor O
signaling O
, O
enhanced O
the O
entry O
of O
viruses O
pseudotyped O
with O
the O
glycoprotein O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
vitro O
. O

In O
testing O
the O
biological O
relevance O
of O
these O
observations O
, O
we O
found O
differences O
in O
neither O
viral O
kinetics O
between O
LCMV O
infections O
of O
Axl O
( O
- O
/ O
- O
) O
and O
wildtype O
mice O
nor O
T O
- O
cell O
responses O
prior O
to O
spontaneous O
viral O
clearance O
. O

Generation B
of I
reactive I
oxygen I
intermediates I
( I
ROI I
) I
following O
antigen O
receptor O
ligation O
is O
critical O
to O
promote O
cellular O
responses O
. O

Mice O
were O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
treated O
with O
Mn O
( O
III O
) O
tetrakis O
( O
4 O
- O
benzoic O
acid O
) O
porphyrin O
chloride O
( O
MnTBAP O
) O
, O
a O
superoxide O
dismutase O
mimetic O
, O
from O
days O
0 O
to O
8 O
postinfection O
. O

On O
day O
8 O
, O
at O
the O
peak O
of O
the O
splenic O
response O
in O
vehicle O
- O
treated O
mice O
, O
virus O
- O
specific O
IgM O
and O
IgG O
antibody B
- I
secreting I
cells I
( I
ASC I
) I
were O
decreased O
22 O
- O
and O
457 O
- O
fold O
in O
MnTBAP O
- O
treated O
animals O
. O

In O
addition O
to O
decreases O
in O
ASC O
, O
MnTBAP O
treatment O
decreased O
the O
number O
of O
functional O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
failure O
of O
the O
adenovirus B
serotype I
5 I
( I
Ad5 I
) I
vector O
- O
based O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
vaccine O
in O
the O
STEP O
study O
has O
led O
to O
the O
development O
of O
adenovirus O
vectors O
derived O
from O
alternative O
serotypes O
, O
such O
as O
Ad26 O
, O
Ad35 O
, O
and O
Ad48 O
. O

We O
have O
recently O
demonstrated O
that O
vaccines O
using O
alternative O
- O
serotype O
Ad O
vectors O
confer O
partial O
protection O
against O
stringent O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
challenges O
in O
rhesus O
monkeys O
. O

Here O
, O
we O
report O
the O
magnitude O
, O
phenotype O
, O
functionality O
, O
and O
recall O
capacity O
of O
memory O
T O
cell O
responses O
elicited O
in O
mice O
by O
Ad5 O
, O
Ad26 O
, O
Ad35 O
, O
and O
Ad48 O
vectors O
expressing O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
glycoprotein I
( I
GP I
) I
. O

CD8 O
( O
+ O
) O
T O
cells O
play O
an O
important O
role O
in O
protection O
against O
both O
acute O
and O
persistent O
viral O
infections O
, O
and O
new O
vaccines O
that O
induce O
CD8 O
( O
+ O
) O
T O
cell O
immunity O
are O
currently O
needed O
. O

Here O
, O
we O
show O
that O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
can O
be O
generated O
in O
response O
to O
a O
nonreplicating O
H2O2 O
- O
inactivated O
whole O
- O
virus O
vaccine O
( O
H2O2 O
- O
LCMV O
) O
. O

Vaccine O
- O
induced O
CD8 O
( O
+ O
) O
T O
cell O
responses O
exhibited O
an O
increased O
ability O
to O
produce O
multiple O
cytokines O
at O
early O
time O
points O
following O
immunization O
compared O
to O
infection O
- O
induced O
responses O
. O

Vaccination O
with O
H2O2 O
- O
LCMV O
induced O
the O
expansion O
of O
a O
narrow O
subset O
of O
the O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
induced O
by O
LCMV O
strain O
Arm O
infection O
, O
resulting O
in O
a O
distinct O
immunodominance O
hierarchy O
. O

Vaccine O
- O
induced O
CD8 O
( O
+ O
) O
T O
cell O
populations O
expanded O
sharply O
in O
response O
to O
challenge O
and O
were O
then O
maintained O
at O
high O
levels O
, O
with O
responses O
to O
individual O
epitopes O
occupying O
up O
to O
40 O
% O
of O
the O
CD8 O
( O
+ O
) O
T O
cell O
compartment O
at O
35 O
days O
after O
challenge O
. O

H2O2 O
- O
LCMV O
vaccination O
protected O
animals O
against O
challenge O
with O
chronic O
LCMV O
clone O
13 O
, O
and O
protection O
was O
mediated O
by O
CD8 O
( O
+ O
) O
T O
cells O
. O

These O
results O
indicate O
that O
vaccination O
with O
an O
H2O2 O
- O
inactivated O
whole O
- O
virus O
vaccine O
induces O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
with O
unique O
functional O
characteristics O
and O
provides O
a O
useful O
model O
for O
studying O
CD8 O
+ O
T O
cells O
elicited O
in O
the O
absence O
of O
active O
viral O
infection O
. O

type B
I I
interferons I
( I
IFNs I
) I
, O
predominantly O
IFN O
- O
alpha O
and O
- O
beta O
, O
play O
critical O
roles O
in O
both O
innate O
and O
adaptive O
immune O
responses O
against O
viral O
infections O
. O

interferon B
regulatory I
factor I
7 I
( I
IRF7 I
) I
, O
a O
key O
innate O
immune O
molecule O
in O
the O
type O
I O
IFN O
signaling O
pathway O
, O
is O
essential O
for O
the O
type O
I O
IFN O
response O
to O
many O
viruses O
, O
including O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Here O
, O
we O
show O
that O
although O
IRF7 O
knockout B
( I
KO I
) I
mice O
failed O
to O
control O
the O
replication O
of O
LCMV O
in O
the O
early O
stages O
of O
infection O
, O
they O
were O
capable O
of O
clearing O
LCMV O
infection O
. O

Despite O
the O
lack O
of O
type O
I O
IFN O
production O
, O
IRF7 O
KO O
mice O
generated O
normal O
CD4 O
( O
+ O
) O
T O
cell O
responses O
, O
and O
the O
expansion O
of O
naive O
CD8 O
( O
+ O
) O
T O
cells O
into O
primary O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
LCMV O
GP O
( O
33 O
- O
41 O
) O
was O
relatively O
normal O
. O

In O
contrast O
, O
the O
expansion O
of O
the O
LCMV O
NP396 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
was O
severely O
impaired O
in O
IRF7 O
KO O
mice O
. O

We O
demonstrated O
that O
this O
defective O
CD8 O
( O
+ O
) O
T O
cell O
response O
is O
due O
neither O
to O
an O
impaired O
antigen O
- O
presenting O
system O
nor O
to O
any O
intrinsic O
role O
of O
IRF7 O
in O
CD8 O
( O
+ O
) O
T O
cells O
. O

The O
lack O
of O
a O
type O
I O
IFN O
response O
in O
IRF7 O
KO O
mice O
did O
not O
affect O
the O
formation O
of O
memory O
CD8 O
( O
+ O
) O
T O
cells O
. O

Thus O
, O
the O
present O
study O
provides O
new O
insight O
into O
the O
impact O
of O
the O
innate O
immune O
system O
on O
viral O
pathogenesis O
and O
demonstrates O
the O
critical O
contribution O
of O
innate O
immunity O
in O
controlling O
virus O
replication O
in O
the O
early O
stages O
of O
infection O
, O
which O
may O
shape O
the O
quality O
of O
CD8 O
( O
+ O
) O
T O
cell O
responses O
. O

The O
transfer O
of O
T B
cell I
receptor I
( I
TCR I
) I
genes O
by O
viral O
vectors O
represents O
a O
promising O
technique O
to O
generate O
antigen O
- O
specific O
T O
cells O
for O
adoptive O
immunotherapy O
. O

The O
induction O
of O
strong O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
against O
infectious O
diseases O
and O
cancer O
has O
remained O
a O
major O
challenge O
. O

Depending O
on O
the O
source O
of O
antigen O
and O
the O
infectious O
agent O
, O
priming O
of O
CD8 O
( O
+ O
) O
T O
cells O
requires O
direct O
and O
/ O
or O
cross O
- O
presentation O
of O
antigenic O
peptides O
on O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
molecules O
by O
professional O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
. O

In O
this O
report O
, O
we O
analyzed O
the O
role O
of O
antigen O
stability O
on O
DNA O
vaccination O
and O
recombinant O
vaccinia B
virus I
( I
VV I
) I
infection O
using O
altered O
versions O
of O
the O
same O
antigen O
. O

The O
long O
- O
lived O
nucleoprotein B
( I
NP I
) I
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
be O
targeted O
for O
degradation O
by O
N O
- O
terminal O
fusion O
to O
ubiquitin O
or O
, O
as O
we O
show O
here O
, O
to O
the O
ubiquitin O
- O
like O
modifier O
FAT10 O
. O

In O
vivo O
, O
however O
, O
the O
highest O
induction O
of O
NP O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
was O
achieved O
in O
the O
presence O
of O
long O
- O
lived O
NP O
. O

Arenaviruses O
perturb O
innate O
antiviral O
defense O
by O
blocking O
induction O
of O
type B
I I
interferon I
( I
IFN I
) I
production O
. O

Accordingly O
, O
the O
arenavirus O
nucleoprotein B
( I
NP I
) I
was O
shown O
to O
block O
activation O
and O
nuclear O
translocation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
in O
response O
to O
virus O
infection O
. O

Consistent O
with O
previous O
studies O
, O
infection O
with O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
prevented O
phosphorylation O
of O
IRF3 O
in O
response O
to O
infection O
with O
Sendai O
virus O
, O
a O
strong O
inducer O
of O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
/ O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
pathway O
of O
innate O
antiviral O
signaling O
. O

Using O
a O
combination O
of O
coimmunoprecipitation O
and O
confocal O
microscopy O
, O
we O
found O
that O
LCMV O
NP O
associates O
with O
the O
I B
kappa I
B I
kinase I
( I
IKK I
) I
- O
related O
kinase O
IKK O
epsilon O
but O
that O
, O
rather O
unexpectedly O
, O
LCMV O
NP O
did O
not O
bind O
to O
the O
closely O
related O
TANK B
- I
binding I
kinase I
1 I
( I
TBK I
- I
1 I
) I
. O

LCMV O
NP O
bound O
the O
kinase O
domain O
( O
KD O
) O
of O
IKK O
epsilon O
( O
IKBKE O
) O
and O
blocked O
its O
autocatalytic O
activity O
and O
its O
ability O
to O
phosphorylate O
IRF3 O
, O
without O
undergoing O
phosphorylation O
. O

The O
RV144 O
trial O
demonstrated O
that O
an O
experimental O
AIDS O
vaccine O
can O
prevent O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
in O
humans O
. O

Because O
of O
its O
limited O
efficacy O
, O
further O
understanding O
of O
the O
mechanisms O
of O
preventive O
AIDS O
vaccines O
remains O
a O
priority O
, O
and O
nonhuman B
primate I
( I
NHP I
) I
models O
of O
lentiviral O
infection O
provide O
an O
opportunity O
to O
define O
immunogens O
, O
vectors O
, O
and O
correlates O
of O
immunity O
. O

In O
this O
study O
, O
we O
show O
that O
prime O
- O
boost O
vaccination O
with O
a O
mismatched O
SIV O
envelope B
( I
env I
) I
gene O
, O
derived O
from O
simian O
immunodeficiency O
virus O
SIVmac239 O
, O
prevents O
infection O
by O
SIVsmE660 O
intrarectally O
. O

Analysis O
of O
different O
gene O
- O
based O
prime O
- O
boost O
immunization O
regimens O
revealed O
that O
recombinant B
adenovirus I
type I
5 I
( I
rAd5 I
) I
prime O
followed O
by O
replication B
- I
defective I
lymphocytic I
choriomeningitis I
virus I
( I
rLCMV I
) I
boost O
elicited O
robust O
CD4 O
and O
CD8 O
T O
- O
cell O
and O
humoral O
immune O
responses O
. O

Arenaviruses O
include O
several O
causative O
agents O
of O
hemorrhagic B
fever I
( I
HF I
) I
disease O
in O
humans O
that O
are O
associated O
with O
high O
morbidity O
and O
significant O
mortality O
. O

We O
demonstrate O
in O
the O
accompanying O
paper O
that O
the O
prototype O
member O
in O
the O
family O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
disables O
the O
host O
innate O
defense O
by O
interfering O
with O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
production O
through O
inhibition O
of O
the O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
activation O
pathway O
and O
that O
the O
viral O
nucleoprotein B
( I
NP I
) I
alone O
is O
responsible O
for O
this O
inhibitory O
effect O
( O
C O
. O

In O
this O
report O
, O
we O
show O
that O
LCMV O
- O
NP O
, O
as O
well O
as O
NPs O
encoded O
by O
representative O
members O
of O
both O
Old B
World I
( I
OW I
) I
and O
New B
World I
( I
NW I
) I
arenaviruses O
, O
also O
inhibits O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
the O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
. O

Similar O
to O
the O
situation O
previously O
reported O
for O
IRF3 O
, O
Tacaribe B
virus I
NP I
( I
TCRV I
- I
NP I
) I
does O
not O
inhibit O
NF O
- O
kappa O
B O
nuclear O
translocation O
and O
transcriptional O
activity O
to O
levels O
comparable O
to O
those O
seen O
with O
other O
members O
in O
the O
family O
. O

The O
T O
cell O
granule O
exocytosis O
pathway O
is O
essential O
to O
control O
hepatotropic O
lymphocytic B
choriomeningitis I
virus I
strain I
WE I
( I
LCMV I
- I
WE I
) I
but O
also O
contributes O
to O
the O
observed O
pathology O
in O
mice O
. O

We O
demonstrate O
here O
that O
LCMV O
- O
immune O
T O
cells O
of O
interleukin B
- I
1 I
receptor I
( I
IL I
- I
1R I
) I
- O
deficient O
mice O
readily O
express O
transcripts O
for O
perforin O
and O
granzymes O
but O
only O
translate O
perforin O
, O
resulting O
in O
the O
lack O
of O
proapoptotic O
potential O
in O
vitro O
. O

transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
is O
another O
immunosuppressive O
cytokine O
known O
to O
impede O
both O
self O
- O
and O
tumor O
- O
specific O
T O
cells O
, O
but O
its O
role O
in O
regulating O
antiviral O
immunity O
is O
not O
entirely O
understood O
. O

Our O
results O
revealed O
that O
these O
inhibitors O
modestly O
elevate O
the O
number O
of O
antiviral O
T O
cells O
following O
infection O
with O
a O
persistent O
variant O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
but O
have O
no O
impact O
on O
viral O
clearance O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
the O
prototype O
arenavirus O
, O
and O
Lassa B
virus I
( I
LASV I
) I
, O
the O
causative O
agent O
of O
Lassa B
fever I
( I
LF I
) I
, O
have O
extensive O
strain O
diversity O
and O
significant O
variations O
in O
pathogenicity O
for O
humans O
and O
experimental O
animals O
. O

The O
WE O
strain O
of O
LCMV O
( O
LCMV O
- O
WE O
) O
, O
but O
not O
the O
Armstrong B
( I
Arm I
) I
strain O
, O
induces O
a O
fatal O
LF O
- O
like O
disease O
in O
rhesus O
macaques O
. O

Here O
we O
have O
shown O
that O
cells O
infected O
with O
LASV O
or O
with O
LCMV O
- O
WE O
suppressed O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
- O
dependent O
proinflammatory O
cytokine O
responses O
. O

The O
persisting O
isolate O
LCMV O
clone B
13 I
( I
CL13 I
) I
also O
failed O
to O
stimulate O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
in O
macrophages O
. O

interferon B
( I
IFN I
) I
regulatory O
factors O
( O
IRFs O
) O
are O
a O
family O
of O
transcription O
factors O
involved O
in O
regulating O
type O
I O
IFN O
genes O
and O
other O
genes O
participating O
in O
the O
early O
antiviral O
host O
response O
. O

To O
better O
understand O
the O
mechanisms O
involved O
in O
virus O
- O
induced O
central B
nervous I
system I
( I
CNS I
) I
inflammation O
, O
we O
studied O
the O
influence O
of O
IRFI O
, O
- O
3 O
, O
- O
7 O
, O
and O
- O
9 O
on O
the O
transcriptional O
activity O
of O
key O
genes O
encoding O
antiviral O
host O
factors O
in O
the O
CNS O
of O
mice O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

interferon B
( I
IFN I
) I
signaling O
is O
crucial O
for O
antiviral O
immunity O
. O

Here O
, O
we O
studied O
the O
roles O
of O
these O
signaling O
factors O
in O
the O
host O
response O
to O
systemic O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

In O
wild B
- I
type I
( I
WT I
) I
mice O
and O
mice O
lacking O
either O
STAT2 O
or O
IRF9 O
, O
LCMV O
infection O
was O
nonlethal O
, O
and O
the O
virus O
either O
was O
cleared O
( O
WT O
) O
or O
established O
persistence O
( O
STAT2 O
knockout O
[ O
KO O
] O
and O
IRF9 O
KO O
) O
. O

This O
lethal O
phenotype O
was O
unaltered O
by O
the O
coabsence O
of O
the O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
receptor O
and O
hence O
was O
not O
dependent O
on O
IFN O
- O
gamma O
. O

Clearance O
of O
LCMV O
is O
mediated O
normally O
by O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
contrast O
, O
depletion O
of O
CD4 O
( O
+ O
) O
T O
cells O
prevented O
lethality O
in O
LCMV O
- O
infected O
STAT1 O
KO O
mice O
and O
was O
associated O
with O
a O
reduction O
in O
tissue O
immune O
pathology O
. O

While O
all O
three O
factors O
are O
required O
to O
limit O
viral O
replication O
and O
spread O
, O
only O
STAT1 O
has O
the O
unique O
function O
of O
preventing O
the O
emergence O
of O
a O
lethal O
antiviral O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
. O

Several O
arenaviruses O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
, O
cause O
hemorrhagic B
fever I
( I
HF I
) I
disease O
in O
humans O
and O
pose O
a O
significant O
public O
health O
concern O
in O
regions O
where O
they O
are O
endemic O
. O

On O
the O
other O
hand O
, O
evidence O
indicates O
that O
the O
globally O
distributed O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
neglected O
human O
pathogen O
. O

The O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
/ O
Akt O
pathway O
participates O
in O
many O
cellular O
processes O
, O
including O
cell O
survival O
and O
differentiation O
, O
and O
also O
has O
been O
shown O
to O
play O
important O
roles O
in O
different O
steps O
of O
the O
life O
cycles O
of O
a O
variety O
of O
viruses O
. O

These O
findings O
, O
together O
with O
those O
previously O
reported O
for O
Junin B
virus I
( I
JUNV I
) I
, O
indicate O
that O
targeting O
the O
PI3K O
/ O
Akt O
pathway O
could O
represent O
a O
novel O
antiviral O
strategy O
to O
combat O
human O
- O
pathogenic O
arenaviruses O
. O

Both O
the O
large B
( I
L I
) I
and O
small B
( I
S I
) I
genome O
segments O
use O
an O
ambisense O
coding O
strategy O
to O
direct O
the O
synthesis O
of O
two O
viral O
proteins O
. O

The O
L O
segment O
encodes O
the O
virus O
polymerase O
( O
L O
protein O
) O
and O
the O
matrix O
Z O
protein O
, O
whereas O
the O
S O
segment O
encodes O
the O
nucleoprotein B
( I
NP I
) I
and O
the O
glycoprotein B
precursor I
( I
GPC I
) I
. O

NPs O
are O
the O
most O
abundant O
viral O
protein O
in O
infected O
cells O
and O
virions O
and O
encapsidate O
genomic O
RNA O
species O
to O
form O
an O
NP O
- O
RNA O
complex O
that O
, O
together O
with O
the O
virus O
L O
polymerase O
, O
forms O
the O
virus O
ribonucleoprotein B
( I
RNP I
) I
core O
capable O
of O
directing O
both O
replication O
and O
transcription O
of O
the O
viral O
genome O
. O

Here O
we O
document O
self O
- O
association O
( O
homotypic O
interaction O
) O
of O
the O
NP O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
as O
well O
as O
those O
of O
the O
hemorrhagic B
fever I
( I
HF I
) I
arenaviruses O
Lassa B
virus I
( I
LASV I
) I
and O
Machupo B
virus I
( I
MACV I
) I
. O

We O
also O
show O
heterotypic O
interaction O
between O
NPs O
from O
both O
closely O
( O
LCMV O
and O
LASV O
) O
and O
distantly O
( O
LCMV O
and O
MACV O
) O
genetically O
related O
arenaviruses O
. O

The O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
system O
constitutes O
one O
of O
the O
most O
widely O
used O
models O
for O
the O
study O
of O
infectious O
disease O
and O
the O
regulation O
of O
virus O
- O
specific O
T O
cell O
immunity O
. O

Here O
, O
we O
have O
reevaluated O
the O
contribution O
of O
CD28 O
- O
CD80 O
/ O
86 O
costimulation O
in O
the O
LCMV O
system O
by O
use O
of O
CD80 O
/ O
86 O
- O
deficient O
mice O
, O
and O
our O
results O
demonstrate O
that O
a O
disruption O
of O
CD28 O
- O
CD80 O
/ O
86 O
signaling O
compromises O
the O
magnitude O
, O
phenotype O
, O
and O
/ O
or O
functionality O
of O
LCMVspecific O
CD8 O
( O
+ O
) O
and O
/ O
or O
CD4 O
( O
+ O
) O
T O
cell O
populations O
in O
all O
stages O
of O
the O
T O
cell O
response O
. O

Notably O
, O
a O
profound O
inhibition O
of O
secondary O
T O
cell O
immunity O
in O
LCMV O
- O
immune O
CD80 O
/ O
86 O
- O
deficient O
mice O
emerged O
as O
a O
composite O
of O
both O
defective O
memory O
T O
cell O
development O
and O
a O
specific O
requirement O
for O
CD80 O
but O
not O
CD86 O
in O
the O
recall O
response O
, O
while O
a O
related O
experimental O
scenario O
of O
CD28 O
- O
dependent O
yet O
CD80 O
/ O
86 O
- O
independent O
secondary O
CD8 O
( O
+ O
) O
T O
cell O
immunity O
suggests O
the O
existence O
of O
a O
CD28 O
ligand O
other O
than O
CD80 O
/ O
86 O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
regulatory O
T O
cells O
( O
TREGs O
) O
, O
the O
homeostasis O
of O
which O
is O
altered O
in O
CD80 O
/ O
86 O
( O
- O
/ O
- O
) O
mice O
, O
contribute O
to O
restrained O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
in O
the O
presence O
of O
CD80 O
/ O
86 O
. O

Although O
O O
- O
mannosylated O
dystroglycan O
is O
a O
receptor O
for O
Lassa O
virus O
, O
a O
causative O
agent O
of O
Lassa O
fever O
, O
recent O
findings O
suggest O
the O
existence O
of O
an O
alternative O
receptor O
( O
s O
) O
. O

Here O
we O
identified O
four O
molecules O
as O
receptors O
for O
Lassa O
virus O
: O
Axl O
and O
Tyro3 O
, O
from O
the O
TAM O
family O
, O
and O
dendritic O
cell O
- O
specific O
intercellular O
adhesion O
molecule O
3 O
- O
grabbing O
nonintegrin O
( O
DC O
- O
SIGN O
) O
and O
liver O
and O
lymph B
node I
sinusoidal I
endothelial I
calcium I
- I
dependent I
lectin I
( I
LSECtin I
) I
, O
from O
the O
C O
- O
type O
lectin O
family O
. O

Several O
arenaviruses O
cause O
hemorrhagic B
fever I
( I
HF I
) I
disease O
in O
humans O
that O
is O
associated O
with O
high O
morbidity O
and O
significant O
mortality O
. O

Arenavirus O
nucleoprotein B
( I
NP I
) I
, O
the O
most O
abundant O
viral O
protein O
in O
infected O
cells O
and O
virions O
, O
encapsidates O
the O
viral O
genome O
RNA O
, O
and O
this O
NP O
- O
RNA O
complex O
, O
together O
with O
the O
viral O
L O
polymerase O
, O
forms O
the O
viral B
ribonucleoprotein I
( I
vRNP I
) I
that O
directs O
viral O
RNA O
replication O
and O
gene O
transcription O
. O

Formation O
of O
infectious O
arenavirus O
progeny O
requires O
packaging O
of O
vRNPs O
into O
budding O
particles O
, O
a O
process O
in O
which O
arenavirus O
matrix O
- O
like O
protein O
( O
Z O
) O
plays O
a O
central O
role O
. O

In O
the O
present O
study O
, O
we O
have O
characterized O
the O
NP O
- O
Z O
interaction O
for O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

The O
LCMV O
NP O
domain O
that O
interacted O
with O
Z O
overlapped O
with O
a O
previously O
documented O
C O
- O
terminal O
domain O
that O
counteracts O
the O
host O
type B
I I
interferon I
( I
IFN I
) I
response O
. O

A O
similar O
NP O
- O
Z O
interaction O
was O
confirmed O
for O
the O
HF O
arenavirus O
Lassa B
virus I
( I
LASV I
) I
. O

Currently O
, O
we O
have O
limited O
understanding O
of O
how O
Toll B
- I
like I
receptor I
( I
TLR I
) I
engagement O
by O
microbial O
products O
influences O
the O
immune O
response O
during O
a O
concurrent O
virus O
infection O
. O

In O
this O
study O
, O
we O
established O
that O
dual O
TLR2 O
plus O
TLR3 O
( O
designated O
TLR2 O
+ O
3 O
) O
stimulation O
alters O
the O
immunodominance O
hierarchies O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
epitopes O
by O
reducing O
NP396 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
and O
shifting O
it O
to O
a O
subdominant O
position O
. O

Taken O
together O
, O
our O
data O
demonstrate O
a O
novel O
role O
for O
TLR O
ligands O
in O
regulating O
antiviral O
CD8 O
( O
+ O
) O
T O
cell O
responses O
due O
to O
the O
regulation O
of O
the O
cross O
- O
presentation O
of O
cell O
- O
associated O
antigens O
. O

Accumulating O
evidence O
suggests O
that O
hypoxia O
- O
inducible O
factor O
( O
HIF O
) O
modulates O
gene O
expression O
of O
the O
viruses O
that O
pass O
through O
a O
DNA O
stage O
, O
contain O
hypoxia O
- O
responsive O
promoter O
elements O
, O
and O
replicate O
in O
the O
nucleus O
. O

Here O
we O
show O
that O
hypoxia O
can O
influence O
the O
gene O
expression O
and O
transmission O
of O
the O
cytoplasmic O
RNA O
virus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
which O
is O
a O
neglected O
human O
pathogen O
and O
teratogen O
. O

Here O
, O
we O
defined O
the O
L O
- O
binding O
domain O
of O
Tacaribe B
virus I
( I
TCRV I
) I
Z O
protein O
and O
the O
structural O
requirements O
mediating O
Z O
homo O
- O
oligomerization O
. O

We O
also O
found O
that O
Z O
protein O
from O
either O
TCRV O
or O
the O
pathogenic O
Junin B
virus I
( I
JUNV I
) I
self O
- O
associates O
into O
oligomeric O
forms O
in O
mammalian O
cells O
. O

Lassa B
virus I
( I
LASV I
) I
causing O
hemorrhagic O
Lassa O
fever O
in O
West O
Africa O
, O
Mopeia B
virus I
( I
MOPV I
) I
from O
East O
Africa O
, O
and O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
are O
the O
main O
representatives O
of O
the O
Old O
World O
arenaviruses O
. O

, O
the O
genome O
, O
nucleoprotein B
( I
NP I
) I
, O
and O
L O
protein O
, O
interact O
. O

Analysis O
of O
LASV O
/ O
LCMV O
NP O
chimeras O
identified O
a O
single O
LCMV O
- O
specific O
NP O
residue O
( O
Ile O
- O
53 O
) O
and O
the O
C O
terminus O
of O
NP O
( O
residues O
340 O
to O
558 O
) O
as O
being O
essential O
for O
LCMV O
L O
protein O
function O
. O

Although O
cellular O
immunity O
to O
acute O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
has O
been O
well O
characterized O
in O
experimental O
studies O
in O
mice O
, O
the O
T O
cell O
response O
to O
this O
virus O
in O
humans O
is O
incompletely O
understood O
. O

Thus O
, O
we O
analyzed O
the O
breadths O
, O
magnitudes O
, O
and O
differentiation O
phenotypes O
of O
memory O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
in O
three O
human O
donors O
displaying O
a O
variety O
of O
disease O
outcomes O
after O
accidental O
needle O
stick O
injury O
or O
exposure O
to O
LCMV O
. O

First O
, O
we O
were O
able O
to O
detect O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
responses O
directly O
ex O
vivo O
at O
4 O
to O
8 O
years O
after O
exposure O
, O
demonstrating O
the O
longevity O
of O
T O
cell O
memory O
in O
humans O
. O

Second O
, O
unlike O
in O
murine O
models O
of O
LCMV O
infection O
, O
we O
found O
that O
the O
breadths O
of O
memory O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
responses O
were O
not O
significantly O
different O
from O
one O
another O
. O

Third O
, O
it O
seemed O
that O
the O
overall O
CD8 O
( O
+ O
) O
T O
cell O
response O
was O
augmented O
with O
increasing O
severity O
of O
disease O
, O
while O
the O
LCMV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cell O
response O
magnitude O
was O
highly O
variable O
between O
the O
three O
different O
donors O
. O

Next O
, O
we O
found O
that O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
three O
donors O
analyzed O
seemed O
to O
undergo O
an O
effector O
memory O
differentiation O
program O
distinct O
from O
that O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

Finally O
, O
the O
levels O
of O
expression O
of O
memory O
, O
costimulatory O
, O
and O
inhibitory O
receptors O
on O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cell O
subsets O
, O
in O
some O
instances O
, O
correlated O
with O
disease O
outcome O
. O

These O
data O
demonstrate O
for O
the O
first O
time O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
T O
cells O
in O
infected O
humans O
and O
begin O
to O
provide O
new O
insights O
into O
memory O
T O
cell O
responses O
following O
an O
acute O
virus O
infection O
. O

All B
- I
trans I
- I
retinoic I
acid I
( I
ATRA I
) I
has O
been O
shown O
to O
act O
physiologically O
to O
induce O
the O
expression O
of O
gut O
- O
homing O
receptors O
on O
lymphocytes O
. O

We O
tested O
whether O
the O
administration O
of O
exogenous O
ATRA O
during O
a O
systemic O
vaccination O
of O
mice O
could O
enhance O
the O
generation O
of O
mucosal O
CD8 O
( O
+ O
) O
T O
cell O
immunity O
, O
which O
might O
represent O
a O
strategy O
for O
establishing O
better O
protection O
from O
viral O
infection O
via O
mucosal O
routes O
. O

ATRA O
induced O
the O
expression O
of O
CCR9 O
and O
alpha O
4 O
beta O
7 O
on O
both O
mouse O
and O
human O
CD8 O
( O
+ O
) O
T O
cells O
activated O
in O
vitro O
. O

The O
administration O
of O
ATRA O
to O
mice O
during O
in O
vivo O
priming O
with O
a O
replication O
- O
defective O
recombinant O
adenovirus O
vector O
expressing O
the O
lymphocytic B
choriomeningitis I
virus I
glycoprotein I
( I
LCMVgp I
) I
( O
Ad5gp O
) O
increased O
numbers O
of O
both O
effector O
and O
memory O
T O
cells O
in O
intestinal O
mucosal O
tissues O
and O
showed O
higher O
frequencies O
of O
systemic O
central O
memory O
- O
like O
T O
cells O
that O
exhibited O
enhanced O
proliferation O
during O
boosting O
immunization O
with O
recombinant O
modified O
vaccinia O
virus O
Ankara O
expressing O
LCMVgp O
( O
MVAgp O
) O
. O

Mice O
that O
received O
ATRA O
during O
Ad5gp O
vaccination O
were O
more O
resistant O
to O
intravaginal O
challenge O
by O
recombinant O
vaccinia O
virus O
expressing O
LCMVgp O
( O
VVgp O
) O
, O
reflecting O
in O
part O
stronger O
T O
cell O
recall O
responses O
in O
situ O
. O

We O
investigated O
the O
effect O
of O
a O
transient O
CD70 O
blockade O
during O
an O
acute O
or O
a O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
in O
mice O
. O

Blockade O
of O
this O
pathway O
during O
acute O
LCMV O
infection O
( O
Armstrong O
strain O
) O
resulted O
in O
delayed O
T O
cell O
responses O
and O
decreased O
CD127 O
( O
interleukin O
- O
7 O
receptor O
alpha O
[ O
IL O
- O
7R O
alpha O
] O
chain O
) O
conversion O
. O

Reduced O
proliferation O
was O
not O
dependent O
on O
Fas O
- O
FasL O
- O
or O
Tumor B
necrosis I
factor I
( I
TNF I
) I
- O
induced O
activation O
- O
induced O
cell O
death O
or O
on O
deficiencies O
of O
antigen O
presentation O
. O

Inhibition O
of O
proliferation O
could O
be O
simulated O
by O
exposure O
of O
T O
cells O
to O
the O
Toll O
- O
like O
receptor O
agonist O
and O
type B
I I
interferon I
( I
IFN I
) I
inducer O
poly O
( O
I O
center O
dot O
C O
) O
. O

T O
cells O
lacking O
IFN O
- O
alpha O
/ O
beta O
receptors O
resisted O
both O
the O
suppressive O
effects O
of O
preexposure O
to O
poly O
( O
I O
center O
dot O
C O
) O
and O
the O
stimulatory O
effects O
of O
type O
I O
IFN O
, O
indicating O
that O
the O
timing O
of O
exposure O
to O
IFN O
can O
have O
negative O
or O
positive O
effects O
on O
T O
cell O
proliferation O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
- O
based O
oncolytic O
virotherapy O
has O
the O
potential O
to O
significantly O
improve O
the O
prognosis O
of O
aggressive O
malignancies O
such O
as O
brain O
cancer O
. O

Given O
that O
this O
neurotropism O
is O
attributed O
to O
the O
glycoprotein O
VSV O
- O
G O
, O
VSV O
was O
pseudotyped O
with O
the O
nonneurotropic O
envelope O
glycoprotein O
of O
the O
lymphocytic O
choriomeningitis O
virus O
( O
LCMV O
- O
GP O
- O
> O
VSV O
- O
GP O
) O
. O

The O
prototypic O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
is O
a O
model O
for O
dissecting O
virus O
- O
host O
interactions O
in O
persistent O
and O
acute O
disease O
. O

While O
residues O
in O
Z O
required O
for O
viral O
budding O
have O
been O
described O
, O
residues O
that O
govern O
the O
Z O
matrix O
function O
( O
s O
) O
have O
yet O
to O
be O
fully O
elucidated O
. O

Our O
findings O
provide O
direct O
experimental O
evidence O
supporting O
a O
role O
for O
Z O
in O
the O
modulation O
of O
the O
activity O
of O
the O
viral O
ribonucleoprotein B
( I
RNP I
) I
complex O
and O
its O
packaging O
into O
mature O
infectious O
viral O
particles O
. O

We O
utilized O
retrovirus O
- O
resistant O
I O
/ O
LnJ O
mice O
, O
which O
control O
infection O
with O
mouse B
mammary I
tumor I
virus I
( I
MMTV I
) I
and O
murine B
leukemia I
virus I
( I
MuLV I
) I
via O
an O
adaptive O
immune O
mechanism O
, O
to O
assess O
the O
contribution O
of O
cellular O
responses O
and O
virus O
- O
neutralizing O
antibodies B
( I
Abs I
) I
to O
the O
control O
of O
retroviral O
infection O
. O

During O
virus O
particle O
assembly O
, O
the O
arenavirus O
nucleoprotein B
( I
NP I
) I
associates O
with O
the O
viral O
genome O
to O
form O
nucleocapsids O
, O
which O
ultimately O
become O
incorporated O
into O
new O
virions O
at O
the O
cell O
membrane O
. O

Virion O
release O
is O
facilitated O
by O
the O
viral O
matrix O
Z O
protein O
through O
its O
interaction O
with O
the O
cellular O
endosomal B
sorting I
complex I
required I
for I
transport I
( I
ESCRT I
) I
machinery O
. O

Here O
, O
we O
demonstrate O
that O
ALIX O
/ O
AIP1 O
, O
an O
ESCRT O
- O
associated O
host O
protein O
, O
is O
required O
for O
the O
incorporation O
of O
the O
NP O
of O
Mopeia O
virus O
, O
a O
close O
relative O
of O
Lassa O
virus O
, O
into O
Z O
- O
induced O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Tacaribe B
virus I
( I
TCRV I
) I
belongs O
to O
the O
Arenaviridae O
family O
. O

Its O
bisegmented O
negative O
- O
stranded O
RNA O
genome O
encodes O
the O
nucleoprotein B
( I
N I
) I
, O
the O
precursor O
of O
the O
envelope O
glycoproteins O
, O
the O
polymerase O
( O
L O
) O
, O
and O
a O
RING O
finger O
matrix O
( O
Z O
) O
protein O
. O

We O
have O
previously O
shown O
that O
the O
interaction O
between O
N O
and O
Z O
is O
required O
for O
assembly O
of O
infectious O
virus B
- I
like I
particles I
( I
VLPs I
) I
( O
J O
. O

A O
series O
of O
deletions O
and O
point O
mutations O
were O
introduced O
into O
the O
N O
- O
coding O
sequence O
, O
and O
the O
ability O
of O
the O
mutants O
to O
sustain O
heterotypic O
( O
N O
- O
Z O
) O
or O
homotypic O
( O
N O
- O
N O
) O
interactions O
was O
analyzed O
. O

Moreover O
, O
further O
analysis O
of O
this O
region O
showed O
that O
the O
integrity O
of O
a O
putative O
zinc O
- O
finger O
motif O
, O
as O
well O
as O
its O
amino O
- O
flanking O
sequence O
( O
residues O
461 O
to O
489 O
) O
, O
are O
critical O
for O
Z O
binding O
and O
N O
incorporation O
into O
VLPs O
. O

In O
this O
regard O
, O
using O
reciprocal O
coimmunoprecipitation O
analysis O
, O
we O
identified O
a O
28 O
- O
residue O
region O
predicted O
to O
form O
a O
coiled O
- O
coil O
domain O
( O
residues O
92 O
to O
119 O
) O
as O
a O
newly O
recognized O
molecular O
determinant O
of O
N O
homotypic O
interactions O
. O

Several O
arenaviruses O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
and O
Junin O
virus O
in O
West O
Africa O
and O
Argentina O
, O
respectively O
, O
cause O
hemorrhagic B
fever I
( I
HF I
) I
disease O
in O
humans O
that O
is O
associated O
with O
high O
morbidity O
and O
significant O
mortality O
. O

The O
investigation O
of O
antiviral O
strategies O
to O
combat O
HF O
arenaviruses O
is O
hampered O
by O
the O
requirement O
of O
biosafety B
level I
4 I
( I
BSL I
- I
4 I
) I
facilities O
to O
work O
with O
these O
viruses O
. O

To O
explore O
this O
concept O
, O
we O
have O
developed O
a O
recombinant O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
( O
rLCMV O
Delta O
GP O
/ O
GFP O
) O
where O
we O
replaced O
the O
viral O
glycoprotein B
( I
GP I
) I
with O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
. O

The O
sensitivity O
of O
the O
GFP O
- O
based O
microneutralization O
assay O
we O
developed O
was O
similar O
to O
that O
obtained O
with O
a O
conventionally O
used O
focus B
reduction I
neutralization I
( I
FRNT I
) I
assay O
. O

Valproic B
acid I
( I
VPA I
) I
is O
a O
short O
- O
chain O
fatty O
acid O
commonly O
used O
for O
treatment O
of O
neurological O
disorders O
. O

VPA O
drastically O
inhibited O
multiplication O
of O
all O
the O
enveloped O
viruses O
tested O
, O
including O
the O
zoonotic O
lymphocytic O
choriomeningitis O
virus O
and O
West B
Nile I
virus I
( I
WNV I
) I
, O
while O
it O
did O
not O
affect O
infection O
by O
the O
nonenveloped O
viruses O
assayed O
. O

Here O
, O
we O
investigated O
the O
role O
of O
the O
host O
cell O
' O
s O
unfolded B
protein I
response I
( I
UPR I
) I
in O
infection O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

In O
mammalian O
cells O
, O
the O
endoplasmic B
reticulum I
( I
ER I
) I
chaperone O
protein O
GRP78 O
/ O
BiP O
functions O
as O
the O
principal O
sensor O
for O
the O
induction O
of O
the O
UPR O
and O
interacts O
with O
three O
mediators O
: O
kinase O
/ O
endonuclease O
inositol B
- I
requiring I
protein I
1 I
( I
IRE1 I
) I
, O
PKR B
- I
like I
ER I
kinase I
( I
PERK I
) I
, O
and O
activating B
transcription I
factor I
6 I
( I
ATF6 I
) I
. O

Expression O
of O
individual O
LCMV O
proteins O
revealed O
that O
the O
viral O
glycoprotein B
precursor I
( I
GPC I
) I
, O
but O
not O
that O
of O
other O
viral O
proteins O
, O
was O
responsible O
for O
the O
induction O
of O
ATF6 O
. O

To O
address O
a O
possible O
role O
of O
ATF6 O
signaling O
in O
LCMV O
infection O
, O
we O
used O
cells O
deficient O
in O
site B
2 I
protease I
( I
S2P I
) I
, O
a O
metalloprotease O
required O
for O
the O
activation O
of O
ATF6 O
. O

Insertion O
of O
5 O
or O
10 O
amino O
acid O
residues O
was O
tolerated O
at O
seven O
sites O
( O
S407 O
, O
G446 O
, O
G467 O
, O
G774 O
, O
G939 O
, O
S1952 O
, O
and O
V2074 O
in O
Lassa O
virus O
AV O
) O
. O

Arenaviruses O
merit O
interest O
as O
clinically O
important O
human O
pathogens O
and O
include O
several O
causative O
agents O
, O
chiefly O
Lassa B
virus I
( I
LASV I
) I
, O
of O
hemorrhagic O
fever O
disease O
in O
humans O
. O

The O
arenavirus O
glycoprotein B
( I
GP I
) I
precursor O
GPC O
is O
processed O
by O
the O
cellular O
site B
1 I
protease I
( I
S1P I
) I
to O
generate O
the O
peripheral O
virion O
attachment O
protein O
GP1 O
and O
the O
fusion O
- O
active O
transmembrane O
protein O
GP2 O
, O
which O
is O
critical O
for O
production O
of O
infectious O
progeny O
and O
virus O
propagation O
. O

PF O
- O
429242 O
efficiently O
prevented O
the O
processing O
of O
GPC O
from O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
LASV O
, O
which O
correlated O
with O
the O
compound O
' O
s O
potent O
antiviral O
activity O
against O
LCMV O
and O
LASV O
in O
cultured O
cells O
. O

The O
arenavirus O
envelope O
glycoprotein B
( I
GPC I
) I
initiates O
infection O
in O
the O
host O
cell O
through O
pH O
- O
induced O
fusion O
of O
the O
viral O
and O
endosomal O
membranes O
. O

As O
in O
other O
class O
I O
viral O
fusion O
proteins O
, O
this O
process O
proceeds O
through O
a O
structural O
reorganization O
in O
GPC O
in O
which O
the O
ectodomain O
of O
the O
transmembrane O
fusion O
subunit O
( O
G2 O
) O
engages O
the O
host O
cell O
membrane O
and O
subsequently O
refolds O
to O
form O
a O
highly O
stable O
six O
- O
helix O
bundle O
structure O
that O
brings O
the O
two O
membranes O
into O
apposition O
for O
fusion O
. O

Rather O
, O
Western O
blot O
analysis O
using O
recombinant O
proteins O
and O
a O
panel O
of O
alanine O
- O
scanning O
GPC O
mutants O
revealed O
that O
F100G5 O
binding O
is O
dependent O
on O
an O
invariant O
lysine O
residue O
( O
K283 O
) O
near O
the O
N O
terminus O
of O
G2 O
, O
in O
the O
so O
- O
called O
fusion O
peptide O
that O
inserts O
into O
the O
host O
cell O
membrane O
during O
the O
fusion O
process O
. O

murine B
norovirus I
( I
MNV I
) I
is O
the O
only O
norovirus O
to O
date O
that O
efficiently O
infects O
cells O
in O
culture O
. O

To O
elucidate O
the O
productive O
route O
of O
infection O
for O
MNV O
- O
1 O
into O
murine O
macrophages O
, O
we O
used O
a O
neutral B
red I
( I
NR I
) I
infectious O
center O
assay O
and O
pharmacological O
inhibitors O
in O
combination O
with O
dominant B
- I
negative I
( I
DN I
) I
and O
small B
interfering I
RNA I
( I
siRNA I
) I
constructs O
to O
show O
that O
clathrin O
- O
and O
caveolin O
- O
mediated O
endocytosis O
did O
not O
play O
a O
role O
in O
entry O
. O

Profound O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
- O
dependent O
attrition O
of O
memory O
CD8 O
and O
CD4 O
T O
cells O
occurs O
early O
during O
many O
infections O
. O

It O
is O
dramatic O
at O
2 O
to O
4 O
days O
following O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
of O
mice O
and O
can O
be O
elicited O
by O
the O
IFN O
- O
inducing O
Toll O
receptor O
agonist O
poly O
( O
I O
: O
C O
) O
. O

Instead O
, O
a O
high O
frequency O
of O
annexin O
V O
- O
reactive O
CD8 O
alpha O
( O
+ O
) O
dendritic B
cells I
( I
DCs I
) I
, O
which O
are O
known O
to O
be O
highly O
phagocytic O
, O
accumulated O
in O
the O
spleen O
as O
the O
memory O
T O
cell O
populations O
disappeared O
. O

After O
short O
in O
vitro O
incubation O
, O
memory O
phenotype O
T O
cells O
isolated O
from O
LCMV O
- O
infected O
mice O
( O
day O
3 O
) O
or O
mice O
treated O
with O
poly O
( O
I O
: O
C O
) O
( O
12 O
h O
) O
displayed O
substantial O
DNA O
fragmentation O
, O
as O
detected O
by O
terminal O
deoxynucleotidyltransferase O
- O
mediated O
dUTP O
- O
biotin O
nick O
end O
labeling O
( O
TUNEL O
) O
assay O
, O
compared O
to O
T O
cells O
isolated O
from O
uninfected O
mice O
, O
indicating O
a O
role O
for O
apoptosis O
in O
the O
memory O
T O
cell O
attrition O
. O

interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
is O
an O
important O
anti O
- O
inflammatory O
molecule O
that O
can O
cause O
immunosuppression O
and O
long O
- O
term O
pathogen O
persistence O
during O
chronic O
infection O
of O
mice O
with O
viruses O
such O
as O
lymphocytic O
choriomeningitis O
virus O
. O

We O
found O
that O
IL O
- O
10 O
plays O
a O
detrimental O
role O
in O
host O
responses O
to O
acute O
influenza O
A O
virus O
since O
IL O
- O
10 O
( O
- O
/ O
- O
) O
mice O
had O
improved O
viral O
clearance O
and O
survival O
after O
infection O
compared O
to O
wild O
- O
type O
mice O
. O

Enhanced O
viral O
clearance O
in O
IL O
- O
10 O
( O
- O
/ O
- O
) O
mice O
was O
not O
correlated O
with O
increased O
CD4 O
( O
+ O
) O
or O
CD8 O
( O
+ O
) O
T O
- O
cell O
recruitment O
into O
the O
lung O
but O
was O
correlated O
with O
increased O
pulmonary O
anti O
- O
influenza O
virus O
antibody O
titers O
, O
and O
this O
was O
dependent O
upon O
the O
presence O
of O
T O
cells O
, O
primarily O
CD4 O
( O
+ O
) O
T O
cells O
. O

In O
addition O
, O
virus O
- O
specific O
antibody O
produced O
during O
the O
early O
stages O
of O
infection O
in O
the O
respiratory O
tract O
of O
IL O
- O
10 O
( O
- O
/ O
- O
) O
but O
not O
wild O
- O
type O
mice O
was O
sufficient O
to O
mediate O
passive O
protection O
against O
viral O
challenge O
of O
naive O
mice O
. O

For O
several O
arenaviruses O
, O
virus B
- I
like I
particle I
( I
VLP I
) I
formation O
requires O
the O
viral O
matrix O
Z O
protein O
. O

Here O
, O
we O
show O
that O
the O
expression O
of O
the O
Z O
protein O
and O
nucleoprotein B
( I
NP I
) I
of O
Mopeia O
virus O
, O
a O
close O
relative O
of O
the O
pathogenic O
Lassa O
virus O
, O
resulted O
in O
the O
highly O
selective O
incorporation O
of O
the O
NP O
protein O
into O
Z O
protein O
- O
induced O
VLPs O
. O

We O
show O
that O
Lassa O
virus O
enters O
polarized O
Madin B
- I
Darby I
canine I
kidney I
( I
MDCK I
) I
cells O
mainly O
via O
the O
basolateral O
route O
, O
consistent O
with O
the O
basolateral O
localization O
of O
the O
cellular O
Lassa O
virus O
receptor O
alpha O
- O
dystroglycan O
. O

Optimal O
induction O
of O
T O
- O
cell O
responses O
involves O
the O
action O
of O
type O
I O
interferons O
( O
IFN O
- O
I O
) O
. O

Influenza O
virus O
expressed O
nonstructural B
protein I
1 I
( I
NS1 I
) I
functions O
as O
an O
inhibitor O
of O
IFN O
- O
I O
and O
promotes O
viral O
growth O
. O

We O
wanted O
to O
examine O
the O
priming O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
influenza O
virus O
in O
the O
absence O
of O
this O
inhibition O
of O
IFN O
- O
I O
production O
. O

Antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
expanded O
upon O
rechallenge O
and O
generated O
increased O
protective O
memory O
T O
- O
cell O
populations O
after O
boosting O
. O

The O
main O
targets O
were O
acidic O
( O
Asp O
and O
Glu O
) O
and O
basic O
residues O
( O
Lys O
and O
Arg O
) O
known O
to O
form O
catalytic O
and O
binding O
sites O
of O
capping O
enzymes O
and O
endoribonucleases O
. O

Seven O
residues O
( O
Asp O
- O
89 O
, O
Glu O
- O
102 O
, O
Asp O
- O
119 O
, O
Lys O
- O
122 O
, O
Asp O
- O
129 O
, O
Glu O
- O
180 O
, O
and O
Arg O
- O
185 O
) O
were O
selectively O
important O
for O
mRNA O
synthesis O
. O

Moreover O
, O
lower O
expression O
of O
PD O
- O
L1 O
in O
some O
locations O
, O
such O
as O
the O
bone O
marrow O
, O
favored O
the O
survival O
of O
PD O
- O
1 O
( O
Hi O
) O
exhausted O
CD8 O
T O
cells O
, O
suggesting O
that O
some O
anatomical O
sites O
might O
provide O
a O
survival O
niche O
for O
subpopulations O
of O
exhausted O
CD8 O
T O
cells O
. O

For O
recognition O
of O
infected O
cells O
by O
CD8 O
T O
cells O
, O
antigenic O
peptides O
are O
presented O
at O
the O
cell O
surface O
, O
bound O
to O
major B
histocompatibility I
complex I
class I
I I
( I
MHC I
- I
I I
) I
molecules O
. O

The O
molecular O
mechanisms O
by O
which O
immunoevasins O
interfere O
with O
the O
MHC O
- O
I O
pathway O
suggest O
, O
however O
, O
that O
this O
downmodulation O
may O
be O
secondary O
to O
an O
interruption O
of O
turnover O
replenishment O
and O
that O
hindrance O
of O
the O
vesicular O
transport O
of O
recently O
generated O
peptide B
- I
MHC I
( I
pMHC I
) I
complexes O
to O
the O
cell O
surface O
is O
the O
actual O
function O
of O
immunoevasins O
. O

Here O
we O
have O
used O
the O
model O
of O
murine B
cytomegalovirus I
( I
MCMV I
) I
infection O
to O
provide O
experimental O
evidence O
for O
this O
hypothesis O
. O

Clade O
B O
of O
the O
New O
World O
arenaviruses O
contains O
both O
pathogenic O
and O
nonpathogenic O
members O
, O
whose O
surface O
glycoproteins B
( I
GPs I
) I
are O
characterized O
by O
different O
abilities O
to O
use O
the O
human B
transferrin I
receptor I
type I
1 I
( I
hTfR1 I
) I
protein O
as O
a O
receptor O
. O

We O
identified O
a O
central O
region O
( O
residues O
85 O
to O
221 O
) O
in O
the O
Guanarito O
virus O
GP1 O
that O
was O
sufficient O
to O
interact O
with O
hTfR1 O
, O
with O
residues O
159 O
to O
221 O
being O
essential O
. O

Although O
much O
is O
known O
about O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
and O
the O
subsequent O
immune O
response O
in O
its O
natural O
murine O
host O
, O
some O
crucial O
aspects O
of O
LCMV O
- O
mediated O
pathogenesis O
remain O
undefined O
, O
including O
the O
underlying O
basis O
of O
the O
characteristic O
central O
nervous O
system O
disease O
that O
occurs O
following O
intracerebral O
( O
i O
. O

While O
immunohistochemical O
analysis O
revealed O
periventricular O
inflammation O
and O
a O
loss O
of O
integrity O
of O
the O
blood B
- I
brain I
barrier I
( I
BBB I
) I
, O
these O
events O
preceded O
seizures O
by O
2 O
to O
3 O
days O
. O

A O
crucial O
step O
in O
the O
arenavirus O
life O
cycle O
is O
the O
biosynthesis O
of O
the O
viral O
envelope O
glycoprotein B
( I
GP I
) I
responsible O
for O
virus O
attachment O
and O
entry O
. O

Processing O
of O
the O
GP B
precursor I
( I
GPC I
) I
by O
the O
cellular O
proprotein O
convertase O
site B
1 I
protease I
( I
S1P I
) I
, O
also O
known O
as O
subtilisin B
- I
kexin I
- I
isozyme I
1 I
( I
SKI I
- I
1 I
) I
, O
is O
crucial O
for O
cell O
- O
to O
- O
cell O
propagation O
of O
infection O
and O
production O
of O
infectious O
virus O
. O

Here O
, O
we O
sought O
to O
evaluate O
arenavirus O
GPC O
processing O
by O
S1P O
as O
a O
target O
for O
antiviral O
therapy O
using O
a O
recently O
developed O
peptide O
- O
based O
S1P O
inhibitor O
, O
decanoyl O
( O
dec O
) O
- O
RRLL O
- O
chloromethylketone B
( I
CMK I
) I
, O
and O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

A O
productiveCD8 O
( O
+ O
) O
T O
- O
cell O
response O
to O
a O
viral O
infection O
requires O
rapid O
division O
and O
proliferation O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Tetramer O
- O
based O
enrichment O
assays O
have O
recently O
given O
estimates O
of O
the O
numbers O
of O
peptide O
- O
major O
histocompatibility O
complex O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
naive O
mice O
, O
but O
precursor O
frequencies O
for O
entire O
viruses O
have O
been O
examined O
only O
by O
using O
in O
vitro O
limiting O
- O
dilution O
assays O
( O
LDAs O
) O
. O

To O
examine O
CD8 O
( O
+ O
) O
T O
- O
cell O
precursor O
frequencies O
for O
whole O
viruses O
, O
we O
developed O
an O
in O
vivo O
LDA O
and O
found O
frequencies O
of O
naive O
CD8 O
( O
+ O
) O
T O
- O
cell O
precursors O
of O
1 O
in O
1 O
, O
444 O
for O
vaccinia B
virus I
( I
VV I
) I
( O
similar O
to O
13 O
, O
850 O
VV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
per O
mouse O
) O
and O
1 O
in O
2 O
, O
958 O
for O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
( O
similar O
to O
6 O
, O
761 O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
per O
mouse O
) O
in O
C57BL O
/ O
6J O
mice O
. O

In O
mice O
immune O
to O
VV O
, O
the O
number O
of O
VV O
- O
specific O
precursors O
, O
not O
surprisingly O
, O
dramatically O
increased O
to O
1 O
in O
13 O
( O
similar O
to O
1 O
, O
538 O
, O
462 O
VV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
per O
mouse O
) O
, O
consistent O
with O
estimates O
of O
VV O
- O
specific O
memory O
T O
cells O
. O

In O
contrast O
, O
precursor O
numbers O
for O
LCMV O
did O
not O
increase O
in O
VV O
- O
immune O
mice O
( O
1 O
in O
4 O
, O
562 O
, O
with O
similar O
to O
4 O
, O
384 O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
per O
VV O
- O
immune O
mouse O
) O
. O

Using O
H O
- O
2D O
( O
b O
) O
- O
restricted O
LCMV O
GP33 O
- O
specific O
P14 O
- O
transgenic O
T O
cells O
, O
we O
found O
that O
, O
after O
donor O
T O
- O
cell O
take O
was O
accounted O
for O
, O
approximately O
every O
T O
cell O
transferred O
underwent O
a O
full O
proliferative O
expansion O
in O
response O
to O
LCMV O
infection O
. O

These O
results O
show O
that O
frequencies O
of O
naive O
and O
memory O
CD8 O
( O
+ O
) O
T O
cell O
precursors O
for O
whole O
viruses O
can O
be O
remarkably O
high O
. O

This O
Z O
budding O
activity O
was O
found O
to O
be O
mediated O
by O
the O
late B
( I
L I
) I
- O
domain O
motifs O
P O
( O
T O
/ O
S O
) O
AP O
and O
PPXY O
, O
located O
at O
the O
C O
terminus O
of O
Z O
. O

Here O
, O
we O
show O
that O
the O
Z O
protein O
of O
Tacaribe B
virus I
( I
TACV I
) I
, O
a O
New O
World O
arenavirus O
, O
buds O
efficiently O
from O
cells O
despite O
lacking O
the O
canonical O
L O
- O
domain O
motifs O
P O
( O
T O
/ O
S O
) O
AP O
and O
PPXY O
. O

To O
evaluate O
the O
impact O
of O
immunodominance O
on O
CD8 O
T O
- O
cell O
properties O
, O
we O
compared O
the O
functional O
properties O
of O
dominant O
and O
subdominant O
populations O
in O
the O
response O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Aiming O
to O
increase O
clonal O
dominance O
, O
we O
examined O
high O
- O
frequency O
transferred O
P14 O
T O
- O
cell O
receptor O
transgenic O
( O
TCR O
Tg O
) O
cells O
. O

In O
this O
study O
, O
we O
have O
characterized O
the O
microdomain O
organization O
of O
the O
virus O
envelope O
glycoprotein B
( I
GPC I
) I
on O
the O
cell O
surface O
by O
using O
immunogold O
electron O
microscopy O
. O

We O
find O
that O
Junin B
virus I
( I
JUNV I
) I
GPC O
clusters O
into O
discrete O
microdomains O
of O
120 O
to O
160 O
nm O
in O
diameter O
and O
that O
this O
property O
of O
GPC O
is O
independent O
of O
its O
myristoylation O
and O
of O
coexpression O
with O
the O
virus O
matrix O
protein O
Z O
. O

Coxsackieviruses O
are O
significant O
human O
pathogens O
, O
and O
the O
neonatal O
central B
nervous I
system I
( I
CNS I
) I
is O
a O
major O
target O
for O
infection O
. O

We O
previously O
described O
a O
neonatal O
mouse O
model O
of O
coxsackievirus B
B3 I
( I
CVB3 I
) I
infection O
and O
determined O
that O
proliferating O
stem O
cells O
in O
the O
CNS O
were O
preferentially O
targeted O
. O

High O
levels O
of O
type O
I O
interferons O
and O
chemokines O
( O
in O
particular O
MCP O
- O
5 O
, O
IP10 O
, O
and O
RANTES O
) O
were O
upregulated O
following O
infection O
and O
remained O
at O
high O
levels O
up O
to O
day O
10 O
postinfection O
( O
p O
. O

i O
at O
high O
abundance O
( O
similar O
to O
10 O
( O
6 O
) O
genomes O
/ O
mouse O
brain O
) O
, O
and O
viral O
genomic O
material O
remained O
detectable O
in O
culture O
after O
two O
rounds O
of O
in O
vitro O
passage O
. O

) O
infection O
of O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
results O
in O
anorexic O
weight O
loss O
, O
mediated O
by O
T O
cells O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

Here O
, O
we O
assessed O
the O
role O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
IFN O
- O
gamma O
on O
immune O
cell O
recruitment O
and O
proinflammatory O
cytokine O
/ O
chemokine O
production O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
after O
i O
. O

We O
found O
that O
T O
- O
cell O
- O
depleted O
mice O
had O
decreased O
recruitment O
of O
hematopoietic O
cells O
to O
the O
CNS O
and O
diminished O
levels O
of O
IFN O
- O
gamma O
, O
CCL2 O
( O
MCP O
- O
1 O
) O
, O
CCL3 O
( O
MIP O
- O
1 O
alpha O
) O
, O
and O
CCL5 O
( O
RANTES O
) O
in O
the O
cerebrospinal B
fluid I
( I
CSF I
) I
. O

Mice O
deficient O
in O
IFN O
- O
gamma O
had O
decreased O
CSF O
levels O
of O
CCL3 O
, O
CCL5 O
, O
and O
CXCL10 O
( O
IP O
- O
10 O
) O
, O
and O
decreased O
activation O
of O
both O
resident O
CNS O
and O
infiltrating O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
. O

The O
effects O
of O
IFN O
- O
gamma O
signaling O
on O
macrophage O
lineage O
cells O
was O
assessed O
using O
transgenic O
mice O
, O
called O
macrophages O
insensitive O
to O
interferon O
gamma O
( O
MIIG O
) O
mice O
, O
that O
express O
a O
dominant O
- O
negative O
IFN O
- O
gamma O
receptor O
under O
the O
control O
of O
the O
CD68 O
promoter O
. O

MIIG O
mice O
had O
decreased O
levels O
of O
CCL2 O
, O
CCL3 O
, O
CCL5 O
, O
and O
CXCL10 O
compared O
to O
controls O
despite O
having O
normal O
numbers O
of O
LCMV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
in O
the O
CNS O
. O

Thus O
, O
these O
data O
suggest O
that O
CD4 O
( O
+ O
) O
T O
- O
cell O
production O
of O
IFN O
- O
gamma O
promotes O
signaling O
in O
macrophage O
lineage O
cells O
, O
which O
control O
( O
i O
) O
the O
production O
of O
proinflammatory O
cytokines O
and O
chemokines O
, O
( O
ii O
) O
the O
recruitment O
of O
macrophages O
to O
the O
CNS O
, O
( O
iii O
) O
the O
activation O
of O
resident O
CNS O
and O
infiltrating O
APC O
populations O
, O
and O
( O
iv O
) O
anorexic O
weight O
loss O
. O

Early O
blockade O
of O
costimulatory O
pathways O
with O
CTLA O
- O
4 O
- O
Fc O
decreased O
the O
secondary O
expansion O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
memory O
T O
cells O
as O
well O
as O
their O
ability O
to O
produce O
antiviral O
cytokines O
and O
purge O
the O
persistent O
infection O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
prototypic O
arenavirus O
containing O
a O
bisegmented O
single O
- O
stranded O
RNA O
genome O
with O
an O
ambisense O
coding O
strategy O
. O

MX O
LCMV O
spreads O
via O
cell O
- O
cell O
contacts O
and O
causes O
persistent O
infection O
with O
high O
production O
of O
viral O
nucleoprotein B
( I
NP I
) I
. O

Using O
a O
proteomic O
approach O
, O
we O
identified O
keratin B
1 I
( I
K1 I
) I
, O
an O
intermediate O
filament O
network O
component O
, O
as O
a O
binding O
partner O
of O
the O
viral O
NP O
. O

Arenaviruses O
, O
such O
as O
Tacaribe B
virus I
( I
TACV I
) I
and O
its O
closely O
related O
pathogenic O
Junin B
virus I
( I
JUNV I
) I
, O
are O
enveloped O
viruses O
with O
a O
bipartite O
negative O
- O
sense O
RNA O
genome O
that O
encodes O
the O
Nucleocapsid B
protein I
( I
N I
) I
, O
the O
precursor O
of O
the O
envelope O
glycoprotein O
complex O
( O
GP O
) O
, O
the O
polymerase O
( O
L O
) O
, O
and O
a O
RING O
finger O
protein O
( O
Z O
) O
, O
which O
is O
the O
driving O
force O
of O
arenavirus O
budding O
. O

We O
have O
established O
a O
plasmid O
- O
based O
system O
which O
allowed O
the O
successful O
packaging O
of O
TacV O
- O
like O
nucleocapsids O
along O
with O
Z O
and O
GP O
of O
JunV O
into O
infectious O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

In O
the O
present O
study O
, O
we O
examined O
the O
effect O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
p24 O
on O
proteasomes O
from O
a O
dendritic O
cell O
line O
( O
JAWS O
II O
) O
, O
from O
a O
macrophage O
cell O
line O
( O
C2 O
. O

Exposure O
of O
JAWS O
II O
cells O
and O
primary O
dendritic O
cells O
to O
HIV O
- O
1 O
p24 O
for O
90 O
min O
significantly O
decreased O
the O
presentation O
of O
ovalbumin O
to O
a O
SIINFEKL O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
hybridoma O
. O

These O
results O
suggest O
that O
early O
antigen O
processing O
kinetics O
could O
influence O
the O
immunogenicity O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
generated O
. O

The O
mature O
arenavirus O
envelope O
glycoprotein O
GPC O
is O
a O
tripartite O
complex O
comprising O
a O
stable B
signal I
peptide I
( I
SSP I
) I
in O
addition O
to O
the O
receptor O
- O
binding O
( O
G1 O
) O
and O
transmembrane O
fusion O
( O
G2 O
) O
subunits O
. O

Four O
second O
- O
site O
mutations O
that O
specifically O
complement O
K33Q O
were O
identified O
( O
D400A O
, O
E410A O
, O
R414A O
, O
and O
K417A O
) O
. O

Moreover O
, O
complementation O
was O
also O
observed O
at O
three O
hydrophobic O
positions O
in O
the O
membrane O
- O
spanning O
domain O
of O
G2 O
( O
F427 O
, O
W428 O
, O
and O
F438 O
) O
. O

The O
bacillus B
Calmette I
- I
Guerin I
( I
BCG I
) I
strain O
of O
Mycobacterium O
bovis O
is O
used O
in O
many O
parts O
of O
the O
world O
as O
a O
vaccine O
against O
Mycobacterium O
tuberculosis O
. O

We O
show O
here O
in O
a O
mouse O
model O
that O
BCG O
immunization O
followed O
by O
antibiotic O
treatment O
to O
clear O
the O
host O
of O
the O
pathogen O
rendered O
three O
strains O
of O
mice O
partially O
resistant O
to O
infection O
with O
vaccinia B
virus I
( I
VV I
) I
but O
not O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

BCG O
- O
but O
not O
LCMV O
- O
immune O
memory O
phenotype O
CD4 O
T O
cells O
preferentially O
produced O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
in O
vivo O
after O
VV O
challenge O
. O

The O
cell O
entry O
and O
humoral O
immune O
response O
of O
the O
human O
pathogen O
Lassa B
virus I
( I
LV I
) I
, O
a O
biosafety B
level I
4 I
( I
BSL4 I
) I
Old O
World O
arenavirus O
, O
are O
not O
well O
characterized O
. O

LV B
pseudoparticles I
( I
LVpp I
) I
are O
a O
surrogate O
model O
system O
that O
has O
been O
used O
to O
decipher O
factors O
and O
routes O
involved O
in O
LV O
cell O
entry O
under O
BSL2 O
conditions O
. O

Myeloid O
differentiation O
factor O
88 O
( O
MyD88 O
) O
is O
an O
essential O
adaptor O
protein O
in O
the O
Toll O
- O
like O
receptor O
- O
mediated O
innate O
signaling O
pathway O
, O
as O
well O
as O
in O
interleukin B
- I
1 I
receptor I
( I
IL I
- I
1R I
) I
and O
IL O
- O
18R O
signaling O
. O

In O
the O
present O
study O
, O
we O
examine O
the O
role O
of O
MyD88 O
in O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
following O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
. O

We O
demonstrate O
that O
wild B
- I
type I
( I
WT I
) I
mice O
developed O
a O
CD4 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
wasting O
disease O
after O
intracranial O
infection O
with O
LCMV O
. O

In O
contrast O
, O
MyD88 O
knockout B
( I
KO I
) I
mice O
did O
not O
develop O
wasting O
disease O
in O
response O
to O
the O
same O
infection O
. O

In O
the O
absence O
of O
MyD88 O
, O
naive O
CD4 O
( O
+ O
) O
T O
cells O
failed O
to O
differentiate O
to O
LCMV O
- O
specific O
CD4 O
T O
cells O
. O

We O
demonstrated O
that O
MyD88 O
KO O
antigen O
- O
presenting O
cells O
are O
capable O
of O
activating O
WT O
CD4 O
( O
+ O
) O
T O
cells O
. O

Importantly O
, O
when O
MyD88 O
KO O
CD4 O
( O
+ O
) O
T O
cells O
were O
reconstituted O
with O
an O
MyD88 O
- O
expressing O
lentivirus O
, O
the O
rescued O
CD4 O
( O
+ O
) O
T O
cells O
were O
able O
to O
respond O
to O
LCMV O
infection O
and O
support O
IgG2a O
antibody O
production O
. O

Overall O
, O
these O
studies O
reveal O
a O
previously O
unknown O
role O
of O
MyD88 O
- O
dependent O
signaling O
in O
CD4 O
( O
+ O
) O
T O
cells O
in O
the O
regulation O
of O
the O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
and O
in O
viral O
infection O
- O
induced O
immunopathology O
in O
the O
central O
nervous O
system O
. O

Infection O
of O
guinea O
pigs O
with O
the O
New O
World O
arenavirus O
Pichinde B
virus I
( I
PICV I
) I
has O
been O
used O
as O
a O
biosafety O
level O
2 O
model O
for O
the O
Lassa O
virus O
. O

Pathway O
analysis O
revealed O
a O
potential O
role O
for O
transcription O
factor O
XBP O
- O
1 O
, O
a O
transcription O
factor O
involved O
in O
major B
histocompatibility I
complex I
II I
( I
MHC I
- I
II I
) I
expression O
; O
differential O
DNA O
- O
binding O
activity O
was O
revealed O
by O
electrophoretic O
mobility O
shift O
assay O
, O
and O
differences O
in O
surface O
MHC O
- O
II O
expression O
were O
seen O
following O
PICV O
infection O
. O

The O
infection O
of O
humans O
with O
the O
rodent O
- O
borne O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
lead O
to O
central O
nervous O
system O
disease O
in O
adults O
or O
severe O
neurological O
disease O
with O
hydrocephalus O
and O
chorioretinitis O
in O
children O
infected O
congenitally O
. O

We O
report O
here O
that O
the O
intraocular O
administration O
of O
the O
neurotropic O
LCMV O
strain O
Armstrong B
( I
Arm I
) I
elicited O
pronounced O
chorioretinitis O
and O
keratitis O
and O
that O
infection O
with O
the O
more O
viscerotropic O
strains O
WE O
and O
Docile O
precipitated O
less O
severe O
immunopathological O
ocular O
disease O
. O

Analyses O
of O
T O
- O
cell O
- O
deficient O
mouse O
strains O
showed O
that O
LCMV O
- O
mediated O
ocular O
disease O
was O
strictly O
dependent O
on O
the O
presence O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
and O
that O
the O
contribution O
of O
CD4 O
( O
+ O
) O
T O
cells O
was O
negligible O
. O

We O
have O
reanalyzed O
recently O
published O
data O
on O
killing O
of O
peptide O
- O
pulsed O
splenocytes O
by O
cytotoxic O
T O
lymphocytes O
and O
memory O
CD8 O
T O
cells O
specific O
to O
NP396 O
and O
GP276 O
epitopes O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
the O
mouse O
spleen O
. O

Tacaribe B
virus I
( I
TACV I
) I
is O
the O
prototype O
of O
the O
New O
World O
group O
of O
arenaviruses O
. O

The O
TacV O
genome O
encodes O
four O
proteins O
: O
the O
nucleoprotein B
( I
N I
) I
, O
the O
glycoprotein O
precursor O
, O
the O
polymerase O
( O
L O
) O
, O
and O
a O
RING O
finger O
protein O
( O
Z O
) O
. O

We O
found O
that O
the O
C O
- O
terminal O
region O
of O
L O
was O
not O
essential O
for O
the O
interaction O
and O
identified O
two O
noncontiguous O
regions O
that O
were O
critical O
for O
binding O
: O
one O
at O
the O
N O
- O
terminus O
of O
L O
between O
residues O
156 O
and O
292 O
and O
a O
second O
one O
in O
the O
polymerase O
domain O
( O
domain O
III O
) O
. O

The O
importance O
of O
domain O
III O
in O
binding O
was O
revealed O
by O
substitutions O
in O
D1188 O
and O
H1189 O
within O
motif O
A O
and O
in O
each O
residue O
of O
the O
conserved O
SDD O
sequence O
( O
residues O
1328 O
, O
1329 O
, O
and O
1330 O
) O
within O
motif O
C O
. O

The O
arenavirus O
envelope O
glycoprotein B
( I
GPC I
) I
mediates O
viral O
entry O
through O
pH O
- O
induced O
membrane O
fusion O
in O
the O
endosome O
. O

Here O
, O
we O
show O
that O
ST O
- O
294 O
interferes O
with O
GPC O
- O
mediated O
membrane O
fusion O
by O
targeting O
the O
interaction O
of O
the O
G2 O
fusion O
subunit O
with O
the O
stable B
signal I
peptide I
( I
SSP I
) I
. O

The O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
of O
arenaviruses O
is O
an O
integral O
part O
of O
the O
L O
protein O
, O
a O
200 O
- O
kDa O
multifunctional O
and O
multidomain O
protein O
. O

Mutation O
of O
two O
adjacent O
residues O
in O
the O
putative O
palm O
- O
thumb O
subdomain O
junction O
, O
G1394 O
and O
D1395 O
( O
strain O
AV O
) O
, O
led O
to O
a O
defect O
in O
mRNA O
synthesis O
but O
did O
not O
affect O
antigenomic O
RNA O
synthesis O
. O

Several O
recent O
studies O
have O
investigated O
immunodominance O
of O
H O
- O
2Dh O
- O
restricted O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
the O
nucleoprotein O
NP366 O
and O
acid O
pollymerase O
PA224 O
epitopes O
during O
influenza O
A O
virus O
infection O
of O
C57BL O
/ O
6 O
mice O
. O

CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
these O
two O
epitopes O
are O
codominant O
during O
primary O
infection O
; O
NP366 O
dominates O
during O
secondary O
infection O
. O

We O
show O
that O
the O
dynamic O
interactions O
between O
CD8 O
( O
+ O
) O
T O
cells O
and O
antigen O
presentation O
lead O
to O
a O
situation O
where O
CD8 O
( O
+ O
) O
T O
cells O
are O
limiting O
during O
the O
initial O
response O
whereas O
antigen O
is O
limiting O
in O
the O
secondary O
response O
. O

This O
numbers O
game O
between O
antigen O
and O
CD8 O
( O
+ O
) O
T O
cells O
can O
reproduce O
the O
observed O
immunodominance O
of O
the O
NP336 O
- O
and O
PA224 O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
, O
thereby O
explaining O
the O
reported O
experimental O
data O
. O

Here O
we O
demonstrate O
that O
two O
identified O
arenavirus O
receptors O
, O
alpha B
- I
dystroglycan I
( I
alpha I
- I
DG I
) I
and O
transferrin B
receptor I
1 I
( I
TfR1 I
) I
, O
are O
expressed O
in O
polarized O
human O
airway O
epithelia O
. O

Here O
, O
we O
demonstrate O
that O
the O
adhesion O
pathway O
mediated O
by O
vascular O
cell O
adhesion O
molecule O
I O
( O
VCAM O
- O
1 O
) O
plays O
a O
role O
in O
regulating O
T O
- O
cell O
- O
mediated O
inflammation O
and O
pathology O
in O
nonlymphoid O
tissues O
, O
including O
the O
central B
nervous I
system I
( I
CNS I
) I
during O
viral O
infection O
. O

The O
ablation O
of O
VCAM O
- O
1 O
expression O
from O
endothelial O
and O
hematopoietic O
cells O
using O
a O
loxP O
- O
Cre O
recombination O
strategy O
had O
no O
major O
effect O
on O
the O
induction O
or O
overall O
tissue O
distribution O
of O
antigen O
- O
specific O
T O
cells O
during O
a O
systemic O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
except O
in O
the O
case O
of O
lung O
tissue O
. O

Interestingly O
, O
analysis O
of O
the O
infiltrating O
populations O
in O
the O
brains O
of O
intracerebrally O
infected O
mice O
revealed O
that O
VCAM O
- O
1 O
deletion O
significantly O
delayed O
migration O
into O
the O
CNS O
of O
antigen O
- O
presenting O
cells O
( O
macrophages O
and O
dendritic O
cells O
) O
, O
which O
are O
critical O
for O
optimal O
stimulation O
of O
migrating O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
initiating O
a O
pathological O
cascade O
. O

Borna B
disease I
virus I
( I
BDV I
) I
can O
persistently O
infect O
the O
central B
nervous I
system I
( I
CNS I
) I
of O
mice O
. O

To O
distinguish O
between O
these O
possibilities O
, O
we O
used O
two O
lines O
of O
transgenic O
mice O
that O
strongly O
express O
the O
N O
protein O
of O
BDV O
in O
either O
neurons O
( O
Neuro O
- O
N O
) O
or O
astrocytes O
( O
Astro O
- O
N O
) O
. O

However O
, O
antibodies O
confer O
little O
or O
no O
protection O
for O
a O
majority O
of O
chronic O
viral O
infections O
that O
require O
active O
involvement O
of O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
have O
been O
shown O
to O
be O
efficient O
inducers O
of O
cell O
- O
mediated O
immune O
responses O
, O
but O
administration O
of O
an O
adjuvant O
is O
generally O
required O
. O

We O
recently O
reported O
the O
generation O
of O
a O
novel O
VLP O
system O
exploiting O
the O
self O
- O
assembly O
property O
of O
the O
papaya O
mosaic O
virus O
( O
PapMV O
) O
coat O
protein O
. O

We O
show O
here O
that O
uptake O
of O
PapMV O
- O
like O
particles O
by O
murine O
splenic O
dendritic B
cells I
( I
DCs I
) I
in O
vivo O
leads O
to O
their O
maturation O
, O
suggesting O
that O
they O
possess O
intrinsic O
adjuvant O
- O
like O
properties O
. O

DCs O
pulsed O
with O
PapMV O
- O
like O
particles O
displaying O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
p33 O
immunodominant O
CTL O
epitope O
( O
PapMV O
- O
p33 O
) O
efficiently O
process O
and O
cross O
- O
present O
the O
viral O
epitope O
to O
p33 O
- O
specific O
transgenic O
T O
cells O
. O

The O
envelope O
glycoprotein O
of O
the O
Junin O
arenavirus O
( O
GP O
- O
C O
) O
mediates O
entry O
into O
target O
cells O
through O
a O
pH O
- O
dependent O
membrane O
fusion O
mechanism O
. O

Unlike O
other O
class O
I O
viral O
fusion O
proteins O
, O
the O
mature O
GP O
- O
C O
complex O
retains O
a O
cleaved O
, O
58 O
- O
amino O
- O
acid O
signal O
peptide O
( O
SSP O
) O
as O
an O
essential O
subunit O
, O
required O
both O
for O
trafficking O
of O
GP O
- O
C O
to O
the O
cell O
surface O
and O
for O
the O
activation O
of O
membrane O
fusion O
. O

SSP O
has O
been O
shown O
to O
associate O
noncovalently O
in O
GP O
- O
C O
via O
the O
cytoplasmic B
domain I
( I
CTD I
) I
of O
the O
transmembrane O
fusion O
subunit O
G2 O
. O

We O
propose O
that O
the O
remaining O
residues O
in O
the O
series O
( O
His O
- O
459 O
, O
Cys O
- O
467 O
, O
and O
Cys O
- O
469 O
) O
form O
an O
intersubunit O
zinc O
- O
binding O
center O
that O
incorporates O
Cys O
- O
57 O
of O
SSP O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
murine O
arenavirus O
whose O
glycoprotein O
consists O
of O
a O
transmembrane O
subunit O
( O
GP O
- O
2 O
) O
and O
a O
receptor O
- O
binding O
subunit O
( O
GP O
- O
1 O
) O
. O

LCMV O
- O
neutralizing B
antibodies I
( I
NAbs I
) I
are O
directed O
against O
a O
single O
site O
on O
GP O
- O
1 O
and O
occur O
I O
month O
after O
the O
infection O
of O
cytotoxic B
- I
T I
- I
lymphocyte I
( I
CTL I
) I
deficient O
mice O
. O

In O
wild O
- O
type O
mice O
, O
however O
, O
CTLs O
control O
early O
infection O
, O
and O
weak O
nAb O
titers O
emerge O
very O
late O
( O
after O
70 O
to O
150 O
days O
) O
if O
at O
all O
. O

Insertion O
of O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
precursor O
glycoprotein B
C I
( I
GP I
- I
C I
) I
into O
the O
membrane O
of O
the O
endoplasmic O
reticulum O
is O
mediated O
by O
an O
unusual O
signal O
peptide O
( O
Sp O
( O
GP O
- O
C O
) O
) O
. O

After O
cleavage O
by O
signal O
peptidase O
, O
Sp O
( O
GP O
- O
c O
) O
accumulates O
in O
cells O
and O
virus O
particles O
. O

In O
the O
present O
study O
, O
we O
identified O
the O
LCMV O
Sp O
( O
GP O
- O
C O
) O
as O
being O
an O
essential O
component O
of O
the O
GP O
complex O
and O
show O
that O
the O
different O
regions O
of O
SPGP O
- O
C O
are O
required O
for O
distinct O
steps O
in O
GP O
maturation O
and O
virus O
infectivity O
. O

More O
specifically O
, O
we O
show O
that O
one O
hydrophobic O
region O
of O
Sp O
( O
GP O
- O
C O
) O
is O
sufficient O
for O
the O
membrane O
insertion O
of O
GP O
- O
C O
, O
while O
both O
hydrophobic O
regions O
are O
required O
for O
the O
processing O
and O
cell O
surface O
expression O
of O
the O
GPs O
. O

The O
N O
- O
terminal O
region O
of O
Sp O
( O
GP O
- O
C O
) O
, O
on O
the O
other O
hand O
, O
is O
essential O
for O
pseudoviral O
infection O
of O
target O
cells O
. O

Furthermore O
, O
we O
show O
that O
unmyristoylated O
Sp O
( O
GP O
- O
C O
) O
exposes O
its O
N O
- O
terminal O
region O
to O
the O
exoplasmic O
side O
. O

This O
Sp O
( O
GP O
- O
C O
) O
can O
promote O
GP O
- O
C O
maturation O
but O
is O
defective O
in O
pseudoviral O
infection O
. O

We O
have O
documented O
that O
the O
nucleoprotein B
( I
NP I
) I
of O
the O
prototypic O
arenavirus O
lymphocytic O
choriomeningitis O
virus O
is O
an O
antagonist O
of O
the O
type O
I O
interferon O
response O
. O

We O
found O
that O
, O
with O
the O
exception O
of O
Tacaribe B
virus I
( I
TCRV I
) I
, O
all O
NPs O
tested O
inhibited O
activation O
of O
beta O
interferon O
and O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
- O
dependent O
promoters O
, O
as O
well O
as O
the O
nuclear O
translocation O
of O
IRF O
- O
3 O
. O

foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
, O
like O
other O
RNA O
viruses O
, O
exhibits O
high O
mutation O
rates O
during O
replication O
that O
have O
been O
suggested O
to O
be O
of O
adaptive O
value O
. O

Here O
, O
we O
present O
the O
results O
of O
20 O
serial O
contact O
transmissions O
of O
the O
highly O
pathogenic O
, O
pig O
- O
adapted O
O O
Taiwan O
97 O
( O
O O
Tw97 O
) O
isolate O
of O
FMDV O
in O
swine O
. O

Unexpectedly O
, O
a O
significant O
reduction O
of O
virulence O
upon O
pig O
passages O
was O
observed O
, O
and O
finally O
, O
interruption O
of O
the O
viral O
transmission O
chain O
occurred O
after O
the O
14th O
pig O
passage O
( O
T14 O
) O
. O

Surprisingly O
, O
the O
region O
encoding O
the O
capsid O
protein O
VP1 O
( O
1D O
) O
did O
not O
show O
amino O
acid O
changes O
during O
in O
vivo O
passages O
. O

We O
have O
attempted O
to O
address O
this O
issue O
by O
analyzing O
CCR5 O
( O
- O
/ O
- O
) O
, O
CXCR3 O
( O
- O
/ O
- O
) O
, O
and O
CCR5 O
/ O
CXCR3 O
( O
- O
/ O
- O
) O
mice O
with O
regard O
to O
virus O
- O
induced O
liver O
inflammation O
, O
generation O
and O
recruitment O
of O
effector O
cells O
, O
virus O
control O
, O
and O
immunopathology O
. O

In O
contrast O
, O
the O
T O
- O
cell O
response O
is O
accelerated O
in O
CCR5 O
( O
- O
/ O
- O
) O
and O
CCR5 O
/ O
CXCR3 O
( O
- O
/ O
- O
) O
mice O
and O
the O
absence O
of O
CCR5 O
is O
associated O
with O
the O
induction O
of O
CD8 O
' O
T O
- O
cell O
- O
mediated O
immunopathology O
consisting O
of O
marked O
hepatic O
microvesicular O
steatosis O
. O

Rhesus O
macaques O
( O
Macaca O
mulatta O
) O
infected O
intravenously O
with O
a O
lethal O
dose O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
provide O
a O
model O
for O
Lassa O
virus O
infection O
of O
humans O
. O

To O
identify O
the O
mechanisms O
responsible O
for O
this O
protracted O
pattern O
of O
infection O
, O
we O
developed O
an O
infant O
infection O
murine O
model O
using O
the O
well O
- O
characterized O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
WE O
strain O
in O
2 O
- O
week O
- O
old O
BALB O
/ O
c O
mice O
. O

The O
stable B
signal I
peptide I
( I
SSP I
) I
of O
the O
lymphocytic O
choriomeningitis O
virus O
surface O
glycoprotein O
precursor O
has O
several O
unique O
characteristics O
. O

alpha O
- O
dystroglycan B
( I
DG I
) I
is O
an O
important O
cellular O
receptor O
for O
extracellular B
matrix I
( I
ECM I
) I
proteins O
and O
also O
serves O
as O
the O
receptor O
for O
Old O
World O
arenaviruses O
Lassa B
fever I
virus I
( I
LFV I
) I
and O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
clade O
C O
New O
World O
arenaviruses O
. O

CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
control O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
in O
H O
- O
2 O
( O
b O
) O
mice O
. O

Although O
antigen O
- O
specific O
responses O
against O
LCW O
infection O
are O
well O
studied O
, O
we O
found O
that O
a O
significant O
fraction O
of O
the O
CD8 O
( O
+ O
) O
CD44 O
( O
hi O
) O
T O
- O
cell O
response O
to O
LCMV O
in O
H O
- O
2 O
( O
b O
) O
mice O
was O
not O
accounted O
for O
by O
known O
epitopes O
. O

We O
screened O
peptides O
predicted O
to O
bind O
major O
histocompatibility O
complex O
class O
I O
and O
overlapping O
15 O
- O
mer O
peptides O
spanning O
the O
complete O
LCW O
proteome O
for O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
induction O
from O
CD8 O
( O
+ O
) O
T O
cells O
derived O
from O
LCW O
- O
infected O
H O
- O
2 O
( O
b O
) O
mice O
. O

Together O
with O
the O
9 O
previously O
known O
, O
these O
epitopes O
account O
for O
the O
total O
CD8 O
( O
+ O
) O
CD44 O
( O
hi O
) O
response O
. O

Thus O
, O
bystander O
T O
- O
cell O
activation O
does O
not O
contribute O
appreciably O
to O
the O
CD8 O
( O
+ O
) O
CD44 O
( O
hi O
) O
pool O
. O

Interestingly O
, O
protection O
from O
viral O
challenge O
was O
best O
correlated O
with O
the O
cytolytic O
potential O
of O
CD8 O
( O
+ O
) O
T O
cells O
, O
whereas O
IFN O
- O
gamma O
production O
and O
peptide O
avidity O
appear O
to O
play O
a O
lesser O
role O
. O

Taken O
together O
, O
these O
findings O
illustrate O
that O
the O
LCW O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
is O
more O
complex O
than O
previously O
appreciated O
. O

The O
stable B
signal I
peptide I
( I
SSP I
) I
of O
the O
GP O
- O
C O
envelope O
glycoprotein O
of O
the O
Junin O
arenavirus O
plays O
a O
critical O
role O
in O
trafficking O
of O
the O
GP O
- O
C O
complex O
to O
the O
cell O
surface O
and O
in O
its O
membrane O
fusion O
activity O
. O

This O
model O
is O
supported O
by O
( O
i O
) O
the O
presence O
of O
two O
conserved O
hydrophobic O
regions O
in O
SSP O
( O
h O
phi O
1 O
and O
h O
phi O
2 O
) O
and O
( O
ii O
) O
our O
previous O
demonstration O
that O
lysine O
- O
33 O
in O
the O
ectodomain O
loop O
is O
essential O
for O
pH O
- O
dependent O
membrane O
fusion O
. O

The O
consequences O
of O
human O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
can O
be O
severe O
, O
including O
aseptic O
meningitis O
in O
immunocompetent O
individuals O
, O
hydrocephalus O
or O
chorioretinitis O
in O
fetal O
infection O
, O
or O
a O
highly O
lethal O
outcome O
in O
immunosuppressed O
individuals O
. O

In O
murine O
models O
of O
LCMV O
infection O
, O
CD8 O
( O
+ O
) O
T O
cells O
play O
a O
primary O
role O
in O
providing O
protective O
immunity O
, O
and O
there O
is O
evidence O
that O
cellular O
immunity O
may O
also O
be O
important O
in O
related O
arenavirus O
infections O
in O
humans O
. O

We O
identified O
four O
HLA O
- O
A O
* O
0201 O
- O
restricted O
peptides O
- O
nucleoprotein O
NP69 O
- O
77 O
, O
glycoprotein O
precursor O
GPC O
( O
10 O
- O
18 O
) O
, O
GPC O
( O
447 O
- O
455 O
) O
, O
and O
zinc O
- O
binding O
protein O
Z O
( O
49 O
- O
58 O
) O
- O
that O
displayed O
high O
- O
affinity O
binding O
( O
< O
= O
275 O
nM O
) O
to O
HLA O
- O
A O
* O
0201 O
, O
induced O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
of O
high O
functional O
avidity O
in O
HLA O
- O
A O
* O
0201 O
transgenic O
mice O
, O
and O
were O
naturally O
processed O
from O
native O
LCMV O
antigens O
in O
HLA O
- O
restricted O
human O
antigen O
presenting O
cells O
. O

One O
of O
the O
epitopes O
( O
GPC O
( O
447 O
- O
455 O
) O
) O
, O
after O
peptide O
immunization O
of O
HLA O
- O
A O
* O
0201 O
mice O
, O
induced O
CD8 O
( O
+ O
) O
T O
cells O
capable O
of O
killing O
peptide O
- O
pulsed O
HLA O
- O
A O
* O
0201 O
- O
restricted O
target O
cells O
in O
vivo O
and O
protected O
mice O
against O
lethal O
intracranial O
challenge O
with O
LCW O
. O

Cowpea B
mosaic I
virus I
( I
CPMV I
) I
, O
a O
plant O
virus O
that O
is O
a O
member O
of O
the O
picornavirus O
superfamily O
, O
is O
increasingly O
being O
used O
for O
nanotechnology O
applications O
, O
including O
material O
science O
, O
vascular O
imaging O
, O
vaccine O
development O
, O
and O
targeted O
drug O
delivery O
. O

Studies O
using O
a O
deficient O
cell O
line O
, O
deglycosidases O
, O
and O
glycosylation O
inhibitors O
showed O
that O
the O
CPMW B
binding I
protein I
( I
CPMV I
- I
BP I
) I
is O
not O
glycosylated O
. O

Here O
, O
we O
use O
several O
techniques O
to O
provide O
a O
more O
complete O
accounting O
of O
the O
CD8 O
T O
- O
cell O
response O
generated O
upon O
infection O
of O
C57BL O
/ O
6 O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Moreover O
, O
the O
response O
targeted O
a O
very O
broad O
array O
of O
peptide O
major O
histocompatibility O
complexes O
( O
MHCs O
) O
, O
even O
though O
we O
examined O
epitopes O
derived O
from O
only O
two O
of O
the O
four O
proteins O
encoded O
by O
the O
LCMV O
genome O
and O
C57BL O
/ O
6 O
mice O
only O
have O
two O
MHC O
class O
I O
alleles O
. O

The O
interferon O
- O
inducible O
adenosine O
deaminase O
that O
acts O
on O
double O
- O
stranded O
RNA O
( O
ADAR1 O
- O
L O
) O
has O
been O
proposed O
to O
be O
one O
of O
the O
antiviral O
effector O
proteins O
within O
the O
complex O
innate O
immune O
response O
. O

Here O
, O
the O
potential O
role O
of O
ADAR1 O
- O
L O
in O
the O
innate O
immune O
response O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
a O
widely O
used O
virus O
model O
, O
was O
studied O
. O

Accordingly O
, O
an O
adenosine O
- O
to O
- O
guanosine O
( O
A O
- O
to O
- O
G O
) O
and O
uracil O
- O
to O
- O
cytidine O
( O
U O
- O
to O
- O
C O
) O
hypermutation O
pattern O
was O
found O
in O
the O
LCW O
genomic O
RNA O
in O
infected O
cell O
lines O
and O
in O
mice O
. O

The O
interferon B
( I
IFN I
) I
- I
stimulated I
genes I
( I
ISGs I
) I
ISG O
- O
49 O
, O
ISG O
- O
54 O
, O
and O
ISG O
- O
56 O
are O
highly O
responsive O
to O
viral O
infection O
, O
yet O
the O
regulation O
and O
function O
of O
these O
genes O
in O
vivo O
are O
unknown O
. O

We O
examined O
the O
simultaneous O
regulation O
of O
these O
ISGs O
in O
the O
brains O
of O
mice O
during O
infection O
with O
either O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
or O
West B
Nile I
virus I
( I
WNV I
) I
. O

Although O
expression O
of O
the O
ISG O
- O
49 O
, O
ISG O
- O
54 O
, O
and O
ISG O
- O
56 O
genes O
was O
increased O
in O
the O
brains O
of O
LCMV O
- O
infected O
STAT1 O
and O
STAT2 O
knockout B
( I
KO I
) I
mice O
, O
this O
was O
blunted O
, O
delayed O
, O
and O
restricted O
to O
the O
choroid O
plexus O
, O
meninges O
, O
and O
endothelium O
. O

Thus O
, O
the O
ISG O
- O
49 O
, O
ISG O
- O
54 O
, O
and O
ISG O
- O
56 O
genes O
are O
coordinately O
upregulated O
in O
the O
brain O
during O
LCMV O
and O
WNV O
infection O
; O
this O
upregulation O
, O
in O
the O
case O
of O
LCMV O
, O
was O
totally O
( O
neurons O
) O
or O
partially O
( O
non O
- O
neurons O
) O
dependent O
on O
the O
IFN O
- O
signaling O
molecules O
STAT1 O
and O
STAT2 O
. O

Live O
vaccinia B
virus I
( I
VV I
) I
vaccination O
has O
been O
highly O
successful O
in O
eradicating O
smallpox O
. O

By O
applying O
the O
concept O
of O
molecular O
mimicry O
to O
identify O
potential O
CD8 O
T O
- O
cell O
epitopes O
that O
stimulate O
cross O
- O
reactive O
T O
cells O
specific O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
VV O
, O
we O
identified O
after O
screening O
only O
115 O
peptides O
two O
VV O
- O
specific O
immunogenic O
epitopes O
that O
mediated O
protective O
immunity O
against O
VV O
. O

An O
immunodominant O
epitope O
, O
VV O
- O
e7r O
( O
130 O
) O
, O
did O
not O
generate O
cross O
- O
reactive O
T O
- O
cell O
responses O
to O
LCMV O
, O
and O
a O
subdominant O
epitope O
, O
VV O
- O
a11r O
( O
198 O
) O
, O
did O
generate O
cross O
- O
reactive O
responses O
to O
LCNV O
. O

Although O
previous O
experiments O
have O
shown O
that O
Bim O
is O
critical O
for O
the O
apoptosis O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
during O
acute O
viral O
infection O
, O
the O
role O
of O
Bim O
during O
chronic O
viral O
infection O
is O
unclear O
. O

Enumeration O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
by O
major O
histocompatibility O
complex O
class O
I O
tetramer O
staining O
revealed O
that O
CD8 O
( O
+ O
) O
D O
( O
b O
) O
NP396 O
- O
404 O
( O
+ O
) O
T O
cells O
, O
which O
undergo O
extensive O
deletion O
in O
wild O
- O
type O
mice O
, O
exhibited O
almost O
no O
decrease O
in O
Bim O
mutant O
mice O
. O

This O
contrasts O
with O
CD8 O
( O
+ O
) O
D O
( O
b O
) O
GP33 O
- O
41 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
D O
( O
b O
) O
GP276 O
- O
286 O
( O
+ O
) O
T O
cells O
that O
underwent O
similar O
decreases O
in O
numbers O
in O
both O
Bim O
mutant O
and O
wild O
- O
type O
mice O
. O

Increased O
numbers O
of O
CD8 O
( O
+ O
) O
D O
( O
b O
) O
Np396 O
- O
404 O
( O
+ O
) O
T O
cells O
in O
Bim O
mutant O
mice O
were O
due O
to O
lack O
of O
apoptosis O
and O
could O
not O
be O
explained O
by O
altered O
proliferation O
, O
differential O
homing O
to O
tissues O
, O
or O
increased O
help O
from O
CD4 O
( O
+ O
) O
T O
cells O
. O

These O
experiments O
demonstrate O
the O
critical O
role O
of O
Bim O
during O
chronic O
viral O
infection O
to O
down O
- O
regulate O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
and O
have O
implications O
for O
designing O
strategies O
for O
optimizing O
immunotherapies O
during O
situations O
where O
antigen O
persists O
, O
such O
as O
chronic O
infection O
, O
autoimmune O
syndromes O
, O
and O
cancer O
. O

Neonatal O
infection O
of O
most O
mouse O
strains O
with O
lymphocytic B
choriomeningitis I
virus I
( I
LCW I
) I
leads O
to O
a O
life O
- O
long O
persistent O
infection O
characterized O
by O
high O
virus O
loads O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
in O
the O
absence O
of O
inflammation O
and O
tissue O
destruction O
. O

To O
model O
the O
natural O
route O
of O
human O
congenital O
CNS O
infection O
observed O
with O
a O
variety O
of O
viruses O
, O
we O
established O
a O
persistently O
infected O
mouse O
colony O
where O
the O
virus O
was O
maintained O
via O
vertical O
transmission O
from O
infected O
mothers O
to O
offspring O
( O
LCMV O
- O
cgP O
' O
i O
) O
. O

The O
majority O
of O
the O
genes O
induced O
in O
the O
brain O
of O
LCW O
- O
cgPi O
mice O
were O
interferon B
( I
IFN I
) I
- I
stimulated I
genes I
( I
ISGs I
) I
and O
included O
the O
transcription O
factors O
STAT1 O
and O
IRF9 O
, O
the O
ISG15 O
protease O
UBP43 O
, O
and O
the O
glucocorticoid O
attenuated O
- O
response O
genes O
GARG16 O
and O
GARG49 O
. O

The O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
formidable O
battle O
horse O
for O
the O
study O
of O
viral O
immunology O
, O
as O
well O
as O
viral O
persistence O
and O
associated O
diseases O
. O

In O
this O
study O
we O
show O
that O
LCMV O
also O
disables O
the O
host O
innate O
defense O
by O
interfering O
with O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
in O
response O
to O
different O
stimuli O
, O
including O
infection O
with O
Sendai O
virus O
and O
liposome O
- O
mediated O
DNA O
transfection O
. O

Inhibition O
of O
IFN O
production O
in O
LCMV O
- O
infected O
cells O
was O
caused O
by O
an O
early O
block O
in O
the O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
activation O
pathway O
. O

Using O
expression O
plasmids O
encoding O
individual O
LCMV O
proteins O
, O
we O
found O
that O
expression O
of O
the O
LCMV O
nucleoprotein B
( I
NP I
) I
was O
sufficient O
to O
inhibit O
both O
IFN O
production O
and O
nuclear O
translocation O
of O
IRF O
- O
3 O
. O

While O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
is O
currently O
in O
clinical O
development O
as O
a O
safe O
vaccine O
against O
smallpox O
and O
heterologous O
infectious O
diseases O
, O
its O
immunogenicity O
is O
likely O
limited O
due O
to O
the O
inability O
of O
the O
virus O
to O
replicate O
productively O
in O
mammalian O
hosts O
. O

In O
light O
of O
recent O
data O
demonstrating O
that O
vaccinia O
viruses O
, O
including O
MVA O
, O
preferentially O
infect O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
that O
play O
crucial O
roles O
in O
generating O
antiviral O
immunity O
, O
we O
hypothesized O
that O
expression O
of O
specific O
cytokines O
and O
chemokines O
that O
mediate O
APC O
recruitment O
and O
activation O
from O
recombinant B
MVA I
( I
rMVA I
) I
vectors O
would O
enhance O
the O
immunogenicity O
of O
these O
vectors O
. O

To O
test O
this O
hypothesis O
, O
we O
generated O
rMVAs O
that O
express O
murine B
granulocyte I
- I
macrophage I
colony I
- I
stimulating I
factor I
( I
mGM I
- I
CSF I
) I
, O
human B
CCL20 I
/ I
human I
macrophage I
inflammatory I
protein I
3 I
alpha I
( I
hCCL20 I
/ I
hMIP I
- I
3 I
alpha I
) I
, O
or O
human B
fins I
- I
like I
tyrosine I
kinase I
3 I
ligand I
( I
hFlt3 I
- I
L I
) I
, O
factors O
predicted O
to O
increase O
levels O
of O
dendritic B
cells I
( I
DCs I
) I
, O
to O
recruit O
DCs O
to O
sites O
of O
immunization O
, O
or O
to O
promote O
maturation O
of O
DCs O
in O
vivo O
, O
respectively O
. O

These O
rMVAs O
also O
coexpress O
the O
well O
- O
characterized O
, O
immunodominant O
lymphocytic O
choriomeningitis O
virus O
nucleoprotein B
( I
NP I
) I
antigen O
that O
enabled O
sensitive O
and O
quantitative O
assessment O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
following O
immunization O
of O
BALB O
/ O
c O
mice O
. O

The O
envelope O
glycoprotein O
of O
the O
arenaviruses O
( O
GP O
- O
C O
) O
is O
unusual O
in O
that O
the O
mature O
complex O
retains O
the O
cleaved O
, O
58 O
- O
amino O
- O
acid O
signal O
peptide O
. O

Association O
of O
this O
stable B
signal I
peptide I
( I
SSP I
) I
has O
been O
shown O
to O
be O
essential O
for O
intracellular O
trafficking O
and O
proteolytic O
maturation O
of O
the O
GP O
- O
C O
complex O
. O

encephalomyocarditis B
virus I
( I
EMCV I
) I
is O
a O
picornavirus O
that O
can O
cause O
paralysis O
, O
diabetes O
, O
and O
myocarditis O
within O
days O
of O
infection O
. O

Interaction O
of O
antigen O
- O
presenting O
cell O
CD1d O
with O
distinct O
natural B
killer I
T I
- I
cell I
( I
NKT I
) I
populations O
can O
induce O
rapid O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
and O
NK O
- O
cell O
activation O
. O

The O
T O
- O
cell O
response O
of O
CD1d O
- O
deficient O
mice O
( O
lacking O
all O
NKT O
cells O
) O
against O
acute O
EMCV O
infection O
was O
further O
studied O
in O
vitro O
and O
in O
vivo O
. O

EMCV O
persisted O
at O
higher O
levels O
in O
CD1d O
- O
knockout B
( I
KO I
) I
splenocyte O
cultures O
infected O
in O
vitro O
. O

However O
, O
this O
was O
not O
reflected O
in O
the O
relative O
levels O
of O
NK O
- O
cell O
activation O
but O
rather O
by O
the O
responses O
of O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
. O

Repeated O
EMCV O
infection O
in O
vitro O
induced O
less O
IFN O
- O
gamma O
and O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
from O
CD1d O
- O
deficient O
splenocytes O
than O
with O
the O
wild O
type O
. O

The O
mature O
GP O
- O
C O
complex O
is O
unusual O
in O
that O
it O
retains O
a O
stable B
signal I
peptide I
( I
SSP I
) I
as O
an O
essential O
component O
in O
association O
with O
the O
typical O
receptor O
- O
binding O
( O
G1 O
) O
and O
transmembrane O
fusion O
( O
G2 O
) O
subunits O
. O

We O
demonstrate O
that O
, O
in O
the O
absence O
of O
SSP O
, O
the O
G1 O
- O
G2 O
precursor O
is O
restricted O
to O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

The O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
glycoprotein I
( I
GP I
) I
consists O
of O
the O
transmembrane O
subunit O
GP O
- O
2 O
and O
the O
receptor O
binding O
subunit O
GP O
- O
1 O
. O

Type O
III O
Interferons B
( I
IFNs I
) I
( O
interleukin O
- O
28 O
/ O
29 O
or O
lambda O
interferon O
[ O
IFN O
- O
lambda O
] O
) O
are O
cytokines O
with O
IFN O
- O
like O
activities O
. O

The O
IFN O
- O
lambda O
s O
were O
- O
unlike O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
- O
induced O
directly O
by O
stimulation O
with O
IFN O
- O
alpha O
or O
- O
lambda O
, O
thus O
identifying O
type O
III O
IFNs O
as O
IFN O
- O
stimulated O
genes O
. O

In O
vitro O
assays O
revealed O
that O
IFN O
- O
lambda O
s O
have O
appreciable O
antiviral O
activity O
against O
encephalomyocarditis B
virus I
( I
EMCV I
) I
but O
limited O
activity O
against O
herpes B
simplex I
virus I
type I
2 I
( I
HSV I
- I
2 I
) I
, O
whereas O
IFN O
- O
alpha O
potently O
restricted O
both O
viruses O
. O

Using O
three O
murine O
models O
for O
generalized O
virus O
infections O
, O
we O
found O
that O
while O
recombinant O
IFN O
- O
alpha O
reduced O
the O
viral O
load O
after O
infection O
with O
EMCV O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
and O
HSV O
- O
2 O
, O
treatment O
with O
recombinant O
IFN O
- O
lambda O
in O
vivo O
did O
not O
affect O
viral O
load O
after O
infection O
with O
EMCV O
or O
LCMV O
but O
did O
reduce O
the O
hepatic O
viral O
titer O
of O
HSV O
- O
2 O
. O

type B
I I
interferons I
( I
IFNs I
) I
, O
the O
primary O
innate O
cytokines O
that O
control O
virus O
growth O
and O
spreading O
, O
can O
influence O
various O
aspects O
of O
adaptive O
immunity O
. O

Using O
two O
strains O
( O
Cantell O
and O
52 O
) O
of O
the O
marine O
respiratory O
Sendai B
virus I
( I
SeV I
) I
with O
differential O
abilities O
to O
induce O
type O
I O
IFN O
production O
from O
infected O
cells O
, O
together O
with O
type O
I O
IFN O
receptor O
- O
deficient O
mice O
, O
we O
examined O
the O
role O
of O
type O
I O
IFNs O
in O
the O
generation O
of O
adaptive O
immunity O
. O

Furthermore O
, O
animals O
that O
are O
unresponsive O
to O
type O
I O
IFN O
develop O
long O
- O
term O
anti O
- O
SeV O
immunity O
, O
including O
CD8 O
( O
+ O
) O
T O
cells O
and O
antibodies O
. O

) O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
one O
of O
the O
most O
studied O
models O
for O
virus O
- O
induced O
immunopathology O
, O
and O
based O
on O
results O
from O
perforin O
- O
deficient O
mice O
, O
it O
is O
currently O
assumed O
that O
fatal O
disease O
directly O
reflects O
perforin O
- O
mediated O
cell O
lysis O
. O

We O
confirmed O
that O
the O
expansion O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
is O
unimpaired O
in O
perforin O
- O
deficient O
mice O
. O

However O
, O
despite O
the O
fact O
that O
the O
virus O
- O
specific O
CD8 O
( O
+ O
) O
effector O
T O
cells O
in O
perforin O
- O
deficient O
mice O
are O
broadly O
impaired O
in O
their O
effector O
function O
, O
these O
mice O
invariably O
succumb O
to O
i O
. O

Upon O
further O
investigation O
, O
we O
found O
that O
this O
delay O
correlates O
with O
the O
delayed O
recruitment O
of O
inflammatory O
cells O
to O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

However O
, O
CD8 O
( O
+ O
) O
effector O
T O
cells O
were O
not O
kept O
from O
the O
CNS O
by O
sequestering O
in O
infected O
extraneural O
organ O
sites O
such O
as O
liver O
or O
lungs O
. O

However O
, O
once O
accumulated O
in O
the O
CNS O
, O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
can O
induce O
fatal O
CNS O
pathology O
despite O
the O
absence O
of O
perforin O
- O
mediated O
lysis O
and O
reduced O
capacity O
to O
produce O
several O
key O
cytokines O
. O

The O
receptor O
for O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
the O
human O
pathogenic O
Lassa B
fever I
virus I
( I
LFV I
) I
, O
and O
clade O
C O
New O
World O
arenaviruses O
is O
et O
- O
dystroglycan O
( O
alpha O
- O
DG O
) O
, O
a O
cell O
surface O
receptor O
for O
proteins O
of O
the O
extracellular B
matrix I
( I
ECM I
) I
. O

alpha B
- I
dystroglycan I
( I
alpha I
- I
DG I
) I
was O
identified O
as O
a O
common O
receptor O
for O
lymphocytic B
choriomeningitis I
virus I
( I
LCMW I
) I
and O
several O
other O
arenaviruses O
including O
the O
human O
pathogenic O
Lassa O
fever O
virus O
. O

Moreover O
, O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
an O
important O
model O
for O
the O
study O
of O
viral O
persistence O
and O
associated O
diseases O
, O
as O
well O
as O
for O
exploring O
therapies O
to O
treat O
viral O
chronic O
infections O
. O

The O
use O
of O
small B
interfering I
RNAs I
( I
siRNAs I
) I
to O
downregulate O
gene O
expression O
via O
RNA B
interference I
( I
RNAi I
) I
has O
emerged O
as O
a O
powerful O
genetic O
tool O
for O
the O
study O
of O
gene O
function O
. O

Using O
the O
mouse O
model O
of O
an O
acute O
and O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
, O
we O
have O
examined O
the O
relative O
importance O
of O
peripheral O
T O
cells O
and O
thymic O
emigrants O
in O
the O
elicitation O
and O
maintenance O
of O
CD8 O
T O
- O
cell O
responses O
. O

Virus O
- O
specific O
CD8 O
T O
- O
cell O
responses O
were O
compared O
between O
mice O
that O
were O
either O
sham O
thymectomized O
or O
thymectomized O
( O
Thx O
) O
at O
similar O
to O
6 O
weeks O
of O
age O
. O

The O
recently O
emerged O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
is O
a O
potent O
pathogen O
of O
humans O
and O
is O
capable O
of O
rapid O
global O
spread O
. O

Peptide B
- I
conjugated I
antisense I
morpholino I
oligomers I
( I
P I
- I
PMO I
) I
were O
designed O
to O
bind O
by O
base O
pairing O
to O
specific O
sequences O
in O
the O
SARS O
- O
CoV O
( O
Tor2 O
strain O
) O
genome O
. O

Two O
P O
- O
PMO O
targeting O
the O
viral O
transcription B
- I
regulatory I
sequence I
( I
TRS I
) I
region O
in O
the O
5 O
' O
untranslated O
region O
were O
the O
most O
effective O
inhibitors O
tested O
. O

Bone O
marrow O
chimeras O
were O
used O
to O
determine O
the O
cellular O
target O
( O
s O
) O
for O
the O
antiviral O
activity O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

By O
transfusing O
such O
mice O
with O
high O
numbers O
of O
naive O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
, O
a O
system O
was O
created O
in O
which O
the O
majority O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
would O
be O
capable O
of O
responding O
to O
IFN O
- O
gamma O
, O
but O
expression O
of O
the O
relevant O
receptor O
on O
non O
- O
T O
cells O
could O
be O
experimentally O
controlled O
. O

Here O
we O
show O
that O
5 O
- O
fluorouracil O
( O
FU O
) O
- O
induced O
mutagenesis O
of O
the O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
resulted O
in O
preextinction O
populations O
whose O
consensus O
genomic O
nucleotide O
sequence O
remained O
unaltered O
. O

Alpha O
/ O
beta O
interferons O
( O
IFNs O
- O
alpha O
/ O
beta O
) O
are O
cytokines O
that O
play O
an O
essential O
role O
in O
the O
host O
defense O
against O
viral O
infection O
. O

Our O
previous O
studies O
have O
shown O
that O
the O
key O
IFN O
signaling O
molecule O
STAT1 O
is O
highly O
elevated O
and O
activated O
in O
central O
nervous O
system O
neurons O
during O
viral O
infection O
and O
in O
transgenic O
mice O
with O
astrocyte O
production O
of O
IFN O
- O
alpha O
( O
glial O
fibrillary O
acidic O
protein O
[ O
GFAP O
] O
- O
IFN O
- O
alpha O
) O
, O
suggesting O
that O
neurons O
are O
a O
very O
responsive O
target O
cell O
population O
for O
IFNs O
. O

Gene O
chip O
analysis O
was O
applied O
to O
RNA O
from O
IFN O
- O
alpha O
- O
treated O
or O
untreated O
primary O
cortical O
neuronal O
cultures O
derived O
from O
embryonic O
day O
15 O
fetal O
wild O
- O
type O
or O
STAT1 O
knockout B
( I
KO I
) I
mice O
. O

To O
examine O
these O
issues O
, O
we O
studied O
the O
impact O
of O
therapeutic O
vaccination O
, O
using O
a O
murine O
model O
of O
chronic O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

The O
arenavirus O
L O
protein O
has O
the O
characteristic O
sequence O
motifs O
conserved O
among O
the O
RNA O
- O
dependent O
RNA O
polymerase O
L O
proteins O
of O
negative O
- O
strand O
( O
NS O
) O
RNA O
viruses O
. O

We O
have O
examined O
the O
role O
of O
these O
conserved O
residues O
in O
the O
polymerase O
activity O
of O
the O
L O
protein O
of O
the O
prototypic O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
in O
vivo O
using O
a O
minigenome O
rescue O
assay O
. O

interferon B
regulatory I
factors I
( I
IRFs I
) I
are O
a O
family O
of O
transcription O
factors O
involved O
in O
the O
regulation O
of O
the O
Interferons B
( I
IFNs I
) I
and O
other O
genes O
that O
may O
have O
an O
essential O
role O
in O
antiviral O
defense O
in O
the O
central O
nervous O
system O
, O
although O
this O
is O
currently O
not O
well O
defined O
. O

Several O
IRF O
genes O
( O
IRF O
- O
2 O
, O
- O
3 O
, O
- O
5 O
, O
- O
7 O
, O
and O
- O
9 O
) O
were O
expressed O
at O
low O
levels O
in O
the O
brain O
of O
uninfected O
mice O
. O

Following O
intracranial O
infection O
with O
lymphocytic B
choriomeningitis I
virus I
( I
LCW I
) I
, O
expression O
of O
the O
IRF O
- O
7 O
and O
IRF O
- O
9 O
genes O
increased O
significantly O
by O
day O
2 O
. O

IRF O
- O
7 O
and O
IRF O
- O
9 O
gene O
expression O
was O
increased O
in O
LCW O
- O
infected O
brain O
from O
IFN O
- O
gamma O
knockout B
( I
KO I
) I
but O
not O
IFN O
- O
alpha O
/ O
beta O
R O
KO O
animals O
. O

Thus O
, O
( O
i O
) O
many O
of O
the O
IRF O
genes O
were O
expressed O
constitutively O
in O
the O
mouse O
brain O
; O
( O
ii O
) O
the O
IRF O
- O
7 O
and O
IRF O
- O
9 O
genes O
were O
upregulated O
during O
viral O
infection O
, O
a O
process O
dependent O
on O
IFN O
- O
alpha O
/ O
beta O
but O
not O
IFN O
- O
gamma O
; O
and O
( O
iii O
) O
IRF O
- O
7 O
but O
not O
IRF O
- O
9 O
gene O
expression O
can O
be O
stimulated O
in O
a O
STAT1 O
- O
independent O
but O
STAT2 O
- O
dependent O
fashion O
via O
unidentified O
indirect O
pathways O
coupled O
to O
the O
activation O
of O
the O
IFN O
- O
alpha O
/ O
beta O
receptor O
. O

The O
cellular O
receptor O
for O
the O
Old O
World O
arenaviruses O
Lassa B
fever I
virus I
( I
LFV I
) I
and O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
has O
recently O
been O
identified O
as O
alpha B
- I
dystroglycan I
( I
alpha I
- I
DG I
) I
, O
a O
cell O
surface O
receptor O
that O
provides O
a O
molecular O
link O
between O
the O
extracellullar O
matrix O
and O
the O
actin O
- O
based O
cytoskeleton O
. O

Recombinant O
vesicular O
stomatitis O
virus O
pseudotyped O
with O
LFV O
glycoprotein B
( I
GP I
) I
adopted O
the O
receptor O
binding O
characteristics O
of O
LFV O
and O
depended O
on O
alpha O
- O
DG O
for O
infection O
of O
cells O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
an O
enveloped O
virus O
with O
a O
genome O
organization O
characteristic O
of O
Mononegavirales O
. O

Antigen O
- O
experienced O
T O
cells O
have O
been O
divided O
into O
CD62L O
( O
+ O
) O
CCR7 O
( O
+ O
) O
central O
memory O
( O
T O
- O
CM O
) O
and O
CD62L O
( O
- O
) O
CCR7 O
( O
- O
) O
effector O
memory O
( O
T O
- O
EM O
) O
cells O
. O

Three O
main O
points O
emerged O
: O
firstly O
, O
memory O
cells O
frequently O
expressed O
a O
mixed O
CD62L O
( O
- O
) O
CCR7 O
( O
+ O
) O
phenotype O
that O
differed O
from O
the O
phenotypes O
of O
classical O
T O
- O
EM O
and O
T O
- O
CM O
cells O
; O
secondly O
, O
T O
- O
EM O
cells O
were O
not O
restricted O
to O
lymphoid O
organs O
but O
were O
also O
present O
in O
significant O
numbers O
in O
nonlymphoid O
tissues O
; O
and O
thirdly O
, O
a O
major O
shift O
from O
a O
T O
- O
CM O
to O
T O
- O
EM O
phenotype O
was O
found O
in O
memory O
cells O
that O
had O
been O
stimulated O
repetitively O
with O
antigen O
. O

Each O
genome O
segment O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
encodes O
two O
genes O
in O
ambisense O
orientation O
, O
separated O
by O
an O
intergenic B
region I
( I
IGR I
) I
. O

We O
have O
studied O
the O
role O
of O
the O
LCMV O
IGR O
by O
using O
a O
minigenome B
( I
MG I
) I
rescue O
system O
based O
on O
RNA O
analogues O
of O
the O
short O
genome O
segment O
. O

An O
ambisense O
MG O
coding O
for O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
and O
green O
fluorescent O
protein O
reporter O
genes O
instead O
of O
the O
nucleoprotein O
and O
glycoprotein O
open O
reading O
frames O
, O
respectively O
, O
served O
as O
a O
template O
for O
synthesis O
of O
full O
- O
length O
anti B
- I
MG I
( I
aMG I
) I
replicate O
and O
subgenomic O
size O
mRNA O
for O
reporter O
gene O
expression O
. O

Two O
interior O
layers O
of O
density O
apposed O
to O
the O
inner O
leaflet O
of O
the O
viral O
lipid O
billayer O
were O
assigned O
as O
protein O
Z O
and O
nucleoprotein B
( I
NP I
) I
molecules O
on O
the O
basis O
of O
their O
appearance O
, O
spacing O
, O
and O
projected O
volume O
. O

A O
virulent O
strain O
of O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
- I
WE I
) I
that O
destroys O
hematopoietic O
, O
vascular O
, O
and O
liver O
functions O
also O
alters O
the O
transcription O
and O
subcellular O
localization O
of O
PRH O
. O

A O
related O
virus O
( O
LCMV O
- O
ARM O
) O
that O
does O
not O
cause O
disease O
in O
primates O
can O
infect O
cells O
without O
affecting O
PRH O
. O

Biochemical O
experiments O
demonstrated O
the O
occurrence O
of O
binding O
between O
the O
viral O
RING O
protein O
( O
Z O
) O
and O
PRH O
, O
and O
genetic O
experiments O
mapped O
the O
PRH O
- O
suppressing O
phenotype O
to O
the O
large B
( I
L I
) I
segment O
of O
the O
viral O
genome O
, O
which O
encodes O
the O
Z O
and O
polymerase O
genes O
. O

The O
role O
of O
Tumor B
necrosis I
factor I
( I
TNF I
) I
in O
regulating O
various O
phases O
of O
the O
antiviral O
T O
- O
cell O
response O
is O
incompletely O
understood O
. O

To O
address O
these O
issues O
, O
we O
have O
investigated O
the O
role O
of O
tumor B
necrosis I
factor I
receptors I
( I
TNFRs I
) I
I O
( O
p55R O
) O
and O
II O
( O
p75R O
) O
in O
regulating O
CD8 O
T O
- O
cell O
responses O
to O
lymphocytic B
choriomeningitis I
virus I
( I
LCNW I
) I
with O
wild O
- O
type O
, O
p55R O
- O
deficient O
( O
p55 O
( O
- O
/ O
- O
) O
) O
, O
p75R O
- O
deficient O
( O
p75 O
( O
- O
/ O
- O
) O
) O
, O
and O
p55R O
- O
and O
p75R O
- O
deficient O
( O
DKO O
) O
mice O
. O

Strikingly O
, O
deficiency O
of O
both O
p55R O
and O
p75R O
had O
a O
more O
dramatic O
effect O
on O
the O
LCW O
- O
specific O
CD8 O
T O
- O
cell O
response O
; O
in O
the O
DKO O
mice O
, O
as O
a O
sequel O
to O
enhanced O
expansion O
and O
a O
reduction O
in O
contraction O
of O
CD8 O
T O
cells O
, O
there O
was O
a O
substantial O
increase O
in O
the O
number O
of O
memory O
CD8 O
T O
cells O
( O
specific O
to O
the O
two O
immunodominant O
epitopes O
) O
. O

While O
the O
majority O
of O
LCW O
- O
specific O
memory O
CD8 O
T O
cells O
in O
wild O
- O
type O
mice O
were O
CD62L O
( O
hi O
) O
CCR7 O
( O
hi O
) O
( O
central O
memory O
) O
, O
a O
major O
proportion O
of O
memory O
CD8 O
T O
cells O
in O
DKO O
mice O
were O
CD62L O
( O
lo O
) O
CCR7 O
( O
hi O
) O
. O

Genomic O
and O
antigenomic O
minigenomes B
( I
MG I
) I
were O
constructed O
consisting O
of O
the O
intergenic O
region O
of O
S O
RNA O
and O
a O
reporter O
gene O
( O
Renilla O
luciferase O
) O
in O
antisense O
orientation O
, O
flanked O
by O
the O
5 O
' O
and O
3 O
' O
untranslated O
regions O
of O
S O
RNA O
. O

nucleoprotein B
( I
NP I
) I
, O
L O
protein O
, O
and O
Z O
protein O
were O
expressed O
from O
plasmids O
containing O
the O
T7 O
promoter O
and O
internal O
ribosomal O
entry O
site O
. O

Transfection O
of O
cells O
stably O
expressing O
T7 O
RNA O
polymerase O
( O
BSR O
T7 O
/ O
5 O
) O
with O
MG O
in O
the O
form O
of O
DNA O
or O
RNA O
and O
plasmids O
for O
the O
expression O
of O
NP O
and O
L O
protein O
resulted O
in O
high O
levels O
of O
Renilla O
luciferase O
expression O
. O

In O
this O
report O
we O
questioned O
the O
current O
view O
that O
the O
two O
principal O
cytotoxic O
pathways O
, O
the O
exocytosis O
and O
the O
Fas B
ligand I
( I
FasL I
) I
/ O
Fas O
- O
mediated O
pathway O
, O
have O
largely O
nonoverlapping O
biological O
roles O
. O

For O
this O
purpose O
we O
have O
analyzed O
the O
response O
of O
mice O
that O
lack O
Fas O
as O
well O
as O
granzyme B
A I
( I
gzmA I
) I
and O
gzmB O
( O
FasxgzmAxB O
( O
- O
/ O
- O
) O
) O
to O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

We O
show O
that O
FasxgzmAxB O
( O
- O
/ O
- O
) O
mice O
, O
in O
contrast O
to O
B6 O
, O
Fas O
( O
- O
/ O
- O
) O
, O
and O
gzmAxB O
( O
- O
/ O
- O
) O
mice O
, O
do O
not O
recover O
from O
a O
primary O
infection O
with O
LCMV O
, O
in O
spite O
of O
the O
expression O
of O
comparable O
numbers O
of O
LCMV O
- O
immune O
and O
gamma O
interferon O
- O
producing O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
in O
all O
mouse O
strains O
tested O
. O

Ex O
vivo O
- O
derived O
FasxgzmAxB O
( O
- O
/ O
- O
) O
CTL O
lacked O
nucleolytic O
activity O
and O
expressed O
reduced O
cytolytic O
activity O
compared O
to O
B6 O
and O
Fas O
( O
- O
/ O
- O
) O
CTL O
. O

Furthermore O
, O
virus O
- O
immune O
CTL O
with O
functional O
FasL O
and O
perforin O
( O
gzmAxB O
( O
- O
/ O
- O
) O
) O
are O
more O
potent O
in O
causing O
target O
cell O
apoptosis O
in O
vitro O
than O
those O
expressing O
FasL O
alone O
( O
perfxgzmAxB O
( O
- O
/ O
- O
) O
) O
. O

This O
synergistic O
effect O
of O
perforin O
on O
Fas O
- O
mediated O
nucleolysis O
of O
target O
cells O
is O
indicated O
by O
the O
fact O
that O
, O
compared O
to O
perfxgzmAxB O
( O
- O
/ O
- O
) O
CTL O
, O
gzmAxB O
( O
- O
/ O
- O
) O
CTL O
induced O
( O
i O
) O
an O
accelerated O
decrease O
in O
mitochondrial O
transmembrane O
potential O
, O
( O
ii O
) O
increased O
generation O
of O
reactive O
oxygen O
species O
, O
and O
( O
iii O
) O
accelerated O
phosphatidylserine O
exposure O
on O
plasma O
membranes O
. O

Lassa B
virus I
( I
LV I
) I
and O
Mopeia B
virus I
( I
MV I
) I
are O
closely O
related O
members O
of O
the O
Arenavirus O
genus O
, O
sharing O
75 O
% O
amino O
acid O
sequence O
identity O
. O

We O
have O
previously O
shown O
that O
antigen B
- I
presenting I
cells I
( I
APC I
) I
- O
macrophages B
( I
MP I
) I
and O
dendritic B
cells I
( I
DC I
) I
- O
sustain O
high O
replication O
rates O
of O
LV O
but O
are O
not O
activated O
, O
suggesting O
that O
they O
play O
a O
role O
in O
the O
immunosuppression O
observed O
in O
severe O
cases O
of O
Lassa O
fever O
. O

Moreover O
, O
unlike O
DC O
, O
MP O
were O
early O
and O
strongly O
activated O
in O
response O
to O
MV O
, O
as O
shown O
by O
the O
increased O
surface O
expression O
of O
CD86 O
, O
CD80 O
, O
CD54 O
, O
CD40 O
, O
and O
HLA O
- O
abc O
and O
by O
the O
production O
of O
mRNA O
encoding O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
IFN O
- O
beta O
, O
tumor O
necrosis O
factor O
alpha O
and O
interleukin O
- O
6 O
. O

Unlike O
naive O
CD8 O
( O
+ O
) O
T O
cells O
, O
antigen O
- O
experienced O
memory O
CD8 O
( O
+ O
) O
T O
cells O
persist O
over O
time O
due O
to O
their O
unique O
ability O
to O
homeostatically O
proliferate O
. O

To O
test O
this O
, O
the O
expression O
levels O
of O
96 O
different O
cell O
cycle O
regulatory O
genes O
were O
compared O
between O
transgenic O
naive O
and O
memory O
CD8 O
( O
+ O
) O
T O
cells O
that O
specifically O
recognize O
the O
GP33 O
- O
41 O
epitope O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Some O
of O
these O
genes O
include O
those O
encoding O
cyclins O
D3 O
, O
D2 O
, O
B1 O
, O
C O
, O
and O
H O
, O
cyclin O
- O
dependent O
kinases O
( O
cdk O
' O
s O
) O
4 O
and O
6 O
, O
the O
cdk O
inhibitors O
p16 O
, O
p15 O
, O
and O
p18 O
, O
and O
other O
genes O
involved O
in O
protein O
degradation O
and O
DNA O
replication O
. O

Importantly O
, O
these O
differences O
were O
observed O
both O
in O
total O
populations O
of O
LCMV O
- O
specific O
naive O
and O
memory O
CD8 O
( O
+ O
) O
cells O
and O
in O
LCW O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
that O
were O
in O
the O
G O
, O
phase O
of O
the O
cell O
cycle O
only O
. O

The O
fact O
that O
memory O
cells O
are O
precharged O
with O
several O
of O
the O
major O
factors O
that O
are O
necessary O
for O
the O
G O
( O
1 O
) O
- O
to O
- O
S O
- O
phase O
transition O
suggests O
they O
may O
require O
a O
lower O
threshold O
of O
stimulation O
to O
enter O
the O
cell O
cycle O
. O

During O
many O
viral O
infections O
, O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
undergo O
large O
- O
scale O
expansion O
. O

After O
viral O
clearance O
, O
the O
vast O
majority O
of O
effector O
CD8 O
( O
+ O
) O
T O
cells O
undergo O
apoptosis O
. O

Previous O
studies O
have O
implicated O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
in O
lymphocyte O
apoptosis O
. O

The O
purpose O
of O
the O
experiments O
presented O
here O
was O
to O
determine O
the O
role O
of O
ROI O
in O
the O
expansion O
and O
contraction O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
vivo O
during O
a O
physiological O
response O
such O
as O
viral O
infection O
. O

Mice O
were O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
treated O
with O
Mn O
( O
III O
) O
tetrakis O
( O
4 O
- O
benzoic O
acid O
) O
porphyrin O
chloride O
( O
MnTBAP O
) O
, O
a O
metalloporphyrin O
- O
mimetic O
compound O
with O
superoxide O
dismutase O
activity O
, O
from O
days O
0 O
to O
8 O
postinfection O
. O

At O
the O
peak O
of O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
, O
on O
day O
8 O
postinfection O
, O
the O
numbers O
of O
antigen O
- O
specific O
cells O
were O
10 O
- O
fold O
lower O
in O
MnTBAP O
- O
treated O
mice O
than O
in O
control O
mice O
. O

From O
days O
8 O
to O
30 O
, O
a O
contraction O
phase O
ensued O
where O
the O
numbers O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
declined O
25 O
- O
fold O
in O
vehicle O
- O
treated O
mice O
compared O
to O
a O
3 O
. O

By O
day O
38 O
, O
the O
numbers O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
memory O
T O
cells O
were O
equivalent O
for O
the O
two O
groups O
. O

The O
administration O
of O
MnTBAP O
during O
secondary O
viral O
infection O
had O
no O
effect O
on O
the O
expansion O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
secondary O
effector O
T O
cells O
. O

These O
data O
suggest O
that O
ROI O
production O
is O
critical O
for O
the O
massive O
expansion O
and O
contraction O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
during O
primary O
, O
but O
not O
secondary O
, O
viral O
infection O
. O

The O
primary O
structure O
of O
Z O
is O
devoid O
of O
hydrophobic O
transmembrane O
domains O
, O
but O
both O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
Lassa O
fever O
virus O
Z O
proteins O
accumulate O
near O
the O
inner O
surface O
of O
the O
plasma O
membrane O
and O
are O
strongly O
membrane O
associated O
. O

All O
known O
arenavirus O
Z O
proteins O
contain O
a O
Glycine B
( I
G I
) I
at O
position O
2 O
, O
which O
is O
a O
potential O
acceptor O
site O
for O
a O
myristoyl O
moiety O
. O

Here O
we O
document O
that O
mutated O
, O
preextinction O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
RNA O
can O
interfere O
with O
and O
delay O
viral O
production O
up O
to O
30 O
h O
when O
cotransfected O
in O
BHK O
- O
21 O
cells O
with O
standard O
RNA O
. O

CD8 O
( O
+ O
) O
T O
cells O
are O
critical O
for O
the O
control O
of O
many O
persistent O
viral O
infections O
, O
such O
as O
human O
immunodeficiency O
virus O
, O
hepatitis O
C O
virus O
, O
Epstein O
- O
Barr O
virus O
, O
and O
cytomegalovirus B
( I
CMV I
) I
. O

In O
most O
infections O
, O
large O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
populations O
are O
induced O
early O
, O
but O
then O
contract O
and O
are O
maintained O
thereafter O
at O
lower O
levels O
. O

In O
contrast O
, O
CD8 O
( O
+ O
) O
T O
cells O
specific O
for O
murine B
CMV I
( I
MCMV I
) I
have O
been O
shown O
to O
gradually O
accumulate O
after O
resolution O
of O
primary O
infection O
. O

This O
unique O
behavior O
is O
restricted O
to O
certain O
epitopes O
, O
including O
an O
immunodominant O
epitope O
derived O
from O
the O
immediate B
- I
early I
1 I
( I
IE1 I
) I
gene O
product O
. O

To O
explore O
the O
mechanism O
behind O
this O
further O
, O
we O
measured O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
- O
mediated O
immunity O
induced O
by O
recombinant O
MCMV O
- O
expressing O
epitopes O
derived O
from O
influenza O
A O
virus O
or O
lymphocytic O
choriomeningitis O
virus O
placed O
under O
the O
control O
of O
an O
IE O
promoter O
. O

We O
observed O
that O
virus O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
populations O
were O
induced O
and O
that O
these O
expanded O
gradually O
over O
time O
. O

Importantly O
, O
these O
CD8 O
( O
+ O
) O
T O
cells O
provided O
long O
- O
term O
protection O
against O
challenge O
without O
boosting O
. O

Arenaviruses O
include O
Lassa B
fever I
virus I
( I
LFV I
) I
and O
the O
South O
American O
hemorrhagic O
fever O
viruses O
. O

Arenaviruses O
are O
enveloped O
viruses O
with O
a O
bisegmented O
negative O
- O
strand O
RNA O
genome O
whose O
proteomic O
capability O
is O
limited O
to O
four O
polypeptides O
: O
nucleoprotein B
( I
NP I
) I
; O
surface B
glycoprotein I
( I
GP I
) I
, O
which O
is O
proteolytically O
processed O
into O
GP1 O
and O
GP2 O
; O
polymerase O
( O
L O
) O
; O
and O
a O
small O
( O
11 O
- O
kDa O
) O
RING O
finger O
protein O
( O
Z O
) O
. O

Our O
investigators O
have O
previously O
shown O
that O
Z O
has O
a O
strong O
inhibitory O
activity O
on O
RNA O
synthesis O
mediated O
by O
the O
polymerase O
of O
the O
prototypic O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

In O
this O
report O
we O
show O
that O
cells O
transduced O
with O
a O
replication O
- O
deficient O
recombinant O
adenovirus O
expressing O
Z O
( O
rAd O
- O
Z O
) O
are O
resistant O
to O
LCMV O
and O
LFV O
infection O
. O

The O
high O
pathogenicity O
of O
Lassa O
virus O
is O
assumed O
to O
involve O
resistance O
to O
the O
effects O
of O
interferon B
( I
IFN I
) I
. O

We O
have O
analyzed O
the O
effects O
of O
alpha O
IFN O
( O
IFN O
- O
alpha O
) O
, O
IFN O
- O
gamma O
, O
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
on O
replication O
of O
Lassa O
virus O
compared O
to O
the O
related O
, O
but O
less O
pathogenic O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Three O
low O
- O
passage O
Lassa O
virus O
strains O
( O
AV O
, O
NL O
, O
and O
CSF O
) O
, O
isolated O
from O
humans O
with O
mild O
to O
fulminant O
Lassa O
fever O
, O
were O
tested O
. O

Furthermore O
, O
cytokine O
effects O
observed O
for O
Lassa O
virus O
and O
LCMV O
( O
strains O
CH O
- O
5692 O
, O
Armstrong O
, O
and O
WE O
) O
were O
similar O
. O

To O
address O
the O
mechanisms O
involved O
in O
the O
IFN O
effect O
, O
we O
used O
cell O
lines O
in O
which O
overexpression O
of O
IFN O
- O
stimulated O
proteins O
promyelocytic B
leukemia I
protein I
( I
PML I
) I
and O
Sp100 O
could O
be O
induced O
. O

The O
immune O
response O
to O
lymphocytic O
choriomeningitis O
virus O
in O
mice O
lacking O
macrophage O
inflammatory O
protein O
- O
1alpha O
( O
MIP O
- O
1alpha O
) O
was O
evaluated O
. O

Here O
we O
demonstrate O
that O
the O
Lassa O
virus O
Z O
protein O
( O
i O
) O
is O
abundant O
in O
viral O
particles O
, O
( O
ii O
) O
is O
strongly O
membrane O
associated O
, O
( O
iii O
) O
is O
sufficient O
in O
the O
absence O
of O
all O
other O
viral O
proteins O
to O
release O
enveloped O
particles O
, O
and O
( O
iv O
) O
contains O
two O
late O
domains O
, O
PTAP O
and O
PPXY O
, O
necessary O
for O
the O
release O
of O
virus O
- O
like O
particles O
. O

Mice O
were O
infected O
in O
the O
footpad O
, O
and O
the O
induced O
CD8 O
( O
+ O
) O
T O
- O
cell O
- O
dependent O
inflammation O
was O
evaluated O
in O
mice O
subjected O
to O
treatment O
with O
vMIP O
- O
II O
. O

In O
vitro O
studies O
revealed O
that O
vMIP O
- O
II O
inhibited O
chemokine O
- O
induced O
migration O
of O
activated O
CD8 O
( O
+ O
) O
T O
cells O
, O
but O
not O
T O
- O
cell O
- O
target O
cell O
contact O
, O
granule O
exocytosis O
, O
or O
cytokine O
release O
. O

The O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
Tat O
protein O
has O
a O
critical O
role O
in O
viral O
transcription O
, O
but O
this O
study O
focuses O
on O
its O
additional O
role O
as O
an O
extracellular O
effector O
of O
lymphocyte O
cell O
death O
. O

It O
is O
well O
known O
that O
Tat O
induces O
tumor B
necrosis I
factor I
- I
related I
apoptosis I
- I
induced I
ligand I
( I
TRAIL I
) I
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
and O
we O
show O
that O
the O
majority O
of O
TRAIL O
is O
produced O
by O
the O
monocyte O
subset O
of O
PBMC O
. O

Using O
different O
strains O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
we O
compared O
responses O
to O
the O
same O
CD8 O
T O
- O
cell O
epitopes O
during O
acute O
or O
chronic O
infection O
. O

The O
envelope O
glycoprotein B
( I
GP I
) I
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
posttranslationally O
cleaved O
into O
two O
subunits O
. O

By O
systematic O
mutational O
analysis O
of O
the O
LCMV O
GP O
cleavage O
site O
, O
we O
determined O
that O
the O
consensus O
motif O
R O
- O
( O
R O
/ O
K O
/ O
H O
) O
- O
L O
- O
( O
A O
/ O
L O
/ O
S O
/ O
T O
/ O
F O
) O
( O
265 O
) O
is O
essential O
for O
the O
endoproteolytic O
processing O
. O

The O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
has O
a O
bisegmented O
negative O
- O
strand O
RNA O
genome O
. O

Each O
segment O
carries O
two O
viral O
genes O
in O
opposite O
orientation O
and O
separated O
by O
an O
intergenic B
region I
( I
IGR I
) I
. O

The O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
L O
of O
LCMV O
produces O
subgenomic O
mRNA O
and O
full O
- O
length O
genomic O
and O
antigenomic O
RNA O
species O
in O
two O
different O
processes O
termed O
transcription O
and O
replication O
, O
respectively O
. O

It O
is O
widely O
accepted O
that O
intracellular O
nucleoprotein B
( I
NP I
) I
levels O
regulate O
these O
two O
processes O
. O

To O
test O
this O
hypothesis O
, O
we O
established O
a O
helper O
- O
virus O
- O
free O
minigenome B
( I
MG I
) I
system O
where O
intracellular O
synthesis O
of O
an O
S O
segment O
analogue O
from O
a O
plasmid O
is O
driven O
by O
RNA O
polymerase O
I O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
Lassa O
virus O
can O
cause O
hemorrhagic O
fever O
and O
liver O
disease O
in O
primates O
. O

The O
WE O
strain O
of O
LCMV O
( O
LCMV O
- O
WE O
) O
causes O
a O
fatal O
Lassa O
fever O
- O
like O
disease O
in O
rhesus O
macaques O
and O
provides O
a O
model O
for O
arenavirus O
pathogenesis O
in O
humans O
. O

LCMV O
- O
WE O
delivered O
intravenously O
or O
intragastrically O
to O
rhesus O
macaques O
targets O
hepatocytes O
and O
induces O
high O
levels O
of O
liver O
enzymes O
, O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
soluble B
IL I
- I
6 I
receptor I
( I
sIL I
- I
6R I
) I
, O
and O
soluble O
tumor O
necrosis O
factor O
receptors O
( O
sTNFRI O
and O
- O
II O
) O
in O
plasma O
during O
acute O
infection O
. O

The O
genome O
of O
the O
prototypic O
arenavirus O
lymphocytic B
choriomeningitis I
virus I
( I
LCW I
) I
consists O
of O
two O
negative O
- O
sense O
, O
single O
- O
strand O
RNA O
segments O
designated O
L O
and O
S O
. O

All O
arenavirus O
genomes O
examined O
to O
date O
have O
a O
conserved O
terminal O
sequence O
element O
( O
3 O
' O
- O
terminal O
20 O
nucleotides O
[ O
nt O
] O
) O
thought O
to O
be O
a O
highly O
conserved O
viral O
promoter O
. O

A O
series O
of O
overlapping O
deletions O
spanning O
the O
3 O
' O
- O
terminal O
20 O
- O
nt O
region O
of O
an O
LCW O
minigenome B
( I
MG I
) I
was O
generated O
, O
and O
the O
mutant O
MGs O
were O
analyzed O
for O
their O
activity O
as O
templates O
for O
RNA O
synthesis O
by O
the O
LCMV O
polymerase O
. O

Here O
we O
show O
that O
DNA O
vaccination O
at O
birth O
results O
in O
the O
rapid O
induction O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
within O
neonatal O
life O
. O

Analyses O
of O
T O
- O
cell O
effector O
functions O
critical O
for O
the O
resolution O
of O
many O
viral O
infections O
revealed O
that O
neonatal O
and O
adult O
CD8 O
( O
+ O
) O
T O
cells O
produce O
similar O
arrays O
of O
cytokines O
. O

Furthermore O
, O
the O
avidities O
of O
neonatal O
and O
adult O
CD8 O
( O
+ O
) O
T O
cells O
for O
peptide O
and O
the O
rapidity O
with O
which O
they O
upregulate O
cytokine O
production O
after O
recall O
encounters O
with O
antigen O
are O
similar O
. O

Protective O
immunity O
against O
the O
arenavirus O
lymphocytic O
choriomeningitis O
virus O
, O
which O
is O
mediated O
by O
CD8 O
( O
+ O
) O
cytotoxic O
T O
cells O
, O
is O
also O
rapidly O
acquired O
within O
the O
neonatal O
period O
. O

Collectively O
these O
data O
imply O
that O
, O
at O
least O
in O
the O
case O
of O
CD8 O
( O
+ O
) O
T O
cells O
, O
neonates O
are O
not O
as O
immunodeficient O
as O
previously O
supposed O
and O
that O
DNA O
vaccines O
may O
be O
an O
effective O
and O
safe O
means O
of O
providing O
critical O
cell O
- O
mediated O
antiviral O
immunity O
extremely O
early O
in O
life O
. O

Targeted O
expression O
of O
biologically O
active O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
in O
astrocytes O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
results O
in O
spontaneous O
neuroinmumological O
disease O
of O
aged O
mice O
. O

Borna B
disease I
virus I
( I
BDV I
) I
can O
readily O
multiply O
in O
the O
mouse O
CNS O
but O
does O
not O
trigger O
disease O
in O
most O
strains O
. O

Histological O
analyses O
showed O
that O
the O
cerebellum O
of O
infected O
IL O
- O
12 O
transgenic O
mice O
, O
which O
is O
the O
brain O
region O
with O
strongest O
transgene O
expression O
, O
contained O
large O
numbers O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
as O
well O
as O
lower O
numbers O
of O
B O
cells O
, O
whereas O
other O
parts O
of O
the O
CNS O
showed O
only O
mild O
infiltration O
by O
lymphocytes O
. O

Pharmacological O
cyclin B
- I
dependent I
kinase I
( I
CDK I
) I
inhibitors O
( O
PCIs O
) O
block O
replication O
of O
several O
viruses O
, O
including O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
and O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

To O
address O
this O
issue O
, O
we O
asked O
whether O
purine B
- I
derived I
PCIs I
( I
P I
- I
PCIs I
) I
inhibit O
HSV O
and O
HIV O
- O
1 O
replication O
by O
targeting O
cellular O
or O
viral O
proteins O
. O

Inoculation O
of O
the O
neonatal O
rat O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
results O
in O
the O
selective O
infection O
of O
several O
neuronal O
populations O
and O
in O
focal O
pathological O
changes O
. O

The O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
an O
enveloped O
virus O
with O
a O
bisegmented O
negative O
- O
strand O
RNA O
genome O
whose O
proteomic O
capability O
is O
limited O
to O
four O
polypeptides O
, O
namely O
, O
nucleoprotein O
; O
surface B
glycoprotein I
( I
GP I
) I
, O
which O
is O
proteolytically O
processed O
into O
GP1 O
and O
GP2 O
; O
polymerase O
( O
L O
) O
; O
and O
a O
small O
( O
11 O
- O
kDa O
) O
RING O
finger O
protein O
( O
Z O
) O
. O

Results O
from O
the O
use O
of O
chimera O
proteins O
between O
Z O
and O
Xenopus O
Neuralized O
, O
a O
nonviral O
RING O
finger O
protein O
, O
indicated O
that O
the O
structural O
integrity O
of O
the O
Z O
RING O
domain O
( O
RD O
) O
was O
required O
but O
not O
sufficient O
for O
the O
inhibitory O
activity O
of O
Z O
. O

Serial O
deletion O
mutants O
of O
the O
N O
and O
C O
termini O
of O
Z O
showed O
that O
the O
N O
terminus O
( O
residues O
1 O
through O
16 O
) O
and O
C O
terminus O
( O
residues O
79 O
through O
90 O
) O
do O
not O
contribute O
to O
the O
Z O
inhibitory O
activity O
. O

A O
highly O
conserved O
Tryptophan B
( I
W I
) I
residue O
located O
at O
position O
36 O
in O
ARM O
- O
Z O
, O
next O
to O
the O
second O
conserved O
cysteine O
( O
C O
) O
residue O
of O
the O
Z O
RD O
, O
also O
contributed O
to O
the O
Z O
inhibitory O
activity O
. O

We O
have O
used O
a O
reverse O
genetic O
approach O
to O
identify O
the O
viral O
proteins O
required O
for O
packaging O
and O
assembly O
of O
the O
prototypic O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Plasmids O
encoding O
individual O
LCMV O
proteins O
under O
the O
control O
of O
an O
RNA O
polymerase O
II O
promoter O
were O
cotransfected O
with O
a O
plasmid O
containing O
an O
LCMV O
minigenome B
( I
MG I
) I
. O

Reconstitution O
of O
LCMV O
- O
specific O
packaging O
and O
passage O
was O
detected O
by O
expression O
of O
the O
chloramphenicol B
acetyl I
transferase I
( I
CAT I
) I
reporter O
gene O
present O
in O
the O
MG O
. O

DNA O
vaccines O
encoding O
isolated O
dominant O
and O
subdominant O
epitopes O
induce O
equivalent O
responses O
, O
confirming O
a O
previous O
demonstration O
that O
coexpression O
of O
dominant O
and O
subdominant O
epitopes O
on O
the O
same O
antigen B
- I
presenting I
cell I
( I
APC I
) I
is O
central O
to O
immunodominance O
. O

In O
addition O
, O
we O
demonstrate O
that O
subdominant O
responses O
are O
actively O
suppressed O
by O
dominant O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
and O
that O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
is O
required O
for O
this O
suppression O
. O

Furthermore O
, O
priming O
of O
CD8 O
( O
+ O
) O
T O
cells O
to O
a O
single O
dominant O
epitope O
results O
in O
strong O
suppression O
of O
responses O
to O
other O
normally O
dominant O
epitopes O
in O
immunocompetent O
mice O
, O
in O
effect O
rendering O
these O
epitopes O
subdominant O
; O
however O
, O
responses O
to O
these O
epitopes O
are O
increased O
6 O
- O
to O
20 O
- O
fold O
in O
mice O
lacking O
IFN O
- O
gamma O
. O

We O
suggest O
that O
, O
in O
agreement O
with O
our O
previous O
observations O
, O
IFN O
- O
gamma O
secretion O
by O
CD8 O
( O
+ O
) O
T O
cells O
is O
highly O
localized O
, O
and O
we O
propose O
that O
its O
immunosuppressive O
effect O
is O
focused O
on O
the O
APC O
with O
which O
the O
dominant O
CD8 O
( O
+ O
) O
T O
cell O
is O
in O
contact O
. O

Viruses O
and O
viral O
components O
can O
be O
potent O
inducers O
of O
Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
. O

In O
culture O
, O
IFN O
- O
alpha O
/ O
beta O
prime O
for O
their O
own O
expression O
, O
in O
response O
to O
viruses O
, O
through O
interferon B
regulatory I
factor I
7 I
( I
IRF I
- I
7 I
) I
induction O
. O

The O
studies O
presented O
here O
evaluated O
the O
requirements O
for O
functional O
IFN O
receptors O
and O
the O
IFN O
signaling O
molecule O
STAT1 O
in O
IFN O
- O
alpha O
/ O
beta O
induction O
during O
infections O
of O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

At O
24 O
h O
after O
infection O
, O
levels O
of O
induced O
IFN O
- O
alpha O
/ O
beta O
in O
serum O
were O
reduced O
90 O
to O
95 O
% O
in O
IFN O
- O
alpha O
/ O
beta O
receptor O
- O
deficient O
( O
IFN O
- O
alpha O
/ O
betaR O
( O
- O
/ O
- O
) O
) O
and O
STAT1 O
( O
- O
/ O
- O
) O
mice O
compared O
to O
those O
in O
wild O
- O
type O
mice O
. O

However O
, O
at O
48 O
h O
, O
these O
mice O
showed O
elevated O
expression O
in O
the O
serum O
whereas O
IFN O
- O
alpha O
/ O
beta O
levels O
were O
still O
reduced O
> O
75 O
% O
in O
IFN O
- O
alpha O
/ O
betagammaR O
( O
- O
/ O
- O
) O
mice O
even O
though O
the O
viral O
burden O
was O
heavy O
. O

IRF O
- O
7 O
mRNA O
was O
induced O
under O
conditions O
of O
IFN O
- O
alpha O
/ O
beta O
production O
, O
including O
late O
production O
in O
IFN O
- O
alpha O
/ O
betaR O
( O
- O
/ O
- O
) O
mice O
. O

alpha B
- I
Dystroglycan I
( I
a I
- I
DG I
) I
has O
been O
identified O
as O
a O
major O
receptor O
for O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
Lassa O
virus O
, O
two O
Old O
World O
arenaviruses O
. O

In O
addition O
, O
GP1 O
amino O
acid O
position O
259 O
also O
appears O
to O
be O
important O
, O
since O
all O
arenaviruses O
showing O
high O
- O
affinity O
alpha O
- O
DG O
binding O
possess O
a O
bulky O
aromatic O
amino O
acid O
( O
tyrosine O
or O
phenylalanine O
) O
at O
this O
position O
. O

recombinant B
vaccinia I
viruses I
( I
rVV I
) I
have O
been O
extensively O
used O
as O
vaccines O
, O
but O
there O
is O
little O
information O
about O
the O
total O
magnitude O
of O
the O
W O
- O
specific O
T O
- O
cell O
response O
and O
how O
this O
compares O
to O
the O
immune O
response O
to O
the O
foreign O
gene O
( O
s O
) O
expressed O
by O
the O
rVV O
. O

To O
address O
this O
issue O
, O
we O
quantitated O
the O
T O
- O
cell O
responses O
to O
both O
the O
viral O
vector O
and O
the O
insert O
following O
the O
infection O
of O
mice O
with O
W O
expressing O
a O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
epitope O
( O
NP118 O
- O
126 O
) O
from O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

( O
i O
) O
VV O
- O
NP118 O
induced O
potent O
and O
long O
- O
lasting O
CD8 O
and O
CD4 O
T O
- O
cell O
responses O
to O
the O
vector O
; O
at O
the O
peak O
of O
the O
response O
( O
similar O
to1 O
week O
) O
, O
there O
were O
similar O
to10 O
( O
7 O
) O
VV O
- O
specific O
CD8 O
T O
cells O
( O
25 O
% O
of O
the O
CD8 O
T O
cells O
) O
and O
similar O
to10 O
( O
6 O
) O
VV O
- O
specific O
CD4 O
T O
cells O
( O
similar O
to5 O
% O
of O
the O
CD4 O
T O
cells O
) O
in O
the O
spleen O
. O

These O
numbers O
decreased O
to O
similar O
to5 O
x O
10 O
( O
5 O
) O
CD8 O
T O
cells O
( O
similar O
to5 O
% O
frequency O
) O
and O
similar O
to10 O
( O
5 O
) O
CD4 O
T O
cells O
( O
similar O
to0 O
. O

( O
ii O
) O
W O
- O
specific O
CD8 O
and O
CD4 O
T O
cells O
were O
capable O
of O
producing O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
and O
interleukin O
- O
2 O
; O
all O
cells O
were O
able O
to O
make O
IFN O
- O
gamma O
, O
a O
subset O
produced O
both O
IFN O
- O
gamma O
and O
TNF O
- O
alpha O
, O
and O
another O
subset O
produced O
all O
three O
cytokines O
. O

( O
iii O
) O
The O
CD8 O
T O
- O
cell O
response O
to O
the O
foreign O
gene O
( O
LCMV O
NP118 O
- O
126 O
epitope O
) O
was O
coordinately O
regulated O
with O
the O
response O
to O
the O
vector O
during O
all O
three O
phases O
( O
expansion O
, O
contraction O
, O
and O
memory O
) O
of O
the O
T O
- O
cell O
response O
. O

The O
importance O
of O
lymphotoxin O
alpha O
( O
LTalpha O
) O
in O
lymphoid O
organogenesis O
is O
well O
established O
. O

To O
determine O
the O
role O
of O
LTalpha O
in O
T O
- O
cell O
activation O
in O
vivo O
, O
we O
compared O
the O
generation O
of O
antigen O
- O
specific O
T O
- O
cell O
responses O
between O
wild O
type O
( O
+ O
/ O
+ O
) O
and O
LTalpha O
- O
deficient O
( O
LTalpha O
( O
- O
/ O
- O
) O
) O
mice O
during O
an O
acute O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Our O
studies O
showed O
that O
LCMV O
- O
infected O
LTalpha O
( O
- O
/ O
- O
) O
mice O
had O
a O
profound O
impairment O
in O
the O
activation O
and O
expansion O
of O
virus O
- O
specific O
CD8 O
T O
cells O
in O
the O
spleen O
, O
as O
determined O
by O
cytotoxicity O
assays O
, O
intracellular O
staining O
for O
gamma O
interferon O
, O
and O
staining O
with O
major O
histocompatibility O
complex O
class O
I O
tetramers O
. O

Further O
, O
the O
non O
- O
lymphoid O
organs O
of O
LTalpha O
( O
- O
/ O
- O
) O
mice O
also O
contained O
substantially O
lower O
number O
of O
LCMV O
- O
specific O
CD8 O
T O
cells O
than O
those O
of O
+ O
/ O
+ O
mice O
. O

Greatly O
reduced O
virus O
- O
specific O
CD8 O
T O
- O
cell O
responses O
in O
LTalpha O
( O
- O
/ O
- O
) O
mice O
led O
to O
a O
defect O
in O
LCMV O
clearance O
from O
the O
tissues O
. O

In O
comparison O
to O
that O
in O
+ O
/ O
+ O
mice O
, O
the O
activation O
of O
LCMV O
- O
specific O
CD4 O
T O
cells O
was O
also O
significantly O
attenuated O
in O
LTalpha O
( O
- O
/ O
- O
) O
mice O
. O

Adoptive O
transfer O
experiments O
were O
conducted O
to O
determine O
if O
abnormal O
lymphoid O
architecture O
in O
LTalpha O
( O
- O
/ O
- O
) O
mice O
caused O
the O
impairment O
in O
the O
activation O
of O
LCMV O
- O
specific O
T O
- O
cell O
responses O
. O

Upon O
adoptive O
transfer O
into O
+ O
/ O
+ O
mice O
, O
the O
activation O
and O
expansion O
of O
LCMV O
- O
specific O
LTalpha O
( O
- O
/ O
- O
) O
T O
cells O
were O
restored O
to O
levels O
comparable O
to O
those O
of O
+ O
/ O
+ O
T O
cells O
. O

In O
a O
reciprocal O
cell O
transfer O
experiment O
, O
activation O
of O
+ O
/ O
+ O
T O
cells O
was O
significantly O
reduced O
upon O
transfer O
into O
LTalpha O
( O
- O
/ O
- O
) O
mice O
. O

These O
results O
showed O
that O
impairment O
in O
the O
activation O
of O
LCMV O
- O
specific O
T O
cells O
in O
LTalpha O
( O
- O
/ O
- O
) O
mice O
may O
be O
due O
to O
abnormal O
lymphoid O
architecture O
and O
not O
to O
an O
intrinsic O
defect O
in O
LTalpha O
( O
- O
/ O
- O
) O
T O
cells O
. O

An O
acute O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
efficiently O
controlled O
by O
the O
cytotoxic B
- I
T I
- I
cell I
( I
CTL I
) I
response O
of O
the O
host O
, O
and O
LCMV O
titers O
in O
the O
spleen O
and O
peripheral O
solid O
organs O
usually O
fall O
sharply O
after O
day O
4 O
to O
6 O
postinfection O
. O

Surprisingly O
, O
infection O
of O
immunodeficient O
recombination O
- O
activating O
gene O
2 O
- O
deficient O
( O
RAG2 O
( O
- O
/ O
- O
) O
) O
juice O
with O
5 O
X O
10 O
( O
2 O
) O
PFU O
of O
LCMV O
- O
WE O
causes O
about O
80 O
- O
fold O
- O
lower O
LCMV O
titers O
in O
the O
spleen O
on O
day O
4 O
postinfection O
compared O
with O
C57BL O
/ O
6 O
control O
mice O
. O

This O
could O
not O
be O
attributed O
to O
NK O
cell O
activity O
, O
since O
common O
gamma O
- O
chain O
- O
deficient O
RAG2 O
( O
- O
/ O
- O
) O
mice O
lacking O
NK O
cells O
show O
low O
LCMV O
titers O
comparable O
to O
those O
for O
RAG2 O
( O
- O
/ O
- O
) O
mice O
. O

Furthermore O
, O
the O
reduced O
early O
LCMV O
production O
in O
spleens O
could O
not O
be O
explained O
by O
an O
enhanced O
gamma O
interferon O
production O
in O
RAG2 O
( O
- O
/ O
- O
) O
mice O
. O

Analysis O
of O
mutant O
mice O
exhibiting O
various O
defects O
in O
the O
splenic O
microarchitecture O
, O
including O
( O
i O
) O
tumor O
necrosis O
factor O
alpha O
- O
negative O
( O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
) O
, O
lymphotoxin O
alpha O
- O
negative O
( O
LTalpha O
( O
- O
/ O
- O
) O
) O
, O
B O
- O
cell O
- O
deficient O
muMT O
mice O
, O
( O
ii O
) O
immunoglobulin O
M O
- O
negative O
mice O
, O
and O
( O
iii O
) O
RAG O
( O
- O
/ O
- O
) O
mice O
reconstituted O
with O
wild O
- O
type O
versus O
TNF O
- O
alpha O
( O
- O
/ O
- O
) O
LTalpha O
( O
- O
/ O
- O
) O
B O
cells O
, O
revealed O
a O
clear O
correlation O
between O
an O
intact O
splenic O
marginal O
zone O
, O
rapid O
early O
replication O
of O
LCMV O
in O
the O
spleen O
, O
and O
efficient O
CTL O
induction O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
a O
noncytopathic O
. O

Here O
, O
we O
combined O
the O
beneficial O
characteristics O
of O
the O
LCMV B
glycoprotein I
( I
LCMV I
- I
GP I
) I
and O
those O
of O
retroviral O
vectors O
to O
generate O
a O
new O
, O
safe O
, O
and O
efficient O
gene O
transfer O
system O
. O

These O
LCMV O
- O
GP O
pseudotypes O
were O
systematically O
compared O
with O
vectors O
, O
containing O
the O
widely O
used O
amphotropic B
murine I
leukemia I
virus I
envelope I
( I
A I
- I
MLVenv I
) I
or O
the O
vesicular B
stomatitis I
virus I
G I
protein I
( I
VSV I
- I
G I
) I
. O

Viral O
persistence O
following O
infection O
with O
invasive O
strains O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
be O
achieved O
by O
selective O
down O
- O
regulation O
of O
virus O
- O
specific O
T O
lymphocytes O
. O

High O
viral O
burden O
in O
the O
onset O
of O
infection O
drives O
responding O
cells O
into O
functional O
unresponsiveness O
, O
( O
anergy O
) O
that O
can O
be O
followed O
by O
their O
physical O
elimination O
. O

In O
this O
report O
, O
we O
studied O
down O
- O
regulation O
of O
the O
virus O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
during O
persistent O
infection O
of O
adult O
mice O
with O
LCMV O
, O
with O
emphasis O
on O
the O
role O
of O
perforin O
- O
, O
Fas O
/ O
FasL O
- O
, O
or O
Tumor B
necrosis I
factor I
receptor I
1 I
( I
TNFR1 I
) I
- O
mediated O
cytolysis O
in O
regulating O
T O
- O
cell O
homeostasis O
. O

The O
results O
reveal O
that O
the O
absence O
of O
perforin O
, O
Fas O
- O
ligand O
, O
or O
TNFR1 O
has O
no O
significant O
effect O
on O
the O
kinetics O
of O
proliferation O
and O
functional O
inactivation O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
onset O
of O
chronic O
LCMV O
infection O
. O

However O
, O
these O
molecules O
play O
a O
critical O
role O
in O
the O
homeostatic O
regulation O
of O
T O
cells O
, O
influencing O
the O
longevity O
of O
the O
virus O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
population O
nonce O
it O
has O
become O
, O
anergic O
. O

Thus O
, O
CD8 O
( O
+ O
) O
T O
cells O
specific O
to O
the O
dominant O
LCMV O
NP396 O
- O
404 O
epitope O
persist O
in O
an O
anergic O
state O
for O
at O
least O
70 O
days O
in O
perforin O
- O
, O
FasL O
- O
, O
or O
TNFR1 O
- O
deficient O
mice O
, O
but O
they O
were O
eliminated O
by O
day O
30 O
in O
C57BL O
/ O
6 O
controls O
. O

These O
effects O
were O
additive O
as O
shown O
by O
a O
deficit O
of O
apoptotic O
death O
of O
NP396 O
- O
404 O
peptide O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
in O
mice O
lacking O
both O
perforin O
and O
TNFR1 O
. O

Moreover O
, O
virus O
- O
specific O
anergic O
CD8 O
( O
+ O
) O
T O
cells O
in O
persistently O
infected O
C57BL O
/ O
6 O
mice O
contain O
higher O
levels O
of O
Bcl O
- O
2 O
and O
Bcl O
- O
XL O
than O
functionally O
intact O
T O
cells O
generated O
during O
acute O
LCMV O
infection O
. O

Systemic O
immunization O
, O
in O
general O
, O
does O
not O
induce O
a O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
at O
the O
mucosal O
surface O
. O

Because O
papillomavirus B
( I
PV I
) I
naturally O
infects O
mucosa O
and O
skin O
, O
we O
determined O
whether O
PV O
pseudovirus O
, O
i O
. O

We O
found O
that O
the O
pseudovirus O
that O
encoded O
the O
lymphocytic O
choriomeningitis O
virus O
gp33 O
epitope O
induced O
a O
stronger O
CTL O
response O
than O
a O
DNA O
vaccine O
( O
plasmid O
) O
encoding O
the O
same O
epitope O
given O
systemically O
. O

Our O
previous O
studies O
have O
shown O
that O
targeting O
DNA O
vaccine O
- O
encoded O
major O
histocompatibility O
complex O
class O
I O
epitopes O
to O
the O
proteasome O
enhanced O
CDS O
' O
T O
- O
cell O
induction O
and O
protection O
against O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
challenge O
. O

Here O
, O
we O
expand O
these O
studies O
to O
evaluate O
CD4 O
( O
+ O
) O
T O
- O
cell O
responses O
induced O
by O
DNA O
immunization O
and O
describe O
a O
system O
for O
targeting O
proteins O
and O
minigenes O
to O
lysosomes O
. O

Full O
- O
length O
proteins O
can O
be O
targeted O
to O
the O
lysosomal O
compartment O
by O
covalent O
attachment O
to O
the O
20 O
- O
amino O
- O
acid O
C O
- O
terminal O
tail O
of O
lysosomal B
integral I
membrane I
protein I
- I
H I
( I
LIMP I
- I
H I
) I
. O

Using O
minigenes O
encoding O
defined O
T O
- O
helper O
epitopes O
from O
lymphocytic O
choriomeningitis O
virus O
, O
we O
show O
that O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
induced O
by O
the O
NP309 O
- O
328 O
epitope O
of O
LCMV O
was O
greatly O
enhanced O
by O
addition O
of O
the O
LIMP O
- O
II O
tail O
. O

However O
, O
the O
immunological O
consequence O
of O
lysosomal O
targeting O
is O
not O
invariably O
positive O
; O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
induced O
by O
the O
GP O
( O
61 O
- O
80 O
) O
epitope O
was O
almost O
abolished O
when O
attached O
to O
the O
LIMP O
- O
Il O
tail O
. O

The O
GP O
( O
61 O
- O
80 O
) O
epitope O
is O
highly O
susceptible O
to O
cleavage O
by O
cathepsin O
D O
, O
an O
aspartic O
endopeptidase O
found O
almost O
exclusively O
in O
lysosomes O
. O

We O
show O
, O
using O
mass O
spectrometry O
, O
that O
the O
GP O
( O
61 O
- O
80 O
) O
peptide O
is O
cleaved O
between O
residues O
F O
- O
74 O
and O
K O
- O
75 O
and O
that O
this O
destroys O
its O
ability O
to O
stimulate O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
. O

We O
analyze O
the O
effects O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
priming O
on O
the O
virus O
- O
specific O
antibody O
and O
CDS O
' O
T O
- O
cell O
responses O
which O
are O
mounted O
after O
virus O
infection O
and O
show O
that O
neither O
response O
appears O
to O
be O
accelerated O
or O
enhanced O
. O

Finally O
, O
we O
evaluate O
the O
protective O
benefits O
of O
CD4 O
( O
+ O
) O
T O
- O
cell O
vaccination O
in O
the O
LCMV O
model O
system O
; O
in O
contrast O
to O
DNA O
vaccine O
- O
induced O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
can O
confer O
solid O
protection O
against O
LCMV O
challenge O
, O
DNA O
vaccine O
- O
mediated O
priming O
of O
CD4 O
( O
+ O
) O
T O
cells O
does O
not O
appear O
to O
enhance O
the O
vaccinee O
' O
s O
ability O
to O
combat O
viral O
challenge O
. O

The O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
during O
acute O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
of O
mice O
is O
characterized O
by O
a O
rapid O
proliferation O
phase O
, O
followed O
by O
a O
rapid O
death O
phase O
and O
long O
- O
term O
memory O
. O

We O
find O
that O
CDS O
' O
cell O
proliferation O
begins O
1 O
to O
2 O
days O
after O
infection O
and O
occurs O
at O
an O
average O
rate O
of O
3 O
day O
( O
- O
1 O
) O
, O
reaching O
the O
maximum O
population O
size O
between O
days O
5 O
and O
6 O
after O
immunization O
. O

5 O
day O
( O
- O
1 O
) O
, O
i O
. O

Arenaviruses O
have O
a O
bisegmented O
negative O
- O
strand O
RNA O
genome O
whose O
proteomic O
capability O
is O
limited O
to O
only O
four O
polypeptides O
, O
namely O
, O
nucleoprotein B
( I
NP I
) I
, O
surface B
glycoprotein I
( I
GP I
) I
that O
is O
proteolytically O
processed O
into O
GP1 O
+ O
GP2 O
, O
polymerase O
( O
L O
) O
, O
and O
a O
small O
( O
11 O
- O
kDa O
) O
RING O
finger O
protein O
( O
Z O
) O
. O

The O
role O
of O
Z O
during O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
life O
cycle O
is O
poorly O
understood O
. O

This O
system O
involves O
an O
LCMV O
minigenome O
and O
the O
minimal O
viral O
tans O
- O
acting O
factors O
( O
NP O
and O
L O
) O
, O
expressed O
from O
separated O
cotransfected O
plasmids O
. O

Under O
conditions O
of O
high O
antigenic O
load O
during O
infection O
with O
invasive O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strains O
, O
virus O
can O
persist O
by O
selective O
clonal O
exhaustion O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
this O
work O
we O
studied O
the O
down O
- O
regulation O
of O
the O
virus O
- O
specific O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
during O
a O
persistent O
infection O
of O
adult O
mice O
, O
with O
particular O
emphasis O
on O
the O
contribution O
of O
the O
interferon O
response O
in O
promoting O
host O
defense O
. O

Studies O
were O
conducted O
by O
infecting O
mice O
deficient O
in O
receptors O
for O
type O
I O
( O
alpha O
/ O
beta O
interferon O
[ O
IFN O
- O
alpha O
/ O
beta O
] O
) O
, O
type O
II O
( O
IFN O
- O
gamma O
) O
, O
and O
both O
type O
I O
and O
II O
IFNs O
with O
LCMV O
isolates O
that O
vary O
in O
their O
capacity O
to O
induce O
T O
- O
cell O
exhaustion O
. O

( O
i O
) O
IFNs O
play O
a O
critical O
role O
in O
LCMV O
infection O
by O
reducing O
viral O
loads O
in O
the O
initial O
stages O
of O
infection O
and O
thus O
modifying O
both O
the O
extent O
of O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
exhaustion O
and O
the O
course O
of O
infection O
. O

( O
ii O
) O
An O
inverse O
correlation O
exists O
between O
antigen O
persistence O
and O
responsiveness O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

This O
results O
in O
distinct O
programs O
of O
activation O
or O
tolerance O
( O
functional O
unresponsiveness O
and O
/ O
or O
physical O
elimination O
of O
antigen O
- O
specific O
cells O
) O
during O
acute O
and O
chronic O
virus O
infections O
, O
respectively O
. O

( O
iii O
) O
A O
successful O
immune O
response O
associated O
with O
definitive O
viral O
clearance O
requires O
an O
appropriate O
balance O
between O
cellular O
and O
humoral O
components O
of O
the O
immune O
system O
. O

This O
property O
has O
been O
exploited O
to O
design O
recombinant O
CyaA O
toxoids O
capable O
of O
delivering O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
- O
restricted O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
into O
antigen O
- O
presenting O
cells O
and O
to O
induce O
specific O
CD8 O
( O
+ O
) O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
in O
vivo O
. O

The O
model O
vaccine O
consisted O
of O
a O
polyepitope O
made O
of O
three O
CTL O
epitopes O
from O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
the O
V3 O
region O
of O
human O
immunodeficiency O
virus O
gp120 O
, O
and O
chicken O
ovalbumin O
, O
inserted O
at O
three O
different O
sites O
of O
the O
catalytic O
domain O
of O
genetically O
detoxified O
CyaA O
. O

This O
subdominant O
sequence O
confers O
immunity O
as O
effective O
as O
that O
induced O
by O
the O
dominant O
epitope O
, O
against O
which O
> O
90 O
% O
of O
the O
antiviral O
CD8 O
( O
+ O
) O
T O
cells O
are O
normally O
directed O
. O

The O
dominant O
CD8 O
( O
+ O
) O
response O
expands O
more O
rapidly O
than O
the O
subdominant O
responses O
, O
but O
after O
virus O
infection O
is O
cleared O
, O
mice O
which O
had O
been O
immunized O
with O
the O
dominant O
vaccine O
have O
a O
pool O
of O
memory O
T O
cells O
focused O
almost O
entirely O
upon O
the O
dominant O
epitope O
. O

During O
the O
acute O
phase O
of O
the O
immune O
response O
, O
the O
acquisition O
of O
cytokine O
responsiveness O
by O
subdominant O
CD8 O
( O
+ O
) O
T O
cells O
precedes O
their O
development O
of O
lytic O
activity O
. O

Thus O
, O
the O
lysis O
( O
low O
) O
- O
cytokine O
( O
competent O
) O
phenotype O
associated O
with O
most O
memory O
CD8 O
( O
+ O
) O
T O
cells O
appears O
to O
develop O
soon O
after O
antigen O
clearance O
. O

Finally O
, O
lytic O
activity O
differs O
among O
CD8 O
( O
+ O
) O
T O
- O
cell O
populations O
with O
different O
epitope O
specificities O
, O
suggesting O
that O
vaccines O
can O
be O
designed O
to O
selectively O
induce O
CD8 O
( O
+ O
) O
T O
cells O
with O
distinct O
functional O
attributes O
. O

Memory O
CD8 O
T O
cells O
( O
CD8 O
( O
+ O
) O
CD44 O
( O
hi O
) O
) O
were O
most O
affected O
, O
During O
acute O
viral O
infection O
, O
transgenic O
T O
cells O
that O
were O
clearly O
defined O
as O
non O
- O
virus O
specific O
decreased O
in O
number O
and O
showed O
an O
increase O
in O
apoptosis O
. O

Also O
, O
use O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
carrier O
mice O
, O
which O
lack O
LCMV O
- O
specific O
T O
cells O
, O
showed O
a O
significant O
decline O
in O
non O
- O
virus O
- O
specific O
memory O
CD8 O
T O
cells O
that O
correlated O
to O
an O
increase O
in O
apoptosis O
in O
response O
to O
the O
proliferation O
of O
adoptively O
transferred O
virus O
- O
specific O
T O
cells O
. O

Attrition O
of O
T O
cells O
early O
during O
infection O
correlated O
with O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
peak O
, O
and O
the O
IFN O
inducer O
poly O
( O
I O
: O
C O
) O
caused O
apoptosis O
and O
attrition O
of O
CD8 O
( O
+ O
) O
CD44 O
( O
hi O
) O
T O
cells O
in O
normal O
mice O
but O
not O
in O
IFN O
- O
alpha O
/ O
beta O
receptor O
- O
deficient O
mice O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
induces O
type O
I O
interferon O
( O
alpha O
and O
beta O
interferon O
[ O
IFN O
- O
alpha O
and O
IFN O
- O
beta O
] O
) O
upon O
infection O
and O
yet O
is O
sensitive O
to O
the O
addition O
of O
type O
II O
interferon O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
) O
to O
the O
culture O
media O
, O
This O
sensitivity O
is O
biologically O
important O
because O
it O
correlates O
inversely O
with O
the O
ability O
of O
certain O
LCMV O
strains O
to O
persist O
in O
mice O
( O
D O
, O
Moskophidis O
, O
M O
. O

Virus O
production O
in O
PML O
- O
/ O
- O
murine B
embryonic I
fibroblasts I
( I
MEF I
) I
exceeds O
virus O
production O
in O
PML O
+ O
/ O
+ O
MEF O
, O
and O
this O
difference O
is O
exacerbated O
by O
IFN O
treatment O
that O
upregulates O
PML O
expression O
, O
IFN O
- O
gamma O
also O
diminishes O
LCMV O
production O
in O
PML O
- O
/ O
- O
cells O
; O
therefore O
, O
viral O
IFN O
sensitivity O
is O
not O
entirely O
due O
to O
PML O
. O

By O
sequence O
comparison O
, O
we O
noted O
that O
eight O
Old O
World O
and O
New O
World O
arenaviruses O
share O
several O
amino O
acids O
with O
the O
nucleoprotein B
( I
NP I
) I
that O
consists O
of O
amino B
acids I
( I
aa I
) I
118 O
to O
126 O
( O
NP O
118 O
- O
126 O
) O
( O
RPQASGVYM O
) O
of O
LCMV O
that O
comprise O
the O
immunodominant O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
epitope O
for O
H O
- O
2 O
( O
d O
) O
mice O
( O
32 O
) O
. O

The O
primary O
H O
- O
2 O
( O
d O
) O
CTL O
anti O
- O
LCMV O
response O
as O
well O
as O
that O
of O
a O
CTL O
clone O
responsive O
to O
LCMV O
NP O
118 O
- O
126 O
recognized O
target O
cells O
coated O
with O
NP O
118 O
- O
126 O
peptides O
derived O
from O
LCMV O
, O
LFV O
, O
and O
Mopeia O
virus O
but O
not O
Sabia O
virus O
, O
indicating O
that O
a O
common O
functional O
NP O
epitope O
exists O
among O
Old O
World O
arenaviruses O
. O

CD8 O
T O
cells O
drive O
the O
protective O
immune O
response O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
and O
are O
thus O
a O
determining O
force O
in O
the O
selection O
of O
viral O
variants O
. O

To O
examine O
how O
escape O
mutations O
affect O
the O
presentation O
and O
recognition O
of O
overlapping O
T O
- O
cell O
epitopes O
, O
we O
isolated O
an O
LCMV O
variant O
that O
is O
not O
recognized O
by O
T B
- I
cell I
receptor I
( I
TCR I
) I
- O
transgenic O
H O
- O
2D O
( O
b O
) O
- O
restricted O
LCMV O
GP33 O
- O
41 O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

The O
variant O
virus O
carried O
a O
single O
- O
amino O
- O
acid O
substitution O
( O
valine O
to O
alanine O
) O
at O
position O
35 O
of O
the O
viral O
glycoprotein O
. O

This O
region O
of O
the O
LCMV O
glycoprotein O
encodes O
both O
the O
D O
- O
b O
- O
restricted O
GP33 O
- O
43 O
epitope O
and O
a O
second O
epitope O
( O
GP34 O
- O
42 O
) O
presented O
by O
the O
K O
- O
b O
molecule O
. O

Although O
lentivirus O
vectors O
are O
efficiently O
pseudotyped O
by O
Env O
proteins O
from O
several O
different O
subtypes O
of O
murine B
leukemia I
virus I
( I
MuLV I
) I
, O
the O
related O
protein O
from O
gibbon B
ape I
leukemia I
virus I
( I
GaLV I
) I
does O
not O
form O
functional O
pseudotypes O
, O
We O
have O
determined O
that O
this O
arises O
because O
of O
an O
inability O
of O
GaLV O
Env O
to O
be O
incorporated O
into O
lentivirus O
vector O
particles O
. O

By O
exploiting O
the O
homology O
between O
the O
GaLV O
and O
MuLV O
Env O
proteins O
, O
we O
have O
mapped O
the O
determinants O
of O
incompatibility O
in O
the O
GaLV O
Env O
, O
Three O
modifications O
that O
allowed O
GaLV O
Env O
to O
pseudotype O
human O
immunodeficiency O
virus O
type O
1 O
particles O
were O
identified O
: O
removal O
of O
the O
R O
peptide O
( O
C O
- O
terminal O
half O
of O
the O
cytoplasmic O
domain O
) O
, O
replacement O
of O
the O
whole O
cytoplasmic O
tail O
with O
the O
corresponding O
MuLV O
region O
, O
and O
mutation O
of O
two O
residues O
upstream O
of O
the O
R O
peptide O
cleavage O
site O
. O

coxsackievirus B
B3 I
( I
CVB3 I
) I
is O
a O
common O
human O
pathogen O
that O
has O
been O
associated O
with O
serious O
diseases O
including O
myocarditis O
and O
pancreatitis O
. O

To O
better O
understand O
the O
effect O
of O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
in O
controlling O
CVB3 O
infection O
, O
we O
have O
inserted O
well O
- O
characterized O
CTL O
epitopes O
into O
the O
CVB3 O
genome O
. O

Constructs O
were O
made O
by O
placing O
the O
epitope O
of O
interest O
upstream O
of O
the O
open O
reading O
frame O
encoding O
the O
CVB3 O
polyprotein O
, O
separated O
by O
a O
poly O
- O
glycine O
linker O
and O
an O
artificial O
3C B
( I
pro I
) I
/ O
3CD O
( O
pro O
) O
cleavage O
site O
. O

In O
this O
study O
, O
we O
cloned O
major O
histocompatibility O
complex O
class O
I O
- O
restricted O
CTL O
epitopes O
from O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
into O
recombinant B
CVB3 I
( I
rCVB3 I
) I
, O
In O
vitro O
, O
rCVB3 O
growth O
kinetics O
showed O
a O
1 O
- O
to O
2 O
- O
h O
lag O
period O
before O
exponential O
growth O
was O
initiated O
, O
and O
peak O
titers O
were O
similar O
to1 O
log O
unit O
lower O
than O
for O
wild O
- O
type O
virus O
. O

Despite O
the O
high O
virus O
titers O
, O
rCVB3 O
infection O
of O
naive O
mice O
failed O
to O
induce O
a O
strong O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
tea O
the O
encoded O
epitope O
; O
this O
has O
implications O
for O
the O
proposed O
role O
of O
cross O
- O
priming O
during O
virus O
infection O
and O
for O
the O
utility O
of O
recombinant O
picornaviruses O
as O
vaccine O
vectors O
. O

Infection O
of O
H O
- O
2 O
( O
b O
) O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
generates O
an O
H O
- O
2D O
( O
b O
) O
- O
restricted O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
whose O
subdominant O
component O
is O
directed O
against O
the O
CP92 O
- O
101 O
( O
CSANNSHHYI O
) O
epitope O
, O
The O
aim O
of O
this O
study O
was O
to O
identify O
the O
functional O
parameters O
accounting O
for O
this O
subdominance O
, O
We O
found O
that O
the O
two O
naturally O
occurring O
( O
genetically O
encoded O
and O
posttranslationally O
modified O
) O
forms O
of O
LCMV O
GP92 O
- O
101 O
were O
immunogenic O
, O
did O
not O
act O
as O
T O
- O
cell O
antagonists O
, O
and O
bound O
efficiently O
to O
but O
were O
unable O
to O
form O
stable O
complexes O
with O
H O
- O
2D O
( O
b O
) O
, O
a O
crucial O
factor O
for O
immunodominance O
. O

Thus O
, O
the O
H O
- O
2D O
( O
b O
) O
- O
restricted O
subdominant O
CTL O
response O
to O
LCMV O
resulted O
not O
from O
altered O
T O
- O
cell O
activation O
but O
from O
impaired O
major O
histocompatibility O
complex O
presentation O
properties O
. O

alpha B
- I
dystroglycan I
( I
alpha I
- I
DG I
) I
was O
recently O
identified O
as O
a O
receptor O
for O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
several O
other O
arenaviruses O
, O
including O
Lassa O
fever O
virus O
( O
W O
. O

In O
addition O
, O
high O
- O
affinity O
binding O
to O
alpha O
- O
DG O
correlated O
with O
an O
ability O
to O
infiltrate O
the O
white O
pulp O
( O
T O
- O
dependent O
) O
area O
of O
the O
spleen O
, O
cause O
ablation O
of O
the O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
by O
day O
7 O
postinfection O
, O
and O
establish O
a O
persistent O
infection O
. O

In O
contrast O
, O
viruses O
, O
vith O
a O
lower O
affinity O
of O
binding O
to O
alpha O
- O
DG O
were O
only O
partially O
inhibited O
from O
infecting O
alpha O
- O
DG O
( O
- O
/ O
- O
) O
embryonic O
stem O
cells O
and O
required O
a O
concentration O
of O
soluble O
alpha O
- O
DG O
higher O
than O
100 O
nM O
to O
prevent O
infection O
of O
mouse O
3T6 O
fibroblasts O
. O

Dependence O
of O
the O
primary O
antiviral O
immune O
response O
on O
costimulatory O
interactions O
between O
CD28 O
/ O
CD80 O
- O
86 O
and O
between O
CD40 O
/ O
CD154 O
( O
CD40 O
ligand O
) O
has O
been O
correlated O
with O
the O
extent O
of O
viral O
replication O
in O
two O
models O
of O
systemic O
infection O
, O
lymphocytic O
choriomeningitis O
virus O
and O
vesicular O
stomatitis O
virus O
. O

To O
determine O
the O
role O
of O
these O
costimulatory O
interactions O
in O
the O
contest O
of O
an O
acute O
cytolytic O
, O
but O
locally O
replicating O
viral O
infection O
, O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
infection O
was O
assessed O
in O
mice O
that O
had O
the O
CD28 O
/ O
CD80 O
- O
86 O
or O
CD40 O
/ O
CD154 O
interactions O
disrupted O
either O
genetically O
or O
with O
blocking O
reagents O
( O
CTLA4Ig O
and O
MR1 O
, O
respectively O
) O
. O

This O
reflected O
an O
almost O
total O
ablation O
of O
the O
anti O
- O
RSV O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
due O
to O
anergy O
and O
reduced O
cell O
numbers O
, O
respectively O
. O

Disruption O
of O
CD40 O
/ O
CD154 O
interactions O
impaired O
survival O
, O
but O
the O
effect O
was O
less O
severe O
than O
that O
observed O
in O
CTLA4Ig O
- O
treated O
mice O
, O
with O
reductions O
observed O
in O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
but O
not O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
. O

The O
immunological O
resistance O
of O
a O
host O
to O
viral O
infections O
may O
be O
strongly O
influenced O
by O
cytokines O
such O
as O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
which O
promote O
T O
helper O
type O
I O
responses O
, O
and O
IL O
- O
4 O
, O
which O
promotes O
T O
helper O
type O
2 O
responses O
. O

Immunization O
with O
a O
live O
attenuated O
vaccine O
virus O
prior O
to O
challenge O
protected O
all O
three O
types O
of O
cytokine O
- O
deficient O
mice O
from O
viremia O
and O
high O
levels O
of O
spleen O
virus O
despite O
the O
finding O
that O
the O
vaccinated O
IFN O
- O
gamma O
- O
deficient O
mice O
were O
unable O
to O
class O
switch O
from O
immunoglobulin O
hi O
( O
IgM O
) O
to O
IgG O
virus O
- O
neutralizing O
antibodies O
. O

Borna B
disease I
virus I
( I
BDV I
) I
infection O
triggers O
an O
immune O
- O
mediated O
encephalomyelitis O
and O
results O
in O
a O
persistent O
infection O
. O

The O
immune O
response O
in O
the O
acute O
phase O
of O
the O
disease O
is O
characterized O
by O
a O
cellular O
response O
in O
which O
CD8 O
( O
+ O
) O
T O
cells O
are O
responsible O
for O
the O
destruction O
of O
virus O
- O
infected O
brain O
cells O
. O

CD4 O
( O
+ O
) O
T O
cells O
function O
as O
helper O
cells O
and O
support O
the O
production O
of O
antiviral O
antibodies O
. O

These O
antibodies O
, O
directed O
against O
the O
major O
glycoprotein O
( O
gp94 O
) O
of O
BDV O
, O
were O
able O
to O
prevent O
Borna O
disease O
if O
given O
prophylactically O
. O

Cytoplasmic O
vector O
systems O
are O
generally O
used O
for O
expression O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
proteins O
. O

Expression O
was O
independent O
of O
other O
LCMV O
proteins O
but O
was O
blocked O
by O
a O
missense O
mutation O
within O
the O
original O
LCMV O
( O
WE O
) O
glycoprotein O
cDNA O
. O

The O
membrane O
- O
anchored O
GP O
- O
2 O
obtained O
from O
purified O
virions O
of O
the O
Josiah O
strain O
revealed O
the O
N O
- O
terminal O
tripeptide O
GTF O
( O
262 O
) O
when O
analyzed O
by O
Edman O
degradation O
. O

Systematic O
mutational O
analysis O
of O
vector O
- O
expressed O
GP O
- O
C O
revealed O
that O
the O
motif O
R O
- O
X O
( O
L O
/ O
I O
/ O
V O
) O
- O
L O
- O
259 O
( O
where O
X O
stands O
for O
L O
, O
I O
, O
or O
V O
) O
is O
essential O
for O
cleavage O
of O
the O
peptide O
bond O
between O
leucine O
( O
259 O
) O
and O
glycine O
( O
260 O
) O
. O

Listeria O
monocytogenes O
is O
an O
attractive O
bacterial O
vector O
to O
elicit O
T O
- O
cell O
immunity O
to O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
because O
it O
specifically O
infects O
monocytes O
, O
key O
antigen O
- O
presenting O
cells O
, O
and O
because O
natural O
infection O
originates O
at O
the O
mucosa O
. O

monocytogenes O
expressing O
HIV O
gag O
elicits O
sustained O
high O
levels O
of O
Gag O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
in O
mice O
. O

The O
recombinant O
bacteria O
are O
attenuated O
at O
Least O
10 O
( O
5 O
) O
- O
fold O
. O

The O
role O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
in O
the O
permanent O
control O
of O
infection O
with O
a O
noncytopathic O
virus O
was O
studied O
by O
comparing O
immune O
responses O
in O
wild O
- O
type O
and O
IFN O
- O
gamma O
- O
deficient O
( O
IFN O
- O
gamma O
- O
/ O
- O
) O
mice O
infected O
with O
a O
slowly O
invasive O
strain O
of O
lymphocytic O
choriomeningitis O
virus O
( O
LCMV O
Armstrong O
) O
. O

Virus O
persistence O
in O
the O
latter O
mice O
did O
not O
reflect O
failure O
to O
generate O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
effecters O
, O
as O
an O
unimpaired O
primary O
CTL O
response O
was O
observed O
. O

The O
prolonged O
effector O
phase O
in O
infected O
IFN O
- O
gamma O
- O
/ O
- O
mice O
was O
associated O
with O
elevated O
numbers O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

However O
, O
despite O
the O
increased O
CD8 O
( O
+ O
) O
T O
- O
cell O
turnover O
, O
which O
might O
have O
resulted O
in O
depletion O
of O
the O
memory O
CTL O
precursor O
pool O
, O
no O
evidence O
for O
exhaustion O
was O
observed O
. O

Borna B
disease I
virus I
( I
BDV I
) I
causes O
CD8 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
meningoencephalitis O
in O
immunocompetent O
mice O
and O
rats O
, O
thus O
providing O
a O
valuable O
animal O
model O
for O
studying O
the O
mechanisms O
of O
virus O
- O
induced O
central B
nervous I
system I
( I
CNS I
) I
immunopathology O
. O

In O
brains O
of O
infected O
mice O
lacking O
CD8 O
( O
+ O
) O
cells O
( O
beta O
2m O
( O
0 O
/ O
0 O
) O
) O
, O
transcripts O
encoding O
IP O
- O
10 O
and O
RANTES O
were O
also O
observed O
. O

CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
ran O
be O
induced O
by O
DNA O
immunization O
, O
but O
little O
is O
known O
about O
the O
kinetics O
of O
these O
responses O
in O
vivo O
in O
the O
absence O
of O
restimulation O
or O
how O
soon O
protective O
immunity O
is O
conferred O
by O
a O
DNA O
vaccine O
. O

It O
is O
also O
unclear O
if O
CD8 O
( O
+ O
) O
T O
cells O
primed O
by O
DNA O
vaccines O
express O
the O
vigorous O
effector O
functions O
characteristic O
of O
cells O
primed O
by O
natural O
infection O
or O
by O
immunization O
with O
a O
recombinant O
live O
virus O
vaccine O
. O

To O
address O
these O
issues O
, O
we O
have O
used O
the O
sensitive O
technique O
of O
intracellular O
cytokine O
staining O
to O
carry O
out O
direct O
ex O
vivo O
kinetic O
and O
phenotypic O
analyses O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
present O
in O
the O
spleens O
of O
mice O
at O
various O
times O
after O
( O
i O
) O
a O
single O
intramuscular O
administration O
of O
a O
plasmid O
expressing O
the O
nucleoprotein B
( I
NP I
) I
gene O
from O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
( O
ii O
) O
infection O
by O
a O
recombinant O
vaccinia O
virus O
carrying O
the O
same O
protein O
( O
vvNP O
) O
, O
or O
( O
iii O
) O
LCMV O
infection O
. O

The O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
in O
DNA O
- O
vaccinated O
mice O
was O
slightly O
delayed O
compared O
to O
LCMV O
or O
vvNP O
vaccinees O
, O
peaking O
at O
15 O
days O
postimmunization O
. O

Interestingly O
, O
the O
percentage O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
present O
in O
the O
spleen O
at O
day O
15 O
and O
later O
time O
points O
was O
similar O
to O
that O
observed O
following O
vvNP O
infection O
. O

Surprisingly O
, O
protection O
from O
both O
lethal O
and O
sublethal O
LCMV O
infections O
was O
conferred O
within O
I O
week O
of O
DNA O
vaccination O
, O
well O
before O
the O
peak O
of O
the O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
. O

To O
determine O
the O
degree O
of O
genetic O
diversity O
among O
Lassa O
virus O
strains O
, O
partial O
nucleoprotein B
( I
NP I
) I
gene O
sequences O
mere O
obtained O
from O
54 O
strains O
and O
analyzed O
. O

A O
method O
for O
amplifying O
and O
cloning O
full O
- O
length O
arenavirus O
S O
RNAs O
was O
developed O
and O
used O
to O
obtain O
the O
complete O
NP O
and O
glycoprotein O
gene O
( O
GP1 O
and O
GP2 O
) O
sequences O
for O
hvo O
representative O
Nigerian O
strains O
of O
Lassa O
virus O
. O

The O
role O
of O
negatively O
signaling O
NK O
cell O
receptors O
of O
the O
Ly49 O
family O
on O
the O
specificity O
of O
the O
acute O
CD8 O
( O
+ O
) O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
was O
investigated O
in O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infected O
C57BL O
/ O
6 O
mice O
. O

Activated O
CD8 O
( O
+ O
) O
T O
cells O
coexpressing O
Ly49G2 O
expanded O
during O
LCMV O
infection O
, O
and O
T O
- O
cell O
receptor O
analyses O
by O
flow O
cytometry O
and O
CDR3 O
spectratyping O
revealed O
a O
unique O
polyclonal O
T O
- O
cell O
population O
in O
the O
Ly49G2 O
( O
+ O
) O
fraction O
. O

Transfection O
of O
these O
sensitive O
targets O
with O
H2D O
( O
d O
) O
, O
a O
ligand O
for O
Ly49G2 O
, O
inhibited O
lysis O
, O
This O
was O
reversed O
by O
antibody O
to O
Ly49G2 O
, O
indicating O
effective O
negative O
signaling O
. O

LCMV O
characteristically O
induces O
an O
anti O
- O
H2 O
( O
d O
) O
allospecific O
T O
- O
cell O
response O
that O
includes O
T O
- O
cell O
clones O
cross O
- O
reactive O
between O
allogeneic O
and O
LCMV O
- O
infected O
syngeneic O
targets O
. O

The O
CD8 O
( O
+ O
) O
Ly49G2 O
( O
+ O
) O
population O
mediated O
no O
allospecific O
killing O
, O
nor O
was O
any O
NK O
- O
like O
killing O
observed O
against O
YAC O
- O
1 O
cells O
. O

This O
study O
shows O
that O
CD8 O
+ O
Ly49G2 O
( O
+ O
) O
cells O
participate O
in O
the O
virus O
- O
induced O
CTL O
response O
but O
lyse O
a O
more O
restricted O
range O
of O
targets O
than O
the O
rest O
of O
the O
virus O
- O
induced O
CTL O
population O
. O

Many O
approaches O
are O
currently O
being O
developed O
to O
deliver O
exogenous O
antigen O
into O
the O
major O
histocompatibility O
complex O
class O
I O
- O
restricted O
antigen O
pathway O
, O
leading O
to O
in O
vivo O
priming O
of O
CD8 O
( O
+ O
) O
cytotoxic O
T O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
strong O
CD8 O
( O
+ O
) O
class O
I O
- O
restricted O
cytotoxic O
responses O
are O
induced O
upon O
intraperitoneal O
immunization O
of O
mice O
with O
different O
peptides O
, O
characterized O
as O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitopes O
, O
bound O
to O
1 O
- O
mu O
m O
synthetic O
latex O
microspheres O
and O
injected O
in O
the O
absence O
of O
adjuvant O
. O

The O
cytotoxic O
response O
induced O
against O
a O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
peptide O
linked O
to O
these O
microspheres O
was O
compared O
to O
the O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
obtained O
upon O
immunization O
with O
the O
nonreplicative O
porcine O
parvovirus O
- O
like O
particles O
( O
PPV O
: O
VLP O
) O
carrying O
the O
same O
peptide O
( O
PPV O
: O
VLP O
- O
LCMV O
) O
previously O
described O
( O
C O
. O

Acad O
, O
Sci O
, O
USA O
94 O
: O
7503 O
- O
7508 O
, O
1997 O
) O
, O
We O
show O
that O
the O
induction O
of O
specific O
CTL O
activity O
by O
peptides O
bound O
to O
microspheres O
requires O
CD4 O
( O
+ O
) O
T O
- O
cell O
help O
in O
contrast O
to O
the O
CTL O
response O
obtained O
with O
the O
peptide O
delivered O
by O
viral O
pseudoparticles O
. O

Analysis O
of O
C57BL O
/ O
6 O
mice O
acutely O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
by O
using O
intracellular O
cytokine O
staining O
revealed O
a O
high O
frequency O
( O
2 O
to O
10 O
% O
) O
of O
CD4 O
( O
+ O
) O
T O
cells O
secreting O
the O
Th1 O
- O
associated O
cytokines O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
and O
tumor O
necrosis O
factor O
alpha O
, O
with O
no O
concomitant O
increase O
in O
the O
frequency O
of O
CD4 O
( O
+ O
) O
T O
cells O
secreting O
the O
Th2 O
- O
associated O
cytokines O
IL O
- O
4 O
, O
IL O
- O
5 O
, O
and O
IL O
- O
10 O
following O
stimulation O
with O
viral O
peptides O
, O
In O
LCMV O
- O
infected O
C57BL O
/ O
6 O
CD8 O
( O
- O
/ O
- O
) O
mice O
, O
more O
than O
20 O
% O
of O
the O
CD4 O
( O
+ O
) O
T O
cells O
secreted O
IFN O
- O
gamma O
after O
viral O
peptide O
stimulation O
, O
whereas O
less O
than O
1 O
% O
of O
the O
CD4 O
( O
+ O
) O
T O
cells O
secreted O
IL O
- O
4 O
under O
these O
same O
conditions O
, O
Mice O
persistently O
infected O
with O
a O
high O
dose O
of O
LCMV O
clone O
13 O
also O
generated O
a O
virtually O
exclusive O
Th1 O
response O
. O

Thus O
, O
LCMV O
induces O
a O
much O
more O
profound O
virus O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
than O
previously O
recognized O
, O
and O
it O
is O
dramatically O
skewed O
to O
a O
Th1 O
phenotype O
. O

Virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
at O
frequencies O
of O
> O
1 O
/ O
1 O
, O
000 O
are O
sufficient O
to O
cause O
insulin B
- I
dependent I
diabetes I
mellitus I
( I
IDDM I
) I
in O
transgenic O
mice O
whose O
pancreatic O
beta O
cells O
express O
as O
self O
' O
antigen O
a O
protein O
from O
a O
virus O
later O
used O
to O
initiate O
infection O
. O

The O
majority O
of O
PML O
is O
present O
in O
nuclear O
bodies O
which O
are O
translocated O
to O
the O
cytoplasm O
by O
infection O
with O
the O
arenavirus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Here O
, O
we O
demonstrate O
an O
association O
between O
Z O
and O
the O
host O
cell O
translation O
factor O
, O
eukaryotic B
initiation I
factor I
4E I
( I
eIF I
- I
4E I
) I
in O
infected O
and O
transfected O
cells O
. O

Specifically O
, O
we O
see O
reduction O
in O
cyclin O
D1 O
protein O
production O
with O
no O
effect O
on O
Glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase I
( I
GAPDH I
) I
in O
cells O
transfected O
with O
Z O
. O

The O
genome O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
consists O
of O
two O
negative O
- O
sense O
single O
- O
stranded O
RNA O
segments O
, O
designated O
L O
and O
S O
. O

Both O
segments O
contain O
two O
viral O
genes O
in O
an O
ambisense O
coding O
strategy O
, O
, O
vith O
the O
genes O
being O
separated O
by O
an O
intergenic B
region I
( I
IGR I
) I
. O

To O
this O
end O
, O
we O
constructed O
an O
LCMV O
S O
minigenome O
consisting O
of O
a O
negative O
- O
sense O
copy O
of O
the O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
reporter O
gene O
flanked O
upstream O
by O
the O
S O
5 B
' I
untranslated I
region I
( I
UTR I
) I
and O
IGR O
and O
downstream O
by O
the O
S O
3 O
' O
UTR O
. O

Treatment O
with O
a O
2 O
- O
week O
course O
of O
anti O
- O
CD154 O
antibody O
and O
a O
single O
transfusion O
of O
donor O
leukocytes O
( O
a O
donor O
- O
specific O
transfusion O
or O
DST O
) O
permits O
skin O
allografts O
to O
survive O
for O
> O
100 O
days O
in O
thymectomized O
mice O
. O

We O
report O
that O
acute O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
induced O
allograft O
rejection O
in O
mice O
treated O
with O
DST O
and O
anti O
- O
CD154 O
antibody O
if O
inoculated O
shortly O
after O
transplantation O
. O

Pichinde O
virus O
also O
induced O
acute O
allograft O
rejection O
, O
but O
murine O
cytomegalovirus O
and O
vaccinia B
virus I
( I
VV I
) I
did O
not O
. O

We O
employ O
a O
sensitive O
technique O
which O
permits O
the O
first O
demonstration O
and O
quantitation O
, O
directly O
ex O
vivo O
, O
of O
virus O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
induced O
by O
DNA O
immunization O
. O

One O
year O
postvaccination O
, O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
readily O
detectable O
and O
constituted O
0 O
. O

5 O
to O
1 O
% O
of O
all O
CD8 O
( O
+ O
) O
T O
cells O
. O

By O
several O
criteria O
- O
including O
cytokine O
production O
, O
perforin O
content O
, O
development O
of O
lytic O
ability O
, O
and O
protective O
capacity O
- O
DNA O
vaccine O
- O
induced O
CD8 O
( O
+ O
) O
memory O
T O
cells O
were O
indistinguishable O
from O
memory O
cells O
induced O
by O
immunization O
with O
a O
conventional O
( O
live O
- O
virus O
) O
vaccine O
. O

Analyses O
of O
long O
- O
term O
humoral O
immune O
responses O
revealed O
that O
, O
in O
contrast O
to O
the O
strong O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
skewing O
of O
the O
humoral O
response O
seen O
after O
conventional O
vaccination O
, O
IgG1 O
and O
IgG2a O
levels O
were O
similar O
in O
DNA O
- O
vaccinated O
neonatal O
and O
adult O
animals O
, O
indicating O
a O
balanced O
T O
helper O
response O
. O

Collectively O
, O
these O
results O
show O
that O
a O
single O
DNA O
vaccination O
within O
hours O
or O
days O
of O
birth O
can O
induce O
long O
- O
lasting O
CD8 O
( O
+ O
) O
T O
- O
and O
B O
- O
cell O
responses O
; O
there O
is O
no O
need O
for O
secondary O
immunization O
( O
boosting O
) O
. O

We O
have O
been O
examining O
the O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
to O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
infection O
. O

Previous O
studies O
have O
identified O
the O
glycoprotein O
E O
- O
derived O
peptide O
from O
residues O
498 O
to O
505 O
( O
gB O
( O
498 O
- O
505 O
) O
) O
as O
one O
of O
at O
least O
three O
determinants O
recognized O
by O
HSV O
- O
1 O
- O
specific O
CTLs O
isolated O
from O
C57BL O
/ O
6 O
mice O
. O

We O
had O
previously O
found O
that O
in O
vitro O
- O
derived O
CTLs O
directed O
to O
gB O
( O
498 O
- O
505 O
) O
show O
a O
characteristic O
pattern O
of O
T B
- I
cell I
receptor I
( I
TCR I
) I
usage O
, O
with O
60 O
% O
of O
gB O
( O
498 O
- O
505 O
) O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
expressing O
BV10 O
( O
+ O
) O
TCR O
beta O
chains O
and O
a O
further O
20 O
% O
expressing O
BV8S1 O
. O

A O
high O
proportion O
of O
activated O
CD8 O
( O
+ O
) O
draining O
lymph O
node O
cells O
were O
found O
to O
express O
these O
dominant O
V O
regions O
, O
suggesting O
that O
a O
substantial O
number O
of O
in O
vivo O
responding O
T O
cells O
were O
directed O
to O
this O
one O
viral O
determinant O
. O

The O
use O
of O
an O
HSV O
- O
1 O
deletion O
mutant O
lacking O
the O
gB O
( O
498 O
- O
505 O
) O
determinant O
in O
combination O
with O
accurate O
intracellular O
gamma O
interferon O
staining O
allowed O
us O
to O
quantify O
the O
extent O
of O
gB O
- O
specific O
T O
- O
cell O
dominance O
. O

Together O
, O
these O
results O
suggested O
that O
between O
70 O
and O
90 O
% O
of O
all O
CD8 O
( O
+ O
) O
HSV O
- O
1 O
- O
specific O
T O
cells O
target O
gB O
( O
498 O
- O
505 O
) O
. O

While O
deletion O
of O
this O
determinant O
resulted O
in O
an O
attenuated O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
, O
it O
also O
permitted O
the O
emergence O
of O
one O
or O
more O
previously O
unidentified O
cryptic O
specificities O
. O

Overall O
, O
HSV O
- O
1 O
infection O
of O
C57BL O
/ O
6 O
mice O
results O
in O
am O
extremely O
focused O
pattern O
of O
CD8 O
( O
+ O
) O
T O
- O
cell O
selection O
in O
terms O
of O
target O
specificity O
and O
TCR O
expression O
. O

We O
investigated O
whether O
induction O
of O
tolerance O
to O
only O
one O
viral O
protein O
could O
reduce O
immunopathology O
caused O
by O
nonlytic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
perforin O
- O
deficient O
hosts O
. O

Earlier O
studies O
had O
shown O
that O
LCMV O
infection O
results O
in O
aplastic O
anemia O
and O
death O
in O
most O
of O
these O
mice O
and O
that O
this O
is O
associated O
with O
bone O
marrow O
infiltration O
by O
antiviral O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
that O
secrete O
inflammatory O
cytokines O
. O

We O
report O
here O
that O
perforin O
- O
deficient O
mice O
exhibit O
severe O
immunopathology O
in O
multiple O
organs O
that O
is O
characterized O
by O
infiltration O
of O
anti O
- O
LCMV O
CTL O
that O
secrete O
large O
amounts O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
. O

importantly O
, O
this O
immunopathology O
is O
significantly O
reduced O
and O
long O
- O
term O
survival O
of O
LCMV O
infection O
is O
increased O
in O
perforin O
- O
deficient O
mice O
expressing O
LCMV O
nucleoprotein B
( I
NP I
) I
in O
the O
thymus O
land O
therefore O
deleting O
most O
of O
their O
LCMV O
- O
NP O
CTL O
) O
compared O
to O
the O
situation O
in O
thymus O
nonexpressors O
. O

This O
is O
due O
to O
the O
selective O
reduction O
of O
NP O
- O
specific O
CTL O
responses O
and O
their O
inflammatory O
- O
cytokine O
( O
IFN O
- O
gamma O
and O
TNF O
- O
alpha O
) O
secretion O
and O
to O
a O
lack O
of O
pathogenetically O
relevant O
compensatory O
responses O
to O
other O
viral O
proteins O
. O

Here O
, O
we O
describe O
a O
novel O
pseudotype O
of O
murine O
leukemia O
virus O
packaged O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
This O
pseudotype O
was O
stable O
during O
ultracentrifugation O
and O
infected O
several O
cell O
lines O
from O
different O
species O
. O

Synthetic O
nonmethylated O
oligonucleotides O
containing O
CpG O
dinucleotides O
( O
CpG O
- O
ODNs O
) O
have O
been O
shown O
to O
exhibit O
immunostimulatory O
activity O
. O

Induction O
of O
protective O
T O
- O
cell O
responses O
against O
challenge O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
or O
with O
recombinant O
vaccinia O
virus O
expressing O
the O
LCMV O
glycoprotein O
was O
achieved O
by O
immunizing O
mice O
with O
the O
immunodominant O
major O
histocompatibility O
complex O
class O
I O
- O
binding O
LCMV O
glycoprotein O
- O
derive O
peptide O
gp33 O
together O
with O
CpG O
- O
ODNs O
, O
In O
these O
experiments O
, O
B O
cells O
, O
potentially O
serving O
as O
CpG O
- O
ODN O
- O
activated O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
, O
were O
not O
required O
for O
induction O
of O
protective O
immunity O
since O
CpG O
- O
ODN O
- O
gp33 O
- O
immunized O
B O
- O
cell O
- O
deficient O
mice O
were O
equally O
protected O
against O
challenge O
infection O
with O
both O
viruses O
. O

We O
previously O
demonstrated O
that O
chimeric O
porcine O
parvovirus O
- O
like O
particles O
( O
PPV O
: O
VLP O
) O
carrying O
heterologous O
epitopes O
, O
when O
injected O
intraperitoneally O
into O
mice O
without O
adjuvant O
, O
activate O
strong O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
specific O
for O
the O
foreign O
epitopes O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
immunogenicity O
of O
PPV O
: O
VLP O
carrying O
a O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
from O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
administered O
by O
mucosal O
routes O
. O

Mice O
immunized O
intranasally O
with O
recombinant O
PPV O
: O
VLP O
, O
in O
the O
absence O
of O
adjuvant O
, O
developed O
high O
levels O
of O
PPV O
- O
specific O
immunoglobulin B
G I
( I
IgC I
) I
and O
/ O
or O
IgA O
in O
their O
serum O
, O
as O
well O
as O
in O
mucosal O
sites O
such O
as O
the O
bronchoalveolar O
and O
intestinal O
fluids O
, O
Antibodies O
in O
sera O
from O
mice O
immunized O
parenterally O
or O
intranasally O
with O
PPV O
: O
VLP O
were O
strongly O
neutralizing O
in O
vitro O
. O

Intranasal O
immunization O
with O
PW O
: O
VLP O
carrying O
the O
LCMV O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
also O
elicited O
a O
strong O
peptide O
- O
specific O
cytotoxic B
- I
TT I
- I
cell I
( I
CTL I
) I
response O
. O

We O
also O
showed O
that O
mice O
primed O
with O
PPV O
: O
VLP O
are O
still O
able O
to O
develop O
strong O
CTL O
responses O
after O
subsequent O
immunization O
with O
chimeric O
PPV O
: O
VLP O
carrying O
a O
foreign O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
, O
These O
results O
highlight O
the O
attractive O
potential O
of O
PPV O
: O
VLP O
as O
a O
safe O
, O
nonreplicating O
antigen O
carrier O
to O
stimulate O
systemic O
and O
mucosal O
immunity O
after O
nasal O
administration O
. O

Perforin O
- O
deficient O
( O
perf O
- O
/ O
- O
) O
mice O
chronically O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
contained O
greater O
numbers O
of O
antiviral O
T O
cells O
compared O
to O
persistently O
infected O
+ O
/ O
+ O
mice O
. O

Mice O
that O
were O
deficient O
in O
both O
perforin O
and O
Fas O
exhibited O
a O
striking O
acceleration O
of O
the O
spontaneous O
lymphoproliferative O
disease O
seen O
in O
Fas O
- O
deficient O
( O
lpr O
) O
mice O
. O

Experimental O
infection O
of O
rats O
with O
Borna B
disease I
virus I
( I
BDV I
) I
and O
natural O
BDV O
infection O
of O
horses O
and O
sheep O
leads O
to O
a O
virus O
- O
induced O
T O
- O
cell O
- O
mediated O
immunopathology O
in O
the O
central O
nervous O
system O
. O

Earlier O
work O
revealed O
the O
importance O
of O
the O
BDV O
- O
specific O
T O
- O
cell O
response O
and O
of O
CD8 O
( O
+ O
) O
effector O
cells O
in O
particular O
in O
the O
destruction O
of O
virus O
- O
infected O
cells O
. O

The O
present O
study O
employed O
different O
vaccinia O
virus O
recombinants O
expressing O
single O
BDV O
- O
specific O
proteins O
to O
investigate O
the O
specificity O
of O
the O
cytolytic O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
response O
, O
revealing O
a O
major O
epitope O
on O
the O
BDV O
nucleoprotein O
p40 O
. O

The O
gastric O
mucosa O
is O
an O
important O
portal O
of O
entry O
for O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infections O
. O

Within O
hours O
after O
intragastric O
( O
i O
, O
g O
, O
) O
inoculation O
, O
virus O
appears O
in O
the O
gastric O
epithelia O
, O
then O
in O
the O
mesenteric O
lymph O
nodes O
and O
spleen O
, O
and O
then O
in O
the O
liver O
and O
brain O
. O

By O
72 O
h O
i O
, O
g O
, O
- O
inoculated O
virus O
is O
widely O
disseminated O
and O
equivalent O
to O
intravenous O
( O
i O
, O
v O
, O
) O
infection O
( O
S O
, O
K O
, O
Rai O
, O
B O
, O
K O
, O
Micales O
, O
M O
, O
S O
, O
Wu O
, O
D O
, O
S O
, O
Cheung O
, O
T O
, O
D O
, O
Pugh O
, O
G O
, O
E O
. O

J O
, O
Pathol O
, O
151 O
: O
633 O
- O
639 O
, O
1997 O
) O
, O
Pretreatment O
of O
mice O
with O
a O
G O
protein O
inhibitor O
, O
pertussis B
toxin I
( I
PTx I
) I
, O
delays O
LCMV O
dissemination O
after O
i O
, O
g O
, O
, O
but O
not O
after O
i O
, O
v O
, O
, O
inoculation O
. O

To O
analyze O
the O
role O
of O
B O
cells O
in O
clearing O
persistent O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
we O
used O
B O
- O
cell O
- O
deficient O
mu O
MT O
/ O
mu O
MT O
( O
B O
- O
/ O
- O
) O
mice O
, O
B O
- O
/ O
- O
mice O
controlled O
an O
acute O
LCMV O
infection O
with O
the O
same O
kinetics O
and O
efficiency O
as O
B O
- O
cell O
- O
competent O
( O
B O
+ O
/ O
+ O
) O
mice O
via O
virus O
- O
specific O
, O
major B
histocompatibility I
complex I
( I
MIIC I
) I
class O
I O
restricted O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
CTL O
from O
B O
- O
/ O
- O
and O
B O
+ O
/ O
+ O
mice O
were O
equivalent O
in O
affinity O
to O
known O
LCMV O
CTL O
epitopes O
and O
had O
similar O
CTL O
precursor O
frequencies O
( O
pCTL O
) O
, O
Adoptive O
transfer O
of O
memory O
cells O
from O
B O
+ O
/ O
+ O
mice O
led O
to O
virus O
clearance O
from O
persistently O
infected O
B O
+ O
/ O
+ O
recipients O
even O
after O
in O
vitro O
depletion O
of O
B O
cells O
, O
indicating O
that O
B O
cells O
or O
immunoglobulins O
are O
not O
required O
in O
the O
transfer O
population O
. O

Instead O
, O
B O
- O
/ O
- O
mice O
were O
found O
to O
have O
a O
profound O
CD4 O
helper O
defect O
, O
Furthermore O
, O
compared O
to O
cultured O
splenocytes O
from O
B O
+ O
/ O
+ O
mice O
, O
those O
from O
B O
- O
/ O
- O
mice O
secreted O
less O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
interleukin O
2 O
, O
with O
differences O
most O
pronounced O
for O
CD8 O
T O
tells O
. O

This O
has O
been O
associated O
with O
the O
enhanced O
sensitivity O
of O
these O
highly O
activated O
T O
cells O
to O
undergo O
apoptosis O
, O
or O
activation B
- I
induced I
cell I
death I
( I
AICD I
) I
, O
upon O
T O
- O
cell O
receptor O
ligation O
. O

Here O
we O
show O
that O
gamma O
interferon O
receptor O
- O
deficient O
( O
IFN O
- O
gamma O
R O
- O
/ O
- O
) O
mice O
mount O
a O
T O
- O
cell O
response O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
but O
fail O
to O
undergo O
the O
transient O
immune O
deficiency O
. O

Wild O
- O
type O
mice O
receiving O
high O
doses O
of O
disseminating O
LCMV O
Clone O
13 O
are O
known O
to O
undergo O
clonal O
exhaustion O
of O
their O
virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

To O
determine O
whether O
this O
process O
was O
mediated O
by O
AICD O
associated O
with O
IFN O
- O
gamma O
or O
with O
Fas O
- O
Fas O
ligand O
interactions O
, O
LCMV O
- O
specific O
precursor O
CTL O
frequencies O
were O
examined O
in O
LCMV O
Clone O
13 O
- O
infected O
IFN O
- O
gamma O
R O
- O
/ O
- O
or O
lpr O
( O
Fas O
- O
deficient O
) O
mice O
. O

To O
address O
these O
issues O
, O
, O
ve O
quantitated O
virus O
- O
specific O
CD4 O
Th1 O
( O
interleukin O
2 O
[ O
IL O
- O
2 O
] O
and O
gamma O
- O
interferon O
) O
and O
Th2 O
( O
IL O
- O
4 O
) O
responses O
in O
mice O
acutely O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Using O
two O
sensitive O
assays O
( O
enzyme O
- O
linked O
immunospot O
assay O
and O
intracellular O
stain O
) O
to O
measure O
cytokine O
production O
at O
the O
single O
- O
cell O
level O
, O
we O
found O
that O
both O
CD4 O
Th1 O
and O
Th2 O
responses O
were O
induced O
during O
primary O
LCMV O
infection O
. O

At O
the O
peak O
( O
day O
8 O
) O
of O
the O
response O
, O
the O
frequency O
of O
LCMV O
- O
specific O
CD4 O
Th1 O
cells O
was O
1 O
/ O
35 O
to O
1 O
/ O
160 O
CD4 O
T O
cells O
, O
and O
the O
frequency O
of O
Th2 O
cells O
was O
1 O
/ O
400 O
. O

VV O
) O
has O
been O
studied O
with O
the O
coxsackievirus B
B3 I
( I
CVB3 I
) I
model O
system O
. O

CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
play O
a O
key O
role O
in O
the O
control O
of O
many O
virus O
infections O
, O
and O
the O
need O
for O
vaccines O
to O
elicit O
strong O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
order O
to O
provide O
optimal O
protection O
in O
such O
infections O
is O
increasingly O
apparent O
. O

In O
this O
study O
, O
we O
investigated O
the O
involvement O
of O
CD40 B
ligand I
( I
CD40L I
) I
- O
mediated O
interactions O
in O
these O
processes O
by O
analyzing O
the O
memory O
CTL O
response O
of O
CD40L O
- O
deficient O
mice O
following O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

The O
maintenance O
of O
memory O
CD8 O
+ O
CTL B
precursors I
( I
CTLp I
) I
at O
stable O
frequencies O
over O
time O
was O
not O
impaired O
in O
CD40L O
deficient O
mice O
. O

CD O
CD40L O
- O
deficient O
mice O
produced O
lower O
levels O
of O
CD8 O
( O
+ O
) O
CTLp O
during O
the O
primary O
immune O
response O
to O
LCMV O
than O
did O
wild O
- O
type O
controls O
, O
despite O
the O
fact O
that O
the O
LCMV O
- O
specific O
effector O
CTL O
response O
of O
CD40C O
- O
deficient O
mice O
was O
indistinguishable O
from O
that O
of O
control O
animals O
. O

The O
differentiation O
of O
naive O
CD8 O
( O
+ O
) O
T O
cells O
into O
effector O
and O
memory O
CTL O
thus O
involves O
pathways O
that O
can O
be O
discriminated O
from O
each O
other O
by O
their O
requirement O
for O
CD40L O
- O
mediated O
interactions O
. O

Expression O
of O
CD40L O
by O
CTLp O
themselves O
was O
not O
an O
essential O
step O
during O
their O
expansion O
and O
differentiation O
from O
naive O
CD8 O
+ O
cells O
into O
memory O
CTLp O
; O
instead O
, O
the O
reduction O
in O
memory O
CTLp O
generation O
in O
CD40L O
- O
deficient O
mice O
was O
likely O
a O
consequence O
of O
defects O
in O
the O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
mounted O
by O
these O
animals O
. O

These O
results O
thus O
suggest O
a O
previously O
unappreciated O
role O
for O
CD40L O
in O
the O
generation O
of O
CD8 O
( O
+ O
) O
memory O
CTLp O
, O
the O
probable O
nature O
of O
which O
is O
discussed O
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
are O
essential O
for O
effective O
immunity O
to O
various O
viral O
infections O
. O

dendritic B
cells I
( I
DC I
) I
have O
been O
shown O
to O
efficiently O
acquire O
, O
transport O
, O
and O
present O
antigens O
to O
naive O
CTL O
in O
vitro O
and O
in O
vivo O
. O

In O
this O
study O
, O
we O
assessed O
the O
potential O
of O
DC O
, O
either O
pulsed O
with O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
- O
specific O
peptide O
GP33 O
- O
41 O
or O
constitutively O
expressing O
the O
respective O
epitope O
, O
to O
induce O
LCMV O
- O
specific O
antiviral O
immunity O
in O
vivo O
. O

Already O
at O
day O
2 O
after O
a O
single O
intravenous O
immunization O
with O
high O
doses O
of O
DC O
( O
1 O
x O
10 O
( O
5 O
) O
to O
5 O
x O
10 O
( O
5 O
) O
) O
, O
mice O
were O
fully O
protected O
against O
LCMV O
challenge O
infection O
, O
and O
direct O
ex O
vivo O
cytotoxicity O
was O
detectable O
at O
day O
4 O
after O
DC O
immunization O
. O

The O
promyelocytic B
leukemia I
( I
PML I
) I
protein O
forms O
nuclear O
bodies O
which O
are O
relocated O
to O
the O
cytoplasm O
by O
the O
RNA O
virus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Others O
have O
observed O
that O
LCMV O
virions O
may O
contain O
ribosomes O
; O
hence O
, O
we O
investigated O
the O
effects O
of O
infection O
on O
the O
distribution O
of O
ribosomal O
P O
proteins O
( O
P0 O
, O
P1 O
, O
and O
P2 O
) O
with O
PML O
as O
a O
reference O
point O
. O

Following O
infection O
of O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
virus O
- O
neutralizing O
antibodies O
appear O
late O
, O
after O
30 O
to O
60 O
days O
. O

Transgenic O
mice O
expressing O
the O
immunoglobulin O
mu O
heavy O
chain O
of O
the O
LCMV O
- O
neutralizing O
monoclonal O
antibody O
KL25 O
( O
H25 O
transgenic O
mice O
) O
mounted O
LCMV O
- O
neutralizing O
Immunoglobulin B
M I
( I
IgM I
) I
serum O
titers O
within O
8 O
days O
after O
infection O
. O

In O
contrast O
, O
mice O
which O
had O
been O
passively O
administered O
LCMV O
- O
neutralizing O
antibodies O
and O
transgenic O
mice O
exhibiting O
spontaneous O
LCMV O
- O
neutralizing O
IgM O
serum O
titers O
( O
HL25 O
transgenic O
mice O
expressing O
the O
immunoglobulin O
mu O
heavy O
and O
the O
kappa O
light O
chain O
) O
showed O
an O
enhancement O
of O
disease O
after O
i O
. O

The O
promyelocytic B
leukemia I
protein I
( I
PML I
) I
forms O
nuclear O
bodies O
which O
are O
altered O
in O
some O
disease O
conditions O
. O

We O
report O
that O
the O
cytoplasmic O
RNA O
virus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
influences O
the O
distribution O
of O
PML O
bodies O
. O

Following O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
normal O
adult O
mice O
generate O
virus O
- O
specific O
, O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
- O
restricted O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
which O
clear O
the O
virus O
after O
intraperitoneal O
infection O
or O
cause O
death O
following O
intracranial O
( O
i O
. O

We O
have O
investigated O
the O
response O
of O
beta O
( O
2 O
) O
- O
microglobulin O
- O
deficient O
( O
beta O
( O
2 O
) O
m O
( O
- O
) O
) O
mice O
of O
the O
H O
- O
2 O
( O
d O
) O
haplotype O
( O
KOD O
mice O
) O
to O
LCMV O
infection O
. O

Unlike O
H O
- O
2 O
( O
b O
) O
beta O
( O
2 O
) O
m O
( O
- O
) O
mice O
, O
which O
generate O
CD4 O
( O
+ O
) O
MHC O
class O
II O
- O
restricted O
CTL O
in O
response O
to O
LCMV O
, O
KOD O
mice O
generate O
high O
levels O
of O
CD8 O
( O
+ O
) O
MHC O
class O
I O
- O
restricted O
, O
virus O
- O
specific O
CTL O
. O

These O
CTL O
are O
specific O
for O
the O
LCMV O
nucleoprotein O
epitope O
( O
residues O
118 O
to O
126 O
) O
in O
association O
with O
the O
L O
- O
d O
class O
I O
molecule O
, O
analogous O
to O
the O
CTL O
response O
in O
wild O
- O
type O
mice O
. O

Similar O
to O
results O
with O
normal O
mice O
, O
lethal O
LCM O
disease O
in O
KOD O
mice O
is O
prevented O
by O
in O
vivo O
depletion O
of O
CD8 O
( O
+ O
) O
T O
cells O
prior O
to O
i O
. O

Overall O
, O
these O
results O
demonstrate O
that O
beta O
( O
2 O
) O
m O
is O
not O
an O
absolute O
requirement O
for O
presentation O
of O
endogenous O
antigen O
on O
L O
- O
d O
or O
for O
induction O
of O
virus O
- O
specific O
L O
- O
d O
- O
restricted O
CTL O
in O
vivo O
. O

DNA O
immunization O
can O
induce O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
antibodies O
, O
and O
protection O
against O
microbial O
challenge O
. O

We O
achieved O
this O
goal O
by O
cotranslational O
ubiquitination O
of O
a O
plasmid O
- O
encoded O
viral O
antigen O
, O
lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
nucleoprotein I
( I
NP I
) I
. O

That O
CTL O
are O
induced O
at O
all O
by O
this O
rapidly O
degraded O
protein O
may O
shed O
light O
on O
the O
mechanism O
by O
which O
CTL O
are O
induced O
by O
DNA O
immunization O
; O
it O
has O
been O
suggested O
that O
CTL O
induction O
following O
intramuscular O
DNA O
injection O
results O
not O
from O
antigen O
presentation O
by O
cells O
taking O
up O
and O
expressing O
the O
DNA O
but O
rather O
from O
uptake O
of O
soluble O
protein O
by O
specialized O
antigen B
- I
presenting I
cells I
( I
APC I
) I
. O

Mice O
immunized O
with O
a O
plasmid O
encoding O
NP O
show O
approximately O
100 O
- O
fold O
reductions O
in O
virus O
titers O
compared O
to O
controls O
, O
while O
mice O
immunized O
with O
a O
plasmid O
encoding O
the O
ubiquitinated O
NP O
show O
reductions O
in O
virus O
load O
of O
at O
least O
5 O
x O
10 O
( O
4 O
) O
- O
to O
5 O
x O
10 O
( O
5 O
) O
- O
fold O
. O

Mice O
lacking O
Itk O
, O
a O
T O
- O
cell O
- O
specific O
protein O
tyrosine O
kinase O
, O
have O
reduced O
numbers O
of O
T O
cells O
and O
reduced O
responses O
to O
allogeneic O
major O
histocompatibility O
molecules O
, O
This O
study O
analyzed O
antiviral O
immune O
responses O
in O
mice O
deficient O
for O
Itk O
, O
Primary O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
were O
analyzed O
after O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
vaccinia B
virus I
( I
VV I
) I
, O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
Ex O
vivo O
CTL O
activity O
was O
consistently O
reduced O
by O
a O
factor O
of O
two O
to O
six O
for O
the O
different O
viruses O
, O
CTL O
responses O
after O
restimulation O
in O
vitro O
were O
similarly O
reduced O
unless O
exogenous O
cytokines O
were O
added O
, O
In O
the O
presence O
of O
interleukin O
- O
2 O
or O
concanavalin O
A O
supernatant O
, O
Itk O
deficient O
and O
control O
mice O
responded O
similarly O
, O
Interestingly O
, O
while O
LCMV O
was O
completely O
eliminated O
by O
day O
8 O
in O
both O
Itk O
- O
deficient O
and O
control O
mice O
, O
VV O
cleared O
from O
itk O
( O
- O
/ O
- O
) O
mice O
with O
delayed O
kinetics O
. O

Antibody O
responses O
were O
evaluated O
after O
VSV O
infection O
, O
Both O
the O
T O
- O
cell O
- O
independent O
neutralizing O
Immunoglobulin B
M I
( I
IgM I
) I
and O
the O
T O
- O
cell O
- O
dependent O
IgG O
responses O
were O
similar O
in O
Itk O
- O
deficient O
and O
control O
mice O
, O
Taken O
together O
, O
the O
results O
show O
that O
CTL O
responses O
are O
reduced O
in O
the O
absence O
of O
Itk O
whereas O
antiviral O
B O
- O
cell O
responses O
are O
not O
affected O
. O

In O
the O
present O
study O
, O
we O
examined O
the O
expression O
of O
multiple O
chemokine O
genes O
during O
the O
course O
of O
lymphocytic B
choriomeningitis I
( I
LCM I
) I
in O
mice O
. O

In O
noninfected O
mice O
, O
no O
detectable O
chemokine O
gene O
expression O
was O
found O
in O
the O
brain O
; O
however O
, O
by O
day O
3 O
postinfection O
, O
the O
induction O
of O
a O
number O
of O
chemokine O
mRNAs O
was O
observed O
as O
follows O
( O
in O
order O
from O
the O
greatest O
to O
the O
least O
) O
; O
cytokine O
responsive O
gene O
- O
2 O
or O
interferon O
- O
inducible O
10 O
- O
kDa O
protein O
( O
Crg O
- O
2 O
/ O
IP O
- O
10 O
) O
, O
RANTES O
, O
monocyte B
chemotactic I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
macrophage O
inflammatory O
protein O
- O
1 O
( O
MIP O
- O
1 O
beta O
) O
, O
and O
MCP O
- O
3 O
. O

Transcript O
for O
T O
- O
cell O
activation O
- O
3 O
was O
not O
detectable O
in O
the O
brain O
at O
any O
time O
following O
LCM O
virus O
( O
LCMV O
) O
infection O
. O

Expression O
of O
Crg O
- O
2 O
/ O
IP O
- O
10 O
RNA O
was O
localized O
to O
predominantly O
resident O
cells O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
overlapped O
with O
sites O
of O
viral O
infection O
and O
immune O
cell O
infiltration O
. O

Conventional O
vaccines O
are O
remarkably O
effective O
in O
adults O
but O
are O
much O
less O
successful O
in O
the O
very O
young O
, O
who O
are O
less O
able O
to O
initiate O
a O
mature O
immune O
response O
and O
who O
mag O
carry O
maternal O
antibodies O
which O
inactivate O
standard O
vaccines O
, O
We O
set O
out O
to O
determine O
whether O
DNA O
immunization O
might O
circumvent O
these O
problems O
, O
We O
have O
previously O
shown O
that O
intramuscular O
injection O
of O
plasmid O
DNA O
encoding O
the O
nucleoprotein B
( I
NP I
) I
gene O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
capable O
of O
inducing O
immune O
responses O
and O
protecting O
50 O
% O
of O
adult O
mice O
against O
lethal O
and O
sublethal O
challenge O
with O
LCMV O
. O

Here O
we O
demonstrate O
that O
mouse O
pups O
injected O
with O
the O
same O
plasmid O
hours O
or O
days O
after O
birth O
produce O
major O
histocompatibility O
complex O
- O
restricted O
, O
NP O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
that O
persist O
into O
adulthood O
; O
18 O
% O
of O
vaccinated O
pups O
responded O
to O
subsequent O
sublethal O
viral O
challenge O
by O
the O
accelerated O
production O
of O
anti O
- O
NP O
LCMV O
- O
specific O
CTL O
, O
indicating O
that O
these O
animals O
had O
been O
successfully O
immunized O
by O
the O
plasmid O
DNA O
. O

In O
addition O
, O
these O
mice O
showed O
a O
> O
95 O
% O
reduction O
in O
splenic O
viral O
titers O
4 O
days O
postinfection O
compared O
to O
control O
mice O
, O
demonstrating O
a O
more O
rapid O
control O
of O
infection O
in O
vivo O
, O
Furthermore O
, O
pups O
born O
of O
and O
suckled O
on O
LCMV O
- O
immune O
dams O
( O
and O
therefore O
containing O
passively O
acquired O
anti O
- O
LCMV O
antibodies O
at O
the O
time O
of O
DNA O
inoculation O
) O
responded O
to O
the O
DNA O
vaccine O
in O
a O
similar O
manner O
, O
showing O
that O
maternally O
derived O
anti O
- O
LCR O
- O
IV O
antibodies O
do O
not O
significantly O
inhibit O
the O
generation O
of O
protective O
immune O
responses O
following O
DNA O
vaccination O
, O
These O
findings O
suggest O
that O
, O
at O
least O
in O
this O
model O
system O
, O
DNA O
immunization O
circumvents O
many O
of O
the O
problems O
associated O
with O
neonatal O
immunization O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
known O
to O
induce O
strong O
, O
polyclonal O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
. O

The O
cytotoxic O
T O
- O
lymphocyte O
response O
against O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
BALB O
/ O
c O
mice O
is O
predominantly O
directed O
against O
a O
single O
, O
L O
- O
d O
- O
restricted O
epitope O
in O
the O
viral O
nucleoprotein O
( O
residues O
118 O
to O
126 O
) O
, O
To O
investigate O
whether O
any O
K O
- O
d O
/ O
D O
- O
d O
- O
restricted O
responses O
were O
activated O
but O
did O
not O
expand O
during O
the O
primary O
response O
, O
me O
used O
a O
BALB O
/ O
c O
mutant O
, O
BALB O
/ O
c O
- O
H O
- O
2 O
( O
dm2 O
) O
, O
which O
does O
not O
express O
the O
Ld O
molecule O
. O

Splenocytes O
from O
LCMC O
- O
infected O
BALB O
/ O
c O
mice O
were O
transferred O
into O
irradiated O
BALB O
/ O
c O
- O
H O
- O
2 O
( O
dm2 O
) O
mice O
and O
rechallenged O
with O
LCMV O
. O

Analysis O
of O
a O
panel O
of O
ha O
binding O
LCMV O
peptides O
revealed O
that O
residues O
283 O
to O
291 O
from O
the O
viral O
glycoprotein O
( O
GP O
( O
283 O
- O
291 O
) O
) O
comprise O
a O
major O
new O
epitope O
in O
the O
adoptive O
transfer O
model O
, O
Because O
the O
donor O
splenocytes O
were O
first O
activated O
during O
the O
primary O
infection O
in O
BALB O
/ O
c O
mice O
, O
the O
GP O
( O
283 O
- O
291 O
) O
epitope O
is O
a O
subdominant O
epitope O
in O
BALB O
/ O
c O
mice O
that O
becomes O
dominant O
after O
rechallenge O
in O
BALB O
/ O
c O
- O
H O
- O
2 O
( O
dm2 O
) O
mice O
, O
This O
study O
makes O
two O
points O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented B
negative I
- I
stranded I
( I
NNS I
) I
RNA O
virus O
, O
prototype O
of O
a O
new O
taxon O
in O
the O
Mononegavirales O
order O
. O

To O
improve O
our O
knowledge O
about O
the O
biology O
of O
this O
novel O
virus O
, O
we O
have O
identified O
and O
characterized O
the O
product O
of O
BDV O
open O
reading O
frame O
IV O
( O
BVp56 O
) O
. O

Expression O
of O
BVp56 O
resulted O
in O
the O
generation O
of O
two O
polypeptides O
with O
molecular O
masses O
of O
about O
84 O
and O
43 O
kDa O
( O
GP O
- O
84 O
and O
GP O
- O
43 O
) O
. O

The O
role O
of O
B7 O
binding O
CD28 O
in O
the O
regulation O
of O
T O
- O
and O
B O
- O
cell O
responses O
against O
viral O
antigens O
was O
assessed O
in O
transgenic O
mice O
expressing O
soluble O
CTLA4 O
- O
H O
gamma O
1 O
( O
CTLA4 O
- O
Ig O
tg O
mice O
) O
that O
blocks O
B7 O
- O
CD28 O
interactions O
. O

The O
results O
indicate O
that O
transgenic O
soluble O
CTLA4 O
does O
not O
significantly O
alter O
cytotoxic O
T O
- O
cell O
responses O
against O
replicating O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
or O
vaccinia O
virus O
but O
drastically O
impairs O
the O
induction O
of O
cytotoxic O
T O
- O
cell O
responses O
against O
abortively O
replicating O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

While O
the O
T O
- O
independent O
neutralizing O
Immunoglobulin B
M I
( I
IgM I
) I
responses O
were O
within O
normal O
ranges O
, O
the O
switch O
to O
IgG O
was O
reduced O
4 O
- O
to O
16 O
- O
fold O
after O
immunization O
with O
abortively O
replicating O
VSV O
and O
more O
than O
30 O
- O
fold O
after O
immunization O
with O
an O
inert O
VSV O
glycoprotein O
antigen O
in O
transgenic O
mice O
. O

Perforin O
- O
deficient O
[ O
perforin O
( O
- O
/ O
- O
) O
] O
mice O
were O
infected O
with O
two O
strains O
of O
JHM B
virus I
( I
JHMV I
) I
to O
analyze O
the O
role O
of O
perforin O
- O
mediated O
cytotoxicity O
in O
acute O
lethal O
and O
subacute O
central B
nervous I
system I
( I
CNS I
) I
infections O
. O

During O
both O
acute O
and O
subacute O
infections O
, O
the O
overall O
mortality O
of O
the O
perforin O
( O
- O
/ O
- O
) O
mice O
was O
not O
different O
from O
that O
of O
the O
controls O
. O

Perforin O
( O
- O
/ O
- O
) O
mice O
survived O
longer O
than O
the O
controls O
, O
consistent O
with O
reduced O
morbidity O
. O

Both O
strains O
of O
virus O
were O
cleared O
from O
the O
perforin O
( O
- O
/ O
- O
) O
mice O
as O
in O
the O
controls O
; O
however O
, O
the O
rate O
of O
clearance O
was O
delayed O
in O
the O
perforin O
( O
- O
/ O
- O
) O
mice O
, O
indicating O
that O
perforin O
- O
mediated O
cytolysis O
is O
involved O
in O
viral O
clearance O
. O

Cells O
undergoing O
apoptosis O
were O
detected O
in O
the O
CNS O
of O
both O
the O
perforin O
( O
- O
/ O
- O
) O
and O
control O
groups O
, O
indicating O
that O
perforin O
is O
not O
essential O
for O
programmed O
cell O
death O
. O

A O
cardinal O
feature O
of O
the O
biology O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
is O
its O
ability O
to O
establish O
persistent O
infections O
in O
mice O
, O
Persistence O
is O
usually O
established O
by O
infection O
of O
the O
mouse O
during O
the O
in O
utero O
or O
neonatal O
period O
. O

The O
establishment O
of O
persistence O
in O
adult O
BALB O
/ O
c O
mice O
by O
the O
immunosuppressive O
, O
macrophage O
- O
tropic O
LCMV O
variant O
, O
clone O
13 O
was O
also O
prevented O
by O
prophylactic O
treatment O
with O
anti O
- O
LCMV O
monoclonal O
antibodies O
, O
However O
, O
the O
protection O
afforded O
by O
passively O
acquired O
antibody O
was O
found O
to O
be O
incomplete O
if O
the O
recipients O
lacked O
functional O
CD8 O
( O
+ O
) O
T O
cells O
. O

While O
65 O
% O
of O
neonatal O
athymic O
( O
nu O
/ O
nu O
) O
mice O
nursed O
by O
immune O
nu O
/ O
+ O
dams O
resisted O
low O
- O
dose O
viral O
challenge O
( O
25 O
PFU O
) O
, O
the O
majority O
of O
nude O
pups O
challenged O
with O
high O
doses O
of O
virus O
( O
100 O
PFU O
) O
became O
persistently O
infected O
. O

Also O
, O
protection O
was O
incomplete O
in O
beta O
( O
2 O
) O
- O
microglobulin O
knockout O
mice O
, O
which O
lack O
functional O
CD8 O
( O
+ O
) O
T O
cells O
, O
suggesting O
that O
a O
cooperative O
effect O
was O
exerted O
by O
the O
combination O
of O
neutralizing O
antibody O
and O
endogenous O
T O
cells O
. O

CD40 O
ligand O
is O
expressed O
on O
activated O
T O
cells O
and O
interacts O
with O
CD40 O
on O
B O
cells O
and O
monocytes O
, O
It O
is O
not O
known O
what O
role O
CD40 O
ligand O
plays O
in O
the O
generation O
of O
immune O
responses O
to O
viral O
infection O
, O
To O
address O
this O
issue O
, O
we O
examined O
virus O
- O
specific O
T O
- O
and O
B O
- O
cell O
responses O
in O
CD40 O
ligand O
- O
deficient O
( O
CD40L O
- O
/ O
- O
) O
mice O
following O
infection O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
We O
found O
that O
primary O
anti O
- O
LCMV O
specific O
antibody O
responses O
were O
severely O
impaired O
in O
CD40L O
- O
/ O
- O
mice O
, O
with O
the O
defect O
being O
most O
striking O
for O
antibody O
of O
the O
Immunoglobulin B
G1 I
( I
IgG1 I
) I
isotype O
, O
Interestingly O
, O
low O
levels O
of O
LCMV O
- O
specific O
antibodies O
of O
the O
IgG2a O
, O
IgG2b O
, O
and O
IgG3 O
isotypes O
were O
made O
in O
the O
CD40L O
- O
/ O
- O
mice O
, O
showing O
that O
IgG1 O
responses O
are O
totally O
dependent O
on O
CD40L O
but O
that O
at O
least O
some O
IgG2a O
, O
IgG2b O
, O
and O
IgG3 O
responses O
can O
be O
CD40L O
independent O
, O
However O
, O
unlike O
CD40L O
+ O
/ O
+ O
mice O
, O
CD40L O
- O
/ O
- O
mice O
were O
unable O
to O
sustain O
virus O
- O
specific O
antibody O
responses O
and O
showed O
a O
gradual O
decline O
in O
serum O
antibody O
levels O
over O
time O
. O

The O
CD40L O
- O
/ O
- O
mice O
were O
also O
deficient O
in O
the O
generation O
of O
memory O
B O
cells O
, O
In O
contrast O
to O
the O
severely O
impaired O
humoral O
responses O
, O
CD40L O
- O
/ O
- O
mice O
generated O
potent O
virus O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic O
T O
- O
lymphocyte O
responses O
after O
LCMV O
infection O
and O
were O
able O
to O
clear O
the O
virus O
, O
These O
results O
show O
that O
CD40L O
does O
not O
play O
a O
role O
in O
generating O
primary O
virus O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic O
T O
- O
lymphocyte O
responses O
but O
does O
affect O
the O
primary O
antibody O
response O
and O
the O
generation O
of O
memory O
B O
cells O
. O

Persistent O
infection O
of O
C3H O
/ O
St O
mice O
with O
certain O
strains O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
causes O
a O
growth B
hormone I
( I
GH I
) I
deficiency O
syndrome O
( O
GHDS O
) O
manifested O
as O
growth O
retardation O
and O
hypoglycemia O
, O
Infected O
mice O
show O
high O
levels O
of O
viral O
replication O
in O
the O
GH O
- O
producing O
cells O
in O
the O
anterior O
pituitary O
leading O
to O
dea O
eased O
synthesis O
of O
GH O
mRNA O
and O
protein O
despite O
the O
absence O
of O
detectable O
virus O
- O
induced O
cell O
structural O
damage O
, O
Virus O
clones O
isolated O
from O
the O
GHDS O
- O
negative O
LCMV O
WE O
strain O
can O
cause O
the O
disease O
, O
while O
others O
cannot O
, O
The O
genetic O
basis O
of O
this O
phenotypic O
difference O
is O
a O
nucleotide O
substitution O
resulting O
in O
a O
single O
amino O
acid O
difference O
in O
the O
vital O
glycoprotein O
. O

Reassortant O
studies O
indicate O
that O
the O
single O
amino O
acid O
substitution O
( O
Ser O
- O
153 O
to O
Phe O
) O
is O
sufficient O
to O
allow O
infection O
of O
the O
GH O
- O
producing O
cells O
and O
cause O
GHDS O
. O

Persistent O
infection O
of O
C3H O
/ O
St O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strain O
Armstrong O
leads O
to O
disordered O
growth O
and O
hypoglycemia O
. O

Both O
host O
and O
viral O
determinants O
contribute O
to O
this O
growth B
hormone I
( I
GH I
) I
deficiency O
syndrome O
( O
GHDS O
) O
. O

The O
T O
- O
cell O
response O
to O
lymphocytic O
choriomeningitis O
virus O
was O
studied O
in O
mice O
with O
deficient O
expression O
of O
beta O
( O
2 O
) O
- O
integrins O
or O
ICAM O
- O
1 O
. O

T O
- O
cell O
- O
mediated O
inflammation O
, O
assessed O
as O
primary O
footpad O
swelling O
and O
susceptibility O
to O
intracerebral O
infection O
, O
was O
slightly O
compromised O
only O
in O
beta O
( O
2 O
) O
- O
integrin O
- O
deficient O
mice O
. O

Infection O
of O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
causes O
a O
major O
expansion O
of O
CD8 O
( O
+ O
) O
T O
cells O
followed O
by O
a O
period O
of O
immune O
downregulation O
that O
coincides O
with O
the O
induction O
of O
lymphocyte O
apoptosis O
in O
the O
mouse O
spleen O
. O

CD95 O
( O
Fas O
) O
and O
its O
ligand O
are O
important O
for O
regulating O
peripheral O
T O
- O
lymphocyte O
numbers O
and O
can O
mediate O
apoptosis O
of O
mature O
T O
lymphocytes O
. O

We O
infected O
CD95 O
- O
and O
CD95L O
- O
deficient O
mice O
( O
lpr O
and O
gld O
, O
respectively O
) O
with O
LCMV O
to O
determine O
if O
the O
immune O
downregulation O
that O
occurred O
following O
resolution O
of O
the O
LCMV O
infection O
was O
due O
to O
a O
CD95 O
- O
dependent O
apoptotic O
mechanism O
. O

In O
vitro O
replication O
of O
coxsackievirus B
B3 I
( I
CVB3 I
) I
in O
cells O
of O
the O
immune O
system O
derived O
from O
uninfected O
adolescent O
A O
/ O
J O
and O
C57BL O
/ O
6J O
mice O
and O
replication O
of O
CVB3 O
in O
and O
association O
with O
immune O
cells O
from O
spleens O
of O
infected O
animals O
in O
vivo O
were O
assessed O
, O
Nonstimulated O
or O
mitogen O
- O
stimulated O
spleen O
cells O
were O
minimally O
permissive O
for O
viral O
replication O
during O
an O
8 O
- O
h O
period O
, O
Three O
days O
postinfection O
( O
p O
. O

0054 O
) O
, O
Although O
the O
pattern O
of O
CVB3 O
RNA O
localization O
was O
different O
, O
the O
total O
load O
of O
infectious O
virus O
( O
PFU O
per O
milligram O
of O
tissue O
) O
was O
not O
different O
. O

Splenic O
CVB3 O
titers O
( O
PFU O
per O
milligram O
of O
tissue O
) O
in O
both O
strains O
were O
maximal O
at O
day O
3 O
or O
4 O
p O
, O
i O
, O
and O
were O
back O
to O
baseline O
by O
day O
7 O
p O
, O
i O
, O
, O
with O
most O
infectious O
virus O
being O
non O
- O
cell O
associated O
. O

CVB3 O
titers O
( O
PFU O
per O
milligram O
of O
tissue O
) O
correlated O
directly O
, O
with O
in O
situ O
hybridization O
positivity O
in O
splenic O
follicles O
and O
extrafollicular O
regions O
in O
both O
murine O
strains O
; O
however O
, O
follicular O
hybridization O
intensity O
was O
greater O
in O
A O
/ O
J O
mice O
at O
day O
5 O
p O
, O
i O
, O
( O
P O
= O
0 O
. O

monocytogenes O
( O
rLM O
) O
strains O
expressing O
the O
full O
length O
nucleoprotein B
( I
NP I
) I
or O
a O
single O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitope O
from O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
we O
analyzed O
antiviral O
CTL O
responses O
induced O
by O
rLM O
vaccination O
, O
After O
vaccination O
, O
rLM O
was O
cleared O
from O
the O
host O
within O
7 O
days O
while O
inducing O
an O
LCMV O
- O
specific O
ex O
vivo O
CD8 O
( O
+ O
) O
effector O
CTL O
response O
, O
Virus O
- O
specific O
CTL O
memory O
was O
maintained O
for O
6 O
months O
postvaccination O
, O
as O
demonstrated O
by O
vigorous O
secondary O
CTL O
responses O
after O
in O
vitro O
stimulation O
, O
A O
single O
immunization O
with O
rLM O
that O
expressed O
either O
the O
full O
- O
length O
NP O
gene O
or O
the O
CTL O
epitope O
alone O
resulted O
in O
LCMV O
NP O
- O
specific O
CTL O
precursor O
frequencies O
of O
approximately O
1 O
/ O
10 O
( O
4 O
) O
CD8 O
( O
+ O
) O
T O
cells O
. O

To O
study O
this O
issue O
, O
we O
continued O
our O
evaluation O
of O
the O
tropism O
of O
a O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
variant O
termed O
clone O
13 O
with O
its O
parental O
virus O
clonal O
pool O
ARM O
53b O
( O
wild O
- O
type O
parent O
) O
for O
neuronal O
cells O
in O
vivo O
. O

Earlier O
in O
vivo O
and O
in O
vitro O
studies O
noted O
that O
the O
wild O
type O
virus O
contained O
a O
Phe O
at O
glycoprotein B
( I
GP I
) I
residue O
260 O
which O
correlated O
, O
vith O
neuron O
tropism O
compared O
with O
LCMV O
variants O
containing O
a O
Leu O
at O
residue O
260 O
which O
showed O
selected O
tropism O
for O
cells O
of O
the O
immune O
system O
( O
C O
. O

Here O
we O
( O
i O
) O
evaluated O
the O
ability O
of O
the O
viral O
variants O
with O
either O
a O
Phe O
or O
Leu O
at O
GP O
residue O
260 O
to O
replicate O
in O
vivo O
in O
the O
spleen O
, O
liver O
, O
or O
brain O
, O
( O
ii O
) O
analyzed O
the O
ability O
of O
these O
viruses O
to O
compete O
against O
each O
other O
for O
cell O
( O
neuron O
) O
- O
specific O
selection O
following O
a O
single O
viral O
inoculation O
of O
different O
ratios O
of O
both O
viruses O
, O
and O
( O
iii O
) O
utilized O
genetic O
reassortants O
of O
both O
viruses O
to O
test O
their O
ability O
to O
replicate O
in O
neurons O
in O
vivo O
. O

Analysis O
of O
inoculations O
with O
viral O
reassortants O
indicated O
that O
genes O
encoded O
on O
the O
short O
RNA O
( O
the O
GP O
and O
nucleoprotein O
, O
not O
the O
L O
[ O
polymerase O
] O
and O
Z O
proteins O
that O
are O
encoded O
by O
the O
large O
RNA O
) O
were O
associated O
with O
neurotropism O
. O

Although O
primary O
antiviral O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
can O
be O
induced O
in O
mice O
depleted O
of O
CD4 O
( O
+ O
) O
T O
cells O
, O
the O
role O
of O
CD4 O
( O
+ O
) O
T O
lymphocytes O
in O
the O
generation O
and O
maintenance O
of O
antiviral O
memory O
CTL O
is O
uncertain O
, O
This O
question O
, O
and O
the O
consequences O
upon O
vaccine O
- O
mediated O
protection O
, O
were O
investigated O
in O
transgenic O
CD4 O
knockout O
( O
CD4ko O
) O
mice O
, O
which O
lack O
CD4 O
( O
+ O
) O
T O
lymphocytes O
, O
Infection O
of O
immunocompetent O
C57BL O
/ O
6 O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
or O
with O
recombinant O
vaccinia O
viruses O
bearing O
appropriate O
LCMV O
sequences O
, O
induces O
long O
- O
lasting O
protective O
immunity O
, O
mediated O
mainly O
by O
antiviral O
CD8 O
( O
+ O
) O
CTL O
, O
Here O
we O
report O
two O
important O
findings O
, O
First O
, O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
memory O
CTL O
are O
maintained O
at O
considerably O
lower O
levels O
in O
CD4ko O
mice O
than O
in O
normal O
C57BL O
/ O
6J O
mice O
; O
we O
demonstrate O
a O
reduction O
in O
precursor O
CTL O
evident O
as O
soon O
as O
30 O
days O
postimmunization O
and O
declining O
, O
by O
day O
120 O
, O
to O
levels O
1 O
to O
2 O
log O
units O
below O
those O
in O
normal O
mice O
, O
Thus O
, O
CD4 O
( O
+ O
) O
T O
cells O
appear O
to O
be O
important O
to O
the O
generation O
and O
maintenance O
of O
their O
CD8 O
( O
+ O
) O
counterparts O
. O

Second O
, O
this O
reduction O
has O
an O
important O
biological O
consequence O
; O
compared O
with O
immunocompetent O
mice O
, O
CD4ko O
mice O
immunized O
with O
vaccinia O
virus O
recombinants O
expressing O
nucleoprotein O
or O
glycoprotein O
of O
LCMV O
are O
less O
effectively O
protected O
from O
subsequent O
LCMV O
challenge O
, O
Thus O
, O
this O
study O
underscores O
the O
potential O
importance O
of O
CD4 O
( O
+ O
) O
T O
lymphocytes O
in O
generation O
of O
appropriate O
levels O
of O
CD8 O
( O
+ O
) O
- O
cell O
- O
mediated O
immunoprotective O
memory O
and O
has O
implications O
for O
vaccine O
efficacy O
in O
individuals O
with O
immune O
defects O
in O
which O
CD4 O
levels O
may O
be O
reduced O
, O
such O
as O
AIDS O
. O

Structural O
characterization O
of O
peptides O
restricted O
by O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
molecules O
has O
identified O
residues O
critical O
for O
MHC O
class O
I O
binding O
and O
for O
T O
- O
cell O
receptor O
recognition O
, O
For O
example O
, O
optimal O
peptides O
fitting O
into O
the O
murine O
MHC O
class O
I O
D O
- O
b O
groove O
are O
9 O
to O
11 O
amino O
acids O
long O
and O
require O
as O
MHC O
anchor O
residues O
an O
Asn O
( O
N O
) O
at O
position O
5 O
and O
also O
either O
a O
hydrophobic O
residue O
, O
a O
Met O
( O
M O
) O
or O
a O
Cys O
( O
C O
) O
, O
at O
the O
carboxy O
terminus O
, O
The O
three O
known O
D O
- O
b O
- O
restricted O
peptides O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
are O
glycoproteins O
GP1 O
( O
amino O
acids O
[ O
aa O
] O
33 O
KAVYNFATC O
) O
, O
GP2 O
( O
aa O
276 O
SGVENPGGYCL O
) O
, O
and O
nucleoprotein O
NP O
( O
aa O
396 O
FQPQNGQFI O
) O
. O

In O
addition O
to O
these O
two O
GP O
and O
one O
NP O
peptides O
, O
computer O
search O
revealed O
11 O
other O
GP O
peptide O
sequences O
and O
20 O
additional O
NP O
sequences O
that O
contained O
the O
Db O
binding O
motif O
, O
By O
Db O
competitive O
binding O
analysis O
, O
only O
two O
of O
these O
11 O
GP O
peptides O
and O
1 O
of O
these O
20 O
NP O
peptides O
bound O
to O
the O
MHC O
Db O
molecule O
with O
an O
affinity O
equivalent O
to O
the O
measured O
affinities O
for O
the O
three O
known O
GP1 O
, O
GP2 O
, O
and O
NP O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
epitopes O
, O
No O
CTL O
specific O
for O
these O
three O
peptides O
were O
generated O
when O
H O
- O
2 O
( O
b O
) O
mice O
were O
inoculated O
with O
viral O
variants O
in O
which O
either O
the O
two O
known O
GP O
epitopes O
( O
GP1 O
and O
GP2 O
; O
termed O
GPV O
) O
or O
the O
GPV O
and O
NP O
epitopes O
( O
termed O
GPV O
+ O
NPV O
) O
were O
mutated O
, O
However O
, O
a O
novel O
CD8 O
( O
+ O
) O
anti O
- O
LCMV O
CTL O
response O
ordinarily O
not O
seen O
in O
H O
- O
2 O
( O
b O
) O
mice O
inoculated O
with O
wild O
- O
type O
virus O
was O
noted O
when O
such O
mice O
were O
inoculated O
with O
the O
GPV O
+ O
NPV O
- O
mutated O
variant O
, O
This O
result O
indicates O
that O
( O
i O
) O
despite O
large O
numbers O
of O
peptides O
containing O
the O
appropriate O
anchor O
residues O
within O
a O
viral O
protein O
, O
only O
a O
restricted O
number O
induce O
CTL O
, O
thereby O
maintaining O
a O
limited O
CTL O
repertoire O
, O
( O
ii O
) O
despite O
the O
limited O
repertoire O
, O
the O
immune O
system O
retains O
the O
flexibility O
to O
generate O
an O
immune O
response O
( O
s O
) O
to O
a O
previously O
silent O
protein O
( O
s O
) O
, O
suggesting O
a O
hierarchial O
control O
mechanism O
, O
and O
( O
iii O
) O
identification O
of O
a O
primary O
amino O
acid O
sequence O
is O
not O
sufficient O
, O
per O
se O
, O
to O
predict O
CTL O
epitopes O
, O
and O
peptide O
conformations O
are O
likely O
more O
complex O
than O
indicated O
by O
simple O
linear O
sequence O
comparisons O
. O

BALB O
/ O
c O
and O
C57BUL O
/ O
6J O
mice O
were O
immunized O
with O
recombinant O
Vaccines O
consisting O
of O
lymphocytic O
choriomeningitis O
virus O
CD8 O
( O
+ O
) O
T O
- O
lymphocyte O
epitopes O
and O
a O
carrier O
protein O
. O

Alpha O
/ O
beta O
interferon B
( I
IFN I
) I
and O
gamma O
IFN O
exert O
widely O
overlapping O
biological O
effects O
. O

To O
investigate O
to O
what O
extent O
the O
two O
IFN O
systems O
are O
functionally O
redundant O
, O
we O
generated O
mice O
with O
a O
combined O
receptor O
defect O
( O
AG129 O
mice O
) O
, O
Like O
mice O
with O
individual O
mutations O
, O
AG129 O
mice O
had O
no O
apparent O
anomalies O
, O
confirming O
that O
in O
the O
mouse O
the O
IFN O
system O
is O
not O
essential O
for O
normal O
development O
. O

These O
mice O
showed O
an O
additive O
phenotype O
with O
respect O
to O
antiviral O
defense O
and O
exhibited O
an O
increased O
susceptibility O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
and O
notably O
vaccinia O
virus O
infection O
, O
Because O
of O
unlimited O
replication O
and O
subsequent O
rapid O
exhaustion O
of O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
precursors O
, O
these O
mice O
were O
unable O
to O
mount O
a O
CTL O
response O
to O
LCMV O
. O

CDSC O
- O
mediated O
immunopathology O
was O
absent O
in O
LCMV O
- O
infected O
mice O
, O
and O
virus O
persisted O
, O
Vaccinia O
virus O
replicated O
much O
faster O
in O
AG129 O
mice O
, O
and O
a O
10 O
( O
4 O
) O
- O
fold O
lower O
dose O
of O
vaccinia O
virus O
was O
sufficient O
to O
prime O
these O
mice O
, O
With O
the O
normal O
priming O
dose O
of O
10 O
( O
6 O
) O
PFU O
, O
cytopathic O
effects O
and O
overwhelming O
infection O
possibly O
causing O
partial O
exhaustion O
of O
CTL O
interfered O
with O
the O
anti O
- O
vaccinia O
virus O
response O
. O

Even O
though O
global O
antiviral O
immunoglobulin B
G I
( I
IgG I
) I
titers O
were O
within O
normal O
ranges O
, O
the O
IgG O
subclass O
distribution O
was O
heavily O
biased O
toward O
IgG1 O
. O

Antiviral O
immune O
responses O
of O
mice O
lacking O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
or O
IL O
- O
4 O
or O
both O
IL O
- O
2 O
and O
IL O
- O
4 O
( O
IL O
- O
2 O
/ O
4 O
) O
were O
compared O
by O
using O
different O
viruses O
. O

Primary O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
against O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
were O
only O
moderately O
reduced O
in O
mice O
lacking O
IL O
- O
2 O
and O
were O
normal O
in O
mice O
lacking O
IL O
- O
4 O
. O

Here O
we O
report O
an O
attenuated O
Mengo O
virus O
recombinant O
, O
vLCMG4 O
, O
that O
encodes O
an O
immunodominant O
cytotoxic O
T O
- O
lymphocyte O
epitope O
of O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
nucleoprotein O
. O

vLCMG4 O
induced O
protective O
immunity O
against O
lethal O
LCMV O
infection O
after O
a O
single O
, O
low O
- O
dose O
immunization O
in O
BALB O
/ O
c O
mice O
and O
elicited O
an O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic O
T O
lymphocyte O
response O
. O

The O
ability O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
to O
passively O
cure O
an O
influenza O
virus O
pneumonia O
in O
the O
absence O
of O
endogenous O
T O
- O
and O
B O
- O
cell O
responses O
was O
investigated O
by O
treating O
C O
. O

B O
- O
17 O
mice O
, O
homozygous O
for O
the O
severe B
combined I
immunodeficiency I
( I
SCID I
) I
mutation O
, O
with O
individual O
monoclonal O
antiviral O
antibodies O
1 O
day O
after O
pulmonary O
infection O
with O
influenza O
virus O
PR8 O
[ O
A O
/ O
PR O
/ O
8 O
/ O
34 O
( O
H1N1 O
) O
] O
. O

By O
contrast O
, O
100 O
% O
of O
infected O
SCID O
mice O
that O
had O
been O
treated O
with O
a O
single O
intraperitoneal O
inoculation O
of O
at O
least O
175 O
mu O
g O
of O
a O
pool O
of O
virus O
- O
neutralizing O
( O
VN O
+ O
) O
antihemagglutinin O
( O
anti O
- O
HA O
) O
MAbs O
survived O
, O
even O
if O
antibody O
treatment O
was O
delayed O
up O
to O
7 O
days O
after O
infection O
. O

The O
use O
of O
individual O
MAbs O
showed O
that O
recovery O
could O
be O
achieved O
by O
VN O
+ O
anti O
- O
HA O
MAbs O
of O
the O
Immunoglobulin B
G1 I
( I
IgG1 I
) I
, O
IgG2a O
, O
IgG2b O
, O
and O
IgG3 O
isotypes O
but O
not O
by O
VN O
+ O
anti O
- O
HA O
MAbs O
of O
the O
IgA O
and O
IgM O
isotypes O
, O
even O
if O
the O
latter O
were O
used O
in O
a O
chronic O
treatment O
protocol O
to O
compensate O
far O
their O
shorter O
half O
- O
lives O
in O
vivo O
, O
Both O
IgA O
and O
IgM O
, O
although O
ineffective O
therapeutically O
, O
protected O
against O
infection O
when O
given O
prophylactically O
, O
i O
. O

, O
before O
exposure O
to O
virus O
, O
An O
Fc O
gamma O
- O
specific O
effector O
mechanism O
was O
not O
an O
absolute O
requirement O
for O
antibody O
- O
mediated O
recovery O
, O
as O
F O
( O
ab O
' O
) O
( O
2 O
) O
preparations O
of O
IgGs O
could O
cure O
the O
disease O
, O
although O
with O
lesser O
efficacy O
, O
than O
intact O
IgG O
. O

Infection O
with O
virus O
variants O
exhibiting O
changes O
in O
the O
peptide O
sequences O
defining O
immunodominant O
determinants O
that O
abolish O
recognition O
by O
antiviral O
cytotoxic B
T I
cells I
( I
CTL I
) I
presents O
a O
considerable O
challenge O
to O
the O
antiviral O
T O
- O
cell O
immune O
system O
and O
may O
enable O
some O
viruses O
to O
persist O
in O
hosts O
. O

The O
potential O
importance O
of O
such O
variants O
with O
respect O
to O
mechanisms O
of O
viral O
persistence O
and O
disease O
pathogenesis O
was O
assessed O
by O
infecting O
adult O
mice O
with O
variants O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strain O
WE O
. O

These O
variants O
were O
selected O
in O
vivo O
or O
in O
vitro O
for O
resistance O
to O
lysis O
by O
CD8 O
( O
+ O
) O
H O
- O
2 O
( O
b O
) O
- O
restricted O
antiviral O
CTL O
. O

The O
majority O
of O
anti O
- O
LCMV O
CTL O
in O
infected O
H O
- O
2 O
( O
b O
) O
mice O
recognize O
epitopes O
defined O
by O
residues O
32 O
to O
42 O
and O
275 O
to O
289 O
( O
epitopes O
32 O
- O
42 O
and O
275 O
- O
289 O
) O
of O
the O
LCMV O
glycoprotein O
or O
397 O
to O
407 O
of O
the O
viral O
nucleoprotein O
. O

7 O
variant O
exhibits O
a O
change O
in O
the O
epitope O
32 O
- O
42 O
( O
Val O
- O
39 O
- O
- O
> O
Leu O
) O
, O
and O
variant O
CL1 O
. O

2 O
exhibits O
a O
change O
in O
the O
epitope O
275 O
- O
289 O
( O
Asn O
- O
280 O
- O
- O
> O
Asp O
) O
of O
the O
wild O
- O
type O
LCMV O
- O
WE O
. O

7 O
and O
an O
additional O
change O
located O
in O
the O
epitope O
275 O
- O
289 O
( O
Asn O
- O
280 O
- O
- O
> O
Ser O
) O
. O

7 O
variant O
peptide O
with O
unchanged O
anchor O
positions O
bound O
efficiently O
to O
H O
- O
2D O
( O
b O
) O
and O
H O
- O
2K O
( O
b O
) O
molecules O
but O
induced O
only O
a O
very O
weak O
CTL O
response O
. O

Infection O
of O
C57BL O
/ O
6 O
mice O
( O
H O
- O
2 O
( O
b O
) O
) O
with O
the O
variants O
exhibiting O
mutations O
of O
one O
of O
the O
CTL O
epitopes O
, O
i O
. O

Consequently O
, O
high O
doses O
( O
10 O
( O
7 O
) O
PFU O
intravenously O
) O
of O
this O
virus O
were O
eliminated O
slowly O
and O
only O
by O
about O
day O
100 O
after O
infection O
. O

7 O
- O
B23 O
failed O
to O
cause O
lethal O
lymphocytic O
choriomeningitis O
after O
intracerebral O
infection O
with O
a O
dose O
of O
> O
10 O
( O
4 O
) O
PFU O
in O
C57BL O
/ O
6 O
mice O
( O
but O
not O
in O
mice O
of O
nonselecting O
H O
- O
2 O
( O
d O
) O
haplotype O
) O
; O
with O
the O
other O
variants O
or O
wild O
- O
type O
LCMV O
, O
doses O
greater O
than O
10 O
( O
6 O
) O
to O
10 O
( O
7 O
) O
PFU O
were O
necessary O
to O
avoid O
lethal O
choriomeningitis O
. O

Infection O
with O
lymphocytic O
choriomeningitis O
virus O
induces O
the O
generation O
of O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

In O
the O
H O
- O
2 O
( O
b O
) O
mouse O
, O
this O
cellular O
immune O
response O
is O
directed O
against O
three O
viral O
structural O
epitopes O
( O
GP1 O
, O
GP2 O
, O
and O
NP O
) O
presented O
by O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
H O
- O
2D O
( O
b O
) O
molecules O
. O

The O
first O
step O
was O
to O
synthesize O
the O
relevant O
peptides O
truncated O
at O
the O
N O
or O
C O
terminus O
and O
flanking O
the O
crucial O
H O
- O
2D O
( O
b O
) O
- O
anchoring O
Asn O
residue O
in O
position O
5 O
. O

These O
peptides O
were O
then O
tested O
( O
i O
) O
for O
their O
binding O
properties O
in O
two O
H O
- O
2D O
( O
b O
) O
- O
specific O
assays O
with O
viable O
cells O
( O
upregulation O
of O
H O
- O
2D O
( O
b O
) O
expression O
on O
the O
surface O
of O
RMA O
- O
S O
cells O
and O
competition O
against O
the O
D O
- O
b O
- O
restricted O
peptide O
I O
- O
125 O
- O
gp276 O
- O
286 O
on O
T2 O
- O
D O
- O
b O
cells O
) O
and O
( O
ii O
) O
for O
their O
abilities O
to O
sensitize O
H O
- O
2 O
( O
b O
) O
target O
cells O
for O
CTL O
lysis O
in O
vitro O
. O

NP O
appeared O
as O
a O
conventional O
9 O
- O
amino O
- O
acid O
( O
aa O
) O
- O
long O
peptide O
, O
np396 O
- O
404 O
( O
FQPQNGQFI O
) O
. O

GP2 O
was O
defined O
as O
a O
longer O
peptide O
( O
11 O
aa O
) O
, O
gp276 O
- O
286 O
( O
SGVENPGGYCL O
) O
. O

Characterization O
of O
the O
GPI O
epitope O
was O
more O
complex O
: O
the O
9 O
- O
aa O
- O
long O
peptide O
gp33 O
- O
41 O
( O
KAVYNFATC O
) O
and O
the O
carboxyl O
- O
extended O
11 O
- O
aa O
- O
long O
peptide O
gp33 O
- O
43 O
( O
KAVYNFATCGI O
) O
were O
both O
established O
as O
possible O
optimal O
sequences O
depending O
on O
the O
cell O
line O
used O
to O
test O
binding O
and O
lysis O
. O

This O
study O
shows O
that O
DNA O
vaccination O
can O
confer O
protection O
against O
a O
persistent O
viral O
infection O
by O
priming O
CD8 O
( O
+ O
) O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

Adult O
BALB O
/ O
c O
( O
H O
- O
2 O
( O
d O
) O
) O
mice O
were O
injected O
intramuscularly O
with O
a O
plasmid O
expressing O
the O
nucleoprotein B
( I
NP I
) I
gene O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
under O
the O
control O
of O
the O
cytomegalovirus O
promoter O
. O

The O
LCMV O
NP O
contains O
the O
immunodominant O
CTL O
epitope O
( O
amino O
acids O
118 O
to O
126 O
) O
recognized O
by O
mice O
of O
the O
H O
- O
2 O
( O
d O
) O
haplotype O
. O

After O
three O
injections O
with O
200 O
mu O
g O
of O
NP O
DNA O
, O
the O
vaccinated O
mice O
were O
challenged O
with O
LCMV O
variants O
( O
clones O
13 O
and O
28b O
) O
that O
establish O
persistent O
infection O
in O
naive O
adult O
mice O
. O

Fifty O
percent O
of O
the O
DNA O
- O
vaccinated O
mice O
were O
protected O
, O
as O
evidenced O
by O
decreased O
levels O
of O
infectious O
virus O
in O
the O
blood O
and O
tissues O
, O
eventual O
clearance O
of O
viral O
antigen O
from O
all O
organs O
tested O
, O
the O
presence O
of O
an O
enhanced O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
CTL O
response O
, O
and O
maintenance O
of O
memory O
CTL O
after O
clearance O
of O
virus O
infection O
. O

DNA O
vaccination O
has O
been O
evaluated O
with O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
model O
system O
. O

Using O
the O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
model O
, O
we O
found O
that O
after O
resolution O
of O
the O
acute O
infection O
, O
when O
antiviral O
plasma O
cells O
in O
the O
spleen O
decline O
, O
a O
population O
of O
virus O
- O
specific O
plasma O
cells O
appears O
in O
the O
bone O
marrow O
and O
constitutes O
the O
major O
source O
of O
long O
- O
term O
antibody O
production O
, O
Following O
infection O
of O
adult O
mice O
, O
LCMV O
- O
specific O
antibody B
- I
secreting I
cells I
( I
ASC I
) I
peaked O
in O
the O
spleen O
at O
8 O
days O
postinfection O
but O
were O
undetectable O
in O
the O
bone O
marrow O
at O
that O
time O
. O

To O
elucidate O
the O
principles O
involved O
, O
we O
analyzed O
the O
mechanism O
by O
which O
a O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
variant O
produces O
a O
generalized O
immune O
suppression O
in O
its O
natural O
host O
, O
the O
mouse O
. O

Callitrichid O
hepatitis O
is O
an O
infection O
of O
New O
World O
primates O
caused O
by O
an O
arenavirus O
, O
currently O
referred O
to O
as O
callitrichid O
hepatitis O
virus O
, O
that O
is O
closely O
related O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

In O
this O
study O
, O
we O
have O
examined O
the O
relative O
contributions O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
controlling O
an O
acute O
or O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
. O

We O
show O
that O
CD4 O
( O
+ O
) O
T O
cells O
are O
not O
necessary O
for O
resolving O
an O
acute O
LCMV O
infection O
. O

CD4 O
( O
+ O
) O
T O
- O
cell O
- O
depleted O
mice O
were O
capable O
of O
generating O
an O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
and O
eliminated O
virus O
with O
kinetics O
similar O
to O
those O
for O
control O
mice O
. O

The O
CD8 O
( O
+ O
) O
CTL O
response O
was O
critical O
for O
resolving O
this O
infection O
, O
since O
beta O
( O
2 O
) O
- O
microglobulin O
knockout O
( O
CDS O
- O
deficient O
) O
mice O
were O
unable O
to O
control O
the O
LCMV O
Armstrong O
infection O
and O
became O
persistently O
infected O
. O

In O
striking O
contrast O
to O
the O
acute O
infection O
, O
even O
a O
transient O
depletion O
of O
CD4 O
( O
+ O
) O
T O
cells O
profoundly O
affected O
the O
outcome O
of O
infection O
with O
the O
macrophage O
- O
and O
lymphocyte O
- O
tropic O
LCMV O
variants O
. O

Unmanipulated O
adult O
mice O
infected O
with O
the O
different O
LCMV O
variants O
contained O
virus O
for O
prolonged O
periods O
( O
23 O
months O
) O
but O
eventually O
eliminated O
infection O
from O
most O
tissues O
, O
and O
all O
of O
these O
mice O
had O
LCMV O
- O
specific O
CD8 O
( O
+ O
) O
CTL O
responses O
. O

These O
results O
clearly O
show O
that O
even O
in O
the O
presence O
of O
an O
overwhelming O
viral O
infection O
of O
the O
immune O
system O
, O
CD8 O
( O
+ O
) O
CTL O
can O
remain O
active O
for O
long O
periods O
and O
eventually O
resolve O
and O
/ O
or O
keep O
the O
virus O
infection O
in O
check O
. O

In O
contrast O
, O
LMCV O
- O
specific O
CTL O
responses O
were O
completely O
lost O
in O
chronically O
infected O
CD4 O
- O
depleted O
mice O
, O
Taken O
together O
, O
these O
results O
show O
that O
CD4 O
( O
+ O
) O
T O
cells O
are O
dispensable O
for O
short O
- O
term O
acute O
infection O
in O
which O
CD8 O
( O
+ O
) O
CTL O
activity O
does O
not O
need O
to O
be O
sustained O
for O
more O
than O
2 O
weeks O
. O

How O
ever O
, O
under O
conditions O
of O
chronic O
infection O
, O
in O
which O
CD8 O
( O
+ O
) O
CTLs O
take O
several O
months O
or O
longer O
to O
clear O
the O
infection O
, O
CD4 O
( O
+ O
) O
T O
- O
cell O
function O
is O
critical O
. O

Thus O
, O
CD4 O
( O
+ O
) O
T O
cells O
play O
an O
important O
role O
in O
sustaining O
virus O
- O
specific O
CD8 O
( O
+ O
) O
CTL O
during O
chronic O
LCMV O
infection O
. O

These O
findings O
have O
implications O
for O
chronic O
viral O
infections O
in O
general O
and O
mag O
provide O
a O
possible O
explanation O
for O
the O
loss O
of O
human O
immunodeficiency O
virus O
- O
specific O
CD8 O
( O
+ O
) O
CTL O
activity O
that O
is O
seen O
during O
the O
late O
stages O
of O
AIDS O
, O
when O
CD4 O
( O
+ O
) O
T O
cells O
become O
limiting O
. O

Expression O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
IFN O
- O
beta O
- O
, O
and O
IFN O
- O
alpha O
/ O
beta O
- O
induced O
genes O
was O
monitored O
during O
the O
development O
of O
lymphocytic B
choriomeningitis I
( I
LCM I
) I
to O
assess O
whether O
a O
restricted O
influence O
of O
these O
antiviral O
cytokines O
could O
be O
found O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

High O
levels O
of O
IFN O
- O
alpha O
( O
83 O
+ O
/ O
- O
42 O
U O
/ O
ml O
) O
were O
present O
int O
he O
blood O
of O
LCM O
virus O
- O
infected O
mice O
3 O
days O
postinfection O
, O
whereas O
IFN O
- O
beta O
was O
not O
detected O
( O
< O
1 O
. O

Infection O
of O
neonatal O
mice O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strain O
Armstrong B
( I
Arm I
) I
results O
in O
a O
lifelong O
persistent O
infection O
. O

Viral O
variants O
( O
cytotoxic O
T O
lymphocyte O
[ O
CTL O
] O
negative O
, O
persistence O
positive O
[ O
CTL O
( O
- O
) O
P O
+ O
] O
) O
can O
be O
isolated O
from O
the O
lymphoid O
tissues O
of O
such O
mice O
. O

Adult O
mice O
inoculated O
with O
these O
CTL O
( O
- O
) O
P O
+ O
viruses O
fail O
to O
generate O
sufficient O
cytotoxic O
T O
lymphocytes O
to O
clear O
the O
acute O
infection O
and O
become O
persistently O
infected O
. O

By O
contrast O
, O
inoculation O
of O
a O
similar O
dose O
of O
the O
parental O
ARM O
virus O
( O
CTL O
( O
+ O
) O
P O
- O
) O
into O
adult O
mice O
leads O
to O
the O
generation O
of O
a O
vigorous O
virus O
- O
specific O
CTL O
response O
that O
clears O
the O
infection O
. O

Sequence O
analysis O
revealed O
a O
phenylalanine O
( O
Phe O
) O
- O
to O
- O
Leucine O
( O
Leu O
) O
change O
at O
amino O
acid O
260 O
of O
the O
viral O
glycoprotein B
( I
GP I
) I
as O
a O
marker O
for O
variant O
viruses O
with O
the O
CTL O
( O
- O
) O
P O
+ O
phenotype O
. O

We O
found O
that O
although O
CTL O
( O
- O
) O
P O
+ O
viruses O
are O
known O
to O
be O
lymphotropic O
, O
mature O
T O
and O
B O
cells O
were O
not O
required O
for O
the O
generation O
and O
selection O
of O
the O
Leu O
at O
GP O
amino O
acid O
260 O
. O

In O
vitro O
studies O
showed O
that O
the O
parental O
LCMV O
ARM O
CTL O
( O
+ O
) O
P O
- O
virus O
replicates O
more O
efficiently O
and O
outcompetes O
CTL O
( O
- O
) O
P O
+ O
virus O
in O
a O
cultured O
neuronal O
cell O
line O
, O
indicating O
that O
differential O
growth O
properties O
in O
neurons O
are O
likely O
the O
basis O
for O
the O
selection O
of O
the O
parental O
virus O
over O
the O
CTL O
( O
- O
) O
P O
+ O
variant O
in O
the O
brain O
. O

Viral O
variants O
with O
different O
biological O
properties O
predominate O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
lymphoid O
tissues O
of O
carrier O
mice O
infected O
at O
birth O
with O
the O
Armstrong O
strain O
of O
lymphocytic O
choriomeningitis O
virus O
. O

Our O
previous O
studies O
have O
identified O
a O
single O
amino O
acid O
change O
in O
the O
viral O
glycoprotein O
, O
a O
phenylalanine O
- O
to O
- O
leucine O
( O
F O
- O
- O
> O
t O
) O
mutation O
at O
residue O
260 O
, O
that O
correlates O
with O
the O
tissue O
- O
specific O
selection O
and O
the O
persistent O
and O
immunosuppressive O
phenotype O
of O
the O
spleen O
isolates O
( O
R O
. O

CD4 O
( O
+ O
) O
T O
cells O
play O
an O
important O
role O
in O
regulating O
the O
immune O
response O
; O
their O
contribution O
to O
virus O
clearance O
is O
variable O
. O

Mice O
that O
lack O
CD4 O
( O
+ O
) O
T O
cells O
( O
CD4 O
( O
- O
/ O
- O
) O
mice O
) O
and O
are O
therefore O
unable O
to O
produce O
neutralizing O
antibodies O
cleared O
viscero O
- O
lymphotropic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strain O
WE O
when O
infected O
intravenously O
with O
a O
low O
dose O
( O
2 O
x O
10 O
( O
2 O
) O
PFU O
) O
because O
of O
an O
effective O
CD8 O
( O
+ O
) O
cytotoxic B
T I
- I
cell I
( I
CTL I
) I
response O
. O

In O
contrast O
, O
infection O
with O
a O
high O
dose O
( O
2 O
x O
10 O
( O
6 O
) O
PFU O
) O
of O
LCMV O
strain O
WE O
led O
to O
expansion O
of O
antiviral O
CTL O
, O
which O
disappeared O
in O
CD4 O
( O
- O
/ O
- O
) O
mice O
; O
in O
contrast O
, O
CD4 O
( O
+ O
) O
T O
- O
cell O
- O
competent O
mice O
developed O
antiviral O
memory O
CTL O
. O

This O
exhaustion O
of O
specific O
CTL O
caused O
viral O
persistence O
in O
CD4 O
( O
- O
/ O
- O
) O
mice O
, O
whereas O
CD4 O
( O
+ O
) O
T O
- O
cell O
- O
competent O
mice O
eliminated O
the O
virus O
. O

After O
infection O
of O
CD4 O
( O
- O
/ O
- O
) O
mice O
with O
the O
faster O
- O
replicating O
LCMV O
strain O
DOCILE O
, O
abrogation O
of O
CTL O
response O
and O
establishment O
of O
viral O
persistence O
developed O
after O
infection O
with O
a O
low O
dose O
( O
5 O
x O
10 O
( O
2 O
) O
PFU O
) O
, O
i O
. O

, O
an O
about O
100 O
- O
fold O
lower O
dose O
than O
in O
CD4 O
( O
+ O
) O
- O
competent O
control O
mice O
. O

By O
this O
method O
, O
we O
were O
able O
to O
assess O
influenza O
virus O
as O
a O
vaccine O
vector O
for O
protecting O
BALB O
/ O
c O
mice O
against O
otherwise O
lethal O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
. O

A O
single O
dose O
of O
influenza O
virus O
[ O
A O
/ O
WSN O
/ O
33 O
( O
H1N1 O
) O
] O
bearing O
a O
cytotoxic O
T O
- O
lymphocyte O
- O
specific O
epitope O
of O
the O
LCMV O
nucleoprotein O
( O
residues O
116 O
to O
127 O
) O
in O
the O
neuraminidase O
stalk O
protected O
mice O
against O
LCMV O
challenge O
for O
at O
least O
4 O
months O
. O

The O
immunity O
was O
mediated O
by O
cytotoxic O
T O
lymphocytes O
and O
was O
haplotype O
specific O
, O
indicating O
that O
the O
observed O
protective O
response O
, O
vas O
solely O
a O
consequence O
of O
prior O
priming O
with O
the O
H O
- O
2 O
( O
d O
) O
LCMV O
nucleoprotein O
epitope O
expressed O
in O
the O
recombinant O
influenza O
virus O
. O

The O
role O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
in O
the O
resolution O
of O
rat B
cytomegalovirus I
( I
RCMV I
) I
infection O
was O
investigated O
. O

The O
susceptibility O
to O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
or O
to O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
of O
various O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
strains O
was O
evaluated O
in O
C57BL O
/ O
6 O
mice O
and O
in O
various O
cell O
lines O
. O

Following O
infection O
of O
the O
H O
- O
2 O
( O
d O
) O
mouse O
by O
lymphocytic O
choriomeningitis O
virus O
, O
the O
newly O
generated O
cytotoxic B
T I
lymphocyte I
( I
CTL I
) I
response O
is O
focused O
to O
a O
single O
9 O
- O
amino O
- O
acid O
peptide O
sequence O
( O
epitope O
) O
of O
the O
virus O
. O

Specifically O
, O
the O
molecular O
structure O
of O
the O
T B
- I
cell I
receptors I
( I
TCRs I
) I
of O
CTLs O
responding O
to O
this O
epitope O
was O
analyzed O
. O

This O
study O
documents O
that O
the O
immunosuppressive O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
variant O
, O
clone O
13 O
, O
shows O
a O
specific O
predilection O
for O
enhanced O
infection O
of O
macrophages O
both O
in O
vitro O
and O
in O
vivo O
and O
that O
single O
amino O
acid O
changes O
in O
the O
viral O
polymerase O
and O
glycoprotein O
are O
responsible O
for O
macrophage O
tropism O
. O

Complete O
sequencing O
of O
the O
clone O
13 O
genome O
, O
along O
with O
genetic O
analysis O
, O
showed O
that O
a O
single O
amino O
acid O
change O
in O
the O
polymerase O
( O
K O
- O
- O
> O
Q O
at O
position O
1079 O
) O
was O
the O
major O
determinant O
of O
virus O
yield O
in O
macrophages O
. O

This O
finding O
was O
further O
strengthened O
by O
showing O
that O
reversion O
at O
this O
site O
back O
to O
lysine O
( O
Q O
- O
- O
> O
K O
) O
resulted O
in O
loss O
of O
macrophage O
tropism O
. O

Thus O
, O
these O
results O
show O
that O
substitution O
of O
the O
positively O
charged O
amino O
acid O
K O
with O
a O
neutral O
amino O
acid O
( O
either O
Q O
or O
N O
) O
at O
residue O
1079 O
of O
the O
polymerase O
resulted O
in O
enhanced O
viral O
replication O
in O
macrophages O
. O

This O
single O
amino O
acid O
change O
in O
the O
glycoprotein O
( O
F O
- O
- O
> O
L O
at O
position O
260 O
) O
did O
not O
affect O
virus O
yield O
per O
macrophage O
but O
was O
critical O
in O
determining O
the O
number O
of O
macrophages O
infected O
. O

We O
have O
investigated O
the O
replication O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
before O
and O
after O
the O
nerve B
growth I
factor I
( I
NGF I
) I
- O
induced O
transdifferentiation O
of O
PC12 O
cells O
from O
the O
chromaffin O
to O
the O
neuron O
- O
like O
phenotype O
. O

The O
reduced O
viral O
yield O
correlated O
with O
restricted O
LCMV O
replication O
and O
transcription O
within O
the O
infected O
cell O
, O
which O
was O
not O
caused O
by O
the O
lack O
of O
cell O
proliferation O
in O
the O
NGF O
- O
treated O
cells O
but O
rather O
was O
related O
to O
the O
induction O
or O
changes O
in O
expression O
levels O
of O
specific O
gene O
product O
( O
s O
) O
associated O
with O
the O
cell O
commitment O
to O
a O
neuronal O
phenotype O
. O

T O
lymphocytes O
isolated O
from O
mice O
acutely O
infected O
with O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
were O
found O
in O
this O
study O
to O
undergo O
activation O
- O
induced O
apoptosis O
upon O
signalling O
through O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
- O
CD3 O
complex O
. O

Cell O
cycling O
in O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
alone O
stimulated O
proliferation O
of O
LCMV O
- O
induced O
T O
cells O
without O
inducing O
apoptosis O
, O
but O
preculturing O
of O
T O
cells O
from O
acutely O
infected O
mice O
in O
IL O
- O
2 O
accelerated O
apoptosis O
upon O
subsequent O
TcR O
- O
CD3 O
cross O
- O
linking O
. O

To O
establish O
persistence O
, O
a O
virus O
must O
establish O
infection O
and O
evade O
eradication O
by O
the O
host O
immune O
response O
, O
in O
particular O
by O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

We O
show O
that O
prior O
immunization O
with O
a O
vaccine O
designed O
to O
induce O
CTL O
( O
in O
the O
absence O
of O
antiviral O
antibody O
) O
confers O
complete O
protection O
against O
subsequent O
establishment O
of O
persistence O
in O
all O
tissues O
analyzed O
. O

Hence O
, O
a O
' O
' O
string O
of O
CTL O
epitopes O
' O
' O
( O
beads O
) O
concept O
for O
vaccination O
is O
feasible O
. O

Recombinant O
vaccinia O
virus O
expressing O
the O
Lassa B
virus I
( I
LV I
) I
envelope O
glycoprotein O
precursor O
, O
V O
- O
LSGPC O
, O
was O
used O
to O
study O
the O
basis O
of O
LV O
- O
induced O
cross O
- O
protective O
immunity O
against O
the O
closely O
related O
arenavirus O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Synthetic O
peptides O
corresponding O
to O
predicted O
T O
- O
cell O
sites O
common O
to O
the O
envelope O
glycoprotein O
precursor O
( O
GP O
- O
C O
) O
of O
LV O
and O
that O
of O
LCMV O
were O
used O
to O
map O
the O
specificity O
of O
the O
proliferative O
response O
to O
an O
epitope O
located O
between O
amino O
acids O
403 O
and O
417 O
of O
LV O
GP O
- O
C O
. O

C9 O
lysed O
I O
- O
A O
( O
K O
) O
- O
bearing O
target O
cells O
, O
and O
when O
adoptively O
transferred O
to O
C3H O
/ O
Hej O
mice O
, O
it O
was O
capable O
of O
mediating O
both O
a O
peptide O
- O
specific O
delayed O
hypersensitivity O
reaction O
and O
resistance O
to O
lethal O
LCMV O
challenge O
. O

The O
3 O
' O
termini O
of O
the O
mRNAs O
lack O
poly O
( O
A O
) O
tails O
, O
and O
we O
have O
shown O
that O
transcription O
termination O
occurs O
at O
heterogeneous O
positions O
within O
the O
intergenic O
region O
of O
the O
S O
RNA O
. O

Viral O
antigens O
are O
presented O
to O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
by O
H O
- O
2 O
- O
restricted O
major B
histocompatibility I
complex I
( I
MHC I
) I
glycoproteins O
. O

Binding O
of O
the O
endogenously O
processed O
viral O
peptides O
( O
epitopes O
) O
to O
their O
specific O
MHC O
molecules O
is O
an O
early O
intracellular O
event O
in O
the O
recognition O
process O
and O
is O
necessary O
for O
subsequent O
killing O
of O
virus O
- O
infected O
cells O
by O
virus O
- O
specific O
CTLs O
. O

It O
is O
now O
well O
established O
that O
interaction O
between O
a O
viral O
antigenic O
peptide O
and O
MHC O
is O
dependent O
on O
the O
primary O
structure O
( O
length O
and O
amino O
acid O
sequence O
) O
of O
that O
antigen O
. O

Here O
we O
show O
, O
using O
the O
H O
- O
2D O
( O
b O
) O
- O
restricted O
epitope O
GP277 O
- O
286 O
of O
lymphocytic O
choriomeningitis O
virus O
as O
a O
model O
, O
that O
the O
secondary O
structure O
( O
conformation O
) O
of O
the O
viral O
sequence O
also O
plays O
a O
crucial O
role O
in O
the O
binding O
of O
a O
viral O
antigen O
to O
MHC O
glycoprotein O
and O
in O
its O
subsequent O
presentation O
to O
virus O
- O
specific O
CTLs O
. O

Mice O
infected O
intracerebrally O
with O
lymphocytic O
choriomeningitis O
virus O
( O
LCM O
virus O
) O
develop O
a O
characteristic O
central O
nervous O
system O
disease O
and O
usually O
die O
. O

The O
attachment O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
to O
murine O
and O
primate O
cell O
lines O
was O
quantitated O
by O
a O
fluorescence O
- O
activated O
cell O
sorter O
assay O
in O
which O
binding O
of O
biotinylated O
virus O
was O
detected O
with O
streptavidin O
- O
fluorescein O
isothiocyanate O
. O

Virus O
bound O
to O
protein O
( O
s O
) O
with O
a O
molecular O
mass O
of O
120 O
to O
140 O
kDa O
in O
membranes O
from O
cell O
lines O
permissive O
for O
LCMV O
but O
not O
from O
nonpermissive O
cell O
lines O
. O

Hence O
, O
LCMV O
attachment O
to O
rodent O
fibroblastic O
cell O
lines O
is O
mediated O
by O
a O
glycoprotein O
( O
s O
) O
with O
a O
molecular O
mass O
of O
120 O
to O
140 O
kDa O
, O
with O
complex O
N O
- O
linked O
sugars O
that O
are O
not O
involved O
in O
virus O
binding O
. O

cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
recognize O
viral O
antigens O
presented O
by O
infected O
cells O
in O
the O
context O
of O
their O
major O
histocompatibility O
complex O
glycoproteins O
. O

Design O
of O
molecules O
controlling O
( O
blocking O
) O
interaction O
between O
CTLs O
and O
infected O
cells O
, O
and O
their O
further O
use O
to O
inhibit O
( O
or O
antagonize O
) O
T O
- O
lymphocyte O
activity O
, O
is O
an O
important O
pharmacologic O
goal O
. O

The O
role O
of O
antiviral O
antibodies O
in O
resistance O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
was O
explored O
. O

Detailed O
investigation O
of O
the O
mechanism O
( O
s O
) O
by O
which O
these O
antiviral O
antibodies O
provided O
protection O
was O
carried O
out O
by O
using O
anti O
- O
LCMV O
monoclonal O
antibodies O
. O

A O
correlation O
was O
also O
found O
between O
immunoglobulin O
isotype O
and O
protection O
: O
all O
of O
the O
protective O
antibodies O
were O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
, O
while O
IgG1 O
antibodies O
mapping O
to O
the O
same O
epitopes O
were O
not O
. O

Functional O
F O
( O
ab O
' O
) O
2 O
fragments O
which O
retained O
in O
vitro O
neutralizing O
activity O
were O
not O
protective O
in O
vivo O
. O

Transgenic O
mice O
expressing O
the O
T B
- I
cell I
receptor I
( I
TCR I
) I
specific O
for O
peptide O
32 O
- O
42 O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
glycoprotein O
1 O
presented O
by O
D O
( O
b O
) O
reacted O
with O
a O
strong O
transgenic O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
response O
starting O
on O
day O
3 O
after O
infection O
with O
a O
high O
dose O
( O
10 O
( O
6 O
) O
PFU O
intravenously O
[ O
i O
. O

] O
) O
of O
the O
WE O
strain O
of O
LCMV O
( O
LCMV O
- O
WE O
) O
; O
LCMV O
- O
specific O
antibody O
production O
in O
the O
spleen O
was O
suppressed O
in O
these O
mice O
. O

Low O
- O
dose O
( O
10 O
( O
2 O
) O
PFU O
i O
. O

7 O
variant O
virus O
( O
which O
is O
not O
recognized O
by O
transgenic O
TCR O
- O
expressing O
CTLs O
because O
of O
a O
point O
mutation O
) O
did O
not O
induce O
suppression O
. O

We O
have O
examined O
infection O
of O
the O
thymus O
during O
congenitally O
acquired O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
of O
mice O
, O
a O
classic O
model O
of O
antigen O
- O
specific O
T O
- O
cell O
tolerance O
. O

Our O
results O
show O
that O
( O
i O
) O
infection O
starts O
at O
the O
fetal O
stage O
and O
is O
maintained O
throughout O
adulthood O
, O
and O
( O
ii O
) O
this O
chronic O
infection O
of O
the O
thymus O
can O
be O
eliminated O
by O
transfer O
of O
virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
that O
infiltrate O
the O
thymus O
and O
clear O
all O
viral O
products O
from O
both O
medullary O
and O
cortical O
regions O
. O

There O
is O
minimal O
infection O
of O
the O
CD8 O
+ O
medullary O
thymocytes O
or O
of O
the O
double O
positive O
( O
CD4 O
+ O
CD8 O
+ O
) O
cells O
present O
in O
the O
cortex O
. O

Interestingly O
, O
there O
is O
infection O
of O
the O
double O
negative O
( O
CD4 O
- O
CD8 O
- O
) O
thymocytes O
in O
the O
adult O
thymus O
, O
showing O
that O
even O
during O
adulthood O
the O
newly O
developing O
T O
cells O
are O
susceptible O
to O
infection O
by O
LCMV O
. O

cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
recognize O
virus O
peptide O
fragments O
complexed O
with O
class O
I O
major B
histocompatibility I
complex I
( I
MHC I
) I
molecules O
on O
the O
surface O
of O
virus O
- O
infected O
cells O
. O

Recognition O
is O
mediated O
by O
a O
membrane O
- O
bound O
T B
- I
cell I
receptor I
( I
TCR I
) I
composed O
of O
alpha O
and O
beta O
chains O
. O

Studies O
of O
the O
CTL O
response O
to O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
in O
H O
- O
2b O
mice O
have O
revealed O
that O
three O
distinct O
viral O
epitopes O
are O
recognized O
by O
CTL O
of O
the O
H O
- O
2b O
haplotype O
and O
that O
all O
of O
the O
three O
epitopes O
are O
restricted O
by O
the O
D O
( O
b O
) O
MHC O
molecule O
. O

The O
immunodominant O
D O
( O
b O
) O
- O
restricted O
CTL O
epitope O
, O
located O
at O
LCMV O
glycoprotein O
amino O
acids O
278 O
to O
286 O
, O
was O
earlier O
noted O
to O
be O
recognized O
by O
TCRs O
that O
consistently O
contained O
V O
- O
alpha O
- O
4 O
segments O
but O
had O
heterogeneous O
V O
- O
beta O
segments O
. O

Here O
we O
show O
that O
CTL O
clones O
recognizing O
the O
other O
two O
H O
- O
2D O
( O
b O
) O
- O
restricted O
epitopes O
, O
LCMV O
glycoprotein O
amino O
acids O
34 O
to O
40 O
and O
nucleoprotein O
amino O
acids O
397 O
to O
407 O
( O
defined O
in O
this O
study O
) O
, O
utilize O
TCR O
alpha O
chains O
which O
do O
not O
belong O
to O
the O
V O
- O
alpha O
- O
4 O
subfamily O
. O

Pichinde B
virus I
( I
PV I
) I
strain O
AN O
3739 O
was O
determined O
to O
be O
sensitive O
to O
natural B
killer I
( I
NK I
) I
cells O
in O
vivo O
by O
enhanced O
replication O
in O
NK O
cell O
- O
depleted O
mice O
. O

An O
NK O
- O
sensitive O
subclone O
( O
PV O
- O
NK O
( O
s1 O
) O
) O
was O
serially O
passed O
in O
mice O
whose O
NK O
cells O
had O
previously O
been O
activated O
by O
an O
interferon O
inducer O
, O
and O
two O
plaque O
isolates O
were O
shown O
to O
be O
resistant O
to O
NK O
cells O
but O
not O
to O
interferon O
. O

Inoculation O
of O
severe O
- O
combined O
- O
immunodeficient O
mice O
with O
PV O
- O
NK O
( O
s1 O
) O
led O
to O
a O
persistent O
infection O
resulting O
in O
an O
NK O
- O
resistant O
viral O
population O
. O

Reasoning O
that O
the O
viruses O
most O
vulnerable O
to O
ribozyme O
intervention O
will O
be O
those O
whose O
complete O
life O
cycle O
is O
based O
on O
RNA O
( O
with O
no O
DNA O
stage O
) O
, O
we O
have O
begun O
to O
develop O
ribozymes O
directed O
toward O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
, O
the O
prototype O
of O
the O
arenavirus O
family O
. O

In O
particular O
, O
whereas O
stimulation O
with O
CpG O
( O
complementary O
to O
positions O
+ O
1 O
and O
+ O
2 O
of O
the O
template O
) O
led O
to O
RNAs O
whose O
5 O
' O
ends O
were O
at O
position O
+ O
1 O
as O
expected O
, O
GpC O
stimulation O
led O
to O
transcripts O
whose O
5 O
' O
ends O
were O
at O
position O
- O
1 O
rather O
than O
at O
position O
+ O
2 O
, O
as O
GpC O
is O
complementary O
to O
positions O
+ O
2 O
and O
+ O
3 O
of O
the O
template O
. O

We O
have O
used O
the O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
technique O
to O
gain O
insight O
into O
the O
pathogenesis O
of O
encephalitis O
caused O
by O
Borna B
disease I
virus I
( I
BDV I
) I
. O

Analysis O
of O
brain O
tissue O
for O
the O
presence O
of O
cytokine O
mRNAs O
revealed O
that O
the O
mRNA O
levels O
of O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
tumor O
necrosis O
factor O
alpha O
, O
and O
IL O
- O
1 O
- O
alpha O
had O
increased O
sharply O
at O
14 O
and O
26 O
days O
p O
. O

Expression O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
mRNA O
, O
which O
was O
not O
observed O
in O
normal O
rat O
brain O
, O
was O
detected O
at O
14 O
days O
p O
. O

Vaccination O
with O
a O
nucleopeptide O
( O
NP O
118 O
; O
amino O
acids O
118 O
to O
132 O
) O
representing O
a O
cytotoxic O
T O
- O
cell O
epitope O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
can O
modulate O
immunopathology O
. O

However O
, O
when O
NP O
118 O
- O
primed O
H O
- O
2d O
mice O
were O
challenged O
intracerebrally O
with O
an O
intermediate O
dose O
( O
5 O
x O
10 O
( O
4 O
) O
PFU O
) O
of O
the O
LCMV O
- O
DOCILE O
strain O
, O
all O
mice O
primed O
with O
NP O
118 O
emulsified O
in O
incomplete O
Freund O
' O
s O
adjuvant O
died O
, O
whereas O
unprimed O
mice O
survived O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
negative O
- O
strand O
RNA O
virus O
which O
produces O
persistent O
infection O
in O
a O
variety O
of O
experimental O
animals O
. O

A O
window O
of O
opportunity O
exists O
after O
birth O
wherein O
inoculation O
with O
BDV O
produces O
a O
persistently O
infected O
rat O
without O
signs O
of O
Borna O
disease O
or O
encephalitis O
( O
persistent O
, O
tolerant O
infection O
- O
newborn O
[ O
PTI O
- O
NB O
] O
rat O
) O
. O

BALB O
/ O
c O
mice O
were O
depleted O
of O
B O
cells O
by O
anti O
- O
mu O
treatment O
to O
investigate O
the O
pathogenesis O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
infection O
in O
the O
absence O
of O
antibody O
. O

Termination O
of O
RSV O
replication O
after O
primary O
infection O
occurred O
with O
the O
same O
kinetics O
in O
anti O
- O
mu O
- O
treated O
mice O
as O
in O
phosphate B
- I
buffered I
saline I
( I
PBS I
) I
- O
treated O
controls O
. O

Callitrichid O
hepatitis O
( O
CH O
) O
is O
an O
acute O
, O
often O
fatal O
viral O
infection O
of O
New O
World O
primates O
from O
the O
family O
Callitrichidae O
. O

We O
report O
here O
the O
isolation O
of O
an O
arenavirus O
from O
a O
common O
marmoset O
( O
Callithrix O
jacchus O
) O
with O
CH O
by O
using O
in O
vitro O
cultures O
of O
marmoset O
hepatocytes O
and O
Vero O
- O
E6 O
cells O
. O

Immunofluorescence O
and O
Western O
immunoblot O
analysis O
using O
CH O
- O
specific O
antisera O
( O
principally O
from O
animals O
exposed O
to O
CH O
during O
zoo O
outbreaks O
) O
revealed O
three O
antigens O
in O
cells O
infected O
with O
this O
CH B
- I
associated I
virus I
( I
CHV I
) I
. O

These O
antigens O
had O
the O
same O
electrophoretic O
mobilities O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
as O
did O
the O
nucleocapsid O
, O
GP2 O
, O
and O
GPC O
proteins O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
. O

Viral O
variants O
of O
different O
phenotypes O
are O
present O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
lymphoid O
tissues O
of O
carrier O
mice O
infected O
at O
birth O
with O
the O
Armstrong O
strain O
of O
lymphocytic O
choriomeningitis O
virus O
. O

This O
Phenylalanine B
( I
F I
) I
- O
to O
- O
leucine B
( I
L I
) I
change O
at O
position O
260 O
of O
the O
viral O
glycoprotein O
was O
seen O
in O
the O
vast O
majority O
( O
43 O
of O
47 O
) O
of O
the O
lymphoid O
isolates O
, O
and O
variants O
with O
L O
at O
this O
residue O
were O
selected O
in O
spleens O
of O
persistently O
infected O
mice O
. O

In O
striking O
contrast O
, O
isolates O
with O
the O
parental O
sequence O
( O
F O
at O
residue O
260 O
) O
predominated O
( O
48 O
of O
59 O
isolates O
) O
in O
the O
CNS O
of O
the O
same O
carrier O
mice O
. O

Complete O
nucleotide O
sequence O
analysis O
of O
the O
major O
structural O
genes O
of O
several O
independently O
derived O
( O
from O
different O
mice O
) O
spleen O
isolates O
showed O
that O
these O
variants O
were O
> O
99 O
. O

The O
ability O
of O
Pseudorabies B
virus I
( I
PRV I
) I
to O
down O
- O
modulate O
expression O
of O
major O
histocompatibility O
complex O
class O
I O
antigens O
in O
murine O
and O
porcine O
cells O
was O
investigated O
. O

When O
quantified O
by O
flow O
cytometry O
, O
surface O
expression O
of O
class O
I O
K O
( O
k O
) O
and O
D O
( O
k O
) O
antigens O
on O
PrV O
- O
infected O
cells O
decreased O
by O
60 O
% O
or O
more O
. O

Isolates O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
that O
elicit O
a O
cytotoxic O
T O
- O
lymphocyte O
response O
( O
CTL O
+ O
) O
have O
been O
compared O
with O
isolates O
that O
suppress O
the O
CTL O
response O
( O
CTL O
- O
) O
in O
an O
effort O
to O
map O
this O
phenotype O
. O

A O
single O
amino O
acid O
change O
in O
the O
glycoprotein O
of O
the O
LCMV O
Armstrong B
( I
Arm I
) I
strain O
is O
consistently O
associated O
with O
the O
CTL O
- O
trait O
and O
the O
ability O
of O
the O
virus O
to O
persist O
( O
P O
+ O
) O
. O

To O
map O
the O
structural O
basis O
of O
the O
phenotype O
, O
the O
complete O
RNA O
sequence O
of O
LCMV O
ARM O
53b O
( O
CTL O
+ O
) O
was O
compared O
with O
that O
of O
its O
variant O
ARM O
clone O
13 O
( O
CTL O
- O
) O
. O

Only O
two O
of O
the O
changes O
distinguishing O
CTL O
+ O
from O
CTL O
- O
isolates O
affect O
amino O
acid O
coding O
: O
lysine O
to O
glutamine O
at O
amino O
acid O
1079 O
of O
the O
polymerase O
protein O
, O
and O
phenylalanine O
to O
leucine O
at O
amino O
acid O
260 O
of O
the O
envelope O
glycoprotein B
( I
GP I
) I
. O

mumps B
virus I
( I
MuV I
) I
caused O
the O
most O
viral O
meningitis O
before O
mass O
immunization O
. O

The O
viral B
RNA I
- I
dependent I
RNA I
polymerase I
( I
vRdRp I
) I
of O
MuV O
consists O
of O
the O
large B
protein I
( I
L I
) I
and O
the O
phosphoprotein B
( I
P I
) I
, O
while O
the O
nucleocapsid B
protein I
( I
NP I
) I
encapsulates O
the O
viral O
RNA O
genome O
. O

In O
this O
study O
, O
we O
performed O
a O
large O
- O
scale O
small B
interfering I
RNA I
( I
siRNA I
) I
screen O
targeting O
host O
kinases O
that O
regulated O
MuV O
replication O
. O

The O
human O
kinase O
ribosomal B
protein I
56 I
kinase I
beta I
- I
1 I
( I
RPS6KB1 I
) I
was O
shown O
to O
play O
a O
role O
in O
MuV O
replication O
and O
transcription O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
an O
emerging O
pathogen O
capable O
of O
causing O
explosive O
outbreaks O
. O

Further O
, O
we O
identified O
a O
factor O
1 O
- O
like O
activity O
in O
CHIKV O
that O
limited O
complement O
by O
inactivating O
C3b O
into O
inactive B
C3b I
( I
iC3b I
) I
, O
the O
complement O
component O
known O
to O
significantly O
contribute O
to O
disease O
severity O
in O
vivo O
, O
but O
this O
activity O
had O
no O
effect O
on O
C4b O
. O

The O
morbidity O
associated O
with O
chikungunya B
virus I
( I
CHIKV I
) I
infection O
, O
neurovirulence O
and O
adaptability O
to O
Aedes O
albopictus O
, O
necessitates O
a O
deeper O
understanding O
of O
the O
interaction O
of O
CHIKV O
with O
the O
host O
immune O
system O
. O

Interestingly O
the O
C3 O
component O
associated O
with O
the O
virion O
was O
found O
to O
be O
inactive B
C3b I
( I
iC3b I
) I
, O
a O
key O
factor O
implicated O
in O
the O
pathogenesis O
and O
disease O
severity O
in O
the O
mouse O
model O
of O
Ross O
River O
virus O
infection O
. O

We O
have O
developed O
a O
high B
- I
throughput I
sequencing I
( I
HTS I
) I
workflow O
for O
investigating O
paramyxovirus O
transcription O
and O
replication O
. O

We O
show O
that O
sequencing O
of O
oligo O
( O
dT O
) O
- O
selected O
polyadenylated O
mRNAs O
, O
without O
considering O
the O
orientation O
of O
the O
RNAs O
from O
which O
they O
had O
been O
generated O
, O
cannot O
accurately O
be O
used O
to O
analyze O
the O
abundance O
of O
viral O
mRNAs O
because O
genomic O
RNA O
copurifies O
with O
the O
viral O
mRNAs O
. O

This O
approach O
has O
the O
advantage O
that O
the O
abundance O
of O
viral O
mRNA O
( O
and O
antigenomes O
) O
and O
genomes O
can O
be O
analyzed O
and O
quantified O
from O
the O
same O
data O
. O

We O
investigated O
the O
kinetics O
of O
viral O
transcription O
and O
replication O
during O
infection O
of O
A549 O
cells O
with O
parainfluenza B
virus I
type I
2 I
( I
PIV2 I
) I
, O
PIV3 O
, O
PIV5 O
, O
or O
mumps O
virus O
and O
determined O
the O
abundances O
of O
individual O
viral O
mRNAs O
and O
readthrough O
mRNAs O
. O

We O
suggest O
that O
rapid O
degradation O
of O
non O
- O
poly O
( O
A O
) O
mRNAs O
may O
be O
primarily O
responsible O
for O
the O
shape O
of O
the O
mRNA O
abundance O
gradient O
in O
parainfluenza O
virus O
3 O
, O
whereas O
a O
combination O
of O
this O
factor O
and O
disengagement O
of O
RNA O
polymerase O
at O
intergenic O
sequences O
, O
particularly O
those O
at O
the O
NP O
: O
P O
and O
P O
: O
M O
gene O
boundaries O
, O
may O
be O
responsible O
in O
the O
other O
viruses O
. O

IMPORTANCE O
high B
- I
throughput I
sequencing I
( I
HTS I
) I
of O
virus O
- O
infected O
cells O
can O
be O
used O
to O
study O
in O
great O
detail O
the O
patterns O
of O
virus O
transcription O
and O
replication O
. O

For O
paramyxoviruses O
, O
and O
by O
analogy O
for O
all O
other O
negative O
- O
strand O
RNA O
viruses O
, O
we O
show O
that O
directional O
sequencing O
must O
be O
used O
to O
distinguish O
between O
genomic O
RNA O
and O
mRNA O
/ O
antigenomic O
RNA O
because O
significant O
amounts O
of O
genomic O
RNA O
copurify O
with O
poly O
( O
A O
) O
- O
selected O
mRNA O
. O

We O
found O
that O
the O
best O
method O
is O
directional O
sequencing O
of O
total O
cell O
RNA O
, O
after O
the O
physical O
removal O
of O
rRNA O
( O
and O
mitochondrial O
RNA O
) O
, O
because O
quantitative O
information O
on O
the O
abundance O
of O
both O
genomic O
RNA O
and O
mRNA O
/ O
antigenomes O
can O
be O
simultaneously O
derived O
. O

Using O
this O
approach O
, O
we O
revealed O
new O
details O
of O
the O
kinetics O
of O
virus O
transcription O
and O
replication O
for O
parainfluenza B
virus I
( I
PIV I
) I
type O
2 O
, O
PIV3 O
, O
PIV5 O
, O
and O
mumps O
virus O
, O
as O
well O
as O
on O
the O
relative O
abundance O
of O
the O
individual O
viral O
mRNAs O
. O

mumps B
virus I
( I
MuV I
) I
is O
an O
important O
aerosol O
- O
transmitted O
human O
pathogen O
causing O
epidemic O
parotitis O
, O
meningitis O
, O
encephalitis O
, O
and O
deafness O
. O

However O
, O
given O
the O
MuV O
tropism O
toward O
glandular O
tissues O
and O
the O
central O
nervous O
system O
, O
an O
additional O
glycan O
motif O
( O
s O
) O
may O
also O
serve O
as O
a O
receptor O
. O

Here O
, O
we O
performed O
a O
large O
- O
scale O
glycan O
array O
screen O
with O
MuV B
hemagglutinin I
- I
neuraminidase I
( I
MuV I
- I
HN I
) I
attachment O
proteins O
by O
using O
600 O
types O
of O
glycans O
from O
The O
Consortium O
for O
Functional O
Glycomics O
Protein O
- O
Glycan O
Interaction O
Core O
in O
an O
effort O
to O
find O
new O
glycan O
receptor O
motif O
( O
s O
) O
. O

According O
to O
the O
results O
of O
the O
glycan O
array O
, O
we O
successfully O
determined O
the O
crystal O
structures O
of O
MuV O
- O
HN O
proteins O
bound O
to O
newly O
identified O
glycan O
motifs O
, O
sialyl B
Lewis I
( I
X I
) I
( I
Sle I
( I
X I
) I
) I
and O
the O
oligosaccharide O
portion O
of O
the O
GM2 B
ganglioside I
( I
GM2 I
- I
glycan I
) I
. O

Interestingly O
, O
the O
complex O
structures O
showed O
that O
SLe O
( O
X O
) O
and O
GM2 O
- O
glycan O
share O
the O
same O
configuration O
with O
the O
reported O
trisaccharide O
motif O
, O
3 B
' I
- I
sialyllactose I
( I
3 I
' I
- I
SL I
) I
, O
at O
the O
binding O
site O
of O
MuV O
- O
HN O
, O
while O
SLe O
( O
X O
) O
and O
GM2 O
- O
glycan O
have O
several O
unique O
interactions O
compared O
with O
those O
of O
3 O
' O
- O
SL O
. O

Thus O
, O
MuV O
- O
HN O
protein O
can O
allow O
an O
additional O
spatial O
modification O
in O
GM2 O
- O
glycan O
and O
SLe O
( O
X O
) O
at O
the O
second O
and O
third O
carbohydrates O
from O
the O
nonreducing O
terminus O
of O
the O
core O
trisaccharide O
structure O
, O
respectively O
. O

Importantly O
, O
MuV O
entry O
was O
efficiently O
inhibited O
in O
the O
presence O
of O
3 O
' O
- O
SL O
, O
SLe O
( O
X O
, O
) O
or O
GM2 O
- O
glycan O
derivatives O
, O
which O
indicates O
that O
these O
motifs O
can O
serve O
as O
MuV O
receptors O
. O

The O
alpha O
2 O
, O
3 O
- O
sialylated O
oligosaccharides O
, O
such O
as O
SLe O
( O
X O
) O
and O
3 O
' O
- O
sialyllactosamine O
, O
are O
broadly O
expressed O
in O
various O
tissues O
, O
and O
GM2 O
exists O
mainly O
in O
neural O
tissues O
and O
the O
adrenal O
gland O
. O

IMPORTANCE O
mumps B
virus I
( I
MuV I
) I
infection O
is O
characterized O
by O
parotid O
gland O
swelling O
and O
can O
cause O
pancreatitis O
, O
orchitis O
, O
meningitis O
, O
and O
encephalitis O
. O

Here O
, O
using O
a O
large O
- O
scale O
glycan O
array O
and O
X O
- O
ray O
crystallography O
, O
we O
show O
that O
MuV O
recognizes O
sialyl O
Lewis O
( O
X O
) O
and O
GM2 O
ganglioside O
as O
receptors O
, O
in O
addition O
to O
a O
previously O
reported O
MuV O
receptor O
, O
a O
trisaccharide O
containing O
an O
alpha O
2 O
, O
3 O
- O
linked O
sialic O
acid O
. O

Mumps O
outbreaks O
among O
vaccinated O
young O
adults O
stress O
the O
need O
for O
a O
better O
understanding O
of O
mumps B
virus I
( I
MuV I
) I
- O
induced O
immunity O
. O

We O
recently O
isolated O
a O
MuV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cell O
clone O
by O
stimulating O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
from O
a O
mumps O
case O
with O
the O
viral O
nucleoprotein O
( O
MuV O
- O
N O
) O
. O

In O
this O
study O
, O
we O
further O
explored O
the O
identity O
and O
relevance O
of O
the O
epitope O
recognized O
by O
the O
CD4 O
( O
+ O
) O
T O
cell O
clone O
and O
ex O
vivo O
by O
T O
cells O
in O
a O
cohort O
of O
mumps O
cases O
. O

Moreover O
, O
the O
CD4 O
( O
+ O
) O
T O
cells O
exerted O
a O
cytotoxic O
phenotype O
and O
specifically O
killed O
cells O
presenting O
MuV O
- O
N110 O
- O
124 O
. O

Furthermore O
, O
the O
identified O
peptide O
is O
widely O
applicable O
to O
the O
general O
population O
since O
it O
is O
predicted O
to O
bind O
various O
common O
HLA O
- O
DR O
molecules O
, O
and O
epitope O
- O
specific O
CD4 O
( O
+ O
) O
T O
cells O
displaying O
cytotoxic O
/ O
Th1 O
- O
type O
properties O
were O
found O
in O
all O
tested O
mumps O
cases O
expressing O
different O
HLA O
- O
DR O
alleles O
. O

This O
first O
broadly O
recognized O
human O
MuV O
- O
specific O
CD4 O
( O
+ O
) O
T O
cell O
epitope O
could O
provide O
a O
useful O
tool O
to O
detect O
and O
evaluate O
virus O
- O
specific O
T O
cell O
responses O
upon O
MuV O
infection O
or O
following O
vaccination O
. O

Humoral O
responses O
against O
mumps B
virus I
( I
MuV I
) I
are O
well O
characterized O
, O
although O
no O
correlate O
of O
protection O
has O
been O
elucidated O
, O
stressing O
the O
need O
to O
better O
understand O
cellular O
MuV O
- O
specific O
immunity O
. O

In O
this O
study O
, O
we O
identified O
the O
first O
MuV O
T O
cell O
epitope O
, O
which O
is O
derived O
from O
the O
viral O
nucleoprotein O
( O
MuV O
- O
N O
) O
and O
was O
recognized O
by O
a O
cytotoxic O
/ O
Th1 O
CD4 O
( O
+ O
) O
T O
cell O
clone O
that O
was O
isolated O
from O
a O
mumps O
case O
. O

Moreover O
, O
the O
epitope O
was O
predicted O
to O
bind O
a O
broad O
variety O
of O
common O
HLA O
- O
DRB1 O
alleles O
, O
which O
was O
confirmed O
by O
the O
epitope O
- O
specific O
cytotoxic O
/ O
Th1 O
CD4 O
( O
+ O
) O
T O
cell O
responses O
observed O
in O
multiple O
mumps O
cases O
with O
various O
HLADRB1 O
genotypes O
. O

The O
acute O
antiviral O
response O
is O
mediated O
by O
a O
family O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
providing O
cell O
- O
intrinsic O
immunity O
. O

One O
family O
of O
ISGs O
with O
antiviral O
function O
is O
the O
interferon B
- I
inducible I
transmembrane I
proteins I
( I
IFITMs I
) I
, O
of O
which O
IFITM3 O
has O
been O
studied O
extensively O
. O

Overexpression O
of O
IFITM1 O
prevented O
infection O
by O
a O
number O
of O
Paramyxoviridae O
and O
Pneumoviridae O
, O
including O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
mumps O
virus O
, O
and O
human B
metapneumovirus I
( I
HMPV I
) I
. O

IFITM1 O
also O
restricted O
infection O
with O
an O
enveloped O
DNA O
virus O
that O
can O
enter O
via O
the O
plasma O
membrane O
, O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
. O

To O
test O
the O
importance O
of O
plasma O
membrane O
localization O
for O
IFITM1 O
function O
, O
we O
identified O
blocks O
of O
amino O
acids O
in O
the O
conserved B
intracellular I
loop I
( I
CIL I
) I
domain O
that O
altered O
the O
subcellular O
localization O
of O
the O
protein O
and O
reduced O
antiviral O
activity O
. O

By O
screening O
reported O
data O
sets O
, O
12 O
rare O
nonsynonymous O
single B
nucleotide I
polymorphisms I
( I
SNPs I
) I
were O
identified O
in O
human O
IFITM1 O
, O
some O
of O
which O
are O
in O
the O
CIL O
domain O
. O

Using O
an O
Ifitm1 O
( O
- O
/ O
- O
) O
mouse O
, O
we O
show O
that O
RSV O
infection O
was O
more O
severe O
, O
thereby O
extending O
the O
range O
of O
viruses O
restricted O
in O
vivo O
by O
IFITM O
proteins O
and O
suggesting O
overall O
that O
IFITM1 O
is O
broadly O
antiviral O
and O
that O
this O
antiviral O
function O
is O
associated O
with O
cell O
surface O
localization O
. O

IMPORTANCE O
Host O
susceptibility O
to O
viral O
infection O
is O
multifactorial O
, O
but O
early O
control O
of O
viruses O
not O
previously O
encountered O
is O
predominantly O
mediated O
by O
the O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
family O
. O

One O
ISG O
located O
at O
the O
plasma O
membrane O
is O
interferon B
- I
inducible I
transmembrane I
protein I
1 I
( I
IFITM1 I
) I
. O

We O
also O
observed O
for O
the O
first O
time O
that O
IFITM1 O
plays O
a O
role O
in O
vivo O
, O
and O
Ifitm1 O
( O
- O
/ O
- O
) O
mice O
were O
more O
susceptible O
to O
viral O
lung O
infection O
. O

J B
paramyxovirus I
( I
JPV I
) I
was O
first O
isolated O
from O
moribund O
mice O
with O
hemorrhagic O
lung O
lesions O
in O
Australia O
in O
1972 O
. O

JPV O
causes O
little O
cytopathic B
effect I
( I
CPE I
) I
in O
tissue O
culture O
cells O
but O
severe O
disease O
in O
mice O
. O

The O
small B
hydrophobic I
( I
SH I
) I
protein O
is O
an O
integral O
membrane O
protein O
encoded O
by O
many O
paramyxoviruses O
, O
such O
as O
mumps B
virus I
( I
MuV I
) I
and O
respiratory B
syncytial I
virus I
( I
RSV I
) I
. O

In O
this O
work O
, O
the O
functions O
of O
SH O
of O
JPV O
, O
MuV O
, O
and O
RSV O
have O
been O
examined O
by O
generating O
recombinant B
JPV I
lacking I
the I
SH I
protein I
( I
rJPV I
- I
Delta I
SH I
) I
or O
replacing O
SH O
of O
JPV O
with O
MuV O
SH O
( O
rJPV O
- O
MuV51 O
- O
1 O
) O
or O
RSV O
SH O
( O
rJPVRSVSH O
) O
. O

However O
, O
more O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
was O
produced O
during O
rJPV O
- O
Delta O
SH O
infection O
, O
confirming O
the O
role O
of O
SH O
in O
inhibiting O
TNF O
- O
alpha O
production O
. O

J B
paramyxovirus I
( I
JPV I
) I
was O
isolated O
from O
moribund O
mice O
in O
Australia O
in O
1972 O
. O

Newly O
isolated O
viruses O
, O
such O
as O
Beilong B
virus I
( I
BeiPV I
) I
and O
Tailam B
virus I
( I
TImPV I
) I
, O
have O
genome O
structures O
similar O
to O
that O
of O
JPV O
. O

small B
hydrophobic I
( I
SH I
) I
protein O
is O
present O
in O
many O
paramyxoviruses O
. O

The O
mumps B
virus I
( I
MuV I
) I
small I
hydrophobic I
protein I
( I
SH I
) I
is O
a O
type O
I O
membrane O
protein O
expressed O
in O
infected O
cells O
. O

SH O
has O
been O
reported O
to O
interfere O
with O
innate O
immunity O
by O
inhibiting O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
- O
mediated O
apoptosis O
and O
NF O
- O
kappa O
B O
activation O
. O

To O
elucidate O
the O
underlying O
mechanism O
, O
we O
generated O
recombinant B
MuVs I
( I
rMuVs I
) I
expressing O
the O
SH O
protein O
with O
an O
N O
- O
terminal O
FLAG O
epitope O
or O
lacking O
SH O
expression O
due O
to O
the O
insertion O
of O
three O
stop O
codons O
into O
the O
SH O
gene O
. O

Since O
SH O
coimmunoprecipitated O
with O
Tumor B
necrosis I
factor I
receptor I
1 I
( I
TNFR1 I
) I
, O
RIP1 O
, O
and O
IRAK1 O
, O
we O
hypothesize O
that O
SH O
exerts O
its O
inhibitory O
function O
by O
interacting O
with O
TNFR1 O
, O
interleukin B
- I
1 I
receptor I
type I
1 I
( I
IL I
- I
1R1 I
) I
, O
and O
TLR3 O
complexes O
in O
the O
plasma O
membrane O
of O
infected O
cells O
. O

We O
thereby O
not O
only O
shed O
light O
on O
the O
mechanisms O
of O
SH O
- O
mediated O
NF O
- O
kappa O
B O
inhibition O
but O
also O
reveal O
that O
SH O
interferes O
with O
NF O
- O
kappa O
B O
activation O
induced O
by O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
and O
double O
- O
stranded O
RNA O
. O

Hendra B
virus I
( I
HeV I
) I
is O
a O
zoonotic O
paramyxovirus O
that O
causes O
deadly O
illness O
in O
horses O
and O
humans O
. O

An O
intriguing O
feature O
of O
HeV O
is O
the O
utilization O
of O
endosomal O
protease O
for O
activation O
of O
the O
viral O
fusion B
protein I
( I
F I
) I
. O

We O
found O
that O
the O
HeV O
matrix B
( I
M I
) I
and O
F O
proteins O
each O
induced O
particle O
release O
when O
they O
were O
expressed O
alone O
but O
that O
their O
coexpression O
led O
to O
coordinated O
assembly O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
that O
were O
morphologically O
and O
physically O
distinct O
from O
M O
- O
only O
or O
F O
- O
only O
VLPs O
. O

The O
F O
and O
M O
proteins O
were O
both O
found O
to O
traffic O
through O
Rab11 O
- O
positive O
recycling B
endosomes I
( I
REs I
) I
, O
suggesting O
a O
model O
in O
which O
F O
and O
M O
trafficking O
pathways O
converge O
at O
REs O
, O
enabling O
these O
proteins O
to O
preassemble O
before O
arriving O
at O
plasma O
membrane O
budding O
sites O
. O

It O
must O
require O
a O
conformational O
change O
in O
the O
Nucleocapsid B
protein I
( I
N I
) I
to O
make O
the O
RNA O
accessible O
to O
the O
viral O
polymerase O
during O
this O
process O
. O

The O
structure O
of O
an O
empty O
mumps B
virus I
( I
MuV I
) I
nucleocapsid O
- O
like O
particle O
was O
determined O
to O
10 O
. O

4 O
- O
angstrom O
resolution O
on O
by O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
image O
reconstruction O
. O

IMPORTANCE O
mumps B
virus I
( I
MuV I
) I
infection O
may O
cause O
serious O
diseases O
, O
including O
hearing O
loss O
, O
orchitis O
, O
oophoritis O
, O
mastitis O
, O
and O
pancreatitis O
. O

They O
all O
make O
their O
own O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

We O
have O
previously O
shown O
that O
IFIT1 O
is O
primarily O
responsible O
for O
the O
antiviral O
action O
of O
interferon B
( I
IFN I
) I
alpha O
/ O
beta O
against O
parainfluenza B
virus I
type I
5 I
( I
PIV5 I
) I
, O
selectively O
inhibiting O
the O
translation O
of O
PIV5 O
mRNAs O
. O

Here O
we O
report O
that O
while O
PIV2 O
, O
PIV5 O
, O
and O
mumps B
virus I
( I
MuV I
) I
are O
sensitive O
to O
IFIT1 O
, O
nonrubulavirus O
members O
of O
the O
paramyxoviridae O
such O
as O
PIV3 O
, O
Sendai B
virus I
( I
SeV I
) I
, O
and O
canine B
distemper I
virus I
( I
CDV I
) I
are O
resistant O
. O

The O
IFIT1 O
sensitivity O
of O
PIV5 O
was O
not O
rescued O
by O
coinfection O
with O
an O
IFIT1 O
- O
resistant O
virus O
( O
PIV3 O
) O
, O
demonstrating O
that O
PIV3 O
does O
not O
specifically O
inhibit O
the O
antiviral O
activity O
of O
IFIT1 O
and O
that O
the O
inhibition O
of O
PIV5 O
mRNAs O
is O
regulated O
by O
cis O
- O
acting O
elements O
. O

Using O
purified O
human O
mRNA O
- O
capping O
enzymes O
, O
we O
show O
biochemically O
that O
efficient O
inhibition O
by O
IFIT1 O
is O
dependent O
upon O
a O
5 O
' O
guanosine O
nucleoside O
cap O
( O
which O
need O
not O
be O
N7 O
methylated O
) O
and O
that O
this O
sensitivity O
is O
partly O
abrogated O
by O
2 O
' O
O O
methylation O
of O
the O
cap O
1 O
ribose O
. O

Thus O
, O
surprisingly O
, O
the O
viral O
polymerases O
( O
which O
have O
2 O
' O
- O
O O
- O
methyltransferase O
activity O
) O
of O
rubulaviruses O
do O
not O
protect O
these O
viruses O
from O
inhibition O
by O
IFIT1 O
. O

One O
factor O
that O
will O
influence O
disease O
outcomes O
is O
how O
they O
interact O
with O
innate O
host O
cell O
defenses O
, O
including O
the O
interferon B
( I
IFN I
) I
system O
. O

The O
viral B
RNA I
- I
dependent I
RNA I
polymerases I
( I
vRdRps I
) I
of O
nonsegmented O
, O
negative B
- I
sense I
viruses I
( I
NNSVs I
) I
consist O
of O
the O
enzymatic O
large B
protein I
( I
L I
) I
and O
the O
phosphoprotein B
( I
P I
) I
. O

In O
this O
study O
, O
we O
investigate O
the O
roles O
that O
viral O
proteins O
play O
in O
the O
phosphorylation O
of O
mumps B
virus I
( I
MuV I
) I
P O
. O

We O
found O
that O
nucleoprotein B
( I
NP I
) I
enhances O
the O
phosphorylation O
of O
P O
. O

We O
have O
identified O
the O
serine O
/ O
threonine O
kinase O
polo B
- I
like I
kinase I
1 I
( I
PLK1 I
) I
as O
a O
host O
kinase O
that O
phosphorylates O
P O
and O
have O
found O
that O
phosphorylation O
of O
P O
by O
PLK1 O
is O
enhanced O
by O
NP O
. O

The O
PLK1 O
binding O
site O
in O
MuV O
P O
was O
mapped O
to O
residues O
146 O
to O
148 O
within O
the O
S O
( O
pS O
/ O
T O
) O
P O
motif O
, O
and O
the O
phosphorylation O
site O
was O
identified O
as O
residues O
S292 O
and O
S294 O
. O

A O
bat O
virus O
with O
high O
phylogenetic O
relatedness O
to O
human O
mumps B
virus I
( I
MuV I
) I
was O
identified O
recently O
at O
the O
nucleic O
acid O
level O
. O

We O
analyzed O
the O
functional O
activities O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
the O
fusion O
( O
F O
) O
proteins O
of O
the O
bat O
virus O
( O
batMuV O
) O
and O
compared O
them O
to O
the O
respective O
proteins O
of O
a O
human O
isolate O
. O

The O
syncytia O
were O
smaller O
, O
and O
they O
were O
present O
in O
lower O
numbers O
than O
those O
observed O
after O
coexpression O
of O
the O
corresponding O
glycoproteins O
of O
a O
clinical O
isolate O
of O
MuV O
( O
hMuV O
) O
. O

IMPORTANCE O
The O
recently O
described O
MuV O
- O
like O
bat O
virus O
is O
unique O
among O
other O
recently O
identified O
human O
- O
like O
bat O
- O
associated O
viruses O
because O
of O
its O
high O
sequence O
homology O
( O
approximately O
90 O
% O
in O
most O
genes O
) O
to O
its O
human O
counterpart O
. O

mumps B
virus I
( I
MuV I
) I
infection O
induces O
formation O
of O
cytoplasmic O
inclusion B
bodies I
( I
IBs I
) I
. O

In O
this O
study O
, O
pulldown O
purification O
and O
N O
- O
terminal O
amino O
acid O
sequencing O
revealed O
that O
stress O
- O
inducible O
heat B
shock I
protein I
70 I
( I
Hsp72 I
) I
was O
a O
binding O
partner O
of O
MuV O
phosphoprotein B
( I
P I
protein I
) I
, O
which O
was O
an O
essential O
component O
of O
the O
IB O
formation O
. O

Knockdown O
of O
Hsp72 O
using O
small B
interfering I
RNAs I
( I
siRNAs I
) I
had O
little O
, O
if O
any O
, O
effect O
on O
viral O
propagation O
in O
cultured O
cells O
. O

IMPORTANCE O
Formation O
of O
cytoplasmic O
inclusion B
bodies I
( I
IBs I
) I
is O
a O
common O
characteristic O
feature O
in O
mononegavirus O
infections O
. O

Here O
, O
we O
identified O
stress O
- O
inducible O
heat B
shock I
protein I
70 I
( I
Hsp72 I
) I
as O
the O
first O
cellular O
partner O
of O
mumps B
virus I
( I
MuV I
) I
phosphoprotein I
( I
P I
protein I
) I
, O
which O
is O
an O
essential O
component O
of O
the O
IBs O
and O
is O
involved O
in O
viral O
RNA O
replication O
/ O
transcription O
. O

Given O
that O
replication O
and O
dissemination O
of O
the O
highly O
pathogenic O
Nipah B
virus I
( I
NiV I
) I
include O
exposure O
to O
environments O
rich O
in O
complement O
factors O
, O
we O
tested O
the O
in O
vitro O
sensitivity O
of O
NiV O
to O
complement O
- O
mediated O
neutralization O
. O

Here O
we O
show O
that O
NiV O
was O
completely O
resistant O
to O
in O
vitro O
neutralization O
by O
normal B
human I
serum I
( I
NHS I
) I
. O

In O
in O
vitro O
reconstitution O
experiments O
, O
NiV O
particles O
provided O
time O
- O
and O
dose O
- O
dependent O
factor O
I O
- O
like O
protease O
activity O
capable O
of O
cleaving O
C3b O
into O
inactive B
C3b I
( I
iC3b I
) I
. O

In O
previous O
work O
, O
a O
prototypic O
recombinant B
vesicular I
stomatitis I
virus I
Indiana I
serotype I
( I
rVSIV I
) I
vector O
expressing O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
gag O
and O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
env O
antigens O
protected O
nonhuman B
primates I
( I
NHPs I
) I
from O
disease O
following O
challenge O
with O
an O
HIV O
- O
1 O
/ O
SIV O
recombinant O
( O
SHIV O
) O
. O

However O
, O
when O
tested O
in O
a O
stringent O
NHP O
neurovirulence B
( I
NV I
) I
model O
, O
this O
vector O
was O
not O
adequately O
attenuated O
for O
clinical O
evaluation O
. O

For O
the O
work O
described O
here O
, O
the O
prototypic O
rVSIV O
vector O
was O
attenuated O
by O
combining O
specific O
G O
protein O
truncations O
with O
either O
N O
gene O
translocations O
or O
mutations O
( O
M33A O
and O
M51A O
) O
that O
ablate O
expression O
of O
subgenic O
M O
polypeptides O
, O
by O
incorporation O
of O
temperature O
- O
sensitive O
mutations O
in O
the O
N O
and O
L O
genes O
, O
and O
by O
deletion O
of O
the O
VSIV O
G O
gene O
to O
generate O
a O
replicon O
that O
is O
dependent O
on O
trans O
expression O
of O
G O
protein O
for O
in O
vitro O
propagation O
. O

Previously O
, O
we O
have O
shown O
that O
clinical O
isolate O
- O
based O
recombinant O
mumps O
viruses O
lacking O
expression O
of O
either O
the O
V O
protein O
( O
rMuV O
Delta O
V O
) O
or O
the O
SH O
protein O
( O
rMuV O
Delta O
SH O
) O
are O
attenuated O
in O
a O
neurovirulence O
test O
using O
newborn O
rat O
brains O
( O
P O
. O

Furthermore O
, O
we O
generated O
recombinant O
mumps O
viruses O
lacking O
expression O
of O
both O
the O
V O
protein O
and O
the O
SH O
protein O
( O
rMuV O
Delta O
SH O
Delta O
V O
) O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
activates O
and O
is O
neutralized O
by O
the O
alternative B
pathway I
( I
AP I
) I
in O
normal B
human I
serum I
( I
NHS I
) I
but O
not O
by O
heat B
- I
inactivated I
( I
HI I
) I
serum O
. O

Recombinant O
PIV5 O
viruses O
with O
enhanced O
fusion O
activity O
were O
generated O
by O
introducing O
point O
mutations O
in O
the O
F O
fusogenic O
peptide O
( O
G3A O
) O
or O
at O
a O
distal O
site O
near O
the O
F O
transmembrane O
domain O
( O
S443P O
) O
. O

In O
contrast O
to O
wild B
- I
type I
( I
WT I
) I
PIV5 O
, O
the O
mutant O
G3A O
and O
S443P O
viruses O
were O
neutralized O
by O
both O
NHS O
and O
HI O
serum O
. O

Animal O
models O
are O
needed O
to O
investigate O
the O
causes O
of O
outbreaks O
and O
to O
understand O
the O
pathogenesis O
of O
mumps B
virus I
( I
MuV I
) I
. O

In O
this O
study O
, O
we O
have O
examined O
the O
infection O
of O
three O
animal O
models O
with O
an O
isolate O
of O
mumps O
virus O
from O
a O
recent O
outbreak O
( O
MuV O
- O
IA O
) O
. O

Mumps O
viral O
antigen O
was O
detected O
in O
parotid O
glands O
by O
Immunohistochemistry B
( I
IHC I
) I
. O

Here O
we O
demonstrate O
that O
mumps B
virus I
( I
MuV I
) I
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
assemble O
to O
include O
CD46 O
and O
CD55 O
, O
two O
host O
cell O
regulators O
which O
inhibit O
propagation O
of O
complement O
pathways O
through O
distinct O
mechanisms O
. O

Virion O
- O
associated O
CD46 O
and O
CD55 O
were O
biologically O
active O
, O
with O
VSV O
showing O
higher O
levels O
of O
activity O
of O
both O
cofactors O
, O
which O
promoted O
factor O
I O
- O
mediated O
cleavage O
of O
C3b O
into O
iC3b O
as O
well O
as O
decay B
- I
accelerating I
factor I
( I
DAF I
) I
activity O
against O
the O
C3 O
convertase O
, O
than O
MuV O
. O

Time O
courses O
of O
in O
vitro O
neutralization O
with O
normal B
human I
serum I
( I
NHS I
) I
showed O
that O
both O
regulators O
could O
delay O
neutralization O
, O
but O
viruses O
containing O
CD46 O
alone O
were O
neutralized O
faster O
and O
more O
completely O
than O
viruses O
containing O
CD55 O
alone O
. O

Deletion O
of O
the O
small B
hydrophobic I
( I
SH I
) I
protein O
of O
certain O
paramyxoviruses O
has O
been O
found O
to O
result O
in O
attenuation O
, O
suggesting O
that O
the O
SH O
protein O
is O
a O
virulence O
factor O
. O

To O
investigate O
the O
role O
of O
the O
mumps B
virus I
( I
MuV I
) I
SH O
protein O
in O
virulence O
, O
multiple O
stop O
codons O
were O
introduced O
into O
The B
open I
reading I
frame I
( I
ORF I
) I
of O
a O
MuV O
molecular O
clone O
( O
r88 O
- O
1961 O
( O
SHstop O
) O
) O
, O
preserving O
genome O
structure O
but O
precluding O
production O
of O
the O
SH O
protein O
. O

No O
differences O
in O
neurovirulence O
were O
seen O
between O
the O
wild O
- O
type O
and O
the O
SH O
( O
stop O
) O
viruses O
. O

Paramyxovirus O
matrix B
( I
M I
) I
proteins O
organize O
virus O
assembly O
, O
linking O
viral O
glycoproteins O
and O
viral O
ribonucleoproteins O
together O
at O
virus O
assembly O
sites O
on O
cellular O
membranes O
. O

Using O
a O
yeast O
two O
- O
hybrid O
screening O
approach O
, O
we O
identified O
14 O
- O
3 O
- O
3 O
as O
a O
binding O
partner O
for O
the O
M O
protein O
of O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
. O

Mutation O
of O
S369 O
within O
the O
PIV5 O
M O
protein O
disrupted O
14 O
- O
3 O
- O
3 O
binding O
and O
improved O
the O
budding O
of O
both O
virus B
- I
like I
particles I
( I
VLPs I
) I
and O
recombinant O
viruses O
, O
suggesting O
that O
14 O
- O
3 O
- O
3 O
binding O
impairs O
virus O
budding O
. O

measles B
virus I
( I
MV I
) I
vaccine O
effectively O
protects O
seronegative O
individuals O
against O
infection O
. O

In O
order O
to O
provide O
such O
a O
stimulus O
, O
we O
generated O
a O
recombinant O
Newcastle B
disease I
virus I
( I
NDV I
) I
expressing O
the O
MV O
hemagglutinin O
( O
NDV O
- O
H O
) O
. O

NDV O
infection O
( O
which O
induces O
alpha O
interferon O
) O
had O
the O
same O
effect O
, O
and O
stimulation O
could O
be O
abrogated O
by O
antibodies O
neutralizing O
alpha O
interferon O
, O
but O
not O
interleukin B
6 I
( I
IL I
- I
6 I
) I
. O

The O
nucleocapsid B
protein I
( I
NP I
) I
of O
mumps B
virus I
( I
MuV I
) I
, O
a O
paramyxovirus O
, O
was O
coexpressed O
with O
the O
phosphoprotein B
( I
P I
) I
in O
Escherichia O
coli O
. O

To O
define O
mumps B
virus I
( I
MuV I
) I
proteins O
important O
for O
this O
process O
, O
viral O
proteins O
were O
expressed O
either O
singly O
or O
in O
combination O
in O
mammalian O
cells O
to O
produce O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Only O
the O
MuV O
matrix B
( I
M I
) I
protein O
when O
expressed O
by O
itself O
was O
capable O
of O
inducing O
particle O
release O
, O
but O
the O
quantity O
of O
these O
M O
- O
alone O
particles O
was O
very O
small O
. O

Efficient O
production O
of O
mumps O
VLPs O
occurred O
only O
when O
the O
M O
protein O
was O
coexpressed O
together O
with O
other O
viral O
proteins O
, O
with O
maximum O
production O
achieved O
upon O
coexpression O
of O
the O
viral O
M O
, O
nucleocapsid B
( I
NP I
) I
, O
and O
fusion O
( O
F O
) O
proteins O
together O
. O

Mumps O
virus O
, O
like O
other O
paramyxoviruses O
in O
the O
Rubulavirus O
genus O
, O
encodes O
a O
V O
protein O
that O
can O
assemble O
a O
ubiquitin O
ligase O
complex O
from O
cellular O
components O
, O
leading O
to O
the O
destruction O
of O
cellular O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins O
. O

Nipah B
virus I
( I
NiV I
) I
is O
predicted O
to O
encode O
four O
proteins O
from O
its O
P O
gene O
( O
P O
, O
V O
, O
W O
, O
and O
C O
) O
via O
mRNA O
editing O
and O
an O
alternate O
open O
reading O
frame O
. O

Disease O
manifestation O
, O
pathology O
, O
and O
tissue O
tropism O
following O
infection O
with O
Tioman B
virus I
( I
TioPV I
) I
, O
a O
newly O
isolated O
, O
bat O
- O
derived O
paramyxovirus O
, O
was O
investigated O
in O
subcutaneously O
( O
n O
= O
12 O
) O
and O
oronasally O
( O
n O
= O
4 O
) O
inoculated O
pigs O
. O

The O
virus O
( O
viral O
antigen O
and O
/ O
or O
genome O
) O
was O
detected O
in O
lymphocytes O
of O
the O
thymus O
, O
tonsils O
, O
spleen O
, O
lymph O
nodes O
and O
Peyer O
' O
s O
patches O
( O
ileum O
) O
, O
tonsillar O
epithelium O
, O
and O
thymic O
epithelioreticular O
cells O
. O

Prior O
to O
the O
introduction O
of O
live O
- O
attenuated O
vaccines O
, O
mumps B
virus I
( I
MuV I
) I
was O
the O
leading O
cause O
of O
virus O
- O
induced O
meningitis O
. O

Recombinant O
viruses O
, O
containing O
the O
envelope O
- O
associated O
genes O
from O
the O
Kilham O
( O
MUVKH O
) O
rodent O
brain O
- O
adapted O
strain O
of O
MuV O
, O
were O
generated O
in O
the O
Jeryl O
Lynn O
5 O
( O
MuV O
( O
JL5 O
) O
) O
vaccine O
strain O
background O
. O

The O
syncytium O
phenotypes O
of O
the O
recombinant O
viruses O
on O
Vero O
cells O
differed O
depending O
on O
the O
source O
of O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoproteins O
, O
with O
heterologous O
combinations O
showing O
either O
an O
increase O
or O
a O
decrease O
in O
the O
level O
of O
cell O
fusion O
compared O
to O
that O
of O
the O
homologous O
parental O
combinations O
. O

Expression O
of O
the O
matrix B
( I
M I
) I
, O
small B
hydrophobic I
( I
SH I
) I
, O
or O
HN O
gene O
in O
isolation O
did O
not O
confer O
a O
neurovirulent O
phenotype O
. O

Infection O
of O
newborn O
Lewis O
rats O
with O
Borna O
disease O
virus O
( O
neonatal O
Borna O
disease O
[ O
NBD O
] O
) O
results O
in O
cerebellar O
damage O
without O
the O
cellular O
inflammation O
associated O
with O
infections O
in O
later O
life O
. O

Purkinie B
cell I
( I
PC I
) I
damage O
has O
been O
reported O
for O
several O
models O
of O
early O
- O
life O
viral O
infection O
, O
including O
NBD O
; O
however O
, O
the O
time O
course O
and O
distribution O
of O
PC O
pathology O
have O
not O
been O
investigated O
rigorously O
. O

Real O
- O
time O
PCR O
at O
postnatal B
day I
28 I
( I
PND28 I
) I
revealed O
decreased O
cerebellar O
levels O
of O
mRNAs O
encoding O
the O
glycolytic O
enzymes O
aldolase O
C O
( O
AldoC O
, O
also O
known O
as O
zebrin O
II O
) O
and O
phosphofructokinase O
C O
and O
the O
excitatory B
amino I
acid I
transporter I
4 I
( I
EAAT4 I
) I
. O

Early O
cell O
loss O
( O
PND28 O
) O
was O
characterized O
by O
preferential O
apoptotic O
loss O
of O
zebrin O
II O
/ O
EAAT4 O
- O
negative O
PC O
subsets O
in O
the O
anterior O
vermis O
. O

canine B
distemper I
virus I
( I
CDV I
) I
, O
a O
member O
of O
the O
Morbillivirus O
genus O
that O
also O
includes O
measles O
virus O
, O
frequently O
causes O
neurologic O
complications O
, O
but O
the O
routes O
and O
timing O
of O
CDV O
invasion O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
are O
poorly O
understood O
. O

To O
characterize O
these O
events O
, O
we O
cloned O
and O
sequenced O
the O
genome O
of O
a O
neurovirulent O
CDV O
( O
strain O
A75 O
/ O
17 O
) O
and O
produced O
an O
infectious O
cDNA O
that O
expresses O
the O
green O
fluorescent O
protein O
. O

mumps B
virus I
( I
MuV I
) I
, O
a O
rubulavirus O
of O
the O
paramyxovirus O
family O
, O
causes O
acute O
infections O
in O
humans O
. O

MuV O
has O
seven O
genes O
including O
a O
small B
hydrophobic I
( I
SH I
) I
gene O
, O
which O
encodes O
a O
type O
I O
membrane O
protein O
of O
57 O
amino O
acid O
residues O
. O

simian B
virus I
5 I
( I
SV5 I
) I
, O
a O
closely O
related O
rubulavirus O
, O
encodes O
a O
44 O
- O
amino O
- O
acid O
- O
residue O
SH O
protein O
. O

Recombinant O
SV5 O
lacking O
the O
SH O
gene O
( O
rSV5 O
Delta O
SH O
) O
is O
viable O
and O
has O
no O
growth O
defect O
in O
tissue O
culture O
cells O
. O

Neutralizing O
antibodies O
against O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
TNF O
- O
alpha O
receptor O
1 O
block O
rSV5 O
Delta O
SH O
- O
induced O
apoptosis O
, O
suggesting O
that O
SV5 O
SH O
plays O
an O
essential O
role O
in O
blocking O
the O
TNF O
- O
alpha O
- O
mediated O
apoptosis O
pathway O
. O

To O
test O
this O
hypothesis O
and O
to O
study O
the O
function O
of O
MuV O
SH O
, O
we O
have O
replaced O
The B
open I
reading I
frame I
( I
ORF I
) I
of O
SV5 O
SH O
with O
the O
ORF O
of O
MuV O
SH O
in O
a O
SV5 O
genome O
background O
. O

The O
recombinant O
SV5 O
( O
rSV5 O
Delta O
SH O
+ O
MuV O
- O
SH O
) O
was O
analyzed O
in O
comparison O
with O
SV5 O
. O

Although O
parainfluenza O
virus O
5 O
( O
simian O
virus O
5 O
[ O
SV5 O
] O
) O
circumvents O
the O
interferon B
( I
IFN I
) I
response O
by O
blocking O
IFN O
signaling O
and O
by O
reducing O
the O
amount O
of O
IFN O
released O
by O
infected O
cells O
, O
its O
ability O
to O
circumvent O
the O
IFN O
response O
is O
not O
absolute O
. O

The O
effects O
of O
IFN O
on O
SV5 O
infection O
were O
examined O
in O
Vero O
cells O
, O
which O
do O
not O
produce O
but O
can O
respond O
to O
IFN O
, O
using O
a O
strain O
of O
SV5 O
( O
CPI O
- O
) O
which O
does O
not O
block O
IFN O
signaling O
. O

IFN O
rapidly O
( O
within O
6 O
h O
) O
induced O
alterations O
in O
the O
relative O
levels O
of O
virus O
mRNA O
and O
protein O
synthesis O
and O
caused O
a O
redistribution O
of O
virus O
proteins O
within O
infected O
cells O
that O
led O
to O
the O
enhanced O
formation O
of O
virus O
cytoplasmic O
inclusion O
bodies O
. O

IFN O
induced O
a O
steeper O
gradient O
of O
mRNA O
transcription O
from O
the O
3 O
' O
to O
the O
5 O
' O
end O
of O
the O
genome O
and O
the O
production O
of O
virus O
mRNAs O
with O
longer O
poly O
( O
A O
) O
tails O
, O
suggesting O
that O
the O
processivity O
of O
the O
virus O
polymerase O
was O
altered O
in O
cells O
in O
an O
IFN O
- O
induced O
antiviral O
state O
. O

simian B
virus I
5 I
( I
SV5 I
) I
targets O
STAT1 O
, O
human O
parainfluenza O
virus O
2 O
targets O
STAT2 O
, O
and O
mumps O
virus O
targets O
both O
STAT1 O
and O
STAT3 O
. O

Analysis O
of O
the O
V B
- I
dependent I
degradation I
complex I
( I
VDC I
) I
composition O
and O
assembly O
revealed O
several O
features O
contributing O
to O
targeting O
specificity O
. O

mumps B
virus I
( I
MuV I
) I
has O
been O
shown O
to O
antagonize O
the O
antiviral O
effects O
of O
interferon B
( I
IFN I
) I
through O
proteasome O
- O
mediated O
complete O
degradation O
of O
STAT1 O
by O
using O
the O
viral O
V O
protein O
( O
T O
. O

In O
MuV O
- O
infected O
cells O
, O
nuclear O
translocation O
and O
phosphorylation O
of O
STAT1 O
and O
STAT2 O
tyrosine O
residue O
( O
Y O
) O
at O
701 O
and O
689 O
, O
respectively O
, O
by O
IFN O
- O
beta O
were O
significantly O
inhibited O
but O
the O
phosphorylation O
of O
Jak1 O
and O
Tyk2 O
was O
not O
inhibited O
. O

Moreover O
, O
we O
show O
that O
gamma O
interferon B
- I
induced I
protein I
10 I
( I
IP I
- I
10 I
) I
is O
highly O
expressed O
by O
mumps O
virus O
- O
infected O
Leydig O
cells O
and O
that O
ribavirin O
does O
not O
block O
IP O
- O
10 O
production O
. O

Sendai B
virus I
( I
SeV I
) I
C O
protein O
functions O
as O
an O
interferon B
( I
IFN I
) I
antagonist O
and O
renders O
cells O
unresponsive O
to O
both O
alpha B
/ I
beta I
IFN I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
. O

We O
have O
recently O
found O
the O
physical O
association O
of O
the O
C O
protein O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
in O
infected O
cells O
. O

In O
infected O
cells O
, O
the O
levels O
of O
tyrosine O
- O
phosphorylated O
( O
pY O
) O
STAT2 O
were O
below O
the O
detection O
level O
irrespective O
of O
duration O
of O
IFN O
- O
alpha O
stimulation O
, O
whereas O
the O
levels O
of O
pY O
- O
STAT1 O
strikingly O
increased O
after O
long O
- O
term O
IFN O
- O
alpha O
stimulation O
. O

An O
in O
vitro O
binding O
assay O
with O
extracts O
from O
( O
STAT1 O
- O
deficient O
) O
U3A O
and O
( O
STAT1 O
- O
expressing O
) O
U3A O
- O
ST1 O
cells O
suggested O
the O
requirement O
of O
STAT1 O
for O
the O
C O
- O
STAT2 O
interaction O
. O

simian B
virus I
5 I
( I
SV5 I
) I
is O
a O
member O
of O
the O
paramyxovirus O
family O
, O
which O
includes O
emerging O
viruses O
such O
as O
Hendra O
virus O
and O
Nipah O
virus O
as O
well O
as O
many O
important O
human O
and O
animal O
pathogens O
that O
have O
been O
known O
for O
years O
. O

SV5 O
encodes O
eight O
known O
viral O
proteins O
, O
including O
a O
small O
hydrophobic O
integral O
membrane O
protein O
( O
SH O
) O
of O
44 O
amino O
acids O
. O

SV5 O
without O
the O
SH O
gene O
( O
rSV5DeltaSH O
) O
is O
viable O
, O
and O
growth O
of O
rSV5DeltaSH O
in O
tissue O
culture O
cells O
and O
viral O
protein O
and O
mRNA O
production O
in O
rSV5DeltaSH O
- O
infected O
cells O
are O
indistinguishable O
from O
those O
of O
the O
wild O
- O
type O
SV5 O
virus O
. O

However O
, O
rSV5DeltaSH O
causes O
increased O
cytopathic B
effect I
( I
CPE I
) I
and O
apoptosis O
in O
MDBK O
cells O
and O
is O
attenuated O
in O
vivo O
, O
suggesting O
the O
SH O
protein O
plays O
an O
important O
role O
in O
SV5 O
pathogenesis O
. O

tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
a O
proinflammatory O
cytokine O
, O
was O
detected O
in O
culture O
media O
of O
rSV5DeltaSH O
- O
infected O
cells O
. O

Apoptosis O
induced O
by O
rSV5DeltaSH O
was O
inhibited O
by O
neutralizing O
antibodies O
against O
TNF O
- O
alpha O
and O
TNF B
- I
alpha I
receptor I
1 I
( I
TNF I
- I
R1 I
) I
, O
suggesting O
that O
TNF O
- O
alpha O
played O
an O
essential O
role O
in O
rSV5DeltaSH O
- O
induced O
apoptosis O
in O
a O
TNF O
- O
R1 O
- O
dependent O
manner O
. O

It O
has O
been O
reported O
that O
mumps O
virus O
protein O
V O
or O
the O
C O
- O
terminal O
Cys O
- O
rich O
region O
of O
protein O
V O
( O
Vsp O
) O
is O
associated O
with O
blocking O
of O
the O
interferon B
( I
IFN I
) I
signal O
transduction O
pathway O
through O
a O
decrease O
in O
STAT O
- O
1 O
production O
. O

A O
significant O
interaction O
between O
V O
protein O
and O
RACK1 O
was O
also O
demonstrated O
in O
cells O
persistently O
infected O
with O
mumps O
virus O
( O
FLMT O
cells O
) O
, O
and O
the O
formation O
of O
the O
complex O
was O
not O
affected O
by O
treatment O
with O
IFN O
. O

in O
FL O
cells O
acutely O
infected O
with O
mumps B
virus I
( I
MuV I
) I
. O

This O
result O
was O
consistent O
with O
that O
observed O
in O
previous O
studies O
and O
experiments O
with O
cells O
persistently O
infected O
with O
MuV O
( O
FLMT O
cells O
) O
. O

There O
was O
a O
marked O
decrease O
in O
the O
amount O
of O
STAT O
- O
1 O
in O
cells O
expressing O
MuV O
accessory O
protein O
V O
( O
MuV O
- O
V O
) O
. O

Furthermore O
, O
single O
amino O
acid O
substitutions O
in O
the O
Cys O
- O
rich O
region O
of O
V O
protein O
( O
Vc189a O
, O
Vc207a O
, O
and O
Vc214a O
) O
showed O
that O
each O
cysteine O
residue O
plays O
an O
important O
role O
in O
the O
decrease O
in O
STAT O
- O
1 O
production O
, O
but O
substitution O
of O
a O
histidine O
residue O
at O
amino O
acid O
position O
203 O
had O
no O
effect O
. O

These O
events O
and O
the O
resultant O
suppression O
of O
the O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
response O
were O
confirmed O
by O
a O
luciferase O
reporter O
gene O
assay O
with O
five O
tandem O
repeats O
of O
the O
IFN O
- O
alpha O
- O
stimulated O
response O
element O
as O
an O
enhancer O
element O
of O
the O
firely O
luciferase O
gene O
. O

Therefore O
, O
the O
C O
- O
terminal O
region O
( O
transcriptional O
activation O
and O
Src O
homology O
2 O
domains O
) O
of O
STAT O
- O
1 O
is O
not O
necessary O
for O
its O
degradation O
caused O
by O
MuV O
- O
V O
. O

A O
complete O
DNA O
copy O
of O
the O
genome O
of O
a O
Jeryl O
Lynn O
strain O
of O
mumps O
virus O
( O
15 O
, O
384 O
nucleotides O
) O
was O
assembled O
from O
cDNA O
fragments O
such O
that O
an O
exact O
antigenome O
RNA O
could O
be O
generated O
following O
transcription O
by O
T7 O
RNA O
, O
polymerase O
and O
cleavage O
by O
hepatitis O
delta O
virus O
ribozyme O
. O

The O
plasmid O
containing O
the O
genome O
sequence O
, O
together O
with O
support O
plasmids O
which O
express O
mumps O
virus O
NP O
, O
P O
, O
and O
L O
proteins O
under O
control O
of O
the O
T7 O
RNA O
polymerase O
promoter O
, O
were O
transfected O
into O
A549 O
cells O
previously O
infected O
with O
recombinant O
vaccinia O
virus O
( O
MVA O
- O
T7 O
) O
that O
expressed O
T7 O
RNA O
polymerase O
. O

The O
only O
coding O
change O
( O
position O
8502 O
, O
A O
to O
G O
) O
in O
the O
cDNA O
clone O
relative O
to O
the O
consensus O
sequence O
of O
the O
Jeryl O
Lynn O
plaque O
isolate O
from O
which O
it O
was O
derived O
, O
resulting O
in O
a O
lysine O
- O
to O
- O
arginine O
substitution O
at O
amino O
acid O
22 O
of O
the O
L O
protein O
, O
did O
not O
prevent O
rescue O
of O
mumps O
virus O
, O
even O
though O
an O
amino O
acid O
alignment O
for O
the O
L O
proteins O
of O
paramyxoviruses O
indicates O
that O
lysine O
is O
highly O
conserved O
at O
that O
position O
, O
This O
system O
may O
provide O
the O
basis O
of O
a O
safe O
and O
effective O
virus O
vector O
for O
the O
in O
vivo O
expression O
of O
immunologically O
and O
biologically O
active O
proteins O
, O
peptides O
, O
and O
RNAs O
. O

Prior O
to O
the O
adoption O
of O
widespread O
vaccination O
programs O
, O
mumps O
virus O
was O
the O
leading O
cause O
of O
virus O
- O
induced O
central B
nervous I
system I
( I
CNS I
) I
disease O
. O

The O
incidence O
of O
the O
cerebellar O
abnormalities O
and O
other O
neuropathological O
and O
clinical O
outcomes O
of O
mumps O
virus O
infection O
of O
the O
neonatal O
rat O
brain O
demonstrated O
the O
ability O
of O
this O
model O
to O
distinguish O
neurovirulent O
( O
Kilham O
) O
from O
nonneurovirulent O
( O
Jeryl O
Lynn O
) O
mumps O
virus O
strains O
. O

Cells O
can O
be O
persistently O
infected O
with O
human O
parainfluenza O
vims O
type O
3 O
( O
HPF3 O
) O
by O
using O
a O
high O
multiplicity B
of I
infection I
( I
MOI I
) I
( O
greater O
- O
than O
- O
or O
- O
equal O
5 O
PFU O
per O
cell O
) O
. O

We O
compare O
the O
outcome O
of O
HPF3 O
infection O
in O
the O
presence O
of O
excess O
neuraminidase O
with O
that O
of O
another O
paramyxovirus O
( O
simian O
virus O
5 O
) O
and O
provide O
evidence O
that O
these O
two O
viruses O
differ O
in O
their O
receptor O
requirements O
for O
mediating O
fusion O
. O

The O
fusion O
glycoprotein O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
genes O
of O
human B
parainfluenza I
virus I
type I
2 I
( I
PI2 I
) I
were O
molecularly O
cloned O
and O
expressed O
in O
HeLa O
- O
T4 O
cells O
by O
using O
the O
vaccinia O
virus O
- O
T7 O
transient O
expression O
system O
. O

Surprisingly O
, O
when O
the O
PI2 O
F O
protein O
was O
expressed O
together O
with O
the O
parainfluenza B
virus I
type I
3 I
( I
PI3 I
) I
HN O
protein O
, O
no O
fusion O
was O
detectable O
in O
the O
transfected O
cells O
. O

Cells O
persistently O
infected O
with O
human B
parainfluenza I
virus I
type I
3 I
( I
HPF3 I
) I
exhibit O
a O
novel O
phenotype O
. O

Neuraminic O
acid O
is O
the O
receptor O
for O
the O
HPF3 O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
, O
the O
molecule O
responsible O
for O
binding O
of O
the O
virus O
to O
cell O
surfaces O
. O

Uninfected O
CV O
- O
1 O
cells O
were O
treated O
with O
neuraminidase O
and O
then O
tested O
for O
their O
ability O
to O
fuse O
with O
the O
Persistently B
Infected I
( I
PI I
) I
cells O
. O

One O
of O
these O
, O
the O
C O
protein O
, O
is O
expressed O
from O
an O
alternative O
open B
reading I
frame I
( I
ORF I
) I
located O
in O
the O
P O
gene O
. O

The O
measles B
virus I
( I
MeV I
) I
C O
protein O
has O
been O
implicated O
in O
modulation O
of O
interferon O
signaling O
, O
but O
has O
more O
recently O
been O
shown O
to O
play O
a O
vital O
role O
in O
regulation O
of O
viral O
transcription O
and O
replication O
, O
preventing O
the O
excessive O
production O
of O
double O
- O
stranded O
RNA O
. O

One O
puzzling O
aspect O
of O
morbillivirus O
C O
protein O
biology O
has O
been O
the O
finding O
that O
a O
C O
- O
deficient O
canine B
distemper I
virus I
( I
CDV I
) I
generated O
by O
a O
similar O
mutagenesis O
strategy O
displayed O
no O
attenuation O
in O
ferrets O
, O
an O
animal O
model O
commonly O
used O
to O
evaluate O
CDV O
pathogenesis O
. O

IMPORTANCE O
The O
measles B
( I
MeV I
) I
and O
canine B
distemper I
( I
CDV I
) I
viruses O
express O
accessory O
proteins O
that O
regulate O
the O
host O
' O
s O
immune O
response O
and O
enhance O
replication O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
nonsegmented B
negative I
- I
sense I
( I
NNS I
) I
RNA O
virus O
and O
shares O
a O
similar O
RNA O
synthesis O
strategy O
with O
other O
members O
of O
NNS O
RNA O
viruses O
, O
such O
as O
measles O
, O
rabies O
virus O
, O
and O
Ebola O
virus O
. O

RSV O
RNA O
synthesis O
is O
catalyzed O
by O
a O
multifunctional O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
, O
which O
is O
composed O
of O
a O
large B
( I
L I
) I
protein O
that O
catalyzes O
three O
distinct O
enzymatic O
functions O
and O
an O
essential O
coenzyme O
phosphoprotein B
( I
P I
) I
. O

Here O
, O
we O
successfully O
prepared O
highly O
pure O
, O
full O
- O
length O
, O
wild O
- O
type O
and O
mutant O
RSV O
polymerase O
( O
L O
- O
P O
) O
complexes O
. O

We O
defined O
the O
minimal O
length O
of O
the O
RNA O
template O
for O
in O
vitro O
de O
novo O
RNA O
synthesis O
using O
the O
purified O
RSV O
polymerase O
as O
8 O
nucleotides B
( I
nt I
) I
, O
shorter O
than O
previously O
reported O
. O

We O
showed O
that O
the O
RSV O
polymerase O
catalyzed O
primerdependent O
RNA O
elongation O
with O
different O
lengths O
of O
primers O
on O
both O
short O
( O
10 O
- O
nt O
) O
and O
long O
( O
25 O
- O
nt O
) O
RNA O
templates O
. O

The O
canine B
distemper I
virus I
( I
CDV I
) I
matrix I
( I
M I
) I
protein O
is O
multifunctional O
; O
it O
orchestrates O
viral O
assembly O
and O
budding O
, O
drives O
the O
formation O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
, O
regulates O
viral O
RNA O
synthesis O
, O
and O
may O
support O
additional O
functions O
. O

CDV O
M O
may O
assemble O
into O
dimers O
, O
where O
each O
protomer O
is O
constituted O
by O
N O
- O
terminal O
and O
C O
- O
terminal O
domains O
( O
NTD O
and O
CTD O
, O
respectively O
) O
. O

Here O
, O
to O
investigate O
whether O
electrostatic O
interactions O
between O
CDV O
M O
and O
the O
plasma B
membrane I
( I
PM I
) I
may O
contribute O
to O
budding O
activity O
, O
selected O
surface O
- O
exposed O
positively O
charged O
lysine O
residues O
, O
which O
are O
located O
within O
a O
large O
basic O
patch O
of O
CTD O
, O
were O
replaced O
by O
amino O
acids O
with O
selected O
properties O
. O

We O
found O
that O
some O
M O
mutants O
harboring O
amino O
acids O
with O
neutral O
and O
positive O
charge O
( O
methionine O
and O
arginine O
, O
respectively O
) O
maintained O
full O
functionality O
, O
including O
proper O
interaction O
and O
localization O
with O
the O
PM O
as O
well O
as O
intact O
VLP O
and O
progeny O
virus O
production O
as O
demonstrated O
by O
employing O
a O
cell O
exitcomplementation O
system O
. O

Conversely O
, O
while O
the O
overall O
structural O
integrity O
remained O
mostly O
unaltered O
, O
most O
of O
the O
nonconservative O
M O
variants O
( O
carrying O
a O
glutamic O
acid O
; O
negatively O
charged O
) O
exhibited O
a O
cytosolic O
phenotype O
secondary O
to O
the O
lack O
of O
inter O
action O
with O
the O
PM O
. O

The O
matrix B
( I
M I
) I
protein O
of O
morbilliviruses O
coordinates O
viral O
assembly O
and O
egress O
through O
interaction O
with O
multiple O
cellular O
and O
viral O
components O
. O

Here O
, O
to O
investigate O
potential O
interactions O
between O
canine B
distemper I
virus I
( I
CDV I
) I
M O
and O
the O
plasma B
membrane I
( I
PM I
) I
, O
we O
combined O
structure O
- O
guided O
mutagenesis O
of O
selected O
surface O
- O
exposed O
lysine O
residues O
with O
biochemical O
, O
cellular O
, O
and O
virological O
assays O
. O

measles B
virus I
( I
MeV I
) I
is O
a O
highly O
immunotropic O
and O
contagious O
pathogen O
that O
can O
even O
diminish O
preexisting O
antibodies O
and O
remains O
a O
major O
cause O
of O
childhood O
morbidity O
and O
mortality O
worldwide O
despite O
the O
availability O
of O
effective O
vaccines O
. O

Moreover O
, O
results O
of O
size O
exclusion O
chromatography O
demonstrated O
that O
addition O
of O
MeV O
- O
V O
displaces O
STAT2 O
- O
core O
, O
a O
rigid O
region O
of O
STAT2 O
lacking O
the O
N O
- O
and O
C O
- O
terminal O
domains O
, O
from O
preformed O
complexes O
of O
STAT2 O
- O
core O
/ O
IRF B
- I
associated I
domain I
( I
IRF9 I
) I
. O

IMPORTANCE O
To O
evade O
host O
immunity O
, O
many O
pathogenic O
viruses O
inactivate O
host O
Janus O
kinase O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
signaling O
pathways O
using O
diverse O
strategies O
. O

We O
prepared O
a O
human O
rotavirus O
vaccine O
strain O
, O
CDC O
- O
9 O
( O
G1P O
[ O
8 O
] O
) O
, O
which O
when O
grown O
in O
MA104 O
cells O
to O
passage O
11 O
or O
12 O
( O
P11 O
/ O
P12 O
) O
had O
no O
nucleotide O
or O
amino O
acid O
sequence O
changes O
from O
the O
original O
virus O
in O
stool O
. O

mumps B
virus I
( I
MuV I
) I
, O
an O
enveloped O
RNA O
virus O
of O
the O
Paramyxoviridae O
family O
and O
the O
causative O
agent O
of O
mumps O
, O
affects O
the O
salivary O
glands O
and O
other O
glandular O
tissues O
as O
well O
as O
the O
central O
nervous O
system O
. O

Membrane O
fusion O
is O
mediated O
by O
MuV O
envelope O
proteins O
: O
the O
hemagglutinin O
- O
neuraminidase O
and O
fusion O
( O
F O
) O
protein O
. O

Cleavage O
of O
the O
MuV B
F I
protein I
( I
MuV I
- I
F I
) I
into O
two O
subunits O
by O
the O
cellular O
protease O
furin O
is O
a O
prerequisite O
for O
fusion O
and O
virus O
infectivity O
. O

Here O
, O
we O
show O
that O
293T O
( O
a O
derivative O
of O
HEK293 O
) O
cells O
do O
not O
produce O
syncytia O
upon O
expression O
of O
MuV O
envelope O
proteins O
or O
MuV O
infection O
. O

An O
expression O
cloning O
strategy O
revealed O
that O
overexpression O
of O
lysosome B
- I
associated I
membrane I
proteins I
( I
LAMPs I
) I
confers O
on O
293T O
cells O
the O
ability O
to O
produce O
syncytia O
upon O
expression O
of O
MuV O
envelope O
proteins O
. O

The O
phosphoprotein B
( I
P I
) I
of O
the O
nonsegmented O
negative O
- O
sense O
RNA O
viruses O
is O
a O
multimeric O
modular O
protein O
that O
is O
essential O
for O
RNA O
transcription O
and O
replication O
. O

Despite O
great O
variability O
in O
length O
and O
sequence O
, O
the O
architecture O
of O
this O
protein O
is O
conserved O
among O
the O
different O
viral O
families O
, O
with O
a O
long O
N O
- O
terminal O
intrinsically O
disordered O
region O
comprising O
a O
nucleoprotein O
chaperone O
module O
, O
a O
central O
multimerization O
domain O
( O
P O
- O
MD O
) O
, O
connected O
by O
a O
disordered O
linker O
to O
a O
C O
- O
terminal O
nucleocapsid O
- O
binding O
domain O
. O

The O
P O
protein O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
forms O
dimers O
, O
and O
here O
we O
investigate O
the O
importance O
of O
its O
dimerization O
domain O
, O
P O
- O
MD O
, O
for O
viral O
gene O
expression O
and O
virus O
growth O
. O

A O
truncated O
P O
protein O
lacking O
the O
central O
dimerization O
domain O
( O
P O
- O
Delta O
MD O
) O
loses O
its O
ability O
to O
form O
dimers O
both O
in O
vitro O
and O
in O
a O
yeast O
two O
- O
hybrid O
system O
but O
conserves O
its O
ability O
to O
bind O
N O
. O

Because O
RNA O
viruses O
have O
high O
mutation O
rates O
, O
it O
is O
unlikely O
that O
a O
structured O
domain O
such O
as O
a O
VSV O
dimerization O
domain O
would O
persist O
in O
the O
absence O
of O
a O
function O
( O
s O
) O
, O
but O
our O
work O
indicates O
that O
it O
is O
not O
required O
for O
the O
functioning O
of O
the O
RNA O
polymerase O
machinery O
or O
for O
the O
assembly O
of O
new O
viruses O
. O

IMPORTANCE O
The O
phosphoprotein B
( I
P I
) I
is O
an O
essential O
and O
conserved O
component O
of O
all O
nonsegmented O
negative O
- O
sense O
RNA O
viruses O
, O
including O
some O
major O
human O
pathogens O
( O
e O
. O

measles B
virus I
( I
MeV I
) I
, O
like O
all O
viruses O
of O
the O
order O
Mononegavirales O
, O
utilizes O
a O
complex O
consisting O
of O
genomic O
RNA O
, O
nucleoprotein O
, O
the O
RNA O
- O
dependent O
RNA O
polymerase O
, O
and O
a O
polymerase O
cofactor O
, O
the O
phosphoprotein B
( I
P I
) I
, O
for O
transcription O
and O
replication O
. O

We O
show O
that O
the O
measles B
virus I
( I
MeV I
) I
C O
protein O
is O
an O
additional O
component O
of O
the O
replication O
complex O
. O

Nonsegmented O
negative O
- O
strand O
RNA O
viruses O
, O
including O
measles B
virus I
( I
MeV I
) I
, O
a O
member O
of O
the O
Paramyxoviridae O
family O
, O
are O
assumed O
to O
replicate O
in O
cytoplasmic O
inclusion O
bodies O
. O

Here O
, O
we O
show O
that O
infection O
with O
MeV O
triggers O
inclusion O
body O
formation O
via O
liquid B
- I
liquid I
phase I
separation I
( I
LLPS I
) I
, O
a O
process O
underlying O
the O
formation O
of O
membraneless O
organelles O
. O

We O
find O
that O
the O
viral O
nucleoprotein B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
are O
sufficient O
to O
trigger O
MeV O
phase O
separation O
, O
with O
the O
C O
- O
terminal O
domains O
of O
the O
viral O
N O
and O
P O
proteins O
playing O
a O
critical O
role O
in O
the O
phase O
transition O
. O

We O
recently O
established O
that O
the O
cellular O
protein O
WD B
repeat I
- I
containing I
protein I
5 I
( I
WDR5 I
) I
enhances O
MeV O
growth O
and O
is O
enriched O
in O
cytoplasmic O
viral O
inclusion O
bodies O
that O
include O
viral O
proteins O
responsible O
for O
RNA O
replication O
. O

Leader O
( O
L O
) O
proteins O
encoded O
by O
cardioviruses O
are O
multifunctional O
proteins O
that O
contribute O
to O
innate O
immunity O
evasion O
. O

L O
proteins O
of O
Theiler B
' I
s I
murine I
encephalomyelitis I
virus I
( I
TMEV I
) I
, O
Saffold B
virus I
( I
SAFV I
) I
, O
and O
encephalomyocarditis B
virus I
( I
EMCV I
) I
were O
reported O
to O
inhibit O
stress O
granule O
assembly O
in O
infected O
cells O
. O

Here O
, O
we O
show O
that O
TMEV O
L O
can O
act O
at O
two O
levels O
in O
the O
stress O
granule O
formation O
pathway O
: O
on O
the O
one O
hand O
, O
it O
can O
inhibit O
sodium O
arsenite O
- O
induced O
stress O
granule O
assembly O
without O
preventing O
eIF2 O
alpha O
phosphorylation O
and O
, O
thus O
, O
acts O
downstream O
of O
eIF2 O
alpha O
; O
on O
the O
other O
hand O
, O
it O
can O
inhibit O
eucaryotic O
translation O
initiation O
factor O
2 O
alpha O
kinase O
2 O
( O
PKR O
) O
activation O
and O
the O
consequent O
PKR O
- O
mediated O
eIF2 O
alpha O
phosphorylation O
. O

Interestingly O
, O
coimmunostaining O
experiments O
revealed O
that O
PKR O
colocalizes O
with O
viral O
doublestranded B
RNA I
( I
dsRNA I
) I
in O
cells O
infected O
with O
L O
- O
mutant O
viruses O
but O
not O
in O
cells O
infected O
with O
the O
wild O
- O
type O
virus O
. O

IMPORTANCE O
The O
leader O
( O
L O
) O
protein O
encoded O
by O
cardioviruses O
is O
a O
very O
short O
multifunctional O
protein O
that O
contributes O
to O
evasion O
of O
the O
host O
innate O
immune O
response O
. O

Using O
Theiler O
' O
s O
virus O
as O
a O
model O
, O
we O
show O
that O
L O
proteins O
can O
act O
at O
two O
levels O
in O
the O
stress O
response O
pathway O
leading O
to O
stress O
granule O
formation O
, O
the O
most O
striking O
one O
being O
the O
inhibition O
of O
eucaryotic O
translation O
initiation O
factor O
2 O
alpha O
kinase O
2 O
( O
PKR O
) O
activation O
. O

The O
presence O
of O
these O
RNAs O
in O
the O
absence O
of O
overt O
central B
nervous I
system I
( I
CNS I
) I
disease O
has O
led O
to O
the O
suggestion O
that O
they O
are O
viral O
remnants O
, O
with O
little O
or O
no O
potential O
to O
reactivate O
. O

Robust O
recrudescence O
of O
viral O
transcription O
and O
protein O
synthesis O
occurs O
after O
experimental O
depletion O
of O
cells O
of O
the O
adaptive O
immune O
response O
and O
is O
associated O
with O
a O
loss O
of O
T O
resident O
memory O
( O
T O
- O
rm O
) O
lymphocytes O
within O
the O
brain O
. O

These O
RNAs O
are O
generally O
considered O
viral O
fossils O
, O
unlikely O
to O
contribute O
to O
central B
nervous I
system I
( I
CNS I
) I
disease O
. O

Using O
a O
mouse O
model O
of O
measles B
virus I
( I
MV I
) I
neuronal O
infection O
, O
we O
show O
that O
MV O
RNA O
is O
maintained O
in O
the O
CNS O
of O
infected O
mice O
long O
after O
acute O
control O
and O
in O
the O
absence O
of O
overt O
disease O
. O

Here O
we O
examined O
the O
role O
of O
a O
third O
sphingolipid O
, O
glucosylceramide O
, O
in O
influenza O
virus O
infection O
following O
clustered B
regularly I
interspaced I
short I
palindromic I
repeats I
with I
Cas9 I
( I
CRISPR I
- I
Cas9 I
) I
- O
mediated O
knockout B
( I
KO I
) I
of O
its O
metabolizing O
enzyme O
glucosylceramidase O
( O
GBA O
) O
. O

After O
confirming O
GBA O
knockout O
of O
HEK O
293 O
and O
A549 O
cells O
by O
both O
Western O
blotting O
and O
lipid O
mass O
spectrometry O
, O
we O
observed O
diminished O
infection O
in O
both O
KO O
cell O
lines O
by O
a O
PR8 O
( O
H1N1 O
) O
green B
fluorescent I
protein I
( I
GFP I
) I
reporter O
virus O
. O

To O
examine O
whether O
GBA O
is O
required O
for O
other O
enveloped O
viruses O
, O
we O
compared O
the O
results O
seen O
with O
entry O
mediated O
by O
the O
glycoproteins O
of O
Ebola O
virus O
, O
influenza O
virus O
, O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
, O
and O
measles O
virus O
in O
GBA O
knockout O
cells O
. O

As O
the O
virus O
studies O
suggested O
a O
general O
role O
for O
GBA O
along O
the O
endocytic O
pathway O
, O
we O
tested O
that O
hypothesis O
and O
found O
that O
trafficking O
of O
epidermal B
growth I
factor I
( I
EGF I
) I
to O
late O
endosomes O
and O
degradation O
of O
its O
receptor O
were O
impaired O
in O
GBA O
knockout O
cells O
. O

We O
also O
provide O
evidence O
that O
promotion O
of O
influenza O
virus O
entry O
by O
glucosylceramidase O
extends O
to O
other O
endosome O
- O
entering O
viruses O
and O
is O
due O
to O
a O
general O
requirement O
for O
this O
enzyme O
, O
and O
hence O
for O
optimal O
levels O
of O
glucosylceramide O
, O
for O
efficient O
trafficking O
of O
endogenous O
cargos O
, O
such O
as O
the O
epidermal B
growth I
factor I
( I
EGF I
) I
receptor O
, O
along O
the O
endocytic O
pathway O
. O

Retinoid O
( O
vitamin O
A O
) O
is O
an O
essential O
diet O
constituent O
that O
governs O
a O
broad O
range O
of O
biological O
processes O
. O

Its O
biologically O
active O
metabolite O
, O
all B
- I
trans I
retinoic I
acid I
( I
ATRA I
) I
, O
exhibits O
a O
potent O
antiviral O
property O
by O
enhancing O
both O
innate O
and O
adaptive O
antiviral O
immunity O
against O
a O
variety O
of O
viral O
pathogens O
, O
such O
as O
, O
but O
not O
limited O
to O
, O
HIV O
, O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
, O
and O
measles O
. O

Even O
though O
the O
hepatocyte O
is O
highly O
enriched O
with O
retinoid O
and O
its O
metabolite O
ATRA O
, O
it O
supports O
the O
establishment O
of O
efficient O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
. O

Here O
, O
we O
demonstrate O
the O
hepatocyte O
- O
specific O
cell O
- O
intrinsic O
mechanism O
by O
which O
ATRA O
exerts O
either O
a O
proviral O
or O
antiviral O
effect O
, O
depending O
on O
how O
it O
engages O
cellular B
retinoic I
acid I
binding I
proteins I
( I
CRABPs I
) I
. O

We O
found O
that O
the O
engagement O
of O
CRABP1 O
by O
ATRA O
potently O
supported O
viral O
infection O
by O
promoting O
the O
accumulation O
of O
lipid B
droplets I
( I
LDs I
) I
, O
which O
robustly O
enhanced O
the O
formation O
of O
a O
replication O
complex O
on O
the O
LD O
- O
associated O
endoplasmic B
reticulum I
( I
ER I
) I
membrane O
. O

The O
recent O
eradication O
of O
rinderpest B
virus I
( I
RPV I
) I
and O
the O
active O
campaigns O
for O
eradication O
of O
the O
human O
- O
specific O
measles B
virus I
( I
MeV I
) I
have O
raised O
significant O
concerns O
that O
the O
remaining O
morbilliviruses O
may O
emerge O
in O
so O
- O
called O
vacated O
ecological O
niches O
. O

Seeking O
to O
assess O
the O
zoonotic O
potential O
of O
non O
- O
human O
morbilliviruses O
within O
human O
populations O
, O
we O
found O
that O
peste B
des I
petits I
ruminants I
virus I
( I
PPRV I
) I
- O
the O
small O
- O
ruminant O
morbillivirus O
- O
is O
restricted O
at O
the O
point O
of O
entry O
into O
human O
cells O
due O
to O
deficient O
interactions O
with O
human O
SLAMF1 O
- O
the O
immune O
cell O
receptor O
for O
morbilliviruses O
. O

Using O
a O
structure O
- O
guided O
approach O
, O
we O
characterized O
a O
single O
amino O
acid O
change O
, O
mapping O
to O
the O
receptor O
- O
binding O
domain O
in O
the O
PPRV O
hemagglutinin B
( I
H I
) I
protein O
, O
which O
overcomes O
this O
restriction O
. O

Peste O
des O
petits O
ruminants O
( O
PPR O
) O
is O
a O
severe O
disease O
of O
goats O
and O
sheep O
that O
is O
widespread O
in O
Africa O
, O
the O
Middle O
East O
, O
and O
Asia O
. O

Several O
effective O
vaccines O
exist O
for O
the O
disease O
, O
based O
on O
attenuated O
strains O
of O
the O
virus O
( O
PPRV O
) O
that O
causes O
PPR O
. O

In O
addition O
, O
while O
the O
vaccine O
derived O
from O
PPRV O
/ O
Nigeria O
/ O
75 O
/ O
1 O
( O
N75 O
) O
is O
used O
in O
many O
countries O
, O
those O
developed O
in O
India O
have O
never O
been O
tested O
for O
their O
efficacy O
outside O
that O
country O
. O

We O
have O
studied O
the O
immune O
response O
in O
goats O
to O
vaccination O
with O
either O
N75 O
or O
the O
main O
Indian O
vaccine O
, O
which O
is O
based O
on O
isolate O
PPRV O
/ O
India O
/ O
Sungri O
/ O
96 O
( O
S96 O
) O
. O

While O
both O
vaccines O
induced O
comparable O
numbers O
of O
PPRV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
, O
S96 O
induced O
a O
higher O
number O
of O
CD4 O
( O
+ O
) O
T O
cells O
specifically O
responding O
to O
virus O
. O

The O
influenza B
A I
virus I
( I
IAV I
) I
M2 O
protein O
is O
a O
multifunctional O
protein O
with O
critical O
roles O
in O
virion O
entry O
, O
assembly O
, O
and O
budding O
. O

To O
determine O
the O
role O
of O
M2 O
protein O
apical O
targeting O
in O
IAV O
replication O
, O
a O
panel O
of O
M2 O
proteins O
with O
basolateral O
plasma O
membrane O
( O
M2 O
- O
Baso O
) O
or O
endoplasmic O
reticulum O
( O
M2 O
- O
ER O
) O
targeting O
sequences O
was O
generated O
. O

However O
, O
in O
primary O
human B
nasal I
epithelial I
cell I
( I
hNEC I
) I
cultures O
, O
viruses O
encoding O
M2 O
- O
Baso O
and O
M2 O
- O
ER O
replicated O
to O
negligible O
titers O
compared O
to O
those O
of O
wild O
- O
type O
virus O
. O

, O
measles O
virus O
[ O
MeV O
] O
and O
canine O
distemper O
virus O
[ O
CDV O
] O
) O
host O
cell O
entry O
is O
coordinated O
by O
two O
interacting O
envelope O
glycoproteins O
, O
namely O
, O
an O
attachment O
( O
H O
) O
protein O
and O
a O
fusion O
( O
F O
) O
protein O
. O

The O
role O
of O
the O
C O
- O
terminal O
module O
of O
the O
H O
- O
stalk O
domain O
( O
termed O
linker O
) O
and O
the O
connector O
, O
although O
putatively O
able O
to O
assume O
flexible O
structures O
and O
allow O
receptor O
- O
induced O
structural O
rearrangements O
, O
remains O
largely O
unexplored O
. O

Our O
data O
demonstrated O
that O
replacing O
isoleucine O
146 O
in O
H O
- O
linker O
( O
H O
- O
I146 O
) O
with O
any O
charged O
amino O
acids O
prevented O
virus O
- O
mediated O
membrane O
fusion O
activity O
, O
despite O
proper O
trafficking O
of O
the O
mutants O
to O
the O
cell O
surface O
and O
preserved O
binding O
efficiency O
to O
the O
SLAM O
/ O
CD150 O
receptor O
. O

Indeed O
, O
the O
neutral O
glycine O
mutant O
( O
H O
- O
I146G O
) O
, O
which O
exhibited O
strong O
covalent O
tetramerization O
propensity O
, O
maintained O
limited O
fusion O
promotion O
activity O
. O

Conversely O
, O
charged O
H O
- O
I146 O
mutants O
, O
which O
additionally O
carried O
alanine O
substitution O
of O
natural O
cysteines O
( O
H O
- O
C139A O
and O
H O
- O
C154A O
) O
and O
thus O
were O
unable O
to O
form O
covalently O
linked O
tetramers O
, O
were O
fusion O
activation O
defective O
. O

Cell O
entry O
is O
orchestrated O
by O
two O
interacting O
glycoproteins O
( O
H O
and O
F O
) O
. O

The O
current O
hypothesis O
postulates O
that O
tetrameric O
H O
ectodomains O
( O
composed O
of O
stalk O
, O
connector O
, O
and O
head O
domains O
) O
undergo O
receptor O
- O
induced O
rearrangements O
to O
productively O
trigger O
F O
; O
these O
conformational O
changes O
may O
be O
regulated O
by O
the O
H O
- O
stalk O
C O
- O
terminal O
module O
( O
linker O
) O
and O
the O
following O
connector O
domain O
. O

We O
found O
earlier O
that O
ectopic O
expression O
of O
the O
cytidine O
deaminase O
APOBEC3G B
( I
A3G I
) I
in O
Vero O
cells O
inhibits O
measles B
virus I
( I
MV I
) I
, O
respiratory O
syncytial O
virus O
, O
and O
mumps O
virus O
, O
while O
the O
mechanism O
of O
inhibition O
remained O
unclear O
. O

One O
of O
the O
most O
upregulated O
host O
cell O
factors O
, O
REDD1 O
( O
regulated O
in O
development O
and O
DNA O
damage O
response O
- O
1 O
, O
also O
called O
DDIT4 O
) O
, O
reduced O
MV O
replication O
similar O
to O
10 O
- O
fold O
upon O
overexpression O
in O
Vero O
cells O
. O

REDD1 O
is O
an O
endogenous O
inhibitor O
of O
mTORC1 O
( O
mammalian O
target O
of O
rapamycin O
complex O
- O
1 O
) O
, O
the O
central O
regulator O
of O
cellular O
metabolism O
. O

In O
primary O
human B
peripheral I
blood I
lymphocytes I
( I
PBL I
) I
, O
expression O
of O
A3G O
and O
REDD1 O
was O
found O
to O
be O
stimulated O
by O
phytohemagglutinin B
( I
PHA I
) I
and O
interleukin O
- O
2 O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
- O
mediated O
depletion O
of O
A3G O
in O
PHA O
- O
stimulated O
PBL O
reduced O
REDD1 O
expression O
and O
increased O
viral O
titers O
, O
which O
corroborates O
our O
findings O
in O
Vero O
cells O
. O

Upon O
infection O
, O
morbilliviruses O
such O
as O
measles O
virus O
, O
rinderpest O
virus O
, O
and O
canine B
distemper I
virus I
( I
CDV I
) I
initially O
target O
immune O
cells O
via O
the O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
before O
spreading O
to O
respiratory O
epithelia O
through O
the O
adherens O
junction O
protein O
nectin O
- O
4 O
. O

IMPORTANCE O
Morbilliviruses O
such O
as O
measles O
virus O
, O
rinderpest O
virus O
, O
and O
canine B
distemper I
virus I
( I
CDV I
) I
are O
highly O
contagious O
. O

In O
a O
ferret O
model O
of O
CDV O
contact O
transmission O
, O
we O
showed O
that O
sequential O
use O
of O
the O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
and O
nectin O
- O
4 O
receptors O
is O
essential O
for O
transmission O
. O

annexin B
A2 I
( I
ANXA2 I
) I
, O
a O
member O
of O
this O
family O
, O
has O
been O
implicated O
in O
a O
variety O
of O
cellular O
functions O
, O
including O
the O
organization O
of O
membrane O
domains O
, O
vesicular O
trafficking O
, O
and O
cell O
- O
cell O
adhesion O
. O

measles B
virus I
( I
MV I
) I
, O
a O
member O
of O
the O
family O
Paramyxoviridae O
, O
is O
an O
enveloped O
virus O
with O
a O
nonsegmented O
negative O
- O
strand O
RNA O
genome O
. O

In O
MV O
- O
infected O
, O
AnxA2 O
knockdown O
cells O
, O
the O
expression O
level O
of O
the O
matrix B
( I
M I
) I
protein O
, O
but O
not O
other O
viral O
proteins O
, O
was O
reduced O
compared O
with O
that O
in O
control O
cells O
, O
and O
the O
distribution O
of O
the O
M O
protein O
at O
the O
plasma O
membrane O
was O
decreased O
. O

These O
results O
indicate O
that O
AnxA2 O
mediates O
the O
localization O
of O
the O
MV O
M O
protein O
at O
the O
plasma O
membrane O
by O
interacting O
with O
its O
N O
- O
terminal O
region O
( O
especially O
residues O
at O
positions O
6 O
to O
10 O
) O
, O
thereby O
aiding O
in O
MV O
assembly O
. O

measles B
virus I
( I
MV I
) I
infection O
of O
immune O
cells O
is O
mediated O
by O
the O
cellular O
receptor O
CD150 O
, O
expressed O
by O
subsets O
of O
lymphocytes O
, O
dendritic O
cells O
, O
macrophages O
, O
and O
thymocytes O
. O

Furthermore O
, O
we O
assessed O
the O
susceptibility O
and O
permissiveness O
of O
various O
functionally O
distinct O
T O
and O
B O
cells O
, O
such O
as O
helper O
T O
( O
T O
- O
H O
) O
cell O
subsets O
and O
IgG O
- O
and O
IgA O
- O
positive O
memory O
B O
cells O
, O
in O
peripheral O
blood O
and O
tonsils O
. O

We O
demonstrated O
that O
T O
( O
H O
) O
1T O
( O
H O
) O
17 O
cells O
and O
plasma O
and O
germinal O
center O
B O
cells O
were O
the O
subsets O
most O
susceptible O
and O
permissive O
to O
MV O
infection O
. O

The O
paramyxovirus O
replication O
machinery O
comprises O
the O
viral O
large B
( I
L I
) I
protein O
and O
phosphoprotein O
( O
P O
- O
protein O
) O
in O
addition O
to O
the O
nucleocapsid B
( I
N I
) I
protein O
, O
which O
encapsidates O
the O
single O
- O
stranded O
RNA O
genome O
. O

Common O
to O
paramyxovirus O
N O
proteins O
is O
a O
C O
- O
terminal O
tail O
( O
Ntail O
) O
. O

Focusing O
initially O
on O
members O
of O
the O
Morbillivirus O
genus O
, O
a O
series O
of O
measles B
virus I
( I
MeV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
N O
proteins O
were O
generated O
with O
internal O
deletions O
in O
the O
unstructured O
tail O
section O
. O

IMPORTANCE O
Investigating O
the O
role O
of O
the O
paramyxovirus O
N O
protein O
tail O
domain O
( O
Ntail O
) O
in O
virus O
replication O
, O
we O
demonstrated O
in O
this O
study O
that O
the O
structurally O
disordered O
central O
Ntail O
region O
is O
a O
determinant O
for O
viral O
pathogenesis O
. O

We O
show O
that O
internal O
deletions O
in O
this O
Ntail O
region O
of O
up O
to O
55 O
amino O
acids O
in O
length O
are O
compatible O
with O
efficient O
replication O
of O
recombinant O
viruses O
in O
cell O
culture O
but O
result O
in O
gradual O
viral O
attenuation O
in O
a O
lethal O
canine B
distemper I
virus I
( I
CDV I
) I
/ O
ferret O
model O
. O

Using O
measles O
virus O
- O
infected O
HeLa O
cells O
, O
we O
found O
that O
the O
WD B
repeat I
- I
containing I
protein I
5 I
( I
WDR5 I
) I
, O
a O
subunit O
of O
histone O
H3 O
lysine O
4 O
methyltransferases O
, O
was O
selectively O
recruited O
to O
virus O
- O
induced O
inclusion O
bodies O
. O

Paramyxovirus O
V O
proteins O
are O
known O
antagonists O
of O
the O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
- O
mediated O
interferon O
induction O
pathway O
, O
interacting O
with O
and O
inhibiting O
the O
RLR O
MDA5 O
. O

These O
interactions O
are O
mediated O
by O
the O
conserved O
C O
- O
terminal O
domain O
of O
the O
V O
protein O
, O
which O
binds O
to O
the O
tandem O
caspase B
activation I
and I
recruitment I
domains I
( I
CARDs I
) I
of O
RIG O
- O
I O
( O
the O
region O
of O
TRIM25 O
ubiquitination O
) O
and O
to O
the O
SPRY O
domain O
of O
TRIM25 O
, O
which O
mediates O
TRIM25 O
interaction O
with O
the O
RIG O
- O
I O
CARDs O
. O

Human B
adenoviruses I
( I
HAdVs I
) I
are O
common O
human O
pathogens O
encoding O
a O
highly O
abundant O
histone O
- O
like O
core O
protein O
, O
VII O
, O
which O
is O
involved O
in O
nuclear O
delivery O
and O
protection O
of O
viral O
DNA O
as O
well O
as O
in O
sequestering O
immune O
danger O
signals O
in O
infected O
cells O
. O

IMPORTANCE O
Human B
adenoviruses I
( I
HAdVs I
) I
are O
common O
pathogens O
causing O
a O
wide O
range O
of O
diseases O
. O

The O
inhibitors O
carbobenzoxy O
( O
Z O
) O
- O
D O
- O
Phe O
- O
L O
- O
Phe O
- O
Gly O
( O
fusion O
inhibitor O
peptide O
[ O
FIP O
] O
) O
and O
4 O
- O
nitro O
- O
2 O
- O
phenylacetyl O
amino O
- O
benzamide O
( O
AS O
- O
48 O
) O
have O
similar O
efficacies O
in O
blocking O
membrane O
fusion O
and O
syncytium O
formation O
mediated O
by O
measles B
virus I
( I
MeV I
) I
. O

These O
10 O
mutations O
were O
localized O
to O
the O
heptad B
repeat I
B I
( I
HRB I
) I
region O
of O
the O
fusion O
protein O
, O
and O
no O
changes O
were O
observed O
in O
the O
viral O
hemagglutinin O
, O
which O
is O
the O
receptor O
attachment O
protein O
. O

Escape O
mutations O
were O
mapped O
upon O
a O
three B
- I
dimensional I
( I
3D I
) I
structure O
modeled O
from O
the O
published O
crystal O
structure O
of O
parainfluenzavirus O
5 O
fusion O
protein O
. O

IMPORTANCE O
Due O
to O
lapses O
in O
vaccination O
worldwide O
that O
have O
caused O
localized O
outbreaks O
, O
measles B
virus I
( I
MeV I
) I
has O
regained O
importance O
as O
a O
pathogen O
. O

Three O
decades O
ago O
, O
the O
small O
hydrophobic O
peptide O
Z O
- O
D O
- O
Phe O
- O
L O
- O
Phe O
- O
Gly O
( O
FIP O
) O
was O
shown O
to O
block O
MeV O
infections O
and O
syncytium O
formation O
in O
monkey O
kidney O
cell O
lines O
. O

Attenuated O
measles B
virus I
( I
MV I
) I
is O
one O
of O
the O
most O
effective O
and O
safe O
vaccines O
available O
, O
making O
it O
an O
attractive O
candidate O
vector O
for O
preventing O
other O
infectious O
diseases O
. O

MV O
vaccine O
strains O
have O
different O
type B
I I
interferon I
( I
IFN I
) I
inducing O
abilities O
that O
partially O
depend O
on O
the O
presence O
of O
5 O
= O
copy O
- O
back O
defective O
interfering O
genomes O
( O
DI O
- O
RNAs O
) O
. O

DI O
- O
RNAs O
are O
pathogen O
- O
associated O
molecular O
patterns O
recognized O
by O
RIG B
- I
I I
- I
like I
receptors I
( I
RLRs I
) I
( O
RIG O
- O
I O
, O
MDA5 O
, O
and O
LGP2 O
) O
that O
activate O
innate O
immune O
signaling O
and O
shape O
the O
adaptive O
immune O
response O
. O

In O
this O
study O
, O
we O
characterized O
the O
DI O
- O
RNAs O
produced O
by O
various O
modified O
recombinant B
MVs I
( I
rMVs I
) I
, O
including O
vaccine O
candidates O
, O
as O
well O
as O
wild O
- O
type O
MV O
. O

IMPORTANCE O
Having O
been O
administered O
to O
hundreds O
of O
millions O
of O
children O
, O
the O
live O
attenuated O
measles B
virus I
( I
MV I
) I
vaccine O
is O
the O
safest O
and O
most O
widely O
used O
human O
vaccine O
, O
providing O
high O
protection O
with O
long O
- O
term O
memory O
. O

Paramyxoviruses O
rely O
on O
the O
matrix B
( I
M I
) I
protein O
to O
orchestrate O
viral O
assembly O
and O
budding O
at O
the O
plasma O
membrane O
. O

To O
gain O
functional O
insights O
, O
we O
employed O
a O
structure O
- O
guided O
mutagenesis O
approach O
to O
investigate O
the O
role O
of O
canine B
distemper I
virus I
( I
CDV I
) I
M O
protein O
self O
- O
assembly O
in O
membrane O
- O
budding O
activity O
. O

Three O
six O
- O
alanine O
- O
block O
( O
6A O
- O
block O
) O
mutants O
with O
mutations O
located O
at O
strategic O
oligomeric O
positions O
were O
initially O
designed O
. O

We O
further O
focused O
on O
the O
core O
of O
the O
dimeric O
interface O
by O
mutating O
asparagine O
138 O
( O
N138 O
) O
to O
several O
nonconservative O
amino O
acids O
. O

These O
phenotypes O
correlated O
with O
deficiencies O
in O
relocating O
CDV O
nucleocapsid O
proteins O
to O
the O
cell O
periphery O
and O
in O
virus B
- I
like I
particle I
( I
VLP I
) I
production O
. O

IMPORTANCE O
Despite O
the O
availability O
of O
effective O
vaccines O
, O
both O
measles B
virus I
( I
MeV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
still O
lead O
to O
significant O
human O
and O
animal O
mortality O
worldwide O
. O

Targeting O
the O
matrix B
( I
M I
) I
protein O
of O
MeV O
/ O
CDV O
is O
attractive O
, O
because O
M O
coordinates O
viral O
assembly O
and O
egress O
through O
interaction O
with O
multiple O
cellular O
and O
viral O
components O
. O

Here O
we O
combined O
structure O
- O
guided O
mutagenesis O
with O
cellular O
, O
biochemical O
, O
and O
functional O
assays O
to O
investigate O
a O
potential O
correlation O
between O
CDV O
M O
self O
- O
assembly O
and O
virus B
- I
like I
particle I
( I
VLP I
) I
formation O
. O

In O
addition O
to O
humans O
, O
only O
certain O
nonhuman O
primates O
are O
naturally O
susceptible O
to O
measles B
virus I
( I
MeV I
) I
infection O
. O

To O
investigate O
if O
squirrel O
monkeys O
( O
Saimiri O
sciureus O
) O
, O
which O
are O
reported O
to O
develop O
a O
course O
of O
disease O
similar O
to O
humans O
, O
may O
be O
better O
suited O
than O
macaques O
for O
the O
identification O
of O
virulence O
determinants O
or O
the O
evaluation O
of O
therapeutics O
, O
we O
infected O
them O
with O
a O
green O
fluorescent O
protein O
- O
expressing O
MeV O
. O

Compared O
to O
cynomolgus O
macaques O
( O
Macaca O
fascicularis O
) O
infected O
with O
the O
same O
virus O
, O
the O
squirrel O
monkeys O
developed O
more O
- O
severe O
immunosuppression O
, O
higher O
viral O
load O
, O
and O
a O
broader O
range O
of O
clinical O
signs O
typical O
for O
measles O
. O

Here O
, O
we O
report O
that O
infection O
of O
squirrel O
monkeys O
( O
Saimiri O
sciureus O
) O
fulfills O
these O
requirements O
. O

The O
measles B
virus I
hemagglutinin I
( I
MeV I
- I
H I
) I
protein O
is O
the O
main O
target O
of O
protective O
neutralizing O
antibodies O
. O

Using O
a O
panel O
of O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
recognize O
known O
major O
antigenic O
sites O
in O
MeV O
- O
H O
, O
we O
identified O
a O
D4 O
genotype O
variant O
that O
escapes O
neutralization O
by O
MAbs O
targeting O
the O
neutralizing B
epitope I
( I
NE I
) I
antigenic O
site O
. O

2 O
, O
this O
virus O
is O
distinguishable O
by O
neutralization O
with O
vaccine O
- O
induced O
monoclonal O
antibodies O
that O
target O
the O
neutralizing B
epitope I
( I
NE I
) I
. O

measles B
virus I
( I
MeV I
) I
is O
a O
member O
of O
the O
family O
Paramixoviridae O
that O
causes O
a O
highly O
contagious O
respiratory O
disease O
but O
has O
emerged O
as O
a O
promising O
oncolytic O
platform O
. O

The O
contribution O
of O
each O
endocytic O
pathway O
has O
been O
examined O
in O
cells O
that O
express O
the O
MeV O
receptors O
SLAM O
( O
signaling O
lymphocyteactivating O
molecule O
) O
and O
PVRL4 O
( O
poliovirus O
receptor O
- O
like O
4 O
) O
( O
nectin O
- O
4 O
) O
. O

However O
, O
MeV O
infection O
was O
blocked O
by O
5 O
- O
( O
N O
- O
ethyl O
- O
N O
- O
propyl O
) O
amiloride O
( O
EIPA O
) O
, O
the O
hallmark O
inhibitor O
of O
macropinocytosis O
, O
as O
well O
as O
inhibitors O
of O
actin O
polymerization O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
p21 B
- I
activated I
kinase I
1 I
( I
PAK1 I
) I
demonstrated O
that O
MeV O
enters O
both O
Vero O
. O

IMPORTANCE O
In O
the O
past O
decades O
, O
measles B
virus I
( I
MeV I
) I
has O
emerged O
as O
a O
promising O
oncolytic O
platform O
. O

Nectin O
- O
4 O
( O
PVRL4 O
) O
was O
recently O
identified O
as O
the O
epithelial O
cell O
receptor O
for O
MeV O
. O

Both O
canine B
distemper I
virus I
( I
CDV I
) I
and O
rabies B
virus I
( I
RABV I
) I
cause O
lethal O
disease O
in O
wild O
and O
domestic O
carnivores O
. O

IMPORTANCE O
Rabies O
virus O
and O
canine B
distemper I
virus I
( I
CDV I
) I
cause O
high O
mortality O
rates O
and O
death O
in O
many O
carnivores O
. O

The O
signaling B
lymphocyte I
activation I
molecule I
F1 I
( I
SLAMF1 I
) I
is O
both O
a O
microbial O
sensor O
and O
entry O
receptor O
for O
measles B
virus I
( I
MeV I
) I
. O

Paramyxoviral O
RNAs O
are O
synthesized O
by O
a O
viral O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
consisting O
of O
the O
large B
( I
L I
) I
protein O
and O
its O
cofactor O
phosphoprotein B
( I
P I
protein I
) I
. O

Growing O
evidence O
shows O
that O
the O
stability O
of O
several O
paramyxovirus O
L O
proteins O
is O
regulated O
by O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
. O

In O
this O
study O
, O
we O
demonstrated O
that O
Hsp90 O
activity O
was O
important O
for O
mumps B
virus I
( I
MuV I
) I
replication O
. O

The O
Hsp90 O
activity O
was O
required O
for O
L O
- O
protein O
stability O
and O
activity O
because O
an O
Hsp90 O
- O
specific O
inhibitor O
, O
17 B
- I
allylamino I
- I
17 I
- I
demethoxygeldanamycin I
( I
17 I
- I
AAG I
) I
, O
destabilized O
the O
MuV O
L O
protein O
and O
suppressed O
viral O
RNA O
synthesis O
. O

When O
the O
Hsp90 O
activity O
was O
inhibited O
, O
the O
MuV O
L O
protein O
was O
degraded O
through O
the O
CHIP O
( O
C O
terminus O
of O
Hsp70 O
- O
interactingprotein O
) O
- O
mediated O
proteasomal O
pathway O
. O

IMPORTANCE O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
is O
nearly O
universally O
required O
for O
viral O
protein O
homeostasis O
. O

Here O
, O
we O
report O
that O
Hsp90 O
activity O
is O
required O
for O
efficient O
propagation O
of O
mumps B
virus I
( I
MuV I
) I
. O

Hsp90 O
functions O
in O
the O
maintenance O
of O
the O
catalytic O
subunit O
of O
viral O
polymerase O
, O
the O
large B
( I
L I
) I
protein O
, O
prior O
to O
formation O
of O
a O
mature O
polymerase O
complex O
with O
the O
polymerase O
cofactor O
of O
L O
, O
phosphoprotein O
. O

measles B
virus I
( I
MV I
) I
infection O
is O
undergoing O
resurgence O
and O
remains O
one O
of O
the O
leading O
causes O
of O
death O
among O
young O
children O
worldwide O
despite O
the O
availability O
of O
an O
effective O
measles O
vaccine O
. O

MV O
infects O
its O
target O
cells O
by O
coordinated O
action O
of O
the O
MV O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
envelope O
glycoproteins O
; O
upon O
receptor O
engagement O
by O
H O
, O
the O
prefusion O
F O
undergoes O
a O
structural O
transition O
, O
extending O
and O
inserting O
into O
the O
target O
cell O
membrane O
and O
then O
refolding O
into O
a O
postfusion O
structure O
that O
fuses O
the O
viral O
and O
cell O
membranes O
. O

By O
interfering O
with O
this O
structural O
transition O
of O
F O
, O
peptides O
derived O
from O
the O
heptad B
repeat I
( I
HR I
) I
regions O
of O
F O
can O
inhibit O
MV O
infection O
at O
the O
entry O
stage O
. O

IMPORTANCE O
measles B
virus I
( I
MV I
) I
infection O
causes O
an O
acute O
illness O
that O
may O
be O
associated O
with O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
severe O
neurological O
disease O
. O

Marburg B
virus I
( I
MARV I
) I
is O
a O
highly O
pathogenic O
filovirus O
that O
is O
classified O
in O
a O
genus O
distinct O
from O
that O
of O
Ebola B
virus I
( I
EBOV I
) I
( O
genera O
Marburgvirus O
and O
Ebolavirus O
, O
respectively O
) O
. O

VP35 O
oligomerizes O
( O
self O
- O
assembles O
) O
in O
order O
to O
function O
, O
yet O
the O
structure O
by O
which O
it O
assembles O
has O
not O
been O
visualized O
. O

In O
the O
current O
study O
, O
we O
generated O
recombinant O
chimeric O
canine B
distemper I
viruses I
( I
CDVs I
) I
by O
replacing O
the O
hemagglutinin B
( I
H I
) I
and O
/ O
or O
phosphoprotein B
( I
P I
) I
gene O
in O
an O
avirulent O
strain O
expressing O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
with O
those O
of O
a O
mouse O
- O
adapted O
neurovirulent O
strain O
. O

These O
cells O
lack O
the O
CDV O
receptors O
that O
have O
been O
identified O
to O
date O
( O
SLAM O
and O
nectin O
- O
4 O
) O
, O
indicating O
that O
the O
H O
protein O
defines O
infectivity O
in O
various O
cell O
lines O
. O

Fusion O
is O
orchestrated O
by O
the O
receptor O
binding O
protein O
hemagglutinin O
- O
neuraminidase O
( O
HN O
; O
also O
called O
H O
or O
G O
depending O
on O
the O
virus O
type O
) O
protein O
and O
a O
fusion O
( O
F O
) O
protein O
, O
the O
latter O
undergoing O
a O
major O
refolding O
process O
to O
merge O
the O
two O
membranes O
. O

Proline O
substitution O
in O
this O
region O
of O
HN O
of O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
and O
Newcastle O
disease O
virus O
HN O
abolishes O
cell O
- O
cell O
fusion O
, O
whereas O
HN O
retains O
receptor O
binding O
and O
neuraminidase O
activity O
. O

Membrane O
fusion O
is O
orchestrated O
via O
interaction O
of O
the O
receptor O
binding O
protein O
( O
HN O
, O
H O
, O
or O
G O
) O
with O
the O
viral O
fusion O
glycoprotein O
( O
F O
) O
. O

Immune O
cells O
within O
the O
airways O
are O
likely O
first O
targets O
of O
infection O
, O
and O
these O
cells O
traffic O
measles B
virus I
( I
MeV I
) I
to O
lymph O
nodes O
for O
amplification O
and O
subsequent O
systemic O
dissemination O
. O

To O
investigate O
this O
process O
, O
we O
collected O
blood O
from O
human O
donors O
and O
generated O
primary O
myeloid O
cells O
, O
specifically O
, O
monocyte B
- I
derived I
macrophages I
( I
MDMs I
) I
and O
dendritic B
cells I
( I
DCs I
) I
. O

MDMs O
and O
DCs O
were O
infected O
with O
MeV O
and O
then O
applied O
to O
primary O
cultures O
of O
well O
- O
differentiated O
airway O
epithelial O
cells O
from O
human O
donors O
( O
HAE O
) O
. O

Our O
studies O
are O
based O
on O
two O
types O
of O
human O
primary O
cells O
: O
( O
i O
) O
myeloid O
cells O
generated O
from O
donated O
blood O
and O
( O
ii O
) O
well O
- O
differentiated O
airway O
epithelial O
cells O
derived O
from O
donor O
lungs O
. O

These O
partners O
have O
coevolved O
with O
the O
acquisition O
of O
the O
permanent O
encapsidation O
of O
the O
entire O
genome O
by O
the O
nucleoprotein B
( I
N I
) I
and O
the O
use O
of O
this O
N O
- O
RNA O
complex O
as O
a O
template O
for O
the O
viral O
polymerase O
composed O
of O
the O
phosphoprotein B
( I
P I
) I
and O
the O
large O
enzymatic O
protein O
( O
L O
) O
. O

By O
using O
NVP O
- O
AUY922 O
and O
/ O
or O
17 O
- O
dimethylaminoethylamino O
- O
17 O
- O
demethoxygeldanamycin O
as O
specific O
inhibitors O
of O
cellular O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
, O
we O
found O
that O
efficient O
chaperoning O
of O
L O
by O
HSP90 O
requires O
P O
in O
the O
measles O
, O
Nipah O
, O
and O
vesicular O
stomatitis O
viruses O
. O

We O
report O
here O
that O
for O
measles O
virus O
, O
successful O
chaperoning O
of O
the O
viral O
L O
polymerase O
mediated O
by O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
requires O
the O
presence O
of O
the O
viral O
phosphoprotein B
( I
P I
) I
. O

Although O
rinderpest B
virus I
( I
RPV I
) I
has O
been O
eradicated O
in O
the O
wild O
, O
efforts O
are O
still O
continuing O
to O
restrict O
the O
extent O
to O
which O
live O
virus O
is O
distributed O
in O
facilities O
around O
the O
world O
and O
to O
prepare O
for O
any O
reappearance O
of O
the O
disease O
, O
whether O
through O
deliberate O
or O
accidental O
release O
. O

In O
an O
effort O
to O
find O
an O
alternative O
vaccine O
which O
could O
be O
used O
in O
place O
of O
the O
traditional O
live O
attenuated O
RPV O
strains O
, O
we O
have O
determined O
whether O
cattle O
can O
be O
protected O
from O
rinderpest O
by O
inoculation O
with O
vaccine O
strains O
of O
the O
related O
morbillivirus O
, O
peste B
des I
petits I
ruminants I
virus I
( I
PPRV I
) I
. O

Nipah B
virus I
( I
NiV I
) I
causes O
fatal O
encephalitic O
infections O
in O
humans O
. O

To O
characterize O
the O
role O
of O
the O
matrix B
( I
M I
) I
protein O
in O
the O
viral O
life O
cycle O
, O
we O
generated O
a O
reverse O
genetics O
system O
based O
on O
NiV O
strain O
Malaysia O
. O

Using O
an O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
- O
expressing O
M O
protein O
- O
deleted O
NiV O
, O
we O
observed O
a O
slightly O
increased O
cell O
- O
cell O
fusion O
, O
slow O
replication O
kinetics O
, O
and O
significantly O
reduced O
peak O
titers O
compared O
to O
the O
parental O
virus O
. O

Therefore O
, O
these O
viruses O
can O
be O
studied O
only O
in O
bio B
- I
safety I
level I
4 I
( I
BSL I
- I
4 I
) I
laboratories O
, O
making O
it O
more O
challenging O
to O
characterize O
their O
life O
cycle O
. O

The O
enveloped O
negative O
- O
stranded O
RNA O
virus O
measles B
virus I
( I
MeV I
) I
is O
an O
important O
human O
pathogen O
. O

The O
nucleoprotein O
( O
N O
- O
0 O
) O
assembles O
with O
the O
viral O
RNA O
into O
helical O
ribonucleocapsids O
( O
NC O
) O
which O
are O
, O
in O
turn O
, O
coated O
by O
a O
helical O
layer O
of O
the O
matrix O
protein O
. O

The O
N O
- O
0 O
assembly O
onto O
the O
NC O
and O
the O
activity O
of O
the O
polymerase O
are O
regulated O
by O
the O
viral O
phosphoprotein B
( I
P I
) I
. O

In O
this O
study O
, O
we O
pulled O
down O
an O
N O
- O
1 O
- O
408 O
( O
0 O
) O
fragment O
lacking O
most O
of O
its O
C O
- O
terminal O
tail O
domain O
by O
several O
affinity O
- O
tagged O
, O
N O
- O
terminal O
P O
fragments O
to O
map O
the O
N O
- O
0 O
- O
binding O
region O
of O
P O
to O
the O
first O
48 O
amino O
acids O
. O

We O
fused O
an O
N O
- O
0 O
binding O
peptide O
, O
P1 O
- O
48 O
, O
to O
the O
C O
terminus O
of O
an O
N O
- O
21 O
- O
408 O
( O
0 O
) O
fragment O
lacking O
both O
the O
N O
- O
terminal O
peptide O
and O
the O
C O
- O
terminal O
tail O
of O
N O
protein O
to O
reconstitute O
and O
crystallize O
the O
N O
- O
0 O
- O
P O
complex O
. O

In O
this O
study O
, O
we O
report O
on O
the O
activation O
of O
type B
I I
interferon I
( I
IFN I
) I
production O
by O
a O
Defective B
interfering I
( I
DI I
) I
RNA O
isolated O
from O
the O
Hu O
- O
191 O
vaccine O
strain O
of O
measles O
virus O
. O

measles B
virus I
( I
MeV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
possess O
tetrameric O
attachment O
proteins O
( O
H O
) O
and O
trimeric O
fusion O
proteins O
, O
which O
cooperate O
with O
either O
SLAM O
or O
nectin O
4 O
receptors O
to O
trigger O
membrane O
fusion O
for O
cell O
entry O
. O

In O
one O
of O
the O
conformations O
, O
two O
SLAM O
units O
were O
sandwiched O
between O
two O
discrete O
H O
head O
domains O
, O
thus O
spotlighting O
two O
binding O
interfaces O
( O
front O
and O
back O
) O
. O

While O
alanine O
- O
scanning O
mutagenesis O
identified O
five O
critical O
regulatory O
residues O
in O
the O
front O
H O
- O
binding O
site O
of O
SLAM O
, O
the O
replacement O
of O
a O
conserved O
glutamate O
residue O
( O
E O
at O
position O
123 O
, O
replaced O
with O
A O
[ O
E123A O
] O
) O
led O
to O
the O
most O
pronounced O
impact O
on O
fusion O
promotion O
. O

However O
, O
our O
data O
additionally O
support O
the O
hypothesis O
that O
other O
microdomain O
( O
s O
) O
of O
both O
glycoproteins O
( O
including O
the O
back O
H O
- O
binding O
site O
) O
might O
be O
required O
to O
achieve O
fully O
productive O
H O
- O
SLAM O
interactions O
. O

Paramyxoviruses O
include O
several O
insidious O
and O
ubiquitous O
pathogens O
of O
humans O
and O
animals O
, O
with O
measles B
virus I
( I
MeV I
) I
being O
a O
prominent O
one O
. O

The O
MeV O
membrane O
fusion O
apparatus O
consists O
of O
a O
receptor O
binding O
protein O
( O
hemagglutinin O
[ O
H O
] O
) O
tetramer O
and O
a O
fusion O
( O
F O
) O
protein O
trimer O
. O

The O
genome O
of O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
a O
prototypical O
paramyxovirus O
, O
encodes O
a O
V O
protein O
that O
inhibits O
viral O
RNA O
synthesis O
. O

Both O
regions O
interact O
with O
the O
nucleocapsid B
protein I
( I
NP I
) I
, O
an O
essential O
component O
of O
the O
viral O
RNA O
genome O
complex O
( O
RNP O
) O
. O

Interestingly O
, O
V O
also O
inhibited O
the O
synthesis O
of O
the O
RNA O
of O
other O
paramyxoviruses O
, O
such O
as O
Nipah B
virus I
( I
NiV I
) I
, O
human B
parainfluenza I
virus I
3 I
( I
HPIV3 I
) I
, O
measles B
virus I
( I
MeV I
) I
, O
mumps B
virus I
( I
MuV I
) I
, O
and O
respiratory B
syncytial I
virus I
( I
RSV I
) I
. O

mumps B
virus I
( I
MuV I
) I
is O
an O
airborne O
virus O
that O
causes O
a O
systemic O
infection O
in O
patients O
. O

In O
polarized O
cells O
, O
intracellular O
transport O
of O
viral B
ribonucleoprotein I
( I
vRNP I
) I
complexes O
was O
dependent O
on O
Rab11 O
- O
positive O
endosomes O
, O
and O
vRNP O
complexes O
were O
transported O
to O
the O
apical O
membrane O
. O

Expression O
of O
a O
dominant O
negative O
form O
of O
Rab11 O
( O
Rab11S25N O
) O
reduced O
the O
progeny O
virus O
release O
in O
polarized O
cells O
but O
not O
in O
nonpolarized O
cells O
. O

IMPORTANCE O
mumps B
virus I
( I
MuV I
) I
is O
the O
etiological O
agent O
of O
mumps O
and O
causes O
a O
systemic O
infection O
. O

The O
mumps B
virus I
( I
MuV I
) I
genome O
encodes O
a O
phosphoprotein B
( I
P I
) I
that O
is O
important O
for O
viral O
RNA O
synthesis O
. O

P O
forms O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
with O
the O
large B
protein I
( I
L I
) I
. O

P O
also O
interacts O
with O
the O
viral O
nucleoprotein B
( I
NP I
) I
and O
self O
- O
associates O
to O
form O
a O
homotetramer O
. O

The O
P O
protein O
consists O
of O
three O
domains O
, O
the O
N O
- O
terminal O
domain O
( O
P O
- O
N O
) O
, O
the O
oligomerization O
domain O
( O
P O
- O
O O
) O
, O
and O
the O
C O
- O
terminal O
domain O
( O
P O
- O
C O
) O
. O

Using O
this O
trans O
- O
complementation O
system O
, O
we O
found O
that O
P O
forms O
parallel O
dimers O
( O
P O
- O
N O
to O
P O
- O
N O
and O
P O
- O
C O
to O
P O
- O
C O
) O
. O

In O
permissive O
mouse O
central B
nervous I
system I
( I
CNS I
) I
neurons O
, O
measles B
virus I
( I
MV I
) I
spreads O
in O
the O
absence O
of O
hallmark O
viral O
budding O
or O
neuronal O
death O
, O
with O
transmission O
occurring O
efficiently O
and O
exclusively O
via O
the O
synapse O
. O

MV O
infection O
also O
initiates O
a O
robust O
type B
I I
interferon I
( I
IFN I
) I
response O
, O
resulting O
in O
the O
synthesis O
of O
a O
large O
number O
of O
genes O
, O
including O
bone B
marrow I
stromal I
antigen I
2 I
( I
Bst2 I
) I
/ O
tetherin O
/ O
CD317 O
. O

The O
magnitude O
of O
induction O
of O
neuronal O
Bst2 O
RNA O
and O
protein O
following O
IFN O
exposure O
and O
viral O
infection O
was O
notably O
higher O
than O
in O
similarly O
treated O
mouse B
embryo I
fibroblasts I
( I
MEFs I
) I
. O

Here O
we O
identify O
type O
I O
interferon O
signaling O
as O
a O
key O
inducer O
of O
a O
known O
antiviral O
protein O
( O
Bst2 O
) O
in O
neurons O
. O

In O
measles B
virus I
( I
MV I
) I
- O
infected O
cells O
, O
the O
ribonucleoprotein B
( I
RNP I
) I
complex O
, O
comprised O
of O
the O
viral O
genome O
and O
the O
nucleocapsid B
( I
N I
) I
protein O
, O
phosphoprotein B
( I
P I
protein I
) I
, O
and O
large O
protein O
, O
assembles O
at O
the O
perinuclear O
region O
and O
synthesizes O
viral O
RNAs O
. O

IMPORTANCE O
Many O
RNA O
viruses O
induce O
within O
infected O
cells O
the O
structure O
called O
the O
ribonucleoprotein B
( I
RNP I
) I
complex O
in O
which O
viral O
RNA O
synthesis O
occurs O
. O

In O
this O
report O
, O
we O
show O
that O
cofilin O
, O
an O
actin O
- O
modulating O
host O
protein O
, O
binds O
to O
the O
measles B
virus I
( I
MV I
) I
nucleocapsid O
protein O
and O
plays O
an O
important O
role O
in O
the O
formation O
of O
the O
MV O
RNP O
complex O
and O
MV O
RNA O
synthesis O
. O

measles B
virus I
( I
MeV I
) I
causes O
several O
unique O
syndromes O
, O
including O
transient O
immunosuppression O
. O

MeV O
infection O
inactivated O
cellular O
protein B
phosphatase I
5 I
( I
PP5 I
) I
that O
consequently O
inactivated O
DNA O
- O
dependent O
protein O
kinase O
, O
which O
reduced O
Sp1 O
phosphorylation O
levels O
, O
and O
c O
- O
Myc O
degradation O
, O
both O
of O
which O
downregulated O
the O
expression O
of O
many O
housekeeping O
genes O
. O

IMPORTANCE O
measles B
virus I
( I
MeV I
) I
is O
one O
of O
the O
most O
important O
pathogens O
in O
humans O
. O

By O
examining O
this O
phenomenon O
, O
we O
clarified O
the O
molecular O
mechanism O
underlying O
the O
constitutive O
expression O
of O
housekeeping O
genes O
in O
cells O
, O
which O
is O
maintained O
by O
cellular O
protein B
phosphatase I
5 I
( I
PP5 I
) I
and O
DNA O
- O
dependent O
protein O
kinase O
. O

To O
induce O
and O
trigger O
innate O
and O
adaptive O
immune O
responses O
, O
antigen B
- I
presenting I
cells I
( I
APCs I
) I
take O
up O
and O
process O
antigens O
. O

Here O
, O
we O
demonstrate O
the O
capacity O
of O
lentiviral O
protein O
transfer O
vectors O
( O
PTVs O
) O
for O
targeted O
antigen O
transfer O
directly O
into O
APCs O
and O
thereby O
induction O
of O
cytotoxic O
T O
cell O
responses O
. O

Targeting O
of O
lentiviral O
PTVs O
to O
APCs O
can O
be O
achieved O
analogously O
to O
gene O
transfer O
vectors O
by O
pseudotyping O
the O
particles O
with O
truncated O
wild O
- O
type O
measles B
virus I
( I
MV I
) I
glycoproteins I
( I
GPs I
) I
, O
which O
use O
human O
SLAM B
( I
signaling I
lymphocyte I
activation I
molecule I
) I
as O
a O
main O
entry O
receptor O
. O

SLAM O
- O
targeted O
PTVs O
transferred O
the O
reporter O
protein O
green B
fluorescent I
protein I
( I
GFP I
) I
or O
Cre O
recombinase O
with O
strict O
receptor O
specificity O
into O
SLAM O
- O
expressing O
CHO O
and O
B O
cell O
lines O
, O
in O
contrast O
to O
broadly O
transducing O
vesicular B
stomatitis I
virus I
G I
protein I
( I
VSV I
- I
G I
) I
pseudotyped O
PTVs O
. O

Primary O
myeloid B
dendritic I
cells I
( I
mDCs I
) I
incubated O
with O
targeted O
or O
nontargeted O
ovalbumin B
( I
OVA I
) I
- O
transferring O
PTVs O
stimulated O
Ova O
- O
specific O
T O
lymphocytes O
, O
especially O
CD8 O
( O
+ O
) O
T O
cells O
. O

Administration O
of O
Ova O
- O
PTVs O
into O
SLAM O
- O
transgenic O
and O
control O
mice O
confirmed O
the O
observed O
predominant O
induction O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
and O
demonstrated O
the O
capacity O
of O
protein O
transfer O
vectors O
as O
suitable O
vaccines O
for O
the O
induction O
of O
antigen O
- O
specific O
immune O
responses O
. O

The O
observed O
predominant O
activation O
of O
antigen O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
indicates O
the O
suitability O
of O
SLAM O
- O
targeted O
and O
also O
nontargeted O
PTVs O
as O
a O
vaccine O
for O
the O
induction O
of O
cytotoxic O
immune O
responses O
. O

Since O
cytotoxic O
CD8 O
( O
+ O
) O
T O
lymphocytes O
are O
a O
mainstay O
of O
antitumoral O
immune O
responses O
, O
PTVs O
could O
be O
engineered O
for O
the O
transfer O
of O
specific O
tumor O
antigens O
provoking O
tailored O
antitumoral O
immunity O
. O

Defective B
interfering I
RNAs I
( I
DI I
- I
RNAs I
) I
of O
the O
viral O
genome O
can O
form O
during O
infections O
of O
negative O
- O
strand O
RNA O
viruses O
and O
outgrow O
full O
- O
length O
viral O
genomes O
, O
thereby O
modulating O
the O
severity O
and O
duration O
of O
infection O
. O

Here O
we O
document O
the O
frequent O
de O
novo O
generation O
of O
copy O
- O
back O
DI O
- O
RNAs O
from O
independent O
rescue O
events O
both O
for O
a O
vaccine O
measles O
virus O
( O
vac2 O
) O
and O
for O
a O
wildtype O
measles O
virus O
( O
IC323 O
) O
as O
early O
as O
passage O
1 O
after O
virus O
rescue O
. O

Moreover O
, O
vaccine O
and O
wild O
- O
type O
C O
- O
protein O
- O
deficient O
( O
C O
- O
protein O
- O
knockout O
[ O
C O
- O
KO O
] O
) O
measles O
viruses O
generated O
about O
10 O
times O
more O
DI O
- O
RNAs O
than O
parental O
virus O
, O
suggesting O
that O
C O
enhances O
the O
processivity O
of O
the O
viral O
polymerase O
. O

Sequences O
flanking O
these O
mutation O
sites O
were O
characteristic O
of O
those O
favored O
by O
adenosine B
deaminase I
acting I
on I
RNA I
- I
1 I
( I
ADAR1 I
) I
, O
which O
catalyzes O
in O
double O
- O
stranded O
RNA O
the O
C O
- O
6 O
deamination O
of O
adenosine O
to O
produce O
inosine O
, O
which O
is O
recognized O
as O
guanosine O
, O
a O
process O
known O
as O
A O
- O
to O
- O
I O
RNA O
editing O
. O

IMPORTANCE O
Recombinant O
measles B
viruses I
( I
MVs I
) I
are O
in O
clinical O
trials O
as O
cancer O
therapeutics O
and O
as O
vectored O
vaccines O
for O
HIV O
- O
AIDS O
and O
other O
infectious O
diseases O
. O

Here O
we O
document O
that O
copy O
- O
back O
Defective B
interfering I
RNAs I
( I
DI I
- I
RNAs I
) I
are O
generated O
by O
recombinant O
vaccine O
and O
wild O
- O
type O
MVs O
immediately O
after O
rescue O
. O

We O
frequently O
detected O
clusters O
of O
A O
- O
to O
- O
G O
or O
U O
- O
to O
- O
C O
transitions O
and O
noted O
that O
sequences O
flanking O
individual O
mutations O
contain O
motifs O
favoring O
recognition O
by O
the O
adenosine B
deaminase I
acting I
on I
RNA I
- I
1 I
( I
ADAR1 I
) I
. O

The O
ADAR1 O
- O
mediated O
biased O
hypermutation O
events O
are O
consistent O
with O
the O
protein B
kinase I
R I
( I
PKR I
) I
- O
ADAR1 O
balancing O
model O
of O
innate O
immunity O
activation O
. O

The O
discovery O
that O
measles B
virus I
( I
MV I
) I
uses O
the O
adherens O
junction O
protein O
nectin O
- O
4 O
as O
its O
epithelial O
receptor O
provides O
a O
new O
vantage O
point O
from O
which O
to O
characterize O
its O
rapid O
spread O
in O
the O
airway O
epithelium O
. O

We O
show O
here O
that O
in O
well O
- O
differentiated O
primary O
cultures O
of O
airway O
epithelial O
cells O
from O
human O
donors O
( O
HAE O
) O
, O
MV O
infectious O
centers O
form O
rapidly O
and O
become O
larger O
than O
those O
of O
other O
respiratory O
pathogens O
: O
human O
respiratory O
syncytial O
virus O
, O
parainfluenza O
virus O
5 O
, O
and O
Sendai O
virus O
. O

While O
visible O
syncytia O
do O
not O
form O
after O
MV O
infection O
of O
HAE O
, O
the O
cytoplasm O
of O
an O
infected O
cell O
suddenly O
flows O
into O
an O
adjacent O
cell O
, O
as O
visualized O
through O
wild O
- O
type O
MV O
- O
expressed O
cytoplasmic O
green B
fluorescent I
protein I
( I
GFP I
) I
. O

IMPORTANCE O
measles B
virus I
( I
MV I
) I
, O
while O
targeted O
for O
eradication O
, O
still O
causes O
about O
120 O
, O
000 O
deaths O
per O
year O
worldwide O
. O

mumps B
virus I
( I
MuV I
) I
is O
a O
paramyxovirus O
with O
a O
negative O
- O
sense O
nonsegmented O
RNA O
genome O
. O

The O
viral O
RNA O
genome O
is O
encapsidated O
by O
the O
nucleocapsid B
protein I
( I
NP I
) I
to O
form O
the O
ribonucleoprotein B
( I
RNP I
) I
, O
which O
serves O
as O
a O
template O
for O
transcription O
and O
replication O
. O

Using O
both O
liquid B
chromatography I
- I
mass I
spectrometry I
( I
LC I
- I
MS I
) I
and O
in O
silico O
modeling O
, O
we O
identified O
nine O
putative O
phosphorylated O
residues O
within O
NP O
. O

Mutation O
of O
the O
serine O
residue O
at O
position O
439 O
to O
alanine O
( O
S439A O
) O
was O
found O
to O
reduce O
the O
phosphorylation O
of O
NP O
in O
transfected O
cells O
by O
over O
90 O
% O
. O

IMPORTANCE O
mumps B
virus I
( I
MuV I
) I
, O
a O
paramyxovirus O
, O
is O
an O
important O
human O
pathogen O
that O
is O
reemerging O
in O
human O
populations O
. O

nucleocapsid B
protein I
( I
NP I
) I
of O
MuV O
is O
essential O
for O
viral O
RNA O
synthesis O
. O

Measles O
and O
canine O
distemper O
viruses O
( O
MeV O
and O
CDV O
, O
respectively O
) O
first O
replicate O
in O
lymphatic O
and O
epithelial O
tissues O
by O
using O
SLAM O
and O
nectin O
- O
4 O
as O
entry O
receptors O
, O
respectively O
. O

The O
viruses O
may O
also O
invade O
the O
brain O
to O
establish O
persistent O
infections O
, O
triggering O
fatal O
complications O
, O
such O
as O
subacute B
sclerosis I
pan I
- I
encephalitis I
( I
SSPE I
) I
in O
MeV O
infection O
or O
chronic O
, O
multiple O
sclerosis O
- O
like O
, O
multifocal O
demyelinating O
lesions O
in O
the O
case O
of O
CDV O
infection O
. O

In O
both O
diseases O
, O
persistence O
is O
mediated O
by O
viral O
nucleocapsids O
that O
do O
not O
require O
packaging O
into O
particles O
for O
infectivity O
but O
are O
directly O
transmitted O
from O
cell O
to O
cell O
( O
neurons O
in O
SSPE O
or O
astrocytes O
in O
distemper O
encephalitis O
) O
, O
presumably O
by O
relying O
on O
restricted O
microfusion O
events O
. O

IMPORTANCE O
While O
persistent O
measles B
virus I
( I
MeV I
) I
infection O
induces O
SSPE O
in O
humans O
, O
persistent O
canine B
distemper I
virus I
( I
CDV I
) I
infection O
causes O
chronic O
progressive O
or O
relapsing O
demyelination O
in O
carnivores O
. O

Common O
to O
both O
central B
nervous I
system I
( I
CNS I
) I
infections O
is O
that O
persistence O
is O
based O
on O
noncytolytic O
cell O
- O
to O
- O
cell O
spread O
, O
which O
, O
in O
the O
case O
of O
CDV O
, O
was O
demonstrated O
to O
rely O
on O
functional O
membrane O
fusion O
machinery O
complexes O
. O

Here O
, O
we O
provide O
evidence O
that O
CDV O
induces O
such O
microfusions O
in O
a O
SLAM O
- O
and O
nectin O
- O
4 O
- O
independent O
manner O
, O
thereby O
strongly O
suggesting O
the O
existence O
of O
a O
third O
receptor O
expressed O
in O
glial O
cells O
( O
referred O
to O
as O
GliaR O
) O
. O

dendritic B
cells I
( I
DCs I
) I
are O
the O
most O
efficient O
antigen O
- O
presenting O
cells O
, O
playing O
a O
key O
role O
in O
the O
adaptive O
immune O
responses O
to O
viral O
infections O
. O

Our O
studies O
demonstrate O
that O
wild B
- I
type I
( I
wt I
) I
rabies I
virus I
( I
RABV I
) I
does O
not O
activate O
DCs O
. O

Adoptive O
transfer O
of O
DCs O
primed O
with O
wt O
RABV O
did O
not O
activate O
DCs O
, O
stimulate O
virus B
neutralizing I
antibodies I
( I
VNA I
) I
, O
or O
protect O
recipients O
against O
challenge O
. O

In O
vitro O
studies O
with O
recombinant O
RABV O
( O
laboratory O
- O
attenuated O
RABV O
expressing O
the O
glycoprotein O
or O
the O
phosphoprotein O
from O
wt O
RABV O
) O
demonstrate O
that O
DC O
activation O
is O
dependent O
on O
the O
glycoprotein O
and O
involves O
the O
IPS O
- O
1 O
pathway O
. O

Since O
DCs O
play O
a O
key O
role O
in O
the O
adaptive O
immune O
responses O
to O
viral O
infections O
, O
we O
investigated O
the O
ability O
of O
rabies B
virus I
( I
RABV I
) I
to O
activate O
DCs O
. O

Although O
live O
- O
attenuated O
measles B
virus I
( I
MV I
) I
vaccines O
have O
been O
used O
successfully O
for O
over O
50 O
years O
, O
the O
target O
cells O
that O
sustain O
virus O
replication O
in O
vivo O
are O
still O
unknown O
. O

We O
generated O
a O
reverse O
genetics O
system O
for O
the O
live O
- O
attenuated O
MV O
vaccine O
strain O
Edmonston B
- I
Zagreb I
( I
EZ I
) I
, O
allowing O
recovery O
of O
recombinant O
( O
r O
) O
MVEZ O
. O

Three O
recombinant O
viruses O
were O
generated O
that O
contained O
the O
open O
reading O
frame O
encoding O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
within O
an O
additional B
transcriptional I
unit I
( I
ATU I
) I
at O
various O
positions O
within O
the O
genome O
. O

rMV O
( O
EZ O
) O
EGFP O
( O
1 O
) O
, O
rMV O
( O
EZ O
) O
EGFP O
( O
3 O
) O
, O
and O
rMV O
( O
EZ O
) O
EGFP O
( O
6 O
) O
contained O
the O
ATU O
upstream O
of O
the O
N O
gene O
, O
following O
the O
P O
gene O
, O
and O
following O
the O
H O
gene O
, O
respectively O
. O

The O
viruses O
were O
compared O
in O
vitro O
by O
growth O
curves O
, O
which O
indicated O
that O
rMV O
( O
EZ O
) O
EGFP O
( O
1 O
) O
was O
overattenuated O
. O

rMV O
( O
EZ O
) O
EGFP O
( O
1 O
) O
and O
rMV O
( O
EZ O
) O
EGFP O
( O
6 O
) O
did O
not O
induce O
satisfactory O
serum O
antibody O
responses O
, O
whereas O
both O
in O
vitro O
and O
in O
vivo O
rMV O
( O
EZ O
) O
EGFP O
( O
3 O
) O
was O
functionally O
equivalent O
to O
the O
commercial O
MVEZ O
- O
containing O
vaccine O
. O

Intramuscular O
vaccination O
of O
macaques O
with O
rMV O
( O
EZ O
) O
EGFP O
( O
3 O
) O
resulted O
in O
the O
identification O
of O
EGFP O
( O
+ O
) O
cells O
in O
the O
muscle O
at O
days O
3 O
, O
5 O
, O
and O
7 O
postvaccination O
. O

IMPORTANCE O
Even O
though O
MV O
strain O
Edmonston O
- O
Zagreb O
has O
long O
been O
used O
as O
a O
live B
- I
attenuated I
vaccine I
( I
LAV I
) I
to O
protect O
against O
measles O
, O
nothing O
is O
known O
about O
the O
primary O
cells O
in O
which O
the O
virus O
replicates O
in O
vivo O
. O

Membrane O
fusion O
for O
morbillivirus O
cell O
entry O
relies O
on O
critical O
interactions O
between O
the O
viral O
fusion O
( O
F O
) O
and O
attachment O
( O
H O
) O
envelope O
glycoproteins O
. O

measles B
virus I
( I
MV I
) I
infection O
is O
undergoing O
resurgence O
and O
remains O
one O
of O
the O
leading O
causes O
of O
death O
among O
young O
children O
worldwide O
despite O
the O
availability O
of O
an O
effective O
measles O
vaccine O
. O

MV O
infects O
its O
target O
cells O
by O
coordinated O
action O
of O
the O
MV O
H O
and O
the O
fusion O
( O
F O
) O
envelope O
glycoprotein O
; O
upon O
receptor O
engagement O
by O
H O
, O
the O
prefusion O
F O
undergoes O
a O
structural O
transition O
, O
extending O
and O
inserting O
into O
the O
target O
cell O
membrane O
and O
then O
refolding O
into O
a O
postfusion O
structure O
that O
fuses O
the O
viral O
and O
cell O
membranes O
. O

By O
interfering O
with O
this O
structural O
transition O
of O
F O
, O
peptides O
derived O
from O
the O
heptad B
- I
repeat I
( I
HR I
) I
regions O
of O
F O
can O
potently O
inhibit O
MV O
infection O
at O
the O
entry O
stage O
. O

IMPORTANCE O
measles B
virus I
( I
MV I
) I
infection O
causes O
an O
acute O
illness O
that O
may O
be O
associated O
with O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
severe O
neurological O
disease O
. O

The O
negative O
- O
strand O
RNA O
virus O
measles B
virus I
( I
MeV I
) I
uses O
tissue O
- O
specific O
nectin O
- O
4 O
, O
and O
the O
positive O
- O
strand O
RNA O
virus O
poliovirus O
uses O
nectin B
- I
like I
5 I
( I
necl I
- I
5 I
) I
, O
also O
known O
as O
poliovirus O
receptor O
. O

Here O
we O
show O
that O
the O
same O
key O
residues O
in O
the O
BC O
and O
FG O
loops O
of O
nectin O
- O
4 O
govern O
binding O
to O
the O
MeV O
attachment O
protein O
hemagglutinin B
( I
H I
) I
and O
cell O
entry O
, O
nectin O
- O
4 O
homodimerization O
, O
and O
heterodimerization O
with O
nectin O
- O
1 O
. O

The O
multidomain O
polymerase O
protein O
( O
L O
) O
of O
nonsegmented B
negative I
- I
strand I
( I
NNS I
) I
RNA O
viruses O
catalyzes O
transcription O
and O
replication O
of O
the O
virus O
genome O
. O

To O
gain O
insight O
into O
putative O
transient O
interactions O
between O
L O
domains O
during O
viral O
RNA O
synthesis O
, O
we O
exchanged O
each O
of O
the O
four O
distinct O
regions O
encompassing O
the O
appendage O
region O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
Indiana O
serotype O
L O
protein O
with O
their O
counterparts O
from O
VSV O
New O
Jersey O
and O
analyzed O
effects O
on O
virus O
polymerase O
activity O
in O
a O
minigenome O
system O
. O

Further O
probing O
of O
the O
putative O
linker O
segment O
using O
in O
- O
frame O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
insertions O
similarly O
abrogated O
activity O
. O

Avian B
metapneumovirus I
( I
AMPV I
) I
, O
also O
known O
as O
avian O
pneumovirus O
or O
turkey O
rhinotracheitis O
virus O
, O
is O
the O
causative O
agent O
of O
turkey O
rhinotracheitis O
and O
is O
associated O
with O
swollen O
head O
syndrome O
in O
chickens O
. O

The O
conserved B
region I
VI I
( I
CR I
VI I
) I
of O
the O
large B
( I
L I
) I
polymerase O
proteins O
of O
paramyxoviruses O
catalyzes O
methyltransferase B
( I
MTase I
) I
activities O
that O
typically O
methylate O
viral O
mRNAs O
at O
guanine B
N I
- I
7 I
( I
G I
- I
N I
- I
7 I
) I
and O
ribose O
2 O
' O
- O
O O
positions O
. O

In O
this O
study O
, O
we O
generated O
a O
panel O
of O
recombinant B
aMPV I
( I
raMPV I
) I
Colorado O
strains O
carrying O
mutations O
in O
the O
S B
- I
adenosyl I
methionine I
( I
SAM I
) I
binding O
site O
in O
the O
CR O
VI O
of O
L O
protein O
. O

These O
recombinant O
viruses O
were O
specifically O
defective O
in O
ribose O
2 O
' O
- O
O O
, O
but O
not O
G O
- O
N O
- O
7 O
methylation O
and O
were O
genetically O
stable O
and O
highly O
attenuated O
in O
cell O
culture O
and O
viral O
replication O
in O
the O
upper O
and O
lower O
respiratory O
tracts O
of O
specific B
- I
pathogen I
- I
free I
( I
SPF I
) I
young O
turkeys O
. O

Collectively O
, O
our O
results O
indicate O
( O
i O
) O
that O
aMPV O
lacking O
2 O
' O
- O
O O
methylation O
is O
highly O
attenuated O
in O
vitro O
and O
in O
vivo O
and O
( O
ii O
) O
that O
inhibition O
of O
mRNA O
cap O
MTase O
can O
serve O
as O
a O
novel O
target O
to O
rationally O
design O
live O
attenuated O
vaccines O
for O
aMPV O
and O
perhaps O
other O
paramyxoviruses O
. O

IMPORTANCE O
Paramyxoviruses O
include O
many O
economically O
and O
agriculturally O
important O
viruses O
such O
as O
Avian B
metapneumovirus I
( I
AMPV I
) I
, O
and O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
human O
pathogens O
such O
as O
human O
respiratory O
syncytial O
virus O
, O
human O
metapneumovirus O
, O
human O
parainfluenza O
virus O
type O
3 O
, O
and O
measles O
virus O
, O
and O
highly O
lethal O
emerging O
pathogens O
such O
as O
Nipah O
virus O
and O
Hendra O
virus O
. O

Using O
aMPV O
as O
a O
model O
, O
we O
found O
that O
viral O
ribose O
2 O
' O
- O
O O
methyltransferase B
( I
MTase I
) I
is O
a O
novel O
approach O
to O
rationally O
attenuate O
the O
virus O
for O
vaccine O
purpose O
. O

recombinant B
aMPV I
( I
raMPV I
) I
lacking O
2 O
' O
- O
O O
MTase O
were O
not O
only O
highly O
attenuated O
in O
turkeys O
but O
also O
provided O
complete O
protection O
against O
the O
challenge O
of O
homologous O
and O
heterologous O
aMPV O
strains O
. O

Ebola B
virus I
( I
EBOV I
) I
belongs O
to O
the O
group O
of O
nonsegmented O
negative O
- O
sense O
RNA O
viruses O
. O

The O
seven O
EBOV O
genes O
are O
separated O
by O
variable O
gene O
borders O
, O
including O
short O
( O
4 O
- O
or O
5 O
- O
nucleotide O
) O
intergenic B
regions I
( I
IRs I
) I
, O
a O
single O
long O
( O
144 O
- O
nucleotide O
) O
IR O
, O
and O
gene O
overlaps O
, O
where O
the O
neighboring O
gene O
end O
and O
start O
signals O
share O
five O
conserved O
nucleotides O
. O

The O
genome O
of O
nonsegmented O
negative O
- O
strand O
RNA O
viruses O
is O
tightly O
embedded O
within O
a O
nucleocapsid O
made O
of O
a O
nucleoprotein B
( I
N I
) I
homopolymer O
. O

To O
ensure O
processive O
RNA O
synthesis O
, O
the O
viral O
polymerase O
L O
in O
complex O
with O
its O
cofactor O
phosphoprotein B
( I
P I
) I
binds O
the O
nucleocapsid O
that O
constitutes O
the O
functional O
template O
. O

While O
binding O
of O
the O
P O
amino O
terminus O
with O
the O
core O
of O
N O
( O
N O
- O
CORE O
) O
prevents O
illegitimate O
encapsidation O
of O
cellular O
RNA O
, O
the O
interaction O
between O
their O
C O
- O
terminal O
domains O
, O
P O
- O
XD O
and O
N O
- O
TAIL O
is O
required O
for O
viral O
RNA O
synthesis O
. O

Pancreatic B
ductal I
adenocarcinoma I
( I
PDA I
) I
is O
the O
most O
lethal O
form O
of O
human O
cancer O
, O
with O
dismal O
survival O
rates O
due O
to O
late O
- O
stage O
diagnoses O
and O
a O
lack O
of O
efficacious O
therapies O
. O

Building O
on O
the O
observation O
that O
avian O
influenza B
A I
viruses I
( I
IAVs I
) I
have O
a O
tropism O
for O
the O
pancreas O
in O
vivo O
, O
the O
present O
study O
was O
aimed O
at O
testing O
the O
efficacy O
of O
IAVs O
as O
oncolytic O
agents O
for O
killing O
human O
PDA O
cell O
lines O
. O

Studies O
into O
possible O
correlates O
of O
protection O
found O
that O
antibodies O
specific O
to O
the O
V1 O
and O
V2 O
( O
V1 O
/ O
V2 O
) O
region O
of O
envelope O
correlated O
inversely O
with O
infection O
risk O
and O
that O
viruses O
isolated O
from O
trial O
participants O
contained O
genetic O
signatures O
of O
vaccine O
- O
induced O
pressure O
in O
the O
V1 O
/ O
V2 O
region O
. O

The O
predicted O
escape O
depended O
on O
class O
I O
HLA O
A O
( O
star O
) O
02 O
- O
and O
A O
( O
star O
) O
11 O
- O
restricted O
epitopes O
in O
the O
MN O
strain O
rgp120 O
vaccine O
immunogen O
. O

Though O
we O
hypothesized O
that O
this O
was O
indicative O
of O
postacquisition O
selection O
pressure O
, O
we O
also O
found O
that O
vaccine B
efficacy I
( I
VE I
) I
was O
greater O
in O
A O
( O
star O
) O
02 O
- O
positive O
( O
A O
( O
star O
) O
02 O
( O
+ O
) O
) O
participants O
than O
in O
A O
( O
star O
) O
02 O
( O
- O
) O
participants O
( O
VE O
= O
54 O
% O
versus O
3 O
% O
, O
P O
= O
0 O
. O

Vaccine O
efficacy O
against O
viruses O
with O
a O
lysine O
residue O
at O
site O
169 O
, O
important O
to O
antibody O
binding O
and O
implicated O
in O
vaccine O
- O
induced O
immune O
pressure O
, O
was O
also O
greater O
in O
A O
( O
star O
) O
02 O
( O
+ O
) O
participants O
( O
VE O
= O
74 O
% O
versus O
15 O
% O
, O
P O
= O
0 O
. O

Additionally O
, O
a O
reanalysis O
of O
vaccine O
- O
induced O
immune O
responses O
that O
focused O
on O
those O
that O
were O
shown O
to O
correlate O
with O
infection O
risk O
suggested O
that O
the O
humoral O
responses O
may O
have O
differed O
in O
A O
( O
star O
) O
02 O
( O
+ O
) O
participants O
. O

Though O
we O
hypothesized O
that O
the O
observed O
sieve O
effect O
indicated O
postacquisition O
T O
- O
cell O
selection O
, O
we O
also O
found O
that O
vaccine O
efficacy O
was O
greater O
for O
participants O
who O
expressed O
HLA O
A O
( O
star O
) O
02 O
, O
an O
allele O
implicated O
in O
the O
sieve O
analysis O
. O

VSV O
- O
FH O
is O
a O
hybrid O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
with O
a O
deletion O
of O
its O
G O
glycoprotein O
and O
encoding O
the O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
and O
hemagglutinin B
( I
H I
) I
envelope O
glycoproteins O
. O

While O
syncytium O
size O
reached O
a O
plateau O
and O
did O
not O
increase O
further O
in O
MV O
- O
infected O
CHO O
cells O
expressing O
> O
= O
4 O
, O
620 O
CD46 O
copies O
/ O
cell O
, O
there O
was O
a O
corresponding O
increase O
in O
syncytium O
size O
with O
increases O
in O
CD46 O
levels O
in O
VSV O
- O
FH O
- O
infected O
CD46 O
- O
expressing O
CHO O
( O
CHO O
- O
CD46 O
) O
cells O
. O

IMPORTANCE O
We O
studied O
the O
cytotoxic O
activity O
of O
a O
vesicular O
stomatitis O
/ O
measles O
hybrid O
virus O
( O
VSV O
- O
FH O
) O
, O
which O
is O
superior O
to O
that O
of O
measles B
virus I
( I
MV I
) I
, O
in O
different O
cancer O
cell O
lines O
. O

The O
interferon O
antiviral O
system O
is O
a O
primary O
barrier O
to O
virus O
replication O
triggered O
upon O
recognition O
of O
nonself O
RNAs O
by O
the O
cytoplasmic O
sensors O
encoded O
by O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
, O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
, O
and O
laboratory B
of I
genetics I
and I
physiology I
gene I
2 I
( I
LGP2 I
) I
. O

To O
directly O
evaluate O
the O
impact O
of O
LGP2 O
interference O
, O
MDA5 O
and O
LGP2 O
variants O
unable O
to O
be O
recognized O
by O
measles O
virus O
and O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
V O
proteins O
were O
tested O
in O
signaling O
assays O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
a O
member O
of O
the O
Paramyxoviridae O
family O
of O
nonsegmented O
, O
negative O
- O
sense O
, O
single O
- O
stranded O
RNA O
genome O
viruses O
, O
is O
a O
leading O
cause O
of O
lower O
respiratory O
tract O
infections O
in O
infants O
, O
young O
children O
, O
and O
the O
elderly O
or O
immunocompromised O
. O

There O
are O
many O
open O
questions O
regarding O
the O
processes O
that O
regulate O
human B
RSV I
( I
hRSV I
) I
assembly O
and O
budding O
. O

The O
three O
particle O
morphologies O
maintained O
a O
similar O
organization O
of O
the O
surface O
glycoproteins O
, O
matrix B
protein I
( I
M I
) I
, O
M2 O
- O
1 O
, O
and O
the O
ribonucleoprotein B
( I
RNP I
) I
. O

RNP O
filaments O
were O
traced O
in O
three O
dimensions O
( O
3D O
) O
, O
and O
their O
total O
length O
was O
calculated O
. O

Using O
fluorescence B
light I
microscopy I
( I
fLM I
) I
, O
direct B
stochastic I
optical I
reconstruction I
microscopy I
( I
dSTORM I
) I
, O
and O
a O
proximity B
ligation I
assay I
( I
PLA I
) I
, O
we O
provide O
evidence O
illustrating O
that O
M2 O
- O
1 O
is O
located O
between O
RNP O
and O
M O
in O
isolated O
viral O
particles O
. O

In O
addition O
, O
regular O
spacing O
of O
the O
M2 O
- O
1 O
densities O
was O
resolved O
when O
hRSV O
viruses O
were O
imaged O
using O
Zernike B
phase I
contrast I
( I
ZPC I
) I
cryo O
- O
electron O
tomography O
. O

The O
measles B
virus I
( I
MeV I
) I
membrane O
fusion O
apparatus O
consists O
of O
a O
fusion O
protein O
trimer O
and O
an O
attachment O
protein O
tetramer O
. O

To O
trigger O
membrane O
fusion O
, O
the O
heads O
of O
the O
MeV O
attachment O
protein O
, O
hemagglutinin B
( I
H I
) I
, O
bind O
cellular O
receptors O
while O
the O
96residue O
- O
long O
H O
stalk O
transmits O
the O
triggering O
signal O
. O

Structural O
and O
functional O
studies O
of O
the O
triggering O
mechanism O
of O
other O
paramyxoviruses O
suggest O
that O
receptor O
binding O
to O
their O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
results O
in O
signal O
transmission O
through O
the O
central O
segments O
of O
their O
stalks O
. O

Orthoreovirus O
fusion B
- I
associated I
small I
transmembrane I
( I
FAST I
) I
proteins O
are O
dedicated O
cell O
- O
cell O
fusogens O
responsible O
for O
multinucleated O
syncytium O
formation O
and O
are O
virulence O
determinants O
of O
the O
fusogenic O
reoviruses O
. O

We O
now O
report O
that O
RNA B
interference I
( I
RNAi I
) I
knockdown O
of O
annexin B
A1 I
( I
AX1 I
) I
expression O
dramatically O
reduced O
both O
reptilian O
reovirus O
p14 O
and O
measles O
virus O
F O
and O
H O
protein O
- O
mediated O
pore O
expansion O
during O
syncytiogenesis O
but O
had O
no O
effect O
on O
pore O
formation O
. O

Coimmunoprecipitation O
revealed O
calcium O
- O
dependent O
interaction O
between O
AX1 O
and O
p14 O
or O
measles O
virus O
F O
and O
H O
proteins O
, O
and O
fluorescence B
resonance I
energy I
transfer I
( I
FRET I
) I
demonstrated O
calcium O
- O
dependent O
p14 O
- O
AX1 O
interactions O
in O
cellulo O
. O

In O
particular O
, O
little O
is O
known O
about O
the O
role O
of O
autophagy O
in O
infection O
by O
attenuated O
measles B
virus I
of I
the I
Edmonston I
strain I
( I
MV I
- I
Edm I
) I
. O

We O
report O
that O
MV O
- O
Edm O
exploits O
selective O
autophagy O
to O
mitigate O
the O
innate O
immune O
response O
mediated O
by O
DDX58 O
/ O
RIG B
- I
I I
like I
receptors I
( I
RLRs I
) I
in O
non B
- I
small I
cell I
lung I
cancer I
( I
NSCLC I
) I
cells O
. O

Both O
RNA B
interference I
( I
RNAi I
) I
and O
overexpression O
approaches O
demonstrate O
that O
autophagy O
enhances O
viral O
replication O
and O
inhibits O
the O
production O
of O
type O
I O
interferons O
regulated O
by O
RLRs O
. O

We O
show O
that O
MV O
- O
Edm O
unexpectedly O
triggers O
SQSTM1 O
/ O
p62 O
- O
mediated O
mitophagy O
, O
resulting O
in O
decreased O
mitochondrion O
- O
tethered O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
and O
subsequently O
weakening O
the O
innate O
immune O
response O
. O

Human B
herpesvirus I
6 I
( I
HHV I
- I
6 I
) I
is O
widely O
spread O
in O
the O
human O
population O
and O
has O
been O
associated O
with O
several O
neuroinflammatory O
diseases O
, O
including O
multiple O
sclerosis O
. O

We O
showed O
that O
HHV O
- O
6A O
( O
GS O
) O
infection O
results O
in O
the O
expression O
of O
viral O
transcripts O
in O
primary O
brain O
glial O
cultures O
from O
CD46 O
- O
expressing O
mice O
, O
while O
HHV O
- O
6B O
( O
Z29 O
) O
infection O
was O
inefficient O
. O

HHV O
- O
6A O
- O
induced O
production O
of O
chemokines O
in O
the O
primary O
glial O
cultures O
was O
dependent O
on O
the O
stimulation O
of O
Toll B
- I
like I
receptor I
9 I
( I
TLR9 I
) I
. O

measles B
virus I
( I
MV I
) I
is O
being O
considered O
for O
global O
eradication O
, O
which O
would O
likely O
reduce O
compliance O
with O
MV O
vaccination O
. O

As O
a O
result O
, O
children O
will O
grow O
up O
without O
MV O
- O
specific O
immunity O
, O
creating O
a O
potential O
niche O
for O
closely O
related O
animal O
morbilliviruses O
such O
as O
canine B
distemper I
virus I
( I
CDV I
) I
. O

In O
naive O
animals O
CDV O
caused O
viremia O
and O
fever O
and O
predominantly O
infected O
CD150 O
( O
+ O
) O
lymphocytes O
and O
dendritic O
cells O
. O

In O
particular O
, O
the O
V O
protein O
of O
the O
genus O
Morbillivirus O
interferes O
with O
the O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
, O
STAT2 O
, O
and O
Melanoma B
Differentiation I
- I
Associated I
protein I
5 I
( I
MDA5 I
) I
signaling O
pathways O
. O

To O
characterize O
the O
contributions O
of O
these O
pathways O
to O
canine B
distemper I
virus I
( I
CDV I
) I
pathogenesis O
, O
we O
took O
advantage O
of O
the O
knowledge O
about O
the O
mechanisms O
of O
interaction O
between O
the O
measles O
virus O
V O
protein O
with O
these O
key O
regulators O
of O
innate O
immunity O
. O

For O
morbilliviruses O
, O
the O
V O
protein O
is O
known O
to O
interact O
with O
the O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( I
STAT1 I
) I
and O
STAT2 O
and O
the O
Melanoma B
Differentiation I
- I
Associated I
protein I
5 I
( I
MDA5 I
) I
, O
which O
are O
involved O
in O
interferon O
signaling O
. O

The O
morbillivirus O
cell O
entry O
machinery O
consists O
of O
a O
fusion O
( O
F O
) O
protein O
trimer O
that O
refolds O
to O
mediate O
membrane O
fusion O
following O
receptor O
- O
induced O
conformational O
changes O
in O
its O
binding O
partner O
, O
the O
tetrameric O
attachment O
( O
H O
) O
protein O
. O

To O
identify O
molecular O
determinants O
that O
control O
F O
refolding O
, O
we O
generated O
F O
chimeras O
between O
measles B
virus I
( I
MeV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
. O

IMPORTANCE O
With O
the O
aim O
to O
better O
characterize O
the O
thermodynamic O
basis O
of O
morbillivirus O
membrane O
fusion O
for O
cell O
entry O
and O
spread O
, O
we O
report O
here O
that O
the O
activation O
energy O
barrier O
of O
prefusion O
F O
trimers O
together O
with O
the O
molecular O
nature O
of O
the O
triggering O
stimulus O
( O
attachment O
protein O
and O
receptor O
types O
) O
define O
a O
triggering O
range O
, O
which O
governs O
the O
initiation O
of O
the O
membrane O
fusion O
process O
. O

measles B
virus I
( I
MV I
) I
immunosuppression O
is O
due O
to O
infection O
of O
SLAM O
- O
positive O
immune O
cells O
, O
whereas O
respiratory O
shedding O
and O
virus O
transmission O
are O
due O
to O
infection O
of O
nectin4 O
- O
positive O
airway O
epithelial O
cells O
. O

The O
vaccine O
lineage O
MV B
strain I
Edmonston I
( I
MV I
- I
Edm I
) I
acquired O
an O
additional O
tropism O
for O
CD46 O
which O
is O
the O
basis O
of O
its O
oncolytic O
specificity O
. O

VSVFH O
is O
a O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
encoding O
the O
MV O
- O
Edm O
F O
and O
H O
entry O
proteins O
in O
place O
of O
G O
. O

Two O
transmembrane O
glycoproteins O
form O
spikes O
on O
the O
surface O
of O
Sendai O
virus O
, O
a O
member O
of O
the O
Respirovirus O
genus O
of O
the O
Paramyxovirinae O
subfamily O
of O
the O
Paramyxoviridae O
family O
: O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
the O
fusion O
( O
F O
) O
proteins O
. O

This O
relied O
on O
formation O
of O
disulfide O
- O
bound O
heterodimers O
carried O
out O
by O
the O
two O
cysteines O
present O
in O
the O
HN O
80 O
- O
amino O
- O
acid O
( O
aa O
) O
ectodomain O
. O

measles B
virus I
( I
MV I
) I
lacking O
expression O
of O
C O
protein O
( O
C O
- O
KO O
) O
is O
a O
potent O
activator O
of O
the O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
dependent O
protein B
kinase I
( I
PKR I
) I
, O
whereas O
the O
isogenic O
parental O
virus O
expressing O
C O
protein O
is O
not O
. O

quantitative B
PCR I
( I
qPCR I
) I
analyses O
revealed O
reduced O
viral O
RNA O
synthesis O
and O
a O
steepened O
transcription O
gradient O
in O
C O
- O
KO O
virus O
- O
infected O
cells O
compared O
to O
those O
in O
parental O
virus O
- O
infected O
cells O
. O

After O
one O
subsequent O
passage O
of O
the O
C O
- O
KO O
virus O
, O
defective B
interfering I
RNA I
( I
DI I
- I
RNA I
) I
with O
a O
duplex O
structure O
was O
obtained O
that O
was O
not O
seen O
with O
the O
parental O
virus O
. O

In O
our O
present O
study O
, O
we O
identified O
nine O
putative O
phosphorylation O
sites O
by O
mass O
spectrometry O
and O
demonstrated O
that O
threonine B
residue I
279 I
( I
T279 I
) I
is O
functionally O
significant O
. O

Reovirus O
nonstructural O
protein O
sigma O
1s O
is O
implicated O
in O
cell O
cycle O
arrest O
at O
the O
G O
( O
2 O
) O
/ O
M O
boundary O
and O
induction O
of O
apoptosis O
. O

Following O
infection O
with O
wildtype O
virus O
, O
we O
observed O
an O
increase O
in O
the O
percentage O
of O
cells O
in O
G O
( O
2 O
) O
/ O
M O
, O
whereas O
the O
proportion O
of O
cells O
in O
G O
( O
2 O
) O
/ O
M O
following O
infection O
with O
the O
sigma O
1s O
- O
null O
mutant O
was O
unaffected O
. O

We O
sought O
proof O
of O
principle O
that O
tumor O
- O
targeting O
ligands O
can O
be O
displayed O
on O
the O
surface O
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
by O
engineering O
its O
glycoprotein O
. O

By O
using O
a O
rational O
approach O
, O
we O
investigated O
various O
feasible O
insertion O
sites O
on O
the O
G O
protein O
of O
VSV O
( O
VSV O
- O
G O
) O
for O
display O
of O
tumor O
vasculature O
- O
targeting O
ligands O
, O
cyclic B
RGD I
( I
cRGD I
) I
and O
echistatin O
. O

Since O
the O
low B
- I
density I
lipoprotein I
receptor I
( I
LDLr I
) I
was O
recently O
identified O
as O
a O
major O
receptor O
for O
VSV O
, O
we O
investigated O
the O
entry O
of O
ligand O
- O
displaying O
viruses O
after O
masking O
LDLR O
. O

measles B
virus I
( I
MV I
) I
infection O
causes O
an O
acute O
childhood O
disease O
that O
can O
include O
infection O
of O
the O
central O
nervous O
system O
and O
can O
rarely O
progress O
to O
severe O
neurological O
disease O
for O
which O
there O
is O
no O
specific O
treatment O
. O

The O
measles B
virus I
( I
MV I
) I
nucleoprotein O
associates O
with O
the O
viral O
RNA O
genome O
to O
form O
the O
N O
- O
RNA O
complex O
, O
providing O
a O
template O
for O
viral O
RNA O
synthesis O
. O

In O
this O
study O
, O
we O
rescued O
recombinant B
MVs I
( I
rMVs I
) I
whose O
phosphorylation O
sites O
in O
the O
nucleoprotein O
were O
substituted O
( O
rMV O
- O
S479A O
, O
rMV O
- O
S510A O
, O
and O
rMV O
- O
S479A O
/ O
S510A O
) O
by O
reverse O
genetics O
and O
used O
them O
in O
subsequent O
analyses O
. O

The O
nucleoprotein B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
interaction O
of O
nonsegmented O
negative O
- O
strand O
RNA O
viruses O
is O
essential O
for O
viral O
replication O
; O
this O
includes O
N O
- O
0 O
- O
P O
( O
N O
- O
0 O
, O
free O
of O
RNA O
) O
interaction O
and O
the O
interaction O
of O
N O
- O
RNA O
with O
P O
. O

The O
precise O
site O
( O
s O
) O
within O
N O
that O
mediates O
the O
N O
- O
P O
interaction O
and O
the O
detailed O
regulating O
mechanism O
, O
however O
, O
are O
less O
clear O
. O

Using O
a O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
minigenome O
assay O
, O
we O
found O
that O
an O
N O
mutant O
( O
N O
- O
L478A O
) O
did O
not O
support O
reporter O
gene O
expression O
. O

Using O
in O
vivo O
and O
in O
vitro O
coimmunoprecipitation O
, O
we O
found O
that O
N O
- O
L478A O
maintains O
the O
ability O
to O
form O
N O
- O
L478A O
( O
0 O
) O
- O
P O
, O
to O
self O
- O
assemble O
, O
and O
to O
form O
N O
- O
L478A O
- O
RNA O
but O
that O
N O
- O
L478A O
- O
RNA O
does O
not O
interact O
with O
P O
. O

Having O
identified O
a O
pair O
of O
unrelated O
pathogenic O
myxoviruses O
( O
influenza O
A O
virus O
and O
measles O
virus O
) O
with O
comparable O
replication O
kinetics O
, O
we O
observed O
unimpaired O
coreplication O
of O
both O
viruses O
, O
generated O
suitable O
firefly O
and O
Renilla O
luciferase O
reporter O
constructs O
, O
respectively O
, O
and O
validated O
the O
protocol O
for O
up O
to O
a O
384 O
- O
well O
plate O
format O
. O

The O
major O
inducible O
70 O
- O
kDa O
heat O
shock O
protein O
( O
hsp70 O
) O
protects O
against O
measles B
virus I
( I
MeV I
) I
neurovirulence O
in O
the O
mouse O
that O
is O
caused O
by O
a O
cell O
- O
associated O
noncytolytic O
neuronal O
infection O
. O

Protection O
is O
type B
I I
interferon I
( I
IFN I
) I
dependent O
, O
and O
we O
have O
established O
a O
novel O
axis O
of O
antiviral O
immunity O
in O
which O
hsp70 O
is O
released O
from O
virus O
- O
infected O
neurons O
to O
induce O
IFN O
- O
beta O
in O
macrophages O
. O

The O
present O
work O
used O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
to O
establish O
the O
relevance O
of O
hsp70 O
- O
dependent O
antiviral O
immunity O
to O
fulminant O
cytopathic O
neuronal O
infections O
. O

Nontransgenic O
mice O
were O
also O
protected O
against O
neurovirulence O
and O
expressed O
increased O
type O
I O
IFN O
mRNA O
in O
brain O
when O
hsp70 O
was O
expressed O
by O
a O
recombinant O
VSV O
( O
rVSV O
- O
hsp70 O
) O
, O
indicating O
that O
hsp70 O
in O
the O
virus O
- O
infected O
cell O
is O
sufficient O
for O
host O
protection O
. O

The O
measles B
virus I
( I
MV I
) I
nonstructural O
C O
protein O
suppresses O
the O
interferon O
response O
, O
thereby O
allowing O
efficient O
viral O
growth O
, O
but O
its O
detailed O
mechanism O
has O
been O
unknown O
. O

We O
identified O
Shc B
Src I
homology I
2 I
domain I
- I
binding I
protein I
1 I
( I
SHCBP1 I
) I
as O
one O
of O
the O
host O
proteins O
interacting O
with O
the O
C O
protein O
. O

A O
highly O
complex O
interaction O
with O
mitochondria O
is O
exerted O
by O
rubella B
virus I
( I
RV I
) I
, O
which O
includes O
an O
increase O
in O
the O
mitochondrial O
membrane O
potential O
as O
a O
general O
marker O
for O
mitochondrial O
activity O
. O

A O
strong O
and O
significant O
increase O
in O
the O
activity O
of O
mitochondrial O
respiratory O
enzyme O
succinate O
: O
ubiquinone O
oxidoreductase O
( O
complex O
II O
) O
and O
a O
moderate O
increase O
of O
ubiquinol O
: O
cytochrome O
c O
oxidoreductase O
( O
complex O
III O
) O
were O
detected O
in O
all O
cell O
lines O
. O

In O
contrast O
, O
the O
activity O
of O
mitochondrial O
respiratory O
enzyme O
cytochrome O
c O
oxidase O
( O
complex O
IV O
) O
was O
significantly O
decreased O
. O

Additionally O
, O
these O
alterations O
of O
the O
respiratory O
chain O
activity O
were O
not O
associated O
with O
an O
elevated O
transcription O
of O
oxidative O
stress O
proteins O
, O
and O
reactive B
oxygen I
species I
( I
ROS I
) I
were O
induced O
only O
marginally O
. O

Moreover O
, O
protein O
and O
/ O
or O
mRNA O
levels O
of O
markers O
for O
mitochondrial O
biogenesis O
and O
structure O
were O
elevated O
, O
such O
as O
nuclear O
respiratory O
factors O
( O
NRFs O
) O
and O
mitofusin B
2 I
( I
Mfn2 I
) I
. O

Wild O
- O
type O
measles B
virus I
( I
MV I
) I
strains O
use O
the O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
; O
CD150 O
) O
and O
the O
adherens O
junction O
protein O
nectin O
- O
4 O
( O
poliovirus O
receptor O
- O
like O
4 O
[ O
PVRL4 O
] O
) O
as O
receptors O
. O

Vaccine O
MV O
strains O
have O
adapted O
to O
use O
ubiquitous O
membrane O
cofactor O
protein O
( O
MCP O
; O
CD46 O
) O
in O
addition O
. O

Recently O
solved O
cocrystal O
structures O
of O
the O
MV O
attachment O
protein O
( O
hemagglutinin O
[ O
H O
] O
) O
with O
each O
receptor O
indicate O
that O
all O
three O
bind O
close O
to O
a O
hydrophobic O
groove O
located O
between O
blades O
4 O
and O
5 O
( O
beta O
4 O
- O
beta O
5 O
groove O
) O
of O
the O
H O
protein O
beta O
- O
propeller O
head O
. O

The O
innate O
immune O
response O
to O
viral O
infection O
frequently O
includes O
induction O
of O
type O
I O
interferons B
( I
IFN I
) I
, O
but O
many O
viruses O
have O
evolved O
ways O
to O
block O
this O
response O
and O
increase O
virulence O
. O

In O
vitro O
studies O
of O
IFN O
production O
after O
infection O
of O
susceptible O
cells O
with O
measles B
virus I
( I
MeV I
) I
have O
often O
reported O
greater O
IFN O
synthesis O
after O
infection O
with O
vaccine O
than O
with O
wild O
- O
type O
strains O
of O
MeV O
. O

However O
, O
the O
possible O
presence O
in O
laboratory O
virus O
stocks O
of O
5 O
' O
copy O
- O
back O
Defective B
interfering I
( I
DI I
) I
RNAs O
that O
induce O
IFN O
independent O
of O
the O
standard O
virus O
has O
frequently O
confounded O
interpretation O
of O
data O
from O
these O
studies O
. O

To O
further O
investigate O
MeV O
strain O
- O
dependent O
differences O
in O
IFN O
induction O
and O
the O
role O
of O
DI O
RNAs O
, O
monocyte B
- I
derived I
dendritic I
cells I
( I
moDCs I
) I
were O
infected O
with O
the O
wild O
- O
type O
Bilthoven O
strain O
and O
the O
vaccine O
Edmonston O
- O
Zagreb O
strain O
with O
and O
without O
DI O
RNAs O
. O

Production O
of O
type O
I O
IFN O
, O
type O
III O
IFN O
, O
and O
the O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
Mx O
and O
ISG56 O
by O
infected O
cells O
was O
assessed O
with O
a O
flow O
cytometry O
- O
based O
IFN O
bioassay O
, O
quantitative O
reverse B
transcriptase I
PCR I
( I
RT I
- I
PCR I
) I
, O
and O
immunoassays O
. O

The O
phosphoprotein B
( I
P I
) I
is O
virally O
encoded O
by O
the O
Rhabdoviridae O
and O
Paramyxoviridae O
in O
the O
order O
Mononegavirales O
. O

P O
is O
a O
selfassociated O
oligomer O
and O
forms O
complexes O
with O
the O
large O
viral O
polymerase O
protein O
( O
L O
) O
, O
the O
Nucleocapsid B
protein I
( I
N I
) I
, O
and O
the O
assembled O
nucleocapsid O
. O

We O
systematically O
mapped O
the O
domains O
in O
mumps B
virus I
( I
MuV I
) I
P O
and O
investigated O
their O
interactions O
with O
nucleocapsidlike B
particles I
( I
NLPs I
) I
. O

By O
pulldown O
assays O
, O
we O
discovered O
that O
in O
addition O
to O
the O
previously O
proposed O
nucleocapsid O
binding O
domain O
( O
residues O
343 O
to O
391 O
) O
, O
the O
N O
- O
terminal O
region O
of O
MuV O
P O
( O
residues O
1 O
to O
194 O
) O
could O
also O
bind O
NLPs O
. O

In O
addition O
, O
we O
defined O
the O
oligomerization O
domain O
( O
P O
- O
OD O
) O
of O
MuV O
P O
as O
residues O
213 O
to O
277 O
and O
determined O
its O
crystal O
structure O
. O

5 O
to O
1 O
mg O
of O
codon O
- O
optimized O
DNA O
encoding O
the O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
of O
measles B
virus I
( I
MeV I
) I
. O

or O
100 O
mu O
g O
of O
DNA O
plus O
phosphate B
- I
buffered I
saline I
( I
PBS I
) I
i O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
producing O
T O
cells O
were O
induced O
more O
rapidly O
than O
antibody O
, O
but O
were O
not O
improved O
with O
Vaxfectin O
. O

This O
immune O
response O
led O
to O
protection O
from O
disease O
( O
rash O
/ O
viremia O
) O
but O
not O
from O
infection O
. O

A O
canine B
distemper I
virus I
( I
CDV I
) I
strain O
, O
CYN07 O
- O
dV O
, O
associated O
with O
a O
lethal O
outbreak O
in O
monkeys O
, O
used O
human O
signaling O
lymphocyte O
activation O
molecule O
as O
a O
receptor O
only O
poorly O
but O
readily O
adapted O
to O
use O
it O
following O
a O
P541S O
substitution O
in O
the O
hemagglutinin O
protein O
. O

measles B
virus I
( I
MV I
) I
attachment O
to O
its O
receptor O
is O
mediated O
by O
the O
hemagglutinin B
( I
H I
) I
, O
which O
is O
thought O
to O
produce O
conformational O
changes O
in O
the O
membrane O
fusion B
protein I
( I
F I
) I
that O
trigger O
insertion O
of O
its O
fusion O
peptide O
into O
the O
target O
cell O
membrane O
. O

measles B
virus I
( I
MV I
) I
possesses O
a O
nonsegmented O
negative O
- O
strand O
RNA O
genome O
that O
encodes O
three O
components O
of O
the O
ribonucleoprotein B
( I
RNP I
) I
complex O
( O
N O
, O
P O
, O
and O
L O
) O
, O
two O
surface O
glycoproteins O
, O
a O
matrix O
protein O
, O
and O
two O
nonstructural O
proteins O
. O

measles B
virus I
( I
MV I
) I
, O
one O
of O
the O
most O
contagious O
viruses O
infecting O
humans O
, O
causes O
a O
systemic O
infection O
leading O
to O
fever O
, O
immune O
suppression O
, O
and O
a O
characteristic O
maculopapular O
rash O
. O

Expression O
of O
PVRL4 O
was O
widespread O
in O
both O
the O
lower O
and O
upper B
respiratory I
tract I
( I
URT I
) I
of O
macaques O
, O
indicating O
MV O
transmission O
can O
be O
facilitated O
by O
more O
than O
only O
epithelial O
cells O
of O
the O
trachea O
. O

However O
, O
the O
only O
established O
host O
receptor O
for O
this O
virus O
is O
the O
immune O
cell O
marker O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
. O

The O
oncolytic O
potential O
of O
measles O
vaccine O
virus O
( O
MeV O
) O
has O
been O
demonstrated O
in O
several O
tumor O
entities O
. O

In O
the O
MeV O
- O
resistant O
cell O
lines O
, O
we O
often O
observed O
an O
inhibition O
of O
viral O
replication O
along O
with O
a O
strong O
upregulation O
of O
the O
intracellular O
virus O
- O
sensing O
molecule O
RIG O
- O
I O
and O
of O
the O
interferon B
( I
IFN I
) I
- O
stimulated O
gene O
IFIT1 O
. O

In O
contrast O
, O
susceptible O
cell O
lines O
showed O
a O
much O
weaker O
, O
delayed O
, O
or O
completely O
missing O
expression O
of O
IFIT1 O
as O
well O
as O
a O
delayed O
or O
only O
transient O
phosphorylation O
of O
Stat1 O
, O
whereas O
exogenic O
stimulation O
with O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
resulted O
in O
a O
comparable O
profound O
activation O
of O
Stat1 O
and O
expression O
of O
IFIT1 O
in O
all O
cell O
lines O
. O

From O
a O
therapeutic O
perspective O
, O
we O
were O
able O
to O
overcome O
resistance O
to O
MeV O
by O
increasing O
the O
multiplicity B
of I
infection I
( I
MOI I
) I
and O
by O
addition O
of O
the O
prodrug O
5 O
- O
fluorocytosine O
( O
FC O
) O
, O
thereby O
exploiting O
the O
suicide O
gene O
function O
of O
virotherapeutic O
vector O
MeV O
- O
SCD O
armed O
with O
the O
SCD O
fusion O
protein O
, O
which O
consists O
of O
yeast O
cytosine O
deaminase O
and O
yeast O
uracil O
phosphoribosyltransferase O
. O

Here O
, O
we O
provide O
direct O
evidence O
that O
the O
receptor O
- O
binding O
site O
of O
measles B
virus I
( I
MV I
) I
hemagglutinin O
protein O
itself O
forms O
an O
effective O
conserved B
neutralizing I
epitope I
( I
CNE I
) I
. O

Since O
interactions O
with O
both O
the O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
and O
nectin4 O
are O
critical O
for O
MV O
pathogenesis O
, O
its O
escape O
, O
which O
results O
from O
loss O
of O
receptor O
- O
binding O
activity O
, O
should O
not O
occur O
in O
nature O
. O

Paramyxovirus O
V O
proteins O
bind O
to O
MDA5 B
( I
melanoma I
differentiation I
- I
associated I
gene I
5 I
) I
and O
LGP2 B
( I
laboratory I
of I
genetics I
and I
physiology I
gene I
2 I
) I
but O
not O
RIG B
- I
I I
( I
retinoic I
acid I
- I
inducible I
gene I
I I
) I
. O

After O
the O
contagion O
measles B
virus I
( I
MV I
) I
crosses O
the O
respiratory O
epithelium O
within O
myeloid O
cells O
that O
express O
the O
primary O
receptor O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
, O
it O
replicates O
briskly O
in O
SLAM O
- O
expressing O
cells O
in O
lymphatic O
organs O
. O

To O
characterize O
the O
mechanisms O
of O
spread O
, O
we O
infected O
groups O
of O
5 O
or O
6 O
cynomolgus O
monkeys O
( O
Macaca O
fascicularis O
) O
with O
either O
a O
wild O
- O
type O
MV O
or O
its O
N4 O
- O
blind O
derivative O
, O
which O
is O
unable O
to O
enter O
nectin O
- O
4 O
- O
expressing O
cells O
because O
of O
the O
targeted O
mutation O
of O
two O
hemagglutinin O
residues O
. O

Analyses O
of O
tracheal O
rings O
obtained O
at O
necropsy O
( O
day O
12 O
) O
documented O
widespread O
infection O
of O
individual O
cells O
or O
small O
cell O
clusters O
in O
the O
subepithelial O
lamina O
propria O
of O
monkeys O
infected O
with O
either O
virus O
. O

Infected O
CD11c O
( O
+ O
) O
myeloid O
( O
macrophage O
or O
dendritic O
) O
cells O
were O
frequently O
observed O
in O
the O
lamina O
propria O
below O
epithelial O
infectious O
centers O
. O

There O
is O
a O
paradox O
between O
the O
remarkable O
genetic O
stability O
of O
measles B
virus I
( I
MV I
) I
in O
the O
field O
and O
the O
high O
mutation O
rates O
implied O
by O
the O
frequency O
of O
the O
appearance O
of O
monoclonal O
antibody O
escape O
mutants O
generated O
when O
the O
virus O
is O
pressured O
to O
revert O
in O
vitro O
( O
S O
. O

We O
established O
a O
highly O
sensitive O
assay O
to O
determine O
frequencies O
of O
various O
categories O
of O
mutations O
in O
large O
populations O
of O
wild O
- O
type O
and O
laboratory O
- O
adapted O
MVs O
using O
recombinant O
viruses O
containing O
an O
additional B
transcription I
unit I
( I
ATU I
) I
encoding O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
. O

8 O
x O
10 O
( O
- O
6 O
) O
per O
base O
per O
replication O
event O
. O

Highly O
pathogenic O
Nipah B
virus I
( I
NiV I
) I
infections O
are O
transmitted O
via O
airway O
secretions O
and O
urine O
, O
commonly O
via O
the O
respiratory O
route O
. O

In O
this O
report O
, O
we O
show O
for O
the O
first O
time O
that O
NiV O
can O
infect O
polarized O
kidney O
epithelial O
cells O
( O
MDCK O
) O
from O
both O
cell O
surfaces O
, O
while O
virus O
release O
is O
primarily O
restricted O
to O
the O
apical O
plasma O
membrane O
. O

Here O
we O
took O
advantage O
of O
the O
natural O
tropism O
of O
Nipah B
virus I
( I
NiV I
) I
, O
whose O
attachment O
envelope O
glycoprotein O
has O
picomolar O
affinity O
for O
ephrinB2 O
, O
a O
molecule O
proposed O
as O
a O
molecular O
marker O
of O
stemness O
( O
present O
on O
embryonic O
, O
hematopoietic O
, O
and O
neural O
stem O
cells O
) O
as O
well O
as O
being O
implicated O
in O
tumorigenesis O
of O
specific O
cancers O
. O

NiV O
entry O
requires O
both O
the O
fusion O
( O
F O
) O
and O
attachment O
( O
G O
) O
glycoproteins O
. O

Truncation O
of O
the O
NiV O
- O
F O
cytoplasmic O
tail O
( O
T5F O
) O
alone O
, O
combined O
with O
full O
- O
length O
NiV O
- O
G O
, O
resulted O
in O
optimal O
titers O
of O
NiV B
- I
pseudotyped I
particles I
( I
NiVpp I
) I
( O
similar O
to O
10 O
( O
6 O
) O
IU O
/ O
ml O
) O
, O
even O
without O
ultracentrifugation O
. O

To O
further O
enhance O
the O
infectivity O
of O
NiVpp O
, O
we O
engineered O
a O
hyperfusogenic O
NiV O
- O
F O
protein O
lacking O
an O
N O
- O
linked O
glycosylation O
site O
( O
T5F O
Delta O
N3 O
) O
. O

T5F O
Delta O
N3 O
/ O
wt O
G O
particles O
exhibited O
enhanced O
infectivity O
on O
less O
permissive O
cell O
lines O
and O
efficiently O
targeted O
ephrinB2 O
( O
+ O
) O
cells O
even O
in O
a O
1 O
, O
000 O
- O
fold O
excess O
of O
ephrinB2 O
- O
negative O
cells O
, O
all O
without O
any O
loss O
of O
specificity O
, O
as O
entry O
was O
abrogated O
by O
soluble O
ephrinB2 O
. O

The O
extraordinary O
specificity O
of O
NiV O
- O
G O
for O
ephrinB2 O
holds O
promise O
for O
targeting O
specific O
ephrinB2 O
( O
+ O
) O
populations O
in O
vivo O
or O
in O
vitro O
. O

Although O
all O
the O
available O
data O
suggest O
that O
measles O
eradication O
is O
biologically O
feasible O
, O
a O
structural O
and O
biochemical O
basis O
for O
the O
single O
serotype O
nature O
of O
measles B
virus I
( I
MV I
) I
remains O
to O
be O
provided O
. O

The O
hemagglutinin B
( I
H I
) I
protein O
, O
which O
binds O
to O
two O
discrete O
proteinaceous O
receptors O
, O
is O
the O
major O
neutralizing O
target O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
recognizing O
distinct O
epitopes O
on O
the O
H O
protein O
were O
characterized O
using O
recombinant O
MVs O
encoding O
the O
H O
gene O
from O
different O
MV O
genotypes O
. O

One O
, O
which O
is O
a O
previously O
recognized O
epitope O
, O
is O
located O
near O
the O
receptor B
- I
binding I
site I
( I
RBS I
) I
, O
and O
thus O
MAbs O
that O
recognize O
this O
epitope O
blocked O
the O
receptor O
binding O
of O
the O
H O
protein O
, O
whereas O
the O
other O
epitope O
is O
located O
at O
the O
position O
distant O
from O
the O
RBS O
. O

Thus O
, O
a O
MAb O
that O
recognizes O
this O
epitope O
did O
not O
inhibit O
the O
receptor O
binding O
of O
the O
H O
protein O
, O
rather O
interfered O
with O
the O
hemagglutinin O
- O
fusion O
( O
H O
- O
F O
) O
interaction O
. O

The O
paramyxovirus O
entry O
machinery O
consists O
of O
two O
glycoproteins O
that O
tightly O
cooperate O
to O
achieve O
membrane O
fusion O
for O
cell O
entry O
: O
the O
tetrameric O
attachment O
protein O
( O
HN O
, O
H O
, O
or O
G O
, O
depending O
on O
the O
paramyxovirus O
genus O
) O
and O
the O
trimeric O
fusion B
protein I
( I
F I
) I
. O

To O
properly O
probe O
F O
conformations O
, O
we O
identified O
anti O
- O
F O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
recognize O
conformation O
- O
dependent O
epitopes O
. O

This O
notion O
was O
further O
validated O
by O
exploring O
the O
conformational O
states O
of O
destabilized O
F O
mutants O
and O
stabilized O
soluble O
F O
variants O
combined O
with O
the O
use O
of O
a O
membrane O
fusion O
inhibitor O
( O
3g O
) O
. O

ADAR1 O
, O
an O
interferon B
( I
IFN I
) I
- O
inducible O
double B
- I
stranded I
( I
ds I
) I
RNA O
- O
specific O
adenosine O
deaminase O
, O
downregulates O
host O
innate O
responses O
, O
including O
activation O
of O
the O
dsRNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
and O
induction O
of O
IFN O
- O
beta O
mRNA O
. O

Conversely O
, O
PKR O
amplifies O
IFN O
- O
beta O
induction O
by O
measles B
virus I
( I
MV I
) I
and O
inhibits O
virus O
protein O
synthesis O
. O

Formation O
of O
Stress B
granules I
( I
SGs I
) I
, O
cytoplasmic O
aggregates O
of O
stalled O
translation O
complexes O
and O
RNA O
- O
binding O
proteins O
, O
is O
a O
host O
response O
to O
virus O
infection O
mediated O
by O
translation O
initiation O
factor O
eIF2 O
alpha O
phosphorylation O
. O

We O
examined O
the O
roles O
of O
PKR O
and O
ADAR1 O
in O
SG O
formation O
using O
HeLa O
cells O
stably O
deficient O
in O
either O
PKR O
( O
PKRkd O
) O
or O
ADAR1 O
( O
ADAR1 O
( O
kd O
) O
) O
compared O
to O
control O
( O
CONkd O
) O
cells O
. O

Infection O
with O
either O
wildtype B
( I
WT I
) I
MV O
or O
an O
isogenic O
mutant O
lacking O
C O
protein O
expression O
( O
C O
- O
ko O
) O
comparably O
induced O
formation O
of O
SG O
in O
ADAR1 O
( O
kd O
) O
cells O
, O
whereas O
only O
the O
Cko O
mutant O
was O
an O
efficient O
inducer O
in O
control O
cells O
. O

Complementation O
of O
ADAR1 O
( O
kd O
) O
cells O
by O
expression O
of O
either O
p150 O
WT O
isoform O
or O
the O
p150 O
Z O
alpha O
( O
Y177A O
) O
Z O
- O
DNA O
- O
binding O
mutant O
of O
ADAR1 O
restored O
suppression O
of O
host O
responses O
, O
including O
SG O
formation O
and O
PKR O
activation O
. O

In O
contrast O
, O
neither O
the O
p110 O
WT O
isoform O
nor O
the O
p150 O
catalytic O
( O
H910A O
, O
E912A O
) O
mutant O
of O
ADAR1 O
complemented O
the O
ADAR1 O
( O
kd O
) O
phenotype O
. O

The O
major O
inducible O
70 O
- O
kDa O
heat O
shock O
protein O
( O
hsp70 O
) O
is O
host O
protective O
in O
a O
mouse O
model O
of O
measles B
virus I
( I
MeV I
) I
brain O
infection O
. O

Transgenic O
constitutive O
expression O
of O
hsp70 O
in O
neurons O
, O
the O
primary O
target O
of O
MeV O
infection O
, O
abrogates O
neurovirulence O
in O
neonatal O
H O
- O
2 O
( O
d O
) O
congenic O
C57BL O
/ O
6 O
mice O
. O

Transcriptome O
analysis O
of O
brains O
from O
transgenic B
( I
Tg I
) I
and O
nontransgenic O
( O
NT O
) O
mice O
5 O
days O
after O
infection O
identified O
type B
I I
interferon I
( I
IFN I
) I
signaling O
, O
macrophage O
activation O
, O
and O
antigen O
presentation O
as O
the O
main O
differences O
linked O
to O
survival O
. O

The O
pivotal O
role O
of O
type O
I O
IFN O
in O
hsp70 O
- O
mediated O
protection O
was O
demonstrated O
in O
mice O
with O
a O
genetically O
disrupted O
type O
I O
IFN O
receptor O
( O
IFNAR O
( O
- O
/ O
- O
) O
) O
, O
where O
IFNAR O
( O
- O
/ O
- O
) O
eliminated O
the O
difference O
in O
survival O
between O
TG O
and O
NT O
mice O
. O

canine B
distemper I
virus I
( I
CDV I
) I
has O
recently O
expanded O
its O
host O
range O
to O
nonhuman O
primates O
. O

A O
CDV O
strain O
( O
CYN07 O
- O
dV O
) O
was O
isolated O
in O
Vero O
cells O
expressing O
dog O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
. O

The O
envelope O
glycoprotein B
( I
GP I
) I
of O
Marburg B
virus I
( I
MARV I
) I
and O
Ebola B
virus I
( I
EBOV I
) I
is O
responsible O
for O
virus O
entry O
into O
host O
cells O
and O
is O
known O
as O
the O
only O
target O
of O
neutralizing O
antibodies O
. O

Here O
we O
show O
that O
MARV O
GP O
- O
specific O
monoclonal O
antibodies O
AGP127 O
- O
8 O
( O
IgG1 O
) O
and O
MGP72 O
- O
17 O
( O
IgM O
) O
, O
which O
do O
not O
inhibit O
the O
GP O
- O
mediated O
entry O
of O
MARV O
into O
host O
cells O
, O
drastically O
reduced O
the O
budding O
and O
release O
of O
progeny O
viruses O
from O
infected O
cells O
. O

These O
antibodies O
similarly O
inhibited O
the O
formation O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
consisting O
of O
GP O
, O
the O
viral O
matrix O
protein O
, O
and O
nucleoprotein O
, O
whereas O
the O
Fab O
fragment O
of O
AGP127 O
- O
8 O
showed O
no O
inhibitory O
effect O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
remains O
a O
serious O
public O
health O
problem O
worldwide O
. O

Toward O
developing O
an O
HCV O
vaccine O
, O
we O
engineered O
two O
recombinant O
measles B
viruses I
( I
MVs I
) I
expressing O
structural O
proteins O
from O
the O
prototypic O
HCV O
subtype O
1a O
strain O
H77 O
. O

One O
virus O
directs O
the O
synthesis O
of O
the O
HCV O
Capsid B
( I
C I
) I
protein O
and O
envelope B
glycoproteins I
( I
E1 I
and I
E2 I
) I
, O
which O
fold O
properly O
and O
form O
a O
heterodimer O
. O

Virions O
encapsidating O
two O
or O
three O
genomes O
( O
approximately O
25 O
% O
of O
total O
) O
were O
also O
observed O
by O
utilizing O
three O
different O
recombinant O
viruses O
expressing O
unique O
fluorescent O
reporters O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
highly O
pathogenic O
, O
negative O
- O
strand O
RNA O
paramyxovirus O
that O
has O
recently O
emerged O
from O
flying O
foxes O
to O
cause O
serious O
human O
disease O
. O

We O
have O
analyzed O
the O
role O
of O
the O
nonstructural O
NiV O
C O
protein O
in O
viral O
immunopathogenesis O
using O
recombinant O
virus O
lacking O
the O
expression O
of O
NiV O
C O
( O
NiV O
Delta O
C O
) O
. O

Compared O
to O
wild O
- O
type O
virus O
, O
NiV O
Delta O
C O
induced O
increased O
expression O
of O
interleukin B
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
, O
IL O
- O
8 O
, O
CXCL2 O
, O
CXCL3 O
, O
CXCL6 O
, O
CCL20 O
, O
and O
beta O
interferon O
. O

Transmission O
of O
measles B
virus I
( I
MV I
) I
to O
T O
cells O
by O
its O
early O
CD150 O
( O
+ O
) O
target O
cells O
is O
considered O
to O
be O
crucial O
for O
viral O
dissemination O
within O
the O
hematopoietic O
compartment O
. O

Using O
cocultures O
involving O
monocyte O
- O
derived O
dendritic B
cells I
( I
DCs I
) I
and O
T O
cells O
, O
we O
now O
show O
that O
T O
cells O
acquire O
MV O
most O
efficiently O
from O
cis O
- O
infected O
DCs O
rather O
than O
DCs O
having O
trapped O
MV O
( O
trans O
- O
infection O
) O
. O

In O
addition O
to O
rare O
association O
with O
actin O
- O
rich O
filopodial O
structures O
, O
the O
formation O
of O
contact O
interfaces O
consistent O
with O
that O
of O
virological B
synapses I
( I
VS I
) I
was O
observed O
where O
viral O
proteins O
accumulated O
and O
CD150 O
was O
redistributed O
in O
an O
actin O
- O
dependent O
manner O
. O

canine B
distemper I
virus I
( I
CDV I
) I
uses O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
, O
expressed O
on O
immune O
cells O
, O
as O
a O
receptor O
. O

Although O
airway O
epithelial O
cells O
represent O
an O
important O
target O
for O
infection O
, O
the O
respiratory O
epithelium O
is O
also O
composed O
of O
an O
elaborate O
network O
of O
dendritic B
cells I
( I
DCs I
) I
that O
are O
essential O
sentinels O
of O
the O
immune O
system O
, O
sensing O
pathogens O
and O
presenting O
foreign O
antigens O
to O
T O
lymphocytes O
. O

In O
this O
report O
, O
we O
show O
that O
in O
vitro O
infection O
by O
human B
coronavirus I
229E I
( I
HCoV I
- I
229E I
) I
induces O
massive O
cytopathic O
effects O
in O
DCs O
, O
including O
the O
formation O
of O
large O
syncytia O
and O
cell O
death O
within O
only O
few O
hours O
. O

measles B
virus I
( I
MV I
) I
infection O
in O
children O
harboring O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
is O
often O
fatal O
, O
even O
in O
the O
presence O
of O
neutralizing O
antibodies O
; O
however O
, O
the O
underlying O
mechanisms O
are O
unclear O
. O

Therefore O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
interaction O
between O
HIV O
- O
1 O
and O
wild O
- O
type O
MV O
( O
MVwt O
) O
or O
an O
MV B
vaccine I
strain I
( I
MVvac I
) I
during O
dual O
infection O
. O

The O
results O
showed O
that O
the O
frequencies O
of O
MVwt O
- O
and O
MVvac O
- O
infected O
CD4 O
( O
+ O
) O
T O
cells O
within O
the O
resting O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
were O
increased O
3 O
- O
to O
4 O
- O
fold O
after O
HIV O
- O
1 O
infection O
, O
and O
this O
was O
associated O
with O
a O
marked O
upregulation O
of O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
expression O
on O
CD4 O
( O
+ O
) O
T O
cells O
but O
not O
on O
CD8 O
( O
+ O
) O
T O
cells O
. O

Notably O
, O
SLAM O
upregulation O
was O
observed O
in O
HIV O
- O
infected O
as O
well O
as O
- O
uninfected O
CD4 O
( O
+ O
) O
T O
cells O
and O
was O
abrogated O
by O
the O
removal O
of O
HLA O
- O
DR O
+ O
cells O
from O
the O
PBMC O
culture O
. O

Rather O
, O
CD4 O
( O
+ O
) O
T O
cell O
activation O
mediated O
through O
direct O
contact O
with O
dendritic O
cells O
via O
leukocyte O
function O
- O
associated O
molecule O
1 O
( O
LFA O
- O
1 O
) O
/ O
intercellular B
adhesion I
molecule I
1 I
( I
ICAM I
- I
1 I
) I
and O
LFA O
- O
3 O
/ O
CD2 O
was O
critical O
. O

Thus O
, O
HIV O
- O
1 O
infection O
induces O
a O
high O
level O
of O
SLAM O
expression O
on O
CD4 O
( O
+ O
) O
T O
cells O
, O
which O
may O
enhance O
their O
susceptibility O
to O
MV O
and O
exacerbate O
measles O
in O
coinfected O
individuals O
. O

acid B
sphingomyelinase I
( I
ASMase I
) I
converts O
the O
lipid O
sphingomyelin B
( I
SM I
) I
to O
phosphocholine O
and O
ceramide O
and O
has O
optimum O
activity O
at O
acidic O
pH O
. O

Each O
plays O
roles O
in O
mediating O
macropinocytosis O
, O
which O
has O
been O
shown O
to O
be O
important O
for O
ebolavirus B
( I
EBOV I
) I
infection O
. O

dendritic B
cells I
( I
DCs I
) I
are O
potent O
antigen O
- O
presenting O
cells O
capable O
of O
promoting O
or O
regulating O
innate O
and O
adaptive O
immune O
responses O
against O
non O
- O
self O
antigens O
. O

Lentiviral B
vectors I
( I
LVs I
) I
have O
conferred O
a O
huge O
advantage O
in O
that O
they O
can O
transduce O
nondividing O
cells O
such O
as O
human B
monocyte I
- I
derived I
DCs I
( I
MDDCs I
) I
but O
required O
high O
amounts O
of O
viral O
particles O
and O
/ O
or O
accessory O
proteins O
such O
as O
Vpx O
or O
Vpr O
to O
achieve O
sufficient O
transduction O
rates O
. O

, O
with O
envelope O
glycoproteins O
from O
the O
measles B
virus I
( I
MV I
) I
, O
we O
demonstrate O
that O
MDDCs O
are O
transduced O
very O
efficiently O
with O
these O
new O
LVs O
compared O
to O
the O
classically O
used O
vesicular O
stomatitis O
virus O
G O
- O
pseudotyped O
LVs O
and O
thus O
allowed O
to O
achieve O
high O
transduction O
rates O
at O
relatively O
low O
multiplicities O
of O
infection O
. O

To O
characterize O
the O
importance O
of O
infection O
of O
epithelial O
cells O
for O
morbillivirus O
pathogenesis O
, O
we O
took O
advantage O
of O
the O
severe O
disease O
caused O
by O
canine B
distemper I
virus I
( I
CDV I
) I
in O
ferrets O
. O

To O
obtain O
a O
CDV O
that O
was O
unable O
to O
enter O
epithelial O
cells O
but O
retained O
the O
ability O
to O
enter O
immune O
cells O
, O
we O
transferred O
to O
its O
attachment O
( O
H O
) O
protein O
two O
mutations O
shown O
to O
interfere O
with O
the O
interaction O
of O
measles O
virus O
H O
with O
its O
epithelial O
receptor O
, O
human O
nectin O
- O
4 O
. O

As O
expected O
for O
an O
epithelial B
receptor I
( I
EpR I
) I
- O
blind O
CDV O
, O
this O
virus O
infected O
dog O
and O
ferret O
epithelial O
cells O
inefficiently O
and O
did O
not O
cause O
cell O
fusion O
or O
syncytium O
formation O
. O

On O
the O
other O
hand O
, O
the O
EpR O
- O
blind O
CDV O
replicated O
in O
cells O
expressing O
canine O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
, O
the O
morbillivirus O
immune O
cell O
receptor O
, O
with O
similar O
kinetics O
to O
those O
of O
wild O
- O
type O
CDV O
. O

Proteolytic O
activation O
of O
the O
fusion O
protein O
of O
the O
highly O
pathogenic O
Nipah B
virus I
( I
NiV I
F I
) I
is O
a O
prerequisite O
for O
the O
production O
of O
infectious O
particles O
and O
for O
virus O
spread O
via O
cell O
- O
to O
- O
cell O
fusion O
. O

Supporting O
the O
idea O
of O
an O
efficient O
F O
cleavage O
in O
early O
and O
recycling O
endosomes O
of O
MDCK O
cells O
, O
endocytosed O
F O
proteins O
and O
cathepsin O
B O
colocalized O
markedly O
with O
the O
endosomal O
marker O
proteins O
early B
endosomal I
antigen I
1 I
( I
EEA I
- I
1 I
) I
, O
Rab4 O
, O
and O
Rab11 O
, O
while O
NiV O
F O
trafficking O
through O
late O
endosomal O
compartments O
was O
not O
needed O
for O
F O
activation O
. O

ADAR1 O
, O
the O
interferon B
( I
IFN I
) I
- O
inducible O
adenosine O
deaminase O
acting O
on O
RNA O
, O
catalyzes O
the O
C O
- O
6 O
deamination O
of O
adenosine O
( O
A O
) O
to O
produce O
inosine O
( O
I O
) O
in O
RNA O
substrates O
with O
a O
double O
- O
stranded O
character O
. O

HeLa O
cells O
made O
stably O
deficient O
in O
ADAR1 O
( O
ADAR1 O
( O
kd O
) O
) O
were O
compared O
to O
vector O
control O
( O
CONkd O
) O
and O
protein B
kinase I
PKR I
- I
deficient I
( I
PKRkd I
) I
cells O
for O
IFN O
- O
beta O
induction O
following O
infection O
with O
either O
parental O
( O
wild O
- O
type O
[ O
WT O
] O
) O
recombinant O
Moraten O
vaccine O
strain O
measles B
virus I
( I
MV I
) I
or O
isogenic O
knockout O
mutants O
deficient O
for O
either O
V O
( O
V O
- O
ko O
) O
or O
C O
( O
C O
- O
ko O
) O
protein O
expression O
. O

A O
major O
difference O
between O
vaccine O
and O
wild O
- O
type O
strains O
of O
measles B
virus I
( I
MV I
) I
in O
vitro O
is O
the O
wider O
cell O
specificity O
of O
vaccine O
strains O
, O
resulting O
from O
the O
receptor O
usage O
of O
the O
hemagglutinin B
( I
H I
) I
protein O
. O

Wild O
- O
type O
H O
proteins O
recognize O
the O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
( O
CD150 O
) O
, O
which O
is O
expressed O
on O
certain O
cells O
of O
the O
immune O
system O
, O
whereas O
vaccine O
H O
proteins O
recognize O
CD46 O
, O
which O
is O
ubiquitously O
expressed O
on O
all O
nucleated O
human O
and O
monkey O
cells O
, O
in O
addition O
to O
SLAM O
. O

To O
examine O
the O
effect O
of O
the O
H O
protein O
on O
the O
tropism O
and O
attenuation O
of O
MV O
, O
we O
generated O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
expressing O
recombinant O
wild O
- O
type O
MV O
strains O
bearing O
the O
Edmonston O
vaccine O
H O
protein O
( O
MV O
- O
EdH O
) O
and O
compared O
them O
to O
EGFP O
- O
expressing O
wild O
- O
type O
MV O
strains O
. O

In O
vitro O
, O
MV O
- O
EdH O
replicated O
in O
SLAM O
( O
+ O
) O
as O
well O
as O
CD46 O
( O
+ O
) O
cells O
, O
including O
primary O
cell O
cultures O
from O
cynomolgus O
monkey O
tissues O
, O
whereas O
the O
wild O
- O
type O
MV O
replicated O
only O
in O
SLAM O
( O
+ O
) O
cells O
. O

Flow O
cytometric O
analysis O
indicated O
that O
SLAM O
( O
+ O
) O
lymphocyte O
cells O
were O
infected O
preferentially O
with O
both O
strains O
. O

The O
species O
B O
Human B
adenoviruses I
( I
HAdVs I
) I
infect O
cells O
upon O
attaching O
to O
CD46 O
or O
desmoglein B
2 I
( I
DSG I
- I
2 I
) I
by O
one O
or O
several O
of O
their O
12 O
fiber B
knob I
trimers I
( I
FKs I
) I
. O

To O
test O
whether O
DSG O
- O
2 O
and O
CD46 O
simultaneously O
serve O
as O
virus O
receptors O
for O
adenovirus B
type I
3 I
( I
Ad3 I
) I
, O
we O
performed O
individual O
and O
combined O
CD46 O
/ O
DSG O
- O
2 O
loss O
- O
of O
- O
function O
studies O
in O
human O
lung O
A549 O
and O
16HBE14o O
cells O
. O

This O
new O
chimeric O
glycoprotein O
, O
which O
has O
been O
named O
the O
Sst B
receptor I
binding I
site I
( I
Sst I
- I
RBS I
) I
, O
gives O
targeted O
transduction O
based O
on O
three O
criteria O
: O
( O
i O
) O
a O
gain O
of O
the O
use O
of O
a O
new O
entry O
receptor O
not O
used O
by O
any O
known O
virus O
; O
( O
ii O
) O
targeted O
entry O
at O
levels O
comparable O
to O
gene O
delivery O
by O
wild O
- O
type O
ecotropic O
Moloney O
murine O
leukemia O
virus O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
G O
glycoproteins O
; O
and O
( O
iii O
) O
a O
loss O
of O
the O
use O
of O
the O
natural O
ecotropic O
virus O
receptor O
. O

Importantly O
, O
vectors O
coated O
with O
the O
Sst O
- O
RBS O
glycoprotein O
gave O
targeted O
entry O
of O
up O
to O
1 O
x O
10 O
( O
6 O
) O
transducing O
U O
/ O
ml O
, O
a O
level O
comparable O
to O
that O
seen O
with O
infection O
of O
vectors O
coated O
with O
the O
parental O
wild O
- O
type O
ecotropic O
Moloney O
murine O
leukemia O
virus O
glycoprotein O
through O
the O
ecotropic O
receptor O
and O
approaching O
that O
of O
infection O
of O
VSV O
G O
- O
coated O
vectors O
through O
the O
VSV O
receptor O
. O

To O
investigate O
this O
concern O
, O
sera O
obtained O
from O
children O
6 O
weeks O
after O
receipt O
of O
measles B
, I
mumps I
, I
and I
rubella I
( I
MMR I
) I
vaccine O
were O
tested O
for O
the O
ability O
to O
neutralize O
a O
carefully O
selected O
group O
of O
genetically O
diverse O
mumps O
virus O
strains O
. O

Transcriptional O
induction O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
through O
pattern O
recognition O
receptors O
is O
a O
key O
event O
in O
the O
host O
defense O
against O
invading O
viruses O
. O

Infection O
of O
cells O
by O
paramyxoviruses O
, O
like O
measles B
virus I
( I
MV I
) I
( O
genus O
Morbillivirus O
) O
, O
is O
sensed O
predominantly O
by O
the O
ubiquitous O
cytoplasmic O
helicase O
RIG O
- O
I O
, O
recognizing O
viral O
5 O
' O
- O
triphosphate O
RNAs O
, O
and O
to O
some O
degree O
by O
MDA5 O
. O

Notably O
, O
C O
proteins O
of O
wild O
- O
type O
MV O
isolates O
, O
which O
are O
poor O
IFN O
- O
beta O
inducers O
, O
were O
found O
to O
comprise O
a O
canonical O
nuclear B
localization I
signal I
( I
NLS I
) I
, O
whereas O
the O
NLSs O
of O
all O
vaccine O
strains O
, O
irrespective O
of O
their O
origins O
, O
were O
mutated O
. O

During O
paramyxovirus O
entry O
into O
a O
host O
cell O
, O
receptor O
engagement O
by O
a O
specialized O
binding O
protein O
triggers O
conformational O
changes O
in O
the O
adjacent O
fusion B
protein I
( I
F I
) I
, O
leading O
to O
fusion O
between O
the O
viral O
and O
cell O
membranes O
. O

For O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
, O
the O
receptor O
binding O
protein O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
) O
has O
three O
functions O
: O
receptor O
binding O
, O
receptor O
cleaving O
, O
and O
activating O
F O
. O

Inflammasomes O
are O
cytosolic O
protein O
complexes O
that O
stimulate O
the O
activation O
of O
caspase O
- O
1 O
, O
which O
in O
turn O
induces O
the O
secretion O
of O
the O
inflammatory O
cytokines O
interleukin B
- I
1 I
beta I
( I
IL I
- I
1 I
beta I
) I
and O
IL O
- O
18 O
. O

Recent O
studies O
have O
indicated O
that O
the O
inflammasome O
known O
as O
the O
NOD O
- O
like O
- O
receptor O
- O
family O
, O
pyrin O
domain O
- O
containing O
3 O
( O
NLRP3 O
) O
inflammasome O
recognizes O
several O
RNA O
viruses O
, O
including O
the O
influenza O
and O
encephalomyocarditis O
viruses O
, O
whereas O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
inflammasome O
may O
detect O
vesicular O
stomatitis O
virus O
. O

We O
demonstrate O
that O
measles B
virus I
( I
MV I
) I
infection O
induces O
caspase O
- O
1 O
- O
dependent O
IL O
- O
1 O
beta O
secretion O
in O
the O
human O
macrophage O
- O
like O
cell O
line O
THP O
- O
1 O
. O

measles B
virus I
( I
MV I
) I
is O
still O
an O
imposing O
threat O
to O
public O
health O
. O

The O
matrix B
( I
M I
) I
protein O
has O
been O
shown O
not O
only O
to O
function O
as O
a O
structure O
block O
in O
the O
assembled O
MV O
virions O
, O
but O
also O
to O
regulate O
viral O
RNA O
synthesis O
, O
playing O
an O
important O
role O
in O
MV O
' O
s O
replication O
and O
assembly O
. O

In O
the O
present O
study O
, O
we O
generated O
a O
panel O
of O
IgG O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
M O
protein O
and O
successfully O
obtained O
one O
IgA O
MAb O
( O
5H7 O
) O
from O
the O
IgG O
panel O
. O

The O
data O
presented O
indicate O
that O
, O
while O
failing O
to O
show O
the O
activities O
of O
traditional O
neutralization O
and O
immune O
exclusion O
, O
M O
- O
specific O
IgA O
MAb O
was O
able O
to O
effectively O
inhibit O
viral O
replication O
by O
intracellular O
neutralization O
( O
78 O
% O
) O
, O
supporting O
the O
notion O
that O
the O
M O
protein O
is O
important O
for O
MV O
assembly O
and O
replication O
and O
implying O
that O
the O
M O
protein O
was O
an O
effective O
target O
antigen O
. O

The O
morbilliviruses O
measles B
virus I
( I
MeV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
both O
rely O
on O
two O
surface O
glycoproteins O
, O
the O
attachment O
( O
H O
) O
and O
fusion O
proteins O
, O
to O
promote O
fusion O
activity O
for O
viral O
cell O
entry O
. O

adenosine B
deaminase I
acting I
on I
RNA I
1 I
( I
ADAR1 I
) I
is O
a O
double O
- O
stranded O
RNA O
binding O
protein O
and O
RNA O
- O
editing O
enzyme O
that O
modifies O
cellular O
and O
viral O
RNAs O
, O
including O
coding O
and O
noncoding O
RNAs O
. O

This O
interferon B
( I
IFN I
) I
- O
induced O
protein O
was O
expected O
to O
have O
an O
antiviral O
role O
, O
but O
recent O
studies O
have O
demonstrated O
that O
it O
promotes O
the O
replication O
of O
many O
RNA O
viruses O
. O

The O
proviral O
activity O
of O
ADAR1 O
occurs O
through O
two O
mechanisms O
: O
RNA O
editing O
and O
inhibition O
of O
RNA B
- I
activated I
protein I
kinase I
( I
PKR I
) I
. O

Transient O
lymphopenia O
is O
a O
hallmark O
of O
measles B
virus I
( I
MV I
) I
- O
induced O
immunosuppression O
. O

To O
address O
to O
what O
extent O
replenishment O
of O
the O
peripheral O
lymphocyte O
compartment O
from O
bone B
marrow I
( I
BM I
) I
progenitor O
/ O
stem O
cells O
might O
be O
affected O
, O
we O
analyzed O
the O
interaction O
of O
wild O
- O
type O
MV O
with O
hematopoietic B
stem I
and I
progenitor I
cells I
( I
HS I
/ I
PCs I
) I
and O
stroma O
cells O
in O
vitro O
. O

Infection O
of O
human O
CD34 O
( O
+ O
) O
HS O
/ O
PCs O
or O
stroma O
cells O
with O
wild O
- O
type O
MV O
is O
highly O
inefficient O
yet O
noncytolytic O
. O

It O
occurs O
independently O
of O
CD150 O
in O
stroma O
cells O
but O
also O
in O
HS O
/ O
PCs O
, O
where O
infection O
is O
established O
in O
CD34 O
( O
+ O
) O
D150 O
( O
- O
) O
and O
CD34 O
( O
+ O
) O
CD150 O
( O
+ O
) O
( O
in O
humans O
representing O
HS O
/ O
PC O
oligopotent O
precursors O
) O
subsets O
. O

Though O
MV O
exposure O
does O
not O
detectably O
affect O
the O
viability O
, O
expansion O
, O
and O
colony O
- O
forming O
activity O
of O
either O
CD150 O
( O
+ O
) O
or O
CD150 O
( O
- O
) O
HS O
/ O
PCs O
in O
vitro O
, O
it O
efficiently O
interferes O
with O
short O
- O
but O
not O
long O
- O
term O
hematopoietic O
reconstitution O
in O
NOD O
/ O
SCID O
mice O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
is O
a O
potential O
oncolytic O
virus O
for O
treating O
glioblastoma B
multiforme I
( I
GBM I
) I
, O
an O
aggressive O
brain O
tumor O
. O

matrix B
( I
M I
) I
protein O
mutants O
of O
VSV O
have O
shown O
greater O
selectivity O
for O
killing O
GBM O
cells O
versus O
normal O
brain O
cells O
than O
VSV O
with O
wild O
- O
type O
M O
protein O
. O

The O
goal O
of O
this O
research O
was O
to O
determine O
the O
contribution O
of O
death O
receptor O
and O
mitochondrial O
pathways O
to O
apoptosis O
induced O
by O
an O
M O
protein O
mutant O
( O
M51R O
) O
VSV O
in O
U87 O
human O
GBM O
tumor O
cells O
. O

Compared O
to O
controls O
, O
U87 O
cells O
expressing O
a O
dominant O
negative O
form O
of O
Fas O
( O
dnFas O
) O
or O
overexpressing O
Bcl O
- O
X O
( O
L O
) O
had O
reduced O
caspase O
- O
3 O
activation O
following O
infection O
with O
M51R O
VSV O
, O
indicating O
that O
both O
the O
death O
receptor O
pathway O
and O
mitochondrial O
pathways O
are O
important O
for O
M51R O
VSV O
- O
induced O
apoptosis O
. O

Death O
receptor O
signaling O
has O
been O
classified O
as O
type O
I O
or O
type O
II O
, O
depending O
on O
whether O
signaling O
is O
independent O
( O
type O
I O
) O
or O
dependent O
on O
the O
mitochondrial O
pathway O
( O
type O
II O
) O
. O

Bcl O
- O
X O
( O
L O
) O
overexpression O
inhibited O
caspase O
activation O
in O
response O
to O
a O
Fas O
- O
inducing O
antibody O
, O
similar O
to O
the O
inhibition O
in O
response O
to O
M51R O
VSV O
infection O
, O
indicating O
that O
U87 O
cells O
behave O
as O
type O
II O
cells O
. O

Murine O
xenografts O
of O
U87 O
cells O
that O
overexpress O
Bcl O
- O
X O
( O
L O
) O
regressed O
with O
a O
time O
course O
similar O
to O
that O
of O
control O
cells O
following O
treatment O
with O
M51R O
VSV O
, O
and O
tumors O
were O
not O
detectable O
at O
21 O
days O
postinoculation O
. O

Immunohistochemical O
analysis O
demonstrated O
similar O
levels O
of O
viral O
antigen O
expression O
but O
reduced O
activation O
of O
caspase O
- O
3 O
following O
virus O
treatment O
of O
Bcl O
- O
X O
( O
L O
) O
- O
overexpressing O
tumors O
compared O
to O
controls O
. O

Further O
, O
the O
pathological O
changes O
in O
tumors O
following O
treatment O
with O
virus O
were O
quite O
different O
in O
the O
presence O
versus O
the O
absence O
of O
Bcl O
- O
X O
( O
L O
) O
overexpression O
. O

Previously O
, O
we O
generated O
Lentiviral B
vectors I
( I
LVs I
) I
pseudotyped O
with O
the O
Edmonston O
measles B
virus I
( I
MV I
) I
hemagglutinin O
and O
fusion O
glycoproteins O
( O
Hgps O
and O
Fgps O
) O
( O
H O
/ O
F O
- O
LVs O
) O
, O
which O
, O
for O
the O
first O
time O
, O
allowed O
efficient O
transduction O
of O
quiescent O
human O
B O
and O
T O
cells O
. O

These O
target O
cells O
express O
both O
MV O
entry O
receptors O
used O
by O
the O
vaccinal O
Edmonston O
strain O
, O
CD46 O
and O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
. O

modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
is O
an O
attenuated O
poxvirus O
strain O
, O
currently O
under O
evaluation O
as O
a O
vaccine O
vector O
in O
various O
clinical O
settings O
. O

It O
has O
been O
reported O
that O
human B
dendritic I
cells I
( I
DCs I
) I
mature O
after O
infection O
with O
MVA O
, O
but O
reports O
on O
the O
functionality O
of O
DCs O
have O
so O
far O
been O
controversial O
. O

Moreover O
, O
infected O
DCs O
produced O
a O
broad O
array O
of O
chemokines O
and O
cytokines O
and O
were O
able O
to O
activate O
and O
induce O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
both O
in O
CD4 O
( O
+ O
) O
and O
in O
CD8 O
( O
+ O
) O
allogeneic O
T O
cells O
and O
in O
specific O
autologous O
peripheral B
blood I
lymphocytes I
( I
PBLs I
) I
. O

Analysis O
of O
DC O
maturation O
following O
infection O
with O
a O
recombinant O
green B
fluorescent I
protein I
( I
GFP I
) I
- O
expressing O
MVA O
revealed O
that O
upregulation O
of O
CD86 O
expression O
was O
mainly O
observed O
in O
GFP O
( O
neg O
) O
( O
bystander O
) O
cells O
. O

While O
GFP O
( O
pos O
) O
( O
infected O
) O
DCs O
produced O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
they O
were O
unable O
to O
produce O
CXCL10 O
and O
were O
less O
efficient O
at O
inducing O
IFN O
- O
gamma O
production O
in O
CEF O
- O
specific O
autologous O
PBLs O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
infection O
of O
most O
cultured O
cell O
lines O
causes O
cell O
- O
cell O
fusion O
and O
death O
. O

Cell O
fusion O
is O
caused O
by O
the O
fusion O
( O
F O
) O
glycoprotein O
and O
is O
clearly O
cytopathic O
, O
but O
other O
aspects O
of O
RSV O
infection O
may O
also O
contribute O
to O
cytopathology O
. O

Transient O
expression O
of O
the O
F O
and O
G O
( O
attachment O
) O
glycoproteins O
supported O
the O
production O
of O
virions O
that O
could O
transfer O
the O
replicon O
into O
most O
cell O
lines O
tested O
. O

nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
transcription O
factors O
are O
involved O
in O
controlling O
numerous O
cellular O
processes O
, O
including O
inflammation O
, O
innate O
and O
adaptive O
immunity O
, O
and O
cell O
survival O
. O

Here O
we O
show O
that O
the O
immunosuppressive O
measles O
virus O
( O
MV O
; O
Morbillivirus O
genus O
, O
Paramyxoviridae O
) O
has O
evolved O
multiple O
functions O
to O
interfere O
with O
canonical O
NF O
- O
kappa O
B O
signaling O
in O
epithelial O
cells O
. O

The O
MV O
P O
, O
V O
, O
and O
C O
proteins O
, O
also O
involved O
in O
preventing O
host O
cell O
interferon O
responses O
, O
were O
found O
to O
individually O
suppress O
NF O
- O
kappa O
B O
- O
dependent O
reporter O
gene O
expression O
in O
response O
to O
activation O
of O
the O
Tumor B
necrosis I
factor I
( I
TNF I
) I
receptor O
, O
RIG O
- O
I O
- O
like O
receptors O
, O
or O
Toll O
- O
like O
receptors O
. O

As O
indicated O
by O
reporter O
gene O
assays O
involving O
overexpression O
of O
the O
I B
kappa I
B I
kinase I
( I
IKK I
) I
complex O
, O
which O
phosphorylates O
the O
inhibitor O
of O
kappa O
B O
to O
liberate O
NF O
- O
kappa O
B O
, O
V O
protein O
targets O
a O
downstream O
step O
in O
the O
signaling O
cascade O
. O

Measles O
is O
a O
highly O
contagious O
human O
disease O
caused O
by O
the O
measles B
virus I
( I
MeV I
) I
. O

In O
this O
study O
, O
by O
proteomic O
analysis O
, O
we O
identified O
peroxiredoxin B
1 I
( I
Prdx1 I
) I
as O
a O
host O
factor O
that O
binds O
to O
the O
C O
- O
terminal O
region O
of O
the O
nucleoprotein O
( O
N O
; O
N O
- O
TAIL O
) O
of O
MeV O
. O

glutathione B
S I
- I
transferase I
( I
GST I
) I
pulldown O
experiments O
showed O
that O
the O
Prdx1 O
- O
binding O
site O
overlapped O
with O
the O
MeV O
phosphoprotein B
( I
P I
) I
- O
binding O
site O
on O
N O
- O
TAIL O
and O
that O
Prdx1 O
competed O
for O
the O
binding O
to O
N O
- O
TAIL O
with O
the O
P O
protein O
, O
which O
is O
a O
component O
of O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
. O

Relative O
quantification O
of O
viral O
RNA O
by O
real B
- I
time I
PCR I
( I
RT I
- I
PCR I
) I
showed O
that O
Prdx1 O
suppression O
not O
only O
reduced O
viral O
RNA O
transcription O
and O
replication O
but O
also O
enhanced O
polar O
attenuation O
in O
viral O
mRNA O
transcription O
. O

Recombinant O
measles O
virus O
nucleoprotein O
- O
RNA O
( O
N O
- O
RNA O
) O
helices O
were O
analyzed O
by O
negative O
- O
stain O
electron O
microscopy O
. O

Three O
- O
dimensional O
reconstructions O
of O
trypsin O
- O
digested O
and O
intact O
nucleocapsids O
coupled O
to O
the O
docking O
of O
the O
atomic O
structure O
of O
the O
respiratory B
syncytial I
virus I
( I
RSV I
) I
N O
- O
RNA O
subunit O
into O
the O
electron O
microscopy O
density O
map O
support O
a O
model O
that O
places O
the O
RNA O
at O
the O
exterior O
of O
the O
helix O
and O
the O
disordered O
C O
- O
terminal O
domain O
toward O
the O
helix O
interior O
, O
and O
they O
suggest O
the O
position O
of O
the O
six O
nucleotides O
with O
respect O
to O
the O
measles O
N O
protomer O
. O

The O
measles B
virus I
( I
MV I
) I
P O
gene O
encodes O
three O
proteins O
( O
P O
, O
V O
, O
and O
C O
) O
that O
interfere O
with O
innate O
immunity O
, O
controlling O
STAT1 O
, O
STAT2 O
, O
mda5 O
, O
and O
perhaps O
other O
key O
regulators O
of O
immune O
function O
. O

This O
information O
was O
used O
to O
generate O
a O
recombinant O
measles O
virus O
unable O
to O
antagonize O
STAT1 O
function O
( O
STAT1 O
- O
blind O
MV O
) O
differing O
only O
in O
these O
three O
residues O
from O
a O
wild O
- O
type O
strain O
of O
well O
- O
defined O
virulence O
. O

When O
a O
group O
of O
six O
rhesus O
monkeys O
( O
Macaca O
mulatta O
) O
was O
inoculated O
intranasally O
with O
STAT1 O
- O
blind O
MV O
, O
viremia O
was O
short O
- O
lived O
, O
and O
the O
skin O
rash O
and O
other O
clinical O
signs O
observed O
with O
wild O
- O
type O
MV O
were O
absent O
. O

Members O
of O
the O
Paramyxovirinae O
subfamily O
rely O
on O
the O
concerted O
action O
of O
two O
envelope O
glycoprotein O
complexes O
, O
attachment O
protein O
H O
and O
the O
fusion O
( O
F O
) O
protein O
oligomer O
, O
to O
achieve O
membrane O
fusion O
for O
viral O
entry O
. O

Despite O
advances O
in O
X O
- O
ray O
information O
, O
the O
organization O
of O
the O
physiological O
attachment O
( O
H O
) O
oligomer O
in O
functional O
fusion O
complexes O
and O
the O
molecular O
mechanism O
linking O
H O
receptor O
binding O
with O
F O
triggering O
remain O
unknown O
. O

Blue O
native O
PAGE O
analysis O
indicates O
that O
native O
H O
complexes O
extract O
predominantly O
in O
the O
form O
of O
loosely O
assembled O
tetramers O
from O
purified O
measles B
virus I
( I
MeV I
) I
particles O
and O
cells O
transiently O
expressing O
the O
viral O
envelope O
glycoproteins O
. O

To O
gain O
functional O
insight O
, O
we O
have O
established O
a O
bimolecular B
complementation I
( I
BiC I
) I
assay O
for O
MeV O
H O
, O
on O
the O
basis O
of O
the O
hypothesis O
that O
physical O
interaction O
of O
H O
with O
F O
complexes O
, O
F O
triggering O
, O
and O
receptor O
binding O
constitute O
distinct O
events O
. O

Having O
experimentally O
confirmed O
three O
distinct O
H O
complementation O
groups O
, O
implementation O
of O
H O
BiC O
( O
H O
- O
BiC O
) O
reveals O
that O
a O
high O
- O
affinity O
receptor O
- O
to O
- O
paramyxovirus O
H O
monomer O
stoichiometry O
below O
parity O
is O
sufficient O
for O
fusion O
initiation O
, O
that O
F O
binding O
and O
fusion O
initiation O
are O
separable O
in O
H O
oligomers O
, O
and O
that O
a O
higher O
relative O
amount O
of O
F O
binding O
- O
competent O
than O
F O
fusion O
initiation O
- O
or O
receptor O
binding O
- O
competent O
H O
monomers O
per O
oligomer O
is O
required O
for O
optimal O
fusion O
. O

The O
V O
protein O
C B
- I
terminal I
domain I
( I
CTD I
) I
is O
an O
evolutionarily O
conserved O
49 O
- O
to O
68 O
- O
amino O
- O
acid O
region O
that O
coordinates O
two O
zinc O
atoms O
per O
protein O
chain O
. O

measles B
virus I
( I
MV I
) I
entry O
requires O
at O
least O
2 O
viral O
proteins O
, O
the O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
. O

We O
describe O
the O
rescue O
and O
characterization O
of O
a O
measles O
virus O
with O
a O
specific O
mutation O
in O
the O
stalk O
region O
of O
H O
- O
( O
I98A O
) O
that O
is O
able O
to O
bind O
normally O
to O
cells O
but O
infects O
at O
a O
lower O
rate O
than O
the O
wild O
type O
due O
to O
a O
reduction O
in O
fusion O
triggering O
. O

canine B
distemper I
virus I
( I
CDV I
) I
causes O
in O
dogs O
a O
severe O
systemic O
infection O
, O
with O
a O
high O
frequency O
of O
demyelinating O
encephalitis O
. O

Among O
the O
six O
genes O
transcribed O
by O
CDV O
, O
the O
P O
gene O
encodes O
the O
polymerase O
cofactor O
protein O
( O
P O
) O
as O
well O
as O
two O
additional O
nonstructural O
proteins O
, O
C O
and O
V O
; O
of O
these O
V O
was O
shown O
to O
act O
as O
a O
virulence O
factor O
. O

We O
investigated O
the O
molecular O
mechanisms O
by O
which O
the O
P O
gene O
products O
of O
the O
neurovirulent O
CDV O
A75 O
/ O
17 O
strain O
disrupt O
type O
I O
interferon O
( O
IFN O
- O
alpha O
/ O
beta O
) O
- O
induced O
signaling O
that O
results O
in O
the O
establishment O
of O
the O
antiviral O
state O
. O

Coimmunoprecipitation O
assays O
identified O
the O
N B
- I
terminal I
region I
of I
V I
( I
VNT I
) I
responsible O
for O
STAT1 O
targeting O
, O
which O
correlated O
with O
its O
ability O
to O
inhibit O
the O
activity O
of O
the O
IFN O
- O
alpha O
/ O
beta O
- O
mediated O
antiviral O
state O
. O

Conversely O
, O
while O
the O
C B
- I
terminal I
domain I
of I
V I
( I
VCT I
) I
could O
not O
function O
autonomously O
, O
when O
fused O
to O
VNT O
it O
optimally O
interacted O
with O
STAT2 O
and O
subsequently O
efficiently O
suppressed O
the O
IFN O
- O
alpha O
/ O
beta O
- O
mediated O
signaling O
pathway O
. O

We O
compared O
HEp O
- O
2 O
- O
derived O
cells O
cured O
of O
persistent O
poliovirus O
infection O
by O
RNA B
interference I
( I
RNAi I
) I
with O
parental O
cells O
, O
to O
investigate O
possible O
changes O
in O
the O
efficiency O
of O
RNAi O
. O

Lower O
levels O
of O
poliovirus O
replication O
were O
observed O
in O
cured O
cells O
, O
possibly O
facilitating O
virus O
silencing O
by O
antiviral O
small B
interfering I
RNAs I
( I
siRNAs I
) I
. O

However O
, O
green B
fluorescent I
protein I
( I
GFP I
) I
produced O
from O
a O
measles O
virus O
vector O
and O
also O
GFP O
and O
luciferase O
produced O
from O
plasmids O
that O
do O
not O
replicate O
in O
human O
cells O
were O
more O
effectively O
silenced O
by O
specific O
siRNAs O
in O
cured O
than O
in O
control O
cells O
. O

Viral O
nucleic O
acids O
in O
trivalent O
oral B
poliovirus I
( I
OPV I
) I
, O
rubella O
, O
measles O
, O
yellow O
fever O
, O
varicella O
- O
zoster O
, O
multivalent O
measles O
/ O
mumps O
/ O
rubella O
, O
and O
two O
rotavirus O
live O
vaccines O
were O
partially O
purified O
, O
randomly O
amplified O
, O
and O
pyrosequenced O
. O

avian B
leukosis I
virus I
( I
ALV I
) I
, O
previously O
shown O
to O
be O
noninfectious O
for O
humans O
, O
was O
present O
as O
RNA O
in O
viral O
particles O
, O
while O
simian B
retrovirus I
( I
SRV I
) I
was O
present O
as O
genetically O
defective O
DNA O
. O

Rotarix O
, O
an O
orally O
administered O
rotavirus O
vaccine O
, O
contained O
porcine B
circovirus I
- I
1 I
( I
PCV1 I
) I
, O
a O
highly O
prevalent O
nonpathogenic O
pig O
virus O
, O
which O
has O
not O
been O
shown O
to O
be O
infectious O
in O
humans O
. O

We O
determined O
the O
crystal O
structure O
of O
the O
unliganded O
six O
- O
bladed O
beta O
- O
propeller O
domain O
and O
compared O
it O
to O
the O
previously O
reported O
structure O
of O
Hendra B
virus I
attachment I
glycoprotein I
( I
HeV I
- I
G I
) I
in O
complex O
with O
its O
cellular O
receptor O
, O
ephrin O
- O
B2 O
. O

We O
therefore O
propose O
that O
the O
overall O
mode O
of O
dimer O
assembly O
is O
conserved O
for O
all O
paramyxoviruses O
; O
however O
, O
while O
the O
geometry O
of O
dimerization O
is O
rather O
closely O
similar O
for O
those O
viruses O
that O
bind O
flexible O
glycan O
receptors O
, O
significant O
( O
up O
to O
60 O
) O
and O
different O
reconfigurations O
of O
the O
subunit O
packing O
( O
associated O
with O
a O
significant O
decrease O
in O
the O
size O
of O
the O
dimer O
interface O
) O
have O
accompanied O
the O
independent O
switching O
to O
high O
- O
affinity O
protein O
receptor O
binding O
in O
Hendra O
and O
measles O
viruses O
. O

The O
standard O
route O
of O
administration O
for O
the O
live O
- O
attenuated O
measles B
virus I
( I
MV I
) I
vaccine O
is O
subcutaneous O
injection O
, O
although O
alternative O
needle O
- O
free O
routes O
, O
including O
aerosol O
delivery O
, O
are O
under O
investigation O
. O

To O
compare O
the O
in O
vivo O
tropism O
of O
attenuated O
and O
pathogenic O
MV O
, O
we O
infected O
cynomolgus O
macaques O
with O
pathogenic O
or O
attenuated O
recombinant O
MV O
expressing O
enhanced B
green I
fluorescent I
protein I
( I
GFP I
) I
( O
strains O
IC323 O
and O
Edmonston O
, O
respectively O
) O
via O
the O
intratracheal O
or O
aerosol O
route O
. O

Human O
adenovirus O
serotype O
35 O
( O
HAdV O
- O
35 O
; O
here O
referred O
to O
as O
Ad35 O
) O
causes O
kidney O
and O
urinary O
tract O
infections O
and O
infects O
respiratory O
organs O
of O
immunocompromised O
individuals O
. O

Ad35 O
infections O
were O
inhibited O
by O
small O
chemicals O
against O
serine O
/ O
threonine O
kinase O
Pak1 O
( O
p21 O
- O
activated O
kinase O
) O
, O
protein B
kinase I
C I
( I
PKC I
) I
, O
sodium O
- O
proton O
exchangers O
, O
actin O
, O
and O
acidic O
organelles O
. O

Remarkably O
, O
the O
F O
- O
actin O
inhibitor O
jasplakinolide O
, O
the O
Pak1 O
inhibitor O
IPA O
- O
3 O
, O
or O
the O
sodium O
- O
proton O
exchange O
inhibitor O
5 O
- O
( O
N O
- O
ethyl O
- O
N O
- O
isopropyl O
) O
amiloride O
( O
EIPA O
) O
blocked O
endocytic O
uptake O
of O
Ad35 O
. O

Dominant O
- O
negative O
proteins O
or O
small O
interfering O
RNAs O
against O
factors O
driving O
macropinocytosis O
, O
including O
the O
small O
GTPase O
Rac1 O
, O
Pak1 O
, O
or O
the O
Pak1 O
effector O
C B
- I
terminal I
binding I
protein I
1 I
( I
CtBP1 I
) I
, O
potently O
inhibited O
Ad35 O
infection O
. O

Our O
results O
extend O
earlier O
observations O
with O
HAdV O
- O
3 O
( O
Ad3 O
) O
and O
establish O
macropinocytosis O
as O
an O
infectious O
pathway O
for O
species O
B O
human O
adenoviruses O
in O
epithelial O
and O
hematopoietic O
cells O
. O

measles B
virus I
( I
MV I
) I
causes O
transient O
severe O
immunosuppression O
in O
patients O
, O
which O
may O
lead O
to O
secondary O
viral O
and O
bacterial O
infections O
, O
largely O
accounting O
for O
measles O
- O
related O
morbidity O
and O
mortality O
. O

MV O
is O
known O
to O
infect O
immune O
cells O
by O
using O
the O
human O
signaling O
lymphocyte O
activation O
molecule O
( O
SLAM O
; O
also O
called O
CD150 O
) O
as O
a O
cellular O
receptor O
, O
but O
the O
mechanism O
by O
which O
MV O
causes O
immunosuppression O
is O
not O
well O
understood O
. O

These O
included O
lymphopenia O
, O
inhibition O
of O
T O
- O
cell O
proliferation O
and O
antibody O
production O
, O
increased O
production O
of O
the O
Th2 O
cytokine O
interleukin B
- I
4 I
( I
IL I
- I
4 I
) I
and O
the O
immunosuppressive O
cytokine O
IL O
- O
10 O
, O
and O
suppression O
of O
contact O
hypersensitivity O
. O

The O
complement O
regulation O
protein O
CD46 O
is O
the O
primary O
attachment O
receptor O
for O
most O
species O
B O
adenoviruses B
( I
Ads I
) I
. O

The O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
; O
CD150 O
) O
is O
the O
immune O
cell O
receptor O
for O
measles B
virus I
( I
MV I
) I
. O

To O
assess O
the O
importance O
of O
the O
SLAM O
- O
MV O
interactions O
for O
virus O
spread O
and O
pathogenesis O
, O
we O
generated O
a O
wild O
- O
type O
IC O
- O
B O
MV O
selectively O
unable O
to O
recognize O
human O
SLAM O
( O
SLAM O
- O
blind O
) O
. O

When O
a O
group O
of O
six O
rhesus O
monkeys O
( O
Macaca O
mulatta O
) O
was O
inoculated O
intranasally O
with O
the O
SLAM O
- O
blind O
virus O
, O
no O
clinical O
symptoms O
were O
documented O
. O

Measles O
remains O
a O
major O
cause O
of O
child O
mortality O
, O
in O
part O
due O
to O
an O
inability O
to O
vaccinate O
young O
infants O
with O
the O
current O
live O
attenuated O
virus O
vaccine O
( O
LAV O
) O
. O

To O
explore O
new O
approaches O
to O
infant O
vaccination O
, O
chimeric O
Venezuelan B
equine I
encephalitis I
/ I
Sindbis I
virus I
( I
VEE I
/ I
SIN I
) I
replicon O
particles O
were O
used O
to O
express O
the O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
of O
measles B
virus I
( I
MV I
) I
. O

Juvenile O
rhesus O
macaques O
vaccinated O
intradermally O
with O
a O
single O
dose O
of O
VEE O
/ O
SIN O
expressing O
H O
or O
H O
and O
F O
proteins O
( O
VEE O
/ O
SIN O
- O
H O
or O
VEE O
/ O
SIN O
- O
H O
+ O
F O
, O
respectively O
) O
developed O
high O
titers O
of O
MV O
- O
specific O
neutralizing O
antibody O
and O
gamma O
- O
interferon O
( O
IFN O
- O
gamma O
) O
- O
producing O
T O
cells O
. O

Control O
animals O
were O
vaccinated O
with O
LAV O
or O
with O
a O
formalinin B
- I
activated I
measles I
vaccine I
( I
FIMV I
) I
. O

To O
establish O
the O
contribution O
of O
N O
glycosylation O
to O
morbillivirus O
attachment O
( O
H O
) O
protein O
function O
and O
overall O
virulence O
, O
we O
first O
determined O
the O
use O
of O
the O
potential O
N O
- O
glycosylation O
sites O
in O
the O
canine B
distemper I
virus I
( I
CDV I
) I
H O
proteins O
. O

Recent O
studies O
of O
primate O
models O
suggest O
that O
wild O
- O
type O
measles B
virus I
( I
MV I
) I
infects O
immune O
cells O
located O
in O
the O
airways O
before O
spreading O
systemically O
, O
but O
the O
identity O
of O
these O
cells O
is O
unknown O
. O

To O
identify O
cells O
supporting O
primary O
MV O
infection O
, O
we O
took O
advantage O
of O
mice O
expressing O
the O
MV O
receptor O
human O
signaling O
lymphocyte O
activation O
molecule O
( O
SLAM O
, O
CD150 O
) O
with O
human O
- O
like O
tissue O
specificity O
. O

We O
infected O
these O
mice O
intranasally O
( O
IN O
) O
with O
a O
wild O
- O
type O
MV O
expressing O
green O
fluorescent O
protein O
. O

One O
, O
two O
, O
or O
three O
days O
after O
inoculation O
, O
nasal B
- I
associated I
lymphoid I
tissue I
( I
NALT I
) I
, O
the O
lungs O
, O
several O
lymph B
nodes I
( I
LNs I
) I
, O
the O
spleen O
, O
and O
the O
thymus O
were O
collected O
and O
analyzed O
by O
microscopy O
and O
flow O
cytometry O
, O
and O
virus O
isolation O
was O
attempted O
. O

5 O
% O
of O
alveolar B
macrophages I
( I
AM I
) I
and O
0 O
. O

5 O
% O
of O
dendritic B
cells I
( I
DC I
) I
. O

In O
contrast O
, O
measles B
virus I
( I
MV I
) I
infection O
leads O
to O
downregulation O
of O
AKT O
. O

In O
vitro O
, O
overexpression O
of O
AKT O
did O
not O
influence O
virus O
replication O
but O
did O
affect O
( O
cell O
- O
type O
dependent O
) O
virus O
release O
. O

measles B
virus I
( I
MV I
) I
, O
a O
member O
of O
the O
family O
Paramyxoviridae O
, O
is O
a O
nonsegmented O
negative O
- O
strand O
RNA O
virus O
. O

The O
RNA B
helicases I
retinoic I
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
and O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
are O
differentially O
involved O
in O
the O
detection O
of O
cytoplasmic O
viral O
RNAs O
and O
induction O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
. O

A O
V O
protein O
- O
deficient O
recombinant O
MV O
( O
MV O
Delta O
V O
) O
induced O
higher O
amounts O
of O
IFN O
- O
beta O
mRNA O
at O
the O
early O
stage O
of O
infection O
in O
H358 O
cells O
compared O
to O
the O
parental O
virus O
. O

The O
measles O
virus O
P O
gene O
products O
V O
and O
C O
antagonize O
the O
host O
interferon B
( I
IFN I
) I
response O
, O
blocking O
both O
IFN O
signaling O
and O
production O
. O

Using O
Moraten O
vaccine O
strain O
- O
derived O
measles O
virus O
and O
isogenic O
mutants O
deficient O
for O
either O
V O
or O
C O
protein O
production O
( O
V O
- O
ko O
and O
C O
- O
ko O
, O
respectively O
) O
, O
we O
observed O
that O
the O
C O
- O
ko O
virus O
was O
a O
potent O
inducer O
of O
IFN O
- O
beta O
, O
while O
induction O
by O
V O
- O
ko O
virus O
was O
an O
order O
of O
magnitude O
lower O
than O
that O
by O
the O
C O
- O
ko O
virus O
. O

The O
enhanced O
IFN O
- O
inducing O
capacity O
of O
the O
C O
- O
ko O
virus O
correlated O
with O
an O
enhanced O
activation O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
NF O
- O
kappa O
B O
, O
and O
ATF O
- O
2 O
in O
C O
- O
ko O
- O
infected O
compared O
to O
V O
- O
ko O
or O
parental O
virus O
- O
infected O
cells O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
common O
respiratory O
viral O
infection O
in O
children O
which O
is O
associated O
with O
immune O
dysregulation O
and O
subsequent O
induction O
and O
exacerbations O
of O
asthma O
. O

We O
recently O
reported O
that O
treatment O
of O
primary B
human I
epithelial I
cells I
( I
PHBE I
cells I
) I
with O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
enhanced O
RSV O
replication O
. O

Attenuated O
live O
vaccines O
of O
measles B
virus I
( I
MV I
) I
have O
been O
developed O
from O
clinical O
isolates O
by O
serial O
propagation O
in O
heterologous O
cells O
, O
mainly O
chicken O
embryonic O
cells O
. O

In O
the O
present O
study O
, O
we O
assessed O
the O
contribution O
of O
each O
gene O
in O
the O
CAM O
- O
70 O
strain O
to O
efficient O
growth O
in O
chicken B
embryonic I
fibroblasts I
( I
CEF I
) I
. O

The O
genome O
of O
measles B
virus I
( I
MV I
) I
is O
encapsidated O
by O
the O
nucleocapsid B
( I
N I
) I
protein O
and O
associates O
with O
RNA O
- O
dependent O
RNA O
polymerase O
to O
form O
the O
ribonucleoprotein O
complex O
. O

The O
matrix B
( I
M I
) I
protein O
is O
believed O
to O
play O
an O
important O
role O
in O
MV O
assembly O
by O
linking O
the O
ribonucleoprotein O
complex O
with O
envelope O
glycoproteins O
. O

Analyses O
using O
a O
yeast O
two O
- O
hybrid O
system O
and O
coimmunoprecipitation O
in O
mammalian O
cells O
revealed O
that O
the O
M O
protein O
interacts O
with O
the O
N O
protein O
and O
that O
two O
leucine O
residues O
at O
the O
carboxyl O
terminus O
of O
the O
N O
protein O
( O
L523 O
and O
L524 O
) O
are O
critical O
for O
the O
interaction O
. O

Intramuscular O
inoculation O
of O
rhesus O
macaques O
with O
one O
or O
more O
doses O
of O
recombinant B
vesicular I
stomatitis I
virus I
( I
rVSV I
) I
expressing O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
( O
rVSVgag O
) O
typically O
elicits O
peak O
cellular O
immune O
responses O
of O
500 O
to O
1 O
, O
000 O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
enzyme I
- I
linked I
immunospots I
( I
ELISPOTS I
) I
/ O
10 O
( O
6 O
) O
peripheral B
blood I
lymphocytes I
( I
PBL I
) I
. O

Here O
, O
we O
describe O
the O
generation O
of O
a O
novel O
recombinant B
mumps I
virus I
( I
rMuV I
) I
expressing O
HIV O
- O
1 O
Gag O
( O
rMuVgag O
) O
and O
measure O
the O
Gag O
- O
specific O
cellular O
immune O
responses O
detected O
in O
rhesus O
macaques O
following O
vaccination O
with O
a O
highly O
attenuated O
form O
of O
rVSV O
expressing O
HIV O
- O
1 O
Gag O
( O
rVSVN4CT1gag1 O
) O
and O
rMuVgag O
in O
various O
prime O
- O
boost O
combinations O
. O

Notably O
, O
peak O
Gag O
- O
specific O
cellular O
immune O
responses O
of O
3 O
, O
000 O
to O
3 O
, O
500 O
ELISPOTS O
/ O
10 O
( O
6 O
) O
PBL O
were O
detected O
in O
macaques O
that O
were O
primed O
with O
rMuVgag O
and O
boosted O
with O
rVSVN4CT1gag1 O
. O

Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
is O
a O
demyelinating O
central O
nervous O
system O
disease O
caused O
by O
a O
persistent O
measles B
virus I
( I
MV I
) I
infection O
of O
neurons O
and O
glial O
cells O
. O

In O
order O
to O
select O
effective O
antiviral O
short O
interfering O
RNAs O
( O
siRNAs O
) O
, O
we O
established O
a O
plasmid O
- O
based O
test O
system O
expressing O
the O
mRNA O
of O
DsRed2 O
fused O
with O
mRNA O
sequences O
of O
single O
viral O
genes O
, O
to O
which O
certain O
siRNAs O
were O
directed O
. O

siRNA O
sequences O
were O
expressed O
as O
short B
hairpin I
RNA I
( I
shRNA I
) I
from O
a O
lentiviral O
vector O
additionally O
expressing O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
as O
an O
indicator O
. O

Evaluation O
by O
flow O
cytometry O
of O
the O
dual O
- O
color O
system O
( O
DsRed O
and O
EGFP O
) O
allowed O
us O
to O
find O
optimal O
shRNA O
sequences O
. O

Using O
the O
most O
active O
shRNA O
constructs O
, O
we O
transduced O
persistently O
infected O
human O
NT2 O
cells O
expressing O
virus O
- O
encoded O
HcRed O
( O
piNT2 O
- O
HcRed O
) O
as O
an O
indicator O
of O
infection O
. O

The O
fraction O
of O
virus O
- O
negative O
cells O
in O
these O
cultures O
was O
constant O
over O
at O
least O
3 O
weeks O
posttransduction O
in O
the O
presence O
of O
a O
fusion O
- O
inhibiting O
peptide O
( O
Z O
- O
Phe O
- O
Phe O
- O
Gly O
) O
, O
preventing O
the O
cell O
fusion O
of O
potentially O
cured O
cells O
with O
persistently O
infected O
cells O
. O

Wild O
- O
type O
measles B
virus I
( I
MV I
) I
isolated O
in O
B95a O
cells O
could O
be O
adapted O
to O
Vero O
cells O
after O
several O
blind O
passages O
. O

In O
this O
study O
, O
we O
have O
determined O
the O
complete O
nucleotide O
sequences O
of O
the O
genomes O
of O
the O
wild O
type O
( O
T11wild O
) O
and O
its O
Vero O
cell O
- O
adapted O
( O
T11Ve O
- O
23 O
) O
MV O
strain O
and O
identified O
amino O
acid O
substitutions O
R516G O
, O
E271K O
, O
D439E O
and O
G464W O
( O
D439E O
/ O
G464W O
) O
, O
N481Y O
/ O
H495R O
, O
and O
Y187H O
/ O
L204F O
in O
the O
nucleocapsid O
, O
V O
, O
fusion O
( O
F O
) O
, O
hemagglutinin B
( I
H I
) I
, O
and O
large O
proteins O
, O
respectively O
. O

Recombinant O
wild O
- O
type O
MV O
strains O
harboring O
the O
F O
protein O
with O
the O
mutations O
D439E O
/ O
G464W O
[ O
F O
( O
D439E O
/ O
G464W O
) O
] O
and O
/ O
or O
H O
( O
N481Y O
/ O
H495R O
) O
protein O
revealed O
that O
both O
mutated O
F O
and O
H O
proteins O
were O
required O
for O
efficient O
syncytium O
formation O
and O
virus O
growth O
in O
Vero O
cells O
. O

Interestingly O
, O
a O
recombinant O
wild O
- O
type O
MV O
strain O
harboring O
the O
H O
( O
N481Y O
/ O
H495R O
) O
protein O
penetrated O
slowly O
into O
Vero O
cells O
, O
while O
a O
recombinant O
wild O
- O
type O
MV O
strain O
harboring O
both O
the O
F O
( O
D439E O
/ O
G464W O
) O
and O
H O
( O
N481Y O
/ O
H495R O
) O
proteins O
penetrated O
efficiently O
into O
Vero O
cells O
, O
indicating O
that O
the O
F O
( O
D439E O
/ O
G464W O
) O
protein O
compensates O
for O
the O
inefficient O
penetration O
of O
a O
wild O
- O
type O
MV O
strain O
harboring O
the O
H O
( O
N481Y O
/ O
H495R O
) O
protein O
. O

The O
Nipah B
virus I
( I
NiV I
) I
phosphoprotein I
( I
P I
) I
gene O
encodes O
the O
C O
, O
P O
, O
V O
, O
and O
W O
proteins O
. O

P O
, O
V O
, O
and O
W O
, O
have O
in O
common O
an O
amino O
- O
terminal O
domain O
sufficient O
to O
bind O
STAT1 O
, O
inhibiting O
its O
interferon B
( I
IFN I
) I
- O
induced O
tyrosine O
phosphorylation O
. O

C O
is O
encoded O
by O
an O
alternate O
open B
reading I
frame I
( I
ORF I
) I
within O
the O
common O
amino O
- O
terminal O
domain O
. O

A O
G121E O
mutation O
, O
which O
abrogated O
inhibition O
of O
STAT1 O
, O
was O
introduced O
into O
a O
C O
protein O
knockout O
background O
( O
C O
- O
ko O
) O
because O
the O
mutation O
would O
otherwise O
also O
alter O
the O
overlapping O
C O
ORF O
. O

This O
is O
encapsidated O
by O
multiple O
copies O
of O
a O
viral O
nucleocapsid O
protein O
N O
to O
form O
a O
helical O
ribonucleoprotein O
complex O
( O
termed O
the O
nucleocapsid O
) O
, O
which O
acts O
as O
the O
template O
for O
both O
transcription O
and O
replication O
. O

Our O
previous O
results O
have O
shown O
that O
treatment O
of O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
with O
human O
serum O
results O
in O
deposition O
of O
complement O
C3 O
- O
derived O
polypeptides O
on O
virion O
particles O
. O

Similar O
results O
were O
obtained O
for O
the O
closely O
related O
mumps B
virus I
( I
MuV I
) I
, O
except O
that O
MuV O
particles O
derived O
from O
CHO O
- O
CD46 O
cells O
had O
higher O
C4b O
cofactor O
activity O
than O
SV5 O
virions O
. O

A O
potential O
mechanism O
is O
the O
reduction O
of O
interleukin B
12 I
( I
IL I
- I
12 I
) I
secretion O
during O
acute O
measles O
, O
resulting O
in O
a O
TH2 O
response O
. O

To O
characterize O
in O
more O
detail O
the O
fate O
of O
the O
immune O
cells O
during O
the O
critical O
first O
week O
, O
we O
evaluated O
the O
overall O
viability O
, O
level O
of O
apoptosis O
, O
cell O
cycle O
status O
, O
and O
extent O
of O
infection O
in O
different O
immune O
tissues O
of O
ferrets O
inoculated O
with O
a O
lethal O
canine B
distemper I
virus I
( I
CDV I
) I
strain O
. O

We O
have O
previously O
shown O
that O
the O
first O
transcription O
start O
signal O
( O
TSS O
) O
of O
Zaire B
Ebola I
virus I
( I
ZEBOV I
) I
is O
involved O
in O
formation O
of O
an O
RNA O
secondary O
structure O
regulating O
VP30 O
- O
dependent O
transcription O
activation O
. O

Interestingly O
, O
transcription O
of O
Marburg B
virus I
( I
MARV I
) I
minigenomes O
occurs O
independently O
of O
VP30 O
. O

We O
developed O
two O
Sindbis O
virus O
DNA O
vaccines O
encoding O
the O
measles O
virus O
hemagglutinin O
( O
pMSIN O
- O
H O
) O
and O
fusion O
proteins O
( O
pMSINH O
- O
FdU O
) O
and O
examined O
their O
immunogenicities O
and O
protective O
efficacies O
when O
administered O
alone O
or O
followed O
by O
the O
live O
measles O
virus O
vaccine O
in O
cotton O
rats O
. O

The O
measles B
virus I
( I
MV I
) I
accessory O
proteins O
V O
and O
C O
play O
important O
roles O
in O
MV O
replication O
and O
pathogenesis O
. O

Infection O
with O
recombinant O
MV O
lacking O
either O
V O
or O
C O
causes O
more O
cell O
death O
than O
infection O
with O
the O
parental O
vaccine O
- O
equivalent O
virus O
( O
MVvac O
) O
, O
and O
C O
- O
deficient O
virus O
grows O
poorly O
relative O
to O
the O
parental O
virus O
. O

Using O
human O
HeLa O
cells O
stably O
deficient O
in O
PKR O
as O
a O
result O
of O
RNA O
interference O
- O
mediated O
knockdown O
( O
PKRkd O
cells O
) O
, O
we O
demonstrated O
that O
a O
reduction O
in O
PKR O
partially O
rescued O
the O
growth O
defect O
of O
C O
knockout O
( O
C O
- O
ko O
) O
virus O
but O
had O
no O
effect O
on O
the O
growth O
of O
either O
wild B
- I
type I
( I
WT I
) I
or O
V O
knockout O
( O
V O
- O
ko O
) O
virus O
. O

The O
central O
role O
of O
plasmacytoid B
dendritic I
cells I
( I
pDC I
) I
in O
activating O
host O
immune O
responses O
stems O
from O
their O
high O
capacity O
to O
express O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
after O
stimulation O
of O
Toll O
- O
like O
receptors O
7 O
and O
9 O
( O
TLR7 O
and O
- O
9 O
) O
. O

This O
involves O
the O
adapter O
MyD88 O
and O
the O
kinases O
interleukin B
- I
1 I
receptor I
- I
associated I
kinase I
1 I
( I
IRAK1 I
) I
, O
IRAK4 O
, O
and O
I O
kappa O
B O
kinase O
alpha O
( O
IKK O
alpha O
) O
, O
which O
activates O
IFN B
regulatory I
factor I
7 I
( I
IRF7 I
) I
and O
is O
independent O
of O
the O
canonical O
kinases O
TBK1 O
and O
IKK O
epsilon O
. O

We O
have O
recently O
shown O
that O
the O
immunosuppressive O
measles B
virus I
( I
MV I
) I
abolishes O
TLR7 O
/ O
9 O
/ O
MyD88 O
- O
dependent O
IFN O
induction O
in O
human O
pDC O
( O
Schlender O
et O
al O
. O

Here O
, O
we O
have O
reconstituted O
the O
pathway O
in O
cell O
lines O
and O
identified O
IKK O
alpha O
and O
IRF7 O
as O
specific O
targets O
of O
the O
MV B
V I
protein I
( I
MV I
- I
V I
) I
. O

Two O
members O
of O
the O
paramyxovirus O
family O
, O
Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
, O
are O
recent O
additions O
to O
a O
growing O
number O
of O
agents O
of O
emergent O
diseases O
which O
use O
bats O
as O
a O
natural O
host O
. O

Here O
we O
present O
the O
structural O
analysis O
of O
the O
protein O
and O
carbohydrate O
components O
of O
the O
unbound O
viral O
attachment O
glycoprotein O
of O
NiV B
glycoprotein I
( I
NiV I
- I
G I
) I
at O
a O
2 O
. O

Live O
attenuated O
vaccines O
against O
measles O
have O
been O
developed O
through O
adaptation O
of O
clinical O
isolates O
of O
measles B
virus I
( I
MV I
) I
in O
various O
cultured O
cells O
. O

The O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
is O
a O
poor O
activator O
of O
human B
dendritic I
cell I
( I
DC I
) I
maturation O
pathways O
in O
vitro O
, O
and O
infected O
DC O
do O
not O
upregulate O
cell O
surface O
costimulatory O
proteins O
or O
secretion O
of O
immunomodulatory O
cytokines O
. O

We O
evaluated O
the O
hypothesis O
that O
activation O
of O
SV5 O
- O
infected O
DC O
would O
be O
enhanced O
by O
engineering O
SV5 O
to O
express O
a O
Toll B
- I
like I
- I
receptor I
( I
TLR I
) I
ligand O
. O

To O
test O
this O
hypothesis O
, O
a O
novel O
virus O
was O
engineered O
such O
that O
the O
gene O
encoding O
an O
intracellular O
form O
of O
the O
TLR5 O
ligand O
flagellin O
was O
expressed O
from O
the O
genome O
of O
wild B
- I
type I
( I
WT I
) I
SV5 O
( O
SV5 O
- O
flagellin O
) O
. O

Infection O
of O
human O
peripheral O
blood O
mononuclear O
cell O
- O
derived O
immature O
DC O
with O
SV5 O
- O
flagellin O
resulted O
in O
enhanced O
levels O
of O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
and O
IL O
- O
12 O
compared O
to O
infection O
with O
DC O
with O
the O
parental O
virus O
, O
WT O
SV5 O
. O

In O
mixed O
- O
culture O
assays O
, O
DC O
infected O
with O
the O
flagellin O
- O
expressing O
virus O
were O
more O
effective O
at O
activating O
gamma O
interferon O
secretion O
from O
both O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
allogeneic O
T O
cells O
than O
DC O
infected O
with O
WT O
SV5 O
. O

varicella B
- I
zoster I
virus I
( I
VZV I
) I
is O
a O
herpesvirus O
and O
is O
the O
causative O
agent O
of O
chicken O
pox O
( O
varicella O
) O
and O
shingles O
( O
herpes O
zoster O
) O
. O

In O
this O
study O
, O
we O
report O
the O
complete O
nucleotide O
sequence O
of O
the O
Varilrix O
( O
Oka O
- O
V O
- O
GSK O
) O
and O
Varivax O
( O
Oka O
- O
V O
- O
Merck O
) O
vaccine O
strain O
genomes O
. O

In O
order O
to O
analyze O
whether O
measles B
virus I
( I
MV I
) I
is O
transported O
via O
transmigrating O
leukocytes O
across O
endothelial O
barriers O
or O
whether O
virus O
spreads O
via O
infection O
of O
endothelial O
cells O
and O
basolateral O
release O
, O
we O
investigated O
the O
migratory O
behavior O
of O
infected O
human O
primary O
T O
lymphocytes O
across O
polarized O
cell O
layers O
of O
human O
brain O
microvascular O
endothelial O
cells O
. O

In O
particular O
, O
the O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
protein O
executes O
membrane O
fusion O
, O
after O
receptor O
binding O
by O
the O
hemagglutinin B
( I
H I
) I
protein O
. O

Structures O
and O
single O
amino O
acids O
influencing O
fusion O
function O
have O
been O
identified O
in O
the O
F O
- O
protein O
ectodomain O
and O
cytoplasmic O
tail O
, O
but O
not O
in O
its O
transmembrane B
( I
TM I
) I
region O
. O

Alanine O
- O
scanning O
mutagenesis O
revealed O
that O
an O
F O
protein O
with O
a O
single O
mutation O
of O
a O
central O
TM O
region O
leucine O
( O
L507A O
) O
was O
more O
fusogenic O
than O
the O
unmodified O
F O
protein O
while O
retaining O
similar O
kinetics O
of O
proteolytic O
processing O
. O

Analysis O
of O
the O
H O
- O
F O
complexes O
with O
reduced O
fusion O
activities O
revealed O
that O
more O
precursor O
( O
F O
- O
0 O
) O
than O
activated O
( O
F1 O
+ O
2 O
) O
protein O
coprecipitated O
with O
H O
. O

Morbilliviruses O
, O
including O
measles O
and O
canine B
distemper I
virus I
( I
CDV I
) I
, O
are O
nonsegmented O
, O
negative O
- O
stranded O
RNA O
viruses O
that O
cause O
severe O
diseases O
in O
humans O
and O
animals O
. O

The O
transcriptional O
units O
in O
their O
genomes O
are O
separated O
by O
untranslated B
regions I
( I
UTRs I
) I
, O
which O
contain O
essential O
transcription O
and O
translation O
signals O
. O

Due O
to O
its O
increased O
length O
, O
the O
region O
between O
the O
matrix B
( I
M I
) I
protein O
and O
fusion O
( O
F O
) O
protein O
open O
reading O
frames O
is O
of O
particular O
interest O
. O

In O
measles O
virus O
, O
the O
entire O
F O
5 O
' O
region O
is O
untranslated O
, O
while O
several O
start O
codons O
are O
found O
in O
most O
other O
morbilliviruses O
, O
resulting O
in O
a O
long O
F B
protein I
signal I
peptide I
( I
Fsp I
) I
. O

To O
characterize O
the O
role O
of O
this O
region O
in O
morbillivirus O
pathogenesis O
, O
we O
constructed O
recombinant O
CDVs O
, O
in O
which O
either O
the O
M O
- O
F O
UTR O
was O
replaced O
with O
that O
between O
the O
nucleocapsid B
( I
N I
) I
and O
phosphoprotein B
( I
P I
) I
genes O
, O
or O
106 O
Fsp O
residues O
were O
deleted O
. O

The O
genome O
of O
measles B
virus I
( I
MV I
) I
, O
the O
causative O
agent O
, O
encodes O
two O
accessory O
products O
, O
V O
and O
C O
proteins O
, O
that O
play O
important O
roles O
in O
MV O
virulence O
. O

The O
V O
but O
not O
the O
C O
protein O
of O
the O
IC O
- O
B O
strain O
( O
a O
well O
- O
characterized O
virulent O
strain O
of O
MV O
) O
has O
been O
shown O
to O
block O
the O
Jak O
/ O
Stat O
signaling O
pathway O
and O
counteract O
the O
cellular O
interferon B
( I
IFN I
) I
response O
. O

The O
V O
protein O
of O
measles O
virus O
is O
an O
important O
virulence O
factor O
that O
can O
interfere O
with O
host O
innate O
immunity O
by O
inactivating O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
signaling O
through O
protein O
interactions O
with O
signal O
transducer O
and O
activator O
of O
transcription O
proteins O
STAT1 O
and O
STAT2 O
. O

human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
is O
released O
from O
the O
apical O
membrane O
of O
polarized O
epithelial O
cells O
. O

Based O
on O
previous O
studies O
showing O
that O
the O
fusion O
( O
F O
) O
glycoprotein O
contained O
an O
intrinsic O
apical O
sorting O
signal O
and O
that O
N O
- O
and O
O O
- O
linked O
glycans O
can O
act O
as O
apical O
targeting O
signals O
, O
we O
investigated O
whether O
the O
glycoproteins O
of O
HRSV O
were O
involved O
in O
its O
directional O
targeting O
and O
release O
. O

The O
Ebola O
virus O
nucleoprotein B
( I
NP I
) I
is O
an O
essential O
component O
of O
the O
nucleocapsid O
, O
required O
for O
filovirus O
particle O
formation O
and O
replication O
. O

Together O
with O
virion B
protein I
35 I
( I
VP35 I
) I
and O
VP24 O
, O
this O
gene O
product O
gives O
rise O
to O
the O
filamentous O
nucleocapsid O
within O
transfected O
cells O
. O

We O
generated O
measles O
virus O
( O
W O
) O
strains O
defective O
for O
the O
expression O
of O
either O
the O
V O
protein O
, O
a O
modulator O
of O
the O
innate O
immune O
response O
, O
or O
the O
C O
protein O
, O
which O
has O
multiple O
functions O
. O

The O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
, O
also O
called O
CD150 O
, O
is O
a O
cellular O
receptor O
for O
measles B
virus I
( I
MV I
) I
, O
presumably O
accounting O
for O
its O
tropism O
for O
immune O
cells O
and O
its O
immunosuppressive O
properties O
. O

In O
this O
study O
, O
we O
show O
that O
wild O
- O
type O
MV O
can O
infect O
and O
produce O
syncytia O
in O
human O
polarized O
epithelial O
cell O
lines O
independently O
of O
SLAM O
and O
CD46 O
( O
a O
receptor O
for O
the O
vaccine O
strains O
of O
MV O
) O
. O

We O
investigated O
the O
ability O
of O
adjuvanted O
, O
inactivated O
split O
- O
virion O
influenza O
A O
virus O
( O
H5N1 O
) O
vaccines O
to O
protect O
against O
infection O
and O
demonstrated O
that O
the O
disease O
exacerbation O
phenomenon O
seen O
with O
adjuvanted O
formaldehyde O
- O
inactivated O
respiratory O
syncytial O
virus O
and O
measles O
virus O
investigational O
vaccines O
did O
not O
occur O
with O
these O
H5N1 O
vaccines O
. O

measles B
virus I
( I
MeV I
) I
infection O
is O
characterized O
by O
the O
formation O
of O
multinuclear B
giant I
cells I
( I
MGC I
) I
. O

We O
report O
that O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
is O
amplified O
in O
vitro O
by O
the O
formation O
of O
virus O
- O
induced O
MGC O
derived O
from O
human O
epithelial O
cells O
or O
mature O
conventional O
dendritic O
cells O
. O

Production O
of O
IFN O
- O
beta O
and O
IFN O
- O
alpha O
was O
also O
observed O
in O
MeV O
- O
infected O
immature B
dendritic I
cells I
( I
iDc I
) I
and O
mature B
dendritic I
cells I
( I
mDC I
) I
. O

The O
amplification O
of O
IFN O
- O
beta O
production O
was O
associated O
with O
a O
sustained O
nuclear O
localizition O
of O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
in O
MeV O
- O
induced O
MGC O
derived O
from O
both O
epithelial O
cells O
and O
mDC O
, O
while O
the O
IRF O
- O
7 O
up O
- O
regulation O
was O
poorly O
sensitive O
to O
the O
fusion O
process O
. O

The O
receptor O
affinities O
of O
their O
attachment O
proteins O
vary O
greatly O
, O
from O
10 O
( O
- O
4 O
) O
M O
to O
10 O
( O
- O
9 O
) O
M O
, O
but O
the O
significance O
of O
this O
is O
unknown O
. O

We O
demonstrate O
that O
insertion O
of O
the O
open O
reading O
frame O
of O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
into O
the O
coding O
sequence O
for O
the O
second O
hinge O
region O
of O
the O
viral O
L B
( I
large I
) I
protein O
( O
RNA O
- O
dependent O
RNA O
polymerase O
) O
attenuates O
a O
wild O
- O
type O
canine O
distemper O
virus O
. O

Thus O
, O
a O
desirable O
level O
of O
attenuation O
could O
be O
reached O
by O
manipulating O
the O
length O
of O
the O
insert O
( O
in O
the O
second O
hinge O
region O
of O
the O
L O
protein O
) O
, O
providing O
additional O
tools O
for O
optimization O
of O
controlled O
attenuation O
. O

The O
nonsegmented O
, O
negative O
- O
sense O
RNA O
genome O
of O
measles B
virus I
( I
MV I
) I
is O
encapsidated O
by O
the O
virus O
- O
encoded O
Nucleocapsid B
protein I
( I
N I
) I
. O

In O
this O
study O
, O
we O
searched O
for O
N O
- O
binding O
cellular O
proteins O
by O
using O
MV O
- O
N O
as O
bait O
and O
screening O
the O
human O
T O
- O
cell O
cDNA O
library O
by O
yeast O
two O
- O
hybrid O
assay O
and O
isolated O
the O
p40 O
subunit O
of O
eukaryotic O
initiation O
factor O
3 O
( O
eIF3 O
- O
p40 O
) O
as O
a O
binding O
partner O
. O

glutathione B
S I
- I
transferase I
( I
GST I
) I
- O
fused O
MV O
- O
N O
( O
GST O
- O
N O
) O
inhibited O
translation O
of O
reporter O
mRNAs O
in O
rabbit O
reticulocyte O
lysate O
translation O
System O
in O
a O
dose O
- O
dependent O
manner O
. O

The O
Morbillivirus O
hemagglutinin B
( I
H I
) I
protein O
mediates O
attachment O
to O
the O
target O
cell O
. O

measles B
virus I
( I
MV I
) I
propagates O
mainly O
in O
lymphoid O
organs O
throughout O
the O
body O
and O
produces O
syncytia O
by O
using O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
as O
a O
receptor O
. O

Persistence O
in O
canine B
distemper I
virus I
( I
CDV I
) I
infection O
is O
correlated O
with O
very O
limited O
cell O
- O
cell O
fusion O
and O
lack O
of O
cytolysis O
induced O
by O
the O
neurovirulent O
A75 O
/ O
17 O
- O
CDV O
compared O
to O
that O
of O
the O
cytolytic O
Onderstepoort O
vaccine O
strain O
. O

We O
have O
previously O
shown O
that O
this O
difference O
was O
at O
least O
in O
part O
due O
to O
the O
amino O
acid O
sequence O
of O
the O
fusion O
( O
F O
) O
protein O
( O
P O
. O

The O
hemagglutinin B
( I
H I
) I
protein O
of O
measles B
virus I
( I
MV I
) I
mediates O
attachment O
to O
cellular O
receptors O
. O

Like O
other O
paramyxovirus O
attachment O
proteins O
, O
MV O
H O
also O
plays O
a O
role O
in O
fusion O
promotion O
, O
which O
is O
mediated O
through O
an O
interaction O
with O
the O
viral O
fusion O
( O
F O
) O
protein O
. O

The O
stalk O
of O
the O
hemagglutininneuraminidase B
( I
HN I
) I
protein O
of O
several O
paramyxoviruses O
determines O
specificity O
for O
the O
homologous O
F O
protein O
. O

In O
addition O
, O
mutations O
in O
a O
conserved O
domain O
in O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
stalk O
result O
in O
a O
sharp O
decrease O
in O
fusion O
and O
an O
impaired O
ability O
to O
interact O
with O
NDV O
F O
in O
a O
cell O
surface O
coimmunoprecipitation B
( I
co I
- I
IP I
) I
assay O
. O

In O
order O
to O
investigate O
the O
CD4 O
T O
- O
cell O
response O
in O
infection O
of O
the O
respiratory O
tract O
, O
we O
have O
defined O
a O
T O
- O
cell O
epitope O
in O
the O
hemagglutinin B
( I
H I
) I
protein O
for O
immunization O
and O
developed O
a O
monoclonal O
antibody O
for O
depletion O
of O
CD4 O
T O
cells O
in O
the O
cotton O
rat O
model O
. O

Immunization O
in O
the O
presence O
of O
maternal O
antibodies O
resulted O
in O
the O
development O
of O
a O
CD4 O
T O
- O
cell O
response O
which O
( O
in O
the O
absence O
of O
neutralizing O
antibodies O
) O
did O
not O
protect O
against O
infection O
. O

Decay B
accelerating I
factor I
( I
DAF I
) I
is O
not O
a O
cell O
receptor O
for O
EV70 O
- O
Rmk O
. O

Interaction O
of O
the O
C O
- O
terminal O
domains O
of O
Sendai B
virus I
( I
SeV I
) I
P O
and O
N O
proteins O
is O
crucial O
for O
RNA O
synthesis O
by O
correctly O
positioning O
the O
polymerase O
complex O
( O
L O
+ O
P O
) O
onto O
the O
nucleocapsid O
( O
N O
/ O
RNA O
) O
. O

To O
better O
understand O
this O
mechanism O
within O
the O
paramyxovirus O
family O
, O
we O
have O
studied O
the O
complex O
formed O
by O
the O
SeV O
C O
- O
terminal O
domains O
of O
P O
( O
PX O
) O
and O
N O
( O
N O
- O
TAIL O
) O
proteins O
by O
solution O
nuclear O
magnetic O
resonance O
spectroscopy O
. O

SeV O
NTAIL O
binds O
with O
residues O
472 O
to O
493 O
, O
which O
have O
a O
helical O
propensity O
( O
residues O
477 O
to O
491 O
) O
to O
the O
surface O
created O
by O
helices O
alpha O
2 O
and O
alpha O
3 O
of O
PX O
with O
a O
1 O
: O
1 O
stoichiometry O
, O
as O
was O
also O
found O
for O
measles B
virus I
( I
MV I
) I
. O

Clinical O
isolates O
of O
measles B
virus I
( I
MV I
) I
use O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
as O
a O
cellular O
receptor O
, O
whereas O
vaccine O
and O
laboratory O
strains O
may O
utilize O
the O
ubiquitously O
expressed O
CD46 O
as O
an O
additional O
receptor O
. O

MVs O
also O
infect O
, O
albeit O
inefficiently O
, O
SLAM O
( O
- O
) O
cells O
, O
via O
a O
SLAM O
- O
and O
CD46 O
- O
independent O
pathway O
. O

Our O
previous O
study O
with O
recombinant O
chimeric O
viruses O
revealed O
that O
not O
only O
the O
receptor O
- O
binding O
hemagglutinin B
( I
H I
) I
but O
also O
the O
matrix B
( I
M I
) I
protein O
of O
the O
Edmonston O
vaccine O
strain O
can O
confer O
on O
an O
W O
clinical O
isolate O
the O
ability O
to O
grow O
well O
in O
SLAM O
- O
Vero O
cells O
. O

Two O
substitutions O
( O
P64S O
and O
E89K O
) O
in O
the O
M O
protein O
which O
are O
present O
in O
many O
vaccine O
strains O
were O
found O
to O
be O
responsible O
for O
the O
efficient O
growth O
of O
recombinant O
virus O
in O
Vero O
cells O
. O

These O
substitutions O
, O
however O
, O
are O
not O
necessarily O
advantageous O
for O
Ws O
, O
as O
they O
inhibit O
SLAM O
- O
dependent O
cell O
- O
cell O
fusion O
, O
thus O
reducing O
virus O
growth O
in O
SLAM O
( O
+ O
) O
B O
- O
lymphoblastoid O
B95a O
cells O
. O

Hendra B
virus I
( I
HeV I
) I
is O
an O
emerging O
paramyxovirus O
capable O
of O
infecting O
and O
causing O
disease O
in O
a O
variety O
of O
mammalian O
species O
, O
including O
humans O
. O

The O
virus O
infects O
its O
host O
cells O
through O
the O
coordinated O
functions O
of O
its O
fusion O
( O
F O
) O
and O
attachment O
( O
G O
) O
glycoproteins O
, O
the O
latter O
of O
which O
is O
responsible O
for O
binding O
the O
virus O
receptors O
ephrinB2 O
and O
ephrinB3 O
. O

By O
using O
a O
series O
of O
overlapping O
synthetic O
peptides O
covering O
98 O
% O
of O
the O
amino O
acid O
sequence O
of O
the O
nucleocapsid B
protein I
( I
NP I
) I
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
, O
four O
helper O
T O
- O
cell O
( O
Th O
) O
epitopes O
( O
NP11 O
, O
residues O
11 O
to O
25 O
; O
NP51 O
, O
residues O
51 O
to O
65 O
; O
NP61 O
, O
residues O
61 O
to O
75 O
; O
and O
NP111 O
, O
residues O
Ill O
to O
125 O
) O
in O
C57BL O
mice O
( O
H O
- O
2 O
( O
b O
) O
) O
, O
four O
( O
NP21 O
, O
residues O
21 O
to O
35 O
; O
NP91 O
, O
residues O
91 O
to O
105 O
; O
NP331 O
, O
residues O
331 O
to O
345 O
; O
and O
NP351 O
, O
residues O
351 O
to O
365 O
) O
in O
C3H O
mice O
( O
H O
- O
2 O
( O
k O
) O
) O
, O
and O
two O
( O
NP81 O
, O
residues O
81 O
to O
95 O
; O
and O
NP351 O
, O
residues O
351 O
to O
365 O
) O
in O
BALB O
/ O
c O
mice O
( O
H O
- O
2 O
( O
d O
) O
) O
have O
been O
identified O
. O

When O
fused O
with O
a O
conserved O
neutralizing O
epitope O
( O
SPI143 O
- O
1157 O
) O
from O
the O
spike O
protein O
of O
SARS O
- O
CoV O
, O
NP111 O
and O
NP351 O
assisted O
in O
the O
production O
of O
high O
- O
titer O
neutralizing O
antibodies O
in O
vivo O
. O

In O
this O
study O
we O
compared O
a O
prime O
- O
boost O
regimen O
with O
two O
serologically O
distinct O
replication O
- O
defective O
adenovirus B
( I
Ad I
) I
vectors O
derived O
from O
chimpanzee O
serotypes O
C68 O
and O
C1 O
expressing O
Gag O
, O
Pol O
, O
gp140 O
, O
and O
Nef O
of O
human O
immunodeficiency O
virus O
type O
I O
with O
a O
regimen O
in O
which O
replication O
- O
defective O
Ad B
vectors I
of I
the I
human I
serotype I
5 I
( I
AdHu5 I
) I
were O
given O
twice O
. O

Expression O
of O
Ebola O
virus O
nucleoprotein B
( I
NP I
) I
in O
mammalian O
cells O
leads O
to O
the O
formation O
of O
helical O
structures O
, O
which O
serve O
as O
a O
scaffold O
for O
the O
nucleocapsid O
. O

To O
identify O
the O
region O
( O
s O
) O
on O
the O
NP O
molecule O
required O
for O
VP40 O
binding O
, O
we O
examined O
the O
interaction O
of O
a O
series O
of O
NP O
deletion O
mutants O
with O
VP40 O
biochemically O
and O
ultrastructurally O
. O

We O
found O
that O
both O
termini O
of O
NP O
( O
amino O
acids O
2 O
to O
150 O
and O
601 O
to O
739 O
) O
are O
essential O
for O
its O
interaction O
with O
VP40 O
and O
for O
its O
incorporation O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

Using O
flow O
cytometry O
and O
fluorescence O
microscopy O
, O
we O
demonstrate O
that O
infection O
of O
cells O
by O
canine B
distemper I
virus I
( I
CDV I
) I
was O
not O
impaired O
after O
cellular O
cholesterol O
had O
been O
depleted O
by O
the O
drug O
methyl O
- O
beta O
- O
cyclodextrin O
. O

Measles O
virus O
( O
W O
) O
possesses O
two O
envelope O
glycoproteins O
, O
namely O
, O
the O
receptor O
- O
binding O
hemagglutinin B
( I
H I
) I
and O
fusion O
proteins O
. O

Wild O
- O
type O
MV O
strains O
isolated O
in O
B O
- O
lymphoid O
cell O
lines O
use O
signaling B
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
, O
but O
not O
CD46 O
, O
as O
a O
cellular O
receptor O
, O
whereas O
MV O
vaccine O
strains O
of O
the O
Edmonston O
lineage O
use O
both O
SLAM O
and O
CD46 O
as O
receptors O
. O

Our O
results O
show O
that O
three O
substitutions O
( O
N3901 O
and O
E492G O
plus O
N416D O
or O
T446S O
) O
, O
in O
addition O
to O
N481Y O
, O
are O
necessary O
for O
the O
IC O
- O
B O
H O
protein O
to O
use O
CD46 O
efficiently O
as O
a O
receptor O
. O

The O
human O
signaling O
lymphocyte O
activation O
molecule O
( O
SLAM O
, O
also O
called O
CD150 O
) O
, O
a O
regulator O
of O
antigen O
- O
driven O
T O
- O
cell O
responses O
and O
macrophage O
functions O
, O
acts O
as O
a O
cellular O
receptor O
for O
measles B
virus I
( I
MV I
) I
, O
and O
its O
V O
domain O
is O
necessary O
and O
sufficient O
for O
receptor O
function O
. O

Unlike O
in O
vitro O
infection O
, O
NW O
could O
grow O
only O
in O
SLAM O
knockin O
mice O
that O
also O
lacked O
the O
type O
I O
interferon O
receptor O
( O
IFNAR O
) O
. O

Splenocytes O
from O
MV O
- O
infected O
IFNAR O
( O
- O
/ O
- O
) O
SLAM O
knockin O
mice O
showed O
suppression O
of O
proliferative O
responses O
to O
concanavalin O
A O
. O

In O
addition O
to O
the O
phosphoprotein O
, O
the O
P O
gene O
of O
measles B
virus I
( I
MV I
) I
also O
encodes O
the O
V O
and O
C O
proteins O
by O
an O
RNA O
editing O
process O
and O
by O
alternative O
initiation O
of O
translation O
in O
a O
different O
reading O
frame O
, O
respectively O
. O

Here O
, O
we O
report O
that O
a O
recombinant O
W O
lacking O
the O
C O
protein O
( O
MV O
Delta O
C O
) O
grew O
poorly O
in O
a O
human O
cell O
line O
possessing O
the O
intact O
interferon B
( I
IFN I
) I
pathway O
and O
that O
this O
growth O
defect O
was O
associated O
with O
reduced O
viral O
translation O
and O
genome O
replication O
. O

The O
NS1 O
protein O
of O
influenza O
virus O
, O
which O
binds O
to O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
and O
consequently O
inhibits O
IFN O
induction O
and O
dsRNA O
- O
dependent O
protein O
kinase O
activation O
, O
complemented O
the O
growth O
defect O
of O
MV O
Delta O
C O
. O

The O
importance O
of O
the O
F O
protein O
cytoplasmic B
tail I
( I
CT I
) I
for O
replication O
of O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
was O
examined O
by O
monitoring O
the O
behavior O
of O
viruses O
expressing O
F O
proteins O
with O
a O
modified O
COOH O
terminus O
. O

The O
effect O
of O
the O
F O
protein O
modifications O
was O
then O
examined O
in O
the O
context O
of O
a O
viral O
infection O
in O
standard O
cell O
types O
( O
Vero O
and O
HEp O
- O
2 O
) O
. O

The O
F O
protein O
modifications O
consisted O
of O
a O
deletion O
of O
the O
predicted O
CT O
or O
a O
replacement O
of O
the O
CT O
with O
the O
CT O
of O
the O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
G O
protein O
. O

In O
addition O
, O
engineered O
HRSVs O
that O
lacked O
all O
homologous O
glycoprotein O
genes O
( O
SH O
, O
G O
, O
and O
F O
) O
and O
expressed O
instead O
either O
the O
authentic O
VSV O
G O
protein O
or O
a O
VSV O
G O
containing O
the O
HRSV O
F O
protein O
CT O
were O
examined O
. O

Sindbis B
virus I
( I
SV I
) I
, O
an O
enveloped O
virus O
with O
a O
single O
- O
stranded O
, O
plus O
- O
sense O
RNA O
genome O
, O
is O
the O
prototype O
alphavirus O
in O
the O
Togaviridae O
family O
. O

sphingomyelin B
( I
SM I
) I
is O
the O
most O
prevalent O
cellular O
sphingolipid O
, O
is O
particularly O
abundant O
in O
the O
nervous O
systems O
of O
mammals O
, O
and O
is O
required O
for O
alphavirus O
fusion O
and O
entry O
. O

A O
defect O
in O
acid B
sphingomyelinase I
( I
ASMase I
) I
results O
in O
SM O
storage O
and O
subsequent O
intracellular O
accumulation O
of O
SM O
. O

ASMase B
knockout I
( I
ASM I
- I
KO I
) I
mice O
were O
more O
susceptible O
to O
SV O
infection O
than O
wild B
- I
type I
( I
WT I
) I
or O
heterozygous B
( I
Het I
) I
animals O
. O

interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
, O
but O
not O
IL O
- O
1 O
beta O
or O
tumor O
necrosis O
factor O
alpha O
, O
was O
elevated O
in O
infected O
ASM O
- O
KO O
mice O
compared O
to O
levels O
in O
WT O
or O
Het O
mice O
, O
but O
studies O
with O
IL O
- O
6 O
- O
KO O
mice O
and O
recombinant O
SV O
expressing O
IL O
- O
6 O
showed O
no O
role O
for O
IL O
- O
6 O
in O
fatal O
disease O
. O

Transient O
hyperthermia O
such O
as O
that O
experienced O
during O
febrile O
episodes O
increases O
expression O
of O
the O
major O
inducible O
70 O
- O
kDa O
heat B
shock I
protein I
( I
hsp72 I
) I
. O

The O
present O
work O
determined O
the O
in O
vivo O
relationship O
between O
hsp72 O
levels O
and O
neurovirulence O
of O
an O
hsp72 O
- O
responsive O
virus O
using O
the O
mouse O
model O
of O
measles B
virus I
( I
MV I
) I
encephalitis O
. O

Transgenic O
C57BL O
/ O
6 O
mice O
were O
created O
to O
constitutively O
overexpress O
hsp72 O
in O
neurons O
, O
and O
these O
mice O
were O
inoculated O
intracranially O
with O
Edmonston O
MV O
( O
Ed O
MV O
) O
at O
42 O
h O
of O
age O
. O

Mice O
were O
also O
challenged O
with O
an O
Ed O
W O
variant O
exhibiting O
an O
attenuated O
in O
vitro O
response O
to O
hsp72 O
- O
dependent O
stimulation O
of O
viral O
transcription O
( O
Ed O
N O
- O
522D O
) O
. O

Paramyxoviruses O
, O
such O
as O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
assemble O
in O
and O
bud O
from O
plasma O
membranes O
of O
infected O
cells O
. O

To O
explore O
the O
role O
of O
each O
of O
the O
NDV O
structural O
proteins O
in O
virion O
assembly O
and O
release O
, O
virus B
- I
like I
particles I
( I
VLPs I
) I
released O
from O
avian O
cells O
expressing O
all O
possible O
combinations O
of O
the O
nucleoprotein B
( I
NP I
) I
, O
membrane O
or O
matrix B
protein I
( I
M I
) I
, O
an O
uncleaved O
fusion O
protein O
( O
F O
- O
K115Q O
) O
, O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
were O
characterized O
for O
densities O
, O
protein O
content O
, O
and O
efficiencies O
of O
release O
. O

16 O
g O
/ O
cm O
( O
3 O
) O
and O
83 O
. O

Here O
, O
we O
demonstrate O
that O
certain O
immunoglobulin B
G I
( I
IgG I
) I
antibodies O
can O
also O
enhance O
the O
entry O
of O
measles O
virus O
( O
W O
) O
into O
monocytes O
and O
macrophages O
. O

Antibody O
- O
dependent O
enhancement O
of O
infectivity O
was O
observed O
in O
mouse O
and O
human O
macrophages O
using O
virions O
opsonized O
by O
a O
murine O
monoclonal O
antibody O
against O
the O
W O
hemagglutinin B
( I
H I
) I
glycoprotein O
, O
polyclonal O
mouse O
anti O
- O
MV O
IgG O
, O
or O
diluted O
measles O
- O
immune O
human O
sera O
. O

Neither O
H O
- O
specific O
Fab O
fragments O
nor O
H O
- O
specific O
IgM O
could O
enhance O
W O
entry O
in O
monocytes O
or O
macrophages O
, O
indicating O
involvement O
of O
a O
Fc B
gamma I
receptor I
( I
Fc I
gamma I
R I
) I
- O
mediated O
mechanism O
. O

Preincubation O
with O
an O
anti O
- O
fusion O
protein O
( O
anti O
- O
F O
) O
monoclonal O
antibody O
or O
a O
fusion O
- O
inhibitory O
peptide O
blocked O
infection O
, O
indicating O
that O
a O
functional O
F O
protein O
was O
required O
for O
viral O
internalization O
. O

As O
a O
preliminary O
to O
the O
localization O
of O
the O
receptor O
- O
binding O
site O
( O
s O
) O
on O
the O
Nipah B
virus I
( I
NiV I
) I
glycoprotein O
( O
NiV O
- O
G O
) O
, O
we O
have O
undertaken O
the O
identification O
of O
NiV O
- O
G O
residues O
that O
play O
a O
role O
in O
fusion O
promotion O
. O

First O
, O
as O
NiV O
and O
Hendra B
virus I
( I
HeV I
) I
share O
a O
common O
receptor O
and O
their O
cellular O
tropism O
is O
similar O
, O
we O
hypothesized O
that O
residues O
functioning O
in O
receptor O
attachment O
could O
be O
conserved O
between O
their O
respective O
G O
proteins O
. O

Our O
initial O
strategy O
was O
to O
target O
charged O
residues O
( O
which O
can O
be O
expected O
to O
be O
at O
the O
surface O
of O
the O
protein O
) O
conserved O
between O
the O
NiV O
- O
G O
and O
HeV O
- O
G O
globular O
heads O
. O

Second O
, O
we O
generated O
NiV O
variants O
that O
escaped O
neutralization O
by O
anti O
- O
NiV O
- O
G O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
neutralize O
NiV O
both O
in O
vitro O
and O
in O
vivo O
, O
likely O
by O
blocking O
receptor O
attachment O
. O

Our O
results O
suggest O
that O
seven O
NiV O
- O
G O
residues O
, O
including O
one O
( O
E533 O
) O
that O
was O
identified O
using O
both O
strategies O
, O
form O
a O
contiguous O
site O
on O
the O
top O
of O
the O
globular O
head O
that O
is O
implicated O
in O
ephrinB2 O
binding O
. O

rinderpest B
virus I
( I
RPV I
) I
is O
a O
paramyxovirus O
closely O
related O
to O
the O
human O
pathogen O
Measles O
virus O
. O

Here O
, O
we O
demonstrate O
that O
RPV O
blocks O
the O
action O
of O
both O
type O
I O
( O
alpha O
) O
and O
type O
II O
( O
gamma O
) O
Interferons B
( I
IFNs I
) I
by O
blocking O
the O
phosphorylation O
and O
nuclear O
translocation O
of O
STAT1 O
and O
STAT2 O
and O
that O
this O
block O
is O
not O
related O
to O
species O
specificity O
. O

Nipah B
virus I
( I
NiV I
) I
, O
of O
the O
family O
Paramyxoviridae O
, O
was O
isolated O
in O
1999 O
in O
Malaysia O
from O
a O
human O
fatality O
in O
an O
outbreak O
of O
severe O
human O
encephalitis O
, O
when O
human O
infections O
were O
linked O
to O
transmission O
of O
the O
virus O
from O
pigs O
. O

Canarypox O
virus O
- O
based O
vaccine O
vectors O
carrying O
the O
gene O
for O
NiV O
glycoprotein O
( O
ALVAC O
- O
G O
) O
or O
the O
fusion O
protein O
( O
ALVAC O
- O
F O
) O
were O
used O
to O
intramuscularly O
immunize O
four O
pigs O
per O
group O
, O
either O
with O
10 O
( O
8 O
) O
PFU O
each O
or O
in O
combination O
. O

5 O
x O
10 O
( O
5 O
) O
PFU O
of O
NiV O
two O
weeks O
later O
. O

The O
combined O
ALVAC O
- O
F O
/ O
G O
vaccine O
induced O
the O
highest O
levels O
of O
neutralization O
antibodies O
( O
2 O
, O
560 O
) O
; O
despite O
the O
low O
neutralizing O
antibody O
levels O
in O
the O
F O
vaccinees O
( O
160 O
) O
, O
all O
vaccinated O
animals O
appeared O
to O
be O
protected O
against O
challenge O
. O

Virus O
was O
not O
isolated O
from O
the O
tissues O
of O
any O
of O
the O
vaccinated O
pigs O
postchallenge O
, O
and O
a O
Real B
- I
time I
reverse I
transcription I
( I
RT I
) I
- O
PCR O
assay O
detected O
only O
small O
amounts O
of O
viral O
RNA O
in O
several O
samples O
. O

measles B
virus I
( I
MV I
) I
infection O
causes O
an O
acute O
childhood O
disease O
, O
associated O
in O
certain O
cases O
with O
infection O
of O
the O
central O
nervous O
system O
and O
development O
of O
a O
severe O
neurological O
disease O
. O

We O
have O
generated O
transgenic O
mice O
ubiquitously O
expressing O
the O
human O
protein O
SLAM B
( I
signaling I
lymphocytic I
activation I
molecule I
) I
, O
or O
CD150 O
, O
recently O
identified O
as O
an O
MV O
receptor O
. O

The O
genomic O
promoter O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
contains O
multiple O
cis O
- O
elements O
controlling O
transcription O
and O
replication O
. O

Previous O
work O
showed O
that O
regions O
1 O
to O
12 O
and O
79 O
to O
96 O
were O
critical O
in O
promoting O
replication O
of O
an O
HPIV3 O
minireplicon O
, O
while O
the O
intergenic O
sequence O
and O
N O
gene O
start O
signal O
( O
IS O
/ O
Ngs O
, O
bases O
49 O
to O
61 O
) O
were O
important O
for O
transcription O
. O

De O
novo O
generation O
of O
negative O
- O
strand O
RNA O
viruses O
depends O
on O
the O
efficient O
expression O
of O
antigenomic O
RNA O
( O
cRNA O
) O
from O
cDNA O
. O

To O
improve O
the O
rescue O
system O
of O
Borna B
disease I
virus I
( I
BDV I
) I
, O
a O
member O
of O
the O
Mononegavirales O
with O
a O
nuclear O
replication O
phase O
, O
we O
evaluated O
different O
RNA O
Polymerase B
( I
Pol I
) I
promoters O
for O
viral O
cRNA O
expression O
. O

Similarly O
, O
rescue O
of O
measles O
virus O
( O
W O
) O
, O
a O
member O
of O
the O
Mononegavirales O
with O
a O
cytoplasmic O
replication O
phase O
, O
was O
strongly O
improved O
by O
Pol O
H O
- O
controlled O
expression O
of O
viral O
cRNA O
. O

Using O
RNase O
III O
- O
generated O
multiple O
short O
interfering O
RNAs O
( O
siRNAs O
) O
against O
the O
six O
measles O
virus O
genes O
, O
we O
found O
efficient O
downregulation O
of O
viral O
gene O
expression O
in O
general O
with O
siRNAs O
against O
the O
nucleocapsid B
( I
N I
) I
, O
phosphoprotein B
( I
P I
) I
, O
and O
polymerase O
( O
L O
) O
mRNAs O
, O
the O
translation O
products O
of O
which O
form O
the O
ribonucleoprotein B
( I
RNP I
) I
complex O
. O

siRNAs O
against O
the O
mRNAs O
for O
the O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
reduced O
the O
extent O
of O
cell O
- O
cell O
fusion O
. O

Interestingly O
, O
siRNA O
- O
mediated O
knockdown O
of O
the O
matrix B
( I
M I
) I
protein O
not O
only O
enhanced O
cell O
- O
cell O
fusion O
but O
also O
increased O
the O
levels O
of O
both O
mRNAs O
and O
genomic O
RNA O
by O
a O
factor O
of O
2 O
to O
2 O
. O

Experimental O
infections O
of O
ferrets O
with O
canine B
distemper I
virus I
( I
CDV I
) I
recapitulate O
many O
hallmarks O
of O
measles O
: O
rash O
, O
high O
fever O
, O
viremia O
, O
depression O
of O
delayed O
- O
type O
hypersensitivity O
responses O
, O
lowered O
leukocyte O
counts O
, O
and O
reduced O
lymphocyte O
proliferation O
activity O
. O

A O
CDV O
unable O
to O
recognize O
the O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
[ O
CD150 O
] O
) O
that O
is O
expressed O
in O
lymphocytes O
and O
other O
immune O
cells O
did O
not O
spread O
. O

Human O
epithelial O
cells O
infected O
with O
the O
parainfluenza O
virus O
simian B
virus I
5 I
( I
SV5 I
) I
show O
minimal O
activation O
of O
host O
cell O
interferon B
( I
IFN I
) I
, O
cytokine O
, O
and O
cell O
death O
pathways O
. O

In O
contrast O
, O
a O
recombinant O
SV5 O
P O
/ O
V O
gene O
mutant O
( O
rSV5P O
/ O
V O
- O
CPI O
- O
) O
overexpresses O
viral O
gene O
products O
and O
is O
a O
potent O
inducer O
of O
IFN O
, O
proinflammatory O
cytokines O
, O
and O
apoptosis O
in O
these O
cells O
. O

In O
this O
study O
, O
we O
have O
compared O
the O
outcomes O
of O
wild B
- I
type I
( I
WT I
) I
SV5 O
and O
rSV5 O
- O
P O
/ O
V O
- O
CPI O
- O
infections O
of O
primary O
human B
dendritic I
cells I
( I
DC I
) I
, O
important O
antigen O
- O
presenting O
cells O
for O
initiating O
adaptive O
immune O
responses O
. O

In O
mixed O
- O
culture O
assays O
, O
WT O
rSV5 O
- O
infected O
DC O
were O
impaired O
in O
the O
ability O
to O
stimulate O
proliferation O
of O
autologous O
CD4 O
( O
+ O
) O
T O
cells O
, O
whereas O
DC O
infected O
with O
the O
P O
/ O
V O
mutant O
were O
very O
effective O
at O
activating O
T O
- O
cell O
proliferation O
. O

dendritic B
cells I
( I
DCs I
) I
are O
involved O
in O
the O
pathogenesis O
of O
measles B
virus I
( I
MV I
) I
infection O
by O
inducing O
immune O
suppression O
and O
possibly O
spreading O
the O
virus O
from O
the O
respiratory O
tract O
to O
lymphatic O
tissues O
. O

DCs O
express O
the O
MV O
receptors O
CD46 O
and O
CD150 O
, O
and O
we O
demonstrate O
that O
the O
C O
- O
type O
lectin O
DC B
- I
specific I
intercellular I
adhesion I
molecule I
3 I
- I
grabbing I
nonintegrin I
( I
DC I
- I
SIGN I
) I
is O
a O
novel O
receptor O
for O
laboratory O
- O
adapted O
and O
wild O
- O
type O
W O
strains O
. O

At O
739 O
amino O
acids O
, O
the O
nucleoprotein B
( I
NP I
) I
of O
Ebola O
virus O
is O
the O
largest O
nucleoprotein O
of O
the O
nonsegmented O
negative O
- O
stranded O
RNA O
viruses O
, O
and O
like O
the O
NPs O
of O
other O
viruses O
, O
it O
plays O
a O
central O
role O
in O
virus O
replication O
. O

Here O
, O
we O
examined O
the O
glycosylation O
of O
Ebola O
virus O
NP O
and O
further O
investigated O
its O
properties O
by O
generating O
deletion O
mutants O
to O
define O
the O
region O
( O
s O
) O
involved O
in O
NP O
- O
NP O
interaction O
( O
self O
- O
assembly O
) O
, O
in O
the O
formation O
of O
nucleocapsid O
- O
like O
structures O
, O
and O
in O
the O
replication O
of O
the O
viral O
genome O
. O

We O
also O
determined O
that O
the O
region O
from O
amino O
acids O
1 O
to O
450 O
is O
important O
for O
NP O
- O
NP O
interaction O
( O
self O
- O
assembly O
) O
. O

These O
data O
advance O
our O
understanding O
of O
the O
functional O
region O
( O
s O
) O
of O
Ebola O
virus O
NP O
, O
which O
in O
turn O
should O
improve O
our O
knowledge O
of O
the O
Ebola O
virus O
life O
cycle O
and O
its O
extreme O
pathogenicity O
. O

The O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
was O
shown O
to O
bind O
to O
the O
bovine O
CD46 O
molecule O
, O
which O
subsequently O
promotes O
entry O
of O
the O
virus O
. O

To O
assess O
the O
receptor O
usage O
of O
BVDV B
type I
1 I
( I
BVDV I
- I
1 I
) I
and O
BVDV O
- O
2 O
, O
30 O
BVDV O
isolates O
including O
clinical O
samples O
were O
assayed O
for O
their O
sensitivity O
to O
anti O
- O
CD46 O
antibodies O
. O

Single O
complement B
control I
protein I
modules I
( I
CCPs I
) I
within O
the O
bovine O
CD46 O
were O
either O
deleted O
or O
replaced O
by O
analogous O
CCPs O
of O
porcine O
CD46 O
, O
which O
does O
not O
bind O
BVDV O
. O

rabies B
virus I
( I
RV I
) I
phosphoprotein O
P O
is O
an O
interferon B
( I
IFN I
) I
antagonist O
counteracting O
transcriptional O
activation O
of O
type O
1 O
IFN O
( O
K O
. O

The O
major O
inducible O
70 O
- O
kDa O
heat B
shock I
protein I
( I
hsp72 I
) I
increases O
measles B
virus I
( I
MV I
) I
transcription O
and O
genome O
replication O
. O

This O
stimulatory O
effect O
is O
attributed O
to O
hsp72 O
interaction O
with O
two O
highly O
conserved O
hydrophobic O
domains O
in O
the O
Nucleocapsid B
protein I
( I
N I
) I
C O
terminus O
of O
Edmonston O
MV O
. O

Both O
parent O
Edmonston O
MV O
( O
Ed O
N O
) O
and O
an O
N522D O
substitution O
mutant O
( O
Ed O
N O
- O
522D O
) O
exhibited O
similar O
growth O
on O
Vero O
and O
murine O
neuroblastoma O
cells O
and O
in O
cotton O
rat O
lung O
, O
although O
Ed O
N O
- O
522D O
virus O
exhibited O
an O
attenuated O
in O
vitro O
response O
to O
hsp72 O
overexpression O
. O

The O
Edmonston O
strain O
of O
measles B
virus I
( I
MV I
) I
was O
obtained O
by O
sequential O
passages O
of O
the O
original O
isolate O
in O
various O
cultured O
cells O
. O

In O
order O
to O
evaluate O
the O
contributions O
of O
individual O
genes O
of O
the O
Edmonston O
strain O
to O
growth O
in O
cultured O
cells O
, O
we O
generated O
a O
series O
of O
recombinant O
viruses O
in O
which O
part O
of O
the O
genome O
of O
the O
clinical O
isolate O
IC O
- O
B O
( O
which O
uses O
CD150 O
as O
a O
receptor O
) O
was O
replaced O
with O
the O
corresponding O
sequences O
of O
the O
Edmonston O
strain O
. O

The O
recombinant O
virus O
possessing O
the O
Edmonston O
hemagglutinin B
( I
H I
) I
gene O
( O
encoding O
the O
receptor O
- O
binding O
protein O
) O
grew O
as O
efficiently O
in O
Vero O
cells O
as O
the O
Edmonston O
strain O
. O

Those O
viruses O
having O
either O
the O
matrix B
( I
M I
) I
or O
large B
( I
L I
) I
protein O
gene O
from O
the O
Edmonston O
strain O
could O
also O
replicate O
well O
in O
Vero O
cells O
, O
although O
they O
entered O
them O
at O
low O
efficiencies O
. O

Negative O
- O
strand O
RNA O
viruses O
encode O
a O
single O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
which O
transcribes O
and O
replicates O
the O
genome O
. O

The O
open O
reading O
frame O
encoding O
the O
RdRp O
from O
a O
virulent O
wild O
- O
type O
strain O
of O
rinderpest B
virus I
( I
RPV I
) I
was O
inserted O
into O
an O
expression O
plasmid O
. O

Sequences O
encoding O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
were O
inserted O
into O
a O
variable O
hinge O
of O
the O
RdRp O
. O

We O
investigated O
the O
potential O
of O
using O
this O
approach O
to O
rationally O
attenuate O
a O
virus O
by O
inserting O
the O
DNA O
sequences O
encoding O
the O
modified O
RdRp O
into O
a O
full O
- O
length O
anti O
- O
genome O
plasmid O
from O
which O
a O
virulent O
virus O
( O
rRPV O
( O
KO O
) O
) O
can O
be O
rescued O
. O

A O
recombinant O
virus O
, O
rRPV O
( O
KO O
) O
L O
- O
RREGFPR O
, O
which O
grew O
at O
an O
indistinguishable O
rate O
and O
to O
an O
identical O
titer O
as O
rRPV O
( O
KO O
) O
in O
vitro O
, O
was O
rescued O
. O

Subcutaneous O
injection O
of O
10 O
( O
4 O
) O
TCID50 O
of O
the O
rRPV O
( O
KO O
) O
parental O
recombinant O
virus O
into O
cattle O
leads O
to O
severe O
disease O
symptoms O
( O
leukopenia O
/ O
diarrhea O
and O
pyrexia O
) O
and O
death O
by O
9 O
days O
postinfection O
. O

The O
causative O
agent O
, O
measles B
virus I
( I
MeV I
) I
, O
is O
an O
enveloped O
virus O
having O
a O
nonsegmented O
negative O
- O
sense O
RNA O
genome O
, O
and O
belongs O
to O
the O
genus O
Morbillivirus O
of O
the O
family O
Paramyxoviridae O
. O

One O
feature O
of O
the O
moribillivirus O
genomes O
is O
that O
the O
M O
and O
F O
genes O
have O
long O
untranslated B
regions I
( I
UTRs I
) I
. O

The O
relative O
contribution O
of O
measles O
virus O
hemagglutinin B
( I
H I
) I
- O
or O
fusion B
protein I
( I
F I
) I
- O
specific O
antibodies O
to O
virus B
neutralization I
( I
VN I
) I
has O
not O
been O
demonstrated O
. O

Although O
Rab9 O
has O
not O
been O
implicated O
in O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
replication O
, O
previous O
reports O
suggested O
that O
the O
late O
endosome O
is O
an O
initiation O
site O
for O
HIV O
assembly O
and O
that O
TIP47 O
- O
dependent O
trafficking O
out O
of O
the O
late O
endosome O
to O
the O
trans O
- O
Golgi O
network O
facilitates O
the O
sorting O
of O
HIV O
Env O
into O
virions O
budding O
at O
the O
plasma O
membrane O
. O

We O
examined O
the O
role O
of O
Rab9 O
in O
the O
life O
cycles O
of O
HIV O
and O
several O
unrelated O
viruses O
, O
using O
small B
interfering I
RNA I
( I
siRNA I
) I
to O
silence O
Rab9 O
expression O
before O
viral O
infection O
. O

In O
addition O
, O
silencing O
studies O
revealed O
that O
HIV O
replication O
was O
dependent O
on O
the O
expression O
of O
Rab11A O
, O
which O
mediates O
trans O
- O
Golgi O
- O
to O
- O
plasma O
- O
membrane O
transport O
, O
and O
that O
increased O
HIV O
Gag O
was O
sequestered O
in O
a O
CD63 O
( O
+ O
) O
endocytic O
compartment O
in O
a O
cell O
line O
stably O
expressing O
Rab9 O
siRNA O
. O

Using O
a O
C O
- O
terminal O
domain O
( O
PCT O
) O
of O
the O
measles B
virus I
( I
MV I
) I
phosphoprotein I
( I
P I
protein I
) I
as O
bait O
in O
a O
yeast O
two O
- O
hybrid O
screen O
, O
a O
cDNA O
identical O
to O
the O
recently O
described O
human B
p53 I
- I
induced I
- I
RING I
- I
H2 I
( I
hPIRH2 I
) I
cDNA O
was O
isolated O
. O

Additionally O
, O
immunoprecipitation O
experiments O
demonstrated O
that O
hPIRH2 O
- O
myc O
, O
MV O
P O
, O
and O
nucleocapsid B
( I
N I
) I
proteins O
form O
a O
ternary O
complex O
. O

measles B
virus I
( I
MV I
) I
hemagglutinin O
( O
MV O
- O
HH O
) O
and O
fusion O
( O
MV O
- O
F O
) O
proteins O
induce O
plaque B
reduction I
neutralizing I
( I
PRN I
) I
antibodies O
and O
cell O
- O
mediated O
immune O
responses O
that O
protect O
against O
clinical O
measles O
. O

To O
address O
this O
question O
, O
we O
generated O
Sindbis O
virus O
- O
based O
pSINCP O
DNA O
vaccines O
that O
encode O
either O
MV O
- O
H O
or O
MV O
- O
F O
alone O
or O
bicistronic O
or O
fusion O
system O
vectors O
that O
encode O
both O
MV O
- O
H O
and O
W O
- O
F O
( O
to O
mimic O
MV O
infection O
where O
both O
MV O
- O
H O
and O
MV O
- O
F O
proteins O
are O
expressed O
by O
the O
same O
mammalian O
cell O
) O
. O

The O
human O
regulator O
of O
complement O
activation O
membrane O
cofactor O
protein O
( O
CD46 O
) O
has O
recently O
been O
identified O
as O
an O
attachment O
receptor O
for O
most O
species O
B O
adenoviruses B
( I
Ads I
) I
, O
including O
Ad B
type I
3 I
( I
Ad3 I
) I
, O
Ad11 O
, O
and O
Ad35 O
, O
as O
well O
as O
species O
D O
Ad37 O
. O

To O
characterize O
the O
interaction O
between O
Ad35 O
and O
CD46 O
, O
hybrid O
receptors O
composed O
of O
different O
CD46 O
short B
consensus I
repeat I
( I
SCR I
) I
domains O
fused O
to O
immunoglobulin O
- O
like O
domains O
of O
CD4 O
and O
a O
set O
of O
36 O
CD46 O
mutants O
containing O
serniconservative O
changes O
of O
single O
amino O
acids O
within O
SCR O
domains O
I O
and O
II O
were O
tested O
in O
binding O
and O
in O
Ad35 O
- O
mediated O
luciferase O
transduction O
assays O
. O

Our O
data O
indicate O
that O
( O
i O
) O
CD46 O
SCR O
I O
or O
SCR O
II O
alone O
confers O
low O
but O
significant O
Ad35 O
binding O
; O
( O
ii O
) O
the O
presence O
of O
SCR O
I O
and O
II O
is O
required O
for O
optimal O
binding O
and O
transgene O
expression O
; O
( O
iii O
) O
transduction O
efficiencies O
equivalent O
to O
that O
of O
full O
- O
length O
CD46 O
are O
obtained O
if O
SCR O
I O
and O
II O
are O
at O
an O
appropriate O
distance O
from O
the O
cell O
membrane O
; O
( O
iv O
) O
ablation O
of O
the O
N O
- O
glycan O
attached O
to O
SCR O
I O
has O
no O
influence O
on O
receptor O
function O
, O
whereas O
ablation O
of O
the O
SCR O
II O
N O
- O
glycan O
results O
in O
about O
a O
two O
- O
to O
threefold O
reduction O
of O
binding O
and O
transgene O
expression O
; O
( O
v O
) O
most O
putative O
Ad35 O
binding O
residues O
are O
located O
on O
the O
same O
solvent O
- O
exposed O
face O
of O
the O
SCR O
I O
or O
SCR O
II O
domain O
, O
which O
are O
twisted O
by O
about O
90 O
degrees O
; O
and O
( O
vi O
) O
the O
putative O
Ad35 O
binding O
sites O
partly O
overlap O
with O
the O
measles O
virus O
binding O
surface O
. O

In O
this O
work O
we O
investigated O
the O
cis O
- O
acting O
signals O
involved O
in O
replication O
of O
Ebola B
virus I
( I
EBOV I
) I
genomic O
RNA O
. O

The O
fusion B
- I
associated I
small I
transmembrane I
( I
FAST I
) I
proteins O
of O
the O
fusogenic O
reoviruses O
are O
the O
only O
known O
examples O
of O
membrane O
fusion O
proteins O
encoded O
by O
nonenveloped O
viruses O
. O

During O
the O
acute O
phase O
of O
measles O
, O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
- O
infected O
children O
have O
a O
transient O
, O
but O
dramatic O
, O
decrease O
in O
plasma O
HIV O
- O
1 O
RNA O
levels O
( O
W O
. O

To O
determine O
the O
mechanism O
( O
s O
) O
by O
which O
coinfection O
with O
measles B
virus I
( I
MV I
) I
decreases O
HlV O
- O
1 O
replication O
, O
we O
established O
an O
in O
vitro O
culture O
system O
that O
reproduces O
this O
effect O
. O

The O
addition O
of O
MV O
to O
CCR5 O
- O
or O
CXCR4 O
- O
tropic O
HIV O
- O
1 O
- O
infected O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMCs I
) I
decreased O
HIV O
- O
1 O
p24 O
antigen O
production O
in O
a O
dose O
- O
dependent O
manner O
. O

Inhibition O
was O
not O
due O
to O
increased O
production O
of O
chemokines O
known O
to O
block O
coreceptor O
usage O
by O
HIV O
- O
1 O
, O
a O
decrease O
in O
the O
percentage O
of O
CD4 O
( O
+ O
) O
T O
cells O
, O
or O
a O
decrease O
in O
chemokine O
receptor O
expression O
by O
CD4 O
( O
+ O
) O
T O
cells O
. O

These O
studies O
showed O
that O
an O
in O
vitro O
system O
of O
coinfected O
PBMCs O
could O
be O
used O
to O
dissect O
the O
mechanism O
( O
s O
) O
by O
which O
MV O
suppresses O
HIV O
- O
1 O
replication O
in O
coinfected O
children O
and O
suggest O
that O
inhibition O
of O
lymphocyte O
proliferation O
by O
MV O
may O
play O
a O
role O
in O
the O
suppression O
of O
HIV O
- O
1 O
p24 O
antigen O
production O
. O

We O
propose O
a O
reference O
model O
of O
the O
kinetics O
of O
a O
viral B
RNA I
- I
dependent I
RNA I
polymerase I
( I
vRdRp I
) I
activities O
and O
its O
regulation O
during O
infection O
of O
eucaryotic O
cells O
. O

Expression O
of O
the O
virus O
nucleoprotein B
( I
N I
) I
prior O
to O
infection O
shifts O
the O
balance O
in O
favor O
of O
replication O
. O

In O
this O
study O
, O
we O
used O
competition O
experiments O
with O
known O
CD46 O
ligands O
, O
CD46 O
- O
specific O
antibodies O
, O
and O
a O
set O
of O
CD46 O
mutants O
to O
localize O
the O
binding O
domain O
for O
the O
group O
B O
adenovirus O
serotype O
35 O
( O
Ad35 O
) O
. O

The O
P O
gene O
of O
measles B
virus I
( I
MV I
) I
encodes O
the O
P O
protein O
and O
three O
accessory O
proteins O
( O
C O
, O
V O
, O
and O
R O
) O
. O

For O
this O
study O
, O
we O
generated O
a O
recombinant O
wild O
- O
type O
MV O
lacking O
the O
C O
protein O
, O
called O
wtW O
( O
C O
- O
) O
, O
by O
using O
a O
reverse O
genetics O
system O
( O
M O
. O

When O
293 O
cells O
expressing O
the O
MV O
receptor O
SLAM O
( O
293 O
/ O
hSLAM O
) O
were O
infected O
with O
wtMV O
( O
C O
- O
) O
or O
parental O
wild B
- I
type I
MV I
( I
wtMV I
) I
, O
the O
growth O
of O
wtMV O
( O
C O
- O
) O
was O
restricted O
, O
particularly O
during O
late O
stages O
. O

Enhanced O
green O
fluorescent O
protein O
- O
expressing O
wtMV O
( O
C O
- O
) O
consistently O
induced O
late O
- O
stage O
cell O
rounding O
and O
cell O
death O
in O
the O
presence O
of O
a O
fusion O
- O
inhibiting O
peptide O
, O
suggesting O
that O
the O
C O
protein O
can O
prevent O
cell O
death O
and O
is O
required O
for O
long O
- O
term O
MV O
infection O
. O

Neutralizing O
antibodies O
against O
alpha O
[ O
beta O
interferon O
did O
not O
restore O
the O
growth O
restriction O
of O
wtMV O
( O
C O
- O
) O
in O
293 O
/ O
hSLAM O
cells O
. O

When O
cynomolgus O
monkeys O
were O
infected O
with O
wtW O
( O
C O
- O
) O
or O
wtMV O
, O
the O
number O
of O
MV O
- O
infected O
cells O
in O
the O
thymus O
was O
> O
1 O
, O
000 O
- O
fold O
smaller O
for O
wtMV O
( O
C O
- O
) O
than O
for O
wtMV O
. O

Immunohistochemical O
analyses O
showed O
strong O
expression O
of O
an O
MV O
antigen O
in O
the O
spleen O
, O
lymph O
nodes O
, O
tonsils O
, O
and O
larynx O
of O
a O
cynomolgus O
monkey O
infected O
with O
wtMV O
but O
dramatically O
reduced O
expression O
in O
the O
same O
tissues O
in O
a O
cynomolgus O
monkey O
infected O
with O
wtMV O
( O
C O
- O
) O
. O

Human B
plasmacytoid I
dendritic I
cells I
( I
PDC I
) I
are O
key O
sentinels O
alerting O
both O
innate O
and O
adaptive O
immune O
responses O
through O
production O
of O
huge O
amounts O
of O
alpha O
/ O
beta O
interferon B
( I
IFN I
) I
. O

IFN O
induction O
in O
PDC O
is O
triggered O
by O
outside O
- O
in O
signal O
transduction O
pathways O
through O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
and O
TLR9 O
as O
well O
as O
by O
recognition O
of O
cytosolic O
virus O
- O
specific O
patterns O
. O

Both O
TLR O
- O
dependent O
and O
- O
independent O
IFN O
responses O
are O
abolished O
in O
human O
PDC O
infected O
with O
clinical O
isolates O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
RSV O
strain O
A2 O
, O
and O
measles O
virus O
Schwarz O
, O
in O
contrast O
to O
RSV O
strain O
Long O
, O
which O
we O
previously O
identified O
as O
a O
potent O
IFN O
inducer O
in O
human O
PDC O
( O
Hornung O
et O
al O
. O

Notably O
, O
IFN O
synthesis O
of O
PDC O
activated O
by O
the O
TLR7 O
and O
TLR9 O
agonists O
resiquimod O
( O
R848 O
) O
and O
CpG O
oligodeoxynucleotide O
2216 O
is O
switched O
off O
by O
subsequent O
infection O
by O
RSV O
A2 O
and O
measles O
virus O
. O

Signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
, O
CD150 O
) O
is O
the O
universal O
morbillivirus O
receptor O
. O

Based O
on O
the O
identification O
of O
measles B
virus I
( I
MV I
) I
hemagglutinin I
( I
H I
) I
amino O
acids O
supporting O
human O
SLAM O
- O
dependent O
cell O
entry O
, O
we O
mutated O
canine B
distemper I
virus I
( I
CDV I
) I
H O
and O
identified O
residues O
necessary O
for O
efficient O
canine O
SLAM O
- O
dependent O
membrane O
fusion O
. O

The O
baculovirus O
Autographa B
californica I
multiple I
nucleopolyhedrovirus I
( I
AcMNPV I
) I
can O
infect O
a O
variety O
of O
mammalian O
cells O
, O
as O
well O
as O
insect O
cells O
, O
facilitating O
its O
use O
as O
a O
viral O
vector O
for O
gene O
delivery O
into O
mammalian O
cells O
. O

We O
constructed O
gp64 O
- O
null O
recombinant O
bacmids O
carrying O
cDNAs O
encoding O
either O
vesicular B
stomatitis I
virus I
G I
protein I
( I
VSVG I
) I
or O
measles O
virus O
receptors O
( O
CD46 O
or O
SLAM O
) O
. O

Since O
animal O
models O
for O
studying O
human B
cytomegalovirus I
( I
HCMV I
) I
replication O
in O
vivo O
and O
pathogenesis O
are O
not O
available O
, O
severe O
combined O
immunodeficiency O
mice O
into O
which O
human O
tissues O
were O
implanted O
( O
SCID O
- O
hu O
mice O
) O
provide O
an O
alternative O
and O
valuable O
model O
for O
such O
studies O
. O

First O
, O
Toledo O
( O
BAC O
) O
virus O
( O
produced O
from O
a O
Toledo O
bacterial O
artificial O
chromosome O
) O
and O
AD169 O
virus O
were O
tested O
for O
growth O
in O
SCID O
- O
hu O
mice O
. O

Toledo O
( O
BAC O
) O
, O
like O
Toledo O
, O
grew O
to O
high O
titers O
in O
implanted O
human O
thymus O
and O
liver O
tissues O
, O
while O
AD169 O
did O
not O
. O

This O
outcome O
showed O
that O
the O
Toledo O
genome O
propagated O
in O
bacteria O
( O
Toledo O
( O
BAC O
) O
) O
retained O
its O
virulence O
. O

The O
15 O
- O
kb O
segment O
was O
then O
deleted O
from O
ToledoBAC O
, O
and O
the O
resulting O
virus O
, O
Toledo O
( O
Delta15kb O
) O
, O
was O
tested O
for O
growth O
in O
both O
human B
foreskin I
fibroblast I
( I
HFF I
) I
cells O
and O
SCID O
- O
hu O
mice O
. O

Toledo O
( O
Delta15kb O
) O
had O
a O
minor O
growth O
defect O
in O
HFF O
but O
completely O
failed O
to O
replicate O
in O
human O
thymus O
and O
liver O
implants O
. O

This O
failure O
to O
grow O
was O
rescued O
when O
the O
15 O
- O
kb O
region O
was O
inserted O
back O
into O
the O
Toledo O
( O
Delta15kb O
) O
genome O
. O

dendritic B
cells I
( I
DCs I
) I
play O
a O
central O
role O
as O
major O
targets O
of O
dengue B
virus I
( I
DV I
) I
infections O
and O
initiators O
of O
antiviral O
immune O
responses O
. O

interleukin B
10 I
( I
IL I
- I
10 I
) I
was O
detected O
in O
supernatants O
from O
cultures O
of O
DV O
- O
infected O
DCs O
and O
cocultures O
of O
DCs O
and O
T O
cells O
. O

The O
measles B
virus I
( I
MV I
) I
P O
gene O
codes O
for O
three O
proteins O
: O
P O
, O
an O
essential O
polymerase O
cofactor O
, O
and O
V O
and O
C O
, O
which O
have O
multiple O
functions O
but O
are O
not O
strictly O
required O
for O
viral O
propagation O
in O
cultured O
cells O
. O

During O
replication O
, O
the O
P O
protein O
binds O
incoming O
monomeric O
nucleocapsid B
( I
N I
) I
proteins O
with O
its O
amino O
- O
terminal O
domain O
and O
positions O
them O
for O
assembly O
into O
the O
nascent O
ribonucleocapsid O
. O

The O
P O
protein O
amino O
- O
terminal O
domain O
is O
natively O
unfolded O
; O
to O
probe O
its O
conformational O
flexibility O
, O
we O
fused O
it O
to O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
, O
thereby O
also O
silencing O
C O
protein O
expression O
. O

A O
recombinant O
virus O
( O
MV O
- O
GFP O
/ O
P O
) O
expressing O
hybrid O
GFP O
/ O
P O
and O
GFP O
/ O
V O
proteins O
in O
place O
of O
standard O
P O
and O
V O
proteins O
and O
not O
expressing O
the O
C O
protein O
was O
rescued O
and O
produced O
normal O
ratios O
of O
mono O
- O
, O
bi O
- O
, O
and O
tricistronic O
RNAs O
, O
but O
its O
replication O
was O
slower O
than O
that O
of O
the O
parental O
virus O
. O

human B
cytomegalovirus I
( I
HCMV I
) I
infection O
in O
immunocompromised O
patients O
is O
associated O
with O
impaired O
immunological O
function O
. O

Measles B
virus I
hemagglutinin I
( I
MVH I
) I
residues O
potentially O
responsible O
for O
attachment O
to O
the O
wild B
- I
type I
( I
WT I
) I
MV O
receptor O
SLAM O
( O
CD150 O
) O
have O
been O
identified O
and O
localized O
on O
the O
MVH O
globular O
head O
by O
reference O
to O
a O
revised O
hypothetical O
structural O
model O
for O
MVH O
( O
www O
. O

In O
the O
three O
- O
dimensional O
surface O
representation O
of O
the O
structural O
model O
, O
three O
of O
these O
residues O
( O
D505 O
, O
D507 O
, O
and O
8533 O
) O
align O
the O
rim O
on O
one O
side O
of O
the O
cavity O
on O
the O
top O
surface O
of O
the O
MVH O
globular O
head O
and O
form O
the O
basis O
of O
a O
single O
continuous O
site O
that O
overlaps O
with O
the O
546 O
- O
548 O
- O
549 O
CD46 O
binding O
site O
. O

The O
relevance O
of O
these O
results O
to O
present O
concepts O
of O
MV O
receptor O
usage O
is O
discussed O
, O
and O
an O
explanation O
is O
proposed O
as O
to O
why O
morbillivirus O
attachment O
proteins O
are O
H O
, O
whereas O
those O
from O
the O
other O
paramyxoviruses O
are O
HN B
( I
hemagglutinin I
- I
neuraminidase I
) I
. O

By O
a O
contact O
- O
dependent O
surface O
interaction O
, O
the O
measles B
virus I
( I
MV I
) I
glycoprotein O
complex O
induces O
a O
pronounced O
inhibition O
of O
T O
- O
cell O
proliferation O
. O

Tyrosine O
phosphorylation O
of O
the O
regulatory O
subunit O
of O
the O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
, O
p85 O
, O
is O
apparently O
normal O
then O
, O
yet O
this O
protein O
fails O
to O
partition O
to O
the O
lipid O
raft O
fraction O
, O
and O
this O
is O
associated O
with O
stable O
expression O
of O
its O
negative O
regulator O
Cbl O
- O
b O
. O

Measles O
virus O
has O
been O
reported O
to O
enter O
host O
cells O
via O
either O
of O
two O
cellular O
receptors O
, O
CD46 O
and O
CD150 O
( O
SLAM O
) O
. O

We O
demonstrated O
that O
expression O
of O
the O
hemagglutinin B
( I
H I
) I
protein O
of O
measles O
virus O
was O
sufficient O
for O
down O
regulation O
. O

Our O
studies O
provided O
evidence O
that O
interactions O
between O
H O
and O
SLAM O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
can O
promote O
the O
down O
regulation O
of O
SLAM O
but O
not O
CD46 O
. O

dendritic B
cells I
( I
DCs I
) I
play O
a O
crucial O
role O
in O
bridging O
innate O
and O
acquired O
immune O
responses O
to O
pathogens O
. O

In O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
, O
immature B
DCs I
( I
iDCs I
) I
are O
also O
main O
targets O
for O
HIV O
- O
1 O
at O
the O
mucosal O
level O
. O

Although O
gp120 O
did O
not O
interfere O
with O
DC O
differentiation O
, O
the O
capacity O
of O
these O
cells O
to O
produce O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
upon O
maturation O
was O
markedly O
reduced O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
newly O
discovered O
pathogen O
associated O
with O
respiratory O
tract O
illness O
, O
primarily O
in O
young O
children O
, O
immunocompromised O
individuals O
, O
and O
the O
elderly O
. O

We O
report O
an O
analysis O
of O
the O
interaction O
between O
the O
P O
protein O
and O
the O
RNA O
- O
associated O
N O
protein O
( O
N O
- O
RNA O
) O
for O
both O
measles O
and O
mumps O
viruses O
with O
proteins O
produced O
in O
a O
bacterial O
expression O
system O
. O

For O
mumps O
virus O
N O
, O
a O
binding O
site O
for O
the O
P O
protein O
maps O
to O
the O
assembly O
domain O
of O
N O
( O
residues O
1 O
to O
398 O
) O
, O
while O
no O
strong O
binding O
of O
the O
P O
protein O
to O
the O
tail O
of O
N O
was O
detected O
. O

Pulldown O
experiments O
demonstrate O
that O
the O
last O
50 O
amino O
acids O
of O
both O
measles O
virus O
and O
mumps O
virus O
P O
( O
measles O
virus O
P O
, O
457 O
to O
507 O
; O
mumps O
virus O
P O
, O
343 O
to O
391 O
) O
by O
themselves O
constitute O
the O
nucleocapsid B
- I
binding I
domain I
( I
NBD I
) I
. O

The O
dissociation O
constant O
( O
K O
- O
d O
) O
was O
determined O
to O
be O
13 O
muM O
at O
20degreesC O
and O
35 O
muM O
at O
37degreesC O
. O

We O
previously O
demonstrated O
that O
the O
rinderpest B
virus I
( I
RPV I
) I
hemagglutinin I
( I
H I
) I
protein O
plays O
an O
important O
role O
in O
determining O
host O
range O
but O
that O
other O
viral O
proteins O
are O
clearly O
required O
for O
full O
RPV O
pathogenicity O
to O
be O
manifest O
in O
different O
species O
. O

To O
examine O
the O
effects O
of O
the O
RPV O
nucleocapsid B
( I
N I
) I
protein O
and O
phosphoprotein B
( I
P I
) I
genes O
on O
RPV O
cross O
- O
species O
pathogenicity O
, O
we O
constructed O
two O
new O
recombinant O
viruses O
in O
which O
the O
H O
and O
P O
or O
the O
H O
, O
N O
, O
and O
P O
genes O
of O
the O
cattle O
- O
derived O
RPV O
RBOK O
vaccine O
were O
replaced O
with O
those O
from O
the O
rabbit O
- O
adapted O
RPV O
- O
Lv O
strain O
, O
which O
is O
highly O
pathogenic O
in O
rabbits O
. O

The O
viruses O
rescued O
were O
designated O
recombinant O
RPV O
- O
lapPH O
( O
rRPV O
- O
lapPH O
) O
and O
rRPV O
- O
lapNPH O
, O
respectively O
. O

Many O
human O
adenovirus B
( I
Ad I
) I
serotypes O
use O
the O
coxsackie O
B O
virus O
- O
Ad O
receptor O
( O
CAR O
) O
. O

Recently O
, O
CD46 O
was O
suggested O
to O
be O
a O
receptor O
of O
species O
B O
Ad B
serotype I
11 I
( I
Ad11 I
) I
, O
Ad14 O
, O
Ad16 O
, O
Ad21 O
, O
Ad35 O
, O
and O
Ad50 O
. O

Pull O
- O
down O
experiments O
with O
recombinant O
Ad3 O
fibers O
and O
a O
soluble O
form O
of O
the O
CD46 O
extracellular O
domain O
linked O
to O
the O
Fc O
portion O
of O
human O
immunoglobulin O
G O
( O
CD46ex O
- O
Fc O
) O
indicated O
direct O
interactions O
of O
the O
AD O
fiber O
knob O
with O
CD46ex O
- O
Fc O
but O
not O
CARex O
- O
Fc O
( O
Fc O
- O
linked O
extracellular O
domain O
of O
CAR O
) O
. O

Natural O
infection O
with O
measles B
virus I
( I
MeV I
) I
is O
initiated O
when O
the O
virus O
reaches O
epithelial O
cells O
in O
the O
respiratory O
tract O
, O
oropharynx O
, O
or O
conjunctivae O
. O

The O
bronchiolar O
epithelial O
cell O
A549 O
showed O
growth O
arrest O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
following O
MeV O
infection O
or O
treatment O
with O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

IFN B
regulatory I
factor I
- I
1 I
( I
IRF I
- I
1 I
) I
was O
upregulated O
during O
MeV O
infection O
, O
although O
A549 O
did O
not O
produce O
IFN O
- O
gamma O
. O

Subgroup O
D O
adenovirus B
( I
Ad I
) I
types O
8 O
, O
19 O
, O
and O
37 O
( O
AM O
, O
- O
19 O
, O
and O
- O
37 O
, O
respectively O
) O
are O
causative O
agents O
of O
epidemic O
keratoconjunctivitis O
and O
genital O
tract O
infections O
. O

Previous O
studies O
showed O
that O
Ad37 O
binds O
to O
a O
50 O
- O
kDa O
membrane O
glycoprotein O
expressed O
on O
human O
ocular O
( O
conjunctival O
) O
cells O
. O

Immunodepletion O
analyses O
demonstrated O
that O
the O
50 O
- O
kDa O
protein O
is O
identical O
to O
CD46 O
( O
also O
known O
as O
membrane O
cofactor O
protein O
) O
. O

human B
parainfluenza I
virus I
type I
1 I
( I
HPIV1 I
) I
is O
a O
significant O
cause O
of O
respiratory O
tract O
disease O
in O
infants O
and O
young O
children O
for O
which O
a O
vaccine O
is O
needed O
. O

The O
introduced O
mutations O
were O
derived O
from O
three O
attenuated O
paramyxoviruses O
: O
( O
i O
) O
HPIV3cp45 O
, O
a O
live O
- O
attenuated O
HPIV3 O
vaccine O
candidate O
containing O
multiple O
attenuating O
mutations O
; O
( O
ii O
) O
the O
respiratory O
syncytial O
virus O
cpts530 O
with O
an O
attenuating O
mutation O
in O
the O
L O
polymerase O
protein O
; O
and O
( O
iii O
) O
a O
murine B
PIV1 I
( I
MPIV1 I
) I
attenuated O
by O
a O
mutation O
in O
the O
accessory O
C O
protein O
. O

Recombinant B
HPIV1 I
( I
rHPIV1 I
) I
mutants O
bearing O
a O
single O
imported O
mutation O
in O
C O
, O
any O
of O
three O
different O
mutations O
in O
L O
, O
or O
a O
pair O
of O
mutations O
in O
F O
exhibited O
a O
100 O
- O
fold O
or O
greater O
reduction O
in O
replication O
in O
the O
upper O
or O
lower O
respiratory O
tract O
of O
hamsters O
. O

Both O
temperature O
- O
sensitive O
( O
is O
) O
( O
mutations O
in O
the O
L O
and O
F O
proteins O
) O
and O
non O
- O
ts O
( O
the O
mutation O
in O
the O
C O
protein O
) O
attenuating O
mutations O
were O
identified O
. O

Previously O
, O
we O
identified O
a O
naturally O
processed O
and O
presented O
measles B
virus I
( I
MV I
) I
19 O
- O
amino O
- O
acid O
peptide O
, O
ASDVETAEGGEIHELLRLQ O
( O
MV O
- O
P O
) O
, O
derived O
from O
the O
phosphoprotein O
and O
eluted O
from O
the O
human B
leukocyte I
antigen I
( I
HLA I
) I
class O
II O
molecule O
by O
using O
mass O
spectrometry O
. O

We O
report O
here O
the O
identification O
of O
a O
14 O
- O
amino O
- O
acid O
peptide O
, O
SAGKVSSTLASELG O
, O
derived O
from O
the O
MV B
nucleoprotein I
( I
MV I
- I
N I
) I
bound O
to O
HLA O
- O
DRB1 O
* O
0301 O
. O

peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
281 O
previously O
vaccinated O
measles B
- I
mumps I
- I
rubella I
II I
( I
MMR I
- I
II I
) I
subjects O
( O
HLA O
discordant O
) O
were O
studied O
for O
peptide O
recognition O
by O
T O
cells O
. O

Significant O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
responses O
to O
MV O
- O
P O
and O
MV O
- O
N O
peptides O
were O
observed O
in O
55 O
. O

MV O
- O
P O
- O
and O
MV O
- O
N O
- O
specific O
interleukin B
- I
4 I
( I
IL I
- I
4 I
) I
responses O
were O
detected O
in O
19 O
. O

The O
anchored O
and O
secreted O
forms O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
89 O
. O

6 O
envelope O
glycoprotein O
, O
either O
complete O
or O
after O
deletion O
of O
the O
V3 O
loop O
, O
were O
expressed O
in O
a O
cloned O
attenuated O
measles B
virus I
( I
MV I
) I
vector O
. O

A O
high O
level O
of O
CD8 O
( O
+ O
) O
and O
CD4 O
( O
+ O
) O
cells O
specific O
for O
HIV O
gp120 O
was O
also O
detected O
in O
MV O
- O
susceptible O
mice O
. O

canine B
distemper I
virus I
( I
CDV I
) I
infects O
many O
carnivores O
, O
including O
ferrets O
and O
dogs O
, O
and O
is O
the O
member O
of O
the O
Morbillivirus O
genus O
most O
easily O
amenable O
to O
experimentation O
in O
a O
homologous O
small O
- O
animal O
system O
. O

Viruses O
in O
which O
the O
envelope O
genes O
( O
matrix O
, O
fusion O
, O
and O
hemagglutinin O
) O
of O
the O
virulent O
strain O
were O
combined O
with O
the O
other O
genes O
of O
the O
attenuated O
strain O
caused O
severe O
rash O
and O
fever O
even O
if O
the O
disease O
onset O
was O
delayed O
. O

Viruses O
in O
which O
the O
nucleocapsid O
, O
polymerase O
, O
and O
phosphoprotein O
genes O
( O
coding O
also O
for O
the O
V O
and O
C O
proteins O
) O
of O
the O
virulent O
strain O
were O
combined O
with O
the O
envelope O
genes O
of O
the O
attenuated O
strain O
caused O
milder O
signs O
of O
disease O
. O

During O
acute O
measles B
virus I
( I
MV I
) I
infection O
, O
an O
efficient O
immune O
response O
occurs O
, O
followed O
by O
a O
transient O
but O
profound O
immunosuppression O
. O

MV B
nucleoprotein I
( I
MV I
- I
N I
) I
has O
been O
reported O
to O
induce O
both O
cellular O
and O
humoral O
immune O
responses O
and O
paradoxically O
to O
account O
for O
immunosuppression O
. O

Here O
, O
we O
show O
that O
apoptosis O
of O
MV O
- O
infected O
human B
thymic I
epithelial I
cells I
( I
TEC I
) I
allows O
the O
release O
of O
NW O
- O
N O
in O
the O
extracellular O
compartment O
. O

This O
new O
receptor O
is O
referred O
to O
as O
nucleoprotein B
receptor I
( I
NR I
) I
. O

We O
show O
that O
the O
region O
of O
MV O
- O
N O
responsible O
for O
binding O
to O
NR O
maps O
to O
the O
C O
- O
terminal O
fragment O
( O
N O
- O
TAIL O
) O
. O

Binding O
of O
MV O
- O
N O
to O
NR O
on O
TEC O
triggers O
sustained O
calcium O
influx O
and O
inhibits O
spontaneous O
cell O
proliferation O
by O
arresting O
cells O
in O
the O
G O
( O
0 O
) O
and O
G O
( O
1 O
) O
phases O
of O
the O
cell O
cycle O
. O

Among O
them O
, O
measles O
virus O
( O
W O
) O
vaccine O
has O
been O
given O
to O
a O
very O
large O
number O
of O
children O
and O
has O
been O
shown O
to O
be O
highly O
efficacious O
and O
safe O
. O

Antibody O
titers O
and O
T O
- O
cell O
responses O
( O
ELISpot O
) O
in O
animals O
inoculated O
with O
low O
doses O
of O
rescued O
virus O
were O
identical O
to O
those O
obtained O
with O
commercial O
Schwarz O
MV O
vaccine O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
induces O
expression O
of O
the O
gene O
products O
of O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
, O
whereas O
IFN O
- O
alpha O
/ O
beta O
can O
interfere O
with O
or O
suppress O
class O
II O
protein O
expression O
. O

In O
separate O
studies O
, O
measles B
virus I
( I
MV I
) I
was O
reported O
to O
induce O
IFN O
- O
alpha O
/ O
beta O
and O
to O
up O
- O
regulate O
MHC O
class O
II O
proteins O
. O

Class O
II O
protein O
expression O
could O
be O
enhanced O
by O
coculture O
of O
purified O
monocytes O
with O
uninfected O
peripheral B
blood I
mononuclear I
cell I
( I
PBMC I
) I
supernatant O
. O

We O
have O
previously O
shown O
that O
canine O
signaling O
lymphocyte O
activation O
molecule O
( O
SLAM O
; O
also O
known O
as O
CD150 O
) O
acts O
as O
a O
cellular O
receptor O
for O
canine B
distemper I
virus I
( I
CDV I
) I
. O

During O
hospitalization O
, O
percentages O
of O
naive O
( O
CD62L O
( O
+ O
) O
, O
CD45RA O
( O
+ O
) O
) O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
lymphocytes O
decreased O
( O
P O
= O
0 O
. O

01 O
for O
both O
) O
, O
and O
activated O
( O
HLA O
- O
DR O
+ O
, O
CD25 O
( O
+ O
) O
, O
or O
CD69 O
( O
+ O
) O
) O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
lymphocytes O
increased O
( O
P O
= O
0 O
. O

T B
- I
cell I
receptor I
rearrangement I
excision I
circles I
( I
TRECs I
) I
in O
measles O
patients O
were O
increased O
in O
CD8 O
( O
+ O
) O
T O
cells O
at O
entry O
compared O
to O
levels O
at O
hospital O
discharge O
( O
P O
= O
0 O
. O

In O
CD4 O
( O
+ O
) O
T O
cells O
, O
the O
increase O
in O
TRECS O
occurred O
later O
but O
was O
more O
sustained O
. O

At O
discharge O
, O
TRECs O
in O
CD4 O
( O
+ O
) O
T O
cells O
( O
P O
= O
0 O
. O

A O
new O
recombinant O
Sendai B
virus I
vector I
( I
SeV I
/ I
DeltaM I
) I
, O
in O
which O
the O
gene O
encoding O
matrix B
( I
M I
) I
protein O
was O
deleted O
, O
was O
recovered O
from O
cDNA O
and O
propagated O
in O
a O
packaging O
cell O
- O
line O
expressing O
M O
protein O
by O
using O
a O
Cre O
/ O
loxP O
induction O
system O
. O

The O
titer O
of O
SeV O
/ O
DeltaM O
carrying O
the O
enhanced O
green O
fluorescent O
protein O
gene O
in O
place O
of O
the O
M O
gene O
was O
7 O
x O
10 O
( O
7 O
) O
cell O
infectious O
units O
/ O
ml O
or O
more O
. O

Because O
cotton O
rat O
respiratory O
tract O
is O
susceptible O
to O
measles B
virus I
( I
MV I
) I
replication O
after O
intranasal O
( O
i O
. O

Pursuing O
a O
new O
measles O
vaccine O
strategy O
that O
might O
be O
effective O
in O
young O
infants O
, O
we O
used O
attenuated O
Salmonella O
enterica O
serovar O
Typhi O
CVD O
908 O
- O
htrA O
and O
Shigella O
fexneri O
2a O
CVD O
1208 O
vaccines O
to O
deliver O
mucosally O
to O
cotton O
rats O
eukaryotic O
expression O
plasmid O
pGA3 O
- O
mH O
and O
Sindbis O
virus O
- O
based O
DNA O
replicon O
pMSIN O
- O
H O
encoding O
MV O
hemagglutinin B
( I
H I
) I
. O

dose O
- O
response O
with O
bacterial O
vectors O
alone O
identified O
a O
well O
- O
tolerated O
dosage O
( O
1 O
x O
10 O
( O
9 O
) O
to O
7 O
x O
10 O
( O
9d O
) O
CFU O
) O
and O
a O
volume O
( O
20 O
mul O
) O
that O
elicited O
strong O
antivector O
immune O
responses O
. O

fiexneri O
can O
deliver O
measles O
DNA O
vaccines O
mucosally O
in O
cotton O
rats O
, O
inducing O
measles O
immune O
responses O
( O
including O
neutralizing O
antibodies O
) O
and O
protection O
, O
boosting O
strategies O
can O
now O
be O
evaluated O
in O
animals O
primed O
with O
MV O
DNA O
vaccines O
. O

To O
assess O
the O
role O
of O
CD8 O
( O
+ O
) O
cytotoxic O
T O
lymphocytes O
in O
measles O
virus O
clearance O
, O
rhesus O
monkeys O
were O
depleted O
of O
CD8 O
( O
+ O
) O
lymphocytes O
by O
monoclonal O
anti O
- O
CD8 O
antibody O
infusion O
and O
challenged O
with O
wild O
- O
type O
measles O
virus O
. O

The O
CD8 O
( O
+ O
) O
lymphocyte O
- O
depleted O
animals O
exhibited O
a O
more O
extensive O
rash O
, O
higher O
viral O
loads O
at O
the O
peak O
of O
virus O
replication O
, O
and O
a O
longer O
duration O
of O
viremia O
than O
did O
the O
control O
antibody O
- O
treated O
animals O
. O

These O
findings O
indicate O
a O
central O
role O
for O
CD8 O
( O
+ O
) O
lymphocytes O
in O
the O
control O
of O
measles O
virus O
infections O
and O
the O
importance O
of O
eliciting O
a O
cell O
- O
mediated O
immune O
response O
in O
new O
measles O
vaccine O
strategies O
. O

The O
absolute O
and O
relative O
abundance O
of O
major O
histocompatibility O
complex O
class O
I O
- O
presented O
viral O
epitopes O
is O
important O
in O
the O
induction O
and O
maintenance O
of O
antiviral O
cytotoxic B
- I
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
. O

We O
demonstrate O
that O
the O
supra O
- O
abundant O
HLA O
- O
A O
* O
0201 O
- O
restricted O
peptide O
KLWESPQEI O
of O
the O
measles O
virus O
nonstructural O
C O
protein O
induces O
strong O
gamma O
interferon O
CD8 O
( O
+ O
) O
- O
T O
- O
cell O
responses O
in O
children O
with O
acute O
measles O
. O

Humans O
are O
the O
only O
natural O
reservoir O
of O
measles B
virus I
( I
MV I
) I
, O
one O
of O
the O
most O
contagious O
viruses O
known O
. O

Human B
signaling I
lymphocytic I
activation I
molecule I
( I
hSLAM I
) I
was O
identified O
as O
a O
receptor O
for O
wild O
- O
type O
MV O
as O
well O
as O
for O
MV O
strains O
prepared O
as O
vaccines O
. O

To O
better O
evaluate O
the O
role O
of O
hSLAM O
in O
MV O
pathogenesis O
and O
MV O
- O
induced O
immunosuppression O
, O
we O
created O
transgenic B
( I
Tg I
) I
mice O
that O
expressed O
the O
hSLAM O
molecule O
under O
the O
control O
of O
the O
lck O
proximal O
promoter O
. O

hSLAM O
was O
expressed O
on O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
in O
the O
blood O
and O
spleen O
and O
also O
on O
CD4 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
, O
and O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
thymocytes O
. O

Additionally O
, O
MV O
infection O
induced O
downregulation O
of O
receptor O
hSLAM O
and O
inhibited O
cell O
division O
and O
proliferation O
of O
hSLAM O
( O
+ O
) O
but O
not O
hSLAM O
- O
T O
cells O
. O

Using O
the O
cotton O
rat O
model O
( O
Sigmodon O
hispidus O
) O
, O
we O
investigated O
whether O
vaccine O
and O
wild O
- O
type O
viruses O
differ O
in O
viral O
spread O
and O
whether O
this O
is O
correlated O
with O
inhibition O
of O
of O
proliferation O
of O
spleen O
cells O
ex O
vivo O
after O
mitogen O
stimulation O
. O

Four O
( O
in O
humans O
and O
/ O
or O
monkeys O
) O
highly O
pathogenic O
virus O
strains O
were O
immunosuppressive O
, O
whereas O
viruses O
of O
vaccine O
virus O
genotype O
A O
were O
not O
. O

Using O
virus O
pairs O
which O
, O
due O
to O
passage O
on O
fibroblasts O
versus O
lymphoid O
cells O
or O
due O
to O
a O
point O
mutation O
in O
the O
hemagglutinin O
( O
N481 O
- O
- O
> O
Y O
) O
, O
differed O
in O
their O
usage O
of O
the O
two O
receptor O
molecules O
CD46 O
and O
CD150 O
on O
human O
cells O
, O
it O
was O
found O
that O
viruses O
using O
exclusively O
CD150 O
in O
vitro O
spread O
to O
mediastinal O
lymph O
nodes O
and O
induced O
strong O
immune O
suppression O
. O

Human B
parainfluenza I
virus I
type I
2 I
( I
HPIV2 I
) I
is O
the O
only O
member O
of O
the O
genus O
that O
has O
been O
reported O
to O
have O
a O
genome O
length O
that O
is O
not O
an O
even O
multiple O
of O
six O
, O
and O
it O
has O
also O
been O
recovered O
from O
a O
full O
- O
length O
antigenomic O
- O
sense O
cDNA O
that O
did O
not O
conform O
to O
the O
rule O
of O
six O
. O

To O
reexamine O
the O
issue O
of O
nucleotide O
length O
in O
natural O
isolates O
of O
HPIV2 O
, O
a O
complete O
consensus O
genomic O
sequence O
was O
determined O
for O
three O
HPIV2 O
strains O
: O
Greer O
, O
Vanderbilt O
/ O
1994 O
( O
V94 O
) O
, O
and O
Vanderbilt O
/ O
1998 O
. O

Each O
of O
these O
strains O
was O
found O
to O
have O
a O
genome O
length O
of O
15 O
, O
654 O
nucleotides B
( I
nt I
) I
, O
thus O
conforming O
in O
each O
case O
to O
the O
rule O
of O
six O
. O

All O
currently O
licensed O
yellow B
fever I
( I
YF I
) I
vaccines O
are O
propagated O
in O
chicken O
embryos O
. O

Recent O
studies O
of O
chick O
cell O
- O
derived O
measles O
and O
mumps O
vaccines O
show O
evidence O
of O
two O
types O
of O
retrovirus O
particles O
, O
the O
endogenous B
avian I
retrovirus I
( I
EAV I
) I
and O
the O
endogenous O
avian B
leukosis I
virus I
( I
ALV I
- I
E I
) I
, O
which O
originate O
from O
the O
chicken O
embryonic O
fibroblast O
substrates O
. O

In O
this O
study O
, O
we O
investigated O
substrate O
- O
derived O
avian O
retrovirus O
contamination O
in O
YF O
vaccines O
currently O
produced O
by O
three O
manufacturers O
( O
YF O
- O
vax O
[ O
Connaught O
Laboratories O
] O
, O
Stamaril O
[ O
Aventis O
] O
, O
and O
YF O
- O
FIOCRUZ O
[ O
FIOCRUZ O
- O
Bio O
- O
Manguinhos O
] O
) O
. O

Testing O
for O
reverse B
transcriptase I
( I
RT I
) I
activity O
was O
not O
possible O
because O
of O
assay O
inhibition O
. O

A O
recombinant O
capripoxvirus O
vaccine O
containing O
a O
cDNA O
of O
the O
peste B
- I
des I
- I
petits I
- I
ruminants I
virus I
( I
PPRV I
) I
fusion O
protein O
gene O
was O
constructed O
. O

Natural O
or O
wild B
- I
type I
( I
wt I
) I
measles I
virus I
( I
MV I
) I
infection O
in O
vivo O
which O
is O
restricted O
to O
humans O
and O
certain O
monkeys O
represents O
an O
enigma O
in O
terms O
of O
receptor O
usage O
. O

Although O
wt O
MV O
is O
known O
to O
use O
the O
protein O
SLAM O
( O
CD150 O
) O
as O
a O
cell O
receptor O
, O
many O
human O
tissues O
, O
including O
respiratory O
epithelium O
in O
which O
the O
infection O
initiates O
, O
are O
SLAM O
negative O
. O

We O
have O
identified O
a O
novel O
CD46 O
binding O
site O
at O
residues O
S548 O
and O
F549 O
, O
in O
the O
hemagglutinin B
( I
H I
) I
protein O
from O
a O
laboratory O
MV O
strain O
, O
which O
is O
also O
present O
in O
wt O
H O
proteins O
. O

Three O
defense O
functions O
of O
immunoglobulin B
A I
( I
IgA I
) I
, O
immune O
exclusion O
, O
intracellular O
neutralization O
, O
and O
virus O
excretion O
, O
were O
assessed O
in O
a O
measles O
virus O
model O
using O
polarized O
epithelial O
cells O
expressing O
the O
polymeric O
immunoglobulin O
receptor O
and O
monoclonal O
antibodies O
against O
the O
viral O
H O
and O
F O
envelope O
proteins O
and O
the O
internal O
N O
protein O
. O

Smac O
/ O
DIABLO O
enhances O
apoptosis O
through O
its O
action O
on O
cellular O
inhibitor B
of I
apoptosis I
proteins I
( I
IAPs I
) I
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
severe O
respiratory O
disease O
in O
infants O
and O
the O
elderly O
. O

RSV O
vaccine O
development O
has O
been O
hampered O
by O
results O
of O
clinical O
trials O
in O
the O
1960s O
, O
when O
formalin B
- I
inactivated I
whole I
- I
RSV I
preparations I
adjuvated I
with I
alum I
( I
FI I
- I
RSV I
) I
were O
found O
to O
predispose O
infants O
for O
enhanced O
disease O
following O
subsequent O
natural O
RSV O
infection O
. O

The O
vaccine O
- O
induced O
RSV O
- O
specific O
T O
cells O
predominantly O
produced O
the O
Th2 O
cytokines O
interleukin B
- I
13 I
( I
IL I
- I
13 I
) I
and O
IL O
- O
5 O
. O

Human B
herpesvirus I
6 I
( I
HHV I
- I
6 I
) I
has O
a O
tropism O
for O
T O
lymphocytes O
and O
monocytes O
/ O
macrophages O
, O
suggesting O
that O
HHV O
- O
6 O
infection O
affects O
the O
immunosurveillance O
system O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
HHV O
- O
6 O
- O
induced O
phenotypic O
and O
functional O
alterations O
of O
dendritic B
cells I
( I
DCs I
) I
, O
which O
are O
professional O
antigen O
- O
presenting O
cells O
. O

In O
contrast O
, O
there O
appeared O
to O
be O
no O
reduction O
in O
the O
capacity O
for O
presentation O
of O
an O
HLA O
class O
II O
- O
binding O
peptide O
to O
the O
peptide O
- O
specific O
CD4 O
( O
+ O
) O
T O
lymphocytes O
. O

Pattern O
recognition O
via O
Toll B
- I
like I
receptors I
( I
TLR I
) I
by O
antigen O
- O
presenting O
cells O
is O
an O
important O
element O
of O
innate O
immunity O
. O

We O
report O
that O
wild O
- O
type O
measles O
virus O
but O
not O
vaccine O
strains O
activate O
cells O
via O
both O
human O
and O
marine O
TLR2 O
, O
and O
this O
is O
a O
property O
of O
the O
hemagglutinin B
( I
H I
) I
protein O
. O

TLR2 O
activation O
by O
MV O
wild O
- O
type O
H O
protein O
stimulates O
induction O
of O
proinflammatory O
cytokines O
such O
as O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
in O
human O
monocytic O
cells O
and O
surface O
expression O
of O
CD150 O
, O
the O
receptor O
for O
all O
MV O
strains O
. O

Confirming O
the O
specificity O
of O
this O
interaction O
, O
wild O
- O
type O
H O
protein O
did O
not O
induce O
IL O
- O
6 O
release O
in O
macrophages O
from O
TLR2 O
( O
- O
/ O
- O
) O
mice O
. O

The O
paramyxovirus O
template O
for O
transcription O
and O
genome O
replication O
consists O
of O
the O
RNA O
genome O
encapsidated O
by O
the O
nucleocapsid B
protein I
( I
N I
protein I
) I
. O

The O
activity O
of O
the O
complex O
, O
consisting O
of O
viral O
polymerase O
plus O
template O
, O
can O
be O
measured O
with O
minireplicons O
in O
which O
the O
genomic O
coding O
sequence O
is O
replaced O
by O
chloramphenical B
acetyltransferase I
( I
CAT I
) I
antisense O
RNA O
. O

Reporter O
gene O
expression O
was O
enhanced O
by O
supplementation O
with O
the O
major O
inducible O
70 O
- O
kDa O
heat B
shock I
protein I
( I
hsp72 I
) I
for O
minireplicons O
with O
the O
N O
protein O
or O
the O
N O
protein O
truncated O
at O
position O
525 O
or O
524 O
but O
not O
in O
systems O
with O
a O
truncation O
at O
position O
523 O
or O
522 O
. O

This O
coalescence O
is O
believed O
to O
require O
interactions O
between O
the O
cytoplasmic O
tails O
of O
surface O
glycoproteins O
and O
the O
matrix B
( I
M I
) I
protein O
. O

For O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
, O
the O
cytoplasmic O
tail O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
has O
been O
shown O
previously O
to O
be O
important O
for O
normal O
virus O
budding O
. O

To O
investigate O
a O
role O
for O
the O
cytoplasmic O
tail O
of O
the O
fusion O
( O
F O
) O
protein O
in O
virus O
assembly O
and O
budding O
, O
we O
generated O
a O
series O
of O
F O
cytoplasmic O
tail O
- O
truncated O
recombinant O
viruses O
. O

The O
efficiency O
with O
which O
different O
measles B
virus I
( I
MV I
) I
strains O
enter O
cells O
through O
the O
immune O
cell O
- O
specific O
protein O
SLAM O
( O
CD150 O
) O
or O
other O
receptors O
, O
including O
the O
ubiquitous O
protein O
CD46 O
, O
may O
influence O
their O
pathogenicity O
. O

We O
compared O
the O
cell O
entry O
efficiency O
of O
recombinant O
MV O
differing O
only O
in O
their O
attachment O
protein O
hemagglutinin B
( I
H I
) I
. O

We O
also O
proved O
formally O
that O
a O
mutation O
in O
H O
protein O
residue O
481 O
( O
asparagine O
to O
tyrosine O
) O
results O
in O
improved O
CD46 O
- O
specific O
entry O
. O

In O
a O
previous O
report O
, O
we O
demonstrated O
that O
in O
vitro O
, O
measles O
virus O
induced O
differentiation O
of O
cortical O
thymic O
epithelial O
cells O
as O
characterized O
by O
( O
i O
) O
cell O
growth O
arrest O
, O
( O
ii O
) O
morphological O
and O
phenotypic O
changes O
, O
and O
( O
iii O
) O
apoptotis O
as O
a O
final O
step O
of O
this O
process O
. O

First O
, O
measles O
virus O
- O
induced O
differentiation O
of O
thymic O
epithelial O
cells O
is O
shown O
to O
be O
strictly O
dependent O
on O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
secretion O
. O

Infectious B
mononucleosis I
( I
IM I
) I
is O
an O
acute O
sporadic O
infection O
that O
usually O
affects O
young O
adults O
, O
and O
during O
infection O
a O
massive O
expansion O
of O
CD8 O
T O
cells O
is O
generally O
considered O
to O
occur O
. O

When O
peripheral O
blood O
mononuclear O
cells O
of O
acute O
IM O
( O
AIM O
) O
patients O
were O
analyzed O
by O
flow O
cytometry O
, O
a O
continuous O
spectrum O
of O
CD28 O
intensity O
ranging O
from O
negative O
to O
high O
, O
which O
could O
be O
separated O
into O
CD28 O
negative O
, O
intermediate O
( O
int O
) O
, O
and O
positive O
, O
was O
seen O
for O
CD8 O
T O
cells O
. O

CD28 O
is O
a O
costimulatory O
molecule O
on O
T O
cells O
, O
and O
its O
expression O
is O
associated O
with O
the O
subdivision O
of O
CD8 O
cells O
into O
cytotoxic O
( O
CD28 O
- O
positive O
) O
and O
suppressor O
( O
CD28 O
- O
negative O
) O
T O
cells O
. O

Herein O
we O
present O
evidence O
that O
measles B
virus I
( I
MV I
) I
disrupts O
hematopoiesis O
by O
infecting O
human O
CD34 O
( O
+ O
) O
cells O
and O
human O
bone O
marrow O
stroma O
. O

MY O
infection O
does O
not O
affect O
the O
hematopoietic O
capability O
of O
hematopoietic B
stem I
cells I
( I
HSCs I
) I
directly O
; O
rather O
, O
the O
infection O
impairs O
the O
ability O
of O
stroma O
to O
support O
development O
of O
HSCs O
. O

Human B
herpesvirus I
6 I
( I
HHV I
- I
6 I
) I
is O
a O
lymphotropic O
betaherpesvirus O
that O
productively O
infects O
T O
cells O
and O
monocytes O
. O

HHV O
- O
6 O
isolates O
can O
be O
differentiated O
into O
two O
groups O
, O
variants O
A O
and O
B O
( O
HHV O
- O
6A O
and O
HHV O
- O
6B O
) O
. O

The O
syncytium O
formation O
induced O
by O
HHV O
- O
6A O
was O
observed O
2 O
It O
after O
infection O
; O
moreover O
, O
it O
was O
found O
in O
the O
presence O
of O
cycloheximide O
, O
indicating O
that O
HHV O
- O
6A O
induced O
fusion B
from I
without I
( I
FFWO I
) I
in O
the O
target O
cells O
. O

In O
addition O
, O
we O
determined O
that O
short B
consensus I
repeat I
2 I
( I
SCR2 I
) I
, O
- O
3 O
, O
and O
- O
4 O
of O
the O
CD46 O
ectodomain O
were O
essential O
for O
the O
formation O
of O
the O
virus O
- O
induced O
syncytia O
. O

The O
relative O
activities O
of O
five O
measles O
virus O
( O
W O
) O
polymerase O
( O
L O
) O
proteins O
were O
compared O
in O
an O
intracellular O
, O
plasmid O
- O
based O
replication O
assay O
. O

measles B
virus I
( I
MV I
) I
is O
the O
type O
species O
of O
the O
Morbillivirus O
genus O
and O
its O
RNA O
- O
dependent O
RNA O
polymerase O
complex O
is O
comprised O
of O
two O
viral O
polypeptides O
, O
the O
large B
( I
L I
) I
and O
the O
phospho O
- O
( O
P O
) O
proteins O
. O

Sequence O
alignments O
of O
morbillivirus O
L O
polymerases O
have O
demonstrated O
the O
existence O
of O
three O
well O
- O
conserved O
domains O
( O
D1 O
, O
D2 O
, O
and O
D3 O
) O
which O
are O
linked O
by O
two O
variable O
hinges O
( O
H1 O
and O
H2 O
) O
. O

Epitope O
tags O
( O
c O
- O
Myc O
) O
were O
introduced O
into O
H1 O
and O
H2 O
to O
investigate O
the O
tolerance O
of O
the O
variable O
regions O
to O
insertions O
and O
to O
probe O
the O
flexibility O
of O
the O
proposed O
domain O
structures O
to O
spatial O
reorientation O
. O

Two O
recombinant O
viruses O
which O
contained O
the O
chimeric O
L O
genes O
EdtagL O
( O
MMc O
- O
mycM O
) O
and O
EdtagL O
( O
MMEGFPM O
) O
were O
generated O
. O

Tagged O
L O
proteins O
were O
detectable O
, O
by O
indirect O
immunofluorescence O
in O
the O
case O
of O
EdtagL O
( O
MMc O
- O
mycM O
) O
and O
by O
autofluorescence O
in O
the O
case O
of O
EdtagL O
( O
MMEGFPM O
) O
. O

The O
mouse O
epithelial O
MODE O
- O
K O
cell O
line O
expressing O
human O
CD46 O
or O
CD150 O
cellular O
receptors O
was O
found O
to O
be O
nonpermissive O
for O
measles B
virus I
( I
MV I
) I
replication O
. O

Several O
human O
x O
mouse O
( O
HeLa O
x O
MODE O
- O
K O
) O
somatic O
hybrid O
clones O
expressing O
human O
CD46 O
were O
isolated O
and O
found O
to O
be O
either O
nonpermissive O
or O
permissive O
according O
to O
their O
human O
chromosomal O
contents O
. O

The O
MV O
- O
restricted O
phenotype O
exhibited O
by O
the O
MODE O
- O
K O
cell O
line O
suggests O
that O
a O
cellular O
factor O
( O
s O
) O
can O
control O
MV O
transcription O
, O
possibly O
by O
stabilizing O
the O
incoming O
virus O
polymerase O
templates O
. O

Borna B
disease I
virus I
( I
BDV I
) I
is O
a O
nonsegmented O
, O
negative O
- O
strand O
RNA O
virus O
that O
causes O
neurological O
diseases O
in O
a O
variety O
of O
warm O
- O
blooded O
animal O
species O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
the O
nucleoside O
analog O
1 O
- O
beta O
- O
D O
- O
arabinofuranosylcytosine O
( O
Ara O
- O
C O
) O
, O
a O
known O
inhibitor O
of O
DNA O
polymerases O
, O
inhibits O
BDV O
replication O
. O

The O
fusion O
( O
F O
) O
proteins O
of O
most O
paramyxoviruses O
are O
classical O
type O
I O
glycoproteins O
with O
a O
short O
hydrophobic O
leader O
sequence O
closely O
following O
the O
translation O
initiation O
codon O
. O

The O
predicted O
reading O
frame O
of O
the O
canine B
distemper I
virus I
( I
CDV I
) I
F O
protein O
is O
more O
complex O
, O
with O
a O
short O
hydrophobic O
sequence O
beginning O
115 O
codons O
downstream O
of O
the O
first O
AUG O
. O

To O
verify O
if O
the O
sequence O
between O
the O
first O
AUG O
and O
the O
hydrophobic O
region O
is O
translated O
, O
we O
produced O
a O
specific O
antiserum O
that O
indeed O
detected O
a O
short O
- O
lived O
F O
protein O
precursor O
that O
we O
named O
PreF O
( O
0 O
) O
. O

A O
peptide O
resulting O
from O
PreF O
( O
0 O
) O
cleavage O
was O
identified O
and O
named O
Pre O
, O
and O
its O
half O
- O
life O
was O
measured O
to O
be O
about O
30 O
min O
. O

PreF O
( O
0 O
) O
cleavage O
was O
completed O
before O
proteolytic O
activation O
of O
F O
- O
0 O
into O
its O
F O
- O
1 O
and O
F O
- O
2 O
subunits O
by O
furin O
. O

The O
plant O
virus O
Cowpea B
mosaic I
virus I
( I
CPMV I
) I
has O
recently O
been O
developed O
as O
a O
biomolecular O
platform O
to O
display O
heterologous O
peptide O
sequences O
. O

This O
study O
utilized O
the O
CPMV O
chimera O
platform O
to O
create O
an O
antiviral O
against O
measles O
virus O
( O
NV O
) O
by O
displaying O
a O
peptide O
known O
to O
inhibit O
W O
infection O
. O

Wild O
- O
type O
measles B
virus I
( I
MV I
) I
isolated O
from O
B95a O
cells O
has O
a O
restricted O
host O
cell O
specificity O
and O
hardly O
replicates O
in O
Vero O
cells O
, O
whereas O
the O
laboratory O
strain O
Edmonston B
( I
ED I
) I
replicates O
in O
a O
variety O
of O
cell O
types O
including O
Vero O
cells O
. O

To O
investigate O
the O
role O
of O
H O
protein O
in O
the O
differential O
MV O
host O
cell O
specificity O
and O
cell O
fusion O
activity O
, O
H O
proteins O
of O
wild O
- O
type O
MV O
( O
IC O
- O
B O
) O
and O
Ed O
were O
coexpressed O
with O
the O
F O
protein O
in O
Vero O
cells O
. O

To O
analyze O
the O
role O
of O
H O
protein O
in O
the O
context O
of O
viral O
infection O
, O
a O
recombinant O
IC O
- O
B O
virus O
bearing O
Ed O
H O
protein O
( O
IC O
/ O
Ed O
- O
H O
) O
and O
a O
recombinant O
Ed O
virus O
bearing O
IC O
- O
B O
H O
protein O
( O
Ed O
/ O
IC O
- O
H O
) O
were O
generated O
from O
cloned O
cDNAs O
. O

These O
results O
indicated O
that O
an O
MV O
protein O
( O
s O
) O
other O
than O
H O
protein O
was O
likely O
involved O
in O
determining O
cell O
fusion O
and O
host O
cell O
specificity O
of O
MV O
in O
the O
case O
of O
our O
recombinants O
. O

SLAM O
( O
CDw150 O
) O
, O
a O
recently O
identified O
cellular O
receptor O
for O
wild O
- O
type O
MV O
, O
was O
not O
expressed O
in O
Vero O
cells O
, O
and O
a O
monoclonal O
antibody O
against O
CD46 O
, O
a O
cellular O
receptor O
for O
Ed O
, O
did O
not O
block O
replication O
or O
syncytium O
formation O
of O
Ed O
/ O
IC O
- O
H O
in O
Vero O
cells O
. O

To O
understand O
the O
molecular O
determinants O
of O
measles B
virus I
( I
MV I
) I
cytopathicity O
, O
we O
have O
characterized O
mutant O
viruses O
exhibiting O
a O
more O
- O
extensive O
cell O
- O
to O
- O
cell O
fusion O
while O
maintaining O
efficient O
replication O
to O
high O
titers O
. O

A O
virus O
which O
is O
modified O
by O
the O
addition O
of O
an O
8 O
- O
amino O
- O
acid O
Flag O
epitope O
tag O
at O
the O
cytoplasmic O
tail O
of O
its O
H O
( O
for O
MV O
hemagglutinin O
) O
envelope O
glycoprotein O
replicates O
efficiently O
, O
has O
an O
increased O
cytopathicity O
, O
possesses O
a O
greater O
infectivity O
per O
particle O
, O
and O
has O
an O
altered O
protein O
composition O
compared O
with O
that O
of O
unmodified O
MV O
. O

The O
mutant O
phenotype O
is O
not O
specifically O
linked O
to O
the O
epitope O
sequence O
, O
since O
an O
alternatively O
added O
HA O
( O
for O
influenza O
virus O
- O
derived O
hemagglutinin O
) O
epitope O
tag O
caused O
similar O
effects O
. O

We O
demonstrate O
that O
both O
epitope O
tags O
weaken O
the O
interaction O
between O
the O
H O
and O
fusion O
( O
F O
) O
glycoproteins O
in O
virus O
- O
infected O
cells O
. O

This O
reduction O
in O
strength O
of O
H O
/ O
F O
interaction O
is O
independent O
of O
the O
presence O
of O
the O
viral O
matrix B
( I
M I
) I
protein O
. O

Using O
an O
in O
vitro O
proliferation O
assay O
, O
we O
have O
shown O
that O
all O
members O
of O
the O
genus O
Morbillivirus O
inhibit O
the O
proliferation O
of O
a O
human B
B I
- I
lymphoblast I
cell I
line I
( I
BJAB I
) I
. O

Proliferation O
of O
freshly O
isolated O
, O
stimulated O
bovine O
and O
caprine O
peripheral O
blood O
lymphocytes O
is O
also O
inhibited O
by O
UV O
- O
inactivated O
rinderpest O
( O
RPV O
) O
and O
peste O
- O
des O
- O
petits O
ruminants O
viruses O
. O

Host O
cells O
respond O
to O
viral O
infection O
through O
the O
activation O
of O
multiple O
signaling O
cascades O
, O
including O
the O
activation O
of O
NF O
- O
kappaB O
, O
e O
- O
Jun O
/ O
ATF O
- O
2 O
( O
AP O
- O
1 O
) O
, O
and O
the O
interferon B
regulatory I
factors I
( I
IRFs I
) I
. O

Although O
viral O
products O
such O
as O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
and O
the O
processes O
of O
viral O
binding O
and O
fusion O
have O
been O
implicated O
in O
the O
activation O
of O
NF O
- O
kappaB O
and O
AP O
- O
1 O
, O
the O
mechanism O
( O
s O
) O
of O
IRF O
- O
1 O
, O
IRF O
- O
3 O
, O
and O
IRF O
- O
7 O
activation O
has O
yet O
to O
be O
fully O
elucidated O
. O

Using O
recombinant O
measles B
virus I
( I
MeV I
) I
constructs O
, O
we O
now O
demonstrate O
that O
phosphorylation O
- O
dependent O
IRF O
- O
3 O
activation O
represents O
a O
novel O
cellular O
detection O
system O
that O
recognizes O
the O
MeV O
nucleocapsid O
structure O
. O

Expression O
of O
the O
MeV O
nucleocapsid B
( I
N I
) I
protein O
, O
without O
the O
requirement O
for O
any O
additional O
viral O
proteins O
or O
the O
generation O
of O
dsRNA O
, O
was O
sufficient O
for O
IRF O
- O
3 O
activation O
. O

Borna B
disease I
virus I
( I
BDV I
) I
establishes O
a O
persistent O
infection O
in O
the O
central O
nervous O
system O
of O
vertebrate O
animal O
species O
as O
well O
as O
in O
tissue O
cultures O
. O

In O
an O
attempt O
to O
characterize O
the O
life O
cycle O
of O
BDV O
in O
persistently O
infected O
cultured O
cells O
, O
we O
developed O
30 O
clones O
by O
single O
- O
cell O
cloning O
from O
a O
human O
oligodendroglioma O
( O
OL O
) O
cell O
line O
after O
infection O
with O
BDV O
. O

According O
to O
the O
percentage O
of O
cells O
expressing O
the O
BDV O
major O
proteins O
, O
p40 O
( O
nucleoprotein O
) O
and O
p24 O
( O
phosphoprotein O
) O
, O
the O
clones O
were O
classified O
into O
two O
types O
: O
type O
I O
( O
> O
20 O
% O
) O
and O
type O
II O
( O
< O
20 O
% O
) O
. O

mRNAs O
corresponding O
to O
both O
proteins O
were O
detected O
by O
in B
situ I
hybridization I
( I
ISH I
) I
in O
a O
percentage O
of O
cells O
consistent O
with O
that O
for O
the O
protein O
expression O
in O
the O
two O
types O
. O

, O
vesicular O
stomatitis O
virus O
and O
Ebola O
virus O
) O
, O
the O
viral O
matrix B
( I
M I
) I
protein O
contains O
all O
of O
the O
information O
needed O
for O
budding O
, O
since O
virus B
- I
like I
particles I
( I
VLPs I
) I
are O
efficiently O
released O
from O
cells O
when O
the O
M O
protein O
is O
expressed O
from O
cDNA O
. O

To O
investigate O
the O
requirements O
for O
budding O
of O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
, O
its O
M O
protein O
was O
expressed O
in O
mammalian O
cells O
, O
and O
it O
was O
found O
that O
SV5 O
M O
protein O
alone O
could O
not O
induce O
vesicle O
budding O
and O
was O
not O
secreted O
from O
cells O
. O

Coexpression O
of O
M O
protein O
with O
the O
viral O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
or O
fusion O
( O
F O
) O
glycoproteins O
also O
failed O
to O
result O
in O
significant O
VLP O
release O
. O

HN O
or O
F O
, O
together O
with O
the O
nucleocapsid B
( I
NP I
) I
protein O
. O

Furthermore O
, O
truncation O
of O
the O
HN O
cytoplasmic O
tail O
was O
found O
to O
be O
inhibitory O
toward O
budding O
, O
since O
it O
prevented O
coexpressed O
wild B
- I
type I
( I
WT I
) I
F O
protein O
from O
directing O
VLP O
budding O
. O

measles B
virus I
( I
MV I
) I
is O
typically O
spread O
by O
aerosol O
droplets O
and O
enters O
via O
the O
respiratory O
tract O
. O

Herein O
we O
report O
the O
use O
of O
a O
replication O
- O
competent O
Edmonston O
vaccine O
strain O
of O
MV O
expressing O
enhanced O
green O
fluorescent O
protein O
( O
MV O
- O
eGFP O
) O
to O
infect O
primary O
cultures O
of O
well O
- O
differentiated O
human O
airway O
epithelia O
. O

Previous O
studies O
with O
polarized O
Caco O
- O
2 O
cells O
( O
intestine O
- O
derived O
human O
epithelia O
) O
and O
MDCK O
cells O
( O
kidney O
- O
derived O
canine O
epithelia O
) O
demonstrated O
that O
MV O
primarily O
infected O
and O
exited O
the O
apical O
surface O
. O

When O
MV O
- O
eGFP O
was O
applied O
apically O
or O
basolaterally O
to O
primary O
cultures O
of O
airway O
epithelia O
, O
discrete O
foci O
of O
eGFP O
expression O
appeared O
and O
grew O
; O
however O
, O
the O
cell O
layer O
integrity O
was O
maintained O
for O
the O
duration O
of O
the O
study O
( O
7 O
days O
) O
. O

Interestingly O
, O
utilizing O
immunohistochemistry O
and O
confocal O
microscopy O
, O
we O
observed O
widespread O
expression O
of O
the O
receptor O
for O
the O
vaccine O
strain O
of O
MV O
( O
CD46 O
) O
at O
greatest O
abundance O
on O
the O
apical O
surface O
of O
the O
differentiated O
human O
airway O
epithelia O
as O
well O
as O
in O
human O
tracheal O
tissue O
sections O
. O

human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
and O
bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
are O
major O
pathogens O
in O
infants O
and O
calves O
, O
respectively O
. O

Experimental O
BRSV O
infection O
of O
calves O
and O
lambs O
is O
associated O
with O
lymphopenia O
and O
a O
reduction O
in O
responsiveness O
of O
peripheral B
blood I
lymphocytes I
( I
PBLs I
) I
to O
mitogens O
ex O
vivo O
. O

The O
protein O
responsible O
was O
identified O
as O
the O
RSV O
fusion B
protein I
( I
F I
) I
, O
as O
cells O
infected O
with O
a O
recombinant O
RSV O
expressing O
F O
as O
the O
single O
envelope O
protein O
or O
cells O
transfected O
with O
a O
plasmid O
encoding O
F O
were O
able O
to O
induce O
this O
effect O
. O

However O
, O
a O
significant O
fraction O
of O
PBLs O
were O
delayed O
or O
defective O
in O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
to O
S O
- O
phase O
transit O
. O

Fresh O
measles B
virus I
( I
MV I
) I
isolates O
replicate O
readily O
in O
several O
human O
and O
simian O
B O
- O
cell O
lines O
but O
need O
a O
period O
of O
adaptation O
to O
other O
types O
of O
cells O
. O

The O
identification O
of O
CD46 O
and O
CD150 O
( O
SLAM O
) O
as O
cellular O
receptors O
for O
MV O
has O
helped O
to O
clarify O
certain O
aspects O
of O
the O
immunobiology O
of O
MV O
infections O
. O

After O
adaptation O
, O
this O
virus O
expressed O
high O
levels O
of O
both O
the O
viral O
glycoproteins O
( O
hemagglutinin O
and O
fusion O
protein O
) O
but O
did O
not O
induce O
fusion O
( O
syncytia O
) O
. O

The O
immunodominant O
epitopes O
on O
the O
hemagglutinin O
protein O
of O
rinderpest B
virus I
( I
RPV I
- I
H I
) I
were O
determined O
by O
analyzing O
selected O
monoclonal B
antibody I
( I
Mab I
) I
- O
resistant O
mutants O
and O
estimating O
the O
level O
of O
antibody O
against O
each O
epitope O
in O
five O
RPV O
- O
infected O
rabbits O
with O
the O
competitive B
enzyme I
- I
linked I
immunosorbent I
assay I
( I
c I
- I
ELISA I
) I
. O

Six O
neutralizing O
epitopes O
were O
identified O
, O
at O
residues O
474 O
( O
epitope O
A O
) O
, O
243 O
( O
B O
) O
, O
548 O
to O
551 O
( O
D O
) O
, O
587 O
to O
592 O
( O
E O
) O
, O
310 O
to O
313 O
( O
G O
) O
, O
and O
383 O
to O
387 O
( O
H O
) O
, O
from O
the O
data O
on O
the O
amino O
acid O
substitutions O
of O
hemagglutinin O
protein O
of O
MAb O
- O
resistant O
mutants O
and O
the O
reactivities O
of O
MAbs O
against O
RPV O
- O
H O
to O
the O
other O
morbilliviruses O
. O

Five O
human O
recombinant O
Fab O
fragments O
( O
Fabs O
) O
specific O
for O
measles B
virus I
( I
MV I
) I
proteins O
were O
isolated O
from O
three O
antibody O
phage O
display O
libraries O
generated O
from O
RNAs O
derived O
from O
bone O
marrow O
or O
splenic O
lymphocytes O
from O
three O
MV O
- O
immune O
individuals O
. O

In O
radioimmunoprecipitation O
assays O
two O
of O
the O
Fabs O
, O
MV12 O
and O
MT14 O
, O
precipitated O
an O
approximate O
to O
80 O
- O
kDa O
protein O
band O
corresponding O
to O
the O
hemagglutinin B
( I
H I
) I
protein O
from O
MV O
- O
infected O
Vero O
cell O
cultures O
, O
while O
two O
other O
Fabs O
, O
MT64 O
and O
GL29 O
, O
precipitated O
an O
approximate O
to O
60 O
- O
kDa O
protein O
corresponding O
the O
nucleocapsid B
( I
N I
) I
protein O
. O

In O
competition O
studies O
with O
MV O
fusion O
, O
H O
- O
and O
N O
protein O
- O
specific O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
the O
H O
- O
specific O
Fabs O
predominantly O
blocked O
the O
binding O
of O
H O
- O
specific O
MAbs O
, O
while O
the O
N O
- O
specific O
Fabs O
blocked O
MAbs O
to O
N O
. O

By O
plaque O
reduction O
assays O
, O
three O
of O
the O
five O
Fabs O
, O
MV4 O
, O
MV12 O
, O
and O
MT14 O
, O
exhibited O
neutralizing O
activity O
( O
80 O
% O
cutoff O
) O
against O
MV O
( O
LEC O
- O
KI O
strain O
) O
at O
concentrations O
ranging O
between O
approximate O
to2 O
and O
7 O
mug O
ml O
( O
- O
1 O
) O
. O

We O
have O
constructed O
a O
recombinant O
vaccinia O
virus O
vaccine O
( O
v2RVFH O
) O
that O
expresses O
both O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
( I
H I
) I
genes O
of O
rinderpest B
virus I
( I
RPV I
) I
under O
strong O
synthetic O
vaccinia O
virus O
promoters O
. O

Cattle O
vaccinated O
intramuscularly O
with O
as O
little O
as O
10 O
( O
3 O
) O
PFU O
of O
v2RVFH O
and O
challenged O
I O
month O
later O
with O
a O
lethal O
dose O
of O
RPV O
were O
completely O
protected O
from O
clinical O
disease O
; O
the O
50 O
% O
protective O
dose O
was O
determined O
to O
be O
10 O
( O
2 O
) O
PFU O
. O

Intramuscular O
vaccination O
of O
cattle O
with O
10 O
( O
8 O
) O
PFU O
of O
v2RVFH O
provided O
long O
- O
term O
sterilizing O
immunity O
against O
rinderpest O
. O

We O
investigated O
the O
roles O
of O
three O
Sendai B
virus I
( I
SV I
) I
membrane O
proteins O
in O
the O
production O
of O
virus O
- O
like O
particles O
. O

Expression O
of O
matrix O
( O
NI O
) O
proteins O
from O
cDNA O
induced O
the O
budding O
and O
release O
of O
virus O
- O
like O
particles O
that O
contained O
M O
, O
as O
was O
previously O
observed O
with O
human B
parainfluenza I
virus I
type I
I I
( I
hPIV1 I
) I
. O

Expression O
of O
SV O
fusion O
( O
F O
) O
glycoprotein O
from O
cDNA O
caused O
the O
release O
of O
virus O
- O
like O
particles O
bearing O
surface O
F O
, O
although O
their O
release O
was O
less O
efficient O
than O
that O
of O
particles O
bearing O
NI O
protein O
. O

Cells O
that O
expressed O
only O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
released O
no O
HN O
- O
containing O
vesicles O
. O

The O
chimeric O
recombinant O
virus O
rHPIV3 O
- O
N O
- O
B O
, O
a O
version O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
that O
is O
attenuated O
due O
to O
the O
presence O
of O
the O
bovine O
PIV3 O
nucleocapsid B
( I
N I
) I
protein O
open B
reading I
frame I
( I
ORF I
) I
in O
place O
of O
the O
HPIV3 O
ORF O
, O
was O
modified O
to O
encode O
the O
measles O
virus O
hemagglutinin B
( I
RA I
) I
inserted O
as O
an O
additional O
, O
supernumerary O
gene O
between O
the O
HPIV3 O
P O
and O
M O
genes O
. O

This O
recombinant O
, O
designated O
rHPIV3 O
- O
N O
( O
B O
) O
HA O
, O
replicated O
like O
its O
attenuated O
rHPIV3 O
- O
N O
- O
B O
parent O
virus O
in O
vitro O
and O
in O
the O
upper O
and O
lower O
respiratory O
tracts O
of O
rhesus O
monkeys O
, O
indicating O
that O
the O
insertion O
of O
the O
measles O
virus O
RA O
did O
not O
further O
attenuate O
rHPIV3 O
- O
N O
- O
B O
in O
, O
vitro O
or O
in O
vivo O
. O

Monkeys O
immunized O
with O
rHPIV3 O
- O
N O
( O
B O
) O
HA O
developed O
a O
vigorous O
immune O
response O
to O
both O
measles O
virus O
and O
HPIV3 O
, O
with O
serum O
antibody O
titers O
to O
both O
measles O
virus O
( O
neutralizing O
antibody O
) O
and O
HPIV3 O
( O
hemagglutination O
inhibiting O
antibody O
) O
of O
over O
1 O
: O
500 O
. O

Chimeric O
bovine B
respiratory I
syncytial I
viruses I
( I
BRSV I
) I
expressing O
glycoproteins O
of O
bovine B
parainfluenza I
virus I
type I
3 I
( I
BPIV I
- I
3 I
) I
instead O
of O
BRSV O
glycoproteins O
were O
generated O
from O
cDNA O
. O

In O
the O
BRSV O
antigenome O
cDNA O
, O
the O
open O
reading O
frames O
of O
the O
major O
BRSV O
glycoproteins O
, O
attachment O
protein O
G O
and O
fusion O
protein O
F O
, O
were O
replaced O
individually O
or O
together O
by O
those O
of O
the O
BPIV O
- O
3 O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
/ O
or O
fusion O
( O
F O
) O
glycoproteins O
. O

It O
has O
been O
reported O
earlier O
that O
experimentally O
selected O
virus O
variants O
escaping O
from O
the O
Monoclonal B
antibodies I
( I
MAbs I
) I
Nc32 O
and O
L77 O
to O
hemagglutinin B
( I
H I
) I
preserved O
their O
neurovirulence O
, O
whereas O
mutants O
escaping O
MAbs O
K71 O
and O
K29 O
were O
found O
to O
be O
strongly O
attenuated O
( O
U O
. O

Using O
these O
recombinant O
viruses O
, O
we O
identified O
the O
amino O
acid O
changes O
conferring O
escape O
from O
the O
MAbs O
L77 O
( O
377R O
- O
- O
> O
Q O
and O
378M O
- O
- O
> O
K O
) O
, O
Nc32 O
( O
388G O
- O
- O
> O
S O
) O
, O
K71 O
( O
492E O
- O
- O
> O
K O
and O
550S O
- O
- O
> O
P O
) O
, O
and O
K29 O
( O
535E O
- O
- O
> O
G O
) O
. O

Recently O
, O
we O
have O
shown O
that O
human B
signaling I
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
is O
a O
cellular O
receptor O
for O
measles O
virus O
. O

The O
Onderstepoort O
vaccine O
strain O
and O
two O
B95a O
( O
marmoset O
B O
cell O
line O
) O
- O
isolated O
strains O
of O
canine O
distemper O
virus O
caused O
extensive O
cytopathic O
effects O
in O
normally O
resistant O
CHO B
( I
Chinese I
hamster I
ovary I
) I
cells O
after O
expression O
of O
canine O
SLAP O
( O
I O
, O
The O
Ako O
vaccine O
strain O
of O
rinderpest O
virus O
produced O
strong O
cytopathic O
effects O
in O
bovine O
SLAM O
- O
expressing O
CHO O
cells O
. O

herpes B
simplex I
viruses I
( I
HSV I
) I
have O
developed O
several O
immunoevasive O
strategies O
. O

Here O
we O
demonstrate O
a O
novel O
mechanism O
by O
which O
HSV O
type O
1 O
may O
interfere O
with O
the O
immune O
response O
through O
infection O
of O
immature O
dendritic B
cells I
( I
DC I
) I
and O
selective O
downmodulation O
of O
costimulatory O
molecules O
. O

Infection O
of O
immature O
DC O
also O
led O
to O
selective O
and O
asynchronous O
downregulation O
of O
CD1a O
, O
CD40 O
, O
CD54 O
( O
ICAM O
- O
1 O
) O
( O
12 O
h O
postinfection O
) O
, O
CD80 O
( O
24 O
h O
postinfection O
) O
, O
and O
CD86 O
( O
48 O
h O
postinfection O
) O
but O
not O
of O
CD11c O
or O
major O
histocompatibility O
complex O
class O
I O
and O
II O
molecules O
when O
compared O
to O
DC O
exposed O
to O
UV O
- O
inactivated O
virus O
. O

canine B
distemper I
virus I
( I
CDV I
) I
and O
measles B
virus I
( I
MV I
) I
cause O
severe O
illnesses O
in O
their O
respective O
hosts O
. O

In O
this O
study O
, O
we O
examined O
the O
determinants O
for O
the O
differential O
fusogenicity O
of O
the O
wild O
- O
type O
CDV O
isolate O
5804Han89 O
( O
CDV5804 O
) O
, O
the O
small O
- O
and O
large O
- O
plaque O
- O
forming O
variants O
of O
the O
CDV O
vaccine O
strain O
Onderstepoort O
( O
CDV O
, O
, O
and O
CDV O
, O
, O
, O
respectively O
) O
, O
and O
the O
MV B
vaccine I
strain I
Edmonston I
B I
( I
MVEdm I
) I
. O

The O
cotransfection O
of O
different O
combinations O
of O
fusion O
( O
F O
) O
and O
hemagglutinin B
( I
H I
) I
genes O
in O
Vero O
cells O
indicated O
that O
the O
H O
protein O
is O
the O
main O
determinant O
of O
fusion O
efficiency O
. O

Both O
CD46 O
and O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
have O
been O
shown O
to O
act O
as O
cellular O
receptors O
for O
measles B
virus I
( I
MV I
) I
. O

measles B
virus I
( I
MV I
) I
interacts O
with O
cellular O
receptors O
on O
the O
surface O
of O
peripheral B
blood I
lymphocytes I
( I
PBL I
) I
which O
mediate O
virus O
binding O
and O
uptake O
. O

We O
selected O
a O
monoclonal O
antibody O
( O
MAb O
, O
5C6 O
) O
directed O
to O
the O
surface O
of O
highly O
MV O
- O
susceptible O
B O
cells O
( O
B95a O
) O
, O
which O
inhibits O
binding O
to O
and O
infection O
of O
cells O
with O
MV O
wild O
- O
type O
and O
vaccine O
strains O
. O

By O
screening O
a O
retroviral O
cDNA O
library O
from O
human O
splenocytes O
( O
ViraPort O
; O
Stratagene O
) O
with O
this O
antibody O
, O
we O
cloned O
and O
identified O
the O
recognized O
molecule O
as O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
; O
CD150 O
) O
, O
which O
is O
identical O
to O
the O
MV O
receptor O
recently O
found O
by O
H O
, O
Tatsuo O
et O
at O
. O

( O
Nature O
406 O
: O
893 O
- O
897 O
, O
2000 O
) O
. O

BALB O
/ O
c O
mice O
are O
resistant O
to O
measles B
virus I
( I
MV I
) I
- O
induced O
encephalitis O
due O
to O
their O
strong O
MV O
- O
specific O
CD4 O
( O
+ O
) O
T O
- O
cell O
response O
. O

Resistance O
is O
broken O
by O
neutralization O
of O
gamma O
interferon O
with O
monoclonal O
antibodies O
, O
indicating O
an O
important O
role O
for O
this O
pleiotropic O
cytokine O
, O
Here O
, O
we O
demonstrate O
that O
mouse O
gamma O
interferon O
has O
no O
direct O
antiviral O
effect O
in O
vitro O
and O
in O
vivo O
, O
The O
breakdown O
of O
resistance O
is O
due O
neither O
to O
a O
switch O
in O
the O
T O
- O
helper O
response O
nor O
to O
an O
impaired O
migration O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

Neutralization O
of O
gamma O
interferon O
interferes O
with O
the O
major O
histocompatibility O
complex O
class O
II O
- O
dependent O
antigen O
presentation O
and O
subsequent O
proliferation O
of O
CD4 O
( O
+ O
) O
T O
cells O
in O
vitro O
and O
in O
vivo O
. O

In O
consequence O
, O
the O
reduction O
in O
numbers O
of O
CD4 O
( O
+ O
) O
T O
cells O
below O
a O
protective O
threshold O
leads O
to O
susceptibility O
to O
MV O
- O
induced O
encephalitis O
. O

Knowledge O
of O
the O
mechanisms O
of O
virus O
dissemination O
in O
acute O
measles O
is O
cursory O
, O
but O
cells O
of O
the O
monocyte B
/ I
macrophage I
( I
MM I
) I
lineage O
appear O
to O
be O
early O
targets O
. O

We O
characterized O
the O
dissemination O
of O
the O
Edmonston O
B O
vaccine O
strain O
of O
measles B
virus I
( I
MV I
- I
Ed I
) I
in O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
of O
two O
mouse O
strains O
expressing O
the O
human O
MV O
- O
Ed O
receptor O
CD46 O
with O
human O
- O
like O
tissue O
specificity O
and O
efficiency O
, O
In O
one O
strain O
the O
alpha O
/ O
beta O
interferon O
receptor O
is O
defective O
, O
allowing O
for O
efficient O
MV O
- O
Ed O
systemic O
spread O
. O

MV O
- O
Ed O
infection O
of O
splenic O
MM O
- O
depleted O
mice O
caused O
strong O
activation O
and O
infection O
of O
splenic O
dendritic B
cells I
( I
DC I
) I
, O
followed O
by O
enhanced O
virus O
replication O
in O
the O
spleen O
. O

The O
ability O
of O
dendritic B
cells I
( I
DCs I
) I
to O
shape O
the O
adaptive O
immune O
response O
to O
viral O
infection O
is O
mediated O
largely O
by O
their O
maturation O
and O
activation O
state O
as O
determined O
by O
the O
surface O
expression O
of O
HLA O
molecules O
, O
costimulatory O
molecules O
, O
and O
cytokine O
production O
. O

Exposure O
to O
live O
dengue O
virus O
led O
to O
maturation O
and O
activation O
of O
both O
the O
infected O
and O
surrounding O
, O
uninfected O
DCs O
and O
stimulated O
production O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
. O

Activation O
of O
the O
dengue O
virus O
- O
infected O
DCs O
was O
blunted O
compared O
to O
the O
surrounding O
, O
uninfected O
DCs O
, O
and O
dengue O
virus O
infection O
induced O
low O
- O
level O
release O
of O
interleukin B
- I
12 I
p70 I
( I
IL I
- I
12 I
p70 I
) I
, O
a O
key O
cytokine O
in O
the O
development O
of O
cell B
- I
mediated I
immunity I
( I
CMI I
) I
. O

Previous O
findings O
of O
low O
levels O
of O
reverse B
transcriptase I
( I
RT I
) I
activity O
in O
chick O
cell O
- O
derived O
measles O
and O
mumps O
vaccines O
showed O
this O
activity O
to O
be O
associated O
with O
virus O
particles O
containing O
RNA O
of O
both O
subgroup O
E B
endogenous I
avian I
leukosis I
viruses I
( I
ALV I
- I
E I
) I
and O
endogenous B
avian I
viruses I
( I
EAV I
) I
. O

These O
particles O
originate O
from O
chicken B
embryonic I
fibroblast I
( I
CEF I
) I
substrates O
used O
for O
propagating O
vaccine O
strains O
. O

To O
better O
characterize O
vaccine O
- O
associated O
ALV O
- O
E O
, O
we O
examined O
the O
endogenous O
ALV O
proviruses O
( O
ev O
loci O
) O
present O
in O
a O
White O
Leghorn O
CEF O
substrate O
pool O
by O
restriction O
fragment O
length O
polymorphism O
. O

Based O
on O
the O
sequences O
of O
the O
ev O
loci O
, O
RT O
- O
PCR O
assays O
were O
developed O
to O
examine O
expression O
of O
ALV O
- O
E O
particles O
( O
EV O
) O
in O
CEF O
supernatants O
. O

To O
redirect O
the O
tropism O
of O
the O
vaccine O
strain O
elf O
measles B
virus I
( I
MV I
) I
, O
Edmonston O
B O
, O
to O
a O
targeted O
cell O
population O
, O
we O
displayed O
on O
the O
viral O
hemagglutinin B
( I
H I
) I
a O
single B
- I
chain I
antibody I
( I
scAb I
) I
specific O
for O
the O
tumor O
- O
associated O
carcinoembryonic B
antigen I
( I
CEA I
) I
, O
, O
We O
generated O
H O
fusion O
proteins O
with O
three O
forms O
of O
the O
scAb O
appended O
, O
differing O
in O
the O
lengths O
of O
the O
linkers O
separating O
the O
V O
- O
H O
and O
V O
- O
L O
domains O
and O
thus O
in O
the O
oligomerization O
states O
of O
the O
scAbs O
. O

Human O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
; O
also O
known O
as O
CDw150 O
) O
has O
been O
shown O
to O
be O
a O
cellular O
receptor O
for O
measles B
virus I
( I
MV I
) I
. O

The O
ectodomain O
of O
SLAM O
comprises O
the O
two O
immunoglobulin O
superfamily O
domains O
( O
V O
and O
C2 O
) O
. O

The O
soluble O
molecules O
possessing O
the O
V O
domain O
of O
human O
SLAM O
were O
shown O
to O
bind O
to O
cells O
expressing O
the O
MV O
hemagglutinin B
( I
H I
) I
protein O
but O
not O
to O
cells O
expressing O
the O
MV O
fusion O
protein O
or O
irrelevant O
envelope O
proteins O
. O

In O
addition O
, O
this O
response O
was O
only O
seen O
when O
viral O
gene O
expression O
was O
inhibited O
, O
suggesting O
that O
a O
newly O
synthesized O
viral O
protein O
( O
s O
) O
may O
function O
as O
an O
inhibitor O
of O
this O
response O
. O

Protein O
- O
encoding O
nucleotide O
sequences O
of O
the O
N O
, O
P O
, O
M O
, O
F O
, O
H O
, O
and O
L O
genes O
were O
determined O
for O
a O
low O
- O
passage O
isolate O
of O
the O
Edmonston O
wild B
- I
type I
( I
WT I
) I
measles O
virus O
and O
five O
Edmonston O
- O
derived O
vaccine O
virus O
strains O
, O
including O
AIK O
- O
C O
, O
Moraten O
, O
Schwarz O
, O
Rubeovax O
, O
and O
Zagreb O
. O

The O
noncoding O
sequence O
of O
five O
Edmonston O
vaccine O
viruses O
( O
AIK O
- O
C O
, O
Moraten O
, O
Rubeovax O
, O
Schwarz O
, O
and O
Zagreb O
) O
and O
those O
of O
a O
low O
- O
passage O
Edmonston O
wild B
- I
type I
( I
WT I
) I
measles O
virus O
have O
been O
determined O
and O
compared O
. O

To O
address O
how O
these O
viruses O
, O
which O
replicate O
poorly O
in O
mammalian O
cells O
, O
might O
be O
immunogenic O
, O
we O
studied O
how O
canarypox O
virus O
( O
ALVAC O
) O
interacts O
with O
primate O
antigen O
- O
presenting O
dendritic B
cells I
( I
DCs I
) I
. O

DC O
maturation O
coincided O
with O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
secretion O
and O
was O
significantly O
blocked O
in O
the O
presence O
of O
anti O
- O
TNF O
- O
alpha O
antibodies O
. O

During O
measles B
virus I
( I
MV I
) I
replication O
, O
approximately O
half O
of O
the O
internal O
M O
and O
N O
proteins O
, O
together O
with O
envelope O
H O
and O
F O
glycoproteins O
, O
are O
selectively O
enriched O
in O
microdomains O
rich O
in O
cholesterol O
and O
sphingolipids O
called O
membrane O
rafts O
. O

Furthermore O
, O
the O
H O
and O
F O
glycoproteins O
from O
released O
virus O
are O
also O
partly O
in O
membrane O
rafts O
( O
S O
, O
N O
, O
Manie O
et O
al O
, O
, O
J O
, O
Virol O
, O
74 O
: O
305 O
- O
311 O
, O
2000 O
) O
, O
When O
expressed O
alone O
, O
the O
M O
but O
not O
N O
protein O
shows O
a O
low O
partitioning O
( O
around O
10 O
% O
) O
into O
rafts O
; O
this O
distribution O
is O
unchanged O
when O
all O
of O
the O
internal O
proteins O
, O
M O
, O
N O
, O
P O
, O
and O
L O
, O
are O
coexpressed O
, O
After O
infection O
with O
MGV O
, O
a O
chimeric O
MV O
where O
both O
H O
and O
F O
proteins O
have O
been O
replaced O
by O
vesicular O
stomatitis O
virus O
G O
protein O
, O
both O
the O
M O
and O
N O
proteins O
were O
found O
enriched O
in O
membrane O
rafts O
, O
whereas O
the O
G O
protein O
was O
not O
. O

We O
sought O
proof O
of O
principle O
that O
one O
of O
the O
safest O
human O
vaccines O
, O
measles B
virus I
Edmonston I
B I
( I
MV I
- I
Edm I
) I
, O
can O
be O
genetically O
modified O
to O
allow O
entry O
via O
cell O
surface O
molecules O
other O
than O
its O
receptor O
CD46 O
. O

Hybrid O
proteins O
consisting O
of O
the O
epidermal B
growth I
factor I
( I
EGF I
) I
or O
the O
insulin O
- O
like O
growth O
factor O
1 O
( O
IGF1 O
) O
linked O
to O
the O
extracellular O
( O
carboxyl O
) O
terminus O
of O
the O
MV O
- O
Edm O
attachment O
protein O
hemagglutinin B
( I
H I
) I
were O
produced O
. O

Virus O
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
play O
a O
major O
role O
in O
the O
clearance O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
infection O
. O

We O
have O
generated O
cytotoxic O
T B
- I
cell I
clones I
( I
TCC I
) I
from O
two O
infants O
who O
had O
just O
recovered O
from O
severe O
RSV O
infection O
. O

These O
TCC O
were O
functionally O
characterized O
and O
used O
to O
identify O
HLA O
class O
I O
( O
B57 O
and O
C12 O
) O
- O
restricted O
CTL O
epitopes O
of O
RSV O
. O

canine B
distemper I
virus I
( I
CDV I
) I
has O
been O
rescued O
from O
a O
full O
- O
length O
cDNA O
done O
. O

Besides O
measles B
virus I
( I
MV I
) I
and O
Rinderpest O
virus O
, O
a O
third O
morbillivirus O
is O
now O
available O
for O
genetic O
analysis O
using O
reverse O
genetics O
. O

A O
plasmid O
p O
( O
+ O
) O
CDV O
was O
constructed O
by O
sequential O
cloning O
using O
the O
Onderstepoort O
vaccine O
strain O
large O
- O
plaque O
- O
forming O
variant O
. O

The O
presence O
of O
a O
T7 O
promoter O
allowed O
transcription O
of O
full O
- O
length O
antigenomic O
RNA O
by O
a O
T7 O
RNA O
polymerase O
, O
which O
, O
vas O
provided O
by O
a O
host O
range O
mutant O
of O
vaccinia O
virus O
( O
MVA O
- O
T7 O
) O
. O

Infection O
of O
HeLa O
cells O
with O
MVA O
- O
T7 O
and O
subsequent O
transfection O
of O
p O
( O
+ O
) O
CDV O
plus O
the O
helper O
plasmids O
led O
to O
syncytium O
formation O
and O
release O
of O
infectious O
recombinant O
( O
r O
) O
CDV O
. O

Sendai B
virus I
( I
SeV I
) I
infection O
of O
interferon B
( I
IFN I
) I
- O
competent O
cells O
is O
one O
of O
the O
most O
efficient O
ways O
of O
inducing O
IFN O
production O
. O

Rinderpest O
( O
RP O
) O
and O
peste B
- I
des I
- I
petits I
- I
ruminants I
( I
PPR I
) I
are O
two O
important O
diseases O
of O
domestic O
ruminants O
. O

To O
improve O
on O
currently O
available O
vaccines O
against O
PPR O
, O
we O
have O
created O
cDNA O
copies O
of O
the O
RP O
virus O
genome O
in O
which O
either O
the O
fusion O
( O
F O
) O
or O
hemagglutinin B
( I
H I
) I
gene O
, O
or O
both O
, O
was O
replaced O
with O
the O
corresponding O
gene O
from O
PPR O
virus O
. O

We O
have O
developed O
a O
quantitative O
biochemical O
assay O
to O
monitor O
the O
budding O
of O
Semliki B
Forest I
virus I
( I
SFV I
) I
, O
an O
enveloped O
alphavirus O
that O
buds O
from O
the O
plasma O
membrane O
in O
a O
reaction O
requiring O
both O
viral O
spike O
proteins O
and O
nucleocapsid O
. O

Recombinant O
human B
parainfluenza I
virus I
type I
3 I
( I
PIV3 I
) I
was O
used O
as O
a O
vector O
to O
express O
the O
major O
protective O
antigen O
of O
measles O
virus O
, O
the O
Hemagglutinin B
( I
HA I
) I
glycoprotein O
, O
in O
order O
to O
create O
a O
bivalent O
PIV3 O
- O
measles O
virus O
that O
can O
be O
administered O
intranasally O
. O

The O
measles O
virus O
HA O
open B
reading I
frame I
( I
ORF I
) I
was O
inserted O
as O
an O
additional O
transcriptional O
unit O
into O
the O
N O
- O
P O
, O
P O
- O
M O
, O
or O
HA O
- O
neuraminidase O
( O
HN O
) O
- O
L O
gene O
junction O
of O
wild O
- O
type O
PIV3 O
or O
into O
the O
N O
- O
P O
or O
P O
- O
hl O
gene O
junction O
of O
an O
attenuated O
derivative O
of O
PIV3 O
, O
termed O
rcp45L O
. O

The O
recombinant B
PIV3 I
( I
rPIV3 I
) I
viruses O
bearing O
the O
IIA O
inserts O
replicated O
more O
slowly O
in O
vitro O
than O
their O
parental O
viruses O
but O
reached O
comparable O
peak O
titers O
of O
greater O
than O
or O
equal O
to O
10 O
( O
7 O
. O

Each O
of O
the O
wild O
- O
type O
or O
cold B
- I
passaged I
45L I
( I
cp35L I
) I
PIV3 O
( O
IIA O
) O
chimeric O
viruses O
replicated O
5 O
- O
to O
10 O
- O
fold O
less O
well O
than O
its O
respective O
parent O
virus O
in O
the O
upper O
respiratory O
tract O
of O
hamsters O
, O
Thus O
, O
insertion O
of O
the O
similar O
to O
2 O
- O
kb O
ORF O
itself O
conferred O
attenuation O
, O
and O
this O
attenuation O
was O
additive O
to O
that O
conferred O
by O
the O
cp35L O
mutations O
. O

The O
attenuated O
cp45L O
PIV3 O
( O
HA O
) O
recombinants O
induced O
a O
high O
level O
of O
resistance O
to O
replication O
of O
PIV3 O
challenge O
virus O
in O
hamsters O
and O
induced O
very O
high O
levels O
of O
measles O
virus O
neutralizing O
antibodies O
( O
> O
1 O
: O
8 O
, O
000 O
) O
that O
are O
well O
in O
excess O
of O
those O
known O
to O
be O
protective O
in O
humans O
. O

This O
suggests O
that O
this O
intranasally O
administered O
PIV3 O
( O
HA O
) O
chimeric O
virus O
can O
be O
used O
to O
immunize O
infants O
with O
maternally O
acquired O
measles O
virus O
antibodies O
in O
whom O
the O
current O
parenterally O
administered O
live O
measles O
virus O
vaccine O
is O
ineffective O
. O

Mature O
dendritic B
cells I
( I
DC I
) I
are O
the O
most O
potent O
antigen O
- O
presenting O
cells O
within O
the O
entire O
immune O
system O
. O

Several O
members O
of O
the O
Herpesviridae O
family O
have O
provided O
examples O
of O
such O
escape O
strategies O
, O
including O
interference O
with O
antigen O
presentation O
and O
production O
of O
homologous O
cytokines O
, O
In O
this O
study O
we O
investigated O
the O
infection O
of O
mature O
DC O
with O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
and O
the O
way O
in O
which O
infection O
alters O
the O
phenotype O
and O
function O
of O
mature O
DC O
. O

Since O
alpha O
/ O
beta O
Interferons B
( I
IFNs I
) I
are O
pivotal O
players O
both O
in O
nonspecific O
antiviral O
immunity O
and O
in O
specific O
cellular O
responses O
, O
their O
induction O
or O
suppression O
by O
measles B
virus I
( I
MV I
) I
could O
influence O
the O
outcome O
of O
a O
viral O
infection O
. O

In O
this O
study O
we O
compare O
the O
IFN O
induction O
and O
sensitivity O
of O
laboratory O
- O
passaged O
attenuated O
MV O
strains O
Edmonston O
and O
Moraten O
with O
those O
of O
recent O
wild O
- O
type O
viruses O
isolated O
and O
passaged O
solely O
on O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMC I
) I
or O
on O
the O
B958 O
marmoset O
B O
- O
cell O
line O
. O

We O
report O
that O
two O
PBMC O
- O
grown O
wild O
- O
type O
measles O
isolates O
and O
two O
B958 O
- O
grown O
strains O
of O
MV O
induce O
10 O
- O
to O
10 O
- O
fold O
- O
lower O
production O
of O
IFN O
by O
phytohemagglutinin O
- O
stimulated O
peripheral B
blood I
lymphocytes I
( I
PBL I
) I
compared O
to O
Edmonston O
and O
Moraten O
strains O
of O
measles O
. O

Expression O
of O
the O
measles O
virus O
( O
Rn O
) O
F O
/ O
H O
complex O
on O
the O
surface O
of O
viral O
particles O
, O
infected O
cells O
, O
or O
cells O
transfected O
to O
express O
these O
proteins O
( O
presenter O
cells O
[ O
PC O
] O
) O
is O
necessary O
and O
sufficient O
to O
induce O
proliferative O
arrest O
in O
both O
human O
and O
rodent O
lymphoid O
cells O
( O
responder O
cells O
[ O
RC O
] O
) O
, O
This O
inhibition O
was O
found O
to O
occur O
independent O
of O
apoptosis O
and O
soluble O
mediators O
excluded O
by O
a O
pore O
size O
filter O
of O
200 O
nm O
released O
from O
either O
PC O
or O
RC O
. O

Using O
an O
inhibitor O
of O
Golgi O
- O
resident O
mannosidases O
( O
deoxymannojirimycin O
) O
, O
we O
found O
that O
complex O
glycosylation O
of O
the O
F O
and O
H O
proteins O
is O
not O
required O
for O
the O
induction O
of O
proliferative O
arrest O
of O
RC O
, O
As O
revealed O
by O
our O
previous O
studies O
, O
proteolytic O
cleavage O
of O
the O
MV O
F O
protein O
precursor O
into O
its O
Fl O
and O
F2 O
subunits O
, O
but O
not O
of O
F O
/ O
H O
- O
mediated O
cellular O
fusion O
, O
was O
found O
to O
be O
required O
, O
since O
fusion O
- O
inhibitory O
peptides O
such O
as O
Z O
- O
D O
- O
Phe O
- O
L O
- O
Phe O
- O
Gly O
( O
Z O
- O
fFG O
) O
did O
not O
interfere O
with O
the O
induction O
of O
proliferative O
inhibition O
. O

canine B
distemper I
virus I
( I
CDV I
) I
causes O
a O
life O
- O
threatening O
disease O
in O
several O
carnivores O
including O
domestic O
dogs O
, O
Recently O
, O
we O
identified O
a O
molecule O
, O
CD9 O
, O
a O
member O
of O
the O
tetraspan O
transmembrane O
protein O
family O
, O
which O
facilitates O
, O
and O
antibodies O
to O
which O
inhibit O
, O
the O
infection O
of O
tissue O
culture O
cells O
with O
CDV O
( O
strain O
Onder O
- O
stepoort O
) O
, O
Here O
we O
describe O
that O
an O
anti O
- O
CD9 O
monoclonal O
antibody O
( O
MAb O
K41 O
) O
did O
not O
interfere O
with O
binding O
of O
CDV O
to O
cells O
and O
uptake O
of O
virus O
. O

canine B
distemper I
virus I
( I
CDV I
) I
infection O
of O
ferrets O
is O
clinically O
and O
immunologically O
similar O
to O
measles O
, O
making O
this O
a O
useful O
model O
for O
the O
human O
disease O
. O

The O
model O
was O
used O
to O
determine O
if O
parenteral O
or O
mucosal O
immunization O
of O
infant O
ferrets O
at O
3 O
and O
6 O
weeks O
of O
age O
with O
attenuated O
vaccinia O
virus O
( O
NYVAC O
) O
or O
canarypox O
virus O
( O
ALVAC O
) O
vaccine O
strains O
expressing O
the O
CDV O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
protein O
genes O
( O
NYVAC O
- O
HF O
and O
ALVAC O
- O
HF O
) O
would O
induce O
serum O
neutralizing O
antibody O
and O
protect O
against O
challenge O
infection O
at O
12 O
weeks O
of O
age O
. O

Ferrets O
without O
maternal O
antibody O
that O
were O
vaccinated O
parenterally O
with O
NYVAC O
- O
HF O
( O
n O
= O
5 O
) O
or O
ALVAC O
- O
HF O
( O
n O
= O
4 O
) O
developed O
significant O
neutralizing O
titers O
( O
log O
( O
10 O
) O
inverse O
mean O
titer O
a O
standard O
deviation O
of O
2 O
. O

Ferrets O
with O
maternal O
antibody O
that O
were O
vaccinated O
parenterally O
with O
NYVAC O
- O
HF O
( O
n O
= O
7 O
) O
and O
ALVAC O
- O
HF O
( O
n O
= O
7 O
) O
developed O
significantly O
higher O
antibody O
titers O
( O
1 O
. O

59 O
; O
n O
= O
7 O
) O
or O
the O
recombinant O
vectors O
expressing O
rabies O
glycoprotein O
( O
RG O
) O
( O
0 O
. O

32 O
; O
n O
= O
8 O
, O
P O
= O
7 O
x O
10 O
( O
- O
6 O
) O
) O
. O

The O
NYVAC O
vaccine O
also O
protected O
against O
weight O
loss O
, O
and O
both O
the O
NYVAC O
and O
attenuated O
CDV O
vaccines O
protected O
against O
the O
development O
of O
some O
clinical O
signs O
of O
infection O
, O
although O
survival O
in O
each O
of O
the O
three O
vaccine O
groups O
was O
low O
( O
one O
of O
seven O
) O
and O
not O
significantly O
different O
from O
the O
RG O
controls O
( O
none O
of O
eight O
) O
. O

- O
parenteral O
immunization O
of O
ferrets O
with O
maternal O
antibody O
using O
NYVAC O
- O
HF O
( O
n O
= O
9 O
) O
produced O
higher O
titers O
( O
1 O
. O

43 O
; O
n O
= O
9 O
, O
P O
= O
3 O
x O
10 O
( O
- O
7 O
) O
) O
, O
and O
survival O
was O
also O
significantly O
better O
in O
the O
i O
. O

- O
parenteral O
group O
( O
3 O
of O
9 O
) O
than O
in O
the O
other O
HP O
- O
vaccinated O
animals O
( O
none O
of O
18 O
) O
or O
in O
controls O
immunized O
with O
RG O
( O
none O
of O
5 O
) O
( O
P O
= O
0 O
. O

We O
sought O
to O
develop O
a O
live O
attenuated O
parainfluenza B
virus I
type I
2 I
( I
PIV2 I
) I
vaccine O
strain O
for O
use O
in O
infants O
and O
young O
children O
, O
using O
reverse O
genetic O
techniques O
that O
previously O
were O
used O
to O
rapidly O
produce O
a O
live O
attenuated O
PIV1 O
vaccine O
candidate O
. O

Viable O
PIV3 O
- O
PIV2 O
chimeras O
were O
recovered O
when O
chimeric O
HN O
and O
F O
open B
reading I
frames I
( I
ORFs I
) I
rather O
than O
complete O
PIV O
; O
I O
F O
and O
HN O
ORFs O
were O
used O
to O
construct O
the O
full O
- O
length O
cDNA O
, O
The O
recovered O
viruses O
, O
designated O
rPIV3 O
- O
2CT O
, O
in O
which O
the O
PIV2 O
ectodomain O
and O
transmembrane O
domain O
were O
fused O
to O
the O
PIV3 O
cytoplasmic O
domain O
, O
and O
rPIV3 O
- O
2TM O
, O
in O
which O
the O
PIV2 O
ectodomain O
was O
fused O
to O
the O
PIV3 O
transmembrane O
and O
cytoplasmic O
tail O
domain O
, O
possessed O
similar O
in O
vitro O
and O
in O
vivo O
phenotypes O
. O

Although O
rPIV3 O
- O
2CT O
and O
rPIV3 O
- O
2TM O
replicated O
efficiently O
in O
vitro O
, O
they O
were O
moderately O
to O
highly O
attenuated O
for O
replication O
in O
the O
respiratory O
tracts O
of O
hamsters O
, O
African B
green I
monkeys I
( I
AGMs I
) I
, O
and O
chimpanzees O
. O

We O
have O
recovered O
a O
virion O
from O
defective O
cDNA O
of O
Sendai B
virus I
( I
SeV I
) I
that O
is O
capable O
of O
self O
- O
replication O
but O
incapable O
of O
transmissible O
- O
virion O
production O
. O

This O
virion O
delivers O
and O
expresses O
foreign O
genes O
in O
infected O
cells O
, O
and O
this O
is O
the O
first O
report O
of O
a O
gene O
expression O
vector O
derived O
from O
a O
defective O
viral O
genome O
of O
the O
Paramyxoviridae O
, O
First O
, O
functional O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
were O
recovered O
from O
SeV O
cloned O
cDNA O
defective O
in O
the O
F O
( O
envelope O
fusion O
protein O
) O
gene O
, O
in O
the O
presence O
of O
plasmids O
expressing O
nucleocapsid O
protein O
and O
viral O
RNA O
polymerase O
. O

5 O
x O
10 O
( O
8 O
) O
to O
1 O
. O

0 O
x O
10 O
( O
8 O
) O
cell O
infectious O
units O
/ O
ml O
and O
contained O
F O
defective O
RNA O
genome O
. O

Reverse O
genetics O
technology O
so O
far O
established O
for O
measles B
virus I
( I
MeV I
) I
is O
based O
on O
the O
Edmonston O
strain O
, O
which O
was O
isolated O
several O
decades O
ago O
, O
has O
been O
passaged O
in O
nonlymphoid O
cell O
lines O
, O
and O
is O
no O
longer O
pathogenic O
in O
monkey O
models O
. O

One O
was O
simple O
cotransfection O
of O
B95a O
cells O
, O
with O
three O
plasmids O
each O
encoding O
the O
nucleocapsid B
( I
N I
) I
, O
phospho O
( O
P O
) O
, O
or O
large B
( I
L I
) I
protein O
, O
respectively O
, O
and O
their O
expression O
was O
driven O
by O
the O
bacteriophage O
T7 O
RNA O
polymerase O
supplied O
by O
coinfecting O
recombinant O
vaccinia O
virus O
vTF7 O
- O
3 O
. O

Laboratory O
strains O
of O
measles B
viruses I
( I
MV I
) I
, O
such O
as O
Edmonston O
and O
Halle O
, O
use O
the O
complement O
regulatory O
protein O
CD46 O
as O
a O
cell O
surface O
receptor O
. O

The O
Edmonston O
strain O
of O
measles B
virus I
( I
MV I
) I
that O
utilizes O
the O
human O
CD46 O
as O
the O
cellular O
receptor O
produced O
cytopathic B
effects I
( I
CPE I
) I
in O
all O
of O
the O
primate O
cell O
lines O
examined O
. O

In O
contrast O
, O
the O
wild O
- O
type O
MV O
strains O
isolated O
in O
a O
marmoset O
B O
- O
cell O
line O
B95a O
( O
the O
KA O
and O
Ichinose O
strains O
) O
replicated O
and O
produced O
CPE O
in O
some O
but O
not O
all O
of O
the O
primate O
lymphoid O
cell O
lines O
. O

To O
determine O
the O
mechanism O
underlying O
this O
difference O
in O
cell O
tropism O
, O
we O
used O
a O
recently O
developed O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
containing O
as O
a O
reporter O
the O
green O
fluorescent O
protein O
gene O
in O
lieu O
of O
the O
VSV O
G O
protein O
gene O
( O
VSV O
Delta O
G O
* O
) O
. O

The O
VSV O
pseudotype O
bearing O
the O
Edmonston O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
protein O
( O
VSV O
Delta O
G O
* O
- O
EdHF O
) O
infected O
all O
cell O
lines O
in O
which O
the O
Edmonston O
strain O
caused O
CPE O
, O
including O
the O
rodent O
cell O
lines O
to O
which O
the O
human O
CD46 O
gene O
was O
stably O
transfected O
. O

The O
pseudotype O
bearing O
the O
wild O
- O
type O
KA O
H O
protein O
and O
Edmonston O
F O
protein O
( O
VSV O
Delta O
G O
* O
- O
KAHF O
) O
infected O
all O
lymphoid O
cell O
lines O
in O
which O
the O
wild O
type O
MV O
strains O
caused O
CPE O
as O
efficiently O
as O
VSV O
Delta O
G O
* O
- O
EdHF O
, O
but O
it O
did O
not O
infect O
any O
of O
the O
cell O
lines O
resistant O
to O
infection O
with O
the O
KA O
strain O
. O

Recombinant O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
, O
encoding O
the O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
and O
hemagglutinin B
( I
H I
) I
( O
MVA O
- O
FH O
) O
glycoproteins O
, O
was O
evaluated O
in O
an O
MV O
vaccination O
- O
challenge O
model O
with O
macaques O
, O
Animals O
were O
vaccinated O
twice O
in O
the O
absence O
or O
presence O
of O
passively O
transferred O
MV O
- O
neutralizing O
macaque O
antibodies O
and O
challenged O
1 O
year O
later O
intratracheally O
with O
wild O
- O
type O
MV O
. O

Mortality O
from O
measles B
virus I
( I
MV I
) I
infection O
is O
caused O
mostly O
by O
secondary O
infections O
associated O
with O
a O
pronounced O
immunosuppression O
. O

dendritic B
cells I
( I
DCs I
) I
represent O
a O
major O
target O
of O
MV O
and O
could O
be O
involved O
in O
immunosuppression O
. O

( O
i O
) O
Fas O
- O
mediated O
apoptosis O
of O
DCs O
facilitates O
MV O
release O
, O
while O
CD40 O
activation O
enhances O
MV O
replication O
in O
DCs O
, O
Indeed O
, O
detailed O
studies O
of O
infectious O
MV O
release O
and O
intracellular O
MV O
nucleoprotein B
( I
NP I
) I
showed O
that O
inhibition O
of O
CD40 O
- O
CD40L O
ligand O
interaction O
blocks O
NP O
synthesis O
. O

( O
ii O
) O
Not O
only O
MV O
- O
infected O
DCs O
but O
also O
bystander O
uninfected O
DCs O
undergo O
a O
maturation O
process O
confirmed O
by O
CD1a O
, O
CD40 O
, O
CD80 O
, O
CD86 O
, O
CD83 O
, O
and O
major O
histocompatibility O
complex O
type O
II O
labeling O
. O

Cyanovirin B
- I
N I
( I
CV I
- I
N I
) I
is O
a O
cyanobacterial O
protein O
with O
potent O
neutralizing O
activity O
against O
human B
immuno I
- I
deficiency I
virus I
( I
HIV I
) I
. O

CV O
- O
N O
has O
been O
shown O
to O
bind O
HIV B
type I
1 I
( I
HIV I
- I
1 I
) I
gp120 O
with O
high O
affinity O
; O
moreover O
, O
it O
blocks O
the O
envelope O
glycoprotein O
- O
mediated O
membrane O
fusion O
reaction O
associated O
with O
HIV O
- O
1 O
entry O
. O

However O
, O
the O
inhibitory O
mechanism O
( O
s O
) O
remains O
unclear O
. O

Consistent O
with O
this O
, O
pretreatment O
of O
gp120 O
with O
CV O
- O
N O
inhibited O
soluble B
CD4 I
( I
sCD4 I
) I
- O
dependent O
binding O
of O
gp120 O
to O
cell O
- O
associated O
CCR5 O
. O

In O
humans O
, O
maternal O
antibodies O
inhibit O
successful O
immunization O
against O
measles O
, O
because O
they O
interfere O
with O
vaccine O
- O
induced O
seroconversion O
, O
We O
have O
investigated O
this O
problem O
using O
the O
cotton O
rat O
model O
( O
Sigmodon O
hispidus O
) O
. O

As O
in O
humans O
, O
passively O
transferred O
antibodies O
inhibit O
the O
induction O
of O
measles B
virus I
( I
MV I
) I
- O
neutralizing O
antibodies O
and O
protection O
after O
immunization O
with O
MV O
, O
In O
contrast O
, O
a O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
expressing O
the O
MV O
hemagglutinin O
( O
VSV O
- O
H O
) O
induces O
high O
titers O
of O
neutralizing O
antibodies O
to O
MV O
in O
the O
presence O
of O
MV O
- O
specific O
antibodies O
. O

A O
chimeric O
fusion O
protein O
encompassing O
the O
CD46 O
ectodomain O
linked O
to O
the O
C O
- O
terminal O
part O
of O
the O
C4b O
binding O
protein O
( O
C4bp O
) O
ex O
chain O
( O
sCD46 O
- O
C4bp O
alpha O
) O
was O
produced O
in O
eukaryotic O
cells O
. O

During O
acute O
infections O
, O
most O
of O
the O
activated O
, O
proliferating O
virus O
- O
specific O
T O
cells O
are O
sensitized O
to O
undergo O
apoptosis O
on O
strong O
T B
- I
cell I
receptor I
( I
TCR I
) I
stimulation O
, O
but O
it O
has O
not O
been O
known O
why O
memory O
T O
cells O
not O
specific O
for O
the O
virus O
fail O
to O
proliferate O
on O
exposure O
to O
their O
cognate O
antigen O
. O

Using O
a O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
model O
in O
which O
LCMV O
- O
immune O
Thy O
1 O
. O

1 O
( O
+ O
) O
splenocytes O
are O
adoptively O
transferred O
into O
Thy O
1 O
. O

2 O
( O
+ O
) O
LCMV O
carrier O
mice O
, O
we O
demonstrate O
here O
that O
T O
cells O
clearly O
defined O
as O
not O
specific O
for O
the O
virus O
are O
sensitized O
to O
undergo O
activation O
- O
induced O
cell O
death O
on O
TCR O
stimulation O
in O
vitro O
. O

This O
bystander O
sensitization O
was O
in O
part O
dependent O
on O
the O
expression O
of O
Fas B
ligand I
( I
FasL I
) I
on O
the O
activated O
virus O
- O
specific O
cells O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
receptor O
expression O
on O
the O
bystander O
T O
cells O
. O

We O
recently O
developed O
a O
system O
for O
the O
generation O
of O
infectious O
bovine B
respiratory I
syncytial I
virus I
( I
BRSV I
) I
from O
cDNA O
. O

Here O
, O
we O
report O
the O
recovery O
of O
fully O
viable O
chimeric O
recombinant O
BRSVs O
( O
rBRSVs O
) O
that O
carry O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
glycoproteins O
in O
place O
of O
their O
BRSV O
counterparts O
, O
thus O
combining O
the O
replication O
machinery O
of O
BRSV O
with O
the O
major O
antigenic O
determinants O
of O
HRSV O
. O

Complement O
regulatory O
protein O
CD46 O
is O
a O
human O
cell O
receptor O
for O
measles B
virus I
( I
MV I
) I
. O

In O
this O
study O
, O
we O
investigated O
why O
mouse O
macrophages O
expressing O
human O
CD46 O
restricted O
MV O
replication O
and O
produced O
higher O
levels O
of O
nitric B
oxide I
( I
NO I
) I
in O
response O
to O
MV O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

The O
dissemination O
of O
the O
Edmonston B
measles I
virus I
( I
Ed I
- I
MV I
) I
vaccine O
strain O
was O
studied O
with O
genetically O
modified O
mice O
defective O
for O
the O
alpha O
/ O
beta O
interferon O
receptor O
and O
expressing O
human O
CD O
16 O
with O
human O
- O
like O
tissue O
specificity O
and O
efficiency O
. O

measles B
virus I
( I
MV I
) I
infection O
causes O
acute O
childhood O
disease O
, O
associated O
in O
certain O
cases O
with O
infection O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
development O
of O
neurological O
disease O
. O

Signs O
of O
clinical O
illness O
( O
lack O
of O
mobility O
, O
tremors O
, O
and O
weight O
loss O
) O
appeared O
within O
5 O
to O
7 O
days O
after O
infection O
, O
followed O
by O
seizures O
, O
paralysis O
, O
and O
death O
of O
the O
infected O
animals O
. O

The O
M2 O
gene O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
encodes O
two O
putative O
proteins O
: O
M2 O
- O
1 O
and O
M2 O
- O
2 O
; O
both O
are O
believed O
to O
be O
involved O
in O
the O
RNA O
transcription O
or O
replication O
process O
. O

Transfection O
of O
HEp O
- O
2 O
cells O
with O
the O
cDNA O
clone O
containing O
the O
M2 O
- O
2 O
deletion O
, O
together O
with O
plasmids O
that O
encoded O
the O
RSV O
N O
, O
P O
, O
and O
L O
proteins O
, O
produced O
a O
recombinant O
RSV O
that O
lacked O
the O
M2 O
- O
2 O
protein O
( O
rA2 O
Delta O
M2 O
- O
2 O
) O
. O

The O
process O
of O
measles B
virus I
( I
MV I
) I
assembly O
and O
subsequent O
budding O
is O
thought O
to O
occur O
in O
localized O
regions O
of O
the O
plasma O
membrane O
, O
to O
favor O
specific O
incorporation O
of O
viral O
components O
, O
and O
to O
facilitate O
the O
exclusion O
of O
host O
proteins O
. O

We O
demonstrate O
that O
during O
the O
course O
of O
virus O
replication O
, O
a O
significant O
proportion O
of O
MV O
structural O
proteins O
were O
selectively O
enriched O
in O
the O
detergent O
- O
resistant O
glycosphingolipids O
and O
cholesterol O
- O
rich O
membranes O
( O
rafts O
) O
. O

Here O
we O
demonstrate O
that O
measles O
virus O
induces O
tumor B
necrosis I
factor I
- I
related I
apoptosis I
- I
inducing I
ligand I
( I
TRAIL I
) I
mRNA O
and O
protein O
expression O
in O
human O
monocyte O
- O
derived O
dendritic O
cells O
. O

Human O
monocyte O
- O
derived O
dendritic B
cells I
( I
DC I
) I
infected O
with O
recombinant B
adenoviruses I
( I
rAd I
) I
are O
promising O
candidate O
vaccines O
for O
inducing O
protective O
immunity O
against O
pathogens O
and O
tumors O
. O

Although O
rAd O
infection O
fails O
to O
induce O
the O
secretion O
of O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
and O
only O
marginally O
induces O
the O
expression O
of O
the O
DC O
maturation O
marker O
CD83 O
, O
it O
acts O
in O
synergy O
with O
CD40 O
triggering O
in O
rendering O
DC O
fully O
mature O
, O
rAd O
- O
infected O
DC O
triggered O
through O
CD40 O
produce O
more O
IL O
- O
12 O
and O
are O
more O
efficient O
in O
eliciting O
T O
- O
helper O
type O
1 O
responses O
than O
DC O
activated O
by O
CD40 O
triggering O
only O
. O

rAd O
lacking O
one O
or O
more O
of O
the O
early O
regions O
, O
E1 O
, O
E2A O
, O
E3 O
, O
and O
E4 O
, O
which O
play O
an O
important O
role O
in O
virus O
- O
host O
cell O
interactions O
are O
equally O
capable O
of O
DC O
activation O
, O
Efficient O
DC O
infection O
requires O
a O
high O
multiplicity O
of O
infection O
( O
> O
1 O
, O
000 O
) O
, O
a O
fact O
which O
can O
be O
attributed O
to O
the O
absence O
of O
the O
coxsackievirus O
and O
adenovirus O
receptor O
on O
this O
cell O
type O
. O

As O
viral O
glycoprotein O
cytoplasmic O
domains O
may O
play O
a O
role O
in O
this O
coordination O
, O
we O
have O
investigated O
the O
importance O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
cytoplasmic O
domain O
in O
the O
assembly O
of O
the O
nonsegmented O
negative O
- O
strand O
RNA O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
. O

These O
viruses O
were O
shown O
to O
be O
replication O
impaired O
, O
as O
judged O
by O
small O
plaque O
size O
, O
reduced O
replication O
rate O
, O
and O
low O
maximum O
titers O
when O
compared O
to O
those O
features O
of O
wild B
- I
type I
( I
WT I
) I
SV5 O
. O

To O
understand O
the O
molecular O
determinants O
of O
measles B
virus I
( I
MV I
) I
virulence O
, O
we O
have O
used O
the O
SCID O
- O
hu O
thymus O
/ O
liver O
xenograft O
model O
( O
SCID O
- O
hu O
thy O
/ O
liv O
) O
in O
which O
in O
vivo O
MV O
virulence O
phenotypes O
are O
faithfully O
duplicated O
. O

To O
determine O
whether O
passage O
of O
an O
avirulent O
vaccine O
strain O
in O
human O
tissue O
increases O
virulence O
, O
we O
studied O
a O
virus O
isolated O
from O
thymic O
tissue O
90 O
days O
after O
infection O
with O
the O
vaccine O
strain O
Moraten O
( O
pMor O
- O
1 O
) O
and O
a O
virus O
isolated O
from O
an O
immunodeficient O
child O
with O
progressive O
vaccine O
- O
induced O
disease O
( O
Hu2 O
) O
. O

These O
viruses O
were O
compared O
to O
a O
minimally O
passaged O
wild O
- O
type O
Edmonston O
strain O
( O
Ed O
- O
wt O
) O
and O
the O
vaccine O
strain O
: O
Moraten O
. O

Sequence O
analysis O
of O
the O
hemagglutinin B
( I
H I
) I
and O
matrix B
( I
M I
) I
genes O
showed O
no O
common O
changes O
in O
Hu2 O
and O
pMor O
- O
1 O
. O

M O
sequences O
were O
identical O
in O
pMor O
- O
1 O
and O
Mor O
and O
varied O
in O
H O
at O
amino O
acid O
469 O
( O
threonine O
to O
alanine O
) O
, O
a O
position O
near O
the O
base O
of O
propeller O
4 O
in O
the O
propeller O
blade O
/ O
stem O
model O
of O
H O
structure O
. O

The O
fusion O
glycoprotein O
( O
F O
) O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
which O
mediates O
membrane O
fusion O
and O
virus O
entry O
, O
was O
shown O
to O
bind O
RhoA O
, O
a O
small O
GTPase O
, O
in O
yeast O
two O
- O
hybrid O
interaction O
studies O
. O

Wild O
- O
type O
, O
lymphotropic O
strains O
of O
measles B
virus I
( I
MV I
) I
and O
tissue O
culture O
- O
adapted O
MV O
vaccine O
strains O
possess O
different O
cell O
tropisms O
. O

We O
have O
functionally O
analyzed O
the O
interactions O
of O
MV O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
of O
vaccine O
( O
Edmonston O
) O
and O
wild B
- I
type I
( I
WTF I
) I
strains O
in O
different O
combinations O
in O
transfected O
cells O
. O

CD46 O
, O
which O
serves O
as O
a O
receptor O
for O
measles O
virus O
( O
MV O
; O
strain O
Edmonston O
) O
, O
is O
rapidly O
downregulated O
from O
the O
cell O
surface O
after O
contact O
with O
viral O
particles O
or O
infected O
cells O
. O

We O
show O
here O
that O
the O
same O
two O
CD46 O
complement B
control I
protein I
( I
CCP I
) I
domains O
responsible O
for O
primary O
MV O
attachment O
mediate O
its O
downregulation O
. O

Nevertheless O
, O
neither O
substances O
inhibiting O
capping O
nor O
the O
fusion B
- I
inhibiting I
peptide I
Z I
- I
D I
- I
Phe I
- I
L I
- I
Phe I
- I
Gly I
- I
OH I
( I
FIP I
) I
blocked O
CD46 O
downregulation O
. O

The O
finding O
that O
the O
contact O
of O
an O
infected O
with O
uninfected O
cells O
results O
in O
transfer O
of O
infectious O
viral O
material O
without O
significant O
( O
complete O
) O
fusion O
of O
the O
donor O
with O
the O
recipient O
cell O
suggests O
that O
microfusion O
events O
and O
/ O
or O
FIP O
- O
independent O
mechanisms O
may O
mediate O
the O
transfer O
of O
MV O
infectivity O
from O
cell O
to O
cell O
. O

Paramyxoviruses O
cotranscriptionally O
edit O
their O
P O
gene O
mRNAs O
by O
expanding O
the O
number O
of O
Gs O
of O
a O
conserved O
A O
( O
n O
) O
G O
( O
n O
) O
run O
. O

We O
found O
that O
the O
template O
stutter O
site O
is O
precisely O
determined O
( O
C O
- O
1052 O
) O
and O
that O
a O
relatively O
short O
region O
( O
similar O
to O
6 O
nucleotides O
) O
just O
upstream O
of O
the O
A O
( O
n O
) O
G O
( O
n O
) O
run O
can O
modulate O
the O
overall O
frequency O
of O
mRNA O
editing O
as O
well O
as O
the O
distribution O
of O
the O
nucleotide O
insertions O
, O
The O
positions O
more O
proximal O
to O
the O
5 O
' O
A O
( O
n O
) O
G O
( O
n O
) O
run O
are O
the O
most O
important O
in O
this O
respect O
. O

Our O
data O
suggest O
how O
paramyxovirus O
mRNA O
editing O
and O
polyadenylation O
are O
related O
mechanistically O
and O
how O
editing O
shes O
may O
have O
evolved O
from O
poly O
( O
A O
) O
- O
termination O
sites O
or O
vice O
versa O
. O

reverse B
transcriptase I
( I
RT I
) I
activity O
has O
been O
detected O
recently O
in O
all O
chicken O
cell O
- O
derived O
measles O
and O
mumps O
vaccines O
. O

A O
study O
of O
a O
vaccine O
manufactured O
in O
Europe O
indicated O
that O
the O
RT O
is O
associated O
with O
particles O
containing O
endogenous O
avian O
retrovirus O
( O
EAV O
- O
0 O
) O
RNA O
and O
originates O
from O
the O
chicken B
embryonic I
fibroblasts I
( I
CEF I
) I
used O
as O
a O
substrate O
for O
propagation O
of O
the O
vaccine O
. O

Additionally O
, O
we O
provide O
new O
evidence O
for O
the O
presence O
of O
avian B
leukosis I
virus I
( I
ALV I
) I
in O
both O
CEF O
supernatants O
and O
vaccines O
. O

Nonetheless O
, O
infectivity O
studies O
on O
susceptible O
15B O
( O
1 O
) O
chicken O
cells O
gave O
no O
evidence O
of O
infectious O
ALV O
, O
which O
is O
consistent O
with O
the O
phenotypes O
of O
the O
ev O
loci O
identified O
in O
the O
CEF O
. O

Laboratory O
- O
adapted O
strains O
of O
measles B
virus I
( I
MV I
) I
bind O
to O
the O
extracellular O
domains O
of O
CD46 O
to O
enter O
human O
cells O
. O

In O
this O
study O
, O
we O
show O
that O
expression O
of O
human O
CD46 O
with O
the O
Cyt1 O
cytoplasmic O
domain O
in O
mouse O
macrophages O
enhances O
production O
of O
nitric B
oxide I
( I
NO I
) I
in O
response O
to O
MV O
infection O
in O
the O
presence O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
. O

These O
results O
reveal O
a O
novel O
function O
of O
CD46 O
dependent O
on O
the O
cytoplasmic O
domains O
( O
especially O
Cyt1 O
) O
, O
which O
augments O
NO O
production O
in O
macrophages O
. O

measles B
virus I
( I
MV I
) I
has O
a O
tropism O
restricted O
to O
humans O
and O
primates O
and O
uses O
the O
human O
CD46 O
molecule O
as O
a O
cellular O
receptor O
. O

MV O
has O
been O
adapted O
to O
grow O
in O
chicken B
embryonic I
fibroblasts I
( I
CEF I
) I
and O
gave O
rise O
to O
an O
attenuated O
live O
vaccine O
. O

Using O
this O
technology O
in O
our O
studies O
of O
measles B
virus I
( I
MV I
) I
, O
we O
found O
that O
the O
efficiency O
of O
the O
measles O
virus O
rescue O
procedure O
( O
F O
. O

Antigen O
- O
specific O
T B
- I
helper I
( I
Th I
) I
lymphocytes O
are O
critical O
for O
the O
development O
of O
antiviral O
humoral O
responses O
and O
the O
expansion O
of O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
, O
Identification O
of O
relevant O
Th O
lymphocyte O
epitopes O
remains O
an O
important O
step O
in O
the O
development O
of O
an O
efficacious O
subunit O
peptide O
vaccine O
against O
equine B
infectious I
anemia I
virus I
( I
EIAV I
) I
, O
a O
naturally O
occurring O
lentivirus O
of O
horses O
. O

This O
study O
describes O
Th O
lymphocyte O
reactivity O
in O
EIAV O
carrier O
horses O
to O
two O
proteins O
, O
p26 O
and O
p15 O
, O
encoded O
by O
the O
relatively O
conserved O
EIAV O
gag O
gene O
, O
Using O
partially O
overlapping O
peptides O
, O
multideterminant O
and O
possibly O
promiscuous O
epitopes O
were O
identified O
within O
p26 O
, O
One O
peptide O
was O
identified O
which O
reacted O
, O
vith O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
from O
all O
five O
EIAV O
- O
infected O
horses O
, O
and O
three O
other O
peptides O
were O
identified O
which O
reacted O
with O
PBMC O
from O
four O
of O
five O
EIAV O
- O
infected O
horses O
. O

One O
of O
the O
major O
mechanisms O
by O
which O
measles B
virus I
( I
MV I
) I
infection O
causes O
disease O
and O
death O
is O
suppression O
of O
the O
immune O
response O
. O

The O
nonresponsiveness O
of O
MV O
- O
infected O
human O
lymphocytes O
to O
mitogens O
and O
a O
partial O
block O
in O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
of O
the O
cell O
cycle O
observed O
in O
vitro O
is O
thought O
to O
reflect O
in O
vivo O
immunosuppression O
. O

MV B
Edmonston I
( I
MV I
- I
Ed I
) I
could O
induce O
and O
maintain O
a O
high O
level O
of O
the O
early O
activation O
marker O
CD69 O
in O
the O
absence O
of O
proliferation O
. O

Analysis O
of O
inhibitors O
of O
progression O
into O
S O
phase O
showed O
that O
a O
high O
level O
of O
p27 O
was O
maintained O
in O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
- O
blocked O
subpopulation O
of O
MV O
- O
Ed O
- O
infected O
cells O
compared O
to O
the O
proliferating O
MV O
- O
infected O
cells O
. O

Furthermore O
, O
cell O
cycle O
- O
related O
upregulation O
of O
retinoblastoma B
( I
Rb I
) I
protein O
synthesis O
did O
not O
occur O
in O
the O
MV O
- O
Ed O
- O
infected O
lymphocytes O
. O

Acridine O
orange O
staining O
, O
which O
distinguishes O
cells O
in O
G O
( O
0 O
) O
from O
cells O
in O
G O
( O
1 O
) O
, O
showed O
that O
RNA O
levels O
mere O
not O
upregulated O
following O
activation O
, O
which O
is O
consistent O
with O
cells O
remaining O
in O
a O
G O
( O
0 O
) O
state O
. O

These O
results O
indicate O
that O
MV O
can O
uncouple O
activation O
of O
T O
lymphocytes O
from O
transition O
of O
G O
( O
0 O
) O
to O
G O
( O
1 O
) O
. O

Measles O
virus O
inhibits O
thymic O
epithelial O
cell O
growth O
and O
induces O
an O
arrest O
in O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phases O
of O
the O
cell O
cycle O
. O

The O
P O
gene O
of O
measles B
virus I
( I
MV I
) I
encodes O
the O
phosphoprotein O
, O
a O
component O
of O
the O
virus O
ribonucleoprotein O
complex O
, O
and O
two O
nonstructural O
proteins O
, O
C O
and O
V O
, O
with O
unknown O
functions O
. O

Growth O
of O
recombinant O
MV O
, O
defective O
in O
C O
or O
V O
expression O
, O
was O
explored O
in O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMC I
) I
. O

The O
mutation O
we O
focused O
on O
, O
which O
can O
be O
screened O
for O
phenotypically O
, O
confers O
resistance O
to O
a O
monoclonal O
antibody O
( O
MAb O
80 O
- O
III O
- O
B2 O
) O
, O
The O
entire O
H O
gene O
of O
a O
subset O
of O
mutants O
was O
sequenced O
to O
verify O
that O
the O
resistance O
phenotype O
was O
associated O
with O
single O
point O
mutations O
. O

Based O
on O
this O
approach O
, O
measles O
virus O
was O
estimated O
to O
have O
a O
mutation O
rate O
of O
9 O
x O
10 O
( O
- O
5 O
) O
per O
base O
per O
replication O
and O
a O
genomic O
mutation O
rate O
of O
1 O
. O

Skewing O
of O
the O
T O
- O
cell O
receptor O
repertoire O
of O
CD8 O
( O
+ O
) O
T O
cells O
has O
been O
shown O
in O
some O
persistent O
infections O
with O
viruses O
, O
such O
as O
human O
immunodeficiency O
virus O
, O
simian O
immunodeficiency O
virus O
, O
and O
Epstein O
- O
Barr O
virus O
. O

In O
addition O
, O
two O
of O
four O
children O
immunized O
with O
live O
, O
attenuated O
measles O
virus O
showed O
larger O
and O
more O
persistent O
CD8 O
( O
+ O
) O
T O
- O
cell O
expansions O
than O
their O
naturally O
infected O
counterparts O
. O

These O
results O
demonstrate O
that O
the O
expansions O
of O
CD8 O
( O
+ O
) O
T O
lymphocytes O
are O
antigen O
driven O
. O

Although O
measles O
virus O
is O
an O
antigenically O
monotypic O
virus O
, O
nucleotide O
sequence O
analysis O
of O
the O
hemagglutinin O
and O
nucleoprotein O
genes O
has O
permitted O
the O
differentiation O
of O
a O
number O
of O
genotypes O
, O
In O
contrast O
, O
the O
fusion O
( O
F O
) O
protein O
is O
highly O
conserved O
; O
only O
three O
amino O
acid O
changes O
have O
been O
reported O
over O
a O
40 O
- O
year O
period O
. O

We O
have O
isolated O
a O
measles O
virus O
strain O
which O
did O
not O
react O
with O
an O
anti O
- O
F O
monoclonal B
antibody I
( I
Mab I
) I
which O
we O
had O
previously O
shown O
to O
be O
directed O
against O
a O
dominant O
antigenic O
site O
. O

A O
single O
amino O
acid O
change O
at O
position O
73 O
( O
R O
- O
- O
> O
W O
) O
was O
observed O
, O
The O
possibility O
of O
selecting O
measles O
virus O
variants O
in O
vaccinated O
populations O
is O
discussed O
. O

However O
, O
we O
found O
that O
once O
CD4 O
( O
+ O
) O
or O
CD8 O
( O
+ O
) O
T O
cells O
were O
activated O
, O
their O
cytolytic O
activity O
was O
intact O
whether O
infected O
with O
measles O
virus O
or O
treated O
with O
soluble O
factor O
. O

There O
is O
evidence O
that O
CD46 O
( O
membrane O
cofactor O
protein O
) O
is O
a O
cellular O
receptor O
for O
vaccine O
and O
laboratory O
- O
passaged O
strains O
of O
measles B
virus I
( I
MV I
) I
. O

The O
MV O
hemagglutinin B
( I
H I
) I
protein O
alone O
is O
capable O
of O
inducing O
this O
downregulation O
. O

In O
this O
study O
we O
show O
that O
CD46 O
is O
also O
downregulated O
to O
the O
same O
extent O
by O
wild O
- O
type O
, O
vaccine O
, O
and O
laboratory O
- O
passaged O
strains O
of O
rinderpest B
virus I
( I
RPV I
) I
, O
although O
CD46 O
did O
not O
appear O
to O
be O
the O
receptor O
for O
RPV O
. O

measles B
virus I
( I
MV I
) I
isolated O
in O
B95a O
cells O
, O
a O
marmoset O
B O
- O
cell O
line O
, O
retains O
full O
pathogenicity O
for O
cynomolgus O
monkeys O
, O
while O
its O
derivative O
obtained O
by O
adaptation O
to O
the O
growth O
in O
Vero O
cells O
, O
a O
monkey O
kidney O
cell O
line O
, O
loses O
the O
pathogenic O
potential O
( O
F O
. O

64 O
: O
700 O
- O
705 O
, O
1990 O
) O
, O
Here O
, O
we O
show O
with O
a O
pair O
of O
strains O
, O
a O
fresh O
isolate O
( O
9301B O
) O
in O
B95a O
cells O
and O
its O
Vero O
cell O
- O
adapted O
form O
( O
9301V O
) O
, O
that O
the O
in O
vivo O
attenuation O
parallels O
the O
decrease O
of O
replication O
and O
syncytium O
- O
inducing O
capabilities O
in O
the O
original O
B95a O
cells O
and O
that O
these O
in O
vitro O
phenotypes O
are O
attributable O
to O
impediment O
of O
transcription O
, O
which O
is O
already O
obvious O
at O
the O
level O
of O
primary O
transcription O
catalyzed O
by O
the O
virion O
- O
associated O
RNA O
polymerase O
. O

Nucleotide O
sequence O
comparison O
between O
the O
9301B O
and O
9301V O
viruses O
revealed O
that O
a O
few O
( O
at O
most O
five O
) O
amino O
acid O
changes O
, O
which O
sporadically O
took O
place O
in O
the O
polymerase O
( O
L O
and O
P O
proteins O
) O
and O
/ O
or O
accessory O
V O
and O
C O
proteins O
, O
were O
responsible O
for O
the O
in O
vitro O
and O
in O
vivo O
attenuation O
through O
adaptation O
to O
growth O
in O
Vero O
cells O
. O

enterovirus B
70 I
( I
EV70 I
) I
, O
like O
several O
other O
human O
enteroviruses O
, O
can O
utilize O
decay O
- O
accelerating O
factor O
( O
DAF O
[ O
CD55 O
] O
) O
as O
an O
attachment O
protein O
, O
Using O
chimeric O
molecules O
composed O
of O
different O
combinations O
of O
the O
short B
consensus I
repeat I
domains I
( I
SCRs I
) I
of O
DAF O
and O
membrane O
cofactor O
protein O
( O
CD46 O
) O
, O
we O
show O
that O
sequences O
in O
SCRI O
of O
DAF O
are O
essential O
for O
EV70 O
binding O
. O

An O
understanding O
of O
the O
determinants O
of O
measles B
virus I
( I
MV I
) I
virulence O
has O
been O
hampered O
by O
the O
lack O
of O
an O
experimental O
model O
of O
infection O
. O

We O
have O
previously O
demonstrated O
that O
virulence O
phenotypes O
in O
human O
infections O
are O
faithfully O
reproduced O
by O
infection O
of O
human O
thymus O
/ O
liver O
( O
thy O
/ O
liv O
) O
implants O
engrafted O
into O
SCID O
mice O
, O
where O
the O
virus O
grows O
primarily O
in O
stromal O
cells O
but O
induces O
thymocyte O
apoptosis O
( O
P O
. O

To O
begin O
to O
elucidate O
the O
roles O
of O
the O
C O
protein O
, O
V O
protein O
, O
and O
the O
5 O
' O
untranslated O
region O
of O
the O
F O
gene O
( O
F O
5 O
' O
UTR O
) O
in O
MV O
infection O
in O
vivo O
, O
the O
replication O
of O
strains O
bearing O
mutations O
of O
these O
genes O
was O
compared O
to O
that O
of O
the O
parent O
sequence O
- O
tagged O
Edmonston O
strain O
( O
EdTag O
) O
. O

A O
mutant O
which O
overexpressed O
V O
in O
Vero O
cells O
( O
V O
+ O
) O
had O
the O
opposite O
phenotype O
of O
the O
A O
mutant O
not O
expressing O
V O
( O
V O
- O
) O
. O

Nonstructural O
proteins O
encoded O
by O
measles B
virus I
( I
MV I
) I
include O
the O
V O
protein O
which O
is O
translated O
from O
an O
edited O
P O
mRNA O
. O

Using O
recombinant O
MVs O
( O
strain O
Edmonston O
[ O
ED O
] O
) O
genetically O
engineered O
to O
overexpress O
V O
protein O
( O
ED O
- O
V O
+ O
) O
or O
to O
be O
deficient O
for O
V O
protein O
( O
ED O
- O
V O
- O
) O
, O
we O
found O
that O
in O
the O
absence O
of O
V O
both O
MV O
- O
specific O
proteins O
and O
RNAs O
accumulated O
to O
levels O
higher O
than O
those O
in O
the O
parental O
MV O
molecular O
clone O
( O
ED O
- O
tag O
) O
, O
whereas O
MV O
- O
specific O
gene O
expression O
was O
strongly O
attenuated O
in O
human O
U O
- O
87 O
glioblastomas O
cells O
after O
infection O
with O
ED O
- O
V O
+ O
. O

Similarly O
, O
significantly O
reduced O
titers O
of O
infectious O
virus O
were O
reisolated O
from O
lung O
tissue O
of O
cotton O
rats O
( O
Sigmodon O
hispidus O
) O
after O
intranasal O
infection O
with O
both O
editing O
mutants O
compared O
to O
titers O
isolated O
from O
ED O
- O
tag O
- O
infected O
animals O
. O

[ O
H O
- O
3 O
] O
palmitic O
acid O
was O
metabolically O
incorporated O
into O
the O
viral O
fusion B
protein I
( I
F I
) I
of O
Edmonston O
or O
freshly O
isolated O
measles B
virus I
( I
MV I
) I
during O
infection O
of O
human O
lymphoid O
or O
Vero O
cells O
. O

In O
cells O
transfected O
with O
the O
cloned O
MV O
F O
gene O
, O
in O
which O
the O
cysteines O
located O
in O
the O
intracytoplasmic O
and O
transmembrane O
domains O
( O
Cys O
506 O
, O
518 O
, O
519 O
, O
520 O
, O
and O
524 O
) O
were O
replaced O
by O
serine O
, O
a O
major O
reduction O
of O
[ O
3H O
] O
palmitic O
acid O
incorporation O
was O
observed O
for O
F O
mutated O
at O
Cys O
506 O
and O
, O
to O
a O
lesser O
extent O
, O
at O
Cys O
518 O
and O
Cys O
524 O
. O

Cell O
fusion O
induced O
by O
cotransfection O
of O
cells O
with O
MV O
F O
and O
H B
( I
hemagglutinin I
) I
genes O
was O
significantly O
reduced O
after O
replacement O
of O
Cys O
506 O
or O
Cys O
519 O
with O
serine O
in O
the O
MV O
F O
gene O
. O

measles B
virus I
( I
MV I
) I
infection O
of O
monocytes O
induces O
leukocyte B
function I
- I
associated I
antigen I
- I
1 I
( I
LFA I
- I
I I
) I
, O
an O
integrin O
that O
mediates O
intercellular O
adhesion O
to O
the O
endothelium O
. O

Thus O
, O
an O
increase O
in O
LFA O
- O
1 O
expression O
could O
lead O
to O
enhanced O
monocyte O
adherence O
and O
virus O
dissemination O
to O
endothelial B
cells I
( I
ECs I
) I
and O
potentially O
be O
an O
important O
means O
of O
distinction O
between O
MV O
strains O
. O

Recombinant O
Sendai O
viruses O
were O
prepared O
which O
cannot O
express O
their O
C O
- O
prime O
, O
C O
, O
or O
C O
- O
prime O
plus O
C O
proteins O
due O
to O
mutation O
of O
their O
respective O
start O
codons O
( O
[ O
C O
- O
prime O
- O
minus O
] O
, O
[ O
C O
- O
minus O
] O
and O
[ O
double O
mutant O
] O
, O
respectively O
) O
. O

The O
[ O
C O
- O
prime O
- O
minus O
] O
and O
[ O
C O
- O
minus O
] O
stocks O
were O
similar O
to O
that O
of O
wild B
- I
type I
( I
WT I
) I
virus O
in O
virus O
titer O
and O
plaque O
formation O
, O
whereas O
the O
double O
- O
mutant O
stock O
had O
a O
much O
- O
reduced O
PFU O
or O
50 O
% O
egg O
infective O
dose O
/ O
particle O
ratio O
and O
produced O
very O
small O
plaques O
. O

The O
hepatitis B
A I
virus I
cellular I
receptor I
1 I
( I
HAVcr I
- I
1 I
) I
cDNA O
codes O
for O
a O
class O
I O
integral O
membrane O
glycoprotein O
, O
termed O
havcr O
- O
1 O
, O
of O
unknown O
natural O
function O
which O
serves O
as O
an O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
cell O
receptor O
for O
HAV O
. O

The O
extracellular O
domain O
of O
haver O
- O
1 O
has O
an O
N O
- O
terminal O
Cys O
- O
rich O
region O
that O
displays O
homology O
with O
sequences O
of O
members O
of O
the O
immunoglobulin O
superfamily O
, O
followed O
by O
a O
Thr O
/ O
Ser O
/ O
Pro O
( O
TSP O
) O
- O
rich O
region O
characteristic O
of O
mucin O
- O
like O
O O
- O
glycosylated O
proteins O
. O

To O
characterize O
havcr O
- O
1 O
and O
define O
region O
( O
s O
) O
involved O
in O
HAV O
receptor O
function O
, O
we O
expressed O
the O
TSP O
- O
rich O
region O
in O
Escherichia O
coli O
fused O
to O
glutathione O
S O
- O
transferase O
and O
generated O
antibodies B
( I
Ab I
) I
in O
rabbits O
( O
anti O
- O
GST2 O
Ab O
) O
, O
Western O
blot O
analysis O
with O
anti O
- O
GST2 O
Ab O
detected O
62 O
- O
and O
65 O
- O
kDa O
bands O
in O
AGMK O
cells O
and O
59 O
- O
, O
62 O
- O
, O
and O
65 O
- O
kDa O
bands O
in O
dog O
cells O
transfected O
with O
the O
HAVcr O
- O
1 O
cDNA O
( O
cr5 O
cells O
) O
but O
not O
in O
dog O
cells O
transfected O
with O
the O
vector O
alone O
( O
DR2 O
cells O
) O
. O

Treatment O
of O
AGMK O
and O
cr5 O
cells O
with O
tunicamycin O
reduced O
binding O
of O
protective O
monoclonal B
Ab I
( I
MAb I
) I
190 O
/ O
4 O
, O
which O
suggested O
that O
N O
- O
glycans O
are O
required O
for O
binding O
of O
MAb O
190 O
/ O
4 O
to O
havcr O
- O
1 O
. O

To O
test O
this O
hypothesis O
, O
havcr O
- O
1 O
mutants O
lacking O
the O
N O
- O
glycosylation O
motif O
at O
the O
first O
site O
( O
mut1 O
) O
, O
second O
site O
( O
mut2 O
) O
, O
and O
both O
( O
mut3 O
) O
sites O
were O
constructed O
and O
transfected O
into O
dog O
cells O
. O

Binding O
of O
MAb O
190 O
/ O
4 O
and O
HAV O
to O
mut1 O
and O
mut3 O
cells O
was O
highly O
reduced O
, O
while O
binding O
to O
mut2 O
cells O
was O
not O
affected O
and O
binding O
to O
dog O
cells O
expressing O
an O
havcr O
- O
1 O
construct O
containing O
a O
deletion O
of O
the O
Cys O
- O
rich O
region O
( O
d1 O
- O
cells O
) O
was O
undetectable O
. O

Several O
studies O
indicate O
that O
paramyxoviruses O
require O
a O
specific O
cellular O
factor O
( O
s O
) O
for O
transcription O
of O
their O
genomic O
RNAs O
. O

We O
previously O
reported O
that O
the O
cellular O
cytoskeletal O
protein O
actin O
, O
in O
its O
polymeric O
form O
, O
participates O
in O
the O
transcription O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
in O
vitro O
. O

As O
one O
would O
expect O
from O
these O
results O
, O
measles O
virus O
could O
not O
be O
propagated O
in O
owl O
monkey O
or O
marmoset O
kidney O
cell O
lines O
, O
but O
surprisingly O
, O
both O
a O
wild O
- O
type O
isolate O
( O
Montefiore O
89 O
) O
and O
the O
Edmonston O
laboratory O
strain O
of O
measles O
virus O
grew O
efficiently O
in O
B95 O
- O
8 O
marmoset O
B O
cells O
. O

A O
direct O
binding O
assay O
with O
insect O
cells O
expressing O
the O
hemagglutinin B
( I
H I
) I
proteins O
of O
either O
the O
Edmonston O
or O
Montefiore O
89 O
measles O
virus O
strains O
was O
used O
to O
probe O
the O
receptors O
on O
these O
B O
cells O
. O

The O
recent O
recovery O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
PIV3 I
) I
from O
cDNA O
, O
together O
with O
the O
availability O
of O
a O
promising O
, O
highly O
characterized O
live O
attenuated O
PIV3 O
vaccine O
virus O
, O
suggested O
a O
novel O
strategy O
for O
the O
rapid O
development O
of O
comparable O
recombinant O
vaccine O
viruses O
for O
human O
PIV1 O
and O
PIV2 O
. O

The O
strategy O
, O
illustrated O
here O
for O
PIV1 O
, O
is O
to O
create O
chimeric O
viruses O
in O
which O
the O
two O
protective O
antigens O
, O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
fusion O
( O
F O
) O
envelope O
glycoproteins O
, O
of O
an O
attenuated O
PIV3 O
variant O
are O
replaced O
by O
those O
of O
PIV1 O
or O
PIV2 O
. O

As O
a O
first O
step O
, O
this O
has O
been O
achieved O
by O
using O
recombinant O
wild B
- I
type I
( I
WT I
) I
PIV3 O
as O
the O
recipient O
for O
PIV1 O
HN O
and O
F O
, O
engineered O
so O
that O
each O
PIV1 O
open O
reading O
frame O
is O
flanked O
by O
the O
existing O
PIV3 O
nontranslated O
regions O
and O
transcription O
signals O
. O

On O
the O
other O
hand O
, O
it O
causes O
an O
extensive O
cytopathic B
effect I
( I
CPE I
) I
in O
LLC O
- O
MK2 O
cultures O
which O
resembles O
that O
of O
its O
PIV3 O
parent O
but O
differs O
from O
that O
of O
its O
noncytopathic O
PIV1 O
parent O
. O

The O
paramyxovirus O
genome O
, O
a O
nonsegmented O
, O
negative O
- O
polarity O
, O
single O
- O
stranded O
RNA O
of O
similar O
to O
15 O
kb O
, O
contains O
six O
transcription O
units O
flanked O
at O
the O
3 O
' O
and O
5 O
' O
ends O
by O
a O
short O
( O
similar O
to O
50 O
- O
to O
60 O
- O
nucleotide O
) O
extracistronic O
sequence O
, O
dubbed O
the O
positive O
and O
negative O
leader O
regions O
. O

These O
leader O
template O
regions O
, O
present O
at O
the O
3 O
' O
end O
of O
the O
genome O
and O
the O
antigenome O
, O
have O
been O
shown O
to O
contain O
essential O
signals O
governing O
RNA O
replication O
activity O
, O
Whether O
they O
are O
sufficient O
to O
promote O
replication O
is O
still O
open O
to O
question O
, O
Ey O
using O
a O
series O
of O
Sendai O
virus O
defective O
interfering O
RNAs O
carrying O
a O
nested O
set O
of O
deletions O
in O
the O
promoter O
regions O
, O
it O
is O
shown O
here O
that O
for O
both O
the O
genomic O
and O
antigenomic O
promoters O
, O
a O
3 O
' O
- O
end O
RNA O
sequence O
of O
96 O
nucleotides O
is O
required O
to O
allow O
replication O
, O
Sequence O
comparison O
of O
active O
and O
inactive O
promoters O
led O
to O
the O
identification O
of O
a O
set O
of O
three O
nucleotide O
hexamers O
( O
nucleotides O
79 O
to O
84 O
, O
85 O
to O
90 O
, O
and O
91 O
to O
96 O
) O
containing O
a O
repeated O
motif O
RXXYXX O
[ O
shown O
as O
5 O
' O
- O
3 O
' O
positive O
- O
strand O
] O
. O

Sequential O
mutation O
of O
each O
hexamer O
into O
its O
complementary O
sequence O
confirmed O
their O
essential O
role O
, O
The O
three O
hexamers O
are O
required O
, O
and O
their O
relative O
positioning O
is O
important O
, O
since O
displacing O
them O
by O
6 O
nucleotides O
destroyed O
promoter O
function O
, O
RNAs O
carrying O
degenerate O
nucleotides O
in O
the O
three O
hexamers O
were O
used O
as O
replication O
templates O
, O
They O
led O
to O
the O
selection O
of O
actively O
replicating O
RNA O
species O
exclusively O
carrying O
the O
basic O
motif O
( O
GNNNNN O
) O
( O
3 O
) O
from O
nucleotides O
79 O
to O
96 O
. O

measles B
virus I
( I
MV I
) I
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
are O
both O
members O
of O
the O
Monoegavirales O
but O
are O
only O
distantly O
related O
, O
We O
generated O
two O
genetically O
stable O
chimeric O
viruses O
. O

In O
contrast O
to O
MG O
/ O
FV O
, O
MGV O
virions O
do O
not O
contain O
the O
MV O
matrix B
( I
M I
) I
protein O
. O

Plasmids O
encoding O
the O
measles O
virus O
Hemagglutinin B
( I
HA I
) I
and O
nucleoprotein B
( I
NP I
) I
proteins O
inoculated O
into O
the O
skin O
of O
BALB O
/ O
c O
mice O
by O
the O
gene O
gun O
method O
induced O
both O
humoral O
and O
cytotoxic O
lymphocyte O
class O
I O
- O
restricted O
immune O
responses O
, O
Although O
intramuscular O
immunization O
induces O
the O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
antibody O
isotype O
for O
both O
antigens O
, O
with O
gene O
gun O
immunization O
, O
the O
NP O
still O
generated O
mainly O
IgG2a O
and O
the O
major O
isotype O
induced O
by O
the O
IU O
was O
IgG1 O
, O
Interestingly O
, O
gene O
gun O
coimmunization O
of O
HA O
and O
NP O
plasmids O
resulted O
in O
a O
dominant O
IgG1 O
HA O
response O
and O
the O
switching O
of O
antibodies O
generated O
against O
the O
NP O
to O
the O
IgG1 O
isotype O
. O

The O
existence O
of O
specific O
rabies B
virus I
( I
RV I
) I
glycoprotein I
( I
G I
) I
binding O
sites O
on O
the O
surfaces O
of O
neuroblastoma O
cells O
is O
demonstrated O
. O

Spodoptera B
frugiperda I
( I
Sf2l I
) I
cells O
expressing O
G O
of O
the O
RV O
strain O
CVS O
( O
Gcvs O
- O
Sf21 O
cells O
) O
bind O
specifically O
to O
neuroblastoma O
cells O
of O
different O
species O
but O
not O
to O
any O
other O
cell O
type O
( O
fibroblast O
, O
myoblast O
, O
epithelial O
, O
or O
glioma O
) O
. O

Our O
data O
strongly O
suggest O
that O
these O
specific O
attachment O
sites O
on O
neuroblastoma O
cells O
represent O
a O
neuronal O
receptor O
( O
s O
) O
used O
by O
RV O
to O
infect O
certain O
types O
of O
neurons O
in O
vivo O
. O

The O
P O
/ O
V O
/ O
C O
gene O
contains O
four O
open O
reading O
frames O
, O
three O
of O
which O
, O
P O
, O
C O
, O
and O
V O
, O
have O
Paramyxovirinae O
counterparts O
, O
The O
P O
and O
C O
proteins O
are O
larger O
and O
smaller O
, O
respectively O
, O
than O
are O
cognate O
proteins O
in O
members O
of O
the O
subfamily O
, O
and O
the O
V O
protein O
is O
made O
as O
a O
result O
of O
a O
single O
G O
insertion O
during O
transcription O
, O
The O
P O
/ O
V O
/ O
C O
gene O
has O
two O
unique O
features O
, O
( O
i O
) O
A O
fourth O
open O
reading O
frame O
is O
located O
between O
those O
of O
the O
C O
and O
V O
proteins O
and O
potentially O
encodes O
a O
small O
basic O
protein O
similar O
to O
those O
found O
in O
some O
members O
of O
the O
Rhabdoviridae O
and O
Filoviridae O
families O
, O
( O
ii O
) O
There O
is O
also O
a O
long O
untranslated O
3 O
' O
sequence O
, O
a O
feature O
common O
in O
Filoviridae O
members O
, O
Sequence O
comparisons O
confirm O
that O
although O
the O
virus O
is O
a O
member O
of O
the O
Paramyxovirinae O
subfamily O
, O
it O
displays O
only O
low O
levels O
of O
homolog O
with O
paramyxoviruses O
and O
morbilliviruses O
and O
negligible O
homologies O
with O
rubulaviruses O
. O

The O
involvement O
of O
moesin O
in O
measles B
virus I
( I
MV I
) I
entry O
was O
investigated O
with O
moesin O
- O
positive O
and O
negative O
mouse O
embryonic B
stem I
( I
ES I
) I
cells O
. O

We O
have O
investigated O
the O
entry O
pathway O
of O
Borna B
disease I
virus I
( I
BDV I
) I
. O

Lysosomotropic O
agents O
( O
ammonium O
chloride O
, O
chloroquine O
, O
and O
amantadine O
) O
, O
as O
well O
as O
energy O
depletion O
, O
prevented O
BDV O
infection O
, O
indicating O
that O
BDV O
enters O
host O
cells O
by O
endocytosis O
and O
requires O
an O
acidic O
intracellular O
compartment O
to O
allow O
membrane O
fusion O
and O
initiate O
infection O
. O

Entry O
of O
enveloped O
viruses O
into O
animal O
cells O
usually O
requires O
the O
membrane O
- O
fusing O
activity O
of O
viral O
surface O
glycoproteins B
( I
GPs I
) I
. O

BDV O
GP O
is O
expressed O
as O
two O
products O
of O
84 O
and O
43 O
kDa O
( O
GP O
- O
84 O
and O
GP O
- O
43 O
, O
respectively O
) O
. O

Soluble O
forms O
of O
decay B
- I
accelerating I
factor I
( I
DAF I
) I
( O
CD55 O
) O
, O
the O
receptor O
for O
echovirus O
7 O
, O
were O
synthesized O
in O
the O
yeast O
Pichia O
pastoris O
. O

In O
contrast O
to O
the O
situation O
with O
poliovirus O
and O
its O
receptor O
, O
the O
neutralization O
of O
echovirus O
7 O
by O
soluble O
DAF O
was O
completely O
reversible O
and O
did O
not O
lead O
to O
the O
formation O
of O
135S O
A O
- O
particles O
, O
Binding O
of O
virus O
to O
susceptible O
cells O
, O
by O
contrast O
, O
did O
lead O
to O
the O
formation O
of O
A O
particles O
, O
mainly O
from O
virus O
that O
had O
been O
internalized O
, O
The O
data O
suggest O
that O
a O
secondary O
factor O
( O
s O
) O
may O
contribute O
to O
A O
- O
particle O
formation O
and O
uncoating O
of O
echovirus O
7 O
. O

Polyclonal O
sera O
obtained O
from O
African O
children O
with O
acute O
measles O
were O
used O
to O
screen O
a O
panel O
of O
15 O
- O
mer O
overlapping O
peptides O
representing O
the O
sequence O
of O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
protein O
. O

An O
immunodominant O
antigenic O
region O
from O
the O
F O
protein O
( O
p32 O
; O
amino O
acids O
388 O
to O
402 O
) O
was O
found O
to O
represent O
an O
amino O
acid O
sequence O
within O
the O
highly O
conserved O
cysteine O
- O
rich O
domain O
of O
the O
F O
protein O
of O
paramyxoviruses O
. O

The O
possible O
role O
of O
immunomodulatory O
peptide O
somatostatin O
( O
SRIF O
) O
in O
measles B
virus I
( I
MV I
) I
- O
induced O
immunopathology O
was O
addressed O
by O
analysis O
of O
SRIF O
receptors O
and O
their O
coupling O
to O
adenylyl O
cyclase O
in O
mitogen O
- O
stimulated O
Jurkat O
T O
cells O
and O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMC I
) I
. O

SRIF O
- O
specific O
receptors O
were O
assayed O
in O
semipurified O
membrane O
preparations O
by O
using O
SRIF14 O
containing O
iodinated O
tyrosine O
at O
the O
first O
position O
in O
the O
amino O
acid O
chain O
( O
[ O
I O
- O
125 O
] O
Tyr O
( O
1 O
) O
) O
as O
a O
radioligand O
. O

A O
determination O
of O
receptor O
number O
by O
saturation O
of O
radioligand O
binding O
at O
equilibrium O
showed O
that O
in O
Jurkat O
cells O
, O
MV O
infection O
led O
to O
a O
dramatic O
decrease O
in O
the O
total O
receptor O
number O
, O
The O
virus O
- O
associated O
disappearance O
of O
one O
( O
K O
- O
i2 O
= O
12 O
+ O
/ O
- O
4 O
nhl O
[ O
mean O
a O
standard O
error O
of O
the O
mean O
{ O
SEM O
} O
] O
n O
= O
4 O
) O
of O
two O
somatostatin O
binding O
sites O
identified O
in O
control O
Jurkat O
cells O
( O
K O
- O
i1 O
= O
78 O
+ O
/ O
- O
3 O
pM O
and O
K O
- O
i2 O
= O
12 O
+ O
/ O
- O
4 O
nM O
[ O
mean O
+ O
/ O
- O
SEM O
] O
: O
n O
= O
4 O
) O
was O
also O
observed O
. O

Almost O
identical O
results O
were O
obtained O
for O
phytohemagglutinin O
- O
activated O
human O
PBMC O
In O
the O
absence O
of O
MV O
infection O
, O
two O
somatostatin O
binding O
sites O
were O
present O
( O
K O
- O
i1 O
= O
111 O
+ O
/ O
- O
31 O
pM O
and O
K O
- O
i2 O
= O
17 O
+ O
/ O
- O
2 O
nM O
[ O
mean O
+ O
/ O
- O
SEM O
] O
; O
n O
= O
2 O
) O
1 O
whereas O
in O
MV O
- O
infected O
cells O
, O
only O
the O
high O
- O
affinity O
. O

( O
K O
- O
i1 O
= O
48 O
+ O
/ O
- O
15 O
pM O
[ O
mean O
+ O
/ O
- O
SEM O
] O
; O
n O
= O
2 O
) O
binding O
site O
remained O
, O
In O
addition O
, O
MV O
infection O
reinforced O
the O
inhibitory O
effects O
of O
SRIF O
on O
adenylyl O
cyclase O
activity O
since O
maximal O
inhibition O
at O
1 O
mu O
M O
peptide O
was O
11 O
% O
+ O
/ O
- O
4 O
% O
in O
control O
cells O
versus O
25 O
% O
+ O
/ O
- O
3 O
% O
( O
P O
< O
0 O
. O

05 O
) O
in O
infected O
Jurkat O
cells O
, O
Moreover O
, O
MV O
infection O
severely O
impaired O
the O
capacity O
of O
adenylyl O
cyclase O
to O
be O
activated O
directly O
( O
by O
forskolin O
) O
or O
indirectly O
( O
via O
Gs O
protein O
- O
coupled O
vasoactive O
intestinal O
peptide O
receptor O
) O
, O
An O
assessment O
of O
[ O
methyl O
- O
H O
- O
3 O
] O
thy O
- O
midine O
incorporation O
showed O
that O
SRIF O
increased O
proliferative O
responses O
to O
mitogens O
only O
in O
control O
cells O
, O
not O
in O
MV O
- O
infected O
cells O
, O
Altogether O
, O
our O
data O
emphasize O
that O
MV O
- O
associated O
alteration O
of O
SRIF O
transduction O
appears O
to O
be O
related O
to O
the O
loss O
of O
SRIF O
- O
dependent O
increase O
of O
mitogen O
- O
induced O
proliferation O
. O

With O
the O
identification O
of O
CD46 O
as O
a O
measles B
virus I
( I
MV I
) I
receptor O
, O
it O
was O
feasible O
to O
generate O
transgenic O
rats O
to O
overcome O
this O
problem O
. O

This O
receptor O
consists O
of O
four O
short O
consensus O
regions O
( O
SCR1 O
to O
SCR4 O
) O
which O
normally O
function O
in O
complement O
regulation O
. O

The O
binding O
of O
a O
recombinant O
soluble O
form O
of O
the O
measles B
virus I
( I
MV I
) I
hemagglutinin O
( O
sH O
) O
to O
cells O
expressing O
hybrid O
CD46 O
/ O
CD4 O
proteins O
was O
compared O
to O
that O
of O
purified O
virus O
. O

For O
binding O
of O
both O
ligands O
, O
both O
CD46 O
external O
short B
consensus I
repeats I
I I
and I
II I
( I
SCR I
I I
and I
II I
) I
in O
the O
natural O
order O
were O
essential O
. O

We O
have O
recently O
shown O
that O
live O
attenuated O
virus O
vaccines O
produced O
on O
chicken O
- O
derived O
cells O
contain O
low O
levels O
of O
particle O
- O
associated O
reverse B
transcriptase I
( I
RT I
) I
. O

A O
product O
of O
the O
endogenous O
avian O
retrovirus O
family O
EAV O
- O
0 O
, O
termed O
EAV O
- O
0 O
( O
B1 O
) O
, O
was O
reproducibly O
generated O
with O
a O
tRNA O
( O
Trp O
) O
- O
derived O
primer O
from O
the O
RT O
peak O
fraction O
of O
a O
sucrose O
density O
gradient O
run O
with O
a O
harvest O
of O
a O
live O
attenuated O
measles O
vaccine O
. O

In O
contrast O
, O
no O
products O
were O
detected O
with O
primers O
derived O
from O
tRNA O
( O
Pro O
) O
, O
tRNA O
( O
1 O
, O
2 O
) O
( O
Lys O
) O
or O
tRNA O
( O
3 O
) O
( O
Lys O
) O
. O

In O
the O
same O
fraction O
, O
genomic O
RNA O
of O
EAV O
- O
0 O
( O
B1 O
) O
was O
demonstrated O
by O
long O
PCR O
. O

Analysis O
of O
several O
sucrose O
density O
gradients O
from O
different O
harvests O
of O
various O
manufacturers O
demonstrated O
accumulation O
of O
and O
colocalization O
with O
, O
RT O
activity O
for O
the O
EAV O
- O
0 O
( O
B1 O
) O
RNA O
but O
not O
for O
a O
chicken O
cellular O
mRNA O
. O

Synthesis O
of O
cDNA O
from O
EAV O
- O
0 O
( O
B1 O
) O
RNA O
with O
RT O
were O
demonstrated O
. O

Further O
, O
these O
genome O
analogs O
can O
be O
replicated O
and O
transcribed O
by O
viral O
proteins O
expressed O
from O
cDNA O
clones O
by O
using O
a O
recombinant O
vaccinia O
virus O
expressing O
T7 O
RNA O
polymerase O
( O
MVA O
- O
T7 O
) O
. O

The O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
polymerase O
is O
thought O
to O
initiate O
transcription O
of O
its O
genome O
by O
first O
copying O
a O
small O
leader O
RNA O
complementary O
to O
the O
3 O
' O
end O
of O
the O
template O
. O

canine B
distemper I
virus I
( I
CDV I
) I
infection O
of O
ferrets O
causes O
an O
acute O
systemic O
disease O
involving O
multiple O
organ O
systems O
, O
including O
the O
respiratory O
tract O
, O
lymphoid O
system O
, O
and O
central B
nervous I
system I
( I
CNS I
) I
. O

We O
have O
tested O
candidate O
CDV O
vaccines O
incorporating O
the O
fusion O
( O
F O
) O
and O
Hemagglutinin B
( I
HA I
) I
proteins O
in O
the O
highly O
attenuated O
NYVAC O
strain O
of O
vaccinia O
virus O
and O
in O
the O
ALVAC O
strain O
of O
canarypox O
virus O
, O
which O
does O
not O
productively O
replicate O
in O
mammalian O
hosts O
. O

Control O
animals O
did O
not O
develop O
neutralizing O
antibody O
and O
succumbed O
to O
distemper O
after O
developing O
fever O
, O
weight O
loss O
, O
leukocytopenia O
, O
decreased O
activity O
, O
conjunctivitis O
, O
an O
erythematous O
rash O
typical O
of O
distemper O
, O
CNS O
signs O
, O
and O
viremia O
in O
peripheral O
blood O
mononuclear O
cells O
( O
as O
measured O
by O
reverse O
transcription O
- O
PCR O
) O
. O

poliovirus B
( I
PV I
) I
is O
the O
causal O
agent O
of O
paralytic O
poliomyelitis O
. O

Antimoesin O
antibodies O
also O
reacted O
with O
CD46 O
/ O
CD4 O
molecules O
containing O
only O
the O
SCR O
I O
and O
II O
domains O
required O
for O
measles B
virus I
( I
MV I
) I
hemagglutinin O
binding O
onto O
CD46 O
. O

To O
investigate O
the O
sequence O
requirements O
for O
measles B
virus I
( I
MV I
) I
- O
induced O
receptor O
down O
regulation O
, O
we O
transfected O
the O
human O
CD46 O
gene O
into O
simian O
cells O
persistently O
infected O
by O
; O
the O
Biken O
strain O
of O
MV O
. O

We O
have O
generated O
transgenic O
mice O
ubiquitously O
expressing O
the O
human O
receptor O
for O
measles B
virus I
( I
MV I
) I
, O
CD46 O
( O
membrane O
cofactor O
protein O
) O
, O
Various O
cell O
types O
were O
isolated O
from O
these O
transgenic O
mice O
acid O
analyzed O
for O
their O
ability O
to O
support O
MV O
replication O
in O
vitro O
, O
Although O
MV O
could O
enter O
into O
all O
CD46 O
- O
expressing O
cells O
, O
differential O
susceptibilities O
to O
MV O
infection O
were O
detected O
depending O
on O
the O
cell O
type O
, O
Cell O
cultures O
obtained O
from O
transgenic O
lungs O
and O
kidneys O
were O
found O
to O
be O
permissive O
of O
MV O
infection O
, O
since O
RNA O
specific O
for O
MV O
genes O
was O
detected O
and O
viral O
particles O
were O
released O
, O
although O
at O
a O
low O
level O
, O
Similarly O
to O
human O
lymphocytes O
, O
activated O
T O
and O
B O
lymphocytes O
isolated O
from O
transgenic O
mice O
could O
support O
MV O
replication O
; O
virus O
could O
enter O
, O
transcribe O
viral O
RNA O
, O
and O
produce O
new O
infectious O
particles O
, O
When O
expressing O
viral O
proteins O
, O
lymphocytes O
down O
- O
regulated O
CD46 O
from O
the O
surface O
, O
Interestingly O
, O
while O
activated O
T O
lymphocytes O
from O
nontransgenic O
mice O
did O
not O
support O
MV O
infection O
, O
activated O
nontransgenic O
murine O
B O
Lymphocytes O
replicated O
MV O
as O
well O
as O
transgenic O
B O
lymphocytes O
, O
suggesting O
the O
use O
of O
an O
alternative O
virus O
receptor O
for O
entry O
. O

vesicular B
stomatitis I
virus I
( I
VSV I
) I
populations O
were O
repeatedly O
passaged O
in O
L O
- O
929 O
cells O
treated O
with O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
at O
levels O
of O
25 O
U O
/ O
ml O
. O

Analysis O
of O
viral O
fitness O
( O
overall O
replicative O
ability O
measured O
in O
direct O
competition O
with O
a O
reference O
wild O
- O
type O
VSV O
) O
after O
21 O
passages O
in O
IFN O
- O
treated O
cells O
showed O
only O
a O
limited O
increase O
or O
no O
increase O
in O
fitness O
, O
compared O
with O
the O
greater O
increase O
upon O
parallel O
passage O
in O
cells O
not O
treated O
with O
IFN O
- O
alpha O
. O

membrane B
cofactor I
protein I
( I
MCP I
) I
( O
CD46 O
) O
, O
a O
complement O
- O
regulatory O
protein O
, O
serves O
as O
a O
cellular O
receptor O
for O
measles O
virus O
. O

Its O
amino O
- O
terminal O
portion O
is O
composed O
of O
four O
short B
consensus I
repeats I
( I
SCR I
) I
, O
three O
of O
which O
( O
SCR1 O
, O
SCR2 O
, O
and O
SCR4 O
) O
carry O
an O
N O
- O
linked O
oligosaccharide O
. O

In O
order O
td O
determine O
the O
importance O
of O
the O
three O
N O
- O
glycans O
for O
the O
function O
of O
MCP O
as O
a O
measles O
virus O
receptor O
, O
we O
established O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cell O
lines O
that O
stably O
express O
mutant O
MCPs O
lacking O
one O
of O
the O
three O
motifs O
for O
N O
glycosylation O
( O
NQ1 O
, O
NQ2 O
, O
and O
NQ4 O
) O
. O

In O
an O
additional O
mutant O
( O
NQ1 O
- O
2 O
) O
, O
two O
glycosylation O
motifs O
were O
altered O
, O
allowing O
the O
addition O
of O
an O
N O
- O
linked O
oligosaccharide O
only O
in O
SCR4 O
. O

The O
abilities O
of O
the O
mutant O
MCPs O
to O
function O
as O
measles O
virus O
receptors O
were O
analyzed O
with O
three O
different O
assays O
: O
( O
i O
) O
binding O
of O
measles O
virus O
hemagglutinin O
to O
MCP O
immobilized O
on O
nitrocellulose O
; O
( O
ii O
) O
binding O
of O
measles O
virus O
to O
CHO O
cells O
expressing O
wild O
- O
type O
or O
mutant O
MCP O
; O
and O
( O
iii O
) O
infection O
of O
the O
transfected O
CHO O
cells O
by O
measles O
virus O
. O

The O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoproteins O
are O
the O
principal O
components O
involved O
in O
virion O
receptor O
binding O
, O
membrane O
penetration O
, O
and O
ultimately O
, O
syncytium O
formation O
. O

In O
addition O
, O
coexpression O
of O
other O
heterologous O
paramyxovirus O
F O
or O
HN O
glycoproteins O
with O
either O
HPIV3 O
F O
or O
HN O
does O
not O
result O
in O
the O
formation O
of O
syncytia O
, O
suggesting O
serotype O
- O
specific O
protein O
differences O
, O
In O
this O
study O
, O
we O
report O
that O
simian O
virus O
5 O
and O
Sendai O
virus O
heterologous O
HN O
proteins O
and O
measles O
virus O
hemagglutinin B
( I
H I
) I
were O
found O
to O
be O
down O
- O
regulated O
when O
coexpressed O
with O
HPIV3 O
F O
. O

As O
an O
alternative O
to O
detecting O
physical O
associations O
of O
these O
proteins O
by O
coimmunoprecipitation O
, O
further O
studies O
were O
performed O
with O
a O
mutant O
HPIV3 O
F O
protein O
( O
F O
- O
KDEL O
) O
lacking O
a O
transmembrane O
anchor O
and O
cytoplasmic O
tail O
and O
containing O
a O
carboxyl O
- O
terminal O
retention O
signal O
for O
the O
endoplasmic B
reticulum I
( I
ER I
) I
. O

In O
contrast O
, O
coexpression O
of O
F O
- O
KDEL O
with O
HPIV3 O
wild O
- O
type O
F O
or O
the O
heterologous O
receptor O
- O
binding O
proteins O
, O
respiratory O
syncytial O
virus O
glycoprotein B
( I
G I
) I
and O
vesicular O
stomatitis O
virus O
glycoprotein B
( I
G I
) I
, O
were O
not O
affected O
in O
transport O
to O
the O
cell O
surface O
. O

Genome O
analogs O
( O
' O
' O
minigenomes O
' O
' O
) O
of O
Sendai O
and O
measles O
viruses O
replicate O
efficiently O
only O
if O
their O
nucleotide O
length O
is O
an O
even O
multiple O
of O
six O
, O
a O
requirement O
called O
the O
rule O
of O
six O
( O
P O
. O

The O
existence O
of O
a O
comparable O
requirement O
was O
tested O
for O
respiratory B
syncytial I
virus I
( I
RSV I
) I
, O
which O
also O
is O
a O
member O
of O
family O
Paramyxoviridae O
and O
whose O
natural O
genome O
length O
also O
is O
a O
multiple O
of O
six O
. O

An O
internally O
truncated O
analog O
of O
RSV O
positive O
- O
sense O
replicative O
intermediate O
RNA O
( O
antigenome O
) O
bearing O
the O
chloramphenicol O
acetyltransferase O
gene O
as O
a O
reporter O
was O
synthesized O
from O
cDNA O
in O
vitro O
. O

Each O
of O
the O
in O
vitro O
- O
synthesized O
miniantigenomes O
used O
in O
transfection O
contained O
a O
nonviral O
extension O
of O
three O
nucleotides O
, O
GGG O
, O
, O
on O
the O
5 O
' O
( O
leader O
) O
end O
contributed O
by O
the O
T7 O
promoter O
. O

Unexpectedly O
, O
each O
recovered O
minigenome O
contained O
the O
complement O
of O
this O
nonviral O
extension O
on O
the O
3 O
' O
( O
leader O
) O
end O
, O
showing O
that O
it O
had O
been O
faithfully O
copied O
and O
maintained O
during O
RNA O
replication O
and O
passage O
. O

We O
have O
used O
site O
- O
directed O
mutagenesis O
of O
the O
hemagglutinin B
( I
H I
) I
glycoprotein O
of O
measles B
virus I
( I
MV I
) I
to O
investigate O
the O
molecular O
basis O
for O
the O
phenotypic O
differences O
observed O
between O
MV O
vaccine O
strains O
and O
recently O
isolated O
wild O
- O
type O
MV O
strains O
. O

Mutagenesis O
of O
two O
amino O
acids O
, O
valine O
and O
tyrosine O
at O
positions O
451 O
and O
481 O
, O
respectively O
, O
in O
the O
H O
protein O
from O
the O
vaccine O
- O
like O
Halle O
MV O
strain O
to O
their O
counterparts O
, O
glutamate O
and O
asparagine O
, O
in O
the O
H O
protein O
from O
the O
wild O
- O
type O
Ma93F O
MV O
strain O
( O
creating O
the O
V451E O
/ O
Y481N O
double O
mutation O
) O
abrogated O
CD46 O
downregulation O
, O
HeLa O
cell O
fusion O
, O
and O
hemadsorption O
, O
The O
converse O
double O
mutagenesis O
of O
the O
Ma93F O
H O
protein O
( O
E451V O
/ O
N481Y O
) O
transferred O
the O
CD16 O
- O
downregulating O
, O
fusogenic O
, O
and O
hemadsorption O
functions O
to O
this O
protein O
, O
The O
data O
provide O
the O
first O
mapping O
study O
of O
the O
functional O
domains O
of O
MV O
H O
. O

Bovine O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
were O
infected O
with O
the O
pathogenic O
Saudi O
isolate O
of O
rinderpest B
virus I
( I
RPV I
) I
in O
order O
to O
identify O
the O
cell O
subpopulation O
( O
s O
) O
susceptible O
to O
active O
replication O
of O
this O
virus O
. O

The O
activation O
of O
PBMC O
with O
concanavalin O
A O
before O
infection O
resulted O
in O
an O
increase O
in O
the O
capacity O
of O
lymphocytes O
to O
support O
RPV O
replication O
; O
> O
90 O
% O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
lymphocytes O
expressed O
viral O
antigen O
at O
3 O
days O
postinfection O
, O
although O
less O
than O
or O
equal O
to O
40 O
% O
of O
gamma O
/ O
delta O
T O
cells O
were O
productively O
infected O
, O
B O
- O
lymphocyte O
activation O
with O
pokeweed O
mitogen O
also O
resulted O
in O
increased O
replication O
of O
this O
virus O
in O
these O
cells O
, O
involving O
up O
to O
40 O
% O
of O
B O
lymphocytes O
, O
An O
enhancement O
of O
lymphocyte O
susceptibility O
to O
infection O
and O
active O
replication O
by O
RPV O
was O
observed O
upon O
coculture O
of O
RPV O
- O
infected O
PBMC O
on O
bovine O
endothelial O
cells O
, O
Such O
enhancement O
was O
most O
marked O
with O
the O
B O
- O
cell O
and O
CD4 O
( O
+ O
) O
T O
- O
cell O
subpopulations O
. O

The O
pH O
- O
independent O
fusion O
of O
membranes O
induced O
by O
measles B
virus I
( I
MV I
) I
requires O
, O
in O
addition O
to O
the O
fusion O
- O
competent O
protein O
F O
, O
hemagglutinin B
( I
H I
) I
, O
and O
on O
the O
target O
membrane O
, O
the O
virus O
receptor O
CD46 O
. O

We O
constructed O
hybrid O
receptors O
composed O
of O
different O
numbers O
and O
combinations O
of O
the O
four O
CD46 O
short B
consensus I
repeat I
( I
SCR I
) I
domains O
, O
followed O
by O
immunoglobulin O
- O
like O
domains O
of O
another O
cell O
surface O
protein O
, O
CD4 O
. O

Hybrid O
proteins O
containing O
SCRs O
I O
and O
II O
bound O
MV O
particles O
and O
conferred O
fusion O
competence O
to O
rodent O
cells O
, O
SCRs O
III O
and O
/ O
or O
TV O
strengthened O
MV O
binding O
, O
Increasing O
the O
distance O
between O
the O
MV O
binding O
site O
and O
the O
transmembrane O
domain O
enhanced O
virus O
binding O
but O
reduced O
fusion O
efficiency O
, O
A O
hybrid O
protein O
predicted O
to O
be O
about O
120 O
Angstrom O
( O
12 O
nm O
) O
longer O
than O
the O
standard O
receptor O
lost O
fusion O
support O
function O
and O
was O
dominant O
negative O
over O
a O
functional O
receptor O
, O
These O
data O
indicate O
that O
receptor O
protein O
length O
influences O
virus O
binding O
and O
determines O
fusion O
efficiency O
. O

Mortality O
from O
measles O
is O
caused O
mostly O
by O
secondary O
infections O
associated O
with O
the O
depression O
of O
cellular O
immunity O
, O
The O
mechanism O
of O
immune O
suppression O
and O
the O
role O
of O
virus O
strain O
differences O
on O
the O
immune O
system O
are O
incompletely O
understood O
, O
SCID O
- O
hu O
mice O
were O
used O
to O
determine O
the O
effects O
of O
virulent O
, O
wild O
- O
type O
( O
Chicago O
- O
1 O
) O
and O
avirulent O
, O
vaccine O
( O
Moraten O
) O
strains O
of O
measles B
virus I
( I
MV I
) I
on O
the O
human O
thymus O
in O
vivo O
. O

Recently O
, O
it O
has O
been O
observed O
that O
the O
infection O
of O
human O
target O
cells O
with O
certain O
measles B
virus I
( I
MV I
) I
strains O
leads O
to O
the O
downregulation O
of O
the O
major O
MV O
receptor O
CD46 O
. O

Here O
we O
report O
that O
CD46 O
downregulation O
can O
be O
rapidly O
induced O
in O
uninfected O
cells O
after O
surface O
contact O
with O
MV O
particles O
or O
MV O
- O
infected O
cells O
, O
Receptor O
modulation O
is O
detectable O
after O
30 O
min O
of O
cocultivation O
of O
uninfected O
cells O
with O
MV O
- O
infected O
cells O
and O
is O
complete O
after O
2 O
to O
4 O
h O
, O
a O
time O
after O
which O
newly O
synthesized O
MV B
hemagglutinin I
( I
MV I
- I
H I
) I
cannot O
be O
detected O
in O
freshly O
infected O
target O
cells O
, O
This O
contact O
- O
mediated O
receptor O
modulation O
is O
also O
induced O
by O
recombinant O
MV O
- O
H O
expressed O
by O
vaccinia O
virus O
and O
is O
inhibitable O
with O
antibodies O
against O
CD46 O
and O
MV O
- O
H O
. O

We O
have O
previously O
demonstrated O
that O
two O
mouse O
cell O
lines O
that O
are O
poorly O
infectible O
by O
reovirus O
become O
highly O
susceptible O
upon O
transfection O
with O
the O
gene O
encoding O
the O
epidermal B
growth I
factor I
receptor I
( I
EGFR I
) I
( O
J O
. O

This O
enhancement O
of O
infection O
efficiency O
requires O
a O
functional O
EGFR O
, O
since O
such O
an O
enhancement O
is O
not O
observed O
in O
cells O
expressing O
a O
mutated O
( O
kinase O
- O
inactive O
) O
EGFR O
. O

Control O
NIH O
3T3 O
cells O
, O
which O
are O
poorly O
infectible O
by O
reovirus O
( O
serotype O
3 O
, O
strain O
Dearing O
) O
, O
and O
NIH O
3T3 O
cells O
transfected O
with O
the O
v O
- O
erbB O
oncogene O
( O
THC O
- O
11 O
) O
were O
assayed O
for O
their O
susceptibilities O
to O
reovirus O
infection O
. O

Persistently O
infected O
cultures O
of O
DBT O
cells O
were O
established O
with O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
and O
the O
evolution O
of O
the O
MHV O
leader O
RNA O
and O
5 O
' O
end O
of O
the O
genome O
was O
studied O
through O
119 O
days O
postinfection O
. O

2 O
x O
10 O
( O
- O
3 O
) O
to O
6 O
. O

7 O
x O
10 O
( O
- O
3 O
) O
. O

2 O
x O
10 O
( O
- O
5 O
) O
to O
7 O
. O

6 O
x O
10 O
( O
- O
5 O
) O
per O
nucleotide B
( I
nt I
) I
per O
day O
. O

Rather O
, O
a O
5 B
' I
untranslated I
region I
( I
UTR I
) I
A O
- O
to O
- O
G O
mutation O
at O
nt O
77 O
in O
the O
genomic O
RNA O
emerged O
by O
day O
56 O
and O
accumulated O
until O
50 O
to O
80 O
% O
of O
the O
genome O
- O
length O
molecules O
retained O
the O
mutation O
by O
119 O
days O
postinfection O
. O

The O
5 O
' O
UTR O
nt O
77 O
mutation O
resulted O
in O
an O
18 O
- O
amino O
- O
acid O
open B
reading I
frame I
( I
ORF I
) I
upstream O
of O
the O
ORF O
1a O
AUG O
start O
site O
. O

Variant O
viruses O
, O
containing O
either O
the O
nt O
77 O
A O
- O
to O
- O
G O
mutation O
( O
V16 O
- O
ATG O
( O
+ O
) O
) O
or O
wild O
- O
type O
sequences O
at O
this O
locus O
( O
V1 O
- O
ATG O
( O
- O
) O
) O
, O
were O
isolated O
at O
119 O
days O
postinfection O
. O

5 O
- O
fold O
) O
in O
p28 O
expression O
was O
also O
observed O
with O
the O
mutant O
virus O
( O
V16 O
- O
ATG O
( O
+ O
) O
) O
in O
DBT O
cells O
compared O
with O
that O
in O
wild O
- O
type O
controls O
. O

A O
solid O
- O
phase O
8 O
- O
mer O
random O
combinatorial O
peptide O
library O
was O
used O
to O
generate O
a O
panel O
of O
minotopes O
of O
an O
epitope O
recognized O
by O
a O
monoclonal O
antibody O
to O
the O
F O
protein O
of O
measles B
virus I
( I
MV I
) I
. O

BALB O
/ O
c O
mice O
were O
coimmunized O
with O
the O
individual O
mimotopes O
and O
a O
T O
- O
helper O
epitope O
peptide O
( O
from O
MV O
fusion O
protein O
) O
, O
and O
the O
reactivity O
of O
the O
induced O
anti O
- O
mimotope O
antibodies O
with O
the O
corresponding O
peptides O
and O
with O
MV O
was O
determined O
. O

9 O
X O
10 O
( O
5 O
) O
to O
4 O
. O

4 O
X O
10 O
( O
7 O
) O
liters O
/ O
mol O
. O

Members O
of O
the O
Paramyxoviridae O
family O
utilize O
a O
variety O
of O
different O
strategies O
to O
increase O
coding O
capacity O
within O
their O
P O
cistrons O
, O
Translation O
initiation O
at O
alternative O
5 O
' O
- O
proximal O
AUG O
codons O
is O
used O
by O
measles B
virus I
( I
MV I
) I
to O
express O
the O
virus O
- O
specific O
P O
and O
C O
proteins O
from O
overlapping O
reading O
frames O
on O
their O
mRNAs O
. O

Some O
ribosomes O
which O
have O
initiated O
translation O
of O
the O
P O
protein O
mRNA O
use O
the O
sequence O
TCC O
CCG O
AG O
( O
24 O
nucleotides O
upstream O
of O
the O
V O
protein O
stop O
codon O
) O
to O
slip O
into O
the O
- O
1 O
reading O
frame O
, O
thus O
translating O
the O
sequence O
as O
TC O
CCC O
GAG O
. O

Recently O
, O
we O
found O
that O
several O
lymphotropic O
wild O
- O
type O
isolates O
of O
measles B
virus I
( I
MV I
) I
did O
not O
lead O
to O
the O
downregulation O
of O
CD46 O
following O
infection O
. O

Conventional O
strategies O
of O
viral O
peptide O
immunizations O
often O
elicit O
low O
- O
affinity O
antibody O
responses O
and O
have O
limited O
ability O
to O
elicit O
immune O
responses O
in O
outbred O
animals O
of O
diverse O
major B
histocompatibility I
( I
MHC I
) I
haplotypes O
. O

Promiscuous O
T O
- O
cell O
epitopes O
from O
tetanus O
toxin O
( O
amino O
acids O
[ O
aa O
] O
580 O
to O
599 O
) O
and O
the O
measles O
virus O
F O
protein O
( O
aa O
288 O
to O
302 O
) O
that O
bind O
to O
several O
isotypic O
and O
allotypic O
forms O
of O
human O
MHC O
class O
II O
molecules O
have O
been O
identified O
and O
have O
been O
used O
in O
highly O
immunogenic O
constructs O
to O
overcome O
haplotype O
- O
restricted O
immune O
responses O
. O

Chimeric O
and O
beta O
- O
template O
peptide O
constructs O
incorporating O
known O
Human B
T I
- I
lymphotropic I
virus I
type I
1 I
( I
HTLV I
- I
1 I
) I
B O
- O
and O
T O
- O
cell O
epitopes O
from O
the O
surface O
envelope O
protein O
gp46 O
( O
SP2 O
[ O
aa O
86 O
to O
107 O
] O
and O
SP4a O
[ O
aa O
190 O
to O
209 O
] O
) O
and O
promiscuous O
T O
- O
cell O
peptides O
were O
synthesized O
, O
and O
their O
immunogenicities O
were O
evaluated O
in O
both O
rabbits O
and O
mouse O
strains O
of O
divergent O
haplotypes O
( O
C3H O
/ O
HeJ O
[ O
H O
- O
2 O
( O
k O
) O
] O
, O
C57BL O
/ O
6 O
[ O
H O
- O
2 O
( O
b O
) O
] O
, O
and O
BALB O
/ O
c O
[ O
H O
- O
2 O
( O
d O
) O
] O
) O
. O

Immunogenicity O
of O
the O
peptide O
constructs O
was O
evaluated O
by O
direct O
and O
competitive O
enzyme B
- I
linked I
immunosorbant I
assay I
( I
ELISA I
) I
, O
as O
well O
as O
by O
radioimmunoprecipitation O
, O
syncytium O
inhibition O
, O
and O
antigen O
- O
induced O
lymphocyte O
proliferation O
assays O
. O

Immunization O
with O
the O
SP4a O
peptide O
without O
conjugation O
to O
a O
carrier O
protein O
produced O
antibodies O
specific O
for O
SP4a O
in O
two O
mouse O
strains O
( O
C3H O
/ O
HeJ O
and O
C57BL O
/ O
6 O
) O
. O

CD55 O
, O
of O
decay B
- I
accelerating I
factor I
( I
DAF I
) I
, O
is O
a O
cell O
surface O
glycoprotein O
which O
regulates O
complement O
activity O
by O
accelerating O
the O
decay O
of O
C3 O
/ O
C5 O
convertases O
. O

DAF O
consists O
of O
five O
domains O
: O
four O
short B
consensus I
repeats I
( I
SCRs I
) I
and O
a O
serine O
/ O
threonine O
- O
rich O
region O
, O
attached O
to O
the O
cell O
surface O
by O
a O
glycosylphosphatidyl O
inositol O
anchor O
. O

The O
monoclonal O
antibody O
used O
to O
identify O
DAF O
as O
an O
echovirus O
receptor O
, O
and O
which O
inhibits O
binding O
of O
the O
virus O
( O
monoclonal O
antibody O
854 O
) O
, O
binds O
to O
SCR3 O
. O

measles B
virus I
( I
MV I
) I
, O
human O
immunodeficiency O
virus O
, O
Epstein O
- O
Barr O
virus O
, O
and O
other O
leukotropic O
viruses O
can O
modulate O
the O
expression O
of O
leukocyte B
function I
antigen I
1 I
( I
LFA I
- I
1 I
) I
on O
the O
surface O
of O
infected O
and O
nearby O
leukocytes O
. O

However O
, O
the O
mechanism O
( O
s O
) O
involved O
in O
virus O
- O
mediated O
regulation O
of O
LFA O
- O
1 O
is O
unknown O
. O

Evidence O
is O
presented O
in O
this O
report O
that O
it O
is O
the O
MV O
hemagglutinin B
( I
H I
) I
protein O
that O
initiates O
up O
- O
regulation O
of O
LFA O
- O
1 O
expression O
in O
leukocyte O
cultures O
infected O
with O
this O
virus O
. O

Indeed O
, O
comparison O
of O
the O
abilities O
of O
different O
MV O
strains O
to O
modulate O
LFA O
- O
1 O
expression O
, O
examination O
of O
published O
nucleotide O
sequences O
for O
the O
H O
proteins O
of O
different O
vaccine O
strains O
, O
and O
competitive O
inhibition O
assays O
using O
oligopeptides O
homologous O
or O
heterologous O
to O
a O
region O
of O
the O
H O
protein O
gene O
encompassing O
amino O
acid O
116 O
( O
from O
the O
amino O
terminus O
) O
all O
suggest O
that O
it O
is O
this O
portion O
of O
the O
H O
protein O
that O
is O
responsible O
for O
MV O
- O
induced O
alteration O
of O
LFA O
- O
1 O
. O

We O
analyzed O
the O
roles O
of O
the O
individual O
measles B
virus I
( I
MV I
) I
surface O
glycoproteins O
in O
mediating O
functional O
and O
structural O
interactions O
with O
human O
CD46 O
, O
the O
primary O
MV O
receptor O
. O

On O
one O
cell O
population O
, O
recombinant O
vaccinia O
virus O
vectors O
were O
used O
to O
produce O
the O
MV O
hemagglutinin O
( O
II O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
. O

As O
fusion O
partner O
cells O
, O
various O
cell O
types O
were O
examined O
, O
without O
or O
with O
human O
CD46 O
( O
endogenous O
or O
recombinant O
vaccinia O
virus O
encoded O
) O
, O
Fusion O
between O
the O
two O
cell O
populations O
was O
monitored O
by O
a O
quantitative O
reporter O
gene O
activation O
assay O
and O
by O
syncytium O
formation O
, O
MV O
glycoproteins O
promoted O
fusion O
with O
primate O
cells O
but O
not O
with O
nonprimate O
cells O
; O
recombinant O
CD46 O
rendered O
nonprimate O
cells O
competent O
for O
MV O
glycoprotein O
- O
mediated O
fusion O
, O
Markedly O
different O
fusion O
specificity O
was O
observed O
for O
another O
morbillivirus O
, O
canine B
distemper I
virus I
( I
CDV I
) I
: O
recombinant O
CDV O
glycoproteins O
promoted O
fusion O
with O
primate O
and O
nonprimate O
cells O
independently O
of O
CD46 O
. O

To O
determine O
the O
mechanism O
of O
measles O
virus O
- O
induced O
cell O
death O
, O
we O
studied O
the O
infection O
of O
Vero O
cells O
and O
monocytic O
cell O
lines O
with O
wild O
- O
type O
( O
Chicago O
- O
1 O
) O
and O
vaccine O
( O
Edmonston O
) O
strains O
of O
measles O
virus O
. O

We O
have O
identified O
the O
major O
cellular O
endoprotease O
that O
activates O
the O
fusion O
( O
F O
) O
glycoprotein O
of O
measles B
virus I
( I
MV I
) I
and O
have O
engineered O
a O
serine O
protease O
inhibitor O
( O
serpin O
) O
to O
target O
the O
endoprotease O
and O
inhibit O
the O
production O
of O
infectious O
MV O
. O

A O
human O
serpin O
alpha O
( O
1 O
) O
- O
antitrypsin O
variant O
was O
engineered O
to O
specifically O
inhibit O
furin O
. O

When O
expressed O
from O
a O
recombinant O
vaccinia O
virus O
in O
primate O
cells O
infected O
by O
MV O
, O
the O
engineered O
serpin O
( O
alpha O
( O
1 O
) O
- O
PDX O
) O
specifically O
inhibited O
furin O
- O
catalyzed O
cleavage O
of O
the O
F O
- O
protein O
precursor O
without O
affecting O
synthesis O
of O
other O
MV O
proteins O
. O

We O
generated O
human O
glioma O
cells O
stably O
expressing O
alpha O
( O
1 O
) O
- O
PDX O
. O

Recently O
, O
two O
cellular O
membrane O
proteins O
, O
the O
membrane O
cofactor O
protein O
CD46 O
and O
the O
membrane O
- O
organizing O
external O
spike O
protein O
, O
moesin O
, O
have O
been O
identified O
to O
be O
functionally O
associated O
with O
measles B
virus I
( I
MV I
) I
infectivity O
of O
cells O
. O

Synthetic O
peptides O
representing O
T O
- O
and O
B O
- O
cell O
epitopes O
from O
the O
fusion O
( O
F O
) O
protein O
of O
measles B
virus I
( I
MV I
) I
were O
tested O
for O
their O
ability O
to O
induce O
a O
protective O
immune O
response O
against O
intracerebral O
challenge O
with O
neuroadapted O
strains O
of O
MV O
and O
canine B
distemper I
virus I
( I
CDV I
) I
in O
mice O
. O

Of O
the O
panel O
of O
peptides O
tested O
, O
only O
a O
chimeric O
peptide O
consisting O
of O
two O
copies O
of O
a O
promiscuous O
T O
- O
cell O
epitope O
( O
representing O
residues O
288 O
to O
302 O
of O
MV O
F O
protein O
) O
synthesized O
at O
the O
amino O
terminus O
of O
a O
B O
- O
cell O
epitope O
( O
representing O
residues O
404 O
to O
414 O
of O
MV O
F O
protein O
) O
was O
able O
to O
induce O
a O
protective O
response O
against O
challenge O
with O
MV O
and O
CDV O
in O
inbred O
mice O
. O

The O
protective O
response O
induced O
by O
this O
peptide O
( O
TTB O
) O
was O
associated O
with O
a O
significant O
reduction O
in O
mortality O
, O
histological O
absence O
of O
acute O
encephalitis O
, O
and O
greatly O
reduced O
titers O
of O
virus O
in O
the O
brains O
of O
TTB O
- O
immune O
mice O
following O
challenge O
compared O
with O
the O
results O
for O
nonimmunized O
controls O
. O

A O
chimeric O
peptide O
comprising O
one O
copy O
of O
the O
T O
- O
cell O
epitope O
and O
one O
copy O
of O
the O
B O
- O
cell O
epitope O
( O
TB O
) O
did O
not O
induce O
a O
protective O
response O
. O

measles B
virus I
( I
MV I
) I
and O
canine B
distemper I
virus I
( I
CDV I
) I
are O
morbilliviruses O
that O
cause O
acute O
illnesses O
and O
several O
persistent O
central O
nervous O
system O
infections O
in O
humans O
and O
in O
dogs O
, O
respectively O
, O
Characteristically O
, O
the O
cytopathic O
effect O
of O
these O
viruses O
is O
the O
formation O
of O
syncytia O
in O
permissive O
cells O
. O

In O
this O
study O
, O
a O
vaccinia O
virus O
expression O
system O
was O
used O
to O
express O
MV O
and O
CDV O
Hemagglutinin B
( I
HA I
) I
and O
fusion O
( O
F O
) O
envelope O
proteins O
. O

Two O
of O
the O
hybrids O
containing O
human O
chromosome O
19 O
formed O
syncytia O
following O
CDV O
infection O
, O
In O
addition O
, O
these O
two O
hybrids O
underwent O
cell O
fusion O
when O
cotransfected O
, O
vith O
CDV O
- O
F O
and O
CDV O
- O
HA O
( O
but O
not O
MV O
- O
F O
and O
MV O
- O
HA O
) O
glycoproteins O
by O
using O
the O
vaccinia O
virus O
expression O
system O
, O
To O
discover O
the O
viral O
component O
responsible O
for O
cell O
specificity O
, O
complementation O
experiments O
coexpressing O
CDV O
- O
HA O
with O
MV O
- O
F O
or O
CDV O
- O
F O
with O
MV O
- O
HA O
in O
the O
CDV O
- O
sensitive O
hybrids O
were O
performed O
, O
We O
found O
that O
syncytia O
were O
formed O
only O
in O
the O
presence O
of O
CDV O
- O
HA O
, O
These O
results O
support O
the O
idea O
that O
the O
HA O
protein O
is O
responsible O
for O
cell O
tropism O
, O
Furthermore O
, O
while O
the O
F O
protein O
is O
necessary O
for O
the O
fusion O
process O
, O
it O
is O
interchangeable O
with O
the O
F O
protein O
from O
other O
morbilliviruses O
. O

A O
coxsackievirus B
B3 I
( I
CB3 I
) I
isolate O
adapted O
to O
growth O
in O
RD O
cells O
shows O
an O
alteration O
in O
cell O
tropism O
as O
a O
result O
of O
its O
capacity O
to O
bind O
a O
70 O
- O
kDa O
cell O
surface O
molecule O
expressed O
on O
these O
cells O
, O
We O
now O
show O
that O
this O
molecule O
is O
the O
complement O
regulatory O
protein O
, O
decay B
- I
accelerating I
factor I
( I
DAF I
) I
( O
CD55 O
) O
, O
Anti O
- O
DAF O
antibodies O
prevented O
CB3 O
attachment O
to O
the O
cell O
surface O
. O

Radiolabeled O
CB3 O
adapted O
to O
growth O
in O
RD O
cells O
bound O
to O
CHO O
cells O
transfected O
with O
human O
DAF O
, O
whereas O
CB3 O
( O
strain O
Nancy O
) O
, O
the O
parental O
strain O
, O
did O
not O
bind O
to O
DAF O
transfectants O
. O

The O
expression O
of O
chimeric O
proteins O
was O
performed O
for O
the O
localization O
of O
monoclonal B
antibody I
( I
Mab I
) I
epitopes O
and O
functional O
domains O
in O
the O
hemagglutinin B
( I
H I
) I
protein O
of O
measles O
virus O
. O

Immune O
regulation O
of O
measles B
virus I
( I
MV I
) I
expression O
was O
studied O
in O
a O
persistently O
infected O
mouse O
macrophage O
cell O
line O
. O

The O
hemagglutinin B
( I
H I
) I
glycoprotein O
was O
isolated O
in O
a O
soluble O
form O
by O
digesting O
measles O
virus O
particles O
with O
an O
endoproteinase O
, O
Asp O
- O
N O
( O
from O
a O
Pseudomonas O
fragi O
mutant O
) O
. O

Digestion O
of O
H O
with O
Asp O
- O
N O
brought O
about O
glycopeptides O
in O
three O
different O
forms O
, O
depending O
on O
the O
cleaving O
site O
: O
AHD O
, O
which O
has O
an O
M O
( O
r O
) O
of O
66 O
, O
000 O
as O
determined O
by O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
and O
which O
formed O
a O
disulfide O
- O
linked O
homodimer O
with O
an O
M O
( O
r O
) O
of O
132 O
, O
0 O
, O
and O
two O
monomeric O
digestion O
products O
, O
AHM O
- O
1 O
( O
with O
an O
M O
( O
r O
) O
of O
64 O
, O
000 O
) O
and O
AHM O
- O
2 O
( O
with O
an O
M O
( O
r O
) O
of O
58 O
, O
000 O
) O
. O

The O
CD46 O
molecule O
is O
a O
receptor O
for O
measles B
virus I
( I
MV I
) I
, O
CD46 O
, O
which O
protects O
autologous O
cells O
from O
complement O
- O
mediated O
damage O
, O
exists O
in O
several O
isoforms O
which O
are O
variably O
expressed O
in O
different O
human O
tissues O
, O
These O
isoforms O
differ O
in O
their O
cytoplasmic O
and O
transmembrane O
regions O
and O
in O
a O
small O
portion O
of O
their O
proximal O
extracytoplasmic O
regions O
. O

To O
examine O
the O
role O
of O
the O
cytoplasmic O
and O
transmembrane O
regions O
of O
CD46 O
in O
MV O
infection O
, O
mouse O
M12 O
B O
cells O
stably O
expressing O
a O
transmembrane O
or O
a O
chimeric O
glycosylphosphatidylinositol B
( I
GPI I
) I
- O
anchored O
form O
of O
CD46 O
( O
CD46 O
- O
GPI O
) O
were O
used O
. O

measles B
virus I
( I
MV I
) I
- O
specific O
transcription O
in O
human O
brain O
cells O
is O
characterized O
by O
particularly O
low O
abundances O
of O
the O
distal O
mRNAs O
encoding O
the O
MV O
envelope O
proteins O
. O

After O
stable O
transfection O
of O
MxA O
, O
human O
glioblastoma O
cells O
( O
U O
- O
87 O
- O
MxA O
) O
released O
50 O
- O
to O
100 O
- O
fold O
less O
infectious O
virus O
and O
expression O
of O
viral O
proteins O
was O
highly O
restricted O
. O

Two O
cellular O
proteins O
, O
membrane B
cofactor I
protein I
( I
MCP I
) I
and O
moesin O
, O
were O
reported O
recently O
to O
be O
functionally O
associated O
with O
the O
initiation O
of O
a O
measles O
virus O
infection O
. O

Among O
surface O
- O
biotinylated O
proteins O
from O
a O
human B
rectal I
tumor I
cell I
line I
( I
HRT I
) I
, O
measles O
virus O
was O
able O
to O
bind O
only O
to O
a O
67 O
- O
kDa O
protein O
that O
was O
identified O
as O
MCP O
. O

The O
virus O
recognized O
different O
isoforms O
of O
MCP O
expressed O
from O
human O
( O
HRT O
and O
HeLa O
) O
and O
simian O
( O
Vero O
) O
cell O
lines O
. O

Membrane O
fusion O
caused O
by O
measles B
virus I
( I
MV I
) I
is O
a O
function O
of O
the O
fusion O
( O
F O
) O
protein O
. O

The O
biological O
activity O
of O
the O
MV O
F O
protein O
is O
generated O
by O
endoproteolytic O
cleavage O
of O
a O
precursor O
protein O
( O
F O
- O
0 O
) O
into O
a O
large O
F O
- O
1 O
subunit O
and O
a O
smaller O
F O
- O
2 O
subunit O
held O
together O
by O
disulfide O
bonds O
. O

The O
cleavage O
site O
consists O
of O
a O
cluster O
of O
five O
basic O
amino O
acids O
( O
amino O
acids O
108 O
to O
112 O
) O
within O
the O
predicted O
primary O
structure O
of O
the O
F O
protein O
. O

To O
investigate O
the O
role O
of O
the O
arginine O
residue O
at O
the O
carboxy O
terminus O
of O
the O
F O
- O
2 O
subunit O
( O
arginine O
112 O
) O
, O
site O
- O
directed O
mutagenesis O
was O
used O
to O
construct O
a O
cleavage O
mutant O
of O
the O
MV O
F O
protein O
in O
which O
this O
arginine O
residue O
was O
changed O
to O
a O
leucine O
residue O
. O

Epstein B
- I
Barr I
virus I
( I
EBV I
) I
, O
a O
herpesvirus O
with O
oncogenic O
potential O
, O
is O
camouflaged O
with O
glycoprotein O
350 O
/ O
220 O
, O
which O
mimics O
the O
human O
ligand O
C3dg O
and O
thereby O
binds O
to O
and O
exploits O
complement O
receptor O
type O
2 O
( O
CR2 O
; O
CD21 O
) O
, O
the O
EBV O
receptor O
. O

We O
have O
previously O
demonstrated O
that O
Borna B
disease I
virus I
( I
BDV I
) I
has O
a O
negative B
nonsegmented I
single I
- I
stranded I
( I
NNS I
) I
RNA O
genome O
that O
replicates O
in O
the O
nucleus O
of O
infected O
cells O
. O

We O
have O
identified O
five O
main O
open B
reading I
frames I
( I
ORFs I
) I
. O

The O
role O
of O
N O
- O
linked O
glycosylation O
in O
the O
biological O
activity O
of O
the O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
protein O
was O
analyzed O
by O
expressing O
glycosylation O
mutants O
with O
recombinant O
vaccinia O
virus O
vectors O
. O

6 O
) O
which O
inhibited O
measles B
virus I
( I
MV I
) I
binding O
to O
host O
cells O
was O
previously O
used O
to O
characterize O
a O
57 O
- O
to O
67 O
- O
kDa O
cell O
surface O
glycoprotein O
as O
a O
potential O
MV O
receptor O
. O

In O
the O
present O
work O
, O
this O
glycoprotein O
( O
gp57 O
/ O
67 O
) O
was O
immunopurified O
, O
and O
N O
- O
terminal O
amino O
acid O
sequencing O
identified O
it O
as O
human O
membrane O
cofactor O
protein O
( O
CD46 O
) O
, O
a O
member O
of O
the O
regulators O
of O
complement O
activation O
gene O
cluster O
. O

We O
have O
obtained O
a O
polyclonal O
antiserum O
, O
N O
- O
BE O
, O
against O
the O
denatured O
, O
amino O
- O
terminal O
half O
of O
the O
measles B
virus I
( I
MV I
) I
nucleocapsid I
( I
N I
) I
protein O
and O
a O
monoclonal B
antibody I
( I
Mab I
) I
, O
N46 O
, O
which O
recognizes O
a O
conformation O
- O
dependent O
epitope O
in O
the O
same O
region O
. O

The O
mature O
N O
protein O
is O
a O
target O
for O
interaction O
with O
the O
phosphoprotein B
( I
P I
protein I
) I
of O
MV O
. O

Reconstituted O
Sendai O
virus O
envelopes O
containing O
both O
the O
fusion O
( O
F O
) O
protein O
and O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
( O
F O
, O
HN O
- O
virosomes O
) O
or O
only O
the O
F O
protein O
( O
F O
- O
virosomes O
) O
were O
prepared O
by O
solubilization O
of O
the O
intact O
virus O
with O
Triton O
X O
- O
100 O
followed O
by O
its O
removal O
by O
using O
SM2 O
Bio O
- O
Beads O
. O

Viral O
envelopes O
containing O
HN O
whose O
disulfide O
bonds O
were O
irreversibly O
reduced O
( O
HN O
( O
red O
) O
) O
were O
also O
prepared O
by O
treating O
the O
envelopes O
with O
dithiothreitol O
followed O
by O
dialysis O
( O
F O
, O
HN O
( O
red O
) O
- O
virosomes O
) O
. O

Both O
F O
- O
virosomes O
and O
F O
, O
HN O
( O
red O
) O
- O
virosomes O
induced O
hemolysis O
of O
erythrocytes O
in O
the O
presence O
of O
wheat O
germ O
agglutinin O
, O
but O
the O
rates O
and O
extents O
were O
markedly O
lower O
than O
those O
for O
hemolysis O
induced O
by O
F O
, O
HN O
- O
virosomes O
. O

The O
expression O
of O
measles B
virus I
( I
MV I
) I
in O
six O
different O
permanent O
human O
glioma O
cell O
lines O
( O
D O
- O
54 O
, O
U O
- O
251 O
, O
U O
- O
138 O
, O
U O
- O
105 O
, O
U O
- O
373 O
, O
and O
D O
- O
32 O
) O
was O
analyzed O
. O

This O
pronounced O
restriction O
was O
not O
paralleled O
to O
a O
comparable O
level O
by O
an O
inhibition O
of O
the O
synthesis O
and O
biological O
activity O
in O
vitro O
of O
virus O
- O
specific O
mRNAs O
as O
shown O
by O
quantitative O
Northern O
( O
RNA O
) O
blot O
analyses O
and O
in O
vitro O
translation O
. O

The O
transmembrane O
fusion O
( O
F O
) O
glycoprotein O
of O
measles O
virus O
is O
an O
important O
target O
antigen O
of O
human O
HLA O
class O
I O
- O
and O
class O
II O
- O
restricted O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
. O

Three O
distinct O
sequences O
recognized O
by O
three O
different O
HLA O
class O
II O
( O
DQw1 O
, O
DR2 O
, O
and O
DR4 O
/ O
w53 O
) O
- O
restricted O
CTL O
clones O
appear O
to O
cluster O
between O
amino O
acids O
379 O
and O
466 O
of O
F O
, O
thus O
defining O
an O
important O
T O
- O
cell O
epitope O
area O
of O
F O
. O

The O
etiological O
agent O
, O
rinderpest B
virus I
( I
RPV I
) I
, O
is O
a O
member O
of O
the O
family O
Paramyxoviridae O
and O
the O
genus O
Morbillivirus O
. O

Immune O
responses O
to O
both O
the O
hemagglutinin B
( I
H I
) I
and O
the O
fusion O
( O
F O
) O
antigens O
of O
morbilliviruses O
play O
an O
important O
role O
in O
the O
prevention O
of O
infection O
, O
and O
only O
attenuated O
live O
vaccines O
have O
been O
shown O
to O
provide O
protective O
immunity O
against O
the O
group O
. O

Our O
previous O
study O
, O
however O
, O
demonstrated O
complete O
protection O
of O
cattle O
vaccinated O
with O
infectious O
vaccinia O
virus B
recombinants I
expressing I
the I
H I
( I
vRVH I
) I
or O
F O
( O
vRVF O
) O
protein O
alone O
, O
even O
in O
the O
presence O
of O
only O
4 O
U O
of O
serum B
- I
neutralizing I
( I
SN I
) I
antibody O
to O
RPV O
( O
T O
. O

We O
have O
constructed O
recombinant O
baculoviruses O
that O
express O
the O
F O
( O
F O
( O
b O
) O
) O
and O
H O
( O
H O
( O
b O
) O
) O
glycoproteins O
of O
RPV O
. O

Cattle O
vaccinated O
with O
F O
( O
b O
) O
or O
H O
( O
b O
) O
or O
a O
mixture O
of O
both O
antigens O
were O
not O
protected O
from O
challenge O
inoculation O
with O
RPV O
, O
even O
when O
the O
SN O
titer O
was O
greater O
than O
in O
cattle O
vaccinated O
with O
vRVF O
alone O
. O

The O
genomic O
3 O
' O
noncoding B
region I
( I
NCR I
) I
of O
nonsegmented O
negative O
- O
strand O
RNA O
viruses O
contains O
recognition O
site O
( O
s O
) O
for O
the O
polymerase O
complex O
, O
while O
the O
RNA O
plus O
- O
strand O
leader B
sequence I
( I
LS I
) I
is O
probably O
involved O
in O
RNA O
encapsidation O
. O

Here O
we O
report O
that O
cellular O
proteins O
interact O
with O
the O
genomic O
3 O
' O
NCR O
and O
with O
the O
plus O
- O
strand O
LS O
RNA O
of O
an O
important O
human O
pathogen O
, O
measles B
virus I
( I
MV I
) I
, O
a O
member O
of O
the O
family O
Paramyxoviridae O
. O

measles B
virus I
( I
MV I
) I
infection O
of O
U937 O
cell O
or O
peripheral O
blood O
leukocyte O
cultures O
was O
shown O
to O
induce O
changes O
in O
the O
expression O
of O
leukocyte B
function I
antigen I
1 I
( I
LFA I
- I
1 I
) I
and O
cause O
marked O
aggregation O
of O
these O
cells O
. O

Street B
rabies I
virus I
( I
SRV I
) I
- O
infected O
T O
- O
lymphocyte O
- O
deficient O
( O
nude O
) O
mice O
, O
in O
contrast O
to O
euthymic O
mice O
, O
did O
not O
develop O
hindlimb O
paralysis O
prior O
to O
death O
. O

To O
document O
the O
role O
of O
T O
lymphocytes O
in O
rabies O
virus O
- O
associated O
paralysis O
, O
10 O
( O
8 O
) O
spleen O
cells O
from O
normal O
immunocompetent O
euthymic O
mice O
were O
transferred O
to O
nude O
mice O
and O
the O
recipient O
mice O
were O
challenged O
with O
SRV O
. O

Mice O
receiving O
10 O
( O
8 O
) O
rabies O
virus O
- O
immune O
spleen O
cells O
did O
not O
become O
paralyzed O
and O
did O
not O
die O
. O

cDNA O
clones O
of O
the O
genes O
encoding O
either O
the O
Hemagglutinin B
( I
HA I
) I
or O
fusion O
( O
F O
) O
proteins O
of O
the O
Edmonston O
strain O
of O
measles B
virus I
( I
MV I
) I
were O
expressed O
in O
vaccina O
virus O
recombinants O
. O

Inoculation O
of O
dogs O
with O
the O
vaccinia B
virus I
- I
MV I
F I
recombinant I
( I
VV I
- I
MVF I
) I
did O
not O
give O
rise O
to O
detectable O
MV O
- O
neutralizing O
antibody O
. O

Inoculation O
of O
dogs O
with O
the O
vaccinia B
virus I
- I
MV I
HA I
recombinant I
( I
VV I
- I
MVHA I
) I
or O
coinoculation O
with O
both O
recombinants O
( O
VV O
- O
MVF O
and O
VV O
- O
MVHA O
) O
induced O
significant O
MV O
- O
neutralizing O
titers O
that O
were O
increased O
following O
a O
booster O
inoculation O
. O

Inoculation O
of O
dogs O
with O
the O
vaccinia O
virus O
recombinants O
or O
with O
MV O
failed O
to O
induce O
canine B
distemper I
virus I
( I
CDV I
) I
- O
neutralizing O
antibodies O
. O

Upon O
challenge O
with O
a O
lethal O
dose O
of O
virulent O
CDV O
, O
signs O
of O
infection O
were O
observed O
in O
dogs O
inoculated O
with O
( O
VV O
- O
MVF O
) O
. O

An O
edited O
mRNA O
transcribed O
from O
the O
phosphoprotein B
( I
P I
) I
gene O
of O
measles B
virus I
( I
MV I
) I
has O
been O
predicted O
to O
encode O
a O
cysteine O
- O
rich O
protein O
designated O
V O
. O

The O
MV O
V O
protein O
( O
40 O
kDa O
) O
was O
detected O
in O
MV O
- O
infected O
cells O
in O
a O
diffuse O
cytoplasmic O
distribution O
, O
a O
predominant O
subcellular O
localization O
distinct O
from O
that O
of O
virus O
nucleocapsids O
. O

Antiserum O
directed O
against O
a O
peptide O
( O
PV2 O
) O
corresponding O
to O
amino O
acids O
65 O
to O
87 O
of O
the O
V O
protein O
amino O
acid O
recognized O
the O
P O
protein O
but O
not O
the O
V O
protein O
, O
indicating O
that O
the O
P O
and O
V O
proteins O
may O
be O
folded O
differently O
at O
or O
near O
this O
region O
so O
that O
the O
PV2 O
sequence O
is O
in O
an O
exposed O
position O
at O
the O
surface O
of O
the O
P O
protein O
but O
not O
at O
the O
surface O
of O
the O
V O
protein O
. O

The O
nucleotide O
sequence O
of O
the O
P O
gene O
of O
human B
parainfluenza I
virus I
type I
1 I
( I
PIV1 I
) I
was O
determined O
from O
cloned O
cDNA O
copies O
of O
the O
mRNA O
. O

By O
analogy O
with O
the O
gene O
organization O
of O
Sendai O
virus O
, O
two O
open O
reading O
frames O
in O
the O
mRNA O
sense O
of O
the O
gene O
were O
identified O
as O
coding O
sequences O
for O
the O
P O
protein O
( O
568 O
amino O
acids O
with O
an O
estimated O
molecular O
weight O
of O
64 O
, O
655 O
) O
and O
the O
C O
protein O
( O
204 O
amino O
acids O
with O
an O
estimated O
molecular O
weight O
of O
24 O
, O
108 O
) O
. O

measles B
virus I
( I
MeV I
) I
is O
an O
enveloped O
RNA O
virus O
bearing O
two O
envelope O
glycoproteins O
, O
the O
hemagglutinin B
( I
H I
) I
and O
fusion O
( O
F O
) O
proteins O
. O

MeV O
may O
persist O
in O
the O
brain O
, O
infecting O
neurons O
and O
causing O
fatal O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

Since O
neurons O
do O
not O
express O
either O
of O
the O
MeV O
receptors O
, O
signaling O
lymphocytic O
activation O
molecule O
( O
SLAM O
; O
also O
called O
CD150 O
) O
and O
nectin O
- O
4 O
, O
how O
MeV O
propagates O
in O
neurons O
is O
unknown O
. O

The O
results O
suggest O
that O
weak O
interactions O
of O
the O
H O
protein O
with O
certain O
molecules O
( O
putative O
neuron O
receptors O
) O
trigger O
hyperfusogenic O
F O
proteins O
in O
SSPE O
patients O
. O

IMPORTANCE O
measles B
virus I
( I
MeV I
) I
may O
persist O
in O
the O
brain O
, O
causing O
incurable O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

Because O
neurons O
, O
the O
main O
target O
in O
SSPE O
, O
do O
not O
express O
receptors O
for O
wild B
- I
type I
( I
WT I
) I
MeV O
, O
how O
MeV O
propagates O
in O
the O
brain O
is O
a O
key O
question O
for O
the O
disease O
. O

Recent O
studies O
have O
demonstrated O
that O
specific O
substitutions O
in O
the O
MeV O
fusion O
( O
F O
) O
protein O
are O
critical O
for O
neuropathogenicity O
. O

Fatal O
neurological O
syndromes O
can O
occur O
after O
measles B
virus I
( I
MeV I
) I
infection O
of O
the O
brain O
. O

The O
mechanisms O
controlling O
MeV O
spread O
within O
the O
central B
nervous I
system I
( I
CNS I
) I
remain O
poorly O
understood O
. O

We O
analyzed O
the O
role O
of O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
receptor O
( O
IFNAR O
) O
signaling O
in O
the O
control O
of O
MeV O
infection O
in O
a O
murine O
model O
of O
brain O
infection O
. O

Using O
organotypic O
brain O
cultures O
( O
OBC O
) O
from O
wild O
- O
type O
and O
IFNAR O
- O
knockout O
( O
IFNAR O
( O
KO O
) O
) O
transgenic O
mice O
ubiquitously O
expressing O
the O
human O
SLAM O
( O
CD150 O
) O
receptor O
, O
the O
heterogeneity O
of O
the O
permissiveness O
of O
different O
CNS O
cell O
types O
to O
MeV O
infection O
was O
characterized O
. O

This O
selective O
loss O
of O
permissiveness O
to O
MeV O
infection O
was O
not O
observed O
in O
IFNAR O
( O
KO O
) O
mouse O
OBC O
. O

IMPORTANCE O
measles B
virus I
( I
MeV I
) I
can O
infect O
the O
central B
nervous I
system I
( I
CNS I
) I
, O
with O
dramatic O
consequences O
. O

Here O
, O
we O
highlight O
for O
the O
first O
time O
the O
crucial O
role O
of O
the O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
response O
not O
only O
in O
the O
control O
of O
CNS O
invasion O
but O
also O
in O
the O
early O
permissiveness O
of O
glial O
cells O
to O
measles O
virus O
infection O
. O

During O
a O
measles B
virus I
( I
MeV I
) I
epidemic O
in O
2009 O
in O
South O
Africa O
, O
measles B
inclusion I
body I
encephalitis I
( I
MIBE I
) I
was O
identified O
in O
several O
HIV O
- O
infected O
patients O
. O

Years O
later O
, O
children O
are O
presenting O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

IMPORTANCE O
Measles O
virus O
can O
invade O
the O
central B
nervous I
system I
( I
CNS I
) I
and O
cause O
severe O
neurological O
complications O
, O
such O
as O
MIBE O
and O
SSPE O
. O

measles B
virus I
( I
MV I
) I
usually O
causes O
acute O
infection O
but O
in O
rare O
cases O
persists O
in O
the O
brain O
, O
resulting O
in O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

Since O
human O
neurons O
, O
an O
important O
target O
affected O
in O
the O
disease O
, O
do O
not O
express O
the O
known O
MV O
receptors O
( O
signaling O
lymphocyte O
activation O
molecule O
[ O
SLAM O
] O
and O
nectin O
4 O
) O
, O
how O
MV O
infects O
neurons O
and O
spreads O
between O
them O
is O
unknown O
. O

Recent O
studies O
have O
shown O
that O
many O
virus O
strains O
isolated O
from O
SSPE O
patients O
possess O
substitutions O
in O
the O
extracellular O
domain O
of O
the O
fusion O
( O
F O
) O
protein O
which O
confer O
enhanced O
fusion O
activity O
. O

We O
show O
here O
that O
a O
hyperfusogenic O
mutant O
MV O
, O
IC323 O
- O
F O
( O
T461I O
) O
- O
EGFP O
( O
IC323 O
with O
a O
fusion O
- O
enhancing O
T461I O
substitution O
in O
the O
F O
protein O
and O
expressing O
enhanced O
green O
fluorescent O
protein O
) O
, O
but O
not O
the O
wild O
- O
type O
MV O
, O
spreads O
in O
differentiated O
NT2 O
cells O
, O
a O
widely O
used O
human O
neuron O
model O
. O

Confocal O
time O
- O
lapse O
imaging O
revealed O
the O
cell O
- O
to O
- O
cell O
spread O
of O
IC323 O
- O
F O
( O
T461I O
) O
- O
EGFP O
between O
NT2 O
neurons O
without O
syncytium O
formation O
. O

The O
spread O
of O
IC323F O
( O
T461I O
) O
- O
EGFP O
was O
inhibited O
by O
a O
fusion O
inhibitor O
peptide O
as O
well O
as O
by O
some O
but O
not O
all O
of O
the O
anti O
- O
hemagglutinin O
antibodies O
which O
neutralize O
SLAM O
- O
or O
nectin O
- O
4 O
- O
dependent O
MV O
infection O
, O
suggesting O
the O
presence O
of O
a O
distinct O
neuronal O
receptor O
. O

IMPORTANCE O
measles B
virus I
( I
MV I
) I
, O
in O
rare O
cases O
, O
persists O
in O
the O
human B
central I
nervous I
system I
( I
CNS I
) I
and O
causes O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
several O
years O
after O
acute O
infection O
. O

Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
is O
caused O
by O
persistent O
measles B
virus I
( I
MV I
) I
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

Since O
human O
neurons O
, O
its O
main O
target O
cells O
, O
do O
not O
express O
known O
MV O
receptors O
( O
signaling O
lymphocyte O
activation O
molecule O
[ O
SLAM O
] O
and O
nectin O
4 O
) O
, O
it O
remains O
to O
be O
understood O
how O
MV O
infects O
and O
spreads O
in O
them O
. O

We O
have O
recently O
reported O
that O
fusion O
- O
enhancing O
substitutions O
in O
the O
extracellular O
domain O
of O
the O
MV O
fusion O
( O
F O
) O
protein O
( O
T461I O
and O
S103I O
/ O
N462S O
/ O
N465S O
) O
, O
which O
are O
found O
in O
multiple O
SSPE O
virus O
isolates O
, O
promote O
MV O
spread O
in O
human O
neuroblastoma O
cell O
lines O
and O
brains O
of O
suckling O
hamsters O
. O

IMPORTANCE O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
is O
a O
fatal O
disease O
caused O
by O
persistent O
measles B
virus I
( I
MV I
) I
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

measles B
virus I
( I
MV I
) I
isolates O
from O
patients O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
differ O
from O
wild O
- O
type O
MV O
virologically O
. O

When O
nude O
mice O
were O
challenged O
with O
2 O
x O
10 O
( O
2 O
) O
PFU O
of O
the O
brain O
- O
derived O
virus O
, O
the O
mean O
survival O
duration O
was O
34 O
. O

7 O
days O
, O
which O
was O
significantly O
shorter O
than O
that O
of O
the O
mice O
challenged O
with O
4 O
x O
10 O
( O
4 O
) O
PFU O
of O
the O
Edmonston O
strain O
( O
P O
< O
0 O
. O

Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
is O
a O
fatal O
degenerative O
disease O
caused O
by O
persistent O
measles B
virus I
( I
MV I
) I
infection O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
. O

From O
the O
genetic O
study O
of O
MV O
isolates O
obtained O
from O
SSPE O
patients O
, O
it O
is O
thought O
that O
defects O
of O
the O
matrix B
( I
M I
) I
protein O
play O
a O
crucial O
role O
in O
MV O
pathogenicity O
in O
the O
CNS O
. O

In O
this O
study O
, O
we O
report O
several O
notable O
mutations O
in O
the O
extracellular O
domain O
of O
the O
MV O
fusion O
( O
F O
) O
protein O
, O
including O
those O
found O
in O
multiple O
SSPE O
strains O
. O

The O
F O
proteins O
with O
these O
mutations O
induced O
syncytium O
formation O
in O
cells O
lacking O
SLAM O
and O
nectin O
4 O
( O
receptors O
used O
by O
wild O
- O
type O
MV O
) O
, O
including O
human O
neuronal O
cell O
lines O
, O
when O
expressed O
together O
with O
the O
attachment O
protein O
hemagglutinin O
. O

Actin B
filament I
( I
F I
- I
actin I
) I
is O
believed O
to O
be O
involved O
in O
measles B
virus I
( I
MV I
) I
assembly O
as O
a O
cellular O
factor O
, O
but O
the O
precise O
roles O
remain O
unknown O
. O

Here O
we O
show O
that O
Phe O
at O
position O
50 O
of O
the O
MV O
matrix B
( I
M I
) I
protein O
is O
important O
for O
its O
association O
with O
F O
- O
actin O
, O
through O
which O
the O
function O
of O
the O
M O
protein O
is O
regulated O
. O

In O
plasmid O
- O
expressed O
or O
MV O
- O
infected O
cells O
, O
a O
coimmunoprecipitation O
study O
revealed O
that O
the O
wild B
- I
type I
M I
( I
M I
- I
WT I
) I
protein O
associated O
strongly O
with O
F O
- O
actin O
but O
only O
weakly O
with O
the O
cytoplasmic O
tail O
of O
the O
hemagglutinin B
( I
H I
) I
protein O
. O

Since O
the O
F50P O
mutation O
allowed O
the O
M O
protein O
the O
enhanced O
interaction O
with O
the O
H O
protein O
in O
return O
for O
the O
sharply O
declined O
association O
with O
F O
- O
actin O
, O
the O
mutant O
M O
( O
M O
- O
F50P O
) O
protein O
strongly O
inhibited O
MV O
cell O
- O
cell O
fusion O
and O
promoted O
the O
uptake O
of O
the O
H O
protein O
into O
virus O
particles O
. O

Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
is O
a O
fatal O
sequela O
associated O
with O
measles O
and O
is O
caused O
by O
persistent O
infection O
of O
the O
brain O
with O
measles B
virus I
( I
MV I
) I
. O

Through O
the O
establishment O
of O
an O
efficient O
reverse O
genetics O
system O
, O
a O
recombinant B
SI I
strain I
expressing I
a I
green I
fluorescent I
protein I
( I
rSI I
- I
AcGFP I
) I
was O
generated O
. O

Analyses O
using O
a O
recombinant O
MV O
possessing O
a O
chimeric O
genome O
between O
those O
of O
the O
SI O
strain O
and O
a O
wild O
- O
type O
MV O
strain O
indicated O
that O
the O
membrane O
- O
associated O
protein O
genes O
( O
M O
, O
F O
, O
and O
H O
) O
were O
responsible O
for O
the O
altered O
growth O
phenotype O
of O
the O
SI O
strain O
. O

In O
paramyxoviruses O
, O
the O
matrix B
( I
M I
) I
protein O
mediates O
the O
interaction O
between O
the O
envelope O
and O
internal O
proteins O
during O
particle O
assembly O
and O
egress O
. O

In O
measles B
virus I
( I
MeV I
) I
, O
M O
mutations O
, O
such O
as O
those O
found O
in O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
strains O
, O
and O
differences O
in O
vaccine O
and O
wild O
- O
type O
M O
proteins O
can O
affect O
the O
strength O
of O
interaction O
with O
the O
envelope O
glycoproteins O
, O
assembly O
efficiency O
, O
and O
spread O
. O

However O
, O
the O
contribution O
of O
the O
M O
protein O
to O
the O
replication O
and O
pathogenesis O
of O
the O
closely O
related O
canine B
distemper I
virus I
( I
CDV I
) I
has O
not O
been O
characterized O
. O

measles B
virus I
( I
MV I
) I
is O
the O
causative O
agent O
for O
acute O
measles O
and O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

The O
recombinant O
MV O
system O
was O
adapted O
for O
the O
current O
study O
to O
identify O
the O
gene O
( O
s O
) O
responsible O
for O
neurovirulence O
in O
our O
hamster O
model O
. O

Measles O
is O
a O
highly O
contagious O
human O
disease O
caused O
by O
measles B
virus I
( I
MeV I
) I
and O
remains O
the O
leading O
cause O
of O
death O
in O
children O
, O
particularly O
in O
developing O
countries O
. O

Wild O
- O
type O
MeV O
preferentially O
infects O
lymphocytes O
by O
using O
signaling B
lymphocytic I
activation I
molecule I
( I
SLAM I
) I
, O
whose O
expression O
is O
restricted O
to O
hematopoietic O
cells O
, O
as O
a O
receptor O
. O

Here O
we O
identified O
CD147 O
/ O
EMMPRIN O
( O
extracellular O
matrix O
metalloproteinase O
inducer O
) O
, O
a O
transmembrane O
glycoprotein O
, O
which O
acts O
as O
a O
receptor O
for O
MeV O
on O
epithelial O
cells O
. O

Furthermore O
, O
we O
found O
the O
incorporation O
of O
cyclophilin B
B I
( I
CyPB I
) I
, O
a O
cellular O
ligand O
for O
CD147 O
, O
in O
MeV O
virions O
, O
and O
showed O
that O
inhibition O
of O
CypB O
incorporation O
significantly O
attenuated O
SLAM O
- O
independent O
infection O
on O
epithelial O
cells O
, O
while O
it O
had O
no O
effect O
on O
SLAM O
- O
dependent O
infection O
. O

To O
date O
, O
MeV O
infection O
was O
considered O
to O
be O
triggered O
by O
binding O
of O
its O
hemagglutinin B
( I
H I
) I
protein O
and O
cellular O
receptors O
. O

Our O
previous O
studies O
using O
intranasal O
inoculation O
of O
mice O
with O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
vaccine O
vectors O
showed O
persistence O
of O
vector O
genomic B
RNA I
( I
gRNA I
) I
for O
at O
least O
60 O
days O
in O
lymph O
nodes O
in O
the O
absence O
of O
detectable O
infectious O
virus O
. O

A O
functional O
enrichment O
analysis O
to O
identify O
which O
host O
pathways O
were O
perturbed O
during O
each O
of O
these O
infections O
identified O
several O
pathways O
related O
to O
cholesterol O
biosynthesis O
, O
including O
cholesterol O
metabolic O
processes O
, O
hydroxymethyl O
- O
glutaryl O
- O
coenzyme B
A I
( I
CoA I
) I
reductase O
activity O
, O
and O
acetyl O
- O
CoA O
C O
- O
acetyltransferase O
activity O
. O

Infectious O
and O
inflammatory O
diseases O
of O
the O
CNS O
are O
often O
characterized O
by O
a O
robust O
B O
- O
cell O
response O
that O
manifests O
as O
increased O
intrathecal O
immunoglobulin B
G I
( I
IgG I
) I
synthesis O
and O
the O
presence O
of O
oligoclonal O
bands O
. O

We O
previously O
used O
laser O
capture O
microdissection O
and O
single O
- O
cell O
PCR O
to O
analyze O
the O
IgG O
variable O
regions O
of O
plasma O
cells O
from O
the O
brain O
of O
a O
patient O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

Five O
of O
eight O
human O
IgG1 O
recombinant B
antibodies I
( I
rAbs I
) I
derived O
from O
SSPE O
brain O
plasma O
cell O
clones O
recognized O
the O
measles B
virus I
( I
MV I
) I
nucleocapsid O
protein O
, O
confirming O
that O
the O
antibody O
response O
in O
SSPE O
targets O
primarily O
the O
agent O
causing O
disease O
. O

gamma B
interferon I
( I
IFN I
- I
gamma I
) I
has O
been O
shown O
to O
be O
increased O
in O
sera O
from O
patients O
with O
acute O
measles O
and O
after O
vaccination O
, O
to O
exhibit O
protective O
functions O
in O
brains O
of O
patients O
with O
subacute O
sclerosing O
panencephalitis O
, O
and O
to O
mediate O
a O
noncytolytic O
clearance O
of O
measles B
virus I
( I
MV I
) I
from O
rodent O
brains O
. O

The O
antiviral O
activity O
induced O
by O
IFN O
- O
gamma O
correlates O
with O
the O
induction O
of O
indoleamine B
2 I
, I
3 I
- I
dioxygenase I
( I
IDO I
) I
, O
an O
enzyme O
of O
the O
tryptophan O
degradation O
pathway O
known O
to O
mediate O
antiviral O
as O
well O
as O
antibacterial O
and O
antiparasitic O
effects O
. O

Numerous O
mutations O
are O
found O
in O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
viruses O
, O
and O
the O
M O
gene O
is O
the O
gene O
most O
commonly O
affected O
. O

The O
deletion O
of O
a O
single O
U O
residue O
in O
the O
U O
tract O
of O
the O
Osaka O
- O
1 O
strain O
( O
3 O
' O
- O
UAAUAUUUUU O
- O
5 O
' O
) O
compared O
with O
the O
consensus O
sequence O
resulted O
in O
a O
marked O
reduction O
of O
the O
expression O
of O
the O
downstream O
reporter O
gene O
. O

In O
addition O
, O
the O
expression O
of O
the O
downstream O
gene O
was O
markedly O
decreased O
by O
( O
i O
) O
the O
substitution O
of O
a O
C O
residue O
in O
the O
U O
tract O
of O
the O
P O
gene O
end O
of O
the O
OSA O
- O
2 O
/ O
Fr O
/ O
B O
strain O
of O
the O
Osaka O
- O
2 O
virus O
( O
3 O
' O
- O
UGAUAUUCUU O
- O
5 O
' O
compared O
with O
the O
sequence O
3 O
' O
- O
UGAUAUUUUU O
- O
5 O
' O
from O
a O
sibling O
virus O
of O
the O
same O
strain O
, O
OSA O
- O
2 O
/ O
Fr O
/ O
V O
) O
, O
and O
( O
ii O
) O
the O
substitution O
of O
a O
G O
in O
the O
sequence O
of O
the O
P O
gene O
end O
of O
the O
Yamagata O
- O
1 O
strain O
at O
a O
variable O
site O
immediately O
upstream O
from O
the O
six O
- O
U O
tract O
( O
3 O
' O
- O
UGAUGUUUUUU O
- O
5 O
' O
instead O
of O
3 O
' O
- O
UGAUUUUUUUU O
- O
5 O
' O
) O
. O

Wild O
- O
type O
measles B
virus I
( I
MV I
) I
strains O
use O
human B
signaling I
lymphocyte I
activation I
molecule I
( I
SLAM I
) I
as O
a O
cellular O
receptor O
, O
while O
vaccine O
strains O
such O
as O
the O
Edmonston O
strain O
can O
use O
both O
SLAM O
and O
CD46 O
as O
receptors O
. O

Although O
the O
expression O
of O
SLAM O
is O
restricted O
to O
cells O
of O
the O
immune O
system O
( O
lymphocytes O
, O
dendritic O
cells O
, O
and O
monocytes O
) O
, O
histopathological O
studies O
with O
humans O
and O
experimentally O
infected O
monkeys O
have O
shown O
that O
MV O
also O
infects O
SLAM O
- O
negative O
cells O
, O
including O
epithelial O
, O
endothelial O
, O
and O
neuronal O
cells O
. O

In O
an O
attempt O
to O
explain O
these O
findings O
, O
we O
produced O
the O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
- O
expressing O
recombinant O
MV O
( O
IC323 O
- O
EGFP O
) O
based O
on O
the O
wild O
- O
type O
IC O
- O
B O
strain O
. O

These O
results O
indicate O
that O
W O
can O
infect O
a O
variety O
of O
cells O
, O
albeit O
with O
a O
low O
efficiency O
, O
by O
using O
an O
as O
yet O
unidentified O
receptor O
( O
s O
) O
other O
than O
SLAM O
or O
CD46 O
, O
in O
part O
explaining O
the O
observed O
MV O
infection O
of O
SLAM O
- O
negative O
cells O
in O
vivo O
. O

measles B
virus I
( I
MV I
) I
can O
infect O
the O
central O
nervous O
system O
and O
, O
in O
rare O
cases O
, O
causes O
subacute O
sclerosing O
panencephalitis O
, O
characterized O
by O
a O
progressive O
degeneration O
of O
neurons O
. O

MV O
glycoproteins O
, O
the O
fusion B
protein I
( I
F I
) I
and O
hemagglutinin B
( I
H I
) I
, O
the O
matrix B
protein I
( I
M I
) I
, O
and O
the O
phosphoprotein B
( I
P I
) I
, O
which O
is O
part O
of O
the O
viral O
ribonucleoprotein O
complex O
, O
were O
all O
sorted O
to O
the O
dendrites O
. O

Neurons O
of O
the O
mammalian O
central B
nervous I
system I
( I
CNS I
) I
are O
an O
essential O
and O
largely O
nonrenewable O
cell O
population O
. O

In O
a O
transgenic O
mouse O
model O
of O
measles B
virus I
( I
MV I
) I
infection O
of O
neurons O
, O
we O
have O
previously O
shown O
that O
the O
host O
T O
- O
cell O
response O
was O
required O
for O
resolution O
of O
infection O
in O
susceptible O
adult O
mice O
. O

When O
susceptible O
mice O
were O
intercrossed O
with O
specific O
immune O
knockout O
mice O
, O
a O
critical O
role O
for O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
was O
identified O
in O
protection O
against O
MV O
infection O
and O
CNS O
disease O
. O

An O
undifferentiated O
mouse O
neuroblastoma O
cell O
line O
( O
TMN O
) O
was O
infected O
with O
the O
vaccine O
strain O
of O
measles O
virus O
( O
MveGFP O
) O
, O
which O
expresses O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
, O
MVeGFP O
infected O
the O
cells O
, O
and O
cell O
- O
to O
- O
cell O
spread O
was O
studied O
by O
virtue O
of O
the O
resulting O
EGFP O
autofluorescence O
, O
using O
real O
- O
time O
confocal O
microscopy O
, O
Cells O
were O
differentiated O
to O
a O
neuronal O
phenotype O
, O
and O
extended O
processes O
, O
which O
interconnected O
the O
cells O
, O
were O
observed O
. O

It O
was O
also O
possible O
to O
infect O
the O
differentiated O
neuroblastoma O
cells O
( O
dTMN O
) O
with O
MVeGFP O
, O
Single O
autofluorescent O
EGFP O
- O
positive O
cells O
were O
selected O
at O
the O
earliest O
possible O
point O
in O
the O
infection O
, O
and O
the O
spread O
of O
EGFP O
autofluorescence O
was O
monitored O
. O

Human O
neuroblastoma O
cells O
( O
SH O
- O
SY O
- O
5Y O
) O
were O
also O
infected O
with O
MVeGFP O
. O

A O
productive O
infection O
ensued O
, O
and O
the O
mice O
exhibited O
clinical O
signs O
of O
infection O
, O
such O
as O
ataxia O
and O
an O
awkward O
gait O
, O
identical O
to O
those O
previously O
observed O
for O
the O
parental O
virus O
( O
Edtag O
) O
, O
Mice O
were O
sacrificed O
, O
and O
brain O
sections O
were O
examined O
for O
EGFP O
autofluorescence O
by O
confocal O
scanning O
laser O
microscopy O
over O
a O
period O
of O
6 O
h O
, O
EGFP O
was O
detected O
in O
discrete O
focal O
regions O
of O
the O
brain O
and O
in O
processes O
, O
which O
extended O
deep O
into O
the O
parenchyma O
, O
Collectively O
, O
these O
results O
indicate O
( O
i O
) O
that O
MVeGFP O
can O
be O
used O
to O
monitor O
virus O
replication O
sensitively O
, O
in O
real O
time O
, O
in O
animal O
tissues O
, O
Cii O
) O
that O
infection O
of O
ependymal O
cells O
and O
neuroblasts O
provides O
a O
route O
by O
which O
measles O
virus O
can O
enter O
the O
central O
nervous O
system O
in O
mouse O
models O
of O
encephalitis O
, O
and O
( O
iii O
) O
that O
upon O
infection O
, O
the O
virus O
spreads O
transneuronally O
. O

A O
recombinant O
measles O
virus O
which O
expresses O
enhanced O
green O
fluorescent O
protein O
( O
MVeGFP O
) O
has O
been O
used O
to O
infect O
two O
astrocytoma O
cell O
lines O
( O
GCCM O
and O
U O
- O
251 O
) O
to O
study O
the O
effect O
of O
virus O
infection O
on O
the O
cytoskeleton O
. O

No O
alteration O
of O
the O
actin O
, O
tubulin O
, O
or O
vimentin O
components O
of O
the O
cytoskeleton O
was O
observed O
in O
either O
cell O
type O
, O
whereas O
a O
disruption O
of O
the O
glial B
- I
fibrillary I
- I
acidic I
protein I
filament I
( I
GFAP I
) I
network O
was O
noted O
in O
MVeGFP O
- O
infected O
U O
- O
251 O
cells O
. O

In O
central B
nervous I
system I
( I
CNS I
) I
infectious O
and O
inflammatory O
diseases O
of O
known O
cause O
, O
oligoclonal O
bands O
represent O
antibody O
directed O
against O
the O
causative O
agent O
. O

To O
determine O
whether O
disease O
- O
relevant O
antibodies O
can O
be O
cloned O
from O
diseased O
brain O
, O
we O
prepared O
an O
antibody O
phage O
display O
library O
from O
the O
brain O
of O
a O
human O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
, O
a O
chronic O
encephalitis O
caused O
by O
measles O
virus O
, O
and O
selected O
the O
library O
against O
SSPE O
brain O
sections O
. O

In O
patients O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
, O
which O
is O
associated O
, O
vith O
persistent O
measles B
virus I
( I
MV I
) I
infection O
in O
the O
brain O
, O
little O
infectious O
virus O
can O
be O
recovered O
despite O
the O
presence O
of O
viral O
RNA O
and O
protein O
. O

Based O
on O
studies O
of O
brain O
tissue O
from O
SSPE O
patients O
and O
our O
work O
with O
MV O
- O
infected O
NSE O
- O
CD46 O
( O
+ O
) O
mice O
, O
which O
express O
the O
measles O
receptor O
CD46 O
on O
neurons O
, O
several O
lines O
of O
evidence O
suggest O
that O
the O
mechanism O
of O
viral O
spread O
in O
the O
central O
nervous O
system O
differs O
from O
that O
in O
nonneuronal O
cells O
. O

To O
examine O
this O
alternate O
mechanism O
of O
viral O
spread O
, O
as O
well O
as O
the O
basis O
for O
the O
loss O
of O
normal O
transmission O
mechanisms O
, O
infection O
and O
spread O
of O
MV O
Edmonston O
was O
evaluated O
in O
primary O
CD46 O
( O
+ O
) O
neurons O
from O
transgenic O
mice O
and O
differentiated O
human O
NT2 O
neurons O
. O

Cocultures O
of O
CD46 O
( O
+ O
) O
and O
CD46 O
( O
- O
) O
neurons O
showed O
that O
cell O
contact O
but O
not O
CD46 O
expression O
is O
required O
for O
MV O
spread O
between O
neurons O
. O

A O
recombinant O
measles B
virus I
( I
MV I
) I
which O
expresses O
enhanced B
green I
fluorescent I
protein I
( I
EGFP I
) I
has O
been O
rescued O
. O

The O
recombinant O
virus O
was O
used O
to O
infect O
human O
astrocytoma O
cells O
( O
GCCM O
) O
. O

Immunocytochemistry B
( I
ICC I
) I
together O
with O
EGFP O
autofluorescence O
showed O
that O
EGFP O
is O
both O
an O
early O
and O
very O
sensitive O
indicator O
of O
cell O
infection O
. O

Attenuated O
Edmonston B
measles I
virus I
( I
MV I
- I
Edm I
) I
is O
not O
pathogenic O
in O
standard O
mice O
. O

measles B
virus I
( I
MV I
) I
infection O
of O
the O
human B
central I
nervous I
system I
( I
CNS I
) I
typically O
involves O
widespread O
infection O
of O
neurons O
. O

In O
mixed O
cultures O
containing O
differentiated O
human O
neuronal O
( O
hNT2 O
) O
cells O
and O
neuroepithelial O
cells O
, O
immunofluorescence O
studies O
show O
that O
the O
neurons O
, O
unlike O
both O
their O
NT2 O
progenitors O
and O
the O
neuroepithelial O
cells O
, O
are O
not O
initially O
susceptible O
to O
MV O
infection O
. O

The O
cytoplasmic O
tail O
of O
the O
measles B
virus I
( I
MV I
) I
fusion O
( O
F O
) O
protein O
is O
often O
altered O
in O
viruses O
which O
spread O
through O
the O
brain O
of O
patients O
suffering O
from O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

Similarly O
, O
we O
constructed O
and O
transferred O
mutated O
tail O
- O
encoding O
regions O
of O
the O
other O
viral O
glycoprotein O
hemagglutinin B
( I
H I
) I
gene O
, O
From O
the O
mutated O
genomic O
cDNAs O
, O
we O
achieved O
rescue O
of O
viruses O
that O
harbor O
different O
alterations O
of O
the O
F O
tail O
, O
deletions O
in O
the O
membrane O
distal O
half O
of O
the O
H O
tail O
, O
and O
combinations O
of O
these O
mutations O
, O
Viruses O
with O
alterations O
in O
any O
of O
the O
tails O
spread O
rapidly O
through O
the O
monolayer O
via O
enhanced O
cell O
- O
cell O
fusion O
. O

Analysis O
of O
the O
protein O
composition O
of O
released O
mutant O
viral O
particles O
indicated O
that O
the O
tails O
are O
necessary O
for O
accurate O
virus O
envelope O
assembly O
and O
suggested O
a O
direct O
F O
tail O
- O
matrix B
( I
M I
) I
protein O
interaction O
. O

Monkey O
cells O
persistently O
infected O
by O
measles B
virus I
( I
MV I
) I
Biken O
strain O
( O
Biken O
- O
CV O
- O
1 O
cells O
) O
showed O
no O
cytopathic O
effects O
and O
lacked O
surface O
expression O
of O
a O
homolog O
of O
human O
cell O
receptor O
, O
membrane O
cofactor O
protein O
CD46 O
. O

Fusion O
of O
Biken O
- O
CV O
- O
1 O
cells O
required O
the O
extracellular O
hemagglutinin O
( O
H O
- O
protein O
) O
- O
binding O
domain O
but O
not O
the O
cytoplasmic O
domain O
. O

Persistent O
infections O
of O
C6 O
rat O
astrocytoma O
cells O
with O
measles O
( O
subacute O
sclerosing O
panencephalitis O
[ O
SSPE O
] O
) O
virus O
( O
C6 O
/ O
SSPE O
cells O
) O
or O
canine O
distemper O
virus O
( O
C6 O
/ O
CDV O
cells O
) O
cause O
a O
loss O
of O
endothelin O
- O
1 O
( O
ET O
- O
1 O
) O
binding O
to O
its O
specific O
receptors O
( O
ETR O
( O
A O
) O
type O
) O
and O
subsequent O
ET O
- O
1 O
- O
induced O
Ca2 O
+ O
signaling O
. O

By O
using O
an O
RNase O
protection O
assay O
, O
it O
was O
found O
that O
ETR O
( O
A O
) O
mRNA O
disappears O
, O
whereas O
other O
cellular O
mRNA O
species O
, O
e O
. O

canine B
distemper I
virus I
( I
CDV I
) I
, O
a O
negative O
strand O
RNA O
morbillivirus O
, O
causes O
a O
progressive O
demyelinating O
disease O
in O
which O
virus O
persistence O
plays O
an O
essential O
role O
. O

In O
the O
present O
investigation O
, O
we O
studied O
several O
aspects O
of O
virus O
replication O
in O
primary O
dog B
brain I
cell I
cultures I
( I
DBCC I
) I
, O
comparing O
an O
attenuated O
CDV O
strain O
and O
a O
virulent O
CDV O
strain O
. O

ribonucleoprotein B
( I
RNP I
) I
cores O
extracted O
from O
virions O
of O
wild O
- O
type O
( O
Edmonston O
strain O
) O
measles B
virus I
( I
MV I
) I
or O
obtained O
from O
MV O
- O
infected O
cells O
( O
cRNP O
) O
were O
shown O
to O
be O
capable O
of O
transcribing O
RNA O
in O
vitro O
but O
at O
relatively O
low O
efficiency O
. O

The O
tightly O
bound O
matrix B
( I
M I
) I
protein O
could O
be O
effectively O
removed O
from O
virion B
RNP I
( I
vRNP I
) I
and O
from O
cRNP O
by O
exposure O
to O
buffers O
of O
high O
ionic O
strength O
( O
0 O
. O

M O
- O
gene O
cDNA O
clones O
derived O
from O
three O
strains O
of O
wild B
- I
type I
( I
WT I
) I
MV O
and O
10 O
clones O
from O
mRNAs O
isolated O
from O
the O
brain O
tissue O
of O
patients O
who O
had O
died O
from O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
and O
from O
measles B
inclusion I
body I
encephalitis I
( I
MIBE I
) I
were O
recloned O
in O
the O
pTM O
- O
1 O
expression O
vector O
driven O
by O
the O
bacteriophage O
T7 O
RNA O
polymerase O
expressed O
by O
a O
coinfecting O
vaccinia O
virus O
recombinant O
. O

The O
only O
plausible O
explanations O
for O
loss O
of O
transcription O
inhibition O
activity O
by O
the O
four O
SSPE O
/ O
MIBE O
M O
proteins O
were O
exceedingly O
high O
degrees O
of O
hypermutations O
leading O
to O
U O
- O
- O
> O
C O
transitions O
and O
cloning O
- O
corrected O
mutations O
in O
the O
initiator O
codon O
( O
ATG O
- O
- O
> O
ACG O
) O
of O
the O
four O
M O
genes O
. O

The O
alpha O
/ O
beta O
( O
type O
I O
) O
interferon O
- O
inducible O
human O
MxA O
protein O
confers O
resistance O
to O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
influenza O
A O
virus O
in O
MxA B
- I
transfected I
mouse I
3T3 I
cells I
( I
3T3 I
/ I
MxA I
) I
. O

We O
investigated O
the O
inhibitory O
effects O
of O
the O
MxA O
protein O
on O
measles B
virus I
( I
MV I
) I
and O
VSV O
in O
the O
human O
monocytic O
cell O
line O
U937 O
. O

In O
transfected O
U937 O
clones O
which O
constitutively O
express O
MxA O
( O
U937 O
/ O
MxA O
) O
, O
the O
release O
of O
infectious O
MV O
and O
VSV O
was O
reduced O
approximately O
100 O
- O
fold O
in O
comparison O
with O
control O
titers O
. O

We O
have O
developed O
an O
in O
vitro O
nucleocapsid O
- O
binding O
assay O
for O
studying O
the O
function O
of O
the O
matrix B
( I
M I
) I
protein O
of O
measles B
virus I
( I
MV I
) I
( O
A O
. O

In O
this O
communication O
we O
show O
that O
the O
M O
proteins O
of O
three O
MV O
strains O
that O
cause O
acute O
infection O
( O
Nagahata O
, O
Edmonston O
, O
and O
YN O
) O
bind O
efficiently O
to O
the O
viral O
nucleocapsids O
whereas O
the O
M O
proteins O
of O
four O
MV O
strains O
isolated O
from O
patients O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
( O
Biken O
, O
IP O
- O
3 O
, O
Niigata O
, O
and O
Yamagata O
) O
fail O
to O
bind O
to O
the O
viral O
nucleocapsids O
. O

MV O
Biken O
( O
an O
SSPE O
- O
related O
virus O
) O
produces O
variant O
M O
sequences O
which O
encode O
two O
antigenically O
distinct O
forms O
of O
M O
protein O
. O

MV O
IP O
- O
3 O
( O
an O
SSPE O
- O
related O
virus O
) O
also O
produces O
variant O
M O
sequences O
, O
some O
of O
which O
have O
been O
postulated O
to O
encode O
a O
functional O
M O
protein O
responsible O
for O
the O
production O
of O
an O
infectious O
revertant O
virus O
. O

measles B
virus I
( I
MV I
) I
rarely O
induces O
lethal O
diseases O
of O
the O
human O
central O
nervous O
system O
characterized O
by O
reduced O
expression O
of O
the O
viral O
envelope O
proteins O
and O
by O
lack O
of O
viral O
budding O
. O

The O
MV O
envelope O
contains O
two O
integral O
membrane O
proteins O
, O
termed O
fusion O
( O
F O
) O
protein O
and O
hemagglutinin B
( I
H I
) I
protein O
, O
and O
a O
membrane O
- O
associated O
matrix B
( I
M I
) I
protein O
. O

In O
measles B
virus I
( I
MV I
) I
infection O
in O
humans O
, O
meninigitis O
and O
encephalitis O
are O
important O
complications O
. O

We O
have O
examined O
the O
role O
of O
cytotoxic B
T I
lymphocytes I
( I
CTL I
) I
in O
a O
mouse O
model O
of O
MV O
- O
induced O
encephalitis O
. O

We O
report O
here O
that O
the O
resistance O
of O
inbred O
strains O
of O
mice O
to O
MV O
- O
induced O
encephalitis O
correlated O
with O
the O
major B
histocompatibility I
complex I
( I
MHC I
) I
haplotype O
and O
that O
only O
resistant O
mouse O
strains O
mounted O
an O
effective O
CTL O
response O
to O
MV O
. O

Mice O
with O
low O
susceptibility O
to O
MV O
infection O
, O
such O
as O
the O
BALB O
/ O
c O
strain O
( O
H O
- O
2d O
) O
, O
generated O
CTL O
, O
whereas O
the O
highly O
susceptible O
strains O
, O
C3H O
( O
H O
- O
2k O
) O
and O
C57BL O
/ O
6 O
( O
H O
- O
2b O
) O
, O
revealed O
very O
poor O
CTL O
responses O
. O

Interaction O
between O
the O
Edmonston O
or O
Nagahata O
strain O
of O
acute O
measles B
virus I
( I
MV I
) I
and O
the O
defective O
Biken O
strain O
of O
MV O
isolated O
from O
a O
patient O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
was O
examined O
by O
a O
cell O
fusion O
protocol O
. O

The O
matrix B
( I
M I
) I
gene O
of O
a O
measles B
virus I
( I
MV I
) I
variant O
passaged O
in O
IMR O
- O
32 O
human O
neuroblastoma O
cells O
displays O
numerous O
uridine O
- O
to O
- O
cytosine O
transitions O
called O
biased O
hypermutation O
. O

We O
identified O
an O
acute O
measles O
virus O
( O
Nagahata O
strain O
) O
closely O
related O
to O
a O
defective O
virus O
( O
Biken O
strain O
) O
isolated O
from O
a O
patient O
with O
Subacute B
sclerosing I
panencephalitis I
( I
SSPE I
) I
. O

However O
, O
the O
nucleotide O
sequence O
of O
the O
Nagahata O
matrix B
( I
M I
) I
gene O
is O
significantly O
different O
from O
the O
M O
genes O
of O
all O
the O
acute O
measles O
virus O
strains O
studied O
to O
date O
. O

These O
conformation O
- O
specific O
epitopes O
are O
also O
absent O
in O
the O
cryptic O
M O
proteins O
encoded O
by O
the O
hypermutated O
M O
genes O
of O
two O
other O
defective O
SSPE O
viruses O
( O
Niigata O
and O
Yamagata O
strains O
) O
. O

Lewis O
rats O
immunized O
with O
recombinant O
vaccinia O
virus O
expressing O
the O
nucleocapsid B
( I
N I
) I
protein O
of O
measles O
virus O
were O
protected O
from O
encephalitis O
when O
subsequently O
challenged O
by O
intracerebral O
infection O
with O
neurotropic O
measles O
virus O
. O

Infection O
with O
Zaire O
ebolavirus B
( I
EBOV I
) I
, O
a O
member O
of O
the O
Filoviridae O
family O
, O
causes O
a O
disease O
characterized O
by O
high O
levels O
of O
viremia O
, O
aberrant O
inflammation O
, O
coagulopathy O
, O
and O
lymphopenia O
. O

EBOV O
initially O
replicates O
in O
lymphoid O
tissues O
and O
disseminates O
via O
dendritic B
cells I
( I
DCs I
) I
and O
monocytes O
to O
liver O
, O
spleen O
, O
adrenal O
gland O
, O
and O
other O
secondary O
organs O
. O

nonhuman B
primates I
( I
NHPs I
) I
immunized O
with O
a O
high O
dose O
( O
5 O
x O
10 O
( O
5 O
) O
PFU O
) O
of O
recombinant O
EBOV O
containing O
a O
mutated O
VP35 O
( O
VP35m O
) O
are O
protected O
from O
challenge O
with O
wild B
- I
type I
EBOV I
( I
wtEBOV I
) I
. O

Therefore O
, O
we O
conducted O
a O
transcriptional O
analysis O
of O
axillary O
and O
inguinal O
lymph O
nodes O
and O
spleen O
tissues O
of O
NHPs O
infected O
with O
a O
low O
dose O
( O
2 O
x10 O
( O
4 O
) O
PFU O
) O
of O
VP35m O
and O
then O
back O
- O
challenged O
with O
a O
lethal O
dose O
of O
wtEBOV O
. O

IMPORTANCE O
Zaire O
Ebola B
virus I
( I
EBOV I
) I
infection O
causes O
a O
severe O
and O
often O
fatal O
disease O
characterized O
by O
inflammation O
, O
coagulation O
defects O
, O
and O
organ O
failure O
driven O
by O
a O
defective O
host O
immune O
response O
. O

A O
recent O
study O
demonstrated O
that O
infection O
with O
an O
EBOV O
encoding O
a O
mutant O
VP35 O
, O
a O
viral O
protein O
that O
antagonizes O
host O
immunity O
, O
can O
protect O
nonhuman B
primates I
( I
NHPs I
) I
against O
lethal O
EBOV O
challenge O
. O

Marburg B
virus I
( I
MARV I
) I
is O
a O
filovirus O
related O
to O
Ebola B
virus I
( I
EBOV I
) I
associated O
with O
human O
hemorrhagic O
disease O
. O

We O
have O
developed O
an O
inactivated O
rabies O
virus O
- O
vectored O
MARV O
vaccine O
( O
FILORAB3 O
) O
to O
protect O
against O
Marburg O
virus O
disease O
. O

Immunogenicity O
studies O
in O
our O
labs O
have O
shown O
that O
a O
Th1 O
- O
biased O
seroconversion O
to O
both O
rabies O
virus O
and O
MARV O
glycoproteins B
( I
GPs I
) I
is O
beneficial O
for O
protection O
in O
a O
preclinical O
murine O
model O
. O

As O
such O
, O
we O
adjuvanted O
FILORAB3 O
with O
glucopyranosyl B
lipid I
adjuvant I
( I
GLA I
) I
, O
a O
Toll O
- O
like O
receptor O
4 O
agonist O
, O
in O
a O
squalene O
- O
in O
- O
water O
emulsion O
. O

Across O
two O
different O
BALB O
/ O
c O
mouse O
challenge O
models O
, O
we O
achieved O
92 O
% O
protection O
against O
murine O
- O
adapted O
Marburg B
virus I
( I
ma I
- I
MARV I
) I
. O

Through O
both O
in O
vitro O
and O
in O
vivo O
approaches O
, O
we O
elucidated O
a O
critical O
role O
for O
NK O
cell O
- O
dependent O
antibody B
- I
mediated I
cellular I
cytotoxicity I
( I
ADCC I
) I
in O
vaccine O
- O
induced O
protection O
. O

IMPORTANCE O
Marburg B
virus I
( I
MARV I
) I
is O
a O
virus O
similar O
to O
Ebola O
virus O
and O
also O
causes O
a O
hemorrhagic O
disease O
which O
is O
highly O
lethal O
. O

Zaire O
and O
Sudan O
ebolavirus O
species O
cause O
a O
severe O
disease O
in O
humans O
and O
nonhuman B
primates I
( I
NHPs I
) I
characterized O
by O
a O
high O
mortality O
rate O
. O

There O
are O
no O
licensed O
therapies O
or O
vaccines O
against O
Ebola B
virus I
disease I
( I
EVD I
) I
, O
and O
the O
recent O
2013 O
to O
2016 O
outbreak O
in O
West O
Africa O
highlighted O
the O
need O
for O
EVD O
- O
specific O
medical O
countermeasures O
. O

Here O
, O
we O
generated O
and O
characterized O
head O
- O
to O
- O
head O
the O
immunogenicity O
and O
efficacy O
of O
five O
vaccine O
candidates O
against O
Zaire O
ebolavirus B
( I
EBOV I
) I
and O
Sudan B
ebolavirus I
( I
SUDV I
) I
based O
on O
the O
highly O
attenuated O
poxvirus O
vector O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
expressing O
either O
the O
virus O
glycoprotein B
( I
GP I
) I
or O
GP O
together O
with O
the O
virus B
protein I
40 I
( I
VP40 I
) I
forming O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

In O
a O
human O
monocytic O
cell O
line O
, O
the O
different O
MVA O
vectors O
( O
termed O
MVA O
- O
EBOVs O
and O
MVA O
- O
SUDVs O
) O
triggered O
robust O
innate O
immune O
responses O
, O
with O
production O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
, O
proinflammatory O
cytokines O
, O
and O
chemokines O
. O

After O
immunization O
of O
mice O
with O
a O
homologous O
prime O
/ O
boost O
protocol O
( O
MVA O
/ O
MVA O
) O
, O
total O
IgG O
antibodies O
against O
GP O
or O
VP40 O
from O
Zaire O
and O
Sudan O
ebolavirus O
were O
differentially O
induced O
by O
these O
vectors O
, O
which O
were O
mainly O
of O
the O
IgG1 O
and O
IgG3 O
isotypes O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
severe O
hemorrhagic O
fever O
in O
humans O
and O
other O
primates O
with O
a O
high O
case O
fatality O
rate O
. O

Studies O
on O
EBOV O
have O
been O
hampered O
because O
experimentations O
involving O
live O
virus O
are O
restricted O
to O
biosafety B
level I
4 I
( I
BSL4 I
) I
laboratories O
. O

The O
minigenomic O
RNA O
harboring O
a O
Gaussia O
luciferase O
and O
hygromycin O
- O
resistant O
marker O
can O
replicate O
for O
months O
in O
a O
helper O
cell O
stably O
expressing O
viral O
nucleoprotein B
( I
NP I
) I
, O
viral B
protein I
35 I
( I
VP35 I
) I
, O
VP30 O
, O
and O
L O
proteins O
. O

Quantification O
of O
viral B
RNA I
( I
vRNA I
) I
, O
cRNA O
, O
and O
mRNA O
levels O
of O
the O
EBOV O
minigenome O
demonstrated O
that O
the O
stable O
EBOV O
replicon O
had O
much O
- O
more O
- O
active O
minigenome O
replication O
than O
previously O
developed O
transient O
- O
transfection O
- O
based O
EBOV O
minigenome O
systems O
, O
which O
recapitulate O
viral O
primary O
transcription O
more O
than O
genome O
replication O
. O

IMPORTANCE O
The O
scope O
and O
severity O
of O
the O
recent O
Ebola O
outbreak O
in O
Western O
Africa O
justified O
a O
more O
comprehensive O
investigation O
of O
the O
causative O
risk O
group O
4 O
agent O
Ebola B
virus I
( I
EBOV I
) I
. O

Ebola B
virus I
( I
EBOV I
) I
, O
a O
member O
of O
the O
Filoviridae O
family O
, O
is O
a O
highly O
pathogenic O
virus O
that O
causes O
severe O
hemorrhagic O
fever O
in O
humans O
and O
is O
responsible O
for O
epidemics O
throughout O
sub O
- O
Saharan O
, O
central O
, O
and O
West O
Africa O
. O

The O
EBOV O
genome O
encodes O
VP35 O
, O
an O
important O
viral O
protein O
involved O
in O
virus O
replication O
by O
acting O
as O
an O
essential O
cofactor O
of O
the O
viral O
polymerase O
as O
well O
as O
a O
potent O
antagonist O
of O
the O
host O
antiviral O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
system O
. O

By O
using O
mass O
spectrometry O
analysis O
and O
co O
- O
immunoprecipitation O
assays O
, O
we O
show O
here O
that O
VP35 O
is O
ubiquitinated O
on O
lysine O
309 O
( O
K309 O
) O
, O
a O
residue O
located O
on O
its O
IFN O
antagonist O
domain O
. O

We O
also O
found O
that O
VP35 O
interacts O
with O
TRIM6 O
, O
a O
member O
of O
the O
E3 O
- O
ubiquitin O
ligase O
tripartite B
motif I
( I
TRIM I
) I
family O
. O

IMPORTANCE O
EBOV O
belongs O
to O
a O
family O
of O
highly O
pathogenic O
viruses O
that O
cause O
severe O
hemorrhagic O
fever O
in O
humans O
and O
other O
mammals O
with O
high O
mortality O
rates O
( O
40 O
to O
90 O
% O
) O
. O

The O
recent O
Ebola B
virus I
( I
EBOV I
) I
epidemic O
in O
West O
Africa O
demonstrates O
the O
potential O
for O
a O
significant O
public O
health O
burden O
caused O
by O
filoviral O
infections O
. O

To O
expand O
the O
vaccine O
options O
potentially O
available O
, O
we O
assessed O
protection O
conferred O
by O
an O
EBOV O
vaccine O
composed O
of O
vesicular O
stomatitis O
virus O
pseudovirions O
that O
lack O
native O
G O
glycoprotein O
( O
VSV O
Delta O
G O
) O
and O
bear O
EBOV O
glycoprotein B
( I
GP I
) I
. O

Both O
single O
- O
dose O
and O
prime O
/ O
boost O
vaccination O
regimens O
protected O
mice O
against O
lethal O
challenge O
with O
mouse B
- I
adapted I
Ebola I
virus I
( I
ma I
- I
EBOV I
) I
in O
a O
dose O
- O
dependent O
manner O
. O

As O
N O
- O
linked O
glycans O
are O
thought O
to O
shield O
conserved O
regions O
of O
the O
EBOV O
GP O
receptor B
- I
binding I
domain I
( I
RBD I
) I
, O
thereby O
blocking O
epitopes O
within O
the O
RBD O
, O
we O
also O
tested O
whether O
VSV O
Delta O
G O
bearing O
EBOV O
GPs O
that O
lack O
GP1 O
N O
- O
linked O
glycans O
provided O
effective O
immunity O
against O
challenge O
with O
ma O
- O
EBOV O
or O
a O
more O
distantly O
related O
virus O
, O
Sudan O
virus O
. O

Using O
a O
prime O
/ O
boost O
strategy O
, O
high O
doses O
of O
GP O
/ O
VSV O
Delta O
G O
partially O
or O
fully O
denuded O
of O
N O
- O
linked O
glycans O
on O
GP1 O
protected O
mice O
against O
ma O
- O
EBOV O
challenge O
, O
but O
these O
mutants O
were O
no O
more O
effective O
than O
wild B
- I
type I
( I
WT I
) I
GP O
/ O
VSV O
Delta O
G O
and O
did O
not O
provide O
cross O
protection O
against O
Sudan O
virus O
. O

There O
are O
currently O
no O
approved O
therapeutics O
or O
vaccines O
to O
treat O
or O
protect O
against O
the O
severe O
hemorrhagic O
fever O
and O
death O
caused O
by O
Ebola B
virus I
( I
EBOV I
) I
. O

Ebola B
virus I
- I
like I
particles I
( I
EBOV I
VLPs I
) I
consisting O
of O
the O
matrix O
protein O
VP40 O
, O
the O
glycoprotein B
( I
GP I
) I
, O
and O
the O
nucleoprotein B
( I
NP I
) I
are O
highly O
immunogenic O
and O
protective O
in O
nonhuman O
primates O
against O
Ebola B
virus I
disease I
( I
EVD I
) I
. O

We O
have O
constructed O
a O
modified B
vaccinia I
virus I
Ankara I
- I
Bavarian I
Nordic I
( I
MVA I
- I
BN I
) I
recombinant O
coexpressing O
VP40 O
and O
GP O
of O
EBOV O
Mayinga O
and O
the O
NP O
of O
Tai B
Forest I
virus I
( I
TAFV I
) I
( O
MVA O
- O
BN O
- O
EBOV O
- O
VLP O
) O
to O
launch O
noninfectious O
EBOV O
VLPs O
as O
a O
second O
vaccine O
modality O
in O
the O
MVA O
- O
BN O
- O
EBOV O
- O
VLP O
- O
vaccinated O
organism O
. O

IMPORTANCE O
The O
recent O
outbreak O
of O
Ebola B
virus I
( I
EBOV I
) I
, O
claiming O
more O
than O
11 O
, O
000 O
lives O
, O
has O
underscored O
the O
need O
to O
advance O
the O
development O
of O
safe O
and O
effective O
filovirus O
vaccines O
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
, O
as O
well O
as O
recombinant O
viral O
vectors O
, O
have O
proved O
to O
be O
promising O
vaccine O
candidates O
. O

modified B
vaccinia I
virus I
Ankara I
- I
Bavarian I
Nordic I
( I
MVA I
- I
BN I
) I
is O
a O
safe O
and O
immunogenic O
vaccine O
vector O
with O
a O
large O
capacity O
to O
accommodate O
multiple O
foreign O
genes O
. O

Marburg B
( I
MARV I
) I
and O
Ebola B
( I
EBOV I
) I
viruses O
are O
zoonotic O
pathogens O
that O
cause O
severe O
hemorrhagic O
fever O
in O
humans O
. O

The O
natural O
reservoir O
of O
MARV O
is O
the O
Egyptian O
rousette O
bat O
( O
Rousettus O
aegyptiacus O
) O
; O
that O
of O
EBOV O
is O
unknown O
but O
believed O
to O
be O
another O
bat O
species O
. O

Interaction O
of O
filoviruses O
with O
hosts O
is O
greatly O
affected O
by O
the O
viral O
interferon B
( I
IFN I
) I
- O
inhibiting B
domains I
( I
IID I
) I
. O

Bundibugyo B
virus I
( I
BDBV I
) I
is O
the O
etiological O
agent O
of O
a O
severe O
hemorrhagic O
fever O
in O
humans O
with O
a O
case O
- O
fatality O
rate O
ranging O
from O
25 O
to O
36 O
% O
. O

Ferrets O
were O
also O
infected O
with O
Ebola B
virus I
( I
EBOV I
) I
to O
confirm O
their O
susceptibility O
to O
another O
filovirus O
species O
and O
to O
potentially O
establish O
a O
virus O
transmission O
model O
. O

Bundibugyo B
virus I
( I
BDBV I
) I
is O
a O
member O
of O
the O
genus O
Ebolavirus O
and O
has O
caused O
outbreaks O
in O
the O
past O
but O
is O
relatively O
understudied O
, O
likely O
due O
to O
the O
lack O
of O
a O
suitable O
small O
animal O
model O
. O

Marburg B
virus I
( I
MARV I
) I
, O
which O
belongs O
to O
the O
virus O
family O
Filoviridae O
, O
causes O
hemorrhagic O
fever O
in O
humans O
and O
nonhuman O
primates O
that O
is O
often O
fatal O
. O

MARV O
carries O
seven O
genes O
, O
one O
of O
which O
encodes O
its O
matrix B
protein I
VP40 I
( I
mVP40 I
) I
, O
which O
regulates O
the O
assembly O
and O
budding O
of O
the O
virions O
. O

Marburg B
virus I
( I
MARV I
) I
induces O
severe O
hemorrhagic O
fever O
in O
humans O
and O
nonhuman O
primates O
but O
only O
transient O
nonlethal O
disease O
in O
rodents O
. O

Guinea O
pig O
- O
adapted O
MARV O
contains O
one O
mutation O
in O
the O
viral O
matrix O
protein O
VP40 O
at O
position O
184 O
( O
VP40 O
( O
D184N O
) O
) O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
recombinant O
MARV O
containing O
the O
D184N O
mutation O
in O
VP40 O
[ O
rMARV O
( O
VP40 O
( O
D184N O
) O
) O
] O
grew O
to O
higher O
titers O
than O
wild O
- O
type O
recombinant O
MARV O
( O
rMARV O
( O
WT O
) O
) O
in O
guinea O
pig O
cells O
. O

Moreover O
, O
rMARV O
( O
VP40 O
( O
D184N O
) O
) O
displayed O
higher O
infectivity O
in O
guinea O
pig O
cells O
. O

Comparative O
analysis O
of O
VP40 O
functions O
indicated O
that O
neither O
the O
interferon B
( I
IFN I
) I
- O
antagonistic O
function O
nor O
the O
membrane O
binding O
capabilities O
of O
VP40 O
were O
affected O
by O
the O
D184N O
mutation O
. O

However O
, O
the O
production O
of O
VP40 O
- O
induced O
virus B
- I
like I
particles I
( I
VLPs I
) I
and O
the O
recruitment O
of O
other O
viral O
proteins O
to O
the O
budding O
site O
was O
improved O
by O
the O
D184N O
mutation O
in O
guinea O
pig O
cells O
, O
which O
resulted O
in O
the O
higher O
infectivity O
of O
VP40 O
( O
D184N O
) O
- O
induced O
infectious O
VLPs O
( O
iVLPs O
) O
compared O
to O
that O
of O
VP40 O
- O
induced O
iVLPs O
. O

Our O
results O
showed O
that O
the O
improved O
viral O
fitness O
of O
rMARV O
( O
VP40 O
( O
D184N O
) O
) O
in O
guinea O
pig O
cells O
was O
due O
to O
the O
better O
viral O
assembly O
function O
of O
VP40 O
( O
D184N O
) O
and O
its O
lower O
inhibitory O
effect O
on O
viral O
transcription O
and O
replication O
rather O
than O
modulation O
of O
the O
VP40 O
- O
mediated O
suppression O
of O
IFN O
signaling O
. O

Marburg B
virus I
( I
MARV I
) I
, O
a O
member O
of O
the O
filovirus O
family O
, O
causes O
severe O
hemorrhagic O
fever O
with O
up O
to O
90 O
% O
lethality O
. O

The O
unprecedented O
2014 O
- O
2015 O
Ebola B
virus I
disease I
( I
EVD I
) I
outbreak O
in O
West O
Africa O
has O
highlighted O
the O
need O
for O
effective O
therapeutics O
against O
filoviruses O
. O

monoclonal B
antibody I
( I
Mab I
) I
cocktails O
have O
shown O
great O
potential O
as O
EVD O
therapeutics O
; O
however O
, O
the O
existing O
protective O
MAbs O
are O
virus O
species O
specific O
. O

Infections O
with O
Sudan B
virus I
( I
SUDV I
) I
, O
a O
member O
of O
the O
genus O
Ebolavirus O
, O
result O
in O
a O
severe O
hemorrhagic O
fever O
with O
a O
fatal O
outcome O
in O
over O
50 O
% O
of O
human O
cases O
. O

By O
repeatedly O
passaging O
SUDV O
within O
the O
livers O
and O
spleens O
of O
guinea O
pigs O
in O
vivo O
, O
a O
guinea O
pig O
- O
adapted O
SUDV O
variant O
( O
SUDV O
- O
GA O
) O
uniformly O
lethal O
to O
these O
animals O
, O
with O
a O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
of O
5 O
. O

3 O
x O
10 O
( O
- O
2 O
) O
50 B
% I
tissue I
culture I
infective I
doses I
( I
TCID50 I
) I
, O
was O
developed O
. O

Current O
immunotherapeutic O
options O
for O
filoviruses O
are O
mostly O
specific O
to O
Ebola B
virus I
( I
EBOV I
) I
, O
although O
other O
members O
of O
Filoviridae O
such O
as O
Sudan B
virus I
( I
SUDV I
) I
, O
Bundibugyo B
virus I
( I
BDBV I
) I
, O
and O
Marburg B
virus I
( I
MARV I
) I
have O
also O
caused O
sizeable O
human O
outbreaks O
. O

Here O
we O
report O
a O
set O
of O
pan O
- O
ebolavirus O
and O
pan O
- O
filovirus O
Monoclonal B
antibodies I
( I
MAbs I
) I
derived O
from O
cynomolgus O
macaques O
immunized O
repeatedly O
with O
a O
mixture O
of O
engineered O
glycoproteins B
( I
GPs I
) I
and O
virus B
- I
like I
particles I
( I
VLPs I
) I
for O
three O
different O
filovirus O
species O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
a O
severe O
hemorrhagic O
fever O
with O
a O
deficient O
immune O
response O
, O
lymphopenia O
, O
and O
lymphocyte O
apoptosis O
. O

dendritic B
cells I
( I
DC I
) I
, O
which O
trigger O
the O
adaptive O
response O
, O
do O
not O
mature O
despite O
EBOV O
infection O
. O

We O
recently O
demonstrated O
that O
DC O
maturation O
is O
unblocked O
by O
disabling O
the O
innate O
response O
antagonizing O
domains O
( O
IRADs O
) O
in O
EBOV O
VP35 O
and O
VP24 O
by O
the O
mutations O
R312A O
and O
K142A O
, O
respectively O
. O

Human O
monocyte O
- O
derived O
DC O
were O
infected O
by O
wild B
- I
type I
( I
WT I
) I
EBOV O
or O
EBOVs O
carrying O
the O
mutation O
in O
VP35 O
( O
EBOV O
/ O
VP35m O
) O
, O
VP24 O
( O
EBOV O
/ O
VP24m O
) O
, O
or O
both O
( O
EBOV O
/ O
VP35m O
/ O
VP24m O
) O
. O

Global O
gene O
expression O
at O
8 O
and O
24 O
h O
was O
analyzed O
by O
deep O
sequencing O
, O
and O
the O
expression O
of O
interferon B
( I
IFN I
) I
subtypes O
up O
to O
5 O
days O
postinfection O
was O
analyzed O
by O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
. O

Filoviruses O
, O
including O
both O
Ebola B
virus I
( I
EBOV I
) I
and O
Marburg B
virus I
( I
MARV I
) I
, O
can O
infect O
humans O
and O
other O
animals O
, O
causing O
hemorrhagic O
fever O
with O
a O
high O
mortality O
rate O
. O

Entry O
of O
these O
viruses O
into O
the O
host O
is O
mediated O
by O
a O
single O
filoviral O
glycoprotein B
( I
GP I
) I
. O

GP O
is O
composed O
of O
two O
subunits O
: O
GP1 O
, O
which O
is O
responsible O
for O
attachment O
and O
binding O
to O
receptor O
( O
s O
) O
on O
susceptible O
cells O
, O
and O
GP2 O
, O
which O
mediates O
viral O
and O
cell O
membrane O
fusion O
. O

Although O
numerous O
host O
factors O
have O
been O
implicated O
in O
the O
entry O
process O
, O
the O
initial O
attachment O
receptor O
( O
s O
) O
has O
not O
been O
well O
defined O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
exostosin B
1 I
( I
EXT1 I
) I
, O
which O
is O
involved O
in O
biosynthesis O
of O
heparan B
sulfate I
( I
HS I
) I
, O
plays O
a O
role O
in O
filovirus O
entry O
. O

Expression O
knockdown O
of O
EXT1 O
by O
small B
interfering I
RNAs I
( I
siRNAs I
) I
impairs O
GP O
- O
mediated O
pseudoviral O
entry O
and O
that O
of O
infectious O
EBOV O
and O
MARV O
in O
tissue O
cultured O
cells O
. O

Furthermore O
, O
HS O
, O
heparin O
, O
and O
other O
related O
glycosaminoglycans B
( I
GAGs I
) I
, O
to O
different O
extents O
, O
can O
bind O
to O
and O
block O
GP O
- O
mediated O
viral O
entry O
and O
that O
of O
infectious O
filoviruses O
. O

The O
development O
of O
treatments O
for O
Ebola B
virus I
disease I
( I
EVD I
) I
has O
been O
hampered O
by O
the O
lack O
of O
small O
- O
animal O
models O
that O
mimick O
human O
disease O
. O

The O
Ebola B
virus I
( I
EBOV I
) I
surface O
glycoprotein O
( O
GP O
( O
1 O
, O
2 O
) O
) O
mediates O
host O
cell O
attachment O
and O
fusion O
and O
is O
the O
primary O
target O
for O
host O
neutralizing O
antibodies O
. O

Expression O
of O
GP O
( O
1 O
, O
2 O
) O
at O
high O
levels O
disrupts O
normal O
cell O
physiology O
, O
and O
EBOV O
uses O
an O
RNA O
- O
editing O
mechanism O
to O
regulate O
expression O
of O
the O
GP O
gene O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
high O
levels O
of O
GP O
( O
1 O
, O
2 O
) O
expression O
impair O
production O
and O
release O
of O
EBOV O
virus B
- I
like I
particles I
( I
VLPs I
) I
as O
well O
as O
infectivity O
of O
GP O
( O
1 O
, O
2 O
) O
- O
pseudotyped O
viruses O
. O

First O
, O
high O
levels O
of O
GP O
( O
1 O
, O
2 O
) O
expression O
reduce O
synthesis O
of O
other O
proteins O
needed O
for O
virus O
assembly O
. O

Second O
, O
viruses O
containing O
high O
levels O
of O
GP O
( O
1 O
, O
2 O
) O
are O
intrinsically O
less O
infectious O
, O
possibly O
due O
to O
impaired O
receptor O
binding O
or O
endosomal O
processing O
. O

Importantly O
, O
proteolysis O
can O
rescue O
the O
infectivity O
of O
high O
- O
GP O
( O
1 O
, O
2 O
) O
- O
containing O
viruses O
. O

Taken O
together O
, O
our O
findings O
indicate O
that O
GP O
( O
1 O
, O
2 O
) O
expression O
levels O
have O
a O
profound O
effect O
on O
factors O
that O
contribute O
to O
virus O
fitness O
and O
that O
RNA O
editing O
may O
be O
an O
important O
mechanism O
employed O
by O
EBOV O
to O
regulate O
GP O
( O
1 O
, O
2 O
) O
expression O
in O
order O
to O
optimize O
virus O
production O
and O
infectivity O
. O

IMPORTANCE O
The O
Ebola B
virus I
( I
EBOV I
) I
, O
as O
well O
as O
other O
members O
of O
the O
Filoviridae O
family O
, O
causes O
severe O
hemorrhagic O
fever O
that O
is O
highly O
lethal O
, O
with O
up O
to O
90 O
% O
mortality O
. O

The O
EBOV O
surface O
glycoprotein O
( O
GP O
( O
1 O
, O
2 O
) O
) O
plays O
important O
roles O
in O
virus O
infection O
and O
pathogenesis O
, O
and O
its O
expression O
is O
tightly O
regulated O
by O
an O
RNA O
- O
editing O
mechanism O
during O
virus O
replication O
. O

Our O
study O
demonstrates O
that O
the O
level O
of O
GP O
( O
1 O
, O
2 O
) O
expression O
profoundly O
affects O
virus O
particle O
production O
and O
release O
and O
uncovers O
a O
new O
mechanism O
by O
which O
Ebola O
virus O
infectivity O
is O
regulated O
by O
the O
level O
of O
GP O
( O
1 O
, O
2 O
) O
expression O
. O

It O
also O
functions O
as O
an O
interferon B
( I
IFN I
) I
signaling O
antagonist O
by O
targeting O
Janus B
kinase I
1 I
( I
JAK1 I
) I
. O

A O
previous O
study O
demonstrated O
that O
the O
VP40 O
protein O
of O
the O
Ravn O
strain O
of O
Marburg O
virus O
( O
Ravn O
virus O
[ O
RAVV O
] O
) O
failed O
to O
block O
IFN O
signaling O
in O
mouse O
cells O
, O
whereas O
the O
mouse B
- I
adapted I
RAVV I
( I
maRAVV I
) I
VP40 O
acquired O
the O
ability O
to O
inhibit O
IFN O
responses O
in O
mouse O
cells O
. O

Infections O
with O
Marburg B
virus I
( I
MARV I
) I
and O
Ebola B
virus I
( I
EBOV I
) I
cause O
severe O
hemorrhagic O
fever O
in O
humans O
and O
nonhuman B
primates I
( I
NHPs I
) I
with O
fatality O
rates O
up O
to O
90 O
% O
. O

Here O
we O
report O
the O
development O
of O
a O
mouse O
model O
for O
studying O
the O
pathogenesis O
of O
MARV B
Angola I
( I
MARV I
/ I
Ang I
) I
, O
the O
most O
virulent O
strain O
of O
MARV O
. O

Infection O
with O
the O
wild O
- O
type O
virus O
does O
not O
cause O
disease O
in O
mice O
, O
but O
the O
adapted O
virus O
( O
MARV O
/ O
Ang O
- O
MA O
) O
recovered O
from O
liver O
homogenates O
after O
24 O
serial O
passages O
in O
severe B
combined I
immunodeficient I
( I
SCID I
) I
mice O
caused O
severe O
disease O
when O
administered O
intranasally O
( O
i O
. O

The B
median I
lethal I
dose I
( I
LD50 I
) I
was O
determined O
to O
be O
0 O
. O

015 O
50 O
% O
TCID50 O
( O
tissue O
culture O
infective O
dose O
) O
of O
MARV O
/ O
Ang O
- O
MA O
in O
SCID O
mice O
, O
and O
i O
. O

Virus O
titers O
reached O
10 O
( O
8 O
) O
TCID50 O
/ O
ml O
in O
the O
blood O
and O
between O
10 O
( O
6 O
) O
and O
1010 O
TCID50 O
/ O
g O
tissue O
in O
the O
intestines O
, O
kidney O
, O
lungs O
, O
brain O
, O
spleen O
, O
and O
liver O
. O

IMPORTANCE O
The O
Angola O
strain O
of O
Marburg O
virus O
( O
MARV O
/ O
Ang O
) O
was O
responsible O
for O
the O
largest O
outbreak O
ever O
documented O
for O
Marburg O
viruses O
. O

Zaire O
ebolavirus B
( I
EBOV I
) I
VP35 O
is O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
binding O
protein O
that O
inhibits O
RIG O
- O
I O
signaling O
and O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
responses O
by O
both O
dsRNA O
- O
binding O
- O
dependent O
and O
- O
independent O
mechanisms O
. O

VP35 O
also O
suppresses O
dendritic B
cell I
( I
DC I
) I
maturation O
. O

Wildtype B
VP35 I
( I
VP35 I
- I
WT I
) I
and O
two O
well O
- O
characterized O
VP35 O
mutants O
( O
F239A O
and O
R322A O
) O
that O
independently O
ablate O
dsRNA O
binding O
and O
RIG O
- O
I O
inhibition O
were O
delivered O
to O
primary O
human B
monocyte I
- I
derived I
DCs I
( I
MDDCs I
) I
using O
a O
lentivirus O
- O
based O
expression O
system O
. O

VP35 O
- O
WT O
suppressed O
not O
only O
IFN O
- O
alpha O
/ O
beta O
but O
also O
proinflammatory O
responses O
following O
stimulation O
of O
MDDCs O
with O
activators O
of O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
signaling O
, O
including O
RIG O
- O
I O
activators O
such O
as O
Sendai B
virus I
( I
SeV I
) I
or O
5 O
' O
- O
triphosphate O
RNA O
, O
or O
MDA5 O
activators O
such O
as O
encephalomyocarditis B
virus I
( I
EMCV I
) I
or O
poly O
( O
I O
. O

In O
contrast O
to O
the O
RLR O
activators O
, O
VP35 O
- O
WT O
and O
the O
VP35 O
mutants O
impaired O
IFN O
- O
alpha O
production O
induced O
by O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
or O
TLR4 O
agonists O
but O
failed O
to O
inhibit O
proinflammatory O
cytokine O
production O
induced O
by O
TLR2 O
, O
TLR3 O
, O
or O
TLR4 O
agonists O
. O

Furthermore O
, O
VP35 O
did O
not O
prevent O
lipopolysaccharide B
( I
LPS I
) I
- O
induced O
upregulation O
of O
surface O
markers O
of O
MDDC O
maturation O
and O
did O
not O
prevent O
LPS O
- O
triggered O
allogeneic O
T O
cell O
stimulation O
. O

IMPORTANCE O
The O
VP35 O
protein O
, O
which O
is O
an O
inhibitor O
of O
RIG O
- O
I O
signaling O
and O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
responses O
, O
has O
been O
implicated O
as O
an O
EBOV O
- O
encoded O
factor O
that O
contributes O
to O
suppression O
of O
dendritic B
cell I
( I
DC I
) I
function O
. O

Our O
data O
demonstrate O
that O
VP35 O
is O
a O
general O
inhibitor O
of O
RIG B
- I
I I
- I
like I
receptor I
( I
RLR I
) I
signaling O
that O
blocks O
not O
only O
RIG O
- O
I O
- O
but O
also O
MDA5 O
- O
mediated O
induction O
of O
IFN O
- O
alpha O
/ O
beta O
responses O
. O

Work O
with O
infectious O
Ebola O
viruses O
is O
restricted O
to O
biosafety B
level I
4 I
( I
BSL4 I
) I
laboratories O
, O
presenting O
a O
significant O
barrier O
for O
studying O
these O
viruses O
. O

Life O
cycle O
modeling O
systems O
, O
including O
minigenome O
systems O
and O
transcription B
- I
and I
replication I
- I
competent I
virus I
- I
like I
particle I
( I
trVLP I
) I
systems O
, O
allow O
modeling O
of O
the O
virus O
life O
cycle O
under O
BSL2 O
conditions O
; O
however O
, O
all O
current O
systems O
model O
only O
certain O
aspects O
of O
the O
virus O
life O
cycle O
, O
rely O
on O
plasmid O
- O
based O
viral O
protein O
expression O
, O
and O
have O
been O
used O
to O
model O
only O
single O
infectious O
cycles O
. O

We O
have O
developed O
a O
novel O
life O
cycle O
modeling O
system O
allowing O
continuous O
passaging O
of O
infectious O
trVLPs O
containing O
a O
tetracistronic O
minigenome O
that O
encodes O
a O
reporter O
and O
the O
viral O
proteins O
VP40 O
, O
VP24 O
, O
and O
GP O
( O
1 O
, O
2 O
) O
. O

Lloviu B
virus I
( I
LLOV I
) I
, O
a O
novel O
filovirus O
detected O
in O
bats O
, O
is O
phylogenetically O
distinct O
from O
viruses O
in O
the O
genera O
Ebolavirus O
and O
Marburgvirus O
in O
the O
family O
Filoviridae O
. O

To O
examine O
the O
properties O
of O
LLOV O
, O
we O
characterized O
its O
envelope O
glycoprotein B
( I
GP I
) I
, O
which O
likely O
plays O
a O
key O
role O
in O
viral O
tropism O
and O
pathogenicity O
. O

Similar O
to O
the O
other O
filoviruses O
, O
virus B
- I
like I
particles I
( I
VLPs I
) I
produced O
by O
transient O
expression O
of O
LLOV O
GP O
, O
matrix O
protein O
, O
and O
nucleoprotein O
in O
293T O
cells O
had O
densely O
arrayed O
GP O
spikes O
on O
a O
filamentous O
particle O
. O

For O
functional O
study O
of O
LLOV O
GP O
, O
we O
utilized O
a O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
pseudotype O
system O
and O
found O
that O
LLOV O
GP O
requires O
low O
endosomal O
pH O
and O
cathepsin O
L O
, O
and O
that O
human O
C O
- O
type O
lectins O
act O
as O
attachment O
factors O
for O
LLOV O
entry O
into O
cells O
. O

Ebola B
virus I
( I
EBOV I
) I
is O
the O
causative O
agent O
of O
a O
severe O
hemorrhagic O
fever O
in O
humans O
with O
reported O
case O
fatality O
rates O
as O
high O
as O
90 O
% O
. O

heme B
oxygenase I
- I
1 I
( I
HO I
- I
1 I
) I
, O
an O
enzyme O
that O
catalyzes O
the O
rate O
- O
limiting O
step O
in O
heme O
degradation O
, O
has O
antioxidative O
properties O
and O
protects O
cells O
from O
various O
stresses O
. O

To O
determine O
whether O
the O
upregulation O
of O
HO O
- O
1 O
attenuates O
EBOV O
replication O
, O
we O
treated O
cells O
with O
cobalt B
protoporphyrin I
( I
CoPP I
) I
, O
a O
selective O
HO O
- O
1 O
inducer O
, O
and O
assessed O
its O
effects O
on O
EBOV O
replication O
. O

Ebola B
virus I
( I
EBOV I
) I
infections O
are O
characterized O
by O
deficient O
T O
lymphocyte O
responses O
, O
T O
lymphocyte O
apoptosis O
, O
and O
lymphopenia O
in O
the O
absence O
of O
direct O
infection O
of O
T O
lymphocytes O
. O

In O
contrast O
, O
dendritic B
cells I
( I
DC I
) I
are O
infected O
but O
fail O
to O
mature O
appropriately O
, O
thereby O
impairing O
the O
T O
cell O
response O
. O

They O
included O
envelope O
glycoprotein B
( I
GP I
) I
domains O
, O
as O
well O
as O
innate B
response I
antagonist I
domains I
( I
IRADs I
) I
previously O
identified O
in O
the O
VP24 O
and O
VP35 O
proteins O
. O

Viruses O
in O
the O
Ebolavirus O
and O
Marburgvirus O
genera O
( O
family O
Filoviridae O
) O
have O
been O
associated O
with O
large O
outbreaks O
of O
hemorrhagic O
fever O
in O
human O
and O
nonhuman O
primates O
. O

46 O
x O
10 O
( O
- O
4 O
) O
nucleotide O
substitutions O
/ O
site O
/ O
year O
for O
Sudan O
ebolavirus O
to O
8 O
. O

21 O
x O
10 O
( O
- O
4 O
) O
nucleotide O
substitutions O
/ O
site O
/ O
year O
for O
Reston O
ebolavirus O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
a O
lethal O
hemorrhagic O
fever O
for O
which O
there O
is O
no O
approved O
effective O
treatment O
or O
prevention O
strategy O
. O

VP35 O
is O
also O
an O
RNA B
silencing I
suppressor I
( I
RSS I
) I
. O

In O
addition O
, O
wild O
- O
type O
VP35 O
C B
- I
terminal I
domain I
( I
CTD I
) I
protein O
fusions O
were O
shown O
to O
bind O
small B
interfering I
RNA I
( I
siRNA I
) I
. O

Analysis O
of O
mutant O
proteins O
demonstrated O
that O
reporter O
activity O
in O
RSS O
assays O
did O
not O
correlate O
with O
their O
ability O
to O
antagonize O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
- O
activated O
protein B
kinase I
R I
( I
PKR I
) I
or O
bind O
siRNA O
. O

The O
results O
suggest O
the O
importance O
of O
VP35 O
- O
protein O
interactions O
in O
blocking O
silencing O
in O
a O
system O
( O
mammalian O
) O
that O
cannot O
amplify O
dsRNA O
. O

With O
the O
exception O
of O
Reston O
and O
Lloviu O
viruses O
, O
filoviruses O
( O
marburgviruses O
, O
ebolaviruses O
, O
and O
cuevaviruses O
) O
cause O
severe O
viral O
hemorrhagic O
fevers O
in O
humans O
. O

Filoviruses O
use O
a O
class O
I O
fusion O
protein O
, O
GP O
( O
1 O
, O
2 O
) O
, O
to O
bind O
to O
an O
unknown O
, O
but O
shared O
, O
cell O
surface O
receptor O
to O
initiate O
virus O
- O
cell O
fusion O
. O

In O
addition O
to O
GP O
( O
1 O
, O
2 O
) O
, O
ebolaviruses O
and O
cuevaviruses O
, O
but O
not O
marburgviruses O
, O
express O
two O
secreted O
glycoproteins O
, O
soluble B
GP I
( I
sGP I
) I
and O
small B
soluble I
GP I
( I
ssGP I
) I
. O

All O
three O
glycoproteins O
have O
identical O
N O
termini O
that O
include O
the O
receptor O
- O
binding O
region O
( O
RBR O
) O
but O
differ O
in O
their O
C O
termini O
. O

Neither O
sGP O
- O
Fc O
nor O
ssGP O
- O
Fc O
bound O
to O
filovirus O
- O
permissive O
cells O
or O
inhibited O
GP O
( O
1 O
, O
2 O
) O
- O
mediated O
cell O
entry O
of O
pseudotyped O
retroviruses O
. O

Surprisingly O
, O
several O
Fc O
- O
tagged O
Delta O
- O
peptides O
, O
which O
are O
small O
C O
- O
terminal O
cleavage O
products O
of O
sGP O
secreted O
by O
ebolavirus O
- O
infected O
cells O
, O
inhibited O
entry O
of O
retroviruses O
pseudotyped O
with O
Marburg O
virus O
GP O
( O
1 O
, O
2 O
) O
, O
as O
well O
as O
Marburg O
virus O
and O
Ebola O
virus O
infection O
in O
a O
dose O
- O
dependent O
manner O
and O
at O
low O
molarity O
despite O
absence O
of O
sequence O
similarity O
to O
filovirus O
RBRs O
. O

Fc O
- O
tagged O
Delta O
- O
peptides O
from O
three O
ebolaviruses O
( O
Ebola O
virus O
, O
Sudan O
virus O
, O
and O
Ta O
Forest O
virus O
) O
inhibited O
GP O
( O
1 O
, O
2 O
) O
- O
mediated O
entry O
and O
infection O
of O
viruses O
comparably O
to O
or O
better O
than O
the O
Fc O
- O
tagged O
RBRs O
, O
whereas O
the O
Delta O
- O
peptide O
- O
Fc O
of O
an O
ebolavirus O
nonpathogenic O
for O
humans O
( O
Reston O
virus O
) O
and O
that O
of O
an O
ebolavirus O
with O
lower O
lethality O
for O
humans O
( O
Bundibugyo O
virus O
) O
had O
little O
effect O
. O

In O
primate O
cells O
, O
the O
Lake O
Victoria O
marburgvirus O
Musoke B
strain I
( I
MARV I
) I
VP40 O
matrix O
protein O
antagonizes O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
and O
IFN O
- O
gamma O
signaling O
by O
inhibiting O
the O
activation O
of O
the O
cellular O
tyrosine O
kinase O
Jak1 O
. O

Here O
, O
VP40 O
from O
the O
Ravn B
strain I
( I
RAVV I
VP40 I
) I
- O
from O
a O
distinct O
Marburg O
virus O
clade O
- O
is O
demonstrated O
to O
also O
inhibit O
IFN O
signaling O
in O
human O
cells O
. O

In O
contrast O
, O
the O
VP40 O
from O
a O
mouse B
- I
adapted I
RAVV I
( I
maRAVV I
) I
did O
inhibit O
IFN O
signaling O
. O

Of O
the O
seven O
amino O
acid O
changes O
that O
accumulated O
in O
VP40 O
during O
mouse O
adaptation O
, O
two O
( O
V57A O
and O
T165A O
) O
are O
sufficient O
to O
allow O
efficient O
IFN O
signaling O
antagonism O
by O
RAVV O
VP40 O
in O
mouse O
cells O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
severe O
hemorrhagic O
fever O
, O
for O
which O
therapeutic O
options O
are O
not O
available O
. O

To O
identify O
inhibitors O
of O
EBOV O
entry O
, O
the O
EBOV O
envelope O
glycoprotein O
( O
EBOV O
- O
GP O
) O
gene O
was O
used O
to O
generate O
pseudotype O
viruses O
for O
screening O
of O
chemical O
libraries O
. O

A O
benzodiazepine O
derivative O
( O
compound O
7 O
) O
was O
identified O
from O
a O
high B
- I
throughput I
screen I
( I
HTS I
) I
of O
small O
- O
molecule O
compound O
libraries O
utilizing O
the O
pseudotype O
virus O
. O

Compound O
7 O
was O
validated O
as O
an O
inhibitor O
of O
infectious O
EBOV O
and O
Marburg B
virus I
( I
MARV I
) I
in O
cell O
- O
based O
assays O
, O
with O
50 B
% I
inhibitory I
concentrations I
( I
IC I
( I
50 I
) I
s I
) I
of O
10 O
mu O
M O
and O
12 O
mu O
M O
, O
respectively O
. O

Axl O
, O
a O
plasma O
membrane O
- O
associated O
Tyro3 B
/ I
Axl I
/ I
Mer I
( I
TAM I
) I
family O
member O
, O
is O
necessary O
for O
optimal O
Zaire B
Ebolavirus I
( I
ZEBOV I
) I
glycoprotein B
( I
GP I
) I
- O
dependent O
entry O
into O
some O
permissive O
cells O
but O
not O
others O
. O

Through O
the O
use O
of O
biochemical O
inhibitors O
, O
interfering O
RNA O
( O
RNAi O
) O
, O
and O
dominant O
negative O
constructs O
, O
we O
demonstrate O
that O
ZEBOV O
- O
GP O
- O
dependent O
entry O
into O
these O
cells O
occurs O
through O
multiple O
uptake O
pathways O
, O
including O
both O
clathrin O
- O
dependent O
and O
caveola O
/ O
lipid O
raft O
- O
mediated O
endocytosis O
. O

Ebola B
virus I
( I
EBOV I
) I
protein O
VP35 O
is O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
binding O
inhibitor O
of O
host O
interferon B
( I
IFN I
) I
- O
alpha O
/ O
beta O
responses O
that O
also O
functions O
as O
a O
viral O
polymerase O
cofactor O
. O

Solution O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
spectroscopy O
and O
X O
- O
ray O
crystallography O
reveal O
minimal O
structural O
perturbations O
in O
the O
K319A O
/ O
R322A O
VP35 O
double O
mutant O
and O
suggest O
that O
loss O
of O
basic O
charge O
leads O
to O
altered O
function O
. O

ebolavirus B
( I
EBOV I
) I
is O
the O
etiological O
agent O
of O
a O
severe O
hemorrhagic O
fever O
with O
a O
high O
mortality O
rate O
. O

The O
spike O
glycoprotein B
( I
GP I
) I
is O
believed O
to O
be O
one O
of O
the O
major O
determinants O
of O
virus O
pathogenicity O
. O

Protection O
of O
mice O
immunized O
with O
Ebola O
Delta O
VP30 O
was O
associated O
with O
a O
high O
antibody O
response O
to O
the O
Ebolavirus O
glycoprotein O
and O
the O
generation O
of O
an O
Ebolavirus O
NP O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
. O

Recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
vectors O
expressing O
homologous O
filoviral O
glycoproteins O
can O
completely O
protect O
rhesus O
monkeys O
against O
Marburg O
virus O
when O
administered O
after O
exposure O
and O
can O
partially O
protect O
macaques O
after O
challenge O
with O
Zaire O
ebolavirus O
. O

Here O
, O
we O
administered O
a O
VSV O
vector O
expressing O
the O
Sudan B
ebolavirus I
( I
SEBOV I
) I
glycoprotein O
to O
four O
rhesus O
macaques O
shortly O
after O
exposure O
to O
SEBOV O
. O

The O
Zaire O
ebolavirus O
protein O
VP24 O
was O
previously O
demonstrated O
to O
inhibit O
alpha O
/ O
beta O
interferon O
( O
IFN O
- O
( O
alpha O
/ O
beta O
) O
and O
IFN O
- O
gamma O
- O
induced O
nuclear O
accumulation O
of O
tyrosine B
- I
phosphorylated I
STAT1 I
( I
PY I
- I
STAT1 I
) I
and O
to O
inhibit O
IFN O
- O
alpha O
/ O
beta O
- O
and O
IFN O
- O
gamma O
- O
induced O
gene O
expression O
. O

The O
filoviruses O
Ebola B
virus I
( I
EBOV I
) I
and O
Marburg B
virus I
( I
MARV I
) I
are O
responsible O
for O
devastating O
hemorrhagic O
fever O
outbreaks O
. O

An O
understanding O
of O
filoviral O
glycoprotein B
1 I
( I
GP1 I
) I
residues O
involved O
in O
entry O
events O
would O
facilitate O
the O
development O
of O
antivirals O
. O

Mutant O
GPs O
were O
evaluated O
for O
their O
incorporation O
onto O
feline B
immunodeficiency I
virus I
( I
FIV I
) I
particles O
, O
transduction O
efficiency O
, O
receptor O
binding O
, O
and O
ability O
to O
be O
cleaved O
by O
cathepsins O
L O
and O
B O
. O

Nine O
additional O
mutant O
GPs O
( O
G87A O
/ O
F88A O
, O
K114A O
/ O
KI15A O
, O
K140A O
, O
G143A O
, O
P146A O
/ O
C147A O
, O
F153A O
/ O
H154A O
, O
F159A O
, O
F160A O
, O
and O
Y162A O
) O
competed O
poorly O
with O
wild O
- O
type O
GP O
for O
binding O
to O
permissive O
cells O
. O

Four O
of O
these O
nine O
mutants O
( O
P146A O
/ O
C147A O
, O
F153A O
/ O
H154A O
, O
F159A O
, O
and O
F160A O
) O
were O
also O
inefficiently O
cleaved O
by O
cathepsins O
. O

An O
additional O
four O
mutant O
GPs O
( O
K84A O
, O
R134A O
, O
D150A O
, O
and O
E305 O
/ O
E306A O
) O
that O
were O
partially O
defective O
in O
transduction O
were O
found O
to O
compete O
effectively O
for O
receptor O
binding O
and O
were O
readily O
cleaved O
by O
cathepsins O
. O

The O
C O
- O
type O
lectins O
DC O
- O
SIGN O
and O
DC O
- O
SIGNR O
( O
collectively O
referred O
to O
as O
DC O
- O
SIGN O
/ O
R O
) O
bind O
to O
the O
ebolavirus B
glycoprotein I
( I
EBOV I
- I
GP I
) I
and O
augment O
viral O
infectivity O
. O

Zaire O
( O
ZEBOV O
) O
but O
have O
a O
much O
less O
pronounced O
effect O
on O
infection O
mediated O
by O
the O
GP O
of O
EBOV O
subspecies O
. O

Sudan B
( I
SEBOV I
) I
. O

In O
March O
2005 O
, O
the O
Centers B
for I
Disease I
Control I
and I
Prevention I
( I
CDC I
) I
investigated O
a O
large O
hemorrhagic B
fever I
( I
HF I
) I
outbreak O
in O
Uige O
Province O
in O
northern O
Angola O
, O
West O
Africa O
. O

Surprisingly O
, O
marburgvirus O
was O
confirmed O
( O
12 O
of O
15 O
specimens O
) O
as O
the O
cause O
of O
the O
outbreak O
. O

The O
outbreak O
likely O
began O
in O
October O
2004 O
and O
ended O
in O
July O
2005 O
, O
and O
it O
included O
252 O
cases O
and O
227 O
( O
90 O
% O
) O
fatalities O
( O
report O
from O
the O
Ministry O
of O
Health O
, O
Republic O
of O
Angola O
, O
2005 O
) O
, O
making O
it O
the O
largest O
Marburg O
HF O
outbreak O
on O
record O
. O

Partial O
marburgvirus O
RNA O
sequence O
analysis O
revealed O
up O
to O
21 O
% O
nucleotide O
divergence O
among O
the O
previously O
characterized O
East O
African O
strains O
, O
with O
the O
most O
distinct O
being O
Ravn O
from O
Kenya O
( O
1987 O
) O
. O

The O
Angolan O
strain O
was O
less O
different O
( O
similar O
to O
7 O
% O
) O
from O
the O
main O
group O
of O
East O
African O
marburgviruses O
than O
one O
might O
expect O
given O
the O
large O
geographic O
separation O
. O

To O
more O
precisely O
analyze O
the O
virus O
genetic O
differences O
between O
outbreaks O
and O
among O
viruses O
within O
the O
Angola O
outbreak O
itself O
, O
a O
total O
of O
16 O
complete O
virus O
genomes O
were O
determined O
, O
including O
those O
of O
the O
virus O
isolates O
Ravn O
( O
Kenya O
, O
1987 O
) O
and O
05DRC O
, O
07DRC O
, O
and O
09DRC O
( O
Democratic O
Republic O
of O
Congo O
, O
1998 O
) O
and O
the O
reference O
Angolan O
virus O
isolate O
( O
Ang1379v O
) O
. O

While O
the O
marburgviruses O
exhibit O
high O
overall O
genetic O
diversity O
( O
up O
to O
22 O
% O
) O
, O
only O
6 O
. O

07 O
% O
) O
, O
consistent O
with O
an O
outbreak O
scenario O
in O
which O
a O
single O
( O
or O
rare O
) O
introduction O
of O
virus O
from O
the O
reservoir O
species O
into O
the O
human O
population O
was O
followed O
by O
person O
- O
to O
- O
person O
transmission O
with O
little O
accumulation O
of O
mutations O
. O

This O
is O
in O
contrast O
to O
the O
1998 O
to O
2000 O
marburgvirus O
outbreak O
, O
where O
evidence O
of O
several O
virus O
genetic O
lineages O
( O
with O
up O
to O
21 O
% O
divergence O
) O
and O
multiple O
virus O
introductions O
into O
the O
human O
population O
was O
found O
. O

Ebola B
virus I
( I
EBOV I
) I
causes O
a O
severe O
hemorrhagic O
fever O
for O
which O
there O
are O
currently O
no O
vaccines O
or O
effective O
treatments O
. O

Two O
species O
of O
EBOV O
, O
Sudan B
ebolavirus I
( I
SEBOV I
) I
and O
Zaire B
Ebolavirus I
( I
ZEBOV I
) I
, O
have O
been O
responsible O
for O
all O
of O
the O
deadly O
human O
outbreaks O
resulting O
from O
this O
virus O
. O

Here O
, O
we O
describe O
the O
bivalent O
cAdVaxE O
( O
GPs O
/ O
z O
) O
vaccine O
, O
which O
includes O
the O
SEBOV O
glycoprotein B
( I
GP I
) I
and O
ZEBOV O
GP O
genes O
together O
in O
a O
single O
complex B
adenovirus I
- I
based I
vaccine I
( I
cAdVax I
) I
vector O
. O

Vaccination O
of O
mice O
with O
the O
bivalent O
cAdVaxE O
( O
GPs O
/ O
z O
) O
vaccine O
led O
to O
efficient O
induction O
of O
EBOV O
- O
specific O
antibody O
and O
cell O
- O
mediated O
immune O
responses O
to O
both O
species O
of O
EBOV O
. O

In O
addition O
, O
the O
cAdVax O
technology O
demonstrated O
induction O
of O
a O
100 O
% O
protective O
immune O
response O
in O
mice O
, O
as O
all O
vaccinated O
C57BL O
/ O
6 O
and O
BALB O
/ O
c O
mice O
survived O
challenge O
with O
a O
lethal O
dose O
of O
ZEBOV O
( O
30 O
, O
000 O
times O
the O
50 O
% O
lethal O
dose O
) O
. O

While O
the O
transmembrane O
glycoprotein O
GP O
( O
1 O
, O
2 O
) O
has O
been O
shown O
to O
cause O
endothelial O
cell O
destruction O
, O
the O
role O
of O
the O
soluble O
glycoproteins O
in O
pathogenesis O
is O
largely O
unknown O
; O
however O
, O
they O
are O
hypothesized O
to O
be O
of O
biological O
relevance O
in O
terms O
of O
target O
cell O
activation O
and O
/ O
or O
increase O
of O
endothelial O
permeability O
. O

Here O
we O
show O
that O
virus B
- I
like I
particles I
( I
VLPs I
) I
consisting O
of O
the O
Ebola O
virus O
matrix O
protein O
VP40 O
and O
GP O
( O
1 O
, O
2 O
) O
were O
able O
to O
activate O
endothelial O
cells O
and O
induce O
a O
decrease O
in O
barrier O
function O
as O
determined O
by O
impedance O
spectroscopy O
and O
hydraulic O
conductivity O
measurements O
. O

The O
VLP O
- O
induced O
decrease O
in O
barrier O
function O
was O
further O
enhanced O
by O
the O
cytokine O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
which O
is O
known O
to O
induce O
a O
long O
- O
lasting O
decrease O
in O
endothelial O
cell O
barrier O
function O
and O
is O
hypothesized O
to O
play O
a O
key O
role O
in O
Ebola O
virus O
pathogenesis O
. O

Our O
results O
demonstrate O
that O
Ebola O
virus O
GP O
( O
1 O
, O
2 O
) O
in O
its O
particle O
- O
associated O
form O
mediates O
endothelial O
cell O
activation O
and O
a O
decrease O
in O
endothelial O
cell O
barrier O
function O
. O

In O
order O
to O
develop O
a O
tool O
to O
explore O
potential O
roles O
for O
transcription O
and O
replication O
in O
the O
reduced O
pathogenicity O
of O
Reston O
ebolavirus O
, O
we O
developed O
an O
RNA B
polymerase I
I I
( I
Pol I
I I
) I
- O
driven O
minigenome O
system O
. O

The O
Pol O
I O
- O
driven O
Reston O
ebolavirus O
minigenome O
system O
provides O
a O
higher O
signal O
intensity O
with O
less O
background O
( O
higher O
signal O
- O
to O
- O
noise O
ratio O
) O
than O
a O
comparable O
T7 O
- O
driven O
Reston O
ebolavirus O
minigenome O
system O
which O
was O
developed O
simultaneously O
. O

Ebola O
virus O
efficiently O
produces O
four O
soluble O
glycoproteins O
during O
infection O
: O
sGP O
, O
delta O
peptide O
( O
Delta O
- O
peptide O
) O
, O
GP O
( O
1 O
) O
, O
and O
GP O
( O
1 O
, O
2Delta O
) O
. O

While O
the O
presence O
of O
these O
glycoproteins O
has O
been O
confirmed O
in O
blood O
( O
sGP O
) O
and O
in O
vitro O
systems O
, O
it O
is O
hypothesized O
that O
they O
are O
of O
biological O
relevance O
in O
pathogenesis O
, O
particularly O
target O
cell O
activation O
. O

Primary O
human O
macrophages O
were O
treated O
with O
glycoproteins O
and O
virus O
- O
like O
particles O
and O
subsequently O
tested O
for O
activation O
by O
detection O
of O
several O
critical O
proinflammatory O
cytokines O
( O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
- O
6 O
[ O
IL O
- O
6 O
] O
, O
and O
IL O
- O
1 O
beta O
) O
and O
the O
chemokine O
IL O
- O
8 O
. O

We O
propose O
that O
the O
presentation O
of O
GP O
( O
1 O
, O
2 O
) O
in O
the O
rigid O
form O
such O
as O
that O
observed O
on O
the O
surface O
of O
particles O
is O
critical O
for O
initiating O
a O
sufficient O
signal O
for O
the O
activation O
of O
primary O
target O
cells O
. O

To O
analyze O
the O
entry O
and O
fusion O
properties O
of O
Ebola O
virus O
, O
we O
adapted O
a O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
virion O
- O
based O
fusion O
assay O
by O
substituting O
Ebola O
virus O
glycoprotein B
( I
GP I
) I
for O
the O
HIV O
- O
1 O
envelope O
. O

Entry O
and O
fusion O
induced O
by O
the O
Ebola O
virus O
GP O
occurred O
with O
much O
slower O
kinetics O
than O
with O
vesicular B
stomatitis I
virus I
G I
protein I
( I
VSV I
- I
G I
) I
and O
were O
blocked O
by O
depletion O
of O
membrane O
cholesterol O
and O
by O
inhibition O
of O
vesicular O
acidification O
with O
bafilomycin O
A1 O
. O

Entry O
and O
fusion O
of O
Ebola O
virus O
GP O
pseudotypes O
, O
but O
not O
VSV O
- O
G O
or O
HIV O
- O
1 O
Env O
pseudotypes O
, O
were O
impaired O
in O
the O
presence O
of O
the O
microtubule O
- O
disrupting O
agent O
nocodazole O
but O
were O
enhanced O
in O
the O
presence O
of O
the O
microtubule O
- O
stabilizing O
agent O
paclitaxel O
( O
Taxol O
) O
. O

The O
Marburg B
virus I
( I
MARV I
) I
envelope O
consists O
of O
a O
lipid O
membrane O
and O
two O
major O
proteins O
, O
the O
matrix O
protein O
VP40 O
and O
the O
glycoprotein O
GP O
. O

In O
the O
present O
study O
, O
we O
identified O
the O
intracellular O
site O
where O
the O
two O
major O
envelope O
proteins O
of O
MARV O
come O
together O
as O
peripheral O
multivesicular B
bodies I
( I
MVBs I
) I
. O

Peripheral O
blood O
samples O
obtained O
from O
patients O
during O
an O
outbreak O
of O
Ebola O
virus O
( O
Sudan O
species O
) O
disease O
in O
Uganda O
in O
2000 O
were O
used O
to O
phenotype O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
quantitate O
gene O
expression O
, O
measure O
antigenemia O
, O
and O
determine O
nitric O
oxide O
levels O
. O

Blood O
smears O
revealed O
thrombocytopenia O
, O
a O
left O
shift O
in O
neutrophils O
( O
in O
some O
cases O
degenerating O
) O
, O
and O
atypical O
lymphocytes O
. O

Infected O
patients O
who O
died O
had O
reduced O
numbers O
of O
T O
cells O
, O
CD8 O
( O
+ O
) O
T O
cells O
, O
and O
activated O
( O
HLA O
- O
DR O
+ O
) O
CD8 O
( O
+ O
) O
T O
cells O
, O
while O
the O
opposite O
was O
noted O
for O
patients O
who O
survived O
the O
disease O
. O

Expression O
levels O
of O
cytokines O
, O
Fas O
antigen O
, O
and O
Fas O
ligand O
( O
TaqMan O
quantitation O
) O
in O
PBMC O
from O
infected O
patients O
were O
not O
significantly O
different O
from O
those O
in O
uninfected O
patients O
( O
treated O
in O
the O
same O
isolation O
wards O
) O
, O
nor O
was O
there O
a O
significant O
increase O
in O
expression O
compared O
to O
healthy O
volunteers O
( O
United O
States O
) O
. O

Ebola O
virus O
RNA O
levels O
( O
virus O
load O
) O
in O
PBMC O
specimens O
were O
found O
to O
be O
much O
higher O
in O
infected O
patients O
who O
died O
than O
patients O
who O
survived O
the O
disease O
. O

Similarly O
, O
blood O
levels O
of O
nitric O
oxide O
were O
much O
higher O
in O
fatal O
cases O
( O
increasing O
with O
disease O
severity O
) O
, O
and O
extremely O
elevated O
levels O
( O
greater O
than O
or O
equal O
to150 O
muM O
) O
would O
have O
negatively O
affected O
vascular O
tone O
and O
contributed O
to O
virus O
- O
induced O
shock O
. O

Replication O
- O
competent O
recombinant B
vesicular I
stomatitis I
viruses I
( I
rVSVs I
) I
expressing O
the O
type O
1 O
transmembrane O
glycoproteins O
and O
selected O
soluble O
glycoproteins O
of O
several O
viral O
hemorrhagic O
fever O
agents O
( O
Marburg O
virus O
, O
Ebola O
virus O
, O
and O
Lassa O
virus O
) O
were O
generated O
and O
characterized O
. O

Ebola B
Zaire I
virus I
( I
EBO I
- I
Z I
) I
causes O
severe O
hemorrhagic O
fever O
in O
humans O
, O
with O
a O
high O
mortality O
rate O
. O

Because O
it O
is O
known O
that O
liposome O
- O
encapsulated O
antigens O
induce O
both O
antibody O
and O
cellular O
responses O
, O
we O
evaluated O
the O
protective O
efficacy O
of O
liposome O
- O
encapsulated O
irradiated O
EBO O
- O
Z O
[ O
L O
( O
EV O
) O
] O
, O
which O
contains O
all O
of O
the O
native O
EBO O
- O
Z O
proteins O
. O

In O
a O
series O
of O
experiments O
, O
mice O
immunized O
intravenously O
with O
L O
( O
EV O
) O
were O
completely O
protected O
( O
94 O
/ O
94 O
mice O
) O
against O
illness O
and O
death O
when O
they O
were O
challenged O
with O
a O
uniformly O
lethal O
mouse O
- O
adapted O
variant O
of O
EBO O
- O
Z O
. O

In O
contrast O
, O
only O
55 O
% O
of O
mice O
immunized O
intravenously O
with O
nonencapsulated O
irradiated O
virus O
( O
EV O
) O
survived O
challenge O
, O
and O
all O
became O
ill O
. O

Treatment O
with O
anti O
- O
CD4 O
antibodies O
before O
or O
during O
immunization O
with O
L O
( O
EV O
) O
eliminated O
protection O
, O
while O
treatment O
with O
anti O
- O
CD8 O
antibodies O
had O
no O
effect O
, O
thus O
indicating O
a O
requirement O
for O
CD4 O
( O
+ O
) O
T O
lymphocytes O
for O
successful O
immunization O
. O

After O
immunization O
with O
L O
( O
EV O
) O
, O
antigen O
- O
specific O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
secreting O
CD4 O
( O
+ O
) O
T O
lymphocytes O
were O
induced O
as O
analyzed O
by O
enzyme O
- O
linked O
immunospot O
assay O
. O

Anti O
- O
CD4 O
monoclonal O
antibody O
treatment O
abolished O
IFNgamma O
production O
( O
80 O
to O
90 O
% O
inhibition O
compared O
to O
that O
for O
untreated O
mice O
) O
. O

Mice O
immunized O
with O
L O
( O
EV O
) O
, O
but O
not O
EV O
, O
developed O
cytotoxic O
T O
lymphocytes O
specific O
to O
two O
peptides O
( O
amino O
acids O
[ O
aa O
] O
161 O
to O
169 O
and O
aa O
231 O
to O
239 O
) O
present O
in O
the O
amino O
- O
terminal O
end O
of O
the O
EBO O
- O
Z O
surface O
glycoprotein O
. O

Because O
of O
the O
highly O
successful O
results O
in O
the O
mouse O
model O
, O
L O
( O
EV O
) O
was O
also O
tested O
in O
three O
cynomolgus O
monkeys O
. O

Although O
immunization O
of O
the O
monkeys O
with O
L O
( O
EV O
) O
- O
induced O
virus O
- O
neutralizing O
antibodies O
against O
EBO O
- O
Z O
caused O
a O
slight O
delay O
in O
the O
onset O
of O
illness O
, O
it O
did O
not O
prevent O
death O
. O

Here O
we O
exploit O
a O
reverse O
genetics O
system O
that O
allows O
the O
generation O
of O
Ebola O
virus O
from O
cloned O
cDNA O
to O
engineer O
a O
mutant O
Ebola O
virus O
with O
an O
altered O
furin O
recognition O
motif O
in O
the O
glycoprotein B
( I
GP I
) I
. O

To O
this O
end O
, O
we O
established O
an O
MDCKII O
cell O
line O
that O
was O
able O
to O
express O
GP O
permanently O
( O
MDCK O
- O
GP O
) O
. O

Here O
, O
we O
demonstrate O
that O
Marburg B
virus I
( I
MBG I
) I
, O
a O
filovirus O
causing O
a O
severe O
form O
of O
hemorrhagic O
fever O
in O
humans O
, O
replicates O
in O
human O
monocytes O
/ O
macrophages O
, O
resulting O
in O
cytolytic O
infection O
and O
release O
of O
infectious O
virus O
particles O
. O

Monocytes O
/ O
macrophages O
were O
activated O
by O
MBG O
infection O
as O
indicated O
by O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
release O
. O

Hendra B
virus I
( I
HeV I
) I
is O
a O
zoonotic O
paramyxovirus O
that O
utilizes O
a O
trimeric O
fusion O
( O
F O
) O
protein O
within O
its O
lipid O
bilayer O
to O
mediate O
membrane O
merger O
with O
a O
cell O
membrane O
for O
entry O
. O

Previous O
HeV O
F O
studies O
showed O
that O
transmembrane B
domain I
( I
TMD I
) I
interactions O
are O
important O
for O
stabilizing O
the O
prefusion O
conformation O
of O
the O
protein O
prior O
to O
triggering O
. O

HeV O
F O
constructs O
( O
T483C O
/ O
V484C O
, O
V484C O
/ O
N485C O
, O
and O
N485C O
/ O
P486C O
) O
were O
generated O
with O
double O
cysteine O
substitutions O
near O
the O
N O
- O
terminal O
region O
of O
the O
TMD O
to O
study O
the O
effect O
of O
altered O
flexibility O
in O
this O
region O
. O

IMPORTANCE O
The O
paramyxovirus O
Hendra B
virus I
( I
HeV I
) I
causes O
severe O
respiratory O
illness O
and O
encephalitis O
in O
humans O
. O

Knowledge O
gained O
in O
studies O
of O
the O
HeV O
fusion O
( O
F O
) O
protein O
may O
be O
applicable O
to O
a O
broad O
span O
of O
enveloped O
viruses O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
disulfide O
bonds O
introduced O
between O
the O
HeV O
F O
transmembrane B
domains I
( I
TMDs I
) I
block O
fusion O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
highly O
lethal O
paramyxovirus O
that O
recently O
emerged O
as O
a O
causative O
agent O
of O
febrile O
encephalitis O
and O
severe O
respiratory O
disease O
in O
humans O
. O

Using O
recombinant B
NiVs I
( I
rNiVs I
) I
, O
we O
examine O
the O
sole O
contribution O
of O
the O
NiV O
C O
protein O
and O
the O
combined O
contributions O
of O
the O
C O
and O
W O
proteins O
in O
the O
ferret O
model O
of O
NiV O
pathogenesis O
. O

Hendra B
virus I
( I
HeV I
) I
is O
a O
zoonotic O
emerging O
virus O
belonging O
to O
the O
family O
Paramyxoviridae O
. O

A O
number O
of O
animal O
models O
have O
been O
developed O
for O
studying O
HeV O
infection O
, O
with O
the O
African B
green I
monkey I
( I
AGM I
) I
appearing O
to O
most O
faithfully O
reproduce O
the O
human O
disease O
. O

Here O
, O
we O
assessed O
the O
utility O
of O
a O
newly O
developed O
recombinant O
subunit O
vaccine O
based O
on O
the O
HeV O
attachment O
( O
G O
) O
glycoprotein O
in O
the O
AGM O
model O
. O

Four O
AGMs O
were O
vaccinated O
with O
two O
doses O
of O
the O
HeV O
vaccine O
( O
sG O
( O
HeV O
) O
) O
containing O
Alhydrogel O
, O
four O
AGMs O
received O
the O
sG O
( O
HeV O
) O
with O
Alhydrogel O
and O
CpG O
, O
and O
four O
control O
animals O
did O
not O
receive O
the O
sG O
( O
HeV O
) O
vaccine O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
nonsegmented O
, O
single O
- O
stranded O
, O
negative O
- O
sense O
RNA O
virus O
belonging O
to O
the O
genus O
Henipavirus O
, O
family O
Paramyxoviridae O
. O

The O
genomes O
of O
henipaviruses O
are O
about O
18 O
, O
246 O
nucleotides B
( I
nt I
) I
long O
, O
which O
is O
longer O
than O
those O
of O
other O
paramyxoviruses O
( O
around O
15 O
, O
384 O
nt O
) O
. O

This O
difference O
is O
caused O
by O
the O
noncoding O
RNA O
region O
, O
particularly O
the O
3 B
' I
untranslated I
region I
( I
UTR I
) I
, O
which O
occupies O
more O
than O
half O
of O
the O
noncoding O
RNA O
region O
. O

To O
determine O
the O
function O
( O
s O
) O
of O
the O
NiV O
noncoding O
RNA O
region O
, O
we O
investigated O
the O
effects O
of O
NiV O
3 O
' O
UTRs O
on O
reporter O
gene O
expression O
. O

The O
NiV O
N O
3 O
' O
UTR O
( O
nt O
1 O
to O
100 O
) O
demonstrated O
strong O
repressor O
activity O
associated O
with O
hnRNP O
D O
protein O
binding O
to O
that O
region O
. O

Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
are O
deadly O
zoonotic O
viruses O
for O
which O
no O
vaccines O
or O
therapeutics O
are O
licensed O
for O
human O
use O
. O

The O
growth O
kinetics O
of O
NiV O
- O
Malaysia O
, O
NiV O
- O
Bangladesh O
, O
and O
HeV O
were O
determined O
in O
bronchial O
/ O
tracheal O
epithelial O
cells O
( O
NHBE O
) O
and O
small B
airway I
epithelial I
cells I
( I
SAEC I
) I
. O

These O
responses O
were O
highest O
during O
HeV O
infection O
in O
SAEC O
, O
as O
characterized O
by O
the O
levels O
of O
key O
cytokines O
( O
interleukin O
6 O
[ O
IL O
- O
6 O
] O
, O
IL O
- O
8 O
, O
IL O
- O
1 O
alpha O
, O
monocyte O
chemoattractant O
protein O
1 O
[ O
MCP O
- O
1 O
] O
, O
and O
colony O
- O
stimulating O
factors O
) O
responsible O
for O
immune O
cell O
recruitment O
. O

Nipah B
virus I
( I
NiV I
) I
is O
a O
recently O
emerged O
zoonotic O
paramyxovirus O
whose O
natural O
reservoirs O
are O
several O
species O
of O
Pteropus O
fruit O
bats O
. O

The O
henipaviruses O
, O
Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
, O
are O
emerging O
zoonotic O
paramyxoviruses O
that O
can O
cause O
severe O
and O
often O
lethal O
neurologic O
and O
/ O
or O
respiratory O
disease O
in O
a O
wide O
variety O
of O
mammalian O
hosts O
, O
including O
humans O
. O

Guinea O
pigs O
, O
hamsters O
, O
cats O
, O
and O
ferrets O
, O
have O
been O
evaluated O
as O
animal O
models O
of O
human O
HeV O
infection O
, O
but O
studies O
in O
nonhuman B
primates I
( I
NHP I
) I
have O
not O
been O
reported O
, O
and O
the O
development O
and O
approval O
of O
any O
vaccine O
or O
antiviral O
for O
human O
use O
will O
likely O
require O
efficacy O
studies O
in O
an O
NHP O
model O
. O

Here O
, O
we O
examined O
the O
pathogenesis O
of O
HeV O
in O
the O
African B
green I
monkey I
( I
AGM I
) I
following O
intratracheal O
inoculation O
. O

Nipah O
( O
NiV O
) O
and O
Hendra O
( O
HeV O
) O
viruses O
are O
emerging O
zoonotic O
paramyxoviruses O
that O
cause O
encephalitis O
in O
humans O
, O
with O
fatality O
rates O
of O
up O
to O
75 O
% O
. O

We O
designed O
a O
new O
high B
- I
throughput I
screening I
( I
HTS I
) I
assay O
for O
inhibitors O
of O
infection O
based O
on O
envelope O
glycoprotein O
pseudotypes O
. O

The O
assay O
simulates O
multicycle O
replication O
and O
thus O
identifies O
inhibitors O
that O
target O
several O
stages O
of O
the O
viral O
life O
cycle O
, O
but O
it O
still O
can O
be O
carried O
out O
under O
biosafety B
level I
2 I
( I
BSL I
- I
2 I
) I
conditions O
. O

Chloroquine O
inhibited O
infection O
with O
live O
HeV O
and O
NiV O
at O
a O
concentration O
of O
1 O
mu O
M O
in O
vitro O
( O
50 O
% O
inhibitory O
concentration O
, O
2 O
mu O
M O
) O
, O
which O
is O
less O
than O
the O
plasma O
concentrations O
present O
in O
humans O
receiving O
chloroquine O
treatment O
for O
malaria O
. O

The O
henipaviruses O
, O
Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
, O
are O
lethal O
emerging O
paramyxoviruses O
. O

Here O
we O
show O
that O
( O
i O
) O
soluble B
NiV I
attachment I
protein I
G I
( I
sNiV I
- I
G I
) I
bound O
to O
cell O
surface O
- O
expressed O
ephrinB3 O
with O
a O
30 O
- O
fold O
higher O
affinity O
than O
that O
of O
sHeV O
- O
G O
, O
( O
ii O
) O
NiV B
envelope I
pseudotyped I
reporter I
virus I
( I
NiVpp I
) I
entered O
ephrinB3 O
- O
expres O
sing O
cells O
much O
more O
efficiently O
than O
did O
HeV B
pseudotyped I
particles I
( I
HeVpp I
) I
, O
and O
( O
iii O
) O
NiVpp O
but O
not O
HeVpp O
entry O
was O
inhibited O
efficiently O
by O
soluble O
ephrinB3 O
. O

We O
further O
defined O
surrounding O
mutations O
( O
W504A O
and O
E505A O
) O
that O
diminished O
ephrinB3 O
- O
dependent O
binding O
and O
viral O
entry O
without O
compromising O
ephrin O
] O
32 O
receptor O
usage O
and O
another O
mutation O
( O
E533Q O
) O
that O
abrogated O
both O
ephrinB2 O
and O
- O
B3 O
usage O
. O

Paramyxoviruses O
utilize O
both O
an O
attachment O
protein O
and O
a O
fusion O
( O
F O
) O
protein O
to O
drive O
virus O
- O
cell O
and O
cell O
- O
cell O
fusion O
. O

Alignment O
and O
analysis O
of O
a O
set O
of O
paramyxovirus O
F O
protein O
sequences O
identified O
three O
conserved O
blocks O
( O
CB O
) O
: O
one O
in O
the O
fusion O
peptide O
/ O
heptad O
repeat O
A O
domain O
, O
known O
to O
play O
important O
roles O
in O
fusion O
promotion O
, O
one O
in O
the O
region O
between O
the O
heptad O
repeats O
of O
F O
, O
( O
CBF O
) O
( O
A O
. O

To O
analyze O
the O
functions O
of O
CBF2 O
alanine O
substitutions O
at O
conserved O
positions O
were O
created O
in O
both O
the O
simian B
virus I
5 I
( I
SV5 I
) I
and O
Hendra O
virus O
F O
proteins O
. O

Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
are O
paramyxoviruses O
capable O
of O
causing O
considerable O
morbidity O
and O
mortality O
in O
a O
number O
of O
mammalian O
species O
, O
including O
humans O
. O

Here O
we O
have O
assessed O
the O
cat O
as O
a O
model O
of O
experimental O
NiV O
infection O
and O
use O
it O
in O
the O
evaluation O
of O
a O
subunit O
vaccine O
comprised O
of O
soluble O
G O
glycoprotein O
( O
sG O
) O
. O

Two O
groups O
of O
two O
adult O
cats O
each O
were O
inoculated O
subcutaneously O
with O
either O
500 O
or O
5 O
, O
000 O
50 O
% O
tissue O
culture O
infective O
dose O
( O
s O
) O
( O
TCID50 O
) O
of O
NiV O
. O

Hendra B
virus I
( I
HeV I
) I
and O
Nipah B
virus I
( I
NiV I
) I
are O
closely O
related O
emerging O
viruses O
comprising O
the O
Henipavirus O
genus O
of O
the O
Paramyxovirinae O
. O

These O
viruses O
infect O
cells O
by O
a O
pH O
- O
independent O
membrane O
fusion O
event O
mediated O
by O
their O
attachment O
( O
G O
) O
and O
fusion O
( O
F O
) O
envelope B
glycoproteins I
( I
Envs I
) I
. O

Seven O
Fabs O
, O
m101 O
to O
- O
7 O
, O
were O
selected O
for O
their O
significant O
binding O
to O
a O
soluble O
form O
of O
Hendra O
G O
( O
sG O
) O
which O
was O
used O
as O
the O
antigen O
for O
panning O
of O
a O
large O
naive O
human O
antibody O
library O
. O

The O
conversion O
of O
the O
most O
potent O
neutralizer O
of O
infectious O
HeV O
, O
Fab O
m101 O
, O
to O
Immunoglobulin B
G1 I
( I
IgG1 I
) I
significantly O
increased O
its O
cell O
fusion O
inhibitory O
activity O
: O
the O
50 O
% O
inhibitory O
concentration O
was O
decreased O
more O
than O
10 O
- O
fold O
to O
approximately O
1 O
mu O
g O
/ O
ml O
. O

The O
IgG1 O
m101 O
was O
also O
exceptionally O
potent O
in O
neutralizing O
infectious O
HeV O
; O
complete O
( O
100 O
% O
) O
neutralization O
was O
achieved O
with O
12 O
. O

We O
show O
that O
both O
of O
the O
Nipah O
virus O
glycoproteins O
( O
G O
and O
F O
) O
when O
expressed O
as O
vaccinia O
virus O
recombinants O
induced O
an O
immune O
response O
in O
hamsters O
which O
protected O
against O
a O
lethal O
challenge O
by O
Nipah O
virus O
. O

The O
V O
proteins O
of O
other O
paramyxovirus O
species O
have O
been O
linked O
with O
evasion O
of O
host O
cell O
interferon B
( I
IFN I
) I
signal O
transduction O
and O
subsequent O
antiviral O
responses O
by O
inducing O
proteasomal O
degradation O
of O
the O
IFN O
- O
responsive O
transcription O
factors O
, O
STAT1 O
or O
STAT2 O
. O

The O
causative O
agent O
was O
a O
new O
member O
of O
the O
family O
Paramyxoviridae O
, O
The O
virus O
was O
originally O
called O
Equine O
morbillivirus O
but O
was O
renamed O
Hendra B
virus I
( I
HeV I
) I
when O
molecular O
characterization O
highlighted O
differences O
between O
it O
and O
members O
of O
the O
genus O
Morbillivirus O
, O
Less O
than O
5 O
years O
later O
, O
the O
closely O
related O
Nipah B
virus I
( I
NiV I
) I
emerged O
in O
Malaysia O
, O
spread O
rapidly O
through O
the O
pig O
population O
, O
and O
caused O
the O
deaths O
of O
over O
100 O
people O
. O

In O
the O
highly O
conserved O
region O
of O
the O
L O
protein O
, O
the O
HeV O
sequence O
GDNE O
differs O
from O
the O
GDNQ O
found O
in O
almost O
all O
other O
nonsegmented B
negative I
- I
strand I
( I
NNS I
) I
RNA O
viruses O
. O

HeV O
has O
an O
absolutely O
conserved O
intergenic O
trinucleotide O
sequence O
, O
3 O
' O
- O
GAA O
- O
5 O
' O
, O
and O
highly O
conserved O
transcription O
initiation O
and O
termination O
sequences O
similar O
to O
those O
of O
respiroviruses O
and O
morbilliviruses O
, O
The O
large O
genome O
size O
( O
18 O
, O
234 O
nucleotides O
) O
, O
the O
unique O
complementary O
genome O
terminal O
sequences O
of O
HeV O
, O
and O
the O
limited O
homology O
with O
other O
members O
of O
the O
Paramyxoviridae O
suggest O
that O
HeV O
, O
together O
with O
NiV O
, O
should O
be O
classified O
in O
a O
new O
genus O
in O
this O
family O
. O

To O
study O
mechanisms O
of O
this O
disease O
, O
we O
used O
a O
clinically O
relevant O
animal O
model O
of O
murine B
cytomegalovirus I
( I
MCMV I
) I
retinitis O
with O
retrovirus O
- O
induced O
murine B
AIDS I
( I
MAIDS I
) I
that O
mimics O
the O
progression O
of O
AIDS O
in O
humans O
. O

We O
found O
in O
this O
model O
that O
MCMV O
infection O
significantly O
stimulates O
ocular O
suppressor B
of I
cytokine I
signaling I
1 I
( I
SOCS1 I
) I
and O
SOCS3 O
, O
host O
proteins O
which O
hinder O
immune O
- O
related O
signaling O
by O
cytokines O
, O
including O
antiviral O
type O
I O
and O
type O
II O
interferons O
. O

In O
sharp O
contrast O
, O
when O
MCMV O
is O
directly O
inoculated O
into O
the O
eyes O
of O
retinitis O
- O
susceptible O
MAIDS O
mice O
, O
high O
levels O
of O
intraocular O
SOCS1 O
and O
SOCS3 O
mRNA O
and O
protein O
are O
produced O
which O
are O
associated O
with O
significant O
intraocular O
upregulation O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
mRNA O
expression O
. O

Myeloid B
- I
derived I
suppressor I
cells I
( I
MDSCs I
) I
have O
been O
characterized O
in O
several O
disease O
settings O
, O
especially O
in O
many O
tumor O
systems O
. O

These O
MDSCs O
express O
a O
cell O
surface O
marker O
signature O
( O
CD11b O
( O
+ O
) O
Gr O
- O
1 O
( O
+ O
) O
Ly6C O
( O
+ O
) O
) O
characteristic O
of O
monocyte O
- O
type O
MDSCs O
. O

Such O
MDSCs O
profoundly O
inhibit O
immune O
responsiveness O
by O
a O
cell O
dose O
- O
and O
substantially O
inducible B
nitric I
oxide I
synthase I
( I
iNOS I
) I
- O
dependent O
mechanism O
that O
is O
independent O
of O
arginase O
activity O
, O
PD O
- O
1 O
- O
PD O
- O
L1 O
expression O
, O
and O
interleukin B
10 I
( I
IL I
- I
10 I
) I
production O
. O

Retroviral O
load O
measurements O
indicated O
that O
the O
suppressive O
Ly6G O
( O
low O
/ O
+ O
/ O
- O
) O
Ly6C O
( O
+ O
) O
CD11b O
( O
+ O
) O
- O
enriched O
MDSC O
subset O
was O
positive O
for O
LP O
- O
BM5 O
, O
albeit O
at O
a O
significantly O
lower O
level O
than O
that O
of O
nonfractionated O
splenocytes O
from O
LP O
- O
BM5 O
- O
infected O
mice O
. O

LP O
- O
BM5 O
retrovirus O
induces O
a O
complex O
disease O
featuring O
an O
acquired O
immunodeficiency O
syndrome O
termed O
murine B
AIDS I
( I
MAIDS I
) I
in O
susceptible O
strains O
of O
mice O
, O
such O
as O
C57BL O
/ O
6 O
( O
B6 O
) O
. O

We O
have O
discovered O
an O
immunodominant O
cytolytic B
T I
lymphocyte I
( I
CTL I
) I
epitope O
encoded O
in O
a O
previously O
unrecognized O
LP O
- O
BM5 O
retroviral O
alternative O
( O
+ O
1 O
nucleotide O
[ O
nt O
] O
) O
gag O
translational O
open O
reading O
frame O
. O

However O
, O
uninfected O
B6 O
mice O
primed O
by O
LP O
- O
BM5 O
- O
induced O
tumors O
can O
generate O
CTL O
responses O
to O
an O
LP O
- O
BM5 O
retrovirus O
infection O
- O
associated O
epitope O
( O
s O
) O
that O
is O
especially O
prevalent O
on O
such O
MAIDS O
tumor O
cells O
, O
indicating O
the O
potential O
to O
mount O
a O
protective O
CD8 O
T O
- O
cell O
response O
. O

Thus O
, O
following O
in O
vivo O
depletion O
of O
CD4 O
T O
regulatory O
( O
T O
( O
reg O
) O
) O
cells O
and O
/ O
or O
selective O
interruption O
of O
PD O
- O
1 O
negative O
signaling O
in O
the O
CD8 O
T O
- O
cell O
compartment O
, O
retroviral O
pathogenesis O
was O
significantly O
decreased O
, O
with O
the O
combined O
treatment O
of O
CD4 O
T O
( O
reg O
) O
cell O
depletion O
and O
PD O
- O
1 O
blockade O
working O
in O
a O
synergistic O
fashion O
to O
substantially O
reduce O
the O
induction O
of O
MAIDS O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
is O
a O
common O
human O
pathogen O
that O
causes O
lifelong O
latent O
infection O
of O
sensory O
neurons O
. O

We O
report O
that O
chebulagic B
acid I
( I
CHLA I
) I
and O
punicalagin B
( I
PUG I
) I
, O
two O
hydrolyzable O
tannins O
isolated O
from O
the O
dried O
fruits O
of O
Terminalia O
chebula O
Retz O
. O

( O
Combretaceae O
) O
, O
inhibit O
HSV O
- O
1 O
entry O
at O
noncytotoxic O
doses O
in O
A549 O
human O
lung O
cells O
. O

It O
has O
been O
demonstrated O
previously O
that O
HIV O
- O
1 O
particles O
acquire O
the O
costimulatory O
molecule O
CD40L O
when O
budding O
from O
activated O
CD4 O
( O
+ O
) O
T O
cells O
. O

Among O
modulated O
genes O
, O
many O
cytokines O
/ O
chemokines O
( O
CCL17 O
, O
CCL22 O
) O
, O
surface O
molecules O
( O
CD23 O
, O
CD80 O
, O
ICAM O
- O
1 O
) O
, O
members O
of O
the O
TNF O
superfamily O
( O
FAS O
, O
A20 O
, O
TNIP1 O
, O
CD40 O
, O
lymphotoxin O
alpha O
, O
lymphotoxin O
beta O
) O
, O
transcription O
factors O
and O
associated O
proteins O
( O
NFKB1 O
, O
NFKBIA O
, O
NFKBIE O
) O
, O
second O
messengers O
involved O
in O
CD40 O
signaling O
( O
TRAF1 O
, O
TRAF3 O
, O
MAP2K1 O
, O
phosphatidylinositol O
3 O
- O
kinase O
) O
, O
and O
the O
activation B
- I
induced I
cytidine I
deaminase I
( I
AID I
) I
were O
identified O
. O

Moreover O
, O
we O
show O
that O
soluble O
factors O
induced O
upon O
the O
exposure O
of O
B O
cells O
to O
CD40L O
- O
bearing O
virions O
can O
exert O
chemoattractant O
properties O
toward O
CD4 O
( O
+ O
) O
T O
cells O
. O

We O
thus O
propose O
that O
a O
positive O
feedback O
loop O
involving O
CD40L O
- O
bearing O
HIV O
- O
1 O
particles O
issued O
from O
CD4 O
( O
+ O
) O
T O
cells O
productively O
infected O
with O
HIV O
- O
1 O
play O
a O
role O
in O
the O
virus O
- O
induced O
dysfunction O
of O
humoral O
immunity O
by O
chronically O
activating O
B O
cells O
through O
sustained O
CD40 O
signaling O
. O

Rearrangements O
of O
the O
JC B
virus I
( I
JCV I
) I
regulatory I
region I
( I
RR I
) I
are O
consistently O
found O
in O
the O
brains O
of O
patients O
with O
progressive B
multifocal I
leukoencephalopathy I
( I
PML I
) I
, O
whereas O
the O
archetype O
RR O
is O
present O
in O
their O
kidneys O
. O

In O
addition O
, O
the O
C O
terminus O
of O
the O
large B
T I
antigen I
( I
T I
- I
Ag I
) I
shows O
greater O
variability O
in O
PML O
than O
does O
the O
rest O
of O
the O
coding O
region O
. O

To O
determine O
whether O
similar O
changes O
in O
simian B
virus I
40 I
( I
SV40 I
) I
are O
necessary O
for O
disease O
induction O
in O
monkeys O
, O
we O
sequenced O
the O
SV40 O
RR O
and O
the O
C O
terminus O
of O
the O
T O
- O
Ag O
from O
the O
brain O
of O
simian B
/ I
human I
immunodeficiency I
virus I
( I
SHIV I
) I
- O
infected O
monkey O
18429 O
, O
which O
presented O
spontaneously O
with O
an O
SV40 O
- O
associated O
PML O
- O
like O
disease O
, O
as O
well O
as O
from O
the O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
, O
kidneys O
, O
and O
brains O
of O
SV40 O
- O
seronegative O
, O
SHIV O
- O
infected O
monkeys O
21289 O
and O
21306 O
, O
which O
were O
inoculated O
with O
the O
18429 O
brain O
SV40 O
isolate O
. O

In O
the O
absence O
of O
immune O
surveillance O
, O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- O
infected O
B O
cells O
generate O
neoplasms O
in O
vivo O
and O
transformed O
cell O
lines O
in O
vitro O
. O

In O
an O
in O
vitro O
system O
which O
modeled O
the O
first O
steps O
of O
in O
vivo O
immune O
control O
over O
posttransplant O
lymphoproliferative O
disease O
and O
lymphomas O
, O
our O
investigators O
previously O
demonstrated O
that O
memory O
CD4 O
( O
+ O
) O
T O
cells O
reactive O
to O
EBV O
were O
necessary O
and O
sufficient O
to O
prevent O
proliferation O
of O
B O
cells O
newly O
infected O
by O
EBV O
( O
S O
. O

Here O
, O
we O
show O
that O
three O
CD4 O
( O
+ O
) O
- O
T O
- O
cell O
clones O
reactive O
to O
the O
latent O
EBV O
antigen O
EBNA1 O
also O
prevent O
the O
proliferation O
of O
newly O
infected O
B O
cells O
from O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
- O
matched O
donors O
, O
a O
crucial O
first O
step O
in O
the O
transformation O
process O
. O

Since O
EBNA1 O
is O
recognized O
by O
CD4 O
( O
+ O
) O
T O
cells O
from O
nearly O
all O
EBV O
- O
seropositive O
individuals O
and O
evades O
detection O
by O
CD8 O
( O
+ O
) O
T O
cells O
, O
EBNA1 O
- O
reactive O
CD4 O
( O
+ O
) O
T O
cells O
may O
control O
de O
novo O
expansion O
of O
B O
cells O
following O
EBV O
infection O
in O
vivo O
. O

Thus O
, O
EBNA1 O
- O
reactive O
CD4 O
( O
+ O
) O
- O
T O
- O
cell O
clones O
may O
find O
use O
as O
adoptive O
immunotherapy O
against O
EBV O
- O
related O
lymphoproliferative O
disease O
and O
many O
other O
EBV O
- O
associated O
tumors O
. O

Endemic O
simian B
retrovirus I
( I
SRV I
) I
infection O
can O
cause O
fatal O
simian O
AIDS O
in O
Macaca O
fascicularis O
, O
but O
many O
individuals O
survive O
with O
few O
clinical O
signs O
. O

Herpes B
Simplex I
Virus I
( I
HSV I
) I
DNA O
Polymerase B
( I
Pol I
) I
mutations O
can O
confer O
resistance O
to O
all O
currently O
available O
antiherpetic O
drugs O
. O

A O
new O
system O
is O
reported O
for O
rapid O
generation O
of O
recombinant O
HSV B
type I
1 I
( I
HSV I
- I
1 I
) I
DNA O
Pol O
mutants O
based O
on O
transfection O
of O
a O
set O
of O
overlapping O
viral O
cosmids O
and O
plasmids O
. O

With O
this O
approach O
, O
twenty O
HSV O
- O
1 O
recombinants O
with O
single O
or O
dual O
mutations O
within O
the O
DNA O
pol O
gene O
were O
successfully O
generated O
and O
subsequently O
evaluated O
for O
their O
susceptibilities O
to O
acyclovir B
( I
ACV I
) I
, O
foscarnet B
( I
FOS I
) I
, O
cidofovir B
( I
CDV I
) I
, O
and O
adefovir B
( I
ADV I
) I
. O

Mutations O
within O
DNA O
Pol O
conserved O
regions O
II O
( O
A719T O
and O
S724N O
) O
, O
VL O
( O
L778M O
, O
D780N O
, O
and O
L7821 O
) O
, O
and O
I O
( O
F891C O
) O
were O
shown O
to O
induce O
cross O
- O
resistance O
to O
ACV O
, O
FOS O
, O
and O
ADV O
, O
with O
two O
of O
these O
mutations O
( O
S724N O
and O
L778M O
) O
also O
conferring O
significant O
reduction O
in O
CDV O
susceptibility O
. O

One O
mutation O
( O
D907V O
) O
lying O
outside O
of O
the O
conserved O
regions O
was O
also O
associated O
with O
this O
ACV O
- O
, O
FOS O
- O
, O
and O
ADV O
- O
resistant O
phenotype O
. O

Some O
mutations O
( O
K522E O
and O
Y577H O
) O
within O
the O
delta O
- O
region O
C O
were O
lethal O
, O
whereas O
others O
( O
P561S O
and O
V573M O
) O
induced O
no O
resistance O
to O
any O
of O
the O
drugs O
tested O
. O

Recombinants O
harboring O
mutations O
within O
conserved O
regions O
V O
( O
N961K O
) O
and O
VII O
( O
Y941H O
) O
were O
resistant O
to O
ACV O
but O
susceptible O
to O
FOS O
. O

We O
previously O
identified O
retroperitoneal B
fibromatosis I
- I
associated I
herpesvirus I
( I
RFHV I
) I
as O
a O
simian O
homolog O
of O
Kaposi B
' I
s I
sarcoma I
- I
associated I
herpesvirus I
( I
KSHV I
) I
in O
a O
fibroproliferative O
malignancy O
of O
macaques O
that O
has O
similarities O
to O
Kaposi O
' O
s O
sarcoma O
. O

3 O
kb O
of O
divergent B
locus I
B I
( I
DL I
- I
B I
) I
flanking O
the O
DNA O
polymerase O
gene O
from O
two O
variants O
of O
RFHV O
from O
different O
species O
of O
macaque O
with O
a O
consensus O
degenerate O
hybrid O
oligonucleotide O
primer O
approach O
. O

Within O
the O
DL O
- O
B O
region O
of O
RFHV O
, O
viral O
homologs O
of O
the O
cellular O
interleukin O
- O
6 O
, O
dihydrofolate O
reductase O
, O
and O
thymidylate O
synthase O
genes O
were O
identified O
, O
along O
with O
a O
homolog O
of O
the O
gammaherpesvirus O
open B
reading I
frame I
( I
ORF I
) I
10 O
. O

AIDS O
- O
related O
human B
cytomegalovirus I
( I
HCMV I
) I
retinitis O
continues O
to O
be O
a O
chronic O
ophthalmologic O
problem O
among O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
- O
infected O
patients O
who O
do O
not O
respond O
to O
highly O
active O
antiretroviral O
therapy O
. O

Although O
HCMV O
retinitis O
occurs O
during O
HIV O
- O
1 O
- O
induced O
immunosuppression O
, O
the O
precise O
effector O
mechanism O
( O
s O
) O
that O
fails O
during O
the O
immunopathogenesis O
of O
AIDS O
to O
allow O
onset O
and O
progression O
of O
HCMV O
retinal O
disease O
remains O
unclear O
. O

We O
therefore O
performed O
a O
series O
of O
experiments O
to O
explore O
the O
relative O
roles O
of O
distinct O
pathways O
of O
lymphocyte O
- O
mediated O
cytotoxicity O
in O
either O
resistance O
or O
susceptibility O
to O
experimental O
murine B
cytomegalovirus I
( I
MCMV I
) I
retinitis O
in O
mice O
. O

Whereas O
mutant O
C57BL O
/ O
6 O
mice O
deficient O
in O
the O
Fas O
/ O
FasL O
cytotoxic O
pathway O
( O
gld O
mice O
) O
were O
identical O
to O
normal O
C57BL O
/ O
6 O
mice O
and O
exhibited O
absolute O
resistance O
to O
retinal O
necrosis O
following O
subretinal O
MCMV O
inoculation O
, O
knockout O
C57BL O
/ O
6 O
mice O
deficient O
in O
the O
perforin B
cytotoxic I
pathway I
( I
PKO I
mice I
) I
were O
susceptible O
to O
MCMV O
retinitis O
. O

Since O
mice B
with I
retrovirus I
- I
induced I
immunodeficiency I
syndrome I
( I
MAIDS I
) I
exhibited O
a O
frequency O
and O
severity O
of O
MCMV O
retinitis O
that O
were O
equivalent O
to O
those O
observed O
in O
PKO O
mice O
, O
we O
hypothesized O
that O
susceptibility O
to O
MCMV O
retinitis O
during O
MAIDS O
correlates O
with O
a O
decrease O
in O
the O
perforin O
cytotoxic O
pathway O
. O

Clinical O
resistance O
of O
Herpes B
Simplex I
Virus I
( I
HSV I
) I
types O
1 O
and O
2 O
to O
acyclovir B
( I
ACV I
) I
is O
usually O
caused O
by O
the O
presence O
of O
point O
mutations O
within O
the O
coding O
region O
of O
the O
viral O
thymidine B
kinase I
( I
TK I
) I
gene O
. O

The O
viral O
TK O
genes O
from O
5 O
ACV O
- O
susceptible O
and O
13 O
ACV O
- O
resistant O
clinical O
HSV O
isolates O
and O
from O
the O
reference O
strains O
MS2 O
( O
type O
2 O
) O
and O
KOS O
( O
type O
I O
) O
were O
transfected O
as O
part O
of O
an O
episomal O
expression O
vector O
in O
Leishmania O
, O
The O
susceptibility O
of O
TK O
- O
recombinant O
parasites O
to O
ganciclovir B
( I
GCV I
) I
, O
a O
closely O
related O
nucleoside O
analogue O
, O
was O
evaluated O
by O
a O
simple O
measurement O
of O
the O
absorbance O
of O
Leishmania O
cultures O
grown O
in O
the O
presence O
of O
the O
drug O
. O

The O
natural O
history O
of O
type B
D I
simian I
retrovirus I
( I
SRV I
) I
infection O
is O
poorly O
characterized O
in O
terms O
of O
viral O
load O
, O
antibody O
status O
, O
and O
sequence O
variation O
. O

To O
investigate O
this O
, O
blood O
samples O
were O
taken O
from O
a O
small O
cohort O
of O
mostly O
asymptomatic O
cynomolgus O
macaques O
( O
Macaca O
fascicularis O
) O
, O
naturally O
infected O
with O
SRV B
type I
2 I
( I
SRV I
- I
2 I
) I
, O
some O
of O
which O
were O
followed O
over O
an O
8 O
- O
month O
period O
with O
blood O
taken O
every O
2 O
months O
. O

Previous O
studies O
have O
reported O
that O
infection O
of O
monocytes O
by O
viruses O
such O
as O
cytomegalovirus O
and O
human O
immunodeficiency O
virus O
weakens O
host O
natural O
immunity O
, O
In O
the O
present O
study O
, O
we O
demonstrated O
the O
capability O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
to O
infect O
and O
replicate O
in O
freshly O
isolated O
human O
monocytes O
, O
Using O
electron O
microscopy O
analysis O
, O
we O
observed O
the O
presence O
of O
EBV O
virions O
in O
the O
cytoplasm O
and O
nuclei O
of O
approximately O
20 O
% O
of O
monocytes O
. O

This O
was O
supported O
by O
the O
detection O
of O
immediate O
- O
early O
lytic O
mRNA O
BZLF O
- O
1 O
transcripts O
, O
and O
by O
the O
presence O
of O
two O
early O
lytic O
transcripts O
( O
BALF O
- O
2 O
, O
which O
appears O
to O
function O
in O
DNA O
replication O
, O
and O
BHRF O
- O
1 O
, O
also O
associated O
with O
the O
replicative O
cycle O
) O
, O
The O
late O
lytic O
BcLF O
- O
1 O
transcripts O
, O
which O
code O
for O
the O
major O
nucleocapsid O
protein O
, O
were O
also O
detected O
, O
as O
well O
as O
EBNA O
- O
1 O
transcripts O
. O

human B
herpesvirus I
8 I
( I
HHV8 I
) I
infects O
Kaposi B
' I
s I
sarcoma I
( I
KS I
) I
spindle O
cells O
in O
situ O
, O
as O
well O
as O
the O
lesional O
endothelial O
cells O
considered O
to O
be O
spindle O
cell O
precursors O
. O

In O
vivo O
depletions O
of O
T O
- O
cell O
subsets O
in O
persistently O
infected O
mice O
revealed O
a O
critical O
role O
for O
CD4 O
( O
+ O
) O
T O
cells O
in O
controlling O
virus O
replication O
, O
spread O
to O
the O
erythroid O
lineage O
, O
and O
induction O
of O
erythroleukemia O
, O
The O
CD4 O
( O
+ O
) O
T O
- O
cell O
effect O
was O
independent O
of O
CD8 O
( O
+ O
) O
T O
cells O
and O
in O
some O
cases O
was O
also O
independent O
of O
virus O
- O
neutralizing O
antibody O
responses O
. O

Thus O
, O
the O
CD4 O
( O
+ O
) O
T O
cells O
may O
have O
had O
a O
direct O
antiviral O
effect O
. O

These O
results O
may O
have O
relevance O
for O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
infections O
where O
loss O
of O
CD4 O
( O
+ O
) O
T O
cells O
is O
associated O
, O
vith O
an O
increase O
in O
HIV O
replication O
, O
reactivation O
of O
persistent O
viruses O
, O
and O
a O
high O
incidence O
of O
virus O
- O
associated O
cancers O
. O

A O
herpesvirus O
that O
is O
related O
to O
but O
distinct O
from O
the O
Kaposi B
' I
s I
sarcoma I
- I
associated I
herpesvirus I
( I
KSHV I
, I
or I
human I
herpesvirus I
8 I
) I
was O
isolated O
from O
rhesus O
monkeys O
. O

In O
the O
majority O
of O
cases O
, O
the O
mechanism O
underlying O
the O
resistance O
to O
acyclovir B
( I
ACV I
) I
of O
herpes B
simplex I
viruses I
( I
HSVs I
) I
is O
thymidine B
kinase I
( I
TK I
) I
deficiency O
, O
Plaque O
isolates O
from O
eight O
ACV O
- O
resistant O
( O
ACV O
( O
r O
) O
) O
clinical O
isolates O
from O
AIDS O
patients O
, O
of O
which O
five O
reactivated O
, O
were O
sequenced O
to O
determine O
the O
genetic O
lesion O
within O
the O
tk O
gene O
conferring O
resistance O
and O
whether O
this O
may O
have O
correlated O
with O
reactivation O
potential O
, O
Mutations O
were O
clustered O
within O
two O
homopolymer O
nucleotide O
stretches O
, O
Three O
plaque O
isolates O
( O
1737 O
- O
14 O
, O
90 O
- O
150 O
- O
3 O
, O
and O
89 O
- O
650 O
- O
5 O
) O
had O
insertion O
mutations O
within O
a O
stretch O
of O
7 O
guanosines O
, O
while O
two O
isolates O
( O
89 O
- O
063 O
- O
1 O
and O
89 O
- O
353 O
- O
1 O
) O
had O
frameshift O
mutations O
within O
a O
stretch O
of O
6 O
cytosines O
( O
a O
deletion O
and O
an O
insertion O
, O
respectively O
) O
, O
Mutations O
resulted O
in O
premature O
termination O
codons O
, O
and O
the O
predicted O
28 O
- O
and O
32 O
- O
kDa O
truncated O
TK O
products O
were O
detected O
by O
Western O
blot O
analysis O
of O
virus O
- O
infected O
cell O
extracts O
, O
The O
repair O
of O
one O
homopolymer O
frameshift O
mutation O
( O
in O
isolate O
1737 O
- O
14 O
) O
restored O
TK O
activity O
demonstrating O
that O
this O
mutation O
is O
the O
basis O
of O
TK O
deficiency O
, O
Of O
the O
five O
reactivated O
isolates O
, O
four O
were O
TK O
deficient O
and O
contained O
frameshift O
mutations O
while O
the O
fifth O
retained O
TK O
activity O
because O
of O
its O
altered O
- O
TK O
or O
Pol O
( O
- O
) O
phenotype O
. O

These O
data O
demonstrate O
that O
the O
majority O
of O
ACV O
( O
r O
) O
clinical O
isolates O
contain O
frameshift O
mutations O
within O
two O
long O
homopolymer O
nucleotide O
stretches O
which O
function O
as O
hot O
spots O
within O
the O
HSV O
tk O
gene O
and O
produce O
nonfunctional O
, O
truncated O
TK O
proteins O
. O

Simian B
retroperitoneal I
fibromatosis I
( I
RF I
) I
is O
a O
vascular O
fibroproliferative O
neoplasm O
which O
has O
many O
morphological O
and O
histological O
similarities O
to O
human B
Kaposi I
' I
s I
sarcoma I
( I
KS I
) I
. O

Like O
epidemic O
KS O
in O
AIDS O
patients O
, O
RF O
is O
highly O
associated O
with O
an O
immunodeficiency O
syndrome O
( O
simian O
acquired O
immunodeficiency O
syndrome O
[ O
SAIDS O
] O
) O
caused O
by O
a O
retrovirus O
infection O
, O
Recently O
, O
a O
new O
gammaherpesvirus O
, O
called O
Kaposi B
' I
s I
sarcoma I
- I
associated I
herpesvirus I
( I
KSHV I
) I
or O
human B
herpesvirus I
8 I
( I
HHV8 I
) I
, O
has O
been O
identified O
in O
KS O
tumors O
, O
suggesting O
that O
KS O
has O
a O
viral O
etiology O
, O
Our O
previous O
experimental O
transmission O
studies O
and O
epidemiological O
data O
suggest O
that O
RF O
also O
has O
an O
infectious O
etiology O
, O
In O
order O
to O
determine O
whether O
a O
similar O
virus O
is O
also O
associated O
with O
RF O
, O
we O
have O
assayed O
for O
the O
presence O
of O
an O
unknown O
herpesvirus O
using O
degenerate O
PCR O
primers O
targeting O
the O
highly O
conserved O
DNA O
polymerase O
genes O
of O
the O
herpesvirus O
family O
, O
Here O
we O
provide O
DNA O
sequence O
evidence O
for O
two O
new O
herpesviruses O
closely O
related O
to O
KSHV O
from O
RF O
tissues O
of O
two O
macaque O
species O
, O
Macaca O
nemestrina O
and O
Macaca O
mulatta O
. O

The O
Pr60 O
( O
gag O
) O
protein O
of O
the O
murine B
AIDS I
( I
MAIDS I
) I
defective O
virus O
promotes O
the O
proliferation O
of O
the O
infected O
target O
B O
cells O
and O
is O
responsible O
for O
inducing O
a O
severe O
immunodeficiency O
disease O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
identified O
the O
SH3 O
domain O
of O
c O
- O
Abl O
as O
interacting O
with O
the O
proline O
- O
rich O
p12 O
domain O
of O
pr60 O
( O
gag O
) O
. O

Overexpression O
of O
Pr60 O
( O
gag O
) O
in O
these O
cells O
led O
to O
a O
detectable O
increase O
of O
the O
levels O
of O
c O
- O
Abl O
protein O
and O
to O
its O
translocation O
at O
the O
membrane O
. O

Subcutaneous O
injection O
of O
FK506 O
( O
10 O
mg O
/ O
kg O
of O
body O
weight O
) O
completely O
blocked O
the O
clonal O
expansion O
of O
staphylococcal B
enterotoxin I
A I
( I
SEA I
) I
- O
reactive O
T O
cells O
in O
healthy O
( O
control O
) O
mice O
after O
SEA O
injection O
but O
did O
not O
disturb O
it O
in O
mice O
with O
murine B
AIDS I
( I
MAIDS I
) I
caused O
by O
infection O
with O
LP O
- O
BM5 O
murine O
leukemia O
virus O
. O

The O
murine B
AIDS I
( I
MAIDS I
) I
virus O
has O
a O
unique O
sequence O
in O
its O
p12 B
( I
gag I
) I
region O
, O
which O
is O
responsible O
for O
MAIDS O
development O
. O

Compared O
with O
the O
nucleotide O
sequence O
of O
the O
helper O
LP O
- O
BM5 O
ecotropic O
virus O
, O
the O
pathogenic O
replication O
- O
defective O
MAIDS O
virus O
has O
a O
16 O
- O
bp O
deletion O
and O
a O
1 O
- O
bp O
insertion O
in O
the O
5 O
' O
and O
3 O
' O
regions O
of O
the O
p12 B
( I
gag I
) I
sequence O
, O
respectively O
, O
and O
the O
Edv O
transcript O
contains O
only O
a O
3 O
- O
bp O
deletion O
. O

Therefore O
, O
the O
amino O
acid O
sequence O
of O
the O
defective O
MAIDS O
virus O
p12 B
( I
gag I
) I
region O
is O
not O
homologous O
to O
that O
of O
the O
helper O
virus O
and O
the O
Edv O
transcript O
because O
of O
the O
frameshift O
. O

To O
determine O
whether O
the O
amino O
acid O
sequence O
resulting O
from O
the O
frameshift O
is O
critical O
for O
MAIDS O
development O
, O
we O
constructed O
chimeric O
viruses O
that O
contained O
the O
p12 B
( I
gag I
) I
regions O
of O
the O
helper O
virus O
and O
the O
Edv O
transcript O
, O
respectively O
, O
with O
and O
without O
the O
same O
frame O
as O
the O
defective O
MAIDS O
virus O
by O
the O
artificial O
frameshift O
mutations O
. O

These O
results O
suggested O
that O
the O
MAIDS O
virus O
was O
generated O
by O
frameshift O
mutations O
in O
the O
p12 B
( I
gag I
) I
region O
of O
Edv O
or O
a O
related O
sequence O
. O

B O
- O
cell O
immortalization O
by O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
is O
dependent O
on O
permanent O
control O
of O
the O
cellular O
processes O
which O
normally O
regulate O
cell O
division O
and O
apoptosis O
, O
functions O
possessed O
by O
p53 O
in O
a O
number O
of O
normal O
cell O
types O
, O
In O
studies O
initiated O
to O
evaluate O
relationships O
between O
EBV O
latent O
genes O
and O
p53 O
, O
p53 O
levels O
were O
found O
to O
increase O
approximately O
Ill O
- O
fold O
4 O
to O
5 O
days O
after O
EBV O
infection O
of O
purified O
resting O
human O
B O
cells O
; O
the O
induced O
p53 O
was O
transcriptionally O
active O
, O
Latent O
membrane O
protein O
1 O
and O
, O
to O
a O
Lesser O
extent O
, O
EBV O
nuclear O
antigen O
2 O
mediated O
the O
increase O
in O
p53 O
levels O
via O
activation O
of O
the O
NF O
- O
kappa O
B O
transcription O
factor O
. O

We O
describe O
the O
molecular O
cloning O
of O
a O
serogroup O
2 O
simian O
retrovirus O
( O
SRV O
; O
D2 O
/ O
RHE O
/ O
OR O
) O
and O
present O
the O
sequence O
of O
its O
envelope B
( I
env I
) I
glycoprotein O
gene O
and O
3 O
' O
long O
terminal O
repeat O
region O
. O

The O
etiologic O
agent O
of O
progressive O
multifocal O
leukoencephalopathy O
, O
a O
subacute O
demyelinating O
disease O
of O
the O
central O
nervous O
system O
, O
is O
the O
human B
polyomavirus I
JC I
virus I
( I
JCV I
) I
, O
which O
causes O
a O
lytic O
infection O
of O
myelin O
- O
producing O
oligodendrocytes O
. O

Using O
mobility O
shift O
assays O
and O
a O
radiolabeled O
oligonucleotide O
from O
the O
JCV B
promoter I
- I
enhancer I
region I
( I
JCV I
bp I
130 I
to I
160 I
) I
, O
referred O
to O
as O
domain O
B O
, O
we O
were O
able O
to O
detect O
specific O
bands O
of O
the O
same O
mobility O
in O
nuclear O
extracts O
from O
human O
fetal O
glial O
cells O
, O
U O
- O
251 O
glioma O
cells O
, O
different O
B O
- O
cell O
lines O
, O
and O
in O
vitro O
- O
activated O
tonsillar O
B O
lymphocytes O
but O
not O
from O
T O
cells O
. O

Patients O
with O
AIDS O
often O
experience O
recurrent O
infections O
with O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
requiring O
repeated O
or O
prolonged O
treatment O
with O
acyclovir B
( I
ACV I
) I
, O
which O
may O
lead O
to O
the O
development O
of O
ACV O
resistance O
. O

The O
ACV O
resistance O
of O
isolates O
recovered O
from O
such O
patients O
is O
associated O
with O
diminished O
VZV O
thymidine B
kinase I
( I
TK I
) I
function O
. O

These O
TK O
- O
deficient O
strains O
were O
cross O
resistant O
to O
the O
TK O
- O
dependent O
antiviral O
agents O
ACV O
, O
9 O
- O
( O
4 O
- O
hydroxy O
- O
3 O
- O
hydroxymethylbutyl O
- O
yl O
) O
guanine O
( O
penciclovir O
) O
, O
and O
1 O
- O
beta O
- O
D O
- O
ambinofuranosyl O
- O
E O
- O
5 O
- O
( O
2 O
- O
bromovinyl O
) O
uracil O
( O
BVaraU O
) O
. O

Maternal O
transmission O
of O
a O
murine B
leukemia I
virus I
( I
MuLV I
) I
mixture O
named O
LP O
- O
BM5 O
MuLV O
, O
which O
is O
known O
to O
induce O
murine B
AIDS I
( I
MAIDS I
) I
, O
was O
investigated O
. O

Virus O
isolates O
recovered O
from O
different O
individuals O
exhibited O
minimal O
restriction O
enzyme O
polymorphism O
, O
which O
was O
mostly O
confined O
to O
heterogenous B
( I
het I
) I
sequences O
in O
the O
genome O
. O

Mice O
given O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
( O
Miyama O
+ O
GC O
strain O
) O
intragastrically O
via O
a O
stainless O
- O
steel O
cannula O
were O
rendered O
immune O
to O
subsequent O
lethal O
intraperitoneal O
( O
i O
. O

Nucleotide O
and O
amino O
acid O
sequence O
analysis O
as O
well O
as O
immunologic O
reactivity O
indicated O
that O
the O
isolated O
virus O
was O
highly O
related O
to O
Mason B
- I
Pfizer I
monkey I
virus I
( I
MPMV I
) I
. O

In O
addition O
, O
the O
patient O
' O
s O
serum O
contained O
antibodies O
which O
recognized O
type O
D O
viral O
env O
proteins O
( O
gp70 O
and O
gp20 O
) O
and O
gag O
proteins O
( O
p27 O
and O
p14 O
) O
. O

Antigenic O
and O
genetic O
variations O
have O
been O
analyzed O
in O
eight O
consecutive O
isolates O
recovered O
from O
a O
child O
with O
severe O
combined O
immunodeficiency O
syndrome O
persistently O
infected O
with O
naturally O
acquired O
type O
A O
( O
H1N1 O
) O
influenza O
virus O
over O
a O
10 O
- O
month O
period O
. O

Hemagglutination O
inhibition O
reactions O
and O
T1 O
oligonucleotide O
fingerprinting O
demonstrated O
that O
these O
viruses O
were O
related O
to O
strains O
causing O
outbreaks O
in O
the O
United O
States O
at O
that O
time O
( O
1983 O
to O
1984 O
) O
but O
that O
antigenic O
and O
genetic O
differences O
between O
consecutive O
isolates O
could O
be O
detected O
. O

This O
variation O
between O
isolates O
was O
examined O
further O
by O
sequencing O
the O
RNAs O
encoding O
the O
HA1 O
region O
of O
the O
Hemagglutinin B
( I
HA I
) I
and O
the O
nucleoprotein B
( I
NP I
) I
in O
five O
of O
the O
consecutive O
isolates O
. O

8 O
x O
10 O
( O
- O
3 O
) O
to O
17 O
x O
10 O
( O
- O
3 O
) O
substitutions O
per O
nucleotide O
site O
per O
year O
were O
detected O
in O
the O
RNAs O
encoding O
the O
HA1 O
, O
and O
3 O
. O

5 O
x O
10 O
( O
- O
3 O
) O
to O
24 O
x O
10 O
( O
- O
3 O
) O
substitutions O
per O
nucleotide O
site O
per O
year O
were O
detected O
in O
detected O
in O
the O
NP O
gene O
. O

A O
progressive O
accumulation O
of O
mutations O
over O
time O
was O
not O
observed O
, O
suggesting O
that O
the O
genetic O
diversity O
of O
these O
viruses O
may O
best O
be O
interpreted O
as O
the O
result O
of O
shifts O
in O
the O
population O
equilibrium O
( O
quasispecies O
) O
of O
replicating O
variant O
genomes O
. O

Louis O
encephalitis O
virus O
( O
SLEV O
) O
is O
a O
mosquito O
- O
borne O
flavivirus O
responsible O
for O
several O
human O
encephalitis O
outbreaks O
over O
the O
last O
80 O
years O
. O

Mature O
flavivirus O
virions O
are O
coated O
with O
dimeric O
envelope B
( I
E I
) I
proteins O
that O
mediate O
attachment O
and O
fusion O
with O
host O
cells O
. O

Domains O
II O
and O
III O
( O
DII O
and O
DIII O
) O
of O
SLEV O
E O
also O
adopt O
different O
angles O
relative O
to O
DI O
, O
which O
suggests O
that O
the O
DI O
- O
DII O
joint O
may O
accommodate O
spheroidal O
motions O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
New O
World O
Alphavirus O
that O
can O
cause O
neurological O
disease O
and O
death O
in O
humans O
and O
equines O
following O
transmission O
from O
infected O
mosquitoes O
. O

To O
further O
explore O
the O
population O
- O
level O
resistance O
profiles O
of O
ML336 O
, O
we O
developed O
a O
wholegenome O
next B
- I
generation I
sequencing I
( I
NGS I
) I
approach O
to O
examine O
single B
nucleotide I
polymorphisms I
( I
SNPs I
) I
from O
virus O
passaged O
in O
dose O
escalation O
studies O
in O
a O
nonhuman O
primate O
kidney O
epithelial O
and O
a O
human O
astrocyte O
cell O
line O
, O
Vero O
76 O
and O
SVGA O
, O
respectively O
. O

NGS O
revealed O
several O
prominent O
mutations O
in O
the O
nonstructural B
protein I
( I
nsp I
) I
3 O
and O
nsP4 O
genes O
that O
emerged O
consistently O
in O
these O
two O
distinct O
in O
vitro O
environments O
- O
notably O
, O
a O
mutation O
at O
Q210 O
in O
nsP4 O
. O

IMPORTANCE O
RNA O
viruses O
, O
including O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
, O
have O
high O
mutation O
rates O
that O
allow O
for O
rapid O
adaptation O
to O
selective O
pressures O
in O
their O
environment O
. O

In O
this O
work O
, O
we O
report O
the O
generation O
and O
characterization O
of O
an O
alphavirus O
replicon O
vaccine O
platform O
based O
on O
a O
non O
- O
select O
agent O
, O
attenuated O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
virus O
vaccine O
, O
strain O
3526 O
( O
VRP O
3526 O
) O
. O

Importantly O
, O
packaging O
under O
biosafety B
level I
2 I
( I
BSL2 I
) I
conditions O
distinguishes O
VRP O
3526 O
from O
previously O
reported O
alphavirus O
platforms O
and O
makes O
this O
approach O
accessible O
to O
the O
majority O
of O
laboratories O
around O
the O
world O
. O

chikungunya B
virus I
( I
CHIKV I
) I
is O
a O
rapidly O
emerging O
mosquito O
- O
borne O
human O
pathogen O
causing O
major O
outbreaks O
in O
Africa O
, O
Asia O
, O
and O
the O
Americas O
. O

Here O
, O
the O
multiplicity B
of I
cellular I
infection I
( I
MOI I
) I
and O
population O
bottlenecks O
were O
quantified O
during O
primary O
mosquito O
infection O
by O
Venezuelan O
equine O
encephalitis O
virus O
, O
an O
arbovirus O
causing O
neurological O
disease O
in O
humans O
and O
equids O
. O

Neonatal O
immune O
responses O
to O
infection O
and O
vaccination O
are O
biased O
toward O
T O
( O
H O
) O
2 O
at O
the O
cost O
of O
proinflammatory O
T O
( O
H O
) O
1 O
responses O
needed O
to O
combat O
intracellular O
pathogens O
. O

However O
, O
upon O
appropriate O
stimulation O
, O
the O
neonatal O
immune O
system O
can O
induce O
adult O
- O
like O
T O
( O
H O
) O
1 O
responses O
. O

The O
GVI3000 O
adjuvant O
is O
a O
safe O
, O
nonpropagating O
, O
truncated O
derivative O
of O
Venezuelan O
equine O
encephalitis O
virus O
that O
targets O
dendritic B
cells I
( I
DCs I
) I
in O
the O
draining B
lymph I
node I
( I
DLN I
) I
and O
produces O
intracellular O
viral O
RNA O
without O
propagating O
to O
other O
cells O
. O

The O
adjuvant O
properties O
of O
GVI3000 O
were O
tested O
in O
a O
neonatal O
BALB O
/ O
c O
mouse O
model O
using O
inactivated O
influenza O
virus O
( O
iFlu O
) O
. O

After O
a O
single O
immunization O
, O
mice O
immunized O
with O
iFlu O
with O
the O
GVI3000 O
adjuvant O
( O
GVI3000 O
- O
adjuvanted O
iFlu O
) O
had O
significantly O
higher O
and O
sustained O
influenza O
virus O
- O
specific O
IgG O
antibodies O
, O
mainly O
IgG2a O
( O
T O
( O
H O
) O
1 O
) O
, O
compared O
to O
the O
mice O
immunized O
with O
antigen O
only O
. O

As O
seen O
in O
adult O
mice O
, O
the O
GVI3000 O
adjuvant O
increased O
the O
DC O
population O
in O
the O
DLNs O
, O
caused O
activation O
and O
maturation O
of O
DCs O
, O
and O
induced O
proinflammatory O
cytokines O
and O
chemokines O
in O
the O
DLNs O
soon O
after O
immunization O
, O
including O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
granulocyte B
colony I
- I
stimulating I
factor I
( I
G I
- I
CSF I
) I
, O
and O
interleukin B
6 I
( I
IL I
- I
6 I
) I
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
one O
of O
the O
most O
pathogenic O
members O
of O
the O
Alphavirus O
genus O
in O
the O
Togaviridae O
family O
. O

One O
of O
these O
nonstructural O
proteins O
, O
nsP3 O
, O
contains O
a O
hypervariable B
domain I
( I
HVD I
) I
, O
which O
demonstrates O
very O
low O
overall O
similarity O
between O
different O
alphaviruses O
, O
suggesting O
the O
possibility O
of O
its O
function O
in O
virus O
adaptation O
to O
different O
hosts O
and O
vectors O
. O

( O
i O
) O
Phosphorylation O
of O
the O
VEEV O
nsP3 O
- O
specific O
HVD O
does O
not O
play O
a O
critical O
role O
in O
virus O
replication O
in O
cells O
of O
vertebrate O
origin O
but O
is O
important O
for O
virus O
replication O
in O
mosquito O
cells O
. O

( O
ii O
) O
The O
VEEV O
HVD O
is O
not O
required O
for O
viral O
RNA O
replication O
in O
the O
highly O
permissive O
BHK O
- O
21 O
cell O
line O
. O

( O
iii O
) O
However O
, O
the O
carboxy O
- O
terminal O
repeat O
in O
the O
VEEV O
HVD O
is O
indispensable O
for O
VEEV O
replication O
in O
the O
cell O
lines O
other O
than O
BHK O
- O
21 O
and O
plays O
a O
critical O
role O
in O
formation O
of O
VEEV O
- O
specific O
cytoplasmic O
protein O
complexes O
. O

We O
have O
previously O
shown O
that O
delivery O
of O
the O
porcine B
type I
I I
interferon I
gene I
( I
poIFN I
- I
alpha I
/ I
beta I
) I
with O
a O
replication O
- O
defective O
human O
adenovirus O
vector O
( O
adenovirus O
5 O
[ O
Ad5 O
] O
) O
can O
sterilely O
protect O
swine O
challenged O
with O
foot B
- I
and I
- I
mouth I
disease I
virus I
( I
FMDV I
) I
1 O
day O
later O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
empty O
replicon O
particles O
( O
VRPs O
) O
can O
induce O
rapid O
protection O
of O
mice O
against O
either O
homologous O
or O
, O
in O
some O
cases O
, O
heterologous O
virus O
challenge O
. O

As O
an O
alternative O
approach O
to O
induce O
rapid O
protection O
against O
FMDV O
, O
we O
have O
examined O
the O
ability O
of O
VRPs O
containing O
either O
the O
gene O
for O
green O
fluorescent O
protein O
( O
VRP O
- O
GFP O
) O
or O
poIFN O
- O
alpha O
( O
VRP O
- O
poIFN O
- O
alpha O
) O
to O
block O
FMDV O
replication O
in O
vitro O
and O
in O
vivo O
. O

Furthermore O
, O
mice O
pretreated O
with O
either O
10 O
( O
7 O
) O
or O
10 O
( O
8 O
) O
infectious O
units O
of O
VRP O
- O
GFP O
and O
challenged O
with O
a O
lethal O
dose O
of O
FMDV O
24 O
h O
later O
were O
protected O
from O
death O
. O

Previously O
, O
a O
replicon O
vaccine O
based O
on O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
demonstrated O
protective O
efficacy O
against O
Marburg O
virus O
in O
nonhuman O
primates O
. O

Here O
, O
we O
report O
the O
protective O
efficacy O
of O
Sudan B
virus I
( I
SUDV I
) I
- O
and O
Ebola B
virus I
( I
EBOV I
) I
- O
specific O
VEEV B
replicon I
particle I
( I
VRP I
) I
vaccines O
in O
nonhuman O
primates O
. O

VRP O
vaccines O
were O
developed O
to O
express O
the O
glycoprotein B
( I
GP I
) I
of O
either O
SUDV O
or O
EBOV O
. O

We O
found O
that O
nsP3 O
proteins O
of O
Sindbis B
virus I
( I
SINV I
) I
and O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
form O
cytoplasmic O
complexes O
with O
different O
morphologies O
and O
protein O
compositions O
. O

Importantly O
, O
the O
morphology O
of O
the O
complexes O
and O
the O
specificity O
of O
the O
interaction O
with O
cellular O
proteins O
are O
largely O
determined O
by O
the O
hypervariable B
domain I
( I
HVD I
) I
of O
nsP3 O
. O

To O
address O
this O
issue O
, O
we O
have O
developed O
a O
noncytopathic O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
mutant O
that O
can O
persistently O
replicate O
in O
cells O
defective O
in O
type B
I I
interferon I
( I
IFN I
) I
production O
or O
signaling O
but O
is O
cleared O
from O
IFN O
signaling O
- O
competent O
cells O
. O

Using O
this O
mutant O
, O
we O
analyzed O
( O
i O
) O
the O
spectrum O
of O
cellular O
genes O
activated O
by O
virus O
replication O
in O
the O
persistently O
infected O
cells O
and O
( O
ii O
) O
the O
spectrum O
of O
genes O
activated O
during O
noncytopathic O
virus O
clearance O
. O

By O
applying O
microarray O
- O
based O
technology O
and O
bioinformatic O
analysis O
, O
we O
identified O
a O
number O
of O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
specifically O
activated O
during O
VEEV O
clearance O
. O

One O
of O
these O
gene O
products O
, O
the O
long O
isoform O
of O
PARP12 O
( O
PARP12L O
) O
, O
demonstrated O
an O
inhibitory O
effect O
on O
the O
replication O
of O
VEEV O
, O
as O
well O
as O
other O
alphaviruses O
and O
several O
different O
types O
of O
other O
RNA O
viruses O
. O

However O
, O
safety O
concerns O
prevent O
the O
development O
of O
attenuated O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
as O
a O
vaccine O
candidate O
. O

The O
genome O
from O
the O
alphavirus O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
was O
modified O
to O
express O
SHIV89 O
. O

Infection O
of O
CD4 O
( O
+ O
) O
cells O
with O
chimeric O
lentivirus O
- O
like O
particles O
was O
specific O
and O
productive O
, O
resulting O
in O
RNA O
replication O
, O
expression O
of O
Gag O
and O
Env O
, O
and O
generation O
of O
progeny O
chimeric O
particles O
. O

Further O
genome O
modifications O
designed O
to O
enhance O
encapsidation O
of O
the O
chimeric O
virus O
genome O
and O
to O
express O
an O
attenuated O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
protease O
for O
particle O
maturation O
improved O
the O
ability O
of O
chimeric O
lentivirus O
- O
like O
particles O
to O
propagate O
in O
cell O
culture O
. O

In O
- O
depth O
sequencing O
of O
an O
original O
field O
isolate O
of O
subtype O
IE O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
demonstrated O
the O
presence O
of O
multiple O
deletions O
within O
the O
6 O
, O
000 O
- O
molecular O
- O
weight O
( O
6K O
) O
protein O
gene O
. O

Six O
monoclonal O
antibodies O
were O
isolated O
that O
exhibited O
specificity O
for O
a O
furin O
cleavage O
site O
deletion O
mutant O
( O
V3526 O
) O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
. O

These O
antibodies O
neutralized O
V3526 O
virus O
infectivity O
but O
did O
not O
neutralize O
the O
parental O
strain O
of O
Trinidad B
donkey I
( I
TrD I
) I
VEEV O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
significant O
human O
and O
animal O
pathogen O
. O

The O
highlight O
of O
VEEV O
replication O
in O
vitro O
, O
in O
cells O
of O
vertebrate O
origin O
, O
is O
the O
rapid O
development O
of O
cytopathic B
effect I
( I
CPE I
) I
, O
which O
is O
strongly O
dependent O
upon O
the O
expression O
of O
viral O
capsid O
protein O
. O

Besides O
being O
an O
integral O
part O
of O
virions O
, O
the O
latter O
protein O
is O
capable O
of O
( O
i O
) O
binding O
both O
the O
nuclear O
import O
and O
nuclear O
export O
receptors O
, O
( O
ii O
) O
accumulating O
in O
the O
nuclear O
pore O
complexes O
, O
( O
iii O
) O
inhibiting O
nucleocytoplasmic O
trafficking O
, O
and O
( O
iv O
) O
inhibiting O
transcription O
of O
cellular O
ribosomal O
and O
messenger O
RNAs O
. O

In O
cell O
lines O
that O
have O
defects O
in O
type B
I I
interferon I
( I
IFN I
) I
signaling O
, O
the O
capsid O
mutants O
demonstrated O
very O
efficient O
persistent O
replication O
. O

However O
, O
ultimately O
, O
these O
cells O
also O
developed O
a O
persistent O
infection O
, O
characterized O
by O
continuous O
virus O
replication O
and O
beta O
IFN O
( O
IFN O
- O
beta O
) O
release O
. O

Salmonid B
alphavirus I
( I
SAV I
) I
is O
an O
emerging O
virus O
in O
salmonid O
aquaculture O
, O
with O
SAV O
- O
3 O
being O
the O
only O
subtype O
found O
in O
Norway O
. O

Until O
now O
, O
there O
has O
been O
little O
focus O
on O
the O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
- O
induced O
antiviral O
responses O
during O
virus O
infection O
in O
vivo O
or O
in O
vitro O
in O
fish O
. O

In O
this O
study O
, O
the O
two O
IFNs O
were O
cloned O
and O
expressed O
as O
recombinant O
proteins O
( O
recombinant O
IFN O
- O
alpha O
[ O
rIFN O
- O
alpha O
] O
and O
rIFN O
- O
gamma O
) O
and O
used O
for O
in O
vitro O
studies O
. O

SAV O
- O
3 O
infection O
in O
a O
permissive O
salmon O
cell O
line O
( O
TO O
cells O
) O
results O
in O
IFN O
- O
alpha O
and O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
mRNA O
upregulation O
. O

Preinfection O
treatment O
( O
4 O
to O
24 O
h O
prior O
to O
infection O
) O
with O
salmon O
rIFN O
- O
alpha O
induces O
an O
antiviral O
state O
that O
inhibits O
the O
replication O
of O
SAV O
- O
3 O
and O
protects O
the O
cells O
against O
virus O
- O
induced O
cytopathic B
effects I
( I
CPE I
) I
. O

By O
40 O
h O
postinfection O
, O
the O
alpha O
subunit O
of O
eukaryotic B
initiation I
factor I
2 I
( I
eIF2 I
alpha I
) I
is O
phosphorylated O
concomitant O
with O
the O
expression O
of O
the O
E2 O
protein O
as O
assessed O
by O
Western O
blotting O
. O

We O
have O
previously O
shown O
that O
rhesus O
macaques O
were O
partially O
protected O
against O
high O
- O
dose O
intravenous O
challenge O
with O
simian O
- O
human O
immunodeficiency O
virus O
SHIVSF162P4 O
following O
sequential O
immunization O
with O
alphavirus O
replicon O
particles O
( O
VRP O
) O
of O
a O
chimeric O
recombinant O
VEE O
/ O
SIN O
alphavirus O
( O
derived O
from O
Venezuelan O
equine O
encephalitis O
virus O
[ O
VEE O
] O
and O
the O
Sindbis O
virus O
[ O
SIN O
] O
) O
encoding O
human O
immunodeficiency O
virus O
type O
1 O
HIV O
- O
1 O
( O
SF162 O
) O
gp140 O
Delta O
V2 O
envelope B
( I
env I
) I
and O
trimeric O
Env O
protein O
in O
MF59 O
adjuvant O
( O
R O
. O

The O
protection O
did O
not O
require O
T O
- O
cell O
immune O
responses O
directed O
toward O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
Gag O
. O

The O
macaques O
in O
the O
vaccination O
groups O
were O
primed O
with O
VRP O
and O
then O
boosted O
with O
Env O
protein O
in O
MF59 O
adjuvant O
, O
or O
they O
were O
given O
VRP O
intramuscular O
immunizations O
alone O
and O
then O
challenged O
with O
SHIVSF162P4 O
( O
intrarectal O
challenge O
) O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
pathogenic O
strain O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
has O
developed O
a O
unique O
mechanism O
of O
nuclear O
import O
inhibition O
. O

The O
eastern B
equine I
encephalitis I
( I
EEE I
) I
complex O
consists O
of O
four O
distinct O
genetic O
lineages O
: O
one O
that O
circulates O
in O
North O
America O
( O
NA O
EEEV O
) O
and O
the O
Caribbean O
and O
three O
that O
circulate O
in O
Central O
and O
South O
America O
( O
SA O
EEEV O
) O
. O

2 O
x O
10 O
( O
- O
4 O
) O
) O
was O
lower O
and O
more O
consistent O
than O
that O
for O
NA O
EEEV O
( O
2 O
. O

7 O
x O
10 O
( O
- O
4 O
) O
) O
, O
which O
exhibited O
considerable O
rate O
variation O
among O
constituent O
clades O
. O

A O
phylogenetic O
comparison O
of O
SA O
EEEV O
and O
Venezuelan B
equine I
encephalitis I
viruses I
( I
VEEV I
) I
demonstrated O
similar O
genetic O
and O
evolutionary O
patterns O
, O
consistent O
with O
the O
well O
- O
documented O
use O
of O
mammalian O
reservoir O
hosts O
by O
VEEV O
. O

Here O
, O
utilizing O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
replicon O
particles O
( O
VRP O
) O
to O
limit O
infection O
to O
the O
initially O
infected O
cells O
in O
vivo O
, O
a O
rapid O
activation O
of O
the O
antiviral O
response O
was O
demonstrated O
not O
only O
within O
the O
murine O
draining O
lymph O
node O
, O
where O
replication O
was O
confined O
, O
but O
also O
within O
distal O
tissues O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
important O
human O
and O
veterinary O
pathogen O
causing O
sporadic O
epizootic O
outbreaks O
of O
potentially O
fatal O
encephalitis O
. O

The O
type B
I I
interferon I
( I
IFN I
) I
system O
plays O
a O
central O
role O
in O
controlling O
VEEV O
and O
other O
alphavirus O
infections O
, O
and O
IFN O
evasion O
is O
likely O
an O
important O
determinant O
of O
whether O
these O
viruses O
disseminate O
and O
cause O
disease O
within O
their O
hosts O
. O

Analyses O
of O
cells O
infected O
with O
VEEV O
and O
VEEV B
replicon I
particles I
( I
VRP I
) I
demonstrate O
that O
viral O
infection O
rapidly O
disrupts O
tyrosine O
phosphorylation O
and O
nuclear O
translocation O
of O
the O
transcription O
factor O
STAT1 O
in O
response O
to O
both O
IFN O
- O
beta O
and O
IFN O
- O
gamma O
. O

human B
metapneumovirus I
( I
HMPV I
) I
is O
a O
recently O
discovered O
paramyxovirus O
that O
causes O
upper O
and O
lower O
respiratory O
tract O
infections O
in O
infants O
, O
the O
elderly O
, O
and O
immunocompromised O
individuals O
worldwide O
. O

Here O
, O
we O
developed O
Venezuelan O
equine O
encephalitis O
virus B
replicon I
particles I
( I
VRPs I
) I
encoding O
hMPV O
fusion O
( O
F O
) O
or O
attachment O
( O
G O
) O
glycoproteins O
and O
evaluated O
the O
immunogenicity O
and O
protective O
efficacy O
of O
these O
vaccine O
candidates O
in O
mice O
and O
cotton O
rats O
. O

VRPs O
encoding O
hMPV O
F O
protein O
, O
when O
administered O
intranasally O
, O
induced O
F O
- O
specific O
virus O
- O
neutralizing O
antibodies O
in O
serum O
and O
immunoglobulin B
A I
( I
IgA I
) I
antibodies O
in O
secretions O
at O
the O
respiratory O
mucosa O
. O

Eastern O
and O
Venezuelan O
equine O
encephalitis O
viruses O
( O
EEEV O
and O
VEEV O
, O
respectively O
) O
cause O
severe O
morbidity O
and O
mortality O
in O
equines O
and O
humans O
. O

Like O
other O
mosquito O
- O
borne O
viruses O
, O
VEEV O
infects O
dendritic B
cells I
( I
DCs I
) I
and O
macrophages O
in O
lymphoid O
tissues O
, O
fueling O
a O
serum O
viremia O
and O
facilitating O
neuroinvasion O
. O

alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
responses O
did O
not O
mediate O
the O
restriction O
, O
as O
infectivity O
was O
not O
restored O
in O
the O
absence O
of O
double O
- O
stranded O
RNA O
- O
dependent O
protein O
kinase O
, O
RNase O
L O
, O
or O
IFN O
- O
alpha O
/ O
beta O
receptor O
- O
mediated O
signaling O
. O

The O
results O
of O
our O
study O
suggest O
that O
Sindbis B
virus I
( I
SINV I
) I
infection O
in O
BHK O
- O
21 O
cells O
leads O
to O
the O
formation O
of O
at O
least O
two O
types O
of O
nsP3 O
- O
containing O
complexes O
, O
one O
of O
which O
was O
found O
in O
association O
with O
the O
plasma O
membrane O
and O
endosome O
- O
like O
vesicles O
, O
while O
the O
second O
was O
coisolated O
with O
cell O
nuclei O
. O

Besides O
viral O
nsPs O
, O
in O
the O
mammalian O
cells O
, O
both O
complexes O
contained O
G3BP1 O
and O
G3BP2 O
( O
which O
were O
found O
in O
different O
ratios O
) O
, O
YBX1 O
, O
and O
HSC70 O
. O

The O
endosome O
- O
and O
plasma O
membrane O
- O
associated O
complexes O
contained O
a O
high O
concentration O
of O
double B
- I
stranded I
RNAs I
( I
dsRNAs I
) I
, O
which O
is O
indicative O
of O
their O
function O
in O
viral O
- O
RNA O
synthesis O
. O

A O
novel O
genetic O
vaccine O
that O
is O
based O
on O
a O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
replicon O
launched O
from O
plasmid O
DNA O
is O
described O
. O

The O
plasmid O
encodes O
a O
VEE O
replicon O
under O
the O
transcriptional O
control O
of O
the O
cytomegalovirus O
immediate O
- O
early O
promoter O
( O
VEE O
DNA O
) O
. O

Moreover O
, O
the O
DNA O
- O
launched O
VEE O
replicon O
induced O
an O
efficient O
prime O
to O
a O
VEE B
replicon I
particle I
( I
VRP I
) I
boost O
, O
increasing O
humoral O
and O
cellular O
immunity O
by O
at O
least O
1 O
order O
of O
magnitude O
compared O
to O
VEE O
DNA O
only O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
an O
important O
viral O
pathogen O
that O
causes O
severe O
lower O
respiratory O
tract O
infection O
in O
infants O
, O
the O
elderly O
, O
and O
immunocompromised O
individuals O
. O

Previously O
, O
immunization O
with O
Venezuelan O
equine O
encephalitis O
virus B
replicon I
particles I
( I
VRPs I
) I
demonstrated O
effectiveness O
in O
inducing O
mucosal O
protection O
against O
various O
pathogens O
. O

In O
this O
study O
, O
we O
developed O
VRPs O
encoding O
RSV O
fusion O
( O
F O
) O
or O
attachment O
( O
G O
) O
glycoproteins O
and O
evaluated O
the O
immunogenicity O
and O
efficacy O
of O
these O
vaccine O
candidates O
in O
mice O
and O
cotton O
rats O
. O

VRPs O
, O
when O
administered O
intranasally O
, O
induced O
surface O
glycoprotein O
- O
specific O
virus O
neutralizing O
antibodies O
in O
serum O
and O
immunoglobulin B
A I
( I
IgA I
) I
antibodies O
in O
secretions O
at O
the O
respiratory O
mucosa O
. O

In O
addition O
, O
fusion O
protein O
- O
encoding O
VRPs O
induced O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
secreting O
T O
cells O
in O
the O
lungs O
and O
spleen O
, O
as O
measured O
by O
reaction O
with O
an O
H O
- O
2K O
( O
d O
) O
- O
restricted O
CD8 O
( O
+ O
) O
T O
- O
cell O
epitope O
. O

A O
candidate O
vaccine O
( O
D1ME O
- O
VR O
- O
P O
) O
expressing O
dengue O
virus O
type O
I O
premembrane O
and O
envelope O
proteins O
in O
a O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
virus O
replicon O
particle O
( O
VR O
- O
P O
) O
system O
was O
constructed O
and O
tested O
in O
conjunction O
with O
a O
plasmid O
DNA O
vaccine O
( O
DIME O
- O
DNA O
) O
expressing O
identical O
dengue O
virus O
sequences O
. O

Cynomolgus O
macaques O
were O
vaccinated O
with O
three O
doses O
of O
DNA O
( O
DDD O
) O
, O
three O
doses O
of O
VRP O
( O
VVV O
group O
) O
, O
or O
a O
heterologous O
DNA O
prime O
- O
VRP O
boost O
regimen O
( O
DDV O
) O
using O
two O
doses O
of O
DNA O
vaccine O
and O
a O
third O
dose O
of O
VRP O
vaccine O
. O

DDV O
- O
immunized O
animals O
were O
completely O
protected O
from O
viremia O
( O
mean O
time O
of O
viremia O
= O
0 O
days O
) O
, O
whereas O
DDD O
- O
and O
VVV O
- O
vaccinated O
animals O
had O
mean O
times O
of O
viremia O
of O
0 O
. O

alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
produces O
antiviral O
effects O
through O
upregulation O
of O
many O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
whose O
protein O
products O
are O
effectors O
of O
the O
antiviral O
state O
. O

Previous O
data O
from O
our O
laboratory O
have O
shown O
that O
IFN O
- O
alpha O
/ O
beta O
can O
limit O
Sindbis B
virus I
( I
SB I
) I
replication O
through O
protein B
kinase I
R I
( I
PKR I
) I
- O
dependent O
and O
PKR O
- O
independent O
mechanisms O
and O
that O
one O
PKR O
- O
independent O
mechanism O
inhibits O
translation O
of O
the O
infecting O
virus O
genome O
( O
K O
. O

In O
the O
current O
studies O
, O
we O
have O
begun O
analyzing O
these O
gene O
products O
for O
antialphavirus O
activity O
using O
three O
techniques O
: O
( O
i O
) O
overexpression O
of O
the O
protein O
from O
SB O
vectors O
and O
assessment O
of O
virulence O
attenuation O
in O
mice O
; O
( O
ii O
) O
overexpression O
of O
the O
proteins O
in O
a O
stable O
tetracycline O
- O
inducible O
murine O
fibroblast O
culture O
system O
and O
assessment O
of O
effects O
upon O
SB O
replication O
; O
and O
( O
iii O
) O
small O
interfering O
RNA O
- O
mediated O
knockdown O
of O
gene O
mRNA O
in O
fibroblast O
cultures O
followed O
by O
SB O
replication O
assessment O
as O
above O
. O

Tested O
proteins O
included O
those O
we O
hypothesized O
bad O
potential O
to O
affect O
virus O
genome O
translation O
and O
included O
murine O
ISG20 O
, O
ISG15 O
, O
the O
zinc B
finger I
antiviral I
protein I
( I
ZAP I
) I
, O
viperin O
, O
p56 O
, O
p54 O
, O
and O
p49 O
. O

Although O
the O
alphavirus O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
is O
an O
essential O
component O
of O
the O
viral O
replication O
complex O
, O
it O
also O
has O
critical O
auxiliary O
functions O
that O
determine O
the O
outcome O
of O
infection O
in O
the O
host O
. O

We O
demonstrate O
here O
that O
nsP2 O
associates O
with O
ribosomal O
protein O
S6 O
( O
RpS6 O
) O
and O
that O
nsP2 O
is O
present O
in O
the O
ribosome O
- O
containing O
fractions O
of O
a O
polysome O
gradient O
, O
suggesting O
that O
nsP2 O
associates O
with O
RpS6 O
in O
the O
context O
of O
the O
whole O
ribosome O
. O

Epidemics O
of O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
result O
from O
high O
- O
titer O
equine O
viremia O
of O
IAB O
and O
IC O
subtype O
viruses O
that O
mediate O
increased O
mosquito O
transmission O
and O
spillover O
to O
humans O
. O

Here O
we O
report O
the O
production O
of O
murine O
oncoretroviral O
and O
lentiviral O
vectors O
pseudotyped O
with O
the O
envelope O
proteins O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
. O

When O
optimized O
, O
these O
pseudotypes O
achieve O
titers O
of O
10 O
( O
6 O
) O
CFU O
/ O
ml O
, O
which O
is O
5 O
- O
to O
10 O
- O
fold O
higher O
than O
for O
previous O
vectors O
pseudotyped O
with O
envelope O
proteins O
from O
other O
alphaviruses O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
reemerging O
pathogen O
and O
a O
continuing O
threat O
to O
humans O
and O
equines O
in O
the O
Americas O
. O

Infectious O
cDNA O
clones O
were O
generated O
from O
an O
epizootic O
subtype O
IC O
VEEV O
strain O
( O
SH3 O
) O
isolated O
during O
the O
1992 O
Venezuelan O
outbreak O
and O
a O
closely O
related O
enzootic O
, O
sympatric O
subtype O
ID O
strain O
( O
ZPC738 O
) O
. O

Alphavirus O
replicon O
particle O
- O
based O
vaccine O
vectors O
derived O
from O
Sindbis B
virus I
( I
SIN I
) I
, O
Semliki O
Forest O
virus O
, O
and O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
have O
been O
shown O
to O
induce O
robust O
antigen O
- O
specific O
cellular O
, O
Immoral O
, O
and O
mucosal O
immune O
responses O
in O
many O
animal O
models O
of O
infectious O
disease O
and O
cancer O
. O

However O
, O
since O
little O
is O
known O
about O
the O
relative O
potencies O
among O
these O
different O
vectors O
, O
we O
compared O
the O
immunogenicity O
of O
replicon O
particle O
vectors O
derived O
from O
two O
very O
different O
parental O
alphaviruses O
, O
VEE O
and O
SIN O
, O
expressing O
a O
human O
immunodeficiency O
virus O
type O
1 O
p55 O
( O
Gag O
) O
antigen O
. O

Two O
distinct O
strategies O
were O
used O
to O
produce O
particles O
with O
VEE O
- O
p55 O
( O
gag O
) O
replicon O
RNA O
packaged O
within O
SIN O
envelope O
glycoproteins O
and O
SIN O
- O
p55 O
( O
gag O
) O
replicon O
RNA O
within O
VEE O
envelope O
glycoproteins O
. O

Each O
replicon O
particle O
configuration O
induced O
Gag O
- O
specific O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
in O
murine O
models O
when O
administered O
alone O
or O
after O
priming O
with O
DNA O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
important O
, O
naturally O
emerging O
zoonotic O
virus O
. O

VEEV O
was O
a O
significant O
human O
and O
equine O
pathogen O
for O
much O
of O
the O
past O
century O
, O
and O
recent O
outbreaks O
in O
Venezuela O
and O
Colombia O
( O
1995 O
) O
, O
with O
about O
100 O
, O
000 O
human O
cases O
, O
indicate O
that O
this O
virus O
still O
poses O
a O
serious O
public O
health O
threat O
. O

The O
live O
attenuated O
TC O
- O
83 O
vaccine O
strain O
of O
VEEV O
was O
developed O
in O
the O
1960s O
using O
a O
traditional O
approach O
of O
serial O
passaging O
in O
tissue O
culture O
of O
the O
virulent O
Trinidad B
donkey I
( I
TrD I
) I
strain O
. O

To O
overcome O
these O
negative O
effects O
, O
we O
developed O
a O
recombinant O
, O
chimeric O
Sindbis O
/ O
VEE O
virus O
( O
SIN O
- O
83 O
) O
that O
is O
more O
highly O
attenuated O
. O

The O
genome O
of O
this O
virus O
encoded O
the O
replicative O
enzymes O
and O
the O
cis O
- O
acting O
RNA O
elements O
derived O
from O
Sindbis B
virus I
( I
SINV I
) I
, O
one O
of O
the O
least O
human O
- O
pathogenic O
alphaviruses O
. O

We O
have O
studied O
the O
induction O
of O
neutralizing O
antibodies O
by O
in O
vivo O
expression O
of O
the O
human B
immunodeficiency I
virus I
type I
I I
( I
HIV I
- I
1 I
) I
envelope O
by O
using O
a O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
replicon O
system O
with O
mice O
and O
rabbits O
. O

The O
HIV O
- O
1 O
envelope O
, O
clone O
R2 O
, O
has O
broad O
sensitivity O
to O
cross O
- O
reactive O
neutralization O
and O
was O
obtained O
from O
a O
donor O
with O
broadly O
cross O
- O
reactive O
, O
primary O
virus O
- O
neutralizing O
antibodies O
( O
donor O
of O
reference O
serum O
, O
HIV O
- O
1 O
- O
neutralizing O
serum O
2 O
[ O
HNS2 O
] O
) O
. O

This O
activity O
was O
cross O
- O
reactive O
among O
a O
panel O
of O
five O
nonhomologous O
primary O
clade O
B O
strains O
and O
a O
Chinese O
clade O
C O
strain O
and O
minimally O
reactive O
against O
a O
Chinese O
clade O
E O
( O
circulating O
recombinant O
form O
1 O
) O
strain O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
an O
important O
human O
and O
equine O
pathogen O
in O
the O
Americas O
, O
with O
widespread O
reoccurring O
epidemics O
extending O
from O
South O
America O
to O
the O
southern O
United O
States O
. O

Equine O
- O
virulent O
, O
epidemic O
/ O
epizootic O
strains O
of O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
virus O
( O
VEEV O
) O
arise O
via O
mutation O
of O
progenitor O
enzootic O
strains O
that O
replicate O
poorly O
in O
equines O
. O

Sequencing O
studies O
have O
implicated O
positively O
charged O
amino O
acids O
on O
the O
surface O
of O
the O
E2 O
envelope O
glycoprotein O
in O
the O
acquisition O
of O
equine O
virulence O
and O
viremia O
potential O
, O
suggesting O
that O
changes O
in O
binding O
to O
cell O
surface O
glycosaminoglycans B
( I
GAGs I
) I
may O
mediate O
VEE O
emergence O
. O

Therefore O
, O
we O
evaluated O
the O
binding O
of O
natural O
enzootic O
and O
epizootic O
VEEV O
isolates O
to O
Chinese B
hamster I
ovary I
( I
CHO I
) I
cells O
expressing O
normal O
, O
high O
levels O
of O
GAGs O
as O
well O
as O
to O
mutant O
CHO O
cells O
lacking O
GAG O
expression O
. O

Attachment O
of O
Norwalk B
( I
NV I
) I
, O
Snow B
Mountain I
( I
SMV I
) I
, O
and O
Hawaii O
( O
HV O
) O
virus B
- I
like I
particles I
( I
VLPs I
) I
to O
specific O
ABH O
histo O
- O
blood O
group O
antigens O
was O
investigated O
by O
using O
human O
saliva O
and O
synthetic O
biotinylated O
carbohydrates O
. O

The O
three O
distinct O
Norwalk B
- I
like I
viruses I
( I
NLVs I
) I
have O
various O
capacities O
for O
binding O
ABH O
histo O
- O
blood O
group O
antigens O
, O
suggesting O
that O
different O
mechanisms O
for O
NLV O
attachment O
likely O
exist O
. O

Importantly O
, O
antisera O
from O
NV O
- O
infected O
human O
volunteers O
, O
as O
well O
as O
from O
mice O
inoculated O
with O
packaged O
Venezuelan O
equine O
encephalitis O
virus O
replicons O
expressing O
NV O
VLPs O
, O
blocked O
the O
ability O
of O
NV O
VLPs O
to O
bind O
synthetic O
H O
type O
1 O
, O
Le O
( O
b O
) O
, O
and O
H O
type O
3 O
, O
suggesting O
a O
potential O
mechanism O
for O
antibody O
- O
mediated O
neutralization O
of O
NV O
. O

Cell O
culture O
isolates O
of O
salmon B
pancreas I
disease I
virus I
( I
SPDV I
) I
of O
farmed O
Atlantic O
salmon O
and O
sleeping B
disease I
virus I
( I
SDV I
) I
of O
rainbow O
trout O
were O
compared O
. O

Excluding O
the O
poly O
( O
A O
) O
tracts O
, O
the O
genomic O
nucleotide O
sequences O
of O
SPDV O
and O
SDV O
RNAs O
include O
11 O
, O
919 O
and O
11 O
, O
900 O
nucleotides O
, O
respectively O
. O

The O
Norwalk B
virus I
( I
NV I
) I
capsid O
protein O
was O
expressed O
using O
Venezuelan O
equine O
encephalitis O
virus O
replicon O
particles O
( O
VRP O
- O
WI O
) O
. O

Epidemic O
- O
epizootic O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
viruses O
( O
VEEV O
) O
have O
emerged O
repeatedly O
via O
convergent O
evolution O
from O
enzootic O
predecessors O
. O

Norwalk B
- I
like I
viruses I
( I
NLVs I
) I
are O
a O
diverse O
group O
of O
single O
- O
stranded O
, O
nonenveloped O
, O
positive O
- O
polarity O
RNA O
viruses O
and O
are O
the O
leading O
cause O
of O
epidemic O
acute O
gastroenteritis O
in O
the O
United O
States O
. O

In O
this O
study O
, O
the O
major O
capsid O
gene O
of O
Norwalk O
virus O
, O
the O
prototype O
NLV O
, O
has O
been O
cloned O
and O
expressed O
in O
mammalian O
cells O
using O
a O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
replicon O
expression O
system O
. O

Upon O
infection O
of O
baby B
hamster I
kidney I
( I
BHK I
) I
cells O
with O
VEE B
replicon I
particles I
( I
VRPs I
) I
, O
the O
Norwalk O
virus O
capsid O
proteins O
self O
- O
assemble O
to O
generate O
high O
titers O
of O
Norwalk O
virus B
- I
like I
particles I
( I
VLPs I
) I
that O
are O
morphologically O
and O
antigenically O
analogous O
to O
wild O
- O
type O
Norwalk O
virus O
. O

Mice O
inoculated O
subcutaneously O
with O
VRPs O
expressing O
the O
Norwalk O
virus O
capsid O
protein O
( O
VRP O
- O
NV1 O
) O
developed O
systemic O
and O
mucosal O
immune O
responses O
to O
Norwalk O
VLPs O
, O
as O
well O
as O
heterotypic O
antibody O
responses O
to O
the O
major O
capsid O
protein O
from O
another O
genogroup O
I O
NLV O
strain O
( O
NCFL O
) O
isolated O
from O
a O
recent O
outbreak O
. O

A O
second O
Norwalk O
virus O
capsid O
clone O
( O
NV2 O
) O
containing O
three O
amino O
acid O
codon O
mutations O
from O
the O
NV1 O
clone O
was O
also O
expressed O
using O
VEE O
replicons O
( O
VRP O
- O
NV2 O
) O
, O
but O
upon O
infection O
of O
BHK O
cells O
failed O
to O
confer O
VLP O
self O
- O
assembly O
. O

Venezuelan B
equine I
encephalitis I
viruses I
( I
VEEV I
) I
belonging O
to O
subtype O
IC O
have O
caused O
three O
( O
1962 O
- O
1964 O
, O
1992 O
- O
1993 O
and O
1995 O
) O
major O
equine O
epizootics O
and O
epidemics O
. O

Some O
authentic O
epizootic O
IC O
strains O
isolated O
32 O
years O
apart O
showed O
a O
greater O
degree O
of O
sequence O
identity O
than O
did O
isolates O
from O
the O
same O
( O
1962 O
- O
1964 O
or O
1995 O
) O
outbreak O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
is O
an O
important O
equine O
and O
human O
pathogen O
of O
the O
Americas O
. O

A O
single O
change O
( O
G O
to O
A O
) O
at O
nucleotide O
3 O
( O
nt O
3 O
) O
of O
the O
5 B
' I
untranslated I
region I
( I
UTR I
) I
of O
the O
V3000 O
genome O
resulted O
in O
a O
virus O
( O
V3043 O
) O
that O
was O
avirulent O
in O
mice O
. O

inoculation O
showed O
that O
V3043 O
replication O
was O
reduced O
in O
peripheral O
organs O
compared O
to O
that O
of O
V3000 O
, O
titers O
in O
serum O
also O
were O
lower O
, O
and O
V3043 O
was O
cleared O
more O
rapidly O
from O
the O
periphery O
than O
V3000 O
, O
Because O
clearance O
of O
V3043 O
from O
serum O
began O
1 O
to O
2 O
days O
prior O
to O
clearance O
of O
V3000 O
, O
we O
examined O
the O
involvement O
of O
alpha O
/ O
beta O
interferon O
( O
IFN O
alpha O
/ O
beta O
) O
activity O
in O
VEE O
pathogenesis O
. O

In O
IFN O
- O
alpha O
/ O
betaR O
( O
- O
/ O
- O
) O
mice O
, O
the O
course O
of O
the O
wild O
- O
type O
disease O
was O
extremely O
rapid O
, O
with O
all O
animals O
dying O
within O
48 O
h O
( O
average O
survival O
time O
of O
30 O
h O
compared O
to O
7 O
. O

The O
mutant O
V3043 O
was O
as O
virulent O
as O
the O
did O
type O
( O
100 O
% O
mortality O
, O
average O
survival O
time O
of O
30 O
h O
) O
, O
Virus O
titers O
in O
serum O
, O
peripheral O
organs O
, O
and O
the O
brain O
were O
similar O
in O
V3000 O
- O
and O
V3043 O
- O
infected O
IFN O
- O
alpha O
/ O
betaR O
( O
- O
/ O
- O
) O
mice O
at O
all O
time O
points O
up O
until O
the O
death O
of O
the O
animals O
. O

In O
cells O
derived O
from O
IFN O
- O
alpha O
/ O
betaR O
( O
- O
/ O
- O
) O
mice O
, O
the O
mutant O
virus O
showed O
no O
growth O
disadvantage O
compared O
to O
the O
wild O
- O
type O
virus O
, O
suggesting O
that O
IFN O
- O
alpha O
/ O
beta O
plays O
a O
major O
role O
in O
the O
attenuation O
of O
V3043 O
compared O
to O
V3000 O
. O

Among O
a O
myriad O
of O
putative O
functions O
assigned O
to O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
, O
several O
studies O
suggest O
that O
it O
may O
modulate O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
- O
mediated O
initiation O
of O
translation O
. O

We O
compared O
the O
translational O
activity O
of O
dicistronic O
reporter O
transcripts O
containing O
the O
HCV O
IRES O
within O
the O
intercistronic O
space O
fused O
to O
downstream O
sequence O
encoding O
either O
22 O
amino B
acids I
( I
aa I
) I
or O
173 O
aa O
of O
the O
core O
protein O
. O

Similarly O
, O
the O
expression O
of O
core O
protein O
( O
aa O
I O
to O
191 O
) O
in O
trans O
from O
a O
recombinant O
baculovirus O
did O
not O
suppress O
IRES O
- O
directed O
translation O
from O
any O
of O
these O
transcripts O
in O
transfected O
Huh O
- O
7 O
cells O
. O

While O
core O
protein O
expression O
did O
decrease O
IRES O
activity O
in O
HepG2 O
cells O
( O
up O
to O
79 O
% O
suppression O
) O
, O
the O
expression O
of O
beta O
- O
galactosidase O
from O
a O
control O
baculovirus O
also O
suppressed O
IRES O
activity O
( O
up O
to O
56 O
% O
) O
, O
strongly O
suggesting O
that O
this O
suppression O
was O
nonspecific O
. O

Finally O
, O
the O
addition O
of O
purified O
recombinant O
core O
protein O
( O
aa O
1 O
to O
179 O
) O
to O
in O
vitro O
translation O
reactions O
at O
concentrations O
up O
to O
a O
10 O
- O
fold O
molar O
excess O
over O
the O
RNA O
transcripts O
resulted O
in O
no O
significant O
reduction O
in O
IRES O
activity O
. O

RNA O
replicon O
particles O
derived O
from O
a O
vaccine O
strain O
of O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEE I
) I
were O
used O
as O
a O
vector O
for O
expression O
of O
the O
major O
envelope O
proteins O
( O
G O
( O
L O
) O
and O
M O
) O
of O
equine B
arteritis I
virus I
( I
EAV I
) I
, O
both O
individually O
and O
in O
heterodimer O
form O
( O
G O
( O
L O
) O
/ O
M O
) O
. O

Open O
reading O
frame O
5 O
( O
ORF5 O
) O
encodes O
the O
G O
( O
L O
) O
protein O
, O
which O
expresses O
the O
known O
neutralizing O
determinants O
of O
EAV O
( O
U O
. O

ORF5 O
and O
ORF6 O
( O
which O
encodes O
the O
M O
protein O
) O
of O
EAV O
were O
cloned O
into O
two O
different O
VEE O
replicon O
vectors O
that O
contained O
either O
one O
or O
two O
26S O
subgenomic O
mRNA O
. O

The O
immunogenicity O
of O
individual O
replicon O
particle O
preparations O
( O
pVR21 O
- O
G O
( O
L O
) O
, O
pVR21 O
- O
M O
, O
and O
pVR100 O
- O
G O
( O
L O
) O
/ O
M O
) O
in O
BALB O
/ O
c O
mice O
was O
determined O
. O

All O
mice O
developed O
antibodies O
against O
the O
recombinant O
proteins O
with O
which O
they O
were O
immunized O
, O
but O
only O
the O
mice O
inoculated O
with O
replicon O
particles O
expressing O
the O
G O
( O
L O
) O
/ O
M O
heterodimer O
developed O
antibodies O
that O
neutralize O
EAV O
. O

The O
data O
further O
confirmed O
that O
authentic O
posttranslational O
modification O
and O
conformational O
maturation O
of O
the O
recombinant O
G O
( O
L O
) O
protein O
occur O
only O
in O
the O
presence O
of O
the O
M O
protein O
and O
that O
this O
interaction O
is O
necessary O
for O
induction O
of O
neutralizing O
antibodies O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
is O
a O
highly O
infectious O
alphavirus O
endemic O
in O
parts O
of O
Central O
and O
South O
America O
. O

Treatment O
of O
VEEV O
- O
infected O
BALB O
/ O
c O
mice O
with O
polyethylene O
glycol O
- O
conjugated O
alpha O
interferon O
( O
PEG O
IFN O
- O
alpha O
) O
results O
in O
a O
greatly O
enhanced O
survival O
from O
either O
a O
subcutaneous O
or O
an O
aerosol O
infection O
. O

Recent O
studies O
have O
indicated O
that O
epizootic O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
viruses O
can O
evolve O
fi O
om O
enzootic O
subtype O
ID O
strains O
that O
circulate O
continuously O
in O
lowland O
tropical O
forests O
( O
A O
. O

We O
compared O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
sensitivities O
of O
the O
TC O
- O
83 O
vaccine O
strain O
and O
24 O
enzootic O
and O
epizootic O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
isolates O
: O
The O
IFN O
- O
resistant O
or O
- O
sensitive O
phenotype O
correlated O
well O
with O
epizootic O
or O
enzootic O
potential O
. O

IFN O
- O
alpha O
/ O
beta O
resistance O
of O
Trinidad B
donkey I
( I
TrD I
) I
virus O
correlated O
with O
virulence O
determinants O
in O
the O
5 O
' O
noncoding O
region O
and O
glycoproteins O
. O

Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
epidemics O
and O
equine O
epizootics O
occurred O
periodically O
in O
the O
Americas O
from O
the O
1920s O
until O
the O
early O
1970s O
, O
when O
the O
causative O
viruses O
, O
subtypes O
IAB O
and O
IC O
were O
postulated O
to O
have O
become O
extinct O
. O

Within O
the O
Columbia O
/ O
Peru O
/ O
Venezuela O
lineage O
, O
three O
distinct O
monophyletic O
groups O
of O
epidemic O
/ O
epizootic O
viruses O
were O
delineated O
, O
indicating O
that O
VEE O
emergence O
has O
occurred O
independently O
at O
least O
three O
times O
( O
convergent O
evolution O
) O
. O

Evolution O
of O
viruses O
in O
the O
eastern B
equine I
encephalomyelitis I
( I
EEE I
) I
complex O
was O
studied O
by O
analyzing O
RNA O
sequences O
and O
oligonucleotide O
fingerprints O
from O
isolates O
representing O
the O
North O
and O
South O
American O
antigenic O
varieties O
. O

Estimates O
of O
the O
overall O
rate O
of O
EEE O
virus O
evolution O
( O
nucleotide O
substitution O
) O
were O
1 O
. O

6 O
X O
10 O
( O
- O
4 O
) O
substitution O
per O
nucleotide O
per O
year O
for O
the O
North O
American O
group O
and O
4 O
. O

3 O
x O
10 O
( O
- O
4 O
) O
for O
the O
Argentina O
- O
Panama O
South O
American O
group O
. O

Evolutionary O
rate O
estimates O
for O
the O
North O
American O
group O
increased O
over O
10 O
- O
fold O
( O
from O
about O
2 O
x O
10 O
( O
- O
5 O
) O
to O
4 O
x O
10 O
( O
- O
4 O
) O
) O
concurrent O
with O
divergence O
of O
two O
monophyletic O
groups O
during O
the O
early O
1970s O
. O

The O
virulent O
Trinidad B
donkey I
( I
TrD I
) I
strain O
of O
Venezuelan B
equine I
encephalitis I
( I
VEE I
) I
virus O
and O
its O
live O
attenuated O
vaccine O
derivative O
, O
TC O
- O
83 O
virus O
, O
have O
different O
neurovirulence O
characteristics O
. O

This O
study O
aims O
to O
gain O
deeper O
insight O
into O
hepatitis B
E I
virus I
( I
HEV I
) I
- O
induced O
innate O
immunity O
by O
characterizing O
the O
cross O
talk O
between O
the O
virus O
and O
the O
host O
factor O
guanylate B
- I
binding I
protein I
1 I
( I
GBP1 I
) I
. O

Most O
importantly O
, O
silencing O
of O
GBP1 O
abolishes O
the O
antiviral O
effect O
of O
gamma O
interferon O
( O
IFN O
- O
g O
) O
on O
HEV O
. O

Here O
, O
we O
identify O
guanylate B
binding I
protein I
1 I
( I
GBP1 I
) I
as O
a O
restriction O
factor O
affecting O
the O
life O
cycle O
of O
HEV O
. O

The O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
live O
attenuated O
vaccine O
C O
- O
strain O
is O
adaptive O
to O
rabbits O
and O
attenuated O
in O
pigs O
, O
in O
contrast O
with O
the O
highly O
virulent O
CSFV O
Shimen O
strain O
. O

Previously O
, O
we O
demonstrated O
that O
P108 O
and O
T109 O
on O
the O
E2 O
glycoprotein O
( O
E2 O
( O
P108 O
- O
T109 O
) O
) O
in O
domain O
I O
( O
E2 O
( O
Doma O
) O
( O
inl O
) O
) O
rather O
than O
R132 O
, O
S133 O
, O
and O
D191 O
in O
domain O
II O
( O
E2 O
( O
Domainll O
) O
) O
determine O
C O
- O
strain O
' O
s O
adaptation B
to I
rabbits I
( I
ATR I
) I
( O
Y O
. O

In O
this O
study O
, O
three O
chimeric O
viruses O
harboring O
E2 O
( O
P108 O
- O
T109 O
) O
, O
E2 O
( O
Domainl O
) O
, O
or O
E2 O
( O
Domain O
) O
( O
ll O
) O
of O
C O
- O
strain O
based O
on O
the O
non O
- O
rabbit O
- O
adaptive O
Shimen O
mutant O
vSM O
- O
HCLVErns O
carrying O
the O
E O
- O
rns O
glycoprotein O
of O
C O
- O
strain O
were O
generated O
and O
evaluated O
. O

We O
found O
that O
E2 O
( O
P108 O
- O
T O
) O
( O
109 O
) O
or O
E2 O
( O
Doma O
) O
( O
inl O
) O
but O
not O
E2 O
( O
Domain O
) O
( O
ll O
) O
of O
C O
- O
strain O
renders O
vSM O
- O
HCLVErns O
adaptive O
to O
rabbits O
, O
suggesting O
that O
E2 O
( O
P108 O
- O
T109 O
) O
in O
combination O
with O
the O
E O
- O
r O
( O
ns O
) O
glycoprotein O
( O
E2 O
( O
P108 O
- O
T109 O
) O
- O
Ems O
) O
confers O
ATR O
on O
the O
Shimen O
strain O
, O
creating O
new O
rabbit O
- O
adaptive O
CSFVs O
. O

Mechanistically O
, O
E2 O
( O
P108 O
- O
T109 O
) O
- O
E O
- O
rns O
of O
C O
- O
strain O
mediates O
viral O
entry O
during O
infection O
in O
rabbit O
spleen O
lymphocytes O
, O
which O
are O
target O
cells O
of O
C O
- O
strain O
. O

Notably O
, O
pig O
experiments O
showed O
that O
E2 O
( O
P108 O
- O
T109 O
) O
- O
E O
- O
rns O
of O
C O
- O
strain O
does O
not O
affect O
virulence O
compared O
with O
the O
Shimen O
strain O
. O

Conversely O
, O
the O
substitution O
of O
E2 O
( O
Domainll O
) O
and O
E O
- O
rns O
of O
C O
- O
strain O
attenuates O
the O
Shimen O
strain O
in O
pigs O
, O
indicating O
that O
the O
molecular O
basis O
of O
the O
CSFV O
ATR O
and O
that O
of O
virulence O
in O
pigs O
do O
not O
overlap O
. O

IMPORTANCE O
Historically O
, O
live O
attenuated O
vaccines O
produced O
by O
blind O
passage O
usually O
undergo O
adaptation O
in O
cell O
cultures O
or O
nonsusceptible O
hosts O
and O
attenuation O
in O
natural O
hosts O
, O
with O
a O
classical O
example O
being O
the O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
lapinized O
vaccine O
C O
- O
strain O
, O
which O
was O
developed O
by O
hundreds O
of O
passages O
in O
rabbits O
. O

interferon B
lambda I
4 I
( I
IFN I
- I
lambda I
4 I
) I
is O
a O
recently O
identified O
enigmatic O
member O
of O
the O
interferon B
( I
IFN I
) I
lambda O
family O
. O

Being O
induced O
by O
viral O
infection O
is O
a O
defining O
characteristic O
of O
interferons O
, O
but O
viral O
infection O
or O
overexpression O
of O
members O
of O
the O
interferon B
regulatory I
factor I
( I
IRF I
) I
family O
of O
transcription O
factors O
only O
leads O
to O
a O
minute O
induction O
of O
IFNL4 O
. O

IMPORTANCE O
Recent O
genetic O
evidence O
has O
highlighted O
how O
the O
IFNL4 O
gene O
acts O
in O
a O
counterintuitive O
manner O
, O
as O
patients O
with O
a O
nonfunctional O
IFNL4 O
gene O
exhibit O
increased O
clearance O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
but O
also O
increased O
liver O
inflammation O
. O

These O
surprising O
but O
quite O
clear O
genetic O
data O
have O
prompted O
an O
extensive O
examination O
of O
the O
basic O
characteristics O
of O
the O
IFNL4 O
gene O
and O
its O
gene O
product O
, O
interferon B
lambda I
4 I
( I
IFN I
- I
lambda I
4 I
) I
. O

A O
thorough O
investigation O
of O
the O
IFNL4 O
promoter O
revealed O
a O
highly O
conserved O
and O
functional O
promoter O
, O
but O
also O
one O
that O
lacks O
the O
defining O
characteristic O
of O
Interferons B
( I
IFNs I
) I
, O
i O
. O

Avian O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
the O
main O
causative O
agent O
of O
big O
liver O
and O
spleen O
disease O
in O
chickens O
. O

In O
this O
study O
, O
organic B
anion I
- I
transporting I
polypeptide I
1A2 I
( I
OATP1A2 I
) I
from O
chicken O
liver O
cells O
was O
identified O
to O
interact O
with O
ap237 O
, O
a O
truncated O
avian O
HEV O
capsid O
protein O
spanning O
amino O
acids O
313 O
to O
549 O
, O
by O
a O
glutathione B
S I
- I
transferase I
( I
GST I
) I
pulldown O
assay O
. O

GST O
pulldown O
and O
indirect O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISAs I
) I
further O
confirmed O
that O
the O
extracellular O
domain O
of O
OATP1A2 O
directly O
binds O
with O
ap237 O
. O

In O
this O
study O
, O
a O
total O
of O
seven O
host O
proteins O
were O
screened O
in O
chicken O
liver O
cells O
by O
a O
truncated O
avian O
HEV O
capsid O
protein O
( O
ap237 O
) O
in O
which O
the O
host O
protein O
OATP1A2 O
interacted O
with O
ap237 O
. O

Hepatitis O
C O
is O
a O
liver O
disease O
caused O
by O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
affecting O
71 O
million O
people O
worldwide O
with O
no O
licensed O
vaccines O
that O
prevent O
infection O
. O

Here O
, O
we O
have O
generated O
four O
novel O
alphavirus O
- O
based O
DNA O
- O
launched O
self O
- O
amplifying O
RNA O
replicon O
( O
DREP O
) O
vaccines O
expressing O
either O
structural O
core O
- O
E1 O
- O
E2 O
or O
nonstructural O
p7 O
- O
NS2 O
- O
NS3 O
HCV O
proteins O
of O
genotype O
1a O
placed O
under O
the O
control O
of O
an O
alphavirus O
promoter O
, O
with O
or O
without O
an O
alphaviral O
translational O
enhancer O
( O
grouped O
as O
DREP O
- O
HCV O
or O
DREP O
- O
e O
- O
HCV O
, O
respectively O
) O
. O

Immunization O
of O
mice O
with O
the O
DREP O
vaccines O
as O
the O
priming O
immunization O
followed O
by O
a O
heterologous O
boost O
with O
a O
recombinant O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
vector O
expressing O
the O
nearly O
full O
- O
length O
genome O
of O
HCV O
( O
MVA O
- O
HCV O
) O
induced O
potent O
and O
long O
- O
lasting O
HCV O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
immune O
responses O
that O
were O
significantly O
stronger O
than O
those O
of O
a O
homologous O
MVA O
- O
HCV O
prime O
/ O
boost O
immunization O
, O
with O
the O
DREP O
- O
e O
- O
HCV O
/ O
MVA O
- O
HCV O
combination O
the O
most O
immunogenic O
regimen O
. O

HCV O
- O
specific O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
were O
highly O
polyfunctional O
, O
had O
an O
effector O
memory O
phenotype O
, O
and O
were O
mainly O
directed O
against O
E1 O
- O
E2 O
and O
NS2 O
- O
NS3 O
, O
respectively O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
zoonotic O
and O
a O
major O
cause O
of O
acute O
viral O
hepatitis O
worldwide O
. O

Recently O
, O
we O
identified O
a O
novel O
HEV B
genotype I
8 I
( I
HEV8 I
) I
in O
Bactrian O
camels O
in O
Xinjiang O
, O
China O
. O

Fresh O
fecal O
and O
milk O
samples O
from O
Bactrian O
camels O
collected O
from O
four O
provinces O
/ O
regions O
in O
China O
were O
screened O
for O
HEV O
RNA O
by O
reverse B
transcriptase I
PCR I
( I
RT I
- I
PCR I
) I
. O

Extrahepatic O
replication O
was O
tested O
by O
using O
reverse B
transcriptase I
quantitative I
PCR I
( I
RT I
- I
qPCR I
) I
and O
immunofluorescence O
assays O
. O

4 O
% O
( O
4 O
/ O
295 O
) O
, O
and O
positive O
samples O
were O
found O
in O
three O
different O
provinces O
/ O
regions O
in O
China O
. O

IMPORTANCE O
It O
is O
estimated O
that O
one O
- O
third O
of O
the O
world O
population O
have O
been O
exposed O
to O
hepatitis B
E I
virus I
( I
HEV I
) I
. O

hepatitis B
E I
virus I
( I
HEV I
) I
generally O
causes O
self O
- O
limiting O
acute O
viral O
hepatitis O
in O
normal O
individuals O
. O

Previous O
studies O
have O
demonstrated O
the O
essential O
role O
of O
the O
interaction O
between O
the O
PSAP O
motif O
of O
the O
viral O
open O
reading O
frame O
3 O
protein O
( O
ORF3 O
- O
PSAP O
) O
and O
the O
UEV O
domain O
of O
the O
host O
tumor B
susceptibility I
gene I
101 I
( I
TSG101 I
) I
protein O
( O
UEV O
- O
TSG101 O
) O
in O
mediating O
the O
release O
of O
genotype O
3 O
HEV O
. O

Cyclic B
peptide I
( I
CP I
) I
inhibitors O
of O
the O
interaction O
between O
the O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
gag O
- O
PTAP O
motif O
and O
UEV O
- O
TSG101 O
are O
known O
to O
block O
the O
release O
of O
HIV O
. O

Two O
independent O
assays O
confirmed O
the O
ability O
of O
a O
cyclic O
peptide O
( O
CP11 O
) O
to O
inhibit O
the O
ORF3 O
- O
TSG101 O
interaction O
. O

CP11 O
treatment O
also O
reduced O
the O
release O
of O
both O
genotype O
1 O
and O
genotype O
3 O
HEV O
by O
approximately O
90 O
% O
, O
with O
a O
50 O
% O
inhibitory O
concentration O
( O
IC O
) O
of O
2 O
/ O
AM O
. O

IMPORTANCE O
There O
is O
no O
specific O
therapy O
against O
hepatitis B
E I
virus I
( I
HEV I
) I
- O
induced O
hepatic O
and O
nonhepatic O
health O
problems O
. O

apolipoprotein B
E I
( I
ApoE I
) I
plays O
an O
important O
role O
in O
the O
maturation O
and O
infectivity O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

This O
colocalization O
was O
marginally O
detected O
in O
HCV O
- O
infected O
cells O
, O
apparently O
due O
to O
the O
depletion O
of O
ApoE O
by O
HCV O
, O
as O
treatment O
with O
bafilomycin B
A1 I
( I
BafA1 I
) I
, O
a O
vacuolar O
ATPase O
inhibitor O
that O
inhibits O
autophagic O
protein O
degradation O
, O
partially O
restored O
the O
ApoE O
level O
and O
enhanced O
its O
colocalization O
with O
autophagosomes O
in O
HCV O
- O
infected O
cells O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
one O
of O
the O
most O
important O
human O
pathogens O
. O

Its O
virion O
is O
associated O
with O
apolipoprotein B
E I
( I
ApoE I
) I
, O
which O
enhances O
its O
infectivity O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
clinically O
important O
positive O
- O
sense O
RNA O
virus O
. O

It O
is O
not O
clear O
whether O
the O
ORF1 B
polyprotein I
( I
pORF1 I
) I
is O
processed O
into O
distinct O
enzymatic O
domains O
. O

The O
treatment O
of O
a O
liver O
cell O
line O
with O
a O
serine O
protease O
inhibitor O
as O
well O
as O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
thrombin O
and O
factor O
Xa O
resulted O
in O
significant O
reduction O
in O
the O
replication O
of O
HEV O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
causes O
a O
liver O
disorder O
called O
hepatitis O
in O
humans O
, O
which O
is O
mostly O
an O
acute O
and O
self O
- O
limiting O
infection O
in O
adults O
. O

The O
genetic O
diversity O
( O
cloud O
size O
) O
and O
composition O
of O
this O
mutant O
cloud O
may O
influence O
several O
important O
phenotypic O
features O
of O
the O
virus O
, O
including O
its O
replication O
capacity O
. O

We O
applied O
a O
straightforward O
, O
bacterium O
- O
free O
approach O
using O
error O
- O
prone O
PCR O
coupled O
with O
reverse O
genetics O
to O
generate O
infectious O
mutant O
RNA O
clouds O
with O
various O
levels O
of O
genetic O
diversity O
from O
a O
genotype O
1 O
strain O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
. O

Cloning O
and O
sequencing O
of O
a O
genomic O
fragment O
encompassing O
70 O
% O
of O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
or O
of O
the O
full O
genome O
from O
variants O
in O
the O
resultant O
clouds O
showed O
the O
occurrence O
of O
nucleotide O
mutations O
at O
a O
frequency O
on O
the O
order O
of O
10 O
( O
- O
3 O
) O
per O
nucleotide O
copied O
and O
the O
existence O
of O
marked O
genetic O
diversity O
, O
with O
a O
high O
normalized O
Shannon O
entropy O
value O
. O

Cross O
- O
sectional O
data O
from O
these O
cell O
cultures O
supported O
the O
existence O
of O
differential O
effects O
of O
clouds O
of O
various O
sizes O
and O
compositions O
on O
phenotypic O
characteristics O
, O
such O
as O
the O
replication O
level O
of O
( O
+ O
) O
- O
RNA O
progeny O
, O
the O
amounts O
of O
double O
- O
stranded O
RNA O
( O
a O
surrogate O
for O
the O
rate O
of O
viral O
replication O
) O
and O
ORF1 O
protein O
, O
and O
the O
expression O
of O
interferon O
- O
stimulated O
genes O
. O

We O
developed O
a O
simple O
and O
rapid O
method O
for O
synthesizing O
mutant O
clouds O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
, O
a O
single O
- O
stranded O
( O
+ O
) O
- O
RNA O
[ O
ss O
( O
+ O
) O
RNA O
] O
virus O
, O
with O
various O
and O
controllable O
levels O
of O
genetic O
diversity O
, O
which O
could O
then O
be O
used O
in O
a O
cell O
culture O
system O
to O
study O
the O
effects O
of O
cloud O
size O
and O
composition O
on O
viral O
phenotype O
. O

This O
method O
should O
thus O
provide O
a O
useful O
model O
for O
understanding O
the O
phenotypic O
behavior O
of O
ss O
( O
+ O
) O
RNA O
viruses O
. O

Our O
previous O
studies O
demonstrated O
that O
membrane O
- O
associated O
hepatitis B
E I
virus I
( I
HEV I
) I
particles O
- O
now O
considered O
quasi O
- O
enveloped O
particles O
- O
are O
present O
in O
the O
multivesicular O
body O
with O
intraluminal O
vesicles O
( O
exosomes O
) O
in O
infected O
cells O
and O
that O
the O
release O
of O
HEV O
virions O
is O
related O
to O
the O
exosomal O
pathway O
. O

Purified O
CD63 O
- O
, O
CD9 O
- O
, O
or O
CD81 O
- O
positive O
exosomes O
derived O
from O
the O
culture O
supernatants O
of O
HEV O
- O
infected O
cells O
that O
had O
been O
cultivated O
in O
serum O
- O
free O
medium O
were O
found O
to O
contain O
HEV O
RNA O
and O
the O
viral O
capsid O
( O
ORF2 O
) O
and O
ORF3 O
proteins O
, O
as O
determined O
by O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
and O
Western O
blotting O
, O
respectively O
. O

9 O
nm O
, O
and O
the O
treated O
particles O
became O
accessible O
with O
an O
anti O
- O
HEV O
ORF2 O
monoclonal B
antibody I
( I
Mab I
) I
. O

Interactions O
between O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
lipoproteins O
in O
humans O
play O
an O
important O
role O
in O
the O
efficient O
establishment O
of O
chronic O
infection O
. O

apolipoprotein B
E I
( I
ApoE I
) I
on O
the O
HCV O
envelope O
mediates O
virus O
attachment O
to O
host O
cells O
as O
well O
as O
immune O
evasion O
. O

In O
the O
present O
study O
, O
we O
found O
that O
secreted B
ApoE I
( I
sApoE I
) I
can O
also O
bind O
to O
viral O
particles O
via O
its O
C O
- O
terminal O
domain O
after O
HCV O
is O
released O
from O
the O
cell O
. O

In O
this O
study O
, O
we O
found O
that O
secreted B
ApoE I
( I
sApoE I
) I
, O
an O
exchangeable O
component O
found O
in O
lipoproteins O
, O
participates O
in O
extracellular O
interactions O
with O
HCV O
virions O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
the O
most O
common O
cause O
of O
acute O
viral O
hepatitis O
globally O
. O

Genome O
- O
wide O
estimates O
of O
the O
ratio O
of O
nonsynonymous O
to O
synonymous O
evolutionary O
changes O
( O
dN O
/ O
dS O
ratio O
) O
located O
a O
region O
of O
overlapping O
reading O
frames O
, O
which O
is O
subject O
to O
positive O
selection O
in O
genotypes O
3 O
and O
4 O
. O

The O
open B
reading I
frames I
( I
ORFs I
) I
involved O
have O
functions O
related O
to O
host O
- O
pathogen O
interaction O
, O
so O
genotype O
- O
specific O
evolution O
of O
these O
regions O
may O
reflect O
their O
fitness O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
increasingly O
recognized O
as O
a O
pathogen O
that O
affects O
both O
the O
developing O
and O
the O
developed O
world O
. O

Human O
TIM O
and O
TAM O
family O
proteins O
were O
recently O
found O
to O
serve O
as O
Phosphatidylserine B
( I
PS I
) I
receptors O
which O
promote O
infections O
by O
many O
different O
viruses O
, O
including O
dengue O
virus O
, O
West O
Nile O
virus O
, O
Ebola O
virus O
, O
Marburg O
virus O
, O
and O
Zika O
virus O
. O

In O
the O
present O
study O
, O
we O
provide O
substantial O
evidence O
demonstrating O
that O
TIM O
- O
1 O
is O
important O
for O
efficient O
infection O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Additionally O
, O
HCV O
infection O
and O
cell O
attachment O
were O
inhibited O
by O
PS O
but O
not O
by O
phosphatidylcholine B
( I
PC I
) I
, O
demonstrating O
that O
TIM O
- O
1 O
- O
mediated O
enhancement O
of O
HCV O
infection O
is O
PS O
dependent O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
particles O
are O
described O
as O
lipoviroparticles O
which O
are O
released O
similarly O
to O
very B
- I
low I
- I
density I
lipoproteins I
( I
VLDLs I
) I
. O

However O
, O
the O
release O
mechanism O
is O
still O
poorly O
understood O
; O
the O
canonical O
endoplasmic B
reticulum I
- I
Golgi I
intermediate I
compartment I
( I
ERGIC I
) I
pathway O
as O
well O
as O
endosome O
- O
dependent O
release O
has O
been O
proposed O
. O

To O
investigate O
the O
relevance O
of O
multivesicular B
bodies I
( I
MVBs I
) I
for O
viral O
morphogenesis O
and O
release O
, O
the O
MVB O
inhibitor O
U18666A O
was O
used O
. O

In O
U18666A O
- O
treated O
cells O
, O
intact O
infectious O
viral O
particles O
accumulate O
in O
CD63 O
- O
positive O
exosomal O
structures O
and O
large O
dysfunctional O
lysosomal O
structures O
( O
multilamellar O
bodies O
) O
. O

Use O
of O
the O
MVB B
( I
multivesicular I
body I
) I
inhibitor O
U18666A O
enabled O
a O
detailed O
analysis O
of O
the O
impact O
of O
MVBs O
for O
viral O
morphogenesis O
and O
release O
. O

E2 O
, O
the O
major O
envelope O
glycoprotein O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
is O
involved O
in O
several O
critical O
virus O
functions O
, O
including O
cell O
attachment O
, O
host O
range O
susceptibility O
, O
and O
virulence O
in O
natural O
hosts O
. O

Functional O
structural O
analysis O
of O
E2 O
based O
on O
a O
Wimley O
- O
White O
interfacial O
hydrophobicity O
distribution O
predicted O
the O
involvement O
of O
a O
loop O
( O
residues O
864 O
to O
881 O
) O
stabilized O
by O
a O
disulfide O
bond O
( O
( O
869 O
) O
CKWGGNWTCV O
( O
878 O
) O
, O
named O
FPII O
) O
in O
establishing O
interactions O
with O
the O
host O
cell O
membrane O
. O

This O
loop O
further O
contains O
an O
( O
872 O
) O
GG O
( O
873 O
) O
dipeptide O
, O
as O
well O
as O
two O
aromatic O
residues O
( O
W O
- O
871 O
and O
W O
- O
875 O
) O
accessible O
to O
solvent O
. O

Reverse O
genetics O
utilizing O
a O
full O
- O
length O
infectious O
clone O
of O
the O
highly O
virulent O
CSFV O
strain O
Brescia O
( O
BICv O
) O
was O
used O
to O
evaluate O
how O
amino O
acid O
substitutions O
within O
FPII O
may O
affect O
replication O
of O
BICv O
in O
vitro O
and O
virus O
virulence O
in O
swine O
. O

2 O
) O
, O
demonstrated O
a O
significantly O
decreased O
ability O
to O
replicate O
in O
a O
swine O
cell O
line O
( O
SK6 O
) O
and O
swine O
macrophage O
primary O
cell O
cultures O
. O

IMPORTANCE O
This O
report O
describes O
the O
identification O
and O
characterization O
of O
a O
putative O
fusion B
peptide I
( I
FP I
) I
in O
the O
major O
structural O
protein O
E2 O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
. O

Human B
astrovirus I
( I
HAstV I
) I
is O
a O
leading O
cause O
of O
viral O
diarrhea O
in O
infants O
and O
young O
children O
worldwide O
. O

The O
capsid B
protein I
( I
CP I
) I
of O
HAstV O
is O
synthesized O
as O
a O
90 O
- O
kDa O
precursor O
( O
VP90 O
) O
that O
can O
be O
divided O
into O
three O
linear O
domains O
: O
a O
conserved O
N O
- O
terminal O
domain O
, O
a O
hypervariable O
domain O
, O
and O
an O
acidic O
C O
- O
terminal O
domain O
. O

We O
have O
now O
solved O
the O
crystal O
structure O
of O
VP90 O
( O
71 O
- O
415 O
) O
( O
amino O
acids O
[ O
aa O
] O
71 O
to O
415 O
of O
VP90 O
) O
of O
human O
astrovirus O
serotype O
8 O
at O
a O
2 O
. O

VP90 O
( O
71 O
- O
415 O
) O
encompasses O
the O
conserved O
N O
- O
terminal O
domain O
of O
VP90 O
but O
lacks O
the O
hypervariable O
domain O
, O
which O
forms O
the O
capsid O
surface O
spikes O
. O

The O
structure O
of O
VP90 O
( O
71 O
- O
41 O
) O
5 O
is O
comprised O
of O
two O
domains O
: O
an O
S O
domain O
, O
which O
adopts O
the O
typical O
jelly O
- O
roll O
beta O
- O
barrel O
fold O
, O
and O
a O
P1 O
domain O
, O
which O
forms O
a O
squashed O
beta O
- O
barrel O
consisting O
of O
six O
antiparallel O
beta O
- O
strands O
similar O
to O
what O
was O
observed O
in O
the O
hepatitis B
E I
virus I
( I
HEV I
) I
capsid O
structure O
. O

Fitting O
of O
the O
VP90 O
( O
71 O
- O
415 O
) O
structure O
into O
the O
cryo O
- O
electron B
microscopy I
( I
EM I
) I
maps O
of O
HAstV O
produced O
an O
atomic O
model O
for O
a O
continuous O
, O
T O
= O
3 O
icosahedral O
capsid O
shell O
. O

Such O
information O
has O
potential O
applications O
in O
the O
development O
of O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
vaccine O
as O
well O
as O
small O
- O
molecule O
drugs O
targeting O
astrovirus O
assembly O
/ O
maturation O
. O

IMPORTANCE O
Human B
astrovirus I
( I
HAstV I
) I
is O
a O
leading O
cause O
of O
viral O
diarrhea O
in O
infants O
and O
young O
children O
worldwide O
. O

As O
a O
nonenveloped O
virus O
, O
HAstV O
exhibits O
an O
intriguing O
feature O
in O
that O
its O
maturation O
requires O
extensive O
proteolytic O
processing O
of O
the O
astrovirus O
capsid B
protein I
( I
CP I
) I
both O
inside O
and O
outside O
the O
host O
cell O
. O

We O
have O
solved O
the O
crystal O
structure O
of O
VP90 O
( O
71 O
- O
415 O
) O
of O
human O
astrovirus O
serotype O
8 O
. O

VP90 O
( O
71 O
- O
415 O
) O
encompasses O
the O
conserved O
N O
- O
terminal O
domain O
of O
the O
viral O
CP O
. O

Fitting O
of O
the O
VP90 O
( O
71 O
- O
415 O
) O
structure O
into O
the O
cryo O
- O
EM O
maps O
of O
HAstV O
produced O
an O
atomic O
model O
for O
the O
T O
= O
3 O
icosahedral O
capsid O
. O

The O
coronavirus O
membrane B
( I
M I
) I
protein O
is O
the O
central O
actor O
in O
virion O
morphogenesis O
. O

Morganizes O
the O
components O
of O
the O
viral O
membrane O
, O
and O
interactions O
of O
M O
with O
itself O
and O
with O
the O
nucleocapsid B
( I
N I
) I
protein O
drive O
virus O
assembly O
and O
budding O
. O

In O
order O
to O
further O
define O
M O
- O
M O
and O
M O
- O
N O
interactions O
, O
we O
constructed O
mutants O
of O
the O
model O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
in O
which O
all O
or O
part O
of O
the O
M O
protein O
was O
replaced O
by O
its O
phylogenetically O
divergent O
counterpart O
from O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
. O

The O
SARS O
- O
CoV O
M O
chimera O
exhibited O
a O
conditional O
growth O
defect O
that O
was O
partially O
suppressed O
by O
mutations O
in O
the O
envelope B
( I
E I
) I
protein O
. O

Moreover O
, O
virions O
of O
the O
M O
chimera O
were O
markedly O
deficient O
in O
spike B
( I
S I
) I
protein O
incorporation O
. O

The O
hepatitis B
E I
virus I
( I
HEV I
) I
sheds O
into O
feces O
as O
nonenveloped O
virions O
but O
circulates O
in O
the O
blood O
in O
a O
membrane O
- O
associated O
, O
quasi O
- O
enveloped O
form O
( O
eHEV O
) O
. O

We O
recently O
identified O
a O
natural O
molecule O
, O
epigallocatechin B
- I
3 I
- I
gallate I
( I
EGCG I
) I
, O
as O
an O
inhibitor O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
targeting O
the O
viral O
particle O
. O

IMPORTANCE O
In O
this O
article O
, O
we O
identify O
a O
new O
inhibitor O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
delphinidin O
, O
that O
prevents O
HCV O
entry O
. O

Many O
viruses O
that O
replicate O
in O
the O
cytoplasm O
of O
eukaryotes O
have O
evolved O
2 O
' O
- O
O O
- O
methyltransferases O
( O
2 O
' O
- O
O O
- O
MTase O
) O
to O
autonomously O
modify O
their O
mRNAs O
and O
carry O
a O
cap O
- O
1 O
structure O
( O
m7GpppNm O
) O
at O
the O
5 O
' O
end O
, O
thereby O
facilitating O
viral O
replication O
and O
escaping O
innate O
immune O
recognition O
in O
host O
cells O
. O

Previous O
studies O
showed O
that O
the O
2 O
' O
- O
O O
- O
MTase O
activity O
of O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
nonstructural I
protein I
16 I
( I
nsp16 I
) I
needs O
to O
be O
activated O
by O
nsp10 O
, O
whereas O
nsp16 O
of O
feline B
coronavirus I
( I
FCoV I
) I
alone O
possesses O
2 O
' O
- O
O O
- O
MTase O
activity O
( O
E O
. O

Based O
on O
our O
current O
and O
previous O
studies O
, O
we O
designed O
a O
peptide O
( O
TP29 O
) O
from O
the O
sequence O
of O
the O
interaction O
interface O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
nsp10 O
and O
demonstrated O
that O
the O
peptide O
inhibits O
the O
2 O
' O
- O
O O
- O
MTase O
activity O
of O
different O
coronaviruses O
in O
biochemical O
assays O
and O
the O
viral O
replication O
in O
MHV O
infection O
and O
SARS O
- O
CoV O
replicon O
models O
. O

Recent O
studies O
demonstrated O
that O
transgenic O
mice O
expressing O
key O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
receptors O
are O
susceptible O
to O
HCV O
infection O
, O
albeit O
at O
very O
low O
efficiency O
. O

Fractionation O
analysis O
of O
mouse O
serum O
in O
conjunction O
with O
targeted O
mass O
spectrometric O
analysis O
suggested O
that O
serum O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
was O
responsible O
for O
the O
blockade O
of O
HCV O
cell O
attachment O
, O
as O
VLDL O
- O
depleted O
mouse O
serum O
lost O
HCV O
- O
inhibitory O
activity O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
important O
but O
extremely O
understudied O
human O
pathogen O
. O

The O
adaptation O
of O
the O
Kernow O
C O
- O
1 O
P6 O
HEV O
to O
propagate O
in O
HepG2C3A O
cells O
selected O
for O
a O
rare O
virus O
recombinant O
that O
contains O
an O
insertion O
of O
a O
171 O
- O
nucleotide O
sequence O
encoding O
amino O
acids O
21 O
to O
76 O
of O
the O
human B
ribosomal I
protein I
S17 I
( I
RPS17 I
) I
within O
the O
hypervariable B
region I
( I
HVR I
) I
of O
the O
HEV O
ORF1 O
protein O
. O

The O
virus O
causes O
high O
mortality O
( O
up O
to O
30 O
% O
) O
in O
pregnant O
women O
and O
has O
been O
recognized O
to O
cause O
chronic O
hepatitis O
in O
immunocompromised O
populations O
. O

Recently O
, O
insertions O
and O
rearrangements O
of O
the O
hypervariable B
region I
( I
HVR I
) I
within O
the O
HEV O
genome O
, O
allowing O
for O
cell O
culture O
adaptation O
and O
expansion O
of O
the O
host O
range O
, O
have O
been O
reported O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
acute O
enterically O
transmitted O
hepatitis O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
responsible O
for O
acute O
hepatitis O
, O
with O
clinical O
symptoms O
ranging O
from O
asymptomatic O
to O
self O
- O
limiting O
acute O
hepatitis O
, O
chronic O
infection O
, O
or O
fulminant O
hepatitis O
. O

The O
assembly O
of O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
is O
tightly O
linked O
to O
components O
of O
the O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
pathway O
. O

We O
and O
others O
have O
shown O
that O
apolipoprotein B
E I
( I
ApoE I
) I
plays O
a O
major O
role O
in O
production O
of O
infectious O
HCV O
particles O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
both O
endemic O
and O
epidemic O
human O
hepatitis O
by O
fecal O
- O
oral O
transmission O
in O
many O
parts O
of O
the O
world O
. O

C O
) O
- O
induced O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
expression O
and O
that O
the O
HEV O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
product O
was O
responsible O
for O
this O
inhibition O
. O

Two O
domains O
, O
X O
and O
the O
papain O
- O
like O
cysteine O
protease O
domain O
( O
PCP O
) O
, O
of O
HEV O
ORF1 O
were O
identified O
as O
the O
putative O
IFN O
antagonists O
. O

When O
overexpressed O
in O
HEK293T O
cells O
, O
the O
X O
domain O
( O
or O
macro O
domain O
) O
inhibited O
poly O
( O
I O
. O

C O
) O
- O
induced O
phosphorylation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
, O
which O
is O
the O
key O
transcription O
factor O
for O
IFN O
induction O
. O

Furthermore O
, O
replication O
of O
a O
HEV O
replicon O
containing O
green B
fluorescent I
protein I
( I
GFP I
) I
( O
E2 O
- O
GFP O
) O
in O
hepatoma O
cells O
led O
to O
impaired O
phosphorylation O
of O
IRF O
- O
3 O
and O
reduced O
ubiquitination O
of O
RIG O
- O
I O
and O
TBK O
- O
1 O
, O
which O
confirmed O
our O
observations O
of O
X O
and O
PCP O
inhibitory O
effects O
in O
HEK293T O
cells O
. O

IMPORTANCE O
type B
I I
interferons I
( I
IFNs I
) I
are O
important O
components O
of O
innate O
immunity O
and O
play O
a O
crucial O
role O
against O
viral O
infection O
. O

There O
is O
little O
knowledge O
about O
how O
hepatitis B
E I
virus I
( I
HEV I
) I
inhibits O
induction O
of O
host O
IFNs O
, O
though O
the O
viral O
genome O
was O
sequenced O
more O
than O
2 O
decades O
ago O
. O

By O
screening O
all O
the O
domains O
in O
the O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
polyprotein O
, O
we O
identified O
two O
IFN O
antagonists O
and O
performed O
further O
research O
to O
determine O
how O
and O
at O
which O
step O
in O
the O
IFN O
induction O
pathway O
they O
antagonize O
host O
IFN O
induction O
. O

Members O
of O
the O
family O
Picornaviridae O
consist O
of O
small O
positive O
- O
sense O
single O
- O
stranded O
RNA O
( O
+ O
ssRNA O
) O
viruses O
capable O
of O
infecting O
various O
vertebrate O
species O
, O
including O
birds O
. O

One O
of O
the O
recently O
identified O
avian O
picornaviruses O
, O
with O
a O
remarkably O
long O
( O
> O
9 O
, O
040 O
- O
nucleotide O
) O
but O
still O
incompletely O
sequenced O
genome O
, O
is O
turkey O
hepatitis O
virus O
1 O
( O
THV O
- O
1 O
; O
species O
Melegrivirus O
A O
, O
genus O
Megrivirus O
) O
, O
a O
virus O
associated O
with O
liver O
necrosis O
and O
enteritis O
in O
commercial O
turkeys O
( O
Meleagris O
gallopavo O
) O
. O

KF961187 O
) O
( O
Gallus O
gallus O
domesticus O
) O
and O
turkey O
( O
turkey O
/ O
B407 O
- O
THV O
/ O
2011 O
/ O
HUN O
, O
GenBank O
accession O
no O
. O

KF961188 O
) O
( O
Meleagris O
gallopavo O
) O
with O
the O
largest O
picornavirus O
genome O
( O
up O
to O
9 O
, O
739 O
nucleotides O
) O
so O
far O
described O
. O

The O
close O
phylogenetic O
relationship O
to O
THV O
- O
1 O
in O
the O
nonstructural O
protein O
- O
coding O
genome O
region O
and O
possession O
of O
the O
same O
internal O
ribosomal O
entry O
site O
type O
( O
IVB O
- O
like O
) O
suggest O
that O
the O
study O
strains O
belong O
to O
the O
genus O
Megrivirus O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
cause O
of O
chronic O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
in O
humans O
. O

The O
life O
cycle O
of O
HCV O
is O
closely O
associated O
with O
the O
metabolism O
of O
lipids O
, O
especially O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
in O
hepatocytes O
. O

hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
, O
the O
most O
abundant O
transcription O
factor O
in O
the O
liver O
, O
regulates O
the O
VLDL O
secretory O
pathway O
. O

HNF4 O
alpha O
downregulation O
resulted O
in O
rearrangement O
of O
cytosolic O
lipid B
droplets I
( I
LDs I
) I
, O
as O
evidenced O
by O
the O
aggregation O
of O
large O
LDs O
and O
distorted O
cytosolic O
distribution O
. O

Phospholipase O
A O
( O
2 O
) O
GXIIB O
( O
PLA O
( O
2 O
) O
GXIIB O
) O
, O
an O
HNF4 O
alpha O
- O
regulated O
factor O
involved O
in O
VLDL O
secretion O
, O
was O
found O
to O
be O
crucial O
in O
HCV O
secretion O
. O

PLA O
( O
2 O
) O
GXIIB O
expression O
was O
upregulated O
in O
hepatocytes O
harboring O
HCV O
sub O
- O
genomic O
replicons O
or O
in O
HCV O
- O
infected O
hepatocytes O
. O

Furthermore O
, O
PLA O
( O
2 O
) O
GXIIB O
combined O
with O
microsomal O
triglyceride O
transfer O
protein O
was O
found O
to O
be O
responsible O
for O
the O
regulation O
of O
HNF4 O
alpha O
- O
induced O
HCV O
infectivity O
. O

These O
results O
suggest O
that O
HNF4 O
alpha O
and O
its O
downstream O
PLA O
( O
2 O
) O
GXIIB O
are O
important O
factors O
affecting O
the O
late O
stage O
of O
the O
HCV O
life O
cycle O
and O
may O
serve O
as O
potential O
drug O
targets O
for O
the O
treatment O
of O
HCV O
infection O
. O

IMPORTANCE O
The O
assembly O
and O
secretion O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
closely O
correlated O
with O
the O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
secretory O
pathway O
. O

In O
this O
study O
, O
we O
report O
the O
function O
of O
hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
, O
the O
most O
abundant O
liver O
- O
enriched O
transcription O
factor O
, O
in O
HCV O
assembly O
and O
release O
. O

We O
also O
determined O
that O
PLA O
( O
2 O
) O
GXIIB O
, O
a O
direct O
target O
factor O
of O
HNF4 O
alpha O
involved O
in O
VLDL O
secretion O
, O
was O
upregulated O
upon O
HCV O
infection O
. O

These O
results O
suggest O
that O
PLA O
( O
2 O
) O
GXIIB O
is O
required O
in O
the O
late O
stage O
of O
the O
HCV O
life O
cycle O
and O
that O
the O
VLDL O
secretory O
pathway O
is O
important O
for O
HCV O
assembly O
and O
secretion O
. O

Genotype O
1 O
hepatitis O
E O
viruses O
( O
HEVs O
) O
are O
restricted O
to O
primate O
hosts O
, O
whereas O
genotype O
3 O
HEVs O
predominantly O
infect O
swine O
, O
in O
addition O
to O
primates O
. O

The O
virus O
, O
provisionally O
named O
parvovirus B
- I
like I
hybrid I
virus I
( I
PHV I
) I
, O
is O
nearly O
identical O
by O
sequence O
to O
another O
DNA O
virus O
, O
NIH O
- O
CQV O
, O
previously O
detected O
in O
Chinese O
patients O
with O
seronegative O
( O
non O
- O
A O
- O
E O
) O
hepatitis O
. O

Analysis O
of O
environmental O
metagenome O
libraries O
detected O
PHV O
sequences O
in O
coastal O
marine O
waters O
of O
North O
America O
, O
suggesting O
that O
a O
potential O
association O
between O
PHV O
and O
diatoms O
( O
algae O
) O
that O
generate O
the O
silica O
matrix O
used O
in O
the O
spin O
columns O
may O
have O
resulted O
in O
inadvertent O
viral O
contamination O
during O
manufacture O
. O

Although O
the O
C B
- I
terminal I
52 I
amino I
acids I
( I
C52aa I
) I
of O
hepatitis B
E I
virus I
( I
HEV I
) I
capsid O
are O
not O
essential O
for O
morphology O
, O
the O
C52aa O
- O
encoding O
region O
is O
required O
for O
replication O
. O

Transfection O
of O
a O
C52aa O
knockdown O
mutant O
showed O
transient O
growth O
, O
and O
the O
earliest O
population O
included O
a O
majority O
of O
noninfectious O
( O
possibly O
empty O
) O
particles O
and O
a O
minority O
of O
infectious O
particles O
with O
C O
- O
terminal O
capsid O
degradation O
. O

The O
classification O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
variants O
is O
currently O
in O
transition O
without O
agreed O
definitions O
for O
genotypes O
and O
subtypes O
or O
for O
deeper O
taxonomic O
groupings O
into O
species O
and O
genera O
that O
could O
incorporate O
more O
recently O
characterized O
viruses O
assigned O
to O
the O
Hepeviridae O
family O
that O
infect O
birds O
, O
bats O
, O
rodents O
, O
and O
fish O
. O

Analysis O
of O
complete O
genome O
sequences O
or O
concatenated O
ORF1 O
/ O
ORF2 O
amino O
acid O
sequences O
indicated O
that O
HEV O
variants O
most O
closely O
related O
to O
those O
infecting O
humans O
can O
be O
consistently O
divided O
into O
six O
genotypes O
( O
types O
1 O
to O
4 O
and O
two O
additional O
genotypes O
from O
wild O
boar O
) O
. O

Analysis O
of O
amino O
acid O
sequences O
from O
these O
viruses O
with O
the O
more O
divergent O
variants O
from O
chickens O
, O
bats O
, O
and O
rodents O
in O
three O
conserved O
subgenomic O
regions O
( O
residues O
1 O
to O
452 O
or O
974 O
to O
1534 O
of O
ORF1 O
or O
residues O
105 O
to O
458 O
of O
ORF2 O
) O
provided O
consistent O
support O
for O
a O
division O
into O
4 O
groups O
, O
corresponding O
to O
HEV O
variants O
infecting O
humans O
and O
pigs O
, O
those O
infecting O
rats O
and O
ferrets O
, O
those O
from O
bats O
, O
and O
those O
from O
chickens O
. O

This O
approach O
may O
form O
the O
basis O
for O
a O
future O
genetic O
classification O
of O
HEV O
into O
four O
species O
, O
with O
the O
more O
divergent O
HEV O
- O
like O
virus O
from O
fish O
( O
cutthroat O
trout O
virus O
) O
representing O
a O
second O
genus O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
- O
mediated O
liver O
disease O
progression O
may O
reflect O
distinct O
molecular O
mechanisms O
for O
increased O
hepatocyte O
growth O
and O
hepatic O
stellate O
cell O
activation O
. O

To O
understand O
the O
changes O
at O
the O
molecular O
level O
, O
we O
examined O
epithelial B
- I
mesenchymal I
transition I
( I
EMT I
) I
markers O
. O

An O
increased O
expression O
level O
of O
fibroblast O
- O
specific O
protein O
1 O
( O
FSP O
- O
1 O
) O
in O
the O
infected O
hepatocytes O
was O
also O
evident O
, O
indicating O
a O
type O
2 O
EMT O
state O
. O

Infected O
hepatocytes O
had O
significantly O
increased O
levels O
of O
phosphorylated O
beta O
- O
catenin O
( O
Ser O
( O
552 O
) O
) O
as O
an O
EMT O
mediator O
, O
which O
translocated O
into O
the O
nucleus O
and O
activated O
Akt O
. O

The O
phosphorylation O
level O
of O
beta O
- O
catenin O
at O
Thr O
( O
41 O
) O
/ O
Ser O
( O
45 O
) O
moieties O
was O
specifically O
higher O
in O
control O
than O
in O
HCV O
- O
infected O
hepatocytes O
, O
implicating O
an O
inactivation O
of O
beta O
- O
catenin O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
single O
- O
strand O
positive O
- O
sense O
RNA O
virus O
in O
the O
family O
Hepeviridae O
. O

Stress B
granules I
( I
SGs I
) I
are O
cytoplasmic O
structures O
that O
are O
induced O
in O
response O
to O
environmental O
stress O
, O
including O
viral O
infections O
. O

Here O
we O
report O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
triggers O
the O
appearance O
of O
SGs O
in O
a O
PKR O
- O
and O
interferon B
( I
IFN I
) I
- O
dependent O
manner O
. O

Finally O
, O
in O
short B
hairpin I
RNA I
( I
shRNA I
) I
knockdown O
experiments O
, O
we O
found O
that O
the O
stress O
granule O
proteins O
T B
- I
cell I
- I
restricted I
intracellular I
antigen I
1 I
( I
TIA I
- I
1 I
) I
, O
TIA1 B
- I
related I
protein I
( I
TIAR I
) I
, O
and O
RasGAP B
- I
SH3 I
domain I
binding I
protein I
1 I
( I
G3BP1 I
) I
are O
required O
for O
efficient O
HCV O
RNA O
and O
protein O
accumulation O
at O
early O
time O
points O
in O
the O
infection O
and O
that O
G3BP1 O
and O
TIA O
- O
1 O
are O
required O
for O
intracellular O
and O
extracellular O
infectious O
virus O
production O
late O
in O
the O
infection O
, O
suggesting O
that O
they O
are O
required O
for O
virus O
assembly O
. O

During O
a O
study O
of O
the O
fecal O
microbiomes O
from O
two O
healthy O
piglets O
using O
high B
- I
throughput I
sequencing I
( I
HTS I
) I
, O
we O
identified O
a O
viral O
genome O
containing O
an O
open O
reading O
frame O
encoding O
a O
predicted O
polyprotein O
of O
2 O
, O
133 O
amino O
acids O
. O

This O
novel O
viral O
genome O
displayed O
the O
typical O
organization O
of O
picornaviruses O
, O
containing O
three O
structural O
proteins O
( O
VP0 O
, O
VP3 O
, O
and O
VP1 O
) O
, O
followed O
by O
seven O
nonstructural O
proteins O
( O
2A O
, O
2B O
, O
2C O
, O
3A O
, O
3B O
, O
3C B
( I
pro I
) I
, O
and O
3D O
( O
Pol O
) O
) O
. O

Given O
its O
particular O
relationship O
with O
Parechovirus O
, O
we O
propose O
to O
name O
it O
Pasivirus O
for O
Parecho O
sister O
clade O
virus O
, O
with O
Swine B
pasivirus I
1 I
( I
SPaV1 I
) I
as O
the O
type O
species O
. O

Fecal O
samples O
collected O
at O
an O
industrial O
farm O
from O
healthy O
sows O
and O
piglets O
from O
the O
same O
herd O
( O
25 O
and O
75 O
, O
respectively O
) O
with O
ages O
ranging O
from O
4 O
to O
28 O
weeks O
were O
analyzed O
for O
the O
presence O
of O
SPaV1 O
by O
one O
- O
step O
reverse B
transcription I
( I
RT I
) I
- O
PCR O
targeting O
a O
3D O
region O
of O
151 O
bp O
. O

SPaV1 O
was O
detected O
in O
fecal O
samples O
from O
51 O
/ O
75 O
healthy O
piglets O
( O
68 O
% O
of O
the O
animals O
) O
and O
in O
none O
of O
the O
25 O
fecal O
samples O
from O
healthy O
sows O
, O
indicating O
that O
SPaV1 O
circulates O
through O
enteric O
infection O
of O
healthy O
piglets O
. O

The O
ubiquitin B
- I
proteasome I
system I
( I
UPS I
) I
is O
involved O
in O
the O
replication O
of O
a O
broad O
range O
of O
viruses O
. O

Since O
replication O
of O
the O
murine B
hepatitis I
virus I
( I
MHV I
) I
is O
impaired O
upon O
proteasomal O
inhibition O
, O
the O
relevance O
of O
the O
UPS O
for O
the O
replication O
of O
the O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
was O
investigated O
in O
this O
study O
. O

Induction O
of O
autophagy O
by O
MG132 O
treatment O
was O
excluded O
from O
playing O
a O
role O
, O
and O
no O
changes O
in O
SARS O
- O
CoV O
titers O
were O
observed O
during O
infection O
of O
wild O
- O
type O
or O
autophagy O
- O
deficient O
ATG5 O
( O
- O
/ O
- O
) O
mouse O
embryonic O
fibroblasts O
overexpressing O
the O
human O
SARS O
- O
CoV O
receptor O
, O
angiotensin B
- I
converting I
enzyme I
2 I
( I
ACE2 I
) I
. O

Since O
MG132 O
also O
inhibits O
the O
cysteine O
protease O
m O
- O
calpain O
, O
we O
addressed O
the O
role O
of O
calpains O
in O
the O
early O
SARS O
- O
CoV O
life O
cycle O
using O
calpain O
inhibitors O
III O
( O
MDL28170 O
) O
and O
VI O
( O
SJA6017 O
) O
. O

In O
fact O
, O
m O
- O
calpain O
inhibition O
with O
MDL28170 O
resulted O
in O
an O
even O
more O
pronounced O
inhibition O
of O
SARS O
- O
CoV O
replication O
( O
> O
7 O
orders O
of O
magnitude O
) O
than O
did O
MG132 O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
one O
of O
the O
most O
common O
causes O
of O
acute O
hepatitis O
in O
tropical O
and O
temperate O
climates O
. O

Zoonotic O
reservoirs O
( O
mainly O
pigs O
, O
wild O
boar O
, O
and O
deer O
) O
are O
considered O
for O
genotypes O
3 O
and O
4 O
, O
which O
exist O
in O
temperate O
climates O
. O

hepatitis B
E I
virus I
( I
HEY I
) I
infections O
are O
responsible O
for O
chronic O
hepatitis O
in O
immunocompromised O
patients O
, O
and O
this O
can O
evolve O
to O
cirrhosis O
. O

We O
cloned O
and O
sequenced O
the O
region O
encoding O
the O
M O
and O
P O
capsid O
domains O
of O
HEV O
from O
eight O
solid B
- I
organ I
transplant I
( I
SOT I
) I
patients O
with O
acute O
HEY O
infection O
who O
subsequently O
cleared O
the O
virus O
and O
from O
eight O
SOT O
patients O
whose O
infection O
became O
chronic O
. O

The O
patients O
who O
developed O
chronic O
infection O
had O
lower O
serum O
concentrations O
of O
interleukin B
- I
1 I
( I
IL I
- I
1 I
) I
receptor O
antagonist O
and O
soluble O
IL O
- O
2 O
receptor O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
, O
an O
enterically O
transmitted O
pathogen O
, O
is O
one O
of O
the O
major O
causes O
of O
acute O
hepatitis O
in O
humans O
worldwide O
, O
being O
responsible O
for O
outbreaks O
and O
epidemics O
in O
regions O
with O
suboptimal O
sanitary O
conditions O
, O
in O
many O
of O
which O
it O
is O
endemic O
. O

hepatitis B
E I
virus I
( I
HEY I
) I
is O
a O
zoonotic O
pathogen O
of O
which O
several O
species O
of O
animal O
were O
reported O
as O
reservoirs O
. O

In O
a O
previous O
study O
, O
we O
sequenced O
the O
complete O
genome O
of O
a O
human O
genotype O
4 O
HEY O
strain O
( O
HM439284 O
) O
that O
is O
prevalent O
in O
Jiangsu O
Province O
, O
China O
. O

Phylogenetic O
analysis O
indicated O
that O
the O
swine O
HEY O
strain O
in O
the O
present O
study O
has O
high O
sequence O
homology O
( O
> O
92 O
% O
) O
with O
the O
genotype O
4 O
HEV O
strains O
prevalent O
in O
the O
human O
population O
of O
Jiangsu O
Province O
. O

The O
maturation O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
protein O
requires O
proteolytic O
processing O
by O
two O
host O
proteases O
: O
signal B
peptidase I
( I
SP I
) I
and O
the O
intramembrane O
- O
cleaving O
protease O
signal B
peptide I
peptidase I
( I
SPP I
) I
. O

Previous O
work O
on O
HCV O
genotype B
1a I
( I
Gt1a I
) I
and O
GT2a O
has O
identified O
crucial O
residues O
required O
for O
efficient O
signal O
peptide O
processing O
by O
SPP O
, O
which O
in O
turn O
has O
an O
effect O
on O
the O
production O
of O
infectious O
virus O
particles O
. O

Through O
mutagenesis O
studies O
, O
we O
identified O
crucial O
residues O
required O
for O
core O
- O
E1 O
signal O
peptide O
processing O
, O
including O
a O
GT3a O
sequence O
- O
specific O
histidine B
( I
His I
) I
at O
position O
187 O
. O

Finally O
, O
our O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
structural O
analysis O
of O
a O
synthetic O
HCV O
JFH1 O
GT2a O
core O
- O
El O
signal O
peptide O
provides O
an O
essential O
structural O
template O
for O
a O
further O
understanding O
of O
core O
processing O
as O
well O
as O
the O
first O
model O
for O
an O
SPP O
substrate O
within O
its O
membrane O
environment O
. O

Chronic O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
can O
lead O
to O
liver O
cirrhosis O
in O
up O
to O
20 O
% O
of O
individuals O
, O
often O
requiring O
liver O
transplantation O
. O

Although O
the O
new O
liver O
is O
known O
to O
be O
rapidly O
reinfected O
, O
the O
dynamics O
and O
source O
of O
the O
reinfecting O
virus O
( O
es O
) O
are O
unclear O
, O
resulting O
in O
some O
confusion O
concerning O
the O
relationship O
between O
clinical O
outcome O
and O
viral O
characteristics O
. O

High O
- O
throughput O
sequencing O
of O
bile O
and O
feces O
from O
two O
pigs O
experimentally O
infected O
with O
human O
hepatitis B
E I
virus I
( I
HEV I
) I
of O
genotype O
3f O
revealed O
the O
same O
full O
- O
length O
consensus O
sequence O
as O
in O
the O
human O
sample O
. O

The O
ORF3 O
protein O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
multifunctional O
protein O
important O
for O
virus O
replication O
. O

The O
ORF3 O
proteins O
from O
human O
, O
swine O
, O
and O
avian O
strains O
of O
HEY O
contain O
a O
conserved O
PXXP O
amino O
acid O
motif O
, O
resembling O
either O
Src B
homology I
3 I
( I
SH3 I
) I
cell O
signaling O
interaction O
motifs O
or O
late O
domains O
involved O
in O
host O
cell O
interactions O
aiding O
in O
particle O
release O
. O

Using O
an O
avian O
strain O
of O
HEY O
, O
we O
determined O
the O
roles O
of O
the O
conserved O
prolines O
within O
the O
PREPSAPP O
motif O
in O
HEY O
replication O
and O
infectivity O
in O
Leghorn O
male O
hepatoma O
( O
LMH O
) O
chicken O
liver O
cells O
and O
in O
chickens O
. O

Each O
proline O
was O
changed O
to O
alanine O
to O
produce O
8 O
avian O
HEY O
mutants O
containing O
single O
mutations O
( O
P64 O
, O
P67 O
, O
P70 O
, O
and O
P71 O
to O
A O
) O
, O
double O
mutations O
( O
P64167A O
, O
P64 O
/ O
70A O
, O
and O
P67 O
/ O
70A O
) O
, O
and O
triple O
mutations O
( O
P64 O
/ O
67 O
/ O
70A O
) O
. O

We O
also O
showed O
that O
the O
PSAP O
motif O
interacts O
with O
the O
host O
protein O
tumor B
suppressor I
gene I
101 I
( I
TSG101 I
) I
and O
that O
altering O
any O
proline O
within O
the O
PSAP O
motif O
disrupts O
this O
interaction O
. O

However O
, O
we O
showed O
that O
the O
ORF2 O
protein O
expressed O
in O
LMH O
cells O
is O
efficiently O
released O
from O
the O
cells O
in O
the O
absence O
of O
ORF3 O
and O
that O
coexpression O
of O
ORF2 O
and O
ORF3 O
did O
not O
act O
synergistically O
in O
this O
release O
, O
suggesting O
that O
another O
factor O
( O
s O
) O
such O
as O
ORF1 O
or O
viral O
genomic O
RNA O
may O
be O
necessary O
for O
proper O
particle O
release O
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
a O
novel O
Betacoronavirus O
subgroup O
A O
coronavirus O
, O
rabbit O
coronavirus O
HKU14 O
( O
RbCoV O
HKU14 O
) O
, O
from O
domestic O
rabbits O
. O

1 O
% O
) O
of O
136 O
rabbit O
fecal O
samples O
by O
reverse B
transcriptase I
PCR I
( I
RT I
- I
PCR I
) I
, O
with O
a O
viral O
load O
of O
up O
to O
10 O
( O
8 O
) O
copies O
/ O
ml O
. O

A O
comparison O
of O
the O
conserved O
replicase O
domains O
showed O
that O
RbCoV O
HKU14 O
possessed O
< O
90 O
% O
amino O
acid O
identities O
to O
most O
members O
of O
Betacoronavirus O
1 O
in O
ADP B
- I
ribose I
1 I
' I
' I
- I
phosphatase I
( I
ADRP I
) I
and O
nidoviral B
uridylate I
- I
specific I
endoribonuclease I
( I
NendoU I
) I
, O
indicating O
that O
RbCoV O
HKU14 O
should O
represent O
a O
separate O
species O
. O

RbCoV O
HKU14 O
also O
possessed O
genomic O
features O
distinct O
from O
those O
of O
other O
Betacoronavirus O
subgroup O
A O
coronaviruses O
, O
including O
a O
unique O
NS2a O
region O
with O
a O
variable O
number O
of O
small O
open B
reading I
frames I
( I
ORFs I
) I
. O

Molecular O
clock O
analysis O
using O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
genes O
dated O
the O
most O
recent O
common O
ancestor O
of O
RbCoV O
HKU14 O
to O
around O
2002 O
, O
suggesting O
that O
this O
virus O
has O
emerged O
relatively O
recently O
. O

Antibody O
against O
RbCoV O
was O
detected O
in O
20 O
( O
67 O
% O
) O
of O
30 O
rabbit O
sera O
tested O
by O
an O
N O
- O
protein O
- O
based O
Western O
blot O
assay O
, O
whereas O
neutralizing O
antibody O
was O
detected O
in O
1 O
of O
these O
20 O
rabbits O
. O

The O
mechanism O
of O
hepatitis B
E I
virus I
( I
HEY I
) I
replication O
remains O
largely O
unknown O
. O

Pestiviruses O
, O
like O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
bear O
a O
striking O
degree O
of O
similarity O
to O
HCV O
concerning O
polyprotein O
organization O
, O
processing O
, O
and O
function O
. O

Along O
this O
line O
, O
in O
both O
systems O
, O
release O
of O
nonstructural B
protein I
3 I
( I
NS3 I
) I
is O
essential O
for O
viral O
RNA O
replication O
. O

We O
previously O
employed O
systems O
biology O
approaches O
to O
identify O
the O
mitochondrial O
fatty O
acid O
oxidation O
enzyme O
dodecenoyl O
coenzyme O
A O
delta O
isomerase O
( O
DCI O
) O
as O
a O
bottleneck O
protein O
controlling O
host O
metabolic O
reprogramming O
during O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

HCV O
growth O
and O
RNA O
replication O
in O
hepatoma O
cell O
lines O
stably O
expressing O
DCI O
- O
targeting O
short B
hairpin I
RNA I
( I
shRNA I
) I
were O
abrogated O
, O
indicating O
that O
DCI O
is O
required O
for O
productive O
infection O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
important O
but O
extremely O
understudied O
human O
pathogen O
, O
and O
the O
mechanisms O
of O
HEV O
replication O
and O
pathogenesis O
are O
largely O
unknown O
. O

We O
previously O
identified O
an O
attenuated O
genotype O
3 O
HEV O
mutant O
( O
pSHEV O
- O
1 O
) O
containing O
three O
unique O
amino O
acid O
mutations O
( O
F51L O
, O
T59A O
, O
and O
S390L O
) O
in O
the O
capsid O
protein O
. O

To O
determine O
the O
role O
of O
each O
of O
these O
mutations O
, O
we O
constructed O
three O
HEV O
single O
mutants O
( O
rF51L O
, O
rT59A O
, O
and O
rS390L O
) O
which O
were O
all O
found O
to O
be O
replication O
competent O
in O
Huh7 O
liver O
cells O
. O

To O
determine O
the O
pathogenicities O
of O
the O
mutants O
, O
we O
utilized O
the O
specific B
- I
pathogen I
- I
free I
( I
SPF I
) I
pig O
model O
for O
HEV O
and O
a O
unique O
inoculation O
procedure O
that O
bypasses O
the O
need O
for O
propagating O
infectious O
HEV O
in O
vitro O
. O

A O
total O
of O
60 O
pigs O
were O
intrahepatically O
inoculated O
, O
via O
an O
ultrasound O
- O
guided O
technique O
, O
with O
in O
vitro O
- O
transcribed O
full O
- O
length O
capped O
RNA O
transcripts O
from O
the O
infectious O
clones O
of O
each O
single O
mutant O
, O
the O
pSHEV O
- O
1 O
triple O
mutant O
, O
wild O
- O
type O
pSHEV O
- O
3 O
, O
or O
phosphate B
- I
buffered I
saline I
( I
PBS I
) I
buffer O
( O
n O
= O
10 O
) O
. O

Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
glycoprotein B
E I
( I
gE I
) I
mediates O
cell O
- O
to O
- O
cell O
spread O
and O
functions O
as O
an O
IgG O
Fc O
receptor O
( O
Fc O
gamma O
R O
) O
that O
blocks O
the O
Fc O
domain O
of O
antibody O
targeting O
the O
virus O
or O
infected O
cell O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
major O
worldwide O
health O
problem O
. O

Here O
we O
developed O
a O
trans O
- O
complementation O
system O
that O
allows O
the O
production O
of O
infectious O
HCV O
particles O
in O
whose O
genome O
the O
regions O
encoding O
envelope O
proteins O
are O
deleted O
( O
HCV O
Delta O
E O
) O
. O

Interestingly O
, O
we O
found O
that O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
glycoproteins O
could O
efficiently O
rescue O
the O
production O
of O
HCV O
lacking O
endogenous O
envelope O
proteins O
, O
which O
no O
longer O
required O
apolipoprotein O
E O
for O
virus O
production O
. O

, O
GW5074 O
, O
Flt3 O
inhibitor O
II O
, O
TTP O
- O
8307 O
, O
and O
AN O
- O
12 O
- O
H5 O
, O
are O
known O
to O
have O
similar O
mutations O
in O
the O
3A O
protein O
- O
encoding O
region O
causing O
resistance O
to O
enviroxime O
( O
a O
G5318A O
[ O
3A O
- O
Ala70Thr O
] O
mutation O
in O
poliovirus O
[ O
PV O
] O
) O
and O
are O
considered O
enviroxime O
- O
like O
compounds O
. O

Recently O
, O
antienterovirus O
activity O
of O
a O
phosphatidylinositol B
4 I
- I
kinase I
III I
beta I
( I
PI4KB I
) I
inhibitor O
, O
PIK93 O
, O
was O
reported O
, O
suggesting O
that O
PI4KB O
is O
an O
important O
host O
factor O
targetable O
by O
antienterovirus O
compounds O
( O
N O
. O

In O
this O
study O
, O
we O
analyzed O
the O
inhibitory O
effects O
of O
previously O
identified O
enviroxime O
- O
like O
compounds O
( O
GW5074 O
and O
AN O
- O
12 O
- O
H5 O
) O
and O
a O
newly O
identified O
antienterovirus O
compound O
, O
T O
- O
00127 O
- O
HEV1 O
, O
on O
phosphoinositide O
( O
PI O
) O
kinases O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
screening O
targeting O
PI O
kinases O
identified O
PI4KB O
is O
a O
target O
of O
GW5074 O
and O
T O
- O
00127 O
- O
HEV1 O
, O
but O
not O
of O
AN O
- O
12 O
- O
H5 O
, O
for O
anti O
- O
PV O
activity O
. O

Interestingly O
, O
T O
- O
00127 O
- O
HEV1 O
and O
GW5074 O
did O
not O
inhibit O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
, O
in O
contrast O
to O
a O
strong O
inhibitory O
effect O
of O
AN O
- O
12 O
- O
H5 O
. O

These O
results O
suggested O
that O
PI4KB O
is O
an O
enterovirus O
- O
specific O
host O
factor O
required O
for O
the O
replication O
process O
and O
targeted O
by O
some O
enviroxime O
- O
like O
compounds O
( O
T O
- O
00127 O
- O
HEV1 O
and O
GW5074 O
) O
and O
that O
enviroxime O
- O
like O
compounds O
may O
have O
targets O
other O
than O
PI O
kinases O
for O
their O
antiviral O
effect O
. O

The O
delivery O
of O
foreign O
epitopes O
by O
a O
replicating O
nonpathogenic O
avian O
infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
was O
explored O
. O

By O
using O
a O
cDNA O
- O
based O
reverse O
genetics O
system O
, O
insertions O
or O
substitutions O
of O
sequences O
encoding O
epitope O
tags O
( O
FLAG O
, O
c O
- O
Myc O
, O
or O
hepatitis O
C O
virus O
epitopes O
) O
were O
engineered O
in O
the O
open O
reading O
frames O
of O
a O
nonstructural O
protein O
( O
VP5 O
) O
and O
the O
capsid O
protein O
( O
VP2 O
) O
. O

Attempts O
were O
also O
made O
to O
generate O
recombinant O
IBDV O
that O
displayed O
foreign O
epitopes O
in O
the O
exposed O
loops O
( O
P O
- O
BC O
and O
P O
- O
HI O
) O
of O
the O
VP2 O
trimer O
. O

We O
successfully O
recovered O
recombinant O
IBDVs O
expressing O
c O
- O
Myc O
and O
two O
different O
virus O
- O
neutralizing O
epitopes O
of O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E O
in O
the O
VP5 O
region O
. O

The O
coronavirus O
small O
envelope B
( I
E I
) I
protein O
plays O
a O
crucial O
, O
but O
poorly O
defined O
, O
role O
in O
the O
assembly O
of O
virions O
. O

To O
investigate O
E O
protein O
function O
, O
we O
previously O
generated O
E O
gene O
point O
mutants O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
that O
were O
defective O
in O
growth O
and O
assembled O
virions O
with O
anomalous O
morphologies O
. O

We O
subsequently O
constructed O
an O
E O
gene O
deletion O
( O
Delta O
E O
) O
mutant O
that O
was O
only O
minimally O
viable O
. O

Remarkably O
, O
the O
net O
result O
of O
each O
duplication O
was O
the O
creation O
of O
a O
variant O
version O
of O
the O
membrane B
protein I
( I
M I
) I
gene O
that O
was O
situated O
upstream O
of O
the O
native O
copy O
of O
the O
M O
gene O
. O

Each O
different O
variant O
M O
gene O
encoded O
an O
expressed O
protein O
( O
M O
* O
) O
containing O
a O
truncated O
endodomain O
. O

The O
roles O
of O
conserved O
nucleotides O
on O
the O
stem B
- I
loop I
( I
SL I
) I
structure O
in O
the O
intergenic O
region O
of O
the O
hepatitis B
E I
virus I
( I
HEV I
) I
genome O
in O
virus O
replication O
were O
determined O
by O
using O
Huh7 O
cells O
transfected O
with O
HEV O
SL O
mutant O
replicons O
containing O
reporter O
genes O
. O

In O
this O
study O
, O
the O
host O
responses O
to O
two O
dissimilar O
viruses O
, O
hepatitis B
E I
virus I
( I
HEV I
) I
and O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
were O
compared O
in O
multiple O
experimentally O
infected O
chimpanzees O
. O

Coronavirus O
membrane B
( I
M I
) I
proteins O
play O
key O
roles O
in O
virus O
assembly O
, O
through O
M O
- O
M O
, O
M O
- O
spike B
( I
S I
) I
, O
and O
M O
- O
nucleocapsid B
( I
N I
) I
protein O
interactions O
. O

The O
M O
carboxy O
- O
terminal O
endodomain O
contains O
a O
conserved O
domain O
( O
CD O
) O
following O
the O
third O
transmembrane B
( I
TM I
) I
domain O
. O

The O
importance O
of O
the O
CD O
( O
SWWSFNPETNNL O
) O
in O
mouse O
hepatitis O
virus O
was O
investigated O
with O
a O
panel O
of O
mutant O
proteins O
, O
using O
genetic O
analysis O
and O
transient O
- O
expression O
assays O
. O

Lysine B
( I
K I
) I
and O
Arginine B
( I
R I
) I
substitutions O
were O
replaced O
in O
recovered O
viruses O
by O
neutrally O
charged O
Glutamine B
( I
Q I
) I
and O
leucine B
( I
L I
) I
, O
respectively O
, O
after O
only O
one O
passage O
. O

E O
( O
121 O
) O
Q O
and O
E121L O
M O
proteins O
were O
capable O
of O
forming O
virus B
- I
like I
particles I
( I
VLPs I
) I
when O
coexpressed O
with O
E O
, O
whereas O
E121R O
and O
E121K O
proteins O
were O
not O
. O

Virus O
egress O
from O
cells O
depended O
on O
open B
reading I
frame I
3 I
( I
ORF3 I
) I
protein O
, O
and O
a O
proline O
- O
rich O
sequence O
in O
ORF3 O
was O
important O
for O
egress O
from O
cultured O
cells O
and O
for O
infection O
of O
macaques O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
causative O
agent O
of O
acute O
hepatitis O
, O
and O
it O
is O
the O
sole O
member O
of O
the O
genus O
Hepevirus O
in O
the O
family O
Hepeviridae O
. O

The O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
protein O
of O
HEV O
encodes O
nonstructural O
polyprotein O
with O
putative O
domains O
for O
methyltransferase O
, O
cysteine O
protease O
, O
helicase O
and O
RNA O
- O
dependent O
RNA O
polymerase O
. O

On O
the O
basis O
of O
amino O
acid O
conserved O
motifs O
, O
HEV O
helicase O
has O
been O
grouped O
into O
helicase O
superfamily B
1 I
( I
SF I
- I
1 I
) I
. O

In O
order O
to O
examine O
the O
RNA O
helicase O
activity O
of O
the O
NTPase O
/ O
helicase O
domain O
of O
HEV O
, O
the O
region O
( O
amino O
acids O
960 O
to O
1204 O
) O
was O
cloned O
and O
expressed O
as O
histidine O
- O
tagged O
protein O
in O
Escherichia O
coli O
( O
HEV O
Hel O
) O
and O
purified O
. O

Helicase O
mutant O
I O
, O
with O
substitution O
in O
the O
nucleotide O
- O
binding O
motif O
I O
( O
GKS O
to O
GAS O
) O
, O
showed O
30 O
% O
ATPase O
activity O
. O

Helicase O
mutant O
II O
, O
with O
substitutions O
in O
the O
Mg2 O
+ O
binding O
motif O
II O
( O
DEAP O
to O
AAAP O
) O
, O
showed O
50 O
% O
ATPase O
activity O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
an O
acute O
self O
- O
limiting O
disease O
that O
is O
endemic O
in O
developing O
countries O
. O

Previous O
studies O
suggested O
that O
the O
ORF3 O
protein O
( O
pORF3 O
) O
of O
HEV O
is O
required O
for O
infection O
in O
vivo O
and O
is O
likely O
to O
modulate O
the O
host O
response O
. O

Our O
previous O
work O
showed O
that O
pORF3 O
localizes O
to O
early O
and O
recycling O
endosomes O
and O
causes O
a O
delay O
in O
the O
postinternalization O
trafficking O
of O
epidermal B
growth I
factor I
receptor I
( I
EGFR I
) I
to O
late O
endosomes O
/ O
lysosomes O
. O

Here O
we O
report O
that O
pORF3 O
also O
delays O
the O
trafficking O
and O
degradation O
of O
activated O
hepatocyte O
growth O
factor O
receptor O
( O
c O
- O
Met O
) O
and O
delineate O
the O
mechanistic O
details O
of O
these O
effects O
. O

, O
phosphorylation O
and O
methylation O
) O
of O
the O
small B
hepatitis I
delta I
antigen I
( I
SHDAg I
) I
are O
required O
for O
hepatitis B
delta I
virus I
( I
HDV I
) I
replication O
from O
antigenomic O
to O
genomic O
RNA O
. O

The O
phosphorylation O
of O
SHDAg O
at O
serine O
177 O
( O
Ser O
( O
177 O
) O
) O
is O
involved O
in O
this O
step O
, O
and O
this O
residue O
is O
crucial O
for O
interaction O
with O
RNA B
polymerase I
II I
( I
RNAP I
II I
) I
, O
the O
enzyme O
assumed O
to O
be O
responsible O
for O
antigenomic O
RNA O
replication O
. O

This O
study O
demonstrated O
that O
SHDAg O
dephosphorylated O
at O
Ser O
( O
177 O
) O
interacted O
preferentially O
with O
hypophosphorylated O
RNAP B
II I
( I
RNAP I
IIA I
) I
, O
which O
generally O
binds O
at O
the O
transcription O
initiation O
sites O
. O

In O
contrast O
, O
the O
Ser O
( O
177 O
) O
- O
phosphorylated O
counterpart O
( O
pSer O
( O
177 O
) O
- O
SHDAg O
) O
exhibited O
preferential O
binding O
to O
hyperphosphorylated O
RNAP O
II O
( O
RNAP O
IIO O
) O
. O

In O
addition O
, O
RNAP O
IIO O
associated O
with O
pSer O
( O
177 O
) O
- O
SHDAg O
was O
hyperphosphorylated O
at O
both O
the O
Ser O
( O
2 O
) O
and O
Ser O
( O
5 O
) O
residues O
of O
its O
carboxyl B
- I
terminal I
domain I
( I
CTD I
) I
, O
which O
is O
a O
hallmark O
of O
the O
transcription O
elongation O
isoform O
. O

Moreover O
, O
the O
RNAP O
II O
CTD O
kinase O
inhibitor O
5 O
, O
6 O
- O
dichloro O
- O
1 O
- O
beta O
- O
D O
- O
ribofuranosyl O
- O
benzimidazole O
( O
DRB O
) O
not O
only O
blocked O
the O
interaction O
between O
pSer O
( O
177 O
) O
- O
SHDAg O
and O
RNAP O
IIO O
but O
also O
inhibited O
HDV O
antigenomic O
replication O
. O

Our O
results O
suggest O
that O
the O
phosphorylation O
of O
SHDAg O
at O
Ser O
( O
177 O
) O
shifted O
its O
affinity O
toward O
the O
RNA O
RNAP O
IIO O
isoform O
and O
thus O
is O
a O
switch O
for O
HDV O
antigenomic O
RNA O
replication O
from O
the O
initiation O
to O
the O
elongation O
stage O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
the O
causative O
agent O
of O
hepatitis O
E O
, O
a O
major O
form O
of O
viral O
hepatitis O
in O
developing O
countries O
. O

The O
open B
reading I
frame I
3 I
( I
ORF3 I
) I
of O
HEV O
encodes O
a O
phosphoprotein O
with O
a O
molecular O
mass O
of O
approximately O
13 O
kDa O
( O
hereinafter O
called O
vp13 O
) O
. O

Induction O
of O
an O
antigenically O
broad O
and O
vigorous O
primary O
T O
- O
cell O
immune O
response O
by O
myeloid O
dendritic B
cells I
( I
DC I
) I
in O
blood O
and O
tissues O
could O
be O
important O
for O
an O
effective O
prophylactic O
or O
therapeutic O
vaccine O
to O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
. O

Here O
we O
show O
that O
a O
primary O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
can O
be O
induced O
by O
HIV O
- O
1 O
peptide O
- O
loaded O
DC O
derived O
from O
blood O
monocytes O
of O
HIV O
- O
1 O
- O
negative O
adults O
and O
neonates O
( O
moDC O
) O
and O
by O
Langerhans B
cells I
( I
LC I
) I
and O
interstitial O
, O
dermal O
- O
intestinal O
DC O
( O
idDC O
) O
derived O
from O
CD34 O
( O
+ O
) O
stem O
cells O
of O
neonatal O
cord O
blood O
. O

Optimal O
priming O
of O
single O
- O
cell O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
production O
by O
CD8 O
( O
+ O
) O
T O
cells O
required O
CD4 O
( O
+ O
) O
T O
cells O
and O
was O
broadly O
directed O
to O
multiple O
regions O
of O
Gag O
, O
Env O
, O
and O
Nef O
that O
corresponded O
to O
known O
and O
predicted O
major O
histocompatibility O
complex O
class O
I O
epitopes O
. O

Polyfunctional O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
, O
defined O
as O
single O
- O
cell O
production O
of O
more O
than O
one O
cytokine O
( O
IFN O
- O
gamma O
, O
interleukin O
2 O
, O
or O
tumor O
necrosis O
factor O
alpha O
) O
, O
chemokine O
( O
macrophage O
inhibitory O
factor O
1 O
beta O
) O
, O
or O
cytotoxic O
degranulation O
marker O
CD107a O
, O
were O
primed O
by O
moDC O
, O
LC O
, O
and O
idDC O
to O
HIV O
- O
1 O
Gag O
and O
reverse O
transcriptase O
epitopes O
, O
as O
well O
as O
to O
Epstein O
- O
Barr O
virus O
and O
influenza O
A O
virus O
epitopes O
. O

, O
moDC O
, O
LC O
, O
and O
idDC O
, O
can O
prime O
multispecific O
, O
polyfunctional O
CD8 O
( O
+ O
) O
T O
- O
cell O
responses O
to O
HIV O
- O
1 O
and O
other O
viral O
antigens O
. O

Here O
, O
we O
tracked O
the O
fate O
of O
virus O
- O
specific O
CD8 O
T O
cells O
in O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
- O
infected O
mice O
during O
viral O
clearance O
, O
the O
persistence O
of O
wild O
- O
type O
virus O
, O
or O
the O
selection O
and O
persistence O
of O
a O
viral O
variant O
that O
abrogates O
the O
presentation O
of O
a O
single O
epitope O
. O

Viral O
clearance O
results O
in O
PD O
- O
1 O
( O
lo O
) O
functional O
virus O
- O
specific O
CD8 O
T O
cells O
, O
while O
the O
persistence O
of O
wild O
- O
type O
LCMV O
results O
in O
high O
PD O
- O
1 O
levels O
and O
T O
- O
cell O
exhaustion O
. O

In O
the O
same O
animals O
and O
under O
identical O
environmental O
conditions O
, O
CD8 O
T O
cells O
recognizing O
nonmutated O
viral O
epitopes O
became O
physically O
deleted O
or O
were O
PD O
- O
1 O
( O
hi O
) O
and O
nonfunctional O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
expresses O
two O
structural O
forms O
of O
the O
nucleoprotein O
, O
the O
intracellular O
nucleocapsid O
( O
hepatitis O
core O
antigen O
[ O
HBcAg O
] O
) O
and O
the O
secreted O
nonparticulate O
form O
( O
hepatitis O
e O
antigen O
[ O
HBeAg O
] O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
ability O
of O
HBcAg O
- O
and O
HBeAg O
- O
specific O
genetic O
immunogens O
to O
induce O
HBc O
/ O
HBeAg O
- O
specific O
CD4 O
( O
+ O
) O
/ O
CD8 O
( O
+ O
) O
T O
- O
cell O
immune O
responses O
and O
the O
potential O
to O
induce O
liver O
injury O
in O
HBV O
- O
transgenic B
( I
Tg I
) I
mice O
. O

Both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
were O
important O
for O
priming O
/ O
effector O
functions O
of O
HBc O
/ O
HBeAg O
- O
specific O
cytotoxic B
T I
- I
lymphocyte I
( I
CTL I
) I
responses O
. O

The O
finding O
that O
hepatocytes O
expressing O
wild O
- O
type O
HBV O
( O
containing O
both O
HBcAg O
and O
HBeAg O
) O
are O
more O
susceptible O
to O
CTL O
- O
mediated O
clearance O
than O
hepatocytes O
expressing O
only O
HBcAg O
suggest O
that O
the O
HBeAg O
- O
negative O
variant O
may O
have O
a O
selective O
advantage O
over O
wild O
- O
type O
HBV O
within O
the O
livers O
of O
patients O
with O
chronic O
infection O
during O
an O
immune O
response O
and O
may O
represent O
a O
CTL O
escape O
mutant O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
important O
human O
pathogen O
, O
although O
little O
is O
known O
about O
its O
biology O
and O
replication O
. O

Comparative O
sequence O
analysis O
revealed O
a O
hypervariable B
region I
( I
HVR I
) I
with O
extensive O
sequence O
variations O
in O
open O
reading O
frame O
1 O
of O
HEV O
. O

To O
elucidate O
the O
role O
of O
the O
HVR O
in O
HEV O
replication O
, O
we O
first O
constructed O
two O
HVR O
deletion O
mutants O
, O
hHVRd1 O
and O
hHVRd2 O
, O
with O
in O
- O
frame O
deletion O
of O
amino B
acids I
( I
aa I
) I
711 O
to O
777 O
and O
747 O
to O
761 O
in O
the O
HVR O
of O
a O
genotype O
1 O
human O
HEV O
replicon O
. O

To O
confirm O
the O
in O
vitro O
results O
, O
we O
constructed O
three O
avian O
HEV O
mutants O
with O
various O
HVR O
deletions O
: O
mutants O
aHVRd1 O
, O
with O
deletion O
of O
aa O
557 O
to O
585 O
( O
Delta O
557 O
- O
585 O
) O
; O
aHVRd2 O
( O
Delta O
612 O
- O
641 O
) O
; O
and O
aHVRd3 O
( O
Delta O
557 O
- O
641 O
) O
. O

Mutants O
sHVRd2 O
( O
Delta O
722 O
- O
781 O
) O
, O
sHVRd3 O
( O
Delta O
735 O
- O
765 O
) O
, O
and O
sHVRd4 O
( O
Delta O
712 O
- O
765 O
) O
were O
shown O
to O
tolerate O
deletions O
and O
were O
infectious O
in O
pigs O
intrahepatically O
inoculated O
with O
capped O
RNA O
transcripts O
from O
the O
mutants O
, O
whereas O
mutant O
sHVRd1 O
( O
Delta O
712 O
- O
790 O
) O
, O
with O
a O
nearly O
complete O
HVR O
deletion O
, O
exhibited O
an O
attenuation O
phenotype O
in O
infected O
pigs O
. O

Here O
we O
report O
an O
unexpected O
correlation O
between O
the O
expression O
of O
a O
functional O
X O
domain O
encoded O
by O
the O
hepatotropic O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
the O
high O
- O
level O
production O
of O
inflammatory O
cytokines O
, O
and O
the O
induction O
of O
acute O
viral O
hepatitis O
in O
mice O
. O

X O
- O
domain O
( O
also O
called O
macro O
domain O
) O
proteins O
possess O
poly O
- O
ADP O
- O
ribose O
binding O
and O
/ O
or O
ADP B
- I
ribose I
- I
1 I
' I
' I
- I
phosphatase I
( I
ADRP I
) I
activity O
. O

In O
vitro O
, O
the O
mutant O
virus O
induced O
only O
low O
levels O
of O
the O
inflammatory O
cytokines O
tumor O
necrosis O
factor O
alpha O
and O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
. O

The O
coronavirus O
assembly O
process O
encloses O
a O
ribonucleoprotein O
genome O
into O
vesicles O
containing O
the O
lipid O
- O
embedded O
proteins O
S B
( I
spike I
) I
, O
E B
( I
envelope I
) I
, O
and O
M B
( I
membrane I
) I
. O

To O
determine O
whether O
specific O
palmitoylations O
influence O
coronavirus O
assembly O
, O
we O
introduced O
plasmid O
DNAs O
encoding O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
S O
, O
E O
, O
M O
, O
and O
N B
( I
nucleocapsid I
) I
into O
293T O
cells O
and O
found O
that O
virus B
- I
like I
particles I
( I
VLPs I
) I
were O
robustly O
assembled O
and O
secreted O
into O
culture O
medium O
. O

Coronavirus O
envelope B
( I
E I
) I
proteins O
play O
an O
important O
, O
not O
fully O
understood O
role O
( O
s O
) O
in O
the O
virus O
life O
cycle O
. O

Double O
- O
and O
triple O
- O
mutant O
E O
proteins O
resulted O
in O
decreased O
virus O
- O
like O
particle O
output O
when O
coexpressed O
with O
the O
membrane B
( I
M I
) I
protein O
. O

Pestiviruses O
, O
including O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
are O
important O
animal O
pathogens O
and O
close O
relatives O
of O
hepatitis O
C O
virus O
. O

Pestivirus O
particles O
are O
composed O
of O
an O
RNA O
- O
genome O
, O
a O
host O
- O
derived O
lipid O
envelope O
, O
and O
four O
virion O
- O
encoded O
structural O
proteins O
, O
core B
( I
C I
) I
, O
E O
- O
rns O
, O
E1 O
, O
and O
E2 O
. O

Bats O
have O
been O
identified O
as O
the O
natural O
reservoir O
of O
severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
- O
like O
and O
SARS O
coronaviruses O
( O
SLCoV O
and O
SCoV O
) O
. O

The O
MHV O
- O
JHM O
strain O
of O
the O
murine O
coronavirus O
mouse O
hepatitis O
virus O
is O
much O
more O
neurovirulent O
than O
the O
MHV O
- O
A59 O
strain O
, O
although O
both O
strains O
use O
murine B
CEACAM1a I
( I
mCEACAM1a I
) I
as O
the O
receptor O
to O
infect O
murine O
cells O
. O

We O
previously O
showed O
that O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
are O
completely O
resistant O
to O
MHV O
- O
A59 O
infection O
( O
E O
. O

To O
determine O
whether O
MHV O
- O
JHM O
could O
infect O
and O
spread O
in O
the O
brain O
independent O
of O
mCEACAM1a O
, O
we O
inoculated O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
. O

Although O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
were O
completely O
resistant O
to O
i O
. O

inoculation O
with O
10 O
( O
6 O
) O
PFU O
of O
recombinant O
wild O
- O
type O
MHV O
- O
A59 O
( O
RA59 O
) O
virus O
, O
these O
mice O
were O
killed O
by O
recombinant B
MHV I
- I
JHM I
( I
RJHM I
) I
and O
a O
chimeric O
virus O
containing O
the O
spike B
of I
MHV I
- I
JHM I
in I
the I
MHV I
- I
A59 I
genome I
( I
SJHM I
/ I
RA59 I
) I
. O

Immunohistochemistry O
showed O
that O
RJHM O
and O
SJHM O
/ O
RA59 O
infected O
all O
neural O
cell O
types O
and O
induced O
severe O
microgliosis O
in O
both O
Ceacam1a O
( O
- O
/ O
- O
) O
and O
wild O
- O
type O
mice O
. O

For O
RJHM O
, O
the O
50 B
% I
lethal I
dose I
( I
LD50 I
) I
is O
< O
10 O
( O
1 O
. O

1 O
) O
in O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
. O

6 O
) O
in O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
. O

RJHM O
can O
initiate O
infection O
in O
the O
brains O
of O
Ceacam1a O
( O
- O
/ O
- O
) O
mice O
, O
but O
expression O
of O
mCEACAM1a O
increases O
susceptibility O
to O
infection O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
enveloped O
virus O
that O
belongs O
to O
the O
genus O
Hepacivirus O
of O
the O
family O
Flaviviridae O
. O

Here O
, O
using O
infectious O
HCV B
pseudoparticles I
( I
HCVpp I
) I
, O
we O
investigated O
the O
molecular O
basis O
of O
HCV O
membrane O
fusion O
. O

This O
was O
achieved O
by O
( O
i O
) O
quantifying O
the O
infectivity O
of O
the O
pseudoparticles O
, O
( O
ii O
) O
studying O
the O
incorporation O
of O
E1E2 O
and O
their O
capacity O
to O
mediate O
receptor O
binding O
, O
and O
( O
iii O
) O
determining O
their O
fusion O
capacity O
in O
cell O
- O
cell O
and O
liposome O
/ O
HCVpp O
fusion O
assays O
. O

The O
coronavirus O
membrane B
( I
M I
) I
protein O
carboxy O
tail O
interacts O
with O
the O
nucleocapsid O
during O
virus O
assembly O
. O

Previous O
studies O
demonstrated O
that O
the O
two O
terminal O
residues O
are O
important O
, O
and O
the O
charged O
residue O
( O
R227 O
) O
in O
the O
penultimate O
position O
in O
the O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
A59 O
M O
protein O
was O
suggested O
to O
participate O
in O
intermolecular O
interactions O
with O
negative O
charges O
in O
the O
nucleocapsid B
( I
N I
) I
protein O
. O

To O
determine O
the O
significance O
of O
the O
positive O
charge O
at O
position O
227 O
, O
we O
substituted O
the O
arginine O
with O
Lysine B
( I
K I
) I
, O
Aspartic B
acid I
( I
D I
) I
, O
Glutamic B
acid I
( I
E I
) I
, O
or O
Alanine B
( I
A I
) I
and O
studied O
these O
by O
reverse O
genetics O
in O
the O
context O
of O
a O
MHV O
full O
- O
length O
infectious O
clone O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
Positive O
- O
strand O
RNA O
virus O
that O
is O
prevalent O
in O
much O
of O
the O
developing O
world O
. O

Conserved O
among O
all O
coronaviruses O
are O
four O
structural O
proteins O
: O
the O
matrix B
( I
M I
) I
, O
small O
envelope B
( I
E I
) I
, O
and O
spike B
( I
S I
) I
proteins O
that O
are O
embedded O
in O
the O
viral O
membrane O
and O
the O
nucleocapsid O
phosphoprotein O
( O
N O
) O
, O
which O
exists O
in O
a O
ribonucleoprotein O
complex O
in O
the O
lumen O
. O

The O
N O
- O
terminal O
domain O
of O
coronaviral O
N O
proteins O
( O
N O
- O
NTD O
) O
provides O
a O
scaffold O
for O
RNA O
binding O
, O
while O
the O
C O
- O
terminal O
domain O
( O
N O
- O
CTD O
) O
mainly O
acts O
as O
oligomerization O
modules O
during O
assembly O
. O

We O
characterized O
the O
structures O
of O
N O
- O
NTD O
from O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
in O
two O
crystal O
forms O
, O
at O
1 O
. O

17 O
angstrom O
( O
monoclinic O
) O
and O
at O
1 O
. O

85 O
angstrom O
( O
cubic O
) O
, O
respectively O
, O
resolved O
by O
molecular O
replacement O
using O
the O
homologous O
avian B
infectious I
bronchitis I
virus I
( I
IBV I
) I
structure O
. O

To O
determine O
the O
initiation O
strategy O
of O
the O
hepatitis B
E I
virus I
( I
HEV I
) I
open I
reading I
frame I
3 I
( I
ORF3 I
) I
, O
we O
constructed O
five O
HEV O
mutants O
with O
desired O
mutations O
in O
the O
ORFI O
and O
ORF2 O
junction O
region O
and O
tested O
their O
levels O
of O
in O
vivo O
infectivity O
in O
pigs O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
proteins O
are O
known O
to O
interfere O
at O
several O
levels O
with O
both O
innate O
and O
adaptive O
responses O
of O
the O
host O
. O

A O
key O
target O
in O
these O
effects O
is O
the O
interferon B
( I
IFN I
) I
signaling O
pathway O
. O

We O
investigated O
the O
effect O
of O
HCV O
structural O
proteins O
on O
the O
expression O
of O
interferon B
regulatory I
factor I
1 I
( I
IRF I
- I
1 I
) I
, O
a O
secondary O
transcription O
factor O
of O
the O
IFN O
system O
responsible O
for O
inducing O
several O
key O
antiviral O
and O
immunomodulatory O
genes O
. O

The O
core O
protein O
in O
turn O
exerted O
a O
transcriptional O
repression O
of O
several O
interferon O
- O
stimulated O
genes O
, O
targets O
of O
IRF O
- O
1 O
, O
including O
interleukin B
- I
15 I
( I
IL I
- I
15 I
) I
, O
IL O
- O
12 O
, O
and O
low O
- O
molecular O
- O
mass O
polypeptide O
2 O
. O

The O
3A O
protein O
of O
the O
coxsackievirus B
B3 I
( I
CVB3 I
) I
, O
an O
enterovirus O
that O
belongs O
to O
the O
family O
of O
the O
picorna O
- O
viruses O
, O
inhibits O
endoplasmic O
reticulum O
- O
to O
- O
Golgi O
transport O
. O

Recently O
, O
we O
elucidated O
the O
underlying O
mechanism O
by O
showing O
that O
CVB3 O
3A O
interferes O
with O
ADP B
- I
ribosylation I
factor I
I I
( I
Arf1 I
) I
- O
dependent O
COP O
- O
1 O
recruitment O
to O
membranes O
by O
binding O
and O
inhibiting O
the O
function O
of O
GBF1 O
, O
a O
guanine O
nucleotide O
exchange O
factor O
that O
is O
required O
for O
the O
activation O
of O
Arf1 O
( O
E O
. O

No O
interference O
with O
protein O
transport O
or O
COP O
- O
I O
recruitment O
was O
observed O
for O
the O
3A O
proteins O
of O
any O
of O
the O
other O
picornaviruses O
tested O
here O
( O
human O
rhinovirus O
[ O
HRV O
] O
, O
encephalomyocarditis O
virus O
, O
foot O
- O
and O
- O
mouth O
disease O
virus O
, O
and O
hepatitis O
A O
virus O
) O
. O

To O
study O
the O
process O
of O
spike B
( I
S I
) I
- O
receptor O
interaction O
during O
coronavirus O
entry O
, O
we O
evaluated O
the O
contributions O
of O
mutations O
in O
different O
regions O
of O
the O
murine B
hepatitis I
virus I
( I
MRV I
) I
S O
protein O
to O
natural O
receptor O
murine O
carcinoembryonic B
antigen I
- I
related I
cell I
adhesion I
molecule I
la I
( I
CEACAM1a I
) I
dependence O
and O
to O
the O
acquisition O
of O
extended O
host O
range O
. O

Substitutions O
in O
a O
restricted O
, O
downstream O
part O
of O
the O
S O
protein O
encompassing O
heptad B
repeat I
region I
1 I
( I
HR1 I
) I
and O
putative O
fusion B
peptide I
( I
FP I
) I
did O
not O
alter O
the O
CEACAM1a O
dependence O
. O

Here O
, O
we O
characterized O
the O
macro O
domains O
from O
hepatitis O
E O
virus O
, O
Semliki O
Forest O
virus O
, O
and O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
. O

The O
data O
revealed O
that O
viral O
macro O
domains O
have O
relatively O
poor O
ADP O
- O
ribose O
1 O
- O
phosphohydrolase O
activities O
( O
which O
were O
previously O
proposed O
to O
be O
their O
biologically O
relevant O
function O
) O
but O
bind O
efficiently O
free O
and O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
I O
- O
bound O
poly O
( O
ADP O
- O
ribose O
) O
in O
vitro O
. O

Perturbation O
of O
the O
function O
of O
endoplasmic B
reticulum I
( I
ER I
) I
causes O
stress O
leading O
to O
the O
activation O
of O
cell O
signaling O
pathways O
known O
as O
the O
unfolded B
protein I
response I
( I
UPR I
) I
. O

severe B
acute I
respiratory I
syndrome I
( I
SARS I
) I
coronavirus O
( O
SARS O
- O
CoV O
) O
uses O
ER O
as O
a O
site O
for O
synthesis O
and O
processing O
of O
viral O
proteins O
. O

A O
comparison O
with O
M O
, O
E O
, O
and O
NSP6 O
proteins O
indicates O
that O
SARS O
- O
CoV O
spike B
( I
S I
) I
protein O
sufficiently O
induces O
transcriptional O
activation O
of O
several O
UPR O
effectors O
, O
including O
glucose B
- I
regulated I
protein I
78 I
( I
GRP78 I
) I
, O
GRP94 O
, O
and O
C O
/ O
EBP O
homologous O
protein O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
enters O
cells O
through O
the O
activities O
of O
a O
spike B
protein I
( I
S I
) I
which O
has O
receptor O
- O
binding O
( O
S1 O
) O
and O
membrane O
fusion O
( O
S2 O
) O
regions O
. O

of O
a O
purified O
recombinant O
S O
ectodomain O
( O
S O
- O
e O
) O
comprising O
S1 O
and O
the O
ectodomain O
of O
S2 O
. O

The O
two O
major O
constituents O
of O
coronavirus O
virions O
are O
the O
membrane B
( I
M I
) I
and O
nucleocapsid B
( I
N I
) I
proteins O
. O

In O
previous O
work O
with O
the O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
, O
a O
highly O
defective O
M O
protein O
mutant O
, O
M O
Delta O
2 O
, O
was O
constructed O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
noncultivable O
virus O
that O
causes O
acute O
liver O
failure O
in O
humans O
. O

The O
virus O
' O
s O
major O
capsid O
protein O
is O
encoded O
by O
an O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
gene O
. O

When O
the O
recombinant O
protein O
consisting O
of O
amino B
acid I
( I
aa I
) I
residues O
112 O
to O
660 O
of O
ORF2 O
is O
expressed O
with O
a O
recombinant O
baculovirus O
, O
the O
protein O
self O
- O
assembles O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
( O
T O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
, O
a O
human O
plus O
- O
stranded O
RNA O
virus O
, O
contains O
three O
open B
reading I
frames I
( I
ORF I
) I
. O

Recently O
, O
using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
a O
human O
cDNA O
liver O
library O
, O
we O
have O
isolated O
and O
characterized O
AMBP O
( O
alpha O
( O
1 O
) O
- O
microglobulin O
/ O
bikunin O
precursor O
) O
, O
which O
specifically O
interacts O
with O
the O
ORF3 O
protein O
of O
HEV O
. O

The O
ORF3 O
protein O
expedites O
the O
processing O
and O
secretion O
of O
alpha O
( O
1 O
) O
- O
microglobulin O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
is O
a O
major O
global O
health O
problem O
. O

, O
interleukin O
- O
2 O
and O
gamma O
interferon O
) O
by O
CD4 O
( O
+ O
) O
T O
cells O
and O
that O
the O
retention O
of O
these O
cells O
was O
associated O
with O
more O
pronounced O
necroinflammatory O
lesions O
in O
the O
liver O
. O

Taken O
together O
, O
these O
data O
suggest O
that O
augmented O
, O
parenchymal O
antigen O
presentation O
conferred O
by O
hepatocyte O
CD86 O
expression O
alters O
homeostasis O
and O
effector O
functions O
of O
CD4 O
( O
+ O
) O
T O
cells O
and O
contributes O
to O
liver O
injury O
. O

Cellular O
mechanisms O
of O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
entry O
in O
MDBK O
cells O
were O
investigated O
. O

Phylogenetic O
and O
recombination O
analysis O
was O
performed O
on O
32 O
complete O
hepatitis B
E I
virus I
( I
HEV I
) I
genomes O
from O
infected O
humans O
and O
pigs O
. O

An O
infectious O
cDNA O
clone O
of O
hepatitis O
E O
virus O
was O
mutated O
in O
order O
to O
prevent O
synthesis O
of O
either O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
protein O
or O
ORF3 O
protein O
. O

An O
interesting O
approach O
to O
improve O
DNA O
vaccines O
is O
to O
fuse O
bioactive O
domains O
, O
like O
cytotoxic B
- I
T I
- I
lymphocyte I
- I
associated I
protein I
4 I
( I
CTLA I
- I
4 I
) I
, O
to O
an O
antigen O
. O

Plasmids O
expressing O
the O
nucleocapsid O
protein O
( O
WHcAg O
) O
and O
e O
antigen O
( O
WHeAg O
) O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
alone O
or O
in O
fusion O
to O
the O
extracellular O
domain O
of O
woodchuck O
CTLA O
- O
4 O
and O
CD28 O
were O
constructed O
. O

Immunizations O
of O
mice O
with O
plasmids O
expressing O
WHcAg O
or O
WHeAg O
led O
to O
a O
specific O
Immunoglobulin B
G2a I
( I
IgG2a I
) I
- O
dominant O
antibody O
response O
. O

swine B
hepatitis I
E I
virus I
( I
swine I
HEV I
) I
, O
the O
first O
animal O
strain O
of O
HEV O
to O
be O
isolated O
, O
is O
a O
zoonotic O
agent O
. O

Multiple O
site O
- O
based O
site O
- O
directed O
mutagenesis O
was O
performed O
to O
generate O
three O
new O
cDNA O
clones O
( O
pSHEV O
- O
1 O
, O
pSHEV O
- O
2 O
, O
and O
pSHEV O
- O
3 O
) O
which O
differed O
from O
each O
other O
. O

Studies O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
replication O
have O
become O
possible O
with O
the O
development O
of O
subgenomic O
replicons O
. O

Using O
this O
assay O
, O
we O
extended O
our O
results O
and O
demonstrated O
that O
( O
i O
) O
inactivating O
NS5A O
mutations O
affecting O
the O
amino O
- O
terminal O
amphipathic O
helix O
cannot O
be O
complemented O
in O
trans O
; O
( O
ii O
) O
replication O
of O
the O
helper O
RNA O
is O
not O
necessary O
to O
allow O
efficient O
trans O
- O
complementation O
; O
and O
( O
iii O
) O
the O
minimal O
sequence O
required O
for O
trans O
- O
complementation O
of O
lethal O
NS5A O
mutations O
is O
NS3 O
to O
- O
5A O
, O
whereas O
NS5A O
expressed O
alone O
does O
not O
restore O
RNA O
replication O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
replication O
is O
not O
well O
understood O
, O
mainly O
because O
the O
virus O
does O
not O
infect O
cultured O
cells O
efficiently O
. O

However O
, O
Huh O
- O
7 O
cells O
transfected O
with O
full O
- O
length O
genomes O
produce O
open O
reading O
frame O
2 O
protein O
, O
indicative O
of O
genome O
replication O
( O
6 O
) O
. O

In O
order O
to O
better O
quantify O
HEV O
replication O
in O
cell O
culture O
, O
we O
constructed O
an O
HEV O
replicon O
with O
a O
reporter O
( O
luciferase O
) O
. O

, O
in O
hepatitis O
C O
virus O
) O
increase O
the O
ability O
of O
RNA O
replication O
to O
resist O
the O
antiviral O
action O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
; O
others O
( O
e O
. O

Using O
puromycin O
- O
selectable O
Kunjin B
virus I
( I
KUN I
) I
replicon O
RNA O
, O
we O
identified O
two O
adaptive O
mutations O
in O
the O
NS2A O
gene O
( O
producing O
Ala30 O
- O
to O
- O
Pro O
and O
Asn101 O
- O
to O
- O
Asp O
mutations O
in O
the O
gene O
product O
; O
for O
simplicity O
, O
these O
will O
be O
referred O
to O
hereafter O
as O
Ala30 O
- O
to O
- O
Pro O
and O
Asn101 O
- O
to O
- O
Asp O
mutations O
) O
that O
, O
when O
introduced O
individually O
or O
together O
into O
the O
original O
wild B
- I
type I
( I
WT I
) I
replicon O
RNA O
, O
resulted O
in O
similar O
to15 O
- O
to O
50 O
- O
fold O
more O
efficient O
establishment O
of O
persistent O
replication O
in O
hamster O
( O
BHK21 O
) O
and O
human O
( O
HEK293 O
and O
HEp O
- O
2 O
) O
cell O
lines O
. O

Murine O
coronavirus O
mouse B
hepatitis I
virus I
( I
MHV I
) I
gene O
1 O
encodes O
several O
nonstructural O
proteins O
. O

Cell O
cycle O
analysis O
by O
How O
cytometry O
demonstrated O
that O
p28 O
expression O
induced O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
cell O
cycle O
arrest O
. O

Characterization O
of O
various O
cellular O
proteins O
that O
are O
involved O
in O
regulating O
cell O
cycle O
progression O
demonstrated O
that O
p28 O
expression O
resulted O
in O
an O
accumulation O
of O
hypophosphorylated O
retinoblastoma B
protein I
( I
pRB I
) I
, O
tumor O
suppressor O
p53 O
, O
and O
cyclin B
- I
dependent I
kinase I
( I
CDK I
) I
inhibitor O
p21 O
( O
Cip1 O
) O
. O

Expression O
of O
p28 O
did O
not O
alter O
the O
amount O
of O
p53 O
transcripts O
yet O
increased O
the O
amount O
of O
p21 O
( O
Cip1 O
) O
transcripts O
, O
suggesting O
that O
p28 O
expression O
increased O
p53 O
stability O
and O
that O
p21 O
( O
Cip1 O
) O
was O
transcriptionally O
activated O
in O
a O
p53 O
- O
dependent O
manner O
. O

Our O
present O
data O
suggest O
the O
following O
model O
of O
p28 O
- O
induced O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
cell O
cycle O
arrest O
. O

Expressed O
cytoplasmic O
p28 O
induces O
the O
stabilization O
of O
p53 O
, O
and O
accumulated O
p53 O
causes O
transcriptional O
upregulation O
of O
p21 O
( O
Cip1 O
) O
. O

The O
increased O
amount O
of O
p21 O
( O
Cip1 O
) O
suppresses O
cyclin O
E O
/ O
Cdk2 O
activity O
, O
resulting O
in O
the O
inhibition O
of O
pRb O
hyperphosphorylation O
. O

Accumulation O
of O
hypophosphorylated O
pRb O
thus O
prevents O
cell O
cycle O
progression O
from O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
to O
S O
phase O
. O

The O
severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
genome O
contains O
open B
reading I
frames I
( I
ORFs I
) I
that O
encode O
for O
several O
genes O
that O
are O
homologous O
to O
proteins O
found O
in O
all O
known O
coronaviruses O
. O

These O
are O
the O
replicase O
gene O
1a O
/ O
1b O
and O
the O
four O
structural O
proteins O
, O
nucleocapsid B
( I
N I
) I
, O
spike B
( I
S I
) I
, O
membrane B
( I
M I
) I
, O
and O
envelope B
( I
E I
) I
, O
and O
these O
proteins O
are O
expected O
to O
be O
essential O
for O
the O
replication O
of O
the O
virus O
. O

The O
largest O
among O
these O
is O
the O
first O
ORF O
of O
the O
second O
longest O
subgenomic O
RNA O
, O
and O
this O
protein O
( O
termed O
U274 O
in O
the O
present O
study O
) O
consists O
of O
274 O
amino O
acids O
and O
contains O
three O
putative O
transmembrane O
domains O
. O

Knowing O
that O
subtle O
mutations O
in O
the O
carboxy O
- O
terminal O
endodomain O
of O
the O
M O
protein O
are O
already O
lethal O
, O
we O
have O
now O
probed O
the O
equivalent O
domain O
of O
the O
spike B
( I
S I
) I
protein O
by O
extending O
it O
terminally O
with O
a O
foreign O
sequence O
of O
27 O
kDa O
: O
the O
green B
fluorescent I
protein I
( I
GFP I
) I
. O

The O
wild O
- O
type O
S O
gene O
of O
mouse B
hepatitis I
coronavirus I
( I
MHV I
) I
was O
subsequently O
replaced O
by O
the O
chimeric O
construct O
through O
targeted O
recombination O
. O

mouse B
hepatitis I
virus I
( I
MHV I
) I
replication O
in O
actively O
growing O
DBT O
and O
17CI O
- O
1 O
cells O
resulted O
in O
the O
inhibition O
of O
host O
cellular O
DNA O
synthesis O
and O
the O
accumulation O
of O
infected O
cells O
in O
the O
G O
, O
G O
, O
phase O
of O
the O
cell O
cycle O
. O

MHV O
replication O
inhibited O
hyperphosphorylation O
of O
the O
retinoblastoma B
protein I
( I
pRB I
) I
, O
the O
event O
that O
is O
necessary O
for O
cell O
cycle O
progression O
through O
late O
G O
, O
and O
into O
the O
S O
phase O
. O

While O
the O
amounts O
of O
the O
cellular O
cyclin B
- I
dependent I
kinase I
( I
CDK I
) I
inhibitors O
p21 O
( O
Cip1 O
) O
, O
p27 O
( O
Kip1 O
) O
, O
and O
p16 O
( O
INK4a O
) O
did O
not O
change O
in O
infected O
cells O
, O
MHV O
infection O
in O
asynchronous O
cultures O
induced O
a O
clear O
reduction O
in O
the O
amounts O
of O
Cdk4 O
and O
G O
( O
1 O
) O
cyclins O
( O
cyclins O
D1 O
, O
D2 O
, O
D3 O
, O
and O
E O
) O
in O
both O
DBT O
and O
17CI O
- O
1 O
cells O
and O
a O
reduction O
in O
Cdk6 O
levels O
in O
17CI O
- O
1 O
cells O
. O

Our O
data O
suggested O
that O
a O
reduction O
in O
the O
amounts O
of O
G O
( O
1 O
) O
cyclin O
- O
Cdk O
complexes O
in O
MHV O
- O
infected O
cells O
led O
to O
a O
reduction O
in O
Cdk O
activities O
and O
insufficient O
hyperphosphorylation O
of O
pRb O
, O
resulting O
in O
inhibition O
of O
the O
cell O
cycle O
in O
the O
G O
( O
0 O
) O
/ O
G O
( O
1 O
) O
phase O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
RNA O
replication O
occurred O
in O
seven O
of O
nine O
primate O
cell O
cultures O
transfected O
with O
in O
vitro O
transcripts O
of O
an O
infectious O
cDNA O
clone O
. O

Since O
steady O
- O
state O
levels O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
replicon O
RNA O
were O
shown O
to O
be O
dependent O
on O
exponential O
growth O
of O
Huh O
- O
7 O
cells O
, O
the O
effects O
of O
antimetabolites O
for O
several O
nucleoside O
biosynthesis O
pathways O
on O
cell O
growth O
and O
HCV O
RNA O
levels O
were O
investigated O
. O

A O
specific O
anti O
- O
HCV O
replicon O
effect O
was O
defined O
as O
( O
i O
) O
minimal O
interference O
with O
the O
exponential O
cell O
growth O
, O
( O
ii O
) O
minimal O
reduction O
in O
cellular O
host O
RNA O
levels O
, O
and O
( O
iii O
) O
reduction O
of O
the O
HCV O
RNA O
copy O
number O
per O
cell O
compared O
to O
that O
of O
the O
untreated O
control O
. O

To O
identify O
potential O
cellular O
regulators O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
RNA O
- O
dependent O
RNA O
pollymerase O
( O
NS5B O
) O
, O
we O
searched O
- O
for O
cellular O
proteins O
interacting O
with O
NS5B O
protein O
by O
yeast O
two O
- O
hybrid O
screening O
of O
a O
human O
hepatocyte O
cDNA O
library O
. O

We O
identified O
a O
ubiquitin O
- O
like O
protein O
, O
hPLIC1 O
( O
for O
human O
homolog O
1 O
of O
protein O
linking O
intergrin O
- O
associated O
protein O
and O
cytoskeleton O
) O
, O
which O
is O
expressed O
in O
the O
liver O
( O
M O
. O

The O
importance O
of O
the O
small O
envelope B
( I
E I
) I
protein O
in O
the O
assembly O
of O
coronaviruses O
has O
been O
demonstrated O
in O
several O
studies O
. O

We O
have O
previously O
generated O
E O
gene O
mutants O
of O
mouse B
hepatitis I
virus I
( I
MHV I
) I
that O
had O
marked O
defects O
in O
viral O
growth O
and O
produced O
virions O
that O
were O
aberrantly O
assembled O
in O
comparison O
to O
mild O
- O
type O
virions O
. O

This O
mutant O
( O
DeltaE O
) O
was O
obtained O
by O
a O
targeted O
RNA O
recombination O
method O
that O
makes O
use O
of O
a O
powerful O
host O
range O
- O
based O
selection O
system O
. O

Despite O
their O
high O
frequency O
of O
RNA O
recombination O
, O
the O
plus O
- O
strand O
coronaviruses O
have O
a O
characteristic O
, O
strictly O
conserved O
genome O
organization O
with O
the O
essential O
genes O
occurring O
in O
the O
order O
5 O
' O
- O
Polymerase B
( I
Pol I
) I
- O
SE O
- O
M O
- O
N O
- O
3 O
' O
. O

Presumably O
due O
to O
the O
capability O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
to O
evade O
the O
antiviral O
effects O
of O
alpha O
interferon O
, O
treatment O
is O
ineffective O
in O
more O
than O
half O
of O
chronically O
genotype O
HCV O
type O
1 O
( O
HCV O
- O
1 O
) O
- O
infected O
patients O
. O

Previous O
approaches O
to O
correlate O
the O
number O
of O
amino O
acid O
mutations O
within O
regions O
of O
HCV O
nonstructural B
( I
NS I
) I
- O
5A O
protein O
with O
virologic O
treatment O
response O
provided O
conflicting O
results O
. O

Replication O
- O
competent O
propagation O
- O
deficient O
virus O
vectors O
based O
on O
the O
transmissible B
gastroenteritis I
coronavirus I
( I
TGEV I
) I
genome O
that O
are O
deficient O
in O
the O
essential O
E O
gene O
have O
been O
developed O
by O
complementation O
within O
E O
+ O
packaging O
cell O
lines O
. O

Recombinant O
TGEV O
deficient O
in O
the O
nonessential O
3a O
and O
3b O
genes O
and O
the O
essential O
E O
gene O
( O
rTGEV O
- O
Delta3abDeltaE O
) O
was O
successfully O
rescued O
in O
these O
cell O
lines O
. O

rTGEV O
- O
Delta3abDeltaE O
reached O
high O
titers O
( O
10 O
( O
7 O
) O
PFU O
/ O
ml O
) O
in O
baby O
hamster O
kidney O
cells O
expressing O
porcine O
aminopeptidase O
N O
( O
BHK O
- O
pAPN O
) O
, O
the O
cellular O
receptor O
for O
TGEV O
, O
using O
Sindbis O
replicon O
and O
reached O
titers O
up O
to O
5 O
X O
10 O
( O
- O
5 O
) O
PFU O
/ O
ml O
in O
cells O
stably O
expressing O
E O
protein O
under O
the O
control O
of O
the O
CW O
promoter O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
contains O
a O
viroid O
- O
like O
circular O
RNA O
that O
is O
presumed O
to O
replicate O
via O
a O
rolling O
circle O
replication O
mechanism O
mediated O
by O
cellular O
RNA O
polymerases O
. O

Finally O
, O
in O
lysolecithin O
- O
permeabilized O
cells O
, O
the O
synthesis O
of O
full O
- O
length O
antigenomic O
HDV O
RNA O
was O
completely O
resistant O
to O
high O
concentrations O
( O
100 O
mug O
/ O
ml O
) O
of O
alpha O
- O
amanitin O
. O

Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
- O
derived O
lentiviral O
vectors O
are O
very O
effective O
in O
transducing O
rare O
, O
nondividing O
stem O
cell O
populations O
( O
e O
. O

We O
developed O
a O
strategy O
for O
transcriptional O
targeting O
of O
lentiviral O
vectors O
based O
on O
replacing O
the O
viral O
long B
terminal I
repeat I
( I
LTR I
) I
enhancer O
with O
cell O
lineage O
- O
specific O
, O
genomic O
control O
elements O
. O

An O
upstream O
enhancer O
( O
HS2 O
) O
of O
the O
erythroid O
- O
specific O
GATA O
- O
1 O
gene O
was O
used O
to O
replace O
most O
of O
the O
U3 O
region O
of O
the O
LTR O
, O
immediately O
upstream O
of O
the O
HIV B
type I
1 I
( I
HIV I
- I
1 I
) I
promoter O
. O

The O
modified O
LTR O
was O
used O
to O
drive O
the O
expression O
of O
a O
reporter O
gene O
( O
the O
green O
fluorescent O
protein O
[ O
GFP O
] O
gene O
) O
, O
while O
a O
second O
gene O
( O
a O
truncated O
form O
of O
the O
p75 O
nerve O
growth O
factor O
receptor O
[ O
DeltaLNGFR O
] O
) O
was O
placed O
under O
the O
control O
of O
an O
internal O
constitutive O
promoter O
to O
monitor O
cell O
transduction O
, O
or O
to O
immunoselect O
transduced O
cells O
, O
independently O
from O
the O
expression O
of O
the O
targeted O
promoter O
. O

The O
transcriptionally O
targeted O
vectors O
were O
used O
to O
transduce O
cell O
lines O
, O
human O
CD34 O
( O
+ O
) O
hematopoietic O
stem O
- O
progenitor O
cells O
, O
and O
murine O
bone B
marrow I
( I
BM I
) I
- O
repopulating O
stem O
cells O
. O

We O
have O
previously O
shown O
that O
the O
E O
protein O
of O
the O
coronavirus O
infectious B
bronchitis I
virus I
( I
IBV I
) I
is O
localized O
to O
the O
Golgi O
complex O
when O
expressed O
exogenously O
from O
c O
DNA O
. O

However O
, O
an O
N O
- O
terminal O
truncation O
containing O
only O
the O
cytoplasmic B
domain I
( I
CTE I
) I
was O
efficiently O
localized O
to O
the O
Golgi O
complex O
, O
and O
this O
domain O
could O
retain O
a O
reporter O
protein O
in O
the O
Golgi O
. O

The O
transcription B
regulatory I
sequences I
( I
TRSs I
) I
of O
the O
coronavirus O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
have O
been O
characterized O
by O
using O
a O
helper O
virus O
- O
dependent O
expression O
system O
based O
on O
coronavirus O
- O
derived O
minigenomes O
to O
study O
the O
synthesis O
of O
subgenomic O
mRNAs O
. O

The O
TRSs O
are O
located O
at O
the O
5 O
' O
end O
of O
TGEV O
genes O
and O
include O
a O
highly O
conserved O
core B
sequence I
( I
CS I
) I
, O
5 O
' O
- O
CUAAAC O
- O
3 O
' O
, O
that O
is O
essential O
for O
mediating O
a O
100 O
- O
to O
1 O
, O
000 O
- O
fold O
increase O
in O
mRNA O
synthesis O
when O
it O
is O
located O
in O
the O
appropriate O
context O
. O

Sequences O
from O
virus O
genes O
flanking O
the O
CS O
influenced O
transcription O
levels O
from O
moderate O
( O
10 O
- O
to O
20 O
- O
fold O
variation O
) O
to O
complete O
mRNA O
synthesis O
silencing O
, O
as O
shown O
for O
a O
canonical O
CS O
at O
nucleotide B
( I
nt I
) I
120 O
from O
the O
initiation O
codon O
of O
the O
S O
gene O
that O
did O
not O
lead O
to O
the O
production O
of O
the O
corresponding O
mRNA O
. O

The O
expression O
of O
a O
reporter O
gene O
( O
beta O
- O
glucuronidase O
) O
by O
using O
the O
selected O
TRS O
led O
to O
the O
production O
of O
2 O
to O
8 O
mug O
of O
protein O
per O
10 O
( O
6 O
) O
cells O
. O

Turnip B
crinkle I
virus I
( I
TCV I
) I
is O
a O
small O
, O
plus O
- O
sense O
, O
single O
- O
stranded O
RNA O
virus O
of O
plants O
. O

In O
vitro O
assays O
revealed O
that O
the O
recombinant O
p88 O
has O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
activity O
and O
can O
also O
bind O
to O
RNA O
. O

GB O
virus O
C O
( O
GBV O
- O
C O
or O
hepatitis O
G O
virus O
) O
is O
a O
recently O
described O
flavivirus O
which O
frequently O
leads O
to O
chronic O
viremia O
in O
humans O
. O

Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
transfected O
with O
full O
- O
length O
RNA O
transcripts O
from O
this O
GBV O
- O
C O
clone O
resulted O
in O
viral O
replication O
. O

To O
study O
the O
existence O
of O
GB O
virus O
C O
/ O
hepatitis O
G O
virus O
( O
GBV O
- O
C O
/ O
HGV O
) O
variants O
with O
different O
tropism O
, O
we O
have O
analyzed O
the O
heterogeneity O
and O
quasispecies O
composition O
of O
GBV O
- O
C O
/ O
HGV O
isolated O
from O
in O
vitro O
- O
infected O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
and O
from O
sera O
, O
livers O
, O
and O
PBMC O
from O
two O
chronically O
infected O
patients O
. O

For O
this O
purpose O
, O
the O
GBV O
- O
C O
/ O
HGV O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
was O
amplified O
by O
reverse O
transcription O
- O
PCR O
and O
the O
amplified O
products O
were O
cloned O
and O
sequenced O
, O
These O
analyses O
show O
- O
ed O
that O
the O
master O
5 O
' O
NCR O
sequences O
isolated O
from O
the O
in O
vitro O
- O
infected O
PBMC O
and O
from O
the O
PBMC O
isolated O
from O
the O
patient O
whose O
serum O
was O
used O
as O
the O
inoculum O
were O
identical O
but O
different O
from O
that O
of O
the O
inoculum O
, O
Furthermore O
, O
phylogenetic O
analysis O
revealed O
that O
all O
PBMC O
sequences O
grouped O
together O
into O
a O
branch O
which O
was O
separate O
from O
those O
of O
the O
inoculum O
, O
For O
one O
of O
the O
two O
chronically O
infected O
patients O
, O
all O
the O
sequences O
from O
the O
PBMC O
and O
one O
from O
the O
liver O
clustered O
into O
a O
single O
branch O
while O
the O
sequences O
from O
the O
serum O
and O
all O
the O
other O
liver O
sequences O
grouped O
together O
in O
the O
other O
branch O
. O

me O
studied O
the O
macromolecular O
interactions O
involved O
in O
coronavirus O
assembly O
in O
cells O
infected O
with O
a O
murine O
coronavirus O
, O
mouse B
hepatitis I
virus I
( I
MHV I
) I
. O

These O
data O
indicated O
that O
while O
the O
M O
protein O
- O
N O
protein O
interaction O
, O
which O
is O
independent O
of O
viral O
RNA O
, O
occurred O
in O
the O
M O
protein O
- O
nucleocapsid O
complex O
, O
some O
MHV O
function O
( O
s O
) O
was O
necessary O
for O
the O
initiation O
of O
M O
protein O
- O
nucleocapsid O
interaction O
. O

glyceraldehyde B
3 I
- I
phosphate I
dehydrogenase I
( I
GAPDH I
) I
, O
a O
cellular O
enzyme O
involved O
in O
glycolysis O
, O
binds O
specifically O
to O
several O
viral O
RNAs O
, O
but O
the O
functional O
significance O
of O
this O
interaction O
is O
uncertain O
. O

Both O
GAPDH O
and O
polypyrimidine B
tract I
binding I
protein I
( I
PTB I
) I
bind O
to O
overlapping O
sites O
in O
stem O
- O
loop O
IIIa O
of O
the O
internal B
ribosome I
entry I
site I
( I
IRES I
) I
of O
hepatitis B
A I
virus I
( I
HAV I
) I
, O
a O
picornavirus O
. O

To O
test O
this O
hypothesis O
, O
we O
constructed O
plasmids O
containing O
a O
dicistronic O
transcriptional O
unit O
in O
which O
the O
HAV O
IRES O
was O
placed O
between O
an O
upstream O
GAPDH O
- O
coding O
sequence O
and O
a O
downstream O
Renilla B
luciferase I
( I
Rluc I
) I
sequence O
. O

In O
transfection O
experiments O
, O
GAPDH O
overexpression O
significantly O
suppressed O
HAV O
IRES O
activity O
in O
BSC O
- O
1 O
and O
FRhK O
- O
4 O
cells O
but O
not O
in O
Huh O
- O
7 O
cells O
, O
which O
have O
a O
significantly O
greater O
cytoplasmic O
abundance O
of O
PTB O
, O
GAPDH O
suppression O
of O
HAV O
translation O
was O
greater O
with O
the O
wild O
- O
type O
HAV O
IRES O
than O
with O
the O
IRES O
from O
a O
cell O
culture O
- O
adapted O
virus O
( O
HM175 O
/ O
P16 O
) O
that O
has O
reproducibly O
higher O
basal O
translational O
activity O
in O
BSC O
- O
1 O
cells O
. O

Two O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
the O
ORF2 O
protein O
of O
the O
SAR O
- O
55 O
strain O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
were O
isolated O
by O
phage O
display O
from O
a O
cDNA O
library O
of O
chimpanzee O
( O
Pan O
troglodytes O
) O
gamma O
1 O
/ O
kappa O
antibody O
genes O
. O

Both O
MAbs O
, O
HEV#4 O
and O
HEV#31 O
, O
bound O
to O
reduced O
, O
denatured O
Open B
reading I
frame I
2 I
( I
ORF2 I
) I
protein O
in O
a O
Western O
blot O
, O
suggesting O
that O
they O
recognize O
linear O
epitopes O
, O
The O
affinities O
( O
equilibrium O
dissociation O
constants O
, O
K O
- O
d O
) O
for O
the O
SAR O
- O
55 O
ORF2 O
protein O
were O
1 O
. O

Each O
MAb O
blocked O
the O
subsequent O
binding O
of O
the O
other O
MAb O
to O
homologous O
ORF2 O
protein O
in O
indirect O
competition O
assays O
, O
suggesting O
that O
they O
recognize O
the O
same O
or O
overlapping O
epitopes O
, O
Radioimmunoprecipitation O
assays O
suggested O
that O
at O
least O
part O
of O
the O
linear O
epitope O
( O
s O
) O
recognized O
by O
the O
two O
MAbs O
is O
located O
between O
amino O
acids O
578 O
and O
607 O
. O

MAbs O
were O
mixed O
with O
homologous O
HEV O
in O
vitro O
and O
then O
inoculated O
into O
rhesus O
monkeys O
( O
Macaca O
mulatta O
) O
to O
determine O
their O
neutralizing O
ability O
. O

Whereas O
all O
control O
animals O
developed O
hepatitis O
( O
elevated O
liver O
enzyme O
levels O
in O
serum O
) O
and O
seroconverted O
to O
HEV O
, O
those O
receiving O
an O
inoculum O
incubated O
with O
either O
HEV#4 O
or O
HEV#31 O
were O
not O
infected O
. O

We O
are O
interested O
in O
the O
role O
of O
E O
in O
the O
intracellular O
targeting O
of O
infectious B
bronchitis I
virus I
( I
IBV I
) I
membrane O
proteins O
. O

TT B
virus I
( I
TTV I
) I
is O
a O
recently O
discovered O
infectious O
agent O
originally O
obtained O
from O
transfusion O
- O
related O
hepatitis O
, O
However O
, O
the O
causative O
link O
between O
the O
TTV O
infection O
and O
liver O
disease O
remains O
uncertain O
, O
Recent O
studies O
demonstrated O
that O
genome O
sequences O
of O
different O
TTV O
strains O
are O
significantly O
divergent O
. O

To O
assess O
genetic O
heterogeneity O
of O
the O
Tm O
genome O
in O
more O
detail O
, O
a O
sequence O
analysis O
of O
PCR O
fragments O
( O
271 O
bp O
) O
amplified O
from O
open B
reading I
frame I
1 I
( I
ORF1 I
) I
was O
performed O
. O

The O
small O
envelope B
( I
E I
) I
protein O
has O
recently O
been O
shown O
to O
play O
an O
essential O
role O
in O
the O
assembly O
of O
coronaviruses O
. O

Expression O
studies O
revealed O
that O
for O
formation O
of O
the O
viral O
envelope O
, O
actually O
only O
the O
E O
protein O
and O
the O
membrane B
( I
M I
) I
protein O
are O
required O
. O

Since O
little O
is O
known O
about O
this O
generally O
low O
- O
abundance O
virion O
component O
, O
we O
have O
characterized O
the O
E O
protein O
of O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
, O
an O
83 O
- O
residue O
polypeptide O
. O

Studies O
on O
the O
replication O
of O
the O
pestivirus O
bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
were O
considerably O
facilitated O
by O
the O
recent O
discovery O
of O
an O
autonomous O
subgenomic O
BVDV O
RNA O
replicon O
( O
DI9c O
) O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
is O
an O
unclassified O
virus O
with O
a O
positive O
- O
sense O
RNA O
genome O
and O
an O
undefined O
replication O
strategy O
. O

In O
order O
to O
determine O
whether O
the O
HEV O
genome O
is O
capped O
or O
not O
, O
we O
developed O
a O
reverse O
transcription O
- O
PCR O
assay O
that O
is O
based O
on O
the O
ability O
of O
a O
monoclonal O
antibody O
to O
recognize O
7 O
- O
methylguanosine O
( O
m O
( O
7 O
) O
G O
) O
, O
Antibody O
to O
m7G O
bound O
RNA O
extracted O
from O
virions O
of O
two O
different O
HEV O
genotypes O
, O
The O
cap O
analog O
competitively O
inhibited O
the O
binding O
of O
virion O
RNAs O
, O
demonstrating O
that O
HEV O
has O
a O
capped O
RNA O
genome O
. O

equine B
arteritis I
virus I
( I
EAV I
) I
is O
a O
positive O
- O
stranded O
RNA O
virus O
that O
synthesizes O
a O
5 O
' O
- O
and O
3 O
' O
- O
coterminal O
nested O
set O
of O
six O
subgenomic O
mRNAs O
. O

Subgenomic O
mRNA O
transcription O
and O
genome O
replication O
are O
directed O
by O
the O
viral O
replicase O
, O
which O
is O
expressed O
in O
the O
form O
of O
two O
polyproteins O
and O
subsequently O
processed O
into O
smaller O
nonstructural B
proteins I
( I
nsPs I
) I
, O
During O
the O
recent O
construction O
of O
an O
EAV O
infectious O
cDNA O
clone O
( O
pEAV030 O
[ O
L O
. O

USA O
94 O
: O
991 O
- O
996 O
, O
1997 O
] O
) O
, O
a O
mutant O
cDNA O
clone O
( O
pEAV030F O
) O
which O
carries O
a O
single O
replicase O
point O
mutation O
was O
obtained O
, O
This O
substitution O
( O
Ser O
- O
2429 O
- O
- O
> O
Pro O
) O
is O
located O
in O
the O
nsp10 O
subunit O
and O
renders O
the O
EAV030F O
virus O
deficient O
in O
subgenomic O
mRNA O
synthesis O
. O

murine B
hepatitis I
virus I
( I
MHV I
) I
gene O
1 O
, O
the O
22 O
- O
kb O
Polymerase B
( I
Pol I
) I
gene O
, O
is O
first O
translated O
into O
a O
polyprotein O
and O
subsequently O
processed O
into O
multiple O
proteins O
by O
viral O
autoproteases O
, O
Genetic O
complementation O
analyses O
suggest O
that O
the O
majority O
of O
the O
gene O
1 O
products O
are O
required O
for O
viral O
RNA O
synthesis O
. O

Immunoprecipitation O
experiments O
showed O
that O
these O
antisera O
detected O
proteins O
representing O
the O
two O
papain O
- O
like O
proteases O
and O
the O
JC O
- O
like O
protease O
encoded O
by O
open B
reading I
frame I
( I
ORF I
) I
la O
, O
the O
putative O
polymerase O
( O
p100 O
) O
and O
a O
p35 O
encoded O
by O
ORF O
Ib O
, O
and O
their O
precursors O
, O
De O
novo O
- O
synthesized O
viral O
RNA O
was O
labeled O
with O
bromouridine O
triphosphate O
in O
lysolecithin O
- O
permeabilized O
MHV O
- O
infected O
cells O
. O

bovine B
viral I
diarrhea I
virus I
( I
BVDV I
) I
, O
a O
member O
of O
the O
genus O
Pestivirus O
in O
the O
family O
Flaviviridae O
, O
has O
a O
positive O
- O
stranded O
RNA O
genome O
consisting O
of O
a O
single O
open O
reading O
frame O
and O
untranslated B
regions I
( I
UTRs I
) I
at O
the O
5 O
' O
and O
3 O
' O
ends O
, O
Computer O
modeling O
suggested O
the O
3 O
' O
UTR O
comprised O
single O
- O
stranded O
regions O
as O
well O
as O
stem O
- O
loop O
structures O
- O
- O
features O
that O
were O
suspected O
of O
being O
essentially O
implicated O
in O
the O
viral O
RNA O
replication O
pathway O
. O

Employing O
a O
subgenomic O
BVDV O
RNA O
( O
DI9c O
) O
that O
was O
shown O
to O
function O
as O
an O
autonomous O
RNA O
replicon O
( O
S O
. O

Meyers O
, O
and O
N O
, O
Tautz O
, O
J O
, O
Virol O
, O
72 O
: O
2364 O
- O
2372 O
, O
1998 O
) O
the O
goal O
of O
this O
study O
was O
to O
determine O
the O
RNA O
secondary O
structure O
of O
the O
3 O
' O
UTR O
by O
experimental O
means O
and O
to O
investigate O
the O
significance O
of O
defined O
RNA O
motifs O
for O
the O
RNA O
replication O
pathway O
, O
Enzymatic O
and O
chemical O
structure O
probing O
revealed O
mainly O
the O
conserved O
terminal O
part O
( O
termed O
3 O
' O
C O
) O
of O
the O
DI9c O
3 O
' O
UTR O
containing O
distinctive O
RNA O
motifs O
, O
i O
. O

USA O
93 O
: O
1412 O
- O
1417 O
, O
1996 O
) O
have O
demonstrated O
that O
the O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
of O
poliovirus B
( I
PV I
) I
can O
be O
functionally O
replaced O
by O
the O
related O
genetic O
element O
from O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
One O
important O
finding O
of O
this O
study O
was O
that O
open O
reading O
frame O
sequences O
3 O
' O
of O
the O
initiating O
AUG O
, O
corresponding O
to O
the O
open O
reading O
frame O
of O
the O
HCV O
core O
polypeptide O
, O
are O
required O
to O
create O
a O
viable O
chimeric O
virus O
. O

This O
made O
necessary O
the O
inclusion O
of O
a O
PV O
3C O
protease O
( O
3C B
( I
pro I
) I
) O
cleavage O
site O
for O
proper O
polyprotein O
processing O
to O
create O
the O
authentic O
N O
terminus O
of O
the O
PV O
capsid O
precursor O
. O

Chimeric O
PV O
/ O
HCV O
( O
P O
/ O
H O
) O
viruses O
, O
however O
, O
grew O
poorly O
relative O
to O
PV O
, O
The O
goal O
of O
this O
study O
was O
to O
determine O
the O
molecular O
basis O
of O
impaired O
replication O
and O
enhance O
the O
growth O
properties O
of O
this O
chimeric O
virus O
. O

Genetic O
modifications O
leading O
to O
a O
different O
proteinase O
( O
PV O
2A B
( I
pro I
) I
) O
cleavage O
site O
between O
the O
HCV O
core O
sequence O
and O
the O
PV O
polyprotein O
( O
P O
/ O
H701 O
- O
2A O
) O
proved O
far O
superior O
with O
respect O
to O
viral O
protein O
expression O
, O
core O
- O
PV O
fusion O
polyprotein O
processing O
, O
plaque O
phenotype O
, O
and O
viral O
titer O
than O
the O
original O
prototype O
PV O
/ O
HCV O
chimera O
containing O
the O
PV O
3C B
( I
pro I
) I
- O
specific O
cleavage O
site O
( O
P O
/ O
H701 O
) O
. O

The O
novel O
P O
/ O
H O
chimera O
described O
here O
are O
suitable O
models O
for O
analyzing O
the O
function O
( O
s O
) O
of O
the O
HCV O
elements O
by O
genetic O
analyses O
in O
vivo O
and O
for O
antiviral O
drug O
discovery O
. O

Prior O
to O
the O
recent O
discovery O
of O
the O
swine B
hepatitis I
E I
virus I
( I
swine I
HEV I
) I
in O
pigs O
from O
the O
midwestern O
United O
States O
, O
HEV O
was O
not O
considered O
endemic O
to O
this O
country O
. O

Although O
the O
sequence O
of O
swine O
HEV O
varied O
extensively O
from O
those O
of O
most O
human O
strains O
of O
HEV O
, O
it O
was O
very O
closely O
related O
to O
the O
two O
strains O
of O
human O
HEV O
( O
US O
- O
1 O
and O
US O
- O
2 O
) O
isolated O
in O
the O
United O
States O
. O

As O
a O
step O
toward O
understanding O
the O
function O
of O
the O
mouse B
hepatitis I
virus I
( I
MHV I
) I
E O
protein O
, O
we O
carried O
out O
clustered O
charged O
to O
- O
alanine O
mutagenesis O
on O
the O
E O
gene O
and O
incorporated O
the O
resulting O
mutations O
into O
the O
MHV O
genome O
by O
targeted O
recombination O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural I
3 I
protein I
( I
NS3 I
) I
contains O
at O
least O
two O
domains O
associated O
with O
multiple O
enzymatic O
activities O
; O
a O
serine O
protease O
activity O
resides O
in O
the O
N O
- O
terminal O
one O
- O
third O
of O
the O
protein O
, O
whereas O
RNA O
helicase O
activity O
and O
RNA O
- O
stimulated O
nucleoside O
triphosphatase O
activity O
are O
associated O
with O
the O
C O
- O
terminal O
portion O
. O

Using O
this O
envelope O
assembly O
assay O
, O
we O
have O
studied O
the O
primary O
sequence O
requirements O
for O
particle O
formation O
of O
the O
mouse B
hepatitis I
virus I
( I
MEN I
) I
M O
protein O
, O
the O
major O
protein O
of O
the O
coronavirion O
membrane O
. O

Mutations O
( O
deletions O
, O
insertions O
, O
point O
mutations O
) O
in O
the O
luminal O
domain O
, O
the O
transmembrane O
domains O
, O
the O
amphiphilic O
domain O
, O
or O
the O
carboxy O
- O
terminal O
domain O
had O
effects O
on O
the O
assembly O
of O
M O
into O
enveloped O
particles O
, O
Strikingly O
, O
the O
extreme O
carboxy O
- O
terminal O
residue O
is O
crucial O
. O

The O
small O
, O
195 O
- O
amino O
- O
acid O
form O
of O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
antigen O
( O
delta O
Ag O
- O
S O
) O
is O
essential O
for O
genome O
replication O
, O
i O
. O

To O
better O
understand O
this O
requirement O
, O
we O
used O
purified O
recombinant O
delta O
Ag O
- O
S O
and O
HDV O
RNA O
synthesized O
in O
vitro O
to O
assemble O
high O
- O
molecular O
- O
weight O
ribonucleoprotein B
( I
RNP I
) I
structures O
. O

Characterizations O
of O
genetic O
variations O
among O
hepatitis B
delta I
virus I
( I
HDV I
) I
isolates O
have O
focused O
principally O
on O
phylogenetic O
analysis O
of O
sequences O
, O
which O
vary O
by O
30 O
to O
40 O
% O
among O
three O
genotypes O
and O
about O
10 O
to O
15 O
% O
among O
isolates O
of O
the O
same O
genotype O
. O

In O
transfected O
Huh O
- O
7 O
cells O
, O
the O
functional O
roles O
of O
the O
two O
forms O
of O
the O
viral O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
, O
in O
HDV O
RNA O
replication O
are O
similar O
for O
both O
genotypes O
I O
and O
III O
; O
the O
short O
form O
is O
required O
for O
RNA O
replication O
, O
while O
the O
long O
form O
inhibits O
replication O
, O
Far O
both O
genotypes O
, O
HDAg O
was O
able O
to O
support O
replication O
of O
RNAs O
of O
the O
same O
genotype O
that O
were O
mutated O
so O
as O
to O
be O
defective O
for O
HDAg O
production O
. O

In O
this O
study O
, O
, O
ve O
investigated O
the O
role O
of O
the O
coronavirus O
spike O
protein O
, O
because O
of O
its O
prominent O
position O
in O
the O
virion O
the O
prime O
sorting O
candidate O
, O
in O
the O
directionality O
of O
virus O
release O
, O
Three O
independent O
approaches O
were O
taken O
, O
( O
i O
) O
The O
inhibition O
of O
N O
glycosylation O
by O
tunicamycin O
resulted O
in O
the O
synthesis O
of O
spikeless O
virions O
, O
The O
absence O
of O
spikes O
, O
however O
, O
did O
not O
influence O
the O
polarity O
in O
the O
release O
of O
virions O
, O
Thus O
, O
murine B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
was O
still O
secreted O
from O
the O
basolateral O
membranes O
of O
mTAL O
and O
LMR O
cells O
and O
from O
the O
apical O
sides O
of O
MDCKMHVR O
cells O
, O
whereas O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
was O
still O
released O
from O
the O
apical O
surfaces O
of O
LMR O
cells O
, O
( O
ii O
) O
Spikeless O
virions O
were O
also O
studied O
by O
using O
the O
MHV O
- O
A59 O
temperature O
- O
sensitive O
mutant O
Albany O
18 O
, O
When O
these O
virions O
were O
produced O
in O
infected O
LMR O
and O
MDCKMHVR O
cells O
at O
the O
nonpermissive O
temperature O
, O
they O
were O
again O
preferentially O
released O
from O
basolateral O
and O
apical O
membranes O
, O
respectively O
, O
( O
iii O
) O
We O
recently O
demonstrated O
that O
coronavirus O
- O
like O
particles O
resembling O
normal O
virions O
were O
assembled O
and O
released O
when O
the O
envelope O
proteins O
M O
and O
E O
were O
coexpressed O
in O
cells O
( O
H O
. O

Aminopeptidase O
N O
is O
a O
species O
- O
specific O
receptor O
for O
transmissible B
gastroenteritis I
virus I
( I
TGEV I
) I
, O
which O
infects O
piglets O
, O
and O
for O
the O
229E O
virus O
, O
which O
infects O
humans O
. O

We O
have O
studied O
the O
interaction O
between O
TGEV O
and O
a O
cell O
line O
( O
MDCK O
) O
stably O
expressing O
recombinant O
pig B
aminopeptidase I
N I
( I
pAPN I
) I
. O

Ammonium O
chloride O
and O
bafilomycin O
A O
( O
1 O
) O
markedly O
inhibited O
the O
TGEV O
infection O
as O
judged O
from O
virus O
production O
and O
protein O
biosynthesis O
analyses O
but O
did O
so O
only O
when O
added O
early O
in O
the O
course O
of O
the O
infection O
, O
i O
. O

The O
spike B
protein I
( I
S I
) I
of O
the O
murine O
coronavirus O
mouse B
hepatitis I
virus I
strain I
A59 I
( I
MHV I
- I
A59 I
) I
induces O
both O
virus O
- O
to O
- O
cell O
fusion O
during O
infection O
and O
syncytium O
formation O
. O

We O
have O
recently O
described O
a O
system O
in O
which O
viral O
infectivity O
is O
mimicked O
by O
using O
virus B
- I
like I
particles I
( I
VLPs I
) I
and O
reporter O
defective B
- I
interfering I
( I
DI I
) I
RNAs O
( O
E O
. O

Infectivity O
aas O
blocked O
upon O
treatment O
of O
the O
VLPs O
with O
MHV O
- O
A59 O
- O
neutralizing O
anti O
- O
S O
monoclonal B
antibody I
( I
Mab I
) I
A2 O
. O

The O
NS5B O
protein O
of O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
( O
S O
. O

15 O
: O
12 O
- O
22 O
, O
1996 O
) O
that O
is O
assumed O
to O
be O
required O
for O
replication O
of O
the O
viral O
genome O
, O
To O
further O
study O
the O
biochemical O
and O
structural O
properties O
of O
this O
enzyme O
, O
an O
NS5B O
- O
hexahistidine O
fusion O
protein O
was O
expressed O
with O
recombinant O
baculoviruses O
in O
insect O
cells O
and O
purified O
to O
near O
homogeneity O
, O
The O
enzyme O
was O
found O
to O
have O
a O
primer O
- O
dependent O
RdRp O
activity O
that O
was O
able O
to O
copy O
a O
complete O
in O
vitro O
- O
transcribed O
HCV O
genome O
in O
the O
absence O
of O
additional O
viral O
or O
cellular O
factors O
, O
Filter O
binding O
assays O
and O
competition O
experiments O
showed O
that O
the O
purified O
enzyme O
binds O
RNA O
with O
no O
clear O
preference O
for O
HCV O
3 O
' O
- O
end O
sequences O
, O
Binding O
to O
homopolymeric O
RNAs O
was O
also O
examined O
, O
and O
the O
following O
order O
of O
specificity O
was O
observed O
: O
poly O
( O
U O
) O
> O
poly O
( O
G O
) O
> O
poly O
( O
A O
) O
> O
poly O
( O
C O
) O
. O

An O
inverse O
order O
was O
found O
for O
the O
RdRp O
activity O
, O
which O
used O
poly O
( O
C O
) O
most O
efficiently O
as O
a O
template O
but O
was O
inactive O
on O
poly O
( O
U O
) O
and O
poly O
( O
G O
) O
, O
suggesting O
that O
a O
high O
binding O
affinity O
between O
polymerase O
and O
template O
interferes O
with O
processivity O
, O
By O
using O
a O
mutational O
analysis O
, O
four O
amino O
acid O
sequence O
motifs O
crucial O
for O
RdRp O
activity O
were O
identified O
, O
While O
most O
substitutions O
of O
conserved O
residues O
within O
these O
motifs O
severely O
reduced O
the O
enzymatic O
activities O
, O
a O
single O
substitution O
in O
motif O
D O
which O
enhanced O
the O
RdRp O
activity O
by O
about O
50 O
% O
was O
found O
. O

Two O
prominent O
features O
distinguish O
hepatitis B
A I
virus I
( I
HAV I
) I
from O
other O
members O
of O
the O
picornavirus O
family O
. O

Using O
an O
in O
vivo O
expression O
system O
, O
we O
show O
that O
proteolytic O
liberation O
of O
VP1 O
from O
its O
precursors O
P1 O
- O
2A O
and O
VP1 O
- O
2A O
is O
catalyzed O
by O
the O
virus O
- O
encoded O
proteinase O
3C B
( I
pro I
) I
, O
Among O
the O
proposed O
cleavage O
sites O
within O
VP1 O
- O
2A O
, O
the O
Glu O
/ O
Ser O
pair O
found O
at O
VP1 O
amino O
acid O
position O
273 O
/ O
274 O
of O
most O
HAV O
strains O
is O
efficiently O
processed O
, O
whereas O
proteolysis O
of O
the O
Val O
/ O
Ser O
site O
of O
the O
attenuated O
HM175 O
strain O
is O
protracted O
. O

Two O
mutations O
within O
VP1 O
- O
2A O
( O
Lys O
[ O
297 O
] O
Arg O
and O
Ser O
[ O
330 O
] O
Asn O
) O
had O
no O
effect O
on O
3C B
( I
pro I
) I
- O
mediated O
cleavage O
at O
this O
site O
. O

Mutations O
in O
the O
5 B
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
of O
an O
attenuated O
, O
cell O
culture O
- O
adapted O
hepatitis B
A I
virus I
( I
HAV I
) I
, O
HM175 O
/ O
P16 O
, O
enhance O
growth O
in O
cultured O
African O
green O
monkey O
kidney O
( O
BS O
- O
C O
- O
I O
) O
cells O
but O
not O
in O
fetal B
rhesus I
monkey I
kidney I
( I
FRhK I
- I
4 I
) I
cells O
( O
S O
. O

To O
determine O
whether O
these O
mutations O
enhance O
cap O
- O
independent O
translation O
directed O
by O
the O
HAV O
internal B
ribosomal I
entry I
site I
( I
IRES I
) I
, O
we O
compared O
the O
translational O
activities O
of O
the O
5 O
' O
NTRs O
of O
wild O
- O
type O
and O
HM175 O
/ O
P16 O
viruses O
in O
two O
stably O
transformed O
cell O
lines O
( O
BT7 O
- O
H O
and O
FRhK O
- O
T7 O
) O
which O
constitutively O
express O
cytoplasmic O
bacteriophage O
T7 O
RNA O
polymerase O
and O
which O
are O
derived O
from O
BS O
- O
C O
- O
1 O
and O
FRhK O
- O
4 O
cells O
, O
respectively O
, O
Translational O
activity O
was O
assessed O
by O
monitoring O
expression O
of O
a O
reporter O
protein O
, O
chloramphenicol B
acetyltransferase I
( I
CAT I
) I
, O
following O
transfection O
with O
plasmid O
DNAs O
containing O
bicistronic O
T7 O
transcriptional O
units O
of O
the O
form O
luciferase O
- O
5 O
' O
NTR O
- O
CAT O
. O

In O
both O
cell O
types O
, O
transcripts O
containing O
the O
5 O
' O
NTR O
of O
HM175 O
/ O
P16 O
expressed O
CAT O
at O
levels O
that O
were O
50 O
- O
to O
100 O
- O
fold O
lower O
than O
transcripts O
containing O
the O
IRES O
elements O
of O
Sabin O
type O
1 O
poliovirus O
or O
encephalomyocarditis O
virus O
, O
confirming O
the O
low O
activity O
of O
the O
HAV O
IRES O
, O
However O
, O
in O
BT7 O
- O
H O
cells O
, O
transcripts O
containing O
the O
5 O
' O
NTR O
of O
HM175 O
/ O
P16 O
expressed O
CAT O
with O
four O
- O
to O
fivefold O
greater O
efficiency O
than O
transcripts O
containing O
the O
5 O
' O
NTR O
of O
wild O
- O
type O
virus O
, O
This O
translational O
enhancement O
was O
due O
to O
additive O
effects O
of O
a O
UU O
deletion O
at O
nucleotides O
203 O
and O
204 O
and O
a O
U O
- O
to O
- O
G O
substitution O
at O
nucleotide O
687 O
of O
HM175 O
/ O
P16 O
, O
These O
mutations O
did O
not O
enhance O
translation O
in O
FRhK O
- O
T7 O
or O
Huh O
- O
T7 O
cells O
( O
a O
T7 O
polymerase O
- O
expressing O
cell O
line O
derived O
from O
human O
hepatoblastoma O
cells O
) O
or O
in O
vitro O
in O
rabbit O
reticulocyte O
lysates O
, O
These O
results O
demonstrate O
that O
mutations O
in O
the O
5 O
' O
NTR O
of O
a O
cell O
culture O
- O
adapted O
HAV O
enhance O
viral O
replication O
by O
facilitating O
cap O
- O
independent O
translation O
in O
a O
cell O
- O
type O
- O
specific O
fashion O
and O
support O
the O
concept O
that O
picornaviral O
host O
range O
is O
determined O
in O
part O
by O
differences O
in O
cellular O
translation O
initiation O
factors O
. O

hepatitis B
A I
virus I
( I
HAV I
) I
mutants O
containing O
large O
deletions O
within O
the O
first O
pyrimidine O
- O
rich O
tract O
( O
pY1 O
; O
nucleotides O
[ O
nt O
] O
99 O
to O
138 O
) O
of O
the O
5 B
' I
nontranslated I
RNA I
( I
5 I
' I
NTR I
) I
replicate O
well O
in O
cultured O
cells O
, O
while O
those O
with O
pY1 O
deletions O
which O
extend O
in O
a O
3 O
' O
direction O
to O
include O
nt O
140 O
to O
144 O
( O
CUUGU O
) O
have O
a O
temperature B
- I
sensitive I
( I
ts I
) I
replication O
phenotype O
( O
D O
. O

To O
characterize O
this O
replication O
defect O
, O
the O
ts O
mutant O
Delta O
131 O
- O
144 O
was O
grown O
under O
one O
- O
step O
conditions O
at O
the O
nonpermissive O
temperature O
( O
37 O
degrees O
C O
) O
. O

A O
shift O
to O
the O
permissive O
temperature O
( O
31 O
degrees O
C O
) O
for O
the O
first O
18 O
h O
of O
the O
viral O
replication O
cycle O
did O
not O
enhance O
virus O
yields O
, O
indicating O
that O
temperature O
sensitivity O
is O
not O
due O
to O
a O
defect O
in O
viral O
entry O
or O
uncoating O
. O

Analysis O
of O
the O
nucleotide O
sequence O
surrounding O
the O
deletion O
in O
a O
non O
- O
ts O
revertant O
derived O
from O
Delta O
116 O
- O
144 O
virus O
revealed O
that O
a O
single O
U O
- O
to O
- O
G O
transversion O
at O
nt O
114 O
( O
CUUUU O
- O
- O
> O
CUUGU O
) O
had O
restored O
the O
sequence O
normally O
present O
between O
nt O
140 O
and O
144 O
. O

Cell O
culture O
- O
adapted O
variants O
of O
hepatitis B
A I
virus I
( I
HAV I
) I
in O
which O
the O
first O
pyrimidine O
- O
rich O
tract O
( O
pY1 O
; O
nucleotides O
99 O
to O
138 O
) O
of O
the O
5 O
' O
nontranslated O
region O
has O
been O
deleted O
( O
Delta O
96 O
- O
137 O
or O
Delta O
96 O
- O
139 O
) O
replicate O
as O
well O
as O
parental O
virus O
in O
cultured O
cells O
( O
D O
. O

To O
determine O
whether O
viruses O
with O
such O
large O
deletion O
mutations O
are O
able O
to O
replicate O
and O
to O
produce O
acute O
hepatitis O
in O
primates O
, O
we O
reconstructed O
the O
Delta O
96 O
- O
137 O
deletion O
in O
the O
genetic O
background O
of O
a O
virulent O
virus O
which O
differs O
from O
the O
wild O
type O
by O
only O
one O
mutation O
in O
the O
2B O
- O
coding O
region O
( O
HM175 O
/ O
8Y O
) O
. O

Full O
- O
length O
synthetic O
Delta O
96 O
- O
137 O
/ O
8Y O
RNA O
was O
injected O
into O
the O
livers O
of O
two O
HAV O
- O
seronegative O
marmosets O
( O
Saguinus O
mystax O
) O
. O

Gene O
1 O
of O
the O
murine O
coronavirus O
, O
MHV O
- O
A59 O
, O
encodes O
approximately O
800 O
kDa O
of O
protein O
products O
within O
two O
overlapping O
open O
reading O
frames O
( O
ORFs O
1a O
and O
1b O
) O
, O
The O
gene O
is O
expressed O
as O
a O
polyprotein O
that O
is O
processed O
into O
individual O
proteins O
, O
presumably O
by O
virus O
- O
encoded O
proteinases O
, O
ORF O
1a O
has O
been O
predicted O
to O
encode O
proteins O
with O
similarity O
to O
viral O
and O
cellular O
proteinases O
, O
such O
as O
papain O
, O
and O
to O
the O
3C O
proteinases O
of O
the O
picornaviruses O
( O
A O
. O

We O
previously O
reported O
that O
a O
clone O
of O
a O
human O
lymphocytic O
cell O
line O
, O
HPBMa O
clone O
10 O
- O
2 O
, O
supports O
the O
genome O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Using O
standard O
genetic O
recombination O
techniques O
, O
studies O
in O
our O
laboratory O
suggest O
that O
recombination O
rates O
are O
very O
high O
and O
vary O
in O
different O
portions O
of O
the O
mouse B
hepatitis I
virus I
( I
MIN I
) I
genome O
. O

Complementation O
group O
F O
RNA O
( O
+ O
) O
ts O
mutants O
( O
LA7 O
, O
NC6 O
, O
and O
NC16 O
) O
each O
contained O
a O
unique O
mutation O
which O
was O
tightly O
linked O
to O
the O
ts O
phenotype O
and O
resulted O
in O
a O
conservative O
or O
nonconservative O
amino O
acid O
change O
in O
the O
MHV O
S O
glycoprotein O
gene O
. O

To O
determine O
the O
map O
coordinates O
of O
the O
MHV O
polymerase O
genes O
, O
several O
RNA O
- O
mutants O
and O
their O
revertants O
belonging O
to O
complementation O
groups O
C O
( O
NC3 O
and O
LA9 O
) O
and O
E O
( O
LA18 O
and O
NC4 O
) O
were O
also O
sequenced O
. O

89 O
) O
x O
10 O
( O
- O
4 O
) O
substitutions O
per O
nucleotide O
site O
per O
round O
of O
template O
copying O
. O

Recombinant O
vaccinia O
viruses O
were O
used O
to O
study O
the O
processing O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
nonstructural O
polyprotein O
precursor O
. O

A O
polyprotein O
beginning O
with O
20 O
amino O
acids O
derived O
from O
the O
carboxy O
terminus O
of O
NS2 O
and O
ending O
with O
the O
NS5B O
stop O
codon O
( O
amino O
acids O
1007 O
to O
3011 O
) O
was O
cleaved O
at O
the O
NS3 O
/ O
4A O
, O
NS4A O
/ O
4B O
, O
NS4B O
/ O
5A O
, O
and O
NS5A O
/ O
5B O
sites O
, O
whereas O
a O
polyprotein O
in O
which O
the O
putative O
active O
site O
serine O
residue O
was O
replaced O
by O
an O
alanine O
remained O
unprocessed O
, O
demonstrating O
that O
the O
NS3 O
- O
encoded O
serine O
- O
type O
proteinase O
is O
essential O
for O
cleavage O
at O
these O
sites O
. O

The O
trans O
- O
cleavage O
assay O
was O
also O
used O
to O
show O
that O
( O
i O
) O
the O
first O
211 O
amino O
acids O
of O
NS3 O
were O
sufficient O
for O
processing O
at O
all O
trans O
sites O
and O
( O
ii O
) O
small O
deletions O
from O
the O
amino O
terminus O
of O
NS3 O
selectively O
affected O
cleavage O
at O
the O
NS4B O
/ O
5A O
site O
, O
whereas O
more O
extensive O
deletions O
also O
decreased O
processing O
efficiencies O
at O
the O
other O
sites O
. O

Previous O
work O
has O
shown O
that O
when O
a O
large O
spectrum O
of O
the O
quasispecies O
is O
transferred O
, O
natural O
selection O
operates O
, O
leading O
to O
elimination O
of O
noncompetitive O
( O
inferior O
) O
genomes O
and O
rapid O
gains O
in O
fitness O
. O

Finally O
, O
we O
found O
that O
following O
only O
60 O
h O
of O
selection O
( O
15 O
passages O
in O
which O
virus O
yields O
were O
harvested O
after O
4 O
h O
) O
, O
RNA O
virus O
populations O
can O
undergo O
a O
250 O
% O
average O
increase O
in O
fitness O
, O
even O
on O
a O
host O
cell O
type O
to O
which O
they O
were O
already O
well O
adapted O
. O

The O
hepatitis B
delta I
virus I
( I
HDV I
) I
genome O
is O
a O
circular O
, O
single O
- O
stranded O
, O
rod O
- O
shaped O
, O
1 O
. O

HDV O
expresses O
two O
forms O
of O
a O
single O
protein O
, O
the O
small O
and O
large O
delta O
antigens O
( O
delta O
Ag O
- O
S O
and O
delta O
Ag O
- O
L O
) O
, O
which O
associate O
with O
viral O
RNA O
in O
a O
ribonucleoprotein B
( I
RNP I
) I
structure O
. O

( O
i O
) O
The O
cleavage O
and O
ligation O
reactions O
did O
not O
require O
either O
delta O
antigen O
and O
were O
not O
inhibited O
in O
their O
presence O
. O

( O
ii O
) O
delta O
Ag O
- O
L O
, O
in O
the O
absence O
of O
delta O
Ag O
- O
S O
, O
formed O
an O
RNP O
with O
HDV O
RNA O
which O
could O
be O
assembled O
into O
secreted O
virus O
- O
like O
particles O
, O
( O
iii O
) O
Full O
- O
length O
HDV O
RNAs O
were O
stabilized O
in O
the O
presence O
of O
either O
delta O
antigen O
and O
accumulated O
to O
much O
higher O
levels O
than O
in O
their O
absence O
. O

( O
iv O
) O
As O
few O
as O
348 O
nucleotides O
of O
HDV O
RNA O
were O
Competent O
for O
circle O
formation O
, O
RNP O
assembly O
, O
and O
incorporation O
into O
virus O
- O
Like O
particles O
. O

( O
v O
) O
An O
HDV O
RNA O
incapable O
of O
folding O
into O
the O
rod O
- O
like O
structure O
was O
not O
packaged O
by O
delta O
Ag O
- O
L O
. O

The O
human O
hepatitis B
C I
virus I
( I
HCV I
) I
contains O
a O
long O
5 B
' I
noncoding I
region I
( I
5 I
' I
NCR I
) I
. O

Screening O
of O
lambdagt11 O
libraries O
identified O
three O
different O
but O
overlapping O
clones O
( O
A43 O
, O
A35 O
, O
and O
A1 O
) O
and O
one O
independent O
clone O
( O
A14 O
) O
that O
reacted O
with O
serum O
from O
a O
rabbit O
repeatedly O
immunized O
with O
purified O
astrovirus O
particles O
but O
not O
with O
its O
preimmunization O
serum O
. O

Venezuelan O
and O
western O
equine O
encephalitis O
viruses O
( O
VEEV O
and O
WEEV O
; O
Alphavirus O
; O
Togaviridae O
) O
are O
mosquito O
- O
borne O
pathogens O
causing O
central B
nervous I
system I
( I
CNS I
) I
disease O
in O
humans O
and O
equids O
. O

) O
route O
, O
showed O
that O
VEEV O
and O
WEEV O
enter O
the O
brain O
through O
olfactory B
sensory I
neurons I
( I
OSNs I
) I
. O

In O
this O
study O
, O
we O
injected O
the O
mouse O
footpad O
with O
recombinant O
WEEV O
( O
McMillan O
) O
or O
VEEV O
( O
subtype O
IC O
strain O
3908 O
) O
expressing O
firefly B
luciferase I
( I
FLuc I
) I
to O
simulate O
mosquito O
infection O
and O
examined O
alphavirus O
entry O
in O
the O
CNS O
. O

Luciferase O
expression O
served O
as O
a O
marker O
of O
infection O
detected O
as O
bioluminescence B
( I
BLM I
) I
by O
in O
vivo O
and O
ex O
vivo O
imaging O
. O

BLM O
imaging O
detected O
WEEV O
and O
VEEV O
at O
12 O
h B
postinoculation I
( I
hpi I
) I
at O
the O
injection O
site O
( O
footpad O
) O
and O
as O
early O
as O
72 O
hpi O
in O
the O
brain O
. O

3908 O
- O
fLUC O
injections O
was O
initially O
detected O
in O
the O
brain O
' O
s O
circumventricular B
organs I
( I
CVOs I
) I
. O

In O
this O
study O
, O
we O
injected O
VEEV O
or O
WEEV O
, O
engineered O
to O
express O
bioluminescent O
or O
fluorescent O
reporters O
( O
fLUC O
and O
DsRed O
, O
respectively O
) O
, O
into O
the O
footpads O
of O
outbred O
CD O
- O
1 O
mice O
to O
simulate O
transmission O
by O
a O
mosquito O
. O

We O
observed O
that O
specific O
areas O
of O
the O
brain O
( O
circumventricular O
organs O
[ O
CVOs O
] O
) O
consistently O
showed O
the O
earliest O
signs O
of O
infection O
with O
VEEV O
and O
WEEV O
. O

Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
is O
an O
arbovirus O
from O
the O
genus O
Alphavirus O
, O
family O
Togaviridae O
, O
which O
circulates O
in O
North O
America O
between O
birds O
and O
mosquitoes O
, O
occasionally O
causing O
disease O
in O
humans O
and O
equids O
. O

Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
and O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
, O
two O
New O
World O
alphaviruses O
, O
can O
cause O
fatal O
encephalitis O
, O
and O
EEEV O
is O
a O
select O
agent O
of O
concern O
in O
biodefense O
. O

In O
an O
effort O
to O
develop O
new O
tools O
for O
a O
broader O
response O
to O
outbreaks O
, O
we O
designed O
and O
tested O
a O
novel O
alphavirus O
vaccine O
comprised O
of O
cationic B
lipid I
nucleic I
acid I
complexes I
( I
CLNCs I
) I
and O
the O
ectodomain O
of O
WEEV O
E1 O
protein O
( O
E1ecto O
) O
. O

Immunization O
with O
the O
CLNC O
- O
WEEV O
E1ecto O
mixture O
( O
lipid O
- O
antigennucleic O
acid O
complexes O
[ O
LANACs O
] O
) O
using O
a O
prime O
- O
boost O
regimen O
provided O
100 O
% O
protection O
in O
mice O
challenged O
with O
WEEV O
subcutaneously O
, O
intranasally O
, O
or O
via O
mosquito O
. O

Cell O
- O
intrinsic O
innate O
immune O
responses O
mediated O
by O
the O
transcription O
factor O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
are O
often O
vital O
for O
early O
pathogen O
control O
, O
and O
effective O
responses O
in O
neurons O
may O
be O
crucial O
to O
prevent O
the O
irreversible O
loss O
of O
these O
critical O
central O
nervous O
system O
cells O
after O
infection O
with O
neurotropic O
pathogens O
. O

To O
investigate O
this O
hypothesis O
, O
we O
used O
targeted O
molecular O
and O
genetic O
approaches O
with O
cultured O
neurons O
to O
study O
cell O
- O
intrinsic O
host O
defense O
pathways O
primarily O
using O
the O
neurotropic O
alphavirus O
Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
. O

We O
investigated O
the O
ability O
of O
western B
equine I
encephalitis I
virus I
envelope I
glycoproteins I
( I
WEEV I
GP I
) I
to O
pseudotype O
lentiviral O
vectors O
. O

The O
titers O
of O
WEEV O
GP O
- O
pseudotyped O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
) O
ranged O
as O
high O
as O
8 O
. O

0 O
X O
10 O
( O
4 O
) O
IU O
/ O
ml O
on O
permissive O
cells O
. O

Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
represents O
a O
continuous O
public O
health O
threat O
in O
the O
United O
States O
. O

The O
encephalitogenic O
New O
World O
alphaviruses O
, O
including O
Venezuelan B
( I
VEEV I
) I
, O
eastern O
( O
EEEV O
) O
, O
and O
western O
equine O
encephalitis O
viruses O
, O
constitute O
a O
continuing O
public O
health O
threat O
in O
the O
United O
States O
. O

The O
identified O
VEEV O
- O
specific O
peptide O
C O
( O
VEE O
) O
33 O
- O
68 O
includes O
two O
domains O
with O
distinct O
functions O
: O
the O
alpha O
- O
helix O
domain O
, O
helix O
I O
, O
which O
is O
critically O
involved O
in O
supporting O
the O
balance O
between O
the O
presence O
of O
the O
protein O
in O
the O
cytoplasm O
and O
nucleus O
, O
and O
the O
downstream O
peptide O
, O
which O
might O
contain O
a O
functional O
nuclear O
localization O
signal O
( O
s O
) O
. O

During O
the O
last O
few O
thousand O
years O
, O
the O
New O
World O
viruses O
, O
including O
Venezuelan B
equine I
encephalitis I
virus I
( I
VEEV I
) I
and O
Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
, O
evolved O
separately O
from O
those O
of O
the O
Old O
World O
, O
i O
. O

, O
Sindbis B
virus I
( I
SINV I
) I
and O
Semliki B
Forest I
virus I
( I
SFV I
) I
. O

These O
data O
provide O
new O
insights O
into O
alphavirus O
evolution O
and O
present O
a O
plausible O
explanation O
for O
the O
particular O
recombination O
events O
that O
led O
to O
the O
formation O
of O
Western B
equine I
encephalitis I
virus I
( I
WEEV I
) I
from O
SINV O
- O
and O
EEEV O
- O
like O
ancestors O
. O

The O
C O
- O
terminal O
two O
- O
thirds O
of O
capsid B
protein I
( I
CP I
) I
, O
residues O
81 O
to O
264 O
in O
Sindbis B
virus I
( I
SINV I
) I
, O
have O
been O
previously O
shown O
to O
have O
all O
the O
RNA O
- O
CP O
and O
CP O
- O
CP O
contacts O
required O
for O
core O
assembly O
in O
vitro O
. O

We O
examined O
the O
ability O
of O
heterologous O
alphavirus O
CPs O
to O
dimerize O
and O
form O
phenotypically O
mixed O
core B
- I
like I
particles I
( I
CLPs I
) I
using O
an O
in O
vitro O
assembly O
system O
. O

The O
CPs O
of O
SINV O
and O
Ross B
River I
virus I
( I
RRV I
) I
do O
not O
form O
phenotypically O
mixed O
CLPs O
, O
but O
SINV O
and O
Western O
equine O
encephalitis O
virus O
CPs O
do O
form O
mixed O
cores O
. O

In O
contrast O
, O
an O
N O
- O
terminal O
truncated O
SINV O
CP O
( O
residues O
81 O
to O
264 O
) O
forms O
phenotypically O
mixed O
CLPs O
when O
it O
is O
assembled O
with O
full O
- O
length O
heterologous O
CPs O
, O
suggesting O
that O
the O
region O
that O
controls O
the O
mixing O
is O
present O
in O
the O
N O
- O
terminal O
80 O
residues O
. O

Replacing O
helix O
I O
with O
the O
entire O
leucine O
zipper O
domain O
of O
GCN4 O
( O
residues O
250 O
to O
281 O
) O
produced O
a O
virus O
with O
the O
wild O
- O
type O
phenotype O
as O
determined O
by O
plaque O
assay O
and O
one O
- O
step O
growth O
analysis O
. O

Western B
equine I
encephalomyelitis I
( I
WEE I
) I
virus O
( O
Togaviridae O
: O
Alphavirus O
) O
was O
shown O
previously O
to O
have O
arisen O
by O
recombination O
between O
eastern B
equine I
encephalomyelitis I
( I
EEE I
) I
- O
and O
Sindbis O
- O
like O
viruses O
( O
C O
. O

8 O
x O
10 O
( O
- O
4 O
) O
substitutions O
per O
nucleotide O
per O
year O
) O
obtained O
from O
E1 O
- O
3 O
' O
sequences O
of O
WEE O
viruses O
, O
we O
estimated O
that O
the O
recombination O
event O
occurred O
in O
the O
New O
World O
1 O
, O
300 O
to O
1 O
, O
900 O
years O
ago O
. O

The O
NS2A O
protein O
of O
Dengue B
Virus I
( I
DENV I
) I
has O
eight O
predicted O
transmembrane O
segments O
( O
pTMS1 O
to O
- O
8 O
) O
and O
participates O
in O
RNA O
replication O
, O
virion O
assembly O
, O
and O
host O
antiviral O
response O
. O

Here O
, O
we O
explore O
the O
function O
of O
DENV O
NS2A O
by O
introducing O
a O
series O
of O
alanine O
substitutions O
into O
the O
N O
- O
terminal O
half O
( O
pTMS1 O
to O
- O
4 O
) O
of O
the O
protein O
in O
the O
context O
of O
a O
DENV O
infectious O
clone O
or O
subgenomic O
replicon O
. O

Six O
NS2A O
mutants O
( O
NM5 O
, O
- O
7 O
, O
- O
9 O
, O
and O
- O
17 O
to O
- O
19 O
) O
around O
pTMS1 O
and O
- O
2 O
displayed O
a O
novel O
phenotype O
showing O
a O
> O
1 O
, O
000 O
- O
fold O
reduction O
in O
virus O
yield O
, O
an O
absence O
of O
plaque O
formation O
despite O
wild O
- O
type O
- O
like O
replicon O
activity O
, O
and O
infectious O
- O
virus O
- O
like O
particle O
yields O
. O

HEK O
- O
293 O
cells O
infected O
with O
the O
six O
NS2A O
mutant O
viruses O
failed O
to O
cause O
a O
virus O
- O
induced O
cytopathic B
effect I
( I
CPE I
) I
by O
Mito O
- O
Capture O
staining O
, O
cell O
proliferation O
, O
and O
lactate O
dehydrogenase O
release O
assays O
. O

Sequencing O
analyses O
of O
pseudorevertant O
viruses O
derived O
from O
lethal O
- O
mutant O
viruses O
revealed O
two O
consensus O
reversion O
mutations O
, O
leucine O
to O
phenylalanine O
at O
codon O
181 O
( O
L181F O
) O
within O
pTMS7 O
of O
NS2A O
and O
isoleucine O
to O
threonine O
at O
codon O
114 O
( O
I114T O
) O
within O
NS2B O
. O

The O
introduction O
of O
an O
NS2A O
- O
L181F O
mutation O
into O
the O
lethal O
( O
NM15 O
, O
- O
16 O
, O
- O
25 O
, O
and O
- O
33 O
) O
and O
CPE O
- O
defective O
( O
NM7 O
, O
- O
9 O
, O
and O
- O
19 O
) O
mutants O
substantially O
rescued O
virus O
infectivity O
and O
virus O
- O
induced O
CPE O
, O
respectively O
, O
whereas O
the O
NS2B O
- O
L114T O
mutation O
rescued O
the O
NM16 O
, O
- O
25 O
, O
and O
- O
33 O
mutants O
. O

IMPORTANCE O
The O
characterization O
of O
the O
N O
- O
terminal O
( O
current O
study O
) O
and O
C O
- O
terminal O
halves O
of O
DENV O
NS2A O
is O
the O
most O
comprehensive O
mutagenesis O
study O
to O
date O
to O
investigate O
the O
function O
of O
NS2A O
during O
the O
flaviviral O
life O
cycle O
. O

A O
novel O
region O
responsible O
for O
virus O
- O
induced O
cytopathic B
effect I
( I
CPE I
) I
within O
pTMS1 O
and O
- O
2 O
of O
DENV O
NS2A O
was O
identified O
. O

DNAJC14 O
, O
a O
heat B
shock I
protein I
40 I
( I
Hsp40 I
) I
cochaperone O
, O
assists O
with O
Hsp70 O
- O
mediated O
protein O
folding O
. O

Overexpressed O
DNAJC14 O
is O
targeted O
to O
sites O
of O
yellow B
fever I
virus I
( I
YFV I
) I
replication I
complex I
( I
RC I
) I
formation O
, O
where O
it O
interacts O
with O
viral O
nonstructural B
( I
NS I
) I
proteins O
and O
inhibits O
viral O
RNA O
replication O
. O

NS1 O
is O
the O
only O
nonstructural O
protein O
that O
enters O
the O
lumen O
of O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
where O
NS1 O
is O
glycosylated O
, O
forms O
a O
dimer O
, O
and O
is O
subsequently O
secreted O
during O
flavivirus O
replication O
as O
dimers O
or O
hexamers O
, O
which O
appear O
to O
be O
highly O
immunogenic O
to O
the O
infected O
host O
, O
as O
protective O
immunity O
can O
be O
elicited O
against O
homologous O
flavivirus O
infections O
. O

Here O
, O
by O
using O
a O
trans O
- O
complementation O
assay O
, O
we O
identified O
the O
C O
- O
terminal O
end O
of O
NS1 O
derived O
from O
Japanese B
Encephalitis I
Virus I
( I
JEV I
) I
, O
which O
was O
more O
flexible O
than O
other O
regions O
in O
terms O
of O
housing O
foreign O
epitopes O
without O
a O
significant O
impact O
on O
virus O
replication O
. O

Despite O
becoming O
attenuated O
, O
recombinant O
JEV O
with O
insertion O
of O
a O
neutralizing O
epitope O
derived O
from O
enterovirus B
71 I
( I
EV71 I
) I
into O
the O
C O
- O
terminal O
end O
of O
NS1 O
not O
only O
could O
be O
normally O
released O
from O
infected O
cells O
, O
but O
also O
induced O
dual O
protective O
immunity O
for O
the O
host O
to O
counteract O
lethal O
challenge O
with O
either O
JEV O
or O
EV71 O
in O
neonatal O
mice O
. O

A O
new O
flavivirus O
, O
Ecuador B
Paraiso I
Escondido I
virus I
( I
EPEV I
) I
, O
named O
after O
the O
village O
where O
it O
was O
discovered O
, O
was O
isolated O
from O
sand O
flies O
( O
Psathyromyia O
abonnenci O
, O
formerly O
Lutzomyia O
abonnenci O
) O
that O
are O
unique O
to O
the O
New O
World O
. O

EPEV O
replicated O
in O
C6 O
/ O
36 O
mosquito O
cells O
, O
yielding O
high O
infectious O
titers O
, O
but O
failed O
to O
reproduce O
either O
in O
vertebrate O
cell O
lines O
( O
Vero O
, O
BHK O
, O
SW13 O
, O
and O
XTC O
cells O
) O
or O
in O
suckling O
mouse O
brains O
. O

IMPORTANCE O
The O
flaviviruses O
are O
rarely O
( O
if O
ever O
) O
vectored O
by O
sand O
fly O
species O
, O
at O
least O
in O
the O
Old O
World O
. O

We O
have O
identified O
the O
first O
representative O
of O
a O
sand O
fly O
- O
associated O
flavivirus O
, O
Ecuador B
Paraiso I
Escondido I
virus I
( I
EPEV I
) I
, O
in O
the O
New O
World O
. O

The O
four O
serotypes O
of O
dengue O
virus O
( O
DENV O
- O
1 O
to O
- O
4 O
) O
represent O
the O
most O
prevalent O
mosquito O
- O
borne O
viral O
pathogens O
in O
humans O
. O

The O
compound O
selectively O
inhibits O
DENV O
- O
2 O
and O
- O
3 O
( O
50 O
% O
effective O
concentration O
[ O
EC50 O
] O
, O
10 O
to O
80 O
nM O
) O
but O
not O
DENV O
- O
1 O
and O
- O
4 O
( O
EC50 O
, O
> O
20 O
mu O
M O
) O
. O

Resistance O
analysis O
showed O
that O
a O
mutation O
at O
amino O
acid O
63 O
of O
DENV O
- O
2 O
NS4B O
( O
a O
nonenzymatic O
transmembrane O
protein O
and O
a O
component O
of O
the O
viral O
replication O
complex O
) O
could O
confer O
resistance O
to O
compound O
inhibition O
. O

Medicinal O
chemistry O
improved O
the O
physicochemical O
properties O
of O
the O
initial O
hit O
( O
compound O
1 O
) O
, O
leading O
to O
compound O
14a O
, O
which O
has O
good O
in O
vivo O
pharmacokinetics O
. O

IMPORTANCE O
Dengue B
Virus I
( I
DENV I
) I
threatens O
up O
to O
2 O
. O

The O
compound O
potently O
inhibits O
two O
of O
the O
four O
serotypes O
of O
DENV O
( O
DENV O
- O
2 O
and O
- O
3 O
) O
both O
in O
vitro O
and O
in O
vivo O
. O

We O
identified O
a O
unique O
amino O
acid O
of O
NS2A O
( O
113 O
) O
, O
phenylalanine O
, O
that O
affects O
the O
efficient O
propagation O
of O
two O
Japanese O
encephalitis O
virus O
strains O
, O
JaTH160 O
and O
JaOArS982 O
, O
in O
neuroblastoma O
Neuro O
- O
2a O
cells O
but O
not O
in O
cell O
lines O
of O
extraneural O
origin O
. O

To O
further O
understand O
its O
role O
in O
this O
process O
, O
a O
charged O
- O
to O
- O
alanine O
scanning O
analysis O
was O
performed O
on O
NS2A O
encoded O
by O
an O
infectious O
cDNA O
clone O
of O
yellow B
fever I
virus I
( I
YFV I
) I
. O

Five O
of O
them O
did O
not O
produce O
infectious O
particles O
, O
whereas O
efficient O
RNA O
replication O
was O
detectable O
for O
two O
of O
the O
five O
NS2A O
mutants O
( O
R22A O
- O
K23A O
- O
R24A O
and O
R99A O
- O
E100A O
- O
R101A O
mutants O
) O
. O

Besides O
suppressor O
mutants O
in O
NS2A O
, O
a O
compensating O
second O
- O
site O
mutation O
in O
NS3 O
( O
D343G O
) O
arose O
for O
the O
NS2A O
R22A O
- O
K23A O
- O
R24A O
mutant O
. O

Wongabel O
virus O
( O
WONV O
) O
is O
an O
arthropod O
- O
borne O
rhabdovirus O
that O
infects O
birds O
. O

In O
addition O
to O
the O
five O
canonical O
rhabdovirus O
structural O
protein O
genes O
( O
N O
, O
P O
, O
M O
, O
G O
, O
and O
L O
) O
, O
the O
13 O
. O

2 O
- O
kb O
negative O
- O
sense O
single B
- I
stranded I
RNA I
( I
ssRNA I
) I
WONV O
genome O
contains O
five O
uncharacterized O
accessory O
genes O
, O
one O
overlapping O
the O
N O
gene O
( O
Nx O
or O
U4 O
) O
, O
three O
located O
between O
the O
P O
andMgenes O
( O
U1 O
to O
U3 O
) O
, O
and O
a O
fifth O
one O
overlapping O
the O
G O
gene O
( O
Gx O
or O
U5 O
) O
. O

A O
yeast O
two O
- O
hybrid O
screen O
against O
a O
mosquito O
cell O
cDNA O
library O
identified O
that O
WONV O
U3 O
interacts O
with O
the O
83 O
- O
amino O
- O
acid O
( O
aa O
) O
C O
- O
terminal O
domain O
of O
SNF5 O
, O
a O
component O
of O
the O
SWI O
/ O
SNF O
chromatin O
remodeling O
complex O
. O

Gene O
expression O
studies O
showed O
that O
SNF5 O
transcripts O
are O
upregulated O
during O
infection O
of O
mosquito O
cells O
with O
WONV O
, O
as O
well O
as O
West O
Nile O
virus O
( O
Flaviviridae O
) O
and O
bovine O
ephemeral O
fever O
virus O
( O
Rhabdoviridae O
) O
, O
and O
that O
SNF5 O
knockdown O
results O
in O
increased O
WONV O
replication O
. O

In O
addition O
to O
the O
major O
structural O
proteins O
( O
N O
, O
P O
, O
M O
, O
G O
, O
and O
L O
) O
, O
many O
rhabdoviruses O
encode O
a O
diverse O
array O
of O
accessory O
proteins O
of O
largely O
unknown O
function O
. O

We O
also O
show O
that O
U3 O
inhibits O
SNF5 O
- O
regulated O
expression O
of O
the O
cytokine O
colony B
- I
stimulating I
factor I
1 I
( I
CSF1 I
) I
, O
suggesting O
that O
it O
targets O
the O
chromatin O
remodeling O
complex O
to O
block O
the O
host O
response O
to O
infection O
. O

Dengue B
Virus I
( I
DENV I
) I
, O
the O
etiologic O
agent O
of O
dengue O
fever O
, O
is O
transmitted O
during O
probing O
of O
human O
skin O
by O
infected O
- O
mosquito O
bite O
. O

We O
assayed O
these O
sites O
3 O
h O
postinoculation O
with O
transcript O
arrays O
for O
the O
Toll B
- I
like I
receptor I
( I
TLR I
) I
, O
RIG O
- O
I O
- O
like O
receptor O
, O
and O
NOD O
- O
like O
receptor O
signaling O
pathways O
of O
the O
innate O
immune O
system O
. O

We O
then O
chose O
TLR7 O
, O
transcription O
factor O
p65 O
( O
RelA O
) O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
and O
IFN O
- O
gamma O
- O
inducible B
protein I
10 I
( I
IP I
- I
10 I
) I
from O
the O
arrays O
for O
further O
investigation O
and O
assayed O
these O
transcripts O
at O
10 O
min O
, O
3 O
h O
, O
and O
6 O
h O
postinoculation O
. O

Arboviruses O
such O
as O
yellow B
fever I
virus I
( I
YFV I
) I
are O
transmitted O
between O
arthropod O
vectors O
and O
vertebrate O
hosts O
. O

To O
investigate O
whether O
arboviruses O
encounter O
bottlenecks O
during O
dissemination O
in O
the O
vertebrate O
host O
, O
we O
infected O
immunocompetent O
mice O
and O
immune O
- O
deficient O
mice O
lacking O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
receptors O
( O
IFNAR O
( O
- O
/ O
- O
) O
mice O
) O
with O
a O
pool O
of O
genetically O
marked O
viruses O
to O
evaluate O
dissemination O
and O
host O
barriers O
. O

Conversely O
, O
32 O
% O
of O
intramuscularly O
injected O
IFNAR O
( O
- O
/ O
- O
) O
mice O
developed O
disease O
. O

By O
following O
the O
genetically O
marked O
viruses O
over O
time O
, O
we O
found O
broad O
dissemination O
in O
IFNAR O
( O
- O
/ O
- O
) O
mice O
followed O
by O
clearance O
. O

We O
show O
that O
interferon O
- O
induced O
transmembrane O
protein O
1 O
( O
IFITM O
- O
1 O
) O
, O
IFITM O
- O
2 O
, O
and O
IFITM O
- O
3 O
exhibit O
a O
broad O
spectrum O
of O
antiviral O
activity O
against O
several O
members O
of O
the O
Bunyaviridae O
family O
, O
including O
Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
La O
Crosse O
virus O
, O
Andes O
virus O
, O
and O
Hantaan O
virus O
, O
all O
of O
which O
can O
cause O
severe O
disease O
in O
humans O
and O
animals O
. O

Indeed O
, O
at O
low O
doses O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
, O
IFITM O
- O
2 O
and O
- O
3 O
mediated O
more O
than O
half O
of O
the O
antiviral O
activity O
of O
IFN O
- O
alpha O
against O
RVFV O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
is O
an O
emerging O
RNA O
virus O
with O
devastating O
economic O
and O
social O
consequences O
. O

It O
is O
known O
that O
type B
I I
interferon I
( I
IFN I
) I
responses O
can O
be O
protective O
against O
severe O
pathology O
; O
however O
, O
it O
is O
unknown O
which O
innate O
immune O
receptor O
pathways O
are O
crucial O
for O
mounting O
this O
response O
. O

Using O
both O
in O
vitro O
assays O
and O
in O
vivo O
mucosal O
mouse O
challenge O
, O
we O
demonstrate O
here O
that O
RNA O
helicases O
are O
critical O
for O
IFN O
production O
by O
immune O
cells O
and O
that O
signaling O
through O
the O
helicase O
adaptor O
molecule O
MAVS B
( I
mitochondrial I
antiviral I
signaling I
) I
is O
protective O
against O
mortality O
and O
more O
subtle O
pathology O
during O
RVFV O
infection O
. O

We O
previously O
reported O
that O
mice O
lacking O
alpha O
/ O
beta O
and O
gamma O
interferon O
receptors O
( O
IFN O
- O
alpha O
/ O
beta O
R O
and O
- O
gamma O
R O
) O
uniformly O
exhibit O
paralysis O
following O
infection O
with O
the O
Dengue B
Virus I
( I
DENV I
) I
clinical O
isolate O
PL046 O
, O
while O
only O
a O
subset O
of O
mice O
lacking O
the O
IFN O
- O
gamma O
R O
alone O
and O
virtually O
no O
mice O
lacking O
the O
IFN O
- O
alpha O
/ O
beta O
R O
alone O
develop O
paralysis O
. O

Clearance O
of O
DENV O
, O
on O
the O
other O
hand O
, O
occurred O
in O
the O
absence O
of O
IFN O
- O
gamma O
R O
, O
except O
in O
the O
central B
nervous I
system I
( I
CNS I
) I
( O
brain O
and O
spinal O
cord O
) O
, O
where O
clearance O
relied O
on O
IFN O
- O
gamma O
from O
CD8 O
( O
+ O
) O
T O
cells O
. O

These O
results O
demonstrate O
the O
roles O
of O
IFN O
- O
gamma O
R O
signaling O
in O
protection O
from O
initial O
systemic O
and O
subsequent O
CNS O
disease O
following O
DENV O
infection O
and O
demonstrate O
the O
importance O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
preventing O
DENV O
- O
induced O
CNS O
disease O
. O

Human O
postmortem O
studies O
of O
natural O
Dengue B
Virus I
( I
DENV I
) I
infection O
have O
reported O
systemically O
distributed O
viral O
antigen O
. O

Here O
we O
demonstrate O
that O
within O
6 O
h O
, O
DENV O
traffics O
to O
and O
replicates O
in O
both O
CD169 O
( O
+ O
) O
and O
SIGN O
- O
R1 O
( O
+ O
) O
macrophages O
of O
the O
splenic O
marginal O
zone O
or O
draining O
lymph O
node O
, O
respectively O
, O
following O
intravenous O
or O
intrafootpad O
inoculation O
. O

Subsequently O
, O
high O
levels O
of O
replication O
are O
detected O
in O
F4 O
/ O
80 O
( O
+ O
) O
splenic O
red O
pulp O
macrophages O
and O
in O
the O
bone O
marrow O
, O
lymph O
nodes O
, O
and O
Peyer O
' O
s O
patches O
. O

In O
particular O
, O
high O
levels O
of O
replication O
occur O
in O
CD68 O
( O
+ O
) O
macrophages O
of O
the O
kidneys O
, O
heart O
, O
thymus O
, O
and O
gastrointestinal O
tract O
. O

Analogous O
to O
observations O
in O
RNA O
viruses O
such O
as O
human O
immunodeficiency O
virus O
, O
genetic O
variation O
associated O
with O
intrahost O
Dengue B
Virus I
( I
DENV I
) I
populations O
has O
been O
postulated O
to O
influence O
viral O
fitness O
and O
disease O
pathogenesis O
. O

Using O
this O
approach O
, O
we O
sequenced O
DENV O
- O
2 O
genomes O
from O
the O
serum O
of O
22 O
Nicaraguan O
individuals O
with O
secondary O
DENV O
infection O
and O
captured O
similar O
to O
75 O
% O
of O
the O
DENV O
genome O
in O
each O
sample O
( O
range O
, O
40 O
to O
98 O
% O
) O
. O

During O
the O
course O
of O
structure O
- O
activity O
relationship O
analysis O
, O
a O
molecule O
within O
this O
family O
, O
( O
E O
) O
- O
{ O
3 O
- O
[ O
5 O
- O
( O
4 O
- O
tert O
- O
butylbenzylidene O
) O
- O
4 O
- O
oxo O
- O
2 O
- O
thioxo O
- O
1 O
, O
3 O
- O
thiazolidin O
- O
3 O
- O
yl O
] O
propanoic O
acid O
} O
( O
BG O
- O
323 O
) O
, O
was O
found O
to O
possess O
significant O
antiviral O
activity O
in O
a O
dengue O
virus O
subgenomic O
replicon O
assay O
. O

We O
report O
a O
novel O
inhibitor O
that O
selectively O
suppresses O
Dengue B
Virus I
( I
DENV I
) I
by O
targeting O
viral O
NS4B O
protein O
. O

8 O
- O
million O
- O
compound O
library O
using O
a O
luciferase O
replicon O
of O
DENV B
serotype I
2 I
( I
DENV I
- I
2 I
) I
. O

The O
compound O
specifically O
inhibits O
all O
four O
serotypes O
of O
DENV O
( O
50 O
% O
effective O
concentration O
[ O
EC50 O
] O
, O
1 O
to O
4 O
mu O
M O
; O
and O
50 O
% O
cytotoxic O
concentration O
[ O
CC50 O
] O
, O
> O
40 O
mu O
M O
) O
, O
but O
it O
does O
not O
inhibit O
closely O
related O
flaviviruses O
( O
West O
Nile O
virus O
and O
yellow O
fever O
virus O
) O
or O
nonflaviviruses O
( O
Western O
equine O
encephalomyelitis O
virus O
, O
Chikungunya O
virus O
, O
and O
vesicular O
stomatitis O
virus O
) O
. O

Sequencing O
of O
the O
resistant O
replicons O
revealed O
two O
mutations O
( O
P104L O
and O
A119T O
) O
in O
the O
viral O
NS4B O
protein O
. O

The O
envelope B
( I
E I
) I
of O
Dengue B
Virus I
( I
DENV I
) I
is O
a O
determinant O
of O
tropism O
and O
virulence O
. O

At O
the O
C O
terminus O
of O
E O
protein O
, O
there O
is O
a O
stem O
region O
containing O
two O
amphipathic O
alpha O
- O
helical O
domains O
( O
EH1 O
and O
EH2 O
) O
and O
a O
stretch O
of O
conserved O
sequences O
in O
between O
. O

Site O
- O
directed O
mutagenesis O
was O
carried O
out O
to O
replace O
each O
of O
the O
stem O
residues O
at O
the O
hydrophobic O
face O
with O
an O
alanine O
or O
proline O
in O
a O
DENV B
serotype I
4 I
( I
DENV4 I
) I
precursor I
membrane I
( I
prM I
) I
/ O
E O
expression O
construct O
. O

Most O
of O
the O
15 O
proline O
mutations O
at O
either O
EH1 O
or O
EH2 O
severely O
affected O
the O
assembly O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

The O
ubiquitin O
ligase O
CBLL1 O
( O
also O
known O
as O
HAKAI O
) O
has O
been O
proposed O
to O
be O
a O
critical O
cellular O
factor O
exploited O
by O
West B
Nile I
virus I
( I
WNV I
) I
for O
productive O
infection O
. O

Follow O
- O
up O
experiments O
showed O
that O
HeLa O
cells O
knocked O
down O
for O
CBLL1 O
by O
a O
small B
interfering I
RNA I
( I
siRNA I
) I
failed O
to O
internalize O
WNV O
particles O
and O
resisted O
infection O
. O

Dengue O
infection O
, O
although O
frequently O
mild O
, O
can O
lead O
to O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
which O
can O
be O
life O
threatening O
. O

Domain O
3 O
of O
the O
dengue O
virus O
envelope O
protein O
( O
ED3 O
) O
has O
been O
suggested O
as O
one O
such O
candidate O
because O
it O
contains O
neutralizing O
epitopes O
and O
it O
was O
originally O
thought O
that O
relatively O
few O
cross O
- O
reactive O
antibodies O
are O
directed O
to O
this O
domain O
. O

On O
the O
basis O
of O
these O
findings O
, O
we O
propose O
a O
simple O
in O
vitro O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
to O
diagnose O
the O
original O
dengue O
infection O
in O
secondary O
dengue O
cases O
. O

Cells O
and O
mice O
infected O
with O
arthropod O
- O
borne O
flaviviruses O
produce O
a O
small O
subgenomic O
RNA O
that O
is O
colinear O
with O
the O
distal O
part O
of O
the O
viral O
3 B
' I
- I
untranslated I
region I
( I
UTR I
) I
. O

This O
small O
subgenomic B
flavivirus I
RNA I
( I
sfRNA I
) I
results O
from O
the O
incomplete O
degradation O
of O
the O
viral O
genome O
by O
the O
host O
5 O
' O
- O
3 O
' O
exonuclease O
XRN1 O
. O

This O
study O
not O
only O
presents O
a O
detailed O
description O
of O
the O
yellow B
fever I
virus I
( I
YFV I
) I
sfRNA O
but O
, O
more O
importantly O
, O
describes O
for O
the O
first O
time O
the O
molecular O
characteristics O
of O
the O
stalling O
site O
for O
XRN1 O
in O
the O
flavivirus O
genome O
. O

Dengue B
viruses I
( I
DENV I
) I
comprise O
a O
family O
of O
related O
positive O
- O
strand O
RNA O
viruses O
that O
infect O
up O
to O
100 O
million O
people O
annually O
. O

Protection O
against O
DENV O
is O
associated O
with O
the O
development O
of O
neutralizing O
antibodies O
that O
recognize O
the O
viral O
envelope B
( I
E I
) I
protein O
. O

Here O
, O
with O
the O
goal O
of O
identifying O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
can O
function O
as O
postexposure O
therapy O
, O
we O
generated O
a O
panel O
of O
82 O
new O
MAbs O
against O
DENV O
- O
3 O
, O
including O
24 O
highly O
neutralizing O
MAbs O
. O

Using O
yeast O
surface O
display O
, O
we O
localized O
the O
epitopes O
of O
the O
most O
strongly O
neutralizing O
MAbs O
to O
the O
lateral O
ridge O
of O
domain B
III I
( I
DIII I
) I
of O
the O
DENV B
type I
3 I
( I
DENV I
- I
3 I
) I
E O
protein O
. O

Many O
viruses O
escape O
the O
cellular O
immune O
response O
by O
downregulating O
cell O
surface O
expression O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
molecules O
. O

In O
this O
study O
we O
analyzed O
the O
expression O
of O
MHC O
class O
I O
in O
K562 O
and O
THP O
- O
1 O
human O
cell O
lines O
that O
were O
stably O
transfected O
with O
self O
- O
replicating O
subgenomic O
dengue O
virus O
RNA O
( O
replicons O
) O
and O
express O
all O
the O
dengue O
virus O
nonstructural O
proteins O
together O
. O

We O
show O
that O
MHC O
class O
I O
expression O
is O
upregulated O
in O
the O
dengue O
virus O
replicon O
- O
expressing O
cells O
and O
that O
the O
binding O
of O
natural B
killer I
( I
NK I
) I
inhibitory O
receptors O
to O
these O
cells O
is O
augmented O
. O

Finally O
, O
replicon O
- O
expressing O
K562 O
cells O
manifested O
increased O
TAP O
( O
transporter O
associated O
with O
antigen O
processing O
) O
and O
LMP O
( O
low O
- O
molecular O
- O
mass O
protein O
) O
gene O
transcription O
, O
while O
replicon O
- O
expressing O
THP O
- O
1 O
cells O
manifested O
increased O
NF O
- O
kappa O
B O
activity O
and O
MHC O
class O
I O
transcription O
. O

Flaviviruses O
encode O
a O
single O
methyltransferase O
domain O
that O
sequentially O
catalyzes O
two O
methylations O
of O
the O
viral O
RNA O
cap O
, O
GpppA O
- O
RNA O
- O
> O
m O
( O
7 O
) O
GpppA O
- O
RNA O
- O
> O
m O
( O
7 O
) O
GpppAm O
- O
RNA O
, O
by O
using O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( I
SAM I
) I
as O
a O
methyl O
donor O
. O

In O
this O
mechanism O
, O
guanine O
N7 O
of O
substrate O
GpppA O
- O
RNA O
is O
first O
positioned O
to O
SAM O
to O
generate O
m O
( O
7 O
) O
GpppA O
- O
RNA O
, O
after O
which O
the O
m O
( O
7 O
) O
G O
moiety O
is O
repositioned O
to O
the O
GTP O
- O
binding O
pocket O
to O
register O
the O
2 O
' O
- O
OH O
of O
the O
adenosine O
with O
SAM O
, O
generating O
m O
( O
7 O
) O
GpppAm O
- O
RNA O
. O

By O
use O
of O
a O
trans O
- O
packaging O
system O
that O
involved O
packaging O
a O
yellow B
fever I
virus I
( I
YFV I
) I
replicon O
into O
pseudo O
- O
infectious O
particles O
by O
supplying O
the O
YFV O
structural O
proteins O
using O
a O
Sindbis O
virus O
helper O
construct O
, O
the O
functional O
elements O
within O
the O
YFV O
capsid O
protein O
( O
YFC O
) O
were O
characterized O
. O

The O
S O
- O
adenosyl O
methionine O
transferase O
activity O
resides O
within O
its O
N O
- O
terminal O
domain O
, O
and O
residues O
270 O
to O
900 O
form O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
catalytic O
domain O
. O

The O
plus O
- O
strand O
RNA O
genome O
of O
flavivirus O
contains O
a O
5 O
' O
terminal O
cap O
1 O
structure O
( O
m O
( O
7 O
) O
GpppAmG O
) O
. O

Representative O
flavivirus O
methyltransferases O
from O
dengue O
, O
yellow O
fever O
, O
and O
West B
Nile I
virus I
( I
WNV I
) I
sequentially O
generate O
GpppA O
- O
> O
m O
( O
7 O
) O
GpppA O
- O
> O
m O
( O
7 O
) O
GpppAm O
. O

The O
2 O
' O
- O
O O
methylation O
can O
be O
uncoupled O
from O
the O
N O
- O
7 O
methylation O
, O
since O
m O
( O
7 O
) O
GpppA O
- O
RNA O
can O
be O
readily O
methylated O
to O
m O
( O
7 O
) O
GpppAm O
- O
RNA O
. O

8 O
angstrom O
resolution O
showed O
a O
single O
binding O
site O
for O
S B
- I
adenosyl I
- I
L I
- I
methionine I
( I
SAM I
) I
, O
the O
methyl O
donor O
. O

Our O
previous O
studies O
using O
trans O
- O
complementation O
analysis O
of O
Kunjin B
virus I
( I
KUN I
) I
full O
- O
length O
cDNA O
clones O
harboring O
in O
- O
frame O
deletions O
in O
the O
NS3 O
gene O
demonstrated O
the O
inability O
of O
these O
defective O
complemented O
RNAs O
to O
be O
packaged O
into O
virus O
particles O
( O
W O
. O

dengue B
virus I
( I
DEN I
) I
and O
other O
flaviviruses O
, O
such O
as O
West O
Nile O
and O
yellow O
fever O
viruses O
, O
contain O
a O
5 O
' O
m O
( O
7 O
) O
GpppN O
- O
capped O
positive O
- O
sense O
RNA O
genome O
with O
a O
nonpolyadenylated O
3 B
' I
untranslated I
region I
( I
UTR I
) I
that O
has O
been O
presumed O
to O
undergo O
translation O
in O
a O
cap O
- O
dependent O
manner O
. O

We O
further O
show O
that O
under O
cellular O
conditions O
in O
which O
translation O
factors O
are O
limiting O
, O
DEN O
can O
alternate O
between O
canonical O
cap O
- O
dependent O
translation O
initiation O
and O
a O
noncanonical O
mechanism O
that O
appears O
not O
to O
require O
a O
functional O
M O
( O
7 O
) O
G O
cap O
. O

Chimeric O
dengue O
serotype O
2 O
/ O
West O
Nile O
( O
D2 O
/ O
WN O
) O
viruses O
expressing O
prM O
- O
E O
of O
WN O
NY99 O
virus O
in O
the O
genetic O
background O
of O
wild O
- O
type O
D2 O
16681 O
virus O
and O
two O
candidate O
D2 O
PDK O
- O
53 O
vaccine O
variants O
( O
PDK53 O
- O
E O
and O
PDK53 O
- O
V O
) O
were O
engineered O
. O

Two O
D2 O
/ O
WN O
chimeras O
( O
D2 O
/ O
WN O
- O
E2 O
and O
- O
V2 O
) O
engineered O
in O
the O
backbone O
of O
the O
PDK53 O
- O
E O
and O
- O
V O
viruses O
retained O
all O
of O
the O
PDK O
- O
53 O
vaccine O
characteristic O
phenotypic O
markers O
of O
attenuation O
and O
were O
immunogenic O
in O
mice O
and O
protected O
mice O
from O
a O
high O
- O
dose O
10 O
( O
7 O
) O
PFU O
challenge O
with O
wild O
- O
type O
WN O
NY99 O
virus O
. O

Five O
dengue B
( I
DEN I
) I
virus O
- O
specific O
R5F2R4 O
peptide O
- O
conjugated O
phosphorodiamidate O
morpholino O
oligomers O
( O
P4 O
- O
PMOs O
) O
were O
evaluated O
for O
their O
ability O
to O
inhibit O
replication O
of O
DEN O
virus O
serotype O
2 O
( O
DEN O
- O
2 O
virus O
) O
in O
mammalian O
cell O
culture O
. O

9 O
log O
( O
10 O
) O
, O
respectively O
) O
. O

8 O
- O
log O
( O
10 O
) O
reductions O
. O

Two O
P4 O
- O
PMO O
compounds O
, O
5 O
' O
SL O
and O
3 O
' O
CS O
( O
targeting O
the O
5 O
' O
- O
terminal O
nucleotides O
and O
the O
3 O
' O
cyclization O
sequence O
region O
, O
respectively O
) O
, O
were O
highly O
efficacious O
, O
each O
reducing O
the O
viral O
titer O
by O
greater O
than O
5 O
. O

7 O
log O
( O
10 O
) O
compared O
to O
controls O
at O
6 O
days O
after O
infection O
with O
DEN O
- O
2 O
virus O
. O

, O
DEN O
- O
1 O
( O
strain O
16007 O
) O
, O
DEN O
- O
2 O
( O
16681 O
) O
, O
DEN O
- O
3 O
( O
16562 O
) O
, O
and O
DEN O
- O
4 O
( O
1036 O
) O
viruses O
by O
over O
4 O
log O
( O
10 O
) O
, O
in O
most O
cases O
to O
below O
detectable O
limits O
. O

The O
epitope O
determinants O
of O
chimpanzee O
Fab O
antibody O
1A5 O
, O
which O
have O
been O
shown O
to O
be O
broadly O
reactive O
to O
flaviviruses O
and O
efficient O
for O
cross O
- O
neutralization O
of O
dengue O
virus O
type O
1 O
and O
type O
2 O
( O
DENV O
- O
1 O
and O
DENV O
- O
2 O
) O
, O
were O
studied O
by O
analysis O
of O
DENV O
- O
2 O
antigenic O
variants O
. O

Sequence O
analysis O
showed O
that O
one O
antigenic O
variant O
contained O
a O
Gly O
- O
to O
- O
Val O
substitution O
at O
position O
106 O
within O
the O
flavivirus O
- O
conserved O
fusion O
peptide O
loop O
of O
the O
envelope B
protein I
( I
E I
) I
, O
and O
another O
variant O
contained O
a O
His O
- O
to O
- O
Gln O
substitution O
at O
position O
317 O
in O
E O
. O

Substitution O
of O
Gly O
( O
106 O
) O
Val O
in O
DENV O
- O
2 O
E O
reduced O
the O
binding O
affinity O
of O
Fab O
1A5 O
by O
approximately O
80 O
- O
fold O
, O
whereas O
substitution O
of O
HiS O
( O
317 O
) O
Gln O
had O
little O
or O
no O
effect O
on O
antibody O
binding O
compared O
to O
the O
parental O
virus O
. O

In O
the O
three O
- O
dimensional O
structure O
of O
E O
, O
Gly O
( O
106 O
) O
in O
domain O
II O
and O
His O
( O
317 O
) O
in O
domain O
III O
of O
the O
opposite O
E O
monomer O
were O
spatially O
close O
. O

The O
flavivirus O
genome O
is O
a O
positive O
- O
stranded O
similar O
to O
11 O
- O
kb O
RNA O
including O
5 O
' O
and O
3 O
' O
noncoding B
regions I
( I
NCR I
) I
of O
approximately O
100 O
and O
400 O
to O
600 O
nucleotides B
( I
nt I
) I
, O
respectively O
. O

The O
3 O
' O
NCR O
contains O
adjacent O
, O
thermodynamically O
stable O
, O
conserved O
short O
and O
long O
stem O
- O
and O
- O
loop O
structures O
( O
the O
3 O
' O
SL O
) O
, O
formed O
by O
the O
3 O
' O
terminal O
similar O
to O
100 O
nt O
. O

We O
examined O
the O
requirement O
for O
the O
3 O
' O
- O
SL O
in O
the O
context O
of O
dengue B
virus I
type I
2 I
( I
DEN2 I
) I
replication O
by O
mutagenesis O
of O
an O
infectious O
cDNA O
copy O
of O
a O
DEN2 O
genome O
. O

A O
substitution O
mutation O
, O
in O
which O
the O
3 O
' O
- O
terminal O
93 O
nt O
constituting O
the O
wild B
- I
type I
( I
WT I
) I
DEN2 O
3 O
' O
- O
SL O
sequence O
were O
replaced O
by O
the O
96 O
- O
nt O
sequence O
of O
the O
West O
Nile O
virus O
Wn O
) O
3 O
' O
- O
SL O
, O
was O
sublethal O
for O
virus O
replication O
. O

One O
of O
the O
late O
processing O
events O
in O
the O
flavivirus O
replication O
cycle O
involves O
cleavage O
of O
the O
intracellular O
form O
of O
the O
flavivirus O
capsid O
protein O
( O
C O
- O
int O
) O
to O
the O
mature O
virion O
form O
( O
C O
- O
vir O
) O
lacking O
the O
carboxy O
- O
terminal O
stretch O
of O
hydrophobic O
amino O
acids O
which O
serves O
as O
a O
signal O
peptide O
for O
the O
downstream O
prM O
protein O
. O

According O
to O
the O
existing O
model O
of O
flavivirus O
polyprotein O
processing O
, O
one O
of O
the O
cleavages O
in O
the O
amino O
- O
terminal O
part O
of O
the O
flavivirus O
polyprotein O
by O
host O
cell O
signalases O
results O
in O
formation O
of O
prM O
( O
precursor O
to O
one O
of O
the O
structural O
proteins O
, O
M O
) O
and O
the O
membrane O
- O
bound O
intracellular O
form O
of O
the O
viral O
capsid O
protein O
( O
C O
- O
int O
) O
retaining O
the O
prM O
signal O
sequence O
at O
its O
carboxy O
terminus O
. O

This O
hydrophobic O
anchor O
is O
subsequently O
removed O
by O
the O
viral O
protease O
, O
resulting O
in O
formation O
of O
the O
mature O
viral O
capsid O
protein O
found O
in O
virions O
( O
C O
- O
vir O
) O
. O

Precursor O
frequency O
determination O
by O
limiting O
dilution O
in O
the O
presence O
of O
noninfectious O
dengue O
virus O
antigens O
revealed O
a O
frequency O
of O
antigen O
- O
reactive O
cells O
of O
1 O
in O
1 O
, O
686 O
peripheral B
blood I
mononuclear I
cells I
( I
PBMC I
) I
for O
dengue O
virus O
type O
1 O
, O
1 O
in O
9 O
, O
870 O
PBMC O
for O
dengue O
virus O
type O
3 O
, O
1 O
in O
14 O
, O
053 O
PBMC O
for O
dengue O
virus O
type O
2 O
, O
and O
1 O
in O
17 O
, O
690 O
PBMC O
for O
dengue O
virus O
type O
4 O
. O

Analysis O
of O
human B
leukocyte I
antigen I
( I
HLA I
) I
restriction O
revealed O
that O
five O
clones O
are O
HLA O
- O
DRw52 O
restricted O
, O
one O
clone O
is O
HLA O
- O
DP3 O
restricted O
, O
and O
one O
clone O
is O
HLA O
- O
DP4 O
restricted O
. O

The O
present O
paper O
analyzes O
the O
influence O
of O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
II O
( O
Ir O
) O
genes O
on O
MHC O
class O
II O
- O
restricted O
T O
- O
cell O
responses O
to O
West B
Nile I
virus I
( I
WNV I
) I
and O
recombinant O
vaccinia O
virus O
- O
derived O
Kunjin O
virus O
antigens O
and O
identifies O
the O
immunodominant O
Kunjin O
virus O
antigens O
. O

Generally O
, O
mice O
were O
primed O
by O
intravenous O
infection O
with O
WNV O
or O
Kunjin O
virus O
, O
and O
their O
CD4 O
+ O
T O
cells O
were O
stimulated O
in O
vitro O
14 O
days O
later O
with O
WNV O
or O
Kunjin O
virus O
antigens O
to O
pulse O
macrophage O
or O
B O
- O
cell O
antigen B
- I
presenting I
cells I
( I
APC I
) I
. O

When O
recombinant O
vaccinia O
virus O
- O
derived O
Kunjin O
virus O
antigen O
preparations O
were O
tested O
in O
vitro O
, O
Kunjin O
virus O
- O
immune O
T O
cells O
of O
H O
- O
2b O
haplotype O
responded O
most O
strongly O
to O
structural O
( O
prM O
, O
C O
, O
E O
) O
and O
membrane O
- O
associated O
nonstructural O
( O
NS1 O
) O
proteins O
encoded O
by O
VK O
- O
V O
1031 O
and O
showed O
weaker O
responses O
to O
cytosolic O
nonstructural O
protein O
NS5 O
( O
VKV O
1022 O
) O
, O
whereas O
the O
responders O
of O
H O
- O
2k O
haplotype O
responded O
most O
strongly O
to O
the O
antigens O
encoded O
by O
VKV O
1022 O
and O
gave O
lesser O
responses O
to O
VK O
- O
V O
1031 O
. O

The O
cleavages O
at O
the O
junctions O
of O
the O
flavivrus O
nonstructural B
( I
NS I
) I
proteins O
NS2A O
/ O
NS2B O
, O
NS2B O
/ O
NS3 O
, O
NS3 O
/ O
NS4A O
, O
and O
NS4B O
/ O
NS5 O
share O
an O
amino O
acid O
sequence O
motif O
and O
are O
presumably O
catalyzed O
by O
a O
virus O
- O
encoded O
protease O
. O

These O
clones O
were O
examined O
for O
virus O
specificity O
and O
human B
leukocyte I
antigen I
( I
HLA I
) I
restriction O
in O
cytotoxic O
assays O
. O

One O
flavivirus O
- O
cross O
- O
reactive O
clone O
recognized O
dengue O
virus O
types O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
and O
West B
Nile I
virus I
( I
WNV I
) I
, O
but O
did O
not O
recognize O
yellow B
fever I
virus I
( I
YFV I
) I
, O
whereas O
three O
flavivirus O
- O
cross O
- O
reactive O
clones O
recongized O
dengue O
virus O
types O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
, O
WNV O
, O
and O
YFV O
. O

Andes B
virus I
( I
ANDV I
) I
causes O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
and O
is O
the O
only O
hantavirus O
shown O
to O
spread O
person O
to O
person O
and O
cause O
a O
highly O
lethal O
HPS O
- O
like O
disease O
in O
Syrian O
hamsters O
. O

The O
unique O
ability O
of O
ANDV O
N O
protein O
to O
inhibit O
beta O
interferon O
( O
IFN O
beta O
) O
induction O
may O
contribute O
to O
its O
virulence O
and O
spread O
. O

Here O
we O
analyzed O
IFN O
beta O
regulation O
by O
ANDV O
N O
protein O
substituted O
with O
divergent O
residues O
from O
the O
nearly O
identical O
Maporal B
virus I
( I
MAPV I
) I
N O
protein O
. O

We O
found O
that O
MAPV O
N O
fails O
to O
inhibit O
IFN O
beta O
signaling O
and O
that O
replacing O
ANDV O
residues O
252 O
to O
296 O
with O
a O
hypervariable B
domain I
( I
HVD I
) I
from O
MAPV O
N O
prevents O
IFN O
beta O
regulation O
. O

In O
contrast O
, O
replacing O
serine O
with O
phosphoserine O
- O
mimetic O
aspartic O
acid O
( O
S386D O
) O
in O
ANDV O
N O
robustly O
inhibited O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
phosphorylation O
and O
IFN O
beta O
induction O
. O

Here O
, O
we O
describe O
the O
crystal O
structure O
of O
the O
Gn O
glycoprotein O
ectodomain O
from O
the O
Asiatic O
Hantaan B
virus I
( I
HTNV I
) I
, O
the O
most O
prevalent O
pathogenic O
hantavirus O
. O

Structural O
overlay O
analysis O
reveals O
that O
the O
HTNV O
Gn O
fold O
is O
highly O
similar O
to O
the O
Gn O
of O
Puumala B
virus I
( I
PUUV I
) I
, O
a O
genetically O
and O
geographically O
distinct O
and O
less O
pathogenic O
hantavirus O
found O
predominantly O
in O
northeastern O
Europe O
, O
confirming O
that O
the O
hantaviral O
Gn O
fold O
is O
architecturally O
conserved O
across O
hantavirus O
clades O
. O

IMPORTANCE O
Although O
outbreaks O
of O
Korean O
hemorrhagic O
fever O
were O
first O
recognized O
during O
the O
Korean O
War O
( O
1950 O
to O
1953 O
) O
, O
it O
was O
not O
until O
1978 O
that O
they O
were O
found O
to O
be O
caused O
by O
Hantaan B
virus I
( I
HTNV I
) I
, O
the O
most O
prevalent O
pathogenic O
hantavirus O
. O

Andes B
virus I
( I
ANDV I
) I
is O
associated O
with O
a O
lethal O
vascular O
leak O
syndrome O
in O
humans O
termed O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Depletion O
also O
did O
not O
significantly O
reduce O
the O
amount O
of O
virus O
in O
the O
lung O
of O
ANDV O
- O
infected O
hamsters O
but O
altered O
neutrophil O
recruitment O
, O
MIP O
- O
1 O
alpha O
and O
MIP O
- O
2 O
chemokine O
expression O
, O
and O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
levels O
in O
hamster O
Bronchoalveolar B
lavage I
( I
BAL I
) I
fluid O
early O
after O
intranasal O
challenge O
. O

hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
is O
a O
rodent O
- O
borne O
disease O
with O
a O
high O
case O
- O
fatality O
rate O
that O
is O
caused O
by O
several O
New O
World O
hantaviruses O
. O

Deer O
mice O
( O
Peromyscus O
maniculatus O
) O
are O
the O
natural O
reservoirs O
of O
Sin B
Nombre I
virus I
( I
SNV I
) I
, O
the O
etiologic O
agent O
of O
most O
HCPS O
cases O
in O
North O
America O
. O

Deer O
mice O
are O
also O
susceptible O
to O
Andes B
hantavirus I
( I
ANDV I
) I
, O
which O
causes O
most O
HCPS O
cases O
in O
South O
America O
; O
however O
, O
deer O
mice O
clear O
ANDV O
. O

Examination O
of O
lymph O
node O
cell O
antigen O
recall O
responses O
identified O
elevated O
immune O
gene O
expression O
in O
deer O
mice O
infected O
with O
ANDV O
and O
suggested O
maturation O
toward O
a O
Th2 O
or O
T O
follicular O
helper O
phenotype O
in O
some O
ANDV O
- O
infected O
deer O
mice O
, O
including O
activation O
of O
the O
interleukin B
4 I
( I
IL I
- I
4 I
) I
pathway O
in O
T O
cells O
and O
B O
cells O
. O

B O
- O
17 O
severe B
combined I
immunodeficiency I
( I
SCID I
) I
mice O
lacking O
functional O
T O
cells O
and O
B O
cells O
. O

Hantaviruses O
successfully O
replicate O
in O
primary O
human O
endothelial O
cells O
by O
restricting O
the O
early O
induction O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
and O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

Gn O
proteins O
from O
NY O
- O
1V O
, O
ANDV O
, O
and O
TULV O
, O
but O
not O
PHV O
, O
harbor O
elements O
in O
their O
142 O
- O
residue O
cytoplasmic O
tails O
( O
GnTs O
) O
that O
inhibit O
RIG O
- O
I O
/ O
MAVS O
/ O
TBK1 O
- O
TRAF3 O
- O
directed O
IFN O
- O
beta O
induction O
. O

We O
observed O
that O
GnTs O
bind O
TRAF3 O
via O
residues O
within O
the O
TRAF O
- O
N O
domain O
( O
residues O
392 O
to O
415 O
) O
and O
that O
binding O
is O
independent O
of O
the O
MAVS O
- O
interactive O
TRAF O
- O
C O
domain O
( O
residues O
415 O
to O
568 O
) O
. O

Mutagenesis O
of O
the O
NY O
- O
1V O
GnT O
revealed O
that O
altering O
tyrosine O
627 O
( O
Y627A O
/ O
S O
/ O
F O
) O
abolished O
GnT O
regulation O
of O
RIG O
- O
I O
/ O
TBK1 O
- O
directed O
IRF3 O
phosphorylation O
and O
transcriptional O
responses O
of O
ISRE O
, O
kappa O
B O
, O
and O
IFN O
- O
beta O
promoters O
. O

Sin B
Nombre I
virus I
( I
SNV I
) I
is O
a O
rodent O
- O
borne O
hantavirus O
that O
causes O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
predominantly O
in O
North O
America O
. O

SNV O
infection O
of O
immunocompetent O
hamsters O
results O
in O
an O
asymptomatic O
infection O
; O
the O
only O
lethal O
disease O
model O
for O
a O
pathogenic O
hantavirus O
is O
Andes B
virus I
( I
ANDV I
) I
infection O
of O
Syrian O
hamsters O
. O

Andes B
virus I
( I
ANDV I
) I
is O
a O
South O
American O
hantavirus O
that O
causes O
a O
highly O
lethal O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
characterized O
by O
hypoxia O
, O
thrombocytopenia O
, O
and O
vascular O
leakage O
leading O
to O
acute O
pulmonary O
edema O
. O

ANDV O
infects O
human O
pulmonary O
microvascular B
and I
lymphatic I
endothelial I
cells I
( I
MECs I
and I
LECs I
, I
respectively I
) I
and O
nonlytically O
enhances O
the O
permeability O
of O
interendothelial O
cell O
adherence O
junctions O
in O
response O
to O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
. O

In O
contrast O
to O
infection O
of O
cells O
with O
nonpathogenic O
Tula B
virus I
( I
TULV I
) I
, O
we O
observed O
that O
exposure O
of O
ANDV O
- O
infected O
MECs O
and O
LECs O
to O
hypoxic O
conditions O
resulted O
in O
a O
3 O
- O
to O
6 O
- O
fold O
increase O
in O
monolayer O
permeability O
and O
the O
formation O
of O
giant O
cells O
3 O
x O
to O
5 O
x O
normal O
size O
. O

ANDV O
infection O
in O
combination O
with O
hypoxic O
conditions O
resulted O
in O
the O
enhancement O
of O
hypoxia B
- I
inducible I
factor I
1 I
alpha I
( I
HIF1 I
alpha I
) I
- O
directed O
VEGF O
A O
, O
angiopoietin O
4 O
, O
and O
EGLN3 O
transcriptional O
responses O
. O

To O
date O
, O
a O
laboratory O
animal O
model O
for O
the O
study O
of O
Sin B
Nombre I
virus I
( I
SNV I
) I
infection O
or O
associated O
disease O
has O
not O
been O
described O
. O

Unlike O
infection O
with O
Andes O
virus O
, O
which O
causes O
lethal O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
- O
like O
disease O
in O
hamsters O
, O
SNV O
infection O
is O
short O
- O
lived O
, O
with O
no O
viremia O
and O
little O
dissemination O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
a O
severe O
respiratory O
disease O
characterized O
by O
pulmonary O
edema O
, O
with O
fatality O
rates O
of O
35 O
to O
45 O
% O
. O

Disease O
occurs O
following O
infection O
with O
pathogenic O
New O
World O
hantaviruses O
, O
such O
as O
Andes B
virus I
( I
ANDV I
) I
, O
which O
targets O
lung O
microvascular O
endothelial O
cells O
. O

During O
replication O
, O
the O
virus O
scavenges O
5 O
' O
- O
m O
( O
7 O
) O
G O
caps O
from O
cellular O
mRNA O
to O
ensure O
efficient O
translation O
of O
viral O
proteins O
by O
the O
host O
cell O
cap O
- O
dependent O
translation O
machinery O
. O

In O
cells O
, O
the O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
regulates O
the O
activity O
of O
host O
cap O
- O
dependent O
translation O
by O
integrating O
amino O
acid O
, O
energy O
, O
and O
oxygen O
availability O
signals O
. O

Here O
, O
we O
demonstrate O
that O
treatment O
with O
the O
FDA O
- O
approved O
rapamycin O
analogue O
temsirolimus O
( O
CCI O
- O
779 O
) O
blocks O
ANDV O
protein O
expression O
and O
virion O
release O
but O
not O
entry O
into O
primary O
human O
microvascular O
endothelial O
cells O
. O

We O
confirmed O
that O
temsirolimus O
targeted O
host O
mTOR B
complex I
1 I
( I
mTORC1 I
) I
and O
not O
a O
viral O
protein O
, O
as O
knockdown O
of O
mTORC1 O
and O
mTORC1 O
activators O
but O
not O
mTOR O
complex O
2 O
components O
reduced O
ANDV O
replication O
. O

We O
sequenced O
multiple O
novel O
and O
previously O
described O
viruses O
( O
Anajatuba O
, O
Laguna O
Negra O
- O
like O
, O
two O
genotypes O
of O
Castelo O
dos O
Sonhos O
, O
and O
two O
genotypes O
of O
Rio O
Mamore O
) O
from O
Brazilian O
Oligoryzomys O
rodents O
and O
hantavirus O
pulmonary O
syndrome O
cases O
and O
identified O
a O
previously O
uncharacterized O
species O
of O
Oligoryzomys O
associated O
with O
a O
new O
genotype O
of O
Rio O
Mamore O
virus O
. O

To O
determine O
whether O
rat O
alveolar B
macrophages I
( I
AMs I
) I
and O
lung B
microvascular I
endothelial I
cells I
( I
LMVECs I
) I
support O
Seoul B
virus I
( I
SEOV I
) I
replication O
and O
contribute O
to O
the O
induction O
of O
an O
environment O
that O
polarizes O
CD4 O
( O
+ O
) O
T O
cell O
differentiation O
toward O
a O
regulatory B
T I
( I
Treg I
) I
cell O
phenotype O
, O
cultured O
primary O
rat O
AMs O
and O
LMVECs O
were O
mock O
infected O
or O
infected O
with O
SEOV O
and O
analyzed O
for O
viral O
replication O
, O
cytokine O
and O
chemokine O
responses O
, O
and O
expression O
of O
cell O
surface O
markers O
that O
are O
related O
to O
T O
cell O
activation O
. O

Allogeneic O
CD4 O
( O
+ O
) O
T O
cells O
were O
cocultured O
with O
SEOV O
- O
infected O
or O
mock O
- O
infected O
AMs O
or O
LMVECs O
and O
analyzed O
for O
helper O
T O
cell O
( O
i O
. O

Expression O
of O
Ifn O
beta O
, O
Ccl5 O
, O
and O
Cxcl10 O
and O
surface O
major B
histocompatibility I
complex I
class I
II I
( I
MHC I
- I
II I
) I
and O
MHC O
- O
I O
was O
not O
altered O
by O
SEOV O
infection O
in O
either O
cell O
type O
. O

SEOV O
infection O
significantly O
increased O
Tgf O
beta O
mRNA O
in O
AMs O
and O
the O
amount O
of O
programmed B
cell I
death I
1 I
ligand I
1 I
( I
PD I
- I
L1 I
) I
in O
LMVECs O
. O

SEOV O
- O
infected O
LMVECs O
, O
but O
not O
AMs O
, O
induced O
a O
significant O
increase O
in O
Foxp3 O
expression O
and O
Treg O
cell O
frequency O
in O
allogeneic O
CD4 O
( O
+ O
) O
T O
cells O
, O
which O
was O
virus O
replication O
and O
cell O
contact O
dependent O
. O

Splenic O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
expression O
was O
elevated O
early O
in O
infection O
, O
declined O
, O
and O
then O
was O
elevated O
again O
late O
in O
infection O
. O

Hantaviruses O
primarily O
infect O
endothelial B
cells I
( I
ECs I
) I
and O
nonlytically O
cause O
vascular O
changes O
that O
result O
in O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
and O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Uniquely O
regulated O
lymphatic B
ECs I
( I
LECs I
) I
control O
fluid O
clearance O
, O
although O
roles O
for O
lymphatics O
in O
hantavirus O
disease O
remain O
undetermined O
. O

Here O
we O
report O
that O
hantaviruses O
productively O
infect O
LECs O
and O
that O
LEC O
infection O
by O
HPS O
causing O
Andes B
virus I
( I
ANDY I
) I
and O
HFRS O
causing O
Hantaan B
virus I
( I
HTNV I
) I
are O
inhibited O
by O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrin O
antibodies O
. O

Although O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
regulate O
permeabilizing O
responses O
directed O
by O
vascular B
endothelial I
growth I
factor I
receptor I
2 I
( I
VEGFR2 I
) I
, O
we O
found O
that O
only O
ANDV O
- O
infected O
LECs O
were O
hyperpermeabilized O
by O
the O
addition O
of O
VEGF O
- O
A O
. O

Giant O
cells O
are O
associated O
with O
constitutive O
mammalian B
target I
of I
rapamycin I
( I
mTOR I
) I
activation O
, O
and O
we O
found O
that O
both O
giant O
LECs O
and O
LEG O
permeability O
were O
sensitive O
to O
rapamycin O
, O
an O
mTOR O
inhibitor O
, O
and O
VEGF O
- O
C O
addition O
. O

Andes B
virus I
( I
ANDV I
) I
is O
a O
highly O
pathogenic O
South O
American O
hantavirus O
that O
causes O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

We O
generated O
and O
characterized O
a O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
vector O
expressing O
the O
ANDV O
surface O
glycoprotein O
precursor O
( O
VSV O
Delta O
G O
/ O
ANDVGPC O
) O
as O
a O
possible O
vaccine O
candidate O
and O
tested O
its O
efficacy O
in O
the O
only O
lethal O
- O
disease O
animal O
model O
of O
HPS O
. O

The O
vaccine O
was O
able O
to O
generate O
high O
levels O
of O
neutralizing O
anti O
- O
ANDV O
G O
( O
N O
) O
/ O
G O
( O
C O
) O
antibodies O
, O
which O
seem O
to O
play O
a O
role O
as O
a O
mechanism O
of O
vaccine O
protection O
. O

Tula B
virus I
( I
TULV I
) I
and O
Prospect B
Hill I
virus I
( I
PHV I
) I
are O
hantaviruses O
which O
infect O
human O
endothelial O
cells O
but O
fail O
to O
cause O
human O
disease O
. O

PHV O
is O
unable O
to O
inhibit O
early O
interferon B
( I
IFN I
) I
responses O
and O
fails O
to O
replicate O
within O
human O
endothelial O
cells O
. O

We O
observed O
a O
> O
300 O
- O
fold O
reduction O
in O
the O
IFN B
- I
stimulated I
genes I
( I
ISGs I
) I
MxA O
and O
ISG56 O
following O
TULV O
versus O
PHV O
infection O
of O
endothelial O
cells O
1 O
day O
postinfection O
. O

Similar O
to O
results O
with O
pathogenic O
hantaviruses O
, O
expressing O
the O
TULV O
Gn O
protein O
cytoplasmic O
tail O
( O
Gn O
- O
T O
) O
blocked O
RIG O
- O
I O
- O
and O
TBK1 O
- O
directed O
transcription O
from O
IFN B
- I
stimulated I
response I
elements I
( I
ISREs I
) I
and O
IFN O
- O
beta O
promoters O
( O
> O
90 O
% O
) O
but O
not O
transcription O
directed O
by O
constitutively O
active O
IFN O
regulatory O
factor O
- O
3 O
( O
IRF3 O
) O
. O

Analysis O
of O
Gn O
- O
T O
truncations O
demonstrated O
that O
the O
C O
- O
terminal O
42 O
residues O
of O
the O
Gn O
- O
T O
( O
Gn O
- O
T O
- O
C42 O
) O
from O
TULV O
, O
but O
not O
PHV O
, O
inhibited O
IFN O
induction O
> O
70 O
% O
. O

In O
contrast O
to O
pathogenic O
hantavirus O
Gn O
- O
Ts O
, O
the O
TULV O
Gn O
- O
T O
lacks O
a O
C O
- O
terminal O
degron O
domain O
and O
failed O
to O
bind O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
- I
associated I
factor I
3 I
( I
TRAF3 I
) I
, O
a O
TBK1 O
complex O
component O
required O
for O
IRF3 O
activation O
. O

Andes B
virus I
( I
ANDV I
) I
causes O
a O
highly O
lethal O
acute O
pulmonary O
edema O
termed O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

ANDV O
infection O
enhances O
the O
permeability O
of O
endothelial O
cells O
in O
response O
to O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
by O
increasing O
signaling O
responses O
directed O
by O
the O
VEGFR2 O
- O
Src O
- O
VE O
- O
cadherin O
pathway O
, O
which O
directs O
adherens B
junction I
( I
AJ I
) I
disassembly O
. O

Here O
we O
demonstrate O
that O
inhibiting O
pathway O
- O
specific O
VEGFR2 O
and O
Src B
family I
kinases I
( I
SFKs I
) I
blocks O
ANDV O
- O
induced O
endothelial O
cell O
permeability O
. O

small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
Src O
within O
ANDV O
- O
infected O
endothelial O
cells O
resulted O
in O
an O
similar O
to O
70 O
% O
decrease O
in O
endothelial O
cell O
permeability O
compared O
to O
that O
for O
siRNA O
controls O
. O

Consistent O
with O
their O
kinase O
- O
inhibitory O
concentrations O
, O
dasatinib O
, O
PP1 O
, O
and O
pazopanib O
inhibited O
ANDV O
- O
induced O
permeability O
at O
1 O
, O
10 O
, O
and O
100 O
nanomolar O
50 B
% I
inhibitory I
concentrations I
( I
IC I
( I
50 I
) I
s I
) I
, O
respectively O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
and O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
are O
severe O
diseases O
associated O
with O
hantavirus O
infection O
. O

VE O
- O
cadherin O
is O
a O
major O
component O
of O
adherens O
junctions O
, O
and O
its O
interaction O
with O
the O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
receptor O
, O
VEGF O
- O
R2 O
, O
is O
important O
for O
maintaining O
the O
integrity O
of O
the O
endothelial O
barrier O
. O

Evasion O
of O
interferon B
( I
IFN I
) I
- O
mediated O
antiviral O
signaling O
is O
a O
common O
defense O
strategy O
for O
pathogenic O
RNA O
viruses O
. O

The O
host O
IFN O
response O
has O
two O
phases O
, O
an O
initiation O
phase O
, O
resulting O
in O
the O
induction O
of O
alpha B
/ I
beta I
IFN I
( I
IFN I
- I
alpha I
/ I
beta I
) I
, O
and O
an O
amplification O
phase O
, O
whereby O
IFN O
- O
alpha O
/ O
beta O
signals O
through O
the O
Jak O
/ O
STAT O
pathway O
, O
resulting O
in O
the O
establishment O
of O
the O
cellular O
antiviral O
state O
. O

We O
observed O
delayed O
cellular O
responses O
in O
both O
Andes B
virus I
( I
ANDV I
) I
- O
and O
Sin B
Nombre I
virus I
( I
SNV I
) I
- O
infected O
A549 O
and O
Huh7 O
- O
TLR3 O
cells O
. O

We O
found O
that O
IFN O
- O
beta O
induction O
is O
inhibited O
by O
coexpression O
of O
ANDV O
nucleocapsid B
protein I
( I
NP I
) I
and O
glycoprotein B
precursor I
( I
GPC I
) I
and O
is O
robustly O
inhibited O
by O
SNV O
GPC O
alone O
. O

Hantaviruses O
infect O
human B
endothelial I
cells I
( I
ECs I
) I
and O
cause O
two O
diseases O
marked O
by O
vascular O
permeability O
defects O
, O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
and O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

ECs O
infected O
by O
pathogenic O
hantaviruses O
are O
hyperresponsive O
to O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
, O
and O
this O
alters O
the O
fluid O
barrier O
function O
of O
EC O
adherens O
junctions O
, O
resulting O
in O
enhanced O
paracellular O
permeability O
. O

Vascular O
permeability O
and O
VEGF O
- O
directed O
responses O
are O
determined O
by O
EC O
- O
specific O
microRNAs B
( I
miRNAs I
) I
, O
which O
regulate O
cellular O
mRNA O
transcriptional O
responses O
. O

miRNAs O
mature O
within O
cytoplasmic O
processing B
bodies I
( I
P I
bodies I
) I
, O
and O
the O
hantavirus O
nucleocapsid B
( I
N I
) I
protein O
binds O
RNA O
and O
localizes O
to O
P O
bodies O
, O
suggesting O
that O
hantaviruses O
may O
modify O
miRNA O
functions O
within O
infected O
ECs O
. O

Here O
we O
assessed O
changes O
in O
EC O
miRNAs O
following O
infection O
by O
the O
HPS O
- O
causing O
Andes B
hantavirus I
( I
ANDV I
) I
. O

We O
analyzed O
352 O
human O
miRNAs O
within O
ANDV O
- O
infected O
ECs O
using O
quantitative O
real O
- O
time O
( O
RT O
) O
- O
PCR O
arrays O
. O

While O
miR O
- O
126 O
levels O
were O
only O
slightly O
altered O
, O
we O
found O
that O
SPRED1 O
and O
PIK3R2 O
mRNA O
levels O
were O
increased O
10 O
- O
and O
7 O
- O
fold O
, O
respectively O
, O
in O
ANDV O
- O
infected O
ECs O
but O
were O
unaltered O
in O
ECs O
infected O
by O
the O
nonpathogenic O
Tula B
hantavirus I
( I
TULV I
) I
. O

Moreover O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
SPRED1 O
dramatically O
decreased O
the O
permeability O
of O
ANDV O
- O
infected O
ECs O
in O
response O
to O
VEGF O
, O
suggesting O
that O
increased O
SPRED1 O
contributes O
to O
EC O
permeability O
following O
ANDV O
infection O
. O

Pathogenic O
hantaviruses O
enhance O
the O
permeability O
of O
endothelial O
cells O
in O
response O
to O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
. O

The O
paracellular O
permeability O
of O
endothelial O
cells O
is O
uniquely O
determined O
by O
the O
homophilic O
assembly O
of O
vascular B
endothelial I
cadherin I
( I
VE I
- I
cadherin I
) I
within O
adherens O
junctions O
, O
which O
is O
regulated O
by O
VEGF B
receptor I
- I
2 I
( I
VEGFR2 I
) I
responses O
. O

Here O
, O
we O
investigated O
VEGFR2 O
phosphorylation O
and O
the O
internalization O
of O
VE O
- O
cadherin O
within O
endothelial O
cells O
infected O
by O
pathogenic O
Andes B
virus I
( I
ANDV I
) I
and O
Hantaan B
virus I
( I
HTNV I
) I
and O
nonpathogenic O
Tula B
virus I
( I
TULV I
) I
hantaviruses O
. O

Addition O
of O
angiopoietin B
- I
1 I
( I
Ang I
- I
1 I
) I
or O
sphingosine B
- I
1 I
- I
phosphate I
( I
S1P I
) I
to O
ANDV O
- O
or O
HTNV O
- O
infected O
cells O
blocked O
VE O
- O
cadherin O
internalization O
in O
response O
to O
VEGF O
. O

The O
role O
of O
beta O
( O
3 O
) O
integrins O
in O
hemostasis O
and O
the O
inactivation O
of O
beta O
( O
3 O
) O
integrin O
receptors O
by O
pathogenic O
hantaviruses O
suggest O
the O
involvement O
of O
hantaviruses O
in O
altered O
platelet O
and O
endothelial O
cell O
functions O
that O
regulate O
permeability O
. O

Here O
, O
we O
determined O
that O
pathogenic O
hantaviruses O
bind O
to O
quiescent O
platelets O
via O
a O
beta O
( O
3 O
) O
integrin O
- O
dependent O
mechanism O
. O

This O
suggests O
that O
platelets O
may O
contribute O
to O
hantavirus O
dissemination O
within O
infected O
patients O
and O
provides O
a O
means O
by O
which O
hantavirus O
binding O
to O
beta O
( O
3 O
) O
integrin O
receptors O
prevents O
platelet O
activation O
. O

Our O
findings O
indicate O
that O
Andes B
virus I
( I
ANDV I
) I
- O
or O
Hantaan B
virus I
( I
HTNV I
) I
- O
infected O
endothelial O
cells O
specifically O
direct O
the O
adherence O
of O
calcein O
- O
labeled O
platelets O
. O

In O
contrast O
, O
cells O
comparably O
infected O
with O
nonpathogenic O
Tula B
virus I
( I
TULV I
) I
failed O
to O
recruit O
platelets O
to O
the O
endothelial O
cell O
surface O
. O

Platelet O
adherence O
was O
dependent O
on O
endothelial O
cell O
beta O
( O
3 O
) O
integrins O
and O
neutralized O
by O
the O
addition O
of O
the O
anti O
- O
beta O
( O
3 O
) O
Fab O
fragment O
, O
c7E3 O
, O
or O
specific O
ANDV O
- O
or O
HTNV O
- O
neutralizing O
antibodies O
. O

Andes B
virus I
( I
ANDV I
) I
causes O
a O
fatal O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
in O
humans O
and O
Syrian O
hamsters O
. O

Human O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
are O
receptors O
for O
several O
pathogenic O
hantaviruses O
, O
and O
the O
function O
of O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
on O
endothelial O
cells O
suggests O
a O
role O
for O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
in O
hantavirus O
directed O
vascular O
permeability O
. O

We O
determined O
here O
that O
ANDV O
infection O
of O
human O
endothelial O
cells O
or O
Syrian O
hamster O
- O
derived O
BHK O
- O
21 O
cells O
was O
selectively O
inhibited O
by O
the O
high O
- O
affinity O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrin O
ligand O
vitronectin O
and O
by O
antibodies O
to O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
. O

Further O
, O
antibodies O
to O
the O
beta O
( O
3 O
) O
integrin O
PSI O
domain O
, O
as O
well O
as O
PSI O
domain O
polypeptides O
derived O
from O
human O
and O
Syrian O
hamster O
beta O
( O
3 O
) O
subunits O
, O
but O
not O
murine O
or O
bovine O
beta O
( O
3 O
) O
, O
inhibited O
ANDV O
infection O
of O
both O
BHK O
- O
21 O
and O
human O
endothelial O
cells O
. O

These O
findings O
suggest O
that O
ANDV O
interacts O
with O
beta O
( O
3 O
) O
subunits O
through O
PSI O
domain O
residues O
conserved O
in O
both O
Syrian O
hamster O
and O
human O
beta O
( O
3 O
) O
integrins O
. O

Sequencing O
the O
Syrian O
hamster O
beta O
( O
3 O
) O
integrin O
PSI O
domain O
revealed O
eight O
differences O
between O
Syrian O
hamster O
and O
human O
beta O
( O
3 O
) O
integrins O
. O

Analysis O
of O
residues O
within O
the O
PSI O
domains O
of O
human O
, O
Syrian O
hamster O
, O
murine O
, O
and O
bovine O
beta O
( O
3 O
) O
integrins O
identified O
unique O
proline O
substitutions O
at O
residues O
32 O
and O
33 O
of O
murine O
and O
bovine O
PSI O
domains O
that O
could O
determine O
ANDV O
recognition O
. O

Mutagenizing O
the O
human O
beta O
( O
3 O
) O
PSI O
domain O
to O
contain O
the O
L33P O
substitution O
present O
in O
bovine O
beta O
( O
3 O
) O
integrin O
abolished O
the O
ability O
of O
the O
PSI O
domain O
to O
inhibit O
ANDV O
infectivity O
. O

Conversely O
, O
mutagenizing O
either O
the O
bovine O
PSI O
domain O
, O
P33L O
, O
or O
the O
murine O
PSI O
domain O
, O
S32P O
, O
to O
the O
residue O
present O
human O
beta O
( O
3 O
) O
permitted O
PSI O
mutants O
to O
inhibit O
ANDV O
infection O
. O

Similarly O
, O
CHO O
cells O
transfected O
with O
the O
full O
- O
length O
bovine O
beta O
( O
3 O
) O
integrin O
containing O
the O
P33L O
mutation O
permitted O
infection O
by O
ANDV O
. O

These O
findings O
indicate O
that O
human O
and O
Syrian O
hamster O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
are O
key O
receptors O
for O
ANDV O
and O
that O
specific O
residues O
within O
the O
beta O
( O
3 O
) O
integrin O
PSI O
domain O
are O
required O
for O
ANDV O
infection O
. O

Since O
L33P O
is O
a O
naturally O
occurring O
human O
beta O
( O
3 O
) O
polymorphism O
, O
these O
findings O
further O
suggest O
the O
importance O
of O
specific O
beta O
( O
3 O
) O
integrin O
residues O
in O
hantavirus O
infection O
. O

These O
findings O
rationalize O
determining O
the O
role O
of O
beta O
( O
3 O
) O
integrins O
in O
hantavirus O
pathogenesis O
in O
the O
Syrian O
hamster O
model O
. O

To O
examine O
the O
host O
association O
of O
Tula B
virus I
( I
TULV I
) I
, O
a O
hantavirus O
present O
in O
large O
parts O
of O
Europe O
, O
we O
investigated O
a O
total O
of O
791 O
rodents O
representing O
469 O
Microtus O
arvalis O
and O
322 O
Microtus O
agrestis O
animals O
from O
northeast O
, O
northwest O
, O
and O
southeast O
Germany O
, O
including O
geographical O
regions O
with O
sympatric O
occurrence O
of O
both O
vole O
species O
, O
for O
the O
presence O
of O
TULV O
infections O
. O

Based O
on O
serological O
investigation O
, O
reverse O
transcriptase O
PCR O
, O
and O
subsequent O
sequence O
analysis O
of O
partial O
small B
( I
S I
) I
and O
medium B
( I
M I
) I
segments O
, O
we O
herein O
show O
that O
TULV O
is O
carried O
not O
only O
by O
its O
commonly O
known O
host O
M O
. O

Specific O
therapy O
is O
not O
available O
for O
hantavirus O
cardiopulmonary O
syndrome O
caused O
by O
Andes B
virus I
( I
ANDV I
) I
. O

Nonreplicating O
adenovirus B
( I
Ad I
) I
vectors O
that O
express O
Andes B
hantavirus I
( I
ANDV I
) I
nucleocapsid O
protein O
( O
AdN O
) O
or O
glycoproteins O
( O
AdG O
( O
N O
) O
and O
AdG O
( O
C O
) O
) O
were O
constructed O
. O

Further O
, O
hantavirus O
RNA O
was O
not O
detected O
by O
sensitive O
reverse O
transcription O
- O
PCR O
in O
tissues O
and O
blood O
of O
hamsters O
immunized O
with O
both O
AdG O
( O
N O
) O
and O
AdG O
( O
C O
) O
. O

Moreover O
, O
hamsters O
vaccinated O
with O
AdN O
, O
AdG O
( O
N O
) O
, O
or O
AdG O
( O
C O
) O
produced O
no O
detectable O
neutralizing O
antibodies O
yet O
were O
protected O
. O

These O
Ad O
vectors O
represent O
the O
first O
vaccines O
that O
prevent O
lethal O
hantavirus O
disease O
and O
, O
in O
some O
instances O
( O
AdG O
( O
N O
) O
and O
AdG O
( O
C O
) O
) O
, O
provide O
sterile O
immunity O
. O

hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
is O
a O
highly O
pathogenic O
emerging O
disease O
( O
40 O
% O
case O
fatality O
rate O
) O
caused O
by O
New O
World O
hantaviruses O
. O

In O
this O
study O
, O
we O
show O
that O
Andes B
virus I
( I
ANDV I
) I
interacts O
with O
human O
apolipoprotein B
H I
( I
ApoH I
) I
and O
that O
ApoH O
- O
coated O
magnetic O
beads O
or O
ApoH O
- O
coated O
enzyme O
- O
linked O
immunosorbent O
assay O
plates O
can O
be O
used O
to O
capture O
and O
concentrate O
the O
virus O
from O
complex O
biological O
mixtures O
, O
such O
as O
serum O
and O
urine O
, O
allowing O
it O
to O
be O
detected O
by O
both O
immunological O
and O
molecular O
approaches O
. O

Andes B
virus I
( I
ANDV I
) I
is O
the O
predominant O
etiologic O
agent O
of O
hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
in O
southern O
South O
America O
. O

In O
Chile O
, O
serologically O
confirmed O
human O
hantavirus O
infections O
have O
occurred O
throughout O
a O
wide O
latitudinal O
distribution O
extending O
from O
the O
regions O
of O
Valparaiso O
( O
32 O
to O
33 O
S O
) O
to O
Aysen O
( O
46 O
S O
) O
in O
southern O
Patagonia O
. O

In O
this O
study O
, O
we O
found O
seropositive O
rodents O
further O
north O
in O
the O
Coquimbo O
region O
( O
30 O
S O
) O
in O
Chile O
. O

We O
sequenced O
partial O
ANDV O
small B
( I
S I
) I
segment O
RNA O
from O
6 O
HCPS O
patients O
and O
32 O
rodents O
of O
four O
different O
species O
collected O
throughout O
the O
known O
range O
of O
hantavirus O
infection O
in O
Chile O
. O

Phylogenetic O
analyses O
showed O
two O
major O
ANDV O
South O
( O
ANDV O
Sout O
) O
clades O
, O
congruent O
with O
two O
major O
Chilean O
ecoregions O
, O
Mediterranean O
( O
Chilean O
matorral O
[ O
shrubland O
] O
) O
and O
Valdivian O
temperate O
forest O
. O

Phylogenetic O
comparative O
analyses O
of O
portions O
of O
S O
and O
medium O
segments O
( O
encoding O
glycoproteins O
Gn O
and O
Gc O
) O
from O
a O
subset O
of O
rodent O
specimens O
exhibited O
similar O
topologies O
, O
corroborating O
two O
major O
ANDV O
Sout O
clades O
in O
Chile O
and O
suggesting O
that O
yet O
unknown O
factors O
influence O
viral O
gene O
flow O
and O
persistence O
throughout O
the O
two O
Chilean O
ecoregions O
. O

Hantaviruses O
such O
as O
Hantaan B
virus I
( I
HTNV I
) I
and O
Andes O
virus O
cause O
two O
human O
diseases O
, O
hemorrhagic O
fever O
with O
renal O
syndrome O
and O
hantavirus O
pulmonary O
syndrome O
, O
respectively O
. O

For O
both O
, O
disease O
pathogenesis O
is O
thought O
to O
be O
immunologically O
mediated O
and O
there O
have O
been O
numerous O
reports O
of O
patients O
with O
elevated O
levels O
of O
proinflammatory O
and O
inflammatory O
cytokines O
, O
including O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
in O
their O
sera O
. O

Multiple O
viruses O
have O
developed O
evasion O
strategies O
to O
circumvent O
the O
host O
cell O
inflammatory O
process O
, O
with O
one O
of O
the O
most O
prevalent O
being O
the O
disruption O
of O
nuclear B
factor I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
activation O
. O

We O
report O
here O
that O
the O
nucleocapsid B
( I
N I
) I
protein O
of O
HTNV O
was O
able O
to O
inhibit O
TNF O
- O
alpha O
- O
induced O
activation O
of O
NF O
- O
kappa O
B O
, O
as O
measured O
by O
a O
reporter O
assay O
, O
and O
the O
activation O
of O
endogenous O
p65 O
, O
an O
NF O
- O
kappa O
B O
subunit O
. O

Surprisingly O
, O
there O
was O
no O
defect O
in O
the O
degradation O
of O
the O
inhibitor O
of O
NF O
- O
kappa O
B O
( O
I O
kappa O
B O
) O
protein O
, O
nor O
was O
there O
any O
alteration O
in O
the O
level O
of O
p65 O
expression O
in O
HTNV O
N O
- O
expressing O
cells O
. O

In O
order O
to O
replicate O
in O
endothelial O
cells O
pathogenic O
hantaviruses O
inhibit O
the O
early O
induction O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
. O

Here O
we O
report O
that O
the O
NY B
- I
1 I
virus I
( I
NY I
- I
1V I
) I
Gn O
tail O
inhibits O
both O
TBK1 O
- O
directed O
NF O
- O
kappa O
B O
activation O
and O
TBK1 O
- O
directed O
transcription O
from O
promoters O
containing O
IFN O
- O
stimulated O
response O
elements O
. O

In O
contrast O
, O
the O
Gn O
tail O
of O
the O
nonpathogenic O
hantavirus O
Prospect B
Hill I
virus I
( I
PHV I
) I
failed O
to O
coprecipitate O
TRAF3 O
or O
inhibit O
NF O
- O
kappa O
B O
or O
IFN O
- O
beta O
transcriptional O
responses O
. O

However O
, O
pathogenic O
hantaviruses O
inhibit O
the O
function O
of O
alpha O
v O
beta O
3 O
integrins O
on O
endothelial O
cells O
, O
and O
hemorrhagic O
disease O
and O
vascular O
permeability O
deficits O
are O
consequences O
of O
dysfunctional O
beta O
3 O
integrins O
that O
normally O
regulate O
permeabilizing O
vascular B
endothelial I
growth I
factor I
( I
VEGF I
) I
responses O
. O

Pathogenic O
hantaviruses O
directed O
endothelial O
cell O
permeability O
2 O
to O
3 O
days O
postinfection O
, O
coincident O
with O
pathogenic O
hantavirus O
inhibition O
of O
alpha O
v O
beta O
3 O
integrin O
functions O
, O
and O
hantavirus O
- O
directed O
permeability O
was O
inhibited O
by O
antibodies O
to O
VEGF B
receptor I
2 I
( I
VEGFR2 I
) I
. O

Using O
the O
hantavirus O
permeability O
assay O
we O
further O
demonstrate O
that O
the O
endothelial O
- O
cell O
- O
specific O
growth O
factor O
angiopoietin B
1 I
( I
Ang I
- I
1 I
) I
and O
the O
platelet O
- O
derived O
lipid O
mediator O
sphingosine B
1 I
- I
phosphate I
( I
S1P I
) I
inhibit O
hantavirus O
directed O
endothelial O
cell O
permeability O
at O
physiologic O
concentrations O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
a O
highly O
pathogenic O
disease O
( O
40 O
% O
case O
fatality O
rate O
) O
carried O
by O
rodents O
chronically O
infected O
with O
certain O
viruses O
within O
the O
genus O
Hantavirus O
of O
the O
family O
Bunyaviridae O
. O

Person O
- O
to O
- O
person O
transmission O
of O
HPS O
caused O
by O
one O
species O
of O
hantavirus O
, O
Andes B
virus I
( I
ANDV I
) I
, O
has O
been O
reported O
. O

Remarkably O
, O
even O
at O
very O
low O
doses O
, O
ANDV O
was O
highly O
pathogenic O
when O
it O
was O
introduced O
by O
the O
mucosal O
routes O
( O
50 O
% O
lethal O
dose O
[ O
LD50 O
] O
, O
similar O
to O
100 O
PFU O
) O
. O

Hamsters O
that O
were O
administered O
immune O
serum O
on O
days O
- O
1 O
and O
+ O
5 O
relative O
to O
challenge O
were O
protected O
against O
intranasal O
challenge O
( O
21 O
LD50 O
) O
. O

Pathogenic O
hantaviruses O
cause O
two O
human O
diseases O
: O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
and O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
. O

The O
hantavirus O
G1 O
protein O
contains O
a O
long O
, O
142 O
- O
amino O
- O
acid O
cytoplasmic O
tail O
, O
which O
in O
NY B
- I
1 I
virus I
( I
NY I
- I
1V I
) I
is O
ubiquitinated O
and O
proteasomally O
degraded O
( O
E O
. O

Here O
we O
report O
that O
the O
G1 O
cytoplasmic O
tails O
of O
pathogenic O
Andes O
( O
HPS O
) O
and O
Hantaan O
( O
HFRS O
) O
viruses O
are O
also O
degraded O
by O
the O
proteasome O
and O
that O
, O
in O
contrast O
, O
the O
G1 O
tail O
of O
nonpathogenic O
Prospect B
Hill I
virus I
( I
PHV I
) I
is O
stable O
and O
not O
proteasomally O
degraded O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
a O
severe O
respiratory O
disease O
which O
is O
thought O
to O
result O
from O
a O
dysregulated O
immune O
response O
to O
infection O
with O
pathogenic O
hantaviruses O
, O
such O
as O
Sin O
Nombre O
virus O
or O
Andes B
virus I
( I
ANDV I
) I
. O

Other O
New O
World O
hantaviruses O
, O
such O
as O
Prospect B
Hill I
virus I
( I
PHV I
) I
, O
have O
not O
been O
associated O
with O
human O
disease O
. O

PHV O
, O
but O
not O
ANDV O
, O
was O
found O
to O
induce O
a O
robust O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
response O
early O
after O
infection O
of O
primary O
lung O
endothelial O
cells O
. O

The O
level O
of O
IFN O
induction O
correlated O
with O
IFN B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
activation O
, O
in O
that O
IRF O
- O
3 O
dimerization O
and O
nuclear O
translocation O
were O
detected O
in O
PHV O
but O
not O
ANDV O
infection O
. O

Some O
individuals O
infected O
with O
dengue O
virus O
develop O
dengue B
hemorrhagic I
fever I
( I
DHF I
) I
, O
a O
viral O
hemorrhagic O
disease O
characterized O
by O
a O
transient O
period O
of O
localized O
plasma O
leakage O
. O

To O
determine O
the O
importance O
of O
vascular O
endothelial O
growth O
factor O
A O
( O
VEGF O
- O
A O
) O
in O
this O
syndrome O
, O
we O
compared O
plasma O
levels O
of O
VEGF O
- O
A O
and O
the O
soluble O
forms O
of O
its O
receptors O
in O
patients O
with O
DHF O
to O
patients O
with O
dengue B
fever I
( I
DF I
) I
, O
a O
milder O
form O
of O
dengue O
virus O
infection O
without O
plasma O
leakage O
. O

This O
was O
associated O
with O
a O
decline O
in O
the O
soluble O
form O
of O
VEGF B
receptor I
2 I
( I
VEGFR2 I
) I
and O
VEGF O
- O
soluble O
VEGFR2 O
complexes O
, O
but O
not O
the O
soluble O
form O
of O
VEGFR1 O
. O

In O
contrast O
to O
pathogenic O
NY B
- I
1 I
virus I
( I
NY I
- I
1V I
) I
and O
Hantaan B
virus I
( I
HTNV I
) I
, O
nonpathogenic O
Prospect B
Hill I
virus I
( I
PHV I
) I
elicits O
early O
interferon O
responses O
following O
infection O
of O
human O
endothelial O
cells O
. O

The O
addition O
of O
antibodies O
to O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
blocked O
interferon O
- O
directed O
MxA O
induction O
by O
> O
90 O
% O
and O
demonstrated O
that O
hantavirus O
infection O
induces O
the O
secretion O
of O
IFN O
- O
beta O
from O
endothelial O
cells O
. O

Further O
, O
neither O
the O
NY O
- O
1V O
nor O
PHV O
GI O
tails O
inhibited O
transcriptional O
responses O
directed O
by O
a O
constitutively O
active O
form O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
5D I
) I
, O
and O
IRF O
- O
3 O
is O
a O
direct O
target O
of O
TBK O
- O
1 O
phosphorylation O
. O

Pathogenic O
hantaviruses O
are O
not O
cytotoxic O
, O
but O
elevated O
levels O
of O
serum O
lactate B
dehydrogenase I
( I
LDH I
) I
, O
indicative O
of O
cellular O
damage O
, O
are O
observed O
in O
patients O
. O

Transgenic O
mice O
expressing O
a O
recombinant B
human I
monoclonal I
antibody I
( I
rHMAb I
) I
against O
hantavirus O
were O
generated O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
an O
acute O
disease O
resulting O
from O
infection O
with O
any O
one O
of O
a O
number O
of O
New O
World O
hantaviruses O
. O

Maladaptive O
immune O
responses O
are O
considered O
to O
be O
important O
factors O
in O
the O
pathogenesis O
of O
the O
two O
diseases O
caused O
by O
hantaviruses O
, O
hemorrhagic O
fever O
with O
renal O
syndrome O
and O
hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
. O

To O
investigate O
early O
events O
in O
the O
innate O
response O
to O
Sin B
Nombre I
virus I
( I
SNV I
) I
, O
the O
principal O
etiologic O
agent O
of O
HCPS O
in O
North O
America O
, O
we O
treated O
human O
endothelial O
cells O
with O
live O
virus O
, O
or O
virus O
subjected O
to O
inactivation O
by O
UV O
irradiation O
at O
minimal O
doses O
required O
to O
inhibit O
replication O
, O
and O
assayed O
host O
expression O
of O
interferon B
- I
stimulated I
genes I
( I
ISG I
) I
by O
microarray O
and O
reverse O
transcription O
- O
PCR O
. O

The O
levels O
of O
such O
induction O
at O
early O
time O
points O
( O
before O
24 O
h O
) O
were O
generally O
higher O
in O
cells O
treated O
with O
SNV O
particles O
that O
had O
been O
killed O
by O
exposure O
to O
UV O
irradiation O
. O

Lassa B
virus I
( I
LASV I
) I
and O
Mopeia B
virus I
( I
MOPV I
) I
are O
closely O
related O
Old O
World O
arenaviruses O
that O
can O
exchange O
genomic O
segments O
( O
reassort O
) O
during O
coinfection O
. O

Clone O
ML29 O
, O
selected O
from O
a O
library O
of O
MOPV O
/ O
LASV O
( O
MOP O
/ O
LAS O
) O
reassortants O
, O
encodes O
the O
major O
antigens O
( O
nucleocapsid O
and O
glycoprotein O
) O
of O
LASV O
and O
the O
RNA O
polymerase O
and O
zinc O
- O
binding O
protein O
of O
MOPV O
. O

The O
nucleocapsid B
( I
N I
) I
protein O
is O
the O
- O
principal O
structural O
component O
of O
the O
viral O
capsid O
. O

We O
used O
trimeric O
glutathione B
S I
- I
transferase I
( I
GST I
) I
- O
N O
protein O
and O
small O
RNA O
panhandles O
to O
examine O
the O
requirements O
for O
specific O
recognition O
by O
Sin O
Nombre O
hantavirus O
N O
. O

Trimeric O
GST O
- O
N O
recognizes O
the O
panhandles O
of O
the O
three O
viral O
RNAs O
( O
S O
, O
M O
, O
and O
L O
) O
with O
high O
affinity O
, O
whereas O
the O
corresponding O
plus O
- O
strand O
panhandles O
of O
the O
complementary O
RNA O
are O
recognized O
with O
lower O
affinity O
. O

Immunohistochemistry O
, O
using O
antibodies O
against O
Andes O
( O
AND O
) O
hantavirus O
proteins O
, O
revealed O
strong O
reactions O
in O
the O
lung O
and O
salivary O
glands O
, O
supporting O
the O
possibility O
of O
oral O
transmission O
. O

Hantaviruses O
represent O
important O
human O
pathogens O
and O
can O
induce O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
, O
which O
is O
characterized O
by O
endothelial O
dysfunction O
. O

We O
compared O
the O
antiviral O
responses O
triggered O
by O
Hantaan B
virus I
( I
HTNV I
) I
, O
a O
pathogenic O
hantavirus O
associated O
with O
HFRS O
, O
and O
Tula B
virus I
( I
TULV I
) I
, O
a O
rather O
nonpathogenic O
hantavirus O
, O
in O
human B
umbilical I
vein I
endothelial I
cells I
( I
HUVECs I
) I
. O

Interestingly O
, O
HTNV O
clearly O
induced O
the O
production O
of O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
, O
whereas O
expression O
of O
this O
cytokine O
was O
barely O
detectable O
in O
the O
supernatant O
or O
in O
extracts O
from O
TULV O
- O
infected O
HUVECs O
. O

Hantavirus O
pulmonary O
syndrome O
- O
associated O
hantaviruses O
contain O
conserved O
tyrosine O
residues O
near O
the O
C O
terminus O
of O
G1 O
which O
form O
an O
immunoreceptor B
tyrosine I
activation I
motif I
( I
ITAM I
) I
and O
interact O
with O
Src O
and O
Syk O
family O
kinases O
. O

Site O
- O
directed O
mutagenesis O
of O
both O
ITAM O
tyrosines O
( O
Y619 O
and O
Y632 O
) O
to O
phenylalanine O
also O
blocked O
polyubiquitination O
of O
G1 O
proteins O
and O
dramatically O
enhanced O
G1 O
protein O
stability O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
a O
rapidly O
progressing O
human O
disease O
with O
one O
of O
the O
highest O
case O
fatality O
rates O
( O
30 O
to O
50 O
% O
) O
of O
any O
acute O
viral O
disease O
known O
. O

In O
an O
attempt O
to O
develop O
HPS O
medical O
countermeasures O
, O
we O
constructed O
an O
expression O
plasmid O
, O
pWRG O
/ O
AND O
- O
M O
, O
that O
contains O
the O
full O
- O
length O
M O
genome O
segment O
of O
Andes B
virus I
( I
ANDV I
) I
, O
a O
South O
American O
hantavirus O
. O

Infection O
of O
adult O
C57BL O
/ O
6 O
( O
B6 O
) O
mice O
with O
mouse B
adenovirus I
type I
1 I
( I
MAV I
- I
1 I
) I
results O
in O
dose O
- O
dependent O
encephalomyelitis O
. O

T O
cells O
, O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
, O
and O
perforin O
contributed O
to O
acute O
disease O
signs O
at O
8 O
days O
postinfection O
( O
p O
. O

MAV O
- O
1 O
was O
cleared O
in O
mice O
lacking O
perforin O
, O
MHC O
class O
I O
or O
II O
, O
CD4 O
( O
+ O
) O
T O
cells O
, O
or O
CD8 O
( O
+ O
) O
T O
cells O
. O

Our O
results O
are O
consistent O
with O
a O
model O
in O
which O
either O
CD8 O
( O
+ O
) O
or O
CD4 O
( O
+ O
) O
T O
cells O
are O
sufficient O
for O
clearance O
of O
MAV O
- O
1 O
. O

Hantaviruses O
infect O
human O
endothelial O
and O
immune O
cells O
, O
causing O
two O
human O
diseases O
, O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
and O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

We O
have O
identified O
key O
signaling O
elements O
termed O
immunoreceptor B
tyrosine I
- I
based I
activation I
motifs I
( I
ITAMs I
) I
within O
the O
G1 O
cytoplasmic O
tail O
of O
all O
HPS O
- O
causing O
hantaviruses O
. O

hantavirus B
cardiopulmonary I
syndrome I
( I
HCPS I
) I
is O
a O
life O
- O
threatening O
respiratory O
disease O
characterized O
by O
profound O
pulmonary O
edema O
and O
myocardial O
depression O
. O

Most O
cases O
of O
HCPS O
in O
North O
America O
are O
caused O
by O
Sin B
Nombre I
virus I
( I
SNV I
) I
, O
which O
is O
carried O
asymptomatically O
by O
deer O
mice O
( O
Peromyscus O
maniculatus O
) O
. O

We O
hypothesized O
that O
pathogenic O
SNV O
infection O
results O
in O
increased O
generation O
of O
reactive B
oxygen I
/ I
nitrogen I
species I
( I
RONS I
) I
, O
which O
contribute O
to O
the O
morbidity O
and O
mortality O
of O
HCPS O
. O

Human O
disease O
following O
infection O
with O
SNV O
or O
Andes O
virus O
was O
associated O
with O
increased O
nitrotyrosine B
( I
NT I
) I
adduct O
formation O
in O
the O
lungs O
, O
heart O
, O
and O
plasma O
and O
increased O
expression O
of O
inducible B
nitric I
oxide I
synthase I
( I
iNOS I
) I
in O
the O
lungs O
compared O
to O
the O
results O
obtained O
for O
normal O
human O
volunteers O
. O

In O
a O
murine O
( O
Mus O
musculus O
) O
model O
of O
HCPS O
( O
infection O
of O
NZB O
/ O
BLNJ O
mice O
with O
lymphocytic O
choriomeningitis O
virus O
clone O
13 O
) O
, O
HCPS O
- O
like O
disease O
was O
associated O
with O
elevated O
expression O
of O
iNOS O
in O
the O
lungs O
and O
NT O
formation O
in O
plasma O
, O
cardiac O
tissue O
, O
and O
the O
lungs O
. O

The O
Nucleocapsid B
protein I
( I
N I
) I
is O
relatively O
conserved O
among O
hantaviruses O
and O
highly O
immunogenic O
in O
both O
laboratory O
animals O
and O
humans O
, O
and O
it O
has O
been O
shown O
to O
induce O
efficient O
protective O
immunity O
in O
animal O
models O
. O

To O
investigate O
the O
ability O
of O
recombinant O
N O
( O
rN O
) O
from O
different O
hantaviruses O
to O
elicit O
cross O
- O
protection O
, O
we O
immunized O
bank O
voles O
with O
rN O
from O
Puumala B
( I
PUUV I
) I
, O
Topografov B
( I
TOPV I
) I
, O
Andes B
( I
ANDV I
) I
, O
and O
Dobrava B
( I
DOBV I
) I
viruses O
and O
subsequently O
challenged O
them O
with O
PUUV O
. O

These O
are O
made O
of O
( O
i O
) O
Lechiguanas O
- O
like O
virus O
genotypes O
, O
( O
ii O
) O
Maciel O
virus O
and O
Pergamino O
virus O
genotypes O
, O
and O
( O
iii O
) O
strains O
of O
the O
Andes O
virus O
. O

Four O
hantaviruses O
- O
Hantaan B
virus I
( I
HTNV I
) I
, O
Seoul B
virus I
( I
SEOV I
) I
, O
Dobrava B
virus I
( I
DOBV I
) I
and O
Puumala O
virus O
- O
are O
known O
to O
cause O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
in O
Europe O
and O
Asia O
. O

HTN O
- O
V O
causes O
the O
most O
severe O
form O
of O
HFRS O
( O
5 O
to O
15 O
% O
case O
- O
fatality O
rate O
) O
and O
afflicts O
tens O
of O
thousands O
of O
people O
annually O
. O

Sin B
Nombre I
virus I
( I
SNV I
) I
and O
Hantaan B
virus I
( I
HTN I
) I
infect O
endothelial O
cells O
and O
are O
associated O
with O
different O
patterns O
of O
increased O
vascular O
permeability O
during O
human O
disease O
. O

In O
this O
study O
, O
the O
ability O
of O
hantavirus O
to O
directly O
induce O
activation O
of O
human B
lung I
microvascular I
endothelial I
cells I
( I
HMVEC I
- I
Ls I
) I
was O
examined O
. O

No O
virus O
- O
specific O
modulation O
in O
the O
constitutive O
or O
cytokine O
- O
induced O
expression O
of O
cellular O
adhesion O
molecules O
( O
CD40 O
, O
CD54 O
, O
CD61 O
, O
CD62E O
, O
CD62P O
, O
CD106 O
, O
and O
major O
histocompatibility O
complex O
classes O
I O
and O
II O
) O
or O
in O
cytokines O
and O
chemokines O
( O
eotaxin O
, O
tumor O
necrosis O
factor O
alpha O
, O
interleukin O
Ip O
[ O
IL O
- O
1 O
beta O
] O
, O
IL O
- O
6 O
, O
IL O
- O
8 O
, O
MCP O
- O
1 O
, O
MIP O
- O
1 O
alpha O
, O
and O
MIP O
- O
1 O
beta O
) O
was O
detected O
at O
either O
the O
protein O
or O
message O
level O
in O
hantavirus O
- O
infected O
HMVEC O
- O
Ls O
. O

Furthermore O
, O
no O
virus O
- O
specific O
enhancement O
of O
paracellular O
or O
transcellular O
permeability O
or O
changes O
in O
the O
organization O
and O
distribution O
of O
endothelial O
intercellular O
junctional O
proteins O
was O
observed O
, O
However O
, O
infection O
with O
either O
HTN O
or O
SNV O
resulted O
in O
detectable O
levels O
of O
the O
chemokines O
RANTES O
and O
IP O
- O
IO O
( O
the O
10 O
- O
kDa O
interferon O
- O
inducible O
protein O
) O
in O
HMVEC O
- O
Ls O
within O
72 O
h O
and O
was O
associated O
with O
nuclear O
translocation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF I
- I
3 I
) I
and O
IRF O
- O
7 O
, O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
- O
induced O
expression O
of O
RANTES O
and O
IP O
- O
10 O
could O
also O
be O
detected O
in O
uninfected O
HMVEC O
- O
Ls O
and O
was O
associated O
with O
nuclear O
translocation O
of O
IRF O
- O
1 O
and O
IRF O
- O
3 O
. O

Black B
Creek I
Canal I
virus I
( I
BCCV I
) I
is O
a O
New O
World O
hantavirus O
which O
is O
associated O
with O
hantavirus O
pulmonary O
syndrome O
. O

We O
have O
examined O
the O
site O
of O
expression O
of O
the O
BCCV O
nucleocapsid O
protein O
( O
NBCCV O
) O
in O
the O
absence O
of O
BCCV O
glycoproteins O
and O
found O
that O
the O
majority O
of O
the O
protein O
is O
localized O
to O
the O
Golgi O
region O
. O

Immunofluorescence O
analysis O
of O
BHK21 O
cells O
expressing O
the O
NBCCV B
and I
La I
Crosse I
virus I
nucleocapsid I
protein I
( I
NLACV I
) I
showed O
different O
intracellular O
localization O
patterns O
of O
these O
proteins O
within O
the O
same O
cell O
: O
NLACV O
is O
cytoplasmic O
, O
whereas O
NBCCV O
is O
perinuclear O
. O

The O
viral O
genomes O
consist O
of O
three O
RNA O
segments O
: O
the O
L O
segment O
encodes O
the O
viral O
polymerase O
, O
the O
M O
segment O
encodes O
the O
viral O
surface O
glycoproteins O
G1 O
and O
G2 O
, O
and O
the O
S O
segment O
encodes O
the O
nucleocapsid B
( I
N I
) I
protein O
. O

Previous O
data O
indicate O
that O
immune O
mechanisms O
may O
be O
involved O
in O
developing O
capillary O
leakage O
during O
Sin B
Nombre I
virus I
( I
SNV I
) I
infection O
. O

Therefore O
, O
we O
investigated O
production O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
by O
human O
alveolar O
macrophages O
and O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVEC O
) O
after O
infection O
with O
SNV O
. O

Two O
Hantaan O
virus O
strains O
, O
clone O
1 O
( O
cl O
- O
1 O
) O
, O
which O
is O
virulent O
in O
newborn O
mice O
, O
and O
its O
attenuated O
mutant O
( O
mul1E10 O
) O
, O
were O
used O
to O
examine O
the O
pathogenesis O
of O
Hantaan O
virus O
infection O
in O
a O
mouse O
model O
and O
identify O
virus O
factors O
relating O
to O
virulence O
. O

Sequence O
comparison O
detected O
a O
single O
deduced O
amino O
acid O
change O
( O
cl O
- O
l O
Ile O
to O
mul1E10 O
Thr O
) O
at O
amino O
acid O
number O
515 O
in O
glycoprotein O
G1 O
. O

Data O
from O
naturally O
infected O
deer O
mice O
( O
Peromyscus O
maniculatus O
) O
were O
used O
to O
investigate O
vertical O
transmission O
of O
Sin B
Nombre I
virus I
( I
SNV I
) I
and O
SNV O
- O
specific O
antibody O
. O

The O
antibody O
prevalence O
in O
juvenile O
mice O
( O
14 O
g O
or O
less O
) O
was O
inversely O
proportional O
to O
the O
mass O
of O
the O
animal O
, O
with O
juvenile O
deer O
mice O
weighing O
less O
than O
11 O
g O
most O
likely O
to O
be O
antibody O
positive O
( O
26 O
. O

Ten O
juvenile O
deer O
mice O
were O
identified O
that O
had O
initially O
tested O
positive O
for O
SNV O
- O
specific O
immunoglobulin B
G I
( I
IgG I
) I
by O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
but O
had O
subsequently O
tested O
negative O
when O
recaptured O
as O
adults O
. O

SNV O
RNA O
was O
detected O
by O
reverse B
transcriptase I
PCR I
( I
RT I
- I
PCR I
) I
in O
the O
blood O
of O
ELISA O
- O
positive O
adult O
deer O
mice O
but O
not O
in O
the O
blood O
of O
ELISA O
- O
positive O
juveniles O
, O
One O
of O
the O
juvenile O
mice O
initially O
tested O
negative O
for O
SNV O
RNA O
but O
later O
tested O
positive O
when O
recaptured O
as O
an O
ELISA O
- O
positive O
adult O
. O

Sin B
Nombre I
virus I
( I
SNV I
) I
is O
thought O
to O
establish O
a O
persistent O
infection O
in O
its O
natural O
reservoir O
, O
the O
deer O
mouse O
( O
Peromyscus O
maniculatus O
) O
, O
despite O
a O
strong O
host O
immune O
response O
; O
SNV O
- O
specific O
neutralizing O
antibodies O
were O
routinely O
detected O
in O
deer O
mice O
which O
maintained O
virus O
RNA O
in O
the O
blood O
and O
lungs O
. O

Analysis O
of O
organ O
- O
specific O
viral O
clones O
revealed O
major O
disparities O
in O
the O
level O
of O
viral O
diversity O
between O
organs O
, O
specifically O
between O
the O
spleen O
( O
high O
diversity O
) O
and O
the O
lung O
and O
liver O
( O
low O
diversity O
) O
. O

Rift B
Valley I
fever I
virus I
( I
RVFV I
) I
, O
a O
phlebovirus O
of O
the O
Bungaviridae O
family O
, O
is O
an O
arthropod O
- O
borne O
virus O
which O
emerges O
periodically O
throughout O
Africa O
, O
emphasizing O
that O
it O
poses O
a O
major O
threat O
fur O
animal O
and O
human O
populations O
. O

To O
assess O
the O
genetic O
variability O
of O
RVFV O
, O
several O
isolates O
from O
diverse O
localities O
of O
Africa O
were O
investigated O
, O
by O
means O
of O
reverse O
transcription O
- O
PCR O
followed O
by O
direct O
sequencing O
of O
a O
region O
of O
the O
small B
( I
S I
) I
, O
medium B
( I
M I
) I
, O
and O
large B
( I
L I
) I
genomic O
segments O
. O

Hantaviruses O
replicate O
primarily O
in O
the O
vascular O
endothelium O
and O
cause O
two O
human O
diseases O
, O
hemorrhagic B
fever I
with I
renal I
syndrome I
( I
HFRS I
) I
and O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

Infection O
of O
human O
umbilical O
vein O
endothelial O
cells O
and O
Vero O
E6 O
cells O
by O
the O
HFRS O
- O
causing O
hantaviruses O
Hantaan B
( I
HTN I
) I
, O
Seoul B
( I
SEO I
) I
, O
and O
Puumala B
( I
PUU I
) I
is O
inhibited O
by O
antibodies O
to O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
and O
by O
the O
integrin O
ligand O
vitronectin O
. O

The O
cellular O
entry O
of O
HTN O
, O
SEO O
, O
and O
PUU O
viruses O
, O
but O
not O
the O
nonpathogenic O
Prospect B
Hill I
( I
PH I
) I
hantavirus O
( O
i O
. O

, O
a O
virus O
with O
no O
associated O
human O
disease O
) O
, O
was O
also O
mediated O
by O
introducing O
recombinant O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
or O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
integrins O
into O
beta O
( O
3 O
) O
- O
integrin O
- O
deficient O
CHO O
cells O
. O

In O
addition O
, O
PH O
infectivity O
was O
not O
inhibited O
by O
alpha O
( O
v O
) O
beta O
( O
3 O
) O
- O
specific O
sera O
or O
vitronectin O
but O
was O
blocked O
by O
alpha O
( O
5 O
) O
beta O
( O
1 O
) O
- O
specific O
sera O
and O
the O
integrin O
ligand O
fibronectin O
. O

Further O
, O
a O
mouse O
- O
human O
hybrid O
beta O
( O
3 O
) O
integrin O
- O
specific O
Fab O
fragment O
, O
c7E3 O
( O
ReoPro O
) O
, O
also O
inhibited O
the O
infectivity O
of O
HTN O
, O
SEO O
, O
and O
PUU O
as O
well O
as O
HPS O
- O
associated O
hantaviruses O
, O
Sin B
Nombre I
( I
SN I
) I
and O
New B
York I
- I
1 I
( I
NY I
- I
1 I
) I
. O

These O
findings O
indicate O
that O
pathogenic O
HPS O
- O
and O
HFRS O
- O
causing O
hantaviruses O
enter O
cells O
via O
beta O
( O
3 O
) O
integrins O
, O
which O
are O
present O
on O
the O
surfaces O
of O
platelets O
, O
endothelial O
cells O
, O
and O
macrophages O
. O

Since O
beta O
( O
3 O
) O
integrins O
regulate O
vascular O
permeability O
and O
platelet O
function O
, O
these O
findings O
also O
correlate O
beta O
( O
3 O
) O
integrin O
usage O
with O
common O
elements O
of O
hantavirus O
pathogenesis O
. O

To O
examine O
the O
evolution O
of O
Tula B
hantavirus I
( I
TUL I
) I
, O
tarried O
by O
the O
European O
common O
vole O
( O
Microtus O
arvalis O
and O
M O
. O

Phylogenetic B
analysis I
( I
PHYLIP I
) I
based O
on O
either O
partial O
( O
nucleotides O
[ O
nt O
] O
441 O
to O
898 O
) O
or O
complete O
N O
- O
protein O
- O
encoding O
sequences O
divided O
Slovakian O
TUL O
variants O
into O
two O
main O
lineages O
: O
( O
i O
) O
strains O
from O
eastern O
Slovakia O
, O
which O
clustered O
with O
Russian O
strains O
, O
and O
( O
ii O
) O
strains O
from O
western O
Slovakia O
situated O
closer O
to O
those O
from O
the O
Czech O
Republic O
. O

Phylogenetic O
analysis O
of O
the O
3 B
' I
noncoding I
region I
( I
3 I
' I
- I
NCR I
) I
, O
however O
, O
placed O
the O
eastern O
Slovakian O
strains O
closer O
to O
those O
from O
western O
Slovakia O
and O
the O
Czech O
Republic O
, O
with O
a O
greater O
distance O
to O
the O
Russian O
strains O
, O
suggesting O
a O
recombinant O
nature O
of O
the O
S O
segment O
in O
the O
eastern O
Slovakian O
TUL O
lineage O
. O

A O
bootscan O
search O
of O
the O
S O
- O
segment O
sequences O
of O
TUL O
strains O
revealed O
at O
least O
two O
recombination O
points O
in O
the O
S O
sequences O
of O
eastern O
Slovakian O
TUL O
strains O
( O
nt O
100 O
to O
415 O
and O
around O
1200 O
) O
which O
agreed O
well O
with O
the O
pattern O
of O
amino O
acid O
substitutions O
in O
the O
N O
protein O
and O
deletions O
/ O
insertions O
in O
the O
3 O
' O
- O
NCR O
of O
the O
S O
segment O
. O

We O
have O
investigated O
the O
involvement O
of O
cytoskeletal O
proteins O
in O
the O
morphogenesis O
of O
Black B
Creek I
Canal I
virus I
( I
BCCV I
) I
, O
a O
New O
World O
hantavirus O
. O

Double O
immunofluorescence O
staining O
of O
BCCV O
- O
infected O
Vero O
cells O
with O
anti O
- O
BCCV O
nucleocapsid B
( I
N I
) I
monoclonal O
antibody O
and O
phalloidin O
revealed O
a O
colocalization O
of O
the O
BCCV O
N O
protein O
with O
actin O
microfilaments O
. O

Nucleotide O
sequences O
were O
determined O
for O
the O
complete O
M O
genome O
segments O
of O
two O
distinct O
hantavirus O
genetic O
lineages O
which O
were O
detected O
in O
hantavirus O
antibody O
- O
and O
PCR O
- O
positive O
white O
- O
footed O
mice O
( O
Peromyscus O
leucopus O
) O
from O
Indiana O
and O
Oklahoma O
. O

Taken O
together O
, O
our O
current O
data O
suggests O
that O
both O
cospeciation O
of O
Peromyscus O
- O
borne O
hantaviruses O
with O
their O
specific O
rodent O
hosts O
and O
biogeographic O
factors O
( O
such O
as O
allopatric O
migrations O
, O
geographic O
separation O
, O
and O
isolation O
) O
have O
played O
important O
roles O
in O
establishment O
of O
the O
current O
genetic O
diversity O
and O
geographic O
distribution O
of O
Sin O
Nombre O
- O
like O
hantaviruses O
. O

Black B
Creek I
Canal I
( I
BCC I
) I
virus O
is O
a O
newly O
identified O
hantavirus O
from O
Florida O
which O
is O
carried O
by O
the O
cotton O
rat O
( O
Sigmodon O
hispidus O
) O
and O
is O
associated O
with O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

This O
study O
reports O
completion O
of O
the O
genetic O
characterization O
of O
the O
entire O
genome O
of O
Sin B
Nombre I
( I
SN I
) I
virus O
( O
NMH10 O
) O
detected O
in O
autopsy O
tissues O
from O
a O
patient O
who O
died O
of O
hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
. O

The O
large B
( I
L I
) I
genome O
segment O
was O
found O
to O
be O
6 O
, O
562 O
nucleotides O
in O
length O
and O
encoded O
a O
putative O
L O
polymerase O
that O
was O
2 O
, O
153 O
amino O
acids O
in O
length O
. O

No O
evidence O
of O
segment O
reassortment O
with O
other O
well O
- O
characterized O
hantaviruses O
was O
obtained O
, O
The O
sequence O
of O
the O
entire O
S O
, O
M O
, O
and O
L O
genome O
segments O
of O
SN O
virus O
( O
strain O
NMR11 O
) O
isolated O
from O
a O
mouse O
( O
trapped O
in O
the O
residence O
of O
the O
patient O
infected O
with O
SN O
virus O
[ O
NMH10 O
] O
) O
by O
passage O
two O
times O
in O
Peromyscus O
maniculatus O
and O
then O
by O
five O
passages O
in O
E6 O
Vero O
cells O
was O
determined O
and O
compared O
with O
that O
of O
the O
virus O
detected O
in O
autopsy O
tissues O
, O
Only O
16 O
nucleotide O
differences O
were O
detected O
between O
the O
virus O
genomes O
, O
and O
none O
of O
these O
resulted O
in O
virus O
protein O
amino O
acid O
substitutions O
, O
Determination O
of O
the O
exact O
5 O
' O
- O
and O
3 O
' O
- O
terminal O
sequences O
of O
all O
genome O
segments O
of O
SN O
virus O
and O
representatives O
of O
other O
serologic O
groups O
in O
the O
Hantavirus O
genus O
, O
family O
Bunyaviridae O
, O
showed O
the O
existence O
of O
conserved O
nucleotide O
domains O
that O
may O
be O
involved O
in O
important O
regulatory O
mechanisms O
, O
such O
as O
RNA O
encapsidation O
, O
polymerase O
binding O
, O
and O
control O
of O
transcription O
and O
replication O
. O

hantavirus B
pulmonary I
syndrome I
( I
HPS I
) I
is O
a O
human O
disease O
caused O
by O
a O
newly O
identified O
hantavirus O
, O
which O
we O
will O
refer O
to O
as O
Four B
Corners I
virus I
( I
FCV I
) I
. O

FCV O
is O
related O
most O
closely O
to O
Puumala B
virus I
( I
PUU I
) I
and O
to O
Prospect B
Hill I
virus I
( I
PHV I
) I
. O

Twenty O
- O
five O
acute O
HPS O
serum O
samples O
were O
tested O
for O
immunoglobulin B
G I
( I
IgG I
) I
and O
IgM O
antibody O
reactivities O
to O
FCV O
- O
encoded O
recombinant O
proteins O
in O
Western O
blot O
( O
immunoblot O
) O
assays O
. O

All O
HPS O
serum O
samples O
contained O
both O
IgG O
and O
IgM O
antibodies O
to O
the O
FCV O
nucleocapsid B
( I
N I
) I
protein O
. O

A O
dominant O
FCV O
N O
epitope O
was O
mapped O
to O
the O
segment O
between O
amino O
acids O
17 O
and O
59 O
( O
QLVTARQKLKDAERAVELDPDDVNKSTLQSRRAAVSALETKLG O
) O
. O

All O
HP O
S O
serum O
samples O
contained O
IgG O
antibodies O
to O
the O
FCV O
glycoprotein B
- I
1 I
( I
G1 I
) I
protein O
, O
and O
21 O
of O
25 O
serum O
samples O
contained O
FCV O
G1 O
IgM O
antibodies O
. O

The O
FCV O
G1 O
type O
- O
specific O
antibody O
reactivity O
mapped O
to O
a O
segment O
between O
amino O
acids O
59 O
and O
89 O
( O
LKIESSCNFDLHVPATTTQKYNQVDWTKKSS O
) O
. O

We O
previously O
demonstrated O
that O
W O
proteins O
from O
different O
Newcastle B
disease I
virus I
( I
NDV I
) I
strains O
localize O
in O
either O
the O
cytoplasm O
( O
e O
. O

This O
revealed O
that O
the O
key O
region O
for O
determining O
W O
protein O
localization O
is O
from O
180 O
to O
227 O
amino B
acids I
( I
aa I
) I
. O

Further O
experiments O
found O
there O
is O
a O
nuclear B
export I
signal I
( I
NES I
) I
motif O
in O
the O
W O
protein O
at O
211 O
to O
224 O
aa O
. O

W O
protein O
could O
be O
transported O
into O
the O
nucleus O
via O
interaction O
with O
KPNA1 O
, O
KPNA2 O
, O
and O
KPNA6 O
in O
a O
nuclear O
localization O
signal O
- O
dependent O
manner O
, O
and O
W O
protein O
containing O
an O
NES O
was O
transported O
back O
to O
the O
cytoplasm O
in O
a O
chromosomal B
maintenance I
1 I
( I
CRM1 I
) I
- O
independent O
manner O
. O

IMPORTANCE O
In O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
the O
W O
protein O
, O
like O
the O
V O
protein O
, O
is O
a O
nonstructural O
protein O
encoded O
by O
the O
P O
gene O
via O
RNA O
editing O
. O

We O
found O
that O
W O
protein O
localization O
differences O
impact O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
, O
consequently O
affecting O
NDV O
virulence O
, O
replication O
, O
and O
pathogenicity O
. O

A O
genetically O
modified O
, O
recombinant B
form I
of I
Newcastle I
disease I
virus I
( I
rNDV I
) I
undergoes O
ionic O
strength O
- O
dependent O
changes O
in O
morphology O
, O
as O
observed O
by O
cryo B
- I
electron I
microscopy I
( I
cEM I
) I
. O

Concomitantly O
, O
we O
measured O
infectious O
titers O
of O
these O
same O
rNDV O
samples O
at O
different O
ionic O
strengths O
using O
a O
fluorescent B
focus I
assay I
( I
FFA I
) I
. O

These O
structural O
and O
functional O
observations O
, O
in O
combination O
, O
suggest O
that O
infectivity O
( O
and O
, O
by O
inference O
, O
oncolytic O
activity O
) O
of O
rNDV O
virions O
is O
fully O
maintained O
in O
their O
pleomorphic O
forms O
. O

We O
have O
developed O
a O
genetically O
modified O
recombinant B
NDV I
( I
rNDV I
) I
that O
has O
much O
reduced O
pathogenicity O
in O
chickens O
but O
is O
highly O
oncolytic O
. O

The O
morphology O
of O
rNDV O
transitions O
from O
spherical O
at O
very O
low O
salt O
concentrations O
to O
a O
heterogeneous O
population O
of O
spherical O
and O
elongated O
virions O
in O
isotonic O
( O
physiologic O
salt O
concentration O
) O
and O
hypertonic O
solutions O
. O

The O
infectivity O
( O
cell O
- O
killing O
activity O
by O
infecting O
cells O
) O
of O
rNDV O
is O
unaltered O
by O
changes O
in O
salt O
concentration O
despite O
morphological O
changes O
. O

In O
each O
case O
, O
the O
presence O
of O
the O
virus O
was O
confirmed O
by O
reverse B
transcription I
( I
RT I
) I
- O
PCR O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
an O
attractive O
candidate O
for O
oncolytic O
immunotherapy O
due O
to O
its O
ability O
to O
replicate O
in O
tumor O
cells O
and O
potentially O
to O
overcome O
the O
inherently O
immunosuppressive O
nature O
of O
the O
tumor O
microenvironment O
. O

In O
this O
study O
, O
we O
engineered O
six O
different O
recombinant O
viruses O
: O
NDVs O
expressing O
checkpoint O
inhibitors O
( O
rNDV O
- O
anti O
- O
PD1 O
and O
rNDV O
- O
anti O
- O
PDL1 O
) O
; O
superagonists O
( O
rNDV O
- O
anti O
- O
CD28 O
) O
; O
and O
immunocytokines O
, O
where O
the O
antibodies O
are O
fused O
to O
an O
immunostimulatory O
cytokine O
, O
such O
as O
interleukin B
12 I
( I
IL I
- I
12 I
) I
( O
rNDV O
- O
anti O
- O
CD28 O
- O
murine O
IL O
- O
12 O
[ O
mIL O
- O
12 O
] O
, O
rNDV O
- O
anti O
- O
PD1 O
- O
mIL O
- O
12 O
, O
and O
rNDV O
- O
anti O
- O
PDL1 O
- O
mIL O
- O
12 O
) O
. O

porcine B
reproductive I
and I
respiratory I
syndrome I
virus I
( I
PRRSV I
) I
poses O
a O
major O
threat O
to O
global O
pork O
production O
and O
has O
been O
notorious O
for O
its O
rapid O
genetic O
evolution O
in O
the O
field O
. O

The O
nonstructural B
protein I
2 I
( I
nsP2 I
) I
replicase O
protein O
represents O
the O
fastest O
evolving O
region O
of O
PRRSV O
, O
but O
the O
underlying O
biological O
significance O
has O
remained O
poorly O
understood O
. O

323 O
- O
521 O
) O
in O
its O
hypervariable O
region O
was O
found O
to O
lose O
infectivity O
in O
primary O
porcine B
alveolar I
macrophages I
( I
PAMs I
) I
, O
although O
it O
could O
replicate O
relatively O
efficiently O
in O
the O
supporting O
cell O
line O
MARC O
- O
145 O
. O

Further O
dissection O
of O
the O
viral O
life O
cycle O
revealed O
that O
the O
mutant O
had O
a O
defect O
( O
or O
defects O
) O
lying O
in O
the O
steps O
between O
virus O
penetration O
and O
negative O
- O
stranded O
RNA O
synthesis O
. O

However O
, O
the O
cellular O
proteins O
of O
the O
central B
nervous I
system I
( I
CNS I
) I
involved O
in O
avian O
neurotropic O
virus O
infection O
have O
not O
been O
completely O
elucidated O
. O

Here O
, O
we O
employed O
a O
gene O
microarray O
to O
identify O
caspase B
recruitment I
domain I
- I
containing I
protein I
11 I
( I
CARD11 I
) I
, O
a O
lymphoma O
- O
associated O
scaffold O
protein O
presenting O
brain O
- O
specific O
upregulated O
expression O
in O
a O
virulent O
neurotropic O
Newcastle B
disease I
virus I
( I
NDV I
) I
- O
infected O
natural O
host O
. O

The O
inhibition O
of O
viral O
replication O
by O
CARD11 O
could O
not O
be O
blocked O
with O
CARD11 O
- O
Bcl10 O
- O
MALT1 O
( O
CBM O
) O
signalosome O
and O
NF O
- O
kappa O
B O
signaling O
inhibitors O
. O

CARD11 O
was O
found O
to O
interact O
directly O
with O
the O
viral O
phosphoprotein B
( I
P I
) I
through O
its O
CC1 O
domain O
and O
the O
X O
domain O
of O
P O
; O
this O
X O
domain O
also O
mediated O
the O
interaction O
between O
P O
and O
the O
viral O
large O
polymerase O
protein O
( O
L O
) O
. O

The O
CARD11 O
CC1 O
domain O
and O
L O
competitively O
bound O
to O
P O
via O
the O
X O
domain O
that O
hindered O
the O
P O
- O
L O
interaction O
of O
the O
viral O
ribonucleoprotein B
( I
RNP I
) I
complex O
, O
resulting O
in O
a O
reduction O
of O
viral O
polymerase O
activity O
in O
a O
minigenome O
assay O
and O
inhibition O
of O
viral O
replication O
. O

IMPORTANCE O
Newcastle B
disease I
virus I
( I
NDV I
) I
substantially O
impacts O
the O
poultry O
industry O
worldwide O
and O
causes O
viral O
encephalitis O
and O
neurological O
disorders O
leading O
to O
brain O
damage O
, O
paralysis O
, O
and O
death O
. O

The O
mechanism O
of O
interaction O
between O
this O
neurotropic O
virus O
and O
the O
avian O
central B
nervous I
system I
( I
CNS I
) I
is O
largely O
unknown O
. O

Here O
, O
we O
report O
that O
host O
protein O
CARD11 O
presented O
brain O
- O
specific O
upregulated O
expression O
that O
inhibited O
NDV O
replication O
, O
which O
was O
not O
due O
to O
CARD11 O
- O
Bcl10 O
- O
MALT1 O
( O
CBM O
) O
complex O
- O
triggered O
activation O
of O
its O
downstream O
signaling O
pathways O
. O

The O
inhibitory O
mechanism O
of O
viral O
replication O
is O
through O
the O
CARD11 O
CC1 O
domain O
, O
and O
the O
viral O
large O
polymerase O
protein O
( O
L O
) O
competitively O
interacts O
with O
the O
X O
domain O
of O
the O
viral O
phosphoprotein B
( I
P I
) I
, O
which O
hampers O
the O
P O
- O
L O
interaction O
, O
suppressing O
the O
viral O
polymerase O
activity O
and O
viral O
replication O
. O

Of O
the O
various O
pattern O
recognition O
receptors O
in O
the O
host O
, O
the O
cytosolic O
RNA O
helicases O
interact O
with O
viral O
RNA O
to O
activate O
the O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
and O
subsequent O
cellular O
interferon B
( I
IFN I
) I
response O
. O

In O
this O
study O
, O
we O
found O
that O
Newcastle B
disease I
virus I
( I
NDV I
) I
infection O
induced O
MAVS O
degradation O
. O

In O
this O
article O
, O
we O
demonstrate O
that O
the O
V O
proteins O
of O
NDV O
and O
several O
other O
paramyxoviruses O
target O
MAVS O
for O
ubiquitin O
- O
mediated O
degradation O
through O
E3 O
ubiquitin O
ligase O
RING B
- I
finger I
protein I
5 I
( I
RNF5 I
) I
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
an O
enveloped O
paramyxovirus O
. O

The O
matrix O
protein O
of O
the O
virus O
( O
M O
- O
NDV O
) O
has O
an O
innate O
propensity O
to O
produce O
virus O
- O
like O
particles O
budding O
from O
the O
plasma O
membrane O
of O
the O
expressing O
cell O
without O
recruiting O
other O
viral O
proteins O
. O

IMPORTANCE O
The O
matrix O
protein O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
is O
one O
of O
the O
most O
abundant O
viral O
proteins O
that O
regulates O
the O
formation O
of O
progeny O
virions O
. O

We O
have O
engineered O
a O
novel O
hybrid O
vector O
comprising O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
and O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
named O
recombinant B
VSV I
- I
NDV I
( I
rVSV I
- I
NDV I
) I
, O
wherein O
the O
VSV O
backbone O
is O
conserved O
but O
its O
glycoprotein O
has O
been O
replaced O
by O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
the O
modified O
, O
hyperfusogenic O
fusion O
( O
F O
) O
envelope O
proteins O
of O
recombinant O
NDV O
. O

CB17 O
- O
prkdoc O
' O
d O
/ O
NCrCrl O
( O
NOD O
- O
SCID O
) O
mice O
, O
which O
are O
highly O
susceptible O
to O
wild O
- O
type O
VSV O
. O

Finally O
, O
systemic O
administration O
of O
rVSV O
- O
NDV O
in O
orthotopic O
hepatocellular B
carcinoma I
( I
HCC I
) I
- O
bearing O
immunecompetent O
mice O
resulted O
in O
significant O
survival O
prolongation O
. O

Oral B
live I
poliovirus I
vaccine I
( I
OPV I
) I
, O
while O
affordable O
and O
effective O
, O
occasionally O
causes O
the O
disease O
in O
the O
primary O
recipients O
, O
and O
the O
attenuated O
viruses O
rapidly O
regain O
virulence O
and O
can O
cause O
poliomyelitis O
outbreaks O
. O

Inactivated B
poliovirus I
vaccine I
( I
IPV I
) I
is O
safe O
but O
expensive O
and O
does O
not O
induce O
the O
mucosal O
immunity O
necessary O
to O
interrupt O
virus O
transmission O
. O

Here O
we O
demonstrate O
a O
different O
design O
of O
an O
antipoliovirus O
vaccine O
based O
on O
in O
situ O
production O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
. O

The O
poliovirus O
capsid O
protein O
precursor O
, O
together O
with O
a O
protease O
required O
for O
its O
processing O
, O
are O
expressed O
from O
a O
Newcastle B
disease I
virus I
( I
NDV I
) I
vector O
, O
a O
negative O
- O
strand O
RNA O
virus O
with O
mucosal O
tropism O
. O

Hendra B
virus I
( I
HeV I
) I
is O
a O
zoonotic O
paramyxovirus O
belonging O
to O
the O
genus O
Henipavirus O
. O

Among O
the O
genes O
that O
HeV O
encodes O
, O
the O
matrix B
( I
M I
) I
protein O
forms O
an O
integral O
part O
of O
the O
virion O
structure O
and O
plays O
critical O
roles O
in O
coordinating O
viral O
assembly O
and O
budding O
. O

The O
dimeric O
structural O
configuration O
of O
HeV O
M O
is O
similar O
to O
that O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
M O
and O
is O
fundamental O
to O
protein O
stability O
and O
effective O
virus O
- O
likeparticle O
( O
VLP O
) O
formation O
. O

The O
disruption O
of O
the O
alpha O
1 O
- O
alpha O
2 O
interactions O
using O
engineered O
charge O
reversal O
substitutions O
( O
R57E O
, O
R57D O
, O
and O
E108R O
) O
resulted O
in O
significant O
reduction O
or O
abrogation O
of O
VLP O
production O
. O

It O
is O
classified O
as O
a O
biosafety B
level I
4 I
( I
BSL4 I
) I
agent O
, O
and O
there O
are O
currently O
no O
preventive O
or O
therapeutic O
treatments O
available O
against O
HeV O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
an O
oncolytic O
virus O
being O
developed O
for O
the O
treatment O
of O
cancer O
. O

Following O
infection O
of O
a O
human B
ovarian I
cancer I
cell I
line I
( I
OVCAR3 I
) I
with O
a O
recombinant O
low O
- O
pathogenic O
NDV O
, O
persistent O
infection O
was O
established O
in O
a O
subset O
of O
tumor O
cells O
. O

Persistently B
Infected I
( I
PI I
) I
cells O
exhibited O
resistance O
to O
superinfection O
with O
NDV O
and O
established O
an O
antiviral O
state O
, O
as O
demonstrated O
by O
upregulation O
of O
interferon O
and O
interferon O
- O
induced O
genes O
such O
as O
myxoma B
resistance I
gene I
1 I
( I
Mx1 I
) I
and O
retinoic B
acid I
- I
inducing I
gene I
- I
I I
( I
RIG I
- I
I I
) I
. O

Two O
mutations O
, O
one O
in O
the O
fusion O
( O
F O
) O
protein O
cleavage O
site O
, O
F117S O
( O
F117S O
) O
, O
and O
another O
in O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
, O
G169R O
( O
HN169R O
) O
, O
located O
in O
the O
second O
sialic O
acid O
binding O
region O
, O
were O
responsible O
for O
the O
hyperfusogenic O
phenotype O
. O

The O
entry O
of O
Avian B
metapneumovirus I
( I
AMPV I
) I
into O
host O
cells O
initially O
requires O
the O
fusion O
of O
viral O
and O
cell O
membranes O
, O
which O
is O
exclusively O
mediated O
by O
fusion O
( O
F O
) O
protein O
. O

Here O
, O
we O
provide O
the O
first O
evidence O
that O
the O
transmembrane O
serine O
protease O
TMPRSS12 O
facilitates O
the O
cleavage O
of O
subtype O
B O
aMPV O
( O
aMPV O
/ O
B O
) O
F O
protein O
. O

Subsequently O
, O
knockdown O
of O
TMPRSS12 O
with O
specific O
small B
interfering I
RNAs I
( I
siRNAs I
) I
reduced O
aMPV O
/ O
B O
F O
protein O
cleavage O
, O
F O
protein O
fusogenicity O
, O
and O
viral O
replication O
. O

We O
also O
found O
a O
cleavage O
motif O
in O
the O
aMPV O
/ O
B O
F O
protein O
( O
amino O
acids O
100 O
and O
101 O
) O
that O
was O
recognized O
by O
TMPRSS12 O
. O

The O
histidine O
, O
aspartic O
acid O
, O
and O
serine O
residue O
( O
HDS O
) O
triad O
of O
TMPRSS12 O
was O
shown O
to O
be O
essential O
for O
the O
proteolysis O
of O
aMPV O
/ O
B O
F O
protein O
via O
mutation O
analysis O
. O

A O
combination O
of O
analyses O
, O
including O
overexpression O
, O
knockdown O
, O
and O
mutation O
methods O
, O
demonstrated O
that O
the O
transmembrane O
serine O
protease O
TMPRSS12 O
facilitated O
cleavage O
of O
subtype O
B O
aMPV O
( O
aMPV O
/ O
B O
) O
F O
protein O
. O

The O
paramyxoviral O
family O
contains O
many O
medically O
important O
viruses O
, O
including O
measles O
virus O
, O
mumps O
virus O
, O
parainfluenza O
viruses O
, O
respiratory O
syncytial O
virus O
, O
human O
metapneumovirus O
, O
and O
the O
deadly O
zoonotic O
henipaviruses O
Hendra O
and O
Nipah B
virus I
( I
NiV I
) I
. O

To O
both O
enter O
host O
cells O
and O
spread O
from O
cell O
to O
cell O
within O
infected O
hosts O
, O
the O
vast O
majority O
of O
paramyxoviruses O
utilize O
two O
viral O
envelope O
glycoproteins O
: O
the O
attachment O
glycoprotein O
( O
G O
, O
H O
, O
or O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
) O
and O
the O
fusion O
glycoprotein O
( O
F O
) O
. O

Binding O
of O
G O
/ O
H O
/ O
HN O
to O
a O
host O
cell O
receptor O
triggers O
structural O
changes O
in O
G O
/ O
H O
/ O
HN O
that O
in O
turn O
trigger O
F O
to O
undergo O
a O
series O
of O
conformational O
changes O
that O
result O
in O
virus O
- O
cell O
( O
viral O
entry O
) O
or O
cell O
- O
cell O
( O
syncytium O
formation O
) O
membrane O
fusion O
. O

IMPORTANCE O
Nipah B
virus I
( I
NiV I
) I
is O
a O
zoonotic O
paramyxovirus O
that O
causes O
high O
mortality O
rates O
in O
humans O
, O
with O
no O
approved O
treatment O
or O
vaccine O
available O
for O
human O
use O
. O

Viral O
entry O
into O
host O
cells O
relies O
on O
two O
viral O
envelope O
glycoproteins O
: O
the O
attachment O
( O
G O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
. O

Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
and O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
are O
major O
pediatric O
respiratory O
pathogens O
that O
lack O
vaccines O
. O

A O
chimeric O
bovine O
/ O
human O
PIV3 O
( O
rB O
/ O
HPIV3 O
) O
virus O
expressing O
the O
unmodified O
, O
wild B
- I
type I
( I
WT I
) I
RSV O
fusion O
( O
F O
) O
protein O
from O
an O
added O
gene O
was O
previously O
evaluated O
in O
seronegative O
children O
as O
a O
bivalent O
intranasal O
RSV O
/ O
HPIV3 O
vaccine O
, O
and O
it O
was O
well O
tolerated O
but O
insufficiently O
immunogenic O
for O
RSV O
F O
. O

We O
recently O
showed O
that O
rB O
/ O
HPIV3 O
expressing O
a O
partially O
stabilized O
prefusion O
form O
( O
pre O
- O
F O
) O
of O
RSV O
F O
efficiently O
induced O
high O
- O
quality O
RSV O
- O
neutralizing O
antibodies O
, O
defined O
as O
antibodies O
that O
neutralize O
RSV O
in O
vitro O
without O
added O
complement O
( O
B O
. O

In O
the O
present O
study O
, O
we O
modified O
RSV O
F O
by O
replacing O
its O
cytoplasmic B
tail I
( I
CT I
) I
domain O
or O
its O
CT O
and O
transmembrane B
( I
TM I
) I
domains O
( O
TMCT O
) O
with O
counterparts O
from O
BPIV3 O
F O
, O
with O
or O
without O
pre O
- O
F O
stabilization O
. O

Enhanced O
packaging O
was O
substantially O
attenuating O
in O
hamsters O
( O
10 O
- O
to O
100 O
- O
fold O
) O
and O
rhesus O
monkeys O
( O
100 O
- O
to O
1 O
, O
000 O
- O
fold O
) O
. O

Here O
, O
we O
report O
that O
the O
robust O
production O
of O
type O
I O
and O
III O
Interferons B
( I
IFNs I
) I
, O
IFN O
- O
stimulated O
genes O
, O
and O
proinflammatory O
factors O
can O
be O
induced O
by O
influenza O
B O
virus O
rather O
than O
influenza O
A O
virus O
infection O
in O
alveolar O
epithelial O
( O
A549 O
) O
cells O
during O
early O
infection O
. O

This O
response O
is O
mainly O
dependent O
on O
the O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
mediated O
signaling O
pathway O
. O

It O
is O
known O
that O
the O
influenza O
A O
virus O
NS1 O
protein O
( O
NS1 O
- O
A O
) O
interacts O
with O
RIG O
- O
I O
and O
TRIM25 O
to O
suppress O
the O
activation O
of O
RIG O
- O
I O
- O
mediated O
signaling O
. O

However O
, O
the O
present O
results O
indicate O
that O
the O
influenza O
B O
virus O
NS1 O
protein O
( O
NS1 O
- O
B O
) O
is O
unable O
to O
interact O
with O
RIG O
- O
I O
but O
engages O
in O
the O
formation O
of O
a O
RIG O
- O
I O
/ O
TRIM25 O
/ O
NS1 O
- O
B O
ternary O
complex O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
N O
- O
terminal O
RNA B
- I
binding I
domain I
( I
RBD I
) I
of O
NS1 O
- O
B O
is O
responsible O
for O
interaction O
with O
TRIM25 O
and O
that O
this O
interaction O
blocks O
the O
inhibitory O
effect O
of O
the O
NS1 O
- O
B O
C O
- O
terminal B
effector I
domain I
( I
TED I
) I
on O
RIG O
- O
I O
ubiquitination O
. O

Clinical O
development O
of O
a O
mesogenic O
strain O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
as O
an O
oncolytic O
agent O
for O
cancer O
therapy O
has O
been O
hampered O
by O
its O
select O
agent O
status O
due O
to O
its O
pathogenicity O
in O
avian O
species O
. O

This O
recombinant O
NDV O
has O
a O
modification O
at O
the O
fusion B
protein I
( I
F I
) I
cleavage O
site O
to O
reduce O
the O
efficiency O
of O
F O
protein O
cleavage O
and O
an O
insertion O
of O
a O
198 O
- O
nucleotide O
sequence O
into O
the O
HN O
- O
L O
intergenic O
region O
, O
resulting O
in O
reduced O
viral O
gene O
expression O
and O
replication O
in O
avian O
cells O
but O
not O
in O
mammalian O
cells O
. O

In O
mammalian O
cells O
, O
except O
for O
viral O
polymerase O
( O
L O
) O
gene O
expression O
, O
viral O
gene O
expression O
is O
not O
negatively O
impacted O
or O
increased O
by O
the O
HN O
- O
L O
intergenic O
insertion O
. O

Paramyxovirus O
particles O
are O
formed O
by O
a O
budding O
process O
coordinated O
by O
viral O
matrix B
( I
M I
) I
proteins O
. O

M O
proteins O
coalesce O
at O
sites O
underlying O
infected O
cell O
membranes O
and O
induce O
other O
viral O
components O
, O
including O
viral O
glycoproteins O
and O
viral B
ribonucleoprotein I
complexes I
( I
vRNPs I
) I
, O
to O
assemble O
at O
these O
locations O
from O
which O
particles O
bud O
. O

M O
proteins O
interact O
with O
the O
nucleocapsid O
( O
NP O
or O
N O
) O
components O
of O
vRNPs O
, O
and O
these O
interactions O
enable O
production O
of O
infectious O
, O
genome O
- O
containing O
virions O
. O

For O
the O
paramyxoviruses O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
and O
mumps O
virus O
, O
M O
- O
NP O
interaction O
also O
contributes O
to O
efficient O
production O
of O
virus B
- I
like I
particles I
( I
VLPs I
) I
in O
transfected O
cells O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
expressing O
HIV O
- O
1 O
BaL O
gp160 O
was O
evaluated O
either O
alone O
or O
with O
monomeric O
BaL O
gp120 O
and O
BaL O
SOSIP O
gp140 O
protein O
in O
a O
prime O
- O
boost O
combination O
in O
guinea O
pigs O
to O
enhance O
envelope B
( I
env I
) I
- O
specific O
humoral O
and O
mucosal O
immune O
responses O
. O

It O
has O
been O
reported O
that O
lentogenic O
Newcastle B
disease I
virus I
( I
NDV I
) I
isolates O
have O
the O
potential O
to O
become O
velogenic O
after O
their O
transmission O
and O
circulation O
in O
chickens O
, O
but O
the O
underlying O
mechanism O
is O
unclear O
. O

The O
velogenic O
properties O
of O
this O
selected O
variant O
were O
determined O
using O
Mean B
death I
time I
( I
MDT I
) I
assays O
, O
intracerebral B
pathogenicity I
index I
( I
ICPI I
) I
, O
the O
intravenous B
pathogenicity I
index I
( I
IVPI I
) I
, O
histopathology O
, O
and O
the O
analysis O
of O
host O
tissue O
tropism O
. O

In O
contrast O
, O
JS10 O
remained O
lentogenic O
after O
20 O
serial O
passages O
in O
chicken O
eggs O
( O
JS10 O
- O
E20 O
) O
. O

To O
investigate O
the O
mechanism O
for O
virulence O
enhancement O
, O
the O
partial O
genome O
covering O
the O
F0 O
cleavage O
site O
of O
JS10 O
and O
its O
variants O
were O
analyzed O
using O
ultradeep B
pyrosequencing I
( I
UDPS I
) I
and O
the O
proportions O
of O
virulence O
- O
related O
genomes O
in O
the O
quasispecies O
were O
calculated O
. O

Using O
next O
- O
generation O
transcriptome O
sequencing O
( O
mRNA O
- O
seq O
) O
, O
we O
profiled O
the O
transcriptional O
response O
of O
Pteropus B
vampyrus I
bat I
kidney I
( I
PVK I
) I
cells O
to O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
known O
to O
elicit O
a O
strong O
innate O
immune O
response O
in O
mammalian O
cells O
. O

The O
Pteropus O
genus O
is O
a O
known O
reservoir O
of O
Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
. O

Analysis O
of O
the O
200 O
to O
300 O
regulated O
genes O
showed O
that O
genes O
for O
interferon B
( I
IFN I
) I
and O
antiviral O
pathways O
are O
highly O
upregulated O
in O
NDV O
- O
infected O
PVK O
cells O
, O
including O
genes O
for O
beta O
IFN O
, O
RIG O
- O
I O
, O
MDA5 O
, O
ISG15 O
, O
and O
IRF1 O
. O

virus B
- I
like I
particles I
( I
VLPs I
) I
built O
on O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
core O
proteins O
, O
NP O
and O
M O
, O
and O
containing O
two O
chimeric O
proteins O
, O
F O
/ O
F O
and O
H O
/ O
G O
, O
composed O
of O
respiratory B
syncytial I
virus I
( I
RSV I
) I
fusion I
protein I
( I
F I
) I
and O
glycoprotein B
( I
G I
) I
ectodomains O
fused O
to O
the O
transmembrane O
and O
cytoplasmic O
domains O
of O
the O
NDV O
F O
and O
HN O
proteins O
, O
respectively O
, O
stimulate O
durable O
, O
protective O
RSV O
neutralizing O
antibodies O
in O
mice O
. O

Here O
, O
we O
report O
the O
properties O
of O
VLPs O
constructed O
to O
contain O
mutant O
RSV O
F O
protein O
ectodomains O
stabilized O
in O
prefusion O
( O
pre O
- O
F O
/ O
F O
) O
or O
postfusion O
( O
post O
- O
F O
/ O
F O
) O
configurations O
. O

The O
specificities O
of O
anti O
- O
F O
IgG O
induced O
by O
the O
two O
mutant O
VLPs O
were O
assessed O
by O
enzymelinked B
immunosorbent I
assay I
( I
ELISA I
) I
using O
soluble O
forms O
of O
the O
prefusion O
and O
postfusion O
forms O
of O
the O
F O
protein O
as O
targets O
. O

In O
this O
study O
, O
we O
show O
that O
Newcastle B
disease I
virus I
( I
NDV I
) I
- O
vectored O
H7 O
( O
NDV O
- O
H7 O
) O
and O
NDV O
- O
H5 O
vaccines O
are O
able O
to O
induce O
antibodies O
with O
high O
hemagglutination B
inhibition I
( I
HI I
) I
titers O
and O
completely O
protect O
chickens O
from O
challenge O
with O
the O
novel O
H7N9 O
or O
highly O
pathogenic O
H5N1 O
viruses O
, O
respectively O
. O

Membrane O
fusion O
is O
essential O
for O
paramyxovirus O
entry O
into O
target O
cells O
and O
for O
the O
cell O
- O
cell O
fusion O
( O
syncytia O
) O
that O
results O
from O
many O
paramyxoviral O
infections O
. O

The O
concerted O
efforts O
of O
two O
membrane O
- O
integral O
viral O
proteins O
, O
the O
attachment O
( O
HN O
, O
H O
, O
or O
G O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
, O
mediate O
membrane O
fusion O
. O

The O
emergent O
Nipah B
virus I
( I
NiV I
) I
is O
a O
highly O
pathogenic O
and O
deadly O
zoonotic O
paramyxovirus O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
NiV O
- O
G O
stalk O
C O
- O
terminal O
region O
( O
amino O
acids O
159 O
to O
163 O
) O
that O
is O
important O
for O
multiple O
G O
functions O
, O
including O
G O
tetramerization O
, O
conformational O
integrity O
, O
G O
- O
F O
interactions O
, O
receptor O
- O
induced O
conformational O
changes O
in O
G O
, O
and O
F O
triggering O
. O

On O
the O
basis O
of O
these O
results O
, O
we O
propose O
that O
this O
NiV O
- O
G O
region O
serves O
as O
an O
important O
structural O
and O
functional O
linker O
between O
the O
NiV O
- O
G O
head O
and O
the O
rest O
of O
the O
stalk O
and O
is O
critical O
in O
propagating O
the O
F O
- O
triggering O
signal O
via O
specific O
conformational O
changes O
that O
open O
a O
concealed O
F O
- O
triggering O
domain O
( O
s O
) O
in O
the O
G O
stalk O
. O

These O
findings O
broaden O
our O
understanding O
of O
the O
mechanism O
( O
s O
) O
of O
receptor O
- O
induced O
paramyxovirus O
F O
triggering O
during O
viral O
entry O
and O
cell O
- O
cell O
fusion O
. O

measles B
virus I
( I
MeV I
) I
, O
a O
morbillivirus O
within O
the O
paramyxovirus O
family O
, O
expresses O
two O
envelope O
glycoproteins O
. O

The O
attachment O
( O
H O
) O
protein O
mediates O
receptor O
binding O
, O
followed O
by O
triggering O
of O
the O
fusion O
( O
F O
) O
protein O
, O
which O
leads O
to O
merger O
of O
the O
viral O
envelope O
with O
target O
cell O
membranes O
. O

rabies B
virus I
( I
RABV I
) I
spread O
is O
widely O
accepted O
to O
occur O
only O
by O
retrograde O
axonal O
transport O
. O

However O
, O
examples O
of O
anterograde O
RABV O
spread O
in O
peripheral O
neurons O
such O
as O
dorsal B
root I
ganglion I
( I
DRG I
) I
neurons O
indicated O
a O
possible O
bidirectional O
transport O
by O
an O
uncharacterized O
mechanism O
. O

Moreover O
, O
colocalization O
of O
green B
fluorescent I
protein I
( I
GFP I
) I
- O
labeled O
ribonucleoproteins B
( I
RNPs I
) I
and O
glycoprotein O
in O
distal O
axonal O
regions O
as O
well O
as O
cotransport O
of O
labeled O
RNPs O
with O
membrane O
- O
anchored O
mCherry O
reporter O
confirmed O
that O
either O
complete O
enveloped O
virus O
particles O
or O
vesicle O
associated O
RNPs O
were O
transported O
. O

Most O
paramyxoviruses O
infect O
host O
cells O
via O
the O
concerted O
action O
of O
a O
tetrameric O
attachment O
protein O
( O
variously O
called O
HN O
, O
H O
, O
or O
G O
) O
that O
binds O
either O
sialic O
acid O
or O
protein O
receptors O
on O
target O
cells O
and O
a O
trimeric O
fusion B
protein I
( I
F I
) I
that O
merges O
the O
viral O
envelope O
with O
the O
plasma O
membrane O
at O
neutral O
pH O
. O

To O
test O
the O
model O
in O
the O
context O
of O
wild O
- O
type O
viral O
glycoproteins O
, O
we O
used O
a O
restricted O
- O
diversity O
combinatorial O
Fab O
library O
and O
phage O
display O
to O
rapidly O
generate O
synthetic O
antibodies O
( O
sAbs O
) O
against O
multiple O
domains O
of O
the O
paramyxovirus O
parainfluenza O
5 O
( O
PIV5 O
) O
pre O
- O
and O
postfusion O
F O
and O
HN O
. O

As O
predicted O
by O
the O
model O
, O
sAbs O
that O
bind O
to O
the O
critical O
F O
- O
triggering O
region O
of O
the O
HN O
stalk O
do O
not O
disrupt O
receptor O
binding O
or O
neuraminidase B
( I
NA I
) I
activity O
but O
are O
potent O
inhibitors O
of O
fusion O
. O

The O
viruses O
bind O
to O
cells O
via O
their O
receptor O
binding O
protein O
and O
then O
enter O
cells O
by O
fusion O
of O
their O
envelope O
with O
the O
host O
cell O
plasma O
membrane O
, O
a O
process O
mediated O
by O
a O
metastable O
viral O
fusion O
( O
F O
) O
protein O
. O

To O
overcome O
this O
obstacle O
, O
we O
generated O
a O
Recombinant B
Newcastle I
disease I
virus I
( I
rNDV I
) I
- O
vectored O
experimental O
norovirus O
vaccine O
by O
expressing O
the O
capsid O
protein O
( O
VP1 O
) O
of O
norovirus O
strain O
VA387 O
. O

We O
further O
demonstrated O
that O
the O
VP1 O
protein O
produced O
by O
rNDVs O
was O
able O
to O
self O
- O
assemble O
into O
virus B
- I
like I
particles I
( I
VLPs I
) I
that O
are O
morphologically O
similar O
to O
baculovirus O
- O
expressed O
VLPs O
. O

The O
rNDV O
vectors O
predominantly O
induced O
IgG2a O
subclass O
antibody O
for O
the O
Th1 O
response O
, O
and O
specifically O
, O
high O
levels O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
, O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
and O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
were O
detected O
in O
splenocytes O
. O

In O
this O
study O
, O
we O
have O
evaluated O
Newcastle B
disease I
virus I
( I
NDV I
) I
as O
a O
vaccine O
vector O
for O
norovirus O
. O

Immunization O
with O
virus B
- I
like I
particles I
( I
VLPs I
) I
containing O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
core O
proteins O
, O
NP O
and O
M O
, O
and O
two O
chimera O
proteins O
( O
F O
/ O
F O
and O
H O
/ O
G O
) O
containing O
the O
respiratory B
syncytial I
virus I
( I
RSV I
) I
F O
- O
and O
G O
- O
protein O
ectodomains O
fused O
to O
the O
transmembrane O
and O
cytoplasmic O
domains O
of O
NDV O
F O
and O
HN O
proteins O
, O
respectively O
, O
stimulated O
durable O
RSV O
- O
neutralizing O
antibodies O
, O
F O
- O
protein O
- O
specific O
long O
- O
lived O
, O
bone O
marrow O
- O
associated O
plasma O
cells O
( O
LLPCs O
) O
, O
and O
B O
cell O
memory O
, O
in O
striking O
contrast O
to O
RSV O
infection O
, O
which O
did O
not O
( O
M O
. O

Here O
we O
report O
the O
characterization O
of O
a O
VLP O
with O
an O
RSV O
F O
- O
protein O
ectodomain O
fused O
to O
the O
NDV O
F O
- O
protein O
heptad B
repeat I
2 I
( I
HR2 I
) I
, O
transmembrane O
, O
and O
cytoplasmic O
domain O
sequences O
, O
creating O
a O
chimera O
with O
two O
tandem O
HR2 O
domains O
, O
one O
from O
the O
RSV O
F O
protein O
and O
the O
other O
from O
the O
NDV O
F O
- O
protein O
ectodomain O
( O
F O
/ O
HR2F O
) O
. O

This O
VLP O
( O
VLP O
- O
H O
/ O
G O
+ O
F O
/ O
HR2F O
) O
stimulated O
anti O
- O
F O
- O
protein O
and O
anti O
- O
G O
- O
protein O
IgG O
, O
durable O
RSV O
- O
neutralizing O
antibodies O
, O
and O
anti O
- O
RSV O
F O
- O
protein O
- O
secreting O
LLPCs O
. O

However O
, O
the O
subtypes O
of O
anti O
- O
F O
- O
protein O
IgG O
induced O
were O
different O
from O
those O
elicited O
by O
VLPs O
containing O
the O
F O
/ O
F O
chimera O
( O
VLP O
- O
H O
/ O
G O
+ O
F O
/ O
F O
) O
. O

IMPORTANCE O
The O
development O
of O
vaccines O
for O
respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
hampered O
by O
a O
lack O
of O
a O
clear O
understanding O
of O
the O
requirements O
for O
eliciting O
protective O
as O
well O
as O
durable O
human O
immune O
responses O
to O
virus O
antigens O
. O

Infectious B
laryngotracheitis I
( I
ILT I
) I
is O
a O
highly O
contagious O
acute O
respiratory O
disease O
of O
chickens O
caused O
by O
infectious B
laryngotracheitis I
virus I
( I
ILTV I
) I
. O

The O
disease O
is O
controlled O
mainly O
through O
biosecurity O
and O
vaccination O
with O
live O
attenuated O
strains O
of O
ILTV O
and O
vectored O
vaccines O
based O
on O
turkey B
herpesvirus I
( I
HVT I
) I
and O
fowlpox B
virus I
( I
FPV I
) I
. O

The O
current O
live O
attenuated O
vaccines O
( O
chicken O
embryo O
origin O
[ O
CEO O
] O
and O
tissue O
culture O
origin O
[ O
TCO O
] O
) O
, O
although O
effective O
, O
can O
regain O
virulence O
, O
whereas O
HVT O
- O
and O
FPV O
- O
vectored O
ILTV O
vaccines O
are O
less O
efficacious O
than O
live O
attenuated O
vaccines O
. O

In O
the O
present O
study O
, O
we O
generated O
Newcastle B
disease I
virus I
( I
NDV I
) I
recombinants O
, O
based O
on O
the O
LaSota O
vaccine O
strain O
, O
expressing O
glycoproteins O
B O
( O
gB O
) O
and O
D O
( O
gD O
) O
of O
ILTV O
using O
reverse O
genetics O
technology O
. O

IMPORTANCE O
This O
paper O
describes O
the O
development O
and O
evaluation O
of O
novel O
bivalent O
vaccines O
against O
chicken O
Infectious B
laryngotracheitis I
( I
ILT I
) I
and O
Newcastle B
disease I
( I
ND I
) I
, O
two O
of O
the O
most O
economically O
important O
infectious O
diseases O
of O
poultry O
. O

In O
the O
present O
study O
, O
we O
generated O
Newcastle B
disease I
virus I
( I
NDV I
) I
recombinants O
expressing O
glycoproteins O
B O
( O
gB O
) O
and O
D O
( O
gD O
) O
of O
infectious B
laryngotracheitis I
virus I
( I
ILTV I
) I
using O
reverse O
genetics O
technology O
. O

Naturally O
occurring O
Newcastle B
disease I
virus I
( I
NDV I
) I
strains O
vary O
greatly O
in O
virulence O
. O

The O
presence O
of O
multibasic O
residues O
at O
the O
proteolytic O
cleavage O
site O
of O
the O
fusion O
( O
F O
) O
protein O
has O
been O
shown O
to O
be O
a O
primary O
determinant O
differentiating O
virulent O
versus O
avirulent O
strains O
. O

In O
this O
study O
, O
we O
evaluated O
the O
contribution O
of O
each O
viral O
gene O
to O
virulence O
individually O
and O
in O
different O
combinations O
by O
exchanging O
genes O
between O
velogenic O
( O
highly O
virulent O
) O
strain O
GB B
Texas I
( I
GBT I
) I
and O
mesogenic O
( O
moderately O
virulent O
) O
strain O
Beaudette B
C I
( I
BC I
) I
. O

These O
two O
strains O
are O
phylogenetically O
closely O
related O
, O
and O
their O
F O
proteins O
contain O
identical O
cleavage O
site O
sequences O
, O
( O
112 O
) O
RRQKR O
down O
arrow O
F O
- O
117 O
. O

Two O
viral O
integral O
membrane O
glycoproteins O
( O
fusion O
[ O
F O
] O
and O
attachment O
[ O
HN O
, O
H O
, O
or O
G O
] O
) O
mediate O
a O
concerted O
process O
of O
host O
receptor O
recognition O
, O
followed O
by O
the O
fusion O
of O
viral O
and O
cellular O
membranes O
, O
resulting O
in O
viral O
nucleocapsid O
entry O
into O
the O
cytoplasm O
. O

Two O
viral O
integral O
membrane O
glycoproteins O
( O
fusion O
[ O
F O
] O
and O
attachment O
[ O
HN O
, O
H O
, O
or O
G O
] O
) O
mediate O
a O
concerted O
process O
of O
host O
receptor O
recognition O
, O
followed O
by O
the O
fusion O
of O
viral O
and O
cellular O
membranes O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
an O
important O
avian O
pathogen O
. O

We O
demonstrated O
that O
NDV O
infection O
induced O
steady O
- O
state O
autophagy O
in O
chicken O
- O
derived O
DF O
- O
1 O
cells O
and O
in O
primary O
chicken B
embryo I
fibroblast I
( I
CEF I
) I
cells O
, O
evident O
through O
increased O
double O
- O
or O
single O
- O
membrane O
vesicles O
, O
the O
accumulation O
of O
green B
fluorescent I
protein I
( I
GFP I
) I
- O
LC3 O
dots O
, O
and O
the O
conversion O
of O
LC3 O
- O
I O
to O
LC3 O
- O
II O
. O

J B
paramyxovirus I
( I
JPV I
) I
was O
first O
isolated O
from O
moribund O
mice O
with O
hemorrhagic O
lung O
lesions O
in O
Australia O
in O
the O
1970s O
. O

Recent O
sequencing O
of O
JPV O
( O
JPV O
- O
LW O
) O
confirms O
that O
JPV O
is O
a O
paramyxovirus O
with O
several O
unique O
features O
. O

However O
, O
neither O
JPV O
- O
LW O
nor O
a O
recombinant O
JPV O
based O
on O
its O
sequence O
( O
rJPV O
- O
LW O
) O
caused O
obvious O
illness O
in O
mice O
. O

In O
this O
work O
, O
we O
analyzed O
a O
different O
JPV O
isolate O
( O
JPV O
- O
BH O
) O
, O
which O
behaved O
differently O
from O
JPV O
- O
LW O
; O
JPV O
- O
BH O
grew O
more O
slowly O
in O
Vero O
cells O
and O
had O
less O
of O
a O
cytopathic O
effect O
on O
tissue O
culture O
cells O
but O
caused O
severe O
disease O
in O
mice O
. O

To O
understand O
the O
roles O
of O
these O
nucleotide O
sequence O
differences O
in O
pathogenicity O
in O
mice O
, O
we O
generated O
a O
recombinant O
JPV O
- O
BH O
strain O
( O
rJPV O
- O
BH O
) O
and O
hybrid O
rJPV O
- O
BH O
strains O
with O
sequences O
from O
the O
leader O
sequence O
( O
rJPV O
- O
BH O
- O
Le O
- O
LW O
) O
, O
the O
GX O
gene O
( O
rJPV O
- O
BH O
- O
GX O
- O
LW O
) O
, O
and O
the O
L O
gene O
( O
rJPV O
- O
BH O
- O
L O
- O
LW O
) O
of O
JPV O
- O
LW O
and O
compared O
their O
pathogenicities O
in O
mice O
. O

Paramyxovirus O
membrane O
glycoproteins O
F B
( I
fusion I
protein I
) I
and O
HN O
, O
H O
, O
or O
G O
( O
attachment O
protein O
) O
are O
critical O
for O
virus O
entry O
, O
which O
occurs O
through O
fusion O
of O
viral O
and O
cellular O
envelopes O
. O

However O
, O
it O
is O
not O
clear O
how O
the O
attachment O
protein O
, O
known O
as O
HN O
in O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
interacts O
with O
F O
and O
triggers O
F O
to O
initiate O
fusion O
. O

By O
extensive O
study O
of O
F O
protein O
cleavage O
activation O
, O
surface O
expression O
, O
and O
energetics O
of O
fusion O
triggering O
, O
we O
found O
a O
role O
for O
an O
immunoglobulin O
- O
like O
( O
Ig O
- O
like O
) O
domain O
, O
where O
multiple O
hydrophobic O
residues O
on O
the O
PIV5 O
F O
protein O
may O
mediate O
F O
- O
HN O
interactions O
. O

Paramyxoviruses O
, O
including O
the O
human O
pathogen O
measles B
virus I
( I
MV I
) I
and O
the O
avian O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
enter O
host O
cells O
through O
fusion O
of O
the O
viral O
envelope O
with O
the O
target O
cell O
membrane O
. O

This O
fusion O
is O
driven O
by O
the O
concerted O
action O
of O
two O
viral O
envelope O
glycoproteins O
: O
the O
receptor O
binding O
protein O
and O
the O
fusion B
protein I
( I
F I
) I
. O

The O
MV O
receptor O
binding O
protein O
( O
hemagglutinin O
[ O
H O
] O
) O
attaches O
to O
proteinaceous O
receptors O
on O
host O
cells O
, O
while O
the O
receptor O
binding O
protein O
of O
NDV O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
) O
interacts O
with O
sialic O
acid O
- O
containing O
receptors O
. O

Paramyxovirus O
attachment O
and O
fusion O
( O
F O
) O
envelope O
glycoprotein O
complexes O
mediate O
membrane O
fusion O
required O
for O
viral O
entry O
. O

The O
measles B
virus I
( I
MeV I
) I
attachment O
( O
H O
) O
protein O
stalk O
domain O
is O
thought O
to O
directly O
engage O
F O
for O
fusion O
promotion O
. O

Paramyxoviruses O
, O
including O
the O
emerging O
lethal O
human B
Nipah I
virus I
( I
NiV I
) I
and O
the O
avian O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
enter O
host O
cells O
through O
fusion O
of O
the O
viral O
and O
target O
cell O
membranes O
. O

For O
paramyxoviruses O
, O
membrane O
fusion O
is O
the O
result O
of O
the O
concerted O
action O
of O
two O
viral O
envelope O
glycoproteins O
: O
a O
receptor O
binding O
protein O
and O
a O
fusion B
protein I
( I
F I
) I
. O

The O
NiV O
receptor O
binding O
protein O
( O
G O
) O
attaches O
to O
ephrin O
B2 O
or O
B3 O
on O
host O
cells O
, O
whereas O
the O
corresponding O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
attachment O
protein O
of O
NDV O
interacts O
with O
sialic O
acid O
moieties O
on O
target O
cells O
through O
two O
regions O
of O
its O
globular O
domain O
. O

retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
is O
a O
key O
sensor O
for O
recognizing O
nucleic O
acids O
derived O
from O
RNA O
viruses O
and O
triggers O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
production O
. O

Overexpression O
of O
SEC14L1 O
inhibited O
transcriptional O
activity O
of O
the O
IFN O
- O
beta O
promoter O
induced O
by O
RIG O
- O
I O
but O
not O
TANK B
- I
binding I
kinase I
1 I
( I
TBK1 I
) I
and O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
. O

SEC14L1 O
interacted O
with O
the O
N O
- O
terminal O
domain O
of O
RIG O
- O
I O
( O
RIG O
- O
I O
caspase O
activation O
and O
recruitment O
domain O
[ O
RIG O
- O
I O
- O
CARD O
] O
) O
and O
competed O
with O
VISA O
/ O
MAVS O
/ O
IPS O
- O
1 O
/ O
Cardif O
for O
RIG O
- O
I O
- O
CARD O
binding O
. O

The O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion I
protein I
( I
F I
) I
mediates O
fusion O
of O
viral O
and O
host O
cell O
membranes O
and O
is O
a O
major O
determinant O
of O
NDV O
pathogenicity O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
the O
effects O
of O
functional O
properties O
of O
F O
cytoplasmic B
tail I
( I
CT I
) I
amino O
acids O
on O
virus O
replication O
and O
pathogenesis O
. O

Out O
of O
a O
series O
of O
C O
- O
terminal O
deletions O
in O
the O
CT O
, O
we O
were O
able O
to O
rescue O
mutant O
viruses O
lacking O
two O
or O
four O
residues O
( O
r O
Delta O
2 O
and O
r O
Delta O
4 O
) O
. O

We O
further O
rescued O
viral O
mutants O
with O
individual O
amino O
acid O
substitutions O
at O
each O
of O
these O
four O
terminal O
residues O
( O
rM553A O
, O
rK552A O
, O
rT551A O
, O
and O
rT550A O
) O
. O

In O
addition O
, O
the O
NDV O
F O
CT O
has O
two O
conserved O
tyrosine O
residues O
( O
Y524 O
and O
Y527 O
) O
and O
a O
dileucine O
motif O
( O
LL536 O
- O
537 O
) O
. O

The O
human B
parainfluenza I
virus I
( I
hPIV I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
protein O
binds O
( O
H O
) O
oligosaccharide O
receptors O
that O
contain O
N B
- I
acetylneuraminic I
acid I
( I
Neu5Ac I
) I
and O
cleaves O
( O
N O
) O
Neu5Ac O
from O
these O
oligosaccharides O
. O

We O
compared O
the O
dissociation O
constant O
( O
K O
- O
d O
) O
values O
from O
these O
experiments O
with O
previously O
determined O
Michaelis O
- O
Menten O
constants O
( O
K O
( O
m O
) O
s O
) O
for O
the O
enzyme O
activity O
. O

In O
previous O
work O
, O
we O
designed O
peptides O
that O
showed O
potent O
inhibition O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
and O
infectious B
bronchitis I
virus I
( I
IBV I
) I
infections O
in O
chicken O
embryos O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
peptides O
modified O
with O
cholesterol O
or O
3 O
U O
of O
polyethylene O
glycol O
( O
PEG O
( O
3 O
) O
) O
conjugated O
to O
the O
peptides O
' O
N O
termini O
showed O
even O
more O
promising O
antiviral O
activities O
when O
tested O
in O
animal O
models O
. O

Both O
cholesterol O
- O
and O
cholesterol O
- O
PEG O
( O
3 O
) O
- O
tagged O
peptides O
were O
able O
to O
protect O
chicken O
embryos O
from O
infection O
with O
different O
serotypes O
of O
NDV O
and O
IBV O
when O
administered O
12 O
h O
prior O
to O
virus O
inoculation O
. O

It O
also O
has O
the O
potential O
to O
cross O
the O
blood O
- O
brain O
barrier O
to O
enter O
the O
avian O
central B
nervous I
system I
( I
CNS I
) I
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
- O
induced O
membrane O
fusion O
requires O
formation O
of O
a O
complex O
between O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
fusion O
( O
F O
) O
proteins O
. O

Recombinant B
Sendai I
virus I
( I
rSeV I
) I
was O
used O
as O
a O
live O
, O
attenuated O
vaccine O
vector O
for O
intranasal O
inoculation O
and O
mucosal O
expression O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
surface O
glycoprotein O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
. O

Two O
vaccine O
candidates O
rSeV O
- O
HPIV3HN O
( O
P O
- O
M O
) O
and O
rSeV O
- O
HPIV3 O
( O
F O
- O
HN O
) O
were O
constructed O
in O
which O
the O
HPIV3 O
HN O
open O
reading O
frame O
and O
an O
additional O
gene O
junction O
was O
inserted O
in O
the O
P O
- O
M O
and O
F O
- O
HN O
gene O
junctions O
of O
rSeV O
, O
respectively O
. O

The O
rSeV O
- O
HPIV3HN O
( O
P O
- O
M O
) O
virus O
was O
attenuated O
compared O
to O
rSeV O
- O
HPIV3 O
( O
F O
- O
HN O
) O
in O
LLC O
- O
MK2 O
cells O
, O
and O
yet O
both O
vaccine O
candidates O
grew O
to O
similar O
extents O
in O
NHBE O
cells O
and O
in O
the O
respiratory O
tracts O
of O
cotton O
rats O
. O

Compared O
to O
vaccination O
with O
a O
high O
dose O
( O
2 O
, O
0 O
, O
000 O
PFU O
) O
, O
intranasal O
inoculation O
with O
a O
low O
dose O
( O
200 O
PFU O
) O
resulted O
in O
a O
10 O
- O
fold O
decrease O
in O
vector O
growth O
in O
the O
nasal O
cavity O
and O
trachea O
and O
a O
50 O
- O
fold O
decrease O
in O
the O
lungs O
. O

Oncolytic O
virus O
( O
OV O
) O
therapies O
of O
cancer O
are O
based O
on O
the O
use O
of O
replication O
- O
competent O
, O
tumor O
- O
selective O
viruses O
with O
limited O
toxicity O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
is O
a O
promising O
OV O
and O
is O
inherently O
tumor O
selective O
and O
cytotoxic O
only O
to O
tumor O
cells O
. O

We O
engineered O
the O
F O
protein O
of O
NDV O
and O
generated O
a O
recombinant B
NDV I
( I
rNDV I
) I
whose O
F O
protein O
is O
cleavable O
exclusively O
by O
prostate B
- I
specific I
antigen I
( I
PSA I
) I
. O

The O
rNDV O
replicated O
efficiently O
and O
specifically O
in O
prostate O
cancer O
( O
CaP O
) O
cells O
and O
3 O
- O
dimensional O
prostaspheres O
but O
failed O
to O
replicate O
in O
the O
absence O
of O
PSA O
. O

Induction O
of O
intracellular O
PSA O
production O
by O
a O
synthetic O
androgen O
analog O
( O
R1881 O
) O
enhanced O
fusogenicity O
in O
androgen O
- O
responsive O
CaP O
cells O
. O

Further O
, O
PSA O
- O
cleavable O
rNDV O
caused O
specific O
lysis O
of O
androgen O
- O
independent O
and O
androgen O
- O
responsive O
/ O
nonresponsive O
CaP O
cells O
and O
prostaspheres O
, O
with O
a O
half B
- I
maximal I
effective I
concentration I
( I
EC50 I
) I
ranging O
from O
a O
multiplicity O
of O
infection O
of O
0 O
. O

The O
promotion O
of O
membrane O
fusion O
by O
most O
paramyxoviruses O
requires O
an O
interaction O
between O
the O
viral O
attachment O
and O
fusion O
( O
F O
) O
proteins O
to O
enable O
receptor O
binding O
by O
the O
former O
to O
trigger O
the O
activation O
of O
the O
latter O
for O
fusion O
. O

Numerous O
studies O
demonstrate O
that O
the O
F O
- O
interactive O
sites O
on O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
and O
measles B
virus I
( I
MV I
) I
hemagglutinin I
( I
H I
) I
proteins O
reside O
entirely O
within O
the O
stalk O
regions O
of O
those O
proteins O
. O

However O
, O
despite O
extensive O
efforts O
, O
the O
F O
- O
interactive O
site O
( O
s O
) O
on O
the O
Nipah B
virus I
( I
NiV I
) I
G O
attachment O
glycoprotein O
has O
not O
been O
identified O
. O

Mesogenic O
vaccine O
strains O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
are O
widely O
used O
in O
many O
countries O
of O
Asia O
and O
Africa O
to O
control O
the O
Newcastle O
disease O
of O
poultry O
. O

At O
least O
11 O
genotypes O
of O
class O
II O
viruses O
have O
been O
identified O
since O
the O
discovery O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
in O
1926 O
. O

We O
report O
here O
the O
complete O
genomic O
sequence O
of O
a O
novel O
Newcastle B
disease I
virus I
( I
NDV I
) I
strain O
, O
egret O
/ O
China O
/ O
Guangxi O
/ O
2011 O
, O
isolated O
from O
an O
egret O
in O
Guangxi O
Province O
, O
southern O
China O
. O

3 O
% O
) O
with O
the O
sequence O
of O
strain O
chicken O
/ O
Sukorejo O
/ O
019 O
/ O
10 O
( O
GenBank O
accession O
number O
HQ697255 O
) O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
is O
inherently O
tumor O
selective O
and O
is O
currently O
being O
considered O
as O
a O
clinical O
oncolytic O
virus O
and O
vaccine O
vector O
. O

Fresh O
normal B
human I
serum I
( I
NHS I
) I
neutralized O
NDV O
by O
multiple O
pathways O
of O
complement O
activation O
, O
independent O
of O
neutralizing O
antibodies O
. O

To O
confirm O
whether O
the O
incorporation O
of O
regulators B
of I
complement I
activity I
( I
RCA I
) I
into O
the O
viral O
envelope O
afforded O
complement O
resistance O
, O
we O
grew O
NDV O
in O
CHO O
cells O
stably O
transfected O
with O
CD46 O
or O
HeLa O
cells O
, O
which O
strongly O
express O
CD46 O
and O
CD55 O
. O

In O
2010 O
and O
2011 O
, O
several O
devastating O
Newcastle B
disease I
( I
ND I
) I
outbreaks O
occurred O
in O
China O
, O
affecting O
broilers O
, O
layers O
, O
and O
breeders O
. O

The O
CK O
- O
JSX1 O
- O
201005 O
virus O
was O
isolated O
from O
broiler O
breeder O
flocks O
vaccinated O
with O
the O
classical O
ND O
virus O
( O
NDV O
) O
vaccine O
program O
, O
but O
laying O
rate O
decreased O
from O
80 O
% O
to O
30 O
to O
40 O
% O
in O
the O
clinic O
. O

Although O
respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
significant O
human O
pathogen O
, O
no O
RSV O
vaccines O
are O
available O
. O

We O
have O
reported O
that O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
RSV O
vaccine O
candidate O
stimulated O
, O
in O
mice O
, O
robust O
, O
protective O
anti O
- O
RSV O
glycoprotein O
T O
( O
H O
) O
1 O
biased O
immune O
responses O
without O
enhanced O
respiratory O
disease O
upon O
RSV O
challenge O
. O

Adoptive O
transfer O
of O
enriched O
splenic O
B O
cells O
from O
VLP O
- O
immunized O
mice O
into O
immunodeficient O
rag O
( O
- O
/ O
- O
) O
mice O
resulted O
in O
anti O
- O
F O
and O
anti O
- O
G O
protein O
serum O
IgG O
antibody O
responses O
, O
in O
recipient O
mice O
, O
that O
were O
protective O
upon O
RSV O
challenge O
. O

Immunization O
with O
VLPs O
stimulated O
the O
formation O
of O
germinal O
center O
GL7 O
( O
+ O
) O
B O
cells O
in O
normal O
mice O
. O

VLP O
immunization O
of O
TCR O
beta O
delta O
( O
- O
/ O
- O
) O
T O
- O
cell O
- O
deficient O
mice O
did O
not O
induce O
anti O
- O
RSV O
IgG O
antibodies O
, O
results O
consistent O
with O
T O
- O
cell O
- O
dependent O
immune O
responses O
. O

The O
genus O
Metapneumovirus O
within O
the O
subfamily O
Pneumovirinae O
of O
the O
family O
Paramyxoviridae O
includes O
two O
members O
, O
human B
metapneumovirus I
( I
HMPV I
) I
and O
Avian B
metapneumovirus I
( I
AMPV I
) I
, O
causing O
respiratory O
tract O
infections O
in O
humans O
and O
birds O
, O
respectively O
. O

Here O
, O
we O
show O
that O
the O
fusion O
( O
F O
) O
proteins O
of O
aMPV O
promote O
fusion O
in O
the O
absence O
of O
the O
attachment O
protein O
and O
low O
pH O
is O
not O
required O
. O

The O
complete O
genome O
sequence O
of O
an O
African O
Newcastle B
disease I
virus I
( I
NDV I
) I
strain O
isolated O
from O
a O
chicken O
in O
Togo O
in O
2009 O
was O
determined O
. O

The O
genome O
is O
15 O
, O
198 O
nucleotides B
( I
nt I
) I
in O
length O
and O
is O
classified O
in O
genotype O
VII O
in O
the O
class O
II O
cluster O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
was O
isolated O
from O
an O
outbreak O
in O
layer O
chickens O
in O
the O
Dominican O
Republic O
in O
2008 O
. O

Currently O
, O
the O
spatial O
distribution O
of O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
proteins O
and O
RNAs O
in O
infected O
cells O
is O
still O
under O
investigation O
, O
with O
many O
unanswered O
questions O
regarding O
the O
interaction O
of O
virus O
- O
induced O
structures O
and O
the O
innate O
immune O
system O
. O

Very O
few O
studies O
of O
hRSV O
have O
used O
subcellular O
imaging O
as O
a O
means O
to O
explore O
the O
changes O
in O
localization O
of O
retinoicacid B
- I
inducible I
gene I
- I
I I
( I
RIG I
- I
I I
) I
- O
like O
receptors O
or O
the O
mitochondrial B
antiviral I
signaling I
( I
MAVS I
) I
protein O
, O
in O
response O
to O
the O
infection O
and O
formation O
of O
viral O
structures O
. O

In O
this O
investigation O
, O
we O
found O
that O
both O
RIG O
- O
I O
and O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
colocalized O
with O
viral O
genomic O
RNA O
and O
the O
nucleoprotein B
( I
N I
) I
as O
early O
as O
6 O
h B
postinfection I
( I
hpi I
) I
. O

By O
12 O
hpi O
, O
MDA5 O
and O
MAVS O
were O
observed O
within O
large O
viral O
Inclusion B
bodies I
( I
IB I
) I
. O

We O
used O
a O
proximity B
ligation I
assay I
( I
PLA I
) I
and O
determined O
that O
the O
N O
protein O
was O
in O
close O
proximity O
to O
MDA5 O
and O
MAVS O
in O
IBs O
throughout O
the O
course O
of O
the O
infection O
. O

Similar O
results O
were O
found O
with O
the O
transient O
coexpression O
of O
N O
and O
the O
phosphoprotein B
( I
P I
) I
. O

The O
V O
protein O
of O
Sendai B
virus I
( I
SeV I
) I
suppresses O
innate O
immunity O
, O
resulting O
in O
enhancement O
of O
viral O
growth O
in O
mouse O
lungs O
and O
viral O
pathogenicity O
. O

The O
innate O
immunity O
restricted O
by O
the O
V O
protein O
is O
induced O
through O
activation O
of O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
. O

The O
V O
protein O
has O
been O
shown O
to O
interact O
with O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
and O
to O
inhibit O
beta O
interferon O
production O
. O

Paramyxoviruses O
initiate O
entry O
through O
the O
concerted O
action O
of O
the O
tetrameric O
attachment O
glycoprotein O
( O
HN O
, O
H O
, O
or O
G O
) O
and O
the O
trimeric O
fusion O
glycoprotein O
( O
F O
) O
. O

The O
G O
attachment O
protein O
stalk O
domain O
of O
the O
highly O
pathogenic O
Nipah B
virus I
( I
NiV I
) I
contains O
a O
distinct O
but O
uncharacterized O
cluster O
of O
three O
cysteine O
residues O
( O
C146 O
, O
C158 O
, O
C162 O
) O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
paramyxoviruses O
carries O
out O
three O
distinct O
activities O
contributing O
to O
the O
ability O
of O
HN O
to O
promote O
viral O
fusion O
and O
entry O
: O
receptor O
binding O
, O
receptor O
cleavage O
( O
neuraminidase O
) O
, O
and O
activation O
of O
the O
fusion O
protein O
. O

For O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
one O
bifunctional O
site O
( O
site O
I O
) O
on O
HN O
' O
s O
globular O
head O
can O
mediate O
both O
receptor O
binding O
and O
neuraminidase O
activities O
, O
and O
a O
second O
site O
( O
site O
II O
) O
in O
the O
globular O
head O
is O
also O
capable O
of O
mediating O
receptor O
binding O
. O

Comparison O
of O
chimeric O
proteins O
in O
which O
the O
globular O
head O
of O
NDV O
HN O
is O
connected O
to O
the O
stalk O
region O
of O
either O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
or O
Nipah O
virus O
receptor O
binding O
proteins O
indicates O
that O
receptor O
binding O
to O
NDV O
HN O
site O
II O
not O
only O
can O
activate O
its O
own O
fusion O
( O
F O
) O
protein O
but O
can O
also O
activate O
the O
heterotypic O
fusion O
proteins O
. O

Eight O
highly O
virulent O
Newcastle B
disease I
virus I
( I
NDV I
) I
strains O
were O
isolated O
from O
vaccinated O
commercial O
chickens O
in O
Indonesia O
during O
outbreaks O
in O
2009 O
and O
2010 O
. O

The O
complete O
genome O
sequences O
of O
two O
NDV O
strains O
and O
the O
sequences O
of O
the O
surface O
protein O
genes O
( O
F O
and O
HN O
) O
of O
six O
other O
strains O
were O
determined O
. O

We O
constructed O
a O
reverse O
genetics O
system O
for O
avian B
paramyxovirus I
serotype I
7 I
( I
APMV I
- I
7 I
) I
to O
investigate O
the O
role O
of O
the O
fusion O
F O
glycoprotein O
in O
tissue O
tropism O
and O
virulence O
. O

The O
AMPV O
- O
7 O
F O
protein O
has O
a O
single O
basic O
residue O
Arginine B
( I
R I
) I
at O
position O
- O
1 O
in O
the O
F O
cleavage O
site O
sequence O
and O
also O
is O
unusual O
in O
having O
alanine O
at O
position O
+ O
2 O
( O
LPSS O
( O
R O
) O
under O
bar O
down O
arrow O
FA O
) O
( O
underlining O
indicates O
the O
basic O
amino O
acids O
at O
the O
F O
protein O
cleavage O
site O
, O
and O
the O
arrow O
indicates O
the O
site O
of O
cleavage O
. O

Two O
mutants O
were O
successfully O
recovered O
in O
which O
the O
cleavage O
site O
was O
modified O
to O
mimic O
sites O
that O
are O
found O
in O
virulent O
Newcastle O
disease O
virus O
isolates O
and O
to O
contain O
4 O
or O
5 O
basic O
residues O
as O
well O
as O
isoleucine O
in O
the O
+ O
2 O
position O
: O
( O
( O
RR O
) O
under O
barQ O
( O
KR O
) O
under O
bar O
down O
arrow O
FI O
) O
or O
( O
( O
RRKKR O
) O
under O
bar O
down O
arrow O
FI O
) O
, O
named O
Fcs O
- O
4B O
or O
Fcs O
- O
5B O
, O
respectively O
. O

This O
indicated O
the O
importance O
of O
the O
single O
additional O
basic O
residue O
( O
K O
) O
at O
position O
- O
3 O
. O

The O
role O
of O
N O
- O
linked O
glycosylation O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
in O
viral O
replication O
and O
pathogenesis O
was O
examined O
by O
eliminating O
potential O
acceptor O
sites O
using O
a O
reverse O
genetics O
system O
for O
the O
moderately O
pathogenic O
strain O
Beaudette B
C I
( I
BC I
) I
. O

The O
NDV O
- O
BC O
F O
protein O
contains O
six O
potential O
acceptor O
sites O
for O
N O
- O
linked O
glycosylation O
at O
residues O
85 O
, O
191 O
, O
366 O
, O
447 O
, O
471 O
, O
and O
541 O
( O
sites O
Ng1 O
to O
Ng6 O
, O
respectively O
) O
. O

The O
sites O
at O
Ng2 O
and O
Ng5 O
are O
present O
in O
heptad B
repeat I
( I
HR I
) I
domains O
HR1 O
and O
HR2 O
, O
respectively O
, O
and O
thus O
might O
affect O
fusion O
. O

Each O
N O
- O
glycosylation O
site O
was O
eliminated O
individually O
by O
replacing O
Asparagine B
( I
N I
) I
with O
Glutamine B
( I
Q I
) I
, O
and O
a O
double O
mutant O
( O
Ng2 O
+ O
5 O
) O
involving O
the O
two O
HR O
domains O
was O
also O
made O
. O

Fusion O
is O
mediated O
by O
the O
viral O
fusion O
( O
F O
) O
protein O
, O
and O
it O
undergoes O
large O
irreversible O
conformational O
changes O
to O
cause O
membrane O
merger O
. O

The O
C O
terminus O
of O
PIV5 O
F O
contains O
a O
membrane B
- I
proximal I
7 I
- I
residue I
external I
region I
( I
MPER I
) I
, O
followed O
by O
the O
transmembrane B
( I
TM I
) I
domain O
and O
a O
20 O
- O
residue O
cytoplasmic O
tail O
. O

To O
study O
the O
sequence O
requirements O
of O
the O
F O
protein O
C O
terminus O
for O
fusion O
, O
we O
constructed O
chimeras O
containing O
the O
ectodomain O
of O
parainfluenza B
virus I
5 I
F I
( I
PIV5 I
F I
) I
and O
either O
the O
MPER O
, O
the O
TM O
domain O
, O
or O
the O
cytoplasmic O
tail O
of O
the O
F O
proteins O
of O
the O
paramyxoviruses O
measles O
virus O
, O
mumps O
virus O
, O
Newcastle O
disease O
virus O
, O
human O
parainfluenza O
virus O
3 O
, O
and O
Nipah O
virus O
. O

Fusion O
could O
be O
restored O
by O
decreasing O
the O
activation O
energy O
of O
refolding O
through O
introduction O
of O
a O
destabilizing O
mutation O
( O
S443P O
) O
. O

Paramyxovirus O
entry O
into O
cells O
requires O
the O
fusion B
protein I
( I
F I
) I
and O
a O
receptor O
binding O
protein O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
, O
H O
, O
or O
G O
) O
. O

The O
multifunctional O
HN O
protein O
of O
some O
paramyxoviruses O
, O
besides O
functioning O
as O
the O
receptor O
( O
sialic O
acid O
) O
binding O
protein O
( O
hemagglutinin O
activity O
) O
and O
the O
receptor O
- O
destroying O
protein O
( O
neuraminidase O
activity O
) O
, O
enhances O
F O
activity O
, O
presumably O
by O
lowering O
the O
activation O
energy O
required O
for O
F O
to O
mediate O
fusion O
of O
viral O
and O
cellular O
membranes O
. O

parainfluenza B
virus I
5 I
( I
PIV5 I
) I
HN O
exists O
as O
a O
noncovalent O
dimer O
- O
of O
- O
dimers O
on O
the O
surface O
of O
cells O
, O
linked O
by O
a O
single O
disulfide O
bond O
in O
the O
stalk O
. O

65 O
angstrom O
, O
revealing O
a O
four B
- I
helix I
bundle I
( I
4HB I
) I
with O
an O
upper O
( O
N O
- O
terminal O
) O
straight O
region O
and O
a O
lower O
( O
C O
- O
terminal O
) O
supercoiled O
part O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
human B
parainfluenza I
viruses I
( I
hPIVs I
) I
both O
binds O
( O
H O
) O
and O
cleaves O
( O
N O
) O
oligosaccharides O
that O
contain O
N B
- I
acetylneuraminic I
acid I
( I
Neu5Ac I
) I
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
- O
induced O
membrane O
fusion O
requires O
an O
interaction O
between O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
attachment O
and O
the O
fusion O
( O
F O
) O
proteins O
, O
triggered O
by O
HN O
' O
s O
binding O
to O
receptors O
. O

By O
characterizing O
the O
effect O
on O
receptor O
binding O
avidity O
and O
F O
- O
interactive O
capability O
of O
HN O
dimer O
interface O
mutations O
, O
we O
present O
evidence O
consistent O
with O
( O
i O
) O
receptor O
engagement O
by O
site O
I O
triggering O
the O
interaction O
with O
F O
and O
( O
ii O
) O
site O
II O
functioning O
to O
maintain O
high O
- O
avidity O
receptor O
binding O
during O
the O
fusion O
process O
. O

The O
recombination O
rate O
in O
Newcastle B
disease I
virus I
( I
NDV I
) I
was O
as O
high O
as O
10 O
% O
in O
RDP O
analysis O
with O
full O
- O
length O
NDV O
genome O
sequences O
available O
in O
GenBank O
. O

human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
is O
transmitted O
mainly O
through O
mucosal O
sites O
. O

We O
therefore O
sought O
to O
evaluate O
the O
induction O
of O
systemic O
and O
mucosal O
immune O
responses O
by O
the O
use O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
as O
a O
vaccine O
vector O
. O

We O
generated O
a O
recombinant O
NDV O
, O
designated O
rLaSota O
/ O
gp160 O
, O
expressing O
the O
gp160 O
envelope B
( I
env I
) I
protein O
of O
HIV O
- O
1 O
from O
an O
added O
gene O
. O

Expression O
of O
gp160 O
did O
not O
increase O
the O
virulence O
of O
recombinant B
NDV I
( I
rNDV I
) I
strain O
LaSota O
. O

Virulent O
and O
moderately O
virulent O
strains O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
representing O
avian B
paramyxovirus I
serotype I
1 I
( I
APMV I
- I
1 I
) I
, O
cause O
respiratory O
and O
neurological O
disease O
in O
chickens O
and O
other O
species O
of O
birds O
. O

We O
investigated O
the O
role O
of O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
envelope O
glycoproteins O
in O
these O
contrasting O
phenotypes O
by O
designing O
chimeric O
viruses O
in O
which O
the O
F O
and O
HN O
glycoproteins O
or O
their O
ectodomains O
were O
exchanged O
individually O
or O
together O
between O
the O
moderately O
virulent O
, O
neurotropic O
NDV O
strain O
Beaudette B
C I
( I
BC I
) I
and O
the O
avirulent O
APMV O
- O
2 O
strain O
Yucaipa O
. O

When O
we O
attempted O
to O
exchange O
the O
complete O
F O
and O
HN O
glycoproteins O
individually O
and O
together O
between O
the O
two O
viruses O
, O
the O
only O
construct O
that O
could O
be O
recovered O
was O
recombinant B
APMV I
- I
2 I
strain I
Yucaipa I
( I
rAPMV I
- I
2 I
) I
, O
containing O
the O
NDV O
F O
glycoprotein O
in O
place O
of O
its O
own O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
belongs O
to O
serotype O
1 O
of O
the O
avian B
paramyxoviruses I
( I
APMV I
- I
1 I
) I
and O
causes O
severe O
disease O
in O
chickens O
. O

Two O
recombinant O
viruses O
, O
rAPMV3 O
- O
F O
and O
rAPMV3 O
- O
HN O
, O
were O
generated O
expressing O
the O
NDV O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
proteins O
, O
respectively O
, O
from O
added O
genes O
. O

With O
oculonasal O
or O
intramuscular O
challenge O
, O
all O
three O
recombinant O
viruses O
( O
rAPMV3 O
, O
rAPMV3 O
- O
F O
, O
and O
rAPMV3 O
- O
HN O
) O
were O
protective O
, O
while O
all O
unvaccinated O
birds O
succumbed O
to O
death O
. O

The O
matrix B
( I
M I
) I
protein O
of O
the O
respiratory O
pathogen O
human B
metapneumovirus I
( I
HMPV I
) I
contains O
two O
such O
conserved O
motifs O
- O
YSKL O
and O
YAGL O
. O

The O
YAGL O
motif O
did O
not O
act O
as O
a O
late B
( I
L I
) I
domain O
, O
however O
, O
since O
hMPV O
budding O
was O
independent O
of O
the O
cellular O
endosomal B
sorting I
complex I
required I
for I
transport I
( I
ESCRT I
) I
machinery O
and O
because O
replacement O
of O
the O
YAGL O
motif O
with O
classical O
L O
domains O
generated O
defective O
viruses O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
a O
negative O
- O
sense O
RNA O
virus O
that O
has O
been O
shown O
to O
possess O
oncolytic O
activity O
. O

Here O
we O
demonstrate O
that O
NDV O
possesses O
oncolytic O
activity O
in O
tumor O
cells O
capable O
of O
a O
robust O
type B
I I
interferon I
( I
IFN I
) I
response O
, O
suggesting O
that O
another O
mechanism O
underlies O
NDV O
' O
s O
tumor O
specificity O
. O

Avian B
paramyxovirus I
serotype I
2 I
( I
APMV I
- I
2 I
) I
is O
one O
of O
the O
nine O
serotypes O
of O
APMV O
, O
which O
infect O
a O
wide O
variety O
of O
avian O
species O
around O
the O
world O
. O

In O
this O
study O
, O
we O
constructed O
a O
reverse O
genetics O
system O
for O
recovery O
of O
infectious O
recombinant O
APMV B
- I
2 I
strain I
Yucaipa I
( I
APMV I
- I
2 I
/ I
Yuc I
) I
from O
cloned O
cDNA O
. O

The O
rescued O
recombinant O
virus O
( O
rAPMV O
- O
2 O
) O
resembled O
the O
biological O
virus O
in O
growth O
properties O
in O
vitro O
and O
in O
pathogenicity O
in O
vivo O
. O

The O
reverse O
genetics O
system O
was O
used O
to O
analyze O
the O
role O
of O
the O
cleavage O
site O
of O
the O
fusion O
( O
F O
) O
protein O
in O
viral O
replication O
and O
pathogenesis O
. O

The O
cleavage O
site O
of O
APMV O
- O
2 O
/ O
Yuc O
( O
KPASR O
down O
arrow O
F O
) O
contains O
only O
a O
single O
basic O
residue O
( O
position O
- O
1 O
) O
that O
matches O
the O
preferred O
furin O
cleavage O
site O
[ O
RX O
( O
K O
/ O
R O
) O
R O
down O
arrow O
] O
. O

For O
most O
paramyxoviruses O
, O
virus O
type O
- O
specific O
interaction O
between O
fusion O
( O
F O
) O
protein O
and O
attachment O
protein O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
, O
hemagglutinin O
[ O
H O
] O
, O
or O
glycoprotein O
[ O
G O
] O
) O
is O
a O
prerequisite O
for O
mediating O
virus O
- O
cell O
fusion O
and O
cell O
- O
cell O
fusion O
. O

Our O
previous O
cell O
- O
cell O
fusion O
assay O
using O
the O
chimeric O
F O
proteins O
of O
human B
parainfluenza I
virus I
2 I
( I
HPIV2 I
) I
and O
simian O
virus O
41 O
( O
SV41 O
) O
suggested O
that O
the O
middle O
region O
of O
the O
HPIV2 O
F O
protein O
contains O
the O
site O
( O
s O
) O
that O
determines O
its O
specificity O
for O
the O
HPIV2 O
HN O
protein O
. O

By O
analyzing O
the O
reported O
structure O
of O
the O
F O
protein O
of O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
, O
we O
found O
that O
four O
major O
domains O
( O
M1 O
, O
M2 O
, O
M3 O
, O
and O
M4 O
) O
and O
five O
minor O
domains O
( O
A O
to O
E O
) O
in O
the O
middle O
region O
of O
the O
PIV5 O
F O
protein O
were O
exposed O
on O
the O
trimer O
surface O
. O

The O
results O
showed O
that O
a O
chimera O
designated O
M O
( O
1 O
+ O
2 O
) O
, O
which O
harbored O
SV41 O
F O
- O
derived O
domains O
M1 O
and O
M2 O
, O
mediated O
cell O
- O
cell O
fusion O
with O
the O
coexpressed O
SV41 O
HN O
protein O
, O
suggesting O
that O
these O
domains O
are O
involved O
in O
determining O
the O
HN O
protein O
specificity O
. O

Intriguingly O
, O
another O
chimera O
which O
harbored O
the O
SV41 O
F O
- O
derived O
domain O
B O
in O
addition O
to O
domains O
M1 O
and O
M2 O
showed O
increased O
specificity O
for O
the O
SV41 O
HN O
protein O
compared O
to O
that O
of O
M O
( O
1 O
+ O
2 O
) O
, O
although O
it O
was O
capable O
of O
mediating O
cell O
- O
cell O
fusion O
by O
itself O
. O

The O
role O
of O
specific O
sequences O
in O
the O
transmembrane B
( I
TM I
) I
domain O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
in O
the O
structure O
and O
function O
of O
this O
protein O
was O
assessed O
by O
replacing O
this O
domain O
with O
the O
F O
protein O
TM O
domains O
from O
two O
other O
paramyxoviruses O
, O
Sendai B
virus I
( I
SV I
) I
and O
measles B
virus I
( I
MV I
) I
, O
or O
the O
TM O
domain O
of O
the O
unrelated O
glycoprotein B
( I
G I
) I
of O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

In O
contrast O
to O
the O
wild O
- O
type O
protein O
, O
the O
mutant O
proteins O
did O
not O
form O
detectable O
complexes O
with O
the O
NDV O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
. O

For O
paramyxoviruses O
, O
viral O
matrix B
( I
M I
) I
proteins O
are O
key O
drivers O
of O
virus O
assembly O
and O
budding O
. O

However O
, O
other O
paramyxovirus O
proteins O
, O
including O
glycoproteins O
, O
nucleocapsid O
( O
NP O
or O
N O
) O
proteins O
, O
and O
C O
proteins O
, O
are O
also O
important O
for O
particle O
formation O
in O
some O
cases O
. O

To O
investigate O
the O
role O
of O
NP O
protein O
in O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
particle O
formation O
, O
NP O
protein O
truncation O
and O
substitution O
mutants O
were O
analyzed O
. O

Alterations O
near O
the O
C O
- O
terminal O
end O
of O
NP O
protein O
completely O
disrupted O
its O
virus B
- I
like I
particle I
( I
VLP I
) I
production O
function O
and O
significantly O
impaired O
M O
- O
NP O
protein O
interaction O
. O

Two O
of O
the O
Vero O
- O
propagated O
viruses O
acquired O
the O
same O
mutation O
, O
V O
/ O
P O
( O
S157F O
) O
, O
found O
previously O
to O
be O
responsible O
for O
elevated O
viral O
gene O
expression O
induced O
by O
a O
well O
- O
characterized O
variant O
of O
PIV5 O
, O
P O
/ O
V O
- O
CPI O
- O
. O

Both O
Vero O
- O
and O
MDBK O
- O
propagated O
viruses O
exhibited O
infectivity O
defects O
and O
altered O
polypeptide O
composition O
, O
consistent O
with O
poor O
incorporation O
of O
viral O
ribonucleoprotein B
complexes I
( I
RNPs I
) I
into O
budding O
virions O
. O

Individual O
Nipah O
virus O
immune O
antagonists O
( O
phosphoprotein O
and O
V O
and O
W O
proteins O
) O
were O
expressed O
from O
recombinant O
Newcastle O
disease O
viruses O
, O
and O
the O
responses O
of O
infected O
human O
monocyte O
- O
derived O
dendritic O
cells O
were O
determined O
. O

Dengue B
Virus I
( I
DENV I
) I
is O
the O
most O
prevalent O
arthropod O
- O
borne O
human O
virus O
, O
able O
to O
infect O
and O
replicate O
in O
human B
dendritic I
cells I
( I
DCs I
) I
, O
inducing O
their O
activation O
and O
the O
production O
of O
proinflammatory O
cytokines O
. O

Several O
mechanisms O
of O
immune O
evasion O
have O
been O
suggested O
for O
DENV O
, O
most O
of O
them O
involving O
interference O
with O
type B
I I
interferon I
( I
IFN I
) I
signaling O
. O

In O
this O
article O
, O
we O
report O
that O
DENV O
also O
reduces O
the O
ability O
of O
DCs O
to O
produce O
type O
I O
IFN O
in O
response O
to O
several O
inducers O
, O
such O
as O
infection O
with O
other O
viruses O
or O
exposure O
to O
Toll B
- I
like I
receptor I
( I
TLR I
) I
ligands O
, O
indicating O
that O
DENV O
antagonizes O
the O
type O
I O
IFN O
production O
pathway O
in O
human O
DCs O
. O

DENV O
- O
infected O
human O
DCs O
showed O
a O
reduced O
type O
I O
IFN O
response O
to O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
Sendai B
virus I
( I
SeV I
) I
, O
and O
Semliki B
Forest I
virus I
( I
SFV I
) I
infection O
and O
to O
the O
TLR3 O
agonist O
poly O
( O
I O
: O
C O
) O
. O

Virulent O
strains O
of O
Newcastle O
disease O
virus O
( O
[ O
NDV O
] O
also O
known O
as O
avian O
paramyxovirus O
type O
1 O
) O
can O
be O
discriminated O
from O
low O
- O
virulence O
strains O
by O
the O
presence O
of O
multiple O
basic O
amino O
acid O
residues O
at O
the O
proteolytic O
cleavage O
site O
of O
the O
fusion O
( O
F O
) O
protein O
. O

However O
, O
some O
NDV O
variants O
isolated O
from O
pigeons O
( O
pigeon O
paramyxovirus O
type O
1 O
[ O
PPMV O
- O
1 O
] O
) O
have O
low O
levels O
of O
virulence O
, O
despite O
the O
fact O
that O
their O
F O
protein O
cleavage O
sites O
contain O
a O
multibasic O
amino O
acid O
sequence O
and O
have O
the O
same O
functionality O
as O
that O
of O
virulent O
strains O
. O

Using O
reverse O
genetics O
, O
the O
genes O
encoding O
the O
nucleoprotein B
( I
NP I
) I
, O
phosphoprotein B
( I
P I
) I
, O
matrix B
protein I
( I
M I
) I
, O
and O
large O
polymerase O
protein O
( O
L O
) O
were O
exchanged O
between O
the O
nonvirulent O
PPMV O
- O
1 O
strain O
AV324 O
and O
the O
highly O
virulent O
NDV O
strain O
Herts O
. O

Despite O
substantial O
efforts O
to O
control O
H5N1 O
avian B
influenza I
viruses I
( I
AIVs I
) I
, O
the O
viruses O
have O
continued O
to O
evolve O
and O
cause O
disease O
outbreaks O
in O
poultry O
and O
infections O
in O
humans O
. O

Twelve O
genotypes O
of O
AIVs O
in O
southern O
China O
bear O
similar O
H5 O
Hemagglutinin B
( I
HA I
) I
genes O
( O
clade O
2 O
. O

These O
AIVs O
did O
not O
display O
antigenic O
drift O
and O
could O
be O
completely O
protected O
against O
by O
the O
A O
/ O
goose O
/ O
Guangdong O
/ O
1 O
/ O
96 O
( O
GS O
/ O
GD O
/ O
1 O
/ O
96 O
) O
- O
based O
oil O
- O
adjuvanted O
killed O
vaccine O
and O
recombinant O
Newcastle O
disease O
virus O
vaccine O
, O
which O
have O
been O
used O
in O
China O
. O

In O
addition O
, O
antigenically O
drifted O
H5N1 O
viruses O
, O
represented O
by O
A O
/ O
chicken O
/ O
Shanxi O
/ O
2 O
/ O
06 O
( O
CK O
/ O
SX O
/ O
2 O
/ O
06 O
) O
, O
were O
detected O
in O
chickens O
from O
several O
provinces O
in O
northern O
China O
. O

type B
I I
interferons I
( I
IFNs I
) I
are O
considered O
to O
be O
important O
mediators O
of O
innate O
immunity O
due O
to O
their O
inherent O
antiviral O
activity O
, O
ability O
to O
drive O
the O
transcription O
of O
a O
number O
of O
genes O
involved O
in O
viral O
clearance O
, O
and O
their O
role O
in O
the O
initiation O
of O
innate O
and O
adaptive O
immune O
responses O
. O

Due O
to O
the O
central O
role O
of O
type O
I O
IFNs O
, O
we O
sought O
to O
determine O
their O
importance O
in O
the O
generation O
of O
immunity O
to O
a O
recombinant O
vaccine O
vector O
fowlpox B
virus I
( I
FPV I
) I
. O

In O
analyzing O
the O
role O
of O
type O
I O
IFNs O
in O
immunity O
to O
FPV O
, O
we O
show O
that O
they O
are O
critical O
to O
the O
secretion O
of O
a O
number O
of O
innate O
and O
proinflammatory O
cytokines O
, O
including O
type O
I O
IFNs O
themselves O
as O
well O
as O
interleukin B
- I
12 I
( I
IL I
- I
12 I
) I
, O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
IL O
- O
6 O
, O
and O
IL O
- O
1 O
beta O
, O
and O
that O
deficiency O
leads O
to O
enhanced O
virus O
- O
mediated O
antigen O
expression O
. O

Interestingly O
, O
however O
, O
type O
I O
IFNs O
were O
not O
required O
for O
adaptive O
immune O
responses O
to O
recombinant O
FPV O
even O
though O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
, O
the O
primary O
producers O
of O
type O
I O
IFNs O
, O
have O
been O
shown O
to O
be O
requisite O
for O
this O
to O
occur O
. O

Dengue B
Virus I
( I
DENV I
) I
infects O
human O
immune O
cells O
in O
vitro O
and O
likely O
infects O
dendritic B
cells I
( I
DCs I
) I
in O
vivo O
. O

DENV O
- O
2 O
productive O
infection O
induces O
activation O
and O
release O
of O
high O
levels O
of O
chemokines O
and O
proinflammatory O
cytokines O
in O
monocyte B
- I
derived I
DCs I
( I
moDCs I
) I
, O
with O
the O
notable O
exception O
of O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
is O
tumor O
selective O
and O
intrinsically O
oncolytic O
because O
of O
its O
potent O
ability O
to O
induce O
apoptosis O
. O

Several O
studies O
have O
demonstrated O
that O
NDV O
is O
selectively O
cytotoxic O
to O
tumor O
cells O
but O
not O
normal O
cells O
due O
to O
defects O
in O
the O
interferon B
( I
IFN I
) I
antiviral O
responses O
of O
tumor O
cells O
. O

We O
compared O
the O
cell O
killing O
abilities O
of O
( O
i O
) O
a O
recombinant B
NDV I
( I
rNDV I
) I
strain O
, O
Beaudette O
C O
, O
containing O
an O
IFN O
- O
antagonistic O
, O
wild O
- O
type O
V O
protein O
( O
rBC O
) O
, O
( O
ii O
) O
an O
isogenic O
recombinant O
virus O
with O
a O
mutant O
V O
protein O
( O
rBC O
- O
Edit O
virus O
) O
that O
induces O
increased O
IFN O
in O
infected O
cells O
and O
whose O
replication O
is O
restricted O
in O
normal O
human O
cells O
, O
and O
( O
iii O
) O
a O
recombinant O
LaSota O
virus O
with O
a O
virulent O
F O
protein O
cleavage O
site O
that O
is O
as O
interferon O
sensitive O
as O
rBC O
- O
Edit O
virus O
( O
LaSota O
V O
. O

To O
gain O
insight O
into O
the O
role O
of O
untranslated B
regions I
( I
UTRs I
) I
in O
regulation O
of O
foreign O
gene O
expression O
, O
replication O
, O
and O
pathogenicity O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
a O
green B
fluorescent I
protein I
( I
GFP I
) I
gene O
flanked O
by O
5 O
' O
and O
3 O
' O
UTRs O
of O
each O
NDV O
gene O
was O
individually O
expressed O
by O
recombinant O
NDVs O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
plays O
a O
critical O
role O
in O
parainfluenza O
virus O
replication O
. O

We O
recently O
found O
that O
in O
addition O
to O
the O
catalytic O
binding O
site O
, O
HN O
of O
human O
parainfluenza O
virus O
type O
1 O
( O
hPIV O
- O
1 O
) O
may O
have O
a O
second O
receptor O
- O
binding O
site O
covered O
by O
an O
N O
- O
linked O
glycan O
at O
residue O
173 O
, O
which O
is O
near O
the O
region O
of O
the O
second O
receptor O
- O
binding O
site O
identified O
in O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
( O
I O
. O

Removal O
of O
this O
N O
- O
linked O
glycosylation O
site O
by O
an O
Asn O
- O
to O
- O
Asp O
substitution O
at O
residue O
523 O
( O
N523D O
) O
changed O
the O
spectrum O
of O
the O
mutant O
virus O
' O
s O
receptor O
specificity O
, O
delayed O
its O
elution O
from O
both O
turkey O
and O
chicken O
red O
blood O
cells O
, O
reduced O
mutant O
sensitivity O
( O
by O
about O
half O
) O
to O
the O
selective O
HN O
inhibitor O
BCX O
2855 O
in O
hemagglutination O
inhibition O
tests O
, O
and O
slowed O
its O
growth O
in O
LLC O
- O
MK O
2 O
cells O
. O

H5N1 O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
causes O
periodic O
outbreaks O
in O
humans O
, O
resulting O
in O
severe O
infections O
with O
a O
high O
( O
60 O
% O
) O
incidence O
of O
mortality O
. O

We O
previously O
engineered O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
as O
a O
vector O
to O
express O
the O
HPAIV O
Hemagglutinin B
( I
HA I
) I
protein O
, O
and O
we O
showed O
that O
this O
vaccine O
( O
NDV O
/ O
HA O
) O
induced O
a O
high O
level O
of O
HPAIV O
- O
specific O
mucosal O
and O
serum O
antibodies O
in O
primates O
when O
administered O
through O
the O
respiratory O
tract O
. O

Here O
we O
developed O
additional O
NDV O
- O
vectored O
vaccines O
expressing O
either O
HPAIV O
HA O
in O
which O
the O
polybasic O
cleavage O
site O
was O
replaced O
with O
that O
from O
a O
low O
- O
pathogenicity O
strain O
of O
influenza O
virus O
[ O
HA O
( O
RV O
) O
] O
, O
in O
order O
to O
address O
concerns O
of O
enhanced O
vector O
replication O
or O
genetic O
exchange O
, O
or O
HPAIV O
neuraminidase B
( I
NA I
) I
. O

The O
three O
vaccine O
viruses O
[ O
NDV O
/ O
HA O
, O
NDV O
/ O
HA O
( O
RV O
) O
, O
and O
NDV O
/ O
NA O
] O
were O
administered O
separately O
to O
groups O
of O
African O
green O
monkeys O
by O
the O
intranasal O
/ O
intratracheal O
route O
. O

All O
groups O
developed O
high O
levels O
of O
neutralizing O
antibodies O
against O
homologous O
and O
heterologous O
strains O
of O
HPAIV O
and O
were O
protected O
against O
challenge O
with O
2 O
x O
10 O
( O
7 O
) O
PFU O
of O
homologous O
HPAIV O
. O

Thus O
, O
needle O
- O
free O
, O
highly O
attenuated O
NDV O
- O
vectored O
vaccines O
expressing O
either O
HPAIV O
HA O
, O
HA O
( O
RV O
) O
, O
or O
NA O
have O
been O
developed O
and O
demonstrated O
to O
be O
individually O
immunogenic O
and O
protective O
in O
a O
primate O
model O
of O
HPAIV O
infection O
. O

The O
finding O
that O
HA O
( O
RV O
) O
was O
protective O
indicates O
that O
it O
would O
be O
preferred O
for O
inclusion O
in O
a O
vaccine O
. O

The O
entry O
of O
enveloped O
viruses O
into O
host O
cells O
is O
preceded O
by O
membrane O
fusion O
, O
which O
in O
paramyxoviruses O
is O
triggered O
by O
the O
fusion O
( O
F O
) O
protein O
. O

Here O
we O
examined O
the O
effects O
of O
mutations O
of O
individual O
residues O
of O
the O
F O
protein O
of O
Newcastle O
disease O
virus O
, O
located O
at O
critical O
regions O
of O
the O
protein O
, O
such O
as O
the O
C O
terminus O
of O
the O
N O
- O
terminal O
heptad B
repeat I
( I
HRA I
) I
and O
the O
N O
terminus O
of O
the O
C O
- O
terminal O
heptad O
repeat O
( O
HRB O
) O
. O

Moreover O
, O
the O
N211A O
, O
I463A O
, O
and O
I463F O
mutants O
exhibited O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
- O
independent O
activity O
when O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
was O
coexpressed O
as O
an O
attachment O
protein O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
the O
leading O
cause O
of O
serious O
respiratory O
infections O
in O
children O
as O
well O
as O
a O
serious O
cause O
of O
disease O
in O
elderly O
and O
immunosuppressed O
populations O
. O

We O
have O
developed O
a O
virus B
- I
like I
particle I
( I
VLP I
) I
vaccine O
candidate O
for O
protection O
from O
RSV O
. O

The O
VLP O
is O
composed O
of O
the O
NP O
and O
M O
proteins O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
and O
a O
chimeric O
protein O
containing O
the O
cytoplasmic O
and O
transmembrane O
domains O
of O
the O
NDV O
HN O
protein O
and O
the O
ectodomain O
of O
the O
human O
RSV O
G O
protein O
( O
H O
/ O
G O
) O
. O

Upon O
RSV O
challenge O
of O
VLP O
- O
H O
/ O
G O
- O
immunized O
mice O
, O
no O
enhanced O
pathology O
in O
the O
lungs O
was O
observed O
, O
although O
lungs O
of O
mice O
immunized O
in O
parallel O
with O
formalin B
- I
inactivated I
RSV I
( I
FI I
- I
RSV I
) I
showed O
the O
significant O
pathology O
that O
has O
previously O
been O
documented O
after O
immunization O
with O
FI O
- O
RSV O
. O

One O
factor O
responsible O
for O
the O
poor O
prognosis O
of O
melanoma O
is O
the O
inhibitor B
of I
apoptosis I
protein I
( I
IAP I
) I
family O
member O
Livin O
. O

In O
this O
study O
, O
we O
applied O
a O
novel O
approach O
for O
the O
treatment O
of O
melanoma O
, O
using O
a O
unique O
strain O
of O
the O
oncolytic O
Newcastle O
disease O
virus O
( O
NDV O
- O
HUJ O
) O
. O

For O
paramyxoviruses O
, O
entry O
requires O
a O
receptor O
- O
binding O
protein O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
, O
H O
, O
or O
G O
) O
and O
a O
fusion B
protein I
( I
F I
) I
. O

HN O
may O
serve O
as O
a O
clamp O
that O
stabilizes O
F O
in O
its O
prefusion O
state O
until O
HN O
binds O
the O
target O
cell O
( O
the O
clamp O
model O
) O
. O

Alternatively O
, O
HN O
itself O
may O
undergo O
a O
conformational O
change O
after O
receptor O
binding O
that O
destabilizes O
F O
and O
causes O
F O
to O
trigger O
( O
the O
provocateur O
model O
) O
. O

To O
examine O
F O
- O
HN O
interactions O
by O
bimolecular B
fluorescence I
complementation I
( I
BiFC I
) I
, O
the O
cytoplasmic O
tails O
of O
parainfluenza B
virus I
5 I
( I
PIV5 I
) I
F O
and O
HN O
were O
fused O
to O
complementary O
fragments O
of O
yellow B
fluorescent I
protein I
( I
YFP I
) I
. O

We O
hypothesize O
that O
the O
increase O
in O
fusion O
occurs O
because O
the O
BiFC O
tags O
bring O
F O
and O
HN O
together O
more O
frequently O
than O
occurs O
in O
a O
wild B
- I
type I
( I
WT I
) I
scenario O
. O

Lymphocytic B
choriomeningitis I
virus I
( I
LCVM I
) I
nucleoprotein B
( I
NP I
) I
counteracts O
the O
host O
type B
I I
interferon I
( I
IFN I
) I
response O
by O
inhibiting O
activation O
of O
the O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
. O

We O
used O
reverse O
genetics O
to O
rescue O
a O
recombinant O
LCMV O
strain O
carrying O
mutation O
D382A O
in O
its O
NP O
[ O
rLCMV O
/ O
NP O
* O
( O
D382A O
) O
] O
. O

Compared O
to O
wild B
- I
type I
( I
WT I
) I
LCMV O
, O
rLCMV O
/ O
NP O
* O
( O
D382A O
) O
exhibited O
a O
higher O
level O
of O
attenuation O
in O
IFN O
- O
competent O
than O
IFN O
- O
deficient O
cells O
. O

In O
addition O
, O
A549 O
cells O
infected O
with O
rLCMV O
/ O
NP O
* O
( O
D382A O
) O
, O
but O
not O
with O
WT O
LCMV O
, O
produced O
IFN O
and O
failed O
to O
rescue O
replication O
of O
the O
IFN O
- O
sensitive O
Newcastle O
disease O
virus O
. O

The O
spatial O
organization O
of O
metastable O
paramyxovirus O
fusion O
( O
F O
) O
and O
attachment O
glycoprotein O
heterooligomers O
is O
largely O
unknown O
. O

To O
further O
elucidate O
the O
organization O
of O
functional O
fusion O
complexes O
of O
measles B
virus I
( I
MeV I
) I
, O
an O
archetype O
of O
the O
paramyxovirus O
family O
, O
we O
subjected O
central O
predictions O
of O
alternative O
docking O
models O
to O
experimental O
testing O
using O
three O
distinct O
approaches O
. O

Carbohydrate O
shielding O
through O
engineered O
N O
- O
glycans O
indicates O
close O
proximity O
of O
a O
membrane O
- O
distal O
, O
but O
not O
membrane O
- O
proximal O
, O
section O
of O
the O
MeV O
attachment O
( O
H O
) O
protein O
stalk O
domain O
to O
F O
. O

To O
determine O
the O
role O
of O
amino O
acid O
sequences O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
cytoplasmic O
tail O
in O
Newcastle B
disease I
virus I
( I
NDV I
) I
replication O
and O
pathogenicity O
, O
we O
generated O
recombinant O
NDVs O
with O
a O
deletion O
or O
point O
mutation O
in O
the O
N O
- O
terminal O
cytoplasmic O
tail O
. O

The O
avian O
paramyxovirus O
Newcastle B
disease I
virus I
( I
NDV I
) I
selectively O
replicates O
in O
tumor O
cells O
and O
is O
known O
to O
stimulate O
T O
- O
cell O
- O
, O
macrophage O
- O
, O
and O
NK O
cell O
- O
mediated O
responses O
. O

hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
of O
the O
virus O
serves O
as O
a O
ligand O
structure O
for O
NKp44 O
and O
NKp46 O
, O
as O
indicated O
by O
the O
blockade O
of O
binding O
to O
NDV O
- O
infected O
cells O
and O
viral O
particles O
in O
the O
presence O
of O
anti O
- O
HN O
antibodies O
and O
by O
binding O
to O
cells O
transfected O
with O
HN O
cDNA O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
is O
a O
multifunctional O
protein O
that O
plays O
a O
crucial O
role O
in O
virus O
infectivity O
. O

In O
this O
study O
, O
using O
the O
mesogenic O
strain O
Beaudette B
C I
( I
BC I
) I
, O
we O
mutated O
three O
conserved O
amino O
acids O
thought O
to O
be O
part O
of O
the O
binding O
/ O
catalytic O
active O
site O
in O
the O
HN O
protein O
. O

To O
determine O
the O
role O
of O
untranslated B
regions I
( I
UTRs I
) I
in O
replication O
and O
pathogenesis O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
we O
generated O
recombinant O
viruses O
with O
deletions O
in O
5 O
' O
and O
3 O
' O
UTRs O
of O
the O
HN O
mRNA O
. O

In O
particular O
, O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
has O
been O
shown O
to O
be O
essential O
for O
the O
induction O
of O
an O
antiviral O
response O
. O

Upon O
entry O
of O
replication O
- O
deficient O
Newcastle B
disease I
virus I
( I
NDV I
) I
particles O
, O
however O
, O
we O
failed O
to O
detect O
IRF3 O
dimerization O
or O
hyperphosphorylation O
, O
despite O
robust O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
and O
antiviral O
state O
induction O
and O
confirmation O
by O
small O
interfering O
RNA O
knockdown O
that O
IRF3 O
is O
essential O
for O
this O
response O
. O

Most O
paramyxovirus O
fusion O
proteins O
require O
coexpression O
of O
and O
activation O
by O
a O
homotypic O
attachment O
protein O
, O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
, O
to O
promote O
membrane O
fusion O
. O

We O
previously O
showed O
that O
the O
incorporation O
of O
a O
monohistidylated O
lipid O
into O
F O
- O
virosome O
( O
Sendai O
viral O
envelope O
containing O
only O
fusion O
protein O
) O
enhanced O
its O
fusion O
to O
hepatocytes O
, O
suggesting O
that O
the O
histidine O
residue O
in O
the O
lipid O
accelerated O
membrane O
fusion O
. O

In O
membrane O
fusion O
assays O
, O
the O
histidine O
substitution O
mutants O
of O
HN O
( O
H247A O
of O
Sendai O
virus O
and O
H245A O
of O
human O
parainfluenza O
virus O
3 O
) O
had O
impaired O
membrane O
fusion O
promotion O
activity O
without O
significant O
changes O
in O
other O
biological O
activities O
. O

One O
attractive O
strategy O
for O
the O
development O
of O
a O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
vaccine O
is O
the O
use O
of O
viral O
vectors O
with O
a O
proven O
safety O
profile O
and O
an O
absence O
of O
preexisting O
immunity O
in O
humans O
, O
such O
as O
Newcastle B
disease I
virus I
( I
NDV I
) I
. O

Our O
in O
vivo O
experiments O
revealed O
that O
higher O
HIV O
Gag O
protein O
expression O
positively O
correlates O
with O
an O
enhanced O
CD8 O
( O
+ O
) O
T O
- O
cell O
- O
mediated O
immune O
response O
and O
protective O
immunity O
against O
challenge O
with O
vaccinia O
virus O
expressing O
HIV O
Gag O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
entry O
into O
host O
cells O
is O
mediated O
by O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
fusion O
( O
F O
) O
glycoproteins O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
directs O
membrane O
fusion O
, O
which O
is O
required O
for O
virus O
entry O
and O
cell O
- O
cell O
fusion O
. O

Extending O
these O
observations O
, O
we O
evaluated O
the O
role O
of O
the O
overexpression O
of O
two O
disulfide O
bond O
isomerases O
, O
protein B
disulfide I
isomerase I
( I
PDI I
) I
and O
ERdj5 O
, O
in O
cell O
- O
cell O
fusion O
mediated O
by O
NDV O
glycoproteins O
. O

The O
overexpression O
of O
these O
isomerases O
enhanced O
the O
production O
of O
free O
thiols O
in O
F O
protein O
when O
expressed O
without O
hemagglutination O
- O
neuraminidase O
( O
HN O
) O
protein O
but O
decreased O
free O
thiols O
in O
F O
protein O
expressed O
with O
HN O
protein O
. O

Hendra B
virus I
( I
HeV I
) I
is O
a O
member O
of O
the O
broadly O
tropic O
and O
highly O
pathogenic O
paramyxovirus O
genus O
Henipavirus O
. O

HeV O
is O
enveloped O
and O
infects O
cells O
by O
using O
membrane O
- O
anchored O
attachment O
( O
G O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
. O

Nine O
of O
12 O
individual O
HeV O
G O
alanine O
substitution O
mutants O
possessed O
a O
complete O
defect O
in O
fusion O
- O
promotion O
activity O
yet O
were O
cell O
surface O
expressed O
and O
recognized O
by O
a O
panel O
of O
conformation O
- O
dependent O
Monoclonal B
antibodies I
( I
MAbs I
) I
and O
maintained O
their O
oligomeric O
structure O
. O

Sendai B
virus I
( I
SeV I
) I
C O
protein O
is O
a O
multifunctional O
protein O
that O
plays O
important O
roles O
in O
regulating O
viral O
genome O
replication O
and O
transcription O
, O
antagonizing O
the O
host O
interferon O
system O
, O
suppressing O
virus O
- O
induced O
apoptosis O
, O
and O
facilitating O
virus O
assembly O
and O
budding O
. O

We O
here O
report O
a O
novel O
role O
of O
SeV O
C O
protein O
, O
the O
limitation O
of O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
generation O
for O
maintaining O
the O
rate O
of O
protein O
synthesis O
in O
infected O
cells O
. O

It O
was O
found O
that O
the O
intracellular O
protein O
synthesis O
rate O
was O
maintained O
even O
after O
wild B
- I
type I
( I
WT I
) I
SeV O
infection O
, O
but O
markedly O
suppressed O
following O
C O
- O
knockout O
SeV O
infection O
. O

In O
contrast O
to O
wt O
SeV O
infection O
, O
C O
- O
knockout O
SeV O
infection O
caused O
phosphorylation O
of O
both O
the O
translation O
initiation O
factor O
eIF2 O
alpha O
and O
dsRNA B
- I
dependent I
protein I
kinase I
( I
PKR I
) I
. O

C O
protein O
, O
however O
, O
could O
inhibit O
neither O
poly O
( O
I O
) O
: O
poly O
( O
C O
) O
- O
activated O
nor O
Newcastle O
disease O
virus O
- O
induced O
phosphorylation O
of O
PKR O
and O
eIF2 O
alpha O
, O
suggesting O
that O
C O
protein O
does O
not O
target O
common O
pathways O
leading O
to O
PKR O
activation O
. O

The O
monoclonal O
antibody O
M1 O
- O
1A O
, O
specific O
for O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
human B
parainfluenza I
type I
2 I
virus I
( I
HPIV2 I
) I
, O
blocks O
virus O
- O
induced O
cell O
- O
cell O
fusion O
without O
affecting O
the O
hemagglutinating O
and O
neuraminidase O
activities O
. O

BCX O
2798 O
( O
4 O
- O
azido O
- O
5 O
- O
isobutyrylamino O
- O
2 O
, O
3 O
- O
didehydro O
- O
2 O
, O
3 O
, O
4 O
, O
5 O
- O
tetradeoxy O
- O
d O
- O
glycero O
- O
d O
- O
galacto O
- O
2 O
- O
nonulopyranosic O
acid O
) O
effectively O
inhibited O
the O
activities O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
of O
human B
parainfluenza I
viruses I
( I
hPIV I
) I
in O
vitro O
and O
protected O
mice O
from O
lethal O
infection O
with O
a O
recombinant O
Sendai O
virus O
whose O
HN O
was O
replaced O
with O
that O
of O
hPIV O
- O
1 O
( O
rSeV O
[ O
hPIV O
- O
1HN O
] O
) O
( O
I O
. O

A O
variant O
with O
an O
Asn O
- O
to O
- O
Ser O
mutation O
at O
residue O
173 O
( O
N173S O
) O
in O
HN O
was O
recovered O
from O
mice O
after O
a O
second O
passage O
of O
rSeV O
( O
hPIV O
- O
1HN O
) O
in O
the O
presence O
of O
BCX O
2798 O
( O
10 O
mg O
/ O
kg O
of O
body O
weight O
daily O
) O
. O

The O
N173S O
mutant O
remained O
sensitive O
to O
BCX O
2798 O
in O
neuraminidase O
inhibition O
assays O
but O
was O
more O
than O
10 O
, O
000 O
- O
fold O
less O
sensitive O
to O
the O
compound O
in O
hemagglutination O
inhibition O
tests O
than O
rSeV O
( O
hPIV O
- O
1HN O
) O
. O

Its O
susceptibility O
to O
BCX O
2798 O
in O
plaque O
reduction O
assays O
was O
reduced O
fivefold O
and O
did O
not O
differ O
from O
that O
of O
rSeV O
( O
hPIV O
- O
1HN O
) O
in O
mice O
. O

Naturally O
occurring O
Newcastle B
disease I
virus I
( I
NDV I
) I
strains O
vary O
greatly O
in O
virulence O
, O
ranging O
from O
no O
apparent O
infection O
to O
severe O
disease O
causing O
100 O
% O
mortality O
in O
chickens O
. O

The O
N O
, O
P O
, O
and O
L O
genes O
were O
exchanged O
individually O
between O
an O
avirulent O
NDV O
strain O
, O
LaSota O
, O
and O
an O
intermediate O
virulent O
NDV O
strain O
, O
Beaudette B
C I
( I
BC I
) I
, O
and O
the O
N O
and O
P O
genes O
were O
also O
exchanged O
together O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
a O
member O
of O
the O
family O
Paramyxoviridae O
, O
has O
a O
nonsegmented O
negative O
- O
sense O
RNA O
genome O
consisting O
of O
six O
genes O
( O
3 O
' O
- O
NP O
- O
P O
- O
M O
- O
F O
- O
HN O
' O
- O
L O
- O
5 O
' O
) O
. O

The O
first O
three O
3 O
' O
- O
end O
intergenic B
sequences I
( I
IGSs I
) I
are O
single O
nucleotides B
( I
nt I
) I
, O
whereas O
the O
F O
- O
HN O
and O
HN O
- O
L O
IGSs O
are O
31 O
and O
47 O
nt O
, O
respectively O
. O

The O
level O
of O
transcription O
of O
each O
mRNA O
species O
( O
NP O
, O
F O
, O
HN O
, O
and O
L O
) O
was O
examined O
by O
Northern O
blot O
analysis O
. O

RIG O
- O
I O
senses O
intracellular O
virus O
- O
specific O
nucleic O
acid O
structures O
and O
initiates O
an O
antiviral O
response O
that O
induces O
interferon B
( I
IFN I
) I
production O
, O
which O
, O
in O
turn O
, O
activates O
the O
transcription O
of O
RIG O
- O
I O
to O
increase O
RIG O
- O
I O
protein O
levels O
. O

Upon O
intracellular O
poly O
( O
I O
: O
C O
) O
stimulation O
, O
however O
, O
the O
levels O
of O
RIG O
- O
I O
protein O
did O
not O
correlate O
with O
the O
expression O
patterns O
of O
RIG O
- O
I O
transcripts O
. O

In O
Ube1L O
( O
- O
/ O
- O
) O
cells O
, O
which O
lack O
the O
ability O
to O
conjugate O
ISG15 O
, O
basal O
levels O
of O
both O
RIG O
- O
I O
protein O
and O
transcripts O
were O
increased O
compared O
to O
those O
in O
wild O
- O
type O
cells O
. O

As O
a O
result O
, O
enhanced O
production O
of O
ISGs O
and O
enhanced O
IFN O
promoter O
activity O
in O
Ube1L O
( O
- O
/ O
- O
) O
cells O
were O
observed O
, O
and O
the O
phenotype O
was O
restored O
to O
that O
of O
wild O
- O
type O
cells O
by O
the O
overexpression O
of O
Ube1L O
. O

The O
peptides O
derived O
from O
the O
heptad B
repeat I
( I
HRP I
) I
of O
Severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SCoV I
) I
spike O
protein O
( O
sHRPs O
) O
are O
known O
to O
inhibit O
SCoV O
infection O
, O
yet O
their O
efficacies O
are O
fairly O
low O
. O

We O
developed O
an O
experimental O
live O
- O
attenuated O
vaccine O
for O
direct O
inoculation O
of O
the O
respiratory O
tract O
based O
on O
recombinant O
avian O
Newcastle B
disease I
virus I
( I
NDV I
) I
expressing O
the O
Hemagglutinin B
( I
HA I
) I
glycoprotein O
of O
H5N1 O
HPAIV O
( O
NDV O
- O
HA O
) O
. O

NDV O
- O
RA O
was O
administered O
to O
African O
green O
monkeys O
in O
two O
doses O
of O
2 O
x O
10 O
( O
7 O
) O
infectious O
units O
each O
with O
a O
28 O
- O
day O
interval O
to O
evaluate O
the O
systemic O
and O
local O
antibody O
responses O
specific O
to O
H5N1 O
HPAIV O
. O

In O
light O
of O
the O
recurrent O
outbreaks O
of O
low B
pathogenic I
avian I
influenza I
( I
LPAI I
) I
and O
highly B
pathogenic I
avian I
influenza I
( I
HPAI I
) I
, O
there O
is O
a O
pressing O
need O
for O
the O
development O
of O
vaccines O
that O
allow O
rapid O
mass O
vaccination O
. O

In O
this O
study O
, O
we O
introduced O
by O
reverse O
genetics O
temperature O
- O
sensitive O
mutations O
in O
the O
PB1 O
and O
PB2 O
genes O
of O
an O
avian O
influenza O
virus O
, O
A O
/ O
Guinea O
Fowl O
/ O
Hong O
Kong O
/ O
WF10 O
/ O
99 O
( O
H9N2 O
) O
( O
WF10 O
) O
. O

Further O
genetic O
modifications O
were O
introduced O
into O
the O
PB1 O
gene O
to O
enhance O
the O
attenuated B
( I
att I
) I
phenotype O
of O
the O
virus O
in O
vivo O
. O

Using O
the O
att O
WF10 O
as O
a O
backbone O
, O
we O
substituted O
neuraminidase B
( I
NA I
) I
for O
Hemagglutinin B
( I
HA I
) I
for O
vaccine O
purposes O
. O

The O
respiratory O
tract O
is O
a O
major O
mucosal O
site O
for O
microorganism O
entry O
into O
the O
body O
, O
and O
type B
I I
interferon I
( I
IFN I
) I
and O
dendritic O
cells O
constitute O
a O
first O
line O
of O
defense O
against O
viral O
infections O
. O

Our O
data O
show O
that O
murine O
gammaherpesvirus O
68 O
( O
gamma O
HV68 O
) O
inhibits O
type O
I O
IFN O
secretion O
by O
dendritic O
cells O
and O
that O
plasmacytoid O
dendritic O
cells O
are O
necessary O
for O
conventional O
dendritic O
cell O
maturation O
in O
response O
to O
H O
gamma O
V68 O
. O

type B
I I
interferon I
( I
IFN I
) I
induction O
is O
an O
immediate O
response O
to O
virus O
infection O
, O
and O
very O
high O
levels O
of O
these O
cytokines O
are O
produced O
when O
the O
Toll B
- I
like I
receptors I
( I
TLRs I
) I
expressed O
at O
high O
levels O
by O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
are O
triggered O
by O
viral O
nucleic O
acids O
. O

Unlike O
many O
RNA O
viruses O
, O
respiratory B
syncytial I
virus I
( I
RSV I
) I
does O
not O
appear O
to O
activate O
pDCs O
through O
their O
TLRs O
and O
it O
is O
not O
clear O
how O
this O
difference O
affects O
IFN O
- O
alpha O
/ O
beta O
induction O
in O
vivo O
. O

Here O
we O
report O
that O
specific O
residues O
in O
the O
cytoplasmic O
tail O
of O
the O
Nipah B
virus I
fusion I
protein I
( I
NiV I
- I
F I
) I
modulate O
its O
fusogenic O
activity O
. O

7 O
, O
r O
( O
2 O
) O
= O
0 O
. O

Viruses O
have O
evolved O
a O
multitude O
of O
strategies O
to O
subvert O
the O
innate O
immune O
system O
by O
interfering O
with O
components O
of O
the O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
induction O
and O
signaling O
pathway O
. O

Central O
players O
in O
the O
IFN O
- O
alpha O
/ O
beta O
induction O
cascade O
are O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
IRF7 O
. O

Recently O
, O
it O
was O
proposed O
that O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
, O
the O
porcine O
pestivirus O
, O
induced O
the O
loss O
of O
IRF3 O
by O
inhibiting O
the O
transcription O
of O
IRF3 O
mRNA O
. O

In O
the O
present O
study O
, O
we O
show O
that O
endogenous O
IRF3 O
and O
IRF3 O
expressed O
from O
a O
cytomegallovirus B
( I
CMV I
) I
promoter O
are O
depleted O
in O
the O
presence O
of O
CSFV O
by O
means O
of O
N O
- O
pro O
, O
while O
CSFV O
does O
not O
inhibit O
CMV O
promoter O
- O
driven O
protein O
expression O
. O

During O
viral O
entry O
, O
the O
paramyxovirus O
fusion O
( O
F O
) O
protein O
fuses O
the O
viral O
envelope O
to O
a O
cellular O
membrane O
. O

Similar O
to O
other O
class O
I O
viral O
fusion O
glycoproteins O
, O
the O
F O
protein O
has O
two O
heptad O
repeat O
regions O
( O
HRA O
and O
HRB O
) O
that O
are O
important O
in O
membrane O
fusion O
and O
can O
be O
targeted O
by O
antiviral O
inhibitors O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
paramyxoviruses O
carries O
out O
three O
discrete O
activities O
that O
each O
affect O
the O
ability O
of O
HN O
to O
promote O
viral O
fusion O
and O
entry O
: O
receptor O
binding O
, O
receptor O
cleaving O
( O
neuraminidase O
) O
, O
and O
triggering O
of O
the O
fusion O
protein O
. O

For O
human B
parainfluenza I
type I
3 I
( I
HPIV3 I
) I
, O
one O
bifunctional O
site O
on O
HN O
can O
carry O
out O
both O
receptor O
binding O
and O
neuraminidase O
activities O
, O
and O
this O
site O
' O
s O
receptor O
binding O
can O
be O
inhibited O
by O
the O
small O
receptor O
analog O
zanamivir O
. O

The O
Sendai B
virus I
( I
SeV I
) I
C O
protein O
blocks O
signal O
transduction O
of O
interferon B
( I
IFN I
) I
, O
thereby O
counteracting O
the O
antiviral O
actions O
of O
IFN O
. O

Using O
HeLa O
cell O
lines O
expressing O
truncated O
or O
mutated O
SeV O
C O
proteins O
, O
we O
found O
that O
the O
C O
- O
terminal O
half O
has O
anti O
- O
IFN O
capacity O
, O
and O
that O
K O
( O
151 O
) O
A O
, O
E O
( O
153 O
) O
A O
, O
and O
R O
( O
154 O
) O
A O
substitutions O
in O
the O
C O
protein O
eliminated O
this O
capacity O
. O

Here O
, O
we O
further O
created O
the O
mutant O
virus O
SeV O
Cm O
* O
, O
in O
which O
K O
( O
151 O
) O
A O
, O
( O
EK O
) O
- O
K O
- O
153 O
, O
and O
( O
RL O
) O
- O
L O
- O
157 O
substitutions O
in O
the O
C O
protein O
were O
introduced O
without O
changing O
the O
amino O
acid O
sequence O
of O
overlapped O
P O
, O
V O
, O
and O
W O
proteins O
. O

Intranasally O
inoculated O
SeV O
Cm O
* O
could O
propagate O
in O
the O
lungs O
of O
STAT1 O
( O
- O
/ O
- O
) O
mice O
but O
was O
cleared O
from O
those O
of O
STAT1 O
( O
+ O
/ O
+ O
) O
mice O
without O
propagation O
. O

5 O
cells O
acutely O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
genotype O
2a O
( O
chimeric O
strain O
J6 O
/ O
JFH O
) O
and O
cells O
harboring O
HCV O
genotype O
1a O
, O
1b O
, O
or O
2a O
full O
- O
length O
or O
subgenomic O
replicons O
were O
resistant O
to O
infection O
with O
cell O
culture O
- O
produced O
HCV O
( O
HCVcc O
) O
. O

With O
the O
exception O
of O
cells O
harboring O
a O
J6 O
/ O
JFH O
- O
FLneo O
replicon O
, O
infected O
or O
replicon O
- O
containing O
cells O
were O
permissive O
for O
HCV B
pseudoparticle I
( I
HCVpp I
) I
entry O
, O
demonstrating O
a O
postentry O
superinfection O
block O
downstream O
of O
primary O
translation O
. O

Further O
analyses O
indicated O
that O
J6 O
/ O
JFH O
may O
be O
toxic O
for O
cells O
expressing O
high O
levels O
of O
CD81 O
, O
thus O
selecting O
for O
a O
CD81 O
( O
low O
) O
population O
. O

Eastern B
equine I
encephalitis I
virus I
( I
EEEV I
) I
causes O
sporadic O
but O
often O
severe O
cases O
of O
human O
and O
equine O
neurological O
disease O
in O
North O
America O
. O

To O
determine O
how O
EEEV O
may O
evade O
innate O
immune O
responses O
, O
we O
screened O
individual O
EEEV O
proteins O
for O
the O
ability O
to O
rescue O
the O
growth O
of O
a O
Newcastle B
disease I
virus I
expressing I
green I
fluorescent I
protein I
( I
NDV I
- I
GFP I
) I
from O
the O
antiviral O
effects O
of O
interferon B
( I
IFN I
) I
. O

While O
Newcastle B
disease I
virus I
( I
NDV I
) I
causes O
serious O
infections O
in O
birds O
, O
it O
is O
apparently O
nonpathogenic O
in O
mammalian O
species O
, O
including O
humans O
. O

Apoptosis O
was O
accompanied O
by O
virus O
replication O
in O
two O
tumor O
cell O
lines O
tested O
( O
PC12 O
cells O
and O
HeLa O
human O
cervical O
cells O
) O
, O
and O
signs O
of O
endoplasmic O
reticulum O
stress O
( O
phosphorylation O
of O
protein O
kinase O
R O
- O
like O
endoplasmic O
reticulum O
kinase O
and O
eIF2 O
alpha O
) O
were O
also O
detected O
in O
transformed O
cells O
. O

H5N1 O
Highly B
pathogenic I
avian I
influenza I
virus I
( I
HPAIV I
) I
has O
continued O
to O
spread O
and O
poses O
a O
significant O
threat O
to O
both O
animal O
and O
human O
health O
. O

Vaccine O
strains O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
however O
, O
have O
been O
used O
successfully O
to O
easily O
vaccinate O
large O
numbers O
of O
animals O
. O

In O
this O
study O
, O
we O
used O
reverse O
genetics O
to O
construct O
a O
NDV O
that O
expressed O
an O
H5 O
subtype O
avian B
influenza I
virus I
( I
AIV I
) I
hemagglutinin I
( I
HA I
) I
. O

Both O
a O
wild O
- O
type O
and O
a O
mutated O
HA O
open B
reading I
frame I
( I
ORF I
) I
from O
the O
HPAIV O
wild O
bird O
isolate O
, O
A O
/ O
Bar O
- O
headed O
goose O
/ O
Qinghai O
/ O
3 O
/ O
2005 O
( O
115N1 O
) O
, O
were O
inserted O
into O
the O
intergenic O
region O
between O
the O
P O
and O
M O
genes O
of O
the O
LaSota O
NDV O
vaccine O
strain O
. O

It O
has O
been O
shown O
previously O
that O
the O
fusion O
glycoprotein O
of O
human B
respiratory I
syncytial I
virus I
( I
RSV I
- I
F I
) I
interacts O
with O
cellular O
heparan O
sulfate O
. O

Synthetic O
overlapping O
peptides O
derived O
from O
the O
F O
- O
protein O
sequence O
of O
RSV O
subtype O
A O
( O
strain O
A2 O
) O
were O
tested O
for O
their O
ability O
to O
bind O
heparin O
using O
heparin O
- O
agarose O
affinity O
chromatography O
( O
HAAC O
) O
. O

This O
evaluation O
identified O
15 O
peptides O
representing O
eight O
linear O
heparin O
- O
binding O
domains O
( O
HBDs O
) O
located O
within O
F O
- O
1 O
and O
F O
- O
2 O
and O
spanning O
the O
protease O
cleavage O
activation O
site O
. O

Three O
RSV O
- O
F O
HBD O
peptides O
( O
F16 O
, O
F26 O
, O
and O
F55 O
) O
inhibited O
virus O
infectivity O
; O
two O
of O
these O
peptides O
( O
F16 O
and O
F55 O
) O
inhibited O
binding O
of O
virus O
to O
Vero O
cells O
, O
while O
the O
third O
( O
F26 O
) O
did O
not O
. O

E2 O
is O
one O
of O
the O
three O
envelope O
glycoproteins O
of O
classical B
swine I
fever I
virus I
( I
CSFV I
) I
. O

Seven O
putative O
glycosylation O
sites O
in O
E2 O
were O
modified O
by O
site O
- O
directed O
mutagenesis O
of O
a O
CSFV O
Brescia B
infectious I
clone I
( I
BICv I
) I
. O

Single O
mutations O
of O
each O
of O
the O
E2 O
glycosylation O
sites O
showed O
that O
amino O
acid O
N116 O
( O
N1v O
virus O
) O
was O
responsible O
for O
BICv O
attenuation O
. O

The O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
is O
a O
multifunctional O
protein O
mediating O
hemagglutination B
( I
HA I
) I
, O
neuraminidase B
( I
NA I
) I
, O
and O
fusion O
promotion O
activities O
. O

To O
clear O
the O
issue O
, O
we O
determined O
the O
presence O
of O
the O
second O
binding O
site O
on O
human B
parainfluenza I
virus I
( I
hPIV I
) I
type O
1 O
, O
2 O
, O
and O
3 O
and O
Sendai B
virus I
( I
SeV I
) I
HN O
proteins O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
, O
an O
avian O
paramyxovirus O
, O
is O
tumor O
selective O
and O
intrinsically O
oncolytic O
. O

NDV O
infection O
results O
in O
the O
loss O
of O
mitochondrial O
membrane O
potential O
and O
the O
subsequent O
release O
of O
the O
mitochondrial O
protein O
cytochrome O
c O
, O
but O
the O
second O
mitochondrion O
- O
derived O
activator O
of O
caspase O
( O
Smac O
/ O
DLABLO O
) O
is O
not O
released O
. O

In O
contrast O
, O
cleavage O
of O
caspase O
- O
8 O
, O
which O
is O
predominantly O
activated O
by O
the O
death O
receptor O
pathway O
, O
is O
a O
TNF O
- O
related O
, O
apoptosis O
- O
inducing O
ligand O
( O
TRAIL O
) O
- O
induced O
late O
event O
in O
NDV O
- O
mediated O
apoptosis O
of O
tumor O
cells O
. O

Our O
data O
, O
therefore O
, O
indicate O
that O
the O
death O
signal O
( O
s O
) O
generated O
by O
NDV O
in O
tumor O
cells O
ultimately O
converges O
at O
the O
mitochondria O
and O
that O
it O
acts O
independently O
of O
the O
death O
receptor O
pathway O
. O

Interestingly O
, O
we O
found O
that O
human B
dendritic I
cells I
( I
DCs I
) I
infected O
with O
influenza O
A O
virus O
have O
lower O
allospecific O
Th1 O
- O
cell O
stimulatory O
abilities O
than O
DCs O
activated O
by O
other O
stimuli O
, O
such O
as O
lipopolysaccharide O
and O
Newcastle O
disease O
virus O
infection O
. O

The O
NS1 O
protein O
is O
an O
important O
virulence O
factor O
associated O
with O
the O
suppression O
of O
innate O
immunity O
via O
the O
inhibition O
of O
type B
I I
interferon I
( I
IFN I
) I
production O
in O
infected O
cells O
. O

Among O
the O
genes O
affected O
by O
NS1 O
are O
those O
coding O
for O
macrophage O
inflammatory O
protein O
1 O
beta O
, O
interleukin O
- O
12 O
p35 O
( O
IL O
- O
12 O
p35 O
) O
, O
IL O
- O
23 O
p19 O
, O
RANTES O
, O
IL O
- O
8 O
, O
IFN O
- O
alpha O
/ O
beta O
, O
and O
CCR7 O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
is O
a O
negative O
- O
strand O
RNA O
virus O
with O
oncolytic O
activity O
against O
human O
tumors O
. O

Here O
we O
show O
that O
the O
spread O
of O
NDV O
infection O
is O
drastically O
different O
in O
normal O
cell O
lines O
than O
in O
tumor O
cell O
lines O
and O
that O
the O
two O
cell O
types O
respond O
differently O
to O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
treatment O
. O

Infectious O
particles O
of O
measles B
virus I
( I
MeV I
) I
, O
a O
member O
of O
the O
family O
Paramyxoviridae O
in O
the O
order O
Mononegavirales O
, O
with O
two O
or O
three O
RNA O
genome O
segments O
( O
2 O
seg O
- O
or O
3 O
seg O
- O
MeV O
) O
were O
generated O
using O
a O
highly O
efficient O
reverse O
genetics O
system O
. O

To O
determine O
whether O
intranasal O
inoculation O
with O
a O
paramyxovirus O
- O
vectored O
vaccine O
can O
induce O
protective O
immunity O
against O
Ebola B
virus I
( I
EV I
) I
, O
recombinant O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
was O
modified O
to O
express O
either O
the O
EV O
structural O
glycoprotein B
( I
GP I
) I
by O
itself O
( O
HPIV3 O
/ O
EboGP O
) O
or O
together O
with O
the O
EV O
nucleoprotein B
( I
NP I
) I
( O
HPIV3 O
/ O
EboGP O
- O
NP O
) O
. O

When O
these O
animals O
were O
challenged O
with O
an O
intraperitoneal O
injection O
of O
10 O
( O
3 O
) O
PFU O
of O
EV O
, O
there O
were O
no O
outward O
signs O
of O
disease O
, O
no O
viremia O
or O
detectable O
EV O
antigen O
in O
the O
blood O
, O
and O
no O
evidence O
of O
infection O
in O
the O
spleen O
, O
liver O
, O
and O
lungs O
. O

Receptor O
binding O
of O
paramyxovirus O
attachment O
proteins O
and O
the O
interactions O
between O
attachment O
and O
fusion O
( O
F O
) O
proteins O
are O
thought O
to O
be O
central O
to O
activation O
of O
the O
F O
protein O
activity O
; O
however O
, O
mechanisms O
involved O
are O
unclear O
. O

To O
explore O
the O
relationships O
between O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
and O
F O
protein O
interactions O
and O
HN O
protein O
attachment O
to O
sialic O
acid O
receptors O
, O
HN O
and O
F O
protein O
- O
containing O
complexes O
were O
detected O
and O
quantified O
by O
reciprocal O
coimmunoprecipitation O
from O
extracts O
of O
transfected O
avian O
cells O
. O

In O
contrast O
, O
high O
levels O
of O
complexes O
containing O
HN O
protein O
and O
an O
uncleaved O
F O
protein O
( O
F O
- O
K11SQ O
) O
were O
detected O
, O
and O
those O
levels O
were O
unaffected O
by O
neuraminidase O
treatment O
of O
cell O
monolayers O
or O
by O
incubation O
with O
target O
cells O
. O

respiratory B
syncytial I
virus I
( I
RSV I
) I
is O
a O
major O
cause O
of O
severe O
lower O
respiratory O
tract O
disease O
in O
infants O
and O
the O
elderly O
, O
but O
no O
safe O
and O
effective O
RSV O
vaccine O
is O
yet O
available O
. O

We O
have O
tested O
the O
hypothesis O
that O
weak O
stimulation O
of O
innate O
immunity O
by O
RSV O
correlates O
with O
ineffective O
adaptive O
responses O
by O
asking O
whether O
expression O
of O
the O
fusion O
glycoprotein O
of O
RSV O
by O
Newcastle B
disease I
virus I
( I
NDV I
) I
would O
stimulate O
a O
more O
robust O
immune O
response O
to O
RSV O
than O
primary O
RSV O
infection O
. O

NDV O
is O
a O
potent O
inducer O
of O
both O
alpha B
/ I
beta I
interferon I
( I
IFN I
- I
alpha I
/ I
beta I
) I
production O
and O
dendritic O
cell O
maturation O
, O
while O
RSV O
is O
not O
. O

When O
a O
recombinant O
NDV O
expressing O
the O
RSV O
fusion O
glycoprotein O
was O
administered O
to O
BALB O
/ O
c O
mice O
, O
they O
were O
protected O
from O
RSV O
challenge O
, O
and O
this O
protection O
correlated O
with O
a O
robust O
anti O
- O
F O
CD8 O
( O
+ O
) O
T O
- O
cell O
response O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
paramyxoviruses O
carries O
out O
three O
different O
activities O
: O
receptor O
binding O
, O
receptor O
cleaving O
( O
neuraminidase O
) O
, O
and O
triggering O
of O
the O
fusion O
protein O
. O

Only O
certain O
receptor O
mimics O
effectively O
activate O
the O
second O
site O
( O
site O
II O
) O
via O
occupation O
of O
site O
I O
; O
yet O
without O
activation O
of O
this O
second O
site O
, O
binding O
is O
mediated O
entirely O
by O
site O
I O
. O

We O
previously O
described O
a O
panel O
of O
compounds O
that O
specifically O
prevent O
fusion O
induced O
by O
measles B
virus I
( I
MV I
) I
, O
most O
likely O
by O
interfering O
with O
conformational O
rearrangements O
of O
the O
MV O
fusion O
( O
F O
) O
protein O
. O

Several O
mutations O
emerged O
independently O
at O
F O
position O
462 O
, O
which O
is O
located O
in O
the O
C O
- O
terminal O
heptad O
repeat O
( O
HR O
- O
B O
) O
domain O
. O

Most O
paramyxovirus O
fusion O
( O
F O
) O
proteins O
require O
the O
coexpression O
of O
the O
homologous O
attachment O
( O
HN O
) O
protein O
to O
promote O
membrane O
fusion O
, O
consistent O
with O
the O
existence O
of O
a O
virus O
- O
specific O
interaction O
between O
the O
two O
proteins O
. O

Finally O
, O
N O
- O
glycan O
addition O
in O
another O
region O
of O
HN O
( O
residues O
124 O
to O
152 O
) O
, O
predicted O
by O
a O
peptide O
- O
based O
analysis O
to O
mediate O
the O
interaction O
with O
F O
, O
does O
not O
significantly O
reduce O
the O
level O
of O
fusion O
, O
arguing O
strongly O
against O
this O
site O
being O
part O
of O
the O
F O
- O
interactive O
domain O
in O
HN O
. O

We O
calculated O
D O
, O
, O
values O
( O
fluence O
producing O
on O
average O
one O
lethal O
hit O
per O
virion O
and O
reducing O
viable O
virus O
to O
37 O
% O
) O
from O
all O
available O
data O
. O

We O
defined O
size B
- I
normalized I
sensitivity I
( I
SnS I
) I
by O
multiplying O
UV254 O
sensitivities O
( O
D O
- O
37 O
values O
) O
by O
the O
genome O
size O
, O
and O
SnS O
values O
were O
relatively O
constant O
for O
viruses O
with O
similar O
genetic O
composition O
. O

Infectious B
salmon I
anemia I
virus I
( I
ISAV I
) I
is O
an O
orthomyxovirus O
causing O
serious O
disease O
in O
Atlantic O
salmon O
( O
Salmo O
salar O
L O
. O

This O
study O
presents O
the O
characterization O
of O
the O
ISAV O
50 O
- O
kDa O
glycoprotein O
encoded O
by O
segment O
5 O
, O
here O
termed O
the O
viral O
membrane O
fusion B
protein I
( I
F I
) I
. O

The O
Hendra O
virus O
fusion O
( O
F O
) O
protein O
is O
synthesized O
as O
a O
precursor O
protein O
, O
F O
- O
0 O
, O
which O
is O
proteolytically O
processed O
to O
the O
mature O
form O
, O
F O
- O
1 O
+ O
F O
- O
2 O
. O

To O
analyze O
the O
potential O
role O
of O
endocytosis O
in O
the O
processing O
and O
membrane O
fusion O
promotion O
of O
the O
Hendra O
virus O
F O
protein O
, O
mutation O
of O
tyrosine O
525 O
to O
alanine O
( O
Hendra O
virus O
F O
Y525A O
) O
or O
phenylalanine O
( O
Hendra O
virus O
F O
Y525F O
) O
was O
performed O
. O

The O
rate O
of O
endocytosis O
of O
Hendra O
virus O
F O
Y525A O
was O
significantly O
reduced O
compared O
to O
that O
of O
the O
wild B
- I
type I
( I
WT I
) I
F O
protein O
, O
confirming O
the O
functional O
importance O
of O
the O
endocytosis O
motif O
. O

The O
sequence O
and O
structure O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
are O
consistent O
with O
its O
classification O
as O
a O
type O
1 O
glycoprotein O
. O

One O
form O
is O
the O
classical O
type O
I O
glycoprotein O
, O
while O
the O
other O
is O
a O
polytopic O
form O
in O
which O
approximately O
200 O
amino O
acids O
of O
the O
aminoterminal O
end O
as O
well O
as O
the O
cytoplasmic B
domain I
( I
CT I
) I
are O
translocated O
across O
membranes O
. O

To O
engineer O
a O
targeting O
envelope O
for O
gene O
and O
oncolytic O
vector O
delivery O
, O
we O
characterized O
and O
modified O
the O
envelope O
proteins O
of O
Tupaia B
paramyxovirus I
( I
TPMV I
) I
, O
a O
relative O
of O
the O
morbilli O
- O
and O
henipaviruses O
that O
neither O
infects O
humans O
nor O
has O
cross O
- O
reactive O
relatives O
that O
infect O
humans O
. O

We O
completed O
the O
TPMV O
genomic O
sequence O
and O
noted O
that O
the O
predicted O
fusion O
( O
F O
) O
protein O
cleavage O
- O
activation O
site O
is O
not O
preceded O
by O
a O
canonical O
furin O
cleavage O
sequence O
. O

Coexpression O
of O
the O
TPMV O
F O
and O
hemagglutinin B
( I
H I
) I
proteins O
induced O
fusion O
of O
Tupaia O
baby O
fibroblasts O
but O
not O
of O
human O
cells O
, O
a O
finding O
consistent O
with O
the O
restricted O
TPMV O
host O
range O
. O

Toward O
this O
end O
, O
we O
displayed O
a O
single O
- O
chain O
antibody O
( O
scFv O
) O
specific O
for O
the O
designated O
receptor O
human O
carcinoembryonic O
antigen O
on O
the O
TPMV O
H O
ectodomain O
. O

By O
using O
reverse O
genetics O
of O
Sendai B
virus I
( I
SeV I
) I
, O
we O
demonstrate O
that O
chimeric O
respiratory B
syncytial I
virus I
( I
RSV I
) I
fusion O
proteins O
containing O
either O
the O
cytoplasmic O
domain O
of O
the O
SeV O
fusion O
protein O
or O
in O
addition O
the O
transmembrane O
domain O
were O
efficiently O
incorporated O
into O
SeV O
particles O
provided O
the O
homotypic O
SeV O
- O
F O
was O
deleted O
. O

However O
, O
replication O
of O
this O
virus O
also O
relied O
on O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
as O
pretreatment O
of O
cells O
with O
neurarninidase O
significantly O
reduced O
the O
infection O
rate O
. O

human B
metapneumovirus I
( I
HMPV I
) I
, O
a O
recently O
described O
paramyxovirus O
, O
is O
a O
major O
etiological O
agent O
for O
lower O
respiratory O
tract O
disease O
in O
young O
children O
that O
can O
manifest O
with O
severe O
cough O
, O
bronchiolitis O
, O
and O
pneumonia O
. O

The O
hMPV O
fusion O
glycoprotein O
( O
F O
) O
shares O
conserved O
functional O
domains O
with O
other O
paramyxovirus O
F O
proteins O
that O
are O
important O
for O
virus O
entry O
and O
spread O
. O

For O
other O
paramyxovirus O
F O
proteins O
, O
cleavage O
of O
a O
precursor O
protein O
( O
F O
- O
0 O
) O
into O
F O
- O
1 O
and O
F O
- O
2 O
exposes O
a O
fusion O
peptide O
at O
the O
N O
terminus O
of O
the O
F O
- O
1 O
fragment O
, O
a O
likely O
prerequisite O
for O
fusion O
activity O
. O

The O
contribution O
of O
this O
single O
amino O
acid O
change O
was O
verified O
directly O
by O
generating O
recombinant O
virus O
( O
rhMPV O
/ O
NL O
/ O
1 O
/ O
00 O
) O
with O
either O
proline O
or O
serine O
at O
position O
101 O
in O
F O
. O

Here O
we O
report O
that O
V O
and O
W O
proteins O
also O
block O
virus O
activation O
of O
the O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
promoter O
and O
the O
IFN B
regulatory I
factor I
3 I
( I
IRF3 I
) I
- O
responsive O
IFN O
- O
stimulated O
gene O
54 O
promoter O
. O

Surprisingly O
, O
only O
W O
protein O
shows O
strong O
inhibition O
of O
promoter O
activation O
in O
response O
to O
stimulation O
of O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
by O
extracellular O
double O
- O
stranded O
RNA O
. O

Within O
the O
unique O
C O
- O
terminal O
domain O
of O
W O
protein O
, O
we O
have O
identified O
a O
nuclear B
localization I
signal I
( I
NLS I
) I
that O
requires O
basic O
residues O
at O
positions O
439 O
, O
440 O
, O
and O
442 O
. O

Formation O
of O
a O
six O
- O
helix O
bundle O
comprised O
of O
three O
C O
- O
terminal O
heptad O
repeat O
regions O
in O
antiparallel O
orientation O
in O
the O
grooves O
of O
an O
N O
- O
terminal O
coiled O
- O
coil O
is O
critical O
for O
promotion O
of O
membrane O
fusion O
by O
paramyxovirus O
fusion O
( O
F O
) O
proteins O
. O

We O
have O
examined O
the O
effect O
of O
mutations O
in O
four O
residues O
of O
the O
N O
- O
terminal O
heptad O
repeat O
in O
the O
simian B
virus I
5 I
( I
SV5 I
) I
F O
protein O
on O
protein O
folding O
, O
transport O
, O
and O
fusogenic O
activity O
. O

In O
order O
to O
examine O
functions O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
that O
quantitatively O
influence O
fusion O
promotion O
, O
human B
parainfluenza I
virus I
3 I
( I
HPIV3 I
) I
variants O
with O
alterations O
in O
HN O
were O
studied O
. O

The O
variant O
HNs O
have O
mutations O
that O
affect O
either O
receptor O
binding O
avidity O
, O
neuraminidase O
activity O
, O
or O
fusion B
protein I
( I
F I
) I
activation O
. O

F O
activation O
was O
assessed O
by O
quantitating O
the O
irreversible O
binding O
of O
target O
erythrocytes O
( O
RBC O
) O
to O
HN O
/ O
F O
- O
coexpressing O
cells O
in O
the O
presence O
of O
4 O
- O
GU O
- O
DANA O
( O
zanamivir O
) O
to O
release O
target O
cells O
bound O
only O
by O
HN O
- O
receptor O
interactions O
; O
the O
remaining O
, O
irreversibly O
bound O
target O
cells O
are O
retained O
via O
the O
fusion O
protein O
. O

In O
cells O
coexpressing O
wild B
- I
type I
( I
WT I
) I
or O
variant O
HNs O
with O
wt O
F O
, O
the O
fusion O
promotion O
capacity O
of O
HN O
was O
distinguished O
from O
target O
cell O
binding O
by O
measuring O
changes O
with O
time O
in O
the O
amounts O
of O
target O
RBC O
that O
were O
( O
i O
) O
reversibly O
bound O
by O
HN O
- O
receptor O
interaction O
( O
released O
only O
upon O
the O
addition O
of O
4 O
- O
GU O
- O
DANA O
) O
, O
( O
ii O
) O
released O
by O
HN O
' O
s O
neuraminidase O
, O
and O
( O
iii O
) O
irreversibly O
bound O
by O
F O
- O
insertion O
or O
fusion O
( O
F O
triggered O
) O
. O

For O
wt O
HN O
, O
lowering O
the O
pH O
( O
to O
approach O
the O
optimum O
for O
HPIV3 O
neuraminidase O
) O
decreased O
F O
triggering O
via O
release O
of O
HN O
from O
its O
receptor O
. O

Any O
particular O
HN O
' O
s O
competence O
to O
promote O
F O
- O
mediated O
fusion O
depends O
on O
the O
balance O
between O
its O
inherent O
F O
- O
triggering O
efficacy O
and O
its O
receptor O
- O
attachment O
regulatory O
functions O
( O
binding O
and O
receptor O
cleavage O
) O
. O

It O
has O
been O
shown O
that O
the O
L289A O
- O
mutated O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
gains O
the O
ability O
to O
promote O
fusion O
of O
Cos O
- O
7 O
cells O
independent O
of O
the O
viral O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
and O
exhibits O
a O
50 O
% O
enhancement O
in O
HN O
- O
dependent O
fusion O
over O
wild B
- I
type I
( I
WT I
) I
F O
protein O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
Newcastle O
disease O
virus O
mediates O
attachment O
to O
sialic O
acid O
receptors O
, O
as O
well O
as O
cleavage O
of O
the O
same O
moiety O
. O

HN O
also O
interacts O
with O
the O
other O
viral O
glycoprotein O
, O
the O
fusion O
( O
F O
) O
protein O
, O
to O
promote O
membrane O
fusion O
. O

The O
most O
conserved O
part O
of O
the O
stalk O
consists O
of O
two O
heptad O
repeats O
separated O
by O
a O
nonhelical O
intervening O
region O
( O
residues O
89 O
to O
95 O
) O
. O

The O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
is O
a O
multifunctional O
protein O
responsible O
for O
attachment O
to O
receptors O
containing O
sialic O
acid O
, O
neuraminidase B
( I
NA I
) I
activity O
, O
and O
the O
promotion O
of O
membrane O
fusion O
, O
which O
is O
induced O
by O
the O
fusion O
protein O
. O

Analysis O
of O
the O
three O
- O
dimensional O
structure O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
protein O
revealed O
the O
presence O
of O
a O
large O
pocket O
, O
which O
mediates O
both O
receptor O
binding O
and O
NA O
activities O
. O

Recently O
, O
a O
second O
sialic O
acid O
binding O
site O
on O
HN O
was O
revealed O
by O
cocrystallization O
of O
the O
HN O
with O
a O
thiosialoside O
Neu5Ac O
- O
2 O
- O
S O
- O
alpha O
( O
2 O
, O
6 O
) O
Gal1OMe O
, O
suggesting O
that O
NDV O
HN O
contains O
an O
additional O
sialic O
acid O
binding O
site O
. O

Hydrophobic O
fusion B
peptides I
( I
FPs I
) I
are O
the O
most O
highly O
conserved O
regions O
of O
class O
I O
viral B
fusion I
- I
mediating I
glycoproteins I
( I
vFGPs I
) I
. O

Unexpectedly O
, O
a O
mutation O
of O
glycine O
residues O
in O
the O
FP O
of O
the O
fusion O
( O
F O
) O
protein O
from O
the O
paramyxovirus O
simian B
parainfluenza I
virus I
5 I
( I
SV5 I
) I
resulted O
in O
mutant O
F O
proteins O
with O
hyperactive O
fusion O
phenotypes O
( O
C O
. O

Here O
, O
we O
constructed O
G3A O
and O
G7A O
mutations O
into O
the O
F O
proteins O
of O
SV5 O
( O
W3A O
and O
WR O
isolates O
) O
, O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
and O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
. O

The O
G3A O
and O
G7A O
mutations O
cause O
SV5 O
WR O
F O
, O
but O
not O
NDV O
F O
or O
HPIV3 O
F O
, O
to O
be O
triggered O
to O
cause O
fusion O
in O
the O
absence O
of O
coexpression O
of O
its O
homotypic O
receptor O
- O
binding O
protein O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
, O
suggesting O
that O
NDV O
and O
HPIV3 O
F O
have O
stricter O
requirements O
for O
homotypic O
HN O
for O
fusion O
activation O
. O

Zanamivir O
( O
4 O
- O
guanidino O
- O
Neu5Ac2en O
[ O
4 O
- O
GU O
- O
DANA O
] O
) O
inhibits O
not O
only O
the O
neuraminidase O
activity O
but O
also O
the O
receptor O
interaction O
of O
the O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV3 I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
, O
blocking O
receptor O
binding O
and O
subsequent O
fusion O
promotion O
. O

All O
activities O
of O
the O
HPIV3 O
variant O
ZM1 O
HN O
( O
T193I O
/ O
I567V O
) O
are O
less O
sensitive O
to O
4 O
- O
GU O
- O
DANA O
' O
s O
effects O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
and O
HPIV3 O
HN O
respond O
differently O
to O
inhibition O
in O
ways O
that O
suggest O
a O
fundamental O
distinction O
between O
them O
. O

A O
Recombinant B
Newcastle I
disease I
virus I
( I
rNDV I
) I
expressing O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
Gag O
protein O
( O
rNDV O
/ O
SIVgag O
) O
was O
generated O
. O

This O
was O
evidenced O
by O
the O
inhibition O
of O
growth O
of O
recombinant O
vaccinia O
virus O
expressing O
an O
identical O
Gag O
antigen O
( O
rVac O
/ O
SIVgag O
) O
but O
not O
of O
wild O
- O
type O
vaccinia O
virus O
in O
rNDV O
/ O
SIVgag O
- O
immunized O
mice O
. O

Nipah B
virus I
( I
NiV I
) I
, O
a O
highly O
pathogenic O
paramyxovirus O
, O
causes O
a O
systemic O
infection O
in O
vivo O
and O
is O
able O
to O
replicate O
in O
cultured O
cells O
of O
many O
species O
and O
organs O
. O

Such O
pantropic O
paramyxoviruses O
generally O
encode O
fusion O
( O
F O
) O
proteins O
with O
multibasic O
cleavage O
sites O
activated O
by O
furin O
or O
other O
ubiquitous O
intracellular O
host O
cell O
proteases O
. O

In O
contrast O
, O
NiV O
has O
an O
F O
protein O
with O
a O
single O
arginine O
( O
R O
- O
109 O
) O
at O
the O
cleavage O
site O
, O
as O
is O
the O
case O
with O
paramyxoviruses O
that O
are O
activated O
by O
trypsin O
- O
like O
proteases O
only O
present O
in O
specific O
cells O
or O
tissues O
and O
therefore O
only O
cause O
localized O
infections O
. O

infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
causes O
a O
highly O
immunosuppressive O
disease O
in O
chickens O
. O

By O
using O
the O
reverse O
genetics O
approach O
, O
we O
devised O
a O
recombinant O
Newcastle B
disease I
virus I
( I
NDV I
) I
vector O
from O
a O
commonly O
used O
vaccine O
strain O
LaSota O
to O
express O
the O
host O
- O
protective O
immunogen O
VP2 O
of O
a O
variant O
IBDV O
strain O
GLS O
- O
5 O
. O

The O
trimeric O
fusion O
( O
F O
) O
glycoproteins O
of O
morbilliviruses O
are O
activated O
by O
furin O
cleavage O
of O
the O
precursor O
F O
, O
into O
the O
F O
- O
1 O
and O
F O
- O
2 O
subunits O
. O

We O
initially O
observed O
that O
the O
ectodomain O
of O
approximately O
one O
in O
three O
measles B
virus I
( I
MV I
) I
F O
proteins O
is O
cleaved O
proximal O
to O
the O
membrane O
. O

We O
also O
detected O
the O
F O
- O
1b O
fragment O
, O
including O
the O
transmembrane O
domain O
and O
cytoplasmic O
tail O
, O
in O
cells O
expressing O
the O
canine B
distemper I
virus I
( I
CDV I
) I
or O
mumps O
virus O
F O
protein O
. O

SER O
virus O
, O
a O
paramyxovirus O
that O
is O
closely O
related O
to O
simian B
virus I
5 I
( I
SV5 I
) I
, O
is O
unusual O
in O
that O
it O
fails O
to O
induce O
syncytium O
formation O
. O

The O
SER O
virus O
F O
protein O
has O
an O
unusually O
long O
cytoplasmic B
tail I
( I
CT I
) I
, O
and O
it O
was O
previously O
observed O
that O
truncations O
or O
specific O
mutations O
of O
this O
domain O
result O
in O
enhanced O
syncytium O
formation O
. O

Sendai B
virus I
( I
SeV I
) I
encodes O
two O
accessory O
proteins O
, O
V O
and O
C O
, O
in O
the O
alternative O
reading O
frames O
in O
the O
P O
gene O
that O
are O
accessed O
transcriptionally O
( O
V O
) O
or O
transtationally O
( O
C O
) O
. O

Using O
HeLa O
cell O
lines O
constitutively O
expressing O
the O
various O
C O
proteins O
, O
we O
previously O
found O
that O
the O
smallest O
( O
the O
175 O
- O
residue O
Y2 O
) O
of O
the O
four O
C O
proteins O
was O
fully O
capable O
of O
counteracting O
the O
antiviral O
action O
of O
Interferons B
( I
IFNs I
) I
and O
inhibiting O
viral O
RNA O
synthesis O
and O
that O
the O
C O
- O
terminal O
half O
of O
106 O
residues O
was O
sufficient O
for O
both O
of O
these O
inhibitory O
functions O
( O
A O
. O

Here O
, O
we O
further O
generated O
HeLa O
cell O
lines O
expressing O
the O
mutated O
C O
( O
Cm O
) O
proteins O
with O
charged O
amino O
acids O
substituted O
for O
alanine O
residues O
at O
either O
positions O
77 O
and O
80 O
; O
114 O
and O
115 O
; O
139 O
and O
142 O
; O
151 O
, O
153 O
, O
and O
154 O
; O
156 O
; O
or O
173 O
, O
175 O
, O
and O
176 O
. O

In O
previous O
reports O
it O
was O
demonstrated O
that O
the O
Nipah O
virus O
V O
and O
W O
proteins O
have O
interferon B
( I
IFN I
) I
antagonist O
activity O
due O
to O
their O
ability O
to O
block O
signaling O
from O
the O
IFN O
- O
alpha O
/ O
beta O
receptor O
( O
J O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
is O
an O
important O
determinant O
of O
its O
virulence O
. O

We O
investigated O
the O
role O
of O
each O
of O
the O
four O
functional O
N O
- O
linked O
glycosylation O
sites O
( O
G1 O
to O
G4 O
) O
of O
the O
HN O
glycoprotein O
of O
NDV O
on O
its O
pathogenicity O
. O

The O
N O
- O
linked O
glycosylation O
sites O
G1 O
to O
G4 O
at O
residues O
119 O
, O
341 O
, O
433 O
, O
and O
481 O
, O
respectively O
, O
of O
a O
moderately O
pathogenic O
NDV O
strain O
Beaudette B
C I
( I
BC I
) I
were O
eliminated O
individually O
by O
site O
- O
directed O
mutagenesis O
on O
a O
full O
- O
length O
cDNA O
clone O
of O
BC O
. O

A O
double O
mutant O
( O
G12 O
) O
was O
also O
created O
by O
eliminating O
the O
first O
and O
second O
glycosylation O
sites O
at O
residues O
119 O
and O
341 O
, O
respectively O
. O

The O
fusogenicity O
of O
the O
double O
mutant O
virus O
( O
G12 O
) O
was O
significantly O
higher O
than O
that O
of O
the O
parental O
virus O
. O

The O
antigenic O
reactivities O
of O
the O
mutants O
to O
a O
panel O
of O
monoclonal O
antibodies O
against O
the O
HN O
protein O
indicated O
that O
removal O
of O
glycosylation O
from O
the O
HN O
protein O
increased O
( O
G1 O
, O
G3 O
, O
and O
G12 O
) O
or O
decreased O
( O
G2 O
and O
G4 O
) O
the O
formation O
of O
antigenic O
sites O
, O
depending O
on O
their O
location O
. O

The O
Newcastle B
disease I
virus I
( I
NDV I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
protein O
mediates O
attachment O
to O
cellular O
receptors O
. O

The O
fusion O
( O
F O
) O
protein O
promotes O
viral O
entry O
and O
spread O
. O

A O
point O
mutation O
of O
I175E O
in O
the O
neuraminidase B
( I
NA I
) I
active O
site O
converts O
the O
HN O
of O
the O
Australia O
- O
Victoria O
isolate O
of O
the O
virus O
to O
a O
form O
that O
can O
interact O
with O
the O
F O
protein O
despite O
negligible O
receptor O
recognition O
and O
fusion O
- O
promoting O
activities O
. O

Several O
paramyxoviruses O
possess O
a O
surface O
glycoprotein O
, O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
, O
that O
is O
involved O
in O
attachment O
to O
sialic O
acid O
receptors O
, O
promotion O
of O
fusion O
, O
and O
removal O
of O
sialic O
acid O
from O
infected O
cells O
and O
progeny O
virions O
. O

Previously O
we O
showed O
that O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
contained O
a O
pliable O
sialic O
acid O
recognition O
site O
that O
could O
take O
two O
states O
, O
a O
binding O
state O
and O
a O
catalytic O
state O
. O

The O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
plays O
a O
crucial O
role O
in O
the O
process O
of O
infection O
. O

By O
use O
of O
reverse O
genetics O
procedures O
, O
the O
HN O
genes O
of O
a O
virulent O
recombinant O
NDV O
strain O
, O
rBeaudette B
C I
( I
rBC I
) I
, O
and O
an O
avirulent O
recombinant O
NDV O
strain O
, O
rLaSota O
, O
were O
exchanged O
. O

The O
chimeric O
viruses O
with O
reciprocal O
HN O
proteins O
either O
gained O
or O
lost O
virulence O
, O
as O
determined O
by O
a O
standard O
intracerebral O
pathogenicity O
index O
test O
of O
chickens O
and O
by O
the O
mean O
death O
time O
in O
chicken O
embryos O
( O
a O
measure O
devised O
to O
classify O
these O
viruses O
) O
, O
indicating O
that O
virulence O
is O
a O
function O
of O
the O
amino O
acid O
differences O
in O
the O
HN O
protein O
. O

One O
of O
the O
most O
effective O
innate O
antiviral O
responses O
is O
the O
production O
of O
alpha O
/ O
beta O
interferon O
and O
the O
subsequent O
induction O
of O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
whose O
products O
collectively O
limit O
virus O
replication O
and O
spread O
. O

Following O
viral O
infection O
, O
interferon O
is O
produced O
in O
a O
biphasic O
fashion O
that O
involves O
a O
number O
of O
transcription O
factors O
, O
including O
the O
interferon B
regulatory I
, I
factors I
( I
IRFs I
) I
1 O
, O
3 O
, O
7 O
, O
and O
9 O
. O

Previously O
, O
we O
and O
others O
demonstrated O
that O
herpes B
simplex I
virus I
type I
1 I
( I
HSV I
- I
1 I
) I
induces O
ISGs O
and O
an O
antiviral O
response O
in O
fibroblasts O
in O
the O
absence O
of O
both O
interferon O
production O
and O
virus O
replication O
. O

The O
complete O
RNA O
genome O
sequence O
of O
the O
archetype O
reptilian O
paramyxovirus O
, O
Fer B
- I
de I
- I
Lance I
virus I
( I
FDLV I
) I
, O
has O
been O
determined O
. O

The O
gene O
designated O
U O
( O
unknown O
) O
, O
encodes O
a O
deduced O
protein O
of O
19 O
. O

measles B
virus I
( I
MV I
) I
enters O
cells O
either O
through O
the O
signaling O
lymphocyte O
activation O
molecule O
SLAM O
( O
CD150 O
) O
expressed O
only O
in O
immune O
cells O
or O
through O
the O
ubiquitously O
expressed O
regulator O
of O
complement O
activation O
, O
CD46 O
. O

To O
identify O
residues O
on O
the O
attachment O
protein O
hemagglutinin B
( I
H I
) I
essential O
for O
fusion O
support O
through O
either O
receptor O
, O
we O
devised O
a O
strategy O
based O
on O
analysis O
of O
morbillivirus O
H O
- O
protein O
sequences O
, O
iterative O
cycles O
of O
mutant O
protein O
production O
followed O
by O
receptor O
- O
based O
functional O
assays O
, O
and O
a O
novel O
MV O
H O
three O
- O
dimensional O
model O
. O

We O
identified O
seven O
amino O
acids O
important O
for O
SLAM O
- O
and O
nine O
for O
CD46 O
( O
Vero O
cell O
receptor O
) O
induced O
fusion O
. O

The O
MV O
H O
three O
- O
dimensional O
model O
suggests O
( O
i O
) O
that O
SLAM O
- O
and O
CD46 O
- O
relevant O
residues O
are O
located O
in O
contiguous O
areas O
in O
propeller O
P O
- O
sheets O
5 O
and O
4 O
, O
respectively O
; O
( O
ii O
) O
that O
two O
clusters O
of O
SLAM O
- O
relevant O
residues O
exist O
and O
that O
they O
are O
accessible O
for O
receptor O
contact O
; O
and O
( O
iii O
) O
that O
several O
CD46 O
- O
relevant O
amino O
acids O
may O
be O
shielded O
from O
direct O
receptor O
contacts O
. O

We O
and O
others O
have O
presented O
evidence O
for O
a O
direct O
interaction O
between O
the O
Matrix B
( I
MA I
) I
domain O
of O
the O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Gag O
protein O
and O
the O
cytoplasmic O
tail O
of O
the O
transmembrane O
envelope B
( I
env I
) I
glycoprotein O
gp41 O
. O

Together O
, O
these O
results O
raise O
the O
possibility O
that O
the O
interaction O
between O
the O
gp41 O
cytoplasmic O
tail O
and O
MA O
is O
regulated O
by O
Protease B
( I
Pr I
) I
- O
mediated O
Gag O
processing O
, O
perhaps O
affecting O
Env O
function O
. O

To O
examine O
whether O
Gag O
processing O
affects O
Env O
- O
mediated O
fusion O
, O
we O
compared O
the O
ability O
of O
wild B
- I
type I
( I
WT I
) I
HIV O
- O
1 O
Env O
and O
a O
mutant O
lacking O
the O
gp41 O
cytoplasmic O
tail O
to O
induce O
fusion O
in O
the O
context O
of O
an O
active O
( O
PR O
+ O
) O
or O
inactive O
( O
PR O
- O
) O
viral O
PR O
. O

To O
explore O
the O
association O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
with O
cholesterol O
- O
rich O
membrane O
domains O
, O
its O
localization O
in O
detergent B
- I
resistant I
membranes I
( I
DRMs I
) I
in O
transfected O
cells O
was O
characterized O
. O

Association O
of O
the O
F O
protein O
with O
this O
cell O
fraction O
was O
unaffected O
by O
the O
cleavage O
of O
F O
- O
0 O
to O
F O
- O
1 O
and O
F O
- O
2 O
or O
by O
coexpression O
of O
the O
NDV O
attachment O
protein O
, O
the O
hemagglutinin B
- I
neuraminidase I
protein I
( I
HN I
) I
. O

We O
have O
characterized O
the O
three O
glycans O
attached O
to O
fusion O
( O
F O
) O
proteins O
of O
the O
morbilliviruses O
canine O
distemper O
virus O
and O
measles O
virus O
. O

The O
individual O
Morbillivirus O
glycans O
have O
similar O
functional O
properties O
: O
the O
glycan O
at O
position O
68 O
is O
essential O
for O
protein O
transport O
, O
and O
those O
at O
positions O
36 O
and O
75 O
modulate O
fusion O
( O
numbering O
according O
to O
the O
Newcastle O
disease O
virus O
[ O
NDV O
] O
F O
protein O
sequence O
) O
. O

The O
activation O
of O
most O
paramyxovirus O
fusion B
proteins I
( I
F I
proteins I
) I
requires O
not O
only O
cleavage O
of O
F O
- O
0 O
to O
F O
- O
1 O
and O
F O
- O
2 O
but O
also O
coexpression O
of O
the O
homologous O
attachment O
protein O
, O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
or O
hemagglutinin B
( I
H I
) I
. O

Using O
biotin O
- O
labeled O
peptides O
with O
sequences O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
F O
protein O
heptad B
repeat I
2 I
( I
HR2 I
) I
domain O
, O
we O
detected O
a O
specific O
interaction O
with O
amino O
acids O
124 O
to O
152 O
from O
the O
NDV O
HN O
protein O
. O

Biotin O
- O
labeled O
HR2 O
peptides O
bound O
to O
glutathione B
S I
- I
transferase I
( I
GST I
) I
fusion O
proteins O
containing O
these O
HN O
protein O
sequences O
but O
not O
to O
GST O
or O
to O
GST O
containing O
HN O
protein O
sequences O
corresponding O
to O
amino O
acids O
49 O
to O
118 O
. O

Editing O
of O
P O
- O
gene O
mRNA O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
enables O
the O
formation O
of O
two O
additional O
proteins O
( O
V O
and O
W O
) O
by O
inserting O
one O
or O
two O
nontemplated O
G O
residues O
at O
a O
conserved O
editing O
site O
( O
5 O
' O
- O
AAAAAGGG O
) O
. O

A O
recombinant O
virus O
possessing O
a O
nucleotide O
substitution O
within O
the O
A O
- O
stretch O
( O
5 O
' O
- O
AAgAAGGG O
) O
produced O
20 O
- O
fold O
- O
less O
V O
protein O
and O
, O
in O
consequence O
, O
was O
impaired O
in O
replication O
capacity O
and O
completely O
attenuated O
in O
pathogenicity O
for O
chicken O
embryos O
. O

Determining O
the O
sequence O
around O
the O
editing O
site O
of O
the O
virus O
at O
passage O
7 O
revealed O
a O
C O
- O
to O
- O
U O
mutation O
at O
the O
second O
nucleotide O
immediately O
upstream O
of O
the O
5 O
' O
- O
A O
( O
5 O
) O
stretch O
( O
5 O
' O
- O
GuUAAgAAGGG O
) O
. O

In O
addition O
, O
similar O
defects O
in O
another O
mutant O
possessing O
a O
different O
substitution O
mutation O
( O
5 O
' O
- O
AAAcAGGG O
) O
were O
restored O
in O
an O
identical O
manner O
within O
a O
total O
of O
seven O
serial O
passages O
. O

Introduction O
of O
the O
above O
C O
- O
to O
- O
U O
mutation O
into O
the O
parent O
virus O
( O
5 O
' O
- O
GuUAAAAAGGG O
) O
altered O
the O
frequency O
of O
P O
, O
V O
, O
and O
W O
mRNAs O
from O
68 O
, O
28 O
, O
and O
4 O
% O
to O
15 O
, O
44 O
, O
and O
41 O
% O
, O
respectively O
, O
demonstrating O
that O
the O
U O
at O
this O
position O
is O
a O
key O
determinant O
in O
modulating O
P O
- O
gene O
mRNA O
editing O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
edits O
its O
P O
gene O
by O
inserting O
one O
or O
two O
G O
residues O
at O
the O
conserved O
editing O
site O
( O
UUUUUCCC O
, O
genome O
sense O
) O
and O
transcribes O
the O
P O
mRNA O
( O
unedited O
) O
, O
the O
V O
mRNA O
( O
with O
a O
+ O
1 O
frameshift O
) O
, O
and O
the O
W O
mRNA O
( O
with O
a O
+ O
2 O
frameshift O
) O
. O

An O
interferon B
( I
IFN I
) I
sensitivity O
assay O
showed O
that O
the O
parental O
virus O
was O
more O
resistant O
to O
the O
antiviral O
effect O
of O
IFN O
than O
the O
mutant O
viruses O
. O

classical B
swine I
fever I
virus I
( I
CSFV I
) I
replicates O
efficiently O
in O
cell O
lines O
and O
monocytic O
cells O
, O
including O
macrophages B
( I
MPhi I
) I
, O
without O
causing O
a O
cytopathic O
effect O
or O
inducing O
interferon B
( I
IFN I
) I
secretion O
. O

When O
the O
porcine O
kidney O
cell O
line O
SK O
- O
6 O
was O
infected O
with O
CSFV O
, O
there O
was O
a O
100 O
- O
fold O
increased O
capacity O
to O
resist O
to O
apoptosis O
induced O
by O
polyinosinic O
- O
polycytidylic O
acid O
[ O
poly O
( O
IC O
) O
] O
, O
a O
synthetic O
double O
- O
stranded O
RNA O
. O

In O
M O
( O
D O
, O
the O
virus O
infection O
inhibited O
poly O
( O
IC O
) O
- O
induced O
alpha O
/ O
beta O
IFN O
( O
type O
I O
IFN O
) O
synthesis O
. O

Mutants O
lacking O
the O
N O
- O
pro O
gene O
( O
DeltaN O
( O
pro O
) O
CSFV O
) O
did O
not O
protect O
SK O
- O
6 O
cells O
from O
poly O
( O
IC O
) O
- O
induced O
apoptosis O
, O
despite O
growth O
properties O
and O
protein O
expression O
levels O
similar O
to O
those O
of O
the O
wild O
- O
type O
virus O
. O

Furthermore O
, O
DeltaN O
( O
pro O
) O
CSFV O
did O
not O
prevent O
poly O
( O
IC O
) O
- O
induced O
type O
I O
IFN O
production O
in O
MPhi O
) O
but O
rather O
induced O
type O
I O
IFN O
in O
the O
absence O
of O
poly O
( O
IC O
) O
in O
both O
MPhi O
and O
the O
porcine O
kidney O
cell O
line O
PK O
- O
15 O
, O
but O
not O
in O
SK O
- O
6 O
cells O
. O

With O
MPhi O
and O
PK O
- O
15 O
, O
an O
impaired O
replication O
of O
the O
DeltaN O
( O
pro O
) O
CSFV O
compared O
with O
wild O
- O
type O
virus O
was O
noted O
. O

In O
addition O
, O
DeltaN O
( O
pro O
) O
CSFV O
, O
but O
not O
wild O
- O
type O
CSFV O
, O
could O
interfere O
with O
vesicular O
stomatitis O
virus O
replication O
in O
PK O
- O
15 O
cells O
. O

The O
SER O
virus O
F O
protein O
has O
a O
long O
cytoplasmic B
tail I
( I
CT I
) I
, O
and O
truncation O
or O
mutations O
of O
the O
CT O
result O
in O
enhanced O
syncytium O
formation O
( O
S O
. O

We O
observed O
that O
the O
hemifusion O
, O
cytoplasmic O
content O
mixing O
, O
and O
syncytium O
formation O
ability O
of O
the O
wild O
- O
type O
SER O
virus O
F O
coexpressed O
with O
the O
SER O
virus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
was O
enhanced O
, O
both O
qualitatively O
and O
quantitatively O
, O
at O
elevated O
temperatures O
. O

The O
tetrameric O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
mediates O
attachment O
to O
sialic O
acid O
- O
containing O
receptors O
as O
well O
as O
cleavage O
of O
the O
same O
moiety O
via O
its O
neuraminidase B
( I
NA I
) I
activity O
. O

The O
X O
- O
ray O
crystallographic O
structure O
of O
an O
HN O
dimer O
from O
Newcastle B
disease I
virus I
( I
NDV I
) I
suggests O
that O
a O
single O
site O
in O
two O
different O
conformations O
mediates O
both O
of O
these O
activities O
. O

Instead O
, O
the O
interface O
mutations O
acted O
by O
weakening O
the O
interaction O
between O
HN O
and O
its O
receptor O
( O
s O
) O
. O

The O
fusion O
( O
F O
) O
glycoproteins O
of O
measles B
virus I
strains I
Edmonston I
( I
MV I
- I
Edm I
) I
and O
wtF O
( O
W O
- O
wtF O
) O
confer O
distinct O
cytopathic O
effects O
and O
strengths O
of O
hemagglutinin B
( I
H I
) I
interaction O
on O
a O
recombinant O
W O
- O
Edm O
virus O
. O

By O
comparing O
the O
sequence O
of O
MV O
F O
with O
those O
of O
the O
parainfluenza O
virus O
SV5 O
and O
Newcastle B
disease I
virus I
( I
NDV I
) I
F O
proteins O
, O
the O
structures O
of O
which O
are O
known O
, O
we O
show O
that O
MV O
F O
- O
2 O
also O
possesses O
a O
potential O
heptad B
repeat I
( I
HR I
) I
C O
domain O
. O

For O
human O
parainfluenza O
virus O
type O
3 O
and O
many O
other O
paramyxoviruses O
, O
membrane O
fusion O
mediated O
by O
the O
fusion B
protein I
( I
F I
) I
has O
a O
stringent O
requirement O
for O
the O
presence O
of O
the O
homotypic O
hemagglutinin B
- I
neuraminidase I
protein I
( I
HN I
) I
. O

In O
this O
method O
, O
HN O
/ O
F O
- O
coexpressing O
cells O
with O
red B
blood I
cells I
( I
RBC I
) I
bound O
to O
them O
at O
4degreesC O
are O
transferred O
to O
22degreesC O
, O
and O
at O
different O
times O
after O
transfer O
4 B
- I
guanidino I
- I
Neu5Ac2en I
( I
4 I
- I
GU I
- I
DANA I
) I
is O
added O
; O
this O
inhibitor O
of O
the O
HN O
- O
receptor O
interaction O
then O
releases O
all O
reversibly O
bound O
RBC O
but O
not O
those O
in O
which O
F O
insertion O
in O
the O
target O
membrane O
or O
fusion O
has O
occurred O
. O

Thus O
, O
the O
amount O
of O
irreversibly O
bound O
( O
nonreleased O
) O
RBC O
provides O
a O
measure O
of O
F O
activation O
, O
and O
the O
use O
of O
fluorescently O
labeled O
RBC O
permits O
microscopic O
assessment O
of O
the O
extent O
to O
which O
F O
insertion O
has O
progressed O
to O
fusion O
. O

C28a O
but O
not O
C28 O
exhibits O
a O
slow O
fusion O
phenotype O
, O
although O
determination O
of O
the O
HNs O
' O
receptor O
- O
binding O
avidity O
( O
with O
our O
sensitive O
method O
, O
employing O
RBC O
with O
different O
degrees O
of O
receptor O
depletion O
) O
showed O
that O
the O
receptor O
- O
binding O
avidity O
of O
C28a O
or O
C28 O
HN O
was O
not O
lower O
than O
that O
of O
the O
wild O
type O
. O

The O
synthesis O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
in O
a O
cell O
- O
free O
protein O
- O
synthesizing O
system O
containing O
membranes O
was O
characterized O
. O

Furthermore O
, O
a O
10 O
- O
kDa O
polypeptide O
derived O
from O
the O
cytoplasmic B
domain I
( I
CT I
) I
was O
also O
protected O
from O
protease O
digestion O
by O
the O
membranes O
. O

A O
polypeptide O
with O
the O
size O
of O
the O
partially O
translocated O
F O
protein O
was O
detected O
by O
Western O
analysis O
of O
proteins O
in O
total O
- O
cell O
extracts O
of O
NDV O
strain O
B1 O
( O
avirulent O
) O
- O
infected O
Cos O
- O
7 O
cells O
. O

SER O
virus O
is O
closely O
related O
to O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
but O
is O
defective O
in O
syncytium O
formation O
. O

The O
SER O
virus O
F O
protein O
has O
a O
long O
cytoplasmic B
tail I
( I
CT I
) I
domain O
that O
has O
been O
shown O
to O
inhibit O
membrane O
fusion O
, O
and O
this O
inhibitory O
effect O
could O
be O
eliminated O
by O
truncation O
of O
the O
C O
- O
terminal O
sequence O
( O
S O
. O

Entry O
and O
fusion O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPF3 I
) I
require O
the O
interaction O
of O
the O
viral O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
with O
its O
sialic O
acid O
receptor O
. O

We O
previously O
generated O
a O
4 O
- O
GU O
- O
DANA O
- O
resistant O
HPF3 O
virus O
variant O
( O
ZM1 O
) O
with O
a O
markedly O
fusogenic O
plaque O
morphology O
that O
harbored O
two O
HN O
gene O
mutations O
resulting O
in O
amino O
acid O
alterations O
. O

We O
have O
generated O
a O
recombinant O
Newcastle B
disease I
virus I
( I
NDV I
) I
that O
expresses O
the O
green B
fluorescence I
protein I
( I
GFP I
) I
in O
infected O
chicken B
embryo I
fibroblasts I
( I
CEFs I
) I
. O

This O
virus O
is O
interferon B
( I
IFN I
) I
sensitive O
, O
and O
pretreatment O
of O
cells O
with O
chicken O
alpha B
/ I
beta I
IFN I
( I
IFN I
- I
alpha I
/ I
beta I
) I
completely O
blocks O
viral O
GFP O
expression O
. O

Conformational O
changes O
in O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
protein O
during O
activation O
of O
fusion O
and O
the O
role O
of O
HN O
protein O
in O
these O
changes O
were O
characterized O
with O
a O
polyclonal O
antibody O
. O

Anti O
- O
HR1 O
antibody O
inhibited O
the O
fusion O
of O
R18 O
( O
octadecyl O
rhodamine O
B O
chloride O
) O
- O
labeled O
red O
blood O
cells O
to O
syncytia O
expressing O
HN O
and O
wild O
- O
type O
F O
proteins O
. O

hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
, O
which O
is O
responsible O
for O
virus O
attachment O
, O
interacts O
with O
the O
fusion O
protein O
in O
a O
virus O
type O
- O
specific O
manner O
to O
induce O
efficient O
membrane O
fusion O
. O

Nipah B
virus I
( I
NiV I
) I
and O
Hendra B
virus I
( I
HeV I
) I
are O
novel O
paramyxoviruses O
from O
pigs O
and O
horses O
, O
respectively O
, O
that O
are O
responsible O
for O
fatal O
zoonotic O
infections O
of O
humans O
. O

These O
viruses O
are O
most O
closely O
related O
to O
members O
of O
the O
genus O
Morbillivirus O
and O
infect O
cells O
through O
a O
pH O
- O
independent O
membrane O
fusion O
event O
mediated O
by O
the O
actions O
of O
their O
attachment O
( O
G O
) O
and O
fusion O
( O
F O
) O
glycoproteins O
. O

The O
C O
proteins O
are O
extremely O
versatile O
and O
have O
been O
shown O
to O
counteract O
the O
antiviral O
action O
of O
Interferons B
( I
IFNs I
) I
, O
to O
down O
- O
regulate O
viral O
RNA O
synthesis O
, O
and O
to O
promote O
virus O
assembly O
. O

Truncation O
from O
the O
amino O
terminus O
to O
the O
middle O
of O
the O
C O
protein O
maintained O
the O
inhibition O
of O
the O
signal O
transduction O
of O
IFNs O
, O
the O
formation O
of O
IFN B
- I
stimulated I
gene I
factor I
3 I
( I
ISGF3 I
) I
complex O
, O
the O
generation O
of O
the O
anti O
- O
vesicular O
stomatitis O
virus O
state O
, O
and O
the O
synthesis O
of O
viral O
RNA O
, O
but O
further O
truncation O
resulted O
in O
the O
simultaneous O
loss O
of O
all O
of O
these O
inhibitory O
activities O
. O

The O
generation O
of O
replication O
- O
competent O
measles B
virus I
( I
MV I
) I
depends O
on O
the O
incorporation O
of O
biologically O
active O
, O
fusogenic O
glycoprotein O
complexes O
, O
which O
are O
required O
for O
attachment O
and O
penetration O
into O
susceptible O
host O
cells O
and O
for O
direct O
virus O
spread O
by O
cell O
- O
to O
- O
cell O
fusion O
. O

Whereas O
multiple O
studies O
have O
analyzed O
the O
importance O
of O
the O
ectodomains O
of O
the O
MV O
glycoproteins O
hemagglutinin B
( I
H I
) I
and O
fusion B
protein I
( I
F I
) I
, O
we O
have O
investigated O
the O
role O
of O
the O
cytoplasmic O
tails O
of O
the O
F O
and O
H O
proteins O
for O
the O
formation O
of O
fusogenic O
complexes O
. O

By O
using O
reverse O
genetics O
, O
a O
recombinant O
MV O
with O
an O
F O
tail O
of O
three O
amino O
acids O
( O
rMV O
- O
FcDelta30 O
) O
, O
as O
well O
as O
an O
MV O
with O
an O
H O
tail O
of O
14 O
residues O
( O
rMV O
- O
HcDelta20 O
) O
, O
could O
be O
rescued O
, O
whereas O
generation O
of O
viruses O
with O
shorter O
H O
tails O
failed O
. O

In O
this O
study O
, O
two O
herpesvirus O
of O
turkey O
recombinants O
( O
rHVTs O
) O
expressing O
large O
amounts O
of O
infectious B
bursal I
disease I
virus I
( I
IBDV I
) I
VP2 O
antigen O
under O
the O
control O
of O
a O
human B
cytomegalovirus I
( I
CMV I
) I
promoter O
or O
CMV O
/ O
beta O
- O
actin O
chimera O
promoter O
( O
Pec O
promoter O
) O
( O
rHVT O
- O
cmvVP2 O
and O
rHVT O
- O
pecVP2 O
) O
were O
constructed O
. O

We O
recently O
reported O
the O
first O
crystal O
structure O
of O
a O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
from O
Newcastle O
disease O
virus O
. O

This O
multifunctional O
protein O
is O
responsible O
for O
binding O
to O
cellular O
sialyl O
- O
glycoconjugate O
receptors O
, O
promotion O
of O
fusion O
through O
interaction O
with O
the O
second O
viral O
surface O
fusion O
( O
F O
) O
glycoprotein O
, O
and O
processing O
progeny O
virions O
by O
removal O
of O
sialic O
acid O
from O
newly O
synthesized O
viral O
coat O
proteins O
. O

A O
complete O
cDNA O
clone O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
vaccine O
strain O
Hitchner O
B1 O
was O
constructed O
, O
and O
infectious O
recombinant O
virus O
expressing O
an O
influenza O
virus O
hemagglutinin O
was O
generated O
by O
reverse O
genetics O
. O

The O
fusion O
( O
F O
) O
protein O
of O
simian B
virus I
5 I
( I
SV5 I
) I
strain O
W3A O
is O
known O
to O
induce O
cell O
fusion O
in O
the O
absence O
of O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
. O

When O
Leu O
- O
22 O
in O
the O
subunit O
F2 O
of O
the O
WR O
F O
protein O
is O
replaced O
with O
the O
counterpart O
( O
Pro O
) O
in O
the O
W3A O
F O
protein O
, O
the O
resulting O
mutant O
L22P O
induces O
extensive O
cell O
fusion O
by O
itself O
. O

In O
the O
present O
study O
, O
we O
obtained O
anti O
- O
L22P O
Monoclonal B
antibodies I
( I
MAbs I
) I
21 O
- O
1 O
and O
6 O
- O
7 O
, O
whose O
epitopes O
were O
located O
in O
the O
middle O
( O
amino O
acids O
[ O
aa O
] O
227 O
to O
320 O
) O
of O
subunit O
Fl O
. O

The O
amino O
- O
terminal O
region O
( O
aa O
20 O
to O
47 O
) O
of O
subunit O
F2 O
was O
also O
involved O
in O
the O
formation O
of O
Nub O
21 O
- O
1 O
epitope O
. O

Hunan B
parainfluenza I
type I
2 I
virus I
( I
hPIV I
- I
2 I
) I
- O
infected O
HeLa O
( O
HeLa O
- O
CA O
) O
cells O
and O
hPIV O
- O
2 O
V O
- O
expressing O
HeLa O
( O
HeLa O
- O
V O
) O
cells O
show O
high O
resistance O
to O
Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
irrespective O
of O
whether O
vesicular O
stomatitis O
virus O
or O
Sindbis O
virus O
is O
used O
as O
a O
challenge O
virus O
. O

The O
envelope O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPF3 I
) I
contains O
two O
viral O
glycoproteins O
, O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
and O
the O
fusion B
protein I
( I
F I
) I
. O

HN O
, O
which O
is O
responsible O
for O
receptor O
attachment O
and O
for O
promoting O
F O
- O
mediated O
fusion O
, O
also O
possesses O
neuraminidase O
( O
receptor O
- O
destroying O
) O
activity O
. O

We O
reported O
previously O
that O
4 B
- I
guanidino I
- I
Neu5Ac2en I
( I
4 I
- I
GU I
- I
DANA I
) I
and O
related O
sialic O
acid O
- O
based O
inhibitors O
of O
HPF3 O
neuraminidase O
activity O
also O
inhibit O
HN O
- O
mediated O
receptor O
binding O
and O
fusion O
processes O
not O
involving O
neuraminidase O
activity O
. O

We O
have O
now O
examined O
this O
mechanism O
, O
as O
well O
as O
neuraminidase O
' O
s O
role O
in O
the O
viral O
life O
cycle O
, O
using O
a O
neuraminidase O
- O
deficient O
HPF3 O
variant O
( O
C28a O
) O
and O
stable O
cell O
lines O
expressing O
C28a O
or O
wild B
- I
type I
( I
WT I
) I
HN O
. O

Cells O
expressing O
C28a O
RN O
did O
not O
bind O
erythrocytes O
at O
4 O
degreesC O
unless O
pretreated O
with O
neuraminidase O
, O
but O
no O
such O
pretreatment O
was O
required O
for O
hemadsorption B
activity I
( I
HAD I
) I
at O
22 O
or O
37 O
degreesC O
. O

Entry O
and O
fusion O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPF3 I
) I
requires O
interaction O
of O
the O
viral O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
, O
vith O
its O
sialic O
acid O
receptor O
. O

4 O
Guanidino O
2 O
, O
4 O
- O
dideoxy O
- O
2 O
, O
3 O
- O
dehydro O
- O
N O
- O
acetylneuraminic O
acid O
( O
4 O
GU O
- O
DANA O
; O
zanamivir O
) O
, O
a O
sialic O
acid O
transition O
- O
state O
analog O
designed O
to O
fit O
the O
influenza O
virus O
neuraminidase O
catalytic O
site O
, O
possesses O
antiviral O
activity O
at O
nanomolar O
concentrations O
in O
vitro O
. O

In O
the O
present O
study O
, O
a O
4 O
- O
GU O
- O
DANA O
- O
resistant O
HPF3 O
virus O
variant O
( O
ZM1 O
) O
was O
generated O
by O
serial O
passage O
in O
the O
presence O
of O
4 O
- O
GU O
- O
DANA O
. O

Neuraminidase O
assays O
revealed O
a O
15 O
fold O
reduction O
in O
4 O
- O
GU O
- O
DANA O
sensitivity O
for O
ZM1 O
relative O
to O
the O
wild B
type I
( I
Wt I
) I
and O
C O
- O
0 O
, O
The O
ability O
of O
ZM1 O
to O
bind O
sialic O
acid O
receptors O
was O
inhibited O
10 O
- O
fold O
less O
than O
for O
both O
WT O
and O
C O
- O
0 O
in O
the O
presence O
of O
1 O
mM O
4 O
GU O
- O
DANA O
. O

In O
some O
cell O
types O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
causes O
little O
cytopathic B
effect I
( I
CPE I
) I
and O
infection O
continues O
productively O
for O
long O
periods O
of O
time O
; O
e O
. O

g O
, O
, O
SV5 O
can O
be O
produced O
from O
MDBK O
cells O
for O
up O
to O
40 O
days O
with O
little O
CPE O
, O
SV5 O
differs O
from O
most O
paramyxoviruses O
in O
that O
it O
encodes O
a O
small O
( O
44 O
- O
amino O
- O
acid O
) O
hydrophobic O
integral O
membrane O
protein O
( O
SH O
) O
. O

When O
MDBK O
cells O
were O
infected O
with O
a O
recombinant O
SV5 O
containing O
a O
deletion O
of O
the O
SH O
gene O
( O
rSV5 O
Delta O
SH O
) O
, O
the O
MDBK O
cells O
exhibited O
an O
increase O
in O
CPE O
compared O
to O
cells O
infected O
with O
wild O
- O
type O
SV5 O
( O
recovered O
from O
cDNA O
; O
rSV5 O
) O
. O

The O
increased O
CPE O
correlated O
with O
an O
increase O
in O
apoptosis O
in O
rSV5SH O
- O
infected O
cells O
over O
mock O
- O
infected O
and O
rSV5 O
- O
infected O
cells O
when O
assayed O
for O
annexin O
V O
binding O
, O
DNA O
content O
( O
propidium O
iodide O
staining O
) O
, O
and O
DNA O
fragmentation O
( O
terminal O
deoxynucleotidyltransferase O
- O
mediated O
dUTP O
- O
biotin O
nick O
end O
labeling O
assay O
) O
. O

The O
human O
respiratory O
syncytial O
virus O
( O
Long O
strain O
) O
fusion O
protein O
contains O
six O
potential O
N O
- O
glycosylation O
sites O
: O
N27 O
, O
N70 O
, O
N116 O
, O
N120 O
, O
N126 O
, O
and O
N500 O
, O
Site O
- O
directed O
mutagenesis O
of O
these O
positions O
revealed O
that O
the O
mature O
fusion O
protein O
contains O
three O
N O
- O
linked O
oligosaccharides O
, O
attached O
to O
N27 O
, O
N70 O
, O
and O
N500 O
. O

Elimination O
of O
both O
N O
- O
glycans O
( O
N27 O
/ O
70Q O
mutant O
) O
reduced O
the O
fusion O
activity O
by O
about O
50 O
% O
. O

The O
terminal O
globular O
domain O
of O
the O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
spike O
has O
a O
number O
of O
conserved O
residues O
that O
are O
predicted O
to O
form O
its O
neuraminidase B
( I
NA I
) I
active O
site O
, O
by O
analogy O
to O
the O
influenza O
virus O
neuraminidase O
protein O
. O

We O
have O
performed O
a O
site O
- O
directed O
mutational O
analysis O
of O
the O
role O
of O
these O
residues O
in O
the O
functional O
activity O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
protein O
. O

In O
addition O
to O
providing O
support O
for O
the O
homology O
- O
based O
predictions O
for O
the O
structure O
of O
HN O
, O
these O
findings O
argue O
that O
( O
i O
) O
the O
HN O
residues O
that O
mediate O
its O
NA O
activity O
are O
not O
critical O
to O
its O
attachment O
function O
and O
( O
ii O
) O
NA O
activity O
is O
required O
for O
the O
protein O
to O
mediate O
binding O
to O
receptors O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
edits O
its O
P O
- O
gene O
mRNA O
by O
inserting O
a O
nontemplated O
G O
residue O
( O
s O
) O
at O
a O
conserved O
editing O
site O
( O
3 O
' O
- O
UUUUUCCC O
- O
template O
strand O
) O
. O

In O
addition O
, O
both O
mutants O
were O
unable O
to O
propagate O
in O
9 O
- O
to O
Ii O
- O
day O
- O
old O
embryonated O
specific B
- I
pathogen I
- I
free I
( I
SPF I
) I
chicken O
eggs O
. O

In O
contrast O
, O
a O
mutant O
( O
NDV O
- O
P1 O
) O
with O
one O
nucleotide O
substitution O
( O
UUCUUCCC O
) O
grew O
in O
eggs O
, O
albeit O
with O
a O
100 O
- O
fold O
- O
lower O
infectious O
titer O
than O
the O
parent O
virus O
. O

sodium B
dodecyl I
sulfate I
( I
SDS I
) I
- O
polyacrylamide O
gel O
electrophoresis O
and O
Western O
blot O
analysis O
revealed O
little O
or O
no O
change O
in O
the O
mobility O
of O
virion O
- O
associated O
gp120 O
after O
digestion O
with O
high O
concentrations O
of O
N O
- O
glycosidase O
F O
, O
endoglycosidase O
F O
, O
endoglycosidase O
H O
, O
and O
endo O
- O
beta O
- O
galactosidase O
. O

This O
study O
examines O
the O
contribution O
of O
the O
fusion O
( O
f O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
genes O
of O
bovine B
parainfluenza I
virus I
type I
3 I
( I
BPIV3 I
) I
to O
its O
restricted O
replication O
in O
the O
respiratory O
tract O
of O
nonhuman O
primates O
. O

, O
A O
chimeric O
recombinant O
human B
parainfluenza I
type I
3 I
virus I
( I
HPIV3 I
) I
containing O
BPIV3 O
F O
and O
HN O
glycoprotein O
genes O
in O
place O
of O
its O
own O
and O
the O
reciprocal O
recombinant O
consisting O
of O
BPIV3 O
bearing O
the O
HPIV3 O
F O
and O
HN O
genes O
( O
rBPIV3 O
- O
FHHNH O
) O
were O
generated O
to O
assess O
the O
effect O
of O
glycoprotein O
substitution O
on O
replication O
of O
HPIV3 O
and O
BPIV3 O
in O
the O
upper O
and O
lower O
respiratory O
tract O
of O
rhesus O
monkeys O
. O

We O
identified O
an O
interferon B
regulatory I
factor I
motif I
( I
IRF I
- I
E I
) I
upstream O
of O
an O
NF O
- O
kappa O
B O
binding O
site O
in O
the O
interleukin B
- I
15 I
( I
IL I
- I
15 I
) I
promoter O
. O

To O
test O
this O
hypothesis O
, O
L929 O
cells O
were O
infected O
with O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
which O
led O
to O
the O
induction O
of O
IL O
- O
15 O
mRNA O
and O
protein O
expression O
. O

Attachment O
of O
measles B
virus I
( I
MV I
) I
to O
its O
cellular O
receptor O
is O
mediated O
by O
the O
viral O
envelope O
glycoprotein O
hemagglutinin B
( I
H I
) I
. O

The O
role O
of O
a O
leucine O
heptad O
repeat O
motif O
between O
amino O
acids O
268 O
and O
289 O
in O
the O
structure O
and O
function O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
F O
protein O
was O
explored O
by O
introducing O
single O
point O
mutations O
into O
the O
F O
gene O
cDNA O
, O
The O
mutations O
affected O
either O
folding O
of O
the O
protein O
or O
the O
fusion O
activity O
of O
the O
protein O
. O

The O
P O
/ O
C O
mRNA O
of O
Sendai B
virus I
( I
SeV I
) I
encodes O
a O
nested O
set O
of O
accessory O
proteins O
, O
C O
' O
, O
C O
, O
Y1 O
, O
and O
Y2 O
, O
referred O
to O
collectively O
as O
C O
proteins O
, O
using O
the O
+ O
1 O
frame O
relative O
to O
the O
open O
reading O
frame O
of O
phospho O
( O
P O
) O
protein O
and O
initiation O
codons O
at O
different O
positions O
. O

We O
previously O
created O
a O
4C O
( O
- O
) O
SeV O
, O
which O
expresses O
none O
of O
the O
four O
C O
proteins O
, O
and O
concluded O
that O
the O
C O
proteins O
are O
categorically O
nonessential O
gene O
products O
but O
greatly O
contribute O
to O
viral O
full O
replication O
and O
infectivity O
( O
A O
. O

Kurotani O
et O
al O
, O
, O
Genes O
Cells O
3 O
: O
111 O
- O
124 O
, O
1998 O
) O
, O
Here O
, O
we O
further O
characterized O
the O
4C O
( O
- O
) O
virus O
multiplication O
in O
cultured O
cells O
. O

The O
viral O
protein O
and O
mRNA O
synthesis O
was O
enhanced O
with O
the O
mutant O
virus O
relative O
to O
the O
parental O
wild B
- I
type I
( I
WT I
) I
SeV O
. O

However O
, O
the O
viral O
yields O
were O
greatly O
reduced O
, O
in O
addition O
, O
the O
4C O
( O
- O
) O
virions O
appeared O
to O
be O
highly O
anomalous O
in O
size O
, O
shape O
, O
and O
sedimentation O
profile O
in O
a O
sucrose O
gradient O
and O
exhibited O
the O
ratios O
of O
infectivity O
to O
hemagglutination O
units O
significantly O
lower O
than O
those O
of O
the O
WT O
. O

In O
the O
WT O
infected O
cells O
, O
C O
proteins O
appeared O
to O
colocalize O
almost O
perfectly O
with O
the O
matrix B
( I
M I
) I
proteins O
, O
pretty O
well O
with O
an O
external O
envelope O
glycoprotein O
( O
hemagglutinin O
- O
neuraminidase O
[ O
HN O
] O
) O
, O
and O
very O
poorly O
with O
the O
internal O
P O
protein O
. O

In O
the O
absence O
of O
C O
proteins O
, O
there O
was O
a O
significant O
delay O
of O
the O
incorporation O
of O
M O
protein O
and O
both O
of O
the O
envelope O
proteins O
, O
HN O
and O
fusion O
( O
F O
) O
proteins O
, O
into O
progeny O
virions O
. O

Immunosuppression O
induced O
by O
measles B
virus I
( I
MV I
) I
is O
associated O
with O
unresponsiveness O
of O
peripheral B
blood I
lymphocytes I
( I
PBL I
) I
to O
mitogenic O
stimulation O
ex O
vivo O
and O
in O
vitro O
. O

In O
mixed O
lymphocyte O
cultures O
and O
in O
an O
experimental O
animal O
model O
, O
the O
expression O
of O
the O
MV O
glycoproteins O
on O
the O
surface O
of O
UV O
- O
inactivated O
MV O
particles O
, O
MV O
- O
infected O
cells O
, O
or O
cells O
transfected O
to O
coexpress O
the O
MV O
fusion O
( O
F O
) O
and O
the O
hemagglutinin B
( I
H I
) I
proteins O
was O
found O
to O
be O
necessary O
and O
sufficient O
for O
this O
phenomenon O
. O

Proteolytic O
cleavage O
of O
MV O
F O
- O
0 O
protein O
by O
cellular O
proteases O
, O
such O
as O
furin O
, O
into O
the O
F O
- O
1 O
- O
F O
- O
2 O
subunits O
is O
, O
however O
, O
an O
absolute O
requirement O
, O
since O
( O
i O
) O
the O
inhibitory O
activity O
of O
MV O
- O
infected O
BJAB O
cells O
was O
significantly O
impaired O
in O
the O
presence O
of O
a O
furin O
- O
inhibitory O
peptide O
and O
( O
ii O
) O
cells O
expressing O
or O
viruses O
containing O
uncleaved O
F O
- O
0 O
proteins O
revealed O
a O
strongly O
reduced O
inhibitory O
activity O
which O
was O
improved O
following O
trypsin O
treatment O
. O

Typical O
of O
many O
viral O
fusion O
proteins O
, O
the O
sequence O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
protein O
has O
several O
heptad O
repeat O
regions O
. O

The O
structure O
and O
function O
of O
a O
synthetic O
peptide O
with O
a O
sequence O
from O
the O
region O
of O
tbe O
NDV O
HR1 O
region O
( O
amino O
acids O
150 O
to O
173 O
) O
were O
characterized O
. O

A O
full O
- O
length O
cDNA O
clone O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
vaccine O
strain O
LaSota O
was O
assembled O
from O
subgenomic O
overlapping O
cDNA O
fragments O
and O
cloned O
in O
a O
transcription O
plasmid O
between O
the O
T7 O
RNA O
polymerase O
promoter O
and O
the O
autocatalytic O
hepatitis O
delta O
virus O
ribozyme O
. O

By O
introducing O
three O
nucleotide O
changes O
in O
the O
cDNA O
, O
we O
generated O
a O
genetically O
tagged O
derivative O
of O
the O
LaSota O
strain O
in O
which O
the O
amino O
acid O
sequence O
of O
the O
protease O
cleavage O
site O
( O
GGRQGR O
down O
arrow O
L O
) O
of O
the O
fusion O
protein O
F0 O
was O
changed O
to O
the O
consensus O
cleavage O
site O
of O
virulent O
NDV O
strains O
( O
GRRQRR O
down O
arrow O
F O
) O
. O

The O
stalk O
region O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
protein O
has O
been O
implicated O
in O
both O
fusion O
promotion O
and O
virus O
specificity O
of O
that O
activity O
, O
The O
NDV O
F O
protein O
contains O
two O
heptad O
repeat O
motifs O
which O
have O
been O
shown O
by O
site O
- O
directed O
mutagenesis O
to O
be O
critical O
for O
fusion O
( O
R O
. O

To O
this O
end O
, O
we O
examined O
the O
specificity O
of O
HN O
incorporation O
into O
progeny O
virions O
by O
transiently O
transfecting O
HN O
cDNA O
genes O
into O
Sendai B
virus I
( I
SV I
) I
infected O
cells O
. O

SV O
HN O
expressed O
from O
cDNA O
was O
efficiently O
incorporated O
into O
progeny O
Sendai O
virions O
, O
whereas O
Newcastle B
disease I
virus I
( I
NDV I
) I
HN O
was O
not O
. O

Further O
analysis O
identified O
five O
consecutive O
amino O
acids O
( O
residues O
10 O
to O
14 O
) O
that O
were O
required O
for O
the O
specific O
incorporation O
of O
HN O
into O
SV O
. O

These O
results O
suggest O
that O
this O
region O
near O
the O
N O
terminus O
of O
HN O
interacts O
with O
another O
viral O
protein O
( O
s O
) O
to O
lead O
to O
the O
specific O
incorporation O
of O
HN O
into O
progeny O
virions O
. O

The O
membrane O
fusion O
reaction O
promoted O
by O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
and O
human B
parainfluenza I
virus I
type I
3 I
( I
HPN I
- I
3 I
) I
fusion O
( O
F O
) O
proteins O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
proteins O
was O
characterized O
when O
the O
surface O
densities O
of O
F O
and O
HN O
were O
varied O
. O

Human O
sera O
contain O
high O
levels O
of O
natural O
antibody B
( I
Ab I
) I
to O
Gal O
alpha O
1 O
- O
3Gal O
, O
a O
terminal O
glycosidic O
structure O
expressed O
on O
the O
surface O
of O
cells O
of O
mammals O
other O
than O
Old O
World O
primates O
. O

Incorporation O
of O
this O
determinant O
onto O
retroviral O
membranes O
by O
passage O
of O
viruses O
in O
cells O
encoding O
alpha O
- O
1 O
- O
3 O
- O
galactosyltransferase B
( I
GT I
) I
renders O
retroviruses O
sensitive O
to O
lysis O
by O
natural O
Ab O
and O
complement O
in O
normal O
human O
serum O
( O
MHS O
) O
, O
Plasma O
membrane O
- O
budding O
viruses O
representing O
four O
additional O
virus O
groups O
were O
examined O
for O
their O
sensitivities O
to O
serum O
inactivation O
after O
passage O
through O
human O
cell O
lines O
that O
lack O
a O
functional O
GT O
or O
human O
cells O
expressing O
recombinant O
porcine O
GT O
. O

The O
inactivation O
of O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
by O
NHS O
directly O
correlated O
with O
host O
modification O
of O
the O
virus O
via O
expression O
of O
Gal O
alpha O
1 O
- O
3Gal O
and O
was O
blocked O
by O
incorporation O
of O
soluble O
Gal O
alpha O
1 O
- O
3Gal O
disaccharide O
into O
the O
inactivation O
assay O
. O

GT O
- O
deficient O
mice O
immunized O
to O
make O
high O
levels O
of O
Ab O
to O
Gal O
alpha O
1 O
- O
3Gal O
( O
anti O
- O
Gal O
Ab O
) O
were O
tested O
for O
resistance O
to O
LCMV O
passaged O
in O
GT O
- O
expressing O
cells O
. O

Newcastle O
disease O
virus O
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
were O
inactivated O
by O
NHS O
regardless O
of O
cell O
passage O
history O
, O
whereas O
Sindbis B
virus I
( I
SV I
) I
passaged O
in O
human O
cells O
resisted O
inactivation O
. O

The O
effects O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
( O
F O
) O
glycoprotein O
cleavage O
mutants O
on O
the O
cleavage O
and O
syncytium O
- O
forming O
activity O
of O
the O
wild O
- O
type O
F O
protein O
were O
examined O
. O

F O
protein O
cleavage O
mutants O
were O
made O
by O
altering O
amino O
acids O
in O
the O
furin O
recognition O
region O
( O
amino O
acids O
112 O
to O
116 O
) O
in O
the O
F O
protein O
of O
a O
virulent O
strain O
of O
NDV O
. O

The O
fusion O
( O
F O
) O
protein O
of O
simian O
virus O
5 O
( O
strain O
W3A O
) O
induced O
extensive O
cell O
fusion O
in O
BHK O
cells O
when O
expressed O
alone O
, O
while O
that O
of O
strain O
WR O
did O
not O
. O

The O
Sendai O
virus O
V O
protein O
is O
a O
nonstructural O
trans O
frame O
protein O
whose O
cysteine O
- O
rich O
e O
- O
terminal O
half O
is O
fused O
to O
the O
acidic O
N O
- O
terminal O
half O
of O
the O
P O
protein O
via O
mRNA O
editing O
, O
We O
recently O
created O
a O
mutant O
by O
disrupting O
the O
editing O
motif O
, O
which O
is O
devoid O
of O
mRNA O
editing O
and O
hence O
unable O
to O
produce O
the O
V O
protein O
, O
and O
demonstrated O
that O
this O
V O
( O
- O
) O
virus O
replicated O
normally O
or O
even O
faster O
with O
augmented O
gene O
expression O
and O
cytopathogenicity O
in O
cells O
in O
vitro O
, O
but O
was O
strongly O
attenuated O
in O
pathogenicity O
for O
mice O
( O
A O
. O

Here O
, O
we O
created O
another O
version O
of O
a O
V O
- O
deficient O
mutant O
, O
V O
- O
Delta O
C O
, O
encoding O
only O
the O
N O
- O
terminal O
half O
but O
not O
the O
V O
- O
specific O
C O
- O
terminal O
half O
, O
by O
introducing O
a O
stop O
codon O
in O
the O
trans O
- O
V O
frame O
, O
and O
then O
we O
compared O
its O
in O
vitro O
and O
in O
vivo O
phenotypes O
with O
those O
of O
the O
V O
( O
- O
) O
and O
wild O
- O
type O
viruses O
, O
The O
V O
- O
Delta O
C O
virus O
was O
found O
to O
be O
similar O
to O
the O
wild O
- O
type O
virus O
in O
vitro O
with O
no O
augmented O
gene O
expression O
and O
cytopathogenicity O
, O
but O
in O
vivo O
, O
it O
resembled O
the O
V O
( O
- O
) O
virus O
, O
displaying O
a O
similarly O
attenuated O
phenotype O
. O

Thus O
, O
the O
pathogenicity O
determinant O
in O
the O
V O
protein O
was O
mapped O
to O
the O
C O
- O
terminal O
half O
, O
The O
N O
- O
terminal O
half O
was O
likely O
sufficient O
to O
confer O
normal O
( O
wild O
- O
type O
) O
in O
vitro O
phenotypes O
. O

For O
many O
paramyxoviruses O
, O
including O
Newcastle B
disease I
virus I
( I
NDV I
) I
, O
syncytium O
formation O
requires O
the O
expression O
of O
both O
surface O
glycoproteins O
( O
HN O
and O
F O
) O
in O
the O
same O
cell O
, O
and O
evidence O
Suggests O
that O
fusion O
involves O
a O
specific O
interaction O
between O
the O
HN O
and O
F O
proteins O
, O
Because O
a O
potential O
interaction O
in O
paramyxovirus O
- O
infected O
cells O
has O
never O
been O
demonstrated O
, O
such O
as O
interaction O
was O
explored O
by O
using O
; O
coimmunoprecipitation O
and O
cross O
- O
linking O
Both O
HN O
and O
F O
proteins O
could O
be O
precipitated O
, O
vith O
heterologous O
antisera O
after O
a O
5 O
- O
min O
radioactive O
pulse O
as O
well O
as O
after O
a O
2 O
- O
h O
chase O
in O
nonradioactive O
medium O
, O
but O
at O
low O
levels O
. O

On O
the O
basis O
of O
the O
conservation O
of O
neuraminidase O
( O
N O
) O
active O
- O
site O
residues O
in O
influenza O
virus O
N O
and O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
, O
it O
has O
been O
suggested O
that O
the O
three B
- I
dimensional I
( I
3D I
) I
structures O
of O
the O
globular O
heads O
of O
the O
two O
proteins O
are O
broadly O
similar O
. O

This O
multiple O
sequence O
alignment O
of O
paramyxovirus O
HN O
proteins O
was O
used O
as O
an O
intermediate O
to O
align O
the O
morbillivirus O
hemagglutinin B
( I
H I
) I
proteins O
with O
neuraminidase O
. O

We O
have O
investigated O
the O
association O
of O
the O
influenza O
virus O
matrix O
( O
M1 O
) O
and O
nucleoprotein B
( I
NP I
) I
with O
the O
host O
cell O
cytoskeletal O
elements O
in O
influenza O
virus O
infected O
MDCK O
and O
MDBK O
cells O
. O

5 O
h O
postinfection O
, O
the O
newly O
synthesized O
M1 O
was O
Triton B
X I
100 I
( I
TX I
- I
100 I
) I
extractable O
but O
became O
resistant O
to O
TX O
- O
100 O
extraction O
during O
the O
chase O
with O
a O
t O
( O
1 O
/ O
2 O
) O
of O
20 O
min O
, O
NP O
, O
on O
the O
other O
hand O
, O
acquired O
TX O
- O
100 O
resistance O
immediately O
after O
synthesis O
. O

Significant O
fractions O
of O
both O
M1 O
and O
NP O
remained O
resistant O
to O
differential O
detergent O
( O
Triton O
X O
- O
114 O
, O
3 O
- O
[ O
( O
3 O
- O
cholamidopropyl O
) O
dimethylammonio O
] O
- O
1 O
- O
propanesulfonate O
[ O
CHAPS O
] O
, O
octylglucoside O
) O
extraction O
, O
suggesting O
that O
M1 O
and O
NP O
were O
interacting O
with O
the O
cytoskeletal O
elements O
. O

However O
, O
the O
high O
- O
molecular O
- O
weight O
form O
of O
the O
viral O
transmembrane O
protein O
Hemagglutinin B
( I
HA I
) I
, O
which O
had O
undergone O
complex O
glycosylation O
, O
also O
became O
resistant O
to O
TX O
- O
100 O
extraction O
but O
was O
sensitive O
to O
octylglucoside O
detergent O
extraction O
, O
indicating O
that O
HA O
, O
unlike O
M1 O
or O
NP O
, O
was O
interacting O
with O
TX O
- O
100 O
- O
insoluble O
lipids O
and O
not O
with O
cytoskeletal O
elements O
. O

M1 O
also O
did O
not O
acquire O
TX O
- O
100 O
insolubility O
in O
ts O
56 O
( O
a O
temperature O
- O
sensitive O
mutant O
with O
a O
defect O
in O
NP O
protein O
) O
- O
infected O
cells O
at O
the O
nonpermissive O
temperature O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
M1 O
and O
NP O
interact O
with O
host O
microfilaments O
in O
virus O
- O
infected O
cells O
and O
that O
hll O
requires O
other O
viral O
proteins O
or O
subviral O
components O
( O
possibly O
viral O
ribonucleoprotein O
) O
for O
interaction O
with O
host O
cytoskeletal O
components O
. O

Determinants O
of O
glycosylation O
site O
usage O
were O
explored O
by O
using O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
of O
the O
paramyxovirus O
Newcastle O
disease O
virus O
. O

The O
sequence O
of O
this O
protein O
also O
has O
13 O
cysteine O
residues O
in O
the O
ectodomain O
( O
C2 O
to O
C14 O
) O
. O

We O
previously O
observed O
that O
cell O
fusion O
caused O
by O
human O
parainfluenza O
virus O
type O
2 O
or O
type O
3 O
requires O
the O
expression O
of O
both O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoproteins O
from O
the O
same O
virus O
type O
, O
indicating O
that O
a O
type O
- O
specific O
interaction O
between O
F O
and O
HN O
is O
needed O
for O
the O
induction O
of O
cell O
fusion O
, O
In O
the O
present O
study O
we O
have O
further O
investigated O
the O
fusion O
properties O
of O
F O
and O
HN O
proteins O
of O
parainfluenza B
virus I
type I
1 I
( I
PI1 I
) I
, O
type O
2 O
( O
PI2 O
) O
, O
and O
type O
3 O
( O
PI3 O
) O
, O
Sendai B
virus I
( I
SN I
) I
, O
and O
simian B
virus I
5 I
( I
SV5 I
) I
by O
expression O
of O
their O
glycoprotein O
genes O
in O
HeLa O
T4 O
cells O
using O
the O
vaccinia O
virus O
- O
T7 O
transient O
expression O
system O
. O

The O
cell O
fusion O
activity O
of O
most O
paramyxoviruses O
requires O
coexpression O
of O
a O
fusion B
protein I
( I
F I
) I
and O
a O
hemagglutinin B
- I
neuraminidase I
protein I
( I
HN I
) I
which O
are O
derived O
from O
the O
same O
virus O
type O
, O
To O
define O
the O
domain O
of O
the O
HN O
protein O
which O
interacts O
with O
the O
F O
protein O
in O
a O
type O
- O
specific O
manner O
, O
a O
series O
of O
chimeric O
HN O
proteins O
between O
two O
different O
paramyxoviruses O
, O
Sendai B
virus I
( I
SN I
) I
and O
human B
parainfluenza I
virus I
type I
3 I
( I
PI3 I
) I
, O
was O
constructed O
and O
coexpressed O
with O
the O
SN O
- O
F O
protein O
by O
using O
the O
vaccinia O
virus O
T7 O
RNA O
polymerase O
transient O
- O
expression O
system O
, O
Quantitative O
assays O
were O
used O
to O
evaluate O
cell O
surface O
expression O
as O
well O
as O
fusion O
- O
promoting O
activities O
of O
the O
chimeric O
HN O
molecules O
. O

A O
chimeric O
HN O
protein O
[ O
SN O
( O
140 O
) O
] O
containing O
140 O
N O
- O
terminal O
amino O
acids O
derived O
from O
SN O
- O
HN O
and O
the O
remainder O
( O
432 O
amino O
acids O
) O
derived O
from O
PI3 O
- O
HN O
was O
found O
to O
promote O
cell O
fusion O
with O
the O
SN O
- O
F O
protein O
, O
In O
contrast O
, O
a O
second O
chimeric O
HN O
with O
137 O
amino O
acids O
from O
SN O
- O
HN O
at O
the O
N O
terminus O
could O
not O
promote O
fusion O
with O
SN O
- O
F O
, O
even O
though O
the O
protein O
was O
expressed O
on O
the O
cell O
surface O
, O
A O
construct O
in O
which O
the O
PI3 O
- O
HN O
cytoplasmic O
tail O
and O
transmembrane O
domain O
were O
substituted O
for O
those O
of O
SN O
in O
the O
SN O
( O
140 O
) O
chimera O
still O
maintained O
the O
ability O
to O
promote O
cell O
fusion O
. O

murine B
AIDS I
( I
MAIDS I
) I
is O
caused O
by O
a O
defective O
retrovirus O
present O
in O
the O
LP O
- O
BM5 O
murine O
leukemia O
virus O
mixture O
, O
Strains O
of O
inbred O
mice O
differ O
in O
resistance O
to O
MAIDS O
development O
; O
some O
are O
susceptible O
( O
e O
. O

BR O
) O
, O
As O
an O
early O
block O
to O
viral O
replication O
in O
resistant O
mice O
has O
been O
demonstrated O
previously O
by O
PCR O
studies O
, O
we O
postulated O
that O
Alpha B
/ I
beta I
interferons I
( I
IFN I
- I
alpha I
/ I
beta I
) I
may O
be O
involved O
in O
resistance O
to O
MAIDS O
, O
Susceptible O
C57BL O
/ O
6 O
mice O
infected O
with O
LP O
- O
BM5 O
were O
treated O
with O
IFN O
- O
alpha O
/ O
beta O
or O
Newcastle O
disease O
virus O
, O
Newcastle O
disease O
virus O
induces O
high O
endogenous O
IFN O
- O
alpha O
/ O
beta O
production O
in O
mice O
, O
Both O
treatments O
delayed O
the O
development O
of O
MAIDS O
, O
as O
assessed O
by O
splenomegaly O
and O
T O
- O
and O
B O
- O
cell O
proliferation O
, O
In O
addition O
, O
an O
IFN O
- O
alpha O
/ O
beta O
response O
was O
detected O
by O
reverse O
transcription O
- O
PCR O
and O
dot O
blotting O
3 O
, O
6 O
, O
and O
9 O
h O
after O
LP O
- O
BM5 O
infection O
in O
resistant O
mice O
but O
not O
in O
susceptible O
mice O
, O
These O
results O
suggest O
that O
the O
ability O
to O
produce O
IFN O
- O
alpha O
/ O
beta O
in O
response O
to O
LP O
- O
BM5 O
infection O
may O
contribute O
to O
host O
resistance O
to O
MAIDS O
. O

To O
compare O
the O
requirements O
for O
paramyxovirus O
- O
mediated O
cell O
fusion O
, O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoproteins O
of O
simian B
virus I
5 I
( I
SV5 I
) I
, O
human B
parainfluenza I
virus I
3 I
( I
HPIV I
- I
3 I
) I
, O
and O
Newcastle B
disease I
virus I
( I
NDV I
) I
were O
expressed O
individually O
or O
coexpressed O
in O
either O
homologous O
or O
heterologous O
combinations O
in O
CV O
- O
1 O
or O
HeLa O
- O
T4 O
cells O
, O
using O
the O
vaccinia O
virus O
- O
T7 O
polymerase O
transient O
expression O
system O
, O
The O
contribution O
of O
individual O
glycoproteins O
in O
virus O
- O
induced O
membrane O
fusion O
was O
examined O
by O
using O
a O
quantitative O
assay O
for O
lipid O
mixing O
based O
on O
the O
relief O
of O
self O
- O
quenching O
( O
dequenching O
) O
of O
fluorescence O
of O
the O
lipid O
probe O
octadecyl O
rhodamine O
( O
R18 O
) O
and O
a O
quantitative O
assay O
for O
content O
mixing O
based O
on O
the O
cytoplasmic O
activation O
of O
a O
reporter O
gene O
, O
beta O
- O
galactosidase O
. O

In O
these O
assays O
, O
expression O
of O
the O
individual O
F O
glycoproteins O
did O
not O
induce O
significant O
levels O
of O
cell O
fusion O
and O
no O
cell O
fusion O
was O
observed O
in O
experiments O
when O
cells O
individually O
expressing O
homologous O
F O
or O
HN O
proteins O
were O
mixed O
, O
However O
, O
coexpression O
of O
homologous O
F O
and O
HN O
glycoproteins O
resulted O
in O
extensive O
cell O
fusion O
, O
The O
kinetics O
of O
fusion O
were O
found O
to O
be O
very O
similar O
for O
all O
three O
paramyxoviruses O
studied O
, O
With O
NDV O
and O
HPIV O
- O
3 O
, O
no O
cell O
fusion O
was O
detected O
when O
F O
proteins O
were O
coexpressed O
with O
heterologous O
HN O
proteins O
or O
influenza O
virus O
Hemagglutinin B
( I
HA I
) I
. O

To O
determine O
the O
role O
of O
the O
conserved O
leucines O
in O
the O
oligomeric O
structure O
and O
biological O
activity O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
fusion O
protein O
, O
the O
heptadic O
leucines O
at O
amino O
acids O
481 O
, O
488 O
, O
and O
495 O
were O
changed O
individually O
and O
in O
combination O
to O
an O
alanine O
residue O
. O

When O
the O
polar O
face O
of O
the O
potential O
alpha O
helix O
was O
altered O
by O
nonconservative O
changes O
of O
serine O
to O
alanine O
( O
position O
473 O
) O
, O
glutamic O
acid O
to O
lysine O
or O
alanine O
( O
position O
482 O
) O
, O
asparagine O
to O
lysine O
( O
position O
485 O
) O
, O
or O
aspartic O
acid O
to O
alanine O
( O
position O
489 O
) O
, O
the O
fusogenic O
ability O
of O
the O
protein O
was O
not O
significantly O
disrupted O
, O
In O
addition O
, O
a O
double O
mutant O
( O
E482A O
, O
D489A O
) O
which O
removed O
negative O
charges O
along O
one O
side O
of O
the O
helix O
had O
negligible O
effects O
on O
fusion O
activity O
. O

measles B
virus I
( I
MV I
) I
fusion O
requires O
the O
participation O
of O
both O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
( I
H I
) I
glycoproteins O
. O

The O
canine B
distemper I
virus I
fusion I
protein I
( I
CDVF I
) I
cannot O
substitute O
for O
the O
measles B
virus I
fusion I
protein I
( I
MVF I
) I
in O
this O
process O
. O

We O
have O
found O
that O
interleukin B
- I
4 I
( I
IL I
- I
4 I
) I
abrogated O
constitutive O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
synthesis O
in O
mouse O
macrophages O
. O

Analysis O
of O
endogenous O
IFN O
mRNA O
by O
reverse O
transcription O
- O
PCR O
clearly O
documented O
the O
presence O
of O
IFN O
- O
beta O
but O
not O
of O
IFN O
- O
alpha O
transcripts O
in O
RNA O
from O
bone B
marrow I
- I
derived I
macrophages I
( I
BMM I
) I
. O

The O
sequence O
NRKSCS O
constitutes O
the O
longest O
linear O
stretch O
in O
the O
amino O
acid O
sequence O
of O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
of O
the O
paramyxoviruses O
that O
is O
completely O
conserved O
among O
all O
viruses O
in O
the O
group O
. O

This O
is O
evidenced O
by O
( O
i O
) O
the O
diminished O
recognition O
of O
the O
protein O
only O
by O
monoclonal O
antibodies O
thought O
to O
bind O
at O
the O
neuraminidase O
active O
site O
, O
among O
an O
extensive O
panel O
of O
conformation O
- O
specific O
antibodies O
, O
and O
( O
ii O
) O
the O
slower O
rate O
of O
migration O
in O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
for O
all O
except O
the O
K O
- O
236 O
- O
- O
> O
Q O
mutation O
. O

The O
mature O
fusion O
( O
F O
) O
glycoprotein O
of O
the O
paramyxovirus O
family O
consists O
of O
two O
disulfide O
- O
linked O
subunits O
, O
the O
N O
- O
terminal O
F O
- O
2 O
and O
the O
C O
- O
terminal O
F O
- O
1 O
subunits O
, O
and O
contains O
10 O
cysteine O
residues O
which O
are O
highly O
conserved O
at O
specific O
positions O
. O

Both O
trypsin O
- O
resistant O
and O
elastase O
- O
sensitive O
mutations O
were O
additionally O
introduced O
to O
an O
LLC O
- O
MK O
( O
2 O
) O
- O
cell O
- O
adapted O
and O
attenuated O
mutant O
derived O
from O
one O
of O
the O
fresh O
isolates O
. O

This O
protease O
activation O
mutant O
( O
MVCESI O
) O
showed O
the O
same O
antigenicity O
as O
the O
fresh O
isolates O
, O
and O
as O
a O
result O
of O
a O
single O
cycle O
of O
growth O
in O
lungs O
, O
it O
could O
confer O
better O
protection O
on O
mice O
against O
challenge O
infection O
, O
vith O
the O
currently O
prevailing O
Sendai O
virus O
than O
TR O
- O
5 O
, O
which O
is O
a O
trypsin O
- O
resistant O
mutant O
derived O
from O
the O
Fushimi O
strain O
. O

Specifically O
, O
our O
data O
demonstrated O
that O
a O
small O
fraction O
( O
8 O
to O
16 O
% O
) O
of O
M O
protein O
becomes O
membrane O
associated O
in O
the O
absence O
of O
Sendai O
virus O
glycoproteins O
, O
while O
> O
75 O
% O
becomes O
membrane O
bound O
in O
the O
presence O
of O
both O
F O
and O
HN O
proteins O
. O

Selective O
expression O
of O
M O
protein O
together O
, O
vith O
either O
F O
or O
HN O
protein O
showed O
that O
each O
viral O
glycoprotein O
is O
individually O
sufficient O
to O
promote O
efficient O
( O
56 O
to O
73 O
% O
) O
M O
protein O
- O
membrane O
binding O
. O

The O
replication O
of O
LLC O
- O
MK2 O
- O
grown O
noninfectious O
Sendai O
virus O
, O
containing O
exclusively O
fusion O
( O
F O
) O
glycoprotein O
precursors O
, O
was O
examined O
in O
the O
mouse O
lung O
to O
study O
the O
accessibility O
of O
virus O
inoculated O
intranasally O
to O
the O
virus O
activator O
present O
in O
the O
lung O
. O

When O
mice O
were O
intranasally O
inoculated O
with O
various O
doses O
of O
the O
virus O
after O
in O
vitro O
activation O
with O
trypsin O
, O
the O
50 B
% I
mouse I
infectious I
dose I
( I
MID50 I
) I
was O
determined O
to O
be O
0 O
. O

7 O
cell B
- I
infectious I
units I
( I
CIU I
) I
per O
mouse O
, O
indicating O
that O
one O
infectious O
unit O
of O
Sendai O
virus O
is O
enough O
to O
initiate O
replication O
in O
the O
mouse O
lung O
and O
that O
the O
present O
experimental O
system O
is O
highly O
sensitive O
. O

5 O
CIU O
per O
mouse O
( O
here O
, O
CIU O
were O
assayed O
after O
in O
vitro O
trypsin O
treatment O
) O
. O

When O
mice O
were O
infected O
with O
20 O
MID50 O
of O
trypsin O
- O
treated O
infectious O
and O
untreated O
noninfectious O
viruses O
( O
an O
approximately O
100 O
- O
fold O
greater O
amount O
of O
noninfectious O
virus O
than O
of O
infectious O
virus O
was O
used O
) O
, O
the O
noninfectious O
virus O
was O
found O
to O
require O
2 O
more O
days O
of O
incubation O
than O
the O
infectious O
virus O
, O
and O
many O
of O
the O
F O
proteins O
synthesized O
in O
the O
lungs O
of O
mice O
infected O
with O
the O
F0 O
- O
containing O
virus O
were O
present O
in O
the O
cleaved O
form O
. O

These O
results O
indicate O
tbat O
Sendai O
virus O
can O
initiate O
replication O
in O
the O
mouse O
lung O
even O
with O
the O
F0 O
- O
containing O
noninfectious O
virus O
and O
strongly O
suggest O
that O
this O
infection O
process O
is O
mediated O
by O
cleavage O
activation O
of O
the O
F0 O
proteins O
of O
inoculated O
viruses O
by O
a O
serine O
protease O
( O
s O
) O
present O
in O
the O
lumen O
of O
the O
mouse O
respiratory O
tract O
but O
that O
activation O
of O
the O
noninfectious O
virus O
is O
an O
inefficient O
process O
. O

Sialic O
acid O
is O
the O
receptor O
for O
the O
human B
parainfluenza I
virus I
type I
3 I
( I
HPF3 I
) I
hemagglutinin I
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
, O
the O
molecule O
responsible O
for O
binding O
of O
the O
virus O
to O
cell O
surfaces O
. O

In O
order O
for O
the O
fusion B
protein I
( I
F I
) I
or O
HPF3 O
to O
promote O
membrane O
fusion O
, O
the O
HN O
must O
interact O
with O
its O
receptor O
. O

Domain O
I O
( O
residues O
1 O
to O
399 O
) O
seems O
to O
contain O
all O
of O
the O
structural O
information O
necessary O
for O
assembly O
, O
while O
domain O
II O
( O
residues O
400 O
to O
524 O
) O
is O
not O
involved O
in O
nucleocapsid O
formation O
. O

A O
model O
is O
proposed O
for O
the O
three O
- O
dimensional O
structure O
of O
the O
paramyxovirus O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
. O

Eight O
stable O
fowlpox B
virus I
( I
FPV I
) I
recombinants O
which O
express O
the O
envelope O
glycoprotein O
of O
the O
spleen B
necrosis I
virus I
( I
SNV I
) I
strain O
of O
reticuloendotheliosis B
virus I
( I
REV I
) I
, O
an O
avian O
retrovirus O
, O
were O
constructed O
. O

One O
of O
the O
recombinants O
( O
f29R O
- O
SNenv O
) O
was O
used O
for O
vaccination O
of O
1 O
- O
day O
- O
old O
chickens O
. O

Recombinant O
cDNA O
clones O
representing O
the O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
proteins O
of O
two O
mumps O
virus O
strains O
different O
in O
fusogenicity O
were O
constructed O
. O

40 O
cells O
to O
Newcastle O
disease O
virus O
results O
from O
the O
failure O
to O
cleave O
the O
viral O
envelope O
precursor O
glycoprotein O
Fo O
to O
fusion O
glycoprotein O
F1 O
at O
the O
consensus O
sequence O
( O
Lys O
/ O
Arg O
) O
- O
Arg O
- O
Gln O
- O
( O
Lys O
/ O
Arg O
) O
- O
Arg O
. O

The O
fusion O
glycoprotein O
precursor O
of O
Newcastle O
disease O
virus O
is O
ubiquitously O
cleaved O
in O
the O
constitutive O
secretory O
pathway O
if O
it O
possesses O
an O
oligobasic O
cleavage O
motif O
( O
RRQR O
/ O
KR O
) O
, O
whereas O
the O
precursor O
is O
refractory O
to O
cleavage O
if O
the O
motif O
is O
monobasic O
( O
GR O
/ O
KQGR O
) O
. O

We O
examined O
the O
cleavage O
activity O
of O
the O
mammalian O
subtilisin O
- O
related O
proteinases O
furin O
/ O
PACE O
, O
PC2 O
, O
and O
PC1 O
/ O
PC3 O
, O
which O
are O
thought O
to O
be O
responsible O
for O
proprotein O
processing O
in O
either O
the O
constitutive O
( O
furin O
/ O
PACE O
) O
or O
the O
regulated O
( O
PC2 O
and O
PC1 O
/ O
PC3 O
) O
secretory O
pathway O
, O
for O
the O
viral O
precursors O
with O
different O
cleavage O
motifs O
. O

The O
Australia B
- I
Victoria I
( I
Av I
) I
isolate O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
induces O
fusion O
from O
within O
but O
not O
fusion O
from O
without O
. O

L1 O
, O
a O
neuraminidase B
( I
NA I
) I
- O
deficient O
virus O
derived O
from O
AV O
, O
has O
the O
opposite O
fusion O
phenotype O
from O
the O
wild O
- O
type O
virus O
. O

Monoclonal O
antibodies O
to O
antigenic O
site O
23 O
on O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
have O
previously O
been O
shown O
to O
select O
variants O
of O
the O
AV O
isolate O
that O
have O
altered O
NA O
activity O
or O
receptor O
- O
binding O
affinity O
. O

Extracts O
made O
from O
Human B
respiratory I
syncytial I
virus I
( I
RSV I
) I
- O
infected O
Hep O
- O
2 O
cells O
synthesized O
mRNAs O
encoded O
by O
all O
known O
viral O
genes O
. O

In O
contrast O
, O
RSV O
ribonucleoproteins O
purified O
from O
infected O
cells O
failed O
to O
transcribe O
in O
vitro O
; O
transcription O
was O
restored O
by O
addition O
of O
a O
cytoplasmic O
extract O
of O
uninfected O
Hep O
- O
2 O
cells O
, O
demonstrating O
that O
a O
cellular O
factor O
( O
s O
) O
has O
a O
role O
in O
RSV O
gene O
expression O
. O

Newcastle B
disease I
virus I
( I
NDV I
) I
- O
infected O
HeLa O
and O
FL O
cells O
showed O
small O
polykaryocytes O
at O
a O
postinfection O
, O
while O
the O
addition O
of O
anti O
- O
FL O
- O
cell O
rabbit O
, O
rat O
, O
or O
mouse O
serum O
to O
the O
NDV O
- O
infected O
cells O
gave O
rise O
to O
giant O
polykaryocytes O
at O
15 O
b O
postinfection O
. O

We O
isolated O
three O
Monoclonal B
antibodies I
( I
MAbs I
) I
( O
4 O
- O
5 O
- O
1 O
, O
6 O
- O
1 O
- O
13 O
, O
and O
7 O
- O
2 O
- O
1 O
) O
capable O
of O
enhancing O
giant O
polykaryocyte O
formation O
in O
NDV O
- O
infected O
HeLa O
cells O
. O

A O
functionally O
intact O
F O
protein O
was O
essential O
for O
antibody O
- O
enhanced O
cell O
fusion O
, O
and O
hemagglutinating O
( O
receptor O
- O
binding O
) O
activity O
of O
HN O
protein O
was O
involved O
in O
the O
fusion O
at O
an O
early O
stage O
; O
that O
is O
, O
the O
MAbs O
enhanced O
NDV O
- O
mediated O
syncytium O
formation O
. O

These O
molecules O
were O
considered O
to O
have O
the O
ability O
to O
regulate O
NDV O
- O
mediated O
cell O
fusion O
and O
thus O
were O
designated O
fusion O
regulation O
protein O
( O
FRP O
) O
- O
1 O
( O
gp80 O
) O
and O
FRP O
- O
2 O
( O
gp135 O
) O
. O

At O
a O
nonpermissive O
temperature O
, O
the O
group O
D O
temperature O
- O
sensitive O
mutants O
of O
Newcastle O
disease O
virus O
strain O
Australia B
- I
Victoria I
( I
Av I
) I
are O
defective O
in O
plaque O
formation O
, O
in O
inducing O
infected O
cells O
to O
fuse O
, O
and O
in O
incorporating O
the O
cleaved O
fusion O
glycoprotein O
, O
F1 O
+ O
F2 O
, O
into O
virus O
particles O
. O

The O
F O
genes O
of O
mutants O
D1 O
, O
D2 O
, O
and O
D3 O
were O
found O
to O
contain O
single O
mutations O
relative O
to O
the O
AV O
sequence O
, O
clustered O
within O
a O
predicted O
amphipathic B
alpha I
helix I
( I
AAH I
) I
adjacent O
to O
the O
hydrophobic O
amino O
terminus O
of O
F1 O
. O

The O
fusion O
( O
F O
) O
and O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoproteins O
of O
the O
paramyxovirus O
simian B
virus I
5 I
( I
SV5 I
) I
were O
expressed O
individually O
or O
coexpressed O
in O
CV O
- O
1 O
cells O
by O
using O
SV40 O
- O
based O
vectors O
and O
recombinant O
vaccinia O
viruses O
. O

A O
large O
proportion O
of O
the O
Newcastle B
disease I
virus I
( I
NDV I
) I
matrix I
( I
M I
) I
protein O
is O
found O
in O
the O
nuclei O
of O
infected O
chicken O
embryo O
cells O
. O

The O
role O
of O
residues O
in O
the O
conserved O
hydrophobic O
N O
- O
terminal O
fusion O
peptide O
of O
the O
paramyxovirus O
fusion O
( O
F O
) O
protein O
in O
causing O
cell O
- O
cell O
fusion O
was O
examined O
. O

Mutations O
were O
introduced O
into O
the O
cDNA O
encoding O
the O
simian B
virus I
5 I
( I
SV5 I
) I
F O
protein O
, O
the O
altered O
F O
proteins O
were O
expressed O
by O
using O
an O
eukaryotic O
vector O
, O
and O
their O
ability O
to O
mediate O
syncytium O
formation O
was O
determined O
. O

In O
macrophages O
from O
inbred O
mice O
, O
the O
magnitude O
of O
the O
interferon B
( I
IFN I
) I
response O
to O
Newcastle B
disease I
virus I
( I
NDV I
) I
infection O
is O
under O
genetic O
control O
of O
the O
If O
- O
1 O
locus O
, O
which O
carries O
the O
allele O
for O
either O
high O
( O
h O
) O
or O
low O
( O
l O
) O
IFN O
production O
. O

Preculture O
of O
bone B
marrow I
- I
derived I
macrophages I
( I
BMM I
) I
from O
BALB O
/ O
c O
( O
If O
- O
1l O
) O
mice O
in O
macrophage O
colony O
- O
stimulating O
factor O
plus O
anti O
- O
IFN O
- O
beta O
provoked O
a O
30 O
- O
to O
50 O
- O
fold O
increase O
in O
NDV O
- O
induced O
cytokine O
production O
compared O
with O
induced O
control O
cultures O
in O
macrophage O
colony O
- O
stimulating O
factor O
alone O
, O
whereas O
only O
a O
4 O
- O
to O
6 O
- O
fold O
increase O
was O
observed O
in O
anti O
- O
IFN O
- O
beta O
- O
treated O
BMM O
from O
C57BL O
/ O
6 O
( O
If O
- O
1h O
) O
mice O
. O

Monoclonal B
antibodies I
( I
MAbs I
) I
to O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
glycoprotein O
of O
Newcastle O
disease O
virus O
delineate O
seven O
overlapping O
antigenic O
sites O
which O
form O
a O
continuum O
on O
the O
surface O
of O
the O
molecule O
. O

These O
epitopes O
are O
defined O
, O
at O
least O
in O
part O
, O
by O
three O
domains O
on O
HN O
: O
residues O
193 O
to O
201 O
; O
345 O
to O
353 O
( O
which O
include O
the O
only O
linear O
epitope O
we O
have O
identified O
in O
HN O
) O
; O
and O
a O
C O
- O
terminal O
domain O
composed O
of O
residues O
494 O
, O
513 O
to O
521 O
, O
and O
569 O
. O

5 O
- O
to O
3 O
- O
fold O
more O
resistant O
to O
periodate O
treatment O
of O
erythrocytes O
than O
the O
wild O
- O
type O
virus O
, O
suggesting O
that O
this O
residue O
influences O
the O
binding O
of O
virus O
to O
a O
sialic O
acid O
- O
containing O
receptor O
( O
s O
) O
on O
the O
cell O
surface O
. O

Purified O
ribonucleoprotein O
complexes O
of O
human B
parainfluenza I
virus I
type I
3 I
( I
HPIV I
- I
3 I
) I
virions O
required O
, O
in O
addition O
to O
the O
viral O
proteins O
, O
soluble O
cytoplasmic O
proteins O
from O
unifected O
cells O
for O
the O
synthesis O
of O
mRNAs O
in O
vitro O
. O

Moreover O
, O
cytoplasmic O
extract O
depleted O
of O
tubulin O
by O
immunoprecipitation O
stimulated O
HPIV O
- O
3 O
transcription O
effectively O
, O
suggesting O
involvement O
of O
a O
host O
protein O
( O
s O
) O
other O
than O
tubulin O
in O
the O
HPIV O
- O
3 O
transcription O
process O
. O

In O
Western O
blot O
( O
immunoblot O
) O
analysis O
, O
this O
protein O
reacted O
with O
antiactin O
antibody O
, O
suggesting O
that O
the O
43 O
- O
kDa O
polypeptide O
is O
actin O
. O

The O
cDNA O
derived O
from O
the O
fusion O
gene O
of O
the O
virulent O
AV O
strain O
of O
Newcastle B
disease I
virus I
( I
NDV I
) I
was O
expressed O
in O
chicken O
embryo O
cells O
by O
using O
a O
retrovirus O
vector O
. O

Monolayers O
of O
these O
cells O
would O
plaque O
, O
in O
the O
absence O
of O
trypsin O
, O
avirulent O
NDV O
strains O
( O
strains O
which O
encode O
a O
fusion O
protein O
which O
is O
not O
cleaved O
in O
tissue O
culture O
) O
. O

Fusion O
protein O
- O
expressing O
cells O
would O
not O
fuse O
if O
mixed O
with O
uninfected O
cells O
or O
uninfected O
cells O
expressing O
the O
hemagglutinin B
- I
neuraminidase I
( I
HN I
) I
protein O
. O

tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
louping B
ill I
virus I
( I
LIV I
) I
are O
members O
of O
the O
tick B
- I
borne I
flaviviruses I
( I
TBFVs I
) I
in O
the O
family O
Flaviviridae O
which O
cause O
encephalomeningitis O
and O
encephalitis O
in O
humans O
and O
other O
animals O
. O

Several O
neutralizing O
Monoclonal B
antibodies I
( I
MAbs I
) I
show O
promising O
effectiveness O
in O
the O
control O
of O
TBFVs O
, O
but O
the O
underlying O
molecular O
mechanisms O
are O
yet O
to O
be O
characterized O
. O

Here O
, O
we O
determined O
the O
crystal O
structures O
of O
the O
LIV O
envelope B
( I
E I
) I
protein O
and O
report O
the O
comparative O
structural O
analysis O
of O
a O
TBFV O
broadly O
neutralizing O
murine O
MAb O
( O
MAb O
4 O
. O

2 O
binds O
to O
the O
lateral O
ridge O
of O
domain O
III O
of O
the O
E O
protein O
( O
EDIII O
) O
of O
LIV O
or O
TBEV O
, O
an O
epitope O
also O
reported O
for O
other O
potently O
neutralizing O
MAbs O
against O
mosquito B
- I
borne I
flaviviruses I
( I
MBFVs I
) I
, O
but O
adopts O
a O
unique O
binding O
orientation O
. O

These O
findings O
extend O
our O
understanding O
of O
the O
vulnerability O
of O
TBFVs O
and O
other O
flaviviruses O
( O
including O
MBFVs O
) O
and O
provide O
an O
avenue O
for O
antibody O
- O
based O
TBFV O
antiviral O
development O
. O

tick B
- I
borne I
encephalitis I
virus I
( I
TBEV I
) I
and O
louping B
ill I
virus I
( I
LIV I
) I
are O
tick B
- I
borne I
flaviviruses I
( I
TBFVs I
) I
in O
the O
family O
Flaviviridae O
. O

In O
this O
study O
, O
we O
solved O
the O
crystal O
structures O
of O
the O
LIV O
envelope B
protein I
( I
E I
) I
and O
a O
broadly O
neutralizing O
/ O
protective O
TBFV O
MAb O
, O
MAb O
4 O
. O

The O
current O
lack O
of O
envelope O
glycoprotein O
immunogens O
that O
elicit O
broadly O
neutralizing O
antibody O
responses O
remains O
a O
major O
challenge O
for O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
vaccine O
development O
. O

Here O
, O
we O
describe O
the O
biochemical O
and O
immunogenic O
properties O
of O
soluble O
HIV O
- O
1 O
envelope O
glycoprotein O
trimers O
expressed O
by O
recombinant B
Semliki I
Forest I
virus I
( I
rSFV I
) I
. O

A O
strain O
of O
Tick O
- O
borne O
encephalitis O
virus O
designated O
Zausaev B
( I
Za I
) I
was O
isolated O
in O
Siberia O
from O
a O
patient O
who O
died O
of O
a O
progressive O
( O
2 O
- O
year O
) O
form O
of O
tick O
- O
borne O
encephalitis O
10 O
years O
after O
being O
bitten O
by O
a O
tick O
. O

We O
demonstrate O
( O
i O
) O
that O
the O
antibody O
fragment O
was O
antigen O
binding O
and O
( O
ii O
) O
that O
louping O
ill O
virus O
infectivity O
was O
significantly O
reduced O
in O
the O
presence O
of O
intracellular O
antibody O
expressed O
by O
the O
superinfecting O
recombinant O
Sindbis O
virus O
. O

Guanylate B
- I
binding I
protein I
7 I
( I
GBP7 I
) I
belongs O
to O
the O
GBP O
family O
, O
which O
plays O
key O
roles O
in O
mediating O
innate O
immune O
responses O
to O
intracellular O
pathogens O
. O

However O
, O
the O
relationship O
between O
GBP7 O
and O
influenza B
A I
virus I
( I
IAV I
) I
replication O
is O
unknown O
. O

Here O
, O
we O
showed O
that O
GBP7 O
expression O
was O
significantly O
upregulated O
in O
the O
lungs O
of O
mice O
, O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMCs I
) I
, O
and O
A549 O
cells O
during O
IAV O
infection O
. O

Using O
the O
CRISPR O
- O
Cas9 O
system O
and O
overexpression O
approaches O
, O
it O
was O
found O
that O
GBP7 O
knockout O
inhibited O
IAV O
replication O
by O
enhancing O
the O
expression O
of O
IAV O
- O
induced O
type B
I I
interferon I
( I
IFN I
) I
, O
type O
III O
IFN O
, O
and O
proinflammatory O
cytokines O
. O

Furthermore O
, O
GBP7 O
knockout O
enhanced O
IAVinduced O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappa I
B I
) I
activation O
and O
phosphorylation O
of O
stat1 O
and O
stat2 O
; O
overexpression O
of O
GBP7 O
had O
the O
opposite O
effect O
. O

IMPORTANCE O
So O
far O
, O
few O
studies O
have O
mentioned O
the O
distinct O
function O
of O
guanylatebinding B
protein I
7 I
( I
GBP7 I
) I
on O
virus O
infection O
. O

GBP7 O
facilitated O
IAV O
replication O
by O
suppressing O
the O
expression O
of O
type B
I I
interferon I
( I
IFN I
) I
, O
type O
III O
IFN O
, O
and O
proinflammatory O
cytokines O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
transcription O
and O
replication O
increase O
progressively O
throughout O
postnatal O
liver O
development O
with O
maximal O
viral O
biosynthesis O
occurring O
at O
around O
4 O
weeks O
of O
age O
in O
the O
HBV O
transgenic O
mouse O
model O
of O
chronic O
infection O
. O

The O
loss O
of O
DNA O
methylation O
is O
associated O
with O
increasing O
levels O
of O
5 B
- I
hydroxymethylcytosine I
( I
5hmC I
) I
residues O
which O
correlate O
with O
increased O
liver O
enriched O
pioneer O
transcription O
factor O
Forkhead B
box I
protein I
A I
( I
FoxA I
) I
RNA O
levels O
, O
a O
rapid O
decline O
in O
postnatal O
liver O
DNA B
methyltransferase I
( I
Dnmt I
) I
transcripts O
, O
and O
a O
very O
modest O
reduction O
in O
ten B
- I
eleven I
translocation I
( I
Tet I
) I
methylcytosine O
dioxygenase O
expression O
. O

MicroRNA O
let O
- O
7b O
expression O
is O
induced O
by O
infection O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
and O
is O
involved O
in O
the O
regulation O
of O
HCV O
replication O
by O
directly O
targeting O
the O
HCV O
genome O
. O

The O
current O
study O
demonstrated O
that O
let O
- O
7b O
directly O
targets O
negative O
regulators O
of O
type B
I I
interferon I
( I
IFN I
) I
signaling O
thereby O
limiting O
HCV O
replication O
in O
the O
early O
stage O
of O
HCV O
infection O
. O

Let O
- O
7b O
- O
regulated O
genes O
which O
are O
involved O
in O
host O
cellular O
responses O
to O
HCV O
infection O
were O
unveiled O
by O
microarray O
profiling O
and O
bioinformatic O
analyses O
, O
followed O
by O
various O
molecular O
and O
cellular O
assays O
using O
Huh7 O
cells O
expressing O
wild B
- I
type I
( I
WT I
) I
or O
the O
seed O
region O
- O
mutated O
let O
- O
7b O
. O

Let O
- O
7b O
targeted O
the O
cytokine O
signaling O
1 O
( O
SOCS1 O
) O
protein O
, O
a O
negative O
regulator O
of O
JAK O
/ O
STAT O
signaling O
, O
which O
then O
enhanced O
STAT1 O
- O
Y701 O
phosphorylation O
leading O
to O
increased O
expression O
of O
the O
downstream O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
. O

Let O
- O
7b O
augmented O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
signaling O
, O
but O
not O
MDA5 O
, O
to O
phosphorylate O
and O
nuclear O
translocate O
IRF3 O
leading O
to O
increased O
expression O
of O
IFN O
- O
b O
. O

Let O
- O
7b O
directly O
targeted O
the O
ATG12 O
and O
I B
kappa I
B I
kinase I
alpha I
( I
IKKa I
) I
transcripts O
and O
reduced O
the O
interaction O
of O
the O
ATG5 O
- O
ATG12 O
conjugate O
and O
RIG O
- O
I O
leading O
to O
increased O
expression O
of O
IFN O
, O
which O
may O
further O
stimulate O
JAK O
/ O
STAT O
signaling O
. O

During O
HCV O
infection O
, O
type B
I I
interferon I
( I
IFN I
) I
signaling O
displays O
potent O
antiviral O
and O
immunomodulatory O
effects O
. O

Host O
factors O
, O
including O
microRNAs B
( I
miRNAs I
) I
, O
play O
a O
role O
in O
upregulating O
IFN O
signaling O
to O
limit O
HCV O
replication O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
let O
- O
7b O
, O
as O
a O
positive O
regulator O
of O
type O
I O
IFN O
signaling O
, O
plays O
dual O
roles O
against O
HCV O
replication O
by O
increasing O
the O
expression O
of O
IFN O
and O
interferon B
- I
sensitive I
response I
element I
( I
ISRE I
) I
- O
driven O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
in O
the O
early O
stage O
of O
HCV O
infection O
. O

Current O
therapies O
rarely O
cure O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
due O
to O
the O
persistence O
of O
the O
viral O
episome O
, O
the O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
in O
hepatocytes O
. O

The O
hepatitis B
B I
virus I
core I
- I
related I
antigen I
( I
HBcrAg I
) I
, O
a O
mixture O
of O
the O
viral O
precore O
/ O
core O
gene O
products O
, O
has O
emerged O
as O
one O
potential O
marker O
to O
monitor O
the O
levels O
and O
activities O
of O
intrahepatic O
cccDNA O
. O

In O
this O
study O
, O
a O
comprehensive O
characterization O
of O
precore O
/ O
core O
gene O
products O
revealed O
that O
HBcrAg O
components O
included O
the O
classical O
hepatitis O
B O
virus O
core O
antigen O
( O
HBc O
) O
and O
e O
antigen O
( O
HBeAg O
) O
and O
, O
additionally O
, O
the O
precore O
- O
related O
antigen O
, O
PreC O
, O
retaining O
the O
N O
- O
terminal O
signal O
peptide O
. O

IMPORTANCE O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
afflicts O
approximately O
257 O
million O
people O
, O
who O
are O
at O
high O
risk O
of O
progressing O
to O
chronic O
liver O
diseases O
, O
including O
fibrosis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

Current O
therapies O
rarely O
achieve O
cure O
of O
HBV O
infection O
due O
to O
the O
persistence O
of O
the O
HBV O
episome O
, O
the O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
in O
the O
nuclei O
of O
infected O
hepatocytes O
. O

Serum O
hepatitis O
B O
core O
- O
related O
antigen O
( O
HBcrAg O
) O
is O
one O
such O
emerging O
peripheral O
marker O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
chronically O
infects O
approximately O
350 O
million O
people O
worldwide O
, O
and O
600 O
, O
000 O
deaths O
are O
caused O
by O
HBV O
- O
related O
hepatic O
failure O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
annually O
. O

This O
study O
demonstrated O
that O
osteopetrosis B
- I
associated I
transmembrane I
protein I
1 I
( I
Ostm1 I
) I
plays O
an O
inhibitory O
role O
in O
HBV O
replication O
. O

Detailed O
studies O
further O
demonstrated O
that O
Ostm1 O
binds O
to O
and O
recruits O
the O
RNA O
exosome O
complex O
to O
promote O
the O
degradation O
of O
HBV O
RNAs O
, O
and O
knockdown O
of O
the O
RNA O
exosome B
component I
exonuclease I
3 I
( I
Exosc3 I
) I
leads O
to O
the O
elimination O
of O
Ostm1 O
- O
mediated O
repression O
of O
HBV O
replication O
. O

Moreover O
, O
Ostm1 O
production O
is O
not O
regulated O
by O
interferon O
- O
alpha O
( O
IFN O
- O
alpha O
) O
or O
IFN O
- O
gamma O
, O
and O
the O
expression O
of O
IFN O
signaling O
components O
is O
not O
affected O
by O
Ostm1 O
, O
suggesting O
that O
Ostm1 O
anti O
- O
HBV O
activity O
is O
independent O
of O
the O
IFN O
signaling O
pathway O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
human O
pathogen O
infecting O
the O
liver O
to O
cause O
a O
variety O
of O
diseases O
ranging O
from O
acute O
hepatitis O
to O
advanced O
liver O
diseases O
, O
fulminate O
hepatitis O
, O
liver O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
, O
thereby O
causing O
a O
major O
health O
problem O
worldwide O
. O

Immunotherapy O
represents O
an O
attractive O
option O
for O
the O
treatment O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
. O

The O
HBV O
proteins O
Polymerase B
( I
Pol I
) I
and O
HBx O
are O
of O
special O
interest O
for O
antigen O
- O
specific O
immunotherapy O
because O
they O
are O
essential O
for O
viral O
replication O
and O
have O
been O
associated O
with O
viral O
control O
( O
Pol O
) O
or O
are O
still O
expressed O
upon O
viral O
DNA O
integration O
( O
HBx O
) O
. O

Subsequently O
, O
we O
demonstrated O
interferon O
gamma O
( O
IFN O
- O
gamma O
) O
production O
in O
response O
to O
5 O
of O
the O
novel O
HBx O
- O
derived O
binders O
and O
17 O
of O
the O
novel O
Pol O
- O
derived O
binders O
. O

Astroviruses B
( I
AstV I
) I
are O
a O
leading O
cause O
of O
diarrhea O
, O
especially O
in O
the O
very O
young O
, O
the O
elderly O
, O
and O
immunocompromised O
populations O
. O

In O
this O
study O
, O
we O
fill O
this O
gap O
in O
knowledge O
and O
demonstrate O
that O
the O
FDA O
- O
approved O
broad O
- O
spectrum O
anti O
- O
infective O
drug O
nitazoxanide B
( I
NTZ I
) I
blocks O
astrovirus O
replication O
in O
vitro O
with O
a O
50 B
% I
effective I
concentration I
( I
EC50 I
) I
of O
approximately O
1 O
. O

IMPORTANCE O
Human B
astroviruses I
( I
HAstV I
) I
are O
thought O
to O
cause O
between O
2 O
and O
9 O
% O
of O
acute O
, O
nonbacterial O
diarrhea O
cases O
in O
children O
worldwide O
. O

Recent O
publications O
have O
reported O
the O
proviral O
effect O
of O
autophagy O
induction O
on O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
defective O
virus O
and O
an O
occasional O
obligate O
satellite O
of O
HBV O
. O

It O
is O
worth O
noting O
that O
the O
two O
isoforms O
of O
the O
HDV O
protein O
, O
the O
small B
HDAg I
( I
S I
- I
HDAg I
) I
and O
large B
HDAg I
( I
L I
- I
HDAg I
) I
isoforms O
, O
can O
also O
efficiently O
promote O
autophagosome O
accumulation O
and O
disturb O
autophagic O
flux O
. O

Using O
CRISPR O
- O
Cas9 O
technology O
to O
generate O
specific O
knockouts O
, O
we O
demonstrate O
that O
the O
autophagy O
machinery O
, O
specifically O
the O
proteins O
implicated O
in O
the O
elongation O
step O
( O
ATG7 O
, O
ATG5 O
, O
and O
LC3 O
) O
, O
is O
important O
for O
the O
release O
of O
HBV O
without O
affecting O
the O
level O
of O
intracellular O
HBV O
genomes O
. O

IMPORTANCE O
Hepatitis O
delta O
virus O
is O
a O
defective O
RNA O
virus O
that O
requires O
hepatitis O
B O
virus O
envelope O
proteins O
( O
HBsAg O
) O
to O
fulfill O
its O
life O
cycle O
. O

Thus O
, O
HDV O
can O
only O
infect O
individuals O
at O
the O
same O
time O
as O
HBV O
( O
coinfection O
) O
or O
superinfect O
individuals O
who O
are O
already O
chronic O
carriers O
of O
HBV O
. O

Equid B
herpesvirus I
1 I
( I
EHV I
- I
1 I
) I
is O
a O
viral O
pathogen O
of O
horse O
populations O
worldwide O
spread O
by O
the O
respiratory O
route O
and O
is O
known O
for O
causing O
outbreaks O
of O
neurologic O
syndromes O
and O
abortion O
storms O
. O

Previously O
, O
we O
demonstrated O
that O
an O
EHV O
- O
1 O
strain O
of O
the O
neuropathogenic O
genotype O
, O
T953 O
, O
downregulates O
the O
Beta B
interferon I
( I
IFN I
- I
beta I
) I
response O
in O
vitro O
in O
equine B
endothelial I
cells I
( I
EECs I
) I
at O
12 O
h B
postinfection I
( I
hpi I
) I
. O

Data O
from O
our O
study O
revealed O
that O
EHV O
- O
1 O
infection O
of O
EECs O
significantly O
reduced O
both O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
and O
TLR4 O
mRNA O
expression O
at O
6 O
hpi O
and O
12 O
hpi O
. O

While O
EHV O
- O
1 O
was O
able O
to O
significantly O
reduce O
IRF9 O
mRNA O
at O
both O
6 O
hpi O
and O
12 O
hpi O
, O
the O
virus O
significantly O
reduced O
IFN B
regulatory I
factor I
7 I
( I
IRF7 I
) I
mRNA O
only O
at O
12 O
hpi O
. O

EHV O
- O
1 O
did O
not O
alter O
the O
cellular O
level O
of O
Janus O
- O
activated O
kinase O
1 O
( O
JAK1 O
) O
at O
any O
time O
point O
. O

However O
, O
EHV O
- O
1 O
reduced O
the O
cellular O
level O
of O
expression O
of O
tyrosine B
kinase I
2 I
( I
TYK2 I
) I
at O
12 O
hpi O
. O

Downstream O
of O
JAK1 O
- O
TYK2 O
signaling O
, O
EHV O
- O
1 O
blocked O
the O
phosphorylation O
and O
activation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
2 I
( I
STAT2 I
) I
when O
coincubated O
with O
exogenous O
IFN O
, O
at O
12 O
hpi O
, O
although O
not O
at O
3 O
or O
6 O
hpi O
. O

IMPORTANCE O
To O
date O
, O
no O
commercial O
vaccine O
label O
has O
a O
claim O
to O
be O
fully O
protective O
against O
the O
diseases O
caused O
by O
Equid B
herpesvirus I
1 I
( I
EHV I
- I
1 I
) I
, O
especially O
the O
neurologic O
form O
. O

The O
interferon B
( I
IFN I
) I
system O
, O
of O
which O
type O
I O
IFN O
is O
of O
great O
importance O
, O
still O
remains O
a O
viable O
immunotherapeutic O
option O
against O
EHV O
- O
1 O
infection O
. O

The O
current O
state O
of O
research O
on O
how O
EHV O
- O
1 O
interferes O
with O
the O
protective O
effect O
of O
type O
I O
IFN O
has O
indicated O
transient O
induction O
of O
type O
I O
IFN O
production O
followed O
by O
a O
rapid O
shutdown O
in O
vitro O
in O
equine B
endothelial I
cells I
( I
EECs I
) I
. O

We O
previously O
reported O
that O
the O
short O
- O
peptide O
fusion O
inhibitor O
2P23 O
and O
its O
lipid O
derivative O
possess O
highly O
potent O
antiviral O
activities O
against O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
, O
HIV O
- O
2 O
, O
and O
Simian B
immunodeficiency I
virus I
( I
SIV I
) I
. O

To O
develop O
a O
sterilizing O
or O
functional O
- O
cure O
strategy O
, O
here O
we O
genetically O
linked O
2P23 O
and O
two O
control O
peptides O
( O
HIV O
- O
1 O
fusion O
inhibitor O
C34 O
and O
hepatitis O
B O
virus O
[ O
HBV O
] O
entry O
inhibitor O
4B10 O
) O
with O
a O
glycosylphos B
- I
phatidylinositol I
( I
GPI I
) I
attachment O
signal O
. O

GPI O
- O
anchored O
2P23 O
( O
GPI O
- O
2P23 O
) O
completely O
protected O
TZM O
- O
bl O
cells O
from O
infections O
of O
divergent O
HIV O
- O
1 O
, O
HIV O
- O
2 O
, O
and O
SIV O
isolates O
as O
well O
as O
a O
panel O
of O
enfuvirtide O
( O
T20 O
) O
- O
resistant O
mutants O
. O

Moreover O
, O
GPI O
- O
2P23 O
- O
modified O
human O
CD4 O
( O
+ O
) O
T O
cells O
( O
CEMss O
- O
CCR5 O
) O
fully O
blocked O
both O
R5 O
- O
and O
X4 O
- O
tropic O
HIV O
- O
1 O
isolates O
and O
displayed O
a O
robust O
survival O
advantage O
over O
unmodified O
cells O
during O
HIV O
- O
1 O
infection O
. O

Membrane O
- O
bound O
2P23 O
also O
effectively O
blocks O
HIV O
- O
1 O
Env O
- O
mediated O
cell O
- O
cell O
fusion O
and O
cell O
- O
associated O
virion O
- O
mediated O
cell O
- O
cell O
transmission O
, O
renders O
CD4 O
( O
+ O
) O
T O
cells O
nonpermissive O
to O
infection O
, O
and O
confers O
a O
robust O
survival O
advantage O
over O
unmodified O
cells O
. O

With O
a O
yearly O
death O
toll O
of O
880 O
, O
0 O
, O
hepatitis B
B I
virus I
( I
HBV I
) I
remains O
a O
major O
health O
problem O
worldwide O
, O
despite O
an O
effective O
prophylactic O
vaccine O
and O
well O
- O
tolerated O
, O
effective O
antivirals O
. O

HBV O
is O
a O
DNA O
virus O
that O
utilizes O
a O
virus O
- O
encoded O
reverse O
transcriptase O
to O
convert O
an O
RNA O
intermediate O
, O
termed O
pregenomic O
RNA O
, O
into O
the O
relaxed O
circular O
DNA O
genome O
, O
which O
is O
subsequently O
converted O
into O
a O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
in O
the O
host O
cell O
nucleus O
. O

Participants O
were O
randomized O
into O
four O
groups O
based O
on O
the O
interval O
between O
prime O
and O
boost O
immunizations O
( O
28 O
or O
56 O
days O
) O
and O
the O
sequence O
in O
which O
Ad26 O
. O

Consecutive O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
measurements O
of O
the O
IgG O
binding O
antibody O
concentrations O
against O
the O
Kikwit O
glycoprotein B
( I
GP I
) I
were O
available O
for O
177 O
participants O
to O
assess O
the O
humoral O
immune O
response O
up O
to O
1 O
year O
postprime O
. O

Ordinary B
differential I
equations I
( I
ODEs I
) I
described O
the O
dynamics O
of O
antibody O
response O
and O
two O
populations O
of O
antibody B
- I
secreting I
cells I
( I
ASCs I
) I
, O
short B
- I
lived I
( I
SL I
) I
and O
long B
- I
lived I
( I
LL I
) I
. O

Viruses O
are O
considered O
to O
use O
vesicular O
trafficking O
in O
infected O
cells O
, O
but O
the O
details O
of O
assembly O
/ O
release O
pathways O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
still O
unknown O
. O

To O
identify O
key O
regulators O
of O
HBV O
production O
, O
we O
performed O
Short B
interfering I
RNA I
( I
siRNA I
) I
screening O
for O
Rab O
proteins O
, O
which O
are O
considered O
to O
act O
as O
molecular O
switches O
in O
vesicular O
trafficking O
using O
HepG2 O
. O

1 O
- O
kb O
mRNA O
coding O
envelope O
proteins O
containing O
large O
hepatitis O
B O
surface O
protein O
( O
LHBs O
) O
was O
increased O
. O

Analysis O
of O
hepatocyte B
nuclear I
factors I
( I
HNFs I
) I
showed O
that O
transcription O
of O
HNF4 O
alpha O
, O
which O
is O
known O
to O
enhance O
2 O
. O

Also O
, O
it O
was O
revealed O
that O
LHBs O
had O
accumulated O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
after O
Rab5B O
depletion O
but O
not O
in O
the O
multivesicular B
body I
( I
MVB I
) I
, O
which O
is O
thought O
to O
be O
an O
organelle O
utilized O
for O
HBV O
envelope O
formation O
. O

In O
order O
to O
identify O
host O
cellular O
DNA O
metabolic O
enzymes O
that O
are O
involved O
in O
the O
biosynthesis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
covalently I
closed I
circular I
( I
CCC I
) I
DNA O
, O
we O
developed O
a O
cell O
- O
based O
assay O
supporting O
synchronized O
and O
rapid O
cccDNA O
synthesis O
from O
intracellular O
progeny O
nucleocapsid O
DNA O
. O

This O
was O
achieved O
by O
arresting O
HBV O
DNA O
replication O
in O
HepAD38 O
cells O
with O
phosphonoformic B
acid I
( I
PFA I
) I
, O
a O
reversible O
HBV O
DNA O
polymerase O
inhibitor O
, O
at O
the O
stage O
of O
single O
- O
stranded O
DNA O
and O
was O
followed O
by O
removal O
of O
PFA O
to O
allow O
the O
synchronized O
synthesis O
of O
relaxed B
circular I
DNA I
( I
rcDNA I
) I
and O
subsequent O
conversion O
into O
cccDNA O
within O
12 O
to O
24 O
h O
. O

Using O
this O
assay O
, O
we O
found O
that O
all O
the O
tested O
topoisomerase O
I O
and O
II O
( O
TOP1 O
and O
TOP2 O
, O
respectively O
) O
poisons O
as O
well O
as O
topoisomerase O
II O
DNA O
binding O
and O
ATPase O
inhibitors O
significantly O
reduced O
the O
levels O
of O
cccDNA O
. O

It O
was O
further O
demonstrated O
that O
these O
inhibitors O
also O
disrupted O
cccDNA O
synthesis O
during O
de O
novo O
HBV O
infection O
of O
HepG2 O
cells O
expressing O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
. O

Moreover O
, O
small B
interfering I
RNA I
( I
siRNA I
) I
knockdown O
of O
topoisomerase O
II O
significantly O
reduced O
cccDNA O
amplification O
. O

natural B
killer I
( I
NK I
) I
cells O
during O
chronic O
viral O
infection O
have O
been O
well O
studied O
in O
the O
past O
. O

Using O
cell O
sorting O
, O
we O
obtained O
CD3 O
( O
- O
) O
CD56 O
( O
+ O
) O
NK O
cells O
from O
blood O
of O
6 O
HIV O
- O
, O
8 O
HCV O
- O
, O
and O
32 O
HBV O
- O
infected O
patients O
without O
treatment O
. O

In O
HBV O
- O
infected O
patients O
, O
viral O
load O
and O
alanine B
aminotransferase I
( I
ALT I
) I
variation O
had O
little O
effect O
on O
genes O
related O
to O
NK O
effector O
function O
. O

IMPORTANCE O
Three O
viruses O
exist O
that O
can O
result O
in O
persistently O
high O
viral O
loads O
in O
immunocompetent O
humans O
: O
Human B
Immunodeficiency I
Virus I
( I
HIV I
) I
, O
hepatitis O
C O
virus O
, O
and O
hepatitis O
B O
virus O
. O

covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
forms O
the O
basis O
for O
replication O
and O
persistence O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
in O
the O
chronically O
infected O
liver O
. O

We O
have O
previously O
shown O
that O
viral O
transcription O
is O
subject O
to O
regulation O
by O
posttranslational B
modifications I
( I
PTMs I
) I
of O
histone O
proteins O
bound O
to O
cccDNA O
through O
analysis O
of O
de O
novo O
HBV O
- O
infected O
cell O
lines O
. O

We O
now O
report O
the O
successful O
adaptation O
of O
this O
chromatin B
immunoprecipitation I
sequencing I
( I
ChIPseq I
) I
approach O
for O
analysis O
of O
fine O
- O
needle O
patient O
liver O
biopsy O
specimens O
to O
investigate O
the O
role O
of O
histone O
PTMs O
in O
chronically O
HBV O
- O
infected O
patients O
. O

However O
, O
we O
show O
a O
striking O
interpatient O
variability O
of O
its O
deposition O
in O
this O
patient O
cohort O
correlated O
with O
viral O
transcription O
and O
patient O
HBV O
early O
antigen O
( O
HBeAg O
) O
status O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
global O
health O
concern O
, O
chronically O
infecting O
millions O
of O
patients O
and O
contributing O
to O
a O
rising O
burden O
of O
liver O
disease O
. O

hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
satellite O
of O
hepatitis O
B O
virus O
that O
increases O
the O
severity O
of O
acute O
and O
chronic O
liver O
disease O
. O

HDV O
produces O
three O
processed O
RNAs O
that O
accumulate O
in O
infected O
cells O
: O
the O
circular O
genome O
; O
the O
circular O
antigenome O
, O
which O
serves O
as O
a O
replication O
intermediate O
; O
and O
lesser O
amounts O
of O
the O
mRNA O
, O
which O
encodes O
the O
sole O
viral O
protein O
, O
hepatitis B
delta I
antigen I
( I
HDAg I
) I
. O

IMPORTANCE O
hepatitis B
delta I
virus I
( I
HDV I
) I
is O
a O
satellite O
of O
hepatitis O
B O
virus O
that O
increases O
the O
severity O
of O
liver O
disease O
; O
approximately O
15 O
million O
people O
are O
chronically O
infected O
worldwide O
. O

The O
development O
of O
a O
prophylactic O
vaccine O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
remains O
a O
global O
health O
challenge O
. O

Accordingly O
, O
we O
performed O
head O
- O
to O
- O
head O
molecular O
, O
antigenic O
, O
and O
immunogenic O
comparisons O
of O
soluble O
E2 O
( O
sE2 O
) O
produced O
in O
( O
i O
) O
mammalian O
( O
HEK293 O
) O
cells O
, O
which O
confer O
mostly O
complex O
- O
and O
high O
- O
mannose O
- O
type O
glycans O
; O
and O
( O
ii O
) O
insect O
( O
Sf9 O
) O
cells O
, O
which O
impart O
mainly O
paucimannose O
- O
type O
glycans O
. O

IMPORTANCE O
The O
development O
of O
a O
vaccine O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
remains O
a O
global O
health O
challenge O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
the O
leading O
cause O
of O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
liver B
cirrhosis I
( I
LC I
) I
, O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

HBV O
activates O
homeobox B
A10 I
( I
HoxA10 I
) I
in O
human O
hepatocytes O
, O
leukocytes O
, O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
, O
HepG2 O
- O
NTCP O
cells O
, O
leukocytes O
isolated O
from O
CHB O
patients O
, O
and O
HBV O
- O
associated O
HCC O
tissues O
. O

Interestingly O
, O
we O
show O
that O
during O
early O
HBV O
infection O
, O
p38 O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
and O
signal B
transducer I
and I
activator I
of I
transcription I
3 I
( I
STAT3 I
) I
were O
activated O
to O
facilitate O
HBV O
replication O
; O
however O
, O
during O
late O
HBV O
infection O
, O
HoxA10 O
was O
induced O
to O
attenuate O
HBV O
replication O
. O

Detailed O
studies O
reveal O
that O
HoxA10 O
binds O
to O
p38 O
MAPK O
, O
recruits O
SH2 B
- I
containing I
protein I
tyrosine I
phosphatase I
1 I
( I
SHP I
- I
1 I
) I
to O
facilitate O
SHP O
- O
1 O
in O
catalyzing O
dephosphorylation O
of O
p38 O
MAPK O
/ O
STAT3 O
, O
and O
thereby O
attenuates O
p38 O
MAPK O
/ O
STAT3 O
activation O
and O
HBV O
replication O
. O

Furthermore O
, O
HoxA10 O
binds O
to O
the O
HBV O
enhancer B
element I
I I
( I
EnhI I
) I
/ O
X O
promoter O
, O
competes O
with O
STAT3 O
for O
binding O
of O
the O
promoter O
, O
and O
thereby O
represses O
HBV O
transcription O
. O

Thus O
, O
the O
function O
of O
HoxA10 O
is O
similar O
to O
the O
action O
of O
interferon B
( I
IFN I
) I
in O
terms O
of O
inhibition O
of O
HBV O
infection O
; O
however O
, O
the O
mechanism O
of O
HoxA10 O
- O
mediated O
repression O
of O
HBV O
replication O
is O
different O
from O
the O
mechanism O
underlying O
IFN O
- O
induced O
inhibition O
of O
HBV O
infection O
. O

IMPORTANCE O
Two O
billion O
people O
have O
been O
infected O
with O
HBV O
worldwide O
; O
about O
240 O
million O
infected O
patients O
developed O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
and O
650 O
, O
000 O
die O
each O
year O
from O
liver B
cirrhosis I
( I
LC I
) I
or O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
risk O
factor O
for O
the O
development O
of O
chronic O
liver O
diseases O
, O
including O
cirrhosis O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

A O
growing O
body O
of O
evidence O
suggests O
that O
HBV B
X I
protein I
( I
HBx I
) I
plays O
a O
crucial O
role O
in O
viral O
replication O
and O
HCC O
development O
. O

Here O
, O
we O
identified O
peroxiredoxin B
1 I
( I
Prdx1 I
) I
, O
a O
cellular O
hydrogen O
peroxide O
scavenger O
, O
as O
a O
novel O
HBx O
- O
interacting O
protein O
. O

Knockdown O
of O
Prdx1 O
by O
siRNA O
significantly O
increased O
the O
levels O
of O
intracellular O
HBV O
RNA O
, O
HBV O
antigens O
, O
and O
extracellular O
HBV O
DNA O
, O
whereas O
knockdown O
of O
Prdx1 O
did O
not O
increase O
the O
activities O
of O
HBV O
core O
, O
enhancer B
I I
( I
Enh1 I
) I
/ O
X O
, O
preS1 O
, O
and O
preS2 O
/ O
S O
promoters O
. O

The O
exosome B
component I
5 I
( I
Exosc5 I
) I
, O
a O
member O
of O
the O
RNA O
exosome O
complexes O
, O
was O
coimmunoprecipitated O
with O
Prdx1 O
, O
suggesting O
its O
role O
in O
regulation O
of O
HBV O
RNA O
stability O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
global O
health O
problem O
. O

The O
parvulin B
14 I
( I
Par14 I
) I
and O
parvulin B
17 I
( I
Par17 I
) I
proteins O
, O
which O
are O
both O
encoded O
by O
the O
PIN4 O
gene O
, O
play O
roles O
in O
protein O
folding O
, O
chromatin O
remodeling O
, O
DNA O
binding O
, O
ribosome O
biogenesis O
, O
and O
cell O
cycle O
progression O
. O

In O
this O
study O
, O
we O
found O
that O
, O
in O
the O
presence O
of O
HBx O
, O
either O
Par14 O
or O
Par17 O
could O
upregulate O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
, O
whereas O
in O
the O
absence O
of O
HBx O
, O
neither O
Par14 O
nor O
Par17 O
had O
any O
effect O
on O
replication O
. O

Overexpression O
of O
Par14 O
/ O
Par17 O
markedly O
increased O
the O
formation O
of O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
, O
synthesis O
of O
HBV O
RNA O
and O
DNA O
, O
and O
virion O
secretion O
. O

Coimmunoprecipitation O
revealed O
that O
Par14 O
/ O
Par17 O
engaged O
in O
direct O
physical O
interactions O
with O
HBx O
in O
the O
cytoplasm O
, O
nucleus O
, O
and O
mitochondria O
, O
possibly O
mediated O
through O
substrate O
- O
binding O
residues O
on O
Par14 O
/ O
Par17 O
( O
E46 O
/ O
D74 O
and O
E71 O
/ O
D99 O
, O
respectively O
) O
and O
conserved O
19R20P O
- O
28R29P O
motifs O
on O
HBx O
. O

Chromatin O
immunoprecipitation O
assays O
revealed O
that O
, O
in O
the O
presence O
of O
HBx O
, O
Par14 O
/ O
Par17 O
were O
efficiently O
recruited O
to O
cccDNA O
and O
promoted O
transcriptional O
activation O
via O
specific O
DNA O
- O
binding O
residues O
( O
S19 O
/ O
44 O
) O
. O

We O
found O
that O
substrate O
- O
binding O
residues O
on O
the O
human O
parvulin O
peptidylprolyl O
cis O
/ O
trans O
isomerase O
proteins O
Par14 O
and O
Par17 O
bound O
to O
conserved O
arginine O
- O
proline O
( O
RP O
) O
motifs O
on O
HBx O
in O
the O
cytoplasm O
, O
nucleus O
, O
and O
mitochondria O
. O

Encapsidation O
of O
pregenomic B
RNA I
( I
pgRNA I
) I
is O
a O
crucial O
step O
in O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
. O

Binding O
by O
viral O
Polymerase B
( I
Pol I
) I
to O
the O
epsilon O
stem O
- O
loop O
( O
e O
) O
on O
the O
5 O
' O
- O
terminal O
region O
( O
TR O
) O
of O
pgRNA O
is O
required O
for O
pgRNA O
packaging O
. O

RNA B
- I
binding I
motif I
protein I
24 I
( I
RBM24 I
) I
inhibits O
core O
translation O
by O
binding O
to O
the O
5 O
' O
- O
TR O
of O
pgRNA O
. O

RBM24 O
directly O
binds O
to O
the O
lower O
bulge O
of O
e O
via O
RNA B
recognition I
submotifs I
( I
RNPs I
) I
. O

The O
alanine O
- O
rich O
domain O
( O
ARD O
) O
of O
RBM24 O
and O
the O
reverse B
transcriptase I
( I
RT I
) I
domain O
of O
Pol O
are O
essential O
for O
binding O
between O
RBM24 O
and O
Pol O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
ubiquitous O
human O
pathogen O
, O
and O
HBV O
infection O
is O
a O
major O
global O
health O
burden O
. O

In O
this O
study O
, O
we O
found O
that O
the O
host O
factor O
RBM24 O
is O
involved O
in O
pregenomic B
RNA I
( I
pgRNA I
) I
packaging O
and O
regulates O
HBV O
replication O
. O

human B
hepatitis I
B I
virus I
( I
HBV I
) I
is O
a O
global O
health O
problem O
, O
affecting O
more O
than O
250 O
million O
people O
worldwide O
. O

We O
found O
that O
NTCP O
, O
but O
not O
GPC5 O
, O
has O
evolved O
under O
positive O
selection O
in O
primates O
( O
27 O
species O
) O
, O
rodents O
( O
18 O
species O
) O
, O
and O
bats O
( O
21 O
species O
) O
although O
at O
distinct O
residues O
. O

IMPORTANCE O
Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
cause O
of O
liver O
disease O
and O
cancer O
in O
humans O
. O

Distinct O
populations O
of O
hepatocytes O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
or O
only O
harboring O
HBV O
DNA O
integrations O
coexist O
within O
an O
HBV O
chronically O
infected O
liver O
. O

These O
hepatocytes O
express O
HBV O
antigens O
at O
different O
levels O
and O
with O
different O
intracellular O
localizations O
, O
but O
it O
is O
not O
known O
whether O
this O
heterogeneity O
of O
viral O
antigen O
expression O
could O
result O
in O
an O
uneven O
hepatic O
presentation O
of O
distinct O
HBV O
epitopes O
/ O
HLA O
class O
I O
complexes O
triggering O
different O
levels O
of O
activation O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Using O
antibodies O
specific O
to O
two O
distinct O
HLA O
- O
A O
* O
02 O
: O
01 O
/ O
HBV O
epitope O
complexes O
of O
HBV O
nucleocapsid O
and O
envelope O
proteins O
, O
we O
mapped O
their O
topological O
distributions O
in O
liver O
biopsy O
specimens O
of O
two O
anti O
- O
hepatitis O
B O
e O
antigen O
- O
positive O
( O
HBe O
+ O
) O
chronic O
HBV O
( O
CHB O
) O
patients O
. O

We O
demonstrated O
that O
the O
core O
and O
envelope O
CD8 O
( O
+ O
) O
T O
cell O
epitopes O
were O
not O
uniformly O
distributed O
in O
the O
liver O
parenchyma O
but O
preferentially O
located O
in O
distinct O
and O
sometimes O
mutually O
exclusive O
hepatic O
zones O
. O

The O
efficiency O
of O
HBV O
epitope O
presentation O
was O
then O
tested O
in O
vitro O
utilizing O
HLA O
- O
A O
* O
02 O
: O
01 O
/ O
HBV O
epitope O
- O
specific O
antibodies O
and O
the O
corresponding O
CD8 O
( O
+ O
) O
T O
cells O
in O
primary O
human O
hepatocyte O
and O
hepatoma O
cell O
lines O
either O
infected O
with O
HBV O
or O
harboring O
HBV O
DNA O
integration O
. O

We O
confirmed O
the O
existence O
of O
a O
marked O
variability O
in O
the O
efficiency O
of O
HLA O
class O
I O
/ O
HBV O
epitope O
presentation O
among O
the O
different O
targets O
that O
was O
influenced O
by O
the O
presence O
of O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
availability O
of O
newly O
translated O
viral O
antigens O
. O

As O
a O
consequence O
, O
CD8 O
( O
+ O
) O
T O
cells O
of O
different O
HBV O
specificities O
might O
have O
different O
antiviral O
efficacies O
. O

IMPORTANCE O
The O
inability O
of O
patients O
with O
chronic O
HBV O
infection O
to O
clear O
HBV O
is O
associated O
with O
defective O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
this O
work O
, O
analysis O
of O
CHB O
patient O
liver O
parenchyma O
and O
in O
vitro O
HBV O
infection O
models O
shows O
a O
nonuniform O
distribution O
of O
HBV O
CD8 O
( O
+ O
) O
T O
cell O
epitopes O
that O
is O
influenced O
by O
the O
presence O
of O
IFN O
- O
gamma O
and O
availability O
of O
newly O
translated O
viral O
antigens O
. O

These O
results O
suggest O
that O
CD8 O
( O
+ O
) O
T O
cells O
recognizing O
different O
HBV O
epitopes O
can O
be O
necessary O
for O
efficient O
immune O
therapeutic O
control O
of O
chronic O
HBV O
infection O
. O

Yearly O
, O
similar O
to O
2 O
million O
people O
become O
hepatitis B
C I
virus I
( I
HCV I
) I
infected O
, O
resulting O
in O
an O
elevated O
lifetime O
risk O
for O
severe O
liver O
- O
related O
chronic O
illnesses O
. O

Characterizing O
epitopes O
of O
broadly O
neutralizing B
antibodies I
( I
NAbs I
) I
, O
such O
as O
AR3A O
, O
is O
critical O
to O
guide O
vaccine O
development O
. O

Previously O
identified O
alanine O
substitutions O
that O
can O
reduce O
AR3A O
binding O
to O
expressed O
H77 O
envelope O
were O
introduced O
into O
chimeric O
cell O
culture O
- O
infectious O
HCV O
recombinants O
( O
HCVcc O
) O
H77 O
( O
core O
- O
NS2 O
) O
/ O
JFH1 O
. O

Using O
highly O
NAb O
- O
sensitive O
hypervariable B
region I
1 I
( I
HVR1 I
) I
- O
deleted O
HCVcc O
, O
H77 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
and O
J6 O
( O
core O
- O
NS2 O
) O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
, O
we O
previously O
reported O
a O
low O
barrier O
to O
developing O
AR5A O
NAb O
resistance O
substitutions O
. O

5 O
cells O
infected O
with O
H77 O
/ O
JFH1 O
, O
H77 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
, O
or O
J6 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
with O
AR3A O
. O

We O
identified O
the O
resistance O
envelope O
substitutions O
M345T O
in O
H77 O
/ O
JFH1 O
, O
L438S O
and O
F442Y O
in O
H77 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
, O
and O
D431G O
in O
J6 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
. O

M345T O
increased O
infectivity O
and O
conferred O
low O
- O
level O
AR3A O
resistance O
to O
H77 O
/ O
JFH1 O
but O
not O
H77 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
. O

L438S O
and O
F442Y O
conferred O
high O
- O
level O
AR3A O
resistance O
to O
H77 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
but O
abrogated O
the O
infectivity O
of O
H77 O
/ O
JFH1 O
. O

D431G O
conferred O
AR3A O
resistance O
to O
J6 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
but O
not O
J6 O
/ O
JFH1 O
. O

This O
was O
possibly O
because O
D431G O
conferred O
broadly O
increased O
neutralization O
sensitivity O
to O
J6 O
/ O
JFH1 O
( O
D431G O
) O
but O
not O
J6 O
/ O
JFH1 O
( O
Delta O
HVR1 O
) O
/ O
D431G O
while O
decreasing O
scavenger O
receptor O
class O
B O
type O
I O
coreceptor O
dependency O
. O

Common O
substitutions O
at O
positions O
431 O
and O
442 O
did O
not O
confer O
high O
- O
level O
resistance O
in O
other O
genotype O
2a O
recombinants O
[ O
JFH1 O
or O
T9 O
( O
core O
- O
NS2 O
) O
/ O
JFH1 O
] O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
leading O
cause O
of O
liver O
- O
related O
mortality O
, O
and O
limited O
treatment O
accessibility O
makes O
vaccine O
development O
a O
high O
priority O
. O

The O
vaccine O
- O
relevant O
cross O
- O
genotype O
- O
reactive O
antibody O
AR3A O
has O
shown O
high O
potency O
, O
but O
the O
ability O
of O
the O
virus O
to O
rapidly O
escape O
by O
mutating O
the O
AR3A O
epitope O
( O
barrier O
to O
resistance O
) O
remains O
unexplored O
. O

Furthermore O
, O
we O
identify O
AR3A O
resistance O
substitutions O
that O
have O
hypervariable B
region I
1 I
( I
HVR1 I
) I
- O
dependent O
effects O
on O
HCV O
viability O
and O
on O
broad O
neutralization O
sensitivity O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
cause O
of O
chronic O
liver O
diseases O
, O
includ O
- O
ing O
hepatitis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

The O
discovery O
of O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
as O
an O
HBV O
receptor O
has O
been O
a O
landmark O
advance O
in O
HBV O
research O
in O
recent O
years O
. O

More O
significantly O
, O
we O
developed O
robust O
HBV O
cell O
culture O
models O
by O
treating O
the O
HBV O
- O
infected O
cells O
with O
dimethyl B
sulfoxide I
( I
DMSO I
) I
and O
hy O
- O
drocortisone O
, O
which O
significantly O
promoted O
HBV O
replication O
and O
production O
. O

alpha B
interferon I
( I
IFN I
- I
alpha I
) I
induces O
the O
transfer O
of O
resistance O
to O
hepatitis B
B I
virus I
( I
HBV I
) I
from O
liver B
nonparenchymal I
cells I
( I
LNPCs I
) I
to O
hepatocytes O
via O
exosomes O
. O

In O
this O
study O
, O
we O
found O
that O
macrophage O
exosomes O
uniquely O
depend O
on O
T O
cell O
immunoglobulin O
and O
mucin O
receptor O
1 O
( O
TIM O
- O
1 O
) O
, O
a O
hepatitis B
A I
virus I
( I
HAV I
) I
receptor O
, O
to O
enter O
hepatocytes O
for O
delivering O
IFN O
- O
alpha O
- O
induced O
anti O
- O
HBV O
activity O
. O

Moreover O
, O
two O
primary O
endocytic O
routes O
for O
virus O
infection O
, O
clathrin B
- I
mediated I
endocytosis I
( I
CME I
) I
and O
macropinocytosis O
, O
collaborate O
to O
permit O
exosome O
entry O
and O
anti O
- O
HBV O
activity O
transfer O
. O

Subsequently O
, O
lysobisphosphatidic B
acid I
( I
LBPA I
) I
, O
an O
anionic O
lipid O
closely O
related O
to O
endosome O
penetration O
of O
virus O
, O
facilitates O
membrane O
fusion O
of O
exosomes O
in O
late B
endosomes I
/ I
multivesicular I
bodies I
( I
LEs I
/ I
MVBs I
) I
and O
the O
accompanying O
exosomal O
cargo O
uncoating O
. O

Extracellular O
HBV O
RNA O
has O
been O
detected O
in O
both O
HBV O
- O
replicating O
cell O
culture O
media O
and O
sera O
from O
chronic B
hepatitis I
B I
( I
CHB I
) I
patients O
, O
but O
its O
exact O
origin O
and O
composition O
remain O
controversial O
. O

Moreover O
, O
HBV O
RNAs O
in O
hepatitis O
B O
patients O
' O
blood O
circulation O
were O
localized O
in O
unenveloped O
capsids O
in O
the O
form O
of O
capsid B
- I
antibody I
complexes I
( I
CACs I
) I
and O
in O
virions O
. O

In O
addition O
to O
the O
infectious O
virions O
, O
HBV O
is O
known O
to O
secrete O
several O
species O
of O
incomplete O
viral O
particles O
, O
including O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
particles O
, O
naked O
capsids O
, O
and O
empty O
virions O
, O
during O
its O
replication O
cycle O
. O

Moreover O
, O
extracellular O
HBV O
RNAs O
are O
heterogeneous O
in O
length O
and O
represent O
either O
pregenomic B
RNA I
( I
pgRNA I
) I
or O
products O
of O
incomplete O
reverse O
transcription O
during O
viral O
replication O
. O

CD8 O
( O
) O
( O
+ O
) O
T O
cells O
are O
the O
key O
cellular O
effectors O
mediating O
the O
clearance O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infections O
. O

However O
, O
early O
immunological O
events O
surrounding O
the O
priming O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
remain O
poorly O
understood O
. O

This O
study O
examined O
the O
importance O
of O
priming O
location O
and O
the O
relative O
contribution O
of O
endogenous O
antigen O
presentation O
by O
hepatocytes O
versus O
cross O
presentation O
by O
bone O
marrow O
- O
derived O
cells O
to O
the O
induction O
of O
functional O
HBV O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
using O
the O
animal O
models O
of O
acute O
and O
chronic O
HBV O
infection O
. O

Functional O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
could O
be O
induced O
to O
intrahepatically O
expressed O
HBV O
even O
when O
T O
cell O
homing O
to O
the O
lymphoid O
tissues O
was O
severely O
suppressed O
, O
suggesting O
that O
functional O
priming O
could O
occur O
in O
the O
liver O
. O

The O
expansion O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
was O
significantly O
reduced O
in O
the O
mice O
whose O
major B
histocompatibility I
complex I
( I
MHC I
) I
class O
I O
expression O
was O
mostly O
restricted O
to O
nonhematopoietic O
cells O
, O
suggesting O
the O
importance O
of O
cross O
- O
presentation O
by O
hematopoietic O
cells O
in O
the O
induction O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

Strikingly O
, O
the O
expansion O
and O
cytolytic O
differentiation O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
were O
reduced O
even O
more O
severely O
in O
the O
mice O
whose O
MHC O
class O
I O
expression O
was O
restricted O
to O
hematopoietic O
cells O
. O

Collectively O
, O
these O
results O
indicate O
that O
cross O
- O
presentation O
is O
required O
but O
relatively O
inefficient O
in O
terms O
of O
inducing O
the O
cytolytic O
differentiation O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
by O
itself O
. O

Instead O
, O
the O
expansion O
and O
functional O
differentiation O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
are O
primarily O
dependent O
on O
hepatocellular O
antigen O
presentation O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
causes O
acute O
and O
chronic O
hepatitis O
. O

It O
is O
widely O
accepted O
that O
antigen O
inexperienced O
CD8 O
( O
+ O
) O
T O
cells O
should O
be O
initially O
activated O
by O
professional O
antigen O
- O
presenting O
cells O
( O
pAPCs O
) O
in O
lymphoid O
tissues O
to O
differentiate O
into O
effector O
CD8 O
( O
+ O
) O
T O
cells O
. O

However O
, O
this O
notion O
has O
not O
been O
tested O
for O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cells O
. O

In O
this O
study O
, O
we O
show O
that O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
can O
be O
induced O
in O
the O
liver O
. O

Surprisingly O
, O
antigen O
presentation O
by O
hepatocytes O
is O
more O
important O
than O
cross O
- O
presentation O
by O
hematopoietic O
cells O
for O
the O
induction O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
. O

These O
results O
revealed O
a O
previously O
unappreciated O
role O
of O
antigen O
presentation O
by O
hepatocytes O
in O
the O
induction O
of O
HBV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
, O
the O
causative O
agent O
of O
hepatitis O
E O
, O
is O
an O
important O
but O
incompletely O
understood O
pathogen O
causing O
high O
mortality O
during O
pregnancy O
and O
leading O
to O
chronic O
hepatitis O
in O
immunocompromised O
individuals O
. O

In O
this O
study O
, O
immunoglobulin B
( I
lg I
) I
heavy O
chain O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
gnotobiotic O
pigs O
were O
generated O
using O
CRISPR O
/ O
Cas9 O
technology O
to O
deplete O
the O
B O
- O
lymphocyte O
population O
, O
resulting O
in O
an O
inability O
to O
generate O
a O
humoral O
immune O
response O
to O
genotype O
3 O
HEV O
infection O
. O

Compared O
to O
wild O
- O
type O
gnotobiotic O
piglets O
, O
the O
frequencies O
of O
B O
- O
lymphocytes O
in O
the O
Ig O
heavy O
chain O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
, O
knockouts O
were O
significantly O
lower O
, O
despite O
similar O
levels O
of O
other O
innate O
and O
adaptive O
T O
- O
lymphocyte O
cell O
populations O
. O

The O
dynamic O
of O
acute O
HEV O
infection O
was O
subsequently O
determined O
in O
heavy O
chain O
J O
( O
H O
- O
/ O
- O
) O
knockout O
and O
wild O
- O
type O
gnotobiotic O
pigs O
. O

The O
data O
showed O
that O
wild O
- O
type O
piglets O
had O
higher O
viral O
RNA O
loads O
in O
feces O
and O
sera O
compared O
to O
the O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
pigs O
, O
suggesting O
that O
the O
Ig O
heavy O
chain O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
in O
pigs O
actually O
decreased O
the O
level O
of O
HEV O
replication O
. O

Both O
HEV O
- O
infected O
wild O
- O
type O
and O
J O
( O
H O
) O
( O
- O
) O
( O
/ O
- O
) O
knockout O
gnotobiotic O
piglets O
developed O
more O
pronounced O
lym O
- O
phoplasmacytic O
hepatitis O
and O
hepatocellular O
necrosis O
lesions O
than O
other O
studies O
with O
conventional O
pigs O
. O

The O
HEV O
- O
infected O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
pigs O
also O
had O
significantly O
enlarged O
livers O
both O
grossly O
and O
as O
a O
ratio O
of O
liver O
/ O
body O
weight O
compared O
to O
phosphate O
- O
buffered O
saline O
- O
inoculated O
groups O
. O

Here O
, O
we O
successfully O
generated O
immunoglobulin O
heavy O
chain O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
gnotobiotic O
pigs O
using O
CRISPR O
/ O
Cas9 O
technology O
, O
established O
a O
novel O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
and O
wild O
- O
type O
gnotobiotic O
pig O
model O
for O
HEV O
, O
and O
systematically O
determined O
the O
dynamic O
of O
acute O
HEV O
infection O
in O
gnotobiotic O
pigs O
. O

Infected O
wild O
- O
type O
and O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
gnotobiotic O
piglets O
developed O
more O
pronounced O
HEV O
- O
specific O
lesions O
than O
other O
studies O
using O
conventional O
pigs O
, O
and O
the O
infected O
J O
( O
H O
) O
( O
- O
/ O
- O
) O
knockout O
pigs O
had O
significantly O
enlarged O
livers O
. O

PJA1 O
restricts O
the O
DNA O
viruses O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
Herpes B
simplex I
virus I
1 I
( I
HSV I
- I
1 I
) I
but O
not O
the O
RNA O
viruses O
enterovirus B
71 I
( I
EV71 I
) I
and O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
. O

In O
addition O
, O
PJA1 O
has O
no O
effect O
on O
endogenous O
type O
I O
and O
II O
Interferons B
( I
IFNs I
) I
and O
interferon B
- I
stimulated I
genes I
( I
ISGs I
) I
, O
suggesting O
that O
PJA1 O
silences O
DNA O
viruses O
independent O
of O
the O
IFN O
pathways O
. O

Interestingly O
, O
PJA1 O
interacts O
with O
the O
SMC5 O
/ O
6 O
complex O
( O
a O
complex O
essential O
for O
chromosome O
maintenance O
and O
HBV O
restriction O
) O
to O
facilitate O
the O
binding O
of O
the O
complex O
to O
viral O
and O
episomal O
DNAs O
in O
the O
cell O
nucleus O
. O

Moreover O
, O
treatment O
with O
inhibitors O
of O
DNA O
topoisomerases O
( O
Tops O
) O
and O
knockdown O
of O
Tops O
release O
PJA1 O
- O
mediated O
silencing O
of O
viral O
and O
extrachromosomal O
DNAs O
. O

This O
work O
demonstrates O
that O
an O
important O
cellular O
factor O
( O
PJA1 O
) O
suppresses O
DNA O
viruses O
and O
transfected O
plasmids O
independent O
of O
type O
I O
and O
II O
interferon B
( I
IFN I
) I
pathways O
. O

Instead O
, O
PJA1 O
interacts O
with O
the O
chromosome O
maintenance O
complex O
( O
SMC5 O
/ O
6 O
) O
, O
facilitates O
the O
complex O
to O
recognize O
and O
bind O
viral O
and O
episomal O
DNAs O
, O
and O
recruits O
DNA O
topoisomerases O
to O
restrict O
the O
foreign O
molecules O
. O

RNA B
interference I
( I
RNAi I
) I
is O
widely O
used O
in O
gene O
knockdown O
analysis O
and O
as O
a O
tool O
to O
screen O
host O
genes O
involved O
in O
viral O
infection O
. O

Owing O
to O
the O
limitations O
of O
transducing O
cells O
with O
synthetic O
small B
interfering I
RNAs I
( I
siRNAs I
) I
, O
lentiviral O
short B
hairpin I
RNA I
( I
shRNA I
) I
vectors O
are O
more O
widely O
used O
. O

However O
, O
we O
found O
that O
stable O
transduction O
with O
lentiviral O
shRNA O
vectors O
inhibited O
hepatitis B
C I
virus I
( I
HCV I
) I
propagation O
in O
human O
hepatoma O
cells O
. O

We O
found O
by O
microRNA B
( I
miRNA I
) I
microarray O
analysis O
that O
this O
inhibition O
was O
induced O
by O
the O
alteration O
of O
host O
miRNA O
expression O
. O

In O
addition O
to O
one O
miRNA O
( O
miR O
- O
196b O
- O
5p O
) O
previously O
reported O
to O
be O
involved O
in O
HCV O
infection O
, O
other O
miRNAs O
( O
miR O
- O
216a O
- O
5p O
, O
- O
216b O
- O
5p O
, O
217 O
, O
and O
- O
30b O
- O
5p O
) O
were O
found O
to O
influence O
HCV O
infection O
in O
this O
study O
. O

Emerging O
evidence O
indicates O
that O
long O
noncoding O
RNAs O
( O
lncRNAs O
) O
regulate O
various O
biological O
processes O
, O
especially O
innate O
and O
adaptive O
immunity O
. O

However O
, O
the O
relationship O
between O
lncRNAs O
and O
the O
interferon B
( I
IFN I
) I
pathway O
remains O
largely O
unknown O
. O

Here O
, O
we O
report O
that O
lncRNA O
ITPRIP O
- O
1 O
( O
lncITPRIP O
- O
1 O
) O
is O
involved O
in O
viral O
infection O
and O
plays O
a O
crucial O
role O
in O
the O
virus O
- O
triggered O
IFN O
signaling O
pathway O
through O
the O
targeting O
of O
melanoma B
differentiation I
- I
associated I
gene I
5 I
( I
MDA5 I
) I
. O

Amazingly O
, O
we O
also O
found O
that O
MDA5 O
can O
suppress O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
independently O
of O
IFN O
signaling O
through O
its O
C O
- O
terminal O
- O
deficient O
domain O
bound O
to O
viral O
RNA O
, O
in O
which O
lncITPRIP O
- O
1 O
plays O
a O
role O
as O
an O
assistant O
. O

sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
has O
been O
identified O
as O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
receptor O
, O
and O
its O
overexpression O
in O
HepG2 O
cell O
lines O
leads O
to O
efficient O
secretion O
of O
hepatitis B
B I
e I
antigen I
( I
HBeAg I
) I
following O
challenge O
with O
a O
large O
dose O
of O
cell O
culture O
- O
derived O
HBV O
( O
cHBV O
) O
particles O
. O

However O
, O
NTCP O
- O
reconstituted O
HepG2 O
cells O
are O
inefficiently O
infected O
by O
patient O
serum O
- O
derived O
HBV O
( O
sHBV O
) O
and O
release O
very O
little O
hepatitis B
B I
surface I
antigen I
( I
HBsAg I
) I
following O
cHBV O
infection O
, O
unlike O
differentiated O
HepaRG O
cells O
, O
which O
are O
naturally O
susceptible O
to O
both O
cHBV O
and O
sHBV O
particles O
. O

The O
responsible O
host O
factor O
( O
s O
) O
remains O
to O
be O
identified O
. O

Virus O
- O
specific O
CD8 O
T O
cell O
response O
seems O
to O
play O
a O
significant O
role O
in O
the O
outcome O
of O
hepatitis B
delta I
virus I
( I
HDV I
) I
infection O
. O

In O
this O
study O
, O
we O
predicted O
peptide O
epitopes O
binding O
the O
most O
frequent O
human B
leukocyte I
antigen I
( I
HLA I
) I
types O
and O
assessed O
their O
HLA O
binding O
capacities O
. O

These O
epitopes O
were O
characterized O
in O
HDV O
- O
infected O
patients O
by O
intracellular O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
staining O
. O

Sequence O
analysis O
of O
large B
hepatitis I
delta I
antigen I
( I
L I
- I
HDAg I
) I
and O
HLA O
typing O
were O
performed O
in O
104 O
patients O
. O

IMPORTANCE O
hepatitis B
delta I
virus I
( I
HDV I
) I
causes O
severe O
chronic O
hepatitis O
, O
which O
affects O
20 O
million O
people O
worldwide O
. O

During O
the O
morphogenesis O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
an O
enveloped O
virus O
, O
two O
types O
of O
virions O
are O
secreted O
: O
( O
i O
) O
a O
minor O
population O
of O
complete O
virions O
containing O
a O
mature O
nucleocapsid O
with O
the O
characteristic O
, O
partially O
double O
- O
stranded O
, O
relaxed O
circular O
DNA O
genome O
and O
( O
ii O
) O
a O
major O
population O
containing O
an O
empty O
capsid O
with O
no O
DNA O
or O
RNA O
( O
empty O
virions O
) O
. O

Secretion O
of O
both O
types O
of O
virions O
requires O
interactions O
between O
the O
HBV O
capsid O
or O
core O
protein O
( O
HBc O
) O
and O
the O
viral O
surface O
or O
envelope O
proteins O
. O

S O
mutations O
that O
blocked O
secretion O
of O
the O
hepatitis B
D I
virus I
( I
HDV I
) I
, O
an O
HBV O
satellite O
, O
did O
not O
block O
secretion O
of O
either O
empty O
or O
complete O
HBV O
virions O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
cause O
of O
severe O
liver O
diseases O
, O
including O
cirrhosis O
and O
cancer O
. O

In O
particular O
, O
the O
empty O
( O
or O
genome O
- O
free O
) O
virion O
shares O
with O
the O
complete O
virion O
the O
outer O
envelope O
and O
interior O
capsid O
but O
contains O
no O
genome O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
liver O
disease O
in O
humans O
and O
is O
thought O
to O
be O
a O
zoonotic O
infection O
, O
with O
domestic O
animals O
, O
including O
swine O
and O
rabbits O
, O
being O
a O
reservoir O
. O

Four O
Monoclonal B
antibodies I
( I
MAbs I
) I
, O
three O
novel O
, O
1 O
. O

00E O
+ O
04 O
, O
2C7 O
, O
and O
2G9 O
, O
and O
one O
previously O
characterized O
, O
1B5 O
, O
were O
evaluated O
for O
binding O
to O
the O
capsid O
protein O
from O
genotype O
4 O
swine O
HEV O
. O

The O
results O
indicated O
that O
( O
DFCP628 O
) O
- O
D O
- O
625 O
, O
( O
PSRPF462 O
) O
- O
P O
- O
458 O
, O
and O
( O
EPTV410 O
) O
- O
E O
- O
407 O
peptides O
on O
the O
capsid O
protein O
comprised O
minimal O
amino O
acid O
sequence O
motifs O
recognized O
by O
1E4 O
, O
2C7 O
, O
and O
2G9 O
, O
respectively O
. O

Truncated O
genotype O
4 O
swine O
HEV O
capsid O
protein O
( O
sp239 O
, O
amino O
acids O
368 O
to O
606 O
) O
can O
exist O
in O
multimeric O
forms O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
replication O
and O
assembly O
occur O
at O
the O
specialized O
site O
of O
endoplasmic B
reticulum I
( I
ER I
) I
membranes O
and O
lipid B
droplets I
( I
LDs I
) I
, O
respectively O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
the O
important O
relationship O
among O
osteopontin B
( I
OPN I
) I
, O
the O
ER O
, O
and O
LDs O
. O

OPN O
is O
a O
secreted O
phosphoprotein O
, O
and O
overexpression O
of O
OPN O
in O
hepatocellular B
carcinoma I
( I
HCC I
) I
tissue O
can O
lead O
to O
invasion O
and O
metastasis O
. O

In O
this O
study O
, O
we O
showed O
a O
significant O
reduction O
in O
HCV O
replication O
, O
assembly O
, O
and O
infectivity O
in O
HCV O
- O
infected O
cells O
transfected O
with O
small B
interfering I
RNA I
( I
siRNA I
) I
against O
OPN O
, O
alpha O
V O
beta O
3 O
, O
and O
CD44 O
. O

We O
also O
observed O
the O
association O
of O
endogenous O
OPN O
with O
HCV O
proteins O
( O
NS3 O
, O
NS5A O
, O
NS4A O
/ O
B O
, O
NS5B O
, O
and O
core O
) O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
consists O
of O
an O
N O
- O
terminal O
assembly O
domain O
and O
a O
C B
- I
terminal I
domain I
( I
CTD I
) I
with O
seven O
conserved O
serines O
or O
threonines O
that O
are O
dynamically O
phosphorylated O
/ O
dephosphorylated O
during O
the O
viral O
replication O
cycle O
. O

Sulfamoylbenzamide O
derivatives O
are O
small O
molecular O
core B
protein I
allosteric I
modulators I
( I
CpAMs I
) I
that O
bind O
to O
the O
heteroaryldihydropyrimidine B
( I
HAP I
) I
pocket O
between O
the O
core O
protein O
dimer O
- O
dimer O
interfaces O
. O

CpAM O
binding O
alters O
the O
kinetics O
and O
pathway O
of O
capsid O
assembly O
and O
can O
result O
in O
the O
formation O
of O
morphologically O
normal O
capsids O
devoid O
of O
viral O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
DNA O
polymerase O
. O

Interestingly O
, O
inhibition O
of O
pgRNA O
encapsidation O
by O
a O
heat B
shock I
protein I
90 I
( I
Hsp90 I
) I
inhibitor O
prevented O
core O
protein O
dephosphorylation O
. O

Here O
, O
we O
found O
that O
disruption O
of O
core O
protein O
interaction O
at O
dimer O
- O
dimer O
interfaces O
during O
nucleocapsid O
assembly O
( O
by O
CpAMs O
or O
mutagenesis O
) O
inhibited O
core O
protein O
dephosphorylation O
and O
pgRNA O
packaging O
. O

The O
molecular O
mechanisms O
of O
liver O
pathology O
and O
clinical O
disease O
in O
hepatitis B
E I
virus I
( I
HEV I
) I
infection O
remain O
unclear O
. O

microRNAs B
( I
miRNAs I
) I
are O
known O
to O
modulate O
viral O
pathogenesis O
either O
by O
directly O
altering O
viral O
gene O
expression O
or O
by O
enhancing O
cellular O
antiviral O
responses O
. O

Given O
the O
importance O
of O
microRNA B
- I
122 I
( I
miR I
- I
122 I
) I
in O
liver O
pathobiology O
, O
we O
investigated O
possible O
role O
of O
miR O
- O
122 O
in O
HEV O
infection O
. O

In O
silico O
predictions O
using O
HEV B
genotype I
1 I
( I
HEV I
- I
1 I
) I
, O
HEV O
- O
2 O
, O
HEV O
- O
3 O
, O
and O
HEV O
- O
4 O
sequences O
showed O
that O
the O
majority O
of O
genomes O
( O
203 O
/ O
222 O
) O
harbor O
at O
least O
one O
miR122 O
/ O
microRNA B
- I
122 I
- I
3p I
( I
miR I
- I
122 I
* I
) I
target O
site O
. O

Interestingly O
, O
HEV O
- O
1 O
genomes O
showed O
a O
highly O
( O
97 O
% O
) O
conserved O
miR O
- O
122 O
target O
site O
in O
the O
RNA B
- I
dependent I
RNA I
polymerase I
( I
RdRp I
) I
region O
( O
RdRp O
( O
c O
) O
) O
. O

We O
analyzed O
the O
significance O
of O
miR O
- O
122 O
target O
sites O
in O
HEV O
- O
1 O
/ O
HEV O
- O
3 O
( O
HEV O
- O
1 O
/ O
3 O
) O
genomes O
by O
using O
a O
replicon O
- O
based O
cell O
culture O
system O
. O

Mutant O
HEV O
- O
1 O
replicons O
with O
an O
altered O
target O
RdRp O
( O
c O
) O
sequence O
( O
CACTCC O
) O
showed O
a O
drastic O
decrease O
in O
virus O
replication O
, O
whereas O
introduction O
of O
alternative O
miR O
- O
122 O
target O
sites O
in O
mutant O
replicons O
rescued O
viral O
replication O
. O

Currently O
, O
off O
- O
label O
use O
of O
ribavirin B
( I
RBV I
) I
and O
polyethylene B
glycol I
- I
interferon I
( I
PEG I
- I
IFN I
) I
as O
antiviral O
therapy O
has O
shown O
promising O
results O
in O
both O
acute O
and O
chronic O
hepatitis O
E O
patients O
; O
however O
, O
the O
teratogenicity O
of O
RBV O
limits O
its O
use O
during O
pregnancy O
, O
while O
alpha O
IFN O
( O
IFN O
- O
alpha O
) O
increases O
the O
risk O
of O
transplant O
rejections O
. O

During O
hepatitis B
B I
virus I
( I
HBV I
) I
infections O
, O
subviral B
particles I
( I
SVP I
) I
consisting O
only O
of O
viral O
envelope O
proteins O
and O
lipids O
are O
secreted O
. O

S O
is O
synthesized O
as O
a O
transmembrane O
protein O
with O
N O
- O
terminal O
( O
TM1 O
) O
, O
central O
( O
TM2 O
) O
, O
and O
hydrophobic B
C I
- I
terminal I
( I
HCR I
) I
transmembrane O
domains O
. O

The O
loops O
between O
TM1 O
and O
TM2 O
( O
the O
cytosolic O
loop O
[ O
CL O
] O
) O
and O
between O
TM2 O
and O
the O
HCR O
( O
the O
luminal O
loop O
[ O
LL O
] O
) O
are O
located O
in O
the O
cytosol O
and O
the O
endoplasmic B
reticulum I
( I
ER I
) I
lumen O
, O
respectively O
. O

Furthermore O
, O
the O
oligomerization O
of O
S O
was O
measured O
with O
a O
fluorescence B
- I
activated I
cell I
sorter I
( I
FACS I
) I
- O
based O
Forster B
resonance I
energy I
transfer I
( I
FRET I
) I
assay O
. O

Chronic O
infection O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
the O
major O
contributor O
to O
liver O
disease O
worldwide O
. O

Though O
HBV O
replicates O
via O
a O
nuclear O
episomal O
DNA O
( O
covalently O
closed O
circular O
DNA O
[ O
cccDNA O
] O
) O
, O
integration O
of O
HBV O
DNA O
into O
the O
host O
cell O
genome O
is O
regularly O
observed O
in O
the O
liver O
in O
infected O
patients O
. O

While O
reported O
as O
a O
prooncogenic O
alteration O
, O
the O
mechanism O
( O
s O
) O
and O
timing O
of O
HBV O
DNA O
integration O
are O
not O
well O
understood O
, O
chiefly O
due O
to O
the O
lack O
of O
in O
vitro O
infection O
models O
that O
have O
detectable O
integration O
events O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
common O
blood O
- O
borne O
pathogen O
and O
, O
following O
a O
chronic O
infection O
, O
can O
cause O
liver O
cancer O
and O
liver O
cirrhosis O
. O

However O
, O
when O
and O
the O
mechanism O
( O
s O
) O
by O
which O
HBV O
DNA O
integration O
occurs O
are O
not O
clear O
. O

By O
using O
a O
model O
persistent O
infection O
with O
the O
natural O
murine O
pathogen O
lymphocytic O
choriomeningitis O
virus O
clone O
13 O
( O
LCMV O
Cl13 O
) O
we O
investigated O
the O
role O
of O
one O
such O
cytokine O
, O
interleukin B
- I
27 I
( I
IL I
- I
27 I
) I
, O
in O
the O
control O
of O
chronic O
infection O
. O

We O
found O
that O
IL B
- I
27 I
receptor I
( I
IL I
- I
27R I
) I
signaling O
promoted O
control O
of O
LCMV O
Cl13 O
as O
early O
as O
days O
1 O
and O
5 O
after O
infection O
and O
that O
il27p28 O
transcripts O
were O
rapidly O
elevated O
in O
multiple O
subsets O
of O
dendritic B
cells I
( I
DCs I
) I
and O
myeloid O
cells O
. O

In O
particular O
, O
plasmacytoid B
DCs I
( I
pDCs I
) I
, O
the O
most O
potent O
type B
1 I
interferon I
( I
IFN I
- I
I I
) I
- O
producing O
cells O
, O
significantly O
increased O
il27p28 O
in O
a O
Toll B
- I
like I
receptor I
7 I
( I
TLR7 I
) I
dependent O
fashion O
. O

Notably O
, O
mice O
deficient O
in O
an O
IL O
- O
27 O
- O
specific O
receptor O
, O
WSX O
- O
1 O
, O
exhibited O
a O
pleiotropy O
of O
innate O
and O
adaptive O
immune O
alterations O
after O
chronic O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
infection O
, O
including O
compromised O
NK O
cell O
cytotoxicity O
and O
antibody O
responses O
. O

While O
, O
the O
majority O
of O
these O
immune O
alterations O
appeared O
to O
be O
cell O
extrinsic O
, O
cell O
- O
intrinsic O
IL O
- O
27R O
was O
necessary O
to O
maintain O
early O
pDC O
numbers O
, O
which O
, O
alongside O
lower O
IFN O
- O
I O
transcription O
in O
CD11b O
( O
+ O
) O
DCs O
and O
myeloid O
cells O
, O
may O
explain O
the O
compromised O
IFN O
- O
I O
elevation O
that O
we O
observed O
early O
after O
LCMV O
Cl13 O
infection O
in O
IL O
- O
27R O
- O
deficient O
mice O
. O

Using O
a O
persistently O
replicating O
rodent O
pathogen O
, O
LCMV O
, O
in O
its O
natural O
host O
, O
we O
identified O
the O
cellular O
sources O
and O
effects O
of O
one O
important O
regulatory O
pathway O
, O
interleukin O
- O
27 O
receptor O
WSX O
- O
1 O
signaling O
, O
that O
is O
required O
for O
both O
very O
early O
and O
late O
restriction O
of O
chronic O
( O
but O
not O
acute O
) O
infection O
. O

Current O
evidence O
supports O
a O
protective O
role O
for O
virus O
- O
neutralizing O
antibodies O
in O
immunity O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
. O

Previous O
clinical O
trials O
have O
shown O
that O
a O
gpE1 O
/ O
gpE2 O
vaccine O
can O
induce O
antibodies O
that O
neutralize O
the O
in O
vitro O
infectivity O
of O
all O
the O
major O
cell B
culture I
- I
derived I
HCV I
( I
HCVcc I
) I
genotypes O
around O
the O
world O
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
at O
the O
amino O
terminus O
of O
glycoprotein O
E2 O
has O
been O
shown O
to O
restrict O
access O
to O
many O
neutralizing O
antibodies O
. O

In O
this O
study O
, O
we O
examined O
the O
immunogenicity O
of O
recombinant O
gpE1 O
/ O
gpE2 O
lacking O
HVR1 O
( O
Delta O
HVR1 O
) O
. O

Our O
results O
indicate O
that O
wild B
- I
type I
( I
WT I
) I
and O
Delta O
HVR1 O
gpE1 O
/ O
gpE2 O
antigens O
induced O
antibodies O
targeting O
many O
well O
- O
characterized O
cross O
- O
genotype O
- O
neutralizing O
epitopes O
. O

However O
, O
while O
the O
WT O
gpE1 O
/ O
gpE2 O
vaccine O
can O
induce O
cross O
- O
genotype O
protection O
against O
various O
genotypes O
of O
HCVcc O
and O
/ O
or O
HCV O
- O
pseudotyped O
virus O
( O
HCVpp O
) O
, O
antisera O
from O
Delta O
HVR1 O
gpE1 O
/ O
gpE2 O
- O
immunized O
animals O
exhibited O
either O
reduced O
homologous O
neutralization O
activity O
compared O
to O
that O
of O
the O
WT O
or O
heterologous O
neutralization O
activity O
similar O
to O
that O
of O
the O
WT O
. O

Cytidine O
deaminases O
inhibit O
replication O
of O
a O
broad O
range O
of O
DNA O
viruses O
by O
deaminating O
cytidines O
on O
single B
- I
stranded I
DNA I
( I
ssDNA I
) I
to O
generate O
uracil O
. O

While O
several O
lines O
of O
evidence O
have O
revealed O
hepatitis B
B I
virus I
( I
HBV I
) I
genome O
editing O
by O
deamination O
, O
it O
is O
still O
unclear O
which O
nucleic O
acid O
intermediate O
of O
HBV O
is O
modified O
. O

Hepatitis O
B O
virus O
has O
a O
relaxed B
circular I
double I
- I
stranded I
DNA I
( I
rcDNA I
) I
genome O
that O
is O
reverse O
transcribed O
within O
virus O
cores O
from O
a O
RNA O
template O
. O

The O
HBV O
genome O
also O
persists O
as O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
in O
the O
nucleus O
of O
an O
infected O
cell O
. O

We O
found O
no O
deamination O
on O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
indicating O
that O
an O
intact O
genome O
is O
en O
- O
capsidated O
and O
deaminated O
during O
or O
after O
reverse O
transcription O
. O

Five O
matching O
sets O
of O
nonmalignant O
liver O
tissues O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
samples O
from O
individuals O
chronically O
infected O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
were O
examined O
. O

In O
the O
majority O
of O
HCC O
samples O
, O
the O
levels O
of O
pregenomic O
/ O
precore O
RNA O
( O
pgRNA O
) O
and O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
were O
lower O
than O
those O
in O
liver O
tissue O
counterparts O
. O

Regardless O
of O
the O
presence O
of O
HBV O
replication O
markers O
, O
( O
i O
) O
integrant B
- I
derived I
HBV I
RNAs I
( I
id I
- I
RNAs I
) I
were O
found O
in O
all O
tissues O
by O
reverse B
transcription I
- I
PCR I
( I
RT I
- I
PCR I
) I
analysis O
and O
were O
considerably O
abundant O
or O
predominant O
in O
6 O
/ O
10 O
tissue O
samples O
( O
2 O
liver O
and O
4 O
HCC O
samples O
) O
, O
( O
ii O
) O
RNAs O
that O
were O
polyadenylated O
using O
the O
cryptic O
HBV O
polyadenylation O
signal O
and O
therefore O
could O
be O
produced O
by O
HBV O
replication O
or O
derived O
from O
integrated O
HBV O
DNA O
were O
found O
in O
5 O
/ O
10 O
samples O
( O
3 O
liver O
and O
2 O
HCC O
samples O
) O
and O
were O
considerably O
abundant O
species O
in O
3 O
/ O
10 O
tissues O
( O
2 O
livers O
and O
1 O
HCC O
) O
, O
and O
( O
iii O
) O
cccDNA O
- O
transcribed O
RNAs O
polyadenylated O
near O
position O
1931 O
were O
not O
abundant O
in O
7 O
/ O
10 O
tissues O
( O
2 O
liver O
and O
5 O
HCC O
samples O
) O
and O
were O
predominant O
in O
only O
two O
liver O
samples O
. O

IMPORTANCE O
The O
relative O
abundance O
of O
integrant B
- I
derived I
HBV I
RNAs I
( I
id I
- I
RNAs I
) I
in O
chronically O
infected O
tissues O
suggest O
that O
id O
- O
RNAs O
coding O
for O
the O
envelope O
proteins O
may O
facilitate O
the O
production O
of O
a O
considerable O
fraction O
of O
surface O
antigens O
( O
HBsAg O
) O
in O
infected O
cells O
bearing O
HBV O
integrants O
. O

Furthermore O
, O
the O
production O
of O
HBsAg O
from O
id O
- O
RNAs O
independently O
of O
viral O
replication O
may O
explain O
at O
least O
in O
part O
why O
treatment O
with O
interferon O
or O
nucleos O
( O
t O
) O
ides O
in O
most O
cases O
fails O
to O
achieve O
a O
loss O
of O
serum O
HBsAg O
. O

The O
hepatitis B
A I
virus I
( I
HAV I
) I
cellular O
receptor O
1 O
( O
HAVCR1 O
) O
, O
classified O
as O
CD365 O
, O
was O
initially O
discovered O
as O
an O
HAV O
cellular O
receptor O
using O
an O
expression O
cloning O
strategy O
. O

Here O
, O
we O
show O
that O
an O
anti O
- O
HAVCR1 O
monoclonal O
antibody O
that O
protected O
African B
green I
monkey I
kidney I
( I
AGMK I
) I
cells O
against O
HAV O
infection O
only O
partially O
protected O
monkey O
Vero O
E6 O
cells O
and O
human O
hepatoma O
Huh7 O
cells O
, O
indicating O
that O
these O
two O
cell O
lines O
express O
alternative O
yet O
unidentified O
HAV O
receptors O
. O

The O
resulting O
AGMK O
HAVCR1 O
knockout B
( I
KO I
) I
cells O
lost O
susceptibility O
to O
HAV O
infection O
, O
including O
HAV O
- O
free O
viral O
particles O
( O
vpHAV O
) O
and O
exosomes O
purified O
from O
HAV O
- O
infected O
cells O
( O
exo O
- O
HAV O
) O
. O

Multiple O
steps O
of O
the O
life O
cycle O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
are O
known O
to O
be O
coupled O
to O
hepatic O
metabolism O
. O

Hepatic O
lipid O
metabolism O
is O
controlled O
by O
a O
complicated O
transcription O
factor O
network O
centered O
on O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
. O

The O
RXR O
- O
specific O
agonist O
bexarotene O
inhibits O
HBV O
in O
HepG2 O
cells O
expressing O
the O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
( O
HepG2 O
- O
NTCP O
) O
, O
HepaRG O
cells O
, O
and O
Primary B
Tupaia I
hepatocytes I
( I
PTHs I
) I
; O
reducing O
RXR O
alpha O
expression O
significantly O
enhanced O
HBV O
infection O
in O
the O
cells O
. O

Transcriptome O
sequencing O
( O
RNA O
- O
seq O
) O
analysis O
of O
HepG2 O
- O
NTCP O
cells O
with O
a O
disrupted O
RXR O
alpha O
gene O
revealed O
that O
reduced O
gene O
expression O
in O
arachidonic B
acid I
( I
AA I
) I
/ O
eicosanoid O
biosynthesis O
pathways O
, O
including O
the O
AA O
synthases O
phospholipase B
A2 I
group I
IIA I
( I
PLA2G2A I
) I
, O
is O
associated O
with O
increased O
HBV O
infection O
. O

By O
a O
series O
of O
genetic O
studies O
in O
combination O
with O
transcriptome O
analysis O
and O
pharmacological O
assays O
, O
we O
here O
investigated O
the O
role O
of O
cellular O
retinoid B
X I
receptor I
alpha I
( I
RXR I
alpha I
) I
, O
a O
crucial O
transcription O
factor O
for O
controlling O
hepatic O
lipid O
metabolism O
, O
in O
de O
novo O
HBV O
infection O
in O
cell O
cultures O
. O

We O
found O
that O
silencing O
of O
RXR O
alpha O
resulted O
in O
elevated O
HBV O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
formation O
and O
viral O
antigen O
production O
, O
while O
activation O
of O
RXR O
alpha O
reduced O
HBV O
infection O
efficiency O
. O

Our O
results O
also O
showed O
that O
silencing O
phospholipase B
A2 I
group I
IIA I
( I
PLA2G2A I
) I
, O
a O
key O
enzyme O
of O
arachidonic B
acid I
( I
AA I
) I
synthases O
, O
enhanced O
HBV O
infection O
efficiency O
in O
HepG2 O
- O
NTCP O
cells O
and O
that O
exogenous O
AA O
treatment O
reduced O
de O
novo O
HBV O
infection O
in O
the O
cells O
. O

Previous O
studies O
indicated O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
stimulates O
autophagy O
to O
favor O
its O
production O
. O

RNA O
interference O
- O
mediated O
silencing O
of O
Atg5 O
, O
Atg12 O
, O
and O
Atg16L1 O
, O
which O
promote O
autophagophore O
expansion O
and O
LC3 O
membrane O
conjugation O
, O
interfered O
with O
viral O
core O
/ O
nucleocapsid B
( I
NC I
) I
formation O
/ O
stability O
and O
strongly O
diminished O
virus O
yields O
. O

IMPORTANCE O
Infections O
with O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
an O
enveloped O
pararetrovirus O
, O
cause O
about O
1 O
million O
deaths O
per O
year O
, O
as O
current O
therapies O
rarely O
achieve O
a O
cure O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
has O
been O
shown O
to O
regulate O
microRNA O
130a O
( O
miR O
- O
130a O
) O
in O
patient O
biopsy O
specimens O
and O
in O
cultured O
cells O
. O

We O
sought O
to O
identify O
miR O
- O
130a O
target O
genes O
and O
to O
explore O
the O
mechanisms O
by O
which O
miR O
- O
130a O
regulates O
HCV O
and O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
. O

miR O
- O
130a O
and O
its O
target O
genes O
were O
overexpressed O
or O
were O
knocked O
down O
by O
use O
of O
small B
interfering I
RNA I
( I
siRNA I
) I
or O
clustered B
regularly I
interspaced I
short I
palindromic I
repeat I
( I
CRISPR I
) I
/ O
Cas9 O
guide O
RNA O
( O
gRNA O
) O
. O

1 O
cells O
, O
and O
HCV O
JFH1 O
- O
infected O
primary B
human I
hepatocytes I
( I
PHHs I
) I
and O
HBV O
replication O
in O
HepAD38 O
cells O
, O
HBV O
- O
infected O
NTCP O
- O
Huh7 O
. O

1 O
cells O
, O
and O
HBV O
- O
infected O
PHHs O
, O
were O
measured O
by O
quantitative B
reverse I
transcription I
- I
PCR I
( I
qRT I
- I
PCR I
) I
and O
Western O
blotting O
, O
respectively O
. O

Of O
these O
, O
the O
gene O
encoding O
pyruvate B
kinase I
in I
liver I
and I
red I
blood I
cell I
( I
PKLR I
) I
was O
confirmed O
to O
be O
regulated O
by O
miR O
- O
130a O
overexpression O
. O

miR O
- O
130a O
overexpression O
( O
via O
a O
mimic O
) O
knocked O
down O
PKLR O
mRNA O
and O
protein O
levels O
. O

Previously O
, O
we O
reported O
that O
each O
of O
the O
2B O
, O
2BC O
, O
2C O
, O
3A O
, O
and O
3AB O
proteins O
of O
Aichi B
virus I
( I
AiV I
) I
, O
a O
picornavirus O
, O
forms O
a O
complex O
with O
the O
Golgi O
apparatus O
protein O
ACBD3 O
and O
phosphatidylinositol B
4 I
- I
kinase I
III I
beta I
( I
PI4KB I
) I
at O
viral O
RNA O
replication O
sites O
( O
replication O
organelles O
[ O
ROs O
] O
) O
, O
enhancing O
PI4KB O
- O
dependent O
phosphatidylinositol B
4 I
- I
phosphate I
( I
PI4P I
) I
production O
. O

Here O
, O
we O
demonstrate O
AiV O
hijacking O
of O
the O
cellular O
cholesterol O
transport O
system O
involving O
oxysterol B
- I
binding I
protein I
( I
OSBP I
) I
, O
a O
PI4P O
- O
binding O
cholesterol O
transfer O
protein O
. O

AiV O
RNA O
replication O
was O
inhibited O
by O
silencing O
cellular O
proteins O
known O
to O
be O
components O
of O
this O
pathway O
, O
OSBP O
, O
the O
ER O
membrane O
proteins O
VAPA O
and O
VAPB O
( O
VAP O
- O
A O
/ O
B O
) O
, O
the O
PI4P O
- O
phosphatase O
SAC1 O
, O
and O
PItransfer O
protein O
beta O
. O

We O
also O
found O
various O
previously O
unknown O
interactions O
among O
the O
AiV O
proteins O
( O
2B O
, O
2BC O
, O
2C O
, O
3A O
, O
and O
3AB O
) O
, O
ACBD3 O
, O
OSBP O
, O
VAP O
- O
A O
/ O
B O
, O
and O
SAC1 O
, O
and O
the O
interactions O
were O
suggested O
to O
be O
involved O
in O
recruiting O
the O
component O
proteins O
to O
AiV O
ROs O
. O

Previously O
, O
we O
demonstrated O
that O
Aichi B
virus I
( I
AiV I
) I
, O
a O
picornavirus O
, O
forms O
a O
complex O
comprising O
certain O
proteins O
of O
AiV O
, O
the O
Golgi O
apparatus O
protein O
ACBD3 O
, O
and O
the O
lipid O
kinase O
PI4KB O
to O
synthesize O
PI4P O
lipid O
at O
the O
sites O
for O
AiV O
RNA O
replication O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
entry O
into O
host O
cells O
is O
a O
multistep O
process O
requiring O
various O
host O
factors O
, O
including O
the O
tight O
junction O
protein O
occludin B
( I
OCLN I
) I
, O
which O
has O
been O
shown O
to O
be O
essential O
for O
HCV O
infection O
in O
in O
vitro O
cell O
culture O
systems O
. O

In O
this O
study O
, O
we O
successfully O
generated O
four O
rat O
anti O
- O
OCLN O
Monoclonal B
antibodies I
( I
MAbs I
) I
by O
the O
genetic O
immunization O
method O
and O
unique O
cell O
differential O
screening O
. O

These O
four O
MAbs O
bound O
to O
human O
OCLN O
with O
a O
very O
high O
affinity O
( O
antibody O
dissociation O
constant O
of O
< O
1 O
nM O
) O
. O

Kinetic O
studies O
with O
anti O
- O
OCLN O
and O
anti O
- O
Claudin B
- I
1 I
( I
CLDN1 I
) I
MAbs O
demonstrated O
that O
OCLN O
interacts O
with O
HCV O
after O
CLDN1 O
in O
the O
internalization O
step O
. O

In O
this O
study O
, O
an O
in O
vitro O
infection O
model O
for O
the O
hepatitis B
delta I
virus I
( I
HDV I
) I
was O
used O
to O
evaluate O
the O
antiviral O
effects O
of O
phosphorothioate O
nucleic B
acid I
polymers I
( I
NAPs I
) I
and O
investigate O
their O
mechanism O
of O
action O
. O

NAP O
antiviral O
activity O
was O
effective O
against O
HDV O
virions O
bearing O
the O
main O
hepatitis B
B I
virus I
( I
HBV I
) I
immune O
escape O
substitutions O
( O
D144A O
and O
G145R O
) O
and O
was O
pangenomic O
with O
regard O
to O
HBV O
envelope O
proteins O
. O

The O
significance O
of O
our O
study O
is O
in O
demonstrating O
that O
nucleic B
acid I
polymers I
( I
NAPs I
) I
are O
active O
against O
HDV O
by O
targeting O
the O
envelope O
of O
HDV O
virions O
. O

Although O
a O
crucial O
role O
of O
CD169 O
( O
+ O
) O
cells O
during O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
infections O
is O
increasingly O
recognized O
, O
factors O
regulating O
CD169 O
( O
+ O
) O
cells O
during O
viral O
infections O
remain O
unclear O
. O

Here O
, O
we O
show O
that O
tumor O
necrosis O
factor O
is O
produced O
by O
CD11b O
( O
+ O
) O
Ly6C O
( O
+ O
) O
Ly6G O
( O
+ O
) O
cells O
following O
infection O
with O
VSV O
. O

The O
absence O
of O
TNF O
or O
TNF B
receptor I
1 I
( I
TNFR1 I
) I
resulted O
in O
reduced O
numbers O
of O
CD169 O
( O
+ O
) O
cells O
and O
in O
reduced O
type B
I I
interferon I
( I
IFN I
- I
I I
) I
production O
during O
VSV O
infection O
, O
with O
a O
severe O
disease O
outcome O
. O

Specifically O
, O
TNF O
triggered O
RelA O
translocation O
into O
the O
nuclei O
of O
CD169 O
( O
+ O
) O
cells O
; O
this O
translocation O
was O
inhibited O
when O
the O
paracaspase O
MALT O
- O
1 O
was O
absent O
. O

These O
findings O
indicate O
that O
TNF O
mediates O
the O
maintenance O
of O
CD169 O
( O
+ O
) O
cells O
and O
innate O
and O
adaptive O
immune O
activation O
during O
VSV O
infection O
. O

IMPORTANCE O
Over O
the O
last O
decade O
, O
strategically O
placed O
CD169 O
( O
+ O
) O
metallophilic O
macrophages O
in O
the O
marginal O
zone O
of O
the O
murine O
spleen O
and O
Lymph B
nodes I
( I
LN I
) I
have O
been O
shown O
to O
play O
a O
very O
important O
role O
in O
host O
defense O
against O
viral O
pathogens O
. O

CD169 O
( O
+ O
) O
macrophages O
have O
been O
shown O
to O
activate O
innate O
and O
adaptive O
immunity O
via O
enforced O
virus O
replication O
, O
a O
controlled O
amplification O
of O
virus O
particles O
. O

However O
, O
the O
factors O
regulating O
the O
CD169 O
( O
+ O
) O
macrophages O
remain O
to O
be O
studied O
. O

In O
this O
paper O
, O
we O
show O
that O
after O
vesicular O
stomatitis O
virus O
infection O
, O
phagocytes O
produce O
Tumor B
necrosis I
factor I
( I
TNF I
) I
, O
which O
signals O
via O
TNFR1 O
, O
and O
promote O
enforced O
virus O
replication O
in O
CD169 O
( O
+ O
) O
macrophages O
. O

Accumulated O
evidence O
indicates O
that O
immune O
cells O
can O
support O
the O
replication O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
in O
infected O
patients O
and O
in O
culture O
. O

We O
investigated O
the O
ability O
of O
authentic O
, O
patient O
- O
derived O
HCV O
to O
infect O
in O
vitro O
two O
closely O
related O
but O
functionally O
distinct O
immune O
cell O
types O
, O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
lymphocytes O
, O
and O
assessed O
the O
properties O
of O
the O
virus O
produced O
by O
these O
cells O
. O

The O
HCV O
replication O
system O
in O
intermittently O
mitogen O
- O
stimulated O
T O
cells O
was O
adapted O
to O
infect O
primary O
human O
CD4 O
( O
+ O
) O
or O
CD8 O
( O
+ O
) O
T O
lymphocytes O
. O

HCV O
replicated O
in O
both O
cell O
types O
although O
at O
significantly O
higher O
levels O
in O
CD4 O
( O
+ O
) O
than O
in O
CD8 O
( O
+ O
) O
T O
cells O
. O

Thus O
, O
the O
HCV O
RNA O
replicative O
( O
negative O
) O
strand O
was O
detected O
in O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cells O
at O
estimated O
mean O
levels O
+ O
/ O
- O
standard O
errors O
of O
the O
means O
of O
6 O
. O

7 O
x O
10 O
( O
2 O
) O
+ O
/ O
- O
3 O
. O

8 O
x O
10 O
( O
2 O
) O
and O
1 O
. O

2 O
x O
10 O
( O
2 O
) O
+ O
/ O
- O
0 O
. O

8 O
x O
10 O
( O
2 O
) O
copies O
/ O
mu O
g O
RNA O
, O
respectively O
( O
P O
< O
0 O
. O

9 O
% O
of O
CD4 O
( O
+ O
) O
and O
in O
1 O
. O

2 O
% O
of O
CD8 O
( O
+ O
) O
T O
cells O
. O

Furthermore O
, O
an O
HCV O
- O
specific O
protease O
inhibitor O
, O
telaprevir O
, O
inhibited O
infection O
in O
both O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cells O
. O

We O
show O
that O
authentic O
, O
patient O
- O
derived O
HCV O
productively O
replicates O
in O
vitro O
in O
two O
closely O
related O
but O
functionally O
distinct O
types O
of O
T O
lymphocytes O
, O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
cells O
. O

Infection O
of O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cells O
, O
which O
are O
central O
to O
adaptive O
antiviral O
immune O
responses O
, O
can O
directly O
affect O
HCV O
clearance O
, O
favor O
virus O
persistence O
, O
and O
decisively O
influence O
the O
development O
and O
progression O
of O
hepatitis O
C O
. O

Similar O
to O
other O
positive O
- O
strand O
RNA O
viruses O
, O
hepatitis B
C I
virus I
( I
HCV I
) I
causes O
massive O
rearrangements O
of O
intracellular O
membranes O
, O
resulting O
in O
a O
membranous B
web I
( I
MW I
) I
composed O
of O
predominantly O
double B
- I
membrane I
vesicles I
( I
DMVs I
) I
, O
the O
presumed O
sites O
of O
RNA O
replication O
. O

Here O
we O
focused O
on O
selected O
lipid O
transfer O
proteins O
implicated O
in O
direct O
lipid O
transfer O
at O
various O
endoplasmic B
reticulum I
( I
ER I
) I
- O
membrane O
contact O
sites O
. O

RNA B
interference I
( I
RNAi I
) I
- O
mediated O
knockdown O
identified O
several O
hitherto O
unknown O
HCV O
dependency O
factors O
, O
such O
as O
steroidogenic B
acute I
regulatory I
protein I
- I
related I
lipid I
transfer I
domain I
protein I
3 I
( I
STARD3 I
) I
, O
oxysterol B
- I
binding I
protein I
- I
related I
protein I
1A I
and I
- I
B I
( I
OSBPL1A I
and I
- I
B I
) I
, O
and O
Niemann B
- I
Pick I
- I
type I
C1 I
( I
NPC1 I
) I
, O
all O
residing O
at O
late O
endosome O
and O
lysosome O
membranes O
and O
required O
for O
efficient O
HCV O
RNA O
replication O
but O
not O
for O
replication O
of O
the O
closely O
related O
dengue O
virus O
. O

IMPORTANCE O
A O
key O
feature O
of O
the O
replication O
of O
positive O
- O
strand O
RNA O
viruses O
is O
the O
rearrangement O
of O
the O
host O
cell O
endomembrane O
system O
to O
produce O
a O
membranous O
replication B
organelle I
( I
RO I
) I
. O

In O
this O
report O
, O
we O
provide O
evidence O
that O
HCV O
RNA O
replication O
depends O
on O
functional O
lipid O
transport O
along O
the O
endosomal O
- O
lysosomal O
pathway O
that O
is O
mediated O
by O
several O
lipid O
transfer O
proteins O
, O
such O
as O
the O
Niemann B
- I
Pick I
type I
C1 I
( I
NPC1 I
) I
protein O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
single O
- O
stranded O
positive O
- O
sense O
RNA O
hepatotropic O
virus O
. O

Several O
unbiased O
screens O
identified O
nucleosome B
assembly I
protein I
1 I
- I
like I
1 I
( I
NAP1L1 I
) I
as O
an O
interaction O
partner O
of O
HCV O
NS5A O
. O

Among O
those O
, O
we O
showed O
that O
lack O
of O
NAP1L1 O
leads O
to O
a O
decrease O
of O
RELA O
protein O
levels O
and O
a O
strong O
defect O
of O
IRF3 O
TBK1 O
/ O
IKK O
epsilon O
- O
mediated O
phosphorylation O
, O
leading O
to O
inefficient O
RIG O
- O
I O
and O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
responses O
. O

This O
factor O
, O
called O
nucleosome B
assembly I
protein I
1 I
- I
like I
1 I
( I
NAP1L1 I
) I
, O
is O
a O
nuclear O
chaperone O
involved O
in O
the O
remodeling O
of O
chromatin O
during O
transcription O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
- O
encoded O
X O
protein O
( O
HBx O
) O
plays O
a O
critical O
role O
in O
HBV O
- O
related O
hepatocarcinoma O
development O
. O

Consistently O
, O
the O
expression O
of O
HBx O
- O
regulated O
genes O
( O
IL O
- O
8 O
, O
MMP9 O
, O
and O
YAP O
) O
and O
HBV O
transcription O
( O
the O
activity O
of O
HBV O
enhancer O
and O
the O
amount O
of O
pgRNA O
transcribed O
from O
cccDNA O
) O
were O
significantly O
higher O
in O
cells O
expressing O
wild B
- I
type I
( I
WT I
) I
HBx O
than O
that O
in O
cells O
expressing O
mutant O
HBx O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
HBx O
protein O
plays O
a O
critical O
role O
in O
viral O
replication O
and O
hepatocarcinogenesis O
. O

We O
provide O
a O
new O
evidence O
to O
show O
the O
positive O
correlation O
between O
HDM2 O
and O
HBx O
in O
clinical O
hepatocellular B
carcinoma I
( I
HCC I
) I
samples O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
exists O
as O
a O
lipoprotein O
- O
virus O
hybrid O
lipoviroparticle B
( I
LVP I
) I
. O

In O
vitro O
studies O
have O
demonstrated O
the O
importance O
of O
apolipoproteins O
in O
HCV O
secretion O
and O
infectivity O
, O
leading O
to O
the O
notion O
that O
HCV O
coopts O
the O
secretion O
of O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
for O
its O
egress O
. O

The O
biogenesis O
of O
VLDL O
particles O
occurs O
in O
the O
endoplasmic B
reticulum I
( I
ER I
) I
, O
followed O
by O
subsequent O
lipidation O
in O
the O
ER O
and O
Golgi O
compartment O
. O

Biophysical O
characterization O
of O
COPII O
vesicles O
fractionated O
on O
an O
iodixanol O
gradient O
revealed O
that O
HCV O
RNA O
is O
enriched O
in O
the O
highly O
buoyant O
COPII O
vesicle O
fractions O
and O
cofractionates O
with O
apolipoprotein B
B I
( I
ApoB I
) I
, O
ApoE O
, O
and O
the O
HCV O
core O
and O
envelope O
proteins O
. O

Using O
immunoprecipitation O
of O
COPII O
vesicles O
and O
immuno O
- O
gold O
electron B
microscopy I
( I
EM I
) I
, O
we O
characterize O
the O
existence O
of O
LVPs O
that O
co O
- O
fractionate O
with O
lipoproteins O
, O
viral O
proteins O
, O
RNA O
, O
and O
vesicular O
components O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
is O
a O
global O
public O
health O
problem O
. O

In O
an O
effort O
toward O
discovery O
of O
novel O
antiviral O
agents O
against O
HBV O
, O
a O
group O
of O
benzamide O
( O
BA O
) O
derivatives O
that O
significantly O
reduced O
the O
amount O
of O
cytoplasmic O
HBV O
DNA O
were O
discovered O
. O

Interestingly O
, O
similar O
to O
our O
previously O
reported O
sulfamoylbenzamides B
( I
SBAs I
) I
, O
the O
BAs O
promote O
the O
formation O
of O
empty O
capsids O
through O
specific O
interaction O
with O
HBV O
core O
protein O
but O
not O
other O
viral O
and O
host O
cellular O
components O
. O

Genetic O
evidence O
suggested O
that O
both O
SBAs O
and O
BAs O
inhibited O
HBV O
nucleocapsid O
assembly O
by O
binding O
to O
the O
heteroaryldihydropyrimidine B
( I
HAP I
) I
pocket O
between O
core O
protein O
dimer O
- O
dimer O
interfaces O
. O

In O
addition O
to O
packaging O
viral O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
DNA O
polymerase O
complex O
into O
nucleocapsids O
for O
reverse O
transcriptional O
DNA O
replication O
to O
take O
place O
, O
the O
core O
protein O
dimers O
, O
existing O
in O
several O
different O
quaternary O
structures O
in O
infected O
hepatocytes O
, O
participate O
in O
and O
regulate O
HBV O
virion O
assembly O
, O
capsid O
uncoating O
, O
and O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
formation O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
requires O
multiple O
receptors O
for O
its O
attachment O
to O
and O
entry O
into O
cells O
. O

Our O
previous O
studies O
found O
that O
human O
syndecan B
- I
1 I
( I
SDC I
- I
1 I
) I
, O
SDC O
- O
2 O
, O
and O
T B
cell I
immunoglobulin I
and I
mucin I
domain I
- I
containing I
protein I
1 I
( I
TIM I
- I
1 I
) I
are O
HCV O
attachment O
receptors O
. O

Other O
cell O
surface O
molecules O
, O
such O
as O
CD81 O
, O
Claudin B
- I
1 I
( I
CLDN1 I
) I
, O
occludin B
( I
OCLN I
) I
, O
SR O
- O
BI O
, O
and O
low B
- I
density I
lipoprotein I
receptor I
( I
LDLr I
) I
, O
function O
mainly O
at O
postattachment O
steps O
and O
are O
considered O
postattachment O
receptors O
. O

In O
the O
present O
study O
, O
we O
used O
a O
clustered B
regularly I
interspaced I
short I
palindromic I
repeat I
( I
CRISPR I
) I
- O
Cas9 O
technology O
, O
gene O
- O
specific O
small O
interfering O
RNAs O
, O
and O
a O
newly O
developed O
luciferase O
- O
based O
reporter O
system O
to O
quantitatively O
determine O
the O
importance O
of O
individual O
receptors O
in O
HCV O
cell O
- O
free O
and O
cell O
- O
to O
- O
cell O
transmission O
. O

Additionally O
, O
apolipoprotein O
E O
was O
found O
to O
be O
important O
for O
HCV O
cell O
- O
to O
- O
cell O
spread O
, O
but O
very B
- I
low I
- I
density I
lipoprotein I
( I
VLDL I
) I
- O
containing O
mouse O
serum O
did O
not O
affect O
HCV O
cell O
- O
to O
- O
cell O
transmission O
, O
although O
it O
inhibited O
cell O
- O
free O
infection O
. O

Likewise O
, O
apolipoprotein B
E I
( I
ApoE I
) I
is O
critically O
important O
for O
HCV O
cell O
- O
to O
- O
cell O
spread O
, O
unlike O
VLDL O
- O
containing O
mouse O
serum O
, O
which O
did O
not O
affect O
HCV O
cell O
- O
to O
- O
cell O
spread O
. O

These O
findings O
suggest O
that O
the O
mechanism O
( O
s O
) O
of O
HCV O
cell O
- O
to O
- O
cell O
spread O
differs O
from O
that O
of O
cell O
- O
free O
infection O
. O

microRNAs B
( I
miRNAs I
) I
are O
a O
class O
of O
small O
, O
single O
- O
stranded O
, O
noncoding O
, O
functional O
RNAs O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
an O
enveloped O
DNA O
virus O
with O
virions O
and O
subviral O
forms O
of O
particles O
that O
lack O
a O
core O
. O

Here O
, O
we O
identified O
an O
HBV O
- O
encoded O
miRNA O
( O
called O
HBV O
- O
miR O
- O
3 O
) O
by O
deep O
sequencing O
and O
Northern O
blotting O
. O

HBV O
- O
miR O
- O
3 O
is O
located O
at O
nucleotides B
( I
nt I
) I
373 O
to O
393 O
of O
the O
HBV O
genome O
and O
was O
generated O
from O
3 O
. O

1 O
- O
kb O
HBV O
in O
a O
classic O
miRNA O
biogenesis O
( O
Drosha O
- O
Dicer O
- O
dependent O
) O
manner O
. O

5 O
- O
kb O
transcript O
to O
specifically O
reduce O
HBc O
protein O
expression O
, O
levels O
of O
pregenomic B
RNA I
( I
pgRNA I
) I
, O
and O
HBV B
replication I
intermediate I
( I
HBV I
- I
RI I
) I
generation O
but O
does O
not O
affect O
the O
HBV O
DNA O
polymerase O
level O
, O
thus O
suppressing O
HBV O
virion O
production O
( O
replication O
) O
. O

IMPORTANCE O
Hepatitis O
B O
is O
a O
liver O
infection O
caused O
by O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
that O
can O
become O
a O
long O
- O
term O
, O
chronic O
infection O
and O
lead O
to O
cirrhosis O
or O
liver O
cancer O
. O

microRNA B
( I
miRNA I
) I
, O
a O
small O
( O
similar O
to O
22 O
- O
nt O
) O
noncoding O
RNA O
, O
was O
recently O
found O
to O
be O
an O
important O
regulator O
of O
gene O
expression O
. O

We O
found O
that O
HBV O
encodes O
miRNA O
( O
HBV O
- O
miR O
- O
3 O
) O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
may O
cause O
acute O
hepatitis O
B O
, O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
liver O
cirrhosis O
, O
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Here O
, O
we O
revealed O
that O
matrix B
metalloproteinase I
9 I
( I
MMP I
- I
9 I
) I
is O
activated O
in O
Peripheral B
blood I
mononuclear I
cells I
( I
PBMCs I
) I
of O
HBV O
- O
infected O
patients O
, O
and O
HBV O
stimulates O
MMP O
- O
9 O
expression O
in O
macrophages O
and O
PBMCs O
isolated O
from O
healthy O
individuals O
. O

MMP O
- O
9 O
also O
regulates O
respiratory B
syncytial I
virus I
( I
RSV I
) I
replication O
, O
but O
the O
mechanism O
underlying O
such O
regulation O
is O
unknown O
. O

We O
further O
demonstrated O
that O
MMP O
- O
9 O
facilitates O
HBV O
replication O
by O
repressing O
the O
interferon B
( I
IFN I
) I
/ O
Janus B
kinase I
( I
JAK I
) I
/ O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
pathway O
, O
IFN O
action O
, O
STAT1 O
/ O
2 O
phosphorylation O
, O
and O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
expression O
. O

Moreover O
, O
MMP O
- O
9 O
binds O
to O
type O
I O
IFN B
receptor I
1 I
( I
IFNAR1 I
) I
and O
facilitates O
IFNAR1 O
phosphorylation O
, O
ubiquitination O
, O
subcellular O
distribution O
, O
and O
degradation O
to O
interfere O
with O
the O
binding O
of O
IFANR1 O
to O
IFN O
- O
gamma O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
may O
cause O
chronic B
hepatitis I
B I
( I
CHB I
) I
and O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

matrix B
metalloproteinase I
9 I
( I
MMP I
- I
9 I
) I
plays O
important O
roles O
in O
the O
facilitation O
of O
tumor O
progression O
, O
invasion O
, O
metastasis O
, O
and O
angiogenesis O
. O

Moreover O
, O
MMP O
- O
9 O
interacts O
with O
type O
I O
interferon B
receptor I
1 I
( I
IFNAR1 I
) I
to O
disturb O
the O
binding O
of O
IFN O
- O
gamma O
to O
IFNAR1 O
and O
facilitate O
the O
phosphorylation O
, O
ubiquitination O
, O
subcellular O
distribution O
, O
and O
degradation O
of O
IFNAR1 O
. O

The O
heterodimer O
formed O
by O
glycoproteins O
E1 O
and O
E2 O
within O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
lipid O
envelope O
is O
a O
potential O
vaccine O
candidate O
and O
antiviral O
target O
. O

Furthermore O
, O
a O
variety O
of O
additional O
experimental O
data O
is O
available O
to O
support O
computational O
predictions O
of O
E1 O
/ O
E2 O
structure O
, O
such O
as O
data O
from O
antibody O
binding O
studies O
, O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
, O
mutational O
analyses O
, O
peptide O
binding O
analysis O
, O
linker O
- O
scanning O
mutagenesis O
, O
and O
Nuclear B
magnetic I
resonance I
( I
NMR I
) I
studies O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E2 O
is O
the O
major O
target O
of O
broadly O
neutralizing O
antibodies O
in O
vivo O
and O
is O
the O
focus O
of O
efforts O
in O
the O
rational O
design O
of O
a O
universal O
B O
cell O
vaccine O
against O
HCV O
. O

The O
E2 O
glycoprotein O
exhibits O
a O
high O
degree O
of O
amino O
acid O
variability O
which O
localizes O
to O
three O
discrete O
regions O
: O
hypervariable B
region I
1 I
( I
HVR1 I
) I
, O
hypervariable B
region I
2 I
( I
HVR2 I
) I
, O
and O
the O
intergenotypic B
variable I
region I
( I
IgVR I
) I
. O

To O
obtain O
further O
information O
on O
E2 O
, O
we O
characterized O
the O
role O
of O
all O
three O
variable O
regions O
in O
E2 O
ectodomain O
folding O
and O
function O
in O
the O
context O
of O
a O
recombinant B
ectodomain I
fragment I
( I
rE2 I
) I
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
affects O
similar O
to O
2 O
% O
of O
the O
population O
globally O
, O
and O
no O
vaccine O
is O
available O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
encodes O
a O
multifunction O
reverse O
transcriptase O
or O
polymerase B
( I
P I
) I
, O
which O
is O
composed O
of O
several O
domains O
. O

The O
terminal B
protein I
( I
TP I
) I
domain O
is O
unique O
to O
HBV O
and O
related O
hepadnaviruses O
and O
is O
required O
for O
specifically O
binding O
to O
the O
viral O
pregenomic B
RNA I
( I
pgRNA I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infects O
2 O
to O
3 O
% O
of O
the O
world O
population O
and O
is O
a O
leading O
cause O
of O
liver O
diseases O
such O
as O
fibrosis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

Among O
these O
assays O
, O
the O
HCV B
- I
dependent I
fluorescence I
relocalization I
( I
HDFR I
) I
system O
allowed O
live O
- O
cell O
visualization O
of O
infection O
without O
modifying O
the O
viral O
genome O
, O
but O
this O
strategy O
required O
careful O
recognition O
of O
the O
fluorescence O
relocalization O
pattern O
for O
its O
high O
fluorescence O
background O
in O
the O
cytoplasm O
. O

In O
this O
study O
, O
to O
achieve O
background O
- O
free O
visualization O
of O
HCV O
infection O
, O
a O
viral B
infection I
- I
activated I
split I
- I
intein I
- I
mediated I
reporter I
system I
( I
VISI I
) I
was O
devised O
. O

1 O
- O
VISI O
cells O
with O
either O
green B
fluorescent I
protein I
( I
GFP I
) I
or O
mCherry O
. O

Additionally O
, O
depletion O
of O
apolipoprotein B
E I
( I
ApoE I
) I
from O
donor O
cells O
but O
not O
from O
recipient O
cells O
significantly O
reduced O
HCV O
cell O
- O
to O
- O
cell O
transmission O
efficiency O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
infects O
hepatocytes O
via O
two O
pathways O
: O
cell O
- O
free O
infection O
and O
cell O
- O
to O
- O
cell O
transmission O
. O

While O
natural O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
results O
in O
highly O
diverse O
quasispecies O
of O
related O
viruses O
over O
time O
, O
mutations O
accumulate O
more O
slowly O
in O
tissue O
culture O
, O
in O
part O
because O
of O
the O
inefficiency O
of O
replication O
in O
cells O
. O

We O
evaluated O
these O
mutants O
for O
changes O
in O
particle O
- O
to O
- O
infectious O
- O
unit O
ratio O
, O
sensitivity O
to O
neutralizing O
antibody O
or O
CD81 B
large I
extracellular I
loop I
( I
CD81 I
- I
LEL I
) I
inhibition O
, O
entry O
factor O
usage O
, O
and O
buoyant O
density O
profiles O
. O

Remarkably O
, O
all O
nine O
variants O
showed O
reduced O
dependence O
on O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
for O
infection O
. O

In O
a O
high O
- O
throughput O
screening O
campaign O
, O
we O
identified O
an O
acetic O
acid O
benzodiazepine O
( O
BDAA O
) O
compound O
which O
potently O
inhibits O
yellow B
fever I
virus I
( I
YFV I
) I
. O

Selection O
and O
genetic O
analysis O
of O
drug O
- O
resistant O
viruses O
revealed O
that O
replacement O
of O
the O
proline O
at O
amino O
acid O
219 O
( O
P219 O
) O
of O
the O
Nonstructural B
protein I
4B I
( I
NS4B I
) I
with O
serine O
, O
threonine O
, O
or O
alanine O
conferred O
YFV O
with O
resistance O
to O
BDAA O
without O
apparent O
loss O
of O
replication O
fitness O
in O
cultured O
mammalian O
cells O
. O

Tumor B
necrosis I
factor I
receptor I
( I
TNFR I
) I
- O
associated O
factor O
6 O
( O
TRAF6 O
) O
is O
an O
important O
adaptor O
molecule O
that O
mediates O
the O
TNFR O
family O
and O
interleukin B
- I
1 I
( I
IL I
- I
1 I
) I
/ O
Toll B
- I
like I
receptor I
( I
TLR I
) I
signaling O
cascades O
. O

In O
this O
report O
, O
we O
demonstrated O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
depleted O
TRAF6 O
from O
its O
host O
cells O
through O
a O
posttranslational O
mechanism O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
cause O
of O
liver O
diseases O
, O
including O
hepatocellular B
carcinoma I
( I
HCC I
) I
, O
and O
more O
than O
650 O
, O
000 O
people O
die O
annually O
due O
to O
HBV O
- O
associated O
liver O
failure O
. O

Here O
, O
we O
provide O
a O
comprehensive O
map O
of O
HBV O
transcription B
start I
sites I
( I
TSSs I
) I
in O
human O
liver O
, O
HCC O
, O
and O
blood O
, O
as O
well O
as O
several O
experimental O
replication O
systems O
, O
at O
a O
single O
- O
nucleotide O
resolution O
. O

Using O
CAGE B
( I
cap I
analysis I
of I
gene I
expression I
) I
analysis O
of O
16 O
HCC O
/ O
nontumor O
liver O
pairs O
, O
we O
identify O
17 O
robust O
TSSs O
, O
including O
a O
novel O
promoter O
for O
the O
X O
gene O
located O
in O
the O
middle O
of O
the O
gene O
body O
, O
which O
potentially O
produces O
a O
shorter O
X O
protein O
translated O
from O
the O
conserved O
second O
start O
codon O
, O
and O
two O
minor O
antisense O
transcripts O
that O
might O
represent O
viral O
noncoding O
RNAs O
. O

We O
deeply O
sequenced O
the O
HBV O
RNA5 O
' O
ends O
in O
clinical O
human O
samples O
and O
experimental O
models O
by O
using O
a O
new O
, O
sensitive O
and O
quantitative O
method O
termed O
cap B
analysis I
of I
gene I
expression I
( I
CAGE I
) I
. O

HBx O
, O
a O
small O
regulatory O
protein O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
augments O
viral O
DNA O
replication O
by O
stimulating O
viral O
transcription O
. O

Here O
, O
using O
a O
hepatitis B
C I
virus I
( I
HCV I
) I
cell O
culture O
system O
, O
we O
identified O
neoechinulin B
B I
( I
NeoB I
) I
, O
a O
fungus O
- O
derived O
compound O
, O
as O
an O
inhibitor O
of O
the O
liver B
X I
receptor I
( I
LXR I
) I
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
highly O
dependent O
on O
host O
factors O
for O
efficient O
replication O
. O

Our O
results O
identified O
neoechinulin B
B I
( I
NeoB I
) I
as O
a O
novel O
inhibitor O
of O
the O
liver B
X I
receptor I
( I
LXR I
) I
. O

Under O
physiological O
conditions O
, O
the O
Liver B
sinusoidal I
endothelial I
cells I
( I
LSECs I
) I
mediate O
hepatic O
immune O
tolerance O
toward O
self O
or O
foreign O
antigens O
through O
constitutive O
expression O
of O
anti O
- O
inflammatory O
mediators O
. O

However O
, O
upon O
viral O
infection O
or O
Toll B
- I
like I
receptor I
2 I
( I
TLR2 I
) I
activation O
, O
LSECs O
can O
achieve O
proinflammatory O
functions O
, O
but O
their O
role O
in O
hepatic O
inflammation O
during O
acute O
viral O
hepatitis O
is O
unknown O
. O

Using O
the O
highly O
virulent O
mouse B
hepatitis I
virus I
type I
3 I
( I
MHV3 I
) I
and O
the O
attenuated O
variants O
51 O
. O

Such O
hepatic O
inflammatory O
disorders O
correlated O
with O
disturbed O
production O
of O
interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
and O
vascular O
factors O
by O
LSECs O
. O

Liver B
sinusoidal I
endothelial I
cells I
( I
LSECs I
) I
can O
express O
both O
anti O
- O
and O
proinflammatory O
functions O
, O
but O
their O
role O
in O
acute O
viral O
hepatitis O
has O
never O
been O
investigated O
. O

Using O
mouse B
hepatitis I
virus I
( I
MHV I
) I
infections O
as O
animal O
models O
of O
viral O
hepatitis O
, O
we O
report O
for O
the O
first O
time O
that O
in O
vitro O
and O
in O
vivo O
infection O
of O
LSECs O
by O
the O
pathogenic O
MHV3 O
serotype O
leads O
to O
a O
reversion O
of O
their O
intrinsic O
anti O
- O
inflammatory O
phenotype O
toward O
a O
proinflammatory O
profile O
as O
well O
to O
as O
disorders O
in O
vascular O
factors O
, O
correlating O
with O
the O
severity O
of O
hepatitis O
. O

Exchangeable O
apolipoproteins O
( O
ApoA O
, O
- O
C O
, O
and O
- O
E O
) O
have O
been O
shown O
to O
redundantly O
participate O
in O
the O
formation O
of O
infectious O
hepatitis B
C I
virus I
( I
HCV I
) I
particles O
during O
the O
assembly O
process O
, O
although O
their O
precise O
role O
in O
the O
viral O
life O
cycle O
is O
not O
well O
understood O
. O

Recently O
, O
it O
was O
shown O
that O
the O
exogenous O
expression O
of O
only O
short O
sequences O
containing O
amphipathic O
alpha O
- O
helices O
from O
various O
apolipoproteins O
is O
sufficient O
to O
restore O
the O
formation O
of O
infectious O
HCV O
particles O
in O
ApoB O
and O
ApoE O
double O
- O
gene O
- O
knockout O
Huh7 O
( O
BE O
- O
KO O
) O
cells O
. O

In O
this O
study O
, O
through O
the O
expression O
of O
a O
small O
library O
of O
human O
secretory O
proteins O
containing O
amphipathic O
alpha O
- O
helix O
structures O
, O
we O
identified O
the O
human O
cathelicidin O
antimicrobial O
peptide O
( O
CAMP O
) O
, O
the O
only O
known O
member O
of O
the O
cathelicidin O
family O
of O
antimicrobial B
peptides I
( I
AMPs I
) I
in O
humans O
and O
expressed O
mainly O
in O
bone O
marrow O
and O
leukocytes O
. O

In O
chronic B
hepatitis I
B I
( I
CHB I
) I
, O
failure O
to O
control O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
associated O
with O
T O
cell O
dysfunction O
. O

To O
date O
, O
the O
tolerant O
state O
of O
CD8 O
( O
+ O
) O
T O
cells O
in O
these O
animals O
could O
be O
altered O
only O
by O
strong O
immunogens O
or O
by O
immunization O
with O
HBV O
antigen O
- O
pulsed O
dendritic O
cells O
; O
however O
, O
the O
effectors O
induced O
were O
unable O
to O
suppress O
viral O
gene O
expression O
or O
replication O
. O

Because O
of O
the O
known O
stimulatory O
properties O
of O
alpha B
interferon I
( I
IFN I
- I
alpha I
) I
and O
interleukin B
- I
15 I
( I
IL I
- I
15 I
) I
, O
this O
study O
explored O
the O
therapeutic O
potential O
of O
liver O
- O
directed O
gene O
transfer O
of O
these O
cytokines O
in O
a O
murine O
model O
of O
CHB O
using O
adeno B
- I
associated I
virus I
( I
AAV I
) I
delivery O
. O

This O
combination O
not O
only O
resulted O
in O
a O
reduction O
in O
the O
viral O
load O
in O
the O
liver O
and O
the O
induction O
of O
an O
antibody O
response O
but O
also O
gave O
rise O
to O
functional O
and O
specific O
CD8 O
( O
+ O
) O
immunity O
. O

Hence O
, O
we O
demonstrated O
synergy O
between O
two O
stimulating O
cytokines O
, O
IL O
- O
15 O
and O
IFN O
- O
alpha O
, O
which O
, O
given O
together O
, O
constitute O
a O
potent O
approach O
to O
significantly O
enhance O
the O
CD8 O
( O
+ O
) O
T O
cell O
response O
in O
a O
state O
of O
immune O
hyporesponsiveness O
. O

IMPORTANCE O
With O
350 O
million O
people O
affected O
worldwide O
and O
600 O
, O
000 O
annual O
deaths O
due O
to O
HBV O
- O
induced O
liver O
cirrhosis O
and O
/ O
or O
hepatocellular O
carcinoma O
, O
chronic B
hepatitis I
B I
( I
CHB I
) I
is O
a O
major O
health O
problem O
. O

A O
lack O
of O
immunocompetent O
- O
small O
- O
primate O
models O
has O
been O
an O
obstacle O
for O
developing O
hepatitis B
C I
virus I
( I
HCV I
) I
vaccines O
and O
affordable O
antiviral O
drugs O
. O

In O
this O
study O
, O
HCV O
/ O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
chimeric O
virus O
carrying O
the O
major O
nonstructural O
proteins O
NS2 O
to O
NS4A O
( O
HCV O
NS2 O
to O
- O
4A O
chimera O
) O
was O
produced O
and O
used O
to O
infect O
common O
marmosets O
, O
since O
HCV O
NS2 O
to O
NS4A O
proteins O
are O
critical O
proteases O
and O
major O
antigens O
. O

Three O
animals O
used O
as O
controls O
were O
injected O
with O
phosphate B
- I
buffered I
saline I
( I
PBS I
) I
or O
GBV O
- O
B O
, O
respectively O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
is O
a O
flavivirus O
related O
to O
HCV O
. O

Hepadnaviruses O
( O
hepatitis O
B O
viruses O
[ O
HBVs O
] O
) O
are O
the O
only O
animal O
viruses O
that O
replicate O
their O
DNA O
by O
reverse O
transcription O
of O
an O
RNA O
intermediate O
. O

Bluegill B
hepadnavirus I
( I
BGHBV I
) I
was O
characterized O
from O
in O
- O
house O
viral O
metagenomic O
sequencing O
. O

The O
African B
cichlid I
hepadnavirus I
( I
ACHBV I
) I
and O
the O
Tibetan B
frog I
hepadnavirus I
( I
TFHBV I
) I
were O
discovered O
using O
in O
silico O
analyses O
of O
the O
whole O
- O
genome O
shotgun O
and O
transcriptome O
shotgun O
assembly O
databases O
. O

Residues O
in O
the O
hydrophobic O
base O
of O
the O
capsid O
( O
core O
) O
proteins O
, O
designated O
motifs O
I O
, O
II O
, O
and O
III O
, O
are O
highly O
conserved O
, O
suggesting O
that O
structural O
constraints O
for O
proper O
capsid O
folding O
are O
key O
to O
capsid O
protein O
evolution O
. O

IMPORTANCE O
Hepadnaviruses O
are O
responsible O
for O
significant O
disease O
in O
humans O
( O
hepatitis O
B O
virus O
) O
and O
have O
been O
reported O
from O
a O
diverse O
range O
of O
vertebrates O
as O
both O
exogenous O
and O
endogenous O
viruses O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
can O
cause O
chronic O
liver O
disease O
, O
which O
is O
associated O
with O
increased O
risk O
of O
liver O
cirrhosis O
, O
liver O
failure O
, O
and O
liver O
cancer O
. O

dendritic B
cells I
( I
DC I
) I
play O
a O
pivotal O
role O
in O
the O
regulation O
of O
antiviral O
immunity O
. O

Here O
, O
we O
investigated O
the O
interaction O
between O
HBV B
surface I
antigen I
( I
HBsAg I
) I
, O
the O
main O
envelope O
glycoprotein O
of O
HBV O
, O
and O
BDCA1 O
( O
+ O
) O
myeloid B
dendritic I
cells I
( I
mDC I
) I
. O

Exposure O
of O
peripheral O
blood O
- O
derived O
BDCA1 O
( O
+ O
) O
mDC O
to O
HBsAg O
resulted O
in O
strong O
DC O
maturation O
, O
cytokine O
production O
, O
and O
enhanced O
capacity O
to O
activate O
antigen O
- O
specific O
cytotoxic B
T I
cells I
( I
CTLs I
) I
. O

By O
using O
neutralizing O
antibodies O
, O
crucial O
roles O
for O
CD14 O
and O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
in O
HBsAg O
- O
mediated O
BDCA1 O
( O
+ O
) O
mDC O
maturation O
were O
identified O
. O

Concordantly O
, O
HBsAg O
- O
mediated O
DC O
maturation O
required O
fetal B
calf I
serum I
( I
FCS I
) I
or O
human O
plasma O
, O
naturally O
containing O
soluble B
CD14 I
( I
sCD14 I
) I
. O

A O
direct O
interaction O
between O
sCD14 O
and O
HBsAg O
was O
demonstrated O
by O
using O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
. O

The O
abundance O
of O
sCD14 O
- O
HBsAg O
complexes O
varied O
between O
chronic O
HBV O
disease O
stages O
and O
correlated O
with O
activation O
of O
BDCA1 O
( O
+ O
) O
mDC O
in O
vivo O
. O

We O
conclude O
that O
HBsAg O
activates O
BDCA1 O
( O
+ O
) O
DC O
via O
an O
sCD14 O
- O
dependent O
mechanism O
. O

In O
this O
study O
, O
we O
show O
that O
the O
HIV O
- O
1 O
Tat O
protein O
interacts O
with O
rapid O
kinetics O
to O
engage O
the O
Toll B
- I
like I
receptor I
4 I
( I
TLR4 I
) I
pathway O
, O
leading O
to O
the O
production O
of O
proinflammatory O
and O
anti O
- O
inflammatory O
cytokines O
. O

The O
pretreatment O
of O
human O
monocytes O
with O
Tat O
protein O
for O
10 O
to O
30 O
min O
suffices O
to O
irreversibly O
engage O
the O
activation O
of O
the O
TLR4 O
pathway O
, O
leading O
to O
the O
production O
of O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
and O
interleukin B
- I
10 I
( I
IL I
- I
10 I
) I
, O
two O
cytokines O
strongly O
implicated O
in O
the O
chronic O
activation O
and O
dysregulation O
of O
the O
immune O
system O
during O
HIV O
- O
1 O
infection O
. O

Using O
three O
complementary O
approaches O
, O
including O
mice O
deficient O
in O
the O
MyD88 O
, O
TIRAP O
/ O
MAL O
, O
or O
TRIF O
adaptor O
, O
biochemical O
analysis O
, O
and O
the O
use O
of O
specific O
small B
interfering I
RNAs I
( I
siRNAs I
) I
, O
we O
demonstrated O
( O
i O
) O
that O
Tat O
was O
able O
to O
activate O
both O
the O
MyD88 O
and O
TRIF O
pathways O
, O
( O
ii O
) O
the O
capacity O
of O
Tat O
to O
induce O
TIRAP O
/ O
MAL O
degradation O
, O
( O
iii O
) O
the O
crucial O
role O
of O
the O
MyD88 O
pathway O
in O
the O
production O
of O
Tat O
- O
induced O
TNF O
- O
alpha O
and O
IL O
- O
10 O
, O
( O
iv O
) O
a O
reduction O
but O
not O
abrogation O
of O
IL O
- O
10 O
and O
TNF O
- O
alpha O
by O
Tat O
- O
stimulated O
macrophages O
from O
mice O
deficient O
in O
TIRAP O
/ O
MAL O
, O
and O
( O
v O
) O
the O
crucial O
role O
of O
the O
TRIF O
pathway O
in O
Tat O
- O
induced O
IL O
- O
10 O
production O
. O

Further O
, O
we O
showed O
that O
downstream O
of O
the O
MyD88 O
and O
TRIF O
pathways O
, O
the O
Tat O
protein O
activated O
the O
protein B
kinase I
C I
( I
PKC I
) I
beta O
II O
isoform O
, O
the O
mitogen B
- I
activated I
protein I
( I
MAP I
) I
kinases O
p38 O
and O
extracellular B
signal I
- I
regulated I
kinase I
1 I
/ I
2 I
( I
ERK1 I
/ I
2 I
) I
, O
and O
NF O
- O
kappa O
B O
in O
a O
TLR4 O
- O
dependent O
manner O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
triggers O
innate O
immunity O
signaling O
in O
the O
infected O
cell O
. O

Replication O
of O
the O
viral O
genome O
is O
dispensable O
for O
this O
phenotype O
, O
and O
we O
along O
with O
others O
have O
recently O
shown O
that O
NS5B O
, O
the O
viral O
RNA O
- O
dependent O
RNA O
polymerase O
, O
synthesizes O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
from O
cellular O
templates O
, O
thus O
eliciting O
an O
inflammatory O
response O
, O
notably O
via O
activation O
of O
type O
I O
interferon O
and O
lymphotoxin O
beta O
. O

Using O
HepaRG O
cells O
, O
a O
model O
that O
largely O
recapitulates O
the O
in O
vivo O
complexities O
of O
the O
innate O
immunity O
receptor O
signaling O
, O
we O
have O
confirmed O
that O
NS5B O
triggered O
increased O
expression O
of O
the O
canonical O
pattern B
recognition I
receptors I
( I
PRRs I
) I
specific O
for O
dsRNA O
, O
namely O
, O
RIG O
- O
I O
, O
MDA5 O
, O
and O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
. O

NOD1 O
activation O
, O
confirmed O
by O
analysis O
of O
its O
downstream O
targets O
, O
was O
likely O
due O
to O
its O
interaction O
with O
dsRNA O
and O
was O
independent O
of O
RIG O
- O
I O
and O
mitochondrial O
antiviral O
signaling O
protein O
( O
MAVS O
/ O
IPS O
- O
1 O
/ O
Cardif O
/ O
VISA O
) O
signaling O
. O

Inflammation O
may O
be O
maladaptive O
to O
the O
control O
of O
viral O
infection O
when O
it O
impairs O
interferon B
( I
IFN I
) I
responses O
, O
enhancing O
viral O
replication O
and O
spread O
. O

Dysregulated O
immunity O
as O
a O
result O
of O
inappropriate O
innate O
inflammatory O
responses O
is O
a O
hallmark O
of O
chronic O
viral O
infections O
such O
as O
, O
hepatitis O
B O
virus O
and O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

Previous O
studies O
from O
our O
laboratory O
have O
shown O
that O
expression O
of O
an O
IFN B
- I
stimulated I
gene I
( I
ISG I
) I
, O
ubiquitin B
- I
like I
protease I
( I
USP I
) I
18 O
is O
upregulated O
in O
chronic O
HCV O
infection O
, O
leading O
to O
impaired O
hepatocyte O
responses O
to O
IFN O
- O
alpha O
. O

We O
examined O
the O
ability O
of O
inflammatory O
stimuli O
, O
including O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
, O
lipopolysaccharide B
( I
LPS I
) I
, O
interleukin B
- I
6 I
( I
IL I
- I
6 I
) I
and O
IL O
- O
10 O
to O
upregulate O
hepatocyte O
USP18 O
expression O
and O
blunt O
the O
IFN O
- O
alpha O
response O
. O

Human O
hepatoma O
cells O
and O
primary O
murine O
hepatocytes O
were O
treated O
with O
TNF O
- O
alpha O
/ O
LPS O
/ O
IL O
- O
6 O
/ O
IL O
- O
10 O
and O
USP18 O
, O
phosphorylated O
( O
p O
) O
- O
STAT1 O
and O
myxovirus O
( O
influenza O
virus O
) O
resistance O
1 O
( O
Mx1 O
) O
expression O
was O
determined O
. O

These O
data O
demonstrate O
that O
certain O
inflammatory O
stimuli O
( O
TNF O
- O
alpha O
and O
LPS O
) O
but O
not O
others O
( O
IL O
- O
6 O
and O
IL O
- O
10 O
) O
target O
USP18 O
expression O
and O
thus O
inhibit O
IFN O
signaling O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
enters O
hepatocytes O
via O
its O
receptor O
, O
human B
sodium I
taurocholate I
cotransporting I
polypeptide I
( I
hNTCP I
) I
. O

Here O
, O
the O
first O
mouse O
liver O
cell O
line O
( O
AML12 O
) O
which O
gains O
susceptibility O
to O
HBV O
upon O
hNTCP O
expression O
is O
described O
. O

Subviral O
particles O
form O
spheres O
( O
22 O
- O
nm O
particles O
) O
and O
filaments O
. O

Filaments O
contain O
a O
much O
larger O
amount O
of O
the O
large B
surface I
protein I
( I
LHBs I
) I
compared O
to O
spheres O
. O

Spheres O
are O
released O
via O
the O
constitutive O
secretory O
pathway O
, O
while O
viral O
particles O
are O
ESCRT O
- O
dependently O
released O
via O
multivesicular B
bodies I
( I
MVBs I
) I
. O

Inhibition O
of O
MVB O
biogenesis O
by O
the O
small O
- O
molecule O
inhibitor O
U18666A O
or O
inhibition O
of O
ESCRT O
functionality O
by O
coexpression O
of O
transdominant O
negative O
mutants O
( O
Vps4A O
, O
Vps4B O
, O
and O
CHMP3 O
) O
abolishes O
the O
release O
of O
filaments O
while O
the O
secretion O
of O
spheres O
is O
not O
affected O
. O

Geminiviruses O
are O
important O
plant O
pathogens O
characterized O
by O
circular O
, O
single B
- I
stranded I
DNA I
( I
ssDNA I
) I
genomes O
. O

However O
, O
in O
the O
nuclei O
of O
infected O
cells O
, O
viral O
double B
- I
stranded I
DNA I
( I
dsDNA I
) I
associates O
with O
host O
histones O
to O
form O
a O
minichromosome O
. O

Nevertheless O
, O
geminiviruses O
are O
both O
inducers O
and O
targets O
of O
the O
host O
posttranscriptional O
gene O
silencing O
( O
PTGS O
) O
and O
Transcriptional B
gene I
silencing I
( I
TGS I
) I
machinery O
. O

We O
have O
previously O
characterized O
a O
recovery O
phenomenon O
observed O
in O
pepper O
plants O
infected O
with O
Pepper B
golden I
mosaic I
virus I
( I
PepGMV I
) I
that O
is O
associated O
with O
a O
reduction O
of O
viral O
DNA O
and O
RNA O
levels O
, O
the O
presence O
of O
virus O
- O
related O
siRNAs O
, O
and O
an O
increase O
in O
the O
levels O
of O
viral O
DNA O
methylation O
. O

After O
further O
purification O
using O
sucrose O
gradient O
sedimentation O
, O
we O
also O
observed O
that O
minichromosomes O
isolated O
from O
symptomatic O
tissue O
showed O
a O
relaxed O
conformation O
( O
based O
on O
their O
sedimentation O
rate O
) O
, O
are O
associated O
with O
a O
chromatin O
activation O
marker O
( O
H3K4me3 O
) O
, O
and O
present O
a O
low O
level O
of O
DNA O
methylation O
. O

The O
minichromosome O
population O
obtained O
from O
recovered O
tissue O
, O
on O
the O
other O
hand O
, O
sedimented O
as O
a O
compact O
structure O
, O
is O
associated O
with O
a O
chromatin O
- O
repressive O
marker O
( O
H3K9me2 O
) O
, O
and O
presents O
a O
high O
level O
of O
DNA O
methylation O
. O

Attrition O
within O
the O
CD4 O
( O
+ O
) O
T O
cell O
compartment O
, O
high O
viremia O
, O
and O
a O
cytokine O
storm O
characterize O
the O
early O
days O
after O
HIV O
infection O
. O

When O
the O
first O
emerging O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
gain O
control O
over O
viral O
replication O
it O
is O
incomplete O
, O
and O
clearance O
of O
HIV O
infection O
is O
not O
achieved O
even O
in O
the O
rare O
cases O
of O
individuals O
who O
spontaneously O
control O
viral O
replication O
to O
nearly O
immeasurably O
low O
levels O
. O

Thus O
, O
despite O
their O
partial O
ability O
to O
control O
viremia O
, O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
are O
insufficient O
to O
clear O
HIV O
infection O
. O

Studying O
individuals O
in O
the O
first O
few O
days O
of O
acute O
HIV O
infection O
, O
we O
detected O
the O
emergence O
of O
a O
unique O
population O
of O
CD38 O
( O
+ O
) O
CD27 O
- O
CD8 O
( O
+ O
) O
T O
cells O
characterized O
by O
the O
low O
expression O
of O
the O
CD8 O
receptor O
( O
CD8 O
( O
dim O
) O
) O
. O

Interestingly O
, O
while O
high O
frequencies O
of O
HIV O
- O
specific O
CD8 O
( O
+ O
) O
T O
cell O
responses O
occur O
within O
the O
CD38 O
( O
+ O
) O
CD27 O
( O
- O
) O
CD8 O
( O
dim O
) O
T O
cell O
population O
, O
the O
minority O
populations O
of O
CD8 O
( O
bright O
) O
T O
cells O
are O
significantly O
more O
effective O
in O
inhibiting O
HIV O
replication O
. O

Furthermore O
, O
the O
frequency O
of O
CD8 O
( O
dim O
) O
T O
cells O
directly O
correlates O
with O
viral O
load O
and O
clinical O
predictors O
of O
more O
rapid O
disease O
progression O
. O

We O
found O
that O
a O
canonical O
burst O
of O
proliferative O
cytokines O
coincides O
with O
the O
emergence O
of O
CD8 O
( O
dim O
) O
T O
cells O
, O
and O
the O
size O
of O
this O
population O
inversely O
correlates O
with O
the O
acute O
loss O
of O
CD4 O
( O
+ O
) O
T O
cells O
. O

These O
data O
indicate O
, O
for O
the O
first O
time O
, O
that O
early O
CD4 O
( O
+ O
) O
T O
cell O
loss O
coincides O
with O
the O
expansion O
of O
a O
functionally O
impaired O
HIV O
- O
specific O
CD8 O
( O
dim O
) O
T O
cell O
population O
less O
efficient O
in O
controlling O
HIV O
viremia O
. O

IMPORTANCE O
A O
distinct O
population O
of O
activated O
CD8 O
( O
+ O
) O
T O
cells O
appears O
during O
acute O
HIV O
infection O
with O
diminished O
capacity O
to O
inhibit O
HIV O
replication O
and O
is O
predictive O
of O
viral O
set O
point O
, O
offering O
the O
first O
immunologic O
evidence O
of O
CD8 O
( O
+ O
) O
T O
cell O
dysfunction O
during O
acute O
infection O
. O

Despite O
significant O
advances O
in O
the O
treatment O
of O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
, O
the O
need O
to O
develop O
preventative O
vaccines O
remains O
. O

Full O
- O
length O
E1E2 O
clones O
were O
PCR O
amplified O
from O
patient O
- O
derived O
serum O
samples O
, O
cloned O
into O
an O
expression O
vector O
, O
and O
used O
to O
generate O
viral O
pseudoparticles O
( O
HCVpp O
) O
. O

In O
addition O
, O
some O
of O
these O
clones O
were O
used O
to O
generate O
cell O
culture O
infectious O
( O
HCVcc O
) O
clones O
. O

Though O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
core O
protein O
is O
an O
important O
participant O
in O
many O
aspects O
of O
the O
viral O
life O
cycle O
, O
its O
best O
- O
characterized O
activity O
is O
self O
- O
assembly O
into O
240 O
- O
monomer O
capsids O
. O

Small O
molecules O
that O
target O
core O
protein O
( O
core O
protein O
allosteric O
modulators O
[ O
CpAMs O
] O
) O
represent O
a O
promising O
antiviral O
strategy O
. O

core B
protein I
allosteric I
modulators I
( I
CpAMs I
) I
are O
an O
experimental O
class O
of O
antivirals O
that O
bind O
core O
protein O
. O

Individuals O
chronically O
infected O
with O
hepatitis B
C I
virus I
( I
HCV I
) I
commonly O
exhibit O
hepatic O
intracellular O
lipid O
accumulation O
, O
termed O
steatosis O
. O

We O
have O
recently O
identified O
a O
liver O
protein O
, O
the O
cell B
death I
- I
inducing I
DFFA I
- I
like I
effector I
b I
( I
CIDEB I
) I
, O
as O
an O
HCV O
entry O
host O
dependence O
factor O
that O
is O
downregulated O
by O
HCV O
infection O
in O
a O
cell O
culture O
model O
. O

HCV O
infection O
in O
a O
mouse O
model O
downregulated O
CIDEB O
in O
the O
liver O
tissue O
, O
and O
knockout O
of O
the O
CIDEB O
gene O
in O
a O
hepatoma O
cell O
line O
results O
in O
multiple O
aspects O
of O
lipid O
dysregulation O
that O
can O
contribute O
to O
hepatic O
steatosis O
, O
including O
reduced O
triglyceride O
secretion O
, O
lower O
lipidation O
of O
very O
- O
low O
- O
density O
lipoproteins O
, O
and O
increased O
lipid B
droplet I
( I
LD I
) I
stability O
. O

High B
- I
mobility I
group I
box I
1 I
( I
HMGB1 I
) I
protein O
is O
a O
highly O
conserved O
nuclear O
protein O
involved O
in O
multiple O
human O
diseases O
, O
including O
infectious O
diseases O
, O
immune O
disorders O
, O
metabolic O
disorders O
, O
and O
cancer O
. O

HMGB1 O
is O
comprised O
of O
two O
tandem O
HMG O
boxes O
( O
the O
A O
box O
and O
the O
B O
box O
) O
containing O
DNA O
- O
binding O
domains O
and O
an O
acidic O
C O
- O
terminal O
peptide O
. O

However O
, O
its O
role O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
replication O
is O
unknown O
. O

Moreover O
, O
the O
A O
box O
of O
HMGB1 O
is O
the O
pivotal O
domain O
to O
interact O
with O
stem B
- I
loop I
4 I
( I
SL4 I
) I
of O
the O
HCV O
5 O
' O
untranslated O
region O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
global O
health O
threat O
, O
affecting O
more O
than O
170 O
million O
people O
infection O
worldwide O
. O

Arbidol B
( I
ARB I
) I
is O
a O
synthetic O
antiviral O
originally O
developed O
to O
combat O
influenza O
viruses O
. O

We O
have O
previously O
shown O
that O
ARB O
inhibits O
in O
vitro O
hepatitis B
C I
virus I
( I
HCV I
) I
by O
blocking O
HCV O
entry O
and O
replication O
. O

In O
this O
report O
, O
we O
expand O
the O
list O
of O
viruses O
that O
are O
inhibited O
by O
ARB O
and O
demonstrate O
that O
ARB O
suppresses O
in O
vitro O
infection O
of O
mammalian O
cells O
with O
Ebola B
virus I
( I
EBOV I
) I
, O
Tacaribe O
arenavirus O
, O
and O
human B
herpesvirus I
8 I
( I
HHV I
- I
8 I
) I
. O

Experiments O
with O
recombinant O
vesicular B
stomatitis I
virus I
( I
VSV I
) I
expressing O
the O
EBOV O
Zaire O
glycoprotein O
showed O
that O
infection O
was O
inhibited O
by O
ARB O
at O
early O
stages O
, O
most O
likely O
at O
the O
level O
of O
viral O
entry O
into O
host O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
has O
been O
implicated O
as O
a O
potential O
trigger O
of O
hepatic O
steatosis O
although O
molecular O
mechanisms O
involved O
in O
the O
pathogenesis O
of O
HBV O
- O
associated O
hepatic O
steatosis O
still O
remain O
elusive O
. O

Our O
prior O
work O
has O
revealed O
that O
the O
expression O
level O
of O
liver O
fatty B
acid I
binding I
protein I
1 I
( I
FABP1 I
) I
, O
a O
key O
regulator O
of O
hepatic O
lipid O
metabolism O
, O
was O
elevated O
in O
HBV O
- O
producing O
hepatoma O
cells O
. O

In O
this O
study O
, O
the O
effects O
of O
HBV B
X I
protein I
( I
HBx I
) I
mediated O
FABP1 O
regulation O
on O
hepatic O
steatosis O
and O
the O
underlying O
mechanism O
were O
determined O
. O

mRNA O
and O
protein O
levels O
of O
FABP1 O
were O
measured O
by O
quantitative B
RT I
- I
PCR I
( I
qPCR I
) I
and O
Western O
blotting O
. O

Hepatitis O
Cvirus O
( O
HCV O
) O
productively O
infects O
hepatocytes O
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
mainly O
replicates O
within O
the O
liver O
. O

Antiviral O
CD8 O
( O
+ O
) O
T O
cells O
are O
a O
key O
component O
of O
the O
adaptive O
immune O
response O
against O
HCV O
, O
but O
their O
impact O
on O
viral O
control O
is O
influenced O
by O
preexisting O
viral O
variants O
in O
important O
target O
epitopes O
and O
the O
development O
of O
viral O
escape O
mutations O
. O

Here O
, O
we O
characterized O
the O
CD8 O
( O
+ O
) O
T O
cell O
response O
against O
the O
highly O
conserved O
HLA O
- O
B O
* O
51 O
- O
restricted O
epitope O
IPFYGKAI O
( O
1373 O
- O
1380 O
) O
located O
in O
the O
helicase O
domain O
of O
NS3 O
in O
people B
who I
inject I
drugs I
( I
PWID I
) I
exposed O
predominantly O
to O
HCV O
genotypes O
1a O
and O
3a O
. O

Despite O
this O
epitope O
being O
conserved O
in O
both O
genotypes O
, O
the O
corresponding O
CD8 O
( O
+ O
) O
T O
cell O
response O
was O
detected O
only O
in O
PWID O
infected O
with O
genotype O
3a O
and O
HCV O
- O
RNA O
negative O
PWID O
, O
but O
not O
in O
PWID O
infected O
with O
genotype O
1a O
. O

In O
genotype O
3a O
, O
the O
detection O
of O
strong O
CD8 O
( O
+ O
) O
T O
cell O
responses O
was O
associated O
with O
epitope O
variants O
in O
the O
autologous O
virus O
consistent O
with O
immune O
escape O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infects O
hundreds O
of O
millions O
of O
people O
worldwide O
and O
causes O
acute O
and O
chronic O
hepatitis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

HBV O
is O
an O
enveloped O
virus O
with O
a O
relaxed B
circular I
( I
RC I
) I
DNA O
genome O
. O

In O
the O
nuclei O
of O
infected O
human O
hepatocytes O
, O
conversion O
of O
RC O
DNA O
from O
the O
incoming O
virion O
or O
cytoplasmic O
mature O
nucleocapsid B
( I
NC I
) I
to O
the O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
which O
serves O
as O
the O
template O
for O
producing O
all O
viral O
transcripts O
, O
is O
essential O
to O
establish O
and O
sustain O
viral O
replication O
. O

A O
prerequisite O
for O
CCC O
DNA O
formation O
is O
the O
uncoating O
( O
disassembly O
) O
of O
NCs O
to O
expose O
their O
RC O
DNA O
content O
for O
conversion O
to O
CCC O
DNA O
. O

IMPORTANCE O
Chronic O
infection O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
afflicts O
hundreds O
of O
millions O
worldwide O
and O
is O
sustained O
by O
the O
episomal O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
in O
the O
nuclei O
of O
infected O
hepatocytes O
. O

Release O
of O
viral O
genomic O
DNA O
from O
cytoplasmic O
nucleocapsids B
( I
NCs I
) I
( O
NC O
disassembly O
or O
uncoating O
) O
is O
a O
prerequisite O
for O
its O
conversion O
to O
CCC O
DNA O
, O
which O
can O
also O
potentially O
expose O
the O
viral O
DNA O
to O
host O
DNA O
sensors O
and O
trigger O
an O
innate O
immune O
response O
. O

Human B
myxovirus I
resistance I
2 I
( I
MX2 I
/ I
MXB I
) I
is O
an O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
and O
was O
recently O
identified O
as O
a O
late O
postentry O
suppressor O
of O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
infection O
, O
inhibiting O
the O
nuclear O
accumulation O
of O
viral O
cDNAs O
. O

Although O
the O
HIV O
- O
1 O
capsid B
( I
CA I
) I
protein O
is O
believed O
to O
be O
the O
viral O
determinant O
of O
MX2 O
- O
mediated O
inhibition O
, O
the O
precise O
mechanism O
of O
antiviral O
action O
remains O
unclear O
. O

The O
MX O
family O
of O
dynamin O
- O
like O
GTPases O
also O
includes O
MX1 O
/ O
MXA O
, O
a O
well O
- O
studied O
inhibitor O
of O
a O
range O
of O
RNA O
and O
DNA O
viruses O
, O
including O
influenza B
A I
virus I
( I
FLUAV I
) I
and O
hepatitis O
B O
virus O
but O
not O
retroviruses O
. O

However O
, O
MX2 O
possesses O
an O
extended O
N O
terminus O
that O
is O
essential O
for O
antiviral O
function O
and O
confers O
anti O
- O
HIV O
- O
1 O
activity O
on O
MX1 O
[ O
MX1 O
( O
NMX2 O
) O
] O
. O

Here O
, O
we O
performed O
structure O
- O
function O
studies O
to O
investigate O
the O
requirements O
for O
oligomerization O
of O
both O
MX2 O
and O
chimeric O
MX1 O
( O
NMX2 O
) O
for O
the O
inhibition O
of O
HIV O
- O
1 O
infection O
. O

We O
show O
that O
while O
monomeric O
MX2 O
and O
MX1 O
( O
NMX2 O
) O
mutants O
are O
not O
antiviral O
, O
higher O
- O
order O
oligomerization O
does O
not O
appear O
to O
be O
required O
for O
full O
antiviral O
activity O
of O
either O
protein O
. O

Anti O
- O
hepatitis B
B I
virus I
( I
HBV I
) I
drugs O
are O
currently O
limited O
to O
nucleos O
( O
t O
) O
ide O
analogs O
( O
NAs O
) O
and O
interferons O
. O

Vanitaracin O
A O
inhibited O
the O
viral O
entry O
process O
with O
a O
submicromolar O
50 B
% I
inhibitory I
concentration I
( I
IC50 I
) I
( O
IC50 O
= O
0 O
. O

23 O
mu O
M O
) O
, O
without O
evident O
cytotoxicity O
( O
50 O
% O
cytotoxic O
concentration O
of O
> O
256 O
mu O
M O
; O
selectivity O
index O
value O
of O
> O
419 O
) O
in O
primary O
human O
hepatocytes O
. O

This O
compound O
was O
found O
to O
directly O
interact O
with O
the O
HBV O
entry O
receptor O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
and O
impaired O
its O
bile O
acid O
transport O
activity O
. O

Consistent O
with O
this O
NTCP O
targeting O
, O
antiviral O
activity O
of O
vanitaracin O
A O
was O
observed O
with O
hepatitis B
D I
virus I
( I
HDV I
) I
but O
not O
hepatitis O
C O
virus O
. O

Importantly O
, O
vanitaracin O
A O
inhibited O
infection O
by O
all O
HBV O
genotypes O
tested O
( O
genotypes O
A O
to O
D O
) O
and O
clinically O
relevant O
NA O
- O
resistant O
HBV O
isolate O
. O

This O
compound O
, O
or O
its O
related O
analogs O
, O
could O
be O
part O
of O
an O
antiviral O
strategy O
for O
preventing O
reinfection O
with O
HBV O
, O
including O
clinically O
relevant O
nucleos O
( O
t O
) O
ide O
analog O
- O
resistant O
virus O
. O

IMPORTANCE O
For O
achieving O
better O
treatment O
and O
prevention O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
anti O
- O
HBV O
agents O
targeting O
a O
new O
molecule O
are O
in O
great O
demand O
. O

Although O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
has O
recently O
been O
reported O
to O
be O
an O
essential O
host O
factor O
for O
HBV O
entry O
, O
there O
is O
a O
limited O
number O
of O
reports O
that O
identify O
new O
compounds O
targeting O
NTCP O
and O
inhibiting O
HBV O
entry O
. O

Here O
, O
from O
an O
uncharacterized O
chemical O
library O
, O
we O
isolated O
a O
structurally O
new O
compound O
, O
named O
vanitaracin O
A O
, O
which O
inhibited O
the O
process O
of O
entry O
of O
HBV O
and O
hepatitis B
D I
virus I
( I
HDV I
) I
. O

Importantly O
, O
vanitaracin O
A O
inhibited O
the O
entry O
of O
all O
HBV O
genotypes O
examined O
and O
of O
a O
clinically O
relevant O
nucleos O
( O
t O
) O
ide O
analog O
- O
resistant O
HBV O
isolate O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
only O
infects O
humans O
and O
chimpanzees O
, O
while O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
another O
hepatotropic O
hepacivirus O
, O
infects O
small O
New O
World O
primates O
( O
tamarins O
and O
marmosets O
) O
. O

In O
an O
effort O
to O
develop O
an O
immunocompetent O
small O
primate O
model O
for O
HCV O
infection O
to O
study O
HCV O
pathogenesis O
and O
vaccine O
approaches O
, O
we O
investigated O
the O
HCV O
life O
cycle O
step O
( O
s O
) O
that O
may O
be O
restricted O
in O
small O
primate O
hepatocytes O
. O

Next O
, O
HCV O
entry O
into O
small O
primate O
hepatocytes O
was O
examined O
directly O
using O
HCV B
- I
pseudotyped I
retroviral I
particles I
( I
HCV I
- I
pp I
) I
. O

IMPORTANCE O
hepatitis B
C I
virus I
( I
HCV I
) I
is O
an O
important O
human O
pathogen O
that O
infects O
over O
150 O
million O
individuals O
worldwide O
and O
leads O
to O
chronic O
liver O
disease O
. O

In O
seeking O
to O
establish O
a O
small O
primate O
model O
for O
HCV O
, O
we O
first O
attempted O
to O
generate O
recombinants O
between O
HCV O
and O
GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
a O
hepacivirus O
that O
infects O
small O
New O
World O
primates O
( O
tamarins O
and O
marmosets O
) O
. O

The O
small O
envelope O
proteins O
( O
HBsAgS O
) O
derived O
from O
hepatitis B
B I
virus I
( I
HBV I
) I
represent O
the O
antigenic O
components O
of O
the O
HBV O
vaccine O
and O
are O
platforms O
for O
the O
delivery O
of O
foreign O
antigenic O
sequences O
. O

To O
investigate O
structure O
- O
immunogenicity O
relationships O
for O
the O
design O
of O
improved O
immunization O
vectors O
, O
we O
have O
generated O
biochemically O
modified O
virus B
- I
like I
particles I
( I
VLPs I
) I
exhibiting O
glycoengineered O
HBsAgS O
. O

For O
the O
generation O
of O
hypoglycosylated O
VLPs O
, O
the O
wild B
- I
type I
( I
WT I
) I
HBsAgS O
N146 O
glycosylation O
site O
was O
converted O
to O
N146Q O
; O
for O
constructing O
hyperglycosylated O
VLPs O
, O
potential O
glycosylation O
sites O
were O
introduced O
in O
the O
HBsAgS O
external O
loop O
region O
at O
positions O
T116 O
and O
G130 O
in O
addition O
to O
the O
WT O
site O
. O

We O
have O
generated O
virus B
- I
like I
particles I
( I
VLPs I
) I
composed O
of O
hepatitis B
B I
virus I
envelope I
proteins I
( I
HBsAgS I
) I
with O
additional O
N O
- O
glycosylation O
sites O
. O

We O
have O
previously O
reported O
that O
hepatitis B
C I
virus I
( I
HCV I
) I
infection O
of O
primary B
human I
hepatocytes I
( I
PHH I
) I
induces O
the O
epithelial B
mesenchymal I
transition I
( I
EMT I
) I
state O
and O
extends O
hepatocyte O
life O
span O
( O
S O
. O

The O
sphere O
- O
forming O
hepatocytes O
expressed O
a O
number O
of O
cancer B
stem I
- I
like I
cell I
( I
CSC I
) I
markers O
, O
including O
high O
levels O
of O
the O
stem O
cell O
factor O
receptor O
c O
- O
Kit O
. O

The O
c O
- O
Kit O
receptor O
is O
regarded O
as O
one O
of O
the O
CSC O
markers O
in O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

We O
also O
found O
c O
- O
Kit O
is O
highly O
expressed O
in O
transformed B
human I
hepatocytes I
( I
THH I
) I
infected O
in O
vitro O
with O
cell O
culture O
- O
grown O
HCV O
genotype O
2a O
. O

HCV O
- O
infected O
primary O
and O
transformed O
human O
hepatocytes O
( O
PHH O
or O
THH O
) O
generated O
CSC O
. O

However O
, O
there O
is O
little O
information O
available O
on O
which O
NK O
cell O
populations O
, O
as O
defined O
by O
the O
inhibitory B
NK I
cell I
receptors I
( I
iNKRs I
) I
they O
express O
, O
respond O
to O
autologous O
HIV O
- O
infected O
CD4 O
( O
+ O
) O
( O
iCD4 O
) O
T O
cells O
. O

NK O
cells O
acquire O
antiviral O
functions O
through O
education O
, O
which O
requires O
signals O
received O
from O
iNKRs O
, O
such O
as O
NKG2A O
and O
KIR3DL1 O
( O
here O
, O
3DL1 O
) O
, O
engaging O
their O
ligands O
. O

Flow O
cytometry O
was O
used O
to O
gate O
on O
each O
NKG2A O
( O
+ O
) O
/ O
NKG2A O
( O
- O
) O
3DL1 O
( O
+ O
) O
/ O
3DL1 O
( O
- O
) O
( O
NKG2A O
( O
+ O
) O
/ O
( O
- O
) O
3DL1 O
( O
+ O
) O
/ O
( O
- O
) O
) O
population O
and O
to O
measure O
the O
frequency O
of O
all O
possible O
combinations O
of O
CD107a O
expression O
and O
gamma B
interferon I
( I
IFN I
- I
gamma I
) I
and O
CCL4 O
secretion O
. O

The O
highest O
frequency O
of O
functional O
NK O
cells O
responding O
to O
HLA O
- O
null O
cell O
stimulation O
was O
the O
NKG2A O
( O
+ O
) O
3DL1 O
( O
+ O
) O
NK O
cell O
population O
. O

This O
was O
the O
case O
for O
the O
functional O
subsets O
characterized O
by O
the O
sum O
of O
all O
functions O
tested O
( O
total O
responsiveness O
) O
, O
as O
well O
as O
by O
the O
trifunctional O
CD107a O
( O
+ O
) O
IFN O
- O
gamma O
( O
+ O
) O
CCL4 O
( O
+ O
) O
, O
CD107a O
( O
+ O
) O
IFN O
- O
gamma O
( O
+ O
) O
, O
total O
CD107a O
( O
+ O
) O
, O
and O
total O
IFN O
- O
gamma O
( O
+ O
) O
functional O
subsets O
. O

IMPORTANCE O
HIV O
- O
infected O
CD4 O
( O
iCD4 O
) O
cells O
activate O
NK O
cells O
, O
which O
then O
control O
HIV O
replication O
. O

Here O
, O
we O
examine O
the O
frequency O
of O
NK O
cell O
populations O
, O
defined O
by O
the O
presence O
/ O
absence O
of O
the O
NK B
cell I
receptors I
( I
NKRs I
) I
NKG2A O
and O
3DL1 O
, O
that O
respond O
to O
iCD4 O
cells O
. O

A O
higher O
frequency O
of O
NKG2A O
( O
+ O
) O
than O
NKG2A O
( O
- O
) O
NK O
cells O
responded O
to O
iCD4 O
cells O
by O
developing O
antiviral O
functions O
such O
as O
CD107a O
expression O
, O
which O
correlates O
with O
NK O
cell O
killing O
, O
and O
secretion O
of O
gamma O
interferon O
and O
CCL4 O
. O

Coexpression O
of O
3DL1 O
on O
the O
NKG2A O
( O
+ O
) O
and O
NKG2A O
( O
- O
) O
NK O
cells O
did O
not O
modulate O
responses O
to O
iCD4 O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
- O
specific O
cytotoxic B
T I
lymphocytes I
( I
CTLs I
) I
are O
critical O
in O
eliminating O
infection O
. O

After O
HBV O
inoculation O
in O
human O
hepatocyte O
- O
transplanted O
herpes O
simplex O
virus O
type O
- O
1 O
thymidine O
kinase O
- O
NOG O
mice O
, O
human B
peripheral I
blood I
mononuclear I
cells I
( I
PBMCs I
) I
were O
administered O
, O
and O
albumin O
, O
HBV O
DNA O
, O
alanine B
aminotransferase I
( I
ALT I
) I
, O
and O
cytokine O
levels O
were O
analyzed O
. O

Histopathological O
and O
flow O
- O
cytometric O
analysis O
of O
infiltrating O
human O
immune O
cells O
were O
performed O
, O
and O
the O
efficacy O
of O
CTL B
- I
associated I
antigen I
- I
4 I
immunoglobulin I
( I
CTLA4Ig I
) I
against O
liver O
damage O
was O
evaluated O
. O

Serum O
hepatitis B
B I
surface I
( I
HBs I
) I
antigen O
became O
negative O
, O
and O
HBs O
antibody O
appeared O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
particle O
is O
an O
icosahedral O
nucleocapsid O
surrounded O
by O
a O
lipid O
envelope O
containing O
viral O
surface O
proteins O
. O

A O
small O
domain O
( O
matrix O
domain O
[ O
MD O
] O
) O
in O
the O
large O
surface O
protein O
L O
and O
a O
narrow O
region O
( O
matrix O
binding O
domain O
[ O
MBD O
] O
) O
including O
isoleucine O
126 O
on O
the O
capsid O
surface O
have O
been O
mapped O
, O
in O
which O
point O
mutations O
such O
as O
core O
I126A O
specifically O
blocked O
nucleocapsid O
envelopment O
. O

By O
the O
systematic B
evolution I
of I
ligands I
by I
exponential I
enrichment I
( I
SELEX I
) I
method O
, O
we O
evolved O
DNA O
aptamers O
from O
an O
oligonucleotide O
library O
binding O
to O
purified O
recombinant O
capsids O
but O
not O
binding O
to O
the O
corresponding O
I126A O
mutant O
capsids O
. O

The O
main O
aptamer O
, O
AO O
- O
01 O
( O
13 O
clones O
, O
18 O
% O
) O
, O
showed O
the O
lowest O
dissociation O
constant O
( O
K O
- O
d O
) O
of O
180 O
+ O
/ O
- O
82 O
nM O
for O
capsid O
binding O
among O
the O
four O
molecules O
. O

We O
selected O
a O
55 O
- O
base O
- O
long O
single O
- O
stranded O
DNA O
molecule O
( O
aptamer O
) O
which O
binds O
with O
relatively O
high O
affinity O
to O
a O
region O
on O
the O
HBV O
capsid O
interacting O
with O
viral O
envelope O
proteins O
during O
budding O
. O

Early O
biochemical O
studies O
of O
viral O
replication O
suggested O
that O
most O
viruses O
produce O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
, O
which O
is O
essential O
for O
the O
induction O
of O
the O
host O
immune O
response O
. O

dsRNA O
was O
also O
detected O
in O
cells O
infected O
with O
lymphocytic O
choriomeningitis O
virus O
, O
an O
ambisense O
RNA O
virus O
, O
and O
minute B
virus I
of I
mice I
( I
MVM I
) I
, O
a O
single B
- I
stranded I
DNA I
( I
ssDNA I
) I
parvovirus O
, O
but O
not O
hepatitis O
B O
virus O
. O

double B
- I
stranded I
RNA I
( I
dsRNA I
) I
is O
a O
viral O
product O
essential O
for O
the O
induction O
of O
innate O
immunity O
, O
leading O
to O
the O
production O
of O
type B
I I
interferons I
( I
IFNs I
) I
and O
the O
activation O
of O
hundreds O
of O
IFN O
- O
stimulated O
genes O
. O

The O
nucleus O
is O
unlikely O
to O
have O
pathogen B
- I
associated I
molecular I
pattern I
( I
PAMP I
) I
receptors O
for O
dsRNA O
because O
of O
the O
presence O
of O
host O
dsRNA O
molecules O
. O

The O
infectivity O
of O
hepadnavirus O
virions O
produced O
during O
either O
acute O
or O
chronic O
stages O
of O
infection O
was O
compared O
by O
testing O
the O
ability O
of O
the O
virions O
of O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
to O
induce O
productive O
acute O
infection O
in O
naive O
adult O
woodchucks O
. O

Serum O
WHV O
collected O
during O
acute O
infection O
was O
compared O
to O
virions O
harvested O
from O
WHV O
- O
infected O
woodchucks O
during O
either O
( O
i O
) O
early O
chronic O
infection O
, O
when O
WHV O
- O
induced O
hepatocellular B
carcinoma I
( I
HCC I
) I
was O
not O
yet O
developed O
, O
or O
( O
ii O
) O
late O
chronic O
infection O
, O
when O
established O
HCC O
was O
terminal O
. O

Our O
novel O
results O
provided O
several O
lines O
of O
further O
evidence O
supporting O
the O
idea O
that O
during O
the O
state O
of O
chronic O
infection O
in O
vivo O
, O
the O
limitations O
of O
hepadnavirus O
cell O
- O
to O
- O
cell O
spread O
/ O
superinfection O
( O
observed O
recently O
in O
the O
woodchuck O
model O
) O
are O
not O
due O
to O
the O
diminished O
infectivity O
of O
the O
virions O
circulating O
in O
the O
blood O
and O
likely O
are O
( O
i O
) O
related O
to O
the O
properties O
of O
hepatocytes O
( O
i O
. O

, O
their O
capacity O
to O
support O
hepadnavirus O
infection O
/ O
replication O
) O
and O
( O
ii O
) O
influenced O
by O
the O
immune O
system O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infects O
hundreds O
of O
millions O
of O
people O
worldwide O
and O
causes O
acute O
and O
chronic O
hepatitis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

HBV O
is O
an O
enveloped O
virus O
with O
a O
relaxed B
circular I
( I
RC I
) I
DNA O
genome O
. O

In O
the O
nuclei O
of O
infected O
human O
hepatocytes O
, O
conversion O
of O
RC O
DNA O
from O
the O
incoming O
virion O
or O
cytoplasmic O
mature O
nucleocapsid B
( I
NC I
) I
to O
the O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
, O
which O
serves O
as O
the O
template O
for O
producing O
all O
viral O
transcripts O
, O
is O
essential O
to O
establish O
and O
sustain O
viral O
replication O
. O

IMPORTANCE O
Persistent O
infection O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
afflicting O
hundreds O
of O
millions O
worldwide O
, O
is O
sustained O
by O
the O
episomal O
viral O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
in O
the O
nuclei O
of O
infected O
hepatocytes O
. O

CCC O
DNA O
is O
converted O
from O
the O
viral O
genomic O
( O
precursor O
) O
DNA O
contained O
in O
cytoplasmic O
viral O
nucleocapsids O
. O

This O
ability O
correlates O
with O
increased O
instability O
of O
viral O
nucleocapsids O
in O
these O
cells O
, O
which O
likely O
facilitates O
nucleocapsid O
disassembly O
( O
uncoating O
) O
to O
release O
the O
genomic O
DNA O
for O
conversion O
to O
CCC O
DNA O
. O

In O
our O
study O
, O
we O
characterized O
the O
effect O
of O
monensin O
, O
an O
ionophore O
that O
is O
known O
to O
raise O
the O
intracellular O
pH O
, O
on O
the O
hepatitis B
C I
virus I
( I
HCV I
) I
life O
cycle O
. O

Characterization O
of O
this O
mutant O
led O
to O
the O
identification O
of O
two O
mutations O
in O
envelope O
proteins O
, O
the O
Y297H O
mutation O
in O
E1 O
and O
the O
I399T O
mutation O
in O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
E2 O
, O
which O
confer O
resistance O
to O
monensin O
and O
thus O
allow O
HCV O
to O
use O
a O
pH O
- O
independent O
entry O
route O
. O

Interestingly O
, O
the O
I399T O
mutation O
introduces O
an O
N O
- O
glycosylation O
site O
within O
HVR1 O
and O
increases O
the O
density O
of O
virions O
and O
their O
sensitivity O
to O
neutralization O
with O
anti O
- O
apolipoprotein O
E O
( O
anti O
- O
ApoE O
) O
antibodies O
, O
suggesting O
that O
this O
mutation O
likely O
induces O
conformational O
changes O
in O
HVR1 O
that O
in O
turn O
modulate O
the O
association O
with O
ApoE O
. O

IMPORTANCE O
Although O
several O
cell O
surface O
proteins O
have O
been O
identified O
as O
entry O
factors O
for O
hepatitis B
C I
virus I
( I
HCV I
) I
, O
the O
precise O
mechanisms O
regulating O
its O
transmission O
to O
hepatic O
cells O
are O
still O
unclear O
. O

Thanks O
to O
these O
mutants O
, O
we O
highlighted O
the O
importance O
of O
hypervariable B
region I
1 I
( I
HVR1 I
) I
of O
the O
E2 O
envelope O
protein O
for O
the O
association O
of O
particles O
with O
apolipoprotein O
E O
, O
which O
in O
turn O
might O
control O
the O
pH O
dependency O
of O
cell O
- O
free O
and O
cell O
- O
to O
- O
cell O
transmission O
. O

Previously O
, O
we O
reported O
that O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
can O
induce O
physiological O
stress O
. O

A O
real O
- O
time O
PCR O
array O
targeting O
genes O
related O
to O
chemokines O
and O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
were O
carried O
out O
to O
detect O
the O
specific O
chemokines O
produced O
by O
Huh7 O
cells O
and O
HepG2 O
cells O
infected O
with O
various O
HBV O
genotypes O
. O

The O
expressions O
of O
CX3CL1 O
mRNA O
and O
protein O
were O
significantly O
different O
among O
HBV O
genotypes O
A O
, O
B O
, O
and O
C O
and O
control O
cells O
( O
mock O
) O
( O
P O
< O
0 O
. O

CD56 O
( O
+ O
) O
NK O
cells O
and O
CD8 O
( O
+ O
) O
T O
cells O
migrated O
to O
the O
hepatoma O
cells O
with O
HBV O
replication O
. O

The O
expression O
level O
of O
NKG2D O
on O
CX3CR1 O
( O
+ O
) O
NK O
cells O
in O
HCC O
with O
HBV O
infection O
was O
significantly O
lower O
than O
that O
in O
hepatocellular B
carcinoma I
( I
HCC I
) I
with O
HCV O
infection O
and O
chronic O
hepatitis O
B O
and O
C O
patients O
( O
P O
< O
0 O
. O

On O
the O
other O
hand O
, O
the O
frequency O
of O
PD O
- O
1 O
( O
high O
) O
CX3CR1 O
( O
+ O
) O
CD8 O
( O
+ O
) O
T O
cells O
in O
HCC O
with O
HBV O
infection O
was O
significantly O
higher O
than O
that O
in O
HCC O
with O
HCV O
infection O
and O
chronic O
hepatitis O
B O
and O
C O
( O
P O
< O
0 O
. O

Not O
only O
the O
differential O
expression O
of O
CX3CL1 O
among O
the O
genotypes O
but O
also O
the O
phenotype O
of O
CX3CR1 O
( O
+ O
) O
NK O
cells O
and O
T O
cells O
were O
gradually O
changed O
during O
the O
progression O
of O
the O
disease O
status O
. O

Only O
a O
few O
of O
these O
cytokines O
mount O
an O
antiviral O
response O
, O
including O
type O
I O
, O
II O
, O
and O
III O
Interferons B
( I
IFNs I
) I
. O

Here O
, O
we O
performed O
the O
largest O
cytokine O
and O
chemokine O
screen O
( O
the O
human O
cytokinome O
, O
with O
> O
240 O
members O
) O
to O
investigate O
their O
modulation O
of O
type O
I O
and O
type O
II O
IFN O
responses O
in O
a O
cell O
line O
model O
. O

We O
evaluated O
the O
cytokine O
activities O
in O
both O
IFN B
- I
stimulated I
response I
element I
( I
ISRE I
) I
and O
IFN B
- I
gamma I
activation I
sequence I
( I
GAS I
) I
reporter O
systems O
. O

We O
identified O
novel O
modulators O
of O
IFN O
response O
- O
betacellulin B
( I
BTC I
) I
, O
interleukin B
11 I
( I
IL I
- I
11 I
) I
, O
and O
IL O
- O
17F O
- O
that O
caused O
time O
- O
dependent O
induction O
of O
the O
IFN O
response O
. O

One O
mediator O
is O
interferon B
( I
IFN I
) I
, O
which O
activates O
a O
cascade O
of O
biochemical O
events O
that O
aim O
to O
control O
the O
virus O
life O
cycle O
. O

Antisera O
raised O
against O
the O
avian O
hepatitis B
E I
virus I
( I
HEV I
) I
capsid O
protein O
are O
cross O
- O
reactive O
with O
human O
and O
swine O
HEV O
capsid O
proteins O
. O

In O
this O
study O
, O
two O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
the O
avian O
HEV O
capsid O
protein O
, O
namely O
, O
3E8 O
and O
1B5 O
, O
were O
shown O
to O
cross O
- O
react O
with O
the O
swine O
HEV O
capsid O
protein O
. O

The O
motifs O
involved O
in O
binding O
both O
MAbs O
were O
identified O
and O
characterized O
using O
phage O
display O
biopanning O
, O
peptide O
synthesis O
, O
and O
truncated O
or O
mutated O
protein O
expression O
, O
along O
with O
indirect O
enzyme B
- I
linked I
immunosorbent I
assay I
( I
ELISA I
) I
and O
Western O
blotting O
. O

IMPORTANCE O
More O
and O
more O
evidence O
indicates O
that O
the O
host O
range O
diversity O
of O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
global O
public O
health O
concern O
. O

In O
this O
study O
, O
we O
compared O
the O
effect O
of O
liver O
inflammation O
induced O
by O
the O
Toll O
- O
like O
receptor O
4 O
ligand O
lipopolysaccharide B
( I
LPS I
) I
with O
that O
of O
a O
persistent O
virus O
, O
Lymphocytic B
choriomeningitis I
virus I
( I
LCMV I
) I
clone O
13 O
, O
on O
early O
innate O
intrahepatic O
immune O
responses O
in O
mice O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
entry O
into O
host O
cells O
is O
a O
complex O
process O
requiring O
multiple O
host O
factors O
, O
including O
Claudin B
- I
1 I
( I
CLDN1 I
) I
. O

Four O
hybridomas O
were O
obtained O
, O
which O
produced O
Monoclonal B
antibodies I
( I
MAbs I
) I
that O
interacted O
with O
the O
parental O
Huh7 O
. O

IMPORTANCE O
Safe O
and O
effective O
therapeutic O
entry O
inhibitors O
against O
hepatitis B
C I
virus I
( I
HCV I
) I
are O
very O
useful O
for O
combination O
therapies O
with O
other O
anti O
- O
HCV O
drugs O
, O
such O
as O
direct O
- O
acting O
antivirals O
. O

In O
this O
study O
, O
we O
first O
showed O
an O
effective O
strategy O
for O
developing O
functional O
Monoclonal B
antibodies I
( I
MAbs I
) I
against O
extracellular O
domains O
of O
a O
multimembrane O
- O
spanning O
target O
protein O
, O
Claudin B
- I
1 I
( I
CLDN1 I
) I
, O
by O
using O
parental O
cells O
expressing O
the O
intact O
target O
membrane O
protein O
and O
target O
- O
defective O
cells O
. O

The O
evolutionary O
rates O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
estimated O
using O
contemporary O
sequences O
are O
10 O
( O
2 O
) O
to O
10 O
( O
4 O
) O
times O
higher O
than O
those O
derived O
from O
archaeological O
and O
genetic O
evidence O
. O

IMPORTANCE O
It O
is O
known O
that O
the O
estimated O
hepatitis B
B I
virus I
( I
HBV I
) I
substitution O
rate O
is O
time O
dependent O
, O
but O
the O
reason O
behind O
this O
observation O
is O
still O
elusive O
. O

IRF3 O
was O
recently O
demonstrated O
to O
be O
indispensable O
for O
Sendai B
virus I
( I
SeV I
) I
- O
induced O
apoptosis O
, O
but O
the O
underlying O
mechanism O
is O
not O
fully O
understood O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
entry O
involves O
binding O
to O
cell O
surface O
heparan B
sulfate I
( I
HS I
) I
structures O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infects O
approximately O
130 O
million O
individuals O
worldwide O
, O
with O
the O
majority O
of O
cases O
remaining O
undiagnosed O
and O
untreated O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
small O
enveloped O
DNA O
virus O
, O
chronically O
infects O
more O
than O
350 O
million O
people O
worldwide O
and O
causes O
liver O
diseases O
from O
hepatitis O
to O
cirrhosis O
and O
liver O
cancer O
. O

Here O
, O
we O
report O
that O
hepatocyte B
nuclear I
factor I
6 I
( I
HNF6 I
) I
, O
a O
liver O
- O
enriched O
transcription O
factor O
, O
can O
inhibit O
HBV O
gene O
expression O
and O
DNA O
replication O
. O

Detailed O
analysis O
showed O
that O
a O
cis O
element O
on O
the O
HBV O
genome O
( O
nucleotides O
[ O
nt O
] O
3009 O
to O
3019 O
) O
was O
responsible O
for O
the O
inhibition O
of O
the O
SP2 O
promoter O
by O
HNF6 O
. O

Moreover O
, O
further O
analysis O
showed O
that O
HNF6 O
reduced O
viral O
pregenomic B
RNA I
( I
pgRNA I
) I
posttranscriptionally O
via O
accelerating O
the O
degradation O
of O
HBV O
pgRNA O
independent O
of O
La O
protein O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
enters O
its O
target O
cell O
via O
clathrin O
- O
mediated O
endocytosis O
. O

AP O
- O
2 O
- O
associated O
protein O
kinase O
1 O
( O
AAK1 O
) O
and O
cyclin O
G B
- I
associated I
kinase I
( I
GAK I
) I
are O
host O
kinases O
that O
regulate O
clathrin O
adaptor B
protein I
( I
AP I
) I
- O
mediated O
trafficking O
in O
the O
endocytic O
and O
secretory O
pathways O
. O

AAK1 O
or O
GAK O
depletion O
impaired O
epidermal B
growth I
factor I
( I
EGF I
) I
- O
mediated O
enhanced O
HCV O
entry O
and O
endocytosis O
of O
EGF B
receptor I
( I
EGFR I
) I
, O
an O
HCV O
entry O
cofactor O
and O
erlotinib O
' O
s O
cancer O
target O
. O

Together O
, O
these O
results O
validate O
AAK1 O
and O
GAK O
as O
critical O
regulators O
of O
HCV O
entry O
that O
function O
in O
part O
by O
activating O
EGFR O
, O
AP2M1 O
, O
and O
NUMB O
and O
as O
the O
molecular O
targets O
underlying O
the O
antiviral O
effect O
of O
sunitinib O
and O
erlotinib O
( O
in O
addition O
to O
EGFR O
) O
, O
respectively O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
infection O
causes O
chronic O
hepatitis O
in O
hundreds O
of O
millions O
of O
people O
worldwide O
, O
which O
can O
eventually O
lead O
to O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Previously O
, O
we O
found O
that O
HBV O
mRNAs O
can O
absorb O
microRNA B
- I
15a I
( I
miR I
- I
15a I
) I
to O
affect O
apoptosis O
through O
the O
Bcl O
- O
2 O
pathway O
. O

In O
this O
study O
, O
we O
found O
that O
the O
transforming B
growth I
factor I
beta I
( I
TGF I
- I
beta I
) I
pathway O
- O
inhibitory O
factor O
Smad7 O
is O
a O
novel O
target O
of O
miR O
- O
15a O
. O

IMPORTANCE O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
causes O
chronic O
hepatitis O
, O
which O
can O
eventually O
lead O
to O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

Our O
study O
provides O
evidence O
to O
support O
the O
idea O
that O
viral O
RNAs O
can O
exert O
their O
functions O
as O
competing B
endogenous I
RNAs I
( I
ceRNAs I
) I
toward O
microRNA O
and O
participate O
in O
important O
cellular O
processes O
. O

Mutational O
analyses O
have O
indicated O
that O
the O
carboxyl B
- I
terminal I
domain I
( I
CTD I
) I
of O
hepadnavirus O
core O
protein O
and O
its O
state O
of O
phosphorylation O
are O
critical O
for O
multiple O
steps O
in O
viral O
replication O
. O

To O
ascertain O
the O
role O
of O
CTD O
in O
viral O
replication O
without O
perturbing O
its O
sequence O
and O
the O
role O
of O
CTD O
- O
host O
interactions O
, O
CTD O
of O
the O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
or O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
core O
protein O
, O
either O
the O
wild B
type I
( I
Wt I
) I
or O
with O
alanine O
or O
glutamic O
acid O
/ O
aspartic O
acid O
substitutions O
at O
the O
phosphorylation O
sites O
, O
was O
expressed O
in O
cells O
replicating O
DHBV O
with O
the O
WT O
core O
protein O
. O

A O
dramatic O
decrease O
in O
phosphorylation O
of O
the O
DHBV B
core I
protein I
( I
DHBc I
) I
was O
observed O
when O
the O
WT O
and O
most O
HBV B
core I
protein I
CTD I
( I
HCTD I
) I
variants O
were O
coexpressed O
in O
trans O
, O
which O
was O
accompanied O
by O
a O
profound O
reduction O
of O
viral O
core O
DNA O
and O
, O
in O
particular O
, O
the O
double O
- O
stranded O
DNA O
. O

All O
WT O
and O
variant O
HCTDs O
and O
DHBc B
CTDs I
( I
DCTDs I
) I
decreased O
the O
DHBV O
covalently B
closed I
circular I
( I
CCC I
) I
DNA O
. O

IMPORTANCE O
Mutational O
analyses O
have O
suggested O
that O
the O
carboxyl B
- I
terminal I
domain I
( I
CTD I
) I
of O
hepadnavirus O
core O
protein O
is O
critical O
for O
viral O
replication O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
proteins O
( O
Cps O
) O
assemble O
around O
the O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
viral O
reverse O
transcriptase O
( O
P O
) O
. O

pgRNA O
is O
then O
reverse O
transcribed O
to O
double B
- I
stranded I
DNA I
( I
dsDNA I
) I
within O
the O
capsid O
. O

IMPORTANCE O
The O
hepatitis B
B I
virus I
( I
HBV I
) I
capsid O
plays O
a O
central O
role O
in O
the O
virus O
life O
cycle O
and O
has O
been O
studied O
as O
a O
potential O
antiviral O
target O
. O

The O
capsid B
protein I
( I
CP I
) I
packages O
the O
viral O
pregenomic B
RNA I
( I
pgRNA I
) I
and O
polymerase O
to O
form O
the O
HBV O
core O
. O

Hepatitis O
B O
, O
which O
caused O
by O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
, O
remains O
a O
major O
health O
threat O
worldwide O
. O

Proinflammatory O
tumor B
necrosis I
factor I
alpha I
( I
TNF I
- I
alpha I
) I
has O
been O
implicated O
as O
a O
major O
inducer O
of O
liver O
cell O
death O
during O
viral O
hepatitis O
. O

Here O
, O
we O
report O
that O
in O
hepatoma O
cell O
lines O
and O
in O
primary O
mouse O
and O
human O
hepatocytes O
, O
expression O
of O
hepatitis B
B I
virus I
core I
( I
HBc I
) I
protein O
made O
cells O
susceptible O
to O
TNF O
- O
alpha O
- O
induced O
apoptosis O
. O

We O
found O
by O
tandem O
affinity O
purification O
and O
mass O
spectrometry O
that O
receptor B
of I
activated I
protein I
kinase I
C I
1 I
( I
RACK1 I
) I
interacted O
with O
HBc O
. O

RACK1 O
was O
recently O
reported O
as O
a O
scaffold O
protein O
that O
facilitates O
the O
phosphorylation O
of O
mitogen B
- I
activated I
protein I
kinase I
kinase I
7 I
( I
MKK7 I
) I
by O
its O
upstream O
activators O
. O

Our O
study O
showed O
that O
HBc O
abrogated O
the O
interaction O
between O
MKK7 O
and O
RACK1 O
by O
competitively O
binding O
to O
RACK1 O
, O
thereby O
downregulating O
TNF O
- O
alpha O
- O
induced O
phosphorylation O
of O
MKK7 O
and O
the O
activation O
of O
c B
- I
Jun I
N I
- I
terminal I
kinase I
( I
JNK I
) I
. O

We O
reported O
previously O
that O
APOBEC3F B
( I
A3F I
) I
was O
highly O
localized O
into O
mature O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
cores O
and O
identified O
that O
L306 O
in O
the O
C O
- O
terminal O
cytidine B
deaminase I
( I
CD I
) I
domain O
contributed O
to O
its O
core O
localization O
( O
C O
. O

We O
have O
now O
determined O
an O
additional O
genetic O
determinant O
( O
s O
) O
for O
A3F O
localization O
to O
HIV O
- O
1 O
cores O
. O

These O
are O
A3F O
L306 O
/ O
L368 O
( O
C O
- O
terminal O
domain O
) O
and O
A3F O
L122 O
/ O
L184 O
( O
N O
- O
terminal O
domain O
) O
. O

Alterations O
to O
one O
of O
these O
specific O
leucine O
residues O
in O
either O
of O
the O
two O
A3F O
CD O
domains O
( O
A3F O
L368A O
, O
L122A O
, O
and O
L184A O
) O
decreased O
core O
localization O
and O
diminished O
HIV O
restriction O
without O
changing O
virion O
packaging O
. O

Furthermore O
, O
double O
mutants O
in O
these O
leucine O
residues O
in O
each O
of O
A3F O
' O
s O
two O
CD O
domains O
( O
A3F O
L368A O
plus O
L184A O
or O
A3F O
L368A O
plus O
L122A O
) O
still O
were O
packaged O
into O
virions O
but O
completely O
lost O
core O
localization O
and O
anti O
- O
HIV O
activity O
. O

The O
beginning O
of O
the O
second O
century O
of O
research O
in O
the O
field O
of O
virology O
( O
the O
first O
virus O
was O
discovered O
in O
1898 O
) O
was O
marked O
by O
its O
amalgamation O
with O
bioinformatics O
, O
resulting O
in O
the O
birth O
of O
a O
new O
domain O
- O
viroinformatics O
. O

) O
as O
well O
as O
distinct O
applications O
( O
comparative O
/ O
diversity O
analysis O
, O
viral O
recombination O
, O
small O
interfering O
RNA O
[ O
siRNA O
] O
/ O
short O
hairpin O
RNA O
[ O
shRNA O
] O
/ O
microRNA O
[ O
miRNA O
] O
studies O
, O
RNA O
folding O
, O
protein O
- O
protein O
interaction O
, O
structural O
analysis O
, O
and O
phylotyping O
and O
genotyping O
) O
will O
definitely O
aid O
the O
development O
of O
effective O
drugs O
and O
vaccines O
. O

In O
this O
study O
, O
we O
characterized O
the O
molecular O
basis O
for O
binding O
of O
Adenovirus B
( I
AdV I
) I
to O
the O
cytoplasmic O
face O
of O
the O
nuclear B
pore I
complex I
( I
NPC I
) I
, O
a O
key O
step O
during O
delivery O
of O
the O
viral O
genome O
into O
the O
nucleus O
. O

We O
used O
RNA B
interference I
( I
RNAi I
) I
to O
deplete O
cells O
of O
either O
Nup214 O
or O
Nup358 O
, O
the O
two O
major O
Phe O
- O
Gly O
( O
FG O
) O
repeat O
nucleoporins O
localized O
on O
the O
cytoplasmic O
side O
of O
the O
NPC O
, O
and O
evaluated O
the O
impact O
on O
hexon O
binding O
and O
AdV O
infection O
. O

The O
accumulation O
of O
purified O
hexon O
trimers O
or O
partially O
disassembled O
AdV O
at O
the O
nuclear B
envelope I
( I
NE I
) I
was O
observed O
in O
digitonin O
- O
permeabilized O
cells O
in O
the O
absence O
of O
cytosolic O
factors O
. O

The O
expression O
of O
an O
NPC O
- O
targeted O
N O
- O
terminal O
domain O
of O
Nup214 O
in O
Nup214 O
- O
depleted O
cells O
restored O
the O
binding O
of O
hexon O
at O
the O
NE O
and O
the O
nuclear O
import O
of O
protein B
VII I
( I
pVII I
) I
, O
indicating O
that O
this O
region O
is O
sufficient O
to O
allow O
AdV O
binding O
. O

The O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
DNA O
virus O
that O
causes O
chronic O
hepatitis O
, O
has O
been O
shown O
to O
inhibit O
RNA O
helicase O
RIG O
- O
I O
- O
mediated O
interferon B
( I
IFN I
) I
induction O
. O

Here O
we O
report O
that O
in O
transiently O
HBV O
- O
transfected O
Huh7 O
cells O
, O
the O
stably O
HBV O
- O
producing O
cell O
line O
HepAD38 O
, O
and O
HBV O
- O
infected O
HepaRG O
cells O
and O
primary O
human O
hepatocytes O
, O
HBV O
markedly O
interfered O
with O
IFN O
- O
beta O
induction O
and O
antiviral O
immunity O
mediated O
by O
the O
stimulator B
of I
interferon I
genes I
( I
STING I
) I
, O
which O
has O
been O
identified O
as O
a O
central O
factor O
in O
foreign O
DNA O
recognition O
and O
antiviral O
innate O
immunity O
. O

Screening O
analysis O
demonstrated O
that O
the O
viral O
Polymerase B
( I
Pol I
) I
, O
but O
not O
other O
HBV O
- O
encoded O
proteins O
, O
was O
able O
to O
inhibit O
STING O
- O
stimulated O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
activation O
and O
IFN O
- O
beta O
induction O
. O

Moreover O
, O
the O
reverse B
transcriptase I
( I
RT I
) I
and O
the O
RNase B
H I
( I
RH I
) I
domains O
of O
Pol O
were O
identified O
to O
be O
responsible O
for O
the O
inhibitory O
effects O
. O

A O
long O
- O
standing O
unresolved O
argument O
in O
the O
hepatitis B
B I
virus I
( I
HBV I
) I
research O
field O
suggests O
that O
during O
chronic O
hepadnaviral O
infection O
, O
cell O
- O
to O
- O
cell O
spread O
of O
hepadnavirus O
is O
at O
least O
very O
inefficient O
( O
if O
it O
occurs O
at O
all O
) O
, O
virus O
superinfection O
is O
an O
unlikely O
event O
, O
and O
chronic O
hepadnavirus O
infection O
can O
be O
maintained O
exclusively O
via O
division O
of O
infected O
hepatocytes O
in O
the O
absence O
of O
virus O
spread O
. O

Superinfection O
exclusion O
was O
previously O
shown O
for O
duck O
HBV O
, O
but O
it O
was O
not O
demonstrated O
for O
HBV O
or O
HBV O
- O
related O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
. O

Three O
woodchucks O
, O
which O
were O
chronically O
infected O
with O
the O
strain O
WHV7 O
and O
already O
developed O
WHV O
- O
induced O
hepatocellular B
carcinomas I
( I
HCCs I
) I
, O
were O
superinfected O
with O
another O
WHV O
strain O
, O
WHVNY O
. O

The O
WHVNY O
superinfection O
was O
demonstrated O
by O
using O
WHV O
strain O
- O
specific O
PCR O
assays O
and O
( O
i O
) O
finding O
WHVNY O
relaxed O
circular O
DNA O
in O
the O
serum O
samples O
collected O
from O
all O
superinfected O
animals O
during O
weeks O
one O
through O
six O
after O
the O
superinfection O
, O
( O
ii O
) O
detecting O
replication O
- O
derived O
WHVNY O
RNA O
in O
the O
tissue O
samples O
of O
the O
livers O
and O
HCCs O
collected O
from O
three O
superinfected O
woodchucks O
, O
and O
( O
iii O
) O
finding O
WHVNY O
DNA O
replication O
intermediates O
in O
tissues O
harvested O
after O
the O
superinfection O
. O

The O
generated O
data O
suggest O
that O
in O
the O
livers O
chronically O
infected O
with O
woodchuck O
hepatitis O
virus O
, O
( O
i O
) O
hepadnavirus O
superinfection O
and O
cell O
- O
to O
- O
cell O
spread O
likely O
continue O
to O
occur O
and O
( O
ii O
) O
the O
virus O
spread O
is O
apparently O
inefficient O
, O
which O
is O
consistent O
with O
the O
interpretation O
that O
a O
limited O
number O
of O
cells O
in O
the O
livers O
facilitates O
the O
spread O
of O
hepadnavirus O
. O

Chronic O
infection O
with O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
risk O
factor O
for O
developing O
liver O
diseases O
such O
as O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

HBx O
can O
activate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( I
PI3K I
) I
/ O
AKT O
signaling O
pathway O
in O
some O
cell O
lines O
; O
however O
, O
whether O
HBx O
regulates O
PI3K O
/ O
AKT O
signaling O
in O
normal O
hepatocytes O
has O
not O
been O
evaluated O
. O

We O
show O
that O
the O
transcription O
factor O
hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
is O
a O
target O
of O
HBx O
- O
regulated O
AKT O
, O
and O
we O
link O
HNF4 O
alpha O
to O
HBx O
- O
regulated O
AKT O
modulation O
of O
HBV O
transcription O
and O
replication O
. O

IMPORTANCE O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
is O
a O
common O
cause O
of O
the O
development O
of O
liver O
cancer O
. O

AKT O
regulates O
HBV O
replication O
by O
reducing O
the O
activity O
of O
the O
transcription O
factor O
hepatocyte B
nuclear I
factor I
4 I
alpha I
( I
HNF4 I
alpha I
) I
. O

Congenital O
human B
cytomegalovirus I
( I
HCMV I
) I
infection O
is O
a O
leading O
cause O
of O
birth O
defects O
, O
primarily O
manifesting O
as O
neurological O
disorders O
. O

HCMV O
infection O
alters O
expression O
of O
cellular O
microRNAs O
( O
miRs O
) O
and O
induces O
cell O
cycle O
arrest O
, O
which O
in O
turn O
modifies O
the O
cellular O
environment O
to O
favor O
virus O
replication O
. O

Previous O
observations O
found O
that O
HCMV O
infection O
reduces O
miR O
- O
21 O
expression O
in O
neural B
progenitor I
/ I
stem I
cells I
( I
NPCs I
) I
. O

IMPORTANCE O
human B
cytomegalovirus I
( I
HCMV I
) I
is O
a O
ubiquitous O
pathogen O
and O
has O
very O
high O
prevalence O
among O
population O
, O
especially O
in O
China O
, O
and O
congenital O
HCMV O
infection O
is O
a O
major O
cause O
for O
birth O
defects O
. O

We O
previously O
identified O
DDX3 O
as O
a O
hepatitis B
B I
virus I
( I
HBV I
) I
polymerase I
( I
Pol I
) I
binding O
protein O
, O
and O
by O
using O
a O
transient O
transfection O
, O
we O
found O
that O
DDX3 O
inhibits O
HBV O
replication O
at O
the O
posttranscriptional O
level O
, O
perhaps O
following O
encapsidation O
. O

Importantly O
, O
knockdown O
of O
DDX3 O
by O
short O
hairpin O
RNA O
resulted O
in O
augmentation O
of O
HBV O
RNAs O
in O
two O
distinct O
HBV O
replication O
systems O
: O
( O
i O
) O
tetracycline O
- O
inducible O
HBV O
- O
producing O
cells O
and O
( O
ii O
) O
constitutive O
HBV O
- O
producing O
HepG2 O
. O

Moreover O
, O
DDX3 O
knockdown O
in O
HBV O
- O
susceptible O
HepG2 O
- O
NTCP O
cells O
, O
where O
covalently B
closed I
circular I
DNA I
( I
cccDNA I
) I
serves O
as O
the O
template O
for O
viral O
transcription O
, O
resulted O
in O
increased O
HBV O
RNAs O
, O
validating O
that O
transcription O
regulation O
by O
DDX3 O
occurs O
on O
a O
physiological O
template O
. O

In O
contrast O
to O
the O
case O
with O
retroviruses O
, O
little O
is O
known O
about O
host O
factors O
that O
restrict O
hepatitis B
B I
virus I
( I
HBV I
) I
, O
a O
virus O
distantly O
related O
to O
retroviruses O
. O

woodchuck B
hepatitis I
virus I
( I
WHV I
) I
, O
a O
close O
relative O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
, O
has O
been O
a O
key O
model O
for O
disease O
progression O
and O
clinical O
studies O
. O

Sequences O
of O
the O
assembly O
domain O
of O
WHV O
and O
HBV O
core O
proteins O
( O
wCp149 O
and O
hCp149 O
, O
respectively O
) O
have O
65 O
% O
identity O
, O
suggesting O
similar O
assembly O
behaviors O
. O

We O
report O
a O
cryo B
- I
electron I
microscopy I
( I
cryo I
- I
EM I
) I
structure O
of O
the O
WHV O
capsid O
at O
nanometer O
resolution O
and O
characterization O
of O
wCp149 O
assembly O
. O

Although O
effective O
hepatitis B
C I
virus I
( I
HCV I
) I
antivirals O
are O
on O
the O
horizon O
, O
a O
global O
prophylactic O
vaccine O
for O
HCV O
remains O
elusive O
. O

Despite O
the O
diversity O
, O
many O
Monoclonal B
antibodies I
( I
MAbs I
) I
with O
broadly O
cross O
- O
neutralizing O
activity O
have O
been O
described O
, O
suggesting O
the O
presence O
of O
conserved O
epitopes O
that O
can O
be O
targeted O
to O
prevent O
infection O
. O

Similarly O
, O
a O
vaccine O
comprising O
recombinant B
envelope I
glycoproteins I
( I
rE1E2 I
) I
derived O
from O
the O
genotype O
1a O
HCV O
- O
1 O
strain O
has O
been O
shown O
to O
be O
capable O
of O
eliciting O
cross O
- O
neutralizing O
antibodies O
in O
guinea O
pigs O
, O
chimpanzees O
, O
and O
healthy O
human O
volunteers O
. O

Furthermore O
, O
antisera O
from O
five O
immunized O
human O
vaccinees O
were O
shown O
to O
compete O
with O
five O
preselected O
MAbs O
( O
AP33 O
, O
AR3B O
, O
AR4A O
, O
AR5A O
, O
and O
IGH526 O
) O
. O

Importantly O
, O
this O
work O
provides O
further O
support O
for O
a O
vaccine O
comprising O
recombinant O
envelope O
glycoproteins O
, O
perhaps O
in O
a O
formulation O
with O
a O
vaccine O
component O
eliciting O
strong O
anti O
- O
HCV O
CD4 O
( O
+ O
) O
and O
CD8 O
( O
+ O
) O
T O
cell O
responses O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
particles O
associate O
with O
lipoproteins O
and O
infect O
cells O
by O
using O
at O
least O
four O
cell O
entry O
factors O
. O

These O
factors O
include O
scavenger B
receptor I
class I
B I
type I
I I
( I
SR I
- I
BI I
) I
, O
CD81 O
, O
claudin B
1 I
( I
CLDN1 I
) I
, O
and O
occludin B
( I
OCLN I
) I
. O

hypervariable B
region I
1 I
( I
HVR1 I
) I
within O
viral O
envelope B
protein I
2 I
( I
E2 I
) I
is O
involved O
in O
the O
usage O
of O
SR O
- O
BI O
and O
conceals O
the O
viral O
CD81 O
binding O
site O
. O

Analysis O
of O
affinity O
- O
purified O
virions O
revealed O
comparable O
levels O
of O
apolipoprotein B
E I
( I
ApoE I
) I
incorporation O
into O
viruses O
with O
or O
without O
HVR1 O
. O

The O
experimental O
evidence O
obtained O
in O
this O
study O
suggests O
that O
the O
autophagic O
flux O
is O
blocked O
at O
the O
final O
steps O
during O
the O
reactivation O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
from O
latency O
. O

Beta B
interferon I
( I
IFN I
- I
beta I
) I
is O
involved O
in O
a O
wide O
range O
of O
cellular O
functions O
, O
and O
its O
secretion O
must O
be O
tightly O
controlled O
to O
inhibit O
viral O
spreading O
while O
minimizing O
cellular O
damage O
. O

Intracellular O
viral O
replication O
triggers O
cellular O
signaling O
cascades O
leading O
to O
the O
activation O
of O
the O
transcription O
factors O
NF O
- O
kappa O
B O
and O
interferon B
regulatory I
factor I
3 I
( I
IRF3 I
) I
and O
IRF7 O
( O
IRF3 O
/ O
7 O
) O
, O
which O
synergistically O
bind O
to O
the O
IFN O
- O
beta O
gene O
promoter O
to O
induce O
its O
expression O
. O

The O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
is O
a O
governing O
adaptor O
protein O
that O
mediates O
signaling O
communications O
between O
virus O
- O
sensing O
proteins O
and O
transcription O
factors O
. O

Pulldown O
experiments O
using O
wild O
- O
type O
and O
mutant O
MAVS O
showed O
that O
mindbomb B
E3 I
ubiquitin I
protein I
ligase I
2 I
( I
MIB2 I
) I
binds O
to O
the O
DLAIS O
motif O
. O

IMPORTANCE O
mitochondrial B
antiviral I
signaling I
protein I
( I
MAVS I
) I
mediates O
signaling O
from O
virus O
- O
sensing O
proteins O
to O
transcription O
factors O
for O
the O
induction O
of O
beta O
interferon O
. O

However O
, O
the O
mechanism O
underlying O
activation O
of O
MAVS O
- O
mediated O
interferon B
regulatory I
factors I
3 I
and I
7 I
( I
IRF3 I
/ I
7 I
) I
is O
not O
completely O
understood O
. O

We O
found O
a O
highly O
conserved O
DLAIS O
motif O
in O
MAVS O
that O
is O
indispensable O
for O
IRF3 O
/ O
7 O
activation O
through O
TANK B
- I
binding I
kinase I
1 I
( I
TBK1 I
) I
and O
identified O
it O
as O
the O
binding O
site O
for O
mindbomb B
E3 I
ubiquitin I
protein I
ligase I
2 I
( I
MIB2 I
) I
. O

We O
investigated O
the O
crucial O
events O
during O
virus O
entry O
using O
a O
combination O
of O
single O
- O
virus O
tracking O
and O
biochemical O
assays O
, O
based O
on O
the O
established O
virus O
- O
cell O
infection O
model O
for O
Singapore B
grouper I
iridovirus I
( I
SGIV I
) I
. O

Inhibition O
of O
key O
regulators O
of O
macropinocytosis O
, O
including O
Na O
+ O
/ O
H O
+ O
exchanger O
, O
Rac1 O
GTPase O
, O
p21 B
- I
activated I
kinase I
1 I
( I
PAK1 I
) I
, O
protein B
kinase I
C I
( I
PKC I
) I
, O
and O
myosin O
II O
, O
significantly O
reduced O
SGIV O
uptake O
. O

Singapore B
grouper I
iridovirus I
( I
SGIV I
) I
is O
a O
novel O
marine O
fish O
DNA O
virus O
which O
belongs O
to O
genus O
Ranavirus O
, O
family O
Iridoviridae O
. O

The O
small B
hydrophobic I
( I
SH I
) I
protein O
is O
a O
64 O
- O
amino O
- O
acid O
polypeptide O
encoded O
by O
the O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
. O

SH O
protein O
has O
a O
single O
alpha O
- O
helical O
transmembrane B
( I
TM I
) I
domain O
that O
forms O
pentameric O
ion O
channels O
. O

IMPORTANCE O
The O
human B
respiratory I
syncytial I
virus I
( I
HRSV I
) I
is O
responsible O
for O
64 O
million O
reported O
cases O
of O
infection O
and O
160 O
, O
000 O
deaths O
each O
year O
. O

The O
small B
hydrophobic I
( I
SH I
) I
protein O
is O
a O
64 O
- O
amino O
- O
acid O
polypeptide O
encoded O
by O
hRSV O
and O
other O
paramyxoviruses O
, O
and O
its O
absence O
leads O
to O
viral O
attenuation O
in O
vivo O
and O
early O
apoptosis O
in O
infected O
cells O
. O

Black B
lipid I
membrane I
( I
BLM I
) I
experiments O
confirm O
that O
protonation O
of O
both O
histidine O
residues O
reduces O
stability O
and O
channel O
activity O
. O

severe B
acute I
respiratory I
syndrome I
coronavirus I
( I
SARS I
- I
CoV I
) I
caused O
an O
acute O
human O
respiratory O
illness O
with O
high O
morbidity O
and O
mortality O
in O
2002 O
- O
2003 O
. O

Several O
studies O
have O
demonstrated O
the O
role O
of O
neutralizing O
antibodies O
induced O
by O
the O
spike B
( I
S I
) I
glycoprotein O
in O
protecting O
susceptible O
hosts O
from O
lethal O
infection O
. O

We O
demonstrate O
that O
memory O
CD8 O
T O
cells O
specific O
for O
a O
single O
immunodominant O
epitope O
( O
S436 O
or O
S525 O
) O
substantially O
protected O
8 O
- O
to O
10 O
- O
month O
- O
old O
mice O
from O
lethal O
SARS O
- O
CoV O
infection O
. O

Intravenous O
immunization O
with O
peptide O
- O
loaded O
dendritic B
cells I
( I
DCs I
) I
followed O
by O
intranasal O
boosting O
with O
recombinant B
vaccinia I
virus I
( I
rVV I
) I
encoding O
S436 O
or O
S525 O
resulted O
in O
accumulation O
of O
virus O
- O
specific O
memory O
CD8 O
T O
cells O
in O
bronchoalveolar B
lavage I
fluid I
( I
BAL I
) I
, O
lungs O
, O
and O
spleen O
. O

Upon O
challenge O
with O
a O
lethal O
dose O
of O
SARS O
- O
CoV O
, O
virus O
- O
specific O
memory O
CD8 O
T O
cells O
efficiently O
produced O
multiple O
effector O
cytokines O
( O
gamma O
interferon O
[ O
IFN O
- O
gamma O
] O
, O
tumor O
necrosis O
factor O
alpha O
[ O
TNF O
- O
alpha O
] O
, O
and O
interleukin O
2 O
[ O
IL O
- O
2 O
] O
) O
and O
cytolytic O
molecules O
( O
granzyme O
B O
) O
and O
reduced O
lung O
viral O
loads O
. O

The O
hepatitis B
C I
virus I
( I
HCV I
) I
envelope O
glycoprotein O
E1E2 O
complex O
is O
a O
candidate O
vaccine O
antigen O
. O

In O
this O
study O
, O
we O
investigated O
the O
antibody O
responses O
of O
mice O
immunized O
with O
E1E2 O
and O
a O
novel O
soluble B
form I
of I
E1E2 I
( I
sE1E2 I
) I
by O
a O
DNA O
prime O
and O
protein O
boost O
strategy O
. O

In O
order O
to O
understand O
the O
contrasting O
results O
of O
binding O
and O
serum O
neutralizing O
activities O
, O
epitopes O
targeted O
by O
the O
polyclonal O
antibody O
responses O
were O
mapped O
and O
Monoclonal B
antibodies I
( I
MAbs I
) I
were O
generated O
. O

The O
results O
showed O
that O
the O
majority O
of O
serum O
antibodies O
were O
directed O
to O
the O
E1 O
region O
211 O
to O
250 O
and O
the O
E2 O
regions O
421 O
to O
469 O
, O
512 O
to O
539 O
, O
568 O
to O
609 O
, O
and O
638 O
to O
651 O
, O
instead O
of O
the O
well O
- O
known O
immunodominant O
E2 O
hypervariable B
region I
1 I
( I
HVR1 I
) I
. O

Hepadnaviruses O
selectively O
package O
capsids O
containing O
mature O
double B
- I
stranded I
DNA I
( I
dsDNA I
) I
genomes O
in O
virions O
. O

Snow B
goose I
hepatitis I
B I
virus I
( I
SGHBV I
) I
is O
the O
only O
known O
hepadnavirus O
that O
packages O
capsids O
containing O
single B
- I
stranded I
DNA I
( I
ssDNA I
) I
in O
virions O
. O

We O
determined O
that O
SGHBV O
capsid O
and O
envelope O
proteins O
independently O
contribute O
to O
the O
production O
of O
virions O
containing O
ssDNA O
, O
with O
the O
capsid B
protein I
( I
CP I
) I
making O
a O
larger O
contribution O
. O

When O
we O
changed O
these O
residues O
in O
duck B
hepatitis I
B I
virus I
( I
DHBV I
) I
Cp O
, O
capsids O
containing O
immature O
ssDNA O
were O
packaged O
in O
virions O
. O

Our O
finding O
sheds O
new O
light O
on O
the O
mechanisms O
underlying O
virion O
morphogenesis O
and O
challenges O
the O
dogma O
that O
capsid O
maturation O
, O
and O
therefore O
the O
capsid B
protein I
( I
CP I
) I
, O
is O
solely O
responsible O
for O
the O
selective O
production O
of O
virions O
containing O
mature O
dsDNA O
genomes O
. O

We O
have O
previously O
shown O
that O
poly O
( O
I O
: O
C O
) O
activates O
murine O
hepatic O
cells O
to O
produce O
interferon B
( I
IFN I
) I
and O
suppresses O
hepatitis B
B I
virus I
( I
HBV I
) I
replication O
in O
vitro O
. O

Therefore O
, O
we O
addressed O
whether O
poly O
( O
I O
: O
C O
) O
is O
able O
to O
induce O
the O
clearance O
of O
HBV O
in O
vivo O
. O

The O
chronic O
HBV O
replication O
mouse O
model O
was O
established O
by O
the O
hydrodynamic B
injection I
( I
HI I
) I
of O
pAAV O
- O
HBV1 O
. O

2 O
, O
mice O
were O
administered O
poly O
( O
I O
: O
C O
) O
by O
intraperitoneal O
injection O
, O
intramuscular O
injection O
, O
or O
HI O
. O

Only O
treatment O
of O
poly O
( O
I O
: O
C O
) O
by O
HI O
led O
to O
HBV O
clearance O
in O
wild O
- O
type O
C57BL O
/ O
6 O
mice O
. O

Serum O
HBsAg O
disappeared O
within O
40 O
days O
postinfection O
( O
dpi O
) O
in O
mice O
that O
received O
poly O
( O
I O
: O
C O
) O
by O
HI O
, O
and O
this O
was O
accompanied O
by O
the O
appearance O
of O
anti O
- O
HBs O
antibodies O
. O

HBV O
- O
specific O
T O
- O
cell O
and O
antibody O
responses O
were O
significantly O
enhanced O
by O
HI O
of O
poly O
( O
I O
: O
C O
) O
. O

HI O
of O
poly O
( O
I O
: O
C O
) O
induced O
the O
production O
of O
IFNs O
in O
mice O
and O
enhanced O
the O
levels O
of O
cytokines O
, O
IFN O
- O
stimulated O
genes O
, O
and O
T O
- O
cell O
markers O
in O
the O
liver O
. O

Importantly O
, O
poly O
( O
I O
: O
C O
) O
- O
induced O
HBV O
clearance O
was O
impaired O
in O
IFN O
- O
alpha O
/ O
beta O
R O
- O
, O
IFN O
- O
gamma O
- O
, O
and O
CXCR3 O
- O
deficient O
mice O
, O
indicating O
that O
the O
induction O
of O
type O
I O
IFN O
and O
the O
stimulation O
and O
recruitment O
of O
T O
cells O
into O
the O
liver O
are O
essential O
for O
HBV O
clearance O
in O
this O
model O
. O

Taken O
together O
, O
the O
application O
of O
poly O
( O
I O
: O
C O
) O
by O
HI O
into O
the O
liver O
enhances O
innate O
and O
adaptive O
immune O
responses O
and O
leads O
to O
HBV O
clearance O
in O
an O
HBV O
mouse O
model O
, O
implicating O
the O
potential O
of O
intrahepatic O
toll B
- I
like I
receptor I
3 I
( I
TLR3 I
) I
activation O
for O
the O
treatment O
of O
chronic O
hepatitis O
B O
patients O
. O

Recently O
, O
combinations O
of O
antiviral O
treatment O
and O
therapeutic O
vaccinations O
were O
evaluated O
for O
therapies O
of O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
. O

For O
the O
first O
time O
, O
we O
showed O
that O
HBV O
clearance O
in O
this O
model O
is O
dependent O
not O
only O
on O
type B
I I
interferon I
( I
IFN I
) I
but O
also O
on O
type O
II O
IFN O
, O
indicating O
a O
coordinated O
action O
of O
innate O
and O
adaptive O
immune O
responses O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
causes O
not O
only O
severe O
liver O
problems O
but O
also O
extrahepatic O
manifestations O
, O
such O
as O
insulin B
resistance I
( I
IR I
) I
. O

Wild B
- I
type I
peroxisome I
proliferator I
- I
activated I
receptor I
gamma I
coactivator I
1 I
alpha I
( I
WT I
- I
PGC I
- I
1 I
alpha I
) I
is O
essential O
in O
hepatic O
gluconeogenesis O
and O
has O
recently O
been O
demonstrated O
to O
link O
HCV O
infection O
to O
hepatic O
insulin B
resistance I
( I
IR I
) I
. O

A O
recent O
study O
has O
characterized O
a O
novel O
human B
liver I
- I
specific I
PGC I
- I
1 I
alpha I
( I
L I
- I
PGC I
- I
1 I
alpha I
) I
transcript O
, O
which O
is O
proposed O
to O
reflect O
human O
adaption O
to O
more O
complex O
pathways O
. O

By O
using O
promoter O
- O
luciferase O
reporters O
, O
kinase O
inhibitors O
, O
and O
dominant O
negative O
mutants O
, O
we O
further O
observed O
that O
the O
HCV O
- O
induced O
upregulation O
of O
WT O
- O
PGC O
- O
1 O
alpha O
was O
mediated O
by O
the O
phosphorylation O
of O
cyclic B
AMP I
( I
cAMP I
) I
- O
responsive O
element O
- O
binding O
protein O
( O
CREB O
) O
, O
whereas O
that O
of O
L O
- O
PGC O
- O
1 O
alpha O
was O
mediated O
by O
CREB O
phosphorylation O
and O
forkhead O
box O
O1 O
dephosphorylation O
. O

Moreover O
, O
HCV O
infection O
induced O
endoplasmic B
reticulum I
( I
ER I
) I
stress O
, O
and O
pharmacological O
induction O
of O
ER O
stress O
upregulated O
WT O
- O
PGC1 O
alpha O
/ O
L O
- O
PGC O
- O
1 O
alpha O
and O
phosphorylated O
CREB O
. O

IMPORTANCE O
HCV O
causes O
not O
only O
severe O
liver O
problems O
but O
also O
extrahepatic O
manifestations O
, O
such O
as O
insulin B
resistance I
( I
IR I
) I
. O

A O
recent O
study O
has O
characterized O
a O
novel O
human B
liver I
- I
specific I
PGC I
- I
1 I
alpha I
( I
L I
- I
PGC I
- I
1 I
alpha I
) I
, O
which O
reflects O
human O
adaption O
to O
more O
complex O
pathways O
. O

hepatitis B
E I
virus I
( I
HEV I
) I
causes O
both O
the O
endemic O
and O
epidemic O
spread O
of O
acute O
hepatitis O
in O
many O
parts O
of O
the O
world O
. O

HEV O
open B
reading I
frame I
3 I
( I
ORF3 I
) I
encodes O
a O
13 O
- O
kDa O
multifunctional O
protein O
( O
vp13 O
) O
that O
is O
essential O
for O
HEV O
infection O
of O
animals O
. O

In O
this O
study O
, O
vp13 O
was O
found O
to O
enhance O
interferon B
( I
IFN I
) I
production O
induced O
by O
poly O
( O
I O
C O
) O
, O
a O
synthetic O
analog O
of O
double O
- O
stranded O
RNA O
. O

Poly O
( O
I O
C O
) O
treatment O
induced O
a O
higher O
level O
of O
IFN O
- O
beta O
mRNA O
in O
HeLa O
cells O
stably O
expressing O
vp13 O
than O
in O
control O
cells O
. O

Using O
a O
luciferase O
reporter O
construct O
driven O
by O
the O
IFN O
- O
beta O
promoter O
, O
we O
demonstrated O
that O
vp13 O
enhanced O
retinoic B
acid I
- I
inducible I
gene I
I I
( I
RIG I
- I
I I
) I
- O
dependent O
luciferase O
expression O
. O

In O
HEV O
- O
infected O
hepatoma O
cells O
, O
wild O
- O
type O
HEV O
led O
to O
a O
higher O
level O
of O
RIG O
- O
I O
and O
more O
poly O
( O
I O
C O
) O
- O
induced O
IFN O
- O
beta O
expression O
than O
did O
ORF3 O
- O
null O
mutants O
. O

IMPORTANCE O
hepatitis B
E I
virus I
( I
HEV I
) I
is O
a O
significant O
pathogen O
causing O
hepatitis O
in O
many O
parts O
of O
the O
world O
, O
yet O
it O
is O
understudied O
compared O
with O
other O
viral O
hepatitis O
pathogens O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
- O
induced O
chronic O
liver O
disease O
is O
one O
of O
the O
leading O
causes O
of O
hepatocellular B
carcinoma I
( I
HCC I
) I
. O

microRNAs B
( I
miRNAs I
) I
have O
been O
implicated O
in O
the O
control O
of O
many O
biological O
processes O
, O
and O
their O
deregulation O
is O
associated O
with O
different O
viral O
infections O
. O

In O
this O
study O
, O
we O
observed O
that O
HCV O
infection O
of O
hepatocytes O
transcriptionally O
downregulates O
miR O
- O
181c O
expression O
by O
modulating O
CCAAT B
/ I
enhancer I
binding I
protein I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
. O

In O
silico O
prediction O
suggests O
that O
homeobox B
A1 I
( I
HOXA1 I
) I
is O
a O
direct O
target O
of O
miR O
- O
181c O
. O

We O
have O
further O
demonstrated O
that O
inhibition O
of O
miR O
- O
181c O
upregulates O
homeobox B
A1 I
( I
HOXA1 I
) I
, O
which O
is O
important O
for O
hepatocyte O
growth O
promotion O
. O

GB B
virus I
B I
( I
GBV I
- I
B I
) I
, O
which O
is O
hepatotropic O
in O
experimentally O
infected O
small O
New O
World O
primates O
, O
is O
a O
member O
of O
the O
Hepacivirus O
genus O
but O
phylogenetically O
relatively O
distant O
from O
hepatitis B
C I
virus I
( I
HCV I
) I
. O

To O
gain O
insights O
into O
the O
role O
and O
specificity O
of O
hepaciviral O
nonstructural B
protein I
2 I
( I
NS2 I
) I
, O
which O
is O
required O
for O
HCV O
polyprotein O
processing O
and O
particle O
morphogenesis O
, O
we O
investigated O
whether O
NS2 O
structural O
and O
functional O
features O
are O
conserved O
between O
HCV O
and O
GBV O
- O
B O
. O

A O
model O
for O
GBV O
- O
B O
NS2 O
membrane O
topology O
was O
experimentally O
established O
by O
determining O
the O
membrane O
association O
properties O
of O
NS2 O
segments O
fused O
to O
green B
fluorescent I
protein I
( I
GFP I
) I
and O
their O
nuclear O
magnetic O
resonance O
structures O
using O
synthetic O
peptides O
as O
well O
as O
by O
applying O
an O
N O
- O
glycosylation O
scanning O
approach O
. O

High O
- O
risk O
types O
of O
Human B
papillomavirus I
( I
HPV I
) I
are O
the O
causative O
agents O
of O
virtually O
all O
cases O
of O
cervical O
cancer O
and O
a O
significant O
proportion O
of O
other O
anogenital O
cancers O
, O
as O
well O
as O
both O
oral O
and O
pharyngeal O
cancers O
. O

In O
this O
study O
, O
we O
found O
that O
expression O
of O
E6 O
* O
increased O
the O
level O
of O
reactive B
oxygen I
species I
( I
ROS I
) I
in O
both O
HPVpositive O
and O
HPV O
- O
negative O
cells O
. O

This O
increased O
oxidative O
stress O
led O
to O
higher O
levels O
of O
DNA O
damage O
, O
as O
assessed O
by O
the O
comet O
assay O
, O
quantification O
of O
8 O
- O
oxoguanine O
, O
and O
poly O
( O
ADP O
- O
ribose O
) O
polymerase O
1 O
. O

The O
emergence O
of O
drug O
- O
resistant O
hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
problem O
for O
antiviral O
treatment O
in O
chronic O
hepatitis O
B O
infection O
. O

Compared O
to O
the O
rtA181T O
surface O
missense O
mutation O
( O
rtA181T O
/ O
sW172S O
) O
, O
the O
introduction O
of O
rtA181T O
surface O
nonsense O
mutation O
( O
rtA181T O
/ O
sW172 O
* O
) O
resulted O
in O
decreased O
viral O
replication O
and O
increased O
drug O
resistance O
. O

To O
identify O
novel O
stimulators O
of O
the O
innate O
immune O
system O
, O
we O
constructed O
a O
panel O
of O
eight O
HEK293 O
cell O
lines O
double O
positive O
for O
human B
Toll I
- I
like I
receptors I
( I
TLRs I
) I
and O
an O
NF O
- O
B O
- O
inducible O
reporter O
gene O
. O

6 O
kb O
, O
named O
nucleic B
acid I
band I
2 I
( I
NAB2 I
) I
, O
that O
was O
sufficient O
to O
confer O
the O
activation O
of O
TLR3 O
. O

Digests O
with O
single O
- O
and O
double O
- O
strand O
- O
specific O
RNases O
showed O
the O
double O
- O
strand O
nature O
of O
this O
RNA O
, O
and O
its O
sequence O
was O
found O
to O
be O
identical O
to O
that O
of O
the O
genome O
of O
the O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
L O
- O
BC O
virus O
of O
Saccharomyces O
cerevisiae O
. O

NAB2 O
complexed O
with O
the O
cationic O
lipid O
Lipofectin O
but O
neither O
NAB2 O
nor O
Lipofectin O
alone O
induced O
the O
secretion O
of O
interleukin12 O
( O
p70 O
) O
[ O
IL O
- O
12 O
( O
p70 O
) O
] O
, O
alpha O
interferon O
, O
gamma O
interferon O
- O
induced O
protein O
10 O
, O
macrophage O
inflammatory O
protein O
1 O
beta O
, O
or O
IL O
- O
6 O
in O
human O
monocyte O
- O
derived O
dendritic O
cells O
. O

A O
significant O
increase O
of O
RMA O
- O
MUC1 O
tumor O
rejection O
and O
survival O
was O
observed O
in O
C57BL O
/ O
6 O
mice O
after O
prophylactic O
vaccination O
with O
MUC1 O
- O
encoding O
modified B
vaccinia I
virus I
Ankara I
( I
MVA I
) I
and O
NAB2 O
- O
Lipofectin O
. O

This O
combination O
of O
immunotherapies O
strongly O
increased O
at O
the O
injection O
sites O
the O
percentage O
of O
infiltrating O
natural B
killer I
( I
NK I
) I
cells O
and O
plasmacytoid B
dendritic I
cells I
( I
pDCs I
) I
, O
cell O
types O
which O
can O
modulate O
innate O
and O
adaptive O
immune O
responses O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
is O
a O
major O
etiologic O
agent O
of O
chronic O
liver O
diseases O
. O

Although O
the O
HCV O
life O
cycle O
has O
been O
clarified O
by O
studying O
laboratory O
strains O
of O
HCV O
derived O
from O
the O
genotype O
2a O
JFH O
- O
1 O
strain O
( O
cell O
culture O
- O
adapted O
HCV O
[ O
HCVcc O
] O
) O
, O
the O
mechanisms O
of O
particle O
formation O
have O
not O
been O
elucidated O
. O

A O
natural O
subviral O
agent O
of O
human B
hepatitis I
B I
virus I
( I
HBV I
) I
, O
hepatitis B
delta I
virus I
( I
HDV I
) I
, O
requires O
only O
the O
envelope O
proteins O
from O
HBV O
in O
order O
to O
maintain O
persistent O
infection O
. O

HBV B
surface I
antigens I
( I
HBsAgs I
) I
can O
be O
produced O
either O
by O
HBV O
replication O
or O
from O
integrated O
HBV O
DNA O
regardless O
of O
replication O
. O

These O
results O
correlate O
with O
the O
findings O
that O
the O
entire O
open B
reading I
frame I
( I
ORF I
) I
for O
the O
large B
( I
L I
) I
envelope O
protein O
that O
is O
essential O
for O
infectivity O
is O
present O
on O
HBV O
RNAs O
from O
PLC O
/ O
PRF O
/ O
5 O
cells O
, O
while O
an O
L O
protein O
ORF O
that O
was O
truncated O
and O
fused O
to O
inverted O
precore O
sequences O
was O
found O
using O
RNAs O
from O
Hep3B O
cells O
. O

Our O
data O
indicate O
that O
in O
vivo O
chronic O
HDV O
infection O
can O
persist O
in O
the O
absence O
of O
HBV O
replication O
( O
or O
when O
HBV O
replication O
is O
profoundly O
suppressed O
) O
if O
functional O
envelope O
proteins O
are O
supplied O
from O
HBV O
integrants O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infects O
180 O
million O
people O
worldwide O
and O
is O
a O
leading O
cause O
of O
liver O
diseases O
such O
as O
fibrosis O
, O
cirrhosis O
, O
and O
hepatocellular O
carcinoma O
. O

In O
contrast O
, O
the O
very B
low I
density I
lipoprotein I
( I
VLDL I
) I
pathway O
, O
which O
is O
required O
for O
the O
secretion O
of O
cell O
- O
free O
infectious O
virus O
and O
thus O
has O
been O
identified O
as O
an O
antiviral O
target O
for O
blocking O
cell O
- O
free O
virus O
secretion O
/ O
spread O
, O
is O
not O
required O
for O
cell O
- O
to O
- O
cell O
spread O
. O

Noting O
that O
HCV O
cell O
- O
free O
and O
cell O
- O
to O
- O
cell O
spread O
share O
some O
common O
factors O
but O
not O
others O
, O
we O
tested O
the O
therapeutic O
implications O
of O
these O
observations O
and O
demonstrate O
that O
inhibitors O
that O
target O
cell O
factors O
required O
for O
both O
forms O
of O
HCV O
spread O
exhibit O
synergy O
when O
used O
in O
combination O
with O
interferon O
( O
a O
representative O
inhibitor O
of O
intracellular O
HCV O
production O
) O
, O
while O
inhibitors O
that O
block O
only O
cell O
- O
free O
spread O
do O
not O
. O

We O
compared O
the O
kinetics O
and O
magnitude O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
infection O
in O
hepatitis B
C I
virus I
( I
HCV I
) I
- O
naive O
and O
chronically O
HCV O
- O
infected O
chimpanzees O
in O
whose O
livers O
type O
I O
interferon B
- I
stimulated I
gene I
( I
ISG I
) I
expression O
is O
strongly O
induced O
. O

We O
report O
the O
diversity O
of O
latent B
membrane I
protein I
1 I
( I
LMP1 I
) I
gene O
founder O
sequences O
and O
the O
level O
of O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
genome O
variability O
over O
time O
and O
across O
anatomic O
compartments O
by O
using O
virus O
genomes O
amplified O
directly O
from O
oropharyngeal O
wash O
specimens O
and O
peripheral O
blood O
B O
cells O
during O
acute O
infection O
and O
convalescence O
. O

The O
LMP1 O
region O
showing O
the O
greatest O
level O
of O
variability O
in O
both O
compartments O
, O
and O
over O
time O
, O
was O
concentrated O
within O
the O
functional O
carboxyl B
- I
terminal I
activating I
regions I
2 I
and I
3 I
( I
CTAR2 I
and I
CTAR3 I
) I
. O

Interestingly O
, O
a O
deletion O
in O
a O
proline O
- O
rich O
repeat O
region O
( O
amino O
acids O
274 O
to O
289 O
) O
of O
EBV O
commonly O
reported O
in O
EBV O
sequenced O
from O
cancer O
specimens O
was O
not O
observed O
in O
acute B
infectious I
mononucleosis I
( I
AIM I
) I
patients O
. O

Both O
Rhinovirus B
( I
RV I
) I
and O
polyinosinic O
- O
polycytidilic O
acid O
[ O
poly O
( O
I O
center O
dot O
C O
) O
] O
, O
a O
double B
- I
stranded I
RNA I
( I
dsRNA I
) I
mimetic O
, O
cause O
airway O
epithelial O
barrier O
dysfunction O
, O
which O
is O
reactive B
oxygen I
species I
( I
ROS I
) I
dependent O
, O
implying O
that O
dsRNA O
generated O
during O
RV O
replication O
is O
sufficient O
for O
disrupting O
barrier O
function O
. O

We O
also O
demonstrated O
that O
RV O
or O
poly O
( O
I O
center O
dot O
C O
) O
- O
stimulated O
NADPH B
oxidase I
1 I
( I
NOX I
- I
1 I
) I
partially O
accounts O
for O
RV O
- O
induced O
ROS O
generation O
. O

In O
this O
study O
, O
we O
identified O
a O
dsRNA O
receptor O
( O
s O
) O
contributing O
to O
RV O
- O
induced O
maximal O
ROS O
generation O
and O
thus O
barrier O
disruption O
. O

We O
demonstrate O
that O
genetic O
silencing O
of O
the O
newly O
discovered O
dsRNA O
receptor O
Nod B
- I
like I
receptor I
X I
- I
1 I
( I
NLRX I
- I
1 I
) I
, O
but O
not O
other O
previously O
described O
dsRNA O
receptors O
, O
abrogated O
RV O
- O
induced O
ROS O
generation O
and O
reduction O
of O
transepithelial O
resistance O
( O
R O
- O
T O
) O
in O
polarized O
airway O
epithelial O
cells O
. O

In O
addition O
, O
both O
RV O
and O
poly O
( O
I O
center O
dot O
C O
) O
stimulated O
mitochondrial O
ROS O
, O
the O
generation O
of O
which O
was O
dependent O
on O
NLRX O
- O
1 O
. O

Additionally O
, O
NLRX O
- O
1 O
interacts O
with O
RV O
RNA O
and O
poly O
( O
I O
center O
dot O
C O
) O
in O
polarized O
airway O
epithelial O
cells O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
DNA O
replication O
occurs O
within O
the O
HBV O
icosahedral O
core O
particles O
. O

HBV B
core I
protein I
( I
HBc I
) I
contains O
an O
arginine B
- I
rich I
domain I
( I
ARD I
) I
at O
its O
carboxyl O
terminus O
. O

natural B
killer I
( I
NK I
) I
cells O
and O
the O
complement O
system O
play O
critical O
roles O
in O
the O
first O
line O
of O
defense O
against O
pathogens O
. O

The O
synthesis O
of O
complement O
components O
C4 O
and O
C3 O
is O
transcriptionally O
downregulated O
by O
hepatitis B
C I
virus I
( I
HCV I
) I
core O
and O
NS5A O
proteins O
, O
and O
this O
negative O
regulation O
is O
apparent O
in O
chronically O
HCV O
- O
infected O
patients O
. O

Reestablishment O
of O
complement O
protein O
expression O
was O
found O
to O
be O
mediated O
by O
direct O
interaction O
between O
NKG2D O
on O
NK O
cells O
and O
the O
hepatocyte O
protein O
major O
histocompatibility O
complex O
class O
I O
- O
related O
chains O
A O
and O
B O
( O
MICA O
/ O
B O
) O
and O
not O
to O
be O
associated O
with O
specific O
cytokine O
signaling O
events O
. O

We O
previously O
reported O
a O
proof O
- O
of O
- O
concept O
study O
for O
curing O
chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
using O
a O
foreign O
- O
antigen O
recombinant B
HBV I
( I
rHBV I
) I
as O
a O
gene O
therapy O
vector O
. O

Targeted O
elimination O
of O
wild B
- I
type I
HBV I
( I
wtHBV I
) I
- O
infected O
cells O
could O
be O
achieved O
by O
functionally O
activating O
an O
in O
situ O
T O
- O
cell O
response O
against O
the O
foreign O
antigen O
. O

For O
this O
immunotherapeutic O
approach O
to O
be O
practically O
viable O
, O
in O
the O
present O
study O
, O
we O
used O
a O
recombinant B
adenovirus I
( I
rAd I
) I
vector O
for O
rHBV O
delivery O
. O

chronic B
hepatitis I
B I
virus I
( I
HBV I
) I
infection O
is O
a O
major O
risk O
factor O
for O
liver O
cirrhosis O
and O
hepatocellular O
carcinoma O
. O

hepatitis B
B I
virus I
( I
HBV I
) I
is O
a O
major O
human O
pathogen O
that O
causes O
serious O
liver O
disease O
and O
600 O
, O
000 O
deaths O
annually O
. O

Approved O
therapies O
for O
treating O
chronic O
HBV O
infections O
usually O
target O
the O
multifunctional O
viral O
polymerase B
( I
hPOL I
) I
. O

IMPORTANCE O
The O
viral O
polymerase O
from O
human O
hepatitis O
B O
virus O
( O
hPOL O
) O
is O
a O
well O
- O
validated O
therapeutic O
target O
. O

The O
liver O
bile O
acids O
transporter O
sodium B
taurocholate I
cotransporting I
polypeptide I
( I
NTCP I
) I
is O
responsible O
for O
the O
majority O
of O
sodium O
- O
dependent O
bile O
salts O
uptake O
by O
hepatocytes O
. O

NTCP O
also O
functions O
as O
a O
cellular O
receptor O
for O
viral O
entry O
of O
hepatitis B
B I
virus I
( I
HBV I
) I
and O
hepatitis B
D I
virus I
( I
HDV I
) I
through O
a O
specific O
interaction O
between O
NTCP O
and O
the O
pre O
- O
S1 O
domain O
of O
HBV O
large O
envelope O
protein O
. O

The O
mutation O
S267F O
, O
corresponding O
to O
a O
single B
nucleotide I
polymorphism I
( I
SNP I
) I
found O
in O
about O
9 O
% O
of O
the O
East O
Asian O
population O
, O
renders O
NTCP O
without O
either O
taurocholate O
transporting O
activity O
or O
the O
ability O
to O
support O
HBV O
or O
HDV O
infection O
in O
cell O
culture O
. O

hepatitis B
C I
virus I
( I
HCV I
) I
predominantly O
infects O
human O
hepatocytes O
, O
although O
extrahepatic O
virus O
reservoirs O
are O
being O
discussed O
. O

Here O
we O
report O
that O
production O
of O
HCV B
trans I
- I
complemented I
particles I
( I
HCVTCP I
) I
from O
nonliver O
cells O
depends O
on O
ectopic O
expression O
of O
apolipoprotein B
E I
( I
ApoE I
) I
. O

For O
efficient O
virus O
production O
by O
full O
- O
length O
HCV O
genomes O
, O
microRNA B
122 I
( I
miR I
- I
122 I
) I
- O
mediated O
enhancement O
of O
RNA O
replication O
is O
additionally O
required O
. O

Typical O
properties O
of O
cell B
culture I
- I
grown I
HCV I
( I
HCVcc I
) I
particles O
from O
ApoE O
- O
expressing O
nonliver O
cells O
are O
comparable O
to O
those O
of O
virions O
derived O
from O
human O
hepatoma O
cells O
, O
although O
specific O
infectivity O
of O
virions O
is O
modestly O
reduced O
. O

Thus O
, O
apolipoprotein B
B I
( I
ApoB I
) I
, O
microsomal B
triglyceride I
transfer I
protein I
( I
MTTP I
) I
, O
and O
apolipoprotein B
C1 I
( I
ApoC1 I
) I
, O
previously O
implicated O
in O
HCV O
assembly O
, O
are O
dispensable O
for O
production O
of O
infectious O
HCV O
. O

Hepatitis O
B O
virus O
replicates O
a O
DNA O
genome O
through O
reverse O
transcription O
of O
a O
pregenomic B
RNA I
( I
pgRNA I
) I
by O
using O
a O
multifunctional O
polymerase O
( O
HP O
) O
. O

A O
critical O
function O
of O
HP O
is O
its O
specific O
association O
with O
a O
viral O
RNA O
signal O
, O
termed O
epsilon O
( O
H O
epsilon O
) O
, O
located O
on O
pgRNA O
, O
which O
is O
required O
for O
specific O
packaging O
of O
pgRNA O
into O
viral O
nucleocapsids O
and O
initiation O
of O
viral O
reverse O
transcription O
. O

HP O
initiates O
reverse O
transcription O
by O
using O
itself O
as O
a O
protein O
primer O
( O
protein O
priming O
) O
and O
H O
epsilon O
as O
the O
obligatory O
template O
. O

HP O
is O
made O
up O
of O
four O
domains O
, O
including O
the O
terminal B
protein I
( I
TP I
) I
, O
the O
spacer O
, O
the O
reverse B
transcriptase I
( I
RT I
) I
, O
and O
the O
RNase O
H O
domains O
. O

In O
this O
study O
, O
woodchuck B
hepatitis I
virus I
( I
WHV I
) I
transgenic I
( I
Tg I
) I
mouse O
models O
based O
on O
C57BL O
/ O
6 O
mice O
were O
established O
to O
study O
the O
pathogenesis O
associated O
with O
hepadnaviral O
infection O
. O

Two O
lineages O
of O
WHV O
Tg O
mice O
, O
harboring O
the O
WHV O
wild O
- O
type O
genome O
( O
lineage O
1217 O
) O
and O
a O
mutated O
WHV O
genome O
lacking O
surface O
antigen O
( O
lineage O
1281 O
) O
, O
were O
generated O
. O

WHV O
- O
specific O
immune O
responses O
were O
analyzed O
by O
flow O
cytometry O
and O
enzyme B
- I
linked I
immunosorbent I
assays I
( I
ELISAs I
) I
. O

Interestingly O
, O
Tg O
mice O
of O
lineage O
1281 O
spontaneously O
developed O
T O
- O
and O
B O
- O
cell O
responses O
to O
WHV B
core I
protein I
( I
WHcAg I
) I
. O

hepatitis B
C I
virus I
( I
HCV I
) I
infection O
of O
hepatocytes O
leads O
to O
transcriptional O
induction O
of O
the O
chemokine O
CXCL10 O
, O
which O
is O
considered O
an O
interferon B
( I
IFN I
) I
- O
stimulated O
gene O
. O